cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
LIHC	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-23.59	9.95e-74	9.11e-68	-1	-0.79	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-23.56	1.28e-73	1.02e-67	-0.98	-0.79	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-23.46	3.13e-73	2.21e-67	-0.98	-0.79	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-23.35	9.1e-73	6.08e-67	-0.99	-0.78	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-23.33	1.05e-72	6.64e-67	-0.99	-0.78	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	23.29	1.51e-72	9.09e-67	0.99	0.78	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	23.29	1.51e-72	9.09e-67	0.99	0.78	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-23.26	1.91e-72	1.1e-66	-0.98	-0.78	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-23.23	2.7e-72	1.48e-66	-0.99	-0.78	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-23.22	2.84e-72	1.5e-66	-0.99	-0.78	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	23.1	8.2e-72	4.14e-66	0.99	0.78	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-23.09	9.27e-72	4.58e-66	-0.99	-0.78	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
LIHC	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	22.97	2.68e-71	1.25e-65	0.85	0.78	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
LIHC	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	22.74	2.21e-70	9.12e-65	0.99	0.78	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-22.36	7.21e-69	2.74e-63	-0.99	-0.77	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-22.34	8.44e-69	3.16e-63	-0.97	-0.77	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-22.33	8.87e-69	3.27e-63	-0.97	-0.77	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
LIHC	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	22.27	1.53e-68	5.41e-63	0.82	0.77	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
LIHC	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-22.23	2.28e-68	7.72e-63	-0.98	-0.77	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
LIHC	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	22.03	1.36e-67	4.22e-62	0.82	0.77	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
LIHC	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	21.92	3.9e-67	1.15e-61	0.95	0.76	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-21.77	1.51e-66	3.85e-61	-0.96	-0.76	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-21.73	2.26e-66	5.59e-61	-0.96	-0.76	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-21.66	4.17e-66	1.02e-60	-0.96	-0.76	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
LIHC	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	20.29	1.2e-60	1.73e-55	0.93	0.74	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	20.19	3.09e-60	4.2e-55	0.77	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
LIHC	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	19.78	1.34e-58	1.45e-53	0.79	0.73	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-19.75	1.76e-58	1.81e-53	-0.78	-0.73	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-19.75	1.76e-58	1.81e-53	-0.78	-0.73	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-19.68	3.47e-58	3.45e-53	-0.79	-0.73	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-19.68	3.5e-58	3.45e-53	-0.79	-0.73	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-19.67	3.81e-58	3.74e-53	-0.79	-0.73	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	19.61	6.22e-58	5.94e-53	0.79	0.73	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	19.55	1.11e-57	9.52e-53	0.78	0.73	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	19.55	1.11e-57	9.52e-53	0.78	0.73	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	19.55	1.11e-57	9.52e-53	0.78	0.73	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	19.38	5.27e-57	4.43e-52	0.76	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
LIHC	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-19.21	2.76e-56	2.28e-51	-0.78	-0.72	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	19.18	3.48e-56	2.86e-51	0.78	0.72	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-19.12	6.04e-56	4.94e-51	-0.78	-0.72	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	19.1	7.51e-56	6.11e-51	0.78	0.72	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	19.06	1.02e-55	8.21e-51	0.93	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	19	1.77e-55	1.41e-50	0.78	0.72	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	19	1.87e-55	1.48e-50	0.78	0.72	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	18.9	4.76e-55	3.75e-50	0.78	0.71	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-18.8	1.14e-54	8.85e-50	-0.77	-0.71	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	18.73	2.36e-54	1.83e-49	0.77	0.71	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-18.71	2.61e-54	2e-49	-0.77	-0.71	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-18.71	2.61e-54	2e-49	-0.77	-0.71	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	18.71	2.68e-54	2.05e-49	0.78	0.71	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-18.68	3.65e-54	2.78e-49	-0.77	-0.71	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-18.66	4.33e-54	3.28e-49	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-18.63	5.76e-54	4.35e-49	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	18.58	8.96e-54	6.75e-49	0.78	0.71	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-18.58	9.11e-54	6.85e-49	-0.79	-0.71	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000272787.1	KB-226F1.2	-18.56	1.13e-53	8.39e-49	-0.88	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23969211~23969873:+
LIHC	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-18.53	1.48e-53	1.07e-48	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-18.53	1.48e-53	1.07e-48	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-18.53	1.48e-53	1.07e-48	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-18.53	1.48e-53	1.07e-48	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-18.53	1.48e-53	1.07e-48	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	18.53	1.49e-53	1.07e-48	0.77	0.71	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-18.48	2.4e-53	1.7e-48	-0.77	-0.71	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	18.44	3.39e-53	2.4e-48	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-18.41	4.55e-53	3.21e-48	-0.78	-0.71	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
LIHC	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	18.3	1.19e-52	8.31e-48	0.93	0.7	Shingles;	chr7:38346957	chr7:38343894~38350022:-
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	18.29	1.28e-52	8.91e-48	0.73	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
LIHC	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-18.23	2.34e-52	1.61e-47	-1.08	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-18.22	2.51e-52	1.7e-47	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-18.22	2.51e-52	1.7e-47	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	18.22	2.51e-52	1.7e-47	1.07	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-18.16	4.36e-52	2.91e-47	-1.08	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-18.16	4.36e-52	2.91e-47	-1.08	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-18.16	4.36e-52	2.91e-47	-1.08	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000272787.1	KB-226F1.2	-18.13	5.8e-52	3.84e-47	-0.88	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	18.12	6.36e-52	4.19e-47	1.08	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-18.11	7.35e-52	4.78e-47	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	-18.1	8.09e-52	5.25e-47	-0.87	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-18.09	8.22e-52	5.29e-47	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-18.09	8.22e-52	5.29e-47	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-18.06	1.1e-51	6.98e-47	-1.08	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	18.05	1.23e-51	7.77e-47	1.07	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-18.04	1.3e-51	8.24e-47	-0.77	-0.7	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-18	1.92e-51	1.2e-46	-0.77	-0.7	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-17.99	2.16e-51	1.35e-46	-0.76	-0.7	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-17.99	2.16e-51	1.35e-46	-0.76	-0.7	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-17.98	2.35e-51	1.43e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-17.98	2.35e-51	1.43e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-17.98	2.35e-51	1.43e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-17.98	2.35e-51	1.43e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-17.98	2.35e-51	1.43e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	17.98	2.35e-51	1.43e-46	1.07	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	17.98	2.35e-51	1.43e-46	1.07	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	17.98	2.35e-51	1.43e-46	1.07	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-17.97	2.5e-51	1.51e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-17.97	2.5e-51	1.51e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-17.97	2.5e-51	1.51e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000272787.1	KB-226F1.2	17.97	2.6e-51	1.52e-46	0.85	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-17.97	2.61e-51	1.52e-46	-1.06	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-17.96	2.86e-51	1.65e-46	-0.77	-0.7	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-17.96	2.98e-51	1.71e-46	-1.08	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-17.94	3.34e-51	1.91e-46	-0.77	-0.7	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-17.88	6.04e-51	3.38e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-17.88	6.04e-51	3.38e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-17.88	6.11e-51	3.41e-46	-1.07	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	17.87	6.76e-51	3.73e-46	1.07	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-17.87	6.76e-51	3.73e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-17.87	6.76e-51	3.73e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-17.87	6.76e-51	3.73e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-17.87	6.76e-51	3.73e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	17.86	7.31e-51	4.01e-46	1.05	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-17.85	7.82e-51	4.29e-46	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-17.85	7.87e-51	4.29e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-17.85	7.87e-51	4.29e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	17.84	8.69e-51	4.7e-46	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-17.84	8.69e-51	4.7e-46	-1.04	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-17.84	8.85e-51	4.78e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	17.82	1e-50	5.41e-46	1.06	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	17.81	1.18e-50	6.34e-46	1.07	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-17.8	1.26e-50	6.66e-46	-1.07	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-17.78	1.52e-50	7.9e-46	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-17.78	1.52e-50	7.9e-46	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-17.78	1.52e-50	7.9e-46	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-17.78	1.52e-50	7.9e-46	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	17.78	1.54e-50	7.99e-46	1.05	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-17.76	1.74e-50	9.02e-46	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	17.76	1.84e-50	9.51e-46	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
LIHC	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-17.73	2.34e-50	1.19e-45	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-17.73	2.34e-50	1.19e-45	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-17.73	2.34e-50	1.19e-45	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-17.73	2.34e-50	1.19e-45	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-17.71	2.93e-50	1.48e-45	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	17.71	3e-50	1.5e-45	1.06	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	17.71	3e-50	1.5e-45	1.06	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	17.7	3.13e-50	1.56e-45	1.06	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-17.68	3.82e-50	1.89e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-17.68	3.82e-50	1.89e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-17.68	3.82e-50	1.89e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	17.67	4.23e-50	2.09e-45	0.82	0.69	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-17.65	5.09e-50	2.5e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-17.65	5.09e-50	2.5e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-17.65	5.09e-50	2.5e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-17.63	5.86e-50	2.88e-45	-0.75	-0.69	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	17.63	5.97e-50	2.93e-45	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-17.62	6.5e-50	3.18e-45	-1.06	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-17.6	7.76e-50	3.77e-45	-0.76	-0.69	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	17.6	7.98e-50	3.86e-45	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	17.6	8.06e-50	3.89e-45	0.82	0.69	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-17.6	8.22e-50	3.96e-45	-0.76	-0.69	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-17.59	8.84e-50	4.25e-45	-1.04	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	17.59	9.07e-50	4.25e-45	0.82	0.69	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	17.59	9.07e-50	4.25e-45	0.82	0.69	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	17.59	9.07e-50	4.25e-45	0.82	0.69	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	17.59	9.07e-50	4.25e-45	0.82	0.69	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	17.59	9.07e-50	4.25e-45	0.82	0.69	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	17.59	9.07e-50	4.25e-45	0.82	0.69	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	17.59	9.07e-50	4.25e-45	0.82	0.69	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000272787.1	KB-226F1.2	-17.56	1.12e-49	5.22e-45	-0.85	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000272787.1	KB-226F1.2	-17.53	1.48e-49	6.87e-45	-0.87	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000272787.1	KB-226F1.2	17.53	1.51e-49	7.02e-45	0.88	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	17.52	1.68e-49	7.78e-45	1.05	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-17.51	1.78e-49	8.26e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-17.51	1.79e-49	8.27e-45	-1.05	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000272787.1	KB-226F1.2	-17.5	1.97e-49	9.07e-45	-0.89	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	17.49	2.15e-49	9.87e-45	0.81	0.69	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	17.49	2.15e-49	9.87e-45	0.81	0.69	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-17.48	2.35e-49	1.08e-44	-0.75	-0.69	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	17.47	2.58e-49	1.18e-44	0.81	0.69	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000272787.1	KB-226F1.2	-17.43	3.71e-49	1.68e-44	-0.88	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23969211~23969873:+
LIHC	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	17.43	3.82e-49	1.71e-44	0.75	0.69	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000272787.1	KB-226F1.2	17.4	4.93e-49	2.21e-44	0.89	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	17.4	5.09e-49	2.27e-44	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	17.4	5.09e-49	2.27e-44	1.04	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	17.4	5.21e-49	2.32e-44	1.05	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-17.39	5.84e-49	2.6e-44	-0.75	-0.68	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	17.37	6.52e-49	2.9e-44	0.81	0.68	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	17.37	6.84e-49	3.03e-44	0.75	0.68	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000272787.1	KB-226F1.2	-17.36	7.23e-49	3.19e-44	-0.87	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	17.35	7.91e-49	3.48e-44	0.81	0.68	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-17.34	9.01e-49	3.95e-44	-1.05	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	17.33	9.48e-49	4.13e-44	1.05	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	17.28	1.5e-48	6.51e-44	0.81	0.68	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	17.28	1.53e-48	6.62e-44	0.81	0.68	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	17.26	1.79e-48	7.74e-44	0.81	0.68	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	17.26	1.84e-48	7.94e-44	0.81	0.68	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	17.25	2.03e-48	8.67e-44	0.83	0.68	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	17.25	2.03e-48	8.67e-44	0.83	0.68	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	17.24	2.24e-48	9.55e-44	0.81	0.68	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000272787.1	KB-226F1.2	-17.24	2.29e-48	9.75e-44	-0.87	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	17.23	2.46e-48	1.05e-43	0.83	0.68	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	17.22	2.6e-48	1.1e-43	0.81	0.68	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	17.18	3.78e-48	1.6e-43	0.8	0.68	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	17.18	3.82e-48	1.61e-43	0.81	0.68	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-17.18	3.86e-48	1.63e-43	-1.04	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000272787.1	KB-226F1.2	-17.18	3.9e-48	1.64e-43	-0.85	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	17.17	4.13e-48	1.73e-43	0.81	0.68	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	17.17	4.41e-48	1.84e-43	0.81	0.68	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	17.17	4.41e-48	1.84e-43	0.81	0.68	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000272787.1	KB-226F1.2	-17.16	4.71e-48	1.97e-43	-0.86	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	17.15	5.29e-48	2.2e-43	0.81	0.68	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	17.12	6.94e-48	2.88e-43	1.03	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000272787.1	KB-226F1.2	-17.11	7.66e-48	3.17e-43	-0.84	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000272787.1	KB-226F1.2	-17.1	8.05e-48	3.32e-43	-0.84	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	17.09	8.64e-48	3.56e-43	0.8	0.68	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	17.07	1.07e-47	4.4e-43	0.81	0.68	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	17.05	1.25e-47	5.1e-43	0.81	0.68	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	17.05	1.25e-47	5.1e-43	0.81	0.68	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	17.05	1.25e-47	5.1e-43	0.81	0.68	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-17.05	1.3e-47	5.3e-43	-0.76	-0.68	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000272787.1	KB-226F1.2	-17	2.06e-47	8.37e-43	-0.86	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000272787.1	KB-226F1.2	-16.98	2.48e-47	1e-42	-0.86	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23969211~23969873:+
LIHC	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-16.97	2.75e-47	1.11e-42	-0.75	-0.68	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	16.96	3.1e-47	1.24e-42	0.8	0.68	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000272787.1	KB-226F1.2	-16.92	4.14e-47	1.64e-42	-0.85	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000272787.1	KB-226F1.2	-16.91	4.61e-47	1.82e-42	-0.85	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-16.86	7.56e-47	2.98e-42	-1.04	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	16.86	7.86e-47	3.1e-42	0.81	0.67	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	16.86	7.9e-47	3.11e-42	0.81	0.67	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	16.86	7.9e-47	3.11e-42	0.81	0.67	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000272787.1	KB-226F1.2	-16.77	1.69e-46	6.58e-42	-0.85	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000272787.1	KB-226F1.2	-16.74	2.25e-46	8.74e-42	-0.83	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23969211~23969873:+
LIHC	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	16.73	2.45e-46	9.54e-42	0.74	0.67	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
LIHC	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-16.73	2.61e-46	1.01e-41	-0.76	-0.67	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
LIHC	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	16.72	2.7e-46	1.05e-41	0.79	0.67	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	16.71	2.91e-46	1.12e-41	1.04	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	16.71	3e-46	1.16e-41	0.8	0.67	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	16.69	3.61e-46	1.39e-41	0.7	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
LIHC	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	16.69	3.78e-46	1.45e-41	0.79	0.67	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	16.58	9.69e-46	3.7e-41	1.03	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	16.58	9.75e-46	3.72e-41	0.78	0.67	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	16.55	1.31e-45	4.97e-41	0.78	0.67	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	16.51	1.94e-45	7.35e-41	0.79	0.67	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000272787.1	KB-226F1.2	-16.5	2.02e-45	7.62e-41	-0.85	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	16.48	2.63e-45	9.81e-41	0.77	0.67	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-16.44	3.73e-45	1.38e-40	-0.99	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	16.41	4.65e-45	1.71e-40	0.78	0.66	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	16.41	4.79e-45	1.76e-40	0.7	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
LIHC	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	16.41	4.98e-45	1.82e-40	1.04	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	16.4	5.4e-45	1.98e-40	0.78	0.66	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	16.36	7.49e-45	2.73e-40	0.77	0.66	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	16.36	7.61e-45	2.75e-40	0.77	0.66	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	16.36	7.61e-45	2.75e-40	0.77	0.66	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	16.36	7.61e-45	2.75e-40	0.77	0.66	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
LIHC	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-16.33	9.6e-45	3.46e-40	-0.83	-0.66	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
LIHC	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-16.33	1.04e-44	3.75e-40	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-16.31	1.24e-44	4.46e-40	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000272787.1	KB-226F1.2	-16.29	1.43e-44	5.1e-40	-0.84	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	16.29	1.49e-44	5.33e-40	0.98	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
LIHC	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	16.27	1.7e-44	6.04e-40	0.86	0.66	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
LIHC	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	16.27	1.71e-44	6.07e-40	0.78	0.66	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	16.27	1.78e-44	6.3e-40	0.87	0.66	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
LIHC	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	16.26	1.89e-44	6.68e-40	0.77	0.66	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	16.26	1.89e-44	6.68e-40	0.77	0.66	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	16.25	2.03e-44	7.15e-40	1.04	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	16.24	2.3e-44	8.06e-40	0.77	0.66	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-16.23	2.62e-44	9.14e-40	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-16.23	2.62e-44	9.14e-40	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	16.22	2.76e-44	9.6e-40	0.77	0.66	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
LIHC	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	16.21	3.05e-44	1.06e-39	0.78	0.66	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
LIHC	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-16.21	3.06e-44	1.06e-39	-0.84	-0.66	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
LIHC	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	16.21	3.09e-44	1.07e-39	1.01	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-16.2	3.23e-44	1.11e-39	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-16.16	4.7e-44	1.61e-39	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	16.15	5.24e-44	1.79e-39	0.96	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	16.15	5.27e-44	1.79e-39	0.77	0.66	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	16.14	5.63e-44	1.91e-39	0.97	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	16.14	5.63e-44	1.91e-39	0.97	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
LIHC	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	16.14	5.82e-44	1.97e-39	0.77	0.66	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
LIHC	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-16.14	6e-44	2.03e-39	-0.75	-0.66	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
LIHC	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-16.13	6.27e-44	2.12e-39	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
LIHC	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	16.11	7.95e-44	2.65e-39	0.77	0.66	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	16.1	8.66e-44	2.88e-39	1.01	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	16.07	1.06e-43	3.51e-39	0.7	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
LIHC	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	16.06	1.17e-43	3.85e-39	1.21	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
LIHC	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	16.05	1.32e-43	4.33e-39	0.87	0.66	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	16.04	1.49e-43	4.9e-39	0.69	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
LIHC	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	16.03	1.53e-43	5e-39	0.86	0.66	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
LIHC	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	16.03	1.58e-43	5.18e-39	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	16.02	1.78e-43	5.8e-39	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	16.02	1.78e-43	5.8e-39	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	16.02	1.78e-43	5.8e-39	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	16	2.04e-43	6.63e-39	1.11	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	16	2.12e-43	6.86e-39	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	16	2.12e-43	6.86e-39	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
LIHC	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	15.99	2.28e-43	7.38e-39	0.76	0.65	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
LIHC	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	15.98	2.6e-43	8.38e-39	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	15.93	4.04e-43	1.29e-38	0.69	0.65	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	15.92	4.25e-43	1.36e-38	1.11	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	15.92	4.25e-43	1.36e-38	1.11	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	15.91	4.94e-43	1.58e-38	0.96	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	15.89	5.54e-43	1.76e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	15.88	6.03e-43	1.91e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	15.88	6.03e-43	1.91e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-15.87	6.96e-43	2.2e-38	-1.14	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	15.87	7.06e-43	2.23e-38	0.86	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
LIHC	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-15.87	7.2e-43	2.27e-38	-0.83	-0.65	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
LIHC	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	15.86	7.47e-43	2.35e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	15.84	9.36e-43	2.93e-38	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	15.82	1.12e-42	3.5e-38	0.67	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
LIHC	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	15.81	1.16e-42	3.61e-38	0.76	0.65	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	15.81	1.24e-42	3.86e-38	0.96	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	15.8	1.33e-42	4.11e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
LIHC	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	15.8	1.34e-42	4.13e-38	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
LIHC	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	15.79	1.4e-42	4.32e-38	1.13	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	15.79	1.41e-42	4.35e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	15.79	1.41e-42	4.35e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
LIHC	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-15.79	1.46e-42	4.49e-38	-0.82	-0.65	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-15.79	1.46e-42	4.49e-38	-0.82	-0.65	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
LIHC	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	15.79	1.49e-42	4.57e-38	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	15.78	1.51e-42	4.63e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	15.78	1.55e-42	4.74e-38	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	15.78	1.55e-42	4.74e-38	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	15.78	1.55e-42	4.74e-38	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	15.78	1.57e-42	4.79e-38	0.77	0.65	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
LIHC	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-15.78	1.59e-42	4.85e-38	-0.75	-0.65	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
LIHC	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	15.77	1.74e-42	5.3e-38	0.76	0.65	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-15.76	1.81e-42	5.49e-38	-0.89	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	15.76	1.88e-42	5.67e-38	1.11	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	15.76	1.88e-42	5.67e-38	1.11	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
LIHC	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-15.75	2.02e-42	6.07e-38	-0.73	-0.65	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
LIHC	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-15.74	2.17e-42	6.52e-38	-0.69	-0.65	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	15.74	2.18e-42	6.54e-38	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	15.74	2.36e-42	7.05e-38	0.84	0.65	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
LIHC	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	15.73	2.42e-42	7.22e-38	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
LIHC	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	15.73	2.56e-42	7.63e-38	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	15.73	2.56e-42	7.63e-38	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
LIHC	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-15.73	2.56e-42	7.63e-38	-0.96	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
LIHC	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	15.72	2.78e-42	8.26e-38	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
LIHC	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-15.72	2.8e-42	8.31e-38	-0.82	-0.65	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-15.71	2.92e-42	8.64e-38	-0.83	-0.65	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-15.71	2.92e-42	8.64e-38	-0.83	-0.65	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
LIHC	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	15.7	3.36e-42	9.89e-38	1.11	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	15.69	3.59e-42	1.06e-37	1.11	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-15.69	3.7e-42	1.09e-37	-0.75	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	15.68	3.91e-42	1.15e-37	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	15.68	3.92e-42	1.15e-37	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
LIHC	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	15.68	3.99e-42	1.17e-37	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
LIHC	cis	rs2260433	0.693	rs11225355	ENSG00000281655.1	RP11-817J15.3	15.68	4.08e-42	1.19e-37	0.98	0.65	Cleft palate;	chr11:102640430	chr11:102681310~102683913:+
LIHC	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-15.68	4.08e-42	1.19e-37	-0.96	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	15.67	4.12e-42	1.2e-37	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
LIHC	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-15.66	4.73e-42	1.37e-37	-0.82	-0.65	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
LIHC	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-15.66	4.76e-42	1.37e-37	-0.81	-0.65	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-15.66	4.76e-42	1.37e-37	-0.81	-0.65	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-15.66	4.76e-42	1.37e-37	-0.81	-0.65	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-15.66	4.76e-42	1.37e-37	-0.81	-0.65	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-15.66	4.76e-42	1.37e-37	-0.81	-0.65	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
LIHC	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	15.66	4.84e-42	1.39e-37	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
LIHC	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-15.65	5e-42	1.43e-37	-0.84	-0.65	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	15.65	5.13e-42	1.47e-37	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
LIHC	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	15.65	5.23e-42	1.49e-37	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	15.65	5.34e-42	1.52e-37	1.2	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
LIHC	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	15.65	5.35e-42	1.52e-37	0.75	0.65	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
LIHC	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-15.64	5.44e-42	1.54e-37	-0.82	-0.65	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-15.64	5.44e-42	1.54e-37	-0.82	-0.65	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-15.64	5.44e-42	1.54e-37	-0.82	-0.65	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
LIHC	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-15.64	5.87e-42	1.66e-37	-1.11	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
LIHC	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-15.63	6.15e-42	1.73e-37	-0.82	-0.65	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
LIHC	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-15.62	6.8e-42	1.91e-37	-0.81	-0.65	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-15.62	6.8e-42	1.91e-37	-0.81	-0.65	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-15.62	6.8e-42	1.91e-37	-0.81	-0.65	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-15.61	7.52e-42	2.11e-37	-0.75	-0.65	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
LIHC	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	15.6	8.3e-42	2.32e-37	1.2	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
LIHC	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-15.59	8.8e-42	2.44e-37	-0.81	-0.64	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-15.59	8.8e-42	2.44e-37	-0.81	-0.64	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-15.59	8.8e-42	2.44e-37	-0.81	-0.64	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	15.59	8.92e-42	2.47e-37	0.96	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
LIHC	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	15.59	9.06e-42	2.51e-37	0.74	0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
LIHC	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-15.59	9.2e-42	2.54e-37	-0.82	-0.64	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
LIHC	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-15.58	9.93e-42	2.74e-37	-0.81	-0.64	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-15.58	9.93e-42	2.74e-37	-0.81	-0.64	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-15.58	9.93e-42	2.74e-37	-0.81	-0.64	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	15.57	1.11e-41	3.06e-37	1.11	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	15.56	1.14e-41	3.13e-37	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	15.56	1.18e-41	3.24e-37	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	15.55	1.28e-41	3.51e-37	0.85	0.64	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
LIHC	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	15.55	1.34e-41	3.65e-37	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
LIHC	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-15.54	1.4e-41	3.8e-37	-0.8	-0.64	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-15.54	1.4e-41	3.8e-37	-0.8	-0.64	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-15.54	1.4e-41	3.8e-37	-0.8	-0.64	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	15.54	1.44e-41	3.91e-37	0.69	0.64	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
LIHC	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-15.53	1.56e-41	4.23e-37	-0.82	-0.64	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	15.53	1.58e-41	4.26e-37	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
LIHC	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	15.51	1.81e-41	4.87e-37	0.73	0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
LIHC	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-15.5	1.95e-41	5.26e-37	-0.68	-0.64	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
LIHC	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	15.49	2.26e-41	6.06e-37	1.19	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
LIHC	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	15.47	2.61e-41	6.98e-37	1.11	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
LIHC	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-15.47	2.79e-41	7.44e-37	-0.8	-0.64	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-15.47	2.79e-41	7.44e-37	-0.8	-0.64	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
LIHC	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	15.46	2.97e-41	7.9e-37	1.2	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
LIHC	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	15.45	3.15e-41	8.36e-37	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	15.44	3.43e-41	9.07e-37	0.69	0.64	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
LIHC	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	15.43	3.92e-41	1.01e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
LIHC	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	15.43	3.92e-41	1.01e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
LIHC	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	15.43	3.95e-41	1.01e-36	1.21	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	15.43	3.95e-41	1.01e-36	1.21	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
LIHC	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	15.43	3.99e-41	1.02e-36	0.81	0.64	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-15.42	4.35e-41	1.11e-36	-0.74	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	15.42	4.41e-41	1.12e-36	0.68	0.64	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
LIHC	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	15.41	4.44e-41	1.13e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
LIHC	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	15.41	4.7e-41	1.19e-36	0.72	0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
LIHC	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	15.41	4.76e-41	1.21e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	15.41	4.85e-41	1.23e-36	0.83	0.64	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
LIHC	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-15.4	5.11e-41	1.29e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	15.4	5.26e-41	1.33e-36	0.98	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	15.39	5.41e-41	1.36e-36	0.76	0.64	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	15.39	5.49e-41	1.38e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-15.39	5.72e-41	1.43e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
LIHC	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	15.38	5.85e-41	1.46e-36	1.18	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	15.38	5.85e-41	1.46e-36	1.18	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
LIHC	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	15.37	6.48e-41	1.61e-36	0.76	0.64	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
LIHC	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-15.37	6.75e-41	1.68e-36	-0.8	-0.64	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
LIHC	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	15.37	6.87e-41	1.68e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
LIHC	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	15.36	7.1e-41	1.73e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
LIHC	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-15.35	8.04e-41	1.94e-36	-0.81	-0.64	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	15.35	8.23e-41	1.98e-36	0.68	0.64	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	15.35	8.23e-41	1.98e-36	0.83	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
LIHC	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	15.33	9.22e-41	2.2e-36	0.85	0.64	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
LIHC	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-15.32	1.02e-40	2.42e-36	-0.8	-0.64	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-15.32	1.07e-40	2.53e-36	-0.8	-0.64	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	15.32	1.09e-40	2.57e-36	0.84	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000272787.1	KB-226F1.2	15.32	1.1e-40	2.6e-36	0.8	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000272787.1	KB-226F1.2	-15.31	1.19e-40	2.79e-36	-0.8	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23969211~23969873:+
LIHC	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	15.31	1.19e-40	2.8e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	15.31	1.19e-40	2.8e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	15.3	1.27e-40	2.96e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	15.3	1.27e-40	2.97e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
LIHC	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	15.3	1.27e-40	2.97e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
LIHC	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-15.28	1.46e-40	3.4e-36	-0.8	-0.64	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-15.28	1.53e-40	3.55e-36	-0.74	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-15.28	1.58e-40	3.64e-36	-1.14	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	15.27	1.72e-40	3.97e-36	0.9	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	15.27	1.74e-40	4e-36	1.13	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	15.26	1.87e-40	4.29e-36	1.14	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
LIHC	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	15.25	1.97e-40	4.52e-36	0.84	0.64	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
LIHC	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	15.25	2.03e-40	4.59e-36	1.15	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	15.25	2.03e-40	4.59e-36	1.15	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	15.25	2.03e-40	4.59e-36	1.15	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	15.25	2.03e-40	4.59e-36	1.15	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	15.25	2.03e-40	4.59e-36	1.15	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	15.25	2.03e-40	4.59e-36	1.15	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-15.25	2.03e-40	4.59e-36	-1.15	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
LIHC	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	15.25	2.05e-40	4.63e-36	0.85	0.64	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000272787.1	KB-226F1.2	-15.24	2.13e-40	4.79e-36	-0.81	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	15.24	2.27e-40	5.11e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	15.23	2.37e-40	5.21e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	15.23	2.37e-40	5.21e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	15.23	2.37e-40	5.21e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	15.23	2.37e-40	5.21e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	15.23	2.37e-40	5.21e-36	0.75	0.64	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-15.23	2.41e-40	5.3e-36	-1.14	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-15.23	2.41e-40	5.3e-36	-1.14	-0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
LIHC	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	15.23	2.47e-40	5.41e-36	0.73	0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	15.23	2.47e-40	5.41e-36	0.73	0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
LIHC	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	15.23	2.49e-40	5.43e-36	0.8	0.64	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-15.23	2.49e-40	5.43e-36	-0.8	-0.64	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-15.23	2.49e-40	5.43e-36	-0.8	-0.64	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-15.23	2.49e-40	5.43e-36	-0.8	-0.64	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-15.23	2.49e-40	5.43e-36	-0.8	-0.64	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	15.22	2.58e-40	5.58e-36	1.12	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
LIHC	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	15.22	2.7e-40	5.8e-36	0.8	0.64	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	15.22	2.7e-40	5.8e-36	0.8	0.64	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	15.19	3.59e-40	7.69e-36	1.14	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-15.18	3.66e-40	7.83e-36	-1.09	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
LIHC	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	15.18	3.72e-40	7.95e-36	0.73	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	15.18	3.73e-40	7.95e-36	0.73	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
LIHC	cis	rs5758659	0.714	rs5758574	ENSG00000237037.8	NDUFA6-AS1	-15.18	3.77e-40	8.03e-36	-0.74	-0.63	Cognitive function;	chr22:42085396	chr22:42090931~42137742:+
LIHC	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	15.18	3.82e-40	8.1e-36	0.8	0.63	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	15.18	3.82e-40	8.1e-36	0.8	0.63	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	15.18	3.82e-40	8.1e-36	0.8	0.63	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	15.18	3.82e-40	8.1e-36	0.8	0.63	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	15.18	3.83e-40	8.12e-36	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	15.17	4.1e-40	8.68e-36	0.65	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
LIHC	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-15.16	4.59e-40	9.69e-36	-0.93	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
LIHC	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	15.15	4.9e-40	1.03e-35	0.72	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
LIHC	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	15.15	4.99e-40	1.05e-35	0.79	0.63	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-15.15	4.99e-40	1.05e-35	-0.79	-0.63	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	15.14	5.24e-40	1.1e-35	0.79	0.63	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	15.14	5.43e-40	1.14e-35	1.11	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	15.14	5.43e-40	1.14e-35	1.11	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	15.14	5.47e-40	1.15e-35	0.8	0.63	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	15.14	5.53e-40	1.16e-35	1.14	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	15.13	5.88e-40	1.23e-35	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	15.13	5.91e-40	1.23e-35	0.84	0.63	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
LIHC	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	15.13	6.07e-40	1.27e-35	1.14	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	15.13	6.12e-40	1.27e-35	1.13	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	15.12	6.73e-40	1.4e-35	0.96	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	15.12	6.73e-40	1.4e-35	0.96	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	15.12	6.73e-40	1.4e-35	0.96	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
LIHC	cis	rs4853012	0.793	rs6723185	ENSG00000217702.2	RP11-287D1.4	15.11	6.92e-40	1.43e-35	0.83	0.63	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74130583~74135395:+
LIHC	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	15.11	7.12e-40	1.47e-35	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
LIHC	cis	rs5758659	0.714	rs2413668	ENSG00000237037.8	NDUFA6-AS1	-15.11	7.18e-40	1.48e-35	-0.73	-0.63	Cognitive function;	chr22:42109837	chr22:42090931~42137742:+
LIHC	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	15.1	7.56e-40	1.56e-35	0.79	0.63	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
LIHC	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	15.1	8.06e-40	1.66e-35	0.83	0.63	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
LIHC	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-15.09	8.32e-40	1.69e-35	-1.13	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-15.09	8.32e-40	1.69e-35	-1.13	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-15.09	8.32e-40	1.69e-35	-1.13	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-15.09	8.32e-40	1.69e-35	-1.13	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-15.09	8.32e-40	1.69e-35	-1.13	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-15.09	8.32e-40	1.69e-35	-1.13	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	15.09	8.37e-40	1.7e-35	1.14	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-15.09	8.39e-40	1.7e-35	-1.14	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-15.09	8.39e-40	1.7e-35	-1.14	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-15.09	8.39e-40	1.7e-35	-1.14	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
LIHC	cis	rs2260433	0.624	rs10895331	ENSG00000281655.1	RP11-817J15.3	15.09	8.56e-40	1.73e-35	0.98	0.63	Cleft palate;	chr11:102641005	chr11:102681310~102683913:+
LIHC	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-15.09	8.62e-40	1.74e-35	-0.81	-0.63	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
LIHC	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-15.09	8.68e-40	1.74e-35	-1.16	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
LIHC	cis	rs5758659	0.714	rs133373	ENSG00000237037.8	NDUFA6-AS1	15.08	9.01e-40	1.8e-35	0.73	0.63	Cognitive function;	chr22:42069784	chr22:42090931~42137742:+
LIHC	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-15.08	9.1e-40	1.81e-35	-0.8	-0.63	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-15.08	9.1e-40	1.81e-35	-0.8	-0.63	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
LIHC	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-15.08	9.1e-40	1.81e-35	-0.8	-0.63	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	15.08	9.61e-40	1.91e-35	0.84	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
LIHC	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-15.06	1.08e-39	2.14e-35	-0.73	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	15.06	1.1e-39	2.17e-35	1.13	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
LIHC	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-15.06	1.11e-39	2.19e-35	-0.8	-0.63	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	15.05	1.2e-39	2.36e-35	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	15.05	1.2e-39	2.36e-35	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	15.05	1.2e-39	2.36e-35	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	15.05	1.2e-39	2.36e-35	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
LIHC	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	15.05	1.22e-39	2.41e-35	0.79	0.63	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
LIHC	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	15.05	1.24e-39	2.43e-35	0.85	0.63	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
LIHC	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	15.05	1.25e-39	2.46e-35	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
LIHC	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-15.05	1.26e-39	2.46e-35	-0.8	-0.63	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
LIHC	cis	rs2260433	0.693	rs1940061	ENSG00000281655.1	RP11-817J15.3	15.04	1.35e-39	2.64e-35	0.95	0.63	Cleft palate;	chr11:102639722	chr11:102681310~102683913:+
LIHC	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	15.04	1.38e-39	2.7e-35	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	15.03	1.44e-39	2.81e-35	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
LIHC	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	15.03	1.49e-39	2.9e-35	0.79	0.63	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
LIHC	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-15.02	1.57e-39	3.05e-35	-1.17	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
LIHC	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	15.02	1.58e-39	3.06e-35	0.92	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	15.02	1.68e-39	3.26e-35	1.12	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	15.02	1.68e-39	3.26e-35	1.12	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	15.02	1.68e-39	3.26e-35	1.12	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	15.02	1.68e-39	3.26e-35	1.12	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
LIHC	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-15.01	1.75e-39	3.38e-35	-0.79	-0.63	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	15.01	1.79e-39	3.46e-35	0.83	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
LIHC	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	15.01	1.81e-39	3.5e-35	0.85	0.63	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
LIHC	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	15	1.86e-39	3.59e-35	0.79	0.63	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	15	1.88e-39	3.61e-35	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	15	1.93e-39	3.72e-35	1.12	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
LIHC	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-14.99	2.1e-39	4.04e-35	-0.79	-0.63	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
LIHC	cis	rs2260433	0.624	rs11225353	ENSG00000281655.1	RP11-817J15.3	14.99	2.16e-39	4.15e-35	1	0.63	Cleft palate;	chr11:102639104	chr11:102681310~102683913:+
LIHC	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	14.98	2.27e-39	4.35e-35	0.72	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
LIHC	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	14.98	2.31e-39	4.42e-35	0.8	0.63	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
LIHC	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	14.97	2.47e-39	4.72e-35	0.73	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
LIHC	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	14.97	2.59e-39	4.93e-35	0.78	0.63	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
LIHC	cis	rs5758659	0.714	rs2284087	ENSG00000237037.8	NDUFA6-AS1	-14.96	2.74e-39	5.22e-35	-0.73	-0.63	Cognitive function;	chr22:42089667	chr22:42090931~42137742:+
LIHC	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-14.96	2.84e-39	5.39e-35	-0.66	-0.63	Breast cancer;	chr11:743813	chr11:779617~780755:+
LIHC	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	14.96	2.9e-39	5.5e-35	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
LIHC	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-14.95	3e-39	5.67e-35	-0.79	-0.63	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
LIHC	cis	rs5758659	0.657	rs5758587	ENSG00000237037.8	NDUFA6-AS1	-14.95	3.07e-39	5.8e-35	-0.73	-0.63	Cognitive function;	chr22:42121632	chr22:42090931~42137742:+
LIHC	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-14.94	3.21e-39	6.06e-35	-0.74	-0.63	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
LIHC	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	14.94	3.39e-39	6.39e-35	0.8	0.63	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	14.94	3.39e-39	6.39e-35	0.8	0.63	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
LIHC	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	14.94	3.48e-39	6.55e-35	0.73	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
LIHC	cis	rs2260433	0.693	rs10895329	ENSG00000281655.1	RP11-817J15.3	14.93	3.54e-39	6.64e-35	0.95	0.63	Cleft palate;	chr11:102638497	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.693	rs10895330	ENSG00000281655.1	RP11-817J15.3	14.93	3.54e-39	6.64e-35	0.95	0.63	Cleft palate;	chr11:102638544	chr11:102681310~102683913:+
LIHC	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-14.93	3.82e-39	7.16e-35	-1.11	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	14.9	4.66e-39	8.71e-35	1.1	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	14.89	5.07e-39	9.43e-35	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	14.89	5.07e-39	9.43e-35	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
LIHC	cis	rs2260433	0.693	rs12363883	ENSG00000281655.1	RP11-817J15.3	14.88	5.61e-39	1.04e-34	0.94	0.63	Cleft palate;	chr11:102638621	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.693	rs12363884	ENSG00000281655.1	RP11-817J15.3	14.88	5.61e-39	1.04e-34	0.94	0.63	Cleft palate;	chr11:102638629	chr11:102681310~102683913:+
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	14.87	6.19e-39	1.14e-34	0.67	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
LIHC	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	14.86	7.12e-39	1.31e-34	0.73	0.63	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
LIHC	cis	rs5758659	0.714	rs5758578	ENSG00000237037.8	NDUFA6-AS1	-14.84	8e-39	1.46e-34	-0.72	-0.63	Cognitive function;	chr22:42094288	chr22:42090931~42137742:+
LIHC	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	14.83	8.72e-39	1.59e-34	0.74	0.63	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	14.83	8.89e-39	1.62e-34	0.79	0.63	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
LIHC	cis	rs5769707	0.967	rs8141807	ENSG00000188511.11	C22orf34	14.83	8.96e-39	1.63e-34	0.73	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49414524~49657542:-
LIHC	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-14.82	9.54e-39	1.73e-34	-1.1	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	14.82	1.03e-38	1.87e-34	0.91	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	14.82	1.03e-38	1.87e-34	1.11	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
LIHC	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	14.81	1.12e-38	2.03e-34	0.71	0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
LIHC	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-14.8	1.14e-38	2.07e-34	-0.71	-0.62	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
LIHC	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	14.8	1.19e-38	2.15e-34	0.74	0.62	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	14.8	1.19e-38	2.15e-34	0.65	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
LIHC	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	14.79	1.34e-38	2.41e-34	0.71	0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
LIHC	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	14.79	1.35e-38	2.43e-34	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	14.78	1.4e-38	2.53e-34	0.65	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
LIHC	cis	rs2260433	0.693	rs11225351	ENSG00000281655.1	RP11-817J15.3	-14.78	1.42e-38	2.54e-34	-0.93	-0.62	Cleft palate;	chr11:102637740	chr11:102681310~102683913:+
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	14.78	1.43e-38	2.57e-34	0.65	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
LIHC	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-14.78	1.44e-38	2.57e-34	-1.15	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
LIHC	cis	rs2260433	0.693	rs11225352	ENSG00000281655.1	RP11-817J15.3	14.78	1.47e-38	2.63e-34	0.94	0.62	Cleft palate;	chr11:102637990	chr11:102681310~102683913:+
LIHC	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-14.77	1.6e-38	2.87e-34	-0.7	-0.62	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-14.77	1.63e-38	2.91e-34	-0.73	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-14.76	1.67e-38	2.99e-34	-0.83	-0.62	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
LIHC	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-14.76	1.72e-38	3.04e-34	-0.77	-0.62	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-14.76	1.72e-38	3.04e-34	-0.77	-0.62	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-14.76	1.72e-38	3.04e-34	-0.77	-0.62	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	14.76	1.72e-38	3.04e-34	0.77	0.62	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
LIHC	cis	rs2260433	0.693	rs11225350	ENSG00000281655.1	RP11-817J15.3	14.76	1.75e-38	3.09e-34	0.94	0.62	Cleft palate;	chr11:102637649	chr11:102681310~102683913:+
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-14.74	2.11e-38	3.71e-34	-0.83	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
LIHC	cis	rs5769707	0.967	rs9616713	ENSG00000188511.11	C22orf34	14.72	2.45e-38	4.29e-34	0.73	0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49414524~49657542:-
LIHC	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-14.72	2.56e-38	4.49e-34	-0.77	-0.62	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	14.71	2.6e-38	4.54e-34	0.79	0.62	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-14.71	2.65e-38	4.62e-34	-0.77	-0.62	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-14.71	2.65e-38	4.62e-34	-0.77	-0.62	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	14.71	2.65e-38	4.62e-34	0.77	0.62	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	14.71	2.65e-38	4.62e-34	0.77	0.62	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	14.71	2.65e-38	4.62e-34	0.77	0.62	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	14.71	2.72e-38	4.73e-34	1.11	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
LIHC	cis	rs5758659	0.714	rs5758589	ENSG00000237037.8	NDUFA6-AS1	-14.7	2.85e-38	4.92e-34	-0.72	-0.62	Cognitive function;	chr22:42122378	chr22:42090931~42137742:+
LIHC	cis	rs5769707	0.935	rs9616332	ENSG00000188511.11	C22orf34	14.7	3.03e-38	5.22e-34	0.72	0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49414524~49657542:-
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-14.69	3.13e-38	5.37e-34	-0.65	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
LIHC	cis	rs5758659	0.714	rs133376	ENSG00000237037.8	NDUFA6-AS1	14.66	4.41e-38	7.52e-34	0.73	0.62	Cognitive function;	chr22:42070901	chr22:42090931~42137742:+
LIHC	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	14.65	4.44e-38	7.57e-34	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	14.65	4.44e-38	7.57e-34	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	14.65	4.71e-38	8e-34	0.78	0.62	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	14.65	4.71e-38	8e-34	0.78	0.62	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-14.63	5.5e-38	9.31e-34	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	14.61	6.66e-38	1.12e-33	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-14.6	7.54e-38	1.27e-33	-1.1	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	14.59	7.66e-38	1.28e-33	0.8	0.62	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
LIHC	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	14.59	7.93e-38	1.33e-33	0.84	0.62	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
LIHC	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	14.58	8.39e-38	1.4e-33	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	14.58	9.03e-38	1.5e-33	0.77	0.62	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	14.58	9.03e-38	1.5e-33	0.77	0.62	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
LIHC	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	14.57	9.74e-38	1.61e-33	1.16	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
LIHC	cis	rs5758659	0.714	rs5751216	ENSG00000237037.8	NDUFA6-AS1	-14.57	9.88e-38	1.63e-33	-0.72	-0.62	Cognitive function;	chr22:42112933	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-14.56	1.04e-37	1.72e-33	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-14.56	1.04e-37	1.72e-33	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	14.54	1.24e-37	2.03e-33	0.79	0.62	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	14.54	1.3e-37	2.13e-33	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	14.53	1.34e-37	2.19e-33	0.77	0.62	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	14.52	1.57e-37	2.56e-33	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	14.51	1.64e-37	2.67e-33	0.79	0.62	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	14.51	1.67e-37	2.72e-33	0.77	0.62	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000272787.1	KB-226F1.2	14.51	1.7e-37	2.77e-33	0.79	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	14.5	1.72e-37	2.81e-33	0.94	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	14.5	1.87e-37	3.04e-33	0.83	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	14.49	1.89e-37	3.07e-33	0.65	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	14.49	1.9e-37	3.09e-33	0.65	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
LIHC	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	14.49	1.93e-37	3.13e-33	0.73	0.62	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
LIHC	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	14.48	2.23e-37	3.61e-33	0.77	0.62	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	14.47	2.36e-37	3.81e-33	0.77	0.62	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	14.46	2.64e-37	4.25e-33	0.77	0.62	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	14.45	2.72e-37	4.38e-33	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-14.45	2.72e-37	4.38e-33	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
LIHC	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-14.45	2.79e-37	4.49e-33	-1.09	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
LIHC	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	14.44	3.01e-37	4.82e-33	0.79	0.62	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	14.44	3.01e-37	4.82e-33	0.79	0.62	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	14.42	3.86e-37	6.17e-33	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	14.42	3.86e-37	6.17e-33	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	14.41	3.97e-37	6.34e-33	0.79	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
LIHC	cis	rs5758659	0.653	rs133383	ENSG00000237037.8	NDUFA6-AS1	14.41	4.08e-37	6.51e-33	0.73	0.61	Cognitive function;	chr22:42077599	chr22:42090931~42137742:+
LIHC	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	14.41	4.23e-37	6.75e-33	0.79	0.61	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
LIHC	cis	rs5758659	0.714	rs6002607	ENSG00000237037.8	NDUFA6-AS1	-14.38	5.12e-37	8.14e-33	-0.73	-0.61	Cognitive function;	chr22:42100502	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	14.37	5.71e-37	9.07e-33	0.79	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
LIHC	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-14.36	6.12e-37	9.71e-33	-0.78	-0.61	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
LIHC	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	14.36	6.23e-37	9.86e-33	0.73	0.61	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	14.36	6.23e-37	9.86e-33	0.79	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
LIHC	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	14.33	8.18e-37	1.29e-32	0.62	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
LIHC	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	14.33	8.62e-37	1.35e-32	0.76	0.61	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	14.33	8.62e-37	1.35e-32	0.76	0.61	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	14.31	9.85e-37	1.54e-32	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
LIHC	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	14.31	9.98e-37	1.56e-32	0.73	0.61	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
LIHC	cis	rs5758659	0.714	rs5751220	ENSG00000237037.8	NDUFA6-AS1	-14.31	1.01e-36	1.58e-32	-0.73	-0.61	Cognitive function;	chr22:42120201	chr22:42090931~42137742:+
LIHC	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	14.31	1.02e-36	1.59e-32	0.77	0.61	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	14.29	1.17e-36	1.83e-32	0.7	0.61	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	14.29	1.21e-36	1.89e-32	0.76	0.61	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-14.28	1.28e-36	1.99e-32	-0.73	-0.61	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
LIHC	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	14.26	1.54e-36	2.38e-32	0.76	0.61	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-14.26	1.54e-36	2.39e-32	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-14.26	1.61e-36	2.49e-32	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	14.26	1.63e-36	2.51e-32	0.76	0.61	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-14.25	1.67e-36	2.59e-32	-0.72	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
LIHC	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	14.25	1.68e-36	2.6e-32	0.76	0.61	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	14.24	1.79e-36	2.76e-32	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
LIHC	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	14.24	1.81e-36	2.79e-32	0.76	0.61	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	14.24	1.82e-36	2.8e-32	0.71	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
LIHC	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-14.19	2.95e-36	4.46e-32	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-14.19	2.95e-36	4.46e-32	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
LIHC	cis	rs5758659	0.714	rs6002626	ENSG00000237037.8	NDUFA6-AS1	-14.18	3.12e-36	4.71e-32	-0.72	-0.61	Cognitive function;	chr22:42121985	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	14.16	3.84e-36	5.77e-32	0.64	0.61	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-14.15	4.17e-36	6.26e-32	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-14.15	4.17e-36	6.26e-32	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
LIHC	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	14.14	4.46e-36	6.67e-32	0.71	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
LIHC	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	14.14	4.64e-36	6.93e-32	0.73	0.61	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	14.14	4.75e-36	7.08e-32	0.8	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	14.13	4.81e-36	7.17e-32	0.79	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-14.13	5.06e-36	7.53e-32	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-14.12	5.5e-36	8.16e-32	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-14.12	5.71e-36	8.45e-32	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
LIHC	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-14.11	5.96e-36	8.82e-32	-0.75	-0.61	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	14.1	6.41e-36	9.46e-32	0.63	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
LIHC	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	14.1	6.57e-36	9.7e-32	0.69	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
LIHC	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	14.09	6.88e-36	1.01e-31	0.71	0.61	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
LIHC	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	14.09	6.92e-36	1.02e-31	0.71	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000272787.1	KB-226F1.2	-14.09	7.24e-36	1.06e-31	-0.75	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23969211~23969873:+
LIHC	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	14.08	7.92e-36	1.16e-31	0.71	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
LIHC	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	14.07	8.54e-36	1.25e-31	0.72	0.61	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	14.07	8.68e-36	1.27e-31	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	14.07	8.85e-36	1.29e-31	0.64	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
LIHC	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	14.07	8.95e-36	1.3e-31	1.09	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
LIHC	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	14.06	9.13e-36	1.33e-31	0.7	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	14.06	9.21e-36	1.34e-31	0.63	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
LIHC	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	14.06	9.37e-36	1.36e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	14.06	9.37e-36	1.36e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	14.06	9.37e-36	1.36e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	14.06	9.37e-36	1.36e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	14.06	9.37e-36	1.36e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	14.06	9.37e-36	1.36e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	14.06	9.37e-36	1.36e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-14.06	9.66e-36	1.4e-31	-0.66	-0.61	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	14.05	1.01e-35	1.42e-31	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
LIHC	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-14.05	1.03e-35	1.45e-31	-0.75	-0.6	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
LIHC	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	14.04	1.09e-35	1.52e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	14.04	1.11e-35	1.55e-31	0.65	0.6	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-14.03	1.23e-35	1.71e-31	-0.77	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-14.03	1.27e-35	1.75e-31	-0.65	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	14.03	1.27e-35	1.77e-31	0.65	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
LIHC	cis	rs5758659	0.967	rs5758670	ENSG00000237037.8	NDUFA6-AS1	14.03	1.28e-35	1.78e-31	0.7	0.6	Cognitive function;	chr22:42240681	chr22:42090931~42137742:+
LIHC	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	14.01	1.46e-35	2.01e-31	1.11	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	14.01	1.46e-35	2.01e-31	1.11	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-14	1.63e-35	2.24e-31	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	14	1.64e-35	2.25e-31	0.97	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	13.99	1.82e-35	2.49e-31	0.64	0.6	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	13.99	1.82e-35	2.49e-31	0.64	0.6	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	13.99	1.82e-35	2.49e-31	0.64	0.6	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	13.98	1.88e-35	2.56e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	13.98	1.88e-35	2.56e-31	0.64	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
LIHC	cis	rs5758659	0.714	rs7245	ENSG00000237037.8	NDUFA6-AS1	-13.98	1.98e-35	2.69e-31	-0.73	-0.6	Cognitive function;	chr22:42085845	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000272787.1	KB-226F1.2	-13.97	2.14e-35	2.91e-31	-0.77	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23969211~23969873:+
LIHC	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	13.97	2.15e-35	2.92e-31	0.72	0.6	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
LIHC	cis	rs5758659	0.967	rs5751250	ENSG00000237037.8	NDUFA6-AS1	13.97	2.19e-35	2.94e-31	0.7	0.6	Cognitive function;	chr22:42243639	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-13.97	2.19e-35	2.94e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-13.97	2.19e-35	2.94e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-13.97	2.19e-35	2.94e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-13.97	2.19e-35	2.94e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-13.97	2.19e-35	2.94e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-13.97	2.19e-35	2.94e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	13.96	2.4e-35	3.22e-31	0.65	0.6	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
LIHC	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	13.95	2.43e-35	3.26e-31	0.7	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
LIHC	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-13.95	2.46e-35	3.3e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	13.95	2.46e-35	3.3e-31	0.72	0.6	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
LIHC	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	13.95	2.47e-35	3.31e-31	0.69	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	13.95	2.47e-35	3.31e-31	0.69	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	13.94	2.73e-35	3.65e-31	0.7	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
LIHC	cis	rs5758659	1	rs5758677	ENSG00000237037.8	NDUFA6-AS1	13.94	2.8e-35	3.74e-31	0.7	0.6	Cognitive function;	chr22:42247033	chr22:42090931~42137742:+
LIHC	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	13.93	3.08e-35	4.09e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	13.93	3.08e-35	4.09e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	13.93	3.08e-35	4.09e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
LIHC	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	13.93	3.08e-35	4.09e-31	0.71	0.6	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	13.93	3.08e-35	4.09e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	13.93	3.08e-35	4.09e-31	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	13.93	3.14e-35	4.17e-31	1.1	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	13.92	3.18e-35	4.22e-31	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-13.91	3.63e-35	4.79e-31	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
LIHC	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	13.91	3.68e-35	4.85e-31	1.08	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
LIHC	cis	rs5769707	0.749	rs7286706	ENSG00000188511.11	C22orf34	13.91	3.73e-35	4.92e-31	0.71	0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49414524~49657542:-
LIHC	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	13.9	3.76e-35	4.96e-31	0.69	0.6	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	13.9	3.78e-35	4.98e-31	0.98	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	13.9	3.83e-35	5.04e-31	0.97	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	13.9	3.88e-35	5.11e-31	0.72	0.6	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	13.9	3.92e-35	5.16e-31	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	13.9	4e-35	5.26e-31	0.63	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
LIHC	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	13.89	4.13e-35	5.42e-31	0.72	0.6	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
LIHC	cis	rs5758659	1	rs134873	ENSG00000237037.8	NDUFA6-AS1	13.88	4.64e-35	6.08e-31	0.69	0.6	Cognitive function;	chr22:42261560	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	13.88	4.69e-35	6.13e-31	0.79	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
LIHC	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	13.88	4.86e-35	6.35e-31	0.72	0.6	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	13.88	4.89e-35	6.38e-31	0.98	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
LIHC	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	13.87	5.07e-35	6.59e-31	0.77	0.6	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-13.87	5.08e-35	6.6e-31	-0.81	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-13.87	5.29e-35	6.86e-31	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	13.86	5.72e-35	7.39e-31	0.73	0.6	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	13.84	6.71e-35	8.63e-31	0.98	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	13.84	6.78e-35	8.71e-31	0.72	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
LIHC	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	13.84	6.88e-35	8.84e-31	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	13.83	7.13e-35	9.14e-31	0.78	0.6	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	13.83	7.37e-35	9.44e-31	0.72	0.6	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-13.83	7.44e-35	9.52e-31	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	13.82	7.72e-35	9.87e-31	0.97	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
LIHC	cis	rs5758659	1	rs5758660	ENSG00000237037.8	NDUFA6-AS1	13.82	7.8e-35	9.96e-31	0.7	0.6	Cognitive function;	chr22:42227712	chr22:42090931~42137742:+
LIHC	cis	rs5758659	1	rs134869	ENSG00000237037.8	NDUFA6-AS1	13.82	8.19e-35	1.05e-30	0.69	0.6	Cognitive function;	chr22:42256068	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-13.82	8.28e-35	1.06e-30	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
LIHC	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-13.81	8.51e-35	1.08e-30	-1.05	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	13.81	8.58e-35	1.09e-30	0.62	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
LIHC	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	13.81	8.67e-35	1.1e-30	0.77	0.6	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	13.8	9.44e-35	1.2e-30	0.77	0.6	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	13.8	9.78e-35	1.24e-30	0.63	0.6	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-13.8	9.83e-35	1.25e-30	-0.63	-0.6	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-13.79	1.02e-34	1.29e-30	-0.63	-0.6	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	13.79	1.03e-34	1.31e-30	0.71	0.6	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-13.79	1.06e-34	1.34e-30	-0.66	-0.6	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	13.78	1.1e-34	1.38e-30	0.71	0.6	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	13.78	1.11e-34	1.39e-30	0.63	0.6	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	13.78	1.11e-34	1.39e-30	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	13.78	1.11e-34	1.39e-30	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	13.78	1.11e-34	1.39e-30	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
LIHC	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	13.78	1.15e-34	1.43e-30	0.71	0.6	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
LIHC	cis	rs5758659	0.904	rs5758653	ENSG00000237037.8	NDUFA6-AS1	13.78	1.15e-34	1.43e-30	0.7	0.6	Cognitive function;	chr22:42217479	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	13.78	1.15e-34	1.43e-30	0.64	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
LIHC	cis	rs5758659	0.935	rs134879	ENSG00000237037.8	NDUFA6-AS1	13.78	1.17e-34	1.45e-30	0.69	0.6	Cognitive function;	chr22:42268195	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-13.78	1.17e-34	1.45e-30	-0.63	-0.6	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-13.78	1.17e-34	1.45e-30	-0.63	-0.6	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-13.77	1.2e-34	1.49e-30	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	13.77	1.24e-34	1.53e-30	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-13.77	1.26e-34	1.56e-30	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	13.77	1.28e-34	1.58e-30	0.71	0.6	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
LIHC	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	13.77	1.29e-34	1.59e-30	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-13.76	1.32e-34	1.63e-30	-0.77	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-13.76	1.35e-34	1.66e-30	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	13.76	1.37e-34	1.69e-30	0.64	0.6	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	13.76	1.42e-34	1.74e-30	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-13.75	1.44e-34	1.77e-30	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	13.75	1.53e-34	1.87e-30	0.71	0.6	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
LIHC	cis	rs5758659	0.904	rs134877	ENSG00000237037.8	NDUFA6-AS1	13.75	1.54e-34	1.88e-30	0.69	0.6	Cognitive function;	chr22:42266365	chr22:42090931~42137742:+
LIHC	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	13.75	1.55e-34	1.9e-30	1.09	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	13.74	1.65e-34	2.01e-30	0.63	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	13.73	1.8e-34	2.19e-30	0.63	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
LIHC	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	13.73	1.82e-34	2.21e-30	0.7	0.6	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	13.73	1.85e-34	2.24e-30	0.62	0.6	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	13.72	1.92e-34	2.32e-30	0.98	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
LIHC	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	13.71	2.06e-34	2.48e-30	0.71	0.6	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	13.71	2.06e-34	2.48e-30	0.71	0.6	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	13.71	2.06e-34	2.48e-30	0.71	0.6	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	13.71	2.06e-34	2.48e-30	0.71	0.6	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	13.71	2.06e-34	2.48e-30	0.71	0.6	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	13.71	2.14e-34	2.58e-30	0.98	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-13.71	2.16e-34	2.61e-30	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
LIHC	cis	rs5758659	1	rs5758659	ENSG00000237037.8	NDUFA6-AS1	13.71	2.18e-34	2.62e-30	0.7	0.6	Cognitive function;	chr22:42225997	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-13.71	2.21e-34	2.66e-30	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-13.7	2.24e-34	2.69e-30	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	13.7	2.28e-34	2.74e-30	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-13.7	2.31e-34	2.78e-30	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
LIHC	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	13.7	2.41e-34	2.89e-30	0.76	0.6	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
LIHC	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-13.69	2.47e-34	2.96e-30	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	13.69	2.5e-34	3e-30	0.79	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
LIHC	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-13.69	2.55e-34	3.05e-30	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-13.69	2.55e-34	3.05e-30	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
LIHC	cis	rs5769707	0.777	rs739243	ENSG00000188511.11	C22orf34	13.69	2.55e-34	3.05e-30	0.69	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49414524~49657542:-
LIHC	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	13.69	2.59e-34	3.1e-30	0.69	0.59	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
LIHC	cis	rs5758659	0.845	rs5758645	ENSG00000237037.8	NDUFA6-AS1	13.69	2.63e-34	3.15e-30	0.71	0.59	Cognitive function;	chr22:42202945	chr22:42090931~42137742:+
LIHC	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	13.69	2.66e-34	3.17e-30	0.71	0.59	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
LIHC	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	13.68	2.67e-34	3.19e-30	0.69	0.59	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	13.68	2.68e-34	3.2e-30	0.77	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
LIHC	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	13.68	2.73e-34	3.26e-30	0.71	0.59	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
LIHC	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	13.68	2.77e-34	3.3e-30	0.76	0.59	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	13.68	2.77e-34	3.3e-30	0.76	0.59	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
LIHC	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	13.68	2.83e-34	3.37e-30	0.78	0.59	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
LIHC	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	13.68	2.91e-34	3.45e-30	0.76	0.59	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	13.68	2.91e-34	3.45e-30	0.76	0.59	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	13.68	2.91e-34	3.45e-30	0.76	0.59	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	13.68	2.91e-34	3.45e-30	0.76	0.59	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	13.68	2.91e-34	3.45e-30	0.76	0.59	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
LIHC	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	13.67	2.94e-34	3.48e-30	0.78	0.59	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
LIHC	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	13.67	3.04e-34	3.6e-30	0.97	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
LIHC	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-13.67	3.05e-34	3.61e-30	-0.75	-0.59	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
LIHC	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-13.66	3.23e-34	3.79e-30	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-13.66	3.23e-34	3.79e-30	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-13.66	3.23e-34	3.79e-30	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-13.66	3.23e-34	3.79e-30	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-13.66	3.23e-34	3.79e-30	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-13.66	3.23e-34	3.79e-30	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	13.65	3.63e-34	4.26e-30	0.97	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	13.65	3.63e-34	4.26e-30	0.97	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	13.65	3.68e-34	4.31e-30	0.64	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
LIHC	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	13.65	3.8e-34	4.45e-30	0.79	0.59	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-13.63	4.18e-34	4.88e-30	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	13.63	4.22e-34	4.92e-30	0.98	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	13.63	4.35e-34	5.07e-30	0.99	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	13.63	4.39e-34	5.11e-30	0.63	0.59	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-13.63	4.44e-34	5.17e-30	-0.64	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000272787.1	KB-226F1.2	-13.63	4.5e-34	5.23e-30	-0.76	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23969211~23969873:+
LIHC	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	13.61	5.1e-34	5.91e-30	0.63	0.59	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	13.61	5.16e-34	5.98e-30	0.95	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-13.59	6.04e-34	6.99e-30	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	13.59	6.04e-34	6.99e-30	0.69	0.59	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-13.58	7.08e-34	8.16e-30	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	13.56	7.87e-34	9.07e-30	0.64	0.59	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	13.56	8.36e-34	9.62e-30	0.96	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
LIHC	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-13.55	8.6e-34	9.89e-30	-0.72	-0.59	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000272787.1	KB-226F1.2	-13.55	9e-34	1.04e-29	-0.75	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23969211~23969873:+
LIHC	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	13.55	9.07e-34	1.04e-29	0.63	0.59	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
LIHC	cis	rs5758659	1	rs5751255	ENSG00000237037.8	NDUFA6-AS1	13.53	1.03e-33	1.18e-29	0.69	0.59	Cognitive function;	chr22:42252402	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000272787.1	KB-226F1.2	-13.53	1.08e-33	1.24e-29	-0.76	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23969211~23969873:+
LIHC	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	13.51	1.22e-33	1.4e-29	0.97	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	13.51	1.25e-33	1.43e-29	0.64	0.59	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	13.5	1.41e-33	1.61e-29	0.78	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
LIHC	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	13.49	1.5e-33	1.71e-29	0.96	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000272787.1	KB-226F1.2	-13.49	1.51e-33	1.72e-29	-0.77	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23969211~23969873:+
LIHC	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-13.49	1.52e-33	1.73e-29	-0.63	-0.59	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	13.49	1.56e-33	1.77e-29	0.64	0.59	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	13.48	1.64e-33	1.86e-29	0.64	0.59	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	13.47	1.73e-33	1.95e-29	0.63	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
LIHC	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-13.47	1.83e-33	2.05e-29	-0.78	-0.59	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-13.47	1.84e-33	2.06e-29	-0.75	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
LIHC	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-13.47	1.86e-33	2.08e-29	-0.73	-0.59	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
LIHC	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-13.47	1.88e-33	2.1e-29	-0.63	-0.59	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	13.45	2.1e-33	2.35e-29	0.62	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
LIHC	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-13.44	2.24e-33	2.5e-29	-0.74	-0.59	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
LIHC	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-13.44	2.35e-33	2.62e-29	-0.74	-0.59	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	13.43	2.64e-33	2.93e-29	0.62	0.59	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-13.42	2.75e-33	3.04e-29	-0.65	-0.59	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
LIHC	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	13.42	2.83e-33	3.14e-29	0.75	0.59	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
LIHC	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-13.42	2.89e-33	3.2e-29	-0.74	-0.59	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
LIHC	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-13.4	3.31e-33	3.62e-29	-0.64	-0.59	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-13.38	3.83e-33	4.16e-29	-0.95	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-13.37	4.32e-33	4.68e-29	-0.63	-0.59	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-13.37	4.35e-33	4.7e-29	-0.68	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	13.34	5.76e-33	6.2e-29	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
LIHC	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-13.33	6.33e-33	6.8e-29	-0.77	-0.58	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
LIHC	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	13.32	6.82e-33	7.31e-29	0.74	0.58	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-13.32	7.06e-33	7.56e-29	-0.6	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
LIHC	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-13.31	7.41e-33	7.92e-29	-0.74	-0.58	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-13.31	7.41e-33	7.92e-29	-0.74	-0.58	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
LIHC	cis	rs5758659	1	rs134882	ENSG00000237037.8	NDUFA6-AS1	13.3	7.72e-33	8.22e-29	0.68	0.58	Cognitive function;	chr22:42274959	chr22:42090931~42137742:+
LIHC	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-13.3	8.16e-33	8.68e-29	-0.67	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
LIHC	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	13.3	8.27e-33	8.79e-29	0.64	0.58	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-13.28	9.61e-33	1.01e-28	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-13.28	9.61e-33	1.01e-28	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-13.28	9.61e-33	1.01e-28	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	13.28	9.9e-33	1.04e-28	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	13.28	9.97e-33	1.05e-28	0.77	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
LIHC	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	13.27	1.09e-32	1.15e-28	0.96	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
LIHC	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-13.26	1.13e-32	1.19e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-13.26	1.19e-32	1.25e-28	-0.64	-0.58	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
LIHC	cis	rs2260433	0.556	rs11606477	ENSG00000281655.1	RP11-817J15.3	-13.25	1.24e-32	1.29e-28	-0.89	-0.58	Cleft palate;	chr11:102633548	chr11:102681310~102683913:+
LIHC	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	13.25	1.25e-32	1.3e-28	0.76	0.58	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
LIHC	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-13.25	1.27e-32	1.32e-28	-0.64	-0.58	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	13.22	1.61e-32	1.67e-28	0.62	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
LIHC	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	13.22	1.67e-32	1.73e-28	0.97	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
LIHC	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-13.22	1.67e-32	1.73e-28	-0.85	-0.58	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
LIHC	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	13.21	1.71e-32	1.77e-28	0.7	0.58	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	13.21	1.71e-32	1.77e-28	0.7	0.58	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
LIHC	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-13.2	2.01e-32	2.07e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-13.2	2.01e-32	2.07e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-13.2	2.01e-32	2.07e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	13.19	2.04e-32	2.1e-28	0.69	0.58	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
LIHC	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	13.19	2.06e-32	2.13e-28	0.67	0.58	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
LIHC	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-13.19	2.16e-32	2.23e-28	-0.64	-0.58	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-13.19	2.2e-32	2.26e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-13.19	2.2e-32	2.26e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
LIHC	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-13.18	2.23e-32	2.3e-28	-0.86	-0.58	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
LIHC	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-13.18	2.36e-32	2.42e-28	-0.76	-0.58	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
LIHC	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-13.17	2.58e-32	2.65e-28	-0.86	-0.58	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
LIHC	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	13.17	2.59e-32	2.66e-28	0.73	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
LIHC	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	13.15	2.91e-32	2.97e-28	0.62	0.58	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	13.15	3e-32	3.06e-28	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
LIHC	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	13.15	3.02e-32	3.08e-28	0.68	0.58	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-13.15	3.15e-32	3.21e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-13.15	3.15e-32	3.21e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	13.14	3.32e-32	3.38e-28	0.62	0.58	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	13.14	3.38e-32	3.44e-28	0.8	0.58	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
LIHC	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-13.14	3.39e-32	3.44e-28	-0.64	-0.58	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
LIHC	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-13.14	3.39e-32	3.44e-28	-0.64	-0.58	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
LIHC	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-13.13	3.69e-32	3.73e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-13.13	3.69e-32	3.73e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-13.12	4.03e-32	4.03e-28	-0.64	-0.58	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
LIHC	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-13.12	4.03e-32	4.03e-28	-0.64	-0.58	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
LIHC	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-13.11	4.2e-32	4.19e-28	-0.7	-0.58	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
LIHC	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	13.1	4.76e-32	4.73e-28	0.72	0.58	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
LIHC	cis	rs2260433	0.556	rs11225348	ENSG00000281655.1	RP11-817J15.3	13.1	4.79e-32	4.75e-28	0.89	0.58	Cleft palate;	chr11:102633740	chr11:102681310~102683913:+
LIHC	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-13.09	4.94e-32	4.89e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
LIHC	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	13.09	4.96e-32	4.92e-28	0.72	0.58	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	13.06	6.39e-32	6.29e-28	0.78	0.58	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-13.05	7.17e-32	7.02e-28	-0.75	-0.58	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-13.04	7.88e-32	7.66e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-13.04	7.88e-32	7.66e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-13.04	7.88e-32	7.66e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-13.04	7.88e-32	7.66e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-13.04	7.88e-32	7.66e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-13.04	7.88e-32	7.66e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	13.03	8.44e-32	8.19e-28	0.66	0.58	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-13.03	9.02e-32	8.74e-28	-0.66	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-13.02	9.09e-32	8.8e-28	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
LIHC	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	13.02	9.78e-32	9.41e-28	0.7	0.58	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	13.02	9.83e-32	9.41e-28	0.69	0.58	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	13.02	9.83e-32	9.41e-28	0.69	0.58	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	13.01	9.94e-32	9.51e-28	0.69	0.58	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	13.01	1.04e-31	9.98e-28	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
LIHC	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-13	1.17e-31	1.11e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	12.99	1.23e-31	1.17e-27	0.69	0.57	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
LIHC	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-12.99	1.24e-31	1.18e-27	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	12.97	1.47e-31	1.39e-27	0.77	0.57	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	12.96	1.57e-31	1.49e-27	0.6	0.57	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-12.95	1.76e-31	1.65e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	12.94	1.85e-31	1.74e-27	0.75	0.57	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
LIHC	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	12.94	1.87e-31	1.75e-27	0.72	0.57	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	12.94	1.87e-31	1.75e-27	0.72	0.57	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	12.94	1.87e-31	1.75e-27	0.72	0.57	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
LIHC	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-12.94	1.89e-31	1.78e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-12.92	2.27e-31	2.12e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	12.92	2.3e-31	2.14e-27	0.74	0.57	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-12.92	2.32e-31	2.16e-27	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
LIHC	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	12.91	2.38e-31	2.22e-27	0.75	0.57	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
LIHC	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-12.91	2.51e-31	2.33e-27	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000272787.1	KB-226F1.2	-12.9	2.78e-31	2.57e-27	-0.73	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23969211~23969873:+
LIHC	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-12.9	2.78e-31	2.58e-27	-0.64	-0.57	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
LIHC	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	12.9	2.8e-31	2.6e-27	0.72	0.57	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
LIHC	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-12.87	3.39e-31	3.11e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-12.87	3.39e-31	3.11e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-12.87	3.39e-31	3.11e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
LIHC	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	12.87	3.39e-31	3.11e-27	0.86	0.57	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	12.87	3.39e-31	3.11e-27	0.86	0.57	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	12.87	3.53e-31	3.22e-27	0.86	0.57	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
LIHC	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-12.85	4.07e-31	3.7e-27	-0.63	-0.57	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
LIHC	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	12.85	4.17e-31	3.78e-27	0.73	0.57	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
LIHC	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	12.85	4.2e-31	3.81e-27	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
LIHC	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-12.85	4.27e-31	3.87e-27	-0.71	-0.57	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
LIHC	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	12.84	4.73e-31	4.27e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	12.84	4.73e-31	4.27e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	12.84	4.73e-31	4.27e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
LIHC	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	12.83	5.04e-31	4.54e-27	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	12.83	5.04e-31	4.54e-27	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	12.83	5.04e-31	4.54e-27	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	12.83	5.04e-31	4.54e-27	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	12.83	5.04e-31	4.54e-27	0.76	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
LIHC	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	12.82	5.34e-31	4.81e-27	0.72	0.57	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
LIHC	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	12.82	5.4e-31	4.86e-27	0.69	0.57	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	12.82	5.4e-31	4.86e-27	0.69	0.57	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-12.82	5.56e-31	5e-27	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	12.81	6.03e-31	5.41e-27	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
LIHC	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	12.8	6.2e-31	5.56e-27	0.85	0.57	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
LIHC	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-12.8	6.29e-31	5.64e-27	-0.62	-0.57	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	12.8	6.62e-31	5.93e-27	0.69	0.57	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
LIHC	cis	rs916888	0.821	rs199499	ENSG00000214401.4	KANSL1-AS1	12.79	6.83e-31	6.11e-27	1.23	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46193576~46196723:+
LIHC	cis	rs2260433	0.556	rs61893868	ENSG00000281655.1	RP11-817J15.3	12.79	7.3e-31	6.52e-27	0.87	0.57	Cleft palate;	chr11:102633068	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.556	rs61893869	ENSG00000281655.1	RP11-817J15.3	12.79	7.3e-31	6.52e-27	0.87	0.57	Cleft palate;	chr11:102633373	chr11:102681310~102683913:+
LIHC	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	12.78	7.74e-31	6.89e-27	0.84	0.57	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	12.78	7.74e-31	6.89e-27	0.84	0.57	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	12.78	7.74e-31	6.89e-27	0.84	0.57	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	12.78	7.74e-31	6.89e-27	0.84	0.57	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
LIHC	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	12.78	7.89e-31	7.01e-27	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	12.78	7.89e-31	7.01e-27	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
LIHC	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	12.78	7.93e-31	7.03e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	12.78	7.93e-31	7.03e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	12.78	7.93e-31	7.03e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	12.78	7.93e-31	7.03e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	12.78	7.93e-31	7.03e-27	0.87	0.57	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
LIHC	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	12.77	8.46e-31	7.5e-27	0.75	0.57	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
LIHC	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	12.76	9.25e-31	8.19e-27	0.71	0.57	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
LIHC	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	12.75	1e-30	8.86e-27	0.65	0.57	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
LIHC	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	12.74	1.08e-30	9.51e-27	0.61	0.57	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	12.74	1.08e-30	9.53e-27	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
LIHC	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-12.73	1.2e-30	1.06e-26	-0.71	-0.57	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	12.72	1.29e-30	1.14e-26	0.72	0.57	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	12.72	1.29e-30	1.14e-26	0.72	0.57	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	12.72	1.29e-30	1.14e-26	0.72	0.57	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	12.72	1.29e-30	1.14e-26	0.72	0.57	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
LIHC	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	12.72	1.31e-30	1.15e-26	0.62	0.57	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-12.72	1.35e-30	1.18e-26	-0.62	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
LIHC	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	12.72	1.35e-30	1.18e-26	0.68	0.57	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
LIHC	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	12.71	1.47e-30	1.28e-26	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-12.7	1.56e-30	1.36e-26	-1	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
LIHC	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	12.7	1.56e-30	1.36e-26	0.75	0.57	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	12.7	1.6e-30	1.39e-26	0.74	0.57	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000272787.1	KB-226F1.2	-12.68	1.88e-30	1.63e-26	-0.72	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23969211~23969873:+
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000272787.1	KB-226F1.2	12.67	1.93e-30	1.67e-26	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23969211~23969873:+
LIHC	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	12.66	2.2e-30	1.9e-26	0.71	0.56	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	12.66	2.26e-30	1.95e-26	0.71	0.56	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
LIHC	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	12.65	2.4e-30	2.06e-26	0.65	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
LIHC	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	12.64	2.56e-30	2.19e-26	0.73	0.56	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	12.64	2.56e-30	2.19e-26	0.73	0.56	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	12.64	2.7e-30	2.31e-26	0.75	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
LIHC	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	12.63	2.74e-30	2.34e-26	0.73	0.56	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	12.63	2.74e-30	2.34e-26	0.73	0.56	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
LIHC	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	12.63	2.86e-30	2.44e-26	0.84	0.56	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
LIHC	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-12.62	3.19e-30	2.71e-26	-0.74	-0.56	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
LIHC	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	12.61	3.33e-30	2.82e-26	0.72	0.56	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
LIHC	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	12.59	4.11e-30	3.44e-26	0.74	0.56	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	12.59	4.11e-30	3.44e-26	0.74	0.56	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
LIHC	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-12.58	4.35e-30	3.63e-26	-0.67	-0.56	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
LIHC	cis	rs5758659	0.737	rs10854749	ENSG00000237037.8	NDUFA6-AS1	12.58	4.45e-30	3.71e-26	0.68	0.56	Cognitive function;	chr22:42051337	chr22:42090931~42137742:+
LIHC	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	12.57	4.66e-30	3.88e-26	0.72	0.56	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
LIHC	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	12.56	5.14e-30	4.28e-26	0.67	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	12.56	5.18e-30	4.31e-26	0.74	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
LIHC	cis	rs2739330	0.796	rs1006771	ENSG00000272787.1	KB-226F1.2	-12.54	6.23e-30	5.17e-26	-0.68	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23969211~23969873:+
LIHC	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	12.54	6.37e-30	5.29e-26	0.72	0.56	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
LIHC	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	12.51	7.73e-30	6.39e-26	0.83	0.56	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
LIHC	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	12.51	7.76e-30	6.42e-26	0.75	0.56	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	12.51	8.31e-30	6.85e-26	0.75	0.56	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	12.49	9.1e-30	7.48e-26	0.65	0.56	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	12.49	9.12e-30	7.5e-26	0.75	0.56	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	12.49	9.22e-30	7.57e-26	0.75	0.56	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-12.48	9.94e-30	8.16e-26	-0.67	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
LIHC	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-12.45	1.34e-29	1.09e-25	-0.61	-0.56	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
LIHC	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	12.44	1.47e-29	1.19e-25	0.86	0.56	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	12.43	1.59e-29	1.29e-25	0.68	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
LIHC	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	12.43	1.6e-29	1.3e-25	0.84	0.56	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	12.43	1.6e-29	1.3e-25	0.84	0.56	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
LIHC	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	12.41	1.87e-29	1.51e-25	0.7	0.56	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
LIHC	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	12.41	1.88e-29	1.52e-25	0.84	0.56	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
LIHC	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-12.4	1.98e-29	1.6e-25	-0.62	-0.56	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
LIHC	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	12.4	2.07e-29	1.67e-25	0.7	0.56	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	12.4	2.07e-29	1.67e-25	0.7	0.56	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-12.39	2.19e-29	1.76e-25	-0.68	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
LIHC	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-12.38	2.41e-29	1.93e-25	-0.62	-0.56	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
LIHC	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	12.36	2.8e-29	2.24e-25	0.83	0.56	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
LIHC	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	12.36	3.02e-29	2.41e-25	0.67	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
LIHC	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-12.35	3.14e-29	2.5e-25	-0.62	-0.56	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
LIHC	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-12.35	3.26e-29	2.6e-25	-0.72	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
LIHC	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-12.34	3.41e-29	2.71e-25	-0.72	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
LIHC	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-12.34	3.41e-29	2.71e-25	-0.72	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
LIHC	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-12.34	3.41e-29	2.71e-25	-0.72	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
LIHC	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	12.34	3.42e-29	2.72e-25	0.65	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
LIHC	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	12.34	3.46e-29	2.75e-25	0.83	0.56	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
LIHC	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	12.34	3.49e-29	2.77e-25	0.69	0.56	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
LIHC	cis	rs5758659	1	rs134900	ENSG00000237037.8	NDUFA6-AS1	12.34	3.52e-29	2.8e-25	0.64	0.55	Cognitive function;	chr22:42287337	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	12.33	3.74e-29	2.96e-25	0.74	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
LIHC	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	12.33	3.86e-29	3.06e-25	0.66	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
LIHC	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	12.33	3.89e-29	3.08e-25	0.85	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
LIHC	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	12.32	4.12e-29	3.26e-25	0.71	0.55	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
LIHC	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	12.32	4.14e-29	3.27e-25	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
LIHC	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	12.32	4.26e-29	3.37e-25	0.66	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
LIHC	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	12.3	4.66e-29	3.68e-25	0.7	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
LIHC	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	12.3	4.76e-29	3.75e-25	0.66	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
LIHC	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	12.3	4.89e-29	3.86e-25	0.67	0.55	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-12.29	5.32e-29	4.18e-25	-0.64	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
LIHC	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	12.29	5.34e-29	4.2e-25	0.85	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	12.29	5.34e-29	4.2e-25	0.85	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	12.29	5.34e-29	4.2e-25	0.85	0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
LIHC	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	12.29	5.36e-29	4.21e-25	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
LIHC	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-12.28	5.68e-29	4.45e-25	-0.62	-0.55	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
LIHC	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-12.27	6.46e-29	5.06e-25	-0.62	-0.55	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
LIHC	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	12.27	6.48e-29	5.07e-25	0.65	0.55	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
LIHC	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	12.26	6.69e-29	5.22e-25	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	12.26	6.69e-29	5.22e-25	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
LIHC	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-12.26	6.71e-29	5.24e-25	-0.74	-0.55	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
LIHC	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	12.26	6.81e-29	5.31e-25	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
LIHC	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-12.25	7.43e-29	5.78e-25	-0.72	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
LIHC	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	12.23	9.07e-29	7.04e-25	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	12.22	9.5e-29	7.36e-25	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	12.22	9.5e-29	7.36e-25	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	12.22	9.5e-29	7.36e-25	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	12.22	9.58e-29	7.42e-25	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
LIHC	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	12.22	9.72e-29	7.52e-25	0.65	0.55	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
LIHC	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	12.22	9.78e-29	7.56e-25	0.81	0.55	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
LIHC	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	12.22	9.96e-29	7.7e-25	0.66	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
LIHC	cis	rs5758659	1	rs134902	ENSG00000237037.8	NDUFA6-AS1	12.21	1.02e-28	7.87e-25	0.63	0.55	Cognitive function;	chr22:42287991	chr22:42090931~42137742:+
LIHC	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-12.21	1.03e-28	7.94e-25	-0.74	-0.55	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
LIHC	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	12.21	1.04e-28	8.01e-25	0.7	0.55	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
LIHC	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-12.21	1.08e-28	8.29e-25	-0.7	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
LIHC	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-12.2	1.13e-28	8.68e-25	-0.71	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
LIHC	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-12.2	1.13e-28	8.68e-25	-0.71	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
LIHC	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	12.2	1.18e-28	9.05e-25	0.71	0.55	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
LIHC	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-12.2	1.18e-28	9.08e-25	-0.72	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
LIHC	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	12.19	1.2e-28	9.21e-25	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
LIHC	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	12.19	1.26e-28	9.65e-25	0.66	0.55	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	12.19	1.27e-28	9.75e-25	0.6	0.55	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
LIHC	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	12.19	1.29e-28	9.92e-25	0.66	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
LIHC	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	12.18	1.33e-28	1.01e-24	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	12.18	1.33e-28	1.01e-24	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
LIHC	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-12.15	1.75e-28	1.33e-24	-0.71	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
LIHC	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	12.12	2.25e-28	1.7e-24	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	12.12	2.25e-28	1.7e-24	0.82	0.55	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
LIHC	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	12.11	2.4e-28	1.81e-24	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	12.11	2.51e-28	1.89e-24	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
LIHC	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	12.11	2.55e-28	1.92e-24	0.7	0.55	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
LIHC	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	12.1	2.62e-28	1.96e-24	0.81	0.55	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	12.1	2.62e-28	1.96e-24	0.81	0.55	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
LIHC	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-12.1	2.63e-28	1.97e-24	-0.85	-0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
LIHC	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	12.1	2.7e-28	2.02e-24	0.71	0.55	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
LIHC	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	12.1	2.75e-28	2.05e-24	0.76	0.55	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
LIHC	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	12.1	2.77e-28	2.07e-24	0.66	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
LIHC	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	12.09	2.81e-28	2.1e-24	0.84	0.55	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	12.09	2.81e-28	2.1e-24	0.84	0.55	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	12.09	2.81e-28	2.1e-24	0.84	0.55	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
LIHC	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-12.09	2.89e-28	2.16e-24	-0.71	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
LIHC	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	12.07	3.49e-28	2.6e-24	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
LIHC	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	12.07	3.53e-28	2.61e-24	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	12.07	3.53e-28	2.61e-24	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	12.07	3.53e-28	2.61e-24	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	12.07	3.53e-28	2.61e-24	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	12.07	3.53e-28	2.61e-24	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	12.07	3.53e-28	2.61e-24	0.83	0.55	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
LIHC	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	12.07	3.58e-28	2.65e-24	0.69	0.55	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
LIHC	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	12.06	3.88e-28	2.87e-24	0.65	0.55	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	12.05	4.15e-28	3.06e-24	0.66	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
LIHC	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	12.05	4.27e-28	3.15e-24	0.69	0.55	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
LIHC	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	12.05	4.29e-28	3.16e-24	0.65	0.55	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
LIHC	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-12.04	4.47e-28	3.29e-24	-0.69	-0.55	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
LIHC	cis	rs858239	0.512	rs55788996	ENSG00000230658.1	KLHL7-AS1	12.03	4.81e-28	3.53e-24	0.7	0.55	Cerebrospinal fluid biomarker levels;	chr7:23153230	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-12.03	5.05e-28	3.7e-24	-0.65	-0.55	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	12.02	5.13e-28	3.75e-24	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	12.01	5.82e-28	4.25e-24	0.66	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
LIHC	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	12.01	5.92e-28	4.32e-24	0.72	0.54	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	12.01	6.02e-28	4.38e-24	0.72	0.54	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	12.01	6.02e-28	4.38e-24	0.72	0.54	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
LIHC	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	12	6.04e-28	4.4e-24	0.68	0.54	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
LIHC	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-12	6.13e-28	4.46e-24	-0.66	-0.54	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-12	6.37e-28	4.62e-24	-0.7	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
LIHC	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	11.99	7.12e-28	5.15e-24	0.68	0.54	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
LIHC	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	11.99	7.12e-28	5.15e-24	0.68	0.54	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
LIHC	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-11.97	7.97e-28	5.74e-24	-0.71	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
LIHC	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	11.96	8.73e-28	6.26e-24	0.8	0.54	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
LIHC	cis	rs9828933	0.701	rs7621544	ENSG00000280620.1	SCAANT1	11.96	8.86e-28	6.34e-24	0.75	0.54	Type 2 diabetes;	chr3:63943005	chr3:63911518~63911772:-
LIHC	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	11.96	8.98e-28	6.42e-24	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
LIHC	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	11.96	9.1e-28	6.5e-24	0.65	0.54	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	11.96	9.1e-28	6.5e-24	0.65	0.54	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	11.95	9.25e-28	6.6e-24	0.65	0.54	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-11.95	9.53e-28	6.8e-24	-0.65	-0.54	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-11.95	9.67e-28	6.89e-24	-0.64	-0.54	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
LIHC	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	11.95	9.83e-28	7e-24	0.83	0.54	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
LIHC	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-11.95	1e-27	7.12e-24	-0.64	-0.54	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-11.95	1e-27	7.12e-24	-0.64	-0.54	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-11.95	1e-27	7.12e-24	-0.64	-0.54	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-11.95	1e-27	7.12e-24	-0.64	-0.54	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-11.95	1e-27	7.12e-24	-0.64	-0.54	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-11.95	1e-27	7.12e-24	-0.64	-0.54	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	11.94	1.01e-27	7.14e-24	0.64	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	11.94	1.01e-27	7.14e-24	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
LIHC	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	11.94	1.03e-27	7.3e-24	0.83	0.54	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
LIHC	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	11.94	1.03e-27	7.34e-24	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
LIHC	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-11.94	1.05e-27	7.43e-24	-0.62	-0.54	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
LIHC	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-11.93	1.12e-27	7.91e-24	-0.64	-0.54	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-11.93	1.12e-27	7.91e-24	-0.64	-0.54	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-11.93	1.15e-27	8.05e-24	-0.64	-0.54	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs6004657	ENSG00000100058.11	CRYBB2P1	11.93	1.17e-27	8.19e-24	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25448105~25520854:+
LIHC	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-11.93	1.19e-27	8.31e-24	-0.7	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
LIHC	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-11.92	1.27e-27	8.83e-24	-0.64	-0.54	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-11.92	1.27e-27	8.83e-24	-0.64	-0.54	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	11.92	1.29e-27	8.96e-24	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	11.92	1.29e-27	8.96e-24	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	11.92	1.29e-27	8.96e-24	0.83	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	11.91	1.31e-27	9.12e-24	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	11.91	1.33e-27	9.26e-24	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	11.91	1.33e-27	9.26e-24	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
LIHC	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	11.91	1.33e-27	9.26e-24	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
LIHC	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	11.91	1.37e-27	9.53e-24	0.66	0.54	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
LIHC	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	11.9	1.42e-27	9.87e-24	0.61	0.54	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
LIHC	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-11.9	1.44e-27	1e-23	-0.74	-0.54	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
LIHC	cis	rs2260433	0.867	rs1940477	ENSG00000281655.1	RP11-817J15.3	11.9	1.48e-27	1.03e-23	0.68	0.54	Cleft palate;	chr11:102637049	chr11:102681310~102683913:+
LIHC	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-11.9	1.49e-27	1.03e-23	-0.64	-0.54	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-11.9	1.49e-27	1.03e-23	-0.64	-0.54	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	11.89	1.57e-27	1.09e-23	0.64	0.54	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	11.89	1.57e-27	1.09e-23	0.64	0.54	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	11.89	1.6e-27	1.1e-23	0.64	0.54	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	11.89	1.6e-27	1.1e-23	0.64	0.54	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	11.89	1.6e-27	1.1e-23	0.64	0.54	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-11.89	1.61e-27	1.11e-23	-0.74	-0.54	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
LIHC	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	11.89	1.67e-27	1.14e-23	0.86	0.54	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	11.89	1.67e-27	1.14e-23	0.86	0.54	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
LIHC	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	11.88	1.74e-27	1.19e-23	0.85	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
LIHC	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	11.88	1.75e-27	1.2e-23	0.64	0.54	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	11.87	1.83e-27	1.25e-23	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
LIHC	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	11.87	1.88e-27	1.28e-23	0.71	0.54	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-11.87	1.91e-27	1.31e-23	-0.64	-0.54	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-11.87	1.91e-27	1.31e-23	-0.64	-0.54	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-11.87	1.96e-27	1.33e-23	-0.72	-0.54	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	11.86	2.02e-27	1.38e-23	0.69	0.54	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
LIHC	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-11.86	2.06e-27	1.4e-23	-0.64	-0.54	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-11.86	2.09e-27	1.42e-23	-0.72	-0.54	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-11.86	2.15e-27	1.45e-23	-0.64	-0.54	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
LIHC	cis	rs2260433	0.782	rs7109663	ENSG00000281655.1	RP11-817J15.3	11.85	2.25e-27	1.52e-23	0.66	0.54	Cleft palate;	chr11:102641030	chr11:102681310~102683913:+
LIHC	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	11.85	2.34e-27	1.57e-23	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
LIHC	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-11.84	2.4e-27	1.61e-23	-0.7	-0.54	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
LIHC	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	11.84	2.44e-27	1.63e-23	0.72	0.54	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	11.84	2.44e-27	1.63e-23	0.72	0.54	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-11.84	2.45e-27	1.64e-23	-0.72	-0.54	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-11.84	2.53e-27	1.69e-23	-0.72	-0.54	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-11.84	2.53e-27	1.69e-23	-0.72	-0.54	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-11.84	2.53e-27	1.69e-23	-0.72	-0.54	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-11.84	2.53e-27	1.69e-23	-0.72	-0.54	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-11.83	2.61e-27	1.74e-23	-0.72	-0.54	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
LIHC	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	11.83	2.69e-27	1.79e-23	0.6	0.54	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
LIHC	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-11.83	2.71e-27	1.8e-23	-0.72	-0.54	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-11.83	2.71e-27	1.8e-23	-0.72	-0.54	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	11.81	3.12e-27	2.06e-23	0.72	0.54	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	11.81	3.18e-27	2.1e-23	0.87	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
LIHC	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-11.81	3.28e-27	2.16e-23	-0.72	-0.54	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-11.8	3.42e-27	2.25e-23	-0.71	-0.54	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-11.8	3.47e-27	2.28e-23	-0.72	-0.54	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	11.8	3.54e-27	2.32e-23	0.69	0.54	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-11.79	3.69e-27	2.43e-23	-0.72	-0.54	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	11.79	3.72e-27	2.44e-23	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
LIHC	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-11.79	3.84e-27	2.51e-23	-0.64	-0.54	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
LIHC	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-11.78	3.93e-27	2.57e-23	-0.52	-0.54	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
LIHC	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-11.78	3.93e-27	2.57e-23	-0.52	-0.54	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
LIHC	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-11.78	3.99e-27	2.61e-23	-0.71	-0.54	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-11.77	4.26e-27	2.78e-23	-0.71	-0.54	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-11.77	4.41e-27	2.86e-23	-0.71	-0.54	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-11.77	4.41e-27	2.86e-23	-0.71	-0.54	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-11.77	4.41e-27	2.86e-23	-0.71	-0.54	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-11.77	4.41e-27	2.86e-23	-0.71	-0.54	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	11.77	4.48e-27	2.91e-23	0.85	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
LIHC	cis	rs2260433	0.782	rs7109522	ENSG00000281655.1	RP11-817J15.3	11.76	4.66e-27	3.02e-23	0.66	0.54	Cleft palate;	chr11:102640944	chr11:102681310~102683913:+
LIHC	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	11.76	4.7e-27	3.04e-23	0.75	0.54	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
LIHC	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-11.76	4.72e-27	3.06e-23	-0.52	-0.54	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-11.76	4.72e-27	3.06e-23	-0.52	-0.54	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
LIHC	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	11.76	4.73e-27	3.06e-23	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
LIHC	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-11.76	4.78e-27	3.09e-23	-0.72	-0.54	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-11.76	4.89e-27	3.15e-23	-0.87	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
LIHC	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-11.76	4.89e-27	3.15e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
LIHC	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	11.76	4.99e-27	3.21e-23	0.64	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
LIHC	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	11.75	5.38e-27	3.45e-23	0.64	0.54	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	11.75	5.38e-27	3.45e-23	0.69	0.54	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
LIHC	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	11.74	5.77e-27	3.69e-23	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
LIHC	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	11.74	5.84e-27	3.73e-23	0.59	0.54	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
LIHC	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	11.73	5.97e-27	3.81e-23	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
LIHC	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-11.73	6.06e-27	3.85e-23	-0.71	-0.54	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	11.73	6.16e-27	3.9e-23	0.65	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
LIHC	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-11.73	6.27e-27	3.97e-23	-0.66	-0.54	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
LIHC	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-11.73	6.43e-27	4.06e-23	-0.71	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
LIHC	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-11.73	6.43e-27	4.06e-23	-0.62	-0.54	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
LIHC	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	11.73	6.45e-27	4.06e-23	0.84	0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
LIHC	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	11.72	6.49e-27	4.09e-23	0.69	0.54	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
LIHC	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-11.72	6.65e-27	4.18e-23	-0.65	-0.54	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
LIHC	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	11.71	7.17e-27	4.48e-23	0.59	0.54	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
LIHC	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	11.71	7.17e-27	4.48e-23	0.59	0.54	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
LIHC	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	11.71	7.17e-27	4.48e-23	0.59	0.54	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
LIHC	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-11.71	7.29e-27	4.55e-23	-0.53	-0.53	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
LIHC	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-11.71	7.44e-27	4.64e-23	-0.64	-0.53	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	11.71	7.5e-27	4.68e-23	0.71	0.53	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
LIHC	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-11.7	7.75e-27	4.82e-23	-0.52	-0.53	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
LIHC	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-11.7	7.75e-27	4.82e-23	-0.52	-0.53	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
LIHC	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-11.7	7.75e-27	4.82e-23	-0.52	-0.53	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-11.7	7.75e-27	4.82e-23	-0.52	-0.53	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-11.7	7.75e-27	4.82e-23	-0.52	-0.53	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-11.7	7.75e-27	4.82e-23	-0.52	-0.53	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-11.7	8.01e-27	4.97e-23	-0.52	-0.53	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
LIHC	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	11.69	8.38e-27	5.18e-23	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	11.69	8.38e-27	5.18e-23	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
LIHC	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	11.69	8.64e-27	5.33e-23	0.72	0.53	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	11.69	8.68e-27	5.35e-23	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
LIHC	cis	rs5769707	0.777	rs8141219	ENSG00000188511.11	C22orf34	11.69	8.78e-27	5.41e-23	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49650898	chr22:49414524~49657542:-
LIHC	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	11.68	9.73e-27	5.97e-23	0.77	0.53	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
LIHC	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	11.67	1e-26	6.16e-23	0.65	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
LIHC	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-11.67	1.02e-26	6.25e-23	-0.62	-0.53	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
LIHC	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	11.67	1.02e-26	6.26e-23	0.82	0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
LIHC	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-11.67	1.03e-26	6.3e-23	-0.62	-0.53	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-11.67	1.05e-26	6.38e-23	-0.62	-0.53	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
LIHC	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	11.67	1.05e-26	6.43e-23	0.79	0.53	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
LIHC	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	11.66	1.07e-26	6.51e-23	0.65	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
LIHC	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-11.66	1.1e-26	6.7e-23	-0.52	-0.53	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
LIHC	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-11.65	1.22e-26	7.39e-23	-0.61	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
LIHC	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-11.65	1.25e-26	7.54e-23	-0.55	-0.53	Breast cancer;	chr11:825777	chr11:779617~780755:+
LIHC	cis	rs2260433	0.556	rs61895694	ENSG00000281655.1	RP11-817J15.3	11.64	1.33e-26	8e-23	0.83	0.53	Cleft palate;	chr11:102632269	chr11:102681310~102683913:+
LIHC	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-11.64	1.33e-26	8.01e-23	-0.52	-0.53	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
LIHC	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-11.64	1.35e-26	8.1e-23	-0.64	-0.53	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
LIHC	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	11.63	1.43e-26	8.58e-23	0.63	0.53	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	11.62	1.52e-26	9.06e-23	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
LIHC	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
LIHC	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
LIHC	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-11.62	1.56e-26	9.24e-23	-0.51	-0.53	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-11.62	1.59e-26	9.44e-23	-0.52	-0.53	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
LIHC	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	11.61	1.7e-26	1.01e-22	0.64	0.53	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
LIHC	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-11.61	1.75e-26	1.04e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-11.61	1.75e-26	1.04e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
LIHC	cis	rs2260433	0.744	rs7109815	ENSG00000281655.1	RP11-817J15.3	11.61	1.75e-26	1.04e-22	0.65	0.53	Cleft palate;	chr11:102641173	chr11:102681310~102683913:+
LIHC	cis	rs5769707	0.681	rs739236	ENSG00000188511.11	C22orf34	11.6	1.87e-26	1.1e-22	0.65	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49414524~49657542:-
LIHC	cis	rs17711722	0.583	rs11768292	ENSG00000226824.5	RP4-756H11.3	11.6	1.89e-26	1.11e-22	0.77	0.53	Calcium levels;	chr7:66009814	chr7:66654538~66669855:+
LIHC	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-11.6	1.89e-26	1.11e-22	-0.52	-0.53	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
LIHC	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-11.6	1.89e-26	1.11e-22	-0.52	-0.53	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
LIHC	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-11.6	1.89e-26	1.11e-22	-0.52	-0.53	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
LIHC	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-11.6	1.92e-26	1.13e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
LIHC	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-11.59	1.94e-26	1.14e-22	-0.51	-0.53	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
LIHC	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-11.59	1.94e-26	1.14e-22	-0.51	-0.53	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-11.59	1.94e-26	1.14e-22	-0.51	-0.53	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
LIHC	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-11.59	1.94e-26	1.14e-22	-0.51	-0.53	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-11.59	1.94e-26	1.14e-22	-0.51	-0.53	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-11.59	1.94e-26	1.14e-22	-0.51	-0.53	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000272787.1	KB-226F1.2	11.59	2.03e-26	1.19e-22	0.73	0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23969211~23969873:+
LIHC	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-11.58	2.11e-26	1.23e-22	-0.51	-0.53	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
LIHC	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-11.58	2.16e-26	1.26e-22	-0.87	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
LIHC	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-11.58	2.24e-26	1.3e-22	-0.64	-0.53	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
LIHC	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-11.57	2.28e-26	1.33e-22	-0.88	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
LIHC	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-11.57	2.33e-26	1.34e-22	-0.86	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
LIHC	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-11.57	2.36e-26	1.36e-22	-0.62	-0.53	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-11.57	2.36e-26	1.36e-22	-0.62	-0.53	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-11.57	2.36e-26	1.36e-22	-0.62	-0.53	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-11.57	2.36e-26	1.36e-22	-0.62	-0.53	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-11.57	2.36e-26	1.36e-22	-0.62	-0.53	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
LIHC	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-11.56	2.55e-26	1.47e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-11.55	2.83e-26	1.61e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-11.55	2.83e-26	1.61e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-11.55	2.83e-26	1.61e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-11.55	2.83e-26	1.61e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
LIHC	cis	rs2260433	0.556	rs61895692	ENSG00000281655.1	RP11-817J15.3	11.55	2.87e-26	1.63e-22	0.83	0.53	Cleft palate;	chr11:102632135	chr11:102681310~102683913:+
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	11.54	3.03e-26	1.72e-22	0.65	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
LIHC	cis	rs2260433	0.556	rs61895693	ENSG00000281655.1	RP11-817J15.3	11.54	3.13e-26	1.78e-22	0.83	0.53	Cleft palate;	chr11:102632144	chr11:102681310~102683913:+
LIHC	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-11.53	3.25e-26	1.84e-22	-0.51	-0.53	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
LIHC	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	11.53	3.3e-26	1.87e-22	0.65	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
LIHC	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-11.53	3.35e-26	1.9e-22	-0.63	-0.53	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
LIHC	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-11.53	3.35e-26	1.9e-22	-0.63	-0.53	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
LIHC	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	11.53	3.42e-26	1.93e-22	0.63	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
LIHC	cis	rs2260433	0.867	rs7927404	ENSG00000281655.1	RP11-817J15.3	11.52	3.58e-26	2.02e-22	0.66	0.53	Cleft palate;	chr11:102639459	chr11:102681310~102683913:+
LIHC	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-11.51	3.85e-26	2.17e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-11.51	3.89e-26	2.19e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
LIHC	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-11.5	4.38e-26	2.44e-22	-0.63	-0.53	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
LIHC	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-11.49	4.55e-26	2.52e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
LIHC	cis	rs2260433	0.556	rs78769223	ENSG00000281655.1	RP11-817J15.3	11.49	4.55e-26	2.52e-22	0.82	0.53	Cleft palate;	chr11:102632067	chr11:102681310~102683913:+
LIHC	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	11.49	4.63e-26	2.56e-22	0.79	0.53	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
LIHC	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-11.49	4.69e-26	2.59e-22	-0.63	-0.53	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
LIHC	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-11.49	4.73e-26	2.61e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-11.49	4.79e-26	2.64e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-11.49	4.79e-26	2.64e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-11.49	4.79e-26	2.64e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-11.49	4.79e-26	2.64e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-11.48	4.98e-26	2.74e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-11.48	4.98e-26	2.74e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-11.48	4.98e-26	2.74e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-11.48	4.98e-26	2.74e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-11.48	5.18e-26	2.85e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-11.48	5.18e-26	2.85e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-11.48	5.18e-26	2.85e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
LIHC	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-11.48	5.21e-26	2.86e-22	-0.64	-0.53	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
LIHC	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-11.47	5.55e-26	3.04e-22	-0.65	-0.53	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
LIHC	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-11.47	5.65e-26	3.09e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-11.47	5.65e-26	3.09e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
LIHC	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-11.46	5.74e-26	3.14e-22	-0.63	-0.53	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
LIHC	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	11.46	5.78e-26	3.16e-22	0.58	0.53	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
LIHC	cis	rs5769707	0.681	rs916360	ENSG00000188511.11	C22orf34	11.46	6.08e-26	3.32e-22	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49414524~49657542:-
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000272787.1	KB-226F1.2	11.45	6.23e-26	3.4e-22	0.69	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23969211~23969873:+
LIHC	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-11.45	6.23e-26	3.4e-22	-0.63	-0.53	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
LIHC	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-11.45	6.37e-26	3.48e-22	-0.5	-0.53	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
LIHC	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-11.45	6.55e-26	3.57e-22	-0.87	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
LIHC	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	11.45	6.73e-26	3.66e-22	0.65	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
LIHC	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	11.45	6.73e-26	3.66e-22	0.85	0.53	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	11.45	6.73e-26	3.66e-22	0.85	0.53	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	11.45	6.73e-26	3.66e-22	0.85	0.53	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
LIHC	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	11.45	6.73e-26	3.66e-22	0.85	0.53	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
LIHC	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-11.44	6.85e-26	3.72e-22	-0.51	-0.53	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-11.44	6.98e-26	3.79e-22	-0.52	-0.53	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
LIHC	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	11.44	7.12e-26	3.86e-22	0.58	0.53	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
LIHC	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-11.43	7.37e-26	4e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
LIHC	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-11.43	7.49e-26	4.06e-22	-0.7	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
LIHC	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-11.43	7.55e-26	4.09e-22	-0.81	-0.53	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
LIHC	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-11.43	7.6e-26	4.11e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-11.43	7.6e-26	4.11e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-11.43	7.6e-26	4.11e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-11.43	7.6e-26	4.11e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
LIHC	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	11.43	7.68e-26	4.15e-22	0.61	0.53	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
LIHC	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	11.43	7.82e-26	4.22e-22	0.58	0.53	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
LIHC	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-11.43	7.96e-26	4.3e-22	-0.53	-0.53	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
LIHC	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-11.42	8.3e-26	4.47e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-11.42	8.3e-26	4.47e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-11.42	8.3e-26	4.47e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-11.42	8.3e-26	4.47e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-11.42	8.3e-26	4.47e-22	-0.59	-0.53	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
LIHC	cis	rs5769707	0.681	rs1107514	ENSG00000188511.11	C22orf34	11.42	8.57e-26	4.61e-22	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	11.41	8.7e-26	4.68e-22	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
LIHC	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-11.41	9.06e-26	4.86e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-11.41	9.06e-26	4.86e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-11.41	9.06e-26	4.86e-22	-0.6	-0.53	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
LIHC	cis	rs2260433	0.867	rs11225349	ENSG00000281655.1	RP11-817J15.3	11.41	9.19e-26	4.93e-22	0.66	0.53	Cleft palate;	chr11:102637462	chr11:102681310~102683913:+
LIHC	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-11.41	9.31e-26	4.99e-22	-0.66	-0.52	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
LIHC	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-11.41	9.36e-26	5.01e-22	-0.63	-0.52	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
LIHC	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-11.4	9.57e-26	5.12e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-11.4	9.57e-26	5.12e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-11.4	9.63e-26	5.15e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
LIHC	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	11.4	9.9e-26	5.29e-22	0.82	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
LIHC	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	11.4	1e-25	5.35e-22	0.64	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
LIHC	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-11.4	1.02e-25	5.43e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
LIHC	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	11.39	1.06e-25	5.67e-22	0.62	0.52	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-11.39	1.09e-25	5.78e-22	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
LIHC	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-11.39	1.09e-25	5.78e-22	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
LIHC	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-11.39	1.09e-25	5.78e-22	-0.84	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
LIHC	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-11.38	1.13e-25	5.98e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-11.38	1.13e-25	5.98e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-11.38	1.13e-25	5.98e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-11.38	1.13e-25	5.98e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-11.38	1.13e-25	5.98e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-11.38	1.13e-25	5.98e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-11.38	1.13e-25	5.98e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
LIHC	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	11.38	1.14e-25	6.03e-22	0.65	0.52	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
LIHC	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-11.38	1.15e-25	6.11e-22	-0.62	-0.52	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-11.38	1.17e-25	6.2e-22	-0.62	-0.52	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-11.38	1.17e-25	6.2e-22	-0.62	-0.52	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-11.38	1.18e-25	6.25e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
LIHC	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-11.38	1.19e-25	6.29e-22	-0.62	-0.52	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-11.38	1.19e-25	6.29e-22	-0.62	-0.52	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
LIHC	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	11.37	1.24e-25	6.56e-22	0.69	0.52	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
LIHC	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-11.37	1.24e-25	6.57e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-11.37	1.27e-25	6.71e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-11.37	1.27e-25	6.71e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	11.37	1.3e-25	6.86e-22	0.64	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
LIHC	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.18e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.18e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.18e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.18e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.18e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.18e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.18e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.2e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-11.36	1.37e-25	7.2e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-11.36	1.38e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-11.36	1.38e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-11.36	1.38e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-11.36	1.38e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-11.36	1.38e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-11.36	1.38e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-11.36	1.38e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-11.36	1.39e-25	7.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
LIHC	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-11.36	1.39e-25	7.27e-22	-0.65	-0.52	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
LIHC	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	11.36	1.4e-25	7.31e-22	0.64	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
LIHC	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-11.35	1.53e-25	7.95e-22	-0.7	-0.52	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-11.34	1.59e-25	8.24e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
LIHC	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-11.34	1.66e-25	8.58e-22	-0.63	-0.52	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
LIHC	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-11.33	1.71e-25	8.85e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
LIHC	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-11.33	1.76e-25	9.07e-22	-0.62	-0.52	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
LIHC	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	11.33	1.78e-25	9.15e-22	0.64	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
LIHC	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-11.33	1.78e-25	9.16e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-11.32	1.88e-25	9.63e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-11.32	1.88e-25	9.63e-22	-0.59	-0.52	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-11.32	1.97e-25	1.01e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
LIHC	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-11.31	2e-25	1.02e-21	-0.83	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
LIHC	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-11.31	2.08e-25	1.06e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
LIHC	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	11.31	2.14e-25	1.09e-21	0.63	0.52	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
LIHC	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-11.31	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-11.31	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-11.31	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-11.31	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-11.31	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-11.31	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-11.31	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-11.3	2.16e-25	1.1e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
LIHC	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-11.3	2.19e-25	1.11e-21	-0.85	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
LIHC	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-11.3	2.26e-25	1.14e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-11.3	2.3e-25	1.17e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-11.3	2.3e-25	1.17e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-11.29	2.36e-25	1.19e-21	-0.6	-0.52	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.867	rs13227219	ENSG00000226824.5	RP4-756H11.3	-11.29	2.36e-25	1.2e-21	-0.62	-0.52	Aortic root size;	chr7:66379075	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-11.29	2.42e-25	1.23e-21	-0.62	-0.52	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-11.29	2.46e-25	1.24e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
LIHC	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	11.28	2.58e-25	1.3e-21	0.49	0.52	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
LIHC	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	11.28	2.67e-25	1.35e-21	0.65	0.52	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
LIHC	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-11.28	2.69e-25	1.36e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-11.27	2.82e-25	1.42e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-11.27	2.87e-25	1.44e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-11.27	2.87e-25	1.44e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
LIHC	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-11.27	2.95e-25	1.49e-21	-0.69	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
LIHC	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-11.27	2.95e-25	1.49e-21	-0.69	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
LIHC	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-11.27	3e-25	1.51e-21	-0.62	-0.52	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-11.27	3.01e-25	1.51e-21	-0.62	-0.52	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	11.26	3.03e-25	1.53e-21	0.62	0.52	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	11.26	3.04e-25	1.53e-21	0.62	0.52	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
LIHC	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-11.26	3.06e-25	1.54e-21	-0.6	-0.52	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
LIHC	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-11.26	3.06e-25	1.54e-21	-0.62	-0.52	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-11.26	3.06e-25	1.54e-21	-0.62	-0.52	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-11.26	3.08e-25	1.55e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
LIHC	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-11.26	3.11e-25	1.56e-21	-0.53	-0.52	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
LIHC	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	11.26	3.14e-25	1.58e-21	0.62	0.52	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	11.25	3.37e-25	1.69e-21	0.7	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
LIHC	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-11.25	3.53e-25	1.76e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-11.25	3.53e-25	1.76e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-11.25	3.53e-25	1.76e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-11.25	3.53e-25	1.76e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-11.25	3.53e-25	1.76e-21	-0.62	-0.52	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	11.25	3.55e-25	1.76e-21	0.62	0.52	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-11.24	3.6e-25	1.79e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
LIHC	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-11.24	3.63e-25	1.8e-21	-0.85	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
LIHC	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-11.24	3.79e-25	1.88e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-11.24	3.79e-25	1.88e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
LIHC	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	11.23	3.88e-25	1.92e-21	0.68	0.52	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
LIHC	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	11.23	3.88e-25	1.92e-21	0.68	0.52	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
LIHC	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-11.23	3.93e-25	1.94e-21	-0.53	-0.52	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
LIHC	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	11.23	4.05e-25	2e-21	1	0.52	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
LIHC	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	11.23	4.18e-25	2.06e-21	0.69	0.52	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
LIHC	cis	rs296381	0.641	rs17272617	ENSG00000259108.2	CTD-3098H1.2	-11.22	4.2e-25	2.06e-21	-0.91	-0.52	Blood metabolite levels;	chr19:47854103	chr19:47863483~47865341:-
LIHC	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	11.22	4.34e-25	2.13e-21	0.51	0.52	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
LIHC	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-11.22	4.34e-25	2.14e-21	-0.59	-0.52	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
LIHC	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	11.22	4.51e-25	2.21e-21	0.68	0.52	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
LIHC	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	11.22	4.51e-25	2.21e-21	0.71	0.52	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
LIHC	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	11.21	4.56e-25	2.24e-21	0.98	0.52	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
LIHC	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-11.21	4.61e-25	2.26e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
LIHC	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	11.21	4.61e-25	2.26e-21	0.68	0.52	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
LIHC	cis	rs5758659	0.504	rs133367	ENSG00000237037.8	NDUFA6-AS1	-11.21	4.75e-25	2.32e-21	-0.6	-0.52	Cognitive function;	chr22:42067362	chr22:42090931~42137742:+
LIHC	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-11.21	4.78e-25	2.34e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-11.21	4.88e-25	2.38e-21	-0.62	-0.52	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-11.2	4.97e-25	2.43e-21	-0.62	-0.52	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-11.2	4.97e-25	2.43e-21	-0.62	-0.52	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
LIHC	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	11.2	5.16e-25	2.52e-21	0.49	0.52	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
LIHC	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	11.2	5.16e-25	2.52e-21	0.49	0.52	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
LIHC	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	11.2	5.34e-25	2.6e-21	0.68	0.52	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
LIHC	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	11.19	5.38e-25	2.62e-21	0.69	0.52	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-11.19	5.47e-25	2.66e-21	-0.62	-0.52	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	11.19	5.54e-25	2.69e-21	0.58	0.52	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	11.19	5.65e-25	2.75e-21	0.56	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
LIHC	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	11.19	5.75e-25	2.79e-21	0.98	0.52	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
LIHC	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	11.19	5.75e-25	2.79e-21	0.98	0.52	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
LIHC	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-11.19	5.8e-25	2.82e-21	-0.8	-0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
LIHC	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	11.18	5.87e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	11.18	5.87e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	11.18	5.87e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	11.18	5.89e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	11.18	5.89e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	11.18	5.89e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	11.18	5.89e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	11.18	5.89e-25	2.85e-21	0.62	0.52	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-11.18	5.89e-25	2.85e-21	-0.62	-0.52	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-11.17	6.37e-25	3.07e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-11.17	6.37e-25	3.07e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-11.17	6.49e-25	3.13e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-11.17	6.49e-25	3.13e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-11.17	6.49e-25	3.13e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-11.17	6.49e-25	3.13e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
LIHC	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-11.17	6.52e-25	3.14e-21	-0.63	-0.52	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
LIHC	cis	rs5758659	0.819	rs134871	ENSG00000237037.8	NDUFA6-AS1	11.17	6.55e-25	3.15e-21	0.57	0.52	Cognitive function;	chr22:42256710	chr22:42090931~42137742:+
LIHC	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	11.17	6.68e-25	3.22e-21	0.61	0.52	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	11.17	6.87e-25	3.3e-21	0.62	0.52	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-11.16	6.92e-25	3.32e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-11.16	6.92e-25	3.32e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-11.16	6.92e-25	3.32e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
LIHC	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-11.16	7.1e-25	3.41e-21	-0.64	-0.52	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
LIHC	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	11.16	7.16e-25	3.44e-21	0.5	0.52	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
LIHC	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-11.16	7.26e-25	3.48e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-11.16	7.39e-25	3.54e-21	-0.61	-0.52	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
LIHC	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-11.16	7.39e-25	3.54e-21	-0.63	-0.52	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
LIHC	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	11.16	7.43e-25	3.56e-21	0.63	0.52	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
LIHC	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	11.15	7.63e-25	3.65e-21	0.98	0.52	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
LIHC	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	11.15	7.74e-25	3.7e-21	0.58	0.52	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-11.15	7.82e-25	3.74e-21	-0.7	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
LIHC	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	11.15	8.03e-25	3.84e-21	0.58	0.52	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
LIHC	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	11.14	8.16e-25	3.9e-21	0.82	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
LIHC	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	11.14	8.33e-25	3.98e-21	0.68	0.52	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
LIHC	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-11.14	8.39e-25	4.01e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
LIHC	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	11.14	8.44e-25	4.03e-21	0.66	0.52	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
LIHC	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-11.14	8.54e-25	4.07e-21	-0.62	-0.52	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
LIHC	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-11.13	9.02e-25	4.3e-21	-0.61	-0.52	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	11.13	9.02e-25	4.3e-21	0.61	0.52	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-11.13	9.29e-25	4.42e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-11.13	9.31e-25	4.43e-21	-0.62	-0.52	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	11.13	9.44e-25	4.49e-21	0.8	0.52	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
LIHC	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-11.12	9.59e-25	4.54e-21	-0.62	-0.52	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-11.12	9.62e-25	4.55e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-11.12	9.62e-25	4.55e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
LIHC	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-11.12	9.92e-25	4.69e-21	-0.62	-0.52	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-11.12	1.02e-24	4.82e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-11.12	1.02e-24	4.82e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-11.12	1.02e-24	4.82e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-11.12	1.02e-24	4.82e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
LIHC	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	11.12	1.03e-24	4.87e-21	0.98	0.52	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
LIHC	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	11.12	1.03e-24	4.87e-21	0.98	0.52	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
LIHC	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	11.12	1.03e-24	4.87e-21	0.98	0.52	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
LIHC	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-11.11	1.06e-24	4.98e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-11.11	1.06e-24	4.98e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-11.11	1.06e-24	4.98e-21	-0.58	-0.52	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
LIHC	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	11.1	1.15e-24	5.43e-21	0.62	0.51	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	11.1	1.15e-24	5.43e-21	0.62	0.51	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	11.1	1.2e-24	5.62e-21	0.71	0.51	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-11.1	1.21e-24	5.7e-21	-0.61	-0.51	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
LIHC	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	11.09	1.26e-24	5.9e-21	0.65	0.51	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
LIHC	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	11.09	1.33e-24	6.21e-21	0.69	0.51	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-11.08	1.36e-24	6.38e-21	-0.61	-0.51	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
LIHC	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-11.08	1.36e-24	6.38e-21	-0.63	-0.51	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
LIHC	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-11.08	1.37e-24	6.41e-21	-0.62	-0.51	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
LIHC	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-11.08	1.38e-24	6.43e-21	-0.59	-0.51	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	11.08	1.4e-24	6.56e-21	0.61	0.51	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	11.08	1.44e-24	6.7e-21	0.61	0.51	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-11.07	1.45e-24	6.76e-21	-0.61	-0.51	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
LIHC	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	11.07	1.45e-24	6.79e-21	0.56	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
LIHC	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	11.07	1.46e-24	6.81e-21	0.81	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
LIHC	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	11.07	1.46e-24	6.84e-21	0.62	0.51	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
LIHC	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-11.07	1.47e-24	6.87e-21	-0.58	-0.51	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
LIHC	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-11.07	1.5e-24	6.98e-21	-0.71	-0.51	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
LIHC	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	11.07	1.5e-24	7e-21	0.69	0.51	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
LIHC	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	11.07	1.5e-24	7e-21	0.69	0.51	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
LIHC	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-11.07	1.54e-24	7.17e-21	-0.59	-0.51	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-11.07	1.54e-24	7.18e-21	-0.58	-0.51	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-11.07	1.54e-24	7.18e-21	-0.58	-0.51	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-11.07	1.54e-24	7.18e-21	-0.58	-0.51	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-11.07	1.55e-24	7.21e-21	-0.61	-0.51	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-11.07	1.56e-24	7.26e-21	-0.61	-0.51	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	11.06	1.57e-24	7.31e-21	0.58	0.51	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
LIHC	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	11.06	1.6e-24	7.44e-21	0.79	0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
LIHC	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	11.06	1.61e-24	7.47e-21	0.59	0.51	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
LIHC	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-11.06	1.62e-24	7.53e-21	-0.76	-0.51	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
LIHC	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	11.06	1.64e-24	7.61e-21	0.61	0.51	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	11.06	1.64e-24	7.61e-21	0.61	0.51	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	11.06	1.64e-24	7.61e-21	0.61	0.51	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	11.06	1.64e-24	7.61e-21	0.61	0.51	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	11.05	1.71e-24	7.9e-21	0.61	0.51	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-11.05	1.71e-24	7.93e-21	-0.58	-0.51	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-11.05	1.76e-24	8.14e-21	-0.62	-0.51	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-11.05	1.76e-24	8.14e-21	-0.62	-0.51	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-11.05	1.76e-24	8.14e-21	-0.62	-0.51	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-11.05	1.76e-24	8.14e-21	-0.62	-0.51	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-11.05	1.78e-24	8.24e-21	-0.62	-0.51	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-11.05	1.79e-24	8.26e-21	-0.83	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
LIHC	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-11.05	1.79e-24	8.26e-21	-0.83	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
LIHC	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-11.05	1.79e-24	8.26e-21	-0.83	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
LIHC	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	11.05	1.8e-24	8.31e-21	0.74	0.51	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
LIHC	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-11.05	1.81e-24	8.35e-21	-0.63	-0.51	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
LIHC	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-11.05	1.82e-24	8.4e-21	-0.61	-0.51	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
LIHC	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-11.05	1.83e-24	8.44e-21	-0.6	-0.51	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-11.05	1.83e-24	8.44e-21	-0.6	-0.51	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-11.05	1.83e-24	8.44e-21	-0.6	-0.51	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-11.05	1.83e-24	8.44e-21	-0.6	-0.51	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-11.05	1.83e-24	8.44e-21	-0.6	-0.51	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
LIHC	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	11.05	1.83e-24	8.44e-21	0.61	0.51	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
LIHC	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-11.04	1.91e-24	8.8e-21	-0.63	-0.51	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
LIHC	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-11.04	1.96e-24	9e-21	-0.58	-0.51	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
LIHC	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-11.04	1.97e-24	9.06e-21	-0.83	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
LIHC	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-11.04	1.97e-24	9.06e-21	-0.63	-0.51	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
LIHC	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-11.03	2.02e-24	9.29e-21	-0.63	-0.51	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
LIHC	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-11.03	2.04e-24	9.36e-21	-0.59	-0.51	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
LIHC	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-11.03	2.05e-24	9.39e-21	-0.57	-0.51	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-11.03	2.05e-24	9.39e-21	-0.57	-0.51	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-11.03	2.05e-24	9.39e-21	-0.57	-0.51	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-11.03	2.05e-24	9.39e-21	-0.57	-0.51	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-11.03	2.05e-24	9.39e-21	-0.57	-0.51	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-11.03	2.05e-24	9.39e-21	-0.57	-0.51	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
LIHC	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-11.03	2.06e-24	9.44e-21	-0.59	-0.51	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
LIHC	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	11.03	2.1e-24	9.63e-21	0.49	0.51	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
LIHC	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-11.02	2.21e-24	1.01e-20	-0.52	-0.51	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
LIHC	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-11.02	2.36e-24	1.08e-20	-0.58	-0.51	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
LIHC	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	11.01	2.39e-24	1.09e-20	0.62	0.51	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000272787.1	KB-226F1.2	-11.01	2.39e-24	1.09e-20	-0.67	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23969211~23969873:+
LIHC	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	11	2.62e-24	1.19e-20	0.49	0.51	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
LIHC	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-11	2.65e-24	1.21e-20	-0.62	-0.51	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-11	2.65e-24	1.21e-20	-0.62	-0.51	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
LIHC	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-11	2.66e-24	1.21e-20	-0.66	-0.51	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs6004657	ENSG00000272977.1	CTA-390C10.10	-10.99	2.82e-24	1.28e-20	-0.82	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25476218~25479971:+
LIHC	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	10.99	2.88e-24	1.31e-20	0.55	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	10.99	2.99e-24	1.36e-20	0.62	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	10.98	3.08e-24	1.4e-20	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
LIHC	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-10.98	3.1e-24	1.4e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
LIHC	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-10.98	3.12e-24	1.41e-20	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
LIHC	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	10.98	3.15e-24	1.43e-20	0.68	0.51	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
LIHC	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	10.98	3.2e-24	1.45e-20	0.62	0.51	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	10.98	3.2e-24	1.45e-20	0.62	0.51	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	10.98	3.2e-24	1.45e-20	0.62	0.51	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	10.98	3.2e-24	1.45e-20	0.62	0.51	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	10.98	3.2e-24	1.45e-20	0.62	0.51	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	10.98	3.25e-24	1.47e-20	0.56	0.51	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
LIHC	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	10.98	3.26e-24	1.48e-20	0.57	0.51	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
LIHC	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-10.98	3.27e-24	1.48e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-10.98	3.27e-24	1.48e-20	-0.59	-0.51	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-10.97	3.41e-24	1.54e-20	-0.57	-0.51	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
LIHC	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-10.96	3.68e-24	1.66e-20	-0.78	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
LIHC	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	10.96	3.84e-24	1.73e-20	0.67	0.51	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
LIHC	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	10.96	3.84e-24	1.73e-20	0.67	0.51	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
LIHC	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	10.95	3.99e-24	1.79e-20	0.62	0.51	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	10.95	3.99e-24	1.79e-20	0.62	0.51	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
LIHC	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-10.95	4.07e-24	1.83e-20	-0.7	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
LIHC	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	10.94	4.23e-24	1.9e-20	0.49	0.51	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
LIHC	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	10.94	4.25e-24	1.91e-20	0.59	0.51	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
LIHC	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	10.94	4.37e-24	1.96e-20	0.57	0.51	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-10.94	4.4e-24	1.97e-20	-0.58	-0.51	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-10.94	4.42e-24	1.98e-20	-0.57	-0.51	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
LIHC	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-10.94	4.45e-24	1.99e-20	-0.71	-0.51	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
LIHC	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-10.94	4.45e-24	1.99e-20	-0.61	-0.51	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	10.94	4.47e-24	2e-20	0.62	0.51	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	10.93	4.66e-24	2.09e-20	0.59	0.51	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
LIHC	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	10.92	4.95e-24	2.2e-20	0.61	0.51	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	10.92	4.95e-24	2.2e-20	0.61	0.51	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	10.92	4.95e-24	2.2e-20	0.61	0.51	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	10.92	4.95e-24	2.2e-20	0.61	0.51	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	10.92	4.95e-24	2.2e-20	0.61	0.51	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	10.92	4.95e-24	2.2e-20	0.61	0.51	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	10.92	4.95e-24	2.2e-20	0.61	0.51	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	10.92	4.99e-24	2.22e-20	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
LIHC	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	10.92	5.02e-24	2.23e-20	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	10.92	5.02e-24	2.23e-20	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	10.92	5.02e-24	2.23e-20	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	10.92	5.02e-24	2.23e-20	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	10.92	5.02e-24	2.23e-20	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
LIHC	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	10.92	5.14e-24	2.29e-20	0.49	0.51	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
LIHC	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	10.92	5.14e-24	2.29e-20	0.49	0.51	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
LIHC	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-10.92	5.26e-24	2.34e-20	-0.58	-0.51	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
LIHC	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	10.91	5.59e-24	2.48e-20	0.74	0.51	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
LIHC	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	10.91	5.69e-24	2.53e-20	0.61	0.51	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
LIHC	cis	rs2260433	0.867	rs10895328	ENSG00000281655.1	RP11-817J15.3	10.9	5.83e-24	2.59e-20	0.64	0.51	Cleft palate;	chr11:102637617	chr11:102681310~102683913:+
LIHC	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-10.9	5.91e-24	2.62e-20	-0.6	-0.51	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	10.9	5.94e-24	2.63e-20	0.58	0.51	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
LIHC	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-10.9	5.99e-24	2.65e-20	-0.58	-0.51	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
LIHC	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-10.9	6.02e-24	2.67e-20	-0.71	-0.51	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	10.9	6.07e-24	2.69e-20	0.73	0.51	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
LIHC	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-10.89	6.62e-24	2.93e-20	-0.61	-0.51	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
LIHC	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-10.88	6.93e-24	3.06e-20	-0.58	-0.51	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
LIHC	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-10.88	6.96e-24	3.07e-20	-0.71	-0.51	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-10.88	7.35e-24	3.25e-20	-0.71	-0.51	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
LIHC	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-10.88	7.35e-24	3.25e-20	-0.71	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-10.88	7.35e-24	3.25e-20	-0.71	-0.51	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
LIHC	cis	rs5758659	0.729	rs134866	ENSG00000237037.8	NDUFA6-AS1	10.88	7.41e-24	3.27e-20	0.57	0.51	Cognitive function;	chr22:42254657	chr22:42090931~42137742:+
LIHC	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-10.87	7.53e-24	3.32e-20	-0.57	-0.51	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-10.87	7.53e-24	3.32e-20	-0.57	-0.51	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
LIHC	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-10.87	7.53e-24	3.32e-20	-0.57	-0.51	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	10.87	7.82e-24	3.45e-20	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
LIHC	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-10.87	7.91e-24	3.49e-20	-0.6	-0.51	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
LIHC	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-10.86	8.49e-24	3.74e-20	-0.7	-0.51	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
LIHC	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-10.86	8.69e-24	3.82e-20	-0.6	-0.51	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
LIHC	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-10.85	8.84e-24	3.88e-20	-0.81	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
LIHC	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-10.85	8.84e-24	3.88e-20	-0.81	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
LIHC	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-10.85	8.84e-24	3.88e-20	-0.81	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
LIHC	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-10.85	9.1e-24	4e-20	-0.64	-0.51	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
LIHC	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-10.85	9.2e-24	4.04e-20	-0.6	-0.51	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
LIHC	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-10.85	9.24e-24	4.06e-20	-0.81	-0.51	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
LIHC	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	10.85	9.34e-24	4.1e-20	0.57	0.51	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
LIHC	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	10.84	9.76e-24	4.28e-20	0.58	0.51	Height;	chr11:118703185	chr11:118688039~118690600:-
LIHC	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	10.84	9.76e-24	4.28e-20	0.58	0.51	Height;	chr11:118703207	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	10.84	9.76e-24	4.28e-20	0.58	0.51	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
LIHC	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	10.84	9.96e-24	4.36e-20	0.95	0.51	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
LIHC	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	10.84	9.96e-24	4.36e-20	0.95	0.51	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
LIHC	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	10.84	9.96e-24	4.36e-20	0.95	0.51	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
LIHC	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	10.83	1.06e-23	4.64e-20	0.59	0.51	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
LIHC	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	10.83	1.11e-23	4.86e-20	0.59	0.51	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
LIHC	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-10.82	1.14e-23	4.98e-20	-0.6	-0.51	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
LIHC	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-10.82	1.15e-23	5.04e-20	-0.58	-0.51	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
LIHC	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	10.82	1.2e-23	5.24e-20	0.62	0.5	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	10.82	1.2e-23	5.24e-20	0.62	0.5	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	10.82	1.2e-23	5.24e-20	0.62	0.5	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	10.82	1.21e-23	5.26e-20	0.65	0.5	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-10.81	1.23e-23	5.36e-20	-0.58	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
LIHC	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	10.81	1.29e-23	5.63e-20	0.62	0.5	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	10.81	1.29e-23	5.63e-20	0.62	0.5	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
LIHC	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-10.81	1.3e-23	5.65e-20	-0.58	-0.5	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
LIHC	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	10.8	1.34e-23	5.81e-20	0.95	0.5	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
LIHC	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-10.8	1.39e-23	6.03e-20	-0.57	-0.5	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
LIHC	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	10.8	1.39e-23	6.04e-20	0.77	0.5	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
LIHC	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	10.8	1.39e-23	6.04e-20	0.77	0.5	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
LIHC	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	10.8	1.39e-23	6.04e-20	0.77	0.5	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
LIHC	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	10.79	1.45e-23	6.28e-20	0.66	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
LIHC	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-10.78	1.57e-23	6.8e-20	-0.65	-0.5	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
LIHC	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	10.78	1.57e-23	6.81e-20	0.95	0.5	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
LIHC	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	10.78	1.61e-23	6.97e-20	0.95	0.5	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
LIHC	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-10.78	1.64e-23	7.08e-20	-0.7	-0.5	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
LIHC	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-10.78	1.65e-23	7.12e-20	-0.59	-0.5	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
LIHC	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	10.78	1.66e-23	7.17e-20	0.73	0.5	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
LIHC	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-10.77	1.68e-23	7.28e-20	-0.58	-0.5	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
LIHC	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-10.77	1.76e-23	7.6e-20	-0.48	-0.5	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
LIHC	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-10.77	1.79e-23	7.72e-20	-0.59	-0.5	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-10.77	1.79e-23	7.72e-20	-0.59	-0.5	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
LIHC	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	10.77	1.79e-23	7.75e-20	0.95	0.5	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
LIHC	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-10.77	1.8e-23	7.78e-20	-0.58	-0.5	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
LIHC	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	10.76	1.84e-23	7.95e-20	0.72	0.5	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
LIHC	cis	rs5758659	0.692	rs5751251	ENSG00000237037.8	NDUFA6-AS1	10.76	1.88e-23	8.09e-20	0.58	0.5	Cognitive function;	chr22:42244600	chr22:42090931~42137742:+
LIHC	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-10.75	1.97e-23	8.51e-20	-0.58	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
LIHC	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	10.75	2e-23	8.62e-20	0.67	0.5	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
LIHC	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	10.75	2.12e-23	9.14e-20	0.74	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
LIHC	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	10.74	2.15e-23	9.24e-20	0.57	0.5	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
LIHC	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	10.74	2.2e-23	9.46e-20	0.59	0.5	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-10.74	2.21e-23	9.51e-20	-0.58	-0.5	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
LIHC	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	10.74	2.29e-23	9.83e-20	0.58	0.5	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
LIHC	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	10.74	2.3e-23	9.85e-20	0.67	0.5	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
LIHC	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	10.74	2.3e-23	9.88e-20	0.63	0.5	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	10.74	2.31e-23	9.89e-20	0.61	0.5	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
LIHC	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	10.73	2.35e-23	1.01e-19	0.67	0.5	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
LIHC	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	10.73	2.43e-23	1.04e-19	0.58	0.5	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
LIHC	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	10.73	2.43e-23	1.04e-19	0.58	0.5	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	10.73	2.44e-23	1.04e-19	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
LIHC	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-10.72	2.54e-23	1.09e-19	-0.58	-0.5	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
LIHC	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-10.72	2.66e-23	1.13e-19	-0.73	-0.5	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
LIHC	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-10.71	2.74e-23	1.17e-19	-0.89	-0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
LIHC	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-10.71	2.81e-23	1.2e-19	-0.51	-0.5	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
LIHC	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-10.71	2.89e-23	1.23e-19	-0.62	-0.5	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
LIHC	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	10.71	2.94e-23	1.24e-19	0.91	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-10.7	3.01e-23	1.27e-19	-0.66	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
LIHC	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	10.7	3.09e-23	1.3e-19	0.58	0.5	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
LIHC	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	10.7	3.09e-23	1.3e-19	0.58	0.5	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
LIHC	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	10.69	3.24e-23	1.36e-19	0.65	0.5	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
LIHC	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-10.68	3.69e-23	1.55e-19	-0.57	-0.5	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
LIHC	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	10.68	3.72e-23	1.57e-19	0.65	0.5	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	10.67	3.94e-23	1.65e-19	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
LIHC	cis	rs5758659	0.716	rs5758661	ENSG00000237037.8	NDUFA6-AS1	10.67	4.01e-23	1.68e-19	0.57	0.5	Cognitive function;	chr22:42228439	chr22:42090931~42137742:+
LIHC	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-10.67	4.02e-23	1.69e-19	-0.74	-0.5	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
LIHC	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	10.67	4.03e-23	1.69e-19	0.65	0.5	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	10.66	4.08e-23	1.71e-19	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
LIHC	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-10.66	4.31e-23	1.81e-19	-0.57	-0.5	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-10.66	4.4e-23	1.84e-19	-0.57	-0.5	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
LIHC	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	10.65	4.61e-23	1.93e-19	0.9	0.5	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
LIHC	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	10.65	4.64e-23	1.94e-19	0.81	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-10.64	5.08e-23	2.12e-19	-0.53	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	10.64	5.13e-23	2.14e-19	0.67	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
LIHC	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-10.64	5.16e-23	2.15e-19	-0.58	-0.5	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
LIHC	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-10.63	5.41e-23	2.26e-19	-0.57	-0.5	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
LIHC	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-10.63	5.49e-23	2.29e-19	-0.6	-0.5	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
LIHC	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	10.62	5.65e-23	2.36e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
LIHC	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-10.62	5.68e-23	2.37e-19	-0.72	-0.5	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
LIHC	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-10.62	5.69e-23	2.37e-19	-0.57	-0.5	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
LIHC	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-10.62	5.72e-23	2.38e-19	-0.6	-0.5	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
LIHC	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-10.62	5.76e-23	2.4e-19	-0.6	-0.5	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
LIHC	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-10.62	5.78e-23	2.4e-19	-0.57	-0.5	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
LIHC	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-10.62	5.9e-23	2.45e-19	-0.6	-0.5	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
LIHC	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-10.62	5.9e-23	2.45e-19	-0.6	-0.5	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-10.62	5.9e-23	2.45e-19	-0.6	-0.5	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
LIHC	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-10.62	5.99e-23	2.49e-19	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	10.61	6.19e-23	2.56e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	10.61	6.22e-23	2.57e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	10.61	6.3e-23	2.6e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	10.61	6.3e-23	2.6e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	10.61	6.3e-23	2.6e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	10.61	6.3e-23	2.6e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
LIHC	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-10.61	6.35e-23	2.62e-19	-0.65	-0.5	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-10.61	6.41e-23	2.64e-19	-0.57	-0.5	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-10.61	6.41e-23	2.64e-19	-0.57	-0.5	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
LIHC	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-10.61	6.42e-23	2.65e-19	-0.6	-0.5	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
LIHC	cis	rs5758659	0.716	rs2143138	ENSG00000237037.8	NDUFA6-AS1	10.6	6.63e-23	2.73e-19	0.57	0.5	Cognitive function;	chr22:42222334	chr22:42090931~42137742:+
LIHC	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	10.59	7.53e-23	3.09e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	10.59	7.53e-23	3.09e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	10.58	7.81e-23	3.2e-19	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
LIHC	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	10.58	7.86e-23	3.22e-19	0.64	0.5	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-10.58	7.97e-23	3.27e-19	-0.61	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
LIHC	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-10.57	8.51e-23	3.48e-19	-0.73	-0.5	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
LIHC	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-10.56	9.16e-23	3.74e-19	-0.79	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
LIHC	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	10.56	9.2e-23	3.75e-19	0.58	0.5	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-10.56	9.35e-23	3.81e-19	-0.56	-0.5	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
LIHC	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-10.56	9.72e-23	3.96e-19	-0.58	-0.5	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
LIHC	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-10.55	1.01e-22	4.12e-19	-0.57	-0.5	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
LIHC	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-10.55	1.03e-22	4.18e-19	-0.57	-0.5	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
LIHC	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-10.55	1.05e-22	4.25e-19	-0.63	-0.5	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
LIHC	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-10.55	1.06e-22	4.3e-19	-0.58	-0.5	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
LIHC	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	10.54	1.08e-22	4.36e-19	0.9	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	10.54	1.11e-22	4.48e-19	0.61	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
LIHC	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	10.54	1.11e-22	4.5e-19	0.73	0.5	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
LIHC	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-10.53	1.16e-22	4.71e-19	-0.72	-0.49	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
LIHC	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-10.53	1.21e-22	4.91e-19	-0.66	-0.49	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
LIHC	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	10.53	1.23e-22	4.97e-19	0.58	0.49	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	10.53	1.23e-22	4.97e-19	0.58	0.49	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	10.53	1.23e-22	4.97e-19	0.58	0.49	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	10.53	1.23e-22	4.97e-19	0.58	0.49	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	10.53	1.23e-22	4.97e-19	0.58	0.49	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	10.53	1.23e-22	4.97e-19	0.58	0.49	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-10.53	1.23e-22	4.97e-19	-0.7	-0.49	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
LIHC	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	10.52	1.29e-22	5.19e-19	0.62	0.49	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
LIHC	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	10.52	1.31e-22	5.24e-19	0.9	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	10.52	1.31e-22	5.24e-19	0.9	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	10.52	1.31e-22	5.24e-19	0.9	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	10.52	1.31e-22	5.24e-19	0.9	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
LIHC	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	10.52	1.35e-22	5.4e-19	0.58	0.49	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-10.51	1.37e-22	5.47e-19	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-10.51	1.37e-22	5.48e-19	-0.57	-0.49	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
LIHC	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-10.51	1.39e-22	5.55e-19	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	10.51	1.41e-22	5.63e-19	0.6	0.49	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	10.51	1.41e-22	5.63e-19	0.6	0.49	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
LIHC	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	10.51	1.45e-22	5.75e-19	0.57	0.49	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
LIHC	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	10.51	1.45e-22	5.77e-19	0.6	0.49	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
LIHC	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-10.5	1.49e-22	5.91e-19	-0.56	-0.49	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
LIHC	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-10.5	1.56e-22	6.18e-19	-0.59	-0.49	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-10.5	1.56e-22	6.18e-19	-0.59	-0.49	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-10.5	1.56e-22	6.18e-19	-0.59	-0.49	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	10.5	1.57e-22	6.23e-19	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
LIHC	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	10.5	1.59e-22	6.31e-19	0.72	0.49	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
LIHC	cis	rs5758659	0.679	rs134870	ENSG00000237037.8	NDUFA6-AS1	10.49	1.6e-22	6.34e-19	0.56	0.49	Cognitive function;	chr22:42256311	chr22:42090931~42137742:+
LIHC	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-10.49	1.64e-22	6.49e-19	-0.56	-0.49	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-10.49	1.64e-22	6.49e-19	-0.56	-0.49	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	10.49	1.71e-22	6.76e-19	0.6	0.49	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	10.48	1.75e-22	6.91e-19	0.58	0.49	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
LIHC	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-10.48	1.81e-22	7.14e-19	-0.56	-0.49	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
LIHC	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-10.48	1.83e-22	7.19e-19	-0.58	-0.49	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
LIHC	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-10.48	1.83e-22	7.19e-19	-0.6	-0.49	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
LIHC	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-10.47	1.94e-22	7.64e-19	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	10.47	1.95e-22	7.65e-19	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
LIHC	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	10.47	1.95e-22	7.67e-19	0.58	0.49	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-10.46	2.06e-22	8.07e-19	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-10.46	2.06e-22	8.07e-19	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	10.46	2.07e-22	8.1e-19	0.59	0.49	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	10.46	2.08e-22	8.14e-19	0.64	0.49	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
LIHC	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	10.46	2.08e-22	8.15e-19	0.69	0.49	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
LIHC	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-10.46	2.1e-22	8.22e-19	-0.58	-0.49	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
LIHC	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-10.46	2.12e-22	8.29e-19	-0.42	-0.49	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
LIHC	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-10.46	2.12e-22	8.29e-19	-0.57	-0.49	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
LIHC	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-10.46	2.12e-22	8.29e-19	-0.57	-0.49	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
LIHC	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-10.46	2.15e-22	8.37e-19	-0.69	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
LIHC	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-10.45	2.26e-22	8.79e-19	-0.58	-0.49	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
LIHC	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	10.45	2.28e-22	8.88e-19	0.57	0.49	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
LIHC	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	10.45	2.3e-22	8.94e-19	0.68	0.49	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
LIHC	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-10.45	2.31e-22	8.98e-19	-0.68	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
LIHC	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-10.45	2.31e-22	8.98e-19	-0.68	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
LIHC	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	10.45	2.33e-22	9.04e-19	0.57	0.49	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
LIHC	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	10.44	2.48e-22	9.6e-19	0.62	0.49	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
LIHC	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	10.44	2.53e-22	9.8e-19	0.89	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	10.43	2.64e-22	1.02e-18	0.53	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
LIHC	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	10.43	2.69e-22	1.04e-18	0.89	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	10.43	2.7e-22	1.04e-18	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
LIHC	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-10.43	2.71e-22	1.05e-18	-0.62	-0.49	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
LIHC	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	10.43	2.72e-22	1.05e-18	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
LIHC	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	10.43	2.75e-22	1.06e-18	0.64	0.49	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
LIHC	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	10.42	2.85e-22	1.1e-18	0.6	0.49	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	10.42	2.85e-22	1.1e-18	0.6	0.49	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	10.42	2.85e-22	1.1e-18	0.6	0.49	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	10.42	2.89e-22	1.11e-18	0.6	0.49	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
LIHC	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-10.42	2.95e-22	1.13e-18	-0.59	-0.49	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
LIHC	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-10.42	2.97e-22	1.14e-18	-0.65	-0.49	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
LIHC	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	10.42	3.01e-22	1.16e-18	0.64	0.49	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
LIHC	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-10.42	3.02e-22	1.16e-18	-0.56	-0.49	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
LIHC	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-10.41	3.04e-22	1.17e-18	-0.57	-0.49	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
LIHC	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	10.41	3.12e-22	1.2e-18	0.7	0.49	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
LIHC	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-22	1.2e-18	-0.58	-0.49	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-22	1.2e-18	-0.58	-0.49	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-22	1.2e-18	-0.58	-0.49	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-22	1.2e-18	-0.58	-0.49	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-22	1.2e-18	-0.58	-0.49	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-22	1.2e-18	-0.58	-0.49	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-10.41	3.15e-22	1.21e-18	-0.54	-0.49	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
LIHC	cis	rs5758659	0.716	rs86669	ENSG00000237037.8	NDUFA6-AS1	10.41	3.16e-22	1.21e-18	0.55	0.49	Cognitive function;	chr22:42284794	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	10.41	3.16e-22	1.21e-18	0.57	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
LIHC	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	10.41	3.17e-22	1.22e-18	0.59	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
LIHC	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	10.41	3.17e-22	1.22e-18	0.64	0.49	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
LIHC	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-10.41	3.23e-22	1.24e-18	-0.65	-0.49	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
LIHC	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	10.4	3.3e-22	1.26e-18	0.56	0.49	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
LIHC	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	10.4	3.31e-22	1.27e-18	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
LIHC	cis	rs5758659	0.633	rs762995	ENSG00000237037.8	NDUFA6-AS1	10.4	3.37e-22	1.29e-18	0.56	0.49	Cognitive function;	chr22:42276118	chr22:42090931~42137742:+
LIHC	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-10.4	3.44e-22	1.31e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
LIHC	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	10.4	3.46e-22	1.32e-18	0.89	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
LIHC	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-10.4	3.47e-22	1.32e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
LIHC	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-10.4	3.48e-22	1.33e-18	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-10.4	3.55e-22	1.35e-18	-0.58	-0.49	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
LIHC	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-10.39	3.57e-22	1.36e-18	-0.66	-0.49	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
LIHC	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-10.39	3.57e-22	1.36e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-10.39	3.57e-22	1.36e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-10.39	3.57e-22	1.36e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-10.39	3.57e-22	1.36e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-10.39	3.57e-22	1.36e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
LIHC	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-10.39	3.58e-22	1.36e-18	-0.56	-0.49	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
LIHC	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	10.39	3.65e-22	1.38e-18	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	10.39	3.65e-22	1.38e-18	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
LIHC	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	10.39	3.65e-22	1.38e-18	0.6	0.49	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	10.39	3.65e-22	1.38e-18	0.6	0.49	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	10.39	3.65e-22	1.38e-18	0.6	0.49	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	10.39	3.65e-22	1.38e-18	0.6	0.49	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	10.39	3.65e-22	1.38e-18	0.6	0.49	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	10.39	3.65e-22	1.38e-18	0.6	0.49	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	10.39	3.65e-22	1.38e-18	0.6	0.49	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
LIHC	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-10.39	3.74e-22	1.41e-18	-0.64	-0.49	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
LIHC	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-10.39	3.81e-22	1.44e-18	-0.62	-0.49	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
LIHC	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-10.38	3.9e-22	1.47e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
LIHC	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-10.38	3.91e-22	1.48e-18	-0.66	-0.49	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
LIHC	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-10.38	4.04e-22	1.52e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-10.38	4.04e-22	1.52e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-10.38	4.04e-22	1.52e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-10.38	4.04e-22	1.52e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-10.38	4.13e-22	1.56e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
LIHC	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	10.36	4.66e-22	1.75e-18	0.53	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
LIHC	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	10.36	4.7e-22	1.77e-18	0.65	0.49	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
LIHC	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-10.36	4.73e-22	1.78e-18	-0.56	-0.49	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
LIHC	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-10.36	4.74e-22	1.78e-18	-0.57	-0.49	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	10.36	4.74e-22	1.78e-18	0.57	0.49	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
LIHC	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-10.36	4.84e-22	1.81e-18	-0.65	-0.49	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
LIHC	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-10.36	4.86e-22	1.82e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
LIHC	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-10.35	4.97e-22	1.86e-18	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
LIHC	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	10.35	5.2e-22	1.95e-18	0.46	0.49	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
LIHC	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-10.34	5.37e-22	2.01e-18	-0.68	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
LIHC	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	10.34	5.54e-22	2.07e-18	0.58	0.49	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	10.34	5.64e-22	2.11e-18	0.6	0.49	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
LIHC	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	10.34	5.67e-22	2.12e-18	0.89	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
LIHC	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-10.33	5.76e-22	2.15e-18	-0.64	-0.49	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	10.33	5.8e-22	2.16e-18	0.57	0.49	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	10.33	5.8e-22	2.16e-18	0.57	0.49	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
LIHC	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-10.33	5.8e-22	2.16e-18	-0.7	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
LIHC	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-10.33	5.83e-22	2.17e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
LIHC	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	10.33	5.87e-22	2.19e-18	0.57	0.49	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	10.33	5.87e-22	2.19e-18	0.57	0.49	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	10.33	5.87e-22	2.19e-18	0.57	0.49	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	10.33	5.87e-22	2.19e-18	0.57	0.49	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	10.33	5.87e-22	2.19e-18	0.57	0.49	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
LIHC	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-10.33	5.89e-22	2.19e-18	-0.58	-0.49	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
LIHC	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-10.33	5.9e-22	2.2e-18	-0.56	-0.49	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
LIHC	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-10.33	5.93e-22	2.21e-18	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	10.33	6.01e-22	2.24e-18	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	10.33	6.01e-22	2.24e-18	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	10.33	6.01e-22	2.24e-18	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
LIHC	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-10.33	6.06e-22	2.25e-18	-0.67	-0.49	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
LIHC	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-10.33	6.11e-22	2.27e-18	-0.57	-0.49	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	10.33	6.16e-22	2.28e-18	0.6	0.49	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-10.32	6.28e-22	2.31e-18	-0.57	-0.49	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	10.32	6.38e-22	2.35e-18	0.59	0.49	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
LIHC	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	10.32	6.41e-22	2.36e-18	0.61	0.49	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
LIHC	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	10.32	6.44e-22	2.37e-18	0.59	0.49	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
LIHC	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	10.31	6.96e-22	2.56e-18	0.86	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
LIHC	cis	rs1023500	0.573	rs133380	ENSG00000237037.8	NDUFA6-AS1	10.31	7.03e-22	2.58e-18	0.56	0.49	Schizophrenia;	chr22:42072906	chr22:42090931~42137742:+
LIHC	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-10.31	7.16e-22	2.63e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-10.31	7.16e-22	2.63e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
LIHC	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	10.3	7.27e-22	2.67e-18	0.72	0.49	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
LIHC	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-10.3	7.34e-22	2.7e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
LIHC	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-10.3	7.86e-22	2.89e-18	-0.68	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
LIHC	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	10.29	8e-22	2.94e-18	0.88	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
LIHC	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	10.29	8.04e-22	2.95e-18	0.56	0.49	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	10.29	8.13e-22	2.98e-18	0.64	0.49	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
LIHC	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-10.29	8.34e-22	3.05e-18	-0.57	-0.49	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
LIHC	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-10.29	8.41e-22	3.08e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-10.29	8.41e-22	3.08e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-10.29	8.41e-22	3.08e-18	-0.56	-0.49	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
LIHC	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-10.29	8.5e-22	3.11e-18	-0.7	-0.49	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
LIHC	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-10.28	8.53e-22	3.12e-18	-0.59	-0.49	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
LIHC	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	10.28	8.61e-22	3.15e-18	0.58	0.49	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
LIHC	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-10.28	8.62e-22	3.15e-18	-0.57	-0.49	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-10.28	8.62e-22	3.15e-18	-0.57	-0.49	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-10.28	8.62e-22	3.15e-18	-0.57	-0.49	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	10.28	8.72e-22	3.18e-18	0.57	0.49	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	10.28	8.72e-22	3.18e-18	0.57	0.49	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	10.28	8.72e-22	3.18e-18	0.57	0.49	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	10.28	8.72e-22	3.18e-18	0.57	0.49	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	10.28	8.72e-22	3.18e-18	0.57	0.49	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-10.28	8.72e-22	3.18e-18	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	10.28	8.75e-22	3.19e-18	0.57	0.49	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-10.28	8.8e-22	3.21e-18	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-10.28	8.83e-22	3.22e-18	-0.57	-0.49	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-10.28	8.83e-22	3.22e-18	-0.57	-0.49	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-10.28	8.83e-22	3.22e-18	-0.57	-0.49	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
LIHC	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-10.28	8.86e-22	3.23e-18	-0.65	-0.49	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
LIHC	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-10.28	8.86e-22	3.23e-18	-0.65	-0.49	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
LIHC	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-10.28	9.07e-22	3.3e-18	-0.7	-0.49	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	10.28	9.14e-22	3.33e-18	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
LIHC	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	10.27	9.33e-22	3.4e-18	0.62	0.49	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	10.26	1e-21	3.63e-18	0.57	0.49	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	10.26	1.04e-21	3.77e-18	0.59	0.49	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-10.26	1.04e-21	3.78e-18	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-10.25	1.11e-21	4.01e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-10.25	1.11e-21	4.01e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
LIHC	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	10.25	1.13e-21	4.08e-18	0.93	0.48	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-10.25	1.14e-21	4.13e-18	-0.56	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
LIHC	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-10.25	1.15e-21	4.16e-18	-0.55	-0.48	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
LIHC	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	10.24	1.19e-21	4.29e-18	0.57	0.48	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
LIHC	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-10.24	1.21e-21	4.36e-18	-0.57	-0.48	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
LIHC	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	10.24	1.23e-21	4.42e-18	0.85	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
LIHC	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	10.24	1.24e-21	4.46e-18	0.54	0.48	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
LIHC	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	10.24	1.24e-21	4.47e-18	0.57	0.48	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	10.24	1.24e-21	4.47e-18	0.57	0.48	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	10.24	1.24e-21	4.47e-18	0.57	0.48	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	10.24	1.24e-21	4.47e-18	0.57	0.48	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
LIHC	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-10.23	1.33e-21	4.78e-18	-0.68	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
LIHC	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-10.22	1.4e-21	5.02e-18	-0.57	-0.48	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
LIHC	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	10.22	1.41e-21	5.06e-18	0.57	0.48	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
LIHC	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-10.22	1.44e-21	5.14e-18	-0.56	-0.48	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
LIHC	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-10.22	1.44e-21	5.16e-18	-0.57	-0.48	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
LIHC	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-10.22	1.47e-21	5.26e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	10.22	1.47e-21	5.26e-18	0.62	0.48	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
LIHC	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	10.22	1.47e-21	5.26e-18	0.55	0.48	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
LIHC	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-10.22	1.48e-21	5.27e-18	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-10.22	1.48e-21	5.27e-18	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	10.21	1.48e-21	5.3e-18	0.57	0.48	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	10.21	1.53e-21	5.47e-18	0.59	0.48	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	10.21	1.55e-21	5.54e-18	0.58	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	10.21	1.55e-21	5.54e-18	0.58	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
LIHC	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	10.21	1.55e-21	5.54e-18	0.58	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
LIHC	cis	rs1939012	0.565	rs2846707	ENSG00000281655.1	RP11-817J15.3	-10.21	1.6e-21	5.7e-18	-0.73	-0.48	Epilepsy;	chr11:102705627	chr11:102681310~102683913:+
LIHC	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-10.2	1.64e-21	5.85e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
LIHC	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	10.2	1.66e-21	5.93e-18	0.66	0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
LIHC	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	10.2	1.67e-21	5.93e-18	0.57	0.48	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
LIHC	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-10.2	1.69e-21	6.02e-18	-0.57	-0.48	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-10.2	1.71e-21	6.09e-18	-0.57	-0.48	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-10.2	1.71e-21	6.09e-18	-0.57	-0.48	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
LIHC	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	10.19	1.74e-21	6.2e-18	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
LIHC	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-10.19	1.77e-21	6.29e-18	-0.61	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
LIHC	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	10.19	1.77e-21	6.31e-18	0.76	0.48	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
LIHC	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-10.19	1.79e-21	6.35e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
LIHC	cis	rs1939012	0.544	rs947875	ENSG00000281655.1	RP11-817J15.3	-10.19	1.84e-21	6.52e-18	-0.73	-0.48	Epilepsy;	chr11:102706938	chr11:102681310~102683913:+
LIHC	cis	rs1939012	0.565	rs1276284	ENSG00000281655.1	RP11-817J15.3	-10.19	1.84e-21	6.52e-18	-0.73	-0.48	Epilepsy;	chr11:102711137	chr11:102681310~102683913:+
LIHC	cis	rs1939012	0.544	rs1276283	ENSG00000281655.1	RP11-817J15.3	-10.19	1.84e-21	6.52e-18	-0.73	-0.48	Epilepsy;	chr11:102711187	chr11:102681310~102683913:+
LIHC	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-10.19	1.84e-21	6.54e-18	-0.58	-0.48	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
LIHC	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-10.18	1.9e-21	6.74e-18	-0.64	-0.48	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
LIHC	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-10.18	1.96e-21	6.94e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-10.17	2.03e-21	7.18e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-10.17	2.03e-21	7.18e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-10.17	2.03e-21	7.18e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-10.17	2.03e-21	7.18e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-10.17	2.04e-21	7.2e-18	-0.57	-0.48	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-10.17	2.09e-21	7.38e-18	-0.57	-0.48	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-10.17	2.09e-21	7.38e-18	-0.57	-0.48	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-10.17	2.09e-21	7.38e-18	-0.57	-0.48	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
LIHC	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-10.17	2.1e-21	7.4e-18	-0.65	-0.48	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
LIHC	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-10.17	2.11e-21	7.46e-18	-0.57	-0.48	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
LIHC	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-10.17	2.13e-21	7.5e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	10.17	2.19e-21	7.71e-18	0.57	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
LIHC	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-10.16	2.23e-21	7.86e-18	-0.57	-0.48	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
LIHC	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	10.16	2.26e-21	7.97e-18	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	10.16	2.26e-21	7.97e-18	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	10.16	2.26e-21	7.97e-18	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	10.16	2.26e-21	7.97e-18	0.87	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	10.16	2.26e-21	7.97e-18	0.87	0.48	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
LIHC	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-10.16	2.27e-21	7.98e-18	-0.7	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
LIHC	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-10.16	2.33e-21	8.19e-18	-0.58	-0.48	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
LIHC	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-10.15	2.39e-21	8.41e-18	-0.64	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.704	rs199656	ENSG00000230658.1	KLHL7-AS1	-10.15	2.39e-21	8.41e-18	-0.64	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23297996	chr7:23101228~23105703:-
LIHC	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	10.15	2.47e-21	8.68e-18	0.56	0.48	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
LIHC	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	10.15	2.48e-21	8.68e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	10.15	2.56e-21	8.95e-18	0.84	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
LIHC	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-10.14	2.58e-21	9e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-10.14	2.59e-21	9.06e-18	-0.55	-0.48	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	10.14	2.66e-21	9.26e-18	0.57	0.48	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
LIHC	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	10.14	2.69e-21	9.35e-18	0.57	0.48	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
LIHC	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	10.14	2.69e-21	9.35e-18	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-10.14	2.69e-21	9.36e-18	-0.6	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
LIHC	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	10.13	2.93e-21	1.02e-17	0.66	0.48	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
LIHC	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-10.13	2.97e-21	1.03e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-10.13	3e-21	1.04e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-10.12	3.2e-21	1.11e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-10.12	3.2e-21	1.11e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-10.12	3.2e-21	1.11e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
LIHC	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-10.12	3.23e-21	1.12e-17	-0.6	-0.48	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	10.11	3.3e-21	1.14e-17	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
LIHC	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-10.11	3.42e-21	1.18e-17	-0.57	-0.48	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
LIHC	cis	rs296381	0.561	rs62128816	ENSG00000259108.2	CTD-3098H1.2	10.11	3.47e-21	1.2e-17	0.88	0.48	Blood metabolite levels;	chr19:47846773	chr19:47863483~47865341:-
LIHC	cis	rs296381	0.561	rs62128818	ENSG00000259108.2	CTD-3098H1.2	10.11	3.47e-21	1.2e-17	0.88	0.48	Blood metabolite levels;	chr19:47847835	chr19:47863483~47865341:-
LIHC	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-10.1	3.6e-21	1.25e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
LIHC	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	10.1	3.64e-21	1.26e-17	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
LIHC	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-10.1	3.66e-21	1.26e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
LIHC	cis	rs296381	0.598	rs10426277	ENSG00000259108.2	CTD-3098H1.2	10.1	3.75e-21	1.3e-17	0.87	0.48	Blood metabolite levels;	chr19:47850904	chr19:47863483~47865341:-
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	10.09	3.84e-21	1.32e-17	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
LIHC	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-10.09	3.92e-21	1.35e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
LIHC	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-10.09	3.96e-21	1.36e-17	-0.56	-0.48	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-10.09	3.96e-21	1.36e-17	-0.56	-0.48	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
LIHC	cis	rs296381	0.598	rs76234461	ENSG00000259108.2	CTD-3098H1.2	10.09	4.03e-21	1.39e-17	0.87	0.48	Blood metabolite levels;	chr19:47850161	chr19:47863483~47865341:-
LIHC	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-10.09	4.1e-21	1.41e-17	-0.57	-0.48	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
LIHC	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	10.08	4.18e-21	1.44e-17	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
LIHC	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-10.08	4.19e-21	1.44e-17	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-10.08	4.21e-21	1.44e-17	-0.56	-0.48	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-10.08	4.21e-21	1.44e-17	-0.56	-0.48	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-10.08	4.21e-21	1.44e-17	-0.56	-0.48	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-10.08	4.21e-21	1.44e-17	-0.56	-0.48	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-10.08	4.21e-21	1.44e-17	-0.56	-0.48	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
LIHC	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-10.08	4.32e-21	1.48e-17	-0.57	-0.48	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
LIHC	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-10.08	4.32e-21	1.48e-17	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-10.08	4.32e-21	1.48e-17	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	10.08	4.37e-21	1.5e-17	0.56	0.48	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	10.08	4.4e-21	1.51e-17	0.56	0.48	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	10.08	4.4e-21	1.51e-17	0.56	0.48	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	10.08	4.4e-21	1.51e-17	0.56	0.48	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
LIHC	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-10.07	4.53e-21	1.55e-17	-0.57	-0.48	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-10.06	4.83e-21	1.65e-17	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
LIHC	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-10.06	5.11e-21	1.75e-17	-0.56	-0.48	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
LIHC	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-10.06	5.17e-21	1.77e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
LIHC	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-10.05	5.42e-21	1.85e-17	-0.5	-0.48	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	10.04	5.79e-21	1.97e-17	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
LIHC	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-10.04	5.83e-21	1.98e-17	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-10.04	5.91e-21	2.01e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
LIHC	cis	rs1799949	0.931	rs9891977	ENSG00000198496.9	NBR2	-10.04	5.92e-21	2.01e-17	-0.55	-0.48	Menopause (age at onset);	chr17:43360030	chr17:43125610~43153671:+
LIHC	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	10.04	5.94e-21	2.02e-17	0.85	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	10.03	6.27e-21	2.13e-17	0.57	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
LIHC	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-10.03	6.32e-21	2.15e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-10.03	6.32e-21	2.15e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
LIHC	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-10.03	6.43e-21	2.18e-17	-0.68	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
LIHC	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-10.03	6.46e-21	2.19e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
LIHC	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-10.03	6.48e-21	2.2e-17	-0.68	-0.48	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
LIHC	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-10.02	6.66e-21	2.26e-17	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-10.02	6.79e-21	2.3e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-10.01	7.14e-21	2.41e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
LIHC	cis	rs296381	0.598	rs10408997	ENSG00000259108.2	CTD-3098H1.2	10.01	7.15e-21	2.42e-17	0.85	0.48	Blood metabolite levels;	chr19:47852502	chr19:47863483~47865341:-
LIHC	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-10.01	7.17e-21	2.42e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-10.01	7.35e-21	2.48e-17	-0.55	-0.48	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-10	7.73e-21	2.61e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
LIHC	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-10	7.75e-21	2.61e-17	-0.69	-0.48	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
LIHC	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	10	7.99e-21	2.69e-17	0.57	0.48	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
LIHC	cis	rs9828933	0.577	rs832193	ENSG00000280620.1	SCAANT1	-10	8.05e-21	2.71e-17	-0.68	-0.48	Type 2 diabetes;	chr3:63868769	chr3:63911518~63911772:-
LIHC	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	10	8.23e-21	2.77e-17	0.53	0.48	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
LIHC	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-10	8.33e-21	2.81e-17	-0.68	-0.48	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	9.99	8.47e-21	2.85e-17	0.56	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
LIHC	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-9.99	8.52e-21	2.87e-17	-0.54	-0.48	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
LIHC	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	9.99	8.58e-21	2.89e-17	0.55	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	9.99	8.58e-21	2.89e-17	0.55	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	9.99	8.65e-21	2.91e-17	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
LIHC	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	9.99	8.75e-21	2.94e-17	0.58	0.48	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
LIHC	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-9.99	8.85e-21	2.98e-17	-0.41	-0.48	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
LIHC	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	9.99	8.88e-21	2.99e-17	0.53	0.48	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
LIHC	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	9.99	8.91e-21	3e-17	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	9.99	8.91e-21	3e-17	0.86	0.48	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	9.99	8.91e-21	3e-17	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	9.99	8.91e-21	3e-17	0.86	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
LIHC	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-9.98	9.55e-21	3.21e-17	-0.54	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
LIHC	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	9.98	9.59e-21	3.22e-17	0.44	0.47	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
LIHC	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-9.97	9.82e-21	3.29e-17	-0.54	-0.47	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
LIHC	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-9.97	9.89e-21	3.32e-17	-0.67	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	9.97	9.95e-21	3.34e-17	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
LIHC	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-9.96	1.09e-20	3.64e-17	-0.68	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
LIHC	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	9.96	1.13e-20	3.77e-17	0.55	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-9.94	1.24e-20	4.14e-17	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-9.94	1.24e-20	4.14e-17	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
LIHC	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	9.94	1.29e-20	4.3e-17	0.8	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
LIHC	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	9.93	1.34e-20	4.46e-17	0.53	0.47	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
LIHC	cis	rs858239	0.931	rs9690941	ENSG00000230658.1	KLHL7-AS1	9.93	1.37e-20	4.57e-17	0.6	0.47	Cerebrospinal fluid biomarker levels;	chr7:23242134	chr7:23101228~23105703:-
LIHC	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-9.93	1.39e-20	4.62e-17	-0.67	-0.47	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
LIHC	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	9.93	1.4e-20	4.65e-17	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	9.93	1.4e-20	4.65e-17	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	9.93	1.4e-20	4.65e-17	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	9.93	1.4e-20	4.65e-17	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
LIHC	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	9.93	1.42e-20	4.71e-17	0.55	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	9.93	1.42e-20	4.71e-17	0.55	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	9.91	1.6e-20	5.28e-17	0.54	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
LIHC	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	9.91	1.62e-20	5.36e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
LIHC	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	9.91	1.63e-20	5.39e-17	0.51	0.47	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
LIHC	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-9.91	1.64e-20	5.43e-17	-0.6	-0.47	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
LIHC	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-9.91	1.65e-20	5.47e-17	-0.55	-0.47	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-9.91	1.65e-20	5.47e-17	-0.55	-0.47	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-9.91	1.66e-20	5.49e-17	-0.54	-0.47	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
LIHC	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-9.91	1.68e-20	5.54e-17	-0.6	-0.47	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
LIHC	cis	rs2260433	0.503	rs10750652	ENSG00000281655.1	RP11-817J15.3	9.9	1.76e-20	5.81e-17	0.61	0.47	Cleft palate;	chr11:102646775	chr11:102681310~102683913:+
LIHC	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-9.9	1.81e-20	5.96e-17	-0.55	-0.47	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-9.9	1.81e-20	5.96e-17	-0.55	-0.47	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-9.9	1.81e-20	5.96e-17	-0.55	-0.47	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-9.89	1.83e-20	6.03e-17	-0.55	-0.47	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
LIHC	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	9.89	1.83e-20	6.03e-17	0.69	0.47	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
LIHC	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-9.89	1.85e-20	6.09e-17	-0.54	-0.47	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-9.89	1.9e-20	6.26e-17	-0.54	-0.47	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
LIHC	cis	rs5758659	0.512	rs4822072	ENSG00000237037.8	NDUFA6-AS1	9.89	1.95e-20	6.41e-17	0.57	0.47	Cognitive function;	chr22:41964829	chr22:42090931~42137742:+
LIHC	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	9.89	1.96e-20	6.46e-17	0.62	0.47	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
LIHC	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	9.88	1.99e-20	6.53e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
LIHC	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-9.88	2.02e-20	6.6e-17	-0.54	-0.47	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
LIHC	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	9.88	2.02e-20	6.62e-17	0.55	0.47	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
LIHC	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	9.88	2.03e-20	6.64e-17	0.53	0.47	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
LIHC	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	9.88	2.04e-20	6.67e-17	0.55	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	9.88	2.04e-20	6.67e-17	0.55	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
LIHC	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	9.88	2.09e-20	6.84e-17	0.67	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
LIHC	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	9.88	2.11e-20	6.89e-17	0.44	0.47	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	9.87	2.18e-20	7.11e-17	0.55	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
LIHC	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	9.87	2.2e-20	7.18e-17	0.53	0.47	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
LIHC	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	9.87	2.21e-20	7.2e-17	0.44	0.47	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
LIHC	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-9.87	2.22e-20	7.24e-17	-0.66	-0.47	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
LIHC	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-9.87	2.24e-20	7.29e-17	-0.55	-0.47	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
LIHC	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-9.87	2.24e-20	7.31e-17	-0.54	-0.47	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
LIHC	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	9.87	2.27e-20	7.4e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	9.87	2.27e-20	7.4e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	9.87	2.27e-20	7.4e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
LIHC	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-9.87	2.28e-20	7.43e-17	-0.62	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
LIHC	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-9.86	2.3e-20	7.49e-17	-0.59	-0.47	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
LIHC	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	9.86	2.31e-20	7.53e-17	0.7	0.47	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
LIHC	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-9.86	2.33e-20	7.57e-17	-0.56	-0.47	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-9.86	2.33e-20	7.57e-17	-0.56	-0.47	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
LIHC	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-9.86	2.39e-20	7.78e-17	-0.57	-0.47	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
LIHC	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	9.86	2.42e-20	7.86e-17	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
LIHC	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-9.86	2.45e-20	7.97e-17	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	9.86	2.47e-20	8e-17	0.56	0.47	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	9.86	2.47e-20	8e-17	0.56	0.47	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
LIHC	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	9.85	2.54e-20	8.24e-17	0.61	0.47	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
LIHC	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	9.85	2.56e-20	8.31e-17	0.55	0.47	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
LIHC	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	9.85	2.65e-20	8.58e-17	0.44	0.47	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
LIHC	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	9.85	2.65e-20	8.58e-17	0.44	0.47	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
LIHC	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-9.84	2.69e-20	8.7e-17	-0.59	-0.47	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
LIHC	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	9.84	2.82e-20	9.12e-17	0.44	0.47	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
LIHC	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	9.83	2.9e-20	9.37e-17	0.55	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
LIHC	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-9.83	2.95e-20	9.53e-17	-0.51	-0.47	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
LIHC	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-9.83	3e-20	9.7e-17	-0.55	-0.47	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
LIHC	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	9.83	3.12e-20	1.01e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
LIHC	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	9.82	3.13e-20	1.01e-16	0.39	0.47	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
LIHC	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-9.82	3.2e-20	1.03e-16	-0.49	-0.47	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
LIHC	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	9.82	3.21e-20	1.03e-16	0.5	0.47	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
LIHC	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	9.82	3.21e-20	1.04e-16	0.84	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
LIHC	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	9.82	3.21e-20	1.04e-16	0.91	0.47	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
LIHC	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-9.82	3.22e-20	1.04e-16	-0.57	-0.47	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	9.82	3.33e-20	1.07e-16	0.55	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	9.82	3.34e-20	1.07e-16	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
LIHC	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-9.82	3.35e-20	1.08e-16	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	9.82	3.37e-20	1.08e-16	0.54	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
LIHC	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	9.81	3.42e-20	1.1e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	9.81	3.42e-20	1.1e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	9.81	3.42e-20	1.1e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	9.81	3.42e-20	1.1e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
LIHC	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-9.81	3.5e-20	1.13e-16	-0.63	-0.47	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
LIHC	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	9.81	3.57e-20	1.15e-16	0.55	0.47	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
LIHC	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-9.81	3.58e-20	1.15e-16	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	9.8	3.68e-20	1.18e-16	0.55	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-9.8	3.72e-20	1.19e-16	-0.55	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
LIHC	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	9.8	3.78e-20	1.21e-16	0.63	0.47	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
LIHC	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-9.8	3.85e-20	1.23e-16	-0.67	-0.47	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
LIHC	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-9.8	3.86e-20	1.24e-16	-0.55	-0.47	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-9.8	3.86e-20	1.24e-16	-0.55	-0.47	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-9.8	3.86e-20	1.24e-16	-0.55	-0.47	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
LIHC	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	9.8	3.94e-20	1.26e-16	0.5	0.47	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	9.79	3.97e-20	1.27e-16	0.5	0.47	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
LIHC	cis	rs2260433	0.503	rs6590981	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102643876	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs4631843	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102644465	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs10750649	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102645284	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs10791582	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102645453	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs10895333	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102645949	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs10791584	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102646272	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs10791585	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102646454	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs10895335	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102646565	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.535	rs10791587	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102646902	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.503	rs10736624	ENSG00000281655.1	RP11-817J15.3	9.79	4.04e-20	1.29e-16	0.6	0.47	Cleft palate;	chr11:102647066	chr11:102681310~102683913:+
LIHC	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	9.79	4.06e-20	1.29e-16	0.54	0.47	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
LIHC	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-9.78	4.4e-20	1.4e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-9.78	4.4e-20	1.4e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-9.78	4.4e-20	1.4e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	9.78	4.45e-20	1.42e-16	0.53	0.47	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
LIHC	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	9.78	4.49e-20	1.43e-16	0.56	0.47	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
LIHC	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-9.78	4.55e-20	1.45e-16	-0.53	-0.47	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
LIHC	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-9.77	4.61e-20	1.47e-16	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
LIHC	cis	rs296381	0.561	rs58784223	ENSG00000259108.2	CTD-3098H1.2	9.77	4.8e-20	1.52e-16	0.82	0.47	Blood metabolite levels;	chr19:47847236	chr19:47863483~47865341:-
LIHC	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	9.76	5.03e-20	1.6e-16	0.58	0.47	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
LIHC	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-9.76	5.06e-20	1.61e-16	-0.55	-0.47	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
LIHC	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	9.76	5.16e-20	1.64e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	9.76	5.2e-20	1.65e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
LIHC	cis	rs2260433	0.503	rs4433535	ENSG00000281655.1	RP11-817J15.3	9.76	5.25e-20	1.67e-16	0.6	0.47	Cleft palate;	chr11:102644130	chr11:102681310~102683913:+
LIHC	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-9.75	5.41e-20	1.71e-16	-0.54	-0.47	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
LIHC	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-9.75	5.44e-20	1.73e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	9.75	5.52e-20	1.75e-16	0.55	0.47	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	9.75	5.52e-20	1.75e-16	0.55	0.47	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
LIHC	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	9.75	5.56e-20	1.76e-16	0.52	0.47	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
LIHC	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	9.75	5.56e-20	1.76e-16	0.52	0.47	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
LIHC	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	9.75	5.61e-20	1.78e-16	0.54	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
LIHC	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	9.75	5.77e-20	1.83e-16	0.57	0.47	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-9.74	5.83e-20	1.84e-16	-0.54	-0.47	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-9.74	5.83e-20	1.84e-16	-0.54	-0.47	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-9.74	5.86e-20	1.85e-16	-0.54	-0.47	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
LIHC	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-9.74	5.87e-20	1.86e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
LIHC	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	9.74	5.9e-20	1.86e-16	0.52	0.47	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
LIHC	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-9.74	5.93e-20	1.87e-16	-0.56	-0.47	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	9.74	6e-20	1.89e-16	0.62	0.47	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-9.74	6.07e-20	1.92e-16	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
LIHC	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	9.74	6.12e-20	1.93e-16	0.54	0.47	Height;	chr11:118760944	chr11:118688039~118690600:-
LIHC	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	9.74	6.2e-20	1.95e-16	0.57	0.47	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	9.73	6.3e-20	1.98e-16	0.5	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
LIHC	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-9.73	6.46e-20	2.03e-16	-0.86	-0.47	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
LIHC	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-9.73	6.47e-20	2.03e-16	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-9.73	6.57e-20	2.07e-16	-0.59	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
LIHC	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	9.73	6.62e-20	2.08e-16	0.59	0.47	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
LIHC	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-9.73	6.63e-20	2.08e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-9.73	6.63e-20	2.08e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-9.73	6.66e-20	2.09e-16	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
LIHC	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-9.73	6.73e-20	2.11e-16	-0.52	-0.47	Height;	chr11:118703185	chr11:118704607~118750263:+
LIHC	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-9.73	6.73e-20	2.11e-16	-0.52	-0.47	Height;	chr11:118703207	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-9.73	6.73e-20	2.11e-16	-0.52	-0.47	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	9.72	6.96e-20	2.18e-16	0.55	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
LIHC	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	9.72	7.08e-20	2.22e-16	0.52	0.47	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	9.72	7.08e-20	2.22e-16	0.52	0.47	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	9.72	7.08e-20	2.22e-16	0.52	0.47	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
LIHC	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-9.72	7.19e-20	2.25e-16	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-9.72	7.19e-20	2.25e-16	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-9.72	7.19e-20	2.25e-16	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-9.72	7.19e-20	2.25e-16	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	9.72	7.2e-20	2.25e-16	0.61	0.47	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
LIHC	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-9.71	7.45e-20	2.33e-16	-0.52	-0.46	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
LIHC	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-9.71	7.47e-20	2.34e-16	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-9.71	7.55e-20	2.36e-16	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
LIHC	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	9.71	7.63e-20	2.38e-16	0.5	0.46	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
LIHC	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	9.7	8e-20	2.5e-16	0.52	0.46	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
LIHC	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-9.7	8.13e-20	2.54e-16	-0.52	-0.46	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
LIHC	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	9.7	8.15e-20	2.54e-16	0.57	0.46	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
LIHC	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	9.7	8.15e-20	2.54e-16	0.57	0.46	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
LIHC	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-9.7	8.16e-20	2.54e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-9.7	8.16e-20	2.54e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-9.7	8.28e-20	2.58e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
LIHC	cis	rs296381	0.561	rs62128815	ENSG00000259108.2	CTD-3098H1.2	9.69	8.56e-20	2.67e-16	0.82	0.46	Blood metabolite levels;	chr19:47846001	chr19:47863483~47865341:-
LIHC	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-9.69	8.7e-20	2.71e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
LIHC	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	9.69	8.85e-20	2.75e-16	0.58	0.46	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	9.69	9e-20	2.8e-16	0.54	0.46	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
LIHC	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	9.69	9.04e-20	2.81e-16	0.57	0.46	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
LIHC	cis	rs9828933	0.577	rs832194	ENSG00000280620.1	SCAANT1	-9.68	9.32e-20	2.89e-16	-0.67	-0.46	Type 2 diabetes;	chr3:63871395	chr3:63911518~63911772:-
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	9.68	9.36e-20	2.9e-16	0.54	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
LIHC	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-9.68	9.45e-20	2.93e-16	-0.53	-0.46	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
LIHC	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-9.68	9.57e-20	2.96e-16	-0.52	-0.46	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
LIHC	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-9.68	9.7e-20	3e-16	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-9.68	9.7e-20	3e-16	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
LIHC	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-9.68	9.71e-20	3.01e-16	-0.54	-0.46	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
LIHC	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-9.68	9.79e-20	3.03e-16	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
LIHC	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-9.68	9.91e-20	3.06e-16	-0.56	-0.46	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
LIHC	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-9.68	9.92e-20	3.07e-16	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-9.67	9.96e-20	3.08e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-9.67	9.96e-20	3.08e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
LIHC	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	9.67	1.05e-19	3.23e-16	0.57	0.46	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
LIHC	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	9.66	1.07e-19	3.31e-16	0.53	0.46	Height;	chr11:118761813	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-9.66	1.13e-19	3.48e-16	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
LIHC	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	9.66	1.16e-19	3.56e-16	0.58	0.46	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
LIHC	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	9.65	1.17e-19	3.58e-16	0.53	0.46	Height;	chr11:118773873	chr11:118688039~118690600:-
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-9.65	1.17e-19	3.59e-16	-0.49	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
LIHC	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	9.65	1.18e-19	3.63e-16	0.49	0.46	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
LIHC	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-9.65	1.22e-19	3.75e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-9.65	1.24e-19	3.81e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
LIHC	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-9.64	1.27e-19	3.88e-16	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
LIHC	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	9.64	1.29e-19	3.96e-16	0.52	0.46	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
LIHC	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-9.64	1.3e-19	3.98e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
LIHC	cis	rs1150668	1	rs1150668	ENSG00000216901.1	AL022393.7	9.64	1.32e-19	4.05e-16	0.53	0.46	Pubertal anthropometrics;	chr6:28162011	chr6:28176188~28176674:+
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	9.63	1.35e-19	4.14e-16	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
LIHC	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-9.63	1.36e-19	4.15e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	9.63	1.38e-19	4.2e-16	0.62	0.46	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
LIHC	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	9.63	1.38e-19	4.21e-16	0.67	0.46	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
LIHC	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-9.63	1.41e-19	4.3e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-9.63	1.43e-19	4.35e-16	-0.53	-0.46	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
LIHC	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-9.62	1.46e-19	4.45e-16	-0.63	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
LIHC	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-9.62	1.51e-19	4.61e-16	-0.52	-0.46	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
LIHC	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-9.62	1.54e-19	4.68e-16	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
LIHC	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-9.62	1.57e-19	4.77e-16	-0.54	-0.46	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
LIHC	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-9.62	1.57e-19	4.77e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-9.62	1.57e-19	4.77e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
LIHC	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	9.61	1.62e-19	4.92e-16	0.49	0.46	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
LIHC	cis	rs2260433	0.503	rs10895338	ENSG00000281655.1	RP11-817J15.3	9.61	1.63e-19	4.96e-16	0.59	0.46	Cleft palate;	chr11:102647462	chr11:102681310~102683913:+
LIHC	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-9.61	1.65e-19	5.01e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
LIHC	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	9.61	1.66e-19	5.03e-16	0.64	0.46	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
LIHC	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-9.61	1.66e-19	5.05e-16	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
LIHC	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-9.61	1.67e-19	5.07e-16	-0.63	-0.46	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
LIHC	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-9.61	1.69e-19	5.11e-16	-0.55	-0.46	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-9.61	1.69e-19	5.11e-16	-0.55	-0.46	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
LIHC	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-9.61	1.7e-19	5.14e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
LIHC	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	9.6	1.71e-19	5.19e-16	0.52	0.46	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
LIHC	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-9.6	1.75e-19	5.29e-16	-0.53	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
LIHC	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	9.6	1.76e-19	5.31e-16	0.62	0.46	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-9.6	1.77e-19	5.34e-16	-0.52	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
LIHC	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-9.6	1.77e-19	5.34e-16	-0.63	-0.46	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-9.6	1.77e-19	5.34e-16	-0.63	-0.46	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
LIHC	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-9.6	1.8e-19	5.42e-16	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-9.6	1.8e-19	5.43e-16	-0.53	-0.46	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
LIHC	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	9.6	1.81e-19	5.47e-16	0.53	0.46	Height;	chr11:118764443	chr11:118688039~118690600:-
LIHC	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	9.6	1.83e-19	5.52e-16	0.62	0.46	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
LIHC	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	9.59	1.94e-19	5.84e-16	0.52	0.46	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	9.59	1.94e-19	5.84e-16	0.52	0.46	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
LIHC	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-9.59	1.96e-19	5.89e-16	-0.56	-0.46	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
LIHC	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-9.59	1.96e-19	5.92e-16	-0.54	-0.46	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
LIHC	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	9.59	1.97e-19	5.94e-16	0.62	0.46	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	9.58	2.05e-19	6.17e-16	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
LIHC	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-9.58	2.1e-19	6.33e-16	-0.54	-0.46	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
LIHC	cis	rs296381	0.561	rs58914460	ENSG00000259108.2	CTD-3098H1.2	9.58	2.11e-19	6.35e-16	0.83	0.46	Blood metabolite levels;	chr19:47847590	chr19:47863483~47865341:-
LIHC	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-9.58	2.12e-19	6.36e-16	-0.53	-0.46	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
LIHC	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	9.56	2.4e-19	7.2e-16	0.53	0.46	Height;	chr11:118746590	chr11:118688039~118690600:-
LIHC	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-9.56	2.42e-19	7.25e-16	-0.58	-0.46	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
LIHC	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-9.56	2.46e-19	7.38e-16	-0.54	-0.46	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
LIHC	cis	rs1150668	0.965	rs1654774	ENSG00000216901.1	AL022393.7	9.55	2.57e-19	7.71e-16	0.53	0.46	Pubertal anthropometrics;	chr6:28128502	chr6:28176188~28176674:+
LIHC	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-9.55	2.62e-19	7.83e-16	-0.73	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	9.54	2.73e-19	8.16e-16	0.53	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	9.54	2.78e-19	8.31e-16	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
LIHC	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-9.54	2.87e-19	8.56e-16	-0.7	-0.46	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-9.54	2.87e-19	8.56e-16	-0.7	-0.46	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
LIHC	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-9.53	3.02e-19	8.99e-16	-0.53	-0.46	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
LIHC	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	9.53	3.04e-19	9.05e-16	0.53	0.46	Height;	chr11:118742526	chr11:118688039~118690600:-
LIHC	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	9.52	3.27e-19	9.72e-16	0.55	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
LIHC	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-9.51	3.41e-19	1.01e-15	-0.54	-0.46	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
LIHC	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-9.51	3.41e-19	1.01e-15	-0.51	-0.46	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
LIHC	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-9.51	3.46e-19	1.03e-15	-0.55	-0.46	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-9.51	3.5e-19	1.04e-15	-0.53	-0.46	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
LIHC	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	9.51	3.51e-19	1.04e-15	0.53	0.46	Height;	chr11:118747911	chr11:118688039~118690600:-
LIHC	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-9.51	3.54e-19	1.05e-15	-0.53	-0.46	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
LIHC	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	9.5	3.65e-19	1.08e-15	0.55	0.46	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	9.5	3.65e-19	1.08e-15	0.55	0.46	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	9.5	3.65e-19	1.08e-15	0.55	0.46	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	9.5	3.65e-19	1.08e-15	0.55	0.46	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	9.5	3.65e-19	1.08e-15	0.55	0.46	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
LIHC	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-9.5	3.68e-19	1.09e-15	-0.59	-0.46	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
LIHC	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-9.5	3.68e-19	1.09e-15	-0.53	-0.46	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-9.5	3.68e-19	1.09e-15	-0.53	-0.46	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
LIHC	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-9.5	3.87e-19	1.14e-15	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
LIHC	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-9.5	3.92e-19	1.16e-15	-0.56	-0.46	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
LIHC	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-9.49	3.94e-19	1.16e-15	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-9.49	4.02e-19	1.19e-15	-0.53	-0.46	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-9.49	4.02e-19	1.19e-15	-0.53	-0.46	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-9.49	4.02e-19	1.19e-15	-0.53	-0.46	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
LIHC	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-9.49	4.11e-19	1.21e-15	-0.56	-0.46	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-9.49	4.11e-19	1.21e-15	-0.56	-0.46	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
LIHC	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	9.49	4.12e-19	1.21e-15	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
LIHC	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	9.49	4.14e-19	1.22e-15	0.52	0.46	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
LIHC	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	9.49	4.19e-19	1.23e-15	0.52	0.46	Height;	chr11:118749988	chr11:118688039~118690600:-
LIHC	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-9.49	4.2e-19	1.24e-15	-0.53	-0.46	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
LIHC	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-9.49	4.21e-19	1.24e-15	-0.53	-0.46	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
LIHC	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-9.49	4.21e-19	1.24e-15	-0.5	-0.46	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
LIHC	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-9.49	4.23e-19	1.24e-15	-0.55	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
LIHC	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	9.48	4.29e-19	1.26e-15	0.61	0.46	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-9.48	4.34e-19	1.28e-15	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-9.48	4.43e-19	1.3e-15	-0.53	-0.46	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
LIHC	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-9.48	4.47e-19	1.31e-15	-0.55	-0.46	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-9.48	4.47e-19	1.31e-15	-0.55	-0.46	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	9.48	4.51e-19	1.33e-15	0.54	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
LIHC	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-9.48	4.55e-19	1.34e-15	-0.54	-0.46	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-9.48	4.55e-19	1.34e-15	-0.54	-0.46	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-9.47	4.62e-19	1.35e-15	-0.53	-0.46	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	9.47	4.63e-19	1.36e-15	0.6	0.46	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-9.47	4.64e-19	1.36e-15	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
LIHC	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-9.47	4.71e-19	1.38e-15	-0.53	-0.46	Height;	chr11:118758322	chr11:118688039~118690600:-
LIHC	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-9.47	4.8e-19	1.41e-15	-0.53	-0.46	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
LIHC	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-9.47	4.81e-19	1.41e-15	-0.7	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	9.46	5.13e-19	1.5e-15	0.6	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
LIHC	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	9.46	5.2e-19	1.52e-15	0.57	0.46	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
LIHC	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	9.46	5.21e-19	1.52e-15	0.81	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
LIHC	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-9.46	5.21e-19	1.52e-15	-0.53	-0.46	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
LIHC	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	9.46	5.25e-19	1.53e-15	0.63	0.46	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
LIHC	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-9.46	5.28e-19	1.54e-15	-0.54	-0.46	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
LIHC	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-9.45	5.42e-19	1.58e-15	-0.53	-0.46	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
LIHC	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-9.45	5.45e-19	1.59e-15	-0.53	-0.46	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
LIHC	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-9.45	5.61e-19	1.64e-15	-0.54	-0.45	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
LIHC	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-9.45	5.72e-19	1.67e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
LIHC	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-9.44	6.02e-19	1.75e-15	-0.54	-0.45	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
LIHC	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	9.44	6.05e-19	1.76e-15	0.61	0.45	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
LIHC	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-9.43	6.37e-19	1.84e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
LIHC	cis	rs7208859	0.673	rs9903862	ENSG00000263531.1	RP13-753N3.1	9.43	6.5e-19	1.88e-15	0.86	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879415	chr17:30863921~30864940:-
LIHC	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-9.43	6.6e-19	1.91e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
LIHC	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	9.42	6.75e-19	1.95e-15	0.52	0.45	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	9.41	7.23e-19	2.08e-15	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	9.41	7.23e-19	2.08e-15	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	9.41	7.23e-19	2.08e-15	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	9.41	7.23e-19	2.08e-15	0.78	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
LIHC	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	9.41	7.3e-19	2.1e-15	0.69	0.45	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-9.41	7.39e-19	2.13e-15	-0.6	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
LIHC	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	9.4	7.84e-19	2.25e-15	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
LIHC	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-9.4	7.86e-19	2.26e-15	-0.53	-0.45	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
LIHC	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-9.4	8.1e-19	2.33e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
LIHC	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	9.4	8.14e-19	2.34e-15	0.86	0.45	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
LIHC	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-9.4	8.14e-19	2.34e-15	-0.53	-0.45	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
LIHC	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	9.4	8.2e-19	2.35e-15	0.68	0.45	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
LIHC	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-9.39	8.51e-19	2.44e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-9.39	8.51e-19	2.44e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-9.39	8.55e-19	2.45e-15	-0.52	-0.45	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
LIHC	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	9.39	8.87e-19	2.54e-15	0.55	0.45	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
LIHC	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	9.39	8.98e-19	2.57e-15	0.52	0.45	Height;	chr11:118737916	chr11:118688039~118690600:-
LIHC	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-9.38	9.06e-19	2.59e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
LIHC	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-9.38	9.08e-19	2.6e-15	-0.55	-0.45	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
LIHC	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	9.38	9.34e-19	2.67e-15	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
LIHC	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	9.38	9.43e-19	2.7e-15	0.69	0.45	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
LIHC	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	9.38	9.58e-19	2.74e-15	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
LIHC	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-9.37	9.8e-19	2.79e-15	-0.58	-0.45	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
LIHC	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-9.37	9.83e-19	2.8e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-9.37	9.83e-19	2.8e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-9.37	9.83e-19	2.8e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-9.37	9.83e-19	2.8e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-9.37	9.83e-19	2.8e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-9.37	9.83e-19	2.8e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-9.37	9.83e-19	2.8e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
LIHC	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-9.37	1e-18	2.86e-15	-0.53	-0.45	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
LIHC	cis	rs9843304	0.868	rs4681516	ENSG00000244503.1	RP11-278L15.6	-9.37	1.02e-18	2.9e-15	-0.42	-0.45	Gallstone disease;	chr3:149494338	chr3:149494660~149495995:+
LIHC	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-9.37	1.05e-18	2.98e-15	-0.55	-0.45	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
LIHC	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	9.37	1.05e-18	2.98e-15	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	9.37	1.05e-18	2.98e-15	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
LIHC	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-9.36	1.06e-18	3.02e-15	-0.59	-0.45	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
LIHC	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-9.36	1.07e-18	3.04e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-9.36	1.08e-18	3.06e-15	-0.53	-0.45	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
LIHC	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-9.36	1.1e-18	3.12e-15	-0.53	-0.45	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
LIHC	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-9.36	1.11e-18	3.15e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-9.35	1.14e-18	3.22e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
LIHC	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	9.35	1.14e-18	3.22e-15	0.61	0.45	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
LIHC	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-9.35	1.15e-18	3.26e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	9.35	1.15e-18	3.26e-15	0.53	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
LIHC	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-9.35	1.21e-18	3.43e-15	-0.53	-0.45	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
LIHC	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-9.35	1.21e-18	3.43e-15	-0.53	-0.45	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
LIHC	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	9.34	1.25e-18	3.54e-15	0.53	0.45	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-9.33	1.35e-18	3.8e-15	-0.51	-0.45	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
LIHC	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	9.33	1.35e-18	3.82e-15	0.42	0.45	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
LIHC	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-9.33	1.38e-18	3.88e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
LIHC	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	9.33	1.39e-18	3.93e-15	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
LIHC	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-9.32	1.45e-18	4.1e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
LIHC	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	9.32	1.46e-18	4.12e-15	0.52	0.45	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
LIHC	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-9.32	1.48e-18	4.18e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
LIHC	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	9.31	1.55e-18	4.36e-15	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	9.31	1.55e-18	4.36e-15	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
LIHC	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-9.31	1.56e-18	4.38e-15	-0.57	-0.45	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
LIHC	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	9.31	1.57e-18	4.41e-15	0.61	0.45	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
LIHC	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-9.31	1.64e-18	4.6e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
LIHC	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-9.3	1.67e-18	4.69e-15	-0.45	-0.45	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
LIHC	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-9.3	1.67e-18	4.69e-15	-0.45	-0.45	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
LIHC	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-9.3	1.77e-18	4.96e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	9.29	1.84e-18	5.13e-15	0.53	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
LIHC	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	9.29	1.84e-18	5.15e-15	0.67	0.45	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	9.29	1.84e-18	5.15e-15	0.67	0.45	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
LIHC	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	9.29	1.85e-18	5.17e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	9.29	1.87e-18	5.22e-15	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
LIHC	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	9.29	1.89e-18	5.28e-15	0.78	0.45	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
LIHC	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-9.28	1.92e-18	5.36e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
LIHC	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-9.28	1.96e-18	5.46e-15	-0.46	-0.45	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
LIHC	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-9.28	1.97e-18	5.49e-15	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	9.28	1.98e-18	5.5e-15	0.77	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
LIHC	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-9.28	1.99e-18	5.53e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
LIHC	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-9.27	2.13e-18	5.92e-15	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-9.27	2.16e-18	5.99e-15	-0.52	-0.45	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
LIHC	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-9.27	2.21e-18	6.11e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
LIHC	cis	rs296381	0.866	rs2637115	ENSG00000259108.2	CTD-3098H1.2	-9.26	2.24e-18	6.2e-15	-0.76	-0.45	Blood metabolite levels;	chr19:47882370	chr19:47863483~47865341:-
LIHC	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	9.26	2.27e-18	6.28e-15	0.45	0.45	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
LIHC	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	9.26	2.27e-18	6.28e-15	0.45	0.45	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	9.26	2.27e-18	6.28e-15	0.45	0.45	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
LIHC	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	9.26	2.27e-18	6.28e-15	0.45	0.45	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
LIHC	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	9.26	2.36e-18	6.52e-15	0.59	0.45	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
LIHC	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	9.26	2.37e-18	6.55e-15	0.67	0.45	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
LIHC	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	9.26	2.38e-18	6.58e-15	0.45	0.45	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
LIHC	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	9.26	2.38e-18	6.58e-15	0.45	0.45	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	9.26	2.38e-18	6.58e-15	0.45	0.45	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	9.26	2.38e-18	6.58e-15	0.45	0.45	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	9.26	2.38e-18	6.58e-15	0.45	0.45	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
LIHC	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-9.26	2.39e-18	6.61e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-9.26	2.39e-18	6.61e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-9.26	2.39e-18	6.61e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-9.26	2.39e-18	6.61e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-9.26	2.39e-18	6.61e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-9.26	2.39e-18	6.61e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
LIHC	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	9.26	2.4e-18	6.62e-15	0.77	0.45	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
LIHC	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-9.25	2.41e-18	6.64e-15	-0.83	-0.45	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
LIHC	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-9.25	2.45e-18	6.76e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
LIHC	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	9.25	2.47e-18	6.82e-15	0.76	0.45	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
LIHC	cis	rs9843304	0.772	rs4681515	ENSG00000244503.1	RP11-278L15.6	-9.25	2.51e-18	6.87e-15	-0.41	-0.45	Gallstone disease;	chr3:149494289	chr3:149494660~149495995:+
LIHC	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-9.25	2.52e-18	6.89e-15	-0.53	-0.45	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
LIHC	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	9.25	2.54e-18	6.96e-15	0.45	0.45	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	9.25	2.54e-18	6.96e-15	0.45	0.45	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	9.25	2.54e-18	6.96e-15	0.45	0.45	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
LIHC	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-9.24	2.63e-18	7.2e-15	-0.56	-0.45	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
LIHC	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-9.24	2.69e-18	7.34e-15	-0.53	-0.45	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
LIHC	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-9.24	2.7e-18	7.37e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
LIHC	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	9.24	2.72e-18	7.44e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	9.24	2.72e-18	7.44e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
LIHC	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-9.24	2.73e-18	7.44e-15	-0.76	-0.45	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
LIHC	cis	rs9843304	0.9	rs6774253	ENSG00000244503.1	RP11-278L15.6	-9.24	2.74e-18	7.49e-15	-0.41	-0.45	Gallstone disease;	chr3:149494110	chr3:149494660~149495995:+
LIHC	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	9.23	2.82e-18	7.69e-15	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	9.23	2.82e-18	7.69e-15	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	9.23	2.82e-18	7.69e-15	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	9.23	2.82e-18	7.69e-15	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	9.23	2.82e-18	7.69e-15	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	9.23	2.85e-18	7.75e-15	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	9.23	2.85e-18	7.77e-15	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-9.23	2.87e-18	7.8e-15	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
LIHC	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	9.23	2.87e-18	7.81e-15	0.53	0.45	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
LIHC	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	9.23	2.94e-18	7.98e-15	0.77	0.45	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
LIHC	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-9.23	2.94e-18	7.98e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
LIHC	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	9.23	2.97e-18	8.08e-15	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	9.23	2.97e-18	8.08e-15	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
LIHC	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-9.23	3e-18	8.14e-15	-0.52	-0.45	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
LIHC	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-9.22	3.01e-18	8.17e-15	-0.66	-0.45	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
LIHC	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-9.22	3.02e-18	8.21e-15	-0.55	-0.45	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
LIHC	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-9.22	3.05e-18	8.28e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
LIHC	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	9.22	3.06e-18	8.3e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
LIHC	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	9.22	3.07e-18	8.32e-15	0.76	0.45	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
LIHC	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	9.22	3.07e-18	8.32e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-9.22	3.09e-18	8.36e-15	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	9.22	3.09e-18	8.36e-15	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
LIHC	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	9.22	3.09e-18	8.36e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
LIHC	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	9.22	3.09e-18	8.36e-15	0.53	0.45	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	9.22	3.09e-18	8.36e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	9.22	3.09e-18	8.36e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	9.22	3.09e-18	8.36e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
LIHC	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	9.22	3.11e-18	8.42e-15	0.55	0.45	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
LIHC	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	9.22	3.11e-18	8.42e-15	0.55	0.45	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
LIHC	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-9.22	3.16e-18	8.56e-15	-0.52	-0.45	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
LIHC	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	9.22	3.18e-18	8.6e-15	0.75	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
LIHC	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-9.22	3.22e-18	8.71e-15	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	9.22	3.23e-18	8.73e-15	0.55	0.45	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-9.21	3.24e-18	8.77e-15	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-9.21	3.27e-18	8.84e-15	-0.51	-0.45	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
LIHC	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	9.21	3.29e-18	8.89e-15	0.53	0.45	Temperament;	chr17:13996939	chr17:14024514~14025488:+
LIHC	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	9.21	3.37e-18	9.09e-15	0.55	0.45	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
LIHC	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	9.21	3.38e-18	9.11e-15	0.56	0.45	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
LIHC	cis	rs296381	0.808	rs10426201	ENSG00000259108.2	CTD-3098H1.2	-9.21	3.43e-18	9.25e-15	-0.76	-0.45	Blood metabolite levels;	chr19:47881492	chr19:47863483~47865341:-
LIHC	cis	rs1577917	0.74	rs9450302	ENSG00000234155.1	RP11-30P6.6	-9.21	3.46e-18	9.33e-15	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85579955	chr6:85387219~85390186:-
LIHC	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	9.2	3.63e-18	9.76e-15	0.77	0.45	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
LIHC	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	9.2	3.65e-18	9.82e-15	0.53	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
LIHC	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-9.2	3.69e-18	9.93e-15	-0.52	-0.45	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
LIHC	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-9.2	3.75e-18	1.01e-14	-0.55	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	9.2	3.75e-18	1.01e-14	0.51	0.45	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-9.19	3.78e-18	1.02e-14	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	9.19	3.79e-18	1.02e-14	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-9.19	3.83e-18	1.03e-14	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-9.19	3.83e-18	1.03e-14	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	9.19	3.85e-18	1.03e-14	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
LIHC	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	9.19	3.85e-18	1.03e-14	0.77	0.45	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	9.19	3.89e-18	1.04e-14	0.51	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
LIHC	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-9.19	3.92e-18	1.05e-14	-0.56	-0.45	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-9.19	3.92e-18	1.05e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
LIHC	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	9.19	4.03e-18	1.08e-14	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
LIHC	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	9.18	4.08e-18	1.09e-14	0.41	0.44	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
LIHC	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-9.18	4.33e-18	1.16e-14	-0.45	-0.44	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
LIHC	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-9.18	4.34e-18	1.16e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
LIHC	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-9.17	4.38e-18	1.17e-14	-0.62	-0.44	Migraine;	chr4:56853383	chr4:56960927~56961373:-
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	9.17	4.4e-18	1.18e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
LIHC	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	9.17	4.41e-18	1.18e-14	0.52	0.44	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
LIHC	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	9.17	4.43e-18	1.18e-14	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-9.17	4.52e-18	1.2e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-9.17	4.52e-18	1.2e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
LIHC	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-9.17	4.53e-18	1.21e-14	-0.55	-0.44	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
LIHC	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	9.17	4.56e-18	1.22e-14	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-9.17	4.59e-18	1.22e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
LIHC	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	9.17	4.63e-18	1.23e-14	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
LIHC	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	9.16	4.77e-18	1.27e-14	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
LIHC	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	9.16	4.95e-18	1.32e-14	0.76	0.44	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
LIHC	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	9.16	4.99e-18	1.33e-14	0.54	0.44	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
LIHC	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	9.15	5.09e-18	1.35e-14	0.62	0.44	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-9.15	5.26e-18	1.39e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
LIHC	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	9.15	5.27e-18	1.4e-14	0.67	0.44	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
LIHC	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	9.15	5.3e-18	1.4e-14	0.5	0.44	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.673	rs57432042	ENSG00000263531.1	RP13-753N3.1	9.15	5.32e-18	1.41e-14	0.82	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30914020	chr17:30863921~30864940:-
LIHC	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-9.15	5.35e-18	1.42e-14	-0.5	-0.44	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
LIHC	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-9.15	5.36e-18	1.42e-14	-0.55	-0.44	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
LIHC	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	9.15	5.44e-18	1.44e-14	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-9.14	5.45e-18	1.44e-14	-0.56	-0.44	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
LIHC	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	9.14	5.51e-18	1.45e-14	0.42	0.44	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
LIHC	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-9.14	5.56e-18	1.47e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-9.14	5.57e-18	1.47e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
LIHC	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	9.14	5.59e-18	1.47e-14	0.41	0.44	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
LIHC	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-9.14	5.68e-18	1.5e-14	-0.61	-0.44	Migraine;	chr4:56851192	chr4:56960927~56961373:-
LIHC	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-9.14	5.68e-18	1.5e-14	-0.61	-0.44	Migraine;	chr4:56852087	chr4:56960927~56961373:-
LIHC	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-9.14	5.72e-18	1.51e-14	-0.57	-0.44	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
LIHC	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	9.14	5.82e-18	1.53e-14	0.44	0.44	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
LIHC	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	9.13	5.9e-18	1.55e-14	0.67	0.44	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
LIHC	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	9.13	5.91e-18	1.55e-14	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
LIHC	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-9.13	5.94e-18	1.56e-14	-0.57	-0.44	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-9.13	5.94e-18	1.56e-14	-0.57	-0.44	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
LIHC	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	9.13	5.98e-18	1.57e-14	0.42	0.44	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
LIHC	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-9.13	6.11e-18	1.6e-14	-0.6	-0.44	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
LIHC	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	9.13	6.18e-18	1.62e-14	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-9.13	6.24e-18	1.64e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	9.12	6.35e-18	1.66e-14	0.79	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	9.12	6.35e-18	1.66e-14	0.79	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	9.12	6.35e-18	1.66e-14	0.79	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	9.12	6.38e-18	1.67e-14	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
LIHC	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-9.12	6.52e-18	1.71e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	9.12	6.69e-18	1.75e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
LIHC	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	9.12	6.76e-18	1.77e-14	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	9.12	6.78e-18	1.77e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
LIHC	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-9.12	6.79e-18	1.78e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-9.12	6.79e-18	1.78e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
LIHC	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-9.12	6.8e-18	1.78e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-9.11	6.82e-18	1.78e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-9.11	6.82e-18	1.78e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-9.11	6.82e-18	1.78e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
LIHC	cis	rs10916248	0.559	rs56023673	ENSG00000232628.4	RP11-365O16.3	9.11	6.84e-18	1.79e-14	0.67	0.44	QT interval (drug interaction);	chr1:224180821	chr1:224208747~224213279:-
LIHC	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-9.11	6.89e-18	1.8e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	9.11	7.01e-18	1.83e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
LIHC	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	9.11	7.04e-18	1.83e-14	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-9.11	7.08e-18	1.85e-14	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
LIHC	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	9.11	7.12e-18	1.86e-14	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
LIHC	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-9.11	7.19e-18	1.87e-14	-0.51	-0.44	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
LIHC	cis	rs1577917	0.655	rs9359658	ENSG00000234155.1	RP11-30P6.6	-9.11	7.21e-18	1.88e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85596051	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-9.11	7.29e-18	1.9e-14	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
LIHC	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-9.1	7.36e-18	1.92e-14	-0.65	-0.44	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
LIHC	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-9.1	7.37e-18	1.92e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-9.1	7.37e-18	1.92e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
LIHC	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	9.1	7.39e-18	1.92e-14	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.74	rs9344533	ENSG00000234155.1	RP11-30P6.6	-9.1	7.47e-18	1.94e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85526470	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.74	rs9353320	ENSG00000234155.1	RP11-30P6.6	-9.1	7.47e-18	1.94e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85535130	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.74	rs7775864	ENSG00000234155.1	RP11-30P6.6	-9.1	7.47e-18	1.94e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85538041	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.655	rs7742691	ENSG00000234155.1	RP11-30P6.6	-9.1	7.48e-18	1.94e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85568973	chr6:85387219~85390186:-
LIHC	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	9.1	7.6e-18	1.97e-14	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
LIHC	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-9.1	7.7e-18	2e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-9.1	7.7e-18	2e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
LIHC	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-9.1	7.72e-18	2e-14	-0.51	-0.44	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
LIHC	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	9.1	7.85e-18	2.04e-14	0.5	0.44	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
LIHC	cis	rs1577917	0.71	rs9342041	ENSG00000234155.1	RP11-30P6.6	-9.09	7.97e-18	2.06e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85571157	chr6:85387219~85390186:-
LIHC	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	9.09	8e-18	2.07e-14	0.66	0.44	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
LIHC	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	9.09	8.09e-18	2.09e-14	0.54	0.44	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
LIHC	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-9.09	8.1e-18	2.1e-14	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-9.09	8.23e-18	2.13e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
LIHC	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-9.09	8.35e-18	2.16e-14	-0.51	-0.44	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
LIHC	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	9.09	8.41e-18	2.17e-14	0.52	0.44	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	9.09	8.43e-18	2.18e-14	0.5	0.44	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	9.09	8.43e-18	2.18e-14	0.5	0.44	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	9.09	8.43e-18	2.18e-14	0.5	0.44	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
LIHC	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-9.08	8.56e-18	2.21e-14	-0.52	-0.44	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
LIHC	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	9.08	8.57e-18	2.21e-14	0.52	0.44	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
LIHC	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-9.08	8.66e-18	2.23e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-9.08	8.66e-18	2.23e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-9.08	8.66e-18	2.23e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
LIHC	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	9.08	8.71e-18	2.25e-14	0.51	0.44	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
LIHC	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-9.08	8.78e-18	2.26e-14	-0.56	-0.44	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
LIHC	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-9.08	8.8e-18	2.27e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-9.08	8.81e-18	2.27e-14	-0.51	-0.44	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	9.08	8.87e-18	2.28e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
LIHC	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-9.08	8.98e-18	2.31e-14	-0.57	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
LIHC	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-9.08	9e-18	2.32e-14	-0.41	-0.44	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
LIHC	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-9.07	9.38e-18	2.41e-14	-0.5	-0.44	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
LIHC	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-9.07	9.43e-18	2.42e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
LIHC	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	9.07	9.46e-18	2.42e-14	0.44	0.44	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
LIHC	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	9.07	9.46e-18	2.42e-14	0.62	0.44	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
LIHC	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-9.07	9.57e-18	2.45e-14	-0.55	-0.44	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-9.07	9.73e-18	2.49e-14	-0.51	-0.44	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
LIHC	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	9.07	9.87e-18	2.52e-14	0.43	0.44	Breast cancer;	chr11:750849	chr11:779617~780755:+
LIHC	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	9.06	1.01e-17	2.57e-14	0.52	0.44	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
LIHC	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	9.06	1.01e-17	2.58e-14	0.62	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	9.06	1.01e-17	2.58e-14	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
LIHC	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	9.06	1.02e-17	2.6e-14	0.44	0.44	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
LIHC	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	9.06	1.02e-17	2.6e-14	0.44	0.44	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
LIHC	cis	rs1577917	0.74	rs2758843	ENSG00000234155.1	RP11-30P6.6	9.06	1.02e-17	2.6e-14	0.51	0.44	Response to antipsychotic treatment;	chr6:85618713	chr6:85387219~85390186:-
LIHC	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-9.06	1.02e-17	2.6e-14	-0.57	-0.44	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
LIHC	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-9.06	1.04e-17	2.66e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	9.06	1.06e-17	2.69e-14	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
LIHC	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-9.06	1.06e-17	2.69e-14	-0.46	-0.44	Temperament;	chr17:14033087	chr17:14024514~14025488:+
LIHC	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	9.05	1.06e-17	2.71e-14	0.63	0.44	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	9.05	1.06e-17	2.71e-14	0.63	0.44	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	9.05	1.06e-17	2.71e-14	0.63	0.44	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
LIHC	cis	rs1577917	0.74	rs2842614	ENSG00000234155.1	RP11-30P6.6	9.05	1.06e-17	2.71e-14	0.51	0.44	Response to antipsychotic treatment;	chr6:85596351	chr6:85387219~85390186:-
LIHC	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	9.05	1.08e-17	2.75e-14	0.67	0.44	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
LIHC	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-9.05	1.08e-17	2.75e-14	-0.6	-0.44	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.74	rs2758842	ENSG00000234155.1	RP11-30P6.6	9.05	1.08e-17	2.75e-14	0.51	0.44	Response to antipsychotic treatment;	chr6:85599013	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.572	rs911927	ENSG00000234155.1	RP11-30P6.6	9.05	1.08e-17	2.75e-14	0.51	0.44	Response to antipsychotic treatment;	chr6:85618142	chr6:85387219~85390186:-
LIHC	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	9.05	1.12e-17	2.85e-14	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
LIHC	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	9.04	1.15e-17	2.91e-14	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
LIHC	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-9.04	1.16e-17	2.93e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-9.04	1.16e-17	2.93e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
LIHC	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	9.04	1.19e-17	3.01e-14	0.41	0.44	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
LIHC	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-9.04	1.2e-17	3.04e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
LIHC	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-9.03	1.24e-17	3.14e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-9.03	1.24e-17	3.14e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
LIHC	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-9.03	1.27e-17	3.22e-14	-0.5	-0.44	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	9.03	1.28e-17	3.22e-14	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
LIHC	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-9.03	1.28e-17	3.23e-14	-0.47	-0.44	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
LIHC	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	9.03	1.28e-17	3.23e-14	0.62	0.44	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
LIHC	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-9.03	1.28e-17	3.24e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-9.03	1.28e-17	3.24e-14	-0.53	-0.44	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
LIHC	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-9.03	1.29e-17	3.26e-14	-0.56	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
LIHC	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	9.03	1.3e-17	3.27e-14	0.65	0.44	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
LIHC	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	9.03	1.3e-17	3.28e-14	0.54	0.44	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
LIHC	cis	rs8062405	0.728	rs11642449	ENSG00000259982.1	CDC37P1	9.03	1.31e-17	3.29e-14	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.728	rs8056890	ENSG00000259982.1	CDC37P1	9.03	1.31e-17	3.29e-14	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-9.03	1.31e-17	3.31e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	9.03	1.32e-17	3.33e-14	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
LIHC	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	9.02	1.34e-17	3.37e-14	0.54	0.44	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
LIHC	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-9.02	1.36e-17	3.42e-14	-0.61	-0.44	Migraine;	chr4:56850720	chr4:56960927~56961373:-
LIHC	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-9.02	1.39e-17	3.49e-14	-0.44	-0.44	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	9.02	1.41e-17	3.54e-14	0.44	0.44	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
LIHC	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	9.02	1.41e-17	3.54e-14	0.62	0.44	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
LIHC	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-9.01	1.44e-17	3.63e-14	-0.51	-0.44	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	9.01	1.5e-17	3.77e-14	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
LIHC	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	9.01	1.51e-17	3.78e-14	0.44	0.44	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
LIHC	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-9.01	1.53e-17	3.83e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
LIHC	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	9	1.56e-17	3.92e-14	0.55	0.44	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
LIHC	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	9	1.64e-17	4.1e-14	0.57	0.44	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
LIHC	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-9	1.64e-17	4.11e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
LIHC	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-9	1.65e-17	4.12e-14	-0.41	-0.44	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
LIHC	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-8.99	1.69e-17	4.23e-14	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
LIHC	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	8.99	1.7e-17	4.25e-14	0.63	0.44	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
LIHC	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-8.99	1.73e-17	4.31e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
LIHC	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-8.99	1.73e-17	4.32e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
LIHC	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-8.99	1.74e-17	4.34e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
LIHC	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-8.99	1.76e-17	4.4e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
LIHC	cis	rs296381	0.866	rs296360	ENSG00000259108.2	CTD-3098H1.2	8.99	1.77e-17	4.41e-14	0.8	0.44	Blood metabolite levels;	chr19:47885401	chr19:47863483~47865341:-
LIHC	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	8.99	1.77e-17	4.42e-14	0.58	0.44	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
LIHC	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-8.98	1.78e-17	4.44e-14	-0.43	-0.44	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
LIHC	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-8.98	1.78e-17	4.44e-14	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	8.98	1.79e-17	4.47e-14	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
LIHC	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-8.98	1.8e-17	4.49e-14	-0.46	-0.44	Temperament;	chr17:14075460	chr17:14024514~14025488:+
LIHC	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-8.98	1.82e-17	4.52e-14	-0.5	-0.44	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
LIHC	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-8.98	1.87e-17	4.65e-14	-0.44	-0.44	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
LIHC	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-8.98	1.88e-17	4.67e-14	-0.5	-0.44	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-8.98	1.88e-17	4.67e-14	-0.5	-0.44	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
LIHC	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	8.98	1.9e-17	4.71e-14	0.53	0.44	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.74	rs7771612	ENSG00000234155.1	RP11-30P6.6	-8.98	1.9e-17	4.71e-14	-0.51	-0.44	Response to antipsychotic treatment;	chr6:85554656	chr6:85387219~85390186:-
LIHC	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	8.98	1.9e-17	4.71e-14	0.49	0.44	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
LIHC	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	8.97	1.92e-17	4.76e-14	0.75	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	8.97	1.99e-17	4.93e-14	0.77	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
LIHC	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	8.97	2e-17	4.95e-14	0.54	0.44	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
LIHC	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-8.97	2.02e-17	5e-14	-0.5	-0.44	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-8.97	2.02e-17	5e-14	-0.5	-0.44	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
LIHC	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	8.96	2.15e-17	5.3e-14	0.52	0.44	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-8.96	2.21e-17	5.43e-14	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
LIHC	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.24e-17	5.5e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
LIHC	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-8.95	2.24e-17	5.51e-14	-0.52	-0.44	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
LIHC	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-8.95	2.25e-17	5.52e-14	-0.51	-0.44	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
LIHC	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-8.95	2.27e-17	5.56e-14	-0.45	-0.44	Temperament;	chr17:14007232	chr17:14024514~14025488:+
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000206090.4	AP000350.7	8.95	2.38e-17	5.83e-14	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23939998~23942798:+
LIHC	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-8.94	2.42e-17	5.92e-14	-0.51	-0.44	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
LIHC	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	8.94	2.43e-17	5.96e-14	0.5	0.44	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-8.94	2.45e-17	6e-14	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
LIHC	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-8.94	2.47e-17	6.03e-14	-0.56	-0.44	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
LIHC	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-8.94	2.47e-17	6.03e-14	-0.52	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
LIHC	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-8.94	2.53e-17	6.15e-14	-0.73	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
LIHC	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	8.93	2.58e-17	6.27e-14	0.43	0.44	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
LIHC	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-8.93	2.62e-17	6.36e-14	-0.54	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
LIHC	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-8.93	2.64e-17	6.4e-14	-0.52	-0.43	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
LIHC	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	8.93	2.64e-17	6.41e-14	0.54	0.43	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	8.93	2.66e-17	6.44e-14	0.54	0.43	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
LIHC	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-8.93	2.69e-17	6.5e-14	-0.5	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
LIHC	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	8.93	2.76e-17	6.67e-14	0.44	0.43	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
LIHC	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-8.92	2.77e-17	6.69e-14	-0.6	-0.43	Migraine;	chr4:56852029	chr4:56960927~56961373:-
LIHC	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-8.92	2.78e-17	6.71e-14	-0.51	-0.43	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
LIHC	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	8.92	2.78e-17	6.72e-14	0.44	0.43	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
LIHC	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	8.92	2.88e-17	6.95e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	8.92	2.88e-17	6.95e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	8.92	2.88e-17	6.95e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	8.92	2.88e-17	6.95e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	8.92	2.88e-17	6.95e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	8.92	2.88e-17	6.95e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	8.92	2.88e-17	6.95e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
LIHC	cis	rs2487048	1	rs2487046	ENSG00000226334.1	RP11-217B7.2	-8.92	2.91e-17	7.01e-14	-0.59	-0.43	Intraocular pressure;	chr9:104929948	chr9:104927553~104928892:+
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000206090.4	AP000350.7	-8.92	2.93e-17	7.07e-14	-0.51	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23939998~23942798:+
LIHC	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-8.91	3e-17	7.22e-14	-0.51	-0.43	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
LIHC	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	8.91	3.01e-17	7.26e-14	0.4	0.43	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
LIHC	cis	rs1577917	0.682	rs6935918	ENSG00000234155.1	RP11-30P6.6	-8.91	3.04e-17	7.3e-14	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85573857	chr6:85387219~85390186:-
LIHC	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-8.91	3.1e-17	7.43e-14	-0.43	-0.43	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
LIHC	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	8.91	3.1e-17	7.45e-14	0.74	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
LIHC	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-8.91	3.11e-17	7.45e-14	-0.51	-0.43	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
LIHC	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-8.91	3.14e-17	7.53e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-8.91	3.15e-17	7.56e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-8.91	3.15e-17	7.56e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-8.91	3.15e-17	7.56e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
LIHC	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	8.9	3.23e-17	7.72e-14	0.53	0.43	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
LIHC	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	8.9	3.3e-17	7.88e-14	0.63	0.43	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	8.9	3.3e-17	7.88e-14	0.63	0.43	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
LIHC	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-8.9	3.3e-17	7.89e-14	-0.43	-0.43	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
LIHC	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	8.9	3.31e-17	7.92e-14	0.53	0.43	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
LIHC	cis	rs11647589	0.834	rs6497491	ENSG00000260762.1	ACSM5P1	8.9	3.33e-17	7.95e-14	0.44	0.43	Blood metabolite levels;	chr16:20468691	chr16:20586550~20607107:-
LIHC	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.38e-17	8.08e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.38e-17	8.08e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.39e-17	8.09e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
LIHC	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	8.9	3.4e-17	8.13e-14	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
LIHC	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.41e-17	8.15e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.41e-17	8.15e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.41e-17	8.15e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-8.9	3.41e-17	8.15e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-8.89	3.5e-17	8.36e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
LIHC	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-8.89	3.54e-17	8.45e-14	-0.55	-0.43	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
LIHC	cis	rs2260433	0.66	rs7129790	ENSG00000281655.1	RP11-817J15.3	8.89	3.56e-17	8.5e-14	0.51	0.43	Cleft palate;	chr11:102641383	chr11:102681310~102683913:+
LIHC	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	8.89	3.57e-17	8.52e-14	0.49	0.43	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	8.89	3.6e-17	8.55e-14	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
LIHC	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-8.89	3.6e-17	8.55e-14	-0.65	-0.43	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-8.89	3.6e-17	8.55e-14	-0.65	-0.43	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-8.89	3.6e-17	8.55e-14	-0.65	-0.43	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-8.89	3.6e-17	8.55e-14	-0.65	-0.43	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
LIHC	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-8.89	3.68e-17	8.72e-14	-0.52	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
LIHC	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	8.89	3.68e-17	8.74e-14	0.43	0.43	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
LIHC	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-8.88	3.73e-17	8.83e-14	-0.43	-0.43	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
LIHC	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	8.88	3.74e-17	8.83e-14	0.77	0.43	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	8.88	3.74e-17	8.83e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	8.88	3.74e-17	8.83e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	8.88	3.74e-17	8.83e-14	0.77	0.43	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	8.88	3.74e-17	8.83e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	8.88	3.74e-17	8.83e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	8.88	3.74e-17	8.83e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
LIHC	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-8.88	3.91e-17	9.2e-14	-0.56	-0.43	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
LIHC	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-8.88	3.91e-17	9.22e-14	-0.54	-0.43	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
LIHC	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-8.88	3.99e-17	9.38e-14	-0.55	-0.43	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
LIHC	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	8.87	4e-17	9.4e-14	0.48	0.43	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
LIHC	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-8.87	4.06e-17	9.52e-14	-0.5	-0.43	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
LIHC	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-8.87	4.12e-17	9.59e-14	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	8.87	4.12e-17	9.59e-14	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	8.87	4.2e-17	9.76e-14	0.58	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
LIHC	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	8.87	4.23e-17	9.84e-14	0.56	0.43	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
LIHC	cis	rs7617773	0.962	rs6797587	ENSG00000229759.1	MRPS18AP1	-8.87	4.26e-17	9.9e-14	-0.48	-0.43	Coronary artery disease;	chr3:48156124	chr3:48256350~48256938:-
LIHC	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-8.86	4.34e-17	1.01e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
LIHC	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-8.86	4.34e-17	1.01e-13	-0.55	-0.43	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
LIHC	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-8.86	4.41e-17	1.02e-13	-0.49	-0.43	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
LIHC	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	8.86	4.46e-17	1.03e-13	0.41	0.43	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
LIHC	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	8.86	4.46e-17	1.03e-13	0.41	0.43	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
LIHC	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-8.86	4.49e-17	1.04e-13	-0.53	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
LIHC	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	8.86	4.54e-17	1.05e-13	0.63	0.43	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
LIHC	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-8.85	4.73e-17	1.09e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-8.85	4.73e-17	1.09e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-8.85	4.73e-17	1.09e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	8.85	4.73e-17	1.09e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	8.85	4.73e-17	1.09e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	8.85	4.76e-17	1.1e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
LIHC	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-8.85	4.76e-17	1.1e-13	-0.52	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	8.85	4.77e-17	1.1e-13	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
LIHC	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	8.85	4.79e-17	1.11e-13	0.5	0.43	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
LIHC	cis	rs11647589	0.678	rs7198521	ENSG00000260762.1	ACSM5P1	8.85	4.91e-17	1.13e-13	0.42	0.43	Blood metabolite levels;	chr16:20441382	chr16:20586550~20607107:-
LIHC	cis	rs1577917	0.74	rs12212560	ENSG00000234155.1	RP11-30P6.6	8.85	4.93e-17	1.14e-13	0.5	0.43	Response to antipsychotic treatment;	chr6:85632961	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-8.85	4.94e-17	1.14e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-8.85	4.94e-17	1.14e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
LIHC	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	8.85	4.95e-17	1.14e-13	0.51	0.43	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
LIHC	cis	rs1577917	0.74	rs2758845	ENSG00000234155.1	RP11-30P6.6	8.84	5.04e-17	1.16e-13	0.5	0.43	Response to antipsychotic treatment;	chr6:85625130	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.696	rs2842603	ENSG00000234155.1	RP11-30P6.6	8.84	5.04e-17	1.16e-13	0.5	0.43	Response to antipsychotic treatment;	chr6:85626619	chr6:85387219~85390186:-
LIHC	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-8.84	5.16e-17	1.19e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-8.84	5.16e-17	1.19e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
LIHC	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-8.84	5.2e-17	1.19e-13	-0.52	-0.43	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
LIHC	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-8.83	5.44e-17	1.25e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-8.83	5.47e-17	1.26e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
LIHC	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-8.83	5.48e-17	1.26e-13	-0.49	-0.43	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
LIHC	cis	rs6844153	1	rs4557251	ENSG00000240005.4	RP11-293A21.1	-8.83	5.49e-17	1.26e-13	-0.54	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26848285	chr4:26859806~26860599:-
LIHC	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-8.83	5.51e-17	1.26e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-8.83	5.51e-17	1.26e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.682	rs6909767	ENSG00000234155.1	RP11-30P6.6	-8.83	5.51e-17	1.26e-13	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85518391	chr6:85387219~85390186:-
LIHC	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-8.83	5.54e-17	1.27e-13	-0.52	-0.43	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
LIHC	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-8.83	5.63e-17	1.29e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
LIHC	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-8.83	5.69e-17	1.3e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
LIHC	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	8.83	5.71e-17	1.31e-13	0.67	0.43	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
LIHC	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-8.82	5.93e-17	1.35e-13	-0.48	-0.43	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
LIHC	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	8.82	5.98e-17	1.36e-13	0.63	0.43	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
LIHC	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-8.82	6.03e-17	1.37e-13	-0.49	-0.43	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
LIHC	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-8.82	6.08e-17	1.38e-13	-0.48	-0.43	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
LIHC	cis	rs296381	0.866	rs212099	ENSG00000259108.2	CTD-3098H1.2	8.82	6.17e-17	1.4e-13	0.82	0.43	Blood metabolite levels;	chr19:47885745	chr19:47863483~47865341:-
LIHC	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	8.81	6.21e-17	1.41e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
LIHC	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-8.81	6.3e-17	1.43e-13	-0.5	-0.43	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
LIHC	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	8.81	6.36e-17	1.44e-13	0.54	0.43	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
LIHC	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	8.81	6.62e-17	1.5e-13	0.76	0.43	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
LIHC	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	8.8	6.67e-17	1.51e-13	0.44	0.43	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
LIHC	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-8.8	6.69e-17	1.52e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
LIHC	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-8.8	6.8e-17	1.54e-13	-0.55	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
LIHC	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-8.8	6.82e-17	1.54e-13	-0.52	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
LIHC	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	8.8	6.83e-17	1.55e-13	0.66	0.43	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
LIHC	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-8.8	6.9e-17	1.56e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
LIHC	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-8.8	6.98e-17	1.58e-13	-0.54	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
LIHC	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-8.8	7e-17	1.58e-13	-0.48	-0.43	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
LIHC	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	8.8	7.06e-17	1.59e-13	0.76	0.43	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	8.79	7.14e-17	1.61e-13	0.71	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
LIHC	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	8.79	7.14e-17	1.61e-13	0.79	0.43	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
LIHC	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-8.79	7.25e-17	1.64e-13	-0.53	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
LIHC	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-8.79	7.35e-17	1.66e-13	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	8.79	7.41e-17	1.67e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	8.79	7.52e-17	1.69e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	8.79	7.52e-17	1.69e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	8.79	7.52e-17	1.69e-13	0.76	0.43	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	8.79	7.52e-17	1.69e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	8.79	7.52e-17	1.69e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	8.79	7.52e-17	1.69e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
LIHC	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	8.79	7.55e-17	1.7e-13	0.64	0.43	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
LIHC	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	8.78	7.74e-17	1.74e-13	0.75	0.43	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	8.78	7.74e-17	1.74e-13	0.75	0.43	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	8.78	7.74e-17	1.74e-13	0.75	0.43	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	8.78	7.74e-17	1.74e-13	0.75	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	8.78	7.93e-17	1.78e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	8.78	7.93e-17	1.78e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	8.78	7.93e-17	1.78e-13	0.76	0.43	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	8.78	7.93e-17	1.78e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	8.78	7.93e-17	1.78e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
LIHC	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	8.78	8.09e-17	1.81e-13	0.54	0.43	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
LIHC	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-8.78	8.12e-17	1.82e-13	-0.53	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
LIHC	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	8.78	8.22e-17	1.84e-13	0.58	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
LIHC	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	8.77	8.26e-17	1.84e-13	0.77	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-8.77	8.3e-17	1.85e-13	-0.76	-0.43	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
LIHC	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-8.76	9.1e-17	2.01e-13	-0.48	-0.43	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
LIHC	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-8.76	9.16e-17	2.02e-13	-0.74	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	8.76	9.18e-17	2.02e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	8.76	9.18e-17	2.02e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
LIHC	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-8.76	9.2e-17	2.03e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-8.76	9.2e-17	2.03e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-8.76	9.2e-17	2.03e-13	-0.51	-0.43	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
LIHC	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-8.76	9.25e-17	2.04e-13	-0.5	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
LIHC	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-8.76	9.41e-17	2.07e-13	-0.5	-0.43	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
LIHC	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	8.76	9.51e-17	2.09e-13	0.5	0.43	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
LIHC	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-8.75	9.65e-17	2.12e-13	-0.43	-0.43	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
LIHC	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	8.75	9.9e-17	2.17e-13	0.53	0.43	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
LIHC	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-8.75	1.01e-16	2.21e-13	-0.57	-0.43	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
LIHC	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	8.75	1.01e-16	2.22e-13	0.59	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
LIHC	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-8.74	1.03e-16	2.25e-13	-0.51	-0.43	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
LIHC	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-8.74	1.04e-16	2.26e-13	-0.42	-0.43	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-8.74	1.04e-16	2.26e-13	-0.42	-0.43	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
LIHC	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-8.74	1.04e-16	2.26e-13	-0.42	-0.43	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-8.74	1.04e-16	2.26e-13	-0.42	-0.43	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
LIHC	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-8.74	1.04e-16	2.26e-13	-0.42	-0.43	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
LIHC	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-8.74	1.04e-16	2.27e-13	-0.54	-0.43	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	8.74	1.05e-16	2.28e-13	0.5	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
LIHC	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	8.74	1.08e-16	2.36e-13	0.55	0.43	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
LIHC	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	8.73	1.1e-16	2.41e-13	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	8.73	1.12e-16	2.45e-13	0.59	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
LIHC	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-8.73	1.13e-16	2.47e-13	-0.5	-0.43	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
LIHC	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-8.73	1.16e-16	2.52e-13	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-8.73	1.16e-16	2.52e-13	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-8.73	1.16e-16	2.52e-13	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
LIHC	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-8.73	1.16e-16	2.53e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
LIHC	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	8.73	1.16e-16	2.53e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
LIHC	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-8.73	1.18e-16	2.56e-13	-0.49	-0.43	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
LIHC	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	8.73	1.18e-16	2.57e-13	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
LIHC	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-8.72	1.21e-16	2.62e-13	-0.5	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
LIHC	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	8.72	1.22e-16	2.64e-13	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
LIHC	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	8.72	1.22e-16	2.66e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
LIHC	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	8.72	1.24e-16	2.69e-13	0.51	0.43	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	8.72	1.24e-16	2.69e-13	0.51	0.43	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
LIHC	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	8.72	1.25e-16	2.71e-13	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
LIHC	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-8.72	1.25e-16	2.72e-13	-0.53	-0.43	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
LIHC	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-8.72	1.26e-16	2.72e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
LIHC	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-8.72	1.26e-16	2.72e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-8.72	1.26e-16	2.72e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
LIHC	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-8.72	1.26e-16	2.72e-13	-0.5	-0.43	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
LIHC	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-8.72	1.27e-16	2.74e-13	-0.51	-0.43	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
LIHC	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	8.72	1.27e-16	2.75e-13	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
LIHC	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-8.71	1.28e-16	2.77e-13	-0.53	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
LIHC	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	8.71	1.29e-16	2.8e-13	0.62	0.43	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
LIHC	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-8.71	1.3e-16	2.81e-13	-0.53	-0.43	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-8.71	1.3e-16	2.81e-13	-0.53	-0.43	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-8.71	1.3e-16	2.81e-13	-0.53	-0.43	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-8.71	1.3e-16	2.81e-13	-0.53	-0.43	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
LIHC	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-8.71	1.32e-16	2.85e-13	-0.42	-0.43	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
LIHC	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	8.71	1.33e-16	2.86e-13	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
LIHC	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	8.71	1.33e-16	2.88e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	8.71	1.33e-16	2.88e-13	0.76	0.43	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	8.71	1.33e-16	2.88e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	8.71	1.33e-16	2.88e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	8.71	1.33e-16	2.88e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	8.71	1.34e-16	2.89e-13	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
LIHC	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-8.71	1.35e-16	2.91e-13	-0.48	-0.43	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
LIHC	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	8.71	1.36e-16	2.93e-13	0.55	0.43	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
LIHC	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	8.71	1.36e-16	2.93e-13	0.55	0.43	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
LIHC	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	8.71	1.37e-16	2.94e-13	0.55	0.43	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
LIHC	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	8.71	1.37e-16	2.94e-13	0.55	0.43	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
LIHC	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	8.7	1.38e-16	2.96e-13	0.76	0.43	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
LIHC	cis	rs11647589	0.688	rs28556968	ENSG00000260762.1	ACSM5P1	8.7	1.39e-16	2.98e-13	0.41	0.43	Blood metabolite levels;	chr16:20469357	chr16:20586550~20607107:-
LIHC	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	8.7	1.41e-16	3.04e-13	0.49	0.43	Height;	chr11:118786602	chr11:118688039~118690600:-
LIHC	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-8.7	1.42e-16	3.04e-13	-0.54	-0.43	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
LIHC	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-8.7	1.44e-16	3.09e-13	-0.39	-0.43	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
LIHC	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-8.7	1.45e-16	3.12e-13	-0.42	-0.43	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
LIHC	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	8.7	1.45e-16	3.12e-13	0.8	0.43	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
LIHC	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-8.7	1.46e-16	3.13e-13	-0.48	-0.43	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
LIHC	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	8.7	1.47e-16	3.16e-13	0.62	0.43	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
LIHC	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-8.69	1.49e-16	3.2e-13	-0.51	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
LIHC	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-8.69	1.49e-16	3.2e-13	-0.51	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
LIHC	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	8.69	1.5e-16	3.22e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
LIHC	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-8.69	1.55e-16	3.31e-13	-0.54	-0.43	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
LIHC	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	8.69	1.55e-16	3.32e-13	0.76	0.43	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	8.69	1.55e-16	3.32e-13	0.76	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
LIHC	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	8.69	1.56e-16	3.33e-13	0.55	0.43	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
LIHC	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	8.69	1.56e-16	3.33e-13	0.55	0.43	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
LIHC	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	8.69	1.56e-16	3.33e-13	0.55	0.43	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
LIHC	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-8.69	1.57e-16	3.36e-13	-0.52	-0.43	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
LIHC	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-8.69	1.57e-16	3.36e-13	-0.49	-0.43	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-8.69	1.57e-16	3.36e-13	-0.49	-0.43	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
LIHC	cis	rs7178615	1	rs7178615	ENSG00000259471.1	LINC01169	8.69	1.58e-16	3.38e-13	0.57	0.43	Diastolic blood pressure;	chr15:66576734	chr15:66582190~66685794:+
LIHC	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	8.68	1.59e-16	3.4e-13	0.49	0.43	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	8.68	1.59e-16	3.4e-13	0.49	0.43	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	8.68	1.62e-16	3.46e-13	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
LIHC	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-8.68	1.62e-16	3.46e-13	-0.48	-0.42	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
LIHC	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	8.68	1.64e-16	3.5e-13	0.55	0.42	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
LIHC	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-8.68	1.66e-16	3.55e-13	-0.39	-0.42	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
LIHC	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	8.68	1.68e-16	3.59e-13	0.55	0.42	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
LIHC	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	8.67	1.71e-16	3.64e-13	0.53	0.42	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
LIHC	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-8.67	1.72e-16	3.67e-13	-0.48	-0.42	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
LIHC	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	8.67	1.73e-16	3.68e-13	0.76	0.42	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
LIHC	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	8.67	1.76e-16	3.73e-13	0.48	0.42	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	8.67	1.76e-16	3.73e-13	0.48	0.42	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
LIHC	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-8.67	1.76e-16	3.74e-13	-0.42	-0.42	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
LIHC	cis	rs7195287	0.591	rs63744561	ENSG00000276791.1	CTD-2270P14.5	8.67	1.76e-16	3.74e-13	0.44	0.42	Eosinophil counts;	chr16:2778171	chr16:2777319~2780568:+
LIHC	cis	rs1577917	0.696	rs2842617	ENSG00000234155.1	RP11-30P6.6	8.67	1.77e-16	3.76e-13	0.49	0.42	Response to antipsychotic treatment;	chr6:85599980	chr6:85387219~85390186:-
LIHC	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	8.67	1.79e-16	3.81e-13	0.76	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
LIHC	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-8.67	1.8e-16	3.82e-13	-0.53	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
LIHC	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	8.67	1.81e-16	3.84e-13	0.39	0.42	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
LIHC	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-8.67	1.81e-16	3.85e-13	-0.54	-0.42	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
LIHC	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-8.67	1.81e-16	3.85e-13	-0.54	-0.42	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-8.67	1.81e-16	3.85e-13	-0.54	-0.42	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
LIHC	cis	rs296381	0.866	rs2547231	ENSG00000259108.2	CTD-3098H1.2	8.67	1.82e-16	3.87e-13	0.7	0.42	Blood metabolite levels;	chr19:47881800	chr19:47863483~47865341:-
LIHC	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-8.66	1.87e-16	3.97e-13	-0.51	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
LIHC	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-8.66	1.89e-16	3.99e-13	-0.42	-0.42	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
LIHC	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-8.66	1.89e-16	3.99e-13	-0.42	-0.42	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
LIHC	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	8.66	1.89e-16	4.01e-13	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
LIHC	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-8.66	1.93e-16	4.07e-13	-0.44	-0.42	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
LIHC	cis	rs11647589	0.735	rs2221448	ENSG00000260762.1	ACSM5P1	8.66	1.93e-16	4.08e-13	0.41	0.42	Blood metabolite levels;	chr16:20473548	chr16:20586550~20607107:-
LIHC	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	8.65	2.02e-16	4.26e-13	0.42	0.42	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
LIHC	cis	rs2487048	1	rs2487048	ENSG00000226334.1	RP11-217B7.2	-8.65	2.07e-16	4.36e-13	-0.58	-0.42	Intraocular pressure;	chr9:104929542	chr9:104927553~104928892:+
LIHC	cis	rs2335455	1	rs2335455	ENSG00000276791.1	CTD-2270P14.5	8.65	2.09e-16	4.41e-13	0.44	0.42	Sum eosinophil basophil counts;	chr16:2778172	chr16:2777319~2780568:+
LIHC	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	8.65	2.11e-16	4.44e-13	0.48	0.42	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
LIHC	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	8.64	2.12e-16	4.47e-13	0.55	0.42	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
LIHC	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	8.64	2.16e-16	4.55e-13	0.52	0.42	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-8.64	2.16e-16	4.55e-13	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-8.64	2.16e-16	4.55e-13	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-8.64	2.16e-16	4.55e-13	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
LIHC	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	8.64	2.18e-16	4.59e-13	0.62	0.42	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
LIHC	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	8.64	2.2e-16	4.63e-13	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
LIHC	cis	rs6844153	0.887	rs62302533	ENSG00000240005.4	RP11-293A21.1	-8.63	2.27e-16	4.76e-13	-0.5	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955309	chr4:26859806~26860599:-
LIHC	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	8.63	2.29e-16	4.81e-13	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-8.63	2.29e-16	4.81e-13	-0.74	-0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	8.63	2.36e-16	4.94e-13	0.57	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
LIHC	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-8.63	2.37e-16	4.95e-13	-0.75	-0.42	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
LIHC	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-8.63	2.37e-16	4.96e-13	-0.62	-0.42	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
LIHC	cis	rs2260433	0.66	rs7109950	ENSG00000281655.1	RP11-817J15.3	8.63	2.39e-16	5e-13	0.49	0.42	Cleft palate;	chr11:102641320	chr11:102681310~102683913:+
LIHC	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-8.63	2.41e-16	5.04e-13	-0.42	-0.42	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
LIHC	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	8.62	2.45e-16	5.12e-13	0.51	0.42	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
LIHC	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	8.62	2.49e-16	5.2e-13	0.6	0.42	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
LIHC	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	8.62	2.51e-16	5.24e-13	0.49	0.42	Height;	chr11:118791319	chr11:118688039~118690600:-
LIHC	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	8.62	2.54e-16	5.29e-13	0.57	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
LIHC	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	8.62	2.57e-16	5.35e-13	0.49	0.42	Height;	chr11:118809363	chr11:118688039~118690600:-
LIHC	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	8.62	2.59e-16	5.4e-13	0.75	0.42	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	8.62	2.59e-16	5.4e-13	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
LIHC	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	8.62	2.59e-16	5.4e-13	0.48	0.42	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
LIHC	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	8.62	2.62e-16	5.44e-13	0.76	0.42	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	8.62	2.62e-16	5.44e-13	0.76	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	8.62	2.62e-16	5.44e-13	0.76	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-8.61	2.68e-16	5.57e-13	-0.56	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
LIHC	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	8.61	2.72e-16	5.65e-13	0.49	0.42	Depression;	chr6:28240757	chr6:28176188~28176674:+
LIHC	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-8.61	2.75e-16	5.7e-13	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
LIHC	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-8.61	2.78e-16	5.78e-13	-0.6	-0.42	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
LIHC	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	8.61	2.79e-16	5.78e-13	0.53	0.42	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
LIHC	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	8.61	2.8e-16	5.81e-13	0.74	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
LIHC	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	8.61	2.8e-16	5.81e-13	0.51	0.42	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
LIHC	cis	rs2245008	0.671	rs907036	ENSG00000260932.1	RP11-483P21.6	-8.61	2.81e-16	5.83e-13	-0.6	-0.42	Pursuit maintenance gain;	chr16:83956245	chr16:83929796~83931223:-
LIHC	cis	rs2260433	0.683	rs11225360	ENSG00000281655.1	RP11-817J15.3	8.6	2.86e-16	5.93e-13	0.49	0.42	Cleft palate;	chr11:102642685	chr11:102681310~102683913:+
LIHC	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-8.6	2.87e-16	5.94e-13	-0.48	-0.42	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-8.6	2.87e-16	5.94e-13	-0.48	-0.42	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-8.6	2.87e-16	5.94e-13	-0.48	-0.42	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-8.6	2.87e-16	5.94e-13	-0.48	-0.42	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
LIHC	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	8.6	2.88e-16	5.95e-13	0.58	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	8.6	2.95e-16	6.08e-13	0.57	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
LIHC	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-8.6	2.99e-16	6.15e-13	-0.53	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
LIHC	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	8.6	3.01e-16	6.19e-13	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	8.59	3.04e-16	6.25e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	8.59	3.04e-16	6.25e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
LIHC	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	8.59	3.07e-16	6.32e-13	0.49	0.42	Height;	chr11:118808920	chr11:118688039~118690600:-
LIHC	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-8.59	3.1e-16	6.37e-13	-0.5	-0.42	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
LIHC	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	8.59	3.11e-16	6.39e-13	0.51	0.42	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
LIHC	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-8.59	3.14e-16	6.45e-13	-0.53	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
LIHC	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-8.59	3.2e-16	6.57e-13	-0.54	-0.42	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
LIHC	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	8.58	3.26e-16	6.7e-13	0.54	0.42	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
LIHC	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	8.58	3.27e-16	6.71e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	8.58	3.27e-16	6.71e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	8.58	3.27e-16	6.71e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
LIHC	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	8.58	3.28e-16	6.74e-13	0.42	0.42	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
LIHC	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-8.58	3.34e-16	6.85e-13	-0.56	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
LIHC	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	8.58	3.43e-16	7.03e-13	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	8.58	3.43e-16	7.03e-13	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
LIHC	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	8.58	3.44e-16	7.06e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
LIHC	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	8.58	3.49e-16	7.14e-13	0.51	0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
LIHC	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	8.57	3.49e-16	7.16e-13	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
LIHC	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-8.57	3.5e-16	7.16e-13	-0.48	-0.42	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
LIHC	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	8.57	3.57e-16	7.3e-13	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
LIHC	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	8.57	3.61e-16	7.39e-13	0.58	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
LIHC	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-8.57	3.66e-16	7.48e-13	-0.52	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
LIHC	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	8.57	3.7e-16	7.54e-13	0.81	0.42	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	8.57	3.7e-16	7.54e-13	0.81	0.42	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	8.57	3.7e-16	7.54e-13	0.81	0.42	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	8.57	3.7e-16	7.54e-13	0.81	0.42	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
LIHC	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-8.56	3.82e-16	7.77e-13	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-8.56	3.82e-16	7.77e-13	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
LIHC	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-8.56	3.82e-16	7.77e-13	-0.48	-0.42	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
LIHC	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	8.56	3.9e-16	7.94e-13	0.54	0.42	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
LIHC	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	8.56	3.9e-16	7.94e-13	0.54	0.42	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
LIHC	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	8.56	3.94e-16	8e-13	0.64	0.42	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
LIHC	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	8.56	3.98e-16	8.09e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
LIHC	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-8.56	3.99e-16	8.11e-13	-0.54	-0.42	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
LIHC	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-8.56	3.99e-16	8.11e-13	-0.54	-0.42	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
LIHC	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	8.56	4e-16	8.13e-13	0.61	0.42	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
LIHC	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	8.56	4.01e-16	8.16e-13	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
LIHC	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-8.55	4.06e-16	8.25e-13	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
LIHC	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-8.55	4.14e-16	8.39e-13	-0.48	-0.42	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-8.55	4.14e-16	8.39e-13	-0.48	-0.42	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
LIHC	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-8.55	4.14e-16	8.4e-13	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
LIHC	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	8.55	4.15e-16	8.43e-13	0.42	0.42	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
LIHC	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-8.55	4.21e-16	8.55e-13	-0.54	-0.42	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
LIHC	cis	rs9807368	1	rs9807368	ENSG00000263627.1	PPP4R1-AS1	-8.55	4.22e-16	8.56e-13	-0.69	-0.42	Platelet distribution width;	chr18:9620161	chr18:9615264~9619363:+
LIHC	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	8.55	4.24e-16	8.6e-13	0.45	0.42	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
LIHC	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-8.55	4.26e-16	8.63e-13	-0.62	-0.42	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
LIHC	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	8.55	4.27e-16	8.65e-13	0.54	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
LIHC	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	8.55	4.27e-16	8.65e-13	0.54	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
LIHC	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-8.54	4.33e-16	8.76e-13	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
LIHC	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-8.54	4.33e-16	8.76e-13	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
LIHC	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-8.54	4.34e-16	8.79e-13	-0.66	-0.42	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
LIHC	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-8.54	4.35e-16	8.82e-13	-0.44	-0.42	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
LIHC	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	8.54	4.44e-16	8.97e-13	0.62	0.42	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	8.54	4.44e-16	8.97e-13	0.62	0.42	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	8.54	4.44e-16	8.97e-13	0.62	0.42	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
LIHC	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-8.54	4.47e-16	9.04e-13	-0.52	-0.42	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
LIHC	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	8.54	4.5e-16	9.08e-13	0.61	0.42	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	8.54	4.5e-16	9.08e-13	0.61	0.42	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8.54	4.5e-16	9.08e-13	0.61	0.42	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	8.54	4.5e-16	9.08e-13	0.61	0.42	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.54	4.5e-16	9.08e-13	0.61	0.42	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.54	4.5e-16	9.08e-13	0.61	0.42	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
LIHC	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	8.54	4.5e-16	9.1e-13	0.48	0.42	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
LIHC	cis	rs2260433	0.66	rs4754861	ENSG00000281655.1	RP11-817J15.3	8.54	4.5e-16	9.1e-13	0.49	0.42	Cleft palate;	chr11:102643155	chr11:102681310~102683913:+
LIHC	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	8.54	4.52e-16	9.13e-13	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
LIHC	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	8.54	4.52e-16	9.13e-13	0.54	0.42	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
LIHC	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-8.54	4.57e-16	9.23e-13	-0.5	-0.42	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
LIHC	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-8.54	4.58e-16	9.24e-13	-0.41	-0.42	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
LIHC	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-8.54	4.58e-16	9.24e-13	-0.41	-0.42	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
LIHC	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-8.54	4.58e-16	9.24e-13	-0.41	-0.42	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
LIHC	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	8.54	4.62e-16	9.31e-13	0.51	0.42	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
LIHC	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	8.53	4.72e-16	9.52e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
LIHC	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	8.53	4.76e-16	9.58e-13	0.46	0.42	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
LIHC	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	8.53	4.77e-16	9.61e-13	0.75	0.42	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
LIHC	cis	rs2260433	0.66	rs10160697	ENSG00000281655.1	RP11-817J15.3	8.53	4.79e-16	9.63e-13	0.49	0.42	Cleft palate;	chr11:102641623	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.66	rs10160700	ENSG00000281655.1	RP11-817J15.3	8.53	4.79e-16	9.63e-13	0.49	0.42	Cleft palate;	chr11:102641687	chr11:102681310~102683913:+
LIHC	cis	rs2260433	0.66	rs11225358	ENSG00000281655.1	RP11-817J15.3	8.53	4.79e-16	9.63e-13	0.49	0.42	Cleft palate;	chr11:102642149	chr11:102681310~102683913:+
LIHC	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	8.53	4.82e-16	9.7e-13	0.56	0.42	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
LIHC	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	8.53	4.83e-16	9.72e-13	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
LIHC	cis	rs2260433	0.66	rs11225359	ENSG00000281655.1	RP11-817J15.3	8.53	4.85e-16	9.75e-13	0.49	0.42	Cleft palate;	chr11:102642254	chr11:102681310~102683913:+
LIHC	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-8.53	4.89e-16	9.83e-13	-0.48	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
LIHC	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-8.53	4.89e-16	9.84e-13	-0.48	-0.42	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-8.53	4.89e-16	9.84e-13	-0.48	-0.42	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
LIHC	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-8.53	4.91e-16	9.87e-13	-0.48	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
LIHC	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-8.53	4.98e-16	1e-12	-0.47	-0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
LIHC	cis	rs1577917	0.682	rs1173419	ENSG00000234155.1	RP11-30P6.6	8.52	5.09e-16	1.02e-12	0.48	0.42	Response to antipsychotic treatment;	chr6:85692445	chr6:85387219~85390186:-
LIHC	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	8.52	5.1e-16	1.02e-12	0.75	0.42	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
LIHC	cis	rs11647589	0.553	rs6497484	ENSG00000260762.1	ACSM5P1	8.52	5.14e-16	1.03e-12	0.4	0.42	Blood metabolite levels;	chr16:20428396	chr16:20586550~20607107:-
LIHC	cis	rs2260433	0.66	rs4754862	ENSG00000281655.1	RP11-817J15.3	8.52	5.23e-16	1.05e-12	0.49	0.42	Cleft palate;	chr11:102643427	chr11:102681310~102683913:+
LIHC	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	8.51	5.53e-16	1.11e-12	0.46	0.42	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
LIHC	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	8.51	5.55e-16	1.11e-12	0.47	0.42	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
LIHC	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	8.51	5.57e-16	1.11e-12	0.74	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
LIHC	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-8.51	5.58e-16	1.12e-12	-0.48	-0.42	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
LIHC	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	8.51	5.62e-16	1.12e-12	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
LIHC	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	8.51	5.7e-16	1.14e-12	0.53	0.42	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
LIHC	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-8.51	5.73e-16	1.15e-12	-0.53	-0.42	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
LIHC	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	8.5	5.93e-16	1.18e-12	0.74	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
LIHC	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	8.5	5.97e-16	1.19e-12	0.79	0.42	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
LIHC	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	8.5	6.02e-16	1.2e-12	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
LIHC	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-8.5	6.09e-16	1.21e-12	-0.46	-0.42	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
LIHC	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	8.5	6.14e-16	1.23e-12	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	8.49	6.2e-16	1.24e-12	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
LIHC	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-8.49	6.43e-16	1.28e-12	-0.48	-0.42	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
LIHC	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	8.49	6.47e-16	1.29e-12	0.62	0.42	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	8.49	6.47e-16	1.29e-12	0.62	0.42	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
LIHC	cis	rs6844153	0.941	rs75656258	ENSG00000240005.4	RP11-293A21.1	-8.49	6.52e-16	1.3e-12	-0.52	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26843577	chr4:26859806~26860599:-
LIHC	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	8.49	6.53e-16	1.3e-12	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
LIHC	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	8.49	6.62e-16	1.32e-12	0.5	0.42	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
LIHC	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	8.48	6.62e-16	1.32e-12	0.48	0.42	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-8.48	6.67e-16	1.33e-12	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	8.48	6.72e-16	1.34e-12	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	8.48	6.72e-16	1.34e-12	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
LIHC	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	8.48	6.72e-16	1.34e-12	0.75	0.42	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
LIHC	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	8.48	6.75e-16	1.34e-12	0.61	0.42	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
LIHC	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	8.48	6.77e-16	1.34e-12	0.47	0.42	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
LIHC	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-8.48	6.82e-16	1.35e-12	-0.41	-0.42	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
LIHC	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	8.48	6.88e-16	1.37e-12	0.47	0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
LIHC	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-8.48	6.93e-16	1.37e-12	-0.47	-0.42	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
LIHC	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-8.48	7.03e-16	1.39e-12	-0.48	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
LIHC	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-8.48	7.03e-16	1.39e-12	-0.48	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
LIHC	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-8.48	7.03e-16	1.39e-12	-0.48	-0.42	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
LIHC	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-8.48	7.04e-16	1.4e-12	-0.47	-0.42	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
LIHC	cis	rs2260433	0.621	rs10160727	ENSG00000281655.1	RP11-817J15.3	8.47	7.14e-16	1.41e-12	0.49	0.42	Cleft palate;	chr11:102641640	chr11:102681310~102683913:+
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-8.47	7.22e-16	1.43e-12	-0.5	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
LIHC	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-8.47	7.31e-16	1.45e-12	-0.38	-0.42	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
LIHC	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	8.47	7.33e-16	1.45e-12	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
LIHC	cis	rs11647589	0.687	rs12598584	ENSG00000260762.1	ACSM5P1	-8.47	7.34e-16	1.45e-12	-0.41	-0.42	Blood metabolite levels;	chr16:20476785	chr16:20586550~20607107:-
LIHC	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	8.47	7.48e-16	1.48e-12	0.51	0.42	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
LIHC	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-8.47	7.55e-16	1.49e-12	-0.53	-0.42	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
LIHC	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-8.47	7.63e-16	1.5e-12	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
LIHC	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	8.46	7.68e-16	1.51e-12	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
LIHC	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	8.46	7.75e-16	1.52e-12	0.51	0.42	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
LIHC	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	8.46	7.77e-16	1.53e-12	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	8.46	7.77e-16	1.53e-12	0.75	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	8.46	7.82e-16	1.54e-12	0.74	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	8.46	7.88e-16	1.55e-12	0.69	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	8.46	7.91e-16	1.55e-12	0.74	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
LIHC	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	8.46	7.92e-16	1.56e-12	0.77	0.42	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
LIHC	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-8.46	7.93e-16	1.56e-12	-0.41	-0.42	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
LIHC	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-8.46	7.95e-16	1.56e-12	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-8.46	7.95e-16	1.56e-12	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-8.46	7.95e-16	1.56e-12	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-8.46	7.95e-16	1.56e-12	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-8.46	7.95e-16	1.56e-12	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-8.46	7.95e-16	1.56e-12	-0.63	-0.42	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
LIHC	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-8.46	8.03e-16	1.57e-12	-0.52	-0.42	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
LIHC	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-8.46	8.13e-16	1.59e-12	-0.47	-0.42	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-8.46	8.13e-16	1.59e-12	-0.47	-0.42	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
LIHC	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	8.45	8.23e-16	1.61e-12	0.41	0.42	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
LIHC	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	8.45	8.25e-16	1.61e-12	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	8.45	8.26e-16	1.62e-12	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
LIHC	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	8.45	8.27e-16	1.62e-12	0.54	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
LIHC	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-8.45	8.41e-16	1.64e-12	-0.49	-0.42	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	8.45	8.42e-16	1.65e-12	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
LIHC	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	8.45	8.53e-16	1.67e-12	0.55	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
LIHC	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	8.45	8.61e-16	1.68e-12	0.52	0.42	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
LIHC	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	8.45	8.7e-16	1.7e-12	0.53	0.42	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
LIHC	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	8.44	8.82e-16	1.72e-12	0.43	0.42	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
LIHC	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-8.44	8.93e-16	1.74e-12	-0.52	-0.42	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
LIHC	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	8.44	8.96e-16	1.74e-12	0.68	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
LIHC	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-8.44	8.96e-16	1.74e-12	-0.56	-0.42	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
LIHC	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-8.44	8.96e-16	1.74e-12	-0.53	-0.42	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
LIHC	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-8.44	8.98e-16	1.74e-12	-0.41	-0.42	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
LIHC	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	8.44	9e-16	1.75e-12	0.71	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	8.44	9e-16	1.75e-12	0.71	0.42	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
LIHC	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-8.44	9.03e-16	1.75e-12	-0.62	-0.42	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-8.44	9.03e-16	1.75e-12	-0.62	-0.42	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-8.44	9.03e-16	1.75e-12	-0.62	-0.42	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-8.44	9.03e-16	1.75e-12	-0.62	-0.42	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
LIHC	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	8.44	9.09e-16	1.76e-12	0.54	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
LIHC	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	8.44	9.09e-16	1.76e-12	0.54	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
LIHC	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	8.44	9.09e-16	1.76e-12	0.54	0.42	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
LIHC	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	8.44	9.2e-16	1.78e-12	0.49	0.42	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
LIHC	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	8.44	9.31e-16	1.8e-12	0.53	0.42	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
LIHC	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-8.44	9.32e-16	1.8e-12	-0.63	-0.42	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
LIHC	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-8.43	9.77e-16	1.89e-12	-0.48	-0.41	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	8.43	9.79e-16	1.89e-12	0.47	0.41	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
LIHC	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	8.43	9.88e-16	1.91e-12	0.56	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
LIHC	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-8.43	1e-15	1.94e-12	-0.47	-0.41	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
LIHC	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	8.43	1e-15	1.94e-12	0.53	0.41	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
LIHC	cis	rs4356975	0.83	rs7438033	ENSG00000249956.3	RP11-790I12.2	-8.42	1.03e-15	1.98e-12	-0.46	-0.41	Obesity-related traits;	chr4:69059343	chr4:69408836~69423164:+
LIHC	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-8.42	1.03e-15	1.98e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-8.42	1.03e-15	1.98e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-8.42	1.03e-15	1.98e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
LIHC	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	8.42	1.04e-15	2e-12	0.5	0.41	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
LIHC	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-8.42	1.04e-15	2e-12	-0.51	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-8.42	1.04e-15	2e-12	-0.51	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
LIHC	cis	rs2260433	0.548	rs4754860	ENSG00000281655.1	RP11-817J15.3	8.42	1.06e-15	2.04e-12	0.48	0.41	Cleft palate;	chr11:102642942	chr11:102681310~102683913:+
LIHC	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-8.42	1.06e-15	2.04e-12	-0.44	-0.41	Temperament;	chr17:13999319	chr17:14024514~14025488:+
LIHC	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	8.42	1.07e-15	2.06e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
LIHC	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-8.42	1.08e-15	2.07e-12	-0.48	-0.41	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
LIHC	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-8.41	1.1e-15	2.12e-12	-0.48	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
LIHC	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	8.41	1.13e-15	2.17e-12	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
LIHC	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	8.41	1.14e-15	2.19e-12	0.74	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	8.41	1.14e-15	2.19e-12	0.74	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	8.4	1.17e-15	2.25e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	8.4	1.18e-15	2.26e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
LIHC	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	8.4	1.2e-15	2.29e-12	0.48	0.41	Height;	chr11:118781100	chr11:118688039~118690600:-
LIHC	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	8.4	1.21e-15	2.31e-12	0.47	0.41	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
LIHC	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	8.4	1.21e-15	2.31e-12	0.47	0.41	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
LIHC	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
LIHC	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-8.4	1.21e-15	2.32e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
LIHC	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-8.4	1.24e-15	2.36e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
LIHC	cis	rs1577917	0.771	rs7762321	ENSG00000234155.1	RP11-30P6.6	-8.4	1.24e-15	2.38e-12	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85702428	chr6:85387219~85390186:-
LIHC	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	8.4	1.25e-15	2.39e-12	0.68	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
LIHC	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-8.39	1.26e-15	2.41e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
LIHC	cis	rs2019137	0.539	rs4849181	ENSG00000274877.1	RP11-65I12.1	-8.39	1.26e-15	2.41e-12	-0.52	-0.41	Lymphocyte counts;	chr2:113234393	chr2:113237595~113240825:+
LIHC	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	8.39	1.27e-15	2.42e-12	0.49	0.41	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
LIHC	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-8.39	1.27e-15	2.42e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
LIHC	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	8.39	1.28e-15	2.44e-12	0.53	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
LIHC	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	8.39	1.28e-15	2.44e-12	0.53	0.41	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
LIHC	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-8.39	1.29e-15	2.47e-12	-0.46	-0.41	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-8.39	1.32e-15	2.51e-12	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
LIHC	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-8.39	1.32e-15	2.51e-12	-0.55	-0.41	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
LIHC	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	8.39	1.33e-15	2.53e-12	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
LIHC	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-8.39	1.33e-15	2.53e-12	-0.52	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
LIHC	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-8.38	1.35e-15	2.57e-12	-0.42	-0.41	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
LIHC	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	8.38	1.36e-15	2.59e-12	0.75	0.41	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
LIHC	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	8.38	1.37e-15	2.6e-12	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
LIHC	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-8.38	1.37e-15	2.6e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
LIHC	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-8.38	1.39e-15	2.64e-12	-0.47	-0.41	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-8.38	1.39e-15	2.64e-12	-0.47	-0.41	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
LIHC	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	8.38	1.39e-15	2.65e-12	0.52	0.41	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
LIHC	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-8.38	1.4e-15	2.65e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
LIHC	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	8.38	1.4e-15	2.66e-12	0.75	0.41	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
LIHC	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	8.38	1.41e-15	2.67e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
LIHC	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	8.38	1.42e-15	2.7e-12	0.44	0.41	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
LIHC	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	8.38	1.43e-15	2.71e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
LIHC	cis	rs12744310	1	rs56381773	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305046	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs56096486	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305558	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs57529969	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306011	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs60825180	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306072	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.778	rs61477144	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306121	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.943	rs7521544	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306454	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs7513682	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306495	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs56409354	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307299	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs34008156	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307510	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12744310	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307830	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs56077539	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308270	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs55892603	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308322	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs55929643	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308540	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs34759578	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308678	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.945	rs72665690	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309564	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.945	rs72665691	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309573	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.945	rs72665692	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309707	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs72665694	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309712	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.945	rs72665696	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309757	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs72665698	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309917	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.943	rs12751511	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41310731	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs34073585	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311527	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12756822	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311655	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12036554	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312317	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12036555	ENSG00000235358.1	RP11-399E6.1	8.38	1.43e-15	2.72e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312318	chr1:41242373~41284861:+
LIHC	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-8.37	1.45e-15	2.75e-12	-0.48	-0.41	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
LIHC	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	8.37	1.51e-15	2.86e-12	0.41	0.41	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
LIHC	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-8.36	1.55e-15	2.92e-12	-0.62	-0.41	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
LIHC	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-8.36	1.55e-15	2.94e-12	-0.47	-0.41	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
LIHC	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-8.36	1.55e-15	2.94e-12	-0.47	-0.41	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
LIHC	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	8.36	1.56e-15	2.94e-12	0.5	0.41	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
LIHC	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-8.36	1.56e-15	2.95e-12	-0.45	-0.41	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
LIHC	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	8.36	1.57e-15	2.97e-12	0.49	0.41	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
LIHC	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	8.36	1.58e-15	2.98e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
LIHC	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-8.36	1.59e-15	2.99e-12	-0.52	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
LIHC	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-8.36	1.6e-15	3.02e-12	-0.62	-0.41	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
LIHC	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	8.36	1.61e-15	3.03e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
LIHC	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	8.36	1.62e-15	3.05e-12	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
LIHC	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	8.35	1.66e-15	3.13e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
LIHC	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	8.35	1.69e-15	3.17e-12	0.54	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
LIHC	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	8.35	1.71e-15	3.22e-12	0.79	0.41	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
LIHC	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	8.35	1.73e-15	3.26e-12	0.49	0.41	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
LIHC	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	8.35	1.74e-15	3.27e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
LIHC	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	8.35	1.74e-15	3.27e-12	0.71	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
LIHC	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-8.35	1.78e-15	3.33e-12	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
LIHC	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-8.34	1.78e-15	3.35e-12	-0.52	-0.41	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
LIHC	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	8.34	1.81e-15	3.38e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
LIHC	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	8.34	1.82e-15	3.41e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	8.34	1.82e-15	3.41e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
LIHC	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-8.34	1.83e-15	3.43e-12	-0.6	-0.41	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
LIHC	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	8.34	1.87e-15	3.5e-12	0.53	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
LIHC	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	8.34	1.89e-15	3.53e-12	0.43	0.41	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
LIHC	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-8.34	1.9e-15	3.55e-12	-0.43	-0.41	Temperament;	chr17:14007198	chr17:14024514~14025488:+
LIHC	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-8.34	1.9e-15	3.55e-12	-0.43	-0.41	Temperament;	chr17:14007316	chr17:14024514~14025488:+
LIHC	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	8.33	1.91e-15	3.57e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	8.33	1.91e-15	3.57e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-8.33	1.91e-15	3.57e-12	-0.46	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	8.33	1.91e-15	3.57e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	8.33	1.92e-15	3.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	8.33	1.92e-15	3.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	8.33	1.92e-15	3.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	8.33	1.92e-15	3.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
LIHC	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	8.33	1.95e-15	3.65e-12	0.6	0.41	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
LIHC	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	8.33	1.95e-15	3.65e-12	0.6	0.41	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
LIHC	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	8.33	1.96e-15	3.65e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	8.33	1.96e-15	3.65e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
LIHC	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	8.33	2e-15	3.72e-12	0.68	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
LIHC	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-8.33	2e-15	3.74e-12	-0.53	-0.41	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
LIHC	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	8.33	2.03e-15	3.78e-12	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
LIHC	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-8.32	2.07e-15	3.85e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
LIHC	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-8.32	2.09e-15	3.88e-12	-0.66	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
LIHC	cis	rs8062405	0.625	rs8060365	ENSG00000259982.1	CDC37P1	-8.32	2.1e-15	3.91e-12	-0.51	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28700294~28701540:-
LIHC	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-8.32	2.11e-15	3.93e-12	-0.52	-0.41	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
LIHC	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-8.32	2.11e-15	3.93e-12	-0.52	-0.41	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
LIHC	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-8.32	2.12e-15	3.93e-12	-0.62	-0.41	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
LIHC	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	8.32	2.12e-15	3.93e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
LIHC	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	8.32	2.14e-15	3.97e-12	0.73	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
LIHC	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-8.32	2.15e-15	3.99e-12	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-8.32	2.15e-15	3.99e-12	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-8.32	2.15e-15	3.99e-12	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-8.32	2.15e-15	3.99e-12	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
LIHC	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-8.32	2.15e-15	3.99e-12	-0.49	-0.41	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
LIHC	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	8.32	2.19e-15	4.06e-12	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	8.32	2.19e-15	4.06e-12	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
LIHC	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-8.31	2.2e-15	4.08e-12	-0.45	-0.41	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
LIHC	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	8.31	2.28e-15	4.22e-12	0.47	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
LIHC	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-8.31	2.29e-15	4.24e-12	-0.41	-0.41	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
LIHC	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-8.31	2.33e-15	4.3e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
LIHC	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	8.31	2.33e-15	4.31e-12	0.49	0.41	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
LIHC	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	8.3	2.36e-15	4.36e-12	0.46	0.41	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
LIHC	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-8.3	2.37e-15	4.38e-12	-0.49	-0.41	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
LIHC	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	8.3	2.38e-15	4.4e-12	0.62	0.41	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
LIHC	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-8.3	2.4e-15	4.43e-12	-0.46	-0.41	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	8.3	2.4e-15	4.43e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
LIHC	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	8.3	2.4e-15	4.44e-12	0.69	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	8.3	2.45e-15	4.52e-12	0.73	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
LIHC	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	8.3	2.46e-15	4.53e-12	0.47	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
LIHC	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	8.3	2.49e-15	4.6e-12	0.75	0.41	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
LIHC	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-8.3	2.5e-15	4.6e-12	-0.47	-0.41	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
LIHC	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-8.29	2.54e-15	4.69e-12	-0.41	-0.41	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
LIHC	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	8.29	2.55e-15	4.69e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
LIHC	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	8.29	2.58e-15	4.76e-12	0.73	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	8.29	2.66e-15	4.89e-12	0.73	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
LIHC	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-8.29	2.69e-15	4.94e-12	-0.62	-0.41	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
LIHC	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	8.29	2.69e-15	4.95e-12	0.41	0.41	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
LIHC	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	8.29	2.69e-15	4.95e-12	0.46	0.41	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
LIHC	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	8.29	2.7e-15	4.97e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
LIHC	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-8.28	2.71e-15	4.99e-12	-0.53	-0.41	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
LIHC	cis	rs1577917	0.682	rs1173417	ENSG00000234155.1	RP11-30P6.6	-8.28	2.72e-15	4.99e-12	-0.48	-0.41	Response to antipsychotic treatment;	chr6:85694223	chr6:85387219~85390186:-
LIHC	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	8.28	2.74e-15	5.03e-12	0.51	0.41	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
LIHC	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	8.28	2.74e-15	5.04e-12	0.52	0.41	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
LIHC	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	8.28	2.83e-15	5.19e-12	0.64	0.41	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
LIHC	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	8.28	2.84e-15	5.21e-12	0.49	0.41	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
LIHC	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	8.28	2.84e-15	5.21e-12	0.62	0.41	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
LIHC	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-8.28	2.85e-15	5.23e-12	-0.46	-0.41	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
LIHC	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-8.28	2.89e-15	5.29e-12	-0.48	-0.41	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
LIHC	cis	rs12744310	1	rs68132196	ENSG00000235358.1	RP11-399E6.1	8.28	2.9e-15	5.32e-12	0.54	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41304948	chr1:41242373~41284861:+
LIHC	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	8.27	2.93e-15	5.36e-12	0.44	0.41	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
LIHC	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	8.27	2.93e-15	5.36e-12	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
LIHC	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	8.27	2.93e-15	5.36e-12	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
LIHC	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	8.27	2.94e-15	5.38e-12	0.47	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	8.27	2.94e-15	5.38e-12	0.47	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
LIHC	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	8.27	2.94e-15	5.38e-12	0.54	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
LIHC	cis	rs4356975	0.83	rs3922514	ENSG00000249956.3	RP11-790I12.2	8.27	2.96e-15	5.42e-12	0.45	0.41	Obesity-related traits;	chr4:69060905	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs28775401	ENSG00000249956.3	RP11-790I12.2	8.27	2.96e-15	5.42e-12	0.45	0.41	Obesity-related traits;	chr4:69060999	chr4:69408836~69423164:+
LIHC	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	8.27	2.99e-15	5.46e-12	0.61	0.41	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	8.27	2.99e-15	5.46e-12	0.61	0.41	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
LIHC	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	8.27	3.03e-15	5.53e-12	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
LIHC	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	8.27	3.04e-15	5.55e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	8.27	3.04e-15	5.55e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	8.27	3.07e-15	5.6e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	8.27	3.07e-15	5.6e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	8.27	3.07e-15	5.6e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	8.27	3.07e-15	5.6e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	8.27	3.07e-15	5.6e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	8.27	3.07e-15	5.6e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	8.27	3.08e-15	5.61e-12	0.49	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
LIHC	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	8.27	3.1e-15	5.66e-12	0.54	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
LIHC	cis	rs4356975	1	rs4356975	ENSG00000249956.3	RP11-790I12.2	8.26	3.16e-15	5.75e-12	0.46	0.41	Obesity-related traits;	chr4:69106745	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs4413468	ENSG00000249956.3	RP11-790I12.2	8.26	3.16e-15	5.76e-12	0.45	0.41	Obesity-related traits;	chr4:69061845	chr4:69408836~69423164:+
LIHC	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-8.26	3.19e-15	5.81e-12	-0.46	-0.41	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
LIHC	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	8.26	3.22e-15	5.86e-12	0.78	0.41	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
LIHC	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-8.26	3.22e-15	5.87e-12	-0.4	-0.41	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-8.26	3.26e-15	5.94e-12	-0.54	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
LIHC	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-8.26	3.31e-15	6.03e-12	-0.47	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
LIHC	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-8.25	3.43e-15	6.22e-12	-0.46	-0.41	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-8.25	3.43e-15	6.22e-12	-0.46	-0.41	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-8.25	3.43e-15	6.22e-12	-0.46	-0.41	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-8.25	3.43e-15	6.22e-12	-0.46	-0.41	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-8.25	3.43e-15	6.22e-12	-0.46	-0.41	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
LIHC	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-8.25	3.48e-15	6.3e-12	-0.54	-0.41	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
LIHC	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	8.25	3.5e-15	6.33e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	8.25	3.51e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	8.25	3.51e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
LIHC	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	8.25	3.52e-15	6.36e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
LIHC	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	8.25	3.53e-15	6.37e-12	0.6	0.41	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
LIHC	cis	rs12744310	0.83	rs12028010	ENSG00000235358.1	RP11-399E6.1	8.25	3.53e-15	6.38e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298799	chr1:41242373~41284861:+
LIHC	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	8.25	3.53e-15	6.39e-12	0.41	0.41	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
LIHC	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	8.24	3.59e-15	6.49e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	8.24	3.59e-15	6.49e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	8.24	3.59e-15	6.49e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	8.24	3.59e-15	6.49e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	8.24	3.59e-15	6.49e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	8.24	3.59e-15	6.49e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	8.24	3.59e-15	6.49e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
LIHC	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-8.24	3.61e-15	6.52e-12	-0.52	-0.41	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
LIHC	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	8.24	3.66e-15	6.61e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
LIHC	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	8.24	3.7e-15	6.68e-12	0.72	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	8.24	3.7e-15	6.68e-12	0.72	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	8.24	3.7e-15	6.68e-12	0.72	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
LIHC	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	8.24	3.71e-15	6.69e-12	0.41	0.41	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
LIHC	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	8.24	3.71e-15	6.69e-12	0.41	0.41	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
LIHC	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	8.24	3.71e-15	6.69e-12	0.41	0.41	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
LIHC	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-8.24	3.73e-15	6.72e-12	-0.47	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
LIHC	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	8.24	3.76e-15	6.76e-12	0.63	0.41	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-8.23	3.86e-15	6.93e-12	-0.42	-0.41	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
LIHC	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-8.23	3.87e-15	6.96e-12	-0.45	-0.41	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	8.23	3.92e-15	7.04e-12	0.51	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
LIHC	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	8.23	3.93e-15	7.05e-12	0.72	0.41	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
LIHC	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-8.23	3.93e-15	7.06e-12	-0.52	-0.41	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
LIHC	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	8.23	3.99e-15	7.16e-12	0.41	0.41	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
LIHC	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-8.23	4.03e-15	7.23e-12	-0.45	-0.41	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
LIHC	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	8.23	4.04e-15	7.25e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
LIHC	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	8.23	4.04e-15	7.25e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
LIHC	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-8.23	4.04e-15	7.25e-12	-0.52	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
LIHC	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-8.23	4.04e-15	7.25e-12	-0.45	-0.41	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
LIHC	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	8.23	4.05e-15	7.27e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
LIHC	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	8.23	4.08e-15	7.3e-12	0.6	0.41	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
LIHC	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	8.22	4.13e-15	7.39e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	8.22	4.13e-15	7.39e-12	0.46	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
LIHC	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-8.22	4.16e-15	7.45e-12	-0.47	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	8.22	4.18e-15	7.48e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
LIHC	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	8.22	4.24e-15	7.59e-12	0.42	0.41	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
LIHC	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	8.22	4.26e-15	7.62e-12	0.6	0.41	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
LIHC	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-8.22	4.28e-15	7.65e-12	-0.71	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
LIHC	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	8.22	4.37e-15	7.81e-12	0.45	0.41	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
LIHC	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-8.22	4.39e-15	7.85e-12	-0.4	-0.41	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
LIHC	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-8.22	4.39e-15	7.85e-12	-0.4	-0.41	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
LIHC	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-8.22	4.39e-15	7.85e-12	-0.4	-0.41	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
LIHC	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-8.22	4.39e-15	7.85e-12	-0.4	-0.41	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
LIHC	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-8.22	4.39e-15	7.85e-12	-0.4	-0.41	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
LIHC	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-8.22	4.41e-15	7.87e-12	-0.41	-0.41	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
LIHC	cis	rs12744310	1	rs12029950	ENSG00000235358.1	RP11-399E6.1	8.21	4.5e-15	8.02e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41287493	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.943	rs12027685	ENSG00000235358.1	RP11-399E6.1	8.21	4.5e-15	8.02e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290626	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12024413	ENSG00000235358.1	RP11-399E6.1	8.21	4.5e-15	8.02e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290744	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs34027267	ENSG00000235358.1	RP11-399E6.1	8.21	4.5e-15	8.02e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291005	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12722758	ENSG00000235358.1	RP11-399E6.1	8.21	4.5e-15	8.02e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291343	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12723893	ENSG00000235358.1	RP11-399E6.1	8.21	4.5e-15	8.02e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291368	chr1:41242373~41284861:+
LIHC	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	8.21	4.51e-15	8.04e-12	0.54	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
LIHC	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-8.21	4.52e-15	8.05e-12	-0.46	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
LIHC	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-8.21	4.53e-15	8.06e-12	-0.41	-0.41	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	8.21	4.53e-15	8.07e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
LIHC	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-8.21	4.73e-15	8.41e-12	-0.47	-0.41	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
LIHC	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	8.2	4.75e-15	8.45e-12	0.49	0.41	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
LIHC	cis	rs2260433	0.66	rs7129777	ENSG00000281655.1	RP11-817J15.3	8.2	4.78e-15	8.5e-12	0.47	0.41	Cleft palate;	chr11:102641355	chr11:102681310~102683913:+
LIHC	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	8.2	4.79e-15	8.51e-12	0.55	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
LIHC	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-8.2	4.8e-15	8.52e-12	-0.47	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
LIHC	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	8.2	4.84e-15	8.58e-12	0.41	0.41	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
LIHC	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	8.2	4.84e-15	8.58e-12	0.64	0.41	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
LIHC	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	8.2	4.85e-15	8.61e-12	0.42	0.41	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
LIHC	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-8.2	4.87e-15	8.63e-12	-0.47	-0.41	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
LIHC	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	8.2	4.9e-15	8.69e-12	0.59	0.41	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
LIHC	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	8.2	4.91e-15	8.71e-12	0.52	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
LIHC	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	8.2	4.93e-15	8.74e-12	0.6	0.41	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	8.2	4.93e-15	8.74e-12	0.6	0.41	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
LIHC	cis	rs893363	0.517	rs6445606	ENSG00000271916.1	RP11-884K10.6	-8.2	4.94e-15	8.75e-12	-0.78	-0.41	Axial length;	chr3:53822023	chr3:53797764~53798019:-
LIHC	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-8.2	5.02e-15	8.9e-12	-0.68	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	8.2	5.07e-15	8.98e-12	0.68	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
LIHC	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	8.19	5.12e-15	9.07e-12	0.7	0.41	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
LIHC	cis	rs12744310	0.945	rs1343776	ENSG00000235358.1	RP11-399E6.1	8.19	5.19e-15	9.19e-12	0.53	0.41	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292046	chr1:41242373~41284861:+
LIHC	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	8.19	5.2e-15	9.19e-12	0.43	0.41	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
LIHC	cis	rs9527	0.637	rs12219247	ENSG00000236937.2	PTGES3P4	8.19	5.32e-15	9.41e-12	0.49	0.4	Arsenic metabolism;	chr10:102853604	chr10:102845595~102845950:+
LIHC	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	8.19	5.33e-15	9.42e-12	0.68	0.4	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
LIHC	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-8.19	5.33e-15	9.43e-12	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
LIHC	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	8.19	5.35e-15	9.46e-12	0.63	0.4	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	8.19	5.35e-15	9.46e-12	0.63	0.4	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	8.19	5.35e-15	9.46e-12	0.63	0.4	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	8.19	5.35e-15	9.46e-12	0.63	0.4	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	8.19	5.35e-15	9.46e-12	0.63	0.4	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	8.19	5.35e-15	9.46e-12	0.63	0.4	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	8.19	5.36e-15	9.46e-12	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	8.19	5.41e-15	9.55e-12	0.64	0.4	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	8.19	5.41e-15	9.55e-12	0.64	0.4	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
LIHC	cis	rs4356975	0.83	rs7435274	ENSG00000249956.3	RP11-790I12.2	8.18	5.57e-15	9.82e-12	0.45	0.4	Obesity-related traits;	chr4:69050281	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs7438808	ENSG00000249956.3	RP11-790I12.2	8.18	5.57e-15	9.82e-12	0.45	0.4	Obesity-related traits;	chr4:69050666	chr4:69408836~69423164:+
LIHC	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-8.18	5.58e-15	9.84e-12	-0.45	-0.4	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
LIHC	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	8.18	5.62e-15	9.9e-12	0.63	0.4	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
LIHC	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	8.18	5.62e-15	9.9e-12	0.63	0.4	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
LIHC	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-8.18	5.71e-15	1e-11	-0.59	-0.4	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
LIHC	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	8.18	5.74e-15	1.01e-11	0.7	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
LIHC	cis	rs1165205	0.558	rs531750	ENSG00000242387.1	HIST1H2APS2	8.17	5.84e-15	1.03e-11	0.52	0.4	Urate levels;	chr6:25882414	chr6:25882026~25882395:-
LIHC	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	8.17	5.86e-15	1.03e-11	0.49	0.4	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
LIHC	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	8.17	5.9e-15	1.04e-11	0.43	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
LIHC	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-8.17	5.91e-15	1.04e-11	-0.46	-0.4	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	8.17	5.96e-15	1.04e-11	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
LIHC	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	8.17	6.01e-15	1.05e-11	0.41	0.4	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
LIHC	cis	rs4356975	0.83	rs10012607	ENSG00000249956.3	RP11-790I12.2	8.17	6.02e-15	1.05e-11	0.45	0.4	Obesity-related traits;	chr4:69048866	chr4:69408836~69423164:+
LIHC	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-8.17	6.04e-15	1.06e-11	-0.51	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
LIHC	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	8.17	6.04e-15	1.06e-11	0.67	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
LIHC	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	8.17	6.06e-15	1.06e-11	0.49	0.4	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
LIHC	cis	rs5758659	0.504	rs133367	ENSG00000227370.1	RP4-669P10.19	8.17	6.17e-15	1.08e-11	0.45	0.4	Cognitive function;	chr22:42067362	chr22:42132543~42132998:+
LIHC	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-8.17	6.18e-15	1.08e-11	-0.45	-0.4	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-8.17	6.24e-15	1.09e-11	-0.46	-0.4	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-8.17	6.24e-15	1.09e-11	-0.46	-0.4	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
LIHC	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-8.17	6.24e-15	1.09e-11	-0.46	-0.4	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-8.17	6.24e-15	1.09e-11	-0.46	-0.4	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-8.17	6.24e-15	1.09e-11	-0.46	-0.4	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-8.16	6.28e-15	1.09e-11	-0.46	-0.4	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-8.16	6.28e-15	1.09e-11	-0.46	-0.4	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
LIHC	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-8.16	6.3e-15	1.1e-11	-0.41	-0.4	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
LIHC	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-8.16	6.32e-15	1.1e-11	-0.4	-0.4	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
LIHC	cis	rs12744310	1	rs12035913	ENSG00000235358.1	RP11-399E6.1	-8.16	6.34e-15	1.1e-11	-0.52	-0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291385	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs67483852	ENSG00000235358.1	RP11-399E6.1	8.16	6.38e-15	1.11e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318793	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs36015391	ENSG00000235358.1	RP11-399E6.1	8.16	6.38e-15	1.11e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319133	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs28399806	ENSG00000235358.1	RP11-399E6.1	8.16	6.38e-15	1.11e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319299	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12047875	ENSG00000235358.1	RP11-399E6.1	8.16	6.38e-15	1.11e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319504	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs35932978	ENSG00000235358.1	RP11-399E6.1	8.16	6.38e-15	1.11e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319773	chr1:41242373~41284861:+
LIHC	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	8.16	6.48e-15	1.13e-11	0.54	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
LIHC	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	8.16	6.51e-15	1.13e-11	0.41	0.4	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
LIHC	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	8.16	6.57e-15	1.14e-11	0.53	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
LIHC	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-8.16	6.69e-15	1.16e-11	-0.45	-0.4	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
LIHC	cis	rs4356975	0.932	rs4694159	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69068460	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs4694597	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69068643	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.899	rs4694160	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69068755	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.899	rs7439419	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69069090	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7658748	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69069219	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.899	rs7687336	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69069397	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.899	rs7659138	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69069420	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7674600	ENSG00000249956.3	RP11-790I12.2	8.16	6.69e-15	1.16e-11	0.45	0.4	Obesity-related traits;	chr4:69069614	chr4:69408836~69423164:+
LIHC	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	8.15	6.72e-15	1.17e-11	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
LIHC	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	8.15	6.78e-15	1.18e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	8.15	6.78e-15	1.18e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	8.15	6.78e-15	1.18e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	8.15	6.78e-15	1.18e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	8.15	6.78e-15	1.18e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
LIHC	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-8.15	6.94e-15	1.21e-11	-0.46	-0.4	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
LIHC	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	8.15	6.94e-15	1.21e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
LIHC	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	8.15	6.94e-15	1.21e-11	0.46	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
LIHC	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	8.15	7.02e-15	1.22e-11	0.73	0.4	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
LIHC	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	8.15	7.04e-15	1.22e-11	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
LIHC	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	8.15	7.04e-15	1.22e-11	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
LIHC	cis	rs12744310	1	rs12035012	ENSG00000235358.1	RP11-399E6.1	8.15	7.07e-15	1.23e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41284976	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs35318047	ENSG00000235358.1	RP11-399E6.1	8.15	7.07e-15	1.23e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289494	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.943	rs35493284	ENSG00000235358.1	RP11-399E6.1	8.15	7.07e-15	1.23e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289517	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12025254	ENSG00000235358.1	RP11-399E6.1	8.15	7.07e-15	1.23e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291234	chr1:41242373~41284861:+
LIHC	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	8.15	7.07e-15	1.23e-11	0.4	0.4	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
LIHC	cis	rs12744310	1	rs60552457	ENSG00000235358.1	RP11-399E6.1	8.14	7.23e-15	1.25e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41293827	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12739950	ENSG00000235358.1	RP11-399E6.1	8.14	7.23e-15	1.25e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294219	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.945	rs12740093	ENSG00000235358.1	RP11-399E6.1	8.14	7.23e-15	1.25e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294329	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12038894	ENSG00000235358.1	RP11-399E6.1	8.14	7.23e-15	1.25e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294535	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12038924	ENSG00000235358.1	RP11-399E6.1	8.14	7.23e-15	1.25e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294645	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12032514	ENSG00000235358.1	RP11-399E6.1	8.14	7.23e-15	1.25e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294890	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12039767	ENSG00000235358.1	RP11-399E6.1	8.14	7.23e-15	1.25e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295188	chr1:41242373~41284861:+
LIHC	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-8.14	7.31e-15	1.27e-11	-0.4	-0.4	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
LIHC	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	8.14	7.32e-15	1.27e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
LIHC	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	8.14	7.45e-15	1.29e-11	0.4	0.4	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
LIHC	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	8.14	7.49e-15	1.29e-11	0.52	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
LIHC	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-8.14	7.64e-15	1.32e-11	-0.67	-0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
LIHC	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	8.13	7.74e-15	1.34e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
LIHC	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	8.13	7.75e-15	1.34e-11	0.4	0.4	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
LIHC	cis	rs529413	0.543	rs12915134	ENSG00000259237.1	RP11-209E8.1	8.13	7.81e-15	1.35e-11	0.51	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr15:53159314	chr15:53116365~53129698:+
LIHC	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	8.13	7.89e-15	1.36e-11	0.47	0.4	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-8.13	7.95e-15	1.37e-11	-0.45	-0.4	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
LIHC	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	8.13	8e-15	1.38e-11	0.46	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
LIHC	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	8.13	8e-15	1.38e-11	0.46	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
LIHC	cis	rs11647589	0.784	rs1700804	ENSG00000260762.1	ACSM5P1	-8.13	8.01e-15	1.38e-11	-0.41	-0.4	Blood metabolite levels;	chr16:20477047	chr16:20586550~20607107:-
LIHC	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	8.13	8.08e-15	1.39e-11	0.57	0.4	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
LIHC	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-8.12	8.31e-15	1.43e-11	-0.4	-0.4	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
LIHC	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-8.12	8.48e-15	1.46e-11	-0.45	-0.4	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-8.12	8.48e-15	1.46e-11	-0.45	-0.4	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
LIHC	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	8.12	8.49e-15	1.46e-11	0.52	0.4	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
LIHC	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-8.12	8.51e-15	1.46e-11	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
LIHC	cis	rs2302464	1	rs57326588	ENSG00000214846.4	RP11-115L11.1	8.12	8.59e-15	1.47e-11	0.64	0.4	Cerebrospinal fluid biomarker levels;	chr4:15723813	chr4:15730962~15731627:-
LIHC	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	8.12	8.6e-15	1.48e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
LIHC	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-8.12	8.63e-15	1.48e-11	-0.46	-0.4	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
LIHC	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-8.12	8.63e-15	1.48e-11	-0.46	-0.4	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
LIHC	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	8.12	8.65e-15	1.48e-11	0.74	0.4	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
LIHC	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-8.12	8.73e-15	1.5e-11	-0.41	-0.4	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-8.12	8.73e-15	1.5e-11	-0.41	-0.4	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
LIHC	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	8.12	8.75e-15	1.5e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	8.12	8.75e-15	1.5e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
LIHC	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	8.12	8.79e-15	1.51e-11	0.48	0.4	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
LIHC	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	8.11	8.94e-15	1.53e-11	0.62	0.4	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
LIHC	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	8.11	8.96e-15	1.53e-11	0.51	0.4	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
LIHC	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-8.11	8.98e-15	1.54e-11	-0.47	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
LIHC	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	8.11	9.06e-15	1.55e-11	0.48	0.4	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
LIHC	cis	rs2524005	1	rs2524005	ENSG00000204625.9	HCG9	8.11	9.13e-15	1.56e-11	0.56	0.4	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29975112~29978410:+
LIHC	cis	rs8062405	0.54	rs193628	ENSG00000259982.1	CDC37P1	-8.11	9.18e-15	1.57e-11	-0.44	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28570821	chr16:28700294~28701540:-
LIHC	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-8.11	9.23e-15	1.58e-11	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-8.11	9.23e-15	1.58e-11	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
LIHC	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-8.11	9.32e-15	1.59e-11	-0.45	-0.4	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-8.11	9.32e-15	1.59e-11	-0.45	-0.4	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-8.11	9.32e-15	1.59e-11	-0.45	-0.4	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-8.11	9.32e-15	1.59e-11	-0.45	-0.4	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
LIHC	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-8.11	9.33e-15	1.59e-11	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-8.11	9.33e-15	1.59e-11	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
LIHC	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-8.11	9.36e-15	1.6e-11	-0.47	-0.4	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
LIHC	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-8.11	9.42e-15	1.61e-11	-0.45	-0.4	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
LIHC	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	8.1	9.55e-15	1.63e-11	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
LIHC	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	8.1	9.6e-15	1.64e-11	0.53	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
LIHC	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	8.1	9.65e-15	1.65e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
LIHC	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-8.1	9.66e-15	1.65e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-8.1	9.66e-15	1.65e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-8.1	9.66e-15	1.65e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
LIHC	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-8.1	9.79e-15	1.67e-11	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
LIHC	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	8.1	9.79e-15	1.67e-11	0.56	0.4	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
LIHC	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-8.1	9.85e-15	1.68e-11	-0.59	-0.4	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
LIHC	cis	rs4356975	0.932	rs4694602	ENSG00000249956.3	RP11-790I12.2	8.1	9.91e-15	1.69e-11	0.44	0.4	Obesity-related traits;	chr4:69070955	chr4:69408836~69423164:+
LIHC	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	8.1	9.92e-15	1.69e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	8.1	9.93e-15	1.69e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	8.1	9.93e-15	1.69e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	8.1	9.93e-15	1.69e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	8.1	9.93e-15	1.69e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
LIHC	cis	rs12744310	0.895	rs1892417	ENSG00000235358.1	RP11-399E6.1	8.1	1e-14	1.7e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41314001	chr1:41242373~41284861:+
LIHC	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	8.09	1.02e-14	1.74e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
LIHC	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-8.09	1.03e-14	1.75e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	8.09	1.03e-14	1.75e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	8.09	1.04e-14	1.76e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
LIHC	cis	rs4356975	0.83	rs6600865	ENSG00000249956.3	RP11-790I12.2	8.09	1.05e-14	1.78e-11	0.45	0.4	Obesity-related traits;	chr4:69057904	chr4:69408836~69423164:+
LIHC	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	8.09	1.05e-14	1.78e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
LIHC	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	8.09	1.08e-14	1.83e-11	0.45	0.4	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
LIHC	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	8.09	1.08e-14	1.83e-11	0.46	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
LIHC	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	8.09	1.08e-14	1.83e-11	0.46	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
LIHC	cis	rs4356975	0.83	rs4481286	ENSG00000249956.3	RP11-790I12.2	8.09	1.08e-14	1.83e-11	0.45	0.4	Obesity-related traits;	chr4:69056631	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs4583828	ENSG00000249956.3	RP11-790I12.2	8.09	1.08e-14	1.83e-11	0.45	0.4	Obesity-related traits;	chr4:69056669	chr4:69408836~69423164:+
LIHC	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-8.08	1.09e-14	1.85e-11	-0.47	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
LIHC	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-8.08	1.11e-14	1.88e-11	-0.44	-0.4	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
LIHC	cis	rs11191419	1	rs11191419	ENSG00000236937.2	PTGES3P4	8.08	1.12e-14	1.9e-11	0.48	0.4	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102845595~102845950:+
LIHC	cis	rs12744310	1	rs1343775	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292321	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12731400	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295680	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12032756	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295757	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs55859000	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295769	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12030372	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41296357	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12032162	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297263	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12031417	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297356	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12037588	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298283	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12037657	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298503	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.832	rs12027990	ENSG00000235358.1	RP11-399E6.1	8.08	1.13e-14	1.9e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298765	chr1:41242373~41284861:+
LIHC	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	8.08	1.13e-14	1.92e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
LIHC	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	8.08	1.14e-14	1.92e-11	0.43	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
LIHC	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-8.08	1.15e-14	1.94e-11	-0.44	-0.4	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
LIHC	cis	rs4356975	0.83	rs4235113	ENSG00000249956.3	RP11-790I12.2	8.08	1.15e-14	1.94e-11	0.45	0.4	Obesity-related traits;	chr4:69056739	chr4:69408836~69423164:+
LIHC	cis	rs529413	0.516	rs1396092	ENSG00000259237.1	RP11-209E8.1	8.08	1.15e-14	1.94e-11	0.51	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr15:53160017	chr15:53116365~53129698:+
LIHC	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-8.08	1.15e-14	1.94e-11	-0.43	-0.4	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-8.08	1.15e-14	1.94e-11	-0.43	-0.4	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	8.08	1.15e-14	1.94e-11	0.43	0.4	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
LIHC	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	8.08	1.16e-14	1.95e-11	0.62	0.4	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
LIHC	cis	rs12744310	0.887	rs12045979	ENSG00000235358.1	RP11-399E6.1	8.07	1.17e-14	1.96e-11	0.54	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343805	chr1:41242373~41284861:+
LIHC	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	8.07	1.18e-14	1.99e-11	0.4	0.4	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
LIHC	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	8.07	1.18e-14	1.99e-11	0.51	0.4	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
LIHC	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	8.07	1.19e-14	1.99e-11	0.47	0.4	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
LIHC	cis	rs4356975	0.83	rs6422322	ENSG00000249956.3	RP11-790I12.2	8.07	1.19e-14	2e-11	0.45	0.4	Obesity-related traits;	chr4:69055571	chr4:69408836~69423164:+
LIHC	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-8.07	1.2e-14	2.02e-11	-0.44	-0.4	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-8.07	1.2e-14	2.02e-11	-0.44	-0.4	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
LIHC	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	8.07	1.2e-14	2.02e-11	0.43	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
LIHC	cis	rs4356975	0.83	rs4235114	ENSG00000249956.3	RP11-790I12.2	8.07	1.2e-14	2.02e-11	0.45	0.4	Obesity-related traits;	chr4:69056953	chr4:69408836~69423164:+
LIHC	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.21e-14	2.03e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
LIHC	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	8.07	1.22e-14	2.04e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
LIHC	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-8.07	1.22e-14	2.04e-11	-0.43	-0.4	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
LIHC	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-8.07	1.23e-14	2.06e-11	-0.46	-0.4	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
LIHC	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	8.07	1.24e-14	2.07e-11	0.62	0.4	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
LIHC	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	8.07	1.24e-14	2.07e-11	0.47	0.4	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
LIHC	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	8.06	1.26e-14	2.1e-11	0.73	0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
LIHC	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	8.06	1.27e-14	2.12e-11	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	8.06	1.29e-14	2.15e-11	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
LIHC	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-8.06	1.29e-14	2.15e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	8.05	1.34e-14	2.24e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	8.05	1.34e-14	2.24e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-8.05	1.35e-14	2.24e-11	-0.53	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
LIHC	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	8.05	1.36e-14	2.26e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
LIHC	cis	rs4356975	0.932	rs4400061	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69071281	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs4446390	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69071328	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7434389	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69071698	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.896	rs58496756	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69072070	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.599	rs7660019	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69072135	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.574	rs7660021	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69072143	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.549	rs7687692	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69072154	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.899	rs7687725	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69072229	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs4516791	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69072402	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs4694605	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69072777	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs4694607	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69073025	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.899	rs4410590	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69073381	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs4611997	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69073429	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.899	rs4412058	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69073715	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7436912	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69074077	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs72852416	ENSG00000249956.3	RP11-790I12.2	8.05	1.36e-14	2.26e-11	0.44	0.4	Obesity-related traits;	chr4:69075085	chr4:69408836~69423164:+
LIHC	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-8.05	1.38e-14	2.29e-11	-0.45	-0.4	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
LIHC	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	8.05	1.38e-14	2.3e-11	0.45	0.4	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
LIHC	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-8.05	1.39e-14	2.31e-11	-0.49	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
LIHC	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	8.05	1.4e-14	2.32e-11	0.44	0.4	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
LIHC	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-8.05	1.4e-14	2.33e-11	-0.44	-0.4	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	8.05	1.41e-14	2.34e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	8.05	1.41e-14	2.34e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
LIHC	cis	rs12744310	1	rs34190295	ENSG00000235358.1	RP11-399E6.1	8.05	1.43e-14	2.37e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300207	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.945	rs34961305	ENSG00000235358.1	RP11-399E6.1	8.05	1.43e-14	2.37e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300272	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12030762	ENSG00000235358.1	RP11-399E6.1	8.05	1.43e-14	2.37e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301089	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs35529558	ENSG00000235358.1	RP11-399E6.1	8.05	1.43e-14	2.37e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301350	chr1:41242373~41284861:+
LIHC	cis	rs4356975	0.932	rs4400060	ENSG00000249956.3	RP11-790I12.2	8.05	1.43e-14	2.37e-11	0.44	0.4	Obesity-related traits;	chr4:69071215	chr4:69408836~69423164:+
LIHC	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-8.04	1.44e-14	2.38e-11	-0.4	-0.4	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
LIHC	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-8.04	1.44e-14	2.39e-11	-0.4	-0.4	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
LIHC	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-8.04	1.44e-14	2.39e-11	-0.4	-0.4	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
LIHC	cis	rs4356975	0.806	rs12648808	ENSG00000249956.3	RP11-790I12.2	8.04	1.45e-14	2.4e-11	0.44	0.4	Obesity-related traits;	chr4:69075351	chr4:69408836~69423164:+
LIHC	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	8.04	1.46e-14	2.42e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	8.04	1.46e-14	2.42e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	8.04	1.46e-14	2.42e-11	0.59	0.4	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	8.04	1.46e-14	2.42e-11	0.59	0.4	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
LIHC	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-8.04	1.46e-14	2.42e-11	-0.45	-0.4	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
LIHC	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-8.04	1.47e-14	2.43e-11	-0.51	-0.4	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
LIHC	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	8.04	1.47e-14	2.43e-11	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
LIHC	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-8.04	1.48e-14	2.44e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-8.04	1.48e-14	2.44e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-8.04	1.48e-14	2.44e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-8.04	1.48e-14	2.44e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-8.04	1.48e-14	2.44e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-8.04	1.48e-14	2.44e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-8.04	1.48e-14	2.44e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
LIHC	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	8.04	1.49e-14	2.46e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	8.04	1.49e-14	2.46e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
LIHC	cis	rs4356975	0.83	rs10012215	ENSG00000249956.3	RP11-790I12.2	8.04	1.49e-14	2.46e-11	0.45	0.4	Obesity-related traits;	chr4:69048448	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs10012240	ENSG00000249956.3	RP11-790I12.2	8.04	1.49e-14	2.46e-11	0.45	0.4	Obesity-related traits;	chr4:69048519	chr4:69408836~69423164:+
LIHC	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	8.04	1.49e-14	2.47e-11	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
LIHC	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-8.04	1.5e-14	2.47e-11	-0.59	-0.4	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
LIHC	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	8.04	1.5e-14	2.48e-11	0.43	0.4	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
LIHC	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	8.04	1.51e-14	2.49e-11	0.4	0.4	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
LIHC	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	8.04	1.51e-14	2.49e-11	0.4	0.4	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
LIHC	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-8.04	1.52e-14	2.51e-11	-0.47	-0.4	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
LIHC	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-8.04	1.52e-14	2.51e-11	-0.43	-0.4	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
LIHC	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-8.04	1.53e-14	2.52e-11	-0.45	-0.4	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-8.04	1.53e-14	2.52e-11	-0.45	-0.4	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-8.03	1.54e-14	2.53e-11	-0.45	-0.4	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
LIHC	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-8.03	1.54e-14	2.54e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
LIHC	cis	rs4356975	0.795	rs4694599	ENSG00000249956.3	RP11-790I12.2	8.03	1.55e-14	2.55e-11	0.44	0.4	Obesity-related traits;	chr4:69070858	chr4:69408836~69423164:+
LIHC	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	8.03	1.56e-14	2.56e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	8.03	1.56e-14	2.56e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	8.03	1.56e-14	2.56e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	8.03	1.56e-14	2.56e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	8.03	1.56e-14	2.56e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	8.03	1.56e-14	2.56e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	8.03	1.57e-14	2.59e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
LIHC	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	8.03	1.58e-14	2.6e-11	0.42	0.4	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
LIHC	cis	rs4356975	0.932	rs60814050	ENSG00000249956.3	RP11-790I12.2	8.03	1.58e-14	2.6e-11	0.44	0.4	Obesity-related traits;	chr4:69063770	chr4:69408836~69423164:+
LIHC	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-8.03	1.59e-14	2.61e-11	-0.51	-0.4	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
LIHC	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	8.03	1.61e-14	2.64e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
LIHC	cis	rs12744310	0.887	rs16828067	ENSG00000235358.1	RP11-399E6.1	8.03	1.61e-14	2.65e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317880	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs16828071	ENSG00000235358.1	RP11-399E6.1	8.03	1.61e-14	2.65e-11	0.53	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317931	chr1:41242373~41284861:+
LIHC	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-8.03	1.61e-14	2.65e-11	-0.46	-0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
LIHC	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	8.03	1.62e-14	2.66e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
LIHC	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-8.03	1.62e-14	2.66e-11	-0.45	-0.4	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
LIHC	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-8.03	1.62e-14	2.67e-11	-0.41	-0.4	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
LIHC	cis	rs7657257	1	rs11931532	ENSG00000214846.4	RP11-115L11.1	8.03	1.63e-14	2.67e-11	0.63	0.4	Blood protein levels;	chr4:15724143	chr4:15730962~15731627:-
LIHC	cis	rs12744310	0.943	rs35502198	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302869	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.943	rs34862272	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302981	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs34796305	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303373	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs55707527	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303441	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.943	rs35972058	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303474	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.943	rs12032906	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303486	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs34315814	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303500	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12032191	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303546	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12032215	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303662	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12035353	ENSG00000235358.1	RP11-399E6.1	8.03	1.63e-14	2.67e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303665	chr1:41242373~41284861:+
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	8.03	1.63e-14	2.68e-11	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
LIHC	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-8.03	1.64e-14	2.68e-11	-0.41	-0.4	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
LIHC	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-8.02	1.66e-14	2.72e-11	-0.46	-0.4	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
LIHC	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	8.02	1.66e-14	2.72e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	8.02	1.66e-14	2.72e-11	0.61	0.4	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
LIHC	cis	rs1577917	0.74	rs2475792	ENSG00000234155.1	RP11-30P6.6	-8.02	1.67e-14	2.73e-11	-0.47	-0.4	Response to antipsychotic treatment;	chr6:85682384	chr6:85387219~85390186:-
LIHC	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-8.02	1.69e-14	2.76e-11	-0.45	-0.4	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-8.02	1.69e-14	2.76e-11	-0.45	-0.4	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-8.02	1.69e-14	2.76e-11	-0.45	-0.4	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	8.02	1.7e-14	2.78e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	8.02	1.7e-14	2.78e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	8.02	1.7e-14	2.78e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	8.02	1.7e-14	2.78e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
LIHC	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-8.02	1.7e-14	2.79e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
LIHC	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	8.02	1.71e-14	2.8e-11	0.73	0.4	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
LIHC	cis	rs12744310	1	rs35812095	ENSG00000235358.1	RP11-399E6.1	8.02	1.72e-14	2.81e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300402	chr1:41242373~41284861:+
LIHC	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	8.02	1.72e-14	2.81e-11	0.62	0.4	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
LIHC	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-8.02	1.74e-14	2.84e-11	-0.51	-0.4	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
LIHC	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	8.01	1.8e-14	2.94e-11	0.66	0.4	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	8.01	1.8e-14	2.94e-11	0.66	0.4	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
LIHC	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	8.01	1.81e-14	2.94e-11	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	8.01	1.81e-14	2.94e-11	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
LIHC	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-8.01	1.81e-14	2.95e-11	-0.38	-0.4	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
LIHC	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	8.01	1.82e-14	2.95e-11	0.57	0.4	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
LIHC	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	8.01	1.82e-14	2.95e-11	0.57	0.4	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
LIHC	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	8.01	1.82e-14	2.95e-11	0.57	0.4	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
LIHC	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	8.01	1.86e-14	3.02e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	8.01	1.86e-14	3.02e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	8.01	1.86e-14	3.02e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	8.01	1.86e-14	3.02e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	8.01	1.86e-14	3.02e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	8.01	1.86e-14	3.02e-11	0.6	0.4	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
LIHC	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-8.01	1.86e-14	3.03e-11	-0.51	-0.4	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
LIHC	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	8.01	1.88e-14	3.05e-11	0.66	0.4	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
LIHC	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	8	1.89e-14	3.07e-11	0.47	0.4	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
LIHC	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-8	1.89e-14	3.07e-11	-0.45	-0.4	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	8	1.93e-14	3.13e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	8	1.93e-14	3.13e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	8	1.93e-14	3.13e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	8	1.93e-14	3.13e-11	0.51	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
LIHC	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-8	1.94e-14	3.15e-11	-0.4	-0.4	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
LIHC	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-8	1.95e-14	3.15e-11	-0.44	-0.4	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
LIHC	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-8	1.96e-14	3.17e-11	-0.46	-0.4	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
LIHC	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	8	1.98e-14	3.2e-11	0.4	0.4	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
LIHC	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-8	2e-14	3.24e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
LIHC	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-8	2.01e-14	3.26e-11	-0.66	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
LIHC	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	7.99	2.02e-14	3.27e-11	0.64	0.4	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
LIHC	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	7.99	2.04e-14	3.29e-11	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
LIHC	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	7.99	2.04e-14	3.3e-11	0.44	0.4	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
LIHC	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	7.99	2.05e-14	3.31e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	7.99	2.05e-14	3.31e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	7.99	2.06e-14	3.33e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	7.99	2.08e-14	3.36e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	7.99	2.09e-14	3.38e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
LIHC	cis	rs4356975	0.899	rs72501227	ENSG00000249956.3	RP11-790I12.2	7.99	2.09e-14	3.38e-11	0.44	0.4	Obesity-related traits;	chr4:69069866	chr4:69408836~69423164:+
LIHC	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	7.99	2.13e-14	3.44e-11	0.39	0.4	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
LIHC	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	7.99	2.13e-14	3.44e-11	0.39	0.4	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
LIHC	cis	rs1577917	0.518	rs2475787	ENSG00000234155.1	RP11-30P6.6	-7.99	2.13e-14	3.44e-11	-0.45	-0.4	Response to antipsychotic treatment;	chr6:85705518	chr6:85387219~85390186:-
LIHC	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	7.99	2.14e-14	3.45e-11	0.5	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
LIHC	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-7.99	2.15e-14	3.47e-11	-0.45	-0.4	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-7.99	2.15e-14	3.47e-11	-0.44	-0.4	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
LIHC	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	7.99	2.16e-14	3.47e-11	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
LIHC	cis	rs4356975	0.932	rs4694604	ENSG00000249956.3	RP11-790I12.2	7.99	2.16e-14	3.47e-11	0.44	0.4	Obesity-related traits;	chr4:69072745	chr4:69408836~69423164:+
LIHC	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	7.98	2.16e-14	3.49e-11	0.45	0.4	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
LIHC	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	7.98	2.17e-14	3.5e-11	0.46	0.4	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
LIHC	cis	rs12744310	1	rs12041533	ENSG00000235358.1	RP11-399E6.1	7.98	2.22e-14	3.56e-11	0.52	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302599	chr1:41242373~41284861:+
LIHC	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	7.98	2.22e-14	3.58e-11	0.5	0.4	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
LIHC	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	7.98	2.25e-14	3.62e-11	0.48	0.4	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
LIHC	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-7.98	2.25e-14	3.62e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
LIHC	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	7.98	2.27e-14	3.64e-11	0.74	0.4	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
LIHC	cis	rs7085104	0.7	rs10786712	ENSG00000236937.2	PTGES3P4	-7.97	2.33e-14	3.73e-11	-0.47	-0.4	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102845595~102845950:+
LIHC	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-7.97	2.33e-14	3.74e-11	-0.48	-0.4	Migraine;	chr4:56956882	chr4:56960927~56961373:-
LIHC	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-7.97	2.33e-14	3.74e-11	-0.48	-0.4	Migraine;	chr4:56957291	chr4:56960927~56961373:-
LIHC	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	7.97	2.33e-14	3.74e-11	0.64	0.4	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
LIHC	cis	rs4356975	0.932	rs7662632	ENSG00000249956.3	RP11-790I12.2	7.97	2.34e-14	3.75e-11	0.44	0.4	Obesity-related traits;	chr4:69062256	chr4:69408836~69423164:+
LIHC	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	7.97	2.34e-14	3.75e-11	0.48	0.4	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
LIHC	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	7.97	2.37e-14	3.79e-11	0.47	0.4	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
LIHC	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	7.97	2.38e-14	3.82e-11	0.48	0.4	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
LIHC	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	7.97	2.38e-14	3.82e-11	0.48	0.4	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
LIHC	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	7.97	2.4e-14	3.84e-11	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	7.97	2.4e-14	3.84e-11	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	7.97	2.4e-14	3.84e-11	0.69	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
LIHC	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	7.97	2.41e-14	3.85e-11	0.63	0.4	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
LIHC	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-7.97	2.41e-14	3.85e-11	-0.51	-0.4	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	7.97	2.43e-14	3.88e-11	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
LIHC	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	7.97	2.44e-14	3.91e-11	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
LIHC	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-7.97	2.46e-14	3.93e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-7.97	2.46e-14	3.93e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-7.97	2.46e-14	3.93e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-7.97	2.46e-14	3.93e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
LIHC	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	7.97	2.47e-14	3.95e-11	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
LIHC	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.96	2.48e-14	3.96e-11	-0.45	-0.4	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
LIHC	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-7.96	2.49e-14	3.97e-11	-0.44	-0.4	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-7.96	2.49e-14	3.97e-11	-0.44	-0.4	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-7.96	2.5e-14	4e-11	-0.44	-0.4	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-7.96	2.5e-14	4e-11	-0.44	-0.4	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-7.96	2.5e-14	4e-11	-0.44	-0.4	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
LIHC	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	7.96	2.56e-14	4.08e-11	0.68	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	7.96	2.57e-14	4.1e-11	0.47	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
LIHC	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-7.96	2.57e-14	4.1e-11	-0.59	-0.4	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	7.96	2.57e-14	4.1e-11	0.59	0.4	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	7.96	2.57e-14	4.1e-11	0.59	0.4	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
LIHC	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	7.96	2.59e-14	4.12e-11	0.45	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
LIHC	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	7.96	2.6e-14	4.14e-11	0.42	0.4	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
LIHC	cis	rs4356975	0.932	rs7654272	ENSG00000249956.3	RP11-790I12.2	7.96	2.61e-14	4.15e-11	0.44	0.4	Obesity-related traits;	chr4:69074144	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs6600867	ENSG00000249956.3	RP11-790I12.2	7.96	2.61e-14	4.15e-11	0.44	0.4	Obesity-related traits;	chr4:69074157	chr4:69408836~69423164:+
LIHC	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	7.96	2.63e-14	4.2e-11	0.46	0.4	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
LIHC	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-7.95	2.69e-14	4.28e-11	-0.47	-0.4	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
LIHC	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	7.95	2.71e-14	4.31e-11	0.35	0.4	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
LIHC	cis	rs12744310	1	rs12034357	ENSG00000235358.1	RP11-399E6.1	7.95	2.71e-14	4.31e-11	0.51	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302557	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs7553908	ENSG00000235358.1	RP11-399E6.1	7.95	2.71e-14	4.31e-11	0.51	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302569	chr1:41242373~41284861:+
LIHC	cis	rs12744310	1	rs12031169	ENSG00000235358.1	RP11-399E6.1	7.95	2.71e-14	4.31e-11	0.51	0.4	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302579	chr1:41242373~41284861:+
LIHC	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	7.95	2.72e-14	4.33e-11	0.52	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
LIHC	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	7.95	2.77e-14	4.41e-11	0.44	0.39	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
LIHC	cis	rs4356975	0.932	rs7692377	ENSG00000249956.3	RP11-790I12.2	7.95	2.78e-14	4.41e-11	0.44	0.39	Obesity-related traits;	chr4:69078113	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs61612343	ENSG00000249956.3	RP11-790I12.2	7.95	2.78e-14	4.41e-11	0.44	0.39	Obesity-related traits;	chr4:69078247	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7679418	ENSG00000249956.3	RP11-790I12.2	7.95	2.78e-14	4.41e-11	0.44	0.39	Obesity-related traits;	chr4:69078533	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7680156	ENSG00000249956.3	RP11-790I12.2	7.95	2.78e-14	4.41e-11	0.44	0.39	Obesity-related traits;	chr4:69078868	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7698430	ENSG00000249956.3	RP11-790I12.2	7.95	2.78e-14	4.41e-11	0.44	0.39	Obesity-related traits;	chr4:69078897	chr4:69408836~69423164:+
LIHC	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	7.95	2.8e-14	4.44e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	7.95	2.8e-14	4.44e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	7.95	2.8e-14	4.44e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	7.95	2.8e-14	4.44e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
LIHC	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-7.95	2.8e-14	4.45e-11	-0.44	-0.39	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-7.95	2.8e-14	4.45e-11	-0.45	-0.39	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
LIHC	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-7.95	2.84e-14	4.5e-11	-0.48	-0.39	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
LIHC	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	7.94	2.84e-14	4.5e-11	0.42	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
LIHC	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	7.94	2.84e-14	4.51e-11	0.68	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
LIHC	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	7.94	2.86e-14	4.53e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
LIHC	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-7.94	2.92e-14	4.62e-11	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-7.94	2.95e-14	4.67e-11	-0.52	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
LIHC	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-7.94	2.95e-14	4.68e-11	-0.44	-0.39	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
LIHC	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	7.94	2.96e-14	4.68e-11	0.64	0.39	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
LIHC	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	7.94	2.96e-14	4.68e-11	0.4	0.39	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
LIHC	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-7.94	2.96e-14	4.68e-11	-0.44	-0.39	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
LIHC	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-7.94	2.96e-14	4.68e-11	-0.51	-0.39	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
LIHC	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-7.94	2.96e-14	4.69e-11	-0.59	-0.39	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-7.94	2.96e-14	4.69e-11	-0.59	-0.39	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-7.94	2.96e-14	4.69e-11	-0.59	-0.39	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
LIHC	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	7.94	2.97e-14	4.69e-11	0.62	0.39	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
LIHC	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-7.94	2.97e-14	4.7e-11	-0.54	-0.39	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
LIHC	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	7.94	3e-14	4.75e-11	0.41	0.39	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	7.94	3.02e-14	4.77e-11	0.41	0.39	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	7.94	3.02e-14	4.77e-11	0.41	0.39	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
LIHC	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	7.94	3.02e-14	4.77e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
LIHC	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-7.93	3.09e-14	4.88e-11	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
LIHC	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	7.93	3.1e-14	4.89e-11	0.72	0.39	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
LIHC	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-7.93	3.16e-14	4.98e-11	-0.39	-0.39	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
LIHC	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-7.93	3.17e-14	4.99e-11	-0.45	-0.39	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-7.93	3.17e-14	4.99e-11	-0.45	-0.39	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-7.93	3.17e-14	4.99e-11	-0.45	-0.39	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-7.93	3.17e-14	4.99e-11	-0.45	-0.39	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-7.93	3.17e-14	4.99e-11	-0.45	-0.39	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
LIHC	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	7.93	3.17e-14	4.99e-11	0.66	0.39	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
LIHC	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-7.93	3.19e-14	5.02e-11	-0.49	-0.39	Migraine;	chr4:56940917	chr4:56960927~56961373:-
LIHC	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	7.93	3.2e-14	5.04e-11	0.41	0.39	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
LIHC	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	7.93	3.23e-14	5.08e-11	0.59	0.39	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	7.93	3.23e-14	5.08e-11	0.59	0.39	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
LIHC	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	7.93	3.25e-14	5.11e-11	0.39	0.39	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
LIHC	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-7.92	3.25e-14	5.12e-11	-0.62	-0.39	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
LIHC	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	7.92	3.31e-14	5.2e-11	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
LIHC	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	7.92	3.31e-14	5.2e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	7.92	3.31e-14	5.2e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
LIHC	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-7.92	3.31e-14	5.21e-11	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
LIHC	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	7.92	3.31e-14	5.21e-11	0.58	0.39	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
LIHC	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-7.92	3.39e-14	5.33e-11	-0.58	-0.39	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-7.92	3.42e-14	5.37e-11	-0.63	-0.39	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
LIHC	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-7.92	3.44e-14	5.4e-11	-0.5	-0.39	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-7.92	3.44e-14	5.4e-11	-0.5	-0.39	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-7.92	3.45e-14	5.41e-11	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
LIHC	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	7.92	3.47e-14	5.44e-11	0.56	0.39	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
LIHC	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	7.92	3.47e-14	5.44e-11	0.51	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
LIHC	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	7.92	3.47e-14	5.45e-11	0.51	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
LIHC	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	7.91	3.5e-14	5.48e-11	0.41	0.39	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
LIHC	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	7.91	3.51e-14	5.5e-11	0.57	0.39	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
LIHC	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	7.91	3.51e-14	5.5e-11	0.41	0.39	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
LIHC	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.91	3.52e-14	5.51e-11	-0.45	-0.39	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
LIHC	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-7.91	3.52e-14	5.51e-11	-0.45	-0.39	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
LIHC	cis	rs12744310	0.887	rs12724625	ENSG00000235358.1	RP11-399E6.1	7.91	3.52e-14	5.51e-11	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316598	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12041352	ENSG00000235358.1	RP11-399E6.1	7.91	3.52e-14	5.51e-11	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317109	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs28566545	ENSG00000235358.1	RP11-399E6.1	7.91	3.52e-14	5.51e-11	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317561	chr1:41242373~41284861:+
LIHC	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	7.91	3.55e-14	5.55e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	7.91	3.55e-14	5.55e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	7.91	3.55e-14	5.55e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	7.91	3.55e-14	5.55e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
LIHC	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-7.91	3.55e-14	5.56e-11	-0.39	-0.39	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
LIHC	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-7.91	3.56e-14	5.56e-11	-0.44	-0.39	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
LIHC	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-7.91	3.57e-14	5.58e-11	-0.58	-0.39	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-7.91	3.57e-14	5.58e-11	-0.58	-0.39	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
LIHC	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	7.91	3.57e-14	5.59e-11	0.43	0.39	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
LIHC	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-7.91	3.57e-14	5.59e-11	-0.57	-0.39	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
LIHC	cis	rs1577917	0.518	rs6454482	ENSG00000234155.1	RP11-30P6.6	-7.91	3.59e-14	5.61e-11	-0.45	-0.39	Response to antipsychotic treatment;	chr6:85708470	chr6:85387219~85390186:-
LIHC	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-7.91	3.59e-14	5.62e-11	-0.49	-0.39	Migraine;	chr4:56943905	chr4:56960927~56961373:-
LIHC	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-7.91	3.6e-14	5.63e-11	-0.44	-0.39	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
LIHC	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	7.91	3.6e-14	5.63e-11	0.59	0.39	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
LIHC	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	7.91	3.62e-14	5.65e-11	0.48	0.39	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
LIHC	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	7.91	3.62e-14	5.66e-11	0.48	0.39	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
LIHC	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	7.91	3.63e-14	5.66e-11	0.4	0.39	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
LIHC	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	7.91	3.66e-14	5.71e-11	0.41	0.39	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
LIHC	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	7.91	3.7e-14	5.78e-11	0.57	0.39	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
LIHC	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-7.91	3.71e-14	5.78e-11	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
LIHC	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	7.91	3.71e-14	5.78e-11	0.39	0.39	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
LIHC	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-7.9	3.72e-14	5.81e-11	-0.51	-0.39	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
LIHC	cis	rs4356975	0.932	rs4694610	ENSG00000249956.3	RP11-790I12.2	7.9	3.82e-14	5.95e-11	0.44	0.39	Obesity-related traits;	chr4:69079224	chr4:69408836~69423164:+
LIHC	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	7.9	3.88e-14	6.04e-11	0.44	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	7.9	3.89e-14	6.06e-11	0.61	0.39	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
LIHC	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-7.9	3.91e-14	6.09e-11	-0.45	-0.39	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
LIHC	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-7.9	3.94e-14	6.13e-11	-0.45	-0.39	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
LIHC	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	7.9	3.94e-14	6.13e-11	0.69	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
LIHC	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	7.9	3.97e-14	6.15e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	7.9	3.97e-14	6.15e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	7.9	3.97e-14	6.15e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	7.9	3.97e-14	6.15e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
LIHC	cis	rs4356975	0.83	rs7666894	ENSG00000249956.3	RP11-790I12.2	7.9	3.97e-14	6.15e-11	0.43	0.39	Obesity-related traits;	chr4:69078780	chr4:69408836~69423164:+
LIHC	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	7.89	4e-14	6.18e-11	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
LIHC	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-7.89	4.01e-14	6.19e-11	-0.46	-0.39	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
LIHC	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	7.89	4.02e-14	6.22e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
LIHC	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-7.89	4.06e-14	6.28e-11	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
LIHC	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	7.89	4.07e-14	6.28e-11	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	7.89	4.09e-14	6.31e-11	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
LIHC	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	7.89	4.11e-14	6.35e-11	0.44	0.39	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
LIHC	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	7.89	4.13e-14	6.36e-11	0.36	0.39	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
LIHC	cis	rs831571	0.774	rs40610	ENSG00000280620.1	SCAANT1	7.89	4.13e-14	6.37e-11	0.51	0.39	Type 2 diabetes;	chr3:64023832	chr3:63911518~63911772:-
LIHC	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	7.89	4.17e-14	6.42e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	7.89	4.17e-14	6.42e-11	0.62	0.39	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	7.89	4.17e-14	6.42e-11	0.62	0.39	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
LIHC	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-7.89	4.19e-14	6.45e-11	-0.43	-0.39	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
LIHC	cis	rs4356975	0.768	rs4518318	ENSG00000249956.3	RP11-790I12.2	-7.89	4.2e-14	6.47e-11	-0.44	-0.39	Obesity-related traits;	chr4:69045479	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs4351079	ENSG00000249956.3	RP11-790I12.2	-7.89	4.2e-14	6.47e-11	-0.44	-0.39	Obesity-related traits;	chr4:69045631	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.798	rs4607293	ENSG00000249956.3	RP11-790I12.2	-7.89	4.2e-14	6.47e-11	-0.44	-0.39	Obesity-related traits;	chr4:69045714	chr4:69408836~69423164:+
LIHC	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	7.89	4.21e-14	6.48e-11	0.48	0.39	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
LIHC	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	7.89	4.25e-14	6.55e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
LIHC	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	7.88	4.28e-14	6.59e-11	0.39	0.39	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
LIHC	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	7.88	4.29e-14	6.61e-11	0.59	0.39	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
LIHC	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	7.88	4.32e-14	6.65e-11	0.44	0.39	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
LIHC	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	7.88	4.4e-14	6.76e-11	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
LIHC	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	7.88	4.41e-14	6.77e-11	0.61	0.39	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
LIHC	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-7.88	4.42e-14	6.79e-11	-0.5	-0.39	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
LIHC	cis	rs4356975	0.867	rs6600869	ENSG00000249956.3	RP11-790I12.2	7.88	4.43e-14	6.8e-11	0.43	0.39	Obesity-related traits;	chr4:69075937	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.836	rs6600870	ENSG00000249956.3	RP11-790I12.2	7.88	4.43e-14	6.8e-11	0.43	0.39	Obesity-related traits;	chr4:69075944	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs7442394	ENSG00000249956.3	RP11-790I12.2	7.88	4.43e-14	6.8e-11	0.43	0.39	Obesity-related traits;	chr4:69076309	chr4:69408836~69423164:+
LIHC	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	7.88	4.44e-14	6.82e-11	0.39	0.39	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
LIHC	cis	rs893363	0.61	rs893362	ENSG00000271916.1	RP11-884K10.6	-7.88	4.48e-14	6.87e-11	-0.72	-0.39	Axial length;	chr3:53813767	chr3:53797764~53798019:-
LIHC	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-7.88	4.49e-14	6.88e-11	-0.59	-0.39	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-7.88	4.49e-14	6.88e-11	-0.59	-0.39	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-7.88	4.49e-14	6.88e-11	-0.59	-0.39	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-7.88	4.49e-14	6.88e-11	-0.59	-0.39	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
LIHC	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	7.88	4.49e-14	6.89e-11	0.56	0.39	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
LIHC	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	7.88	4.49e-14	6.89e-11	0.56	0.39	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	7.88	4.49e-14	6.89e-11	0.56	0.39	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
LIHC	cis	rs1577917	0.74	rs7752502	ENSG00000234155.1	RP11-30P6.6	-7.88	4.49e-14	6.89e-11	-0.46	-0.39	Response to antipsychotic treatment;	chr6:85700933	chr6:85387219~85390186:-
LIHC	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	7.88	4.56e-14	6.98e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
LIHC	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-7.87	4.56e-14	6.99e-11	-0.56	-0.39	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
LIHC	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	7.87	4.57e-14	6.99e-11	0.39	0.39	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
LIHC	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	7.87	4.58e-14	7.01e-11	0.56	0.39	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
LIHC	cis	rs9326248	0.515	rs2727793	ENSG00000236267.1	AP006216.5	7.87	4.58e-14	7.01e-11	0.39	0.39	Blood protein levels;	chr11:116812658	chr11:116813204~116814003:-
LIHC	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	7.87	4.58e-14	7.02e-11	0.45	0.39	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
LIHC	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	7.87	4.64e-14	7.09e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
LIHC	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-7.87	4.64e-14	7.09e-11	-0.44	-0.39	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
LIHC	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-7.87	4.65e-14	7.1e-11	-0.45	-0.39	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
LIHC	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	7.87	4.66e-14	7.12e-11	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
LIHC	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-7.87	4.69e-14	7.17e-11	-0.39	-0.39	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
LIHC	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-7.87	4.71e-14	7.19e-11	-0.57	-0.39	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
LIHC	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-7.87	4.71e-14	7.19e-11	-0.43	-0.39	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
LIHC	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-7.87	4.71e-14	7.2e-11	-0.59	-0.39	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
LIHC	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	7.87	4.77e-14	7.29e-11	0.56	0.39	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
LIHC	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	7.87	4.77e-14	7.29e-11	0.56	0.39	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
LIHC	cis	rs6686842	0.689	rs2885697	ENSG00000235358.1	RP11-399E6.1	-7.87	4.78e-14	7.29e-11	-0.47	-0.39	Height;	chr1:41078607	chr1:41242373~41284861:+
LIHC	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-7.87	4.79e-14	7.31e-11	-0.49	-0.39	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-7.87	4.79e-14	7.31e-11	-0.49	-0.39	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
LIHC	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	7.87	4.8e-14	7.32e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	7.87	4.8e-14	7.32e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	7.87	4.8e-14	7.32e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	7.87	4.8e-14	7.32e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
LIHC	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-7.87	4.81e-14	7.34e-11	-0.48	-0.39	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
LIHC	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	7.87	4.81e-14	7.34e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
LIHC	cis	rs4356975	0.798	rs4694588	ENSG00000249956.3	RP11-790I12.2	-7.87	4.81e-14	7.34e-11	-0.44	-0.39	Obesity-related traits;	chr4:69044664	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs7693166	ENSG00000249956.3	RP11-790I12.2	-7.87	4.81e-14	7.34e-11	-0.44	-0.39	Obesity-related traits;	chr4:69044866	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.83	rs6422321	ENSG00000249956.3	RP11-790I12.2	-7.87	4.81e-14	7.34e-11	-0.44	-0.39	Obesity-related traits;	chr4:69044911	chr4:69408836~69423164:+
LIHC	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	7.87	4.86e-14	7.4e-11	0.46	0.39	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
LIHC	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	7.87	4.88e-14	7.43e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	7.86	4.91e-14	7.48e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-7.86	4.96e-14	7.55e-11	-0.49	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
LIHC	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	7.86	4.99e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	7.86	4.99e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	7.86	4.99e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	7.86	5e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	7.86	5e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	7.86	5e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	7.86	5e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	7.86	5e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	7.86	5e-14	7.59e-11	0.48	0.39	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
LIHC	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	7.86	5.05e-14	7.67e-11	0.43	0.39	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
LIHC	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-7.86	5.06e-14	7.68e-11	-0.48	-0.39	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
LIHC	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	7.86	5.11e-14	7.75e-11	0.39	0.39	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
LIHC	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-7.86	5.15e-14	7.8e-11	-0.44	-0.39	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
LIHC	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	7.86	5.15e-14	7.8e-11	0.42	0.39	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
LIHC	cis	rs831571	0.955	rs35837	ENSG00000280620.1	SCAANT1	7.86	5.17e-14	7.83e-11	0.55	0.39	Type 2 diabetes;	chr3:64027573	chr3:63911518~63911772:-
LIHC	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-7.86	5.19e-14	7.86e-11	-0.49	-0.39	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
LIHC	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	7.85	5.25e-14	7.93e-11	0.57	0.39	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
LIHC	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-7.85	5.33e-14	8.05e-11	-0.34	-0.39	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
LIHC	cis	rs4718428	0.576	rs12698546	ENSG00000273142.1	RP11-458F8.4	-7.85	5.33e-14	8.05e-11	-0.4	-0.39	Corneal structure;	chr7:66801919	chr7:66902857~66906297:+
LIHC	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	7.85	5.36e-14	8.09e-11	0.39	0.39	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
LIHC	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.85	5.39e-14	8.13e-11	-0.45	-0.39	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.85	5.39e-14	8.13e-11	-0.45	-0.39	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
LIHC	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	7.85	5.43e-14	8.19e-11	0.61	0.39	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
LIHC	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.43e-14	8.19e-11	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.43e-14	8.19e-11	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.43e-14	8.19e-11	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.43e-14	8.19e-11	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.43e-14	8.19e-11	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.43e-14	8.19e-11	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-7.85	5.43e-14	8.19e-11	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
LIHC	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-7.85	5.45e-14	8.21e-11	-0.5	-0.39	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
LIHC	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	7.85	5.49e-14	8.27e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	7.85	5.49e-14	8.27e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
LIHC	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-7.85	5.5e-14	8.29e-11	-0.46	-0.39	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
LIHC	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	7.85	5.54e-14	8.33e-11	0.6	0.39	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
LIHC	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-7.85	5.56e-14	8.37e-11	-0.59	-0.39	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
LIHC	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	7.84	5.62e-14	8.45e-11	0.58	0.39	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
LIHC	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	7.84	5.65e-14	8.5e-11	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-7.84	5.67e-14	8.53e-11	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
LIHC	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	7.84	5.7e-14	8.57e-11	0.66	0.39	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
LIHC	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-7.84	5.71e-14	8.59e-11	-0.51	-0.39	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-7.84	5.71e-14	8.59e-11	-0.51	-0.39	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-7.84	5.71e-14	8.59e-11	-0.51	-0.39	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-7.84	5.71e-14	8.59e-11	-0.51	-0.39	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-7.84	5.71e-14	8.59e-11	-0.51	-0.39	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-7.84	5.71e-14	8.59e-11	-0.51	-0.39	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
LIHC	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	7.84	5.77e-14	8.66e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	7.84	5.77e-14	8.66e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	7.84	5.77e-14	8.66e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	7.84	5.77e-14	8.66e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	7.84	5.77e-14	8.66e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	7.84	5.77e-14	8.66e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	7.84	5.77e-14	8.66e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
LIHC	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-7.84	5.85e-14	8.78e-11	-0.44	-0.39	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
LIHC	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-7.84	5.93e-14	8.89e-11	-0.42	-0.39	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
LIHC	cis	rs6844153	0.941	rs73116683	ENSG00000240005.4	RP11-293A21.1	-7.84	5.93e-14	8.89e-11	-0.46	-0.39	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955376	chr4:26859806~26860599:-
LIHC	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	7.84	5.97e-14	8.94e-11	0.39	0.39	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	7.83	6.03e-14	9.02e-11	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
LIHC	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	7.83	6.06e-14	9.08e-11	0.59	0.39	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
LIHC	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	7.83	6.07e-14	9.08e-11	0.46	0.39	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
LIHC	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	7.83	6.08e-14	9.1e-11	0.48	0.39	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
LIHC	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-7.83	6.12e-14	9.15e-11	-0.45	-0.39	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
LIHC	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-7.83	6.13e-14	9.17e-11	-0.59	-0.39	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
LIHC	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-7.83	6.16e-14	9.21e-11	-0.5	-0.39	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
LIHC	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	7.83	6.17e-14	9.22e-11	0.61	0.39	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	7.83	6.17e-14	9.22e-11	0.61	0.39	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	7.83	6.23e-14	9.31e-11	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
LIHC	cis	rs7208859	0.673	rs216411	ENSG00000263531.1	RP13-753N3.1	-7.83	6.27e-14	9.36e-11	-0.66	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30863921~30864940:-
LIHC	cis	rs7085104	0.66	rs3781286	ENSG00000236937.2	PTGES3P4	7.83	6.3e-14	9.4e-11	0.46	0.39	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102845595~102845950:+
LIHC	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	7.82	6.47e-14	9.64e-11	0.44	0.39	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
LIHC	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-7.82	6.56e-14	9.77e-11	-0.66	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-7.82	6.6e-14	9.82e-11	-0.53	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
LIHC	cis	rs12744310	0.887	rs2363810	ENSG00000235358.1	RP11-399E6.1	7.82	6.63e-14	9.86e-11	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318201	chr1:41242373~41284861:+
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-7.82	6.67e-14	9.91e-11	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
LIHC	cis	rs9543976	0.623	rs7986566	ENSG00000261553.4	RP11-29G8.3	7.82	6.75e-14	1e-10	0.53	0.39	Diabetic retinopathy;	chr13:75623795	chr13:75549773~75807120:+
LIHC	cis	rs12744310	0.887	rs35410722	ENSG00000235358.1	RP11-399E6.1	7.82	6.83e-14	1.01e-10	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41330592	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs34539673	ENSG00000235358.1	RP11-399E6.1	7.82	6.83e-14	1.01e-10	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331145	chr1:41242373~41284861:+
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	7.82	6.83e-14	1.01e-10	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
LIHC	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	7.81	6.87e-14	1.02e-10	0.51	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
LIHC	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	7.81	6.9e-14	1.02e-10	0.69	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	7.81	6.9e-14	1.02e-10	0.69	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	7.81	6.9e-14	1.02e-10	0.69	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
LIHC	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-7.81	6.97e-14	1.03e-10	-0.56	-0.39	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
LIHC	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	7.81	6.98e-14	1.03e-10	0.58	0.39	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
LIHC	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-7.81	7.02e-14	1.04e-10	-0.4	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
LIHC	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	7.81	7.09e-14	1.05e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	7.81	7.09e-14	1.05e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	7.81	7.09e-14	1.05e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	7.81	7.09e-14	1.05e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	7.81	7.09e-14	1.05e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	7.81	7.09e-14	1.05e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	7.81	7.09e-14	1.05e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-7.81	7.09e-14	1.05e-10	-0.49	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
LIHC	cis	rs10899021	0.915	rs11236198	ENSG00000279353.1	RP11-864N7.4	7.81	7.14e-14	1.05e-10	0.98	0.39	Response to metformin (IC50);	chr11:74661155	chr11:74698231~74699658:-
LIHC	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-7.81	7.15e-14	1.06e-10	-0.47	-0.39	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
LIHC	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	7.81	7.28e-14	1.07e-10	0.65	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	7.8	7.35e-14	1.08e-10	0.68	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
LIHC	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	7.8	7.37e-14	1.09e-10	0.53	0.39	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	7.8	7.37e-14	1.09e-10	0.53	0.39	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	7.8	7.37e-14	1.09e-10	0.53	0.39	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
LIHC	cis	rs4356975	0.83	rs6600868	ENSG00000249956.3	RP11-790I12.2	7.8	7.47e-14	1.1e-10	0.43	0.39	Obesity-related traits;	chr4:69075923	chr4:69408836~69423164:+
LIHC	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-7.8	7.52e-14	1.11e-10	-0.48	-0.39	Migraine;	chr4:56937339	chr4:56960927~56961373:-
LIHC	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	7.8	7.55e-14	1.11e-10	0.61	0.39	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
LIHC	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-7.8	7.62e-14	1.12e-10	-0.56	-0.39	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
LIHC	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	7.8	7.64e-14	1.12e-10	0.43	0.39	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
LIHC	cis	rs12744310	1	rs36143444	ENSG00000235358.1	RP11-399E6.1	7.8	7.65e-14	1.12e-10	0.5	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298638	chr1:41242373~41284861:+
LIHC	cis	rs1577917	0.74	rs9344542	ENSG00000234155.1	RP11-30P6.6	-7.8	7.76e-14	1.14e-10	-0.45	-0.39	Response to antipsychotic treatment;	chr6:85684187	chr6:85387219~85390186:-
LIHC	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-7.79	7.88e-14	1.15e-10	-0.46	-0.39	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
LIHC	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	7.79	7.89e-14	1.16e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
LIHC	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	7.79	7.93e-14	1.16e-10	0.49	0.39	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
LIHC	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-7.79	7.98e-14	1.17e-10	-0.44	-0.39	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
LIHC	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	7.79	8.03e-14	1.18e-10	0.45	0.39	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
LIHC	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-7.79	8.05e-14	1.18e-10	-0.45	-0.39	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-7.79	8.05e-14	1.18e-10	-0.45	-0.39	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
LIHC	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	7.79	8.06e-14	1.18e-10	0.54	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
LIHC	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-7.79	8.11e-14	1.19e-10	-0.51	-0.39	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
LIHC	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	7.79	8.12e-14	1.19e-10	0.41	0.39	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
LIHC	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-7.79	8.13e-14	1.19e-10	-0.63	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	7.79	8.13e-14	1.19e-10	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
LIHC	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-7.79	8.17e-14	1.19e-10	-0.41	-0.39	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
LIHC	cis	rs4356975	0.692	rs7691361	ENSG00000249956.3	RP11-790I12.2	7.79	8.21e-14	1.2e-10	0.43	0.39	Obesity-related traits;	chr4:69077628	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.72	rs7691362	ENSG00000249956.3	RP11-790I12.2	7.79	8.21e-14	1.2e-10	0.43	0.39	Obesity-related traits;	chr4:69077631	chr4:69408836~69423164:+
LIHC	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-7.79	8.23e-14	1.2e-10	-0.48	-0.39	Migraine;	chr4:56950140	chr4:56960927~56961373:-
LIHC	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-7.79	8.24e-14	1.2e-10	-0.41	-0.39	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
LIHC	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-7.79	8.28e-14	1.21e-10	-0.44	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
LIHC	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-7.79	8.3e-14	1.21e-10	-0.51	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.771	rs9450319	ENSG00000234155.1	RP11-30P6.6	-7.79	8.31e-14	1.21e-10	-0.45	-0.39	Response to antipsychotic treatment;	chr6:85717607	chr6:85387219~85390186:-
LIHC	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	7.78	8.41e-14	1.23e-10	0.45	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
LIHC	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	7.78	8.46e-14	1.23e-10	0.5	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
LIHC	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	7.78	8.48e-14	1.24e-10	0.39	0.39	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
LIHC	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-7.78	8.49e-14	1.24e-10	-0.43	-0.39	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
LIHC	cis	rs4356975	0.932	rs72852450	ENSG00000249956.3	RP11-790I12.2	7.78	8.54e-14	1.25e-10	0.43	0.39	Obesity-related traits;	chr4:69079704	chr4:69408836~69423164:+
LIHC	cis	rs12744310	0.887	rs1892419	ENSG00000235358.1	RP11-399E6.1	7.78	8.65e-14	1.26e-10	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315479	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs1892420	ENSG00000235358.1	RP11-399E6.1	7.78	8.65e-14	1.26e-10	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315738	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs28541673	ENSG00000235358.1	RP11-399E6.1	7.78	8.65e-14	1.26e-10	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316322	chr1:41242373~41284861:+
LIHC	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	7.78	8.73e-14	1.27e-10	0.43	0.39	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	7.78	8.73e-14	1.27e-10	0.43	0.39	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
LIHC	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-7.78	8.76e-14	1.27e-10	-0.58	-0.39	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
LIHC	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	7.78	8.84e-14	1.28e-10	0.47	0.39	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
LIHC	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	7.78	8.84e-14	1.28e-10	0.47	0.39	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
LIHC	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	7.78	8.94e-14	1.3e-10	0.39	0.39	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
LIHC	cis	rs12744310	0.887	rs72667608	ENSG00000235358.1	RP11-399E6.1	7.78	8.95e-14	1.3e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329101	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs72667610	ENSG00000235358.1	RP11-399E6.1	7.78	8.95e-14	1.3e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329138	chr1:41242373~41284861:+
LIHC	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	7.77	8.96e-14	1.3e-10	0.64	0.39	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	7.77	8.96e-14	1.3e-10	0.64	0.39	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	7.77	8.96e-14	1.3e-10	0.64	0.39	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	7.77	8.96e-14	1.3e-10	0.64	0.39	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	7.77	8.96e-14	1.3e-10	0.64	0.39	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
LIHC	cis	rs9527	0.637	rs7096169	ENSG00000236937.2	PTGES3P4	7.77	8.97e-14	1.3e-10	0.47	0.39	Arsenic metabolism;	chr10:102858938	chr10:102845595~102845950:+
LIHC	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	7.77	9e-14	1.31e-10	0.47	0.39	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
LIHC	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	7.77	9e-14	1.31e-10	0.47	0.39	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
LIHC	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	7.77	9.09e-14	1.32e-10	0.34	0.39	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
LIHC	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	7.77	9.17e-14	1.33e-10	0.43	0.39	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
LIHC	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	7.77	9.25e-14	1.34e-10	0.62	0.39	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
LIHC	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-7.77	9.37e-14	1.36e-10	-0.44	-0.39	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
LIHC	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	7.77	9.37e-14	1.36e-10	0.53	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
LIHC	cis	rs12744310	0.887	rs12047161	ENSG00000235358.1	RP11-399E6.1	7.77	9.51e-14	1.38e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41341856	chr1:41242373~41284861:+
LIHC	cis	rs4356975	0.932	rs4694612	ENSG00000249956.3	RP11-790I12.2	7.76	9.58e-14	1.39e-10	0.43	0.39	Obesity-related traits;	chr4:69079446	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.932	rs56879009	ENSG00000249956.3	RP11-790I12.2	7.76	9.58e-14	1.39e-10	0.43	0.39	Obesity-related traits;	chr4:69079589	chr4:69408836~69423164:+
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	7.76	9.71e-14	1.4e-10	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
LIHC	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	7.76	9.78e-14	1.41e-10	0.6	0.39	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-7.76	9.78e-14	1.41e-10	-0.6	-0.39	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
LIHC	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-7.76	9.87e-14	1.42e-10	-0.58	-0.39	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
LIHC	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	7.76	9.91e-14	1.43e-10	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
LIHC	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-7.76	1e-13	1.44e-10	-0.43	-0.39	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
LIHC	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	7.76	1e-13	1.45e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	7.76	1e-13	1.45e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	7.76	1e-13	1.45e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	7.76	1e-13	1.45e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	7.76	1e-13	1.45e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	7.76	1e-13	1.45e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	7.76	1e-13	1.45e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
LIHC	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	7.76	1e-13	1.45e-10	0.6	0.39	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
LIHC	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	7.76	1.01e-13	1.46e-10	0.65	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	7.76	1.02e-13	1.47e-10	0.5	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
LIHC	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-7.76	1.02e-13	1.47e-10	-0.43	-0.39	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
LIHC	cis	rs7085104	0.7	rs10883785	ENSG00000236937.2	PTGES3P4	7.75	1.03e-13	1.48e-10	0.46	0.39	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102845595~102845950:+
LIHC	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-7.75	1.05e-13	1.52e-10	-0.52	-0.39	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
LIHC	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	7.75	1.06e-13	1.52e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
LIHC	cis	rs138857	0.515	rs9616373	ENSG00000278869.1	CITF22-49E9.3	7.75	1.07e-13	1.54e-10	0.81	0.39	Mean platelet volume;	chr22:49914949	chr22:49933198~49934074:-
LIHC	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	7.75	1.07e-13	1.54e-10	0.53	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	7.75	1.08e-13	1.55e-10	0.53	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
LIHC	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	7.75	1.08e-13	1.55e-10	0.64	0.39	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	7.75	1.08e-13	1.55e-10	0.64	0.39	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	7.75	1.08e-13	1.56e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
LIHC	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	7.74	1.1e-13	1.58e-10	0.33	0.39	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
LIHC	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	7.74	1.1e-13	1.58e-10	0.65	0.39	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	7.74	1.1e-13	1.58e-10	0.5	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
LIHC	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	7.74	1.1e-13	1.59e-10	0.47	0.39	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
LIHC	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	7.74	1.11e-13	1.59e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
LIHC	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-7.74	1.12e-13	1.6e-10	-0.48	-0.39	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
LIHC	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-7.74	1.13e-13	1.62e-10	-0.4	-0.39	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	7.74	1.13e-13	1.62e-10	0.61	0.39	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	7.74	1.13e-13	1.62e-10	0.61	0.39	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
LIHC	cis	rs12744310	0.887	rs12046670	ENSG00000235358.1	RP11-399E6.1	7.74	1.14e-13	1.63e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343640	chr1:41242373~41284861:+
LIHC	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-7.74	1.14e-13	1.63e-10	-0.49	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	7.74	1.14e-13	1.64e-10	0.65	0.39	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
LIHC	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-7.74	1.15e-13	1.64e-10	-0.44	-0.39	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-7.74	1.15e-13	1.64e-10	-0.44	-0.39	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
LIHC	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-7.74	1.15e-13	1.64e-10	-0.44	-0.39	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
LIHC	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-7.74	1.15e-13	1.64e-10	-0.48	-0.39	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
LIHC	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-7.74	1.16e-13	1.66e-10	-0.58	-0.39	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
LIHC	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-7.74	1.16e-13	1.66e-10	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-7.74	1.16e-13	1.66e-10	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-7.74	1.16e-13	1.66e-10	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-7.74	1.16e-13	1.66e-10	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-7.74	1.16e-13	1.66e-10	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
LIHC	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	7.74	1.16e-13	1.67e-10	0.34	0.39	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
LIHC	cis	rs832187	0.704	rs832195	ENSG00000280620.1	SCAANT1	-7.74	1.17e-13	1.67e-10	-0.48	-0.39	Schizophrenia;	chr3:63878936	chr3:63911518~63911772:-
LIHC	cis	rs4356975	0.932	rs4694611	ENSG00000249956.3	RP11-790I12.2	7.73	1.17e-13	1.68e-10	0.42	0.39	Obesity-related traits;	chr4:69079387	chr4:69408836~69423164:+
LIHC	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	7.73	1.17e-13	1.68e-10	0.71	0.39	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
LIHC	cis	rs8072100	0.905	rs8078686	ENSG00000228782.6	CTD-2026D20.3	-7.73	1.17e-13	1.68e-10	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47658340	chr17:47450568~47492492:-
LIHC	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	7.73	1.18e-13	1.68e-10	0.48	0.39	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
LIHC	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	7.73	1.18e-13	1.69e-10	0.63	0.39	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
LIHC	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-7.73	1.19e-13	1.69e-10	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
LIHC	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-7.73	1.19e-13	1.69e-10	-0.45	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
LIHC	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-7.73	1.19e-13	1.7e-10	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
LIHC	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-7.73	1.19e-13	1.7e-10	-0.43	-0.39	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
LIHC	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-7.73	1.19e-13	1.7e-10	-0.43	-0.39	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
LIHC	cis	rs9543976	0.623	rs9544004	ENSG00000261553.4	RP11-29G8.3	7.73	1.2e-13	1.71e-10	0.52	0.39	Diabetic retinopathy;	chr13:75617748	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.588	rs7324195	ENSG00000261553.4	RP11-29G8.3	7.73	1.2e-13	1.71e-10	0.52	0.39	Diabetic retinopathy;	chr13:75618386	chr13:75549773~75807120:+
LIHC	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-7.73	1.2e-13	1.71e-10	-0.4	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
LIHC	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	7.73	1.21e-13	1.72e-10	0.62	0.39	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
LIHC	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	7.73	1.21e-13	1.73e-10	0.5	0.39	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
LIHC	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-7.73	1.23e-13	1.75e-10	-0.43	-0.39	Height;	chr11:118773873	chr11:118704607~118750263:+
LIHC	cis	rs1165205	0.558	rs793144	ENSG00000242387.1	HIST1H2APS2	7.73	1.24e-13	1.76e-10	0.48	0.39	Urate levels;	chr6:25879093	chr6:25882026~25882395:-
LIHC	cis	rs1165205	0.5	rs629835	ENSG00000242387.1	HIST1H2APS2	7.73	1.24e-13	1.76e-10	0.48	0.39	Urate levels;	chr6:25879102	chr6:25882026~25882395:-
LIHC	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	7.73	1.25e-13	1.78e-10	0.63	0.39	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	7.73	1.25e-13	1.78e-10	0.63	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	7.73	1.25e-13	1.78e-10	0.63	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
LIHC	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-7.73	1.25e-13	1.78e-10	-0.49	-0.39	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
LIHC	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-7.72	1.25e-13	1.78e-10	-0.43	-0.39	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
LIHC	cis	rs12744310	0.83	rs12045184	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333939	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12724690	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41334585	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs35464028	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41334802	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs34152153	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335736	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs36040148	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335776	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs35807669	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335980	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12026404	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41336240	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12047272	ENSG00000235358.1	RP11-399E6.1	7.72	1.25e-13	1.78e-10	0.51	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41336271	chr1:41242373~41284861:+
LIHC	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	7.72	1.26e-13	1.78e-10	0.59	0.39	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
LIHC	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	7.72	1.27e-13	1.8e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	7.72	1.27e-13	1.8e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	7.72	1.27e-13	1.8e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
LIHC	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	7.72	1.28e-13	1.81e-10	0.47	0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
LIHC	cis	rs151227923	1	rs151227923	ENSG00000273117.1	AC144652.1	7.72	1.28e-13	1.82e-10	0.41	0.39	Stem cell growth factor beta levels;	chr7:155314854	chr7:155295918~155297541:-
LIHC	cis	rs140365914	1	rs140365914	ENSG00000273117.1	AC144652.1	7.72	1.28e-13	1.82e-10	0.41	0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr7:155314860	chr7:155295918~155297541:-
LIHC	cis	rs1577917	0.771	rs4383777	ENSG00000234155.1	RP11-30P6.6	-7.72	1.29e-13	1.82e-10	-0.45	-0.39	Response to antipsychotic treatment;	chr6:85726242	chr6:85387219~85390186:-
LIHC	cis	rs4356975	0.932	rs12648830	ENSG00000249956.3	RP11-790I12.2	-7.72	1.29e-13	1.83e-10	-0.43	-0.39	Obesity-related traits;	chr4:69075436	chr4:69408836~69423164:+
LIHC	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	7.72	1.29e-13	1.83e-10	0.47	0.39	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
LIHC	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	7.72	1.3e-13	1.83e-10	0.47	0.39	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
LIHC	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	7.72	1.3e-13	1.83e-10	0.47	0.39	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
LIHC	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	7.72	1.3e-13	1.83e-10	0.47	0.39	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
LIHC	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	7.72	1.3e-13	1.84e-10	0.56	0.39	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
LIHC	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	7.72	1.31e-13	1.85e-10	0.49	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
LIHC	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-7.72	1.31e-13	1.85e-10	-0.38	-0.39	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	7.72	1.31e-13	1.86e-10	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
LIHC	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-7.72	1.32e-13	1.86e-10	-0.47	-0.39	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
LIHC	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-7.72	1.32e-13	1.87e-10	-0.43	-0.39	Height;	chr11:118749988	chr11:118704607~118750263:+
LIHC	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	7.72	1.32e-13	1.87e-10	0.47	0.39	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
LIHC	cis	rs1577917	0.538	rs7755996	ENSG00000234155.1	RP11-30P6.6	-7.72	1.32e-13	1.87e-10	-0.44	-0.39	Response to antipsychotic treatment;	chr6:85714002	chr6:85387219~85390186:-
LIHC	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-7.71	1.34e-13	1.89e-10	-0.57	-0.38	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
LIHC	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-7.71	1.35e-13	1.9e-10	-0.4	-0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
LIHC	cis	rs12744310	0.887	rs35021924	ENSG00000235358.1	RP11-399E6.1	7.71	1.38e-13	1.94e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321235	chr1:41242373~41284861:+
LIHC	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	7.71	1.39e-13	1.95e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	7.71	1.39e-13	1.95e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	7.71	1.39e-13	1.95e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	7.71	1.39e-13	1.95e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	7.71	1.39e-13	1.95e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	7.71	1.39e-13	1.95e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
LIHC	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-7.71	1.4e-13	1.97e-10	-0.56	-0.38	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
LIHC	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-7.71	1.4e-13	1.97e-10	-0.56	-0.38	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
LIHC	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.71	1.43e-13	2.01e-10	0.56	0.38	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
LIHC	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-7.7	1.43e-13	2.01e-10	-0.39	-0.38	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
LIHC	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-7.7	1.44e-13	2.01e-10	-0.48	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
LIHC	cis	rs296381	0.932	rs296391	ENSG00000259108.2	CTD-3098H1.2	7.7	1.44e-13	2.02e-10	0.57	0.38	Blood metabolite levels;	chr19:47865277	chr19:47863483~47865341:-
LIHC	cis	rs1577917	0.739	rs9450318	ENSG00000234155.1	RP11-30P6.6	-7.7	1.45e-13	2.03e-10	-0.45	-0.38	Response to antipsychotic treatment;	chr6:85717459	chr6:85387219~85390186:-
LIHC	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-7.7	1.45e-13	2.03e-10	-0.44	-0.38	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	7.7	1.45e-13	2.03e-10	0.44	0.38	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
LIHC	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-7.7	1.45e-13	2.04e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-7.7	1.45e-13	2.04e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
LIHC	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-7.7	1.46e-13	2.05e-10	-0.4	-0.38	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-7.7	1.46e-13	2.05e-10	-0.4	-0.38	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
LIHC	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	7.7	1.47e-13	2.05e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
LIHC	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	7.7	1.47e-13	2.06e-10	0.63	0.38	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
LIHC	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-7.7	1.47e-13	2.06e-10	-0.46	-0.38	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-7.7	1.47e-13	2.06e-10	-0.46	-0.38	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
LIHC	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	7.7	1.49e-13	2.08e-10	0.57	0.38	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
LIHC	cis	rs893363	0.61	rs920252	ENSG00000271916.1	RP11-884K10.6	-7.7	1.49e-13	2.08e-10	-0.73	-0.38	Axial length;	chr3:53814645	chr3:53797764~53798019:-
LIHC	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-7.7	1.5e-13	2.09e-10	-0.39	-0.38	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
LIHC	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-7.7	1.5e-13	2.1e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
LIHC	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-7.7	1.5e-13	2.1e-10	-0.49	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
LIHC	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	7.7	1.5e-13	2.1e-10	0.52	0.38	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
LIHC	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-7.7	1.51e-13	2.11e-10	-0.43	-0.38	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
LIHC	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	7.7	1.51e-13	2.11e-10	0.52	0.38	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.623	rs6562914	ENSG00000261553.4	RP11-29G8.3	7.7	1.52e-13	2.13e-10	0.51	0.38	Diabetic retinopathy;	chr13:75593401	chr13:75549773~75807120:+
LIHC	cis	rs1577917	0.696	rs10806334	ENSG00000234155.1	RP11-30P6.6	7.69	1.53e-13	2.13e-10	0.45	0.38	Response to antipsychotic treatment;	chr6:85729611	chr6:85387219~85390186:-
LIHC	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-7.69	1.54e-13	2.14e-10	-0.44	-0.38	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
LIHC	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	7.69	1.54e-13	2.16e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	7.69	1.54e-13	2.16e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	7.69	1.54e-13	2.16e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
LIHC	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-7.69	1.55e-13	2.16e-10	-0.36	-0.38	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
LIHC	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	7.69	1.56e-13	2.17e-10	0.53	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
LIHC	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	7.69	1.58e-13	2.2e-10	0.55	0.38	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
LIHC	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	7.69	1.59e-13	2.21e-10	0.64	0.38	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
LIHC	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	7.69	1.59e-13	2.21e-10	0.5	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
LIHC	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-7.69	1.59e-13	2.22e-10	-0.43	-0.38	Height;	chr11:118761813	chr11:118704607~118750263:+
LIHC	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-7.69	1.59e-13	2.22e-10	-0.54	-0.38	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
LIHC	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-7.69	1.59e-13	2.22e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
LIHC	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	7.69	1.6e-13	2.23e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-7.69	1.61e-13	2.24e-10	-0.59	-0.38	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-7.69	1.61e-13	2.24e-10	-0.59	-0.38	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
LIHC	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-7.69	1.61e-13	2.24e-10	-0.46	-0.38	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
LIHC	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	7.69	1.61e-13	2.24e-10	0.63	0.38	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
LIHC	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	7.69	1.62e-13	2.26e-10	0.44	0.38	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
LIHC	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	7.68	1.64e-13	2.27e-10	0.44	0.38	Height;	chr11:118758322	chr11:118704607~118750263:+
LIHC	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	7.68	1.64e-13	2.28e-10	0.38	0.38	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
LIHC	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	7.68	1.64e-13	2.28e-10	0.4	0.38	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
LIHC	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-7.68	1.66e-13	2.3e-10	-0.43	-0.38	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
LIHC	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	7.68	1.67e-13	2.32e-10	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
LIHC	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	7.68	1.68e-13	2.33e-10	0.42	0.38	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
LIHC	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	7.68	1.69e-13	2.35e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
LIHC	cis	rs12744310	1	rs2364535	ENSG00000235358.1	RP11-399E6.1	7.68	1.69e-13	2.35e-10	0.49	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300564	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12043581	ENSG00000235358.1	RP11-399E6.1	7.68	1.72e-13	2.39e-10	0.49	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41322593	chr1:41242373~41284861:+
LIHC	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-7.68	1.73e-13	2.39e-10	-0.38	-0.38	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
LIHC	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	7.68	1.74e-13	2.4e-10	0.44	0.38	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
LIHC	cis	rs12744310	0.887	rs12757611	ENSG00000235358.1	RP11-399E6.1	7.67	1.75e-13	2.42e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343300	chr1:41242373~41284861:+
LIHC	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	7.67	1.75e-13	2.42e-10	0.38	0.38	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-7.67	1.76e-13	2.43e-10	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
LIHC	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	7.67	1.77e-13	2.45e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
LIHC	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	7.67	1.77e-13	2.45e-10	0.4	0.38	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
LIHC	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-7.67	1.82e-13	2.52e-10	-0.38	-0.38	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
LIHC	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-7.67	1.82e-13	2.52e-10	-0.38	-0.38	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
LIHC	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-7.67	1.83e-13	2.52e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
LIHC	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-7.67	1.84e-13	2.54e-10	-0.56	-0.38	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
LIHC	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	7.67	1.85e-13	2.55e-10	0.43	0.38	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
LIHC	cis	rs7085104	0.7	rs6163	ENSG00000236937.2	PTGES3P4	7.67	1.86e-13	2.56e-10	0.45	0.38	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102845595~102845950:+
LIHC	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-7.67	1.86e-13	2.56e-10	-0.43	-0.38	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
LIHC	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	7.66	1.88e-13	2.59e-10	0.65	0.38	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	7.66	1.88e-13	2.59e-10	0.65	0.38	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
LIHC	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	7.66	1.89e-13	2.6e-10	0.42	0.38	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-7.66	1.89e-13	2.61e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
LIHC	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.61e-10	0.63	0.38	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	7.66	1.9e-13	2.62e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	7.66	1.95e-13	2.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
LIHC	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	7.66	1.96e-13	2.69e-10	0.49	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
LIHC	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-7.66	1.97e-13	2.7e-10	-0.49	-0.38	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
LIHC	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-7.65	2e-13	2.74e-10	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
LIHC	cis	rs10899021	1	rs11236193	ENSG00000279353.1	RP11-864N7.4	7.65	2.01e-13	2.76e-10	0.97	0.38	Response to metformin (IC50);	chr11:74657262	chr11:74698231~74699658:-
LIHC	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	7.65	2.01e-13	2.76e-10	0.63	0.38	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	7.65	2.04e-13	2.8e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	7.65	2.04e-13	2.8e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
LIHC	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	7.65	2.05e-13	2.81e-10	0.42	0.38	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
LIHC	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-7.65	2.05e-13	2.81e-10	-0.44	-0.38	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-7.65	2.05e-13	2.81e-10	-0.44	-0.38	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-7.65	2.05e-13	2.81e-10	-0.44	-0.38	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-7.65	2.05e-13	2.81e-10	-0.44	-0.38	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
LIHC	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	7.65	2.06e-13	2.81e-10	0.43	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	7.65	2.06e-13	2.81e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	7.65	2.06e-13	2.81e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	7.65	2.06e-13	2.81e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	7.65	2.06e-13	2.81e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	7.65	2.06e-13	2.81e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
LIHC	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	7.65	2.06e-13	2.82e-10	0.47	0.38	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
LIHC	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	7.65	2.06e-13	2.82e-10	0.47	0.38	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
LIHC	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-7.65	2.07e-13	2.83e-10	-0.42	-0.38	QT interval;	chr16:28824579	chr16:28700294~28701540:-
LIHC	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	7.65	2.08e-13	2.85e-10	0.52	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
LIHC	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	7.65	2.11e-13	2.88e-10	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
LIHC	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-7.65	2.12e-13	2.88e-10	-0.43	-0.38	Height;	chr11:118746590	chr11:118704607~118750263:+
LIHC	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	7.64	2.14e-13	2.91e-10	0.42	0.38	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
LIHC	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-7.64	2.14e-13	2.92e-10	-0.43	-0.38	Height;	chr11:118760944	chr11:118704607~118750263:+
LIHC	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	7.64	2.18e-13	2.96e-10	0.49	0.38	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
LIHC	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	7.64	2.18e-13	2.96e-10	0.49	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
LIHC	cis	rs12744310	0.887	rs35592291	ENSG00000235358.1	RP11-399E6.1	7.64	2.19e-13	2.97e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41325599	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs2363811	ENSG00000235358.1	RP11-399E6.1	7.64	2.19e-13	2.97e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326193	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12026778	ENSG00000235358.1	RP11-399E6.1	7.64	2.19e-13	2.97e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326602	chr1:41242373~41284861:+
LIHC	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-7.64	2.19e-13	2.98e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
LIHC	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	7.64	2.21e-13	3.01e-10	0.49	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
LIHC	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	7.64	2.21e-13	3.01e-10	0.42	0.38	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
LIHC	cis	rs12744310	0.887	rs12028244	ENSG00000235358.1	RP11-399E6.1	7.64	2.24e-13	3.04e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343490	chr1:41242373~41284861:+
LIHC	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	7.64	2.25e-13	3.06e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	7.64	2.25e-13	3.06e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	7.64	2.25e-13	3.06e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	7.64	2.26e-13	3.07e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	7.64	2.26e-13	3.07e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	7.64	2.26e-13	3.07e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	7.64	2.26e-13	3.07e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	7.64	2.26e-13	3.07e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	7.64	2.26e-13	3.07e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
LIHC	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	7.63	2.29e-13	3.1e-10	0.56	0.38	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
LIHC	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	7.63	2.3e-13	3.12e-10	0.53	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
LIHC	cis	rs9326248	0.59	rs2542063	ENSG00000236267.1	AP006216.5	7.63	2.33e-13	3.16e-10	0.38	0.38	Blood protein levels;	chr11:116814051	chr11:116813204~116814003:-
LIHC	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-7.63	2.34e-13	3.17e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
LIHC	cis	rs10899021	1	rs7102084	ENSG00000279353.1	RP11-864N7.4	7.63	2.35e-13	3.18e-10	0.87	0.38	Response to metformin (IC50);	chr11:74647087	chr11:74698231~74699658:-
LIHC	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-7.63	2.35e-13	3.18e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-7.63	2.35e-13	3.18e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-7.63	2.35e-13	3.18e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-7.63	2.35e-13	3.18e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
LIHC	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-7.63	2.35e-13	3.18e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
LIHC	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-7.63	2.35e-13	3.19e-10	-0.38	-0.38	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
LIHC	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	7.63	2.36e-13	3.19e-10	0.52	0.38	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	7.63	2.36e-13	3.19e-10	0.52	0.38	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
LIHC	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	7.63	2.37e-13	3.2e-10	0.52	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
LIHC	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	7.63	2.39e-13	3.23e-10	0.43	0.38	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
LIHC	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-7.63	2.4e-13	3.24e-10	-0.43	-0.38	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
LIHC	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-7.63	2.4e-13	3.25e-10	-0.48	-0.38	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
LIHC	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-7.63	2.41e-13	3.26e-10	-0.38	-0.38	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
LIHC	cis	rs1577917	0.958	rs12197463	ENSG00000234155.1	RP11-30P6.6	7.63	2.42e-13	3.27e-10	0.45	0.38	Response to antipsychotic treatment;	chr6:85735524	chr6:85387219~85390186:-
LIHC	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	7.62	2.44e-13	3.29e-10	0.46	0.38	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	7.62	2.47e-13	3.33e-10	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
LIHC	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	7.62	2.48e-13	3.35e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	7.62	2.48e-13	3.35e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	7.62	2.48e-13	3.35e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	7.62	2.48e-13	3.35e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	7.62	2.48e-13	3.35e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	7.62	2.48e-13	3.35e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-7.62	2.48e-13	3.35e-10	-0.59	-0.38	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
LIHC	cis	rs739496	0.579	rs7294902	ENSG00000226469.1	ADAM1B	7.62	2.48e-13	3.35e-10	0.48	0.38	Platelet count;	chr12:111916727	chr12:111927018~111929017:+
LIHC	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-7.62	2.49e-13	3.35e-10	-0.46	-0.38	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
LIHC	cis	rs198426	0.506	rs198465	ENSG00000124915.9	DKFZP434K028	7.62	2.49e-13	3.36e-10	0.42	0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61753846	chr11:61746493~61757655:-
LIHC	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	7.62	2.5e-13	3.37e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	7.62	2.51e-13	3.38e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	7.62	2.51e-13	3.38e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	7.62	2.51e-13	3.38e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
LIHC	cis	rs832187	0.704	rs704364	ENSG00000280620.1	SCAANT1	-7.62	2.52e-13	3.4e-10	-0.47	-0.38	Schizophrenia;	chr3:63889058	chr3:63911518~63911772:-
LIHC	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-7.62	2.52e-13	3.4e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
LIHC	cis	rs12744310	0.887	rs4453028	ENSG00000235358.1	RP11-399E6.1	7.62	2.54e-13	3.42e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326851	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12040046	ENSG00000235358.1	RP11-399E6.1	-7.62	2.54e-13	3.42e-10	-0.5	-0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331911	chr1:41242373~41284861:+
LIHC	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	7.62	2.56e-13	3.44e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-7.62	2.56e-13	3.44e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	7.62	2.56e-13	3.44e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
LIHC	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-7.62	2.56e-13	3.44e-10	-0.45	-0.38	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
LIHC	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	7.62	2.57e-13	3.46e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
LIHC	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	7.62	2.57e-13	3.46e-10	0.43	0.38	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
LIHC	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-7.62	2.58e-13	3.46e-10	-0.48	-0.38	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
LIHC	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-7.61	2.62e-13	3.51e-10	-0.4	-0.38	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
LIHC	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	7.61	2.62e-13	3.52e-10	0.39	0.38	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
LIHC	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	7.61	2.62e-13	3.52e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-7.61	2.63e-13	3.53e-10	-0.61	-0.38	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
LIHC	cis	rs10899021	1	rs11236186	ENSG00000279353.1	RP11-864N7.4	7.61	2.64e-13	3.55e-10	0.88	0.38	Response to metformin (IC50);	chr11:74651820	chr11:74698231~74699658:-
LIHC	cis	rs10899021	1	rs7935426	ENSG00000279353.1	RP11-864N7.4	7.61	2.64e-13	3.55e-10	0.88	0.38	Response to metformin (IC50);	chr11:74652845	chr11:74698231~74699658:-
LIHC	cis	rs2442825	0.659	rs1129170	ENSG00000206573.7	THUMPD3-AS1	7.61	2.64e-13	3.55e-10	0.33	0.38	Cerebrospinal fluid clusterin levels;	chr3:9384227	chr3:9349689~9398579:-
LIHC	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	7.61	2.65e-13	3.56e-10	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
LIHC	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	7.61	2.66e-13	3.57e-10	0.4	0.38	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	7.61	2.69e-13	3.59e-10	0.41	0.38	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
LIHC	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-7.61	2.69e-13	3.59e-10	-0.44	-0.38	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
LIHC	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	7.61	2.71e-13	3.61e-10	0.39	0.38	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
LIHC	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	7.61	2.71e-13	3.62e-10	0.52	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
LIHC	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	7.61	2.72e-13	3.62e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
LIHC	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	7.61	2.73e-13	3.64e-10	0.45	0.38	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
LIHC	cis	rs893363	0.621	rs14165	ENSG00000271916.1	RP11-884K10.6	-7.61	2.73e-13	3.64e-10	-0.72	-0.38	Axial length;	chr3:53813381	chr3:53797764~53798019:-
LIHC	cis	rs739496	0.546	rs11066055	ENSG00000226469.1	ADAM1B	7.61	2.75e-13	3.66e-10	0.48	0.38	Platelet count;	chr12:111875412	chr12:111927018~111929017:+
LIHC	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-7.61	2.76e-13	3.67e-10	-0.38	-0.38	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
LIHC	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	7.61	2.77e-13	3.69e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	7.61	2.77e-13	3.69e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	7.6	2.79e-13	3.71e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
LIHC	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	7.6	2.8e-13	3.72e-10	0.52	0.38	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	7.6	2.8e-13	3.72e-10	0.52	0.38	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
LIHC	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	7.6	2.8e-13	3.72e-10	0.52	0.38	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
LIHC	cis	rs739496	0.579	rs57046217	ENSG00000226469.1	ADAM1B	7.6	2.84e-13	3.78e-10	0.48	0.38	Platelet count;	chr12:111847312	chr12:111927018~111929017:+
LIHC	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	7.6	2.88e-13	3.83e-10	0.41	0.38	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
LIHC	cis	rs12744310	0.887	rs12728217	ENSG00000235358.1	RP11-399E6.1	7.6	2.89e-13	3.84e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332597	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs12732820	ENSG00000235358.1	RP11-399E6.1	7.6	2.89e-13	3.84e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333101	chr1:41242373~41284861:+
LIHC	cis	rs893363	0.636	rs4687587	ENSG00000271916.1	RP11-884K10.6	7.6	2.9e-13	3.85e-10	0.72	0.38	Axial length;	chr3:53815483	chr3:53797764~53798019:-
LIHC	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-7.6	2.91e-13	3.86e-10	-0.35	-0.38	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
LIHC	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-7.6	2.93e-13	3.88e-10	-0.46	-0.38	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
LIHC	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	7.6	2.93e-13	3.89e-10	1.01	0.38	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
LIHC	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	7.6	2.93e-13	3.89e-10	1.01	0.38	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
LIHC	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-7.6	2.94e-13	3.89e-10	-0.48	-0.38	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
LIHC	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	7.6	2.94e-13	3.89e-10	0.71	0.38	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
LIHC	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	7.6	2.96e-13	3.92e-10	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
LIHC	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	7.6	2.97e-13	3.93e-10	0.56	0.38	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
LIHC	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-7.59	2.98e-13	3.94e-10	-0.43	-0.38	Height;	chr11:118742526	chr11:118704607~118750263:+
LIHC	cis	rs1577917	0.74	rs9353327	ENSG00000234155.1	RP11-30P6.6	7.59	3.04e-13	4.02e-10	0.44	0.38	Response to antipsychotic treatment;	chr6:85684348	chr6:85387219~85390186:-
LIHC	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-7.59	3.04e-13	4.02e-10	-0.49	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
LIHC	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	7.59	3.08e-13	4.07e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	7.59	3.12e-13	4.11e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
LIHC	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	7.59	3.12e-13	4.12e-10	0.43	0.38	Depression;	chr6:28327262	chr6:28176188~28176674:+
LIHC	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	7.59	3.14e-13	4.14e-10	0.48	0.38	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
LIHC	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	7.59	3.15e-13	4.15e-10	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
LIHC	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	7.59	3.15e-13	4.15e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
LIHC	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	7.59	3.15e-13	4.16e-10	0.55	0.38	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
LIHC	cis	rs12744310	0.83	rs4406620	ENSG00000235358.1	RP11-399E6.1	7.59	3.16e-13	4.17e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327093	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs35436312	ENSG00000235358.1	RP11-399E6.1	7.59	3.16e-13	4.17e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327686	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.887	rs1316274	ENSG00000235358.1	RP11-399E6.1	7.59	3.16e-13	4.17e-10	0.5	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327986	chr1:41242373~41284861:+
LIHC	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	7.58	3.18e-13	4.2e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
LIHC	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-7.58	3.19e-13	4.21e-10	-0.43	-0.38	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	7.58	3.2e-13	4.22e-10	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
LIHC	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-7.58	3.21e-13	4.23e-10	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
LIHC	cis	rs739496	0.579	rs75080921	ENSG00000226469.1	ADAM1B	7.58	3.23e-13	4.25e-10	0.48	0.38	Platelet count;	chr12:111861168	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.615	rs7312260	ENSG00000226469.1	ADAM1B	7.58	3.23e-13	4.25e-10	0.48	0.38	Platelet count;	chr12:111920859	chr12:111927018~111929017:+
LIHC	cis	rs9543976	0.623	rs974373	ENSG00000261553.4	RP11-29G8.3	7.58	3.26e-13	4.29e-10	0.53	0.38	Diabetic retinopathy;	chr13:75589660	chr13:75549773~75807120:+
LIHC	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-7.58	3.26e-13	4.3e-10	-0.62	-0.38	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
LIHC	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-7.58	3.27e-13	4.3e-10	-0.56	-0.38	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
LIHC	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-7.58	3.27e-13	4.3e-10	-0.56	-0.38	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
LIHC	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	7.58	3.28e-13	4.31e-10	0.39	0.38	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
LIHC	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	7.58	3.3e-13	4.34e-10	0.42	0.38	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
LIHC	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	7.58	3.3e-13	4.34e-10	0.42	0.38	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
LIHC	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	7.58	3.32e-13	4.36e-10	0.55	0.38	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
LIHC	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	7.58	3.32e-13	4.36e-10	0.43	0.38	Depression;	chr6:28323463	chr6:28176188~28176674:+
LIHC	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	7.58	3.33e-13	4.38e-10	0.4	0.38	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
LIHC	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-7.58	3.33e-13	4.38e-10	-0.43	-0.38	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
LIHC	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	7.58	3.34e-13	4.4e-10	0.52	0.38	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
LIHC	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	7.58	3.36e-13	4.42e-10	0.43	0.38	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
LIHC	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-7.58	3.38e-13	4.44e-10	-0.42	-0.38	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
LIHC	cis	rs7580658	0.711	rs12469035	ENSG00000236682.1	AC068282.3	-7.58	3.38e-13	4.44e-10	-0.47	-0.38	Protein C levels;	chr2:127227341	chr2:127389130~127400580:+
LIHC	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	7.57	3.4e-13	4.46e-10	0.33	0.38	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
LIHC	cis	rs7085104	0.684	rs7092690	ENSG00000236937.2	PTGES3P4	7.57	3.4e-13	4.47e-10	0.45	0.38	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102845595~102845950:+
LIHC	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	7.57	3.48e-13	4.57e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
LIHC	cis	rs1577917	0.958	rs66807489	ENSG00000234155.1	RP11-30P6.6	7.57	3.55e-13	4.65e-10	0.45	0.38	Response to antipsychotic treatment;	chr6:85730984	chr6:85387219~85390186:-
LIHC	cis	rs7085104	0.7	rs7096183	ENSG00000236937.2	PTGES3P4	7.57	3.56e-13	4.66e-10	0.45	0.38	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102845595~102845950:+
LIHC	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	7.57	3.57e-13	4.67e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	7.57	3.57e-13	4.67e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	7.57	3.57e-13	4.67e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	7.57	3.57e-13	4.67e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	7.57	3.57e-13	4.67e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	7.57	3.57e-13	4.67e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
LIHC	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-7.57	3.59e-13	4.69e-10	-0.38	-0.38	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
LIHC	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	7.56	3.63e-13	4.75e-10	0.42	0.38	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
LIHC	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	7.56	3.63e-13	4.75e-10	0.49	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
LIHC	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	7.56	3.63e-13	4.75e-10	0.49	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
LIHC	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	7.56	3.63e-13	4.75e-10	0.7	0.38	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
LIHC	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-7.56	3.63e-13	4.75e-10	-0.47	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
LIHC	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	7.56	3.64e-13	4.76e-10	0.39	0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
LIHC	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	7.56	3.66e-13	4.78e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	7.56	3.66e-13	4.78e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	7.56	3.66e-13	4.78e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	7.56	3.66e-13	4.78e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	7.56	3.66e-13	4.78e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	7.56	3.66e-13	4.78e-10	0.6	0.38	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
LIHC	cis	rs10899021	0.79	rs59958321	ENSG00000279353.1	RP11-864N7.4	7.56	3.72e-13	4.86e-10	0.84	0.38	Response to metformin (IC50);	chr11:74643569	chr11:74698231~74699658:-
LIHC	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	7.56	3.72e-13	4.86e-10	0.52	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
LIHC	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	7.56	3.75e-13	4.89e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
LIHC	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	7.56	3.75e-13	4.9e-10	0.44	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
LIHC	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	7.56	3.76e-13	4.91e-10	0.52	0.38	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
LIHC	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	7.56	3.76e-13	4.91e-10	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
LIHC	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-7.56	3.79e-13	4.95e-10	-0.61	-0.38	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
LIHC	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-7.56	3.8e-13	4.96e-10	-0.39	-0.38	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
LIHC	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	7.56	3.81e-13	4.97e-10	0.52	0.38	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
LIHC	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	7.56	3.82e-13	4.98e-10	0.41	0.38	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
LIHC	cis	rs9527	0.571	rs4917985	ENSG00000236937.2	PTGES3P4	7.56	3.83e-13	5e-10	0.44	0.38	Arsenic metabolism;	chr10:102864315	chr10:102845595~102845950:+
LIHC	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	7.56	3.84e-13	5.01e-10	0.58	0.38	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
LIHC	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	7.56	3.84e-13	5.01e-10	0.58	0.38	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	7.56	3.84e-13	5.01e-10	0.58	0.38	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
LIHC	cis	rs6490294	0.571	rs12425329	ENSG00000226469.1	ADAM1B	7.56	3.85e-13	5.01e-10	0.52	0.38	Mean platelet volume;	chr12:112004628	chr12:111927018~111929017:+
LIHC	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	7.56	3.86e-13	5.03e-10	0.54	0.38	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
LIHC	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-7.56	3.86e-13	5.03e-10	-0.5	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
LIHC	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	7.55	3.88e-13	5.06e-10	0.43	0.38	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
LIHC	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-7.55	3.91e-13	5.09e-10	-0.4	-0.38	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
LIHC	cis	rs12744310	0.887	rs35690915	ENSG00000235358.1	RP11-399E6.1	7.55	3.91e-13	5.09e-10	0.49	0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332327	chr1:41242373~41284861:+
LIHC	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-7.55	3.92e-13	5.11e-10	-0.55	-0.38	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
LIHC	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	7.55	3.98e-13	5.18e-10	0.48	0.38	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
LIHC	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	7.55	3.99e-13	5.19e-10	0.42	0.38	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
LIHC	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-7.55	4.01e-13	5.21e-10	-0.39	-0.38	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
LIHC	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-7.55	4.01e-13	5.22e-10	-0.57	-0.38	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
LIHC	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-7.55	4.04e-13	5.25e-10	-0.43	-0.38	Height;	chr11:118764443	chr11:118704607~118750263:+
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	7.55	4.04e-13	5.25e-10	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
LIHC	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-7.55	4.08e-13	5.3e-10	-0.39	-0.38	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
LIHC	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	7.54	4.17e-13	5.41e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	7.54	4.19e-13	5.42e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	7.54	4.19e-13	5.42e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
LIHC	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-7.54	4.24e-13	5.46e-10	-0.43	-0.38	Height;	chr11:118737916	chr11:118704607~118750263:+
LIHC	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	7.54	4.25e-13	5.47e-10	0.42	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
LIHC	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.54	4.28e-13	5.51e-10	0.43	0.38	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
LIHC	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-7.54	4.29e-13	5.52e-10	-0.49	-0.38	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
LIHC	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-7.54	4.33e-13	5.58e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
LIHC	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	7.54	4.37e-13	5.62e-10	0.52	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-7.54	4.38e-13	5.63e-10	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
LIHC	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-7.54	4.39e-13	5.64e-10	-0.42	-0.38	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
LIHC	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-7.54	4.4e-13	5.65e-10	-0.6	-0.38	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	7.54	4.41e-13	5.66e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	7.54	4.41e-13	5.66e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	7.54	4.41e-13	5.66e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-7.53	4.42e-13	5.67e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	7.53	4.43e-13	5.69e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
LIHC	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	7.53	4.43e-13	5.69e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	7.53	4.43e-13	5.69e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
LIHC	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-7.53	4.47e-13	5.74e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
LIHC	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-7.53	4.47e-13	5.74e-10	-0.38	-0.38	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
LIHC	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-7.53	4.49e-13	5.76e-10	-0.56	-0.38	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
LIHC	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-7.53	4.54e-13	5.83e-10	-0.55	-0.38	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
LIHC	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	7.53	4.54e-13	5.83e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
LIHC	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	7.53	4.55e-13	5.84e-10	0.45	0.38	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
LIHC	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	7.53	4.58e-13	5.87e-10	0.56	0.38	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
LIHC	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	7.53	4.6e-13	5.9e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	7.53	4.62e-13	5.91e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	7.53	4.62e-13	5.91e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	7.53	4.62e-13	5.91e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
LIHC	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-7.53	4.68e-13	5.99e-10	-0.42	-0.38	Height;	chr11:118809363	chr11:118704607~118750263:+
LIHC	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-7.53	4.7e-13	6.02e-10	-0.4	-0.38	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
LIHC	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	7.52	4.71e-13	6.03e-10	0.4	0.38	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
LIHC	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-7.52	4.73e-13	6.04e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
LIHC	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-7.52	4.76e-13	6.07e-10	-0.46	-0.38	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
LIHC	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	7.52	4.77e-13	6.09e-10	0.63	0.38	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
LIHC	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-7.52	4.8e-13	6.13e-10	-0.46	-0.38	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
LIHC	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	7.52	4.81e-13	6.14e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	7.52	4.86e-13	6.2e-10	0.52	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
LIHC	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-7.52	4.87e-13	6.21e-10	-0.42	-0.38	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
LIHC	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	7.52	4.88e-13	6.22e-10	0.38	0.38	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
LIHC	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	7.52	4.92e-13	6.27e-10	0.52	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
LIHC	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-7.52	4.93e-13	6.28e-10	-0.41	-0.38	QT interval;	chr16:28884339	chr16:28700294~28701540:-
LIHC	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-7.52	4.93e-13	6.29e-10	-0.38	-0.38	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
LIHC	cis	rs1023500	0.573	rs133380	ENSG00000227370.1	RP4-669P10.19	-7.52	4.97e-13	6.33e-10	-0.42	-0.38	Schizophrenia;	chr22:42072906	chr22:42132543~42132998:+
LIHC	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	7.52	4.98e-13	6.34e-10	0.41	0.38	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	7.52	5e-13	6.37e-10	0.58	0.38	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	7.52	5e-13	6.37e-10	0.58	0.38	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-7.51	5.07e-13	6.45e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
LIHC	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
LIHC	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	7.51	5.07e-13	6.45e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
LIHC	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	7.51	5.08e-13	6.45e-10	0.41	0.38	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	7.51	5.08e-13	6.46e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	7.51	5.08e-13	6.46e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	7.51	5.08e-13	6.46e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
LIHC	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	7.51	5.08e-13	6.46e-10	0.39	0.38	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
LIHC	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	7.51	5.08e-13	6.46e-10	0.39	0.38	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
LIHC	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	7.51	5.08e-13	6.46e-10	0.39	0.38	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
LIHC	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	7.51	5.08e-13	6.46e-10	0.39	0.38	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
LIHC	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	7.51	5.08e-13	6.46e-10	0.39	0.38	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
LIHC	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	7.51	5.16e-13	6.56e-10	0.39	0.38	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
LIHC	cis	rs1577917	0.538	rs6454483	ENSG00000234155.1	RP11-30P6.6	-7.51	5.17e-13	6.56e-10	-0.43	-0.38	Response to antipsychotic treatment;	chr6:85708565	chr6:85387219~85390186:-
LIHC	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-7.51	5.25e-13	6.66e-10	-0.39	-0.38	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
LIHC	cis	rs198426	0.506	rs198462	ENSG00000124915.9	DKFZP434K028	7.51	5.27e-13	6.68e-10	0.42	0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61756647	chr11:61746493~61757655:-
LIHC	cis	rs2032447	0.507	rs478349	ENSG00000242387.1	HIST1H2APS2	7.51	5.28e-13	6.69e-10	0.53	0.38	Intelligence (multi-trait analysis);	chr6:25893829	chr6:25882026~25882395:-
LIHC	cis	rs1183201	0.505	rs1165201	ENSG00000242387.1	HIST1H2APS2	7.51	5.29e-13	6.7e-10	0.47	0.38	Uric acid levels;	chr6:25874595	chr6:25882026~25882395:-
LIHC	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-7.51	5.36e-13	6.79e-10	-0.39	-0.38	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
LIHC	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	7.5	5.38e-13	6.81e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	7.5	5.38e-13	6.81e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
LIHC	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-7.5	5.39e-13	6.83e-10	-0.4	-0.38	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
LIHC	cis	rs4820294	1	rs41280035	ENSG00000233360.4	Z83844.1	7.5	5.39e-13	6.83e-10	0.47	0.38	Fat distribution (HIV);	chr22:37658031	chr22:37641832~37658377:-
LIHC	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	7.5	5.4e-13	6.84e-10	0.62	0.38	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	7.5	5.41e-13	6.86e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	7.5	5.41e-13	6.86e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	7.5	5.41e-13	6.86e-10	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
LIHC	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	7.5	5.42e-13	6.86e-10	0.42	0.38	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
LIHC	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-7.5	5.42e-13	6.87e-10	-0.42	-0.38	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
LIHC	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-7.5	5.42e-13	6.87e-10	-0.42	-0.38	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
LIHC	cis	rs10899021	0.92	rs7112384	ENSG00000279353.1	RP11-864N7.4	7.5	5.43e-13	6.87e-10	0.83	0.38	Response to metformin (IC50);	chr11:74637160	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.92	rs7112664	ENSG00000279353.1	RP11-864N7.4	7.5	5.43e-13	6.87e-10	0.83	0.38	Response to metformin (IC50);	chr11:74637381	chr11:74698231~74699658:-
LIHC	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	7.5	5.43e-13	6.87e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
LIHC	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-7.5	5.49e-13	6.95e-10	-0.58	-0.38	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
LIHC	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-7.5	5.53e-13	7e-10	-0.42	-0.38	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
LIHC	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	7.5	5.57e-13	7.05e-10	0.55	0.38	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
LIHC	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	7.5	5.61e-13	7.09e-10	0.61	0.38	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
LIHC	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	7.5	5.67e-13	7.16e-10	0.51	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
LIHC	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-7.5	5.7e-13	7.2e-10	-0.63	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
LIHC	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-7.5	5.72e-13	7.23e-10	-0.38	-0.38	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
LIHC	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-7.5	5.72e-13	7.23e-10	-0.38	-0.38	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
LIHC	cis	rs56091001	0.528	rs9616387	ENSG00000278869.1	CITF22-49E9.3	7.5	5.73e-13	7.23e-10	0.85	0.38	Acne (severe);	chr22:49919571	chr22:49933198~49934074:-
LIHC	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-7.49	5.74e-13	7.25e-10	-0.49	-0.38	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
LIHC	cis	rs198426	0.506	rs198464	ENSG00000124915.9	DKFZP434K028	7.49	5.75e-13	7.26e-10	0.41	0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61754149	chr11:61746493~61757655:-
LIHC	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	7.49	5.78e-13	7.29e-10	0.39	0.38	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	7.49	5.78e-13	7.29e-10	0.39	0.38	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	7.49	5.78e-13	7.29e-10	0.39	0.38	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	7.49	5.78e-13	7.29e-10	0.39	0.38	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
LIHC	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-7.49	5.81e-13	7.33e-10	-0.46	-0.38	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
LIHC	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-7.49	5.84e-13	7.36e-10	-0.4	-0.38	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
LIHC	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	7.49	5.85e-13	7.38e-10	0.39	0.38	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
LIHC	cis	rs6490294	0.528	rs11066126	ENSG00000226469.1	ADAM1B	7.49	5.87e-13	7.39e-10	0.52	0.38	Mean platelet volume;	chr12:112007087	chr12:111927018~111929017:+
LIHC	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-7.49	5.9e-13	7.44e-10	-0.4	-0.38	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-7.49	5.9e-13	7.44e-10	-0.4	-0.38	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
LIHC	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-7.49	5.9e-13	7.44e-10	-0.46	-0.38	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
LIHC	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-7.49	5.94e-13	7.48e-10	-0.51	-0.38	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	7.49	6.03e-13	7.59e-10	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
LIHC	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	7.49	6.04e-13	7.59e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	7.49	6.1e-13	7.66e-10	0.53	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
LIHC	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	7.49	6.11e-13	7.68e-10	0.59	0.38	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	7.49	6.11e-13	7.68e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
LIHC	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-7.48	6.18e-13	7.77e-10	-0.51	-0.38	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
LIHC	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-7.48	6.19e-13	7.78e-10	-0.41	-0.38	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
LIHC	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-7.48	6.19e-13	7.78e-10	-0.38	-0.38	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
LIHC	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	7.48	6.21e-13	7.8e-10	0.45	0.38	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
LIHC	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	7.48	6.21e-13	7.8e-10	0.45	0.38	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
LIHC	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	7.48	6.23e-13	7.81e-10	0.68	0.38	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
LIHC	cis	rs6490294	0.571	rs35662477	ENSG00000226469.1	ADAM1B	7.48	6.25e-13	7.85e-10	0.53	0.38	Mean platelet volume;	chr12:111875404	chr12:111927018~111929017:+
LIHC	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	7.48	6.25e-13	7.85e-10	0.61	0.38	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
LIHC	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	7.48	6.28e-13	7.87e-10	0.39	0.38	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	7.48	6.28e-13	7.87e-10	0.39	0.38	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
LIHC	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-7.48	6.3e-13	7.89e-10	-0.39	-0.37	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
LIHC	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	7.48	6.33e-13	7.94e-10	0.41	0.37	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	7.48	6.44e-13	8.06e-10	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
LIHC	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	7.48	6.45e-13	8.07e-10	0.61	0.37	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
LIHC	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	7.48	6.47e-13	8.1e-10	0.39	0.37	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
LIHC	cis	rs9326248	0.574	rs1263173	ENSG00000236267.1	AP006216.5	7.47	6.62e-13	8.29e-10	0.37	0.37	Blood protein levels;	chr11:116810292	chr11:116813204~116814003:-
LIHC	cis	rs10916248	0.511	rs1060386	ENSG00000232628.4	RP11-365O16.3	7.47	6.64e-13	8.31e-10	0.53	0.37	QT interval (drug interaction);	chr1:224192776	chr1:224208747~224213279:-
LIHC	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	7.47	6.65e-13	8.32e-10	0.58	0.37	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
LIHC	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	7.47	6.66e-13	8.33e-10	0.47	0.37	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
LIHC	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	7.47	6.66e-13	8.33e-10	0.47	0.37	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
LIHC	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	7.47	6.69e-13	8.37e-10	0.37	0.37	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
LIHC	cis	rs10899021	0.92	rs61901540	ENSG00000279353.1	RP11-864N7.4	7.47	6.7e-13	8.38e-10	0.83	0.37	Response to metformin (IC50);	chr11:74603820	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.92	rs61901541	ENSG00000279353.1	RP11-864N7.4	7.47	6.7e-13	8.38e-10	0.83	0.37	Response to metformin (IC50);	chr11:74606940	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.92	rs7122710	ENSG00000279353.1	RP11-864N7.4	7.47	6.7e-13	8.38e-10	0.83	0.37	Response to metformin (IC50);	chr11:74612130	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.92	rs10899014	ENSG00000279353.1	RP11-864N7.4	7.47	6.7e-13	8.38e-10	0.83	0.37	Response to metformin (IC50);	chr11:74614064	chr11:74698231~74699658:-
LIHC	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-7.47	6.74e-13	8.42e-10	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-7.47	6.74e-13	8.42e-10	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
LIHC	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	7.47	6.74e-13	8.43e-10	0.43	0.37	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
LIHC	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	7.47	6.79e-13	8.48e-10	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
LIHC	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	7.47	6.81e-13	8.5e-10	0.67	0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
LIHC	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-7.47	6.82e-13	8.52e-10	-0.42	-0.37	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
LIHC	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	7.47	6.83e-13	8.53e-10	0.6	0.37	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	7.47	6.83e-13	8.53e-10	0.6	0.37	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
LIHC	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	7.47	6.9e-13	8.61e-10	0.4	0.37	QT interval;	chr16:28860645	chr16:28700294~28701540:-
LIHC	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-7.47	6.91e-13	8.62e-10	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	7.47	6.92e-13	8.63e-10	0.47	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
LIHC	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	7.47	6.94e-13	8.66e-10	0.69	0.37	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
LIHC	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-7.47	6.96e-13	8.67e-10	-0.39	-0.37	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
LIHC	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-7.47	6.96e-13	8.68e-10	-0.38	-0.37	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
LIHC	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	7.46	7.01e-13	8.73e-10	0.6	0.37	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	7.46	7.01e-13	8.73e-10	0.6	0.37	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	7.46	7.01e-13	8.73e-10	0.6	0.37	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	7.46	7.01e-13	8.73e-10	0.6	0.37	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
LIHC	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-7.46	7.02e-13	8.75e-10	-0.48	-0.37	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
LIHC	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-7.46	7.06e-13	8.79e-10	-0.39	-0.37	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
LIHC	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	7.46	7.08e-13	8.82e-10	0.39	0.37	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
LIHC	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-7.46	7.11e-13	8.86e-10	-0.47	-0.37	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
LIHC	cis	rs12744310	0.887	rs12042464	ENSG00000235358.1	RP11-399E6.1	-7.46	7.16e-13	8.92e-10	-0.49	-0.37	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321182	chr1:41242373~41284861:+
LIHC	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	7.46	7.17e-13	8.92e-10	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	7.46	7.18e-13	8.93e-10	0.6	0.37	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
LIHC	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	7.46	7.18e-13	8.93e-10	0.38	0.37	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
LIHC	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	7.46	7.28e-13	9.05e-10	0.55	0.37	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
LIHC	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	7.46	7.28e-13	9.05e-10	0.39	0.37	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
LIHC	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	7.46	7.35e-13	9.12e-10	0.38	0.37	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
LIHC	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	7.46	7.42e-13	9.21e-10	0.38	0.37	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
LIHC	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	7.45	7.53e-13	9.34e-10	0.4	0.37	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
LIHC	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	7.45	7.54e-13	9.35e-10	0.37	0.37	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
LIHC	cis	rs1577917	0.958	rs12213343	ENSG00000234155.1	RP11-30P6.6	7.45	7.55e-13	9.36e-10	0.44	0.37	Response to antipsychotic treatment;	chr6:85733301	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12215265	ENSG00000234155.1	RP11-30P6.6	7.45	7.55e-13	9.36e-10	0.44	0.37	Response to antipsychotic treatment;	chr6:85734251	chr6:85387219~85390186:-
LIHC	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	7.45	7.6e-13	9.42e-10	0.59	0.37	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
LIHC	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	7.45	7.61e-13	9.43e-10	0.39	0.37	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
LIHC	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	7.45	7.66e-13	9.48e-10	0.41	0.37	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
LIHC	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	7.45	7.66e-13	9.48e-10	0.41	0.37	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	7.45	7.67e-13	9.49e-10	0.59	0.37	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	7.45	7.67e-13	9.49e-10	0.59	0.37	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
LIHC	cis	rs832187	0.593	rs3774713	ENSG00000280620.1	SCAANT1	7.45	7.69e-13	9.52e-10	0.46	0.37	Schizophrenia;	chr3:63932016	chr3:63911518~63911772:-
LIHC	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-7.45	7.7e-13	9.52e-10	-0.39	-0.37	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
LIHC	cis	rs832187	0.64	rs56293138	ENSG00000280620.1	SCAANT1	7.45	7.77e-13	9.6e-10	0.46	0.37	Schizophrenia;	chr3:63903259	chr3:63911518~63911772:-
LIHC	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-7.45	7.77e-13	9.61e-10	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-7.45	7.77e-13	9.61e-10	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	7.45	7.8e-13	9.64e-10	0.61	0.37	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	7.45	7.8e-13	9.64e-10	0.61	0.37	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	7.45	7.8e-13	9.64e-10	0.61	0.37	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	7.45	7.8e-13	9.64e-10	0.61	0.37	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	7.45	7.8e-13	9.64e-10	0.61	0.37	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	7.45	7.8e-13	9.64e-10	0.61	0.37	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
LIHC	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-7.45	7.81e-13	9.65e-10	-0.42	-0.37	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
LIHC	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	7.45	7.86e-13	9.72e-10	0.42	0.37	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
LIHC	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	7.45	7.86e-13	9.72e-10	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
LIHC	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-7.45	7.88e-13	9.74e-10	-0.46	-0.37	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
LIHC	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-7.45	7.9e-13	9.76e-10	-0.42	-0.37	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
LIHC	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	7.44	7.98e-13	9.85e-10	0.51	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
LIHC	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-7.44	8.02e-13	9.89e-10	-0.47	-0.37	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
LIHC	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-7.44	8.03e-13	9.9e-10	-0.41	-0.37	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
LIHC	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	7.44	8.04e-13	9.91e-10	0.39	0.37	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
LIHC	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-7.44	8.1e-13	9.98e-10	-0.38	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
LIHC	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-7.44	8.18e-13	1.01e-09	-0.35	-0.37	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
LIHC	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-7.44	8.21e-13	1.01e-09	-0.4	-0.37	QT interval;	chr16:28857143	chr16:28700294~28701540:-
LIHC	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	7.44	8.34e-13	1.03e-09	0.48	0.37	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
LIHC	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	7.43	8.49e-13	1.04e-09	0.54	0.37	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
LIHC	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	7.43	8.51e-13	1.05e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	7.43	8.51e-13	1.05e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	7.43	8.51e-13	1.05e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	7.43	8.51e-13	1.05e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
LIHC	cis	rs1577917	0.655	rs2842600	ENSG00000234155.1	RP11-30P6.6	7.43	8.58e-13	1.05e-09	0.44	0.37	Response to antipsychotic treatment;	chr6:85615914	chr6:85387219~85390186:-
LIHC	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-7.43	8.58e-13	1.05e-09	-0.61	-0.37	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-7.43	8.58e-13	1.05e-09	-0.61	-0.37	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	7.43	8.59e-13	1.05e-09	0.51	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
LIHC	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	7.43	8.63e-13	1.06e-09	0.41	0.37	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-7.43	8.76e-13	1.07e-09	-0.58	-0.37	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-7.43	8.76e-13	1.07e-09	-0.58	-0.37	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
LIHC	cis	rs2260433	0.73	rs1940476	ENSG00000281655.1	RP11-817J15.3	-7.43	8.83e-13	1.08e-09	-0.44	-0.37	Cleft palate;	chr11:102637088	chr11:102681310~102683913:+
LIHC	cis	rs5758659	0.652	rs4822084	ENSG00000237037.8	NDUFA6-AS1	-7.43	8.83e-13	1.08e-09	-0.44	-0.37	Cognitive function;	chr22:42039864	chr22:42090931~42137742:+
LIHC	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-7.43	8.88e-13	1.09e-09	-0.42	-0.37	Height;	chr11:118786602	chr11:118704607~118750263:+
LIHC	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	7.43	8.89e-13	1.09e-09	0.43	0.37	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
LIHC	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-7.43	8.91e-13	1.09e-09	-0.38	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
LIHC	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	7.43	8.93e-13	1.09e-09	0.42	0.37	Depression;	chr6:28301886	chr6:28176188~28176674:+
LIHC	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	7.43	8.93e-13	1.09e-09	0.42	0.37	Depression;	chr6:28303421	chr6:28176188~28176674:+
LIHC	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-7.43	9e-13	1.1e-09	-0.47	-0.37	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
LIHC	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.06e-13	1.11e-09	-0.39	-0.37	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
LIHC	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	7.42	9.11e-13	1.11e-09	0.38	0.37	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
LIHC	cis	rs7085104	0.7	rs743572	ENSG00000236937.2	PTGES3P4	7.42	9.18e-13	1.12e-09	0.45	0.37	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102845595~102845950:+
LIHC	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	7.42	9.3e-13	1.13e-09	0.41	0.37	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	7.42	9.32e-13	1.14e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
LIHC	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	7.42	9.33e-13	1.14e-09	0.39	0.37	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
LIHC	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	7.42	9.36e-13	1.14e-09	0.43	0.37	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
LIHC	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	7.42	9.36e-13	1.14e-09	0.43	0.37	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
LIHC	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	7.42	9.36e-13	1.14e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	7.42	9.36e-13	1.14e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	7.42	9.36e-13	1.14e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
LIHC	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.36e-13	1.14e-09	-0.39	-0.37	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
LIHC	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	7.42	9.38e-13	1.14e-09	0.53	0.37	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
LIHC	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-7.42	9.38e-13	1.14e-09	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-7.42	9.38e-13	1.14e-09	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-7.42	9.38e-13	1.14e-09	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-7.42	9.38e-13	1.14e-09	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
LIHC	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-7.42	9.39e-13	1.14e-09	-0.48	-0.37	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
LIHC	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-7.42	9.43e-13	1.15e-09	-0.37	-0.37	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
LIHC	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-7.42	9.46e-13	1.15e-09	-0.56	-0.37	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
LIHC	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	7.42	9.53e-13	1.16e-09	0.42	0.37	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
LIHC	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	7.42	9.56e-13	1.16e-09	0.43	0.37	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
LIHC	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	7.42	9.56e-13	1.16e-09	0.43	0.37	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
LIHC	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.56e-13	1.16e-09	-0.38	-0.37	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.56e-13	1.16e-09	-0.38	-0.37	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.56e-13	1.16e-09	-0.38	-0.37	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.56e-13	1.16e-09	-0.38	-0.37	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.56e-13	1.16e-09	-0.38	-0.37	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
LIHC	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	7.42	9.61e-13	1.17e-09	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
LIHC	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-7.42	9.66e-13	1.17e-09	-0.39	-0.37	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
LIHC	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	7.41	9.68e-13	1.18e-09	0.62	0.37	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-7.41	9.76e-13	1.19e-09	-0.51	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
LIHC	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-7.41	9.8e-13	1.19e-09	-0.34	-0.37	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
LIHC	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	7.41	9.88e-13	1.2e-09	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	7.41	9.92e-13	1.2e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	7.41	9.92e-13	1.2e-09	0.52	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	7.41	9.92e-13	1.2e-09	0.52	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
LIHC	cis	rs1577917	0.56	rs12193777	ENSG00000234155.1	RP11-30P6.6	-7.41	1e-12	1.21e-09	-0.44	-0.37	Response to antipsychotic treatment;	chr6:85536991	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.655	rs9444351	ENSG00000234155.1	RP11-30P6.6	-7.41	1e-12	1.21e-09	-0.44	-0.37	Response to antipsychotic treatment;	chr6:85538081	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.655	rs7766485	ENSG00000234155.1	RP11-30P6.6	-7.41	1e-12	1.21e-09	-0.44	-0.37	Response to antipsychotic treatment;	chr6:85553837	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs10944136	ENSG00000234155.1	RP11-30P6.6	7.41	1.02e-12	1.23e-09	0.44	0.37	Response to antipsychotic treatment;	chr6:85738781	chr6:85387219~85390186:-
LIHC	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	7.41	1.02e-12	1.24e-09	0.56	0.37	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
LIHC	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-7.4	1.03e-12	1.25e-09	-0.37	-0.37	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
LIHC	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-7.4	1.03e-12	1.25e-09	-0.38	-0.37	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
LIHC	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-7.4	1.03e-12	1.25e-09	-0.55	-0.37	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
LIHC	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-7.4	1.04e-12	1.25e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
LIHC	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-7.4	1.04e-12	1.26e-09	-0.38	-0.37	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
LIHC	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	7.4	1.04e-12	1.26e-09	0.48	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
LIHC	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.4	1.04e-12	1.26e-09	-0.43	-0.37	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
LIHC	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	7.4	1.05e-12	1.27e-09	0.38	0.37	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
LIHC	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	7.4	1.06e-12	1.28e-09	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
LIHC	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	7.4	1.06e-12	1.28e-09	0.44	0.37	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-7.4	1.08e-12	1.3e-09	-0.62	-0.37	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-7.4	1.08e-12	1.3e-09	-0.62	-0.37	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
LIHC	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	7.4	1.08e-12	1.31e-09	0.43	0.37	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
LIHC	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-7.4	1.08e-12	1.31e-09	-0.54	-0.37	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
LIHC	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	7.4	1.08e-12	1.31e-09	0.47	0.37	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
LIHC	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	7.4	1.09e-12	1.31e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
LIHC	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-7.4	1.1e-12	1.32e-09	-0.34	-0.37	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
LIHC	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-7.39	1.1e-12	1.33e-09	-0.47	-0.37	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-7.39	1.1e-12	1.33e-09	-0.47	-0.37	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
LIHC	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-7.39	1.1e-12	1.33e-09	-0.48	-0.37	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-7.39	1.1e-12	1.33e-09	-0.48	-0.37	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
LIHC	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	7.39	1.11e-12	1.34e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
LIHC	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	7.39	1.12e-12	1.34e-09	0.39	0.37	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
LIHC	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-7.39	1.12e-12	1.35e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
LIHC	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	7.39	1.12e-12	1.35e-09	0.58	0.37	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	7.39	1.12e-12	1.35e-09	0.58	0.37	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
LIHC	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	7.39	1.12e-12	1.35e-09	0.7	0.37	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
LIHC	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-7.39	1.13e-12	1.36e-09	-0.37	-0.37	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-7.39	1.13e-12	1.36e-09	-0.37	-0.37	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-7.39	1.13e-12	1.36e-09	-0.37	-0.37	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
LIHC	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	7.39	1.13e-12	1.36e-09	0.41	0.37	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
LIHC	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	7.39	1.13e-12	1.36e-09	0.41	0.37	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
LIHC	cis	rs1577917	0.566	rs2842611	ENSG00000234155.1	RP11-30P6.6	7.39	1.13e-12	1.36e-09	0.44	0.37	Response to antipsychotic treatment;	chr6:85592316	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs13207173	ENSG00000234155.1	RP11-30P6.6	7.39	1.13e-12	1.36e-09	0.44	0.37	Response to antipsychotic treatment;	chr6:85747804	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs34795473	ENSG00000234155.1	RP11-30P6.6	7.39	1.13e-12	1.36e-09	0.44	0.37	Response to antipsychotic treatment;	chr6:85752081	chr6:85387219~85390186:-
LIHC	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	7.39	1.14e-12	1.37e-09	0.41	0.37	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
LIHC	cis	rs1577917	0.655	rs9444352	ENSG00000234155.1	RP11-30P6.6	-7.39	1.14e-12	1.37e-09	-0.44	-0.37	Response to antipsychotic treatment;	chr6:85547817	chr6:85387219~85390186:-
LIHC	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-7.39	1.15e-12	1.38e-09	-0.39	-0.37	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
LIHC	cis	rs4356975	0.932	rs7657426	ENSG00000249956.3	RP11-790I12.2	7.39	1.15e-12	1.39e-09	0.41	0.37	Obesity-related traits;	chr4:69079291	chr4:69408836~69423164:+
LIHC	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	7.39	1.16e-12	1.4e-09	0.51	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
LIHC	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-7.39	1.17e-12	1.4e-09	-0.39	-0.37	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
LIHC	cis	rs6490294	0.528	rs57502306	ENSG00000226469.1	ADAM1B	7.39	1.17e-12	1.4e-09	0.52	0.37	Mean platelet volume;	chr12:111852639	chr12:111927018~111929017:+
LIHC	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	7.39	1.17e-12	1.41e-09	0.34	0.37	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
LIHC	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-7.38	1.18e-12	1.41e-09	-0.48	-0.37	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
LIHC	cis	rs9543976	0.623	rs8192764	ENSG00000261553.4	RP11-29G8.3	7.38	1.18e-12	1.41e-09	0.51	0.37	Diabetic retinopathy;	chr13:75605079	chr13:75549773~75807120:+
LIHC	cis	rs10256972	0.64	rs10271082	ENSG00000229043.2	AC091729.9	-7.38	1.18e-12	1.42e-09	-0.43	-0.37	Endometriosis;Longevity;	chr7:1041926	chr7:1160374~1165267:+
LIHC	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-7.38	1.2e-12	1.43e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
LIHC	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	7.38	1.2e-12	1.44e-09	0.55	0.37	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	7.38	1.2e-12	1.44e-09	0.55	0.37	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	7.38	1.2e-12	1.44e-09	0.55	0.37	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
LIHC	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	7.38	1.21e-12	1.45e-09	0.39	0.37	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
LIHC	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	7.38	1.21e-12	1.45e-09	0.46	0.37	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
LIHC	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	7.38	1.21e-12	1.45e-09	0.46	0.37	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
LIHC	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	7.38	1.21e-12	1.45e-09	0.46	0.37	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
LIHC	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-7.38	1.22e-12	1.46e-09	-0.38	-0.37	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
LIHC	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	7.38	1.22e-12	1.46e-09	0.41	0.37	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	7.38	1.22e-12	1.46e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	7.38	1.22e-12	1.46e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	7.38	1.22e-12	1.46e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	7.38	1.22e-12	1.46e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	7.38	1.22e-12	1.46e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	7.38	1.22e-12	1.46e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	7.38	1.22e-12	1.46e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
LIHC	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-7.38	1.23e-12	1.47e-09	-0.38	-0.37	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-7.38	1.23e-12	1.47e-09	-0.38	-0.37	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-7.38	1.23e-12	1.47e-09	-0.38	-0.37	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
LIHC	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	7.38	1.24e-12	1.47e-09	0.61	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
LIHC	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-7.38	1.24e-12	1.48e-09	-0.37	-0.37	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
LIHC	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-7.38	1.24e-12	1.48e-09	-0.6	-0.37	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
LIHC	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-7.38	1.25e-12	1.49e-09	-0.38	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
LIHC	cis	rs9543976	0.623	rs9318361	ENSG00000261553.4	RP11-29G8.3	7.38	1.25e-12	1.49e-09	0.51	0.37	Diabetic retinopathy;	chr13:75602944	chr13:75549773~75807120:+
LIHC	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-7.37	1.26e-12	1.5e-09	-0.46	-0.37	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
LIHC	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	7.37	1.26e-12	1.5e-09	0.38	0.37	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-7.37	1.26e-12	1.5e-09	-0.38	-0.37	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-7.37	1.26e-12	1.5e-09	-0.38	-0.37	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-7.37	1.26e-12	1.5e-09	-0.38	-0.37	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-7.37	1.26e-12	1.5e-09	-0.38	-0.37	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-7.37	1.26e-12	1.5e-09	-0.38	-0.37	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-7.37	1.26e-12	1.5e-09	-0.38	-0.37	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
LIHC	cis	rs2032447	0.531	rs428469	ENSG00000242387.1	HIST1H2APS2	7.37	1.28e-12	1.53e-09	0.53	0.37	Intelligence (multi-trait analysis);	chr6:25898396	chr6:25882026~25882395:-
LIHC	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-7.37	1.29e-12	1.53e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
LIHC	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-7.37	1.31e-12	1.55e-09	-0.42	-0.37	Height;	chr11:118808920	chr11:118704607~118750263:+
LIHC	cis	rs893363	0.594	rs12676	ENSG00000271916.1	RP11-884K10.6	-7.37	1.31e-12	1.56e-09	-0.76	-0.37	Axial length;	chr3:53823776	chr3:53797764~53798019:-
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	7.37	1.31e-12	1.56e-09	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
LIHC	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-7.37	1.31e-12	1.56e-09	-0.47	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
LIHC	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	7.37	1.32e-12	1.56e-09	0.42	0.37	Depression;	chr6:28317705	chr6:28176188~28176674:+
LIHC	cis	rs9527	0.637	rs7085104	ENSG00000236937.2	PTGES3P4	7.37	1.32e-12	1.56e-09	0.44	0.37	Arsenic metabolism;	chr10:102869116	chr10:102845595~102845950:+
LIHC	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-7.37	1.32e-12	1.56e-09	-0.38	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
LIHC	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-7.37	1.33e-12	1.58e-09	-0.37	-0.37	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-7.37	1.33e-12	1.58e-09	-0.37	-0.37	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-7.37	1.33e-12	1.58e-09	-0.37	-0.37	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-7.37	1.33e-12	1.58e-09	-0.37	-0.37	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-7.37	1.33e-12	1.58e-09	-0.37	-0.37	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-7.37	1.33e-12	1.58e-09	-0.37	-0.37	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
LIHC	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-7.37	1.33e-12	1.58e-09	-0.47	-0.37	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	7.37	1.33e-12	1.58e-09	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	7.36	1.34e-12	1.59e-09	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
LIHC	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	7.36	1.34e-12	1.59e-09	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	7.36	1.34e-12	1.59e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	7.36	1.34e-12	1.59e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	7.36	1.34e-12	1.59e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	7.36	1.34e-12	1.59e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	7.36	1.34e-12	1.59e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	7.36	1.34e-12	1.59e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	7.36	1.34e-12	1.59e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
LIHC	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	7.36	1.34e-12	1.59e-09	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
LIHC	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-7.36	1.36e-12	1.61e-09	-0.57	-0.37	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-7.36	1.36e-12	1.61e-09	-0.57	-0.37	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
LIHC	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-7.36	1.36e-12	1.61e-09	-0.39	-0.37	QT interval;	chr16:28877088	chr16:28700294~28701540:-
LIHC	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	7.36	1.36e-12	1.61e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	7.36	1.36e-12	1.61e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	7.36	1.36e-12	1.61e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	7.36	1.36e-12	1.61e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
LIHC	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-7.36	1.37e-12	1.62e-09	-0.37	-0.37	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-7.36	1.37e-12	1.62e-09	-0.37	-0.37	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
LIHC	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	7.36	1.37e-12	1.62e-09	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
LIHC	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	7.36	1.38e-12	1.63e-09	0.67	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
LIHC	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	7.36	1.38e-12	1.63e-09	0.4	0.37	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
LIHC	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	7.36	1.38e-12	1.63e-09	0.4	0.37	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
LIHC	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-7.36	1.4e-12	1.65e-09	-0.38	-0.37	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
LIHC	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-7.36	1.4e-12	1.65e-09	-0.47	-0.37	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
LIHC	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	7.36	1.41e-12	1.66e-09	0.38	0.37	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
LIHC	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	7.36	1.41e-12	1.67e-09	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
LIHC	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	7.36	1.41e-12	1.67e-09	0.33	0.37	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
LIHC	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	7.36	1.41e-12	1.67e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	7.36	1.41e-12	1.67e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	7.36	1.41e-12	1.67e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	7.36	1.41e-12	1.67e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
LIHC	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	7.36	1.41e-12	1.67e-09	0.43	0.37	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
LIHC	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-7.36	1.42e-12	1.67e-09	-0.48	-0.37	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
LIHC	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-7.36	1.42e-12	1.67e-09	-0.46	-0.37	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
LIHC	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	7.36	1.42e-12	1.68e-09	0.37	0.37	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
LIHC	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	7.36	1.42e-12	1.68e-09	0.38	0.37	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
LIHC	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-7.35	1.43e-12	1.68e-09	-0.4	-0.37	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
LIHC	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-7.35	1.44e-12	1.69e-09	-0.4	-0.37	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
LIHC	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	7.35	1.44e-12	1.69e-09	0.33	0.37	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
LIHC	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	7.35	1.44e-12	1.69e-09	0.62	0.37	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
LIHC	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	7.35	1.44e-12	1.7e-09	0.38	0.37	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
LIHC	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	7.35	1.45e-12	1.7e-09	0.46	0.37	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
LIHC	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	7.35	1.45e-12	1.71e-09	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
LIHC	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	7.35	1.45e-12	1.71e-09	0.42	0.37	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
LIHC	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-7.35	1.45e-12	1.71e-09	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	7.35	1.45e-12	1.71e-09	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
LIHC	cis	rs9527	0.571	rs7096249	ENSG00000236937.2	PTGES3P4	7.35	1.46e-12	1.72e-09	0.44	0.37	Arsenic metabolism;	chr10:102858767	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.571	rs10786715	ENSG00000236937.2	PTGES3P4	7.35	1.46e-12	1.72e-09	0.44	0.37	Arsenic metabolism;	chr10:102860978	chr10:102845595~102845950:+
LIHC	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-7.35	1.47e-12	1.72e-09	-0.37	-0.37	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-7.35	1.47e-12	1.72e-09	-0.37	-0.37	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-7.35	1.47e-12	1.72e-09	-0.37	-0.37	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-7.35	1.47e-12	1.72e-09	-0.37	-0.37	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-7.35	1.47e-12	1.72e-09	-0.37	-0.37	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-7.35	1.47e-12	1.72e-09	-0.37	-0.37	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
LIHC	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-7.35	1.48e-12	1.73e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	7.35	1.48e-12	1.74e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	7.35	1.48e-12	1.74e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	7.35	1.49e-12	1.75e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	7.35	1.49e-12	1.75e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	7.35	1.49e-12	1.75e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	7.35	1.49e-12	1.75e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	7.35	1.49e-12	1.75e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	7.35	1.49e-12	1.75e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	7.35	1.49e-12	1.75e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
LIHC	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	7.35	1.5e-12	1.76e-09	0.46	0.37	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
LIHC	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	7.35	1.51e-12	1.77e-09	0.43	0.37	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
LIHC	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	7.35	1.51e-12	1.77e-09	0.43	0.37	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
LIHC	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-7.35	1.51e-12	1.77e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
LIHC	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-7.35	1.52e-12	1.78e-09	-0.38	-0.37	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-7.35	1.52e-12	1.78e-09	-0.38	-0.37	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-7.35	1.52e-12	1.78e-09	-0.38	-0.37	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
LIHC	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	7.35	1.52e-12	1.78e-09	0.51	0.37	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
LIHC	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-7.34	1.53e-12	1.79e-09	-0.48	-0.37	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
LIHC	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-7.34	1.53e-12	1.79e-09	-0.48	-0.37	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
LIHC	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-7.34	1.53e-12	1.79e-09	-0.48	-0.37	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
LIHC	cis	rs6085948	0.861	rs6085947	ENSG00000238102.1	RP11-19D2.1	7.34	1.54e-12	1.79e-09	0.69	0.37	Interleukin-10 levels;	chr20:7252181	chr20:7256580~7258214:-
LIHC	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-7.34	1.54e-12	1.8e-09	-0.57	-0.37	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	7.34	1.55e-12	1.81e-09	0.58	0.37	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	7.34	1.55e-12	1.81e-09	0.58	0.37	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
LIHC	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	7.34	1.56e-12	1.82e-09	0.41	0.37	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
LIHC	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-7.34	1.57e-12	1.83e-09	-0.34	-0.37	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
LIHC	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-7.34	1.57e-12	1.83e-09	-0.38	-0.37	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
LIHC	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	7.34	1.58e-12	1.85e-09	0.43	0.37	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
LIHC	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-7.34	1.58e-12	1.85e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
LIHC	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-7.34	1.59e-12	1.85e-09	-0.43	-0.37	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
LIHC	cis	rs1577917	0.771	rs9362239	ENSG00000234155.1	RP11-30P6.6	-7.34	1.59e-12	1.86e-09	-0.43	-0.37	Response to antipsychotic treatment;	chr6:85719545	chr6:85387219~85390186:-
LIHC	cis	rs9527	0.571	rs12219246	ENSG00000236937.2	PTGES3P4	7.34	1.6e-12	1.86e-09	0.44	0.37	Arsenic metabolism;	chr10:102853598	chr10:102845595~102845950:+
LIHC	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-7.34	1.61e-12	1.87e-09	-0.37	-0.37	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
LIHC	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	7.33	1.62e-12	1.89e-09	0.41	0.37	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	7.33	1.62e-12	1.89e-09	0.62	0.37	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	7.33	1.62e-12	1.89e-09	0.62	0.37	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	7.33	1.62e-12	1.89e-09	0.62	0.37	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
LIHC	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-7.33	1.62e-12	1.89e-09	-0.38	-0.37	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
LIHC	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	7.33	1.64e-12	1.9e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
LIHC	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	7.33	1.64e-12	1.91e-09	0.38	0.37	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
LIHC	cis	rs10899021	1	rs61900635	ENSG00000279353.1	RP11-864N7.4	7.33	1.66e-12	1.92e-09	0.85	0.37	Response to metformin (IC50);	chr11:74647965	chr11:74698231~74699658:-
LIHC	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-7.33	1.66e-12	1.93e-09	-0.37	-0.37	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
LIHC	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	7.33	1.67e-12	1.94e-09	0.43	0.37	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
LIHC	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	7.33	1.68e-12	1.94e-09	0.44	0.37	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
LIHC	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	7.33	1.69e-12	1.96e-09	0.42	0.37	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
LIHC	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	7.33	1.7e-12	1.97e-09	0.47	0.37	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
LIHC	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	7.33	1.7e-12	1.97e-09	0.4	0.37	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-7.33	1.7e-12	1.97e-09	-0.61	-0.37	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
LIHC	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	7.33	1.7e-12	1.97e-09	0.4	0.37	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	7.33	1.72e-12	1.99e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
LIHC	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-7.32	1.73e-12	2e-09	-0.55	-0.37	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
LIHC	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	7.32	1.74e-12	2.01e-09	0.38	0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
LIHC	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-7.32	1.74e-12	2.02e-09	-0.56	-0.37	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
LIHC	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-7.32	1.75e-12	2.02e-09	-0.37	-0.37	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-7.32	1.75e-12	2.02e-09	-0.37	-0.37	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-7.32	1.75e-12	2.02e-09	-0.37	-0.37	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-7.32	1.75e-12	2.02e-09	-0.37	-0.37	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
LIHC	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-7.32	1.75e-12	2.03e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
LIHC	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	7.32	1.76e-12	2.03e-09	0.42	0.37	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
LIHC	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	7.32	1.76e-12	2.04e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
LIHC	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	7.32	1.78e-12	2.05e-09	0.43	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
LIHC	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	7.32	1.78e-12	2.06e-09	0.42	0.37	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
LIHC	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	7.32	1.78e-12	2.06e-09	0.51	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
LIHC	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	7.32	1.81e-12	2.08e-09	0.41	0.37	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
LIHC	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	7.32	1.81e-12	2.08e-09	0.41	0.37	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
LIHC	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	7.32	1.81e-12	2.08e-09	0.65	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	7.32	1.81e-12	2.08e-09	0.65	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
LIHC	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	7.32	1.82e-12	2.09e-09	0.51	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
LIHC	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	7.32	1.82e-12	2.1e-09	0.41	0.37	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
LIHC	cis	rs1577917	0.958	rs12192033	ENSG00000234155.1	RP11-30P6.6	7.32	1.82e-12	2.1e-09	0.43	0.37	Response to antipsychotic treatment;	chr6:85762841	chr6:85387219~85390186:-
LIHC	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-7.32	1.82e-12	2.1e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
LIHC	cis	rs1577917	0.958	rs12195776	ENSG00000234155.1	RP11-30P6.6	7.32	1.83e-12	2.11e-09	0.44	0.37	Response to antipsychotic treatment;	chr6:85778881	chr6:85387219~85390186:-
LIHC	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-7.32	1.83e-12	2.11e-09	-0.37	-0.37	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
LIHC	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-7.31	1.85e-12	2.13e-09	-0.42	-0.37	Height;	chr11:118747911	chr11:118704607~118750263:+
LIHC	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-7.31	1.85e-12	2.13e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-7.31	1.85e-12	2.13e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-7.31	1.85e-12	2.13e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-7.31	1.85e-12	2.13e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
LIHC	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-7.31	1.85e-12	2.13e-09	-0.37	-0.37	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
LIHC	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	7.31	1.86e-12	2.13e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	7.31	1.86e-12	2.13e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	7.31	1.86e-12	2.13e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
LIHC	cis	rs9527	0.637	rs11191424	ENSG00000236937.2	PTGES3P4	7.31	1.86e-12	2.14e-09	0.44	0.37	Arsenic metabolism;	chr10:102866129	chr10:102845595~102845950:+
LIHC	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	7.31	1.86e-12	2.14e-09	0.41	0.37	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	7.31	1.86e-12	2.14e-09	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
LIHC	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-7.31	1.87e-12	2.15e-09	-0.37	-0.37	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
LIHC	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	7.31	1.87e-12	2.15e-09	0.41	0.37	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
LIHC	cis	rs12744310	0.887	rs12032040	ENSG00000235358.1	RP11-399E6.1	7.31	1.88e-12	2.16e-09	0.49	0.37	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41352635	chr1:41242373~41284861:+
LIHC	cis	rs7396835	0.537	rs10892035	ENSG00000236267.1	AP006216.5	7.31	1.89e-12	2.17e-09	0.39	0.37	Quantitative traits;	chr11:116824222	chr11:116813204~116814003:-
LIHC	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	7.31	1.89e-12	2.17e-09	0.44	0.37	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
LIHC	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	7.31	1.9e-12	2.19e-09	0.77	0.37	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
LIHC	cis	rs6085948	0.861	rs8121934	ENSG00000238102.1	RP11-19D2.1	-7.31	1.92e-12	2.2e-09	-0.69	-0.37	Interleukin-10 levels;	chr20:7263706	chr20:7256580~7258214:-
LIHC	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	7.31	1.92e-12	2.2e-09	0.58	0.37	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	7.31	1.92e-12	2.2e-09	0.58	0.37	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	7.31	1.92e-12	2.2e-09	0.58	0.37	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	7.31	1.92e-12	2.2e-09	0.58	0.37	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
LIHC	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-7.31	1.92e-12	2.21e-09	-0.37	-0.37	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
LIHC	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	7.31	1.93e-12	2.21e-09	0.4	0.37	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
LIHC	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-7.31	1.94e-12	2.23e-09	-0.38	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
LIHC	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-7.31	1.95e-12	2.24e-09	-0.37	-0.37	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
LIHC	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	7.31	1.96e-12	2.24e-09	0.61	0.37	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
LIHC	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	7.3	1.97e-12	2.25e-09	0.37	0.37	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
LIHC	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	7.3	1.97e-12	2.26e-09	0.42	0.37	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
LIHC	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	7.3	1.97e-12	2.26e-09	0.41	0.37	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	7.3	1.98e-12	2.26e-09	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
LIHC	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	7.3	1.98e-12	2.26e-09	0.56	0.37	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
LIHC	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	7.3	2.01e-12	2.29e-09	0.59	0.37	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	7.3	2.02e-12	2.3e-09	0.59	0.37	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	7.3	2.02e-12	2.3e-09	0.59	0.37	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	7.3	2.02e-12	2.3e-09	0.59	0.37	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
LIHC	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-7.3	2.02e-12	2.31e-09	-0.55	-0.37	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
LIHC	cis	rs6085948	0.861	rs6085955	ENSG00000238102.1	RP11-19D2.1	-7.3	2.02e-12	2.31e-09	-0.68	-0.37	Interleukin-10 levels;	chr20:7258347	chr20:7256580~7258214:-
LIHC	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	7.3	2.02e-12	2.31e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
LIHC	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-7.3	2.04e-12	2.32e-09	-0.37	-0.37	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
LIHC	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	7.3	2.04e-12	2.33e-09	0.38	0.37	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
LIHC	cis	rs10899021	0.92	rs11236171	ENSG00000279353.1	RP11-864N7.4	7.3	2.04e-12	2.33e-09	0.81	0.37	Response to metformin (IC50);	chr11:74606473	chr11:74698231~74699658:-
LIHC	cis	rs7085104	0.552	rs11191414	ENSG00000236937.2	PTGES3P4	7.3	2.06e-12	2.35e-09	0.43	0.37	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102845595~102845950:+
LIHC	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-7.3	2.07e-12	2.36e-09	-0.47	-0.37	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-7.3	2.07e-12	2.36e-09	-0.47	-0.37	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-7.3	2.07e-12	2.36e-09	-0.47	-0.37	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-7.3	2.07e-12	2.36e-09	-0.47	-0.37	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-7.3	2.07e-12	2.36e-09	-0.47	-0.37	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
LIHC	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	7.3	2.08e-12	2.37e-09	0.38	0.37	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
LIHC	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	7.29	2.1e-12	2.38e-09	0.47	0.37	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
LIHC	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	7.29	2.1e-12	2.39e-09	0.42	0.37	QT interval;	chr12:29310426	chr12:29280418~29317848:-
LIHC	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-7.29	2.15e-12	2.44e-09	-0.42	-0.37	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
LIHC	cis	rs10899021	0.79	rs7932194	ENSG00000279353.1	RP11-864N7.4	7.29	2.15e-12	2.44e-09	0.8	0.37	Response to metformin (IC50);	chr11:74616333	chr11:74698231~74699658:-
LIHC	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	7.29	2.2e-12	2.49e-09	0.42	0.37	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
LIHC	cis	rs9549367	0.713	rs3024757	ENSG00000269125.1	RP11-98F14.11	-7.29	2.2e-12	2.49e-09	-0.47	-0.37	Platelet distribution width;	chr13:113168872	chr13:113165002~113165183:-
LIHC	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-7.29	2.21e-12	2.5e-09	-0.51	-0.37	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
LIHC	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-7.29	2.21e-12	2.51e-09	-0.47	-0.37	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
LIHC	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	7.29	2.21e-12	2.51e-09	0.54	0.37	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
LIHC	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	7.29	2.21e-12	2.51e-09	0.41	0.37	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
LIHC	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	7.29	2.22e-12	2.51e-09	0.65	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
LIHC	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	7.28	2.24e-12	2.53e-09	0.47	0.37	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
LIHC	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	7.28	2.24e-12	2.54e-09	0.43	0.37	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
LIHC	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	7.28	2.27e-12	2.57e-09	0.39	0.37	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	7.28	2.27e-12	2.57e-09	0.39	0.37	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	7.28	2.27e-12	2.57e-09	0.39	0.37	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	7.28	2.27e-12	2.57e-09	0.39	0.37	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	7.28	2.27e-12	2.57e-09	0.39	0.37	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
LIHC	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	7.28	2.29e-12	2.59e-09	0.45	0.37	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
LIHC	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	7.28	2.29e-12	2.59e-09	0.43	0.37	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
LIHC	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-7.28	2.3e-12	2.6e-09	-0.41	-0.37	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
LIHC	cis	rs7396835	0.5	rs5092	ENSG00000236267.1	AP006216.5	7.28	2.3e-12	2.61e-09	0.39	0.37	Quantitative traits;	chr11:116822748	chr11:116813204~116814003:-
LIHC	cis	rs1577917	0.958	rs6454488	ENSG00000234155.1	RP11-30P6.6	7.28	2.31e-12	2.61e-09	0.43	0.37	Response to antipsychotic treatment;	chr6:85741124	chr6:85387219~85390186:-
LIHC	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	7.28	2.31e-12	2.61e-09	0.45	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
LIHC	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	7.28	2.32e-12	2.62e-09	0.37	0.37	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
LIHC	cis	rs6490294	0.808	rs7137270	ENSG00000226469.1	ADAM1B	7.28	2.32e-12	2.62e-09	0.47	0.37	Mean platelet volume;	chr12:111825598	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.652	rs10849974	ENSG00000226469.1	ADAM1B	7.28	2.32e-12	2.62e-09	0.47	0.37	Platelet count;	chr12:111826354	chr12:111927018~111929017:+
LIHC	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-7.28	2.32e-12	2.62e-09	-0.38	-0.37	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
LIHC	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	7.28	2.33e-12	2.63e-09	0.45	0.37	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
LIHC	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-7.28	2.34e-12	2.64e-09	-0.37	-0.37	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
LIHC	cis	rs10899021	0.92	rs12287097	ENSG00000279353.1	RP11-864N7.4	7.28	2.34e-12	2.64e-09	0.79	0.37	Response to metformin (IC50);	chr11:74621619	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.92	rs11236174	ENSG00000279353.1	RP11-864N7.4	7.28	2.34e-12	2.64e-09	0.79	0.37	Response to metformin (IC50);	chr11:74623156	chr11:74698231~74699658:-
LIHC	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-7.28	2.35e-12	2.66e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-7.28	2.35e-12	2.66e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-7.28	2.37e-12	2.68e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-7.28	2.37e-12	2.68e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	7.28	2.38e-12	2.69e-09	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
LIHC	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	7.28	2.38e-12	2.69e-09	0.38	0.37	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
LIHC	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	7.27	2.39e-12	2.7e-09	0.42	0.37	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
LIHC	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-7.27	2.4e-12	2.7e-09	-0.37	-0.37	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
LIHC	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	7.27	2.42e-12	2.72e-09	0.51	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
LIHC	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	7.27	2.44e-12	2.75e-09	0.44	0.37	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
LIHC	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	7.27	2.46e-12	2.77e-09	0.66	0.37	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
LIHC	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-7.27	2.47e-12	2.78e-09	-0.37	-0.37	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
LIHC	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	7.27	2.48e-12	2.79e-09	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
LIHC	cis	rs1577917	0.916	rs4142546	ENSG00000234155.1	RP11-30P6.6	7.27	2.49e-12	2.79e-09	0.43	0.37	Response to antipsychotic treatment;	chr6:85795593	chr6:85387219~85390186:-
LIHC	cis	rs739496	0.579	rs3213628	ENSG00000226469.1	ADAM1B	7.27	2.49e-12	2.79e-09	0.47	0.37	Platelet count;	chr12:111842969	chr12:111927018~111929017:+
LIHC	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-7.27	2.49e-12	2.8e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
LIHC	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	7.27	2.49e-12	2.8e-09	0.42	0.37	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
LIHC	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	7.27	2.49e-12	2.8e-09	0.42	0.37	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
LIHC	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-7.27	2.5e-12	2.8e-09	-0.63	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
LIHC	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	7.27	2.51e-12	2.82e-09	0.57	0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
LIHC	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	7.26	2.55e-12	2.86e-09	0.38	0.37	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
LIHC	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-7.26	2.56e-12	2.87e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-7.26	2.56e-12	2.87e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	7.26	2.59e-12	2.9e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	7.26	2.59e-12	2.9e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
LIHC	cis	rs739496	0.527	rs12427012	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111905570	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs12316525	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111906315	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs73426314	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111907252	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs12582302	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111907830	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs11066077	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111908857	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs10849984	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111909924	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs10849985	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111909950	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs7136469	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Platelet count;	chr12:111910387	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.799	rs11066082	ENSG00000226469.1	ADAM1B	7.26	2.6e-12	2.91e-09	0.47	0.37	Mean platelet volume;	chr12:111913544	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.615	rs57303367	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111827279	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7488629	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111835696	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.748	rs73422316	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Mean platelet volume;	chr12:111835870	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs73422318	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111838169	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7314870	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111838660	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7980569	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111843580	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7970847	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111843689	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs3782885	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111844779	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs11066046	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111846077	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs2158030	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111847787	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.799	rs7315642	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Mean platelet volume;	chr12:111848992	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs12302040	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111850375	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs12322899	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111850398	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs12307192	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111852542	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs12307365	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111852847	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs6489817	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111853438	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7296199	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111854040	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs12313385	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111854343	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7310605	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111854666	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7956495	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111857889	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.748	rs111752063	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Mean platelet volume;	chr12:111859646	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7976557	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111862976	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs11066054	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111868361	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7297760	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111875884	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.799	rs12426566	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Mean platelet volume;	chr12:111877368	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs2097701	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111878970	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7294623	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111879292	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs16941703	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111880930	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs61440627	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111881193	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs3741998	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111902039	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs12319165	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111902930	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs73426310	ENSG00000226469.1	ADAM1B	7.26	2.63e-12	2.93e-09	0.46	0.37	Platelet count;	chr12:111904606	chr12:111927018~111929017:+
LIHC	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-7.26	2.63e-12	2.93e-09	-0.37	-0.37	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
LIHC	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-7.26	2.64e-12	2.94e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
LIHC	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-7.26	2.65e-12	2.95e-09	-0.34	-0.37	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
LIHC	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-7.26	2.66e-12	2.96e-09	-0.45	-0.37	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
LIHC	cis	rs10899021	1	rs61900636	ENSG00000279353.1	RP11-864N7.4	7.26	2.66e-12	2.96e-09	0.85	0.37	Response to metformin (IC50);	chr11:74648546	chr11:74698231~74699658:-
LIHC	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	7.26	2.66e-12	2.96e-09	0.6	0.37	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-7.26	2.66e-12	2.97e-09	-0.38	-0.37	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	7.26	2.67e-12	2.97e-09	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
LIHC	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	7.26	2.68e-12	2.98e-09	0.46	0.37	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
LIHC	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	7.26	2.68e-12	2.98e-09	0.42	0.37	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
LIHC	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-7.26	2.68e-12	2.98e-09	-0.37	-0.37	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
LIHC	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-7.26	2.7e-12	3e-09	-0.51	-0.37	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
LIHC	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-7.26	2.71e-12	3.01e-09	-0.37	-0.37	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
LIHC	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	7.25	2.77e-12	3.06e-09	0.47	0.37	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
LIHC	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	7.25	2.79e-12	3.08e-09	0.41	0.37	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
LIHC	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-7.25	2.79e-12	3.09e-09	-0.37	-0.37	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
LIHC	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-7.25	2.8e-12	3.09e-09	-0.45	-0.36	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
LIHC	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	7.25	2.81e-12	3.11e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
LIHC	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	7.25	2.81e-12	3.11e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
LIHC	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	7.25	2.82e-12	3.11e-09	0.42	0.36	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
LIHC	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	7.25	2.83e-12	3.12e-09	0.42	0.36	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
LIHC	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	7.25	2.83e-12	3.12e-09	0.66	0.36	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
LIHC	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	7.25	2.85e-12	3.14e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
LIHC	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	7.25	2.85e-12	3.15e-09	0.42	0.36	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
LIHC	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-7.25	2.86e-12	3.16e-09	-0.55	-0.36	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
LIHC	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-7.25	2.89e-12	3.19e-09	-0.45	-0.36	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
LIHC	cis	rs12744310	0.887	rs12048805	ENSG00000235358.1	RP11-399E6.1	7.24	2.9e-12	3.2e-09	0.48	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348604	chr1:41242373~41284861:+
LIHC	cis	rs739496	0.579	rs2879603	ENSG00000226469.1	ADAM1B	7.24	2.9e-12	3.2e-09	0.46	0.36	Platelet count;	chr12:111840221	chr12:111927018~111929017:+
LIHC	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-7.24	2.91e-12	3.21e-09	-0.37	-0.36	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-7.24	2.91e-12	3.21e-09	-0.37	-0.36	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-7.24	2.91e-12	3.21e-09	-0.37	-0.36	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-7.24	2.91e-12	3.21e-09	-0.37	-0.36	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-7.24	2.91e-12	3.21e-09	-0.37	-0.36	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-7.24	2.91e-12	3.21e-09	-0.37	-0.36	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
LIHC	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	7.24	2.92e-12	3.22e-09	0.44	0.36	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
LIHC	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-7.24	2.93e-12	3.23e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
LIHC	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-7.24	2.96e-12	3.26e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
LIHC	cis	rs12744310	0.887	rs12022655	ENSG00000235358.1	RP11-399E6.1	7.24	2.97e-12	3.27e-09	0.48	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41350647	chr1:41242373~41284861:+
LIHC	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	7.24	2.98e-12	3.27e-09	0.4	0.36	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
LIHC	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-7.24	2.98e-12	3.28e-09	-0.37	-0.36	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
LIHC	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	7.24	3e-12	3.3e-09	0.38	0.36	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
LIHC	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-7.24	3.03e-12	3.33e-09	-0.55	-0.36	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
LIHC	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	7.24	3.04e-12	3.35e-09	0.43	0.36	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
LIHC	cis	rs6490294	0.571	rs57168159	ENSG00000226469.1	ADAM1B	7.24	3.06e-12	3.36e-09	0.51	0.36	Mean platelet volume;	chr12:112189041	chr12:111927018~111929017:+
LIHC	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	7.24	3.07e-12	3.37e-09	0.4	0.36	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
LIHC	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	7.23	3.09e-12	3.39e-09	0.41	0.36	Depression;	chr6:28314871	chr6:28176188~28176674:+
LIHC	cis	rs6490294	0.528	rs7970181	ENSG00000226469.1	ADAM1B	7.23	3.09e-12	3.39e-09	0.5	0.36	Mean platelet volume;	chr12:112172194	chr12:111927018~111929017:+
LIHC	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-7.23	3.1e-12	3.4e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
LIHC	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	7.23	3.13e-12	3.44e-09	0.53	0.36	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
LIHC	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-7.23	3.14e-12	3.44e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
LIHC	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	7.23	3.18e-12	3.48e-09	0.67	0.36	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	7.23	3.18e-12	3.48e-09	0.67	0.36	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
LIHC	cis	rs739496	0.579	rs57427612	ENSG00000226469.1	ADAM1B	7.23	3.19e-12	3.49e-09	0.46	0.36	Platelet count;	chr12:111856192	chr12:111927018~111929017:+
LIHC	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-7.23	3.2e-12	3.51e-09	-0.37	-0.36	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
LIHC	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-7.23	3.23e-12	3.53e-09	-0.37	-0.36	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
LIHC	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	7.23	3.24e-12	3.55e-09	0.39	0.36	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
LIHC	cis	rs12744310	0.887	rs12047439	ENSG00000235358.1	RP11-399E6.1	7.23	3.24e-12	3.55e-09	0.47	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343968	chr1:41242373~41284861:+
LIHC	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	7.23	3.26e-12	3.56e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
LIHC	cis	rs7085104	0.632	rs4290163	ENSG00000236937.2	PTGES3P4	7.23	3.27e-12	3.58e-09	0.44	0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102845595~102845950:+
LIHC	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-7.23	3.28e-12	3.58e-09	-0.37	-0.36	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
LIHC	cis	rs6490294	0.571	rs58368428	ENSG00000226469.1	ADAM1B	7.23	3.28e-12	3.58e-09	0.51	0.36	Mean platelet volume;	chr12:112024471	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs6489824	ENSG00000226469.1	ADAM1B	7.23	3.28e-12	3.58e-09	0.51	0.36	Mean platelet volume;	chr12:112030613	chr12:111927018~111929017:+
LIHC	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-7.22	3.29e-12	3.59e-09	-0.37	-0.36	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
LIHC	cis	rs739496	0.579	rs3177647	ENSG00000226469.1	ADAM1B	7.22	3.29e-12	3.59e-09	0.47	0.36	Platelet count;	chr12:111839772	chr12:111927018~111929017:+
LIHC	cis	rs17270561	0.609	rs7746502	ENSG00000216436.2	HIST1H2APS1	7.22	3.3e-12	3.6e-09	0.46	0.36	Iron status biomarkers;	chr6:25718534	chr6:25732497~25732827:+
LIHC	cis	rs10899021	1	rs10899025	ENSG00000279353.1	RP11-864N7.4	7.22	3.3e-12	3.6e-09	0.91	0.36	Response to metformin (IC50);	chr11:74655995	chr11:74698231~74699658:-
LIHC	cis	rs1577917	0.958	rs9647601	ENSG00000234155.1	RP11-30P6.6	7.22	3.3e-12	3.61e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85740109	chr6:85387219~85390186:-
LIHC	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	7.22	3.3e-12	3.61e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
LIHC	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	7.22	3.3e-12	3.61e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
LIHC	cis	rs6490294	0.571	rs7973898	ENSG00000226469.1	ADAM1B	7.22	3.31e-12	3.62e-09	0.5	0.36	Mean platelet volume;	chr12:112178363	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs61612992	ENSG00000226469.1	ADAM1B	7.22	3.31e-12	3.62e-09	0.47	0.36	Platelet count;	chr12:111920260	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs7300320	ENSG00000226469.1	ADAM1B	7.22	3.31e-12	3.62e-09	0.47	0.36	Platelet count;	chr12:111922364	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs11066089	ENSG00000226469.1	ADAM1B	7.22	3.31e-12	3.62e-09	0.47	0.36	Platelet count;	chr12:111925463	chr12:111927018~111929017:+
LIHC	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-7.22	3.32e-12	3.62e-09	-0.37	-0.36	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
LIHC	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	7.22	3.33e-12	3.63e-09	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	7.22	3.33e-12	3.63e-09	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
LIHC	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	7.22	3.33e-12	3.63e-09	0.61	0.36	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	7.22	3.33e-12	3.64e-09	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
LIHC	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-7.22	3.34e-12	3.64e-09	-0.36	-0.36	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
LIHC	cis	rs6490294	0.528	rs60690688	ENSG00000226469.1	ADAM1B	7.22	3.35e-12	3.66e-09	0.5	0.36	Mean platelet volume;	chr12:112104179	chr12:111927018~111929017:+
LIHC	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-7.22	3.36e-12	3.66e-09	-0.41	-0.36	Height;	chr11:118791319	chr11:118704607~118750263:+
LIHC	cis	rs6490294	0.571	rs7295294	ENSG00000226469.1	ADAM1B	7.22	3.36e-12	3.66e-09	0.5	0.36	Mean platelet volume;	chr12:112027089	chr12:111927018~111929017:+
LIHC	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	7.22	3.36e-12	3.67e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
LIHC	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-7.22	3.37e-12	3.68e-09	-0.36	-0.36	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
LIHC	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-7.22	3.38e-12	3.68e-09	-0.37	-0.36	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
LIHC	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-7.22	3.39e-12	3.69e-09	-0.55	-0.36	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
LIHC	cis	rs1577917	0.958	rs7453105	ENSG00000234155.1	RP11-30P6.6	7.22	3.41e-12	3.71e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85791043	chr6:85387219~85390186:-
LIHC	cis	rs739496	0.579	rs12321677	ENSG00000226469.1	ADAM1B	-7.22	3.41e-12	3.71e-09	-0.47	-0.36	Platelet count;	chr12:111901211	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.61	rs11752795	ENSG00000234155.1	RP11-30P6.6	-7.22	3.43e-12	3.74e-09	-0.43	-0.36	Response to antipsychotic treatment;	chr6:85577411	chr6:85387219~85390186:-
LIHC	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	7.22	3.44e-12	3.75e-09	0.49	0.36	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
LIHC	cis	rs7085104	0.591	rs4919683	ENSG00000236937.2	PTGES3P4	7.22	3.49e-12	3.79e-09	0.43	0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102845595~102845950:+
LIHC	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-7.21	3.51e-12	3.82e-09	-0.68	-0.36	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
LIHC	cis	rs7085104	0.632	rs6162	ENSG00000236937.2	PTGES3P4	7.21	3.51e-12	3.82e-09	0.43	0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102845595~102845950:+
LIHC	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	7.21	3.52e-12	3.83e-09	0.67	0.36	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
LIHC	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	7.21	3.53e-12	3.84e-09	0.44	0.36	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
LIHC	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	7.21	3.53e-12	3.84e-09	0.49	0.36	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
LIHC	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	7.21	3.53e-12	3.84e-09	0.5	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
LIHC	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-7.21	3.54e-12	3.85e-09	-0.37	-0.36	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-7.21	3.54e-12	3.85e-09	-0.37	-0.36	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
LIHC	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	7.21	3.54e-12	3.85e-09	0.39	0.36	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
LIHC	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-7.21	3.55e-12	3.86e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
LIHC	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-7.21	3.55e-12	3.86e-09	-0.37	-0.36	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
LIHC	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	7.21	3.57e-12	3.87e-09	0.41	0.36	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
LIHC	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-7.21	3.58e-12	3.89e-09	-0.37	-0.36	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
LIHC	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	7.21	3.6e-12	3.91e-09	0.37	0.36	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
LIHC	cis	rs739496	0.579	rs12296574	ENSG00000226469.1	ADAM1B	7.21	3.63e-12	3.94e-09	0.46	0.36	Platelet count;	chr12:111884973	chr12:111927018~111929017:+
LIHC	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-7.21	3.64e-12	3.95e-09	-0.45	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
LIHC	cis	rs739496	0.563	rs61547643	ENSG00000226469.1	ADAM1B	7.21	3.68e-12	3.99e-09	0.46	0.36	Platelet count;	chr12:111828820	chr12:111927018~111929017:+
LIHC	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-7.21	3.69e-12	4e-09	-0.53	-0.36	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
LIHC	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	7.21	3.7e-12	4.01e-09	0.62	0.36	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
LIHC	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	7.21	3.72e-12	4.02e-09	0.44	0.36	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
LIHC	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	7.21	3.72e-12	4.03e-09	0.46	0.36	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	7.21	3.72e-12	4.03e-09	0.46	0.36	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	7.2	3.74e-12	4.05e-09	0.46	0.36	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
LIHC	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-7.2	3.75e-12	4.06e-09	-0.37	-0.36	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
LIHC	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	7.2	3.76e-12	4.07e-09	0.48	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
LIHC	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	7.2	3.76e-12	4.07e-09	0.4	0.36	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	7.2	3.77e-12	4.07e-09	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
LIHC	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	7.2	3.77e-12	4.07e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
LIHC	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	7.2	3.78e-12	4.09e-09	0.57	0.36	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
LIHC	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-7.2	3.79e-12	4.09e-09	-0.46	-0.36	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
LIHC	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	7.2	3.79e-12	4.09e-09	0.41	0.36	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
LIHC	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-7.2	3.85e-12	4.15e-09	-0.66	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
LIHC	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	7.2	3.87e-12	4.17e-09	0.38	0.36	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	7.2	3.87e-12	4.17e-09	0.38	0.36	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	7.2	3.87e-12	4.17e-09	0.38	0.36	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
LIHC	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	7.2	3.87e-12	4.17e-09	0.38	0.36	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
LIHC	cis	rs10899021	0.92	rs11236172	ENSG00000279353.1	RP11-864N7.4	7.2	3.87e-12	4.18e-09	0.81	0.36	Response to metformin (IC50);	chr11:74619843	chr11:74698231~74699658:-
LIHC	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-7.2	3.88e-12	4.18e-09	-0.47	-0.36	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
LIHC	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-7.2	3.88e-12	4.18e-09	-0.47	-0.36	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
LIHC	cis	rs739496	0.579	rs9971746	ENSG00000226469.1	ADAM1B	-7.2	3.88e-12	4.18e-09	-0.46	-0.36	Platelet count;	chr12:111899558	chr12:111927018~111929017:+
LIHC	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-7.2	3.89e-12	4.2e-09	-0.41	-0.36	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
LIHC	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	7.2	3.9e-12	4.21e-09	0.42	0.36	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
LIHC	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-7.2	3.91e-12	4.21e-09	-0.34	-0.36	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
LIHC	cis	rs739496	0.512	rs73422315	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Platelet count;	chr12:111830495	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.917	rs4098044	ENSG00000234155.1	RP11-30P6.6	7.2	3.92e-12	4.23e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85752348	chr6:85387219~85390186:-
LIHC	cis	rs739496	0.579	rs1981517	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Platelet count;	chr12:111885778	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs2269801	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Platelet count;	chr12:111888319	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.748	rs2269802	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Mean platelet volume;	chr12:111888334	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.799	rs73424286	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Mean platelet volume;	chr12:111889338	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7974772	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Platelet count;	chr12:111894479	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.527	rs10849981	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Platelet count;	chr12:111897413	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs10849982	ENSG00000226469.1	ADAM1B	7.2	3.92e-12	4.23e-09	0.46	0.36	Platelet count;	chr12:111897735	chr12:111927018~111929017:+
LIHC	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	7.2	3.95e-12	4.25e-09	0.59	0.36	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
LIHC	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-7.2	3.95e-12	4.25e-09	-0.53	-0.36	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
LIHC	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	7.2	3.97e-12	4.28e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
LIHC	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-7.19	3.98e-12	4.28e-09	-0.37	-0.36	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
LIHC	cis	rs1065852	0.51	rs5751247	ENSG00000237037.8	NDUFA6-AS1	-7.19	3.98e-12	4.29e-09	-0.42	-0.36	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42237048	chr22:42090931~42137742:+
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	7.19	3.99e-12	4.29e-09	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
LIHC	cis	rs7085104	0.513	rs619824	ENSG00000236937.2	PTGES3P4	7.19	3.99e-12	4.3e-09	0.44	0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102845595~102845950:+
LIHC	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	7.19	4e-12	4.3e-09	0.46	0.36	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
LIHC	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-7.19	4.01e-12	4.31e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
LIHC	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-7.19	4.01e-12	4.31e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
LIHC	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	7.19	4.07e-12	4.37e-09	0.59	0.36	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
LIHC	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	7.19	4.08e-12	4.38e-09	0.41	0.36	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
LIHC	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	7.19	4.09e-12	4.39e-09	0.42	0.36	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
LIHC	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	7.19	4.09e-12	4.39e-09	0.42	0.36	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
LIHC	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-7.19	4.1e-12	4.4e-09	-0.46	-0.36	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
LIHC	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-7.19	4.1e-12	4.4e-09	-0.46	-0.36	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
LIHC	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-7.19	4.11e-12	4.41e-09	-0.42	-0.36	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
LIHC	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	7.19	4.13e-12	4.43e-09	0.5	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
LIHC	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-7.19	4.15e-12	4.45e-09	-0.34	-0.36	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
LIHC	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-7.19	4.15e-12	4.45e-09	-0.34	-0.36	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
LIHC	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	7.19	4.18e-12	4.48e-09	0.6	0.36	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
LIHC	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-7.19	4.19e-12	4.49e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
LIHC	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	7.19	4.2e-12	4.5e-09	0.52	0.36	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
LIHC	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	7.19	4.23e-12	4.53e-09	0.63	0.36	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
LIHC	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-7.19	4.23e-12	4.53e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
LIHC	cis	rs1577917	0.655	rs9444354	ENSG00000234155.1	RP11-30P6.6	-7.19	4.23e-12	4.53e-09	-0.43	-0.36	Response to antipsychotic treatment;	chr6:85582217	chr6:85387219~85390186:-
LIHC	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	7.19	4.24e-12	4.54e-09	0.65	0.36	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
LIHC	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-7.18	4.27e-12	4.57e-09	-0.37	-0.36	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
LIHC	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	7.18	4.28e-12	4.58e-09	0.42	0.36	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
LIHC	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	7.18	4.28e-12	4.59e-09	0.52	0.36	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
LIHC	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-7.18	4.32e-12	4.62e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
LIHC	cis	rs916888	0.773	rs169201	ENSG00000262881.1	RP11-669E14.4	-7.18	4.33e-12	4.63e-09	-0.58	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45907670~45910779:-
LIHC	cis	rs4853012	0.793	rs6723185	ENSG00000257800.1	FNBP1P1	7.18	4.37e-12	4.68e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74120680~74123218:+
LIHC	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	7.18	4.38e-12	4.68e-09	0.37	0.36	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
LIHC	cis	rs739496	0.579	rs12319315	ENSG00000226469.1	ADAM1B	7.18	4.39e-12	4.69e-09	0.47	0.36	Platelet count;	chr12:111903215	chr12:111927018~111929017:+
LIHC	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-7.18	4.39e-12	4.69e-09	-0.45	-0.36	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
LIHC	cis	rs6490294	0.571	rs73421065	ENSG00000226469.1	ADAM1B	7.18	4.4e-12	4.7e-09	0.51	0.36	Mean platelet volume;	chr12:112121575	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs58047810	ENSG00000226469.1	ADAM1B	7.18	4.4e-12	4.7e-09	0.51	0.36	Mean platelet volume;	chr12:112124682	chr12:111927018~111929017:+
LIHC	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	7.18	4.41e-12	4.71e-09	0.39	0.36	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
LIHC	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-7.18	4.42e-12	4.73e-09	-0.37	-0.36	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
LIHC	cis	rs916888	0.773	rs1378358	ENSG00000262881.1	RP11-669E14.4	-7.18	4.43e-12	4.73e-09	-0.58	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45907670~45910779:-
LIHC	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	7.18	4.46e-12	4.76e-09	0.39	0.36	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
LIHC	cis	rs10916248	0.511	rs10916515	ENSG00000232628.4	RP11-365O16.3	7.18	4.48e-12	4.78e-09	0.48	0.36	QT interval (drug interaction);	chr1:224222121	chr1:224208747~224213279:-
LIHC	cis	rs6490294	0.571	rs11066120	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:111998391	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7312472	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112000966	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs57439171	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112001483	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7316650	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112001860	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7313773	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112003884	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs12423960	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112004612	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs10849992	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112005213	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7310545	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112006156	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7296841	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112006305	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs11066127	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112008551	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs7980579	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112009556	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7952986	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112010358	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7132863	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112011079	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs12300496	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112012629	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs11066128	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112012950	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7316563	ENSG00000226469.1	ADAM1B	7.18	4.48e-12	4.78e-09	0.5	0.36	Mean platelet volume;	chr12:112015831	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.681	rs4348284	ENSG00000234155.1	RP11-30P6.6	7.18	4.49e-12	4.78e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85640676	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.655	rs12203963	ENSG00000234155.1	RP11-30P6.6	-7.17	4.54e-12	4.83e-09	-0.43	-0.36	Response to antipsychotic treatment;	chr6:85513598	chr6:85387219~85390186:-
LIHC	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	7.17	4.57e-12	4.86e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
LIHC	cis	rs7396835	1	rs7396835	ENSG00000236267.1	AP006216.5	7.17	4.59e-12	4.88e-09	0.41	0.36	Quantitative traits;	chr11:116813312	chr11:116813204~116814003:-
LIHC	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-7.17	4.61e-12	4.9e-09	-0.46	-0.36	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
LIHC	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-7.17	4.62e-12	4.91e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
LIHC	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-7.17	4.63e-12	4.92e-09	-0.42	-0.36	QT interval;	chr12:29321177	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-7.17	4.63e-12	4.92e-09	-0.42	-0.36	QT interval;	chr12:29321323	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-7.17	4.63e-12	4.92e-09	-0.42	-0.36	QT interval;	chr12:29322770	chr12:29280418~29317848:-
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-7.17	4.63e-12	4.92e-09	-0.42	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
LIHC	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	7.17	4.64e-12	4.93e-09	0.6	0.36	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-7.17	4.65e-12	4.94e-09	-0.37	-0.36	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
LIHC	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-7.17	4.65e-12	4.94e-09	-0.36	-0.36	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
LIHC	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	7.17	4.66e-12	4.95e-09	0.59	0.36	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
LIHC	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	7.17	4.66e-12	4.95e-09	0.33	0.36	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
LIHC	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-7.17	4.66e-12	4.95e-09	-0.45	-0.36	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
LIHC	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-7.17	4.67e-12	4.95e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-7.17	4.67e-12	4.95e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
LIHC	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-7.17	4.68e-12	4.97e-09	-0.38	-0.36	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
LIHC	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	7.17	4.69e-12	4.98e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
LIHC	cis	rs916888	0.773	rs538628	ENSG00000262881.1	RP11-669E14.4	-7.17	4.76e-12	5.05e-09	-0.58	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45907670~45910779:-
LIHC	cis	rs1577917	0.958	rs2324817	ENSG00000234155.1	RP11-30P6.6	7.17	4.76e-12	5.05e-09	0.42	0.36	Response to antipsychotic treatment;	chr6:85752936	chr6:85387219~85390186:-
LIHC	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-7.17	4.77e-12	5.05e-09	-0.44	-0.36	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
LIHC	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-7.17	4.78e-12	5.07e-09	-0.46	-0.36	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
LIHC	cis	rs7085104	0.514	rs284855	ENSG00000236937.2	PTGES3P4	-7.17	4.8e-12	5.09e-09	-0.44	-0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102845595~102845950:+
LIHC	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	7.16	4.83e-12	5.12e-09	0.46	0.36	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
LIHC	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-7.16	4.84e-12	5.13e-09	-0.44	-0.36	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	7.16	4.84e-12	5.13e-09	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
LIHC	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	7.16	4.85e-12	5.13e-09	0.38	0.36	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
LIHC	cis	rs1577917	0.958	rs12209259	ENSG00000234155.1	RP11-30P6.6	7.16	4.85e-12	5.14e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85792630	chr6:85387219~85390186:-
LIHC	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-7.16	4.85e-12	5.14e-09	-0.38	-0.36	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
LIHC	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-7.16	4.86e-12	5.15e-09	-0.37	-0.36	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
LIHC	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	7.16	4.87e-12	5.15e-09	0.42	0.36	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.958	rs4707223	ENSG00000234155.1	RP11-30P6.6	7.16	4.89e-12	5.18e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85800084	chr6:85387219~85390186:-
LIHC	cis	rs916888	0.773	rs199445	ENSG00000262881.1	RP11-669E14.4	-7.16	4.92e-12	5.21e-09	-0.57	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.773	rs199443	ENSG00000262881.1	RP11-669E14.4	-7.16	4.92e-12	5.21e-09	-0.57	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45907670~45910779:-
LIHC	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	7.16	4.94e-12	5.22e-09	0.42	0.36	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
LIHC	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-7.16	4.94e-12	5.22e-09	-0.46	-0.36	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
LIHC	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-7.16	4.95e-12	5.24e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
LIHC	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	7.16	4.97e-12	5.26e-09	0.42	0.36	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
LIHC	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-7.16	4.99e-12	5.27e-09	-0.48	-0.36	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
LIHC	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-7.16	5.01e-12	5.3e-09	-0.37	-0.36	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
LIHC	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-7.16	5.03e-12	5.31e-09	-0.46	-0.36	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
LIHC	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-7.16	5.04e-12	5.32e-09	-0.37	-0.36	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
LIHC	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-7.16	5.04e-12	5.32e-09	-0.37	-0.36	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
LIHC	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-7.16	5.08e-12	5.37e-09	-0.38	-0.36	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
LIHC	cis	rs6490294	0.571	rs2272308	ENSG00000226469.1	ADAM1B	7.16	5.1e-12	5.38e-09	0.5	0.36	Mean platelet volume;	chr12:112163446	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs73426401	ENSG00000226469.1	ADAM1B	7.16	5.1e-12	5.39e-09	0.48	0.36	Mean platelet volume;	chr12:111985482	chr12:111927018~111929017:+
LIHC	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-7.16	5.11e-12	5.4e-09	-0.45	-0.36	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
LIHC	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	7.15	5.15e-12	5.43e-09	0.53	0.36	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	7.15	5.15e-12	5.43e-09	0.53	0.36	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	7.15	5.15e-12	5.43e-09	0.53	0.36	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
LIHC	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-7.15	5.16e-12	5.44e-09	-0.33	-0.36	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
LIHC	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-7.15	5.17e-12	5.45e-09	-0.45	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
LIHC	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	7.15	5.18e-12	5.46e-09	0.46	0.36	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
LIHC	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	7.15	5.18e-12	5.46e-09	0.46	0.36	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
LIHC	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	7.15	5.2e-12	5.48e-09	0.37	0.36	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
LIHC	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-7.15	5.28e-12	5.56e-09	-0.45	-0.36	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
LIHC	cis	rs6490294	0.571	rs7965087	ENSG00000226469.1	ADAM1B	7.15	5.28e-12	5.56e-09	0.5	0.36	Mean platelet volume;	chr12:112110758	chr12:111927018~111929017:+
LIHC	cis	rs138880	0.542	rs9616393	ENSG00000278869.1	CITF22-49E9.3	-7.15	5.29e-12	5.57e-09	-0.74	-0.36	Schizophrenia;	chr22:49921161	chr22:49933198~49934074:-
LIHC	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-7.15	5.31e-12	5.59e-09	-0.38	-0.36	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
LIHC	cis	rs7314031	1	rs7314031	ENSG00000226469.1	ADAM1B	7.15	5.32e-12	5.6e-09	0.5	0.36	Reticulocyte count;Reticulocyte fraction of red cells;	chr12:112392775	chr12:111927018~111929017:+
LIHC	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-7.15	5.33e-12	5.6e-09	-0.59	-0.36	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-7.15	5.33e-12	5.6e-09	-0.59	-0.36	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.531	rs1653634	ENSG00000227373.4	RP11-160H22.5	-7.15	5.33e-12	5.6e-09	-0.59	-0.36	Systemic lupus erythematosus;	chr1:174783348	chr1:174115300~174160004:-
LIHC	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-7.15	5.34e-12	5.62e-09	-0.44	-0.36	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
LIHC	cis	rs1577917	0.687	rs1470531	ENSG00000234155.1	RP11-30P6.6	7.15	5.36e-12	5.64e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85797651	chr6:85387219~85390186:-
LIHC	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-7.15	5.46e-12	5.73e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-7.15	5.46e-12	5.73e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	7.15	5.46e-12	5.73e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
LIHC	cis	rs1577917	0.958	rs6900436	ENSG00000234155.1	RP11-30P6.6	7.14	5.5e-12	5.77e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85796570	chr6:85387219~85390186:-
LIHC	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	7.14	5.5e-12	5.77e-09	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
LIHC	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	7.14	5.52e-12	5.79e-09	0.46	0.36	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
LIHC	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-7.14	5.56e-12	5.82e-09	-0.54	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
LIHC	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-7.14	5.58e-12	5.85e-09	-0.46	-0.36	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
LIHC	cis	rs1577917	0.917	rs1414201	ENSG00000234155.1	RP11-30P6.6	7.14	5.64e-12	5.9e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85790598	chr6:85387219~85390186:-
LIHC	cis	rs12744310	0.887	rs12024263	ENSG00000235358.1	RP11-399E6.1	7.14	5.64e-12	5.91e-09	0.48	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41355277	chr1:41242373~41284861:+
LIHC	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	7.14	5.75e-12	6.01e-09	0.42	0.36	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
LIHC	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-7.14	5.78e-12	6.03e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
LIHC	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-7.14	5.79e-12	6.04e-09	-0.44	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
LIHC	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	7.14	5.79e-12	6.05e-09	0.39	0.36	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
LIHC	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-7.14	5.79e-12	6.05e-09	-0.37	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
LIHC	cis	rs10899021	0.92	rs11236181	ENSG00000279353.1	RP11-864N7.4	7.14	5.82e-12	6.08e-09	0.78	0.36	Response to metformin (IC50);	chr11:74634778	chr11:74698231~74699658:-
LIHC	cis	rs6490294	0.571	rs12312538	ENSG00000226469.1	ADAM1B	7.13	5.83e-12	6.08e-09	0.5	0.36	Mean platelet volume;	chr12:112051717	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7959011	ENSG00000226469.1	ADAM1B	7.13	5.83e-12	6.08e-09	0.5	0.36	Mean platelet volume;	chr12:112063433	chr12:111927018~111929017:+
LIHC	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	7.13	5.85e-12	6.11e-09	0.45	0.36	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
LIHC	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	7.13	5.89e-12	6.14e-09	0.45	0.36	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
LIHC	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	7.13	5.91e-12	6.16e-09	0.47	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
LIHC	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	7.13	5.91e-12	6.16e-09	0.37	0.36	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
LIHC	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	7.13	5.93e-12	6.18e-09	0.55	0.36	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
LIHC	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	7.13	5.96e-12	6.21e-09	0.44	0.36	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
LIHC	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-7.13	5.96e-12	6.21e-09	-0.38	-0.36	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	7.13	5.99e-12	6.24e-09	0.37	0.36	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
LIHC	cis	rs7085104	0.632	rs3781287	ENSG00000236937.2	PTGES3P4	7.13	6e-12	6.25e-09	0.42	0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102845595~102845950:+
LIHC	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-7.13	6e-12	6.25e-09	-0.59	-0.36	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-7.13	6.01e-12	6.26e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
LIHC	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-7.13	6.02e-12	6.26e-09	-0.42	-0.36	QT interval;	chr12:29319943	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-7.13	6.02e-12	6.26e-09	-0.42	-0.36	QT interval;	chr12:29331030	chr12:29280418~29317848:-
LIHC	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	7.13	6.06e-12	6.31e-09	0.58	0.36	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
LIHC	cis	rs10899021	0.79	rs12288525	ENSG00000279353.1	RP11-864N7.4	7.13	6.06e-12	6.31e-09	0.74	0.36	Response to metformin (IC50);	chr11:74621544	chr11:74698231~74699658:-
LIHC	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	7.13	6.07e-12	6.31e-09	0.61	0.36	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
LIHC	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-7.13	6.08e-12	6.33e-09	-0.48	-0.36	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
LIHC	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-7.13	6.15e-12	6.4e-09	-0.55	-0.36	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
LIHC	cis	rs7085104	0.632	rs7097872	ENSG00000236937.2	PTGES3P4	7.13	6.18e-12	6.43e-09	0.43	0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102845595~102845950:+
LIHC	cis	rs916888	0.773	rs199448	ENSG00000262881.1	RP11-669E14.4	-7.12	6.25e-12	6.5e-09	-0.57	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45907670~45910779:-
LIHC	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-7.12	6.27e-12	6.52e-09	-0.42	-0.36	QT interval;	chr12:29314736	chr12:29280418~29317848:-
LIHC	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-7.12	6.27e-12	6.52e-09	-0.46	-0.36	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
LIHC	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	7.12	6.29e-12	6.53e-09	0.63	0.36	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
LIHC	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	7.12	6.29e-12	6.53e-09	0.41	0.36	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
LIHC	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	7.12	6.33e-12	6.57e-09	0.41	0.36	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
LIHC	cis	rs5758511	0.514	rs5751211	ENSG00000237037.8	NDUFA6-AS1	-7.12	6.34e-12	6.59e-09	-0.45	-0.36	Birth weight;	chr22:42090052	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.514	rs3985938	ENSG00000237037.8	NDUFA6-AS1	-7.12	6.34e-12	6.59e-09	-0.45	-0.36	Birth weight;	chr22:42115723	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.514	rs5758586	ENSG00000237037.8	NDUFA6-AS1	-7.12	6.34e-12	6.59e-09	-0.45	-0.36	Birth weight;	chr22:42121467	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.514	rs5751222	ENSG00000237037.8	NDUFA6-AS1	-7.12	6.34e-12	6.59e-09	-0.45	-0.36	Birth weight;	chr22:42121918	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.958	rs6921315	ENSG00000234155.1	RP11-30P6.6	7.12	6.35e-12	6.59e-09	0.42	0.36	Response to antipsychotic treatment;	chr6:85761950	chr6:85387219~85390186:-
LIHC	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-7.12	6.35e-12	6.6e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
LIHC	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-7.12	6.39e-12	6.63e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
LIHC	cis	rs1577917	0.681	rs4707211	ENSG00000234155.1	RP11-30P6.6	-7.12	6.41e-12	6.65e-09	-0.43	-0.36	Response to antipsychotic treatment;	chr6:85522992	chr6:85387219~85390186:-
LIHC	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-7.12	6.43e-12	6.68e-09	-0.42	-0.36	QT interval;	chr12:29319476	chr12:29280418~29317848:-
LIHC	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	7.12	6.44e-12	6.68e-09	0.57	0.36	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
LIHC	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	7.12	6.49e-12	6.73e-09	0.67	0.36	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
LIHC	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	7.12	6.52e-12	6.76e-09	0.64	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
LIHC	cis	rs6490294	0.95	rs7313892	ENSG00000226469.1	ADAM1B	7.11	6.63e-12	6.86e-09	0.48	0.36	Mean platelet volume;	chr12:111983548	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs7956483	ENSG00000226469.1	ADAM1B	7.11	6.63e-12	6.86e-09	0.48	0.36	Mean platelet volume;	chr12:111986766	chr12:111927018~111929017:+
LIHC	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-7.11	6.71e-12	6.94e-09	-0.46	-0.36	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-7.11	6.71e-12	6.94e-09	-0.46	-0.36	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-7.11	6.71e-12	6.94e-09	-0.46	-0.36	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
LIHC	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-7.11	6.73e-12	6.95e-09	-0.37	-0.36	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-7.11	6.73e-12	6.95e-09	-0.37	-0.36	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
LIHC	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	7.11	6.74e-12	6.96e-09	0.67	0.36	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
LIHC	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-7.11	6.74e-12	6.97e-09	-0.38	-0.36	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
LIHC	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-7.11	6.74e-12	6.97e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-7.11	6.74e-12	6.97e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
LIHC	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	7.11	6.74e-12	6.97e-09	0.42	0.36	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
LIHC	cis	rs1065852	0.51	rs5758666	ENSG00000237037.8	NDUFA6-AS1	-7.11	6.81e-12	7.03e-09	-0.42	-0.36	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42236827	chr22:42090931~42137742:+
LIHC	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	7.11	6.82e-12	7.03e-09	0.6	0.36	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	7.11	6.82e-12	7.03e-09	0.6	0.36	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
LIHC	cis	rs1577917	0.837	rs806529	ENSG00000234155.1	RP11-30P6.6	7.11	6.83e-12	7.04e-09	0.42	0.36	Response to antipsychotic treatment;	chr6:85757403	chr6:85387219~85390186:-
LIHC	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-7.11	6.89e-12	7.1e-09	-0.36	-0.36	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
LIHC	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-7.11	6.9e-12	7.1e-09	-0.4	-0.36	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
LIHC	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	7.11	6.9e-12	7.11e-09	0.42	0.36	QT interval;	chr12:29379056	chr12:29280418~29317848:-
LIHC	cis	rs5758511	0.514	rs5758580	ENSG00000237037.8	NDUFA6-AS1	-7.11	6.94e-12	7.14e-09	-0.45	-0.36	Birth weight;	chr22:42097871	chr22:42090931~42137742:+
LIHC	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	7.11	6.97e-12	7.17e-09	0.39	0.36	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
LIHC	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	7.11	6.99e-12	7.19e-09	0.45	0.36	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
LIHC	cis	rs916888	0.773	rs199439	ENSG00000262881.1	RP11-669E14.4	-7.1	7.05e-12	7.25e-09	-0.57	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45907670~45910779:-
LIHC	cis	rs6490294	0.904	rs11066098	ENSG00000226469.1	ADAM1B	7.1	7.08e-12	7.28e-09	0.46	0.36	Mean platelet volume;	chr12:111950324	chr12:111927018~111929017:+
LIHC	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	7.1	7.12e-12	7.32e-09	0.42	0.36	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
LIHC	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-7.1	7.15e-12	7.34e-09	-0.57	-0.36	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
LIHC	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-7.1	7.16e-12	7.36e-09	-0.46	-0.36	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
LIHC	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-7.1	7.18e-12	7.38e-09	-0.47	-0.36	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
LIHC	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-7.1	7.19e-12	7.39e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
LIHC	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	7.1	7.27e-12	7.47e-09	0.46	0.36	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
LIHC	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	7.1	7.27e-12	7.47e-09	0.46	0.36	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
LIHC	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	7.1	7.3e-12	7.5e-09	0.61	0.36	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
LIHC	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-7.1	7.31e-12	7.5e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
LIHC	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	7.1	7.36e-12	7.55e-09	0.53	0.36	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	7.1	7.36e-12	7.55e-09	0.53	0.36	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	7.1	7.36e-12	7.55e-09	0.53	0.36	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
LIHC	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-7.1	7.37e-12	7.56e-09	-0.45	-0.36	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
LIHC	cis	rs5758511	0.514	rs5751221	ENSG00000237037.8	NDUFA6-AS1	-7.1	7.4e-12	7.59e-09	-0.45	-0.36	Birth weight;	chr22:42120362	chr22:42090931~42137742:+
LIHC	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-7.1	7.42e-12	7.61e-09	-0.58	-0.36	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
LIHC	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	7.1	7.47e-12	7.66e-09	0.46	0.36	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
LIHC	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-7.09	7.52e-12	7.71e-09	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
LIHC	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	7.09	7.53e-12	7.72e-09	0.37	0.36	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
LIHC	cis	rs1577917	0.916	rs12206726	ENSG00000234155.1	RP11-30P6.6	7.09	7.54e-12	7.73e-09	0.43	0.36	Response to antipsychotic treatment;	chr6:85789998	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs6454487	ENSG00000234155.1	RP11-30P6.6	-7.09	7.59e-12	7.78e-09	-0.42	-0.36	Response to antipsychotic treatment;	chr6:85737150	chr6:85387219~85390186:-
LIHC	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	7.09	7.64e-12	7.83e-09	0.41	0.36	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
LIHC	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-7.09	7.65e-12	7.84e-09	-0.47	-0.36	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
LIHC	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	7.09	7.65e-12	7.84e-09	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
LIHC	cis	rs916888	0.773	rs199451	ENSG00000262881.1	RP11-669E14.4	-7.09	7.71e-12	7.9e-09	-0.57	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45907670~45910779:-
LIHC	cis	rs138880	0.505	rs56248708	ENSG00000278869.1	CITF22-49E9.3	7.09	7.74e-12	7.92e-09	0.77	0.36	Schizophrenia;	chr22:49913321	chr22:49933198~49934074:-
LIHC	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	7.09	7.74e-12	7.93e-09	0.46	0.36	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
LIHC	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	7.09	7.78e-12	7.96e-09	0.66	0.36	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
LIHC	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	7.09	7.79e-12	7.97e-09	0.47	0.36	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
LIHC	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-7.09	7.79e-12	7.97e-09	-0.42	-0.36	QT interval;	chr12:29320175	chr12:29280418~29317848:-
LIHC	cis	rs832187	0.704	rs3774720	ENSG00000280620.1	SCAANT1	7.09	7.87e-12	8.06e-09	0.45	0.36	Schizophrenia;	chr3:63966089	chr3:63911518~63911772:-
LIHC	cis	rs10899021	0.79	rs12280434	ENSG00000279353.1	RP11-864N7.4	7.08	8e-12	8.18e-09	0.76	0.36	Response to metformin (IC50);	chr11:74621782	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.79	rs10899019	ENSG00000279353.1	RP11-864N7.4	7.08	8e-12	8.18e-09	0.76	0.36	Response to metformin (IC50);	chr11:74624117	chr11:74698231~74699658:-
LIHC	cis	rs1577917	0.958	rs1545376	ENSG00000234155.1	RP11-30P6.6	-7.08	8.03e-12	8.21e-09	-0.43	-0.36	Response to antipsychotic treatment;	chr6:85794864	chr6:85387219~85390186:-
LIHC	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	7.08	8.11e-12	8.28e-09	0.37	0.36	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
LIHC	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-7.08	8.17e-12	8.34e-09	-0.37	-0.36	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
LIHC	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-7.08	8.18e-12	8.35e-09	-0.37	-0.36	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
LIHC	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-7.08	8.2e-12	8.37e-09	-0.37	-0.36	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
LIHC	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-7.08	8.2e-12	8.37e-09	-0.39	-0.36	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
LIHC	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	7.08	8.25e-12	8.42e-09	0.37	0.36	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
LIHC	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	7.08	8.25e-12	8.42e-09	0.57	0.36	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
LIHC	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	7.08	8.35e-12	8.51e-09	0.44	0.36	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
LIHC	cis	rs4356975	0.697	rs66666893	ENSG00000249956.3	RP11-790I12.2	7.08	8.35e-12	8.51e-09	0.42	0.36	Obesity-related traits;	chr4:69133393	chr4:69408836~69423164:+
LIHC	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-7.08	8.37e-12	8.53e-09	-0.45	-0.36	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
LIHC	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-7.08	8.43e-12	8.59e-09	-0.33	-0.36	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
LIHC	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-7.08	8.47e-12	8.63e-09	-0.47	-0.36	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
LIHC	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-7.08	8.48e-12	8.64e-09	-0.58	-0.36	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
LIHC	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	7.07	8.51e-12	8.67e-09	0.42	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
LIHC	cis	rs3020736	0.5	rs11090076	ENSG00000227370.1	RP4-669P10.19	7.07	8.55e-12	8.71e-09	0.42	0.36	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42132543~42132998:+
LIHC	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	7.07	8.56e-12	8.71e-09	0.49	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
LIHC	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-7.07	8.58e-12	8.73e-09	-0.37	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
LIHC	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	7.07	8.6e-12	8.75e-09	0.55	0.36	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
LIHC	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	7.07	8.69e-12	8.84e-09	0.58	0.36	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-7.07	8.7e-12	8.84e-09	-0.45	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
LIHC	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-7.07	8.7e-12	8.85e-09	-0.44	-0.36	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
LIHC	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	7.07	8.71e-12	8.85e-09	0.37	0.36	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
LIHC	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-7.07	8.71e-12	8.86e-09	-0.39	-0.36	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-7.07	8.71e-12	8.86e-09	-0.39	-0.36	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-7.07	8.71e-12	8.86e-09	-0.39	-0.36	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
LIHC	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	7.07	8.73e-12	8.88e-09	0.41	0.36	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
LIHC	cis	rs7085104	0.572	rs284856	ENSG00000236937.2	PTGES3P4	-7.07	8.75e-12	8.9e-09	-0.44	-0.36	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102845595~102845950:+
LIHC	cis	rs916888	0.773	rs199457	ENSG00000262881.1	RP11-669E14.4	-7.07	8.8e-12	8.94e-09	-0.57	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.687	rs199456	ENSG00000262881.1	RP11-669E14.4	-7.07	8.8e-12	8.94e-09	-0.57	-0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45907670~45910779:-
LIHC	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-7.07	8.89e-12	9.02e-09	-0.37	-0.36	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
LIHC	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-7.07	8.93e-12	9.06e-09	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
LIHC	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	7.07	8.96e-12	9.09e-09	0.45	0.36	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
LIHC	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	7.07	8.96e-12	9.1e-09	0.46	0.36	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
LIHC	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-7.07	8.99e-12	9.12e-09	-0.39	-0.36	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
LIHC	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-7.07	9e-12	9.13e-09	-0.31	-0.36	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
LIHC	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-7.07	9e-12	9.13e-09	-0.31	-0.36	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
LIHC	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-7.06	9.13e-12	9.25e-09	-0.59	-0.36	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-7.06	9.13e-12	9.25e-09	-0.59	-0.36	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-7.06	9.13e-12	9.25e-09	-0.59	-0.36	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	7.06	9.14e-12	9.26e-09	0.59	0.36	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
LIHC	cis	rs10899021	0.704	rs11236177	ENSG00000279353.1	RP11-864N7.4	7.06	9.15e-12	9.27e-09	0.76	0.36	Response to metformin (IC50);	chr11:74628022	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.79	rs10899022	ENSG00000279353.1	RP11-864N7.4	7.06	9.15e-12	9.27e-09	0.76	0.36	Response to metformin (IC50);	chr11:74628341	chr11:74698231~74699658:-
LIHC	cis	rs10899021	0.79	rs11236180	ENSG00000279353.1	RP11-864N7.4	7.06	9.15e-12	9.27e-09	0.76	0.36	Response to metformin (IC50);	chr11:74631883	chr11:74698231~74699658:-
LIHC	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	7.06	9.21e-12	9.33e-09	0.59	0.36	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	7.06	9.22e-12	9.34e-09	0.59	0.36	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
LIHC	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	7.06	9.35e-12	9.46e-09	0.44	0.36	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
LIHC	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	7.06	9.35e-12	9.46e-09	0.44	0.36	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
LIHC	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	7.06	9.37e-12	9.48e-09	0.41	0.36	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
LIHC	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-7.06	9.39e-12	9.51e-09	-0.37	-0.36	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
LIHC	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-7.06	9.4e-12	9.51e-09	-0.45	-0.36	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
LIHC	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	7.06	9.46e-12	9.57e-09	0.39	0.36	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
LIHC	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-7.06	9.5e-12	9.61e-09	-0.52	-0.36	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
LIHC	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-7.06	9.56e-12	9.66e-09	-0.47	-0.36	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
LIHC	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-7.06	9.58e-12	9.68e-09	-0.31	-0.36	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
LIHC	cis	rs1577917	1	rs791856	ENSG00000234155.1	RP11-30P6.6	-7.06	9.63e-12	9.73e-09	-0.42	-0.36	Response to antipsychotic treatment;	chr6:85972123	chr6:85387219~85390186:-
LIHC	cis	rs138880	0.542	rs9616371	ENSG00000278869.1	CITF22-49E9.3	7.05	9.76e-12	9.86e-09	0.77	0.36	Schizophrenia;	chr22:49912690	chr22:49933198~49934074:-
LIHC	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	7.05	9.81e-12	9.91e-09	0.66	0.36	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
LIHC	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	7.05	9.87e-12	9.96e-09	0.4	0.36	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
LIHC	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-7.05	9.88e-12	9.98e-09	-0.44	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
LIHC	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-7.05	9.96e-12	1e-08	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
LIHC	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-7.05	1e-11	1.01e-08	-0.36	-0.36	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
LIHC	cis	rs1023500	0.596	rs133352	ENSG00000227370.1	RP4-669P10.19	-7.05	1e-11	1.01e-08	-0.42	-0.36	Schizophrenia;	chr22:42038018	chr22:42132543~42132998:+
LIHC	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	7.05	1e-11	1.01e-08	0.36	0.36	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
LIHC	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-7.05	1.01e-11	1.02e-08	-0.45	-0.36	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
LIHC	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-7.05	1.01e-11	1.02e-08	-0.39	-0.36	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
LIHC	cis	rs2032447	0.507	rs199748	ENSG00000242387.1	HIST1H2APS2	7.05	1.02e-11	1.02e-08	0.49	0.36	Intelligence (multi-trait analysis);	chr6:25908817	chr6:25882026~25882395:-
LIHC	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-7.05	1.02e-11	1.03e-08	-0.37	-0.36	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
LIHC	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-7.04	1.03e-11	1.04e-08	-0.44	-0.36	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
LIHC	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-7.04	1.04e-11	1.05e-08	-0.44	-0.36	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
LIHC	cis	rs6085948	0.861	rs11907461	ENSG00000238102.1	RP11-19D2.1	-7.04	1.05e-11	1.05e-08	-0.67	-0.36	Interleukin-10 levels;	chr20:7251766	chr20:7256580~7258214:-
LIHC	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-7.04	1.06e-11	1.07e-08	-0.46	-0.36	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
LIHC	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-7.04	1.07e-11	1.07e-08	-0.44	-0.36	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
LIHC	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-7.04	1.07e-11	1.08e-08	-0.36	-0.36	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-7.04	1.07e-11	1.08e-08	-0.36	-0.36	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-7.04	1.07e-11	1.08e-08	-0.36	-0.36	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
LIHC	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-7.04	1.07e-11	1.08e-08	-0.41	-0.36	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
LIHC	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	7.04	1.09e-11	1.09e-08	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
LIHC	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	7.03	1.09e-11	1.1e-08	0.41	0.36	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
LIHC	cis	rs1023500	0.573	rs1807494	ENSG00000227370.1	RP4-669P10.19	7.03	1.09e-11	1.1e-08	0.41	0.36	Schizophrenia;	chr22:42078134	chr22:42132543~42132998:+
LIHC	cis	rs1023500	0.573	rs133370	ENSG00000227370.1	RP4-669P10.19	-7.03	1.09e-11	1.1e-08	-0.41	-0.36	Schizophrenia;	chr22:42069256	chr22:42132543~42132998:+
LIHC	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-7.03	1.1e-11	1.1e-08	-0.48	-0.36	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
LIHC	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-7.03	1.1e-11	1.1e-08	-0.48	-0.36	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
LIHC	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	7.03	1.1e-11	1.11e-08	0.41	0.36	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
LIHC	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	7.03	1.11e-11	1.11e-08	0.41	0.36	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
LIHC	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	7.03	1.12e-11	1.12e-08	0.52	0.36	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	7.03	1.12e-11	1.12e-08	0.52	0.36	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
LIHC	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	7.03	1.13e-11	1.13e-08	0.38	0.36	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
LIHC	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-7.03	1.13e-11	1.13e-08	-0.37	-0.36	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
LIHC	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-7.03	1.14e-11	1.14e-08	-0.31	-0.36	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
LIHC	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	7.03	1.14e-11	1.14e-08	0.65	0.36	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
LIHC	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	7.03	1.14e-11	1.14e-08	0.37	0.36	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
LIHC	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-7.03	1.15e-11	1.16e-08	-0.37	-0.36	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
LIHC	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	7.02	1.17e-11	1.17e-08	0.46	0.36	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
LIHC	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	7.02	1.17e-11	1.17e-08	0.52	0.36	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	7.02	1.17e-11	1.17e-08	0.52	0.36	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	7.02	1.17e-11	1.17e-08	0.52	0.36	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	7.02	1.17e-11	1.17e-08	0.52	0.36	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	7.02	1.17e-11	1.17e-08	0.52	0.36	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	7.02	1.17e-11	1.17e-08	0.52	0.36	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	7.02	1.17e-11	1.17e-08	0.52	0.36	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
LIHC	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-7.02	1.17e-11	1.17e-08	-0.43	-0.36	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
LIHC	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	7.02	1.17e-11	1.17e-08	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
LIHC	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	7.02	1.18e-11	1.18e-08	0.65	0.36	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	7.02	1.18e-11	1.18e-08	0.65	0.36	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
LIHC	cis	rs1577917	0.958	rs12190603	ENSG00000234155.1	RP11-30P6.6	7.02	1.18e-11	1.18e-08	0.42	0.35	Response to antipsychotic treatment;	chr6:85766000	chr6:85387219~85390186:-
LIHC	cis	rs7085104	0.572	rs284858	ENSG00000236937.2	PTGES3P4	-7.02	1.19e-11	1.19e-08	-0.44	-0.35	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102845595~102845950:+
LIHC	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-7.02	1.19e-11	1.19e-08	-0.35	-0.35	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
LIHC	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	7.02	1.19e-11	1.19e-08	0.39	0.35	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
LIHC	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-7.02	1.19e-11	1.19e-08	-0.52	-0.35	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
LIHC	cis	rs6490294	0.904	rs60217649	ENSG00000226469.1	ADAM1B	7.02	1.2e-11	1.2e-08	0.46	0.35	Mean platelet volume;	chr12:111973116	chr12:111927018~111929017:+
LIHC	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-7.02	1.2e-11	1.2e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
LIHC	cis	rs1577917	1	rs7766645	ENSG00000234155.1	RP11-30P6.6	7.02	1.21e-11	1.2e-08	0.42	0.35	Response to antipsychotic treatment;	chr6:85912520	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1911552	ENSG00000234155.1	RP11-30P6.6	7.02	1.21e-11	1.2e-08	0.42	0.35	Response to antipsychotic treatment;	chr6:85928306	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs9647603	ENSG00000234155.1	RP11-30P6.6	7.02	1.21e-11	1.2e-08	0.42	0.35	Response to antipsychotic treatment;	chr6:85929623	chr6:85387219~85390186:-
LIHC	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	7.02	1.22e-11	1.21e-08	0.59	0.35	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
LIHC	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-7.02	1.22e-11	1.22e-08	-0.42	-0.35	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
LIHC	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-7.02	1.23e-11	1.23e-08	-0.46	-0.35	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
LIHC	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-7.02	1.23e-11	1.23e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-7.02	1.23e-11	1.23e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-7.02	1.23e-11	1.23e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
LIHC	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-7.02	1.23e-11	1.23e-08	-0.36	-0.35	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
LIHC	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	7.02	1.24e-11	1.23e-08	0.64	0.35	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
LIHC	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-7.02	1.24e-11	1.23e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
LIHC	cis	rs2032447	0.507	rs199741	ENSG00000242387.1	HIST1H2APS2	7.01	1.24e-11	1.24e-08	0.51	0.35	Intelligence (multi-trait analysis);	chr6:25931349	chr6:25882026~25882395:-
LIHC	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-7.01	1.25e-11	1.24e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
LIHC	cis	rs1577917	0.655	rs6454472	ENSG00000234155.1	RP11-30P6.6	-7.01	1.26e-11	1.25e-08	-0.42	-0.35	Response to antipsychotic treatment;	chr6:85514335	chr6:85387219~85390186:-
LIHC	cis	rs7085104	0.632	rs7096475	ENSG00000236937.2	PTGES3P4	7.01	1.27e-11	1.26e-08	0.41	0.35	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102845595~102845950:+
LIHC	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	7.01	1.27e-11	1.26e-08	0.47	0.35	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
LIHC	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-7.01	1.29e-11	1.28e-08	-0.37	-0.35	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-7.01	1.29e-11	1.28e-08	-0.37	-0.35	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
LIHC	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	7.01	1.3e-11	1.28e-08	0.66	0.35	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
LIHC	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-7.01	1.3e-11	1.29e-08	-0.59	-0.35	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
LIHC	cis	rs3020736	0.5	rs1801311	ENSG00000227370.1	RP4-669P10.19	7.01	1.3e-11	1.29e-08	0.42	0.35	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42132543~42132998:+
LIHC	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	7.01	1.3e-11	1.29e-08	0.41	0.35	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
LIHC	cis	rs916888	0.773	rs199534	ENSG00000262881.1	RP11-669E14.4	-7.01	1.31e-11	1.29e-08	-0.56	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45907670~45910779:-
LIHC	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	7.01	1.31e-11	1.3e-08	0.59	0.35	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	7.01	1.31e-11	1.3e-08	0.59	0.35	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
LIHC	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	7.01	1.31e-11	1.3e-08	0.36	0.35	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	7.01	1.31e-11	1.3e-08	0.36	0.35	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	7.01	1.31e-11	1.3e-08	0.36	0.35	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
LIHC	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-7.01	1.31e-11	1.3e-08	-0.33	-0.35	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
LIHC	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-7.01	1.32e-11	1.3e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
LIHC	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-7.01	1.32e-11	1.3e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
LIHC	cis	rs1023500	0.573	rs133377	ENSG00000227370.1	RP4-669P10.19	-7.01	1.32e-11	1.3e-08	-0.41	-0.35	Schizophrenia;	chr22:42070946	chr22:42132543~42132998:+
LIHC	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-7	1.32e-11	1.3e-08	-0.31	-0.35	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
LIHC	cis	rs10916248	0.511	rs10916489	ENSG00000232628.4	RP11-365O16.3	-7	1.33e-11	1.32e-08	-0.46	-0.35	QT interval (drug interaction);	chr1:224215164	chr1:224208747~224213279:-
LIHC	cis	rs6490294	0.904	rs11066111	ENSG00000226469.1	ADAM1B	7	1.33e-11	1.32e-08	0.46	0.35	Mean platelet volume;	chr12:111977375	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs11066112	ENSG00000226469.1	ADAM1B	7	1.33e-11	1.32e-08	0.46	0.35	Mean platelet volume;	chr12:111978782	chr12:111927018~111929017:+
LIHC	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	7	1.33e-11	1.32e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	7	1.33e-11	1.32e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	7	1.33e-11	1.32e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	7	1.33e-11	1.32e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
LIHC	cis	rs1023500	0.552	rs5758566	ENSG00000227370.1	RP4-669P10.19	-7	1.33e-11	1.32e-08	-0.42	-0.35	Schizophrenia;	chr22:42058350	chr22:42132543~42132998:+
LIHC	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-7	1.35e-11	1.34e-08	-0.43	-0.35	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
LIHC	cis	rs1577917	0.739	rs6922	ENSG00000234155.1	RP11-30P6.6	-7	1.36e-11	1.34e-08	-0.44	-0.35	Response to antipsychotic treatment;	chr6:85495605	chr6:85387219~85390186:-
LIHC	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	7	1.37e-11	1.35e-08	0.41	0.35	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
LIHC	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	7	1.37e-11	1.36e-08	0.63	0.35	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
LIHC	cis	rs1023500	0.551	rs133355	ENSG00000227370.1	RP4-669P10.19	-7	1.38e-11	1.36e-08	-0.41	-0.35	Schizophrenia;	chr22:42044281	chr22:42132543~42132998:+
LIHC	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-7	1.38e-11	1.36e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
LIHC	cis	rs6490294	0.571	rs7309841	ENSG00000226469.1	ADAM1B	7	1.39e-11	1.38e-08	0.49	0.35	Mean platelet volume;	chr12:112127249	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs7294753	ENSG00000226469.1	ADAM1B	7	1.39e-11	1.38e-08	0.49	0.35	Mean platelet volume;	chr12:112129646	chr12:111927018~111929017:+
LIHC	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	6.99	1.4e-11	1.38e-08	0.36	0.35	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
LIHC	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-6.99	1.4e-11	1.38e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
LIHC	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-6.99	1.4e-11	1.38e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
LIHC	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-6.99	1.4e-11	1.38e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
LIHC	cis	rs916888	0.773	rs199447	ENSG00000262881.1	RP11-669E14.4	-6.99	1.41e-11	1.39e-08	-0.56	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45907670~45910779:-
LIHC	cis	rs1577917	1	rs7747824	ENSG00000234155.1	RP11-30P6.6	6.99	1.42e-11	1.4e-08	0.42	0.35	Response to antipsychotic treatment;	chr6:85937388	chr6:85387219~85390186:-
LIHC	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-6.99	1.42e-11	1.4e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-6.99	1.42e-11	1.4e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
LIHC	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	6.99	1.42e-11	1.4e-08	0.65	0.35	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
LIHC	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	6.99	1.42e-11	1.4e-08	0.44	0.35	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
LIHC	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-6.99	1.44e-11	1.41e-08	-0.58	-0.35	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
LIHC	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-6.99	1.44e-11	1.41e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
LIHC	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-6.99	1.44e-11	1.41e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
LIHC	cis	rs1023500	0.552	rs133368	ENSG00000227370.1	RP4-669P10.19	-6.99	1.45e-11	1.42e-08	-0.41	-0.35	Schizophrenia;	chr22:42067685	chr22:42132543~42132998:+
LIHC	cis	rs739496	0.579	rs7975437	ENSG00000226469.1	ADAM1B	6.99	1.45e-11	1.43e-08	0.46	0.35	Platelet count;	chr12:111939145	chr12:111927018~111929017:+
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	6.99	1.46e-11	1.43e-08	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
LIHC	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-6.99	1.46e-11	1.43e-08	-0.36	-0.35	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-6.99	1.46e-11	1.44e-08	-0.41	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
LIHC	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	6.99	1.46e-11	1.44e-08	0.4	0.35	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
LIHC	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-6.99	1.47e-11	1.45e-08	-0.38	-0.35	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
LIHC	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	6.99	1.48e-11	1.45e-08	0.52	0.35	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
LIHC	cis	rs6085948	0.861	rs17394617	ENSG00000238102.1	RP11-19D2.1	-6.99	1.48e-11	1.45e-08	-0.73	-0.35	Interleukin-10 levels;	chr20:7249043	chr20:7256580~7258214:-
LIHC	cis	rs9543976	0.614	rs4885308	ENSG00000261553.4	RP11-29G8.3	-6.99	1.48e-11	1.46e-08	-0.58	-0.35	Diabetic retinopathy;	chr13:75532357	chr13:75549773~75807120:+
LIHC	cis	rs854624	1	rs854626	ENSG00000278690.1	RP11-104J23.2	6.99	1.49e-11	1.46e-08	0.49	0.35	Blood protein levels;	chr17:36002489	chr17:36012504~36012891:+
LIHC	cis	rs916888	0.773	rs199533	ENSG00000262881.1	RP11-669E14.4	-6.99	1.49e-11	1.47e-08	-0.56	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45907670~45910779:-
LIHC	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-6.98	1.5e-11	1.48e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
LIHC	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-6.98	1.5e-11	1.48e-08	-0.43	-0.35	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-6.98	1.5e-11	1.48e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-6.98	1.5e-11	1.48e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
LIHC	cis	rs6163	0.727	rs284854	ENSG00000236937.2	PTGES3P4	-6.98	1.51e-11	1.48e-08	-0.43	-0.35	Waist circumference;Hip circumference;	chr10:102814805	chr10:102845595~102845950:+
LIHC	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-6.98	1.51e-11	1.49e-08	-0.41	-0.35	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
LIHC	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	6.98	1.52e-11	1.49e-08	0.36	0.35	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
LIHC	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	6.98	1.52e-11	1.49e-08	0.59	0.35	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	6.98	1.52e-11	1.49e-08	0.59	0.35	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
LIHC	cis	rs12744310	0.887	rs6660265	ENSG00000235358.1	RP11-399E6.1	-6.98	1.53e-11	1.5e-08	-0.47	-0.35	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41353004	chr1:41242373~41284861:+
LIHC	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-6.98	1.54e-11	1.51e-08	-0.35	-0.35	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
LIHC	cis	rs138857	0.515	rs9616375	ENSG00000278869.1	CITF22-49E9.3	6.98	1.55e-11	1.52e-08	0.76	0.35	Mean platelet volume;	chr22:49916952	chr22:49933198~49934074:-
LIHC	cis	rs6490294	0.904	rs2339908	ENSG00000226469.1	ADAM1B	6.98	1.56e-11	1.53e-08	0.46	0.35	Mean platelet volume;	chr12:111980692	chr12:111927018~111929017:+
LIHC	cis	rs9543976	0.688	rs56084319	ENSG00000261553.4	RP11-29G8.3	-6.98	1.56e-11	1.53e-08	-0.57	-0.35	Diabetic retinopathy;	chr13:75536543	chr13:75549773~75807120:+
LIHC	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	6.98	1.57e-11	1.54e-08	0.4	0.35	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
LIHC	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	6.98	1.57e-11	1.54e-08	0.59	0.35	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
LIHC	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	6.98	1.57e-11	1.54e-08	0.37	0.35	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
LIHC	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-6.98	1.57e-11	1.54e-08	-0.43	-0.35	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
LIHC	cis	rs6490294	0.904	rs1016078	ENSG00000226469.1	ADAM1B	6.98	1.58e-11	1.55e-08	0.45	0.35	Mean platelet volume;	chr12:111972273	chr12:111927018~111929017:+
LIHC	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	6.98	1.58e-11	1.55e-08	0.36	0.35	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
LIHC	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-6.98	1.59e-11	1.55e-08	-0.36	-0.35	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
LIHC	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-6.97	1.59e-11	1.56e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-6.97	1.59e-11	1.56e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-6.97	1.59e-11	1.56e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-6.97	1.59e-11	1.56e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-6.97	1.59e-11	1.56e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-6.97	1.59e-11	1.56e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-6.97	1.59e-11	1.56e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
LIHC	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-6.97	1.6e-11	1.57e-08	-0.45	-0.35	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
LIHC	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-6.97	1.61e-11	1.57e-08	-0.45	-0.35	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
LIHC	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	6.97	1.61e-11	1.57e-08	0.65	0.35	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	6.97	1.61e-11	1.57e-08	0.65	0.35	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-6.97	1.61e-11	1.57e-08	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
LIHC	cis	rs1023500	0.573	rs8135801	ENSG00000227370.1	RP4-669P10.19	6.97	1.61e-11	1.57e-08	0.41	0.35	Schizophrenia;	chr22:42079564	chr22:42132543~42132998:+
LIHC	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-6.97	1.61e-11	1.58e-08	-0.42	-0.35	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
LIHC	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-6.97	1.62e-11	1.58e-08	-0.36	-0.35	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
LIHC	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-6.97	1.62e-11	1.59e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
LIHC	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-6.97	1.62e-11	1.59e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-6.97	1.62e-11	1.59e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
LIHC	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-6.97	1.63e-11	1.59e-08	-0.38	-0.35	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
LIHC	cis	rs1577917	1	rs35385043	ENSG00000234155.1	RP11-30P6.6	6.97	1.63e-11	1.59e-08	0.42	0.35	Response to antipsychotic treatment;	chr6:85938828	chr6:85387219~85390186:-
LIHC	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	6.97	1.64e-11	1.6e-08	0.61	0.35	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	6.97	1.64e-11	1.6e-08	0.61	0.35	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	6.97	1.64e-11	1.6e-08	0.61	0.35	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
LIHC	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-6.97	1.65e-11	1.61e-08	-0.43	-0.35	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
LIHC	cis	rs7396835	0.741	rs7396851	ENSG00000236267.1	AP006216.5	-6.97	1.66e-11	1.62e-08	-0.4	-0.35	Quantitative traits;	chr11:116813448	chr11:116813204~116814003:-
LIHC	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-6.97	1.66e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-6.97	1.66e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
LIHC	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-6.97	1.66e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-6.97	1.66e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-6.97	1.66e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
LIHC	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-6.97	1.66e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
LIHC	cis	rs3020736	0.5	rs2413669	ENSG00000227370.1	RP4-669P10.19	6.97	1.66e-11	1.62e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6002618	ENSG00000227370.1	RP4-669P10.19	6.97	1.66e-11	1.62e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42132543~42132998:+
LIHC	cis	rs1023500	0.551	rs61665536	ENSG00000227370.1	RP4-669P10.19	6.97	1.66e-11	1.62e-08	0.41	0.35	Schizophrenia;	chr22:42116609	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs2413672	ENSG00000227370.1	RP4-669P10.19	6.97	1.66e-11	1.62e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6002623	ENSG00000227370.1	RP4-669P10.19	6.97	1.66e-11	1.62e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs764481	ENSG00000227370.1	RP4-669P10.19	6.97	1.66e-11	1.62e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42132543~42132998:+
LIHC	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-6.97	1.67e-11	1.62e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
LIHC	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-6.97	1.67e-11	1.62e-08	-0.43	-0.35	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
LIHC	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	6.97	1.67e-11	1.62e-08	0.4	0.35	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
LIHC	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-6.97	1.67e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
LIHC	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-6.97	1.67e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
LIHC	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-6.97	1.67e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
LIHC	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-6.97	1.67e-11	1.62e-08	-0.45	-0.35	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
LIHC	cis	rs7085104	0.572	rs284857	ENSG00000236937.2	PTGES3P4	-6.97	1.67e-11	1.63e-08	-0.43	-0.35	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102845595~102845950:+
LIHC	cis	rs138880	0.58	rs28562884	ENSG00000278869.1	CITF22-49E9.3	6.96	1.71e-11	1.66e-08	0.76	0.35	Schizophrenia;	chr22:49919221	chr22:49933198~49934074:-
LIHC	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	6.96	1.71e-11	1.66e-08	0.44	0.35	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	6.96	1.72e-11	1.67e-08	0.42	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
LIHC	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	6.96	1.73e-11	1.68e-08	0.35	0.35	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-6.96	1.74e-11	1.69e-08	-0.36	-0.35	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
LIHC	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-6.96	1.74e-11	1.7e-08	-0.42	-0.35	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
LIHC	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	6.96	1.74e-11	1.7e-08	0.4	0.35	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	6.96	1.75e-11	1.7e-08	0.41	0.35	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
LIHC	cis	rs4356975	0.899	rs7677996	ENSG00000249956.3	RP11-790I12.2	6.96	1.76e-11	1.71e-08	0.4	0.35	Obesity-related traits;	chr4:69075473	chr4:69408836~69423164:+
LIHC	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-6.96	1.77e-11	1.72e-08	-0.45	-0.35	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
LIHC	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-6.96	1.77e-11	1.72e-08	-0.45	-0.35	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
LIHC	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-6.96	1.77e-11	1.72e-08	-0.45	-0.35	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-6.96	1.77e-11	1.72e-08	-0.45	-0.35	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
LIHC	cis	rs17301013	0.507	rs3118990	ENSG00000227373.4	RP11-160H22.5	-6.96	1.77e-11	1.72e-08	-0.58	-0.35	Systemic lupus erythematosus;	chr1:174818586	chr1:174115300~174160004:-
LIHC	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-6.96	1.77e-11	1.72e-08	-0.44	-0.35	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
LIHC	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-6.96	1.77e-11	1.72e-08	-0.44	-0.35	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
LIHC	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	6.96	1.77e-11	1.72e-08	0.47	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
LIHC	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-6.96	1.78e-11	1.73e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
LIHC	cis	rs1023500	0.551	rs133371	ENSG00000227370.1	RP4-669P10.19	-6.96	1.78e-11	1.73e-08	-0.41	-0.35	Schizophrenia;	chr22:42069570	chr22:42132543~42132998:+
LIHC	cis	rs1023500	0.573	rs133374	ENSG00000227370.1	RP4-669P10.19	-6.96	1.78e-11	1.73e-08	-0.41	-0.35	Schizophrenia;	chr22:42069937	chr22:42132543~42132998:+
LIHC	cis	rs1023500	0.573	rs133378	ENSG00000227370.1	RP4-669P10.19	-6.96	1.78e-11	1.73e-08	-0.41	-0.35	Schizophrenia;	chr22:42071691	chr22:42132543~42132998:+
LIHC	cis	rs1023500	0.573	rs133382	ENSG00000227370.1	RP4-669P10.19	-6.96	1.78e-11	1.73e-08	-0.41	-0.35	Schizophrenia;	chr22:42075770	chr22:42132543~42132998:+
LIHC	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	6.96	1.79e-11	1.73e-08	0.41	0.35	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
LIHC	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-6.96	1.79e-11	1.74e-08	-0.58	-0.35	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
LIHC	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-6.96	1.79e-11	1.74e-08	-0.41	-0.35	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
LIHC	cis	rs6085948	0.817	rs17394645	ENSG00000238102.1	RP11-19D2.1	-6.96	1.8e-11	1.75e-08	-0.72	-0.35	Interleukin-10 levels;	chr20:7250193	chr20:7256580~7258214:-
LIHC	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-6.95	1.81e-11	1.75e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-6.95	1.81e-11	1.75e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-6.95	1.81e-11	1.75e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-6.95	1.81e-11	1.75e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-6.95	1.81e-11	1.75e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-6.95	1.81e-11	1.75e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-6.95	1.81e-11	1.75e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
LIHC	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	6.95	1.81e-11	1.76e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
LIHC	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	6.95	1.81e-11	1.76e-08	0.47	0.35	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
LIHC	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-6.95	1.82e-11	1.76e-08	-0.36	-0.35	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
LIHC	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	6.95	1.82e-11	1.76e-08	0.4	0.35	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
LIHC	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	6.95	1.82e-11	1.76e-08	0.47	0.35	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
LIHC	cis	rs1577917	0.629	rs6927475	ENSG00000234155.1	RP11-30P6.6	-6.95	1.82e-11	1.76e-08	-0.41	-0.35	Response to antipsychotic treatment;	chr6:85497055	chr6:85387219~85390186:-
LIHC	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-6.95	1.83e-11	1.77e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
LIHC	cis	rs138880	0.542	rs9616210	ENSG00000278869.1	CITF22-49E9.3	6.95	1.83e-11	1.78e-08	0.74	0.35	Schizophrenia;	chr22:49923698	chr22:49933198~49934074:-
LIHC	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	6.95	1.84e-11	1.78e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
LIHC	cis	rs916888	0.773	rs199535	ENSG00000262881.1	RP11-669E14.4	-6.95	1.84e-11	1.78e-08	-0.57	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45907670~45910779:-
LIHC	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-6.95	1.86e-11	1.8e-08	-0.36	-0.35	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
LIHC	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-6.95	1.86e-11	1.8e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
LIHC	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-6.95	1.87e-11	1.81e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
LIHC	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-6.95	1.87e-11	1.81e-08	-0.58	-0.35	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
LIHC	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-6.95	1.88e-11	1.82e-08	-0.46	-0.35	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
LIHC	cis	rs2260433	0.505	rs1298740	ENSG00000281655.1	RP11-817J15.3	6.95	1.88e-11	1.82e-08	0.4	0.35	Cleft palate;	chr11:102682048	chr11:102681310~102683913:+
LIHC	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-6.95	1.88e-11	1.82e-08	-0.62	-0.35	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
LIHC	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-6.95	1.88e-11	1.82e-08	-0.44	-0.35	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
LIHC	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-6.95	1.89e-11	1.83e-08	-0.46	-0.35	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
LIHC	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-6.95	1.9e-11	1.83e-08	-0.36	-0.35	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
LIHC	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-6.95	1.9e-11	1.84e-08	-0.42	-0.35	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
LIHC	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-6.94	1.92e-11	1.85e-08	-0.51	-0.35	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
LIHC	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-6.94	1.92e-11	1.86e-08	-0.46	-0.35	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
LIHC	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-6.94	1.92e-11	1.86e-08	-0.48	-0.35	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
LIHC	cis	rs6490294	0.904	rs12423126	ENSG00000226469.1	ADAM1B	6.94	1.92e-11	1.86e-08	0.46	0.35	Mean platelet volume;	chr12:111991665	chr12:111927018~111929017:+
LIHC	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	6.94	1.94e-11	1.87e-08	0.41	0.35	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
LIHC	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	6.94	1.95e-11	1.89e-08	0.4	0.35	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
LIHC	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.94	1.96e-11	1.89e-08	-0.38	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
LIHC	cis	rs10899021	0.92	rs76121309	ENSG00000279353.1	RP11-864N7.4	6.94	1.96e-11	1.9e-08	0.87	0.35	Response to metformin (IC50);	chr11:74632876	chr11:74698231~74699658:-
LIHC	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	6.94	1.98e-11	1.92e-08	0.44	0.35	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	6.94	1.98e-11	1.92e-08	0.44	0.35	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	6.94	1.98e-11	1.92e-08	0.44	0.35	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
LIHC	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	6.94	1.99e-11	1.92e-08	0.34	0.35	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
LIHC	cis	rs3020736	0.5	rs8138678	ENSG00000227370.1	RP4-669P10.19	6.94	2.02e-11	1.95e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42132543~42132998:+
LIHC	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	6.94	2.02e-11	1.95e-08	0.44	0.35	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
LIHC	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-6.94	2.03e-11	1.95e-08	-0.42	-0.35	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
LIHC	cis	rs1577917	0.629	rs9450285	ENSG00000234155.1	RP11-30P6.6	-6.94	2.04e-11	1.96e-08	-0.41	-0.35	Response to antipsychotic treatment;	chr6:85498378	chr6:85387219~85390186:-
LIHC	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	6.93	2.04e-11	1.96e-08	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
LIHC	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-6.93	2.04e-11	1.97e-08	-0.38	-0.35	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
LIHC	cis	rs3020736	0.519	rs5996116	ENSG00000227370.1	RP4-669P10.19	6.93	2.05e-11	1.97e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42132543~42132998:+
LIHC	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	6.93	2.05e-11	1.97e-08	0.37	0.35	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
LIHC	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	6.93	2.05e-11	1.97e-08	0.37	0.35	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
LIHC	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-6.93	2.05e-11	1.97e-08	-0.37	-0.35	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
LIHC	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	6.93	2.05e-11	1.97e-08	0.45	0.35	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
LIHC	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	6.93	2.05e-11	1.98e-08	0.37	0.35	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
LIHC	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	6.93	2.05e-11	1.98e-08	0.64	0.35	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
LIHC	cis	rs739496	0.579	rs16941759	ENSG00000226469.1	ADAM1B	-6.93	2.05e-11	1.98e-08	-0.46	-0.35	Platelet count;	chr12:111930117	chr12:111927018~111929017:+
LIHC	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	6.93	2.06e-11	1.98e-08	0.39	0.35	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
LIHC	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	6.93	2.06e-11	1.98e-08	0.39	0.35	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
LIHC	cis	rs1577917	1	rs13199006	ENSG00000234155.1	RP11-30P6.6	6.93	2.07e-11	1.99e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85898990	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs4707239	ENSG00000234155.1	RP11-30P6.6	6.93	2.07e-11	1.99e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85900999	chr6:85387219~85390186:-
LIHC	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	6.93	2.07e-11	1.99e-08	0.46	0.35	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
LIHC	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	6.93	2.07e-11	2e-08	0.35	0.35	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
LIHC	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-6.93	2.07e-11	2e-08	-0.43	-0.35	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
LIHC	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-6.93	2.08e-11	2.01e-08	-0.42	-0.35	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
LIHC	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-6.93	2.09e-11	2.01e-08	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
LIHC	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-6.93	2.09e-11	2.01e-08	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
LIHC	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-6.93	2.09e-11	2.01e-08	-0.44	-0.35	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
LIHC	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-6.93	2.09e-11	2.02e-08	-0.33	-0.35	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
LIHC	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	6.93	2.1e-11	2.02e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
LIHC	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-6.93	2.11e-11	2.03e-08	-0.4	-0.35	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
LIHC	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-6.93	2.11e-11	2.03e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
LIHC	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	6.93	2.13e-11	2.05e-08	0.43	0.35	Migraine;	chr4:56861145	chr4:56960927~56961373:-
LIHC	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	6.93	2.14e-11	2.06e-08	0.42	0.35	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
LIHC	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-6.93	2.15e-11	2.06e-08	-0.59	-0.35	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
LIHC	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-6.93	2.15e-11	2.07e-08	-0.4	-0.35	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
LIHC	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	6.93	2.16e-11	2.07e-08	0.64	0.35	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
LIHC	cis	rs17301013	0.507	rs10798324	ENSG00000227373.4	RP11-160H22.5	-6.92	2.17e-11	2.08e-08	-0.58	-0.35	Systemic lupus erythematosus;	chr1:174787485	chr1:174115300~174160004:-
LIHC	cis	rs739496	0.579	rs12423041	ENSG00000226469.1	ADAM1B	6.92	2.18e-11	2.09e-08	0.44	0.35	Platelet count;	chr12:111887042	chr12:111927018~111929017:+
LIHC	cis	rs832187	0.629	rs7624403	ENSG00000280620.1	SCAANT1	6.92	2.18e-11	2.09e-08	0.43	0.35	Schizophrenia;	chr3:63984401	chr3:63911518~63911772:-
LIHC	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	6.92	2.18e-11	2.09e-08	0.41	0.35	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
LIHC	cis	rs916888	0.821	rs70600	ENSG00000262881.1	RP11-669E14.4	-6.92	2.18e-11	2.09e-08	-0.56	-0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45907670~45910779:-
LIHC	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	6.92	2.18e-11	2.1e-08	0.4	0.35	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
LIHC	cis	rs1577917	0.771	rs6454486	ENSG00000234155.1	RP11-30P6.6	-6.92	2.19e-11	2.1e-08	-0.42	-0.35	Response to antipsychotic treatment;	chr6:85723869	chr6:85387219~85390186:-
LIHC	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	6.92	2.19e-11	2.1e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
LIHC	cis	rs5760092	0.572	rs738806	ENSG00000272787.1	KB-226F1.2	-6.92	2.19e-11	2.1e-08	-0.5	-0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23969211~23969873:+
LIHC	cis	rs6490294	0.571	rs7970397	ENSG00000226469.1	ADAM1B	6.92	2.19e-11	2.11e-08	0.49	0.35	Mean platelet volume;	chr12:112142267	chr12:111927018~111929017:+
LIHC	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	6.92	2.2e-11	2.11e-08	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
LIHC	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	6.92	2.2e-11	2.11e-08	0.44	0.35	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-6.92	2.2e-11	2.11e-08	-0.44	-0.35	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
LIHC	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	6.92	2.2e-11	2.11e-08	0.42	0.35	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
LIHC	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-6.92	2.2e-11	2.11e-08	-0.44	-0.35	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
LIHC	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-6.92	2.23e-11	2.13e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
LIHC	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-6.92	2.24e-11	2.15e-08	-0.45	-0.35	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
LIHC	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	6.92	2.24e-11	2.15e-08	0.41	0.35	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
LIHC	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-6.92	2.25e-11	2.15e-08	-0.45	-0.35	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
LIHC	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	6.92	2.25e-11	2.16e-08	0.44	0.35	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
LIHC	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-6.92	2.26e-11	2.16e-08	-0.75	-0.35	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
LIHC	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-6.92	2.27e-11	2.18e-08	-0.36	-0.35	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
LIHC	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-6.92	2.28e-11	2.18e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
LIHC	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-6.92	2.28e-11	2.19e-08	-0.43	-0.35	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
LIHC	cis	rs6490294	0.528	rs79761579	ENSG00000226469.1	ADAM1B	6.92	2.29e-11	2.19e-08	0.53	0.35	Mean platelet volume;	chr12:112021081	chr12:111927018~111929017:+
LIHC	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	6.92	2.29e-11	2.19e-08	0.71	0.35	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	6.92	2.29e-11	2.19e-08	0.71	0.35	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	6.92	2.29e-11	2.19e-08	0.71	0.35	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
LIHC	cis	rs7580658	0.963	rs867304	ENSG00000236682.1	AC068282.3	-6.92	2.3e-11	2.2e-08	-0.45	-0.35	Protein C levels;	chr2:127320912	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.963	rs12622436	ENSG00000236682.1	AC068282.3	-6.92	2.3e-11	2.2e-08	-0.45	-0.35	Protein C levels;	chr2:127324106	chr2:127389130~127400580:+
LIHC	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-6.91	2.31e-11	2.21e-08	-0.44	-0.35	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
LIHC	cis	rs7396835	0.866	rs7927820	ENSG00000236267.1	AP006216.5	6.91	2.32e-11	2.22e-08	0.41	0.35	Quantitative traits;	chr11:116811440	chr11:116813204~116814003:-
LIHC	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-6.91	2.32e-11	2.22e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
LIHC	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	6.91	2.33e-11	2.23e-08	0.45	0.35	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
LIHC	cis	rs8028182	0.583	rs9944207	ENSG00000260269.4	CTD-2323K18.1	-6.91	2.35e-11	2.25e-08	-0.46	-0.35	Sudden cardiac arrest;	chr15:75620548	chr15:75527150~75601205:-
LIHC	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	6.91	2.36e-11	2.26e-08	0.73	0.35	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
LIHC	cis	rs1577917	0.655	rs2758849	ENSG00000234155.1	RP11-30P6.6	6.91	2.37e-11	2.26e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85634578	chr6:85387219~85390186:-
LIHC	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	6.91	2.37e-11	2.27e-08	0.4	0.35	Height;	chr11:118855233	chr11:118688039~118690600:-
LIHC	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	6.91	2.37e-11	2.27e-08	0.4	0.35	Height;	chr11:118855938	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.655	rs2758848	ENSG00000234155.1	RP11-30P6.6	6.91	2.38e-11	2.27e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85637887	chr6:85387219~85390186:-
LIHC	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-6.91	2.39e-11	2.28e-08	-0.47	-0.35	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
LIHC	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	6.91	2.39e-11	2.28e-08	0.39	0.35	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
LIHC	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	6.91	2.39e-11	2.28e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	6.91	2.39e-11	2.28e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
LIHC	cis	rs34779708	0.832	rs12764283	ENSG00000230534.5	RP11-297A16.2	6.91	2.4e-11	2.29e-08	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35098006~35127020:-
LIHC	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	6.91	2.4e-11	2.29e-08	0.78	0.35	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
LIHC	cis	rs1577917	0.655	rs2842605	ENSG00000234155.1	RP11-30P6.6	6.91	2.41e-11	2.3e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85625432	chr6:85387219~85390186:-
LIHC	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	6.91	2.41e-11	2.3e-08	0.43	0.35	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	6.91	2.41e-11	2.3e-08	0.43	0.35	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
LIHC	cis	rs2487032	0.573	rs2164560	ENSG00000226334.1	RP11-217B7.2	-6.91	2.41e-11	2.3e-08	-0.48	-0.35	Glaucoma (high intraocular pressure);	chr9:104945072	chr9:104927553~104928892:+
LIHC	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-6.91	2.42e-11	2.31e-08	-0.43	-0.35	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
LIHC	cis	rs832187	0.64	rs704367	ENSG00000280620.1	SCAANT1	-6.91	2.43e-11	2.32e-08	-0.43	-0.35	Schizophrenia;	chr3:63883101	chr3:63911518~63911772:-
LIHC	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-6.91	2.45e-11	2.33e-08	-0.41	-0.35	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
LIHC	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-6.91	2.45e-11	2.33e-08	-0.41	-0.35	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
LIHC	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	6.91	2.45e-11	2.33e-08	0.44	0.35	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
LIHC	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	6.91	2.45e-11	2.33e-08	0.63	0.35	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	6.91	2.45e-11	2.33e-08	0.63	0.35	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
LIHC	cis	rs2836950	0.545	rs11700813	ENSG00000255568.3	BRWD1-AS2	-6.9	2.47e-11	2.35e-08	-0.29	-0.35	Menarche (age at onset);	chr21:39145543	chr21:39313935~39314962:+
LIHC	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	6.9	2.48e-11	2.36e-08	0.36	0.35	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	6.9	2.48e-11	2.36e-08	0.36	0.35	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
LIHC	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-6.9	2.48e-11	2.36e-08	-0.43	-0.35	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
LIHC	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-6.9	2.49e-11	2.37e-08	-0.43	-0.35	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
LIHC	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-6.9	2.52e-11	2.39e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
LIHC	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	6.9	2.53e-11	2.4e-08	0.56	0.35	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
LIHC	cis	rs138880	0.542	rs9616215	ENSG00000278869.1	CITF22-49E9.3	6.9	2.56e-11	2.43e-08	0.74	0.35	Schizophrenia;	chr22:49925186	chr22:49933198~49934074:-
LIHC	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-6.9	2.57e-11	2.44e-08	-0.39	-0.35	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
LIHC	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-6.9	2.57e-11	2.44e-08	-0.43	-0.35	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
LIHC	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-6.9	2.57e-11	2.44e-08	-0.43	-0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	6.9	2.57e-11	2.44e-08	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
LIHC	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	6.9	2.58e-11	2.45e-08	0.4	0.35	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	6.9	2.58e-11	2.45e-08	0.4	0.35	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
LIHC	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-6.9	2.58e-11	2.45e-08	-0.46	-0.35	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
LIHC	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-6.9	2.58e-11	2.45e-08	-0.4	-0.35	QT interval;	chr12:29310155	chr12:29280418~29317848:-
LIHC	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	6.9	2.58e-11	2.45e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
LIHC	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-6.9	2.59e-11	2.45e-08	-0.45	-0.35	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
LIHC	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	6.9	2.6e-11	2.46e-08	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	6.9	2.6e-11	2.46e-08	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
LIHC	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	6.89	2.61e-11	2.48e-08	0.73	0.35	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
LIHC	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	6.89	2.62e-11	2.48e-08	0.36	0.35	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
LIHC	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-6.89	2.63e-11	2.49e-08	-0.43	-0.35	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
LIHC	cis	rs1023500	0.573	rs2269524	ENSG00000227370.1	RP4-669P10.19	6.89	2.63e-11	2.49e-08	0.41	0.35	Schizophrenia;	chr22:42079699	chr22:42132543~42132998:+
LIHC	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	6.89	2.66e-11	2.52e-08	0.4	0.35	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
LIHC	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-6.89	2.67e-11	2.53e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-6.89	2.67e-11	2.53e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-6.89	2.67e-11	2.53e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
LIHC	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	6.89	2.68e-11	2.53e-08	0.59	0.35	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
LIHC	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-6.89	2.68e-11	2.54e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-6.89	2.69e-11	2.54e-08	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
LIHC	cis	rs1577917	0.666	rs6454471	ENSG00000234155.1	RP11-30P6.6	-6.89	2.69e-11	2.54e-08	-0.43	-0.35	Response to antipsychotic treatment;	chr6:85504738	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.665	rs4304137	ENSG00000234155.1	RP11-30P6.6	-6.89	2.69e-11	2.54e-08	-0.43	-0.35	Response to antipsychotic treatment;	chr6:85507730	chr6:85387219~85390186:-
LIHC	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	6.89	2.72e-11	2.57e-08	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
LIHC	cis	rs1939012	0.967	rs1940475	ENSG00000281655.1	RP11-817J15.3	-6.89	2.73e-11	2.58e-08	-0.41	-0.35	Epilepsy;	chr11:102722517	chr11:102681310~102683913:+
LIHC	cis	rs1577917	0.876	rs4618490	ENSG00000234155.1	RP11-30P6.6	6.89	2.73e-11	2.58e-08	0.42	0.35	Response to antipsychotic treatment;	chr6:85808685	chr6:85387219~85390186:-
LIHC	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-6.89	2.74e-11	2.59e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-6.89	2.74e-11	2.59e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-6.89	2.74e-11	2.59e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-6.89	2.74e-11	2.59e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-6.89	2.74e-11	2.59e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
LIHC	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	6.89	2.75e-11	2.59e-08	0.37	0.35	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
LIHC	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-6.89	2.75e-11	2.6e-08	-0.46	-0.35	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
LIHC	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-6.89	2.75e-11	2.6e-08	-0.42	-0.35	QT interval;	chr12:29357436	chr12:29280418~29317848:-
LIHC	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	6.88	2.79e-11	2.63e-08	0.41	0.35	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
LIHC	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	6.88	2.79e-11	2.63e-08	0.61	0.35	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
LIHC	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	6.88	2.79e-11	2.63e-08	0.73	0.35	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
LIHC	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-6.88	2.79e-11	2.63e-08	-0.42	-0.35	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
LIHC	cis	rs5769765	0.542	rs5769751	ENSG00000278869.1	CITF22-49E9.3	-6.88	2.81e-11	2.65e-08	-0.89	-0.35	Schizophrenia;	chr22:49849085	chr22:49933198~49934074:-
LIHC	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-6.88	2.82e-11	2.66e-08	-0.47	-0.35	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
LIHC	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-6.88	2.83e-11	2.67e-08	-0.44	-0.35	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
LIHC	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	6.88	2.87e-11	2.7e-08	0.6	0.35	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
LIHC	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-6.88	2.88e-11	2.71e-08	-0.29	-0.35	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
LIHC	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-6.88	2.9e-11	2.73e-08	-0.32	-0.35	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
LIHC	cis	rs7580658	0.963	rs12052483	ENSG00000236682.1	AC068282.3	-6.88	2.91e-11	2.74e-08	-0.45	-0.35	Protein C levels;	chr2:127379244	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.926	rs4662725	ENSG00000236682.1	AC068282.3	-6.88	2.91e-11	2.74e-08	-0.45	-0.35	Protein C levels;	chr2:127383744	chr2:127389130~127400580:+
LIHC	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-6.88	2.92e-11	2.75e-08	-0.36	-0.35	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
LIHC	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-6.88	2.93e-11	2.76e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-6.88	2.93e-11	2.76e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
LIHC	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	6.88	2.94e-11	2.77e-08	0.45	0.35	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
LIHC	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-6.88	2.95e-11	2.77e-08	-0.38	-0.35	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
LIHC	cis	rs3020736	0.5	rs4147641	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs4147640	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42132543~42132998:+
LIHC	cis	rs1023500	0.507	rs6002600	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Schizophrenia;	chr22:42092902	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6002601	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6002604	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs5996109	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs5996110	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs9620026	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs28791586	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs2839708	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6519306	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6002614	ENSG00000227370.1	RP4-669P10.19	6.88	2.95e-11	2.77e-08	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42132543~42132998:+
LIHC	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-6.87	2.95e-11	2.78e-08	-0.39	-0.35	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
LIHC	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-6.87	2.96e-11	2.78e-08	-0.46	-0.35	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
LIHC	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-6.87	2.96e-11	2.79e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
LIHC	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-6.87	2.96e-11	2.79e-08	-0.48	-0.35	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
LIHC	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-6.87	2.96e-11	2.79e-08	-0.48	-0.35	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
LIHC	cis	rs1939012	1	rs1939012	ENSG00000281655.1	RP11-817J15.3	-6.87	2.96e-11	2.79e-08	-0.41	-0.35	Epilepsy;	chr11:102724404	chr11:102681310~102683913:+
LIHC	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	6.87	2.97e-11	2.8e-08	0.43	0.35	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	6.87	2.97e-11	2.8e-08	0.43	0.35	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
LIHC	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	6.87	2.98e-11	2.8e-08	0.57	0.35	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
LIHC	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-6.87	3.02e-11	2.84e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-6.87	3.02e-11	2.84e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-6.87	3.02e-11	2.84e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-6.87	3.02e-11	2.84e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-6.87	3.02e-11	2.84e-08	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
LIHC	cis	rs1577917	1	rs6914463	ENSG00000234155.1	RP11-30P6.6	6.87	3.03e-11	2.84e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85943697	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs2816821	ENSG00000234155.1	RP11-30P6.6	6.87	3.03e-11	2.84e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85947366	chr6:85387219~85390186:-
LIHC	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-6.87	3.03e-11	2.85e-08	-0.4	-0.35	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
LIHC	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	6.87	3.04e-11	2.85e-08	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
LIHC	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	6.87	3.04e-11	2.85e-08	0.45	0.35	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
LIHC	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	6.87	3.06e-11	2.87e-08	0.41	0.35	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
LIHC	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-6.87	3.08e-11	2.89e-08	-0.46	-0.35	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-6.87	3.08e-11	2.89e-08	-0.46	-0.35	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-6.87	3.08e-11	2.89e-08	-0.46	-0.35	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
LIHC	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-6.87	3.09e-11	2.9e-08	-0.36	-0.35	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
LIHC	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	6.87	3.09e-11	2.9e-08	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
LIHC	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	6.87	3.09e-11	2.9e-08	0.4	0.35	Height;	chr11:118856460	chr11:118688039~118690600:-
LIHC	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	6.87	3.09e-11	2.9e-08	0.4	0.35	Height;	chr11:118856623	chr11:118688039~118690600:-
LIHC	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	6.87	3.09e-11	2.9e-08	0.4	0.35	Height;	chr11:118857611	chr11:118688039~118690600:-
LIHC	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	6.87	3.1e-11	2.9e-08	0.41	0.35	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	6.87	3.1e-11	2.9e-08	0.41	0.35	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	6.87	3.1e-11	2.9e-08	0.41	0.35	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	6.87	3.1e-11	2.9e-08	0.41	0.35	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
LIHC	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	6.87	3.1e-11	2.9e-08	0.44	0.35	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
LIHC	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	6.87	3.1e-11	2.91e-08	0.58	0.35	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
LIHC	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	6.87	3.11e-11	2.92e-08	0.58	0.35	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
LIHC	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-6.87	3.13e-11	2.93e-08	-0.39	-0.35	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
LIHC	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-6.87	3.13e-11	2.93e-08	-0.39	-0.35	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
LIHC	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	6.86	3.16e-11	2.96e-08	0.41	0.35	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	6.86	3.16e-11	2.96e-08	0.41	0.35	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
LIHC	cis	rs1939012	0.875	rs6590983	ENSG00000281655.1	RP11-817J15.3	-6.86	3.18e-11	2.97e-08	-0.42	-0.35	Epilepsy;	chr11:102723645	chr11:102681310~102683913:+
LIHC	cis	rs1939012	0.846	rs3765620	ENSG00000281655.1	RP11-817J15.3	-6.86	3.18e-11	2.97e-08	-0.42	-0.35	Epilepsy;	chr11:102724761	chr11:102681310~102683913:+
LIHC	cis	rs17301013	0.507	rs7515116	ENSG00000227373.4	RP11-160H22.5	-6.86	3.18e-11	2.98e-08	-0.53	-0.35	Systemic lupus erythematosus;	chr1:174474516	chr1:174115300~174160004:-
LIHC	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	6.86	3.19e-11	2.99e-08	0.45	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
LIHC	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	6.86	3.2e-11	3e-08	0.43	0.35	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
LIHC	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-6.86	3.22e-11	3.01e-08	-0.41	-0.35	QT interval;	chr12:29343291	chr12:29280418~29317848:-
LIHC	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	6.86	3.22e-11	3.01e-08	0.43	0.35	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	6.86	3.22e-11	3.01e-08	0.43	0.35	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
LIHC	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	6.86	3.22e-11	3.01e-08	0.44	0.35	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-6.86	3.25e-11	3.04e-08	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
LIHC	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	6.86	3.29e-11	3.08e-08	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
LIHC	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	6.86	3.29e-11	3.08e-08	0.41	0.35	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	6.86	3.29e-11	3.08e-08	0.41	0.35	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
LIHC	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-6.86	3.31e-11	3.09e-08	-0.42	-0.35	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
LIHC	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-6.86	3.31e-11	3.1e-08	-0.45	-0.35	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
LIHC	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	6.86	3.32e-11	3.1e-08	0.73	0.35	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
LIHC	cis	rs1577917	1	rs2812972	ENSG00000234155.1	RP11-30P6.6	6.86	3.33e-11	3.11e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85960162	chr6:85387219~85390186:-
LIHC	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	6.85	3.36e-11	3.13e-08	0.58	0.35	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
LIHC	cis	rs6490294	0.528	rs60998439	ENSG00000226469.1	ADAM1B	6.85	3.36e-11	3.13e-08	0.52	0.35	Mean platelet volume;	chr12:112008165	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.727	rs9344539	ENSG00000234155.1	RP11-30P6.6	6.85	3.36e-11	3.13e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85643903	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs9362232	ENSG00000234155.1	RP11-30P6.6	6.85	3.36e-11	3.13e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85643904	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.655	rs9450311	ENSG00000234155.1	RP11-30P6.6	-6.85	3.37e-11	3.14e-08	-0.41	-0.35	Response to antipsychotic treatment;	chr6:85666868	chr6:85387219~85390186:-
LIHC	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-6.85	3.37e-11	3.14e-08	-0.38	-0.35	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
LIHC	cis	rs6490294	0.571	rs11066117	ENSG00000226469.1	ADAM1B	6.85	3.38e-11	3.16e-08	0.48	0.35	Mean platelet volume;	chr12:111994905	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs11066118	ENSG00000226469.1	ADAM1B	6.85	3.38e-11	3.16e-08	0.48	0.35	Mean platelet volume;	chr12:111996348	chr12:111927018~111929017:+
LIHC	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	6.85	3.4e-11	3.17e-08	0.4	0.35	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
LIHC	cis	rs6490294	0.528	rs12579851	ENSG00000226469.1	ADAM1B	6.85	3.4e-11	3.17e-08	0.54	0.35	Mean platelet volume;	chr12:112230951	chr12:111927018~111929017:+
LIHC	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-6.85	3.42e-11	3.19e-08	-0.52	-0.35	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
LIHC	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-6.85	3.42e-11	3.19e-08	-0.36	-0.35	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
LIHC	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-6.85	3.42e-11	3.19e-08	-0.36	-0.35	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
LIHC	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	6.85	3.42e-11	3.19e-08	0.7	0.35	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
LIHC	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-6.85	3.42e-11	3.19e-08	-0.29	-0.35	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
LIHC	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-6.85	3.43e-11	3.2e-08	-0.4	-0.35	QT interval;	chr12:29309811	chr12:29280418~29317848:-
LIHC	cis	rs1577917	0.56	rs9450288	ENSG00000234155.1	RP11-30P6.6	-6.85	3.43e-11	3.2e-08	-0.42	-0.35	Response to antipsychotic treatment;	chr6:85511868	chr6:85387219~85390186:-
LIHC	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-6.85	3.45e-11	3.21e-08	-0.43	-0.35	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-6.85	3.45e-11	3.22e-08	-0.43	-0.35	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
LIHC	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-6.85	3.46e-11	3.22e-08	-0.44	-0.35	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
LIHC	cis	rs6490294	0.571	rs6489830	ENSG00000226469.1	ADAM1B	6.85	3.47e-11	3.23e-08	0.49	0.35	Mean platelet volume;	chr12:112144736	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.571	rs12422864	ENSG00000226469.1	ADAM1B	6.85	3.47e-11	3.23e-08	0.49	0.35	Mean platelet volume;	chr12:112146397	chr12:111927018~111929017:+
LIHC	cis	rs7085104	0.513	rs192569	ENSG00000236937.2	PTGES3P4	-6.85	3.47e-11	3.23e-08	-0.43	-0.35	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102845595~102845950:+
LIHC	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	6.85	3.49e-11	3.25e-08	0.39	0.35	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
LIHC	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-6.85	3.5e-11	3.26e-08	-0.43	-0.35	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
LIHC	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-6.85	3.51e-11	3.27e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
LIHC	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	6.85	3.51e-11	3.27e-08	0.41	0.35	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	6.85	3.51e-11	3.27e-08	0.41	0.35	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
LIHC	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-6.85	3.53e-11	3.29e-08	-0.35	-0.35	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
LIHC	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	6.85	3.54e-11	3.29e-08	0.41	0.35	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
LIHC	cis	rs1023500	0.551	rs2301521	ENSG00000227370.1	RP4-669P10.19	-6.84	3.56e-11	3.31e-08	-0.42	-0.35	Schizophrenia;	chr22:42027106	chr22:42132543~42132998:+
LIHC	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	6.84	3.57e-11	3.32e-08	0.64	0.35	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
LIHC	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-6.84	3.58e-11	3.33e-08	-0.4	-0.35	QT interval;	chr12:29306357	chr12:29280418~29317848:-
LIHC	cis	rs1062753	0.771	rs932376	ENSG00000237037.8	NDUFA6-AS1	-6.84	3.6e-11	3.34e-08	-0.4	-0.35	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42218356	chr22:42090931~42137742:+
LIHC	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-6.84	3.6e-11	3.35e-08	-0.45	-0.35	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
LIHC	cis	rs7580658	0.963	rs12991768	ENSG00000236682.1	AC068282.3	-6.84	3.62e-11	3.36e-08	-0.45	-0.35	Protein C levels;	chr2:127388669	chr2:127389130~127400580:+
LIHC	cis	rs6490294	0.528	rs74187049	ENSG00000226469.1	ADAM1B	6.84	3.62e-11	3.36e-08	0.53	0.35	Mean platelet volume;	chr12:112180114	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs16941909	ENSG00000226469.1	ADAM1B	6.84	3.62e-11	3.36e-08	0.53	0.35	Mean platelet volume;	chr12:112188420	chr12:111927018~111929017:+
LIHC	cis	rs7580658	0.926	rs79789049	ENSG00000236682.1	AC068282.3	-6.84	3.62e-11	3.36e-08	-0.45	-0.35	Protein C levels;	chr2:127387896	chr2:127389130~127400580:+
LIHC	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	6.84	3.65e-11	3.38e-08	0.4	0.35	Height;	chr11:118854014	chr11:118688039~118690600:-
LIHC	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	6.84	3.65e-11	3.39e-08	0.36	0.35	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
LIHC	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-6.84	3.65e-11	3.39e-08	-0.39	-0.35	Height;	chr11:118781100	chr11:118704607~118750263:+
LIHC	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	6.84	3.65e-11	3.39e-08	0.5	0.35	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
LIHC	cis	rs1023500	0.551	rs2859438	ENSG00000227370.1	RP4-669P10.19	-6.84	3.66e-11	3.39e-08	-0.4	-0.35	Schizophrenia;	chr22:42070976	chr22:42132543~42132998:+
LIHC	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-6.84	3.67e-11	3.4e-08	-0.35	-0.35	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
LIHC	cis	rs6490294	0.528	rs57866673	ENSG00000226469.1	ADAM1B	6.84	3.67e-11	3.41e-08	0.53	0.35	Mean platelet volume;	chr12:112195500	chr12:111927018~111929017:+
LIHC	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	6.84	3.7e-11	3.43e-08	0.45	0.35	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
LIHC	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	6.84	3.71e-11	3.44e-08	0.41	0.35	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
LIHC	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-6.84	3.74e-11	3.47e-08	-0.54	-0.35	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
LIHC	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.84	3.75e-11	3.47e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
LIHC	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.84	3.75e-11	3.47e-08	-0.41	-0.35	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
LIHC	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	6.84	3.75e-11	3.48e-08	0.42	0.35	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
LIHC	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	6.84	3.75e-11	3.48e-08	0.42	0.35	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
LIHC	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-6.84	3.76e-11	3.48e-08	-0.59	-0.35	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
LIHC	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	6.84	3.76e-11	3.48e-08	0.44	0.35	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
LIHC	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	6.84	3.76e-11	3.48e-08	0.44	0.35	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
LIHC	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-6.83	3.79e-11	3.51e-08	-0.44	-0.35	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
LIHC	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	6.83	3.83e-11	3.54e-08	0.65	0.35	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
LIHC	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-6.83	3.83e-11	3.55e-08	-0.36	-0.35	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
LIHC	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	6.83	3.85e-11	3.57e-08	0.34	0.35	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
LIHC	cis	rs4820294	1	rs4820294	ENSG00000233360.4	Z83844.1	6.83	3.87e-11	3.58e-08	0.44	0.35	Fat distribution (HIV);	chr22:37675036	chr22:37641832~37658377:-
LIHC	cis	rs3020736	0.5	rs6002616	ENSG00000227370.1	RP4-669P10.19	6.83	3.88e-11	3.59e-08	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs7364293	ENSG00000227370.1	RP4-669P10.19	6.83	3.88e-11	3.59e-08	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42132543~42132998:+
LIHC	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	6.83	3.91e-11	3.61e-08	0.53	0.35	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
LIHC	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-6.83	3.92e-11	3.62e-08	-0.4	-0.35	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
LIHC	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-6.83	3.92e-11	3.62e-08	-0.4	-0.35	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
LIHC	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-6.83	3.96e-11	3.66e-08	-0.35	-0.35	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
LIHC	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	6.83	3.99e-11	3.68e-08	0.44	0.35	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
LIHC	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	6.83	3.99e-11	3.68e-08	0.39	0.35	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
LIHC	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-6.83	3.99e-11	3.69e-08	-0.34	-0.35	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
LIHC	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	6.83	4.01e-11	3.7e-08	0.63	0.35	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
LIHC	cis	rs6490294	0.528	rs77211491	ENSG00000226469.1	ADAM1B	6.82	4.02e-11	3.71e-08	0.51	0.35	Mean platelet volume;	chr12:111884974	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs77030808	ENSG00000226469.1	ADAM1B	6.82	4.02e-11	3.71e-08	0.51	0.35	Mean platelet volume;	chr12:111891224	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs12580246	ENSG00000226469.1	ADAM1B	6.82	4.02e-11	3.71e-08	0.51	0.35	Mean platelet volume;	chr12:111893513	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.771	rs2842608	ENSG00000234155.1	RP11-30P6.6	6.82	4.03e-11	3.72e-08	0.43	0.35	Response to antipsychotic treatment;	chr6:85586140	chr6:85387219~85390186:-
LIHC	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	6.82	4.03e-11	3.72e-08	0.4	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
LIHC	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-6.82	4.04e-11	3.72e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
LIHC	cis	rs1577917	0.958	rs1337843	ENSG00000234155.1	RP11-30P6.6	6.82	4.04e-11	3.72e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85965827	chr6:85387219~85390186:-
LIHC	cis	rs1023500	0.596	rs5751204	ENSG00000227370.1	RP4-669P10.19	-6.82	4.05e-11	3.73e-08	-0.41	-0.35	Schizophrenia;	chr22:42037797	chr22:42132543~42132998:+
LIHC	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-6.82	4.06e-11	3.74e-08	-0.44	-0.35	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-6.82	4.06e-11	3.74e-08	-0.44	-0.35	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-6.82	4.06e-11	3.74e-08	-0.44	-0.35	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-6.82	4.06e-11	3.74e-08	-0.44	-0.35	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
LIHC	cis	rs1577917	0.771	rs4419647	ENSG00000234155.1	RP11-30P6.6	-6.82	4.07e-11	3.75e-08	-0.43	-0.35	Response to antipsychotic treatment;	chr6:85516021	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs9353318	ENSG00000234155.1	RP11-30P6.6	-6.82	4.07e-11	3.75e-08	-0.43	-0.35	Response to antipsychotic treatment;	chr6:85522003	chr6:85387219~85390186:-
LIHC	cis	rs6490294	0.528	rs74636821	ENSG00000226469.1	ADAM1B	6.82	4.08e-11	3.76e-08	0.52	0.35	Mean platelet volume;	chr12:112078108	chr12:111927018~111929017:+
LIHC	cis	rs3020736	0.5	rs8143153	ENSG00000227370.1	RP4-669P10.19	6.82	4.09e-11	3.77e-08	0.4	0.35	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42132543~42132998:+
LIHC	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	6.82	4.09e-11	3.77e-08	0.57	0.35	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	6.82	4.1e-11	3.77e-08	0.42	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
LIHC	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-6.82	4.1e-11	3.78e-08	-0.35	-0.35	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
LIHC	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	6.82	4.11e-11	3.78e-08	0.44	0.35	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
LIHC	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-6.82	4.12e-11	3.79e-08	-0.45	-0.35	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
LIHC	cis	rs6490294	0.528	rs12423572	ENSG00000226469.1	ADAM1B	6.82	4.12e-11	3.8e-08	0.52	0.35	Mean platelet volume;	chr12:112178115	chr12:111927018~111929017:+
LIHC	cis	rs1023500	0.529	rs133375	ENSG00000227370.1	RP4-669P10.19	-6.82	4.13e-11	3.8e-08	-0.4	-0.35	Schizophrenia;	chr22:42070505	chr22:42132543~42132998:+
LIHC	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	6.82	4.13e-11	3.8e-08	0.35	0.35	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
LIHC	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-6.82	4.14e-11	3.81e-08	-0.45	-0.35	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
LIHC	cis	rs7580658	0.963	rs6732279	ENSG00000236682.1	AC068282.3	-6.82	4.15e-11	3.82e-08	-0.44	-0.35	Protein C levels;	chr2:127331964	chr2:127389130~127400580:+
LIHC	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	6.82	4.15e-11	3.82e-08	0.39	0.35	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
LIHC	cis	rs6490294	0.571	rs77176084	ENSG00000226469.1	ADAM1B	6.82	4.16e-11	3.83e-08	0.52	0.35	Mean platelet volume;	chr12:112077508	chr12:111927018~111929017:+
LIHC	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	6.82	4.17e-11	3.83e-08	0.46	0.35	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
LIHC	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-6.82	4.17e-11	3.84e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
LIHC	cis	rs7580658	0.963	rs62157555	ENSG00000236682.1	AC068282.3	-6.82	4.18e-11	3.85e-08	-0.44	-0.35	Protein C levels;	chr2:127349600	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.963	rs12479003	ENSG00000236682.1	AC068282.3	-6.82	4.18e-11	3.85e-08	-0.44	-0.35	Protein C levels;	chr2:127360977	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.963	rs10803585	ENSG00000236682.1	AC068282.3	-6.82	4.18e-11	3.85e-08	-0.44	-0.35	Protein C levels;	chr2:127372532	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.963	rs2090574	ENSG00000236682.1	AC068282.3	-6.82	4.18e-11	3.85e-08	-0.44	-0.35	Protein C levels;	chr2:127373815	chr2:127389130~127400580:+
LIHC	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-6.82	4.25e-11	3.91e-08	-0.4	-0.35	QT interval;	chr16:28845498	chr16:28700294~28701540:-
LIHC	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	6.82	4.25e-11	3.91e-08	0.42	0.35	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
LIHC	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	6.82	4.26e-11	3.91e-08	0.58	0.35	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
LIHC	cis	rs1577917	0.771	rs4351223	ENSG00000234155.1	RP11-30P6.6	-6.82	4.27e-11	3.92e-08	-0.43	-0.35	Response to antipsychotic treatment;	chr6:85528079	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs7452605	ENSG00000234155.1	RP11-30P6.6	-6.82	4.27e-11	3.92e-08	-0.43	-0.35	Response to antipsychotic treatment;	chr6:85531233	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs9294337	ENSG00000234155.1	RP11-30P6.6	-6.82	4.27e-11	3.92e-08	-0.43	-0.35	Response to antipsychotic treatment;	chr6:85538742	chr6:85387219~85390186:-
LIHC	cis	rs10916248	0.511	rs10916512	ENSG00000232628.4	RP11-365O16.3	6.81	4.27e-11	3.92e-08	0.46	0.35	QT interval (drug interaction);	chr1:224220968	chr1:224208747~224213279:-
LIHC	cis	rs6490294	0.898	rs57646770	ENSG00000226469.1	ADAM1B	6.81	4.27e-11	3.92e-08	0.45	0.35	Mean platelet volume;	chr12:111993408	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.958	rs12191340	ENSG00000234155.1	RP11-30P6.6	6.81	4.28e-11	3.93e-08	0.41	0.35	Response to antipsychotic treatment;	chr6:85811682	chr6:85387219~85390186:-
LIHC	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-6.81	4.29e-11	3.94e-08	-0.41	-0.35	QT interval;	chr12:29344573	chr12:29280418~29317848:-
LIHC	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-6.81	4.29e-11	3.94e-08	-0.42	-0.35	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
LIHC	cis	rs10899021	0.79	rs12296094	ENSG00000279353.1	RP11-864N7.4	6.81	4.31e-11	3.96e-08	0.76	0.35	Response to metformin (IC50);	chr11:74610655	chr11:74698231~74699658:-
LIHC	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	6.81	4.31e-11	3.96e-08	0.44	0.35	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
LIHC	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	6.81	4.31e-11	3.96e-08	0.44	0.35	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
LIHC	cis	rs55665837	0.701	rs12286408	ENSG00000251991.1	RNU7-49P	6.81	4.32e-11	3.97e-08	0.38	0.35	Vitamin D levels;	chr11:14557830	chr11:14478892~14478953:+
LIHC	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-6.81	4.36e-11	4e-08	-0.43	-0.35	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
LIHC	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-6.81	4.38e-11	4.02e-08	-0.52	-0.35	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
LIHC	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-6.81	4.39e-11	4.03e-08	-0.46	-0.35	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
LIHC	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-6.81	4.4e-11	4.03e-08	-0.41	-0.35	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-6.81	4.4e-11	4.03e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
LIHC	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-6.81	4.42e-11	4.05e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
LIHC	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-6.81	4.43e-11	4.06e-08	-0.43	-0.35	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
LIHC	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-6.81	4.45e-11	4.08e-08	-0.43	-0.35	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
LIHC	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	6.81	4.5e-11	4.12e-08	0.73	0.35	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	6.81	4.5e-11	4.12e-08	0.73	0.35	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
LIHC	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	6.81	4.5e-11	4.12e-08	0.43	0.35	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
LIHC	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-6.81	4.53e-11	4.15e-08	-0.36	-0.35	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
LIHC	cis	rs1003645	0.569	rs7222922	ENSG00000278690.1	RP11-104J23.2	6.81	4.53e-11	4.15e-08	0.45	0.35	Blood protein levels;	chr17:36008654	chr17:36012504~36012891:+
LIHC	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-6.8	4.55e-11	4.17e-08	-0.46	-0.35	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
LIHC	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-6.8	4.55e-11	4.17e-08	-0.46	-0.35	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
LIHC	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-6.8	4.59e-11	4.2e-08	-0.32	-0.35	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
LIHC	cis	rs2033711	0.811	rs9304814	ENSG00000269473.1	CTD-2619J13.19	6.8	4.6e-11	4.21e-08	0.4	0.35	Uric acid clearance;	chr19:58440444	chr19:58440448~58445849:+
LIHC	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-6.8	4.61e-11	4.22e-08	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
LIHC	cis	rs831571	0.774	rs254858	ENSG00000280620.1	SCAANT1	-6.8	4.61e-11	4.22e-08	-0.47	-0.35	Type 2 diabetes;	chr3:64070579	chr3:63911518~63911772:-
LIHC	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-6.8	4.62e-11	4.22e-08	-0.35	-0.35	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
LIHC	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-6.8	4.65e-11	4.25e-08	-0.28	-0.35	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
LIHC	cis	rs17270561	0.609	rs7746609	ENSG00000216436.2	HIST1H2APS1	6.8	4.65e-11	4.25e-08	0.42	0.35	Iron status biomarkers;	chr6:25727768	chr6:25732497~25732827:+
LIHC	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-6.8	4.66e-11	4.26e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-6.8	4.66e-11	4.26e-08	-0.42	-0.35	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
LIHC	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	6.8	4.67e-11	4.27e-08	0.36	0.35	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
LIHC	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	6.8	4.67e-11	4.27e-08	0.44	0.35	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
LIHC	cis	rs1023500	0.573	rs4822088	ENSG00000227370.1	RP4-669P10.19	-6.8	4.67e-11	4.27e-08	-0.4	-0.35	Schizophrenia;	chr22:42074585	chr22:42132543~42132998:+
LIHC	cis	rs1577917	1	rs6923148	ENSG00000234155.1	RP11-30P6.6	-6.8	4.71e-11	4.3e-08	-0.41	-0.35	Response to antipsychotic treatment;	chr6:86058068	chr6:85387219~85390186:-
LIHC	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-6.8	4.71e-11	4.31e-08	-0.28	-0.35	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
LIHC	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	6.8	4.72e-11	4.31e-08	0.42	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
LIHC	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	6.8	4.73e-11	4.32e-08	0.48	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
LIHC	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	6.8	4.74e-11	4.33e-08	0.42	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	6.8	4.74e-11	4.33e-08	0.42	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
LIHC	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-6.8	4.74e-11	4.33e-08	-0.41	-0.35	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-6.8	4.78e-11	4.37e-08	-0.45	-0.34	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.917	rs1838959	ENSG00000234155.1	RP11-30P6.6	6.8	4.79e-11	4.37e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85847086	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.917	rs1579886	ENSG00000234155.1	RP11-30P6.6	6.8	4.79e-11	4.37e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85847473	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs1816937	ENSG00000234155.1	RP11-30P6.6	6.8	4.79e-11	4.37e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85847533	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs7382798	ENSG00000234155.1	RP11-30P6.6	6.8	4.79e-11	4.37e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85850116	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs1838958	ENSG00000234155.1	RP11-30P6.6	6.8	4.79e-11	4.37e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85854250	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.917	rs12665464	ENSG00000234155.1	RP11-30P6.6	6.8	4.79e-11	4.37e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85864415	chr6:85387219~85390186:-
LIHC	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-6.8	4.81e-11	4.39e-08	-0.35	-0.34	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
LIHC	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	6.8	4.82e-11	4.4e-08	0.28	0.34	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
LIHC	cis	rs1577917	0.771	rs9450290	ENSG00000234155.1	RP11-30P6.6	-6.79	4.83e-11	4.41e-08	-0.43	-0.34	Response to antipsychotic treatment;	chr6:85523679	chr6:85387219~85390186:-
LIHC	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-6.79	4.85e-11	4.42e-08	-0.46	-0.34	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
LIHC	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-6.79	4.87e-11	4.44e-08	-0.4	-0.34	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
LIHC	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	6.79	4.88e-11	4.45e-08	0.34	0.34	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	6.79	4.88e-11	4.45e-08	0.35	0.34	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
LIHC	cis	rs1065852	0.906	rs9611734	ENSG00000237037.8	NDUFA6-AS1	-6.79	4.93e-11	4.49e-08	-0.43	-0.34	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42106066	chr22:42090931~42137742:+
LIHC	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	6.79	4.93e-11	4.49e-08	0.43	0.34	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
LIHC	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.79	4.95e-11	4.51e-08	0.63	0.34	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.79	4.95e-11	4.51e-08	0.63	0.34	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	6.79	4.97e-11	4.52e-08	0.64	0.34	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	6.79	4.97e-11	4.52e-08	0.64	0.34	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	6.79	4.97e-11	4.52e-08	0.64	0.34	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
LIHC	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-6.79	4.97e-11	4.52e-08	-0.39	-0.34	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
LIHC	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-6.79	4.97e-11	4.53e-08	-0.46	-0.34	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
LIHC	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-6.79	4.99e-11	4.54e-08	-0.4	-0.34	QT interval;	chr12:29306799	chr12:29280418~29317848:-
LIHC	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	6.79	5e-11	4.55e-08	0.36	0.34	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
LIHC	cis	rs1939012	0.846	rs3758857	ENSG00000281655.1	RP11-817J15.3	-6.79	5e-11	4.56e-08	-0.4	-0.34	Epilepsy;	chr11:102727628	chr11:102681310~102683913:+
LIHC	cis	rs1939012	0.875	rs3758858	ENSG00000281655.1	RP11-817J15.3	-6.79	5e-11	4.56e-08	-0.4	-0.34	Epilepsy;	chr11:102727726	chr11:102681310~102683913:+
LIHC	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-6.79	5.01e-11	4.56e-08	-0.34	-0.34	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
LIHC	cis	rs1577917	0.958	rs2660576	ENSG00000234155.1	RP11-30P6.6	6.79	5.03e-11	4.58e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85941885	chr6:85387219~85390186:-
LIHC	cis	rs1023500	0.596	rs133369	ENSG00000227370.1	RP4-669P10.19	-6.79	5.09e-11	4.63e-08	-0.4	-0.34	Schizophrenia;	chr22:42067810	chr22:42132543~42132998:+
LIHC	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	6.79	5.1e-11	4.64e-08	0.43	0.34	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
LIHC	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-6.79	5.11e-11	4.65e-08	-0.43	-0.34	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
LIHC	cis	rs17270561	0.609	rs4132072	ENSG00000216436.2	HIST1H2APS1	-6.78	5.15e-11	4.69e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25717615	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs7453371	ENSG00000216436.2	HIST1H2APS1	-6.78	5.15e-11	4.69e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25719028	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs7450798	ENSG00000216436.2	HIST1H2APS1	-6.78	5.15e-11	4.69e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25719052	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4712957	ENSG00000216436.2	HIST1H2APS1	-6.78	5.15e-11	4.69e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25719586	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.666	rs17320090	ENSG00000216436.2	HIST1H2APS1	-6.78	5.15e-11	4.69e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25719987	chr6:25732497~25732827:+
LIHC	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	6.78	5.17e-11	4.7e-08	0.64	0.34	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
LIHC	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	6.78	5.18e-11	4.71e-08	0.45	0.34	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
LIHC	cis	rs1939012	0.846	rs11225395	ENSG00000281655.1	RP11-817J15.3	-6.78	5.21e-11	4.73e-08	-0.41	-0.34	Epilepsy;	chr11:102725749	chr11:102681310~102683913:+
LIHC	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-6.78	5.22e-11	4.75e-08	-0.47	-0.34	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
LIHC	cis	rs739496	0.579	rs3752630	ENSG00000226469.1	ADAM1B	6.78	5.24e-11	4.76e-08	0.44	0.34	Platelet count;	chr12:111938186	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7973309	ENSG00000226469.1	ADAM1B	6.78	5.24e-11	4.76e-08	0.44	0.34	Platelet count;	chr12:111944447	chr12:111927018~111929017:+
LIHC	cis	rs17270561	0.636	rs9393656	ENSG00000216436.2	HIST1H2APS1	-6.78	5.25e-11	4.76e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25721831	chr6:25732497~25732827:+
LIHC	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-6.78	5.27e-11	4.79e-08	-0.39	-0.34	QT interval;	chr12:29303562	chr12:29280418~29317848:-
LIHC	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	6.78	5.28e-11	4.8e-08	0.64	0.34	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
LIHC	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-6.78	5.3e-11	4.81e-08	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
LIHC	cis	rs6490294	0.851	rs1016079	ENSG00000226469.1	ADAM1B	-6.78	5.31e-11	4.82e-08	-0.44	-0.34	Mean platelet volume;	chr12:111972382	chr12:111927018~111929017:+
LIHC	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-6.78	5.32e-11	4.83e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
LIHC	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	6.78	5.33e-11	4.83e-08	0.47	0.34	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	6.78	5.33e-11	4.83e-08	0.47	0.34	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
LIHC	cis	rs6490294	0.528	rs12580175	ENSG00000226469.1	ADAM1B	6.78	5.36e-11	4.86e-08	0.51	0.34	Mean platelet volume;	chr12:111926708	chr12:111927018~111929017:+
LIHC	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	6.78	5.38e-11	4.88e-08	0.43	0.34	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	6.78	5.38e-11	4.88e-08	0.43	0.34	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
LIHC	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	6.78	5.39e-11	4.89e-08	0.44	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
LIHC	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	6.78	5.41e-11	4.9e-08	0.45	0.34	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	6.78	5.41e-11	4.91e-08	0.46	0.34	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
LIHC	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-6.78	5.42e-11	4.91e-08	-0.43	-0.34	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
LIHC	cis	rs1577917	0.57	rs114854865	ENSG00000234155.1	RP11-30P6.6	6.78	5.43e-11	4.92e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85844518	chr6:85387219~85390186:-
LIHC	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-6.78	5.45e-11	4.94e-08	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs3097773	ENSG00000205771.5	CATSPER2P1	6.77	5.45e-11	4.94e-08	0.47	0.34	Lung cancer in ever smokers;	chr15:43600874	chr15:43726918~43747094:-
LIHC	cis	rs1062753	0.771	rs5751245	ENSG00000237037.8	NDUFA6-AS1	-6.77	5.46e-11	4.95e-08	-0.39	-0.34	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42224934	chr22:42090931~42137742:+
LIHC	cis	rs6490294	0.528	rs12423268	ENSG00000226469.1	ADAM1B	6.77	5.48e-11	4.96e-08	0.52	0.34	Mean platelet volume;	chr12:112203903	chr12:111927018~111929017:+
LIHC	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	6.77	5.49e-11	4.97e-08	0.41	0.34	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
LIHC	cis	rs1939012	0.846	rs1939014	ENSG00000281655.1	RP11-817J15.3	-6.77	5.49e-11	4.97e-08	-0.4	-0.34	Epilepsy;	chr11:102727181	chr11:102681310~102683913:+
LIHC	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-6.77	5.51e-11	4.99e-08	-0.37	-0.34	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
LIHC	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	6.77	5.52e-11	5e-08	0.45	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
LIHC	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-6.77	5.53e-11	5e-08	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
LIHC	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-6.77	5.56e-11	5.03e-08	-0.42	-0.34	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
LIHC	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-6.77	5.56e-11	5.03e-08	-0.43	-0.34	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
LIHC	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	6.77	5.56e-11	5.03e-08	0.44	0.34	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
LIHC	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	6.77	5.57e-11	5.04e-08	0.37	0.34	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-6.77	5.58e-11	5.04e-08	-0.37	-0.34	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
LIHC	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-6.77	5.58e-11	5.05e-08	-0.42	-0.34	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
LIHC	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-6.77	5.6e-11	5.07e-08	-0.42	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
LIHC	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-6.77	5.6e-11	5.07e-08	-0.42	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
LIHC	cis	rs7396835	0.8	rs6589572	ENSG00000236267.1	AP006216.5	6.77	5.61e-11	5.07e-08	0.41	0.34	Quantitative traits;	chr11:116810847	chr11:116813204~116814003:-
LIHC	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-6.77	5.64e-11	5.09e-08	-0.45	-0.34	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	6.77	5.64e-11	5.09e-08	0.45	0.34	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
LIHC	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	6.77	5.65e-11	5.11e-08	0.4	0.34	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
LIHC	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	6.77	5.72e-11	5.16e-08	0.34	0.34	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	6.77	5.72e-11	5.16e-08	0.34	0.34	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	6.77	5.72e-11	5.16e-08	0.34	0.34	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
LIHC	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	6.77	5.74e-11	5.18e-08	0.51	0.34	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
LIHC	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	6.77	5.74e-11	5.18e-08	0.41	0.34	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
LIHC	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-6.77	5.75e-11	5.19e-08	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
LIHC	cis	rs6085948	0.861	rs6117729	ENSG00000238102.1	RP11-19D2.1	-6.77	5.76e-11	5.2e-08	-0.52	-0.34	Interleukin-10 levels;	chr20:7267542	chr20:7256580~7258214:-
LIHC	cis	rs6490294	0.528	rs61012856	ENSG00000226469.1	ADAM1B	6.77	5.79e-11	5.22e-08	0.51	0.34	Mean platelet volume;	chr12:111927687	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs59131168	ENSG00000226469.1	ADAM1B	6.77	5.79e-11	5.22e-08	0.51	0.34	Mean platelet volume;	chr12:111930559	chr12:111927018~111929017:+
LIHC	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-6.76	5.83e-11	5.26e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
LIHC	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-6.76	5.86e-11	5.28e-08	-0.42	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
LIHC	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-6.76	5.86e-11	5.28e-08	-0.42	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
LIHC	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-6.76	5.86e-11	5.28e-08	-0.42	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
LIHC	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-6.76	5.88e-11	5.3e-08	-0.29	-0.34	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
LIHC	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-6.76	5.94e-11	5.35e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-6.76	5.94e-11	5.35e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-6.76	5.94e-11	5.35e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-6.76	5.94e-11	5.35e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-6.76	5.94e-11	5.35e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-6.76	5.94e-11	5.35e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-6.76	5.94e-11	5.35e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
LIHC	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	6.76	5.95e-11	5.36e-08	0.35	0.34	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
LIHC	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-6.76	5.95e-11	5.36e-08	-0.41	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
LIHC	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-6.76	5.95e-11	5.36e-08	-0.41	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
LIHC	cis	rs9527	0.571	rs3740400	ENSG00000236937.2	PTGES3P4	6.76	5.97e-11	5.37e-08	0.41	0.34	Arsenic metabolism;	chr10:102869708	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.571	rs7904113	ENSG00000236937.2	PTGES3P4	6.76	6e-11	5.4e-08	0.41	0.34	Arsenic metabolism;	chr10:102873357	chr10:102845595~102845950:+
LIHC	cis	rs8028182	0.583	rs4886722	ENSG00000260269.4	CTD-2323K18.1	-6.76	6e-11	5.4e-08	-0.45	-0.34	Sudden cardiac arrest;	chr15:75629295	chr15:75527150~75601205:-
LIHC	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-6.76	6e-11	5.4e-08	-0.42	-0.34	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
LIHC	cis	rs9527	0.525	rs12770034	ENSG00000236937.2	PTGES3P4	6.76	6.03e-11	5.43e-08	0.41	0.34	Arsenic metabolism;	chr10:102875838	chr10:102845595~102845950:+
LIHC	cis	rs1577917	0.655	rs1059307	ENSG00000234155.1	RP11-30P6.6	-6.76	6.06e-11	5.45e-08	-0.41	-0.34	Response to antipsychotic treatment;	chr6:85678170	chr6:85387219~85390186:-
LIHC	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-6.76	6.11e-11	5.49e-08	-0.39	-0.34	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-6.76	6.11e-11	5.49e-08	-0.39	-0.34	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-6.76	6.11e-11	5.49e-08	-0.39	-0.34	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-6.76	6.11e-11	5.49e-08	-0.39	-0.34	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
LIHC	cis	rs10899021	1	rs10899021	ENSG00000279353.1	RP11-864N7.4	-6.76	6.14e-11	5.52e-08	-0.72	-0.34	Response to metformin (IC50);	chr11:74627009	chr11:74698231~74699658:-
LIHC	cis	rs1939012	0.846	rs10750653	ENSG00000281655.1	RP11-817J15.3	-6.76	6.14e-11	5.52e-08	-0.4	-0.34	Epilepsy;	chr11:102729275	chr11:102681310~102683913:+
LIHC	cis	rs1577917	1	rs35760725	ENSG00000234155.1	RP11-30P6.6	6.76	6.14e-11	5.52e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85939267	chr6:85387219~85390186:-
LIHC	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-6.76	6.15e-11	5.53e-08	-0.39	-0.34	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
LIHC	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	6.75	6.16e-11	5.54e-08	0.46	0.34	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
LIHC	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	6.75	6.18e-11	5.55e-08	0.4	0.34	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	6.75	6.18e-11	5.55e-08	0.4	0.34	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	6.75	6.18e-11	5.55e-08	0.4	0.34	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	6.75	6.18e-11	5.55e-08	0.4	0.34	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
LIHC	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-6.75	6.19e-11	5.56e-08	-0.5	-0.34	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
LIHC	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-6.75	6.2e-11	5.57e-08	-0.51	-0.34	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-6.75	6.2e-11	5.57e-08	-0.51	-0.34	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
LIHC	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	6.75	6.2e-11	5.57e-08	0.46	0.34	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	6.75	6.2e-11	5.57e-08	0.46	0.34	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	6.75	6.2e-11	5.57e-08	0.46	0.34	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
LIHC	cis	rs1023500	0.573	rs133381	ENSG00000227370.1	RP4-669P10.19	-6.75	6.21e-11	5.57e-08	-0.4	-0.34	Schizophrenia;	chr22:42074604	chr22:42132543~42132998:+
LIHC	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-6.75	6.22e-11	5.59e-08	-0.45	-0.34	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
LIHC	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-6.75	6.27e-11	5.63e-08	-0.42	-0.34	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-6.75	6.27e-11	5.63e-08	-0.43	-0.34	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
LIHC	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-6.75	6.29e-11	5.64e-08	-0.42	-0.34	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
LIHC	cis	rs1023500	0.551	rs2854837	ENSG00000227370.1	RP4-669P10.19	-6.75	6.35e-11	5.7e-08	-0.4	-0.34	Schizophrenia;	chr22:42062477	chr22:42132543~42132998:+
LIHC	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-6.75	6.46e-11	5.79e-08	-0.37	-0.34	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
LIHC	cis	rs6085948	0.861	rs6077169	ENSG00000238102.1	RP11-19D2.1	-6.75	6.46e-11	5.79e-08	-0.52	-0.34	Interleukin-10 levels;	chr20:7267815	chr20:7256580~7258214:-
LIHC	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	6.75	6.48e-11	5.8e-08	0.42	0.34	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
LIHC	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-6.75	6.49e-11	5.81e-08	-0.31	-0.34	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
LIHC	cis	rs6490294	0.851	rs56814171	ENSG00000226469.1	ADAM1B	6.75	6.49e-11	5.81e-08	0.44	0.34	Mean platelet volume;	chr12:111965146	chr12:111927018~111929017:+
LIHC	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	6.75	6.5e-11	5.82e-08	0.4	0.34	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	6.75	6.5e-11	5.82e-08	0.4	0.34	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	6.75	6.5e-11	5.82e-08	0.4	0.34	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	6.75	6.5e-11	5.82e-08	0.4	0.34	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	6.75	6.5e-11	5.82e-08	0.4	0.34	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	6.75	6.5e-11	5.82e-08	0.4	0.34	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	6.75	6.5e-11	5.82e-08	0.4	0.34	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
LIHC	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-6.75	6.52e-11	5.84e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-6.75	6.52e-11	5.84e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-6.75	6.52e-11	5.84e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-6.75	6.52e-11	5.84e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
LIHC	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	6.74	6.58e-11	5.89e-08	0.4	0.34	QT interval;	chr12:29284120	chr12:29280418~29317848:-
LIHC	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-6.74	6.59e-11	5.89e-08	-0.44	-0.34	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
LIHC	cis	rs932287	0.58	rs10743098	ENSG00000254860.4	TMEM9B-AS1	-6.74	6.6e-11	5.9e-08	-0.36	-0.34	Colonoscopy-negative controls vs population controls;	chr11:9038003	chr11:8964675~8977527:+
LIHC	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-6.74	6.6e-11	5.9e-08	-0.36	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
LIHC	cis	rs739496	0.579	rs3752631	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Platelet count;	chr12:111938353	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7959619	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Platelet count;	chr12:111938793	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs11066095	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Platelet count;	chr12:111939733	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs7133881	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Platelet count;	chr12:111940964	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.748	rs7295665	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Mean platelet volume;	chr12:111941467	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.614	rs7137889	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Platelet count;	chr12:111941783	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs80017658	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Platelet count;	chr12:111942568	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs73426362	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Platelet count;	chr12:111942666	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs12579298	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Mean platelet volume;	chr12:111956218	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs12306814	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Mean platelet volume;	chr12:111966009	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs12423061	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Mean platelet volume;	chr12:111967091	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs112426410	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Mean platelet volume;	chr12:111969634	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.904	rs9971871	ENSG00000226469.1	ADAM1B	6.74	6.61e-11	5.9e-08	0.44	0.34	Mean platelet volume;	chr12:111970572	chr12:111927018~111929017:+
LIHC	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	6.74	6.61e-11	5.9e-08	0.57	0.34	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
LIHC	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	6.74	6.62e-11	5.91e-08	0.62	0.34	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
LIHC	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	6.74	6.63e-11	5.92e-08	0.28	0.34	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
LIHC	cis	rs1577917	0.958	rs10455448	ENSG00000234155.1	RP11-30P6.6	6.74	6.64e-11	5.93e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85823893	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.917	rs13196576	ENSG00000234155.1	RP11-30P6.6	6.74	6.64e-11	5.93e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85824348	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs3857480	ENSG00000234155.1	RP11-30P6.6	6.74	6.64e-11	5.93e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85825431	chr6:85387219~85390186:-
LIHC	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	6.74	6.64e-11	5.93e-08	0.43	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
LIHC	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-6.74	6.65e-11	5.93e-08	-0.42	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
LIHC	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	6.74	6.68e-11	5.96e-08	0.4	0.34	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
LIHC	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-6.74	6.7e-11	5.98e-08	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.74	6.7e-11	5.98e-08	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
LIHC	cis	rs6490294	0.571	rs58886972	ENSG00000226469.1	ADAM1B	6.74	6.74e-11	6.01e-08	0.52	0.34	Mean platelet volume;	chr12:112071477	chr12:111927018~111929017:+
LIHC	cis	rs2734839	0.507	rs2245805	ENSG00000270179.1	RP11-159N11.4	-6.74	6.8e-11	6.06e-08	-0.39	-0.34	Information processing speed;	chr11:113419977	chr11:113368478~113369117:+
LIHC	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	6.74	6.83e-11	6.09e-08	0.39	0.34	Height;	chr11:118859432	chr11:118688039~118690600:-
LIHC	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-6.74	6.89e-11	6.14e-08	-0.45	-0.34	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
LIHC	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-6.74	6.95e-11	6.19e-08	-0.35	-0.34	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-6.74	6.95e-11	6.19e-08	-0.35	-0.34	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
LIHC	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-6.73	6.96e-11	6.2e-08	-0.45	-0.34	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-6.73	6.96e-11	6.2e-08	-0.45	-0.34	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
LIHC	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-6.73	6.99e-11	6.22e-08	-0.38	-0.34	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.958	rs4707229	ENSG00000234155.1	RP11-30P6.6	6.73	7e-11	6.23e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85836519	chr6:85387219~85390186:-
LIHC	cis	rs2243480	0.908	rs4718273	ENSG00000164669.11	INTS4P1	-6.73	7.01e-11	6.24e-08	-0.6	-0.34	Diabetic kidney disease;	chr7:65751112	chr7:65141225~65234216:+
LIHC	cis	rs4820294	1	rs929039	ENSG00000233360.4	Z83844.1	6.73	7.06e-11	6.28e-08	0.44	0.34	Fat distribution (HIV);	chr22:37675504	chr22:37641832~37658377:-
LIHC	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-6.73	7.09e-11	6.31e-08	-0.36	-0.34	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
LIHC	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-6.73	7.1e-11	6.31e-08	-0.45	-0.34	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-6.73	7.11e-11	6.32e-08	-0.46	-0.34	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
LIHC	cis	rs3020736	0.5	rs4147638	ENSG00000227370.1	RP4-669P10.19	6.73	7.13e-11	6.33e-08	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6002605	ENSG00000227370.1	RP4-669P10.19	6.73	7.13e-11	6.33e-08	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42132543~42132998:+
LIHC	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	6.73	7.13e-11	6.34e-08	0.58	0.34	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
LIHC	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	6.73	7.17e-11	6.37e-08	0.38	0.34	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
LIHC	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	6.73	7.17e-11	6.38e-08	0.4	0.34	Height;	chr11:118852670	chr11:118688039~118690600:-
LIHC	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-6.73	7.2e-11	6.39e-08	-0.45	-0.34	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
LIHC	cis	rs1023500	0.573	rs2413666	ENSG00000227370.1	RP4-669P10.19	-6.73	7.2e-11	6.4e-08	-0.4	-0.34	Schizophrenia;	chr22:42063618	chr22:42132543~42132998:+
LIHC	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	6.73	7.24e-11	6.43e-08	0.46	0.34	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
LIHC	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	6.73	7.29e-11	6.48e-08	0.39	0.34	Height;	chr11:118860890	chr11:118688039~118690600:-
LIHC	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	6.73	7.29e-11	6.48e-08	0.39	0.34	Height;	chr11:118861053	chr11:118688039~118690600:-
LIHC	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	6.73	7.31e-11	6.49e-08	0.36	0.34	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
LIHC	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-6.73	7.33e-11	6.51e-08	-0.32	-0.34	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
LIHC	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	6.73	7.35e-11	6.53e-08	0.36	0.34	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	6.73	7.35e-11	6.53e-08	0.36	0.34	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	6.73	7.35e-11	6.53e-08	0.36	0.34	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
LIHC	cis	rs55665837	0.701	rs12787709	ENSG00000251991.1	RNU7-49P	6.73	7.36e-11	6.53e-08	0.39	0.34	Vitamin D levels;	chr11:14617711	chr11:14478892~14478953:+
LIHC	cis	rs7580658	0.68	rs2069931	ENSG00000236682.1	AC068282.3	-6.73	7.39e-11	6.55e-08	-0.43	-0.34	Protein C levels;	chr2:127427993	chr2:127389130~127400580:+
LIHC	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-6.72	7.39e-11	6.56e-08	-0.42	-0.34	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
LIHC	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-6.72	7.45e-11	6.61e-08	-0.55	-0.34	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
LIHC	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-6.72	7.47e-11	6.62e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
LIHC	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-6.72	7.52e-11	6.66e-08	-0.45	-0.34	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-6.72	7.52e-11	6.66e-08	-0.45	-0.34	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
LIHC	cis	rs1023500	0.573	rs6002592	ENSG00000227370.1	RP4-669P10.19	6.72	7.53e-11	6.68e-08	0.39	0.34	Schizophrenia;	chr22:42080750	chr22:42132543~42132998:+
LIHC	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-6.72	7.56e-11	6.7e-08	-0.34	-0.34	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
LIHC	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	6.72	7.59e-11	6.73e-08	0.39	0.34	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
LIHC	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	6.72	7.6e-11	6.74e-08	0.34	0.34	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
LIHC	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-6.72	7.62e-11	6.75e-08	-0.43	-0.34	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
LIHC	cis	rs6490294	0.528	rs16941724	ENSG00000226469.1	ADAM1B	6.72	7.66e-11	6.79e-08	0.51	0.34	Mean platelet volume;	chr12:111889253	chr12:111927018~111929017:+
LIHC	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-6.72	7.68e-11	6.8e-08	-0.42	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
LIHC	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-6.72	7.68e-11	6.8e-08	-0.34	-0.34	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-6.72	7.68e-11	6.8e-08	-0.34	-0.34	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
LIHC	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-6.72	7.68e-11	6.8e-08	-0.34	-0.34	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-6.72	7.68e-11	6.8e-08	-0.34	-0.34	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-6.72	7.68e-11	6.8e-08	-0.34	-0.34	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
LIHC	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-6.72	7.69e-11	6.81e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-6.72	7.69e-11	6.81e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
LIHC	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	6.72	7.78e-11	6.88e-08	0.34	0.34	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
LIHC	cis	rs4718428	0.576	rs12698546	ENSG00000226824.5	RP4-756H11.3	-6.72	7.82e-11	6.92e-08	-0.46	-0.34	Corneal structure;	chr7:66801919	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs4718270	ENSG00000164669.11	INTS4P1	6.72	7.83e-11	6.92e-08	0.59	0.34	Diabetic kidney disease;	chr7:65737415	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs2900904	ENSG00000164669.11	INTS4P1	6.72	7.83e-11	6.92e-08	0.59	0.34	Diabetic kidney disease;	chr7:65739282	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs6460260	ENSG00000164669.11	INTS4P1	-6.72	7.83e-11	6.92e-08	-0.59	-0.34	Diabetic kidney disease;	chr7:65750468	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs6460261	ENSG00000164669.11	INTS4P1	-6.72	7.83e-11	6.92e-08	-0.59	-0.34	Diabetic kidney disease;	chr7:65750593	chr7:65141225~65234216:+
LIHC	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	6.71	7.89e-11	6.97e-08	0.58	0.34	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	6.71	7.89e-11	6.97e-08	0.58	0.34	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
LIHC	cis	rs6490294	0.615	rs78729142	ENSG00000226469.1	ADAM1B	6.71	7.91e-11	6.99e-08	0.51	0.34	Mean platelet volume;	chr12:111919456	chr12:111927018~111929017:+
LIHC	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	6.71	7.94e-11	7.02e-08	0.42	0.34	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
LIHC	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	6.71	7.95e-11	7.02e-08	0.61	0.34	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
LIHC	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-6.71	7.96e-11	7.03e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	6.71	8.01e-11	7.07e-08	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
LIHC	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	6.71	8.08e-11	7.13e-08	0.34	0.34	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
LIHC	cis	rs6085948	0.861	rs6085954	ENSG00000238102.1	RP11-19D2.1	-6.71	8.1e-11	7.15e-08	-0.65	-0.34	Interleukin-10 levels;	chr20:7257602	chr20:7256580~7258214:-
LIHC	cis	rs9843304	0.616	rs34783865	ENSG00000244503.1	RP11-278L15.6	6.71	8.15e-11	7.19e-08	0.37	0.34	Gallstone disease;	chr3:149488005	chr3:149494660~149495995:+
LIHC	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-6.71	8.17e-11	7.21e-08	-0.45	-0.34	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
LIHC	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	6.71	8.19e-11	7.23e-08	0.39	0.34	QT interval;	chr12:29304617	chr12:29280418~29317848:-
LIHC	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	6.71	8.2e-11	7.23e-08	0.39	0.34	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
LIHC	cis	rs17270561	0.609	rs12529272	ENSG00000216436.2	HIST1H2APS1	-6.71	8.21e-11	7.24e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25731114	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9393659	ENSG00000216436.2	HIST1H2APS1	-6.71	8.21e-11	7.24e-08	-0.42	-0.34	Iron status biomarkers;	chr6:25731130	chr6:25732497~25732827:+
LIHC	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-6.71	8.27e-11	7.29e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
LIHC	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	6.71	8.27e-11	7.3e-08	0.49	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
LIHC	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	6.71	8.27e-11	7.3e-08	0.45	0.34	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	6.71	8.27e-11	7.3e-08	0.45	0.34	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	6.71	8.27e-11	7.3e-08	0.45	0.34	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
LIHC	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-6.71	8.33e-11	7.34e-08	-0.35	-0.34	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
LIHC	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-6.7	8.35e-11	7.36e-08	-0.36	-0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
LIHC	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-6.7	8.38e-11	7.38e-08	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
LIHC	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-6.7	8.38e-11	7.39e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
LIHC	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-6.7	8.39e-11	7.4e-08	-0.35	-0.34	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
LIHC	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-6.7	8.44e-11	7.43e-08	-0.36	-0.34	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
LIHC	cis	rs2734839	0.507	rs1076562	ENSG00000270179.1	RP11-159N11.4	-6.7	8.49e-11	7.47e-08	-0.38	-0.34	Information processing speed;	chr11:113425286	chr11:113368478~113369117:+
LIHC	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	6.7	8.52e-11	7.49e-08	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
LIHC	cis	rs2735413	0.564	rs1882595	ENSG00000276007.1	RP11-358L22.3	6.7	8.53e-11	7.5e-08	0.46	0.34	Systolic blood pressure (alcohol consumption interaction);	chr16:78066787	chr16:78123243~78124332:+
LIHC	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-6.7	8.53e-11	7.5e-08	-0.36	-0.34	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
LIHC	cis	rs739496	0.653	rs11613713	ENSG00000226469.1	ADAM1B	6.7	8.54e-11	7.51e-08	0.46	0.34	Platelet count;	chr12:111779334	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs79976090	ENSG00000226469.1	ADAM1B	6.7	8.54e-11	7.51e-08	0.51	0.34	Mean platelet volume;	chr12:111928314	chr12:111927018~111929017:+
LIHC	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	6.7	8.55e-11	7.51e-08	0.36	0.34	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
LIHC	cis	rs1023500	0.596	rs5758562	ENSG00000227370.1	RP4-669P10.19	-6.7	8.62e-11	7.57e-08	-0.4	-0.34	Schizophrenia;	chr22:42052234	chr22:42132543~42132998:+
LIHC	cis	rs1023500	0.596	rs5751209	ENSG00000227370.1	RP4-669P10.19	-6.7	8.62e-11	7.57e-08	-0.4	-0.34	Schizophrenia;	chr22:42055599	chr22:42132543~42132998:+
LIHC	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-6.7	8.68e-11	7.63e-08	-0.5	-0.34	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-6.7	8.68e-11	7.63e-08	-0.5	-0.34	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
LIHC	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	6.7	8.7e-11	7.64e-08	0.33	0.34	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
LIHC	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-6.7	8.71e-11	7.65e-08	-0.38	-0.34	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
LIHC	cis	rs1577917	0.739	rs9344532	ENSG00000234155.1	RP11-30P6.6	-6.7	8.72e-11	7.66e-08	-0.42	-0.34	Response to antipsychotic treatment;	chr6:85524352	chr6:85387219~85390186:-
LIHC	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-6.7	8.73e-11	7.66e-08	-0.39	-0.34	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
LIHC	cis	rs3020736	0.5	rs6002597	ENSG00000227370.1	RP4-669P10.19	6.7	8.76e-11	7.69e-08	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs7292241	ENSG00000227370.1	RP4-669P10.19	6.7	8.76e-11	7.69e-08	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs6002603	ENSG00000227370.1	RP4-669P10.19	6.7	8.76e-11	7.69e-08	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs5996111	ENSG00000227370.1	RP4-669P10.19	6.7	8.76e-11	7.69e-08	0.4	0.34	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42132543~42132998:+
LIHC	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-6.7	8.76e-11	7.69e-08	-0.33	-0.34	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
LIHC	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-6.7	8.78e-11	7.7e-08	-0.43	-0.34	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
LIHC	cis	rs1939012	0.846	rs6590985	ENSG00000281655.1	RP11-817J15.3	-6.7	8.78e-11	7.71e-08	-0.4	-0.34	Epilepsy;	chr11:102727924	chr11:102681310~102683913:+
LIHC	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	6.7	8.81e-11	7.73e-08	0.46	0.34	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
LIHC	cis	rs1577917	1	rs2816815	ENSG00000234155.1	RP11-30P6.6	6.7	8.83e-11	7.75e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85981938	chr6:85387219~85390186:-
LIHC	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-6.69	8.86e-11	7.77e-08	-0.37	-0.34	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
LIHC	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-6.69	8.9e-11	7.8e-08	-0.38	-0.34	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-6.69	8.9e-11	7.8e-08	-0.38	-0.34	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
LIHC	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-6.69	8.93e-11	7.83e-08	-0.42	-0.34	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
LIHC	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-6.69	8.93e-11	7.83e-08	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
LIHC	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-6.69	8.97e-11	7.87e-08	-0.39	-0.34	QT interval;	chr12:29300845	chr12:29280418~29317848:-
LIHC	cis	rs62229266	1	rs62229266	ENSG00000231106.2	LINC01436	6.69	8.99e-11	7.88e-08	0.37	0.34	Mitral valve prolapse;	chr21:36087973	chr21:36005338~36007838:+
LIHC	cis	rs9527	0.571	rs12765337	ENSG00000236937.2	PTGES3P4	6.69	9.02e-11	7.9e-08	0.41	0.34	Arsenic metabolism;	chr10:102875587	chr10:102845595~102845950:+
LIHC	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-6.69	9.04e-11	7.92e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
LIHC	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-6.69	9.07e-11	7.95e-08	-0.42	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
LIHC	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-6.69	9.08e-11	7.95e-08	-0.4	-0.34	QT interval;	chr12:29349303	chr12:29280418~29317848:-
LIHC	cis	rs1939012	0.846	rs948218	ENSG00000281655.1	RP11-817J15.3	-6.69	9.13e-11	7.99e-08	-0.4	-0.34	Epilepsy;	chr11:102722311	chr11:102681310~102683913:+
LIHC	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-6.69	9.13e-11	8e-08	-0.48	-0.34	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
LIHC	cis	rs1577917	0.958	rs1414199	ENSG00000234155.1	RP11-30P6.6	6.69	9.15e-11	8.01e-08	0.41	0.34	Response to antipsychotic treatment;	chr6:85812652	chr6:85387219~85390186:-
LIHC	cis	rs739496	0.615	rs11609628	ENSG00000226469.1	ADAM1B	6.69	9.15e-11	8.01e-08	0.45	0.34	Platelet count;	chr12:111779404	chr12:111927018~111929017:+
LIHC	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-6.69	9.15e-11	8.01e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-6.69	9.15e-11	8.01e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-6.69	9.15e-11	8.01e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
LIHC	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	6.69	9.19e-11	8.05e-08	0.34	0.34	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
LIHC	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-6.69	9.19e-11	8.05e-08	-0.46	-0.34	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
LIHC	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-6.69	9.2e-11	8.05e-08	-0.45	-0.34	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
LIHC	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	6.69	9.21e-11	8.06e-08	0.41	0.34	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
LIHC	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	6.69	9.21e-11	8.06e-08	0.41	0.34	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
LIHC	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	6.69	9.23e-11	8.07e-08	0.4	0.34	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
LIHC	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-6.69	9.24e-11	8.08e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
LIHC	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-6.69	9.38e-11	8.2e-08	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
LIHC	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-6.69	9.4e-11	8.22e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
LIHC	cis	rs8028182	0.525	rs9920028	ENSG00000260269.4	CTD-2323K18.1	-6.68	9.45e-11	8.26e-08	-0.44	-0.34	Sudden cardiac arrest;	chr15:75635376	chr15:75527150~75601205:-
LIHC	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-6.68	9.48e-11	8.29e-08	-0.34	-0.34	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
LIHC	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-6.68	9.51e-11	8.31e-08	-0.43	-0.34	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
LIHC	cis	rs1023500	0.596	rs133350	ENSG00000227370.1	RP4-669P10.19	-6.68	9.56e-11	8.35e-08	-0.4	-0.34	Schizophrenia;	chr22:42033045	chr22:42132543~42132998:+
LIHC	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-6.68	9.58e-11	8.37e-08	-0.44	-0.34	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
LIHC	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-6.68	9.61e-11	8.39e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
LIHC	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	6.68	9.61e-11	8.39e-08	0.58	0.34	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
LIHC	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	6.68	9.65e-11	8.43e-08	0.46	0.34	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	6.68	9.65e-11	8.43e-08	0.46	0.34	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
LIHC	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	6.68	9.68e-11	8.44e-08	0.4	0.34	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
LIHC	cis	rs2735413	0.564	rs78769909	ENSG00000276007.1	RP11-358L22.3	6.68	9.69e-11	8.45e-08	0.48	0.34	Systolic blood pressure (alcohol consumption interaction);	chr16:78070105	chr16:78123243~78124332:+
LIHC	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-6.68	9.7e-11	8.46e-08	-0.39	-0.34	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
LIHC	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-6.68	9.7e-11	8.46e-08	-0.28	-0.34	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
LIHC	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-6.68	9.75e-11	8.5e-08	-0.36	-0.34	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
LIHC	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-6.68	9.77e-11	8.52e-08	-0.31	-0.34	Breast cancer;	chr11:743813	chr11:781645~782105:+
LIHC	cis	rs8028182	0.501	rs7166281	ENSG00000260269.4	CTD-2323K18.1	6.68	9.78e-11	8.52e-08	0.43	0.34	Sudden cardiac arrest;	chr15:75635851	chr15:75527150~75601205:-
LIHC	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-6.68	9.78e-11	8.53e-08	-0.49	-0.34	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
LIHC	cis	rs1577917	0.74	rs6926049	ENSG00000234155.1	RP11-30P6.6	-6.68	9.85e-11	8.59e-08	-0.43	-0.34	Response to antipsychotic treatment;	chr6:85556415	chr6:85387219~85390186:-
LIHC	cis	rs12681287	0.752	rs4427148	ENSG00000250569.1	NTAN1P2	6.68	9.86e-11	8.59e-08	0.41	0.34	Caudate activity during reward;	chr8:86238439	chr8:86481754~86483002:-
LIHC	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-6.68	9.87e-11	8.6e-08	-0.39	-0.34	QT interval;	chr12:29287150	chr12:29280418~29317848:-
LIHC	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	6.68	9.9e-11	8.62e-08	0.46	0.34	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
LIHC	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	6.68	9.92e-11	8.64e-08	0.38	0.34	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
LIHC	cis	rs7914558	0.752	rs7896519	ENSG00000236937.2	PTGES3P4	6.68	9.92e-11	8.64e-08	0.41	0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102845595~102845950:+
LIHC	cis	rs916888	0.821	rs199504	ENSG00000262881.1	RP11-669E14.4	6.68	9.95e-11	8.66e-08	0.54	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45907670~45910779:-
LIHC	cis	rs1939012	0.967	rs3758859	ENSG00000281655.1	RP11-817J15.3	-6.67	1e-10	8.74e-08	-0.39	-0.34	Epilepsy;	chr11:102727749	chr11:102681310~102683913:+
LIHC	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-6.67	1e-10	8.74e-08	-0.46	-0.34	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
LIHC	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-6.67	1.01e-10	8.78e-08	-0.44	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
LIHC	cis	rs916888	0.773	rs9896243	ENSG00000262881.1	RP11-669E14.4	-6.67	1.01e-10	8.79e-08	-0.52	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45907670~45910779:-
LIHC	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	6.67	1.01e-10	8.83e-08	0.39	0.34	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	6.67	1.01e-10	8.83e-08	0.39	0.34	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
LIHC	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	6.67	1.02e-10	8.84e-08	0.4	0.34	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
LIHC	cis	rs12681287	0.752	rs10104138	ENSG00000250569.1	NTAN1P2	6.67	1.02e-10	8.89e-08	0.41	0.34	Caudate activity during reward;	chr8:86235430	chr8:86481754~86483002:-
LIHC	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	6.67	1.02e-10	8.89e-08	0.48	0.34	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
LIHC	cis	rs2243480	1	rs56291018	ENSG00000164669.11	INTS4P1	6.67	1.02e-10	8.9e-08	0.6	0.34	Diabetic kidney disease;	chr7:65925352	chr7:65141225~65234216:+
LIHC	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	6.67	1.03e-10	8.92e-08	0.46	0.34	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	6.67	1.03e-10	8.92e-08	0.46	0.34	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
LIHC	cis	rs1939012	0.704	rs2186602	ENSG00000281655.1	RP11-817J15.3	-6.67	1.05e-10	9.11e-08	-0.4	-0.34	Epilepsy;	chr11:102721214	chr11:102681310~102683913:+
LIHC	cis	rs1577917	0.916	rs4706252	ENSG00000234155.1	RP11-30P6.6	6.67	1.05e-10	9.12e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85845462	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12202188	ENSG00000234155.1	RP11-30P6.6	6.67	1.05e-10	9.12e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85852982	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs36035797	ENSG00000234155.1	RP11-30P6.6	6.67	1.05e-10	9.12e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85853162	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.917	rs2084293	ENSG00000234155.1	RP11-30P6.6	6.67	1.05e-10	9.12e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85856284	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12209668	ENSG00000234155.1	RP11-30P6.6	6.67	1.05e-10	9.12e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85856799	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs11752180	ENSG00000234155.1	RP11-30P6.6	6.67	1.05e-10	9.12e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85863447	chr6:85387219~85390186:-
LIHC	cis	rs4820294	0.926	rs62236671	ENSG00000233360.4	Z83844.1	6.67	1.05e-10	9.14e-08	0.43	0.34	Fat distribution (HIV);	chr22:37673298	chr22:37641832~37658377:-
LIHC	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-6.67	1.06e-10	9.14e-08	-0.43	-0.34	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
LIHC	cis	rs2734839	0.507	rs2002453	ENSG00000270179.1	RP11-159N11.4	-6.67	1.06e-10	9.14e-08	-0.38	-0.34	Information processing speed;	chr11:113418576	chr11:113368478~113369117:+
LIHC	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-6.67	1.06e-10	9.16e-08	-0.37	-0.34	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
LIHC	cis	rs2243480	1	rs437889	ENSG00000164669.11	INTS4P1	6.67	1.06e-10	9.16e-08	0.58	0.34	Diabetic kidney disease;	chr7:66044247	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs402418	ENSG00000164669.11	INTS4P1	6.67	1.06e-10	9.16e-08	0.58	0.34	Diabetic kidney disease;	chr7:66044482	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs423187	ENSG00000164669.11	INTS4P1	6.67	1.06e-10	9.16e-08	0.58	0.34	Diabetic kidney disease;	chr7:66044512	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs431318	ENSG00000164669.11	INTS4P1	6.67	1.06e-10	9.16e-08	0.58	0.34	Diabetic kidney disease;	chr7:66046610	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs73150014	ENSG00000164669.11	INTS4P1	6.67	1.06e-10	9.17e-08	0.59	0.34	Diabetic kidney disease;	chr7:65985932	chr7:65141225~65234216:+
LIHC	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-6.67	1.06e-10	9.18e-08	-0.38	-0.34	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
LIHC	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	6.66	1.07e-10	9.23e-08	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
LIHC	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-6.66	1.07e-10	9.23e-08	-0.39	-0.34	QT interval;	chr12:29302457	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-6.66	1.07e-10	9.23e-08	-0.39	-0.34	QT interval;	chr12:29302458	chr12:29280418~29317848:-
LIHC	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-6.66	1.07e-10	9.28e-08	-0.49	-0.34	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
LIHC	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	6.66	1.07e-10	9.29e-08	0.42	0.34	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
LIHC	cis	rs9843304	0.721	rs4681176	ENSG00000244503.1	RP11-278L15.6	6.66	1.07e-10	9.29e-08	0.35	0.34	Gallstone disease;	chr3:149484167	chr3:149494660~149495995:+
LIHC	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-6.66	1.07e-10	9.3e-08	-0.41	-0.34	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
LIHC	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-6.66	1.08e-10	9.32e-08	-0.39	-0.34	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
LIHC	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	6.66	1.1e-10	9.47e-08	0.42	0.34	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
LIHC	cis	rs2243480	1	rs3885839	ENSG00000164669.11	INTS4P1	6.66	1.1e-10	9.49e-08	0.6	0.34	Diabetic kidney disease;	chr7:65825416	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs3813708	ENSG00000164669.11	INTS4P1	6.66	1.1e-10	9.49e-08	0.6	0.34	Diabetic kidney disease;	chr7:65840645	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs73142122	ENSG00000164669.11	INTS4P1	6.66	1.1e-10	9.49e-08	0.6	0.34	Diabetic kidney disease;	chr7:65846311	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs73142137	ENSG00000164669.11	INTS4P1	6.66	1.1e-10	9.49e-08	0.6	0.34	Diabetic kidney disease;	chr7:65878455	chr7:65141225~65234216:+
LIHC	cis	rs9843304	0.721	rs13062142	ENSG00000244503.1	RP11-278L15.6	6.66	1.1e-10	9.53e-08	0.35	0.34	Gallstone disease;	chr3:149484196	chr3:149494660~149495995:+
LIHC	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	6.66	1.11e-10	9.55e-08	0.39	0.34	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	6.66	1.11e-10	9.55e-08	0.39	0.34	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	6.66	1.11e-10	9.55e-08	0.39	0.34	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
LIHC	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-6.66	1.11e-10	9.58e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-6.66	1.11e-10	9.58e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-6.66	1.11e-10	9.58e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-6.66	1.11e-10	9.58e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-6.66	1.11e-10	9.58e-08	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
LIHC	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	6.66	1.11e-10	9.59e-08	0.39	0.34	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
LIHC	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-6.66	1.11e-10	9.6e-08	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
LIHC	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	6.66	1.11e-10	9.6e-08	0.54	0.34	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-6.66	1.11e-10	9.6e-08	-0.54	-0.34	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
LIHC	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	6.66	1.12e-10	9.65e-08	0.44	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
LIHC	cis	rs6490294	0.651	rs440	ENSG00000226469.1	ADAM1B	6.66	1.12e-10	9.66e-08	0.45	0.34	Mean platelet volume;	chr12:111790910	chr12:111927018~111929017:+
LIHC	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	6.66	1.12e-10	9.67e-08	0.5	0.34	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
LIHC	cis	rs1577917	0.916	rs7759727	ENSG00000234155.1	RP11-30P6.6	6.66	1.12e-10	9.67e-08	0.4	0.34	Response to antipsychotic treatment;	chr6:85809160	chr6:85387219~85390186:-
LIHC	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-6.66	1.12e-10	9.68e-08	-0.32	-0.34	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
LIHC	cis	rs1023500	0.551	rs133379	ENSG00000227370.1	RP4-669P10.19	-6.66	1.12e-10	9.7e-08	-0.4	-0.34	Schizophrenia;	chr22:42072531	chr22:42132543~42132998:+
LIHC	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-6.66	1.13e-10	9.71e-08	-0.46	-0.34	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
LIHC	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-6.65	1.13e-10	9.78e-08	-0.42	-0.34	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
LIHC	cis	rs7580658	0.963	rs9789510	ENSG00000236682.1	AC068282.3	-6.65	1.14e-10	9.79e-08	-0.43	-0.34	Protein C levels;	chr2:127379436	chr2:127389130~127400580:+
LIHC	cis	rs875971	0.545	rs4441996	ENSG00000164669.11	INTS4P1	6.65	1.14e-10	9.8e-08	0.46	0.34	Aortic root size;	chr7:66123233	chr7:65141225~65234216:+
LIHC	cis	rs6490294	0.8	rs78783055	ENSG00000226469.1	ADAM1B	6.65	1.14e-10	9.8e-08	0.45	0.34	Mean platelet volume;	chr12:111795691	chr12:111927018~111929017:+
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	6.65	1.14e-10	9.82e-08	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
LIHC	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	6.65	1.14e-10	9.84e-08	0.54	0.34	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
LIHC	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	6.65	1.14e-10	9.85e-08	0.46	0.34	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
LIHC	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	6.65	1.14e-10	9.86e-08	0.33	0.34	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	6.65	1.14e-10	9.86e-08	0.33	0.34	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
LIHC	cis	rs739496	0.615	rs4646777	ENSG00000226469.1	ADAM1B	6.65	1.15e-10	9.89e-08	0.45	0.34	Platelet count;	chr12:111792232	chr12:111927018~111929017:+
LIHC	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	6.65	1.15e-10	9.91e-08	0.38	0.34	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
LIHC	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-6.65	1.16e-10	1e-07	-0.38	-0.34	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
LIHC	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-6.65	1.17e-10	1.01e-07	-0.47	-0.34	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
LIHC	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-6.65	1.17e-10	1.01e-07	-0.39	-0.34	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
LIHC	cis	rs1023500	0.573	rs13057094	ENSG00000227370.1	RP4-669P10.19	-6.65	1.17e-10	1.01e-07	-0.4	-0.34	Schizophrenia;	chr22:42074313	chr22:42132543~42132998:+
LIHC	cis	rs2243480	1	rs1723269	ENSG00000164669.11	INTS4P1	6.65	1.17e-10	1.01e-07	0.58	0.34	Diabetic kidney disease;	chr7:66007799	chr7:65141225~65234216:+
LIHC	cis	rs1577917	1	rs4706254	ENSG00000234155.1	RP11-30P6.6	6.65	1.17e-10	1.01e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85893095	chr6:85387219~85390186:-
LIHC	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	6.65	1.17e-10	1.01e-07	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
LIHC	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-6.65	1.17e-10	1.01e-07	-0.35	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
LIHC	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	6.65	1.17e-10	1.01e-07	0.43	0.34	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
LIHC	cis	rs2243480	1	rs34970380	ENSG00000164669.11	INTS4P1	6.65	1.18e-10	1.01e-07	0.59	0.34	Diabetic kidney disease;	chr7:65966506	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs73148097	ENSG00000164669.11	INTS4P1	6.65	1.18e-10	1.01e-07	0.59	0.34	Diabetic kidney disease;	chr7:65966800	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs906134	ENSG00000164669.11	INTS4P1	6.65	1.18e-10	1.01e-07	0.59	0.34	Diabetic kidney disease;	chr7:65979301	chr7:65141225~65234216:+
LIHC	cis	rs1939012	0.811	rs7123658	ENSG00000281655.1	RP11-817J15.3	-6.65	1.18e-10	1.02e-07	-0.41	-0.34	Epilepsy;	chr11:102723248	chr11:102681310~102683913:+
LIHC	cis	rs17270561	0.583	rs7765833	ENSG00000216436.2	HIST1H2APS1	-6.65	1.19e-10	1.02e-07	-0.43	-0.34	Iron status biomarkers;	chr6:25712205	chr6:25732497~25732827:+
LIHC	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.65	1.19e-10	1.02e-07	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
LIHC	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	6.65	1.19e-10	1.02e-07	0.5	0.34	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
LIHC	cis	rs6490294	0.528	rs12579336	ENSG00000226469.1	ADAM1B	6.64	1.2e-10	1.03e-07	0.51	0.34	Mean platelet volume;	chr12:112177734	chr12:111927018~111929017:+
LIHC	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-6.64	1.2e-10	1.03e-07	-0.43	-0.34	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
LIHC	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	6.64	1.2e-10	1.03e-07	0.28	0.34	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
LIHC	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-6.64	1.2e-10	1.03e-07	-0.42	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
LIHC	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-6.64	1.21e-10	1.04e-07	-0.43	-0.34	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
LIHC	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-6.64	1.22e-10	1.05e-07	-0.44	-0.34	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
LIHC	cis	rs17270561	0.609	rs17267614	ENSG00000216436.2	HIST1H2APS1	-6.64	1.23e-10	1.05e-07	-0.42	-0.34	Iron status biomarkers;	chr6:25729799	chr6:25732497~25732827:+
LIHC	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-6.64	1.23e-10	1.05e-07	-0.46	-0.34	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
LIHC	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-6.64	1.23e-10	1.06e-07	-0.38	-0.34	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
LIHC	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	6.64	1.23e-10	1.06e-07	0.46	0.34	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
LIHC	cis	rs12681287	0.752	rs4463401	ENSG00000250569.1	NTAN1P2	6.64	1.23e-10	1.06e-07	0.41	0.34	Caudate activity during reward;	chr8:86238080	chr8:86481754~86483002:-
LIHC	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	6.64	1.24e-10	1.06e-07	0.4	0.34	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
LIHC	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-6.64	1.24e-10	1.07e-07	-0.42	-0.34	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
LIHC	cis	rs12681287	0.752	rs10111095	ENSG00000250569.1	NTAN1P2	6.64	1.25e-10	1.07e-07	0.41	0.34	Caudate activity during reward;	chr8:86238755	chr8:86481754~86483002:-
LIHC	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-6.64	1.26e-10	1.08e-07	-0.45	-0.34	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
LIHC	cis	rs739496	0.615	rs4648328	ENSG00000226469.1	ADAM1B	6.63	1.28e-10	1.1e-07	0.45	0.34	Platelet count;	chr12:111784984	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.958	rs7739241	ENSG00000234155.1	RP11-30P6.6	6.63	1.28e-10	1.1e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85866078	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12202712	ENSG00000234155.1	RP11-30P6.6	6.63	1.28e-10	1.1e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85868823	chr6:85387219~85390186:-
LIHC	cis	rs2243480	1	rs781150	ENSG00000164669.11	INTS4P1	6.63	1.28e-10	1.1e-07	0.58	0.34	Diabetic kidney disease;	chr7:66015986	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs313798	ENSG00000164669.11	INTS4P1	6.63	1.28e-10	1.1e-07	0.58	0.34	Diabetic kidney disease;	chr7:66028044	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35396113	ENSG00000164669.11	INTS4P1	6.63	1.28e-10	1.1e-07	0.58	0.34	Diabetic kidney disease;	chr7:66030474	chr7:65141225~65234216:+
LIHC	cis	rs1577917	0.958	rs12213431	ENSG00000234155.1	RP11-30P6.6	6.63	1.29e-10	1.1e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85791238	chr6:85387219~85390186:-
LIHC	cis	rs7914558	0.966	rs10786719	ENSG00000236937.2	PTGES3P4	-6.63	1.29e-10	1.1e-07	-0.4	-0.34	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102845595~102845950:+
LIHC	cis	rs6490294	0.571	rs11066119	ENSG00000226469.1	ADAM1B	6.63	1.3e-10	1.11e-07	0.46	0.34	Mean platelet volume;	chr12:111996700	chr12:111927018~111929017:+
LIHC	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	6.63	1.3e-10	1.11e-07	0.39	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
LIHC	cis	rs2243480	1	rs313814	ENSG00000164669.11	INTS4P1	6.63	1.31e-10	1.12e-07	0.58	0.34	Diabetic kidney disease;	chr7:66038306	chr7:65141225~65234216:+
LIHC	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	6.63	1.32e-10	1.13e-07	0.46	0.34	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	6.63	1.32e-10	1.13e-07	0.46	0.34	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	6.63	1.32e-10	1.13e-07	0.46	0.34	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	6.63	1.32e-10	1.13e-07	0.46	0.34	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
LIHC	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	6.63	1.32e-10	1.13e-07	0.55	0.34	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
LIHC	cis	rs2243480	1	rs56016656	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65918494	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs55700941	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65924813	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs36033484	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65925571	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs34193460	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65928123	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs34560516	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65939105	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs57057549	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65940751	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.808	rs12698508	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65946971	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs2961102	ENSG00000164669.11	INTS4P1	6.63	1.32e-10	1.13e-07	0.59	0.34	Diabetic kidney disease;	chr7:65959671	chr7:65141225~65234216:+
LIHC	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	6.63	1.32e-10	1.13e-07	0.49	0.34	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
LIHC	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	6.63	1.32e-10	1.13e-07	0.42	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
LIHC	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-6.63	1.33e-10	1.13e-07	-0.43	-0.34	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
LIHC	cis	rs11098499	0.954	rs13145352	ENSG00000260091.1	RP11-33B1.4	6.63	1.34e-10	1.15e-07	0.25	0.34	Corneal astigmatism;	chr4:119488808	chr4:119409333~119410233:+
LIHC	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	6.63	1.34e-10	1.15e-07	0.41	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
LIHC	cis	rs1939012	0.846	rs1939013	ENSG00000281655.1	RP11-817J15.3	-6.63	1.35e-10	1.15e-07	-0.39	-0.34	Epilepsy;	chr11:102727079	chr11:102681310~102683913:+
LIHC	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-6.63	1.35e-10	1.15e-07	-0.28	-0.34	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
LIHC	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-6.62	1.36e-10	1.16e-07	-0.46	-0.34	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
LIHC	cis	rs6504950	0.783	rs7211787	ENSG00000275710.1	RP11-257O5.4	6.62	1.36e-10	1.16e-07	0.53	0.34	Breast cancer;	chr17:55157551	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.783	rs12936639	ENSG00000275710.1	RP11-257O5.4	6.62	1.36e-10	1.16e-07	0.53	0.34	Breast cancer;	chr17:55158621	chr17:54964474~54964679:+
LIHC	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	6.62	1.37e-10	1.17e-07	0.41	0.34	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
LIHC	cis	rs739496	0.615	rs56884502	ENSG00000226469.1	ADAM1B	6.62	1.37e-10	1.17e-07	0.45	0.34	Platelet count;	chr12:111769496	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.642	rs74849450	ENSG00000226469.1	ADAM1B	6.62	1.37e-10	1.17e-07	0.45	0.34	Platelet count;	chr12:111771034	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.579	rs2238152	ENSG00000226469.1	ADAM1B	6.62	1.37e-10	1.17e-07	0.45	0.34	Platelet count;	chr12:111776655	chr12:111927018~111929017:+
LIHC	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-6.62	1.38e-10	1.18e-07	-0.42	-0.34	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
LIHC	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	6.62	1.39e-10	1.18e-07	0.36	0.34	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
LIHC	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-6.62	1.39e-10	1.19e-07	-0.42	-0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
LIHC	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	6.62	1.4e-10	1.19e-07	0.46	0.34	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
LIHC	cis	rs12681287	0.752	rs10086569	ENSG00000250569.1	NTAN1P2	6.62	1.41e-10	1.2e-07	0.4	0.34	Caudate activity during reward;	chr8:86234980	chr8:86481754~86483002:-
LIHC	cis	rs832187	0.594	rs832197	ENSG00000280620.1	SCAANT1	-6.62	1.41e-10	1.2e-07	-0.41	-0.34	Schizophrenia;	chr3:63898616	chr3:63911518~63911772:-
LIHC	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	6.62	1.41e-10	1.2e-07	0.48	0.34	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
LIHC	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	6.62	1.42e-10	1.21e-07	0.43	0.34	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-6.62	1.42e-10	1.21e-07	-0.42	-0.34	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
LIHC	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-6.62	1.43e-10	1.22e-07	-0.45	-0.34	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-6.62	1.43e-10	1.22e-07	-0.45	-0.34	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-6.62	1.43e-10	1.22e-07	-0.45	-0.34	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-6.62	1.43e-10	1.22e-07	-0.45	-0.34	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-6.62	1.43e-10	1.22e-07	-0.45	-0.34	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
LIHC	cis	rs12744310	0.887	rs17362424	ENSG00000235358.1	RP11-399E6.1	-6.62	1.43e-10	1.22e-07	-0.47	-0.34	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328731	chr1:41242373~41284861:+
LIHC	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-6.62	1.43e-10	1.22e-07	-0.43	-0.34	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
LIHC	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	6.62	1.43e-10	1.22e-07	0.47	0.34	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
LIHC	cis	rs832187	0.813	rs704370	ENSG00000280620.1	SCAANT1	-6.61	1.44e-10	1.22e-07	-0.41	-0.34	Schizophrenia;	chr3:63882574	chr3:63911518~63911772:-
LIHC	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.61	1.44e-10	1.23e-07	-0.31	-0.34	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
LIHC	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-6.61	1.44e-10	1.23e-07	-0.37	-0.34	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
LIHC	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	6.61	1.44e-10	1.23e-07	0.36	0.34	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
LIHC	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	6.61	1.44e-10	1.23e-07	0.5	0.34	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
LIHC	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	6.61	1.44e-10	1.23e-07	0.33	0.34	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
LIHC	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-6.61	1.45e-10	1.23e-07	-0.54	-0.34	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
LIHC	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	6.61	1.46e-10	1.24e-07	0.45	0.34	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
LIHC	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-6.61	1.48e-10	1.25e-07	-0.28	-0.34	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-6.61	1.49e-10	1.26e-07	-0.28	-0.34	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-6.61	1.49e-10	1.26e-07	-0.28	-0.34	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
LIHC	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-6.61	1.49e-10	1.26e-07	-0.58	-0.34	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
LIHC	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	6.61	1.49e-10	1.27e-07	0.48	0.34	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
LIHC	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	6.61	1.49e-10	1.27e-07	0.45	0.34	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
LIHC	cis	rs2734839	0.507	rs2005313	ENSG00000270179.1	RP11-159N11.4	-6.61	1.49e-10	1.27e-07	-0.38	-0.34	Information processing speed;	chr11:113419327	chr11:113368478~113369117:+
LIHC	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	6.61	1.49e-10	1.27e-07	0.4	0.34	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
LIHC	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-6.61	1.5e-10	1.27e-07	-0.41	-0.34	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
LIHC	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-6.61	1.5e-10	1.27e-07	-0.52	-0.34	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
LIHC	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-6.61	1.5e-10	1.27e-07	-0.33	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
LIHC	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-6.61	1.5e-10	1.27e-07	-0.32	-0.34	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
LIHC	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-6.61	1.5e-10	1.27e-07	-0.32	-0.34	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
LIHC	cis	rs12681287	0.752	rs10092651	ENSG00000250569.1	NTAN1P2	6.61	1.51e-10	1.28e-07	0.4	0.34	Caudate activity during reward;	chr8:86235449	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs10104242	ENSG00000250569.1	NTAN1P2	6.61	1.51e-10	1.28e-07	0.4	0.34	Caudate activity during reward;	chr8:86235485	chr8:86481754~86483002:-
LIHC	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-6.61	1.51e-10	1.29e-07	-0.33	-0.34	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	6.6	1.53e-10	1.3e-07	0.43	0.34	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
LIHC	cis	rs6061231	0.958	rs2379126	ENSG00000273619.1	RP5-908M14.9	-6.6	1.53e-10	1.3e-07	-0.31	-0.34	Colorectal cancer;	chr20:62377949	chr20:62386303~62386970:-
LIHC	cis	rs6061231	0.958	rs2427304	ENSG00000273619.1	RP5-908M14.9	-6.6	1.53e-10	1.3e-07	-0.31	-0.34	Colorectal cancer;	chr20:62378528	chr20:62386303~62386970:-
LIHC	cis	rs6061231	0.958	rs2427305	ENSG00000273619.1	RP5-908M14.9	-6.6	1.53e-10	1.3e-07	-0.31	-0.34	Colorectal cancer;	chr20:62378693	chr20:62386303~62386970:-
LIHC	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-6.6	1.56e-10	1.32e-07	-0.4	-0.34	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
LIHC	cis	rs739496	0.501	rs441	ENSG00000226469.1	ADAM1B	6.6	1.56e-10	1.32e-07	0.45	0.34	Platelet count;	chr12:111791045	chr12:111927018~111929017:+
LIHC	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	6.6	1.56e-10	1.32e-07	0.5	0.34	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	6.6	1.56e-10	1.32e-07	0.5	0.34	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
LIHC	cis	rs1577917	0.876	rs11752223	ENSG00000234155.1	RP11-30P6.6	6.6	1.56e-10	1.33e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85863676	chr6:85387219~85390186:-
LIHC	cis	rs2243480	1	rs1723270	ENSG00000164669.11	INTS4P1	6.6	1.57e-10	1.33e-07	0.59	0.34	Diabetic kidney disease;	chr7:66004843	chr7:65141225~65234216:+
LIHC	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	6.6	1.57e-10	1.33e-07	0.47	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
LIHC	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	6.6	1.57e-10	1.33e-07	0.56	0.34	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
LIHC	cis	rs2243480	1	rs313809	ENSG00000164669.11	INTS4P1	6.6	1.58e-10	1.34e-07	0.58	0.34	Diabetic kidney disease;	chr7:66034996	chr7:65141225~65234216:+
LIHC	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	6.6	1.58e-10	1.34e-07	0.39	0.34	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
LIHC	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-6.6	1.59e-10	1.34e-07	-0.4	-0.34	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
LIHC	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-6.6	1.59e-10	1.35e-07	-0.46	-0.34	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
LIHC	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-6.6	1.6e-10	1.35e-07	-0.38	-0.34	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
LIHC	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	6.6	1.6e-10	1.35e-07	0.47	0.34	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
LIHC	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-6.6	1.6e-10	1.35e-07	-0.45	-0.34	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
LIHC	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	6.6	1.61e-10	1.36e-07	0.41	0.34	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
LIHC	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-6.6	1.61e-10	1.36e-07	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
LIHC	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-6.6	1.61e-10	1.37e-07	-0.42	-0.34	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
LIHC	cis	rs1577917	0.771	rs12199873	ENSG00000234155.1	RP11-30P6.6	6.59	1.63e-10	1.38e-07	0.42	0.34	Response to antipsychotic treatment;	chr6:85585229	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs2842609	ENSG00000234155.1	RP11-30P6.6	6.59	1.63e-10	1.38e-07	0.42	0.34	Response to antipsychotic treatment;	chr6:85587070	chr6:85387219~85390186:-
LIHC	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	6.59	1.64e-10	1.38e-07	0.38	0.34	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
LIHC	cis	rs2243480	1	rs35820085	ENSG00000164669.11	INTS4P1	6.59	1.64e-10	1.39e-07	0.59	0.34	Diabetic kidney disease;	chr7:65977771	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.908	rs55876148	ENSG00000164669.11	INTS4P1	6.59	1.65e-10	1.39e-07	0.59	0.34	Diabetic kidney disease;	chr7:65914813	chr7:65141225~65234216:+
LIHC	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	6.59	1.65e-10	1.39e-07	0.44	0.34	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
LIHC	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-6.59	1.65e-10	1.4e-07	-0.4	-0.34	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
LIHC	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	6.59	1.65e-10	1.4e-07	0.33	0.34	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
LIHC	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-6.59	1.67e-10	1.41e-07	-0.37	-0.34	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-6.59	1.67e-10	1.41e-07	-0.37	-0.34	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
LIHC	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-6.59	1.67e-10	1.41e-07	-0.39	-0.34	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
LIHC	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	6.59	1.67e-10	1.41e-07	0.4	0.34	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
LIHC	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	6.59	1.67e-10	1.41e-07	0.4	0.34	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
LIHC	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	6.59	1.67e-10	1.41e-07	0.4	0.34	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
LIHC	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	6.59	1.68e-10	1.42e-07	0.43	0.34	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
LIHC	cis	rs1577917	0.816	rs9353349	ENSG00000234155.1	RP11-30P6.6	-6.59	1.68e-10	1.42e-07	-0.4	-0.34	Response to antipsychotic treatment;	chr6:85998007	chr6:85387219~85390186:-
LIHC	cis	rs523522	0.962	rs1050187	ENSG00000278344.1	RP11-18C24.8	-6.59	1.69e-10	1.42e-07	-0.4	-0.34	High light scatter reticulocyte count;	chr12:120464308	chr12:120500735~120501090:-
LIHC	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	6.59	1.69e-10	1.43e-07	0.55	0.34	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
LIHC	cis	rs9527	0.501	rs12244388	ENSG00000236937.2	PTGES3P4	6.59	1.69e-10	1.43e-07	0.4	0.34	Arsenic metabolism;	chr10:102880295	chr10:102845595~102845950:+
LIHC	cis	rs739496	0.615	rs59905228	ENSG00000226469.1	ADAM1B	6.59	1.7e-10	1.43e-07	0.43	0.34	Platelet count;	chr12:111743422	chr12:111927018~111929017:+
LIHC	cis	rs12681287	0.752	rs13256500	ENSG00000250569.1	NTAN1P2	6.59	1.7e-10	1.43e-07	0.4	0.34	Caudate activity during reward;	chr8:86234834	chr8:86481754~86483002:-
LIHC	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	6.59	1.71e-10	1.44e-07	0.49	0.34	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
LIHC	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	6.59	1.71e-10	1.44e-07	0.44	0.34	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
LIHC	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-6.59	1.71e-10	1.44e-07	-0.42	-0.34	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
LIHC	cis	rs6061231	0.916	rs58488796	ENSG00000273619.1	RP5-908M14.9	-6.59	1.71e-10	1.44e-07	-0.31	-0.34	Colorectal cancer;	chr20:62373994	chr20:62386303~62386970:-
LIHC	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	6.59	1.71e-10	1.44e-07	0.47	0.34	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	6.59	1.71e-10	1.44e-07	0.47	0.34	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
LIHC	cis	rs1577917	0.958	rs34994386	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85814417	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs36042496	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85814496	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.917	rs1584273	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85814859	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12198971	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85815727	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs34230196	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85816304	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.917	rs4707226	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85818110	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.876	rs12212808	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85824254	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.917	rs13213603	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85825040	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs2324839	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85827224	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs3900313	ENSG00000234155.1	RP11-30P6.6	6.58	1.72e-10	1.45e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85827436	chr6:85387219~85390186:-
LIHC	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	6.58	1.72e-10	1.45e-07	0.48	0.34	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
LIHC	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.73e-10	1.46e-07	-0.38	-0.34	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
LIHC	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-6.58	1.73e-10	1.46e-07	-0.44	-0.34	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
LIHC	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	6.58	1.73e-10	1.46e-07	0.35	0.34	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
LIHC	cis	rs9843304	0.721	rs4681175	ENSG00000244503.1	RP11-278L15.6	6.58	1.74e-10	1.47e-07	0.35	0.34	Gallstone disease;	chr3:149484076	chr3:149494660~149495995:+
LIHC	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	6.58	1.75e-10	1.47e-07	0.47	0.34	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
LIHC	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	6.58	1.75e-10	1.48e-07	0.7	0.34	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
LIHC	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	6.58	1.75e-10	1.48e-07	0.35	0.34	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
LIHC	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-6.58	1.75e-10	1.48e-07	-0.34	-0.34	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
LIHC	cis	rs2522056	0.808	rs1016988	ENSG00000233006.5	AC034220.3	-6.58	1.75e-10	1.48e-07	-0.36	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132311285~132369916:-
LIHC	cis	rs12681287	0.752	rs4288357	ENSG00000250569.1	NTAN1P2	6.58	1.76e-10	1.48e-07	0.4	0.34	Caudate activity during reward;	chr8:86239604	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs4472493	ENSG00000250569.1	NTAN1P2	6.58	1.76e-10	1.48e-07	0.4	0.34	Caudate activity during reward;	chr8:86239685	chr8:86481754~86483002:-
LIHC	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-6.58	1.76e-10	1.48e-07	-0.38	-0.34	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
LIHC	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	6.58	1.77e-10	1.49e-07	0.42	0.34	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
LIHC	cis	rs1023500	0.506	rs6002625	ENSG00000227370.1	RP4-669P10.19	6.58	1.77e-10	1.49e-07	0.4	0.34	Schizophrenia;	chr22:42121685	chr22:42132543~42132998:+
LIHC	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-6.58	1.78e-10	1.49e-07	-0.51	-0.34	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
LIHC	cis	rs55665837	0.701	rs11023278	ENSG00000251991.1	RNU7-49P	6.58	1.78e-10	1.49e-07	0.37	0.34	Vitamin D levels;	chr11:14619638	chr11:14478892~14478953:+
LIHC	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-6.58	1.78e-10	1.5e-07	-0.47	-0.34	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
LIHC	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	6.58	1.78e-10	1.5e-07	0.35	0.34	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
LIHC	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-6.58	1.79e-10	1.5e-07	-0.51	-0.34	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
LIHC	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-6.58	1.79e-10	1.51e-07	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-6.58	1.79e-10	1.51e-07	-0.5	-0.34	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
LIHC	cis	rs1577917	0.958	rs1447160	ENSG00000234155.1	RP11-30P6.6	6.58	1.79e-10	1.51e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85836405	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12198061	ENSG00000234155.1	RP11-30P6.6	6.58	1.79e-10	1.51e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85841267	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs1838955	ENSG00000234155.1	RP11-30P6.6	6.58	1.79e-10	1.51e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85855731	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.874	rs1838954	ENSG00000234155.1	RP11-30P6.6	6.58	1.79e-10	1.51e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85855760	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs2084294	ENSG00000234155.1	RP11-30P6.6	6.58	1.79e-10	1.51e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85856225	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12660846	ENSG00000234155.1	RP11-30P6.6	6.58	1.79e-10	1.51e-07	0.4	0.34	Response to antipsychotic treatment;	chr6:85864091	chr6:85387219~85390186:-
LIHC	cis	rs4356975	0.697	rs6849081	ENSG00000249956.3	RP11-790I12.2	6.58	1.8e-10	1.51e-07	0.4	0.34	Obesity-related traits;	chr4:69144840	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.649	rs59421013	ENSG00000249956.3	RP11-790I12.2	6.58	1.8e-10	1.51e-07	0.4	0.34	Obesity-related traits;	chr4:69149131	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.697	rs58039330	ENSG00000249956.3	RP11-790I12.2	6.58	1.8e-10	1.51e-07	0.4	0.34	Obesity-related traits;	chr4:69149529	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.66	rs60567038	ENSG00000249956.3	RP11-790I12.2	6.58	1.8e-10	1.51e-07	0.4	0.34	Obesity-related traits;	chr4:69150135	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.697	rs58366569	ENSG00000249956.3	RP11-790I12.2	6.58	1.8e-10	1.51e-07	0.4	0.34	Obesity-related traits;	chr4:69150626	chr4:69408836~69423164:+
LIHC	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-6.58	1.8e-10	1.51e-07	-0.28	-0.34	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
LIHC	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	6.58	1.8e-10	1.51e-07	0.4	0.34	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
LIHC	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-6.58	1.8e-10	1.51e-07	-0.28	-0.34	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
LIHC	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	6.58	1.81e-10	1.52e-07	0.45	0.34	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
LIHC	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-6.58	1.81e-10	1.52e-07	-0.44	-0.34	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
LIHC	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	6.58	1.81e-10	1.52e-07	0.57	0.34	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
LIHC	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-6.58	1.82e-10	1.53e-07	-0.28	-0.33	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
LIHC	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	6.57	1.83e-10	1.53e-07	0.37	0.33	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
LIHC	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	6.57	1.83e-10	1.54e-07	0.48	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
LIHC	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-6.57	1.83e-10	1.54e-07	-0.39	-0.33	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
LIHC	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	6.57	1.85e-10	1.55e-07	0.33	0.33	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
LIHC	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-6.57	1.85e-10	1.55e-07	-0.42	-0.33	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
LIHC	cis	rs739496	0.615	rs12427276	ENSG00000226469.1	ADAM1B	6.57	1.86e-10	1.55e-07	0.42	0.33	Platelet count;	chr12:111675704	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.615	rs847895	ENSG00000226469.1	ADAM1B	6.57	1.86e-10	1.55e-07	0.42	0.33	Platelet count;	chr12:111680772	chr12:111927018~111929017:+
LIHC	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-6.57	1.86e-10	1.56e-07	-0.35	-0.33	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
LIHC	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	6.57	1.86e-10	1.56e-07	0.38	0.33	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
LIHC	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	6.57	1.86e-10	1.56e-07	0.38	0.33	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
LIHC	cis	rs832187	0.776	rs854622	ENSG00000280620.1	SCAANT1	6.57	1.86e-10	1.56e-07	0.4	0.33	Schizophrenia;	chr3:63877166	chr3:63911518~63911772:-
LIHC	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-6.57	1.86e-10	1.56e-07	-0.4	-0.33	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
LIHC	cis	rs854625	1	rs854625	ENSG00000278690.1	RP11-104J23.2	-6.57	1.87e-10	1.57e-07	-0.49	-0.33	Cerebrospinal fluid biomarker levels;	chr17:36001422	chr17:36012504~36012891:+
LIHC	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	6.57	1.87e-10	1.57e-07	0.41	0.33	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
LIHC	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	6.57	1.87e-10	1.57e-07	0.34	0.33	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
LIHC	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-6.57	1.88e-10	1.57e-07	-0.33	-0.33	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
LIHC	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-6.57	1.88e-10	1.58e-07	-0.36	-0.33	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
LIHC	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	6.57	1.89e-10	1.58e-07	0.44	0.33	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
LIHC	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-6.57	1.89e-10	1.58e-07	-0.32	-0.33	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
LIHC	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	6.57	1.89e-10	1.58e-07	0.35	0.33	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
LIHC	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-6.57	1.89e-10	1.58e-07	-0.38	-0.33	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-6.57	1.89e-10	1.58e-07	-0.38	-0.33	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
LIHC	cis	rs12681287	0.752	rs34279109	ENSG00000250569.1	NTAN1P2	6.57	1.89e-10	1.58e-07	0.4	0.33	Caudate activity during reward;	chr8:86235715	chr8:86481754~86483002:-
LIHC	cis	rs739496	0.615	rs4646778	ENSG00000226469.1	ADAM1B	6.57	1.9e-10	1.59e-07	0.45	0.33	Platelet count;	chr12:111797979	chr12:111927018~111929017:+
LIHC	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-6.57	1.9e-10	1.59e-07	-0.49	-0.33	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
LIHC	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	6.57	1.91e-10	1.6e-07	0.34	0.33	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
LIHC	cis	rs1577917	0.958	rs12196230	ENSG00000234155.1	RP11-30P6.6	6.57	1.92e-10	1.61e-07	0.4	0.33	Response to antipsychotic treatment;	chr6:85810242	chr6:85387219~85390186:-
LIHC	cis	rs55665837	0.701	rs2007361	ENSG00000251991.1	RNU7-49P	6.57	1.93e-10	1.61e-07	0.37	0.33	Vitamin D levels;	chr11:14641176	chr11:14478892~14478953:+
LIHC	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	6.56	1.93e-10	1.62e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
LIHC	cis	rs1577917	0.771	rs2842612	ENSG00000234155.1	RP11-30P6.6	6.56	1.93e-10	1.62e-07	0.42	0.33	Response to antipsychotic treatment;	chr6:85593373	chr6:85387219~85390186:-
LIHC	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-6.56	1.94e-10	1.62e-07	-0.37	-0.33	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-6.56	1.94e-10	1.62e-07	-0.37	-0.33	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-6.56	1.94e-10	1.62e-07	-0.37	-0.33	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
LIHC	cis	rs12744310	0.836	rs12048808	ENSG00000235358.1	RP11-399E6.1	6.56	1.94e-10	1.62e-07	0.47	0.33	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348636	chr1:41242373~41284861:+
LIHC	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-6.56	1.95e-10	1.63e-07	-0.44	-0.33	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
LIHC	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-6.56	1.95e-10	1.63e-07	-0.46	-0.33	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
LIHC	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-6.56	1.97e-10	1.64e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-6.56	1.97e-10	1.64e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
LIHC	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-6.56	1.98e-10	1.65e-07	-0.45	-0.33	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
LIHC	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	6.56	1.98e-10	1.65e-07	0.38	0.33	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
LIHC	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	6.56	1.98e-10	1.65e-07	0.4	0.33	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	6.56	1.98e-10	1.65e-07	0.4	0.33	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	6.56	1.98e-10	1.65e-07	0.4	0.33	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
LIHC	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	6.56	1.98e-10	1.65e-07	0.48	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	6.56	1.98e-10	1.65e-07	0.48	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
LIHC	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-6.56	1.99e-10	1.66e-07	-0.38	-0.33	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-6.56	1.99e-10	1.66e-07	-0.38	-0.33	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
LIHC	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	6.56	2e-10	1.67e-07	0.4	0.33	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
LIHC	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	6.56	2e-10	1.67e-07	0.46	0.33	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
LIHC	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	6.56	2e-10	1.67e-07	0.46	0.33	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
LIHC	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	6.56	2.01e-10	1.67e-07	0.42	0.33	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
LIHC	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-6.56	2.02e-10	1.68e-07	-0.49	-0.33	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
LIHC	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-6.56	2.03e-10	1.69e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-6.56	2.03e-10	1.69e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-6.56	2.03e-10	1.69e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-6.56	2.03e-10	1.69e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-6.56	2.03e-10	1.69e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-6.56	2.03e-10	1.69e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
LIHC	cis	rs55665837	0.701	rs10766188	ENSG00000251991.1	RNU7-49P	6.56	2.03e-10	1.69e-07	0.37	0.33	Vitamin D levels;	chr11:14639280	chr11:14478892~14478953:+
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	6.56	2.03e-10	1.69e-07	0.41	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
LIHC	cis	rs832187	0.813	rs704369	ENSG00000280620.1	SCAANT1	-6.56	2.03e-10	1.69e-07	-0.41	-0.33	Schizophrenia;	chr3:63882595	chr3:63911518~63911772:-
LIHC	cis	rs832187	0.813	rs704368	ENSG00000280620.1	SCAANT1	-6.56	2.03e-10	1.69e-07	-0.41	-0.33	Schizophrenia;	chr3:63882661	chr3:63911518~63911772:-
LIHC	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-6.56	2.03e-10	1.69e-07	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
LIHC	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-6.55	2.08e-10	1.73e-07	-0.32	-0.33	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
LIHC	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.55	2.08e-10	1.73e-07	-0.38	-0.33	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
LIHC	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	6.55	2.1e-10	1.74e-07	0.43	0.33	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
LIHC	cis	rs2439831	0.867	rs2260160	ENSG00000205771.5	CATSPER2P1	-6.55	2.1e-10	1.74e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43603445	chr15:43726918~43747094:-
LIHC	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-6.55	2.1e-10	1.74e-07	-0.47	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
LIHC	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-6.55	2.11e-10	1.75e-07	-0.42	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
LIHC	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-6.55	2.12e-10	1.76e-07	-0.42	-0.33	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
LIHC	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-6.55	2.13e-10	1.76e-07	-0.39	-0.33	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
LIHC	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	6.55	2.13e-10	1.77e-07	0.44	0.33	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
LIHC	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-6.55	2.13e-10	1.77e-07	-0.41	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
LIHC	cis	rs2243480	1	rs73142162	ENSG00000164669.11	INTS4P1	6.55	2.13e-10	1.77e-07	0.59	0.33	Diabetic kidney disease;	chr7:65909309	chr7:65141225~65234216:+
LIHC	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	6.55	2.14e-10	1.78e-07	0.35	0.33	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
LIHC	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-6.55	2.15e-10	1.78e-07	-0.28	-0.33	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
LIHC	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-6.55	2.17e-10	1.8e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
LIHC	cis	rs2243480	1	rs73142166	ENSG00000164669.11	INTS4P1	6.55	2.17e-10	1.8e-07	0.59	0.33	Diabetic kidney disease;	chr7:65910845	chr7:65141225~65234216:+
LIHC	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-6.54	2.18e-10	1.81e-07	-0.4	-0.33	Migraine;	chr4:56880190	chr4:56960927~56961373:-
LIHC	cis	rs2243480	1	rs13247184	ENSG00000164669.11	INTS4P1	6.54	2.2e-10	1.82e-07	0.59	0.33	Diabetic kidney disease;	chr7:65893941	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35283677	ENSG00000164669.11	INTS4P1	6.54	2.2e-10	1.82e-07	0.59	0.33	Diabetic kidney disease;	chr7:65894246	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35421653	ENSG00000164669.11	INTS4P1	6.54	2.2e-10	1.82e-07	0.59	0.33	Diabetic kidney disease;	chr7:65898442	chr7:65141225~65234216:+
LIHC	cis	rs17270561	0.609	rs9358878	ENSG00000216436.2	HIST1H2APS1	-6.54	2.21e-10	1.83e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25740045	chr6:25732497~25732827:+
LIHC	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-6.54	2.21e-10	1.83e-07	-0.41	-0.33	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
LIHC	cis	rs17270561	0.609	rs4131670	ENSG00000216436.2	HIST1H2APS1	-6.54	2.23e-10	1.84e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25738391	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4464787	ENSG00000216436.2	HIST1H2APS1	-6.54	2.23e-10	1.85e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25733330	chr6:25732497~25732827:+
LIHC	cis	rs12681287	0.752	rs10085920	ENSG00000250569.1	NTAN1P2	6.54	2.24e-10	1.86e-07	0.4	0.33	Caudate activity during reward;	chr8:86240437	chr8:86481754~86483002:-
LIHC	cis	rs1577917	0.727	rs2758840	ENSG00000234155.1	RP11-30P6.6	6.54	2.24e-10	1.86e-07	0.42	0.33	Response to antipsychotic treatment;	chr6:85594907	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs9362230	ENSG00000234155.1	RP11-30P6.6	6.54	2.24e-10	1.86e-07	0.42	0.33	Response to antipsychotic treatment;	chr6:85595295	chr6:85387219~85390186:-
LIHC	cis	rs17270561	0.636	rs12194699	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25729001	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9379786	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25730027	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9393658	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25730210	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs12203927	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25732462	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs12192077	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25732566	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4711098	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25734111	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs4360128	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25734330	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs3922699	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25734741	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs6924782	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25735588	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs6924794	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25735646	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs3922842	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25736336	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9358876	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25738728	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.583	rs9393661	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25738852	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9356986	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25738891	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.666	rs9356987	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25738959	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9358877	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25739000	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs12663099	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25739290	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9393662	ENSG00000216436.2	HIST1H2APS1	-6.54	2.24e-10	1.86e-07	-0.41	-0.33	Iron status biomarkers;	chr6:25739442	chr6:25732497~25732827:+
LIHC	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-6.54	2.25e-10	1.86e-07	-0.4	-0.33	Migraine;	chr4:56880659	chr4:56960927~56961373:-
LIHC	cis	rs2522056	0.808	rs7704457	ENSG00000233006.5	AC034220.3	6.54	2.25e-10	1.86e-07	0.35	0.33	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132311285~132369916:-
LIHC	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-6.54	2.25e-10	1.86e-07	-0.34	-0.33	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
LIHC	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-6.54	2.25e-10	1.86e-07	-0.46	-0.33	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
LIHC	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	6.54	2.26e-10	1.87e-07	0.44	0.33	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
LIHC	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-6.54	2.27e-10	1.87e-07	-0.37	-0.33	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
LIHC	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-6.54	2.3e-10	1.9e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
LIHC	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	6.53	2.32e-10	1.91e-07	0.42	0.33	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
LIHC	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	6.53	2.33e-10	1.93e-07	0.41	0.33	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
LIHC	cis	rs2243480	1	rs427044	ENSG00000164669.11	INTS4P1	6.53	2.35e-10	1.94e-07	0.57	0.33	Diabetic kidney disease;	chr7:66043558	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs1039664	ENSG00000164669.11	INTS4P1	6.53	2.36e-10	1.95e-07	0.58	0.33	Diabetic kidney disease;	chr7:65984729	chr7:65141225~65234216:+
LIHC	cis	rs9843304	0.568	rs13072639	ENSG00000244503.1	RP11-278L15.6	6.53	2.36e-10	1.95e-07	0.36	0.33	Gallstone disease;	chr3:149489241	chr3:149494660~149495995:+
LIHC	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	6.53	2.37e-10	1.95e-07	0.35	0.33	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
LIHC	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-6.53	2.37e-10	1.96e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-6.53	2.37e-10	1.96e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-6.53	2.37e-10	1.96e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
LIHC	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	6.53	2.38e-10	1.96e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
LIHC	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-6.53	2.38e-10	1.97e-07	-0.36	-0.33	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
LIHC	cis	rs1939012	0.525	rs17099462	ENSG00000281655.1	RP11-817J15.3	-6.53	2.38e-10	1.97e-07	-0.4	-0.33	Epilepsy;	chr11:102729975	chr11:102681310~102683913:+
LIHC	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-6.53	2.39e-10	1.97e-07	-0.32	-0.33	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
LIHC	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	6.53	2.4e-10	1.98e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
LIHC	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-6.53	2.4e-10	1.98e-07	-0.28	-0.33	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
LIHC	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-6.53	2.4e-10	1.98e-07	-0.42	-0.33	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
LIHC	cis	rs1023500	0.505	rs134878	ENSG00000237037.8	NDUFA6-AS1	6.53	2.41e-10	1.99e-07	0.35	0.33	Schizophrenia;	chr22:42267868	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.771	rs4441928	ENSG00000234155.1	RP11-30P6.6	-6.53	2.43e-10	2e-07	-0.41	-0.33	Response to antipsychotic treatment;	chr6:85532176	chr6:85387219~85390186:-
LIHC	cis	rs5758511	0.817	rs133291	ENSG00000237037.8	NDUFA6-AS1	-6.53	2.44e-10	2e-07	-0.41	-0.33	Birth weight;	chr22:41873624	chr22:42090931~42137742:+
LIHC	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	6.53	2.44e-10	2.01e-07	0.4	0.33	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	6.53	2.44e-10	2.01e-07	0.4	0.33	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
LIHC	cis	rs739496	0.615	rs617044	ENSG00000226469.1	ADAM1B	6.53	2.44e-10	2.01e-07	0.43	0.33	Platelet count;	chr12:111695071	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.615	rs602276	ENSG00000226469.1	ADAM1B	6.53	2.44e-10	2.01e-07	0.43	0.33	Platelet count;	chr12:111696120	chr12:111927018~111929017:+
LIHC	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	6.52	2.46e-10	2.02e-07	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
LIHC	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	6.52	2.46e-10	2.03e-07	0.38	0.33	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
LIHC	cis	rs854624	1	rs854626	ENSG00000275944.1	RP11-104J23.1	6.52	2.48e-10	2.04e-07	0.39	0.33	Blood protein levels;	chr17:36002489	chr17:36001419~36011618:+
LIHC	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-6.52	2.48e-10	2.04e-07	-0.35	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
LIHC	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	6.52	2.49e-10	2.05e-07	0.51	0.33	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
LIHC	cis	rs916888	0.61	rs199529	ENSG00000262881.1	RP11-669E14.4	-6.52	2.51e-10	2.06e-07	-0.51	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45907670~45910779:-
LIHC	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-6.52	2.51e-10	2.06e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
LIHC	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	6.52	2.51e-10	2.06e-07	0.39	0.33	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-6.52	2.52e-10	2.07e-07	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
LIHC	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	6.52	2.52e-10	2.07e-07	0.41	0.33	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
LIHC	cis	rs55665837	0.665	rs11023273	ENSG00000251991.1	RNU7-49P	6.52	2.53e-10	2.08e-07	0.36	0.33	Vitamin D levels;	chr11:14609273	chr11:14478892~14478953:+
LIHC	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-6.52	2.53e-10	2.08e-07	-0.39	-0.33	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
LIHC	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-6.52	2.54e-10	2.08e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
LIHC	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-6.52	2.56e-10	2.1e-07	-0.34	-0.33	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
LIHC	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	6.52	2.57e-10	2.11e-07	0.49	0.33	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
LIHC	cis	rs2243480	1	rs1723267	ENSG00000164669.11	INTS4P1	6.52	2.58e-10	2.11e-07	0.57	0.33	Diabetic kidney disease;	chr7:66008327	chr7:65141225~65234216:+
LIHC	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	6.52	2.58e-10	2.12e-07	0.39	0.33	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
LIHC	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-6.52	2.58e-10	2.12e-07	-0.38	-0.33	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
LIHC	cis	rs6490294	0.571	rs57929857	ENSG00000226469.1	ADAM1B	6.52	2.59e-10	2.12e-07	0.5	0.33	Mean platelet volume;	chr12:111995752	chr12:111927018~111929017:+
LIHC	cis	rs55665837	0.701	rs11023272	ENSG00000251991.1	RNU7-49P	6.52	2.59e-10	2.12e-07	0.36	0.33	Vitamin D levels;	chr11:14608824	chr11:14478892~14478953:+
LIHC	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	6.51	2.61e-10	2.14e-07	0.43	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
LIHC	cis	rs1023500	0.505	rs134887	ENSG00000237037.8	NDUFA6-AS1	6.51	2.62e-10	2.14e-07	0.36	0.33	Schizophrenia;	chr22:42278233	chr22:42090931~42137742:+
LIHC	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	6.51	2.62e-10	2.15e-07	0.54	0.33	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
LIHC	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	6.51	2.63e-10	2.15e-07	0.45	0.33	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
LIHC	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-6.51	2.63e-10	2.15e-07	-0.34	-0.33	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
LIHC	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-6.51	2.63e-10	2.16e-07	-0.38	-0.33	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-6.51	2.63e-10	2.16e-07	-0.38	-0.33	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
LIHC	cis	rs55665837	0.701	rs10160597	ENSG00000251991.1	RNU7-49P	6.51	2.64e-10	2.16e-07	0.36	0.33	Vitamin D levels;	chr11:14582446	chr11:14478892~14478953:+
LIHC	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-6.51	2.64e-10	2.16e-07	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
LIHC	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	6.51	2.65e-10	2.17e-07	0.49	0.33	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
LIHC	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	6.51	2.67e-10	2.19e-07	0.39	0.33	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
LIHC	cis	rs854624	1	rs854624	ENSG00000278690.1	RP11-104J23.2	6.51	2.68e-10	2.19e-07	0.47	0.33	Blood protein levels;	chr17:36000884	chr17:36012504~36012891:+
LIHC	cis	rs739496	0.615	rs630616	ENSG00000226469.1	ADAM1B	6.51	2.68e-10	2.19e-07	0.43	0.33	Platelet count;	chr12:111721162	chr12:111927018~111929017:+
LIHC	cis	rs854624	1	rs41508645	ENSG00000278690.1	RP11-104J23.2	-6.51	2.7e-10	2.21e-07	-0.48	-0.33	Blood protein levels;	chr17:36001998	chr17:36012504~36012891:+
LIHC	cis	rs2762353	0.595	rs10498728	ENSG00000242387.1	HIST1H2APS2	6.51	2.7e-10	2.21e-07	0.41	0.33	Blood metabolite levels;	chr6:25751092	chr6:25882026~25882395:-
LIHC	cis	rs2243480	1	rs313803	ENSG00000164669.11	INTS4P1	6.51	2.71e-10	2.21e-07	0.57	0.33	Diabetic kidney disease;	chr7:66049744	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs313802	ENSG00000164669.11	INTS4P1	6.51	2.71e-10	2.21e-07	0.57	0.33	Diabetic kidney disease;	chr7:66051386	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs403089	ENSG00000164669.11	INTS4P1	6.51	2.71e-10	2.21e-07	0.57	0.33	Diabetic kidney disease;	chr7:66052736	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs458291	ENSG00000164669.11	INTS4P1	6.51	2.71e-10	2.21e-07	0.57	0.33	Diabetic kidney disease;	chr7:66055492	chr7:65141225~65234216:+
LIHC	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	6.5	2.76e-10	2.25e-07	0.41	0.33	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
LIHC	cis	rs1577917	0.837	rs10944157	ENSG00000234155.1	RP11-30P6.6	6.5	2.76e-10	2.26e-07	0.4	0.33	Response to antipsychotic treatment;	chr6:85867481	chr6:85387219~85390186:-
LIHC	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-6.5	2.78e-10	2.27e-07	-0.28	-0.33	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
LIHC	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-6.5	2.79e-10	2.28e-07	-0.38	-0.33	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-6.5	2.79e-10	2.28e-07	-0.38	-0.33	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
LIHC	cis	rs832187	1	rs832187	ENSG00000280620.1	SCAANT1	-6.5	2.8e-10	2.28e-07	-0.4	-0.33	Schizophrenia;	chr3:63847374	chr3:63911518~63911772:-
LIHC	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	6.5	2.81e-10	2.3e-07	0.38	0.33	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
LIHC	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	6.5	2.83e-10	2.31e-07	0.35	0.33	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
LIHC	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	6.5	2.83e-10	2.31e-07	0.42	0.33	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
LIHC	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-6.5	2.84e-10	2.31e-07	-0.38	-0.33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
LIHC	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	6.5	2.84e-10	2.32e-07	0.4	0.33	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
LIHC	cis	rs2243480	1	rs781157	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66013324	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs781156	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66014154	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs781149	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66016297	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs451396	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66019087	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs58207111	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66021736	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs1167613	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66022452	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs1715235	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66023407	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs313799	ENSG00000164669.11	INTS4P1	6.5	2.84e-10	2.32e-07	0.57	0.33	Diabetic kidney disease;	chr7:66029343	chr7:65141225~65234216:+
LIHC	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	6.5	2.86e-10	2.33e-07	0.42	0.33	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
LIHC	cis	rs17270561	0.609	rs9379783	ENSG00000216436.2	HIST1H2APS1	-6.5	2.87e-10	2.34e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25724979	chr6:25732497~25732827:+
LIHC	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-6.5	2.87e-10	2.34e-07	-0.36	-0.33	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
LIHC	cis	rs6085948	0.861	rs6054849	ENSG00000238102.1	RP11-19D2.1	-6.5	2.88e-10	2.34e-07	-0.6	-0.33	Interleukin-10 levels;	chr20:7251460	chr20:7256580~7258214:-
LIHC	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	6.5	2.88e-10	2.35e-07	0.33	0.33	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
LIHC	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-6.5	2.89e-10	2.35e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
LIHC	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-6.5	2.9e-10	2.36e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
LIHC	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-6.5	2.91e-10	2.37e-07	-0.36	-0.33	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-6.5	2.91e-10	2.37e-07	-0.36	-0.33	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
LIHC	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-6.5	2.92e-10	2.38e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
LIHC	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-6.49	2.93e-10	2.38e-07	-0.36	-0.33	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
LIHC	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-6.49	2.95e-10	2.4e-07	-0.39	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
LIHC	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-6.49	2.97e-10	2.41e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
LIHC	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	6.49	2.97e-10	2.41e-07	0.57	0.33	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
LIHC	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	6.49	2.98e-10	2.42e-07	0.37	0.33	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
LIHC	cis	rs523522	0.962	rs12309824	ENSG00000278344.1	RP11-18C24.8	6.49	2.98e-10	2.42e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120552779	chr12:120500735~120501090:-
LIHC	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-6.49	2.98e-10	2.42e-07	-0.43	-0.33	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
LIHC	cis	rs7580658	0.751	rs2069924	ENSG00000236682.1	AC068282.3	-6.49	2.98e-10	2.42e-07	-0.42	-0.33	Protein C levels;	chr2:127425418	chr2:127389130~127400580:+
LIHC	cis	rs523522	0.962	rs10744752	ENSG00000278344.1	RP11-18C24.8	6.49	3.01e-10	2.44e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120462751	chr12:120500735~120501090:-
LIHC	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	6.49	3.02e-10	2.46e-07	0.38	0.33	QT interval;	chr12:29292489	chr12:29280418~29317848:-
LIHC	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	6.49	3.03e-10	2.46e-07	0.4	0.33	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
LIHC	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-6.49	3.03e-10	2.46e-07	-0.46	-0.33	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
LIHC	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-6.49	3.06e-10	2.49e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
LIHC	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-6.49	3.06e-10	2.49e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
LIHC	cis	rs2735413	0.564	rs74316728	ENSG00000276007.1	RP11-358L22.3	6.49	3.07e-10	2.49e-07	0.48	0.33	Systolic blood pressure (alcohol consumption interaction);	chr16:78065756	chr16:78123243~78124332:+
LIHC	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	6.49	3.07e-10	2.49e-07	0.57	0.33	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
LIHC	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-6.49	3.08e-10	2.5e-07	-0.36	-0.33	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
LIHC	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-6.49	3.09e-10	2.5e-07	-0.38	-0.33	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
LIHC	cis	rs2243480	1	rs160634	ENSG00000164669.11	INTS4P1	-6.49	3.09e-10	2.5e-07	-0.54	-0.33	Diabetic kidney disease;	chr7:66063677	chr7:65141225~65234216:+
LIHC	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-6.49	3.1e-10	2.52e-07	-0.45	-0.33	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
LIHC	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-6.48	3.12e-10	2.53e-07	-0.36	-0.33	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
LIHC	cis	rs5758659	1	rs134902	ENSG00000227370.1	RP4-669P10.19	-6.48	3.12e-10	2.53e-07	-0.37	-0.33	Cognitive function;	chr22:42287991	chr22:42132543~42132998:+
LIHC	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	6.48	3.13e-10	2.53e-07	0.4	0.33	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
LIHC	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	6.48	3.13e-10	2.53e-07	0.4	0.33	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
LIHC	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-6.48	3.14e-10	2.54e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
LIHC	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-6.48	3.15e-10	2.55e-07	-0.51	-0.33	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
LIHC	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	6.48	3.15e-10	2.55e-07	0.38	0.33	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
LIHC	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	6.48	3.16e-10	2.56e-07	0.39	0.33	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
LIHC	cis	rs1577917	0.958	rs2324840	ENSG00000234155.1	RP11-30P6.6	6.48	3.16e-10	2.56e-07	0.39	0.33	Response to antipsychotic treatment;	chr6:85847902	chr6:85387219~85390186:-
LIHC	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-6.48	3.16e-10	2.56e-07	-0.39	-0.33	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
LIHC	cis	rs916888	0.821	rs199506	ENSG00000262881.1	RP11-669E14.4	6.48	3.17e-10	2.57e-07	0.52	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45907670~45910779:-
LIHC	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-6.48	3.17e-10	2.57e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-6.48	3.17e-10	2.57e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-6.48	3.17e-10	2.57e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-6.48	3.17e-10	2.57e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-6.48	3.17e-10	2.57e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
LIHC	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	6.48	3.18e-10	2.57e-07	0.42	0.33	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
LIHC	cis	rs6061231	0.675	rs755726	ENSG00000273619.1	RP5-908M14.9	-6.48	3.18e-10	2.58e-07	-0.28	-0.33	Colorectal cancer;	chr20:62387568	chr20:62386303~62386970:-
LIHC	cis	rs523522	0.962	rs2235218	ENSG00000278344.1	RP11-18C24.8	6.48	3.2e-10	2.59e-07	0.4	0.33	High light scatter reticulocyte count;	chr12:120450816	chr12:120500735~120501090:-
LIHC	cis	rs55665837	0.701	rs11023265	ENSG00000251991.1	RNU7-49P	6.48	3.2e-10	2.59e-07	0.36	0.33	Vitamin D levels;	chr11:14594492	chr11:14478892~14478953:+
LIHC	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	6.48	3.21e-10	2.6e-07	0.4	0.33	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
LIHC	cis	rs55665837	0.583	rs78843135	ENSG00000251991.1	RNU7-49P	6.48	3.25e-10	2.63e-07	0.35	0.33	Vitamin D levels;	chr11:14389708	chr11:14478892~14478953:+
LIHC	cis	rs2243480	1	rs4718269	ENSG00000164669.11	INTS4P1	-6.48	3.26e-10	2.63e-07	-0.57	-0.33	Diabetic kidney disease;	chr7:65735810	chr7:65141225~65234216:+
LIHC	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	6.48	3.26e-10	2.64e-07	0.4	0.33	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
LIHC	cis	rs12681287	0.604	rs71502657	ENSG00000250569.1	NTAN1P2	6.48	3.28e-10	2.65e-07	0.39	0.33	Caudate activity during reward;	chr8:86466552	chr8:86481754~86483002:-
LIHC	cis	rs1577917	0.917	rs2218594	ENSG00000234155.1	RP11-30P6.6	6.48	3.28e-10	2.65e-07	0.39	0.33	Response to antipsychotic treatment;	chr6:85834048	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs2197648	ENSG00000234155.1	RP11-30P6.6	6.48	3.28e-10	2.65e-07	0.39	0.33	Response to antipsychotic treatment;	chr6:85834169	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs2100109	ENSG00000234155.1	RP11-30P6.6	6.48	3.28e-10	2.65e-07	0.39	0.33	Response to antipsychotic treatment;	chr6:85835208	chr6:85387219~85390186:-
LIHC	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	6.48	3.29e-10	2.66e-07	0.39	0.33	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
LIHC	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	6.47	3.3e-10	2.66e-07	0.33	0.33	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
LIHC	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-6.47	3.3e-10	2.67e-07	-0.49	-0.33	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
LIHC	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	6.47	3.3e-10	2.67e-07	0.45	0.33	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
LIHC	cis	rs1939012	1	rs1940474	ENSG00000281655.1	RP11-817J15.3	-6.47	3.35e-10	2.7e-07	-0.38	-0.33	Epilepsy;	chr11:102722322	chr11:102681310~102683913:+
LIHC	cis	rs1023500	0.573	rs8135801	ENSG00000237037.8	NDUFA6-AS1	-6.47	3.39e-10	2.73e-07	-0.4	-0.33	Schizophrenia;	chr22:42079564	chr22:42090931~42137742:+
LIHC	cis	rs854624	1	rs854624	ENSG00000275944.1	RP11-104J23.1	6.47	3.4e-10	2.75e-07	0.39	0.33	Blood protein levels;	chr17:36000884	chr17:36001419~36011618:+
LIHC	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-6.47	3.42e-10	2.76e-07	-0.4	-0.33	Migraine;	chr4:56879851	chr4:56960927~56961373:-
LIHC	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-6.47	3.43e-10	2.77e-07	-0.44	-0.33	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
LIHC	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-6.47	3.43e-10	2.77e-07	-0.5	-0.33	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
LIHC	cis	rs2243480	1	rs1964692	ENSG00000164669.11	INTS4P1	6.47	3.45e-10	2.78e-07	0.58	0.33	Diabetic kidney disease;	chr7:65989196	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs2456483	ENSG00000164669.11	INTS4P1	6.47	3.45e-10	2.78e-07	0.58	0.33	Diabetic kidney disease;	chr7:65996588	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs2949697	ENSG00000164669.11	INTS4P1	6.47	3.45e-10	2.78e-07	0.58	0.33	Diabetic kidney disease;	chr7:65999249	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs1701750	ENSG00000164669.11	INTS4P1	6.47	3.45e-10	2.78e-07	0.58	0.33	Diabetic kidney disease;	chr7:66002158	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs1701758	ENSG00000164669.11	INTS4P1	6.47	3.45e-10	2.78e-07	0.58	0.33	Diabetic kidney disease;	chr7:66005214	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs1701759	ENSG00000164669.11	INTS4P1	6.47	3.45e-10	2.78e-07	0.58	0.33	Diabetic kidney disease;	chr7:66005945	chr7:65141225~65234216:+
LIHC	cis	rs1577917	0.958	rs4707236	ENSG00000234155.1	RP11-30P6.6	6.47	3.48e-10	2.8e-07	0.39	0.33	Response to antipsychotic treatment;	chr6:85874249	chr6:85387219~85390186:-
LIHC	cis	rs2243480	1	rs313807	ENSG00000164669.11	INTS4P1	6.46	3.5e-10	2.82e-07	0.57	0.33	Diabetic kidney disease;	chr7:66034494	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs313808	ENSG00000164669.11	INTS4P1	6.46	3.5e-10	2.82e-07	0.57	0.33	Diabetic kidney disease;	chr7:66034886	chr7:65141225~65234216:+
LIHC	cis	rs2522056	1	rs1003533	ENSG00000233006.5	AC034220.3	-6.46	3.51e-10	2.82e-07	-0.35	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132311285~132369916:-
LIHC	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-6.46	3.55e-10	2.86e-07	-0.41	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
LIHC	cis	rs2243480	1	rs59794892	ENSG00000164669.11	INTS4P1	6.46	3.55e-10	2.86e-07	0.57	0.33	Diabetic kidney disease;	chr7:65950886	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs36004293	ENSG00000164669.11	INTS4P1	6.46	3.55e-10	2.86e-07	0.57	0.33	Diabetic kidney disease;	chr7:65951525	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs35268390	ENSG00000164669.11	INTS4P1	6.46	3.55e-10	2.86e-07	0.57	0.33	Diabetic kidney disease;	chr7:65951549	chr7:65141225~65234216:+
LIHC	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	6.46	3.57e-10	2.87e-07	0.57	0.33	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
LIHC	cis	rs36093924	0.646	rs5996094	ENSG00000237037.8	NDUFA6-AS1	-6.46	3.59e-10	2.89e-07	-0.41	-0.33	Intelligence;	chr22:41951056	chr22:42090931~42137742:+
LIHC	cis	rs17270561	0.609	rs9348694	ENSG00000216436.2	HIST1H2APS1	-6.46	3.61e-10	2.9e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25753412	chr6:25732497~25732827:+
LIHC	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-6.46	3.62e-10	2.91e-07	-0.39	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-6.46	3.62e-10	2.91e-07	-0.39	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-6.46	3.62e-10	2.91e-07	-0.39	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
LIHC	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-6.46	3.62e-10	2.91e-07	-0.44	-0.33	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
LIHC	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	6.46	3.64e-10	2.92e-07	0.48	0.33	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
LIHC	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-6.46	3.64e-10	2.93e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-6.46	3.64e-10	2.93e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
LIHC	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-6.46	3.66e-10	2.94e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
LIHC	cis	rs12681287	0.64	rs10086340	ENSG00000250569.1	NTAN1P2	6.46	3.67e-10	2.95e-07	0.38	0.33	Caudate activity during reward;	chr8:86434560	chr8:86481754~86483002:-
LIHC	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	6.46	3.68e-10	2.95e-07	0.42	0.33	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
LIHC	cis	rs6061231	0.834	rs2427311	ENSG00000273619.1	RP5-908M14.9	-6.46	3.68e-10	2.95e-07	-0.29	-0.33	Colorectal cancer;	chr20:62395067	chr20:62386303~62386970:-
LIHC	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-6.46	3.69e-10	2.96e-07	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
LIHC	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-6.46	3.69e-10	2.96e-07	-0.4	-0.33	Migraine;	chr4:56880007	chr4:56960927~56961373:-
LIHC	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-6.46	3.7e-10	2.97e-07	-0.36	-0.33	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
LIHC	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.45	3.74e-10	3e-07	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
LIHC	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.45	3.74e-10	3e-07	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
LIHC	cis	rs1003645	0.861	rs6505500	ENSG00000278690.1	RP11-104J23.2	6.45	3.75e-10	3.01e-07	0.43	0.33	Blood protein levels;	chr17:36019746	chr17:36012504~36012891:+
LIHC	cis	rs832187	0.666	rs2241823	ENSG00000280620.1	SCAANT1	6.45	3.76e-10	3.01e-07	0.41	0.33	Schizophrenia;	chr3:63979417	chr3:63911518~63911772:-
LIHC	cis	rs10256972	0.804	rs10275585	ENSG00000229043.2	AC091729.9	-6.45	3.76e-10	3.01e-07	-0.39	-0.33	Endometriosis;Longevity;	chr7:977703	chr7:1160374~1165267:+
LIHC	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-6.45	3.77e-10	3.02e-07	-0.39	-0.33	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
LIHC	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-6.45	3.77e-10	3.02e-07	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
LIHC	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	6.45	3.79e-10	3.03e-07	0.44	0.33	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
LIHC	cis	rs9843304	0.616	rs4681177	ENSG00000244503.1	RP11-278L15.6	6.45	3.81e-10	3.05e-07	0.36	0.33	Gallstone disease;	chr3:149485213	chr3:149494660~149495995:+
LIHC	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	6.45	3.81e-10	3.05e-07	0.39	0.33	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
LIHC	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-6.45	3.82e-10	3.06e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-6.45	3.82e-10	3.06e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.45	3.82e-10	3.06e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
LIHC	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-6.45	3.83e-10	3.06e-07	-0.41	-0.33	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-6.45	3.83e-10	3.06e-07	-0.41	-0.33	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-6.45	3.83e-10	3.06e-07	-0.41	-0.33	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-6.45	3.83e-10	3.06e-07	-0.41	-0.33	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-6.45	3.83e-10	3.06e-07	-0.41	-0.33	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
LIHC	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	6.45	3.84e-10	3.07e-07	0.52	0.33	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	6.45	3.84e-10	3.07e-07	0.52	0.33	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
LIHC	cis	rs739496	0.615	rs7978737	ENSG00000226469.1	ADAM1B	6.45	3.85e-10	3.08e-07	0.43	0.33	Platelet count;	chr12:111758807	chr12:111927018~111929017:+
LIHC	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-6.45	3.86e-10	3.08e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
LIHC	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-6.45	3.88e-10	3.1e-07	-0.4	-0.33	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-6.45	3.88e-10	3.1e-07	-0.4	-0.33	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-6.45	3.88e-10	3.1e-07	-0.4	-0.33	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-6.45	3.88e-10	3.1e-07	-0.4	-0.33	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
LIHC	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	6.45	3.89e-10	3.11e-07	0.49	0.33	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	6.45	3.89e-10	3.11e-07	0.49	0.33	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	6.45	3.89e-10	3.11e-07	0.49	0.33	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
LIHC	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-6.45	3.92e-10	3.13e-07	-0.42	-0.33	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
LIHC	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-6.44	3.94e-10	3.14e-07	-0.37	-0.33	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
LIHC	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-6.44	3.94e-10	3.15e-07	-0.41	-0.33	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
LIHC	cis	rs3829655	0.905	rs4801882	ENSG00000273837.1	LLNLR-470E3.1	-6.44	3.96e-10	3.16e-07	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr19:51623800	chr19:51639478~51639931:-
LIHC	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-6.44	3.97e-10	3.17e-07	-0.49	-0.33	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
LIHC	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	6.44	3.99e-10	3.19e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
LIHC	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	6.44	4.01e-10	3.2e-07	0.39	0.33	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
LIHC	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	6.44	4.03e-10	3.21e-07	0.57	0.33	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
LIHC	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	6.44	4.03e-10	3.21e-07	0.52	0.33	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
LIHC	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-6.44	4.04e-10	3.22e-07	-0.38	-0.33	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
LIHC	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-6.44	4.05e-10	3.23e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
LIHC	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	6.44	4.06e-10	3.23e-07	0.54	0.33	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
LIHC	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-6.44	4.08e-10	3.25e-07	-0.32	-0.33	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
LIHC	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	6.44	4.08e-10	3.25e-07	0.41	0.33	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
LIHC	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-6.44	4.08e-10	3.25e-07	-0.4	-0.33	Migraine;	chr4:56879297	chr4:56960927~56961373:-
LIHC	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-6.44	4.1e-10	3.26e-07	-0.46	-0.33	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
LIHC	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-6.44	4.11e-10	3.27e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
LIHC	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	6.44	4.12e-10	3.28e-07	0.47	0.33	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
LIHC	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-6.44	4.13e-10	3.28e-07	-0.4	-0.33	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
LIHC	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-6.44	4.13e-10	3.29e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
LIHC	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	6.44	4.13e-10	3.29e-07	0.39	0.33	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
LIHC	cis	rs2688482	0.512	rs3103954	ENSG00000224769.1	AC069213.1	6.44	4.14e-10	3.3e-07	0.49	0.33	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195614947~195620233:+
LIHC	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-6.44	4.14e-10	3.3e-07	-0.46	-0.33	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
LIHC	cis	rs1577917	1	rs6454513	ENSG00000234155.1	RP11-30P6.6	-6.44	4.16e-10	3.31e-07	-0.39	-0.33	Response to antipsychotic treatment;	chr6:86010331	chr6:85387219~85390186:-
LIHC	cis	rs11672691	0.829	rs8112363	ENSG00000267107.5	PCAT19	6.44	4.16e-10	3.31e-07	0.39	0.33	Prostate cancer;	chr19:41483803	chr19:41454169~41500649:-
LIHC	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.44	4.16e-10	3.31e-07	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
LIHC	cis	rs2439831	0.867	rs2255440	ENSG00000205771.5	CATSPER2P1	-6.43	4.18e-10	3.33e-07	-0.45	-0.33	Lung cancer in ever smokers;	chr15:43538269	chr15:43726918~43747094:-
LIHC	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-6.43	4.19e-10	3.33e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-6.43	4.19e-10	3.33e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-6.43	4.19e-10	3.33e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-6.43	4.19e-10	3.33e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-6.43	4.19e-10	3.33e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
LIHC	cis	rs17270561	0.609	rs9393655	ENSG00000216436.2	HIST1H2APS1	-6.43	4.2e-10	3.34e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25711110	chr6:25732497~25732827:+
LIHC	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-6.43	4.21e-10	3.34e-07	-0.41	-0.33	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
LIHC	cis	rs1577917	0.958	rs12216074	ENSG00000234155.1	RP11-30P6.6	6.43	4.24e-10	3.37e-07	0.39	0.33	Response to antipsychotic treatment;	chr6:85810284	chr6:85387219~85390186:-
LIHC	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	6.43	4.25e-10	3.38e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	6.43	4.25e-10	3.38e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
LIHC	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-6.43	4.25e-10	3.38e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
LIHC	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	6.43	4.25e-10	3.38e-07	0.38	0.33	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
LIHC	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	6.43	4.27e-10	3.39e-07	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
LIHC	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	6.43	4.27e-10	3.39e-07	0.35	0.33	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
LIHC	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.43	4.28e-10	3.4e-07	-0.37	-0.33	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
LIHC	cis	rs1939012	0.819	rs6590986	ENSG00000281655.1	RP11-817J15.3	-6.43	4.33e-10	3.43e-07	-0.39	-0.33	Epilepsy;	chr11:102728128	chr11:102681310~102683913:+
LIHC	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	6.43	4.33e-10	3.44e-07	0.4	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
LIHC	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-6.43	4.33e-10	3.44e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
LIHC	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-6.43	4.35e-10	3.45e-07	-0.49	-0.33	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
LIHC	cis	rs67079557	1	rs67079557	ENSG00000260269.4	CTD-2323K18.1	-6.43	4.41e-10	3.5e-07	-0.43	-0.33	Breast cancer;	chr15:75637966	chr15:75527150~75601205:-
LIHC	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	6.43	4.42e-10	3.5e-07	0.35	0.33	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	6.43	4.42e-10	3.5e-07	0.35	0.33	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
LIHC	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	6.42	4.45e-10	3.53e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
LIHC	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	6.42	4.46e-10	3.53e-07	0.38	0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
LIHC	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	6.42	4.46e-10	3.54e-07	0.48	0.33	Height;	chr6:109618283	chr6:109382795~109383666:+
LIHC	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	6.42	4.48e-10	3.55e-07	0.39	0.33	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
LIHC	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	6.42	4.51e-10	3.57e-07	0.38	0.33	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
LIHC	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-6.42	4.52e-10	3.57e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
LIHC	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	6.42	4.52e-10	3.58e-07	0.4	0.33	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
LIHC	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-6.42	4.52e-10	3.58e-07	-0.49	-0.33	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
LIHC	cis	rs2439831	0.85	rs28509275	ENSG00000205771.5	CATSPER2P1	-6.42	4.53e-10	3.58e-07	-0.52	-0.33	Lung cancer in ever smokers;	chr15:43805907	chr15:43726918~43747094:-
LIHC	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-6.42	4.53e-10	3.59e-07	-0.27	-0.33	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
LIHC	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	6.42	4.54e-10	3.59e-07	0.38	0.33	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
LIHC	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	6.42	4.55e-10	3.6e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	6.42	4.55e-10	3.6e-07	0.47	0.33	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
LIHC	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-6.42	4.55e-10	3.6e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
LIHC	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-6.42	4.55e-10	3.6e-07	-0.48	-0.33	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
LIHC	cis	rs7085104	0.66	rs7902804	ENSG00000236937.2	PTGES3P4	6.42	4.58e-10	3.62e-07	0.4	0.33	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102845595~102845950:+
LIHC	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	6.42	4.58e-10	3.62e-07	0.49	0.33	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
LIHC	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	6.42	4.59e-10	3.62e-07	0.4	0.33	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
LIHC	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-6.42	4.59e-10	3.63e-07	-0.37	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
LIHC	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-6.42	4.59e-10	3.63e-07	-0.37	-0.33	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
LIHC	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-6.42	4.59e-10	3.63e-07	-0.37	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
LIHC	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	6.42	4.59e-10	3.63e-07	0.48	0.33	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
LIHC	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	6.42	4.59e-10	3.63e-07	0.48	0.33	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
LIHC	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	6.42	4.63e-10	3.66e-07	0.37	0.33	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
LIHC	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.42	4.63e-10	3.66e-07	-0.37	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
LIHC	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	6.42	4.66e-10	3.67e-07	0.39	0.33	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	6.42	4.66e-10	3.67e-07	0.39	0.33	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	6.42	4.66e-10	3.68e-07	0.39	0.33	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
LIHC	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	6.42	4.68e-10	3.69e-07	0.35	0.33	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
LIHC	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-6.42	4.69e-10	3.7e-07	-0.34	-0.33	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
LIHC	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.41	4.69e-10	3.7e-07	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
LIHC	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	6.41	4.72e-10	3.73e-07	0.37	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
LIHC	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-6.41	4.73e-10	3.73e-07	-0.46	-0.33	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
LIHC	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-6.41	4.73e-10	3.73e-07	-0.37	-0.33	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-6.41	4.73e-10	3.73e-07	-0.37	-0.33	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-6.41	4.73e-10	3.73e-07	-0.37	-0.33	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
LIHC	cis	rs4538475	1	rs4538475	ENSG00000214846.4	RP11-115L11.1	6.41	4.74e-10	3.74e-07	0.43	0.33	Parkinson's disease;	chr4:15736314	chr4:15730962~15731627:-
LIHC	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	6.41	4.76e-10	3.75e-07	0.56	0.33	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
LIHC	cis	rs5758659	0.714	rs2413668	ENSG00000227370.1	RP4-669P10.19	6.41	4.77e-10	3.76e-07	0.37	0.33	Cognitive function;	chr22:42109837	chr22:42132543~42132998:+
LIHC	cis	rs6490294	0.528	rs78745958	ENSG00000226469.1	ADAM1B	6.41	4.79e-10	3.78e-07	0.49	0.33	Mean platelet volume;	chr12:111990367	chr12:111927018~111929017:+
LIHC	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-6.41	4.79e-10	3.78e-07	-0.42	-0.33	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
LIHC	cis	rs1003645	0.569	rs7222922	ENSG00000275944.1	RP11-104J23.1	6.41	4.8e-10	3.78e-07	0.36	0.33	Blood protein levels;	chr17:36008654	chr17:36001419~36011618:+
LIHC	cis	rs5758659	0.714	rs6002626	ENSG00000227370.1	RP4-669P10.19	6.41	4.8e-10	3.78e-07	0.38	0.33	Cognitive function;	chr22:42121985	chr22:42132543~42132998:+
LIHC	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	6.41	4.81e-10	3.79e-07	0.55	0.33	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	6.41	4.81e-10	3.79e-07	0.52	0.33	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
LIHC	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-6.41	4.81e-10	3.79e-07	-0.45	-0.33	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
LIHC	cis	rs2243480	0.901	rs57126451	ENSG00000164669.11	INTS4P1	6.41	4.85e-10	3.82e-07	0.57	0.33	Diabetic kidney disease;	chr7:65951319	chr7:65141225~65234216:+
LIHC	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	6.41	4.86e-10	3.83e-07	0.48	0.33	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
LIHC	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	6.41	4.87e-10	3.84e-07	0.4	0.33	Migraine;	chr4:56881468	chr4:56960927~56961373:-
LIHC	cis	rs13068223	0.584	rs345986	ENSG00000243926.1	TIPARP-AS1	-6.41	4.88e-10	3.84e-07	-0.36	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156677540	chr3:156671862~156674378:-
LIHC	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	6.41	4.9e-10	3.86e-07	0.4	0.33	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
LIHC	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	6.41	4.91e-10	3.86e-07	0.39	0.33	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	6.41	4.91e-10	3.86e-07	0.39	0.33	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
LIHC	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	6.41	4.93e-10	3.88e-07	0.46	0.33	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	6.41	4.93e-10	3.88e-07	0.46	0.33	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
LIHC	cis	rs854625	0.661	rs854689	ENSG00000278690.1	RP11-104J23.2	-6.41	4.94e-10	3.89e-07	-0.48	-0.33	Cerebrospinal fluid biomarker levels;	chr17:35996083	chr17:36012504~36012891:+
LIHC	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-6.41	4.97e-10	3.91e-07	-0.38	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
LIHC	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-6.41	4.97e-10	3.91e-07	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
LIHC	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	6.41	4.97e-10	3.91e-07	0.35	0.33	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
LIHC	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	6.4	4.99e-10	3.92e-07	0.5	0.33	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
LIHC	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-6.4	5.04e-10	3.96e-07	-0.45	-0.33	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
LIHC	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-6.4	5.05e-10	3.96e-07	-0.32	-0.33	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
LIHC	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-6.4	5.07e-10	3.98e-07	-0.4	-0.33	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
LIHC	cis	rs9326248	0.569	rs4938315	ENSG00000236267.1	AP006216.5	6.4	5.07e-10	3.98e-07	0.35	0.33	Blood protein levels;	chr11:116860489	chr11:116813204~116814003:-
LIHC	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-6.4	5.07e-10	3.98e-07	-0.38	-0.33	QT interval;	chr12:29297620	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-6.4	5.07e-10	3.98e-07	-0.38	-0.33	QT interval;	chr12:29298788	chr12:29280418~29317848:-
LIHC	cis	rs2243480	1	rs1404147	ENSG00000164669.11	INTS4P1	6.4	5.07e-10	3.98e-07	0.56	0.33	Diabetic kidney disease;	chr7:65799537	chr7:65141225~65234216:+
LIHC	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-6.4	5.08e-10	3.98e-07	-0.33	-0.33	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
LIHC	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-6.4	5.09e-10	3.99e-07	-0.41	-0.33	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
LIHC	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	6.4	5.09e-10	3.99e-07	0.46	0.33	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
LIHC	cis	rs17270561	0.636	rs9379782	ENSG00000216436.2	HIST1H2APS1	-6.4	5.09e-10	4e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25714795	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9348692	ENSG00000216436.2	HIST1H2APS1	-6.4	5.09e-10	4e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25720584	chr6:25732497~25732827:+
LIHC	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	6.4	5.09e-10	4e-07	0.46	0.33	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	6.4	5.09e-10	4e-07	0.46	0.33	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
LIHC	cis	rs5758659	0.657	rs5758587	ENSG00000227370.1	RP4-669P10.19	6.4	5.11e-10	4e-07	0.37	0.33	Cognitive function;	chr22:42121632	chr22:42132543~42132998:+
LIHC	cis	rs1577917	1	rs16876529	ENSG00000234155.1	RP11-30P6.6	6.4	5.11e-10	4e-07	0.38	0.33	Response to antipsychotic treatment;	chr6:85881484	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12204015	ENSG00000234155.1	RP11-30P6.6	6.4	5.11e-10	4e-07	0.38	0.33	Response to antipsychotic treatment;	chr6:85888616	chr6:85387219~85390186:-
LIHC	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	6.4	5.11e-10	4.01e-07	0.37	0.33	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
LIHC	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	6.4	5.12e-10	4.02e-07	0.46	0.33	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
LIHC	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-6.4	5.13e-10	4.02e-07	-0.31	-0.33	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
LIHC	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-6.4	5.14e-10	4.03e-07	-0.41	-0.33	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
LIHC	cis	rs7184046	0.797	rs13737	ENSG00000260269.4	CTD-2323K18.1	-6.4	5.14e-10	4.03e-07	-0.43	-0.33	Height;	chr15:75639788	chr15:75527150~75601205:-
LIHC	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-6.4	5.15e-10	4.03e-07	-0.31	-0.33	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
LIHC	cis	rs523522	0.962	rs3893104	ENSG00000278344.1	RP11-18C24.8	6.4	5.15e-10	4.04e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120466133	chr12:120500735~120501090:-
LIHC	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	6.4	5.17e-10	4.05e-07	0.38	0.33	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
LIHC	cis	rs875971	0.571	rs160641	ENSG00000164669.11	INTS4P1	6.4	5.2e-10	4.07e-07	0.44	0.33	Aortic root size;	chr7:66112359	chr7:65141225~65234216:+
LIHC	cis	rs9843304	0.568	rs13062027	ENSG00000244503.1	RP11-278L15.6	6.4	5.23e-10	4.1e-07	0.35	0.33	Gallstone disease;	chr3:149494892	chr3:149494660~149495995:+
LIHC	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	6.4	5.24e-10	4.1e-07	0.44	0.33	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
LIHC	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-6.4	5.25e-10	4.11e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-6.4	5.25e-10	4.11e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-6.4	5.25e-10	4.11e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-6.4	5.25e-10	4.11e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs313813	ENSG00000164669.11	INTS4P1	6.4	5.25e-10	4.11e-07	0.56	0.33	Diabetic kidney disease;	chr7:66038513	chr7:65141225~65234216:+
LIHC	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-6.39	5.27e-10	4.13e-07	-0.48	-0.33	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
LIHC	cis	rs523522	0.962	rs10774549	ENSG00000278344.1	RP11-18C24.8	6.39	5.27e-10	4.13e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120453369	chr12:120500735~120501090:-
LIHC	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-6.39	5.3e-10	4.15e-07	-0.51	-0.33	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
LIHC	cis	rs523522	0.962	rs9040	ENSG00000278344.1	RP11-18C24.8	6.39	5.32e-10	4.16e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120462471	chr12:120500735~120501090:-
LIHC	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	6.39	5.34e-10	4.17e-07	0.34	0.33	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
LIHC	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-6.39	5.35e-10	4.18e-07	-0.48	-0.33	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
LIHC	cis	rs12291225	0.535	rs11023203	ENSG00000251991.1	RNU7-49P	6.39	5.35e-10	4.18e-07	0.35	0.33	Sense of smell;	chr11:14388269	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.535	rs12806025	ENSG00000251991.1	RNU7-49P	6.39	5.35e-10	4.18e-07	0.35	0.33	Sense of smell;	chr11:14392271	chr11:14478892~14478953:+
LIHC	cis	rs832190	1	rs832190	ENSG00000280620.1	SCAANT1	-6.39	5.36e-10	4.19e-07	-0.4	-0.33	Schizophrenia;	chr3:63856953	chr3:63911518~63911772:-
LIHC	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-6.39	5.4e-10	4.21e-07	-0.31	-0.33	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
LIHC	cis	rs5758659	0.714	rs5751216	ENSG00000227370.1	RP4-669P10.19	6.39	5.44e-10	4.25e-07	0.36	0.33	Cognitive function;	chr22:42112933	chr22:42132543~42132998:+
LIHC	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	6.39	5.46e-10	4.26e-07	0.39	0.33	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
LIHC	cis	rs2243480	1	rs34815098	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65827267	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs4548056	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65833886	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs7456042	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65834791	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35735127	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65835436	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs35256305	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65841418	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs73142121	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65846219	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs34004500	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65847191	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35825738	ENSG00000164669.11	INTS4P1	6.39	5.47e-10	4.27e-07	0.57	0.33	Diabetic kidney disease;	chr7:65853040	chr7:65141225~65234216:+
LIHC	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-6.39	5.48e-10	4.27e-07	-0.31	-0.33	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
LIHC	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	6.39	5.49e-10	4.28e-07	0.46	0.33	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
LIHC	cis	rs7914558	1	rs11191577	ENSG00000236937.2	PTGES3P4	6.39	5.52e-10	4.3e-07	0.39	0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102845595~102845950:+
LIHC	cis	rs12681287	0.604	rs7017716	ENSG00000250569.1	NTAN1P2	6.39	5.53e-10	4.31e-07	0.38	0.33	Caudate activity during reward;	chr8:86416772	chr8:86481754~86483002:-
LIHC	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	6.39	5.55e-10	4.33e-07	0.35	0.33	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
LIHC	cis	rs2243480	1	rs937108	ENSG00000164669.11	INTS4P1	6.38	5.59e-10	4.35e-07	0.56	0.33	Diabetic kidney disease;	chr7:65963465	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35542501	ENSG00000164669.11	INTS4P1	6.38	5.59e-10	4.35e-07	0.56	0.33	Diabetic kidney disease;	chr7:65966228	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.711	rs1626926	ENSG00000164669.11	INTS4P1	6.38	5.59e-10	4.35e-07	0.56	0.33	Diabetic kidney disease;	chr7:65970805	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.708	rs781141	ENSG00000164669.11	INTS4P1	6.38	5.59e-10	4.35e-07	0.56	0.33	Diabetic kidney disease;	chr7:65973566	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs781142	ENSG00000164669.11	INTS4P1	6.38	5.59e-10	4.35e-07	0.56	0.33	Diabetic kidney disease;	chr7:65973791	chr7:65141225~65234216:+
LIHC	cis	rs523522	0.962	rs7488320	ENSG00000278344.1	RP11-18C24.8	6.38	5.61e-10	4.36e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120543827	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs12814055	ENSG00000278344.1	RP11-18C24.8	6.38	5.61e-10	4.36e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120549588	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs3213565	ENSG00000278344.1	RP11-18C24.8	6.38	5.61e-10	4.36e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120554598	chr12:120500735~120501090:-
LIHC	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-6.38	5.62e-10	4.37e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.803	rs160649	ENSG00000164669.11	INTS4P1	6.38	5.64e-10	4.39e-07	0.57	0.33	Diabetic kidney disease;	chr7:66078212	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs160648	ENSG00000164669.11	INTS4P1	6.38	5.64e-10	4.39e-07	0.57	0.33	Diabetic kidney disease;	chr7:66078397	chr7:65141225~65234216:+
LIHC	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	6.38	5.65e-10	4.39e-07	0.35	0.33	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	6.38	5.65e-10	4.39e-07	0.35	0.33	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	6.38	5.65e-10	4.39e-07	0.35	0.33	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	6.38	5.65e-10	4.39e-07	0.35	0.33	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
LIHC	cis	rs6061231	0.701	rs6061505	ENSG00000273619.1	RP5-908M14.9	-6.38	5.66e-10	4.4e-07	-0.27	-0.33	Colorectal cancer;	chr20:62385155	chr20:62386303~62386970:-
LIHC	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	6.38	5.67e-10	4.41e-07	0.44	0.33	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
LIHC	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-6.38	5.68e-10	4.41e-07	-0.4	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
LIHC	cis	rs17270561	0.609	rs9358886	ENSG00000216436.2	HIST1H2APS1	-6.38	5.68e-10	4.41e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25758025	chr6:25732497~25732827:+
LIHC	cis	rs7914558	1	rs7067970	ENSG00000236937.2	PTGES3P4	6.38	5.7e-10	4.43e-07	0.39	0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102845595~102845950:+
LIHC	cis	rs523522	0.962	rs11065145	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120509616	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.923	rs10774553	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120517181	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs11065149	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120519160	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.924	rs11065150	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120521072	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs10849757	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120526211	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs55848094	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120528856	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs3742052	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120529118	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs10849758	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120533346	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs11065154	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120533614	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.926	rs10774555	ENSG00000278344.1	RP11-18C24.8	6.38	5.7e-10	4.43e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120534175	chr12:120500735~120501090:-
LIHC	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	6.38	5.72e-10	4.44e-07	0.43	0.33	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
LIHC	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-6.38	5.72e-10	4.44e-07	-0.52	-0.33	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
LIHC	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-6.38	5.75e-10	4.46e-07	-0.43	-0.33	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
LIHC	cis	rs523522	0.923	rs1048830	ENSG00000278344.1	RP11-18C24.8	6.38	5.77e-10	4.47e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120444414	chr12:120500735~120501090:-
LIHC	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-6.38	5.77e-10	4.47e-07	-0.4	-0.33	Gout;	chr7:66645053	chr7:66902857~66906297:+
LIHC	cis	rs5758659	0.714	rs6002607	ENSG00000227370.1	RP4-669P10.19	6.38	5.8e-10	4.5e-07	0.37	0.33	Cognitive function;	chr22:42100502	chr22:42132543~42132998:+
LIHC	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-6.38	5.82e-10	4.51e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-6.38	5.82e-10	4.51e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
LIHC	cis	rs3020736	0.5	rs4147641	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs4147640	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.507	rs6002600	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Schizophrenia;	chr22:42092902	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6002601	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6002604	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs5996109	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs5996110	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs9620026	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs28791586	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs2839708	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6519306	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6002614	ENSG00000237037.8	NDUFA6-AS1	-6.38	5.83e-10	4.51e-07	-0.39	-0.33	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42090931~42137742:+
LIHC	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	6.38	5.83e-10	4.52e-07	0.46	0.33	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
LIHC	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	6.38	5.85e-10	4.53e-07	0.38	0.33	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
LIHC	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-6.38	5.89e-10	4.56e-07	-0.4	-0.33	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
LIHC	cis	rs523522	0.923	rs2235217	ENSG00000278344.1	RP11-18C24.8	6.38	5.9e-10	4.57e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120446525	chr12:120500735~120501090:-
LIHC	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	6.38	5.91e-10	4.58e-07	0.38	0.33	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
LIHC	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	6.38	5.91e-10	4.58e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	6.38	5.91e-10	4.58e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	6.38	5.91e-10	4.58e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
LIHC	cis	rs17270561	0.609	rs4711095	ENSG00000216436.2	HIST1H2APS1	-6.38	5.91e-10	4.58e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25726546	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4712959	ENSG00000216436.2	HIST1H2APS1	-6.38	5.91e-10	4.58e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25726829	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4712960	ENSG00000216436.2	HIST1H2APS1	-6.38	5.91e-10	4.58e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25727037	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4712961	ENSG00000216436.2	HIST1H2APS1	-6.38	5.91e-10	4.58e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25727106	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9358872	ENSG00000216436.2	HIST1H2APS1	-6.38	5.91e-10	4.58e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25727289	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9356985	ENSG00000216436.2	HIST1H2APS1	-6.38	5.91e-10	4.58e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25727870	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4712964	ENSG00000216436.2	HIST1H2APS1	-6.38	5.92e-10	4.58e-07	-0.4	-0.33	Iron status biomarkers;	chr6:25740594	chr6:25732497~25732827:+
LIHC	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-6.37	5.93e-10	4.59e-07	-0.41	-0.33	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
LIHC	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	6.37	5.94e-10	4.59e-07	0.39	0.33	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
LIHC	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	6.37	5.94e-10	4.6e-07	0.45	0.33	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
LIHC	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-6.37	5.95e-10	4.6e-07	-0.35	-0.33	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
LIHC	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-6.37	5.96e-10	4.61e-07	-0.43	-0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
LIHC	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-6.37	5.96e-10	4.61e-07	-0.43	-0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
LIHC	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-6.37	5.96e-10	4.61e-07	-0.43	-0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
LIHC	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	6.37	5.96e-10	4.61e-07	0.35	0.33	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
LIHC	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-6.37	5.99e-10	4.63e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-6.37	5.99e-10	4.63e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-6.37	5.99e-10	4.63e-07	-0.49	-0.33	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
LIHC	cis	rs523522	0.962	rs12371550	ENSG00000278344.1	RP11-18C24.8	6.37	6e-10	4.64e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120549840	chr12:120500735~120501090:-
LIHC	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-6.37	6.02e-10	4.65e-07	-0.37	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
LIHC	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	6.37	6.04e-10	4.67e-07	0.47	0.33	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
LIHC	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-6.37	6.05e-10	4.67e-07	-0.45	-0.33	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
LIHC	cis	rs11089937	0.926	rs5750601	ENSG00000211639.2	IGLV4-60	6.37	6.06e-10	4.68e-07	0.27	0.33	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22162199~22162681:+
LIHC	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-6.37	6.12e-10	4.73e-07	-0.35	-0.33	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
LIHC	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	6.37	6.12e-10	4.73e-07	0.37	0.33	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
LIHC	cis	rs523522	0.847	rs11065132	ENSG00000278344.1	RP11-18C24.8	6.37	6.13e-10	4.74e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120470656	chr12:120500735~120501090:-
LIHC	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	6.37	6.17e-10	4.76e-07	0.41	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
LIHC	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-6.37	6.2e-10	4.78e-07	-0.5	-0.33	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
LIHC	cis	rs7580658	0.68	rs6710535	ENSG00000236682.1	AC068282.3	6.37	6.23e-10	4.81e-07	0.42	0.33	Protein C levels;	chr2:127433384	chr2:127389130~127400580:+
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-6.37	6.26e-10	4.83e-07	-0.38	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
LIHC	cis	rs113835537	0.569	rs17496586	ENSG00000255517.5	CTD-3074O7.5	-6.36	6.3e-10	4.86e-07	-0.42	-0.33	Airway imaging phenotypes;	chr11:66548041	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-6.36	6.31e-10	4.86e-07	-0.35	-0.33	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
LIHC	cis	rs2243480	0.831	rs7806717	ENSG00000164669.11	INTS4P1	-6.36	6.32e-10	4.86e-07	-0.56	-0.33	Diabetic kidney disease;	chr7:65928187	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs78803505	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65917585	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs34933526	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65918212	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs34577383	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65920739	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs6949812	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65922114	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs6970243	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65923503	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs7794661	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65924743	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs7795242	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65925107	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.708	rs35310401	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65925372	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35058610	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65925938	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs2177703	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65926730	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35432774	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65928032	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs56985706	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65929575	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs60683927	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65929781	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs58062456	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65929865	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs34529418	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65938222	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.901	rs35087093	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65940221	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35046236	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65943626	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs36068983	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65944004	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs68189316	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65944182	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs34804747	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65947955	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs11538349	ENSG00000164669.11	INTS4P1	6.36	6.32e-10	4.86e-07	0.56	0.33	Diabetic kidney disease;	chr7:65956884	chr7:65141225~65234216:+
LIHC	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	6.36	6.33e-10	4.88e-07	0.32	0.33	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
LIHC	cis	rs55665837	0.524	rs61884009	ENSG00000251991.1	RNU7-49P	6.36	6.36e-10	4.89e-07	0.36	0.33	Vitamin D levels;	chr11:14404916	chr11:14478892~14478953:+
LIHC	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-6.36	6.36e-10	4.9e-07	-0.48	-0.33	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
LIHC	cis	rs12291225	0.535	rs10832248	ENSG00000251991.1	RNU7-49P	6.36	6.39e-10	4.92e-07	0.35	0.33	Sense of smell;	chr11:14391541	chr11:14478892~14478953:+
LIHC	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-6.36	6.4e-10	4.92e-07	-0.49	-0.33	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
LIHC	cis	rs2735413	0.711	rs12921476	ENSG00000276007.1	RP11-358L22.3	-6.36	6.4e-10	4.92e-07	-0.36	-0.33	Systolic blood pressure (alcohol consumption interaction);	chr16:78045949	chr16:78123243~78124332:+
LIHC	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	6.36	6.41e-10	4.93e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
LIHC	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-6.36	6.47e-10	4.97e-07	-0.4	-0.33	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
LIHC	cis	rs523522	0.962	rs4767905	ENSG00000278344.1	RP11-18C24.8	6.36	6.47e-10	4.98e-07	0.39	0.33	High light scatter reticulocyte count;	chr12:120493032	chr12:120500735~120501090:-
LIHC	cis	rs2933343	0.716	rs9867404	ENSG00000231305.3	RP11-723O4.2	-6.36	6.48e-10	4.98e-07	-0.37	-0.33	IgG glycosylation;	chr3:128847295	chr3:128861313~128871540:-
LIHC	cis	rs6085948	0.861	rs2224055	ENSG00000238102.1	RP11-19D2.1	-6.36	6.5e-10	5e-07	-0.58	-0.33	Interleukin-10 levels;	chr20:7253521	chr20:7256580~7258214:-
LIHC	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	6.36	6.51e-10	5e-07	0.39	0.33	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
LIHC	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-6.36	6.52e-10	5.01e-07	-0.37	-0.33	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
LIHC	cis	rs4356975	0.563	rs7698645	ENSG00000249956.3	RP11-790I12.2	6.36	6.53e-10	5.02e-07	0.36	0.33	Obesity-related traits;	chr4:69106192	chr4:69408836~69423164:+
LIHC	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	6.36	6.53e-10	5.02e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	6.36	6.53e-10	5.02e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	6.36	6.53e-10	5.02e-07	0.34	0.33	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
LIHC	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	6.36	6.55e-10	5.03e-07	0.44	0.33	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
LIHC	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-6.36	6.57e-10	5.04e-07	-0.4	-0.33	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
LIHC	cis	rs2243480	1	rs34703416	ENSG00000164669.11	INTS4P1	6.36	6.58e-10	5.05e-07	0.57	0.33	Diabetic kidney disease;	chr7:65835655	chr7:65141225~65234216:+
LIHC	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	6.36	6.62e-10	5.08e-07	0.56	0.33	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
LIHC	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	6.36	6.63e-10	5.09e-07	0.42	0.33	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
LIHC	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	6.36	6.63e-10	5.09e-07	0.39	0.33	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
LIHC	cis	rs1577917	0.958	rs16876530	ENSG00000234155.1	RP11-30P6.6	6.36	6.65e-10	5.1e-07	0.38	0.32	Response to antipsychotic treatment;	chr6:85885923	chr6:85387219~85390186:-
LIHC	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-6.35	6.66e-10	5.11e-07	-0.4	-0.32	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
LIHC	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-6.35	6.67e-10	5.12e-07	-0.41	-0.32	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
LIHC	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	6.35	6.68e-10	5.12e-07	0.36	0.32	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
LIHC	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	6.35	6.7e-10	5.14e-07	0.37	0.32	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
LIHC	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	6.35	6.71e-10	5.14e-07	0.51	0.32	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
LIHC	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-6.35	6.73e-10	5.16e-07	-0.4	-0.32	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
LIHC	cis	rs523522	0.962	rs3759394	ENSG00000278344.1	RP11-18C24.8	6.35	6.74e-10	5.17e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120495370	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs2233676	ENSG00000278344.1	RP11-18C24.8	6.35	6.74e-10	5.17e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120495804	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.923	rs3916065	ENSG00000278344.1	RP11-18C24.8	6.35	6.74e-10	5.17e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120496821	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs9788155	ENSG00000278344.1	RP11-18C24.8	6.35	6.74e-10	5.17e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120500605	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs10849754	ENSG00000278344.1	RP11-18C24.8	6.35	6.74e-10	5.17e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120502615	chr12:120500735~120501090:-
LIHC	cis	rs9843304	0.616	rs4131174	ENSG00000244503.1	RP11-278L15.6	6.35	6.74e-10	5.17e-07	0.35	0.32	Gallstone disease;	chr3:149486123	chr3:149494660~149495995:+
LIHC	cis	rs916888	0.779	rs199528	ENSG00000262881.1	RP11-669E14.4	-6.35	6.77e-10	5.19e-07	-0.53	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs199525	ENSG00000262881.1	RP11-669E14.4	-6.35	6.77e-10	5.19e-07	-0.53	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45907670~45910779:-
LIHC	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	6.35	6.77e-10	5.19e-07	0.46	0.32	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
LIHC	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	6.35	6.77e-10	5.19e-07	0.34	0.32	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
LIHC	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	6.35	6.77e-10	5.19e-07	0.37	0.32	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
LIHC	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	6.35	6.79e-10	5.2e-07	0.53	0.32	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	6.35	6.79e-10	5.2e-07	0.53	0.32	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	6.35	6.79e-10	5.2e-07	0.53	0.32	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	6.35	6.79e-10	5.2e-07	0.53	0.32	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	6.35	6.79e-10	5.2e-07	0.53	0.32	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	6.35	6.79e-10	5.2e-07	0.53	0.32	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	6.35	6.79e-10	5.2e-07	0.53	0.32	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
LIHC	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	6.35	6.81e-10	5.22e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
LIHC	cis	rs1023500	0.505	rs134891	ENSG00000237037.8	NDUFA6-AS1	6.35	6.82e-10	5.22e-07	0.35	0.32	Schizophrenia;	chr22:42279876	chr22:42090931~42137742:+
LIHC	cis	rs9326248	0.53	rs2127905	ENSG00000280143.1	AP000892.6	6.35	6.84e-10	5.24e-07	0.41	0.32	Blood protein levels;	chr11:117155658	chr11:117204967~117210292:+
LIHC	cis	rs7115242	0.514	rs4936367	ENSG00000280143.1	AP000892.6	6.35	6.84e-10	5.24e-07	0.41	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.53	rs4604928	ENSG00000280143.1	AP000892.6	6.35	6.84e-10	5.24e-07	0.41	0.32	Blood protein levels;	chr11:117173487	chr11:117204967~117210292:+
LIHC	cis	rs523522	0.962	rs2393590	ENSG00000278344.1	RP11-18C24.8	6.35	6.84e-10	5.24e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120476097	chr12:120500735~120501090:-
LIHC	cis	rs12681287	0.752	rs4310184	ENSG00000250569.1	NTAN1P2	6.35	6.86e-10	5.25e-07	0.39	0.32	Caudate activity during reward;	chr8:86233024	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.711	rs28506490	ENSG00000250569.1	NTAN1P2	6.35	6.86e-10	5.25e-07	0.39	0.32	Caudate activity during reward;	chr8:86233889	chr8:86481754~86483002:-
LIHC	cis	rs12285276	0.536	rs4411261	ENSG00000205106.4	DKFZp779M0652	6.35	6.89e-10	5.27e-07	0.32	0.32	Visceral fat;	chr11:45785530	chr11:45771432~45772358:+
LIHC	cis	rs4356975	0.697	rs5002700	ENSG00000249956.3	RP11-790I12.2	6.35	6.9e-10	5.28e-07	0.39	0.32	Obesity-related traits;	chr4:69155637	chr4:69408836~69423164:+
LIHC	cis	rs2735413	0.599	rs79414963	ENSG00000276007.1	RP11-358L22.3	6.35	6.9e-10	5.28e-07	0.45	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78043132	chr16:78123243~78124332:+
LIHC	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	6.35	6.91e-10	5.29e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	6.35	6.91e-10	5.29e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
LIHC	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-6.35	6.98e-10	5.33e-07	-0.32	-0.32	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
LIHC	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-6.35	6.99e-10	5.34e-07	-0.45	-0.32	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
LIHC	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	6.35	7.01e-10	5.35e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
LIHC	cis	rs4356975	0.563	rs6600885	ENSG00000249956.3	RP11-790I12.2	6.35	7.01e-10	5.36e-07	0.36	0.32	Obesity-related traits;	chr4:69103949	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600886	ENSG00000249956.3	RP11-790I12.2	6.35	7.01e-10	5.36e-07	0.36	0.32	Obesity-related traits;	chr4:69104017	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600887	ENSG00000249956.3	RP11-790I12.2	6.35	7.01e-10	5.36e-07	0.36	0.32	Obesity-related traits;	chr4:69104070	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs6600888	ENSG00000249956.3	RP11-790I12.2	6.35	7.01e-10	5.36e-07	0.36	0.32	Obesity-related traits;	chr4:69104141	chr4:69408836~69423164:+
LIHC	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-6.35	7.02e-10	5.36e-07	-0.38	-0.32	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
LIHC	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	6.35	7.04e-10	5.38e-07	0.45	0.32	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
LIHC	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-6.35	7.05e-10	5.38e-07	-0.41	-0.32	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
LIHC	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	6.34	7.06e-10	5.39e-07	0.4	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
LIHC	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	6.34	7.07e-10	5.4e-07	0.42	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
LIHC	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-6.34	7.07e-10	5.4e-07	-0.27	-0.32	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
LIHC	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	6.34	7.12e-10	5.43e-07	0.46	0.32	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
LIHC	cis	rs60065504	1	rs60065504	ENSG00000251022.5	THAP9-AS1	-6.34	7.13e-10	5.44e-07	-0.33	-0.32	Lymphocyte percentage of white cells;	chr4:82964057	chr4:82893009~82900960:-
LIHC	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-6.34	7.15e-10	5.46e-07	-0.35	-0.32	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
LIHC	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-6.34	7.16e-10	5.47e-07	-0.41	-0.32	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
LIHC	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	6.34	7.22e-10	5.51e-07	0.35	0.32	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
LIHC	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	6.34	7.23e-10	5.51e-07	0.38	0.32	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
LIHC	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	6.34	7.25e-10	5.53e-07	0.38	0.32	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
LIHC	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-6.34	7.3e-10	5.57e-07	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
LIHC	cis	rs17270561	0.609	rs9379785	ENSG00000216436.2	HIST1H2APS1	-6.34	7.32e-10	5.58e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25725985	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9358871	ENSG00000216436.2	HIST1H2APS1	-6.34	7.32e-10	5.58e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25726447	chr6:25732497~25732827:+
LIHC	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	6.34	7.32e-10	5.58e-07	0.34	0.32	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
LIHC	cis	rs9326248	0.53	rs7122944	ENSG00000280143.1	AP000892.6	6.34	7.33e-10	5.58e-07	0.41	0.32	Blood protein levels;	chr11:117163903	chr11:117204967~117210292:+
LIHC	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	6.34	7.35e-10	5.6e-07	0.38	0.32	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-6.34	7.36e-10	5.61e-07	-0.38	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
LIHC	cis	rs7914558	1	rs1926030	ENSG00000236937.2	PTGES3P4	6.34	7.38e-10	5.62e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102845595~102845950:+
LIHC	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-6.34	7.39e-10	5.63e-07	-0.27	-0.32	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-6.34	7.39e-10	5.63e-07	-0.27	-0.32	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
LIHC	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-6.34	7.41e-10	5.64e-07	-0.33	-0.32	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
LIHC	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-6.34	7.43e-10	5.66e-07	-0.37	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
LIHC	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-6.34	7.43e-10	5.66e-07	-0.59	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
LIHC	cis	rs3020736	0.519	rs5996116	ENSG00000237037.8	NDUFA6-AS1	-6.34	7.47e-10	5.69e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42090931~42137742:+
LIHC	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-6.33	7.48e-10	5.69e-07	-0.37	-0.32	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
LIHC	cis	rs11672691	0.871	rs2191139	ENSG00000267107.5	PCAT19	6.33	7.48e-10	5.69e-07	0.38	0.32	Prostate cancer;	chr19:41495302	chr19:41454169~41500649:-
LIHC	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-6.33	7.52e-10	5.72e-07	-0.36	-0.32	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
LIHC	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-6.33	7.56e-10	5.75e-07	-0.52	-0.32	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	6.33	7.56e-10	5.75e-07	0.52	0.32	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	6.33	7.56e-10	5.75e-07	0.52	0.32	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	6.33	7.56e-10	5.75e-07	0.52	0.32	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	6.33	7.56e-10	5.75e-07	0.52	0.32	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
LIHC	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-6.33	7.6e-10	5.78e-07	-0.37	-0.32	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
LIHC	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-6.33	7.63e-10	5.8e-07	-0.35	-0.32	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
LIHC	cis	rs1577917	1	rs2166663	ENSG00000234155.1	RP11-30P6.6	6.33	7.66e-10	5.82e-07	0.37	0.32	Response to antipsychotic treatment;	chr6:85884178	chr6:85387219~85390186:-
LIHC	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	6.33	7.67e-10	5.83e-07	0.43	0.32	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
LIHC	cis	rs7914558	1	rs7896547	ENSG00000236937.2	PTGES3P4	6.33	7.67e-10	5.83e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102845595~102845950:+
LIHC	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	6.33	7.68e-10	5.84e-07	0.41	0.32	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-6.33	7.69e-10	5.84e-07	-0.39	-0.32	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
LIHC	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	6.33	7.7e-10	5.85e-07	0.37	0.32	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
LIHC	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-6.33	7.71e-10	5.86e-07	-0.38	-0.32	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
LIHC	cis	rs55665837	0.524	rs2882128	ENSG00000251991.1	RNU7-49P	6.33	7.73e-10	5.87e-07	0.34	0.32	Vitamin D levels;	chr11:14393088	chr11:14478892~14478953:+
LIHC	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-6.33	7.74e-10	5.88e-07	-0.4	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
LIHC	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	6.33	7.78e-10	5.9e-07	0.33	0.32	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
LIHC	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	6.33	7.78e-10	5.9e-07	0.33	0.32	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
LIHC	cis	rs7916697	0.52	rs12246624	ENSG00000233590.1	RP11-153K11.3	-6.33	7.78e-10	5.91e-07	-0.41	-0.32	Optic disc area;	chr10:68276805	chr10:68233251~68242379:-
LIHC	cis	rs2243480	1	rs67728539	ENSG00000164669.11	INTS4P1	6.33	7.79e-10	5.91e-07	0.56	0.32	Diabetic kidney disease;	chr7:65913137	chr7:65141225~65234216:+
LIHC	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-6.33	7.79e-10	5.92e-07	-0.33	-0.32	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
LIHC	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	6.33	7.8e-10	5.92e-07	0.39	0.32	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
LIHC	cis	rs7914558	0.933	rs2066323	ENSG00000236937.2	PTGES3P4	6.33	7.8e-10	5.92e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs7899084	ENSG00000236937.2	PTGES3P4	6.33	7.8e-10	5.92e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs10748837	ENSG00000236937.2	PTGES3P4	6.33	7.8e-10	5.92e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs12571568	ENSG00000236937.2	PTGES3P4	6.33	7.8e-10	5.92e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs12766205	ENSG00000236937.2	PTGES3P4	6.33	7.8e-10	5.92e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs10883837	ENSG00000236937.2	PTGES3P4	6.33	7.8e-10	5.92e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs746293	ENSG00000236937.2	PTGES3P4	6.33	7.8e-10	5.92e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102845595~102845950:+
LIHC	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	6.33	7.84e-10	5.94e-07	0.5	0.32	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
LIHC	cis	rs7580658	0.613	rs12463538	ENSG00000236682.1	AC068282.3	-6.33	7.84e-10	5.95e-07	-0.4	-0.32	Protein C levels;	chr2:127439278	chr2:127389130~127400580:+
LIHC	cis	rs9843304	0.568	rs71304473	ENSG00000244503.1	RP11-278L15.6	6.33	7.84e-10	5.95e-07	0.34	0.32	Gallstone disease;	chr3:149499403	chr3:149494660~149495995:+
LIHC	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	6.33	7.91e-10	6e-07	0.38	0.32	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
LIHC	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	6.32	7.93e-10	6.01e-07	0.43	0.32	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
LIHC	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	6.32	7.96e-10	6.03e-07	0.39	0.32	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
LIHC	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-6.32	7.96e-10	6.03e-07	-0.38	-0.32	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
LIHC	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-6.32	7.97e-10	6.04e-07	-0.36	-0.32	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
LIHC	cis	rs2735413	0.599	rs77209133	ENSG00000276007.1	RP11-358L22.3	6.32	7.97e-10	6.04e-07	0.45	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78042827	chr16:78123243~78124332:+
LIHC	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	6.32	8.05e-10	6.09e-07	0.38	0.32	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
LIHC	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-6.32	8.1e-10	6.13e-07	-0.35	-0.32	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
LIHC	cis	rs1003645	0.861	rs7222703	ENSG00000278690.1	RP11-104J23.2	6.32	8.11e-10	6.14e-07	0.41	0.32	Blood protein levels;	chr17:36014155	chr17:36012504~36012891:+
LIHC	cis	rs1003645	0.906	rs8065543	ENSG00000278690.1	RP11-104J23.2	6.32	8.11e-10	6.14e-07	0.41	0.32	Blood protein levels;	chr17:36014962	chr17:36012504~36012891:+
LIHC	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	6.32	8.11e-10	6.14e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
LIHC	cis	rs523522	0.962	rs4766968	ENSG00000278344.1	RP11-18C24.8	6.32	8.12e-10	6.14e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120509985	chr12:120500735~120501090:-
LIHC	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	6.32	8.14e-10	6.16e-07	0.34	0.32	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
LIHC	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	6.32	8.22e-10	6.21e-07	0.42	0.32	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
LIHC	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-6.32	8.31e-10	6.28e-07	-0.35	-0.32	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
LIHC	cis	rs2735413	0.564	rs4324138	ENSG00000276007.1	RP11-358L22.3	6.32	8.33e-10	6.29e-07	0.43	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78067475	chr16:78123243~78124332:+
LIHC	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	6.32	8.33e-10	6.29e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
LIHC	cis	rs523522	0.962	rs4767902	ENSG00000278344.1	RP11-18C24.8	6.32	8.38e-10	6.33e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120472201	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs10849753	ENSG00000278344.1	RP11-18C24.8	6.32	8.38e-10	6.33e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120473010	chr12:120500735~120501090:-
LIHC	cis	rs17270561	0.609	rs9356984	ENSG00000216436.2	HIST1H2APS1	6.31	8.42e-10	6.35e-07	0.39	0.32	Iron status biomarkers;	chr6:25725253	chr6:25732497~25732827:+
LIHC	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-6.31	8.43e-10	6.36e-07	-0.38	-0.32	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
LIHC	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	6.31	8.48e-10	6.4e-07	0.39	0.32	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	6.31	8.48e-10	6.4e-07	0.39	0.32	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	6.31	8.48e-10	6.4e-07	0.39	0.32	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	6.31	8.48e-10	6.4e-07	0.39	0.32	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
LIHC	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-6.31	8.48e-10	6.4e-07	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
LIHC	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-6.31	8.5e-10	6.41e-07	-0.42	-0.32	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
LIHC	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-6.31	8.55e-10	6.45e-07	-0.37	-0.32	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
LIHC	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	6.31	8.57e-10	6.46e-07	0.78	0.32	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
LIHC	cis	rs12681287	0.752	rs12675974	ENSG00000250569.1	NTAN1P2	6.31	8.59e-10	6.47e-07	0.39	0.32	Caudate activity during reward;	chr8:86235616	chr8:86481754~86483002:-
LIHC	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	6.31	8.59e-10	6.47e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	6.31	8.59e-10	6.47e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
LIHC	cis	rs9326248	0.53	rs7123517	ENSG00000280143.1	AP000892.6	6.31	8.6e-10	6.48e-07	0.41	0.32	Blood protein levels;	chr11:117157039	chr11:117204967~117210292:+
LIHC	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	6.31	8.62e-10	6.49e-07	0.52	0.32	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
LIHC	cis	rs1023500	0.573	rs133370	ENSG00000237037.8	NDUFA6-AS1	6.31	8.65e-10	6.51e-07	0.39	0.32	Schizophrenia;	chr22:42069256	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.573	rs1807494	ENSG00000237037.8	NDUFA6-AS1	-6.31	8.65e-10	6.51e-07	-0.39	-0.32	Schizophrenia;	chr22:42078134	chr22:42090931~42137742:+
LIHC	cis	rs17270561	0.609	rs4712963	ENSG00000216436.2	HIST1H2APS1	-6.31	8.66e-10	6.52e-07	-0.4	-0.32	Iron status biomarkers;	chr6:25740274	chr6:25732497~25732827:+
LIHC	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	6.31	8.68e-10	6.53e-07	0.35	0.32	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	6.31	8.68e-10	6.53e-07	0.35	0.32	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	6.31	8.68e-10	6.53e-07	0.35	0.32	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
LIHC	cis	rs4356975	0.563	rs7375178	ENSG00000249956.3	RP11-790I12.2	6.31	8.68e-10	6.53e-07	0.36	0.32	Obesity-related traits;	chr4:69103961	chr4:69408836~69423164:+
LIHC	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-6.31	8.7e-10	6.54e-07	-0.53	-0.32	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
LIHC	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-6.31	8.74e-10	6.57e-07	-0.43	-0.32	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
LIHC	cis	rs9326248	1	rs10790175	ENSG00000236267.1	AP006216.5	6.31	8.75e-10	6.57e-07	0.33	0.32	Blood protein levels;	chr11:117164013	chr11:116813204~116814003:-
LIHC	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-6.31	8.8e-10	6.61e-07	-0.46	-0.32	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
LIHC	cis	rs3020736	0.5	rs1801311	ENSG00000237037.8	NDUFA6-AS1	-6.31	8.82e-10	6.63e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42090931~42137742:+
LIHC	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-6.31	8.83e-10	6.63e-07	-0.39	-0.32	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
LIHC	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	6.31	8.84e-10	6.64e-07	0.49	0.32	Depression;	chr6:28109824	chr6:28115628~28116551:+
LIHC	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	6.31	8.87e-10	6.66e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	6.31	8.87e-10	6.66e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	6.31	8.87e-10	6.66e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	6.31	8.87e-10	6.66e-07	0.46	0.32	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
LIHC	cis	rs2243480	1	rs2462569	ENSG00000164669.11	INTS4P1	-6.31	8.87e-10	6.66e-07	-0.55	-0.32	Diabetic kidney disease;	chr7:66009859	chr7:65141225~65234216:+
LIHC	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-6.3	8.93e-10	6.7e-07	-0.41	-0.32	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
LIHC	cis	rs2243480	1	rs34136756	ENSG00000164669.11	INTS4P1	6.3	8.93e-10	6.7e-07	0.56	0.32	Diabetic kidney disease;	chr7:65916269	chr7:65141225~65234216:+
LIHC	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-6.3	8.97e-10	6.73e-07	-0.26	-0.32	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-6.3	8.97e-10	6.73e-07	-0.26	-0.32	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-6.3	8.97e-10	6.73e-07	-0.26	-0.32	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-6.3	8.97e-10	6.73e-07	-0.26	-0.32	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
LIHC	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-6.3	9e-10	6.75e-07	-0.36	-0.32	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
LIHC	cis	rs5758659	0.714	rs5751220	ENSG00000227370.1	RP4-669P10.19	6.3	9.02e-10	6.77e-07	0.37	0.32	Cognitive function;	chr22:42120201	chr22:42132543~42132998:+
LIHC	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-6.3	9.04e-10	6.77e-07	-0.43	-0.32	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
LIHC	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-6.3	9.05e-10	6.78e-07	-0.33	-0.32	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
LIHC	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-6.3	9.05e-10	6.78e-07	-0.33	-0.32	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
LIHC	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	6.3	9.09e-10	6.81e-07	0.39	0.32	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
LIHC	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	6.3	9.1e-10	6.82e-07	0.56	0.32	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
LIHC	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	6.3	9.11e-10	6.82e-07	0.35	0.32	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
LIHC	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	6.3	9.11e-10	6.82e-07	0.41	0.32	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
LIHC	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	6.3	9.11e-10	6.82e-07	0.41	0.32	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
LIHC	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	6.3	9.11e-10	6.82e-07	0.41	0.32	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
LIHC	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	6.3	9.13e-10	6.83e-07	0.52	0.32	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	6.3	9.13e-10	6.83e-07	0.52	0.32	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	6.3	9.13e-10	6.83e-07	0.52	0.32	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
LIHC	cis	rs523522	0.962	rs4767914	ENSG00000278344.1	RP11-18C24.8	6.3	9.16e-10	6.86e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120556014	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs10849759	ENSG00000278344.1	RP11-18C24.8	6.3	9.16e-10	6.86e-07	0.39	0.32	High light scatter reticulocyte count;	chr12:120556685	chr12:120500735~120501090:-
LIHC	cis	rs585510	1	rs585510	ENSG00000278344.1	RP11-18C24.8	6.3	9.16e-10	6.86e-07	0.39	0.32	Reticulocyte fraction of red cells;	chr12:120562330	chr12:120500735~120501090:-
LIHC	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-6.3	9.17e-10	6.86e-07	-0.41	-0.32	AIDS;	chr2:105333211	chr2:105324210~105330529:+
LIHC	cis	rs1020064	0.583	rs2576775	ENSG00000235319.1	AC012360.4	-6.3	9.17e-10	6.86e-07	-0.42	-0.32	AIDS;	chr2:105356755	chr2:105324210~105330529:+
LIHC	cis	rs5758659	0.714	rs7245	ENSG00000227370.1	RP4-669P10.19	6.3	9.19e-10	6.87e-07	0.38	0.32	Cognitive function;	chr22:42085845	chr22:42132543~42132998:+
LIHC	cis	rs13068223	0.584	rs344018	ENSG00000243926.1	TIPARP-AS1	-6.3	9.19e-10	6.88e-07	-0.36	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156698204	chr3:156671862~156674378:-
LIHC	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	6.3	9.23e-10	6.91e-07	0.4	0.32	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
LIHC	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-6.3	9.24e-10	6.91e-07	-0.39	-0.32	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	6.3	9.27e-10	6.93e-07	0.39	0.32	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-6.3	9.27e-10	6.93e-07	-0.39	-0.32	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
LIHC	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	6.3	9.37e-10	7.01e-07	0.39	0.32	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
LIHC	cis	rs3020736	0.5	rs8138678	ENSG00000237037.8	NDUFA6-AS1	-6.3	9.41e-10	7.04e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42090931~42137742:+
LIHC	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	6.29	9.46e-10	7.07e-07	0.46	0.32	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
LIHC	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	6.29	9.56e-10	7.14e-07	0.42	0.32	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
LIHC	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	6.29	9.57e-10	7.15e-07	0.37	0.32	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
LIHC	cis	rs9843304	0.568	rs11720325	ENSG00000244503.1	RP11-278L15.6	6.29	9.65e-10	7.2e-07	0.34	0.32	Gallstone disease;	chr3:149498524	chr3:149494660~149495995:+
LIHC	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-6.29	9.72e-10	7.26e-07	-0.38	-0.32	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
LIHC	cis	rs5758659	1	rs134900	ENSG00000227370.1	RP4-669P10.19	-6.29	9.76e-10	7.28e-07	-0.36	-0.32	Cognitive function;	chr22:42287337	chr22:42132543~42132998:+
LIHC	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-6.29	9.81e-10	7.31e-07	-0.43	-0.32	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
LIHC	cis	rs3020736	0.5	rs2413669	ENSG00000237037.8	NDUFA6-AS1	-6.29	9.84e-10	7.34e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6002618	ENSG00000237037.8	NDUFA6-AS1	-6.29	9.84e-10	7.34e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.551	rs61665536	ENSG00000237037.8	NDUFA6-AS1	-6.29	9.84e-10	7.34e-07	-0.39	-0.32	Schizophrenia;	chr22:42116609	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs2413672	ENSG00000237037.8	NDUFA6-AS1	-6.29	9.84e-10	7.34e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6002623	ENSG00000237037.8	NDUFA6-AS1	-6.29	9.84e-10	7.34e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs764481	ENSG00000237037.8	NDUFA6-AS1	-6.29	9.84e-10	7.34e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42090931~42137742:+
LIHC	cis	rs9527	0.614	rs4919691	ENSG00000236937.2	PTGES3P4	6.29	9.89e-10	7.37e-07	0.39	0.32	Arsenic metabolism;	chr10:102864718	chr10:102845595~102845950:+
LIHC	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	6.29	9.91e-10	7.38e-07	0.34	0.32	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
LIHC	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	6.29	9.91e-10	7.38e-07	0.39	0.32	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
LIHC	cis	rs12681287	0.752	rs4641037	ENSG00000250569.1	NTAN1P2	6.29	9.93e-10	7.4e-07	0.38	0.32	Caudate activity during reward;	chr8:86256150	chr8:86481754~86483002:-
LIHC	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-6.28	1e-09	7.45e-07	-0.3	-0.32	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
LIHC	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	6.28	1e-09	7.45e-07	0.36	0.32	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
LIHC	cis	rs5758659	0.714	rs5758589	ENSG00000227370.1	RP4-669P10.19	6.28	1.01e-09	7.52e-07	0.36	0.32	Cognitive function;	chr22:42122378	chr22:42132543~42132998:+
LIHC	cis	rs4356975	0.563	rs7698846	ENSG00000249956.3	RP11-790I12.2	6.28	1.01e-09	7.52e-07	0.36	0.32	Obesity-related traits;	chr4:69106278	chr4:69408836~69423164:+
LIHC	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-6.28	1.02e-09	7.57e-07	-0.26	-0.32	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-6.28	1.02e-09	7.57e-07	-0.26	-0.32	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
LIHC	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	6.28	1.02e-09	7.57e-07	0.42	0.32	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
LIHC	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	6.28	1.02e-09	7.6e-07	0.43	0.32	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
LIHC	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	6.28	1.03e-09	7.62e-07	0.34	0.32	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
LIHC	cis	rs2933343	0.621	rs4927921	ENSG00000231305.3	RP11-723O4.2	-6.28	1.03e-09	7.64e-07	-0.35	-0.32	IgG glycosylation;	chr3:128850025	chr3:128861313~128871540:-
LIHC	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-6.28	1.03e-09	7.64e-07	-0.36	-0.32	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
LIHC	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-6.28	1.03e-09	7.66e-07	-0.37	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
LIHC	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	6.28	1.03e-09	7.68e-07	0.6	0.32	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
LIHC	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	6.28	1.04e-09	7.69e-07	0.4	0.32	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
LIHC	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	6.28	1.04e-09	7.72e-07	0.34	0.32	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
LIHC	cis	rs10916248	0.559	rs116083281	ENSG00000232628.4	RP11-365O16.3	6.28	1.04e-09	7.72e-07	0.45	0.32	QT interval (drug interaction);	chr1:224199365	chr1:224208747~224213279:-
LIHC	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28070115	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28071237	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28074687	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28076559	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28076704	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28078391	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28080757	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28080760	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28082231	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28082261	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28082984	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28083994	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28084025	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-6.28	1.04e-09	7.72e-07	-0.49	-0.32	Depression;	chr6:28085319	chr6:28115628~28116551:+
LIHC	cis	rs2243480	1	rs466983	ENSG00000164669.11	INTS4P1	6.28	1.05e-09	7.75e-07	0.55	0.32	Diabetic kidney disease;	chr7:66055509	chr7:65141225~65234216:+
LIHC	cis	rs17270561	0.609	rs9358883	ENSG00000216436.2	HIST1H2APS1	-6.28	1.05e-09	7.75e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25755287	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs1937132	ENSG00000216436.2	HIST1H2APS1	-6.28	1.05e-09	7.75e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25756789	chr6:25732497~25732827:+
LIHC	cis	rs2243480	1	rs34702770	ENSG00000164669.11	INTS4P1	6.28	1.05e-09	7.75e-07	0.56	0.32	Diabetic kidney disease;	chr7:65879836	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.803	rs35480979	ENSG00000164669.11	INTS4P1	6.28	1.05e-09	7.75e-07	0.56	0.32	Diabetic kidney disease;	chr7:65892097	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs34637256	ENSG00000164669.11	INTS4P1	6.28	1.05e-09	7.75e-07	0.56	0.32	Diabetic kidney disease;	chr7:65895144	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs35391607	ENSG00000164669.11	INTS4P1	6.28	1.05e-09	7.75e-07	0.56	0.32	Diabetic kidney disease;	chr7:65895842	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs13220979	ENSG00000164669.11	INTS4P1	6.28	1.05e-09	7.75e-07	0.56	0.32	Diabetic kidney disease;	chr7:65898217	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs34974928	ENSG00000164669.11	INTS4P1	6.28	1.05e-09	7.75e-07	0.56	0.32	Diabetic kidney disease;	chr7:65899019	chr7:65141225~65234216:+
LIHC	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-6.28	1.05e-09	7.76e-07	-0.36	-0.32	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
LIHC	cis	rs9843304	0.616	rs67576825	ENSG00000244503.1	RP11-278L15.6	6.28	1.05e-09	7.8e-07	0.34	0.32	Gallstone disease;	chr3:149484896	chr3:149494660~149495995:+
LIHC	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-6.28	1.06e-09	7.82e-07	-0.39	-0.32	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
LIHC	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-6.27	1.06e-09	7.82e-07	-0.5	-0.32	Depression;	chr6:28139049	chr6:28115628~28116551:+
LIHC	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-6.27	1.06e-09	7.82e-07	-0.45	-0.32	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
LIHC	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	6.27	1.06e-09	7.83e-07	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
LIHC	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-6.27	1.06e-09	7.85e-07	-0.44	-0.32	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
LIHC	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	6.27	1.07e-09	7.87e-07	0.45	0.32	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	6.27	1.07e-09	7.87e-07	0.45	0.32	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
LIHC	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-6.27	1.07e-09	7.9e-07	-0.4	-0.32	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
LIHC	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-6.27	1.07e-09	7.9e-07	-0.39	-0.32	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
LIHC	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-6.27	1.07e-09	7.92e-07	-0.34	-0.32	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
LIHC	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-6.27	1.07e-09	7.93e-07	-0.36	-0.32	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
LIHC	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-6.27	1.08e-09	7.94e-07	-0.27	-0.32	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
LIHC	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	6.27	1.08e-09	7.95e-07	0.34	0.32	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	6.27	1.08e-09	7.95e-07	0.34	0.32	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	6.27	1.08e-09	7.95e-07	0.34	0.32	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	6.27	1.08e-09	7.95e-07	0.34	0.32	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
LIHC	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	6.27	1.08e-09	7.96e-07	0.38	0.32	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
LIHC	cis	rs4356975	0.563	rs6600891	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69105878	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs7693957	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69106078	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs12513195	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69106368	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4541594	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69106554	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.583	rs4351080	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69106601	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs5013211	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69107059	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4292394	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69107231	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4337789	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69107326	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4521414	ENSG00000249956.3	RP11-790I12.2	6.27	1.09e-09	8.02e-07	0.36	0.32	Obesity-related traits;	chr4:69107807	chr4:69408836~69423164:+
LIHC	cis	rs17270561	0.609	rs7754733	ENSG00000216436.2	HIST1H2APS1	-6.27	1.09e-09	8.04e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25744821	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs7754814	ENSG00000216436.2	HIST1H2APS1	-6.27	1.09e-09	8.04e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25745015	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs7775354	ENSG00000216436.2	HIST1H2APS1	-6.27	1.09e-09	8.04e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25745038	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9379789	ENSG00000216436.2	HIST1H2APS1	-6.27	1.09e-09	8.04e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25745351	chr6:25732497~25732827:+
LIHC	cis	rs1577917	0.771	rs12205013	ENSG00000234155.1	RP11-30P6.6	6.27	1.09e-09	8.07e-07	0.41	0.32	Response to antipsychotic treatment;	chr6:85623311	chr6:85387219~85390186:-
LIHC	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-6.27	1.09e-09	8.07e-07	-0.4	-0.32	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
LIHC	cis	rs4356975	0.563	rs4314345	ENSG00000249956.3	RP11-790I12.2	6.27	1.1e-09	8.07e-07	0.36	0.32	Obesity-related traits;	chr4:69107922	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4588522	ENSG00000249956.3	RP11-790I12.2	6.27	1.1e-09	8.07e-07	0.36	0.32	Obesity-related traits;	chr4:69107949	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4364327	ENSG00000249956.3	RP11-790I12.2	6.27	1.1e-09	8.07e-07	0.36	0.32	Obesity-related traits;	chr4:69107974	chr4:69408836~69423164:+
LIHC	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-6.27	1.1e-09	8.07e-07	-0.37	-0.32	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
LIHC	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	6.27	1.1e-09	8.07e-07	0.33	0.32	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
LIHC	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	6.27	1.1e-09	8.08e-07	0.34	0.32	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
LIHC	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-6.27	1.1e-09	8.09e-07	-0.35	-0.32	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-6.27	1.1e-09	8.09e-07	-0.35	-0.32	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-6.27	1.1e-09	8.09e-07	-0.35	-0.32	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-6.27	1.1e-09	8.09e-07	-0.35	-0.32	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-6.27	1.1e-09	8.09e-07	-0.35	-0.32	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
LIHC	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-6.27	1.1e-09	8.1e-07	-0.41	-0.32	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
LIHC	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-6.27	1.1e-09	8.11e-07	-0.37	-0.32	Height;	chr6:109432968	chr6:109382795~109383666:+
LIHC	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	6.27	1.1e-09	8.11e-07	0.33	0.32	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
LIHC	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	6.27	1.1e-09	8.13e-07	0.34	0.32	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
LIHC	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-6.27	1.12e-09	8.24e-07	-0.41	-0.32	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
LIHC	cis	rs17270561	0.609	rs4711094	ENSG00000216436.2	HIST1H2APS1	-6.26	1.12e-09	8.25e-07	-0.41	-0.32	Iron status biomarkers;	chr6:25705946	chr6:25732497~25732827:+
LIHC	cis	rs12681287	0.64	rs7833049	ENSG00000250569.1	NTAN1P2	-6.26	1.12e-09	8.25e-07	-0.37	-0.32	Caudate activity during reward;	chr8:86433669	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13253296	ENSG00000250569.1	NTAN1P2	6.26	1.12e-09	8.25e-07	0.37	0.32	Caudate activity during reward;	chr8:86436016	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.604	rs34227066	ENSG00000250569.1	NTAN1P2	6.26	1.12e-09	8.25e-07	0.37	0.32	Caudate activity during reward;	chr8:86437137	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs34794500	ENSG00000250569.1	NTAN1P2	6.26	1.12e-09	8.25e-07	0.37	0.32	Caudate activity during reward;	chr8:86437766	chr8:86481754~86483002:-
LIHC	cis	rs10461617	0.592	rs6450403	ENSG00000271828.1	CTD-2310F14.1	6.26	1.12e-09	8.26e-07	0.43	0.32	Type 2 diabetes;	chr5:56766910	chr5:56927874~56929573:+
LIHC	cis	rs523522	0.962	rs4766966	ENSG00000278344.1	RP11-18C24.8	6.26	1.13e-09	8.28e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120505108	chr12:120500735~120501090:-
LIHC	cis	rs17270561	0.609	rs6941933	ENSG00000216436.2	HIST1H2APS1	-6.26	1.13e-09	8.33e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25745474	chr6:25732497~25732827:+
LIHC	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	6.26	1.13e-09	8.33e-07	0.5	0.32	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	6.26	1.13e-09	8.33e-07	0.5	0.32	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
LIHC	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-6.26	1.14e-09	8.36e-07	-0.27	-0.32	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
LIHC	cis	rs9543976	0.614	rs73223948	ENSG00000261553.4	RP11-29G8.3	-6.26	1.14e-09	8.37e-07	-0.52	-0.32	Diabetic retinopathy;	chr13:75523889	chr13:75549773~75807120:+
LIHC	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	6.26	1.14e-09	8.4e-07	0.47	0.32	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
LIHC	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-6.26	1.15e-09	8.43e-07	-0.5	-0.32	Depression;	chr6:28139876	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-6.26	1.15e-09	8.43e-07	-0.5	-0.32	Depression;	chr6:28139998	chr6:28115628~28116551:+
LIHC	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-6.26	1.15e-09	8.45e-07	-0.38	-0.32	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
LIHC	cis	rs17270561	0.609	rs9366629	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25740988	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.553	rs6456696	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741180	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs6456697	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741206	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs6456698	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741436	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.666	rs4711099	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741581	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4711100	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741726	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4711101	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741742	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4712965	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741794	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.608	rs4711102	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741847	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4711103	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25741996	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9379788	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25742531	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9358879	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25742690	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs9358880	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25742933	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4145216	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25743331	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs4145217	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25743769	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs9393665	ENSG00000216436.2	HIST1H2APS1	-6.26	1.15e-09	8.46e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25744056	chr6:25732497~25732827:+
LIHC	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	6.26	1.16e-09	8.47e-07	0.34	0.32	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
LIHC	cis	rs2762353	0.595	rs12207270	ENSG00000242387.1	HIST1H2APS2	6.26	1.16e-09	8.49e-07	0.39	0.32	Blood metabolite levels;	chr6:25751493	chr6:25882026~25882395:-
LIHC	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-6.26	1.16e-09	8.53e-07	-0.4	-0.32	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
LIHC	cis	rs17270561	0.609	rs7754296	ENSG00000216436.2	HIST1H2APS1	-6.26	1.17e-09	8.54e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25744650	chr6:25732497~25732827:+
LIHC	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	6.26	1.17e-09	8.56e-07	0.38	0.32	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
LIHC	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	6.26	1.18e-09	8.61e-07	0.45	0.32	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
LIHC	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	6.26	1.18e-09	8.63e-07	0.43	0.32	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
LIHC	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	6.26	1.18e-09	8.63e-07	0.57	0.32	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
LIHC	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-6.26	1.18e-09	8.65e-07	-0.41	-0.32	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
LIHC	cis	rs6490294	0.528	rs12422941	ENSG00000226469.1	ADAM1B	-6.26	1.18e-09	8.65e-07	-0.48	-0.32	Mean platelet volume;	chr12:112099934	chr12:111927018~111929017:+
LIHC	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-6.25	1.19e-09	8.69e-07	-0.3	-0.32	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	6.25	1.19e-09	8.69e-07	0.4	0.32	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs55895244	ENSG00000164669.11	INTS4P1	6.25	1.19e-09	8.71e-07	0.55	0.32	Diabetic kidney disease;	chr7:65922691	chr7:65141225~65234216:+
LIHC	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	6.25	1.19e-09	8.73e-07	0.34	0.32	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
LIHC	cis	rs17270561	0.636	rs6923839	ENSG00000216436.2	HIST1H2APS1	-6.25	1.2e-09	8.73e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25745625	chr6:25732497~25732827:+
LIHC	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-6.25	1.2e-09	8.74e-07	-0.48	-0.32	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
LIHC	cis	rs17270561	0.636	rs6923367	ENSG00000216436.2	HIST1H2APS1	-6.25	1.2e-09	8.74e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25745624	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.636	rs4145218	ENSG00000216436.2	HIST1H2APS1	-6.25	1.2e-09	8.74e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25745855	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs1892255	ENSG00000216436.2	HIST1H2APS1	-6.25	1.2e-09	8.74e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25750126	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.609	rs1892254	ENSG00000216436.2	HIST1H2APS1	-6.25	1.2e-09	8.74e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25750302	chr6:25732497~25732827:+
LIHC	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	6.25	1.2e-09	8.75e-07	0.39	0.32	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
LIHC	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-6.25	1.2e-09	8.77e-07	-0.41	-0.32	AIDS;	chr2:105300178	chr2:105324210~105330529:+
LIHC	cis	rs12681287	0.64	rs4961193	ENSG00000250569.1	NTAN1P2	-6.25	1.2e-09	8.78e-07	-0.37	-0.32	Caudate activity during reward;	chr8:86473939	chr8:86481754~86483002:-
LIHC	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-6.25	1.2e-09	8.78e-07	-0.38	-0.32	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-6.25	1.2e-09	8.78e-07	-0.38	-0.32	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
LIHC	cis	rs1577917	0.771	rs2842602	ENSG00000234155.1	RP11-30P6.6	6.25	1.2e-09	8.78e-07	0.4	0.32	Response to antipsychotic treatment;	chr6:85622169	chr6:85387219~85390186:-
LIHC	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-6.25	1.2e-09	8.79e-07	-0.36	-0.32	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
LIHC	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-6.25	1.2e-09	8.79e-07	-0.53	-0.32	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
LIHC	cis	rs523522	0.962	rs4767912	ENSG00000278344.1	RP11-18C24.8	6.25	1.21e-09	8.85e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120543399	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs4766969	ENSG00000278344.1	RP11-18C24.8	6.25	1.21e-09	8.85e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120550435	chr12:120500735~120501090:-
LIHC	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	6.25	1.21e-09	8.86e-07	0.49	0.32	Depression;	chr6:28110525	chr6:28115628~28116551:+
LIHC	cis	rs1263173	0.696	rs1263172	ENSG00000236267.1	AP006216.5	6.25	1.22e-09	8.87e-07	0.3	0.32	HDL cholesterol;	chr11:116810202	chr11:116813204~116814003:-
LIHC	cis	rs6940638	0.615	rs9393801	ENSG00000216901.1	AL022393.7	6.25	1.22e-09	8.9e-07	0.41	0.32	Intelligence (multi-trait analysis);	chr6:27274902	chr6:28176188~28176674:+
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-6.25	1.22e-09	8.9e-07	-0.37	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
LIHC	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-6.25	1.22e-09	8.91e-07	-0.36	-0.32	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
LIHC	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-6.25	1.23e-09	8.93e-07	-0.36	-0.32	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
LIHC	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	6.25	1.23e-09	8.99e-07	0.32	0.32	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
LIHC	cis	rs17270561	0.585	rs9393663	ENSG00000216436.2	HIST1H2APS1	-6.25	1.24e-09	8.99e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25740805	chr6:25732497~25732827:+
LIHC	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-6.25	1.24e-09	9.01e-07	-0.3	-0.32	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
LIHC	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	6.25	1.24e-09	9.01e-07	0.38	0.32	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
LIHC	cis	rs3020736	0.5	rs4147638	ENSG00000237037.8	NDUFA6-AS1	-6.25	1.24e-09	9.02e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6002605	ENSG00000237037.8	NDUFA6-AS1	-6.25	1.24e-09	9.02e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42090931~42137742:+
LIHC	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	6.25	1.24e-09	9.03e-07	0.45	0.32	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
LIHC	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-6.25	1.25e-09	9.06e-07	-0.37	-0.32	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-6.25	1.25e-09	9.06e-07	-0.37	-0.32	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
LIHC	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	6.25	1.25e-09	9.09e-07	0.36	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
LIHC	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	6.25	1.26e-09	9.13e-07	0.38	0.32	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	6.25	1.26e-09	9.13e-07	0.38	0.32	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	6.25	1.26e-09	9.13e-07	0.38	0.32	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	6.25	1.26e-09	9.13e-07	0.38	0.32	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
LIHC	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-6.24	1.26e-09	9.16e-07	-0.4	-0.32	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
LIHC	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	6.24	1.26e-09	9.16e-07	0.47	0.32	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
LIHC	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-6.24	1.26e-09	9.17e-07	-0.32	-0.32	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
LIHC	cis	rs2243480	1	rs313831	ENSG00000164669.11	INTS4P1	6.24	1.27e-09	9.19e-07	0.55	0.32	Diabetic kidney disease;	chr7:66086239	chr7:65141225~65234216:+
LIHC	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	6.24	1.27e-09	9.23e-07	0.34	0.32	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
LIHC	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-6.24	1.27e-09	9.23e-07	-0.35	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
LIHC	cis	rs5758659	0.714	rs133376	ENSG00000227370.1	RP4-669P10.19	-6.24	1.27e-09	9.23e-07	-0.37	-0.32	Cognitive function;	chr22:42070901	chr22:42132543~42132998:+
LIHC	cis	rs7580658	0.613	rs12478656	ENSG00000236682.1	AC068282.3	-6.24	1.27e-09	9.25e-07	-0.4	-0.32	Protein C levels;	chr2:127438944	chr2:127389130~127400580:+
LIHC	cis	rs523522	0.962	rs4767904	ENSG00000278344.1	RP11-18C24.8	6.24	1.28e-09	9.32e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120492995	chr12:120500735~120501090:-
LIHC	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-6.24	1.29e-09	9.33e-07	-0.35	-0.32	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
LIHC	cis	rs6490294	0.528	rs12582100	ENSG00000226469.1	ADAM1B	6.24	1.29e-09	9.36e-07	0.48	0.32	Mean platelet volume;	chr12:111941105	chr12:111927018~111929017:+
LIHC	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	6.24	1.29e-09	9.37e-07	0.3	0.32	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
LIHC	cis	rs523522	0.962	rs2168319	ENSG00000278344.1	RP11-18C24.8	6.24	1.29e-09	9.38e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120495414	chr12:120500735~120501090:-
LIHC	cis	rs9326248	0.689	rs4516002	ENSG00000236267.1	AP006216.5	6.24	1.29e-09	9.38e-07	0.34	0.32	Blood protein levels;	chr11:117128343	chr11:116813204~116814003:-
LIHC	cis	rs832187	0.679	rs9879045	ENSG00000280620.1	SCAANT1	6.24	1.3e-09	9.41e-07	0.42	0.32	Schizophrenia;	chr3:64016249	chr3:63911518~63911772:-
LIHC	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28123153	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28124529	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28127577	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28131566	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28133900	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28136698	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28136856	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28137418	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28138363	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28138981	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-6.24	1.3e-09	9.42e-07	-0.49	-0.32	Depression;	chr6:28139012	chr6:28115628~28116551:+
LIHC	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	6.24	1.3e-09	9.42e-07	0.41	0.32	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
LIHC	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-6.24	1.3e-09	9.42e-07	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
LIHC	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-6.24	1.3e-09	9.42e-07	-0.34	-0.32	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
LIHC	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	6.24	1.3e-09	9.45e-07	0.45	0.32	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
LIHC	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	6.24	1.3e-09	9.45e-07	0.33	0.32	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	6.24	1.3e-09	9.45e-07	0.33	0.32	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	6.24	1.3e-09	9.45e-07	0.33	0.32	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	6.24	1.3e-09	9.45e-07	0.33	0.32	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
LIHC	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-6.24	1.3e-09	9.45e-07	-0.4	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
LIHC	cis	rs523522	0.962	rs4767903	ENSG00000278344.1	RP11-18C24.8	6.24	1.31e-09	9.45e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120492243	chr12:120500735~120501090:-
LIHC	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	6.24	1.31e-09	9.48e-07	0.52	0.32	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
LIHC	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	6.24	1.31e-09	9.51e-07	0.45	0.32	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
LIHC	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	6.24	1.31e-09	9.51e-07	0.49	0.32	Depression;	chr6:28086929	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-6.24	1.31e-09	9.51e-07	-0.49	-0.32	Depression;	chr6:28079011	chr6:28115628~28116551:+
LIHC	cis	rs2243480	1	rs160655	ENSG00000164669.11	INTS4P1	6.24	1.32e-09	9.56e-07	0.55	0.32	Diabetic kidney disease;	chr7:66068227	chr7:65141225~65234216:+
LIHC	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	6.24	1.33e-09	9.59e-07	0.38	0.32	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
LIHC	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	6.24	1.33e-09	9.62e-07	0.32	0.32	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
LIHC	cis	rs7914558	0.966	rs1971589	ENSG00000236937.2	PTGES3P4	6.24	1.33e-09	9.63e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102845595~102845950:+
LIHC	cis	rs523522	1	rs1563333	ENSG00000278344.1	RP11-18C24.8	6.23	1.33e-09	9.64e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120496604	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs7136951	ENSG00000278344.1	RP11-18C24.8	6.23	1.33e-09	9.64e-07	0.38	0.32	High light scatter reticulocyte count;	chr12:120504124	chr12:120500735~120501090:-
LIHC	cis	rs7914558	0.966	rs10748836	ENSG00000236937.2	PTGES3P4	6.23	1.34e-09	9.66e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs10786727	ENSG00000236937.2	PTGES3P4	6.23	1.34e-09	9.66e-07	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102845595~102845950:+
LIHC	cis	rs3020736	0.5	rs11090076	ENSG00000237037.8	NDUFA6-AS1	-6.23	1.34e-09	9.68e-07	-0.39	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42090931~42137742:+
LIHC	cis	rs12681287	0.608	rs13273338	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86441132	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13258126	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86441149	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13256765	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86445604	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs12678720	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86445700	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13253261	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86446271	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13253515	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86446367	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs12541793	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86450329	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs12679811	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86453141	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13264364	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86454156	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs67123356	ENSG00000250569.1	NTAN1P2	6.23	1.34e-09	9.69e-07	0.37	0.32	Caudate activity during reward;	chr8:86441763	chr8:86481754~86483002:-
LIHC	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	6.23	1.35e-09	9.72e-07	0.51	0.32	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	6.23	1.35e-09	9.72e-07	0.51	0.32	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	6.23	1.35e-09	9.72e-07	0.51	0.32	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	6.23	1.35e-09	9.72e-07	0.51	0.32	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
LIHC	cis	rs916888	0.697	rs199516	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs199514	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs199512	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs199509	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs199507	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs415430	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.779	rs430685	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs199505	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45907670~45910779:-
LIHC	cis	rs916888	0.821	rs70602	ENSG00000262881.1	RP11-669E14.4	6.23	1.35e-09	9.72e-07	0.5	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45907670~45910779:-
LIHC	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28089816	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28090857	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28091439	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28091659	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28092227	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28093966	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28094014	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28096077	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28096855	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28099759	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28100648	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28104824	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28107222	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-6.23	1.35e-09	9.74e-07	-0.49	-0.32	Depression;	chr6:28108492	chr6:28115628~28116551:+
LIHC	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-6.23	1.36e-09	9.78e-07	-0.41	-0.32	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
LIHC	cis	rs17270561	0.609	rs4711096	ENSG00000216436.2	HIST1H2APS1	-6.23	1.36e-09	9.79e-07	-0.39	-0.32	Iron status biomarkers;	chr6:25726826	chr6:25732497~25732827:+
LIHC	cis	rs8028182	0.501	rs11072553	ENSG00000260269.4	CTD-2323K18.1	-6.23	1.37e-09	9.88e-07	-0.41	-0.32	Sudden cardiac arrest;	chr15:75640436	chr15:75527150~75601205:-
LIHC	cis	rs2032447	0.517	rs7767546	ENSG00000242387.1	HIST1H2APS2	6.23	1.37e-09	9.89e-07	0.43	0.32	Intelligence (multi-trait analysis);	chr6:25903839	chr6:25882026~25882395:-
LIHC	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	6.23	1.38e-09	9.91e-07	0.33	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
LIHC	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	6.23	1.38e-09	9.93e-07	0.41	0.32	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
LIHC	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-6.23	1.38e-09	9.96e-07	-0.34	-0.32	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
LIHC	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-6.23	1.38e-09	9.98e-07	-0.37	-0.32	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
LIHC	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	6.23	1.39e-09	9.98e-07	0.34	0.32	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
LIHC	cis	rs1577917	0.771	rs2842613	ENSG00000234155.1	RP11-30P6.6	-6.23	1.39e-09	1e-06	-0.4	-0.32	Response to antipsychotic treatment;	chr6:85595984	chr6:85387219~85390186:-
LIHC	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	6.23	1.39e-09	1e-06	0.42	0.32	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
LIHC	cis	rs7085104	0.7	rs3740397	ENSG00000236937.2	PTGES3P4	6.23	1.4e-09	1.01e-06	0.39	0.32	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102845595~102845950:+
LIHC	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	6.23	1.4e-09	1.01e-06	0.39	0.32	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
LIHC	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	6.23	1.4e-09	1.01e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
LIHC	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-6.23	1.41e-09	1.01e-06	-0.35	-0.32	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
LIHC	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	6.22	1.41e-09	1.02e-06	0.36	0.32	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
LIHC	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	6.22	1.42e-09	1.02e-06	0.36	0.32	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
LIHC	cis	rs4356975	0.509	rs6422323	ENSG00000249956.3	RP11-790I12.2	6.22	1.42e-09	1.02e-06	0.37	0.32	Obesity-related traits;	chr4:69087362	chr4:69408836~69423164:+
LIHC	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	6.22	1.42e-09	1.02e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
LIHC	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	6.22	1.43e-09	1.02e-06	0.4	0.32	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
LIHC	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	6.22	1.43e-09	1.02e-06	0.36	0.32	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
LIHC	cis	rs7115242	0.8	rs6589597	ENSG00000280143.1	AP000892.6	-6.22	1.43e-09	1.03e-06	-0.4	-0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117204967~117210292:+
LIHC	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	6.22	1.43e-09	1.03e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
LIHC	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	6.22	1.44e-09	1.03e-06	0.38	0.32	Height;	chr6:109490935	chr6:109382795~109383666:+
LIHC	cis	rs4356975	0.563	rs4356974	ENSG00000249956.3	RP11-790I12.2	6.22	1.44e-09	1.03e-06	0.36	0.32	Obesity-related traits;	chr4:69106696	chr4:69408836~69423164:+
LIHC	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-6.22	1.44e-09	1.04e-06	-0.38	-0.32	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-6.22	1.45e-09	1.04e-06	-0.37	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
LIHC	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	6.22	1.45e-09	1.04e-06	0.4	0.32	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
LIHC	cis	rs2243480	1	rs464895	ENSG00000164669.11	INTS4P1	6.22	1.46e-09	1.05e-06	0.55	0.32	Diabetic kidney disease;	chr7:66062119	chr7:65141225~65234216:+
LIHC	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-6.22	1.46e-09	1.05e-06	-0.35	-0.32	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
LIHC	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	6.22	1.46e-09	1.05e-06	0.4	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
LIHC	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-6.22	1.47e-09	1.05e-06	-0.49	-0.32	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
LIHC	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-6.22	1.47e-09	1.06e-06	-0.38	-0.32	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
LIHC	cis	rs7674212	0.581	rs13150953	ENSG00000230069.3	LRRC37A15P	-6.22	1.47e-09	1.06e-06	-0.3	-0.32	Type 2 diabetes;	chr4:103021341	chr4:102727274~102730721:-
LIHC	cis	rs7674212	0.556	rs13151569	ENSG00000230069.3	LRRC37A15P	-6.22	1.47e-09	1.06e-06	-0.3	-0.32	Type 2 diabetes;	chr4:103021633	chr4:102727274~102730721:-
LIHC	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-6.22	1.49e-09	1.07e-06	-0.49	-0.32	Depression;	chr6:28110254	chr6:28115628~28116551:+
LIHC	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	6.21	1.49e-09	1.07e-06	0.33	0.32	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
LIHC	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-6.21	1.49e-09	1.07e-06	-0.36	-0.32	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
LIHC	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-6.21	1.5e-09	1.07e-06	-0.41	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
LIHC	cis	rs1577917	0.561	rs3087978	ENSG00000234155.1	RP11-30P6.6	-6.21	1.5e-09	1.08e-06	-0.37	-0.32	Response to antipsychotic treatment;	chr6:85678505	chr6:85387219~85390186:-
LIHC	cis	rs3020736	0.5	rs6002616	ENSG00000237037.8	NDUFA6-AS1	-6.21	1.5e-09	1.08e-06	-0.38	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs7364293	ENSG00000237037.8	NDUFA6-AS1	-6.21	1.5e-09	1.08e-06	-0.38	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42090931~42137742:+
LIHC	cis	rs17270561	0.553	rs9379784	ENSG00000216436.2	HIST1H2APS1	-6.21	1.51e-09	1.08e-06	-0.38	-0.32	Iron status biomarkers;	chr6:25725278	chr6:25732497~25732827:+
LIHC	cis	rs227275	0.554	rs223334	ENSG00000230069.3	LRRC37A15P	6.21	1.51e-09	1.08e-06	0.29	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102727274~102730721:-
LIHC	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-6.21	1.52e-09	1.08e-06	-0.4	-0.32	Gout;	chr7:66642037	chr7:66902857~66906297:+
LIHC	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-6.21	1.52e-09	1.08e-06	-0.4	-0.32	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
LIHC	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-6.21	1.52e-09	1.08e-06	-0.44	-0.32	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
LIHC	cis	rs4356975	0.563	rs4327554	ENSG00000249956.3	RP11-790I12.2	-6.21	1.53e-09	1.09e-06	-0.36	-0.32	Obesity-related traits;	chr4:69120690	chr4:69408836~69423164:+
LIHC	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-6.21	1.53e-09	1.09e-06	-0.38	-0.32	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-6.21	1.53e-09	1.09e-06	-0.38	-0.32	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
LIHC	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-6.21	1.53e-09	1.09e-06	-0.46	-0.32	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
LIHC	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	6.21	1.53e-09	1.09e-06	0.39	0.32	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
LIHC	cis	rs9326248	0.773	rs1060211	ENSG00000236267.1	AP006216.5	6.21	1.54e-09	1.1e-06	0.33	0.32	Blood protein levels;	chr11:117169081	chr11:116813204~116814003:-
LIHC	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-6.21	1.54e-09	1.1e-06	-0.33	-0.32	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
LIHC	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-6.21	1.54e-09	1.1e-06	-0.48	-0.32	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
LIHC	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	6.21	1.54e-09	1.1e-06	0.39	0.32	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
LIHC	cis	rs1023500	0.505	rs134885	ENSG00000237037.8	NDUFA6-AS1	6.21	1.55e-09	1.11e-06	0.34	0.32	Schizophrenia;	chr22:42277805	chr22:42090931~42137742:+
LIHC	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	6.21	1.56e-09	1.11e-06	0.33	0.32	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
LIHC	cis	rs12681287	0.752	rs9297861	ENSG00000250569.1	NTAN1P2	6.21	1.56e-09	1.11e-06	0.39	0.32	Caudate activity during reward;	chr8:86242501	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs67615966	ENSG00000250569.1	NTAN1P2	6.21	1.56e-09	1.11e-06	0.39	0.32	Caudate activity during reward;	chr8:86242974	chr8:86481754~86483002:-
LIHC	cis	rs1577917	0.771	rs2475790	ENSG00000234155.1	RP11-30P6.6	6.21	1.56e-09	1.12e-06	0.4	0.32	Response to antipsychotic treatment;	chr6:85658350	chr6:85387219~85390186:-
LIHC	cis	rs494459	0.536	rs7103067	ENSG00000255422.1	AP002954.4	-6.21	1.57e-09	1.12e-06	-0.36	-0.32	Height;	chr11:118852670	chr11:118704607~118750263:+
LIHC	cis	rs11672691	0.792	rs7248215	ENSG00000267107.5	PCAT19	6.21	1.57e-09	1.12e-06	0.38	0.32	Prostate cancer;	chr19:41493212	chr19:41454169~41500649:-
LIHC	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	6.21	1.58e-09	1.12e-06	0.37	0.32	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
LIHC	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-6.2	1.58e-09	1.13e-06	-0.34	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-6.2	1.58e-09	1.13e-06	-0.34	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
LIHC	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-6.2	1.58e-09	1.13e-06	-0.39	-0.32	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
LIHC	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-6.2	1.58e-09	1.13e-06	-0.35	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
LIHC	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-6.2	1.59e-09	1.13e-06	-0.41	-0.32	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
LIHC	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-6.2	1.6e-09	1.14e-06	-0.36	-0.32	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
LIHC	cis	rs7914558	1	rs4917996	ENSG00000236937.2	PTGES3P4	6.2	1.61e-09	1.15e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs6584540	ENSG00000236937.2	PTGES3P4	6.2	1.61e-09	1.15e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs7081075	ENSG00000236937.2	PTGES3P4	6.2	1.61e-09	1.15e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:102845595~102845950:+
LIHC	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-6.2	1.61e-09	1.15e-06	-0.51	-0.32	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
LIHC	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-6.2	1.61e-09	1.15e-06	-0.47	-0.32	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
LIHC	cis	rs7637701	0.517	rs66538320	ENSG00000243926.1	TIPARP-AS1	6.2	1.61e-09	1.15e-06	0.3	0.32	Breast cancer;	chr3:156674346	chr3:156671862~156674378:-
LIHC	cis	rs2439831	0.85	rs2957637	ENSG00000205771.5	CATSPER2P1	-6.2	1.62e-09	1.15e-06	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43658920	chr15:43726918~43747094:-
LIHC	cis	rs7914558	0.966	rs2065977	ENSG00000236937.2	PTGES3P4	6.2	1.62e-09	1.15e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs12569617	ENSG00000236937.2	PTGES3P4	6.2	1.62e-09	1.15e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.933	rs1538204	ENSG00000236937.2	PTGES3P4	6.2	1.62e-09	1.15e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102845595~102845950:+
LIHC	cis	rs1577917	0.771	rs2842601	ENSG00000234155.1	RP11-30P6.6	6.2	1.62e-09	1.15e-06	0.4	0.32	Response to antipsychotic treatment;	chr6:85620415	chr6:85387219~85390186:-
LIHC	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	6.2	1.62e-09	1.15e-06	0.38	0.32	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
LIHC	cis	rs5758659	0.714	rs5758574	ENSG00000227370.1	RP4-669P10.19	6.2	1.62e-09	1.15e-06	0.36	0.32	Cognitive function;	chr22:42085396	chr22:42132543~42132998:+
LIHC	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	6.2	1.63e-09	1.16e-06	0.5	0.32	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
LIHC	cis	rs7914558	1	rs10786740	ENSG00000236937.2	PTGES3P4	6.2	1.63e-09	1.16e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:102845595~102845950:+
LIHC	cis	rs17270561	0.609	rs9358873	ENSG00000216436.2	HIST1H2APS1	-6.2	1.64e-09	1.17e-06	-0.39	-0.32	Iron status biomarkers;	chr6:25731555	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.666	rs3923725	ENSG00000216436.2	HIST1H2APS1	-6.2	1.64e-09	1.17e-06	-0.39	-0.32	Iron status biomarkers;	chr6:25734692	chr6:25732497~25732827:+
LIHC	cis	rs5769765	0.908	rs4058453	ENSG00000278869.1	CITF22-49E9.3	-6.2	1.65e-09	1.18e-06	-0.6	-0.32	Schizophrenia;	chr22:49856649	chr22:49933198~49934074:-
LIHC	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-6.2	1.66e-09	1.18e-06	-0.49	-0.32	Depression;	chr6:28126588	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-6.2	1.66e-09	1.18e-06	-0.49	-0.32	Depression;	chr6:28126953	chr6:28115628~28116551:+
LIHC	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-6.2	1.66e-09	1.18e-06	-0.44	-0.32	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
LIHC	cis	rs2442825	0.691	rs2600182	ENSG00000206573.7	THUMPD3-AS1	6.2	1.66e-09	1.18e-06	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9396376	chr3:9349689~9398579:-
LIHC	cis	rs950027	0.62	rs1145077	ENSG00000259433.2	CTD-2651B20.4	6.2	1.66e-09	1.18e-06	0.46	0.32	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45330209~45332634:-
LIHC	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-6.2	1.67e-09	1.19e-06	-0.38	-0.32	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-6.2	1.67e-09	1.19e-06	-0.38	-0.32	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
LIHC	cis	rs12291225	0.535	rs16930126	ENSG00000251991.1	RNU7-49P	-6.2	1.67e-09	1.19e-06	-0.34	-0.32	Sense of smell;	chr11:14383437	chr11:14478892~14478953:+
LIHC	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-6.2	1.67e-09	1.19e-06	-0.39	-0.32	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
LIHC	cis	rs12681287	0.752	rs12679266	ENSG00000250569.1	NTAN1P2	6.2	1.67e-09	1.19e-06	0.38	0.32	Caudate activity during reward;	chr8:86246604	chr8:86481754~86483002:-
LIHC	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	6.2	1.67e-09	1.19e-06	0.52	0.32	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
LIHC	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28111382	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28111650	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28112175	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28113616	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28113851	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28114487	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28114933	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28115743	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Depression;	chr6:28116411	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-6.19	1.68e-09	1.19e-06	-0.49	-0.32	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
LIHC	cis	rs7914558	0.966	rs11191471	ENSG00000236937.2	PTGES3P4	6.19	1.69e-09	1.2e-06	0.38	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102845595~102845950:+
LIHC	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	6.19	1.69e-09	1.2e-06	0.4	0.32	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
LIHC	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-6.19	1.69e-09	1.2e-06	-0.37	-0.32	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-6.19	1.69e-09	1.2e-06	-0.37	-0.32	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
LIHC	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-6.19	1.69e-09	1.2e-06	-0.36	-0.32	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
LIHC	cis	rs1799810	0.899	rs6753288	ENSG00000236682.1	AC068282.3	-6.19	1.69e-09	1.2e-06	-0.46	-0.32	Self-rated health;	chr2:127412323	chr2:127389130~127400580:+
LIHC	cis	rs1799810	0.899	rs4662726	ENSG00000236682.1	AC068282.3	6.19	1.69e-09	1.2e-06	0.46	0.32	Self-rated health;	chr2:127413086	chr2:127389130~127400580:+
LIHC	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-6.19	1.69e-09	1.2e-06	-0.36	-0.32	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
LIHC	cis	rs6490294	0.528	rs12578195	ENSG00000226469.1	ADAM1B	6.19	1.7e-09	1.2e-06	0.48	0.32	Mean platelet volume;	chr12:111956130	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs12423689	ENSG00000226469.1	ADAM1B	6.19	1.7e-09	1.2e-06	0.48	0.32	Mean platelet volume;	chr12:111965331	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs12423699	ENSG00000226469.1	ADAM1B	6.19	1.7e-09	1.2e-06	0.48	0.32	Mean platelet volume;	chr12:111965357	chr12:111927018~111929017:+
LIHC	cis	rs6490294	0.528	rs12426312	ENSG00000226469.1	ADAM1B	6.19	1.7e-09	1.2e-06	0.48	0.32	Mean platelet volume;	chr12:111968945	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.615	rs609230	ENSG00000226469.1	ADAM1B	-6.19	1.7e-09	1.2e-06	-0.41	-0.32	Platelet count;	chr12:111709107	chr12:111927018~111929017:+
LIHC	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-6.19	1.7e-09	1.21e-06	-0.48	-0.32	Depression;	chr6:28091242	chr6:28115628~28116551:+
LIHC	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	6.19	1.71e-09	1.21e-06	0.37	0.32	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
LIHC	cis	rs7176527	0.784	rs62021162	ENSG00000189136.7	UBE2Q2P1	-6.19	1.71e-09	1.21e-06	-0.27	-0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84526781~84571216:-
LIHC	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	6.19	1.72e-09	1.22e-06	0.38	0.32	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
LIHC	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	6.19	1.72e-09	1.22e-06	0.38	0.32	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
LIHC	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-6.19	1.72e-09	1.22e-06	-0.47	-0.32	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
LIHC	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-6.19	1.72e-09	1.22e-06	-0.38	-0.32	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
LIHC	cis	rs2735413	0.709	rs1319049	ENSG00000276007.1	RP11-358L22.3	6.19	1.74e-09	1.23e-06	0.36	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78050713	chr16:78123243~78124332:+
LIHC	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	6.19	1.74e-09	1.23e-06	0.38	0.32	Height;	chr6:109494148	chr6:109382795~109383666:+
LIHC	cis	rs7115242	0.748	rs1035237	ENSG00000236267.1	AP006216.5	6.19	1.74e-09	1.23e-06	0.35	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:116813204~116814003:-
LIHC	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	6.19	1.75e-09	1.24e-06	0.34	0.32	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
LIHC	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-6.19	1.76e-09	1.24e-06	-0.44	-0.32	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
LIHC	cis	rs2033711	0.936	rs7257999	ENSG00000269473.1	CTD-2619J13.19	6.19	1.76e-09	1.24e-06	0.38	0.32	Uric acid clearance;	chr19:58453493	chr19:58440448~58445849:+
LIHC	cis	rs6490294	0.904	rs76300790	ENSG00000226469.1	ADAM1B	6.19	1.76e-09	1.25e-06	0.43	0.32	Mean platelet volume;	chr12:111964865	chr12:111927018~111929017:+
LIHC	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	6.19	1.77e-09	1.25e-06	0.38	0.32	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
LIHC	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	6.19	1.77e-09	1.25e-06	0.37	0.32	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
LIHC	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-6.19	1.77e-09	1.25e-06	-0.3	-0.32	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
LIHC	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-6.19	1.77e-09	1.25e-06	-0.33	-0.32	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
LIHC	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	6.18	1.77e-09	1.25e-06	0.44	0.32	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
LIHC	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-6.18	1.77e-09	1.25e-06	-0.43	-0.32	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
LIHC	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-6.18	1.78e-09	1.26e-06	-0.43	-0.32	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
LIHC	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	6.18	1.78e-09	1.26e-06	0.36	0.32	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
LIHC	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-6.18	1.78e-09	1.26e-06	-0.36	-0.32	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
LIHC	cis	rs5758659	0.714	rs2284087	ENSG00000227370.1	RP4-669P10.19	6.18	1.79e-09	1.26e-06	0.35	0.32	Cognitive function;	chr22:42089667	chr22:42132543~42132998:+
LIHC	cis	rs2735413	0.599	rs76440854	ENSG00000276007.1	RP11-358L22.3	6.18	1.81e-09	1.27e-06	0.46	0.32	Systolic blood pressure (alcohol consumption interaction);	chr16:78046986	chr16:78123243~78124332:+
LIHC	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-6.18	1.81e-09	1.28e-06	-0.39	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
LIHC	cis	rs523522	0.962	rs7471	ENSG00000278344.1	RP11-18C24.8	6.18	1.81e-09	1.28e-06	0.38	0.32	High light scatter reticulocyte count;	chr12:120503412	chr12:120500735~120501090:-
LIHC	cis	rs1023500	0.573	rs2269524	ENSG00000237037.8	NDUFA6-AS1	-6.18	1.81e-09	1.28e-06	-0.38	-0.32	Schizophrenia;	chr22:42079699	chr22:42090931~42137742:+
LIHC	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-6.18	1.82e-09	1.29e-06	-0.4	-0.32	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
LIHC	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	6.18	1.82e-09	1.29e-06	0.42	0.32	Depression;	chr6:28364057	chr6:28943877~28944537:+
LIHC	cis	rs5769765	0.542	rs761878	ENSG00000278869.1	CITF22-49E9.3	-6.18	1.83e-09	1.29e-06	-0.6	-0.32	Schizophrenia;	chr22:49856029	chr22:49933198~49934074:-
LIHC	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	6.18	1.83e-09	1.29e-06	0.5	0.32	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
LIHC	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	6.18	1.84e-09	1.3e-06	0.38	0.32	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
LIHC	cis	rs12681287	0.752	rs12677470	ENSG00000250569.1	NTAN1P2	6.18	1.84e-09	1.3e-06	0.38	0.32	Caudate activity during reward;	chr8:86248330	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs10435563	ENSG00000250569.1	NTAN1P2	6.18	1.84e-09	1.3e-06	0.38	0.32	Caudate activity during reward;	chr8:86253831	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs10435564	ENSG00000250569.1	NTAN1P2	6.18	1.84e-09	1.3e-06	0.38	0.32	Caudate activity during reward;	chr8:86254010	chr8:86481754~86483002:-
LIHC	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	6.18	1.85e-09	1.31e-06	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
LIHC	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-6.18	1.85e-09	1.31e-06	-0.39	-0.32	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
LIHC	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	6.18	1.86e-09	1.31e-06	0.41	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
LIHC	cis	rs523522	0.962	rs509445	ENSG00000278344.1	RP11-18C24.8	6.18	1.86e-09	1.31e-06	0.38	0.32	High light scatter reticulocyte count;	chr12:120579440	chr12:120500735~120501090:-
LIHC	cis	rs11603023	0.569	rs573905	ENSG00000255239.1	AP002954.6	6.18	1.87e-09	1.31e-06	0.37	0.32	Cholesterol, total;	chr11:118701558	chr11:118688039~118690600:-
LIHC	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-6.18	1.87e-09	1.32e-06	-0.36	-0.32	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
LIHC	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-6.17	1.88e-09	1.32e-06	-0.35	-0.32	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
LIHC	cis	rs5758659	0.714	rs5758578	ENSG00000227370.1	RP4-669P10.19	6.17	1.89e-09	1.33e-06	0.35	0.32	Cognitive function;	chr22:42094288	chr22:42132543~42132998:+
LIHC	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-6.17	1.89e-09	1.33e-06	-0.39	-0.32	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-6.17	1.89e-09	1.33e-06	-0.39	-0.32	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-6.17	1.89e-09	1.33e-06	-0.39	-0.32	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-6.17	1.89e-09	1.33e-06	-0.39	-0.32	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
LIHC	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-6.17	1.89e-09	1.33e-06	-0.3	-0.32	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
LIHC	cis	rs7567389	0.511	rs61185143	ENSG00000236682.1	AC068282.3	6.17	1.9e-09	1.34e-06	0.45	0.32	Self-rated health;	chr2:127407902	chr2:127389130~127400580:+
LIHC	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	6.17	1.91e-09	1.34e-06	0.5	0.32	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
LIHC	cis	rs1023500	0.551	rs133371	ENSG00000237037.8	NDUFA6-AS1	6.17	1.91e-09	1.34e-06	0.38	0.32	Schizophrenia;	chr22:42069570	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.573	rs133374	ENSG00000237037.8	NDUFA6-AS1	6.17	1.91e-09	1.34e-06	0.38	0.32	Schizophrenia;	chr22:42069937	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.573	rs133378	ENSG00000237037.8	NDUFA6-AS1	6.17	1.91e-09	1.34e-06	0.38	0.32	Schizophrenia;	chr22:42071691	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.573	rs133382	ENSG00000237037.8	NDUFA6-AS1	6.17	1.91e-09	1.34e-06	0.38	0.32	Schizophrenia;	chr22:42075770	chr22:42090931~42137742:+
LIHC	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-6.17	1.91e-09	1.34e-06	-0.63	-0.32	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
LIHC	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	6.17	1.92e-09	1.35e-06	0.41	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
LIHC	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-6.17	1.92e-09	1.35e-06	-0.39	-0.32	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
LIHC	cis	rs4356975	0.522	rs7679184	ENSG00000249956.3	RP11-790I12.2	6.17	1.93e-09	1.35e-06	0.35	0.32	Obesity-related traits;	chr4:69100212	chr4:69408836~69423164:+
LIHC	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	6.17	1.93e-09	1.35e-06	0.38	0.32	Height;	chr6:109494760	chr6:109382795~109383666:+
LIHC	cis	rs4356975	0.509	rs4587017	ENSG00000249956.3	RP11-790I12.2	6.17	1.93e-09	1.35e-06	0.36	0.32	Obesity-related traits;	chr4:69081680	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.509	rs4458521	ENSG00000249956.3	RP11-790I12.2	6.17	1.93e-09	1.35e-06	0.36	0.32	Obesity-related traits;	chr4:69086240	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.509	rs4694169	ENSG00000249956.3	RP11-790I12.2	6.17	1.93e-09	1.35e-06	0.36	0.32	Obesity-related traits;	chr4:69088433	chr4:69408836~69423164:+
LIHC	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	6.17	1.93e-09	1.35e-06	0.39	0.32	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
LIHC	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	6.17	1.94e-09	1.36e-06	0.43	0.32	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
LIHC	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-6.17	1.94e-09	1.36e-06	-0.38	-0.32	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
LIHC	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	6.17	1.94e-09	1.36e-06	0.45	0.32	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	6.17	1.95e-09	1.37e-06	0.45	0.32	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
LIHC	cis	rs2933343	0.716	rs9872706	ENSG00000231305.3	RP11-723O4.2	-6.17	1.96e-09	1.37e-06	-0.37	-0.32	IgG glycosylation;	chr3:128848262	chr3:128861313~128871540:-
LIHC	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	6.17	1.97e-09	1.38e-06	0.52	0.32	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	6.17	1.97e-09	1.38e-06	0.52	0.32	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
LIHC	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-6.17	1.97e-09	1.38e-06	-0.34	-0.32	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
LIHC	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-6.17	1.97e-09	1.38e-06	-0.34	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
LIHC	cis	rs523522	0.962	rs603574	ENSG00000278344.1	RP11-18C24.8	6.17	1.98e-09	1.38e-06	0.38	0.32	High light scatter reticulocyte count;	chr12:120560640	chr12:120500735~120501090:-
LIHC	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	6.17	1.98e-09	1.38e-06	0.37	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
LIHC	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	6.17	1.98e-09	1.38e-06	0.44	0.32	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
LIHC	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-6.17	1.98e-09	1.39e-06	-0.37	-0.32	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
LIHC	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-6.17	1.98e-09	1.39e-06	-0.35	-0.32	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000206090.4	AP000350.7	-6.16	1.99e-09	1.39e-06	-0.4	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23939998~23942798:+
LIHC	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	6.16	2e-09	1.4e-06	0.41	0.32	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
LIHC	cis	rs12681287	0.64	rs7007855	ENSG00000250569.1	NTAN1P2	-6.16	2e-09	1.4e-06	-0.37	-0.32	Caudate activity during reward;	chr8:86417262	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.57	rs10956830	ENSG00000250569.1	NTAN1P2	-6.16	2e-09	1.4e-06	-0.37	-0.32	Caudate activity during reward;	chr8:86418254	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.604	rs28378899	ENSG00000250569.1	NTAN1P2	-6.16	2e-09	1.4e-06	-0.37	-0.32	Caudate activity during reward;	chr8:86422271	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs10098356	ENSG00000250569.1	NTAN1P2	-6.16	2e-09	1.4e-06	-0.37	-0.32	Caudate activity during reward;	chr8:86430438	chr8:86481754~86483002:-
LIHC	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-6.16	2.01e-09	1.41e-06	-0.41	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
LIHC	cis	rs4814920	0.818	rs6046387	ENSG00000275142.1	RP5-999L4.2	-6.16	2.02e-09	1.41e-06	-0.63	-0.32	Bipolar disorder (body mass index interaction);	chr20:19869186	chr20:19871891~19872284:+
LIHC	cis	rs6085948	0.861	rs6054847	ENSG00000238102.1	RP11-19D2.1	-6.16	2.02e-09	1.41e-06	-0.62	-0.32	Interleukin-10 levels;	chr20:7249794	chr20:7256580~7258214:-
LIHC	cis	rs6085948	0.861	rs11908494	ENSG00000238102.1	RP11-19D2.1	-6.16	2.02e-09	1.41e-06	-0.62	-0.32	Interleukin-10 levels;	chr20:7250266	chr20:7256580~7258214:-
LIHC	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-6.16	2.02e-09	1.41e-06	-0.39	-0.32	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
LIHC	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-6.16	2.03e-09	1.41e-06	-0.43	-0.32	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
LIHC	cis	rs12681287	0.64	rs7846090	ENSG00000250569.1	NTAN1P2	6.16	2.03e-09	1.42e-06	0.37	0.32	Caudate activity during reward;	chr8:86455495	chr8:86481754~86483002:-
LIHC	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-6.16	2.04e-09	1.42e-06	-0.39	-0.32	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
LIHC	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-6.16	2.04e-09	1.42e-06	-0.3	-0.32	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
LIHC	cis	rs4538475	0.697	rs16892260	ENSG00000214846.4	RP11-115L11.1	6.16	2.04e-09	1.43e-06	0.44	0.32	Parkinson's disease;	chr4:15711380	chr4:15730962~15731627:-
LIHC	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-6.16	2.04e-09	1.43e-06	-0.31	-0.32	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
LIHC	cis	rs1577917	0.771	rs2758844	ENSG00000234155.1	RP11-30P6.6	6.16	2.05e-09	1.43e-06	0.4	0.32	Response to antipsychotic treatment;	chr6:85620397	chr6:85387219~85390186:-
LIHC	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	6.16	2.05e-09	1.43e-06	0.48	0.32	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
LIHC	cis	rs7914558	0.899	rs7913682	ENSG00000236937.2	PTGES3P4	6.16	2.05e-09	1.43e-06	0.37	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102845595~102845950:+
LIHC	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	6.16	2.06e-09	1.44e-06	0.4	0.32	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
LIHC	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-6.16	2.07e-09	1.44e-06	-0.26	-0.32	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
LIHC	cis	rs3020736	0.5	rs8143153	ENSG00000237037.8	NDUFA6-AS1	-6.16	2.07e-09	1.45e-06	-0.38	-0.32	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42090931~42137742:+
LIHC	cis	rs2762353	0.595	rs12200838	ENSG00000242387.1	HIST1H2APS2	-6.16	2.08e-09	1.45e-06	-0.39	-0.32	Blood metabolite levels;	chr6:25753375	chr6:25882026~25882395:-
LIHC	cis	rs2762353	0.595	rs1892256	ENSG00000242387.1	HIST1H2APS2	-6.16	2.08e-09	1.45e-06	-0.39	-0.32	Blood metabolite levels;	chr6:25754043	chr6:25882026~25882395:-
LIHC	cis	rs2439831	0.571	rs689883	ENSG00000205771.5	CATSPER2P1	-6.16	2.09e-09	1.46e-06	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43520398	chr15:43726918~43747094:-
LIHC	cis	rs7914558	0.966	rs4532960	ENSG00000236937.2	PTGES3P4	6.16	2.1e-09	1.46e-06	0.37	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs10786724	ENSG00000236937.2	PTGES3P4	6.16	2.1e-09	1.46e-06	0.37	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs2297786	ENSG00000236937.2	PTGES3P4	6.16	2.1e-09	1.46e-06	0.37	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102845595~102845950:+
LIHC	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	6.16	2.1e-09	1.46e-06	0.42	0.32	Depression;	chr6:28386473	chr6:28943877~28944537:+
LIHC	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-6.16	2.1e-09	1.46e-06	-0.56	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
LIHC	cis	rs7119038	0.818	rs73003215	ENSG00000255239.1	AP002954.6	-6.15	2.1e-09	1.46e-06	-0.4	-0.32	Sjögren's syndrome;	chr11:118778803	chr11:118688039~118690600:-
LIHC	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	6.15	2.11e-09	1.47e-06	0.39	0.32	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	6.15	2.11e-09	1.47e-06	0.39	0.32	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
LIHC	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-6.15	2.12e-09	1.47e-06	-0.38	-0.32	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
LIHC	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	6.15	2.12e-09	1.47e-06	0.49	0.32	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	6.15	2.12e-09	1.47e-06	0.49	0.32	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	6.15	2.12e-09	1.47e-06	0.49	0.32	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
LIHC	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-6.15	2.12e-09	1.48e-06	-0.39	-0.32	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
LIHC	cis	rs7914558	0.966	rs7096269	ENSG00000236937.2	PTGES3P4	6.15	2.12e-09	1.48e-06	0.37	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.933	rs10883814	ENSG00000236937.2	PTGES3P4	6.15	2.12e-09	1.48e-06	0.37	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102845595~102845950:+
LIHC	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	6.15	2.13e-09	1.48e-06	0.38	0.32	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
LIHC	cis	rs2243480	1	rs12698509	ENSG00000164669.11	INTS4P1	6.15	2.13e-09	1.48e-06	0.55	0.32	Diabetic kidney disease;	chr7:65953889	chr7:65141225~65234216:+
LIHC	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-6.15	2.13e-09	1.48e-06	-0.41	-0.32	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
LIHC	cis	rs904251	0.523	rs9349039	ENSG00000204110.6	RP1-153P14.8	-6.15	2.13e-09	1.49e-06	-0.38	-0.32	Cognitive performance;	chr6:37512616	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.523	rs9366935	ENSG00000204110.6	RP1-153P14.8	-6.15	2.13e-09	1.49e-06	-0.38	-0.32	Cognitive performance;	chr6:37512628	chr6:37507348~37535616:+
LIHC	cis	rs2565722	0.825	rs1247540	ENSG00000243831.1	RP1-81D8.4	6.15	2.14e-09	1.49e-06	0.49	0.32	Blood protein levels;	chr6:160831984	chr6:160666228~160676523:-
LIHC	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-6.15	2.14e-09	1.49e-06	-0.35	-0.32	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-6.15	2.14e-09	1.49e-06	-0.35	-0.32	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
LIHC	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	6.15	2.15e-09	1.49e-06	0.42	0.32	Depression;	chr6:28391932	chr6:28943877~28944537:+
LIHC	cis	rs9843304	0.616	rs4681174	ENSG00000244503.1	RP11-278L15.6	6.15	2.15e-09	1.5e-06	0.34	0.32	Gallstone disease;	chr3:149483839	chr3:149494660~149495995:+
LIHC	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-6.15	2.16e-09	1.5e-06	-0.36	-0.32	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
LIHC	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-6.15	2.16e-09	1.5e-06	-0.39	-0.32	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
LIHC	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	6.15	2.17e-09	1.51e-06	0.47	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
LIHC	cis	rs1023500	0.505	rs134874	ENSG00000237037.8	NDUFA6-AS1	6.15	2.17e-09	1.51e-06	0.33	0.32	Schizophrenia;	chr22:42265138	chr22:42090931~42137742:+
LIHC	cis	rs4538475	1	rs4273468	ENSG00000214846.4	RP11-115L11.1	-6.15	2.17e-09	1.51e-06	-0.41	-0.32	Parkinson's disease;	chr4:15736240	chr4:15730962~15731627:-
LIHC	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	6.15	2.17e-09	1.51e-06	0.29	0.32	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
LIHC	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-6.15	2.18e-09	1.51e-06	-0.55	-0.32	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
LIHC	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-6.15	2.18e-09	1.51e-06	-0.43	-0.32	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
LIHC	cis	rs1023500	0.573	rs6002592	ENSG00000237037.8	NDUFA6-AS1	-6.15	2.18e-09	1.52e-06	-0.38	-0.32	Schizophrenia;	chr22:42080750	chr22:42090931~42137742:+
LIHC	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-6.15	2.19e-09	1.52e-06	-0.33	-0.32	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-6.15	2.19e-09	1.52e-06	-0.33	-0.32	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	6.15	2.19e-09	1.52e-06	0.33	0.32	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
LIHC	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.15	2.2e-09	1.53e-06	0.41	0.32	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
LIHC	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	6.15	2.21e-09	1.53e-06	0.44	0.32	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
LIHC	cis	rs1577917	0.771	rs2783171	ENSG00000234155.1	RP11-30P6.6	-6.15	2.21e-09	1.54e-06	-0.4	-0.32	Response to antipsychotic treatment;	chr6:85673047	chr6:85387219~85390186:-
LIHC	cis	rs6801605	0.963	rs6445607	ENSG00000271916.1	RP11-884K10.6	-6.15	2.22e-09	1.54e-06	-0.45	-0.32	Blood protein levels;	chr3:53843122	chr3:53797764~53798019:-
LIHC	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	6.14	2.23e-09	1.55e-06	0.38	0.32	Height;	chr6:109495102	chr6:109382795~109383666:+
LIHC	cis	rs7914558	0.966	rs10786745	ENSG00000236937.2	PTGES3P4	6.14	2.24e-09	1.55e-06	0.37	0.32	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102845595~102845950:+
LIHC	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-6.14	2.24e-09	1.56e-06	-0.51	-0.32	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
LIHC	cis	rs1577917	0.74	rs2842604	ENSG00000234155.1	RP11-30P6.6	6.14	2.25e-09	1.56e-06	0.4	0.32	Response to antipsychotic treatment;	chr6:85626582	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs2842607	ENSG00000234155.1	RP11-30P6.6	6.14	2.25e-09	1.56e-06	0.4	0.32	Response to antipsychotic treatment;	chr6:85635321	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.771	rs2758847	ENSG00000234155.1	RP11-30P6.6	6.14	2.25e-09	1.56e-06	0.4	0.32	Response to antipsychotic treatment;	chr6:85639385	chr6:85387219~85390186:-
LIHC	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-6.14	2.26e-09	1.57e-06	-0.48	-0.32	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
LIHC	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	6.14	2.26e-09	1.57e-06	0.41	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
LIHC	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	6.14	2.26e-09	1.57e-06	0.41	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
LIHC	cis	rs17270561	0.609	rs1937131	ENSG00000216436.2	HIST1H2APS1	6.14	2.26e-09	1.57e-06	0.38	0.32	Iron status biomarkers;	chr6:25744603	chr6:25732497~25732827:+
LIHC	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	6.14	2.27e-09	1.57e-06	0.33	0.32	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
LIHC	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	6.14	2.27e-09	1.57e-06	0.36	0.32	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
LIHC	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-6.14	2.28e-09	1.58e-06	-0.36	-0.32	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
LIHC	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	6.14	2.28e-09	1.58e-06	0.47	0.32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
LIHC	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-6.14	2.28e-09	1.58e-06	-0.4	-0.32	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
LIHC	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	6.14	2.28e-09	1.58e-06	0.38	0.32	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	6.14	2.29e-09	1.58e-06	0.35	0.32	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	6.14	2.29e-09	1.58e-06	0.35	0.32	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
LIHC	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-6.14	2.29e-09	1.59e-06	-0.32	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
LIHC	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-6.14	2.3e-09	1.59e-06	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-6.14	2.3e-09	1.59e-06	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs486301	ENSG00000205771.5	CATSPER2P1	-6.14	2.3e-09	1.59e-06	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43544751	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-6.14	2.3e-09	1.59e-06	-0.43	-0.32	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
LIHC	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	6.14	2.3e-09	1.59e-06	0.32	0.32	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
LIHC	cis	rs9527	0.551	rs28606370	ENSG00000236937.2	PTGES3P4	6.14	2.31e-09	1.59e-06	0.38	0.32	Arsenic metabolism;	chr10:102911075	chr10:102845595~102845950:+
LIHC	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-6.14	2.32e-09	1.6e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-6.14	2.32e-09	1.6e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
LIHC	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-6.14	2.34e-09	1.61e-06	-0.26	-0.31	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
LIHC	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-6.14	2.34e-09	1.62e-06	-0.36	-0.31	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
LIHC	cis	rs9341808	0.718	rs9352806	ENSG00000272129.1	RP11-250B2.6	6.14	2.34e-09	1.62e-06	0.31	0.31	Sitting height ratio;	chr6:80270340	chr6:80355424~80356859:+
LIHC	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-6.14	2.34e-09	1.62e-06	-0.48	-0.31	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
LIHC	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	6.14	2.35e-09	1.62e-06	0.38	0.31	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
LIHC	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-6.13	2.35e-09	1.63e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
LIHC	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	6.13	2.36e-09	1.63e-06	0.42	0.31	Depression;	chr6:28379133	chr6:28943877~28944537:+
LIHC	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	6.13	2.36e-09	1.63e-06	0.42	0.31	Depression;	chr6:28379168	chr6:28943877~28944537:+
LIHC	cis	rs9326248	0.954	rs10790177	ENSG00000236267.1	AP006216.5	6.13	2.36e-09	1.63e-06	0.32	0.31	Blood protein levels;	chr11:117177701	chr11:116813204~116814003:-
LIHC	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-6.13	2.37e-09	1.64e-06	-0.37	-0.31	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
LIHC	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-6.13	2.38e-09	1.64e-06	-0.39	-0.31	Gout;	chr7:66654674	chr7:66902857~66906297:+
LIHC	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-6.13	2.38e-09	1.64e-06	-0.39	-0.31	Gout;	chr7:66661502	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs313832	ENSG00000164669.11	INTS4P1	6.13	2.38e-09	1.64e-06	0.55	0.31	Diabetic kidney disease;	chr7:66085904	chr7:65141225~65234216:+
LIHC	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	6.13	2.38e-09	1.65e-06	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
LIHC	cis	rs12285276	0.636	rs7114337	ENSG00000205106.4	DKFZp779M0652	6.13	2.39e-09	1.65e-06	0.33	0.31	Visceral fat;	chr11:45779608	chr11:45771432~45772358:+
LIHC	cis	rs5758659	0.737	rs10854749	ENSG00000227370.1	RP4-669P10.19	-6.13	2.39e-09	1.65e-06	-0.37	-0.31	Cognitive function;	chr22:42051337	chr22:42132543~42132998:+
LIHC	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-6.13	2.4e-09	1.65e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
LIHC	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	6.13	2.4e-09	1.65e-06	0.45	0.31	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
LIHC	cis	rs854624	1	rs41508645	ENSG00000275944.1	RP11-104J23.1	-6.13	2.41e-09	1.66e-06	-0.38	-0.31	Blood protein levels;	chr17:36001998	chr17:36001419~36011618:+
LIHC	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-6.13	2.41e-09	1.66e-06	-0.34	-0.31	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
LIHC	cis	rs5758659	0.653	rs133383	ENSG00000227370.1	RP4-669P10.19	-6.13	2.41e-09	1.66e-06	-0.36	-0.31	Cognitive function;	chr22:42077599	chr22:42132543~42132998:+
LIHC	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-6.13	2.41e-09	1.66e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
LIHC	cis	rs12285276	0.534	rs57467722	ENSG00000205106.4	DKFZp779M0652	6.13	2.41e-09	1.66e-06	0.31	0.31	Visceral fat;	chr11:45773301	chr11:45771432~45772358:+
LIHC	cis	rs12285276	0.662	rs60923315	ENSG00000205106.4	DKFZp779M0652	6.13	2.41e-09	1.66e-06	0.31	0.31	Visceral fat;	chr11:45773302	chr11:45771432~45772358:+
LIHC	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	6.13	2.42e-09	1.67e-06	0.39	0.31	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	6.13	2.42e-09	1.67e-06	0.39	0.31	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	6.13	2.42e-09	1.67e-06	0.39	0.31	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	6.13	2.42e-09	1.67e-06	0.36	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
LIHC	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	6.13	2.43e-09	1.67e-06	0.33	0.31	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
LIHC	cis	rs6085948	0.953	rs6077166	ENSG00000238102.1	RP11-19D2.1	6.13	2.43e-09	1.67e-06	0.46	0.31	Interleukin-10 levels;	chr20:7252921	chr20:7256580~7258214:-
LIHC	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-6.13	2.44e-09	1.68e-06	-0.34	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
LIHC	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-6.13	2.44e-09	1.68e-06	-0.53	-0.31	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
LIHC	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-6.13	2.44e-09	1.68e-06	-0.36	-0.31	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-6.13	2.44e-09	1.68e-06	-0.36	-0.31	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-6.13	2.44e-09	1.68e-06	-0.36	-0.31	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-6.13	2.44e-09	1.68e-06	-0.36	-0.31	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-6.13	2.44e-09	1.68e-06	-0.36	-0.31	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-6.13	2.44e-09	1.68e-06	-0.36	-0.31	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-6.13	2.44e-09	1.68e-06	-0.36	-0.31	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
LIHC	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-6.13	2.45e-09	1.68e-06	-0.39	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
LIHC	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-6.13	2.45e-09	1.68e-06	-0.34	-0.31	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
LIHC	cis	rs17270561	0.609	rs4711097	ENSG00000216436.2	HIST1H2APS1	-6.13	2.45e-09	1.69e-06	-0.38	-0.31	Iron status biomarkers;	chr6:25732086	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.608	rs9358875	ENSG00000216436.2	HIST1H2APS1	-6.13	2.45e-09	1.69e-06	-0.38	-0.31	Iron status biomarkers;	chr6:25737780	chr6:25732497~25732827:+
LIHC	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-6.13	2.45e-09	1.69e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-6.13	2.45e-09	1.69e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-6.13	2.45e-09	1.69e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
LIHC	cis	rs854625	1	rs854625	ENSG00000275944.1	RP11-104J23.1	-6.13	2.45e-09	1.69e-06	-0.38	-0.31	Cerebrospinal fluid biomarker levels;	chr17:36001422	chr17:36001419~36011618:+
LIHC	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-6.13	2.46e-09	1.7e-06	-0.37	-0.31	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
LIHC	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	6.13	2.47e-09	1.7e-06	0.53	0.31	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
LIHC	cis	rs1023500	0.552	rs133368	ENSG00000237037.8	NDUFA6-AS1	6.13	2.47e-09	1.7e-06	0.38	0.31	Schizophrenia;	chr22:42067685	chr22:42090931~42137742:+
LIHC	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-6.13	2.47e-09	1.7e-06	-0.32	-0.31	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
LIHC	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-6.13	2.48e-09	1.7e-06	-0.36	-0.31	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
LIHC	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-6.13	2.48e-09	1.7e-06	-0.41	-0.31	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
LIHC	cis	rs9326248	0.53	rs2075292	ENSG00000236267.1	AP006216.5	6.13	2.48e-09	1.71e-06	0.35	0.31	Blood protein levels;	chr11:116861796	chr11:116813204~116814003:-
LIHC	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	6.13	2.49e-09	1.71e-06	0.48	0.31	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
LIHC	cis	rs7580658	0.613	rs6754999	ENSG00000236682.1	AC068282.3	-6.12	2.49e-09	1.71e-06	-0.4	-0.31	Protein C levels;	chr2:127437811	chr2:127389130~127400580:+
LIHC	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-6.12	2.5e-09	1.72e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
LIHC	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	6.12	2.5e-09	1.72e-06	0.31	0.31	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
LIHC	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-6.12	2.5e-09	1.72e-06	-0.38	-0.31	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-6.12	2.5e-09	1.72e-06	-0.38	-0.31	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
LIHC	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	6.12	2.51e-09	1.73e-06	0.33	0.31	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
LIHC	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-6.12	2.52e-09	1.73e-06	-0.47	-0.31	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
LIHC	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	6.12	2.53e-09	1.74e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	6.12	2.53e-09	1.74e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	6.12	2.53e-09	1.74e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	6.12	2.53e-09	1.74e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	6.12	2.53e-09	1.74e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	6.12	2.53e-09	1.74e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
LIHC	cis	rs4356975	0.563	rs35402056	ENSG00000249956.3	RP11-790I12.2	6.12	2.53e-09	1.74e-06	0.35	0.31	Obesity-related traits;	chr4:69108549	chr4:69408836~69423164:+
LIHC	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-6.12	2.54e-09	1.74e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-6.12	2.54e-09	1.75e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-6.12	2.54e-09	1.75e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
LIHC	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-6.12	2.55e-09	1.75e-06	-0.43	-0.31	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
LIHC	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-6.12	2.55e-09	1.75e-06	-0.4	-0.31	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
LIHC	cis	rs3812049	0.784	rs2250127	ENSG00000245937.6	LINC01184	-6.12	2.55e-09	1.75e-06	-0.42	-0.31	Lymphocyte counts;Red cell distribution width;	chr5:128053152	chr5:127940426~128083172:-
LIHC	cis	rs2933343	0.679	rs789254	ENSG00000231305.3	RP11-723O4.2	6.12	2.57e-09	1.76e-06	0.35	0.31	IgG glycosylation;	chr3:128855750	chr3:128861313~128871540:-
LIHC	cis	rs2243480	0.522	rs431168	ENSG00000164669.11	INTS4P1	6.12	2.57e-09	1.76e-06	0.58	0.31	Diabetic kidney disease;	chr7:66046617	chr7:65141225~65234216:+
LIHC	cis	rs1577917	0.727	rs9351065	ENSG00000234155.1	RP11-30P6.6	6.12	2.57e-09	1.77e-06	0.39	0.31	Response to antipsychotic treatment;	chr6:85650710	chr6:85387219~85390186:-
LIHC	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	6.12	2.58e-09	1.77e-06	0.51	0.31	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
LIHC	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	6.12	2.59e-09	1.78e-06	0.36	0.31	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
LIHC	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	6.12	2.6e-09	1.78e-06	0.51	0.31	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
LIHC	cis	rs1023500	0.505	rs134886	ENSG00000237037.8	NDUFA6-AS1	-6.12	2.6e-09	1.78e-06	-0.34	-0.31	Schizophrenia;	chr22:42277850	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.739	rs2758846	ENSG00000234155.1	RP11-30P6.6	6.12	2.62e-09	1.8e-06	0.4	0.31	Response to antipsychotic treatment;	chr6:85639852	chr6:85387219~85390186:-
LIHC	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-6.12	2.63e-09	1.8e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
LIHC	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-6.12	2.63e-09	1.8e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
LIHC	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-6.11	2.64e-09	1.81e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
LIHC	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	6.11	2.64e-09	1.81e-06	0.49	0.31	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
LIHC	cis	rs11089937	0.963	rs5757078	ENSG00000211639.2	IGLV4-60	6.11	2.64e-09	1.81e-06	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22162199~22162681:+
LIHC	cis	rs4356975	0.563	rs7439152	ENSG00000249956.3	RP11-790I12.2	6.11	2.65e-09	1.81e-06	0.35	0.31	Obesity-related traits;	chr4:69103288	chr4:69408836~69423164:+
LIHC	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-6.11	2.65e-09	1.82e-06	-0.43	-0.31	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
LIHC	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	6.11	2.65e-09	1.82e-06	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
LIHC	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-6.11	2.65e-09	1.82e-06	-0.37	-0.31	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
LIHC	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-6.11	2.66e-09	1.82e-06	-0.43	-0.31	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
LIHC	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	6.11	2.67e-09	1.83e-06	0.45	0.31	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
LIHC	cis	rs2735413	0.564	rs73574780	ENSG00000276007.1	RP11-358L22.3	6.11	2.67e-09	1.83e-06	0.42	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78054207	chr16:78123243~78124332:+
LIHC	cis	rs7914558	1	rs11191541	ENSG00000236937.2	PTGES3P4	6.11	2.67e-09	1.83e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102845595~102845950:+
LIHC	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-6.11	2.68e-09	1.83e-06	-0.38	-0.31	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
LIHC	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	6.11	2.68e-09	1.83e-06	0.49	0.31	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
LIHC	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	6.11	2.68e-09	1.83e-06	0.32	0.31	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
LIHC	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	6.11	2.7e-09	1.85e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
LIHC	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	6.11	2.71e-09	1.85e-06	0.42	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
LIHC	cis	rs9326248	1	rs7946257	ENSG00000236267.1	AP006216.5	6.11	2.71e-09	1.85e-06	0.32	0.31	Blood protein levels;	chr11:117182449	chr11:116813204~116814003:-
LIHC	cis	rs1023500	0.573	rs133377	ENSG00000237037.8	NDUFA6-AS1	6.11	2.71e-09	1.85e-06	0.38	0.31	Schizophrenia;	chr22:42070946	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.559	rs1173418	ENSG00000234155.1	RP11-30P6.6	-6.11	2.71e-09	1.85e-06	-0.37	-0.31	Response to antipsychotic treatment;	chr6:85693198	chr6:85387219~85390186:-
LIHC	cis	rs7580658	0.68	rs12468304	ENSG00000236682.1	AC068282.3	6.11	2.71e-09	1.85e-06	0.38	0.31	Protein C levels;	chr2:127436236	chr2:127389130~127400580:+
LIHC	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	6.11	2.72e-09	1.86e-06	0.34	0.31	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
LIHC	cis	rs7914558	1	rs7094843	ENSG00000236937.2	PTGES3P4	6.11	2.73e-09	1.86e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs4917994	ENSG00000236937.2	PTGES3P4	6.11	2.73e-09	1.86e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs2275271	ENSG00000236937.2	PTGES3P4	6.11	2.73e-09	1.86e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs11191539	ENSG00000236937.2	PTGES3P4	6.11	2.73e-09	1.86e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs943038	ENSG00000236937.2	PTGES3P4	6.11	2.73e-09	1.86e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102845595~102845950:+
LIHC	cis	rs9326248	0.798	rs10892079	ENSG00000236267.1	AP006216.5	6.11	2.73e-09	1.86e-06	0.32	0.31	Blood protein levels;	chr11:117146108	chr11:116813204~116814003:-
LIHC	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-6.11	2.73e-09	1.87e-06	-0.4	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
LIHC	cis	rs12285276	0.636	rs7120031	ENSG00000205106.4	DKFZp779M0652	6.11	2.74e-09	1.87e-06	0.33	0.31	Visceral fat;	chr11:45794469	chr11:45771432~45772358:+
LIHC	cis	rs1023500	0.505	rs134889	ENSG00000237037.8	NDUFA6-AS1	6.11	2.74e-09	1.87e-06	0.34	0.31	Schizophrenia;	chr22:42278344	chr22:42090931~42137742:+
LIHC	cis	rs1577917	0.771	rs4145082	ENSG00000234155.1	RP11-30P6.6	6.11	2.74e-09	1.87e-06	0.4	0.31	Response to antipsychotic treatment;	chr6:85642298	chr6:85387219~85390186:-
LIHC	cis	rs17270561	0.636	rs6456694	ENSG00000216436.2	HIST1H2APS1	-6.11	2.75e-09	1.88e-06	-0.37	-0.31	Iron status biomarkers;	chr6:25712666	chr6:25732497~25732827:+
LIHC	cis	rs7914558	0.966	rs1591915	ENSG00000236937.2	PTGES3P4	6.11	2.75e-09	1.88e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102845595~102845950:+
LIHC	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-6.11	2.77e-09	1.89e-06	-0.35	-0.31	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
LIHC	cis	rs1023500	0.573	rs2413666	ENSG00000237037.8	NDUFA6-AS1	6.11	2.77e-09	1.89e-06	0.38	0.31	Schizophrenia;	chr22:42063618	chr22:42090931~42137742:+
LIHC	cis	rs6490294	0.747	rs632650	ENSG00000226469.1	ADAM1B	6.11	2.77e-09	1.89e-06	0.42	0.31	Mean platelet volume;	chr12:111693894	chr12:111927018~111929017:+
LIHC	cis	rs7914558	0.966	rs56946876	ENSG00000236937.2	PTGES3P4	6.11	2.78e-09	1.9e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.933	rs12763665	ENSG00000236937.2	PTGES3P4	6.11	2.78e-09	1.9e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs10786721	ENSG00000236937.2	PTGES3P4	6.11	2.78e-09	1.9e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102845595~102845950:+
LIHC	cis	rs9326248	0.768	rs4936366	ENSG00000236267.1	AP006216.5	6.11	2.79e-09	1.9e-06	0.32	0.31	Blood protein levels;	chr11:117156169	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.861	rs4938352	ENSG00000236267.1	AP006216.5	6.11	2.79e-09	1.9e-06	0.32	0.31	Blood protein levels;	chr11:117156765	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.861	rs4938353	ENSG00000236267.1	AP006216.5	6.11	2.79e-09	1.9e-06	0.32	0.31	Blood protein levels;	chr11:117175481	chr11:116813204~116814003:-
LIHC	cis	rs4356975	0.563	rs6858558	ENSG00000249956.3	RP11-790I12.2	6.1	2.79e-09	1.9e-06	0.35	0.31	Obesity-related traits;	chr4:69103825	chr4:69408836~69423164:+
LIHC	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-6.1	2.8e-09	1.91e-06	-0.38	-0.31	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
LIHC	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	6.1	2.81e-09	1.91e-06	0.37	0.31	Height;	chr6:109497088	chr6:109382795~109383666:+
LIHC	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-6.1	2.81e-09	1.91e-06	-0.26	-0.31	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
LIHC	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	6.1	2.81e-09	1.92e-06	0.37	0.31	Height;	chr6:109496680	chr6:109382795~109383666:+
LIHC	cis	rs1577917	0.771	rs10944133	ENSG00000234155.1	RP11-30P6.6	6.1	2.81e-09	1.92e-06	0.39	0.31	Response to antipsychotic treatment;	chr6:85649266	chr6:85387219~85390186:-
LIHC	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-6.1	2.82e-09	1.92e-06	-0.46	-0.31	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
LIHC	cis	rs1023500	0.529	rs133375	ENSG00000237037.8	NDUFA6-AS1	6.1	2.82e-09	1.92e-06	0.38	0.31	Schizophrenia;	chr22:42070505	chr22:42090931~42137742:+
LIHC	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	6.1	2.82e-09	1.92e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
LIHC	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	6.1	2.84e-09	1.93e-06	0.53	0.31	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
LIHC	cis	rs2735413	0.709	rs8051521	ENSG00000276007.1	RP11-358L22.3	6.1	2.84e-09	1.94e-06	0.35	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78054259	chr16:78123243~78124332:+
LIHC	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-6.1	2.85e-09	1.94e-06	-0.35	-0.31	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
LIHC	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-6.1	2.85e-09	1.94e-06	-0.36	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
LIHC	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-6.1	2.85e-09	1.94e-06	-0.39	-0.31	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
LIHC	cis	rs7916697	0.626	rs3858146	ENSG00000233590.1	RP11-153K11.3	-6.1	2.85e-09	1.94e-06	-0.37	-0.31	Optic disc area;	chr10:68253493	chr10:68233251~68242379:-
LIHC	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-6.1	2.86e-09	1.95e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-6.1	2.86e-09	1.95e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-6.1	2.86e-09	1.95e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-6.1	2.86e-09	1.95e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-6.1	2.86e-09	1.95e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-6.1	2.86e-09	1.95e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
LIHC	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-6.1	2.86e-09	1.95e-06	-0.33	-0.31	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
LIHC	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-6.1	2.87e-09	1.95e-06	-0.36	-0.31	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
LIHC	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-6.1	2.87e-09	1.95e-06	-0.38	-0.31	Height;	chr6:109497253	chr6:109382795~109383666:+
LIHC	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-6.1	2.88e-09	1.96e-06	-0.38	-0.31	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-6.1	2.88e-09	1.96e-06	-0.38	-0.31	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
LIHC	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-6.1	2.88e-09	1.96e-06	-0.46	-0.31	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
LIHC	cis	rs7914558	1	rs12780843	ENSG00000236937.2	PTGES3P4	6.1	2.88e-09	1.96e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102845595~102845950:+
LIHC	cis	rs111326718	1	rs111326718	ENSG00000236937.2	PTGES3P4	6.1	2.88e-09	1.96e-06	0.37	0.31	Reticulocyte count;	chr10:103011454	chr10:102845595~102845950:+
LIHC	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-6.1	2.89e-09	1.97e-06	-0.43	-0.31	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
LIHC	cis	rs7914558	0.966	rs10748835	ENSG00000236937.2	PTGES3P4	6.1	2.89e-09	1.97e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900499	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs10450373	ENSG00000236937.2	PTGES3P4	6.1	2.89e-09	1.97e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102845595~102845950:+
LIHC	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	6.1	2.9e-09	1.97e-06	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
LIHC	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	6.1	2.9e-09	1.97e-06	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
LIHC	cis	rs7927592	0.731	rs11228275	ENSG00000212093.1	AP000807.1	-6.1	2.9e-09	1.97e-06	-0.31	-0.31	Total body bone mineral density;	chr11:68536512	chr11:68506083~68506166:-
LIHC	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	6.1	2.9e-09	1.97e-06	0.51	0.31	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	6.1	2.9e-09	1.97e-06	0.51	0.31	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	6.1	2.9e-09	1.97e-06	0.51	0.31	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	6.1	2.9e-09	1.97e-06	0.51	0.31	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	6.1	2.9e-09	1.97e-06	0.51	0.31	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	6.1	2.9e-09	1.97e-06	0.51	0.31	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
LIHC	cis	rs7914558	0.966	rs11191518	ENSG00000236937.2	PTGES3P4	6.1	2.9e-09	1.97e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102845595~102845950:+
LIHC	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-6.1	2.91e-09	1.98e-06	-0.42	-0.31	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
LIHC	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-6.1	2.92e-09	1.98e-06	-0.44	-0.31	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
LIHC	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-6.1	2.92e-09	1.98e-06	-0.36	-0.31	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
LIHC	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	6.1	2.92e-09	1.99e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
LIHC	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-6.1	2.92e-09	1.99e-06	-0.51	-0.31	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
LIHC	cis	rs2033711	0.905	rs1077420	ENSG00000269473.1	CTD-2619J13.19	6.1	2.92e-09	1.99e-06	0.39	0.31	Uric acid clearance;	chr19:58457508	chr19:58440448~58445849:+
LIHC	cis	rs2033711	0.905	rs893186	ENSG00000269473.1	CTD-2619J13.19	6.1	2.92e-09	1.99e-06	0.39	0.31	Uric acid clearance;	chr19:58457812	chr19:58440448~58445849:+
LIHC	cis	rs7914558	1	rs4917380	ENSG00000236937.2	PTGES3P4	6.1	2.93e-09	1.99e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs7914558	ENSG00000236937.2	PTGES3P4	6.1	2.93e-09	1.99e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102845595~102845950:+
LIHC	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-6.09	2.95e-09	2.01e-06	-0.39	-0.31	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-6.09	2.95e-09	2.01e-06	-0.39	-0.31	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
LIHC	cis	rs7914558	1	rs7071373	ENSG00000236937.2	PTGES3P4	6.09	2.95e-09	2.01e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102845595~102845950:+
LIHC	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-6.09	2.95e-09	2.01e-06	-0.45	-0.31	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
LIHC	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-6.09	2.96e-09	2.01e-06	-0.34	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
LIHC	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	6.09	2.97e-09	2.01e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
LIHC	cis	rs2243480	0.522	rs12698511	ENSG00000164669.11	INTS4P1	6.09	2.97e-09	2.02e-06	0.58	0.31	Diabetic kidney disease;	chr7:66009932	chr7:65141225~65234216:+
LIHC	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	6.09	2.97e-09	2.02e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
LIHC	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	6.09	2.97e-09	2.02e-06	0.32	0.31	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
LIHC	cis	rs7914558	0.901	rs35525740	ENSG00000236937.2	PTGES3P4	6.09	2.98e-09	2.02e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.869	rs10883842	ENSG00000236937.2	PTGES3P4	6.09	2.98e-09	2.02e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:102845595~102845950:+
LIHC	cis	rs1023500	0.551	rs133355	ENSG00000237037.8	NDUFA6-AS1	6.09	2.98e-09	2.02e-06	0.38	0.31	Schizophrenia;	chr22:42044281	chr22:42090931~42137742:+
LIHC	cis	rs7914558	0.966	rs10883805	ENSG00000236937.2	PTGES3P4	6.09	3e-09	2.03e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.933	rs10786729	ENSG00000236937.2	PTGES3P4	6.09	3e-09	2.03e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs12255047	ENSG00000236937.2	PTGES3P4	6.09	3.02e-09	2.05e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102845595~102845950:+
LIHC	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	6.09	3.02e-09	2.05e-06	0.54	0.31	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-6.09	3.03e-09	2.06e-06	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
LIHC	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-6.09	3.04e-09	2.06e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
LIHC	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	6.09	3.05e-09	2.07e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
LIHC	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-6.09	3.05e-09	2.07e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
LIHC	cis	rs854625	0.661	rs854689	ENSG00000275944.1	RP11-104J23.1	-6.09	3.05e-09	2.07e-06	-0.39	-0.31	Cerebrospinal fluid biomarker levels;	chr17:35996083	chr17:36001419~36011618:+
LIHC	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-6.09	3.06e-09	2.07e-06	-0.34	-0.31	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
LIHC	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-6.09	3.08e-09	2.09e-06	-0.46	-0.31	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	6.09	3.09e-09	2.09e-06	0.5	0.31	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
LIHC	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-6.09	3.1e-09	2.1e-06	-0.35	-0.31	Height;	chr11:118859432	chr11:118704607~118750263:+
LIHC	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-6.09	3.1e-09	2.1e-06	-0.38	-0.31	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
LIHC	cis	rs1577917	0.771	rs9362233	ENSG00000234155.1	RP11-30P6.6	6.09	3.1e-09	2.1e-06	0.39	0.31	Response to antipsychotic treatment;	chr6:85648529	chr6:85387219~85390186:-
LIHC	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	6.09	3.11e-09	2.1e-06	0.44	0.31	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
LIHC	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	6.09	3.11e-09	2.1e-06	0.39	0.31	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	6.09	3.11e-09	2.1e-06	0.39	0.31	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	6.09	3.11e-09	2.1e-06	0.39	0.31	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	6.09	3.11e-09	2.1e-06	0.39	0.31	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	6.09	3.11e-09	2.1e-06	0.39	0.31	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	6.09	3.11e-09	2.1e-06	0.39	0.31	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
LIHC	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	6.09	3.11e-09	2.1e-06	0.45	0.31	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	6.09	3.11e-09	2.1e-06	0.45	0.31	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
LIHC	cis	rs4356975	0.509	rs4309908	ENSG00000249956.3	RP11-790I12.2	6.08	3.12e-09	2.11e-06	0.36	0.31	Obesity-related traits;	chr4:69086022	chr4:69408836~69423164:+
LIHC	cis	rs2762353	0.574	rs16890999	ENSG00000242387.1	HIST1H2APS2	-6.08	3.14e-09	2.13e-06	-0.39	-0.31	Blood metabolite levels;	chr6:25755355	chr6:25882026~25882395:-
LIHC	cis	rs9388451	0.874	rs13209968	ENSG00000237742.5	RP11-624M8.1	-6.08	3.15e-09	2.13e-06	-0.29	-0.31	Brugada syndrome;	chr6:125768139	chr6:125578558~125749190:-
LIHC	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-6.08	3.18e-09	2.15e-06	-0.4	-0.31	AIDS;	chr2:105311539	chr2:105324210~105330529:+
LIHC	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-6.08	3.18e-09	2.15e-06	-0.4	-0.31	AIDS;	chr2:105321650	chr2:105324210~105330529:+
LIHC	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	6.08	3.18e-09	2.15e-06	0.49	0.31	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	6.08	3.18e-09	2.15e-06	0.49	0.31	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	6.08	3.18e-09	2.15e-06	0.49	0.31	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	6.08	3.18e-09	2.15e-06	0.49	0.31	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
LIHC	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	6.08	3.18e-09	2.15e-06	0.31	0.31	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
LIHC	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	6.08	3.18e-09	2.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
LIHC	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	6.08	3.19e-09	2.15e-06	0.39	0.31	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
LIHC	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-6.08	3.21e-09	2.17e-06	-0.36	-0.31	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
LIHC	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-6.08	3.23e-09	2.18e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
LIHC	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	6.08	3.24e-09	2.18e-06	0.37	0.31	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
LIHC	cis	rs9326248	1	rs4938354	ENSG00000236267.1	AP006216.5	6.08	3.24e-09	2.19e-06	0.32	0.31	Blood protein levels;	chr11:117180449	chr11:116813204~116814003:-
LIHC	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-6.08	3.24e-09	2.19e-06	-0.37	-0.31	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
LIHC	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-6.08	3.24e-09	2.19e-06	-0.37	-0.31	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
LIHC	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	6.08	3.24e-09	2.19e-06	0.37	0.31	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
LIHC	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-6.08	3.24e-09	2.19e-06	-0.37	-0.31	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
LIHC	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	6.08	3.27e-09	2.2e-06	0.36	0.31	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
LIHC	cis	rs6085948	1	rs6077170	ENSG00000238102.1	RP11-19D2.1	6.08	3.28e-09	2.21e-06	0.45	0.31	Interleukin-10 levels;	chr20:7268888	chr20:7256580~7258214:-
LIHC	cis	rs8028182	0.636	rs4886715	ENSG00000260269.4	CTD-2323K18.1	-6.08	3.28e-09	2.21e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75539108	chr15:75527150~75601205:-
LIHC	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	6.08	3.29e-09	2.22e-06	0.27	0.31	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
LIHC	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	6.08	3.29e-09	2.22e-06	0.38	0.31	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
LIHC	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-6.08	3.3e-09	2.22e-06	-0.37	-0.31	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
LIHC	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-6.08	3.3e-09	2.22e-06	-0.35	-0.31	Height;	chr11:118860890	chr11:118704607~118750263:+
LIHC	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-6.08	3.3e-09	2.22e-06	-0.35	-0.31	Height;	chr11:118861053	chr11:118704607~118750263:+
LIHC	cis	rs12681287	0.64	rs7460342	ENSG00000250569.1	NTAN1P2	6.08	3.3e-09	2.23e-06	0.36	0.31	Caudate activity during reward;	chr8:86462908	chr8:86481754~86483002:-
LIHC	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-6.07	3.31e-09	2.23e-06	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
LIHC	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-6.07	3.31e-09	2.23e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-6.07	3.31e-09	2.23e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-6.07	3.31e-09	2.23e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
LIHC	cis	rs12681287	0.752	rs9283958	ENSG00000250569.1	NTAN1P2	6.07	3.32e-09	2.24e-06	0.38	0.31	Caudate activity during reward;	chr8:86240819	chr8:86481754~86483002:-
LIHC	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-6.07	3.32e-09	2.24e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
LIHC	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-6.07	3.32e-09	2.24e-06	-0.36	-0.31	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
LIHC	cis	rs4356975	0.563	rs7657423	ENSG00000249956.3	RP11-790I12.2	-6.07	3.33e-09	2.24e-06	-0.35	-0.31	Obesity-related traits;	chr4:69090196	chr4:69408836~69423164:+
LIHC	cis	rs7914558	0.966	rs10786725	ENSG00000236937.2	PTGES3P4	6.07	3.34e-09	2.25e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102845595~102845950:+
LIHC	cis	rs523522	0.962	rs651627	ENSG00000278344.1	RP11-18C24.8	6.07	3.34e-09	2.25e-06	0.38	0.31	High light scatter reticulocyte count;	chr12:120571395	chr12:120500735~120501090:-
LIHC	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-6.07	3.34e-09	2.25e-06	-0.41	-0.31	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
LIHC	cis	rs2243480	1	rs316331	ENSG00000164669.11	INTS4P1	-6.07	3.35e-09	2.25e-06	-0.54	-0.31	Diabetic kidney disease;	chr7:66139635	chr7:65141225~65234216:+
LIHC	cis	rs1799810	1	rs1799810	ENSG00000236682.1	AC068282.3	-6.07	3.35e-09	2.25e-06	-0.44	-0.31	Self-rated health;	chr2:127418464	chr2:127389130~127400580:+
LIHC	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-6.07	3.35e-09	2.25e-06	-0.37	-0.31	Gout;	chr7:66671562	chr7:66902857~66906297:+
LIHC	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	6.07	3.35e-09	2.26e-06	0.33	0.31	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	6.07	3.35e-09	2.26e-06	0.33	0.31	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	6.07	3.37e-09	2.27e-06	0.38	0.31	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
LIHC	cis	rs4356975	0.563	rs12642938	ENSG00000249956.3	RP11-790I12.2	6.07	3.38e-09	2.27e-06	0.35	0.31	Obesity-related traits;	chr4:69110499	chr4:69408836~69423164:+
LIHC	cis	rs12681287	0.547	rs13261956	ENSG00000250569.1	NTAN1P2	6.07	3.42e-09	2.3e-06	0.37	0.31	Caudate activity during reward;	chr8:86466536	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs71502658	ENSG00000250569.1	NTAN1P2	6.07	3.42e-09	2.3e-06	0.37	0.31	Caudate activity during reward;	chr8:86466556	chr8:86481754~86483002:-
LIHC	cis	rs9326248	0.569	rs10892082	ENSG00000236267.1	AP006216.5	6.07	3.43e-09	2.3e-06	0.35	0.31	Blood protein levels;	chr11:117168609	chr11:116813204~116814003:-
LIHC	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-6.07	3.44e-09	2.31e-06	-0.43	-0.31	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
LIHC	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-6.07	3.44e-09	2.31e-06	-0.32	-0.31	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
LIHC	cis	rs2243480	1	rs2257790	ENSG00000164669.11	INTS4P1	6.07	3.44e-09	2.31e-06	0.54	0.31	Diabetic kidney disease;	chr7:66135463	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs316332	ENSG00000164669.11	INTS4P1	6.07	3.44e-09	2.31e-06	0.54	0.31	Diabetic kidney disease;	chr7:66139312	chr7:65141225~65234216:+
LIHC	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-6.07	3.45e-09	2.32e-06	-0.34	-0.31	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
LIHC	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-6.07	3.45e-09	2.32e-06	-0.43	-0.31	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
LIHC	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-6.07	3.45e-09	2.32e-06	-0.41	-0.31	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
LIHC	cis	rs1023500	0.505	rs134901	ENSG00000237037.8	NDUFA6-AS1	6.07	3.46e-09	2.32e-06	0.34	0.31	Schizophrenia;	chr22:42287514	chr22:42090931~42137742:+
LIHC	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-6.07	3.47e-09	2.33e-06	-0.35	-0.31	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
LIHC	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	6.07	3.48e-09	2.34e-06	0.36	0.31	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
LIHC	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-6.07	3.49e-09	2.34e-06	-0.36	-0.31	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
LIHC	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-6.06	3.5e-09	2.35e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
LIHC	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-6.06	3.5e-09	2.35e-06	-0.49	-0.31	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
LIHC	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-6.06	3.51e-09	2.35e-06	-0.32	-0.31	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
LIHC	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	6.06	3.51e-09	2.35e-06	0.38	0.31	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	6.06	3.51e-09	2.35e-06	0.38	0.31	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	6.06	3.51e-09	2.35e-06	0.38	0.31	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
LIHC	cis	rs4356975	0.563	rs4694177	ENSG00000249956.3	RP11-790I12.2	6.06	3.52e-09	2.36e-06	0.35	0.31	Obesity-related traits;	chr4:69110141	chr4:69408836~69423164:+
LIHC	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-6.06	3.53e-09	2.36e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-6.06	3.53e-09	2.36e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-6.06	3.53e-09	2.36e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	6.06	3.53e-09	2.36e-06	0.39	0.31	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	6.06	3.53e-09	2.36e-06	0.39	0.31	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	6.06	3.53e-09	2.36e-06	0.39	0.31	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	6.06	3.53e-09	2.36e-06	0.39	0.31	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	6.06	3.53e-09	2.36e-06	0.39	0.31	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
LIHC	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-6.06	3.53e-09	2.37e-06	-0.36	-0.31	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
LIHC	cis	rs8028182	0.636	rs7495610	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75492100	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs4299117	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75497103	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs12708519	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75510859	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs8029112	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75516631	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs4886712	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75520547	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs8030802	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75520812	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.577	rs8023268	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75522331	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs8023815	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75522363	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs11636031	ENSG00000260269.4	CTD-2323K18.1	-6.06	3.55e-09	2.37e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75523417	chr15:75527150~75601205:-
LIHC	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-6.06	3.56e-09	2.39e-06	-0.31	-0.31	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
LIHC	cis	rs2762353	0.595	rs13194155	ENSG00000242387.1	HIST1H2APS2	-6.06	3.58e-09	2.4e-06	-0.39	-0.31	Blood metabolite levels;	chr6:25755280	chr6:25882026~25882395:-
LIHC	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-6.06	3.58e-09	2.4e-06	-0.44	-0.31	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
LIHC	cis	rs2734839	0.507	rs4648318	ENSG00000270179.1	RP11-159N11.4	-6.06	3.59e-09	2.4e-06	-0.35	-0.31	Information processing speed;	chr11:113442667	chr11:113368478~113369117:+
LIHC	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	6.06	3.6e-09	2.41e-06	0.37	0.31	Height;	chr6:109498751	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	6.06	3.6e-09	2.41e-06	0.37	0.31	Height;	chr6:109500687	chr6:109382795~109383666:+
LIHC	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-6.06	3.62e-09	2.42e-06	-0.36	-0.31	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
LIHC	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	6.06	3.62e-09	2.42e-06	0.49	0.31	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
LIHC	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	6.06	3.62e-09	2.42e-06	0.37	0.31	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
LIHC	cis	rs1577917	0.771	rs2475791	ENSG00000234155.1	RP11-30P6.6	6.06	3.63e-09	2.42e-06	0.39	0.31	Response to antipsychotic treatment;	chr6:85658446	chr6:85387219~85390186:-
LIHC	cis	rs10022260	1	rs10022260	ENSG00000251022.5	THAP9-AS1	-6.06	3.66e-09	2.45e-06	-0.35	-0.31	Adult asthma;	chr4:82872768	chr4:82893009~82900960:-
LIHC	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-6.06	3.66e-09	2.45e-06	-0.38	-0.31	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
LIHC	cis	rs12681287	0.64	rs8635	ENSG00000250569.1	NTAN1P2	6.06	3.67e-09	2.45e-06	0.36	0.31	Caudate activity during reward;	chr8:86467581	chr8:86481754~86483002:-
LIHC	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-6.06	3.67e-09	2.45e-06	-0.35	-0.31	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-6.06	3.67e-09	2.45e-06	-0.35	-0.31	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-6.06	3.67e-09	2.45e-06	-0.35	-0.31	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-6.06	3.67e-09	2.45e-06	-0.35	-0.31	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-6.06	3.67e-09	2.45e-06	-0.35	-0.31	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
LIHC	cis	rs7580658	0.55	rs62160290	ENSG00000236682.1	AC068282.3	-6.06	3.67e-09	2.45e-06	-0.39	-0.31	Protein C levels;	chr2:127443119	chr2:127389130~127400580:+
LIHC	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-6.06	3.67e-09	2.45e-06	-0.31	-0.31	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
LIHC	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	6.06	3.68e-09	2.46e-06	0.38	0.31	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
LIHC	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-6.06	3.69e-09	2.46e-06	-0.62	-0.31	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
LIHC	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-6.06	3.7e-09	2.47e-06	-0.37	-0.31	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
LIHC	cis	rs7914558	0.966	rs1890185	ENSG00000236937.2	PTGES3P4	6.05	3.7e-09	2.47e-06	0.36	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102845595~102845950:+
LIHC	cis	rs9326248	1	rs7107152	ENSG00000236267.1	AP006216.5	-6.05	3.72e-09	2.49e-06	-0.31	-0.31	Blood protein levels;	chr11:117185364	chr11:116813204~116814003:-
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-6.05	3.73e-09	2.49e-06	-0.37	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
LIHC	cis	rs12025262	0.934	rs10924961	ENSG00000227671.4	RP11-488L18.4	6.05	3.73e-09	2.49e-06	0.2	0.31	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247198985	chr1:247189851~247210856:-
LIHC	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-6.05	3.74e-09	2.5e-06	-0.34	-0.31	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
LIHC	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-6.05	3.75e-09	2.5e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
LIHC	cis	rs1023500	0.596	rs133352	ENSG00000237037.8	NDUFA6-AS1	6.05	3.75e-09	2.51e-06	0.38	0.31	Schizophrenia;	chr22:42038018	chr22:42090931~42137742:+
LIHC	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-6.05	3.75e-09	2.51e-06	-0.37	-0.31	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
LIHC	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-6.05	3.76e-09	2.51e-06	-0.38	-0.31	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
LIHC	cis	rs2243480	1	rs410128	ENSG00000164669.11	INTS4P1	6.05	3.76e-09	2.51e-06	0.56	0.31	Diabetic kidney disease;	chr7:66138186	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-6.05	3.76e-09	2.51e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
LIHC	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-6.05	3.77e-09	2.51e-06	-0.32	-0.31	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-6.05	3.77e-09	2.51e-06	-0.32	-0.31	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-6.05	3.77e-09	2.51e-06	-0.32	-0.31	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-6.05	3.77e-09	2.51e-06	-0.32	-0.31	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-6.05	3.77e-09	2.51e-06	-0.32	-0.31	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
LIHC	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-6.05	3.77e-09	2.51e-06	-0.36	-0.31	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
LIHC	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	6.05	3.77e-09	2.51e-06	0.38	0.31	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
LIHC	cis	rs5769765	0.542	rs1033666	ENSG00000278869.1	CITF22-49E9.3	-6.05	3.78e-09	2.52e-06	-0.57	-0.31	Schizophrenia;	chr22:49859135	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.526	rs5770722	ENSG00000278869.1	CITF22-49E9.3	-6.05	3.78e-09	2.52e-06	-0.57	-0.31	Schizophrenia;	chr22:49859572	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.542	rs5770725	ENSG00000278869.1	CITF22-49E9.3	-6.05	3.78e-09	2.52e-06	-0.57	-0.31	Schizophrenia;	chr22:49862661	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.505	rs4561759	ENSG00000278869.1	CITF22-49E9.3	-6.05	3.78e-09	2.52e-06	-0.57	-0.31	Schizophrenia;	chr22:49863038	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.565	rs8137232	ENSG00000278869.1	CITF22-49E9.3	-6.05	3.78e-09	2.52e-06	-0.57	-0.31	Schizophrenia;	chr22:49863237	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.657	rs8136116	ENSG00000278869.1	CITF22-49E9.3	-6.05	3.78e-09	2.52e-06	-0.57	-0.31	Schizophrenia;	chr22:49863238	chr22:49933198~49934074:-
LIHC	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	6.05	3.78e-09	2.52e-06	0.34	0.31	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
LIHC	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-6.05	3.8e-09	2.53e-06	-0.41	-0.31	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
LIHC	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-6.05	3.8e-09	2.53e-06	-0.37	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-6.05	3.8e-09	2.53e-06	-0.37	-0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
LIHC	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-6.05	3.8e-09	2.53e-06	-0.52	-0.31	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
LIHC	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	6.05	3.81e-09	2.54e-06	0.38	0.31	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.53	rs6589575	ENSG00000236267.1	AP006216.5	6.05	3.81e-09	2.54e-06	0.34	0.31	Blood protein levels;	chr11:116862594	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.53	rs718847	ENSG00000236267.1	AP006216.5	6.05	3.81e-09	2.54e-06	0.34	0.31	Blood protein levels;	chr11:116863430	chr11:116813204~116814003:-
LIHC	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-6.05	3.83e-09	2.55e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
LIHC	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-6.05	3.83e-09	2.55e-06	-0.36	-0.31	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
LIHC	cis	rs12681287	0.64	rs13251006	ENSG00000250569.1	NTAN1P2	6.05	3.83e-09	2.55e-06	0.36	0.31	Caudate activity during reward;	chr8:86456876	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13269259	ENSG00000250569.1	NTAN1P2	6.05	3.83e-09	2.55e-06	0.36	0.31	Caudate activity during reward;	chr8:86458224	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs7461413	ENSG00000250569.1	NTAN1P2	6.05	3.83e-09	2.55e-06	0.36	0.31	Caudate activity during reward;	chr8:86458749	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs12550142	ENSG00000250569.1	NTAN1P2	6.05	3.83e-09	2.55e-06	0.36	0.31	Caudate activity during reward;	chr8:86459632	chr8:86481754~86483002:-
LIHC	cis	rs831571	0.636	rs831565	ENSG00000280620.1	SCAANT1	-6.05	3.85e-09	2.57e-06	-0.43	-0.31	Type 2 diabetes;	chr3:64090682	chr3:63911518~63911772:-
LIHC	cis	rs7914558	0.966	rs3977751	ENSG00000236937.2	PTGES3P4	6.05	3.86e-09	2.57e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102845595~102845950:+
LIHC	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-6.05	3.86e-09	2.57e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-6.05	3.86e-09	2.57e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-6.05	3.86e-09	2.57e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-6.05	3.86e-09	2.57e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
LIHC	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-6.05	3.87e-09	2.57e-06	-0.34	-0.31	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-6.05	3.87e-09	2.57e-06	-0.34	-0.31	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
LIHC	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-6.05	3.89e-09	2.59e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-6.05	3.9e-09	2.59e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
LIHC	cis	rs3020736	0.5	rs6002597	ENSG00000237037.8	NDUFA6-AS1	-6.05	3.9e-09	2.59e-06	-0.38	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs7292241	ENSG00000237037.8	NDUFA6-AS1	-6.05	3.9e-09	2.59e-06	-0.38	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs6002603	ENSG00000237037.8	NDUFA6-AS1	-6.05	3.9e-09	2.59e-06	-0.38	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42090931~42137742:+
LIHC	cis	rs3020736	0.5	rs5996111	ENSG00000237037.8	NDUFA6-AS1	-6.05	3.9e-09	2.59e-06	-0.38	-0.31	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42090931~42137742:+
LIHC	cis	rs12681287	0.752	rs13277670	ENSG00000250569.1	NTAN1P2	6.04	3.92e-09	2.61e-06	0.38	0.31	Caudate activity during reward;	chr8:86247691	chr8:86481754~86483002:-
LIHC	cis	rs2243480	1	rs387676	ENSG00000164669.11	INTS4P1	6.04	3.95e-09	2.62e-06	0.54	0.31	Diabetic kidney disease;	chr7:66133233	chr7:65141225~65234216:+
LIHC	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-6.04	3.95e-09	2.62e-06	-0.65	-0.31	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
LIHC	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	6.04	3.96e-09	2.63e-06	0.38	0.31	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
LIHC	cis	rs12681287	0.64	rs6471314	ENSG00000250569.1	NTAN1P2	-6.04	3.96e-09	2.63e-06	-0.37	-0.31	Caudate activity during reward;	chr8:86388230	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs7830480	ENSG00000250569.1	NTAN1P2	-6.04	3.96e-09	2.63e-06	-0.37	-0.31	Caudate activity during reward;	chr8:86390908	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.604	rs6471316	ENSG00000250569.1	NTAN1P2	-6.04	3.96e-09	2.63e-06	-0.37	-0.31	Caudate activity during reward;	chr8:86391358	chr8:86481754~86483002:-
LIHC	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	6.04	3.98e-09	2.64e-06	0.31	0.31	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
LIHC	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	6.04	3.99e-09	2.65e-06	0.51	0.31	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
LIHC	cis	rs4356975	0.509	rs10006452	ENSG00000249956.3	RP11-790I12.2	6.04	3.99e-09	2.65e-06	0.35	0.31	Obesity-related traits;	chr4:69112090	chr4:69408836~69423164:+
LIHC	cis	rs8028182	0.636	rs4322627	ENSG00000260269.4	CTD-2323K18.1	-6.04	4.01e-09	2.66e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75518318	chr15:75527150~75601205:-
LIHC	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-6.04	4.02e-09	2.67e-06	-0.41	-0.31	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
LIHC	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	6.04	4.04e-09	2.68e-06	0.36	0.31	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
LIHC	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-6.04	4.05e-09	2.68e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-6.04	4.05e-09	2.68e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-6.04	4.05e-09	2.68e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-6.04	4.05e-09	2.68e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-6.04	4.05e-09	2.68e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-6.04	4.05e-09	2.68e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-6.04	4.05e-09	2.68e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	6.04	4.05e-09	2.68e-06	0.33	0.31	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	6.04	4.05e-09	2.68e-06	0.33	0.31	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	6.04	4.05e-09	2.68e-06	0.33	0.31	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
LIHC	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	6.04	4.05e-09	2.69e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
LIHC	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-6.04	4.05e-09	2.69e-06	-0.39	-0.31	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
LIHC	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-6.04	4.05e-09	2.69e-06	-0.49	-0.31	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
LIHC	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	6.04	4.06e-09	2.69e-06	0.37	0.31	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
LIHC	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	6.04	4.07e-09	2.7e-06	0.38	0.31	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
LIHC	cis	rs12681287	0.577	rs13257414	ENSG00000250569.1	NTAN1P2	6.04	4.07e-09	2.7e-06	0.37	0.31	Caudate activity during reward;	chr8:86481909	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.609	rs13281414	ENSG00000250569.1	NTAN1P2	6.04	4.07e-09	2.7e-06	0.37	0.31	Caudate activity during reward;	chr8:86483025	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.546	rs12546802	ENSG00000250569.1	NTAN1P2	6.04	4.07e-09	2.7e-06	0.37	0.31	Caudate activity during reward;	chr8:86487106	chr8:86481754~86483002:-
LIHC	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-6.04	4.07e-09	2.7e-06	-0.37	-0.31	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
LIHC	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-6.04	4.07e-09	2.7e-06	-0.35	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
LIHC	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	6.04	4.09e-09	2.71e-06	0.38	0.31	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	6.04	4.09e-09	2.71e-06	0.38	0.31	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
LIHC	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	6.04	4.09e-09	2.71e-06	0.52	0.31	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
LIHC	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-6.04	4.09e-09	2.71e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-6.04	4.09e-09	2.71e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-6.04	4.09e-09	2.71e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-6.04	4.09e-09	2.71e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-6.04	4.09e-09	2.71e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
LIHC	cis	rs12285276	0.673	rs12283175	ENSG00000205106.4	DKFZp779M0652	6.04	4.12e-09	2.73e-06	0.32	0.31	Visceral fat;	chr11:45781619	chr11:45771432~45772358:+
LIHC	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-6.04	4.12e-09	2.73e-06	-0.63	-0.31	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
LIHC	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-6.04	4.12e-09	2.73e-06	-0.39	-0.31	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
LIHC	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-6.04	4.13e-09	2.74e-06	-0.4	-0.31	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
LIHC	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-6.03	4.14e-09	2.74e-06	-0.38	-0.31	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
LIHC	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	6.03	4.15e-09	2.74e-06	0.48	0.31	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
LIHC	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	6.03	4.15e-09	2.74e-06	0.35	0.31	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	6.03	4.15e-09	2.74e-06	0.35	0.31	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	6.03	4.15e-09	2.74e-06	0.35	0.31	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
LIHC	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	6.03	4.15e-09	2.74e-06	0.38	0.31	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-6.03	4.15e-09	2.74e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
LIHC	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-6.03	4.15e-09	2.74e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
LIHC	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-6.03	4.15e-09	2.75e-06	-0.31	-0.31	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
LIHC	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-6.03	4.16e-09	2.75e-06	-0.36	-0.31	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
LIHC	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-6.03	4.16e-09	2.75e-06	-0.35	-0.31	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
LIHC	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	6.03	4.17e-09	2.76e-06	0.38	0.31	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	6.03	4.17e-09	2.76e-06	0.38	0.31	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
LIHC	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	6.03	4.19e-09	2.77e-06	0.31	0.31	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
LIHC	cis	rs2243480	0.764	rs2460423	ENSG00000164669.11	INTS4P1	6.03	4.19e-09	2.77e-06	0.54	0.31	Diabetic kidney disease;	chr7:66136229	chr7:65141225~65234216:+
LIHC	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-6.03	4.22e-09	2.78e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
LIHC	cis	rs5758659	0.652	rs4822084	ENSG00000227370.1	RP4-669P10.19	6.03	4.22e-09	2.79e-06	0.36	0.31	Cognitive function;	chr22:42039864	chr22:42132543~42132998:+
LIHC	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	6.03	4.23e-09	2.79e-06	0.4	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
LIHC	cis	rs12681287	0.785	rs13263353	ENSG00000250569.1	NTAN1P2	6.03	4.24e-09	2.8e-06	0.37	0.31	Caudate activity during reward;	chr8:86232353	chr8:86481754~86483002:-
LIHC	cis	rs2735413	0.564	rs73578735	ENSG00000276007.1	RP11-358L22.3	6.03	4.24e-09	2.8e-06	0.44	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78071039	chr16:78123243~78124332:+
LIHC	cis	rs55665837	0.701	rs1522633	ENSG00000251991.1	RNU7-49P	6.03	4.25e-09	2.81e-06	0.33	0.31	Vitamin D levels;	chr11:14623692	chr11:14478892~14478953:+
LIHC	cis	rs12285276	0.711	rs12274152	ENSG00000205106.4	DKFZp779M0652	6.03	4.26e-09	2.81e-06	0.32	0.31	Visceral fat;	chr11:45786272	chr11:45771432~45772358:+
LIHC	cis	rs12285276	0.75	rs4756024	ENSG00000205106.4	DKFZp779M0652	6.03	4.26e-09	2.81e-06	0.32	0.31	Visceral fat;	chr11:45789727	chr11:45771432~45772358:+
LIHC	cis	rs1023500	0.573	rs4822088	ENSG00000237037.8	NDUFA6-AS1	6.03	4.26e-09	2.81e-06	0.37	0.31	Schizophrenia;	chr22:42074585	chr22:42090931~42137742:+
LIHC	cis	rs2243480	1	rs316313	ENSG00000164669.11	INTS4P1	6.03	4.27e-09	2.82e-06	0.54	0.31	Diabetic kidney disease;	chr7:66128561	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs316312	ENSG00000164669.11	INTS4P1	6.03	4.27e-09	2.82e-06	0.54	0.31	Diabetic kidney disease;	chr7:66131504	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs419603	ENSG00000164669.11	INTS4P1	6.03	4.27e-09	2.82e-06	0.54	0.31	Diabetic kidney disease;	chr7:66132354	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs431076	ENSG00000164669.11	INTS4P1	6.03	4.27e-09	2.82e-06	0.54	0.31	Diabetic kidney disease;	chr7:66135333	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs2460422	ENSG00000164669.11	INTS4P1	6.03	4.27e-09	2.82e-06	0.54	0.31	Diabetic kidney disease;	chr7:66136518	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs316334	ENSG00000164669.11	INTS4P1	6.03	4.27e-09	2.82e-06	0.54	0.31	Diabetic kidney disease;	chr7:66137139	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs316330	ENSG00000164669.11	INTS4P1	6.03	4.27e-09	2.82e-06	0.54	0.31	Diabetic kidney disease;	chr7:66140385	chr7:65141225~65234216:+
LIHC	cis	rs523522	0.962	rs687873	ENSG00000278344.1	RP11-18C24.8	6.03	4.28e-09	2.82e-06	0.37	0.31	High light scatter reticulocyte count;	chr12:120581831	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs670568	ENSG00000278344.1	RP11-18C24.8	6.03	4.28e-09	2.82e-06	0.37	0.31	High light scatter reticulocyte count;	chr12:120583403	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.885	rs524735	ENSG00000278344.1	RP11-18C24.8	6.03	4.28e-09	2.82e-06	0.37	0.31	High light scatter reticulocyte count;	chr12:120584296	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.962	rs655530	ENSG00000278344.1	RP11-18C24.8	6.03	4.28e-09	2.82e-06	0.37	0.31	High light scatter reticulocyte count;	chr12:120584472	chr12:120500735~120501090:-
LIHC	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	6.03	4.28e-09	2.82e-06	0.34	0.31	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	6.03	4.28e-09	2.82e-06	0.34	0.31	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
LIHC	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-6.03	4.29e-09	2.83e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
LIHC	cis	rs8028182	0.636	rs11634863	ENSG00000260269.4	CTD-2323K18.1	-6.03	4.29e-09	2.83e-06	-0.41	-0.31	Sudden cardiac arrest;	chr15:75474331	chr15:75527150~75601205:-
LIHC	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-6.03	4.29e-09	2.83e-06	-0.35	-0.31	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
LIHC	cis	rs4934494	0.911	rs34486602	ENSG00000232936.4	RP11-80H5.2	6.03	4.32e-09	2.85e-06	0.39	0.31	Red blood cell count;	chr10:89655895	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.911	rs6586213	ENSG00000232936.4	RP11-80H5.2	6.03	4.32e-09	2.85e-06	0.39	0.31	Red blood cell count;	chr10:89656327	chr10:89645282~89650667:+
LIHC	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	6.03	4.33e-09	2.85e-06	0.49	0.31	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
LIHC	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-6.03	4.33e-09	2.85e-06	-0.34	-0.31	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
LIHC	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	6.03	4.33e-09	2.85e-06	0.34	0.31	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
LIHC	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-6.03	4.34e-09	2.86e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
LIHC	cis	rs4535700	0.501	rs10245725	ENSG00000226278.1	PSPHP1	-6.03	4.34e-09	2.86e-06	-0.35	-0.31	Macular telangiectasia type 2;	chr7:55908855	chr7:55764797~55773288:+
LIHC	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-6.03	4.34e-09	2.86e-06	-0.34	-0.31	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
LIHC	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-6.03	4.34e-09	2.86e-06	-0.35	-0.31	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
LIHC	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-6.03	4.36e-09	2.87e-06	-0.34	-0.31	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
LIHC	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	6.02	4.37e-09	2.88e-06	0.38	0.31	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
LIHC	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	6.02	4.38e-09	2.89e-06	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
LIHC	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-6.02	4.41e-09	2.9e-06	-0.37	-0.31	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
LIHC	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-6.02	4.43e-09	2.92e-06	-0.39	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
LIHC	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-6.02	4.43e-09	2.92e-06	-0.34	-0.31	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
LIHC	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	6.02	4.43e-09	2.92e-06	0.38	0.31	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.02	4.44e-09	2.92e-06	-0.4	-0.31	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
LIHC	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-6.02	4.44e-09	2.92e-06	-0.36	-0.31	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
LIHC	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-6.02	4.47e-09	2.94e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-6.02	4.47e-09	2.94e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-6.02	4.47e-09	2.94e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-6.02	4.47e-09	2.94e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-6.02	4.47e-09	2.94e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-6.02	4.47e-09	2.94e-06	-0.33	-0.31	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
LIHC	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-6.02	4.47e-09	2.94e-06	-0.38	-0.31	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
LIHC	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-6.02	4.5e-09	2.96e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
LIHC	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-6.02	4.53e-09	2.98e-06	-0.34	-0.31	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
LIHC	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-6.02	4.53e-09	2.98e-06	-0.33	-0.31	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
LIHC	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	6.02	4.53e-09	2.98e-06	0.45	0.31	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
LIHC	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-6.02	4.54e-09	2.99e-06	-0.39	-0.31	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
LIHC	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	6.02	4.55e-09	2.99e-06	0.38	0.31	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
LIHC	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-6.02	4.56e-09	2.99e-06	-0.3	-0.31	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
LIHC	cis	rs1023500	0.596	rs5751204	ENSG00000237037.8	NDUFA6-AS1	6.02	4.57e-09	3e-06	0.38	0.31	Schizophrenia;	chr22:42037797	chr22:42090931~42137742:+
LIHC	cis	rs8028182	0.636	rs4545784	ENSG00000260269.4	CTD-2323K18.1	-6.02	4.58e-09	3.01e-06	-0.41	-0.31	Sudden cardiac arrest;	chr15:75463310	chr15:75527150~75601205:-
LIHC	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	6.02	4.59e-09	3.01e-06	0.39	0.31	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
LIHC	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-6.02	4.59e-09	3.01e-06	-0.36	-0.31	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
LIHC	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-6.02	4.59e-09	3.01e-06	-0.52	-0.31	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
LIHC	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-6.02	4.59e-09	3.01e-06	-0.35	-0.31	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
LIHC	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	6.02	4.6e-09	3.02e-06	0.41	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
LIHC	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-6.02	4.6e-09	3.02e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
LIHC	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	6.02	4.61e-09	3.02e-06	0.37	0.31	Height;	chr6:109494237	chr6:109382795~109383666:+
LIHC	cis	rs12681287	0.546	rs11539113	ENSG00000250569.1	NTAN1P2	6.02	4.61e-09	3.03e-06	0.37	0.31	Caudate activity during reward;	chr8:86484947	chr8:86481754~86483002:-
LIHC	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	6.01	4.64e-09	3.05e-06	0.33	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
LIHC	cis	rs523522	0.673	rs643372	ENSG00000278344.1	RP11-18C24.8	6.01	4.65e-09	3.05e-06	0.37	0.31	High light scatter reticulocyte count;	chr12:120584837	chr12:120500735~120501090:-
LIHC	cis	rs4356975	0.563	rs6422324	ENSG00000249956.3	RP11-790I12.2	6.01	4.66e-09	3.06e-06	0.35	0.31	Obesity-related traits;	chr4:69087385	chr4:69408836~69423164:+
LIHC	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-6.01	4.67e-09	3.06e-06	-0.43	-0.31	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
LIHC	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	6.01	4.67e-09	3.06e-06	0.51	0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
LIHC	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-6.01	4.7e-09	3.08e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
LIHC	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	6.01	4.72e-09	3.09e-06	0.33	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
LIHC	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	6.01	4.72e-09	3.1e-06	0.34	0.31	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
LIHC	cis	rs4356975	0.503	rs11938761	ENSG00000249956.3	RP11-790I12.2	6.01	4.74e-09	3.1e-06	0.35	0.31	Obesity-related traits;	chr4:69083992	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.545	rs11935886	ENSG00000249956.3	RP11-790I12.2	6.01	4.74e-09	3.1e-06	0.35	0.31	Obesity-related traits;	chr4:69083994	chr4:69408836~69423164:+
LIHC	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-6.01	4.74e-09	3.1e-06	-0.36	-0.31	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
LIHC	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	6.01	4.74e-09	3.1e-06	0.44	0.31	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
LIHC	cis	rs8028182	0.636	rs28610581	ENSG00000260269.4	CTD-2323K18.1	-6.01	4.76e-09	3.12e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75520133	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs8036758	ENSG00000260269.4	CTD-2323K18.1	-6.01	4.76e-09	3.12e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75525221	chr15:75527150~75601205:-
LIHC	cis	rs2243480	1	rs316307	ENSG00000164669.11	INTS4P1	6.01	4.77e-09	3.12e-06	0.53	0.31	Diabetic kidney disease;	chr7:66105184	chr7:65141225~65234216:+
LIHC	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-6.01	4.78e-09	3.13e-06	-0.35	-0.31	Height;	chr11:118854014	chr11:118704607~118750263:+
LIHC	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-6.01	4.79e-09	3.14e-06	-0.39	-0.31	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
LIHC	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	6.01	4.79e-09	3.14e-06	0.31	0.31	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
LIHC	cis	rs10833905	0.641	rs34946681	ENSG00000246225.5	RP11-17A1.3	-6.01	4.8e-09	3.14e-06	-0.41	-0.31	Sudden cardiac arrest;	chr11:22935960	chr11:22829380~22945393:+
LIHC	cis	rs12291225	0.546	rs11023199	ENSG00000251991.1	RNU7-49P	6.01	4.81e-09	3.15e-06	0.32	0.31	Sense of smell;	chr11:14372712	chr11:14478892~14478953:+
LIHC	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-6.01	4.81e-09	3.15e-06	-0.48	-0.31	Depression;	chr6:28135913	chr6:28115628~28116551:+
LIHC	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-6.01	4.81e-09	3.15e-06	-0.37	-0.31	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
LIHC	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	6.01	4.82e-09	3.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	6.01	4.82e-09	3.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	6.01	4.82e-09	3.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	6.01	4.82e-09	3.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	6.01	4.82e-09	3.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	6.01	4.82e-09	3.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	6.01	4.82e-09	3.15e-06	0.38	0.31	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
LIHC	cis	rs7115242	0.8	rs6589597	ENSG00000236267.1	AP006216.5	-6.01	4.82e-09	3.15e-06	-0.34	-0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:116813204~116814003:-
LIHC	cis	rs1023500	0.573	rs13057094	ENSG00000237037.8	NDUFA6-AS1	6.01	4.82e-09	3.16e-06	0.38	0.31	Schizophrenia;	chr22:42074313	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.505	rs134899	ENSG00000237037.8	NDUFA6-AS1	6.01	4.82e-09	3.16e-06	0.34	0.31	Schizophrenia;	chr22:42287024	chr22:42090931~42137742:+
LIHC	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-6.01	4.83e-09	3.16e-06	-0.34	-0.31	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
LIHC	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-6.01	4.84e-09	3.17e-06	-0.4	-0.31	AIDS;	chr2:105319955	chr2:105324210~105330529:+
LIHC	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.01	4.85e-09	3.17e-06	-0.4	-0.31	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-6.01	4.85e-09	3.17e-06	-0.4	-0.31	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-6.01	4.85e-09	3.17e-06	-0.4	-0.31	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
LIHC	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-6.01	4.86e-09	3.17e-06	-0.34	-0.31	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
LIHC	cis	rs5758659	0.714	rs133373	ENSG00000227370.1	RP4-669P10.19	-6.01	4.88e-09	3.19e-06	-0.35	-0.31	Cognitive function;	chr22:42069784	chr22:42132543~42132998:+
LIHC	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-6.01	4.89e-09	3.19e-06	-0.47	-0.31	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
LIHC	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	6.01	4.89e-09	3.19e-06	0.38	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
LIHC	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	6.01	4.89e-09	3.2e-06	0.32	0.31	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
LIHC	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-6	4.9e-09	3.21e-06	-0.45	-0.31	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
LIHC	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-6	4.91e-09	3.21e-06	-0.34	-0.31	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
LIHC	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	6	4.92e-09	3.21e-06	0.36	0.31	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
LIHC	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-6	4.94e-09	3.23e-06	-0.37	-0.31	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
LIHC	cis	rs7927592	0.673	rs2510392	ENSG00000212093.1	AP000807.1	6	4.96e-09	3.24e-06	0.31	0.31	Total body bone mineral density;	chr11:68626989	chr11:68506083~68506166:-
LIHC	cis	rs7176527	0.519	rs12148368	ENSG00000189136.7	UBE2Q2P1	-6	4.97e-09	3.24e-06	-0.25	-0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84526781~84571216:-
LIHC	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-6	4.98e-09	3.25e-06	-0.34	-0.31	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
LIHC	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-6	4.98e-09	3.25e-06	-0.4	-0.31	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-6	4.98e-09	3.25e-06	-0.4	-0.31	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
LIHC	cis	rs12681287	0.64	rs28561640	ENSG00000250569.1	NTAN1P2	-6	5.01e-09	3.27e-06	-0.36	-0.31	Caudate activity during reward;	chr8:86413409	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs10095498	ENSG00000250569.1	NTAN1P2	-6	5.01e-09	3.27e-06	-0.36	-0.31	Caudate activity during reward;	chr8:86413422	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs6992287	ENSG00000250569.1	NTAN1P2	-6	5.01e-09	3.27e-06	-0.36	-0.31	Caudate activity during reward;	chr8:86406731	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs6992944	ENSG00000250569.1	NTAN1P2	-6	5.01e-09	3.27e-06	-0.36	-0.31	Caudate activity during reward;	chr8:86407079	chr8:86481754~86483002:-
LIHC	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	6	5.04e-09	3.29e-06	0.34	0.31	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
LIHC	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	6	5.04e-09	3.29e-06	0.34	0.31	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
LIHC	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-6	5.07e-09	3.31e-06	-0.39	-0.31	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
LIHC	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-6	5.07e-09	3.31e-06	-0.37	-0.31	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-6	5.07e-09	3.31e-06	-0.37	-0.31	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
LIHC	cis	rs7396835	0.866	rs6589571	ENSG00000236267.1	AP006216.5	6	5.09e-09	3.32e-06	0.4	0.31	Quantitative traits;	chr11:116809702	chr11:116813204~116814003:-
LIHC	cis	rs8028182	0.636	rs11637586	ENSG00000260269.4	CTD-2323K18.1	-6	5.1e-09	3.33e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75498771	chr15:75527150~75601205:-
LIHC	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	6	5.11e-09	3.33e-06	0.34	0.31	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	6	5.11e-09	3.33e-06	0.34	0.31	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
LIHC	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-6	5.13e-09	3.34e-06	-0.35	-0.31	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
LIHC	cis	rs1023500	0.551	rs2301521	ENSG00000237037.8	NDUFA6-AS1	6	5.13e-09	3.35e-06	0.39	0.31	Schizophrenia;	chr22:42027106	chr22:42090931~42137742:+
LIHC	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-6	5.14e-09	3.35e-06	-0.5	-0.31	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
LIHC	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	6	5.15e-09	3.35e-06	0.34	0.31	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	6	5.15e-09	3.35e-06	0.34	0.31	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
LIHC	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	6	5.16e-09	3.36e-06	0.36	0.31	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
LIHC	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	6	5.16e-09	3.36e-06	0.32	0.31	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
LIHC	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	6	5.17e-09	3.37e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
LIHC	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-5.99	5.17e-09	3.37e-06	-0.39	-0.31	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
LIHC	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	5.99	5.17e-09	3.37e-06	0.42	0.31	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
LIHC	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-5.99	5.18e-09	3.37e-06	-0.34	-0.31	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
LIHC	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-5.99	5.19e-09	3.38e-06	-0.29	-0.31	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
LIHC	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	5.99	5.2e-09	3.38e-06	0.38	0.31	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	5.99	5.2e-09	3.38e-06	0.38	0.31	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	5.99	5.2e-09	3.38e-06	0.38	0.31	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	5.99	5.2e-09	3.38e-06	0.38	0.31	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	5.99	5.2e-09	3.38e-06	0.38	0.31	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	5.99	5.2e-09	3.38e-06	0.38	0.31	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
LIHC	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-5.99	5.2e-09	3.38e-06	-0.41	-0.31	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
LIHC	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	5.99	5.2e-09	3.38e-06	0.41	0.31	Depression;	chr6:28399846	chr6:28943877~28944537:+
LIHC	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-5.99	5.2e-09	3.39e-06	-0.39	-0.31	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
LIHC	cis	rs7119038	0.818	rs6589685	ENSG00000255239.1	AP002954.6	-5.99	5.2e-09	3.39e-06	-0.39	-0.31	Sjögren's syndrome;	chr11:118741488	chr11:118688039~118690600:-
LIHC	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	5.99	5.21e-09	3.39e-06	0.36	0.31	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
LIHC	cis	rs1023500	0.596	rs133350	ENSG00000237037.8	NDUFA6-AS1	5.99	5.22e-09	3.39e-06	0.38	0.31	Schizophrenia;	chr22:42033045	chr22:42090931~42137742:+
LIHC	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-5.99	5.22e-09	3.4e-06	-0.45	-0.31	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
LIHC	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-5.99	5.23e-09	3.4e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-5.99	5.23e-09	3.4e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-5.99	5.23e-09	3.4e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
LIHC	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-5.99	5.25e-09	3.41e-06	-0.35	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
LIHC	cis	rs1023500	0.505	rs2143139	ENSG00000237037.8	NDUFA6-AS1	5.99	5.26e-09	3.42e-06	0.33	0.31	Schizophrenia;	chr22:42218395	chr22:42090931~42137742:+
LIHC	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-5.99	5.26e-09	3.42e-06	-0.38	-0.31	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-5.99	5.26e-09	3.42e-06	-0.38	-0.31	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-5.99	5.26e-09	3.42e-06	-0.38	-0.31	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
LIHC	cis	rs2933343	0.818	rs6764681	ENSG00000231305.3	RP11-723O4.2	-5.99	5.26e-09	3.42e-06	-0.35	-0.31	IgG glycosylation;	chr3:128849537	chr3:128861313~128871540:-
LIHC	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-5.99	5.28e-09	3.43e-06	-0.39	-0.31	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-5.99	5.28e-09	3.43e-06	-0.39	-0.31	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-5.99	5.28e-09	3.43e-06	-0.39	-0.31	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-5.99	5.28e-09	3.43e-06	-0.39	-0.31	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
LIHC	cis	rs2735413	0.709	rs4395084	ENSG00000276007.1	RP11-358L22.3	-5.99	5.28e-09	3.43e-06	-0.35	-0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78054114	chr16:78123243~78124332:+
LIHC	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	5.99	5.29e-09	3.44e-06	0.45	0.31	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
LIHC	cis	rs2762353	0.574	rs11756503	ENSG00000242387.1	HIST1H2APS2	-5.99	5.31e-09	3.45e-06	-0.39	-0.31	Blood metabolite levels;	chr6:25710204	chr6:25882026~25882395:-
LIHC	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	5.99	5.31e-09	3.45e-06	0.4	0.31	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
LIHC	cis	rs916888	0.821	rs199513	ENSG00000262881.1	RP11-669E14.4	5.99	5.32e-09	3.45e-06	0.47	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45907670~45910779:-
LIHC	cis	rs9326248	0.861	rs7931335	ENSG00000236267.1	AP006216.5	5.99	5.32e-09	3.46e-06	0.32	0.31	Blood protein levels;	chr11:117166089	chr11:116813204~116814003:-
LIHC	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-5.99	5.34e-09	3.47e-06	-0.43	-0.31	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
LIHC	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	5.99	5.36e-09	3.48e-06	0.31	0.31	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
LIHC	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-5.99	5.38e-09	3.49e-06	-0.37	-0.31	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
LIHC	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-5.99	5.41e-09	3.51e-06	-0.32	-0.31	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
LIHC	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	5.99	5.43e-09	3.53e-06	0.52	0.31	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	5.99	5.43e-09	3.53e-06	0.52	0.31	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	5.99	5.43e-09	3.53e-06	0.52	0.31	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
LIHC	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	5.99	5.44e-09	3.53e-06	0.44	0.31	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
LIHC	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	5.99	5.45e-09	3.53e-06	0.38	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
LIHC	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-5.99	5.45e-09	3.54e-06	-0.35	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
LIHC	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-5.99	5.45e-09	3.54e-06	-0.36	-0.31	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
LIHC	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-5.98	5.47e-09	3.54e-06	-0.39	-0.31	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-5.98	5.47e-09	3.54e-06	-0.39	-0.31	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-5.98	5.47e-09	3.54e-06	-0.39	-0.31	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-5.98	5.47e-09	3.54e-06	-0.39	-0.31	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
LIHC	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	5.98	5.47e-09	3.55e-06	0.46	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
LIHC	cis	rs11710088	0.626	rs6803863	ENSG00000244503.1	RP11-278L15.6	-5.98	5.48e-09	3.55e-06	-0.32	-0.31	QRS duration;	chr3:149507931	chr3:149494660~149495995:+
LIHC	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-5.98	5.48e-09	3.55e-06	-0.37	-0.31	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
LIHC	cis	rs1005277	0.522	rs9418276	ENSG00000263064.2	RP11-291L22.7	5.98	5.5e-09	3.56e-06	0.32	0.31	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.522	rs7072977	ENSG00000263064.2	RP11-291L22.7	5.98	5.5e-09	3.56e-06	0.32	0.31	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38448689~38448949:+
LIHC	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-5.98	5.5e-09	3.56e-06	-0.42	-0.31	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
LIHC	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	5.98	5.51e-09	3.57e-06	0.34	0.31	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
LIHC	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	5.98	5.52e-09	3.58e-06	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
LIHC	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	5.98	5.53e-09	3.58e-06	0.26	0.31	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
LIHC	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-5.98	5.55e-09	3.6e-06	-0.33	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-5.98	5.55e-09	3.6e-06	-0.33	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
LIHC	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-5.98	5.56e-09	3.6e-06	-0.35	-0.31	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-5.98	5.56e-09	3.6e-06	-0.35	-0.31	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-5.98	5.57e-09	3.61e-06	-0.35	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
LIHC	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	5.98	5.57e-09	3.61e-06	0.47	0.31	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
LIHC	cis	rs4934494	0.911	rs7081788	ENSG00000232936.4	RP11-80H5.2	5.98	5.58e-09	3.61e-06	0.38	0.31	Red blood cell count;	chr10:89648999	chr10:89645282~89650667:+
LIHC	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-5.98	5.6e-09	3.62e-06	-0.3	-0.31	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
LIHC	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-5.98	5.6e-09	3.62e-06	-0.3	-0.31	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
LIHC	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-5.98	5.6e-09	3.62e-06	-0.3	-0.31	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
LIHC	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-5.98	5.61e-09	3.63e-06	-0.52	-0.31	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
LIHC	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	5.98	5.62e-09	3.63e-06	0.38	0.31	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
LIHC	cis	rs7914558	0.966	rs10748839	ENSG00000236937.2	PTGES3P4	5.98	5.62e-09	3.63e-06	0.36	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102845595~102845950:+
LIHC	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	5.98	5.63e-09	3.64e-06	0.34	0.31	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
LIHC	cis	rs7119038	0.818	rs10892279	ENSG00000255239.1	AP002954.6	-5.98	5.63e-09	3.64e-06	-0.39	-0.31	Sjögren's syndrome;	chr11:118741072	chr11:118688039~118690600:-
LIHC	cis	rs4356975	0.563	rs7658752	ENSG00000249956.3	RP11-790I12.2	5.98	5.64e-09	3.65e-06	0.34	0.31	Obesity-related traits;	chr4:69112350	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs12506962	ENSG00000249956.3	RP11-790I12.2	5.98	5.64e-09	3.65e-06	0.34	0.31	Obesity-related traits;	chr4:69100306	chr4:69408836~69423164:+
LIHC	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-5.98	5.65e-09	3.65e-06	-0.38	-0.31	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
LIHC	cis	rs12285276	0.75	rs7116816	ENSG00000205106.4	DKFZp779M0652	5.98	5.65e-09	3.65e-06	0.31	0.31	Visceral fat;	chr11:45783444	chr11:45771432~45772358:+
LIHC	cis	rs1577917	0.633	rs7770835	ENSG00000234155.1	RP11-30P6.6	5.98	5.66e-09	3.66e-06	0.37	0.31	Response to antipsychotic treatment;	chr6:85899189	chr6:85387219~85390186:-
LIHC	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-5.98	5.67e-09	3.66e-06	-0.36	-0.31	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
LIHC	cis	rs4356975	0.563	rs4131317	ENSG00000249956.3	RP11-790I12.2	5.98	5.71e-09	3.69e-06	0.35	0.31	Obesity-related traits;	chr4:69083280	chr4:69408836~69423164:+
LIHC	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	5.98	5.72e-09	3.69e-06	0.34	0.31	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
LIHC	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	5.98	5.73e-09	3.7e-06	0.41	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
LIHC	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	5.98	5.73e-09	3.7e-06	0.35	0.31	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
LIHC	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-5.98	5.74e-09	3.71e-06	-0.36	-0.31	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
LIHC	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-5.98	5.74e-09	3.71e-06	-0.31	-0.31	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
LIHC	cis	rs9326248	0.813	rs474488	ENSG00000236267.1	AP006216.5	5.98	5.76e-09	3.72e-06	0.32	0.31	Blood protein levels;	chr11:117198261	chr11:116813204~116814003:-
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-5.98	5.77e-09	3.73e-06	-0.35	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
LIHC	cis	rs7916697	0.52	rs4745957	ENSG00000233590.1	RP11-153K11.3	5.98	5.78e-09	3.73e-06	0.4	0.31	Optic disc area;	chr10:68284945	chr10:68233251~68242379:-
LIHC	cis	rs7115242	0.844	rs645258	ENSG00000236267.1	AP006216.5	5.97	5.78e-09	3.73e-06	0.4	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:116813204~116814003:-
LIHC	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	5.97	5.8e-09	3.74e-06	0.31	0.31	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
LIHC	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	5.97	5.81e-09	3.75e-06	0.37	0.31	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
LIHC	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-5.97	5.82e-09	3.75e-06	-0.34	-0.31	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
LIHC	cis	rs4356975	0.527	rs12643840	ENSG00000249956.3	RP11-790I12.2	5.97	5.82e-09	3.75e-06	0.35	0.31	Obesity-related traits;	chr4:69082245	chr4:69408836~69423164:+
LIHC	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-5.97	5.82e-09	3.76e-06	-0.39	-0.31	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
LIHC	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	5.97	5.82e-09	3.76e-06	0.41	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
LIHC	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-5.97	5.83e-09	3.76e-06	-0.48	-0.31	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
LIHC	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-5.97	5.85e-09	3.77e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-5.97	5.85e-09	3.77e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-5.97	5.85e-09	3.77e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-5.97	5.85e-09	3.77e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-5.97	5.85e-09	3.77e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-5.97	5.85e-09	3.77e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
LIHC	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-5.97	5.91e-09	3.81e-06	-0.31	-0.31	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	5.97	5.91e-09	3.81e-06	0.31	0.31	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
LIHC	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	5.97	5.92e-09	3.82e-06	0.35	0.31	Height;	chr6:109440234	chr6:109382795~109383666:+
LIHC	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-5.97	5.92e-09	3.82e-06	-0.36	-0.31	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
LIHC	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	5.97	5.93e-09	3.82e-06	0.32	0.31	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
LIHC	cis	rs4356975	0.545	rs11249525	ENSG00000249956.3	RP11-790I12.2	5.97	5.93e-09	3.82e-06	0.35	0.31	Obesity-related traits;	chr4:69080923	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4443355	ENSG00000249956.3	RP11-790I12.2	5.97	5.93e-09	3.82e-06	0.35	0.31	Obesity-related traits;	chr4:69083026	chr4:69408836~69423164:+
LIHC	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-5.97	5.93e-09	3.82e-06	-0.38	-0.31	Gout;	chr7:66679692	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	5.97	5.93e-09	3.82e-06	0.38	0.31	Gout;	chr7:66682070	chr7:66902857~66906297:+
LIHC	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	5.97	5.93e-09	3.82e-06	0.38	0.31	Gout;	chr7:66682162	chr7:66902857~66906297:+
LIHC	cis	rs12681287	0.64	rs13267782	ENSG00000250569.1	NTAN1P2	5.97	5.94e-09	3.83e-06	0.36	0.31	Caudate activity during reward;	chr8:86469658	chr8:86481754~86483002:-
LIHC	cis	rs7914558	0.966	rs7908280	ENSG00000236937.2	PTGES3P4	5.97	5.95e-09	3.83e-06	0.37	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102845595~102845950:+
LIHC	cis	rs2735413	0.564	rs17776122	ENSG00000276007.1	RP11-358L22.3	5.97	5.96e-09	3.84e-06	0.44	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78072389	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.564	rs7193020	ENSG00000276007.1	RP11-358L22.3	5.97	5.96e-09	3.84e-06	0.44	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78072543	chr16:78123243~78124332:+
LIHC	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	5.97	5.97e-09	3.84e-06	0.51	0.31	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
LIHC	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	5.97	5.97e-09	3.84e-06	0.37	0.31	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
LIHC	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	5.97	5.97e-09	3.84e-06	0.33	0.31	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
LIHC	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-5.97	5.98e-09	3.85e-06	-0.33	-0.31	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
LIHC	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	5.97	6e-09	3.86e-06	0.37	0.31	Height;	chr6:109496073	chr6:109382795~109383666:+
LIHC	cis	rs4356975	0.527	rs62296943	ENSG00000249956.3	RP11-790I12.2	5.97	6.02e-09	3.87e-06	0.34	0.31	Obesity-related traits;	chr4:69093465	chr4:69408836~69423164:+
LIHC	cis	rs9326248	0.53	rs2471884	ENSG00000280143.1	AP000892.6	5.97	6.04e-09	3.88e-06	0.39	0.31	Blood protein levels;	chr11:117139604	chr11:117204967~117210292:+
LIHC	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-5.97	6.04e-09	3.89e-06	-0.35	-0.31	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
LIHC	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	5.97	6.05e-09	3.89e-06	0.36	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
LIHC	cis	rs7914558	0.966	rs11191438	ENSG00000236937.2	PTGES3P4	5.97	6.06e-09	3.9e-06	0.36	0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102845595~102845950:+
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-5.97	6.06e-09	3.9e-06	-0.35	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
LIHC	cis	rs2522056	1	rs10900807	ENSG00000233006.5	AC034220.3	-5.97	6.07e-09	3.9e-06	-0.33	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132421788	chr5:132311285~132369916:-
LIHC	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	5.97	6.07e-09	3.91e-06	0.39	0.31	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
LIHC	cis	rs2735413	0.709	rs9938043	ENSG00000276007.1	RP11-358L22.3	-5.97	6.1e-09	3.92e-06	-0.34	-0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78057529	chr16:78123243~78124332:+
LIHC	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-5.97	6.1e-09	3.92e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
LIHC	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	5.97	6.1e-09	3.92e-06	0.41	0.31	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
LIHC	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-5.96	6.12e-09	3.93e-06	-0.36	-0.31	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
LIHC	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-5.96	6.15e-09	3.95e-06	-0.33	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
LIHC	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	5.96	6.16e-09	3.95e-06	0.38	0.31	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
LIHC	cis	rs4356975	0.583	rs4632729	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69080286	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.545	rs11249524	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69080653	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.545	rs11249526	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69080934	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.602	rs7674851	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69081113	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7679550	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69081187	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4478248	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69081498	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7680709	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69081745	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4540108	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69083614	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.545	rs4640729	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69083642	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4522933	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69083780	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs11937683	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69084102	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7659306	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69084560	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4454000	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69084853	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4273534	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69084927	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs4642304	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69085832	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4446391	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69086364	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7437174	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69086885	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600874	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69087695	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6843382	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69087884	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4694171	ENSG00000249956.3	RP11-790I12.2	5.96	6.18e-09	3.97e-06	0.35	0.31	Obesity-related traits;	chr4:69088579	chr4:69408836~69423164:+
LIHC	cis	rs17270561	0.583	rs6908713	ENSG00000216436.2	HIST1H2APS1	5.96	6.19e-09	3.98e-06	0.38	0.31	Iron status biomarkers;	chr6:25703383	chr6:25732497~25732827:+
LIHC	cis	rs17270561	0.583	rs6908407	ENSG00000216436.2	HIST1H2APS1	5.96	6.19e-09	3.98e-06	0.38	0.31	Iron status biomarkers;	chr6:25703428	chr6:25732497~25732827:+
LIHC	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	5.96	6.19e-09	3.98e-06	0.3	0.31	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
LIHC	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.96	6.21e-09	3.98e-06	0.36	0.31	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.96	6.21e-09	3.98e-06	0.36	0.31	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.96	6.21e-09	3.98e-06	0.36	0.31	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
LIHC	cis	rs4356975	0.509	rs4371688	ENSG00000249956.3	RP11-790I12.2	5.96	6.21e-09	3.99e-06	0.36	0.31	Obesity-related traits;	chr4:69124323	chr4:69408836~69423164:+
LIHC	cis	rs12681287	0.64	rs72606633	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86464007	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs61106663	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86464852	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13252046	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86465522	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13261901	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86466488	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs7017706	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86468661	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.608	rs13272148	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86469624	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.608	rs1135451	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86471379	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs13260345	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86471492	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13282351	ENSG00000250569.1	NTAN1P2	5.96	6.23e-09	3.99e-06	0.36	0.31	Caudate activity during reward;	chr8:86472440	chr8:86481754~86483002:-
LIHC	cis	rs10833905	0.641	rs10833850	ENSG00000246225.5	RP11-17A1.3	-5.96	6.26e-09	4.01e-06	-0.4	-0.31	Sudden cardiac arrest;	chr11:22930969	chr11:22829380~22945393:+
LIHC	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	5.96	6.27e-09	4.02e-06	0.47	0.31	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
LIHC	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-5.96	6.29e-09	4.03e-06	-0.37	-0.31	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
LIHC	cis	rs2762353	0.595	rs12207313	ENSG00000242387.1	HIST1H2APS2	-5.96	6.3e-09	4.04e-06	-0.38	-0.31	Blood metabolite levels;	chr6:25740799	chr6:25882026~25882395:-
LIHC	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.96	6.3e-09	4.04e-06	0.36	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
LIHC	cis	rs2735413	0.564	rs2222897	ENSG00000276007.1	RP11-358L22.3	5.96	6.33e-09	4.05e-06	0.43	0.31	Systolic blood pressure (alcohol consumption interaction);	chr16:78058138	chr16:78123243~78124332:+
LIHC	cis	rs5769765	0.913	rs28670284	ENSG00000278869.1	CITF22-49E9.3	5.96	6.33e-09	4.06e-06	0.56	0.31	Schizophrenia;	chr22:49828325	chr22:49933198~49934074:-
LIHC	cis	rs3812049	0.784	rs3749748	ENSG00000245937.6	LINC01184	-5.96	6.37e-09	4.08e-06	-0.4	-0.31	Lymphocyte counts;Red cell distribution width;	chr5:128014857	chr5:127940426~128083172:-
LIHC	cis	rs202072	0.818	rs405078	ENSG00000215022.6	RP1-257A7.4	-5.96	6.37e-09	4.08e-06	-0.35	-0.31	HIV-1 viral setpoint;	chr6:13279635	chr6:13264861~13295586:-
LIHC	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	5.96	6.38e-09	4.09e-06	0.34	0.31	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	5.96	6.38e-09	4.09e-06	0.34	0.31	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	5.96	6.38e-09	4.09e-06	0.34	0.31	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	5.96	6.38e-09	4.09e-06	0.34	0.31	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	5.96	6.38e-09	4.09e-06	0.34	0.31	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
LIHC	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-5.96	6.39e-09	4.09e-06	-0.38	-0.31	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-5.96	6.39e-09	4.09e-06	-0.38	-0.31	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-5.96	6.39e-09	4.09e-06	-0.38	-0.31	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-5.96	6.39e-09	4.09e-06	-0.38	-0.31	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-5.96	6.39e-09	4.09e-06	-0.38	-0.31	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-5.96	6.39e-09	4.09e-06	-0.38	-0.31	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-5.96	6.39e-09	4.09e-06	-0.38	-0.31	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
LIHC	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	5.96	6.39e-09	4.09e-06	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
LIHC	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-5.96	6.4e-09	4.09e-06	-0.37	-0.31	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
LIHC	cis	rs17270561	0.609	rs9467572	ENSG00000216436.2	HIST1H2APS1	5.96	6.4e-09	4.1e-06	0.38	0.31	Iron status biomarkers;	chr6:25703898	chr6:25732497~25732827:+
LIHC	cis	rs9341808	0.718	rs9343978	ENSG00000272129.1	RP11-250B2.6	5.96	6.41e-09	4.1e-06	0.29	0.31	Sitting height ratio;	chr6:80262261	chr6:80355424~80356859:+
LIHC	cis	rs9341808	0.754	rs9341810	ENSG00000272129.1	RP11-250B2.6	5.96	6.41e-09	4.1e-06	0.29	0.31	Sitting height ratio;	chr6:80265121	chr6:80355424~80356859:+
LIHC	cis	rs9341808	0.7	rs12215236	ENSG00000272129.1	RP11-250B2.6	5.96	6.41e-09	4.1e-06	0.29	0.31	Sitting height ratio;	chr6:80265341	chr6:80355424~80356859:+
LIHC	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-5.96	6.42e-09	4.11e-06	-0.33	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-5.96	6.42e-09	4.11e-06	-0.33	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
LIHC	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-5.96	6.43e-09	4.12e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
LIHC	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-5.95	6.47e-09	4.14e-06	-0.34	-0.31	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
LIHC	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-5.95	6.48e-09	4.15e-06	-0.31	-0.31	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
LIHC	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	5.95	6.51e-09	4.16e-06	0.38	0.31	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
LIHC	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-5.95	6.51e-09	4.16e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
LIHC	cis	rs12744310	0.697	rs11209802	ENSG00000235358.1	RP11-399E6.1	5.95	6.52e-09	4.17e-06	0.36	0.31	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291154	chr1:41242373~41284861:+
LIHC	cis	rs4356975	0.509	rs28375964	ENSG00000249956.3	RP11-790I12.2	5.95	6.52e-09	4.17e-06	0.35	0.31	Obesity-related traits;	chr4:69098070	chr4:69408836~69423164:+
LIHC	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-5.95	6.57e-09	4.2e-06	-0.48	-0.31	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
LIHC	cis	rs6435862	0.517	rs6757091	ENSG00000229267.2	AC072062.1	5.95	6.58e-09	4.2e-06	0.36	0.31	Neuroblastoma (high-risk);	chr2:214808069	chr2:214810229~214963274:+
LIHC	cis	rs6435862	0.5	rs6756902	ENSG00000229267.2	AC072062.1	5.95	6.58e-09	4.2e-06	0.36	0.31	Neuroblastoma (high-risk);	chr2:214808103	chr2:214810229~214963274:+
LIHC	cis	rs6435862	0.5	rs12477063	ENSG00000229267.2	AC072062.1	5.95	6.58e-09	4.2e-06	0.36	0.31	Neuroblastoma (high-risk);	chr2:214808940	chr2:214810229~214963274:+
LIHC	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	5.95	6.6e-09	4.22e-06	0.36	0.31	Depression;	chr6:28273214	chr6:28176188~28176674:+
LIHC	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	5.95	6.6e-09	4.22e-06	0.36	0.31	Depression;	chr6:28273215	chr6:28176188~28176674:+
LIHC	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	5.95	6.6e-09	4.22e-06	0.34	0.31	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	5.95	6.6e-09	4.22e-06	0.34	0.31	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	5.95	6.6e-09	4.22e-06	0.34	0.31	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	5.95	6.6e-09	4.22e-06	0.34	0.31	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
LIHC	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	5.95	6.62e-09	4.23e-06	0.39	0.31	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	5.95	6.62e-09	4.23e-06	0.39	0.31	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	5.95	6.62e-09	4.23e-06	0.52	0.31	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	5.95	6.63e-09	4.23e-06	0.37	0.31	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
LIHC	cis	rs1005277	0.522	rs289643	ENSG00000263064.2	RP11-291L22.7	5.95	6.65e-09	4.24e-06	0.31	0.31	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38448689~38448949:+
LIHC	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-5.95	6.65e-09	4.25e-06	-0.39	-0.31	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
LIHC	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-5.95	6.65e-09	4.25e-06	-0.39	-0.31	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
LIHC	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	5.95	6.66e-09	4.25e-06	0.3	0.31	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
LIHC	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-5.95	6.66e-09	4.25e-06	-0.36	-0.31	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
LIHC	cis	rs6061231	0.631	rs927133	ENSG00000273619.1	RP5-908M14.9	-5.95	6.68e-09	4.26e-06	-0.26	-0.31	Colorectal cancer;	chr20:62397053	chr20:62386303~62386970:-
LIHC	cis	rs1023500	0.551	rs133379	ENSG00000237037.8	NDUFA6-AS1	5.95	6.7e-09	4.27e-06	0.37	0.31	Schizophrenia;	chr22:42072531	chr22:42090931~42137742:+
LIHC	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-5.95	6.73e-09	4.29e-06	-0.34	-0.31	Height;	chr11:118855233	chr11:118704607~118750263:+
LIHC	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-5.95	6.73e-09	4.29e-06	-0.34	-0.31	Height;	chr11:118855938	chr11:118704607~118750263:+
LIHC	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-5.95	6.75e-09	4.3e-06	-0.4	-0.31	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
LIHC	cis	rs7119038	0.818	rs2155433	ENSG00000255239.1	AP002954.6	-5.95	6.77e-09	4.32e-06	-0.39	-0.31	Sjögren's syndrome;	chr11:118742212	chr11:118688039~118690600:-
LIHC	cis	rs9326248	0.911	rs11216284	ENSG00000236267.1	AP006216.5	5.95	6.79e-09	4.33e-06	0.31	0.31	Blood protein levels;	chr11:117132344	chr11:116813204~116814003:-
LIHC	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	5.95	6.8e-09	4.33e-06	0.32	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
LIHC	cis	rs12681287	0.752	rs10103229	ENSG00000250569.1	NTAN1P2	-5.94	6.83e-09	4.35e-06	-0.38	-0.31	Caudate activity during reward;	chr8:86236725	chr8:86481754~86483002:-
LIHC	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.94	6.85e-09	4.36e-06	0.36	0.31	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.94	6.85e-09	4.36e-06	0.36	0.31	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.94	6.85e-09	4.36e-06	0.36	0.31	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
LIHC	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	5.94	6.86e-09	4.37e-06	0.31	0.31	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
LIHC	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	5.94	6.86e-09	4.37e-06	0.45	0.31	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
LIHC	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-5.94	6.89e-09	4.39e-06	-0.36	-0.31	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
LIHC	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-5.94	6.93e-09	4.41e-06	-0.38	-0.31	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
LIHC	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	5.94	6.93e-09	4.41e-06	0.31	0.31	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
LIHC	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-5.94	6.94e-09	4.42e-06	-0.52	-0.31	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
LIHC	cis	rs2762353	0.574	rs9467573	ENSG00000242387.1	HIST1H2APS2	-5.94	6.95e-09	4.42e-06	-0.39	-0.31	Blood metabolite levels;	chr6:25703962	chr6:25882026~25882395:-
LIHC	cis	rs11723261	0.513	rs2353623	ENSG00000275426.1	CH17-262A2.1	5.94	6.95e-09	4.42e-06	0.34	0.31	Immune response to smallpox vaccine (IL-6);	chr4:95673	chr4:149738~150317:+
LIHC	cis	rs12908161	1	rs58416181	ENSG00000259295.5	CSPG4P12	5.94	6.96e-09	4.43e-06	0.42	0.31	Schizophrenia;	chr15:84721230	chr15:85191438~85213905:+
LIHC	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	5.94	6.97e-09	4.44e-06	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
LIHC	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	5.94	6.98e-09	4.44e-06	0.34	0.31	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-5.94	7e-09	4.45e-06	-0.31	-0.31	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
LIHC	cis	rs10833905	0.641	rs10766981	ENSG00000246225.5	RP11-17A1.3	-5.94	7e-09	4.46e-06	-0.4	-0.31	Sudden cardiac arrest;	chr11:22920950	chr11:22829380~22945393:+
LIHC	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-5.94	7.02e-09	4.46e-06	-0.52	-0.31	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
LIHC	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-5.94	7.03e-09	4.47e-06	-0.37	-0.31	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
LIHC	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	5.94	7.04e-09	4.48e-06	0.38	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
LIHC	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	5.94	7.04e-09	4.48e-06	0.38	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
LIHC	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-5.94	7.05e-09	4.48e-06	-0.37	-0.31	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
LIHC	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-5.94	7.06e-09	4.49e-06	-0.48	-0.31	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
LIHC	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-5.94	7.08e-09	4.5e-06	-0.38	-0.31	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
LIHC	cis	rs5758511	0.573	rs1883205	ENSG00000237037.8	NDUFA6-AS1	5.94	7.11e-09	4.52e-06	0.36	0.31	Birth weight;	chr22:41847016	chr22:42090931~42137742:+
LIHC	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.94	7.12e-09	4.52e-06	0.36	0.31	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
LIHC	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	5.94	7.12e-09	4.52e-06	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
LIHC	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	5.94	7.12e-09	4.53e-06	0.44	0.31	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
LIHC	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	5.94	7.13e-09	4.53e-06	0.3	0.31	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
LIHC	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-5.94	7.14e-09	4.54e-06	-0.31	-0.31	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
LIHC	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	5.94	7.16e-09	4.55e-06	0.38	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
LIHC	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	5.94	7.16e-09	4.55e-06	0.35	0.31	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
LIHC	cis	rs8028182	0.636	rs4243034	ENSG00000260269.4	CTD-2323K18.1	-5.94	7.17e-09	4.55e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75458628	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs6495182	ENSG00000260269.4	CTD-2323K18.1	-5.94	7.2e-09	4.57e-06	-0.4	-0.31	Sudden cardiac arrest;	chr15:75522047	chr15:75527150~75601205:-
LIHC	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-5.93	7.22e-09	4.59e-06	-0.38	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
LIHC	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	5.93	7.26e-09	4.61e-06	0.34	0.31	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
LIHC	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	5.93	7.27e-09	4.62e-06	0.35	0.31	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
LIHC	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	5.93	7.28e-09	4.62e-06	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
LIHC	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	5.93	7.28e-09	4.62e-06	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
LIHC	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	5.93	7.34e-09	4.66e-06	0.41	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
LIHC	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-5.93	7.34e-09	4.66e-06	-0.42	-0.31	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
LIHC	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-5.93	7.34e-09	4.66e-06	-0.47	-0.31	Depression;	chr6:28071808	chr6:28115628~28116551:+
LIHC	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	5.93	7.36e-09	4.67e-06	0.52	0.31	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
LIHC	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	5.93	7.36e-09	4.67e-06	0.52	0.31	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
LIHC	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	5.93	7.37e-09	4.67e-06	0.35	0.31	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
LIHC	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	5.93	7.37e-09	4.67e-06	0.38	0.31	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	5.93	7.37e-09	4.67e-06	0.38	0.31	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	5.93	7.37e-09	4.67e-06	0.38	0.31	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	5.93	7.37e-09	4.67e-06	0.38	0.31	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	5.93	7.37e-09	4.67e-06	0.38	0.31	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	5.93	7.37e-09	4.67e-06	0.38	0.31	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
LIHC	cis	rs4356975	0.563	rs6600893	ENSG00000249956.3	RP11-790I12.2	5.93	7.37e-09	4.68e-06	0.34	0.31	Obesity-related traits;	chr4:69113183	chr4:69408836~69423164:+
LIHC	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	5.93	7.38e-09	4.68e-06	0.33	0.31	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
LIHC	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-5.93	7.4e-09	4.69e-06	-0.34	-0.31	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
LIHC	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.93	7.42e-09	4.7e-06	-0.39	-0.31	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
LIHC	cis	rs1023500	0.506	rs6002625	ENSG00000237037.8	NDUFA6-AS1	-5.93	7.44e-09	4.72e-06	-0.37	-0.31	Schizophrenia;	chr22:42121685	chr22:42090931~42137742:+
LIHC	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	5.93	7.45e-09	4.72e-06	0.41	0.31	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
LIHC	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-5.93	7.47e-09	4.73e-06	-0.44	-0.31	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
LIHC	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-5.93	7.47e-09	4.73e-06	-0.34	-0.31	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-5.93	7.47e-09	4.73e-06	-0.34	-0.31	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
LIHC	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	5.93	7.48e-09	4.74e-06	0.44	0.31	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
LIHC	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-5.93	7.49e-09	4.74e-06	-0.46	-0.31	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
LIHC	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-5.93	7.5e-09	4.75e-06	-0.53	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
LIHC	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-5.93	7.51e-09	4.76e-06	-0.3	-0.31	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
LIHC	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-5.93	7.51e-09	4.76e-06	-0.34	-0.31	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
LIHC	cis	rs1023500	0.596	rs133369	ENSG00000237037.8	NDUFA6-AS1	5.93	7.54e-09	4.77e-06	0.37	0.31	Schizophrenia;	chr22:42067810	chr22:42090931~42137742:+
LIHC	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-5.93	7.55e-09	4.78e-06	-0.34	-0.31	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
LIHC	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	5.93	7.59e-09	4.8e-06	0.5	0.31	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
LIHC	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	5.93	7.6e-09	4.81e-06	0.38	0.31	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
LIHC	cis	rs9326248	0.954	rs4938349	ENSG00000236267.1	AP006216.5	5.93	7.61e-09	4.81e-06	0.31	0.31	Blood protein levels;	chr11:117151207	chr11:116813204~116814003:-
LIHC	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-5.93	7.61e-09	4.82e-06	-0.34	-0.31	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
LIHC	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	5.92	7.64e-09	4.83e-06	0.48	0.31	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	5.92	7.64e-09	4.83e-06	0.48	0.31	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
LIHC	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-5.92	7.64e-09	4.83e-06	-0.36	-0.31	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
LIHC	cis	rs916888	0.738	rs199515	ENSG00000262881.1	RP11-669E14.4	5.92	7.69e-09	4.86e-06	0.46	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45907670~45910779:-
LIHC	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-5.92	7.72e-09	4.88e-06	-0.42	-0.31	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
LIHC	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	5.92	7.73e-09	4.89e-06	0.45	0.3	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
LIHC	cis	rs9326248	0.727	rs4938347	ENSG00000236267.1	AP006216.5	5.92	7.75e-09	4.89e-06	0.31	0.3	Blood protein levels;	chr11:117151043	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.861	rs4938348	ENSG00000236267.1	AP006216.5	5.92	7.75e-09	4.89e-06	0.31	0.3	Blood protein levels;	chr11:117151161	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.813	rs4938350	ENSG00000236267.1	AP006216.5	5.92	7.75e-09	4.89e-06	0.31	0.3	Blood protein levels;	chr11:117151560	chr11:116813204~116814003:-
LIHC	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-5.92	7.76e-09	4.9e-06	-0.33	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
LIHC	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-5.92	7.76e-09	4.9e-06	-0.31	-0.3	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
LIHC	cis	rs2735413	0.563	rs72800910	ENSG00000276007.1	RP11-358L22.3	5.92	7.76e-09	4.9e-06	0.4	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78014005	chr16:78123243~78124332:+
LIHC	cis	rs9326248	0.53	rs7123517	ENSG00000236267.1	AP006216.5	5.92	7.78e-09	4.91e-06	0.34	0.3	Blood protein levels;	chr11:117157039	chr11:116813204~116814003:-
LIHC	cis	rs1799810	1	rs1799809	ENSG00000236682.1	AC068282.3	5.92	7.8e-09	4.93e-06	0.43	0.3	Self-rated health;	chr2:127418299	chr2:127389130~127400580:+
LIHC	cis	rs2243480	1	rs160639	ENSG00000164669.11	INTS4P1	5.92	7.81e-09	4.93e-06	0.52	0.3	Diabetic kidney disease;	chr7:66115000	chr7:65141225~65234216:+
LIHC	cis	rs1023500	0.552	rs5758566	ENSG00000237037.8	NDUFA6-AS1	5.92	7.81e-09	4.93e-06	0.37	0.3	Schizophrenia;	chr22:42058350	chr22:42090931~42137742:+
LIHC	cis	rs6061231	0.63	rs62196294	ENSG00000273619.1	RP5-908M14.9	-5.92	7.85e-09	4.96e-06	-0.25	-0.3	Colorectal cancer;	chr20:62398376	chr20:62386303~62386970:-
LIHC	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	5.92	7.9e-09	4.98e-06	0.32	0.3	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
LIHC	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.92	7.9e-09	4.99e-06	0.36	0.3	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
LIHC	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	5.92	7.92e-09	5e-06	0.34	0.3	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	5.92	7.92e-09	5e-06	0.34	0.3	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
LIHC	cis	rs5758511	0.573	rs2267438	ENSG00000237037.8	NDUFA6-AS1	5.92	7.92e-09	5e-06	0.36	0.3	Birth weight;	chr22:41841561	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.573	rs2284082	ENSG00000237037.8	NDUFA6-AS1	5.92	7.92e-09	5e-06	0.36	0.3	Birth weight;	chr22:41844793	chr22:42090931~42137742:+
LIHC	cis	rs6490294	0.747	rs659964	ENSG00000226469.1	ADAM1B	5.92	7.94e-09	5.01e-06	0.4	0.3	Mean platelet volume;	chr12:111692395	chr12:111927018~111929017:+
LIHC	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	5.92	7.95e-09	5.01e-06	0.47	0.3	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
LIHC	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-5.92	7.95e-09	5.01e-06	-0.32	-0.3	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
LIHC	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	5.92	7.97e-09	5.02e-06	0.41	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
LIHC	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	5.92	7.97e-09	5.02e-06	0.41	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
LIHC	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-5.92	7.98e-09	5.03e-06	-0.31	-0.3	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	5.92	7.98e-09	5.03e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	5.92	7.98e-09	5.03e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	5.92	7.98e-09	5.03e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	5.92	7.98e-09	5.03e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	5.92	7.98e-09	5.03e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
LIHC	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	5.92	7.98e-09	5.03e-06	0.41	0.3	Depression;	chr6:28428413	chr6:28943877~28944537:+
LIHC	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	5.92	7.98e-09	5.03e-06	0.41	0.3	Depression;	chr6:28430971	chr6:28943877~28944537:+
LIHC	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	5.92	7.98e-09	5.03e-06	0.41	0.3	Depression;	chr6:28431469	chr6:28943877~28944537:+
LIHC	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	5.92	7.98e-09	5.03e-06	0.41	0.3	Depression;	chr6:28432562	chr6:28943877~28944537:+
LIHC	cis	rs17270561	0.609	rs7772382	ENSG00000216436.2	HIST1H2APS1	-5.92	7.99e-09	5.03e-06	-0.38	-0.3	Iron status biomarkers;	chr6:25707888	chr6:25732497~25732827:+
LIHC	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	5.92	8.02e-09	5.05e-06	0.35	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
LIHC	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-5.92	8.02e-09	5.05e-06	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
LIHC	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-5.92	8.05e-09	5.07e-06	-0.38	-0.3	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
LIHC	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-5.91	8.05e-09	5.07e-06	-0.45	-0.3	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
LIHC	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	5.91	8.06e-09	5.08e-06	0.47	0.3	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	5.91	8.06e-09	5.08e-06	0.47	0.3	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
LIHC	cis	rs12681287	0.752	rs1436628	ENSG00000250569.1	NTAN1P2	-5.91	8.07e-09	5.08e-06	-0.36	-0.3	Caudate activity during reward;	chr8:86301116	chr8:86481754~86483002:-
LIHC	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-5.91	8.08e-09	5.09e-06	-0.38	-0.3	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-5.91	8.08e-09	5.09e-06	-0.38	-0.3	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
LIHC	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	5.91	8.09e-09	5.09e-06	0.47	0.3	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
LIHC	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	5.91	8.11e-09	5.1e-06	0.34	0.3	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
LIHC	cis	rs9326248	0.813	rs588534	ENSG00000236267.1	AP006216.5	5.91	8.13e-09	5.11e-06	0.31	0.3	Blood protein levels;	chr11:117197788	chr11:116813204~116814003:-
LIHC	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	5.91	8.14e-09	5.12e-06	0.36	0.3	Height;	chr6:109354092	chr6:109382795~109383666:+
LIHC	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-5.91	8.15e-09	5.13e-06	-0.42	-0.3	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
LIHC	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-5.91	8.15e-09	5.13e-06	-0.3	-0.3	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
LIHC	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-5.91	8.16e-09	5.13e-06	-0.36	-0.3	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
LIHC	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-5.91	8.16e-09	5.13e-06	-0.51	-0.3	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
LIHC	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	5.91	8.2e-09	5.15e-06	0.35	0.3	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000206090.4	AP000350.7	-5.91	8.21e-09	5.16e-06	-0.37	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23939998~23942798:+
LIHC	cis	rs12744310	0.697	rs11209838	ENSG00000235358.1	RP11-399E6.1	5.91	8.23e-09	5.17e-06	0.36	0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307285	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.697	rs11209839	ENSG00000235358.1	RP11-399E6.1	5.91	8.23e-09	5.17e-06	0.36	0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307332	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.731	rs12755632	ENSG00000235358.1	RP11-399E6.1	5.91	8.23e-09	5.17e-06	0.36	0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41310951	chr1:41242373~41284861:+
LIHC	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-5.91	8.24e-09	5.18e-06	-0.29	-0.3	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
LIHC	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	5.91	8.29e-09	5.21e-06	0.3	0.3	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
LIHC	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-5.91	8.3e-09	5.21e-06	-0.34	-0.3	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
LIHC	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	5.91	8.3e-09	5.21e-06	0.26	0.3	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
LIHC	cis	rs2243480	1	rs13310597	ENSG00000164669.11	INTS4P1	5.91	8.31e-09	5.22e-06	0.53	0.3	Diabetic kidney disease;	chr7:66133553	chr7:65141225~65234216:+
LIHC	cis	rs2522056	0.935	rs1981524	ENSG00000233006.5	AC034220.3	-5.91	8.31e-09	5.22e-06	-0.33	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132311285~132369916:-
LIHC	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	5.91	8.31e-09	5.22e-06	0.34	0.3	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
LIHC	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-5.91	8.32e-09	5.22e-06	-0.46	-0.3	Depression;	chr6:28096845	chr6:28115628~28116551:+
LIHC	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	5.91	8.34e-09	5.23e-06	0.29	0.3	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
LIHC	cis	rs2762353	0.574	rs34067542	ENSG00000242387.1	HIST1H2APS2	-5.91	8.36e-09	5.24e-06	-0.4	-0.3	Blood metabolite levels;	chr6:25727982	chr6:25882026~25882395:-
LIHC	cis	rs2762353	0.538	rs35670731	ENSG00000242387.1	HIST1H2APS2	-5.91	8.36e-09	5.24e-06	-0.4	-0.3	Blood metabolite levels;	chr6:25728007	chr6:25882026~25882395:-
LIHC	cis	rs2735413	0.564	rs73578752	ENSG00000276007.1	RP11-358L22.3	5.91	8.36e-09	5.25e-06	0.43	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78073657	chr16:78123243~78124332:+
LIHC	cis	rs7529073	0.545	rs340884	ENSG00000274895.1	RP11-478J18.2	5.91	8.39e-09	5.26e-06	0.32	0.3	Schizophrenia;	chr1:213972046	chr1:213983793~213986419:-
LIHC	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-5.91	8.39e-09	5.26e-06	-0.3	-0.3	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
LIHC	cis	rs1577917	0.655	rs9342045	ENSG00000234155.1	RP11-30P6.6	-5.91	8.41e-09	5.27e-06	-0.36	-0.3	Response to antipsychotic treatment;	chr6:85715430	chr6:85387219~85390186:-
LIHC	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	5.91	8.42e-09	5.28e-06	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
LIHC	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	5.91	8.43e-09	5.29e-06	0.37	0.3	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
LIHC	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-5.91	8.44e-09	5.29e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-5.91	8.44e-09	5.29e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
LIHC	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-5.91	8.46e-09	5.3e-06	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-5.91	8.46e-09	5.3e-06	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
LIHC	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	5.9	8.51e-09	5.33e-06	0.35	0.3	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
LIHC	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	5.9	8.51e-09	5.33e-06	0.35	0.3	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
LIHC	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	5.9	8.51e-09	5.33e-06	0.35	0.3	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
LIHC	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	5.9	8.53e-09	5.34e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
LIHC	cis	rs1023500	0.505	rs134888	ENSG00000237037.8	NDUFA6-AS1	5.9	8.57e-09	5.37e-06	0.33	0.3	Schizophrenia;	chr22:42278275	chr22:42090931~42137742:+
LIHC	cis	rs9843304	0.568	rs10935763	ENSG00000244503.1	RP11-278L15.6	-5.9	8.67e-09	5.43e-06	-0.3	-0.3	Gallstone disease;	chr3:149501283	chr3:149494660~149495995:+
LIHC	cis	rs4356975	0.563	rs7442453	ENSG00000249956.3	RP11-790I12.2	5.9	8.69e-09	5.44e-06	0.35	0.3	Obesity-related traits;	chr4:69103462	chr4:69408836~69423164:+
LIHC	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	5.9	8.7e-09	5.45e-06	0.39	0.3	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
LIHC	cis	rs4538475	0.556	rs4613561	ENSG00000214846.4	RP11-115L11.1	5.9	8.72e-09	5.46e-06	0.39	0.3	Parkinson's disease;	chr4:15736267	chr4:15730962~15731627:-
LIHC	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	5.9	8.72e-09	5.46e-06	0.33	0.3	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	5.9	8.72e-09	5.46e-06	0.33	0.3	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	5.9	8.72e-09	5.46e-06	0.33	0.3	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
LIHC	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	5.9	8.75e-09	5.47e-06	0.31	0.3	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
LIHC	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-5.9	8.78e-09	5.49e-06	-0.39	-0.3	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
LIHC	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	5.9	8.79e-09	5.49e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
LIHC	cis	rs1023500	0.551	rs2854837	ENSG00000237037.8	NDUFA6-AS1	5.9	8.83e-09	5.52e-06	0.37	0.3	Schizophrenia;	chr22:42062477	chr22:42090931~42137742:+
LIHC	cis	rs6061231	0.631	rs2427317	ENSG00000273619.1	RP5-908M14.9	-5.9	8.87e-09	5.54e-06	-0.25	-0.3	Colorectal cancer;	chr20:62400669	chr20:62386303~62386970:-
LIHC	cis	rs6061231	0.631	rs2427318	ENSG00000273619.1	RP5-908M14.9	-5.9	8.87e-09	5.54e-06	-0.25	-0.3	Colorectal cancer;	chr20:62400671	chr20:62386303~62386970:-
LIHC	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	5.9	8.88e-09	5.55e-06	0.44	0.3	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
LIHC	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	5.9	8.91e-09	5.56e-06	0.47	0.3	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
LIHC	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-5.9	8.96e-09	5.59e-06	-0.34	-0.3	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
LIHC	cis	rs1577917	0.727	rs9444361	ENSG00000234155.1	RP11-30P6.6	-5.9	8.97e-09	5.6e-06	-0.39	-0.3	Response to antipsychotic treatment;	chr6:85691182	chr6:85387219~85390186:-
LIHC	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	5.9	8.98e-09	5.6e-06	0.3	0.3	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
LIHC	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	5.89	9.04e-09	5.64e-06	0.35	0.3	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000206090.4	AP000350.7	5.89	9.04e-09	5.64e-06	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23939998~23942798:+
LIHC	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-5.89	9.05e-09	5.64e-06	-0.43	-0.3	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
LIHC	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-5.89	9.05e-09	5.65e-06	-0.39	-0.3	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
LIHC	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-5.89	9.06e-09	5.65e-06	-0.46	-0.3	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-5.89	9.07e-09	5.66e-06	-0.46	-0.3	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-5.89	9.07e-09	5.66e-06	-0.46	-0.3	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-5.89	9.07e-09	5.66e-06	-0.46	-0.3	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
LIHC	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-5.89	9.07e-09	5.66e-06	-0.39	-0.3	AIDS;	chr2:105313444	chr2:105324210~105330529:+
LIHC	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	5.89	9.1e-09	5.67e-06	0.37	0.3	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
LIHC	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	5.89	9.11e-09	5.68e-06	0.37	0.3	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	5.89	9.11e-09	5.68e-06	0.37	0.3	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
LIHC	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-5.89	9.11e-09	5.68e-06	-0.37	-0.3	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
LIHC	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-5.89	9.13e-09	5.69e-06	-0.46	-0.3	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
LIHC	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-5.89	9.16e-09	5.71e-06	-0.42	-0.3	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
LIHC	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	5.89	9.17e-09	5.72e-06	0.34	0.3	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	5.89	9.17e-09	5.72e-06	0.34	0.3	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	5.89	9.17e-09	5.72e-06	0.34	0.3	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	5.89	9.17e-09	5.72e-06	0.34	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
LIHC	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-5.89	9.18e-09	5.72e-06	-0.35	-0.3	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
LIHC	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	5.89	9.23e-09	5.75e-06	0.35	0.3	Height;	chr6:109443332	chr6:109382795~109383666:+
LIHC	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-5.89	9.24e-09	5.75e-06	-0.33	-0.3	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
LIHC	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-5.89	9.24e-09	5.75e-06	-0.39	-0.3	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
LIHC	cis	rs4356975	0.563	rs12512526	ENSG00000249956.3	RP11-790I12.2	5.89	9.25e-09	5.76e-06	0.34	0.3	Obesity-related traits;	chr4:69100700	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs34386959	ENSG00000249956.3	RP11-790I12.2	5.89	9.25e-09	5.76e-06	0.34	0.3	Obesity-related traits;	chr4:69100837	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs55834557	ENSG00000249956.3	RP11-790I12.2	5.89	9.25e-09	5.76e-06	0.34	0.3	Obesity-related traits;	chr4:69100876	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs56388229	ENSG00000249956.3	RP11-790I12.2	5.89	9.25e-09	5.76e-06	0.34	0.3	Obesity-related traits;	chr4:69100940	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs34318523	ENSG00000249956.3	RP11-790I12.2	5.89	9.25e-09	5.76e-06	0.34	0.3	Obesity-related traits;	chr4:69101135	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.583	rs34630750	ENSG00000249956.3	RP11-790I12.2	5.89	9.25e-09	5.76e-06	0.34	0.3	Obesity-related traits;	chr4:69101208	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs12508257	ENSG00000249956.3	RP11-790I12.2	5.89	9.25e-09	5.76e-06	0.34	0.3	Obesity-related traits;	chr4:69101921	chr4:69408836~69423164:+
LIHC	cis	rs12291225	0.585	rs4757250	ENSG00000251991.1	RNU7-49P	5.89	9.25e-09	5.76e-06	0.32	0.3	Sense of smell;	chr11:14354137	chr11:14478892~14478953:+
LIHC	cis	rs6061231	0.631	rs2427310	ENSG00000273619.1	RP5-908M14.9	-5.89	9.28e-09	5.77e-06	-0.25	-0.3	Colorectal cancer;	chr20:62394873	chr20:62386303~62386970:-
LIHC	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	5.89	9.29e-09	5.78e-06	0.33	0.3	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	5.89	9.29e-09	5.78e-06	0.33	0.3	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
LIHC	cis	rs3096299	0.838	rs3102384	ENSG00000274627.1	RP11-104N10.2	5.89	9.32e-09	5.8e-06	0.32	0.3	Multiple myeloma (IgH translocation);	chr16:89345253	chr16:89516797~89522217:+
LIHC	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-5.89	9.34e-09	5.81e-06	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
LIHC	cis	rs2522056	1	rs62385693	ENSG00000233006.5	AC034220.3	-5.89	9.34e-09	5.81e-06	-0.32	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132311285~132369916:-
LIHC	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-5.89	9.38e-09	5.83e-06	-0.62	-0.3	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
LIHC	cis	rs3096299	0.9	rs744327	ENSG00000261118.1	RP11-104N10.1	5.89	9.39e-09	5.84e-06	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89492017~89504460:-
LIHC	cis	rs12681287	0.64	rs7460650	ENSG00000250569.1	NTAN1P2	5.89	9.41e-09	5.85e-06	0.35	0.3	Caudate activity during reward;	chr8:86461856	chr8:86481754~86483002:-
LIHC	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-5.89	9.42e-09	5.85e-06	-0.34	-0.3	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
LIHC	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-5.89	9.43e-09	5.86e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
LIHC	cis	rs2933343	0.621	rs883843	ENSG00000231305.3	RP11-723O4.2	-5.89	9.45e-09	5.87e-06	-0.34	-0.3	IgG glycosylation;	chr3:128848540	chr3:128861313~128871540:-
LIHC	cis	rs11672691	0.67	rs4802119	ENSG00000267107.5	PCAT19	5.89	9.46e-09	5.88e-06	0.37	0.3	Prostate cancer;	chr19:41484417	chr19:41454169~41500649:-
LIHC	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-5.89	9.46e-09	5.88e-06	-0.25	-0.3	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
LIHC	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-5.89	9.48e-09	5.89e-06	-0.38	-0.3	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
LIHC	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	5.89	9.48e-09	5.89e-06	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
LIHC	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	5.89	9.49e-09	5.89e-06	0.34	0.3	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
LIHC	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-5.89	9.49e-09	5.89e-06	-0.4	-0.3	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
LIHC	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	5.88	9.55e-09	5.93e-06	0.34	0.3	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
LIHC	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	5.88	9.56e-09	5.94e-06	0.37	0.3	Height;	chr6:109498586	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	5.88	9.56e-09	5.94e-06	0.37	0.3	Height;	chr6:109499759	chr6:109382795~109383666:+
LIHC	cis	rs9326248	0.954	rs8521	ENSG00000236267.1	AP006216.5	5.88	9.58e-09	5.95e-06	0.31	0.3	Blood protein levels;	chr11:117196983	chr11:116813204~116814003:-
LIHC	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-5.88	9.6e-09	5.96e-06	-0.33	-0.3	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
LIHC	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	5.88	9.63e-09	5.98e-06	0.3	0.3	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
LIHC	cis	rs67180937	0.583	rs2936054	ENSG00000272750.1	RP11-378J18.8	5.88	9.66e-09	5.99e-06	0.36	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222627290	chr1:222658867~222661512:-
LIHC	cis	rs2243480	0.908	rs313822	ENSG00000164669.11	INTS4P1	5.88	9.68e-09	6e-06	0.51	0.3	Diabetic kidney disease;	chr7:66108952	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs313820	ENSG00000164669.11	INTS4P1	5.88	9.68e-09	6e-06	0.51	0.3	Diabetic kidney disease;	chr7:66109479	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs313824	ENSG00000164669.11	INTS4P1	5.88	9.68e-09	6e-06	0.51	0.3	Diabetic kidney disease;	chr7:66116220	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs186378	ENSG00000164669.11	INTS4P1	5.88	9.68e-09	6e-06	0.51	0.3	Diabetic kidney disease;	chr7:66117071	chr7:65141225~65234216:+
LIHC	cis	rs2243480	1	rs160637	ENSG00000164669.11	INTS4P1	5.88	9.68e-09	6e-06	0.51	0.3	Diabetic kidney disease;	chr7:66119331	chr7:65141225~65234216:+
LIHC	cis	rs1555322	0.556	rs7272884	ENSG00000126005.14	MMP24-AS1	-5.88	9.7e-09	6.01e-06	-0.47	-0.3	Attention deficit hyperactivity disorder;	chr20:35295212	chr20:35216462~35278131:-
LIHC	cis	rs1211375	0.628	rs3859141	ENSG00000268836.1	LA16c-OS12.2	5.88	9.71e-09	6.02e-06	0.32	0.3	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:195080	chr16:185748~186294:-
LIHC	cis	rs5758511	0.573	rs5996074	ENSG00000237037.8	NDUFA6-AS1	5.88	9.72e-09	6.02e-06	0.36	0.3	Birth weight;	chr22:41840333	chr22:42090931~42137742:+
LIHC	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	5.88	9.8e-09	6.07e-06	0.33	0.3	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	5.88	9.8e-09	6.07e-06	0.33	0.3	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	5.88	9.8e-09	6.07e-06	0.33	0.3	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	5.88	9.8e-09	6.07e-06	0.33	0.3	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	5.88	9.8e-09	6.07e-06	0.33	0.3	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	5.88	9.8e-09	6.07e-06	0.33	0.3	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	5.88	9.8e-09	6.07e-06	0.33	0.3	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
LIHC	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-5.88	9.81e-09	6.08e-06	-0.34	-0.3	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-5.88	9.82e-09	6.08e-06	-0.34	-0.3	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-5.88	9.82e-09	6.08e-06	-0.34	-0.3	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
LIHC	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-5.88	9.82e-09	6.08e-06	-0.47	-0.3	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
LIHC	cis	rs3829655	0.504	rs7251234	ENSG00000273837.1	LLNLR-470E3.1	5.88	9.82e-09	6.08e-06	0.31	0.3	Cerebrospinal fluid biomarker levels;	chr19:51614767	chr19:51639478~51639931:-
LIHC	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	5.88	9.84e-09	6.09e-06	0.34	0.3	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
LIHC	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-5.88	9.84e-09	6.09e-06	-0.51	-0.3	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
LIHC	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-5.88	9.86e-09	6.1e-06	-0.3	-0.3	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
LIHC	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-5.88	9.86e-09	6.11e-06	-0.42	-0.3	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
LIHC	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	5.88	9.89e-09	6.12e-06	0.35	0.3	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
LIHC	cis	rs2243480	1	rs383402	ENSG00000164669.11	INTS4P1	-5.88	9.91e-09	6.13e-06	-0.52	-0.3	Diabetic kidney disease;	chr7:66121666	chr7:65141225~65234216:+
LIHC	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-5.88	9.91e-09	6.13e-06	-0.33	-0.3	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
LIHC	cis	rs6686842	1	rs6686842	ENSG00000235358.1	RP11-399E6.1	5.88	9.92e-09	6.14e-06	0.33	0.3	Height;	chr1:41065199	chr1:41242373~41284861:+
LIHC	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	5.88	9.94e-09	6.15e-06	0.37	0.3	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
LIHC	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	5.88	9.96e-09	6.16e-06	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
LIHC	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	5.88	9.96e-09	6.16e-06	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
LIHC	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	5.88	9.96e-09	6.16e-06	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
LIHC	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-5.88	9.96e-09	6.16e-06	-0.39	-0.3	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
LIHC	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-5.88	9.97e-09	6.16e-06	-0.42	-0.3	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
LIHC	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-5.88	9.97e-09	6.17e-06	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
LIHC	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-5.88	1e-08	6.19e-06	-0.36	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
LIHC	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-5.87	1e-08	6.2e-06	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
LIHC	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-5.87	1e-08	6.21e-06	-0.36	-0.3	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-5.87	1e-08	6.21e-06	-0.36	-0.3	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
LIHC	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-5.87	1e-08	6.21e-06	-0.36	-0.3	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	5.87	1e-08	6.21e-06	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
LIHC	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-5.87	1.01e-08	6.25e-06	-0.43	-0.3	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
LIHC	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-5.87	1.01e-08	6.26e-06	-0.37	-0.3	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-5.87	1.01e-08	6.26e-06	-0.37	-0.3	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-5.87	1.01e-08	6.26e-06	-0.37	-0.3	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-5.87	1.02e-08	6.31e-06	-0.37	-0.3	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-5.87	1.02e-08	6.31e-06	-0.37	-0.3	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-5.87	1.02e-08	6.31e-06	-0.37	-0.3	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
LIHC	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	5.87	1.02e-08	6.32e-06	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
LIHC	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	5.87	1.03e-08	6.33e-06	0.43	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
LIHC	cis	rs4356975	0.583	rs6600877	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69091505	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600878	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69092618	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs57216626	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69093105	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs59415892	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69093191	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs62296942	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69093401	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7437039	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69093758	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7439792	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69093881	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.545	rs62296944	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69094492	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600879	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69094669	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600880	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69094762	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4554144	ENSG00000249956.3	RP11-790I12.2	5.87	1.03e-08	6.33e-06	0.34	0.3	Obesity-related traits;	chr4:69094837	chr4:69408836~69423164:+
LIHC	cis	rs12908161	0.92	rs35738019	ENSG00000259295.5	CSPG4P12	5.87	1.03e-08	6.35e-06	0.41	0.3	Schizophrenia;	chr15:84736979	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs34570071	ENSG00000259295.5	CSPG4P12	5.87	1.03e-08	6.35e-06	0.41	0.3	Schizophrenia;	chr15:84736981	chr15:85191438~85213905:+
LIHC	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	5.87	1.03e-08	6.36e-06	0.33	0.3	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
LIHC	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-5.87	1.03e-08	6.37e-06	-0.34	-0.3	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-5.87	1.03e-08	6.38e-06	-0.33	-0.3	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
LIHC	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-5.87	1.04e-08	6.38e-06	-0.37	-0.3	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-5.87	1.04e-08	6.38e-06	-0.37	-0.3	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
LIHC	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-5.87	1.04e-08	6.39e-06	-0.36	-0.3	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
LIHC	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-5.87	1.04e-08	6.39e-06	-0.33	-0.3	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
LIHC	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-5.87	1.04e-08	6.4e-06	-0.33	-0.3	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
LIHC	cis	rs4356975	0.563	rs6851533	ENSG00000249956.3	RP11-790I12.2	5.87	1.04e-08	6.41e-06	0.34	0.3	Obesity-related traits;	chr4:69113032	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7666195	ENSG00000249956.3	RP11-790I12.2	5.87	1.04e-08	6.41e-06	0.34	0.3	Obesity-related traits;	chr4:69113765	chr4:69408836~69423164:+
LIHC	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-5.87	1.04e-08	6.41e-06	-0.34	-0.3	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
LIHC	cis	rs12744310	0.731	rs12030420	ENSG00000235358.1	RP11-399E6.1	5.87	1.04e-08	6.42e-06	0.35	0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41296484	chr1:41242373~41284861:+
LIHC	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	5.87	1.04e-08	6.43e-06	0.42	0.3	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
LIHC	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	5.87	1.05e-08	6.44e-06	0.37	0.3	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	5.87	1.05e-08	6.44e-06	0.37	0.3	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	5.87	1.05e-08	6.44e-06	0.37	0.3	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
LIHC	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-5.87	1.05e-08	6.45e-06	-0.46	-0.3	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
LIHC	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-5.87	1.05e-08	6.45e-06	-0.5	-0.3	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
LIHC	cis	rs9388451	0.839	rs10457469	ENSG00000237742.5	RP11-624M8.1	-5.87	1.05e-08	6.47e-06	-0.28	-0.3	Brugada syndrome;	chr6:125762512	chr6:125578558~125749190:-
LIHC	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-5.87	1.05e-08	6.49e-06	-0.55	-0.3	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
LIHC	cis	rs1023500	0.596	rs5758562	ENSG00000237037.8	NDUFA6-AS1	5.87	1.06e-08	6.5e-06	0.37	0.3	Schizophrenia;	chr22:42052234	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.596	rs5751209	ENSG00000237037.8	NDUFA6-AS1	5.87	1.06e-08	6.5e-06	0.37	0.3	Schizophrenia;	chr22:42055599	chr22:42090931~42137742:+
LIHC	cis	rs7927592	0.673	rs498782	ENSG00000212093.1	AP000807.1	5.87	1.06e-08	6.5e-06	0.3	0.3	Total body bone mineral density;	chr11:68508383	chr11:68506083~68506166:-
LIHC	cis	rs4356975	0.563	rs6600876	ENSG00000249956.3	RP11-790I12.2	5.86	1.06e-08	6.53e-06	0.34	0.3	Obesity-related traits;	chr4:69091212	chr4:69408836~69423164:+
LIHC	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	5.86	1.06e-08	6.54e-06	0.48	0.3	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
LIHC	cis	rs4356975	0.509	rs6600884	ENSG00000249956.3	RP11-790I12.2	5.86	1.06e-08	6.55e-06	0.35	0.3	Obesity-related traits;	chr4:69102348	chr4:69408836~69423164:+
LIHC	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	5.86	1.06e-08	6.55e-06	0.38	0.3	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
LIHC	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-5.86	1.07e-08	6.56e-06	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
LIHC	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	5.86	1.07e-08	6.56e-06	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
LIHC	cis	rs1005277	0.54	rs289638	ENSG00000263064.2	RP11-291L22.7	5.86	1.07e-08	6.56e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.54	rs7903942	ENSG00000263064.2	RP11-291L22.7	-5.86	1.07e-08	6.56e-06	-0.31	-0.3	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38448689~38448949:+
LIHC	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-5.86	1.07e-08	6.57e-06	-0.35	-0.3	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
LIHC	cis	rs2243480	1	rs160643	ENSG00000164669.11	INTS4P1	5.86	1.07e-08	6.59e-06	0.49	0.3	Diabetic kidney disease;	chr7:66093235	chr7:65141225~65234216:+
LIHC	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	5.86	1.07e-08	6.6e-06	0.33	0.3	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
LIHC	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	5.86	1.08e-08	6.61e-06	0.38	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
LIHC	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	5.86	1.08e-08	6.61e-06	0.38	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
LIHC	cis	rs5758659	1	rs134869	ENSG00000227370.1	RP4-669P10.19	-5.86	1.08e-08	6.64e-06	-0.34	-0.3	Cognitive function;	chr22:42256068	chr22:42132543~42132998:+
LIHC	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	5.86	1.08e-08	6.64e-06	0.33	0.3	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	5.86	1.08e-08	6.64e-06	0.33	0.3	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	5.86	1.08e-08	6.64e-06	0.33	0.3	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	5.86	1.08e-08	6.64e-06	0.33	0.3	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
LIHC	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-5.86	1.08e-08	6.65e-06	-0.45	-0.3	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
LIHC	cis	rs7916697	0.593	rs3740587	ENSG00000233590.1	RP11-153K11.3	5.86	1.08e-08	6.65e-06	0.36	0.3	Optic disc area;	chr10:68261045	chr10:68233251~68242379:-
LIHC	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-5.86	1.08e-08	6.65e-06	-0.36	-0.3	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
LIHC	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	5.86	1.08e-08	6.65e-06	0.33	0.3	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
LIHC	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-5.86	1.08e-08	6.66e-06	-0.38	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
LIHC	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-5.86	1.09e-08	6.67e-06	-0.38	-0.3	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
LIHC	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	5.86	1.09e-08	6.68e-06	0.39	0.3	Depression;	chr6:28402301	chr6:28176188~28176674:+
LIHC	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	5.86	1.09e-08	6.71e-06	0.48	0.3	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	5.86	1.09e-08	6.71e-06	0.48	0.3	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	5.86	1.09e-08	6.71e-06	0.48	0.3	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
LIHC	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-5.86	1.1e-08	6.73e-06	-0.4	-0.3	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
LIHC	cis	rs12744310	0.697	rs12030183	ENSG00000235358.1	RP11-399E6.1	5.86	1.1e-08	6.74e-06	0.35	0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295548	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.638	rs12027245	ENSG00000235358.1	RP11-399E6.1	5.86	1.1e-08	6.74e-06	0.35	0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298791	chr1:41242373~41284861:+
LIHC	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	5.86	1.1e-08	6.76e-06	0.49	0.3	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
LIHC	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	5.86	1.1e-08	6.76e-06	0.3	0.3	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
LIHC	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	5.86	1.1e-08	6.77e-06	0.31	0.3	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
LIHC	cis	rs1023500	0.551	rs2859438	ENSG00000237037.8	NDUFA6-AS1	5.86	1.1e-08	6.78e-06	0.36	0.3	Schizophrenia;	chr22:42070976	chr22:42090931~42137742:+
LIHC	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-5.86	1.11e-08	6.79e-06	-0.36	-0.3	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-5.86	1.11e-08	6.79e-06	-0.36	-0.3	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
LIHC	cis	rs5758511	0.573	rs4501042	ENSG00000237037.8	NDUFA6-AS1	5.86	1.11e-08	6.79e-06	0.36	0.3	Birth weight;	chr22:41849759	chr22:42090931~42137742:+
LIHC	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-5.86	1.11e-08	6.79e-06	-0.39	-0.3	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
LIHC	cis	rs4356975	0.583	rs62296935	ENSG00000249956.3	RP11-790I12.2	5.86	1.11e-08	6.8e-06	0.34	0.3	Obesity-related traits;	chr4:69082878	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs62296936	ENSG00000249956.3	RP11-790I12.2	5.86	1.11e-08	6.8e-06	0.34	0.3	Obesity-related traits;	chr4:69082903	chr4:69408836~69423164:+
LIHC	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-5.86	1.11e-08	6.81e-06	-0.37	-0.3	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
LIHC	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	5.86	1.11e-08	6.82e-06	0.33	0.3	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	5.86	1.11e-08	6.82e-06	0.33	0.3	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
LIHC	cis	rs8028182	0.636	rs28783769	ENSG00000260269.4	CTD-2323K18.1	-5.86	1.11e-08	6.82e-06	-0.39	-0.3	Sudden cardiac arrest;	chr15:75556668	chr15:75527150~75601205:-
LIHC	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	5.86	1.11e-08	6.83e-06	0.35	0.3	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
LIHC	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	5.86	1.12e-08	6.84e-06	0.4	0.3	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
LIHC	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-5.86	1.12e-08	6.85e-06	-0.36	-0.3	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
LIHC	cis	rs4356975	0.563	rs11249527	ENSG00000249956.3	RP11-790I12.2	5.85	1.12e-08	6.86e-06	0.34	0.3	Obesity-related traits;	chr4:69089267	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6846298	ENSG00000249956.3	RP11-790I12.2	5.85	1.12e-08	6.86e-06	0.34	0.3	Obesity-related traits;	chr4:69089278	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs11249528	ENSG00000249956.3	RP11-790I12.2	5.85	1.12e-08	6.86e-06	0.34	0.3	Obesity-related traits;	chr4:69089337	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.545	rs55757747	ENSG00000249956.3	RP11-790I12.2	5.85	1.12e-08	6.86e-06	0.34	0.3	Obesity-related traits;	chr4:69089919	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs56217918	ENSG00000249956.3	RP11-790I12.2	5.85	1.12e-08	6.86e-06	0.34	0.3	Obesity-related traits;	chr4:69089925	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7663584	ENSG00000249956.3	RP11-790I12.2	5.85	1.12e-08	6.86e-06	0.34	0.3	Obesity-related traits;	chr4:69090392	chr4:69408836~69423164:+
LIHC	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	5.85	1.12e-08	6.87e-06	0.33	0.3	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
LIHC	cis	rs12681287	0.64	rs4587306	ENSG00000250569.1	NTAN1P2	-5.85	1.12e-08	6.87e-06	-0.36	-0.3	Caudate activity during reward;	chr8:86373282	chr8:86481754~86483002:-
LIHC	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-5.85	1.13e-08	6.9e-06	-0.42	-0.3	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
LIHC	cis	rs8028182	0.636	rs7184046	ENSG00000260269.4	CTD-2323K18.1	-5.85	1.13e-08	6.91e-06	-0.39	-0.3	Sudden cardiac arrest;	chr15:75573809	chr15:75527150~75601205:-
LIHC	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	5.85	1.13e-08	6.91e-06	0.33	0.3	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	5.85	1.13e-08	6.91e-06	0.34	0.3	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	5.85	1.13e-08	6.91e-06	0.34	0.3	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
LIHC	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-5.85	1.13e-08	6.93e-06	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
LIHC	cis	rs5769765	0.542	rs1535189	ENSG00000278869.1	CITF22-49E9.3	-5.85	1.13e-08	6.93e-06	-0.54	-0.3	Schizophrenia;	chr22:49855483	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.542	rs738707	ENSG00000278869.1	CITF22-49E9.3	-5.85	1.13e-08	6.93e-06	-0.54	-0.3	Schizophrenia;	chr22:49857179	chr22:49933198~49934074:-
LIHC	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	5.85	1.13e-08	6.93e-06	0.47	0.3	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	5.85	1.13e-08	6.93e-06	0.47	0.3	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	5.85	1.13e-08	6.93e-06	0.47	0.3	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	5.85	1.13e-08	6.93e-06	0.47	0.3	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
LIHC	cis	rs7927592	0.731	rs488381	ENSG00000212093.1	AP000807.1	-5.85	1.14e-08	6.96e-06	-0.3	-0.3	Total body bone mineral density;	chr11:68524225	chr11:68506083~68506166:-
LIHC	cis	rs7119038	0.686	rs55894437	ENSG00000255239.1	AP002954.6	-5.85	1.14e-08	6.96e-06	-0.39	-0.3	Sjögren's syndrome;	chr11:118736708	chr11:118688039~118690600:-
LIHC	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	5.85	1.14e-08	6.96e-06	0.38	0.3	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
LIHC	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	5.85	1.14e-08	6.96e-06	0.33	0.3	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	5.85	1.14e-08	6.96e-06	0.33	0.3	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
LIHC	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-5.85	1.14e-08	6.98e-06	-0.31	-0.3	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
LIHC	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-5.85	1.14e-08	6.98e-06	-0.46	-0.3	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
LIHC	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	5.85	1.15e-08	7e-06	0.39	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
LIHC	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	5.85	1.15e-08	7.02e-06	0.49	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
LIHC	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-5.85	1.15e-08	7.03e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
LIHC	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-5.85	1.15e-08	7.05e-06	-0.32	-0.3	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
LIHC	cis	rs1577917	0.883	rs13212415	ENSG00000234155.1	RP11-30P6.6	5.85	1.16e-08	7.06e-06	0.36	0.3	Response to antipsychotic treatment;	chr6:85898365	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.839	rs1447159	ENSG00000234155.1	RP11-30P6.6	5.85	1.16e-08	7.06e-06	0.36	0.3	Response to antipsychotic treatment;	chr6:85899531	chr6:85387219~85390186:-
LIHC	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	5.85	1.16e-08	7.09e-06	0.39	0.3	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
LIHC	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	5.85	1.16e-08	7.09e-06	0.36	0.3	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
LIHC	cis	rs6589219	0.866	rs4477469	ENSG00000196167.8	COLCA1	-5.85	1.16e-08	7.09e-06	-0.34	-0.3	Colorectal cancer;	chr11:111290028	chr11:111290787~111305045:-
LIHC	cis	rs4356975	0.563	rs7438135	ENSG00000249956.3	RP11-790I12.2	5.85	1.17e-08	7.11e-06	0.34	0.3	Obesity-related traits;	chr4:69095621	chr4:69408836~69423164:+
LIHC	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-5.85	1.17e-08	7.11e-06	-0.3	-0.3	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
LIHC	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-5.85	1.17e-08	7.12e-06	-0.35	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
LIHC	cis	rs12681287	0.609	rs13279850	ENSG00000250569.1	NTAN1P2	5.85	1.17e-08	7.14e-06	0.35	0.3	Caudate activity during reward;	chr8:86465571	chr8:86481754~86483002:-
LIHC	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-5.85	1.17e-08	7.15e-06	-0.39	-0.3	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	5.85	1.17e-08	7.15e-06	0.37	0.3	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
LIHC	cis	rs7396835	0.551	rs10750098	ENSG00000236267.1	AP006216.5	5.85	1.17e-08	7.16e-06	0.35	0.3	Quantitative traits;	chr11:116834852	chr11:116813204~116814003:-
LIHC	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	5.85	1.17e-08	7.17e-06	0.46	0.3	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
LIHC	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-5.85	1.18e-08	7.17e-06	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
LIHC	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
LIHC	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	5.85	1.18e-08	7.18e-06	0.37	0.3	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
LIHC	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	5.85	1.18e-08	7.18e-06	0.33	0.3	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
LIHC	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	5.85	1.18e-08	7.18e-06	0.31	0.3	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
LIHC	cis	rs4356975	0.563	rs7662029	ENSG00000249956.3	RP11-790I12.2	5.85	1.18e-08	7.19e-06	0.34	0.3	Obesity-related traits;	chr4:69096194	chr4:69408836~69423164:+
LIHC	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-5.85	1.18e-08	7.19e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
LIHC	cis	rs2522056	1	rs2106854	ENSG00000233006.5	AC034220.3	-5.84	1.18e-08	7.2e-06	-0.31	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132311285~132369916:-
LIHC	cis	rs9326248	0.53	rs7122944	ENSG00000236267.1	AP006216.5	5.84	1.19e-08	7.22e-06	0.34	0.3	Blood protein levels;	chr11:117163903	chr11:116813204~116814003:-
LIHC	cis	rs5769707	0.777	rs8141219	ENSG00000235111.1	RP1-29C18.8	-5.84	1.19e-08	7.24e-06	-0.36	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49650898	chr22:49612657~49615716:-
LIHC	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-5.84	1.19e-08	7.27e-06	-0.34	-0.3	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
LIHC	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-5.84	1.19e-08	7.27e-06	-0.37	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
LIHC	cis	rs4356975	0.583	rs6819757	ENSG00000249956.3	RP11-790I12.2	5.84	1.19e-08	7.27e-06	0.34	0.3	Obesity-related traits;	chr4:69092946	chr4:69408836~69423164:+
LIHC	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-5.84	1.2e-08	7.3e-06	-0.35	-0.3	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
LIHC	cis	rs12681287	0.64	rs7832493	ENSG00000250569.1	NTAN1P2	-5.84	1.2e-08	7.32e-06	-0.36	-0.3	Caudate activity during reward;	chr8:86359304	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs7816275	ENSG00000250569.1	NTAN1P2	-5.84	1.2e-08	7.32e-06	-0.36	-0.3	Caudate activity during reward;	chr8:86361175	chr8:86481754~86483002:-
LIHC	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	5.84	1.2e-08	7.32e-06	0.44	0.3	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
LIHC	cis	rs3096299	0.935	rs3102387	ENSG00000261118.1	RP11-104N10.1	5.84	1.2e-08	7.33e-06	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89492017~89504460:-
LIHC	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-5.84	1.21e-08	7.34e-06	-0.38	-0.3	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-5.84	1.21e-08	7.34e-06	-0.38	-0.3	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-5.84	1.21e-08	7.34e-06	-0.38	-0.3	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
LIHC	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-5.84	1.21e-08	7.35e-06	-0.36	-0.3	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
LIHC	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-5.84	1.21e-08	7.38e-06	-0.36	-0.3	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-5.84	1.21e-08	7.38e-06	-0.36	-0.3	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-5.84	1.21e-08	7.38e-06	-0.36	-0.3	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-5.84	1.21e-08	7.38e-06	-0.36	-0.3	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
LIHC	cis	rs6686842	0.965	rs1121866	ENSG00000235358.1	RP11-399E6.1	5.84	1.21e-08	7.38e-06	0.33	0.3	Height;	chr1:41242427	chr1:41242373~41284861:+
LIHC	cis	rs3096299	0.869	rs748941	ENSG00000261118.1	RP11-104N10.1	5.84	1.22e-08	7.38e-06	0.3	0.3	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89492017~89504460:-
LIHC	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-5.84	1.22e-08	7.41e-06	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
LIHC	cis	rs5758511	0.573	rs2267439	ENSG00000237037.8	NDUFA6-AS1	5.84	1.22e-08	7.44e-06	0.36	0.3	Birth weight;	chr22:41841765	chr22:42090931~42137742:+
LIHC	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-5.84	1.23e-08	7.44e-06	-0.59	-0.3	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
LIHC	cis	rs4356975	0.563	rs7441750	ENSG00000249956.3	RP11-790I12.2	5.84	1.23e-08	7.45e-06	0.33	0.3	Obesity-related traits;	chr4:69098803	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7441774	ENSG00000249956.3	RP11-790I12.2	5.84	1.23e-08	7.45e-06	0.33	0.3	Obesity-related traits;	chr4:69098836	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs7434332	ENSG00000249956.3	RP11-790I12.2	5.84	1.23e-08	7.45e-06	0.33	0.3	Obesity-related traits;	chr4:69099141	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs4293848	ENSG00000249956.3	RP11-790I12.2	5.84	1.23e-08	7.45e-06	0.33	0.3	Obesity-related traits;	chr4:69099784	chr4:69408836~69423164:+
LIHC	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-5.84	1.23e-08	7.45e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
LIHC	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-5.84	1.23e-08	7.49e-06	-0.4	-0.3	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
LIHC	cis	rs4356975	0.563	rs4455491	ENSG00000249956.3	RP11-790I12.2	5.84	1.24e-08	7.5e-06	0.33	0.3	Obesity-related traits;	chr4:69095215	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.522	rs11940220	ENSG00000249956.3	RP11-790I12.2	5.84	1.24e-08	7.5e-06	0.33	0.3	Obesity-related traits;	chr4:69095222	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs11940316	ENSG00000249956.3	RP11-790I12.2	5.84	1.24e-08	7.5e-06	0.33	0.3	Obesity-related traits;	chr4:69095409	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7668258	ENSG00000249956.3	RP11-790I12.2	5.84	1.24e-08	7.5e-06	0.33	0.3	Obesity-related traits;	chr4:69096360	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs58544196	ENSG00000249956.3	RP11-790I12.2	5.84	1.24e-08	7.5e-06	0.33	0.3	Obesity-related traits;	chr4:69097740	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7439326	ENSG00000249956.3	RP11-790I12.2	5.84	1.24e-08	7.5e-06	0.33	0.3	Obesity-related traits;	chr4:69098462	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs7438244	ENSG00000249956.3	RP11-790I12.2	5.84	1.24e-08	7.5e-06	0.33	0.3	Obesity-related traits;	chr4:69098491	chr4:69408836~69423164:+
LIHC	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-5.84	1.24e-08	7.5e-06	-0.37	-0.3	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
LIHC	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-5.84	1.24e-08	7.5e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-5.84	1.24e-08	7.5e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
LIHC	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.52e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.52e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.52e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.52e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.52e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
LIHC	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-5.84	1.24e-08	7.52e-06	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
LIHC	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.52e-06	-0.38	-0.3	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
LIHC	cis	rs12571093	0.656	rs3858147	ENSG00000233590.1	RP11-153K11.3	-5.84	1.24e-08	7.53e-06	-0.46	-0.3	Optic nerve measurement (disc area);	chr10:68253507	chr10:68233251~68242379:-
LIHC	cis	rs12681287	0.57	rs4961188	ENSG00000250569.1	NTAN1P2	-5.84	1.24e-08	7.53e-06	-0.36	-0.3	Caudate activity during reward;	chr8:86370804	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs4490816	ENSG00000250569.1	NTAN1P2	-5.84	1.24e-08	7.53e-06	-0.36	-0.3	Caudate activity during reward;	chr8:86372709	chr8:86481754~86483002:-
LIHC	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-5.84	1.24e-08	7.53e-06	-0.34	-0.3	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
LIHC	cis	rs12908161	1	rs60957376	ENSG00000259295.5	CSPG4P12	5.84	1.24e-08	7.53e-06	0.41	0.3	Schizophrenia;	chr15:84737561	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs11632465	ENSG00000259295.5	CSPG4P12	5.84	1.24e-08	7.53e-06	0.41	0.3	Schizophrenia;	chr15:84738814	chr15:85191438~85213905:+
LIHC	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	5.84	1.24e-08	7.53e-06	0.41	0.3	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
LIHC	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.53e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.53e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-5.84	1.24e-08	7.53e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
LIHC	cis	rs2998286	0.715	rs2993985	ENSG00000254635.4	WAC-AS1	-5.84	1.24e-08	7.53e-06	-0.37	-0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28510311	chr10:28522652~28532743:-
LIHC	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-5.83	1.25e-08	7.57e-06	-0.37	-0.3	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
LIHC	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	5.83	1.25e-08	7.57e-06	0.4	0.3	Depression;	chr6:28407125	chr6:28943877~28944537:+
LIHC	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-5.83	1.25e-08	7.59e-06	-0.45	-0.3	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
LIHC	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	5.83	1.26e-08	7.61e-06	0.32	0.3	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
LIHC	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	5.83	1.26e-08	7.61e-06	0.3	0.3	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
LIHC	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-5.83	1.26e-08	7.63e-06	-0.43	-0.3	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
LIHC	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	5.83	1.26e-08	7.63e-06	0.41	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
LIHC	cis	rs5758659	1	rs5751255	ENSG00000227370.1	RP4-669P10.19	-5.83	1.26e-08	7.65e-06	-0.34	-0.3	Cognitive function;	chr22:42252402	chr22:42132543~42132998:+
LIHC	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	5.83	1.27e-08	7.66e-06	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
LIHC	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-5.83	1.27e-08	7.66e-06	-0.34	-0.3	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
LIHC	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	5.83	1.27e-08	7.67e-06	0.28	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
LIHC	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-5.83	1.27e-08	7.67e-06	-0.42	-0.3	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
LIHC	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	5.83	1.27e-08	7.71e-06	0.37	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
LIHC	cis	rs6504950	0.679	rs9908752	ENSG00000275710.1	RP11-257O5.4	5.83	1.28e-08	7.72e-06	0.39	0.3	Breast cancer;	chr17:54905855	chr17:54964474~54964679:+
LIHC	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-5.83	1.28e-08	7.74e-06	-0.33	-0.3	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
LIHC	cis	rs9326248	0.53	rs2127905	ENSG00000236267.1	AP006216.5	5.83	1.28e-08	7.74e-06	0.34	0.3	Blood protein levels;	chr11:117155658	chr11:116813204~116814003:-
LIHC	cis	rs7115242	0.514	rs4936367	ENSG00000236267.1	AP006216.5	5.83	1.28e-08	7.74e-06	0.34	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.53	rs4604928	ENSG00000236267.1	AP006216.5	5.83	1.28e-08	7.74e-06	0.34	0.3	Blood protein levels;	chr11:117173487	chr11:116813204~116814003:-
LIHC	cis	rs2524005	1	rs2524005	ENSG00000181126.12	HLA-V	5.83	1.29e-08	7.77e-06	0.41	0.3	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29790954~29797811:+
LIHC	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	5.83	1.29e-08	7.77e-06	0.37	0.3	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
LIHC	cis	rs4356975	0.522	rs12647681	ENSG00000249956.3	RP11-790I12.2	5.83	1.29e-08	7.78e-06	0.33	0.3	Obesity-related traits;	chr4:69097442	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs12647682	ENSG00000249956.3	RP11-790I12.2	5.83	1.29e-08	7.78e-06	0.33	0.3	Obesity-related traits;	chr4:69097450	chr4:69408836~69423164:+
LIHC	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-5.83	1.29e-08	7.79e-06	-0.34	-0.3	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
LIHC	cis	rs34779708	0.733	rs60616028	ENSG00000230534.5	RP11-297A16.2	5.83	1.29e-08	7.8e-06	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35254874	chr10:35098006~35127020:-
LIHC	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-5.83	1.29e-08	7.8e-06	-0.35	-0.3	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-5.83	1.29e-08	7.8e-06	-0.35	-0.3	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
LIHC	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	5.83	1.29e-08	7.8e-06	0.3	0.3	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
LIHC	cis	rs5758659	0.904	rs134877	ENSG00000227370.1	RP4-669P10.19	-5.83	1.29e-08	7.81e-06	-0.33	-0.3	Cognitive function;	chr22:42266365	chr22:42132543~42132998:+
LIHC	cis	rs9527	1	rs4919690	ENSG00000236937.2	PTGES3P4	-5.83	1.3e-08	7.83e-06	-0.43	-0.3	Arsenic metabolism;	chr10:102856743	chr10:102845595~102845950:+
LIHC	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	5.83	1.3e-08	7.84e-06	0.33	0.3	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
LIHC	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-5.83	1.3e-08	7.85e-06	-0.33	-0.3	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
LIHC	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-5.83	1.3e-08	7.85e-06	-0.33	-0.3	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
LIHC	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	5.83	1.3e-08	7.85e-06	0.3	0.3	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	5.83	1.3e-08	7.85e-06	0.3	0.3	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
LIHC	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	5.83	1.3e-08	7.85e-06	0.37	0.3	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
LIHC	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-5.83	1.3e-08	7.86e-06	-0.25	-0.3	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
LIHC	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-5.83	1.3e-08	7.87e-06	-0.33	-0.3	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
LIHC	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-5.83	1.31e-08	7.91e-06	-0.37	-0.3	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
LIHC	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-5.83	1.31e-08	7.92e-06	-0.38	-0.3	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
LIHC	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-5.83	1.31e-08	7.92e-06	-0.38	-0.3	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
LIHC	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-5.83	1.31e-08	7.92e-06	-0.38	-0.3	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
LIHC	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-5.83	1.31e-08	7.92e-06	-0.38	-0.3	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
LIHC	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-5.83	1.31e-08	7.92e-06	-0.38	-0.3	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
LIHC	cis	rs7916697	0.626	rs3858144	ENSG00000233590.1	RP11-153K11.3	-5.83	1.31e-08	7.92e-06	-0.35	-0.3	Optic disc area;	chr10:68251597	chr10:68233251~68242379:-
LIHC	cis	rs4356975	0.563	rs4538548	ENSG00000249956.3	RP11-790I12.2	5.83	1.32e-08	7.93e-06	0.33	0.3	Obesity-related traits;	chr4:69094951	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600883	ENSG00000249956.3	RP11-790I12.2	5.83	1.32e-08	7.93e-06	0.33	0.3	Obesity-related traits;	chr4:69094953	chr4:69408836~69423164:+
LIHC	cis	rs5758659	0.935	rs134879	ENSG00000227370.1	RP4-669P10.19	-5.82	1.32e-08	7.95e-06	-0.33	-0.3	Cognitive function;	chr22:42268195	chr22:42132543~42132998:+
LIHC	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-5.82	1.33e-08	7.99e-06	-0.37	-0.3	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
LIHC	cis	rs4934494	0.813	rs12775783	ENSG00000232936.4	RP11-80H5.2	5.82	1.33e-08	7.99e-06	0.39	0.3	Red blood cell count;	chr10:89646494	chr10:89645282~89650667:+
LIHC	cis	rs10899021	0.512	rs10219168	ENSG00000279353.1	RP11-864N7.4	-5.82	1.33e-08	8.01e-06	-0.44	-0.3	Response to metformin (IC50);	chr11:74663408	chr11:74698231~74699658:-
LIHC	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-5.82	1.33e-08	8.01e-06	-0.37	-0.3	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
LIHC	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	5.82	1.33e-08	8.03e-06	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
LIHC	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-5.82	1.34e-08	8.04e-06	-0.34	-0.3	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
LIHC	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66692349	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66693028	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66693433	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66694214	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66701371	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66702658	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66706390	chr7:66902857~66906297:+
LIHC	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66710076	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66715944	chr7:66902857~66906297:+
LIHC	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-5.82	1.34e-08	8.04e-06	-0.37	-0.3	Gout;	chr7:66721259	chr7:66902857~66906297:+
LIHC	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	5.82	1.34e-08	8.04e-06	0.32	0.3	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
LIHC	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	5.82	1.34e-08	8.05e-06	0.37	0.3	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
LIHC	cis	rs1005277	0.505	rs7099777	ENSG00000263064.2	RP11-291L22.7	-5.82	1.34e-08	8.05e-06	-0.31	-0.3	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.505	rs1208689	ENSG00000263064.2	RP11-291L22.7	5.82	1.34e-08	8.06e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38448689~38448949:+
LIHC	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	5.82	1.34e-08	8.08e-06	0.32	0.3	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	5.82	1.34e-08	8.08e-06	0.32	0.3	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
LIHC	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-5.82	1.34e-08	8.09e-06	-0.42	-0.3	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
LIHC	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	5.82	1.35e-08	8.1e-06	0.39	0.3	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
LIHC	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-5.82	1.35e-08	8.11e-06	-0.19	-0.3	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
LIHC	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-5.82	1.35e-08	8.11e-06	-0.34	-0.3	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
LIHC	cis	rs6085948	1	rs1033603	ENSG00000238102.1	RP11-19D2.1	5.82	1.35e-08	8.12e-06	0.43	0.3	Interleukin-10 levels;	chr20:7267540	chr20:7256580~7258214:-
LIHC	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-5.82	1.35e-08	8.14e-06	-0.49	-0.3	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
LIHC	cis	rs12681287	0.64	rs7841690	ENSG00000250569.1	NTAN1P2	-5.82	1.35e-08	8.14e-06	-0.36	-0.3	Caudate activity during reward;	chr8:86353130	chr8:86481754~86483002:-
LIHC	cis	rs150992	0.631	rs79399563	ENSG00000248489.1	CTD-2007H13.3	5.82	1.36e-08	8.15e-06	0.46	0.3	Body mass index;	chr5:98993275	chr5:98929171~98995013:+
LIHC	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-5.82	1.36e-08	8.15e-06	-0.32	-0.3	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
LIHC	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	5.82	1.36e-08	8.15e-06	0.35	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
LIHC	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-5.82	1.36e-08	8.16e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
LIHC	cis	rs6940638	0.662	rs6915678	ENSG00000216901.1	AL022393.7	5.82	1.36e-08	8.16e-06	0.38	0.3	Intelligence (multi-trait analysis);	chr6:27268087	chr6:28176188~28176674:+
LIHC	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-5.82	1.36e-08	8.18e-06	-0.34	-0.3	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-5.82	1.36e-08	8.18e-06	-0.34	-0.3	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
LIHC	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	5.82	1.36e-08	8.18e-06	0.35	0.3	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
LIHC	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	5.82	1.36e-08	8.18e-06	0.35	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
LIHC	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	5.82	1.37e-08	8.2e-06	0.3	0.3	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
LIHC	cis	rs1005277	0.505	rs7917943	ENSG00000263064.2	RP11-291L22.7	-5.82	1.37e-08	8.2e-06	-0.31	-0.3	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38448689~38448949:+
LIHC	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-5.82	1.37e-08	8.22e-06	-0.35	-0.3	Height;	chr6:109501793	chr6:109382795~109383666:+
LIHC	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-5.82	1.37e-08	8.24e-06	-0.33	-0.3	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
LIHC	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-5.82	1.37e-08	8.24e-06	-0.42	-0.3	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
LIHC	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-5.82	1.37e-08	8.24e-06	-0.42	-0.3	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
LIHC	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-5.82	1.37e-08	8.25e-06	-0.37	-0.3	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
LIHC	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-5.82	1.38e-08	8.28e-06	-0.29	-0.3	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
LIHC	cis	rs2735413	0.632	rs4436790	ENSG00000276007.1	RP11-358L22.3	5.82	1.38e-08	8.29e-06	0.34	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78063355	chr16:78123243~78124332:+
LIHC	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-5.82	1.38e-08	8.29e-06	-0.36	-0.3	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
LIHC	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	5.82	1.38e-08	8.31e-06	0.33	0.3	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
LIHC	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-5.82	1.39e-08	8.31e-06	-0.51	-0.3	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-5.82	1.39e-08	8.31e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
LIHC	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	5.82	1.39e-08	8.31e-06	0.37	0.3	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
LIHC	cis	rs2998286	0.862	rs2993981	ENSG00000254635.4	WAC-AS1	-5.82	1.39e-08	8.34e-06	-0.37	-0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506552	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.862	rs2993982	ENSG00000254635.4	WAC-AS1	-5.82	1.39e-08	8.34e-06	-0.37	-0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506559	chr10:28522652~28532743:-
LIHC	cis	rs1023500	0.573	rs133381	ENSG00000237037.8	NDUFA6-AS1	5.81	1.4e-08	8.38e-06	0.36	0.3	Schizophrenia;	chr22:42074604	chr22:42090931~42137742:+
LIHC	cis	rs2522056	0.932	rs1012793	ENSG00000233006.5	AC034220.3	-5.81	1.4e-08	8.38e-06	-0.31	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132311285~132369916:-
LIHC	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	5.81	1.4e-08	8.4e-06	0.36	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
LIHC	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	5.81	1.4e-08	8.4e-06	0.39	0.3	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
LIHC	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	5.81	1.41e-08	8.45e-06	0.33	0.3	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
LIHC	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-5.81	1.41e-08	8.46e-06	-0.36	-0.3	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-5.81	1.41e-08	8.46e-06	-0.36	-0.3	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-5.81	1.41e-08	8.46e-06	-0.36	-0.3	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-5.81	1.41e-08	8.46e-06	-0.36	-0.3	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
LIHC	cis	rs9326248	0.817	rs6589598	ENSG00000236267.1	AP006216.5	5.81	1.41e-08	8.46e-06	0.3	0.3	Blood protein levels;	chr11:117131687	chr11:116813204~116814003:-
LIHC	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	5.81	1.41e-08	8.46e-06	0.35	0.3	Height;	chr6:109357369	chr6:109382795~109383666:+
LIHC	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-5.81	1.41e-08	8.46e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
LIHC	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-5.81	1.41e-08	8.47e-06	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
LIHC	cis	rs6686842	1	rs11209718	ENSG00000235358.1	RP11-399E6.1	5.81	1.42e-08	8.48e-06	0.33	0.3	Height;	chr1:41223266	chr1:41242373~41284861:+
LIHC	cis	rs6686842	1	rs12134073	ENSG00000235358.1	RP11-399E6.1	5.81	1.42e-08	8.48e-06	0.33	0.3	Height;	chr1:41223611	chr1:41242373~41284861:+
LIHC	cis	rs6686842	0.896	rs11209725	ENSG00000235358.1	RP11-399E6.1	5.81	1.42e-08	8.48e-06	0.33	0.3	Height;	chr1:41228345	chr1:41242373~41284861:+
LIHC	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-5.81	1.42e-08	8.48e-06	-0.33	-0.3	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
LIHC	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-5.81	1.42e-08	8.48e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
LIHC	cis	rs7119038	0.774	rs7945144	ENSG00000255239.1	AP002954.6	-5.81	1.42e-08	8.49e-06	-0.38	-0.3	Sjögren's syndrome;	chr11:118738007	chr11:118688039~118690600:-
LIHC	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-5.81	1.42e-08	8.49e-06	-0.32	-0.3	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
LIHC	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	5.81	1.42e-08	8.49e-06	0.33	0.3	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
LIHC	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	5.81	1.42e-08	8.5e-06	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
LIHC	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	5.81	1.42e-08	8.51e-06	0.34	0.3	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
LIHC	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-5.81	1.42e-08	8.52e-06	-0.34	-0.3	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
LIHC	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-5.81	1.42e-08	8.52e-06	-0.34	-0.3	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
LIHC	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-5.81	1.43e-08	8.54e-06	-0.34	-0.3	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
LIHC	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	5.81	1.43e-08	8.57e-06	0.33	0.3	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
LIHC	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-5.81	1.43e-08	8.57e-06	-0.35	-0.3	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
LIHC	cis	rs6061231	0.654	rs2427322	ENSG00000273619.1	RP5-908M14.9	-5.81	1.43e-08	8.57e-06	-0.25	-0.3	Colorectal cancer;	chr20:62404314	chr20:62386303~62386970:-
LIHC	cis	rs1003645	0.861	rs6505500	ENSG00000275944.1	RP11-104J23.1	5.81	1.44e-08	8.59e-06	0.32	0.3	Blood protein levels;	chr17:36019746	chr17:36001419~36011618:+
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-5.81	1.44e-08	8.59e-06	-0.35	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
LIHC	cis	rs1577917	0.793	rs9362245	ENSG00000234155.1	RP11-30P6.6	5.81	1.44e-08	8.59e-06	0.36	0.3	Response to antipsychotic treatment;	chr6:85786602	chr6:85387219~85390186:-
LIHC	cis	rs6589219	0.908	rs7130173	ENSG00000196167.8	COLCA1	-5.81	1.44e-08	8.63e-06	-0.33	-0.3	Colorectal cancer;	chr11:111283347	chr11:111290787~111305045:-
LIHC	cis	rs12908161	0.96	rs11633450	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84764056	chr15:85191438~85213905:+
LIHC	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	5.81	1.45e-08	8.64e-06	0.44	0.3	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
LIHC	cis	rs12908161	0.959	rs34028043	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84688354	chr15:85191438~85213905:+
LIHC	cis	rs12908161	0.959	rs34784022	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84688675	chr15:85191438~85213905:+
LIHC	cis	rs12908161	0.959	rs12908699	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84697172	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs35316992	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84704902	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs4643294	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84707022	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs62021219	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84712928	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs34900908	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84714368	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs35524990	ENSG00000259295.5	CSPG4P12	5.81	1.45e-08	8.64e-06	0.41	0.3	Schizophrenia;	chr15:84714972	chr15:85191438~85213905:+
LIHC	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	5.81	1.45e-08	8.64e-06	0.49	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
LIHC	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-5.81	1.45e-08	8.65e-06	-0.36	-0.3	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-5.81	1.45e-08	8.65e-06	-0.36	-0.3	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
LIHC	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-5.81	1.45e-08	8.66e-06	-0.52	-0.3	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
LIHC	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-5.81	1.45e-08	8.68e-06	-0.34	-0.3	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-5.81	1.45e-08	8.68e-06	-0.34	-0.3	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-5.81	1.45e-08	8.68e-06	-0.34	-0.3	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-5.81	1.45e-08	8.68e-06	-0.34	-0.3	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
LIHC	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	5.81	1.46e-08	8.69e-06	0.33	0.3	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
LIHC	cis	rs4934494	1	rs4934494	ENSG00000232936.4	RP11-80H5.2	5.81	1.46e-08	8.69e-06	0.37	0.3	Red blood cell count;	chr10:89687662	chr10:89645282~89650667:+
LIHC	cis	rs2762353	0.574	rs9461204	ENSG00000242387.1	HIST1H2APS2	-5.81	1.46e-08	8.69e-06	-0.39	-0.3	Blood metabolite levels;	chr6:25718238	chr6:25882026~25882395:-
LIHC	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-5.81	1.46e-08	8.71e-06	-0.36	-0.3	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
LIHC	cis	rs72627509	1	rs72627509	ENSG00000269949.1	RP11-738E22.3	5.81	1.46e-08	8.72e-06	0.41	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972885	chr4:56960927~56961373:-
LIHC	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-5.81	1.46e-08	8.72e-06	-0.48	-0.3	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
LIHC	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-5.81	1.47e-08	8.74e-06	-0.37	-0.3	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
LIHC	cis	rs2735413	0.563	rs117731654	ENSG00000276007.1	RP11-358L22.3	5.81	1.47e-08	8.75e-06	0.4	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78013450	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.563	rs72800909	ENSG00000276007.1	RP11-358L22.3	5.81	1.47e-08	8.75e-06	0.4	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78013605	chr16:78123243~78124332:+
LIHC	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-5.8	1.47e-08	8.78e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
LIHC	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	5.8	1.48e-08	8.81e-06	0.33	0.3	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
LIHC	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-5.8	1.48e-08	8.81e-06	-0.4	-0.3	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
LIHC	cis	rs6686842	1	rs2749418	ENSG00000235358.1	RP11-399E6.1	-5.8	1.48e-08	8.82e-06	-0.33	-0.3	Height;	chr1:41044002	chr1:41242373~41284861:+
LIHC	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	5.8	1.48e-08	8.82e-06	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
LIHC	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	5.8	1.48e-08	8.84e-06	0.3	0.3	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	5.8	1.48e-08	8.84e-06	0.3	0.3	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	5.8	1.48e-08	8.84e-06	0.3	0.3	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
LIHC	cis	rs6801605	1	rs6801605	ENSG00000271916.1	RP11-884K10.6	5.8	1.49e-08	8.85e-06	0.42	0.3	Blood protein levels;	chr3:53842191	chr3:53797764~53798019:-
LIHC	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-5.8	1.49e-08	8.85e-06	-0.35	-0.3	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
LIHC	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-5.8	1.49e-08	8.88e-06	-0.38	-0.3	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
LIHC	cis	rs9326248	0.53	rs7112513	ENSG00000236267.1	AP006216.5	5.8	1.49e-08	8.88e-06	0.34	0.3	Blood protein levels;	chr11:117166645	chr11:116813204~116814003:-
LIHC	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-5.8	1.49e-08	8.88e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
LIHC	cis	rs645901	1	rs645901	ENSG00000254851.1	RP11-109L13.1	-5.8	1.5e-08	8.9e-06	-0.38	-0.3	Plateletcrit;	chr11:116831646	chr11:117135528~117138582:+
LIHC	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-5.8	1.5e-08	8.95e-06	-0.32	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
LIHC	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	5.8	1.51e-08	8.95e-06	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
LIHC	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	8.95e-06	-0.37	-0.3	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
LIHC	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-5.8	1.51e-08	8.97e-06	-0.44	-0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
LIHC	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-5.8	1.51e-08	8.98e-06	-0.34	-0.3	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-5.8	1.51e-08	8.98e-06	-0.34	-0.3	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-5.8	1.51e-08	8.98e-06	-0.34	-0.3	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
LIHC	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	5.8	1.51e-08	8.99e-06	0.33	0.3	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
LIHC	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	5.8	1.51e-08	8.99e-06	0.44	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
LIHC	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	5.8	1.51e-08	8.99e-06	0.44	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
LIHC	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	5.8	1.51e-08	8.99e-06	0.45	0.3	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
LIHC	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-5.8	1.51e-08	8.99e-06	-0.38	-0.3	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
LIHC	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-5.8	1.51e-08	9e-06	-0.35	-0.3	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
LIHC	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-5.8	1.51e-08	9e-06	-0.36	-0.3	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
LIHC	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	5.8	1.52e-08	9.03e-06	0.33	0.3	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
LIHC	cis	rs9341808	0.754	rs3805885	ENSG00000272129.1	RP11-250B2.6	-5.8	1.52e-08	9.03e-06	-0.29	-0.3	Sitting height ratio;	chr6:80287034	chr6:80355424~80356859:+
LIHC	cis	rs12744310	0.666	rs34762587	ENSG00000235358.1	RP11-399E6.1	5.8	1.54e-08	9.13e-06	0.35	0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41286793	chr1:41242373~41284861:+
LIHC	cis	rs1005277	0.522	rs289645	ENSG00000263064.2	RP11-291L22.7	5.8	1.54e-08	9.16e-06	0.31	0.3	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38448689~38448949:+
LIHC	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-5.8	1.54e-08	9.17e-06	-0.31	-0.3	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
LIHC	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	5.8	1.55e-08	9.19e-06	0.4	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-5.79	1.55e-08	9.22e-06	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
LIHC	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-5.79	1.56e-08	9.27e-06	-0.35	-0.3	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
LIHC	cis	rs9388451	0.874	rs9398787	ENSG00000237742.5	RP11-624M8.1	-5.79	1.56e-08	9.27e-06	-0.28	-0.3	Brugada syndrome;	chr6:125769462	chr6:125578558~125749190:-
LIHC	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	5.79	1.56e-08	9.27e-06	0.33	0.3	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	5.79	1.56e-08	9.27e-06	0.33	0.3	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
LIHC	cis	rs12681287	0.64	rs12544463	ENSG00000250569.1	NTAN1P2	5.79	1.56e-08	9.27e-06	0.35	0.3	Caudate activity during reward;	chr8:86468885	chr8:86481754~86483002:-
LIHC	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-5.79	1.57e-08	9.29e-06	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
LIHC	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-5.79	1.57e-08	9.29e-06	-0.33	-0.3	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
LIHC	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	5.79	1.57e-08	9.29e-06	0.36	0.3	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
LIHC	cis	rs523522	0.892	rs4767916	ENSG00000278344.1	RP11-18C24.8	5.79	1.57e-08	9.29e-06	0.36	0.3	High light scatter reticulocyte count;	chr12:120586229	chr12:120500735~120501090:-
LIHC	cis	rs523522	0.926	rs10849766	ENSG00000278344.1	RP11-18C24.8	5.79	1.57e-08	9.29e-06	0.36	0.3	High light scatter reticulocyte count;	chr12:120588091	chr12:120500735~120501090:-
LIHC	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	5.79	1.57e-08	9.3e-06	0.33	0.3	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
LIHC	cis	rs7115242	1	rs7115242	ENSG00000236267.1	AP006216.5	-5.79	1.57e-08	9.31e-06	-0.38	-0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:116813204~116814003:-
LIHC	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-5.79	1.58e-08	9.36e-06	-0.49	-0.3	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
LIHC	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-5.79	1.58e-08	9.36e-06	-0.35	-0.3	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
LIHC	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-5.79	1.58e-08	9.37e-06	-0.31	-0.3	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-5.79	1.58e-08	9.37e-06	-0.3	-0.3	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
LIHC	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-5.79	1.58e-08	9.39e-06	-0.38	-0.3	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
LIHC	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-5.79	1.58e-08	9.39e-06	-0.31	-0.3	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
LIHC	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-5.79	1.59e-08	9.4e-06	-0.37	-0.3	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-5.79	1.59e-08	9.4e-06	-0.37	-0.3	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
LIHC	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-5.79	1.59e-08	9.42e-06	-0.36	-0.3	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
LIHC	cis	rs5758511	0.573	rs1569451	ENSG00000237037.8	NDUFA6-AS1	5.79	1.59e-08	9.44e-06	0.35	0.3	Birth weight;	chr22:41836287	chr22:42090931~42137742:+
LIHC	cis	rs9549367	0.804	rs9549704	ENSG00000269125.1	RP11-98F14.11	-5.79	1.59e-08	9.45e-06	-0.38	-0.3	Platelet distribution width;	chr13:113230873	chr13:113165002~113165183:-
LIHC	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	5.79	1.6e-08	9.45e-06	0.32	0.3	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
LIHC	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	5.79	1.6e-08	9.47e-06	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
LIHC	cis	rs3808502	0.527	rs2736374	ENSG00000255394.4	C8orf49	-5.79	1.6e-08	9.47e-06	-0.42	-0.3	Neuroticism;	chr8:11256319	chr8:11761256~11763223:+
LIHC	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-5.79	1.6e-08	9.48e-06	-0.51	-0.3	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
LIHC	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-5.79	1.6e-08	9.48e-06	-0.51	-0.3	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
LIHC	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	5.79	1.61e-08	9.51e-06	0.38	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
LIHC	cis	rs2522056	0.808	rs2706373	ENSG00000233006.5	AC034220.3	-5.79	1.61e-08	9.51e-06	-0.31	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132468564	chr5:132311285~132369916:-
LIHC	cis	rs2522056	1	rs2522062	ENSG00000233006.5	AC034220.3	-5.79	1.61e-08	9.51e-06	-0.31	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132469724	chr5:132311285~132369916:-
LIHC	cis	rs2522056	1	rs2522063	ENSG00000233006.5	AC034220.3	-5.79	1.61e-08	9.51e-06	-0.31	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132469899	chr5:132311285~132369916:-
LIHC	cis	rs2522056	1	rs2706379	ENSG00000233006.5	AC034220.3	-5.79	1.61e-08	9.51e-06	-0.31	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132470043	chr5:132311285~132369916:-
LIHC	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	5.79	1.61e-08	9.53e-06	0.47	0.3	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	5.79	1.61e-08	9.53e-06	0.47	0.3	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
LIHC	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-5.79	1.61e-08	9.53e-06	-0.38	-0.3	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
LIHC	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-5.79	1.61e-08	9.53e-06	-0.38	-0.3	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
LIHC	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	5.79	1.61e-08	9.54e-06	0.35	0.3	Height;	chr6:109391084	chr6:109382795~109383666:+
LIHC	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-5.79	1.62e-08	9.55e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-5.79	1.62e-08	9.55e-06	-0.36	-0.3	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
LIHC	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-5.79	1.62e-08	9.56e-06	-0.32	-0.3	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
LIHC	cis	rs9341808	0.754	rs3812126	ENSG00000272129.1	RP11-250B2.6	-5.79	1.62e-08	9.56e-06	-0.29	-0.3	Sitting height ratio;	chr6:80242984	chr6:80355424~80356859:+
LIHC	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	5.79	1.62e-08	9.57e-06	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
LIHC	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-5.79	1.62e-08	9.59e-06	-0.36	-0.3	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
LIHC	cis	rs2565722	0.508	rs1620969	ENSG00000243831.1	RP1-81D8.4	-5.79	1.63e-08	9.61e-06	-0.4	-0.3	Blood protein levels;	chr6:160776036	chr6:160666228~160676523:-
LIHC	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-5.79	1.63e-08	9.61e-06	-0.33	-0.3	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
LIHC	cis	rs9326248	0.861	rs4938343	ENSG00000236267.1	AP006216.5	5.79	1.63e-08	9.62e-06	0.31	0.3	Blood protein levels;	chr11:117132812	chr11:116813204~116814003:-
LIHC	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-5.79	1.63e-08	9.63e-06	-0.48	-0.3	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
LIHC	cis	rs9388451	0.839	rs3799709	ENSG00000237742.5	RP11-624M8.1	-5.79	1.63e-08	9.63e-06	-0.27	-0.3	Brugada syndrome;	chr6:125757215	chr6:125578558~125749190:-
LIHC	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	5.79	1.64e-08	9.66e-06	0.43	0.3	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
LIHC	cis	rs17301013	0.507	rs2760057	ENSG00000227373.4	RP11-160H22.5	5.79	1.64e-08	9.67e-06	0.5	0.3	Systemic lupus erythematosus;	chr1:174743384	chr1:174115300~174160004:-
LIHC	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	5.78	1.64e-08	9.67e-06	0.32	0.3	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
LIHC	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	5.78	1.64e-08	9.67e-06	0.33	0.3	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
LIHC	cis	rs1005277	0.54	rs1814077	ENSG00000263064.2	RP11-291L22.7	5.78	1.64e-08	9.69e-06	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38448689~38448949:+
LIHC	cis	rs9326248	0.861	rs7120309	ENSG00000236267.1	AP006216.5	5.78	1.65e-08	9.72e-06	0.31	0.3	Blood protein levels;	chr11:117172100	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.861	rs7120449	ENSG00000236267.1	AP006216.5	5.78	1.65e-08	9.72e-06	0.31	0.3	Blood protein levels;	chr11:117172183	chr11:116813204~116814003:-
LIHC	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	5.78	1.65e-08	9.72e-06	0.39	0.3	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	5.78	1.65e-08	9.72e-06	0.39	0.3	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	5.78	1.65e-08	9.72e-06	0.39	0.3	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
LIHC	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-5.78	1.65e-08	9.73e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-5.78	1.65e-08	9.73e-06	-0.37	-0.3	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
LIHC	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-5.78	1.65e-08	9.75e-06	-0.51	-0.3	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
LIHC	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-5.78	1.65e-08	9.75e-06	-0.5	-0.3	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
LIHC	cis	rs5769707	0.681	rs9616329	ENSG00000235111.1	RP1-29C18.8	-5.78	1.66e-08	9.77e-06	-0.35	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49612657~49615716:-
LIHC	cis	rs2243480	1	rs422164	ENSG00000164669.11	INTS4P1	5.78	1.66e-08	9.77e-06	0.51	0.3	Diabetic kidney disease;	chr7:66121618	chr7:65141225~65234216:+
LIHC	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	5.78	1.66e-08	9.79e-06	0.33	0.3	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	5.78	1.66e-08	9.79e-06	0.33	0.3	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	5.78	1.66e-08	9.79e-06	0.33	0.3	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	5.78	1.66e-08	9.79e-06	0.33	0.3	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	5.78	1.66e-08	9.79e-06	0.33	0.3	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
LIHC	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-5.78	1.67e-08	9.8e-06	-0.36	-0.3	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
LIHC	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	5.78	1.67e-08	9.8e-06	0.33	0.3	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
LIHC	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	5.78	1.67e-08	9.84e-06	0.44	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
LIHC	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-5.78	1.68e-08	9.87e-06	-0.25	-0.3	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
LIHC	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-5.78	1.68e-08	9.87e-06	-0.25	-0.3	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
LIHC	cis	rs4356975	0.563	rs7676472	ENSG00000249956.3	RP11-790I12.2	5.78	1.68e-08	9.9e-06	0.33	0.3	Obesity-related traits;	chr4:69090226	chr4:69408836~69423164:+
LIHC	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	5.78	1.69e-08	9.91e-06	0.35	0.3	Height;	chr6:109367528	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	5.78	1.69e-08	9.91e-06	0.35	0.3	Height;	chr6:109368704	chr6:109382795~109383666:+
LIHC	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-5.78	1.69e-08	9.92e-06	-0.47	-0.3	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
LIHC	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-5.78	1.69e-08	9.92e-06	-0.34	-0.3	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
LIHC	cis	rs2735413	0.563	rs11640933	ENSG00000276007.1	RP11-358L22.3	5.78	1.69e-08	9.93e-06	0.42	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78031710	chr16:78123243~78124332:+
LIHC	cis	rs7131987	0.903	rs7308125	ENSG00000257176.2	RP11-996F15.2	-5.78	1.7e-08	9.97e-06	-0.34	-0.3	QT interval;	chr12:29272278	chr12:29280418~29317848:-
LIHC	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	5.78	1.7e-08	9.97e-06	0.4	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
LIHC	cis	rs6589219	0.954	rs3802840	ENSG00000196167.8	COLCA1	5.78	1.7e-08	1e-05	0.33	0.3	Colorectal cancer;	chr11:111300921	chr11:111290787~111305045:-
LIHC	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-5.78	1.71e-08	1e-05	-0.3	-0.3	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
LIHC	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	5.78	1.71e-08	1e-05	0.33	0.3	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
LIHC	cis	rs12681287	0.64	rs6471309	ENSG00000250569.1	NTAN1P2	5.78	1.71e-08	1.01e-05	0.36	0.3	Caudate activity during reward;	chr8:86375531	chr8:86481754~86483002:-
LIHC	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-5.78	1.71e-08	1.01e-05	-0.38	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
LIHC	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-5.78	1.71e-08	1.01e-05	-0.32	-0.3	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
LIHC	cis	rs12681287	0.673	rs4464946	ENSG00000250569.1	NTAN1P2	5.78	1.72e-08	1.01e-05	0.36	0.3	Caudate activity during reward;	chr8:86314030	chr8:86481754~86483002:-
LIHC	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-5.78	1.72e-08	1.01e-05	-0.39	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
LIHC	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.78	1.72e-08	1.01e-05	0.35	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
LIHC	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-5.78	1.72e-08	1.01e-05	-0.32	-0.3	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
LIHC	cis	rs9341808	0.727	rs9352809	ENSG00000272129.1	RP11-250B2.6	5.78	1.72e-08	1.01e-05	0.29	0.3	Sitting height ratio;	chr6:80289599	chr6:80355424~80356859:+
LIHC	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-5.78	1.72e-08	1.01e-05	-0.38	-0.3	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
LIHC	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.78	1.72e-08	1.01e-05	0.3	0.3	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	5.78	1.72e-08	1.01e-05	0.33	0.3	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	5.78	1.72e-08	1.01e-05	0.33	0.3	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
LIHC	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	5.78	1.73e-08	1.01e-05	0.34	0.3	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
LIHC	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	5.78	1.73e-08	1.01e-05	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
LIHC	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-5.78	1.73e-08	1.01e-05	-0.49	-0.3	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
LIHC	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	5.78	1.73e-08	1.01e-05	0.48	0.3	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	5.78	1.73e-08	1.01e-05	0.48	0.3	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	5.78	1.73e-08	1.01e-05	0.48	0.3	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	5.78	1.73e-08	1.01e-05	0.48	0.3	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
LIHC	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-5.78	1.73e-08	1.01e-05	-0.43	-0.3	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
LIHC	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	5.77	1.73e-08	1.01e-05	0.35	0.3	Height;	chr6:109390638	chr6:109382795~109383666:+
LIHC	cis	rs1577917	0.959	rs2816822	ENSG00000234155.1	RP11-30P6.6	5.77	1.73e-08	1.01e-05	0.36	0.3	Response to antipsychotic treatment;	chr6:85948574	chr6:85387219~85390186:-
LIHC	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-5.77	1.73e-08	1.01e-05	-0.44	-0.3	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
LIHC	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	5.77	1.74e-08	1.02e-05	0.41	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000206090.4	AP000350.7	5.77	1.74e-08	1.02e-05	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23939998~23942798:+
LIHC	cis	rs6589219	0.954	rs4520624	ENSG00000196167.8	COLCA1	-5.77	1.74e-08	1.02e-05	-0.34	-0.3	Colorectal cancer;	chr11:111301485	chr11:111290787~111305045:-
LIHC	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	5.77	1.74e-08	1.02e-05	0.39	0.3	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
LIHC	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-5.77	1.74e-08	1.02e-05	-0.32	-0.3	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-5.77	1.74e-08	1.02e-05	-0.32	-0.3	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
LIHC	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	5.77	1.75e-08	1.02e-05	0.39	0.3	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
LIHC	cis	rs739496	0.843	rs598711	ENSG00000226469.1	ADAM1B	5.77	1.75e-08	1.03e-05	0.37	0.3	Platelet count;	chr12:111535336	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs598710	ENSG00000226469.1	ADAM1B	5.77	1.75e-08	1.03e-05	0.37	0.3	Platelet count;	chr12:111535337	chr12:111927018~111929017:+
LIHC	cis	rs10833905	0.641	rs11026854	ENSG00000246225.5	RP11-17A1.3	-5.77	1.75e-08	1.03e-05	-0.39	-0.3	Sudden cardiac arrest;	chr11:22940325	chr11:22829380~22945393:+
LIHC	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-5.77	1.76e-08	1.03e-05	-0.35	-0.3	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-5.77	1.76e-08	1.03e-05	-0.35	-0.3	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-5.77	1.76e-08	1.03e-05	-0.35	-0.3	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-5.77	1.76e-08	1.03e-05	-0.35	-0.3	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-5.77	1.76e-08	1.03e-05	-0.35	-0.3	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
LIHC	cis	rs8028182	0.636	rs4886716	ENSG00000260269.4	CTD-2323K18.1	-5.77	1.76e-08	1.03e-05	-0.39	-0.3	Sudden cardiac arrest;	chr15:75563681	chr15:75527150~75601205:-
LIHC	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-5.77	1.76e-08	1.03e-05	-0.32	-0.3	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
LIHC	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	5.77	1.76e-08	1.03e-05	0.36	0.3	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-5.77	1.76e-08	1.03e-05	-0.36	-0.3	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
LIHC	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-5.77	1.76e-08	1.03e-05	-0.23	-0.3	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
LIHC	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-5.77	1.76e-08	1.03e-05	-0.4	-0.3	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
LIHC	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	5.77	1.76e-08	1.03e-05	0.43	0.3	Height;	chr6:109573151	chr6:109382795~109383666:+
LIHC	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-5.77	1.77e-08	1.03e-05	-0.37	-0.3	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-5.77	1.77e-08	1.03e-05	-0.37	-0.3	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-5.77	1.77e-08	1.03e-05	-0.37	-0.3	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-5.77	1.77e-08	1.03e-05	-0.37	-0.3	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-5.77	1.77e-08	1.03e-05	-0.37	-0.3	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
LIHC	cis	rs11098499	1	rs1011054	ENSG00000260091.1	RP11-33B1.4	5.77	1.77e-08	1.04e-05	0.22	0.3	Corneal astigmatism;	chr4:119281232	chr4:119409333~119410233:+
LIHC	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	5.77	1.78e-08	1.04e-05	0.4	0.3	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
LIHC	cis	rs12681287	0.547	rs6471360	ENSG00000250569.1	NTAN1P2	-5.77	1.78e-08	1.04e-05	-0.36	-0.3	Caudate activity during reward;	chr8:86501240	chr8:86481754~86483002:-
LIHC	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	5.77	1.78e-08	1.04e-05	0.3	0.3	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
LIHC	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	5.77	1.78e-08	1.04e-05	0.3	0.3	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
LIHC	cis	rs4356975	0.563	rs7685151	ENSG00000249956.3	RP11-790I12.2	5.77	1.78e-08	1.04e-05	0.33	0.3	Obesity-related traits;	chr4:69114055	chr4:69408836~69423164:+
LIHC	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	5.77	1.78e-08	1.04e-05	0.39	0.3	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
LIHC	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	5.77	1.78e-08	1.04e-05	0.33	0.3	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
LIHC	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	5.77	1.79e-08	1.04e-05	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
LIHC	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-5.77	1.79e-08	1.04e-05	-0.34	-0.3	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
LIHC	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	5.77	1.79e-08	1.05e-05	0.33	0.3	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	5.77	1.79e-08	1.05e-05	0.33	0.3	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
LIHC	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	5.77	1.79e-08	1.05e-05	0.41	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
LIHC	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-5.77	1.8e-08	1.05e-05	-0.35	-0.3	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
LIHC	cis	rs2998286	0.862	rs2807728	ENSG00000254635.4	WAC-AS1	5.77	1.8e-08	1.05e-05	0.36	0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526504	chr10:28522652~28532743:-
LIHC	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	5.77	1.8e-08	1.05e-05	0.36	0.3	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
LIHC	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	5.77	1.8e-08	1.05e-05	0.39	0.3	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	5.77	1.8e-08	1.05e-05	0.39	0.3	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
LIHC	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-5.77	1.8e-08	1.05e-05	-0.33	-0.3	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
LIHC	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	5.77	1.8e-08	1.05e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
LIHC	cis	rs9326248	0.53	rs1242229	ENSG00000280143.1	AP000892.6	5.77	1.8e-08	1.05e-05	0.38	0.3	Blood protein levels;	chr11:117191654	chr11:117204967~117210292:+
LIHC	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-5.77	1.81e-08	1.05e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
LIHC	cis	rs7115242	0.8	rs7131536	ENSG00000236267.1	AP006216.5	5.77	1.81e-08	1.05e-05	0.33	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:116813204~116814003:-
LIHC	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	5.77	1.81e-08	1.05e-05	0.34	0.3	Height;	chr6:109454233	chr6:109382795~109383666:+
LIHC	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	5.77	1.81e-08	1.05e-05	0.33	0.3	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	5.77	1.81e-08	1.05e-05	0.33	0.3	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	5.77	1.81e-08	1.05e-05	0.33	0.3	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	5.77	1.81e-08	1.05e-05	0.33	0.3	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	5.77	1.81e-08	1.05e-05	0.33	0.3	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
LIHC	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-5.77	1.81e-08	1.06e-05	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
LIHC	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	5.77	1.82e-08	1.06e-05	0.47	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
LIHC	cis	rs4356975	0.563	rs4508963	ENSG00000249956.3	RP11-790I12.2	5.77	1.82e-08	1.06e-05	0.34	0.3	Obesity-related traits;	chr4:69118770	chr4:69408836~69423164:+
LIHC	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-5.77	1.82e-08	1.06e-05	-0.49	-0.3	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
LIHC	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-5.77	1.82e-08	1.06e-05	-0.38	-0.3	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
LIHC	cis	rs2735413	0.564	rs73580867	ENSG00000276007.1	RP11-358L22.3	5.77	1.82e-08	1.06e-05	0.4	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78087056	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.564	rs8051817	ENSG00000276007.1	RP11-358L22.3	5.77	1.82e-08	1.06e-05	0.4	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78087357	chr16:78123243~78124332:+
LIHC	cis	rs13068223	0.503	rs34277251	ENSG00000243926.1	TIPARP-AS1	5.77	1.82e-08	1.06e-05	0.28	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156671862~156674378:-
LIHC	cis	rs1003645	0.861	rs7222703	ENSG00000275944.1	RP11-104J23.1	5.77	1.82e-08	1.06e-05	0.32	0.3	Blood protein levels;	chr17:36014155	chr17:36001419~36011618:+
LIHC	cis	rs1003645	0.906	rs8065543	ENSG00000275944.1	RP11-104J23.1	5.77	1.82e-08	1.06e-05	0.32	0.3	Blood protein levels;	chr17:36014962	chr17:36001419~36011618:+
LIHC	cis	rs12908161	1	rs12911736	ENSG00000259295.5	CSPG4P12	5.76	1.83e-08	1.07e-05	0.41	0.3	Schizophrenia;	chr15:84696777	chr15:85191438~85213905:+
LIHC	cis	rs6589219	1	rs6589220	ENSG00000196167.8	COLCA1	-5.76	1.83e-08	1.07e-05	-0.34	-0.3	Colorectal cancer;	chr11:111302565	chr11:111290787~111305045:-
LIHC	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	5.76	1.83e-08	1.07e-05	0.34	0.3	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
LIHC	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-5.76	1.83e-08	1.07e-05	-0.27	-0.3	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
LIHC	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	5.76	1.84e-08	1.07e-05	0.35	0.3	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
LIHC	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-5.76	1.84e-08	1.07e-05	-0.37	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-5.76	1.85e-08	1.08e-05	-0.37	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
LIHC	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-5.76	1.85e-08	1.08e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
LIHC	cis	rs17711722	0.565	rs73372653	ENSG00000228409.4	CCT6P1	-5.76	1.85e-08	1.08e-05	-0.24	-0.3	Calcium levels;	chr7:65977808	chr7:65751142~65763354:+
LIHC	cis	rs9326248	0.53	rs6589576	ENSG00000236267.1	AP006216.5	-5.76	1.85e-08	1.08e-05	-0.33	-0.3	Blood protein levels;	chr11:116865072	chr11:116813204~116814003:-
LIHC	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	5.76	1.85e-08	1.08e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	5.76	1.85e-08	1.08e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	5.76	1.85e-08	1.08e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	5.76	1.85e-08	1.08e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	5.76	1.85e-08	1.08e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	5.76	1.85e-08	1.08e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
LIHC	cis	rs4356975	0.583	rs11936822	ENSG00000249956.3	RP11-790I12.2	5.76	1.86e-08	1.08e-05	0.33	0.3	Obesity-related traits;	chr4:69114229	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs34814736	ENSG00000249956.3	RP11-790I12.2	5.76	1.86e-08	1.08e-05	0.33	0.3	Obesity-related traits;	chr4:69114760	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs11933459	ENSG00000249956.3	RP11-790I12.2	5.76	1.86e-08	1.08e-05	0.33	0.3	Obesity-related traits;	chr4:69116045	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600895	ENSG00000249956.3	RP11-790I12.2	5.76	1.86e-08	1.08e-05	0.33	0.3	Obesity-related traits;	chr4:69117694	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs12505466	ENSG00000249956.3	RP11-790I12.2	5.76	1.86e-08	1.08e-05	0.33	0.3	Obesity-related traits;	chr4:69119944	chr4:69408836~69423164:+
LIHC	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-5.76	1.86e-08	1.08e-05	-0.33	-0.3	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
LIHC	cis	rs739496	0.843	rs10774629	ENSG00000226469.1	ADAM1B	-5.76	1.86e-08	1.08e-05	-0.37	-0.3	Platelet count;	chr12:111582410	chr12:111927018~111929017:+
LIHC	cis	rs1577917	0.804	rs2786854	ENSG00000234155.1	RP11-30P6.6	5.76	1.86e-08	1.08e-05	0.36	0.3	Response to antipsychotic treatment;	chr6:85959022	chr6:85387219~85390186:-
LIHC	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-5.76	1.87e-08	1.09e-05	-0.49	-0.3	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
LIHC	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-5.76	1.88e-08	1.09e-05	-0.36	-0.3	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-5.76	1.88e-08	1.09e-05	-0.36	-0.3	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
LIHC	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	5.76	1.88e-08	1.09e-05	0.33	0.3	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
LIHC	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.76	1.89e-08	1.1e-05	-0.38	-0.3	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
LIHC	cis	rs17301013	0.861	rs2038025	ENSG00000227373.4	RP11-160H22.5	5.76	1.89e-08	1.1e-05	0.38	0.3	Systemic lupus erythematosus;	chr1:174574712	chr1:174115300~174160004:-
LIHC	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-5.76	1.89e-08	1.1e-05	-0.42	-0.3	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000206090.4	AP000350.7	5.76	1.89e-08	1.1e-05	0.35	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23939998~23942798:+
LIHC	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	5.76	1.89e-08	1.1e-05	0.38	0.3	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
LIHC	cis	rs5769765	0.646	rs9627789	ENSG00000278869.1	CITF22-49E9.3	5.76	1.9e-08	1.1e-05	0.47	0.3	Schizophrenia;	chr22:49906914	chr22:49933198~49934074:-
LIHC	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-5.76	1.9e-08	1.1e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
LIHC	cis	rs5769707	0.632	rs135872	ENSG00000235111.1	RP1-29C18.8	-5.76	1.9e-08	1.1e-05	-0.36	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49612657~49615716:-
LIHC	cis	rs6589219	0.908	rs10789822	ENSG00000196167.8	COLCA1	-5.76	1.9e-08	1.1e-05	-0.33	-0.3	Colorectal cancer;	chr11:111291966	chr11:111290787~111305045:-
LIHC	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-5.76	1.9e-08	1.1e-05	-0.27	-0.3	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
LIHC	cis	rs5769707	0.681	rs916360	ENSG00000235111.1	RP1-29C18.8	-5.76	1.91e-08	1.11e-05	-0.36	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49612657~49615716:-
LIHC	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-5.76	1.91e-08	1.11e-05	-0.33	-0.3	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
LIHC	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	5.76	1.92e-08	1.11e-05	0.47	0.3	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
LIHC	cis	rs9388451	0.874	rs1159974	ENSG00000237742.5	RP11-624M8.1	5.76	1.92e-08	1.11e-05	0.27	0.3	Brugada syndrome;	chr6:125769131	chr6:125578558~125749190:-
LIHC	cis	rs2933343	0.621	rs6764682	ENSG00000231305.3	RP11-723O4.2	-5.76	1.92e-08	1.11e-05	-0.33	-0.3	IgG glycosylation;	chr3:128849540	chr3:128861313~128871540:-
LIHC	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	5.76	1.92e-08	1.11e-05	0.39	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
LIHC	cis	rs1029738	0.659	rs1608553	ENSG00000228649.7	AC005682.5	5.76	1.92e-08	1.11e-05	0.35	0.3	Fibrinogen levels;	chr7:22856612	chr7:22854178~22861579:+
LIHC	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-5.75	1.93e-08	1.12e-05	-0.5	-0.3	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
LIHC	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	5.75	1.93e-08	1.12e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	5.75	1.93e-08	1.12e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	5.75	1.93e-08	1.12e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	5.75	1.93e-08	1.12e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	5.75	1.93e-08	1.12e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
LIHC	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-5.75	1.94e-08	1.12e-05	-0.33	-0.3	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-5.75	1.94e-08	1.12e-05	-0.33	-0.3	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-5.75	1.94e-08	1.12e-05	-0.33	-0.3	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
LIHC	cis	rs7824557	0.564	rs13260727	ENSG00000255394.4	C8orf49	5.75	1.94e-08	1.12e-05	0.42	0.3	Retinal vascular caliber;	chr8:11375351	chr8:11761256~11763223:+
LIHC	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	5.75	1.94e-08	1.12e-05	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
LIHC	cis	rs12291225	0.585	rs10832246	ENSG00000251991.1	RNU7-49P	5.75	1.94e-08	1.12e-05	0.31	0.3	Sense of smell;	chr11:14359282	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.585	rs11023197	ENSG00000251991.1	RNU7-49P	5.75	1.94e-08	1.12e-05	0.31	0.3	Sense of smell;	chr11:14359452	chr11:14478892~14478953:+
LIHC	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	5.75	1.94e-08	1.12e-05	0.37	0.3	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
LIHC	cis	rs1577917	0.92	rs1337842	ENSG00000234155.1	RP11-30P6.6	5.75	1.95e-08	1.13e-05	0.36	0.3	Response to antipsychotic treatment;	chr6:85965379	chr6:85387219~85390186:-
LIHC	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-5.75	1.95e-08	1.13e-05	-0.33	-0.3	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-5.75	1.95e-08	1.13e-05	-0.33	-0.3	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
LIHC	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	5.75	1.95e-08	1.13e-05	0.37	0.3	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
LIHC	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-5.75	1.95e-08	1.13e-05	-0.37	-0.3	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
LIHC	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	5.75	1.96e-08	1.14e-05	0.32	0.3	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
LIHC	cis	rs2998286	0.862	rs2807740	ENSG00000254635.4	WAC-AS1	-5.75	1.97e-08	1.14e-05	-0.36	-0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28495554	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.862	rs2807738	ENSG00000254635.4	WAC-AS1	-5.75	1.97e-08	1.14e-05	-0.36	-0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28496479	chr10:28522652~28532743:-
LIHC	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-5.75	1.97e-08	1.14e-05	-0.36	-0.3	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-5.75	1.97e-08	1.14e-05	-0.36	-0.3	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-5.75	1.97e-08	1.14e-05	-0.36	-0.3	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
LIHC	cis	rs9326248	0.813	rs7115562	ENSG00000236267.1	AP006216.5	5.75	1.97e-08	1.14e-05	0.31	0.3	Blood protein levels;	chr11:117149754	chr11:116813204~116814003:-
LIHC	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-5.75	1.98e-08	1.14e-05	-0.43	-0.3	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
LIHC	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	5.75	1.99e-08	1.15e-05	0.43	0.3	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
LIHC	cis	rs2998286	0.784	rs2993987	ENSG00000254635.4	WAC-AS1	-5.75	1.99e-08	1.15e-05	-0.37	-0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28511241	chr10:28522652~28532743:-
LIHC	cis	rs12681287	0.517	rs13249753	ENSG00000250569.1	NTAN1P2	5.75	1.99e-08	1.15e-05	0.35	0.3	Caudate activity during reward;	chr8:86500987	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs10956786	ENSG00000250569.1	NTAN1P2	5.75	1.99e-08	1.15e-05	0.37	0.3	Caudate activity during reward;	chr8:86289008	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs10112123	ENSG00000250569.1	NTAN1P2	5.75	1.99e-08	1.15e-05	0.37	0.3	Caudate activity during reward;	chr8:86290099	chr8:86481754~86483002:-
LIHC	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-5.75	1.99e-08	1.15e-05	-0.34	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
LIHC	cis	rs12744310	0.666	rs7548367	ENSG00000235358.1	RP11-399E6.1	-5.75	2e-08	1.15e-05	-0.34	-0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295408	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.666	rs6660666	ENSG00000235358.1	RP11-399E6.1	-5.75	2e-08	1.15e-05	-0.34	-0.3	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297346	chr1:41242373~41284861:+
LIHC	cis	rs7131987	0.903	rs67517901	ENSG00000257176.2	RP11-996F15.2	-5.75	2e-08	1.15e-05	-0.34	-0.3	QT interval;	chr12:29268413	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.903	rs6487796	ENSG00000257176.2	RP11-996F15.2	-5.75	2e-08	1.15e-05	-0.34	-0.3	QT interval;	chr12:29269831	chr12:29280418~29317848:-
LIHC	cis	rs6589219	0.954	rs7122375	ENSG00000196167.8	COLCA1	-5.75	2e-08	1.15e-05	-0.33	-0.3	Colorectal cancer;	chr11:111300346	chr11:111290787~111305045:-
LIHC	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-5.75	2.01e-08	1.15e-05	-0.36	-0.3	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
LIHC	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	5.75	2.01e-08	1.16e-05	0.41	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
LIHC	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	5.75	2.01e-08	1.16e-05	0.41	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
LIHC	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	5.75	2.02e-08	1.16e-05	0.32	0.3	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	5.75	2.02e-08	1.16e-05	0.32	0.3	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
LIHC	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	5.75	2.02e-08	1.16e-05	0.47	0.3	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
LIHC	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	5.75	2.02e-08	1.16e-05	0.47	0.3	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
LIHC	cis	rs2735413	0.563	rs8046446	ENSG00000276007.1	RP11-358L22.3	5.75	2.03e-08	1.17e-05	0.4	0.3	Systolic blood pressure (alcohol consumption interaction);	chr16:78015689	chr16:78123243~78124332:+
LIHC	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-5.75	2.03e-08	1.17e-05	-0.42	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
LIHC	cis	rs1029738	0.615	rs3757447	ENSG00000228649.7	AC005682.5	5.75	2.03e-08	1.17e-05	0.35	0.3	Fibrinogen levels;	chr7:22855116	chr7:22854178~22861579:+
LIHC	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	5.74	2.03e-08	1.17e-05	0.34	0.3	Height;	chr6:109447092	chr6:109382795~109383666:+
LIHC	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	5.74	2.05e-08	1.18e-05	0.31	0.3	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
LIHC	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-5.74	2.05e-08	1.18e-05	-0.34	-0.3	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
LIHC	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-5.74	2.05e-08	1.18e-05	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
LIHC	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-5.74	2.05e-08	1.18e-05	-0.33	-0.3	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
LIHC	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	5.74	2.06e-08	1.18e-05	0.28	0.3	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
LIHC	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	5.74	2.06e-08	1.18e-05	0.33	0.3	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
LIHC	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	5.74	2.07e-08	1.19e-05	0.32	0.3	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
LIHC	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	5.74	2.07e-08	1.19e-05	0.33	0.3	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
LIHC	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	5.74	2.07e-08	1.19e-05	0.35	0.3	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
LIHC	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	5.74	2.07e-08	1.19e-05	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
LIHC	cis	rs12908161	0.96	rs34452033	ENSG00000259295.5	CSPG4P12	5.74	2.07e-08	1.19e-05	0.41	0.3	Schizophrenia;	chr15:84678762	chr15:85191438~85213905:+
LIHC	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-5.74	2.08e-08	1.19e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-5.74	2.08e-08	1.19e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-5.74	2.08e-08	1.19e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-5.74	2.08e-08	1.19e-05	-0.32	-0.3	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
LIHC	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-5.74	2.08e-08	1.19e-05	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
LIHC	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	5.74	2.08e-08	1.19e-05	0.39	0.3	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	5.74	2.08e-08	1.19e-05	0.39	0.3	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	5.74	2.08e-08	1.19e-05	0.39	0.3	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	5.74	2.08e-08	1.19e-05	0.39	0.3	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	5.74	2.08e-08	1.19e-05	0.39	0.3	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
LIHC	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-5.74	2.08e-08	1.19e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-5.74	2.08e-08	1.2e-05	-0.31	-0.3	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
LIHC	cis	rs739496	0.793	rs655107	ENSG00000226469.1	ADAM1B	5.74	2.09e-08	1.2e-05	0.36	0.3	Platelet count;	chr12:111558753	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs642536	ENSG00000226469.1	ADAM1B	5.74	2.09e-08	1.2e-05	0.36	0.3	Platelet count;	chr12:111559219	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs848129	ENSG00000226469.1	ADAM1B	5.74	2.09e-08	1.2e-05	0.36	0.3	Platelet count;	chr12:111559698	chr12:111927018~111929017:+
LIHC	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-5.74	2.09e-08	1.2e-05	-0.38	-0.3	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-5.74	2.09e-08	1.2e-05	-0.38	-0.3	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-5.74	2.09e-08	1.2e-05	-0.38	-0.3	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-5.74	2.09e-08	1.2e-05	-0.38	-0.3	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	5.74	2.09e-08	1.2e-05	0.27	0.3	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	5.74	2.09e-08	1.2e-05	0.27	0.3	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	5.74	2.09e-08	1.2e-05	0.27	0.3	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
LIHC	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-5.74	2.09e-08	1.2e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
LIHC	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	5.74	2.09e-08	1.2e-05	0.42	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
LIHC	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-5.74	2.1e-08	1.2e-05	-0.31	-0.3	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
LIHC	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	5.74	2.1e-08	1.2e-05	0.63	0.3	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
LIHC	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-5.74	2.1e-08	1.2e-05	-0.34	-0.3	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-5.74	2.1e-08	1.2e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-5.74	2.1e-08	1.2e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
LIHC	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	5.74	2.11e-08	1.21e-05	0.35	0.3	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
LIHC	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	5.74	2.11e-08	1.21e-05	0.37	0.3	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
LIHC	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-5.74	2.11e-08	1.21e-05	-0.39	-0.3	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
LIHC	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	5.74	2.11e-08	1.21e-05	0.52	0.3	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
LIHC	cis	rs2522056	1	rs2522056	ENSG00000233006.5	AC034220.3	-5.74	2.11e-08	1.21e-05	-0.31	-0.3	Fibrinogen;Lymphocyte counts;	chr5:132466034	chr5:132311285~132369916:-
LIHC	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	5.74	2.12e-08	1.21e-05	0.44	0.3	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
LIHC	cis	rs12285276	0.75	rs11038658	ENSG00000205106.4	DKFZp779M0652	-5.74	2.12e-08	1.21e-05	-0.3	-0.3	Visceral fat;	chr11:45791762	chr11:45771432~45772358:+
LIHC	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-5.74	2.12e-08	1.21e-05	-0.31	-0.3	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-5.74	2.12e-08	1.21e-05	-0.31	-0.3	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
LIHC	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	5.74	2.13e-08	1.22e-05	0.32	0.3	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
LIHC	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	5.74	2.13e-08	1.22e-05	0.39	0.3	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
LIHC	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	5.74	2.13e-08	1.22e-05	0.48	0.3	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
LIHC	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-5.74	2.14e-08	1.22e-05	-0.39	-0.3	Depression;	chr6:28422360	chr6:28943877~28944537:+
LIHC	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	5.74	2.14e-08	1.22e-05	0.36	0.3	Height;	chr6:109358227	chr6:109382795~109383666:+
LIHC	cis	rs1029738	0.615	rs717624	ENSG00000228649.7	AC005682.5	5.74	2.15e-08	1.23e-05	0.35	0.3	Fibrinogen levels;	chr7:22854868	chr7:22854178~22861579:+
LIHC	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	5.73	2.15e-08	1.23e-05	0.31	0.3	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
LIHC	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-5.73	2.15e-08	1.23e-05	-0.38	-0.3	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
LIHC	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
LIHC	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-5.73	2.16e-08	1.23e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
LIHC	cis	rs2522056	1	rs6874639	ENSG00000233006.5	AC034220.3	5.73	2.16e-08	1.24e-05	0.31	0.3	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132311285~132369916:-
LIHC	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-5.73	2.16e-08	1.24e-05	-0.38	-0.3	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-5.73	2.16e-08	1.24e-05	-0.38	-0.3	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-5.73	2.16e-08	1.24e-05	-0.38	-0.3	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	5.73	2.16e-08	1.24e-05	0.38	0.3	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	5.73	2.16e-08	1.24e-05	0.38	0.3	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
LIHC	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-5.73	2.16e-08	1.24e-05	-0.3	-0.3	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-5.73	2.16e-08	1.24e-05	-0.3	-0.3	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
LIHC	cis	rs2243480	1	rs160646	ENSG00000164669.11	INTS4P1	5.73	2.17e-08	1.24e-05	0.5	0.3	Diabetic kidney disease;	chr7:66091293	chr7:65141225~65234216:+
LIHC	cis	rs1005277	0.522	rs11011343	ENSG00000263064.2	RP11-291L22.7	5.73	2.17e-08	1.24e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38448689~38448949:+
LIHC	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-5.73	2.17e-08	1.24e-05	-0.46	-0.3	Depression;	chr6:28173770	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-5.73	2.17e-08	1.24e-05	-0.46	-0.3	Depression;	chr6:28174809	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-5.73	2.17e-08	1.24e-05	-0.46	-0.3	Depression;	chr6:28175233	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-5.73	2.17e-08	1.24e-05	-0.46	-0.3	Depression;	chr6:28176973	chr6:28115628~28116551:+
LIHC	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-5.73	2.17e-08	1.24e-05	-0.37	-0.3	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
LIHC	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-5.73	2.17e-08	1.24e-05	-0.36	-0.3	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
LIHC	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-5.73	2.18e-08	1.24e-05	-0.34	-0.3	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
LIHC	cis	rs7119038	0.818	rs11217040	ENSG00000255239.1	AP002954.6	-5.73	2.18e-08	1.24e-05	-0.38	-0.3	Sjögren's syndrome;	chr11:118809939	chr11:118688039~118690600:-
LIHC	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	5.73	2.18e-08	1.24e-05	0.35	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
LIHC	cis	rs3096299	0.685	rs2911244	ENSG00000261118.1	RP11-104N10.1	5.73	2.18e-08	1.24e-05	0.3	0.3	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89492017~89504460:-
LIHC	cis	rs739496	0.843	rs616559	ENSG00000226469.1	ADAM1B	-5.73	2.19e-08	1.25e-05	-0.35	-0.3	Platelet count;	chr12:111565546	chr12:111927018~111929017:+
LIHC	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	5.73	2.2e-08	1.25e-05	0.32	0.3	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
LIHC	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-5.73	2.2e-08	1.26e-05	-0.39	-0.3	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
LIHC	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-5.73	2.21e-08	1.26e-05	-0.36	-0.3	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
LIHC	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-5.73	2.21e-08	1.26e-05	-0.49	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
LIHC	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-5.73	2.21e-08	1.26e-05	-0.49	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
LIHC	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-5.73	2.21e-08	1.26e-05	-0.35	-0.3	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
LIHC	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	5.73	2.22e-08	1.26e-05	0.4	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
LIHC	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-5.73	2.23e-08	1.27e-05	-0.36	-0.3	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
LIHC	cis	rs6686842	0.965	rs1472570	ENSG00000235358.1	RP11-399E6.1	-5.73	2.23e-08	1.27e-05	-0.32	-0.3	Height;	chr1:41248412	chr1:41242373~41284861:+
LIHC	cis	rs12681287	0.604	rs13279589	ENSG00000250569.1	NTAN1P2	5.73	2.23e-08	1.27e-05	0.35	0.3	Caudate activity during reward;	chr8:86465494	chr8:86481754~86483002:-
LIHC	cis	rs4453827	0.865	rs11705918	ENSG00000271916.1	RP11-884K10.6	5.73	2.23e-08	1.27e-05	0.71	0.3	Blood protein levels;	chr3:53755671	chr3:53797764~53798019:-
LIHC	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	5.73	2.23e-08	1.27e-05	0.29	0.3	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	5.73	2.23e-08	1.27e-05	0.29	0.3	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
LIHC	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-5.73	2.25e-08	1.28e-05	-0.31	-0.3	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
LIHC	cis	rs8040855	0.77	rs8023774	ENSG00000259295.5	CSPG4P12	-5.73	2.25e-08	1.28e-05	-0.46	-0.3	Bulimia nervosa;	chr15:85155685	chr15:85191438~85213905:+
LIHC	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-5.73	2.25e-08	1.28e-05	-0.43	-0.3	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-5.73	2.25e-08	1.28e-05	-0.43	-0.3	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
LIHC	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-5.73	2.25e-08	1.28e-05	-0.36	-0.3	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
LIHC	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	5.73	2.25e-08	1.28e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
LIHC	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	5.73	2.26e-08	1.29e-05	0.43	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
LIHC	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-5.73	2.26e-08	1.29e-05	-0.32	-0.3	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
LIHC	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	5.72	2.27e-08	1.29e-05	0.47	0.3	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
LIHC	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	5.72	2.27e-08	1.29e-05	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
LIHC	cis	rs12681287	0.888	rs13042	ENSG00000250569.1	NTAN1P2	5.72	2.27e-08	1.29e-05	0.34	0.3	Caudate activity during reward;	chr8:86472684	chr8:86481754~86483002:-
LIHC	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	5.72	2.27e-08	1.29e-05	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
LIHC	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	5.72	2.27e-08	1.29e-05	0.37	0.3	Depression;	chr6:28399886	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	5.72	2.27e-08	1.29e-05	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
LIHC	cis	rs4934494	0.768	rs67111731	ENSG00000232936.4	RP11-80H5.2	5.72	2.27e-08	1.29e-05	0.38	0.3	Red blood cell count;	chr10:89659528	chr10:89645282~89650667:+
LIHC	cis	rs1005277	0.505	rs13503	ENSG00000263064.2	RP11-291L22.7	-5.72	2.27e-08	1.29e-05	-0.3	-0.3	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.505	rs7069702	ENSG00000263064.2	RP11-291L22.7	-5.72	2.27e-08	1.29e-05	-0.3	-0.3	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38448689~38448949:+
LIHC	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	5.72	2.27e-08	1.29e-05	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
LIHC	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-5.72	2.28e-08	1.29e-05	-0.29	-0.3	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
LIHC	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-5.72	2.28e-08	1.29e-05	-0.48	-0.3	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-5.72	2.28e-08	1.29e-05	-0.48	-0.3	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-5.72	2.28e-08	1.29e-05	-0.48	-0.3	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-5.72	2.28e-08	1.29e-05	-0.48	-0.3	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-5.72	2.28e-08	1.29e-05	-0.48	-0.3	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
LIHC	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-5.72	2.28e-08	1.3e-05	-0.4	-0.3	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
LIHC	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-5.72	2.28e-08	1.3e-05	-0.28	-0.3	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
LIHC	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-5.72	2.29e-08	1.3e-05	-0.44	-0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
LIHC	cis	rs1005277	0.522	rs289649	ENSG00000263064.2	RP11-291L22.7	5.72	2.29e-08	1.3e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38448689~38448949:+
LIHC	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-5.72	2.29e-08	1.3e-05	-0.38	-0.3	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
LIHC	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-5.72	2.3e-08	1.3e-05	-0.38	-0.3	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
LIHC	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-5.72	2.3e-08	1.31e-05	-0.3	-0.3	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
LIHC	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	5.72	2.3e-08	1.31e-05	0.35	0.3	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	5.72	2.3e-08	1.31e-05	0.35	0.3	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
LIHC	cis	rs9326248	1	rs664922	ENSG00000236267.1	AP006216.5	5.72	2.31e-08	1.31e-05	0.3	0.3	Blood protein levels;	chr11:117200179	chr11:116813204~116814003:-
LIHC	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-5.72	2.31e-08	1.31e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-5.72	2.31e-08	1.31e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
LIHC	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	5.72	2.32e-08	1.32e-05	0.33	0.3	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
LIHC	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	5.72	2.32e-08	1.32e-05	0.38	0.3	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
LIHC	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-5.72	2.32e-08	1.32e-05	-0.36	-0.3	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
LIHC	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-5.72	2.33e-08	1.32e-05	-0.3	-0.3	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
LIHC	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	5.72	2.33e-08	1.32e-05	0.42	0.3	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
LIHC	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-5.72	2.33e-08	1.32e-05	-0.35	-0.3	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-5.72	2.33e-08	1.32e-05	-0.35	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
LIHC	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-5.72	2.33e-08	1.32e-05	-0.38	-0.3	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-5.72	2.33e-08	1.32e-05	-0.38	-0.3	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.883	rs2660575	ENSG00000234155.1	RP11-30P6.6	5.72	2.34e-08	1.32e-05	0.35	0.3	Response to antipsychotic treatment;	chr6:85975277	chr6:85387219~85390186:-
LIHC	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-5.72	2.34e-08	1.32e-05	-0.36	-0.3	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
LIHC	cis	rs1005277	0.522	rs289648	ENSG00000263064.2	RP11-291L22.7	5.72	2.34e-08	1.32e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38448689~38448949:+
LIHC	cis	rs4453827	0.821	rs73092085	ENSG00000271916.1	RP11-884K10.6	5.72	2.34e-08	1.33e-05	0.72	0.3	Blood protein levels;	chr3:53750295	chr3:53797764~53798019:-
LIHC	cis	rs12681287	0.752	rs4389908	ENSG00000250569.1	NTAN1P2	5.72	2.35e-08	1.33e-05	0.37	0.3	Caudate activity during reward;	chr8:86262623	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs12681438	ENSG00000250569.1	NTAN1P2	5.72	2.35e-08	1.33e-05	0.37	0.3	Caudate activity during reward;	chr8:86280860	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs13262673	ENSG00000250569.1	NTAN1P2	5.72	2.35e-08	1.33e-05	0.37	0.3	Caudate activity during reward;	chr8:86281371	chr8:86481754~86483002:-
LIHC	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	5.72	2.35e-08	1.33e-05	0.47	0.3	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	5.72	2.35e-08	1.33e-05	0.47	0.3	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	5.72	2.35e-08	1.33e-05	0.47	0.3	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
LIHC	cis	rs2998286	0.862	rs2993980	ENSG00000254635.4	WAC-AS1	-5.72	2.35e-08	1.33e-05	-0.37	-0.3	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506286	chr10:28522652~28532743:-
LIHC	cis	rs1005277	0.522	rs7090858	ENSG00000263064.2	RP11-291L22.7	-5.72	2.35e-08	1.33e-05	-0.3	-0.3	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38448689~38448949:+
LIHC	cis	rs12681287	0.752	rs4534114	ENSG00000250569.1	NTAN1P2	5.72	2.35e-08	1.33e-05	0.37	0.3	Caudate activity during reward;	chr8:86259727	chr8:86481754~86483002:-
LIHC	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	5.72	2.36e-08	1.33e-05	0.32	0.3	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
LIHC	cis	rs739496	0.843	rs610769	ENSG00000226469.1	ADAM1B	5.72	2.36e-08	1.34e-05	0.36	0.3	Platelet count;	chr12:111561766	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs595529	ENSG00000226469.1	ADAM1B	5.72	2.36e-08	1.34e-05	0.36	0.3	Platelet count;	chr12:111562844	chr12:111927018~111929017:+
LIHC	cis	rs228614	0.51	rs223438	ENSG00000230069.3	LRRC37A15P	5.72	2.36e-08	1.34e-05	0.26	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102727274~102730721:-
LIHC	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-5.72	2.36e-08	1.34e-05	-0.32	-0.3	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
LIHC	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	5.72	2.37e-08	1.34e-05	0.4	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
LIHC	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-5.72	2.37e-08	1.34e-05	-0.32	-0.3	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
LIHC	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	5.72	2.38e-08	1.34e-05	0.35	0.3	Height;	chr6:109384807	chr6:109382795~109383666:+
LIHC	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-5.72	2.38e-08	1.35e-05	-0.48	-0.3	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
LIHC	cis	rs4934494	0.768	rs2094214	ENSG00000232936.4	RP11-80H5.2	5.72	2.38e-08	1.35e-05	0.38	0.3	Red blood cell count;	chr10:89649624	chr10:89645282~89650667:+
LIHC	cis	rs9326248	0.861	rs1871757	ENSG00000236267.1	AP006216.5	5.72	2.38e-08	1.35e-05	0.3	0.3	Blood protein levels;	chr11:117159865	chr11:116813204~116814003:-
LIHC	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-5.71	2.39e-08	1.35e-05	-0.35	-0.3	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
LIHC	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	5.71	2.4e-08	1.36e-05	0.39	0.3	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
LIHC	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-5.71	2.4e-08	1.36e-05	-0.48	-0.3	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
LIHC	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-5.71	2.4e-08	1.36e-05	-0.33	-0.3	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
LIHC	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-5.71	2.4e-08	1.36e-05	-0.41	-0.3	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
LIHC	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	5.71	2.4e-08	1.36e-05	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
LIHC	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-5.71	2.4e-08	1.36e-05	-0.43	-0.3	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
LIHC	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-5.71	2.41e-08	1.36e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
LIHC	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-5.71	2.41e-08	1.36e-05	-0.39	-0.3	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
LIHC	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-5.71	2.42e-08	1.37e-05	-0.36	-0.3	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
LIHC	cis	rs71007656	1	rs71007656	ENSG00000263064.2	RP11-291L22.7	5.71	2.42e-08	1.37e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.54	rs2145487	ENSG00000263064.2	RP11-291L22.7	5.71	2.42e-08	1.37e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.54	rs4934907	ENSG00000263064.2	RP11-291L22.7	5.71	2.42e-08	1.37e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.54	rs11011351	ENSG00000263064.2	RP11-291L22.7	5.71	2.42e-08	1.37e-05	0.3	0.3	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38448689~38448949:+
LIHC	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	5.71	2.43e-08	1.37e-05	0.39	0.3	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
LIHC	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	5.71	2.43e-08	1.37e-05	0.38	0.3	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
LIHC	cis	rs9326248	1	rs664082	ENSG00000236267.1	AP006216.5	5.71	2.43e-08	1.37e-05	0.3	0.3	Blood protein levels;	chr11:117200354	chr11:116813204~116814003:-
LIHC	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	5.71	2.43e-08	1.37e-05	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	5.71	2.43e-08	1.37e-05	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
LIHC	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-5.71	2.43e-08	1.37e-05	-0.36	-0.3	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-5.71	2.43e-08	1.37e-05	-0.36	-0.3	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
LIHC	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	5.71	2.43e-08	1.37e-05	0.46	0.3	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
LIHC	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-5.71	2.44e-08	1.38e-05	-0.46	-0.3	Depression;	chr6:28180209	chr6:28115628~28116551:+
LIHC	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-5.71	2.44e-08	1.38e-05	-0.36	-0.3	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
LIHC	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-5.71	2.46e-08	1.39e-05	-0.36	-0.29	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
LIHC	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	5.71	2.47e-08	1.39e-05	0.33	0.29	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
LIHC	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-5.71	2.47e-08	1.39e-05	-0.36	-0.29	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
LIHC	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-5.71	2.47e-08	1.39e-05	-0.33	-0.29	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
LIHC	cis	rs4356203	1	rs4356203	ENSG00000272034.1	SNORD14A	5.71	2.48e-08	1.4e-05	0.34	0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17138601	chr11:17074654~17074744:-
LIHC	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	5.71	2.49e-08	1.4e-05	0.37	0.29	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000228409.4	CCT6P1	5.71	2.49e-08	1.4e-05	0.23	0.29	Calcium levels;	chr7:66046172	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-5.71	2.49e-08	1.4e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
LIHC	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-5.71	2.49e-08	1.4e-05	-0.34	-0.29	Height;	chr11:118856460	chr11:118704607~118750263:+
LIHC	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-5.71	2.49e-08	1.4e-05	-0.34	-0.29	Height;	chr11:118856623	chr11:118704607~118750263:+
LIHC	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-5.71	2.49e-08	1.4e-05	-0.34	-0.29	Height;	chr11:118857611	chr11:118704607~118750263:+
LIHC	cis	rs9326248	0.53	rs1242229	ENSG00000236267.1	AP006216.5	5.71	2.5e-08	1.41e-05	0.33	0.29	Blood protein levels;	chr11:117191654	chr11:116813204~116814003:-
LIHC	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	5.71	2.51e-08	1.41e-05	0.39	0.29	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
LIHC	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	5.71	2.51e-08	1.41e-05	0.45	0.29	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
LIHC	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-5.71	2.51e-08	1.41e-05	-0.33	-0.29	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
LIHC	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	5.71	2.51e-08	1.41e-05	0.4	0.29	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
LIHC	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	5.71	2.52e-08	1.41e-05	0.33	0.29	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
LIHC	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-5.7	2.53e-08	1.42e-05	-0.39	-0.29	Depression;	chr6:28422360	chr6:28176188~28176674:+
LIHC	cis	rs9326248	1	rs585849	ENSG00000236267.1	AP006216.5	5.7	2.53e-08	1.42e-05	0.3	0.29	Blood protein levels;	chr11:117198345	chr11:116813204~116814003:-
LIHC	cis	rs1005277	0.577	rs4934906	ENSG00000263064.2	RP11-291L22.7	5.7	2.53e-08	1.42e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38448689~38448949:+
LIHC	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	5.7	2.53e-08	1.42e-05	0.34	0.29	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
LIHC	cis	rs2998286	0.906	rs2807742	ENSG00000254635.4	WAC-AS1	-5.7	2.53e-08	1.42e-05	-0.36	-0.29	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28492438	chr10:28522652~28532743:-
LIHC	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	5.7	2.54e-08	1.43e-05	0.49	0.29	Height;	chr6:109645257	chr6:109382795~109383666:+
LIHC	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-5.7	2.54e-08	1.43e-05	-0.42	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
LIHC	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	5.7	2.54e-08	1.43e-05	0.35	0.29	Height;	chr6:109424139	chr6:109382795~109383666:+
LIHC	cis	rs2072510	0.722	rs2540496	ENSG00000257715.1	RP11-256L6.2	-5.7	2.54e-08	1.43e-05	-0.3	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96012725	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.722	rs2540495	ENSG00000257715.1	RP11-256L6.2	-5.7	2.54e-08	1.43e-05	-0.3	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96012945	chr12:96025323~96027971:+
LIHC	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-5.7	2.55e-08	1.43e-05	-0.35	-0.29	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
LIHC	cis	rs2522056	1	rs7730247	ENSG00000233006.5	AC034220.3	-5.7	2.55e-08	1.43e-05	-0.31	-0.29	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132311285~132369916:-
LIHC	cis	rs739496	0.843	rs616668	ENSG00000226469.1	ADAM1B	5.7	2.56e-08	1.44e-05	0.36	0.29	Platelet count;	chr12:111536476	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs583140	ENSG00000226469.1	ADAM1B	5.7	2.56e-08	1.44e-05	0.36	0.29	Platelet count;	chr12:111548150	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs848132	ENSG00000226469.1	ADAM1B	5.7	2.56e-08	1.44e-05	0.36	0.29	Platelet count;	chr12:111552175	chr12:111927018~111929017:+
LIHC	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-5.7	2.57e-08	1.44e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
LIHC	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-5.7	2.57e-08	1.44e-05	-0.36	-0.29	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
LIHC	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	5.7	2.57e-08	1.44e-05	0.36	0.29	Height;	chr6:109370985	chr6:109382795~109383666:+
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-5.7	2.57e-08	1.44e-05	-0.35	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
LIHC	cis	rs12681287	0.547	rs60982560	ENSG00000250569.1	NTAN1P2	5.7	2.58e-08	1.44e-05	0.35	0.29	Caudate activity during reward;	chr8:86502817	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs13280468	ENSG00000250569.1	NTAN1P2	5.7	2.58e-08	1.44e-05	0.35	0.29	Caudate activity during reward;	chr8:86326223	chr8:86481754~86483002:-
LIHC	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-5.7	2.59e-08	1.45e-05	-0.36	-0.29	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-5.7	2.59e-08	1.45e-05	-0.36	-0.29	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
LIHC	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	5.7	2.59e-08	1.45e-05	0.28	0.29	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
LIHC	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	5.7	2.59e-08	1.45e-05	0.28	0.29	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
LIHC	cis	rs7131987	0.65	rs11050208	ENSG00000275476.1	RP11-996F15.4	-5.7	2.59e-08	1.45e-05	-0.36	-0.29	QT interval;	chr12:29357436	chr12:29277397~29277882:-
LIHC	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	5.7	2.59e-08	1.45e-05	0.33	0.29	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
LIHC	cis	rs1005277	0.505	rs200939	ENSG00000263064.2	RP11-291L22.7	5.7	2.59e-08	1.45e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38448689~38448949:+
LIHC	cis	rs7916697	0.593	rs7912895	ENSG00000233590.1	RP11-153K11.3	-5.7	2.59e-08	1.45e-05	-0.36	-0.29	Optic disc area;	chr10:68261741	chr10:68233251~68242379:-
LIHC	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	5.7	2.59e-08	1.45e-05	0.28	0.29	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
LIHC	cis	rs4356975	0.527	rs60423649	ENSG00000249956.3	RP11-790I12.2	5.7	2.6e-08	1.45e-05	0.35	0.29	Obesity-related traits;	chr4:69127952	chr4:69408836~69423164:+
LIHC	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	5.7	2.6e-08	1.45e-05	0.39	0.29	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
LIHC	cis	rs1005277	0.505	rs200935	ENSG00000263064.2	RP11-291L22.7	5.7	2.6e-08	1.45e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.505	rs200936	ENSG00000263064.2	RP11-291L22.7	5.7	2.6e-08	1.45e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.505	rs200937	ENSG00000263064.2	RP11-291L22.7	5.7	2.6e-08	1.45e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.505	rs200910	ENSG00000263064.2	RP11-291L22.7	5.7	2.6e-08	1.45e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38448689~38448949:+
LIHC	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	5.7	2.6e-08	1.46e-05	0.29	0.29	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
LIHC	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	5.7	2.6e-08	1.46e-05	0.29	0.29	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
LIHC	cis	rs12908161	0.959	rs3748376	ENSG00000259295.5	CSPG4P12	5.7	2.61e-08	1.46e-05	0.41	0.29	Schizophrenia;	chr15:84785121	chr15:85191438~85213905:+
LIHC	cis	rs1005277	0.505	rs719569	ENSG00000263064.2	RP11-291L22.7	-5.7	2.61e-08	1.46e-05	-0.3	-0.29	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.522	rs200943	ENSG00000263064.2	RP11-291L22.7	5.7	2.61e-08	1.46e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38448689~38448949:+
LIHC	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	5.7	2.62e-08	1.46e-05	0.32	0.29	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
LIHC	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	5.7	2.62e-08	1.46e-05	0.34	0.29	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
LIHC	cis	rs12908161	0.959	rs34342559	ENSG00000259295.5	CSPG4P12	5.7	2.62e-08	1.46e-05	0.4	0.29	Schizophrenia;	chr15:84788040	chr15:85191438~85213905:+
LIHC	cis	rs12908161	0.959	rs62019472	ENSG00000259295.5	CSPG4P12	5.7	2.62e-08	1.46e-05	0.4	0.29	Schizophrenia;	chr15:84788262	chr15:85191438~85213905:+
LIHC	cis	rs12908161	0.959	rs35557864	ENSG00000259295.5	CSPG4P12	5.7	2.62e-08	1.46e-05	0.4	0.29	Schizophrenia;	chr15:84788398	chr15:85191438~85213905:+
LIHC	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	5.7	2.63e-08	1.47e-05	0.35	0.29	Height;	chr6:109374782	chr6:109382795~109383666:+
LIHC	cis	rs931127	0.532	rs4930304	ENSG00000265874.1	MIR4489	5.7	2.63e-08	1.47e-05	0.42	0.29	Systemic lupus erythematosus;	chr11:65695976	chr11:65649192~65649253:+
LIHC	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-5.7	2.63e-08	1.47e-05	-0.36	-0.29	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
LIHC	cis	rs4925166	1	rs4925166	ENSG00000260647.1	RP1-178F10.1	5.7	2.63e-08	1.47e-05	0.34	0.29	Multiple sclerosis;	chr17:18307496	chr17:18268080~18268828:+
LIHC	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	5.7	2.64e-08	1.47e-05	0.46	0.29	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
LIHC	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-5.7	2.64e-08	1.48e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-5.7	2.64e-08	1.48e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-5.7	2.64e-08	1.48e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-5.7	2.64e-08	1.48e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-5.7	2.64e-08	1.48e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
LIHC	cis	rs6589219	0.954	rs3802841	ENSG00000196167.8	COLCA1	-5.7	2.64e-08	1.48e-05	-0.33	-0.29	Colorectal cancer;	chr11:111300947	chr11:111290787~111305045:-
LIHC	cis	rs6589219	0.954	rs3802842	ENSG00000196167.8	COLCA1	-5.7	2.64e-08	1.48e-05	-0.33	-0.29	Colorectal cancer;	chr11:111300984	chr11:111290787~111305045:-
LIHC	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-5.7	2.65e-08	1.48e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
LIHC	cis	rs6589219	0.908	rs10891246	ENSG00000196167.8	COLCA1	-5.7	2.65e-08	1.48e-05	-0.33	-0.29	Colorectal cancer;	chr11:111299815	chr11:111290787~111305045:-
LIHC	cis	rs6589219	0.954	rs10789823	ENSG00000196167.8	COLCA1	-5.7	2.65e-08	1.48e-05	-0.34	-0.29	Colorectal cancer;	chr11:111301678	chr11:111290787~111305045:-
LIHC	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	5.7	2.65e-08	1.48e-05	0.36	0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
LIHC	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	5.7	2.66e-08	1.48e-05	0.35	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
LIHC	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	5.69	2.66e-08	1.49e-05	0.4	0.29	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
LIHC	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	5.69	2.66e-08	1.49e-05	0.39	0.29	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	5.69	2.66e-08	1.49e-05	0.39	0.29	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	5.69	2.66e-08	1.49e-05	0.39	0.29	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
LIHC	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-5.69	2.67e-08	1.49e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
LIHC	cis	rs8027365	1	rs8027365	ENSG00000260269.4	CTD-2323K18.1	-5.69	2.67e-08	1.49e-05	-0.38	-0.29	Breast cancer;	chr15:75516399	chr15:75527150~75601205:-
LIHC	cis	rs4356975	0.509	rs5014975	ENSG00000249956.3	RP11-790I12.2	5.69	2.68e-08	1.49e-05	0.35	0.29	Obesity-related traits;	chr4:69130244	chr4:69408836~69423164:+
LIHC	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-5.69	2.68e-08	1.49e-05	-0.34	-0.29	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-5.69	2.68e-08	1.49e-05	-0.34	-0.29	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
LIHC	cis	rs12681287	0.571	rs10097450	ENSG00000250569.1	NTAN1P2	-5.69	2.68e-08	1.5e-05	-0.35	-0.29	Caudate activity during reward;	chr8:86346448	chr8:86481754~86483002:-
LIHC	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	5.69	2.69e-08	1.5e-05	0.33	0.29	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-5.69	2.69e-08	1.5e-05	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
LIHC	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	5.69	2.69e-08	1.5e-05	0.37	0.29	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
LIHC	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-5.69	2.69e-08	1.5e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
LIHC	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	5.69	2.7e-08	1.5e-05	0.39	0.29	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
LIHC	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-5.69	2.7e-08	1.5e-05	-0.3	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
LIHC	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	5.69	2.71e-08	1.51e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	5.69	2.71e-08	1.51e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
LIHC	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-5.69	2.71e-08	1.51e-05	-0.48	-0.29	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
LIHC	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	5.69	2.72e-08	1.51e-05	0.37	0.29	Depression;	chr6:28363475	chr6:28176188~28176674:+
LIHC	cis	rs9326248	0.569	rs4938315	ENSG00000280143.1	AP000892.6	5.69	2.72e-08	1.52e-05	0.36	0.29	Blood protein levels;	chr11:116860489	chr11:117204967~117210292:+
LIHC	cis	rs10833905	0.697	rs10766983	ENSG00000246225.5	RP11-17A1.3	-5.69	2.73e-08	1.52e-05	-0.38	-0.29	Sudden cardiac arrest;	chr11:22924603	chr11:22829380~22945393:+
LIHC	cis	rs12908161	1	rs11638290	ENSG00000259295.5	CSPG4P12	5.69	2.73e-08	1.52e-05	0.4	0.29	Schizophrenia;	chr15:84684405	chr15:85191438~85213905:+
LIHC	cis	rs4538475	0.53	rs6449168	ENSG00000214846.4	RP11-115L11.1	5.69	2.73e-08	1.52e-05	0.38	0.29	Parkinson's disease;	chr4:15726090	chr4:15730962~15731627:-
LIHC	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	5.69	2.73e-08	1.52e-05	0.33	0.29	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
LIHC	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-5.69	2.75e-08	1.53e-05	-0.33	-0.29	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
LIHC	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	5.69	2.75e-08	1.53e-05	0.48	0.29	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
LIHC	cis	rs9326248	0.53	rs2471884	ENSG00000236267.1	AP006216.5	5.69	2.75e-08	1.53e-05	0.33	0.29	Blood protein levels;	chr11:117139604	chr11:116813204~116814003:-
LIHC	cis	rs6686842	1	rs213754	ENSG00000235358.1	RP11-399E6.1	-5.69	2.75e-08	1.53e-05	-0.32	-0.29	Height;	chr1:41133176	chr1:41242373~41284861:+
LIHC	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-5.69	2.75e-08	1.53e-05	-0.48	-0.29	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
LIHC	cis	rs12681287	1	rs12681287	ENSG00000250569.1	NTAN1P2	-5.69	2.75e-08	1.53e-05	-0.36	-0.29	Caudate activity during reward;	chr8:86257307	chr8:86481754~86483002:-
LIHC	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-5.69	2.76e-08	1.53e-05	-0.28	-0.29	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-5.69	2.76e-08	1.53e-05	-0.28	-0.29	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
LIHC	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	5.69	2.76e-08	1.54e-05	0.33	0.29	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
LIHC	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	5.69	2.77e-08	1.54e-05	0.36	0.29	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
LIHC	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	5.69	2.77e-08	1.54e-05	0.33	0.29	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	5.69	2.77e-08	1.54e-05	0.33	0.29	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
LIHC	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	5.69	2.78e-08	1.54e-05	0.39	0.29	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
LIHC	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-5.69	2.78e-08	1.54e-05	-0.37	-0.29	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
LIHC	cis	rs9326248	1	rs4938344	ENSG00000236267.1	AP006216.5	5.69	2.79e-08	1.55e-05	0.3	0.29	Blood protein levels;	chr11:117133033	chr11:116813204~116814003:-
LIHC	cis	rs8028182	0.636	rs7163907	ENSG00000260269.4	CTD-2323K18.1	-5.69	2.79e-08	1.55e-05	-0.38	-0.29	Sudden cardiac arrest;	chr15:75552756	chr15:75527150~75601205:-
LIHC	cis	rs5769765	0.773	rs9616751	ENSG00000278869.1	CITF22-49E9.3	5.69	2.8e-08	1.55e-05	0.53	0.29	Schizophrenia;	chr22:49828588	chr22:49933198~49934074:-
LIHC	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-5.69	2.8e-08	1.56e-05	-0.34	-0.29	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
LIHC	cis	rs6589219	1	rs6589219	ENSG00000196167.8	COLCA1	-5.69	2.81e-08	1.56e-05	-0.34	-0.29	Colorectal cancer;	chr11:111302186	chr11:111290787~111305045:-
LIHC	cis	rs11672691	0.627	rs6508981	ENSG00000267107.5	PCAT19	5.68	2.81e-08	1.56e-05	0.36	0.29	Prostate cancer;	chr19:41483668	chr19:41454169~41500649:-
LIHC	cis	rs12681287	0.517	rs34596274	ENSG00000250569.1	NTAN1P2	5.68	2.81e-08	1.56e-05	0.35	0.29	Caudate activity during reward;	chr8:86505450	chr8:86481754~86483002:-
LIHC	cis	rs7131987	0.801	rs6487804	ENSG00000257176.2	RP11-996F15.2	-5.68	2.81e-08	1.56e-05	-0.33	-0.29	QT interval;	chr12:29302001	chr12:29280418~29317848:-
LIHC	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	5.68	2.82e-08	1.57e-05	0.42	0.29	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
LIHC	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-5.68	2.83e-08	1.57e-05	-0.38	-0.29	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
LIHC	cis	rs2762353	0.553	rs9467581	ENSG00000242387.1	HIST1H2APS2	-5.68	2.84e-08	1.57e-05	-0.37	-0.29	Blood metabolite levels;	chr6:25710320	chr6:25882026~25882395:-
LIHC	cis	rs7115242	0.748	rs1035237	ENSG00000280143.1	AP000892.6	5.68	2.84e-08	1.57e-05	0.36	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117204967~117210292:+
LIHC	cis	rs2522056	0.932	rs2522064	ENSG00000233006.5	AC034220.3	-5.68	2.84e-08	1.57e-05	-0.3	-0.29	Fibrinogen;Lymphocyte counts;	chr5:132470796	chr5:132311285~132369916:-
LIHC	cis	rs12681287	1	rs7833786	ENSG00000250569.1	NTAN1P2	-5.68	2.84e-08	1.58e-05	-0.35	-0.29	Caudate activity during reward;	chr8:86259145	chr8:86481754~86483002:-
LIHC	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-5.68	2.84e-08	1.58e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000206090.4	AP000350.7	5.68	2.84e-08	1.58e-05	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23939998~23942798:+
LIHC	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	5.68	2.85e-08	1.58e-05	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	5.68	2.85e-08	1.58e-05	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	5.68	2.85e-08	1.58e-05	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
LIHC	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	5.68	2.85e-08	1.58e-05	0.31	0.29	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
LIHC	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	5.68	2.85e-08	1.58e-05	0.31	0.29	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
LIHC	cis	rs6589219	0.908	rs7103178	ENSG00000196167.8	COLCA1	-5.68	2.86e-08	1.58e-05	-0.32	-0.29	Colorectal cancer;	chr11:111294284	chr11:111290787~111305045:-
LIHC	cis	rs8028182	0.636	rs62027209	ENSG00000260269.4	CTD-2323K18.1	-5.68	2.86e-08	1.58e-05	-0.38	-0.29	Sudden cardiac arrest;	chr15:75579285	chr15:75527150~75601205:-
LIHC	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	5.68	2.86e-08	1.58e-05	0.48	0.29	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
LIHC	cis	rs9388451	0.874	rs7739566	ENSG00000237742.5	RP11-624M8.1	-5.68	2.86e-08	1.58e-05	-0.27	-0.29	Brugada syndrome;	chr6:125773611	chr6:125578558~125749190:-
LIHC	cis	rs9388451	0.839	rs4897155	ENSG00000237742.5	RP11-624M8.1	-5.68	2.86e-08	1.58e-05	-0.27	-0.29	Brugada syndrome;	chr6:125773998	chr6:125578558~125749190:-
LIHC	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-5.68	2.88e-08	1.6e-05	-0.32	-0.29	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
LIHC	cis	rs1005277	0.522	rs1208767	ENSG00000263064.2	RP11-291L22.7	5.68	2.89e-08	1.6e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38448689~38448949:+
LIHC	cis	rs12681287	0.547	rs7465511	ENSG00000250569.1	NTAN1P2	5.68	2.89e-08	1.6e-05	0.35	0.29	Caudate activity during reward;	chr8:86509252	chr8:86481754~86483002:-
LIHC	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-5.68	2.89e-08	1.6e-05	-0.27	-0.29	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
LIHC	cis	rs739496	0.843	rs621899	ENSG00000226469.1	ADAM1B	5.68	2.89e-08	1.6e-05	0.36	0.29	Platelet count;	chr12:111547047	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs625093	ENSG00000226469.1	ADAM1B	5.68	2.89e-08	1.6e-05	0.36	0.29	Platelet count;	chr12:111550628	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.843	rs638791	ENSG00000226469.1	ADAM1B	5.68	2.89e-08	1.6e-05	0.36	0.29	Platelet count;	chr12:111551432	chr12:111927018~111929017:+
LIHC	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	5.68	2.9e-08	1.6e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	5.68	2.9e-08	1.6e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
LIHC	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-5.68	2.9e-08	1.6e-05	-0.33	-0.29	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
LIHC	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	5.68	2.9e-08	1.61e-05	0.34	0.29	Height;	chr6:109446727	chr6:109382795~109383666:+
LIHC	cis	rs12291225	0.585	rs12270374	ENSG00000251991.1	RNU7-49P	5.68	2.91e-08	1.61e-05	0.31	0.29	Sense of smell;	chr11:14353533	chr11:14478892~14478953:+
LIHC	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-5.68	2.92e-08	1.61e-05	-0.36	-0.29	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
LIHC	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-5.68	2.92e-08	1.61e-05	-0.3	-0.29	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
LIHC	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	5.68	2.93e-08	1.62e-05	0.4	0.29	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
LIHC	cis	rs7119038	0.818	rs6589686	ENSG00000255239.1	AP002954.6	-5.68	2.93e-08	1.62e-05	-0.37	-0.29	Sjögren's syndrome;	chr11:118741856	chr11:118688039~118690600:-
LIHC	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-5.68	2.94e-08	1.63e-05	-0.32	-0.29	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
LIHC	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	5.68	2.95e-08	1.63e-05	0.31	0.29	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
LIHC	cis	rs12681287	0.571	rs13254675	ENSG00000250569.1	NTAN1P2	5.68	2.95e-08	1.63e-05	0.35	0.29	Caudate activity during reward;	chr8:86341365	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.605	rs13262672	ENSG00000250569.1	NTAN1P2	5.68	2.95e-08	1.63e-05	0.35	0.29	Caudate activity during reward;	chr8:86343583	chr8:86481754~86483002:-
LIHC	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	5.68	2.95e-08	1.63e-05	0.43	0.29	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
LIHC	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	5.68	2.95e-08	1.63e-05	0.29	0.29	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
LIHC	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	5.68	2.95e-08	1.63e-05	0.37	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
LIHC	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	5.68	2.95e-08	1.63e-05	0.35	0.29	Height;	chr6:109393881	chr6:109382795~109383666:+
LIHC	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	5.68	2.95e-08	1.63e-05	0.31	0.29	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	5.68	2.95e-08	1.63e-05	0.31	0.29	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
LIHC	cis	rs227275	0.525	rs7698608	ENSG00000230069.3	LRRC37A15P	-5.67	2.96e-08	1.63e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102727274~102730721:-
LIHC	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-5.67	2.96e-08	1.63e-05	-0.29	-0.29	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
LIHC	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	5.67	2.96e-08	1.64e-05	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
LIHC	cis	rs4934494	0.635	rs12572869	ENSG00000232936.4	RP11-80H5.2	5.67	2.99e-08	1.65e-05	0.38	0.29	Red blood cell count;	chr10:89653611	chr10:89645282~89650667:+
LIHC	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	5.67	2.99e-08	1.65e-05	0.28	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
LIHC	cis	rs734999	0.967	rs10752745	ENSG00000225931.3	RP3-395M20.7	5.67	3e-08	1.65e-05	0.32	0.29	Ulcerative colitis;	chr1:2576499	chr1:2566410~2569888:+
LIHC	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	5.67	3e-08	1.65e-05	0.32	0.29	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
LIHC	cis	rs4356975	0.527	rs57102579	ENSG00000249956.3	RP11-790I12.2	5.67	3e-08	1.65e-05	0.35	0.29	Obesity-related traits;	chr4:69125476	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.527	rs4385139	ENSG00000249956.3	RP11-790I12.2	5.67	3e-08	1.65e-05	0.35	0.29	Obesity-related traits;	chr4:69125911	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.527	rs4694645	ENSG00000249956.3	RP11-790I12.2	5.67	3e-08	1.65e-05	0.35	0.29	Obesity-related traits;	chr4:69127200	chr4:69408836~69423164:+
LIHC	cis	rs12908161	0.92	rs35758837	ENSG00000259295.5	CSPG4P12	5.67	3e-08	1.65e-05	0.4	0.29	Schizophrenia;	chr15:84768151	chr15:85191438~85213905:+
LIHC	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-5.67	3e-08	1.65e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
LIHC	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-5.67	3.01e-08	1.66e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-5.67	3.01e-08	1.66e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
LIHC	cis	rs739496	0.793	rs76604970	ENSG00000226469.1	ADAM1B	5.67	3.01e-08	1.66e-05	0.36	0.29	Platelet count;	chr12:111529351	chr12:111927018~111929017:+
LIHC	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	5.67	3.02e-08	1.66e-05	0.36	0.29	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
LIHC	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-5.67	3.02e-08	1.67e-05	-0.3	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
LIHC	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	5.67	3.04e-08	1.67e-05	0.3	0.29	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	5.67	3.04e-08	1.67e-05	0.3	0.29	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
LIHC	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	5.67	3.05e-08	1.68e-05	0.38	0.29	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
LIHC	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-5.67	3.05e-08	1.68e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
LIHC	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-5.67	3.06e-08	1.68e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
LIHC	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-5.67	3.06e-08	1.68e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
LIHC	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	5.67	3.07e-08	1.69e-05	0.26	0.29	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	5.67	3.07e-08	1.69e-05	0.26	0.29	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
LIHC	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	5.67	3.07e-08	1.69e-05	0.38	0.29	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
LIHC	cis	rs12908161	1	rs36033486	ENSG00000259295.5	CSPG4P12	5.67	3.07e-08	1.69e-05	0.4	0.29	Schizophrenia;	chr15:84776461	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs12908549	ENSG00000259295.5	CSPG4P12	5.67	3.07e-08	1.69e-05	0.4	0.29	Schizophrenia;	chr15:84779120	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs12903134	ENSG00000259295.5	CSPG4P12	5.67	3.07e-08	1.69e-05	0.4	0.29	Schizophrenia;	chr15:84794468	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs35726233	ENSG00000259295.5	CSPG4P12	5.67	3.07e-08	1.69e-05	0.4	0.29	Schizophrenia;	chr15:84794569	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs35960805	ENSG00000259295.5	CSPG4P12	5.67	3.07e-08	1.69e-05	0.4	0.29	Schizophrenia;	chr15:84800749	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs12912388	ENSG00000259295.5	CSPG4P12	5.67	3.07e-08	1.69e-05	0.4	0.29	Schizophrenia;	chr15:84801319	chr15:85191438~85213905:+
LIHC	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	5.67	3.07e-08	1.69e-05	0.35	0.29	Myopia;	chr6:28302807	chr6:28176188~28176674:+
LIHC	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	5.67	3.08e-08	1.69e-05	0.33	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	5.67	3.08e-08	1.69e-05	0.33	0.29	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
LIHC	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-5.67	3.08e-08	1.69e-05	-0.36	-0.29	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
LIHC	cis	rs12681287	0.752	rs7822268	ENSG00000250569.1	NTAN1P2	5.67	3.09e-08	1.7e-05	0.36	0.29	Caudate activity during reward;	chr8:86294211	chr8:86481754~86483002:-
LIHC	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-5.67	3.09e-08	1.7e-05	-0.34	-0.29	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
LIHC	cis	rs2735413	0.918	rs4888731	ENSG00000276007.1	RP11-358L22.3	-5.67	3.09e-08	1.7e-05	-0.31	-0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78046521	chr16:78123243~78124332:+
LIHC	cis	rs12681287	0.888	rs2976201	ENSG00000250569.1	NTAN1P2	5.67	3.09e-08	1.7e-05	0.35	0.29	Caudate activity during reward;	chr8:86323708	chr8:86481754~86483002:-
LIHC	cis	rs1577917	0.816	rs12664099	ENSG00000234155.1	RP11-30P6.6	5.67	3.09e-08	1.7e-05	0.35	0.29	Response to antipsychotic treatment;	chr6:85938854	chr6:85387219~85390186:-
LIHC	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-5.67	3.09e-08	1.7e-05	-0.32	-0.29	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
LIHC	cis	rs6686842	1	rs12125555	ENSG00000235358.1	RP11-399E6.1	5.67	3.09e-08	1.7e-05	0.32	0.29	Height;	chr1:41241439	chr1:41242373~41284861:+
LIHC	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-5.67	3.09e-08	1.7e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
LIHC	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	5.67	3.1e-08	1.7e-05	0.32	0.29	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
LIHC	cis	rs2933343	0.729	rs1683816	ENSG00000231305.3	RP11-723O4.2	-5.67	3.1e-08	1.7e-05	-0.32	-0.29	IgG glycosylation;	chr3:128932352	chr3:128861313~128871540:-
LIHC	cis	rs7115242	0.858	rs6589592	ENSG00000236267.1	AP006216.5	5.67	3.11e-08	1.71e-05	0.39	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:116813204~116814003:-
LIHC	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-5.67	3.11e-08	1.71e-05	-0.36	-0.29	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
LIHC	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-5.66	3.12e-08	1.71e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
LIHC	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	5.66	3.12e-08	1.71e-05	0.41	0.29	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
LIHC	cis	rs2688482	0.512	rs3103954	ENSG00000242086.7	LINC00969	5.66	3.13e-08	1.72e-05	0.37	0.29	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195658062~195739964:+
LIHC	cis	rs5769707	0.632	rs5770601	ENSG00000235111.1	RP1-29C18.8	-5.66	3.16e-08	1.73e-05	-0.36	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49612657~49615716:-
LIHC	cis	rs5756813	0.87	rs5756812	ENSG00000233360.4	Z83844.1	-5.66	3.16e-08	1.73e-05	-0.37	-0.29	Optic cup area;Vertical cup-disc ratio;	chr22:37777106	chr22:37641832~37658377:-
LIHC	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-5.66	3.16e-08	1.73e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
LIHC	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	5.66	3.17e-08	1.74e-05	0.28	0.29	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
LIHC	cis	rs4698412	0.874	rs3213710	ENSG00000214846.4	RP11-115L11.1	-5.66	3.17e-08	1.74e-05	-0.37	-0.29	Parkinson's disease;	chr4:15715698	chr4:15730962~15731627:-
LIHC	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	5.66	3.17e-08	1.74e-05	0.29	0.29	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
LIHC	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	5.66	3.18e-08	1.74e-05	0.51	0.29	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
LIHC	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-5.66	3.19e-08	1.75e-05	-0.36	-0.29	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-5.66	3.19e-08	1.75e-05	-0.36	-0.29	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-5.66	3.19e-08	1.75e-05	-0.36	-0.29	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-5.66	3.19e-08	1.75e-05	-0.36	-0.29	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
LIHC	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	5.66	3.19e-08	1.75e-05	0.31	0.29	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
LIHC	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-5.66	3.19e-08	1.75e-05	-0.24	-0.29	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	5.66	3.2e-08	1.75e-05	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
LIHC	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	5.66	3.2e-08	1.75e-05	0.38	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
LIHC	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-5.66	3.2e-08	1.75e-05	-0.47	-0.29	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
LIHC	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-5.66	3.21e-08	1.75e-05	-0.36	-0.29	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
LIHC	cis	rs4934494	0.768	rs12572608	ENSG00000232936.4	RP11-80H5.2	-5.66	3.21e-08	1.76e-05	-0.37	-0.29	Red blood cell count;	chr10:89647170	chr10:89645282~89650667:+
LIHC	cis	rs12681287	0.605	rs6471296	ENSG00000250569.1	NTAN1P2	-5.66	3.22e-08	1.76e-05	-0.35	-0.29	Caudate activity during reward;	chr8:86362425	chr8:86481754~86483002:-
LIHC	cis	rs6686842	1	rs213748	ENSG00000235358.1	RP11-399E6.1	-5.66	3.22e-08	1.76e-05	-0.32	-0.29	Height;	chr1:41163058	chr1:41242373~41284861:+
LIHC	cis	rs6686842	1	rs213747	ENSG00000235358.1	RP11-399E6.1	-5.66	3.22e-08	1.76e-05	-0.32	-0.29	Height;	chr1:41163066	chr1:41242373~41284861:+
LIHC	cis	rs6686842	1	rs2363803	ENSG00000235358.1	RP11-399E6.1	5.66	3.22e-08	1.76e-05	0.32	0.29	Height;	chr1:41171857	chr1:41242373~41284861:+
LIHC	cis	rs6686842	1	rs34454389	ENSG00000235358.1	RP11-399E6.1	5.66	3.22e-08	1.76e-05	0.32	0.29	Height;	chr1:41197564	chr1:41242373~41284861:+
LIHC	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	5.66	3.23e-08	1.76e-05	0.25	0.29	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
LIHC	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	5.66	3.23e-08	1.77e-05	0.32	0.29	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	5.66	3.23e-08	1.77e-05	0.32	0.29	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	5.66	3.23e-08	1.77e-05	0.32	0.29	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
LIHC	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-5.66	3.24e-08	1.77e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-5.66	3.24e-08	1.77e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-5.66	3.24e-08	1.77e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-5.66	3.24e-08	1.77e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-5.66	3.24e-08	1.77e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-5.66	3.24e-08	1.77e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-5.66	3.24e-08	1.77e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
LIHC	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	5.66	3.24e-08	1.77e-05	0.32	0.29	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
LIHC	cis	rs12681287	0.517	rs68008113	ENSG00000250569.1	NTAN1P2	5.66	3.24e-08	1.77e-05	0.35	0.29	Caudate activity during reward;	chr8:86508665	chr8:86481754~86483002:-
LIHC	cis	rs3096299	0.719	rs2353581	ENSG00000261118.1	RP11-104N10.1	5.66	3.24e-08	1.77e-05	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89492017~89504460:-
LIHC	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	5.66	3.25e-08	1.77e-05	0.31	0.29	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
LIHC	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	5.66	3.25e-08	1.77e-05	0.22	0.29	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
LIHC	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	5.66	3.25e-08	1.78e-05	0.27	0.29	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
LIHC	cis	rs5756813	1	rs1074407	ENSG00000233360.4	Z83844.1	-5.66	3.25e-08	1.78e-05	-0.35	-0.29	Optic cup area;Vertical cup-disc ratio;	chr22:37760176	chr22:37641832~37658377:-
LIHC	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	5.66	3.25e-08	1.78e-05	0.34	0.29	Height;	chr6:109391534	chr6:109382795~109383666:+
LIHC	cis	rs4934494	0.911	rs7098233	ENSG00000232936.4	RP11-80H5.2	-5.66	3.26e-08	1.78e-05	-0.36	-0.29	Red blood cell count;	chr10:89663111	chr10:89645282~89650667:+
LIHC	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-5.66	3.26e-08	1.78e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
LIHC	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	5.66	3.26e-08	1.78e-05	0.44	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
LIHC	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	5.66	3.26e-08	1.78e-05	0.44	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
LIHC	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	5.66	3.27e-08	1.79e-05	0.45	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
LIHC	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	5.66	3.28e-08	1.79e-05	0.32	0.29	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
LIHC	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	5.66	3.28e-08	1.79e-05	0.31	0.29	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
LIHC	cis	rs854624	0.818	rs1719201	ENSG00000278690.1	RP11-104J23.2	5.66	3.29e-08	1.79e-05	0.42	0.29	Blood protein levels;	chr17:36011795	chr17:36012504~36012891:+
LIHC	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-5.66	3.29e-08	1.79e-05	-0.36	-0.29	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
LIHC	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	5.66	3.29e-08	1.79e-05	0.26	0.29	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
LIHC	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-5.66	3.29e-08	1.79e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
LIHC	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	5.65	3.3e-08	1.8e-05	0.47	0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
LIHC	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	5.65	3.3e-08	1.8e-05	0.33	0.29	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
LIHC	cis	rs12681287	0.752	rs6985427	ENSG00000250569.1	NTAN1P2	5.65	3.31e-08	1.8e-05	0.36	0.29	Caudate activity during reward;	chr8:86290516	chr8:86481754~86483002:-
LIHC	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-5.65	3.31e-08	1.81e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-5.65	3.32e-08	1.81e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-5.65	3.32e-08	1.81e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-5.65	3.32e-08	1.81e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
LIHC	cis	rs12908161	0.959	rs12906348	ENSG00000259295.5	CSPG4P12	5.65	3.32e-08	1.81e-05	0.4	0.29	Schizophrenia;	chr15:84786190	chr15:85191438~85213905:+
LIHC	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-5.65	3.32e-08	1.81e-05	-0.32	-0.29	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
LIHC	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-5.65	3.32e-08	1.81e-05	-0.32	-0.29	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
LIHC	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	5.65	3.33e-08	1.81e-05	0.42	0.29	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
LIHC	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-5.65	3.34e-08	1.82e-05	-0.38	-0.29	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
LIHC	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	5.65	3.34e-08	1.82e-05	0.39	0.29	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	5.65	3.34e-08	1.82e-05	0.39	0.29	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
LIHC	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	5.65	3.34e-08	1.82e-05	0.46	0.29	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
LIHC	cis	rs7176527	0.5	rs895571	ENSG00000189136.7	UBE2Q2P1	-5.65	3.35e-08	1.82e-05	-0.24	-0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:84526781~84571216:-
LIHC	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-5.65	3.35e-08	1.82e-05	-0.32	-0.29	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
LIHC	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-5.65	3.35e-08	1.82e-05	-0.32	-0.29	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
LIHC	cis	rs11672691	0.67	rs758643	ENSG00000267107.5	PCAT19	-5.65	3.36e-08	1.83e-05	-0.35	-0.29	Prostate cancer;	chr19:41485616	chr19:41454169~41500649:-
LIHC	cis	rs12157904	0.793	rs6000849	ENSG00000233360.4	Z83844.1	5.65	3.36e-08	1.83e-05	0.58	0.29	Response to anti-depressant treatment in major depressive disorder;	chr22:37635922	chr22:37641832~37658377:-
LIHC	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	5.65	3.36e-08	1.83e-05	0.4	0.29	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
LIHC	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	5.65	3.36e-08	1.83e-05	0.29	0.29	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
LIHC	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	5.65	3.36e-08	1.83e-05	0.29	0.29	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
LIHC	cis	rs1577917	0.545	rs9294338	ENSG00000234155.1	RP11-30P6.6	-5.65	3.36e-08	1.83e-05	-0.35	-0.29	Response to antipsychotic treatment;	chr6:85764650	chr6:85387219~85390186:-
LIHC	cis	rs3785309	0.519	rs7197253	ENSG00000268836.1	LA16c-OS12.2	-5.65	3.36e-08	1.83e-05	-0.54	-0.29	Immature fraction of reticulocytes;	chr16:226550	chr16:185748~186294:-
LIHC	cis	rs9326248	0.954	rs521171	ENSG00000236267.1	AP006216.5	5.65	3.37e-08	1.83e-05	0.3	0.29	Blood protein levels;	chr11:117193977	chr11:116813204~116814003:-
LIHC	cis	rs2762353	0.574	rs9467574	ENSG00000242387.1	HIST1H2APS2	-5.65	3.37e-08	1.83e-05	-0.37	-0.29	Blood metabolite levels;	chr6:25705490	chr6:25882026~25882395:-
LIHC	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-5.65	3.38e-08	1.84e-05	-0.36	-0.29	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
LIHC	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-5.65	3.38e-08	1.84e-05	-0.34	-0.29	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
LIHC	cis	rs3096299	0.754	rs3096296	ENSG00000274627.1	RP11-104N10.2	5.65	3.38e-08	1.84e-05	0.3	0.29	Multiple myeloma (IgH translocation);	chr16:89344602	chr16:89516797~89522217:+
LIHC	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	5.65	3.38e-08	1.84e-05	0.35	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
LIHC	cis	rs498872	1	rs498872	ENSG00000255239.1	AP002954.6	5.65	3.38e-08	1.84e-05	0.38	0.29	Glioma;	chr11:118606652	chr11:118688039~118690600:-
LIHC	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-5.65	3.38e-08	1.84e-05	-0.46	-0.29	Depression;	chr6:28151096	chr6:28115628~28116551:+
LIHC	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-5.65	3.39e-08	1.84e-05	-0.28	-0.29	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
LIHC	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-5.65	3.39e-08	1.84e-05	-0.32	-0.29	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
LIHC	cis	rs3858145	0.546	rs7912806	ENSG00000233590.1	RP11-153K11.3	5.65	3.39e-08	1.84e-05	0.39	0.29	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68296578	chr10:68233251~68242379:-
LIHC	cis	rs8028182	0.609	rs8038760	ENSG00000260269.4	CTD-2323K18.1	-5.65	3.4e-08	1.85e-05	-0.38	-0.29	Sudden cardiac arrest;	chr15:75449754	chr15:75527150~75601205:-
LIHC	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	5.65	3.4e-08	1.85e-05	0.29	0.29	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
LIHC	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-5.65	3.4e-08	1.85e-05	-0.36	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
LIHC	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	5.65	3.4e-08	1.85e-05	0.35	0.29	Height;	chr6:109360263	chr6:109382795~109383666:+
LIHC	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	5.65	3.4e-08	1.85e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	5.65	3.4e-08	1.85e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	5.65	3.4e-08	1.85e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
LIHC	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	5.65	3.4e-08	1.85e-05	0.4	0.29	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
LIHC	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	5.65	3.41e-08	1.85e-05	0.48	0.29	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
LIHC	cis	rs13068223	0.568	rs7636965	ENSG00000243926.1	TIPARP-AS1	5.65	3.41e-08	1.85e-05	0.31	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156700615	chr3:156671862~156674378:-
LIHC	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-5.65	3.41e-08	1.85e-05	-0.37	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
LIHC	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-5.65	3.41e-08	1.85e-05	-0.42	-0.29	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
LIHC	cis	rs12681287	0.547	rs13249177	ENSG00000250569.1	NTAN1P2	5.65	3.42e-08	1.86e-05	0.35	0.29	Caudate activity during reward;	chr8:86500805	chr8:86481754~86483002:-
LIHC	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	5.65	3.43e-08	1.86e-05	0.38	0.29	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
LIHC	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-5.65	3.44e-08	1.87e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
LIHC	cis	rs12681287	0.752	rs1080170	ENSG00000250569.1	NTAN1P2	5.65	3.44e-08	1.87e-05	0.36	0.29	Caudate activity during reward;	chr8:86297879	chr8:86481754~86483002:-
LIHC	cis	rs4535700	0.501	rs6943341	ENSG00000226278.1	PSPHP1	5.65	3.44e-08	1.87e-05	0.35	0.29	Macular telangiectasia type 2;	chr7:55907489	chr7:55764797~55773288:+
LIHC	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	5.65	3.44e-08	1.87e-05	0.36	0.29	Height;	chr6:109482392	chr6:109382795~109383666:+
LIHC	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	5.65	3.45e-08	1.87e-05	0.48	0.29	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
LIHC	cis	rs1799810	1	rs1158867	ENSG00000236682.1	AC068282.3	5.65	3.45e-08	1.87e-05	0.42	0.29	Self-rated health;	chr2:127419801	chr2:127389130~127400580:+
LIHC	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-5.65	3.46e-08	1.87e-05	-0.31	-0.29	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
LIHC	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-5.65	3.46e-08	1.87e-05	-0.35	-0.29	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
LIHC	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-5.65	3.46e-08	1.88e-05	-0.32	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
LIHC	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-5.65	3.47e-08	1.88e-05	-0.36	-0.29	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
LIHC	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-5.65	3.47e-08	1.88e-05	-0.3	-0.29	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
LIHC	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-5.65	3.47e-08	1.88e-05	-0.29	-0.29	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
LIHC	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	5.65	3.47e-08	1.88e-05	0.48	0.29	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
LIHC	cis	rs17270561	0.583	rs12662869	ENSG00000216436.2	HIST1H2APS1	5.65	3.47e-08	1.88e-05	0.36	0.29	Iron status biomarkers;	chr6:25784253	chr6:25732497~25732827:+
LIHC	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	5.64	3.48e-08	1.88e-05	0.33	0.29	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
LIHC	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	5.64	3.48e-08	1.89e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	5.64	3.48e-08	1.89e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	5.64	3.48e-08	1.89e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	5.64	3.48e-08	1.89e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
LIHC	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-5.64	3.48e-08	1.89e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
LIHC	cis	rs4356975	0.563	rs6600896	ENSG00000249956.3	RP11-790I12.2	5.64	3.49e-08	1.89e-05	0.33	0.29	Obesity-related traits;	chr4:69121000	chr4:69408836~69423164:+
LIHC	cis	rs4356975	0.563	rs6600897	ENSG00000249956.3	RP11-790I12.2	5.64	3.49e-08	1.89e-05	0.33	0.29	Obesity-related traits;	chr4:69121531	chr4:69408836~69423164:+
LIHC	cis	rs12681287	0.608	rs2953511	ENSG00000250569.1	NTAN1P2	5.64	3.49e-08	1.89e-05	0.35	0.29	Caudate activity during reward;	chr8:86328641	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.647	rs2953510	ENSG00000250569.1	NTAN1P2	5.64	3.49e-08	1.89e-05	0.35	0.29	Caudate activity during reward;	chr8:86329685	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.605	rs2953509	ENSG00000250569.1	NTAN1P2	5.64	3.49e-08	1.89e-05	0.35	0.29	Caudate activity during reward;	chr8:86330965	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs7816629	ENSG00000250569.1	NTAN1P2	5.64	3.49e-08	1.89e-05	0.35	0.29	Caudate activity during reward;	chr8:86338559	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.64	rs7820234	ENSG00000250569.1	NTAN1P2	5.64	3.49e-08	1.89e-05	0.35	0.29	Caudate activity during reward;	chr8:86338721	chr8:86481754~86483002:-
LIHC	cis	rs9409565	0.502	rs509022	ENSG00000231806.2	PCAT7	5.64	3.5e-08	1.89e-05	0.35	0.29	Colorectal cancer (alcohol consumption interaction);	chr9:94566989	chr9:94555069~94568127:+
LIHC	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-5.64	3.5e-08	1.89e-05	-0.35	-0.29	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-5.64	3.5e-08	1.89e-05	-0.35	-0.29	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
LIHC	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-5.64	3.5e-08	1.9e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
LIHC	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-5.64	3.51e-08	1.9e-05	-0.48	-0.29	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
LIHC	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	5.64	3.51e-08	1.9e-05	0.29	0.29	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-5.64	3.51e-08	1.9e-05	-0.28	-0.29	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
LIHC	cis	rs13068223	0.84	rs11709829	ENSG00000243926.1	TIPARP-AS1	5.64	3.51e-08	1.9e-05	0.28	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156716300	chr3:156671862~156674378:-
LIHC	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-5.64	3.52e-08	1.9e-05	-0.31	-0.29	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
LIHC	cis	rs4731207	0.592	rs6967988	ENSG00000224897.5	POT1-AS1	5.64	3.52e-08	1.9e-05	0.34	0.29	Cutaneous malignant melanoma;	chr7:124930418	chr7:124929873~125179315:+
LIHC	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-5.64	3.52e-08	1.9e-05	-0.34	-0.29	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
LIHC	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-5.64	3.52e-08	1.9e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-5.64	3.53e-08	1.91e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
LIHC	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-5.64	3.53e-08	1.91e-05	-0.32	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
LIHC	cis	rs7734985	0.659	rs12517958	ENSG00000250551.1	RP11-254I22.1	5.64	3.53e-08	1.91e-05	0.36	0.29	IgG glycosylation;	chr5:96173749	chr5:96050115~96215519:+
LIHC	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	5.64	3.54e-08	1.92e-05	0.33	0.29	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
LIHC	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-5.64	3.55e-08	1.92e-05	-0.38	-0.29	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
LIHC	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-5.64	3.55e-08	1.92e-05	-0.38	-0.29	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
LIHC	cis	rs12681287	0.547	rs66808088	ENSG00000250569.1	NTAN1P2	5.64	3.56e-08	1.92e-05	0.35	0.29	Caudate activity during reward;	chr8:86508983	chr8:86481754~86483002:-
LIHC	cis	rs2522056	0.808	rs17771891	ENSG00000233006.5	AC034220.3	5.64	3.56e-08	1.92e-05	0.32	0.29	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132311285~132369916:-
LIHC	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-5.64	3.57e-08	1.93e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
LIHC	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	5.64	3.57e-08	1.93e-05	0.36	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
LIHC	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	5.64	3.57e-08	1.93e-05	0.29	0.29	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
LIHC	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-5.64	3.58e-08	1.93e-05	-0.38	-0.29	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
LIHC	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	5.64	3.58e-08	1.94e-05	0.35	0.29	Height;	chr6:109390116	chr6:109382795~109383666:+
LIHC	cis	rs739496	0.843	rs10774631	ENSG00000226469.1	ADAM1B	-5.64	3.58e-08	1.94e-05	-0.36	-0.29	Platelet count;	chr12:111585197	chr12:111927018~111929017:+
LIHC	cis	rs7119038	0.509	rs10892260	ENSG00000255239.1	AP002954.6	-5.64	3.58e-08	1.94e-05	-0.39	-0.29	Sjögren's syndrome;	chr11:118712816	chr11:118688039~118690600:-
LIHC	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	5.64	3.59e-08	1.94e-05	0.38	0.29	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
LIHC	cis	rs12908161	0.96	rs62019463	ENSG00000259295.5	CSPG4P12	5.64	3.59e-08	1.94e-05	0.4	0.29	Schizophrenia;	chr15:84744856	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs62019464	ENSG00000259295.5	CSPG4P12	5.64	3.59e-08	1.94e-05	0.4	0.29	Schizophrenia;	chr15:84751238	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs12910012	ENSG00000259295.5	CSPG4P12	5.64	3.59e-08	1.94e-05	0.4	0.29	Schizophrenia;	chr15:84755431	chr15:85191438~85213905:+
LIHC	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	5.64	3.6e-08	1.94e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	5.64	3.6e-08	1.94e-05	0.36	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	5.64	3.6e-08	1.94e-05	0.36	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
LIHC	cis	rs12908161	1	rs12905057	ENSG00000259295.5	CSPG4P12	5.64	3.6e-08	1.94e-05	0.4	0.29	Schizophrenia;	chr15:84667534	chr15:85191438~85213905:+
LIHC	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	5.64	3.6e-08	1.95e-05	0.35	0.29	Height;	chr6:109367335	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	5.64	3.6e-08	1.95e-05	0.35	0.29	Height;	chr6:109368228	chr6:109382795~109383666:+
LIHC	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	5.64	3.61e-08	1.95e-05	0.41	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
LIHC	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	5.64	3.61e-08	1.95e-05	0.33	0.29	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
LIHC	cis	rs1577917	0.839	rs6929514	ENSG00000234155.1	RP11-30P6.6	5.64	3.61e-08	1.95e-05	0.35	0.29	Response to antipsychotic treatment;	chr6:85816050	chr6:85387219~85390186:-
LIHC	cis	rs12681287	0.517	rs7462883	ENSG00000250569.1	NTAN1P2	5.64	3.62e-08	1.95e-05	0.35	0.29	Caudate activity during reward;	chr8:86514562	chr8:86481754~86483002:-
LIHC	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-5.64	3.62e-08	1.96e-05	-0.36	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
LIHC	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	5.64	3.64e-08	1.96e-05	0.4	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
LIHC	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	5.64	3.64e-08	1.96e-05	0.33	0.29	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	5.64	3.64e-08	1.96e-05	0.33	0.29	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
LIHC	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-5.64	3.64e-08	1.96e-05	-0.31	-0.29	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
LIHC	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-5.64	3.64e-08	1.96e-05	-0.35	-0.29	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
LIHC	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-5.64	3.65e-08	1.97e-05	-0.38	-0.29	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
LIHC	cis	rs2522056	1	rs2706339	ENSG00000233006.5	AC034220.3	-5.64	3.65e-08	1.97e-05	-0.31	-0.29	Fibrinogen;Lymphocyte counts;	chr5:132464413	chr5:132311285~132369916:-
LIHC	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	5.64	3.66e-08	1.97e-05	0.4	0.29	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
LIHC	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	5.64	3.66e-08	1.97e-05	0.47	0.29	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
LIHC	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	5.64	3.66e-08	1.97e-05	0.33	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
LIHC	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	5.63	3.66e-08	1.97e-05	0.3	0.29	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
LIHC	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-5.63	3.67e-08	1.98e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-5.63	3.67e-08	1.98e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-5.63	3.67e-08	1.98e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
LIHC	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	5.63	3.67e-08	1.98e-05	0.36	0.29	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
LIHC	cis	rs12681287	0.547	rs56752411	ENSG00000250569.1	NTAN1P2	5.63	3.68e-08	1.98e-05	0.35	0.29	Caudate activity during reward;	chr8:86502927	chr8:86481754~86483002:-
LIHC	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-5.63	3.69e-08	1.99e-05	-0.38	-0.29	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
LIHC	cis	rs2762353	0.526	rs3936052	ENSG00000216436.2	HIST1H2APS1	-5.63	3.71e-08	2e-05	-0.35	-0.29	Blood metabolite levels;	chr6:25715306	chr6:25732497~25732827:+
LIHC	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	5.63	3.71e-08	2e-05	0.3	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
LIHC	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-5.63	3.71e-08	2e-05	-0.34	-0.29	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
LIHC	cis	rs2735413	0.599	rs73562710	ENSG00000276007.1	RP11-358L22.3	5.63	3.71e-08	2e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78090709	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.564	rs79006334	ENSG00000276007.1	RP11-358L22.3	5.63	3.71e-08	2e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78091057	chr16:78123243~78124332:+
LIHC	cis	rs12681287	0.752	rs2917557	ENSG00000250569.1	NTAN1P2	5.63	3.72e-08	2e-05	0.36	0.29	Caudate activity during reward;	chr8:86301842	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.752	rs4282548	ENSG00000250569.1	NTAN1P2	5.63	3.73e-08	2.01e-05	0.36	0.29	Caudate activity during reward;	chr8:86258563	chr8:86481754~86483002:-
LIHC	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-5.63	3.73e-08	2.01e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
LIHC	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-5.63	3.73e-08	2.01e-05	-0.31	-0.29	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-5.63	3.73e-08	2.01e-05	-0.31	-0.29	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-5.63	3.73e-08	2.01e-05	-0.31	-0.29	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
LIHC	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-5.63	3.73e-08	2.01e-05	-0.36	-0.29	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
LIHC	cis	rs523522	1	rs523522	ENSG00000278344.1	RP11-18C24.8	5.63	3.73e-08	2.01e-05	0.35	0.29	High light scatter reticulocyte count;	chr12:120582447	chr12:120500735~120501090:-
LIHC	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-5.63	3.74e-08	2.01e-05	-0.35	-0.29	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-5.63	3.74e-08	2.01e-05	-0.35	-0.29	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-5.63	3.74e-08	2.01e-05	-0.36	-0.29	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
LIHC	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	5.63	3.74e-08	2.01e-05	0.34	0.29	Height;	chr6:109351795	chr6:109382795~109383666:+
LIHC	cis	rs860295	1	rs822490	ENSG00000203761.5	MSTO2P	-5.63	3.75e-08	2.01e-05	-0.23	-0.29	Body mass index;	chr1:155853180	chr1:155745829~155750137:+
LIHC	cis	rs12744310	0.887	rs12037129	ENSG00000235358.1	RP11-399E6.1	5.63	3.75e-08	2.01e-05	0.4	0.29	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328629	chr1:41242373~41284861:+
LIHC	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-5.63	3.75e-08	2.01e-05	-0.35	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
LIHC	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-5.63	3.75e-08	2.02e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
LIHC	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	5.63	3.76e-08	2.02e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
LIHC	cis	rs12291225	0.585	rs4517475	ENSG00000251991.1	RNU7-49P	5.63	3.77e-08	2.02e-05	0.31	0.29	Sense of smell;	chr11:14364599	chr11:14478892~14478953:+
LIHC	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	5.63	3.77e-08	2.02e-05	0.31	0.29	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
LIHC	cis	rs739496	0.744	rs848130	ENSG00000226469.1	ADAM1B	5.63	3.77e-08	2.02e-05	0.35	0.29	Platelet count;	chr12:111572027	chr12:111927018~111929017:+
LIHC	cis	rs2522056	1	rs2522054	ENSG00000233006.5	AC034220.3	-5.63	3.77e-08	2.03e-05	-0.31	-0.29	Fibrinogen;Lymphocyte counts;	chr5:132463834	chr5:132311285~132369916:-
LIHC	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	5.63	3.78e-08	2.03e-05	0.44	0.29	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
LIHC	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-5.63	3.79e-08	2.04e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
LIHC	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	5.63	3.8e-08	2.04e-05	0.28	0.29	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
LIHC	cis	rs3858145	0.5	rs4633337	ENSG00000233590.1	RP11-153K11.3	5.63	3.8e-08	2.04e-05	0.4	0.29	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68233251~68242379:-
LIHC	cis	rs2735413	0.564	rs11863846	ENSG00000276007.1	RP11-358L22.3	5.63	3.82e-08	2.05e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78085660	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.564	rs7192226	ENSG00000276007.1	RP11-358L22.3	5.63	3.82e-08	2.05e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78086363	chr16:78123243~78124332:+
LIHC	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	5.63	3.82e-08	2.05e-05	0.32	0.29	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
LIHC	cis	rs1577917	0.883	rs1415749	ENSG00000234155.1	RP11-30P6.6	-5.63	3.83e-08	2.05e-05	-0.35	-0.29	Response to antipsychotic treatment;	chr6:86069366	chr6:85387219~85390186:-
LIHC	cis	rs2284219	0.565	rs2284217	ENSG00000226874.1	AC005154.8	-5.63	3.83e-08	2.06e-05	-0.34	-0.29	Type 2 diabetes;	chr7:30673992	chr7:30544053~30544431:+
LIHC	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	5.63	3.83e-08	2.06e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
LIHC	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	5.63	3.84e-08	2.06e-05	0.38	0.29	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
LIHC	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-5.63	3.84e-08	2.06e-05	-0.32	-0.29	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
LIHC	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	5.63	3.84e-08	2.06e-05	0.44	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
LIHC	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	5.63	3.84e-08	2.06e-05	0.31	0.29	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	5.63	3.84e-08	2.06e-05	0.31	0.29	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	5.63	3.84e-08	2.06e-05	0.31	0.29	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
LIHC	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	5.63	3.84e-08	2.06e-05	0.48	0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
LIHC	cis	rs5769707	0.656	rs135878	ENSG00000235111.1	RP1-29C18.8	-5.62	3.87e-08	2.07e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49612657~49615716:-
LIHC	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	5.62	3.87e-08	2.07e-05	0.3	0.29	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
LIHC	cis	rs12908161	1	rs17600551	ENSG00000259295.5	CSPG4P12	5.62	3.87e-08	2.07e-05	0.39	0.29	Schizophrenia;	chr15:84776027	chr15:85191438~85213905:+
LIHC	cis	rs12908161	1	rs62019469	ENSG00000259295.5	CSPG4P12	5.62	3.87e-08	2.07e-05	0.39	0.29	Schizophrenia;	chr15:84777989	chr15:85191438~85213905:+
LIHC	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-5.62	3.88e-08	2.08e-05	-0.48	-0.29	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
LIHC	cis	rs227275	0.554	rs223421	ENSG00000230069.3	LRRC37A15P	-5.62	3.9e-08	2.09e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102727274~102730721:-
LIHC	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	5.62	3.91e-08	2.09e-05	0.29	0.29	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
LIHC	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-5.62	3.91e-08	2.1e-05	-0.37	-0.29	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
LIHC	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-5.62	3.91e-08	2.1e-05	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
LIHC	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-5.62	3.91e-08	2.1e-05	-0.28	-0.29	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
LIHC	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-5.62	3.92e-08	2.1e-05	-0.35	-0.29	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
LIHC	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	5.62	3.93e-08	2.11e-05	0.38	0.29	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
LIHC	cis	rs9326248	0.911	rs474339	ENSG00000236267.1	AP006216.5	5.62	3.93e-08	2.11e-05	0.29	0.29	Blood protein levels;	chr11:117188836	chr11:116813204~116814003:-
LIHC	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-5.62	3.93e-08	2.11e-05	-0.36	-0.29	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-5.62	3.93e-08	2.11e-05	-0.36	-0.29	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
LIHC	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-5.62	3.93e-08	2.11e-05	-0.37	-0.29	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
LIHC	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-5.62	3.93e-08	2.11e-05	-0.35	-0.29	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-5.62	3.93e-08	2.11e-05	-0.35	-0.29	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-5.62	3.93e-08	2.11e-05	-0.35	-0.29	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
LIHC	cis	rs12681287	0.511	rs7839601	ENSG00000250569.1	NTAN1P2	5.62	3.94e-08	2.11e-05	0.35	0.29	Caudate activity during reward;	chr8:86491610	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs7459877	ENSG00000250569.1	NTAN1P2	5.62	3.94e-08	2.11e-05	0.35	0.29	Caudate activity during reward;	chr8:86493431	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs7837569	ENSG00000250569.1	NTAN1P2	5.62	3.94e-08	2.11e-05	0.35	0.29	Caudate activity during reward;	chr8:86495137	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.517	rs34367154	ENSG00000250569.1	NTAN1P2	5.62	3.94e-08	2.11e-05	0.35	0.29	Caudate activity during reward;	chr8:86496520	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs9942792	ENSG00000250569.1	NTAN1P2	5.62	3.94e-08	2.11e-05	0.35	0.29	Caudate activity during reward;	chr8:86496817	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs9942793	ENSG00000250569.1	NTAN1P2	5.62	3.94e-08	2.11e-05	0.35	0.29	Caudate activity during reward;	chr8:86496862	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs9942823	ENSG00000250569.1	NTAN1P2	5.62	3.94e-08	2.11e-05	0.35	0.29	Caudate activity during reward;	chr8:86496948	chr8:86481754~86483002:-
LIHC	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	5.62	3.95e-08	2.11e-05	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
LIHC	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-5.62	3.96e-08	2.12e-05	-0.31	-0.29	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
LIHC	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-5.62	3.97e-08	2.12e-05	-0.37	-0.29	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
LIHC	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	5.62	3.97e-08	2.12e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	5.62	3.97e-08	2.12e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	5.62	3.97e-08	2.12e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	5.62	3.97e-08	2.12e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	5.62	3.97e-08	2.12e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	5.62	3.97e-08	2.12e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	5.62	3.97e-08	2.12e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
LIHC	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-5.62	3.97e-08	2.12e-05	-0.35	-0.29	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
LIHC	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-5.62	3.97e-08	2.12e-05	-0.36	-0.29	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
LIHC	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	5.62	3.98e-08	2.13e-05	0.32	0.29	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
LIHC	cis	rs5758511	0.68	rs5758662	ENSG00000237037.8	NDUFA6-AS1	-5.62	3.98e-08	2.13e-05	-0.37	-0.29	Birth weight;	chr22:42232082	chr22:42090931~42137742:+
LIHC	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	5.62	3.99e-08	2.13e-05	0.36	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
LIHC	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-5.62	3.99e-08	2.14e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
LIHC	cis	rs7131987	0.622	rs7294598	ENSG00000275476.1	RP11-996F15.4	5.62	4e-08	2.14e-05	0.34	0.29	QT interval;	chr12:29379056	chr12:29277397~29277882:-
LIHC	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-5.62	4e-08	2.14e-05	-0.36	-0.29	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-5.62	4e-08	2.14e-05	-0.36	-0.29	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-5.62	4.01e-08	2.14e-05	-0.36	-0.29	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-5.62	4.01e-08	2.14e-05	-0.36	-0.29	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
LIHC	cis	rs3096299	0.9	rs3114867	ENSG00000261118.1	RP11-104N10.1	5.62	4.01e-08	2.14e-05	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89492017~89504460:-
LIHC	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	5.62	4.01e-08	2.15e-05	0.32	0.29	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
LIHC	cis	rs6686842	0.965	rs10157966	ENSG00000235358.1	RP11-399E6.1	-5.62	4.02e-08	2.15e-05	-0.32	-0.29	Height;	chr1:41256904	chr1:41242373~41284861:+
LIHC	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-5.62	4.02e-08	2.15e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
LIHC	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	5.62	4.02e-08	2.15e-05	0.45	0.29	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
LIHC	cis	rs62229266	0.605	rs11701331	ENSG00000231106.2	LINC01436	5.62	4.03e-08	2.15e-05	0.32	0.29	Mitral valve prolapse;	chr21:36086094	chr21:36005338~36007838:+
LIHC	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-5.62	4.03e-08	2.15e-05	-0.42	-0.29	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
LIHC	cis	rs2072510	0.722	rs2247330	ENSG00000257715.1	RP11-256L6.2	5.62	4.03e-08	2.15e-05	0.29	0.29	Metabolite levels (small molecules and protein measures);	chr12:96030344	chr12:96025323~96027971:+
LIHC	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	5.62	4.03e-08	2.15e-05	0.28	0.29	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
LIHC	cis	rs5758659	1	rs134873	ENSG00000227370.1	RP4-669P10.19	-5.62	4.04e-08	2.16e-05	-0.32	-0.29	Cognitive function;	chr22:42261560	chr22:42132543~42132998:+
LIHC	cis	rs2735413	0.564	rs7201557	ENSG00000276007.1	RP11-358L22.3	5.62	4.04e-08	2.16e-05	0.4	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78076162	chr16:78123243~78124332:+
LIHC	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	5.62	4.05e-08	2.16e-05	0.35	0.29	Height;	chr6:109370741	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	5.62	4.05e-08	2.16e-05	0.35	0.29	Height;	chr6:109371524	chr6:109382795~109383666:+
LIHC	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	5.62	4.06e-08	2.17e-05	0.28	0.29	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
LIHC	cis	rs2243480	1	rs2243480	ENSG00000164669.11	INTS4P1	5.62	4.06e-08	2.17e-05	0.51	0.29	Diabetic kidney disease;	chr7:66134209	chr7:65141225~65234216:+
LIHC	cis	rs13068223	0.617	rs13061457	ENSG00000243926.1	TIPARP-AS1	5.61	4.07e-08	2.17e-05	0.27	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156671862~156674378:-
LIHC	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	5.61	4.08e-08	2.18e-05	0.31	0.29	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
LIHC	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-5.61	4.09e-08	2.18e-05	-0.38	-0.29	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
LIHC	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	5.61	4.1e-08	2.19e-05	0.38	0.29	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
LIHC	cis	rs7131987	0.903	rs11050161	ENSG00000257176.2	RP11-996F15.2	-5.61	4.1e-08	2.19e-05	-0.34	-0.29	QT interval;	chr12:29267116	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.903	rs11050162	ENSG00000257176.2	RP11-996F15.2	-5.61	4.1e-08	2.19e-05	-0.34	-0.29	QT interval;	chr12:29267121	chr12:29280418~29317848:-
LIHC	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-5.61	4.1e-08	2.19e-05	-0.4	-0.29	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
LIHC	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-5.61	4.1e-08	2.19e-05	-0.4	-0.29	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
LIHC	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-5.61	4.11e-08	2.19e-05	-0.36	-0.29	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
LIHC	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-5.61	4.11e-08	2.19e-05	-0.37	-0.29	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
LIHC	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	5.61	4.12e-08	2.2e-05	0.42	0.29	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
LIHC	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-5.61	4.12e-08	2.2e-05	-0.32	-0.29	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
LIHC	cis	rs2735413	0.522	rs2075737	ENSG00000276007.1	RP11-358L22.3	5.61	4.12e-08	2.2e-05	0.36	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78023077	chr16:78123243~78124332:+
LIHC	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-5.61	4.12e-08	2.2e-05	-0.36	-0.29	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
LIHC	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-5.61	4.13e-08	2.2e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
LIHC	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	5.61	4.14e-08	2.21e-05	0.33	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	5.61	4.14e-08	2.21e-05	0.33	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
LIHC	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-5.61	4.15e-08	2.21e-05	-0.32	-0.29	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
LIHC	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	5.61	4.16e-08	2.22e-05	0.33	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
LIHC	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-5.61	4.16e-08	2.22e-05	-0.36	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
LIHC	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-5.61	4.16e-08	2.22e-05	-0.37	-0.29	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
LIHC	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	5.61	4.17e-08	2.22e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
LIHC	cis	rs62229266	0.605	rs2835275	ENSG00000231106.2	LINC01436	5.61	4.17e-08	2.22e-05	0.32	0.29	Mitral valve prolapse;	chr21:36087703	chr21:36005338~36007838:+
LIHC	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	5.61	4.17e-08	2.22e-05	0.37	0.29	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
LIHC	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-5.61	4.17e-08	2.22e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
LIHC	cis	rs950169	0.84	rs62019457	ENSG00000259295.5	CSPG4P12	5.61	4.18e-08	2.23e-05	0.39	0.29	Schizophrenia;	chr15:84558911	chr15:85191438~85213905:+
LIHC	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-5.61	4.18e-08	2.23e-05	-0.45	-0.29	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
LIHC	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	5.61	4.21e-08	2.24e-05	0.4	0.29	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
LIHC	cis	rs5769707	0.605	rs9616702	ENSG00000235111.1	RP1-29C18.8	-5.61	4.21e-08	2.24e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49612657~49615716:-
LIHC	cis	rs9326248	0.53	rs7940310	ENSG00000236267.1	AP006216.5	5.61	4.22e-08	2.24e-05	0.32	0.29	Blood protein levels;	chr11:117153765	chr11:116813204~116814003:-
LIHC	cis	rs5758659	0.845	rs5758645	ENSG00000227370.1	RP4-669P10.19	-5.61	4.23e-08	2.25e-05	-0.34	-0.29	Cognitive function;	chr22:42202945	chr22:42132543~42132998:+
LIHC	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	5.61	4.23e-08	2.25e-05	0.29	0.29	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
LIHC	cis	rs887829	0.641	rs10179094	ENSG00000233445.1	RPL17P11	5.61	4.23e-08	2.25e-05	0.31	0.29	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233689179	chr2:233721522~233722065:-
LIHC	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	5.61	4.24e-08	2.26e-05	0.63	0.29	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
LIHC	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-5.61	4.25e-08	2.26e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
LIHC	cis	rs12681287	0.547	rs6998303	ENSG00000250569.1	NTAN1P2	5.61	4.26e-08	2.27e-05	0.35	0.29	Caudate activity during reward;	chr8:86497956	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs13267858	ENSG00000250569.1	NTAN1P2	5.61	4.26e-08	2.27e-05	0.35	0.29	Caudate activity during reward;	chr8:86498642	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs7461366	ENSG00000250569.1	NTAN1P2	5.61	4.26e-08	2.27e-05	0.35	0.29	Caudate activity during reward;	chr8:86499456	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs4961197	ENSG00000250569.1	NTAN1P2	5.61	4.26e-08	2.27e-05	0.35	0.29	Caudate activity during reward;	chr8:86500207	chr8:86481754~86483002:-
LIHC	cis	rs17301013	0.861	rs12568655	ENSG00000227373.4	RP11-160H22.5	5.61	4.27e-08	2.27e-05	0.37	0.29	Systemic lupus erythematosus;	chr1:174465194	chr1:174115300~174160004:-
LIHC	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-5.61	4.27e-08	2.27e-05	-0.35	-0.29	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
LIHC	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-5.61	4.27e-08	2.27e-05	-0.31	-0.29	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
LIHC	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	5.61	4.28e-08	2.27e-05	0.36	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
LIHC	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-5.61	4.28e-08	2.27e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
LIHC	cis	rs2735413	0.563	rs17776016	ENSG00000276007.1	RP11-358L22.3	-5.61	4.28e-08	2.28e-05	-0.38	-0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78013920	chr16:78123243~78124332:+
LIHC	cis	rs12681287	0.547	rs11992656	ENSG00000250569.1	NTAN1P2	-5.61	4.28e-08	2.28e-05	-0.35	-0.29	Caudate activity during reward;	chr8:86522641	chr8:86481754~86483002:-
LIHC	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-5.61	4.28e-08	2.28e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
LIHC	cis	rs35828350	1	rs35828350	ENSG00000259295.5	CSPG4P12	5.61	4.28e-08	2.28e-05	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:85191438~85213905:+
LIHC	cis	rs10461617	0.617	rs1423623	ENSG00000271828.1	CTD-2310F14.1	-5.6	4.3e-08	2.28e-05	-0.37	-0.29	Type 2 diabetes;	chr5:56769748	chr5:56927874~56929573:+
LIHC	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	5.6	4.3e-08	2.28e-05	0.31	0.29	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
LIHC	cis	rs12908161	1	rs12899981	ENSG00000259295.5	CSPG4P12	5.6	4.31e-08	2.29e-05	0.4	0.29	Schizophrenia;	chr15:84759142	chr15:85191438~85213905:+
LIHC	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-5.6	4.31e-08	2.29e-05	-0.4	-0.29	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
LIHC	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	5.6	4.31e-08	2.29e-05	0.46	0.29	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
LIHC	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-5.6	4.32e-08	2.29e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
LIHC	cis	rs12157904	0.793	rs2071767	ENSG00000233360.4	Z83844.1	5.6	4.33e-08	2.3e-05	0.56	0.29	Response to anti-depressant treatment in major depressive disorder;	chr22:37629814	chr22:37641832~37658377:-
LIHC	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	5.6	4.33e-08	2.3e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
LIHC	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-5.6	4.34e-08	2.3e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
LIHC	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	5.6	4.35e-08	2.31e-05	0.39	0.29	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
LIHC	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	5.6	4.35e-08	2.31e-05	0.37	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
LIHC	cis	rs8059260	0.541	rs12917947	ENSG00000274038.1	RP11-66H6.4	-5.6	4.36e-08	2.31e-05	-0.5	-0.29	Alcohol consumption over the past year;	chr16:11116386	chr16:11056556~11057034:+
LIHC	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	5.6	4.36e-08	2.31e-05	0.45	0.29	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
LIHC	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-5.6	4.38e-08	2.32e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-5.6	4.38e-08	2.32e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
LIHC	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	5.6	4.39e-08	2.33e-05	0.31	0.29	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
LIHC	cis	rs2735413	0.564	rs6564508	ENSG00000276007.1	RP11-358L22.3	5.6	4.39e-08	2.33e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78082678	chr16:78123243~78124332:+
LIHC	cis	rs12681287	0.511	rs4129535	ENSG00000250569.1	NTAN1P2	5.6	4.4e-08	2.33e-05	0.35	0.29	Caudate activity during reward;	chr8:86511865	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs6985066	ENSG00000250569.1	NTAN1P2	5.6	4.4e-08	2.33e-05	0.35	0.29	Caudate activity during reward;	chr8:86514210	chr8:86481754~86483002:-
LIHC	cis	rs10510102	0.935	rs11200263	ENSG00000226864.1	ATE1-AS1	5.6	4.4e-08	2.33e-05	0.48	0.29	Breast cancer;	chr10:121922836	chr10:121928312~121951965:+
LIHC	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	5.6	4.4e-08	2.33e-05	0.3	0.29	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
LIHC	cis	rs9326248	1	rs3736120	ENSG00000236267.1	AP006216.5	5.6	4.4e-08	2.33e-05	0.3	0.29	Blood protein levels;	chr11:117161409	chr11:116813204~116814003:-
LIHC	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-5.6	4.4e-08	2.33e-05	-0.41	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
LIHC	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	5.6	4.41e-08	2.34e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	5.6	4.41e-08	2.34e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	5.6	4.41e-08	2.34e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
LIHC	cis	rs12157904	0.793	rs2051593	ENSG00000233360.4	Z83844.1	-5.6	4.41e-08	2.34e-05	-0.58	-0.29	Response to anti-depressant treatment in major depressive disorder;	chr22:37652027	chr22:37641832~37658377:-
LIHC	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	5.6	4.41e-08	2.34e-05	0.35	0.29	Height;	chr6:109382188	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	5.6	4.41e-08	2.34e-05	0.35	0.29	Height;	chr6:109383239	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	5.6	4.41e-08	2.34e-05	0.35	0.29	Height;	chr6:109383248	chr6:109382795~109383666:+
LIHC	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-5.6	4.41e-08	2.34e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
LIHC	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-5.6	4.41e-08	2.34e-05	-0.35	-0.29	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-5.6	4.41e-08	2.34e-05	-0.35	-0.29	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-5.6	4.41e-08	2.34e-05	-0.35	-0.29	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-5.6	4.41e-08	2.34e-05	-0.35	-0.29	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-5.6	4.41e-08	2.34e-05	-0.35	-0.29	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
LIHC	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-5.6	4.43e-08	2.34e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-5.6	4.43e-08	2.34e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-5.6	4.43e-08	2.34e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
LIHC	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	5.6	4.43e-08	2.34e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	5.6	4.43e-08	2.34e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
LIHC	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	5.6	4.44e-08	2.35e-05	0.32	0.29	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
LIHC	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-5.6	4.44e-08	2.35e-05	-0.28	-0.29	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-5.6	4.44e-08	2.35e-05	-0.28	-0.29	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	5.6	4.44e-08	2.35e-05	0.28	0.29	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	5.6	4.44e-08	2.35e-05	0.28	0.29	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	5.6	4.44e-08	2.35e-05	0.28	0.29	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	5.6	4.44e-08	2.35e-05	0.28	0.29	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
LIHC	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	5.6	4.44e-08	2.35e-05	0.3	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
LIHC	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	5.6	4.44e-08	2.35e-05	0.3	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
LIHC	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	5.6	4.44e-08	2.35e-05	0.3	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
LIHC	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	5.6	4.44e-08	2.35e-05	0.3	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
LIHC	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	5.6	4.44e-08	2.35e-05	0.3	0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
LIHC	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	5.6	4.44e-08	2.35e-05	0.29	0.29	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
LIHC	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-5.6	4.44e-08	2.35e-05	-0.39	-0.29	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
LIHC	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-5.6	4.44e-08	2.35e-05	-0.46	-0.29	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
LIHC	cis	rs831571	0.703	rs831566	ENSG00000280620.1	SCAANT1	-5.6	4.46e-08	2.36e-05	-0.4	-0.29	Type 2 diabetes;	chr3:64090262	chr3:63911518~63911772:-
LIHC	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-5.6	4.46e-08	2.36e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-5.6	4.46e-08	2.36e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-5.6	4.46e-08	2.36e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.554	rs223319	ENSG00000230069.3	LRRC37A15P	-5.6	4.47e-08	2.36e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.509	rs223318	ENSG00000230069.3	LRRC37A15P	-5.6	4.47e-08	2.36e-05	-0.26	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223315	ENSG00000230069.3	LRRC37A15P	-5.6	4.47e-08	2.36e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102727274~102730721:-
LIHC	cis	rs12458462	0.851	rs62097746	ENSG00000274828.1	RP11-567M16.6	5.6	4.48e-08	2.37e-05	0.31	0.29	Monocyte count;	chr18:79727508	chr18:79677287~79679358:-
LIHC	cis	rs12458462	0.851	rs60298379	ENSG00000274828.1	RP11-567M16.6	5.6	4.48e-08	2.37e-05	0.31	0.29	Monocyte count;	chr18:79728422	chr18:79677287~79679358:-
LIHC	cis	rs12458462	0.812	rs36073957	ENSG00000274828.1	RP11-567M16.6	5.6	4.48e-08	2.37e-05	0.31	0.29	Monocyte count;	chr18:79728441	chr18:79677287~79679358:-
LIHC	cis	rs12458462	0.851	rs2169249	ENSG00000274828.1	RP11-567M16.6	5.6	4.48e-08	2.37e-05	0.31	0.29	Monocyte count;	chr18:79729649	chr18:79677287~79679358:-
LIHC	cis	rs12681287	0.752	rs12548328	ENSG00000250569.1	NTAN1P2	5.6	4.5e-08	2.38e-05	0.36	0.29	Caudate activity during reward;	chr8:86298990	chr8:86481754~86483002:-
LIHC	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-5.6	4.5e-08	2.38e-05	-0.29	-0.29	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
LIHC	cis	rs7916697	0.891	rs7897809	ENSG00000233590.1	RP11-153K11.3	-5.6	4.5e-08	2.38e-05	-0.35	-0.29	Optic disc area;	chr10:68240536	chr10:68233251~68242379:-
LIHC	cis	rs12908161	1	rs11637142	ENSG00000259295.5	CSPG4P12	5.6	4.51e-08	2.38e-05	0.39	0.29	Schizophrenia;	chr15:84752696	chr15:85191438~85213905:+
LIHC	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	5.6	4.52e-08	2.39e-05	0.31	0.29	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
LIHC	cis	rs2933343	0.553	rs789212	ENSG00000231305.3	RP11-723O4.2	5.6	4.52e-08	2.39e-05	0.32	0.29	IgG glycosylation;	chr3:128968069	chr3:128861313~128871540:-
LIHC	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	5.6	4.53e-08	2.39e-05	0.45	0.29	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
LIHC	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	5.59	4.53e-08	2.39e-05	0.39	0.29	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	5.59	4.53e-08	2.39e-05	0.39	0.29	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	5.59	4.53e-08	2.39e-05	0.39	0.29	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
LIHC	cis	rs5769707	0.681	rs739236	ENSG00000235111.1	RP1-29C18.8	-5.59	4.54e-08	2.4e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49612657~49615716:-
LIHC	cis	rs739496	0.947	rs2339816	ENSG00000226469.1	ADAM1B	5.59	4.54e-08	2.4e-05	0.35	0.29	Platelet count;	chr12:111474384	chr12:111927018~111929017:+
LIHC	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	5.59	4.55e-08	2.4e-05	0.49	0.29	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
LIHC	cis	rs2072510	0.683	rs2540486	ENSG00000257715.1	RP11-256L6.2	-5.59	4.56e-08	2.41e-05	-0.29	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96037229	chr12:96025323~96027971:+
LIHC	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-5.59	4.56e-08	2.41e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
LIHC	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-5.59	4.56e-08	2.41e-05	-0.32	-0.29	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
LIHC	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	5.59	4.57e-08	2.41e-05	0.34	0.29	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
LIHC	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	5.59	4.58e-08	2.41e-05	0.28	0.29	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
LIHC	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
LIHC	cis	rs9341808	0.754	rs3793000	ENSG00000272129.1	RP11-250B2.6	5.59	4.58e-08	2.42e-05	0.28	0.29	Sitting height ratio;	chr6:80285420	chr6:80355424~80356859:+
LIHC	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	5.59	4.58e-08	2.42e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
LIHC	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	5.59	4.59e-08	2.42e-05	0.35	0.29	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
LIHC	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	5.59	4.59e-08	2.42e-05	0.27	0.29	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
LIHC	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	5.59	4.6e-08	2.42e-05	0.36	0.29	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
LIHC	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	5.59	4.6e-08	2.43e-05	0.3	0.29	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
LIHC	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-5.59	4.61e-08	2.43e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-5.59	4.61e-08	2.43e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-5.59	4.61e-08	2.43e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	5.59	4.61e-08	2.43e-05	0.48	0.29	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	5.59	4.61e-08	2.43e-05	0.48	0.29	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	5.59	4.61e-08	2.43e-05	0.48	0.29	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	5.59	4.61e-08	2.43e-05	0.48	0.29	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	5.59	4.61e-08	2.43e-05	0.48	0.29	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
LIHC	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-5.59	4.62e-08	2.43e-05	-0.29	-0.29	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
LIHC	cis	rs2933343	0.729	rs813732	ENSG00000231305.3	RP11-723O4.2	5.59	4.62e-08	2.44e-05	0.32	0.29	IgG glycosylation;	chr3:128900514	chr3:128861313~128871540:-
LIHC	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	5.59	4.63e-08	2.44e-05	0.38	0.29	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
LIHC	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-5.59	4.63e-08	2.44e-05	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
LIHC	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-5.59	4.63e-08	2.44e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-5.59	4.63e-08	2.44e-05	-0.28	-0.29	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
LIHC	cis	rs12908161	1	rs17601029	ENSG00000259295.5	CSPG4P12	5.59	4.63e-08	2.44e-05	0.39	0.29	Schizophrenia;	chr15:84804478	chr15:85191438~85213905:+
LIHC	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-5.59	4.64e-08	2.44e-05	-0.4	-0.29	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
LIHC	cis	rs228614	0.51	rs223328	ENSG00000230069.3	LRRC37A15P	-5.59	4.64e-08	2.44e-05	-0.26	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.536	rs223325	ENSG00000230069.3	LRRC37A15P	-5.59	4.64e-08	2.44e-05	-0.26	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102727274~102730721:-
LIHC	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	5.59	4.65e-08	2.45e-05	0.36	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
LIHC	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-5.59	4.68e-08	2.46e-05	-0.26	-0.29	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
LIHC	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-5.59	4.68e-08	2.46e-05	-0.35	-0.29	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
LIHC	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	5.59	4.68e-08	2.46e-05	0.44	0.29	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	5.59	4.68e-08	2.46e-05	0.44	0.29	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	5.59	4.68e-08	2.46e-05	0.44	0.29	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
LIHC	cis	rs734999	0.967	rs6671426	ENSG00000225931.3	RP3-395M20.7	5.59	4.69e-08	2.47e-05	0.32	0.29	Ulcerative colitis;	chr1:2572795	chr1:2566410~2569888:+
LIHC	cis	rs12681287	0.752	rs13255058	ENSG00000250569.1	NTAN1P2	5.59	4.69e-08	2.47e-05	0.36	0.29	Caudate activity during reward;	chr8:86275216	chr8:86481754~86483002:-
LIHC	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	5.59	4.69e-08	2.47e-05	0.39	0.29	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
LIHC	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-5.59	4.7e-08	2.47e-05	-0.38	-0.29	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
LIHC	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-5.59	4.7e-08	2.47e-05	-0.32	-0.29	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
LIHC	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	5.59	4.71e-08	2.48e-05	0.37	0.29	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
LIHC	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	5.59	4.74e-08	2.49e-05	0.41	0.29	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
LIHC	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-5.59	4.76e-08	2.5e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
LIHC	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-5.59	4.77e-08	2.5e-05	-0.35	-0.29	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
LIHC	cis	rs860295	0.812	rs11264413	ENSG00000203761.5	MSTO2P	-5.59	4.77e-08	2.51e-05	-0.24	-0.29	Body mass index;	chr1:155818865	chr1:155745829~155750137:+
LIHC	cis	rs9532669	0.927	rs9532670	ENSG00000168852.11	TPTE2P5	-5.58	4.77e-08	2.51e-05	-0.33	-0.29	Cervical cancer;	chr13:40927691	chr13:40822296~40921749:-
LIHC	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-5.58	4.78e-08	2.51e-05	-0.37	-0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
LIHC	cis	rs1023500	0.505	rs134899	ENSG00000227370.1	RP4-669P10.19	-5.58	4.78e-08	2.51e-05	-0.31	-0.29	Schizophrenia;	chr22:42287024	chr22:42132543~42132998:+
LIHC	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	5.58	4.78e-08	2.51e-05	0.31	0.29	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
LIHC	cis	rs2522056	1	rs11242113	ENSG00000233006.5	AC034220.3	-5.58	4.78e-08	2.51e-05	-0.3	-0.29	Fibrinogen;Lymphocyte counts;	chr5:132441542	chr5:132311285~132369916:-
LIHC	cis	rs62229266	0.647	rs59397717	ENSG00000231106.2	LINC01436	5.58	4.78e-08	2.51e-05	0.32	0.29	Mitral valve prolapse;	chr21:36079427	chr21:36005338~36007838:+
LIHC	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-5.58	4.79e-08	2.52e-05	-0.35	-0.29	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-5.58	4.79e-08	2.52e-05	-0.35	-0.29	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
LIHC	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	5.58	4.79e-08	2.52e-05	0.42	0.29	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
LIHC	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-5.58	4.79e-08	2.52e-05	-0.38	-0.29	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
LIHC	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-5.58	4.79e-08	2.52e-05	-0.34	-0.29	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
LIHC	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	5.58	4.8e-08	2.52e-05	0.47	0.29	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
LIHC	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	5.58	4.81e-08	2.52e-05	0.41	0.29	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
LIHC	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-5.58	4.82e-08	2.53e-05	-0.55	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
LIHC	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-5.58	4.82e-08	2.53e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-5.58	4.82e-08	2.53e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	5.58	4.83e-08	2.53e-05	0.46	0.29	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
LIHC	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-5.58	4.83e-08	2.53e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-5.58	4.83e-08	2.53e-05	-0.3	-0.29	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
LIHC	cis	rs11722779	0.844	rs223345	ENSG00000230069.3	LRRC37A15P	-5.58	4.83e-08	2.53e-05	-0.26	-0.29	Schizophrenia;	chr4:102859366	chr4:102727274~102730721:-
LIHC	cis	rs1005277	0.522	rs289647	ENSG00000263064.2	RP11-291L22.7	5.58	4.84e-08	2.54e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38448689~38448949:+
LIHC	cis	rs9326248	0.953	rs488962	ENSG00000236267.1	AP006216.5	-5.58	4.84e-08	2.54e-05	-0.29	-0.29	Blood protein levels;	chr11:117201809	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.953	rs634960	ENSG00000236267.1	AP006216.5	-5.58	4.84e-08	2.54e-05	-0.29	-0.29	Blood protein levels;	chr11:117202247	chr11:116813204~116814003:-
LIHC	cis	rs12681287	0.927	rs2976177	ENSG00000250569.1	NTAN1P2	5.58	4.84e-08	2.54e-05	0.34	0.29	Caudate activity during reward;	chr8:86320103	chr8:86481754~86483002:-
LIHC	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	5.58	4.84e-08	2.54e-05	0.29	0.29	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
LIHC	cis	rs5769707	0.681	rs2071902	ENSG00000235111.1	RP1-29C18.8	-5.58	4.85e-08	2.54e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49612657~49615716:-
LIHC	cis	rs11722779	0.873	rs223344	ENSG00000230069.3	LRRC37A15P	-5.58	4.85e-08	2.54e-05	-0.26	-0.29	Schizophrenia;	chr4:102859765	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.775	rs223341	ENSG00000230069.3	LRRC37A15P	-5.58	4.85e-08	2.54e-05	-0.26	-0.29	Schizophrenia;	chr4:102862343	chr4:102727274~102730721:-
LIHC	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	5.58	4.85e-08	2.54e-05	0.32	0.29	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
LIHC	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-5.58	4.85e-08	2.54e-05	-0.38	-0.29	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	5.58	4.86e-08	2.55e-05	0.39	0.29	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	5.58	4.86e-08	2.55e-05	0.39	0.29	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
LIHC	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	5.58	4.87e-08	2.55e-05	0.46	0.29	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
LIHC	cis	rs12744310	0.525	rs12406967	ENSG00000235358.1	RP11-399E6.1	5.58	4.87e-08	2.55e-05	0.34	0.29	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319742	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.502	rs2154317	ENSG00000235358.1	RP11-399E6.1	5.58	4.87e-08	2.55e-05	0.34	0.29	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41320120	chr1:41242373~41284861:+
LIHC	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-5.58	4.87e-08	2.55e-05	-0.23	-0.29	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
LIHC	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-5.58	4.89e-08	2.56e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
LIHC	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-5.58	4.89e-08	2.56e-05	-0.38	-0.29	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
LIHC	cis	rs1005277	0.505	rs10827836	ENSG00000263064.2	RP11-291L22.7	-5.58	4.9e-08	2.57e-05	-0.3	-0.29	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38448689~38448949:+
LIHC	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	5.58	4.91e-08	2.57e-05	0.39	0.29	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	5.58	4.91e-08	2.57e-05	0.39	0.29	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	5.58	4.91e-08	2.57e-05	0.39	0.29	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	5.58	4.91e-08	2.57e-05	0.39	0.29	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
LIHC	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-5.58	4.92e-08	2.58e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
LIHC	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28143758	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28144784	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28145952	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28147378	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28147406	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28148143	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28149979	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28152885	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28153120	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28154567	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28156691	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28158424	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28159056	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28159843	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28162053	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28163375	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28163759	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28164580	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28164825	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28164948	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28165025	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28165528	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28169019	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28169249	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28169676	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28169755	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28169791	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-5.58	4.93e-08	2.58e-05	-0.45	-0.29	Depression;	chr6:28170075	chr6:28115628~28116551:+
LIHC	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-5.58	4.93e-08	2.58e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
LIHC	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	5.58	4.93e-08	2.58e-05	0.3	0.29	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
LIHC	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	5.58	4.94e-08	2.58e-05	0.32	0.29	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
LIHC	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	5.58	4.94e-08	2.58e-05	0.32	0.29	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
LIHC	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-5.58	4.94e-08	2.59e-05	-0.35	-0.29	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
LIHC	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-5.58	4.94e-08	2.59e-05	-0.35	-0.29	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
LIHC	cis	rs739496	0.602	rs79209359	ENSG00000226469.1	ADAM1B	5.58	4.95e-08	2.59e-05	0.35	0.29	Platelet count;	chr12:111529357	chr12:111927018~111929017:+
LIHC	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-5.58	4.96e-08	2.59e-05	-0.37	-0.29	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
LIHC	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	5.58	4.96e-08	2.59e-05	0.3	0.29	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
LIHC	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-5.58	4.98e-08	2.6e-05	-0.26	-0.29	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
LIHC	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-5.58	4.99e-08	2.6e-05	-0.37	-0.29	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
LIHC	cis	rs2688482	0.512	rs3103953	ENSG00000242086.7	LINC00969	-5.58	4.99e-08	2.61e-05	-0.37	-0.29	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195658062~195739964:+
LIHC	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	5.58	4.99e-08	2.61e-05	0.39	0.29	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
LIHC	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	5.58	4.99e-08	2.61e-05	0.44	0.29	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	5.58	4.99e-08	2.61e-05	0.44	0.29	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	5.58	4.99e-08	2.61e-05	0.44	0.29	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	5.58	4.99e-08	2.61e-05	0.44	0.29	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
LIHC	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-5.58	5e-08	2.61e-05	-0.33	-0.29	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
LIHC	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-5.58	5e-08	2.61e-05	-0.3	-0.29	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
LIHC	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	5.58	5.02e-08	2.62e-05	0.44	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
LIHC	cis	rs4934494	0.727	rs2418929	ENSG00000232936.4	RP11-80H5.2	5.58	5.03e-08	2.62e-05	0.36	0.29	Red blood cell count;	chr10:89741720	chr10:89645282~89650667:+
LIHC	cis	rs7914558	0.902	rs3736922	ENSG00000236937.2	PTGES3P4	-5.58	5.03e-08	2.62e-05	-0.34	-0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102845595~102845950:+
LIHC	cis	rs5758511	0.68	rs17002902	ENSG00000237037.8	NDUFA6-AS1	-5.57	5.04e-08	2.63e-05	-0.36	-0.29	Birth weight;	chr22:42229503	chr22:42090931~42137742:+
LIHC	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	5.57	5.05e-08	2.63e-05	0.44	0.29	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
LIHC	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	5.57	5.05e-08	2.63e-05	0.44	0.29	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
LIHC	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-5.57	5.05e-08	2.64e-05	-0.38	-0.29	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
LIHC	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	5.57	5.06e-08	2.64e-05	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
LIHC	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-5.57	5.07e-08	2.64e-05	-0.32	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
LIHC	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-5.57	5.07e-08	2.64e-05	-0.48	-0.29	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
LIHC	cis	rs2442825	0.526	rs6443237	ENSG00000206573.7	THUMPD3-AS1	-5.57	5.08e-08	2.65e-05	-0.31	-0.29	Cerebrospinal fluid clusterin levels;	chr3:9395777	chr3:9349689~9398579:-
LIHC	cis	rs1577917	0.771	rs9362237	ENSG00000234155.1	RP11-30P6.6	-5.57	5.08e-08	2.65e-05	-0.37	-0.29	Response to antipsychotic treatment;	chr6:85699346	chr6:85387219~85390186:-
LIHC	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-5.57	5.09e-08	2.65e-05	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
LIHC	cis	rs1577917	0.839	rs12664634	ENSG00000234155.1	RP11-30P6.6	5.57	5.1e-08	2.66e-05	0.34	0.29	Response to antipsychotic treatment;	chr6:85869696	chr6:85387219~85390186:-
LIHC	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
LIHC	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-5.57	5.1e-08	2.66e-05	-0.41	-0.29	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
LIHC	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-5.57	5.1e-08	2.66e-05	-0.35	-0.29	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
LIHC	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	5.57	5.1e-08	2.66e-05	0.36	0.29	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
LIHC	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	5.57	5.1e-08	2.66e-05	0.39	0.29	Depression;	chr6:28399846	chr6:28176188~28176674:+
LIHC	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	5.57	5.11e-08	2.66e-05	0.35	0.29	Height;	chr6:109347707	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	5.57	5.11e-08	2.66e-05	0.34	0.29	Height;	chr6:109403734	chr6:109382795~109383666:+
LIHC	cis	rs7119038	0.509	rs10790261	ENSG00000255239.1	AP002954.6	5.57	5.13e-08	2.67e-05	0.38	0.29	Sjögren's syndrome;	chr11:118709038	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.509	rs11216960	ENSG00000255239.1	AP002954.6	-5.57	5.13e-08	2.67e-05	-0.38	-0.29	Sjögren's syndrome;	chr11:118707164	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.509	rs10892256	ENSG00000255239.1	AP002954.6	-5.57	5.13e-08	2.67e-05	-0.38	-0.29	Sjögren's syndrome;	chr11:118707996	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.509	rs10892257	ENSG00000255239.1	AP002954.6	-5.57	5.13e-08	2.67e-05	-0.38	-0.29	Sjögren's syndrome;	chr11:118708618	chr11:118688039~118690600:-
LIHC	cis	rs7131987	0.903	rs2194519	ENSG00000257176.2	RP11-996F15.2	5.57	5.13e-08	2.67e-05	0.33	0.29	QT interval;	chr12:29270650	chr12:29280418~29317848:-
LIHC	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	5.57	5.14e-08	2.67e-05	0.33	0.29	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	5.57	5.14e-08	2.67e-05	0.33	0.29	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
LIHC	cis	rs739496	0.843	rs7398705	ENSG00000226469.1	ADAM1B	-5.57	5.14e-08	2.67e-05	-0.34	-0.29	Platelet count;	chr12:111578212	chr12:111927018~111929017:+
LIHC	cis	rs227275	0.554	rs223333	ENSG00000230069.3	LRRC37A15P	-5.57	5.15e-08	2.68e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102727274~102730721:-
LIHC	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-5.57	5.15e-08	2.68e-05	-0.5	-0.29	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
LIHC	cis	rs9326248	0.652	rs7128382	ENSG00000236267.1	AP006216.5	5.57	5.16e-08	2.68e-05	0.3	0.29	Blood protein levels;	chr11:117152771	chr11:116813204~116814003:-
LIHC	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	5.57	5.16e-08	2.68e-05	0.34	0.29	Height;	chr6:109402736	chr6:109382795~109383666:+
LIHC	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-5.57	5.16e-08	2.69e-05	-0.3	-0.29	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
LIHC	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	5.57	5.17e-08	2.69e-05	0.37	0.29	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
LIHC	cis	rs12787909	1	rs12787909	ENSG00000278768.1	BACE1-AS	5.57	5.17e-08	2.69e-05	0.53	0.29	Lipoprotein (a) - cholesterol levels;	chr11:117675767	chr11:117290874~117293571:+
LIHC	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-5.57	5.18e-08	2.69e-05	-0.34	-0.29	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
LIHC	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-5.57	5.2e-08	2.7e-05	-0.32	-0.29	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
LIHC	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	5.57	5.2e-08	2.7e-05	0.31	0.29	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
LIHC	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-5.57	5.21e-08	2.71e-05	-0.36	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
LIHC	cis	rs2735413	0.564	rs73578755	ENSG00000276007.1	RP11-358L22.3	5.57	5.21e-08	2.71e-05	0.4	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78074912	chr16:78123243~78124332:+
LIHC	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-5.57	5.21e-08	2.71e-05	-0.48	-0.29	Gout;	chr7:66645053	chr7:66654538~66669855:+
LIHC	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	5.57	5.22e-08	2.71e-05	0.3	0.29	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	5.57	5.22e-08	2.71e-05	0.3	0.29	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	5.57	5.22e-08	2.71e-05	0.3	0.29	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
LIHC	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-5.57	5.22e-08	2.71e-05	-0.32	-0.29	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-5.57	5.23e-08	2.72e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
LIHC	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	5.57	5.24e-08	2.72e-05	0.37	0.29	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
LIHC	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-5.57	5.26e-08	2.73e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
LIHC	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-5.57	5.26e-08	2.73e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
LIHC	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	5.57	5.27e-08	2.73e-05	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
LIHC	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	5.57	5.27e-08	2.74e-05	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
LIHC	cis	rs739496	0.649	rs666727	ENSG00000226469.1	ADAM1B	5.57	5.27e-08	2.74e-05	0.35	0.29	Platelet count;	chr12:111551854	chr12:111927018~111929017:+
LIHC	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	5.57	5.27e-08	2.74e-05	0.32	0.29	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
LIHC	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-5.57	5.28e-08	2.74e-05	-0.47	-0.29	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
LIHC	cis	rs17711722	0.523	rs365896	ENSG00000228409.4	CCT6P1	5.57	5.28e-08	2.74e-05	0.22	0.29	Calcium levels;	chr7:66045710	chr7:65751142~65763354:+
LIHC	cis	rs3096299	0.642	rs12934829	ENSG00000261118.1	RP11-104N10.1	5.57	5.28e-08	2.74e-05	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89492017~89504460:-
LIHC	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	5.57	5.29e-08	2.75e-05	0.32	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
LIHC	cis	rs1005277	0.522	rs1208681	ENSG00000263064.2	RP11-291L22.7	5.57	5.29e-08	2.75e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38448689~38448949:+
LIHC	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-5.56	5.31e-08	2.76e-05	-0.31	-0.29	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
LIHC	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-5.56	5.33e-08	2.76e-05	-0.32	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
LIHC	cis	rs9411298	0.63	rs9411299	ENSG00000268996.3	MAN1B1-AS1	-5.56	5.33e-08	2.76e-05	-0.33	-0.29	Monocyte percentage of white cells;	chr9:137044341	chr9:137084946~137086817:-
LIHC	cis	rs1322639	0.531	rs11751421	ENSG00000261039.2	RP11-417E7.2	5.56	5.33e-08	2.77e-05	0.3	0.29	Pulse pressure;	chr6:169174898	chr6:169175304~169182740:-
LIHC	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	5.56	5.34e-08	2.77e-05	0.38	0.29	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
LIHC	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-5.56	5.34e-08	2.77e-05	-0.31	-0.29	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
LIHC	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-5.56	5.34e-08	2.77e-05	-0.35	-0.29	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-5.56	5.34e-08	2.77e-05	-0.35	-0.29	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-5.56	5.34e-08	2.77e-05	-0.35	-0.29	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
LIHC	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	5.56	5.36e-08	2.78e-05	0.36	0.29	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
LIHC	cis	rs5769707	0.681	rs4622843	ENSG00000235111.1	RP1-29C18.8	-5.56	5.36e-08	2.78e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49612657~49615716:-
LIHC	cis	rs3096299	0.9	rs4785663	ENSG00000261118.1	RP11-104N10.1	5.56	5.36e-08	2.78e-05	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89492017~89504460:-
LIHC	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-5.56	5.36e-08	2.78e-05	-0.35	-0.29	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
LIHC	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-5.56	5.36e-08	2.78e-05	-0.3	-0.29	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
LIHC	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-5.56	5.37e-08	2.78e-05	-0.35	-0.29	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
LIHC	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-5.56	5.37e-08	2.78e-05	-0.4	-0.29	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
LIHC	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-5.56	5.38e-08	2.79e-05	-0.35	-0.29	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
LIHC	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	5.56	5.38e-08	2.79e-05	0.33	0.29	Height;	chr6:109358652	chr6:109382795~109383666:+
LIHC	cis	rs9388451	0.839	rs9401845	ENSG00000237742.5	RP11-624M8.1	-5.56	5.38e-08	2.79e-05	-0.27	-0.29	Brugada syndrome;	chr6:125782972	chr6:125578558~125749190:-
LIHC	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-5.56	5.39e-08	2.79e-05	-0.26	-0.29	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
LIHC	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	5.56	5.39e-08	2.79e-05	0.37	0.29	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
LIHC	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-5.56	5.39e-08	2.79e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-5.56	5.39e-08	2.79e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-5.56	5.39e-08	2.79e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
LIHC	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-5.56	5.4e-08	2.79e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-5.56	5.4e-08	2.79e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-5.56	5.4e-08	2.79e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
LIHC	cis	rs2243480	1	rs709607	ENSG00000164669.11	INTS4P1	-5.56	5.4e-08	2.8e-05	-0.51	-0.29	Diabetic kidney disease;	chr7:65984554	chr7:65141225~65234216:+
LIHC	cis	rs7916697	0.947	rs1900004	ENSG00000233590.1	RP11-153K11.3	-5.56	5.41e-08	2.8e-05	-0.34	-0.29	Optic disc area;	chr10:68241124	chr10:68233251~68242379:-
LIHC	cis	rs2998286	0.862	rs1339704	ENSG00000254635.4	WAC-AS1	-5.56	5.41e-08	2.8e-05	-0.36	-0.29	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28527400	chr10:28522652~28532743:-
LIHC	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	5.56	5.44e-08	2.82e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	5.56	5.44e-08	2.82e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
LIHC	cis	rs5758511	0.68	rs5758667	ENSG00000237037.8	NDUFA6-AS1	-5.56	5.44e-08	2.82e-05	-0.36	-0.29	Birth weight;	chr22:42237198	chr22:42090931~42137742:+
LIHC	cis	rs4432842	0.646	rs10037593	ENSG00000249198.1	RP11-772C9.1	5.56	5.45e-08	2.82e-05	0.35	0.29	Birth weight;	chr5:57762092	chr5:57751192~57751717:-
LIHC	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-5.56	5.45e-08	2.82e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-5.56	5.45e-08	2.82e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
LIHC	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-5.56	5.45e-08	2.82e-05	-0.35	-0.29	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
LIHC	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	5.56	5.46e-08	2.82e-05	0.32	0.29	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
LIHC	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	5.56	5.46e-08	2.82e-05	0.46	0.29	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
LIHC	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-5.56	5.46e-08	2.82e-05	-0.32	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
LIHC	cis	rs12908161	0.959	rs17534709	ENSG00000259295.5	CSPG4P12	5.56	5.47e-08	2.83e-05	0.39	0.29	Schizophrenia;	chr15:84771166	chr15:85191438~85213905:+
LIHC	cis	rs2735413	0.564	rs8059851	ENSG00000276007.1	RP11-358L22.3	5.56	5.47e-08	2.83e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78084435	chr16:78123243~78124332:+
LIHC	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-5.56	5.48e-08	2.83e-05	-0.45	-0.29	Depression;	chr6:28140454	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-5.56	5.48e-08	2.83e-05	-0.45	-0.29	Depression;	chr6:28141189	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-5.56	5.48e-08	2.83e-05	-0.45	-0.29	Depression;	chr6:28141484	chr6:28115628~28116551:+
LIHC	cis	rs2735413	0.564	rs11859770	ENSG00000276007.1	RP11-358L22.3	5.56	5.48e-08	2.83e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78092837	chr16:78123243~78124332:+
LIHC	cis	rs2762353	0.526	rs6456693	ENSG00000216436.2	HIST1H2APS1	5.56	5.49e-08	2.83e-05	0.35	0.29	Blood metabolite levels;	chr6:25709859	chr6:25732497~25732827:+
LIHC	cis	rs10510102	1	rs6585764	ENSG00000226864.1	ATE1-AS1	5.56	5.49e-08	2.84e-05	0.46	0.29	Breast cancer;	chr10:121837308	chr10:121928312~121951965:+
LIHC	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-5.56	5.51e-08	2.84e-05	-0.35	-0.29	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-5.56	5.51e-08	2.84e-05	-0.35	-0.29	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-5.56	5.51e-08	2.84e-05	-0.35	-0.29	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
LIHC	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	5.56	5.52e-08	2.85e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
LIHC	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	5.56	5.52e-08	2.85e-05	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
LIHC	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-5.56	5.52e-08	2.85e-05	-0.3	-0.29	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
LIHC	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-5.56	5.56e-08	2.87e-05	-0.31	-0.29	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
LIHC	cis	rs5769707	0.632	rs135876	ENSG00000235111.1	RP1-29C18.8	-5.56	5.57e-08	2.87e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49612657~49615716:-
LIHC	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	5.56	5.57e-08	2.87e-05	0.31	0.29	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
LIHC	cis	rs17711722	0.565	rs4275112	ENSG00000228409.4	CCT6P1	5.56	5.57e-08	2.87e-05	0.23	0.29	Calcium levels;	chr7:65733651	chr7:65751142~65763354:+
LIHC	cis	rs9326248	1	rs9326248	ENSG00000236267.1	AP006216.5	5.56	5.58e-08	2.88e-05	0.29	0.29	Blood protein levels;	chr11:117128509	chr11:116813204~116814003:-
LIHC	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	5.56	5.59e-08	2.88e-05	0.3	0.29	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
LIHC	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	5.55	5.59e-08	2.88e-05	0.3	0.29	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	5.55	5.59e-08	2.88e-05	0.3	0.29	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
LIHC	cis	rs5756813	1	rs1129448	ENSG00000233360.4	Z83844.1	-5.55	5.6e-08	2.88e-05	-0.35	-0.29	Optic cup area;Vertical cup-disc ratio;	chr22:37774019	chr22:37641832~37658377:-
LIHC	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	5.55	5.6e-08	2.89e-05	0.52	0.29	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
LIHC	cis	rs2243480	0.522	rs431168	ENSG00000273142.1	RP11-458F8.4	-5.55	5.62e-08	2.89e-05	-0.38	-0.29	Diabetic kidney disease;	chr7:66046617	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-5.55	5.62e-08	2.9e-05	-0.35	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
LIHC	cis	rs227275	0.554	rs223424	ENSG00000230069.3	LRRC37A15P	-5.55	5.62e-08	2.9e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102727274~102730721:-
LIHC	cis	rs9388451	0.805	rs1028481	ENSG00000237742.5	RP11-624M8.1	-5.55	5.63e-08	2.9e-05	-0.27	-0.29	Brugada syndrome;	chr6:125785427	chr6:125578558~125749190:-
LIHC	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	5.55	5.65e-08	2.91e-05	0.34	0.29	Height;	chr6:109397362	chr6:109382795~109383666:+
LIHC	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-5.55	5.66e-08	2.92e-05	-0.48	-0.29	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
LIHC	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	5.55	5.67e-08	2.92e-05	0.34	0.29	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
LIHC	cis	rs227275	0.554	rs223422	ENSG00000230069.3	LRRC37A15P	-5.55	5.68e-08	2.92e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.524	rs223423	ENSG00000230069.3	LRRC37A15P	-5.55	5.68e-08	2.92e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102727274~102730721:-
LIHC	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-5.55	5.68e-08	2.92e-05	-0.26	-0.29	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
LIHC	cis	rs8028182	0.636	rs7171507	ENSG00000260269.4	CTD-2323K18.1	-5.55	5.69e-08	2.93e-05	-0.38	-0.29	Sudden cardiac arrest;	chr15:75444946	chr15:75527150~75601205:-
LIHC	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	5.55	5.7e-08	2.93e-05	0.34	0.29	Height;	chr6:109383848	chr6:109382795~109383666:+
LIHC	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	5.55	5.7e-08	2.93e-05	0.32	0.29	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
LIHC	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	5.55	5.71e-08	2.94e-05	0.37	0.29	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
LIHC	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	5.55	5.72e-08	2.94e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
LIHC	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-5.55	5.72e-08	2.94e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
LIHC	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-5.55	5.72e-08	2.94e-05	-0.49	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
LIHC	cis	rs6686842	0.965	rs4660184	ENSG00000235358.1	RP11-399E6.1	-5.55	5.73e-08	2.95e-05	-0.31	-0.29	Height;	chr1:41058866	chr1:41242373~41284861:+
LIHC	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-5.55	5.73e-08	2.95e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-5.55	5.73e-08	2.95e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-5.55	5.73e-08	2.95e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-5.55	5.73e-08	2.95e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
LIHC	cis	rs5758511	0.514	rs5751240	ENSG00000237037.8	NDUFA6-AS1	-5.55	5.73e-08	2.95e-05	-0.36	-0.29	Birth weight;	chr22:42199252	chr22:42090931~42137742:+
LIHC	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	5.55	5.74e-08	2.95e-05	0.27	0.29	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
LIHC	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-5.55	5.74e-08	2.95e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-5.55	5.74e-08	2.95e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-5.55	5.74e-08	2.95e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
LIHC	cis	rs3096299	0.667	rs2965947	ENSG00000261118.1	RP11-104N10.1	5.55	5.75e-08	2.96e-05	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89492017~89504460:-
LIHC	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-5.55	5.76e-08	2.96e-05	-0.6	-0.29	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
LIHC	cis	rs1005277	0.522	rs1208684	ENSG00000263064.2	RP11-291L22.7	5.55	5.76e-08	2.96e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38448689~38448949:+
LIHC	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	5.55	5.77e-08	2.96e-05	0.37	0.29	Depression;	chr6:28402301	chr6:28943877~28944537:+
LIHC	cis	rs1005277	0.522	rs9417256	ENSG00000263064.2	RP11-291L22.7	5.55	5.77e-08	2.97e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38448689~38448949:+
LIHC	cis	rs2998286	0.862	rs2993989	ENSG00000254635.4	WAC-AS1	-5.55	5.78e-08	2.97e-05	-0.36	-0.29	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512986	chr10:28522652~28532743:-
LIHC	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	5.55	5.78e-08	2.97e-05	0.32	0.29	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
LIHC	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-5.55	5.79e-08	2.98e-05	-0.37	-0.29	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
LIHC	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-5.55	5.79e-08	2.98e-05	-0.44	-0.29	Depression;	chr6:28159666	chr6:28115628~28116551:+
LIHC	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	5.55	5.8e-08	2.98e-05	0.47	0.29	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
LIHC	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	5.55	5.8e-08	2.98e-05	0.39	0.29	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
LIHC	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	5.55	5.81e-08	2.98e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
LIHC	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-5.55	5.81e-08	2.98e-05	-0.4	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
LIHC	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-5.55	5.82e-08	2.99e-05	-0.42	-0.29	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
LIHC	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-5.55	5.84e-08	3e-05	-0.3	-0.29	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
LIHC	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-5.55	5.84e-08	3e-05	-0.35	-0.29	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
LIHC	cis	rs12908161	0.959	rs61074241	ENSG00000259295.5	CSPG4P12	5.55	5.84e-08	3e-05	0.41	0.29	Schizophrenia;	chr15:84790165	chr15:85191438~85213905:+
LIHC	cis	rs734999	1	rs10797432	ENSG00000225931.3	RP3-395M20.7	5.55	5.86e-08	3.01e-05	0.31	0.29	Ulcerative colitis;	chr1:2569899	chr1:2566410~2569888:+
LIHC	cis	rs3096299	0.591	rs748940	ENSG00000261118.1	RP11-104N10.1	5.55	5.87e-08	3.01e-05	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89492017~89504460:-
LIHC	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	5.55	5.87e-08	3.01e-05	0.33	0.29	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
LIHC	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-5.55	5.88e-08	3.02e-05	-0.32	-0.29	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
LIHC	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	5.54	5.89e-08	3.02e-05	0.33	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
LIHC	cis	rs7734985	0.634	rs10062171	ENSG00000250551.1	RP11-254I22.1	5.54	5.89e-08	3.02e-05	0.35	0.29	IgG glycosylation;	chr5:96173996	chr5:96050115~96215519:+
LIHC	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	5.54	5.89e-08	3.02e-05	0.47	0.29	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	5.54	5.89e-08	3.02e-05	0.47	0.29	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	5.54	5.89e-08	3.02e-05	0.47	0.29	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	5.54	5.89e-08	3.02e-05	0.47	0.29	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	5.54	5.89e-08	3.02e-05	0.47	0.29	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	5.54	5.89e-08	3.02e-05	0.47	0.29	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	5.54	5.89e-08	3.02e-05	0.47	0.29	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
LIHC	cis	rs9326248	0.53	rs6589575	ENSG00000280143.1	AP000892.6	5.54	5.9e-08	3.03e-05	0.35	0.29	Blood protein levels;	chr11:116862594	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.53	rs718847	ENSG00000280143.1	AP000892.6	5.54	5.9e-08	3.03e-05	0.35	0.29	Blood protein levels;	chr11:116863430	chr11:117204967~117210292:+
LIHC	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	5.54	5.9e-08	3.03e-05	0.46	0.29	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
LIHC	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-5.54	5.91e-08	3.03e-05	-0.35	-0.29	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
LIHC	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-5.54	5.93e-08	3.04e-05	-0.29	-0.29	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
LIHC	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-5.54	5.93e-08	3.04e-05	-0.32	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
LIHC	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-5.54	5.93e-08	3.04e-05	-0.37	-0.29	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
LIHC	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-5.54	5.94e-08	3.04e-05	-0.29	-0.29	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
LIHC	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-5.54	5.96e-08	3.05e-05	-0.35	-0.29	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-5.54	5.96e-08	3.05e-05	-0.35	-0.29	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
LIHC	cis	rs3096299	0.967	rs2911257	ENSG00000261118.1	RP11-104N10.1	5.54	5.97e-08	3.06e-05	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89492017~89504460:-
LIHC	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-5.54	5.97e-08	3.06e-05	-0.35	-0.29	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-5.54	5.97e-08	3.06e-05	-0.35	-0.29	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-5.54	5.97e-08	3.06e-05	-0.35	-0.29	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-5.54	5.97e-08	3.06e-05	-0.35	-0.29	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
LIHC	cis	rs227275	0.527	rs223308	ENSG00000230069.3	LRRC37A15P	-5.54	5.98e-08	3.06e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102727274~102730721:-
LIHC	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-5.54	5.99e-08	3.07e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-5.54	5.99e-08	3.07e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-5.54	5.99e-08	3.07e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-5.54	5.99e-08	3.07e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-5.54	5.99e-08	3.07e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-5.54	5.99e-08	3.07e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-5.54	5.99e-08	3.07e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
LIHC	cis	rs2072510	0.722	rs2660895	ENSG00000257715.1	RP11-256L6.2	-5.54	6e-08	3.07e-05	-0.29	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96029669	chr12:96025323~96027971:+
LIHC	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-5.54	6e-08	3.07e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-5.54	6e-08	3.07e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-5.54	6e-08	3.07e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-5.54	6e-08	3.07e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-5.54	6e-08	3.07e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
LIHC	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-5.54	6e-08	3.07e-05	-0.29	-0.29	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
LIHC	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-5.54	6.01e-08	3.07e-05	-0.37	-0.29	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
LIHC	cis	rs4356203	0.905	rs11024148	ENSG00000272034.1	SNORD14A	-5.54	6.01e-08	3.07e-05	-0.31	-0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074512	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs7107283	ENSG00000272034.1	SNORD14A	5.54	6.01e-08	3.07e-05	0.31	0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17067856	chr11:17074654~17074744:-
LIHC	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	5.54	6.02e-08	3.08e-05	0.34	0.29	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
LIHC	cis	rs739496	0.947	rs28362508	ENSG00000226469.1	ADAM1B	5.54	6.02e-08	3.08e-05	0.35	0.29	Platelet count;	chr12:111446611	chr12:111927018~111929017:+
LIHC	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	5.54	6.03e-08	3.08e-05	0.34	0.29	Height;	chr6:109501402	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	5.54	6.03e-08	3.08e-05	0.34	0.29	Height;	chr6:109501429	chr6:109382795~109383666:+
LIHC	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-5.54	6.03e-08	3.08e-05	-0.44	-0.29	Depression;	chr6:28162598	chr6:28115628~28116551:+
LIHC	cis	rs860295	0.65	rs28662267	ENSG00000203761.5	MSTO2P	-5.54	6.04e-08	3.09e-05	-0.24	-0.29	Body mass index;	chr1:155710658	chr1:155745829~155750137:+
LIHC	cis	rs228614	0.536	rs223420	ENSG00000230069.3	LRRC37A15P	-5.54	6.05e-08	3.09e-05	-0.26	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102727274~102730721:-
LIHC	cis	rs1577917	0.839	rs6454492	ENSG00000234155.1	RP11-30P6.6	5.54	6.06e-08	3.1e-05	0.35	0.29	Response to antipsychotic treatment;	chr6:85773496	chr6:85387219~85390186:-
LIHC	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-5.54	6.07e-08	3.1e-05	-0.31	-0.29	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
LIHC	cis	rs227275	0.554	rs223409	ENSG00000230069.3	LRRC37A15P	-5.54	6.07e-08	3.1e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102727274~102730721:-
LIHC	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-5.54	6.09e-08	3.11e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	5.54	6.1e-08	3.11e-05	0.25	0.29	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
LIHC	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-5.54	6.1e-08	3.11e-05	-0.32	-0.29	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
LIHC	cis	rs12908161	1	rs12908161	ENSG00000259295.5	CSPG4P12	5.54	6.11e-08	3.12e-05	0.4	0.29	Schizophrenia;	chr15:84664594	chr15:85191438~85213905:+
LIHC	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-5.54	6.11e-08	3.12e-05	-0.32	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
LIHC	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	5.54	6.12e-08	3.12e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
LIHC	cis	rs12681287	0.752	rs7846635	ENSG00000250569.1	NTAN1P2	5.54	6.14e-08	3.13e-05	0.35	0.29	Caudate activity during reward;	chr8:86292052	chr8:86481754~86483002:-
LIHC	cis	rs2735413	0.563	rs72800918	ENSG00000276007.1	RP11-358L22.3	5.54	6.15e-08	3.13e-05	0.4	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78026834	chr16:78123243~78124332:+
LIHC	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	5.54	6.15e-08	3.13e-05	0.34	0.29	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
LIHC	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	5.54	6.16e-08	3.14e-05	0.36	0.29	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
LIHC	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-5.54	6.16e-08	3.14e-05	-0.46	-0.29	Height;	chr6:109625358	chr6:109382795~109383666:+
LIHC	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-5.54	6.17e-08	3.14e-05	-0.45	-0.29	Depression;	chr6:28159925	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-5.54	6.17e-08	3.14e-05	-0.45	-0.29	Depression;	chr6:28159932	chr6:28115628~28116551:+
LIHC	cis	rs2504916	0.83	rs2504934	ENSG00000272841.1	RP3-428L16.2	5.54	6.18e-08	3.15e-05	0.42	0.29	Response to hepatitis C treatment;	chr6:160360634	chr6:160990318~160992342:-
LIHC	cis	rs12291225	0.546	rs12291662	ENSG00000251991.1	RNU7-49P	5.54	6.18e-08	3.15e-05	0.3	0.29	Sense of smell;	chr11:14321403	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.545	rs11023187	ENSG00000251991.1	RNU7-49P	5.54	6.18e-08	3.15e-05	0.3	0.29	Sense of smell;	chr11:14324013	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.585	rs11023194	ENSG00000251991.1	RNU7-49P	5.54	6.18e-08	3.15e-05	0.3	0.29	Sense of smell;	chr11:14348223	chr11:14478892~14478953:+
LIHC	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-5.54	6.18e-08	3.15e-05	-0.35	-0.29	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
LIHC	cis	rs3858145	0.505	rs12765827	ENSG00000233590.1	RP11-153K11.3	5.53	6.22e-08	3.17e-05	0.4	0.29	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68286821	chr10:68233251~68242379:-
LIHC	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-5.53	6.24e-08	3.17e-05	-0.38	-0.29	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
LIHC	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	5.53	6.24e-08	3.17e-05	0.47	0.29	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-5.53	6.24e-08	3.18e-05	-0.26	-0.29	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
LIHC	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-5.53	6.25e-08	3.18e-05	-0.25	-0.29	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-5.53	6.25e-08	3.18e-05	-0.25	-0.29	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-5.53	6.25e-08	3.18e-05	-0.25	-0.29	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-5.53	6.25e-08	3.18e-05	-0.25	-0.29	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
LIHC	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	5.53	6.26e-08	3.18e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
LIHC	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-5.53	6.26e-08	3.18e-05	-0.35	-0.29	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
LIHC	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	5.53	6.26e-08	3.19e-05	0.31	0.29	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
LIHC	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	5.53	6.27e-08	3.19e-05	0.4	0.29	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
LIHC	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	5.53	6.27e-08	3.19e-05	0.4	0.29	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
LIHC	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	5.53	6.27e-08	3.19e-05	0.4	0.29	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
LIHC	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-5.53	6.29e-08	3.2e-05	-0.38	-0.29	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
LIHC	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-5.53	6.29e-08	3.2e-05	-0.33	-0.29	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
LIHC	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	5.53	6.29e-08	3.2e-05	0.44	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
LIHC	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	5.53	6.29e-08	3.2e-05	0.44	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
LIHC	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	5.53	6.29e-08	3.2e-05	0.44	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
LIHC	cis	rs4356203	0.905	rs17472886	ENSG00000272034.1	SNORD14A	-5.53	6.3e-08	3.2e-05	-0.31	-0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17074654~17074744:-
LIHC	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-5.53	6.3e-08	3.2e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
LIHC	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-5.53	6.31e-08	3.21e-05	-0.23	-0.29	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
LIHC	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	5.53	6.31e-08	3.21e-05	0.41	0.29	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
LIHC	cis	rs739496	0.947	rs2301621	ENSG00000226469.1	ADAM1B	5.53	6.31e-08	3.21e-05	0.35	0.29	Platelet count;	chr12:111457468	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.895	rs2283357	ENSG00000226469.1	ADAM1B	5.53	6.31e-08	3.21e-05	0.35	0.29	Platelet count;	chr12:111459575	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.947	rs7134740	ENSG00000226469.1	ADAM1B	5.53	6.31e-08	3.21e-05	0.35	0.29	Platelet count;	chr12:111489935	chr12:111927018~111929017:+
LIHC	cis	rs9326248	0.53	rs2075292	ENSG00000280143.1	AP000892.6	5.53	6.31e-08	3.21e-05	0.36	0.29	Blood protein levels;	chr11:116861796	chr11:117204967~117210292:+
LIHC	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-5.53	6.33e-08	3.21e-05	-0.26	-0.29	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
LIHC	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-5.53	6.33e-08	3.21e-05	-0.26	-0.29	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
LIHC	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	5.53	6.33e-08	3.22e-05	0.47	0.29	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	5.53	6.33e-08	3.22e-05	0.47	0.29	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	5.53	6.33e-08	3.22e-05	0.47	0.29	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-5.53	6.33e-08	3.22e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
LIHC	cis	rs8028182	0.636	rs11637068	ENSG00000260269.4	CTD-2323K18.1	-5.53	6.33e-08	3.22e-05	-0.38	-0.29	Sudden cardiac arrest;	chr15:75450661	chr15:75527150~75601205:-
LIHC	cis	rs12681287	0.927	rs2953517	ENSG00000250569.1	NTAN1P2	5.53	6.34e-08	3.22e-05	0.34	0.29	Caudate activity during reward;	chr8:86319784	chr8:86481754~86483002:-
LIHC	cis	rs7119038	0.774	rs73005426	ENSG00000255239.1	AP002954.6	-5.53	6.34e-08	3.22e-05	-0.36	-0.29	Sjögren's syndrome;	chr11:118810374	chr11:118688039~118690600:-
LIHC	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-5.53	6.35e-08	3.23e-05	-0.32	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
LIHC	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-5.53	6.36e-08	3.23e-05	-0.35	-0.29	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
LIHC	cis	rs4356975	0.563	rs3924192	ENSG00000249956.3	RP11-790I12.2	-5.53	6.38e-08	3.24e-05	-0.34	-0.29	Obesity-related traits;	chr4:69105246	chr4:69408836~69423164:+
LIHC	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	5.53	6.38e-08	3.24e-05	0.41	0.29	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
LIHC	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-5.53	6.38e-08	3.24e-05	-0.38	-0.29	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
LIHC	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	5.53	6.4e-08	3.25e-05	0.39	0.29	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
LIHC	cis	rs860295	0.812	rs6657670	ENSG00000203761.5	MSTO2P	-5.53	6.4e-08	3.25e-05	-0.23	-0.29	Body mass index;	chr1:155818076	chr1:155745829~155750137:+
LIHC	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-5.53	6.4e-08	3.25e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-5.53	6.4e-08	3.25e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	5.53	6.4e-08	3.25e-05	0.47	0.29	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	5.53	6.4e-08	3.25e-05	0.47	0.29	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	5.53	6.4e-08	3.25e-05	0.27	0.29	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
LIHC	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	5.53	6.41e-08	3.25e-05	0.33	0.29	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	5.53	6.41e-08	3.25e-05	0.33	0.29	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
LIHC	cis	rs496547	0.588	rs473298	ENSG00000255422.1	AP002954.4	-5.53	6.42e-08	3.25e-05	-0.32	-0.29	Hip minimal joint space width;	chr11:118808678	chr11:118704607~118750263:+
LIHC	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-5.53	6.42e-08	3.26e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	5.53	6.42e-08	3.26e-05	0.34	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
LIHC	cis	rs12908161	1	rs56864281	ENSG00000259295.5	CSPG4P12	5.53	6.44e-08	3.26e-05	0.4	0.29	Schizophrenia;	chr15:84814418	chr15:85191438~85213905:+
LIHC	cis	rs6686842	0.931	rs4360513	ENSG00000235358.1	RP11-399E6.1	5.53	6.45e-08	3.27e-05	0.31	0.29	Height;	chr1:41015127	chr1:41242373~41284861:+
LIHC	cis	rs739496	0.793	rs607316	ENSG00000226469.1	ADAM1B	5.53	6.45e-08	3.27e-05	0.34	0.29	Platelet count;	chr12:111531644	chr12:111927018~111929017:+
LIHC	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-5.53	6.46e-08	3.27e-05	-0.23	-0.29	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-5.53	6.47e-08	3.28e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
LIHC	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-5.53	6.48e-08	3.28e-05	-0.38	-0.29	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
LIHC	cis	rs12744310	0.502	rs2363812	ENSG00000235358.1	RP11-399E6.1	5.53	6.49e-08	3.29e-05	0.34	0.29	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326895	chr1:41242373~41284861:+
LIHC	cis	rs752590	0.806	rs4849174	ENSG00000189223.12	PAX8-AS1	-5.53	6.49e-08	3.29e-05	-0.4	-0.29	Mucinous ovarian carcinoma;	chr2:113215890	chr2:113211522~113276581:+
LIHC	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-5.53	6.5e-08	3.29e-05	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
LIHC	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-5.53	6.5e-08	3.29e-05	-0.35	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
LIHC	cis	rs12744310	0.502	rs12725272	ENSG00000235358.1	RP11-399E6.1	5.53	6.51e-08	3.3e-05	0.33	0.29	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41324190	chr1:41242373~41284861:+
LIHC	cis	rs12571093	0.773	rs61854802	ENSG00000233590.1	RP11-153K11.3	-5.53	6.51e-08	3.3e-05	-0.46	-0.29	Optic nerve measurement (disc area);	chr10:68249815	chr10:68233251~68242379:-
LIHC	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-5.53	6.51e-08	3.3e-05	-0.3	-0.29	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
LIHC	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-5.53	6.52e-08	3.3e-05	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
LIHC	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	5.53	6.53e-08	3.3e-05	0.29	0.29	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
LIHC	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	5.52	6.54e-08	3.31e-05	0.32	0.29	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
LIHC	cis	rs1577917	0.545	rs1335443	ENSG00000234155.1	RP11-30P6.6	5.52	6.55e-08	3.31e-05	0.33	0.29	Response to antipsychotic treatment;	chr6:85769019	chr6:85387219~85390186:-
LIHC	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-5.52	6.55e-08	3.31e-05	-0.31	-0.29	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
LIHC	cis	rs6480314	0.636	rs61854790	ENSG00000233590.1	RP11-153K11.3	-5.52	6.56e-08	3.32e-05	-0.45	-0.29	Optic nerve measurement (disc area);	chr10:68242491	chr10:68233251~68242379:-
LIHC	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-5.52	6.56e-08	3.32e-05	-0.32	-0.29	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
LIHC	cis	rs2072510	0.683	rs2246973	ENSG00000257715.1	RP11-256L6.2	-5.52	6.57e-08	3.32e-05	-0.29	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96034097	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.683	rs2246972	ENSG00000257715.1	RP11-256L6.2	-5.52	6.57e-08	3.32e-05	-0.29	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96034111	chr12:96025323~96027971:+
LIHC	cis	rs2735413	0.564	rs78898310	ENSG00000276007.1	RP11-358L22.3	5.52	6.57e-08	3.32e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78081613	chr16:78123243~78124332:+
LIHC	cis	rs4660456	0.572	rs10789191	ENSG00000237899.1	RP4-739H11.3	5.52	6.59e-08	3.33e-05	0.36	0.29	Platelet count;	chr1:40690819	chr1:40669089~40687588:-
LIHC	cis	rs7131987	0.65	rs6487808	ENSG00000275476.1	RP11-996F15.4	5.52	6.59e-08	3.33e-05	0.33	0.29	QT interval;	chr12:29310426	chr12:29277397~29277882:-
LIHC	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-5.52	6.6e-08	3.34e-05	-0.35	-0.29	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
LIHC	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-5.52	6.6e-08	3.34e-05	-0.41	-0.29	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
LIHC	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-5.52	6.61e-08	3.34e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
LIHC	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	5.52	6.62e-08	3.35e-05	0.41	0.29	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	5.52	6.62e-08	3.35e-05	0.41	0.29	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	5.52	6.62e-08	3.35e-05	0.41	0.29	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	5.52	6.62e-08	3.35e-05	0.41	0.29	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	5.52	6.62e-08	3.35e-05	0.41	0.29	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
LIHC	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-5.52	6.64e-08	3.35e-05	-0.35	-0.29	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-5.52	6.64e-08	3.35e-05	-0.35	-0.29	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-5.52	6.64e-08	3.35e-05	-0.35	-0.29	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
LIHC	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-5.52	6.64e-08	3.35e-05	-0.4	-0.29	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
LIHC	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-5.52	6.64e-08	3.35e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
LIHC	cis	rs1862618	0.853	rs1833896	ENSG00000271828.1	CTD-2310F14.1	5.52	6.66e-08	3.36e-05	0.4	0.29	Initial pursuit acceleration;	chr5:56801842	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs1862619	ENSG00000271828.1	CTD-2310F14.1	5.52	6.66e-08	3.36e-05	0.4	0.29	Initial pursuit acceleration;	chr5:56802429	chr5:56927874~56929573:+
LIHC	cis	rs1862618	0.853	rs1559282	ENSG00000271828.1	CTD-2310F14.1	5.52	6.66e-08	3.36e-05	0.4	0.29	Initial pursuit acceleration;	chr5:56803548	chr5:56927874~56929573:+
LIHC	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	5.52	6.68e-08	3.37e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-5.52	6.68e-08	3.37e-05	-0.29	-0.29	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
LIHC	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	5.52	6.68e-08	3.37e-05	0.44	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
LIHC	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	5.52	6.68e-08	3.37e-05	0.3	0.29	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
LIHC	cis	rs9388451	0.839	rs11154331	ENSG00000237742.5	RP11-624M8.1	-5.52	6.69e-08	3.37e-05	-0.26	-0.29	Brugada syndrome;	chr6:125790283	chr6:125578558~125749190:-
LIHC	cis	rs7927592	0.513	rs901823	ENSG00000212093.1	AP000807.1	5.52	6.69e-08	3.37e-05	0.29	0.29	Total body bone mineral density;	chr11:68438110	chr11:68506083~68506166:-
LIHC	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-5.52	6.7e-08	3.38e-05	-0.32	-0.29	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
LIHC	cis	rs6480314	0.636	rs61854792	ENSG00000233590.1	RP11-153K11.3	-5.52	6.7e-08	3.38e-05	-0.45	-0.29	Optic nerve measurement (disc area);	chr10:68243902	chr10:68233251~68242379:-
LIHC	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-5.52	6.74e-08	3.4e-05	-0.44	-0.29	Depression;	chr6:28140307	chr6:28115628~28116551:+
LIHC	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-5.52	6.75e-08	3.4e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
LIHC	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-5.52	6.76e-08	3.41e-05	-0.22	-0.29	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
LIHC	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	5.52	6.76e-08	3.41e-05	0.43	0.29	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
LIHC	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-5.52	6.78e-08	3.41e-05	-0.29	-0.29	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
LIHC	cis	rs1577917	0.796	rs12661231	ENSG00000234155.1	RP11-30P6.6	5.52	6.78e-08	3.41e-05	0.34	0.29	Response to antipsychotic treatment;	chr6:85834753	chr6:85387219~85390186:-
LIHC	cis	rs2735413	0.563	rs11647117	ENSG00000276007.1	RP11-358L22.3	5.52	6.79e-08	3.42e-05	0.38	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78024165	chr16:78123243~78124332:+
LIHC	cis	rs202072	0.872	rs445714	ENSG00000215022.6	RP1-257A7.4	-5.52	6.79e-08	3.42e-05	-0.33	-0.29	HIV-1 viral setpoint;	chr6:13280726	chr6:13264861~13295586:-
LIHC	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	5.52	6.79e-08	3.42e-05	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
LIHC	cis	rs4535700	0.501	rs9642405	ENSG00000226278.1	PSPHP1	5.52	6.79e-08	3.42e-05	0.34	0.29	Macular telangiectasia type 2;	chr7:55910473	chr7:55764797~55773288:+
LIHC	cis	rs10510102	1	rs7923678	ENSG00000226864.1	ATE1-AS1	5.52	6.81e-08	3.43e-05	0.45	0.29	Breast cancer;	chr10:121832546	chr10:121928312~121951965:+
LIHC	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	5.52	6.81e-08	3.43e-05	0.63	0.29	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
LIHC	cis	rs496547	0.719	rs472641	ENSG00000255422.1	AP002954.4	-5.52	6.82e-08	3.43e-05	-0.33	-0.29	Hip minimal joint space width;	chr11:118746835	chr11:118704607~118750263:+
LIHC	cis	rs2072510	0.722	rs2247323	ENSG00000257715.1	RP11-256L6.2	-5.52	6.83e-08	3.44e-05	-0.28	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96030478	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.722	rs2247313	ENSG00000257715.1	RP11-256L6.2	-5.52	6.83e-08	3.44e-05	-0.28	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96030669	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.722	rs2247309	ENSG00000257715.1	RP11-256L6.2	-5.52	6.83e-08	3.44e-05	-0.28	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96030764	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.75	rs2660898	ENSG00000257715.1	RP11-256L6.2	-5.52	6.83e-08	3.44e-05	-0.28	-0.29	Metabolite levels (small molecules and protein measures);	chr12:96032219	chr12:96025323~96027971:+
LIHC	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	5.52	6.83e-08	3.44e-05	0.27	0.29	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	5.52	6.83e-08	3.44e-05	0.27	0.29	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
LIHC	cis	rs6480314	0.542	rs17231637	ENSG00000233590.1	RP11-153K11.3	5.52	6.84e-08	3.45e-05	0.44	0.29	Optic nerve measurement (disc area);	chr10:68270137	chr10:68233251~68242379:-
LIHC	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	5.52	6.85e-08	3.45e-05	0.38	0.29	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	5.52	6.85e-08	3.45e-05	0.38	0.29	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
LIHC	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	5.52	6.85e-08	3.45e-05	0.29	0.29	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
LIHC	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-5.52	6.85e-08	3.45e-05	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
LIHC	cis	rs4731207	0.596	rs6980448	ENSG00000224897.5	POT1-AS1	5.52	6.86e-08	3.45e-05	0.33	0.29	Cutaneous malignant melanoma;	chr7:124929364	chr7:124929873~125179315:+
LIHC	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-5.52	6.86e-08	3.45e-05	-0.45	-0.29	Depression;	chr6:28168434	chr6:28115628~28116551:+
LIHC	cis	rs6480314	0.636	rs7914274	ENSG00000233590.1	RP11-153K11.3	-5.52	6.87e-08	3.46e-05	-0.45	-0.29	Optic nerve measurement (disc area);	chr10:68240300	chr10:68233251~68242379:-
LIHC	cis	rs9890032	0.934	rs3760318	ENSG00000263531.1	RP13-753N3.1	5.52	6.87e-08	3.46e-05	0.35	0.29	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30863921~30864940:-
LIHC	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	5.52	6.88e-08	3.46e-05	0.6	0.29	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
LIHC	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-5.52	6.89e-08	3.46e-05	-0.29	-0.29	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
LIHC	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	5.51	6.89e-08	3.47e-05	0.35	0.29	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
LIHC	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	5.51	6.91e-08	3.48e-05	0.38	0.29	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
LIHC	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-5.51	6.91e-08	3.48e-05	-0.26	-0.29	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
LIHC	cis	rs5758659	0.904	rs5758653	ENSG00000227370.1	RP4-669P10.19	-5.51	6.92e-08	3.48e-05	-0.32	-0.29	Cognitive function;	chr22:42217479	chr22:42132543~42132998:+
LIHC	cis	rs12681287	0.577	rs11992955	ENSG00000250569.1	NTAN1P2	-5.51	6.93e-08	3.49e-05	-0.35	-0.29	Caudate activity during reward;	chr8:86518257	chr8:86481754~86483002:-
LIHC	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-5.51	6.94e-08	3.49e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
LIHC	cis	rs2735413	0.564	rs73580821	ENSG00000276007.1	RP11-358L22.3	5.51	6.94e-08	3.49e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78076407	chr16:78123243~78124332:+
LIHC	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	5.51	6.94e-08	3.49e-05	0.33	0.29	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
LIHC	cis	rs860295	0.812	rs3820594	ENSG00000203761.5	MSTO2P	-5.51	6.96e-08	3.5e-05	-0.23	-0.29	Body mass index;	chr1:155859720	chr1:155745829~155750137:+
LIHC	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-5.51	6.97e-08	3.5e-05	-0.36	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-5.51	6.97e-08	3.5e-05	-0.36	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-5.51	6.97e-08	3.5e-05	-0.36	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
LIHC	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-5.51	6.98e-08	3.51e-05	-0.34	-0.29	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
LIHC	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-5.51	6.99e-08	3.51e-05	-0.31	-0.29	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
LIHC	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-5.51	6.99e-08	3.51e-05	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
LIHC	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	5.51	7e-08	3.51e-05	0.4	0.29	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
LIHC	cis	rs2877649	0.793	rs10140911	ENSG00000258744.1	RP11-80A15.1	-5.51	7.01e-08	3.52e-05	-0.55	-0.29	Smooth-surface caries;	chr14:24446177	chr14:24501594~24508688:+
LIHC	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-5.51	7.01e-08	3.52e-05	-0.33	-0.29	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
LIHC	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	5.51	7.01e-08	3.52e-05	0.38	0.29	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	5.51	7.01e-08	3.52e-05	0.38	0.29	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	5.51	7.01e-08	3.52e-05	0.38	0.29	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
LIHC	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	5.51	7.01e-08	3.52e-05	0.38	0.29	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
LIHC	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	5.51	7.03e-08	3.53e-05	0.37	0.29	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	5.51	7.03e-08	3.53e-05	0.37	0.29	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	5.51	7.03e-08	3.53e-05	0.37	0.29	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
LIHC	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-5.51	7.03e-08	3.53e-05	-0.36	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
LIHC	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	5.51	7.03e-08	3.53e-05	0.34	0.29	Height;	chr6:109375548	chr6:109382795~109383666:+
LIHC	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-5.51	7.03e-08	3.53e-05	-0.48	-0.29	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
LIHC	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-5.51	7.05e-08	3.54e-05	-0.29	-0.29	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-5.51	7.05e-08	3.54e-05	-0.29	-0.29	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
LIHC	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-5.51	7.06e-08	3.54e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
LIHC	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	5.51	7.06e-08	3.54e-05	0.31	0.29	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
LIHC	cis	rs6480314	0.542	rs12572967	ENSG00000233590.1	RP11-153K11.3	-5.51	7.07e-08	3.55e-05	-0.44	-0.29	Optic nerve measurement (disc area);	chr10:68270873	chr10:68233251~68242379:-
LIHC	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-5.51	7.07e-08	3.55e-05	-0.45	-0.29	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
LIHC	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-5.51	7.07e-08	3.55e-05	-0.45	-0.29	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
LIHC	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-5.51	7.07e-08	3.55e-05	-0.45	-0.29	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
LIHC	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	5.51	7.08e-08	3.55e-05	0.3	0.29	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
LIHC	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-5.51	7.08e-08	3.55e-05	-0.32	-0.29	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
LIHC	cis	rs739496	0.947	rs11608565	ENSG00000226469.1	ADAM1B	5.51	7.09e-08	3.56e-05	0.35	0.29	Platelet count;	chr12:111484122	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.947	rs55851737	ENSG00000226469.1	ADAM1B	5.51	7.09e-08	3.56e-05	0.35	0.29	Platelet count;	chr12:111499034	chr12:111927018~111929017:+
LIHC	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-5.51	7.09e-08	3.56e-05	-0.3	-0.29	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
LIHC	cis	rs4356203	0.905	rs7938820	ENSG00000272034.1	SNORD14A	5.51	7.1e-08	3.56e-05	0.31	0.29	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17074654~17074744:-
LIHC	cis	rs4934494	0.768	rs12571268	ENSG00000232936.4	RP11-80H5.2	5.51	7.1e-08	3.56e-05	0.36	0.29	Red blood cell count;	chr10:89698830	chr10:89645282~89650667:+
LIHC	cis	rs9388451	0.839	rs3799711	ENSG00000237742.5	RP11-624M8.1	5.51	7.1e-08	3.56e-05	0.26	0.29	Brugada syndrome;	chr6:125754167	chr6:125578558~125749190:-
LIHC	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	5.51	7.11e-08	3.56e-05	0.45	0.29	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
LIHC	cis	rs5758659	1	rs5758677	ENSG00000227370.1	RP4-669P10.19	-5.51	7.12e-08	3.57e-05	-0.32	-0.29	Cognitive function;	chr22:42247033	chr22:42132543~42132998:+
LIHC	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	5.51	7.12e-08	3.57e-05	0.29	0.29	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
LIHC	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-5.51	7.12e-08	3.57e-05	-0.35	-0.29	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
LIHC	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	5.51	7.13e-08	3.57e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	5.51	7.13e-08	3.57e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	5.51	7.13e-08	3.57e-05	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
LIHC	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-5.51	7.14e-08	3.58e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
LIHC	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-5.51	7.17e-08	3.59e-05	-0.35	-0.29	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
LIHC	cis	rs228614	0.51	rs223415	ENSG00000230069.3	LRRC37A15P	-5.51	7.18e-08	3.59e-05	-0.26	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102727274~102730721:-
LIHC	cis	rs17301013	0.861	rs10912824	ENSG00000227373.4	RP11-160H22.5	5.51	7.19e-08	3.6e-05	0.37	0.29	Systemic lupus erythematosus;	chr1:174625846	chr1:174115300~174160004:-
LIHC	cis	rs12681287	0.927	rs7003059	ENSG00000250569.1	NTAN1P2	5.51	7.2e-08	3.6e-05	0.34	0.29	Caudate activity during reward;	chr8:86318484	chr8:86481754~86483002:-
LIHC	cis	rs6480314	0.636	rs77760458	ENSG00000233590.1	RP11-153K11.3	-5.51	7.21e-08	3.61e-05	-0.45	-0.29	Optic nerve measurement (disc area);	chr10:68244248	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.636	rs61854797	ENSG00000233590.1	RP11-153K11.3	-5.51	7.21e-08	3.61e-05	-0.45	-0.29	Optic nerve measurement (disc area);	chr10:68245854	chr10:68233251~68242379:-
LIHC	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	5.51	7.21e-08	3.61e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	5.51	7.21e-08	3.61e-05	0.29	0.29	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
LIHC	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	5.51	7.22e-08	3.61e-05	0.37	0.29	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
LIHC	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	5.51	7.23e-08	3.62e-05	0.26	0.29	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
LIHC	cis	rs228614	0.51	rs223410	ENSG00000230069.3	LRRC37A15P	-5.51	7.23e-08	3.62e-05	-0.26	-0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102727274~102730721:-
LIHC	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	5.51	7.25e-08	3.63e-05	0.39	0.29	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
LIHC	cis	rs2072510	0.593	rs2540499	ENSG00000257715.1	RP11-256L6.2	5.51	7.25e-08	3.63e-05	0.42	0.29	Metabolite levels (small molecules and protein measures);	chr12:96006091	chr12:96025323~96027971:+
LIHC	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-5.5	7.26e-08	3.63e-05	-0.35	-0.29	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-5.5	7.26e-08	3.63e-05	-0.35	-0.29	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-5.5	7.26e-08	3.63e-05	-0.35	-0.29	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-5.5	7.26e-08	3.63e-05	-0.35	-0.29	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-5.5	7.26e-08	3.63e-05	-0.35	-0.29	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-5.5	7.26e-08	3.63e-05	-0.35	-0.29	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
LIHC	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-5.5	7.26e-08	3.63e-05	-0.29	-0.29	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
LIHC	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-5.5	7.27e-08	3.64e-05	-0.33	-0.29	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
LIHC	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	5.5	7.29e-08	3.64e-05	0.42	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
LIHC	cis	rs17711722	0.565	rs73372653	ENSG00000226002.1	RP11-460N20.5	5.5	7.3e-08	3.65e-05	0.3	0.29	Calcium levels;	chr7:65977808	chr7:65084103~65100232:+
LIHC	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-5.5	7.31e-08	3.65e-05	-0.47	-0.29	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
LIHC	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-5.5	7.31e-08	3.65e-05	-0.35	-0.29	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-5.5	7.31e-08	3.65e-05	-0.35	-0.29	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-5.5	7.31e-08	3.65e-05	-0.35	-0.29	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
LIHC	cis	rs2297363	0.502	rs4709393	ENSG00000213073.4	RP11-288H12.3	-5.5	7.31e-08	3.65e-05	-0.28	-0.29	Total cholesterol levels;Blood protein levels;	chr6:160051000	chr6:160093082~160096212:+
LIHC	cis	rs4535700	0.501	rs57251705	ENSG00000226278.1	PSPHP1	5.5	7.31e-08	3.65e-05	0.34	0.29	Macular telangiectasia type 2;	chr7:55913390	chr7:55764797~55773288:+
LIHC	cis	rs9467711	0.651	rs17587597	ENSG00000216436.2	HIST1H2APS1	5.5	7.31e-08	3.66e-05	0.75	0.29	Autism spectrum disorder or schizophrenia;	chr6:25986223	chr6:25732497~25732827:+
LIHC	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-5.5	7.33e-08	3.66e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-5.5	7.33e-08	3.66e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-5.5	7.33e-08	3.66e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-5.5	7.33e-08	3.66e-05	-0.46	-0.29	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
LIHC	cis	rs227275	0.554	rs223357	ENSG00000230069.3	LRRC37A15P	-5.5	7.34e-08	3.67e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102727274~102730721:-
LIHC	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	5.5	7.35e-08	3.67e-05	0.43	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
LIHC	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	5.5	7.35e-08	3.67e-05	0.37	0.29	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
LIHC	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	5.5	7.35e-08	3.67e-05	0.35	0.29	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
LIHC	cis	rs227275	0.554	rs223359	ENSG00000230069.3	LRRC37A15P	-5.5	7.36e-08	3.68e-05	-0.26	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102727274~102730721:-
LIHC	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	5.5	7.36e-08	3.68e-05	0.42	0.29	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
LIHC	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	5.5	7.37e-08	3.68e-05	0.38	0.29	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
LIHC	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	5.5	7.37e-08	3.68e-05	0.35	0.29	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
LIHC	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	5.5	7.37e-08	3.68e-05	0.59	0.29	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
LIHC	cis	rs2933343	0.553	rs35979399	ENSG00000231305.3	RP11-723O4.2	5.5	7.37e-08	3.68e-05	0.32	0.29	IgG glycosylation;	chr3:128978470	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.533	rs11915889	ENSG00000231305.3	RP11-723O4.2	5.5	7.37e-08	3.68e-05	0.32	0.29	IgG glycosylation;	chr3:128982023	chr3:128861313~128871540:-
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-5.5	7.37e-08	3.68e-05	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
LIHC	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-5.5	7.38e-08	3.68e-05	-0.37	-0.29	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000206090.4	AP000350.7	5.5	7.38e-08	3.69e-05	0.34	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23939998~23942798:+
LIHC	cis	rs6686842	0.965	rs2802551	ENSG00000235358.1	RP11-399E6.1	5.5	7.39e-08	3.69e-05	0.31	0.29	Height;	chr1:41031771	chr1:41242373~41284861:+
LIHC	cis	rs6686842	0.866	rs2802550	ENSG00000235358.1	RP11-399E6.1	5.5	7.39e-08	3.69e-05	0.31	0.29	Height;	chr1:41031956	chr1:41242373~41284861:+
LIHC	cis	rs7914558	1	rs7920251	ENSG00000236937.2	PTGES3P4	5.5	7.39e-08	3.69e-05	0.34	0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102845595~102845950:+
LIHC	cis	rs2735413	0.564	rs73580826	ENSG00000276007.1	RP11-358L22.3	5.5	7.39e-08	3.69e-05	0.39	0.29	Systolic blood pressure (alcohol consumption interaction);	chr16:78076992	chr16:78123243~78124332:+
LIHC	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-5.5	7.4e-08	3.69e-05	-0.3	-0.29	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
LIHC	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-5.5	7.4e-08	3.7e-05	-0.35	-0.29	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
LIHC	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-5.5	7.42e-08	3.7e-05	-0.35	-0.29	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
LIHC	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	5.5	7.43e-08	3.71e-05	0.32	0.29	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
LIHC	cis	rs7131987	0.683	rs3782511	ENSG00000275476.1	RP11-996F15.4	-5.5	7.45e-08	3.72e-05	-0.34	-0.29	QT interval;	chr12:29343291	chr12:29277397~29277882:-
LIHC	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	5.5	7.46e-08	3.72e-05	0.34	0.29	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
LIHC	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	5.5	7.46e-08	3.72e-05	0.38	0.29	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
LIHC	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	5.5	7.48e-08	3.73e-05	0.32	0.29	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
LIHC	cis	rs1577917	0.545	rs7755958	ENSG00000234155.1	RP11-30P6.6	-5.5	7.5e-08	3.74e-05	-0.33	-0.29	Response to antipsychotic treatment;	chr6:85778793	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.839	rs1596990	ENSG00000234155.1	RP11-30P6.6	5.5	7.52e-08	3.75e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85840974	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.916	rs12661611	ENSG00000234155.1	RP11-30P6.6	5.5	7.52e-08	3.75e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85844117	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.637	rs1838957	ENSG00000234155.1	RP11-30P6.6	5.5	7.52e-08	3.75e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85855338	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.839	rs1838956	ENSG00000234155.1	RP11-30P6.6	5.5	7.52e-08	3.75e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85855545	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.839	rs12216103	ENSG00000234155.1	RP11-30P6.6	5.5	7.52e-08	3.75e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85861410	chr6:85387219~85390186:-
LIHC	cis	rs7916697	0.578	rs4745951	ENSG00000233590.1	RP11-153K11.3	5.5	7.52e-08	3.75e-05	0.36	0.28	Optic disc area;	chr10:68236867	chr10:68233251~68242379:-
LIHC	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	5.5	7.53e-08	3.75e-05	0.29	0.28	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
LIHC	cis	rs7119038	0.509	rs10892258	ENSG00000255239.1	AP002954.6	5.5	7.53e-08	3.75e-05	0.37	0.28	Sjögren's syndrome;	chr11:118709156	chr11:118688039~118690600:-
LIHC	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-5.5	7.54e-08	3.76e-05	-0.33	-0.28	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
LIHC	cis	rs2072510	0.722	rs2540489	ENSG00000257715.1	RP11-256L6.2	-5.5	7.55e-08	3.76e-05	-0.29	-0.28	Metabolite levels (small molecules and protein measures);	chr12:96032724	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.683	rs2246990	ENSG00000257715.1	RP11-256L6.2	-5.5	7.55e-08	3.76e-05	-0.29	-0.28	Metabolite levels (small molecules and protein measures);	chr12:96033524	chr12:96025323~96027971:+
LIHC	cis	rs887829	0.641	rs10197460	ENSG00000233445.1	RPL17P11	5.5	7.55e-08	3.76e-05	0.3	0.28	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233680544	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.641	rs10167119	ENSG00000233445.1	RPL17P11	5.5	7.55e-08	3.76e-05	0.3	0.28	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233680666	chr2:233721522~233722065:-
LIHC	cis	rs929596	0.501	rs4530361	ENSG00000233445.1	RPL17P11	5.5	7.55e-08	3.76e-05	0.3	0.28	Total bilirubin levels in HIV-1 infection;	chr2:233681395	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.641	rs7586110	ENSG00000233445.1	RPL17P11	5.5	7.55e-08	3.76e-05	0.3	0.28	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233681881	chr2:233721522~233722065:-
LIHC	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-5.5	7.56e-08	3.76e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
LIHC	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-5.5	7.57e-08	3.77e-05	-0.41	-0.28	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
LIHC	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-5.5	7.58e-08	3.77e-05	-0.29	-0.28	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
LIHC	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	5.5	7.59e-08	3.78e-05	0.37	0.28	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
LIHC	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	5.5	7.59e-08	3.78e-05	0.6	0.28	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
LIHC	cis	rs831571	0.668	rs34723451	ENSG00000280620.1	SCAANT1	5.5	7.59e-08	3.78e-05	0.42	0.28	Type 2 diabetes;	chr3:64096160	chr3:63911518~63911772:-
LIHC	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	5.5	7.59e-08	3.78e-05	0.34	0.28	Height;	chr6:109558247	chr6:109382795~109383666:+
LIHC	cis	rs6589219	0.788	rs11213823	ENSG00000196167.8	COLCA1	-5.5	7.59e-08	3.78e-05	-0.32	-0.28	Colorectal cancer;	chr11:111299265	chr11:111290787~111305045:-
LIHC	cis	rs2735413	0.563	rs11646833	ENSG00000276007.1	RP11-358L22.3	5.5	7.6e-08	3.78e-05	0.38	0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78023482	chr16:78123243~78124332:+
LIHC	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	5.5	7.6e-08	3.78e-05	0.33	0.28	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
LIHC	cis	rs5756813	0.715	rs5756825	ENSG00000233360.4	Z83844.1	-5.5	7.61e-08	3.79e-05	-0.34	-0.28	Optic cup area;Vertical cup-disc ratio;	chr22:37803943	chr22:37641832~37658377:-
LIHC	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-5.5	7.62e-08	3.79e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-5.5	7.62e-08	3.79e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-5.5	7.62e-08	3.79e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
LIHC	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	5.5	7.63e-08	3.8e-05	0.29	0.28	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	5.5	7.63e-08	3.8e-05	0.29	0.28	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
LIHC	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-5.5	7.64e-08	3.8e-05	-0.29	-0.28	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
LIHC	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	5.49	7.65e-08	3.8e-05	0.37	0.28	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	5.49	7.65e-08	3.8e-05	0.37	0.28	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
LIHC	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	5.49	7.66e-08	3.81e-05	0.3	0.28	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
LIHC	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	5.49	7.68e-08	3.81e-05	0.25	0.28	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-5.49	7.68e-08	3.81e-05	-0.25	-0.28	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
LIHC	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	5.49	7.7e-08	3.82e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
LIHC	cis	rs6686842	0.864	rs6662279	ENSG00000235358.1	RP11-399E6.1	-5.49	7.7e-08	3.82e-05	-0.31	-0.28	Height;	chr1:41087889	chr1:41242373~41284861:+
LIHC	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	5.49	7.71e-08	3.83e-05	0.45	0.28	Depression;	chr6:28167882	chr6:28115628~28116551:+
LIHC	cis	rs7914558	0.932	rs4307650	ENSG00000236937.2	PTGES3P4	5.49	7.71e-08	3.83e-05	0.34	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102845595~102845950:+
LIHC	cis	rs4731207	0.596	rs6466968	ENSG00000224897.5	POT1-AS1	-5.49	7.72e-08	3.83e-05	-0.34	-0.28	Cutaneous malignant melanoma;	chr7:124943303	chr7:124929873~125179315:+
LIHC	cis	rs2072510	0.722	rs763874	ENSG00000257715.1	RP11-256L6.2	-5.49	7.72e-08	3.83e-05	-0.29	-0.28	Metabolite levels (small molecules and protein measures);	chr12:96026435	chr12:96025323~96027971:+
LIHC	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-5.49	7.74e-08	3.84e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
LIHC	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	5.49	7.77e-08	3.86e-05	0.37	0.28	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
LIHC	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-5.49	7.77e-08	3.86e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
LIHC	cis	rs11722779	0.81	rs223417	ENSG00000230069.3	LRRC37A15P	-5.49	7.78e-08	3.86e-05	-0.26	-0.28	Schizophrenia;	chr4:102810568	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.805	rs223416	ENSG00000230069.3	LRRC37A15P	-5.49	7.78e-08	3.86e-05	-0.26	-0.28	Schizophrenia;	chr4:102810580	chr4:102727274~102730721:-
LIHC	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	5.49	7.78e-08	3.86e-05	0.32	0.28	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
LIHC	cis	rs6589219	0.908	rs3087967	ENSG00000196167.8	COLCA1	-5.49	7.78e-08	3.86e-05	-0.32	-0.28	Colorectal cancer;	chr11:111286111	chr11:111290787~111305045:-
LIHC	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	5.49	7.78e-08	3.86e-05	0.27	0.28	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
LIHC	cis	rs7119038	0.509	rs11216964	ENSG00000255239.1	AP002954.6	-5.49	7.78e-08	3.86e-05	-0.38	-0.28	Sjögren's syndrome;	chr11:118711186	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.509	rs10892259	ENSG00000255239.1	AP002954.6	-5.49	7.78e-08	3.86e-05	-0.38	-0.28	Sjögren's syndrome;	chr11:118712293	chr11:118688039~118690600:-
LIHC	cis	rs12681287	0.64	rs12549332	ENSG00000250569.1	NTAN1P2	5.49	7.78e-08	3.86e-05	0.34	0.28	Caudate activity during reward;	chr8:86341163	chr8:86481754~86483002:-
LIHC	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	5.49	7.79e-08	3.86e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
LIHC	cis	rs227275	0.524	rs150894	ENSG00000230069.3	LRRC37A15P	-5.49	7.79e-08	3.86e-05	-0.26	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102727274~102730721:-
LIHC	cis	rs7119038	0.509	rs11216961	ENSG00000255239.1	AP002954.6	-5.49	7.79e-08	3.86e-05	-0.38	-0.28	Sjögren's syndrome;	chr11:118709629	chr11:118688039~118690600:-
LIHC	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	5.49	7.8e-08	3.87e-05	0.27	0.28	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
LIHC	cis	rs4535700	0.501	rs2135116	ENSG00000226278.1	PSPHP1	5.49	7.81e-08	3.87e-05	0.34	0.28	Macular telangiectasia type 2;	chr7:55923451	chr7:55764797~55773288:+
LIHC	cis	rs11722779	0.692	rs223414	ENSG00000230069.3	LRRC37A15P	-5.49	7.82e-08	3.88e-05	-0.26	-0.28	Schizophrenia;	chr4:102811688	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223405	ENSG00000230069.3	LRRC37A15P	-5.49	7.84e-08	3.88e-05	-0.26	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102727274~102730721:-
LIHC	cis	rs1577917	0.71	rs1059306	ENSG00000234155.1	RP11-30P6.6	-5.49	7.84e-08	3.89e-05	-0.36	-0.28	Response to antipsychotic treatment;	chr6:85678391	chr6:85387219~85390186:-
LIHC	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-5.49	7.86e-08	3.89e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
LIHC	cis	rs7131987	0.834	rs12228468	ENSG00000257176.2	RP11-996F15.2	5.49	7.86e-08	3.89e-05	0.32	0.28	QT interval;	chr12:29300677	chr12:29280418~29317848:-
LIHC	cis	rs12571093	0.803	rs61854829	ENSG00000233590.1	RP11-153K11.3	-5.49	7.86e-08	3.89e-05	-0.45	-0.28	Optic nerve measurement (disc area);	chr10:68273286	chr10:68233251~68242379:-
LIHC	cis	rs1023500	0.505	rs134901	ENSG00000227370.1	RP4-669P10.19	-5.49	7.87e-08	3.9e-05	-0.3	-0.28	Schizophrenia;	chr22:42287514	chr22:42132543~42132998:+
LIHC	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-5.49	7.88e-08	3.9e-05	-0.39	-0.28	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
LIHC	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-5.49	7.88e-08	3.9e-05	-0.25	-0.28	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
LIHC	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-5.49	7.89e-08	3.9e-05	-0.47	-0.28	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
LIHC	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-5.49	7.89e-08	3.91e-05	-0.45	-0.28	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-5.49	7.89e-08	3.91e-05	-0.45	-0.28	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-5.49	7.89e-08	3.91e-05	-0.45	-0.28	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-5.49	7.89e-08	3.91e-05	-0.45	-0.28	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	5.49	7.89e-08	3.91e-05	0.45	0.28	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
LIHC	cis	rs638893	1	rs28827279	ENSG00000255422.1	AP002954.4	-5.49	7.9e-08	3.91e-05	-0.46	-0.28	Vitiligo;	chr11:118830054	chr11:118704607~118750263:+
LIHC	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-5.49	7.92e-08	3.92e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
LIHC	cis	rs5756813	0.833	rs5756819	ENSG00000233360.4	Z83844.1	-5.49	7.93e-08	3.92e-05	-0.35	-0.28	Optic cup area;Vertical cup-disc ratio;	chr22:37792188	chr22:37641832~37658377:-
LIHC	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-5.49	7.94e-08	3.93e-05	-0.3	-0.28	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
LIHC	cis	rs4934494	0.768	rs17125834	ENSG00000232936.4	RP11-80H5.2	5.49	7.94e-08	3.93e-05	0.36	0.28	Red blood cell count;	chr10:89673405	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.768	rs12571918	ENSG00000232936.4	RP11-80H5.2	5.49	7.94e-08	3.93e-05	0.36	0.28	Red blood cell count;	chr10:89674920	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.768	rs12776306	ENSG00000232936.4	RP11-80H5.2	5.49	7.94e-08	3.93e-05	0.36	0.28	Red blood cell count;	chr10:89676300	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.768	rs7078321	ENSG00000232936.4	RP11-80H5.2	5.49	7.94e-08	3.93e-05	0.36	0.28	Red blood cell count;	chr10:89678341	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.768	rs34379399	ENSG00000232936.4	RP11-80H5.2	5.49	7.94e-08	3.93e-05	0.36	0.28	Red blood cell count;	chr10:89683526	chr10:89645282~89650667:+
LIHC	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	5.49	7.95e-08	3.93e-05	0.34	0.28	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
LIHC	cis	rs11992162	1	rs7460395	ENSG00000255394.4	C8orf49	5.49	7.96e-08	3.94e-05	0.39	0.28	Monocyte count;	chr8:11977866	chr8:11761256~11763223:+
LIHC	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	5.49	7.96e-08	3.94e-05	0.27	0.28	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
LIHC	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	5.49	7.97e-08	3.94e-05	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
LIHC	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	5.49	7.98e-08	3.95e-05	0.29	0.28	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
LIHC	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-5.49	7.99e-08	3.95e-05	-0.32	-0.28	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
LIHC	cis	rs496547	0.719	rs598373	ENSG00000255422.1	AP002954.4	-5.49	8e-08	3.95e-05	-0.33	-0.28	Hip minimal joint space width;	chr11:118793668	chr11:118704607~118750263:+
LIHC	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	5.49	8e-08	3.96e-05	0.29	0.28	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
LIHC	cis	rs12291225	0.546	rs12795545	ENSG00000251991.1	RNU7-49P	5.49	8.02e-08	3.97e-05	0.3	0.28	Sense of smell;	chr11:14334018	chr11:14478892~14478953:+
LIHC	cis	rs2072510	0.722	rs2540490	ENSG00000257715.1	RP11-256L6.2	-5.49	8.02e-08	3.97e-05	-0.29	-0.28	Metabolite levels (small molecules and protein measures);	chr12:96032494	chr12:96025323~96027971:+
LIHC	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-5.49	8.02e-08	3.97e-05	-0.37	-0.28	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
LIHC	cis	rs1005277	0.505	rs10827835	ENSG00000263064.2	RP11-291L22.7	-5.49	8.03e-08	3.97e-05	-0.29	-0.28	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38448689~38448949:+
LIHC	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	5.49	8.03e-08	3.97e-05	0.59	0.28	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
LIHC	cis	rs7916697	0.593	rs10762198	ENSG00000233590.1	RP11-153K11.3	5.49	8.04e-08	3.97e-05	0.34	0.28	Optic disc area;	chr10:68263296	chr10:68233251~68242379:-
LIHC	cis	rs9388451	0.807	rs1268070	ENSG00000237742.5	RP11-624M8.1	-5.49	8.05e-08	3.98e-05	-0.27	-0.28	Brugada syndrome;	chr6:125720018	chr6:125578558~125749190:-
LIHC	cis	rs116175783	0.557	rs62197071	ENSG00000227403.1	AC009299.3	5.48	8.07e-08	3.99e-05	0.43	0.28	Intelligence (multi-trait analysis);	chr2:161292703	chr2:161244739~161249050:+
LIHC	cis	rs116175783	0.557	rs16845757	ENSG00000227403.1	AC009299.3	5.48	8.07e-08	3.99e-05	0.43	0.28	Intelligence (multi-trait analysis);	chr2:161299749	chr2:161244739~161249050:+
LIHC	cis	rs7927592	0.645	rs7950900	ENSG00000212093.1	AP000807.1	5.48	8.07e-08	3.99e-05	0.3	0.28	Total body bone mineral density;	chr11:68526077	chr11:68506083~68506166:-
LIHC	cis	rs62229266	0.587	rs62229264	ENSG00000231106.2	LINC01436	5.48	8.08e-08	3.99e-05	0.32	0.28	Mitral valve prolapse;	chr21:36079915	chr21:36005338~36007838:+
LIHC	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	5.48	8.09e-08	3.99e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
LIHC	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-5.48	8.09e-08	4e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
LIHC	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-5.48	8.1e-08	4e-05	-0.35	-0.28	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-5.48	8.11e-08	4e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
LIHC	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-5.48	8.12e-08	4.01e-05	-0.35	-0.28	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
LIHC	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	5.48	8.12e-08	4.01e-05	0.26	0.28	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
LIHC	cis	rs227275	0.554	rs149576	ENSG00000230069.3	LRRC37A15P	-5.48	8.12e-08	4.01e-05	-0.26	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.873	rs223346	ENSG00000230069.3	LRRC37A15P	-5.48	8.13e-08	4.01e-05	-0.25	-0.28	Schizophrenia;	chr4:102859339	chr4:102727274~102730721:-
LIHC	cis	rs887829	0.667	rs7577677	ENSG00000233445.1	RPL17P11	5.48	8.13e-08	4.01e-05	0.3	0.28	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233681970	chr2:233721522~233722065:-
LIHC	cis	rs1005277	0.54	rs1987431	ENSG00000263064.2	RP11-291L22.7	5.48	8.14e-08	4.02e-05	0.29	0.28	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38448689~38448949:+
LIHC	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	8.14e-08	4.02e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
LIHC	cis	rs2933343	0.533	rs13086121	ENSG00000231305.3	RP11-723O4.2	5.48	8.17e-08	4.03e-05	0.32	0.28	IgG glycosylation;	chr3:128985447	chr3:128861313~128871540:-
LIHC	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	5.48	8.18e-08	4.03e-05	0.41	0.28	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	5.48	8.18e-08	4.03e-05	0.41	0.28	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	5.48	8.18e-08	4.03e-05	0.41	0.28	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	5.48	8.18e-08	4.03e-05	0.41	0.28	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
LIHC	cis	rs879620	1	rs879620	ENSG00000262185.1	RP11-462G12.1	5.48	8.18e-08	4.04e-05	0.36	0.28	Hip circumference;Body mass index;	chr16:3965728	chr16:3947609~3950444:-
LIHC	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-5.48	8.19e-08	4.04e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-5.48	8.19e-08	4.04e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-5.48	8.19e-08	4.04e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
LIHC	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	5.48	8.19e-08	4.04e-05	0.34	0.28	Height;	chr6:109346560	chr6:109382795~109383666:+
LIHC	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-5.48	8.2e-08	4.04e-05	-0.31	-0.28	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
LIHC	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-5.48	8.21e-08	4.05e-05	-0.35	-0.28	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
LIHC	cis	rs4934494	0.768	rs17126269	ENSG00000232936.4	RP11-80H5.2	5.48	8.22e-08	4.05e-05	0.36	0.28	Red blood cell count;	chr10:89694974	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.768	rs768805	ENSG00000232936.4	RP11-80H5.2	5.48	8.22e-08	4.05e-05	0.36	0.28	Red blood cell count;	chr10:89695448	chr10:89645282~89650667:+
LIHC	cis	rs4356203	0.905	rs7927240	ENSG00000272034.1	SNORD14A	-5.48	8.23e-08	4.05e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs7946165	ENSG00000272034.1	SNORD14A	-5.48	8.23e-08	4.05e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.875	rs7939614	ENSG00000272034.1	SNORD14A	-5.48	8.23e-08	4.05e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs9919600	ENSG00000272034.1	SNORD14A	-5.48	8.23e-08	4.05e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs9919540	ENSG00000272034.1	SNORD14A	-5.48	8.23e-08	4.05e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17074654~17074744:-
LIHC	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	5.48	8.23e-08	4.06e-05	0.44	0.28	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
LIHC	cis	rs228614	0.51	rs223412	ENSG00000230069.3	LRRC37A15P	-5.48	8.24e-08	4.06e-05	-0.26	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102727274~102730721:-
LIHC	cis	rs3096299	0.685	rs4785568	ENSG00000261118.1	RP11-104N10.1	5.48	8.24e-08	4.06e-05	0.28	0.28	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89492017~89504460:-
LIHC	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-5.48	8.24e-08	4.06e-05	-0.26	-0.28	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
LIHC	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-5.48	8.26e-08	4.07e-05	-0.35	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
LIHC	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	8.27e-08	4.07e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
LIHC	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-5.48	8.27e-08	4.07e-05	-0.35	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
LIHC	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-5.48	8.28e-08	4.08e-05	-0.29	-0.28	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
LIHC	cis	rs5769707	0.632	rs135877	ENSG00000235111.1	RP1-29C18.8	-5.48	8.3e-08	4.08e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49612657~49615716:-
LIHC	cis	rs496547	0.52	rs11216963	ENSG00000255239.1	AP002954.6	-5.48	8.3e-08	4.08e-05	-0.38	-0.28	Hip minimal joint space width;	chr11:118710105	chr11:118688039~118690600:-
LIHC	cis	rs17711722	0.565	rs4717276	ENSG00000228409.4	CCT6P1	-5.48	8.31e-08	4.09e-05	-0.22	-0.28	Calcium levels;	chr7:65829754	chr7:65751142~65763354:+
LIHC	cis	rs5758659	1	rs134882	ENSG00000227370.1	RP4-669P10.19	-5.48	8.31e-08	4.09e-05	-0.32	-0.28	Cognitive function;	chr22:42274959	chr22:42132543~42132998:+
LIHC	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	5.48	8.31e-08	4.09e-05	0.44	0.28	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	5.48	8.31e-08	4.09e-05	0.44	0.28	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
LIHC	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-5.48	8.32e-08	4.09e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
LIHC	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-5.48	8.33e-08	4.09e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
LIHC	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	5.48	8.33e-08	4.1e-05	0.46	0.28	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	5.48	8.33e-08	4.1e-05	0.46	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	5.48	8.33e-08	4.1e-05	0.46	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	5.48	8.33e-08	4.1e-05	0.46	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	5.48	8.33e-08	4.1e-05	0.46	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	5.48	8.33e-08	4.1e-05	0.46	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
LIHC	cis	rs6504950	0.548	rs714896	ENSG00000275710.1	RP11-257O5.4	5.48	8.35e-08	4.11e-05	0.48	0.28	Breast cancer;	chr17:55179621	chr17:54964474~54964679:+
LIHC	cis	rs6504950	0.579	rs7212321	ENSG00000275710.1	RP11-257O5.4	5.48	8.35e-08	4.11e-05	0.48	0.28	Breast cancer;	chr17:55181076	chr17:54964474~54964679:+
LIHC	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-5.48	8.36e-08	4.11e-05	-0.33	-0.28	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
LIHC	cis	rs2072510	0.683	rs2660840	ENSG00000257715.1	RP11-256L6.2	-5.48	8.38e-08	4.12e-05	-0.29	-0.28	Metabolite levels (small molecules and protein measures);	chr12:96038729	chr12:96025323~96027971:+
LIHC	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	5.48	8.4e-08	4.13e-05	0.46	0.28	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	5.48	8.4e-08	4.13e-05	0.46	0.28	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.681	rs8137111	ENSG00000235111.1	RP1-29C18.8	-5.48	8.41e-08	4.13e-05	-0.35	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49612657~49615716:-
LIHC	cis	rs62229266	0.572	rs4816518	ENSG00000231106.2	LINC01436	5.48	8.42e-08	4.14e-05	0.32	0.28	Mitral valve prolapse;	chr21:36081009	chr21:36005338~36007838:+
LIHC	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	5.48	8.42e-08	4.14e-05	0.46	0.28	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
LIHC	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	5.48	8.42e-08	4.14e-05	0.44	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
LIHC	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	5.48	8.43e-08	4.14e-05	0.35	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
LIHC	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	5.48	8.43e-08	4.14e-05	0.35	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
LIHC	cis	rs12157904	0.793	rs8142714	ENSG00000233360.4	Z83844.1	5.48	8.47e-08	4.16e-05	0.58	0.28	Response to anti-depressant treatment in major depressive disorder;	chr22:37641931	chr22:37641832~37658377:-
LIHC	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	5.48	8.47e-08	4.16e-05	0.44	0.28	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
LIHC	cis	rs4731207	0.689	rs1481341	ENSG00000224897.5	POT1-AS1	5.48	8.48e-08	4.16e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:124927069	chr7:124929873~125179315:+
LIHC	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-5.48	8.48e-08	4.16e-05	-0.32	-0.28	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
LIHC	cis	rs2976388	0.524	rs7012804	ENSG00000253196.1	RP11-706C16.7	5.47	8.49e-08	4.17e-05	0.28	0.28	Urinary tract infection frequency;	chr8:142763232	chr8:142763116~142766427:+
LIHC	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	5.47	8.49e-08	4.17e-05	0.39	0.28	Height;	chr6:109372084	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	5.47	8.49e-08	4.17e-05	0.34	0.28	Height;	chr6:109392096	chr6:109382795~109383666:+
LIHC	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	5.47	8.49e-08	4.17e-05	0.38	0.28	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-5.47	8.5e-08	4.17e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	5.47	8.5e-08	4.17e-05	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
LIHC	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-5.47	8.51e-08	4.17e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-5.47	8.51e-08	4.17e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
LIHC	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	5.47	8.51e-08	4.17e-05	0.29	0.28	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
LIHC	cis	rs739496	0.843	rs688812	ENSG00000226469.1	ADAM1B	5.47	8.52e-08	4.18e-05	0.35	0.28	Platelet count;	chr12:111524777	chr12:111927018~111929017:+
LIHC	cis	rs17301013	0.829	rs2006197	ENSG00000227373.4	RP11-160H22.5	5.47	8.52e-08	4.18e-05	0.36	0.28	Systemic lupus erythematosus;	chr1:174432825	chr1:174115300~174160004:-
LIHC	cis	rs875971	0.522	rs1617484	ENSG00000164669.11	INTS4P1	-5.47	8.54e-08	4.19e-05	-0.39	-0.28	Aortic root size;	chr7:65998108	chr7:65141225~65234216:+
LIHC	cis	rs6480314	0.542	rs61854804	ENSG00000233590.1	RP11-153K11.3	-5.47	8.55e-08	4.2e-05	-0.45	-0.28	Optic nerve measurement (disc area);	chr10:68255819	chr10:68233251~68242379:-
LIHC	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	5.47	8.57e-08	4.2e-05	0.37	0.28	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	5.47	8.57e-08	4.2e-05	0.37	0.28	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	5.47	8.57e-08	4.2e-05	0.37	0.28	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	5.47	8.57e-08	4.2e-05	0.37	0.28	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	5.47	8.57e-08	4.2e-05	0.37	0.28	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	5.47	8.57e-08	4.2e-05	0.37	0.28	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
LIHC	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-5.47	8.57e-08	4.2e-05	-0.51	-0.28	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
LIHC	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-5.47	8.57e-08	4.2e-05	-0.35	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-5.47	8.57e-08	4.2e-05	-0.35	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
LIHC	cis	rs17711722	0.523	rs313812	ENSG00000228409.4	CCT6P1	5.47	8.58e-08	4.21e-05	0.22	0.28	Calcium levels;	chr7:66040056	chr7:65751142~65763354:+
LIHC	cis	rs4934494	0.768	rs1409357	ENSG00000232936.4	RP11-80H5.2	5.47	8.58e-08	4.21e-05	0.36	0.28	Red blood cell count;	chr10:89669719	chr10:89645282~89650667:+
LIHC	cis	rs7131987	0.617	rs3764953	ENSG00000275476.1	RP11-996F15.4	-5.47	8.59e-08	4.21e-05	-0.34	-0.28	QT interval;	chr12:29349303	chr12:29277397~29277882:-
LIHC	cis	rs1577917	0.839	rs6454504	ENSG00000234155.1	RP11-30P6.6	5.47	8.61e-08	4.22e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85870612	chr6:85387219~85390186:-
LIHC	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-5.47	8.61e-08	4.22e-05	-0.31	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
LIHC	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-5.47	8.62e-08	4.22e-05	-0.29	-0.28	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
LIHC	cis	rs4535700	0.501	rs28828764	ENSG00000226278.1	PSPHP1	5.47	8.63e-08	4.23e-05	0.34	0.28	Macular telangiectasia type 2;	chr7:55920986	chr7:55764797~55773288:+
LIHC	cis	rs11722779	0.815	rs223347	ENSG00000230069.3	LRRC37A15P	-5.47	8.63e-08	4.23e-05	-0.25	-0.28	Schizophrenia;	chr4:102858815	chr4:102727274~102730721:-
LIHC	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	5.47	8.64e-08	4.23e-05	0.36	0.28	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
LIHC	cis	rs7131987	0.903	rs1035604	ENSG00000257176.2	RP11-996F15.2	-5.47	8.65e-08	4.24e-05	-0.33	-0.28	QT interval;	chr12:29240169	chr12:29280418~29317848:-
LIHC	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-5.47	8.65e-08	4.24e-05	-0.38	-0.28	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
LIHC	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-5.47	8.65e-08	4.24e-05	-0.38	-0.28	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
LIHC	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	5.47	8.67e-08	4.25e-05	0.32	0.28	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
LIHC	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	5.47	8.67e-08	4.25e-05	0.31	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-5.47	8.69e-08	4.25e-05	-0.31	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
LIHC	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-5.47	8.7e-08	4.26e-05	-0.39	-0.28	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
LIHC	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-5.47	8.7e-08	4.26e-05	-0.31	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
LIHC	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	5.47	8.71e-08	4.26e-05	0.4	0.28	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
LIHC	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-5.47	8.71e-08	4.27e-05	-0.29	-0.28	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
LIHC	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	5.47	8.72e-08	4.27e-05	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
LIHC	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	5.47	8.73e-08	4.27e-05	0.25	0.28	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
LIHC	cis	rs202072	0.872	rs377704	ENSG00000215022.6	RP1-257A7.4	-5.47	8.73e-08	4.27e-05	-0.33	-0.28	HIV-1 viral setpoint;	chr6:13279787	chr6:13264861~13295586:-
LIHC	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	5.47	8.73e-08	4.27e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
LIHC	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	5.47	8.74e-08	4.28e-05	0.36	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
LIHC	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	5.47	8.74e-08	4.28e-05	0.39	0.28	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
LIHC	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	5.47	8.76e-08	4.28e-05	0.26	0.28	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
LIHC	cis	rs12681287	0.605	rs2976181	ENSG00000250569.1	NTAN1P2	5.47	8.77e-08	4.29e-05	0.34	0.28	Caudate activity during reward;	chr8:86332241	chr8:86481754~86483002:-
LIHC	cis	rs113835537	0.627	rs4630309	ENSG00000255517.5	CTD-3074O7.5	5.47	8.79e-08	4.3e-05	0.34	0.28	Airway imaging phenotypes;	chr11:66565601	chr11:66473490~66480233:-
LIHC	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-5.47	8.8e-08	4.3e-05	-0.32	-0.28	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-5.47	8.81e-08	4.31e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
LIHC	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-5.47	8.82e-08	4.31e-05	-0.35	-0.28	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
LIHC	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-5.47	8.83e-08	4.32e-05	-0.36	-0.28	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
LIHC	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-5.47	8.84e-08	4.32e-05	-0.34	-0.28	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
LIHC	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-5.47	8.84e-08	4.32e-05	-0.35	-0.28	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
LIHC	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-5.47	8.85e-08	4.33e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
LIHC	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-5.47	8.86e-08	4.33e-05	-0.46	-0.28	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
LIHC	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-5.47	8.86e-08	4.33e-05	-0.35	-0.28	Gout;	chr7:66732812	chr7:66902857~66906297:+
LIHC	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-5.47	8.87e-08	4.33e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
LIHC	cis	rs6940638	0.688	rs9393795	ENSG00000216901.1	AL022393.7	5.47	8.87e-08	4.34e-05	0.37	0.28	Intelligence (multi-trait analysis);	chr6:27249940	chr6:28176188~28176674:+
LIHC	cis	rs12681287	0.547	rs9297921	ENSG00000250569.1	NTAN1P2	-5.47	8.89e-08	4.34e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86530058	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs9297922	ENSG00000250569.1	NTAN1P2	-5.47	8.89e-08	4.34e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86530089	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs35871312	ENSG00000250569.1	NTAN1P2	-5.47	8.89e-08	4.34e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86530991	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs10087788	ENSG00000250569.1	NTAN1P2	-5.47	8.89e-08	4.34e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86531946	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.547	rs10956873	ENSG00000250569.1	NTAN1P2	-5.47	8.89e-08	4.34e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86534800	chr8:86481754~86483002:-
LIHC	cis	rs12681287	0.511	rs9297923	ENSG00000250569.1	NTAN1P2	-5.47	8.89e-08	4.34e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86536761	chr8:86481754~86483002:-
LIHC	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	5.47	8.89e-08	4.34e-05	0.33	0.28	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
LIHC	cis	rs12681287	0.577	rs10481197	ENSG00000250569.1	NTAN1P2	-5.47	8.9e-08	4.35e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86534323	chr8:86481754~86483002:-
LIHC	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-5.47	8.91e-08	4.35e-05	-0.3	-0.28	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.554	rs223339	ENSG00000230069.3	LRRC37A15P	-5.47	8.92e-08	4.36e-05	-0.26	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102727274~102730721:-
LIHC	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-5.47	8.92e-08	4.36e-05	-0.47	-0.28	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
LIHC	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-5.46	8.94e-08	4.37e-05	-0.3	-0.28	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-5.46	8.94e-08	4.37e-05	-0.3	-0.28	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.556	rs6842179	ENSG00000230069.3	LRRC37A15P	-5.46	8.98e-08	4.38e-05	-0.26	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102727274~102730721:-
LIHC	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	5.46	8.99e-08	4.39e-05	0.38	0.28	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
LIHC	cis	rs4403732	1	rs4237333	ENSG00000230526.1	RP11-472G21.2	5.46	9.02e-08	4.4e-05	0.36	0.28	Coronary artery disease;	chr10:71877468	chr10:71878356~71879107:+
LIHC	cis	rs2735413	0.563	rs72800915	ENSG00000276007.1	RP11-358L22.3	5.46	9.04e-08	4.41e-05	0.38	0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78021880	chr16:78123243~78124332:+
LIHC	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	5.46	9.06e-08	4.42e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
LIHC	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-5.46	9.07e-08	4.42e-05	-0.25	-0.28	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
LIHC	cis	rs9388451	0.839	rs9321054	ENSG00000237742.5	RP11-624M8.1	5.46	9.07e-08	4.42e-05	0.26	0.28	Brugada syndrome;	chr6:125758822	chr6:125578558~125749190:-
LIHC	cis	rs4535700	0.543	rs2174459	ENSG00000226278.1	PSPHP1	5.46	9.07e-08	4.42e-05	0.34	0.28	Macular telangiectasia type 2;	chr7:55923600	chr7:55764797~55773288:+
LIHC	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-5.46	9.08e-08	4.43e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
LIHC	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-5.46	9.08e-08	4.43e-05	-0.42	-0.28	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
LIHC	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	5.46	9.1e-08	4.43e-05	0.33	0.28	Height;	chr6:109584789	chr6:109382795~109383666:+
LIHC	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	5.46	9.11e-08	4.44e-05	0.28	0.28	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
LIHC	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-5.46	9.11e-08	4.44e-05	-0.26	-0.28	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
LIHC	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-5.46	9.12e-08	4.45e-05	-0.35	-0.28	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
LIHC	cis	rs4356203	0.846	rs1685932	ENSG00000272034.1	SNORD14A	-5.46	9.12e-08	4.45e-05	-0.3	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17202356	chr11:17074654~17074744:-
LIHC	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-5.46	9.13e-08	4.45e-05	-0.35	-0.28	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
LIHC	cis	rs5758659	0.967	rs5758670	ENSG00000227370.1	RP4-669P10.19	-5.46	9.13e-08	4.45e-05	-0.32	-0.28	Cognitive function;	chr22:42240681	chr22:42132543~42132998:+
LIHC	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-5.46	9.14e-08	4.46e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
LIHC	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-5.46	9.14e-08	4.46e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
LIHC	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	5.46	9.16e-08	4.46e-05	0.27	0.28	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	5.46	9.16e-08	4.46e-05	0.27	0.28	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	5.46	9.16e-08	4.46e-05	0.27	0.28	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	5.46	9.16e-08	4.46e-05	0.27	0.28	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
LIHC	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	5.46	9.17e-08	4.46e-05	0.38	0.28	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
LIHC	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-5.46	9.17e-08	4.46e-05	-0.44	-0.28	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
LIHC	cis	rs7131987	0.834	rs1989478	ENSG00000257176.2	RP11-996F15.2	-5.46	9.18e-08	4.47e-05	-0.32	-0.28	QT interval;	chr12:29289296	chr12:29280418~29317848:-
LIHC	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-5.46	9.19e-08	4.48e-05	-0.37	-0.28	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
LIHC	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-5.46	9.2e-08	4.48e-05	-0.25	-0.28	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
LIHC	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66692349	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66693028	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66693433	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66694214	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66701371	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66702658	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66706390	chr7:66654538~66669855:+
LIHC	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66710076	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66715944	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-5.46	9.21e-08	4.48e-05	-0.46	-0.28	Gout;	chr7:66721259	chr7:66654538~66669855:+
LIHC	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	5.46	9.21e-08	4.48e-05	0.39	0.28	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
LIHC	cis	rs228614	0.536	rs223419	ENSG00000230069.3	LRRC37A15P	-5.46	9.21e-08	4.48e-05	-0.26	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.536	rs223418	ENSG00000230069.3	LRRC37A15P	-5.46	9.21e-08	4.48e-05	-0.26	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102727274~102730721:-
LIHC	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	5.46	9.23e-08	4.49e-05	0.39	0.28	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
LIHC	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	5.46	9.23e-08	4.49e-05	0.37	0.28	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
LIHC	cis	rs9388451	0.874	rs3734634	ENSG00000237742.5	RP11-624M8.1	-5.46	9.24e-08	4.49e-05	-0.26	-0.28	Brugada syndrome;	chr6:125790654	chr6:125578558~125749190:-
LIHC	cis	rs4356975	0.563	rs4274916	ENSG00000249956.3	RP11-790I12.2	5.46	9.24e-08	4.49e-05	0.32	0.28	Obesity-related traits;	chr4:69122660	chr4:69408836~69423164:+
LIHC	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	5.46	9.26e-08	4.5e-05	0.37	0.28	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
LIHC	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	5.46	9.26e-08	4.51e-05	0.4	0.28	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
LIHC	cis	rs9467711	0.651	rs72832596	ENSG00000216436.2	HIST1H2APS1	5.46	9.26e-08	4.51e-05	0.77	0.28	Autism spectrum disorder or schizophrenia;	chr6:25962723	chr6:25732497~25732827:+
LIHC	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-5.46	9.27e-08	4.51e-05	-0.37	-0.28	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
LIHC	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	5.46	9.27e-08	4.51e-05	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
LIHC	cis	rs3096299	0.802	rs3102336	ENSG00000261118.1	RP11-104N10.1	5.46	9.29e-08	4.52e-05	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89492017~89504460:-
LIHC	cis	rs2877649	0.793	rs113112510	ENSG00000258744.1	RP11-80A15.1	-5.46	9.32e-08	4.53e-05	-0.59	-0.28	Smooth-surface caries;	chr14:24457648	chr14:24501594~24508688:+
LIHC	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-5.46	9.32e-08	4.53e-05	-0.35	-0.28	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-5.46	9.32e-08	4.53e-05	-0.35	-0.28	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-5.46	9.32e-08	4.53e-05	-0.35	-0.28	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-5.46	9.32e-08	4.53e-05	-0.35	-0.28	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-5.46	9.32e-08	4.53e-05	-0.35	-0.28	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
LIHC	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	5.46	9.33e-08	4.53e-05	0.44	0.28	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
LIHC	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-5.46	9.34e-08	4.54e-05	-0.29	-0.28	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
LIHC	cis	rs9425766	0.566	rs12079820	ENSG00000227373.4	RP11-160H22.5	5.46	9.34e-08	4.54e-05	0.36	0.28	Life satisfaction;	chr1:174240771	chr1:174115300~174160004:-
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-5.46	9.35e-08	4.54e-05	-0.34	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
LIHC	cis	rs4934494	0.768	rs58163515	ENSG00000232936.4	RP11-80H5.2	5.46	9.35e-08	4.54e-05	0.36	0.28	Red blood cell count;	chr10:89637807	chr10:89645282~89650667:+
LIHC	cis	rs734999	1	rs734999	ENSG00000225931.3	RP3-395M20.7	5.46	9.35e-08	4.54e-05	0.31	0.28	Ulcerative colitis;	chr1:2581777	chr1:2566410~2569888:+
LIHC	cis	rs734999	1	rs2016366	ENSG00000225931.3	RP3-395M20.7	5.46	9.35e-08	4.54e-05	0.31	0.28	Ulcerative colitis;	chr1:2582239	chr1:2566410~2569888:+
LIHC	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-5.46	9.37e-08	4.55e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
LIHC	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-5.46	9.38e-08	4.56e-05	-0.37	-0.28	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
LIHC	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-5.46	9.38e-08	4.56e-05	-0.46	-0.28	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
LIHC	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-5.46	9.39e-08	4.56e-05	-0.28	-0.28	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-5.46	9.39e-08	4.56e-05	-0.28	-0.28	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
LIHC	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	5.46	9.39e-08	4.56e-05	0.43	0.28	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
LIHC	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	5.46	9.39e-08	4.56e-05	0.59	0.28	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
LIHC	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	5.46	9.39e-08	4.56e-05	0.59	0.28	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
LIHC	cis	rs9326248	0.817	rs1242127	ENSG00000236267.1	AP006216.5	-5.46	9.41e-08	4.57e-05	-0.28	-0.28	Blood protein levels;	chr11:117205848	chr11:116813204~116814003:-
LIHC	cis	rs5758659	0.512	rs4822072	ENSG00000227370.1	RP4-669P10.19	-5.46	9.41e-08	4.57e-05	-0.33	-0.28	Cognitive function;	chr22:41964829	chr22:42132543~42132998:+
LIHC	cis	rs7131987	0.874	rs10843366	ENSG00000257176.2	RP11-996F15.2	-5.46	9.41e-08	4.57e-05	-0.33	-0.28	QT interval;	chr12:29254970	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.845	rs2042511	ENSG00000257176.2	RP11-996F15.2	-5.46	9.41e-08	4.57e-05	-0.33	-0.28	QT interval;	chr12:29255847	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.903	rs10843371	ENSG00000257176.2	RP11-996F15.2	-5.46	9.41e-08	4.57e-05	-0.33	-0.28	QT interval;	chr12:29261299	chr12:29280418~29317848:-
LIHC	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-5.46	9.41e-08	4.57e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
LIHC	cis	rs12744310	0.502	rs12027253	ENSG00000235358.1	RP11-399E6.1	5.45	9.43e-08	4.58e-05	0.33	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41342569	chr1:41242373~41284861:+
LIHC	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-5.45	9.43e-08	4.58e-05	-0.37	-0.28	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
LIHC	cis	rs12458462	0.665	rs2035085	ENSG00000274828.1	RP11-567M16.6	5.45	9.44e-08	4.58e-05	0.3	0.28	Monocyte count;	chr18:79725280	chr18:79677287~79679358:-
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-5.45	9.44e-08	4.58e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
LIHC	cis	rs2998286	0.862	rs2790448	ENSG00000254635.4	WAC-AS1	-5.45	9.44e-08	4.58e-05	-0.35	-0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512828	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.822	rs2807734	ENSG00000254635.4	WAC-AS1	-5.45	9.44e-08	4.58e-05	-0.35	-0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28513036	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.822	rs2095901	ENSG00000254635.4	WAC-AS1	-5.45	9.44e-08	4.58e-05	-0.35	-0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28514790	chr10:28522652~28532743:-
LIHC	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	5.45	9.46e-08	4.59e-05	0.25	0.28	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
LIHC	cis	rs9425766	0.566	rs56188862	ENSG00000227373.4	RP11-160H22.5	5.45	9.46e-08	4.59e-05	0.36	0.28	Life satisfaction;	chr1:174220131	chr1:174115300~174160004:-
LIHC	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	5.45	9.47e-08	4.59e-05	0.27	0.28	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
LIHC	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	5.45	9.48e-08	4.6e-05	0.38	0.28	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
LIHC	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-5.45	9.48e-08	4.6e-05	-0.28	-0.28	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
LIHC	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-5.45	9.49e-08	4.6e-05	-0.32	-0.28	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
LIHC	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-5.45	9.49e-08	4.6e-05	-0.33	-0.28	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
LIHC	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-5.45	9.49e-08	4.6e-05	-0.33	-0.28	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
LIHC	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-5.45	9.5e-08	4.61e-05	-0.25	-0.28	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
LIHC	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-5.45	9.51e-08	4.61e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
LIHC	cis	rs2877649	0.793	rs111536428	ENSG00000258744.1	RP11-80A15.1	-5.45	9.51e-08	4.61e-05	-0.58	-0.28	Smooth-surface caries;	chr14:24460326	chr14:24501594~24508688:+
LIHC	cis	rs1577917	0.839	rs9450333	ENSG00000234155.1	RP11-30P6.6	5.45	9.53e-08	4.62e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85810037	chr6:85387219~85390186:-
LIHC	cis	rs17301013	0.932	rs1016466	ENSG00000227373.4	RP11-160H22.5	5.45	9.53e-08	4.62e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174570652	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs10753086	ENSG00000227373.4	RP11-160H22.5	5.45	9.53e-08	4.62e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174580802	chr1:174115300~174160004:-
LIHC	cis	rs227275	0.525	rs724446	ENSG00000230069.3	LRRC37A15P	-5.45	9.53e-08	4.62e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102727274~102730721:-
LIHC	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-5.45	9.54e-08	4.63e-05	-0.37	-0.28	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
LIHC	cis	rs2929278	0.638	rs2016840	ENSG00000166763.7	STRCP1	-5.45	9.54e-08	4.63e-05	-0.36	-0.28	Schizophrenia;	chr15:43919670	chr15:43699488~43718184:-
LIHC	cis	rs116175783	0.557	rs1146024	ENSG00000227403.1	AC009299.3	5.45	9.55e-08	4.63e-05	0.43	0.28	Intelligence (multi-trait analysis);	chr2:161282740	chr2:161244739~161249050:+
LIHC	cis	rs638893	1	rs638893	ENSG00000255422.1	AP002954.4	-5.45	9.56e-08	4.64e-05	-0.46	-0.28	Vitiligo;	chr11:118827828	chr11:118704607~118750263:+
LIHC	cis	rs6686842	1	rs213742	ENSG00000235358.1	RP11-399E6.1	-5.45	9.56e-08	4.64e-05	-0.31	-0.28	Height;	chr1:41155455	chr1:41242373~41284861:+
LIHC	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	9.57e-08	4.64e-05	-0.27	-0.28	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
LIHC	cis	rs11647589	0.834	rs6497491	ENSG00000262995.1	CTD-2194A8.2	-5.45	9.58e-08	4.64e-05	-0.27	-0.28	Blood metabolite levels;	chr16:20468691	chr16:20440266~20447000:-
LIHC	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	5.45	9.61e-08	4.65e-05	0.38	0.28	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	5.45	9.61e-08	4.66e-05	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
LIHC	cis	rs6480314	0.573	rs12573244	ENSG00000233590.1	RP11-153K11.3	-5.45	9.62e-08	4.66e-05	-0.45	-0.28	Optic nerve measurement (disc area);	chr10:68241488	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs11814858	ENSG00000233590.1	RP11-153K11.3	-5.45	9.62e-08	4.66e-05	-0.45	-0.28	Optic nerve measurement (disc area);	chr10:68241950	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.636	rs61854788	ENSG00000233590.1	RP11-153K11.3	-5.45	9.62e-08	4.66e-05	-0.45	-0.28	Optic nerve measurement (disc area);	chr10:68241980	chr10:68233251~68242379:-
LIHC	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-5.45	9.62e-08	4.66e-05	-0.28	-0.28	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
LIHC	cis	rs12908161	1	rs35630683	ENSG00000259295.5	CSPG4P12	5.45	9.62e-08	4.66e-05	0.39	0.28	Schizophrenia;	chr15:84806000	chr15:85191438~85213905:+
LIHC	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-5.45	9.63e-08	4.67e-05	-0.28	-0.28	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
LIHC	cis	rs17301013	0.9	rs56347239	ENSG00000227373.4	RP11-160H22.5	5.45	9.65e-08	4.67e-05	0.35	0.28	Systemic lupus erythematosus;	chr1:174564476	chr1:174115300~174160004:-
LIHC	cis	rs2877649	0.793	rs76640748	ENSG00000258744.1	RP11-80A15.1	-5.45	9.65e-08	4.67e-05	-0.59	-0.28	Smooth-surface caries;	chr14:24457239	chr14:24501594~24508688:+
LIHC	cis	rs10510102	1	rs11200181	ENSG00000226864.1	ATE1-AS1	5.45	9.67e-08	4.68e-05	0.45	0.28	Breast cancer;	chr10:121828528	chr10:121928312~121951965:+
LIHC	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-5.45	9.67e-08	4.68e-05	-0.3	-0.28	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
LIHC	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	5.45	9.69e-08	4.69e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	5.45	9.69e-08	4.69e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	5.45	9.69e-08	4.69e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	5.45	9.69e-08	4.69e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	5.45	9.69e-08	4.69e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	5.45	9.69e-08	4.69e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
LIHC	cis	rs1075232	0.51	rs78884938	ENSG00000270055.1	CTD-3092A11.2	-5.45	9.69e-08	4.69e-05	-0.53	-0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31218682	chr15:30487963~30490313:+
LIHC	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-5.45	9.7e-08	4.69e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-5.45	9.7e-08	4.69e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-5.45	9.7e-08	4.69e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-5.45	9.7e-08	4.69e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-5.45	9.7e-08	4.69e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
LIHC	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	5.45	9.7e-08	4.69e-05	0.44	0.28	Depression;	chr6:28142370	chr6:28115628~28116551:+
LIHC	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-5.45	9.7e-08	4.69e-05	-0.37	-0.28	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
LIHC	cis	rs1577917	0.785	rs1885607	ENSG00000234155.1	RP11-30P6.6	-5.45	9.71e-08	4.7e-05	-0.36	-0.28	Response to antipsychotic treatment;	chr6:85685187	chr6:85387219~85390186:-
LIHC	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	5.45	9.72e-08	4.7e-05	0.43	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
LIHC	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	5.45	9.72e-08	4.7e-05	0.25	0.28	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	5.45	9.72e-08	4.7e-05	0.25	0.28	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	5.45	9.72e-08	4.7e-05	0.25	0.28	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
LIHC	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-5.45	9.72e-08	4.7e-05	-0.35	-0.28	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
LIHC	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	5.45	9.72e-08	4.7e-05	0.41	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
LIHC	cis	rs11722779	0.869	rs223323	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Schizophrenia;	chr4:102878412	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223316	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223314	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223313	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs7254	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223311	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.566	rs6822658	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Schizophrenia;	chr4:102891964	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs6823625	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs6846762	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs4699032	ENSG00000230069.3	LRRC37A15P	-5.45	9.76e-08	4.72e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102727274~102730721:-
LIHC	cis	rs17301013	0.932	rs7542389	ENSG00000227373.4	RP11-160H22.5	5.45	9.76e-08	4.72e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174565104	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs12074753	ENSG00000227373.4	RP11-160H22.5	5.45	9.76e-08	4.72e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174565768	chr1:174115300~174160004:-
LIHC	cis	rs12157904	0.793	rs6000853	ENSG00000233360.4	Z83844.1	5.45	9.76e-08	4.72e-05	0.57	0.28	Response to anti-depressant treatment in major depressive disorder;	chr22:37649481	chr22:37641832~37658377:-
LIHC	cis	rs8028182	0.636	rs4886707	ENSG00000260269.4	CTD-2323K18.1	-5.45	9.76e-08	4.72e-05	-0.37	-0.28	Sudden cardiac arrest;	chr15:75463126	chr15:75527150~75601205:-
LIHC	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	5.45	9.77e-08	4.72e-05	0.38	0.28	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
LIHC	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-5.45	9.8e-08	4.73e-05	-0.36	-0.28	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
LIHC	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	5.45	9.8e-08	4.74e-05	0.39	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
LIHC	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	5.45	9.83e-08	4.75e-05	0.35	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
LIHC	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-5.45	9.83e-08	4.75e-05	-0.39	-0.28	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
LIHC	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-5.45	9.83e-08	4.75e-05	-0.28	-0.28	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
LIHC	cis	rs4731207	0.596	rs1026837	ENSG00000224897.5	POT1-AS1	5.45	9.85e-08	4.75e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125033025	chr7:124929873~125179315:+
LIHC	cis	rs4356203	0.905	rs7930058	ENSG00000272034.1	SNORD14A	-5.45	9.85e-08	4.76e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17045071	chr11:17074654~17074744:-
LIHC	cis	rs6480314	0.542	rs61854824	ENSG00000233590.1	RP11-153K11.3	-5.45	9.86e-08	4.76e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68270438	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs12572954	ENSG00000233590.1	RP11-153K11.3	-5.45	9.86e-08	4.76e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68270766	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs12572960	ENSG00000233590.1	RP11-153K11.3	-5.45	9.86e-08	4.76e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68270966	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.803	rs2241969	ENSG00000233590.1	RP11-153K11.3	-5.45	9.86e-08	4.76e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68271253	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs17231644	ENSG00000233590.1	RP11-153K11.3	5.45	9.86e-08	4.76e-05	0.44	0.28	Optic nerve measurement (disc area);	chr10:68270301	chr10:68233251~68242379:-
LIHC	cis	rs4535700	0.504	rs66528253	ENSG00000226278.1	PSPHP1	5.45	9.86e-08	4.76e-05	0.33	0.28	Macular telangiectasia type 2;	chr7:55929070	chr7:55764797~55773288:+
LIHC	cis	rs12744310	0.502	rs12045676	ENSG00000235358.1	RP11-399E6.1	5.45	9.87e-08	4.76e-05	0.33	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41342591	chr1:41242373~41284861:+
LIHC	cis	rs12744310	0.502	rs12044881	ENSG00000235358.1	RP11-399E6.1	5.45	9.87e-08	4.76e-05	0.33	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41342598	chr1:41242373~41284861:+
LIHC	cis	rs6600671	0.899	rs2319971	ENSG00000231429.2	RP11-343N15.2	-5.45	9.88e-08	4.77e-05	-0.34	-0.28	Hip geometry;	chr1:121485184	chr1:121412719~121429274:+
LIHC	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	5.45	9.89e-08	4.77e-05	0.28	0.28	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
LIHC	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-5.45	9.9e-08	4.78e-05	-0.35	-0.28	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
LIHC	cis	rs7927592	0.645	rs7936582	ENSG00000212093.1	AP000807.1	5.44	9.94e-08	4.79e-05	0.29	0.28	Total body bone mineral density;	chr11:68525462	chr11:68506083~68506166:-
LIHC	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-5.44	9.94e-08	4.8e-05	-0.37	-0.28	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
LIHC	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-5.44	9.95e-08	4.8e-05	-0.37	-0.28	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
LIHC	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	5.44	9.95e-08	4.8e-05	0.31	0.28	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
LIHC	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-5.44	9.96e-08	4.8e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
LIHC	cis	rs7916697	0.947	rs9783176	ENSG00000233590.1	RP11-153K11.3	-5.44	9.98e-08	4.81e-05	-0.34	-0.28	Optic disc area;	chr10:68242636	chr10:68233251~68242379:-
LIHC	cis	rs228614	0.51	rs223362	ENSG00000230069.3	LRRC37A15P	-5.44	9.99e-08	4.82e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102727274~102730721:-
LIHC	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	5.44	9.99e-08	4.82e-05	0.34	0.28	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-5.44	1e-07	4.82e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
LIHC	cis	rs12571093	0.803	rs36103935	ENSG00000233590.1	RP11-153K11.3	-5.44	1e-07	4.82e-05	-0.45	-0.28	Optic nerve measurement (disc area);	chr10:68273171	chr10:68233251~68242379:-
LIHC	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-5.44	1e-07	4.82e-05	-0.47	-0.28	Gout;	chr7:66642037	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.616	rs6009786	ENSG00000235111.1	RP1-29C18.8	-5.44	1e-07	4.83e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49612657~49615716:-
LIHC	cis	rs228614	0.543	rs223330	ENSG00000230069.3	LRRC37A15P	-5.44	1e-07	4.84e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223329	ENSG00000230069.3	LRRC37A15P	-5.44	1e-07	4.84e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.536	rs223327	ENSG00000230069.3	LRRC37A15P	-5.44	1e-07	4.84e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223326	ENSG00000230069.3	LRRC37A15P	-5.44	1e-07	4.84e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223324	ENSG00000230069.3	LRRC37A15P	-5.44	1e-07	4.84e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102727274~102730721:-
LIHC	cis	rs4731207	0.564	rs13234634	ENSG00000224897.5	POT1-AS1	5.44	1.01e-07	4.84e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125035979	chr7:124929873~125179315:+
LIHC	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-5.44	1.01e-07	4.85e-05	-0.46	-0.28	Gout;	chr7:66679692	chr7:66654538~66669855:+
LIHC	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	5.44	1.01e-07	4.85e-05	0.46	0.28	Gout;	chr7:66682070	chr7:66654538~66669855:+
LIHC	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	5.44	1.01e-07	4.85e-05	0.46	0.28	Gout;	chr7:66682162	chr7:66654538~66669855:+
LIHC	cis	rs5758659	1	rs5758659	ENSG00000227370.1	RP4-669P10.19	-5.44	1.01e-07	4.85e-05	-0.32	-0.28	Cognitive function;	chr22:42225997	chr22:42132543~42132998:+
LIHC	cis	rs2749592	0.55	rs7917262	ENSG00000263064.2	RP11-291L22.7	-5.44	1.01e-07	4.85e-05	-0.29	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38448689~38448949:+
LIHC	cis	rs2749592	0.55	rs9733309	ENSG00000263064.2	RP11-291L22.7	-5.44	1.01e-07	4.85e-05	-0.29	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38448689~38448949:+
LIHC	cis	rs2749592	0.55	rs7081464	ENSG00000263064.2	RP11-291L22.7	-5.44	1.01e-07	4.85e-05	-0.29	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38448689~38448949:+
LIHC	cis	rs2749592	0.531	rs994804	ENSG00000263064.2	RP11-291L22.7	-5.44	1.01e-07	4.85e-05	-0.29	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38448689~38448949:+
LIHC	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	5.44	1.01e-07	4.85e-05	0.31	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
LIHC	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	5.44	1.01e-07	4.85e-05	0.49	0.28	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
LIHC	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-5.44	1.01e-07	4.86e-05	-0.37	-0.28	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
LIHC	cis	rs4731207	0.596	rs1871776	ENSG00000224897.5	POT1-AS1	5.44	1.01e-07	4.86e-05	0.35	0.28	Cutaneous malignant melanoma;	chr7:125034594	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1871775	ENSG00000224897.5	POT1-AS1	5.44	1.01e-07	4.86e-05	0.35	0.28	Cutaneous malignant melanoma;	chr7:125034598	chr7:124929873~125179315:+
LIHC	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	5.44	1.01e-07	4.86e-05	0.28	0.28	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
LIHC	cis	rs12744310	0.502	rs4660187	ENSG00000235358.1	RP11-399E6.1	5.44	1.01e-07	4.86e-05	0.33	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333488	chr1:41242373~41284861:+
LIHC	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-5.44	1.01e-07	4.86e-05	-0.34	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
LIHC	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	5.44	1.01e-07	4.86e-05	0.38	0.28	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
LIHC	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	5.44	1.01e-07	4.87e-05	0.34	0.28	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
LIHC	cis	rs12744310	0.666	rs6600370	ENSG00000235358.1	RP11-399E6.1	5.44	1.01e-07	4.87e-05	0.32	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302891	chr1:41242373~41284861:+
LIHC	cis	rs228614	0.51	rs150893	ENSG00000230069.3	LRRC37A15P	5.44	1.01e-07	4.88e-05	0.26	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	5.44	1.01e-07	4.88e-05	0.27	0.28	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
LIHC	cis	rs12681287	0.604	rs41469550	ENSG00000250569.1	NTAN1P2	-5.44	1.01e-07	4.88e-05	-0.33	-0.28	Caudate activity during reward;	chr8:86394315	chr8:86481754~86483002:-
LIHC	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	5.44	1.01e-07	4.88e-05	0.35	0.28	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
LIHC	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	5.44	1.02e-07	4.89e-05	0.41	0.28	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
LIHC	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	5.44	1.02e-07	4.9e-05	0.29	0.28	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
LIHC	cis	rs2008905	1	rs2008905	ENSG00000272034.1	SNORD14A	5.44	1.02e-07	4.9e-05	0.33	0.28	Schizophrenia;	chr11:17163076	chr11:17074654~17074744:-
LIHC	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	5.44	1.02e-07	4.91e-05	0.41	0.28	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
LIHC	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	5.44	1.02e-07	4.91e-05	0.38	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
LIHC	cis	rs2998286	0.822	rs2807737	ENSG00000254635.4	WAC-AS1	-5.44	1.02e-07	4.92e-05	-0.34	-0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28501052	chr10:28522652~28532743:-
LIHC	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	5.44	1.02e-07	4.93e-05	0.44	0.28	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
LIHC	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	5.44	1.03e-07	4.93e-05	0.33	0.28	Height;	chr6:109586733	chr6:109382795~109383666:+
LIHC	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	5.44	1.03e-07	4.94e-05	0.52	0.28	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
LIHC	cis	rs227275	0.554	rs223404	ENSG00000230069.3	LRRC37A15P	-5.44	1.03e-07	4.96e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102727274~102730721:-
LIHC	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-5.44	1.03e-07	4.97e-05	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
LIHC	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	5.44	1.04e-07	4.97e-05	0.35	0.28	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
LIHC	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-5.44	1.04e-07	4.97e-05	-0.32	-0.28	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
LIHC	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-5.44	1.04e-07	4.98e-05	-0.37	-0.28	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
LIHC	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	5.44	1.04e-07	4.98e-05	0.32	0.28	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
LIHC	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-5.44	1.04e-07	4.98e-05	-0.37	-0.28	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
LIHC	cis	rs2032366	0.606	rs1377171	ENSG00000267279.1	RP11-879F14.2	-5.44	1.04e-07	4.99e-05	-0.34	-0.28	Obesity-related traits;	chr18:61606810	chr18:61585746~61606916:-
LIHC	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-5.44	1.04e-07	4.99e-05	-0.32	-0.28	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
LIHC	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	5.44	1.04e-07	5e-05	0.43	0.28	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
LIHC	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	5.44	1.04e-07	5e-05	0.25	0.28	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-5.44	1.04e-07	5e-05	-0.25	-0.28	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
LIHC	cis	rs17301013	0.932	rs10912804	ENSG00000227373.4	RP11-160H22.5	5.44	1.04e-07	5.01e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174527412	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.9	rs12088073	ENSG00000227373.4	RP11-160H22.5	5.44	1.04e-07	5.01e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174528504	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs10912807	ENSG00000227373.4	RP11-160H22.5	5.44	1.04e-07	5.01e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174547228	chr1:174115300~174160004:-
LIHC	cis	rs496547	0.686	rs540180	ENSG00000255422.1	AP002954.4	-5.43	1.04e-07	5.01e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118782920	chr11:118704607~118750263:+
LIHC	cis	rs496547	0.686	rs2508916	ENSG00000255422.1	AP002954.4	-5.43	1.04e-07	5.01e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118783942	chr11:118704607~118750263:+
LIHC	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	5.43	1.04e-07	5.01e-05	0.29	0.28	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
LIHC	cis	rs7119038	0.509	rs11216956	ENSG00000255239.1	AP002954.6	-5.43	1.05e-07	5.02e-05	-0.38	-0.28	Sjögren's syndrome;	chr11:118704617	chr11:118688039~118690600:-
LIHC	cis	rs4356203	0.87	rs214900	ENSG00000272034.1	SNORD14A	5.43	1.05e-07	5.02e-05	0.3	0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206215	chr11:17074654~17074744:-
LIHC	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	5.43	1.05e-07	5.02e-05	0.31	0.28	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
LIHC	cis	rs17301013	0.861	rs7521870	ENSG00000227373.4	RP11-160H22.5	-5.43	1.05e-07	5.02e-05	-0.35	-0.28	Systemic lupus erythematosus;	chr1:174497239	chr1:174115300~174160004:-
LIHC	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-5.43	1.05e-07	5.02e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
LIHC	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	5.43	1.05e-07	5.02e-05	0.32	0.28	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
LIHC	cis	rs2836974	0.666	rs4818015	ENSG00000255568.3	BRWD1-AS2	5.43	1.05e-07	5.04e-05	0.24	0.28	Cognitive function;	chr21:39303567	chr21:39313935~39314962:+
LIHC	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	5.43	1.05e-07	5.04e-05	0.25	0.28	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	5.43	1.05e-07	5.04e-05	0.46	0.28	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-5.43	1.05e-07	5.04e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.883	rs1337854	ENSG00000234155.1	RP11-30P6.6	-5.43	1.05e-07	5.04e-05	-0.34	-0.28	Response to antipsychotic treatment;	chr6:86014297	chr6:85387219~85390186:-
LIHC	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-5.43	1.06e-07	5.05e-05	-0.31	-0.28	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
LIHC	cis	rs6589219	0.753	rs4548657	ENSG00000196167.8	COLCA1	-5.43	1.06e-07	5.06e-05	-0.31	-0.28	Colorectal cancer;	chr11:111269318	chr11:111290787~111305045:-
LIHC	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	5.43	1.06e-07	5.07e-05	0.38	0.28	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
LIHC	cis	rs5769707	0.681	rs1107514	ENSG00000235111.1	RP1-29C18.8	-5.43	1.06e-07	5.08e-05	-0.35	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49612657~49615716:-
LIHC	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	5.43	1.06e-07	5.08e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	5.43	1.06e-07	5.08e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
LIHC	cis	rs11098499	0.954	rs11098524	ENSG00000260091.1	RP11-33B1.4	-5.43	1.06e-07	5.08e-05	-0.21	-0.28	Corneal astigmatism;	chr4:119468877	chr4:119409333~119410233:+
LIHC	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	5.43	1.06e-07	5.08e-05	0.38	0.28	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
LIHC	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-5.43	1.06e-07	5.08e-05	-0.28	-0.28	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
LIHC	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	5.43	1.07e-07	5.09e-05	0.45	0.28	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	5.43	1.07e-07	5.09e-05	0.45	0.28	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
LIHC	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	5.43	1.07e-07	5.09e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	5.43	1.07e-07	5.09e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
LIHC	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-5.43	1.07e-07	5.1e-05	-0.5	-0.28	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
LIHC	cis	rs17655730	0.52	rs2178798	ENSG00000277290.1	RP11-326C3.16	-5.43	1.07e-07	5.11e-05	-0.23	-0.28	Mean platelet volume;	chr11:254869	chr11:243099~243483:-
LIHC	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-5.43	1.07e-07	5.11e-05	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
LIHC	cis	rs6686842	1	rs213734	ENSG00000235358.1	RP11-399E6.1	-5.43	1.07e-07	5.11e-05	-0.3	-0.28	Height;	chr1:41110027	chr1:41242373~41284861:+
LIHC	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	5.43	1.07e-07	5.11e-05	0.38	0.28	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
LIHC	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-5.43	1.07e-07	5.11e-05	-0.35	-0.28	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-5.43	1.07e-07	5.11e-05	-0.35	-0.28	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-5.43	1.07e-07	5.11e-05	-0.35	-0.28	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-5.43	1.07e-07	5.11e-05	-0.35	-0.28	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-5.43	1.07e-07	5.11e-05	-0.35	-0.28	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-5.43	1.07e-07	5.11e-05	-0.35	-0.28	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
LIHC	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-5.43	1.07e-07	5.11e-05	-0.36	-0.28	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
LIHC	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	5.43	1.07e-07	5.12e-05	0.29	0.28	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
LIHC	cis	rs7916697	0.898	rs1900005	ENSG00000233590.1	RP11-153K11.3	5.43	1.07e-07	5.12e-05	0.34	0.28	Optic disc area;	chr10:68238298	chr10:68233251~68242379:-
LIHC	cis	rs860295	0.812	rs10908481	ENSG00000203761.5	MSTO2P	-5.43	1.07e-07	5.12e-05	-0.23	-0.28	Body mass index;	chr1:155743859	chr1:155745829~155750137:+
LIHC	cis	rs5758659	1	rs5758660	ENSG00000227370.1	RP4-669P10.19	-5.43	1.08e-07	5.13e-05	-0.32	-0.28	Cognitive function;	chr22:42227712	chr22:42132543~42132998:+
LIHC	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-5.43	1.08e-07	5.14e-05	-0.32	-0.28	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
LIHC	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	5.43	1.08e-07	5.14e-05	0.38	0.28	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	5.43	1.08e-07	5.14e-05	0.38	0.28	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
LIHC	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	5.43	1.08e-07	5.14e-05	0.41	0.28	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
LIHC	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-5.43	1.08e-07	5.14e-05	-0.39	-0.28	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
LIHC	cis	rs227275	0.555	rs223403	ENSG00000230069.3	LRRC37A15P	-5.43	1.08e-07	5.15e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102727274~102730721:-
LIHC	cis	rs3096299	0.719	rs2911262	ENSG00000261118.1	RP11-104N10.1	5.43	1.08e-07	5.15e-05	0.28	0.28	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89492017~89504460:-
LIHC	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-5.43	1.08e-07	5.16e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
LIHC	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	5.43	1.08e-07	5.16e-05	0.27	0.28	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	5.43	1.08e-07	5.16e-05	0.27	0.28	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
LIHC	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	5.43	1.09e-07	5.18e-05	0.32	0.28	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
LIHC	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	5.43	1.09e-07	5.18e-05	0.32	0.28	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
LIHC	cis	rs2072510	0.593	rs2540498	ENSG00000257715.1	RP11-256L6.2	-5.43	1.09e-07	5.19e-05	-0.41	-0.28	Metabolite levels (small molecules and protein measures);	chr12:96006791	chr12:96025323~96027971:+
LIHC	cis	rs12681287	0.608	rs13270090	ENSG00000250569.1	NTAN1P2	-5.43	1.09e-07	5.19e-05	-0.34	-0.28	Caudate activity during reward;	chr8:86541069	chr8:86481754~86483002:-
LIHC	cis	rs1223397	0.938	rs20500	ENSG00000215022.6	RP1-257A7.4	5.43	1.09e-07	5.19e-05	0.32	0.28	Blood pressure;	chr6:13294744	chr6:13264861~13295586:-
LIHC	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	5.43	1.09e-07	5.19e-05	0.31	0.28	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
LIHC	cis	rs4862307	0.688	rs6552741	ENSG00000250726.1	RP11-616K6.1	-5.43	1.09e-07	5.19e-05	-0.29	-0.28	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184069182	chr4:184072403~184073039:+
LIHC	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-5.43	1.09e-07	5.19e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
LIHC	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	5.43	1.09e-07	5.2e-05	0.33	0.28	Height;	chr6:109589051	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	5.43	1.09e-07	5.2e-05	0.33	0.28	Height;	chr6:109592105	chr6:109382795~109383666:+
LIHC	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	5.43	1.09e-07	5.2e-05	0.34	0.28	Height;	chr6:109551060	chr6:109382795~109383666:+
LIHC	cis	rs4731207	0.596	rs7806530	ENSG00000224897.5	POT1-AS1	-5.43	1.09e-07	5.2e-05	-0.34	-0.28	Cutaneous malignant melanoma;	chr7:125019830	chr7:124929873~125179315:+
LIHC	cis	rs227275	0.524	rs223337	ENSG00000230069.3	LRRC37A15P	-5.43	1.1e-07	5.22e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102727274~102730721:-
LIHC	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-5.42	1.1e-07	5.25e-05	-0.25	-0.28	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
LIHC	cis	rs496547	0.686	rs477014	ENSG00000255422.1	AP002954.4	-5.42	1.1e-07	5.26e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118808277	chr11:118704607~118750263:+
LIHC	cis	rs496547	0.557	rs516719	ENSG00000255422.1	AP002954.4	-5.42	1.1e-07	5.26e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118808736	chr11:118704607~118750263:+
LIHC	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	5.42	1.11e-07	5.26e-05	0.35	0.28	Depression;	chr6:28363475	chr6:28943877~28944537:+
LIHC	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-5.42	1.11e-07	5.26e-05	-0.43	-0.28	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
LIHC	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	5.42	1.11e-07	5.27e-05	0.4	0.28	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
LIHC	cis	rs5769707	0.681	rs8140095	ENSG00000235111.1	RP1-29C18.8	-5.42	1.11e-07	5.27e-05	-0.35	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49612657~49615716:-
LIHC	cis	rs6686842	1	rs213733	ENSG00000235358.1	RP11-399E6.1	-5.42	1.11e-07	5.27e-05	-0.3	-0.28	Height;	chr1:41111317	chr1:41242373~41284861:+
LIHC	cis	rs7914558	1	rs10748838	ENSG00000236937.2	PTGES3P4	5.42	1.11e-07	5.28e-05	0.33	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs3758543	ENSG00000236937.2	PTGES3P4	5.42	1.11e-07	5.28e-05	0.33	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs4917997	ENSG00000236937.2	PTGES3P4	5.42	1.11e-07	5.28e-05	0.33	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs7077097	ENSG00000236937.2	PTGES3P4	5.42	1.11e-07	5.28e-05	0.33	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:102845595~102845950:+
LIHC	cis	rs7914558	1	rs7077291	ENSG00000236937.2	PTGES3P4	5.42	1.11e-07	5.28e-05	0.33	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:102845595~102845950:+
LIHC	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-5.42	1.11e-07	5.28e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
LIHC	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-5.42	1.11e-07	5.28e-05	-0.4	-0.28	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
LIHC	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	5.42	1.11e-07	5.28e-05	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
LIHC	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	5.42	1.11e-07	5.29e-05	0.4	0.28	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	5.42	1.11e-07	5.29e-05	0.4	0.28	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	5.42	1.11e-07	5.29e-05	0.4	0.28	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	5.42	1.11e-07	5.29e-05	0.4	0.28	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
LIHC	cis	rs4731207	0.596	rs2017928	ENSG00000224897.5	POT1-AS1	5.42	1.11e-07	5.29e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125032269	chr7:124929873~125179315:+
LIHC	cis	rs9341808	0.683	rs7771449	ENSG00000272129.1	RP11-250B2.6	5.42	1.12e-07	5.3e-05	0.27	0.28	Sitting height ratio;	chr6:80210260	chr6:80355424~80356859:+
LIHC	cis	rs5769765	0.955	rs4075330	ENSG00000278869.1	CITF22-49E9.3	5.42	1.12e-07	5.3e-05	0.43	0.28	Schizophrenia;	chr22:49909601	chr22:49933198~49934074:-
LIHC	cis	rs9341808	0.718	rs910266	ENSG00000272129.1	RP11-250B2.6	5.42	1.12e-07	5.3e-05	0.27	0.28	Sitting height ratio;	chr6:80211453	chr6:80355424~80356859:+
LIHC	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	5.42	1.12e-07	5.31e-05	0.41	0.28	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	5.42	1.12e-07	5.31e-05	0.41	0.28	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
LIHC	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-5.42	1.12e-07	5.31e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
LIHC	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-5.42	1.12e-07	5.31e-05	-0.37	-0.28	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
LIHC	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	5.42	1.12e-07	5.31e-05	0.46	0.28	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
LIHC	cis	rs5758511	0.68	rs739146	ENSG00000237037.8	NDUFA6-AS1	-5.42	1.12e-07	5.31e-05	-0.35	-0.28	Birth weight;	chr22:42264408	chr22:42090931~42137742:+
LIHC	cis	rs9341808	0.718	rs2143887	ENSG00000272129.1	RP11-250B2.6	5.42	1.12e-07	5.31e-05	0.27	0.28	Sitting height ratio;	chr6:80207570	chr6:80355424~80356859:+
LIHC	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-5.42	1.12e-07	5.32e-05	-0.35	-0.28	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
LIHC	cis	rs6686842	1	rs6600365	ENSG00000235358.1	RP11-399E6.1	-5.42	1.12e-07	5.32e-05	-0.3	-0.28	Height;	chr1:41090581	chr1:41242373~41284861:+
LIHC	cis	rs6686842	0.932	rs1008505	ENSG00000235358.1	RP11-399E6.1	-5.42	1.12e-07	5.32e-05	-0.3	-0.28	Height;	chr1:41094563	chr1:41242373~41284861:+
LIHC	cis	rs6686842	1	rs17571940	ENSG00000235358.1	RP11-399E6.1	-5.42	1.12e-07	5.32e-05	-0.3	-0.28	Height;	chr1:41100519	chr1:41242373~41284861:+
LIHC	cis	rs6686842	1	rs479493	ENSG00000235358.1	RP11-399E6.1	-5.42	1.12e-07	5.32e-05	-0.3	-0.28	Height;	chr1:41101530	chr1:41242373~41284861:+
LIHC	cis	rs6686842	1	rs656917	ENSG00000235358.1	RP11-399E6.1	-5.42	1.12e-07	5.32e-05	-0.3	-0.28	Height;	chr1:41104036	chr1:41242373~41284861:+
LIHC	cis	rs2522056	1	rs886286	ENSG00000233006.5	AC034220.3	-5.42	1.12e-07	5.33e-05	-0.29	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132459905	chr5:132311285~132369916:-
LIHC	cis	rs2522056	1	rs757105	ENSG00000233006.5	AC034220.3	-5.42	1.12e-07	5.33e-05	-0.29	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132459971	chr5:132311285~132369916:-
LIHC	cis	rs2522056	1	rs2522047	ENSG00000233006.5	AC034220.3	-5.42	1.12e-07	5.33e-05	-0.29	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132460190	chr5:132311285~132369916:-
LIHC	cis	rs2522056	1	rs2706393	ENSG00000233006.5	AC034220.3	-5.42	1.12e-07	5.33e-05	-0.29	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132460375	chr5:132311285~132369916:-
LIHC	cis	rs2522056	1	rs2706395	ENSG00000233006.5	AC034220.3	-5.42	1.12e-07	5.33e-05	-0.29	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132461111	chr5:132311285~132369916:-
LIHC	cis	rs10912872	0.564	rs11807475	ENSG00000225704.2	RP4-798A17.5	5.42	1.12e-07	5.33e-05	0.25	0.28	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171371960	chr1:171345089~171345320:+
LIHC	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	5.42	1.12e-07	5.33e-05	0.32	0.28	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
LIHC	cis	rs12291225	0.585	rs10832242	ENSG00000251991.1	RNU7-49P	-5.42	1.12e-07	5.34e-05	-0.29	-0.28	Sense of smell;	chr11:14318958	chr11:14478892~14478953:+
LIHC	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	5.42	1.13e-07	5.35e-05	0.38	0.28	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
LIHC	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-5.42	1.13e-07	5.36e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-5.42	1.13e-07	5.36e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-5.42	1.13e-07	5.36e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
LIHC	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-5.42	1.13e-07	5.36e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
LIHC	cis	rs227275	0.525	rs13150426	ENSG00000230069.3	LRRC37A15P	-5.42	1.13e-07	5.36e-05	-0.26	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102727274~102730721:-
LIHC	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	5.42	1.13e-07	5.36e-05	0.34	0.28	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
LIHC	cis	rs2933343	0.553	rs35076317	ENSG00000231305.3	RP11-723O4.2	5.42	1.13e-07	5.38e-05	0.31	0.28	IgG glycosylation;	chr3:128996692	chr3:128861313~128871540:-
LIHC	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	5.42	1.14e-07	5.38e-05	0.37	0.28	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
LIHC	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-5.42	1.14e-07	5.39e-05	-0.31	-0.28	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
LIHC	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-5.42	1.14e-07	5.39e-05	-0.29	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
LIHC	cis	rs5756813	0.705	rs6000886	ENSG00000233360.4	Z83844.1	-5.42	1.14e-07	5.39e-05	-0.35	-0.28	Optic cup area;Vertical cup-disc ratio;	chr22:37780663	chr22:37641832~37658377:-
LIHC	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-5.42	1.14e-07	5.39e-05	-0.32	-0.28	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
LIHC	cis	rs202072	0.872	rs413120	ENSG00000215022.6	RP1-257A7.4	5.42	1.14e-07	5.4e-05	0.31	0.28	HIV-1 viral setpoint;	chr6:13280409	chr6:13264861~13295586:-
LIHC	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	5.42	1.14e-07	5.4e-05	0.25	0.28	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
LIHC	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-5.42	1.14e-07	5.41e-05	-0.25	-0.28	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
LIHC	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-5.42	1.14e-07	5.41e-05	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
LIHC	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	5.42	1.14e-07	5.42e-05	0.33	0.28	Height;	chr6:109430292	chr6:109382795~109383666:+
LIHC	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-5.42	1.15e-07	5.43e-05	-0.3	-0.28	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
LIHC	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-5.42	1.15e-07	5.44e-05	-0.33	-0.28	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
LIHC	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	5.42	1.15e-07	5.44e-05	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
LIHC	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	5.42	1.15e-07	5.45e-05	0.34	0.28	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
LIHC	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-5.42	1.15e-07	5.45e-05	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
LIHC	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	5.42	1.15e-07	5.45e-05	0.4	0.28	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
LIHC	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-5.42	1.15e-07	5.46e-05	-0.28	-0.28	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
LIHC	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	5.41	1.16e-07	5.47e-05	0.38	0.28	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
LIHC	cis	rs17301013	0.896	rs6425287	ENSG00000227373.4	RP11-160H22.5	5.41	1.16e-07	5.48e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174566264	chr1:174115300~174160004:-
LIHC	cis	rs4731207	0.596	rs9332427	ENSG00000224897.5	POT1-AS1	5.41	1.16e-07	5.48e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:124936904	chr7:124929873~125179315:+
LIHC	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-5.41	1.16e-07	5.48e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-5.41	1.16e-07	5.48e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
LIHC	cis	rs4934494	0.727	rs12572012	ENSG00000232936.4	RP11-80H5.2	5.41	1.16e-07	5.48e-05	0.35	0.28	Red blood cell count;	chr10:89727892	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.727	rs3758388	ENSG00000232936.4	RP11-80H5.2	5.41	1.16e-07	5.48e-05	0.35	0.28	Red blood cell count;	chr10:89729222	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.727	rs12783582	ENSG00000232936.4	RP11-80H5.2	5.41	1.16e-07	5.48e-05	0.35	0.28	Red blood cell count;	chr10:89735210	chr10:89645282~89650667:+
LIHC	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	5.41	1.16e-07	5.49e-05	0.28	0.28	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
LIHC	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	5.41	1.16e-07	5.49e-05	0.41	0.28	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
LIHC	cis	rs6589219	0.788	rs1987128	ENSG00000196167.8	COLCA1	-5.41	1.16e-07	5.5e-05	-0.31	-0.28	Colorectal cancer;	chr11:111281771	chr11:111290787~111305045:-
LIHC	cis	rs9425766	0.541	rs4652274	ENSG00000227373.4	RP11-160H22.5	5.41	1.17e-07	5.51e-05	0.36	0.28	Life satisfaction;	chr1:174249434	chr1:174115300~174160004:-
LIHC	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	5.41	1.17e-07	5.52e-05	0.39	0.28	Height;	chr6:109375848	chr6:109382795~109383666:+
LIHC	cis	rs1577917	0.839	rs12055653	ENSG00000234155.1	RP11-30P6.6	5.41	1.17e-07	5.52e-05	0.34	0.28	Response to antipsychotic treatment;	chr6:85836945	chr6:85387219~85390186:-
LIHC	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-5.41	1.17e-07	5.52e-05	-0.47	-0.28	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
LIHC	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-5.41	1.17e-07	5.52e-05	-0.47	-0.28	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
LIHC	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	5.41	1.17e-07	5.53e-05	0.34	0.28	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
LIHC	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	5.41	1.17e-07	5.53e-05	0.39	0.28	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
LIHC	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	5.41	1.17e-07	5.54e-05	0.3	0.28	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
LIHC	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-5.41	1.17e-07	5.54e-05	-0.32	-0.28	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
LIHC	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	5.41	1.17e-07	5.55e-05	0.32	0.28	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
LIHC	cis	rs3858145	0.588	rs10998059	ENSG00000233590.1	RP11-153K11.3	5.41	1.18e-07	5.56e-05	0.37	0.28	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68302750	chr10:68233251~68242379:-
LIHC	cis	rs12285276	1	rs12285276	ENSG00000205106.4	DKFZp779M0652	5.41	1.18e-07	5.56e-05	0.28	0.28	Visceral fat;	chr11:45792030	chr11:45771432~45772358:+
LIHC	cis	rs5758659	0.967	rs5751250	ENSG00000227370.1	RP4-669P10.19	-5.41	1.18e-07	5.56e-05	-0.31	-0.28	Cognitive function;	chr22:42243639	chr22:42132543~42132998:+
LIHC	cis	rs9425766	0.591	rs2049991	ENSG00000227373.4	RP11-160H22.5	5.41	1.18e-07	5.56e-05	0.36	0.28	Life satisfaction;	chr1:174356428	chr1:174115300~174160004:-
LIHC	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-5.41	1.18e-07	5.56e-05	-0.31	-0.28	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
LIHC	cis	rs7131987	0.683	rs12366505	ENSG00000275476.1	RP11-996F15.4	-5.41	1.18e-07	5.56e-05	-0.33	-0.28	QT interval;	chr12:29321177	chr12:29277397~29277882:-
LIHC	cis	rs7131987	0.65	rs12366527	ENSG00000275476.1	RP11-996F15.4	-5.41	1.18e-07	5.56e-05	-0.33	-0.28	QT interval;	chr12:29321323	chr12:29277397~29277882:-
LIHC	cis	rs7131987	0.65	rs7311912	ENSG00000275476.1	RP11-996F15.4	-5.41	1.18e-07	5.56e-05	-0.33	-0.28	QT interval;	chr12:29322770	chr12:29277397~29277882:-
LIHC	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-5.41	1.18e-07	5.56e-05	-0.32	-0.28	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
LIHC	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	5.41	1.18e-07	5.57e-05	0.33	0.28	Height;	chr6:109588639	chr6:109382795~109383666:+
LIHC	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-5.41	1.18e-07	5.57e-05	-0.29	-0.28	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
LIHC	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-5.41	1.18e-07	5.58e-05	-0.39	-0.28	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
LIHC	cis	rs5769765	0.954	rs910799	ENSG00000278869.1	CITF22-49E9.3	-5.41	1.18e-07	5.59e-05	-0.43	-0.28	Schizophrenia;	chr22:49884920	chr22:49933198~49934074:-
LIHC	cis	rs860295	0.812	rs7556519	ENSG00000203761.5	MSTO2P	-5.41	1.18e-07	5.59e-05	-0.23	-0.28	Body mass index;	chr1:155857755	chr1:155745829~155750137:+
LIHC	cis	rs4284742	1	rs4284742	ENSG00000273837.1	LLNLR-470E3.1	5.41	1.19e-07	5.61e-05	0.34	0.28	Aggressive periodontitis;	chr19:51628480	chr19:51639478~51639931:-
LIHC	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	5.41	1.19e-07	5.61e-05	0.37	0.28	Depression;	chr6:28364057	chr6:28176188~28176674:+
LIHC	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	5.41	1.19e-07	5.61e-05	0.31	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs28445579	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	5.62e-05	-0.26	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102727274~102730721:-
LIHC	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	5.41	1.19e-07	5.62e-05	0.24	0.28	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
LIHC	cis	rs227275	0.556	rs4235407	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	5.62e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	5.41	1.19e-07	5.63e-05	0.27	0.28	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
LIHC	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	5.41	1.19e-07	5.63e-05	0.34	0.28	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
LIHC	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	5.41	1.19e-07	5.63e-05	0.42	0.28	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
LIHC	cis	rs11722779	0.935	rs7676736	ENSG00000230069.3	LRRC37A15P	-5.41	1.19e-07	5.63e-05	-0.26	-0.28	Schizophrenia;	chr4:103016729	chr4:102727274~102730721:-
LIHC	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	5.41	1.2e-07	5.64e-05	0.41	0.28	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
LIHC	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	5.41	1.2e-07	5.64e-05	0.37	0.28	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
LIHC	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-5.41	1.2e-07	5.66e-05	-0.33	-0.28	Height;	chr6:109360458	chr6:109382795~109383666:+
LIHC	cis	rs6686842	0.965	rs2802548	ENSG00000235358.1	RP11-399E6.1	-5.41	1.2e-07	5.66e-05	-0.31	-0.28	Height;	chr1:41035441	chr1:41242373~41284861:+
LIHC	cis	rs6686842	0.897	rs2802565	ENSG00000235358.1	RP11-399E6.1	-5.41	1.2e-07	5.67e-05	-0.31	-0.28	Height;	chr1:41086147	chr1:41242373~41284861:+
LIHC	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-5.41	1.2e-07	5.68e-05	-0.34	-0.28	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
LIHC	cis	rs227275	0.556	rs11722779	ENSG00000230069.3	LRRC37A15P	-5.41	1.21e-07	5.68e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102727274~102730721:-
LIHC	cis	rs9425766	0.566	rs10912773	ENSG00000227373.4	RP11-160H22.5	5.41	1.21e-07	5.69e-05	0.36	0.28	Life satisfaction;	chr1:174374567	chr1:174115300~174160004:-
LIHC	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-5.41	1.21e-07	5.69e-05	-0.38	-0.28	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
LIHC	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	5.41	1.21e-07	5.69e-05	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
LIHC	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	5.41	1.21e-07	5.7e-05	0.36	0.28	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
LIHC	cis	rs227275	0.556	rs223426	ENSG00000230069.3	LRRC37A15P	-5.41	1.21e-07	5.72e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223425	ENSG00000230069.3	LRRC37A15P	-5.41	1.21e-07	5.72e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102727274~102730721:-
LIHC	cis	rs6686842	0.965	rs2802566	ENSG00000235358.1	RP11-399E6.1	-5.41	1.22e-07	5.73e-05	-0.31	-0.28	Height;	chr1:41086309	chr1:41242373~41284861:+
LIHC	cis	rs5769765	0.773	rs9616391	ENSG00000278869.1	CITF22-49E9.3	5.4	1.22e-07	5.74e-05	0.46	0.28	Schizophrenia;	chr22:49920925	chr22:49933198~49934074:-
LIHC	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-5.4	1.22e-07	5.75e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
LIHC	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-5.4	1.22e-07	5.75e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
LIHC	cis	rs3096299	0.685	rs4785676	ENSG00000261118.1	RP11-104N10.1	5.4	1.22e-07	5.75e-05	0.28	0.28	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89492017~89504460:-
LIHC	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-5.4	1.22e-07	5.76e-05	-0.35	-0.28	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-5.4	1.22e-07	5.76e-05	-0.35	-0.28	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-5.4	1.22e-07	5.76e-05	-0.35	-0.28	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-5.4	1.22e-07	5.76e-05	-0.35	-0.28	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-5.4	1.22e-07	5.76e-05	-0.35	-0.28	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
LIHC	cis	rs6589219	0.754	rs7105857	ENSG00000196167.8	COLCA1	-5.4	1.22e-07	5.76e-05	-0.31	-0.28	Colorectal cancer;	chr11:111300019	chr11:111290787~111305045:-
LIHC	cis	rs4356203	0.875	rs7125607	ENSG00000272034.1	SNORD14A	-5.4	1.23e-07	5.77e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074603	chr11:17074654~17074744:-
LIHC	cis	rs950169	0.922	rs11635505	ENSG00000259295.5	CSPG4P12	-5.4	1.23e-07	5.77e-05	-0.37	-0.28	Schizophrenia;	chr15:84553803	chr15:85191438~85213905:+
LIHC	cis	rs4731207	0.698	rs962863	ENSG00000224897.5	POT1-AS1	-5.4	1.23e-07	5.77e-05	-0.33	-0.28	Cutaneous malignant melanoma;	chr7:124918285	chr7:124929873~125179315:+
LIHC	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	5.4	1.23e-07	5.79e-05	0.31	0.28	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
LIHC	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-5.4	1.23e-07	5.8e-05	-0.36	-0.28	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
LIHC	cis	rs1577917	0.771	rs3812133	ENSG00000234155.1	RP11-30P6.6	5.4	1.23e-07	5.8e-05	0.39	0.28	Response to antipsychotic treatment;	chr6:85644693	chr6:85387219~85390186:-
LIHC	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-5.4	1.23e-07	5.8e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-5.4	1.23e-07	5.8e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-5.4	1.23e-07	5.8e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-5.4	1.23e-07	5.8e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-5.4	1.23e-07	5.8e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
LIHC	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-5.4	1.24e-07	5.81e-05	-0.3	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
LIHC	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	5.4	1.24e-07	5.81e-05	0.27	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
LIHC	cis	rs3096299	0.679	rs3102338	ENSG00000261118.1	RP11-104N10.1	5.4	1.24e-07	5.82e-05	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89492017~89504460:-
LIHC	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-5.4	1.24e-07	5.83e-05	-0.35	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
LIHC	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-5.4	1.24e-07	5.83e-05	-0.35	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
LIHC	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	5.4	1.24e-07	5.83e-05	0.33	0.28	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
LIHC	cis	rs4731207	0.698	rs4731218	ENSG00000224897.5	POT1-AS1	5.4	1.24e-07	5.83e-05	0.33	0.28	Cutaneous malignant melanoma;	chr7:124831961	chr7:124929873~125179315:+
LIHC	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	5.4	1.24e-07	5.83e-05	0.41	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
LIHC	cis	rs228614	0.51	rs170565	ENSG00000230069.3	LRRC37A15P	-5.4	1.24e-07	5.83e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	5.4	1.24e-07	5.83e-05	0.25	0.28	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
LIHC	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	5.4	1.24e-07	5.84e-05	0.31	0.28	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
LIHC	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-5.4	1.24e-07	5.84e-05	-0.34	-0.28	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
LIHC	cis	rs227275	0.555	rs223402	ENSG00000230069.3	LRRC37A15P	-5.4	1.24e-07	5.84e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102727274~102730721:-
LIHC	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-5.4	1.25e-07	5.85e-05	-0.29	-0.28	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
LIHC	cis	rs7131987	0.903	rs1991114	ENSG00000257176.2	RP11-996F15.2	-5.4	1.25e-07	5.85e-05	-0.32	-0.28	QT interval;	chr12:29239149	chr12:29280418~29317848:-
LIHC	cis	rs6686842	0.932	rs3157	ENSG00000235358.1	RP11-399E6.1	5.4	1.25e-07	5.85e-05	0.31	0.28	Height;	chr1:41027439	chr1:41242373~41284861:+
LIHC	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	5.4	1.25e-07	5.86e-05	0.32	0.28	Height;	chr6:109405536	chr6:109382795~109383666:+
LIHC	cis	rs227275	0.556	rs7676765	ENSG00000230069.3	LRRC37A15P	5.4	1.25e-07	5.86e-05	0.26	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102727274~102730721:-
LIHC	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	5.4	1.26e-07	5.89e-05	0.32	0.28	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
LIHC	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	5.4	1.26e-07	5.89e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
LIHC	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	5.4	1.26e-07	5.89e-05	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
LIHC	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	5.4	1.26e-07	5.89e-05	0.27	0.28	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	5.4	1.26e-07	5.89e-05	0.27	0.28	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	5.4	1.26e-07	5.89e-05	0.27	0.28	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-5.4	1.26e-07	5.89e-05	-0.27	-0.28	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-5.4	1.26e-07	5.89e-05	-0.27	-0.28	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
LIHC	cis	rs11722779	0.869	rs223350	ENSG00000230069.3	LRRC37A15P	-5.4	1.26e-07	5.91e-05	-0.26	-0.28	Schizophrenia;	chr4:102856899	chr4:102727274~102730721:-
LIHC	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-5.4	1.26e-07	5.91e-05	-0.26	-0.28	Breast cancer;	chr11:825777	chr11:781645~782105:+
LIHC	cis	rs4731207	0.596	rs6964090	ENSG00000224897.5	POT1-AS1	5.4	1.26e-07	5.92e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125027062	chr7:124929873~125179315:+
LIHC	cis	rs2522056	1	rs2706383	ENSG00000233006.5	AC034220.3	-5.4	1.26e-07	5.92e-05	-0.29	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132456710	chr5:132311285~132369916:-
LIHC	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-5.4	1.26e-07	5.93e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
LIHC	cis	rs227275	0.556	rs6815526	ENSG00000230069.3	LRRC37A15P	-5.4	1.27e-07	5.93e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs28367331	ENSG00000230069.3	LRRC37A15P	-5.4	1.27e-07	5.93e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs6824070	ENSG00000230069.3	LRRC37A15P	-5.4	1.27e-07	5.93e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.935	rs6856176	ENSG00000230069.3	LRRC37A15P	-5.4	1.27e-07	5.93e-05	-0.25	-0.28	Schizophrenia;	chr4:102902574	chr4:102727274~102730721:-
LIHC	cis	rs4934494	0.681	rs1129777	ENSG00000232936.4	RP11-80H5.2	5.4	1.27e-07	5.94e-05	0.35	0.28	Red blood cell count;	chr10:89709168	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.727	rs3824607	ENSG00000232936.4	RP11-80H5.2	5.4	1.27e-07	5.94e-05	0.35	0.28	Red blood cell count;	chr10:89711258	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.681	rs3740035	ENSG00000232936.4	RP11-80H5.2	5.4	1.27e-07	5.94e-05	0.35	0.28	Red blood cell count;	chr10:89716708	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.681	rs34591435	ENSG00000232936.4	RP11-80H5.2	5.4	1.27e-07	5.94e-05	0.35	0.28	Red blood cell count;	chr10:89721691	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.727	rs12783845	ENSG00000232936.4	RP11-80H5.2	5.4	1.27e-07	5.94e-05	0.35	0.28	Red blood cell count;	chr10:89722872	chr10:89645282~89650667:+
LIHC	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	5.4	1.27e-07	5.94e-05	0.28	0.28	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
LIHC	cis	rs916888	0.821	rs199499	ENSG00000262881.1	RP11-669E14.4	-5.4	1.27e-07	5.95e-05	-0.52	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:45907670~45910779:-
LIHC	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-5.4	1.27e-07	5.96e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
LIHC	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	5.4	1.27e-07	5.97e-05	0.42	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
LIHC	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-5.4	1.28e-07	5.98e-05	-0.35	-0.28	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-5.4	1.28e-07	5.98e-05	-0.35	-0.28	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-5.4	1.28e-07	5.98e-05	-0.35	-0.28	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-5.4	1.28e-07	5.98e-05	-0.35	-0.28	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
LIHC	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-5.4	1.28e-07	5.99e-05	-0.36	-0.28	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
LIHC	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	5.4	1.28e-07	5.99e-05	0.29	0.28	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
LIHC	cis	rs4356203	0.905	rs7939750	ENSG00000272034.1	SNORD14A	-5.4	1.28e-07	5.99e-05	-0.31	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17074654~17074744:-
LIHC	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	5.4	1.28e-07	5.99e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
LIHC	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-5.4	1.28e-07	5.99e-05	-0.25	-0.28	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-5.4	1.28e-07	5.99e-05	-0.25	-0.28	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-5.4	1.28e-07	5.99e-05	-0.25	-0.28	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-5.4	1.28e-07	5.99e-05	-0.25	-0.28	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
LIHC	cis	rs3096299	0.632	rs4399533	ENSG00000261118.1	RP11-104N10.1	5.4	1.28e-07	6e-05	0.28	0.28	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89492017~89504460:-
LIHC	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	5.39	1.28e-07	6.01e-05	0.41	0.28	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
LIHC	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-5.39	1.29e-07	6.02e-05	-0.32	-0.28	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
LIHC	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	5.39	1.29e-07	6.03e-05	0.45	0.28	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
LIHC	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	5.39	1.29e-07	6.03e-05	0.41	0.28	Height;	chr6:109441837	chr6:109382795~109383666:+
LIHC	cis	rs17301013	0.861	rs61826916	ENSG00000227373.4	RP11-160H22.5	5.39	1.29e-07	6.03e-05	0.36	0.28	Systemic lupus erythematosus;	chr1:174616048	chr1:174115300~174160004:-
LIHC	cis	rs6589219	0.721	rs12296076	ENSG00000196167.8	COLCA1	-5.39	1.29e-07	6.04e-05	-0.3	-0.28	Colorectal cancer;	chr11:111295779	chr11:111290787~111305045:-
LIHC	cis	rs4538475	0.556	rs4266290	ENSG00000214846.4	RP11-115L11.1	5.39	1.29e-07	6.05e-05	0.35	0.28	Parkinson's disease;	chr4:15735495	chr4:15730962~15731627:-
LIHC	cis	rs4538475	0.556	rs4403048	ENSG00000214846.4	RP11-115L11.1	5.39	1.29e-07	6.05e-05	0.35	0.28	Parkinson's disease;	chr4:15735497	chr4:15730962~15731627:-
LIHC	cis	rs4731207	0.565	rs1904972	ENSG00000224897.5	POT1-AS1	5.39	1.29e-07	6.05e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125029633	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.536	rs1904971	ENSG00000224897.5	POT1-AS1	5.39	1.29e-07	6.05e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125029641	chr7:124929873~125179315:+
LIHC	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-5.39	1.29e-07	6.05e-05	-0.25	-0.28	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
LIHC	cis	rs1577917	0.545	rs9450325	ENSG00000234155.1	RP11-30P6.6	-5.39	1.29e-07	6.05e-05	-0.32	-0.28	Response to antipsychotic treatment;	chr6:85766096	chr6:85387219~85390186:-
LIHC	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-5.39	1.3e-07	6.06e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
LIHC	cis	rs5769707	0.837	rs5770599	ENSG00000235111.1	RP1-29C18.8	-5.39	1.3e-07	6.06e-05	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49612657~49615716:-
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-5.39	1.3e-07	6.1e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
LIHC	cis	rs496547	0.721	rs2508570	ENSG00000255422.1	AP002954.4	-5.39	1.3e-07	6.1e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118807900	chr11:118704607~118750263:+
LIHC	cis	rs496547	0.686	rs591756	ENSG00000255422.1	AP002954.4	-5.39	1.3e-07	6.1e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118808172	chr11:118704607~118750263:+
LIHC	cis	rs5769707	0.604	rs1018814	ENSG00000235111.1	RP1-29C18.8	-5.39	1.3e-07	6.1e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49612657~49615716:-
LIHC	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-5.39	1.31e-07	6.11e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-5.39	1.31e-07	6.11e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
LIHC	cis	rs11722779	0.935	rs11938650	ENSG00000230069.3	LRRC37A15P	-5.39	1.31e-07	6.11e-05	-0.26	-0.28	Schizophrenia;	chr4:103021639	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-5.39	1.31e-07	6.11e-05	-0.25	-0.28	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
LIHC	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-5.39	1.31e-07	6.11e-05	-0.44	-0.28	Depression;	chr6:28161802	chr6:28115628~28116551:+
LIHC	cis	rs12157904	0.744	rs34680058	ENSG00000233360.4	Z83844.1	5.39	1.31e-07	6.12e-05	0.57	0.28	Response to anti-depressant treatment in major depressive disorder;	chr22:37657901	chr22:37641832~37658377:-
LIHC	cis	rs227275	0.525	rs4698874	ENSG00000230069.3	LRRC37A15P	-5.39	1.31e-07	6.12e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102727274~102730721:-
LIHC	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	5.39	1.31e-07	6.12e-05	0.35	0.28	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
LIHC	cis	rs10910092	1	rs10910092	ENSG00000225931.3	RP3-395M20.7	5.39	1.31e-07	6.13e-05	0.3	0.28	Ulcerative colitis;	chr1:2570077	chr1:2566410~2569888:+
LIHC	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	5.39	1.31e-07	6.13e-05	0.38	0.28	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	5.39	1.31e-07	6.13e-05	0.38	0.28	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	5.39	1.31e-07	6.13e-05	0.38	0.28	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
LIHC	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-5.39	1.31e-07	6.13e-05	-0.5	-0.28	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
LIHC	cis	rs3096299	0.933	rs889576	ENSG00000261118.1	RP11-104N10.1	-5.39	1.31e-07	6.14e-05	-0.28	-0.28	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89492017~89504460:-
LIHC	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	5.39	1.32e-07	6.15e-05	0.39	0.28	Height;	chr6:109365409	chr6:109382795~109383666:+
LIHC	cis	rs17711722	0.528	rs73138179	ENSG00000228409.4	CCT6P1	-5.39	1.32e-07	6.16e-05	-0.22	-0.28	Calcium levels;	chr7:65829495	chr7:65751142~65763354:+
LIHC	cis	rs4731207	0.596	rs7782410	ENSG00000224897.5	POT1-AS1	5.39	1.32e-07	6.17e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:124931050	chr7:124929873~125179315:+
LIHC	cis	rs2032366	0.606	rs9965972	ENSG00000267279.1	RP11-879F14.2	-5.39	1.32e-07	6.18e-05	-0.34	-0.28	Obesity-related traits;	chr18:61609468	chr18:61585746~61606916:-
LIHC	cis	rs4535700	0.501	rs11765577	ENSG00000226278.1	PSPHP1	5.39	1.33e-07	6.19e-05	0.33	0.28	Macular telangiectasia type 2;	chr7:55930245	chr7:55764797~55773288:+
LIHC	cis	rs17301013	0.896	rs13375788	ENSG00000227373.4	RP11-160H22.5	5.39	1.33e-07	6.2e-05	0.34	0.28	Systemic lupus erythematosus;	chr1:174524207	chr1:174115300~174160004:-
LIHC	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	5.39	1.33e-07	6.21e-05	0.25	0.28	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
LIHC	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-5.39	1.33e-07	6.21e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
LIHC	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	5.39	1.33e-07	6.22e-05	0.39	0.28	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
LIHC	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	5.39	1.33e-07	6.22e-05	0.25	0.28	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	5.39	1.33e-07	6.22e-05	0.25	0.28	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
LIHC	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-5.39	1.33e-07	6.23e-05	-0.44	-0.28	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
LIHC	cis	rs6918586	0.565	rs13196986	ENSG00000216436.2	HIST1H2APS1	5.39	1.34e-07	6.23e-05	0.38	0.28	Schizophrenia;	chr6:26090224	chr6:25732497~25732827:+
LIHC	cis	rs4948102	0.642	rs6593297	ENSG00000226278.1	PSPHP1	5.39	1.34e-07	6.24e-05	0.31	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55764797~55773288:+
LIHC	cis	rs10510102	0.872	rs11200277	ENSG00000226864.1	ATE1-AS1	5.39	1.34e-07	6.24e-05	0.47	0.28	Breast cancer;	chr10:121944295	chr10:121928312~121951965:+
LIHC	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-5.39	1.34e-07	6.24e-05	-0.3	-0.28	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
LIHC	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	5.39	1.34e-07	6.24e-05	0.29	0.28	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
LIHC	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-5.39	1.34e-07	6.24e-05	-0.31	-0.28	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
LIHC	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	5.39	1.34e-07	6.25e-05	0.42	0.28	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	5.39	1.34e-07	6.25e-05	0.42	0.28	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
LIHC	cis	rs2998286	0.862	rs2185293	ENSG00000254635.4	WAC-AS1	-5.39	1.34e-07	6.25e-05	-0.35	-0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519170	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.862	rs2807732	ENSG00000254635.4	WAC-AS1	-5.39	1.34e-07	6.25e-05	-0.35	-0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28520318	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.666	rs2491251	ENSG00000254635.4	WAC-AS1	-5.39	1.34e-07	6.25e-05	-0.35	-0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28525363	chr10:28522652~28532743:-
LIHC	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	5.39	1.34e-07	6.26e-05	0.25	0.28	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
LIHC	cis	rs4731207	0.596	rs10255638	ENSG00000224897.5	POT1-AS1	-5.39	1.34e-07	6.26e-05	-0.34	-0.28	Cutaneous malignant melanoma;	chr7:124936201	chr7:124929873~125179315:+
LIHC	cis	rs7914558	0.901	rs1926034	ENSG00000236937.2	PTGES3P4	5.39	1.34e-07	6.26e-05	0.34	0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103069345	chr10:102845595~102845950:+
LIHC	cis	rs9326248	1	rs664971	ENSG00000236267.1	AP006216.5	-5.39	1.35e-07	6.27e-05	-0.29	-0.28	Blood protein levels;	chr11:117200141	chr11:116813204~116814003:-
LIHC	cis	rs10510102	0.935	rs11200258	ENSG00000226864.1	ATE1-AS1	5.39	1.35e-07	6.27e-05	0.45	0.28	Breast cancer;	chr10:121918392	chr10:121928312~121951965:+
LIHC	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	5.39	1.35e-07	6.27e-05	0.25	0.28	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
LIHC	cis	rs12157904	0.793	rs13055684	ENSG00000233360.4	Z83844.1	5.39	1.35e-07	6.28e-05	0.58	0.28	Response to anti-depressant treatment in major depressive disorder;	chr22:37639908	chr22:37641832~37658377:-
LIHC	cis	rs739496	0.615	rs77684561	ENSG00000226469.1	ADAM1B	5.39	1.35e-07	6.28e-05	0.37	0.28	Platelet count;	chr12:111623919	chr12:111927018~111929017:+
LIHC	cis	rs6480314	0.542	rs7894859	ENSG00000233590.1	RP11-153K11.3	-5.39	1.35e-07	6.28e-05	-0.45	-0.28	Optic nerve measurement (disc area);	chr10:68234620	chr10:68233251~68242379:-
LIHC	cis	rs12908161	0.959	rs2175567	ENSG00000259295.5	CSPG4P12	5.38	1.35e-07	6.29e-05	0.39	0.28	Schizophrenia;	chr15:84657715	chr15:85191438~85213905:+
LIHC	cis	rs12571093	0.803	rs17297418	ENSG00000233590.1	RP11-153K11.3	5.38	1.35e-07	6.29e-05	0.43	0.28	Optic nerve measurement (disc area);	chr10:68271894	chr10:68233251~68242379:-
LIHC	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	5.38	1.35e-07	6.3e-05	0.4	0.28	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
LIHC	cis	rs4919694	0.536	rs12414777	ENSG00000236937.2	PTGES3P4	5.38	1.35e-07	6.3e-05	0.37	0.28	Arsenic metabolism;	chr10:102938024	chr10:102845595~102845950:+
LIHC	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-5.38	1.36e-07	6.31e-05	-0.32	-0.28	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
LIHC	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	5.38	1.36e-07	6.33e-05	0.33	0.28	Height;	chr6:109546439	chr6:109382795~109383666:+
LIHC	cis	rs2060793	0.712	rs6486202	ENSG00000251991.1	RNU7-49P	5.38	1.36e-07	6.34e-05	0.31	0.28	Vitamin D levels;	chr11:14777260	chr11:14478892~14478953:+
LIHC	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-5.38	1.36e-07	6.35e-05	-0.34	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
LIHC	cis	rs5758511	0.68	rs1107553	ENSG00000237037.8	NDUFA6-AS1	-5.38	1.37e-07	6.35e-05	-0.35	-0.28	Birth weight;	chr22:42271467	chr22:42090931~42137742:+
LIHC	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-5.38	1.37e-07	6.36e-05	-0.37	-0.28	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
LIHC	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-5.38	1.37e-07	6.36e-05	-0.25	-0.28	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
LIHC	cis	rs4356203	0.905	rs594034	ENSG00000272034.1	SNORD14A	-5.38	1.37e-07	6.36e-05	-0.3	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17200833	chr11:17074654~17074744:-
LIHC	cis	rs227275	0.525	rs2086499	ENSG00000230069.3	LRRC37A15P	-5.38	1.37e-07	6.37e-05	-0.26	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102727274~102730721:-
LIHC	cis	rs2735413	0.846	rs72800943	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78045658	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.846	rs12923290	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046059	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.881	rs12923218	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046377	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.875	rs12923229	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046405	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs4888733	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046626	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.752	rs11642442	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046903	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs11643649	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78047302	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs56397244	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78047469	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs34094825	ENSG00000276007.1	RP11-358L22.3	-5.38	1.37e-07	6.37e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78047495	chr16:78123243~78124332:+
LIHC	cis	rs496547	0.686	rs524590	ENSG00000255422.1	AP002954.4	-5.38	1.37e-07	6.38e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118769354	chr11:118704607~118750263:+
LIHC	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	5.38	1.37e-07	6.39e-05	0.36	0.28	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
LIHC	cis	rs7916697	0.947	rs7916410	ENSG00000233590.1	RP11-153K11.3	5.38	1.37e-07	6.39e-05	0.34	0.28	Optic disc area;	chr10:68235910	chr10:68233251~68242379:-
LIHC	cis	rs854624	0.818	rs1719201	ENSG00000275944.1	RP11-104J23.1	5.38	1.38e-07	6.39e-05	0.34	0.28	Blood protein levels;	chr17:36011795	chr17:36001419~36011618:+
LIHC	cis	rs4731207	0.596	rs1481337	ENSG00000224897.5	POT1-AS1	5.38	1.38e-07	6.39e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125027742	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1904973	ENSG00000224897.5	POT1-AS1	5.38	1.38e-07	6.39e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125029493	chr7:124929873~125179315:+
LIHC	cis	rs10510102	0.935	rs11200252	ENSG00000226864.1	ATE1-AS1	5.38	1.38e-07	6.4e-05	0.45	0.28	Breast cancer;	chr10:121914728	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12254184	ENSG00000226864.1	ATE1-AS1	5.38	1.38e-07	6.4e-05	0.45	0.28	Breast cancer;	chr10:121914971	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200253	ENSG00000226864.1	ATE1-AS1	5.38	1.38e-07	6.4e-05	0.45	0.28	Breast cancer;	chr10:121915114	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200254	ENSG00000226864.1	ATE1-AS1	5.38	1.38e-07	6.4e-05	0.45	0.28	Breast cancer;	chr10:121915241	chr10:121928312~121951965:+
LIHC	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	5.38	1.38e-07	6.4e-05	0.33	0.28	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
LIHC	cis	rs950169	0.84	rs72748702	ENSG00000259295.5	CSPG4P12	5.38	1.38e-07	6.41e-05	0.37	0.28	Schizophrenia;	chr15:84246494	chr15:85191438~85213905:+
LIHC	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-5.38	1.38e-07	6.41e-05	-0.4	-0.28	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
LIHC	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-5.38	1.38e-07	6.42e-05	-0.25	-0.28	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
LIHC	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	5.38	1.38e-07	6.43e-05	0.27	0.28	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
LIHC	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-5.38	1.39e-07	6.44e-05	-0.49	-0.28	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
LIHC	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	5.38	1.39e-07	6.44e-05	0.24	0.28	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	5.38	1.39e-07	6.44e-05	0.24	0.28	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
LIHC	cis	rs17270561	0.666	rs4712976	ENSG00000216436.2	HIST1H2APS1	-5.38	1.39e-07	6.45e-05	-0.34	-0.28	Iron status biomarkers;	chr6:25841975	chr6:25732497~25732827:+
LIHC	cis	rs4660214	0.666	rs10493087	ENSG00000182109.6	RP11-69E11.4	-5.38	1.39e-07	6.45e-05	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs11205828	ENSG00000182109.6	RP11-69E11.4	-5.38	1.39e-07	6.45e-05	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39522280~39546187:-
LIHC	cis	rs2688482	0.557	rs3103952	ENSG00000242086.7	LINC00969	5.38	1.39e-07	6.45e-05	0.35	0.28	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195658062~195739964:+
LIHC	cis	rs2762353	0.595	rs9467591	ENSG00000242387.1	HIST1H2APS2	5.38	1.4e-07	6.48e-05	0.32	0.28	Blood metabolite levels;	chr6:25742471	chr6:25882026~25882395:-
LIHC	cis	rs4660456	0.619	rs753753	ENSG00000237899.1	RP4-739H11.3	-5.38	1.4e-07	6.48e-05	-0.35	-0.28	Platelet count;	chr1:40771716	chr1:40669089~40687588:-
LIHC	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	5.38	1.4e-07	6.49e-05	0.21	0.28	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
LIHC	cis	rs496547	0.719	rs1790189	ENSG00000255422.1	AP002954.4	-5.38	1.4e-07	6.5e-05	-0.32	-0.28	Hip minimal joint space width;	chr11:118781617	chr11:118704607~118750263:+
LIHC	cis	rs7916697	0.947	rs4745950	ENSG00000233590.1	RP11-153K11.3	5.38	1.4e-07	6.5e-05	0.34	0.28	Optic disc area;	chr10:68236698	chr10:68233251~68242379:-
LIHC	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	5.38	1.4e-07	6.5e-05	0.21	0.28	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
LIHC	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	5.38	1.4e-07	6.51e-05	0.47	0.28	Height;	chr6:109479488	chr6:109382795~109383666:+
LIHC	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	5.38	1.4e-07	6.51e-05	0.42	0.28	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
LIHC	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	5.38	1.41e-07	6.53e-05	0.34	0.28	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
LIHC	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	5.38	1.41e-07	6.54e-05	0.24	0.28	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
LIHC	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-5.38	1.42e-07	6.57e-05	-0.37	-0.28	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
LIHC	cis	rs887829	0.57	rs7608175	ENSG00000233445.1	RPL17P11	-5.38	1.42e-07	6.57e-05	-0.29	-0.28	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233690443	chr2:233721522~233722065:-
LIHC	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	5.37	1.42e-07	6.58e-05	0.31	0.28	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	5.37	1.42e-07	6.58e-05	0.31	0.28	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
LIHC	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-5.37	1.42e-07	6.59e-05	-0.32	-0.28	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	5.37	1.42e-07	6.59e-05	0.33	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
LIHC	cis	rs17711722	0.51	rs11767457	ENSG00000228409.4	CCT6P1	-5.37	1.42e-07	6.59e-05	-0.22	-0.28	Calcium levels;	chr7:65825628	chr7:65751142~65763354:+
LIHC	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-5.37	1.43e-07	6.6e-05	-0.31	-0.28	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
LIHC	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	5.37	1.43e-07	6.6e-05	0.27	0.28	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
LIHC	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	5.37	1.43e-07	6.6e-05	0.27	0.28	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
LIHC	cis	rs7131987	0.621	rs6487805	ENSG00000275476.1	RP11-996F15.4	5.37	1.43e-07	6.62e-05	0.32	0.28	QT interval;	chr12:29304617	chr12:29277397~29277882:-
LIHC	cis	rs227275	0.527	rs223338	ENSG00000230069.3	LRRC37A15P	-5.37	1.43e-07	6.62e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102727274~102730721:-
LIHC	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	5.37	1.43e-07	6.62e-05	0.33	0.28	Height;	chr6:109361200	chr6:109382795~109383666:+
LIHC	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-5.37	1.43e-07	6.62e-05	-0.31	-0.28	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
LIHC	cis	rs10510102	0.935	rs11200257	ENSG00000226864.1	ATE1-AS1	5.37	1.43e-07	6.63e-05	0.45	0.28	Breast cancer;	chr10:121917232	chr10:121928312~121951965:+
LIHC	cis	rs227275	0.554	rs223439	ENSG00000230069.3	LRRC37A15P	-5.37	1.44e-07	6.65e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223436	ENSG00000230069.3	LRRC37A15P	-5.37	1.44e-07	6.65e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102727274~102730721:-
LIHC	cis	rs4660214	0.666	rs7553009	ENSG00000182109.6	RP11-69E11.4	-5.37	1.44e-07	6.66e-05	-0.3	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39522280~39546187:-
LIHC	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-5.37	1.44e-07	6.67e-05	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
LIHC	cis	rs4731207	0.57	rs7784616	ENSG00000224897.5	POT1-AS1	5.37	1.44e-07	6.67e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125037140	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466988	ENSG00000224897.5	POT1-AS1	5.37	1.44e-07	6.67e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125038062	chr7:124929873~125179315:+
LIHC	cis	rs7916697	0.588	rs10823165	ENSG00000233590.1	RP11-153K11.3	5.37	1.44e-07	6.68e-05	0.36	0.28	Optic disc area;	chr10:68248269	chr10:68233251~68242379:-
LIHC	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-5.37	1.45e-07	6.68e-05	-0.24	-0.28	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
LIHC	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	5.37	1.45e-07	6.69e-05	0.4	0.28	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
LIHC	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	5.37	1.45e-07	6.69e-05	0.32	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
LIHC	cis	rs2735413	0.918	rs12931394	ENSG00000276007.1	RP11-358L22.3	-5.37	1.45e-07	6.69e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78047732	chr16:78123243~78124332:+
LIHC	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-5.37	1.45e-07	6.69e-05	-0.34	-0.28	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-5.37	1.45e-07	6.69e-05	-0.34	-0.28	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
LIHC	cis	rs6480314	0.542	rs61854805	ENSG00000233590.1	RP11-153K11.3	-5.37	1.45e-07	6.7e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68255826	chr10:68233251~68242379:-
LIHC	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	5.37	1.45e-07	6.71e-05	0.32	0.28	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
LIHC	cis	rs7131987	0.65	rs10843384	ENSG00000275476.1	RP11-996F15.4	-5.37	1.45e-07	6.72e-05	-0.33	-0.28	QT interval;	chr12:29319476	chr12:29277397~29277882:-
LIHC	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	5.37	1.46e-07	6.72e-05	0.4	0.28	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	5.37	1.46e-07	6.72e-05	0.4	0.28	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
LIHC	cis	rs12571093	0.803	rs61854825	ENSG00000233590.1	RP11-153K11.3	-5.37	1.46e-07	6.73e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68271535	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.803	rs61854826	ENSG00000233590.1	RP11-153K11.3	-5.37	1.46e-07	6.73e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68271801	chr10:68233251~68242379:-
LIHC	cis	rs950169	0.887	rs35986397	ENSG00000259295.5	CSPG4P12	5.37	1.46e-07	6.73e-05	0.38	0.28	Schizophrenia;	chr15:84400409	chr15:85191438~85213905:+
LIHC	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-5.37	1.46e-07	6.74e-05	-0.35	-0.28	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-5.37	1.46e-07	6.74e-05	-0.35	-0.28	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
LIHC	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-5.37	1.46e-07	6.75e-05	-0.25	-0.28	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
LIHC	cis	rs1577917	0.883	rs9450375	ENSG00000234155.1	RP11-30P6.6	-5.37	1.46e-07	6.75e-05	-0.33	-0.28	Response to antipsychotic treatment;	chr6:86046911	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.883	rs2166664	ENSG00000234155.1	RP11-30P6.6	5.37	1.46e-07	6.75e-05	0.33	0.28	Response to antipsychotic treatment;	chr6:85886904	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.883	rs9450348	ENSG00000234155.1	RP11-30P6.6	5.37	1.46e-07	6.75e-05	0.33	0.28	Response to antipsychotic treatment;	chr6:85888318	chr6:85387219~85390186:-
LIHC	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	5.37	1.47e-07	6.77e-05	0.33	0.28	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
LIHC	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	5.37	1.47e-07	6.77e-05	0.46	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	5.37	1.47e-07	6.77e-05	0.46	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
LIHC	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-5.37	1.47e-07	6.77e-05	-0.29	-0.28	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-5.37	1.47e-07	6.77e-05	-0.29	-0.28	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
LIHC	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	5.37	1.47e-07	6.77e-05	0.46	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	5.37	1.47e-07	6.77e-05	0.46	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
LIHC	cis	rs75920871	0.589	rs67201490	ENSG00000254851.1	RP11-109L13.1	-5.37	1.47e-07	6.78e-05	-0.55	-0.28	Subjective well-being;	chr11:117212288	chr11:117135528~117138582:+
LIHC	cis	rs75920871	0.64	rs4938357	ENSG00000254851.1	RP11-109L13.1	-5.37	1.47e-07	6.78e-05	-0.55	-0.28	Subjective well-being;	chr11:117213324	chr11:117135528~117138582:+
LIHC	cis	rs75920871	0.589	rs56081989	ENSG00000254851.1	RP11-109L13.1	-5.37	1.47e-07	6.78e-05	-0.55	-0.28	Subjective well-being;	chr11:117214589	chr11:117135528~117138582:+
LIHC	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	5.37	1.47e-07	6.79e-05	0.29	0.28	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
LIHC	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-5.37	1.47e-07	6.79e-05	-0.28	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
LIHC	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-5.37	1.47e-07	6.79e-05	-0.46	-0.28	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
LIHC	cis	rs228614	0.51	rs6830407	ENSG00000230069.3	LRRC37A15P	-5.37	1.48e-07	6.8e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs4699033	ENSG00000230069.3	LRRC37A15P	-5.37	1.48e-07	6.81e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102727274~102730721:-
LIHC	cis	rs832187	0.64	rs3774729	ENSG00000280620.1	SCAANT1	5.37	1.48e-07	6.82e-05	0.38	0.28	Schizophrenia;	chr3:63996406	chr3:63911518~63911772:-
LIHC	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	5.37	1.48e-07	6.82e-05	0.37	0.28	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
LIHC	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	5.37	1.48e-07	6.83e-05	0.24	0.28	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	5.37	1.48e-07	6.83e-05	0.24	0.28	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	5.37	1.48e-07	6.83e-05	0.24	0.28	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	5.37	1.48e-07	6.83e-05	0.24	0.28	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	5.37	1.48e-07	6.83e-05	0.24	0.28	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
LIHC	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-5.37	1.49e-07	6.84e-05	-0.34	-0.28	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
LIHC	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-5.37	1.49e-07	6.84e-05	-0.33	-0.28	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
LIHC	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-5.37	1.49e-07	6.84e-05	-0.3	-0.28	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
LIHC	cis	rs2877649	0.793	rs10133116	ENSG00000258744.1	RP11-80A15.1	-5.37	1.49e-07	6.84e-05	-0.55	-0.28	Smooth-surface caries;	chr14:24456164	chr14:24501594~24508688:+
LIHC	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	5.37	1.49e-07	6.85e-05	0.41	0.28	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
LIHC	cis	rs2762353	0.526	rs9461203	ENSG00000216436.2	HIST1H2APS1	5.37	1.49e-07	6.86e-05	0.32	0.28	Blood metabolite levels;	chr6:25710327	chr6:25732497~25732827:+
LIHC	cis	rs2762353	0.526	rs6912391	ENSG00000216436.2	HIST1H2APS1	5.37	1.49e-07	6.86e-05	0.32	0.28	Blood metabolite levels;	chr6:25710535	chr6:25732497~25732827:+
LIHC	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	5.37	1.49e-07	6.87e-05	0.24	0.28	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
LIHC	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	5.37	1.49e-07	6.87e-05	0.38	0.28	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
LIHC	cis	rs6085948	1	rs6054856	ENSG00000238102.1	RP11-19D2.1	-5.36	1.5e-07	6.88e-05	-0.4	-0.28	Interleukin-10 levels;	chr20:7266592	chr20:7256580~7258214:-
LIHC	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	5.36	1.5e-07	6.9e-05	0.24	0.28	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
LIHC	cis	rs9425766	0.566	rs4447042	ENSG00000227373.4	RP11-160H22.5	5.36	1.5e-07	6.91e-05	0.36	0.28	Life satisfaction;	chr1:174212747	chr1:174115300~174160004:-
LIHC	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	5.36	1.5e-07	6.91e-05	0.4	0.28	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	5.36	1.5e-07	6.91e-05	0.4	0.28	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	5.36	1.5e-07	6.91e-05	0.4	0.28	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
LIHC	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-5.36	1.5e-07	6.91e-05	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
LIHC	cis	rs2245008	0.762	rs168800	ENSG00000260932.1	RP11-483P21.6	-5.36	1.51e-07	6.92e-05	-0.53	-0.28	Pursuit maintenance gain;	chr16:83946786	chr16:83929796~83931223:-
LIHC	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-5.36	1.51e-07	6.96e-05	-0.31	-0.28	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-5.36	1.51e-07	6.96e-05	-0.31	-0.28	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
LIHC	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	5.36	1.52e-07	6.97e-05	0.37	0.28	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
LIHC	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-5.36	1.52e-07	6.97e-05	-0.42	-0.28	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
LIHC	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	5.36	1.52e-07	6.98e-05	0.49	0.28	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
LIHC	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	5.36	1.52e-07	6.98e-05	0.31	0.28	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
LIHC	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	5.36	1.52e-07	6.99e-05	0.4	0.28	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	5.36	1.52e-07	6.99e-05	0.4	0.28	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	5.36	1.52e-07	6.99e-05	0.4	0.28	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
LIHC	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-5.36	1.52e-07	7e-05	-0.35	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
LIHC	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	5.36	1.52e-07	7e-05	0.32	0.28	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
LIHC	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-5.36	1.52e-07	7e-05	-0.26	-0.28	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
LIHC	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	5.36	1.53e-07	7e-05	0.34	0.28	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
LIHC	cis	rs4934494	0.768	rs34993776	ENSG00000232936.4	RP11-80H5.2	5.36	1.53e-07	7e-05	0.36	0.28	Red blood cell count;	chr10:89681932	chr10:89645282~89650667:+
LIHC	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-5.36	1.53e-07	7e-05	-0.25	-0.28	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
LIHC	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-5.36	1.53e-07	7e-05	-0.25	-0.28	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
LIHC	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-5.36	1.53e-07	7e-05	-0.25	-0.28	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
LIHC	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-5.36	1.53e-07	7.02e-05	-0.34	-0.28	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
LIHC	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-5.36	1.53e-07	7.02e-05	-0.35	-0.28	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-5.36	1.53e-07	7.02e-05	-0.35	-0.28	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
LIHC	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-5.36	1.53e-07	7.02e-05	-0.24	-0.28	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
LIHC	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	5.36	1.53e-07	7.04e-05	0.36	0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
LIHC	cis	rs7916697	0.891	rs4746748	ENSG00000233590.1	RP11-153K11.3	5.36	1.53e-07	7.04e-05	0.33	0.28	Optic disc area;	chr10:68249631	chr10:68233251~68242379:-
LIHC	cis	rs7916697	0.842	rs4746749	ENSG00000233590.1	RP11-153K11.3	5.36	1.53e-07	7.04e-05	0.33	0.28	Optic disc area;	chr10:68249632	chr10:68233251~68242379:-
LIHC	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-5.36	1.53e-07	7.04e-05	-0.28	-0.28	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
LIHC	cis	rs4356203	0.905	rs11024158	ENSG00000272034.1	SNORD14A	5.36	1.54e-07	7.05e-05	0.3	0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17103621	chr11:17074654~17074744:-
LIHC	cis	rs9425766	0.541	rs12691474	ENSG00000227373.4	RP11-160H22.5	5.36	1.54e-07	7.06e-05	0.36	0.28	Life satisfaction;	chr1:174200867	chr1:174115300~174160004:-
LIHC	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	5.36	1.55e-07	7.08e-05	0.4	0.28	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
LIHC	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	5.36	1.55e-07	7.09e-05	0.31	0.28	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
LIHC	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-5.36	1.55e-07	7.09e-05	-0.3	-0.28	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
LIHC	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-5.36	1.55e-07	7.09e-05	-0.25	-0.28	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
LIHC	cis	rs11098499	0.954	rs12510138	ENSG00000260091.1	RP11-33B1.4	-5.36	1.55e-07	7.1e-05	-0.2	-0.28	Corneal astigmatism;	chr4:119502780	chr4:119409333~119410233:+
LIHC	cis	rs12291225	0.585	rs34171876	ENSG00000251991.1	RNU7-49P	5.36	1.55e-07	7.1e-05	0.29	0.28	Sense of smell;	chr11:14332411	chr11:14478892~14478953:+
LIHC	cis	rs739496	0.947	rs7299849	ENSG00000226469.1	ADAM1B	5.36	1.55e-07	7.11e-05	0.34	0.28	Platelet count;	chr12:111417657	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.947	rs7973120	ENSG00000226469.1	ADAM1B	5.36	1.55e-07	7.11e-05	0.34	0.28	Platelet count;	chr12:111418934	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.947	rs739497	ENSG00000226469.1	ADAM1B	5.36	1.55e-07	7.11e-05	0.34	0.28	Platelet count;	chr12:111420282	chr12:111927018~111929017:+
LIHC	cis	rs4731207	0.596	rs10269342	ENSG00000224897.5	POT1-AS1	-5.36	1.55e-07	7.12e-05	-0.34	-0.28	Cutaneous malignant melanoma;	chr7:125053791	chr7:124929873~125179315:+
LIHC	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	5.36	1.56e-07	7.13e-05	0.21	0.28	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	5.36	1.56e-07	7.13e-05	0.21	0.28	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	5.36	1.56e-07	7.13e-05	0.21	0.28	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
LIHC	cis	rs2877649	0.51	rs10083509	ENSG00000258744.1	RP11-80A15.1	5.36	1.56e-07	7.13e-05	0.49	0.28	Smooth-surface caries;	chr14:24438841	chr14:24501594~24508688:+
LIHC	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	5.36	1.56e-07	7.15e-05	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
LIHC	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-5.36	1.56e-07	7.16e-05	-0.25	-0.28	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-5.36	1.56e-07	7.16e-05	-0.25	-0.28	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-5.36	1.56e-07	7.16e-05	-0.25	-0.28	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
LIHC	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-5.36	1.57e-07	7.16e-05	-0.25	-0.28	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
LIHC	cis	rs116175783	0.557	rs10490567	ENSG00000227403.1	AC009299.3	5.36	1.57e-07	7.17e-05	0.42	0.28	Intelligence (multi-trait analysis);	chr2:161317267	chr2:161244739~161249050:+
LIHC	cis	rs638893	0.842	rs480791	ENSG00000255422.1	AP002954.4	-5.36	1.57e-07	7.18e-05	-0.49	-0.28	Vitiligo;	chr11:118833546	chr11:118704607~118750263:+
LIHC	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	5.36	1.57e-07	7.18e-05	0.25	0.28	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-5.36	1.57e-07	7.18e-05	-0.25	-0.28	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-5.36	1.57e-07	7.18e-05	-0.25	-0.28	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-5.36	1.57e-07	7.18e-05	-0.25	-0.28	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-5.36	1.57e-07	7.18e-05	-0.25	-0.28	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-5.36	1.57e-07	7.18e-05	-0.25	-0.28	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
LIHC	cis	rs2439831	1	rs565007	ENSG00000205771.5	CATSPER2P1	-5.36	1.57e-07	7.19e-05	-0.38	-0.28	Lung cancer in ever smokers;	chr15:43424443	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs550239	ENSG00000205771.5	CATSPER2P1	-5.36	1.57e-07	7.19e-05	-0.38	-0.28	Lung cancer in ever smokers;	chr15:43427999	chr15:43726918~43747094:-
LIHC	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	5.36	1.57e-07	7.19e-05	0.42	0.28	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
LIHC	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-5.36	1.57e-07	7.19e-05	-0.36	-0.28	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-5.36	1.57e-07	7.19e-05	-0.36	-0.28	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
LIHC	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-5.35	1.57e-07	7.2e-05	-0.39	-0.28	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
LIHC	cis	rs10899021	0.512	rs2186955	ENSG00000279353.1	RP11-864N7.4	-5.35	1.57e-07	7.2e-05	-0.42	-0.28	Response to metformin (IC50);	chr11:74664430	chr11:74698231~74699658:-
LIHC	cis	rs4660456	0.572	rs1008204	ENSG00000237899.1	RP4-739H11.3	5.35	1.57e-07	7.2e-05	0.34	0.28	Platelet count;	chr1:40700189	chr1:40669089~40687588:-
LIHC	cis	rs4535700	0.501	rs28678267	ENSG00000226278.1	PSPHP1	5.35	1.58e-07	7.22e-05	0.33	0.28	Macular telangiectasia type 2;	chr7:55941797	chr7:55764797~55773288:+
LIHC	cis	rs4535700	0.501	rs11765531	ENSG00000226278.1	PSPHP1	5.35	1.58e-07	7.22e-05	0.33	0.28	Macular telangiectasia type 2;	chr7:55942594	chr7:55764797~55773288:+
LIHC	cis	rs4535700	0.501	rs10227764	ENSG00000226278.1	PSPHP1	5.35	1.58e-07	7.22e-05	0.33	0.28	Macular telangiectasia type 2;	chr7:55944729	chr7:55764797~55773288:+
LIHC	cis	rs4535700	0.501	rs60517461	ENSG00000226278.1	PSPHP1	5.35	1.58e-07	7.22e-05	0.33	0.28	Macular telangiectasia type 2;	chr7:55949952	chr7:55764797~55773288:+
LIHC	cis	rs4934494	0.822	rs3962370	ENSG00000232936.4	RP11-80H5.2	5.35	1.58e-07	7.23e-05	0.34	0.28	Red blood cell count;	chr10:89777763	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.727	rs1590566	ENSG00000232936.4	RP11-80H5.2	5.35	1.58e-07	7.23e-05	0.34	0.28	Red blood cell count;	chr10:89778781	chr10:89645282~89650667:+
LIHC	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-5.35	1.58e-07	7.23e-05	-0.34	-0.28	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
LIHC	cis	rs5769765	0.862	rs56377703	ENSG00000278869.1	CITF22-49E9.3	5.35	1.58e-07	7.24e-05	0.46	0.28	Schizophrenia;	chr22:49913292	chr22:49933198~49934074:-
LIHC	cis	rs950169	0.922	rs12910334	ENSG00000259295.5	CSPG4P12	5.35	1.59e-07	7.25e-05	0.38	0.28	Schizophrenia;	chr15:84403620	chr15:85191438~85213905:+
LIHC	cis	rs6589219	0.826	rs36029541	ENSG00000196167.8	COLCA1	-5.35	1.59e-07	7.25e-05	-0.31	-0.28	Colorectal cancer;	chr11:111269217	chr11:111290787~111305045:-
LIHC	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	5.35	1.59e-07	7.26e-05	0.4	0.28	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
LIHC	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-5.35	1.59e-07	7.27e-05	-0.3	-0.28	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
LIHC	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-5.35	1.59e-07	7.27e-05	-0.38	-0.28	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
LIHC	cis	rs228614	0.51	rs223356	ENSG00000230069.3	LRRC37A15P	-5.35	1.6e-07	7.3e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223353	ENSG00000230069.3	LRRC37A15P	-5.35	1.6e-07	7.3e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223352	ENSG00000230069.3	LRRC37A15P	-5.35	1.6e-07	7.3e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223349	ENSG00000230069.3	LRRC37A15P	-5.35	1.6e-07	7.3e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102727274~102730721:-
LIHC	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-5.35	1.61e-07	7.32e-05	-0.32	-0.28	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
LIHC	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	5.35	1.61e-07	7.33e-05	0.26	0.28	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
LIHC	cis	rs7131987	0.65	rs11050188	ENSG00000275476.1	RP11-996F15.4	-5.35	1.61e-07	7.34e-05	-0.33	-0.28	QT interval;	chr12:29320175	chr12:29277397~29277882:-
LIHC	cis	rs4356203	0.905	rs10832743	ENSG00000272034.1	SNORD14A	-5.35	1.61e-07	7.34e-05	-0.3	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17194933	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs550667	ENSG00000272034.1	SNORD14A	-5.35	1.61e-07	7.34e-05	-0.3	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197428	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs656623	ENSG00000272034.1	SNORD14A	-5.35	1.61e-07	7.34e-05	-0.3	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197632	chr11:17074654~17074744:-
LIHC	cis	rs55665837	0.539	rs10500804	ENSG00000251991.1	RNU7-49P	5.35	1.61e-07	7.35e-05	0.3	0.28	Vitamin D levels;	chr11:14888727	chr11:14478892~14478953:+
LIHC	cis	rs9425766	0.566	rs4442420	ENSG00000227373.4	RP11-160H22.5	5.35	1.61e-07	7.35e-05	0.36	0.28	Life satisfaction;	chr1:174199667	chr1:174115300~174160004:-
LIHC	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	5.35	1.62e-07	7.36e-05	0.33	0.28	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
LIHC	cis	rs11146838	1	rs11146838	ENSG00000275858.1	RP11-291L22.8	5.35	1.62e-07	7.36e-05	0.32	0.28	Breast cancer;	chr10:38856846	chr10:38450738~38451069:-
LIHC	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-5.35	1.62e-07	7.37e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-5.35	1.62e-07	7.37e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
LIHC	cis	rs7916410	0.512	rs1900003	ENSG00000233590.1	RP11-153K11.3	-5.35	1.62e-07	7.37e-05	-0.33	-0.28	Optic disc area;	chr10:68244794	chr10:68233251~68242379:-
LIHC	cis	rs7916697	0.578	rs1900002	ENSG00000233590.1	RP11-153K11.3	-5.35	1.62e-07	7.37e-05	-0.33	-0.28	Optic disc area;	chr10:68244795	chr10:68233251~68242379:-
LIHC	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	5.35	1.62e-07	7.37e-05	0.39	0.28	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
LIHC	cis	rs17301013	0.861	rs1894200	ENSG00000227373.4	RP11-160H22.5	-5.35	1.62e-07	7.37e-05	-0.35	-0.28	Systemic lupus erythematosus;	chr1:174842039	chr1:174115300~174160004:-
LIHC	cis	rs72638986	1	rs6474359	ENSG00000254165.1	RP11-503E24.2	-5.35	1.62e-07	7.37e-05	-0.45	-0.28	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr8:41691676	chr8:42537529~42538304:-
LIHC	cis	rs9326248	0.603	rs7396061	ENSG00000236267.1	AP006216.5	5.35	1.62e-07	7.37e-05	0.28	0.28	Blood protein levels;	chr11:116880158	chr11:116813204~116814003:-
LIHC	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-5.35	1.62e-07	7.38e-05	-0.24	-0.28	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-5.35	1.62e-07	7.38e-05	-0.24	-0.28	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-5.35	1.62e-07	7.38e-05	-0.24	-0.28	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
LIHC	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-5.35	1.62e-07	7.39e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
LIHC	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-5.35	1.63e-07	7.4e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
LIHC	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	5.35	1.63e-07	7.4e-05	0.32	0.28	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
LIHC	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-5.35	1.63e-07	7.43e-05	-0.24	-0.28	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
LIHC	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	5.35	1.63e-07	7.43e-05	0.3	0.28	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
LIHC	cis	rs7131987	0.65	rs11050187	ENSG00000275476.1	RP11-996F15.4	-5.35	1.63e-07	7.43e-05	-0.33	-0.28	QT interval;	chr12:29319943	chr12:29277397~29277882:-
LIHC	cis	rs7131987	0.65	rs16934135	ENSG00000275476.1	RP11-996F15.4	-5.35	1.63e-07	7.43e-05	-0.33	-0.28	QT interval;	chr12:29331030	chr12:29277397~29277882:-
LIHC	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-5.35	1.63e-07	7.43e-05	-0.44	-0.28	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
LIHC	cis	rs227275	0.554	rs223467	ENSG00000230069.3	LRRC37A15P	-5.35	1.63e-07	7.44e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102727274~102730721:-
LIHC	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-5.35	1.64e-07	7.44e-05	-0.41	-0.28	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
LIHC	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-5.35	1.64e-07	7.45e-05	-0.35	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
LIHC	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	5.35	1.64e-07	7.45e-05	0.46	0.28	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
LIHC	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	5.35	1.64e-07	7.47e-05	0.32	0.28	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
LIHC	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-5.35	1.64e-07	7.47e-05	-0.42	-0.28	Depression;	chr6:28184805	chr6:28115628~28116551:+
LIHC	cis	rs75920871	0.589	rs4938342	ENSG00000254851.1	RP11-109L13.1	-5.35	1.64e-07	7.47e-05	-0.54	-0.28	Subjective well-being;	chr11:117132704	chr11:117135528~117138582:+
LIHC	cis	rs7916697	1	rs7916697	ENSG00000233590.1	RP11-153K11.3	5.35	1.65e-07	7.48e-05	0.33	0.28	Optic disc area;	chr10:68232096	chr10:68233251~68242379:-
LIHC	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	5.35	1.65e-07	7.48e-05	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
LIHC	cis	rs4731207	0.596	rs9969187	ENSG00000224897.5	POT1-AS1	5.35	1.65e-07	7.5e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125021418	chr7:124929873~125179315:+
LIHC	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	5.35	1.65e-07	7.51e-05	0.34	0.28	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
LIHC	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-5.35	1.65e-07	7.51e-05	-0.25	-0.28	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
LIHC	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-5.35	1.65e-07	7.51e-05	-0.25	-0.28	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
LIHC	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-5.35	1.65e-07	7.51e-05	-0.25	-0.28	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
LIHC	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-5.35	1.65e-07	7.51e-05	-0.25	-0.28	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
LIHC	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-5.35	1.65e-07	7.51e-05	-0.25	-0.28	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
LIHC	cis	rs6480314	0.542	rs10998045	ENSG00000233590.1	RP11-153K11.3	-5.35	1.65e-07	7.51e-05	-0.43	-0.28	Optic nerve measurement (disc area);	chr10:68269626	chr10:68233251~68242379:-
LIHC	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-5.35	1.65e-07	7.51e-05	-0.46	-0.28	Gout;	chr7:66654674	chr7:66654538~66669855:+
LIHC	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-5.35	1.65e-07	7.51e-05	-0.46	-0.28	Gout;	chr7:66661502	chr7:66654538~66669855:+
LIHC	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	5.35	1.65e-07	7.51e-05	0.39	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
LIHC	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-5.35	1.65e-07	7.52e-05	-0.25	-0.28	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
LIHC	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-5.35	1.66e-07	7.52e-05	-0.32	-0.28	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
LIHC	cis	rs6686842	0.965	rs10889792	ENSG00000235358.1	RP11-399E6.1	-5.34	1.66e-07	7.53e-05	-0.31	-0.28	Height;	chr1:41025213	chr1:41242373~41284861:+
LIHC	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-5.34	1.66e-07	7.54e-05	-0.31	-0.28	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
LIHC	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-5.34	1.66e-07	7.54e-05	-0.25	-0.28	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-5.34	1.66e-07	7.54e-05	-0.25	-0.28	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-5.34	1.66e-07	7.54e-05	-0.25	-0.28	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-5.34	1.66e-07	7.54e-05	-0.25	-0.28	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-5.34	1.66e-07	7.54e-05	-0.25	-0.28	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
LIHC	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	5.34	1.66e-07	7.54e-05	0.31	0.28	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
LIHC	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	5.34	1.67e-07	7.56e-05	0.39	0.28	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
LIHC	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-5.34	1.67e-07	7.57e-05	-0.25	-0.28	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
LIHC	cis	rs17301013	0.861	rs333418	ENSG00000227373.4	RP11-160H22.5	5.34	1.67e-07	7.58e-05	0.36	0.28	Systemic lupus erythematosus;	chr1:174707294	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.828	rs332783	ENSG00000227373.4	RP11-160H22.5	5.34	1.67e-07	7.58e-05	0.36	0.28	Systemic lupus erythematosus;	chr1:174719260	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.861	rs170768	ENSG00000227373.4	RP11-160H22.5	5.34	1.67e-07	7.58e-05	0.36	0.28	Systemic lupus erythematosus;	chr1:174720787	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.861	rs332796	ENSG00000227373.4	RP11-160H22.5	5.34	1.67e-07	7.58e-05	0.36	0.28	Systemic lupus erythematosus;	chr1:174727142	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.861	rs332799	ENSG00000227373.4	RP11-160H22.5	5.34	1.67e-07	7.58e-05	0.36	0.28	Systemic lupus erythematosus;	chr1:174731110	chr1:174115300~174160004:-
LIHC	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-5.34	1.67e-07	7.59e-05	-0.27	-0.28	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
LIHC	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	5.34	1.68e-07	7.6e-05	0.34	0.28	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
LIHC	cis	rs3096299	0.503	rs9925045	ENSG00000261118.1	RP11-104N10.1	5.34	1.68e-07	7.6e-05	0.28	0.28	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89492017~89504460:-
LIHC	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	5.34	1.68e-07	7.62e-05	0.21	0.28	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
LIHC	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	5.34	1.68e-07	7.62e-05	0.26	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
LIHC	cis	rs3096299	0.679	rs3096322	ENSG00000261118.1	RP11-104N10.1	-5.34	1.68e-07	7.63e-05	-0.28	-0.28	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89492017~89504460:-
LIHC	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-5.34	1.68e-07	7.63e-05	-0.34	-0.28	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
LIHC	cis	rs739496	0.947	rs2283358	ENSG00000226469.1	ADAM1B	5.34	1.69e-07	7.65e-05	0.34	0.28	Platelet count;	chr12:111427761	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.947	rs2285520	ENSG00000226469.1	ADAM1B	5.34	1.69e-07	7.65e-05	0.34	0.28	Platelet count;	chr12:111429683	chr12:111927018~111929017:+
LIHC	cis	rs2735413	0.918	rs12918959	ENSG00000276007.1	RP11-358L22.3	-5.34	1.69e-07	7.65e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78047822	chr16:78123243~78124332:+
LIHC	cis	rs684603	1	rs684603	ENSG00000246174.6	KCTD21-AS1	-5.34	1.69e-07	7.65e-05	-0.35	-0.28	Number of common colds;	chr11:78102803	chr11:78139771~78175323:+
LIHC	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	5.34	1.69e-07	7.66e-05	0.33	0.28	Height;	chr6:109332929	chr6:109382795~109383666:+
LIHC	cis	rs12744310	0.502	rs2364531	ENSG00000235358.1	RP11-399E6.1	5.34	1.7e-07	7.67e-05	0.32	0.28	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41338544	chr1:41242373~41284861:+
LIHC	cis	rs4660456	0.529	rs61779237	ENSG00000237899.1	RP4-739H11.3	5.34	1.7e-07	7.68e-05	0.35	0.28	Platelet count;	chr1:40685300	chr1:40669089~40687588:-
LIHC	cis	rs2032366	0.606	rs7226896	ENSG00000267279.1	RP11-879F14.2	-5.34	1.7e-07	7.69e-05	-0.33	-0.28	Obesity-related traits;	chr18:61608946	chr18:61585746~61606916:-
LIHC	cis	rs4731207	0.596	rs12535807	ENSG00000224897.5	POT1-AS1	5.34	1.7e-07	7.69e-05	0.33	0.28	Cutaneous malignant melanoma;	chr7:124951379	chr7:124929873~125179315:+
LIHC	cis	rs638893	0.853	rs4938549	ENSG00000255422.1	AP002954.4	-5.34	1.7e-07	7.69e-05	-0.46	-0.28	Vitiligo;	chr11:118830888	chr11:118704607~118750263:+
LIHC	cis	rs638893	0.898	rs530646	ENSG00000255422.1	AP002954.4	-5.34	1.7e-07	7.69e-05	-0.46	-0.28	Vitiligo;	chr11:118830959	chr11:118704607~118750263:+
LIHC	cis	rs638893	0.947	rs12808822	ENSG00000255422.1	AP002954.4	-5.34	1.7e-07	7.69e-05	-0.46	-0.28	Vitiligo;	chr11:118831560	chr11:118704607~118750263:+
LIHC	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-5.34	1.7e-07	7.69e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-5.34	1.7e-07	7.69e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-5.34	1.7e-07	7.69e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-5.34	1.7e-07	7.69e-05	-0.47	-0.28	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	5.34	1.71e-07	7.71e-05	0.24	0.28	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
LIHC	cis	rs2735413	0.67	rs11861339	ENSG00000276007.1	RP11-358L22.3	5.34	1.71e-07	7.71e-05	0.37	0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78060493	chr16:78123243~78124332:+
LIHC	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	5.34	1.71e-07	7.72e-05	0.42	0.28	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
LIHC	cis	rs4731207	0.596	rs1600737	ENSG00000224897.5	POT1-AS1	5.34	1.71e-07	7.72e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:124999493	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.57	rs1600738	ENSG00000224897.5	POT1-AS1	5.34	1.71e-07	7.72e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:124999495	chr7:124929873~125179315:+
LIHC	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-5.34	1.71e-07	7.72e-05	-0.35	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
LIHC	cis	rs6480314	0.542	rs17297383	ENSG00000233590.1	RP11-153K11.3	-5.34	1.71e-07	7.73e-05	-0.42	-0.28	Optic nerve measurement (disc area);	chr10:68269106	chr10:68233251~68242379:-
LIHC	cis	rs7176527	0.579	rs366717	ENSG00000189136.7	UBE2Q2P1	-5.34	1.71e-07	7.74e-05	-0.24	-0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84526781~84571216:-
LIHC	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	5.34	1.72e-07	7.74e-05	0.45	0.28	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
LIHC	cis	rs739496	0.895	rs7965040	ENSG00000226469.1	ADAM1B	5.34	1.72e-07	7.77e-05	0.33	0.28	Platelet count;	chr12:111482491	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.947	rs6490162	ENSG00000226469.1	ADAM1B	5.34	1.72e-07	7.77e-05	0.33	0.28	Platelet count;	chr12:111503316	chr12:111927018~111929017:+
LIHC	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	5.34	1.72e-07	7.78e-05	0.42	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	5.34	1.72e-07	7.78e-05	0.42	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
LIHC	cis	rs6085948	1	rs4815987	ENSG00000238102.1	RP11-19D2.1	5.34	1.72e-07	7.78e-05	0.4	0.28	Interleukin-10 levels;	chr20:7259968	chr20:7256580~7258214:-
LIHC	cis	rs6085948	0.953	rs6117725	ENSG00000238102.1	RP11-19D2.1	5.34	1.72e-07	7.78e-05	0.4	0.28	Interleukin-10 levels;	chr20:7262362	chr20:7256580~7258214:-
LIHC	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-5.34	1.73e-07	7.78e-05	-0.31	-0.28	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
LIHC	cis	rs2735413	0.881	rs12921945	ENSG00000276007.1	RP11-358L22.3	-5.34	1.73e-07	7.78e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046236	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.846	rs12923626	ENSG00000276007.1	RP11-358L22.3	-5.34	1.73e-07	7.78e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046242	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.881	rs12927515	ENSG00000276007.1	RP11-358L22.3	-5.34	1.73e-07	7.78e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78046244	chr16:78123243~78124332:+
LIHC	cis	rs7474896	0.616	rs2474561	ENSG00000263064.2	RP11-291L22.7	5.34	1.73e-07	7.79e-05	0.33	0.28	Obesity (extreme);	chr10:38084616	chr10:38448689~38448949:+
LIHC	cis	rs7529073	0.545	rs1431985	ENSG00000274895.1	RP11-478J18.2	-5.34	1.73e-07	7.79e-05	-0.3	-0.28	Schizophrenia;	chr1:213974903	chr1:213983793~213986419:-
LIHC	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-5.34	1.73e-07	7.8e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-5.34	1.73e-07	7.8e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-5.34	1.73e-07	7.8e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
LIHC	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-5.34	1.74e-07	7.82e-05	-0.41	-0.28	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
LIHC	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	5.34	1.74e-07	7.83e-05	0.33	0.28	Height;	chr6:109506513	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	5.34	1.74e-07	7.83e-05	0.33	0.28	Height;	chr6:109503623	chr6:109382795~109383666:+
LIHC	cis	rs9291683	0.53	rs17246501	ENSG00000250413.1	RP11-448G15.1	-5.34	1.74e-07	7.84e-05	-0.36	-0.28	Bone mineral density;	chr4:9984086	chr4:10006482~10009725:+
LIHC	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	5.33	1.74e-07	7.85e-05	0.26	0.28	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
LIHC	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	5.33	1.75e-07	7.88e-05	0.39	0.28	Height;	chr6:109373851	chr6:109382795~109383666:+
LIHC	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-5.33	1.75e-07	7.88e-05	-0.29	-0.28	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
LIHC	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-5.33	1.75e-07	7.9e-05	-0.31	-0.28	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
LIHC	cis	rs4731207	0.596	rs3903522	ENSG00000224897.5	POT1-AS1	5.33	1.75e-07	7.9e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125028088	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.535	rs1351471	ENSG00000224897.5	POT1-AS1	5.33	1.75e-07	7.9e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125031961	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1871774	ENSG00000224897.5	POT1-AS1	5.33	1.75e-07	7.9e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125034844	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1871773	ENSG00000224897.5	POT1-AS1	5.33	1.75e-07	7.9e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125034885	chr7:124929873~125179315:+
LIHC	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	5.33	1.75e-07	7.9e-05	0.43	0.28	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
LIHC	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	5.33	1.76e-07	7.9e-05	0.45	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
LIHC	cis	rs12571093	0.773	rs10762197	ENSG00000233590.1	RP11-153K11.3	5.33	1.76e-07	7.91e-05	0.43	0.28	Optic nerve measurement (disc area);	chr10:68249498	chr10:68233251~68242379:-
LIHC	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-5.33	1.76e-07	7.93e-05	-0.31	-0.28	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
LIHC	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	5.33	1.76e-07	7.94e-05	0.32	0.28	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
LIHC	cis	rs1577917	0.771	rs7742201	ENSG00000234155.1	RP11-30P6.6	5.33	1.77e-07	7.95e-05	0.35	0.28	Response to antipsychotic treatment;	chr6:85723212	chr6:85387219~85390186:-
LIHC	cis	rs4356203	0.905	rs214940	ENSG00000272034.1	SNORD14A	-5.33	1.77e-07	7.95e-05	-0.3	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165308	chr11:17074654~17074744:-
LIHC	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-5.33	1.77e-07	7.96e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-5.33	1.77e-07	7.96e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-5.33	1.77e-07	7.96e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-5.33	1.77e-07	7.96e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-5.33	1.77e-07	7.96e-05	-0.46	-0.28	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
LIHC	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	5.33	1.77e-07	7.96e-05	0.37	0.28	Depression;	chr6:28391932	chr6:28176188~28176674:+
LIHC	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-5.33	1.77e-07	7.96e-05	-0.25	-0.28	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
LIHC	cis	rs4731207	0.596	rs12534466	ENSG00000224897.5	POT1-AS1	5.33	1.77e-07	7.97e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125028369	chr7:124929873~125179315:+
LIHC	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	5.33	1.77e-07	7.97e-05	0.3	0.28	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
LIHC	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	5.33	1.78e-07	7.98e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
LIHC	cis	rs5758511	0.68	rs1033459	ENSG00000237037.8	NDUFA6-AS1	-5.33	1.78e-07	7.99e-05	-0.35	-0.28	Birth weight;	chr22:42223061	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.68	rs1033460	ENSG00000237037.8	NDUFA6-AS1	-5.33	1.78e-07	7.99e-05	-0.35	-0.28	Birth weight;	chr22:42223302	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.679	rs55867855	ENSG00000237037.8	NDUFA6-AS1	-5.33	1.78e-07	7.99e-05	-0.35	-0.28	Birth weight;	chr22:42227252	chr22:42090931~42137742:+
LIHC	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	5.33	1.78e-07	7.99e-05	0.29	0.28	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
LIHC	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-5.33	1.78e-07	7.99e-05	-0.34	-0.28	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-5.33	1.78e-07	7.99e-05	-0.34	-0.28	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
LIHC	cis	rs4731207	0.596	rs2219953	ENSG00000224897.5	POT1-AS1	5.33	1.78e-07	8e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125031861	chr7:124929873~125179315:+
LIHC	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-5.33	1.78e-07	8e-05	-0.37	-0.28	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
LIHC	cis	rs56205728	0.546	rs62021888	ENSG00000273855.1	RP11-133K1.12	-5.33	1.78e-07	8e-05	-0.38	-0.28	Schizophrenia;	chr15:40291359	chr15:40285468~40285909:-
LIHC	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-5.33	1.78e-07	8e-05	-0.46	-0.28	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
LIHC	cis	rs227275	0.525	rs17215211	ENSG00000230069.3	LRRC37A15P	-5.33	1.78e-07	8.01e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102727274~102730721:-
LIHC	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	5.33	1.78e-07	8.01e-05	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
LIHC	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	5.33	1.78e-07	8.01e-05	0.5	0.28	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
LIHC	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-5.33	1.79e-07	8.03e-05	-0.25	-0.28	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
LIHC	cis	rs2072510	0.569	rs7970524	ENSG00000257715.1	RP11-256L6.2	-5.33	1.79e-07	8.03e-05	-0.4	-0.28	Metabolite levels (small molecules and protein measures);	chr12:95996374	chr12:96025323~96027971:+
LIHC	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	5.33	1.79e-07	8.03e-05	0.44	0.28	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
LIHC	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	5.33	1.79e-07	8.03e-05	0.33	0.28	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
LIHC	cis	rs227275	0.525	rs1080081	ENSG00000230069.3	LRRC37A15P	-5.33	1.79e-07	8.05e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs4699049	ENSG00000230069.3	LRRC37A15P	-5.33	1.79e-07	8.05e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102727274~102730721:-
LIHC	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-5.33	1.79e-07	8.05e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-5.33	1.79e-07	8.05e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
LIHC	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-5.33	1.8e-07	8.08e-05	-0.34	-0.28	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
LIHC	cis	rs5769707	0.837	rs5769709	ENSG00000235111.1	RP1-29C18.8	-5.33	1.8e-07	8.09e-05	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49612657~49615716:-
LIHC	cis	rs17711722	0.528	rs73138179	ENSG00000226002.1	RP11-460N20.5	5.33	1.8e-07	8.09e-05	0.29	0.28	Calcium levels;	chr7:65829495	chr7:65084103~65100232:+
LIHC	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-5.33	1.81e-07	8.11e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-5.33	1.81e-07	8.11e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-5.33	1.81e-07	8.11e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
LIHC	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-5.33	1.81e-07	8.11e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-5.33	1.81e-07	8.11e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-5.33	1.81e-07	8.11e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
LIHC	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-5.33	1.81e-07	8.11e-05	-0.28	-0.28	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
LIHC	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	5.33	1.81e-07	8.11e-05	0.34	0.28	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-5.33	1.81e-07	8.11e-05	-0.34	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
LIHC	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	5.33	1.81e-07	8.11e-05	0.26	0.28	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	5.33	1.81e-07	8.11e-05	0.26	0.28	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	5.33	1.81e-07	8.11e-05	0.26	0.28	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	5.33	1.81e-07	8.11e-05	0.26	0.28	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
LIHC	cis	rs4934494	0.727	rs67827533	ENSG00000232936.4	RP11-80H5.2	5.33	1.81e-07	8.12e-05	0.35	0.28	Red blood cell count;	chr10:89745626	chr10:89645282~89650667:+
LIHC	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-5.33	1.81e-07	8.13e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-5.33	1.81e-07	8.13e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
LIHC	cis	rs6439153	0.55	rs789223	ENSG00000231305.3	RP11-723O4.2	5.33	1.81e-07	8.13e-05	0.31	0.28	Pneumococcal bacteremia;	chr3:128952303	chr3:128861313~128871540:-
LIHC	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	5.33	1.81e-07	8.13e-05	0.31	0.28	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
LIHC	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-5.33	1.82e-07	8.15e-05	-0.29	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
LIHC	cis	rs5769707	0.837	rs1573726	ENSG00000235111.1	RP1-29C18.8	-5.33	1.82e-07	8.16e-05	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49612657~49615716:-
LIHC	cis	rs9326248	0.53	rs236918	ENSG00000280143.1	AP000892.6	-5.33	1.82e-07	8.16e-05	-0.36	-0.28	Blood protein levels;	chr11:117220893	chr11:117204967~117210292:+
LIHC	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-5.33	1.82e-07	8.17e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
LIHC	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-5.33	1.82e-07	8.17e-05	-0.35	-0.28	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-5.33	1.82e-07	8.17e-05	-0.35	-0.28	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-5.33	1.82e-07	8.17e-05	-0.35	-0.28	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-5.33	1.82e-07	8.17e-05	-0.35	-0.28	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-5.33	1.82e-07	8.17e-05	-0.35	-0.28	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-5.33	1.82e-07	8.17e-05	-0.35	-0.28	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-5.33	1.82e-07	8.17e-05	-0.35	-0.28	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
LIHC	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-5.33	1.82e-07	8.17e-05	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
LIHC	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	5.33	1.82e-07	8.17e-05	0.47	0.28	Height;	chr6:109548647	chr6:109382795~109383666:+
LIHC	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	5.33	1.82e-07	8.17e-05	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
LIHC	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-5.33	1.83e-07	8.18e-05	-0.35	-0.28	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
LIHC	cis	rs2877649	0.793	rs77165598	ENSG00000258744.1	RP11-80A15.1	-5.33	1.83e-07	8.19e-05	-0.56	-0.28	Smooth-surface caries;	chr14:24458813	chr14:24501594~24508688:+
LIHC	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	5.33	1.83e-07	8.2e-05	0.32	0.28	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	5.33	1.83e-07	8.21e-05	0.32	0.28	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
LIHC	cis	rs7131987	0.903	rs10843367	ENSG00000257176.2	RP11-996F15.2	-5.32	1.83e-07	8.21e-05	-0.32	-0.28	QT interval;	chr12:29255447	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.903	rs7302129	ENSG00000257176.2	RP11-996F15.2	-5.32	1.83e-07	8.21e-05	-0.32	-0.28	QT interval;	chr12:29262347	chr12:29280418~29317848:-
LIHC	cis	rs1322639	0.571	rs13204417	ENSG00000261039.2	RP11-417E7.2	5.32	1.83e-07	8.21e-05	0.29	0.28	Pulse pressure;	chr6:169175260	chr6:169175304~169182740:-
LIHC	cis	rs860295	0.812	rs4278368	ENSG00000203761.5	MSTO2P	-5.32	1.83e-07	8.21e-05	-0.22	-0.28	Body mass index;	chr1:155752766	chr1:155745829~155750137:+
LIHC	cis	rs5758511	0.68	rs5758684	ENSG00000237037.8	NDUFA6-AS1	-5.32	1.83e-07	8.21e-05	-0.35	-0.28	Birth weight;	chr22:42253503	chr22:42090931~42137742:+
LIHC	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-5.32	1.84e-07	8.22e-05	-0.35	-0.28	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
LIHC	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	5.32	1.84e-07	8.22e-05	0.28	0.28	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
LIHC	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	5.32	1.84e-07	8.23e-05	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
LIHC	cis	rs228614	0.536	rs223477	ENSG00000230069.3	LRRC37A15P	-5.32	1.84e-07	8.24e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs65671	ENSG00000230069.3	LRRC37A15P	-5.32	1.84e-07	8.24e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102727274~102730721:-
LIHC	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	5.32	1.84e-07	8.24e-05	0.35	0.28	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
LIHC	cis	rs6480314	0.542	rs10998046	ENSG00000233590.1	RP11-153K11.3	-5.32	1.84e-07	8.24e-05	-0.42	-0.28	Optic nerve measurement (disc area);	chr10:68269641	chr10:68233251~68242379:-
LIHC	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-5.32	1.84e-07	8.25e-05	-0.35	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
LIHC	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	5.32	1.84e-07	8.25e-05	0.4	0.28	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
LIHC	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	5.32	1.84e-07	8.25e-05	0.4	0.28	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
LIHC	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-5.32	1.84e-07	8.26e-05	-0.34	-0.28	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
LIHC	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	5.32	1.85e-07	8.26e-05	0.22	0.28	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
LIHC	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	5.32	1.85e-07	8.26e-05	0.24	0.28	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
LIHC	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-5.32	1.85e-07	8.27e-05	-0.34	-0.28	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
LIHC	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	5.32	1.85e-07	8.29e-05	0.33	0.28	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
LIHC	cis	rs4731207	0.698	rs6945104	ENSG00000224897.5	POT1-AS1	5.32	1.86e-07	8.3e-05	0.33	0.28	Cutaneous malignant melanoma;	chr7:124917861	chr7:124929873~125179315:+
LIHC	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	5.32	1.86e-07	8.3e-05	0.36	0.28	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
LIHC	cis	rs8028182	0.549	rs11072542	ENSG00000260269.4	CTD-2323K18.1	5.32	1.86e-07	8.31e-05	0.36	0.28	Sudden cardiac arrest;	chr15:75342258	chr15:75527150~75601205:-
LIHC	cis	rs6085948	0.861	rs11907461	ENSG00000228888.1	LINC01428	-5.32	1.86e-07	8.32e-05	-0.48	-0.28	Interleukin-10 levels;	chr20:7251766	chr20:7146467~7254202:-
LIHC	cis	rs2274273	0.588	rs7145727	ENSG00000258413.1	RP11-665C16.6	-5.32	1.86e-07	8.33e-05	-0.33	-0.28	Protein biomarker;	chr14:55380855	chr14:55262767~55272075:-
LIHC	cis	rs2522056	1	rs2522050	ENSG00000233006.5	AC034220.3	-5.32	1.86e-07	8.33e-05	-0.29	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132460917	chr5:132311285~132369916:-
LIHC	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-5.32	1.87e-07	8.37e-05	-0.31	-0.28	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
LIHC	cis	rs2933343	0.7	rs883602	ENSG00000231305.3	RP11-723O4.2	5.32	1.87e-07	8.37e-05	0.3	0.28	IgG glycosylation;	chr3:128935109	chr3:128861313~128871540:-
LIHC	cis	rs1499614	1	rs34250985	ENSG00000273142.1	RP11-458F8.4	-5.32	1.88e-07	8.38e-05	-0.37	-0.28	Gout;	chr7:66696075	chr7:66902857~66906297:+
LIHC	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	5.32	1.88e-07	8.39e-05	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
LIHC	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-5.32	1.88e-07	8.4e-05	-0.36	-0.28	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
LIHC	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-5.32	1.88e-07	8.4e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-5.32	1.88e-07	8.4e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
LIHC	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-5.32	1.89e-07	8.42e-05	-0.45	-0.28	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-5.32	1.89e-07	8.42e-05	-0.45	-0.28	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-5.32	1.89e-07	8.42e-05	-0.45	-0.28	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-5.32	1.89e-07	8.42e-05	-0.45	-0.28	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
LIHC	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	5.32	1.89e-07	8.43e-05	0.31	0.28	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
LIHC	cis	rs4731207	0.596	rs1994024	ENSG00000224897.5	POT1-AS1	5.32	1.89e-07	8.43e-05	0.33	0.28	Cutaneous malignant melanoma;	chr7:125020791	chr7:124929873~125179315:+
LIHC	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	5.32	1.89e-07	8.45e-05	0.32	0.28	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
LIHC	cis	rs950169	0.84	rs62029595	ENSG00000259295.5	CSPG4P12	5.32	1.89e-07	8.45e-05	0.38	0.28	Schizophrenia;	chr15:84400603	chr15:85191438~85213905:+
LIHC	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	5.32	1.9e-07	8.46e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
LIHC	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	5.32	1.9e-07	8.47e-05	0.31	0.28	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
LIHC	cis	rs2933343	0.7	rs2624910	ENSG00000231305.3	RP11-723O4.2	5.32	1.9e-07	8.47e-05	0.3	0.28	IgG glycosylation;	chr3:128931432	chr3:128861313~128871540:-
LIHC	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-5.32	1.9e-07	8.48e-05	-0.25	-0.28	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-5.32	1.9e-07	8.48e-05	-0.36	-0.28	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
LIHC	cis	rs5758511	0.68	rs58654759	ENSG00000237037.8	NDUFA6-AS1	-5.32	1.9e-07	8.49e-05	-0.35	-0.28	Birth weight;	chr22:42246570	chr22:42090931~42137742:+
LIHC	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	5.32	1.9e-07	8.49e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
LIHC	cis	rs11647589	0.784	rs1700804	ENSG00000262995.1	CTD-2194A8.2	5.32	1.91e-07	8.5e-05	0.26	0.28	Blood metabolite levels;	chr16:20477047	chr16:20440266~20447000:-
LIHC	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-5.32	1.91e-07	8.51e-05	-0.35	-0.28	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
LIHC	cis	rs9527	0.662	rs10883783	ENSG00000236937.2	PTGES3P4	5.32	1.91e-07	8.52e-05	0.38	0.28	Arsenic metabolism;	chr10:102831395	chr10:102845595~102845950:+
LIHC	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-5.32	1.91e-07	8.53e-05	-0.32	-0.28	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
LIHC	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-5.32	1.91e-07	8.53e-05	-0.32	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
LIHC	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	5.32	1.91e-07	8.53e-05	0.32	0.28	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
LIHC	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-5.32	1.91e-07	8.53e-05	-0.45	-0.28	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
LIHC	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-5.32	1.92e-07	8.54e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
LIHC	cis	rs7916410	0.512	rs61854783	ENSG00000233590.1	RP11-153K11.3	-5.32	1.92e-07	8.55e-05	-0.43	-0.28	Optic disc area;	chr10:68236307	chr10:68233251~68242379:-
LIHC	cis	rs831571	0.55	rs153734	ENSG00000280620.1	SCAANT1	5.32	1.93e-07	8.59e-05	0.37	0.28	Type 2 diabetes;	chr3:64092333	chr3:63911518~63911772:-
LIHC	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-5.32	1.93e-07	8.59e-05	-0.25	-0.28	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
LIHC	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	5.31	1.93e-07	8.59e-05	0.36	0.28	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
LIHC	cis	rs5769765	0.908	rs138880	ENSG00000278869.1	CITF22-49E9.3	5.31	1.93e-07	8.6e-05	0.44	0.28	Schizophrenia;	chr22:49824963	chr22:49933198~49934074:-
LIHC	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	5.31	1.93e-07	8.6e-05	0.3	0.28	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
LIHC	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-5.31	1.93e-07	8.6e-05	-0.25	-0.28	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
LIHC	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	5.31	1.93e-07	8.61e-05	0.3	0.28	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	5.31	1.93e-07	8.61e-05	0.3	0.28	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	5.31	1.93e-07	8.61e-05	0.3	0.28	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	5.31	1.93e-07	8.61e-05	0.3	0.28	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	5.31	1.93e-07	8.61e-05	0.3	0.28	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
LIHC	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-5.31	1.93e-07	8.61e-05	-0.35	-0.28	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-5.31	1.93e-07	8.61e-05	-0.35	-0.28	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-5.31	1.93e-07	8.61e-05	-0.35	-0.28	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-5.31	1.93e-07	8.61e-05	-0.35	-0.28	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-5.31	1.93e-07	8.61e-05	-0.35	-0.28	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
LIHC	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-5.31	1.93e-07	8.61e-05	-0.35	-0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-5.31	1.93e-07	8.61e-05	-0.35	-0.28	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
LIHC	cis	rs7714584	1	rs7724558	ENSG00000197083.10	ZNF300P1	5.31	1.93e-07	8.61e-05	0.44	0.28	Crohn's disease;	chr5:150949304	chr5:150930645~150946289:-
LIHC	cis	rs10510102	0.935	rs12245528	ENSG00000226864.1	ATE1-AS1	-5.31	1.94e-07	8.61e-05	-0.45	-0.28	Breast cancer;	chr10:121881006	chr10:121928312~121951965:+
LIHC	cis	rs4731207	0.57	rs2086505	ENSG00000224897.5	POT1-AS1	5.31	1.94e-07	8.62e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125024103	chr7:124929873~125179315:+
LIHC	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	5.31	1.94e-07	8.62e-05	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
LIHC	cis	rs496547	0.654	rs688161	ENSG00000255422.1	AP002954.4	-5.31	1.94e-07	8.63e-05	-0.31	-0.28	Hip minimal joint space width;	chr11:118807001	chr11:118704607~118750263:+
LIHC	cis	rs4356203	0.905	rs11024159	ENSG00000272034.1	SNORD14A	-5.31	1.94e-07	8.64e-05	-0.3	-0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105795	chr11:17074654~17074744:-
LIHC	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-5.31	1.94e-07	8.64e-05	-0.25	-0.28	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
LIHC	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	5.31	1.94e-07	8.64e-05	0.27	0.28	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
LIHC	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-5.31	1.94e-07	8.65e-05	-0.34	-0.28	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-5.31	1.94e-07	8.65e-05	-0.34	-0.28	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
LIHC	cis	rs227275	0.554	rs223399	ENSG00000230069.3	LRRC37A15P	-5.31	1.95e-07	8.65e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102727274~102730721:-
LIHC	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	5.31	1.95e-07	8.65e-05	0.3	0.28	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	5.31	1.95e-07	8.65e-05	0.3	0.28	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	5.31	1.95e-07	8.65e-05	0.3	0.28	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	5.31	1.95e-07	8.65e-05	0.3	0.28	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	5.31	1.95e-07	8.65e-05	0.3	0.28	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
LIHC	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	5.31	1.95e-07	8.66e-05	0.31	0.28	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
LIHC	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	5.31	1.95e-07	8.66e-05	0.29	0.28	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
LIHC	cis	rs2998286	0.862	rs2807763	ENSG00000254635.4	WAC-AS1	5.31	1.95e-07	8.66e-05	0.34	0.28	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528702	chr10:28522652~28532743:-
LIHC	cis	rs4731207	0.596	rs6945951	ENSG00000224897.5	POT1-AS1	5.31	1.95e-07	8.67e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125027146	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs3900363	ENSG00000224897.5	POT1-AS1	5.31	1.95e-07	8.67e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125027907	chr7:124929873~125179315:+
LIHC	cis	rs2267708	0.504	rs3903523	ENSG00000224897.5	POT1-AS1	5.31	1.95e-07	8.67e-05	0.34	0.28	Chronic lymphocytic leukemia;	chr7:125027978	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs3903521	ENSG00000224897.5	POT1-AS1	5.31	1.95e-07	8.67e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125028130	chr7:124929873~125179315:+
LIHC	cis	rs10510102	0.935	rs4627017	ENSG00000226864.1	ATE1-AS1	5.31	1.95e-07	8.67e-05	0.44	0.28	Breast cancer;	chr10:121901878	chr10:121928312~121951965:+
LIHC	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-5.31	1.95e-07	8.69e-05	-0.26	-0.28	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	5.31	1.96e-07	8.7e-05	0.26	0.28	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
LIHC	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-5.31	1.96e-07	8.7e-05	-0.35	-0.28	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-5.31	1.96e-07	8.7e-05	-0.35	-0.28	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-5.31	1.96e-07	8.7e-05	-0.35	-0.28	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-5.31	1.96e-07	8.7e-05	-0.35	-0.28	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
LIHC	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-5.31	1.96e-07	8.7e-05	-0.34	-0.28	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
LIHC	cis	rs2243480	0.522	rs1638736	ENSG00000273142.1	RP11-458F8.4	-5.31	1.96e-07	8.71e-05	-0.37	-0.28	Diabetic kidney disease;	chr7:66627321	chr7:66902857~66906297:+
LIHC	cis	rs2735413	0.918	rs1922621	ENSG00000276007.1	RP11-358L22.3	-5.31	1.96e-07	8.71e-05	-0.3	-0.28	Systolic blood pressure (alcohol consumption interaction);	chr16:78041118	chr16:78123243~78124332:+
LIHC	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	5.31	1.96e-07	8.72e-05	0.41	0.28	Depression;	chr6:28187640	chr6:28115628~28116551:+
LIHC	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	5.31	1.97e-07	8.73e-05	0.34	0.28	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
LIHC	cis	rs2933343	0.7	rs6787833	ENSG00000231305.3	RP11-723O4.2	5.31	1.97e-07	8.75e-05	0.3	0.28	IgG glycosylation;	chr3:128937341	chr3:128861313~128871540:-
LIHC	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-5.31	1.97e-07	8.76e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.556	rs11731885	ENSG00000230069.3	LRRC37A15P	-5.31	1.97e-07	8.76e-05	-0.25	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102727274~102730721:-
LIHC	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	5.31	1.98e-07	8.77e-05	0.58	0.28	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
LIHC	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	5.31	1.98e-07	8.78e-05	0.33	0.28	Height;	chr6:109424122	chr6:109382795~109383666:+
LIHC	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-5.31	1.98e-07	8.8e-05	-0.32	-0.28	Height;	chr2:46640019	chr2:46668870~46670778:+
LIHC	cis	rs4538475	0.556	rs4263397	ENSG00000214846.4	RP11-115L11.1	-5.31	1.98e-07	8.8e-05	-0.34	-0.28	Parkinson's disease;	chr4:15737767	chr4:15730962~15731627:-
LIHC	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	5.31	1.98e-07	8.8e-05	0.41	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
LIHC	cis	rs228614	0.51	rs223358	ENSG00000230069.3	LRRC37A15P	-5.31	1.98e-07	8.8e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102727274~102730721:-
LIHC	cis	rs5758511	0.68	rs5758681	ENSG00000237037.8	NDUFA6-AS1	-5.31	1.98e-07	8.8e-05	-0.34	-0.28	Birth weight;	chr22:42249085	chr22:42090931~42137742:+
LIHC	cis	rs7131987	0.621	rs11050181	ENSG00000275476.1	RP11-996F15.4	-5.31	1.98e-07	8.8e-05	-0.32	-0.28	QT interval;	chr12:29314736	chr12:29277397~29277882:-
LIHC	cis	rs5769765	1	rs1033665	ENSG00000278869.1	CITF22-49E9.3	5.31	1.98e-07	8.8e-05	0.41	0.28	Schizophrenia;	chr22:49858479	chr22:49933198~49934074:-
LIHC	cis	rs4731207	0.596	rs1600739	ENSG00000224897.5	POT1-AS1	-5.31	1.98e-07	8.8e-05	-0.34	-0.28	Cutaneous malignant melanoma;	chr7:124999552	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.57	rs7784614	ENSG00000224897.5	POT1-AS1	5.31	1.99e-07	8.81e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125037137	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466987	ENSG00000224897.5	POT1-AS1	5.31	1.99e-07	8.81e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125037677	chr7:124929873~125179315:+
LIHC	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-5.31	1.99e-07	8.81e-05	-0.43	-0.28	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
LIHC	cis	rs7131987	0.621	rs57803026	ENSG00000275476.1	RP11-996F15.4	-5.31	2e-07	8.85e-05	-0.33	-0.28	QT interval;	chr12:29344573	chr12:29277397~29277882:-
LIHC	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	5.31	2e-07	8.85e-05	0.35	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
LIHC	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	5.31	2e-07	8.86e-05	0.31	0.28	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
LIHC	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-5.31	2e-07	8.88e-05	-0.33	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
LIHC	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-5.31	2e-07	8.88e-05	-0.41	-0.28	Depression;	chr6:28201380	chr6:28115628~28116551:+
LIHC	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	5.31	2e-07	8.88e-05	0.32	0.28	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	5.31	2.01e-07	8.89e-05	0.37	0.28	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
LIHC	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-5.31	2.01e-07	8.91e-05	-0.31	-0.28	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
LIHC	cis	rs4731207	0.591	rs9691875	ENSG00000224897.5	POT1-AS1	5.31	2.01e-07	8.92e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125035651	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs13234368	ENSG00000224897.5	POT1-AS1	5.31	2.01e-07	8.92e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125036000	chr7:124929873~125179315:+
LIHC	cis	rs7209700	0.547	rs8078614	ENSG00000228782.6	CTD-2026D20.3	-5.31	2.02e-07	8.92e-05	-0.35	-0.28	IgG glycosylation;	chr17:47274139	chr17:47450568~47492492:-
LIHC	cis	rs1005277	0.683	rs7923868	ENSG00000263064.2	RP11-291L22.7	5.31	2.02e-07	8.93e-05	0.29	0.28	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38448689~38448949:+
LIHC	cis	rs4731207	0.596	rs9641759	ENSG00000224897.5	POT1-AS1	5.31	2.02e-07	8.93e-05	0.34	0.28	Cutaneous malignant melanoma;	chr7:125026156	chr7:124929873~125179315:+
LIHC	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	5.31	2.02e-07	8.94e-05	0.31	0.28	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
LIHC	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	5.31	2.02e-07	8.95e-05	0.38	0.28	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
LIHC	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	5.31	2.02e-07	8.95e-05	0.45	0.28	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
LIHC	cis	rs6480314	0.522	rs17231602	ENSG00000233590.1	RP11-153K11.3	-5.31	2.03e-07	8.96e-05	-0.44	-0.28	Optic nerve measurement (disc area);	chr10:68252532	chr10:68233251~68242379:-
LIHC	cis	rs10510102	0.935	rs12240893	ENSG00000226864.1	ATE1-AS1	5.31	2.03e-07	8.97e-05	0.45	0.28	Breast cancer;	chr10:121870572	chr10:121928312~121951965:+
LIHC	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	5.3	2.03e-07	8.98e-05	0.37	0.28	Depression;	chr6:28428413	chr6:28176188~28176674:+
LIHC	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	5.3	2.03e-07	8.98e-05	0.37	0.28	Depression;	chr6:28430971	chr6:28176188~28176674:+
LIHC	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	5.3	2.03e-07	8.98e-05	0.37	0.28	Depression;	chr6:28431469	chr6:28176188~28176674:+
LIHC	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	5.3	2.03e-07	8.98e-05	0.37	0.28	Depression;	chr6:28432562	chr6:28176188~28176674:+
LIHC	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-5.3	2.04e-07	9e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
LIHC	cis	rs7209700	0.644	rs7214468	ENSG00000228782.6	CTD-2026D20.3	-5.3	2.04e-07	9.01e-05	-0.31	-0.28	IgG glycosylation;	chr17:47293400	chr17:47450568~47492492:-
LIHC	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-5.3	2.04e-07	9.03e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
LIHC	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	5.3	2.04e-07	9.03e-05	0.3	0.28	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
LIHC	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	5.3	2.05e-07	9.05e-05	0.32	0.28	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
LIHC	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-5.3	2.05e-07	9.05e-05	-0.32	-0.28	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
LIHC	cis	rs603446	1	rs603446	ENSG00000254851.1	RP11-109L13.1	-5.3	2.05e-07	9.06e-05	-0.33	-0.28	Triglycerides;	chr11:116783719	chr11:117135528~117138582:+
LIHC	cis	rs2933343	0.672	rs1872545	ENSG00000231305.3	RP11-723O4.2	5.3	2.05e-07	9.06e-05	0.3	0.28	IgG glycosylation;	chr3:128926196	chr3:128861313~128871540:-
LIHC	cis	rs3096299	0.692	rs4785565	ENSG00000261118.1	RP11-104N10.1	5.3	2.05e-07	9.07e-05	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89492017~89504460:-
LIHC	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-5.3	2.05e-07	9.08e-05	-0.44	-0.28	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
LIHC	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	5.3	2.05e-07	9.08e-05	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
LIHC	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.3	2.06e-07	9.08e-05	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
LIHC	cis	rs228614	0.51	rs3774987	ENSG00000230069.3	LRRC37A15P	-5.3	2.06e-07	9.1e-05	-0.25	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102727274~102730721:-
LIHC	cis	rs4356203	0.933	rs12801545	ENSG00000272034.1	SNORD14A	5.3	2.06e-07	9.1e-05	0.33	0.28	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17244629	chr11:17074654~17074744:-
LIHC	cis	rs9388451	0.839	rs4897157	ENSG00000237742.5	RP11-624M8.1	-5.3	2.07e-07	9.12e-05	-0.26	-0.28	Brugada syndrome;	chr6:125781835	chr6:125578558~125749190:-
LIHC	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	5.3	2.07e-07	9.14e-05	0.21	0.28	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	5.3	2.07e-07	9.14e-05	0.21	0.28	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
LIHC	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	5.3	2.08e-07	9.17e-05	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
LIHC	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	5.3	2.08e-07	9.17e-05	0.38	0.28	Height;	chr6:109387972	chr6:109382795~109383666:+
LIHC	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-5.3	2.08e-07	9.17e-05	-0.48	-0.28	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
LIHC	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	5.3	2.08e-07	9.18e-05	0.32	0.28	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
LIHC	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-5.3	2.08e-07	9.19e-05	-0.26	-0.28	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
LIHC	cis	rs10510102	0.935	rs12264495	ENSG00000226864.1	ATE1-AS1	5.3	2.08e-07	9.19e-05	0.44	0.28	Breast cancer;	chr10:121919967	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11200261	ENSG00000226864.1	ATE1-AS1	5.3	2.08e-07	9.19e-05	0.44	0.28	Breast cancer;	chr10:121921133	chr10:121928312~121951965:+
LIHC	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-5.3	2.08e-07	9.19e-05	-0.34	-0.28	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
LIHC	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	5.3	2.09e-07	9.2e-05	0.37	0.28	Depression;	chr6:28379133	chr6:28176188~28176674:+
LIHC	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	5.3	2.09e-07	9.2e-05	0.37	0.28	Depression;	chr6:28379168	chr6:28176188~28176674:+
LIHC	cis	rs1030877	0.515	rs17030766	ENSG00000235319.1	AC012360.4	5.3	2.09e-07	9.23e-05	0.37	0.28	Obesity-related traits;	chr2:105295448	chr2:105324210~105330529:+
LIHC	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-5.3	2.09e-07	9.24e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
LIHC	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	5.3	2.1e-07	9.26e-05	0.42	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
LIHC	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-5.3	2.1e-07	9.28e-05	-0.31	-0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
LIHC	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-5.3	2.11e-07	9.28e-05	-0.29	-0.28	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-5.3	2.11e-07	9.29e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-5.3	2.11e-07	9.29e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-5.3	2.11e-07	9.29e-05	-0.28	-0.28	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
LIHC	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-5.3	2.11e-07	9.3e-05	-0.34	-0.28	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-5.3	2.11e-07	9.3e-05	-0.34	-0.28	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-5.3	2.11e-07	9.3e-05	-0.34	-0.28	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-5.3	2.11e-07	9.3e-05	-0.34	-0.28	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-5.3	2.11e-07	9.3e-05	-0.34	-0.28	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-5.3	2.11e-07	9.3e-05	-0.34	-0.28	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
LIHC	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	5.3	2.11e-07	9.3e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
LIHC	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	5.3	2.12e-07	9.34e-05	0.38	0.28	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
LIHC	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	5.3	2.12e-07	9.35e-05	0.26	0.28	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	5.3	2.12e-07	9.35e-05	0.26	0.28	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	5.3	2.12e-07	9.35e-05	0.26	0.28	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
LIHC	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-5.3	2.13e-07	9.37e-05	-0.35	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
LIHC	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-5.3	2.13e-07	9.37e-05	-0.35	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
LIHC	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-5.3	2.13e-07	9.37e-05	-0.42	-0.28	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
LIHC	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	5.3	2.13e-07	9.37e-05	0.38	0.28	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	5.3	2.13e-07	9.37e-05	0.38	0.28	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	5.3	2.13e-07	9.37e-05	0.38	0.28	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
LIHC	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	5.29	2.14e-07	9.4e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	5.29	2.14e-07	9.4e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	5.29	2.14e-07	9.4e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	5.29	2.14e-07	9.4e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	5.29	2.14e-07	9.4e-05	0.3	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
LIHC	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-5.29	2.14e-07	9.4e-05	-0.33	-0.28	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
LIHC	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	5.29	2.14e-07	9.41e-05	0.21	0.28	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
LIHC	cis	rs7587476	0.765	rs2121284	ENSG00000229267.2	AC072062.1	5.29	2.14e-07	9.41e-05	0.33	0.28	Neuroblastoma;	chr2:214791536	chr2:214810229~214963274:+
LIHC	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	5.29	2.14e-07	9.41e-05	0.36	0.28	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
LIHC	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	5.29	2.14e-07	9.43e-05	0.32	0.28	Height;	chr6:109409679	chr6:109382795~109383666:+
LIHC	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	5.29	2.14e-07	9.43e-05	0.26	0.28	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
LIHC	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	5.29	2.14e-07	9.44e-05	0.45	0.28	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
LIHC	cis	rs9527	0.641	rs4919684	ENSG00000236937.2	PTGES3P4	5.29	2.15e-07	9.44e-05	0.38	0.28	Arsenic metabolism;	chr10:102827267	chr10:102845595~102845950:+
LIHC	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-5.29	2.15e-07	9.45e-05	-0.34	-0.28	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-5.29	2.15e-07	9.45e-05	-0.34	-0.28	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
LIHC	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-5.29	2.16e-07	9.5e-05	-0.34	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
LIHC	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-5.29	2.17e-07	9.52e-05	-0.31	-0.28	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	5.29	2.17e-07	9.53e-05	0.29	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	5.29	2.17e-07	9.53e-05	0.29	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	5.29	2.17e-07	9.53e-05	0.29	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
LIHC	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	5.29	2.17e-07	9.54e-05	0.4	0.28	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
LIHC	cis	rs2283792	0.677	rs13340063	ENSG00000224086.5	LL22NC03-86G7.1	5.29	2.18e-07	9.56e-05	0.25	0.28	Multiple sclerosis;	chr22:21742717	chr22:21938293~21977632:+
LIHC	cis	rs10510102	0.935	rs11200203	ENSG00000226864.1	ATE1-AS1	5.29	2.18e-07	9.57e-05	0.45	0.28	Breast cancer;	chr10:121874014	chr10:121928312~121951965:+
LIHC	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-5.29	2.18e-07	9.57e-05	-0.32	-0.28	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
LIHC	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-5.29	2.18e-07	9.57e-05	-0.3	-0.28	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
LIHC	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-5.29	2.18e-07	9.58e-05	-0.31	-0.28	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
LIHC	cis	rs10510102	0.935	rs11200218	ENSG00000226864.1	ATE1-AS1	5.29	2.18e-07	9.59e-05	0.43	0.28	Breast cancer;	chr10:121886410	chr10:121928312~121951965:+
LIHC	cis	rs1862618	0.853	rs6450409	ENSG00000271828.1	CTD-2310F14.1	5.29	2.18e-07	9.59e-05	0.38	0.28	Initial pursuit acceleration;	chr5:56805572	chr5:56927874~56929573:+
LIHC	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-5.29	2.19e-07	9.6e-05	-0.31	-0.28	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
LIHC	cis	rs6085948	0.861	rs6117729	ENSG00000228888.1	LINC01428	-5.29	2.19e-07	9.6e-05	-0.39	-0.28	Interleukin-10 levels;	chr20:7267542	chr20:7146467~7254202:-
LIHC	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	5.29	2.19e-07	9.6e-05	0.26	0.28	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	5.29	2.19e-07	9.6e-05	0.26	0.28	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
LIHC	cis	rs638893	1	rs636736	ENSG00000255422.1	AP002954.4	-5.29	2.19e-07	9.61e-05	-0.46	-0.28	Vitiligo;	chr11:118834436	chr11:118704607~118750263:+
LIHC	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-5.29	2.19e-07	9.63e-05	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
LIHC	cis	rs2749592	0.531	rs10764134	ENSG00000263064.2	RP11-291L22.7	-5.29	2.19e-07	9.64e-05	-0.28	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38448689~38448949:+
LIHC	cis	rs2998286	0.862	rs2993990	ENSG00000254635.4	WAC-AS1	-5.29	2.2e-07	9.64e-05	-0.34	-0.27	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28518041	chr10:28522652~28532743:-
LIHC	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	5.29	2.2e-07	9.64e-05	0.44	0.27	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-5.29	2.2e-07	9.64e-05	-0.32	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
LIHC	cis	rs9425766	0.679	rs2049992	ENSG00000227373.4	RP11-160H22.5	5.29	2.2e-07	9.66e-05	0.33	0.27	Life satisfaction;	chr1:174356554	chr1:174115300~174160004:-
LIHC	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-5.29	2.2e-07	9.67e-05	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
LIHC	cis	rs6480314	0.636	rs61854782	ENSG00000233590.1	RP11-153K11.3	-5.29	2.2e-07	9.67e-05	-0.43	-0.27	Optic nerve measurement (disc area);	chr10:68231992	chr10:68233251~68242379:-
LIHC	cis	rs16858210	0.874	rs7618182	ENSG00000234371.6	RPSAP31	5.29	2.2e-07	9.67e-05	0.36	0.27	Menopause (age at onset);	chr3:183889215	chr3:183884924~183888449:+
LIHC	cis	rs2735413	0.875	rs8053987	ENSG00000276007.1	RP11-358L22.3	5.29	2.21e-07	9.68e-05	0.3	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78050937	chr16:78123243~78124332:+
LIHC	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-5.29	2.21e-07	9.69e-05	-0.34	-0.27	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
LIHC	cis	rs7131987	0.903	rs11050152	ENSG00000257176.2	RP11-996F15.2	-5.29	2.22e-07	9.73e-05	-0.32	-0.27	QT interval;	chr12:29251491	chr12:29280418~29317848:-
LIHC	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	5.29	2.22e-07	9.73e-05	0.44	0.27	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
LIHC	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	5.29	2.22e-07	9.73e-05	0.45	0.27	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
LIHC	cis	rs739496	0.895	rs2073950	ENSG00000226469.1	ADAM1B	5.29	2.22e-07	9.73e-05	0.34	0.27	Platelet count;	chr12:111456268	chr12:111927018~111929017:+
LIHC	cis	rs950169	0.922	rs62028133	ENSG00000259295.5	CSPG4P12	5.29	2.22e-07	9.73e-05	0.37	0.27	Schizophrenia;	chr15:84250623	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.723	rs17589320	ENSG00000259295.5	CSPG4P12	5.29	2.22e-07	9.73e-05	0.37	0.27	Schizophrenia;	chr15:84251244	chr15:85191438~85213905:+
LIHC	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	5.29	2.22e-07	9.74e-05	0.61	0.27	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
LIHC	cis	rs2243480	0.522	rs12698511	ENSG00000273142.1	RP11-458F8.4	-5.29	2.22e-07	9.74e-05	-0.36	-0.27	Diabetic kidney disease;	chr7:66009932	chr7:66902857~66906297:+
LIHC	cis	rs227275	0.554	rs223363	ENSG00000230069.3	LRRC37A15P	-5.29	2.23e-07	9.76e-05	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102727274~102730721:-
LIHC	cis	rs5758511	0.68	rs5758682	ENSG00000237037.8	NDUFA6-AS1	-5.29	2.23e-07	9.76e-05	-0.34	-0.27	Birth weight;	chr22:42249196	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.68	rs34107327	ENSG00000237037.8	NDUFA6-AS1	-5.29	2.23e-07	9.76e-05	-0.34	-0.27	Birth weight;	chr22:42252347	chr22:42090931~42137742:+
LIHC	cis	rs4731207	0.596	rs900047	ENSG00000224897.5	POT1-AS1	-5.29	2.23e-07	9.76e-05	-0.33	-0.27	Cutaneous malignant melanoma;	chr7:125033319	chr7:124929873~125179315:+
LIHC	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	5.29	2.23e-07	9.77e-05	0.32	0.27	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
LIHC	cis	rs1577917	0.816	rs1838952	ENSG00000234155.1	RP11-30P6.6	5.29	2.23e-07	9.77e-05	0.32	0.27	Response to antipsychotic treatment;	chr6:85891426	chr6:85387219~85390186:-
LIHC	cis	rs887829	0.57	rs10168333	ENSG00000233445.1	RPL17P11	5.29	2.23e-07	9.78e-05	0.29	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233688342	chr2:233721522~233722065:-
LIHC	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	5.29	2.24e-07	9.8e-05	0.32	0.27	Height;	chr6:109427644	chr6:109382795~109383666:+
LIHC	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	5.29	2.24e-07	9.81e-05	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
LIHC	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	5.29	2.24e-07	9.81e-05	0.36	0.27	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
LIHC	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	5.29	2.24e-07	9.81e-05	0.29	0.27	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
LIHC	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	5.29	2.24e-07	9.82e-05	0.34	0.27	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	5.29	2.24e-07	9.82e-05	0.34	0.27	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	5.29	2.24e-07	9.82e-05	0.34	0.27	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
LIHC	cis	rs4731207	0.596	rs10228686	ENSG00000224897.5	POT1-AS1	5.29	2.24e-07	9.82e-05	0.34	0.27	Cutaneous malignant melanoma;	chr7:125023032	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs1994025	ENSG00000224897.5	POT1-AS1	5.29	2.24e-07	9.82e-05	0.34	0.27	Cutaneous malignant melanoma;	chr7:125023805	chr7:124929873~125179315:+
LIHC	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	5.29	2.24e-07	9.82e-05	0.42	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
LIHC	cis	rs7209700	0.708	rs2292865	ENSG00000228782.6	CTD-2026D20.3	-5.28	2.24e-07	9.83e-05	-0.31	-0.27	IgG glycosylation;	chr17:47287356	chr17:47450568~47492492:-
LIHC	cis	rs10833905	0.756	rs11529712	ENSG00000246225.5	RP11-17A1.3	-5.28	2.25e-07	9.84e-05	-0.35	-0.27	Sudden cardiac arrest;	chr11:22964066	chr11:22829380~22945393:+
LIHC	cis	rs6085948	1	rs6085948	ENSG00000238102.1	RP11-19D2.1	5.28	2.25e-07	9.87e-05	0.4	0.27	Interleukin-10 levels;	chr20:7252703	chr20:7256580~7258214:-
LIHC	cis	rs73193808	0.614	rs2832255	ENSG00000224649.1	AF124730.4	-5.28	2.25e-07	9.87e-05	-0.33	-0.27	Coronary artery disease;	chr21:29191846	chr21:29182027~29187795:-
LIHC	cis	rs9326248	0.861	rs494356	ENSG00000236267.1	AP006216.5	5.28	2.25e-07	9.87e-05	0.29	0.27	Blood protein levels;	chr11:117201254	chr11:116813204~116814003:-
LIHC	cis	rs1577917	0.958	rs12212480	ENSG00000234155.1	RP11-30P6.6	5.28	2.26e-07	9.89e-05	0.36	0.27	Response to antipsychotic treatment;	chr6:85749059	chr6:85387219~85390186:-
LIHC	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	5.28	2.26e-07	9.9e-05	0.3	0.27	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
LIHC	cis	rs7119038	0.818	rs11217042	ENSG00000255239.1	AP002954.6	-5.28	2.26e-07	9.9e-05	-0.35	-0.27	Sjögren's syndrome;	chr11:118811819	chr11:118688039~118690600:-
LIHC	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	5.28	2.26e-07	9.9e-05	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
LIHC	cis	rs755249	0.51	rs1184716	ENSG00000182109.6	RP11-69E11.4	5.28	2.26e-07	9.9e-05	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39522280~39546187:-
LIHC	cis	rs7916697	0.628	rs10998036	ENSG00000233590.1	RP11-153K11.3	5.28	2.28e-07	9.95e-05	0.37	0.27	Optic disc area;	chr10:68256921	chr10:68233251~68242379:-
LIHC	cis	rs1322639	0.697	rs12661910	ENSG00000261039.2	RP11-417E7.2	-5.28	2.28e-07	9.96e-05	-0.37	-0.27	Pulse pressure;	chr6:169184293	chr6:169175304~169182740:-
LIHC	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	5.28	2.28e-07	9.98e-05	0.24	0.27	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	5.28	2.28e-07	9.98e-05	0.24	0.27	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	5.28	2.28e-07	9.98e-05	0.24	0.27	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	5.28	2.28e-07	9.98e-05	0.24	0.27	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	5.28	2.28e-07	9.98e-05	0.24	0.27	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	5.28	2.28e-07	9.98e-05	0.24	0.27	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs73142265	ENSG00000273142.1	RP11-458F8.4	5.28	2.29e-07	1e-04	0.26	0.27	Aortic root size;	chr7:66234510	chr7:66902857~66906297:+
LIHC	cis	rs9326248	0.52	rs2735183	ENSG00000280143.1	AP000892.6	5.28	2.29e-07	1e-04	0.32	0.27	Blood protein levels;	chr11:117144479	chr11:117204967~117210292:+
LIHC	cis	rs4266144	0.562	rs2086667	ENSG00000244515.1	KRT18P34	-5.28	2.29e-07	1e-04	-0.3	-0.27	Coronary artery disease;	chr3:157118728	chr3:157162663~157163932:-
LIHC	cis	rs17711722	0.51	rs11767457	ENSG00000226002.1	RP11-460N20.5	5.28	2.29e-07	1e-04	0.29	0.27	Calcium levels;	chr7:65825628	chr7:65084103~65100232:+
LIHC	cis	rs202072	0.872	rs202042	ENSG00000215022.6	RP1-257A7.4	5.28	2.29e-07	1e-04	0.31	0.27	HIV-1 viral setpoint;	chr6:13277482	chr6:13264861~13295586:-
LIHC	cis	rs8059260	0.541	rs35126143	ENSG00000274038.1	RP11-66H6.4	-5.28	2.3e-07	1e-04	-0.47	-0.27	Alcohol consumption over the past year;	chr16:11070455	chr16:11056556~11057034:+
LIHC	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-5.28	2.3e-07	1e-04	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-5.28	2.3e-07	1e-04	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
LIHC	cis	rs17301013	0.932	rs3737651	ENSG00000227373.4	RP11-160H22.5	-5.28	2.3e-07	0.000101	-0.33	-0.27	Systemic lupus erythematosus;	chr1:174475414	chr1:174115300~174160004:-
LIHC	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-5.28	2.3e-07	0.000101	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-5.28	2.3e-07	0.000101	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
LIHC	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	5.28	2.3e-07	0.000101	0.32	0.27	Height;	chr6:109424305	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	5.28	2.3e-07	0.000101	0.32	0.27	Height;	chr6:109425054	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	5.28	2.3e-07	0.000101	0.32	0.27	Height;	chr6:109426518	chr6:109382795~109383666:+
LIHC	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	5.28	2.3e-07	0.000101	0.37	0.27	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
LIHC	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	5.28	2.3e-07	0.000101	0.3	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
LIHC	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	5.28	2.3e-07	0.000101	0.28	0.27	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
LIHC	cis	rs6600671	1	rs4844381	ENSG00000231429.2	RP11-343N15.2	-5.28	2.31e-07	0.000101	-0.31	-0.27	Hip geometry;	chr1:121443040	chr1:121412719~121429274:+
LIHC	cis	rs12285276	0.576	rs2593756	ENSG00000205106.4	DKFZp779M0652	5.28	2.31e-07	0.000101	0.27	0.27	Visceral fat;	chr11:45746850	chr11:45771432~45772358:+
LIHC	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-5.28	2.31e-07	0.000101	-0.34	-0.27	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
LIHC	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-5.28	2.31e-07	0.000101	-0.36	-0.27	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
LIHC	cis	rs1865760	0.82	rs9348697	ENSG00000216436.2	HIST1H2APS1	-5.28	2.31e-07	0.000101	-0.31	-0.27	Height;	chr6:25890606	chr6:25732497~25732827:+
LIHC	cis	rs7131987	0.65	rs7973786	ENSG00000275476.1	RP11-996F15.4	-5.28	2.32e-07	0.000101	-0.32	-0.27	QT interval;	chr12:29309811	chr12:29277397~29277882:-
LIHC	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-5.28	2.32e-07	0.000101	-0.29	-0.27	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
LIHC	cis	rs9532669	0.926	rs2039119	ENSG00000168852.11	TPTE2P5	-5.28	2.32e-07	0.000101	-0.32	-0.27	Cervical cancer;	chr13:40872432	chr13:40822296~40921749:-
LIHC	cis	rs2522056	1	rs2405528	ENSG00000233006.5	AC034220.3	-5.28	2.32e-07	0.000101	-0.29	-0.27	Fibrinogen;Lymphocyte counts;	chr5:132458606	chr5:132311285~132369916:-
LIHC	cis	rs7131987	0.65	rs4331146	ENSG00000275476.1	RP11-996F15.4	-5.28	2.33e-07	0.000101	-0.32	-0.27	QT interval;	chr12:29287150	chr12:29277397~29277882:-
LIHC	cis	rs9425766	0.64	rs6693423	ENSG00000227373.4	RP11-160H22.5	5.28	2.33e-07	0.000102	0.33	0.27	Life satisfaction;	chr1:174364680	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs60363188	ENSG00000227373.4	RP11-160H22.5	5.28	2.33e-07	0.000102	0.33	0.27	Life satisfaction;	chr1:174375959	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs12084119	ENSG00000227373.4	RP11-160H22.5	5.28	2.33e-07	0.000102	0.33	0.27	Life satisfaction;	chr1:174377138	chr1:174115300~174160004:-
LIHC	cis	rs75920871	0.562	rs68137714	ENSG00000254851.1	RP11-109L13.1	-5.28	2.33e-07	0.000102	-0.52	-0.27	Subjective well-being;	chr11:117154641	chr11:117135528~117138582:+
LIHC	cis	rs860295	0.812	rs12407800	ENSG00000203761.5	MSTO2P	-5.28	2.33e-07	0.000102	-0.22	-0.27	Body mass index;	chr1:155790951	chr1:155745829~155750137:+
LIHC	cis	rs3096299	0.685	rs4785675	ENSG00000261118.1	RP11-104N10.1	5.28	2.34e-07	0.000102	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89492017~89504460:-
LIHC	cis	rs3096299	0.685	rs4238830	ENSG00000261118.1	RP11-104N10.1	5.28	2.34e-07	0.000102	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89492017~89504460:-
LIHC	cis	rs6686842	1	rs6663565	ENSG00000235358.1	RP11-399E6.1	-5.28	2.34e-07	0.000102	-0.3	-0.27	Height;	chr1:41098016	chr1:41242373~41284861:+
LIHC	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	5.28	2.34e-07	0.000102	0.38	0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
LIHC	cis	rs17301013	0.897	rs1793291	ENSG00000227373.4	RP11-160H22.5	-5.28	2.34e-07	0.000102	-0.36	-0.27	Systemic lupus erythematosus;	chr1:174822675	chr1:174115300~174160004:-
LIHC	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	5.28	2.34e-07	0.000102	0.33	0.27	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
LIHC	cis	rs739496	0.947	rs2239195	ENSG00000226469.1	ADAM1B	5.28	2.34e-07	0.000102	0.34	0.27	Platelet count;	chr12:111443505	chr12:111927018~111929017:+
LIHC	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	5.28	2.34e-07	0.000102	0.3	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
LIHC	cis	rs860295	0.812	rs12081192	ENSG00000203761.5	MSTO2P	-5.28	2.34e-07	0.000102	-0.22	-0.27	Body mass index;	chr1:155768253	chr1:155745829~155750137:+
LIHC	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	5.28	2.34e-07	0.000102	0.35	0.27	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
LIHC	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	5.28	2.35e-07	0.000102	0.3	0.27	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
LIHC	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-5.28	2.35e-07	0.000102	-0.36	-0.27	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
LIHC	cis	rs4639966	0.589	rs480958	ENSG00000255239.1	AP002954.6	5.28	2.35e-07	0.000102	0.33	0.27	Systemic lupus erythematosus;	chr11:118707281	chr11:118688039~118690600:-
LIHC	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	5.28	2.35e-07	0.000102	0.43	0.27	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
LIHC	cis	rs10510102	0.935	rs79360006	ENSG00000226864.1	ATE1-AS1	5.28	2.35e-07	0.000102	0.44	0.27	Breast cancer;	chr10:121912856	chr10:121928312~121951965:+
LIHC	cis	rs2243480	0.522	rs778717	ENSG00000273142.1	RP11-458F8.4	-5.28	2.35e-07	0.000103	-0.37	-0.27	Diabetic kidney disease;	chr7:66383164	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-5.28	2.35e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
LIHC	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-5.28	2.35e-07	0.000103	-0.45	-0.27	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	5.28	2.35e-07	0.000103	0.25	0.27	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
LIHC	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-5.27	2.36e-07	0.000103	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
LIHC	cis	rs4731207	0.596	rs6466966	ENSG00000224897.5	POT1-AS1	-5.27	2.36e-07	0.000103	-0.33	-0.27	Cutaneous malignant melanoma;	chr7:124940273	chr7:124929873~125179315:+
LIHC	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	5.27	2.36e-07	0.000103	0.3	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
LIHC	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	5.27	2.36e-07	0.000103	0.33	0.27	Height;	chr6:109534269	chr6:109382795~109383666:+
LIHC	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-5.27	2.37e-07	0.000103	-0.25	-0.27	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
LIHC	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	5.27	2.37e-07	0.000103	0.37	0.27	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
LIHC	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-5.27	2.37e-07	0.000103	-0.31	-0.27	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
LIHC	cis	rs17270561	0.666	rs9356988	ENSG00000216436.2	HIST1H2APS1	-5.27	2.38e-07	0.000103	-0.33	-0.27	Iron status biomarkers;	chr6:25777253	chr6:25732497~25732827:+
LIHC	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	5.27	2.38e-07	0.000103	0.37	0.27	Depression;	chr6:28386473	chr6:28176188~28176674:+
LIHC	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	5.27	2.38e-07	0.000104	0.24	0.27	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	5.27	2.38e-07	0.000104	0.24	0.27	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	5.27	2.38e-07	0.000104	0.24	0.27	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
LIHC	cis	rs4731207	0.698	rs10954045	ENSG00000224897.5	POT1-AS1	5.27	2.38e-07	0.000104	0.32	0.27	Cutaneous malignant melanoma;	chr7:124858101	chr7:124929873~125179315:+
LIHC	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	5.27	2.38e-07	0.000104	0.32	0.27	Height;	chr6:109608105	chr6:109382795~109383666:+
LIHC	cis	rs5756813	1	rs5756813	ENSG00000233360.4	Z83844.1	5.27	2.38e-07	0.000104	0.32	0.27	Optic cup area;Vertical cup-disc ratio;	chr22:37779470	chr22:37641832~37658377:-
LIHC	cis	rs9326248	0.53	rs236918	ENSG00000236267.1	AP006216.5	-5.27	2.38e-07	0.000104	-0.32	-0.27	Blood protein levels;	chr11:117220893	chr11:116813204~116814003:-
LIHC	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	5.27	2.39e-07	0.000104	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
LIHC	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	5.27	2.4e-07	0.000104	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	5.27	2.4e-07	0.000104	0.31	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
LIHC	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-5.27	2.4e-07	0.000104	-0.37	-0.27	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
LIHC	cis	rs10510102	0.935	rs11200201	ENSG00000226864.1	ATE1-AS1	5.27	2.4e-07	0.000104	0.46	0.27	Breast cancer;	chr10:121864790	chr10:121928312~121951965:+
LIHC	cis	rs12701220	0.901	rs12701708	ENSG00000229043.2	AC091729.9	-5.27	2.41e-07	0.000104	-0.37	-0.27	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1160374~1165267:+
LIHC	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-5.27	2.41e-07	0.000104	-0.25	-0.27	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
LIHC	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-5.27	2.41e-07	0.000104	-0.25	-0.27	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
LIHC	cis	rs4731207	0.596	rs10244797	ENSG00000224897.5	POT1-AS1	5.27	2.41e-07	0.000105	0.33	0.27	Cutaneous malignant melanoma;	chr7:124931630	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.505	rs7791488	ENSG00000224897.5	POT1-AS1	5.27	2.41e-07	0.000105	0.33	0.27	Cutaneous malignant melanoma;	chr7:124938214	chr7:124929873~125179315:+
LIHC	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	5.27	2.41e-07	0.000105	0.22	0.27	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
LIHC	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-5.27	2.41e-07	0.000105	-0.34	-0.27	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-5.27	2.41e-07	0.000105	-0.34	-0.27	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
LIHC	cis	rs228614	0.51	rs223397	ENSG00000230069.3	LRRC37A15P	-5.27	2.42e-07	0.000105	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102727274~102730721:-
LIHC	cis	rs2998286	0.784	rs998362	ENSG00000254635.4	WAC-AS1	-5.27	2.42e-07	0.000105	-0.34	-0.27	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528129	chr10:28522652~28532743:-
LIHC	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-5.27	2.43e-07	0.000105	-0.31	-0.27	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
LIHC	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-5.27	2.43e-07	0.000105	-0.34	-0.27	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
LIHC	cis	rs7131987	0.65	rs7957339	ENSG00000275476.1	RP11-996F15.4	-5.27	2.43e-07	0.000106	-0.32	-0.27	QT interval;	chr12:29303562	chr12:29277397~29277882:-
LIHC	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	5.27	2.44e-07	0.000106	0.34	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
LIHC	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	5.27	2.44e-07	0.000106	0.34	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
LIHC	cis	rs2735413	0.918	rs12598024	ENSG00000276007.1	RP11-358L22.3	-5.27	2.44e-07	0.000106	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78045217	chr16:78123243~78124332:+
LIHC	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-5.27	2.44e-07	0.000106	-0.25	-0.27	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
LIHC	cis	rs2933343	0.7	rs1680779	ENSG00000231305.3	RP11-723O4.2	5.27	2.45e-07	0.000106	0.31	0.27	IgG glycosylation;	chr3:128895927	chr3:128861313~128871540:-
LIHC	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-5.27	2.45e-07	0.000106	-0.31	-0.27	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
LIHC	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	5.27	2.45e-07	0.000106	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
LIHC	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-5.27	2.46e-07	0.000106	-0.27	-0.27	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-5.27	2.46e-07	0.000106	-0.27	-0.27	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
LIHC	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-5.27	2.46e-07	0.000107	-0.34	-0.27	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.922	rs12906983	ENSG00000259295.5	CSPG4P12	5.27	2.46e-07	0.000107	0.37	0.27	Schizophrenia;	chr15:84262270	chr15:85191438~85213905:+
LIHC	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-5.27	2.46e-07	0.000107	-0.23	-0.27	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
LIHC	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	5.27	2.48e-07	0.000107	0.3	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
LIHC	cis	rs4731207	0.596	rs12055904	ENSG00000224897.5	POT1-AS1	5.27	2.48e-07	0.000107	0.34	0.27	Cutaneous malignant melanoma;	chr7:125022810	chr7:124929873~125179315:+
LIHC	cis	rs4356203	0.905	rs615358	ENSG00000272034.1	SNORD14A	-5.27	2.48e-07	0.000107	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17188885	chr11:17074654~17074744:-
LIHC	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-5.27	2.48e-07	0.000107	-0.24	-0.27	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
LIHC	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-5.27	2.48e-07	0.000107	-0.29	-0.27	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	5.27	2.48e-07	0.000107	0.28	0.27	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
LIHC	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	5.26	2.49e-07	0.000108	0.26	0.27	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	5.26	2.49e-07	0.000108	0.26	0.27	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	5.26	2.49e-07	0.000108	0.26	0.27	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	5.26	2.49e-07	0.000108	0.26	0.27	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
LIHC	cis	rs16858210	0.874	rs1879256	ENSG00000234371.6	RPSAP31	5.26	2.49e-07	0.000108	0.35	0.27	Menopause (age at onset);	chr3:183891273	chr3:183884924~183888449:+
LIHC	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	5.26	2.49e-07	0.000108	0.32	0.27	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
LIHC	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	5.26	2.49e-07	0.000108	0.36	0.27	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
LIHC	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-5.26	2.49e-07	0.000108	-0.34	-0.27	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
LIHC	cis	rs2836974	0.666	rs12626405	ENSG00000255568.3	BRWD1-AS2	-5.26	2.49e-07	0.000108	-0.23	-0.27	Cognitive function;	chr21:39291195	chr21:39313935~39314962:+
LIHC	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	5.26	2.49e-07	0.000108	0.28	0.27	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
LIHC	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	5.26	2.49e-07	0.000108	0.42	0.27	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
LIHC	cis	rs2032366	0.606	rs6567225	ENSG00000267279.1	RP11-879F14.2	5.26	2.49e-07	0.000108	0.33	0.27	Obesity-related traits;	chr18:61607418	chr18:61585746~61606916:-
LIHC	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	5.26	2.49e-07	0.000108	0.38	0.27	Height;	chr6:109360679	chr6:109382795~109383666:+
LIHC	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	5.26	2.49e-07	0.000108	0.26	0.27	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
LIHC	cis	rs12701220	0.948	rs12690826	ENSG00000229043.2	AC091729.9	-5.26	2.49e-07	0.000108	-0.39	-0.27	Bronchopulmonary dysplasia;	chr7:1041982	chr7:1160374~1165267:+
LIHC	cis	rs5769765	0.862	rs9616392	ENSG00000278869.1	CITF22-49E9.3	5.26	2.5e-07	0.000108	0.44	0.27	Schizophrenia;	chr22:49921057	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs9616394	ENSG00000278869.1	CITF22-49E9.3	5.26	2.5e-07	0.000108	0.44	0.27	Schizophrenia;	chr22:49921279	chr22:49933198~49934074:-
LIHC	cis	rs860295	0.812	rs12024257	ENSG00000203761.5	MSTO2P	-5.26	2.5e-07	0.000108	-0.22	-0.27	Body mass index;	chr1:155810745	chr1:155745829~155750137:+
LIHC	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	5.26	2.5e-07	0.000108	0.33	0.27	Height;	chr6:109486036	chr6:109382795~109383666:+
LIHC	cis	rs2439831	0.702	rs3784275	ENSG00000205771.5	CATSPER2P1	-5.26	2.5e-07	0.000108	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43799188	chr15:43726918~43747094:-
LIHC	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	5.26	2.51e-07	0.000108	0.5	0.27	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
LIHC	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-5.26	2.51e-07	0.000109	-0.28	-0.27	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
LIHC	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	5.26	2.51e-07	0.000109	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-5.26	2.52e-07	0.000109	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
LIHC	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	5.26	2.52e-07	0.000109	0.31	0.27	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
LIHC	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-5.26	2.52e-07	0.000109	-0.33	-0.27	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
LIHC	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-5.26	2.53e-07	0.000109	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
LIHC	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-5.26	2.53e-07	0.000109	-0.3	-0.27	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
LIHC	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-5.26	2.53e-07	0.000109	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
LIHC	cis	rs2836974	0.644	rs9978775	ENSG00000255568.3	BRWD1-AS2	-5.26	2.53e-07	0.000109	-0.23	-0.27	Cognitive function;	chr21:39322600	chr21:39313935~39314962:+
LIHC	cis	rs4731207	0.596	rs1006334	ENSG00000224897.5	POT1-AS1	5.26	2.53e-07	0.000109	0.33	0.27	Cutaneous malignant melanoma;	chr7:124988253	chr7:124929873~125179315:+
LIHC	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-5.26	2.53e-07	0.000109	-0.34	-0.27	Height;	chr6:109485060	chr6:109382795~109383666:+
LIHC	cis	rs6600671	1	rs12047116	ENSG00000231429.2	RP11-343N15.2	-5.26	2.54e-07	0.00011	-0.32	-0.27	Hip geometry;	chr1:121443912	chr1:121412719~121429274:+
LIHC	cis	rs6600671	0.967	rs11249347	ENSG00000231429.2	RP11-343N15.2	-5.26	2.54e-07	0.00011	-0.32	-0.27	Hip geometry;	chr1:121446489	chr1:121412719~121429274:+
LIHC	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	5.26	2.54e-07	0.00011	0.31	0.27	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
LIHC	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	5.26	2.54e-07	0.00011	0.31	0.27	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
LIHC	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	5.26	2.54e-07	0.00011	0.39	0.27	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
LIHC	cis	rs227275	0.586	rs223448	ENSG00000230069.3	LRRC37A15P	-5.26	2.54e-07	0.00011	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223442	ENSG00000230069.3	LRRC37A15P	-5.26	2.54e-07	0.00011	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223441	ENSG00000230069.3	LRRC37A15P	-5.26	2.54e-07	0.00011	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs150895	ENSG00000230069.3	LRRC37A15P	-5.26	2.54e-07	0.00011	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102727274~102730721:-
LIHC	cis	rs7119038	0.818	rs17122453	ENSG00000255239.1	AP002954.6	-5.26	2.54e-07	0.00011	-0.34	-0.27	Sjögren's syndrome;	chr11:118812855	chr11:118688039~118690600:-
LIHC	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-5.26	2.55e-07	0.00011	-0.35	-0.27	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
LIHC	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	5.26	2.55e-07	0.00011	0.47	0.27	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
LIHC	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	5.26	2.55e-07	0.00011	0.5	0.27	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	5.26	2.55e-07	0.00011	0.5	0.27	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
LIHC	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-5.26	2.55e-07	0.00011	-0.25	-0.27	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
LIHC	cis	rs3096299	0.748	rs3102339	ENSG00000261118.1	RP11-104N10.1	5.26	2.56e-07	0.00011	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89492017~89504460:-
LIHC	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	5.26	2.56e-07	0.00011	0.3	0.27	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	5.26	2.56e-07	0.00011	0.3	0.27	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
LIHC	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-5.26	2.56e-07	0.00011	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
LIHC	cis	rs9425766	0.64	rs6685314	ENSG00000227373.4	RP11-160H22.5	5.26	2.56e-07	0.00011	0.33	0.27	Life satisfaction;	chr1:174089905	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.655	rs4652169	ENSG00000227373.4	RP11-160H22.5	5.26	2.56e-07	0.00011	0.33	0.27	Life satisfaction;	chr1:174095343	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs6691711	ENSG00000227373.4	RP11-160H22.5	5.26	2.56e-07	0.00011	0.33	0.27	Life satisfaction;	chr1:174100283	chr1:174115300~174160004:-
LIHC	cis	rs4718428	0.576	rs12698546	ENSG00000232546.1	RP11-458F8.1	-5.26	2.57e-07	0.000111	-0.25	-0.27	Corneal structure;	chr7:66801919	chr7:66848496~66858136:+
LIHC	cis	rs887829	0.57	rs10175809	ENSG00000233445.1	RPL17P11	5.26	2.57e-07	0.000111	0.29	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233688219	chr2:233721522~233722065:-
LIHC	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	5.26	2.58e-07	0.000111	0.44	0.27	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
LIHC	cis	rs2735413	0.881	rs11150036	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78041790	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs11150037	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78041877	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs4888725	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78042864	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.881	rs4888727	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78043141	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs36068555	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78043185	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs4888728	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78043302	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.813	rs11644471	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78043340	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.781	rs11649473	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78043341	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs7190752	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78043533	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.918	rs2344494	ENSG00000276007.1	RP11-358L22.3	-5.26	2.58e-07	0.000111	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78044214	chr16:78123243~78124332:+
LIHC	cis	rs73081554	0.611	rs4681852	ENSG00000272360.1	RP11-359I18.5	-5.26	2.58e-07	0.000111	-0.41	-0.27	Rheumatoid arthritis;	chr3:58423446	chr3:58490830~58491291:-
LIHC	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-5.26	2.58e-07	0.000111	-0.27	-0.27	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-5.26	2.58e-07	0.000111	-0.27	-0.27	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-5.26	2.58e-07	0.000111	-0.27	-0.27	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-5.26	2.58e-07	0.000111	-0.27	-0.27	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
LIHC	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	5.26	2.59e-07	0.000111	0.3	0.27	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
LIHC	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	5.26	2.59e-07	0.000111	0.38	0.27	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
LIHC	cis	rs227275	0.525	rs11097796	ENSG00000230069.3	LRRC37A15P	-5.26	2.59e-07	0.000111	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs11097797	ENSG00000230069.3	LRRC37A15P	-5.26	2.59e-07	0.000111	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102727274~102730721:-
LIHC	cis	rs4731207	0.698	rs7796150	ENSG00000224897.5	POT1-AS1	5.26	2.59e-07	0.000111	0.33	0.27	Cutaneous malignant melanoma;	chr7:124881163	chr7:124929873~125179315:+
LIHC	cis	rs227275	0.525	rs10029073	ENSG00000230069.3	LRRC37A15P	-5.26	2.59e-07	0.000112	-0.25	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102727274~102730721:-
LIHC	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-5.26	2.6e-07	0.000112	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
LIHC	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-5.26	2.6e-07	0.000112	-0.34	-0.27	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-5.26	2.6e-07	0.000112	-0.34	-0.27	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
LIHC	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	5.26	2.6e-07	0.000112	0.24	0.27	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
LIHC	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-5.26	2.61e-07	0.000112	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
LIHC	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	5.26	2.61e-07	0.000112	0.3	0.27	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
LIHC	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-5.26	2.61e-07	0.000112	-0.29	-0.27	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
LIHC	cis	rs1499614	1	rs34250985	ENSG00000226824.5	RP4-756H11.3	-5.25	2.62e-07	0.000112	-0.49	-0.27	Gout;	chr7:66696075	chr7:66654538~66669855:+
LIHC	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-5.25	2.62e-07	0.000112	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
LIHC	cis	rs4731207	0.698	rs10954048	ENSG00000224897.5	POT1-AS1	5.25	2.62e-07	0.000113	0.32	0.27	Cutaneous malignant melanoma;	chr7:124893686	chr7:124929873~125179315:+
LIHC	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	5.25	2.62e-07	0.000113	0.5	0.27	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
LIHC	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	5.25	2.62e-07	0.000113	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
LIHC	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	5.25	2.62e-07	0.000113	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
LIHC	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	5.25	2.63e-07	0.000113	0.31	0.27	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
LIHC	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	5.25	2.63e-07	0.000113	0.3	0.27	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
LIHC	cis	rs4731207	0.623	rs34865746	ENSG00000224897.5	POT1-AS1	5.25	2.63e-07	0.000113	0.33	0.27	Cutaneous malignant melanoma;	chr7:124999865	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7799518	ENSG00000224897.5	POT1-AS1	5.25	2.63e-07	0.000113	0.33	0.27	Cutaneous malignant melanoma;	chr7:124935630	chr7:124929873~125179315:+
LIHC	cis	rs16858210	0.874	rs6792309	ENSG00000234371.6	RPSAP31	5.25	2.64e-07	0.000113	0.35	0.27	Menopause (age at onset);	chr3:183889873	chr3:183884924~183888449:+
LIHC	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-5.25	2.64e-07	0.000113	-0.34	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
LIHC	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-5.25	2.64e-07	0.000113	-0.29	-0.27	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
LIHC	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-5.25	2.64e-07	0.000113	-0.25	-0.27	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-5.25	2.64e-07	0.000113	-0.25	-0.27	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-5.25	2.64e-07	0.000113	-0.25	-0.27	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
LIHC	cis	rs116175783	0.557	rs62197075	ENSG00000227403.1	AC009299.3	5.25	2.65e-07	0.000114	0.41	0.27	Intelligence (multi-trait analysis);	chr2:161312613	chr2:161244739~161249050:+
LIHC	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-5.25	2.65e-07	0.000114	-0.31	-0.27	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
LIHC	cis	rs875971	0.545	rs73142233	ENSG00000273142.1	RP11-458F8.4	5.25	2.66e-07	0.000114	0.26	0.27	Aortic root size;	chr7:66221293	chr7:66902857~66906297:+
LIHC	cis	rs9291683	0.53	rs73227883	ENSG00000250413.1	RP11-448G15.1	-5.25	2.66e-07	0.000114	-0.36	-0.27	Bone mineral density;	chr4:9977655	chr4:10006482~10009725:+
LIHC	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	5.25	2.66e-07	0.000114	0.36	0.27	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
LIHC	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-5.25	2.66e-07	0.000114	-0.36	-0.27	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
LIHC	cis	rs227275	0.554	rs223388	ENSG00000230069.3	LRRC37A15P	-5.25	2.66e-07	0.000114	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223386	ENSG00000230069.3	LRRC37A15P	-5.25	2.66e-07	0.000114	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223385	ENSG00000230069.3	LRRC37A15P	-5.25	2.66e-07	0.000114	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.873	rs223384	ENSG00000230069.3	LRRC37A15P	-5.25	2.66e-07	0.000114	-0.24	-0.27	Schizophrenia;	chr4:102829976	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223383	ENSG00000230069.3	LRRC37A15P	-5.25	2.66e-07	0.000114	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-5.25	2.67e-07	0.000114	-0.25	-0.27	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
LIHC	cis	rs227275	0.554	rs223395	ENSG00000230069.3	LRRC37A15P	-5.25	2.67e-07	0.000115	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102727274~102730721:-
LIHC	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	5.25	2.67e-07	0.000115	0.27	0.27	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
LIHC	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	5.25	2.68e-07	0.000115	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	5.25	2.68e-07	0.000115	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
LIHC	cis	rs2735413	0.75	rs75500355	ENSG00000276007.1	RP11-358L22.3	5.25	2.68e-07	0.000115	0.35	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78041499	chr16:78123243~78124332:+
LIHC	cis	rs4356203	0.87	rs214901	ENSG00000272034.1	SNORD14A	5.25	2.68e-07	0.000115	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206181	chr11:17074654~17074744:-
LIHC	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-5.25	2.68e-07	0.000115	-0.31	-0.27	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-5.25	2.68e-07	0.000115	-0.31	-0.27	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
LIHC	cis	rs4650994	0.544	rs4652301	ENSG00000273384.1	RP5-1098D14.1	5.25	2.68e-07	0.000115	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178530664	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.544	rs10798613	ENSG00000273384.1	RP5-1098D14.1	5.25	2.68e-07	0.000115	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178530887	chr1:178651706~178652282:+
LIHC	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	5.25	2.69e-07	0.000115	0.3	0.27	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
LIHC	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-5.25	2.7e-07	0.000116	-0.28	-0.27	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
LIHC	cis	rs10510102	0.935	rs12262776	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121884532	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12264952	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121885673	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12244866	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121886013	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12266597	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121886062	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12245018	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121886195	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200217	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121886372	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10887008	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121886714	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12268872	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121887426	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs9630107	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121887713	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10887010	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121888542	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11200220	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121889949	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200221	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121890134	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10887011	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121890203	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10887012	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121890454	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11200222	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121891177	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200223	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121891416	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10887013	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121891546	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11200225	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121891948	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200226	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121891988	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10887014	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121892322	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11818735	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121892472	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.81	rs12259902	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121893017	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200228	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121893358	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200229	ENSG00000226864.1	ATE1-AS1	5.25	2.7e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121893519	chr10:121928312~121951965:+
LIHC	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	5.25	2.7e-07	0.000116	0.26	0.27	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
LIHC	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	5.25	2.71e-07	0.000116	0.32	0.27	Height;	chr6:109533040	chr6:109382795~109383666:+
LIHC	cis	rs7119038	0.58	rs7123726	ENSG00000255239.1	AP002954.6	-5.25	2.71e-07	0.000116	-0.35	-0.27	Sjögren's syndrome;	chr11:118823838	chr11:118688039~118690600:-
LIHC	cis	rs6504950	0.579	rs17712917	ENSG00000275710.1	RP11-257O5.4	5.25	2.71e-07	0.000116	0.45	0.27	Breast cancer;	chr17:55194004	chr17:54964474~54964679:+
LIHC	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-5.25	2.71e-07	0.000116	-0.35	-0.27	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
LIHC	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-5.25	2.71e-07	0.000116	-0.43	-0.27	Gout;	chr7:66671562	chr7:66654538~66669855:+
LIHC	cis	rs2749592	0.55	rs10764135	ENSG00000263064.2	RP11-291L22.7	-5.25	2.71e-07	0.000116	-0.28	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38448689~38448949:+
LIHC	cis	rs2749592	0.55	rs12255038	ENSG00000263064.2	RP11-291L22.7	-5.25	2.71e-07	0.000116	-0.28	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38448689~38448949:+
LIHC	cis	rs2749592	0.505	rs7915670	ENSG00000263064.2	RP11-291L22.7	-5.25	2.71e-07	0.000116	-0.28	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38448689~38448949:+
LIHC	cis	rs10510102	0.935	rs10510101	ENSG00000226864.1	ATE1-AS1	5.25	2.71e-07	0.000116	0.43	0.27	Breast cancer;	chr10:121898614	chr10:121928312~121951965:+
LIHC	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-5.25	2.72e-07	0.000116	-0.29	-0.27	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
LIHC	cis	rs992157	0.764	rs1870123	ENSG00000261338.2	RP11-378A13.1	5.25	2.73e-07	0.000117	0.3	0.27	Colorectal cancer;	chr2:218322975	chr2:218255319~218257366:+
LIHC	cis	rs4731207	0.596	rs7810654	ENSG00000224897.5	POT1-AS1	5.25	2.73e-07	0.000117	0.33	0.27	Cutaneous malignant melanoma;	chr7:125005035	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7810299	ENSG00000224897.5	POT1-AS1	5.25	2.73e-07	0.000117	0.33	0.27	Cutaneous malignant melanoma;	chr7:125005050	chr7:124929873~125179315:+
LIHC	cis	rs4660214	0.756	rs11205823	ENSG00000182109.6	RP11-69E11.4	-5.25	2.73e-07	0.000117	-0.3	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39522280~39546187:-
LIHC	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-5.25	2.73e-07	0.000117	-0.34	-0.27	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
LIHC	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-5.25	2.73e-07	0.000117	-0.27	-0.27	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
LIHC	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-5.25	2.74e-07	0.000117	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.841	rs10761720	ENSG00000232075.1	MRPL35P2	-5.25	2.74e-07	0.000117	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63634317~63634827:-
LIHC	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	5.25	2.74e-07	0.000117	0.26	0.27	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
LIHC	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-5.24	2.75e-07	0.000117	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
LIHC	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-5.24	2.75e-07	0.000117	-0.33	-0.27	Migraine;	chr4:56881195	chr4:56960927~56961373:-
LIHC	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	5.24	2.75e-07	0.000117	0.2	0.27	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	5.24	2.75e-07	0.000117	0.2	0.27	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
LIHC	cis	rs3096299	0.685	rs3803682	ENSG00000261118.1	RP11-104N10.1	5.24	2.75e-07	0.000118	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89492017~89504460:-
LIHC	cis	rs3096299	0.685	rs3803681	ENSG00000261118.1	RP11-104N10.1	5.24	2.75e-07	0.000118	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89492017~89504460:-
LIHC	cis	rs4731207	0.596	rs11761669	ENSG00000224897.5	POT1-AS1	-5.24	2.75e-07	0.000118	-0.33	-0.27	Cutaneous malignant melanoma;	chr7:124946247	chr7:124929873~125179315:+
LIHC	cis	rs17301013	0.932	rs2072760	ENSG00000227373.4	RP11-160H22.5	5.24	2.76e-07	0.000118	0.33	0.27	Systemic lupus erythematosus;	chr1:174510186	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs10912797	ENSG00000227373.4	RP11-160H22.5	5.24	2.76e-07	0.000118	0.33	0.27	Systemic lupus erythematosus;	chr1:174511225	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs6668053	ENSG00000227373.4	RP11-160H22.5	5.24	2.76e-07	0.000118	0.33	0.27	Systemic lupus erythematosus;	chr1:174515139	chr1:174115300~174160004:-
LIHC	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-5.24	2.76e-07	0.000118	-0.35	-0.27	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
LIHC	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-5.24	2.76e-07	0.000118	-0.33	-0.27	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
LIHC	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	5.24	2.77e-07	0.000118	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
LIHC	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	5.24	2.77e-07	0.000118	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
LIHC	cis	rs7131987	0.683	rs7954278	ENSG00000275476.1	RP11-996F15.4	-5.24	2.77e-07	0.000118	-0.32	-0.27	QT interval;	chr12:29306357	chr12:29277397~29277882:-
LIHC	cis	rs4660214	0.694	rs16866216	ENSG00000182109.6	RP11-69E11.4	-5.24	2.78e-07	0.000118	-0.29	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39522280~39546187:-
LIHC	cis	rs10510102	0.872	rs7916008	ENSG00000226864.1	ATE1-AS1	5.24	2.78e-07	0.000118	0.46	0.27	Breast cancer;	chr10:121943578	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs7916380	ENSG00000226864.1	ATE1-AS1	5.24	2.78e-07	0.000118	0.46	0.27	Breast cancer;	chr10:121943773	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.808	rs7920024	ENSG00000226864.1	ATE1-AS1	5.24	2.78e-07	0.000118	0.46	0.27	Breast cancer;	chr10:121944063	chr10:121928312~121951965:+
LIHC	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	5.24	2.78e-07	0.000118	0.21	0.27	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
LIHC	cis	rs6480314	0.542	rs1007848	ENSG00000233590.1	RP11-153K11.3	-5.24	2.78e-07	0.000119	-0.43	-0.27	Optic nerve measurement (disc area);	chr10:68258549	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs61854807	ENSG00000233590.1	RP11-153K11.3	-5.24	2.78e-07	0.000119	-0.43	-0.27	Optic nerve measurement (disc area);	chr10:68258948	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.616	rs12571093	ENSG00000233590.1	RP11-153K11.3	-5.24	2.78e-07	0.000119	-0.43	-0.27	Optic nerve measurement (disc area);	chr10:68259614	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs7476012	ENSG00000233590.1	RP11-153K11.3	-5.24	2.78e-07	0.000119	-0.43	-0.27	Optic nerve measurement (disc area);	chr10:68259950	chr10:68233251~68242379:-
LIHC	cis	rs496547	0.686	rs487728	ENSG00000255422.1	AP002954.4	-5.24	2.78e-07	0.000119	-0.31	-0.27	Hip minimal joint space width;	chr11:118750785	chr11:118704607~118750263:+
LIHC	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-5.24	2.79e-07	0.000119	-0.24	-0.27	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
LIHC	cis	rs3096299	0.967	rs7205785	ENSG00000261118.1	RP11-104N10.1	5.24	2.79e-07	0.000119	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89492017~89504460:-
LIHC	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	5.24	2.79e-07	0.000119	0.2	0.27	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
LIHC	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	5.24	2.79e-07	0.000119	0.33	0.27	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
LIHC	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-5.24	2.79e-07	0.000119	-0.25	-0.27	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-5.24	2.79e-07	0.000119	-0.25	-0.27	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
LIHC	cis	rs4356203	0.905	rs11821773	ENSG00000272034.1	SNORD14A	-5.24	2.79e-07	0.000119	-0.3	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17095807	chr11:17074654~17074744:-
LIHC	cis	rs4731207	0.596	rs2170351	ENSG00000224897.5	POT1-AS1	5.24	2.79e-07	0.000119	0.33	0.27	Cutaneous malignant melanoma;	chr7:125002143	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6956910	ENSG00000224897.5	POT1-AS1	5.24	2.79e-07	0.000119	0.33	0.27	Cutaneous malignant melanoma;	chr7:125002310	chr7:124929873~125179315:+
LIHC	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-5.24	2.79e-07	0.000119	-0.28	-0.27	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
LIHC	cis	rs3096299	0.719	rs2965945	ENSG00000261118.1	RP11-104N10.1	5.24	2.8e-07	0.000119	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89492017~89504460:-
LIHC	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-5.24	2.8e-07	0.000119	-0.31	-0.27	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
LIHC	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-5.24	2.8e-07	0.000119	-0.41	-0.27	Depression;	chr6:28193021	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-5.24	2.8e-07	0.000119	-0.41	-0.27	Depression;	chr6:28197321	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-5.24	2.8e-07	0.000119	-0.41	-0.27	Depression;	chr6:28197412	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-5.24	2.8e-07	0.000119	-0.41	-0.27	Depression;	chr6:28198669	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-5.24	2.8e-07	0.000119	-0.41	-0.27	Depression;	chr6:28205175	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	5.24	2.8e-07	0.000119	0.41	0.27	Depression;	chr6:28199145	chr6:28115628~28116551:+
LIHC	cis	rs10833905	0.756	rs12286745	ENSG00000246225.5	RP11-17A1.3	-5.24	2.8e-07	0.000119	-0.35	-0.27	Sudden cardiac arrest;	chr11:22980573	chr11:22829380~22945393:+
LIHC	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-5.24	2.8e-07	0.000119	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-5.24	2.8e-07	0.000119	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-5.24	2.8e-07	0.000119	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-5.24	2.8e-07	0.000119	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-5.24	2.8e-07	0.000119	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-5.24	2.8e-07	0.000119	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.58	rs35516100	ENSG00000259295.5	CSPG4P12	5.24	2.81e-07	0.000119	0.37	0.27	Schizophrenia;	chr15:84652199	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.58	rs62021208	ENSG00000259295.5	CSPG4P12	5.24	2.81e-07	0.000119	0.37	0.27	Schizophrenia;	chr15:84653013	chr15:85191438~85213905:+
LIHC	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	5.24	2.81e-07	0.00012	0.31	0.27	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
LIHC	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	5.24	2.81e-07	0.00012	0.32	0.27	Height;	chr6:109407238	chr6:109382795~109383666:+
LIHC	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	5.24	2.82e-07	0.00012	0.21	0.27	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
LIHC	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-5.24	2.82e-07	0.00012	-0.3	-0.27	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
LIHC	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	5.24	2.82e-07	0.00012	0.43	0.27	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
LIHC	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	5.24	2.82e-07	0.00012	0.43	0.27	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
LIHC	cis	rs5769765	0.773	rs138834	ENSG00000278869.1	CITF22-49E9.3	5.24	2.82e-07	0.00012	0.47	0.27	Schizophrenia;	chr22:49786849	chr22:49933198~49934074:-
LIHC	cis	rs7674212	0.772	rs13113099	ENSG00000230069.3	LRRC37A15P	-5.24	2.82e-07	0.00012	-0.25	-0.27	Type 2 diabetes;	chr4:103052965	chr4:102727274~102730721:-
LIHC	cis	rs2243480	0.522	rs73150635	ENSG00000273142.1	RP11-458F8.4	-5.24	2.82e-07	0.00012	-0.37	-0.27	Diabetic kidney disease;	chr7:66507503	chr7:66902857~66906297:+
LIHC	cis	rs4948102	0.642	rs766333	ENSG00000226278.1	PSPHP1	-5.24	2.82e-07	0.00012	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55764797~55773288:+
LIHC	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	5.24	2.82e-07	0.00012	0.35	0.27	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
LIHC	cis	rs5758511	0.68	rs5758657	ENSG00000237037.8	NDUFA6-AS1	-5.24	2.82e-07	0.00012	-0.34	-0.27	Birth weight;	chr22:42222663	chr22:42090931~42137742:+
LIHC	cis	rs7131987	0.718	rs7976961	ENSG00000275476.1	RP11-996F15.4	-5.24	2.82e-07	0.00012	-0.32	-0.27	QT interval;	chr12:29310155	chr12:29277397~29277882:-
LIHC	cis	rs2762353	0.526	rs12215823	ENSG00000216436.2	HIST1H2APS1	-5.24	2.83e-07	0.00012	-0.32	-0.27	Blood metabolite levels;	chr6:25725846	chr6:25732497~25732827:+
LIHC	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-5.24	2.83e-07	0.00012	-0.3	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
LIHC	cis	rs73081554	0.611	rs4681851	ENSG00000272360.1	RP11-359I18.5	-5.24	2.83e-07	0.00012	-0.41	-0.27	Rheumatoid arthritis;	chr3:58410164	chr3:58490830~58491291:-
LIHC	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-5.24	2.84e-07	0.000121	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
LIHC	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-5.24	2.84e-07	0.000121	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
LIHC	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-5.24	2.84e-07	0.000121	-0.28	-0.27	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
LIHC	cis	rs9527	0.662	rs10786714	ENSG00000236937.2	PTGES3P4	5.24	2.84e-07	0.000121	0.38	0.27	Arsenic metabolism;	chr10:102838849	chr10:102845595~102845950:+
LIHC	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-5.24	2.84e-07	0.000121	-0.28	-0.27	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
LIHC	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-5.24	2.85e-07	0.000121	-0.3	-0.27	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
LIHC	cis	rs3096299	0.632	rs8051537	ENSG00000261118.1	RP11-104N10.1	5.24	2.85e-07	0.000121	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89492017~89504460:-
LIHC	cis	rs75920871	0.841	rs78442878	ENSG00000254851.1	RP11-109L13.1	-5.24	2.85e-07	0.000121	-0.45	-0.27	Subjective well-being;	chr11:117052138	chr11:117135528~117138582:+
LIHC	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	5.24	2.85e-07	0.000121	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.58	rs11630887	ENSG00000259295.5	CSPG4P12	5.24	2.85e-07	0.000121	0.37	0.27	Schizophrenia;	chr15:84649784	chr15:85191438~85213905:+
LIHC	cis	rs113835537	0.877	rs2229456	ENSG00000255517.5	CTD-3074O7.5	-5.24	2.86e-07	0.000121	-0.36	-0.27	Airway imaging phenotypes;	chr11:66561270	chr11:66473490~66480233:-
LIHC	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-5.24	2.86e-07	0.000121	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
LIHC	cis	rs5758511	0.573	rs738248	ENSG00000237037.8	NDUFA6-AS1	5.24	2.86e-07	0.000121	0.32	0.27	Birth weight;	chr22:41800463	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.541	rs6002494	ENSG00000237037.8	NDUFA6-AS1	5.24	2.86e-07	0.000121	0.32	0.27	Birth weight;	chr22:41803856	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.513	rs7292782	ENSG00000237037.8	NDUFA6-AS1	5.24	2.86e-07	0.000121	0.32	0.27	Birth weight;	chr22:41804320	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.573	rs5996069	ENSG00000237037.8	NDUFA6-AS1	5.24	2.86e-07	0.000121	0.32	0.27	Birth weight;	chr22:41805181	chr22:42090931~42137742:+
LIHC	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-5.24	2.87e-07	0.000122	-0.24	-0.27	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-5.24	2.87e-07	0.000122	-0.24	-0.27	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
LIHC	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-5.24	2.87e-07	0.000122	-0.3	-0.27	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
LIHC	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	5.24	2.87e-07	0.000122	0.41	0.27	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
LIHC	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	5.24	2.87e-07	0.000122	0.26	0.27	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
LIHC	cis	rs6589219	0.721	rs6589218	ENSG00000196167.8	COLCA1	-5.24	2.87e-07	0.000122	-0.3	-0.27	Colorectal cancer;	chr11:111296832	chr11:111290787~111305045:-
LIHC	cis	rs5769765	1	rs5770728	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49866336	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.778	rs4574208	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49863090	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs5769760	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49866048	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs2295406	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49866521	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs8139758	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49867475	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.913	rs2319462	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49869722	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs5769761	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49869993	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.954	rs5769762	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49870394	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.908	rs2319464	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49872129	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs2319465	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49872136	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs34774661	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49873860	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs4824106	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49874174	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.954	rs5770739	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49874366	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs5770741	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49876567	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs5770742	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49876661	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs4597652	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49876922	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs5769764	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49877136	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs5769765	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49877528	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.865	rs4824108	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49877780	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.908	rs4824109	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49877812	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.837	rs4824110	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49877983	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs8184990	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49879526	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs5769767	ENSG00000278869.1	CITF22-49E9.3	-5.24	2.88e-07	0.000122	-0.4	-0.27	Schizophrenia;	chr22:49883261	chr22:49933198~49934074:-
LIHC	cis	rs9425766	0.655	rs6666767	ENSG00000227373.4	RP11-160H22.5	5.24	2.88e-07	0.000122	0.33	0.27	Life satisfaction;	chr1:174357564	chr1:174115300~174160004:-
LIHC	cis	rs113835537	0.808	rs10896128	ENSG00000255517.5	CTD-3074O7.5	-5.24	2.88e-07	0.000122	-0.38	-0.27	Airway imaging phenotypes;	chr11:66557058	chr11:66473490~66480233:-
LIHC	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-5.23	2.89e-07	0.000122	-0.28	-0.27	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
LIHC	cis	rs1577917	1	rs1962716	ENSG00000234155.1	RP11-30P6.6	5.23	2.89e-07	0.000123	0.35	0.27	Response to antipsychotic treatment;	chr6:85938718	chr6:85387219~85390186:-
LIHC	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-5.23	2.89e-07	0.000123	-0.33	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
LIHC	cis	rs2439831	1	rs690316	ENSG00000205771.5	CATSPER2P1	-5.23	2.9e-07	0.000123	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43445682	chr15:43726918~43747094:-
LIHC	cis	rs10510102	0.935	rs11200237	ENSG00000226864.1	ATE1-AS1	5.23	2.9e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121900715	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs78525391	ENSG00000226864.1	ATE1-AS1	5.23	2.9e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121901102	chr10:121928312~121951965:+
LIHC	cis	rs6085948	0.861	rs6077169	ENSG00000228888.1	LINC01428	-5.23	2.9e-07	0.000123	-0.39	-0.27	Interleukin-10 levels;	chr20:7267815	chr20:7146467~7254202:-
LIHC	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-5.23	2.9e-07	0.000123	-0.23	-0.27	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
LIHC	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	5.23	2.9e-07	0.000123	0.37	0.27	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
LIHC	cis	rs887829	0.57	rs6736508	ENSG00000233445.1	RPL17P11	5.23	2.9e-07	0.000123	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233687101	chr2:233721522~233722065:-
LIHC	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	5.23	2.91e-07	0.000123	0.31	0.27	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
LIHC	cis	rs4356203	0.905	rs2052188	ENSG00000272034.1	SNORD14A	5.23	2.91e-07	0.000123	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105123	chr11:17074654~17074744:-
LIHC	cis	rs10510102	0.935	rs10887016	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121893830	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10887018	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121894457	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200230	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121895117	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200234	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121895851	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12244951	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121896879	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs74362676	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121898216	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs3750837	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121899080	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs3750836	ENSG00000226864.1	ATE1-AS1	5.23	2.91e-07	0.000123	0.43	0.27	Breast cancer;	chr10:121899087	chr10:121928312~121951965:+
LIHC	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-5.23	2.92e-07	0.000123	-0.34	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
LIHC	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-5.23	2.92e-07	0.000123	-0.34	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
LIHC	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-5.23	2.92e-07	0.000123	-0.24	-0.27	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-5.23	2.92e-07	0.000123	-0.24	-0.27	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-5.23	2.92e-07	0.000123	-0.24	-0.27	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-5.23	2.92e-07	0.000123	-0.24	-0.27	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-5.23	2.92e-07	0.000123	-0.24	-0.27	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
LIHC	cis	rs6480314	0.636	rs34888891	ENSG00000233590.1	RP11-153K11.3	-5.23	2.92e-07	0.000124	-0.41	-0.27	Optic nerve measurement (disc area);	chr10:68242351	chr10:68233251~68242379:-
LIHC	cis	rs4731207	0.596	rs2170354	ENSG00000224897.5	POT1-AS1	5.23	2.92e-07	0.000124	0.34	0.27	Cutaneous malignant melanoma;	chr7:125025865	chr7:124929873~125179315:+
LIHC	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-5.23	2.92e-07	0.000124	-0.34	-0.27	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-5.23	2.92e-07	0.000124	-0.34	-0.27	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
LIHC	cis	rs9326248	0.581	rs10892076	ENSG00000280143.1	AP000892.6	5.23	2.93e-07	0.000124	0.31	0.27	Blood protein levels;	chr11:117118220	chr11:117204967~117210292:+
LIHC	cis	rs1577917	0.959	rs16876540	ENSG00000234155.1	RP11-30P6.6	5.23	2.93e-07	0.000124	0.36	0.27	Response to antipsychotic treatment;	chr6:85902801	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs35761942	ENSG00000234155.1	RP11-30P6.6	5.23	2.93e-07	0.000124	0.36	0.27	Response to antipsychotic treatment;	chr6:85919786	chr6:85387219~85390186:-
LIHC	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	5.23	2.93e-07	0.000124	0.3	0.27	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
LIHC	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-5.23	2.94e-07	0.000124	-0.44	-0.27	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
LIHC	cis	rs116175783	0.557	rs3769968	ENSG00000227403.1	AC009299.3	5.23	2.94e-07	0.000124	0.41	0.27	Intelligence (multi-trait analysis);	chr2:161309640	chr2:161244739~161249050:+
LIHC	cis	rs860295	0.627	rs11264410	ENSG00000203761.5	MSTO2P	-5.23	2.95e-07	0.000125	-0.22	-0.27	Body mass index;	chr1:155775558	chr1:155745829~155750137:+
LIHC	cis	rs10510102	0.935	rs11818001	ENSG00000226864.1	ATE1-AS1	-5.23	2.95e-07	0.000125	-0.42	-0.27	Breast cancer;	chr10:121884830	chr10:121928312~121951965:+
LIHC	cis	rs950169	0.58	rs11633762	ENSG00000259295.5	CSPG4P12	5.23	2.95e-07	0.000125	0.38	0.27	Schizophrenia;	chr15:84643921	chr15:85191438~85213905:+
LIHC	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	5.23	2.95e-07	0.000125	0.27	0.27	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
LIHC	cis	rs8031584	0.672	rs17815726	ENSG00000270015.1	RP11-540B6.6	5.23	2.96e-07	0.000125	0.38	0.27	Huntington's disease progression;	chr15:31021049	chr15:30926514~30928407:+
LIHC	cis	rs4731207	0.596	rs11767649	ENSG00000224897.5	POT1-AS1	-5.23	2.96e-07	0.000125	-0.33	-0.27	Cutaneous malignant melanoma;	chr7:124997463	chr7:124929873~125179315:+
LIHC	cis	rs2735413	0.875	rs8045975	ENSG00000276007.1	RP11-358L22.3	5.23	2.96e-07	0.000125	0.3	0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78056290	chr16:78123243~78124332:+
LIHC	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	5.23	2.96e-07	0.000125	0.58	0.27	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
LIHC	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-5.23	2.96e-07	0.000125	-0.31	-0.27	Height;	chr2:46636733	chr2:46668870~46670778:+
LIHC	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-5.23	2.97e-07	0.000125	-0.25	-0.27	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
LIHC	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-5.23	2.97e-07	0.000125	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
LIHC	cis	rs9291683	0.53	rs6449196	ENSG00000250413.1	RP11-448G15.1	5.23	2.97e-07	0.000125	0.35	0.27	Bone mineral density;	chr4:9972036	chr4:10006482~10009725:+
LIHC	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	5.23	2.97e-07	0.000125	0.32	0.27	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
LIHC	cis	rs5769765	0.632	rs13056783	ENSG00000278869.1	CITF22-49E9.3	-5.23	2.97e-07	0.000126	-0.4	-0.27	Schizophrenia;	chr22:49865504	chr22:49933198~49934074:-
LIHC	cis	rs887829	0.57	rs10203266	ENSG00000233445.1	RPL17P11	5.23	2.98e-07	0.000126	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233687722	chr2:233721522~233722065:-
LIHC	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-5.23	2.98e-07	0.000126	-0.23	-0.27	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
LIHC	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-5.23	2.98e-07	0.000126	-0.23	-0.27	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
LIHC	cis	rs1577917	0.958	rs34622605	ENSG00000234155.1	RP11-30P6.6	5.23	2.98e-07	0.000126	0.36	0.27	Response to antipsychotic treatment;	chr6:85746801	chr6:85387219~85390186:-
LIHC	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-5.23	2.98e-07	0.000126	-0.25	-0.27	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
LIHC	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	5.23	2.98e-07	0.000126	0.33	0.27	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
LIHC	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	5.23	2.98e-07	0.000126	0.47	0.27	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
LIHC	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	5.23	2.98e-07	0.000126	0.47	0.27	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
LIHC	cis	rs4731207	0.698	rs7811608	ENSG00000224897.5	POT1-AS1	-5.23	2.98e-07	0.000126	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124807794	chr7:124929873~125179315:+
LIHC	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	5.23	2.99e-07	0.000126	0.32	0.27	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	5.23	2.99e-07	0.000126	0.32	0.27	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
LIHC	cis	rs591584	0.59	rs7107559	ENSG00000255893.1	RP11-685N10.1	5.23	2.99e-07	0.000126	0.27	0.27	Macrophage Migration Inhibitory Factor levels;	chr11:94590508	chr11:94472908~94473570:-
LIHC	cis	rs202072	0.872	rs375661	ENSG00000215022.6	RP1-257A7.4	-5.23	2.99e-07	0.000126	-0.31	-0.27	HIV-1 viral setpoint;	chr6:13279199	chr6:13264861~13295586:-
LIHC	cis	rs2439831	1	rs690002	ENSG00000205771.5	CATSPER2P1	-5.23	2.99e-07	0.000126	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43437151	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs537115	ENSG00000205771.5	CATSPER2P1	-5.23	2.99e-07	0.000126	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43437750	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2245908	ENSG00000205771.5	CATSPER2P1	-5.23	2.99e-07	0.000126	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43439256	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2444029	ENSG00000205771.5	CATSPER2P1	-5.23	2.99e-07	0.000126	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43445286	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2467740	ENSG00000205771.5	CATSPER2P1	-5.23	2.99e-07	0.000126	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43454594	chr15:43726918~43747094:-
LIHC	cis	rs4356203	0.905	rs621246	ENSG00000272034.1	SNORD14A	-5.23	2.99e-07	0.000126	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17182218	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs635802	ENSG00000272034.1	SNORD14A	-5.23	2.99e-07	0.000126	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17183246	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs662711	ENSG00000272034.1	SNORD14A	-5.23	2.99e-07	0.000126	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17184641	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs598946	ENSG00000272034.1	SNORD14A	-5.23	2.99e-07	0.000126	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17187540	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs545773	ENSG00000272034.1	SNORD14A	-5.23	2.99e-07	0.000126	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192089	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.792	rs677540	ENSG00000272034.1	SNORD14A	-5.23	2.99e-07	0.000126	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192212	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs511119	ENSG00000272034.1	SNORD14A	-5.23	2.99e-07	0.000126	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193570	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs1989405	ENSG00000272034.1	SNORD14A	5.23	2.99e-07	0.000126	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17163272	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs214939	ENSG00000272034.1	SNORD14A	5.23	2.99e-07	0.000126	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165992	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs214936	ENSG00000272034.1	SNORD14A	5.23	2.99e-07	0.000126	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17169472	chr11:17074654~17074744:-
LIHC	cis	rs2739330	0.76	rs1002286	ENSG00000206090.4	AP000350.7	-5.23	2.99e-07	0.000126	-0.31	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23939998~23942798:+
LIHC	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-5.23	2.99e-07	0.000126	-0.34	-0.27	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
LIHC	cis	rs10510102	0.872	rs10887003	ENSG00000226864.1	ATE1-AS1	5.23	2.99e-07	0.000126	0.45	0.27	Breast cancer;	chr10:121864660	chr10:121928312~121951965:+
LIHC	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	5.23	3e-07	0.000126	0.2	0.27	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
LIHC	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-5.23	3e-07	0.000126	-0.33	-0.27	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
LIHC	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	5.23	3e-07	0.000127	0.36	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
LIHC	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-5.23	3e-07	0.000127	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
LIHC	cis	rs36715	0.953	rs2617613	ENSG00000245937.6	LINC01184	5.23	3.01e-07	0.000127	0.33	0.27	Breast cancer;	chr5:128216897	chr5:127940426~128083172:-
LIHC	cis	rs36715	0.868	rs2546147	ENSG00000245937.6	LINC01184	5.23	3.01e-07	0.000127	0.33	0.27	Breast cancer;	chr5:128216898	chr5:127940426~128083172:-
LIHC	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	5.23	3.01e-07	0.000127	0.48	0.27	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
LIHC	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	5.23	3.01e-07	0.000127	0.33	0.27	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
LIHC	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-5.23	3.01e-07	0.000127	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
LIHC	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	5.23	3.01e-07	0.000127	0.33	0.27	QT interval;	chr12:29284120	chr12:29277397~29277882:-
LIHC	cis	rs9533799	0.559	rs9533796	ENSG00000227258.4	SMIM2-AS1	-5.23	3.01e-07	0.000127	-0.32	-0.27	Amyotrophic lateral sclerosis;	chr13:44216310	chr13:44110451~44240517:+
LIHC	cis	rs1577917	0.545	rs9344548	ENSG00000234155.1	RP11-30P6.6	-5.23	3.01e-07	0.000127	-0.31	-0.27	Response to antipsychotic treatment;	chr6:85777619	chr6:85387219~85390186:-
LIHC	cis	rs752590	0.65	rs6751201	ENSG00000189223.12	PAX8-AS1	5.23	3.02e-07	0.000127	0.39	0.27	Mucinous ovarian carcinoma;	chr2:113195122	chr2:113211522~113276581:+
LIHC	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	5.23	3.02e-07	0.000127	0.2	0.27	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
LIHC	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-5.23	3.02e-07	0.000127	-0.38	-0.27	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
LIHC	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-5.23	3.02e-07	0.000127	-0.31	-0.27	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
LIHC	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-5.23	3.02e-07	0.000127	-0.4	-0.27	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
LIHC	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	5.23	3.02e-07	0.000127	0.32	0.27	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	5.23	3.02e-07	0.000127	0.32	0.27	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
LIHC	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-5.23	3.03e-07	0.000128	-0.27	-0.27	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
LIHC	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	5.23	3.03e-07	0.000128	0.36	0.27	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
LIHC	cis	rs228614	0.536	rs223437	ENSG00000230069.3	LRRC37A15P	-5.23	3.03e-07	0.000128	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102727274~102730721:-
LIHC	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	5.23	3.03e-07	0.000128	0.33	0.27	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
LIHC	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-5.22	3.04e-07	0.000128	-0.31	-0.27	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
LIHC	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	5.22	3.04e-07	0.000128	0.37	0.27	Height;	chr6:109381443	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	5.22	3.04e-07	0.000128	0.37	0.27	Height;	chr6:109382480	chr6:109382795~109383666:+
LIHC	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-5.22	3.04e-07	0.000128	-0.45	-0.27	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-5.22	3.04e-07	0.000128	-0.45	-0.27	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-5.22	3.04e-07	0.000128	-0.45	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-5.22	3.04e-07	0.000128	-0.45	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-5.22	3.04e-07	0.000128	-0.45	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-5.22	3.04e-07	0.000128	-0.45	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
LIHC	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-5.22	3.04e-07	0.000128	-0.25	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
LIHC	cis	rs950169	0.58	rs11636189	ENSG00000259295.5	CSPG4P12	5.22	3.04e-07	0.000128	0.37	0.27	Schizophrenia;	chr15:84650323	chr15:85191438~85213905:+
LIHC	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-5.22	3.04e-07	0.000128	-0.29	-0.27	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
LIHC	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	5.22	3.04e-07	0.000128	0.35	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
LIHC	cis	rs1023500	0.505	rs134886	ENSG00000227370.1	RP4-669P10.19	5.22	3.05e-07	0.000128	0.28	0.27	Schizophrenia;	chr22:42277850	chr22:42132543~42132998:+
LIHC	cis	rs804280	0.662	rs11250164	ENSG00000255394.4	C8orf49	-5.22	3.06e-07	0.000129	-0.36	-0.27	Myopia (pathological);	chr8:11753177	chr8:11761256~11763223:+
LIHC	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-5.22	3.06e-07	0.000129	-0.41	-0.27	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
LIHC	cis	rs2522056	0.935	rs757104	ENSG00000233006.5	AC034220.3	-5.22	3.06e-07	0.000129	-0.29	-0.27	Fibrinogen;Lymphocyte counts;	chr5:132459537	chr5:132311285~132369916:-
LIHC	cis	rs75920871	0.513	rs76904522	ENSG00000254851.1	RP11-109L13.1	-5.22	3.06e-07	0.000129	-0.52	-0.27	Subjective well-being;	chr11:117144147	chr11:117135528~117138582:+
LIHC	cis	rs75920871	0.513	rs113560866	ENSG00000254851.1	RP11-109L13.1	-5.22	3.06e-07	0.000129	-0.52	-0.27	Subjective well-being;	chr11:117144473	chr11:117135528~117138582:+
LIHC	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	5.22	3.07e-07	0.000129	0.38	0.27	Height;	chr6:109359125	chr6:109382795~109383666:+
LIHC	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-5.22	3.07e-07	0.000129	-0.31	-0.27	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
LIHC	cis	rs2565722	0.508	rs1652483	ENSG00000243831.1	RP1-81D8.4	5.22	3.07e-07	0.000129	0.36	0.27	Blood protein levels;	chr6:160777051	chr6:160666228~160676523:-
LIHC	cis	rs5756813	0.754	rs4821708	ENSG00000233360.4	Z83844.1	5.22	3.07e-07	0.000129	0.34	0.27	Optic cup area;Vertical cup-disc ratio;	chr22:37768099	chr22:37641832~37658377:-
LIHC	cis	rs2565722	0.508	rs1652486	ENSG00000243831.1	RP1-81D8.4	5.22	3.08e-07	0.000129	0.36	0.27	Blood protein levels;	chr6:160778168	chr6:160666228~160676523:-
LIHC	cis	rs2565722	0.508	rs1782601	ENSG00000243831.1	RP1-81D8.4	5.22	3.08e-07	0.000129	0.36	0.27	Blood protein levels;	chr6:160778181	chr6:160666228~160676523:-
LIHC	cis	rs2565722	0.508	rs1652487	ENSG00000243831.1	RP1-81D8.4	5.22	3.08e-07	0.000129	0.36	0.27	Blood protein levels;	chr6:160778362	chr6:160666228~160676523:-
LIHC	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-5.22	3.08e-07	0.000129	-0.28	-0.27	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
LIHC	cis	rs7131987	0.65	rs7954871	ENSG00000275476.1	RP11-996F15.4	-5.22	3.08e-07	0.000129	-0.32	-0.27	QT interval;	chr12:29306799	chr12:29277397~29277882:-
LIHC	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-5.22	3.09e-07	0.00013	-0.33	-0.27	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
LIHC	cis	rs4356203	0.875	rs214935	ENSG00000272034.1	SNORD14A	-5.22	3.09e-07	0.00013	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17171575	chr11:17074654~17074744:-
LIHC	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	5.22	3.1e-07	0.00013	0.35	0.27	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
LIHC	cis	rs6504950	0.579	rs8075983	ENSG00000275710.1	RP11-257O5.4	5.22	3.1e-07	0.00013	0.45	0.27	Breast cancer;	chr17:55194557	chr17:54964474~54964679:+
LIHC	cis	rs4356203	0.87	rs7936310	ENSG00000272034.1	SNORD14A	5.22	3.11e-07	0.00013	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17074654~17074744:-
LIHC	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	5.22	3.11e-07	0.00013	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	5.22	3.11e-07	0.00013	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	5.22	3.11e-07	0.00013	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
LIHC	cis	rs4731207	0.596	rs12537431	ENSG00000224897.5	POT1-AS1	5.22	3.11e-07	0.00013	0.33	0.27	Cutaneous malignant melanoma;	chr7:124946502	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.561	rs12706631	ENSG00000224897.5	POT1-AS1	5.22	3.11e-07	0.00013	0.33	0.27	Cutaneous malignant melanoma;	chr7:124946526	chr7:124929873~125179315:+
LIHC	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-5.22	3.11e-07	0.00013	-0.44	-0.27	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
LIHC	cis	rs12701220	0.948	rs10275712	ENSG00000229043.2	AC091729.9	-5.22	3.11e-07	0.000131	-0.39	-0.27	Bronchopulmonary dysplasia;	chr7:1043282	chr7:1160374~1165267:+
LIHC	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	5.22	3.11e-07	0.000131	0.3	0.27	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
LIHC	cis	rs950169	0.887	rs12903946	ENSG00000259295.5	CSPG4P12	5.22	3.11e-07	0.000131	0.37	0.27	Schizophrenia;	chr15:84399732	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.887	rs62029593	ENSG00000259295.5	CSPG4P12	5.22	3.11e-07	0.000131	0.37	0.27	Schizophrenia;	chr15:84400482	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.81	rs62029594	ENSG00000259295.5	CSPG4P12	5.22	3.11e-07	0.000131	0.37	0.27	Schizophrenia;	chr15:84400554	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.881	rs62029596	ENSG00000259295.5	CSPG4P12	5.22	3.11e-07	0.000131	0.37	0.27	Schizophrenia;	chr15:84400736	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.881	rs4081123	ENSG00000259295.5	CSPG4P12	5.22	3.11e-07	0.000131	0.37	0.27	Schizophrenia;	chr15:84401537	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.881	rs62029599	ENSG00000259295.5	CSPG4P12	5.22	3.11e-07	0.000131	0.37	0.27	Schizophrenia;	chr15:84401867	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.8	rs4099846	ENSG00000259295.5	CSPG4P12	5.22	3.11e-07	0.000131	0.37	0.27	Schizophrenia;	chr15:84402196	chr15:85191438~85213905:+
LIHC	cis	rs3096299	0.719	rs2965817	ENSG00000261118.1	RP11-104N10.1	5.22	3.12e-07	0.000131	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89492017~89504460:-
LIHC	cis	rs2439831	1	rs471229	ENSG00000205771.5	CATSPER2P1	-5.22	3.12e-07	0.000131	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43441796	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2439841	ENSG00000205771.5	CATSPER2P1	-5.22	3.12e-07	0.000131	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43442551	chr15:43726918~43747094:-
LIHC	cis	rs1577917	0.545	rs1832070	ENSG00000234155.1	RP11-30P6.6	-5.22	3.12e-07	0.000131	-0.31	-0.27	Response to antipsychotic treatment;	chr6:85773454	chr6:85387219~85390186:-
LIHC	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	5.22	3.13e-07	0.000131	0.41	0.27	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
LIHC	cis	rs4948102	0.597	rs12669623	ENSG00000226278.1	PSPHP1	-5.22	3.13e-07	0.000131	-0.31	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55764797~55773288:+
LIHC	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-5.22	3.13e-07	0.000131	-0.34	-0.27	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
LIHC	cis	rs6600671	0.934	rs11249348	ENSG00000231429.2	RP11-343N15.2	-5.22	3.13e-07	0.000131	-0.31	-0.27	Hip geometry;	chr1:121446444	chr1:121412719~121429274:+
LIHC	cis	rs6686842	0.798	rs12037263	ENSG00000235358.1	RP11-399E6.1	5.22	3.14e-07	0.000132	0.3	0.27	Height;	chr1:41016828	chr1:41242373~41284861:+
LIHC	cis	rs739496	0.793	rs73199895	ENSG00000226469.1	ADAM1B	5.22	3.14e-07	0.000132	0.33	0.27	Platelet count;	chr12:111428283	chr12:111927018~111929017:+
LIHC	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	5.22	3.15e-07	0.000132	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
LIHC	cis	rs3096299	0.967	rs2911256	ENSG00000261118.1	RP11-104N10.1	5.22	3.15e-07	0.000132	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89492017~89504460:-
LIHC	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-5.22	3.15e-07	0.000132	-0.33	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
LIHC	cis	rs10510102	0.935	rs12251175	ENSG00000226864.1	ATE1-AS1	5.22	3.15e-07	0.000132	0.43	0.27	Breast cancer;	chr10:121889015	chr10:121928312~121951965:+
LIHC	cis	rs17301013	0.965	rs7548540	ENSG00000227373.4	RP11-160H22.5	5.22	3.15e-07	0.000132	0.33	0.27	Systemic lupus erythematosus;	chr1:174411672	chr1:174115300~174160004:-
LIHC	cis	rs2565722	0.508	rs1652481	ENSG00000243831.1	RP1-81D8.4	5.22	3.15e-07	0.000132	0.36	0.27	Blood protein levels;	chr6:160776850	chr6:160666228~160676523:-
LIHC	cis	rs2072510	0.569	rs61937880	ENSG00000257715.1	RP11-256L6.2	-5.22	3.16e-07	0.000132	-0.41	-0.27	Metabolite levels (small molecules and protein measures);	chr12:95997089	chr12:96025323~96027971:+
LIHC	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	5.22	3.16e-07	0.000132	0.44	0.27	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	5.22	3.16e-07	0.000132	0.44	0.27	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
LIHC	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-5.22	3.16e-07	0.000132	-0.34	-0.27	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
LIHC	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	5.22	3.16e-07	0.000132	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
LIHC	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-5.22	3.16e-07	0.000132	-0.29	-0.27	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
LIHC	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	5.22	3.16e-07	0.000132	0.33	0.27	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
LIHC	cis	rs4731207	0.698	rs12537161	ENSG00000224897.5	POT1-AS1	5.22	3.17e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124898536	chr7:124929873~125179315:+
LIHC	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	5.22	3.17e-07	0.000133	0.24	0.27	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
LIHC	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-5.22	3.17e-07	0.000133	-0.28	-0.27	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
LIHC	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-5.22	3.18e-07	0.000133	-0.23	-0.27	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
LIHC	cis	rs4731207	0.698	rs34600520	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124850884	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10271687	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124853677	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10228376	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124853689	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10156168	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124854356	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs10246553	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124854880	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs11975788	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124857757	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10233306	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124858363	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6959712	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124858949	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4422720	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124859348	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.751	rs4584095	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124860156	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.724	rs57458159	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124860756	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.655	rs7808203	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124862082	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6961292	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124863135	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7782327	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124865897	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7782340	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124865971	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.724	rs6953168	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124866287	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6973812	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124866696	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs12538333	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124868303	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10272583	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124869397	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs12536575	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124870222	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs9886177	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124873396	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4463363	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124873716	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6466954	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124875292	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs6973134	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124875319	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7789859	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124879418	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4379394	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124879573	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4311608	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124879653	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.661	rs6466956	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124880312	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7799938	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124881337	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.671	rs12530981	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124881668	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.697	rs4360235	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124886488	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7778544	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124887427	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4279518	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124888032	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6956638	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124890061	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6960683	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124890314	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.724	rs10224946	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124891284	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6966415	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124891415	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs7357296	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124892662	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4377885	ENSG00000224897.5	POT1-AS1	-5.22	3.18e-07	0.000133	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124893626	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10245872	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124895199	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10954049	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124895396	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7793441	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124896184	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10223980	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124896504	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10228682	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124897982	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10236403	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124899488	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs4283967	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124900481	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.724	rs4383910	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124900787	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.541	rs6960027	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124902957	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs35630355	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124909279	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.724	rs6968693	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124909922	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7794631	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124911871	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.689	rs2054585	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124912393	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs1904975	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124912748	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs3919896	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124912953	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs12538083	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124914003	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7794710	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124921061	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs12533560	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124921828	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.597	rs12536017	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124922247	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs28409696	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124922461	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6968187	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124923286	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6949341	ENSG00000224897.5	POT1-AS1	5.22	3.18e-07	0.000133	0.32	0.27	Cutaneous malignant melanoma;	chr7:124924122	chr7:124929873~125179315:+
LIHC	cis	rs10833905	0.756	rs10833866	ENSG00000246225.5	RP11-17A1.3	-5.22	3.19e-07	0.000133	-0.36	-0.27	Sudden cardiac arrest;	chr11:22955270	chr11:22829380~22945393:+
LIHC	cis	rs113835537	0.735	rs519380	ENSG00000255517.5	CTD-3074O7.5	-5.21	3.19e-07	0.000133	-0.35	-0.27	Airway imaging phenotypes;	chr11:66641938	chr11:66473490~66480233:-
LIHC	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	5.21	3.19e-07	0.000133	0.35	0.27	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
LIHC	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-5.21	3.19e-07	0.000133	-0.27	-0.27	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
LIHC	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-5.21	3.2e-07	0.000133	-0.41	-0.27	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
LIHC	cis	rs4731207	0.596	rs7799523	ENSG00000224897.5	POT1-AS1	5.21	3.2e-07	0.000133	0.33	0.27	Cutaneous malignant melanoma;	chr7:124951979	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.569	rs7799535	ENSG00000224897.5	POT1-AS1	5.21	3.2e-07	0.000133	0.33	0.27	Cutaneous malignant melanoma;	chr7:124952006	chr7:124929873~125179315:+
LIHC	cis	rs17301013	0.965	rs2179214	ENSG00000227373.4	RP11-160H22.5	5.21	3.2e-07	0.000134	0.33	0.27	Systemic lupus erythematosus;	chr1:174413954	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.93	rs7523263	ENSG00000227373.4	RP11-160H22.5	5.21	3.2e-07	0.000134	0.33	0.27	Systemic lupus erythematosus;	chr1:174414542	chr1:174115300~174160004:-
LIHC	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	5.21	3.21e-07	0.000134	0.44	0.27	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
LIHC	cis	rs4731207	0.698	rs11979724	ENSG00000224897.5	POT1-AS1	-5.21	3.21e-07	0.000134	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124810991	chr7:124929873~125179315:+
LIHC	cis	rs3096299	0.658	rs34590044	ENSG00000261118.1	RP11-104N10.1	5.21	3.22e-07	0.000134	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89492017~89504460:-
LIHC	cis	rs2836974	0.623	rs34240248	ENSG00000255568.3	BRWD1-AS2	-5.21	3.22e-07	0.000134	-0.23	-0.27	Cognitive function;	chr21:39313313	chr21:39313935~39314962:+
LIHC	cis	rs2439831	1	rs2467743	ENSG00000205771.5	CATSPER2P1	-5.21	3.23e-07	0.000135	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43458148	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs2245176	ENSG00000205771.5	CATSPER2P1	-5.21	3.23e-07	0.000135	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43458564	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2245054	ENSG00000205771.5	CATSPER2P1	-5.21	3.23e-07	0.000135	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43459711	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs2264876	ENSG00000205771.5	CATSPER2P1	-5.21	3.23e-07	0.000135	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43465221	chr15:43726918~43747094:-
LIHC	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	5.21	3.23e-07	0.000135	0.45	0.27	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
LIHC	cis	rs4731207	0.698	rs10261610	ENSG00000224897.5	POT1-AS1	-5.21	3.23e-07	0.000135	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124810523	chr7:124929873~125179315:+
LIHC	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	5.21	3.24e-07	0.000135	0.3	0.27	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
LIHC	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	5.21	3.24e-07	0.000135	0.34	0.27	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
LIHC	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-5.21	3.24e-07	0.000135	-0.4	-0.27	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
LIHC	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-5.21	3.24e-07	0.000135	-0.28	-0.27	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
LIHC	cis	rs12908161	1	rs35808647	ENSG00000259295.5	CSPG4P12	5.21	3.24e-07	0.000135	0.38	0.27	Schizophrenia;	chr15:84834210	chr15:85191438~85213905:+
LIHC	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-5.21	3.24e-07	0.000135	-0.31	-0.27	Height;	chr2:46641180	chr2:46668870~46670778:+
LIHC	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	5.21	3.24e-07	0.000135	0.5	0.27	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
LIHC	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	5.21	3.24e-07	0.000135	0.3	0.27	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
LIHC	cis	rs1577917	0.771	rs2484355	ENSG00000234155.1	RP11-30P6.6	5.21	3.25e-07	0.000135	0.35	0.27	Response to antipsychotic treatment;	chr6:85684685	chr6:85387219~85390186:-
LIHC	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-5.21	3.25e-07	0.000135	-0.25	-0.27	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
LIHC	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	5.21	3.26e-07	0.000136	0.3	0.27	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
LIHC	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	5.21	3.26e-07	0.000136	0.3	0.27	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
LIHC	cis	rs10510102	0.935	rs11200187	ENSG00000226864.1	ATE1-AS1	5.21	3.26e-07	0.000136	0.44	0.27	Breast cancer;	chr10:121843050	chr10:121928312~121951965:+
LIHC	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	5.21	3.26e-07	0.000136	0.51	0.27	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
LIHC	cis	rs4731207	0.536	rs2127967	ENSG00000224897.5	POT1-AS1	5.21	3.27e-07	0.000136	0.33	0.27	Cutaneous malignant melanoma;	chr7:124965618	chr7:124929873~125179315:+
LIHC	cis	rs2998286	0.862	rs2153300	ENSG00000254635.4	WAC-AS1	-5.21	3.27e-07	0.000136	-0.34	-0.27	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519041	chr10:28522652~28532743:-
LIHC	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	5.21	3.27e-07	0.000136	0.29	0.27	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
LIHC	cis	rs4731207	0.698	rs6977407	ENSG00000224897.5	POT1-AS1	5.21	3.28e-07	0.000136	0.32	0.27	Cutaneous malignant melanoma;	chr7:124858948	chr7:124929873~125179315:+
LIHC	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-5.21	3.28e-07	0.000136	-0.29	-0.27	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
LIHC	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	5.21	3.28e-07	0.000136	0.31	0.27	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
LIHC	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	5.21	3.28e-07	0.000136	0.21	0.27	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
LIHC	cis	rs4660214	0.666	rs587404	ENSG00000182109.6	RP11-69E11.4	5.21	3.28e-07	0.000137	0.29	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39522280~39546187:-
LIHC	cis	rs12701220	0.901	rs12701713	ENSG00000229043.2	AC091729.9	-5.21	3.28e-07	0.000137	-0.37	-0.27	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1160374~1165267:+
LIHC	cis	rs36715	0.909	rs152906	ENSG00000245937.6	LINC01184	5.21	3.28e-07	0.000137	0.33	0.27	Breast cancer;	chr5:128216148	chr5:127940426~128083172:-
LIHC	cis	rs17301013	0.932	rs727279	ENSG00000227373.4	RP11-160H22.5	5.21	3.28e-07	0.000137	0.33	0.27	Systemic lupus erythematosus;	chr1:174496026	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.794	rs6425283	ENSG00000227373.4	RP11-160H22.5	5.21	3.28e-07	0.000137	0.33	0.27	Systemic lupus erythematosus;	chr1:174499853	chr1:174115300~174160004:-
LIHC	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-5.21	3.28e-07	0.000137	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-5.21	3.29e-07	0.000137	-0.33	-0.27	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
LIHC	cis	rs4356203	0.905	rs6486352	ENSG00000272034.1	SNORD14A	5.21	3.29e-07	0.000137	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17150823	chr11:17074654~17074744:-
LIHC	cis	rs10510102	0.872	rs12264046	ENSG00000226864.1	ATE1-AS1	5.21	3.29e-07	0.000137	0.43	0.27	Breast cancer;	chr10:121894996	chr10:121928312~121951965:+
LIHC	cis	rs2749592	0.55	rs4934881	ENSG00000263064.2	RP11-291L22.7	-5.21	3.3e-07	0.000137	-0.28	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38448689~38448949:+
LIHC	cis	rs4731207	0.698	rs34618371	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124856116	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4552839	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124859460	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6466955	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124878712	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7796015	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124881092	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4319000	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124888001	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6415362	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124890596	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.724	rs10229152	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124898231	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10252039	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124899483	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10255209	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124914873	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs2219954	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124915801	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.724	rs4146110	ENSG00000224897.5	POT1-AS1	5.21	3.3e-07	0.000137	0.32	0.27	Cutaneous malignant melanoma;	chr7:124921154	chr7:124929873~125179315:+
LIHC	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-5.21	3.3e-07	0.000137	-0.35	-0.27	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
LIHC	cis	rs9890032	0.934	rs7225461	ENSG00000263531.1	RP13-753N3.1	5.21	3.3e-07	0.000137	0.33	0.27	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30863921~30864940:-
LIHC	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-5.21	3.3e-07	0.000137	-0.34	-0.27	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
LIHC	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	5.21	3.31e-07	0.000137	0.3	0.27	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
LIHC	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	5.21	3.31e-07	0.000137	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
LIHC	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-5.21	3.31e-07	0.000137	-0.29	-0.27	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
LIHC	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	5.21	3.31e-07	0.000138	0.35	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
LIHC	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	5.21	3.31e-07	0.000138	0.35	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
LIHC	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	5.21	3.31e-07	0.000138	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
LIHC	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-5.21	3.32e-07	0.000138	-0.31	-0.27	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
LIHC	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	5.21	3.32e-07	0.000138	0.26	0.27	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
LIHC	cis	rs12908161	0.959	rs1051168	ENSG00000259295.5	CSPG4P12	5.21	3.33e-07	0.000138	0.38	0.27	Schizophrenia;	chr15:84657289	chr15:85191438~85213905:+
LIHC	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-5.21	3.33e-07	0.000138	-0.27	-0.27	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
LIHC	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-5.21	3.33e-07	0.000139	-0.24	-0.27	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
LIHC	cis	rs17301013	0.794	rs1793293	ENSG00000227373.4	RP11-160H22.5	-5.21	3.34e-07	0.000139	-0.35	-0.27	Systemic lupus erythematosus;	chr1:174774451	chr1:174115300~174160004:-
LIHC	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-5.21	3.34e-07	0.000139	-0.32	-0.27	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
LIHC	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-5.21	3.34e-07	0.000139	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
LIHC	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-5.21	3.34e-07	0.000139	-0.41	-0.27	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
LIHC	cis	rs4731207	0.698	rs7801140	ENSG00000224897.5	POT1-AS1	5.21	3.35e-07	0.000139	0.32	0.27	Cutaneous malignant melanoma;	chr7:124865707	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs7782031	ENSG00000224897.5	POT1-AS1	5.21	3.35e-07	0.000139	0.32	0.27	Cutaneous malignant melanoma;	chr7:124865730	chr7:124929873~125179315:+
LIHC	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-5.21	3.35e-07	0.000139	-0.29	-0.27	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-5.21	3.35e-07	0.000139	-0.29	-0.27	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
LIHC	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-5.21	3.35e-07	0.000139	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
LIHC	cis	rs228614	0.509	rs223486	ENSG00000230069.3	LRRC37A15P	-5.21	3.35e-07	0.000139	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102727274~102730721:-
LIHC	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	5.2	3.35e-07	0.000139	0.42	0.27	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
LIHC	cis	rs9425766	0.631	rs10158289	ENSG00000227373.4	RP11-160H22.5	5.2	3.35e-07	0.000139	0.33	0.27	Life satisfaction;	chr1:174081529	chr1:174115300~174160004:-
LIHC	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	5.2	3.36e-07	0.000139	0.21	0.27	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
LIHC	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	5.2	3.36e-07	0.00014	0.35	0.27	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
LIHC	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-5.2	3.36e-07	0.00014	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
LIHC	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	5.2	3.37e-07	0.00014	0.35	0.27	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
LIHC	cis	rs9467711	0.651	rs13192713	ENSG00000216436.2	HIST1H2APS1	5.2	3.37e-07	0.00014	0.73	0.27	Autism spectrum disorder or schizophrenia;	chr6:25943006	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs35778245	ENSG00000216436.2	HIST1H2APS1	5.2	3.37e-07	0.00014	0.73	0.27	Autism spectrum disorder or schizophrenia;	chr6:25944575	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs2051539	ENSG00000216436.2	HIST1H2APS1	5.2	3.37e-07	0.00014	0.73	0.27	Autism spectrum disorder or schizophrenia;	chr6:25947031	chr6:25732497~25732827:+
LIHC	cis	rs2877649	0.51	rs10083379	ENSG00000258744.1	RP11-80A15.1	-5.2	3.37e-07	0.00014	-0.48	-0.27	Smooth-surface caries;	chr14:24438856	chr14:24501594~24508688:+
LIHC	cis	rs10510102	0.935	rs7906667	ENSG00000226864.1	ATE1-AS1	5.2	3.37e-07	0.00014	0.43	0.27	Breast cancer;	chr10:121909142	chr10:121928312~121951965:+
LIHC	cis	rs2836974	0.644	rs61300849	ENSG00000255568.3	BRWD1-AS2	-5.2	3.38e-07	0.00014	-0.23	-0.27	Cognitive function;	chr21:39308268	chr21:39313935~39314962:+
LIHC	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-5.2	3.38e-07	0.00014	-0.58	-0.27	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
LIHC	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-5.2	3.39e-07	0.00014	-0.45	-0.27	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
LIHC	cis	rs4731207	0.596	rs1871772	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125038818	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6948283	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125039469	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs6977613	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125041737	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.562	rs6975534	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125046407	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.561	rs6975148	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125046454	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6959632	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125050992	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466990	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125051458	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1600741	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125052238	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.591	rs1481336	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125056685	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs12537473	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124946657	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs10954053	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124946761	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs13233978	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124947566	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs34555990	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124947790	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs28817916	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124948496	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.57	rs10954055	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124949178	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs12113765	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124949630	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.591	rs11772336	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124949742	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6961441	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124950817	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6971413	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124952614	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs6466970	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124952701	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs2127971	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124955255	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs6466972	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124956195	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10239507	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124956731	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.535	rs28820311	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124958935	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs7777126	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124959688	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs10954056	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124960480	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs12538641	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124960617	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.536	rs13307657	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124960810	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.535	rs7806126	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124961821	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs10260039	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124963492	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs12531844	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124963846	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs922711	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124964250	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs11980178	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124964606	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs1011721	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124965105	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1011722	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124965153	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1011723	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124965207	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466973	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124965372	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs922712	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124966996	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs922713	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124967005	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10276834	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:124967495	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7794538	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125008796	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs10270051	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125009339	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10274384	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125010383	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs7811203	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125013320	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10500098	ENSG00000224897.5	POT1-AS1	5.2	3.39e-07	0.00014	0.33	0.27	Cutaneous malignant melanoma;	chr7:125018001	chr7:124929873~125179315:+
LIHC	cis	rs2836974	0.568	rs2836969	ENSG00000255568.3	BRWD1-AS2	-5.2	3.39e-07	0.00014	-0.23	-0.27	Cognitive function;	chr21:39276339	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.584	rs6517535	ENSG00000255568.3	BRWD1-AS2	-5.2	3.39e-07	0.00014	-0.23	-0.27	Cognitive function;	chr21:39281426	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.627	rs7278985	ENSG00000255568.3	BRWD1-AS2	-5.2	3.39e-07	0.00014	-0.23	-0.27	Cognitive function;	chr21:39281841	chr21:39313935~39314962:+
LIHC	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	5.2	3.39e-07	0.00014	0.33	0.27	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
LIHC	cis	rs7945705	0.967	rs10840147	ENSG00000254860.4	TMEM9B-AS1	-5.2	3.4e-07	0.000141	-0.27	-0.27	Hemoglobin concentration;	chr11:8899157	chr11:8964675~8977527:+
LIHC	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-5.2	3.41e-07	0.000141	-0.29	-0.27	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-5.2	3.41e-07	0.000141	-0.29	-0.27	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-5.2	3.41e-07	0.000141	-0.29	-0.27	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
LIHC	cis	rs5758511	0.596	rs55644935	ENSG00000237037.8	NDUFA6-AS1	-5.2	3.41e-07	0.000141	-0.34	-0.27	Birth weight;	chr22:42270063	chr22:42090931~42137742:+
LIHC	cis	rs4356203	0.875	rs680205	ENSG00000272034.1	SNORD14A	-5.2	3.41e-07	0.000141	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186210	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs536628	ENSG00000272034.1	SNORD14A	-5.2	3.41e-07	0.000141	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186545	chr11:17074654~17074744:-
LIHC	cis	rs4731207	0.596	rs10280341	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124943881	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs12111658	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124944714	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs12111660	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124944741	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.569	rs1600746	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124945041	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1600745	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124945129	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.623	rs1600744	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124945906	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7779594	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124996941	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs11767737	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124997851	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1531715	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124998153	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1531716	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124998484	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1552119	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:124998822	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs13231916	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:125000171	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs11763920	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:125000826	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.569	rs1986124	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:125001663	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1531717	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:125004636	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7810120	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:125004891	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7778875	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:125005392	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs12538171	ENSG00000224897.5	POT1-AS1	5.2	3.42e-07	0.000141	0.33	0.27	Cutaneous malignant melanoma;	chr7:125005516	chr7:124929873~125179315:+
LIHC	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	5.2	3.42e-07	0.000141	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
LIHC	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	5.2	3.42e-07	0.000141	0.35	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
LIHC	cis	rs10510102	0.935	rs7923634	ENSG00000226864.1	ATE1-AS1	5.2	3.42e-07	0.000142	0.43	0.27	Breast cancer;	chr10:121832800	chr10:121928312~121951965:+
LIHC	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-5.2	3.42e-07	0.000142	-0.28	-0.27	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
LIHC	cis	rs1577917	1	rs12192992	ENSG00000234155.1	RP11-30P6.6	5.2	3.42e-07	0.000142	0.36	0.27	Response to antipsychotic treatment;	chr6:85900197	chr6:85387219~85390186:-
LIHC	cis	rs8028182	0.549	rs10775209	ENSG00000260269.4	CTD-2323K18.1	5.2	3.42e-07	0.000142	0.35	0.27	Sudden cardiac arrest;	chr15:75342418	chr15:75527150~75601205:-
LIHC	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-5.2	3.43e-07	0.000142	-0.24	-0.27	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
LIHC	cis	rs4731207	0.698	rs2040926	ENSG00000224897.5	POT1-AS1	5.2	3.43e-07	0.000142	0.32	0.27	Cutaneous malignant melanoma;	chr7:124817241	chr7:124929873~125179315:+
LIHC	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000142	-0.28	-0.27	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000142	-0.28	-0.27	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
LIHC	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	5.2	3.45e-07	0.000143	0.35	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
LIHC	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-5.2	3.45e-07	0.000143	-0.28	-0.27	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
LIHC	cis	rs950169	0.881	rs150965	ENSG00000259295.5	CSPG4P12	5.2	3.45e-07	0.000143	0.37	0.27	Schizophrenia;	chr15:84537296	chr15:85191438~85213905:+
LIHC	cis	rs9326248	0.53	rs6589576	ENSG00000280143.1	AP000892.6	-5.2	3.45e-07	0.000143	-0.34	-0.27	Blood protein levels;	chr11:116865072	chr11:117204967~117210292:+
LIHC	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	5.2	3.46e-07	0.000143	0.25	0.27	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
LIHC	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	5.2	3.46e-07	0.000143	0.3	0.27	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
LIHC	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	5.2	3.46e-07	0.000143	0.2	0.27	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
LIHC	cis	rs1577917	0.958	rs10944137	ENSG00000234155.1	RP11-30P6.6	5.2	3.47e-07	0.000143	0.36	0.27	Response to antipsychotic treatment;	chr6:85744596	chr6:85387219~85390186:-
LIHC	cis	rs36715	0.951	rs36698	ENSG00000245937.6	LINC01184	5.2	3.47e-07	0.000143	0.33	0.27	Breast cancer;	chr5:128214057	chr5:127940426~128083172:-
LIHC	cis	rs5758511	0.68	rs5758651	ENSG00000237037.8	NDUFA6-AS1	-5.2	3.47e-07	0.000143	-0.34	-0.27	Birth weight;	chr22:42213142	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.68	rs5758652	ENSG00000237037.8	NDUFA6-AS1	-5.2	3.47e-07	0.000143	-0.34	-0.27	Birth weight;	chr22:42216402	chr22:42090931~42137742:+
LIHC	cis	rs12908161	0.92	rs12904605	ENSG00000259295.5	CSPG4P12	5.2	3.47e-07	0.000144	0.38	0.27	Schizophrenia;	chr15:84658188	chr15:85191438~85213905:+
LIHC	cis	rs4356203	0.905	rs10832733	ENSG00000272034.1	SNORD14A	-5.2	3.49e-07	0.000144	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17089725	chr11:17074654~17074744:-
LIHC	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	5.2	3.49e-07	0.000144	0.36	0.27	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	5.2	3.49e-07	0.000144	0.36	0.27	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
LIHC	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-5.2	3.49e-07	0.000144	-0.34	-0.27	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-5.2	3.49e-07	0.000144	-0.34	-0.27	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-5.2	3.49e-07	0.000144	-0.34	-0.27	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-5.2	3.49e-07	0.000144	-0.34	-0.27	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
LIHC	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	5.2	3.5e-07	0.000144	0.33	0.27	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
LIHC	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	5.2	3.5e-07	0.000145	0.41	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
LIHC	cis	rs5769765	0.955	rs5770750	ENSG00000278869.1	CITF22-49E9.3	-5.2	3.5e-07	0.000145	-0.4	-0.27	Schizophrenia;	chr22:49883180	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs910800	ENSG00000278869.1	CITF22-49E9.3	-5.2	3.5e-07	0.000145	-0.4	-0.27	Schizophrenia;	chr22:49884994	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.874	rs4624	ENSG00000278869.1	CITF22-49E9.3	-5.2	3.5e-07	0.000145	-0.4	-0.27	Schizophrenia;	chr22:49888269	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs2092982	ENSG00000278869.1	CITF22-49E9.3	-5.2	3.5e-07	0.000145	-0.4	-0.27	Schizophrenia;	chr22:49888556	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs738711	ENSG00000278869.1	CITF22-49E9.3	-5.2	3.5e-07	0.000145	-0.4	-0.27	Schizophrenia;	chr22:49888955	chr22:49933198~49934074:-
LIHC	cis	rs10510102	0.935	rs7098562	ENSG00000226864.1	ATE1-AS1	5.2	3.51e-07	0.000145	0.42	0.27	Breast cancer;	chr10:121902148	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs7098822	ENSG00000226864.1	ATE1-AS1	5.2	3.51e-07	0.000145	0.42	0.27	Breast cancer;	chr10:121902157	chr10:121928312~121951965:+
LIHC	cis	rs4731207	0.735	rs12155120	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124838178	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs12154816	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124838245	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10269011	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124838759	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs12666427	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124839298	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs34014883	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124840523	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.672	rs3213667	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124840815	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs3815221	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124841191	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4728010	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124841366	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4731222	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124841581	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4728011	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124841658	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4728012	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124841744	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs11980925	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124843653	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10085793	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124844112	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs2079368	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124845257	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.671	rs10085867	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124846114	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10085888	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124846337	chr7:124929873~125179315:+
LIHC	cis	rs712039	0.652	rs7226252	ENSG00000276054.1	RP11-378E13.3	5.2	3.51e-07	0.000145	0.33	0.27	Tuberculosis;	chr17:37434812	chr17:37386886~37387926:+
LIHC	cis	rs712039	0.652	rs67879888	ENSG00000276054.1	RP11-378E13.3	5.2	3.51e-07	0.000145	0.33	0.27	Tuberculosis;	chr17:37435211	chr17:37386886~37387926:+
LIHC	cis	rs6479901	0.841	rs10995453	ENSG00000232075.1	MRPL35P2	-5.2	3.51e-07	0.000145	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63174571	chr10:63634317~63634827:-
LIHC	cis	rs4731207	0.596	rs10081375	ENSG00000224897.5	POT1-AS1	5.2	3.51e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124933121	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs13228116	ENSG00000224897.5	POT1-AS1	-5.2	3.51e-07	0.000145	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124840452	chr7:124929873~125179315:+
LIHC	cis	rs5769765	0.865	rs3788730	ENSG00000278869.1	CITF22-49E9.3	-5.2	3.52e-07	0.000145	-0.4	-0.27	Schizophrenia;	chr22:49851047	chr22:49933198~49934074:-
LIHC	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	5.2	3.52e-07	0.000145	0.26	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
LIHC	cis	rs1577917	0.917	rs35738006	ENSG00000234155.1	RP11-30P6.6	5.2	3.52e-07	0.000145	0.36	0.27	Response to antipsychotic treatment;	chr6:85936591	chr6:85387219~85390186:-
LIHC	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	5.2	3.52e-07	0.000145	0.34	0.27	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
LIHC	cis	rs9326248	0.906	rs171052	ENSG00000236267.1	AP006216.5	-5.2	3.52e-07	0.000145	-0.28	-0.27	Blood protein levels;	chr11:117211047	chr11:116813204~116814003:-
LIHC	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-5.2	3.52e-07	0.000145	-0.33	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
LIHC	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	5.19	3.53e-07	0.000145	0.35	0.27	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
LIHC	cis	rs228614	0.534	rs223387	ENSG00000230069.3	LRRC37A15P	-5.19	3.53e-07	0.000145	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102727274~102730721:-
LIHC	cis	rs4731207	0.596	rs6466963	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124932234	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs6466964	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124932346	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.623	rs12706629	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124933991	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10231491	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124934037	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.535	rs11769711	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124934870	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10081290	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124935454	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10081226	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124935475	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs7780392	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124935601	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10272889	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124936587	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1481332	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124937208	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7786384	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124937216	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1481331	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124937271	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10954050	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124937847	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7790975	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124937890	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7791399	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124937918	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7795605	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124938393	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7795611	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124938402	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.505	rs7795233	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124938414	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10252072	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124938582	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10954051	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124939182	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs11981797	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124939397	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1383751	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124939667	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466965	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124939672	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs2402756	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124939728	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1994023	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124940616	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs1994022	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124940823	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.619	rs4461840	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124941011	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10231355	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124941164	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs10279816	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124941526	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.533	rs1481340	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124941997	chr7:124929873~125179315:+
LIHC	cis	rs2267708	0.506	rs1842616	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Chronic lymphocytic leukemia;	chr7:124942118	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1842615	ENSG00000224897.5	POT1-AS1	5.19	3.53e-07	0.000145	0.32	0.27	Cutaneous malignant melanoma;	chr7:124942817	chr7:124929873~125179315:+
LIHC	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-5.19	3.53e-07	0.000146	-0.33	-0.27	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
LIHC	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-5.19	3.53e-07	0.000146	-0.32	-0.27	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
LIHC	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	5.19	3.54e-07	0.000146	0.43	0.27	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
LIHC	cis	rs11722779	0.903	rs13130741	ENSG00000230069.3	LRRC37A15P	-5.19	3.54e-07	0.000146	-0.25	-0.27	Schizophrenia;	chr4:103035799	chr4:102727274~102730721:-
LIHC	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-5.19	3.54e-07	0.000146	-0.31	-0.27	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-5.19	3.54e-07	0.000146	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
LIHC	cis	rs641862	1	rs641862	ENSG00000229152.2	ANKRD10-IT1	5.19	3.55e-07	0.000146	0.34	0.27	Obesity-related traits;	chr13:110137885	chr13:110894639~110899172:-
LIHC	cis	rs4731207	0.698	rs4731217	ENSG00000224897.5	POT1-AS1	-5.19	3.55e-07	0.000146	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124831835	chr7:124929873~125179315:+
LIHC	cis	rs4660214	0.614	rs6688708	ENSG00000182109.6	RP11-69E11.4	-5.19	3.55e-07	0.000146	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39522280~39546187:-
LIHC	cis	rs227275	0.525	rs4699046	ENSG00000230069.3	LRRC37A15P	-5.19	3.55e-07	0.000146	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs4699047	ENSG00000230069.3	LRRC37A15P	-5.19	3.55e-07	0.000146	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102727274~102730721:-
LIHC	cis	rs950169	0.922	rs2033284	ENSG00000259295.5	CSPG4P12	5.19	3.55e-07	0.000146	0.37	0.27	Schizophrenia;	chr15:84391575	chr15:85191438~85213905:+
LIHC	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-5.19	3.56e-07	0.000146	-0.21	-0.27	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
LIHC	cis	rs4731207	0.596	rs10264766	ENSG00000224897.5	POT1-AS1	5.19	3.56e-07	0.000146	0.33	0.27	Cutaneous malignant melanoma;	chr7:124932862	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6971179	ENSG00000224897.5	POT1-AS1	5.19	3.56e-07	0.000146	0.33	0.27	Cutaneous malignant melanoma;	chr7:124952297	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10247349	ENSG00000224897.5	POT1-AS1	5.19	3.56e-07	0.000146	0.33	0.27	Cutaneous malignant melanoma;	chr7:124967441	chr7:124929873~125179315:+
LIHC	cis	rs875971	0.545	rs73142245	ENSG00000273142.1	RP11-458F8.4	5.19	3.56e-07	0.000147	0.26	0.27	Aortic root size;	chr7:66226662	chr7:66902857~66906297:+
LIHC	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	5.19	3.57e-07	0.000147	0.39	0.27	Height;	chr6:109436760	chr6:109382795~109383666:+
LIHC	cis	rs5769707	0.967	rs4524218	ENSG00000235111.1	RP1-29C18.8	-5.19	3.57e-07	0.000147	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49612657~49615716:-
LIHC	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-5.19	3.57e-07	0.000147	-0.28	-0.27	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
LIHC	cis	rs5769707	0.935	rs5770594	ENSG00000235111.1	RP1-29C18.8	-5.19	3.57e-07	0.000147	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49612657~49615716:-
LIHC	cis	rs2267708	0.509	rs6959972	ENSG00000224897.5	POT1-AS1	5.19	3.57e-07	0.000147	0.33	0.27	Chronic lymphocytic leukemia;	chr7:124977054	chr7:124929873~125179315:+
LIHC	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	5.19	3.57e-07	0.000147	0.39	0.27	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
LIHC	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	5.19	3.57e-07	0.000147	0.36	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
LIHC	cis	rs4731207	0.672	rs66823127	ENSG00000224897.5	POT1-AS1	-5.19	3.58e-07	0.000147	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124832275	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10250911	ENSG00000224897.5	POT1-AS1	-5.19	3.58e-07	0.000147	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124832980	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs2896361	ENSG00000224897.5	POT1-AS1	-5.19	3.58e-07	0.000147	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124833771	chr7:124929873~125179315:+
LIHC	cis	rs6589219	0.721	rs7944895	ENSG00000196167.8	COLCA1	-5.19	3.58e-07	0.000147	-0.29	-0.27	Colorectal cancer;	chr11:111297051	chr11:111290787~111305045:-
LIHC	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	5.19	3.58e-07	0.000147	0.29	0.27	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	5.19	3.58e-07	0.000147	0.29	0.27	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.764	rs2891077	ENSG00000261338.2	RP11-378A13.1	5.19	3.58e-07	0.000147	0.29	0.27	Colorectal cancer;	chr2:218319707	chr2:218255319~218257366:+
LIHC	cis	rs992157	0.73	rs2891078	ENSG00000261338.2	RP11-378A13.1	5.19	3.58e-07	0.000147	0.29	0.27	Colorectal cancer;	chr2:218319709	chr2:218255319~218257366:+
LIHC	cis	rs4731207	0.672	rs11983251	ENSG00000224897.5	POT1-AS1	-5.19	3.58e-07	0.000147	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124819871	chr7:124929873~125179315:+
LIHC	cis	rs5769765	0.825	rs7511620	ENSG00000278869.1	CITF22-49E9.3	5.19	3.58e-07	0.000147	0.44	0.27	Schizophrenia;	chr22:49914284	chr22:49933198~49934074:-
LIHC	cis	rs4731207	0.564	rs2127972	ENSG00000224897.5	POT1-AS1	5.19	3.58e-07	0.000147	0.33	0.27	Cutaneous malignant melanoma;	chr7:125025491	chr7:124929873~125179315:+
LIHC	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	5.19	3.59e-07	0.000147	0.37	0.27	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
LIHC	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	5.19	3.59e-07	0.000148	0.3	0.27	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
LIHC	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-5.19	3.59e-07	0.000148	-0.34	-0.27	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
LIHC	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-5.19	3.59e-07	0.000148	-0.44	-0.27	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
LIHC	cis	rs10510102	1	rs10886994	ENSG00000226864.1	ATE1-AS1	5.19	3.6e-07	0.000148	0.44	0.27	Breast cancer;	chr10:121841075	chr10:121928312~121951965:+
LIHC	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	5.19	3.6e-07	0.000148	0.31	0.27	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
LIHC	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-5.19	3.6e-07	0.000148	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.881	rs4842852	ENSG00000259295.5	CSPG4P12	5.19	3.6e-07	0.000148	0.36	0.27	Schizophrenia;	chr15:84387263	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.84	rs4842853	ENSG00000259295.5	CSPG4P12	5.19	3.6e-07	0.000148	0.36	0.27	Schizophrenia;	chr15:84387606	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.922	rs4842946	ENSG00000259295.5	CSPG4P12	5.19	3.6e-07	0.000148	0.36	0.27	Schizophrenia;	chr15:84387633	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.84	rs4842854	ENSG00000259295.5	CSPG4P12	5.19	3.6e-07	0.000148	0.36	0.27	Schizophrenia;	chr15:84387641	chr15:85191438~85213905:+
LIHC	cis	rs12682352	0.535	rs12677550	ENSG00000173295.6	FAM86B3P	-5.19	3.61e-07	0.000148	-0.36	-0.27	Neuroticism;	chr8:8786812	chr8:8228595~8244865:+
LIHC	cis	rs3096299	0.658	rs3934737	ENSG00000261118.1	RP11-104N10.1	5.19	3.61e-07	0.000148	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89492017~89504460:-
LIHC	cis	rs5769765	0.74	rs2103932	ENSG00000278869.1	CITF22-49E9.3	-5.19	3.61e-07	0.000148	-0.4	-0.27	Schizophrenia;	chr22:49878867	chr22:49933198~49934074:-
LIHC	cis	rs3096299	0.503	rs4785677	ENSG00000261118.1	RP11-104N10.1	5.19	3.62e-07	0.000149	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89492017~89504460:-
LIHC	cis	rs4731207	0.724	rs10257255	ENSG00000224897.5	POT1-AS1	-5.19	3.62e-07	0.000149	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124839624	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.671	rs4731221	ENSG00000224897.5	POT1-AS1	-5.19	3.62e-07	0.000149	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124841349	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4731223	ENSG00000224897.5	POT1-AS1	-5.19	3.62e-07	0.000149	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124843218	chr7:124929873~125179315:+
LIHC	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	5.19	3.62e-07	0.000149	0.3	0.27	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
LIHC	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	5.19	3.63e-07	0.000149	0.34	0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
LIHC	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	5.19	3.63e-07	0.000149	0.34	0.27	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
LIHC	cis	rs950169	0.84	rs2896002	ENSG00000259295.5	CSPG4P12	5.19	3.63e-07	0.000149	0.36	0.27	Schizophrenia;	chr15:84390423	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.887	rs3860265	ENSG00000259295.5	CSPG4P12	5.19	3.63e-07	0.000149	0.36	0.27	Schizophrenia;	chr15:84390487	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.724	rs11632668	ENSG00000259295.5	CSPG4P12	5.19	3.63e-07	0.000149	0.36	0.27	Schizophrenia;	chr15:84393989	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.881	rs34591918	ENSG00000259295.5	CSPG4P12	5.19	3.63e-07	0.000149	0.36	0.27	Schizophrenia;	chr15:84396135	chr15:85191438~85213905:+
LIHC	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-5.19	3.63e-07	0.000149	-0.34	-0.27	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-5.19	3.63e-07	0.000149	-0.34	-0.27	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
LIHC	cis	rs75920871	0.589	rs7941150	ENSG00000254851.1	RP11-109L13.1	-5.19	3.63e-07	0.000149	-0.53	-0.27	Subjective well-being;	chr11:117221105	chr11:117135528~117138582:+
LIHC	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-5.19	3.63e-07	0.000149	-0.38	-0.27	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
LIHC	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	5.19	3.64e-07	0.00015	0.36	0.27	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
LIHC	cis	rs2836974	0.605	rs2836971	ENSG00000255568.3	BRWD1-AS2	-5.19	3.64e-07	0.00015	-0.23	-0.27	Cognitive function;	chr21:39280114	chr21:39313935~39314962:+
LIHC	cis	rs9467711	0.538	rs36012762	ENSG00000216436.2	HIST1H2APS1	5.19	3.65e-07	0.00015	0.66	0.27	Autism spectrum disorder or schizophrenia;	chr6:25980295	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs13192365	ENSG00000216436.2	HIST1H2APS1	5.19	3.65e-07	0.00015	0.66	0.27	Autism spectrum disorder or schizophrenia;	chr6:25993740	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs35528636	ENSG00000216436.2	HIST1H2APS1	5.19	3.65e-07	0.00015	0.66	0.27	Autism spectrum disorder or schizophrenia;	chr6:25995473	chr6:25732497~25732827:+
LIHC	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-5.19	3.65e-07	0.00015	-0.24	-0.27	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
LIHC	cis	rs1577917	0.958	rs2225754	ENSG00000234155.1	RP11-30P6.6	5.19	3.65e-07	0.00015	0.35	0.27	Response to antipsychotic treatment;	chr6:85739980	chr6:85387219~85390186:-
LIHC	cis	rs4731207	0.596	rs12113770	ENSG00000224897.5	POT1-AS1	5.19	3.65e-07	0.00015	0.33	0.27	Cutaneous malignant melanoma;	chr7:124949686	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.537	rs6466974	ENSG00000224897.5	POT1-AS1	5.19	3.65e-07	0.00015	0.33	0.27	Cutaneous malignant melanoma;	chr7:124969456	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10264210	ENSG00000224897.5	POT1-AS1	5.19	3.65e-07	0.00015	0.33	0.27	Cutaneous malignant melanoma;	chr7:124971540	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1031956	ENSG00000224897.5	POT1-AS1	5.19	3.65e-07	0.00015	0.33	0.27	Cutaneous malignant melanoma;	chr7:124987129	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs1031959	ENSG00000224897.5	POT1-AS1	5.19	3.65e-07	0.00015	0.33	0.27	Cutaneous malignant melanoma;	chr7:124987259	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs1552118	ENSG00000224897.5	POT1-AS1	5.19	3.65e-07	0.00015	0.33	0.27	Cutaneous malignant melanoma;	chr7:124988804	chr7:124929873~125179315:+
LIHC	cis	rs2836974	0.644	rs719230	ENSG00000255568.3	BRWD1-AS2	-5.19	3.65e-07	0.00015	-0.23	-0.27	Cognitive function;	chr21:39304381	chr21:39313935~39314962:+
LIHC	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	5.19	3.65e-07	0.00015	0.2	0.27	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
LIHC	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-5.19	3.66e-07	0.00015	-0.23	-0.27	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
LIHC	cis	rs5758511	0.68	rs5758688	ENSG00000237037.8	NDUFA6-AS1	-5.19	3.66e-07	0.00015	-0.34	-0.27	Birth weight;	chr22:42266495	chr22:42090931~42137742:+
LIHC	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-5.19	3.66e-07	0.00015	-0.34	-0.27	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
LIHC	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-5.19	3.66e-07	0.00015	-0.34	-0.27	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
LIHC	cis	rs227275	0.525	rs13117110	ENSG00000230069.3	LRRC37A15P	-5.19	3.67e-07	0.000151	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs13144033	ENSG00000230069.3	LRRC37A15P	-5.19	3.67e-07	0.000151	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102727274~102730721:-
LIHC	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-5.19	3.68e-07	0.000151	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
LIHC	cis	rs2836974	0.584	rs7276774	ENSG00000255568.3	BRWD1-AS2	-5.19	3.68e-07	0.000151	-0.23	-0.27	Cognitive function;	chr21:39256799	chr21:39313935~39314962:+
LIHC	cis	rs5769765	0.954	rs6009900	ENSG00000278869.1	CITF22-49E9.3	5.19	3.68e-07	0.000151	0.42	0.27	Schizophrenia;	chr22:49842962	chr22:49933198~49934074:-
LIHC	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	5.19	3.69e-07	0.000151	0.44	0.27	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
LIHC	cis	rs2060793	0.741	rs1542291	ENSG00000251991.1	RNU7-49P	5.19	3.69e-07	0.000151	0.3	0.27	Vitamin D levels;	chr11:14784720	chr11:14478892~14478953:+
LIHC	cis	rs875971	0.545	rs4718325	ENSG00000273142.1	RP11-458F8.4	5.19	3.7e-07	0.000151	0.26	0.27	Aortic root size;	chr7:66215323	chr7:66902857~66906297:+
LIHC	cis	rs4356203	0.905	rs7946010	ENSG00000272034.1	SNORD14A	5.19	3.7e-07	0.000151	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17154510	chr11:17074654~17074744:-
LIHC	cis	rs16858210	0.874	rs11918588	ENSG00000234371.6	RPSAP31	5.19	3.7e-07	0.000152	0.35	0.27	Menopause (age at onset);	chr3:183883927	chr3:183884924~183888449:+
LIHC	cis	rs10510102	0.935	rs11200183	ENSG00000226864.1	ATE1-AS1	5.19	3.7e-07	0.000152	0.43	0.27	Breast cancer;	chr10:121829908	chr10:121928312~121951965:+
LIHC	cis	rs113835537	0.877	rs2229455	ENSG00000255517.5	CTD-3074O7.5	-5.19	3.7e-07	0.000152	-0.36	-0.27	Airway imaging phenotypes;	chr11:66560584	chr11:66473490~66480233:-
LIHC	cis	rs2933343	0.7	rs1683779	ENSG00000231305.3	RP11-723O4.2	5.18	3.71e-07	0.000152	0.3	0.27	IgG glycosylation;	chr3:128923205	chr3:128861313~128871540:-
LIHC	cis	rs17826219	0.561	rs562840	ENSG00000266490.1	CTD-2349P21.9	5.18	3.71e-07	0.000152	0.32	0.27	Body mass index;	chr17:30622372	chr17:30792372~30792833:+
LIHC	cis	rs7674212	1	rs7674212	ENSG00000230069.3	LRRC37A15P	-5.18	3.72e-07	0.000152	-0.25	-0.27	Type 2 diabetes;	chr4:103067742	chr4:102727274~102730721:-
LIHC	cis	rs638893	1	rs649338	ENSG00000255422.1	AP002954.4	-5.18	3.72e-07	0.000152	-0.46	-0.27	Vitiligo;	chr11:118834945	chr11:118704607~118750263:+
LIHC	cis	rs4731207	0.698	rs4728009	ENSG00000224897.5	POT1-AS1	5.18	3.72e-07	0.000152	0.32	0.27	Cutaneous malignant melanoma;	chr7:124830907	chr7:124929873~125179315:+
LIHC	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	5.18	3.72e-07	0.000152	0.37	0.27	Height;	chr6:109403951	chr6:109382795~109383666:+
LIHC	cis	rs5769707	0.967	rs2071904	ENSG00000235111.1	RP1-29C18.8	-5.18	3.72e-07	0.000152	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49612657~49615716:-
LIHC	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-5.18	3.72e-07	0.000152	-0.29	-0.27	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
LIHC	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-5.18	3.73e-07	0.000152	-0.34	-0.27	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
LIHC	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-5.18	3.73e-07	0.000152	-0.34	-0.27	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
LIHC	cis	rs4356203	0.905	rs35933265	ENSG00000272034.1	SNORD14A	-5.18	3.73e-07	0.000153	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17093707	chr11:17074654~17074744:-
LIHC	cis	rs860295	0.756	rs7546258	ENSG00000203761.5	MSTO2P	-5.18	3.73e-07	0.000153	-0.22	-0.27	Body mass index;	chr1:155728854	chr1:155745829~155750137:+
LIHC	cis	rs4965006	0.749	rs6598176	ENSG00000273568.1	RP11-417L19.6	5.18	3.73e-07	0.000153	0.34	0.27	Posterior cortical atrophy and Alzheimer's disease;	chr12:131940903	chr12:131934642~131934928:+
LIHC	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	5.18	3.74e-07	0.000153	0.42	0.27	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
LIHC	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	5.18	3.74e-07	0.000153	0.41	0.27	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
LIHC	cis	rs2735413	0.564	rs11863954	ENSG00000276007.1	RP11-358L22.3	-5.18	3.74e-07	0.000153	-0.36	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78093252	chr16:78123243~78124332:+
LIHC	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-5.18	3.74e-07	0.000153	-0.35	-0.27	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
LIHC	cis	rs10129255	0.585	rs2008440	ENSG00000211970.3	IGHV4-61	-5.18	3.74e-07	0.000153	-0.21	-0.27	Kawasaki disease;	chr14:106654988	chr14:106639119~106639657:-
LIHC	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-5.18	3.75e-07	0.000153	-0.23	-0.27	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-5.18	3.75e-07	0.000153	-0.23	-0.27	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-5.18	3.75e-07	0.000153	-0.23	-0.27	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-5.18	3.75e-07	0.000153	-0.23	-0.27	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-5.18	3.75e-07	0.000153	-0.23	-0.27	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
LIHC	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	5.18	3.75e-07	0.000153	0.25	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
LIHC	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	5.18	3.75e-07	0.000153	0.25	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
LIHC	cis	rs227275	0.554	rs223382	ENSG00000230069.3	LRRC37A15P	-5.18	3.75e-07	0.000153	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223377	ENSG00000230069.3	LRRC37A15P	-5.18	3.75e-07	0.000153	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102727274~102730721:-
LIHC	cis	rs4731207	0.698	rs6960504	ENSG00000224897.5	POT1-AS1	5.18	3.75e-07	0.000153	0.32	0.27	Cutaneous malignant melanoma;	chr7:124890260	chr7:124929873~125179315:+
LIHC	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-5.18	3.75e-07	0.000153	-0.33	-0.27	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
LIHC	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-5.18	3.76e-07	0.000154	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
LIHC	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-5.18	3.76e-07	0.000154	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
LIHC	cis	rs1577917	0.917	rs2197651	ENSG00000234155.1	RP11-30P6.6	5.18	3.76e-07	0.000154	0.36	0.27	Response to antipsychotic treatment;	chr6:85785724	chr6:85387219~85390186:-
LIHC	cis	rs1729407	0.933	rs1729405	ENSG00000236267.1	AP006216.5	5.18	3.76e-07	0.000154	0.26	0.27	Apolipoprotein A-IV levels;	chr11:116808044	chr11:116813204~116814003:-
LIHC	cis	rs1065852	0.526	rs8138080	ENSG00000237037.8	NDUFA6-AS1	5.18	3.77e-07	0.000154	0.37	0.27	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42000367	chr22:42090931~42137742:+
LIHC	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-5.18	3.77e-07	0.000154	-0.35	-0.27	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
LIHC	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-5.18	3.77e-07	0.000154	-0.25	-0.27	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
LIHC	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	5.18	3.77e-07	0.000154	0.49	0.27	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
LIHC	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	5.18	3.78e-07	0.000154	0.35	0.27	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
LIHC	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	5.18	3.78e-07	0.000154	0.35	0.27	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
LIHC	cis	rs10510102	0.872	rs78369301	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000155	0.45	0.27	Breast cancer;	chr10:121858527	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs75339296	ENSG00000226864.1	ATE1-AS1	5.18	3.78e-07	0.000155	0.45	0.27	Breast cancer;	chr10:121859895	chr10:121928312~121951965:+
LIHC	cis	rs4356203	0.905	rs7396382	ENSG00000272034.1	SNORD14A	5.18	3.78e-07	0.000155	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17129925	chr11:17074654~17074744:-
LIHC	cis	rs10510102	0.935	rs77447688	ENSG00000226864.1	ATE1-AS1	5.18	3.79e-07	0.000155	0.45	0.27	Breast cancer;	chr10:121925721	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.688	rs74570569	ENSG00000226864.1	ATE1-AS1	5.18	3.79e-07	0.000155	0.45	0.27	Breast cancer;	chr10:121945347	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs7076727	ENSG00000226864.1	ATE1-AS1	5.18	3.79e-07	0.000155	0.45	0.27	Breast cancer;	chr10:121947000	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.745	rs7076882	ENSG00000226864.1	ATE1-AS1	5.18	3.79e-07	0.000155	0.45	0.27	Breast cancer;	chr10:121947039	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs7077035	ENSG00000226864.1	ATE1-AS1	5.18	3.79e-07	0.000155	0.45	0.27	Breast cancer;	chr10:121947130	chr10:121928312~121951965:+
LIHC	cis	rs4731207	0.596	rs7787605	ENSG00000224897.5	POT1-AS1	5.18	3.8e-07	0.000155	0.33	0.27	Cutaneous malignant melanoma;	chr7:125019928	chr7:124929873~125179315:+
LIHC	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	5.18	3.8e-07	0.000155	0.4	0.27	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	5.18	3.8e-07	0.000155	0.4	0.27	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
LIHC	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	5.18	3.8e-07	0.000155	0.34	0.27	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	5.18	3.8e-07	0.000155	0.34	0.27	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
LIHC	cis	rs4731207	0.596	rs723443	ENSG00000224897.5	POT1-AS1	5.18	3.8e-07	0.000155	0.32	0.27	Cutaneous malignant melanoma;	chr7:125019247	chr7:124929873~125179315:+
LIHC	cis	rs9527	0.662	rs743575	ENSG00000236937.2	PTGES3P4	5.18	3.81e-07	0.000155	0.37	0.27	Arsenic metabolism;	chr10:102835149	chr10:102845595~102845950:+
LIHC	cis	rs8024893	0.764	rs7182721	ENSG00000270055.1	CTD-3092A11.2	5.18	3.81e-07	0.000155	0.38	0.27	Red cell distribution width;	chr15:31239730	chr15:30487963~30490313:+
LIHC	cis	rs4731207	0.536	rs10254199	ENSG00000224897.5	POT1-AS1	5.18	3.81e-07	0.000155	0.33	0.27	Cutaneous malignant melanoma;	chr7:125015062	chr7:124929873~125179315:+
LIHC	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	5.18	3.81e-07	0.000156	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
LIHC	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-5.18	3.82e-07	0.000156	-0.4	-0.27	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
LIHC	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-5.18	3.82e-07	0.000156	-0.34	-0.27	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-5.18	3.83e-07	0.000156	-0.26	-0.27	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
LIHC	cis	rs4660214	0.666	rs11205839	ENSG00000182109.6	RP11-69E11.4	-5.18	3.83e-07	0.000156	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39522280~39546187:-
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-5.18	3.84e-07	0.000156	-0.24	-0.27	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
LIHC	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	5.18	3.84e-07	0.000156	0.3	0.27	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
LIHC	cis	rs4731207	0.596	rs7788458	ENSG00000224897.5	POT1-AS1	5.18	3.85e-07	0.000157	0.33	0.27	Cutaneous malignant melanoma;	chr7:124990087	chr7:124929873~125179315:+
LIHC	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-5.18	3.85e-07	0.000157	-0.3	-0.27	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
LIHC	cis	rs4731207	0.967	rs2267708	ENSG00000224897.5	POT1-AS1	-5.18	3.85e-07	0.000157	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124752458	chr7:124929873~125179315:+
LIHC	cis	rs8028182	0.549	rs7402844	ENSG00000260269.4	CTD-2323K18.1	5.18	3.85e-07	0.000157	0.35	0.27	Sudden cardiac arrest;	chr15:75345055	chr15:75527150~75601205:-
LIHC	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	5.18	3.86e-07	0.000157	0.35	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
LIHC	cis	rs9291683	0.551	rs62295971	ENSG00000250413.1	RP11-448G15.1	-5.18	3.86e-07	0.000157	-0.35	-0.27	Bone mineral density;	chr4:9976518	chr4:10006482~10009725:+
LIHC	cis	rs10510102	0.935	rs12246704	ENSG00000226864.1	ATE1-AS1	5.18	3.87e-07	0.000157	0.43	0.27	Breast cancer;	chr10:121906165	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200243	ENSG00000226864.1	ATE1-AS1	5.18	3.87e-07	0.000157	0.43	0.27	Breast cancer;	chr10:121906888	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200244	ENSG00000226864.1	ATE1-AS1	5.18	3.87e-07	0.000157	0.43	0.27	Breast cancer;	chr10:121906944	chr10:121928312~121951965:+
LIHC	cis	rs7131987	0.834	rs11050167	ENSG00000257176.2	RP11-996F15.2	-5.18	3.88e-07	0.000158	-0.32	-0.27	QT interval;	chr12:29273454	chr12:29280418~29317848:-
LIHC	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	5.18	3.88e-07	0.000158	0.24	0.27	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
LIHC	cis	rs2877649	0.51	rs10083382	ENSG00000258744.1	RP11-80A15.1	5.18	3.88e-07	0.000158	0.48	0.27	Smooth-surface caries;	chr14:24438911	chr14:24501594~24508688:+
LIHC	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-5.18	3.88e-07	0.000158	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-5.18	3.88e-07	0.000158	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-5.18	3.88e-07	0.000158	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-5.18	3.88e-07	0.000158	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
LIHC	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	5.18	3.89e-07	0.000158	0.32	0.27	Myopia;	chr6:28302807	chr6:28943877~28944537:+
LIHC	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	5.17	3.9e-07	0.000159	0.34	0.27	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	5.17	3.9e-07	0.000159	0.34	0.27	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
LIHC	cis	rs4650994	0.525	rs4316329	ENSG00000273384.1	RP5-1098D14.1	5.17	3.91e-07	0.000159	0.33	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178540198	chr1:178651706~178652282:+
LIHC	cis	rs7131987	0.65	rs3782509	ENSG00000275476.1	RP11-996F15.4	-5.17	3.91e-07	0.000159	-0.31	-0.27	QT interval;	chr12:29300845	chr12:29277397~29277882:-
LIHC	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	5.17	3.91e-07	0.000159	0.32	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
LIHC	cis	rs5769765	1	rs4824112	ENSG00000278869.1	CITF22-49E9.3	5.17	3.91e-07	0.000159	0.43	0.27	Schizophrenia;	chr22:49890697	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.913	rs4824111	ENSG00000278869.1	CITF22-49E9.3	-5.17	3.91e-07	0.000159	-0.43	-0.27	Schizophrenia;	chr22:49890657	chr22:49933198~49934074:-
LIHC	cis	rs4731207	0.724	rs2057907	ENSG00000224897.5	POT1-AS1	-5.17	3.91e-07	0.000159	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124803630	chr7:124929873~125179315:+
LIHC	cis	rs2836974	0.674	rs1011413	ENSG00000255568.3	BRWD1-AS2	-5.17	3.92e-07	0.000159	-0.23	-0.27	Cognitive function;	chr21:39266315	chr21:39313935~39314962:+
LIHC	cis	rs17270561	0.666	rs1141034	ENSG00000216436.2	HIST1H2APS1	-5.17	3.92e-07	0.00016	-0.32	-0.27	Iron status biomarkers;	chr6:25780104	chr6:25732497~25732827:+
LIHC	cis	rs4731207	0.672	rs7792883	ENSG00000224897.5	POT1-AS1	-5.17	3.92e-07	0.00016	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124807967	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs2402753	ENSG00000224897.5	POT1-AS1	-5.17	3.92e-07	0.00016	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124808205	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.672	rs2896360	ENSG00000224897.5	POT1-AS1	-5.17	3.92e-07	0.00016	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124808462	chr7:124929873~125179315:+
LIHC	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	5.17	3.93e-07	0.00016	0.31	0.27	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
LIHC	cis	rs4731207	0.596	rs7802007	ENSG00000224897.5	POT1-AS1	5.17	3.94e-07	0.00016	0.33	0.27	Cutaneous malignant melanoma;	chr7:124997980	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs998054	ENSG00000224897.5	POT1-AS1	5.17	3.94e-07	0.00016	0.33	0.27	Cutaneous malignant melanoma;	chr7:125000433	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1481333	ENSG00000224897.5	POT1-AS1	5.17	3.94e-07	0.00016	0.33	0.27	Cutaneous malignant melanoma;	chr7:125003005	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs6466978	ENSG00000224897.5	POT1-AS1	5.17	3.94e-07	0.00016	0.33	0.27	Cutaneous malignant melanoma;	chr7:125003732	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1531718	ENSG00000224897.5	POT1-AS1	5.17	3.94e-07	0.00016	0.33	0.27	Cutaneous malignant melanoma;	chr7:125004723	chr7:124929873~125179315:+
LIHC	cis	rs9595066	0.627	rs4941486	ENSG00000230731.2	RP11-478K15.6	5.17	3.94e-07	0.00016	0.33	0.27	Schizophrenia;	chr13:44175021	chr13:44234118~44243192:-
LIHC	cis	rs5758511	0.68	rs5758687	ENSG00000237037.8	NDUFA6-AS1	-5.17	3.95e-07	0.00016	-0.34	-0.27	Birth weight;	chr22:42260582	chr22:42090931~42137742:+
LIHC	cis	rs4356203	0.905	rs214906	ENSG00000272034.1	SNORD14A	5.17	3.95e-07	0.000161	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17159793	chr11:17074654~17074744:-
LIHC	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	5.17	3.95e-07	0.000161	0.37	0.27	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
LIHC	cis	rs228614	0.51	rs223400	ENSG00000230069.3	LRRC37A15P	-5.17	3.97e-07	0.000161	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102727274~102730721:-
LIHC	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-5.17	3.97e-07	0.000161	-0.3	-0.27	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
LIHC	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-5.17	3.97e-07	0.000161	-0.33	-0.27	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-5.17	3.97e-07	0.000161	-0.33	-0.27	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-5.17	3.97e-07	0.000161	-0.33	-0.27	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-5.17	3.97e-07	0.000161	-0.33	-0.27	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
LIHC	cis	rs755249	0.501	rs1889830	ENSG00000182109.6	RP11-69E11.4	-5.17	3.98e-07	0.000161	-0.29	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39522280~39546187:-
LIHC	cis	rs2439831	1	rs690263	ENSG00000205771.5	CATSPER2P1	-5.17	3.98e-07	0.000162	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43412267	chr15:43726918~43747094:-
LIHC	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-5.17	3.98e-07	0.000162	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-5.17	3.98e-07	0.000162	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-5.17	3.98e-07	0.000162	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-5.17	3.98e-07	0.000162	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
LIHC	cis	rs5758511	0.637	rs5751244	ENSG00000237037.8	NDUFA6-AS1	-5.17	3.98e-07	0.000162	-0.34	-0.27	Birth weight;	chr22:42221405	chr22:42090931~42137742:+
LIHC	cis	rs12571093	0.803	rs2241970	ENSG00000233590.1	RP11-153K11.3	5.17	3.98e-07	0.000162	0.41	0.27	Optic nerve measurement (disc area);	chr10:68271310	chr10:68233251~68242379:-
LIHC	cis	rs887829	0.57	rs4553819	ENSG00000233445.1	RPL17P11	5.17	3.99e-07	0.000162	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233685437	chr2:233721522~233722065:-
LIHC	cis	rs4663969	0.541	rs11902131	ENSG00000233445.1	RPL17P11	5.17	3.99e-07	0.000162	0.28	0.27	Total bilirubin levels in HIV-1 infection;	chr2:233685623	chr2:233721522~233722065:-
LIHC	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-5.17	3.99e-07	0.000162	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
LIHC	cis	rs2565722	0.563	rs1247560	ENSG00000243831.1	RP1-81D8.4	5.17	3.99e-07	0.000162	0.36	0.27	Blood protein levels;	chr6:160783788	chr6:160666228~160676523:-
LIHC	cis	rs9326248	0.53	rs11216316	ENSG00000280143.1	AP000892.6	-5.17	4e-07	0.000162	-0.35	-0.27	Blood protein levels;	chr11:117210784	chr11:117204967~117210292:+
LIHC	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	5.17	4e-07	0.000162	0.2	0.27	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	5.17	4e-07	0.000162	0.2	0.27	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
LIHC	cis	rs116175783	0.557	rs3731768	ENSG00000227403.1	AC009299.3	5.17	4e-07	0.000162	0.42	0.27	Intelligence (multi-trait analysis);	chr2:161250809	chr2:161244739~161249050:+
LIHC	cis	rs36715	1	rs36697	ENSG00000245937.6	LINC01184	5.17	4e-07	0.000162	0.33	0.27	Breast cancer;	chr5:128213921	chr5:127940426~128083172:-
LIHC	cis	rs4731207	0.698	rs2402755	ENSG00000224897.5	POT1-AS1	-5.17	4.01e-07	0.000163	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124808554	chr7:124929873~125179315:+
LIHC	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	5.17	4.02e-07	0.000163	0.36	0.27	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
LIHC	cis	rs2836974	0.584	rs34436313	ENSG00000255568.3	BRWD1-AS2	-5.17	4.02e-07	0.000163	-0.23	-0.27	Cognitive function;	chr21:39313320	chr21:39313935~39314962:+
LIHC	cis	rs599083	0.53	rs491347	ENSG00000212093.1	AP000807.1	-5.17	4.02e-07	0.000163	-0.29	-0.27	Bone mineral density (spine);	chr11:68402220	chr11:68506083~68506166:-
LIHC	cis	rs599083	0.53	rs686921	ENSG00000212093.1	AP000807.1	-5.17	4.02e-07	0.000163	-0.29	-0.27	Bone mineral density (spine);	chr11:68403365	chr11:68506083~68506166:-
LIHC	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	5.17	4.03e-07	0.000163	0.35	0.27	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
LIHC	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-5.17	4.03e-07	0.000164	-0.33	-0.27	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
LIHC	cis	rs10833905	0.756	rs10833870	ENSG00000246225.5	RP11-17A1.3	-5.17	4.03e-07	0.000164	-0.35	-0.27	Sudden cardiac arrest;	chr11:22967878	chr11:22829380~22945393:+
LIHC	cis	rs10833905	0.701	rs4923047	ENSG00000246225.5	RP11-17A1.3	-5.17	4.03e-07	0.000164	-0.35	-0.27	Sudden cardiac arrest;	chr11:22970056	chr11:22829380~22945393:+
LIHC	cis	rs228614	0.51	rs223435	ENSG00000230069.3	LRRC37A15P	-5.17	4.04e-07	0.000164	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223367	ENSG00000230069.3	LRRC37A15P	-5.17	4.05e-07	0.000164	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102727274~102730721:-
LIHC	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	5.17	4.05e-07	0.000164	0.2	0.27	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
LIHC	cis	rs7665090	0.806	rs434644	ENSG00000230069.3	LRRC37A15P	5.17	4.06e-07	0.000164	0.25	0.27	Primary biliary cholangitis;	chr4:102662032	chr4:102727274~102730721:-
LIHC	cis	rs7665090	0.806	rs413967	ENSG00000230069.3	LRRC37A15P	5.17	4.06e-07	0.000164	0.25	0.27	Primary biliary cholangitis;	chr4:102662039	chr4:102727274~102730721:-
LIHC	cis	rs7665090	0.806	rs404574	ENSG00000230069.3	LRRC37A15P	5.17	4.06e-07	0.000164	0.25	0.27	Primary biliary cholangitis;	chr4:102662051	chr4:102727274~102730721:-
LIHC	cis	rs712039	0.652	rs853227	ENSG00000276054.1	RP11-378E13.3	5.17	4.06e-07	0.000165	0.34	0.27	Tuberculosis;	chr17:37437428	chr17:37386886~37387926:+
LIHC	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	5.17	4.06e-07	0.000165	0.39	0.27	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
LIHC	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-5.17	4.07e-07	0.000165	-0.28	-0.27	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
LIHC	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-5.17	4.07e-07	0.000165	-0.28	-0.27	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
LIHC	cis	rs10510102	0.935	rs12255859	ENSG00000226864.1	ATE1-AS1	5.17	4.07e-07	0.000165	0.43	0.27	Breast cancer;	chr10:121831661	chr10:121928312~121951965:+
LIHC	cis	rs9291683	0.53	rs35908990	ENSG00000250413.1	RP11-448G15.1	-5.17	4.07e-07	0.000165	-0.35	-0.27	Bone mineral density;	chr4:9974481	chr4:10006482~10009725:+
LIHC	cis	rs4731207	0.507	rs10954052	ENSG00000224897.5	POT1-AS1	5.17	4.08e-07	0.000165	0.33	0.27	Cutaneous malignant melanoma;	chr7:124946757	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs2170353	ENSG00000224897.5	POT1-AS1	5.17	4.08e-07	0.000165	0.33	0.27	Cutaneous malignant melanoma;	chr7:124955115	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs2402760	ENSG00000224897.5	POT1-AS1	5.17	4.08e-07	0.000165	0.33	0.27	Cutaneous malignant melanoma;	chr7:124955866	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466971	ENSG00000224897.5	POT1-AS1	5.17	4.08e-07	0.000165	0.33	0.27	Cutaneous malignant melanoma;	chr7:124955953	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.623	rs28807101	ENSG00000224897.5	POT1-AS1	5.17	4.08e-07	0.000165	0.33	0.27	Cutaneous malignant melanoma;	chr7:124958772	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs12536146	ENSG00000224897.5	POT1-AS1	5.17	4.08e-07	0.000165	0.33	0.27	Cutaneous malignant melanoma;	chr7:124960577	chr7:124929873~125179315:+
LIHC	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-5.17	4.09e-07	0.000166	-0.28	-0.27	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.525	rs28778380	ENSG00000230069.3	LRRC37A15P	-5.16	4.09e-07	0.000166	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102727274~102730721:-
LIHC	cis	rs916888	0.773	rs1378358	ENSG00000274883.1	Metazoa_SRP	-5.16	4.09e-07	0.000166	-0.42	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45931806~45932083:+
LIHC	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-5.16	4.1e-07	0.000166	-0.23	-0.27	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
LIHC	cis	rs599083	0.53	rs546803	ENSG00000212093.1	AP000807.1	-5.16	4.11e-07	0.000166	-0.3	-0.27	Bone mineral density (spine);	chr11:68418924	chr11:68506083~68506166:-
LIHC	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-5.16	4.11e-07	0.000166	-0.32	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
LIHC	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	5.16	4.11e-07	0.000166	0.34	0.27	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
LIHC	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-5.16	4.11e-07	0.000166	-0.23	-0.27	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
LIHC	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-5.16	4.11e-07	0.000166	-0.23	-0.27	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
LIHC	cis	rs4718428	0.705	rs4718424	ENSG00000230295.1	RP11-458F8.2	-5.16	4.11e-07	0.000166	-0.23	-0.27	Corneal structure;	chr7:66911108	chr7:66880708~66882981:+
LIHC	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	5.16	4.11e-07	0.000166	0.37	0.27	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
LIHC	cis	rs4731207	0.596	rs12112909	ENSG00000224897.5	POT1-AS1	5.16	4.12e-07	0.000167	0.33	0.27	Cutaneous malignant melanoma;	chr7:124944780	chr7:124929873~125179315:+
LIHC	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	5.16	4.12e-07	0.000167	0.2	0.27	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
LIHC	cis	rs950169	0.8	rs4842847	ENSG00000259295.5	CSPG4P12	5.16	4.12e-07	0.000167	0.36	0.27	Schizophrenia;	chr15:84262447	chr15:85191438~85213905:+
LIHC	cis	rs887829	0.57	rs6724485	ENSG00000233445.1	RPL17P11	5.16	4.13e-07	0.000167	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233684170	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.57	rs4347832	ENSG00000233445.1	RPL17P11	5.16	4.13e-07	0.000167	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233684395	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.57	rs4261716	ENSG00000233445.1	RPL17P11	5.16	4.13e-07	0.000167	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233684471	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.57	rs13002774	ENSG00000233445.1	RPL17P11	5.16	4.13e-07	0.000167	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233685060	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.531	rs4338954	ENSG00000233445.1	RPL17P11	5.16	4.13e-07	0.000167	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233685285	chr2:233721522~233722065:-
LIHC	cis	rs4650994	0.525	rs11806608	ENSG00000273384.1	RP5-1098D14.1	5.16	4.13e-07	0.000167	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178542240	chr1:178651706~178652282:+
LIHC	cis	rs4731207	0.698	rs6466948	ENSG00000224897.5	POT1-AS1	-5.16	4.13e-07	0.000167	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124804709	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.671	rs6466949	ENSG00000224897.5	POT1-AS1	-5.16	4.13e-07	0.000167	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124804846	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10270784	ENSG00000224897.5	POT1-AS1	-5.16	4.13e-07	0.000167	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124806154	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10260227	ENSG00000224897.5	POT1-AS1	-5.16	4.13e-07	0.000167	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124806432	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.671	rs7811607	ENSG00000224897.5	POT1-AS1	-5.16	4.13e-07	0.000167	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124807789	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7793258	ENSG00000224897.5	POT1-AS1	-5.16	4.13e-07	0.000167	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124807958	chr7:124929873~125179315:+
LIHC	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	5.16	4.13e-07	0.000167	0.44	0.27	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
LIHC	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	5.16	4.14e-07	0.000167	0.19	0.27	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
LIHC	cis	rs4731207	0.596	rs1471572	ENSG00000224897.5	POT1-AS1	5.16	4.14e-07	0.000167	0.33	0.27	Cutaneous malignant melanoma;	chr7:125010888	chr7:124929873~125179315:+
LIHC	cis	rs9291683	0.53	rs11723970	ENSG00000250413.1	RP11-448G15.1	-5.16	4.14e-07	0.000167	-0.35	-0.27	Bone mineral density;	chr4:9978838	chr4:10006482~10009725:+
LIHC	cis	rs3733585	0.805	rs882222	ENSG00000250413.1	RP11-448G15.1	-5.16	4.14e-07	0.000167	-0.35	-0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9979670	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.53	rs882223	ENSG00000250413.1	RP11-448G15.1	-5.16	4.14e-07	0.000167	-0.35	-0.27	Bone mineral density;	chr4:9980001	chr4:10006482~10009725:+
LIHC	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	5.16	4.14e-07	0.000167	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	5.16	4.14e-07	0.000167	0.3	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	5.16	4.14e-07	0.000167	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
LIHC	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	5.16	4.15e-07	0.000167	0.43	0.27	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	5.16	4.15e-07	0.000167	0.43	0.27	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	5.16	4.15e-07	0.000167	0.43	0.27	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	5.16	4.15e-07	0.000167	0.43	0.27	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	5.16	4.15e-07	0.000167	0.43	0.27	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
LIHC	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	5.16	4.15e-07	0.000167	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
LIHC	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	5.16	4.15e-07	0.000168	0.37	0.27	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
LIHC	cis	rs638893	0.717	rs622690	ENSG00000255422.1	AP002954.4	-5.16	4.15e-07	0.000168	-0.46	-0.27	Vitiligo;	chr11:118833556	chr11:118704607~118750263:+
LIHC	cis	rs5769765	0.955	rs1321	ENSG00000278869.1	CITF22-49E9.3	5.16	4.15e-07	0.000168	0.4	0.27	Schizophrenia;	chr22:49903787	chr22:49933198~49934074:-
LIHC	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	5.16	4.16e-07	0.000168	0.38	0.27	Height;	chr6:109427303	chr6:109382795~109383666:+
LIHC	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-5.16	4.16e-07	0.000168	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-5.16	4.16e-07	0.000168	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
LIHC	cis	rs4662750	0.603	rs10208043	ENSG00000236682.1	AC068282.3	5.16	4.16e-07	0.000168	0.34	0.27	Renal cell carcinoma;	chr2:127631768	chr2:127389130~127400580:+
LIHC	cis	rs4662750	0.58	rs10183797	ENSG00000236682.1	AC068282.3	5.16	4.16e-07	0.000168	0.34	0.27	Renal cell carcinoma;	chr2:127631847	chr2:127389130~127400580:+
LIHC	cis	rs4662750	0.539	rs10186397	ENSG00000236682.1	AC068282.3	5.16	4.16e-07	0.000168	0.34	0.27	Renal cell carcinoma;	chr2:127632049	chr2:127389130~127400580:+
LIHC	cis	rs228614	0.51	rs223434	ENSG00000230069.3	LRRC37A15P	-5.16	4.16e-07	0.000168	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102727274~102730721:-
LIHC	cis	rs4731207	0.596	rs10275296	ENSG00000224897.5	POT1-AS1	5.16	4.16e-07	0.000168	0.33	0.27	Cutaneous malignant melanoma;	chr7:125041238	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466989	ENSG00000224897.5	POT1-AS1	5.16	4.16e-07	0.000168	0.33	0.27	Cutaneous malignant melanoma;	chr7:125050909	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.569	rs75791754	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124824863	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.598	rs2301930	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124825043	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10250202	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124825455	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.672	rs2286174	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124825822	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4731216	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124826458	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10263573	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124829213	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs35184624	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124829533	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs17147583	ENSG00000224897.5	POT1-AS1	-5.16	4.17e-07	0.000168	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124830071	chr7:124929873~125179315:+
LIHC	cis	rs860295	0.967	rs6665227	ENSG00000203761.5	MSTO2P	-5.16	4.18e-07	0.000169	-0.22	-0.27	Body mass index;	chr1:155740669	chr1:155745829~155750137:+
LIHC	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-5.16	4.18e-07	0.000169	-0.27	-0.27	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
LIHC	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-5.16	4.19e-07	0.000169	-0.34	-0.27	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
LIHC	cis	rs1577917	1	rs2324843	ENSG00000234155.1	RP11-30P6.6	5.16	4.2e-07	0.000169	0.36	0.27	Response to antipsychotic treatment;	chr6:85907783	chr6:85387219~85390186:-
LIHC	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-5.16	4.2e-07	0.000169	-0.22	-0.27	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
LIHC	cis	rs4731207	0.596	rs1481339	ENSG00000224897.5	POT1-AS1	5.16	4.2e-07	0.00017	0.33	0.27	Cutaneous malignant melanoma;	chr7:125068183	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.624	rs1031955	ENSG00000224897.5	POT1-AS1	5.16	4.2e-07	0.00017	0.33	0.27	Cutaneous malignant melanoma;	chr7:125070804	chr7:124929873~125179315:+
LIHC	cis	rs860295	0.719	rs490608	ENSG00000203761.5	MSTO2P	-5.16	4.2e-07	0.00017	-0.21	-0.27	Body mass index;	chr1:155713079	chr1:155745829~155750137:+
LIHC	cis	rs3096299	0.685	rs12935112	ENSG00000261118.1	RP11-104N10.1	-5.16	4.21e-07	0.00017	-0.26	-0.27	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89492017~89504460:-
LIHC	cis	rs4660214	0.666	rs7414381	ENSG00000182109.6	RP11-69E11.4	-5.16	4.21e-07	0.00017	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs3116387	ENSG00000182109.6	RP11-69E11.4	-5.16	4.21e-07	0.00017	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.614	rs1537815	ENSG00000182109.6	RP11-69E11.4	-5.16	4.21e-07	0.00017	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.789	rs1984142	ENSG00000182109.6	RP11-69E11.4	-5.16	4.21e-07	0.00017	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39522280~39546187:-
LIHC	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	5.16	4.22e-07	0.00017	0.35	0.27	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
LIHC	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	5.16	4.22e-07	0.00017	0.35	0.27	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
LIHC	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	5.16	4.22e-07	0.00017	0.3	0.27	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
LIHC	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	5.16	4.22e-07	0.00017	0.3	0.27	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
LIHC	cis	rs9467711	0.591	rs28360595	ENSG00000216436.2	HIST1H2APS1	5.16	4.22e-07	0.00017	0.72	0.27	Autism spectrum disorder or schizophrenia;	chr6:26029816	chr6:25732497~25732827:+
LIHC	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	5.16	4.23e-07	0.00017	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
LIHC	cis	rs4731207	0.596	rs10274820	ENSG00000224897.5	POT1-AS1	5.16	4.23e-07	0.00017	0.33	0.27	Cutaneous malignant melanoma;	chr7:124989610	chr7:124929873~125179315:+
LIHC	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	5.16	4.23e-07	0.00017	0.42	0.27	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	5.16	4.23e-07	0.00017	0.42	0.27	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	5.16	4.23e-07	0.00017	0.42	0.27	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
LIHC	cis	rs5758511	0.68	rs5751243	ENSG00000237037.8	NDUFA6-AS1	-5.16	4.23e-07	0.00017	-0.34	-0.27	Birth weight;	chr22:42221171	chr22:42090931~42137742:+
LIHC	cis	rs1023500	0.505	rs134874	ENSG00000227370.1	RP4-669P10.19	-5.16	4.23e-07	0.00017	-0.27	-0.27	Schizophrenia;	chr22:42265138	chr22:42132543~42132998:+
LIHC	cis	rs10833905	0.756	rs11026868	ENSG00000246225.5	RP11-17A1.3	-5.16	4.23e-07	0.000171	-0.35	-0.27	Sudden cardiac arrest;	chr11:22971305	chr11:22829380~22945393:+
LIHC	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-5.16	4.23e-07	0.000171	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
LIHC	cis	rs4731207	0.565	rs7776744	ENSG00000224897.5	POT1-AS1	5.16	4.24e-07	0.000171	0.33	0.27	Cutaneous malignant melanoma;	chr7:124959695	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs13240512	ENSG00000224897.5	POT1-AS1	5.16	4.24e-07	0.000171	0.32	0.27	Cutaneous malignant melanoma;	chr7:124931836	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10231818	ENSG00000224897.5	POT1-AS1	5.16	4.24e-07	0.000171	0.32	0.27	Cutaneous malignant melanoma;	chr7:124934130	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10264288	ENSG00000224897.5	POT1-AS1	5.16	4.24e-07	0.000171	0.32	0.27	Cutaneous malignant melanoma;	chr7:124934473	chr7:124929873~125179315:+
LIHC	cis	rs36715	0.953	rs2546146	ENSG00000245937.6	LINC01184	5.16	4.24e-07	0.000171	0.32	0.27	Breast cancer;	chr5:128210847	chr5:127940426~128083172:-
LIHC	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-5.16	4.24e-07	0.000171	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
LIHC	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-5.16	4.24e-07	0.000171	-0.34	-0.27	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
LIHC	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-5.16	4.24e-07	0.000171	-0.23	-0.27	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
LIHC	cis	rs9467711	0.591	rs13214280	ENSG00000216436.2	HIST1H2APS1	5.16	4.25e-07	0.000171	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:26008392	chr6:25732497~25732827:+
LIHC	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	5.16	4.26e-07	0.000172	0.56	0.27	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
LIHC	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-5.16	4.27e-07	0.000172	-0.53	-0.27	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
LIHC	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-5.16	4.27e-07	0.000172	-0.39	-0.27	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
LIHC	cis	rs7209700	0.6	rs7218632	ENSG00000228782.6	CTD-2026D20.3	-5.16	4.28e-07	0.000172	-0.3	-0.27	IgG glycosylation;	chr17:47287787	chr17:47450568~47492492:-
LIHC	cis	rs3096299	0.967	rs28575874	ENSG00000261118.1	RP11-104N10.1	5.16	4.28e-07	0.000172	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89492017~89504460:-
LIHC	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	5.16	4.29e-07	0.000173	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	5.16	4.29e-07	0.000173	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
LIHC	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	5.16	4.29e-07	0.000173	0.31	0.27	Height;	chr6:109618620	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	5.16	4.29e-07	0.000173	0.31	0.27	Height;	chr6:109620772	chr6:109382795~109383666:+
LIHC	cis	rs7916697	0.947	rs56238729	ENSG00000233590.1	RP11-153K11.3	-5.16	4.29e-07	0.000173	-0.32	-0.27	Optic disc area;	chr10:68241883	chr10:68233251~68242379:-
LIHC	cis	rs860295	1	rs6427287	ENSG00000203761.5	MSTO2P	-5.16	4.29e-07	0.000173	-0.21	-0.27	Body mass index;	chr1:155753629	chr1:155745829~155750137:+
LIHC	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	5.16	4.3e-07	0.000173	0.32	0.27	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
LIHC	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-5.16	4.3e-07	0.000173	-0.3	-0.27	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
LIHC	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	5.15	4.31e-07	0.000173	0.36	0.27	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
LIHC	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	5.15	4.31e-07	0.000173	0.3	0.27	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
LIHC	cis	rs916888	0.773	rs538628	ENSG00000274883.1	Metazoa_SRP	-5.15	4.32e-07	0.000174	-0.42	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45931806~45932083:+
LIHC	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-5.15	4.32e-07	0.000174	-0.32	-0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
LIHC	cis	rs12701220	0.901	rs12701710	ENSG00000229043.2	AC091729.9	5.15	4.33e-07	0.000174	0.37	0.27	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1160374~1165267:+
LIHC	cis	rs3096299	0.658	rs4291902	ENSG00000261118.1	RP11-104N10.1	5.15	4.33e-07	0.000174	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89492017~89504460:-
LIHC	cis	rs10510102	0.688	rs76573813	ENSG00000226864.1	ATE1-AS1	5.15	4.34e-07	0.000174	0.45	0.27	Breast cancer;	chr10:121928955	chr10:121928312~121951965:+
LIHC	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	5.15	4.34e-07	0.000174	0.24	0.27	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
LIHC	cis	rs3096299	0.967	rs2965830	ENSG00000261118.1	RP11-104N10.1	5.15	4.35e-07	0.000175	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89492017~89504460:-
LIHC	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	5.15	4.35e-07	0.000175	0.24	0.27	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
LIHC	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	5.15	4.36e-07	0.000175	0.24	0.27	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
LIHC	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-5.15	4.36e-07	0.000175	-0.41	-0.27	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
LIHC	cis	rs10510102	0.935	rs7083278	ENSG00000226864.1	ATE1-AS1	5.15	4.36e-07	0.000175	0.43	0.27	Breast cancer;	chr10:121853758	chr10:121928312~121951965:+
LIHC	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-5.15	4.36e-07	0.000175	-0.34	-0.27	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-5.15	4.36e-07	0.000175	-0.34	-0.27	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
LIHC	cis	rs1322639	0.614	rs9689800	ENSG00000261039.2	RP11-417E7.2	5.15	4.36e-07	0.000175	0.27	0.27	Pulse pressure;	chr6:169172850	chr6:169175304~169182740:-
LIHC	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	5.15	4.36e-07	0.000175	0.33	0.27	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
LIHC	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	5.15	4.36e-07	0.000175	0.33	0.27	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
LIHC	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	5.15	4.36e-07	0.000175	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-5.15	4.37e-07	0.000176	-0.4	-0.27	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
LIHC	cis	rs10912872	0.672	rs7516677	ENSG00000225704.2	RP4-798A17.5	5.15	4.38e-07	0.000176	0.24	0.27	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171372697	chr1:171345089~171345320:+
LIHC	cis	rs4731207	0.596	rs6466979	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125007975	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs7794565	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125008914	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10270055	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125009352	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7799712	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125009663	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7799771	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125009883	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10258873	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125010435	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10274513	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125010483	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.591	rs1471571	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125010820	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs4507709	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125011479	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1481343	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125012217	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.536	rs7792731	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125013382	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7792654	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125013583	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.651	rs1525619	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125014487	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1525618	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125014652	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs13224820	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125015345	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs9640828	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125015427	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6957525	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125016323	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6466982	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125016734	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs7776821	ENSG00000224897.5	POT1-AS1	5.15	4.38e-07	0.000176	0.33	0.27	Cutaneous malignant melanoma;	chr7:125017450	chr7:124929873~125179315:+
LIHC	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	5.15	4.38e-07	0.000176	0.32	0.27	Height;	chr6:109507364	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	5.15	4.38e-07	0.000176	0.32	0.27	Height;	chr6:109507366	chr6:109382795~109383666:+
LIHC	cis	rs4731207	0.698	rs10227821	ENSG00000224897.5	POT1-AS1	-5.15	4.39e-07	0.000176	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124809533	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.735	rs17147494	ENSG00000224897.5	POT1-AS1	-5.15	4.39e-07	0.000176	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124809781	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs17147496	ENSG00000224897.5	POT1-AS1	-5.15	4.39e-07	0.000176	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124809814	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs11978628	ENSG00000224897.5	POT1-AS1	-5.15	4.39e-07	0.000176	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124809843	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs11978656	ENSG00000224897.5	POT1-AS1	-5.15	4.39e-07	0.000176	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124809911	chr7:124929873~125179315:+
LIHC	cis	rs10510102	0.872	rs116521083	ENSG00000226864.1	ATE1-AS1	5.15	4.4e-07	0.000177	0.46	0.27	Breast cancer;	chr10:121950611	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.748	rs4589226	ENSG00000226864.1	ATE1-AS1	5.15	4.4e-07	0.000177	0.46	0.27	Breast cancer;	chr10:121951073	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.81	rs34738294	ENSG00000226864.1	ATE1-AS1	5.15	4.4e-07	0.000177	0.46	0.27	Breast cancer;	chr10:121951357	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12258234	ENSG00000226864.1	ATE1-AS1	5.15	4.4e-07	0.000177	0.46	0.27	Breast cancer;	chr10:121952828	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.515	rs11200285	ENSG00000226864.1	ATE1-AS1	5.15	4.4e-07	0.000177	0.46	0.27	Breast cancer;	chr10:121953931	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs75831447	ENSG00000226864.1	ATE1-AS1	5.15	4.4e-07	0.000177	0.46	0.27	Breast cancer;	chr10:121953963	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.63	rs79960726	ENSG00000226864.1	ATE1-AS1	5.15	4.4e-07	0.000177	0.46	0.27	Breast cancer;	chr10:121954358	chr10:121928312~121951965:+
LIHC	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	5.15	4.4e-07	0.000177	0.55	0.27	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
LIHC	cis	rs4731207	0.596	rs7789392	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:124971022	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7810643	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:124971356	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs12531996	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:124979406	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6942997	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:125008425	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7794959	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:125009085	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs1471569	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:125010667	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7779244	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:125012876	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs6960622	ENSG00000224897.5	POT1-AS1	5.15	4.4e-07	0.000177	0.32	0.27	Cutaneous malignant melanoma;	chr7:125014026	chr7:124929873~125179315:+
LIHC	cis	rs916888	0.773	rs169201	ENSG00000274883.1	Metazoa_SRP	-5.15	4.4e-07	0.000177	-0.42	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45931806~45932083:+
LIHC	cis	rs2929278	0.561	rs3099045	ENSG00000166763.7	STRCP1	5.15	4.4e-07	0.000177	0.35	0.27	Schizophrenia;	chr15:43631757	chr15:43699488~43718184:-
LIHC	cis	rs4731207	0.698	rs2286173	ENSG00000224897.5	POT1-AS1	-5.15	4.43e-07	0.000178	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124825897	chr7:124929873~125179315:+
LIHC	cis	rs11098499	0.954	rs1480931	ENSG00000260091.1	RP11-33B1.4	-5.15	4.43e-07	0.000178	-0.19	-0.27	Corneal astigmatism;	chr4:119474654	chr4:119409333~119410233:+
LIHC	cis	rs4650994	0.525	rs4650991	ENSG00000273384.1	RP5-1098D14.1	5.15	4.44e-07	0.000178	0.34	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178542030	chr1:178651706~178652282:+
LIHC	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-5.15	4.44e-07	0.000178	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	5.15	4.44e-07	0.000178	0.37	0.27	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	5.15	4.44e-07	0.000178	0.37	0.27	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
LIHC	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	5.15	4.44e-07	0.000178	0.21	0.27	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	5.15	4.44e-07	0.000178	0.21	0.27	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	5.15	4.44e-07	0.000178	0.21	0.27	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
LIHC	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-5.15	4.45e-07	0.000178	-0.25	-0.27	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-5.15	4.45e-07	0.000178	-0.25	-0.27	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
LIHC	cis	rs228614	0.509	rs223480	ENSG00000230069.3	LRRC37A15P	-5.15	4.45e-07	0.000178	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102727274~102730721:-
LIHC	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	5.15	4.45e-07	0.000179	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
LIHC	cis	rs4731207	0.596	rs1026839	ENSG00000224897.5	POT1-AS1	-5.15	4.46e-07	0.000179	-0.33	-0.27	Cutaneous malignant melanoma;	chr7:125032545	chr7:124929873~125179315:+
LIHC	cis	rs4660214	0.666	rs2275187	ENSG00000182109.6	RP11-69E11.4	-5.15	4.46e-07	0.000179	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39522280~39546187:-
LIHC	cis	rs228614	0.536	rs223484	ENSG00000230069.3	LRRC37A15P	-5.15	4.46e-07	0.000179	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-5.15	4.47e-07	0.000179	-0.23	-0.27	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-5.15	4.47e-07	0.000179	-0.23	-0.27	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-5.15	4.47e-07	0.000179	-0.23	-0.27	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-5.15	4.47e-07	0.000179	-0.23	-0.27	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-5.15	4.47e-07	0.000179	-0.23	-0.27	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-5.15	4.47e-07	0.000179	-0.23	-0.27	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
LIHC	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-5.15	4.48e-07	0.000179	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
LIHC	cis	rs4660214	0.639	rs6699928	ENSG00000182109.6	RP11-69E11.4	-5.15	4.48e-07	0.000179	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39522280~39546187:-
LIHC	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
LIHC	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-5.15	4.48e-07	0.000179	-0.44	-0.27	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
LIHC	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-5.15	4.48e-07	0.000179	-0.34	-0.27	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
LIHC	cis	rs4731207	0.509	rs6977699	ENSG00000224897.5	POT1-AS1	5.15	4.49e-07	0.00018	0.33	0.27	Cutaneous malignant melanoma;	chr7:124977055	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10233589	ENSG00000224897.5	POT1-AS1	-5.15	4.49e-07	0.00018	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124828545	chr7:124929873~125179315:+
LIHC	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	5.15	4.49e-07	0.00018	0.42	0.27	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
LIHC	cis	rs4660214	0.666	rs598415	ENSG00000182109.6	RP11-69E11.4	5.15	4.49e-07	0.00018	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39522280~39546187:-
LIHC	cis	rs3096299	0.967	rs28689480	ENSG00000261118.1	RP11-104N10.1	5.15	4.5e-07	0.00018	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89492017~89504460:-
LIHC	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	5.15	4.5e-07	0.00018	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
LIHC	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-5.15	4.5e-07	0.00018	-0.33	-0.27	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
LIHC	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-5.15	4.5e-07	0.00018	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-5.15	4.5e-07	0.00018	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
LIHC	cis	rs5769765	0.954	rs1569954	ENSG00000278869.1	CITF22-49E9.3	-5.15	4.51e-07	0.000181	-0.39	-0.27	Schizophrenia;	chr22:49850423	chr22:49933198~49934074:-
LIHC	cis	rs4356203	0.905	rs7123301	ENSG00000272034.1	SNORD14A	-5.15	4.52e-07	0.000181	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17141880	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs512852	ENSG00000272034.1	SNORD14A	-5.15	4.52e-07	0.000181	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193382	chr11:17074654~17074744:-
LIHC	cis	rs916888	0.773	rs199445	ENSG00000274883.1	Metazoa_SRP	-5.15	4.52e-07	0.000181	-0.42	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.773	rs199443	ENSG00000274883.1	Metazoa_SRP	-5.15	4.52e-07	0.000181	-0.42	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45931806~45932083:+
LIHC	cis	rs4731207	0.596	rs1481330	ENSG00000224897.5	POT1-AS1	5.15	4.52e-07	0.000181	0.33	0.27	Cutaneous malignant melanoma;	chr7:124991309	chr7:124929873~125179315:+
LIHC	cis	rs5769765	1	rs764813	ENSG00000278869.1	CITF22-49E9.3	5.14	4.52e-07	0.000181	0.4	0.27	Schizophrenia;	chr22:49892524	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs768618	ENSG00000278869.1	CITF22-49E9.3	5.14	4.52e-07	0.000181	0.4	0.27	Schizophrenia;	chr22:49893179	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs768619	ENSG00000278869.1	CITF22-49E9.3	5.14	4.52e-07	0.000181	0.4	0.27	Schizophrenia;	chr22:49893618	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.862	rs9616774	ENSG00000278869.1	CITF22-49E9.3	5.14	4.52e-07	0.000181	0.4	0.27	Schizophrenia;	chr22:49896951	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs8138941	ENSG00000278869.1	CITF22-49E9.3	5.14	4.52e-07	0.000181	0.4	0.27	Schizophrenia;	chr22:49897030	chr22:49933198~49934074:-
LIHC	cis	rs10181042	0.581	rs1177285	ENSG00000271889.1	RP11-493E12.1	5.14	4.52e-07	0.000181	0.33	0.27	Crohn's disease;	chr2:61123002	chr2:61151433~61162105:-
LIHC	cis	rs10510102	0.935	rs12243529	ENSG00000226864.1	ATE1-AS1	5.14	4.53e-07	0.000181	0.44	0.27	Breast cancer;	chr10:121880321	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12250677	ENSG00000226864.1	ATE1-AS1	5.14	4.53e-07	0.000181	0.44	0.27	Breast cancer;	chr10:121880575	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12243874	ENSG00000226864.1	ATE1-AS1	5.14	4.53e-07	0.000181	0.44	0.27	Breast cancer;	chr10:121880788	chr10:121928312~121951965:+
LIHC	cis	rs227275	0.525	rs223332	ENSG00000230069.3	LRRC37A15P	-5.14	4.53e-07	0.000181	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102727274~102730721:-
LIHC	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-5.14	4.53e-07	0.000181	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
LIHC	cis	rs4731207	0.698	rs720615	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124812652	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.735	rs720616	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124812907	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.662	rs6466950	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124813020	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.646	rs7783781	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124814359	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10260710	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124815932	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.672	rs62478914	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124816600	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs7781148	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124817990	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs1468378	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124818305	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs1468377	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124818545	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10243736	ENSG00000224897.5	POT1-AS1	-5.14	4.53e-07	0.000181	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124818912	chr7:124929873~125179315:+
LIHC	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	5.14	4.53e-07	0.000181	0.56	0.27	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
LIHC	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	5.14	4.53e-07	0.000181	0.56	0.27	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
LIHC	cis	rs2998286	0.862	rs1416816	ENSG00000254635.4	WAC-AS1	-5.14	4.54e-07	0.000181	-0.33	-0.27	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503491	chr10:28522652~28532743:-
LIHC	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-5.14	4.54e-07	0.000182	-0.28	-0.27	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-5.14	4.54e-07	0.000182	-0.28	-0.27	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-5.14	4.54e-07	0.000182	-0.28	-0.27	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
LIHC	cis	rs4731207	0.565	rs10227119	ENSG00000224897.5	POT1-AS1	5.14	4.55e-07	0.000182	0.32	0.27	Cutaneous malignant melanoma;	chr7:124953726	chr7:124929873~125179315:+
LIHC	cis	rs1577917	0.958	rs12193904	ENSG00000234155.1	RP11-30P6.6	5.14	4.55e-07	0.000182	0.35	0.27	Response to antipsychotic treatment;	chr6:85742985	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs11754330	ENSG00000234155.1	RP11-30P6.6	5.14	4.55e-07	0.000182	0.35	0.27	Response to antipsychotic treatment;	chr6:85745352	chr6:85387219~85390186:-
LIHC	cis	rs3096299	0.658	rs4785679	ENSG00000261118.1	RP11-104N10.1	5.14	4.55e-07	0.000182	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89492017~89504460:-
LIHC	cis	rs10510102	0.81	rs11200240	ENSG00000226864.1	ATE1-AS1	5.14	4.55e-07	0.000182	0.42	0.27	Breast cancer;	chr10:121903265	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.688	rs56094144	ENSG00000226864.1	ATE1-AS1	5.14	4.55e-07	0.000182	0.42	0.27	Breast cancer;	chr10:121903941	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs74914751	ENSG00000226864.1	ATE1-AS1	5.14	4.55e-07	0.000182	0.42	0.27	Breast cancer;	chr10:121904496	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200242	ENSG00000226864.1	ATE1-AS1	5.14	4.55e-07	0.000182	0.42	0.27	Breast cancer;	chr10:121905378	chr10:121928312~121951965:+
LIHC	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	5.14	4.55e-07	0.000182	0.36	0.27	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
LIHC	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-5.14	4.56e-07	0.000182	-0.37	-0.27	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
LIHC	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	5.14	4.57e-07	0.000182	0.34	0.27	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
LIHC	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	5.14	4.58e-07	0.000183	0.34	0.27	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
LIHC	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	5.14	4.58e-07	0.000183	0.28	0.27	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
LIHC	cis	rs887829	0.57	rs13015720	ENSG00000233445.1	RPL17P11	5.14	4.58e-07	0.000183	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233692353	chr2:233721522~233722065:-
LIHC	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-5.14	4.59e-07	0.000183	-0.3	-0.27	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
LIHC	cis	rs4731207	0.698	rs2107936	ENSG00000224897.5	POT1-AS1	-5.14	4.59e-07	0.000183	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124808987	chr7:124929873~125179315:+
LIHC	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	5.14	4.59e-07	0.000183	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	5.14	4.59e-07	0.000183	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	5.14	4.59e-07	0.000183	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	5.14	4.59e-07	0.000183	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	5.14	4.59e-07	0.000183	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	5.14	4.59e-07	0.000183	0.29	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
LIHC	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-5.14	4.59e-07	0.000183	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-5.14	4.59e-07	0.000183	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
LIHC	cis	rs7193541	0.691	rs3851728	ENSG00000261079.1	RP11-252A24.3	5.14	4.59e-07	0.000183	0.29	0.27	Multiple myeloma;	chr16:74446762	chr16:74367462~74369826:+
LIHC	cis	rs17301013	0.932	rs6664764	ENSG00000227373.4	RP11-160H22.5	5.14	4.59e-07	0.000183	0.33	0.27	Systemic lupus erythematosus;	chr1:174443402	chr1:174115300~174160004:-
LIHC	cis	rs4731207	0.596	rs6963594	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124969179	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6967707	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124969301	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs6967420	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124969306	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10226659	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124969814	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10256218	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124969928	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10275346	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124970292	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7806807	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124971246	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs10234592	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124971602	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs2402757	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124971659	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1585967	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124973290	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.591	rs12535300	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124973853	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs10954057	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124973884	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.591	rs28634794	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124974376	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.651	rs28710776	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124974418	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs12539580	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124979350	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs12531311	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124985492	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.503	rs1481325	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124985699	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.533	rs1481326	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124985930	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs10954060	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124985983	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.565	rs4355714	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124987467	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1481327	ENSG00000224897.5	POT1-AS1	5.14	4.59e-07	0.000183	0.33	0.27	Cutaneous malignant melanoma;	chr7:124988228	chr7:124929873~125179315:+
LIHC	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	5.14	4.61e-07	0.000184	0.33	0.27	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
LIHC	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	5.14	4.61e-07	0.000184	0.34	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
LIHC	cis	rs2998286	0.862	rs2486637	ENSG00000254635.4	WAC-AS1	-5.14	4.63e-07	0.000184	-0.33	-0.27	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28505085	chr10:28522652~28532743:-
LIHC	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-5.14	4.63e-07	0.000184	-0.37	-0.27	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
LIHC	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-5.14	4.63e-07	0.000184	-0.37	-0.27	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
LIHC	cis	rs2998286	0.815	rs332132	ENSG00000254635.4	WAC-AS1	-5.14	4.63e-07	0.000184	-0.34	-0.27	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28565185	chr10:28522652~28532743:-
LIHC	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-5.14	4.63e-07	0.000184	-0.3	-0.27	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
LIHC	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	5.14	4.63e-07	0.000184	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
LIHC	cis	rs11722779	0.903	rs4530634	ENSG00000230069.3	LRRC37A15P	-5.14	4.63e-07	0.000185	-0.24	-0.27	Schizophrenia;	chr4:102937924	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs7676943	ENSG00000230069.3	LRRC37A15P	-5.14	4.63e-07	0.000185	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.901	rs28674656	ENSG00000230069.3	LRRC37A15P	-5.14	4.63e-07	0.000185	-0.24	-0.27	Schizophrenia;	chr4:102944396	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.838	rs3974494	ENSG00000230069.3	LRRC37A15P	-5.14	4.63e-07	0.000185	-0.24	-0.27	Schizophrenia;	chr4:102945323	chr4:102727274~102730721:-
LIHC	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-5.14	4.64e-07	0.000185	-0.33	-0.27	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
LIHC	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	5.14	4.64e-07	0.000185	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
LIHC	cis	rs2072510	0.569	rs7134860	ENSG00000257715.1	RP11-256L6.2	-5.14	4.64e-07	0.000185	-0.41	-0.27	Metabolite levels (small molecules and protein measures);	chr12:95996580	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.569	rs7134975	ENSG00000257715.1	RP11-256L6.2	-5.14	4.64e-07	0.000185	-0.41	-0.27	Metabolite levels (small molecules and protein measures);	chr12:95996642	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.569	rs7306086	ENSG00000257715.1	RP11-256L6.2	-5.14	4.64e-07	0.000185	-0.41	-0.27	Metabolite levels (small molecules and protein measures);	chr12:95996724	chr12:96025323~96027971:+
LIHC	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-5.14	4.64e-07	0.000185	-0.33	-0.27	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
LIHC	cis	rs9595908	0.9	rs9591137	ENSG00000212293.1	SNORA16	5.14	4.64e-07	0.000185	0.31	0.27	Body mass index;	chr13:32578345	chr13:32420390~32420516:-
LIHC	cis	rs2836974	0.666	rs1888487	ENSG00000255568.3	BRWD1-AS2	-5.14	4.64e-07	0.000185	-0.23	-0.27	Cognitive function;	chr21:39311333	chr21:39313935~39314962:+
LIHC	cis	rs4731207	0.596	rs10081336	ENSG00000224897.5	POT1-AS1	5.14	4.65e-07	0.000185	0.33	0.27	Cutaneous malignant melanoma;	chr7:124935891	chr7:124929873~125179315:+
LIHC	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-5.14	4.66e-07	0.000186	-0.29	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
LIHC	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-5.14	4.66e-07	0.000186	-0.29	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
LIHC	cis	rs9409565	0.513	rs16912862	ENSG00000231806.2	PCAT7	-5.14	4.66e-07	0.000186	-0.32	-0.27	Colorectal cancer (alcohol consumption interaction);	chr9:94287723	chr9:94555069~94568127:+
LIHC	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	5.14	4.66e-07	0.000186	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
LIHC	cis	rs11098499	0.954	rs9993199	ENSG00000260091.1	RP11-33B1.4	5.14	4.66e-07	0.000186	0.18	0.27	Corneal astigmatism;	chr4:119471718	chr4:119409333~119410233:+
LIHC	cis	rs4731207	0.596	rs1871771	ENSG00000224897.5	POT1-AS1	5.14	4.67e-07	0.000186	0.33	0.27	Cutaneous malignant melanoma;	chr7:125038997	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs6977313	ENSG00000224897.5	POT1-AS1	5.14	4.67e-07	0.000186	0.33	0.27	Cutaneous malignant melanoma;	chr7:125041678	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1026836	ENSG00000224897.5	POT1-AS1	5.14	4.67e-07	0.000186	0.33	0.27	Cutaneous malignant melanoma;	chr7:125043578	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1525612	ENSG00000224897.5	POT1-AS1	5.14	4.67e-07	0.000186	0.33	0.27	Cutaneous malignant melanoma;	chr7:125043993	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs6952915	ENSG00000224897.5	POT1-AS1	5.14	4.67e-07	0.000186	0.33	0.27	Cutaneous malignant melanoma;	chr7:125045898	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.564	rs6466992	ENSG00000224897.5	POT1-AS1	5.14	4.67e-07	0.000186	0.33	0.27	Cutaneous malignant melanoma;	chr7:125052112	chr7:124929873~125179315:+
LIHC	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	5.14	4.68e-07	0.000186	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	5.14	4.68e-07	0.000186	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
LIHC	cis	rs7119038	0.818	rs76704408	ENSG00000255239.1	AP002954.6	-5.14	4.68e-07	0.000186	-0.34	-0.27	Sjögren's syndrome;	chr11:118812618	chr11:118688039~118690600:-
LIHC	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-5.14	4.69e-07	0.000187	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
LIHC	cis	rs1862618	0.853	rs1423620	ENSG00000271828.1	CTD-2310F14.1	5.14	4.69e-07	0.000187	0.37	0.27	Initial pursuit acceleration;	chr5:56805169	chr5:56927874~56929573:+
LIHC	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-5.14	4.69e-07	0.000187	-0.27	-0.27	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
LIHC	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-5.14	4.7e-07	0.000187	-0.25	-0.27	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
LIHC	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	5.14	4.71e-07	0.000187	0.42	0.27	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
LIHC	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	5.14	4.71e-07	0.000187	0.33	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
LIHC	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	5.14	4.71e-07	0.000187	0.2	0.27	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
LIHC	cis	rs12157904	1	rs5995487	ENSG00000233360.4	Z83844.1	5.14	4.71e-07	0.000187	0.59	0.27	Response to anti-depressant treatment in major depressive disorder;	chr22:37636081	chr22:37641832~37658377:-
LIHC	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-5.14	4.72e-07	0.000188	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
LIHC	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	5.14	4.72e-07	0.000188	0.45	0.27	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
LIHC	cis	rs2439831	1	rs2444032	ENSG00000205771.5	CATSPER2P1	-5.14	4.73e-07	0.000188	-0.37	-0.27	Lung cancer in ever smokers;	chr15:43463148	chr15:43726918~43747094:-
LIHC	cis	rs16858210	0.826	rs35494670	ENSG00000234371.6	RPSAP31	5.14	4.74e-07	0.000188	0.34	0.27	Menopause (age at onset);	chr3:183888569	chr3:183884924~183888449:+
LIHC	cis	rs4934494	0.727	rs55823491	ENSG00000232936.4	RP11-80H5.2	5.14	4.74e-07	0.000188	0.34	0.27	Red blood cell count;	chr10:89757598	chr10:89645282~89650667:+
LIHC	cis	rs1223397	0.938	rs20499	ENSG00000215022.6	RP1-257A7.4	-5.13	4.75e-07	0.000188	-0.33	-0.27	Blood pressure;	chr6:13294772	chr6:13264861~13295586:-
LIHC	cis	rs4731207	0.596	rs719972	ENSG00000224897.5	POT1-AS1	5.13	4.75e-07	0.000188	0.32	0.27	Cutaneous malignant melanoma;	chr7:124991743	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1021080	ENSG00000224897.5	POT1-AS1	5.13	4.75e-07	0.000188	0.32	0.27	Cutaneous malignant melanoma;	chr7:124993751	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.535	rs1552120	ENSG00000224897.5	POT1-AS1	5.13	4.75e-07	0.000188	0.32	0.27	Cutaneous malignant melanoma;	chr7:124999184	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs4406330	ENSG00000224897.5	POT1-AS1	5.13	4.75e-07	0.000188	0.32	0.27	Cutaneous malignant melanoma;	chr7:125001437	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1013754	ENSG00000224897.5	POT1-AS1	5.13	4.75e-07	0.000188	0.32	0.27	Cutaneous malignant melanoma;	chr7:125001993	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs12533918	ENSG00000224897.5	POT1-AS1	5.13	4.75e-07	0.000188	0.32	0.27	Cutaneous malignant melanoma;	chr7:125007209	chr7:124929873~125179315:+
LIHC	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-5.13	4.75e-07	0.000189	-0.34	-0.27	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
LIHC	cis	rs9425766	0.64	rs17301013	ENSG00000227373.4	RP11-160H22.5	5.13	4.75e-07	0.000189	0.33	0.27	Life satisfaction;	chr1:174343675	chr1:174115300~174160004:-
LIHC	cis	rs7131987	0.65	rs7301398	ENSG00000275476.1	RP11-996F15.4	-5.13	4.76e-07	0.000189	-0.31	-0.27	QT interval;	chr12:29302457	chr12:29277397~29277882:-
LIHC	cis	rs7131987	0.65	rs7301188	ENSG00000275476.1	RP11-996F15.4	-5.13	4.76e-07	0.000189	-0.31	-0.27	QT interval;	chr12:29302458	chr12:29277397~29277882:-
LIHC	cis	rs4356203	0.87	rs214926	ENSG00000272034.1	SNORD14A	-5.13	4.76e-07	0.000189	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17210255	chr11:17074654~17074744:-
LIHC	cis	rs9467711	0.591	rs116201501	ENSG00000216436.2	HIST1H2APS1	5.13	4.78e-07	0.000189	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:25998921	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs72834617	ENSG00000216436.2	HIST1H2APS1	5.13	4.78e-07	0.000189	0.65	0.27	Autism spectrum disorder or schizophrenia;	chr6:25998947	chr6:25732497~25732827:+
LIHC	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-5.13	4.78e-07	0.000189	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
LIHC	cis	rs4934494	0.768	rs1926139	ENSG00000232936.4	RP11-80H5.2	5.13	4.78e-07	0.000189	0.34	0.27	Red blood cell count;	chr10:89753395	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.727	rs12570750	ENSG00000232936.4	RP11-80H5.2	5.13	4.78e-07	0.000189	0.34	0.27	Red blood cell count;	chr10:89761273	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.723	rs17127001	ENSG00000232936.4	RP11-80H5.2	5.13	4.78e-07	0.000189	0.34	0.27	Red blood cell count;	chr10:89762932	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.727	rs36019294	ENSG00000232936.4	RP11-80H5.2	5.13	4.78e-07	0.000189	0.34	0.27	Red blood cell count;	chr10:89777822	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.636	rs34408087	ENSG00000232936.4	RP11-80H5.2	5.13	4.78e-07	0.000189	0.34	0.27	Red blood cell count;	chr10:89783794	chr10:89645282~89650667:+
LIHC	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	5.13	4.78e-07	0.00019	0.2	0.27	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
LIHC	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-5.13	4.78e-07	0.00019	-0.42	-0.27	Depression;	chr6:28206179	chr6:28115628~28116551:+
LIHC	cis	rs931127	0.554	rs11227261	ENSG00000265874.1	MIR4489	-5.13	4.79e-07	0.00019	-0.37	-0.27	Systemic lupus erythematosus;	chr11:65695372	chr11:65649192~65649253:+
LIHC	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	5.13	4.79e-07	0.00019	0.42	0.27	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
LIHC	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-5.13	4.79e-07	0.00019	-0.31	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
LIHC	cis	rs4731207	0.562	rs6466991	ENSG00000224897.5	POT1-AS1	5.13	4.8e-07	0.00019	0.33	0.27	Cutaneous malignant melanoma;	chr7:125051912	chr7:124929873~125179315:+
LIHC	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	5.13	4.8e-07	0.00019	0.4	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
LIHC	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	5.13	4.8e-07	0.00019	0.34	0.27	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
LIHC	cis	rs10510102	0.872	rs56108883	ENSG00000226864.1	ATE1-AS1	5.13	4.82e-07	0.000191	0.42	0.27	Breast cancer;	chr10:121825567	chr10:121928312~121951965:+
LIHC	cis	rs16858210	0.913	rs1879255	ENSG00000234371.6	RPSAP31	5.13	4.82e-07	0.000191	0.35	0.27	Menopause (age at onset);	chr3:183891657	chr3:183884924~183888449:+
LIHC	cis	rs16858210	0.837	rs1879254	ENSG00000234371.6	RPSAP31	5.13	4.82e-07	0.000191	0.35	0.27	Menopause (age at onset);	chr3:183891683	chr3:183884924~183888449:+
LIHC	cis	rs2060793	0.741	rs10734227	ENSG00000251991.1	RNU7-49P	5.13	4.82e-07	0.000191	0.3	0.27	Vitamin D levels;	chr11:14767471	chr11:14478892~14478953:+
LIHC	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.82e-07	0.000191	-0.31	-0.27	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
LIHC	cis	rs1577917	0.958	rs13213899	ENSG00000234155.1	RP11-30P6.6	5.13	4.82e-07	0.000191	0.35	0.27	Response to antipsychotic treatment;	chr6:85763422	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs10806337	ENSG00000234155.1	RP11-30P6.6	5.13	4.82e-07	0.000191	0.35	0.27	Response to antipsychotic treatment;	chr6:85764531	chr6:85387219~85390186:-
LIHC	cis	rs9326248	0.581	rs10892076	ENSG00000236267.1	AP006216.5	5.13	4.83e-07	0.000191	0.27	0.27	Blood protein levels;	chr11:117118220	chr11:116813204~116814003:-
LIHC	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	5.13	4.84e-07	0.000192	0.41	0.27	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
LIHC	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	5.13	4.84e-07	0.000192	0.45	0.27	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
LIHC	cis	rs2439831	1	rs2584726	ENSG00000205771.5	CATSPER2P1	-5.13	4.84e-07	0.000192	-0.36	-0.27	Lung cancer in ever smokers;	chr15:43423184	chr15:43726918~43747094:-
LIHC	cis	rs7615952	0.546	rs2922194	ENSG00000171084.14	FAM86JP	5.13	4.85e-07	0.000192	0.47	0.27	Blood pressure (smoking interaction);	chr3:125613419	chr3:125916620~125930024:+
LIHC	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	5.13	4.85e-07	0.000192	0.51	0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
LIHC	cis	rs4731207	0.596	rs6954614	ENSG00000224897.5	POT1-AS1	5.13	4.86e-07	0.000192	0.33	0.27	Cutaneous malignant melanoma;	chr7:124989740	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7788066	ENSG00000224897.5	POT1-AS1	5.13	4.86e-07	0.000192	0.33	0.27	Cutaneous malignant melanoma;	chr7:124990091	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.536	rs34630567	ENSG00000224897.5	POT1-AS1	5.13	4.86e-07	0.000192	0.33	0.27	Cutaneous malignant melanoma;	chr7:124990609	chr7:124929873~125179315:+
LIHC	cis	rs10510102	0.872	rs11200267	ENSG00000226864.1	ATE1-AS1	5.13	4.86e-07	0.000193	0.47	0.27	Breast cancer;	chr10:121929851	chr10:121928312~121951965:+
LIHC	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-5.13	4.86e-07	0.000193	-0.39	-0.27	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
LIHC	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	5.13	4.86e-07	0.000193	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	5.13	4.86e-07	0.000193	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	5.13	4.86e-07	0.000193	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	5.13	4.86e-07	0.000193	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	5.13	4.86e-07	0.000193	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	5.13	4.86e-07	0.000193	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
LIHC	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-5.13	4.87e-07	0.000193	-0.29	-0.27	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
LIHC	cis	rs5769765	1	rs5770755	ENSG00000278869.1	CITF22-49E9.3	-5.13	4.88e-07	0.000193	-0.4	-0.27	Schizophrenia;	chr22:49886488	chr22:49933198~49934074:-
LIHC	cis	rs11722779	0.838	rs4533776	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Schizophrenia;	chr4:102912732	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.838	rs6821247	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Schizophrenia;	chr4:102913483	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.514	rs59550147	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs9917919	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs3974608	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs10028116	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs9307281	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.903	rs6533037	ENSG00000230069.3	LRRC37A15P	-5.13	4.88e-07	0.000193	-0.24	-0.27	Schizophrenia;	chr4:102935865	chr4:102727274~102730721:-
LIHC	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	5.13	4.88e-07	0.000193	0.35	0.27	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
LIHC	cis	rs950169	0.58	rs4603535	ENSG00000259295.5	CSPG4P12	5.13	4.89e-07	0.000193	0.37	0.27	Schizophrenia;	chr15:84630641	chr15:85191438~85213905:+
LIHC	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	5.13	4.89e-07	0.000193	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
LIHC	cis	rs4650994	0.544	rs6682815	ENSG00000273384.1	RP5-1098D14.1	5.13	4.89e-07	0.000193	0.33	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178531974	chr1:178651706~178652282:+
LIHC	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	5.13	4.9e-07	0.000194	0.25	0.27	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
LIHC	cis	rs4718428	0.705	rs13227468	ENSG00000230295.1	RP11-458F8.2	-5.13	4.91e-07	0.000194	-0.23	-0.27	Corneal structure;	chr7:66968576	chr7:66880708~66882981:+
LIHC	cis	rs9992667	0.955	rs1962053	ENSG00000231160.8	KLF3-AS1	5.13	4.91e-07	0.000194	0.36	0.27	Eosinophil percentage of granulocytes;	chr4:38610736	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs28510735	ENSG00000231160.8	KLF3-AS1	5.13	4.91e-07	0.000194	0.36	0.27	Eosinophil percentage of granulocytes;	chr4:38612320	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs6819274	ENSG00000231160.8	KLF3-AS1	5.13	4.91e-07	0.000194	0.36	0.27	Eosinophil percentage of granulocytes;	chr4:38614306	chr4:38612701~38664883:-
LIHC	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-5.13	4.93e-07	0.000195	-0.24	-0.27	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
LIHC	cis	rs5769765	0.773	rs9616395	ENSG00000278869.1	CITF22-49E9.3	5.13	4.93e-07	0.000195	0.42	0.27	Schizophrenia;	chr22:49924155	chr22:49933198~49934074:-
LIHC	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-5.13	4.93e-07	0.000195	-0.23	-0.27	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
LIHC	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	5.13	4.94e-07	0.000195	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	5.13	4.94e-07	0.000195	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
LIHC	cis	rs6589219	0.826	rs10891241	ENSG00000196167.8	COLCA1	-5.13	4.95e-07	0.000195	-0.3	-0.27	Colorectal cancer;	chr11:111272783	chr11:111290787~111305045:-
LIHC	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-5.13	4.95e-07	0.000195	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
LIHC	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	5.13	4.95e-07	0.000195	0.4	0.27	Depression;	chr6:28200948	chr6:28115628~28116551:+
LIHC	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	5.13	4.96e-07	0.000196	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
LIHC	cis	rs5769765	0.773	rs9616206	ENSG00000278869.1	CITF22-49E9.3	5.13	4.96e-07	0.000196	0.44	0.27	Schizophrenia;	chr22:49917199	chr22:49933198~49934074:-
LIHC	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	5.13	4.96e-07	0.000196	0.3	0.27	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
LIHC	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	5.13	4.97e-07	0.000196	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
LIHC	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	5.13	4.97e-07	0.000196	0.35	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
LIHC	cis	rs950169	0.922	rs4338765	ENSG00000259295.5	CSPG4P12	5.13	4.98e-07	0.000196	0.36	0.27	Schizophrenia;	chr15:84248084	chr15:85191438~85213905:+
LIHC	cis	rs4731207	0.596	rs1871770	ENSG00000224897.5	POT1-AS1	5.13	4.98e-07	0.000196	0.33	0.27	Cutaneous malignant melanoma;	chr7:124990785	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs1481329	ENSG00000224897.5	POT1-AS1	5.13	4.98e-07	0.000196	0.33	0.27	Cutaneous malignant melanoma;	chr7:124991280	chr7:124929873~125179315:+
LIHC	cis	rs202072	0.769	rs495895	ENSG00000215022.6	RP1-257A7.4	-5.13	4.98e-07	0.000196	-0.31	-0.27	HIV-1 viral setpoint;	chr6:13277683	chr6:13264861~13295586:-
LIHC	cis	rs755249	0.958	rs17264866	ENSG00000182109.6	RP11-69E11.4	5.13	4.98e-07	0.000196	0.37	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39522280~39546187:-
LIHC	cis	rs227275	0.554	rs223381	ENSG00000230069.3	LRRC37A15P	-5.13	4.98e-07	0.000197	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102727274~102730721:-
LIHC	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	5.12	4.99e-07	0.000197	0.35	0.27	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
LIHC	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-5.12	4.99e-07	0.000197	-0.29	-0.27	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
LIHC	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	5.12	4.99e-07	0.000197	0.34	0.27	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
LIHC	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	5.12	5e-07	0.000197	0.38	0.27	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
LIHC	cis	rs4925386	0.808	rs1741634	ENSG00000273619.1	RP5-908M14.9	5.12	5e-07	0.000197	0.21	0.27	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62386303~62386970:-
LIHC	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	5.12	5.01e-07	0.000197	0.46	0.27	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	5.12	5.01e-07	0.000197	0.46	0.27	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
LIHC	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	5.12	5.01e-07	0.000197	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
LIHC	cis	rs4948102	0.667	rs7811270	ENSG00000226278.1	PSPHP1	-5.12	5.02e-07	0.000198	-0.31	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55764797~55773288:+
LIHC	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	5.12	5.02e-07	0.000198	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
LIHC	cis	rs3812049	0.506	rs36694	ENSG00000245937.6	LINC01184	5.12	5.02e-07	0.000198	0.33	0.27	Lymphocyte counts;Red cell distribution width;	chr5:128213263	chr5:127940426~128083172:-
LIHC	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	5.12	5.03e-07	0.000198	0.2	0.27	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
LIHC	cis	rs3096299	0.719	rs2911265	ENSG00000261118.1	RP11-104N10.1	5.12	5.04e-07	0.000198	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89492017~89504460:-
LIHC	cis	rs6977955	0.877	rs9648346	ENSG00000234336.5	JAZF1-AS1	-5.12	5.04e-07	0.000199	-0.38	-0.27	Allergic disease (asthma, hay fever or eczema);	chr7:28120494	chr7:28180322~28243917:+
LIHC	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	5.12	5.05e-07	0.000199	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
LIHC	cis	rs36715	1	rs36693	ENSG00000245937.6	LINC01184	5.12	5.05e-07	0.000199	0.33	0.27	Breast cancer;	chr5:128213008	chr5:127940426~128083172:-
LIHC	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-5.12	5.06e-07	0.000199	-0.34	-0.27	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
LIHC	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	5.12	5.06e-07	0.000199	0.34	0.27	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
LIHC	cis	rs4535700	0.501	rs57153841	ENSG00000226278.1	PSPHP1	5.12	5.07e-07	0.000199	0.33	0.27	Macular telangiectasia type 2;	chr7:55927400	chr7:55764797~55773288:+
LIHC	cis	rs2877649	0.793	rs114984773	ENSG00000258744.1	RP11-80A15.1	-5.12	5.07e-07	0.000199	-0.56	-0.27	Smooth-surface caries;	chr14:24453640	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs112428482	ENSG00000258744.1	RP11-80A15.1	-5.12	5.07e-07	0.000199	-0.56	-0.27	Smooth-surface caries;	chr14:24453907	chr14:24501594~24508688:+
LIHC	cis	rs734999	0.967	rs10797434	ENSG00000225931.3	RP3-395M20.7	5.12	5.07e-07	2e-04	0.29	0.27	Ulcerative colitis;	chr1:2579841	chr1:2566410~2569888:+
LIHC	cis	rs4731207	0.698	rs16871295	ENSG00000224897.5	POT1-AS1	-5.12	5.08e-07	2e-04	-0.32	-0.27	Cutaneous malignant melanoma;	chr7:124821234	chr7:124929873~125179315:+
LIHC	cis	rs5769765	0.955	rs9616204	ENSG00000278869.1	CITF22-49E9.3	5.12	5.08e-07	2e-04	0.43	0.27	Schizophrenia;	chr22:49909882	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs9616368	ENSG00000278869.1	CITF22-49E9.3	5.12	5.08e-07	2e-04	0.43	0.27	Schizophrenia;	chr22:49909885	chr22:49933198~49934074:-
LIHC	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	5.12	5.09e-07	2e-04	0.32	0.27	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
LIHC	cis	rs10829156	0.699	rs10764584	ENSG00000225527.1	RP11-383B4.4	5.12	5.09e-07	2e-04	0.43	0.27	Sudden cardiac arrest;	chr10:18546396	chr10:18531849~18533336:-
LIHC	cis	rs7119038	0.818	rs10892288	ENSG00000255239.1	AP002954.6	-5.12	5.09e-07	2e-04	-0.38	-0.27	Sjögren's syndrome;	chr11:118773985	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.818	rs56043232	ENSG00000255239.1	AP002954.6	-5.12	5.09e-07	2e-04	-0.38	-0.27	Sjögren's syndrome;	chr11:118777664	chr11:118688039~118690600:-
LIHC	cis	rs1577917	0.958	rs34765423	ENSG00000234155.1	RP11-30P6.6	5.12	5.1e-07	0.000201	0.36	0.27	Response to antipsychotic treatment;	chr6:85774730	chr6:85387219~85390186:-
LIHC	cis	rs228614	0.536	rs223475	ENSG00000230069.3	LRRC37A15P	-5.12	5.11e-07	0.000201	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.536	rs223474	ENSG00000230069.3	LRRC37A15P	-5.12	5.11e-07	0.000201	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102727274~102730721:-
LIHC	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	5.12	5.12e-07	0.000201	0.36	0.27	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
LIHC	cis	rs5758511	0.68	rs1107554	ENSG00000237037.8	NDUFA6-AS1	-5.12	5.12e-07	0.000201	-0.33	-0.27	Birth weight;	chr22:42271588	chr22:42090931~42137742:+
LIHC	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-5.12	5.12e-07	0.000201	-0.23	-0.27	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
LIHC	cis	rs11722779	0.935	rs3857200	ENSG00000230069.3	LRRC37A15P	-5.12	5.12e-07	0.000201	-0.24	-0.27	Schizophrenia;	chr4:103001864	chr4:102727274~102730721:-
LIHC	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	5.12	5.13e-07	0.000202	0.3	0.27	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
LIHC	cis	rs4731207	0.596	rs723444	ENSG00000224897.5	POT1-AS1	5.12	5.14e-07	0.000202	0.32	0.27	Cutaneous malignant melanoma;	chr7:125019170	chr7:124929873~125179315:+
LIHC	cis	rs4660214	0.666	rs596062	ENSG00000182109.6	RP11-69E11.4	5.12	5.14e-07	0.000202	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39360333	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs6704246	ENSG00000182109.6	RP11-69E11.4	-5.12	5.14e-07	0.000202	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39343612	chr1:39522280~39546187:-
LIHC	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-5.12	5.15e-07	0.000202	-0.3	-0.27	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
LIHC	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	5.12	5.15e-07	0.000202	0.52	0.27	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
LIHC	cis	rs2735413	0.918	rs4887932	ENSG00000276007.1	RP11-358L22.3	-5.12	5.17e-07	0.000203	-0.29	-0.27	Systolic blood pressure (alcohol consumption interaction);	chr16:78044453	chr16:78123243~78124332:+
LIHC	cis	rs4862307	0.688	rs6552743	ENSG00000250726.1	RP11-616K6.1	5.12	5.18e-07	0.000203	0.28	0.27	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184069363	chr4:184072403~184073039:+
LIHC	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	5.12	5.18e-07	0.000203	0.29	0.27	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
LIHC	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	5.12	5.18e-07	0.000203	0.23	0.27	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
LIHC	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	5.12	5.19e-07	0.000204	0.36	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
LIHC	cis	rs3096299	0.838	rs4785561	ENSG00000261118.1	RP11-104N10.1	5.12	5.19e-07	0.000204	0.3	0.27	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89492017~89504460:-
LIHC	cis	rs2933343	0.729	rs813945	ENSG00000231305.3	RP11-723O4.2	5.12	5.2e-07	0.000204	0.3	0.27	IgG glycosylation;	chr3:128942094	chr3:128861313~128871540:-
LIHC	cis	rs1061377	0.965	rs7690465	ENSG00000249685.1	RP11-360F5.3	5.12	5.2e-07	0.000204	0.32	0.27	Uric acid levels;	chr4:39147015	chr4:39133913~39135608:+
LIHC	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-5.12	5.21e-07	0.000204	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-5.12	5.21e-07	0.000204	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-5.12	5.21e-07	0.000204	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
LIHC	cis	rs2032447	0.714	rs199734	ENSG00000242387.1	HIST1H2APS2	5.12	5.21e-07	0.000204	0.34	0.27	Intelligence (multi-trait analysis);	chr6:25940165	chr6:25882026~25882395:-
LIHC	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-5.12	5.21e-07	0.000204	-0.33	-0.27	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
LIHC	cis	rs4356203	0.905	rs214937	ENSG00000272034.1	SNORD14A	5.12	5.22e-07	0.000204	0.29	0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17168005	chr11:17074654~17074744:-
LIHC	cis	rs9992667	0.911	rs28360925	ENSG00000231160.8	KLF3-AS1	5.12	5.22e-07	0.000205	0.36	0.27	Eosinophil percentage of granulocytes;	chr4:38615676	chr4:38612701~38664883:-
LIHC	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-5.12	5.22e-07	0.000205	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-5.12	5.22e-07	0.000205	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-5.12	5.22e-07	0.000205	-0.27	-0.27	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
LIHC	cis	rs6163	0.588	rs12763284	ENSG00000236937.2	PTGES3P4	-5.12	5.22e-07	0.000205	-0.32	-0.27	Waist circumference;Hip circumference;	chr10:102748445	chr10:102845595~102845950:+
LIHC	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	5.12	5.22e-07	0.000205	0.36	0.27	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
LIHC	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-5.12	5.22e-07	0.000205	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-5.12	5.22e-07	0.000205	-0.31	-0.27	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-5.12	5.22e-07	0.000205	-0.31	-0.27	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	5.12	5.22e-07	0.000205	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-5.12	5.22e-07	0.000205	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
LIHC	cis	rs2032447	0.714	rs199725	ENSG00000242387.1	HIST1H2APS2	5.12	5.22e-07	0.000205	0.33	0.27	Intelligence (multi-trait analysis);	chr6:25953456	chr6:25882026~25882395:-
LIHC	cis	rs5769765	0.908	rs9616390	ENSG00000278869.1	CITF22-49E9.3	5.12	5.23e-07	0.000205	0.44	0.27	Schizophrenia;	chr22:49920641	chr22:49933198~49934074:-
LIHC	cis	rs36715	1	rs251213	ENSG00000245937.6	LINC01184	5.12	5.23e-07	0.000205	0.33	0.27	Breast cancer;	chr5:128209913	chr5:127940426~128083172:-
LIHC	cis	rs36715	1	rs251212	ENSG00000245937.6	LINC01184	5.12	5.23e-07	0.000205	0.33	0.27	Breast cancer;	chr5:128210218	chr5:127940426~128083172:-
LIHC	cis	rs36715	1	rs2617621	ENSG00000245937.6	LINC01184	5.12	5.23e-07	0.000205	0.33	0.27	Breast cancer;	chr5:128210574	chr5:127940426~128083172:-
LIHC	cis	rs36715	1	rs181850	ENSG00000245937.6	LINC01184	5.12	5.23e-07	0.000205	0.33	0.27	Breast cancer;	chr5:128211795	chr5:127940426~128083172:-
LIHC	cis	rs36715	0.953	rs185177	ENSG00000245937.6	LINC01184	5.12	5.23e-07	0.000205	0.33	0.27	Breast cancer;	chr5:128212118	chr5:127940426~128083172:-
LIHC	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	5.12	5.23e-07	0.000205	0.37	0.27	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
LIHC	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	5.12	5.23e-07	0.000205	0.35	0.27	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
LIHC	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-5.12	5.23e-07	0.000205	-0.28	-0.27	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
LIHC	cis	rs1729407	0.647	rs2727791	ENSG00000236267.1	AP006216.5	5.11	5.24e-07	0.000205	0.26	0.27	Apolipoprotein A-IV levels;	chr11:116813846	chr11:116813204~116814003:-
LIHC	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	5.11	5.25e-07	0.000206	0.31	0.27	Height;	chr2:46624894	chr2:46668870~46670778:+
LIHC	cis	rs228614	0.51	rs223447	ENSG00000230069.3	LRRC37A15P	-5.11	5.25e-07	0.000206	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223446	ENSG00000230069.3	LRRC37A15P	-5.11	5.25e-07	0.000206	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223445	ENSG00000230069.3	LRRC37A15P	-5.11	5.25e-07	0.000206	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223443	ENSG00000230069.3	LRRC37A15P	-5.11	5.25e-07	0.000206	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102727274~102730721:-
LIHC	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-5.11	5.25e-07	0.000206	-0.42	-0.27	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
LIHC	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-5.11	5.25e-07	0.000206	-0.29	-0.27	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
LIHC	cis	rs12468226	0.938	rs13392645	ENSG00000273456.1	RP11-686O6.2	5.11	5.26e-07	0.000206	0.37	0.27	Urate levels;	chr2:202270116	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs7568159	ENSG00000273456.1	RP11-686O6.2	5.11	5.26e-07	0.000206	0.37	0.27	Urate levels;	chr2:202286226	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs7585867	ENSG00000273456.1	RP11-686O6.2	5.11	5.26e-07	0.000206	0.37	0.27	Urate levels;	chr2:202287040	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs58834901	ENSG00000273456.1	RP11-686O6.2	5.11	5.26e-07	0.000206	0.37	0.27	Urate levels;	chr2:202288169	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs1474002	ENSG00000273456.1	RP11-686O6.2	5.11	5.26e-07	0.000206	0.37	0.27	Urate levels;	chr2:202290195	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs6753044	ENSG00000273456.1	RP11-686O6.2	5.11	5.26e-07	0.000206	0.37	0.27	Urate levels;	chr2:202300710	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs55681656	ENSG00000273456.1	RP11-686O6.2	5.11	5.26e-07	0.000206	0.37	0.27	Urate levels;	chr2:202319041	chr2:202374932~202375604:-
LIHC	cis	rs12701220	0.857	rs1057558	ENSG00000229043.2	AC091729.9	-5.11	5.27e-07	0.000206	-0.37	-0.27	Bronchopulmonary dysplasia;	chr7:1022730	chr7:1160374~1165267:+
LIHC	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-5.11	5.27e-07	0.000206	-0.24	-0.27	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-5.11	5.27e-07	0.000206	-0.24	-0.27	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
LIHC	cis	rs5769765	0.773	rs9616378	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49918325	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.819	rs9616379	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49918387	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.862	rs9616380	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49918577	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.862	rs9616381	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49918734	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.773	rs58375955	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49918982	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.773	rs9616382	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49919331	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.773	rs9616383	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49919366	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.862	rs9616384	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49919434	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.862	rs9616385	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49919476	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.862	rs9616386	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49919531	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.908	rs9616388	ENSG00000278869.1	CITF22-49E9.3	5.11	5.27e-07	0.000206	0.44	0.27	Schizophrenia;	chr22:49919790	chr22:49933198~49934074:-
LIHC	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-5.11	5.28e-07	0.000207	-0.33	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
LIHC	cis	rs4660214	0.666	rs61783383	ENSG00000182109.6	RP11-69E11.4	-5.11	5.29e-07	0.000207	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341346	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs2256614	ENSG00000182109.6	RP11-69E11.4	5.11	5.29e-07	0.000207	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39359046	chr1:39522280~39546187:-
LIHC	cis	rs6163	0.588	rs67506723	ENSG00000236937.2	PTGES3P4	5.11	5.29e-07	0.000207	0.32	0.27	Waist circumference;Hip circumference;	chr10:102749307	chr10:102845595~102845950:+
LIHC	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	5.11	5.3e-07	0.000207	0.34	0.27	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
LIHC	cis	rs2060793	0.659	rs1839834	ENSG00000251991.1	RNU7-49P	5.11	5.3e-07	0.000207	0.3	0.27	Vitamin D levels;	chr11:14807914	chr11:14478892~14478953:+
LIHC	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	5.11	5.3e-07	0.000207	0.21	0.27	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
LIHC	cis	rs4731207	0.698	rs6942933	ENSG00000224897.5	POT1-AS1	-5.11	5.31e-07	0.000208	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124804468	chr7:124929873~125179315:+
LIHC	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-5.11	5.32e-07	0.000208	-0.34	-0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
LIHC	cis	rs227275	0.554	rs223390	ENSG00000230069.3	LRRC37A15P	-5.11	5.33e-07	0.000208	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102727274~102730721:-
LIHC	cis	rs16858210	0.874	rs35717944	ENSG00000234371.6	RPSAP31	5.11	5.33e-07	0.000208	0.35	0.27	Menopause (age at onset);	chr3:183889573	chr3:183884924~183888449:+
LIHC	cis	rs9595908	0.863	rs11616287	ENSG00000212293.1	SNORA16	5.11	5.33e-07	0.000208	0.32	0.27	Body mass index;	chr13:32580139	chr13:32420390~32420516:-
LIHC	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-5.11	5.34e-07	0.000209	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
LIHC	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	5.11	5.34e-07	0.000209	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.861	rs7538650	ENSG00000227373.4	RP11-160H22.5	-5.11	5.35e-07	0.000209	-0.34	-0.27	Systemic lupus erythematosus;	chr1:174788821	chr1:174115300~174160004:-
LIHC	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-5.11	5.35e-07	0.000209	-0.33	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
LIHC	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	5.11	5.35e-07	0.000209	0.32	0.27	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
LIHC	cis	rs7119038	0.774	rs11217020	ENSG00000255239.1	AP002954.6	-5.11	5.36e-07	0.000209	-0.38	-0.27	Sjögren's syndrome;	chr11:118768644	chr11:118688039~118690600:-
LIHC	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	5.11	5.36e-07	0.000209	0.5	0.27	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
LIHC	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-5.11	5.36e-07	0.00021	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
LIHC	cis	rs227275	0.556	rs223398	ENSG00000230069.3	LRRC37A15P	-5.11	5.37e-07	0.00021	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102727274~102730721:-
LIHC	cis	rs2877649	1	rs75683693	ENSG00000258744.1	RP11-80A15.1	-5.11	5.37e-07	0.00021	-0.53	-0.27	Smooth-surface caries;	chr14:24460434	chr14:24501594~24508688:+
LIHC	cis	rs916888	0.773	rs9896243	ENSG00000274883.1	Metazoa_SRP	-5.11	5.37e-07	0.00021	-0.4	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45931806~45932083:+
LIHC	cis	rs4731207	0.623	rs719973	ENSG00000224897.5	POT1-AS1	5.11	5.37e-07	0.00021	0.32	0.27	Cutaneous malignant melanoma;	chr7:124991673	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7802210	ENSG00000224897.5	POT1-AS1	5.11	5.37e-07	0.00021	0.32	0.27	Cutaneous malignant melanoma;	chr7:124992406	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs10954062	ENSG00000224897.5	POT1-AS1	5.11	5.37e-07	0.00021	0.32	0.27	Cutaneous malignant melanoma;	chr7:124996406	chr7:124929873~125179315:+
LIHC	cis	rs228614	0.51	rs223392	ENSG00000230069.3	LRRC37A15P	-5.11	5.37e-07	0.00021	-0.24	-0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102727274~102730721:-
LIHC	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	5.11	5.37e-07	0.00021	0.42	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
LIHC	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-5.11	5.37e-07	0.00021	-0.35	-0.27	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
LIHC	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-5.11	5.37e-07	0.00021	-0.28	-0.27	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-5.11	5.37e-07	0.00021	-0.28	-0.27	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-5.11	5.37e-07	0.00021	-0.28	-0.27	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-5.11	5.37e-07	0.00021	-0.28	-0.27	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-5.11	5.37e-07	0.00021	-0.28	-0.27	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-5.11	5.37e-07	0.00021	-0.28	-0.27	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
LIHC	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	5.11	5.38e-07	0.00021	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
LIHC	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	5.11	5.38e-07	0.00021	0.38	0.27	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
LIHC	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-5.11	5.39e-07	0.00021	-0.25	-0.27	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
LIHC	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-5.11	5.4e-07	0.000211	-0.35	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
LIHC	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	5.11	5.4e-07	0.000211	0.43	0.27	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
LIHC	cis	rs11603023	0.569	rs573905	ENSG00000255422.1	AP002954.4	-5.11	5.4e-07	0.000211	-0.31	-0.27	Cholesterol, total;	chr11:118701558	chr11:118704607~118750263:+
LIHC	cis	rs5758511	0.68	rs5758686	ENSG00000237037.8	NDUFA6-AS1	-5.11	5.4e-07	0.000211	-0.33	-0.27	Birth weight;	chr22:42259371	chr22:42090931~42137742:+
LIHC	cis	rs950776	0.714	rs17408276	ENSG00000261762.1	RP11-650L12.2	5.11	5.4e-07	0.000211	0.34	0.27	Sudden cardiac arrest;	chr15:78589276	chr15:78589123~78591276:-
LIHC	cis	rs61041384	0.661	rs4759411	ENSG00000256092.2	RP13-942N8.1	-5.11	5.42e-07	0.000212	-0.43	-0.27	Schizophrenia;	chr12:123256296	chr12:123363868~123366113:+
LIHC	cis	rs860295	1	rs6427286	ENSG00000203761.5	MSTO2P	-5.11	5.43e-07	0.000212	-0.21	-0.27	Body mass index;	chr1:155753506	chr1:155745829~155750137:+
LIHC	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	5.11	5.44e-07	0.000212	0.45	0.27	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
LIHC	cis	rs4731207	0.724	rs35535003	ENSG00000224897.5	POT1-AS1	-5.11	5.44e-07	0.000212	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124802410	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs4731214	ENSG00000224897.5	POT1-AS1	-5.11	5.44e-07	0.000212	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124802851	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs2158677	ENSG00000224897.5	POT1-AS1	-5.11	5.44e-07	0.000212	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124803912	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.671	rs5022495	ENSG00000224897.5	POT1-AS1	-5.11	5.44e-07	0.000212	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124803970	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs10248775	ENSG00000224897.5	POT1-AS1	-5.11	5.44e-07	0.000212	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124804153	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.698	rs6963177	ENSG00000224897.5	POT1-AS1	-5.11	5.44e-07	0.000212	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124804550	chr7:124929873~125179315:+
LIHC	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	5.11	5.45e-07	0.000212	0.33	0.27	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
LIHC	cis	rs5769765	0.728	rs6520064	ENSG00000278869.1	CITF22-49E9.3	5.11	5.45e-07	0.000212	0.39	0.27	Schizophrenia;	chr22:49900821	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.773	rs6520065	ENSG00000278869.1	CITF22-49E9.3	5.11	5.45e-07	0.000212	0.39	0.27	Schizophrenia;	chr22:49900822	chr22:49933198~49934074:-
LIHC	cis	rs3733589	1	rs13101772	ENSG00000250413.1	RP11-448G15.1	5.11	5.45e-07	0.000212	0.47	0.27	Renal overload gout;	chr4:9996100	chr4:10006482~10009725:+
LIHC	cis	rs2033711	0.654	rs734380	ENSG00000269473.1	CTD-2619J13.19	5.11	5.45e-07	0.000213	0.32	0.27	Uric acid clearance;	chr19:58387596	chr19:58440448~58445849:+
LIHC	cis	rs4731207	0.596	rs10252579	ENSG00000224897.5	POT1-AS1	5.11	5.45e-07	0.000213	0.33	0.27	Cutaneous malignant melanoma;	chr7:124997052	chr7:124929873~125179315:+
LIHC	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	5.11	5.46e-07	0.000213	0.32	0.27	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
LIHC	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	5.11	5.46e-07	0.000213	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
LIHC	cis	rs17301013	0.932	rs12077622	ENSG00000227373.4	RP11-160H22.5	5.11	5.46e-07	0.000213	0.32	0.27	Systemic lupus erythematosus;	chr1:174442507	chr1:174115300~174160004:-
LIHC	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-5.11	5.47e-07	0.000213	-0.33	-0.27	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-5.11	5.47e-07	0.000213	-0.33	-0.27	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
LIHC	cis	rs150992	0.568	rs34498	ENSG00000248489.1	CTD-2007H13.3	5.11	5.47e-07	0.000213	0.41	0.27	Body mass index;	chr5:98960690	chr5:98929171~98995013:+
LIHC	cis	rs30380	0.632	rs149189	ENSG00000272109.1	CTD-2260A17.3	-5.11	5.47e-07	0.000213	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96802101	chr5:96804353~96806105:+
LIHC	cis	rs30380	0.632	rs26495	ENSG00000272109.1	CTD-2260A17.3	-5.11	5.47e-07	0.000213	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96802137	chr5:96804353~96806105:+
LIHC	cis	rs30380	0.632	rs26496	ENSG00000272109.1	CTD-2260A17.3	-5.11	5.47e-07	0.000213	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96802179	chr5:96804353~96806105:+
LIHC	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-5.11	5.48e-07	0.000213	-0.27	-0.27	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
LIHC	cis	rs6977955	1	rs6977955	ENSG00000234336.5	JAZF1-AS1	5.11	5.48e-07	0.000213	0.38	0.27	Allergic disease (asthma, hay fever or eczema);	chr7:28117268	chr7:28180322~28243917:+
LIHC	cis	rs860295	0.702	rs475550	ENSG00000203761.5	MSTO2P	-5.11	5.48e-07	0.000214	-0.22	-0.27	Body mass index;	chr1:155682290	chr1:155745829~155750137:+
LIHC	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	5.11	5.48e-07	0.000214	0.41	0.27	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
LIHC	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	5.11	5.49e-07	0.000214	0.3	0.27	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
LIHC	cis	rs2836974	0.932	rs2150415	ENSG00000255568.3	BRWD1-AS2	5.11	5.49e-07	0.000214	0.29	0.27	Cognitive function;	chr21:39243441	chr21:39313935~39314962:+
LIHC	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	5.11	5.49e-07	0.000214	0.29	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	5.11	5.49e-07	0.000214	0.29	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	5.11	5.49e-07	0.000214	0.29	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	5.11	5.49e-07	0.000214	0.29	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	5.11	5.49e-07	0.000214	0.29	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
LIHC	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	5.11	5.49e-07	0.000214	0.45	0.27	Height;	chr6:109409645	chr6:109382795~109383666:+
LIHC	cis	rs10510102	0.935	rs10466217	ENSG00000226864.1	ATE1-AS1	5.11	5.5e-07	0.000214	0.44	0.27	Breast cancer;	chr10:121860362	chr10:121928312~121951965:+
LIHC	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-5.11	5.5e-07	0.000214	-0.28	-0.27	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
LIHC	cis	rs6600671	1	rs6600671	ENSG00000231429.2	RP11-343N15.2	5.11	5.5e-07	0.000214	0.33	0.27	Hip geometry;	chr1:121458637	chr1:121412719~121429274:+
LIHC	cis	rs887829	0.57	rs45615240	ENSG00000233445.1	RPL17P11	5.1	5.5e-07	0.000214	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233690650	chr2:233721522~233722065:-
LIHC	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-5.1	5.51e-07	0.000215	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
LIHC	cis	rs5769765	0.908	rs9616370	ENSG00000278869.1	CITF22-49E9.3	-5.1	5.52e-07	0.000215	-0.43	-0.27	Schizophrenia;	chr22:49912668	chr22:49933198~49934074:-
LIHC	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	5.1	5.53e-07	0.000215	0.35	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
LIHC	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	5.1	5.53e-07	0.000215	0.35	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
LIHC	cis	rs7615952	0.546	rs11718647	ENSG00000171084.14	FAM86JP	5.1	5.53e-07	0.000215	0.46	0.27	Blood pressure (smoking interaction);	chr3:125633178	chr3:125916620~125930024:+
LIHC	cis	rs36715	1	rs36702	ENSG00000245937.6	LINC01184	5.1	5.53e-07	0.000215	0.33	0.27	Breast cancer;	chr5:128217031	chr5:127940426~128083172:-
LIHC	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	5.1	5.53e-07	0.000215	0.33	0.27	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
LIHC	cis	rs4731207	0.596	rs6967887	ENSG00000224897.5	POT1-AS1	5.1	5.53e-07	0.000215	0.32	0.27	Cutaneous malignant melanoma;	chr7:124969436	chr7:124929873~125179315:+
LIHC	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	5.1	5.54e-07	0.000215	0.33	0.27	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
LIHC	cis	rs6480314	0.542	rs2120902	ENSG00000233590.1	RP11-153K11.3	-5.1	5.54e-07	0.000215	-0.41	-0.27	Optic nerve measurement (disc area);	chr10:68260465	chr10:68233251~68242379:-
LIHC	cis	rs36715	1	rs40527	ENSG00000245937.6	LINC01184	5.1	5.54e-07	0.000216	0.32	0.27	Breast cancer;	chr5:128214560	chr5:127940426~128083172:-
LIHC	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-5.1	5.54e-07	0.000216	-0.33	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
LIHC	cis	rs9992667	0.955	rs10025499	ENSG00000231160.8	KLF3-AS1	5.1	5.56e-07	0.000216	0.36	0.27	Eosinophil percentage of granulocytes;	chr4:38619373	chr4:38612701~38664883:-
LIHC	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	5.1	5.57e-07	0.000217	0.33	0.27	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
LIHC	cis	rs73193808	0.639	rs2832248	ENSG00000224649.1	AF124730.4	5.1	5.57e-07	0.000217	0.31	0.27	Coronary artery disease;	chr21:29184660	chr21:29182027~29187795:-
LIHC	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-5.1	5.58e-07	0.000217	-0.33	-0.27	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
LIHC	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-5.1	5.58e-07	0.000217	-0.28	-0.27	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
LIHC	cis	rs5769765	0.773	rs9616208	ENSG00000278869.1	CITF22-49E9.3	5.1	5.58e-07	0.000217	0.44	0.27	Schizophrenia;	chr22:49919711	chr22:49933198~49934074:-
LIHC	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-5.1	5.58e-07	0.000217	-0.3	-0.27	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
LIHC	cis	rs4731207	0.672	rs10249081	ENSG00000224897.5	POT1-AS1	-5.1	5.59e-07	0.000217	-0.31	-0.27	Cutaneous malignant melanoma;	chr7:124828465	chr7:124929873~125179315:+
LIHC	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	5.1	5.59e-07	0.000217	0.27	0.27	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	5.1	5.59e-07	0.000217	0.27	0.27	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
LIHC	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	5.1	5.59e-07	0.000217	0.36	0.27	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
LIHC	cis	rs4356203	0.818	rs214927	ENSG00000272034.1	SNORD14A	-5.1	5.59e-07	0.000217	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17209698	chr11:17074654~17074744:-
LIHC	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-5.1	5.61e-07	0.000218	-0.25	-0.27	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
LIHC	cis	rs3096299	0.658	rs12443705	ENSG00000261118.1	RP11-104N10.1	5.1	5.62e-07	0.000218	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89492017~89504460:-
LIHC	cis	rs2439831	0.702	rs495175	ENSG00000205771.5	CATSPER2P1	-5.1	5.62e-07	0.000218	-0.36	-0.27	Lung cancer in ever smokers;	chr15:43506486	chr15:43726918~43747094:-
LIHC	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	5.1	5.62e-07	0.000219	0.35	0.27	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
LIHC	cis	rs3096299	0.933	rs2965823	ENSG00000261118.1	RP11-104N10.1	5.1	5.64e-07	0.000219	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89492017~89504460:-
LIHC	cis	rs599083	0.53	rs2508834	ENSG00000212093.1	AP000807.1	-5.1	5.64e-07	0.000219	-0.29	-0.27	Bone mineral density (spine);	chr11:68407886	chr11:68506083~68506166:-
LIHC	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	5.1	5.64e-07	0.000219	0.33	0.27	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
LIHC	cis	rs4934494	0.768	rs34663515	ENSG00000232936.4	RP11-80H5.2	5.1	5.65e-07	0.000219	0.33	0.27	Red blood cell count;	chr10:89632786	chr10:89645282~89650667:+
LIHC	cis	rs2998286	0.862	rs2790460	ENSG00000254635.4	WAC-AS1	-5.1	5.66e-07	0.00022	-0.32	-0.27	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28502093	chr10:28522652~28532743:-
LIHC	cis	rs2439831	1	rs2256764	ENSG00000205771.5	CATSPER2P1	-5.1	5.66e-07	0.00022	-0.4	-0.27	Lung cancer in ever smokers;	chr15:43443565	chr15:43726918~43747094:-
LIHC	cis	rs2565722	0.563	rs1247559	ENSG00000243831.1	RP1-81D8.4	5.1	5.66e-07	0.00022	0.35	0.27	Blood protein levels;	chr6:160782724	chr6:160666228~160676523:-
LIHC	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-5.1	5.66e-07	0.00022	-0.25	-0.27	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
LIHC	cis	rs4731207	0.596	rs1525614	ENSG00000224897.5	POT1-AS1	5.1	5.67e-07	0.00022	0.32	0.27	Cutaneous malignant melanoma;	chr7:125018546	chr7:124929873~125179315:+
LIHC	cis	rs916888	0.773	rs199451	ENSG00000274883.1	Metazoa_SRP	-5.1	5.67e-07	0.00022	-0.42	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45931806~45932083:+
LIHC	cis	rs5769765	0.908	rs4074304	ENSG00000278869.1	CITF22-49E9.3	5.1	5.68e-07	0.00022	0.44	0.27	Schizophrenia;	chr22:49915798	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.908	rs9616376	ENSG00000278869.1	CITF22-49E9.3	5.1	5.68e-07	0.00022	0.44	0.27	Schizophrenia;	chr22:49917181	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.819	rs9616377	ENSG00000278869.1	CITF22-49E9.3	5.1	5.68e-07	0.00022	0.44	0.27	Schizophrenia;	chr22:49917232	chr22:49933198~49934074:-
LIHC	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	5.1	5.68e-07	0.00022	0.33	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
LIHC	cis	rs7119038	0.818	rs57494551	ENSG00000255239.1	AP002954.6	-5.1	5.68e-07	0.00022	-0.38	-0.27	Sjögren's syndrome;	chr11:118790689	chr11:118688039~118690600:-
LIHC	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-5.1	5.68e-07	0.000221	-0.34	-0.27	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
LIHC	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	5.1	5.69e-07	0.000221	0.29	0.27	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
LIHC	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-5.1	5.7e-07	0.000221	-0.32	-0.27	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-5.1	5.7e-07	0.000221	-0.32	-0.27	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-5.1	5.7e-07	0.000221	-0.32	-0.27	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
LIHC	cis	rs887829	0.57	rs10168155	ENSG00000233445.1	RPL17P11	5.1	5.7e-07	0.000221	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233688190	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.57	rs11680450	ENSG00000233445.1	RPL17P11	5.1	5.7e-07	0.000221	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233688837	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.57	rs10171367	ENSG00000233445.1	RPL17P11	5.1	5.7e-07	0.000221	0.28	0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233689021	chr2:233721522~233722065:-
LIHC	cis	rs9595066	0.715	rs9567366	ENSG00000230731.2	RP11-478K15.6	-5.1	5.71e-07	0.000221	-0.31	-0.27	Schizophrenia;	chr13:44108837	chr13:44234118~44243192:-
LIHC	cis	rs7916697	0.578	rs61854799	ENSG00000233590.1	RP11-153K11.3	-5.1	5.71e-07	0.000222	-0.34	-0.27	Optic disc area;	chr10:68246902	chr10:68233251~68242379:-
LIHC	cis	rs7208859	0.673	rs450585	ENSG00000266490.1	CTD-2349P21.9	5.1	5.72e-07	0.000222	0.31	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30792372~30792833:+
LIHC	cis	rs17711722	0.583	rs10085415	ENSG00000224316.1	RP11-479O9.2	-5.1	5.73e-07	0.000222	-0.27	-0.27	Calcium levels;	chr7:65628655	chr7:65773620~65802067:+
LIHC	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	5.1	5.73e-07	0.000222	0.29	0.27	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
LIHC	cis	rs916888	0.773	rs199448	ENSG00000274883.1	Metazoa_SRP	-5.1	5.74e-07	0.000222	-0.41	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45931806~45932083:+
LIHC	cis	rs2439831	1	rs689826	ENSG00000205771.5	CATSPER2P1	-5.1	5.75e-07	0.000223	-0.36	-0.27	Lung cancer in ever smokers;	chr15:43457718	chr15:43726918~43747094:-
LIHC	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-5.1	5.76e-07	0.000223	-0.28	-0.27	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs6849561	ENSG00000260091.1	RP11-33B1.4	5.1	5.76e-07	0.000223	0.19	0.27	Corneal astigmatism;	chr4:119488539	chr4:119409333~119410233:+
LIHC	cis	rs7615952	0.546	rs111812401	ENSG00000171084.14	FAM86JP	5.1	5.76e-07	0.000223	0.46	0.27	Blood pressure (smoking interaction);	chr3:125642651	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.546	rs2979350	ENSG00000171084.14	FAM86JP	5.1	5.76e-07	0.000223	0.46	0.27	Blood pressure (smoking interaction);	chr3:125643371	chr3:125916620~125930024:+
LIHC	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	5.1	5.76e-07	0.000223	0.33	0.27	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
LIHC	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	5.1	5.76e-07	0.000223	0.43	0.27	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
LIHC	cis	rs7119038	0.774	rs10892290	ENSG00000255239.1	AP002954.6	-5.1	5.77e-07	0.000224	-0.38	-0.27	Sjögren's syndrome;	chr11:118782794	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.774	rs874621	ENSG00000255239.1	AP002954.6	-5.1	5.77e-07	0.000224	-0.38	-0.27	Sjögren's syndrome;	chr11:118784936	chr11:118688039~118690600:-
LIHC	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-5.1	5.78e-07	0.000224	-0.35	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
LIHC	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	5.09	5.78e-07	0.000224	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	5.09	5.78e-07	0.000224	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	5.09	5.78e-07	0.000224	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	5.09	5.78e-07	0.000224	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	5.09	5.78e-07	0.000224	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	5.09	5.78e-07	0.000224	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	5.09	5.78e-07	0.000224	0.31	0.27	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
LIHC	cis	rs887829	0.57	rs6759892	ENSG00000233445.1	RPL17P11	-5.09	5.78e-07	0.000224	-0.28	-0.27	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233693023	chr2:233721522~233722065:-
LIHC	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	5.09	5.79e-07	0.000224	0.3	0.27	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
LIHC	cis	rs1322639	0.574	rs9689193	ENSG00000261039.2	RP11-417E7.2	-5.09	5.79e-07	0.000224	-0.38	-0.27	Pulse pressure;	chr6:169187979	chr6:169175304~169182740:-
LIHC	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-5.09	5.79e-07	0.000224	-0.37	-0.27	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
LIHC	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	5.09	5.8e-07	0.000225	0.41	0.27	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
LIHC	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	5.09	5.81e-07	0.000225	0.33	0.27	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
LIHC	cis	rs599083	0.53	rs576118	ENSG00000212093.1	AP000807.1	-5.09	5.81e-07	0.000225	-0.29	-0.27	Bone mineral density (spine);	chr11:68410240	chr11:68506083~68506166:-
LIHC	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	5.09	5.82e-07	0.000225	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
LIHC	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	5.09	5.82e-07	0.000225	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
LIHC	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	5.09	5.82e-07	0.000225	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
LIHC	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-5.09	5.82e-07	0.000225	-0.37	-0.27	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
LIHC	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-5.09	5.82e-07	0.000225	-0.33	-0.27	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
LIHC	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-5.09	5.83e-07	0.000225	-0.32	-0.27	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-5.09	5.83e-07	0.000225	-0.32	-0.27	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-5.09	5.83e-07	0.000225	-0.32	-0.27	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-5.09	5.83e-07	0.000225	-0.32	-0.27	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
LIHC	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-5.09	5.83e-07	0.000226	-0.24	-0.27	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
LIHC	cis	rs6480314	0.542	rs61854816	ENSG00000233590.1	RP11-153K11.3	-5.09	5.85e-07	0.000226	-0.41	-0.27	Optic nerve measurement (disc area);	chr10:68269051	chr10:68233251~68242379:-
LIHC	cis	rs1577917	0.958	rs12205492	ENSG00000234155.1	RP11-30P6.6	5.09	5.85e-07	0.000226	0.35	0.27	Response to antipsychotic treatment;	chr6:85766258	chr6:85387219~85390186:-
LIHC	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	5.09	5.85e-07	0.000226	0.2	0.27	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
LIHC	cis	rs4660214	0.666	rs2275186	ENSG00000182109.6	RP11-69E11.4	-5.09	5.85e-07	0.000226	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39522280~39546187:-
LIHC	cis	rs2836974	0.565	rs2836939	ENSG00000255568.3	BRWD1-AS2	5.09	5.86e-07	0.000227	0.38	0.27	Cognitive function;	chr21:39206620	chr21:39313935~39314962:+
LIHC	cis	rs17301013	0.932	rs6425282	ENSG00000227373.4	RP11-160H22.5	5.09	5.86e-07	0.000227	0.32	0.27	Systemic lupus erythematosus;	chr1:174493387	chr1:174115300~174160004:-
LIHC	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	5.09	5.86e-07	0.000227	0.4	0.27	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
LIHC	cis	rs5769707	1	rs5769707	ENSG00000235111.1	RP1-29C18.8	-5.09	5.87e-07	0.000227	-0.3	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49612657~49615716:-
LIHC	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	5.09	5.88e-07	0.000227	0.35	0.27	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
LIHC	cis	rs5769765	1	rs2295408	ENSG00000278869.1	CITF22-49E9.3	-5.09	5.88e-07	0.000227	-0.39	-0.27	Schizophrenia;	chr22:49867403	chr22:49933198~49934074:-
LIHC	cis	rs5769765	1	rs2295409	ENSG00000278869.1	CITF22-49E9.3	-5.09	5.88e-07	0.000227	-0.39	-0.27	Schizophrenia;	chr22:49867412	chr22:49933198~49934074:-
LIHC	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	5.09	5.88e-07	0.000227	0.32	0.27	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
LIHC	cis	rs5769707	0.904	rs7288869	ENSG00000235111.1	RP1-29C18.8	-5.09	5.89e-07	0.000227	-0.3	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49612657~49615716:-
LIHC	cis	rs17301013	0.932	rs6425281	ENSG00000227373.4	RP11-160H22.5	5.09	5.89e-07	0.000228	0.33	0.27	Systemic lupus erythematosus;	chr1:174449784	chr1:174115300~174160004:-
LIHC	cis	rs3096299	0.503	rs9940093	ENSG00000261118.1	RP11-104N10.1	5.09	5.89e-07	0.000228	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89492017~89504460:-
LIHC	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	5.09	5.89e-07	0.000228	0.3	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
LIHC	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	5.09	5.9e-07	0.000228	0.36	0.27	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
LIHC	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-5.09	5.9e-07	0.000228	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
LIHC	cis	rs4731207	0.506	rs12531282	ENSG00000224897.5	POT1-AS1	5.09	5.9e-07	0.000228	0.32	0.27	Cutaneous malignant melanoma;	chr7:124985408	chr7:124929873~125179315:+
LIHC	cis	rs11089937	0.609	rs2213158	ENSG00000211639.2	IGLV4-60	5.09	5.91e-07	0.000228	0.23	0.27	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.637	rs2213159	ENSG00000211639.2	IGLV4-60	5.09	5.91e-07	0.000228	0.23	0.27	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22162199~22162681:+
LIHC	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
LIHC	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	5.09	5.92e-07	0.000229	0.4	0.27	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
LIHC	cis	rs7119038	0.731	rs10892283	ENSG00000255239.1	AP002954.6	-5.09	5.93e-07	0.000229	-0.38	-0.27	Sjögren's syndrome;	chr11:118766272	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.818	rs10892286	ENSG00000255239.1	AP002954.6	-5.09	5.93e-07	0.000229	-0.38	-0.27	Sjögren's syndrome;	chr11:118771376	chr11:118688039~118690600:-
LIHC	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-5.09	5.93e-07	0.000229	-0.3	-0.27	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
LIHC	cis	rs4650994	0.525	rs10913567	ENSG00000273384.1	RP5-1098D14.1	5.09	5.95e-07	0.000229	0.33	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178542806	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.507	rs12405456	ENSG00000273384.1	RP5-1098D14.1	5.09	5.95e-07	0.000229	0.33	0.27	HDL cholesterol;HDL cholesterol levels;	chr1:178543196	chr1:178651706~178652282:+
LIHC	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	5.09	5.95e-07	0.00023	0.33	0.27	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
LIHC	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-5.09	5.96e-07	0.00023	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
LIHC	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	5.09	5.97e-07	0.00023	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
LIHC	cis	rs529413	0.61	rs565238	ENSG00000259237.1	RP11-209E8.1	5.09	5.97e-07	0.00023	0.34	0.27	Itch intensity from mosquito bite adjusted by bite size;	chr15:53206017	chr15:53116365~53129698:+
LIHC	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-5.09	5.97e-07	0.00023	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
LIHC	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-5.09	5.97e-07	0.00023	-0.19	-0.27	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
LIHC	cis	rs4934494	0.813	rs34928397	ENSG00000232936.4	RP11-80H5.2	5.09	5.97e-07	0.00023	0.34	0.27	Red blood cell count;	chr10:89766842	chr10:89645282~89650667:+
LIHC	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	5.09	5.97e-07	0.00023	0.2	0.27	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
LIHC	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	5.09	5.97e-07	0.00023	0.2	0.27	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
LIHC	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-5.09	5.98e-07	0.00023	-0.39	-0.27	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
LIHC	cis	rs227275	0.554	rs223454	ENSG00000230069.3	LRRC37A15P	-5.09	5.98e-07	0.000231	-0.24	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	5.09	5.98e-07	0.000231	0.31	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
LIHC	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-5.09	5.98e-07	0.000231	-0.34	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
LIHC	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-5.09	5.98e-07	0.000231	-0.33	-0.27	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
LIHC	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-5.09	5.99e-07	0.000231	-0.3	-0.27	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
LIHC	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-5.09	5.99e-07	0.000231	-0.34	-0.27	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
LIHC	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	5.09	6e-07	0.000231	0.28	0.27	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
LIHC	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	5.09	6.01e-07	0.000232	0.29	0.27	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	5.09	6.01e-07	0.000232	0.29	0.27	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
LIHC	cis	rs4356203	0.811	rs214920	ENSG00000272034.1	SNORD14A	-5.09	6.01e-07	0.000232	-0.29	-0.27	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17216402	chr11:17074654~17074744:-
LIHC	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	5.09	6.01e-07	0.000232	0.44	0.27	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
LIHC	cis	rs4660214	0.666	rs597311	ENSG00000182109.6	RP11-69E11.4	5.09	6.01e-07	0.000232	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355254	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.615	rs597708	ENSG00000182109.6	RP11-69E11.4	5.09	6.01e-07	0.000232	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355291	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs636156	ENSG00000182109.6	RP11-69E11.4	5.09	6.01e-07	0.000232	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356065	chr1:39522280~39546187:-
LIHC	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	5.09	6.01e-07	0.000232	0.35	0.27	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	5.09	6.01e-07	0.000232	0.35	0.27	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
LIHC	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	5.09	6.02e-07	0.000232	0.41	0.27	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
LIHC	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	5.09	6.02e-07	0.000232	0.3	0.27	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
LIHC	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	5.09	6.02e-07	0.000232	0.3	0.27	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
LIHC	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-5.09	6.03e-07	0.000232	-0.28	-0.27	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-5.09	6.03e-07	0.000232	-0.28	-0.27	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-5.09	6.03e-07	0.000232	-0.28	-0.27	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-5.09	6.03e-07	0.000232	-0.28	-0.27	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
LIHC	cis	rs12701220	0.744	rs2030958	ENSG00000229043.2	AC091729.9	-5.09	6.04e-07	0.000233	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:1036374	chr7:1160374~1165267:+
LIHC	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-5.09	6.04e-07	0.000233	-0.33	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
LIHC	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-5.09	6.05e-07	0.000233	-0.33	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
LIHC	cis	rs12285276	0.504	rs7120278	ENSG00000205106.4	DKFZp779M0652	5.09	6.05e-07	0.000233	0.28	0.27	Visceral fat;	chr11:45796560	chr11:45771432~45772358:+
LIHC	cis	rs4862307	0.72	rs12650935	ENSG00000250726.1	RP11-616K6.1	5.09	6.05e-07	0.000233	0.28	0.27	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184068412	chr4:184072403~184073039:+
LIHC	cis	rs7208859	0.623	rs8082537	ENSG00000266490.1	CTD-2349P21.9	5.09	6.05e-07	0.000233	0.32	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30792372~30792833:+
LIHC	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-5.09	6.06e-07	0.000233	-0.3	-0.27	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
LIHC	cis	rs2933343	0.7	rs2249514	ENSG00000231305.3	RP11-723O4.2	5.09	6.06e-07	0.000233	0.3	0.27	IgG glycosylation;	chr3:128924969	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.7	rs2630257	ENSG00000231305.3	RP11-723O4.2	5.09	6.06e-07	0.000233	0.3	0.27	IgG glycosylation;	chr3:128925172	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.729	rs1680785	ENSG00000231305.3	RP11-723O4.2	5.09	6.06e-07	0.000233	0.3	0.27	IgG glycosylation;	chr3:128925973	chr3:128861313~128871540:-
LIHC	cis	rs2933343	0.729	rs1680786	ENSG00000231305.3	RP11-723O4.2	5.09	6.06e-07	0.000233	0.3	0.27	IgG glycosylation;	chr3:128925997	chr3:128861313~128871540:-
LIHC	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-5.09	6.06e-07	0.000233	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-5.09	6.06e-07	0.000233	-0.29	-0.27	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-5.09	6.07e-07	0.000234	-0.29	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
LIHC	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	5.08	6.07e-07	0.000234	0.41	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	5.08	6.07e-07	0.000234	0.41	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
LIHC	cis	rs2741012	0.755	rs2741023	ENSG00000233445.1	RPL17P11	-5.08	6.08e-07	0.000234	-0.39	-0.27	Total bilirubin levels in HIV-1 infection;	chr2:233608068	chr2:233721522~233722065:-
LIHC	cis	rs2565722	0.507	rs1247567	ENSG00000243831.1	RP1-81D8.4	5.08	6.08e-07	0.000234	0.35	0.27	Blood protein levels;	chr6:160787265	chr6:160666228~160676523:-
LIHC	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	5.08	6.09e-07	0.000234	0.29	0.27	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
LIHC	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	5.08	6.09e-07	0.000235	0.44	0.27	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-5.08	6.11e-07	0.000235	-0.34	-0.27	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
LIHC	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-5.08	6.11e-07	0.000235	-0.31	-0.27	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
LIHC	cis	rs3096299	0.685	rs12446145	ENSG00000261118.1	RP11-104N10.1	5.08	6.11e-07	0.000235	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89492017~89504460:-
LIHC	cis	rs7615952	0.546	rs2979340	ENSG00000171084.14	FAM86JP	5.08	6.11e-07	0.000235	0.47	0.27	Blood pressure (smoking interaction);	chr3:125622540	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.546	rs2979338	ENSG00000171084.14	FAM86JP	5.08	6.11e-07	0.000235	0.47	0.27	Blood pressure (smoking interaction);	chr3:125624282	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.546	rs2922171	ENSG00000171084.14	FAM86JP	5.08	6.11e-07	0.000235	0.47	0.27	Blood pressure (smoking interaction);	chr3:125624349	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.546	rs112919177	ENSG00000171084.14	FAM86JP	5.08	6.11e-07	0.000235	0.47	0.27	Blood pressure (smoking interaction);	chr3:125627226	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.546	rs4428131	ENSG00000171084.14	FAM86JP	5.08	6.11e-07	0.000235	0.47	0.27	Blood pressure (smoking interaction);	chr3:125627635	chr3:125916620~125930024:+
LIHC	cis	rs6480314	0.542	rs4592311	ENSG00000233590.1	RP11-153K11.3	-5.08	6.12e-07	0.000235	-0.41	-0.27	Optic nerve measurement (disc area);	chr10:68268492	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs79081413	ENSG00000233590.1	RP11-153K11.3	-5.08	6.12e-07	0.000235	-0.41	-0.27	Optic nerve measurement (disc area);	chr10:68268746	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs17231630	ENSG00000233590.1	RP11-153K11.3	-5.08	6.12e-07	0.000235	-0.41	-0.27	Optic nerve measurement (disc area);	chr10:68268960	chr10:68233251~68242379:-
LIHC	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-5.08	6.12e-07	0.000235	-0.4	-0.27	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
LIHC	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-5.08	6.12e-07	0.000235	-0.4	-0.27	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
LIHC	cis	rs5769765	0.773	rs11090920	ENSG00000278869.1	CITF22-49E9.3	5.08	6.12e-07	0.000235	0.41	0.27	Schizophrenia;	chr22:49926457	chr22:49933198~49934074:-
LIHC	cis	rs1023500	0.505	rs134885	ENSG00000227370.1	RP4-669P10.19	-5.08	6.13e-07	0.000236	-0.27	-0.27	Schizophrenia;	chr22:42277805	chr22:42132543~42132998:+
LIHC	cis	rs3096299	0.874	rs3102342	ENSG00000261118.1	RP11-104N10.1	5.08	6.13e-07	0.000236	0.27	0.27	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89492017~89504460:-
LIHC	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	5.08	6.14e-07	0.000236	0.42	0.27	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
LIHC	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	5.08	6.14e-07	0.000236	0.42	0.27	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
LIHC	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	5.08	6.14e-07	0.000236	0.42	0.27	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
LIHC	cis	rs2032366	0.606	rs713485	ENSG00000267279.1	RP11-879F14.2	-5.08	6.15e-07	0.000236	-0.32	-0.26	Obesity-related traits;	chr18:61603692	chr18:61585746~61606916:-
LIHC	cis	rs17301013	0.861	rs10218528	ENSG00000227373.4	RP11-160H22.5	5.08	6.15e-07	0.000236	0.34	0.26	Systemic lupus erythematosus;	chr1:174478450	chr1:174115300~174160004:-
LIHC	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-5.08	6.15e-07	0.000237	-0.24	-0.26	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
LIHC	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	5.08	6.16e-07	0.000237	0.37	0.26	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
LIHC	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-5.08	6.16e-07	0.000237	-0.3	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
LIHC	cis	rs7412746	0.646	rs1972060	ENSG00000231073.1	RP11-316M1.3	5.08	6.16e-07	0.000237	0.26	0.26	Melanoma;	chr1:150965118	chr1:150973123~150975534:+
LIHC	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-5.08	6.16e-07	0.000237	-0.34	-0.26	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
LIHC	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-5.08	6.16e-07	0.000237	-0.34	-0.26	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
LIHC	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	5.08	6.17e-07	0.000237	0.28	0.26	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
LIHC	cis	rs9527	0.662	rs4919687	ENSG00000236937.2	PTGES3P4	5.08	6.17e-07	0.000237	0.37	0.26	Arsenic metabolism;	chr10:102835491	chr10:102845595~102845950:+
LIHC	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	5.08	6.18e-07	0.000237	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	5.08	6.18e-07	0.000237	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	5.08	6.18e-07	0.000237	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	5.08	6.18e-07	0.000237	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	5.08	6.18e-07	0.000237	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	5.08	6.18e-07	0.000237	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	5.08	6.18e-07	0.000237	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
LIHC	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-5.08	6.18e-07	0.000238	-0.31	-0.26	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
LIHC	cis	rs5769765	0.954	rs5770707	ENSG00000278869.1	CITF22-49E9.3	-5.08	6.19e-07	0.000238	-0.39	-0.26	Schizophrenia;	chr22:49850885	chr22:49933198~49934074:-
LIHC	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-5.08	6.19e-07	0.000238	-0.39	-0.26	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
LIHC	cis	rs860295	1	rs10908482	ENSG00000203761.5	MSTO2P	-5.08	6.22e-07	0.000239	-0.21	-0.26	Body mass index;	chr1:155744082	chr1:155745829~155750137:+
LIHC	cis	rs2033711	0.622	rs975947	ENSG00000269473.1	CTD-2619J13.19	5.08	6.22e-07	0.000239	0.32	0.26	Uric acid clearance;	chr19:58386826	chr19:58440448~58445849:+
LIHC	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	5.08	6.22e-07	0.000239	0.36	0.26	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
LIHC	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	5.08	6.23e-07	0.000239	0.32	0.26	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
LIHC	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	5.08	6.23e-07	0.000239	0.32	0.26	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
LIHC	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	5.08	6.23e-07	0.000239	0.32	0.26	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
LIHC	cis	rs1577917	0.958	rs1335442	ENSG00000234155.1	RP11-30P6.6	5.08	6.23e-07	0.000239	0.35	0.26	Response to antipsychotic treatment;	chr6:85756974	chr6:85387219~85390186:-
LIHC	cis	rs2565722	0.607	rs1247564	ENSG00000243831.1	RP1-81D8.4	5.08	6.24e-07	0.00024	0.35	0.26	Blood protein levels;	chr6:160785618	chr6:160666228~160676523:-
LIHC	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-5.08	6.24e-07	0.00024	-0.29	-0.26	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
LIHC	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	5.08	6.25e-07	0.00024	0.29	0.26	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
LIHC	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	5.08	6.26e-07	0.00024	0.32	0.26	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
LIHC	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-5.08	6.27e-07	0.00024	-0.27	-0.26	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
LIHC	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	5.08	6.27e-07	0.000241	0.36	0.26	Depression;	chr6:28407125	chr6:28176188~28176674:+
LIHC	cis	rs10833905	0.701	rs11026873	ENSG00000246225.5	RP11-17A1.3	-5.08	6.27e-07	0.000241	-0.35	-0.26	Sudden cardiac arrest;	chr11:22983116	chr11:22829380~22945393:+
LIHC	cis	rs6479901	0.793	rs4450077	ENSG00000232075.1	MRPL35P2	-5.08	6.28e-07	0.000241	-0.29	-0.26	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-5.08	6.28e-07	0.000241	-0.29	-0.26	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
LIHC	cis	rs11089937	0.597	rs5757024	ENSG00000211639.2	IGLV4-60	5.08	6.28e-07	0.000241	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.597	rs5757026	ENSG00000211639.2	IGLV4-60	5.08	6.28e-07	0.000241	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.597	rs5757027	ENSG00000211639.2	IGLV4-60	5.08	6.28e-07	0.000241	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22162199~22162681:+
LIHC	cis	rs599083	0.53	rs667126	ENSG00000212093.1	AP000807.1	-5.08	6.29e-07	0.000241	-0.29	-0.26	Bone mineral density (spine);	chr11:68410260	chr11:68506083~68506166:-
LIHC	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	5.08	6.29e-07	0.000241	0.38	0.26	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
LIHC	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	5.08	6.3e-07	0.000242	0.35	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
LIHC	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-5.08	6.31e-07	0.000242	-0.34	-0.26	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-5.08	6.31e-07	0.000242	-0.34	-0.26	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
LIHC	cis	rs7412746	0.658	rs8444	ENSG00000231073.1	RP11-316M1.3	5.08	6.31e-07	0.000242	0.27	0.26	Melanoma;	chr1:150966095	chr1:150973123~150975534:+
LIHC	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	5.08	6.31e-07	0.000242	0.41	0.26	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
LIHC	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	5.08	6.31e-07	0.000242	0.34	0.26	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	5.08	6.31e-07	0.000242	0.34	0.26	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-5.08	6.31e-07	0.000242	-0.34	-0.26	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-5.08	6.31e-07	0.000242	-0.34	-0.26	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-5.08	6.31e-07	0.000242	-0.34	-0.26	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
LIHC	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-5.08	6.31e-07	0.000242	-0.34	-0.26	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
LIHC	cis	rs4731207	0.596	rs1481328	ENSG00000224897.5	POT1-AS1	-5.08	6.31e-07	0.000242	-0.33	-0.26	Cutaneous malignant melanoma;	chr7:124990972	chr7:124929873~125179315:+
LIHC	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	5.08	6.32e-07	0.000242	0.37	0.26	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
LIHC	cis	rs7119038	0.774	rs2004781	ENSG00000255239.1	AP002954.6	-5.08	6.33e-07	0.000242	-0.38	-0.26	Sjögren's syndrome;	chr11:118748544	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.818	rs3889239	ENSG00000255239.1	AP002954.6	-5.08	6.33e-07	0.000242	-0.38	-0.26	Sjögren's syndrome;	chr11:118749251	chr11:118688039~118690600:-
LIHC	cis	rs6600671	0.934	rs12131379	ENSG00000231429.2	RP11-343N15.2	-5.08	6.33e-07	0.000243	-0.3	-0.26	Hip geometry;	chr1:121551639	chr1:121412719~121429274:+
LIHC	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	5.08	6.34e-07	0.000243	0.35	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
LIHC	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	5.08	6.34e-07	0.000243	0.35	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
LIHC	cis	rs227275	0.554	rs223371	ENSG00000230069.3	LRRC37A15P	-5.08	6.35e-07	0.000243	-0.24	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102727274~102730721:-
LIHC	cis	rs6085948	1	rs6077170	ENSG00000228888.1	LINC01428	5.08	6.35e-07	0.000243	0.36	0.26	Interleukin-10 levels;	chr20:7268888	chr20:7146467~7254202:-
LIHC	cis	rs227275	0.556	rs724447	ENSG00000230069.3	LRRC37A15P	5.08	6.36e-07	0.000244	0.24	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102727274~102730721:-
LIHC	cis	rs10833905	1	rs10833902	ENSG00000246225.5	RP11-17A1.3	-5.08	6.36e-07	0.000244	-0.33	-0.26	Sudden cardiac arrest;	chr11:23013647	chr11:22829380~22945393:+
LIHC	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-5.08	6.37e-07	0.000244	-0.39	-0.26	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
LIHC	cis	rs916888	0.773	rs199439	ENSG00000274883.1	Metazoa_SRP	-5.08	6.37e-07	0.000244	-0.41	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45931806~45932083:+
LIHC	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	5.08	6.37e-07	0.000244	0.35	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
LIHC	cis	rs4948102	0.642	rs4948104	ENSG00000226278.1	PSPHP1	-5.07	6.38e-07	0.000244	-0.31	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55764797~55773288:+
LIHC	cis	rs2877649	0.793	rs7157349	ENSG00000258744.1	RP11-80A15.1	-5.07	6.38e-07	0.000244	-0.53	-0.26	Smooth-surface caries;	chr14:24454327	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs7142374	ENSG00000258744.1	RP11-80A15.1	-5.07	6.38e-07	0.000244	-0.53	-0.26	Smooth-surface caries;	chr14:24454903	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs10129753	ENSG00000258744.1	RP11-80A15.1	-5.07	6.38e-07	0.000244	-0.53	-0.26	Smooth-surface caries;	chr14:24455010	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs17103869	ENSG00000258744.1	RP11-80A15.1	-5.07	6.38e-07	0.000244	-0.53	-0.26	Smooth-surface caries;	chr14:24455778	chr14:24501594~24508688:+
LIHC	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	5.07	6.38e-07	0.000244	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
LIHC	cis	rs1577917	0.958	rs11755642	ENSG00000234155.1	RP11-30P6.6	5.07	6.4e-07	0.000245	0.34	0.26	Response to antipsychotic treatment;	chr6:85740348	chr6:85387219~85390186:-
LIHC	cis	rs6600671	1	rs4844607	ENSG00000231429.2	RP11-343N15.2	5.07	6.4e-07	0.000245	0.3	0.26	Hip geometry;	chr1:121442201	chr1:121412719~121429274:+
LIHC	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	5.07	6.4e-07	0.000245	0.36	0.26	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	5.07	6.4e-07	0.000245	0.36	0.26	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
LIHC	cis	rs12701220	0.894	rs13224488	ENSG00000229043.2	AC091729.9	-5.07	6.42e-07	0.000245	-0.37	-0.26	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1160374~1165267:+
LIHC	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	5.07	6.43e-07	0.000246	0.35	0.26	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
LIHC	cis	rs9425766	0.64	rs10912734	ENSG00000227373.4	RP11-160H22.5	5.07	6.45e-07	0.000247	0.32	0.26	Life satisfaction;	chr1:174141977	chr1:174115300~174160004:-
LIHC	cis	rs5769765	0.817	rs8142561	ENSG00000278869.1	CITF22-49E9.3	5.07	6.46e-07	0.000247	0.39	0.26	Schizophrenia;	chr22:49898102	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs8138687	ENSG00000278869.1	CITF22-49E9.3	5.07	6.46e-07	0.000247	0.39	0.26	Schizophrenia;	chr22:49898221	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs8135816	ENSG00000278869.1	CITF22-49E9.3	5.07	6.46e-07	0.000247	0.39	0.26	Schizophrenia;	chr22:49898328	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.818	rs8140681	ENSG00000278869.1	CITF22-49E9.3	5.07	6.46e-07	0.000247	0.39	0.26	Schizophrenia;	chr22:49898433	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.825	rs9616780	ENSG00000278869.1	CITF22-49E9.3	5.07	6.46e-07	0.000247	0.39	0.26	Schizophrenia;	chr22:49899115	chr22:49933198~49934074:-
LIHC	cis	rs11089937	0.597	rs5750582	ENSG00000211639.2	IGLV4-60	5.07	6.46e-07	0.000247	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.626	rs5757028	ENSG00000211639.2	IGLV4-60	5.07	6.46e-07	0.000247	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22162199~22162681:+
LIHC	cis	rs7615952	0.546	rs2979333	ENSG00000171084.14	FAM86JP	5.07	6.46e-07	0.000247	0.46	0.26	Blood pressure (smoking interaction);	chr3:125641499	chr3:125916620~125930024:+
LIHC	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-5.07	6.47e-07	0.000247	-0.27	-0.26	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
LIHC	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-5.07	6.47e-07	0.000247	-0.27	-0.26	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
LIHC	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	5.07	6.47e-07	0.000247	0.2	0.26	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
LIHC	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-5.07	6.47e-07	0.000247	-0.34	-0.26	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
LIHC	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	5.07	6.48e-07	0.000248	0.32	0.26	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
LIHC	cis	rs12908161	0.853	rs12912342	ENSG00000259295.5	CSPG4P12	5.07	6.48e-07	0.000248	0.34	0.26	Schizophrenia;	chr15:84704985	chr15:85191438~85213905:+
LIHC	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-5.07	6.49e-07	0.000248	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
LIHC	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-5.07	6.49e-07	0.000248	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
LIHC	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-5.07	6.49e-07	0.000248	-0.31	-0.26	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
LIHC	cis	rs887829	0.57	rs12623271	ENSG00000233445.1	RPL17P11	5.07	6.49e-07	0.000248	0.28	0.26	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233691295	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.57	rs10445704	ENSG00000233445.1	RPL17P11	5.07	6.49e-07	0.000248	0.28	0.26	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233691628	chr2:233721522~233722065:-
LIHC	cis	rs6085948	0.861	rs8121934	ENSG00000228888.1	LINC01428	-5.07	6.49e-07	0.000248	-0.46	-0.26	Interleukin-10 levels;	chr20:7263706	chr20:7146467~7254202:-
LIHC	cis	rs739496	0.947	rs12580300	ENSG00000226469.1	ADAM1B	5.07	6.5e-07	0.000248	0.32	0.26	Platelet count;	chr12:111411467	chr12:111927018~111929017:+
LIHC	cis	rs739496	0.895	rs7977752	ENSG00000226469.1	ADAM1B	5.07	6.5e-07	0.000248	0.32	0.26	Platelet count;	chr12:111412426	chr12:111927018~111929017:+
LIHC	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-5.07	6.52e-07	0.000249	-0.28	-0.26	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
LIHC	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-5.07	6.52e-07	0.000249	-0.28	-0.26	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-5.07	6.52e-07	0.000249	-0.28	-0.26	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-5.07	6.52e-07	0.000249	-0.28	-0.26	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-5.07	6.52e-07	0.000249	-0.28	-0.26	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
LIHC	cis	rs7587476	0.601	rs6715570	ENSG00000229267.2	AC072062.1	5.07	6.54e-07	0.000249	0.33	0.26	Neuroblastoma;	chr2:214808716	chr2:214810229~214963274:+
LIHC	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-5.07	6.54e-07	0.00025	-0.32	-0.26	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
LIHC	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	5.07	6.54e-07	0.00025	0.29	0.26	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
LIHC	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	5.07	6.55e-07	0.00025	0.32	0.26	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
LIHC	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-5.07	6.55e-07	0.00025	-0.31	-0.26	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
LIHC	cis	rs227275	0.531	rs223460	ENSG00000230069.3	LRRC37A15P	-5.07	6.55e-07	0.00025	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102727274~102730721:-
LIHC	cis	rs4660214	0.568	rs6692769	ENSG00000182109.6	RP11-69E11.4	-5.07	6.56e-07	0.00025	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39217503	chr1:39522280~39546187:-
LIHC	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	5.07	6.56e-07	0.00025	0.3	0.26	Depression;	chr6:28317705	chr6:28943877~28944537:+
LIHC	cis	rs17818399	0.781	rs12105006	ENSG00000279254.1	RP11-536C12.1	5.07	6.59e-07	0.000251	0.32	0.26	Height;	chr2:46635447	chr2:46668870~46670778:+
LIHC	cis	rs887829	0.57	rs6753569	ENSG00000233445.1	RPL17P11	5.07	6.59e-07	0.000251	0.28	0.26	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233687171	chr2:233721522~233722065:-
LIHC	cis	rs887829	0.57	rs6736743	ENSG00000233445.1	RPL17P11	5.07	6.59e-07	0.000251	0.28	0.26	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233687304	chr2:233721522~233722065:-
LIHC	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-5.07	6.59e-07	0.000252	-0.22	-0.26	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
LIHC	cis	rs10510102	0.935	rs11200260	ENSG00000226864.1	ATE1-AS1	5.07	6.6e-07	0.000252	0.43	0.26	Breast cancer;	chr10:121920169	chr10:121928312~121951965:+
LIHC	cis	rs227275	0.525	rs6419160	ENSG00000230069.3	LRRC37A15P	-5.07	6.62e-07	0.000252	-0.24	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-5.07	6.62e-07	0.000252	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-5.07	6.62e-07	0.000252	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.536	rs223478	ENSG00000230069.3	LRRC37A15P	-5.07	6.62e-07	0.000252	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.536	rs150898	ENSG00000230069.3	LRRC37A15P	-5.07	6.62e-07	0.000252	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102727274~102730721:-
LIHC	cis	rs9425766	0.679	rs7552830	ENSG00000227373.4	RP11-160H22.5	5.07	6.62e-07	0.000252	0.32	0.26	Life satisfaction;	chr1:174321643	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs7523938	ENSG00000227373.4	RP11-160H22.5	5.07	6.62e-07	0.000252	0.32	0.26	Life satisfaction;	chr1:174327373	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.64	rs6681780	ENSG00000227373.4	RP11-160H22.5	5.07	6.62e-07	0.000252	0.32	0.26	Life satisfaction;	chr1:174328980	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.55	rs57366619	ENSG00000227373.4	RP11-160H22.5	5.07	6.62e-07	0.000252	0.32	0.26	Life satisfaction;	chr1:174334929	chr1:174115300~174160004:-
LIHC	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-5.07	6.62e-07	0.000252	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000226002.1	RP11-460N20.5	-5.07	6.63e-07	0.000253	-0.28	-0.26	Calcium levels;	chr7:66046172	chr7:65084103~65100232:+
LIHC	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-5.07	6.64e-07	0.000253	-0.31	-0.26	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
LIHC	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-5.07	6.65e-07	0.000253	-0.3	-0.26	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
LIHC	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	5.07	6.66e-07	0.000254	0.41	0.26	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
LIHC	cis	rs36715	1	rs36705	ENSG00000245937.6	LINC01184	5.07	6.66e-07	0.000254	0.33	0.26	Breast cancer;	chr5:128218794	chr5:127940426~128083172:-
LIHC	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-5.07	6.67e-07	0.000254	-0.27	-0.26	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
LIHC	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-5.07	6.67e-07	0.000254	-0.27	-0.26	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
LIHC	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-5.07	6.67e-07	0.000254	-0.27	-0.26	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
LIHC	cis	rs11648785	0.735	rs868372	ENSG00000221819.5	GAS8-AS1	-5.07	6.68e-07	0.000254	-0.35	-0.26	Tanning;	chr16:90031587	chr16:90028908~90029367:-
LIHC	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-5.07	6.69e-07	0.000255	-0.28	-0.26	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
LIHC	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-5.07	6.69e-07	0.000255	-0.28	-0.26	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
LIHC	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	5.07	6.69e-07	0.000255	0.33	0.26	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
LIHC	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	5.06	6.69e-07	0.000255	0.2	0.26	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
LIHC	cis	rs12468226	0.938	rs55668474	ENSG00000273456.1	RP11-686O6.2	5.06	6.69e-07	0.000255	0.37	0.26	Urate levels;	chr2:202265559	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs16824590	ENSG00000273456.1	RP11-686O6.2	5.06	6.69e-07	0.000255	0.37	0.26	Urate levels;	chr2:202272624	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.938	rs77018809	ENSG00000273456.1	RP11-686O6.2	5.06	6.69e-07	0.000255	0.37	0.26	Urate levels;	chr2:202273166	chr2:202374932~202375604:-
LIHC	cis	rs17711722	0.523	rs365896	ENSG00000273024.4	INTS4P2	5.06	6.7e-07	0.000255	0.28	0.26	Calcium levels;	chr7:66045710	chr7:65647864~65715661:+
LIHC	cis	rs2836974	0.526	rs1888488	ENSG00000255568.3	BRWD1-AS2	-5.06	6.71e-07	0.000256	-0.22	-0.26	Cognitive function;	chr21:39314595	chr21:39313935~39314962:+
LIHC	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-5.06	6.72e-07	0.000256	-0.39	-0.26	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
LIHC	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	5.06	6.72e-07	0.000256	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
LIHC	cis	rs2439831	1	rs2467736	ENSG00000205771.5	CATSPER2P1	-5.06	6.73e-07	0.000256	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43492719	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2444250	ENSG00000205771.5	CATSPER2P1	-5.06	6.73e-07	0.000256	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43492853	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs101094	ENSG00000205771.5	CATSPER2P1	-5.06	6.73e-07	0.000256	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43495124	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs689781	ENSG00000205771.5	CATSPER2P1	-5.06	6.73e-07	0.000256	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43499899	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2584725	ENSG00000205771.5	CATSPER2P1	-5.06	6.73e-07	0.000256	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43500937	chr15:43726918~43747094:-
LIHC	cis	rs4731207	0.698	rs727506	ENSG00000224897.5	POT1-AS1	-5.06	6.73e-07	0.000256	-0.31	-0.26	Cutaneous malignant melanoma;	chr7:124821973	chr7:124929873~125179315:+
LIHC	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-5.06	6.73e-07	0.000256	-0.34	-0.26	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
LIHC	cis	rs4639966	0.569	rs603486	ENSG00000255239.1	AP002954.6	5.06	6.74e-07	0.000256	0.32	0.26	Systemic lupus erythematosus;	chr11:118716638	chr11:118688039~118690600:-
LIHC	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	5.06	6.74e-07	0.000256	0.28	0.26	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
LIHC	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-5.06	6.74e-07	0.000257	-0.31	-0.26	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
LIHC	cis	rs2072510	0.593	rs2540497	ENSG00000257715.1	RP11-256L6.2	-5.06	6.75e-07	0.000257	-0.41	-0.26	Metabolite levels (small molecules and protein measures);	chr12:96010497	chr12:96025323~96027971:+
LIHC	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	5.06	6.75e-07	0.000257	0.19	0.26	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
LIHC	cis	rs6600671	1	rs12145080	ENSG00000231429.2	RP11-343N15.2	5.06	6.76e-07	0.000257	0.3	0.26	Hip geometry;	chr1:121443673	chr1:121412719~121429274:+
LIHC	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	6.76e-07	0.000257	-0.24	-0.26	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
LIHC	cis	rs7412746	0.611	rs2280627	ENSG00000231073.1	RP11-316M1.3	5.06	6.77e-07	0.000257	0.26	0.26	Melanoma;	chr1:150963396	chr1:150973123~150975534:+
LIHC	cis	rs9595908	1	rs9591134	ENSG00000212293.1	SNORA16	5.06	6.78e-07	0.000258	0.31	0.26	Body mass index;	chr13:32574079	chr13:32420390~32420516:-
LIHC	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-5.06	6.78e-07	0.000258	-0.21	-0.26	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-5.06	6.78e-07	0.000258	-0.21	-0.26	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
LIHC	cis	rs5769765	0.955	rs9616367	ENSG00000278869.1	CITF22-49E9.3	5.06	6.79e-07	0.000258	0.43	0.26	Schizophrenia;	chr22:49909867	chr22:49933198~49934074:-
LIHC	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-5.06	6.79e-07	0.000258	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
LIHC	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-5.06	6.79e-07	0.000258	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
LIHC	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	5.06	6.79e-07	0.000258	0.4	0.26	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
LIHC	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	5.06	6.8e-07	0.000258	0.43	0.26	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
LIHC	cis	rs7208859	0.673	rs216440	ENSG00000266490.1	CTD-2349P21.9	5.06	6.8e-07	0.000258	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	5.06	6.8e-07	0.000259	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
LIHC	cis	rs2072510	0.569	rs61937881	ENSG00000257715.1	RP11-256L6.2	-5.06	6.8e-07	0.000259	-0.4	-0.26	Metabolite levels (small molecules and protein measures);	chr12:95999809	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.569	rs17677343	ENSG00000257715.1	RP11-256L6.2	-5.06	6.8e-07	0.000259	-0.4	-0.26	Metabolite levels (small molecules and protein measures);	chr12:96003303	chr12:96025323~96027971:+
LIHC	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	5.06	6.82e-07	0.000259	0.36	0.26	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	5.06	6.82e-07	0.000259	0.36	0.26	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
LIHC	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	5.06	6.82e-07	0.000259	0.3	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
LIHC	cis	rs12554020	0.786	rs78547192	ENSG00000227603.1	RP11-165J3.6	5.06	6.82e-07	0.000259	0.46	0.26	Schizophrenia;	chr9:93597221	chr9:93435332~93437121:-
LIHC	cis	rs228614	0.51	rs223472	ENSG00000230069.3	LRRC37A15P	-5.06	6.82e-07	0.000259	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102727274~102730721:-
LIHC	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-5.06	6.83e-07	0.000259	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
LIHC	cis	rs4934494	0.768	rs11330	ENSG00000232936.4	RP11-80H5.2	-5.06	6.83e-07	0.000259	-0.32	-0.26	Red blood cell count;	chr10:89634322	chr10:89645282~89650667:+
LIHC	cis	rs12468226	0.882	rs116437099	ENSG00000273456.1	RP11-686O6.2	5.06	6.83e-07	0.000259	0.36	0.26	Urate levels;	chr2:202299250	chr2:202374932~202375604:-
LIHC	cis	rs1005277	0.579	rs1621040	ENSG00000276805.1	RP11-291L22.6	5.06	6.83e-07	0.00026	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38451030~38451785:+
LIHC	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	5.06	6.85e-07	0.00026	0.28	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
LIHC	cis	rs12908161	0.959	rs11637728	ENSG00000259295.5	CSPG4P12	5.06	6.85e-07	0.00026	0.36	0.26	Schizophrenia;	chr15:84660161	chr15:85191438~85213905:+
LIHC	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	5.06	6.85e-07	0.00026	0.32	0.26	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
LIHC	cis	rs9425766	0.679	rs4650989	ENSG00000227373.4	RP11-160H22.5	5.06	6.86e-07	0.00026	0.32	0.26	Life satisfaction;	chr1:174289739	chr1:174115300~174160004:-
LIHC	cis	rs2337406	1	rs78631692	ENSG00000274576.2	IGHV2-70	-5.06	6.86e-07	0.000261	-0.31	-0.26	Alzheimer's disease (late onset);	chr14:106709371	chr14:106770577~106771020:-
LIHC	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-5.06	6.87e-07	0.000261	-0.27	-0.26	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
LIHC	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	5.06	6.88e-07	0.000261	0.38	0.26	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
LIHC	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-5.06	6.88e-07	0.000261	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
LIHC	cis	rs9425766	0.523	rs6668959	ENSG00000227373.4	RP11-160H22.5	5.06	6.88e-07	0.000261	0.32	0.26	Life satisfaction;	chr1:174088488	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs12563301	ENSG00000227373.4	RP11-160H22.5	5.06	6.88e-07	0.000261	0.32	0.26	Life satisfaction;	chr1:174090924	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.665	rs7553788	ENSG00000227373.4	RP11-160H22.5	5.06	6.88e-07	0.000261	0.32	0.26	Life satisfaction;	chr1:174093773	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs6682017	ENSG00000227373.4	RP11-160H22.5	5.06	6.88e-07	0.000261	0.32	0.26	Life satisfaction;	chr1:174097809	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.655	rs2145376	ENSG00000227373.4	RP11-160H22.5	5.06	6.88e-07	0.000261	0.32	0.26	Life satisfaction;	chr1:174098911	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs6663794	ENSG00000227373.4	RP11-160H22.5	5.06	6.88e-07	0.000261	0.32	0.26	Life satisfaction;	chr1:174099791	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.64	rs6658769	ENSG00000227373.4	RP11-160H22.5	5.06	6.88e-07	0.000261	0.32	0.26	Life satisfaction;	chr1:174100843	chr1:174115300~174160004:-
LIHC	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-5.06	6.89e-07	0.000261	-0.33	-0.26	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
LIHC	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	5.06	6.89e-07	0.000261	0.4	0.26	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
LIHC	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-5.06	6.89e-07	0.000262	-0.43	-0.26	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
LIHC	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-5.06	6.89e-07	0.000262	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
LIHC	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	5.06	6.9e-07	0.000262	0.32	0.26	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
LIHC	cis	rs1499614	1	rs2707832	ENSG00000230295.1	RP11-458F8.2	-5.06	6.9e-07	0.000262	-0.26	-0.26	Gout;	chr7:66671562	chr7:66880708~66882981:+
LIHC	cis	rs11672691	0.519	rs10407939	ENSG00000267107.5	PCAT19	5.06	6.91e-07	0.000262	0.32	0.26	Prostate cancer;	chr19:41502561	chr19:41454169~41500649:-
LIHC	cis	rs712039	0.652	rs712038	ENSG00000276054.1	RP11-378E13.3	5.06	6.91e-07	0.000262	0.33	0.26	Tuberculosis;	chr17:37402468	chr17:37386886~37387926:+
LIHC	cis	rs712039	0.652	rs829160	ENSG00000276054.1	RP11-378E13.3	5.06	6.91e-07	0.000262	0.33	0.26	Tuberculosis;	chr17:37403002	chr17:37386886~37387926:+
LIHC	cis	rs7714584	1	rs59043558	ENSG00000197083.10	ZNF300P1	5.06	6.91e-07	0.000262	0.4	0.26	Crohn's disease;	chr5:150955100	chr5:150930645~150946289:-
LIHC	cis	rs712039	0.652	rs1102920	ENSG00000276054.1	RP11-378E13.3	5.06	6.92e-07	0.000263	0.33	0.26	Tuberculosis;	chr17:37400850	chr17:37386886~37387926:+
LIHC	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	5.06	6.92e-07	0.000263	0.4	0.26	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
LIHC	cis	rs4718428	0.705	rs13220977	ENSG00000230295.1	RP11-458F8.2	5.06	6.93e-07	0.000263	0.22	0.26	Corneal structure;	chr7:66872661	chr7:66880708~66882981:+
LIHC	cis	rs2836974	0.666	rs2836975	ENSG00000255568.3	BRWD1-AS2	-5.06	6.93e-07	0.000263	-0.22	-0.26	Cognitive function;	chr21:39291694	chr21:39313935~39314962:+
LIHC	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-5.06	6.94e-07	0.000263	-0.31	-0.26	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
LIHC	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	5.06	6.96e-07	0.000264	0.37	0.26	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
LIHC	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	5.06	6.97e-07	0.000264	0.31	0.26	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	5.06	6.97e-07	0.000264	0.31	0.26	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
LIHC	cis	rs5756813	0.754	rs4821706	ENSG00000233360.4	Z83844.1	5.06	7e-07	0.000265	0.34	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37758683	chr22:37641832~37658377:-
LIHC	cis	rs916888	0.773	rs199457	ENSG00000274883.1	Metazoa_SRP	-5.06	7.01e-07	0.000265	-0.41	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.687	rs199456	ENSG00000274883.1	Metazoa_SRP	-5.06	7.01e-07	0.000265	-0.41	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45931806~45932083:+
LIHC	cis	rs10510102	1	rs10510102	ENSG00000226864.1	ATE1-AS1	-5.06	7.01e-07	0.000265	-0.44	-0.26	Breast cancer;	chr10:121865675	chr10:121928312~121951965:+
LIHC	cis	rs4731207	0.646	rs67453484	ENSG00000224897.5	POT1-AS1	-5.06	7.01e-07	0.000266	-0.32	-0.26	Cutaneous malignant melanoma;	chr7:124814470	chr7:124929873~125179315:+
LIHC	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-5.06	7.01e-07	0.000266	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
LIHC	cis	rs73186030	0.591	rs56098325	ENSG00000272758.4	RP11-299J3.8	5.06	7.01e-07	0.000266	0.52	0.26	Serum parathyroid hormone levels;	chr3:122342362	chr3:122416207~122443180:+
LIHC	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-5.06	7.02e-07	0.000266	-0.34	-0.26	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-5.06	7.02e-07	0.000266	-0.34	-0.26	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
LIHC	cis	rs4356203	0.87	rs1979603	ENSG00000272034.1	SNORD14A	-5.06	7.02e-07	0.000266	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17074654~17074744:-
LIHC	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	5.06	7.02e-07	0.000266	0.21	0.26	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	5.06	7.02e-07	0.000266	0.21	0.26	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
LIHC	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	5.05	7.04e-07	0.000266	0.28	0.26	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
LIHC	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	5.05	7.05e-07	0.000267	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	5.05	7.05e-07	0.000267	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	5.05	7.05e-07	0.000267	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
LIHC	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	5.05	7.06e-07	0.000267	0.37	0.26	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
LIHC	cis	rs712039	0.652	rs2680719	ENSG00000276054.1	RP11-378E13.3	5.05	7.07e-07	0.000267	0.33	0.26	Tuberculosis;	chr17:37451351	chr17:37386886~37387926:+
LIHC	cis	rs1005277	0.557	rs2983338	ENSG00000276805.1	RP11-291L22.6	5.05	7.07e-07	0.000268	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38451030~38451785:+
LIHC	cis	rs875971	0.54	rs781152	ENSG00000164669.11	INTS4P1	-5.05	7.07e-07	0.000268	-0.38	-0.26	Aortic root size;	chr7:66014585	chr7:65141225~65234216:+
LIHC	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-5.05	7.07e-07	0.000268	-0.44	-0.26	Gout;	chr7:66732812	chr7:66654538~66669855:+
LIHC	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-5.05	7.08e-07	0.000268	-0.32	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
LIHC	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	5.05	7.08e-07	0.000268	0.2	0.26	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
LIHC	cis	rs17711722	0.727	rs781151	ENSG00000164669.11	INTS4P1	-5.05	7.1e-07	0.000269	-0.38	-0.26	Calcium levels;	chr7:66014891	chr7:65141225~65234216:+
LIHC	cis	rs36715	0.953	rs36706	ENSG00000245937.6	LINC01184	5.05	7.1e-07	0.000269	0.33	0.26	Breast cancer;	chr5:128221006	chr5:127940426~128083172:-
LIHC	cis	rs2877649	0.793	rs74805728	ENSG00000258744.1	RP11-80A15.1	-5.05	7.11e-07	0.000269	-0.55	-0.26	Smooth-surface caries;	chr14:24446631	chr14:24501594~24508688:+
LIHC	cis	rs17270561	0.697	rs9366633	ENSG00000216436.2	HIST1H2APS1	-5.05	7.11e-07	0.000269	-0.32	-0.26	Iron status biomarkers;	chr6:25837826	chr6:25732497~25732827:+
LIHC	cis	rs931127	0.554	rs34007146	ENSG00000265874.1	MIR4489	5.05	7.12e-07	0.000269	0.37	0.26	Systemic lupus erythematosus;	chr11:65710483	chr11:65649192~65649253:+
LIHC	cis	rs10912872	0.634	rs10912842	ENSG00000225704.2	RP4-798A17.5	5.05	7.13e-07	0.00027	0.23	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171365688	chr1:171345089~171345320:+
LIHC	cis	rs7208859	0.623	rs216423	ENSG00000266490.1	CTD-2349P21.9	5.05	7.13e-07	0.00027	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30792372~30792833:+
LIHC	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-5.05	7.15e-07	0.00027	-0.38	-0.26	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
LIHC	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-5.05	7.15e-07	0.00027	-0.33	-0.26	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
LIHC	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-5.05	7.16e-07	0.000271	-0.24	-0.26	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
LIHC	cis	rs1005277	0.579	rs2103938	ENSG00000276805.1	RP11-291L22.6	5.05	7.16e-07	0.000271	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38451030~38451785:+
LIHC	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-5.05	7.16e-07	0.000271	-0.28	-0.26	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
LIHC	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	5.05	7.16e-07	0.000271	0.41	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
LIHC	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	5.05	7.18e-07	0.000271	0.41	0.26	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
LIHC	cis	rs6600671	0.934	rs12060031	ENSG00000231429.2	RP11-343N15.2	5.05	7.18e-07	0.000271	0.32	0.26	Hip geometry;	chr1:121501652	chr1:121412719~121429274:+
LIHC	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	5.05	7.18e-07	0.000271	0.4	0.26	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
LIHC	cis	rs2439831	0.867	rs3809481	ENSG00000205771.5	CATSPER2P1	-5.05	7.19e-07	0.000272	-0.42	-0.26	Lung cancer in ever smokers;	chr15:43370631	chr15:43726918~43747094:-
LIHC	cis	rs6480314	0.522	rs61854800	ENSG00000233590.1	RP11-153K11.3	-5.05	7.2e-07	0.000272	-0.44	-0.26	Optic nerve measurement (disc area);	chr10:68248271	chr10:68233251~68242379:-
LIHC	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	5.05	7.21e-07	0.000273	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
LIHC	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	5.05	7.22e-07	0.000273	0.32	0.26	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
LIHC	cis	rs2877649	0.793	rs74984901	ENSG00000258744.1	RP11-80A15.1	-5.05	7.22e-07	0.000273	-0.55	-0.26	Smooth-surface caries;	chr14:24443571	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs77892475	ENSG00000258744.1	RP11-80A15.1	-5.05	7.22e-07	0.000273	-0.55	-0.26	Smooth-surface caries;	chr14:24443683	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs80192295	ENSG00000258744.1	RP11-80A15.1	-5.05	7.22e-07	0.000273	-0.55	-0.26	Smooth-surface caries;	chr14:24445120	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs78663777	ENSG00000258744.1	RP11-80A15.1	-5.05	7.22e-07	0.000273	-0.55	-0.26	Smooth-surface caries;	chr14:24445990	chr14:24501594~24508688:+
LIHC	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-5.05	7.23e-07	0.000273	-0.34	-0.26	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
LIHC	cis	rs7119038	0.818	rs56758835	ENSG00000255239.1	AP002954.6	-5.05	7.23e-07	0.000273	-0.38	-0.26	Sjögren's syndrome;	chr11:118744631	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.818	rs1048024	ENSG00000255239.1	AP002954.6	-5.05	7.23e-07	0.000273	-0.38	-0.26	Sjögren's syndrome;	chr11:118748067	chr11:118688039~118690600:-
LIHC	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	5.05	7.23e-07	0.000273	0.35	0.26	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
LIHC	cis	rs1005277	0.529	rs1780125	ENSG00000276805.1	RP11-291L22.6	5.05	7.25e-07	0.000274	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.502	rs2800484	ENSG00000276805.1	RP11-291L22.6	5.05	7.25e-07	0.000274	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs2800485	ENSG00000276805.1	RP11-291L22.6	5.05	7.25e-07	0.000274	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38451030~38451785:+
LIHC	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-5.05	7.27e-07	0.000274	-0.3	-0.26	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
LIHC	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	5.05	7.27e-07	0.000274	0.32	0.26	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
LIHC	cis	rs6480314	0.542	rs10998044	ENSG00000233590.1	RP11-153K11.3	-5.05	7.27e-07	0.000274	-0.41	-0.26	Optic nerve measurement (disc area);	chr10:68269508	chr10:68233251~68242379:-
LIHC	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-5.05	7.28e-07	0.000275	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
LIHC	cis	rs875971	0.545	rs6460281	ENSG00000273142.1	RP11-458F8.4	5.05	7.29e-07	0.000275	0.25	0.26	Aortic root size;	chr7:66216128	chr7:66902857~66906297:+
LIHC	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-5.05	7.31e-07	0.000276	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
LIHC	cis	rs7412746	0.611	rs752376	ENSG00000231073.1	RP11-316M1.3	5.05	7.31e-07	0.000276	0.26	0.26	Melanoma;	chr1:150968905	chr1:150973123~150975534:+
LIHC	cis	rs7665090	0.51	rs223498	ENSG00000230069.3	LRRC37A15P	5.05	7.31e-07	0.000276	0.24	0.26	Primary biliary cholangitis;	chr4:102730805	chr4:102727274~102730721:-
LIHC	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	5.05	7.31e-07	0.000276	0.38	0.26	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
LIHC	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	5.05	7.31e-07	0.000276	0.47	0.26	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
LIHC	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-5.05	7.33e-07	0.000277	-0.33	-0.26	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
LIHC	cis	rs228614	0.536	rs150897	ENSG00000230069.3	LRRC37A15P	-5.05	7.34e-07	0.000277	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102727274~102730721:-
LIHC	cis	rs7208859	0.673	rs216424	ENSG00000266490.1	CTD-2349P21.9	5.05	7.34e-07	0.000277	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30792372~30792833:+
LIHC	cis	rs417065	0.516	rs6687168	ENSG00000227634.1	RP11-431K24.3	-5.05	7.35e-07	0.000277	-0.32	-0.26	Psoriasis;	chr1:8208853	chr1:8208672~8215210:+
LIHC	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	5.05	7.35e-07	0.000277	0.28	0.26	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
LIHC	cis	rs4650994	0.544	rs6675811	ENSG00000273384.1	RP5-1098D14.1	5.05	7.36e-07	0.000278	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178529933	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.544	rs4132058	ENSG00000273384.1	RP5-1098D14.1	5.05	7.36e-07	0.000278	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178536422	chr1:178651706~178652282:+
LIHC	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-5.05	7.36e-07	0.000278	-0.29	-0.26	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
LIHC	cis	rs2032447	0.714	rs175319	ENSG00000242387.1	HIST1H2APS2	5.05	7.37e-07	0.000278	0.34	0.26	Intelligence (multi-trait analysis);	chr6:25955944	chr6:25882026~25882395:-
LIHC	cis	rs2998286	0.862	rs946594	ENSG00000254635.4	WAC-AS1	-5.04	7.38e-07	0.000278	-0.32	-0.26	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503318	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.862	rs1416817	ENSG00000254635.4	WAC-AS1	-5.04	7.38e-07	0.000278	-0.32	-0.26	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503548	chr10:28522652~28532743:-
LIHC	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-5.04	7.38e-07	0.000278	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
LIHC	cis	rs30380	0.632	rs27045	ENSG00000272109.1	CTD-2260A17.3	-5.04	7.39e-07	0.000279	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96803158	chr5:96804353~96806105:+
LIHC	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-5.04	7.4e-07	0.000279	-0.33	-0.26	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
LIHC	cis	rs529413	0.527	rs1508030	ENSG00000259237.1	RP11-209E8.1	5.04	7.4e-07	0.000279	0.35	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr15:53157752	chr15:53116365~53129698:+
LIHC	cis	rs599083	0.53	rs640569	ENSG00000212093.1	AP000807.1	-5.04	7.41e-07	0.000279	-0.29	-0.26	Bone mineral density (spine);	chr11:68417352	chr11:68506083~68506166:-
LIHC	cis	rs599083	0.53	rs2472415	ENSG00000212093.1	AP000807.1	-5.04	7.41e-07	0.000279	-0.29	-0.26	Bone mineral density (spine);	chr11:68418148	chr11:68506083~68506166:-
LIHC	cis	rs11079159	0.837	rs4794559	ENSG00000263096.1	RP11-515O17.2	5.04	7.41e-07	0.000279	0.36	0.26	QRS duration;	chr17:55286939	chr17:55271504~55273653:-
LIHC	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-5.04	7.41e-07	0.000279	-0.27	-0.26	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
LIHC	cis	rs1065852	0.503	rs9620006	ENSG00000237037.8	NDUFA6-AS1	-5.04	7.42e-07	0.00028	-0.36	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42003543	chr22:42090931~42137742:+
LIHC	cis	rs10256972	0.521	rs7811577	ENSG00000199023.2	MIR339	-5.04	7.44e-07	0.00028	-0.31	-0.26	Endometriosis;Longevity;	chr7:1063193	chr7:1022935~1023045:-
LIHC	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-5.04	7.45e-07	0.00028	-0.27	-0.26	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
LIHC	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	5.04	7.45e-07	0.00028	0.38	0.26	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	5.04	7.45e-07	0.00028	0.38	0.26	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
LIHC	cis	rs4660214	0.666	rs625384	ENSG00000182109.6	RP11-69E11.4	5.04	7.45e-07	0.000281	0.28	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39522280~39546187:-
LIHC	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-5.04	7.45e-07	0.000281	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
LIHC	cis	rs2299587	0.519	rs3850746	ENSG00000253671.1	RP11-806O11.1	5.04	7.46e-07	0.000281	0.31	0.26	Economic and political preferences;	chr8:17930027	chr8:17808941~17820868:+
LIHC	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	5.04	7.46e-07	0.000281	0.28	0.26	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
LIHC	cis	rs638893	0.947	rs1170396	ENSG00000255422.1	AP002954.4	-5.04	7.46e-07	0.000281	-0.44	-0.26	Vitiligo;	chr11:118833108	chr11:118704607~118750263:+
LIHC	cis	rs4731207	0.698	rs886704	ENSG00000224897.5	POT1-AS1	5.04	7.47e-07	0.000281	0.31	0.26	Cutaneous malignant melanoma;	chr7:124782212	chr7:124929873~125179315:+
LIHC	cis	rs9425766	0.679	rs57919173	ENSG00000227373.4	RP11-160H22.5	5.04	7.49e-07	0.000282	0.32	0.26	Life satisfaction;	chr1:174159856	chr1:174115300~174160004:-
LIHC	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-5.04	7.5e-07	0.000282	-0.28	-0.26	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
LIHC	cis	rs10833905	1	rs2114466	ENSG00000246225.5	RP11-17A1.3	-5.04	7.51e-07	0.000283	-0.32	-0.26	Sudden cardiac arrest;	chr11:23014841	chr11:22829380~22945393:+
LIHC	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-5.04	7.51e-07	0.000283	-0.29	-0.26	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
LIHC	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	5.04	7.51e-07	0.000283	0.31	0.26	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
LIHC	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-5.04	7.52e-07	0.000283	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
LIHC	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-5.04	7.52e-07	0.000283	-0.28	-0.26	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-5.04	7.52e-07	0.000283	-0.29	-0.26	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-5.04	7.52e-07	0.000283	-0.29	-0.26	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-5.04	7.52e-07	0.000283	-0.29	-0.26	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-5.04	7.52e-07	0.000283	-0.29	-0.26	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
LIHC	cis	rs7131987	0.509	rs11050173	ENSG00000257176.2	RP11-996F15.2	-5.04	7.53e-07	0.000283	-0.32	-0.26	QT interval;	chr12:29288540	chr12:29280418~29317848:-
LIHC	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	5.04	7.54e-07	0.000284	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
LIHC	cis	rs1322639	0.618	rs9505942	ENSG00000261039.2	RP11-417E7.2	-5.04	7.55e-07	0.000284	-0.36	-0.26	Pulse pressure;	chr6:169191698	chr6:169175304~169182740:-
LIHC	cis	rs1005277	0.579	rs1740735	ENSG00000276805.1	RP11-291L22.6	5.04	7.55e-07	0.000284	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38451030~38451785:+
LIHC	cis	rs116175783	0.557	rs3769963	ENSG00000227403.1	AC009299.3	5.04	7.55e-07	0.000284	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161350999	chr2:161244739~161249050:+
LIHC	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	5.04	7.55e-07	0.000284	0.35	0.26	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
LIHC	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	5.04	7.57e-07	0.000285	0.42	0.26	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
LIHC	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-5.04	7.57e-07	0.000285	-0.27	-0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
LIHC	cis	rs2836974	0.965	rs2836965	ENSG00000255568.3	BRWD1-AS2	-5.04	7.57e-07	0.000285	-0.3	-0.26	Cognitive function;	chr21:39261705	chr21:39313935~39314962:+
LIHC	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	5.04	7.58e-07	0.000285	0.36	0.26	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
LIHC	cis	rs9549367	0.577	rs3024713	ENSG00000269125.1	RP11-98F14.11	-5.04	7.59e-07	0.000285	-0.35	-0.26	Platelet distribution width;	chr13:113159007	chr13:113165002~113165183:-
LIHC	cis	rs228614	0.51	rs50034	ENSG00000230069.3	LRRC37A15P	-5.04	7.6e-07	0.000286	-0.24	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs223380	ENSG00000230069.3	LRRC37A15P	-5.04	7.6e-07	0.000286	-0.24	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs223379	ENSG00000230069.3	LRRC37A15P	-5.04	7.6e-07	0.000286	-0.24	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102727274~102730721:-
LIHC	cis	rs30380	0.632	rs27640	ENSG00000272109.1	CTD-2260A17.3	-5.04	7.6e-07	0.000286	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96792202	chr5:96804353~96806105:+
LIHC	cis	rs30380	0.666	rs26512	ENSG00000272109.1	CTD-2260A17.3	-5.04	7.6e-07	0.000286	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96792697	chr5:96804353~96806105:+
LIHC	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	5.04	7.6e-07	0.000286	0.41	0.26	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
LIHC	cis	rs30380	0.632	rs26489	ENSG00000272109.1	CTD-2260A17.3	-5.04	7.6e-07	0.000286	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96797724	chr5:96804353~96806105:+
LIHC	cis	rs30380	0.632	rs26500	ENSG00000272109.1	CTD-2260A17.3	-5.04	7.6e-07	0.000286	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96798009	chr5:96804353~96806105:+
LIHC	cis	rs2877649	0.51	rs17103743	ENSG00000258744.1	RP11-80A15.1	-5.04	7.6e-07	0.000286	-0.47	-0.26	Smooth-surface caries;	chr14:24438346	chr14:24501594~24508688:+
LIHC	cis	rs7119038	0.865	rs11217044	ENSG00000255239.1	AP002954.6	-5.04	7.61e-07	0.000286	-0.33	-0.26	Sjögren's syndrome;	chr11:118825313	chr11:118688039~118690600:-
LIHC	cis	rs6085948	0.861	rs6085947	ENSG00000228888.1	LINC01428	5.04	7.61e-07	0.000286	0.45	0.26	Interleukin-10 levels;	chr20:7252181	chr20:7146467~7254202:-
LIHC	cis	rs4660214	0.666	rs2490946	ENSG00000182109.6	RP11-69E11.4	5.04	7.61e-07	0.000286	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39522280~39546187:-
LIHC	cis	rs8028182	0.609	rs10220738	ENSG00000260269.4	CTD-2323K18.1	5.04	7.62e-07	0.000286	0.35	0.26	Sudden cardiac arrest;	chr15:75374205	chr15:75527150~75601205:-
LIHC	cis	rs228614	0.509	rs223476	ENSG00000230069.3	LRRC37A15P	-5.04	7.63e-07	0.000287	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.509	rs150896	ENSG00000230069.3	LRRC37A15P	-5.04	7.63e-07	0.000287	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102727274~102730721:-
LIHC	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	5.04	7.63e-07	0.000287	0.32	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
LIHC	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	5.04	7.64e-07	0.000287	0.36	0.26	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
LIHC	cis	rs5756813	0.688	rs56114444	ENSG00000233360.4	Z83844.1	5.04	7.64e-07	0.000287	0.35	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37727357	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.754	rs3788529	ENSG00000233360.4	Z83844.1	5.04	7.64e-07	0.000287	0.34	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37762702	chr22:37641832~37658377:-
LIHC	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-5.04	7.65e-07	0.000287	-0.41	-0.26	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
LIHC	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-5.04	7.65e-07	0.000287	-0.33	-0.26	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
LIHC	cis	rs6480314	0.706	rs2394465	ENSG00000233590.1	RP11-153K11.3	5.04	7.67e-07	0.000288	0.31	0.26	Optic nerve measurement (disc area);	chr10:68224349	chr10:68233251~68242379:-
LIHC	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	5.04	7.67e-07	0.000288	0.29	0.26	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
LIHC	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-5.04	7.68e-07	0.000288	-0.33	-0.26	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
LIHC	cis	rs6984305	0.541	rs17716118	ENSG00000279949.1	RP11-10A14.9	5.04	7.68e-07	0.000288	0.51	0.26	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:9158063~9158621:+
LIHC	cis	rs9425766	0.679	rs12079062	ENSG00000227373.4	RP11-160H22.5	5.04	7.7e-07	0.000289	0.32	0.26	Life satisfaction;	chr1:174110446	chr1:174115300~174160004:-
LIHC	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	5.04	7.71e-07	0.000289	0.33	0.26	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
LIHC	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-5.04	7.72e-07	0.000289	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
LIHC	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-5.04	7.73e-07	0.00029	-0.27	-0.26	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-5.04	7.73e-07	0.00029	-0.27	-0.26	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
LIHC	cis	rs7412746	0.658	rs11204750	ENSG00000231073.1	RP11-316M1.3	5.04	7.73e-07	0.00029	0.26	0.26	Melanoma;	chr1:150967268	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs6656535	ENSG00000231073.1	RP11-316M1.3	5.04	7.73e-07	0.00029	0.26	0.26	Melanoma;	chr1:150967881	chr1:150973123~150975534:+
LIHC	cis	rs228614	0.51	rs223378	ENSG00000230069.3	LRRC37A15P	-5.04	7.74e-07	0.00029	-0.24	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102727274~102730721:-
LIHC	cis	rs901683	0.702	rs17159090	ENSG00000230869.1	CTGLF10P	5.04	7.75e-07	0.00029	0.66	0.26	Mean corpuscular volume;Red blood cell traits;	chr10:45712353	chr10:45678692~45700532:+
LIHC	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	5.03	7.75e-07	0.000291	0.34	0.26	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	5.03	7.75e-07	0.000291	0.34	0.26	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
LIHC	cis	rs6479901	0.639	rs871690	ENSG00000232075.1	MRPL35P2	-5.03	7.75e-07	0.000291	-0.3	-0.26	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63634317~63634827:-
LIHC	cis	rs4934494	0.768	rs72818784	ENSG00000232936.4	RP11-80H5.2	5.03	7.75e-07	0.000291	0.35	0.26	Red blood cell count;	chr10:89789657	chr10:89645282~89650667:+
LIHC	cis	rs950169	0.519	rs7237	ENSG00000259295.5	CSPG4P12	5.03	7.76e-07	0.000291	0.36	0.26	Schizophrenia;	chr15:84643346	chr15:85191438~85213905:+
LIHC	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	5.03	7.77e-07	0.000291	0.18	0.26	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
LIHC	cis	rs10510102	0.688	rs11812208	ENSG00000226864.1	ATE1-AS1	5.03	7.77e-07	0.000291	0.44	0.26	Breast cancer;	chr10:121924831	chr10:121928312~121951965:+
LIHC	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	7.77e-07	0.000291	-0.24	-0.26	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
LIHC	cis	rs7897654	0.571	rs12765002	ENSG00000236937.2	PTGES3P4	5.03	7.78e-07	0.000292	0.34	0.26	Schizophrenia;	chr10:102875591	chr10:102845595~102845950:+
LIHC	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-5.03	7.79e-07	0.000292	-0.41	-0.26	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
LIHC	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	5.03	7.79e-07	0.000292	0.41	0.26	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
LIHC	cis	rs1023500	0.505	rs134891	ENSG00000227370.1	RP4-669P10.19	-5.03	7.8e-07	0.000292	-0.27	-0.26	Schizophrenia;	chr22:42279876	chr22:42132543~42132998:+
LIHC	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-5.03	7.8e-07	0.000292	-0.33	-0.26	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
LIHC	cis	rs9890032	1	rs28539246	ENSG00000263531.1	RP13-753N3.1	5.03	7.8e-07	0.000292	0.32	0.26	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30863921~30864940:-
LIHC	cis	rs9890032	0.967	rs9897628	ENSG00000263531.1	RP13-753N3.1	5.03	7.8e-07	0.000292	0.32	0.26	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30863921~30864940:-
LIHC	cis	rs7209700	0.708	rs15908	ENSG00000228782.6	CTD-2026D20.3	-5.03	7.8e-07	0.000292	-0.29	-0.26	IgG glycosylation;	chr17:47290971	chr17:47450568~47492492:-
LIHC	cis	rs10256972	0.616	rs6957733	ENSG00000199023.2	MIR339	-5.03	7.8e-07	0.000292	-0.31	-0.26	Endometriosis;Longevity;	chr7:1066691	chr7:1022935~1023045:-
LIHC	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	5.03	7.81e-07	0.000293	0.4	0.26	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
LIHC	cis	rs5769765	0.908	rs9616211	ENSG00000278869.1	CITF22-49E9.3	5.03	7.81e-07	0.000293	0.41	0.26	Schizophrenia;	chr22:49924028	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.817	rs9616212	ENSG00000278869.1	CITF22-49E9.3	5.03	7.81e-07	0.000293	0.41	0.26	Schizophrenia;	chr22:49924039	chr22:49933198~49934074:-
LIHC	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	5.03	7.82e-07	0.000293	0.34	0.26	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	5.03	7.82e-07	0.000293	0.34	0.26	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	5.03	7.82e-07	0.000293	0.34	0.26	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	5.03	7.82e-07	0.000293	0.34	0.26	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	5.03	7.82e-07	0.000293	0.34	0.26	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
LIHC	cis	rs6546886	0.536	rs828868	ENSG00000217702.2	RP11-287D1.4	5.03	7.82e-07	0.000293	0.31	0.26	Dialysis-related mortality;	chr2:74097377	chr2:74130583~74135395:+
LIHC	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-5.03	7.83e-07	0.000293	-0.29	-0.26	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
LIHC	cis	rs7119038	0.818	rs2077579	ENSG00000255239.1	AP002954.6	-5.03	7.84e-07	0.000293	-0.38	-0.26	Sjögren's syndrome;	chr11:118748338	chr11:118688039~118690600:-
LIHC	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	5.03	7.86e-07	0.000294	0.4	0.26	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
LIHC	cis	rs73193808	0.614	rs2245023	ENSG00000224649.1	AF124730.4	5.03	7.86e-07	0.000294	0.31	0.26	Coronary artery disease;	chr21:29174539	chr21:29182027~29187795:-
LIHC	cis	rs4356203	0.87	rs7935219	ENSG00000272034.1	SNORD14A	5.03	7.87e-07	0.000294	0.28	0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17146640	chr11:17074654~17074744:-
LIHC	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	5.03	7.87e-07	0.000295	0.34	0.26	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
LIHC	cis	rs1577917	0.958	rs12213331	ENSG00000234155.1	RP11-30P6.6	5.03	7.87e-07	0.000295	0.34	0.26	Response to antipsychotic treatment;	chr6:85795079	chr6:85387219~85390186:-
LIHC	cis	rs916888	0.773	rs199534	ENSG00000274883.1	Metazoa_SRP	-5.03	7.88e-07	0.000295	-0.41	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45931806~45932083:+
LIHC	cis	rs9425766	0.679	rs12085290	ENSG00000227373.4	RP11-160H22.5	-5.03	7.88e-07	0.000295	-0.3	-0.26	Life satisfaction;	chr1:174124699	chr1:174115300~174160004:-
LIHC	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	5.03	7.89e-07	0.000295	0.36	0.26	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
LIHC	cis	rs5769765	0.874	rs11703411	ENSG00000278869.1	CITF22-49E9.3	-5.03	7.89e-07	0.000295	-0.39	-0.26	Schizophrenia;	chr22:49865103	chr22:49933198~49934074:-
LIHC	cis	rs4731207	0.596	rs2402763	ENSG00000224897.5	POT1-AS1	5.03	7.89e-07	0.000295	0.33	0.26	Cutaneous malignant melanoma;	chr7:125069678	chr7:124929873~125179315:+
LIHC	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	5.03	7.89e-07	0.000295	0.39	0.26	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	5.03	7.89e-07	0.000295	0.39	0.26	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	5.03	7.89e-07	0.000295	0.39	0.26	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	5.03	7.89e-07	0.000295	0.39	0.26	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	5.03	7.89e-07	0.000295	0.39	0.26	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
LIHC	cis	rs2836974	0.568	rs4816620	ENSG00000255568.3	BRWD1-AS2	-5.03	7.89e-07	0.000295	-0.22	-0.26	Cognitive function;	chr21:39241860	chr21:39313935~39314962:+
LIHC	cis	rs9291683	0.552	rs17187075	ENSG00000250413.1	RP11-448G15.1	-5.03	7.9e-07	0.000295	-0.33	-0.26	Bone mineral density;	chr4:9988704	chr4:10006482~10009725:+
LIHC	cis	rs17301013	0.932	rs11804941	ENSG00000227373.4	RP11-160H22.5	-5.03	7.9e-07	0.000295	-0.32	-0.26	Systemic lupus erythematosus;	chr1:174624074	chr1:174115300~174160004:-
LIHC	cis	rs202072	0.872	rs202044	ENSG00000215022.6	RP1-257A7.4	-5.03	7.91e-07	0.000296	-0.31	-0.26	HIV-1 viral setpoint;	chr6:13275718	chr6:13264861~13295586:-
LIHC	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	5.03	7.92e-07	0.000296	0.31	0.26	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
LIHC	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	5.03	7.93e-07	0.000296	0.35	0.26	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
LIHC	cis	rs9992667	0.955	rs28560778	ENSG00000231160.8	KLF3-AS1	5.03	7.93e-07	0.000297	0.36	0.26	Eosinophil percentage of granulocytes;	chr4:38609668	chr4:38612701~38664883:-
LIHC	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	5.03	7.94e-07	0.000297	0.2	0.26	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
LIHC	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	5.03	7.95e-07	0.000297	0.43	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
LIHC	cis	rs6977955	1	rs10951192	ENSG00000234336.5	JAZF1-AS1	5.03	7.95e-07	0.000297	0.38	0.26	Allergic disease (asthma, hay fever or eczema);	chr7:28121414	chr7:28180322~28243917:+
LIHC	cis	rs36715	0.868	rs251387	ENSG00000245937.6	LINC01184	5.03	7.96e-07	0.000297	0.32	0.26	Breast cancer;	chr5:128211488	chr5:127940426~128083172:-
LIHC	cis	rs5758511	0.634	rs1001587	ENSG00000237037.8	NDUFA6-AS1	-5.03	7.97e-07	0.000298	-0.33	-0.26	Birth weight;	chr22:42274105	chr22:42090931~42137742:+
LIHC	cis	rs1005277	0.579	rs1780139	ENSG00000276805.1	RP11-291L22.6	5.03	7.98e-07	0.000298	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38451030~38451785:+
LIHC	cis	rs4731207	0.596	rs2402762	ENSG00000224897.5	POT1-AS1	5.03	7.99e-07	0.000298	0.32	0.26	Cutaneous malignant melanoma;	chr7:124959792	chr7:124929873~125179315:+
LIHC	cis	rs9425766	0.679	rs10912761	ENSG00000227373.4	RP11-160H22.5	5.03	8e-07	0.000299	0.32	0.26	Life satisfaction;	chr1:174312466	chr1:174115300~174160004:-
LIHC	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	5.03	8.01e-07	0.000299	0.4	0.26	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
LIHC	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-5.03	8.02e-07	0.000299	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
LIHC	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-5.03	8.02e-07	0.000299	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
LIHC	cis	rs17711722	0.523	rs313812	ENSG00000273024.4	INTS4P2	5.03	8.03e-07	3e-04	0.27	0.26	Calcium levels;	chr7:66040056	chr7:65647864~65715661:+
LIHC	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-5.03	8.04e-07	3e-04	-0.33	-0.26	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
LIHC	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	5.03	8.04e-07	3e-04	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
LIHC	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-5.03	8.04e-07	3e-04	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-5.03	8.04e-07	3e-04	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
LIHC	cis	rs17060993	0.618	rs17056484	ENSG00000228451.3	SDAD1P1	-5.03	8.04e-07	3e-04	-0.46	-0.26	Musician's dystonia;	chr8:26990811	chr8:26379259~26382953:-
LIHC	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	5.03	8.05e-07	3e-04	0.44	0.26	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
LIHC	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	5.03	8.05e-07	3e-04	0.44	0.26	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
LIHC	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	5.03	8.06e-07	0.000301	0.54	0.26	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
LIHC	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-5.03	8.07e-07	0.000301	-0.22	-0.26	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
LIHC	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-5.03	8.07e-07	0.000301	-0.22	-0.26	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
LIHC	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-5.03	8.07e-07	0.000301	-0.22	-0.26	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
LIHC	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-5.03	8.07e-07	0.000301	-0.22	-0.26	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
LIHC	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-5.03	8.07e-07	0.000301	-0.22	-0.26	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
LIHC	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-5.03	8.07e-07	0.000301	-0.34	-0.26	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
LIHC	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-5.03	8.07e-07	0.000301	-0.34	-0.26	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
LIHC	cis	rs2297363	0.502	rs4709395	ENSG00000213073.4	RP11-288H12.3	-5.03	8.08e-07	0.000301	-0.28	-0.26	Total cholesterol levels;Blood protein levels;	chr6:160057757	chr6:160093082~160096212:+
LIHC	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-5.03	8.08e-07	0.000301	-0.28	-0.26	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
LIHC	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-5.03	8.09e-07	0.000301	-0.33	-0.26	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
LIHC	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-5.03	8.1e-07	0.000302	-0.27	-0.26	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
LIHC	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	5.03	8.11e-07	0.000302	0.34	0.26	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
LIHC	cis	rs5758511	0.689	rs5758691	ENSG00000237037.8	NDUFA6-AS1	-5.03	8.11e-07	0.000302	-0.33	-0.26	Birth weight;	chr22:42272498	chr22:42090931~42137742:+
LIHC	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	5.03	8.13e-07	0.000303	0.32	0.26	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	5.03	8.13e-07	0.000303	0.32	0.26	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	5.03	8.13e-07	0.000303	0.32	0.26	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	5.03	8.13e-07	0.000303	0.32	0.26	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	5.03	8.13e-07	0.000303	0.32	0.26	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	5.03	8.13e-07	0.000303	0.32	0.26	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
LIHC	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-5.02	8.15e-07	0.000304	-0.33	-0.26	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
LIHC	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	5.02	8.16e-07	0.000304	0.3	0.26	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
LIHC	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	5.02	8.18e-07	0.000305	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
LIHC	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	5.02	8.18e-07	0.000305	0.41	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
LIHC	cis	rs11098499	0.954	rs12508504	ENSG00000260091.1	RP11-33B1.4	-5.02	8.19e-07	0.000305	-0.19	-0.26	Corneal astigmatism;	chr4:119489452	chr4:119409333~119410233:+
LIHC	cis	rs712039	0.652	rs736424	ENSG00000276054.1	RP11-378E13.3	5.02	8.19e-07	0.000305	0.32	0.26	Tuberculosis;	chr17:37429263	chr17:37386886~37387926:+
LIHC	cis	rs12571093	0.803	rs61854839	ENSG00000233590.1	RP11-153K11.3	-5.02	8.2e-07	0.000305	-0.42	-0.26	Optic nerve measurement (disc area);	chr10:68284859	chr10:68233251~68242379:-
LIHC	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-5.02	8.21e-07	0.000306	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-5.02	8.21e-07	0.000306	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-5.02	8.21e-07	0.000306	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-5.02	8.21e-07	0.000306	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
LIHC	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-5.02	8.21e-07	0.000306	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
LIHC	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-5.02	8.21e-07	0.000306	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
LIHC	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	5.02	8.21e-07	0.000306	0.4	0.26	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
LIHC	cis	rs9425766	0.64	rs7512930	ENSG00000227373.4	RP11-160H22.5	5.02	8.21e-07	0.000306	0.32	0.26	Life satisfaction;	chr1:174319464	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs7523460	ENSG00000227373.4	RP11-160H22.5	5.02	8.21e-07	0.000306	0.32	0.26	Life satisfaction;	chr1:174319664	chr1:174115300~174160004:-
LIHC	cis	rs950169	0.541	rs10795	ENSG00000259295.5	CSPG4P12	5.02	8.22e-07	0.000306	0.36	0.26	Schizophrenia;	chr15:84634066	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.58	rs36126054	ENSG00000259295.5	CSPG4P12	5.02	8.22e-07	0.000306	0.36	0.26	Schizophrenia;	chr15:84634492	chr15:85191438~85213905:+
LIHC	cis	rs603446	0.967	rs180375	ENSG00000254851.1	RP11-109L13.1	5.02	8.22e-07	0.000306	0.32	0.26	Triglycerides;	chr11:116720324	chr11:117135528~117138582:+
LIHC	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-5.02	8.22e-07	0.000306	-0.27	-0.26	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
LIHC	cis	rs117618124	0.546	rs16963169	ENSG00000263823.1	RP11-326K13.4	-5.02	8.23e-07	0.000306	-0.62	-0.26	Breast cancer;Breast cancer (estrogen-receptor negative);	chr18:32343256	chr18:31942575~31944156:+
LIHC	cis	rs11690935	0.879	rs13017585	ENSG00000228389.1	AC068039.4	5.02	8.23e-07	0.000306	0.37	0.26	Schizophrenia;	chr2:171865298	chr2:171773482~171775844:+
LIHC	cis	rs5769765	0.624	rs2285187	ENSG00000278869.1	CITF22-49E9.3	5.02	8.24e-07	0.000307	0.4	0.26	Schizophrenia;	chr22:49791784	chr22:49933198~49934074:-
LIHC	cis	rs17301013	0.507	rs72713512	ENSG00000227373.4	RP11-160H22.5	5.02	8.24e-07	0.000307	0.34	0.26	Systemic lupus erythematosus;	chr1:174283505	chr1:174115300~174160004:-
LIHC	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-5.02	8.26e-07	0.000307	-0.28	-0.26	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
LIHC	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-5.02	8.26e-07	0.000307	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-5.02	8.26e-07	0.000307	-0.27	-0.26	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
LIHC	cis	rs7615952	0.546	rs11717632	ENSG00000171084.14	FAM86JP	5.02	8.26e-07	0.000307	0.45	0.26	Blood pressure (smoking interaction);	chr3:125602286	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.546	rs2922197	ENSG00000171084.14	FAM86JP	5.02	8.26e-07	0.000307	0.45	0.26	Blood pressure (smoking interaction);	chr3:125603188	chr3:125916620~125930024:+
LIHC	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-5.02	8.27e-07	0.000308	-0.21	-0.26	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
LIHC	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	5.02	8.28e-07	0.000308	0.44	0.26	Height;	chr6:109455700	chr6:109382795~109383666:+
LIHC	cis	rs57502260	0.68	rs7104806	ENSG00000212093.1	AP000807.1	5.02	8.28e-07	0.000308	0.34	0.26	Total body bone mineral density (age 45-60);	chr11:68454720	chr11:68506083~68506166:-
LIHC	cis	rs7131987	0.903	rs2194518	ENSG00000257176.2	RP11-996F15.2	-5.02	8.28e-07	0.000308	-0.31	-0.26	QT interval;	chr12:29266527	chr12:29280418~29317848:-
LIHC	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-5.02	8.29e-07	0.000308	-0.36	-0.26	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
LIHC	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-5.02	8.29e-07	0.000308	-0.33	-0.26	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
LIHC	cis	rs5769707	0.967	rs8141807	ENSG00000235111.1	RP1-29C18.8	-5.02	8.31e-07	0.000309	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49612657~49615716:-
LIHC	cis	rs1065852	0.526	rs9623489	ENSG00000237037.8	NDUFA6-AS1	-5.02	8.32e-07	0.000309	-0.36	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42001022	chr22:42090931~42137742:+
LIHC	cis	rs1065852	0.526	rs9623490	ENSG00000237037.8	NDUFA6-AS1	-5.02	8.32e-07	0.000309	-0.36	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002262	chr22:42090931~42137742:+
LIHC	cis	rs1065852	0.526	rs59993856	ENSG00000237037.8	NDUFA6-AS1	-5.02	8.32e-07	0.000309	-0.36	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42007976	chr22:42090931~42137742:+
LIHC	cis	rs7209700	0.962	rs56327427	ENSG00000228782.6	CTD-2026D20.3	-5.02	8.32e-07	0.000309	-0.29	-0.26	IgG glycosylation;	chr17:47277380	chr17:47450568~47492492:-
LIHC	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	5.02	8.32e-07	0.000309	0.35	0.26	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	5.02	8.32e-07	0.000309	0.35	0.26	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
LIHC	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-5.02	8.32e-07	0.000309	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
LIHC	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	5.02	8.32e-07	0.000309	0.29	0.26	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
LIHC	cis	rs7665090	0.87	rs228615	ENSG00000230069.3	LRRC37A15P	5.02	8.36e-07	0.00031	0.25	0.26	Primary biliary cholangitis;	chr4:102658303	chr4:102727274~102730721:-
LIHC	cis	rs11216126	1	rs12421652	ENSG00000254851.1	RP11-109L13.1	5.02	8.37e-07	0.000311	0.4	0.26	HDL cholesterol;	chr11:116755159	chr11:117135528~117138582:+
LIHC	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-5.02	8.38e-07	0.000311	-0.22	-0.26	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
LIHC	cis	rs72627509	0.638	rs78933653	ENSG00000269949.1	RP11-738E22.3	5.02	8.38e-07	0.000311	0.36	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56988674	chr4:56960927~56961373:-
LIHC	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	5.02	8.39e-07	0.000312	0.24	0.26	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
LIHC	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	5.02	8.39e-07	0.000312	0.33	0.26	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
LIHC	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	5.02	8.39e-07	0.000312	0.33	0.26	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
LIHC	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-5.02	8.39e-07	0.000312	-0.33	-0.26	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
LIHC	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	5.02	8.4e-07	0.000312	0.35	0.26	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
LIHC	cis	rs4356203	0.87	rs10741724	ENSG00000272034.1	SNORD14A	-5.02	8.4e-07	0.000312	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231604	chr11:17074654~17074744:-
LIHC	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	5.02	8.4e-07	0.000312	0.34	0.26	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
LIHC	cis	rs9890032	0.967	rs7342976	ENSG00000263531.1	RP13-753N3.1	5.02	8.41e-07	0.000312	0.32	0.26	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30863921~30864940:-
LIHC	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-5.02	8.42e-07	0.000312	-0.24	-0.26	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-5.02	8.42e-07	0.000312	-0.24	-0.26	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
LIHC	cis	rs6600671	1	rs10903159	ENSG00000231429.2	RP11-343N15.2	-5.02	8.42e-07	0.000313	-0.3	-0.26	Hip geometry;	chr1:121440138	chr1:121412719~121429274:+
LIHC	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	5.02	8.43e-07	0.000313	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
LIHC	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	5.02	8.44e-07	0.000313	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
LIHC	cis	rs12701220	0.725	rs13242971	ENSG00000229043.2	AC091729.9	-5.02	8.45e-07	0.000313	-0.37	-0.26	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1160374~1165267:+
LIHC	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-5.02	8.45e-07	0.000313	-0.44	-0.26	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
LIHC	cis	rs228614	0.51	rs223453	ENSG00000230069.3	LRRC37A15P	-5.02	8.45e-07	0.000314	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	5.02	8.47e-07	0.000314	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	5.02	8.47e-07	0.000314	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	5.02	8.47e-07	0.000314	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	5.02	8.47e-07	0.000314	0.29	0.26	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
LIHC	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-5.02	8.47e-07	0.000314	-0.37	-0.26	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
LIHC	cis	rs1499614	1	rs1267817	ENSG00000230295.1	RP11-458F8.2	-5.02	8.49e-07	0.000315	-0.28	-0.26	Gout;	chr7:66645053	chr7:66880708~66882981:+
LIHC	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-5.02	8.5e-07	0.000315	-0.31	-0.26	Height;	chr6:109531713	chr6:109382795~109383666:+
LIHC	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	5.02	8.51e-07	0.000315	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	5.02	8.51e-07	0.000315	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
LIHC	cis	rs4356203	0.87	rs10832751	ENSG00000272034.1	SNORD14A	-5.02	8.51e-07	0.000315	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17074654~17074744:-
LIHC	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	5.02	8.51e-07	0.000315	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
LIHC	cis	rs4356203	0.875	rs11024136	ENSG00000272034.1	SNORD14A	-5.02	8.51e-07	0.000315	-0.29	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17042850	chr11:17074654~17074744:-
LIHC	cis	rs3096299	0.728	rs1011749	ENSG00000261118.1	RP11-104N10.1	5.02	8.52e-07	0.000316	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89492017~89504460:-
LIHC	cis	rs228614	0.51	rs223451	ENSG00000230069.3	LRRC37A15P	-5.01	8.55e-07	0.000316	-0.24	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223450	ENSG00000230069.3	LRRC37A15P	-5.01	8.55e-07	0.000316	-0.24	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102727274~102730721:-
LIHC	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	5.01	8.55e-07	0.000317	0.2	0.26	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
LIHC	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	5.01	8.56e-07	0.000317	0.35	0.26	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
LIHC	cis	rs57502260	0.764	rs3867143	ENSG00000212093.1	AP000807.1	5.01	8.56e-07	0.000317	0.34	0.26	Total body bone mineral density (age 45-60);	chr11:68455606	chr11:68506083~68506166:-
LIHC	cis	rs138341189	1	rs138341189	ENSG00000212093.1	AP000807.1	5.01	8.56e-07	0.000317	0.34	0.26	Monobrow;	chr11:68456954	chr11:68506083~68506166:-
LIHC	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-5.01	8.56e-07	0.000317	-0.29	-0.26	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
LIHC	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-5.01	8.57e-07	0.000317	-0.28	-0.26	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
LIHC	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-5.01	8.58e-07	0.000317	-0.29	-0.26	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
LIHC	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	5.01	8.59e-07	0.000318	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	5.01	8.59e-07	0.000318	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
LIHC	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	5.01	8.6e-07	0.000318	0.42	0.26	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
LIHC	cis	rs5769765	0.954	rs5770709	ENSG00000278869.1	CITF22-49E9.3	-5.01	8.6e-07	0.000318	-0.38	-0.26	Schizophrenia;	chr22:49851548	chr22:49933198~49934074:-
LIHC	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-5.01	8.6e-07	0.000318	-0.31	-0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
LIHC	cis	rs9425766	0.679	rs4650990	ENSG00000227373.4	RP11-160H22.5	5.01	8.61e-07	0.000318	0.32	0.26	Life satisfaction;	chr1:174289943	chr1:174115300~174160004:-
LIHC	cis	rs9326248	0.731	rs90192	ENSG00000236267.1	AP006216.5	5.01	8.61e-07	0.000318	0.27	0.26	Blood protein levels;	chr11:117188631	chr11:116813204~116814003:-
LIHC	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-5.01	8.61e-07	0.000319	-0.2	-0.26	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
LIHC	cis	rs9425766	0.679	rs6670617	ENSG00000227373.4	RP11-160H22.5	5.01	8.62e-07	0.000319	0.32	0.26	Life satisfaction;	chr1:174277574	chr1:174115300~174160004:-
LIHC	cis	rs2032366	0.591	rs7241479	ENSG00000267279.1	RP11-879F14.2	-5.01	8.63e-07	0.000319	-0.32	-0.26	Obesity-related traits;	chr18:61631923	chr18:61585746~61606916:-
LIHC	cis	rs2032366	0.654	rs7227661	ENSG00000267279.1	RP11-879F14.2	-5.01	8.63e-07	0.000319	-0.32	-0.26	Obesity-related traits;	chr18:61632275	chr18:61585746~61606916:-
LIHC	cis	rs9425766	0.679	rs9787001	ENSG00000227373.4	RP11-160H22.5	5.01	8.63e-07	0.000319	0.32	0.26	Life satisfaction;	chr1:174222556	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs972361	ENSG00000227373.4	RP11-160H22.5	5.01	8.63e-07	0.000319	0.32	0.26	Life satisfaction;	chr1:174228270	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs6667267	ENSG00000227373.4	RP11-160H22.5	5.01	8.63e-07	0.000319	0.32	0.26	Life satisfaction;	chr1:174243623	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs2064149	ENSG00000227373.4	RP11-160H22.5	5.01	8.63e-07	0.000319	0.32	0.26	Life satisfaction;	chr1:174255856	chr1:174115300~174160004:-
LIHC	cis	rs6479901	0.639	rs10995448	ENSG00000232075.1	MRPL35P2	-5.01	8.65e-07	0.00032	-0.3	-0.26	Intelligence (multi-trait analysis);	chr10:63127299	chr10:63634317~63634827:-
LIHC	cis	rs6479901	0.639	rs7082200	ENSG00000232075.1	MRPL35P2	-5.01	8.65e-07	0.00032	-0.3	-0.26	Intelligence (multi-trait analysis);	chr10:63128561	chr10:63634317~63634827:-
LIHC	cis	rs2836974	0.563	rs997147	ENSG00000255568.3	BRWD1-AS2	-5.01	8.65e-07	0.00032	-0.22	-0.26	Cognitive function;	chr21:39323399	chr21:39313935~39314962:+
LIHC	cis	rs4650994	0.525	rs2493848	ENSG00000273384.1	RP5-1098D14.1	-5.01	8.65e-07	0.00032	-0.33	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178578703	chr1:178651706~178652282:+
LIHC	cis	rs2836974	0.568	rs11910906	ENSG00000255568.3	BRWD1-AS2	-5.01	8.66e-07	0.00032	-0.22	-0.26	Cognitive function;	chr21:39313736	chr21:39313935~39314962:+
LIHC	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	5.01	8.66e-07	0.00032	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
LIHC	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	5.01	8.66e-07	0.00032	0.36	0.26	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
LIHC	cis	rs4356203	0.87	rs2171615	ENSG00000272034.1	SNORD14A	-5.01	8.66e-07	0.00032	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17074654~17074744:-
LIHC	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	5.01	8.66e-07	0.00032	0.29	0.26	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
LIHC	cis	rs1577917	0.629	rs7761762	ENSG00000234155.1	RP11-30P6.6	-5.01	8.66e-07	0.00032	-0.32	-0.26	Response to antipsychotic treatment;	chr6:85496250	chr6:85387219~85390186:-
LIHC	cis	rs2032366	0.591	rs9783921	ENSG00000267279.1	RP11-879F14.2	5.01	8.67e-07	0.00032	0.31	0.26	Obesity-related traits;	chr18:61635219	chr18:61585746~61606916:-
LIHC	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-5.01	8.67e-07	0.00032	-0.27	-0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
LIHC	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	5.01	8.69e-07	0.000321	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
LIHC	cis	rs9595908	1	rs718444	ENSG00000212293.1	SNORA16	5.01	8.7e-07	0.000321	0.31	0.26	Body mass index;	chr13:32572915	chr13:32420390~32420516:-
LIHC	cis	rs9595908	1	rs7332115	ENSG00000212293.1	SNORA16	5.01	8.7e-07	0.000321	0.31	0.26	Body mass index;	chr13:32573411	chr13:32420390~32420516:-
LIHC	cis	rs9595908	1	rs7332763	ENSG00000212293.1	SNORA16	5.01	8.7e-07	0.000321	0.31	0.26	Body mass index;	chr13:32573751	chr13:32420390~32420516:-
LIHC	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-5.01	8.7e-07	0.000321	-0.28	-0.26	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
LIHC	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-5.01	8.71e-07	0.000322	-0.39	-0.26	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
LIHC	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	5.01	8.72e-07	0.000322	0.39	0.26	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	5.01	8.72e-07	0.000322	0.39	0.26	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
LIHC	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-5.01	8.72e-07	0.000322	-0.29	-0.26	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
LIHC	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-5.01	8.72e-07	0.000322	-0.29	-0.26	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
LIHC	cis	rs4660214	0.666	rs1180376	ENSG00000182109.6	RP11-69E11.4	5.01	8.72e-07	0.000322	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39522280~39546187:-
LIHC	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-5.01	8.73e-07	0.000322	-0.38	-0.26	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
LIHC	cis	rs5769765	0.773	rs4075331	ENSG00000278869.1	CITF22-49E9.3	5.01	8.73e-07	0.000322	0.39	0.26	Schizophrenia;	chr22:49909202	chr22:49933198~49934074:-
LIHC	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-5.01	8.73e-07	0.000322	-0.35	-0.26	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
LIHC	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	5.01	8.74e-07	0.000322	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
LIHC	cis	rs9467711	0.591	rs35902160	ENSG00000216436.2	HIST1H2APS1	5.01	8.74e-07	0.000322	0.67	0.26	Autism spectrum disorder or schizophrenia;	chr6:26128310	chr6:25732497~25732827:+
LIHC	cis	rs202072	0.729	rs202038	ENSG00000215022.6	RP1-257A7.4	5.01	8.74e-07	0.000323	0.31	0.26	HIV-1 viral setpoint;	chr6:13288416	chr6:13264861~13295586:-
LIHC	cis	rs5769765	0.773	rs7410291	ENSG00000278869.1	CITF22-49E9.3	5.01	8.75e-07	0.000323	0.39	0.26	Schizophrenia;	chr22:49906430	chr22:49933198~49934074:-
LIHC	cis	rs4731207	0.596	rs1404898	ENSG00000224897.5	POT1-AS1	5.01	8.75e-07	0.000323	0.32	0.26	Cutaneous malignant melanoma;	chr7:125054285	chr7:124929873~125179315:+
LIHC	cis	rs12701220	0.894	rs12539012	ENSG00000229043.2	AC091729.9	-5.01	8.75e-07	0.000323	-0.37	-0.26	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1160374~1165267:+
LIHC	cis	rs916888	0.773	rs199533	ENSG00000274883.1	Metazoa_SRP	-5.01	8.76e-07	0.000323	-0.41	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45931806~45932083:+
LIHC	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	5.01	8.77e-07	0.000323	0.33	0.26	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
LIHC	cis	rs950169	0.922	rs62029585	ENSG00000259295.5	CSPG4P12	5.01	8.77e-07	0.000324	0.36	0.26	Schizophrenia;	chr15:84397176	chr15:85191438~85213905:+
LIHC	cis	rs755249	0.51	rs613511	ENSG00000182109.6	RP11-69E11.4	5.01	8.78e-07	0.000324	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs629093	ENSG00000182109.6	RP11-69E11.4	5.01	8.78e-07	0.000324	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs663449	ENSG00000182109.6	RP11-69E11.4	5.01	8.78e-07	0.000324	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39522280~39546187:-
LIHC	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-5.01	8.78e-07	0.000324	-0.27	-0.26	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-5.01	8.78e-07	0.000324	-0.27	-0.26	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
LIHC	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-5.01	8.78e-07	0.000324	-0.27	-0.26	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-5.01	8.78e-07	0.000324	-0.27	-0.26	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-5.01	8.78e-07	0.000324	-0.27	-0.26	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-5.01	8.78e-07	0.000324	-0.27	-0.26	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-5.01	8.78e-07	0.000324	-0.27	-0.26	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
LIHC	cis	rs931127	0.617	rs10896027	ENSG00000265874.1	MIR4489	5.01	8.79e-07	0.000324	0.35	0.26	Systemic lupus erythematosus;	chr11:65653289	chr11:65649192~65649253:+
LIHC	cis	rs950027	0.787	rs2433616	ENSG00000259433.2	CTD-2651B20.4	-5.01	8.79e-07	0.000324	-0.35	-0.26	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45330209~45332634:-
LIHC	cis	rs5769707	0.967	rs739248	ENSG00000235111.1	RP1-29C18.8	-5.01	8.8e-07	0.000324	-0.3	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-5.01	8.8e-07	0.000324	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
LIHC	cis	rs2032366	0.606	rs9783923	ENSG00000267279.1	RP11-879F14.2	-5.01	8.8e-07	0.000324	-0.32	-0.26	Obesity-related traits;	chr18:61635518	chr18:61585746~61606916:-
LIHC	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-5.01	8.81e-07	0.000325	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
LIHC	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	5.01	8.82e-07	0.000325	0.39	0.26	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
LIHC	cis	rs4660214	0.666	rs2275188	ENSG00000182109.6	RP11-69E11.4	-5.01	8.82e-07	0.000325	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.51	rs599892	ENSG00000182109.6	RP11-69E11.4	5.01	8.83e-07	0.000325	0.28	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39522280~39546187:-
LIHC	cis	rs5758511	0.633	rs5751258	ENSG00000237037.8	NDUFA6-AS1	-5.01	8.83e-07	0.000325	-0.33	-0.26	Birth weight;	chr22:42267865	chr22:42090931~42137742:+
LIHC	cis	rs2836974	0.666	rs11910705	ENSG00000255568.3	BRWD1-AS2	-5.01	8.86e-07	0.000326	-0.22	-0.26	Cognitive function;	chr21:39313678	chr21:39313935~39314962:+
LIHC	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-5.01	8.86e-07	0.000326	-0.28	-0.26	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-5.01	8.86e-07	0.000326	-0.28	-0.26	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
LIHC	cis	rs5769765	0.908	rs9616217	ENSG00000278869.1	CITF22-49E9.3	5.01	8.86e-07	0.000326	0.4	0.26	Schizophrenia;	chr22:49925298	chr22:49933198~49934074:-
LIHC	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-5.01	8.87e-07	0.000327	-0.44	-0.26	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
LIHC	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-5.01	8.88e-07	0.000327	-0.3	-0.26	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
LIHC	cis	rs6480314	0.542	rs4403687	ENSG00000233590.1	RP11-153K11.3	-5.01	8.89e-07	0.000327	-0.39	-0.26	Optic nerve measurement (disc area);	chr10:68268295	chr10:68233251~68242379:-
LIHC	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-5.01	8.89e-07	0.000327	-0.28	-0.26	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
LIHC	cis	rs2439831	0.85	rs558656	ENSG00000205771.5	CATSPER2P1	-5.01	8.9e-07	0.000327	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43431316	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2467739	ENSG00000205771.5	CATSPER2P1	-5.01	8.9e-07	0.000327	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43447998	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2245790	ENSG00000205771.5	CATSPER2P1	-5.01	8.9e-07	0.000327	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43452259	chr15:43726918~43747094:-
LIHC	cis	rs4356203	0.87	rs214922	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215576	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs214921	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215914	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs214918	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17218302	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs214915	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220226	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs214914	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220345	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.84	rs214911	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220691	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs214910	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221242	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs214909	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221731	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs603618	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17224815	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs618331	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17225789	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs7949699	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17226161	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs10832745	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228128	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs11024204	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228258	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs10832746	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228406	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs10832747	ENSG00000272034.1	SNORD14A	-5.01	8.9e-07	0.000327	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228472	chr11:17074654~17074744:-
LIHC	cis	rs8028182	0.549	rs7402293	ENSG00000260269.4	CTD-2323K18.1	5.01	8.91e-07	0.000328	0.35	0.26	Sudden cardiac arrest;	chr15:75343796	chr15:75527150~75601205:-
LIHC	cis	rs10833905	0.756	rs11026869	ENSG00000246225.5	RP11-17A1.3	-5.01	8.92e-07	0.000328	-0.34	-0.26	Sudden cardiac arrest;	chr11:22973361	chr11:22829380~22945393:+
LIHC	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	5.01	8.92e-07	0.000328	0.31	0.26	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
LIHC	cis	rs7674212	0.865	rs13149311	ENSG00000230069.3	LRRC37A15P	-5.01	8.94e-07	0.000329	-0.24	-0.26	Type 2 diabetes;	chr4:103056543	chr4:102727274~102730721:-
LIHC	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-5.01	8.96e-07	0.000329	-0.29	-0.26	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
LIHC	cis	rs116175783	0.557	rs62197081	ENSG00000227403.1	AC009299.3	5.01	8.96e-07	0.000329	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161336814	chr2:161244739~161249050:+
LIHC	cis	rs4718428	0.705	rs11028	ENSG00000230295.1	RP11-458F8.2	-5	8.96e-07	0.00033	-0.22	-0.26	Corneal structure;	chr7:66811230	chr7:66880708~66882981:+
LIHC	cis	rs4356203	0.875	rs667984	ENSG00000272034.1	SNORD14A	-5	8.96e-07	0.00033	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179219	chr11:17074654~17074744:-
LIHC	cis	rs2877649	0.793	rs10133998	ENSG00000258744.1	RP11-80A15.1	-5	8.98e-07	0.00033	-0.52	-0.26	Smooth-surface caries;	chr14:24447550	chr14:24501594~24508688:+
LIHC	cis	rs2439831	1	rs689596	ENSG00000205771.5	CATSPER2P1	-5	8.99e-07	0.00033	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43469519	chr15:43726918~43747094:-
LIHC	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-5	8.99e-07	0.00033	-0.28	-0.26	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
LIHC	cis	rs5769765	0.955	rs9616366	ENSG00000278869.1	CITF22-49E9.3	5	8.99e-07	0.00033	0.39	0.26	Schizophrenia;	chr22:49907530	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.955	rs8135963	ENSG00000278869.1	CITF22-49E9.3	5	8.99e-07	0.00033	0.39	0.26	Schizophrenia;	chr22:49907828	chr22:49933198~49934074:-
LIHC	cis	rs1865760	0.929	rs12195653	ENSG00000216436.2	HIST1H2APS1	-5	8.99e-07	0.00033	-0.29	-0.26	Height;	chr6:25958393	chr6:25732497~25732827:+
LIHC	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	5	8.99e-07	0.000331	0.38	0.26	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
LIHC	cis	rs2836974	0.666	rs35182074	ENSG00000255568.3	BRWD1-AS2	-5	9e-07	0.000331	-0.22	-0.26	Cognitive function;	chr21:39313358	chr21:39313935~39314962:+
LIHC	cis	rs12554020	0.786	rs78619366	ENSG00000227603.1	RP11-165J3.6	5	9e-07	0.000331	0.46	0.26	Schizophrenia;	chr9:93590541	chr9:93435332~93437121:-
LIHC	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-5	9e-07	0.000331	-0.26	-0.26	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
LIHC	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-5	9e-07	0.000331	-0.37	-0.26	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
LIHC	cis	rs17301013	0.932	rs6671824	ENSG00000227373.4	RP11-160H22.5	5	9e-07	0.000331	0.32	0.26	Systemic lupus erythematosus;	chr1:174603721	chr1:174115300~174160004:-
LIHC	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	5	9.01e-07	0.000331	0.4	0.26	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
LIHC	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-5	9.01e-07	0.000331	-0.47	-0.26	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
LIHC	cis	rs30380	0.632	rs27434	ENSG00000272109.1	CTD-2260A17.3	-5	9.02e-07	0.000331	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96793809	chr5:96804353~96806105:+
LIHC	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-5	9.02e-07	0.000331	-0.28	-0.26	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
LIHC	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-5	9.02e-07	0.000331	-0.28	-0.26	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
LIHC	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	5	9.03e-07	0.000332	0.4	0.26	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
LIHC	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	5	9.04e-07	0.000332	0.55	0.26	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
LIHC	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-5	9.04e-07	0.000332	-0.31	-0.26	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
LIHC	cis	rs7688540	0.68	rs77762064	ENSG00000275426.1	CH17-262A2.1	5	9.06e-07	0.000333	0.34	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:281154	chr4:149738~150317:+
LIHC	cis	rs17711722	0.583	rs10085415	ENSG00000164669.11	INTS4P1	5	9.08e-07	0.000334	0.37	0.26	Calcium levels;	chr7:65628655	chr7:65141225~65234216:+
LIHC	cis	rs4718428	0.705	rs13227468	ENSG00000232546.1	RP11-458F8.1	-5	9.08e-07	0.000334	-0.24	-0.26	Corneal structure;	chr7:66968576	chr7:66848496~66858136:+
LIHC	cis	rs10256972	0.521	rs10280960	ENSG00000199023.2	MIR339	-5	9.09e-07	0.000334	-0.3	-0.26	Endometriosis;Longevity;	chr7:1064061	chr7:1022935~1023045:-
LIHC	cis	rs5758511	0.633	rs5758690	ENSG00000237037.8	NDUFA6-AS1	-5	9.09e-07	0.000334	-0.33	-0.26	Birth weight;	chr22:42272289	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.68	rs1001586	ENSG00000237037.8	NDUFA6-AS1	-5	9.09e-07	0.000334	-0.33	-0.26	Birth weight;	chr22:42274287	chr22:42090931~42137742:+
LIHC	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	5	9.09e-07	0.000334	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
LIHC	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-5	9.1e-07	0.000334	-0.28	-0.26	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	5	9.1e-07	0.000334	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	5	9.1e-07	0.000334	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
LIHC	cis	rs3096299	0.754	rs2965816	ENSG00000261118.1	RP11-104N10.1	-5	9.1e-07	0.000334	-0.25	-0.26	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89492017~89504460:-
LIHC	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	5	9.12e-07	0.000335	0.2	0.26	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
LIHC	cis	rs2877649	0.793	rs77673327	ENSG00000258744.1	RP11-80A15.1	-5	9.12e-07	0.000335	-0.52	-0.26	Smooth-surface caries;	chr14:24446065	chr14:24501594~24508688:+
LIHC	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-5	9.13e-07	0.000335	-0.34	-0.26	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
LIHC	cis	rs2836974	0.59	rs9974757	ENSG00000255568.3	BRWD1-AS2	-5	9.14e-07	0.000335	-0.22	-0.26	Cognitive function;	chr21:39245318	chr21:39313935~39314962:+
LIHC	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-5	9.15e-07	0.000336	-0.36	-0.26	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
LIHC	cis	rs1023500	0.505	rs134889	ENSG00000227370.1	RP4-669P10.19	-5	9.15e-07	0.000336	-0.27	-0.26	Schizophrenia;	chr22:42278344	chr22:42132543~42132998:+
LIHC	cis	rs12478296	0.685	rs6705935	ENSG00000261186.2	RP11-341N2.1	-5	9.15e-07	0.000336	-0.35	-0.26	Obesity-related traits;	chr2:242052959	chr2:242087351~242088457:-
LIHC	cis	rs4356203	0.87	rs7937176	ENSG00000272034.1	SNORD14A	-5	9.16e-07	0.000336	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17074654~17074744:-
LIHC	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	5	9.18e-07	0.000337	0.4	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
LIHC	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	5	9.19e-07	0.000337	0.45	0.26	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	5	9.19e-07	0.000337	0.45	0.26	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
LIHC	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	5	9.21e-07	0.000338	0.3	0.26	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
LIHC	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-5	9.22e-07	0.000338	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
LIHC	cis	rs3096299	0.933	rs747485	ENSG00000261118.1	RP11-104N10.1	5	9.22e-07	0.000338	0.27	0.26	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89492017~89504460:-
LIHC	cis	rs712039	0.652	rs853206	ENSG00000276054.1	RP11-378E13.3	5	9.23e-07	0.000338	0.33	0.26	Tuberculosis;	chr17:37464692	chr17:37386886~37387926:+
LIHC	cis	rs73193808	0.614	rs2832251	ENSG00000224649.1	AF124730.4	5	9.24e-07	0.000339	0.31	0.26	Coronary artery disease;	chr21:29187231	chr21:29182027~29187795:-
LIHC	cis	rs73186030	0.623	rs16832958	ENSG00000272758.4	RP11-299J3.8	5	9.25e-07	0.000339	0.31	0.26	Serum parathyroid hormone levels;	chr3:122299646	chr3:122416207~122443180:+
LIHC	cis	rs12478296	1	rs6743297	ENSG00000261186.2	RP11-341N2.1	-5	9.26e-07	0.000339	-0.35	-0.26	Obesity-related traits;	chr2:242071663	chr2:242087351~242088457:-
LIHC	cis	rs12478296	0.892	rs11897561	ENSG00000261186.2	RP11-341N2.1	-5	9.26e-07	0.000339	-0.35	-0.26	Obesity-related traits;	chr2:242072825	chr2:242087351~242088457:-
LIHC	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-5	9.29e-07	0.00034	-0.25	-0.26	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
LIHC	cis	rs7587476	0.601	rs17489231	ENSG00000229267.2	AC072062.1	5	9.29e-07	0.00034	0.33	0.26	Neuroblastoma;	chr2:214809015	chr2:214810229~214963274:+
LIHC	cis	rs5758511	0.633	rs5758689	ENSG00000237037.8	NDUFA6-AS1	-5	9.31e-07	0.000341	-0.33	-0.26	Birth weight;	chr22:42268966	chr22:42090931~42137742:+
LIHC	cis	rs1150668	0.965	rs1654774	ENSG00000204709.4	LINC01556	5	9.31e-07	0.000341	0.3	0.26	Pubertal anthropometrics;	chr6:28128502	chr6:28943877~28944537:+
LIHC	cis	rs1865760	0.964	rs9295677	ENSG00000216436.2	HIST1H2APS1	-5	9.31e-07	0.000341	-0.3	-0.26	Height;	chr6:25933484	chr6:25732497~25732827:+
LIHC	cis	rs12571093	0.504	rs4443961	ENSG00000233590.1	RP11-153K11.3	5	9.31e-07	0.000341	0.4	0.26	Optic nerve measurement (disc area);	chr10:68285725	chr10:68233251~68242379:-
LIHC	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	5	9.31e-07	0.000341	0.29	0.26	Depression;	chr6:28301886	chr6:28943877~28944537:+
LIHC	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	5	9.31e-07	0.000341	0.29	0.26	Depression;	chr6:28303421	chr6:28943877~28944537:+
LIHC	cis	rs3733585	0.781	rs13103879	ENSG00000250413.1	RP11-448G15.1	5	9.31e-07	0.000341	0.33	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9971255	chr4:10006482~10009725:+
LIHC	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	5	9.32e-07	0.000341	0.32	0.26	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
LIHC	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-5	9.33e-07	0.000341	-0.28	-0.26	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
LIHC	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	5	9.33e-07	0.000341	0.52	0.26	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
LIHC	cis	rs4660214	0.614	rs11205802	ENSG00000182109.6	RP11-69E11.4	-5	9.34e-07	0.000342	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233442	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.614	rs10888715	ENSG00000182109.6	RP11-69E11.4	-5	9.34e-07	0.000342	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233572	chr1:39522280~39546187:-
LIHC	cis	rs5756813	0.688	rs34891095	ENSG00000233360.4	Z83844.1	5	9.35e-07	0.000342	0.35	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37730575	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.688	rs2413483	ENSG00000233360.4	Z83844.1	5	9.35e-07	0.000342	0.35	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37731943	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.688	rs8140207	ENSG00000233360.4	Z83844.1	5	9.35e-07	0.000342	0.35	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37734452	chr22:37641832~37658377:-
LIHC	cis	rs7412746	0.658	rs1546376	ENSG00000231073.1	RP11-316M1.3	5	9.35e-07	0.000342	0.26	0.26	Melanoma;	chr1:150965185	chr1:150973123~150975534:+
LIHC	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-5	9.37e-07	0.000343	-0.33	-0.26	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
LIHC	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	5	9.37e-07	0.000343	0.4	0.26	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
LIHC	cis	rs17301013	0.861	rs1793319	ENSG00000227373.4	RP11-160H22.5	5	9.38e-07	0.000343	0.34	0.26	Systemic lupus erythematosus;	chr1:174795470	chr1:174115300~174160004:-
LIHC	cis	rs4731207	0.698	rs7778956	ENSG00000224897.5	POT1-AS1	4.99	9.41e-07	0.000344	0.31	0.26	Cutaneous malignant melanoma;	chr7:124887679	chr7:124929873~125179315:+
LIHC	cis	rs7208859	0.673	rs73263981	ENSG00000266490.1	CTD-2349P21.9	4.99	9.41e-07	0.000344	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30792372~30792833:+
LIHC	cis	rs4934494	0.834	rs1359624	ENSG00000232936.4	RP11-80H5.2	4.99	9.44e-07	0.000345	0.28	0.26	Red blood cell count;	chr10:89635671	chr10:89645282~89650667:+
LIHC	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	4.99	9.44e-07	0.000345	0.28	0.26	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
LIHC	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.99	9.44e-07	0.000345	0.32	0.26	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
LIHC	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-4.99	9.45e-07	0.000346	-0.31	-0.26	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
LIHC	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	4.99	9.47e-07	0.000346	0.39	0.26	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	4.99	9.47e-07	0.000346	0.39	0.26	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
LIHC	cis	rs10833905	0.756	rs12291247	ENSG00000246225.5	RP11-17A1.3	-4.99	9.47e-07	0.000346	-0.34	-0.26	Sudden cardiac arrest;	chr11:22979817	chr11:22829380~22945393:+
LIHC	cis	rs73193808	0.639	rs2832241	ENSG00000224649.1	AF124730.4	4.99	9.47e-07	0.000346	0.31	0.26	Coronary artery disease;	chr21:29179715	chr21:29182027~29187795:-
LIHC	cis	rs227275	0.525	rs7688940	ENSG00000230069.3	LRRC37A15P	-4.99	9.48e-07	0.000346	-0.24	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102727274~102730721:-
LIHC	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-4.99	9.48e-07	0.000346	-0.33	-0.26	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
LIHC	cis	rs2877649	1	rs737247	ENSG00000258744.1	RP11-80A15.1	-4.99	9.48e-07	0.000346	-0.52	-0.26	Smooth-surface caries;	chr14:24457991	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs737245	ENSG00000258744.1	RP11-80A15.1	-4.99	9.48e-07	0.000346	-0.52	-0.26	Smooth-surface caries;	chr14:24458176	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs59448251	ENSG00000258744.1	RP11-80A15.1	-4.99	9.48e-07	0.000346	-0.52	-0.26	Smooth-surface caries;	chr14:24459246	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs57259303	ENSG00000258744.1	RP11-80A15.1	-4.99	9.48e-07	0.000346	-0.52	-0.26	Smooth-surface caries;	chr14:24459328	chr14:24501594~24508688:+
LIHC	cis	rs2929278	0.736	rs2412823	ENSG00000166763.7	STRCP1	-4.99	9.5e-07	0.000347	-0.32	-0.26	Schizophrenia;	chr15:43935072	chr15:43699488~43718184:-
LIHC	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-4.99	9.51e-07	0.000347	-0.31	-0.26	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
LIHC	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	4.99	9.52e-07	0.000348	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
LIHC	cis	rs2834188	1	rs2834190	ENSG00000272659.1	AP000295.10	4.99	9.52e-07	0.000348	0.37	0.26	Narcolepsy;	chr21:33320706	chr21:33309491~33310181:+
LIHC	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	4.99	9.55e-07	0.000348	0.23	0.26	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
LIHC	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	4.99	9.55e-07	0.000349	0.37	0.26	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
LIHC	cis	rs4356203	0.87	rs7342262	ENSG00000272034.1	SNORD14A	-4.99	9.55e-07	0.000349	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17074654~17074744:-
LIHC	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	4.99	9.56e-07	0.000349	0.31	0.26	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
LIHC	cis	rs599083	0.569	rs685095	ENSG00000212093.1	AP000807.1	-4.99	9.57e-07	0.000349	-0.29	-0.26	Bone mineral density (spine);	chr11:68402908	chr11:68506083~68506166:-
LIHC	cis	rs2877649	0.793	rs1956921	ENSG00000258744.1	RP11-80A15.1	4.99	9.57e-07	0.000349	0.55	0.26	Smooth-surface caries;	chr14:24510210	chr14:24501594~24508688:+
LIHC	cis	rs227275	0.525	rs13113923	ENSG00000230069.3	LRRC37A15P	-4.99	9.58e-07	0.000349	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102727274~102730721:-
LIHC	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	4.99	9.58e-07	0.000349	0.47	0.26	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
LIHC	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-4.99	9.58e-07	0.000349	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
LIHC	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	4.99	9.58e-07	0.00035	0.32	0.26	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
LIHC	cis	rs17270561	0.636	rs9348696	ENSG00000216436.2	HIST1H2APS1	-4.99	9.59e-07	0.00035	-0.31	-0.26	Iron status biomarkers;	chr6:25781710	chr6:25732497~25732827:+
LIHC	cis	rs9291683	0.53	rs4235346	ENSG00000250413.1	RP11-448G15.1	4.99	9.59e-07	0.00035	0.34	0.26	Bone mineral density;	chr4:9943672	chr4:10006482~10009725:+
LIHC	cis	rs6723226	0.75	rs762019	ENSG00000276334.1	AL133243.1	4.99	9.6e-07	0.00035	0.28	0.26	Intelligence (multi-trait analysis);	chr2:32463533	chr2:32521927~32523547:+
LIHC	cis	rs12571093	0.541	rs7893837	ENSG00000233590.1	RP11-153K11.3	-4.99	9.61e-07	0.00035	-0.42	-0.26	Optic nerve measurement (disc area);	chr10:68295578	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs11816028	ENSG00000233590.1	RP11-153K11.3	-4.99	9.61e-07	0.00035	-0.42	-0.26	Optic nerve measurement (disc area);	chr10:68296566	chr10:68233251~68242379:-
LIHC	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-4.99	9.62e-07	0.000351	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
LIHC	cis	rs11089937	0.667	rs5757081	ENSG00000211639.2	IGLV4-60	4.99	9.63e-07	0.000351	0.23	0.26	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22162199~22162681:+
LIHC	cis	rs228614	0.536	rs223375	ENSG00000230069.3	LRRC37A15P	-4.99	9.63e-07	0.000351	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102727274~102730721:-
LIHC	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	4.99	9.63e-07	0.000351	0.44	0.26	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
LIHC	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	4.99	9.63e-07	0.000351	0.4	0.26	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	4.99	9.63e-07	0.000351	0.4	0.26	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	4.99	9.63e-07	0.000351	0.4	0.26	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	4.99	9.63e-07	0.000351	0.4	0.26	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	4.99	9.63e-07	0.000351	0.4	0.26	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
LIHC	cis	rs202072	0.729	rs202040	ENSG00000215022.6	RP1-257A7.4	-4.99	9.64e-07	0.000351	-0.31	-0.26	HIV-1 viral setpoint;	chr6:13288303	chr6:13264861~13295586:-
LIHC	cis	rs4650994	0.525	rs4457535	ENSG00000273384.1	RP5-1098D14.1	-4.99	9.65e-07	0.000352	-0.32	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178528051	chr1:178651706~178652282:+
LIHC	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	4.99	9.65e-07	0.000352	0.37	0.26	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
LIHC	cis	rs113835537	1	rs113835537	ENSG00000255517.5	CTD-3074O7.5	-4.99	9.67e-07	0.000352	-0.35	-0.26	Airway imaging phenotypes;	chr11:66572168	chr11:66473490~66480233:-
LIHC	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-4.99	9.68e-07	0.000353	-0.33	-0.26	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
LIHC	cis	rs12554020	0.579	rs79056932	ENSG00000227603.1	RP11-165J3.6	4.99	9.68e-07	0.000353	0.47	0.26	Schizophrenia;	chr9:93585431	chr9:93435332~93437121:-
LIHC	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-4.99	9.68e-07	0.000353	-0.28	-0.26	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-4.99	9.68e-07	0.000353	-0.28	-0.26	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
LIHC	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	4.99	9.68e-07	0.000353	0.37	0.26	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	4.99	9.68e-07	0.000353	0.37	0.26	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	4.99	9.68e-07	0.000353	0.37	0.26	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	4.99	9.68e-07	0.000353	0.37	0.26	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
LIHC	cis	rs36715	1	rs251386	ENSG00000245937.6	LINC01184	4.99	9.69e-07	0.000353	0.32	0.26	Breast cancer;	chr5:128211606	chr5:127940426~128083172:-
LIHC	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	4.99	9.7e-07	0.000353	0.37	0.26	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
LIHC	cis	rs9595066	0.712	rs4391951	ENSG00000230731.2	RP11-478K15.6	-4.99	9.71e-07	0.000354	-0.3	-0.26	Schizophrenia;	chr13:44180935	chr13:44234118~44243192:-
LIHC	cis	rs2749592	0.513	rs1208708	ENSG00000099251.13	HSD17B7P2	4.99	9.72e-07	0.000354	0.3	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38356380~38378505:+
LIHC	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-4.99	9.72e-07	0.000354	-0.29	-0.26	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
LIHC	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-4.99	9.74e-07	0.000355	-0.23	-0.26	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-4.99	9.75e-07	0.000355	-0.33	-0.26	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
LIHC	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	4.99	9.76e-07	0.000355	0.39	0.26	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	4.99	9.76e-07	0.000355	0.39	0.26	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	4.99	9.76e-07	0.000355	0.39	0.26	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
LIHC	cis	rs10510102	0.935	rs12258426	ENSG00000226864.1	ATE1-AS1	4.99	9.77e-07	0.000355	0.43	0.26	Breast cancer;	chr10:121882189	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12266380	ENSG00000226864.1	ATE1-AS1	4.99	9.77e-07	0.000355	0.43	0.26	Breast cancer;	chr10:121882559	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200212	ENSG00000226864.1	ATE1-AS1	4.99	9.77e-07	0.000355	0.43	0.26	Breast cancer;	chr10:121883145	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs11200213	ENSG00000226864.1	ATE1-AS1	4.99	9.77e-07	0.000355	0.43	0.26	Breast cancer;	chr10:121883228	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs12247749	ENSG00000226864.1	ATE1-AS1	4.99	9.77e-07	0.000355	0.43	0.26	Breast cancer;	chr10:121884196	chr10:121928312~121951965:+
LIHC	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	4.99	9.77e-07	0.000355	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
LIHC	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-4.99	9.77e-07	0.000356	-0.31	-0.26	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-4.99	9.77e-07	0.000356	-0.31	-0.26	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
LIHC	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	4.99	9.78e-07	0.000356	0.26	0.26	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
LIHC	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	4.99	9.79e-07	0.000356	0.27	0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
LIHC	cis	rs2836974	0.555	rs35909862	ENSG00000255568.3	BRWD1-AS2	-4.99	9.8e-07	0.000356	-0.22	-0.26	Cognitive function;	chr21:39249232	chr21:39313935~39314962:+
LIHC	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	4.99	9.8e-07	0.000356	0.3	0.26	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
LIHC	cis	rs4731207	0.623	rs1481342	ENSG00000224897.5	POT1-AS1	4.99	9.81e-07	0.000357	0.32	0.26	Cutaneous malignant melanoma;	chr7:125011425	chr7:124929873~125179315:+
LIHC	cis	rs11089937	0.626	rs4821781	ENSG00000211639.2	IGLV4-60	4.99	9.81e-07	0.000357	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.626	rs5750589	ENSG00000211639.2	IGLV4-60	4.99	9.81e-07	0.000357	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.626	rs5757038	ENSG00000211639.2	IGLV4-60	4.99	9.81e-07	0.000357	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22162199~22162681:+
LIHC	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	4.99	9.82e-07	0.000357	0.27	0.26	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
LIHC	cis	rs4934494	0.768	rs12771413	ENSG00000232936.4	RP11-80H5.2	-4.99	9.83e-07	0.000357	-0.31	-0.26	Red blood cell count;	chr10:89633010	chr10:89645282~89650667:+
LIHC	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	4.99	9.83e-07	0.000357	0.4	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
LIHC	cis	rs11079159	0.606	rs1114603	ENSG00000263096.1	RP11-515O17.2	4.99	9.83e-07	0.000357	0.34	0.26	QRS duration;	chr17:55291706	chr17:55271504~55273653:-
LIHC	cis	rs36715	0.953	rs251214	ENSG00000245937.6	LINC01184	4.99	9.84e-07	0.000358	0.32	0.26	Breast cancer;	chr5:128209046	chr5:127940426~128083172:-
LIHC	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	4.99	9.85e-07	0.000358	0.35	0.26	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
LIHC	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-4.99	9.85e-07	0.000358	-0.36	-0.26	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
LIHC	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	4.98	9.87e-07	0.000359	0.4	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	4.98	9.87e-07	0.000359	0.4	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
LIHC	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	4.98	9.89e-07	0.000359	0.37	0.26	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
LIHC	cis	rs4660214	0.666	rs1775656	ENSG00000182109.6	RP11-69E11.4	4.98	9.89e-07	0.000359	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39522280~39546187:-
LIHC	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-4.98	9.89e-07	0.000359	-0.29	-0.26	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
LIHC	cis	rs6600671	1	rs1591882	ENSG00000231429.2	RP11-343N15.2	-4.98	9.9e-07	0.00036	-0.3	-0.26	Hip geometry;	chr1:121441455	chr1:121412719~121429274:+
LIHC	cis	rs2439831	1	rs561863	ENSG00000205771.5	CATSPER2P1	-4.98	9.9e-07	0.00036	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43469154	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.867	rs689616	ENSG00000205771.5	CATSPER2P1	-4.98	9.9e-07	0.00036	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43469703	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs689647	ENSG00000205771.5	CATSPER2P1	-4.98	9.9e-07	0.00036	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43469998	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2251538	ENSG00000205771.5	CATSPER2P1	-4.98	9.9e-07	0.00036	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43475011	chr15:43726918~43747094:-
LIHC	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	4.98	9.93e-07	0.00036	0.44	0.26	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
LIHC	cis	rs950027	0.787	rs1547487	ENSG00000259433.2	CTD-2651B20.4	-4.98	9.94e-07	0.000361	-0.35	-0.26	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45330209~45332634:-
LIHC	cis	rs17270561	0.609	rs1408271	ENSG00000216436.2	HIST1H2APS1	-4.98	9.94e-07	0.000361	-0.31	-0.26	Iron status biomarkers;	chr6:25859393	chr6:25732497~25732827:+
LIHC	cis	rs950169	0.84	rs12905223	ENSG00000259295.5	CSPG4P12	4.98	9.95e-07	0.000361	0.36	0.26	Schizophrenia;	chr15:84571037	chr15:85191438~85213905:+
LIHC	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-4.98	9.95e-07	0.000361	-0.33	-0.26	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
LIHC	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	4.98	9.96e-07	0.000361	0.23	0.26	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
LIHC	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	4.98	9.96e-07	0.000362	0.44	0.26	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
LIHC	cis	rs9467711	0.591	rs16891235	ENSG00000216436.2	HIST1H2APS1	4.98	9.97e-07	0.000362	0.66	0.26	Autism spectrum disorder or schizophrenia;	chr6:26017314	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs3734528	ENSG00000216436.2	HIST1H2APS1	4.98	9.97e-07	0.000362	0.66	0.26	Autism spectrum disorder or schizophrenia;	chr6:26022016	chr6:25732497~25732827:+
LIHC	cis	rs10998036	0.591	rs10823171	ENSG00000233590.1	RP11-153K11.3	4.98	9.97e-07	0.000362	0.38	0.26	Optic cup area;	chr10:68292171	chr10:68233251~68242379:-
LIHC	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	4.98	9.99e-07	0.000362	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	4.98	9.99e-07	0.000362	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	4.98	9.99e-07	0.000362	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
LIHC	cis	rs7688540	0.709	rs4538423	ENSG00000275426.1	CH17-262A2.1	4.98	9.99e-07	0.000363	0.37	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213241	chr4:149738~150317:+
LIHC	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-4.98	9.99e-07	0.000363	-0.28	-0.26	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-4.98	9.99e-07	0.000363	-0.28	-0.26	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-4.98	9.99e-07	0.000363	-0.28	-0.26	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-4.98	9.99e-07	0.000363	-0.28	-0.26	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-4.98	9.99e-07	0.000363	-0.28	-0.26	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
LIHC	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-4.98	1e-06	0.000363	-0.29	-0.26	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
LIHC	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	4.98	1e-06	0.000363	0.29	0.26	Depression;	chr6:28327262	chr6:28943877~28944537:+
LIHC	cis	rs2834188	0.889	rs8134026	ENSG00000272659.1	AP000295.10	-4.98	1e-06	0.000364	-0.39	-0.26	Narcolepsy;	chr21:33298793	chr21:33309491~33310181:+
LIHC	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	4.98	1e-06	0.000364	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	4.98	1e-06	0.000364	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
LIHC	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-4.98	1e-06	0.000364	-0.27	-0.26	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
LIHC	cis	rs227275	0.554	rs223457	ENSG00000230069.3	LRRC37A15P	-4.98	1.01e-06	0.000365	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102727274~102730721:-
LIHC	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	4.98	1.01e-06	0.000365	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	4.98	1.01e-06	0.000365	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
LIHC	cis	rs5769765	0.671	rs138832	ENSG00000278869.1	CITF22-49E9.3	4.98	1.01e-06	0.000365	0.38	0.26	Schizophrenia;	chr22:49784434	chr22:49933198~49934074:-
LIHC	cis	rs12554020	0.582	rs79565493	ENSG00000227603.1	RP11-165J3.6	4.98	1.01e-06	0.000365	0.49	0.26	Schizophrenia;	chr9:93634820	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs74421510	ENSG00000227603.1	RP11-165J3.6	4.98	1.01e-06	0.000365	0.49	0.26	Schizophrenia;	chr9:93634872	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs55783552	ENSG00000227603.1	RP11-165J3.6	4.98	1.01e-06	0.000365	0.49	0.26	Schizophrenia;	chr9:93637205	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs80228675	ENSG00000227603.1	RP11-165J3.6	4.98	1.01e-06	0.000365	0.49	0.26	Schizophrenia;	chr9:93637918	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs79391190	ENSG00000227603.1	RP11-165J3.6	4.98	1.01e-06	0.000365	0.49	0.26	Schizophrenia;	chr9:93637992	chr9:93435332~93437121:-
LIHC	cis	rs875971	0.502	rs2465121	ENSG00000273142.1	RP11-458F8.4	-4.98	1.01e-06	0.000365	-0.25	-0.26	Aortic root size;	chr7:66156017	chr7:66902857~66906297:+
LIHC	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-4.98	1.01e-06	0.000366	-0.37	-0.26	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
LIHC	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	4.98	1.01e-06	0.000366	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
LIHC	cis	rs10448080	0.879	rs240946	ENSG00000246339.5	EXTL3-AS1	4.98	1.01e-06	0.000366	0.25	0.26	Height;	chr8:28711388	chr8:28696198~28701464:-
LIHC	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	4.98	1.01e-06	0.000366	0.34	0.26	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	4.98	1.01e-06	0.000366	0.34	0.26	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	4.98	1.01e-06	0.000366	0.34	0.26	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
LIHC	cis	rs72627509	0.68	rs79641006	ENSG00000269949.1	RP11-738E22.3	4.98	1.01e-06	0.000366	0.35	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56981277	chr4:56960927~56961373:-
LIHC	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	4.98	1.01e-06	0.000366	0.32	0.26	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-4.98	1.01e-06	0.000366	-0.32	-0.26	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
LIHC	cis	rs6480314	0.522	rs10733842	ENSG00000233590.1	RP11-153K11.3	4.98	1.01e-06	0.000366	0.4	0.26	Optic nerve measurement (disc area);	chr10:68299286	chr10:68233251~68242379:-
LIHC	cis	rs17301013	0.932	rs6664864	ENSG00000227373.4	RP11-160H22.5	4.98	1.01e-06	0.000366	0.31	0.26	Systemic lupus erythematosus;	chr1:174622912	chr1:174115300~174160004:-
LIHC	cis	rs5756813	0.754	rs11089854	ENSG00000233360.4	Z83844.1	4.98	1.01e-06	0.000367	0.34	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37752875	chr22:37641832~37658377:-
LIHC	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-4.98	1.01e-06	0.000367	-0.34	-0.26	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
LIHC	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-4.98	1.01e-06	0.000367	-0.41	-0.26	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
LIHC	cis	rs8067287	0.688	rs11654431	ENSG00000205312.7	KRT17P4	4.98	1.01e-06	0.000368	0.4	0.26	Diabetic kidney disease;	chr17:16941549	chr17:16847635~16852777:-
LIHC	cis	rs8067287	0.688	rs58928848	ENSG00000205312.7	KRT17P4	4.98	1.01e-06	0.000368	0.4	0.26	Diabetic kidney disease;	chr17:16941562	chr17:16847635~16852777:-
LIHC	cis	rs4731207	0.698	rs7795492	ENSG00000224897.5	POT1-AS1	4.98	1.01e-06	0.000368	0.31	0.26	Cutaneous malignant melanoma;	chr7:124884077	chr7:124929873~125179315:+
LIHC	cis	rs1420585	1	rs12597905	ENSG00000260614.1	RP11-491F9.1	-4.98	1.02e-06	0.000368	-0.37	-0.26	Pursuit maintenance gain;	chr16:48968092	chr16:49287430~49290227:+
LIHC	cis	rs7085104	0.727	rs12773892	ENSG00000236937.2	PTGES3P4	4.98	1.02e-06	0.000368	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:102845595~102845950:+
LIHC	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-4.98	1.02e-06	0.000368	-0.32	-0.26	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
LIHC	cis	rs9549367	0.577	rs3024711	ENSG00000269125.1	RP11-98F14.11	-4.98	1.02e-06	0.000368	-0.35	-0.26	Platelet distribution width;	chr13:113158954	chr13:113165002~113165183:-
LIHC	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	4.98	1.02e-06	0.000368	0.31	0.26	Height;	chr6:109518783	chr6:109382795~109383666:+
LIHC	cis	rs5769765	0.955	rs7511159	ENSG00000278869.1	CITF22-49E9.3	4.98	1.02e-06	0.000369	0.39	0.26	Schizophrenia;	chr22:49914248	chr22:49933198~49934074:-
LIHC	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	4.98	1.02e-06	0.000369	0.28	0.26	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
LIHC	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	4.98	1.02e-06	0.000369	0.35	0.26	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
LIHC	cis	rs4356203	0.875	rs527810	ENSG00000272034.1	SNORD14A	-4.98	1.02e-06	0.00037	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179519	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.905	rs589319	ENSG00000272034.1	SNORD14A	-4.98	1.02e-06	0.00037	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17181050	chr11:17074654~17074744:-
LIHC	cis	rs4731207	0.596	rs10257712	ENSG00000224897.5	POT1-AS1	4.98	1.02e-06	0.000371	0.32	0.26	Cutaneous malignant melanoma;	chr7:124958025	chr7:124929873~125179315:+
LIHC	cis	rs7412746	0.634	rs4451553	ENSG00000231073.1	RP11-316M1.3	4.98	1.02e-06	0.000371	0.26	0.26	Melanoma;	chr1:150964853	chr1:150973123~150975534:+
LIHC	cis	rs2836974	0.565	rs34304022	ENSG00000255568.3	BRWD1-AS2	4.98	1.02e-06	0.000371	0.38	0.26	Cognitive function;	chr21:39207693	chr21:39313935~39314962:+
LIHC	cis	rs5769765	0.908	rs9616213	ENSG00000278869.1	CITF22-49E9.3	4.98	1.03e-06	0.000371	0.4	0.26	Schizophrenia;	chr22:49924203	chr22:49933198~49934074:-
LIHC	cis	rs3096299	0.563	rs4600467	ENSG00000261118.1	RP11-104N10.1	4.98	1.03e-06	0.000371	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89492017~89504460:-
LIHC	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	4.98	1.03e-06	0.000371	0.29	0.26	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
LIHC	cis	rs7208859	0.524	rs73263982	ENSG00000266490.1	CTD-2349P21.9	4.98	1.03e-06	0.000371	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs216433	ENSG00000266490.1	CTD-2349P21.9	4.98	1.03e-06	0.000371	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30792372~30792833:+
LIHC	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	4.98	1.03e-06	0.000371	0.31	0.26	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	4.98	1.03e-06	0.000371	0.31	0.26	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	4.98	1.03e-06	0.000371	0.31	0.26	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
LIHC	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-4.98	1.03e-06	0.000372	-0.36	-0.26	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
LIHC	cis	rs599083	0.53	rs583545	ENSG00000212093.1	AP000807.1	-4.98	1.03e-06	0.000372	-0.28	-0.26	Bone mineral density (spine);	chr11:68411167	chr11:68506083~68506166:-
LIHC	cis	rs599083	0.53	rs689179	ENSG00000212093.1	AP000807.1	-4.98	1.03e-06	0.000372	-0.28	-0.26	Bone mineral density (spine);	chr11:68411698	chr11:68506083~68506166:-
LIHC	cis	rs12478296	1	rs56162244	ENSG00000261186.2	RP11-341N2.1	-4.98	1.03e-06	0.000372	-0.35	-0.26	Obesity-related traits;	chr2:242076539	chr2:242087351~242088457:-
LIHC	cis	rs17301013	0.932	rs1754355	ENSG00000227373.4	RP11-160H22.5	-4.98	1.03e-06	0.000372	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174807407	chr1:174115300~174160004:-
LIHC	cis	rs11098499	0.954	rs9998585	ENSG00000260091.1	RP11-33B1.4	-4.98	1.03e-06	0.000372	-0.18	-0.26	Corneal astigmatism;	chr4:119475647	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs6842762	ENSG00000260091.1	RP11-33B1.4	-4.98	1.03e-06	0.000372	-0.18	-0.26	Corneal astigmatism;	chr4:119477081	chr4:119409333~119410233:+
LIHC	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-4.98	1.03e-06	0.000372	-0.31	-0.26	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
LIHC	cis	rs712039	0.652	rs829163	ENSG00000276054.1	RP11-378E13.3	4.98	1.03e-06	0.000372	0.33	0.26	Tuberculosis;	chr17:37405936	chr17:37386886~37387926:+
LIHC	cis	rs860295	1	rs822527	ENSG00000203761.5	MSTO2P	4.98	1.03e-06	0.000374	0.21	0.26	Body mass index;	chr1:155768262	chr1:155745829~155750137:+
LIHC	cis	rs1065852	0.526	rs9611711	ENSG00000237037.8	NDUFA6-AS1	-4.98	1.03e-06	0.000374	-0.36	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014691	chr22:42090931~42137742:+
LIHC	cis	rs1062753	0.922	rs9611712	ENSG00000237037.8	NDUFA6-AS1	-4.98	1.03e-06	0.000374	-0.36	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014989	chr22:42090931~42137742:+
LIHC	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-4.97	1.04e-06	0.000374	-0.3	-0.26	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-4.97	1.04e-06	0.000374	-0.3	-0.26	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-4.97	1.04e-06	0.000374	-0.3	-0.26	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-4.97	1.04e-06	0.000374	-0.3	-0.26	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
LIHC	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	4.97	1.04e-06	0.000374	0.29	0.26	Depression;	chr6:28323463	chr6:28943877~28944537:+
LIHC	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-4.97	1.04e-06	0.000374	-0.28	-0.26	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
LIHC	cis	rs7688540	0.771	rs5003261	ENSG00000275426.1	CH17-262A2.1	4.97	1.04e-06	0.000374	0.37	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213234	chr4:149738~150317:+
LIHC	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	4.97	1.04e-06	0.000374	0.31	0.26	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
LIHC	cis	rs4650994	0.544	rs2811314	ENSG00000273384.1	RP5-1098D14.1	-4.97	1.04e-06	0.000374	-0.32	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178650048	chr1:178651706~178652282:+
LIHC	cis	rs4356975	0.563	rs4535394	ENSG00000249956.3	RP11-790I12.2	-4.97	1.04e-06	0.000375	-0.29	-0.26	Obesity-related traits;	chr4:69122735	chr4:69408836~69423164:+
LIHC	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	4.97	1.04e-06	0.000375	0.18	0.26	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
LIHC	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-4.97	1.04e-06	0.000375	-0.34	-0.26	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
LIHC	cis	rs1223397	0.938	rs3817742	ENSG00000215022.6	RP1-257A7.4	-4.97	1.04e-06	0.000375	-0.31	-0.26	Blood pressure;	chr6:13279320	chr6:13264861~13295586:-
LIHC	cis	rs17301013	0.93	rs6425279	ENSG00000227373.4	RP11-160H22.5	-4.97	1.04e-06	0.000375	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174418717	chr1:174115300~174160004:-
LIHC	cis	rs4356203	0.87	rs214919	ENSG00000272034.1	SNORD14A	-4.97	1.04e-06	0.000376	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs214916	ENSG00000272034.1	SNORD14A	-4.97	1.04e-06	0.000376	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17074654~17074744:-
LIHC	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-4.97	1.04e-06	0.000376	-0.24	-0.26	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
LIHC	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-4.97	1.04e-06	0.000376	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
LIHC	cis	rs5756813	0.635	rs4820301	ENSG00000233360.4	Z83844.1	4.97	1.04e-06	0.000376	0.35	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37730357	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.688	rs12484064	ENSG00000233360.4	Z83844.1	4.97	1.04e-06	0.000376	0.35	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37730739	chr22:37641832~37658377:-
LIHC	cis	rs1005277	0.579	rs1780133	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1780136	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1780138	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.602	rs1780141	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.541	rs1740741	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.528	rs2057228	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1740742	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.602	rs1740743	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1740745	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1740747	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1740749	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1780115	ENSG00000276805.1	RP11-291L22.6	4.97	1.04e-06	0.000376	0.32	0.26	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38451030~38451785:+
LIHC	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	4.97	1.04e-06	0.000376	0.35	0.26	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
LIHC	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-4.97	1.04e-06	0.000376	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
LIHC	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	4.97	1.04e-06	0.000377	0.31	0.26	Height;	chr6:109507271	chr6:109382795~109383666:+
LIHC	cis	rs2836974	0.623	rs7280326	ENSG00000255568.3	BRWD1-AS2	-4.97	1.04e-06	0.000377	-0.21	-0.26	Cognitive function;	chr21:39328482	chr21:39313935~39314962:+
LIHC	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-4.97	1.05e-06	0.000377	-0.39	-0.26	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
LIHC	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-4.97	1.05e-06	0.000377	-0.39	-0.26	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
LIHC	cis	rs10510102	0.935	rs7921873	ENSG00000226864.1	ATE1-AS1	4.97	1.05e-06	0.000377	0.43	0.26	Breast cancer;	chr10:121881736	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	4.97	1.05e-06	0.000378	0.39	0.26	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
LIHC	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-4.97	1.05e-06	0.000378	-0.37	-0.26	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
LIHC	cis	rs875971	0.545	rs6460276	ENSG00000273142.1	RP11-458F8.4	4.97	1.05e-06	0.000378	0.25	0.26	Aortic root size;	chr7:66182290	chr7:66902857~66906297:+
LIHC	cis	rs30380	0.587	rs469674	ENSG00000272109.1	CTD-2260A17.3	-4.97	1.05e-06	0.000378	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96794312	chr5:96804353~96806105:+
LIHC	cis	rs916888	0.773	rs199447	ENSG00000274883.1	Metazoa_SRP	-4.97	1.05e-06	0.000378	-0.41	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45931806~45932083:+
LIHC	cis	rs6479891	1	rs4746149	ENSG00000232075.1	MRPL35P2	-4.97	1.05e-06	0.000378	-0.29	-0.26	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63634317~63634827:-
LIHC	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	4.97	1.05e-06	0.000379	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
LIHC	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-4.97	1.05e-06	0.000379	-0.29	-0.26	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.554	rs223466	ENSG00000230069.3	LRRC37A15P	-4.97	1.05e-06	0.000379	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102727274~102730721:-
LIHC	cis	rs12554020	0.579	rs78814851	ENSG00000227603.1	RP11-165J3.6	4.97	1.05e-06	0.000379	0.45	0.26	Schizophrenia;	chr9:93590652	chr9:93435332~93437121:-
LIHC	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	4.97	1.05e-06	0.000379	0.3	0.26	Height;	chr6:109676091	chr6:109382795~109383666:+
LIHC	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	4.97	1.05e-06	0.00038	0.27	0.26	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
LIHC	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-4.97	1.06e-06	0.00038	-0.3	-0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
LIHC	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-4.97	1.06e-06	0.000381	-0.31	-0.26	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
LIHC	cis	rs5758511	0.689	rs56906457	ENSG00000237037.8	NDUFA6-AS1	-4.97	1.06e-06	0.000381	-0.5	-0.26	Birth weight;	chr22:42232329	chr22:42090931~42137742:+
LIHC	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	4.97	1.06e-06	0.000381	0.25	0.26	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
LIHC	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-4.97	1.06e-06	0.000381	-0.33	-0.26	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
LIHC	cis	rs1577917	0.958	rs12192546	ENSG00000234155.1	RP11-30P6.6	-4.97	1.06e-06	0.000381	-0.35	-0.26	Response to antipsychotic treatment;	chr6:85766766	chr6:85387219~85390186:-
LIHC	cis	rs860295	1	rs822478	ENSG00000203761.5	MSTO2P	4.97	1.06e-06	0.000382	0.21	0.26	Body mass index;	chr1:155824178	chr1:155745829~155750137:+
LIHC	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-4.97	1.06e-06	0.000382	-0.32	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
LIHC	cis	rs6600671	1	rs11249350	ENSG00000231429.2	RP11-343N15.2	-4.97	1.06e-06	0.000383	-0.3	-0.26	Hip geometry;	chr1:121436587	chr1:121412719~121429274:+
LIHC	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-4.97	1.06e-06	0.000383	-0.33	-0.26	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
LIHC	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-4.97	1.06e-06	0.000383	-0.38	-0.26	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
LIHC	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-4.97	1.06e-06	0.000383	-0.33	-0.26	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
LIHC	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-4.97	1.07e-06	0.000383	-0.33	-0.26	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
LIHC	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-4.97	1.07e-06	0.000383	-0.27	-0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
LIHC	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-4.97	1.07e-06	0.000383	-0.27	-0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
LIHC	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-4.97	1.07e-06	0.000383	-0.21	-0.26	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
LIHC	cis	rs16858210	0.647	rs12107414	ENSG00000234371.6	RPSAP31	4.97	1.07e-06	0.000383	0.35	0.26	Menopause (age at onset);	chr3:183856760	chr3:183884924~183888449:+
LIHC	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-4.97	1.07e-06	0.000383	-0.31	-0.26	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-4.97	1.07e-06	0.000383	-0.31	-0.26	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
LIHC	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	4.97	1.07e-06	0.000383	0.37	0.26	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
LIHC	cis	rs227275	0.525	rs1383733	ENSG00000230069.3	LRRC37A15P	-4.97	1.07e-06	0.000384	-0.24	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223463	ENSG00000230069.3	LRRC37A15P	-4.97	1.07e-06	0.000384	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs223462	ENSG00000230069.3	LRRC37A15P	-4.97	1.07e-06	0.000384	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102727274~102730721:-
LIHC	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-4.97	1.07e-06	0.000385	-0.37	-0.26	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
LIHC	cis	rs6600671	1	rs2185281	ENSG00000231429.2	RP11-343N15.2	-4.97	1.07e-06	0.000385	-0.3	-0.26	Hip geometry;	chr1:121438132	chr1:121412719~121429274:+
LIHC	cis	rs5769707	0.521	rs739244	ENSG00000235111.1	RP1-29C18.8	-4.97	1.07e-06	0.000385	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49612657~49615716:-
LIHC	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-4.97	1.07e-06	0.000385	-0.44	-0.26	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
LIHC	cis	rs1062753	0.961	rs9620007	ENSG00000237037.8	NDUFA6-AS1	-4.97	1.07e-06	0.000385	-0.35	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42009653	chr22:42090931~42137742:+
LIHC	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	4.97	1.07e-06	0.000385	0.31	0.26	Height;	chr6:109526846	chr6:109382795~109383666:+
LIHC	cis	rs2442825	0.54	rs35728233	ENSG00000206573.7	THUMPD3-AS1	-4.97	1.07e-06	0.000385	-0.31	-0.26	Cerebrospinal fluid clusterin levels;	chr3:9387510	chr3:9349689~9398579:-
LIHC	cis	rs2998286	0.723	rs332146	ENSG00000254635.4	WAC-AS1	-4.97	1.07e-06	0.000385	-0.33	-0.26	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28580255	chr10:28522652~28532743:-
LIHC	cis	rs1023500	0.505	rs134888	ENSG00000227370.1	RP4-669P10.19	-4.97	1.07e-06	0.000386	-0.27	-0.26	Schizophrenia;	chr22:42278275	chr22:42132543~42132998:+
LIHC	cis	rs4356203	0.87	rs7925692	ENSG00000272034.1	SNORD14A	4.97	1.07e-06	0.000386	0.28	0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17074654~17074744:-
LIHC	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	4.97	1.08e-06	0.000387	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
LIHC	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	4.97	1.08e-06	0.000387	0.32	0.26	Depression;	chr6:28399886	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	4.97	1.08e-06	0.000387	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
LIHC	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-4.97	1.08e-06	0.000387	-0.26	-0.26	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
LIHC	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	4.97	1.08e-06	0.000387	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
LIHC	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	4.97	1.08e-06	0.000387	0.38	0.26	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	4.97	1.08e-06	0.000387	0.38	0.26	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
LIHC	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-4.97	1.08e-06	0.000388	-0.46	-0.26	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
LIHC	cis	rs7412746	0.658	rs6677420	ENSG00000231073.1	RP11-316M1.3	4.97	1.08e-06	0.000388	0.26	0.26	Melanoma;	chr1:150974014	chr1:150973123~150975534:+
LIHC	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	4.97	1.08e-06	0.000388	0.39	0.26	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	4.97	1.08e-06	0.000388	0.39	0.26	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
LIHC	cis	rs9425766	0.692	rs4652294	ENSG00000227373.4	RP11-160H22.5	4.97	1.08e-06	0.000388	0.32	0.26	Life satisfaction;	chr1:174272027	chr1:174115300~174160004:-
LIHC	cis	rs1065852	0.526	rs12166549	ENSG00000237037.8	NDUFA6-AS1	-4.97	1.08e-06	0.000388	-0.35	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014415	chr22:42090931~42137742:+
LIHC	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-4.97	1.08e-06	0.000388	-0.31	-0.26	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
LIHC	cis	rs2739330	0.627	rs9608219	ENSG00000206090.4	AP000350.7	4.97	1.08e-06	0.000389	0.3	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23939998~23942798:+
LIHC	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-4.97	1.08e-06	0.000389	-0.29	-0.26	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
LIHC	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-4.97	1.08e-06	0.000389	-0.38	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
LIHC	cis	rs3096299	0.967	rs2965827	ENSG00000261118.1	RP11-104N10.1	-4.97	1.08e-06	0.000389	-0.26	-0.26	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89492017~89504460:-
LIHC	cis	rs7714584	1	rs59321715	ENSG00000197083.10	ZNF300P1	4.97	1.08e-06	0.000389	0.42	0.26	Crohn's disease;	chr5:150933918	chr5:150930645~150946289:-
LIHC	cis	rs1577917	0.917	rs12202170	ENSG00000234155.1	RP11-30P6.6	4.97	1.09e-06	0.00039	0.34	0.26	Response to antipsychotic treatment;	chr6:85880668	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs10455449	ENSG00000234155.1	RP11-30P6.6	4.97	1.09e-06	0.00039	0.34	0.26	Response to antipsychotic treatment;	chr6:85882508	chr6:85387219~85390186:-
LIHC	cis	rs1115240	0.502	rs10138374	ENSG00000257842.4	NOVA1-AS1	-4.97	1.09e-06	0.00039	-0.27	-0.26	Educational attainment (years of education);	chr14:26696367	chr14:26598412~26806467:+
LIHC	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-4.96	1.09e-06	0.00039	-0.23	-0.26	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
LIHC	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-4.96	1.09e-06	0.00039	-0.3	-0.26	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
LIHC	cis	rs6085948	0.861	rs17394617	ENSG00000228888.1	LINC01428	-4.96	1.09e-06	0.000391	-0.49	-0.26	Interleukin-10 levels;	chr20:7249043	chr20:7146467~7254202:-
LIHC	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	4.96	1.09e-06	0.000391	0.18	0.26	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	4.96	1.09e-06	0.000391	0.18	0.26	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
LIHC	cis	rs752590	0.806	rs4849174	ENSG00000274877.1	RP11-65I12.1	-4.96	1.09e-06	0.000391	-0.34	-0.26	Mucinous ovarian carcinoma;	chr2:113215890	chr2:113237595~113240825:+
LIHC	cis	rs2032366	0.606	rs1452597	ENSG00000267279.1	RP11-879F14.2	-4.96	1.09e-06	0.000392	-0.31	-0.26	Obesity-related traits;	chr18:61590985	chr18:61585746~61606916:-
LIHC	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	4.96	1.09e-06	0.000392	0.33	0.26	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
LIHC	cis	rs9532669	0.926	rs9532657	ENSG00000168852.11	TPTE2P5	-4.96	1.09e-06	0.000392	-0.28	-0.26	Cervical cancer;	chr13:40918208	chr13:40822296~40921749:-
LIHC	cis	rs1577917	1	rs12201571	ENSG00000234155.1	RP11-30P6.6	4.96	1.09e-06	0.000392	0.34	0.26	Response to antipsychotic treatment;	chr6:85900032	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs11759855	ENSG00000234155.1	RP11-30P6.6	4.96	1.09e-06	0.000392	0.34	0.26	Response to antipsychotic treatment;	chr6:85901123	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1857964	ENSG00000234155.1	RP11-30P6.6	4.96	1.09e-06	0.000392	0.34	0.26	Response to antipsychotic treatment;	chr6:85926276	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.798	rs7772384	ENSG00000234155.1	RP11-30P6.6	4.96	1.09e-06	0.000392	0.34	0.26	Response to antipsychotic treatment;	chr6:85929962	chr6:85387219~85390186:-
LIHC	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-4.96	1.09e-06	0.000392	-0.34	-0.26	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
LIHC	cis	rs7208859	0.673	rs216435	ENSG00000266490.1	CTD-2349P21.9	4.96	1.09e-06	0.000392	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30792372~30792833:+
LIHC	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-4.96	1.1e-06	0.000392	-0.23	-0.26	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
LIHC	cis	rs6085948	0.817	rs17394645	ENSG00000228888.1	LINC01428	-4.96	1.1e-06	0.000393	-0.49	-0.26	Interleukin-10 levels;	chr20:7250193	chr20:7146467~7254202:-
LIHC	cis	rs3096299	0.935	rs3114890	ENSG00000261118.1	RP11-104N10.1	4.96	1.1e-06	0.000393	0.27	0.26	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89492017~89504460:-
LIHC	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	4.96	1.1e-06	0.000393	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	4.96	1.1e-06	0.000393	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
LIHC	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	4.96	1.1e-06	0.000393	0.4	0.26	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
LIHC	cis	rs9500256	0.967	rs4928431	ENSG00000272541.1	XXbac-BPGBPG55C20.1	4.96	1.1e-06	0.000394	0.28	0.26	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57855891~57856468:-
LIHC	cis	rs901683	0.702	rs4418752	ENSG00000230869.1	CTGLF10P	-4.96	1.1e-06	0.000394	-0.53	-0.26	Mean corpuscular volume;Red blood cell traits;	chr10:45607523	chr10:45678692~45700532:+
LIHC	cis	rs5769765	0.913	rs8135071	ENSG00000278869.1	CITF22-49E9.3	4.96	1.1e-06	0.000394	0.38	0.26	Schizophrenia;	chr22:49905939	chr22:49933198~49934074:-
LIHC	cis	rs5756813	0.727	rs58765732	ENSG00000233360.4	Z83844.1	4.96	1.1e-06	0.000394	0.33	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37764787	chr22:37641832~37658377:-
LIHC	cis	rs2439831	1	rs28666488	ENSG00000205771.5	CATSPER2P1	-4.96	1.1e-06	0.000394	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43448892	chr15:43726918~43747094:-
LIHC	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	4.96	1.1e-06	0.000394	0.34	0.26	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
LIHC	cis	rs10833905	0.756	rs3866928	ENSG00000246225.5	RP11-17A1.3	-4.96	1.1e-06	0.000395	-0.34	-0.26	Sudden cardiac arrest;	chr11:22981094	chr11:22829380~22945393:+
LIHC	cis	rs4650994	0.525	rs10913574	ENSG00000273384.1	RP5-1098D14.1	4.96	1.1e-06	0.000395	0.33	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178567347	chr1:178651706~178652282:+
LIHC	cis	rs860295	1	rs708611	ENSG00000203761.5	MSTO2P	4.96	1.1e-06	0.000395	0.2	0.26	Body mass index;	chr1:155773519	chr1:155745829~155750137:+
LIHC	cis	rs860295	1	rs7541060	ENSG00000203761.5	MSTO2P	-4.96	1.1e-06	0.000395	-0.2	-0.26	Body mass index;	chr1:155758297	chr1:155745829~155750137:+
LIHC	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	4.96	1.1e-06	0.000395	0.33	0.26	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
LIHC	cis	rs10912872	0.531	rs12407579	ENSG00000225704.2	RP4-798A17.5	4.96	1.11e-06	0.000396	0.23	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171371553	chr1:171345089~171345320:+
LIHC	cis	rs3096299	1	rs3096299	ENSG00000261118.1	RP11-104N10.1	4.96	1.11e-06	0.000396	0.27	0.26	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89492017~89504460:-
LIHC	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	4.96	1.11e-06	0.000396	0.34	0.26	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
LIHC	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-4.96	1.11e-06	0.000397	-0.28	-0.26	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
LIHC	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	4.96	1.11e-06	0.000397	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
LIHC	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-4.96	1.11e-06	0.000397	-0.28	-0.26	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
LIHC	cis	rs2929278	0.617	rs4617832	ENSG00000166763.7	STRCP1	-4.96	1.11e-06	0.000397	-0.34	-0.26	Schizophrenia;	chr15:43738381	chr15:43699488~43718184:-
LIHC	cis	rs30380	0.632	rs30186	ENSG00000272109.1	CTD-2260A17.3	-4.96	1.11e-06	0.000398	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96788744	chr5:96804353~96806105:+
LIHC	cis	rs27434	0.821	rs28337	ENSG00000272109.1	CTD-2260A17.3	-4.96	1.11e-06	0.000398	-0.33	-0.26	Ankylosing spondylitis;	chr5:96789611	chr5:96804353~96806105:+
LIHC	cis	rs30380	0.587	rs30185	ENSG00000272109.1	CTD-2260A17.3	-4.96	1.11e-06	0.000398	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96789762	chr5:96804353~96806105:+
LIHC	cis	rs12478296	0.901	rs59477854	ENSG00000261186.2	RP11-341N2.1	-4.96	1.11e-06	0.000398	-0.35	-0.26	Obesity-related traits;	chr2:242073339	chr2:242087351~242088457:-
LIHC	cis	rs2877649	1	rs12323581	ENSG00000258744.1	RP11-80A15.1	-4.96	1.11e-06	0.000398	-0.51	-0.26	Smooth-surface caries;	chr14:24475358	chr14:24501594~24508688:+
LIHC	cis	rs7119038	0.818	rs10892280	ENSG00000255239.1	AP002954.6	-4.96	1.11e-06	0.000398	-0.37	-0.26	Sjögren's syndrome;	chr11:118741108	chr11:118688039~118690600:-
LIHC	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-4.96	1.12e-06	0.000399	-0.33	-0.26	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
LIHC	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	4.96	1.12e-06	0.000399	0.31	0.26	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	4.96	1.12e-06	0.000399	0.31	0.26	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
LIHC	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-4.96	1.12e-06	0.000399	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-4.96	1.12e-06	0.000399	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-4.96	1.12e-06	0.000399	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-4.96	1.12e-06	0.000399	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
LIHC	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	4.96	1.12e-06	4e-04	0.34	0.26	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
LIHC	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-4.96	1.12e-06	4e-04	-0.28	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
LIHC	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	4.96	1.12e-06	4e-04	0.29	0.26	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	4.96	1.12e-06	4e-04	0.29	0.26	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	4.96	1.12e-06	4e-04	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	4.96	1.12e-06	4e-04	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs3974604	ENSG00000230069.3	LRRC37A15P	-4.96	1.12e-06	4e-04	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102727274~102730721:-
LIHC	cis	rs5756813	0.754	rs34848977	ENSG00000233360.4	Z83844.1	4.96	1.12e-06	4e-04	0.34	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37769580	chr22:37641832~37658377:-
LIHC	cis	rs4356203	0.783	rs7113964	ENSG00000272034.1	SNORD14A	-4.96	1.12e-06	4e-04	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234374	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.87	rs11024208	ENSG00000272034.1	SNORD14A	-4.96	1.12e-06	4e-04	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17238432	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.678	rs1125737	ENSG00000272034.1	SNORD14A	-4.96	1.12e-06	4e-04	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17242386	chr11:17074654~17074744:-
LIHC	cis	rs4731207	0.596	rs7795199	ENSG00000224897.5	POT1-AS1	4.96	1.12e-06	0.000401	0.31	0.26	Cutaneous malignant melanoma;	chr7:124938291	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.596	rs7795218	ENSG00000224897.5	POT1-AS1	4.96	1.12e-06	0.000401	0.31	0.26	Cutaneous malignant melanoma;	chr7:124938326	chr7:124929873~125179315:+
LIHC	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-4.96	1.12e-06	0.000401	-0.36	-0.26	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
LIHC	cis	rs8031584	1	rs35239376	ENSG00000270015.1	RP11-540B6.6	-4.96	1.12e-06	0.000401	-0.35	-0.26	Huntington's disease progression;	chr15:30998335	chr15:30926514~30928407:+
LIHC	cis	rs950776	0.714	rs615470	ENSG00000261762.1	RP11-650L12.2	-4.96	1.12e-06	0.000401	-0.32	-0.26	Sudden cardiac arrest;	chr15:78593646	chr15:78589123~78591276:-
LIHC	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	4.96	1.13e-06	0.000401	0.27	0.26	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
LIHC	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-4.96	1.13e-06	0.000402	-0.33	-0.26	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
LIHC	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-4.96	1.13e-06	0.000402	-0.3	-0.26	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
LIHC	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-4.96	1.13e-06	0.000402	-0.39	-0.26	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
LIHC	cis	rs7674212	0.865	rs1481279	ENSG00000230069.3	LRRC37A15P	4.96	1.13e-06	0.000403	0.24	0.26	Type 2 diabetes;	chr4:103056781	chr4:102727274~102730721:-
LIHC	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-4.96	1.13e-06	0.000403	-0.33	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
LIHC	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	4.96	1.13e-06	0.000403	0.34	0.26	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
LIHC	cis	rs10256972	0.521	rs871019	ENSG00000199023.2	MIR339	-4.96	1.13e-06	0.000403	-0.3	-0.26	Endometriosis;Longevity;	chr7:1065594	chr7:1022935~1023045:-
LIHC	cis	rs4698412	0.531	rs6852450	ENSG00000214846.4	RP11-115L11.1	-4.96	1.13e-06	0.000404	-0.32	-0.26	Parkinson's disease;	chr4:15741363	chr4:15730962~15731627:-
LIHC	cis	rs2836974	0.644	rs4818017	ENSG00000255568.3	BRWD1-AS2	-4.96	1.13e-06	0.000404	-0.21	-0.26	Cognitive function;	chr21:39318635	chr21:39313935~39314962:+
LIHC	cis	rs875971	0.545	rs67775320	ENSG00000273142.1	RP11-458F8.4	4.96	1.13e-06	0.000404	0.25	0.26	Aortic root size;	chr7:66193792	chr7:66902857~66906297:+
LIHC	cis	rs712039	0.687	rs11656455	ENSG00000276054.1	RP11-378E13.3	4.96	1.13e-06	0.000404	0.33	0.26	Tuberculosis;	chr17:37411798	chr17:37386886~37387926:+
LIHC	cis	rs1577917	1	rs13194429	ENSG00000234155.1	RP11-30P6.6	4.96	1.14e-06	0.000405	0.34	0.26	Response to antipsychotic treatment;	chr6:85936987	chr6:85387219~85390186:-
LIHC	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	4.96	1.14e-06	0.000405	0.41	0.26	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
LIHC	cis	rs3096299	0.933	rs28608022	ENSG00000261118.1	RP11-104N10.1	4.96	1.14e-06	0.000405	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89492017~89504460:-
LIHC	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-4.96	1.14e-06	0.000405	-0.37	-0.26	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
LIHC	cis	rs2032447	0.714	rs2051540	ENSG00000242387.1	HIST1H2APS2	4.96	1.14e-06	0.000405	0.33	0.26	Intelligence (multi-trait analysis);	chr6:25946969	chr6:25882026~25882395:-
LIHC	cis	rs4356203	0.87	rs12286505	ENSG00000272034.1	SNORD14A	4.96	1.14e-06	0.000405	0.28	0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17142178	chr11:17074654~17074744:-
LIHC	cis	rs755249	0.51	rs582883	ENSG00000182109.6	RP11-69E11.4	4.96	1.14e-06	0.000405	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39522280~39546187:-
LIHC	cis	rs6828577	1	rs6854328	ENSG00000269893.5	SNHG8	4.96	1.14e-06	0.000405	0.28	0.26	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118762337	chr4:118278709~118279823:+
LIHC	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-4.96	1.14e-06	0.000405	-0.27	-0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
LIHC	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-4.96	1.14e-06	0.000405	-0.27	-0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
LIHC	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-4.96	1.14e-06	0.000405	-0.27	-0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
LIHC	cis	rs5769765	0.908	rs9627788	ENSG00000278869.1	CITF22-49E9.3	4.96	1.14e-06	0.000406	0.38	0.26	Schizophrenia;	chr22:49906790	chr22:49933198~49934074:-
LIHC	cis	rs12478296	0.685	rs35577962	ENSG00000261186.2	RP11-341N2.1	-4.95	1.14e-06	0.000406	-0.35	-0.26	Obesity-related traits;	chr2:242051424	chr2:242087351~242088457:-
LIHC	cis	rs11089937	0.626	rs9622968	ENSG00000211639.2	IGLV4-60	4.95	1.14e-06	0.000406	0.23	0.26	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22162199~22162681:+
LIHC	cis	rs916888	0.821	rs70600	ENSG00000274883.1	Metazoa_SRP	-4.95	1.14e-06	0.000407	-0.41	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45931806~45932083:+
LIHC	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	4.95	1.14e-06	0.000407	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
LIHC	cis	rs10829156	0.66	rs7910506	ENSG00000225527.1	RP11-383B4.4	4.95	1.14e-06	0.000407	0.42	0.26	Sudden cardiac arrest;	chr10:18518128	chr10:18531849~18533336:-
LIHC	cis	rs712039	0.652	rs17137970	ENSG00000276054.1	RP11-378E13.3	4.95	1.14e-06	0.000408	0.32	0.26	Tuberculosis;	chr17:37411739	chr17:37386886~37387926:+
LIHC	cis	rs7734985	0.686	rs6865159	ENSG00000250551.1	RP11-254I22.1	-4.95	1.15e-06	0.000408	-0.33	-0.26	IgG glycosylation;	chr5:96112290	chr5:96050115~96215519:+
LIHC	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-4.95	1.15e-06	0.000408	-0.37	-0.26	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
LIHC	cis	rs1714507	0.533	rs2731118	ENSG00000272087.1	RP11-379F4.7	-4.95	1.15e-06	0.000408	-0.29	-0.26	Subjective well-being;	chr3:158589942	chr3:158693120~158693768:-
LIHC	cis	rs1714507	0.533	rs2573179	ENSG00000272087.1	RP11-379F4.7	-4.95	1.15e-06	0.000408	-0.29	-0.26	Subjective well-being;	chr3:158590018	chr3:158693120~158693768:-
LIHC	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	4.95	1.15e-06	0.000408	0.34	0.26	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-4.95	1.15e-06	0.000408	-0.34	-0.26	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
LIHC	cis	rs10995505	0.578	rs1533068	ENSG00000232075.1	MRPL35P2	-4.95	1.15e-06	0.000408	-0.29	-0.26	Intelligence (multi-trait analysis);	chr10:63132407	chr10:63634317~63634827:-
LIHC	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	4.95	1.15e-06	0.000409	0.33	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
LIHC	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	4.95	1.15e-06	0.000409	0.54	0.26	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
LIHC	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-4.95	1.15e-06	0.000409	-0.31	-0.26	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-4.95	1.15e-06	0.000409	-0.31	-0.26	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
LIHC	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-4.95	1.15e-06	0.00041	-0.32	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
LIHC	cis	rs7131987	0.65	rs67146951	ENSG00000275476.1	RP11-996F15.4	-4.95	1.15e-06	0.00041	-0.3	-0.26	QT interval;	chr12:29297620	chr12:29277397~29277882:-
LIHC	cis	rs7131987	0.65	rs10843382	ENSG00000275476.1	RP11-996F15.4	-4.95	1.15e-06	0.00041	-0.3	-0.26	QT interval;	chr12:29298788	chr12:29277397~29277882:-
LIHC	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-4.95	1.15e-06	0.00041	-0.34	-0.26	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
LIHC	cis	rs9425766	0.679	rs6681390	ENSG00000227373.4	RP11-160H22.5	4.95	1.15e-06	0.00041	0.31	0.26	Life satisfaction;	chr1:174261331	chr1:174115300~174160004:-
LIHC	cis	rs11089937	0.597	rs2213156	ENSG00000211639.2	IGLV4-60	4.95	1.15e-06	0.000411	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.626	rs2213157	ENSG00000211639.2	IGLV4-60	4.95	1.15e-06	0.000411	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.626	rs9622955	ENSG00000211639.2	IGLV4-60	4.95	1.15e-06	0.000411	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22162199~22162681:+
LIHC	cis	rs1577917	0.958	rs72907388	ENSG00000234155.1	RP11-30P6.6	4.95	1.16e-06	0.000411	0.34	0.26	Response to antipsychotic treatment;	chr6:85730489	chr6:85387219~85390186:-
LIHC	cis	rs2929278	0.589	rs2411284	ENSG00000166763.7	STRCP1	-4.95	1.16e-06	0.000412	-0.34	-0.26	Schizophrenia;	chr15:43746701	chr15:43699488~43718184:-
LIHC	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	4.95	1.16e-06	0.000412	0.35	0.26	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
LIHC	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-4.95	1.16e-06	0.000412	-0.23	-0.26	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
LIHC	cis	rs1322639	0.614	rs6937001	ENSG00000261039.2	RP11-417E7.2	4.95	1.16e-06	0.000412	0.37	0.26	Pulse pressure;	chr6:169164991	chr6:169175304~169182740:-
LIHC	cis	rs202072	1	rs202053	ENSG00000215022.6	RP1-257A7.4	-4.95	1.16e-06	0.000412	-0.29	-0.26	HIV-1 viral setpoint;	chr6:13273411	chr6:13264861~13295586:-
LIHC	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-4.95	1.16e-06	0.000412	-0.39	-0.26	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
LIHC	cis	rs4660214	0.666	rs12025847	ENSG00000182109.6	RP11-69E11.4	-4.95	1.16e-06	0.000413	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39522280~39546187:-
LIHC	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-4.95	1.16e-06	0.000413	-0.43	-0.26	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
LIHC	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	4.95	1.16e-06	0.000413	0.31	0.26	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	4.95	1.16e-06	0.000413	0.31	0.26	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	4.95	1.16e-06	0.000413	0.31	0.26	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	4.95	1.16e-06	0.000413	0.31	0.26	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
LIHC	cis	rs860295	1	rs860295	ENSG00000203761.5	MSTO2P	4.95	1.16e-06	0.000413	0.2	0.26	Body mass index;	chr1:155797917	chr1:155745829~155750137:+
LIHC	cis	rs7412746	0.658	rs10888397	ENSG00000231073.1	RP11-316M1.3	-4.95	1.16e-06	0.000413	-0.25	-0.26	Melanoma;	chr1:150914276	chr1:150973123~150975534:+
LIHC	cis	rs11089937	0.589	rs4239891	ENSG00000211639.2	IGLV4-60	4.95	1.16e-06	0.000413	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22162199~22162681:+
LIHC	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	4.95	1.16e-06	0.000413	0.4	0.26	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
LIHC	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-4.95	1.16e-06	0.000414	-0.38	-0.26	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
LIHC	cis	rs9341808	0.935	rs1535825	ENSG00000272129.1	RP11-250B2.6	-4.95	1.17e-06	0.000414	-0.26	-0.26	Sitting height ratio;	chr6:80228869	chr6:80355424~80356859:+
LIHC	cis	rs643506	0.739	rs647071	ENSG00000254990.4	RP11-108O10.2	4.95	1.17e-06	0.000414	0.28	0.26	Breast cancer;	chr11:111790731	chr11:111768668~111778350:-
LIHC	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	4.95	1.17e-06	0.000414	0.31	0.26	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
LIHC	cis	rs9291683	0.53	rs13115193	ENSG00000250413.1	RP11-448G15.1	-4.95	1.17e-06	0.000415	-0.34	-0.26	Bone mineral density;	chr4:9980567	chr4:10006482~10009725:+
LIHC	cis	rs11098499	0.908	rs9995234	ENSG00000260091.1	RP11-33B1.4	-4.95	1.17e-06	0.000415	-0.19	-0.26	Corneal astigmatism;	chr4:119400672	chr4:119409333~119410233:+
LIHC	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-4.95	1.17e-06	0.000416	-0.27	-0.26	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-4.95	1.17e-06	0.000416	-0.27	-0.26	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-4.95	1.17e-06	0.000416	-0.27	-0.26	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-4.95	1.17e-06	0.000416	-0.27	-0.26	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-4.95	1.17e-06	0.000416	-0.27	-0.26	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
LIHC	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-4.95	1.17e-06	0.000416	-0.27	-0.26	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	4.95	1.17e-06	0.000416	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
LIHC	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	4.95	1.17e-06	0.000417	0.29	0.26	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
LIHC	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	4.95	1.17e-06	0.000417	0.31	0.26	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	4.95	1.17e-06	0.000417	0.31	0.26	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	4.95	1.17e-06	0.000417	0.31	0.26	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-4.95	1.17e-06	0.000417	-0.31	-0.26	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
LIHC	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	4.95	1.17e-06	0.000417	0.27	0.26	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	4.95	1.17e-06	0.000417	0.27	0.26	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	4.95	1.17e-06	0.000417	0.27	0.26	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
LIHC	cis	rs6802315	0.604	rs4680467	ENSG00000272087.1	RP11-379F4.7	4.95	1.17e-06	0.000417	0.3	0.26	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158693120~158693768:-
LIHC	cis	rs1499614	1	rs1267818	ENSG00000230295.1	RP11-458F8.2	-4.95	1.18e-06	0.000417	-0.27	-0.26	Gout;	chr7:66642037	chr7:66880708~66882981:+
LIHC	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-4.95	1.18e-06	0.000417	-0.18	-0.26	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
LIHC	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-4.95	1.18e-06	0.000418	-0.2	-0.26	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
LIHC	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	4.95	1.18e-06	0.000419	0.28	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	4.95	1.18e-06	0.000419	0.28	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
LIHC	cis	rs1020064	0.895	rs2250659	ENSG00000235319.1	AC012360.4	-4.95	1.18e-06	0.000419	-0.36	-0.26	AIDS;	chr2:105273227	chr2:105324210~105330529:+
LIHC	cis	rs1030877	0.515	rs2576736	ENSG00000235319.1	AC012360.4	-4.95	1.18e-06	0.000419	-0.36	-0.26	Obesity-related traits;	chr2:105274514	chr2:105324210~105330529:+
LIHC	cis	rs6600671	0.934	rs11249431	ENSG00000231429.2	RP11-343N15.2	4.95	1.18e-06	0.000419	0.32	0.26	Hip geometry;	chr1:121544405	chr1:121412719~121429274:+
LIHC	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	4.95	1.18e-06	0.00042	0.31	0.26	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
LIHC	cis	rs643506	0.817	rs623491	ENSG00000254990.4	RP11-108O10.2	4.95	1.19e-06	0.00042	0.27	0.26	Breast cancer;	chr11:111830546	chr11:111768668~111778350:-
LIHC	cis	rs5758511	0.68	rs739147	ENSG00000237037.8	NDUFA6-AS1	-4.95	1.19e-06	0.00042	-0.32	-0.26	Birth weight;	chr22:42275060	chr22:42090931~42137742:+
LIHC	cis	rs5758511	0.68	rs56111723	ENSG00000237037.8	NDUFA6-AS1	-4.95	1.19e-06	0.000421	-0.32	-0.26	Birth weight;	chr22:42268877	chr22:42090931~42137742:+
LIHC	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	4.95	1.19e-06	0.000422	0.49	0.26	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
LIHC	cis	rs5769765	0.773	rs7290751	ENSG00000278869.1	CITF22-49E9.3	4.95	1.19e-06	0.000422	0.4	0.26	Schizophrenia;	chr22:49924664	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.779	rs12170530	ENSG00000278869.1	CITF22-49E9.3	4.95	1.19e-06	0.000422	0.4	0.26	Schizophrenia;	chr22:49924774	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.908	rs9616216	ENSG00000278869.1	CITF22-49E9.3	4.95	1.19e-06	0.000422	0.4	0.26	Schizophrenia;	chr22:49925279	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.908	rs9627800	ENSG00000278869.1	CITF22-49E9.3	4.95	1.19e-06	0.000422	0.4	0.26	Schizophrenia;	chr22:49925703	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.865	rs10854860	ENSG00000278869.1	CITF22-49E9.3	4.95	1.19e-06	0.000422	0.4	0.26	Schizophrenia;	chr22:49926381	chr22:49933198~49934074:-
LIHC	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	4.95	1.19e-06	0.000422	0.31	0.26	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
LIHC	cis	rs227275	0.525	rs11737544	ENSG00000230069.3	LRRC37A15P	-4.95	1.19e-06	0.000422	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102727274~102730721:-
LIHC	cis	rs58749629	1	rs3827066	ENSG00000269549.2	RP3-461P17.10	4.95	1.19e-06	0.000422	0.54	0.26	Abdominal aortic aneurysm;	chr20:45957384	chr20:45445431~45448580:+
LIHC	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-4.95	1.19e-06	0.000423	-0.32	-0.26	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
LIHC	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-4.95	1.19e-06	0.000423	-0.37	-0.26	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
LIHC	cis	rs3096299	0.933	rs3114848	ENSG00000261118.1	RP11-104N10.1	4.94	1.2e-06	0.000423	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89492017~89504460:-
LIHC	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	4.94	1.2e-06	0.000423	0.37	0.26	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
LIHC	cis	rs7131987	0.621	rs3782506	ENSG00000275476.1	RP11-996F15.4	4.94	1.2e-06	0.000424	0.3	0.26	QT interval;	chr12:29292489	chr12:29277397~29277882:-
LIHC	cis	rs739496	0.894	rs11065898	ENSG00000226469.1	ADAM1B	4.94	1.2e-06	0.000424	0.31	0.26	Platelet count;	chr12:111424771	chr12:111927018~111929017:+
LIHC	cis	rs11089937	0.626	rs5757051	ENSG00000211639.2	IGLV4-60	-4.94	1.2e-06	0.000425	-0.22	-0.26	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22162199~22162681:+
LIHC	cis	rs6479901	0.639	rs10995450	ENSG00000232075.1	MRPL35P2	4.94	1.2e-06	0.000426	0.29	0.26	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63634317~63634827:-
LIHC	cis	rs1223397	0.938	rs9395602	ENSG00000215022.6	RP1-257A7.4	-4.94	1.2e-06	0.000426	-0.29	-0.26	Blood pressure;	chr6:13278521	chr6:13264861~13295586:-
LIHC	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	4.94	1.21e-06	0.000426	0.33	0.26	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
LIHC	cis	rs2439831	1	rs2254321	ENSG00000205771.5	CATSPER2P1	-4.94	1.21e-06	0.000426	-0.36	-0.26	Lung cancer in ever smokers;	chr15:43415344	chr15:43726918~43747094:-
LIHC	cis	rs228614	0.51	rs223459	ENSG00000230069.3	LRRC37A15P	-4.94	1.21e-06	0.000427	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	4.94	1.21e-06	0.000427	0.29	0.26	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
LIHC	cis	rs4650994	0.544	rs11579513	ENSG00000273384.1	RP5-1098D14.1	4.94	1.21e-06	0.000427	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178526957	chr1:178651706~178652282:+
LIHC	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	4.94	1.21e-06	0.000427	0.31	0.26	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
LIHC	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	4.94	1.21e-06	0.000428	0.29	0.26	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
LIHC	cis	rs6802315	0.604	rs2115941	ENSG00000272087.1	RP11-379F4.7	4.94	1.21e-06	0.000428	0.3	0.26	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158693120~158693768:-
LIHC	cis	rs228614	0.51	rs223455	ENSG00000230069.3	LRRC37A15P	-4.94	1.21e-06	0.000428	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	4.94	1.21e-06	0.000428	0.29	0.26	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
LIHC	cis	rs11098499	0.691	rs10028773	ENSG00000260091.1	RP11-33B1.4	4.94	1.21e-06	0.000428	0.18	0.26	Corneal astigmatism;	chr4:119344104	chr4:119409333~119410233:+
LIHC	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-4.94	1.21e-06	0.000428	-0.32	-0.26	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
LIHC	cis	rs8031584	1	rs890159	ENSG00000270015.1	RP11-540B6.6	-4.94	1.21e-06	0.000428	-0.35	-0.26	Huntington's disease progression;	chr15:30999431	chr15:30926514~30928407:+
LIHC	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-4.94	1.21e-06	0.000428	-0.27	-0.26	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
LIHC	cis	rs227275	0.588	rs223458	ENSG00000230069.3	LRRC37A15P	-4.94	1.22e-06	0.000429	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102727274~102730721:-
LIHC	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	4.94	1.22e-06	0.000429	0.39	0.26	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
LIHC	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-4.94	1.22e-06	0.000429	-0.35	-0.26	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
LIHC	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	4.94	1.22e-06	0.000429	0.35	0.26	Height;	chr6:109333018	chr6:109382795~109383666:+
LIHC	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-4.94	1.22e-06	0.00043	-0.38	-0.26	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
LIHC	cis	rs4218	0.689	rs11853828	ENSG00000277144.1	RP11-59H7.4	-4.94	1.22e-06	0.00043	-0.29	-0.26	Social communication problems;	chr15:59136031	chr15:59115547~59116089:-
LIHC	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	4.94	1.22e-06	0.00043	0.34	0.26	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
LIHC	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-4.94	1.22e-06	0.00043	-0.31	-0.26	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
LIHC	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-4.94	1.22e-06	0.000431	-0.27	-0.26	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
LIHC	cis	rs11098499	0.863	rs1010739	ENSG00000260091.1	RP11-33B1.4	-4.94	1.22e-06	0.000431	-0.19	-0.26	Corneal astigmatism;	chr4:119542316	chr4:119409333~119410233:+
LIHC	cis	rs2836974	0.568	rs419469	ENSG00000255568.3	BRWD1-AS2	4.94	1.22e-06	0.000431	0.22	0.26	Cognitive function;	chr21:39165308	chr21:39313935~39314962:+
LIHC	cis	rs2032447	0.714	rs199736	ENSG00000242387.1	HIST1H2APS2	4.94	1.22e-06	0.000431	0.32	0.26	Intelligence (multi-trait analysis);	chr6:25936559	chr6:25882026~25882395:-
LIHC	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-4.94	1.22e-06	0.000431	-0.33	-0.26	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
LIHC	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	4.94	1.22e-06	0.000431	0.37	0.26	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	4.94	1.22e-06	0.000431	0.37	0.26	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	4.94	1.22e-06	0.000431	0.37	0.26	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	4.94	1.22e-06	0.000431	0.37	0.26	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
LIHC	cis	rs202072	0.729	rs202030	ENSG00000215022.6	RP1-257A7.4	-4.94	1.22e-06	0.000431	-0.3	-0.26	HIV-1 viral setpoint;	chr6:13291920	chr6:13264861~13295586:-
LIHC	cis	rs7674212	1	rs7691873	ENSG00000230069.3	LRRC37A15P	4.94	1.23e-06	0.000433	0.24	0.26	Type 2 diabetes;	chr4:103066742	chr4:102727274~102730721:-
LIHC	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-4.94	1.23e-06	0.000433	-0.37	-0.26	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
LIHC	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-4.94	1.23e-06	0.000433	-0.29	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
LIHC	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-4.94	1.23e-06	0.000433	-0.36	-0.26	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
LIHC	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	4.94	1.23e-06	0.000433	0.3	0.26	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
LIHC	cis	rs529413	1	rs504519	ENSG00000259237.1	RP11-209E8.1	4.94	1.23e-06	0.000433	0.35	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr15:53251029	chr15:53116365~53129698:+
LIHC	cis	rs3096299	0.685	rs8050512	ENSG00000261118.1	RP11-104N10.1	4.94	1.23e-06	0.000434	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89492017~89504460:-
LIHC	cis	rs8059260	0.736	rs79361721	ENSG00000274038.1	RP11-66H6.4	-4.94	1.24e-06	0.000435	-0.44	-0.26	Alcohol consumption over the past year;	chr16:10968082	chr16:11056556~11057034:+
LIHC	cis	rs2836974	0.644	rs2836981	ENSG00000255568.3	BRWD1-AS2	-4.94	1.24e-06	0.000435	-0.21	-0.26	Cognitive function;	chr21:39316439	chr21:39313935~39314962:+
LIHC	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-4.94	1.24e-06	0.000435	-0.45	-0.26	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
LIHC	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-4.94	1.24e-06	0.000435	-0.3	-0.26	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
LIHC	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-4.94	1.24e-06	0.000436	-0.33	-0.26	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
LIHC	cis	rs2688482	0.557	rs2550236	ENSG00000242086.7	LINC00969	4.94	1.24e-06	0.000436	0.32	0.26	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195658062~195739964:+
LIHC	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	4.94	1.24e-06	0.000436	0.34	0.26	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
LIHC	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-4.94	1.24e-06	0.000436	-0.33	-0.26	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
LIHC	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-4.94	1.24e-06	0.000436	-0.33	-0.26	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
LIHC	cis	rs1005277	0.522	rs289650	ENSG00000263064.2	RP11-291L22.7	4.94	1.24e-06	0.000437	0.25	0.26	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38448689~38448949:+
LIHC	cis	rs227275	0.525	rs28845922	ENSG00000230069.3	LRRC37A15P	-4.94	1.24e-06	0.000438	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102727274~102730721:-
LIHC	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	4.94	1.25e-06	0.000438	0.27	0.26	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
LIHC	cis	rs4731207	0.596	rs10252798	ENSG00000224897.5	POT1-AS1	4.94	1.25e-06	0.000439	0.31	0.26	Cutaneous malignant melanoma;	chr7:124997157	chr7:124929873~125179315:+
LIHC	cis	rs2565722	0.622	rs1937480	ENSG00000243831.1	RP1-81D8.4	4.94	1.25e-06	0.000439	0.37	0.26	Blood protein levels;	chr6:160883291	chr6:160666228~160676523:-
LIHC	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	4.94	1.25e-06	0.000439	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	4.94	1.25e-06	0.000439	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	4.94	1.25e-06	0.000439	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	4.94	1.25e-06	0.000439	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	4.94	1.25e-06	0.000439	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
LIHC	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
LIHC	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
LIHC	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	4.94	1.25e-06	0.00044	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
LIHC	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	4.94	1.25e-06	0.00044	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
LIHC	cis	rs6600671	0.934	rs67718113	ENSG00000231429.2	RP11-343N15.2	4.94	1.25e-06	0.00044	0.32	0.26	Hip geometry;	chr1:121497112	chr1:121412719~121429274:+
LIHC	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-4.94	1.25e-06	0.00044	-0.19	-0.26	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
LIHC	cis	rs113835537	0.877	rs2275998	ENSG00000255517.5	CTD-3074O7.5	-4.93	1.25e-06	0.000441	-0.34	-0.26	Airway imaging phenotypes;	chr11:66559110	chr11:66473490~66480233:-
LIHC	cis	rs6600671	1	rs4844616	ENSG00000231429.2	RP11-343N15.2	-4.93	1.26e-06	0.000441	-0.3	-0.26	Hip geometry;	chr1:121429348	chr1:121412719~121429274:+
LIHC	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-4.93	1.26e-06	0.000441	-0.4	-0.26	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
LIHC	cis	rs4660214	0.666	rs663892	ENSG00000182109.6	RP11-69E11.4	4.93	1.26e-06	0.000441	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39424005	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs1180384	ENSG00000182109.6	RP11-69E11.4	4.93	1.26e-06	0.000441	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427102	chr1:39522280~39546187:-
LIHC	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-4.93	1.26e-06	0.000442	-0.32	-0.26	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-4.93	1.26e-06	0.000442	-0.32	-0.26	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
LIHC	cis	rs9425766	0.679	rs2860846	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000442	0.31	0.26	Life satisfaction;	chr1:174106786	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs2860847	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000442	0.31	0.26	Life satisfaction;	chr1:174106787	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs6672986	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000442	0.31	0.26	Life satisfaction;	chr1:174107726	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs7533430	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000442	0.31	0.26	Life satisfaction;	chr1:174109279	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs7526024	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000442	0.31	0.26	Life satisfaction;	chr1:174109722	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs12079063	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000442	0.31	0.26	Life satisfaction;	chr1:174110447	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs12094341	ENSG00000227373.4	RP11-160H22.5	4.93	1.26e-06	0.000442	0.31	0.26	Life satisfaction;	chr1:174110562	chr1:174115300~174160004:-
LIHC	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	4.93	1.26e-06	0.000442	0.18	0.26	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
LIHC	cis	rs12571093	0.773	rs4142047	ENSG00000233590.1	RP11-153K11.3	-4.93	1.26e-06	0.000442	-0.4	-0.26	Optic nerve measurement (disc area);	chr10:68261498	chr10:68233251~68242379:-
LIHC	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	4.93	1.26e-06	0.000442	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
LIHC	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	4.93	1.26e-06	0.000443	0.33	0.26	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
LIHC	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-4.93	1.26e-06	0.000443	-0.36	-0.26	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
LIHC	cis	rs4862307	0.514	rs7696176	ENSG00000250726.1	RP11-616K6.1	4.93	1.27e-06	0.000444	0.28	0.26	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184093237	chr4:184072403~184073039:+
LIHC	cis	rs1865760	0.622	rs9968910	ENSG00000216436.2	HIST1H2APS1	-4.93	1.27e-06	0.000445	-0.34	-0.26	Height;	chr6:26071867	chr6:25732497~25732827:+
LIHC	cis	rs10847980	0.623	rs7955367	ENSG00000256092.2	RP13-942N8.1	4.93	1.27e-06	0.000445	0.42	0.26	Adiponectin levels;	chr12:123344245	chr12:123363868~123366113:+
LIHC	cis	rs1247318	1	rs1247318	ENSG00000243831.1	RP1-81D8.4	4.93	1.27e-06	0.000446	0.4	0.26	Aging;	chr6:160912905	chr6:160666228~160676523:-
LIHC	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-4.93	1.27e-06	0.000446	-0.31	-0.26	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
LIHC	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	4.93	1.27e-06	0.000446	0.36	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
LIHC	cis	rs6421571	0.565	rs10892263	ENSG00000255239.1	AP002954.6	-4.93	1.27e-06	0.000446	-0.37	-0.26	Primary biliary cholangitis;	chr11:118716610	chr11:118688039~118690600:-
LIHC	cis	rs227275	0.525	rs223461	ENSG00000230069.3	LRRC37A15P	-4.93	1.27e-06	0.000447	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102727274~102730721:-
LIHC	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-4.93	1.27e-06	0.000447	-0.37	-0.26	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
LIHC	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	4.93	1.28e-06	0.000448	0.35	0.26	Height;	chr6:109339681	chr6:109382795~109383666:+
LIHC	cis	rs11722779	0.844	rs3974602	ENSG00000230069.3	LRRC37A15P	-4.93	1.28e-06	0.000448	-0.23	-0.26	Schizophrenia;	chr4:102928840	chr4:102727274~102730721:-
LIHC	cis	rs7119038	0.818	rs10892289	ENSG00000255239.1	AP002954.6	-4.93	1.28e-06	0.000448	-0.37	-0.26	Sjögren's syndrome;	chr11:118775294	chr11:118688039~118690600:-
LIHC	cis	rs10256972	0.521	rs7457418	ENSG00000199023.2	MIR339	-4.93	1.28e-06	0.000448	-0.3	-0.26	Endometriosis;Longevity;	chr7:1070619	chr7:1022935~1023045:-
LIHC	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-4.93	1.28e-06	0.000449	-0.36	-0.26	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
LIHC	cis	rs9595908	0.9	rs9595850	ENSG00000212293.1	SNORA16	4.93	1.28e-06	0.000449	0.29	0.26	Body mass index;	chr13:32579773	chr13:32420390~32420516:-
LIHC	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	4.93	1.28e-06	0.00045	0.28	0.26	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
LIHC	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-4.93	1.28e-06	0.00045	-0.34	-0.26	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
LIHC	cis	rs9326248	0.53	rs11216316	ENSG00000236267.1	AP006216.5	-4.93	1.28e-06	0.00045	-0.3	-0.26	Blood protein levels;	chr11:117210784	chr11:116813204~116814003:-
LIHC	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-4.93	1.29e-06	0.000451	-0.36	-0.26	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
LIHC	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-4.93	1.29e-06	0.000452	-0.28	-0.26	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
LIHC	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	4.93	1.29e-06	0.000452	0.23	0.26	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
LIHC	cis	rs11722779	0.935	rs3974481	ENSG00000230069.3	LRRC37A15P	-4.93	1.29e-06	0.000453	-0.23	-0.26	Schizophrenia;	chr4:102956834	chr4:102727274~102730721:-
LIHC	cis	rs75920871	0.589	rs56061158	ENSG00000254851.1	RP11-109L13.1	-4.93	1.29e-06	0.000453	-0.52	-0.26	Subjective well-being;	chr11:117216402	chr11:117135528~117138582:+
LIHC	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	4.93	1.29e-06	0.000453	0.44	0.26	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
LIHC	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-4.93	1.29e-06	0.000453	-0.32	-0.26	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
LIHC	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	4.93	1.29e-06	0.000453	0.29	0.26	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
LIHC	cis	rs6479901	0.696	rs931972	ENSG00000232075.1	MRPL35P2	-4.93	1.29e-06	0.000454	-0.28	-0.26	Intelligence (multi-trait analysis);	chr10:63150467	chr10:63634317~63634827:-
LIHC	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	4.93	1.29e-06	0.000454	0.42	0.26	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
LIHC	cis	rs5769765	0.908	rs9616396	ENSG00000278869.1	CITF22-49E9.3	4.93	1.3e-06	0.000454	0.4	0.26	Schizophrenia;	chr22:49924177	chr22:49933198~49934074:-
LIHC	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-4.93	1.3e-06	0.000454	-0.39	-0.26	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
LIHC	cis	rs2932538	0.922	rs4838961	ENSG00000225075.1	RP11-426L16.3	-4.93	1.3e-06	0.000454	-0.33	-0.26	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112621345	chr1:112693688~112696621:-
LIHC	cis	rs61041384	0.661	rs4474478	ENSG00000256092.2	RP13-942N8.1	-4.93	1.3e-06	0.000454	-0.42	-0.26	Schizophrenia;	chr12:123249821	chr12:123363868~123366113:+
LIHC	cis	rs603446	0.967	rs180346	ENSG00000254851.1	RP11-109L13.1	-4.93	1.3e-06	0.000454	-0.33	-0.26	Triglycerides;	chr11:116741943	chr11:117135528~117138582:+
LIHC	cis	rs6600671	1	rs10903161	ENSG00000231429.2	RP11-343N15.2	-4.93	1.3e-06	0.000454	-0.29	-0.26	Hip geometry;	chr1:121436882	chr1:121412719~121429274:+
LIHC	cis	rs860295	0.812	rs2297775	ENSG00000203761.5	MSTO2P	4.93	1.3e-06	0.000455	0.2	0.26	Body mass index;	chr1:155765221	chr1:155745829~155750137:+
LIHC	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-4.93	1.3e-06	0.000455	-0.27	-0.26	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
LIHC	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	4.93	1.3e-06	0.000455	0.35	0.26	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
LIHC	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	4.93	1.3e-06	0.000455	0.29	0.26	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
LIHC	cis	rs1023500	0.505	rs2143139	ENSG00000227370.1	RP4-669P10.19	-4.93	1.3e-06	0.000455	-0.27	-0.26	Schizophrenia;	chr22:42218395	chr22:42132543~42132998:+
LIHC	cis	rs9425766	0.679	rs6695636	ENSG00000227373.4	RP11-160H22.5	4.93	1.3e-06	0.000455	0.31	0.26	Life satisfaction;	chr1:174303087	chr1:174115300~174160004:-
LIHC	cis	rs4650994	0.544	rs4075631	ENSG00000273384.1	RP5-1098D14.1	4.93	1.3e-06	0.000456	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178537459	chr1:178651706~178652282:+
LIHC	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	4.93	1.3e-06	0.000456	0.43	0.26	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
LIHC	cis	rs9425766	0.679	rs7537517	ENSG00000227373.4	RP11-160H22.5	4.93	1.3e-06	0.000456	0.31	0.26	Life satisfaction;	chr1:174207225	chr1:174115300~174160004:-
LIHC	cis	rs4660214	0.666	rs3116398	ENSG00000182109.6	RP11-69E11.4	-4.93	1.3e-06	0.000456	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39522280~39546187:-
LIHC	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-4.93	1.3e-06	0.000456	-0.38	-0.26	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-4.93	1.3e-06	0.000456	-0.38	-0.26	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-4.93	1.3e-06	0.000456	-0.38	-0.26	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-4.93	1.3e-06	0.000456	-0.38	-0.26	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
LIHC	cis	rs5769707	0.872	rs5770604	ENSG00000235111.1	RP1-29C18.8	-4.93	1.3e-06	0.000456	-0.3	-0.26	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49612657~49615716:-
LIHC	cis	rs11671005	0.735	rs34188294	ENSG00000269473.1	CTD-2619J13.19	4.93	1.3e-06	0.000457	0.44	0.26	Mean platelet volume;	chr19:58408190	chr19:58440448~58445849:+
LIHC	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-4.93	1.3e-06	0.000457	-0.36	-0.26	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
LIHC	cis	rs227275	0.525	rs7663876	ENSG00000230069.3	LRRC37A15P	-4.93	1.31e-06	0.000458	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs6821173	ENSG00000230069.3	LRRC37A15P	-4.93	1.31e-06	0.000458	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102727274~102730721:-
LIHC	cis	rs755249	0.529	rs604316	ENSG00000182109.6	RP11-69E11.4	4.93	1.31e-06	0.000458	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39413694	chr1:39522280~39546187:-
LIHC	cis	rs9400467	0.528	rs457492	ENSG00000271789.1	RP5-1112D6.7	-4.93	1.31e-06	0.000458	-0.25	-0.26	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111297126~111298510:+
LIHC	cis	rs10129255	0.544	rs61997583	ENSG00000211970.3	IGHV4-61	-4.93	1.31e-06	0.000458	-0.21	-0.26	Kawasaki disease;	chr14:106654351	chr14:106639119~106639657:-
LIHC	cis	rs2439831	0.85	rs28718261	ENSG00000166763.7	STRCP1	4.93	1.31e-06	0.000458	0.4	0.26	Lung cancer in ever smokers;	chr15:43751595	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28595038	ENSG00000166763.7	STRCP1	4.93	1.31e-06	0.000458	0.4	0.26	Lung cancer in ever smokers;	chr15:43752661	chr15:43699488~43718184:-
LIHC	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	4.93	1.31e-06	0.000459	0.35	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
LIHC	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	4.93	1.31e-06	0.000459	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	4.93	1.31e-06	0.000459	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	4.93	1.31e-06	0.000459	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	4.93	1.31e-06	0.000459	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
LIHC	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	4.93	1.31e-06	0.000459	0.3	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
LIHC	cis	rs1322639	0.614	rs7751131	ENSG00000261039.2	RP11-417E7.2	-4.93	1.31e-06	0.00046	-0.35	-0.26	Pulse pressure;	chr6:169178615	chr6:169175304~169182740:-
LIHC	cis	rs1322639	0.574	rs9364360	ENSG00000261039.2	RP11-417E7.2	-4.93	1.31e-06	0.00046	-0.35	-0.26	Pulse pressure;	chr6:169180079	chr6:169175304~169182740:-
LIHC	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-4.92	1.32e-06	0.00046	-0.33	-0.26	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
LIHC	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-4.92	1.32e-06	0.000461	-0.29	-0.26	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
LIHC	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-4.92	1.32e-06	0.000461	-0.37	-0.26	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-4.92	1.32e-06	0.000461	-0.37	-0.26	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
LIHC	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-4.92	1.32e-06	0.000461	-0.37	-0.26	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
LIHC	cis	rs9525927	0.57	rs7400099	ENSG00000230731.2	RP11-478K15.6	-4.92	1.32e-06	0.000461	-0.29	-0.26	Dupuytren's disease;	chr13:44230344	chr13:44234118~44243192:-
LIHC	cis	rs5769765	0.778	rs8137331	ENSG00000278869.1	CITF22-49E9.3	4.92	1.32e-06	0.000461	0.4	0.26	Schizophrenia;	chr22:49919710	chr22:49933198~49934074:-
LIHC	cis	rs11098499	0.954	rs17005535	ENSG00000260091.1	RP11-33B1.4	-4.92	1.32e-06	0.000462	-0.18	-0.26	Corneal astigmatism;	chr4:119490407	chr4:119409333~119410233:+
LIHC	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	4.92	1.32e-06	0.000462	0.39	0.26	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
LIHC	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	4.92	1.32e-06	0.000462	0.26	0.26	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
LIHC	cis	rs9425766	0.679	rs7555067	ENSG00000227373.4	RP11-160H22.5	4.92	1.33e-06	0.000463	0.31	0.26	Life satisfaction;	chr1:174297504	chr1:174115300~174160004:-
LIHC	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	4.92	1.33e-06	0.000463	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
LIHC	cis	rs2762353	0.526	rs6901027	ENSG00000216436.2	HIST1H2APS1	4.92	1.33e-06	0.000463	0.31	0.26	Blood metabolite levels;	chr6:25708814	chr6:25732497~25732827:+
LIHC	cis	rs875971	0.522	rs1880556	ENSG00000164669.11	INTS4P1	-4.92	1.33e-06	0.000465	-0.37	-0.26	Aortic root size;	chr7:65967557	chr7:65141225~65234216:+
LIHC	cis	rs11089937	0.626	rs5757056	ENSG00000211639.2	IGLV4-60	4.92	1.33e-06	0.000465	0.22	0.26	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22162199~22162681:+
LIHC	cis	rs875971	0.545	rs17138149	ENSG00000273142.1	RP11-458F8.4	4.92	1.33e-06	0.000465	0.24	0.26	Aortic root size;	chr7:66228193	chr7:66902857~66906297:+
LIHC	cis	rs6964833	0.873	rs4717905	ENSG00000277053.3	GTF2IP1	-4.92	1.33e-06	0.000465	-0.31	-0.26	Menarche (age at onset);	chr7:74668903	chr7:75185385~75237696:-
LIHC	cis	rs5769765	0.865	rs9616369	ENSG00000278869.1	CITF22-49E9.3	4.92	1.33e-06	0.000465	0.38	0.26	Schizophrenia;	chr22:49910943	chr22:49933198~49934074:-
LIHC	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-4.92	1.33e-06	0.000466	-0.27	-0.26	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
LIHC	cis	rs1030877	0.515	rs2576742	ENSG00000235319.1	AC012360.4	-4.92	1.34e-06	0.000466	-0.35	-0.26	Obesity-related traits;	chr2:105282365	chr2:105324210~105330529:+
LIHC	cis	rs4356203	0.792	rs620241	ENSG00000272034.1	SNORD14A	-4.92	1.34e-06	0.000466	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17175343	chr11:17074654~17074744:-
LIHC	cis	rs228614	0.51	rs223470	ENSG00000230069.3	LRRC37A15P	-4.92	1.34e-06	0.000467	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223468	ENSG00000230069.3	LRRC37A15P	-4.92	1.34e-06	0.000467	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223465	ENSG00000230069.3	LRRC37A15P	-4.92	1.34e-06	0.000467	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.51	rs223464	ENSG00000230069.3	LRRC37A15P	-4.92	1.34e-06	0.000467	-0.23	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102727274~102730721:-
LIHC	cis	rs2253762	0.527	rs11200323	ENSG00000276742.1	RP11-500G22.4	-4.92	1.34e-06	0.000467	-0.39	-0.26	Breast cancer;	chr10:122008869	chr10:121956782~121957098:+
LIHC	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-4.92	1.34e-06	0.000468	-0.46	-0.26	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
LIHC	cis	rs9425766	0.679	rs2901785	ENSG00000227373.4	RP11-160H22.5	4.92	1.34e-06	0.000468	0.31	0.26	Life satisfaction;	chr1:174135605	chr1:174115300~174160004:-
LIHC	cis	rs755249	0.501	rs2484749	ENSG00000182109.6	RP11-69E11.4	-4.92	1.34e-06	0.000468	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39522280~39546187:-
LIHC	cis	rs1714507	0.533	rs1714516	ENSG00000272087.1	RP11-379F4.7	4.92	1.34e-06	0.000468	0.29	0.26	Subjective well-being;	chr3:158575835	chr3:158693120~158693768:-
LIHC	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	4.92	1.34e-06	0.000469	0.31	0.26	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
LIHC	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	4.92	1.35e-06	0.000469	0.3	0.26	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
LIHC	cis	rs4660214	0.666	rs683135	ENSG00000182109.6	RP11-69E11.4	4.92	1.35e-06	0.000469	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39429788	chr1:39522280~39546187:-
LIHC	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-4.92	1.35e-06	0.00047	-0.36	-0.26	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
LIHC	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	4.92	1.35e-06	0.00047	0.44	0.26	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
LIHC	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	4.92	1.35e-06	0.00047	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
LIHC	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-4.92	1.35e-06	0.00047	-0.26	-0.26	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
LIHC	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	4.92	1.35e-06	0.000471	0.37	0.26	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
LIHC	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-4.92	1.35e-06	0.000471	-0.27	-0.26	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
LIHC	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	4.92	1.35e-06	0.000471	0.34	0.26	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
LIHC	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	4.92	1.35e-06	0.000471	0.34	0.26	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
LIHC	cis	rs1865760	0.622	rs10946807	ENSG00000216436.2	HIST1H2APS1	-4.92	1.35e-06	0.000471	-0.34	-0.26	Height;	chr6:26079410	chr6:25732497~25732827:+
LIHC	cis	rs4650994	0.525	rs2761463	ENSG00000273384.1	RP5-1098D14.1	-4.92	1.35e-06	0.000471	-0.32	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178588002	chr1:178651706~178652282:+
LIHC	cis	rs4660214	0.666	rs588326	ENSG00000182109.6	RP11-69E11.4	4.92	1.35e-06	0.000472	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39443054	chr1:39522280~39546187:-
LIHC	cis	rs12571093	0.571	rs7899387	ENSG00000233590.1	RP11-153K11.3	4.92	1.35e-06	0.000472	0.41	0.26	Optic nerve measurement (disc area);	chr10:68293278	chr10:68233251~68242379:-
LIHC	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	4.92	1.35e-06	0.000472	0.26	0.26	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
LIHC	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-4.92	1.36e-06	0.000472	-0.27	-0.26	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
LIHC	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	4.92	1.36e-06	0.000472	0.35	0.26	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
LIHC	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-4.92	1.36e-06	0.000473	-0.29	-0.26	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
LIHC	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	4.92	1.36e-06	0.000474	0.37	0.26	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
LIHC	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	4.92	1.36e-06	0.000474	0.4	0.26	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
LIHC	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	4.92	1.36e-06	0.000475	0.18	0.26	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
LIHC	cis	rs7702057	0.53	rs17138866	ENSG00000271918.1	CTD-2287O16.5	4.92	1.36e-06	0.000475	0.36	0.26	Amyotrophic lateral sclerosis;	chr5:116088914	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs59429923	ENSG00000271918.1	CTD-2287O16.5	4.92	1.36e-06	0.000475	0.36	0.26	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116083807~116085416:-
LIHC	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-4.92	1.37e-06	0.000475	-0.26	-0.26	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
LIHC	cis	rs2836974	0.644	rs1882779	ENSG00000255568.3	BRWD1-AS2	-4.92	1.37e-06	0.000476	-0.22	-0.26	Cognitive function;	chr21:39319012	chr21:39313935~39314962:+
LIHC	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	4.92	1.37e-06	0.000476	0.2	0.26	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
LIHC	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-4.92	1.37e-06	0.000477	-0.27	-0.26	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
LIHC	cis	rs30380	0.586	rs28119	ENSG00000272109.1	CTD-2260A17.3	-4.92	1.37e-06	0.000477	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96796030	chr5:96804353~96806105:+
LIHC	cis	rs30380	0.632	rs26491	ENSG00000272109.1	CTD-2260A17.3	-4.92	1.37e-06	0.000477	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96798410	chr5:96804353~96806105:+
LIHC	cis	rs1030877	0.515	rs1020064	ENSG00000235319.1	AC012360.4	-4.92	1.37e-06	0.000477	-0.35	-0.26	Obesity-related traits;	chr2:105281283	chr2:105324210~105330529:+
LIHC	cis	rs1030877	0.515	rs2576741	ENSG00000235319.1	AC012360.4	-4.92	1.37e-06	0.000477	-0.35	-0.26	Obesity-related traits;	chr2:105281507	chr2:105324210~105330529:+
LIHC	cis	rs3096299	0.933	rs2965934	ENSG00000261118.1	RP11-104N10.1	4.92	1.37e-06	0.000478	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89492017~89504460:-
LIHC	cis	rs7811142	1	rs6953107	ENSG00000242294.5	STAG3L5P	4.92	1.37e-06	0.000478	0.31	0.26	Platelet count;	chr7:100498041	chr7:100336079~100351900:+
LIHC	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	4.92	1.37e-06	0.000478	0.31	0.26	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
LIHC	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	4.92	1.38e-06	0.000478	0.18	0.26	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
LIHC	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	4.92	1.38e-06	0.000478	0.31	0.26	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
LIHC	cis	rs17826219	0.706	rs609472	ENSG00000266490.1	CTD-2349P21.9	4.92	1.38e-06	0.000479	0.31	0.26	Body mass index;	chr17:30624409	chr17:30792372~30792833:+
LIHC	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	4.92	1.38e-06	0.000479	0.32	0.26	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
LIHC	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	4.92	1.38e-06	0.000479	0.43	0.26	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	4.92	1.38e-06	0.000479	0.43	0.26	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	4.92	1.38e-06	0.000479	0.43	0.26	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
LIHC	cis	rs7119038	0.818	rs11826521	ENSG00000255239.1	AP002954.6	-4.92	1.38e-06	0.000479	-0.37	-0.26	Sjögren's syndrome;	chr11:118739840	chr11:118688039~118690600:-
LIHC	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	4.92	1.38e-06	0.000479	0.38	0.26	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
LIHC	cis	rs36715	0.953	rs36700	ENSG00000245937.6	LINC01184	4.91	1.38e-06	0.00048	0.32	0.26	Breast cancer;	chr5:128215581	chr5:127940426~128083172:-
LIHC	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	4.91	1.38e-06	0.00048	0.34	0.26	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	4.91	1.38e-06	0.00048	0.34	0.26	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
LIHC	cis	rs12157904	1	rs2071770	ENSG00000233360.4	Z83844.1	4.91	1.38e-06	0.00048	0.57	0.26	Response to anti-depressant treatment in major depressive disorder;	chr22:37630740	chr22:37641832~37658377:-
LIHC	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-4.91	1.38e-06	0.00048	-0.47	-0.26	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
LIHC	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-4.91	1.38e-06	0.00048	-0.47	-0.26	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
LIHC	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-4.91	1.38e-06	0.00048	-0.47	-0.26	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
LIHC	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-4.91	1.38e-06	0.00048	-0.47	-0.26	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
LIHC	cis	rs7131987	0.868	rs737160	ENSG00000257176.2	RP11-996F15.2	-4.91	1.38e-06	0.00048	-0.29	-0.26	QT interval;	chr12:29276079	chr12:29280418~29317848:-
LIHC	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	4.91	1.38e-06	0.00048	0.29	0.26	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
LIHC	cis	rs9890032	0.52	rs2321926	ENSG00000263531.1	RP13-753N3.1	4.91	1.38e-06	0.000481	0.34	0.26	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30863921~30864940:-
LIHC	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-4.91	1.38e-06	0.000481	-0.21	-0.26	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
LIHC	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-4.91	1.38e-06	0.000481	-0.26	-0.26	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
LIHC	cis	rs7811142	0.945	rs34989573	ENSG00000242294.5	STAG3L5P	4.91	1.38e-06	0.000481	0.31	0.26	Platelet count;	chr7:100500272	chr7:100336079~100351900:+
LIHC	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	4.91	1.38e-06	0.000481	0.36	0.26	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
LIHC	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-4.91	1.38e-06	0.000481	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
LIHC	cis	rs4660214	0.724	rs10788933	ENSG00000182109.6	RP11-69E11.4	-4.91	1.39e-06	0.000481	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39229483	chr1:39522280~39546187:-
LIHC	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-4.91	1.39e-06	0.000481	-0.27	-0.26	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-4.91	1.39e-06	0.000481	-0.26	-0.26	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
LIHC	cis	rs16858210	0.648	rs79478990	ENSG00000234371.6	RPSAP31	4.91	1.39e-06	0.000482	0.33	0.26	Menopause (age at onset);	chr3:183869306	chr3:183884924~183888449:+
LIHC	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-4.91	1.39e-06	0.000482	-0.2	-0.26	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
LIHC	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-4.91	1.39e-06	0.000482	-0.28	-0.26	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-4.91	1.39e-06	0.000482	-0.28	-0.26	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
LIHC	cis	rs4934494	0.689	rs17127596	ENSG00000232936.4	RP11-80H5.2	-4.91	1.39e-06	0.000482	-0.31	-0.26	Red blood cell count;	chr10:89816128	chr10:89645282~89650667:+
LIHC	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	4.91	1.39e-06	0.000483	0.39	0.26	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
LIHC	cis	rs2836974	0.899	rs114399588	ENSG00000255568.3	BRWD1-AS2	4.91	1.39e-06	0.000483	0.3	0.26	Cognitive function;	chr21:39282032	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.965	rs8131126	ENSG00000255568.3	BRWD1-AS2	4.91	1.39e-06	0.000483	0.3	0.26	Cognitive function;	chr21:39283828	chr21:39313935~39314962:+
LIHC	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	4.91	1.39e-06	0.000483	0.18	0.26	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
LIHC	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-4.91	1.39e-06	0.000483	-0.32	-0.26	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
LIHC	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-4.91	1.39e-06	0.000483	-0.28	-0.26	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
LIHC	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-4.91	1.39e-06	0.000483	-0.27	-0.26	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
LIHC	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-4.91	1.39e-06	0.000483	-0.26	-0.26	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
LIHC	cis	rs2439831	0.85	rs524417	ENSG00000205771.5	CATSPER2P1	-4.91	1.4e-06	0.000484	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43480176	chr15:43726918~43747094:-
LIHC	cis	rs2439831	0.85	rs2439832	ENSG00000205771.5	CATSPER2P1	-4.91	1.4e-06	0.000484	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43487488	chr15:43726918~43747094:-
LIHC	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-4.91	1.4e-06	0.000484	-0.41	-0.26	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
LIHC	cis	rs2439831	0.85	rs60883262	ENSG00000166763.7	STRCP1	4.91	1.4e-06	0.000485	0.39	0.26	Lung cancer in ever smokers;	chr15:43784305	chr15:43699488~43718184:-
LIHC	cis	rs6600671	1	rs11249351	ENSG00000231429.2	RP11-343N15.2	-4.91	1.4e-06	0.000485	-0.29	-0.26	Hip geometry;	chr1:121430082	chr1:121412719~121429274:+
LIHC	cis	rs6600671	0.967	rs12069545	ENSG00000231429.2	RP11-343N15.2	-4.91	1.4e-06	0.000485	-0.29	-0.26	Hip geometry;	chr1:121430343	chr1:121412719~121429274:+
LIHC	cis	rs7937890	0.572	rs2597218	ENSG00000251991.1	RNU7-49P	4.91	1.4e-06	0.000486	0.29	0.26	Mitochondrial DNA levels;	chr11:14510792	chr11:14478892~14478953:+
LIHC	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-4.91	1.4e-06	0.000486	-0.36	-0.26	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-4.91	1.4e-06	0.000486	-0.36	-0.26	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-4.91	1.4e-06	0.000486	-0.36	-0.26	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
LIHC	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	4.91	1.4e-06	0.000487	0.26	0.26	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
LIHC	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	4.91	1.41e-06	0.000488	0.34	0.26	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
LIHC	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-4.91	1.41e-06	0.000488	-0.29	-0.26	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
LIHC	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-4.91	1.41e-06	0.000488	-0.28	-0.26	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
LIHC	cis	rs11098499	0.954	rs10008459	ENSG00000260091.1	RP11-33B1.4	-4.91	1.41e-06	0.000489	-0.18	-0.26	Corneal astigmatism;	chr4:119473076	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs2127821	ENSG00000260091.1	RP11-33B1.4	-4.91	1.41e-06	0.000489	-0.18	-0.26	Corneal astigmatism;	chr4:119473380	chr4:119409333~119410233:+
LIHC	cis	rs3733585	0.781	rs13103690	ENSG00000250413.1	RP11-448G15.1	4.91	1.41e-06	0.000489	0.33	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9971154	chr4:10006482~10009725:+
LIHC	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	4.91	1.41e-06	0.000489	0.36	0.26	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
LIHC	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	4.91	1.41e-06	0.000489	0.29	0.26	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
LIHC	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	4.91	1.41e-06	0.000489	0.49	0.26	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
LIHC	cis	rs11098499	0.954	rs7681544	ENSG00000260091.1	RP11-33B1.4	-4.91	1.41e-06	0.000489	-0.18	-0.26	Corneal astigmatism;	chr4:119490100	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs11940028	ENSG00000260091.1	RP11-33B1.4	-4.91	1.41e-06	0.000489	-0.18	-0.26	Corneal astigmatism;	chr4:119490752	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs11935596	ENSG00000260091.1	RP11-33B1.4	-4.91	1.41e-06	0.000489	-0.18	-0.26	Corneal astigmatism;	chr4:119491302	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs12507964	ENSG00000260091.1	RP11-33B1.4	-4.91	1.41e-06	0.000489	-0.18	-0.26	Corneal astigmatism;	chr4:119491906	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs11098530	ENSG00000260091.1	RP11-33B1.4	-4.91	1.41e-06	0.000489	-0.18	-0.26	Corneal astigmatism;	chr4:119491999	chr4:119409333~119410233:+
LIHC	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-4.91	1.42e-06	0.00049	-0.33	-0.26	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
LIHC	cis	rs228614	0.51	rs223452	ENSG00000230069.3	LRRC37A15P	-4.91	1.42e-06	0.00049	-0.24	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102727274~102730721:-
LIHC	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-4.91	1.42e-06	0.00049	-0.3	-0.26	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
LIHC	cis	rs1150668	1	rs1150668	ENSG00000204709.4	LINC01556	4.91	1.42e-06	0.00049	0.29	0.26	Pubertal anthropometrics;	chr6:28162011	chr6:28943877~28944537:+
LIHC	cis	rs755249	0.501	rs2490945	ENSG00000182109.6	RP11-69E11.4	4.91	1.42e-06	0.00049	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39522280~39546187:-
LIHC	cis	rs2032366	0.63	rs12457579	ENSG00000267279.1	RP11-879F14.2	-4.91	1.42e-06	0.000491	-0.31	-0.26	Obesity-related traits;	chr18:61629575	chr18:61585746~61606916:-
LIHC	cis	rs16858210	0.837	rs11716104	ENSG00000234371.6	RPSAP31	4.91	1.42e-06	0.000491	0.33	0.26	Menopause (age at onset);	chr3:183864211	chr3:183884924~183888449:+
LIHC	cis	rs6600671	0.899	rs6674392	ENSG00000231429.2	RP11-343N15.2	-4.91	1.42e-06	0.000491	-0.3	-0.26	Hip geometry;	chr1:121518864	chr1:121412719~121429274:+
LIHC	cis	rs9595066	0.627	rs4942287	ENSG00000230731.2	RP11-478K15.6	-4.91	1.42e-06	0.000491	-0.3	-0.26	Schizophrenia;	chr13:44160560	chr13:44234118~44243192:-
LIHC	cis	rs9890032	1	rs9890032	ENSG00000263531.1	RP13-753N3.1	-4.91	1.42e-06	0.000491	-0.31	-0.26	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30863921~30864940:-
LIHC	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-4.91	1.42e-06	0.000491	-0.27	-0.26	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-4.91	1.42e-06	0.000491	-0.27	-0.26	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-4.91	1.42e-06	0.000491	-0.27	-0.26	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-4.91	1.42e-06	0.000491	-0.27	-0.26	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-4.91	1.42e-06	0.000491	-0.27	-0.26	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-4.91	1.42e-06	0.000491	-0.27	-0.26	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
LIHC	cis	rs2877649	0.59	rs75152230	ENSG00000258744.1	RP11-80A15.1	-4.91	1.42e-06	0.000491	-0.51	-0.26	Smooth-surface caries;	chr14:24465850	chr14:24501594~24508688:+
LIHC	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	4.91	1.42e-06	0.000491	0.18	0.26	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	4.91	1.42e-06	0.000491	0.18	0.26	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
LIHC	cis	rs734999	0.967	rs10797433	ENSG00000225931.3	RP3-395M20.7	4.91	1.42e-06	0.000491	0.28	0.26	Ulcerative colitis;	chr1:2570571	chr1:2566410~2569888:+
LIHC	cis	rs10847980	0.623	rs28613486	ENSG00000256092.2	RP13-942N8.1	4.91	1.42e-06	0.000491	0.42	0.26	Adiponectin levels;	chr12:123382721	chr12:123363868~123366113:+
LIHC	cis	rs1714507	0.533	rs2731120	ENSG00000272087.1	RP11-379F4.7	-4.91	1.42e-06	0.000491	-0.29	-0.26	Subjective well-being;	chr3:158579844	chr3:158693120~158693768:-
LIHC	cis	rs1714507	0.515	rs2731112	ENSG00000272087.1	RP11-379F4.7	4.91	1.42e-06	0.000491	0.29	0.26	Subjective well-being;	chr3:158572439	chr3:158693120~158693768:-
LIHC	cis	rs1714507	0.533	rs2731122	ENSG00000272087.1	RP11-379F4.7	4.91	1.42e-06	0.000491	0.29	0.26	Subjective well-being;	chr3:158577491	chr3:158693120~158693768:-
LIHC	cis	rs7208859	0.673	rs216420	ENSG00000266490.1	CTD-2349P21.9	4.91	1.42e-06	0.000492	0.3	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30792372~30792833:+
LIHC	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-4.91	1.42e-06	0.000492	-0.36	-0.26	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
LIHC	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-4.91	1.42e-06	0.000492	-0.36	-0.26	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
LIHC	cis	rs2836974	0.644	rs11088471	ENSG00000255568.3	BRWD1-AS2	-4.91	1.42e-06	0.000492	-0.21	-0.26	Cognitive function;	chr21:39327387	chr21:39313935~39314962:+
LIHC	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	4.91	1.42e-06	0.000493	0.39	0.26	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
LIHC	cis	rs12554020	0.681	rs76725109	ENSG00000227603.1	RP11-165J3.6	4.91	1.43e-06	0.000493	0.49	0.26	Schizophrenia;	chr9:93639802	chr9:93435332~93437121:-
LIHC	cis	rs227275	0.556	rs223449	ENSG00000230069.3	LRRC37A15P	-4.91	1.43e-06	0.000493	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102727274~102730721:-
LIHC	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	4.91	1.43e-06	0.000494	0.33	0.26	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
LIHC	cis	rs2412819	0.599	rs2470120	ENSG00000166763.7	STRCP1	4.91	1.43e-06	0.000494	0.33	0.26	Lung cancer;	chr15:43636872	chr15:43699488~43718184:-
LIHC	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	4.91	1.43e-06	0.000494	0.38	0.26	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
LIHC	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	4.91	1.43e-06	0.000494	0.38	0.26	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
LIHC	cis	rs2929278	0.562	rs8033846	ENSG00000166763.7	STRCP1	-4.91	1.43e-06	0.000494	-0.34	-0.26	Schizophrenia;	chr15:43743165	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-4.91	1.43e-06	0.000494	-0.27	-0.26	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-4.91	1.43e-06	0.000494	-0.27	-0.26	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
LIHC	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	4.91	1.43e-06	0.000494	0.5	0.26	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
LIHC	cis	rs2439831	1	rs2439850	ENSG00000205771.5	CATSPER2P1	-4.91	1.43e-06	0.000495	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43492656	chr15:43726918~43747094:-
LIHC	cis	rs2929278	0.617	rs694461	ENSG00000166763.7	STRCP1	-4.91	1.43e-06	0.000495	-0.34	-0.26	Schizophrenia;	chr15:43803865	chr15:43699488~43718184:-
LIHC	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-4.91	1.43e-06	0.000496	-0.32	-0.26	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-4.91	1.43e-06	0.000496	-0.32	-0.26	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
LIHC	cis	rs7937890	0.593	rs2597189	ENSG00000251991.1	RNU7-49P	4.91	1.44e-06	0.000496	0.29	0.26	Mitochondrial DNA levels;	chr11:14490514	chr11:14478892~14478953:+
LIHC	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-4.91	1.44e-06	0.000497	-0.36	-0.26	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
LIHC	cis	rs30380	0.632	rs26497	ENSG00000272109.1	CTD-2260A17.3	-4.91	1.44e-06	0.000497	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96803064	chr5:96804353~96806105:+
LIHC	cis	rs712039	0.652	rs11656503	ENSG00000276054.1	RP11-378E13.3	4.91	1.44e-06	0.000497	0.32	0.26	Tuberculosis;	chr17:37411934	chr17:37386886~37387926:+
LIHC	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-4.91	1.44e-06	0.000497	-0.32	-0.26	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
LIHC	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	4.91	1.44e-06	0.000498	0.32	0.26	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
LIHC	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	4.91	1.44e-06	0.000498	0.39	0.26	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
LIHC	cis	rs875971	0.522	rs781144	ENSG00000164669.11	INTS4P1	-4.91	1.44e-06	0.000499	-0.36	-0.26	Aortic root size;	chr7:65975357	chr7:65141225~65234216:+
LIHC	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-4.91	1.45e-06	0.000499	-0.28	-0.26	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
LIHC	cis	rs4731207	0.596	rs4624966	ENSG00000224897.5	POT1-AS1	4.9	1.45e-06	5e-04	0.31	0.26	Cutaneous malignant melanoma;	chr7:124986417	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.623	rs4506149	ENSG00000224897.5	POT1-AS1	4.9	1.45e-06	5e-04	0.31	0.26	Cutaneous malignant melanoma;	chr7:124986419	chr7:124929873~125179315:+
LIHC	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	4.9	1.45e-06	0.000501	0.32	0.26	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
LIHC	cis	rs4650994	0.507	rs12141152	ENSG00000273384.1	RP5-1098D14.1	4.9	1.45e-06	0.000501	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178545030	chr1:178651706~178652282:+
LIHC	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	4.9	1.45e-06	0.000502	0.39	0.26	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
LIHC	cis	rs2877649	0.793	rs79756911	ENSG00000258744.1	RP11-80A15.1	-4.9	1.45e-06	0.000502	-0.52	-0.26	Smooth-surface caries;	chr14:24438374	chr14:24501594~24508688:+
LIHC	cis	rs2735413	0.918	rs12925605	ENSG00000276007.1	RP11-358L22.3	-4.9	1.45e-06	0.000502	-0.28	-0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78037818	chr16:78123243~78124332:+
LIHC	cis	rs9425766	0.679	rs4652234	ENSG00000227373.4	RP11-160H22.5	4.9	1.46e-06	0.000502	0.31	0.26	Life satisfaction;	chr1:174181712	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.732	rs6658543	ENSG00000227373.4	RP11-160H22.5	4.9	1.46e-06	0.000502	0.31	0.26	Life satisfaction;	chr1:174183338	chr1:174115300~174160004:-
LIHC	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	4.9	1.46e-06	0.000502	0.35	0.26	Height;	chr6:109416945	chr6:109382795~109383666:+
LIHC	cis	rs7412746	0.658	rs12405726	ENSG00000231073.1	RP11-316M1.3	4.9	1.46e-06	0.000502	0.27	0.26	Melanoma;	chr1:150983652	chr1:150973123~150975534:+
LIHC	cis	rs17301013	0.932	rs4233195	ENSG00000227373.4	RP11-160H22.5	-4.9	1.46e-06	0.000503	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174806736	chr1:174115300~174160004:-
LIHC	cis	rs4660214	0.666	rs1180383	ENSG00000182109.6	RP11-69E11.4	4.9	1.46e-06	0.000503	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39522280~39546187:-
LIHC	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-4.9	1.46e-06	0.000503	-0.36	-0.26	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
LIHC	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-4.9	1.46e-06	0.000504	-0.28	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
LIHC	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-4.9	1.46e-06	0.000504	-0.37	-0.26	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
LIHC	cis	rs9834975	0.815	rs9874163	ENSG00000272758.4	RP11-299J3.8	-4.9	1.46e-06	0.000504	-0.28	-0.26	Diastolic blood pressure;	chr3:122386581	chr3:122416207~122443180:+
LIHC	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-4.9	1.46e-06	0.000504	-0.31	-0.26	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
LIHC	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	4.9	1.47e-06	0.000505	0.29	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
LIHC	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	4.9	1.47e-06	0.000505	0.3	0.26	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
LIHC	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	4.9	1.47e-06	0.000506	0.26	0.26	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
LIHC	cis	rs4934494	0.727	rs12764076	ENSG00000232936.4	RP11-80H5.2	4.9	1.47e-06	0.000506	0.32	0.26	Red blood cell count;	chr10:89630443	chr10:89645282~89650667:+
LIHC	cis	rs4934494	0.634	rs12762448	ENSG00000232936.4	RP11-80H5.2	4.9	1.47e-06	0.000506	0.32	0.26	Red blood cell count;	chr10:89630483	chr10:89645282~89650667:+
LIHC	cis	rs2243480	1	rs1404147	ENSG00000228409.4	CCT6P1	4.9	1.47e-06	0.000506	0.27	0.26	Diabetic kidney disease;	chr7:65799537	chr7:65751142~65763354:+
LIHC	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	4.9	1.47e-06	0.000506	0.5	0.26	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
LIHC	cis	rs4660214	0.666	rs1984143	ENSG00000182109.6	RP11-69E11.4	-4.9	1.47e-06	0.000506	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39522280~39546187:-
LIHC	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-4.9	1.47e-06	0.000507	-0.3	-0.26	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
LIHC	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	4.9	1.47e-06	0.000507	0.3	0.26	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
LIHC	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-4.9	1.47e-06	0.000507	-0.36	-0.26	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
LIHC	cis	rs227275	0.525	rs7685399	ENSG00000230069.3	LRRC37A15P	-4.9	1.47e-06	0.000507	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs4623004	ENSG00000230069.3	LRRC37A15P	-4.9	1.47e-06	0.000507	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	4.9	1.47e-06	0.000507	0.29	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
LIHC	cis	rs11672691	0.519	rs12973063	ENSG00000267107.5	PCAT19	4.9	1.47e-06	0.000507	0.31	0.26	Prostate cancer;	chr19:41503757	chr19:41454169~41500649:-
LIHC	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-4.9	1.47e-06	0.000507	-0.28	-0.26	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
LIHC	cis	rs6163	0.588	rs11191392	ENSG00000236937.2	PTGES3P4	4.9	1.47e-06	0.000508	0.31	0.26	Waist circumference;Hip circumference;	chr10:102767194	chr10:102845595~102845950:+
LIHC	cis	rs5769765	0.671	rs138841	ENSG00000278869.1	CITF22-49E9.3	4.9	1.47e-06	0.000508	0.39	0.26	Schizophrenia;	chr22:49788312	chr22:49933198~49934074:-
LIHC	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-4.9	1.47e-06	0.000508	-0.3	-0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
LIHC	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-4.9	1.48e-06	0.000508	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
LIHC	cis	rs2243480	1	rs160634	ENSG00000228409.4	CCT6P1	-4.9	1.48e-06	0.000509	-0.26	-0.26	Diabetic kidney disease;	chr7:66063677	chr7:65751142~65763354:+
LIHC	cis	rs12478296	0.685	rs67829386	ENSG00000261186.2	RP11-341N2.1	-4.9	1.48e-06	0.000509	-0.34	-0.26	Obesity-related traits;	chr2:242050125	chr2:242087351~242088457:-
LIHC	cis	rs9467711	0.591	rs10484435	ENSG00000216436.2	HIST1H2APS1	4.9	1.48e-06	0.000509	0.68	0.26	Autism spectrum disorder or schizophrenia;	chr6:26031583	chr6:25732497~25732827:+
LIHC	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	4.9	1.48e-06	0.000509	0.38	0.26	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
LIHC	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-4.9	1.48e-06	0.00051	-0.23	-0.26	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
LIHC	cis	rs7937890	0.56	rs2597194	ENSG00000251991.1	RNU7-49P	4.9	1.48e-06	0.00051	0.29	0.26	Mitochondrial DNA levels;	chr11:14475723	chr11:14478892~14478953:+
LIHC	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	4.9	1.48e-06	0.00051	0.32	0.26	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
LIHC	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	4.9	1.48e-06	0.00051	0.37	0.26	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
LIHC	cis	rs2836974	0.568	rs2183573	ENSG00000255568.3	BRWD1-AS2	-4.9	1.48e-06	0.00051	-0.22	-0.26	Cognitive function;	chr21:39202379	chr21:39313935~39314962:+
LIHC	cis	rs9425766	0.54	rs2294492	ENSG00000227373.4	RP11-160H22.5	4.9	1.48e-06	0.000511	0.31	0.26	Life satisfaction;	chr1:174157884	chr1:174115300~174160004:-
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-4.9	1.49e-06	0.000512	-0.3	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
LIHC	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	4.9	1.49e-06	0.000512	0.39	0.26	Depression;	chr6:28205232	chr6:28115628~28116551:+
LIHC	cis	rs4356203	0.543	rs214093	ENSG00000272034.1	SNORD14A	-4.9	1.49e-06	0.000513	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.519	rs214092	ENSG00000272034.1	SNORD14A	-4.9	1.49e-06	0.000513	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17074654~17074744:-
LIHC	cis	rs5769765	0.817	rs11912619	ENSG00000278869.1	CITF22-49E9.3	4.9	1.49e-06	0.000513	0.4	0.26	Schizophrenia;	chr22:49923753	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.73	rs62233964	ENSG00000278869.1	CITF22-49E9.3	4.9	1.49e-06	0.000513	0.4	0.26	Schizophrenia;	chr22:49923762	chr22:49933198~49934074:-
LIHC	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	4.9	1.49e-06	0.000513	0.35	0.26	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
LIHC	cis	rs603446	0.678	rs664059	ENSG00000254851.1	RP11-109L13.1	-4.9	1.49e-06	0.000514	-0.3	-0.26	Triglycerides;	chr11:116771421	chr11:117135528~117138582:+
LIHC	cis	rs75920871	0.589	rs73008568	ENSG00000254851.1	RP11-109L13.1	-4.9	1.49e-06	0.000514	-0.52	-0.26	Subjective well-being;	chr11:117194291	chr11:117135528~117138582:+
LIHC	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	4.9	1.5e-06	0.000514	0.38	0.26	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
LIHC	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-4.9	1.5e-06	0.000516	-0.37	-0.26	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
LIHC	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	4.9	1.5e-06	0.000516	0.34	0.26	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
LIHC	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-4.9	1.5e-06	0.000517	-0.32	-0.26	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
LIHC	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	4.9	1.5e-06	0.000517	0.31	0.26	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	4.9	1.5e-06	0.000517	0.31	0.26	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
LIHC	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-4.9	1.5e-06	0.000517	-0.4	-0.26	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
LIHC	cis	rs9467711	0.591	rs35249036	ENSG00000216436.2	HIST1H2APS1	4.9	1.5e-06	0.000517	0.64	0.26	Autism spectrum disorder or schizophrenia;	chr6:26025935	chr6:25732497~25732827:+
LIHC	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-4.9	1.5e-06	0.000517	-0.47	-0.26	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
LIHC	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-4.9	1.5e-06	0.000517	-0.47	-0.26	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
LIHC	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-4.9	1.5e-06	0.000517	-0.47	-0.26	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
LIHC	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-4.9	1.51e-06	0.000518	-0.32	-0.26	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
LIHC	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-4.9	1.51e-06	0.000518	-0.43	-0.26	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-4.9	1.51e-06	0.000518	-0.43	-0.26	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
LIHC	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-4.9	1.51e-06	0.000518	-0.43	-0.26	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
LIHC	cis	rs227275	0.525	rs7672319	ENSG00000230069.3	LRRC37A15P	-4.9	1.51e-06	0.000518	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs6533051	ENSG00000230069.3	LRRC37A15P	-4.9	1.51e-06	0.000518	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102727274~102730721:-
LIHC	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	4.9	1.51e-06	0.000518	0.24	0.26	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
LIHC	cis	rs227275	0.525	rs6533052	ENSG00000230069.3	LRRC37A15P	-4.9	1.51e-06	0.000518	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102727274~102730721:-
LIHC	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-4.9	1.51e-06	0.000519	-0.32	-0.26	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
LIHC	cis	rs30380	0.632	rs26498	ENSG00000272109.1	CTD-2260A17.3	4.9	1.51e-06	0.000519	0.33	0.26	Cerebrospinal fluid biomarker levels;	chr5:96803109	chr5:96804353~96806105:+
LIHC	cis	rs227275	0.525	rs3974485	ENSG00000230069.3	LRRC37A15P	-4.9	1.51e-06	0.000519	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102727274~102730721:-
LIHC	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	4.9	1.51e-06	0.000519	0.2	0.26	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
LIHC	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	4.9	1.51e-06	0.00052	0.35	0.26	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-4.9	1.51e-06	0.00052	-0.35	-0.26	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-4.9	1.51e-06	0.00052	-0.35	-0.26	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-4.9	1.51e-06	0.00052	-0.35	-0.26	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
LIHC	cis	rs9834975	0.967	rs6787230	ENSG00000272758.4	RP11-299J3.8	-4.9	1.51e-06	0.00052	-0.28	-0.26	Diastolic blood pressure;	chr3:122392403	chr3:122416207~122443180:+
LIHC	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	4.9	1.51e-06	0.00052	0.29	0.26	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
LIHC	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-4.9	1.51e-06	0.00052	-0.32	-0.26	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-4.9	1.51e-06	0.00052	-0.32	-0.26	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-4.9	1.51e-06	0.00052	-0.32	-0.26	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
LIHC	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	4.9	1.52e-06	0.000521	0.39	0.26	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	4.9	1.52e-06	0.000521	0.39	0.26	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	4.9	1.52e-06	0.000521	0.39	0.26	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-4.9	1.52e-06	0.000521	-0.39	-0.26	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	4.9	1.52e-06	0.000521	0.39	0.26	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
LIHC	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-4.9	1.52e-06	0.000521	-0.32	-0.26	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-4.9	1.52e-06	0.000521	-0.32	-0.26	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-4.9	1.52e-06	0.000521	-0.32	-0.26	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
LIHC	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-4.9	1.52e-06	0.000521	-0.32	-0.26	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
LIHC	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-4.9	1.52e-06	0.000521	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-4.9	1.52e-06	0.000521	-0.26	-0.26	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
LIHC	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-4.89	1.52e-06	0.000522	-0.32	-0.26	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
LIHC	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-4.89	1.52e-06	0.000522	-0.36	-0.26	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
LIHC	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-4.89	1.52e-06	0.000522	-0.36	-0.26	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
LIHC	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-4.89	1.52e-06	0.000522	-0.36	-0.26	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
LIHC	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-4.89	1.52e-06	0.000522	-0.36	-0.26	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
LIHC	cis	rs240993	0.809	rs11153277	ENSG00000271789.1	RP5-1112D6.7	-4.89	1.52e-06	0.000522	-0.26	-0.26	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111297126~111298510:+
LIHC	cis	rs1865760	0.964	rs9379802	ENSG00000216436.2	HIST1H2APS1	-4.89	1.52e-06	0.000523	-0.29	-0.26	Height;	chr6:25933670	chr6:25732497~25732827:+
LIHC	cis	rs734999	0.933	rs4648648	ENSG00000225931.3	RP3-395M20.7	4.89	1.52e-06	0.000523	0.28	0.26	Ulcerative colitis;	chr1:2581013	chr1:2566410~2569888:+
LIHC	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	4.89	1.52e-06	0.000523	0.29	0.26	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
LIHC	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-4.89	1.52e-06	0.000523	-0.35	-0.26	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
LIHC	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-4.89	1.52e-06	0.000523	-0.35	-0.26	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
LIHC	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-4.89	1.52e-06	0.000523	-0.35	-0.26	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
LIHC	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-4.89	1.52e-06	0.000523	-0.35	-0.26	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
LIHC	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-4.89	1.52e-06	0.000523	-0.35	-0.26	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
LIHC	cis	rs2439831	1	rs2253708	ENSG00000205771.5	CATSPER2P1	-4.89	1.53e-06	0.000524	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43505075	chr15:43726918~43747094:-
LIHC	cis	rs752590	0.806	rs874898	ENSG00000189223.12	PAX8-AS1	-4.89	1.53e-06	0.000524	-0.35	-0.26	Mucinous ovarian carcinoma;	chr2:113216619	chr2:113211522~113276581:+
LIHC	cis	rs734999	0.967	rs4486391	ENSG00000225931.3	RP3-395M20.7	4.89	1.53e-06	0.000525	0.28	0.26	Ulcerative colitis;	chr1:2581616	chr1:2566410~2569888:+
LIHC	cis	rs1729407	0.774	rs2849167	ENSG00000236267.1	AP006216.5	-4.89	1.53e-06	0.000526	-0.25	-0.26	Apolipoprotein A-IV levels;	chr11:116814028	chr11:116813204~116814003:-
LIHC	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	4.89	1.53e-06	0.000527	0.35	0.26	Height;	chr6:109415050	chr6:109382795~109383666:+
LIHC	cis	rs10833905	0.756	rs11026870	ENSG00000246225.5	RP11-17A1.3	-4.89	1.53e-06	0.000527	-0.33	-0.26	Sudden cardiac arrest;	chr11:22973501	chr11:22829380~22945393:+
LIHC	cis	rs10833905	0.756	rs2303514	ENSG00000246225.5	RP11-17A1.3	-4.89	1.54e-06	0.000527	-0.34	-0.26	Sudden cardiac arrest;	chr11:22983988	chr11:22829380~22945393:+
LIHC	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-4.89	1.54e-06	0.000529	-0.32	-0.26	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
LIHC	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	4.89	1.55e-06	0.00053	0.44	0.26	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
LIHC	cis	rs4356203	0.519	rs214097	ENSG00000272034.1	SNORD14A	-4.89	1.55e-06	0.00053	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17074654~17074744:-
LIHC	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-4.89	1.55e-06	0.00053	-0.36	-0.26	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
LIHC	cis	rs2929278	0.561	rs2927071	ENSG00000166763.7	STRCP1	4.89	1.55e-06	0.00053	0.33	0.26	Schizophrenia;	chr15:43626883	chr15:43699488~43718184:-
LIHC	cis	rs5769765	0.908	rs138864	ENSG00000278869.1	CITF22-49E9.3	4.89	1.55e-06	0.000531	0.41	0.26	Schizophrenia;	chr22:49811064	chr22:49933198~49934074:-
LIHC	cis	rs3824488	0.599	rs16909859	ENSG00000237857.2	RP11-435O5.2	-4.89	1.55e-06	0.000531	-0.34	-0.26	Neuroticism;	chr9:95442510	chr9:95414834~95426796:-
LIHC	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	4.89	1.55e-06	0.000532	0.27	0.26	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	4.89	1.55e-06	0.000532	0.27	0.26	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
LIHC	cis	rs2032366	0.63	rs1377172	ENSG00000267279.1	RP11-879F14.2	-4.89	1.55e-06	0.000533	-0.31	-0.26	Obesity-related traits;	chr18:61629148	chr18:61585746~61606916:-
LIHC	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	4.89	1.55e-06	0.000533	0.34	0.26	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
LIHC	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-4.89	1.55e-06	0.000533	-0.34	-0.26	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
LIHC	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-4.89	1.56e-06	0.000534	-0.33	-0.26	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
LIHC	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-4.89	1.56e-06	0.000535	-0.27	-0.26	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-4.89	1.56e-06	0.000535	-0.27	-0.26	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
LIHC	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	4.89	1.56e-06	0.000535	0.18	0.26	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
LIHC	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	4.89	1.56e-06	0.000535	0.31	0.26	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
LIHC	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-4.89	1.56e-06	0.000536	-0.38	-0.26	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
LIHC	cis	rs1065852	0.526	rs2097561	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.57e-06	0.000536	-0.35	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993427	chr22:42090931~42137742:+
LIHC	cis	rs1065852	0.526	rs2097562	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.57e-06	0.000536	-0.35	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993496	chr22:42090931~42137742:+
LIHC	cis	rs1065852	0.526	rs7290907	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.57e-06	0.000536	-0.35	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994205	chr22:42090931~42137742:+
LIHC	cis	rs1065852	0.526	rs7290655	ENSG00000237037.8	NDUFA6-AS1	-4.89	1.57e-06	0.000536	-0.35	-0.26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994221	chr22:42090931~42137742:+
LIHC	cis	rs12701220	0.847	rs10272002	ENSG00000229043.2	AC091729.9	-4.89	1.57e-06	0.000536	-0.36	-0.26	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1160374~1165267:+
LIHC	cis	rs643506	0.817	rs610437	ENSG00000254990.4	RP11-108O10.2	4.89	1.57e-06	0.000537	0.27	0.26	Breast cancer;	chr11:111825716	chr11:111768668~111778350:-
LIHC	cis	rs1030877	0.515	rs1866038	ENSG00000235319.1	AC012360.4	-4.89	1.57e-06	0.000537	-0.35	-0.26	Obesity-related traits;	chr2:105262065	chr2:105324210~105330529:+
LIHC	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-4.89	1.57e-06	0.000537	-0.36	-0.26	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
LIHC	cis	rs4650994	0.525	rs4993304	ENSG00000273384.1	RP5-1098D14.1	4.89	1.57e-06	0.000537	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178566009	chr1:178651706~178652282:+
LIHC	cis	rs17826219	0.561	rs11655876	ENSG00000266490.1	CTD-2349P21.9	4.89	1.57e-06	0.000538	0.3	0.26	Body mass index;	chr17:30690132	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9907197	ENSG00000266490.1	CTD-2349P21.9	4.89	1.57e-06	0.000538	0.3	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9915963	ENSG00000266490.1	CTD-2349P21.9	4.89	1.57e-06	0.000538	0.3	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30792372~30792833:+
LIHC	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	4.89	1.57e-06	0.000538	0.29	0.26	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
LIHC	cis	rs2836974	0.627	rs8127986	ENSG00000255568.3	BRWD1-AS2	-4.89	1.57e-06	0.000539	-0.21	-0.26	Cognitive function;	chr21:39315285	chr21:39313935~39314962:+
LIHC	cis	rs7568498	0.564	rs10490563	ENSG00000227403.1	AC009299.3	4.89	1.57e-06	0.000539	0.33	0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161244739~161249050:+
LIHC	cis	rs7568498	0.564	rs9287807	ENSG00000227403.1	AC009299.3	4.89	1.57e-06	0.000539	0.33	0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161244739~161249050:+
LIHC	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-4.89	1.57e-06	0.000539	-0.26	-0.26	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
LIHC	cis	rs2836974	0.644	rs2410123	ENSG00000255568.3	BRWD1-AS2	-4.89	1.58e-06	0.000539	-0.21	-0.26	Cognitive function;	chr21:39328167	chr21:39313935~39314962:+
LIHC	cis	rs16858210	0.657	rs73177515	ENSG00000234371.6	RPSAP31	4.89	1.58e-06	0.00054	0.34	0.26	Menopause (age at onset);	chr3:183849037	chr3:183884924~183888449:+
LIHC	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-4.89	1.58e-06	0.00054	-0.23	-0.26	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-4.89	1.58e-06	0.00054	-0.23	-0.26	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
LIHC	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	4.89	1.58e-06	0.00054	0.31	0.26	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
LIHC	cis	rs2735413	0.75	rs76833828	ENSG00000276007.1	RP11-358L22.3	4.89	1.58e-06	0.000541	0.34	0.26	Systolic blood pressure (alcohol consumption interaction);	chr16:78037098	chr16:78123243~78124332:+
LIHC	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	4.89	1.58e-06	0.000542	0.26	0.26	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
LIHC	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-4.89	1.58e-06	0.000542	-0.35	-0.26	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
LIHC	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	4.89	1.59e-06	0.000542	0.3	0.26	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
LIHC	cis	rs950169	0.58	rs11634320	ENSG00000259295.5	CSPG4P12	-4.89	1.59e-06	0.000543	-0.34	-0.26	Schizophrenia;	chr15:84628952	chr15:85191438~85213905:+
LIHC	cis	rs4650994	0.525	rs2224811	ENSG00000273384.1	RP5-1098D14.1	-4.89	1.59e-06	0.000543	-0.32	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178575188	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.525	rs2493858	ENSG00000273384.1	RP5-1098D14.1	4.89	1.59e-06	0.000543	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178572075	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.525	rs2493860	ENSG00000273384.1	RP5-1098D14.1	4.89	1.59e-06	0.000543	0.32	0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178572357	chr1:178651706~178652282:+
LIHC	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	4.89	1.59e-06	0.000543	0.36	0.26	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
LIHC	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-4.89	1.59e-06	0.000543	-0.23	-0.26	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
LIHC	cis	rs57502260	0.915	rs7106320	ENSG00000212093.1	AP000807.1	4.89	1.59e-06	0.000543	0.33	0.26	Total body bone mineral density (age 45-60);	chr11:68442650	chr11:68506083~68506166:-
LIHC	cis	rs57502260	0.915	rs75202638	ENSG00000212093.1	AP000807.1	4.89	1.59e-06	0.000543	0.33	0.26	Total body bone mineral density (age 45-60);	chr11:68442953	chr11:68506083~68506166:-
LIHC	cis	rs916888	0.61	rs199436	ENSG00000260075.1	NSFP1	-4.89	1.59e-06	0.000543	-0.31	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46372855~46487141:+
LIHC	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	4.89	1.59e-06	0.000544	0.28	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
LIHC	cis	rs11217036	1	rs11217036	ENSG00000255239.1	AP002954.6	-4.89	1.59e-06	0.000544	-0.37	-0.26	Allergy;	chr11:118805063	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.774	rs11217038	ENSG00000255239.1	AP002954.6	-4.89	1.59e-06	0.000544	-0.37	-0.26	Sjögren's syndrome;	chr11:118806646	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.731	rs28409215	ENSG00000255239.1	AP002954.6	-4.89	1.59e-06	0.000544	-0.37	-0.26	Sjögren's syndrome;	chr11:118808595	chr11:118688039~118690600:-
LIHC	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	4.88	1.59e-06	0.000545	0.35	0.26	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
LIHC	cis	rs4356203	0.543	rs214081	ENSG00000272034.1	SNORD14A	-4.88	1.59e-06	0.000545	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17074654~17074744:-
LIHC	cis	rs16858210	0.874	rs73177525	ENSG00000234371.6	RPSAP31	4.88	1.6e-06	0.000545	0.33	0.26	Menopause (age at onset);	chr3:183852498	chr3:183884924~183888449:+
LIHC	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	4.88	1.6e-06	0.000545	0.18	0.26	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	4.88	1.6e-06	0.000545	0.18	0.26	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	4.88	1.6e-06	0.000545	0.18	0.26	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
LIHC	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	4.88	1.6e-06	0.000546	0.38	0.26	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
LIHC	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	4.88	1.6e-06	0.000546	0.3	0.26	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	4.88	1.6e-06	0.000546	0.3	0.26	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	4.88	1.6e-06	0.000546	0.3	0.26	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	4.88	1.6e-06	0.000546	0.3	0.26	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	4.88	1.6e-06	0.000546	0.3	0.26	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
LIHC	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	4.88	1.6e-06	0.000546	0.3	0.26	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
LIHC	cis	rs4650994	0.525	rs2811295	ENSG00000273384.1	RP5-1098D14.1	-4.88	1.6e-06	0.000547	-0.31	-0.26	HDL cholesterol;HDL cholesterol levels;	chr1:178582132	chr1:178651706~178652282:+
LIHC	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	4.88	1.6e-06	0.000547	0.49	0.26	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
LIHC	cis	rs4356203	0.543	rs214088	ENSG00000272034.1	SNORD14A	-4.88	1.6e-06	0.000547	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.519	rs214084	ENSG00000272034.1	SNORD14A	-4.88	1.6e-06	0.000547	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17074654~17074744:-
LIHC	cis	rs4356203	0.519	rs214082	ENSG00000272034.1	SNORD14A	-4.88	1.6e-06	0.000547	-0.28	-0.26	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17074654~17074744:-
LIHC	cis	rs9992667	0.955	rs9998440	ENSG00000231160.8	KLF3-AS1	-4.88	1.6e-06	0.000547	-0.34	-0.26	Eosinophil percentage of granulocytes;	chr4:38606180	chr4:38612701~38664883:-
LIHC	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	4.88	1.6e-06	0.000547	0.2	0.26	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
LIHC	cis	rs6480314	0.542	rs61854809	ENSG00000233590.1	RP11-153K11.3	-4.88	1.6e-06	0.000547	-0.39	-0.26	Optic nerve measurement (disc area);	chr10:68262847	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs61854810	ENSG00000233590.1	RP11-153K11.3	-4.88	1.6e-06	0.000547	-0.39	-0.26	Optic nerve measurement (disc area);	chr10:68264139	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs61854811	ENSG00000233590.1	RP11-153K11.3	-4.88	1.6e-06	0.000547	-0.39	-0.26	Optic nerve measurement (disc area);	chr10:68264474	chr10:68233251~68242379:-
LIHC	cis	rs9291683	0.509	rs6849717	ENSG00000250413.1	RP11-448G15.1	4.88	1.6e-06	0.000548	0.33	0.26	Bone mineral density;	chr4:9957095	chr4:10006482~10009725:+
LIHC	cis	rs1577917	0.883	rs12214536	ENSG00000234155.1	RP11-30P6.6	4.88	1.6e-06	0.000548	0.31	0.26	Response to antipsychotic treatment;	chr6:86080592	chr6:85387219~85390186:-
LIHC	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-4.88	1.61e-06	0.000548	-0.39	-0.26	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
LIHC	cis	rs6828577	0.817	rs298996	ENSG00000269893.5	SNHG8	4.88	1.61e-06	0.000549	0.26	0.26	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118703590	chr4:118278709~118279823:+
LIHC	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-4.88	1.61e-06	0.000549	-0.32	-0.26	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
LIHC	cis	rs1577917	0.958	rs13213551	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85898983	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.876	rs12201992	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85908501	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12201880	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85917289	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs7756203	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85917989	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs10944161	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85920658	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1857965	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85921058	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs34622557	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85921134	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1911553	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85921174	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs7771342	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85922218	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1995688	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85922601	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12154056	ENSG00000234155.1	RP11-30P6.6	4.88	1.61e-06	0.000549	0.33	0.26	Response to antipsychotic treatment;	chr6:85924376	chr6:85387219~85390186:-
LIHC	cis	rs11098499	0.954	rs10006525	ENSG00000260091.1	RP11-33B1.4	-4.88	1.61e-06	0.000549	-0.18	-0.26	Corneal astigmatism;	chr4:119487776	chr4:119409333~119410233:+
LIHC	cis	rs6480314	0.522	rs10733841	ENSG00000233590.1	RP11-153K11.3	4.88	1.61e-06	0.000549	0.4	0.26	Optic nerve measurement (disc area);	chr10:68293520	chr10:68233251~68242379:-
LIHC	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-4.88	1.61e-06	0.00055	-0.3	-0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
LIHC	cis	rs5758511	0.68	rs5758692	ENSG00000205702.9	CYP2D7	4.88	1.61e-06	0.00055	0.31	0.26	Birth weight;	chr22:42273023	chr22:42140203~42144577:-
LIHC	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-4.88	1.62e-06	0.000551	-0.28	-0.26	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
LIHC	cis	rs11098499	0.954	rs6849171	ENSG00000260091.1	RP11-33B1.4	-4.88	1.62e-06	0.000551	-0.18	-0.26	Corneal astigmatism;	chr4:119488394	chr4:119409333~119410233:+
LIHC	cis	rs5756813	0.782	rs3171656	ENSG00000233360.4	Z83844.1	4.88	1.62e-06	0.000552	0.33	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37776206	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.754	rs15691	ENSG00000233360.4	Z83844.1	4.88	1.62e-06	0.000552	0.33	0.26	Optic cup area;Vertical cup-disc ratio;	chr22:37776373	chr22:37641832~37658377:-
LIHC	cis	rs73193808	0.614	rs9976839	ENSG00000224649.1	AF124730.4	4.88	1.62e-06	0.000552	0.3	0.26	Coronary artery disease;	chr21:29190389	chr21:29182027~29187795:-
LIHC	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-4.88	1.62e-06	0.000552	-0.28	-0.26	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
LIHC	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-4.88	1.62e-06	0.000553	-0.31	-0.26	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
LIHC	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	4.88	1.62e-06	0.000553	0.2	0.26	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
LIHC	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-4.88	1.63e-06	0.000553	-0.42	-0.26	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
LIHC	cis	rs1005277	0.579	rs1740732	ENSG00000276805.1	RP11-291L22.6	4.88	1.63e-06	0.000553	0.31	0.26	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38451030~38451785:+
LIHC	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	4.88	1.63e-06	0.000554	0.34	0.26	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	4.88	1.63e-06	0.000554	0.34	0.26	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
LIHC	cis	rs1577917	0.958	rs7747897	ENSG00000234155.1	RP11-30P6.6	4.88	1.63e-06	0.000554	0.33	0.26	Response to antipsychotic treatment;	chr6:85937631	chr6:85387219~85390186:-
LIHC	cis	rs202072	0.872	rs202045	ENSG00000215022.6	RP1-257A7.4	-4.88	1.63e-06	0.000554	-0.3	-0.26	HIV-1 viral setpoint;	chr6:13275682	chr6:13264861~13295586:-
LIHC	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	4.88	1.63e-06	0.000554	0.28	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
LIHC	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	4.88	1.63e-06	0.000554	0.23	0.26	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
LIHC	cis	rs875971	0.545	rs17138156	ENSG00000273142.1	RP11-458F8.4	4.88	1.63e-06	0.000555	0.24	0.26	Aortic root size;	chr7:66249708	chr7:66902857~66906297:+
LIHC	cis	rs1577917	0.958	rs36053156	ENSG00000234155.1	RP11-30P6.6	4.88	1.63e-06	0.000555	0.34	0.26	Response to antipsychotic treatment;	chr6:85865791	chr6:85387219~85390186:-
LIHC	cis	rs1865760	0.534	rs72834629	ENSG00000216436.2	HIST1H2APS1	-4.88	1.63e-06	0.000555	-0.34	-0.26	Height;	chr6:26022804	chr6:25732497~25732827:+
LIHC	cis	rs2439831	1	rs689754	ENSG00000205771.5	CATSPER2P1	-4.88	1.63e-06	0.000555	-0.35	-0.26	Lung cancer in ever smokers;	chr15:43483697	chr15:43726918~43747094:-
LIHC	cis	rs603446	0.967	rs180365	ENSG00000254851.1	RP11-109L13.1	-4.88	1.63e-06	0.000555	-0.31	-0.26	Triglycerides;	chr11:116725458	chr11:117135528~117138582:+
LIHC	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-4.88	1.63e-06	0.000556	-0.36	-0.26	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
LIHC	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-4.88	1.63e-06	0.000556	-0.36	-0.26	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
LIHC	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-4.88	1.63e-06	0.000556	-0.36	-0.26	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
LIHC	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-4.88	1.63e-06	0.000556	-0.36	-0.26	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
LIHC	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-4.88	1.64e-06	0.000556	-0.26	-0.26	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
LIHC	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-4.88	1.64e-06	0.000557	-0.31	-0.26	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
LIHC	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	4.88	1.64e-06	0.000557	0.33	0.26	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
LIHC	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	4.88	1.64e-06	0.000558	0.42	0.26	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
LIHC	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	4.88	1.64e-06	0.000558	0.3	0.26	Height;	chr6:109642186	chr6:109382795~109383666:+
LIHC	cis	rs6600671	1	rs1832558	ENSG00000231429.2	RP11-343N15.2	-4.88	1.64e-06	0.000558	-0.29	-0.26	Hip geometry;	chr1:121435521	chr1:121412719~121429274:+
LIHC	cis	rs6600671	0.967	rs11249349	ENSG00000231429.2	RP11-343N15.2	-4.88	1.64e-06	0.000558	-0.29	-0.26	Hip geometry;	chr1:121437310	chr1:121412719~121429274:+
LIHC	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	4.88	1.64e-06	0.000559	0.27	0.26	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
LIHC	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-4.88	1.64e-06	0.000559	-0.29	-0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
LIHC	cis	rs6085948	1	rs1033603	ENSG00000228888.1	LINC01428	4.88	1.65e-06	0.00056	0.34	0.26	Interleukin-10 levels;	chr20:7267540	chr20:7146467~7254202:-
LIHC	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	4.88	1.65e-06	0.00056	0.33	0.26	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
LIHC	cis	rs9834975	0.903	rs9873684	ENSG00000272758.4	RP11-299J3.8	-4.88	1.65e-06	0.00056	-0.28	-0.26	Diastolic blood pressure;	chr3:122386273	chr3:122416207~122443180:+
LIHC	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	4.88	1.65e-06	0.000561	0.38	0.26	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
LIHC	cis	rs227275	0.525	rs5028609	ENSG00000230069.3	LRRC37A15P	-4.88	1.65e-06	0.000561	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs6815540	ENSG00000230069.3	LRRC37A15P	-4.88	1.65e-06	0.000561	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs4698867	ENSG00000230069.3	LRRC37A15P	-4.88	1.65e-06	0.000561	-0.23	-0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102727274~102730721:-
LIHC	cis	rs755249	0.501	rs621807	ENSG00000182109.6	RP11-69E11.4	4.88	1.65e-06	0.000562	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39522280~39546187:-
LIHC	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	4.88	1.65e-06	0.000562	0.24	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
LIHC	cis	rs9425766	0.628	rs6425274	ENSG00000227373.4	RP11-160H22.5	4.88	1.65e-06	0.000562	0.31	0.25	Life satisfaction;	chr1:174144270	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.566	rs6696076	ENSG00000227373.4	RP11-160H22.5	4.88	1.65e-06	0.000562	0.31	0.25	Life satisfaction;	chr1:174149900	chr1:174115300~174160004:-
LIHC	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-4.88	1.65e-06	0.000562	-0.27	-0.25	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
LIHC	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	4.88	1.65e-06	0.000562	0.35	0.25	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
LIHC	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-4.88	1.66e-06	0.000563	-0.26	-0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
LIHC	cis	rs5769707	0.846	rs5770610	ENSG00000235111.1	RP1-29C18.8	-4.88	1.66e-06	0.000563	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49612657~49615716:-
LIHC	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-4.88	1.66e-06	0.000563	-0.43	-0.25	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
LIHC	cis	rs2998286	0.723	rs2772435	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28546534	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs2807759	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28548682	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332121	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28552285	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.572	rs332124	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28553545	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332126	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28556866	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332128	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28559399	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs231202	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28560111	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332131	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28564933	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.768	rs332137	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570050	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.768	rs332140	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570431	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332142	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575026	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332143	ENSG00000254635.4	WAC-AS1	-4.88	1.66e-06	0.000564	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575777	chr10:28522652~28532743:-
LIHC	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	4.88	1.66e-06	0.000564	0.31	0.25	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
LIHC	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	4.88	1.66e-06	0.000564	0.31	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
LIHC	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	4.88	1.66e-06	0.000564	0.18	0.25	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	4.88	1.66e-06	0.000564	0.18	0.25	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
LIHC	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-4.88	1.66e-06	0.000565	-0.33	-0.25	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
LIHC	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-4.88	1.66e-06	0.000565	-0.41	-0.25	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
LIHC	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	4.88	1.67e-06	0.000566	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
LIHC	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	4.88	1.67e-06	0.000566	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
LIHC	cis	rs7119038	0.818	rs11217032	ENSG00000255239.1	AP002954.6	-4.88	1.67e-06	0.000566	-0.36	-0.25	Sjögren's syndrome;	chr11:118798896	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.818	rs11217033	ENSG00000255239.1	AP002954.6	-4.88	1.67e-06	0.000566	-0.36	-0.25	Sjögren's syndrome;	chr11:118802997	chr11:118688039~118690600:-
LIHC	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-4.88	1.67e-06	0.000566	-0.27	-0.25	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
LIHC	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-4.88	1.67e-06	0.000566	-0.27	-0.25	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
LIHC	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-4.88	1.67e-06	0.000566	-0.36	-0.25	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
LIHC	cis	rs10975870	0.847	rs10975921	ENSG00000236924.1	RP11-390F4.6	-4.87	1.67e-06	0.000566	-0.31	-0.25	Body mass index;	chr9:6940115	chr9:6645956~6670635:+
LIHC	cis	rs7412746	0.658	rs12067685	ENSG00000231073.1	RP11-316M1.3	4.87	1.67e-06	0.000567	0.26	0.25	Melanoma;	chr1:150980441	chr1:150973123~150975534:+
LIHC	cis	rs2836974	0.644	rs2836982	ENSG00000255568.3	BRWD1-AS2	-4.87	1.67e-06	0.000567	-0.21	-0.25	Cognitive function;	chr21:39317245	chr21:39313935~39314962:+
LIHC	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-4.87	1.67e-06	0.000567	-0.46	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
LIHC	cis	rs3096299	0.933	rs2965824	ENSG00000261118.1	RP11-104N10.1	4.87	1.67e-06	0.000568	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89492017~89504460:-
LIHC	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-4.87	1.67e-06	0.000568	-0.27	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
LIHC	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	4.87	1.68e-06	0.000569	0.18	0.25	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
LIHC	cis	rs6600671	1	rs4844380	ENSG00000231429.2	RP11-343N15.2	-4.87	1.68e-06	0.000569	-0.29	-0.25	Hip geometry;	chr1:121451764	chr1:121412719~121429274:+
LIHC	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-4.87	1.68e-06	0.000569	-0.39	-0.25	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
LIHC	cis	rs73193808	0.639	rs2832237	ENSG00000224649.1	AF124730.4	4.87	1.68e-06	0.000569	0.3	0.25	Coronary artery disease;	chr21:29175362	chr21:29182027~29187795:-
LIHC	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-4.87	1.68e-06	0.000569	-0.38	-0.25	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
LIHC	cis	rs755249	1	rs61779359	ENSG00000182109.6	RP11-69E11.4	4.87	1.68e-06	0.00057	0.34	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.959	rs61781363	ENSG00000182109.6	RP11-69E11.4	4.87	1.68e-06	0.00057	0.34	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39522280~39546187:-
LIHC	cis	rs755249	1	rs4660808	ENSG00000182109.6	RP11-69E11.4	4.87	1.68e-06	0.00057	0.34	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39522280~39546187:-
LIHC	cis	rs755249	1	rs61781364	ENSG00000182109.6	RP11-69E11.4	4.87	1.68e-06	0.00057	0.34	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39522280~39546187:-
LIHC	cis	rs11089937	0.597	rs4145535	ENSG00000211639.2	IGLV4-60	4.87	1.68e-06	0.00057	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22162199~22162681:+
LIHC	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	4.87	1.68e-06	0.00057	0.29	0.25	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
LIHC	cis	rs4356203	0.87	rs10766381	ENSG00000272034.1	SNORD14A	-4.87	1.69e-06	0.000571	-0.28	-0.25	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17074654~17074744:-
LIHC	cis	rs17270561	0.779	rs12210620	ENSG00000272810.1	U91328.22	-4.87	1.69e-06	0.000571	-0.33	-0.25	Iron status biomarkers;	chr6:25884557	chr6:26013241~26013757:+
LIHC	cis	rs1005277	0.579	rs1621040	ENSG00000275858.1	RP11-291L22.8	4.87	1.69e-06	0.000572	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38450738~38451069:-
LIHC	cis	rs887829	0.57	rs7563561	ENSG00000233445.1	RPL17P11	4.87	1.69e-06	0.000572	0.26	0.25	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233690345	chr2:233721522~233722065:-
LIHC	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-4.87	1.69e-06	0.000572	-0.36	-0.25	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
LIHC	cis	rs8067287	0.688	rs11651187	ENSG00000205312.7	KRT17P4	4.87	1.69e-06	0.000572	0.39	0.25	Diabetic kidney disease;	chr17:16942088	chr17:16847635~16852777:-
LIHC	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-4.87	1.69e-06	0.000573	-0.27	-0.25	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-4.87	1.69e-06	0.000573	-0.27	-0.25	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-4.87	1.69e-06	0.000573	-0.27	-0.25	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-4.87	1.69e-06	0.000573	-0.27	-0.25	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
LIHC	cis	rs12554020	0.582	rs77133953	ENSG00000227603.1	RP11-165J3.6	4.87	1.69e-06	0.000573	0.48	0.25	Schizophrenia;	chr9:93635287	chr9:93435332~93437121:-
LIHC	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-4.87	1.69e-06	0.000574	-0.32	-0.25	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
LIHC	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	4.87	1.7e-06	0.000574	0.39	0.25	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	4.87	1.7e-06	0.000574	0.39	0.25	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
LIHC	cis	rs4660214	0.666	rs4660550	ENSG00000182109.6	RP11-69E11.4	-4.87	1.7e-06	0.000574	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39522280~39546187:-
LIHC	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	4.87	1.7e-06	0.000574	0.26	0.25	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
LIHC	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	4.87	1.7e-06	0.000575	0.32	0.25	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
LIHC	cis	rs5769707	0.967	rs9616327	ENSG00000235111.1	RP1-29C18.8	-4.87	1.7e-06	0.000575	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49612657~49615716:-
LIHC	cis	rs4650994	0.525	rs2493865	ENSG00000273384.1	RP5-1098D14.1	-4.87	1.7e-06	0.000576	-0.32	-0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178575881	chr1:178651706~178652282:+
LIHC	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	4.87	1.7e-06	0.000577	0.35	0.25	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
LIHC	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	4.87	1.71e-06	0.000578	0.41	0.25	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
LIHC	cis	rs6546886	0.536	rs828870	ENSG00000217702.2	RP11-287D1.4	-4.87	1.71e-06	0.000578	-0.3	-0.25	Dialysis-related mortality;	chr2:74095117	chr2:74130583~74135395:+
LIHC	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	4.87	1.71e-06	0.000579	0.37	0.25	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
LIHC	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-4.87	1.71e-06	0.000579	-0.33	-0.25	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
LIHC	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	4.87	1.71e-06	0.000579	0.18	0.25	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
LIHC	cis	rs10833905	1	rs12417226	ENSG00000246225.5	RP11-17A1.3	-4.87	1.71e-06	0.000579	-0.31	-0.25	Sudden cardiac arrest;	chr11:23017289	chr11:22829380~22945393:+
LIHC	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	4.87	1.72e-06	0.00058	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	4.87	1.72e-06	0.00058	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	4.87	1.72e-06	0.00058	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	4.87	1.72e-06	0.00058	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
LIHC	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	4.87	1.72e-06	0.00058	0.36	0.25	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
LIHC	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	4.87	1.72e-06	0.00058	0.32	0.25	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	4.87	1.72e-06	0.00058	0.32	0.25	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	4.87	1.72e-06	0.00058	0.32	0.25	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	4.87	1.72e-06	0.00058	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
LIHC	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-4.87	1.72e-06	0.000581	-0.27	-0.25	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
LIHC	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-4.87	1.72e-06	0.000581	-0.35	-0.25	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
LIHC	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-4.87	1.72e-06	0.000581	-0.28	-0.25	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
LIHC	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-4.87	1.72e-06	0.000582	-0.26	-0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
LIHC	cis	rs11098499	0.954	rs12502423	ENSG00000260091.1	RP11-33B1.4	-4.87	1.72e-06	0.000582	-0.18	-0.25	Corneal astigmatism;	chr4:119503017	chr4:119409333~119410233:+
LIHC	cis	rs6600671	0.902	rs2222371	ENSG00000231429.2	RP11-343N15.2	4.87	1.72e-06	0.000582	0.31	0.25	Hip geometry;	chr1:121547320	chr1:121412719~121429274:+
LIHC	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	4.87	1.72e-06	0.000582	0.26	0.25	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
LIHC	cis	rs9388451	1	rs9388451	ENSG00000237742.5	RP11-624M8.1	-4.87	1.73e-06	0.000583	-0.24	-0.25	Brugada syndrome;	chr6:125769231	chr6:125578558~125749190:-
LIHC	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	4.87	1.73e-06	0.000583	0.3	0.25	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
LIHC	cis	rs2439831	0.702	rs7171750	ENSG00000166763.7	STRCP1	4.87	1.73e-06	0.000583	0.39	0.25	Lung cancer in ever smokers;	chr15:43733660	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs11070408	ENSG00000166763.7	STRCP1	4.87	1.73e-06	0.000583	0.39	0.25	Lung cancer in ever smokers;	chr15:43742590	chr15:43699488~43718184:-
LIHC	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	4.87	1.73e-06	0.000584	0.43	0.25	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	4.87	1.73e-06	0.000584	0.43	0.25	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	4.87	1.73e-06	0.000584	0.43	0.25	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	4.87	1.73e-06	0.000584	0.43	0.25	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	4.87	1.73e-06	0.000584	0.43	0.25	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
LIHC	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	4.87	1.73e-06	0.000584	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	4.87	1.73e-06	0.000584	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	4.87	1.73e-06	0.000584	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	4.87	1.73e-06	0.000584	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
LIHC	cis	rs1023500	0.505	rs134878	ENSG00000227370.1	RP4-669P10.19	-4.87	1.73e-06	0.000584	-0.26	-0.25	Schizophrenia;	chr22:42267868	chr22:42132543~42132998:+
LIHC	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-4.87	1.73e-06	0.000584	-0.46	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
LIHC	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-4.87	1.73e-06	0.000584	-0.46	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
LIHC	cis	rs755249	0.508	rs624971	ENSG00000182109.6	RP11-69E11.4	4.87	1.73e-06	0.000585	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39522280~39546187:-
LIHC	cis	rs2836974	0.627	rs9981301	ENSG00000255568.3	BRWD1-AS2	-4.87	1.73e-06	0.000585	-0.21	-0.25	Cognitive function;	chr21:39314152	chr21:39313935~39314962:+
LIHC	cis	rs5769765	0.955	rs61136468	ENSG00000278869.1	CITF22-49E9.3	4.87	1.73e-06	0.000585	0.38	0.25	Schizophrenia;	chr22:49919031	chr22:49933198~49934074:-
LIHC	cis	rs2439831	1	rs2439831	ENSG00000205771.5	CATSPER2P1	-4.87	1.74e-06	0.000585	-0.34	-0.25	Lung cancer in ever smokers;	chr15:43492277	chr15:43726918~43747094:-
LIHC	cis	rs931127	0.554	rs3372	ENSG00000265874.1	MIR4489	4.87	1.74e-06	0.000586	0.38	0.25	Systemic lupus erythematosus;	chr11:65717747	chr11:65649192~65649253:+
LIHC	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-4.87	1.74e-06	0.000586	-0.34	-0.25	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-4.87	1.74e-06	0.000586	-0.34	-0.25	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-4.87	1.74e-06	0.000586	-0.34	-0.25	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
LIHC	cis	rs1865760	0.964	rs3799373	ENSG00000216436.2	HIST1H2APS1	-4.87	1.74e-06	0.000586	-0.28	-0.25	Height;	chr6:25928945	chr6:25732497~25732827:+
LIHC	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	4.87	1.74e-06	0.000587	0.29	0.25	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
LIHC	cis	rs875971	0.545	rs10950029	ENSG00000273142.1	RP11-458F8.4	4.87	1.74e-06	0.000587	0.24	0.25	Aortic root size;	chr7:66169334	chr7:66902857~66906297:+
LIHC	cis	rs1577917	0.958	rs67024565	ENSG00000234155.1	RP11-30P6.6	4.87	1.74e-06	0.000587	0.34	0.25	Response to antipsychotic treatment;	chr6:85844279	chr6:85387219~85390186:-
LIHC	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	4.87	1.74e-06	0.000587	0.34	0.25	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	4.87	1.74e-06	0.000587	0.34	0.25	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
LIHC	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	4.87	1.74e-06	0.000587	0.35	0.25	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
LIHC	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-4.87	1.74e-06	0.000587	-0.35	-0.25	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
LIHC	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-4.87	1.74e-06	0.000587	-0.35	-0.25	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
LIHC	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	4.87	1.74e-06	0.000587	0.28	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
LIHC	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	4.87	1.74e-06	0.000587	0.28	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
LIHC	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-4.87	1.74e-06	0.000588	-0.34	-0.25	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
LIHC	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	4.87	1.75e-06	0.000588	0.31	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
LIHC	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	4.87	1.75e-06	0.000588	0.31	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
LIHC	cis	rs9595908	1	rs7999125	ENSG00000212293.1	SNORA16	4.87	1.75e-06	0.000589	0.3	0.25	Body mass index;	chr13:32571858	chr13:32420390~32420516:-
LIHC	cis	rs9291683	0.53	rs11723591	ENSG00000250413.1	RP11-448G15.1	-4.87	1.75e-06	0.000589	-0.34	-0.25	Bone mineral density;	chr4:9983774	chr4:10006482~10009725:+
LIHC	cis	rs494453	0.883	rs474722	ENSG00000227811.2	FAM212B-AS1	-4.87	1.75e-06	0.00059	-0.29	-0.25	Osteoporosis-related phenotypes;	chr1:111674356	chr1:111739841~111747798:+
LIHC	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	4.86	1.75e-06	0.00059	0.29	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	4.86	1.75e-06	0.00059	0.29	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
LIHC	cis	rs916888	0.821	rs199504	ENSG00000274883.1	Metazoa_SRP	4.86	1.75e-06	0.00059	0.4	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45931806~45932083:+
LIHC	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	4.86	1.75e-06	0.00059	0.36	0.25	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
LIHC	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	4.86	1.75e-06	0.00059	0.36	0.25	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
LIHC	cis	rs10510102	0.872	rs10887032	ENSG00000226864.1	ATE1-AS1	-4.86	1.75e-06	0.00059	-0.42	-0.25	Breast cancer;	chr10:121955887	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12246693	ENSG00000226864.1	ATE1-AS1	4.86	1.75e-06	0.00059	0.42	0.25	Breast cancer;	chr10:121957373	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12248806	ENSG00000226864.1	ATE1-AS1	4.86	1.75e-06	0.00059	0.42	0.25	Breast cancer;	chr10:121958638	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12255832	ENSG00000226864.1	ATE1-AS1	4.86	1.75e-06	0.00059	0.42	0.25	Breast cancer;	chr10:121958762	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12247367	ENSG00000226864.1	ATE1-AS1	4.86	1.75e-06	0.00059	0.42	0.25	Breast cancer;	chr10:121961556	chr10:121928312~121951965:+
LIHC	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	4.86	1.75e-06	0.00059	0.4	0.25	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
LIHC	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-4.86	1.75e-06	0.00059	-0.26	-0.25	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
LIHC	cis	rs10833905	0.756	rs78740029	ENSG00000246225.5	RP11-17A1.3	-4.86	1.75e-06	0.00059	-0.33	-0.25	Sudden cardiac arrest;	chr11:22977330	chr11:22829380~22945393:+
LIHC	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	4.86	1.75e-06	0.000591	0.3	0.25	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
LIHC	cis	rs1865760	1	rs9348698	ENSG00000216436.2	HIST1H2APS1	-4.86	1.76e-06	0.000591	-0.28	-0.25	Height;	chr6:25929461	chr6:25732497~25732827:+
LIHC	cis	rs6480314	0.522	rs2120900	ENSG00000233590.1	RP11-153K11.3	4.86	1.76e-06	0.000591	0.4	0.25	Optic nerve measurement (disc area);	chr10:68296052	chr10:68233251~68242379:-
LIHC	cis	rs7760535	0.656	rs1883136	ENSG00000255389.1	C6orf3	-4.86	1.76e-06	0.000591	-0.24	-0.25	Metabolic traits;	chr6:111585820	chr6:111599875~111602295:+
LIHC	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-4.86	1.76e-06	0.000591	-0.26	-0.25	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
LIHC	cis	rs2877649	1	rs737246	ENSG00000258744.1	RP11-80A15.1	-4.86	1.76e-06	0.000591	-0.5	-0.25	Smooth-surface caries;	chr14:24458107	chr14:24501594~24508688:+
LIHC	cis	rs529413	0.61	rs566855	ENSG00000259237.1	RP11-209E8.1	4.86	1.76e-06	0.000591	0.33	0.25	Itch intensity from mosquito bite adjusted by bite size;	chr15:53205097	chr15:53116365~53129698:+
LIHC	cis	rs1865760	1	rs9393675	ENSG00000216436.2	HIST1H2APS1	-4.86	1.76e-06	0.000592	-0.28	-0.25	Height;	chr6:25929888	chr6:25732497~25732827:+
LIHC	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	4.86	1.76e-06	0.000592	0.3	0.25	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
LIHC	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	4.86	1.76e-06	0.000592	0.36	0.25	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
LIHC	cis	rs755249	0.508	rs12023553	ENSG00000182109.6	RP11-69E11.4	-4.86	1.76e-06	0.000592	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39522280~39546187:-
LIHC	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	4.86	1.76e-06	0.000592	0.19	0.25	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
LIHC	cis	rs1865760	0.786	rs1436308	ENSG00000216436.2	HIST1H2APS1	-4.86	1.76e-06	0.000593	-0.29	-0.25	Height;	chr6:25939339	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.929	rs1436307	ENSG00000216436.2	HIST1H2APS1	-4.86	1.76e-06	0.000593	-0.29	-0.25	Height;	chr6:25939495	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.892	rs9379806	ENSG00000216436.2	HIST1H2APS1	-4.86	1.76e-06	0.000593	-0.29	-0.25	Height;	chr6:25940730	chr6:25732497~25732827:+
LIHC	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	4.86	1.76e-06	0.000593	0.29	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
LIHC	cis	rs1865760	0.929	rs1816546	ENSG00000216436.2	HIST1H2APS1	-4.86	1.76e-06	0.000593	-0.29	-0.25	Height;	chr6:25938024	chr6:25732497~25732827:+
LIHC	cis	rs202072	0.72	rs4602719	ENSG00000215022.6	RP1-257A7.4	-4.86	1.76e-06	0.000593	-0.29	-0.25	HIV-1 viral setpoint;	chr6:13295270	chr6:13264861~13295586:-
LIHC	cis	rs9595908	0.965	rs7335710	ENSG00000212293.1	SNORA16	4.86	1.77e-06	0.000593	0.3	0.25	Body mass index;	chr13:32561287	chr13:32420390~32420516:-
LIHC	cis	rs11971779	0.616	rs6967932	ENSG00000273391.1	RP11-634H22.1	4.86	1.77e-06	0.000593	0.23	0.25	Diisocyanate-induced asthma;	chr7:139337635	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	4.86	1.77e-06	0.000593	0.23	0.25	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
LIHC	cis	rs2836950	0.501	rs2070865	ENSG00000255568.3	BRWD1-AS2	-4.86	1.77e-06	0.000595	-0.21	-0.25	Menarche (age at onset);	chr21:39343593	chr21:39313935~39314962:+
LIHC	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-4.86	1.77e-06	0.000595	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.935	rs9616332	ENSG00000235111.1	RP1-29C18.8	-4.86	1.77e-06	0.000595	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49612657~49615716:-
LIHC	cis	rs5769765	0.908	rs56351880	ENSG00000278869.1	CITF22-49E9.3	4.86	1.77e-06	0.000596	0.4	0.25	Schizophrenia;	chr22:49922949	chr22:49933198~49934074:-
LIHC	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	4.86	1.77e-06	0.000596	0.32	0.25	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
LIHC	cis	rs72627509	0.68	rs3733309	ENSG00000269949.1	RP11-738E22.3	4.86	1.78e-06	0.000596	0.35	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56991022	chr4:56960927~56961373:-
LIHC	cis	rs7811142	0.945	rs6974282	ENSG00000242294.5	STAG3L5P	4.86	1.78e-06	0.000596	0.31	0.25	Platelet count;	chr7:100500672	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.945	rs6978739	ENSG00000242294.5	STAG3L5P	4.86	1.78e-06	0.000596	0.31	0.25	Platelet count;	chr7:100501057	chr7:100336079~100351900:+
LIHC	cis	rs6480314	0.522	rs7902936	ENSG00000233590.1	RP11-153K11.3	4.86	1.78e-06	0.000596	0.4	0.25	Optic nerve measurement (disc area);	chr10:68299584	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.571	rs7903251	ENSG00000233590.1	RP11-153K11.3	4.86	1.78e-06	0.000596	0.4	0.25	Optic nerve measurement (disc area);	chr10:68299969	chr10:68233251~68242379:-
LIHC	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-4.86	1.78e-06	0.000597	-0.45	-0.25	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
LIHC	cis	rs17301013	0.932	rs7555533	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000597	0.31	0.25	Systemic lupus erythematosus;	chr1:174589983	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.861	rs6672148	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000597	0.31	0.25	Systemic lupus erythematosus;	chr1:174604016	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs10912813	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000597	0.31	0.25	Systemic lupus erythematosus;	chr1:174607342	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs67967476	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000597	0.31	0.25	Systemic lupus erythematosus;	chr1:174616119	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs6683602	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000597	0.31	0.25	Systemic lupus erythematosus;	chr1:174617615	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs6696197	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000597	0.31	0.25	Systemic lupus erythematosus;	chr1:174617860	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.612	rs56199565	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000598	0.31	0.25	Systemic lupus erythematosus;	chr1:174640992	chr1:174115300~174160004:-
LIHC	cis	rs1247318	1	rs1247320	ENSG00000243831.1	RP1-81D8.4	4.86	1.78e-06	0.000598	0.35	0.25	Aging;	chr6:160912749	chr6:160666228~160676523:-
LIHC	cis	rs72627509	0.638	rs78272732	ENSG00000269949.1	RP11-738E22.3	4.86	1.78e-06	0.000598	0.35	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57004371	chr4:56960927~56961373:-
LIHC	cis	rs202072	0.72	rs1550526	ENSG00000215022.6	RP1-257A7.4	-4.86	1.78e-06	0.000598	-0.29	-0.25	HIV-1 viral setpoint;	chr6:13295283	chr6:13264861~13295586:-
LIHC	cis	rs10847980	0.623	rs28681105	ENSG00000256092.2	RP13-942N8.1	4.86	1.78e-06	0.000598	0.42	0.25	Adiponectin levels;	chr12:123390978	chr12:123363868~123366113:+
LIHC	cis	rs10847980	0.623	rs28501453	ENSG00000256092.2	RP13-942N8.1	4.86	1.78e-06	0.000598	0.42	0.25	Adiponectin levels;	chr12:123392765	chr12:123363868~123366113:+
LIHC	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	4.86	1.78e-06	0.000599	0.31	0.25	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
LIHC	cis	rs9425766	0.679	rs6656188	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000599	0.31	0.25	Life satisfaction;	chr1:174183550	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs12087441	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000599	0.31	0.25	Life satisfaction;	chr1:174188696	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs4652237	ENSG00000227373.4	RP11-160H22.5	4.86	1.78e-06	0.000599	0.31	0.25	Life satisfaction;	chr1:174189718	chr1:174115300~174160004:-
LIHC	cis	rs4218	0.731	rs11539756	ENSG00000277144.1	RP11-59H7.4	-4.86	1.79e-06	0.000599	-0.29	-0.25	Social communication problems;	chr15:59136912	chr15:59115547~59116089:-
LIHC	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	4.86	1.79e-06	0.000599	0.18	0.25	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
LIHC	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	4.86	1.79e-06	0.000599	0.3	0.25	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
LIHC	cis	rs4731207	0.596	rs12540261	ENSG00000224897.5	POT1-AS1	4.86	1.79e-06	0.000599	0.3	0.25	Cutaneous malignant melanoma;	chr7:124946783	chr7:124929873~125179315:+
LIHC	cis	rs9890032	1	rs3764419	ENSG00000263531.1	RP13-753N3.1	4.86	1.79e-06	6e-04	0.31	0.25	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30863921~30864940:-
LIHC	cis	rs7412746	0.658	rs2272214	ENSG00000231073.1	RP11-316M1.3	4.86	1.79e-06	0.000601	0.25	0.25	Melanoma;	chr1:150958986	chr1:150973123~150975534:+
LIHC	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-4.86	1.79e-06	0.000601	-0.36	-0.25	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
LIHC	cis	rs61160187	0.51	rs4700393	ENSG00000272308.1	RP11-231G3.1	-4.86	1.79e-06	0.000601	-0.3	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60802440	chr5:60866457~60866935:-
LIHC	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-4.86	1.79e-06	0.000601	-0.34	-0.25	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
LIHC	cis	rs5769765	0.646	rs9616205	ENSG00000278869.1	CITF22-49E9.3	4.86	1.79e-06	0.000602	0.4	0.25	Schizophrenia;	chr22:49916267	chr22:49933198~49934074:-
LIHC	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	4.86	1.8e-06	0.000602	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	4.86	1.8e-06	0.000602	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
LIHC	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-4.86	1.8e-06	0.000602	-0.29	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
LIHC	cis	rs2836974	0.568	rs7282604	ENSG00000255568.3	BRWD1-AS2	-4.86	1.8e-06	0.000602	-0.22	-0.25	Cognitive function;	chr21:39164984	chr21:39313935~39314962:+
LIHC	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-4.86	1.8e-06	0.000602	-0.27	-0.25	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-4.86	1.8e-06	0.000602	-0.27	-0.25	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
LIHC	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	4.86	1.8e-06	0.000603	0.34	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
LIHC	cis	rs6085948	0.861	rs6085955	ENSG00000228888.1	LINC01428	-4.86	1.8e-06	0.000603	-0.44	-0.25	Interleukin-10 levels;	chr20:7258347	chr20:7146467~7254202:-
LIHC	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	4.86	1.8e-06	0.000603	0.34	0.25	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
LIHC	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-4.86	1.8e-06	0.000604	-0.33	-0.25	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
LIHC	cis	rs2877649	1	rs17104012	ENSG00000258744.1	RP11-80A15.1	4.86	1.8e-06	0.000604	0.53	0.25	Smooth-surface caries;	chr14:24461115	chr14:24501594~24508688:+
LIHC	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	4.86	1.8e-06	0.000604	0.35	0.25	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
LIHC	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	4.86	1.8e-06	0.000605	0.46	0.25	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
LIHC	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	4.86	1.81e-06	0.000605	0.36	0.25	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
LIHC	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-4.86	1.81e-06	0.000605	-0.32	-0.25	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
LIHC	cis	rs712039	0.652	rs853196	ENSG00000276054.1	RP11-378E13.3	4.86	1.81e-06	0.000605	0.31	0.25	Tuberculosis;	chr17:37488553	chr17:37386886~37387926:+
LIHC	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-4.86	1.81e-06	0.000605	-0.32	-0.25	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
LIHC	cis	rs2836974	0.966	rs2836977	ENSG00000255568.3	BRWD1-AS2	4.86	1.81e-06	0.000605	0.28	0.25	Cognitive function;	chr21:39294140	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.865	rs34778912	ENSG00000255568.3	BRWD1-AS2	4.86	1.81e-06	0.000605	0.28	0.25	Cognitive function;	chr21:39295111	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.865	rs7282624	ENSG00000255568.3	BRWD1-AS2	4.86	1.81e-06	0.000605	0.28	0.25	Cognitive function;	chr21:39295114	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.931	rs13625	ENSG00000255568.3	BRWD1-AS2	4.86	1.81e-06	0.000605	0.28	0.25	Cognitive function;	chr21:39297157	chr21:39313935~39314962:+
LIHC	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	4.86	1.81e-06	0.000606	0.31	0.25	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
LIHC	cis	rs9291683	0.53	rs4697698	ENSG00000250413.1	RP11-448G15.1	-4.86	1.81e-06	0.000606	-0.33	-0.25	Bone mineral density;	chr4:9940953	chr4:10006482~10009725:+
LIHC	cis	rs11722779	0.873	rs6533041	ENSG00000230069.3	LRRC37A15P	-4.86	1.81e-06	0.000607	-0.23	-0.25	Schizophrenia;	chr4:102951615	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs4699037	ENSG00000230069.3	LRRC37A15P	-4.86	1.81e-06	0.000607	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs3857198	ENSG00000230069.3	LRRC37A15P	-4.86	1.81e-06	0.000607	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.935	rs3857199	ENSG00000230069.3	LRRC37A15P	-4.86	1.81e-06	0.000607	-0.23	-0.25	Schizophrenia;	chr4:102957991	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs4699039	ENSG00000230069.3	LRRC37A15P	-4.86	1.81e-06	0.000607	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102727274~102730721:-
LIHC	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-4.86	1.81e-06	0.000607	-0.2	-0.25	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
LIHC	cis	rs4820294	0.516	rs12484441	ENSG00000233360.4	Z83844.1	4.86	1.81e-06	0.000608	0.37	0.25	Fat distribution (HIV);	chr22:37701352	chr22:37641832~37658377:-
LIHC	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	4.86	1.82e-06	0.000608	0.35	0.25	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
LIHC	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	4.86	1.82e-06	0.000608	0.36	0.25	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
LIHC	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-4.86	1.82e-06	0.000608	-0.27	-0.25	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
LIHC	cis	rs3096299	0.933	rs3096297	ENSG00000261118.1	RP11-104N10.1	4.86	1.82e-06	0.000608	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89492017~89504460:-
LIHC	cis	rs227275	0.525	rs6853193	ENSG00000230069.3	LRRC37A15P	-4.86	1.82e-06	0.000609	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102727274~102730721:-
LIHC	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	4.86	1.82e-06	0.000609	0.27	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
LIHC	cis	rs2797160	0.651	rs1269176	ENSG00000237742.5	RP11-624M8.1	-4.86	1.82e-06	0.000609	-0.25	-0.25	Endometrial cancer;	chr6:125708536	chr6:125578558~125749190:-
LIHC	cis	rs9467711	0.651	rs16891264	ENSG00000216436.2	HIST1H2APS1	-4.86	1.82e-06	0.00061	-0.69	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26072217	chr6:25732497~25732827:+
LIHC	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-4.86	1.82e-06	0.00061	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-4.86	1.82e-06	0.00061	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-4.86	1.82e-06	0.00061	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
LIHC	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-4.86	1.82e-06	0.00061	-0.32	-0.25	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-4.86	1.82e-06	0.00061	-0.32	-0.25	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
LIHC	cis	rs7412746	0.611	rs10888398	ENSG00000231073.1	RP11-316M1.3	-4.86	1.82e-06	0.00061	-0.25	-0.25	Melanoma;	chr1:150914306	chr1:150973123~150975534:+
LIHC	cis	rs10510102	0.872	rs7906271	ENSG00000226864.1	ATE1-AS1	-4.86	1.82e-06	0.00061	-0.42	-0.25	Breast cancer;	chr10:121948207	chr10:121928312~121951965:+
LIHC	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	4.86	1.82e-06	0.000611	0.3	0.25	Height;	chr6:109646187	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	4.86	1.82e-06	0.000611	0.3	0.25	Height;	chr6:109652694	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	4.86	1.82e-06	0.000611	0.3	0.25	Height;	chr6:109655791	chr6:109382795~109383666:+
LIHC	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-4.86	1.82e-06	0.000611	-0.28	-0.25	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
LIHC	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	4.86	1.82e-06	0.000611	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
LIHC	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	4.86	1.83e-06	0.000611	0.41	0.25	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
LIHC	cis	rs3096299	0.685	rs4329923	ENSG00000261118.1	RP11-104N10.1	4.86	1.83e-06	0.000611	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89492017~89504460:-
LIHC	cis	rs11672691	0.756	rs8107333	ENSG00000267107.5	PCAT19	4.86	1.83e-06	0.000611	0.3	0.25	Prostate cancer;	chr19:41481965	chr19:41454169~41500649:-
LIHC	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	4.86	1.83e-06	0.000612	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
LIHC	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-4.86	1.83e-06	0.000612	-0.32	-0.25	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
LIHC	cis	rs56205728	0.601	rs3784399	ENSG00000273855.1	RP11-133K1.12	-4.86	1.83e-06	0.000612	-0.35	-0.25	Schizophrenia;	chr15:40306093	chr15:40285468~40285909:-
LIHC	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-4.86	1.83e-06	0.000613	-0.26	-0.25	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
LIHC	cis	rs10256972	0.616	rs6463001	ENSG00000199023.2	MIR339	-4.86	1.83e-06	0.000613	-0.29	-0.25	Endometriosis;Longevity;	chr7:1068636	chr7:1022935~1023045:-
LIHC	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	4.86	1.83e-06	0.000613	0.28	0.25	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
LIHC	cis	rs16858210	0.874	rs34113436	ENSG00000234371.6	RPSAP31	4.85	1.84e-06	0.000615	0.33	0.25	Menopause (age at onset);	chr3:183856048	chr3:183884924~183888449:+
LIHC	cis	rs4660214	0.59	rs11205885	ENSG00000182109.6	RP11-69E11.4	-4.85	1.84e-06	0.000616	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39522280~39546187:-
LIHC	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-4.85	1.85e-06	0.000617	-0.36	-0.25	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-4.85	1.85e-06	0.000618	-0.24	-0.25	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
LIHC	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	4.85	1.85e-06	0.000618	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
LIHC	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	4.85	1.85e-06	0.000618	0.22	0.25	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
LIHC	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	4.85	1.85e-06	0.000618	0.18	0.25	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	4.85	1.85e-06	0.000618	0.18	0.25	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	4.85	1.85e-06	0.000618	0.18	0.25	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
LIHC	cis	rs1577917	1	rs6940458	ENSG00000234155.1	RP11-30P6.6	4.85	1.85e-06	0.000618	0.33	0.25	Response to antipsychotic treatment;	chr6:85935274	chr6:85387219~85390186:-
LIHC	cis	rs1865760	0.534	rs2032444	ENSG00000216436.2	HIST1H2APS1	-4.85	1.85e-06	0.000618	-0.34	-0.25	Height;	chr6:26046516	chr6:25732497~25732827:+
LIHC	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	4.85	1.85e-06	0.000618	0.29	0.25	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
LIHC	cis	rs17270561	0.779	rs17271767	ENSG00000272810.1	U91328.22	-4.85	1.85e-06	0.000619	-0.33	-0.25	Iron status biomarkers;	chr6:25886693	chr6:26013241~26013757:+
LIHC	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	4.85	1.86e-06	0.000619	0.48	0.25	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
LIHC	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-4.85	1.86e-06	0.000619	-0.3	-0.25	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
LIHC	cis	rs1005277	0.579	rs2103938	ENSG00000275858.1	RP11-291L22.8	4.85	1.86e-06	0.00062	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1780139	ENSG00000275858.1	RP11-291L22.8	4.85	1.86e-06	0.00062	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38450738~38451069:-
LIHC	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	4.85	1.86e-06	0.00062	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
LIHC	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	4.85	1.86e-06	0.000621	0.18	0.25	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
LIHC	cis	rs2877649	1	rs9323503	ENSG00000258744.1	RP11-80A15.1	-4.85	1.86e-06	0.000621	-0.49	-0.25	Smooth-surface caries;	chr14:24466389	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs57120899	ENSG00000258744.1	RP11-80A15.1	-4.85	1.86e-06	0.000621	-0.49	-0.25	Smooth-surface caries;	chr14:24467052	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs60777821	ENSG00000258744.1	RP11-80A15.1	-4.85	1.86e-06	0.000621	-0.49	-0.25	Smooth-surface caries;	chr14:24467107	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs10220332	ENSG00000258744.1	RP11-80A15.1	-4.85	1.86e-06	0.000621	-0.49	-0.25	Smooth-surface caries;	chr14:24468273	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs112410718	ENSG00000258744.1	RP11-80A15.1	-4.85	1.86e-06	0.000621	-0.49	-0.25	Smooth-surface caries;	chr14:24473350	chr14:24501594~24508688:+
LIHC	cis	rs2032447	0.677	rs199737	ENSG00000242387.1	HIST1H2APS2	4.85	1.86e-06	0.000621	0.33	0.25	Intelligence (multi-trait analysis);	chr6:25933310	chr6:25882026~25882395:-
LIHC	cis	rs202072	0.585	rs2119485	ENSG00000215022.6	RP1-257A7.4	4.85	1.86e-06	0.000621	0.27	0.25	HIV-1 viral setpoint;	chr6:13278030	chr6:13264861~13295586:-
LIHC	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	4.85	1.86e-06	0.000621	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
LIHC	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-4.85	1.86e-06	0.000622	-0.32	-0.25	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-4.85	1.86e-06	0.000622	-0.32	-0.25	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-4.85	1.86e-06	0.000622	-0.32	-0.25	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
LIHC	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	4.85	1.87e-06	0.000622	0.36	0.25	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
LIHC	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-4.85	1.87e-06	0.000622	-0.29	-0.25	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-4.85	1.87e-06	0.000622	-0.29	-0.25	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
LIHC	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-4.85	1.87e-06	0.000623	-0.39	-0.25	Depression;	chr6:28206812	chr6:28115628~28116551:+
LIHC	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	4.85	1.87e-06	0.000623	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
LIHC	cis	rs10829156	0.625	rs7082235	ENSG00000225527.1	RP11-383B4.4	-4.85	1.87e-06	0.000623	-0.4	-0.25	Sudden cardiac arrest;	chr10:18536765	chr10:18531849~18533336:-
LIHC	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	4.85	1.87e-06	0.000623	0.31	0.25	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	4.85	1.87e-06	0.000623	0.31	0.25	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	4.85	1.87e-06	0.000623	0.31	0.25	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
LIHC	cis	rs2877649	0.51	rs73593299	ENSG00000258744.1	RP11-80A15.1	-4.85	1.87e-06	0.000623	-0.46	-0.25	Smooth-surface caries;	chr14:24438440	chr14:24501594~24508688:+
LIHC	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-4.85	1.87e-06	0.000624	-0.4	-0.25	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
LIHC	cis	rs10975870	0.847	rs10815484	ENSG00000236924.1	RP11-390F4.6	-4.85	1.87e-06	0.000624	-0.31	-0.25	Body mass index;	chr9:6939403	chr9:6645956~6670635:+
LIHC	cis	rs10975870	0.847	rs10815485	ENSG00000236924.1	RP11-390F4.6	-4.85	1.87e-06	0.000624	-0.31	-0.25	Body mass index;	chr9:6939457	chr9:6645956~6670635:+
LIHC	cis	rs10975870	0.847	rs7862859	ENSG00000236924.1	RP11-390F4.6	-4.85	1.87e-06	0.000624	-0.31	-0.25	Body mass index;	chr9:6939866	chr9:6645956~6670635:+
LIHC	cis	rs2439831	0.85	rs7168158	ENSG00000166763.7	STRCP1	4.85	1.87e-06	0.000624	0.39	0.25	Lung cancer in ever smokers;	chr15:43758178	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs7174208	ENSG00000166763.7	STRCP1	4.85	1.87e-06	0.000624	0.39	0.25	Lung cancer in ever smokers;	chr15:43760484	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs12101756	ENSG00000166763.7	STRCP1	4.85	1.87e-06	0.000624	0.39	0.25	Lung cancer in ever smokers;	chr15:43761689	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs3862142	ENSG00000166763.7	STRCP1	4.85	1.87e-06	0.000624	0.39	0.25	Lung cancer in ever smokers;	chr15:43772608	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.702	rs2788	ENSG00000166763.7	STRCP1	4.85	1.87e-06	0.000624	0.39	0.25	Lung cancer in ever smokers;	chr15:43772688	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28891769	ENSG00000166763.7	STRCP1	4.85	1.87e-06	0.000624	0.39	0.25	Lung cancer in ever smokers;	chr15:43780662	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28578398	ENSG00000166763.7	STRCP1	4.85	1.87e-06	0.000624	0.39	0.25	Lung cancer in ever smokers;	chr15:43782848	chr15:43699488~43718184:-
LIHC	cis	rs35099186	0.583	rs10790800	ENSG00000255062.1	RP11-712L6.5	-4.85	1.87e-06	0.000624	-0.3	-0.25	Coronary artery disease;	chr11:126392743	chr11:126294298~126304318:-
LIHC	cis	rs6600671	1	rs1986111	ENSG00000231429.2	RP11-343N15.2	-4.85	1.88e-06	0.000625	-0.3	-0.25	Hip geometry;	chr1:121462934	chr1:121412719~121429274:+
LIHC	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	4.85	1.88e-06	0.000625	0.38	0.25	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	4.85	1.88e-06	0.000625	0.38	0.25	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	4.85	1.88e-06	0.000625	0.38	0.25	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	4.85	1.88e-06	0.000625	0.38	0.25	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	4.85	1.88e-06	0.000625	0.38	0.25	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	4.85	1.88e-06	0.000625	0.38	0.25	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	4.85	1.88e-06	0.000625	0.38	0.25	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
LIHC	cis	rs57502260	0.704	rs2306862	ENSG00000212093.1	AP000807.1	4.85	1.88e-06	0.000625	0.33	0.25	Total body bone mineral density (age 45-60);	chr11:68410042	chr11:68506083~68506166:-
LIHC	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-4.85	1.88e-06	0.000626	-0.29	-0.25	Height;	chr2:46635327	chr2:46668870~46670778:+
LIHC	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	4.85	1.88e-06	0.000626	0.29	0.25	Depression;	chr6:28240757	chr6:28943877~28944537:+
LIHC	cis	rs6445975	0.726	rs7639532	ENSG00000272360.1	RP11-359I18.5	4.85	1.88e-06	0.000627	0.29	0.25	Systemic lupus erythematosus;	chr3:58481929	chr3:58490830~58491291:-
LIHC	cis	rs1865760	1	rs7770139	ENSG00000216436.2	HIST1H2APS1	-4.85	1.88e-06	0.000627	-0.28	-0.25	Height;	chr6:25925595	chr6:25732497~25732827:+
LIHC	cis	rs893363	0.559	rs3774611	ENSG00000271916.1	RP11-884K10.6	-4.85	1.89e-06	0.000628	-0.31	-0.25	Axial length;	chr3:53806638	chr3:53797764~53798019:-
LIHC	cis	rs7119038	0.818	rs6589684	ENSG00000255239.1	AP002954.6	4.85	1.89e-06	0.000628	0.36	0.25	Sjögren's syndrome;	chr11:118740248	chr11:118688039~118690600:-
LIHC	cis	rs2834655	0.861	rs11700925	ENSG00000237945.6	LINC00649	-4.85	1.89e-06	0.000628	-0.45	-0.25	Immune response to smallpox vaccine (IL-6);	chr21:34865359	chr21:33915534~33977691:+
LIHC	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-4.85	1.89e-06	0.000628	-0.35	-0.25	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
LIHC	cis	rs6085948	0.861	rs6054849	ENSG00000228888.1	LINC01428	-4.85	1.89e-06	0.000628	-0.43	-0.25	Interleukin-10 levels;	chr20:7251460	chr20:7146467~7254202:-
LIHC	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	4.85	1.89e-06	0.000629	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
LIHC	cis	rs30380	0.506	rs469735	ENSG00000272109.1	CTD-2260A17.3	-4.85	1.89e-06	0.000629	-0.33	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96794311	chr5:96804353~96806105:+
LIHC	cis	rs5769765	1	rs2319458	ENSG00000278869.1	CITF22-49E9.3	4.85	1.89e-06	0.000629	0.39	0.25	Schizophrenia;	chr22:49842658	chr22:49933198~49934074:-
LIHC	cis	rs12478296	0.901	rs59191623	ENSG00000261186.2	RP11-341N2.1	-4.85	1.89e-06	0.000629	-0.34	-0.25	Obesity-related traits;	chr2:242086444	chr2:242087351~242088457:-
LIHC	cis	rs73193808	0.639	rs9984810	ENSG00000224649.1	AF124730.4	4.85	1.89e-06	0.00063	0.3	0.25	Coronary artery disease;	chr21:29181059	chr21:29182027~29187795:-
LIHC	cis	rs73193808	0.614	rs4817274	ENSG00000224649.1	AF124730.4	4.85	1.89e-06	0.00063	0.3	0.25	Coronary artery disease;	chr21:29181296	chr21:29182027~29187795:-
LIHC	cis	rs73193808	0.639	rs9976274	ENSG00000224649.1	AF124730.4	4.85	1.89e-06	0.00063	0.3	0.25	Coronary artery disease;	chr21:29181615	chr21:29182027~29187795:-
LIHC	cis	rs73193808	0.59	rs2832244	ENSG00000224649.1	AF124730.4	4.85	1.89e-06	0.00063	0.3	0.25	Coronary artery disease;	chr21:29181713	chr21:29182027~29187795:-
LIHC	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-4.85	1.89e-06	0.00063	-0.3	-0.25	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
LIHC	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	4.85	1.9e-06	0.000631	0.33	0.25	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
LIHC	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-4.85	1.9e-06	0.000631	-0.35	-0.25	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
LIHC	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	4.85	1.9e-06	0.000631	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
LIHC	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-4.85	1.9e-06	0.000631	-0.2	-0.25	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
LIHC	cis	rs116175783	0.557	rs16845770	ENSG00000227403.1	AC009299.3	4.85	1.9e-06	0.000631	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161325276	chr2:161244739~161249050:+
LIHC	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	4.85	1.9e-06	0.000632	0.31	0.25	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
LIHC	cis	rs734999	0.967	rs6667605	ENSG00000225931.3	RP3-395M20.7	4.85	1.9e-06	0.000633	0.28	0.25	Ulcerative colitis;	chr1:2571341	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.967	rs6672381	ENSG00000225931.3	RP3-395M20.7	4.85	1.9e-06	0.000633	0.28	0.25	Ulcerative colitis;	chr1:2571395	chr1:2566410~2569888:+
LIHC	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	4.85	1.9e-06	0.000633	0.2	0.25	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
LIHC	cis	rs1865760	0.929	rs2876693	ENSG00000216436.2	HIST1H2APS1	-4.85	1.9e-06	0.000633	-0.28	-0.25	Height;	chr6:25954206	chr6:25732497~25732827:+
LIHC	cis	rs2998286	0.54	rs332158	ENSG00000254635.4	WAC-AS1	-4.85	1.91e-06	0.000634	-0.33	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28595433	chr10:28522652~28532743:-
LIHC	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	4.85	1.91e-06	0.000634	0.31	0.25	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
LIHC	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	4.85	1.91e-06	0.000634	0.55	0.25	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
LIHC	cis	rs12478296	0.901	rs58906257	ENSG00000261186.2	RP11-341N2.1	-4.85	1.91e-06	0.000634	-0.34	-0.25	Obesity-related traits;	chr2:242086097	chr2:242087351~242088457:-
LIHC	cis	rs2836974	0.602	rs2037925	ENSG00000255568.3	BRWD1-AS2	-4.85	1.91e-06	0.000635	-0.21	-0.25	Cognitive function;	chr21:39328005	chr21:39313935~39314962:+
LIHC	cis	rs10129255	0.576	rs2157616	ENSG00000223648.3	IGHV3-64	4.85	1.91e-06	0.000635	0.18	0.25	Kawasaki disease;	chr14:106767802	chr14:106643132~106658258:-
LIHC	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	4.85	1.91e-06	0.000635	0.34	0.25	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
LIHC	cis	rs4934494	0.681	rs12572928	ENSG00000232936.4	RP11-80H5.2	4.85	1.91e-06	0.000636	0.33	0.25	Red blood cell count;	chr10:89793792	chr10:89645282~89650667:+
LIHC	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	4.85	1.92e-06	0.000637	0.24	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
LIHC	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-4.85	1.92e-06	0.000638	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
LIHC	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	4.85	1.92e-06	0.000639	0.18	0.25	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
LIHC	cis	rs17270561	0.779	rs78589800	ENSG00000272810.1	U91328.22	-4.84	1.92e-06	0.000639	-0.33	-0.25	Iron status biomarkers;	chr6:25883272	chr6:26013241~26013757:+
LIHC	cis	rs6421571	0.564	rs11216972	ENSG00000255239.1	AP002954.6	-4.84	1.92e-06	0.000639	-0.35	-0.25	Primary biliary cholangitis;	chr11:118715117	chr11:118688039~118690600:-
LIHC	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-4.84	1.93e-06	0.00064	-0.31	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
LIHC	cis	rs57502260	0.749	rs67446678	ENSG00000212093.1	AP000807.1	4.84	1.93e-06	0.000641	0.32	0.25	Total body bone mineral density (age 45-60);	chr11:68459998	chr11:68506083~68506166:-
LIHC	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-4.84	1.93e-06	0.000641	-0.32	-0.25	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
LIHC	cis	rs6901152	0.508	rs12527836	ENSG00000217648.1	RP1-95L4.4	4.84	1.93e-06	0.000642	0.29	0.25	Acute lymphoblastic leukemia (childhood);	chr6:143370306	chr6:143342246~143343383:+
LIHC	cis	rs3096299	0.967	rs11648663	ENSG00000261118.1	RP11-104N10.1	4.84	1.93e-06	0.000642	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89492017~89504460:-
LIHC	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-4.84	1.94e-06	0.000643	-0.26	-0.25	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
LIHC	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-4.84	1.94e-06	0.000643	-0.32	-0.25	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
LIHC	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	4.84	1.94e-06	0.000644	0.27	0.25	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
LIHC	cis	rs2717559	0.542	rs10956986	ENSG00000253196.1	RP11-706C16.7	-4.84	1.94e-06	0.000644	-0.27	-0.25	Urinary tract infection frequency;	chr8:142805185	chr8:142763116~142766427:+
LIHC	cis	rs5769765	0.908	rs138867	ENSG00000278869.1	CITF22-49E9.3	-4.84	1.94e-06	0.000644	-0.4	-0.25	Schizophrenia;	chr22:49814055	chr22:49933198~49934074:-
LIHC	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-4.84	1.94e-06	0.000644	-0.26	-0.25	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
LIHC	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	4.84	1.94e-06	0.000644	0.38	0.25	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
LIHC	cis	rs61041384	0.661	rs74240771	ENSG00000256092.2	RP13-942N8.1	-4.84	1.94e-06	0.000644	-0.4	-0.25	Schizophrenia;	chr12:123212416	chr12:123363868~123366113:+
LIHC	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-4.84	1.94e-06	0.000644	-0.31	-0.25	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-4.84	1.94e-06	0.000644	-0.31	-0.25	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
LIHC	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	4.84	1.94e-06	0.000645	0.27	0.25	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
LIHC	cis	rs11098499	0.954	rs10518328	ENSG00000260091.1	RP11-33B1.4	-4.84	1.95e-06	0.000645	-0.18	-0.25	Corneal astigmatism;	chr4:119480624	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs6822679	ENSG00000260091.1	RP11-33B1.4	-4.84	1.95e-06	0.000645	-0.18	-0.25	Corneal astigmatism;	chr4:119481547	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs4577559	ENSG00000260091.1	RP11-33B1.4	-4.84	1.95e-06	0.000645	-0.18	-0.25	Corneal astigmatism;	chr4:119482888	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs7656252	ENSG00000260091.1	RP11-33B1.4	-4.84	1.95e-06	0.000645	-0.18	-0.25	Corneal astigmatism;	chr4:119483113	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs28845498	ENSG00000260091.1	RP11-33B1.4	-4.84	1.95e-06	0.000645	-0.18	-0.25	Corneal astigmatism;	chr4:119484031	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs28753180	ENSG00000260091.1	RP11-33B1.4	-4.84	1.95e-06	0.000645	-0.18	-0.25	Corneal astigmatism;	chr4:119484212	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs56270433	ENSG00000260091.1	RP11-33B1.4	-4.84	1.95e-06	0.000645	-0.18	-0.25	Corneal astigmatism;	chr4:119484875	chr4:119409333~119410233:+
LIHC	cis	rs57502260	0.651	rs3781586	ENSG00000212093.1	AP000807.1	4.84	1.95e-06	0.000646	0.33	0.25	Total body bone mineral density (age 45-60);	chr11:68431925	chr11:68506083~68506166:-
LIHC	cis	rs1153858	1	rs4775911	ENSG00000259433.2	CTD-2651B20.4	4.84	1.95e-06	0.000647	0.34	0.25	Homoarginine levels;	chr15:45357589	chr15:45330209~45332634:-
LIHC	cis	rs79040073	0.53	rs1055254	ENSG00000259531.2	RP11-295H24.3	4.84	1.96e-06	0.000648	0.41	0.25	Lung cancer in ever smokers;	chr15:49328003	chr15:49365124~49366685:-
LIHC	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	4.84	1.96e-06	0.000648	0.41	0.25	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
LIHC	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	4.84	1.96e-06	0.000649	0.3	0.25	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
LIHC	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	4.84	1.96e-06	0.000649	0.3	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
LIHC	cis	rs227275	0.525	rs6533050	ENSG00000230069.3	LRRC37A15P	-4.84	1.96e-06	0.00065	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.525	rs10032234	ENSG00000230069.3	LRRC37A15P	-4.84	1.96e-06	0.00065	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs3886723	ENSG00000230069.3	LRRC37A15P	-4.84	1.96e-06	0.00065	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.517	rs3886722	ENSG00000230069.3	LRRC37A15P	-4.84	1.96e-06	0.00065	-0.23	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102727274~102730721:-
LIHC	cis	rs712039	0.617	rs60118041	ENSG00000276054.1	RP11-378E13.3	4.84	1.96e-06	0.00065	0.31	0.25	Tuberculosis;	chr17:37443151	chr17:37386886~37387926:+
LIHC	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-4.84	1.96e-06	0.000651	-0.3	-0.25	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
LIHC	cis	rs5769765	0.671	rs138844	ENSG00000278869.1	CITF22-49E9.3	4.84	1.97e-06	0.000652	0.38	0.25	Schizophrenia;	chr22:49790836	chr22:49933198~49934074:-
LIHC	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	4.84	1.97e-06	0.000652	0.38	0.25	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	4.84	1.97e-06	0.000652	0.38	0.25	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
LIHC	cis	rs11079159	0.585	rs8079998	ENSG00000263096.1	RP11-515O17.2	4.84	1.97e-06	0.000652	0.33	0.25	QRS duration;	chr17:55308138	chr17:55271504~55273653:-
LIHC	cis	rs2836974	0.666	rs4624474	ENSG00000255568.3	BRWD1-AS2	-4.84	1.97e-06	0.000652	-0.21	-0.25	Cognitive function;	chr21:39314401	chr21:39313935~39314962:+
LIHC	cis	rs17270561	0.779	rs12209218	ENSG00000272810.1	U91328.22	-4.84	1.97e-06	0.000653	-0.33	-0.25	Iron status biomarkers;	chr6:25887548	chr6:26013241~26013757:+
LIHC	cis	rs4266290	0.597	rs2286879	ENSG00000214846.4	RP11-115L11.1	4.84	1.97e-06	0.000653	0.33	0.25	Parkinson's disease;	chr4:15739257	chr4:15730962~15731627:-
LIHC	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	4.84	1.97e-06	0.000653	0.31	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
LIHC	cis	rs17301013	0.932	rs6425280	ENSG00000227373.4	RP11-160H22.5	4.84	1.97e-06	0.000653	0.31	0.25	Systemic lupus erythematosus;	chr1:174422186	chr1:174115300~174160004:-
LIHC	cis	rs4934494	0.768	rs12570813	ENSG00000232936.4	RP11-80H5.2	4.84	1.97e-06	0.000653	0.31	0.25	Red blood cell count;	chr10:89630974	chr10:89645282~89650667:+
LIHC	cis	rs12365302	0.617	rs2666907	ENSG00000205106.4	DKFZp779M0652	4.84	1.97e-06	0.000653	0.26	0.25	Diastolic blood pressure;	chr11:45745913	chr11:45771432~45772358:+
LIHC	cis	rs6480314	0.615	rs61857174	ENSG00000233590.1	RP11-153K11.3	-4.84	1.97e-06	0.000654	-0.45	-0.25	Optic nerve measurement (disc area);	chr10:68184233	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.711	rs61857175	ENSG00000233590.1	RP11-153K11.3	-4.84	1.97e-06	0.000654	-0.45	-0.25	Optic nerve measurement (disc area);	chr10:68186026	chr10:68233251~68242379:-
LIHC	cis	rs1865760	0.568	rs2032450	ENSG00000216436.2	HIST1H2APS1	-4.84	1.97e-06	0.000654	-0.29	-0.25	Height;	chr6:25992886	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.713	rs2013063	ENSG00000216436.2	HIST1H2APS1	-4.84	1.97e-06	0.000654	-0.29	-0.25	Height;	chr6:25993870	chr6:25732497~25732827:+
LIHC	cis	rs4356203	0.519	rs214083	ENSG00000272034.1	SNORD14A	-4.84	1.97e-06	0.000654	-0.28	-0.25	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17074654~17074744:-
LIHC	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-4.84	1.98e-06	0.000654	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
LIHC	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	4.84	1.98e-06	0.000656	0.18	0.25	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
LIHC	cis	rs12291225	0.679	rs10832240	ENSG00000251991.1	RNU7-49P	4.84	1.98e-06	0.000656	0.27	0.25	Sense of smell;	chr11:14283198	chr11:14478892~14478953:+
LIHC	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	4.84	1.98e-06	0.000656	0.36	0.25	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
LIHC	cis	rs860295	0.676	rs2666826	ENSG00000203761.5	MSTO2P	-4.84	1.98e-06	0.000657	-0.2	-0.25	Body mass index;	chr1:155688294	chr1:155745829~155750137:+
LIHC	cis	rs202072	0.872	rs202046	ENSG00000215022.6	RP1-257A7.4	-4.84	1.98e-06	0.000657	-0.29	-0.25	HIV-1 viral setpoint;	chr6:13275338	chr6:13264861~13295586:-
LIHC	cis	rs3198697	1	rs3198697	ENSG00000263335.1	AF001548.5	-4.84	1.99e-06	0.000657	-0.39	-0.25	Triglycerides;	chr16:15036083	chr16:15726674~15732993:+
LIHC	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-4.84	1.99e-06	0.000657	-0.27	-0.25	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-4.84	1.99e-06	0.000657	-0.27	-0.25	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
LIHC	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-4.84	1.99e-06	0.000657	-0.32	-0.25	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
LIHC	cis	rs712039	0.583	rs853223	ENSG00000276054.1	RP11-378E13.3	4.84	1.99e-06	0.000658	0.31	0.25	Tuberculosis;	chr17:37431050	chr17:37386886~37387926:+
LIHC	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-4.84	1.99e-06	0.000658	-0.27	-0.25	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
LIHC	cis	rs7115242	0.925	rs7925256	ENSG00000236267.1	AP006216.5	4.84	1.99e-06	0.000659	0.35	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:116813204~116814003:-
LIHC	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	4.84	1.99e-06	0.000659	0.36	0.25	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
LIHC	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-4.84	1.99e-06	0.000659	-0.32	-0.25	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
LIHC	cis	rs7208859	0.673	rs216418	ENSG00000266490.1	CTD-2349P21.9	4.84	1.99e-06	0.000659	0.3	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30792372~30792833:+
LIHC	cis	rs2688482	0.512	rs3103954	ENSG00000207650.1	MIR570	4.84	1.99e-06	0.000659	0.33	0.25	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195699401~195699497:+
LIHC	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-4.84	1.99e-06	0.000659	-0.3	-0.25	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
LIHC	cis	rs6479901	0.723	rs7088045	ENSG00000232075.1	MRPL35P2	-4.84	1.99e-06	0.000659	-0.27	-0.25	Intelligence (multi-trait analysis);	chr10:63319637	chr10:63634317~63634827:-
LIHC	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	4.84	2e-06	0.00066	0.26	0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
LIHC	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	4.84	2e-06	0.00066	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	4.84	2e-06	0.00066	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
LIHC	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	4.84	2e-06	0.00066	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
LIHC	cis	rs42490	0.51	rs218917	ENSG00000251136.7	RP11-37B2.1	-4.84	2e-06	0.00066	-0.23	-0.25	Leprosy;	chr8:89688902	chr8:89609409~89757727:-
LIHC	cis	rs1020064	0.609	rs2576748	ENSG00000235319.1	AC012360.4	4.84	2e-06	0.000661	0.32	0.25	AIDS;	chr2:105294801	chr2:105324210~105330529:+
LIHC	cis	rs7412746	0.658	rs6658066	ENSG00000231073.1	RP11-316M1.3	4.84	2e-06	0.000661	0.25	0.25	Melanoma;	chr1:150946461	chr1:150973123~150975534:+
LIHC	cis	rs950169	0.544	rs2036949	ENSG00000259295.5	CSPG4P12	4.84	2e-06	0.000661	0.35	0.25	Schizophrenia;	chr15:84620374	chr15:85191438~85213905:+
LIHC	cis	rs10829156	0.699	rs4747353	ENSG00000225527.1	RP11-383B4.4	-4.84	2e-06	0.000661	-0.4	-0.25	Sudden cardiac arrest;	chr10:18548028	chr10:18531849~18533336:-
LIHC	cis	rs11098499	0.954	rs10034623	ENSG00000260091.1	RP11-33B1.4	-4.84	2e-06	0.000661	-0.18	-0.25	Corneal astigmatism;	chr4:119476674	chr4:119409333~119410233:+
LIHC	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-4.84	2e-06	0.000662	-0.46	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
LIHC	cis	rs8028182	0.636	rs12909863	ENSG00000260269.4	CTD-2323K18.1	-4.84	2e-06	0.000662	-0.31	-0.25	Sudden cardiac arrest;	chr15:75533481	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs12708520	ENSG00000260269.4	CTD-2323K18.1	-4.84	2e-06	0.000662	-0.31	-0.25	Sudden cardiac arrest;	chr15:75538198	chr15:75527150~75601205:-
LIHC	cis	rs17301013	0.761	rs332805	ENSG00000227373.4	RP11-160H22.5	4.84	2e-06	0.000662	0.31	0.25	Systemic lupus erythematosus;	chr1:174652487	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.861	rs34819375	ENSG00000227373.4	RP11-160H22.5	4.84	2e-06	0.000662	0.31	0.25	Systemic lupus erythematosus;	chr1:174654958	chr1:174115300~174160004:-
LIHC	cis	rs9425766	0.679	rs2143114	ENSG00000227373.4	RP11-160H22.5	4.84	2e-06	0.000662	0.31	0.25	Life satisfaction;	chr1:174192292	chr1:174115300~174160004:-
LIHC	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	4.84	2e-06	0.000662	0.38	0.25	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	4.84	2e-06	0.000662	0.38	0.25	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
LIHC	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	4.84	2e-06	0.000662	0.41	0.25	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
LIHC	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-4.84	2.01e-06	0.000663	-0.27	-0.25	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
LIHC	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	4.84	2.01e-06	0.000663	0.36	0.25	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
LIHC	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	4.84	2.01e-06	0.000664	0.3	0.25	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
LIHC	cis	rs1065852	0.526	rs9611700	ENSG00000237037.8	NDUFA6-AS1	-4.84	2.01e-06	0.000664	-0.35	-0.25	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42005510	chr22:42090931~42137742:+
LIHC	cis	rs1065852	0.526	rs2413663	ENSG00000237037.8	NDUFA6-AS1	-4.84	2.01e-06	0.000664	-0.35	-0.25	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42006395	chr22:42090931~42137742:+
LIHC	cis	rs12291225	0.753	rs1431374	ENSG00000251991.1	RNU7-49P	4.84	2.01e-06	0.000664	0.27	0.25	Sense of smell;	chr11:14282429	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.679	rs7934671	ENSG00000251991.1	RNU7-49P	4.84	2.01e-06	0.000664	0.27	0.25	Sense of smell;	chr11:14283555	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.679	rs11023178	ENSG00000251991.1	RNU7-49P	4.84	2.01e-06	0.000664	0.27	0.25	Sense of smell;	chr11:14288736	chr11:14478892~14478953:+
LIHC	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	4.84	2.01e-06	0.000664	0.43	0.25	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
LIHC	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-4.84	2.01e-06	0.000665	-0.33	-0.25	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
LIHC	cis	rs1005277	0.579	rs1740735	ENSG00000275858.1	RP11-291L22.8	4.84	2.01e-06	0.000665	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38450738~38451069:-
LIHC	cis	rs116175783	0.557	rs1267058	ENSG00000227403.1	AC009299.3	-4.84	2.01e-06	0.000665	-0.39	-0.25	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161244739~161249050:+
LIHC	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-4.84	2.02e-06	0.000665	-0.27	-0.25	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
LIHC	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-4.84	2.02e-06	0.000665	-0.27	-0.25	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
LIHC	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-4.84	2.02e-06	0.000665	-0.27	-0.25	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
LIHC	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	4.83	2.02e-06	0.000666	0.36	0.25	Height;	chr6:109708527	chr6:109382795~109383666:+
LIHC	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	4.83	2.02e-06	0.000666	0.32	0.25	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
LIHC	cis	rs1577917	0.958	rs13219504	ENSG00000234155.1	RP11-30P6.6	4.83	2.02e-06	0.000668	0.34	0.25	Response to antipsychotic treatment;	chr6:85847199	chr6:85387219~85390186:-
LIHC	cis	rs12701220	0.803	rs12701432	ENSG00000229043.2	AC091729.9	-4.83	2.02e-06	0.000668	-0.35	-0.25	Bronchopulmonary dysplasia;	chr7:1012817	chr7:1160374~1165267:+
LIHC	cis	rs9467711	0.651	rs13220395	ENSG00000216436.2	HIST1H2APS1	-4.83	2.02e-06	0.000668	-0.6	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26055140	chr6:25732497~25732827:+
LIHC	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	4.83	2.03e-06	0.000669	0.48	0.25	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	4.83	2.03e-06	0.000669	0.48	0.25	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	4.83	2.03e-06	0.000669	0.48	0.25	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
LIHC	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-4.83	2.03e-06	0.000669	-0.33	-0.25	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
LIHC	cis	rs1065852	0.526	rs56234624	ENSG00000237037.8	NDUFA6-AS1	-4.83	2.03e-06	0.000669	-0.35	-0.25	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41992822	chr22:42090931~42137742:+
LIHC	cis	rs879620	1	rs2531995	ENSG00000262185.1	RP11-462G12.1	-4.83	2.03e-06	0.000669	-0.33	-0.25	Hip circumference;Body mass index;	chr16:3963466	chr16:3947609~3950444:-
LIHC	cis	rs8028182	0.636	rs28432989	ENSG00000260269.4	CTD-2323K18.1	-4.83	2.03e-06	0.000669	-0.32	-0.25	Sudden cardiac arrest;	chr15:75475956	chr15:75527150~75601205:-
LIHC	cis	rs591584	0.59	rs7126782	ENSG00000255893.1	RP11-685N10.1	-4.83	2.03e-06	0.00067	-0.25	-0.25	Macrophage Migration Inhibitory Factor levels;	chr11:94590674	chr11:94472908~94473570:-
LIHC	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	4.83	2.03e-06	0.00067	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
LIHC	cis	rs755249	0.508	rs586057	ENSG00000182109.6	RP11-69E11.4	4.83	2.03e-06	0.00067	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39522280~39546187:-
LIHC	cis	rs1499614	1	rs1638731	ENSG00000230295.1	RP11-458F8.2	-4.83	2.03e-06	0.00067	-0.26	-0.25	Gout;	chr7:66679692	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs1882655	ENSG00000230295.1	RP11-458F8.2	4.83	2.03e-06	0.00067	0.26	0.25	Gout;	chr7:66682070	chr7:66880708~66882981:+
LIHC	cis	rs1499614	0.831	rs3800822	ENSG00000230295.1	RP11-458F8.2	4.83	2.03e-06	0.00067	0.26	0.25	Gout;	chr7:66682162	chr7:66880708~66882981:+
LIHC	cis	rs2439831	1	rs690436	ENSG00000205771.5	CATSPER2P1	-4.83	2.04e-06	0.000671	-0.34	-0.25	Lung cancer in ever smokers;	chr15:43469007	chr15:43726918~43747094:-
LIHC	cis	rs2439831	1	rs2264239	ENSG00000205771.5	CATSPER2P1	-4.83	2.04e-06	0.000671	-0.34	-0.25	Lung cancer in ever smokers;	chr15:43473335	chr15:43726918~43747094:-
LIHC	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	4.83	2.04e-06	0.000671	0.18	0.25	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	4.83	2.04e-06	0.000671	0.18	0.25	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	4.83	2.04e-06	0.000671	0.18	0.25	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	4.83	2.04e-06	0.000671	0.18	0.25	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	4.83	2.04e-06	0.000671	0.18	0.25	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
LIHC	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-4.83	2.04e-06	0.000672	-0.29	-0.25	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
LIHC	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-4.83	2.04e-06	0.000672	-0.31	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
LIHC	cis	rs4650994	0.525	rs4650997	ENSG00000273384.1	RP5-1098D14.1	4.83	2.04e-06	0.000672	0.32	0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178561609	chr1:178651706~178652282:+
LIHC	cis	rs12908161	0.959	rs17598603	ENSG00000259295.5	CSPG4P12	-4.83	2.04e-06	0.000674	-0.35	-0.25	Schizophrenia;	chr15:84656980	chr15:85191438~85213905:+
LIHC	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	4.83	2.05e-06	0.000674	0.18	0.25	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
LIHC	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	4.83	2.05e-06	0.000675	0.36	0.25	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
LIHC	cis	rs2565722	0.622	rs2465844	ENSG00000243831.1	RP1-81D8.4	4.83	2.05e-06	0.000675	0.36	0.25	Blood protein levels;	chr6:160876340	chr6:160666228~160676523:-
LIHC	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-4.83	2.05e-06	0.000675	-0.3	-0.25	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
LIHC	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	4.83	2.05e-06	0.000675	0.29	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
LIHC	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	4.83	2.05e-06	0.000676	0.35	0.25	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	4.83	2.05e-06	0.000676	0.35	0.25	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
LIHC	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	4.83	2.05e-06	0.000676	0.23	0.25	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
LIHC	cis	rs2998286	0.723	rs332152	ENSG00000254635.4	WAC-AS1	-4.83	2.06e-06	0.000677	-0.32	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585602	chr10:28522652~28532743:-
LIHC	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	4.83	2.06e-06	0.000678	0.3	0.25	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
LIHC	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-4.83	2.06e-06	0.000679	-0.23	-0.25	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
LIHC	cis	rs1558001	0.87	rs6963424	ENSG00000230196.1	DDX43P3	4.83	2.07e-06	0.00068	0.27	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81782085	chr7:81610884~81611326:-
LIHC	cis	rs1558001	0.834	rs10242244	ENSG00000230196.1	DDX43P3	4.83	2.07e-06	0.00068	0.27	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81782090	chr7:81610884~81611326:-
LIHC	cis	rs7897654	0.571	rs12767543	ENSG00000236937.2	PTGES3P4	4.83	2.07e-06	0.00068	0.33	0.25	Schizophrenia;	chr10:102871906	chr10:102845595~102845950:+
LIHC	cis	rs7897654	0.571	rs7920697	ENSG00000236937.2	PTGES3P4	4.83	2.07e-06	0.00068	0.33	0.25	Schizophrenia;	chr10:102873580	chr10:102845595~102845950:+
LIHC	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	4.83	2.07e-06	0.000682	0.31	0.25	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
LIHC	cis	rs7208859	0.673	rs9915139	ENSG00000266490.1	CTD-2349P21.9	4.83	2.07e-06	0.000682	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30792372~30792833:+
LIHC	cis	rs11971779	0.68	rs10242419	ENSG00000273391.1	RP11-634H22.1	-4.83	2.08e-06	0.000683	-0.22	-0.25	Diisocyanate-induced asthma;	chr7:139404634	chr7:139359032~139359566:-
LIHC	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	4.83	2.08e-06	0.000683	0.27	0.25	Asthma;	chr2:102440033	chr2:102438713~102440475:+
LIHC	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-4.83	2.08e-06	0.000683	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-4.83	2.08e-06	0.000683	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
LIHC	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	4.83	2.08e-06	0.000684	0.23	0.25	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
LIHC	cis	rs12291225	0.645	rs3763950	ENSG00000251991.1	RNU7-49P	4.83	2.08e-06	0.000684	0.27	0.25	Sense of smell;	chr11:14256503	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-4.83	2.08e-06	0.000684	-0.25	-0.25	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
LIHC	cis	rs7914558	1	rs11191542	ENSG00000236937.2	PTGES3P4	4.83	2.08e-06	0.000685	0.3	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:102845595~102845950:+
LIHC	cis	rs950776	0.79	rs2067808	ENSG00000261762.1	RP11-650L12.2	4.83	2.08e-06	0.000685	0.33	0.25	Sudden cardiac arrest;	chr15:78619438	chr15:78589123~78591276:-
LIHC	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-4.83	2.09e-06	0.000686	-0.32	-0.25	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-4.83	2.09e-06	0.000686	-0.32	-0.25	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-4.83	2.09e-06	0.000686	-0.32	-0.25	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
LIHC	cis	rs1865760	0.713	rs7766342	ENSG00000216436.2	HIST1H2APS1	-4.83	2.09e-06	0.000686	-0.29	-0.25	Height;	chr6:25990446	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.713	rs9461229	ENSG00000216436.2	HIST1H2APS1	-4.83	2.09e-06	0.000686	-0.29	-0.25	Height;	chr6:25992051	chr6:25732497~25732827:+
LIHC	cis	rs7131987	0.801	rs962866	ENSG00000257176.2	RP11-996F15.2	-4.83	2.09e-06	0.000686	-0.28	-0.25	QT interval;	chr12:29281214	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.834	rs7139273	ENSG00000257176.2	RP11-996F15.2	-4.83	2.09e-06	0.000686	-0.28	-0.25	QT interval;	chr12:29281717	chr12:29280418~29317848:-
LIHC	cis	rs17301013	0.896	rs6425292	ENSG00000227373.4	RP11-160H22.5	4.83	2.09e-06	0.000687	0.31	0.25	Systemic lupus erythematosus;	chr1:174618364	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs6689170	ENSG00000227373.4	RP11-160H22.5	4.83	2.09e-06	0.000687	0.31	0.25	Systemic lupus erythematosus;	chr1:174639596	chr1:174115300~174160004:-
LIHC	cis	rs2836974	1	rs2836974	ENSG00000255568.3	BRWD1-AS2	-4.83	2.09e-06	0.000687	-0.28	-0.25	Cognitive function;	chr21:39291255	chr21:39313935~39314962:+
LIHC	cis	rs11098499	0.954	rs7436506	ENSG00000260091.1	RP11-33B1.4	-4.83	2.09e-06	0.000687	-0.18	-0.25	Corneal astigmatism;	chr4:119472614	chr4:119409333~119410233:+
LIHC	cis	rs916888	0.61	rs199453	ENSG00000260075.1	NSFP1	4.83	2.1e-06	0.000688	0.31	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46372855~46487141:+
LIHC	cis	rs2834188	1	rs2834188	ENSG00000272659.1	AP000295.10	-4.83	2.1e-06	0.000688	-0.37	-0.25	Narcolepsy;	chr21:33316948	chr21:33309491~33310181:+
LIHC	cis	rs2834188	0.961	rs8130807	ENSG00000272659.1	AP000295.10	-4.83	2.1e-06	0.000688	-0.37	-0.25	Narcolepsy;	chr21:33317708	chr21:33309491~33310181:+
LIHC	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-4.83	2.1e-06	0.000688	-0.27	-0.25	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
LIHC	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	4.83	2.1e-06	0.000688	0.3	0.25	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
LIHC	cis	rs9890032	0.532	rs1808257	ENSG00000263531.1	RP13-753N3.1	4.83	2.1e-06	0.000688	0.33	0.25	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30863921~30864940:-
LIHC	cis	rs3204270	1	rs3204270	ENSG00000281517.1	Metazoa_SRP	-4.83	2.1e-06	0.000689	-0.56	-0.25	Dental caries;	chr17:81715021	chr17:81718849~81719095:-
LIHC	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-4.83	2.1e-06	0.00069	-0.29	-0.25	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
LIHC	cis	rs2929278	0.589	rs7174732	ENSG00000166763.7	STRCP1	-4.83	2.1e-06	0.00069	-0.33	-0.25	Schizophrenia;	chr15:43746265	chr15:43699488~43718184:-
LIHC	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-4.83	2.11e-06	0.000691	-0.32	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
LIHC	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-4.83	2.11e-06	0.000692	-0.27	-0.25	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
LIHC	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	4.83	2.11e-06	0.000692	0.31	0.25	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	4.83	2.11e-06	0.000692	0.31	0.25	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	4.83	2.11e-06	0.000692	0.31	0.25	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	4.83	2.11e-06	0.000692	0.31	0.25	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	4.83	2.11e-06	0.000692	0.31	0.25	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	4.83	2.11e-06	0.000692	0.31	0.25	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	4.83	2.11e-06	0.000692	0.31	0.25	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
LIHC	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-4.82	2.12e-06	0.000694	-0.37	-0.25	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
LIHC	cis	rs2032447	0.672	rs9379811	ENSG00000242387.1	HIST1H2APS2	4.82	2.12e-06	0.000695	0.32	0.25	Intelligence (multi-trait analysis);	chr6:25954969	chr6:25882026~25882395:-
LIHC	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	4.82	2.12e-06	0.000695	0.5	0.25	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
LIHC	cis	rs7897654	0.571	rs12771681	ENSG00000236937.2	PTGES3P4	4.82	2.12e-06	0.000695	0.33	0.25	Schizophrenia;	chr10:102875863	chr10:102845595~102845950:+
LIHC	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	4.82	2.12e-06	0.000695	0.31	0.25	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
LIHC	cis	rs7412746	0.658	rs4970987	ENSG00000231073.1	RP11-316M1.3	4.82	2.12e-06	0.000695	0.26	0.25	Melanoma;	chr1:150977206	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.634	rs12562939	ENSG00000231073.1	RP11-316M1.3	4.82	2.12e-06	0.000695	0.26	0.25	Melanoma;	chr1:150978976	chr1:150973123~150975534:+
LIHC	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-4.82	2.12e-06	0.000695	-0.2	-0.25	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
LIHC	cis	rs116175783	0.557	rs72876083	ENSG00000227403.1	AC009299.3	4.82	2.12e-06	0.000695	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161327527	chr2:161244739~161249050:+
LIHC	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	4.82	2.12e-06	0.000695	0.22	0.25	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
LIHC	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	4.82	2.12e-06	0.000696	0.35	0.25	Height;	chr6:109331033	chr6:109382795~109383666:+
LIHC	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	4.82	2.13e-06	0.000696	0.56	0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
LIHC	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	4.82	2.13e-06	0.000696	0.31	0.25	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
LIHC	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-4.82	2.13e-06	0.000696	-0.3	-0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
LIHC	cis	rs755249	0.501	rs4660669	ENSG00000182109.6	RP11-69E11.4	-4.82	2.13e-06	0.000697	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39522280~39546187:-
LIHC	cis	rs6977955	1	rs917117	ENSG00000234336.5	JAZF1-AS1	-4.82	2.13e-06	0.000698	-0.36	-0.25	Allergic disease (asthma, hay fever or eczema);	chr7:28136686	chr7:28180322~28243917:+
LIHC	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-4.82	2.13e-06	0.000698	-0.35	-0.25	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
LIHC	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-4.82	2.13e-06	0.000698	-0.35	-0.25	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
LIHC	cis	rs6600671	0.899	rs11249432	ENSG00000231429.2	RP11-343N15.2	-4.82	2.13e-06	0.000698	-0.29	-0.25	Hip geometry;	chr1:121541678	chr1:121412719~121429274:+
LIHC	cis	rs12554020	0.579	rs76025942	ENSG00000227603.1	RP11-165J3.6	4.82	2.13e-06	0.000698	0.44	0.25	Schizophrenia;	chr9:93605618	chr9:93435332~93437121:-
LIHC	cis	rs10429558	0.609	rs76290025	ENSG00000227603.1	RP11-165J3.6	4.82	2.13e-06	0.000698	0.44	0.25	Neuroticism;	chr9:93608100	chr9:93435332~93437121:-
LIHC	cis	rs2836974	0.59	rs11911822	ENSG00000255568.3	BRWD1-AS2	-4.82	2.13e-06	0.000699	-0.21	-0.25	Cognitive function;	chr21:39235917	chr21:39313935~39314962:+
LIHC	cis	rs1322639	0.657	rs12203887	ENSG00000261039.2	RP11-417E7.2	-4.82	2.14e-06	7e-04	-0.35	-0.25	Pulse pressure;	chr6:169172157	chr6:169175304~169182740:-
LIHC	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	4.82	2.14e-06	7e-04	0.37	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
LIHC	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-4.82	2.14e-06	7e-04	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-4.82	2.14e-06	0.000701	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
LIHC	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-4.82	2.14e-06	0.000701	-0.32	-0.25	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
LIHC	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-4.82	2.14e-06	0.000701	-0.32	-0.25	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
LIHC	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-4.82	2.14e-06	0.000701	-0.32	-0.25	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
LIHC	cis	rs5769765	0.908	rs7410318	ENSG00000278869.1	CITF22-49E9.3	4.82	2.14e-06	0.000702	0.39	0.25	Schizophrenia;	chr22:49923401	chr22:49933198~49934074:-
LIHC	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	4.82	2.14e-06	0.000702	0.31	0.25	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
LIHC	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-4.82	2.15e-06	0.000702	-0.29	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
LIHC	cis	rs7208859	0.623	rs9914242	ENSG00000266490.1	CTD-2349P21.9	4.82	2.15e-06	0.000702	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30792372~30792833:+
LIHC	cis	rs1322639	0.614	rs6925188	ENSG00000261039.2	RP11-417E7.2	-4.82	2.15e-06	0.000703	-0.36	-0.25	Pulse pressure;	chr6:169163242	chr6:169175304~169182740:-
LIHC	cis	rs30380	0.553	rs152280	ENSG00000272109.1	CTD-2260A17.3	-4.82	2.15e-06	0.000703	-0.33	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96826239	chr5:96804353~96806105:+
LIHC	cis	rs5769765	0.837	rs7284417	ENSG00000278869.1	CITF22-49E9.3	4.82	2.15e-06	0.000703	0.37	0.25	Schizophrenia;	chr22:49920698	chr22:49933198~49934074:-
LIHC	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-4.82	2.15e-06	0.000704	-0.26	-0.25	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
LIHC	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-4.82	2.15e-06	0.000704	-0.2	-0.25	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
LIHC	cis	rs2439831	1	rs28628574	ENSG00000205771.5	CATSPER2P1	-4.82	2.15e-06	0.000704	-0.41	-0.25	Lung cancer in ever smokers;	chr15:43509840	chr15:43726918~43747094:-
LIHC	cis	rs2836974	0.644	rs2836986	ENSG00000255568.3	BRWD1-AS2	-4.82	2.16e-06	0.000705	-0.21	-0.25	Cognitive function;	chr21:39330210	chr21:39313935~39314962:+
LIHC	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	4.82	2.16e-06	0.000705	0.3	0.25	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
LIHC	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-4.82	2.16e-06	0.000705	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
LIHC	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-4.82	2.16e-06	0.000705	-0.23	-0.25	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
LIHC	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-4.82	2.16e-06	0.000705	-0.23	-0.25	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
LIHC	cis	rs4356203	0.905	rs6486354	ENSG00000272034.1	SNORD14A	-4.82	2.16e-06	0.000705	-0.27	-0.25	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17178561	chr11:17074654~17074744:-
LIHC	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-4.82	2.16e-06	0.000705	-0.29	-0.25	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
LIHC	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-4.82	2.16e-06	0.000706	-0.28	-0.25	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
LIHC	cis	rs5769765	0.908	rs138866	ENSG00000278869.1	CITF22-49E9.3	-4.82	2.16e-06	0.000706	-0.39	-0.25	Schizophrenia;	chr22:49812255	chr22:49933198~49934074:-
LIHC	cis	rs2834188	0.883	rs16997869	ENSG00000272659.1	AP000295.10	4.82	2.16e-06	0.000706	0.37	0.25	Narcolepsy;	chr21:33324562	chr21:33309491~33310181:+
LIHC	cis	rs11079159	1	rs876719	ENSG00000263096.1	RP11-515O17.2	4.82	2.16e-06	0.000707	0.35	0.25	QRS duration;	chr17:55289205	chr17:55271504~55273653:-
LIHC	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-4.82	2.17e-06	0.000707	-0.18	-0.25	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
LIHC	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	4.82	2.17e-06	0.000708	0.4	0.25	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
LIHC	cis	rs2834188	0.924	rs2850015	ENSG00000272659.1	AP000295.10	-4.82	2.17e-06	0.000709	-0.37	-0.25	Narcolepsy;	chr21:33324959	chr21:33309491~33310181:+
LIHC	cis	rs4660214	0.666	rs6698791	ENSG00000182109.6	RP11-69E11.4	-4.82	2.17e-06	0.000709	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39469104	chr1:39522280~39546187:-
LIHC	cis	rs7914558	1	rs10883824	ENSG00000236937.2	PTGES3P4	4.82	2.17e-06	0.000709	0.3	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:102845595~102845950:+
LIHC	cis	rs4660214	0.666	rs7538300	ENSG00000182109.6	RP11-69E11.4	-4.82	2.17e-06	0.000709	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39187092	chr1:39522280~39546187:-
LIHC	cis	rs2072510	0.593	rs2660900	ENSG00000257715.1	RP11-256L6.2	-4.82	2.17e-06	0.00071	-0.39	-0.25	Metabolite levels (small molecules and protein measures);	chr12:96011299	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.593	rs2540493	ENSG00000257715.1	RP11-256L6.2	-4.82	2.17e-06	0.00071	-0.39	-0.25	Metabolite levels (small molecules and protein measures);	chr12:96022064	chr12:96025323~96027971:+
LIHC	cis	rs2072510	0.593	rs2660838	ENSG00000257715.1	RP11-256L6.2	-4.82	2.17e-06	0.00071	-0.39	-0.25	Metabolite levels (small molecules and protein measures);	chr12:96022605	chr12:96025323~96027971:+
LIHC	cis	rs1005277	0.557	rs2983338	ENSG00000275858.1	RP11-291L22.8	4.82	2.17e-06	0.00071	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38450738~38451069:-
LIHC	cis	rs5758511	0.68	rs1107553	ENSG00000205702.9	CYP2D7	4.82	2.18e-06	0.000712	0.3	0.25	Birth weight;	chr22:42271467	chr22:42140203~42144577:-
LIHC	cis	rs10510102	0.872	rs28586586	ENSG00000226864.1	ATE1-AS1	4.82	2.18e-06	0.000712	0.43	0.25	Breast cancer;	chr10:121950228	chr10:121928312~121951965:+
LIHC	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-4.82	2.18e-06	0.000712	-0.42	-0.25	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
LIHC	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-4.82	2.18e-06	0.000712	-0.26	-0.25	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
LIHC	cis	rs7615304	0.617	rs343994	ENSG00000243926.1	TIPARP-AS1	-4.82	2.18e-06	0.000713	-0.24	-0.25	Interleukin-2 levels;	chr3:156787575	chr3:156671862~156674378:-
LIHC	cis	rs73193808	0.639	rs7277858	ENSG00000224649.1	AF124730.4	4.82	2.19e-06	0.000713	0.3	0.25	Coronary artery disease;	chr21:29180556	chr21:29182027~29187795:-
LIHC	cis	rs6600671	1	rs2319969	ENSG00000231429.2	RP11-343N15.2	-4.82	2.19e-06	0.000713	-0.31	-0.25	Hip geometry;	chr1:121465481	chr1:121412719~121429274:+
LIHC	cis	rs4731207	0.741	rs1557969	ENSG00000224897.5	POT1-AS1	-4.82	2.19e-06	0.000714	-0.3	-0.25	Cutaneous malignant melanoma;	chr7:124765684	chr7:124929873~125179315:+
LIHC	cis	rs2836974	0.899	rs68004583	ENSG00000255568.3	BRWD1-AS2	4.82	2.19e-06	0.000715	0.28	0.25	Cognitive function;	chr21:39287661	chr21:39313935~39314962:+
LIHC	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-4.82	2.2e-06	0.000716	-0.33	-0.25	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
LIHC	cis	rs1577917	0.958	rs2875456	ENSG00000234155.1	RP11-30P6.6	4.82	2.2e-06	0.000716	0.34	0.25	Response to antipsychotic treatment;	chr6:85892566	chr6:85387219~85390186:-
LIHC	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-4.82	2.2e-06	0.000716	-0.32	-0.25	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-4.82	2.2e-06	0.000716	-0.32	-0.25	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
LIHC	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-4.82	2.2e-06	0.000717	-0.28	-0.25	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
LIHC	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-4.82	2.2e-06	0.000718	-0.32	-0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
LIHC	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	4.82	2.2e-06	0.000718	0.18	0.25	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
LIHC	cis	rs755249	0.959	rs72663520	ENSG00000182109.6	RP11-69E11.4	4.82	2.2e-06	0.000718	0.33	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39522280~39546187:-
LIHC	cis	rs8028182	0.636	rs28737338	ENSG00000260269.4	CTD-2323K18.1	-4.82	2.2e-06	0.000718	-0.32	-0.25	Sudden cardiac arrest;	chr15:75476338	chr15:75527150~75601205:-
LIHC	cis	rs9500256	0.966	rs1322446	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.82	2.2e-06	0.000719	-0.28	-0.25	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57855891~57856468:-
LIHC	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	4.82	2.21e-06	0.000719	0.31	0.25	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
LIHC	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-4.82	2.21e-06	0.00072	-0.27	-0.25	Breast cancer;	chr11:743813	chr11:777578~784297:+
LIHC	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	4.82	2.21e-06	0.00072	0.3	0.25	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	4.82	2.21e-06	0.00072	0.3	0.25	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	4.82	2.21e-06	0.00072	0.3	0.25	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
LIHC	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	4.82	2.21e-06	0.00072	0.34	0.25	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
LIHC	cis	rs603446	0.935	rs180372	ENSG00000254851.1	RP11-109L13.1	-4.82	2.21e-06	0.00072	-0.31	-0.25	Triglycerides;	chr11:116721218	chr11:117135528~117138582:+
LIHC	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	4.82	2.21e-06	0.000721	0.3	0.25	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
LIHC	cis	rs160451	1	rs160441	ENSG00000251136.7	RP11-37B2.1	4.82	2.21e-06	0.000721	0.23	0.25	Leprosy;	chr8:89644760	chr8:89609409~89757727:-
LIHC	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	4.81	2.22e-06	0.000722	0.38	0.25	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
LIHC	cis	rs7209700	0.894	rs7212751	ENSG00000228782.6	CTD-2026D20.3	-4.81	2.22e-06	0.000722	-0.28	-0.25	IgG glycosylation;	chr17:47278133	chr17:47450568~47492492:-
LIHC	cis	rs7412746	0.611	rs7556661	ENSG00000231073.1	RP11-316M1.3	4.81	2.22e-06	0.000723	0.25	0.25	Melanoma;	chr1:150919533	chr1:150973123~150975534:+
LIHC	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	4.81	2.22e-06	0.000724	0.39	0.25	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
LIHC	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	4.81	2.22e-06	0.000724	0.22	0.25	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
LIHC	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-4.81	2.22e-06	0.000724	-0.32	-0.25	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
LIHC	cis	rs1005277	0.529	rs1780125	ENSG00000275858.1	RP11-291L22.8	4.81	2.22e-06	0.000724	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.502	rs2800484	ENSG00000275858.1	RP11-291L22.8	4.81	2.22e-06	0.000724	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs2800485	ENSG00000275858.1	RP11-291L22.8	4.81	2.22e-06	0.000724	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38450738~38451069:-
LIHC	cis	rs643506	0.874	rs648544	ENSG00000254990.4	RP11-108O10.2	4.81	2.23e-06	0.000725	0.27	0.25	Breast cancer;	chr11:111795404	chr11:111768668~111778350:-
LIHC	cis	rs202072	0.72	rs454563	ENSG00000215022.6	RP1-257A7.4	-4.81	2.23e-06	0.000726	-0.29	-0.25	HIV-1 viral setpoint;	chr6:13295304	chr6:13264861~13295586:-
LIHC	cis	rs1322639	0.614	rs9294967	ENSG00000261039.2	RP11-417E7.2	4.81	2.23e-06	0.000726	0.35	0.25	Pulse pressure;	chr6:169165311	chr6:169175304~169182740:-
LIHC	cis	rs2877649	1	rs76534589	ENSG00000258744.1	RP11-80A15.1	-4.81	2.23e-06	0.000727	-0.52	-0.25	Smooth-surface caries;	chr14:24459703	chr14:24501594~24508688:+
LIHC	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	4.81	2.24e-06	0.000728	0.18	0.25	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
LIHC	cis	rs12291225	0.639	rs61883858	ENSG00000251991.1	RNU7-49P	4.81	2.24e-06	0.000728	0.27	0.25	Sense of smell;	chr11:14273162	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.679	rs11023170	ENSG00000251991.1	RNU7-49P	4.81	2.24e-06	0.000728	0.27	0.25	Sense of smell;	chr11:14273363	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.679	rs11023172	ENSG00000251991.1	RNU7-49P	4.81	2.24e-06	0.000728	0.27	0.25	Sense of smell;	chr11:14273821	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.679	rs4757245	ENSG00000251991.1	RNU7-49P	4.81	2.24e-06	0.000728	0.27	0.25	Sense of smell;	chr11:14276326	chr11:14478892~14478953:+
LIHC	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	4.81	2.24e-06	0.000728	0.41	0.25	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
LIHC	cis	rs12291225	0.679	rs34238445	ENSG00000251991.1	RNU7-49P	4.81	2.24e-06	0.000728	0.27	0.25	Sense of smell;	chr11:14294369	chr11:14478892~14478953:+
LIHC	cis	rs10829156	0.699	rs10828879	ENSG00000225527.1	RP11-383B4.4	-4.81	2.24e-06	0.000728	-0.39	-0.25	Sudden cardiac arrest;	chr10:18546425	chr10:18531849~18533336:-
LIHC	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	4.81	2.24e-06	0.000729	0.34	0.25	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
LIHC	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	4.81	2.24e-06	0.00073	0.3	0.25	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
LIHC	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-4.81	2.24e-06	0.00073	-0.32	-0.25	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
LIHC	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-4.81	2.25e-06	0.00073	-0.27	-0.25	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
LIHC	cis	rs7119038	0.774	rs11217037	ENSG00000255239.1	AP002954.6	-4.81	2.25e-06	0.00073	-0.36	-0.25	Sjögren's syndrome;	chr11:118806377	chr11:118688039~118690600:-
LIHC	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	4.81	2.25e-06	0.000731	0.43	0.25	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	4.81	2.25e-06	0.000731	0.43	0.25	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	4.81	2.25e-06	0.000731	0.43	0.25	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
LIHC	cis	rs30380	1	rs27710	ENSG00000272109.1	CTD-2260A17.3	4.81	2.25e-06	0.000731	0.31	0.25	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96804353~96806105:+
LIHC	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-4.81	2.25e-06	0.000732	-0.32	-0.25	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
LIHC	cis	rs12291225	0.637	rs8570	ENSG00000251991.1	RNU7-49P	4.81	2.25e-06	0.000732	0.27	0.25	Sense of smell;	chr11:14279213	chr11:14478892~14478953:+
LIHC	cis	rs3096299	0.967	rs28644774	ENSG00000261118.1	RP11-104N10.1	4.81	2.26e-06	0.000733	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89492017~89504460:-
LIHC	cis	rs603446	0.967	rs180361	ENSG00000254851.1	RP11-109L13.1	-4.81	2.27e-06	0.000736	-0.31	-0.25	Triglycerides;	chr11:116727933	chr11:117135528~117138582:+
LIHC	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	4.81	2.27e-06	0.000736	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
LIHC	cis	rs11098499	0.954	rs12499324	ENSG00000260091.1	RP11-33B1.4	-4.81	2.27e-06	0.000737	-0.18	-0.25	Corneal astigmatism;	chr4:119472631	chr4:119409333~119410233:+
LIHC	cis	rs513088	0.515	rs476197	ENSG00000225171.2	DUTP6	4.81	2.27e-06	0.000737	0.31	0.25	Schizophrenia;	chr1:166704178	chr1:166868748~166869209:+
LIHC	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-4.81	2.27e-06	0.000737	-0.28	-0.25	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
LIHC	cis	rs6061231	0.546	rs482220	ENSG00000273619.1	RP5-908M14.9	4.81	2.27e-06	0.000737	0.21	0.25	Colorectal cancer;	chr20:62352426	chr20:62386303~62386970:-
LIHC	cis	rs8177253	0.665	rs8177178	ENSG00000244062.1	RP11-404G16.2	4.81	2.27e-06	0.000738	0.26	0.25	Iron status biomarkers;	chr3:133744428	chr3:133760300~133762363:+
LIHC	cis	rs1577917	0.883	rs6454505	ENSG00000234155.1	RP11-30P6.6	4.81	2.27e-06	0.000738	0.3	0.25	Response to antipsychotic treatment;	chr6:85882644	chr6:85387219~85390186:-
LIHC	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-4.81	2.27e-06	0.000738	-0.32	-0.25	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-4.81	2.27e-06	0.000738	-0.32	-0.25	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-4.81	2.27e-06	0.000738	-0.32	-0.25	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
LIHC	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-4.81	2.27e-06	0.000738	-0.32	-0.25	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
LIHC	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	4.81	2.27e-06	0.000738	0.36	0.25	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	4.81	2.27e-06	0.000738	0.36	0.25	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	4.81	2.27e-06	0.000738	0.36	0.25	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	4.81	2.27e-06	0.000738	0.36	0.25	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	4.81	2.27e-06	0.000738	0.36	0.25	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	4.81	2.27e-06	0.000738	0.36	0.25	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	4.81	2.27e-06	0.000738	0.36	0.25	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
LIHC	cis	rs7897654	0.571	rs12764049	ENSG00000236937.2	PTGES3P4	4.81	2.27e-06	0.000739	0.33	0.25	Schizophrenia;	chr10:102875199	chr10:102845595~102845950:+
LIHC	cis	rs1065852	0.526	rs9607869	ENSG00000237037.8	NDUFA6-AS1	-4.81	2.28e-06	0.000739	-0.35	-0.25	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42022106	chr22:42090931~42137742:+
LIHC	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	4.81	2.28e-06	0.000741	0.28	0.25	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
LIHC	cis	rs712039	0.617	rs36081240	ENSG00000276054.1	RP11-378E13.3	4.81	2.28e-06	0.000741	0.32	0.25	Tuberculosis;	chr17:37424955	chr17:37386886~37387926:+
LIHC	cis	rs2834188	1	rs4408796	ENSG00000272659.1	AP000295.10	4.81	2.28e-06	0.000741	0.37	0.25	Narcolepsy;	chr21:33326436	chr21:33309491~33310181:+
LIHC	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	4.81	2.28e-06	0.000741	0.35	0.25	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
LIHC	cis	rs2929278	0.617	rs533143	ENSG00000166763.7	STRCP1	4.81	2.28e-06	0.000741	0.32	0.25	Schizophrenia;	chr15:43896656	chr15:43699488~43718184:-
LIHC	cis	rs11216126	1	rs11602240	ENSG00000254851.1	RP11-109L13.1	4.81	2.28e-06	0.000741	0.39	0.25	HDL cholesterol;	chr11:116762082	chr11:117135528~117138582:+
LIHC	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-4.81	2.29e-06	0.000742	-0.26	-0.25	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
LIHC	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-4.81	2.29e-06	0.000742	-0.32	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
LIHC	cis	rs2836974	0.897	rs35386515	ENSG00000255568.3	BRWD1-AS2	4.81	2.29e-06	0.000742	0.28	0.25	Cognitive function;	chr21:39160121	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.863	rs8128026	ENSG00000255568.3	BRWD1-AS2	4.81	2.29e-06	0.000742	0.28	0.25	Cognitive function;	chr21:39161776	chr21:39313935~39314962:+
LIHC	cis	rs11098499	0.866	rs10518329	ENSG00000260091.1	RP11-33B1.4	-4.81	2.29e-06	0.000743	-0.17	-0.25	Corneal astigmatism;	chr4:119480680	chr4:119409333~119410233:+
LIHC	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	4.81	2.29e-06	0.000743	0.35	0.25	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
LIHC	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-4.81	2.29e-06	0.000744	-0.41	-0.25	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
LIHC	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-4.81	2.29e-06	0.000744	-0.29	-0.25	Height;	chr2:46627569	chr2:46668870~46670778:+
LIHC	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-4.81	2.29e-06	0.000744	-0.29	-0.25	Height;	chr2:46629946	chr2:46668870~46670778:+
LIHC	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-4.81	2.29e-06	0.000744	-0.29	-0.25	Height;	chr2:46630262	chr2:46668870~46670778:+
LIHC	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-4.81	2.29e-06	0.000744	-0.29	-0.25	Height;	chr2:46631182	chr2:46668870~46670778:+
LIHC	cis	rs1005277	0.579	rs1780137	ENSG00000276805.1	RP11-291L22.6	4.81	2.29e-06	0.000744	0.31	0.25	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38451030~38451785:+
LIHC	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-4.81	2.3e-06	0.000745	-0.32	-0.25	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
LIHC	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
LIHC	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	4.81	2.3e-06	0.000745	0.42	0.25	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
LIHC	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	4.81	2.3e-06	0.000746	0.39	0.25	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	4.81	2.3e-06	0.000746	0.39	0.25	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
LIHC	cis	rs4660214	0.666	rs11205739	ENSG00000182109.6	RP11-69E11.4	-4.81	2.3e-06	0.000746	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39190729	chr1:39522280~39546187:-
LIHC	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	4.81	2.3e-06	0.000746	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	4.81	2.3e-06	0.000746	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	4.81	2.3e-06	0.000746	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
LIHC	cis	rs1322639	0.657	rs9355135	ENSG00000261039.2	RP11-417E7.2	-4.81	2.3e-06	0.000746	-0.35	-0.25	Pulse pressure;	chr6:169172911	chr6:169175304~169182740:-
LIHC	cis	rs6480314	0.522	rs61857273	ENSG00000233590.1	RP11-153K11.3	-4.81	2.3e-06	0.000747	-0.41	-0.25	Optic nerve measurement (disc area);	chr10:68307530	chr10:68233251~68242379:-
LIHC	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-4.81	2.3e-06	0.000747	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
LIHC	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-4.81	2.31e-06	0.000747	-0.29	-0.25	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
LIHC	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-4.81	2.31e-06	0.000748	-0.26	-0.25	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-4.81	2.31e-06	0.000748	-0.26	-0.25	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
LIHC	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-4.81	2.32e-06	0.000751	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
LIHC	cis	rs860295	0.966	rs821551	ENSG00000203761.5	MSTO2P	-4.81	2.32e-06	0.000751	-0.21	-0.25	Body mass index;	chr1:155718789	chr1:155745829~155750137:+
LIHC	cis	rs227275	0.525	rs2866417	ENSG00000230069.3	LRRC37A15P	-4.81	2.32e-06	0.000751	-0.23	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102727274~102730721:-
LIHC	cis	rs2032366	0.583	rs1452594	ENSG00000267279.1	RP11-879F14.2	-4.81	2.32e-06	0.000751	-0.3	-0.25	Obesity-related traits;	chr18:61590689	chr18:61585746~61606916:-
LIHC	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	4.81	2.32e-06	0.000751	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
LIHC	cis	rs5769765	0.862	rs7410537	ENSG00000278869.1	CITF22-49E9.3	4.8	2.32e-06	0.000752	0.39	0.25	Schizophrenia;	chr22:49923682	chr22:49933198~49934074:-
LIHC	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	4.8	2.32e-06	0.000753	0.46	0.25	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	4.8	2.32e-06	0.000753	0.46	0.25	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	4.8	2.32e-06	0.000753	0.46	0.25	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	4.8	2.32e-06	0.000753	0.46	0.25	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	4.8	2.32e-06	0.000753	0.46	0.25	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
LIHC	cis	rs12887734	0.546	rs4900597	ENSG00000258534.1	CTD-2134A5.4	4.8	2.33e-06	0.000753	0.28	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103800327	chr14:103854366~103880111:-
LIHC	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-4.8	2.33e-06	0.000753	-0.24	-0.25	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
LIHC	cis	rs2032447	0.714	rs199739	ENSG00000242387.1	HIST1H2APS2	4.8	2.33e-06	0.000753	0.33	0.25	Intelligence (multi-trait analysis);	chr6:25960281	chr6:25882026~25882395:-
LIHC	cis	rs5769765	0.862	rs138870	ENSG00000278869.1	CITF22-49E9.3	4.8	2.33e-06	0.000753	0.4	0.25	Schizophrenia;	chr22:49816089	chr22:49933198~49934074:-
LIHC	cis	rs2834188	1	rs2843994	ENSG00000272659.1	AP000295.10	-4.8	2.33e-06	0.000753	-0.39	-0.25	Narcolepsy;	chr21:33334564	chr21:33309491~33310181:+
LIHC	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	4.8	2.33e-06	0.000754	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
LIHC	cis	rs12478296	0.786	rs55876934	ENSG00000261186.2	RP11-341N2.1	-4.8	2.33e-06	0.000756	-0.36	-0.25	Obesity-related traits;	chr2:242091665	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs56292923	ENSG00000261186.2	RP11-341N2.1	-4.8	2.34e-06	0.000756	-0.36	-0.25	Obesity-related traits;	chr2:242097835	chr2:242087351~242088457:-
LIHC	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	4.8	2.34e-06	0.000757	0.21	0.25	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
LIHC	cis	rs2749592	0.531	rs1208559	ENSG00000099251.13	HSD17B7P2	-4.8	2.35e-06	0.000759	-0.29	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38356380~38378505:+
LIHC	cis	rs1030877	0.515	rs920217	ENSG00000235319.1	AC012360.4	4.8	2.35e-06	0.000759	0.34	0.25	Obesity-related traits;	chr2:105288205	chr2:105324210~105330529:+
LIHC	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	4.8	2.35e-06	0.00076	0.35	0.25	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-4.8	2.35e-06	0.00076	-0.35	-0.25	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
LIHC	cis	rs2749097	0.825	rs11208265	ENSG00000244256.3	RN7SL130P	-4.8	2.35e-06	0.00076	-0.29	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659563	chr1:63655743~63656047:+
LIHC	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	4.8	2.35e-06	0.00076	0.31	0.25	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
LIHC	cis	rs5758511	0.68	rs5758688	ENSG00000205702.9	CYP2D7	4.8	2.35e-06	0.00076	0.3	0.25	Birth weight;	chr22:42266495	chr22:42140203~42144577:-
LIHC	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	4.8	2.35e-06	0.000761	0.3	0.25	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
LIHC	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	4.8	2.35e-06	0.000761	0.3	0.25	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
LIHC	cis	rs712039	0.652	rs853200	ENSG00000276054.1	RP11-378E13.3	4.8	2.35e-06	0.000761	0.32	0.25	Tuberculosis;	chr17:37444013	chr17:37386886~37387926:+
LIHC	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	4.8	2.35e-06	0.000761	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
LIHC	cis	rs4356203	0.87	rs10832748	ENSG00000272034.1	SNORD14A	-4.8	2.36e-06	0.000761	-0.27	-0.25	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17230184	chr11:17074654~17074744:-
LIHC	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-4.8	2.36e-06	0.000762	-0.27	-0.25	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
LIHC	cis	rs2836974	0.831	rs2836964	ENSG00000255568.3	BRWD1-AS2	4.8	2.36e-06	0.000762	0.28	0.25	Cognitive function;	chr21:39259080	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.931	rs2836968	ENSG00000255568.3	BRWD1-AS2	4.8	2.36e-06	0.000762	0.28	0.25	Cognitive function;	chr21:39270460	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.931	rs7283569	ENSG00000255568.3	BRWD1-AS2	4.8	2.36e-06	0.000762	0.28	0.25	Cognitive function;	chr21:39272136	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.931	rs2836972	ENSG00000255568.3	BRWD1-AS2	4.8	2.36e-06	0.000762	0.28	0.25	Cognitive function;	chr21:39280216	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.965	rs7354783	ENSG00000255568.3	BRWD1-AS2	4.8	2.36e-06	0.000762	0.28	0.25	Cognitive function;	chr21:39281066	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.931	rs8132285	ENSG00000255568.3	BRWD1-AS2	4.8	2.36e-06	0.000762	0.28	0.25	Cognitive function;	chr21:39283826	chr21:39313935~39314962:+
LIHC	cis	rs12554020	0.582	rs75018698	ENSG00000227603.1	RP11-165J3.6	4.8	2.36e-06	0.000762	0.46	0.25	Schizophrenia;	chr9:93647025	chr9:93435332~93437121:-
LIHC	cis	rs2834188	1	rs2026254	ENSG00000272659.1	AP000295.10	-4.8	2.36e-06	0.000762	-0.37	-0.25	Narcolepsy;	chr21:33315727	chr21:33309491~33310181:+
LIHC	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	4.8	2.36e-06	0.000762	0.35	0.25	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
LIHC	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	4.8	2.36e-06	0.000762	0.31	0.25	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	4.8	2.36e-06	0.000762	0.31	0.25	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	4.8	2.36e-06	0.000762	0.31	0.25	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	4.8	2.36e-06	0.000762	0.31	0.25	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
LIHC	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	4.8	2.36e-06	0.000763	0.38	0.25	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
LIHC	cis	rs8177253	0.696	rs4459901	ENSG00000244062.1	RP11-404G16.2	4.8	2.36e-06	0.000764	0.25	0.25	Iron status biomarkers;	chr3:133746855	chr3:133760300~133762363:+
LIHC	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-4.8	2.37e-06	0.000764	-0.2	-0.25	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
LIHC	cis	rs529413	1	rs518792	ENSG00000259237.1	RP11-209E8.1	4.8	2.37e-06	0.000764	0.35	0.25	Itch intensity from mosquito bite adjusted by bite size;	chr15:53247959	chr15:53116365~53129698:+
LIHC	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	4.8	2.37e-06	0.000764	0.18	0.25	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
LIHC	cis	rs11098499	0.954	rs11098525	ENSG00000260091.1	RP11-33B1.4	-4.8	2.37e-06	0.000764	-0.18	-0.25	Corneal astigmatism;	chr4:119468997	chr4:119409333~119410233:+
LIHC	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	4.8	2.37e-06	0.000765	0.3	0.25	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
LIHC	cis	rs2836974	0.897	rs34394827	ENSG00000255568.3	BRWD1-AS2	4.8	2.37e-06	0.000765	0.28	0.25	Cognitive function;	chr21:39156161	chr21:39313935~39314962:+
LIHC	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	4.8	2.38e-06	0.000768	0.3	0.25	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
LIHC	cis	rs2836950	0.501	rs1474490	ENSG00000255568.3	BRWD1-AS2	-4.8	2.38e-06	0.000768	-0.21	-0.25	Menarche (age at onset);	chr21:39344210	chr21:39313935~39314962:+
LIHC	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	4.8	2.38e-06	0.000769	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
LIHC	cis	rs875971	0.545	rs6979636	ENSG00000273142.1	RP11-458F8.4	4.8	2.38e-06	0.000769	0.24	0.25	Aortic root size;	chr7:66276638	chr7:66902857~66906297:+
LIHC	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	4.8	2.38e-06	0.000769	0.2	0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
LIHC	cis	rs1198872	0.516	rs1734413	ENSG00000272275.1	RP11-791G15.2	-4.8	2.38e-06	0.000769	-0.3	-0.25	Cardiac Troponin-T levels;	chr2:10772910	chr2:10767875~10770058:-
LIHC	cis	rs7688540	0.713	rs4624608	ENSG00000275426.1	CH17-262A2.1	4.8	2.39e-06	0.00077	0.34	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:149738~150317:+
LIHC	cis	rs712039	0.652	rs853222	ENSG00000276054.1	RP11-378E13.3	4.8	2.39e-06	0.000771	0.32	0.25	Tuberculosis;	chr17:37429923	chr17:37386886~37387926:+
LIHC	cis	rs7131987	0.868	rs7958210	ENSG00000257176.2	RP11-996F15.2	-4.8	2.39e-06	0.000771	-0.29	-0.25	QT interval;	chr12:29242248	chr12:29280418~29317848:-
LIHC	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	4.8	2.39e-06	0.000772	0.3	0.25	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
LIHC	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-4.8	2.39e-06	0.000772	-0.26	-0.25	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
LIHC	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-4.8	2.4e-06	0.000773	-0.34	-0.25	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
LIHC	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	4.8	2.4e-06	0.000773	0.31	0.25	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
LIHC	cis	rs1030877	0.515	rs2576735	ENSG00000235319.1	AC012360.4	-4.8	2.4e-06	0.000773	-0.35	-0.25	Obesity-related traits;	chr2:105272382	chr2:105324210~105330529:+
LIHC	cis	rs3087243	0.519	rs11571315	ENSG00000213925.3	NPM1P33	4.8	2.4e-06	0.000773	0.25	0.25	Rheumatoid arthritis;Type 1 diabetes;Hypothyroidism;	chr2:203866178	chr2:203772631~203773502:-
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	4.8	2.4e-06	0.000774	0.3	0.25	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
LIHC	cis	rs17270561	0.723	rs12213243	ENSG00000272810.1	U91328.22	-4.8	2.4e-06	0.000774	-0.33	-0.25	Iron status biomarkers;	chr6:25889880	chr6:26013241~26013757:+
LIHC	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-4.8	2.4e-06	0.000774	-0.33	-0.25	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-4.8	2.4e-06	0.000774	-0.33	-0.25	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-4.8	2.4e-06	0.000774	-0.33	-0.25	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-4.8	2.4e-06	0.000774	-0.33	-0.25	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
LIHC	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	4.8	2.4e-06	0.000774	0.29	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
LIHC	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-4.8	2.4e-06	0.000775	-0.3	-0.25	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
LIHC	cis	rs887829	0.57	rs6753320	ENSG00000233445.1	RPL17P11	-4.8	2.41e-06	0.000776	-0.26	-0.25	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233686969	chr2:233721522~233722065:-
LIHC	cis	rs1005277	0.579	rs1780133	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1780136	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1780138	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.602	rs1780141	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.541	rs1740741	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.528	rs2057228	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1740742	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.602	rs1740743	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1740745	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1740747	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1740749	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1780115	ENSG00000275858.1	RP11-291L22.8	4.8	2.41e-06	0.000776	0.28	0.25	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38450738~38451069:-
LIHC	cis	rs10510102	0.935	rs7907871	ENSG00000226864.1	ATE1-AS1	4.8	2.41e-06	0.000777	0.44	0.25	Breast cancer;	chr10:121878185	chr10:121928312~121951965:+
LIHC	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	4.8	2.41e-06	0.000777	0.38	0.25	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
LIHC	cis	rs10975870	0.847	rs10975913	ENSG00000236924.1	RP11-390F4.6	-4.8	2.42e-06	0.000778	-0.31	-0.25	Body mass index;	chr9:6935297	chr9:6645956~6670635:+
LIHC	cis	rs9834975	0.935	rs9863881	ENSG00000272758.4	RP11-299J3.8	-4.8	2.42e-06	0.000778	-0.28	-0.25	Diastolic blood pressure;	chr3:122381176	chr3:122416207~122443180:+
LIHC	cis	rs2932538	0.961	rs4240534	ENSG00000225075.1	RP11-426L16.3	-4.8	2.42e-06	0.000778	-0.32	-0.25	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112632807	chr1:112693688~112696621:-
LIHC	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	4.8	2.42e-06	0.000779	0.23	0.25	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	4.8	2.42e-06	0.000779	0.23	0.25	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	4.8	2.42e-06	0.000779	0.23	0.25	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	4.8	2.42e-06	0.000779	0.23	0.25	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
LIHC	cis	rs7208859	0.623	rs426434	ENSG00000266490.1	CTD-2349P21.9	4.8	2.42e-06	0.000779	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30792372~30792833:+
LIHC	cis	rs7914558	1	rs67908413	ENSG00000236937.2	PTGES3P4	4.8	2.42e-06	0.00078	0.29	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102845595~102845950:+
LIHC	cis	rs1888560	0.556	rs12588573	ENSG00000199461.1	Y_RNA	-4.8	2.43e-06	0.000781	-0.31	-0.25	Blood protein levels;	chr14:20678425	chr14:20679411~20679512:+
LIHC	cis	rs11098499	0.954	rs10017543	ENSG00000260091.1	RP11-33B1.4	-4.8	2.43e-06	0.000782	-0.18	-0.25	Corneal astigmatism;	chr4:119400265	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.908	rs7695996	ENSG00000260091.1	RP11-33B1.4	-4.8	2.43e-06	0.000782	-0.18	-0.25	Corneal astigmatism;	chr4:119400878	chr4:119409333~119410233:+
LIHC	cis	rs6085948	0.861	rs6085954	ENSG00000228888.1	LINC01428	-4.79	2.44e-06	0.000784	-0.44	-0.25	Interleukin-10 levels;	chr20:7257602	chr20:7146467~7254202:-
LIHC	cis	rs7131987	0.903	rs11050163	ENSG00000257176.2	RP11-996F15.2	-4.79	2.44e-06	0.000784	-0.29	-0.25	QT interval;	chr12:29267465	chr12:29280418~29317848:-
LIHC	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-4.79	2.44e-06	0.000784	-0.28	-0.25	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-4.79	2.44e-06	0.000784	-0.28	-0.25	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
LIHC	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-4.79	2.44e-06	0.000784	-0.28	-0.25	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
LIHC	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	4.79	2.44e-06	0.000785	0.38	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
LIHC	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	4.79	2.44e-06	0.000785	0.31	0.25	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
LIHC	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	4.79	2.45e-06	0.000786	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	4.79	2.45e-06	0.000786	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
LIHC	cis	rs72675573	0.723	rs6702275	ENSG00000235612.1	RP1-158P9.1	-4.79	2.45e-06	0.000786	-0.33	-0.25	Monocyte count;	chr1:56079811	chr1:56145721~56155224:+
LIHC	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-4.79	2.45e-06	0.000786	-0.29	-0.25	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-4.79	2.45e-06	0.000786	-0.29	-0.25	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-4.79	2.45e-06	0.000786	-0.29	-0.25	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-4.79	2.45e-06	0.000786	-0.29	-0.25	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
LIHC	cis	rs6480314	0.542	rs12570281	ENSG00000233590.1	RP11-153K11.3	-4.79	2.45e-06	0.000786	-0.39	-0.25	Optic nerve measurement (disc area);	chr10:68267237	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.542	rs61854813	ENSG00000233590.1	RP11-153K11.3	-4.79	2.45e-06	0.000786	-0.39	-0.25	Optic nerve measurement (disc area);	chr10:68267464	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.803	rs61854814	ENSG00000233590.1	RP11-153K11.3	-4.79	2.45e-06	0.000786	-0.39	-0.25	Optic nerve measurement (disc area);	chr10:68267639	chr10:68233251~68242379:-
LIHC	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	4.79	2.45e-06	0.000786	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
LIHC	cis	rs6600671	0.934	rs7528274	ENSG00000231429.2	RP11-343N15.2	-4.79	2.45e-06	0.000787	-0.29	-0.25	Hip geometry;	chr1:121545103	chr1:121412719~121429274:+
LIHC	cis	rs2439831	0.85	rs10163054	ENSG00000166763.7	STRCP1	4.79	2.45e-06	0.000787	0.38	0.25	Lung cancer in ever smokers;	chr15:43755440	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs12442129	ENSG00000166763.7	STRCP1	4.79	2.45e-06	0.000787	0.38	0.25	Lung cancer in ever smokers;	chr15:43763658	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.702	rs7175032	ENSG00000166763.7	STRCP1	4.79	2.45e-06	0.000787	0.38	0.25	Lung cancer in ever smokers;	chr15:43768038	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs2277531	ENSG00000166763.7	STRCP1	4.79	2.45e-06	0.000787	0.38	0.25	Lung cancer in ever smokers;	chr15:43776871	chr15:43699488~43718184:-
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000206090.4	AP000350.7	4.79	2.45e-06	0.000787	0.3	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23939998~23942798:+
LIHC	cis	rs9500256	1	rs9500256	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.79	2.45e-06	0.000788	-0.28	-0.25	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57855891~57856468:-
LIHC	cis	rs7209700	0.638	rs4629025	ENSG00000228782.6	CTD-2026D20.3	-4.79	2.45e-06	0.000788	-0.28	-0.25	IgG glycosylation;	chr17:47260069	chr17:47450568~47492492:-
LIHC	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-4.79	2.46e-06	0.000789	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-4.79	2.46e-06	0.000789	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-4.79	2.46e-06	0.000789	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-4.79	2.46e-06	0.000789	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-4.79	2.46e-06	0.000789	-0.37	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
LIHC	cis	rs227275	0.556	rs4455413	ENSG00000230069.3	LRRC37A15P	-4.79	2.46e-06	0.00079	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102727274~102730721:-
LIHC	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-4.79	2.46e-06	0.00079	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-4.79	2.46e-06	0.00079	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-4.79	2.46e-06	0.00079	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
LIHC	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-4.79	2.46e-06	0.000791	-0.37	-0.25	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	4.79	2.46e-06	0.000791	0.37	0.25	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-4.79	2.46e-06	0.000791	-0.37	-0.25	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
LIHC	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	4.79	2.46e-06	0.000791	0.34	0.25	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
LIHC	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	4.79	2.47e-06	0.000791	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
LIHC	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	4.79	2.47e-06	0.000791	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
LIHC	cis	rs8028182	0.636	rs8034317	ENSG00000260269.4	CTD-2323K18.1	-4.79	2.47e-06	0.000793	-0.32	-0.25	Sudden cardiac arrest;	chr15:75472002	chr15:75527150~75601205:-
LIHC	cis	rs1023500	0.505	rs134887	ENSG00000227370.1	RP4-669P10.19	-4.79	2.47e-06	0.000793	-0.26	-0.25	Schizophrenia;	chr22:42278233	chr22:42132543~42132998:+
LIHC	cis	rs2932538	0.885	rs6691025	ENSG00000225075.1	RP11-426L16.3	-4.79	2.47e-06	0.000793	-0.32	-0.25	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112634448	chr1:112693688~112696621:-
LIHC	cis	rs17711722	0.583	rs11768292	ENSG00000164669.11	INTS4P1	4.79	2.47e-06	0.000793	0.38	0.25	Calcium levels;	chr7:66009814	chr7:65141225~65234216:+
LIHC	cis	rs7702057	0.53	rs1129495	ENSG00000271918.1	CTD-2287O16.5	4.79	2.47e-06	0.000793	0.35	0.25	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs61105089	ENSG00000271918.1	CTD-2287O16.5	4.79	2.47e-06	0.000793	0.35	0.25	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs2136213	ENSG00000271918.1	CTD-2287O16.5	4.79	2.47e-06	0.000793	0.35	0.25	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs4921060	ENSG00000271918.1	CTD-2287O16.5	4.79	2.47e-06	0.000793	0.35	0.25	Amyotrophic lateral sclerosis;	chr5:116109004	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs58510083	ENSG00000271918.1	CTD-2287O16.5	4.79	2.47e-06	0.000793	0.35	0.25	Amyotrophic lateral sclerosis;	chr5:116109101	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs61672521	ENSG00000271918.1	CTD-2287O16.5	4.79	2.47e-06	0.000793	0.35	0.25	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116083807~116085416:-
LIHC	cis	rs11216126	1	rs4938309	ENSG00000254851.1	RP11-109L13.1	4.79	2.47e-06	0.000794	0.39	0.25	HDL cholesterol;	chr11:116756339	chr11:117135528~117138582:+
LIHC	cis	rs3096299	0.504	rs4785574	ENSG00000261118.1	RP11-104N10.1	4.79	2.48e-06	0.000794	0.25	0.25	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89492017~89504460:-
LIHC	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-4.79	2.48e-06	0.000795	-0.45	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
LIHC	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-4.79	2.48e-06	0.000795	-0.45	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
LIHC	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	4.79	2.48e-06	0.000795	0.3	0.25	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	4.79	2.48e-06	0.000795	0.3	0.25	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	4.79	2.48e-06	0.000795	0.3	0.25	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	4.79	2.48e-06	0.000795	0.3	0.25	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	4.79	2.48e-06	0.000795	0.3	0.25	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	4.79	2.48e-06	0.000795	0.3	0.25	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	4.79	2.48e-06	0.000795	0.3	0.25	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
LIHC	cis	rs712039	0.652	rs1829453	ENSG00000276054.1	RP11-378E13.3	4.79	2.48e-06	0.000795	0.31	0.25	Tuberculosis;	chr17:37449741	chr17:37386886~37387926:+
LIHC	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-4.79	2.48e-06	0.000795	-0.31	-0.25	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
LIHC	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	4.79	2.48e-06	0.000796	0.22	0.25	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	4.79	2.48e-06	0.000796	0.22	0.25	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
LIHC	cis	rs712039	0.652	rs853224	ENSG00000276054.1	RP11-378E13.3	4.79	2.49e-06	0.000796	0.32	0.25	Tuberculosis;	chr17:37431229	chr17:37386886~37387926:+
LIHC	cis	rs5769765	0.908	rs138889	ENSG00000278869.1	CITF22-49E9.3	4.79	2.49e-06	0.000796	0.38	0.25	Schizophrenia;	chr22:49833025	chr22:49933198~49934074:-
LIHC	cis	rs30380	0.587	rs151940	ENSG00000272109.1	CTD-2260A17.3	-4.79	2.49e-06	0.000797	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96812074	chr5:96804353~96806105:+
LIHC	cis	rs17711722	0.565	rs4275112	ENSG00000273024.4	INTS4P2	4.79	2.49e-06	0.000798	0.27	0.25	Calcium levels;	chr7:65733651	chr7:65647864~65715661:+
LIHC	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	4.79	2.49e-06	0.000798	0.29	0.25	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
LIHC	cis	rs1865760	0.713	rs1130000	ENSG00000216436.2	HIST1H2APS1	-4.79	2.49e-06	0.000798	-0.29	-0.25	Height;	chr6:25985168	chr6:25732497~25732827:+
LIHC	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-4.79	2.49e-06	0.000799	-0.37	-0.25	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
LIHC	cis	rs9500256	0.903	rs726783	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.79	2.5e-06	0.000799	-0.27	-0.25	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57855891~57856468:-
LIHC	cis	rs8028182	0.666	rs4886708	ENSG00000260269.4	CTD-2323K18.1	-4.79	2.5e-06	8e-04	-0.32	-0.25	Sudden cardiac arrest;	chr15:75470267	chr15:75527150~75601205:-
LIHC	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	4.79	2.5e-06	8e-04	0.22	0.25	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
LIHC	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	4.79	2.5e-06	8e-04	0.31	0.25	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	4.79	2.5e-06	8e-04	0.31	0.25	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	4.79	2.5e-06	8e-04	0.31	0.25	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
LIHC	cis	rs7914558	1	rs10883826	ENSG00000236937.2	PTGES3P4	4.79	2.5e-06	0.000802	0.29	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102845595~102845950:+
LIHC	cis	rs1030877	0.515	rs2679893	ENSG00000235319.1	AC012360.4	-4.79	2.51e-06	0.000802	-0.34	-0.25	Obesity-related traits;	chr2:105293097	chr2:105324210~105330529:+
LIHC	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	4.79	2.51e-06	0.000802	0.19	0.25	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
LIHC	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-4.79	2.51e-06	0.000803	-0.29	-0.25	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
LIHC	cis	rs9834975	0.9	rs9878861	ENSG00000272758.4	RP11-299J3.8	-4.79	2.51e-06	0.000804	-0.28	-0.25	Diastolic blood pressure;	chr3:122394139	chr3:122416207~122443180:+
LIHC	cis	rs9834975	0.967	rs9841311	ENSG00000272758.4	RP11-299J3.8	-4.79	2.51e-06	0.000804	-0.28	-0.25	Diastolic blood pressure;	chr3:122394494	chr3:122416207~122443180:+
LIHC	cis	rs5756813	0.727	rs13055462	ENSG00000233360.4	Z83844.1	4.79	2.51e-06	0.000804	0.32	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37788678	chr22:37641832~37658377:-
LIHC	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	4.79	2.52e-06	0.000805	0.3	0.25	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
LIHC	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	4.79	2.52e-06	0.000805	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
LIHC	cis	rs6163	0.588	rs3818708	ENSG00000236937.2	PTGES3P4	4.79	2.52e-06	0.000805	0.3	0.25	Waist circumference;Hip circumference;	chr10:102743827	chr10:102845595~102845950:+
LIHC	cis	rs1577917	0.874	rs11756621	ENSG00000234155.1	RP11-30P6.6	4.79	2.52e-06	0.000805	0.34	0.25	Response to antipsychotic treatment;	chr6:86030345	chr6:85387219~85390186:-
LIHC	cis	rs2929278	0.617	rs12908467	ENSG00000166763.7	STRCP1	-4.79	2.52e-06	0.000806	-0.33	-0.25	Schizophrenia;	chr15:43755232	chr15:43699488~43718184:-
LIHC	cis	rs7131987	0.903	rs10843373	ENSG00000257176.2	RP11-996F15.2	-4.79	2.52e-06	0.000806	-0.29	-0.25	QT interval;	chr12:29267675	chr12:29280418~29317848:-
LIHC	cis	rs12291225	0.679	rs4756786	ENSG00000251991.1	RNU7-49P	4.79	2.52e-06	0.000807	0.27	0.25	Sense of smell;	chr11:14264354	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-4.79	2.53e-06	0.000808	-0.26	-0.25	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-4.79	2.53e-06	0.000808	-0.26	-0.25	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-4.79	2.53e-06	0.000808	-0.26	-0.25	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-4.79	2.53e-06	0.000808	-0.26	-0.25	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
LIHC	cis	rs7131987	0.903	rs67150462	ENSG00000257176.2	RP11-996F15.2	-4.79	2.53e-06	0.000808	-0.29	-0.25	QT interval;	chr12:29240392	chr12:29280418~29317848:-
LIHC	cis	rs4660214	0.666	rs636083	ENSG00000182109.6	RP11-69E11.4	4.79	2.53e-06	0.000809	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39522280~39546187:-
LIHC	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-4.79	2.53e-06	0.000809	-0.25	-0.25	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
LIHC	cis	rs11971779	0.59	rs6467839	ENSG00000273391.1	RP11-634H22.1	4.79	2.53e-06	0.000809	0.22	0.25	Diisocyanate-induced asthma;	chr7:139378044	chr7:139359032~139359566:-
LIHC	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-4.79	2.53e-06	0.000809	-0.26	-0.25	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
LIHC	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-4.79	2.53e-06	0.000809	-0.29	-0.25	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-4.79	2.53e-06	0.000809	-0.29	-0.25	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
LIHC	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	4.79	2.53e-06	0.000809	0.31	0.25	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
LIHC	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-4.79	2.53e-06	0.00081	-0.26	-0.25	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
LIHC	cis	rs7702057	0.53	rs1567330	ENSG00000271918.1	CTD-2287O16.5	4.79	2.54e-06	0.000811	0.34	0.25	Amyotrophic lateral sclerosis;	chr5:116077348	chr5:116083807~116085416:-
LIHC	cis	rs202072	0.676	rs202048	ENSG00000215022.6	RP1-257A7.4	-4.79	2.54e-06	0.000811	-0.3	-0.25	HIV-1 viral setpoint;	chr6:13274269	chr6:13264861~13295586:-
LIHC	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	4.79	2.54e-06	0.000812	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
LIHC	cis	rs2834188	1	rs13050445	ENSG00000272659.1	AP000295.10	4.79	2.54e-06	0.000812	0.38	0.25	Narcolepsy;	chr21:33331291	chr21:33309491~33310181:+
LIHC	cis	rs2834188	1	rs2252930	ENSG00000272659.1	AP000295.10	4.79	2.54e-06	0.000812	0.38	0.25	Narcolepsy;	chr21:33331895	chr21:33309491~33310181:+
LIHC	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-4.79	2.54e-06	0.000812	-0.32	-0.25	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
LIHC	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-4.79	2.54e-06	0.000812	-0.32	-0.25	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
LIHC	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-4.79	2.54e-06	0.000812	-0.32	-0.25	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
LIHC	cis	rs1577917	1	rs955227	ENSG00000234155.1	RP11-30P6.6	4.79	2.54e-06	0.000813	0.34	0.25	Response to antipsychotic treatment;	chr6:85941314	chr6:85387219~85390186:-
LIHC	cis	rs12291225	0.679	rs11605531	ENSG00000251991.1	RNU7-49P	4.79	2.54e-06	0.000813	0.27	0.25	Sense of smell;	chr11:14270048	chr11:14478892~14478953:+
LIHC	cis	rs73193808	0.639	rs2832242	ENSG00000224649.1	AF124730.4	4.79	2.54e-06	0.000813	0.3	0.25	Coronary artery disease;	chr21:29179864	chr21:29182027~29187795:-
LIHC	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	4.79	2.54e-06	0.000813	0.18	0.25	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
LIHC	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-4.79	2.54e-06	0.000813	-0.26	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
LIHC	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	4.79	2.54e-06	0.000813	0.18	0.25	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	4.79	2.54e-06	0.000813	0.18	0.25	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
LIHC	cis	rs9834975	0.901	rs10934600	ENSG00000272758.4	RP11-299J3.8	-4.79	2.55e-06	0.000814	-0.28	-0.25	Diastolic blood pressure;	chr3:122477270	chr3:122416207~122443180:+
LIHC	cis	rs9834975	0.967	rs7642161	ENSG00000272758.4	RP11-299J3.8	-4.79	2.55e-06	0.000814	-0.28	-0.25	Diastolic blood pressure;	chr3:122480385	chr3:122416207~122443180:+
LIHC	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	4.79	2.55e-06	0.000814	0.31	0.25	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
LIHC	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	4.79	2.55e-06	0.000814	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	4.79	2.55e-06	0.000814	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	4.79	2.55e-06	0.000814	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
LIHC	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-4.78	2.55e-06	0.000814	-0.31	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
LIHC	cis	rs645901	1	rs645901	ENSG00000236267.1	AP006216.5	4.78	2.55e-06	0.000814	0.26	0.25	Plateletcrit;	chr11:116831646	chr11:116813204~116814003:-
LIHC	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	4.78	2.55e-06	0.000814	0.23	0.25	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
LIHC	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-4.78	2.55e-06	0.000815	-0.45	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
LIHC	cis	rs11672691	0.519	rs7249258	ENSG00000267107.5	PCAT19	-4.78	2.55e-06	0.000816	-0.3	-0.25	Prostate cancer;	chr19:41501959	chr19:41454169~41500649:-
LIHC	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	4.78	2.56e-06	0.000816	0.18	0.25	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
LIHC	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-4.78	2.56e-06	0.000817	-0.26	-0.25	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
LIHC	cis	rs2836974	0.897	rs8133146	ENSG00000255568.3	BRWD1-AS2	4.78	2.56e-06	0.000817	0.28	0.25	Cognitive function;	chr21:39242372	chr21:39313935~39314962:+
LIHC	cis	rs6480314	0.522	rs4746754	ENSG00000233590.1	RP11-153K11.3	4.78	2.56e-06	0.000817	0.39	0.25	Optic nerve measurement (disc area);	chr10:68289862	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs10762204	ENSG00000233590.1	RP11-153K11.3	4.78	2.56e-06	0.000817	0.39	0.25	Optic nerve measurement (disc area);	chr10:68290006	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.571	rs10762205	ENSG00000233590.1	RP11-153K11.3	4.78	2.56e-06	0.000817	0.39	0.25	Optic nerve measurement (disc area);	chr10:68290145	chr10:68233251~68242379:-
LIHC	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	4.78	2.56e-06	0.000817	0.35	0.25	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
LIHC	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	4.78	2.56e-06	0.000818	0.43	0.25	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
LIHC	cis	rs1577917	1	rs1577917	ENSG00000234155.1	RP11-30P6.6	4.78	2.56e-06	0.000818	0.32	0.25	Response to antipsychotic treatment;	chr6:85982222	chr6:85387219~85390186:-
LIHC	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-4.78	2.57e-06	0.00082	-0.29	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
LIHC	cis	rs875971	0.571	rs160641	ENSG00000273142.1	RP11-458F8.4	-4.78	2.57e-06	0.000821	-0.24	-0.25	Aortic root size;	chr7:66112359	chr7:66902857~66906297:+
LIHC	cis	rs6480314	0.615	rs61857179	ENSG00000233590.1	RP11-153K11.3	-4.78	2.57e-06	0.000821	-0.45	-0.25	Optic nerve measurement (disc area);	chr10:68188243	chr10:68233251~68242379:-
LIHC	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	4.78	2.58e-06	0.000822	0.22	0.25	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
LIHC	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-4.78	2.58e-06	0.000822	-0.32	-0.25	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
LIHC	cis	rs748404	0.697	rs513970	ENSG00000166763.7	STRCP1	4.78	2.58e-06	0.000823	0.31	0.25	Lung cancer;	chr15:43287368	chr15:43699488~43718184:-
LIHC	cis	rs1865760	1	rs2071297	ENSG00000216436.2	HIST1H2APS1	4.78	2.58e-06	0.000824	0.28	0.25	Height;	chr6:25924285	chr6:25732497~25732827:+
LIHC	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	4.78	2.58e-06	0.000824	0.38	0.25	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
LIHC	cis	rs11971779	0.688	rs1862880	ENSG00000273391.1	RP11-634H22.1	4.78	2.58e-06	0.000824	0.23	0.25	Diisocyanate-induced asthma;	chr7:139335354	chr7:139359032~139359566:-
LIHC	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	4.78	2.58e-06	0.000824	0.51	0.25	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
LIHC	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	4.78	2.58e-06	0.000824	0.18	0.25	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
LIHC	cis	rs643506	0.874	rs615642	ENSG00000254990.4	RP11-108O10.2	4.78	2.59e-06	0.000825	0.27	0.25	Breast cancer;	chr11:111778697	chr11:111768668~111778350:-
LIHC	cis	rs9834975	0.967	rs12487598	ENSG00000272758.4	RP11-299J3.8	-4.78	2.59e-06	0.000826	-0.28	-0.25	Diastolic blood pressure;	chr3:122459755	chr3:122416207~122443180:+
LIHC	cis	rs9834975	0.967	rs6771095	ENSG00000272758.4	RP11-299J3.8	-4.78	2.59e-06	0.000826	-0.28	-0.25	Diastolic blood pressure;	chr3:122472888	chr3:122416207~122443180:+
LIHC	cis	rs2877649	1	rs76403925	ENSG00000258744.1	RP11-80A15.1	-4.78	2.59e-06	0.000826	-0.51	-0.25	Smooth-surface caries;	chr14:24461307	chr14:24501594~24508688:+
LIHC	cis	rs11779988	0.528	rs208029	ENSG00000253671.1	RP11-806O11.1	-4.78	2.59e-06	0.000826	-0.33	-0.25	Breast cancer;	chr8:17983478	chr8:17808941~17820868:+
LIHC	cis	rs4925386	0.808	rs1760073	ENSG00000273619.1	RP5-908M14.9	4.78	2.59e-06	0.000827	0.2	0.25	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62351050	chr20:62386303~62386970:-
LIHC	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	4.78	2.59e-06	0.000827	0.22	0.25	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
LIHC	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-4.78	2.6e-06	0.000828	-0.26	-0.25	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
LIHC	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-4.78	2.6e-06	0.000828	-0.29	-0.25	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
LIHC	cis	rs17301013	0.861	rs332770	ENSG00000227373.4	RP11-160H22.5	4.78	2.6e-06	0.000829	0.31	0.25	Systemic lupus erythematosus;	chr1:174681511	chr1:174115300~174160004:-
LIHC	cis	rs9409787	1	rs9409787	ENSG00000231806.2	PCAT7	-4.78	2.6e-06	0.00083	-0.36	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr9:94499290	chr9:94555069~94568127:+
LIHC	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	4.78	2.61e-06	0.00083	0.27	0.25	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
LIHC	cis	rs5769765	0.908	rs138891	ENSG00000278869.1	CITF22-49E9.3	4.78	2.61e-06	0.000831	0.38	0.25	Schizophrenia;	chr22:49834093	chr22:49933198~49934074:-
LIHC	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	4.78	2.61e-06	0.000831	0.39	0.25	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
LIHC	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-4.78	2.61e-06	0.000832	-0.25	-0.25	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
LIHC	cis	rs9467711	0.591	rs13216785	ENSG00000216436.2	HIST1H2APS1	4.78	2.61e-06	0.000832	0.63	0.25	Autism spectrum disorder or schizophrenia;	chr6:26078957	chr6:25732497~25732827:+
LIHC	cis	rs10129255	0.557	rs4043727	ENSG00000211970.3	IGHV4-61	-4.78	2.61e-06	0.000832	-0.2	-0.25	Kawasaki disease;	chr14:106649820	chr14:106639119~106639657:-
LIHC	cis	rs2032366	0.63	rs6567226	ENSG00000267279.1	RP11-879F14.2	-4.78	2.61e-06	0.000833	-0.31	-0.25	Obesity-related traits;	chr18:61635689	chr18:61585746~61606916:-
LIHC	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	4.78	2.62e-06	0.000833	0.28	0.25	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
LIHC	cis	rs2836974	0.644	rs11088472	ENSG00000255568.3	BRWD1-AS2	-4.78	2.62e-06	0.000833	-0.21	-0.25	Cognitive function;	chr21:39327450	chr21:39313935~39314962:+
LIHC	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-4.78	2.62e-06	0.000834	-0.26	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
LIHC	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-4.78	2.62e-06	0.000834	-0.26	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
LIHC	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	4.78	2.62e-06	0.000834	0.3	0.25	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
LIHC	cis	rs5769765	0.624	rs138843	ENSG00000278869.1	CITF22-49E9.3	4.78	2.62e-06	0.000835	0.39	0.25	Schizophrenia;	chr22:49789514	chr22:49933198~49934074:-
LIHC	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	4.78	2.62e-06	0.000835	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
LIHC	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	4.78	2.62e-06	0.000835	0.2	0.25	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	4.78	2.62e-06	0.000835	0.2	0.25	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	4.78	2.62e-06	0.000835	0.2	0.25	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	4.78	2.62e-06	0.000835	0.2	0.25	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
LIHC	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-4.78	2.62e-06	0.000835	-0.24	-0.25	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
LIHC	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-4.78	2.63e-06	0.000837	-0.26	-0.25	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
LIHC	cis	rs12701220	0.894	rs12701406	ENSG00000229043.2	AC091729.9	-4.78	2.63e-06	0.000837	-0.35	-0.25	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1160374~1165267:+
LIHC	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-4.78	2.63e-06	0.000837	-0.31	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-4.78	2.63e-06	0.000837	-0.31	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
LIHC	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-4.78	2.64e-06	0.00084	-0.27	-0.25	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-4.78	2.64e-06	0.00084	-0.27	-0.25	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
LIHC	cis	rs2439831	0.717	rs690170	ENSG00000205771.5	CATSPER2P1	-4.78	2.65e-06	0.000841	-0.39	-0.25	Lung cancer in ever smokers;	chr15:43518224	chr15:43726918~43747094:-
LIHC	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-4.78	2.65e-06	0.000841	-0.26	-0.25	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
LIHC	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	4.78	2.65e-06	0.000842	0.31	0.25	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
LIHC	cis	rs2880765	0.545	rs17553734	ENSG00000259630.2	CTD-2262B20.1	4.78	2.65e-06	0.000842	0.35	0.25	Coronary artery disease;	chr15:85469828	chr15:85415228~85415633:+
LIHC	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-4.78	2.65e-06	0.000842	-0.29	-0.25	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
LIHC	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-4.78	2.65e-06	0.000842	-0.29	-0.25	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
LIHC	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	4.78	2.65e-06	0.000842	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	4.78	2.65e-06	0.000842	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
LIHC	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	4.78	2.65e-06	0.000842	0.28	0.25	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
LIHC	cis	rs10833905	0.756	rs76866579	ENSG00000246225.5	RP11-17A1.3	-4.78	2.65e-06	0.000843	-0.33	-0.25	Sudden cardiac arrest;	chr11:22977331	chr11:22829380~22945393:+
LIHC	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	4.78	2.65e-06	0.000843	0.36	0.25	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
LIHC	cis	rs10871290	1	rs10871290	ENSG00000261079.1	RP11-252A24.3	-4.78	2.65e-06	0.000844	-0.29	-0.25	Breast cancer;	chr16:74438798	chr16:74367462~74369826:+
LIHC	cis	rs3733585	0.781	rs4292328	ENSG00000250413.1	RP11-448G15.1	4.78	2.66e-06	0.000845	0.32	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9969338	chr4:10006482~10009725:+
LIHC	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-4.78	2.66e-06	0.000845	-0.26	-0.25	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
LIHC	cis	rs4820294	0.547	rs62236743	ENSG00000233360.4	Z83844.1	4.78	2.66e-06	0.000845	0.36	0.25	Fat distribution (HIV);	chr22:37700046	chr22:37641832~37658377:-
LIHC	cis	rs4820294	0.516	rs12627973	ENSG00000233360.4	Z83844.1	4.78	2.66e-06	0.000845	0.36	0.25	Fat distribution (HIV);	chr22:37700690	chr22:37641832~37658377:-
LIHC	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	4.78	2.66e-06	0.000845	0.31	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
LIHC	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-4.78	2.66e-06	0.000845	-0.32	-0.25	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
LIHC	cis	rs10129255	0.646	rs55995061	ENSG00000223648.3	IGHV3-64	4.78	2.66e-06	0.000846	0.19	0.25	Kawasaki disease;	chr14:106799309	chr14:106643132~106658258:-
LIHC	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	4.78	2.66e-06	0.000846	0.34	0.25	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
LIHC	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	4.78	2.66e-06	0.000846	0.31	0.25	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
LIHC	cis	rs2836974	0.568	rs452377	ENSG00000255568.3	BRWD1-AS2	4.78	2.66e-06	0.000847	0.21	0.25	Cognitive function;	chr21:39165257	chr21:39313935~39314962:+
LIHC	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-4.78	2.67e-06	0.000847	-0.3	-0.25	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
LIHC	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-4.78	2.67e-06	0.000847	-0.24	-0.25	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
LIHC	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-4.77	2.67e-06	0.000848	-0.24	-0.25	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
LIHC	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-4.77	2.67e-06	0.000849	-0.29	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
LIHC	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	4.77	2.67e-06	0.000849	0.35	0.25	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
LIHC	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-4.77	2.67e-06	0.000849	-0.32	-0.25	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
LIHC	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	4.77	2.67e-06	0.000849	0.41	0.25	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
LIHC	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-4.77	2.68e-06	0.00085	-0.37	-0.25	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
LIHC	cis	rs5758511	0.68	rs5758682	ENSG00000205702.9	CYP2D7	4.77	2.68e-06	0.00085	0.29	0.25	Birth weight;	chr22:42249196	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.68	rs34107327	ENSG00000205702.9	CYP2D7	4.77	2.68e-06	0.00085	0.29	0.25	Birth weight;	chr22:42252347	chr22:42140203~42144577:-
LIHC	cis	rs2310173	0.933	rs4851534	ENSG00000281162.1	LINC01127	-4.77	2.68e-06	0.00085	-0.27	-0.25	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102037937	chr2:101962056~101987167:+
LIHC	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
LIHC	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
LIHC	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	4.77	2.68e-06	0.000851	0.38	0.25	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
LIHC	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-4.77	2.68e-06	0.000852	-0.29	-0.25	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
LIHC	cis	rs113084984	0.642	rs13021546	ENSG00000271952.1	RP11-245G13.2	-4.77	2.68e-06	0.000852	-0.31	-0.25	Breast cancer;	chr2:11540917	chr2:10878269~10885118:+
LIHC	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	4.77	2.68e-06	0.000852	0.37	0.25	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
LIHC	cis	rs1865760	0.929	rs9467646	ENSG00000216436.2	HIST1H2APS1	-4.77	2.68e-06	0.000852	-0.28	-0.25	Height;	chr6:25957180	chr6:25732497~25732827:+
LIHC	cis	rs9834975	0.967	rs7638180	ENSG00000272758.4	RP11-299J3.8	-4.77	2.69e-06	0.000853	-0.28	-0.25	Diastolic blood pressure;	chr3:122431449	chr3:122416207~122443180:+
LIHC	cis	rs3015497	0.653	rs2356456	ENSG00000269906.1	RP11-248J18.2	4.77	2.69e-06	0.000853	0.32	0.25	Mean platelet volume;	chr14:50626498	chr14:50662511~50663178:-
LIHC	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	4.77	2.69e-06	0.000853	0.4	0.25	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
LIHC	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	4.77	2.69e-06	0.000853	0.36	0.25	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
LIHC	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-4.77	2.69e-06	0.000854	-0.22	-0.25	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
LIHC	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-4.77	2.69e-06	0.000855	-0.27	-0.25	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
LIHC	cis	rs9834975	0.935	rs6771201	ENSG00000272758.4	RP11-299J3.8	-4.77	2.7e-06	0.000855	-0.28	-0.25	Diastolic blood pressure;	chr3:122382874	chr3:122416207~122443180:+
LIHC	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	4.77	2.7e-06	0.000855	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
LIHC	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	4.77	2.7e-06	0.000855	0.22	0.25	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
LIHC	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-4.77	2.7e-06	0.000855	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
LIHC	cis	rs5758511	0.637	rs5751244	ENSG00000205702.9	CYP2D7	4.77	2.7e-06	0.000855	0.3	0.25	Birth weight;	chr22:42221405	chr22:42140203~42144577:-
LIHC	cis	rs950169	0.58	rs1061737	ENSG00000259295.5	CSPG4P12	4.77	2.7e-06	0.000856	0.35	0.25	Schizophrenia;	chr15:84640559	chr15:85191438~85213905:+
LIHC	cis	rs7615304	0.617	rs2054880	ENSG00000243926.1	TIPARP-AS1	-4.77	2.7e-06	0.000856	-0.24	-0.25	Interleukin-2 levels;	chr3:156782192	chr3:156671862~156674378:-
LIHC	cis	rs2877649	0.51	rs73593291	ENSG00000258744.1	RP11-80A15.1	-4.77	2.7e-06	0.000856	-0.46	-0.25	Smooth-surface caries;	chr14:24436888	chr14:24501594~24508688:+
LIHC	cis	rs7119038	0.818	rs77209083	ENSG00000255239.1	AP002954.6	-4.77	2.7e-06	0.000857	-0.36	-0.25	Sjögren's syndrome;	chr11:118736860	chr11:118688039~118690600:-
LIHC	cis	rs30380	0.553	rs27527	ENSG00000272109.1	CTD-2260A17.3	-4.77	2.71e-06	0.000857	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96816265	chr5:96804353~96806105:+
LIHC	cis	rs5756813	0.7	rs1894525	ENSG00000233360.4	Z83844.1	4.77	2.71e-06	0.000858	0.32	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37790393	chr22:37641832~37658377:-
LIHC	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	4.77	2.71e-06	0.000858	0.26	0.25	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
LIHC	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-4.77	2.71e-06	0.000858	-0.21	-0.25	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
LIHC	cis	rs4650994	0.623	rs35854525	ENSG00000213057.5	C1orf220	-4.77	2.71e-06	0.000859	-0.22	-0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178649469	chr1:178542752~178548889:+
LIHC	cis	rs7119038	0.509	rs10892258	ENSG00000255422.1	AP002954.4	-4.77	2.71e-06	0.000859	-0.32	-0.25	Sjögren's syndrome;	chr11:118709156	chr11:118704607~118750263:+
LIHC	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	4.77	2.72e-06	0.00086	0.3	0.25	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
LIHC	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	4.77	2.72e-06	0.00086	0.26	0.25	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
LIHC	cis	rs1577917	0.958	rs12198876	ENSG00000234155.1	RP11-30P6.6	4.77	2.72e-06	0.00086	0.34	0.25	Response to antipsychotic treatment;	chr6:85815758	chr6:85387219~85390186:-
LIHC	cis	rs2739330	0.791	rs9612520	ENSG00000206090.4	AP000350.7	4.77	2.72e-06	0.000861	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23939998~23942798:+
LIHC	cis	rs3733585	0.753	rs1122141	ENSG00000250413.1	RP11-448G15.1	4.77	2.72e-06	0.000861	0.32	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9945654	chr4:10006482~10009725:+
LIHC	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	4.77	2.72e-06	0.000861	0.29	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
LIHC	cis	rs7119038	0.629	rs11216994	ENSG00000255239.1	AP002954.6	-4.77	2.72e-06	0.000861	-0.34	-0.25	Sjögren's syndrome;	chr11:118732811	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.629	rs11216995	ENSG00000255239.1	AP002954.6	-4.77	2.72e-06	0.000861	-0.34	-0.25	Sjögren's syndrome;	chr11:118732817	chr11:118688039~118690600:-
LIHC	cis	rs2243480	1	rs1618893	ENSG00000230295.1	RP11-458F8.2	-4.77	2.73e-06	0.000862	-0.24	-0.25	Diabetic kidney disease;	chr7:66631132	chr7:66880708~66882981:+
LIHC	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	4.77	2.73e-06	0.000864	0.3	0.25	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
LIHC	cis	rs6480314	0.522	rs80326649	ENSG00000233590.1	RP11-153K11.3	-4.77	2.73e-06	0.000864	-0.41	-0.25	Optic nerve measurement (disc area);	chr10:68285667	chr10:68233251~68242379:-
LIHC	cis	rs5758511	0.68	rs58654759	ENSG00000205702.9	CYP2D7	4.77	2.73e-06	0.000865	0.29	0.25	Birth weight;	chr22:42246570	chr22:42140203~42144577:-
LIHC	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	4.77	2.73e-06	0.000865	0.38	0.25	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
LIHC	cis	rs9834975	0.935	rs10045	ENSG00000272758.4	RP11-299J3.8	-4.77	2.73e-06	0.000865	-0.28	-0.25	Diastolic blood pressure;	chr3:122426105	chr3:122416207~122443180:+
LIHC	cis	rs4356975	0.697	rs5002700	ENSG00000196472.4	RP13-644M16.4	4.77	2.74e-06	0.000865	0.27	0.25	Obesity-related traits;	chr4:69155637	chr4:69181660~69182372:+
LIHC	cis	rs10912872	0.672	rs1018392	ENSG00000225704.2	RP4-798A17.5	4.77	2.74e-06	0.000867	0.22	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171384725	chr1:171345089~171345320:+
LIHC	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	4.77	2.74e-06	0.000867	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
LIHC	cis	rs5769765	0.862	rs138856	ENSG00000278869.1	CITF22-49E9.3	4.77	2.75e-06	0.000868	0.4	0.25	Schizophrenia;	chr22:49805730	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.862	rs138857	ENSG00000278869.1	CITF22-49E9.3	4.77	2.75e-06	0.000868	0.4	0.25	Schizophrenia;	chr22:49805941	chr22:49933198~49934074:-
LIHC	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	4.77	2.75e-06	0.000868	0.21	0.25	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	4.77	2.75e-06	0.000868	0.21	0.25	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
LIHC	cis	rs17301013	0.896	rs332773	ENSG00000227373.4	RP11-160H22.5	4.77	2.75e-06	0.000868	0.3	0.25	Systemic lupus erythematosus;	chr1:174695711	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs444678	ENSG00000227373.4	RP11-160H22.5	4.77	2.75e-06	0.000868	0.3	0.25	Systemic lupus erythematosus;	chr1:174706080	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.896	rs332791	ENSG00000227373.4	RP11-160H22.5	4.77	2.75e-06	0.000868	0.3	0.25	Systemic lupus erythematosus;	chr1:174709784	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs332795	ENSG00000227373.4	RP11-160H22.5	4.77	2.75e-06	0.000868	0.3	0.25	Systemic lupus erythematosus;	chr1:174726785	chr1:174115300~174160004:-
LIHC	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-4.77	2.75e-06	0.000868	-0.32	-0.25	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
LIHC	cis	rs9425766	0.679	rs6681618	ENSG00000227373.4	RP11-160H22.5	-4.77	2.75e-06	0.000869	-0.3	-0.25	Life satisfaction;	chr1:174201203	chr1:174115300~174160004:-
LIHC	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-4.77	2.75e-06	0.000869	-0.26	-0.25	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
LIHC	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	4.77	2.75e-06	0.000869	0.29	0.25	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
LIHC	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-4.77	2.75e-06	0.00087	-0.27	-0.25	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
LIHC	cis	rs4660214	0.666	rs10888788	ENSG00000182109.6	RP11-69E11.4	-4.77	2.76e-06	0.000871	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39522280~39546187:-
LIHC	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000871	-0.27	-0.25	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000871	-0.27	-0.25	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
LIHC	cis	rs2439831	0.702	rs3759791	ENSG00000166763.7	STRCP1	4.77	2.76e-06	0.000872	0.37	0.25	Lung cancer in ever smokers;	chr15:43798600	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-4.77	2.76e-06	0.000872	-0.26	-0.25	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
LIHC	cis	rs1729407	0.706	rs1268354	ENSG00000236267.1	AP006216.5	4.77	2.76e-06	0.000872	0.23	0.25	Apolipoprotein A-IV levels;	chr11:116819862	chr11:116813204~116814003:-
LIHC	cis	rs12936587	0.535	rs6502615	ENSG00000223979.2	SMCR2	4.77	2.76e-06	0.000872	0.33	0.25	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17708709	chr17:17674026~17677688:-
LIHC	cis	rs1322639	0.614	rs6940913	ENSG00000261039.2	RP11-417E7.2	-4.77	2.76e-06	0.000873	-0.35	-0.25	Pulse pressure;	chr6:169163571	chr6:169175304~169182740:-
LIHC	cis	rs2998286	0.723	rs332161	ENSG00000254635.4	WAC-AS1	4.77	2.76e-06	0.000873	0.31	0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599911	chr10:28522652~28532743:-
LIHC	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-4.77	2.77e-06	0.000873	-0.29	-0.25	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
LIHC	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-4.77	2.77e-06	0.000873	-0.29	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
LIHC	cis	rs9467711	0.591	rs13195692	ENSG00000216436.2	HIST1H2APS1	4.77	2.77e-06	0.000873	0.64	0.25	Autism spectrum disorder or schizophrenia;	chr6:26044145	chr6:25732497~25732827:+
LIHC	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	4.77	2.77e-06	0.000873	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
LIHC	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-4.77	2.77e-06	0.000873	-0.29	-0.25	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
LIHC	cis	rs6445975	0.726	rs4330265	ENSG00000272360.1	RP11-359I18.5	-4.77	2.77e-06	0.000873	-0.29	-0.25	Systemic lupus erythematosus;	chr3:58482301	chr3:58490830~58491291:-
LIHC	cis	rs9890032	0.618	rs55872374	ENSG00000263531.1	RP13-753N3.1	4.77	2.77e-06	0.000873	0.33	0.25	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30863921~30864940:-
LIHC	cis	rs6901152	0.508	rs972151	ENSG00000217648.1	RP1-95L4.4	-4.77	2.77e-06	0.000874	-0.29	-0.25	Acute lymphoblastic leukemia (childhood);	chr6:143364252	chr6:143342246~143343383:+
LIHC	cis	rs12554020	0.681	rs78792144	ENSG00000227603.1	RP11-165J3.6	4.77	2.77e-06	0.000874	0.45	0.25	Schizophrenia;	chr9:93583725	chr9:93435332~93437121:-
LIHC	cis	rs17270561	0.636	rs1575535	ENSG00000216436.2	HIST1H2APS1	-4.77	2.77e-06	0.000874	-0.3	-0.25	Iron status biomarkers;	chr6:25809681	chr6:25732497~25732827:+
LIHC	cis	rs1396485	0.607	rs4921070	ENSG00000271918.1	CTD-2287O16.5	4.77	2.77e-06	0.000874	0.3	0.25	Inflammatory biomarkers;	chr5:116176269	chr5:116083807~116085416:-
LIHC	cis	rs6901152	0.508	rs6928185	ENSG00000217648.1	RP1-95L4.4	-4.77	2.77e-06	0.000874	-0.29	-0.25	Acute lymphoblastic leukemia (childhood);	chr6:143363518	chr6:143342246~143343383:+
LIHC	cis	rs7914558	1	rs943036	ENSG00000236937.2	PTGES3P4	4.77	2.77e-06	0.000874	0.29	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103076290	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs943035	ENSG00000236937.2	PTGES3P4	4.77	2.77e-06	0.000874	0.29	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:102845595~102845950:+
LIHC	cis	rs7914558	0.966	rs7921574	ENSG00000236937.2	PTGES3P4	4.77	2.77e-06	0.000874	0.29	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:102845595~102845950:+
LIHC	cis	rs57502260	0.704	rs41478448	ENSG00000212093.1	AP000807.1	4.77	2.77e-06	0.000874	0.32	0.25	Total body bone mineral density (age 45-60);	chr11:68414153	chr11:68506083~68506166:-
LIHC	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	4.77	2.77e-06	0.000875	0.3	0.25	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
LIHC	cis	rs2274273	0.624	rs2026633	ENSG00000258413.1	RP11-665C16.6	-4.77	2.77e-06	0.000875	-0.29	-0.25	Protein biomarker;	chr14:55322459	chr14:55262767~55272075:-
LIHC	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	4.77	2.77e-06	0.000875	0.27	0.25	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	4.77	2.77e-06	0.000875	0.27	0.25	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
LIHC	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-4.77	2.78e-06	0.000876	-0.35	-0.25	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
LIHC	cis	rs12478296	0.792	rs6755390	ENSG00000261186.2	RP11-341N2.1	-4.77	2.78e-06	0.000876	-0.35	-0.25	Obesity-related traits;	chr2:242070847	chr2:242087351~242088457:-
LIHC	cis	rs5758511	0.68	rs5751243	ENSG00000205702.9	CYP2D7	4.77	2.78e-06	0.000877	0.29	0.25	Birth weight;	chr22:42221171	chr22:42140203~42144577:-
LIHC	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	4.77	2.78e-06	0.000877	0.29	0.25	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
LIHC	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	4.77	2.78e-06	0.000877	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
LIHC	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-4.77	2.78e-06	0.000877	-0.33	-0.25	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
LIHC	cis	rs2688482	0.512	rs3103953	ENSG00000207650.1	MIR570	-4.77	2.78e-06	0.000877	-0.33	-0.25	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195699401~195699497:+
LIHC	cis	rs7760535	0.93	rs7742244	ENSG00000255389.1	C6orf3	-4.77	2.79e-06	0.000878	-0.27	-0.25	Metabolic traits;	chr6:111531459	chr6:111599875~111602295:+
LIHC	cis	rs2976388	0.647	rs2082801	ENSG00000253196.1	RP11-706C16.7	4.77	2.79e-06	0.000878	0.24	0.25	Urinary tract infection frequency;	chr8:142705043	chr8:142763116~142766427:+
LIHC	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	4.77	2.79e-06	0.000878	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	4.77	2.79e-06	0.000878	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
LIHC	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	4.77	2.79e-06	0.000879	0.38	0.25	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	4.77	2.79e-06	0.000879	0.38	0.25	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	4.77	2.79e-06	0.000879	0.38	0.25	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	4.77	2.79e-06	0.000879	0.38	0.25	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	4.77	2.79e-06	0.000879	0.38	0.25	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	4.77	2.79e-06	0.000879	0.38	0.25	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
LIHC	cis	rs4820294	0.516	rs12627943	ENSG00000233360.4	Z83844.1	4.77	2.79e-06	0.000879	0.36	0.25	Fat distribution (HIV);	chr22:37700327	chr22:37641832~37658377:-
LIHC	cis	rs11098499	0.954	rs13107475	ENSG00000260091.1	RP11-33B1.4	-4.77	2.8e-06	0.000881	-0.18	-0.25	Corneal astigmatism;	chr4:119471856	chr4:119409333~119410233:+
LIHC	cis	rs5756813	0.754	rs4821711	ENSG00000233360.4	Z83844.1	4.76	2.8e-06	0.000881	0.32	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37785108	chr22:37641832~37658377:-
LIHC	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	4.76	2.8e-06	0.000882	0.19	0.25	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
LIHC	cis	rs7412746	0.634	rs12409208	ENSG00000231073.1	RP11-316M1.3	4.76	2.8e-06	0.000882	0.25	0.25	Melanoma;	chr1:150887579	chr1:150973123~150975534:+
LIHC	cis	rs860295	0.775	rs822508	ENSG00000203761.5	MSTO2P	-4.76	2.8e-06	0.000883	-0.21	-0.25	Body mass index;	chr1:155880767	chr1:155745829~155750137:+
LIHC	cis	rs1499614	1	rs2659913	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66692349	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs2707840	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66693028	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs2659911	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66693433	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs2707838	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66694214	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs60326618	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66701371	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs2707830	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66702658	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs2707828	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66706390	chr7:66880708~66882981:+
LIHC	cis	rs1499614	0.803	rs1922723	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66710076	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs2659903	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66715944	chr7:66880708~66882981:+
LIHC	cis	rs1499614	1	rs2141924	ENSG00000230295.1	RP11-458F8.2	-4.76	2.81e-06	0.000883	-0.26	-0.25	Gout;	chr7:66721259	chr7:66880708~66882981:+
LIHC	cis	rs12554020	0.892	rs10217595	ENSG00000227603.1	RP11-165J3.6	4.76	2.81e-06	0.000883	0.36	0.25	Schizophrenia;	chr9:93418609	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs10117236	ENSG00000227603.1	RP11-165J3.6	4.76	2.81e-06	0.000883	0.36	0.25	Schizophrenia;	chr9:93419731	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs7863760	ENSG00000227603.1	RP11-165J3.6	4.76	2.81e-06	0.000883	0.36	0.25	Schizophrenia;	chr9:93420287	chr9:93435332~93437121:-
LIHC	cis	rs8031584	0.679	rs34017474	ENSG00000270015.1	RP11-540B6.6	-4.76	2.81e-06	0.000883	-0.25	-0.25	Huntington's disease progression;	chr15:30938408	chr15:30926514~30928407:+
LIHC	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-4.76	2.81e-06	0.000883	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
LIHC	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	4.76	2.81e-06	0.000884	0.19	0.25	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
LIHC	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	4.76	2.81e-06	0.000884	0.27	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
LIHC	cis	rs7209700	0.745	rs8074348	ENSG00000228782.6	CTD-2026D20.3	-4.76	2.81e-06	0.000884	-0.28	-0.25	IgG glycosylation;	chr17:47276047	chr17:47450568~47492492:-
LIHC	cis	rs11079159	1	rs11079159	ENSG00000263096.1	RP11-515O17.2	4.76	2.81e-06	0.000885	0.34	0.25	QRS duration;	chr17:55296189	chr17:55271504~55273653:-
LIHC	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-4.76	2.81e-06	0.000885	-0.31	-0.25	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
LIHC	cis	rs1322639	0.614	rs6900200	ENSG00000261039.2	RP11-417E7.2	-4.76	2.81e-06	0.000886	-0.35	-0.25	Pulse pressure;	chr6:169166078	chr6:169175304~169182740:-
LIHC	cis	rs10256972	0.685	rs10263665	ENSG00000199023.2	MIR339	-4.76	2.82e-06	0.000888	-0.29	-0.25	Endometriosis;Longevity;	chr7:1070992	chr7:1022935~1023045:-
LIHC	cis	rs2442825	0.508	rs2648545	ENSG00000206573.7	THUMPD3-AS1	-4.76	2.82e-06	0.000888	-0.21	-0.25	Cerebrospinal fluid clusterin levels;	chr3:9347539	chr3:9349689~9398579:-
LIHC	cis	rs2836974	0.897	rs2836925	ENSG00000255568.3	BRWD1-AS2	4.76	2.82e-06	0.000888	0.28	0.25	Cognitive function;	chr21:39160427	chr21:39313935~39314962:+
LIHC	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	4.76	2.82e-06	0.000888	0.21	0.25	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
LIHC	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-4.76	2.83e-06	0.00089	-0.22	-0.25	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
LIHC	cis	rs2439831	0.85	rs2957637	ENSG00000275601.1	AC011330.13	-4.76	2.83e-06	0.00089	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43658920	chr15:43642389~43643023:-
LIHC	cis	rs4731207	0.844	rs34204767	ENSG00000224897.5	POT1-AS1	-4.76	2.83e-06	0.00089	-0.3	-0.25	Cutaneous malignant melanoma;	chr7:124761710	chr7:124929873~125179315:+
LIHC	cis	rs5758511	0.68	rs5758686	ENSG00000205702.9	CYP2D7	4.76	2.83e-06	0.00089	0.29	0.25	Birth weight;	chr22:42259371	chr22:42140203~42144577:-
LIHC	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-4.76	2.83e-06	0.00089	-0.29	-0.25	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-4.76	2.83e-06	0.00089	-0.29	-0.25	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-4.76	2.83e-06	0.00089	-0.29	-0.25	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-4.76	2.83e-06	0.00089	-0.29	-0.25	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
LIHC	cis	rs916888	0.61	rs199530	ENSG00000260075.1	NSFP1	-4.76	2.83e-06	0.00089	-0.31	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46372855~46487141:+
LIHC	cis	rs2439831	0.85	rs8023458	ENSG00000166763.7	STRCP1	4.76	2.83e-06	0.000891	0.38	0.25	Lung cancer in ever smokers;	chr15:43788741	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs16963953	ENSG00000166763.7	STRCP1	4.76	2.83e-06	0.000891	0.38	0.25	Lung cancer in ever smokers;	chr15:43789521	chr15:43699488~43718184:-
LIHC	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	4.76	2.83e-06	0.000891	0.34	0.25	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
LIHC	cis	rs417065	0.516	rs6661746	ENSG00000227634.1	RP11-431K24.3	-4.76	2.84e-06	0.000892	-0.31	-0.25	Psoriasis;	chr1:8208560	chr1:8208672~8215210:+
LIHC	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-4.76	2.84e-06	0.000892	-0.29	-0.25	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-4.76	2.84e-06	0.000892	-0.29	-0.25	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
LIHC	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-4.76	2.84e-06	0.000892	-0.29	-0.25	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
LIHC	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	4.76	2.84e-06	0.000893	0.41	0.25	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
LIHC	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-4.76	2.84e-06	0.000894	-0.26	-0.25	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-4.76	2.84e-06	0.000894	-0.26	-0.25	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.556	rs9999303	ENSG00000230069.3	LRRC37A15P	-4.76	2.84e-06	0.000894	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102727274~102730721:-
LIHC	cis	rs5758511	0.68	rs5758662	ENSG00000205702.9	CYP2D7	4.76	2.85e-06	0.000894	0.29	0.25	Birth weight;	chr22:42232082	chr22:42140203~42144577:-
LIHC	cis	rs227275	0.556	rs12508069	ENSG00000230069.3	LRRC37A15P	-4.76	2.85e-06	0.000895	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.527	rs12500379	ENSG00000230069.3	LRRC37A15P	-4.76	2.85e-06	0.000895	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs10015289	ENSG00000230069.3	LRRC37A15P	-4.76	2.85e-06	0.000895	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs6852141	ENSG00000230069.3	LRRC37A15P	-4.76	2.85e-06	0.000895	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102727274~102730721:-
LIHC	cis	rs228614	0.509	rs4455415	ENSG00000230069.3	LRRC37A15P	-4.76	2.85e-06	0.000895	-0.22	-0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102727274~102730721:-
LIHC	cis	rs2836974	0.568	rs442972	ENSG00000255568.3	BRWD1-AS2	-4.76	2.85e-06	0.000895	-0.21	-0.25	Cognitive function;	chr21:39162831	chr21:39313935~39314962:+
LIHC	cis	rs12554020	0.582	rs76849659	ENSG00000227603.1	RP11-165J3.6	4.76	2.85e-06	0.000897	0.46	0.25	Schizophrenia;	chr9:93685420	chr9:93435332~93437121:-
LIHC	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-4.76	2.86e-06	0.000897	-0.32	-0.25	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
LIHC	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-4.76	2.86e-06	0.000897	-0.32	-0.25	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
LIHC	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-4.76	2.86e-06	0.000897	-0.32	-0.25	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
LIHC	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	4.76	2.86e-06	0.000898	0.3	0.25	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
LIHC	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	4.76	2.86e-06	0.000898	0.22	0.25	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
LIHC	cis	rs901683	0.702	rs17157944	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45652818	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs17157945	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45652853	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76130427	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45656835	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs79337279	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45658092	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76025266	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45660828	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs112713257	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45661792	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs77236316	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45662972	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs74572856	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45663334	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs77387136	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45666654	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76555487	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45666706	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs79596920	ENSG00000230869.1	CTGLF10P	-4.76	2.86e-06	0.000898	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45667306	chr10:45678692~45700532:+
LIHC	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-4.76	2.86e-06	0.000898	-0.35	-0.25	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
LIHC	cis	rs10181042	0.514	rs1177283	ENSG00000271889.1	RP11-493E12.1	4.76	2.86e-06	0.000899	0.29	0.25	Crohn's disease;	chr2:61121669	chr2:61151433~61162105:-
LIHC	cis	rs1322639	0.614	rs6908401	ENSG00000261039.2	RP11-417E7.2	4.76	2.87e-06	9e-04	0.34	0.25	Pulse pressure;	chr6:169164621	chr6:169175304~169182740:-
LIHC	cis	rs2060793	0.519	rs1357332	ENSG00000251991.1	RNU7-49P	4.76	2.87e-06	0.000902	0.28	0.25	Vitamin D levels;	chr11:14618570	chr11:14478892~14478953:+
LIHC	cis	rs9291683	0.509	rs998676	ENSG00000250413.1	RP11-448G15.1	4.76	2.87e-06	0.000902	0.32	0.25	Bone mineral density;	chr4:9946940	chr4:10006482~10009725:+
LIHC	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-4.76	2.87e-06	0.000902	-0.26	-0.25	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
LIHC	cis	rs4650994	0.507	rs56229230	ENSG00000273384.1	RP5-1098D14.1	4.76	2.87e-06	0.000902	0.32	0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178557428	chr1:178651706~178652282:+
LIHC	cis	rs7412746	0.566	rs11204743	ENSG00000231073.1	RP11-316M1.3	4.76	2.87e-06	0.000902	0.25	0.25	Melanoma;	chr1:150917930	chr1:150973123~150975534:+
LIHC	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	4.76	2.87e-06	0.000902	0.33	0.25	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
LIHC	cis	rs1577917	0.876	rs66986937	ENSG00000234155.1	RP11-30P6.6	4.76	2.88e-06	0.000903	0.34	0.25	Response to antipsychotic treatment;	chr6:85822473	chr6:85387219~85390186:-
LIHC	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-4.76	2.88e-06	0.000903	-0.29	-0.25	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
LIHC	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	4.76	2.88e-06	0.000903	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
LIHC	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	4.76	2.88e-06	0.000903	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
LIHC	cis	rs1322639	0.614	rs6903921	ENSG00000261039.2	RP11-417E7.2	-4.76	2.88e-06	0.000903	-0.36	-0.25	Pulse pressure;	chr6:169163862	chr6:169175304~169182740:-
LIHC	cis	rs1322639	0.614	rs6925950	ENSG00000261039.2	RP11-417E7.2	-4.76	2.88e-06	0.000903	-0.36	-0.25	Pulse pressure;	chr6:169163863	chr6:169175304~169182740:-
LIHC	cis	rs7131987	0.903	rs918873	ENSG00000257176.2	RP11-996F15.2	-4.76	2.88e-06	0.000904	-0.29	-0.25	QT interval;	chr12:29237568	chr12:29280418~29317848:-
LIHC	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	4.76	2.88e-06	0.000905	0.33	0.25	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	4.76	2.88e-06	0.000905	0.33	0.25	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	4.76	2.88e-06	0.000905	0.33	0.25	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	4.76	2.88e-06	0.000905	0.33	0.25	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
LIHC	cis	rs4731207	0.844	rs2402749	ENSG00000224897.5	POT1-AS1	-4.76	2.88e-06	0.000905	-0.3	-0.25	Cutaneous malignant melanoma;	chr7:124749669	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.844	rs33935352	ENSG00000224897.5	POT1-AS1	-4.76	2.88e-06	0.000905	-0.3	-0.25	Cutaneous malignant melanoma;	chr7:124755256	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.844	rs2267707	ENSG00000224897.5	POT1-AS1	-4.76	2.88e-06	0.000905	-0.3	-0.25	Cutaneous malignant melanoma;	chr7:124756972	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.844	rs2299903	ENSG00000224897.5	POT1-AS1	-4.76	2.88e-06	0.000905	-0.3	-0.25	Cutaneous malignant melanoma;	chr7:124757288	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.844	rs4731208	ENSG00000224897.5	POT1-AS1	-4.76	2.88e-06	0.000905	-0.3	-0.25	Cutaneous malignant melanoma;	chr7:124758142	chr7:124929873~125179315:+
LIHC	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	4.76	2.89e-06	0.000906	0.35	0.25	Height;	chr6:109351533	chr6:109382795~109383666:+
LIHC	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-4.76	2.89e-06	0.000906	-0.4	-0.25	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
LIHC	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-4.76	2.89e-06	0.000906	-0.36	-0.25	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-4.76	2.89e-06	0.000906	-0.36	-0.25	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-4.76	2.89e-06	0.000906	-0.36	-0.25	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-4.76	2.89e-06	0.000906	-0.36	-0.25	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
LIHC	cis	rs12478296	1	rs6732595	ENSG00000261186.2	RP11-341N2.1	-4.76	2.89e-06	0.000906	-0.35	-0.25	Obesity-related traits;	chr2:242093187	chr2:242087351~242088457:-
LIHC	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-4.76	2.89e-06	0.000906	-0.27	-0.25	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
LIHC	cis	rs11098499	0.909	rs9994810	ENSG00000260091.1	RP11-33B1.4	-4.76	2.89e-06	0.000906	-0.18	-0.25	Corneal astigmatism;	chr4:119460435	chr4:119409333~119410233:+
LIHC	cis	rs7119038	0.509	rs11216956	ENSG00000255422.1	AP002954.4	4.76	2.9e-06	0.000908	0.33	0.25	Sjögren's syndrome;	chr11:118704617	chr11:118704607~118750263:+
LIHC	cis	rs2439831	0.85	rs10438303	ENSG00000166763.7	STRCP1	4.76	2.9e-06	0.000908	0.38	0.25	Lung cancer in ever smokers;	chr15:43724219	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28504496	ENSG00000166763.7	STRCP1	4.76	2.9e-06	0.000908	0.38	0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs12441127	ENSG00000166763.7	STRCP1	4.76	2.9e-06	0.000908	0.38	0.25	Lung cancer in ever smokers;	chr15:43728977	chr15:43699488~43718184:-
LIHC	cis	rs6479891	0.722	rs4746951	ENSG00000232075.1	MRPL35P2	4.76	2.9e-06	0.000908	0.27	0.25	Arthritis (juvenile idiopathic);	chr10:63123839	chr10:63634317~63634827:-
LIHC	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-4.76	2.9e-06	0.000909	-0.39	-0.25	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
LIHC	cis	rs7809950	1	rs2520260	ENSG00000238832.1	snoU109	-4.76	2.9e-06	0.000909	-0.3	-0.25	Coronary artery disease;	chr7:107532349	chr7:107603363~107603507:+
LIHC	cis	rs1223397	0.938	rs3817738	ENSG00000215022.6	RP1-257A7.4	-4.76	2.9e-06	0.000909	-0.28	-0.25	Blood pressure;	chr6:13279156	chr6:13264861~13295586:-
LIHC	cis	rs9834975	1	rs9818363	ENSG00000272758.4	RP11-299J3.8	-4.76	2.91e-06	0.00091	-0.28	-0.25	Diastolic blood pressure;	chr3:122393444	chr3:122416207~122443180:+
LIHC	cis	rs9834975	0.873	rs9882772	ENSG00000272758.4	RP11-299J3.8	-4.76	2.91e-06	0.000911	-0.28	-0.25	Diastolic blood pressure;	chr3:122391302	chr3:122416207~122443180:+
LIHC	cis	rs4660214	0.789	rs1180375	ENSG00000182109.6	RP11-69E11.4	4.76	2.91e-06	0.000911	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415368	chr1:39522280~39546187:-
LIHC	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-4.76	2.91e-06	0.000912	-0.25	-0.25	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
LIHC	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-4.76	2.91e-06	0.000912	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
LIHC	cis	rs5769707	0.967	rs9616713	ENSG00000235111.1	RP1-29C18.8	-4.76	2.91e-06	0.000912	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49612657~49615716:-
LIHC	cis	rs728616	1	rs56317427	ENSG00000225484.5	NUTM2B-AS1	-4.76	2.91e-06	0.000912	-0.54	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80102178	chr10:79663088~79826594:-
LIHC	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-4.76	2.92e-06	0.000913	-0.31	-0.25	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
LIHC	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	4.76	2.92e-06	0.000914	0.17	0.25	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
LIHC	cis	rs643506	0.874	rs618421	ENSG00000254990.4	RP11-108O10.2	4.76	2.92e-06	0.000914	0.27	0.25	Breast cancer;	chr11:111778085	chr11:111768668~111778350:-
LIHC	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	4.76	2.92e-06	0.000914	0.26	0.25	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
LIHC	cis	rs916888	0.821	rs199506	ENSG00000274883.1	Metazoa_SRP	4.76	2.92e-06	0.000914	0.39	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45931806~45932083:+
LIHC	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-4.76	2.92e-06	0.000915	-0.25	-0.25	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
LIHC	cis	rs1865760	0.566	rs3752420	ENSG00000216436.2	HIST1H2APS1	-4.76	2.93e-06	0.000916	-0.29	-0.25	Height;	chr6:26026907	chr6:25732497~25732827:+
LIHC	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-4.76	2.93e-06	0.000916	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
LIHC	cis	rs2834188	1	rs2096464	ENSG00000272659.1	AP000295.10	4.76	2.93e-06	0.000916	0.37	0.25	Narcolepsy;	chr21:33313744	chr21:33309491~33310181:+
LIHC	cis	rs1577917	1	rs13196930	ENSG00000234155.1	RP11-30P6.6	4.76	2.93e-06	0.000917	0.33	0.25	Response to antipsychotic treatment;	chr6:85942527	chr6:85387219~85390186:-
LIHC	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	4.76	2.93e-06	0.000917	0.34	0.25	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
LIHC	cis	rs11098499	0.738	rs72918577	ENSG00000260091.1	RP11-33B1.4	-4.76	2.93e-06	0.000917	-0.18	-0.25	Corneal astigmatism;	chr4:119405546	chr4:119409333~119410233:+
LIHC	cis	rs6479891	0.63	rs10995447	ENSG00000232075.1	MRPL35P2	4.75	2.93e-06	0.000917	0.27	0.25	Arthritis (juvenile idiopathic);	chr10:63119761	chr10:63634317~63634827:-
LIHC	cis	rs875971	0.545	rs10950025	ENSG00000273142.1	RP11-458F8.4	4.75	2.93e-06	0.000917	0.24	0.25	Aortic root size;	chr7:66158946	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.52	rs12666485	ENSG00000273142.1	RP11-458F8.4	4.75	2.93e-06	0.000917	0.24	0.25	Aortic root size;	chr7:66160135	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs67688847	ENSG00000273142.1	RP11-458F8.4	4.75	2.93e-06	0.000917	0.24	0.25	Aortic root size;	chr7:66161064	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs12673308	ENSG00000273142.1	RP11-458F8.4	4.75	2.93e-06	0.000917	0.24	0.25	Aortic root size;	chr7:66166374	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs316305	ENSG00000273142.1	RP11-458F8.4	-4.75	2.93e-06	0.000917	-0.24	-0.25	Aortic root size;	chr7:66152984	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs316306	ENSG00000273142.1	RP11-458F8.4	-4.75	2.93e-06	0.000917	-0.24	-0.25	Aortic root size;	chr7:66153687	chr7:66902857~66906297:+
LIHC	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	4.75	2.93e-06	0.000918	0.38	0.25	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
LIHC	cis	rs4650994	0.525	rs2493864	ENSG00000273384.1	RP5-1098D14.1	4.75	2.94e-06	0.000918	0.31	0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178575868	chr1:178651706~178652282:+
LIHC	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	4.75	2.94e-06	0.000919	0.19	0.25	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	4.75	2.94e-06	0.000919	0.19	0.25	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
LIHC	cis	rs12908161	0.853	rs11633788	ENSG00000259295.5	CSPG4P12	4.75	2.94e-06	0.000919	0.31	0.25	Schizophrenia;	chr15:84761911	chr15:85191438~85213905:+
LIHC	cis	rs12478296	0.892	rs60545379	ENSG00000261186.2	RP11-341N2.1	-4.75	2.94e-06	0.000921	-0.35	-0.25	Obesity-related traits;	chr2:242092239	chr2:242087351~242088457:-
LIHC	cis	rs6479901	0.512	rs4746244	ENSG00000232075.1	MRPL35P2	-4.75	2.95e-06	0.000922	-0.3	-0.25	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63634317~63634827:-
LIHC	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	4.75	2.95e-06	0.000923	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	4.75	2.95e-06	0.000923	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
LIHC	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-4.75	2.95e-06	0.000923	-0.31	-0.25	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
LIHC	cis	rs16858210	0.607	rs35205152	ENSG00000234371.6	RPSAP31	4.75	2.95e-06	0.000923	0.35	0.25	Menopause (age at onset);	chr3:183845541	chr3:183884924~183888449:+
LIHC	cis	rs2836974	0.897	rs3945	ENSG00000255568.3	BRWD1-AS2	4.75	2.95e-06	0.000923	0.29	0.25	Cognitive function;	chr21:39194141	chr21:39313935~39314962:+
LIHC	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-4.75	2.95e-06	0.000923	-0.26	-0.25	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
LIHC	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-4.75	2.95e-06	0.000923	-0.31	-0.25	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
LIHC	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	4.75	2.95e-06	0.000924	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
LIHC	cis	rs1223397	0.938	rs3817737	ENSG00000215022.6	RP1-257A7.4	-4.75	2.96e-06	0.000924	-0.29	-0.25	Blood pressure;	chr6:13278850	chr6:13264861~13295586:-
LIHC	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-4.75	2.96e-06	0.000924	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
LIHC	cis	rs4650994	0.816	rs2209169	ENSG00000273384.1	RP5-1098D14.1	-4.75	2.96e-06	0.000925	-0.29	-0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178632357	chr1:178651706~178652282:+
LIHC	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	4.75	2.96e-06	0.000925	0.31	0.25	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
LIHC	cis	rs739496	0.947	rs34368158	ENSG00000226469.1	ADAM1B	4.75	2.96e-06	0.000926	0.31	0.25	Platelet count;	chr12:111408224	chr12:111927018~111929017:+
LIHC	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-4.75	2.96e-06	0.000926	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
LIHC	cis	rs1577917	1	rs10944163	ENSG00000234155.1	RP11-30P6.6	4.75	2.96e-06	0.000927	0.33	0.25	Response to antipsychotic treatment;	chr6:85948975	chr6:85387219~85390186:-
LIHC	cis	rs12554020	0.681	rs75519210	ENSG00000227603.1	RP11-165J3.6	4.75	2.97e-06	0.000927	0.46	0.25	Schizophrenia;	chr9:93661448	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs112401922	ENSG00000227603.1	RP11-165J3.6	4.75	2.97e-06	0.000927	0.46	0.25	Schizophrenia;	chr9:93661517	chr9:93435332~93437121:-
LIHC	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	4.75	2.97e-06	0.000927	0.27	0.25	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
LIHC	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	4.75	2.97e-06	0.000928	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
LIHC	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	4.75	2.97e-06	0.000928	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
LIHC	cis	rs2470135	1	rs2470135	ENSG00000166763.7	STRCP1	4.75	2.97e-06	0.000928	0.31	0.25	Diastolic blood pressure;	chr15:43703591	chr15:43699488~43718184:-
LIHC	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-4.75	2.97e-06	0.000928	-0.3	-0.25	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
LIHC	cis	rs875971	0.545	rs7787063	ENSG00000273142.1	RP11-458F8.4	4.75	2.97e-06	0.000928	0.24	0.25	Aortic root size;	chr7:66164012	chr7:66902857~66906297:+
LIHC	cis	rs11098499	0.821	rs10032151	ENSG00000260091.1	RP11-33B1.4	-4.75	2.97e-06	0.000928	-0.18	-0.25	Corneal astigmatism;	chr4:119470473	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs10032158	ENSG00000260091.1	RP11-33B1.4	-4.75	2.97e-06	0.000928	-0.18	-0.25	Corneal astigmatism;	chr4:119470477	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs6838814	ENSG00000260091.1	RP11-33B1.4	-4.75	2.97e-06	0.000928	-0.18	-0.25	Corneal astigmatism;	chr4:119471288	chr4:119409333~119410233:+
LIHC	cis	rs1322639	0.575	rs9294966	ENSG00000261039.2	RP11-417E7.2	-4.75	2.97e-06	0.000928	-0.35	-0.25	Pulse pressure;	chr6:169165223	chr6:169175304~169182740:-
LIHC	cis	rs1322639	0.614	rs7768154	ENSG00000261039.2	RP11-417E7.2	-4.75	2.97e-06	0.000928	-0.35	-0.25	Pulse pressure;	chr6:169165375	chr6:169175304~169182740:-
LIHC	cis	rs4650994	0.525	rs4651000	ENSG00000273384.1	RP5-1098D14.1	4.75	2.97e-06	0.000929	0.31	0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178563088	chr1:178651706~178652282:+
LIHC	cis	rs16858210	0.529	rs10937154	ENSG00000234371.6	RPSAP31	4.75	2.98e-06	0.000929	0.34	0.25	Menopause (age at onset);	chr3:183851701	chr3:183884924~183888449:+
LIHC	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-4.75	2.98e-06	0.00093	-0.3	-0.25	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
LIHC	cis	rs2836974	0.568	rs377098	ENSG00000255568.3	BRWD1-AS2	-4.75	2.98e-06	0.00093	-0.21	-0.25	Cognitive function;	chr21:39163290	chr21:39313935~39314962:+
LIHC	cis	rs643506	0.874	rs4245045	ENSG00000254990.4	RP11-108O10.2	4.75	2.98e-06	0.000931	0.27	0.25	Breast cancer;	chr11:111789200	chr11:111768668~111778350:-
LIHC	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	4.75	2.98e-06	0.000932	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	4.75	2.98e-06	0.000932	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
LIHC	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-4.75	2.99e-06	0.000932	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
LIHC	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	4.75	2.99e-06	0.000932	0.19	0.25	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
LIHC	cis	rs8028182	0.636	rs4886699	ENSG00000260269.4	CTD-2323K18.1	-4.75	2.99e-06	0.000933	-0.31	-0.25	Sudden cardiac arrest;	chr15:75399962	chr15:75527150~75601205:-
LIHC	cis	rs2834188	1	rs2409488	ENSG00000272659.1	AP000295.10	-4.75	2.99e-06	0.000933	-0.37	-0.25	Narcolepsy;	chr21:33316609	chr21:33309491~33310181:+
LIHC	cis	rs2836974	0.568	rs429955	ENSG00000255568.3	BRWD1-AS2	4.75	2.99e-06	0.000934	0.21	0.25	Cognitive function;	chr21:39167834	chr21:39313935~39314962:+
LIHC	cis	rs929596	0.561	rs7564935	ENSG00000233445.1	RPL17P11	4.75	3e-06	0.000935	0.28	0.25	Total bilirubin levels in HIV-1 infection;	chr2:233736540	chr2:233721522~233722065:-
LIHC	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	4.75	3e-06	0.000935	0.18	0.25	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	4.75	3e-06	0.000935	0.18	0.25	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
LIHC	cis	rs11216126	1	rs4938307	ENSG00000254851.1	RP11-109L13.1	4.75	3e-06	0.000935	0.38	0.25	HDL cholesterol;	chr11:116733798	chr11:117135528~117138582:+
LIHC	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	4.75	3e-06	0.000936	0.3	0.25	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
LIHC	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-4.75	3e-06	0.000936	-0.31	-0.25	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
LIHC	cis	rs7914558	1	rs7911789	ENSG00000236937.2	PTGES3P4	4.75	3e-06	0.000937	0.29	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102845595~102845950:+
LIHC	cis	rs1558001	1	rs6467872	ENSG00000230196.1	DDX43P3	4.75	3e-06	0.000937	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81775566	chr7:81610884~81611326:-
LIHC	cis	rs2310173	0.612	rs3819369	ENSG00000281162.1	LINC01127	-4.75	3e-06	0.000937	-0.27	-0.25	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102016120	chr2:101962056~101987167:+
LIHC	cis	rs7702057	0.53	rs17138879	ENSG00000271918.1	CTD-2287O16.5	-4.75	3e-06	0.000937	-0.34	-0.25	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116083807~116085416:-
LIHC	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-4.75	3.01e-06	0.000938	-0.29	-0.25	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
LIHC	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-4.75	3.01e-06	0.000938	-0.28	-0.25	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
LIHC	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-4.75	3.01e-06	0.000938	-0.31	-0.25	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
LIHC	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-4.75	3.01e-06	0.000939	-0.29	-0.25	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
LIHC	cis	rs2836974	0.965	rs2836967	ENSG00000255568.3	BRWD1-AS2	4.75	3.01e-06	0.000939	0.28	0.25	Cognitive function;	chr21:39267176	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.965	rs8130984	ENSG00000255568.3	BRWD1-AS2	4.75	3.01e-06	0.000939	0.28	0.25	Cognitive function;	chr21:39268040	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.965	rs6517538	ENSG00000255568.3	BRWD1-AS2	4.75	3.01e-06	0.000939	0.28	0.25	Cognitive function;	chr21:39284316	chr21:39313935~39314962:+
LIHC	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	4.75	3.01e-06	0.000939	0.29	0.25	Height;	chr6:109634150	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	4.75	3.01e-06	0.000939	0.29	0.25	Height;	chr6:109640141	chr6:109382795~109383666:+
LIHC	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	4.75	3.01e-06	0.00094	0.47	0.25	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
LIHC	cis	rs30380	0.573	rs469783	ENSG00000272109.1	CTD-2260A17.3	-4.75	3.01e-06	0.00094	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96804353~96806105:+
LIHC	cis	rs12554020	0.786	rs12349299	ENSG00000227603.1	RP11-165J3.6	4.75	3.01e-06	0.00094	0.36	0.25	Schizophrenia;	chr9:93412482	chr9:93435332~93437121:-
LIHC	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	4.75	3.01e-06	0.00094	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
LIHC	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-4.75	3.01e-06	0.00094	-0.22	-0.25	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
LIHC	cis	rs2439831	0.85	rs16965120	ENSG00000275601.1	AC011330.13	-4.75	3.02e-06	0.000942	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43808144	chr15:43642389~43643023:-
LIHC	cis	rs1714507	0.533	rs1620229	ENSG00000272087.1	RP11-379F4.7	4.75	3.02e-06	0.000942	0.28	0.25	Subjective well-being;	chr3:158575469	chr3:158693120~158693768:-
LIHC	cis	rs7662987	0.793	rs7669660	ENSG00000272777.1	RP11-571L19.8	4.75	3.02e-06	0.000942	0.54	0.25	Smoking initiation;	chr4:99071451	chr4:99067256~99068125:-
LIHC	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	4.75	3.02e-06	0.000942	0.2	0.25	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
LIHC	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-4.75	3.02e-06	0.000943	-0.26	-0.25	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
LIHC	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	4.75	3.02e-06	0.000943	0.29	0.25	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
LIHC	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	4.75	3.03e-06	0.000943	0.34	0.25	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
LIHC	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	4.75	3.03e-06	0.000943	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
LIHC	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	4.75	3.03e-06	0.000944	0.29	0.25	Height;	chr6:109446728	chr6:109382795~109383666:+
LIHC	cis	rs10510102	0.935	rs12253283	ENSG00000226864.1	ATE1-AS1	-4.75	3.03e-06	0.000944	-0.39	-0.25	Breast cancer;	chr10:121909740	chr10:121928312~121951965:+
LIHC	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-4.75	3.03e-06	0.000944	-0.41	-0.25	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
LIHC	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	4.75	3.03e-06	0.000945	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	4.75	3.04e-06	0.000946	0.28	0.25	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	4.75	3.04e-06	0.000946	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	4.75	3.04e-06	0.000946	0.28	0.25	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	4.75	3.04e-06	0.000946	0.28	0.25	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
LIHC	cis	rs728616	0.558	rs61859793	ENSG00000225484.5	NUTM2B-AS1	-4.75	3.04e-06	0.000946	-0.48	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79663088~79826594:-
LIHC	cis	rs7246657	0.943	rs4802136	ENSG00000276846.1	CTD-3220F14.3	4.75	3.04e-06	0.000947	0.3	0.25	Coronary artery calcification;	chr19:37358909	chr19:37314868~37315620:-
LIHC	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs10269683	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139416122	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	4.75	3.04e-06	0.000947	0.22	0.25	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
LIHC	cis	rs11089937	0.597	rs11089925	ENSG00000211639.2	IGLV4-60	4.75	3.04e-06	0.000947	0.21	0.25	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22162199~22162681:+
LIHC	cis	rs1003645	1	rs8075916	ENSG00000275944.1	RP11-104J23.1	4.75	3.04e-06	0.000947	0.25	0.25	Blood protein levels;	chr17:36016808	chr17:36001419~36011618:+
LIHC	cis	rs6163	0.588	rs10786706	ENSG00000236937.2	PTGES3P4	4.75	3.05e-06	0.000948	0.3	0.25	Waist circumference;Hip circumference;	chr10:102740902	chr10:102845595~102845950:+
LIHC	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	4.75	3.05e-06	0.000948	0.2	0.25	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
LIHC	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	4.75	3.05e-06	0.000949	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
LIHC	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-4.75	3.05e-06	0.000949	-0.31	-0.25	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
LIHC	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	4.75	3.05e-06	0.00095	0.27	0.25	Asthma;	chr2:102446780	chr2:102438713~102440475:+
LIHC	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	4.75	3.06e-06	0.00095	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
LIHC	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-4.75	3.06e-06	0.000951	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
LIHC	cis	rs12887734	0.524	rs12588797	ENSG00000258534.1	CTD-2134A5.4	4.75	3.06e-06	0.000951	0.27	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103854366~103880111:-
LIHC	cis	rs11722779	0.935	rs6533046	ENSG00000230069.3	LRRC37A15P	-4.75	3.06e-06	0.000952	-0.22	-0.25	Schizophrenia;	chr4:102965917	chr4:102727274~102730721:-
LIHC	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	4.75	3.06e-06	0.000952	0.31	0.25	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	4.75	3.06e-06	0.000952	0.31	0.25	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	4.75	3.06e-06	0.000952	0.31	0.25	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
LIHC	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	4.75	3.06e-06	0.000952	0.28	0.25	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
LIHC	cis	rs2836974	0.863	rs1065242	ENSG00000255568.3	BRWD1-AS2	4.75	3.06e-06	0.000952	0.28	0.25	Cognitive function;	chr21:39195790	chr21:39313935~39314962:+
LIHC	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	4.75	3.06e-06	0.000953	0.38	0.25	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	4.75	3.06e-06	0.000953	0.38	0.25	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
LIHC	cis	rs9467711	0.591	rs13196552	ENSG00000216436.2	HIST1H2APS1	4.75	3.06e-06	0.000953	0.64	0.25	Autism spectrum disorder or schizophrenia;	chr6:25973976	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs56294283	ENSG00000216436.2	HIST1H2APS1	4.75	3.06e-06	0.000953	0.64	0.25	Autism spectrum disorder or schizophrenia;	chr6:25975871	chr6:25732497~25732827:+
LIHC	cis	rs8028182	0.636	rs11636199	ENSG00000260269.4	CTD-2323K18.1	-4.75	3.07e-06	0.000953	-0.31	-0.25	Sudden cardiac arrest;	chr15:75532996	chr15:75527150~75601205:-
LIHC	cis	rs1729407	0.695	rs1263176	ENSG00000236267.1	AP006216.5	4.75	3.07e-06	0.000954	0.23	0.25	Apolipoprotein A-IV levels;	chr11:116819407	chr11:116813204~116814003:-
LIHC	cis	rs12157904	1	rs5995481	ENSG00000233360.4	Z83844.1	4.74	3.07e-06	0.000954	0.49	0.25	Response to anti-depressant treatment in major depressive disorder;	chr22:37608195	chr22:37641832~37658377:-
LIHC	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	4.74	3.07e-06	0.000954	0.33	0.25	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
LIHC	cis	rs5769765	0.658	rs2157536	ENSG00000278869.1	CITF22-49E9.3	4.74	3.07e-06	0.000954	0.38	0.25	Schizophrenia;	chr22:49796532	chr22:49933198~49934074:-
LIHC	cis	rs901683	0.702	rs77819548	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45642760	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs112909171	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45645322	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs78275508	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45645365	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs75203622	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45645457	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs75605891	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45645607	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs74595557	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45648173	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76232026	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45648688	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs17157941	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45651298	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs80162657	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45652344	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs74470893	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45663939	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76238709	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45666294	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs113325959	ENSG00000230869.1	CTGLF10P	-4.74	3.07e-06	0.000955	-0.64	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45670577	chr10:45678692~45700532:+
LIHC	cis	rs2877649	0.51	rs10144287	ENSG00000258744.1	RP11-80A15.1	-4.74	3.08e-06	0.000956	-0.46	-0.25	Smooth-surface caries;	chr14:24437643	chr14:24501594~24508688:+
LIHC	cis	rs5756813	0.727	rs4821703	ENSG00000233360.4	Z83844.1	4.74	3.08e-06	0.000957	0.32	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37740669	chr22:37641832~37658377:-
LIHC	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	4.74	3.08e-06	0.000957	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
LIHC	cis	rs116139393	0.54	rs12539942	ENSG00000187953.9	PMS2CL	-4.74	3.08e-06	0.000957	-0.25	-0.25	Alzheimer's disease (APOE e4 interaction);	chr7:6736954	chr7:6710128~6753862:+
LIHC	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-4.74	3.09e-06	0.00096	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
LIHC	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-4.74	3.09e-06	0.00096	-0.3	-0.25	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
LIHC	cis	rs6931421	1	rs6931421	ENSG00000272129.1	RP11-250B2.6	4.74	3.09e-06	0.00096	0.26	0.25	Sitting height ratio;	chr6:80170421	chr6:80355424~80356859:+
LIHC	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-4.74	3.1e-06	0.000961	-0.3	-0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
LIHC	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-4.74	3.1e-06	0.000961	-0.25	-0.25	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-4.74	3.1e-06	0.000961	-0.25	-0.25	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
LIHC	cis	rs6997458	0.749	rs13270041	ENSG00000253549.4	RP11-317J10.2	4.74	3.1e-06	0.000961	0.27	0.25	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85450734	chr8:85441851~85464915:-
LIHC	cis	rs712039	0.652	rs8069062	ENSG00000276054.1	RP11-378E13.3	4.74	3.1e-06	0.000962	0.31	0.25	Tuberculosis;	chr17:37469202	chr17:37386886~37387926:+
LIHC	cis	rs712039	0.652	rs60112577	ENSG00000276054.1	RP11-378E13.3	4.74	3.1e-06	0.000962	0.31	0.25	Tuberculosis;	chr17:37473105	chr17:37386886~37387926:+
LIHC	cis	rs2439831	0.867	rs12443102	ENSG00000275601.1	AC011330.13	-4.74	3.1e-06	0.000963	-0.37	-0.25	Lung cancer in ever smokers;	chr15:43639905	chr15:43642389~43643023:-
LIHC	cis	rs9467711	0.591	rs34791189	ENSG00000216436.2	HIST1H2APS1	4.74	3.1e-06	0.000963	0.63	0.25	Autism spectrum disorder or schizophrenia;	chr6:26035578	chr6:25732497~25732827:+
LIHC	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	4.74	3.1e-06	0.000964	0.24	0.25	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
LIHC	cis	rs11971779	0.553	rs36002669	ENSG00000273391.1	RP11-634H22.1	4.74	3.11e-06	0.000964	0.22	0.25	Diisocyanate-induced asthma;	chr7:139428415	chr7:139359032~139359566:-
LIHC	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-4.74	3.11e-06	0.000964	-0.27	-0.25	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
LIHC	cis	rs2836974	0.897	rs2836973	ENSG00000255568.3	BRWD1-AS2	4.74	3.11e-06	0.000965	0.28	0.25	Cognitive function;	chr21:39283002	chr21:39313935~39314962:+
LIHC	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-4.74	3.11e-06	0.000966	-0.22	-0.25	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
LIHC	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	4.74	3.12e-06	0.000966	0.47	0.25	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
LIHC	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	4.74	3.12e-06	0.000966	0.47	0.25	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
LIHC	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-4.74	3.12e-06	0.000967	-0.32	-0.25	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
LIHC	cis	rs7208859	0.673	rs73271887	ENSG00000266490.1	CTD-2349P21.9	4.74	3.12e-06	0.000967	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30792372~30792833:+
LIHC	cis	rs7131987	0.934	rs2216854	ENSG00000257176.2	RP11-996F15.2	-4.74	3.12e-06	0.000967	-0.28	-0.25	QT interval;	chr12:29270527	chr12:29280418~29317848:-
LIHC	cis	rs9843304	0.529	rs34895718	ENSG00000244503.1	RP11-278L15.6	4.74	3.12e-06	0.000967	0.25	0.25	Gallstone disease;	chr3:149487430	chr3:149494660~149495995:+
LIHC	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-4.74	3.12e-06	0.000968	-0.29	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
LIHC	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-4.74	3.12e-06	0.000968	-0.45	-0.25	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
LIHC	cis	rs7119038	0.818	rs7942535	ENSG00000255239.1	AP002954.6	4.74	3.13e-06	0.000969	0.31	0.25	Sjögren's syndrome;	chr11:118810755	chr11:118688039~118690600:-
LIHC	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	4.74	3.13e-06	0.000969	0.38	0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
LIHC	cis	rs9890032	0.581	rs62070592	ENSG00000263531.1	RP13-753N3.1	4.74	3.13e-06	0.00097	0.33	0.25	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30863921~30864940:-
LIHC	cis	rs57502260	0.704	rs923346	ENSG00000212093.1	AP000807.1	4.74	3.13e-06	0.00097	0.32	0.25	Total body bone mineral density (age 45-60);	chr11:68414907	chr11:68506083~68506166:-
LIHC	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	4.74	3.14e-06	0.000971	0.45	0.25	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	4.74	3.14e-06	0.000971	0.45	0.25	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	4.74	3.14e-06	0.000971	0.45	0.25	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
LIHC	cis	rs1005277	0.579	rs1780121	ENSG00000276805.1	RP11-291L22.6	4.74	3.14e-06	0.000972	0.31	0.25	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1780122	ENSG00000276805.1	RP11-291L22.6	4.74	3.14e-06	0.000972	0.31	0.25	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1780145	ENSG00000276805.1	RP11-291L22.6	4.74	3.14e-06	0.000972	0.31	0.25	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38451030~38451785:+
LIHC	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	4.74	3.14e-06	0.000972	0.35	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
LIHC	cis	rs5758511	0.68	rs5758667	ENSG00000205702.9	CYP2D7	4.74	3.14e-06	0.000973	0.29	0.25	Birth weight;	chr22:42237198	chr22:42140203~42144577:-
LIHC	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	4.74	3.14e-06	0.000973	0.24	0.25	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
LIHC	cis	rs1558001	0.87	rs6972704	ENSG00000230196.1	DDX43P3	4.74	3.14e-06	0.000974	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81784021	chr7:81610884~81611326:-
LIHC	cis	rs17301013	0.932	rs1793297	ENSG00000227373.4	RP11-160H22.5	-4.74	3.15e-06	0.000975	-0.3	-0.25	Systemic lupus erythematosus;	chr1:174784411	chr1:174115300~174160004:-
LIHC	cis	rs7131987	0.903	rs7974221	ENSG00000257176.2	RP11-996F15.2	-4.74	3.15e-06	0.000975	-0.28	-0.25	QT interval;	chr12:29246515	chr12:29280418~29317848:-
LIHC	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-4.74	3.15e-06	0.000975	-0.32	-0.25	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
LIHC	cis	rs7412746	0.658	rs11581757	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150919768	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs12090215	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150921184	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs72704682	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150925201	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs72704685	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150925211	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs4970986	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150935479	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs59024312	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150936529	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs7521719	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150940658	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs7528773	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150943399	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs3843843	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150945608	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.634	rs2124952	ENSG00000231073.1	RP11-316M1.3	4.74	3.15e-06	0.000975	0.25	0.25	Melanoma;	chr1:150951298	chr1:150973123~150975534:+
LIHC	cis	rs10129255	0.53	rs8008811	ENSG00000211970.3	IGHV4-61	-4.74	3.15e-06	0.000975	-0.2	-0.25	Kawasaki disease;	chr14:106652273	chr14:106639119~106639657:-
LIHC	cis	rs10129255	0.542	rs8009795	ENSG00000211970.3	IGHV4-61	-4.74	3.15e-06	0.000975	-0.2	-0.25	Kawasaki disease;	chr14:106652287	chr14:106639119~106639657:-
LIHC	cis	rs10129255	0.528	rs8008831	ENSG00000211970.3	IGHV4-61	-4.74	3.15e-06	0.000975	-0.2	-0.25	Kawasaki disease;	chr14:106652290	chr14:106639119~106639657:-
LIHC	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-4.74	3.15e-06	0.000976	-0.3	-0.25	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
LIHC	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-4.74	3.15e-06	0.000976	-0.26	-0.25	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-4.74	3.15e-06	0.000976	-0.26	-0.25	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
LIHC	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	4.74	3.15e-06	0.000976	0.32	0.25	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	4.74	3.15e-06	0.000976	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	4.74	3.15e-06	0.000976	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
LIHC	cis	rs2834188	1	rs2252931	ENSG00000272659.1	AP000295.10	-4.74	3.15e-06	0.000976	-0.38	-0.25	Narcolepsy;	chr21:33332014	chr21:33309491~33310181:+
LIHC	cis	rs2060793	0.741	rs10741656	ENSG00000251991.1	RNU7-49P	4.74	3.16e-06	0.000977	0.28	0.25	Vitamin D levels;	chr11:14803699	chr11:14478892~14478953:+
LIHC	cis	rs1729407	0.741	rs1263177	ENSG00000236267.1	AP006216.5	4.74	3.16e-06	0.000978	0.23	0.25	Apolipoprotein A-IV levels;	chr11:116819996	chr11:116813204~116814003:-
LIHC	cis	rs9467711	0.591	rs67296946	ENSG00000216436.2	HIST1H2APS1	4.74	3.16e-06	0.000978	0.64	0.25	Autism spectrum disorder or schizophrenia;	chr6:26048331	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs13201821	ENSG00000216436.2	HIST1H2APS1	4.74	3.16e-06	0.000978	0.64	0.25	Autism spectrum disorder or schizophrenia;	chr6:26057553	chr6:25732497~25732827:+
LIHC	cis	rs2976388	0.647	rs2244163	ENSG00000253196.1	RP11-706C16.7	4.74	3.17e-06	0.00098	0.24	0.25	Urinary tract infection frequency;	chr8:142703082	chr8:142763116~142766427:+
LIHC	cis	rs11089937	0.597	rs5750579	ENSG00000211639.2	IGLV4-60	4.74	3.17e-06	0.000981	0.21	0.25	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22162199~22162681:+
LIHC	cis	rs1065852	0.526	rs11090066	ENSG00000237037.8	NDUFA6-AS1	-4.74	3.17e-06	0.000982	-0.34	-0.25	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002191	chr22:42090931~42137742:+
LIHC	cis	rs498872	0.507	rs10892247	ENSG00000255239.1	AP002954.6	-4.74	3.17e-06	0.000982	-0.34	-0.25	Glioma;	chr11:118619361	chr11:118688039~118690600:-
LIHC	cis	rs2243480	0.708	rs35825036	ENSG00000230295.1	RP11-458F8.2	-4.74	3.18e-06	0.000982	-0.26	-0.25	Diabetic kidney disease;	chr7:66521515	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs13237037	ENSG00000230295.1	RP11-458F8.2	-4.74	3.18e-06	0.000982	-0.26	-0.25	Diabetic kidney disease;	chr7:66532895	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs13237344	ENSG00000230295.1	RP11-458F8.2	-4.74	3.18e-06	0.000982	-0.26	-0.25	Diabetic kidney disease;	chr7:66557269	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1796228	ENSG00000230295.1	RP11-458F8.2	-4.74	3.18e-06	0.000982	-0.26	-0.25	Diabetic kidney disease;	chr7:66568097	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1267820	ENSG00000230295.1	RP11-458F8.2	-4.74	3.18e-06	0.000982	-0.26	-0.25	Diabetic kidney disease;	chr7:66585308	chr7:66880708~66882981:+
LIHC	cis	rs16858210	0.607	rs60244260	ENSG00000234371.6	RPSAP31	4.74	3.18e-06	0.000982	0.34	0.25	Menopause (age at onset);	chr3:183852946	chr3:183884924~183888449:+
LIHC	cis	rs7914558	1	rs10786733	ENSG00000236937.2	PTGES3P4	4.74	3.18e-06	0.000982	0.29	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103035190	chr10:102845595~102845950:+
LIHC	cis	rs9467711	0.591	rs35335639	ENSG00000216436.2	HIST1H2APS1	4.74	3.18e-06	0.000983	0.63	0.25	Autism spectrum disorder or schizophrenia;	chr6:26038453	chr6:25732497~25732827:+
LIHC	cis	rs2739330	0.789	rs5760109	ENSG00000206090.4	AP000350.7	4.74	3.19e-06	0.000985	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23939998~23942798:+
LIHC	cis	rs6442522	0.772	rs3890477	ENSG00000249786.6	EAF1-AS1	4.74	3.19e-06	0.000985	0.29	0.25	Uric acid levels;	chr3:15447816	chr3:15436171~15455940:-
LIHC	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-4.74	3.19e-06	0.000986	-0.25	-0.25	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
LIHC	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	4.74	3.2e-06	0.000987	0.19	0.25	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
LIHC	cis	rs712039	0.652	rs1616371	ENSG00000276054.1	RP11-378E13.3	4.74	3.2e-06	0.000988	0.3	0.25	Tuberculosis;	chr17:37413714	chr17:37386886~37387926:+
LIHC	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-4.74	3.2e-06	0.000988	-0.2	-0.25	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
LIHC	cis	rs4694744	0.576	rs1080755	ENSG00000264696.1	AC108078.1	4.74	3.2e-06	0.000988	0.35	0.25	Bacteremia;	chr4:69478923	chr4:69479331~69479434:+
LIHC	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	4.74	3.2e-06	0.000988	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
LIHC	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	4.74	3.2e-06	0.000988	0.34	0.25	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
LIHC	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-4.74	3.2e-06	0.000988	-0.29	-0.25	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	4.74	3.2e-06	0.000988	0.29	0.25	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
LIHC	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	4.74	3.2e-06	0.000989	0.3	0.25	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
LIHC	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-4.74	3.2e-06	0.000989	-0.26	-0.25	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
LIHC	cis	rs831571	0.703	rs55714137	ENSG00000280620.1	SCAANT1	4.74	3.21e-06	0.00099	0.38	0.25	Type 2 diabetes;	chr3:64091103	chr3:63911518~63911772:-
LIHC	cis	rs6997458	0.742	rs10095352	ENSG00000253549.4	RP11-317J10.2	4.74	3.21e-06	0.000991	0.27	0.25	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85460203	chr8:85441851~85464915:-
LIHC	cis	rs6997458	0.742	rs3758077	ENSG00000253549.4	RP11-317J10.2	4.74	3.21e-06	0.000991	0.27	0.25	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463274	chr8:85441851~85464915:-
LIHC	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-4.73	3.21e-06	0.000992	-0.3	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
LIHC	cis	rs1555322	0.53	rs2425049	ENSG00000279253.1	RP4-614O4.13	-4.73	3.21e-06	0.000992	-0.32	-0.25	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35262727~35264187:-
LIHC	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-4.73	3.21e-06	0.000992	-0.27	-0.25	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
LIHC	cis	rs7412746	0.611	rs11204748	ENSG00000231073.1	RP11-316M1.3	4.73	3.22e-06	0.000992	0.24	0.25	Melanoma;	chr1:150954893	chr1:150973123~150975534:+
LIHC	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-4.73	3.22e-06	0.000993	-0.29	-0.25	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-4.73	3.22e-06	0.000993	-0.29	-0.25	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
LIHC	cis	rs11098499	0.954	rs11098526	ENSG00000260091.1	RP11-33B1.4	-4.73	3.22e-06	0.000993	-0.18	-0.25	Corneal astigmatism;	chr4:119469204	chr4:119409333~119410233:+
LIHC	cis	rs9834975	0.935	rs6788318	ENSG00000272758.4	RP11-299J3.8	-4.73	3.22e-06	0.000994	-0.28	-0.25	Diastolic blood pressure;	chr3:122387672	chr3:122416207~122443180:+
LIHC	cis	rs2565722	0.609	rs9365227	ENSG00000243831.1	RP1-81D8.4	4.73	3.22e-06	0.000995	0.35	0.25	Blood protein levels;	chr6:160876893	chr6:160666228~160676523:-
LIHC	cis	rs2565722	0.665	rs9347466	ENSG00000243831.1	RP1-81D8.4	4.73	3.22e-06	0.000995	0.35	0.25	Blood protein levels;	chr6:160876894	chr6:160666228~160676523:-
LIHC	cis	rs17301013	0.803	rs2187562	ENSG00000227373.4	RP11-160H22.5	4.73	3.23e-06	0.000995	0.29	0.25	Systemic lupus erythematosus;	chr1:174842513	chr1:174115300~174160004:-
LIHC	cis	rs1558001	0.87	rs10233468	ENSG00000230196.1	DDX43P3	4.73	3.23e-06	0.000996	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81788605	chr7:81610884~81611326:-
LIHC	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-4.73	3.23e-06	0.000996	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
LIHC	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-4.73	3.23e-06	0.000996	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-4.73	3.23e-06	0.000996	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
LIHC	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	4.73	3.23e-06	0.000996	0.38	0.25	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
LIHC	cis	rs2836974	0.897	rs8132568	ENSG00000255568.3	BRWD1-AS2	4.73	3.23e-06	0.000996	0.28	0.25	Cognitive function;	chr21:39155990	chr21:39313935~39314962:+
LIHC	cis	rs9843304	0.585	rs9847009	ENSG00000244503.1	RP11-278L15.6	-4.73	3.23e-06	0.000996	-0.3	-0.25	Gallstone disease;	chr3:149490380	chr3:149494660~149495995:+
LIHC	cis	rs7208859	0.673	rs1347359	ENSG00000266490.1	CTD-2349P21.9	4.73	3.24e-06	0.000998	0.29	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30792372~30792833:+
LIHC	cis	rs1865760	0.927	rs6915834	ENSG00000216436.2	HIST1H2APS1	-4.73	3.24e-06	0.000998	-0.28	-0.25	Height;	chr6:25935199	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.892	rs2328903	ENSG00000216436.2	HIST1H2APS1	-4.73	3.24e-06	0.000998	-0.28	-0.25	Height;	chr6:25935537	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.892	rs6456705	ENSG00000216436.2	HIST1H2APS1	-4.73	3.24e-06	0.000998	-0.28	-0.25	Height;	chr6:25935828	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.929	rs9358896	ENSG00000216436.2	HIST1H2APS1	-4.73	3.24e-06	0.000999	-0.28	-0.25	Height;	chr6:25942969	chr6:25732497~25732827:+
LIHC	cis	rs12478296	0.681	rs55802421	ENSG00000261186.2	RP11-341N2.1	-4.73	3.24e-06	0.000999	-0.35	-0.25	Obesity-related traits;	chr2:242091811	chr2:242087351~242088457:-
LIHC	cis	rs12478296	0.681	rs56357900	ENSG00000261186.2	RP11-341N2.1	-4.73	3.24e-06	0.000999	-0.35	-0.25	Obesity-related traits;	chr2:242091815	chr2:242087351~242088457:-
LIHC	cis	rs10829156	0.66	rs11014830	ENSG00000225527.1	RP11-383B4.4	-4.73	3.24e-06	0.000999	-0.39	-0.25	Sudden cardiac arrest;	chr10:18551504	chr10:18531849~18533336:-
LIHC	cis	rs10829156	0.66	rs10828901	ENSG00000225527.1	RP11-383B4.4	-4.73	3.24e-06	0.000999	-0.39	-0.25	Sudden cardiac arrest;	chr10:18552161	chr10:18531849~18533336:-
LIHC	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-4.73	3.24e-06	0.001	-0.26	-0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
LIHC	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-4.73	3.24e-06	0.001	-0.26	-0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
LIHC	cis	rs17301013	0.932	rs332771	ENSG00000227373.4	RP11-160H22.5	4.73	3.24e-06	0.001	0.3	0.25	Systemic lupus erythematosus;	chr1:174704141	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.861	rs332789	ENSG00000227373.4	RP11-160H22.5	4.73	3.24e-06	0.001	0.3	0.25	Systemic lupus erythematosus;	chr1:174735754	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.932	rs461910	ENSG00000227373.4	RP11-160H22.5	4.73	3.24e-06	0.001	0.3	0.25	Systemic lupus erythematosus;	chr1:174736351	chr1:174115300~174160004:-
LIHC	cis	rs6723226	0.75	rs3769597	ENSG00000276334.1	AL133243.1	4.73	3.25e-06	0.001	0.27	0.25	Intelligence (multi-trait analysis);	chr2:32466332	chr2:32521927~32523547:+
LIHC	cis	rs11064837	0.504	rs34500179	ENSG00000248636.5	RP11-768F21.1	4.73	3.25e-06	0.001	0.4	0.25	Schizophrenia;	chr12:119631047	chr12:119387987~119668079:-
LIHC	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-4.73	3.25e-06	0.001	-0.36	-0.25	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
LIHC	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	4.73	3.25e-06	0.001	0.38	0.25	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
LIHC	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	4.73	3.25e-06	0.001	0.3	0.25	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
LIHC	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	4.73	3.25e-06	0.001	0.23	0.25	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
LIHC	cis	rs7662987	0.793	rs7684735	ENSG00000272777.1	RP11-571L19.8	4.73	3.25e-06	0.001	0.54	0.25	Smoking initiation;	chr4:99070355	chr4:99067256~99068125:-
LIHC	cis	rs2836974	0.836	rs8129355	ENSG00000255568.3	BRWD1-AS2	4.73	3.26e-06	0.001	0.28	0.25	Cognitive function;	chr21:39207943	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.899	rs34978594	ENSG00000255568.3	BRWD1-AS2	4.73	3.26e-06	0.001	0.28	0.25	Cognitive function;	chr21:39208077	chr21:39313935~39314962:+
LIHC	cis	rs3733585	0.806	rs7375599	ENSG00000250413.1	RP11-448G15.1	-4.73	3.26e-06	0.001	-0.32	-0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10006482~10009725:+
LIHC	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-4.73	3.26e-06	0.001	-0.45	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
LIHC	cis	rs2749097	0.825	rs11208261	ENSG00000244256.3	RN7SL130P	-4.73	3.26e-06	0.001	-0.29	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63658331	chr1:63655743~63656047:+
LIHC	cis	rs9525916	1	rs9525916	ENSG00000230731.2	RP11-478K15.6	4.73	3.26e-06	0.001	0.27	0.25	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44234118~44243192:-
LIHC	cis	rs1499614	0.803	rs1796229	ENSG00000230295.1	RP11-458F8.2	-4.73	3.26e-06	0.001	-0.26	-0.25	Gout;	chr7:66654674	chr7:66880708~66882981:+
LIHC	cis	rs1499614	0.901	rs3936	ENSG00000230295.1	RP11-458F8.2	-4.73	3.26e-06	0.001	-0.26	-0.25	Gout;	chr7:66661502	chr7:66880708~66882981:+
LIHC	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	4.73	3.26e-06	0.001	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
LIHC	cis	rs2836974	0.932	rs8128734	ENSG00000255568.3	BRWD1-AS2	4.73	3.27e-06	0.00101	0.28	0.25	Cognitive function;	chr21:39197585	chr21:39313935~39314962:+
LIHC	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-4.73	3.27e-06	0.00101	-0.27	-0.25	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
LIHC	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-4.73	3.28e-06	0.00101	-0.3	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
LIHC	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	4.73	3.28e-06	0.00101	0.27	0.25	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
LIHC	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	4.73	3.28e-06	0.00101	0.2	0.25	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
LIHC	cis	rs7209700	0.708	rs2292699	ENSG00000228782.6	CTD-2026D20.3	4.73	3.28e-06	0.00101	0.28	0.25	IgG glycosylation;	chr17:47284929	chr17:47450568~47492492:-
LIHC	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-4.73	3.28e-06	0.00101	-0.29	-0.25	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
LIHC	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	4.73	3.28e-06	0.00101	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
LIHC	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	4.73	3.29e-06	0.00101	0.32	0.25	Height;	chr6:109430398	chr6:109382795~109383666:+
LIHC	cis	rs8031584	1	rs11638409	ENSG00000270015.1	RP11-540B6.6	-4.73	3.29e-06	0.00101	-0.32	-0.25	Huntington's disease progression;	chr15:30995987	chr15:30926514~30928407:+
LIHC	cis	rs8031584	1	rs11634216	ENSG00000270015.1	RP11-540B6.6	-4.73	3.29e-06	0.00101	-0.32	-0.25	Huntington's disease progression;	chr15:30996467	chr15:30926514~30928407:+
LIHC	cis	rs11098499	0.909	rs10017335	ENSG00000260091.1	RP11-33B1.4	4.73	3.29e-06	0.00101	0.18	0.25	Corneal astigmatism;	chr4:119460368	chr4:119409333~119410233:+
LIHC	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	4.73	3.29e-06	0.00101	0.29	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
LIHC	cis	rs1005277	0.579	rs1614236	ENSG00000276805.1	RP11-291L22.6	4.73	3.29e-06	0.00101	0.3	0.25	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38451030~38451785:+
LIHC	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-4.73	3.3e-06	0.00101	-0.33	-0.25	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
LIHC	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	4.73	3.3e-06	0.00101	0.33	0.25	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
LIHC	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	4.73	3.3e-06	0.00101	0.18	0.25	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
LIHC	cis	rs643506	0.874	rs645411	ENSG00000254990.4	RP11-108O10.2	4.73	3.3e-06	0.00101	0.26	0.25	Breast cancer;	chr11:111823766	chr11:111768668~111778350:-
LIHC	cis	rs17270561	0.723	rs12192635	ENSG00000272810.1	U91328.22	-4.73	3.3e-06	0.00101	-0.32	-0.25	Iron status biomarkers;	chr6:25880679	chr6:26013241~26013757:+
LIHC	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	4.73	3.3e-06	0.00101	0.3	0.25	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
LIHC	cis	rs7119038	0.774	rs11217001	ENSG00000255239.1	AP002954.6	-4.73	3.3e-06	0.00102	-0.35	-0.25	Sjögren's syndrome;	chr11:118736337	chr11:118688039~118690600:-
LIHC	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-4.73	3.3e-06	0.00102	-0.29	-0.25	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-4.73	3.3e-06	0.00102	-0.29	-0.25	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
LIHC	cis	rs10510102	0.872	rs12240306	ENSG00000226864.1	ATE1-AS1	4.73	3.3e-06	0.00102	0.42	0.25	Breast cancer;	chr10:121963391	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12240308	ENSG00000226864.1	ATE1-AS1	4.73	3.3e-06	0.00102	0.42	0.25	Breast cancer;	chr10:121963407	chr10:121928312~121951965:+
LIHC	cis	rs4660214	0.724	rs2484751	ENSG00000182109.6	RP11-69E11.4	-4.73	3.31e-06	0.00102	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39522280~39546187:-
LIHC	cis	rs804280	0.509	rs12719915	ENSG00000255495.1	AC145124.2	-4.73	3.31e-06	0.00102	-0.3	-0.25	Myopia (pathological);	chr8:11928746	chr8:12194467~12196280:+
LIHC	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-4.73	3.31e-06	0.00102	-0.41	-0.25	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
LIHC	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	4.73	3.31e-06	0.00102	0.34	0.25	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
LIHC	cis	rs9500256	0.967	rs1012500	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.73	3.31e-06	0.00102	-0.27	-0.25	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57855891~57856468:-
LIHC	cis	rs5756813	0.754	rs8136757	ENSG00000233360.4	Z83844.1	4.73	3.32e-06	0.00102	0.31	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37789964	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.754	rs8137848	ENSG00000233360.4	Z83844.1	4.73	3.32e-06	0.00102	0.31	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37789987	chr22:37641832~37658377:-
LIHC	cis	rs10829156	0.699	rs6482516	ENSG00000225527.1	RP11-383B4.4	-4.73	3.32e-06	0.00102	-0.38	-0.25	Sudden cardiac arrest;	chr10:18550421	chr10:18531849~18533336:-
LIHC	cis	rs875971	0.545	rs67397473	ENSG00000273142.1	RP11-458F8.4	4.73	3.33e-06	0.00102	0.24	0.25	Aortic root size;	chr7:66168318	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs10950027	ENSG00000273142.1	RP11-458F8.4	4.73	3.33e-06	0.00102	0.24	0.25	Aortic root size;	chr7:66169164	chr7:66902857~66906297:+
LIHC	cis	rs13315871	1	rs11706420	ENSG00000272182.1	RP11-802O23.3	-4.73	3.33e-06	0.00102	-0.57	-0.25	Cholesterol, total;	chr3:58406684	chr3:58428255~58428815:+
LIHC	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	4.73	3.33e-06	0.00102	0.3	0.25	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
LIHC	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-4.73	3.33e-06	0.00102	-0.28	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
LIHC	cis	rs4948102	0.551	rs4275190	ENSG00000226278.1	PSPHP1	-4.73	3.33e-06	0.00102	-0.28	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55764797~55773288:+
LIHC	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-4.73	3.33e-06	0.00102	-0.22	-0.25	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
LIHC	cis	rs752590	0.65	rs6751201	ENSG00000274877.1	RP11-65I12.1	4.73	3.33e-06	0.00102	0.33	0.25	Mucinous ovarian carcinoma;	chr2:113195122	chr2:113237595~113240825:+
LIHC	cis	rs1865760	0.566	rs2032445	ENSG00000216436.2	HIST1H2APS1	-4.73	3.34e-06	0.00102	-0.29	-0.25	Height;	chr6:26044584	chr6:25732497~25732827:+
LIHC	cis	rs4650994	0.525	rs4076563	ENSG00000273384.1	RP5-1098D14.1	4.73	3.34e-06	0.00103	0.31	0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178547766	chr1:178651706~178652282:+
LIHC	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-4.73	3.34e-06	0.00103	-0.34	-0.25	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
LIHC	cis	rs9457247	0.602	rs12209395	ENSG00000227598.1	RP1-167A14.2	-4.73	3.35e-06	0.00103	-0.27	-0.25	Crohn's disease;	chr6:167050426	chr6:166969626~166999065:-
LIHC	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	4.73	3.35e-06	0.00103	0.47	0.25	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
LIHC	cis	rs1865760	0.566	rs9358902	ENSG00000216436.2	HIST1H2APS1	-4.73	3.35e-06	0.00103	-0.29	-0.25	Height;	chr6:26058342	chr6:25732497~25732827:+
LIHC	cis	rs603446	0.967	rs108533	ENSG00000254851.1	RP11-109L13.1	4.73	3.36e-06	0.00103	0.29	0.25	Triglycerides;	chr11:116730995	chr11:117135528~117138582:+
LIHC	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	4.73	3.36e-06	0.00103	0.22	0.25	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
LIHC	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	4.73	3.36e-06	0.00103	0.34	0.25	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
LIHC	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-4.73	3.36e-06	0.00103	-0.25	-0.25	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
LIHC	cis	rs643506	0.874	rs614144	ENSG00000254990.4	RP11-108O10.2	4.72	3.37e-06	0.00103	0.26	0.25	Breast cancer;	chr11:111797895	chr11:111768668~111778350:-
LIHC	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	4.72	3.37e-06	0.00103	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
LIHC	cis	rs748404	0.697	rs572959	ENSG00000166763.7	STRCP1	4.72	3.37e-06	0.00103	0.3	0.25	Lung cancer;	chr15:43258304	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs554001	ENSG00000166763.7	STRCP1	4.72	3.37e-06	0.00103	0.3	0.25	Lung cancer;	chr15:43259721	chr15:43699488~43718184:-
LIHC	cis	rs2836974	0.568	rs371625	ENSG00000255568.3	BRWD1-AS2	-4.72	3.37e-06	0.00103	-0.21	-0.25	Cognitive function;	chr21:39163345	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.526	rs418359	ENSG00000255568.3	BRWD1-AS2	-4.72	3.37e-06	0.00103	-0.21	-0.25	Cognitive function;	chr21:39164808	chr21:39313935~39314962:+
LIHC	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-4.72	3.37e-06	0.00103	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
LIHC	cis	rs7662987	0.793	rs4699700	ENSG00000272777.1	RP11-571L19.8	4.72	3.37e-06	0.00103	0.56	0.25	Smoking initiation;	chr4:99077184	chr4:99067256~99068125:-
LIHC	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-4.72	3.37e-06	0.00103	-0.3	-0.25	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
LIHC	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-4.72	3.37e-06	0.00103	-0.22	-0.25	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
LIHC	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	4.72	3.37e-06	0.00103	0.3	0.25	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
LIHC	cis	rs1577917	1	rs12200330	ENSG00000234155.1	RP11-30P6.6	4.72	3.37e-06	0.00103	0.33	0.25	Response to antipsychotic treatment;	chr6:85946935	chr6:85387219~85390186:-
LIHC	cis	rs7615952	0.546	rs11711150	ENSG00000171084.14	FAM86JP	4.72	3.37e-06	0.00103	0.44	0.25	Blood pressure (smoking interaction);	chr3:125596819	chr3:125916620~125930024:+
LIHC	cis	rs2998286	0.723	rs332168	ENSG00000254635.4	WAC-AS1	-4.72	3.38e-06	0.00104	-0.3	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28607488	chr10:28522652~28532743:-
LIHC	cis	rs9467711	0.651	rs1045537	ENSG00000216436.2	HIST1H2APS1	4.72	3.38e-06	0.00104	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26096520	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs35402046	ENSG00000216436.2	HIST1H2APS1	4.72	3.38e-06	0.00104	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26099244	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs66790453	ENSG00000216436.2	HIST1H2APS1	4.72	3.38e-06	0.00104	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26106860	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs13197334	ENSG00000216436.2	HIST1H2APS1	4.72	3.38e-06	0.00104	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26122420	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs16891334	ENSG00000216436.2	HIST1H2APS1	4.72	3.38e-06	0.00104	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26124075	chr6:25732497~25732827:+
LIHC	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-4.72	3.38e-06	0.00104	-0.29	-0.25	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
LIHC	cis	rs950169	0.58	rs11635597	ENSG00000259295.5	CSPG4P12	4.72	3.38e-06	0.00104	0.34	0.25	Schizophrenia;	chr15:84622468	chr15:85191438~85213905:+
LIHC	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	4.72	3.38e-06	0.00104	0.39	0.25	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
LIHC	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	4.72	3.38e-06	0.00104	0.29	0.25	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
LIHC	cis	rs831571	0.668	rs17069879	ENSG00000280620.1	SCAANT1	-4.72	3.38e-06	0.00104	-0.36	-0.25	Type 2 diabetes;	chr3:64097741	chr3:63911518~63911772:-
LIHC	cis	rs11216126	1	rs11216129	ENSG00000254851.1	RP11-109L13.1	4.72	3.4e-06	0.00104	0.37	0.25	HDL cholesterol;	chr11:116749540	chr11:117135528~117138582:+
LIHC	cis	rs2836974	0.897	rs11911112	ENSG00000255568.3	BRWD1-AS2	4.72	3.4e-06	0.00104	0.28	0.25	Cognitive function;	chr21:39156420	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.831	rs11911149	ENSG00000255568.3	BRWD1-AS2	4.72	3.4e-06	0.00104	0.28	0.25	Cognitive function;	chr21:39156449	chr21:39313935~39314962:+
LIHC	cis	rs875971	0.66	rs1860470	ENSG00000273024.4	INTS4P2	4.72	3.4e-06	0.00104	0.28	0.25	Aortic root size;	chr7:66638707	chr7:65647864~65715661:+
LIHC	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-4.72	3.4e-06	0.00104	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-4.72	3.4e-06	0.00104	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-4.72	3.4e-06	0.00104	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-4.72	3.4e-06	0.00104	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-4.72	3.4e-06	0.00104	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-4.72	3.4e-06	0.00104	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
LIHC	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	4.72	3.4e-06	0.00104	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
LIHC	cis	rs1577917	1	rs12208493	ENSG00000234155.1	RP11-30P6.6	4.72	3.4e-06	0.00104	0.33	0.25	Response to antipsychotic treatment;	chr6:85952549	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12213149	ENSG00000234155.1	RP11-30P6.6	4.72	3.4e-06	0.00104	0.33	0.25	Response to antipsychotic treatment;	chr6:85958926	chr6:85387219~85390186:-
LIHC	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-4.72	3.41e-06	0.00104	-0.26	-0.25	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
LIHC	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-4.72	3.41e-06	0.00104	-0.23	-0.25	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
LIHC	cis	rs1577917	0.958	rs10944144	ENSG00000234155.1	RP11-30P6.6	4.72	3.41e-06	0.00105	0.33	0.25	Response to antipsychotic treatment;	chr6:85828037	chr6:85387219~85390186:-
LIHC	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-4.72	3.42e-06	0.00105	-0.35	-0.25	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
LIHC	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	4.72	3.42e-06	0.00105	0.39	0.25	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
LIHC	cis	rs338389	0.542	rs6494709	ENSG00000260657.2	RP11-315D16.4	-4.72	3.42e-06	0.00105	-0.39	-0.25	Survival in rectal cancer;	chr15:68001672	chr15:68267792~68277994:-
LIHC	cis	rs643506	0.874	rs582465	ENSG00000254990.4	RP11-108O10.2	4.72	3.42e-06	0.00105	0.27	0.25	Breast cancer;	chr11:111797861	chr11:111768668~111778350:-
LIHC	cis	rs643506	0.874	rs613292	ENSG00000254990.4	RP11-108O10.2	4.72	3.42e-06	0.00105	0.27	0.25	Breast cancer;	chr11:111798081	chr11:111768668~111778350:-
LIHC	cis	rs683257	0.673	rs72990126	ENSG00000234147.1	RP3-460G2.2	-4.72	3.42e-06	0.00105	-0.4	-0.25	Facial emotion recognition (angry faces);	chr6:140850534	chr6:140845958~140852924:-
LIHC	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	4.72	3.42e-06	0.00105	0.34	0.25	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
LIHC	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	4.72	3.42e-06	0.00105	0.38	0.25	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
LIHC	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-4.72	3.42e-06	0.00105	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-4.72	3.42e-06	0.00105	-0.26	-0.25	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
LIHC	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-4.72	3.43e-06	0.00105	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-4.72	3.43e-06	0.00105	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
LIHC	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	4.72	3.43e-06	0.00105	0.21	0.25	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
LIHC	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	4.72	3.43e-06	0.00105	0.28	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
LIHC	cis	rs831571	0.695	rs73120926	ENSG00000280620.1	SCAANT1	4.72	3.43e-06	0.00105	0.36	0.25	Type 2 diabetes;	chr3:64051274	chr3:63911518~63911772:-
LIHC	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	4.72	3.44e-06	0.00105	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	4.72	3.44e-06	0.00105	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
LIHC	cis	rs11098499	0.909	rs9759478	ENSG00000260091.1	RP11-33B1.4	-4.72	3.44e-06	0.00105	-0.18	-0.25	Corneal astigmatism;	chr4:119446843	chr4:119409333~119410233:+
LIHC	cis	rs6085948	0.953	rs6077166	ENSG00000228888.1	LINC01428	4.72	3.44e-06	0.00105	0.33	0.25	Interleukin-10 levels;	chr20:7252921	chr20:7146467~7254202:-
LIHC	cis	rs11722779	0.787	rs6533040	ENSG00000230069.3	LRRC37A15P	-4.72	3.44e-06	0.00105	-0.22	-0.25	Schizophrenia;	chr4:102951421	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.903	rs6830193	ENSG00000230069.3	LRRC37A15P	-4.72	3.44e-06	0.00105	-0.22	-0.25	Schizophrenia;	chr4:102955457	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.545	rs316324	ENSG00000273142.1	RP11-458F8.4	-4.72	3.45e-06	0.00105	-0.24	-0.25	Aortic root size;	chr7:66145627	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs316323	ENSG00000273142.1	RP11-458F8.4	-4.72	3.45e-06	0.00105	-0.24	-0.25	Aortic root size;	chr7:66146002	chr7:66902857~66906297:+
LIHC	cis	rs1865760	0.713	rs6928951	ENSG00000216436.2	HIST1H2APS1	-4.72	3.45e-06	0.00105	-0.28	-0.25	Height;	chr6:25995326	chr6:25732497~25732827:+
LIHC	cis	rs11089937	0.626	rs5757017	ENSG00000211639.2	IGLV4-60	4.72	3.45e-06	0.00105	0.21	0.25	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22162199~22162681:+
LIHC	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	4.72	3.45e-06	0.00105	0.25	0.25	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
LIHC	cis	rs11722779	0.844	rs10003326	ENSG00000230069.3	LRRC37A15P	-4.72	3.45e-06	0.00106	-0.22	-0.25	Schizophrenia;	chr4:102948193	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	4.72	3.45e-06	0.00106	0.28	0.25	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
LIHC	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-4.72	3.45e-06	0.00106	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
LIHC	cis	rs1005277	0.579	rs1780116	ENSG00000276805.1	RP11-291L22.6	4.72	3.46e-06	0.00106	0.3	0.25	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38451030~38451785:+
LIHC	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-4.72	3.46e-06	0.00106	-0.29	-0.25	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
LIHC	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	4.72	3.46e-06	0.00106	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	4.72	3.46e-06	0.00106	0.31	0.25	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	4.72	3.46e-06	0.00106	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	4.72	3.46e-06	0.00106	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	4.72	3.46e-06	0.00106	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
LIHC	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	4.72	3.46e-06	0.00106	0.29	0.25	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
LIHC	cis	rs2735413	0.75	rs60659587	ENSG00000276007.1	RP11-358L22.3	4.72	3.47e-06	0.00106	0.33	0.25	Systolic blood pressure (alcohol consumption interaction);	chr16:78037657	chr16:78123243~78124332:+
LIHC	cis	rs875971	0.505	rs1167386	ENSG00000164669.11	INTS4P1	4.72	3.47e-06	0.00106	0.35	0.25	Aortic root size;	chr7:66048109	chr7:65141225~65234216:+
LIHC	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	4.72	3.47e-06	0.00106	0.35	0.25	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
LIHC	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	4.72	3.47e-06	0.00106	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
LIHC	cis	rs6480314	0.542	rs7079054	ENSG00000233590.1	RP11-153K11.3	-4.72	3.47e-06	0.00106	-0.38	-0.25	Optic nerve measurement (disc area);	chr10:68266404	chr10:68233251~68242379:-
LIHC	cis	rs929596	0.517	rs3806592	ENSG00000233445.1	RPL17P11	4.72	3.47e-06	0.00106	0.29	0.25	Total bilirubin levels in HIV-1 infection;	chr2:233717290	chr2:233721522~233722065:-
LIHC	cis	rs2060793	0.519	rs7931291	ENSG00000251991.1	RNU7-49P	-4.72	3.47e-06	0.00106	-0.27	-0.25	Vitamin D levels;	chr11:14622880	chr11:14478892~14478953:+
LIHC	cis	rs2749592	0.531	rs1208559	ENSG00000275858.1	RP11-291L22.8	-4.72	3.47e-06	0.00106	-0.27	-0.25	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38450738~38451069:-
LIHC	cis	rs893363	0.559	rs893365	ENSG00000271916.1	RP11-884K10.6	-4.72	3.47e-06	0.00106	-0.3	-0.25	Axial length;	chr3:53807119	chr3:53797764~53798019:-
LIHC	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-4.72	3.47e-06	0.00106	-0.31	-0.25	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
LIHC	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-4.72	3.48e-06	0.00106	-0.25	-0.25	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
LIHC	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	4.72	3.48e-06	0.00106	0.36	0.25	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
LIHC	cis	rs10829156	0.66	rs7918933	ENSG00000225527.1	RP11-383B4.4	-4.72	3.48e-06	0.00106	-0.39	-0.25	Sudden cardiac arrest;	chr10:18517434	chr10:18531849~18533336:-
LIHC	cis	rs11971779	0.793	rs4732366	ENSG00000273391.1	RP11-634H22.1	4.72	3.48e-06	0.00106	0.23	0.25	Diisocyanate-induced asthma;	chr7:139343099	chr7:139359032~139359566:-
LIHC	cis	rs755249	0.501	rs2455648	ENSG00000182109.6	RP11-69E11.4	4.72	3.48e-06	0.00106	0.27	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39522280~39546187:-
LIHC	cis	rs75920871	0.589	rs2075547	ENSG00000254851.1	RP11-109L13.1	-4.72	3.49e-06	0.00106	-0.49	-0.25	Subjective well-being;	chr11:117197818	chr11:117135528~117138582:+
LIHC	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	4.72	3.49e-06	0.00107	0.2	0.25	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
LIHC	cis	rs5758511	0.633	rs5758689	ENSG00000205702.9	CYP2D7	4.72	3.49e-06	0.00107	0.29	0.25	Birth weight;	chr22:42268966	chr22:42140203~42144577:-
LIHC	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-4.72	3.49e-06	0.00107	-0.28	-0.25	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
LIHC	cis	rs9595908	0.9	rs7981943	ENSG00000212293.1	SNORA16	4.72	3.5e-06	0.00107	0.28	0.25	Body mass index;	chr13:32593754	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.9	rs7327429	ENSG00000212293.1	SNORA16	4.72	3.5e-06	0.00107	0.28	0.25	Body mass index;	chr13:32595259	chr13:32420390~32420516:-
LIHC	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-4.72	3.5e-06	0.00107	-0.29	-0.25	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
LIHC	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	4.72	3.5e-06	0.00107	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73271869	ENSG00000266490.1	CTD-2349P21.9	4.72	3.5e-06	0.00107	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73271872	ENSG00000266490.1	CTD-2349P21.9	4.72	3.5e-06	0.00107	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs56146117	ENSG00000266490.1	CTD-2349P21.9	4.72	3.5e-06	0.00107	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.568	rs9907834	ENSG00000266490.1	CTD-2349P21.9	4.72	3.5e-06	0.00107	0.32	0.25	Body mass index;	chr17:30826995	chr17:30792372~30792833:+
LIHC	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.72	3.5e-06	0.00107	0.3	0.25	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
LIHC	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	4.72	3.51e-06	0.00107	0.22	0.25	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
LIHC	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	4.72	3.51e-06	0.00107	0.34	0.25	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
LIHC	cis	rs2439831	0.85	rs28509275	ENSG00000166763.7	STRCP1	4.72	3.51e-06	0.00107	0.4	0.25	Lung cancer in ever smokers;	chr15:43805907	chr15:43699488~43718184:-
LIHC	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-4.72	3.51e-06	0.00107	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-4.72	3.51e-06	0.00107	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-4.72	3.51e-06	0.00107	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
LIHC	cis	rs916888	0.697	rs199516	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs199514	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs199512	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs199509	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs199507	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs415430	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.779	rs430685	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs199505	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs70602	ENSG00000274883.1	Metazoa_SRP	4.72	3.51e-06	0.00107	0.38	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45931806~45932083:+
LIHC	cis	rs2877649	0.51	rs17103735	ENSG00000258744.1	RP11-80A15.1	-4.72	3.51e-06	0.00107	-0.47	-0.25	Smooth-surface caries;	chr14:24436961	chr14:24501594~24508688:+
LIHC	cis	rs5769765	0.704	rs138837	ENSG00000278869.1	CITF22-49E9.3	4.72	3.51e-06	0.00107	0.37	0.25	Schizophrenia;	chr22:49787066	chr22:49933198~49934074:-
LIHC	cis	rs9467711	0.591	rs56195001	ENSG00000216436.2	HIST1H2APS1	4.72	3.52e-06	0.00107	0.63	0.25	Autism spectrum disorder or schizophrenia;	chr6:25975937	chr6:25732497~25732827:+
LIHC	cis	rs7412746	0.646	rs10399947	ENSG00000231073.1	RP11-316M1.3	4.72	3.52e-06	0.00107	0.24	0.25	Melanoma;	chr1:150889484	chr1:150973123~150975534:+
LIHC	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	4.72	3.52e-06	0.00107	0.42	0.25	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	4.72	3.52e-06	0.00107	0.42	0.25	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	4.72	3.52e-06	0.00107	0.42	0.25	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
LIHC	cis	rs11098499	0.754	rs10518300	ENSG00000260091.1	RP11-33B1.4	4.72	3.52e-06	0.00107	0.18	0.25	Corneal astigmatism;	chr4:119328344	chr4:119409333~119410233:+
LIHC	cis	rs1729407	0.786	rs5096	ENSG00000236267.1	AP006216.5	4.72	3.52e-06	0.00107	0.23	0.25	Apolipoprotein A-IV levels;	chr11:116822379	chr11:116813204~116814003:-
LIHC	cis	rs2060793	0.741	rs2060794	ENSG00000251991.1	RNU7-49P	4.72	3.52e-06	0.00107	0.28	0.25	Vitamin D levels;	chr11:14791437	chr11:14478892~14478953:+
LIHC	cis	rs2060793	0.741	rs3740823	ENSG00000251991.1	RNU7-49P	4.72	3.52e-06	0.00107	0.28	0.25	Vitamin D levels;	chr11:14804158	chr11:14478892~14478953:+
LIHC	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-4.72	3.52e-06	0.00107	-0.3	-0.25	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
LIHC	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	4.72	3.52e-06	0.00108	0.28	0.25	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	4.72	3.52e-06	0.00108	0.28	0.25	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	4.71	3.53e-06	0.00108	0.28	0.25	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
LIHC	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-4.71	3.53e-06	0.00108	-0.25	-0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
LIHC	cis	rs17301013	0.73	rs12060177	ENSG00000227373.4	RP11-160H22.5	4.71	3.54e-06	0.00108	0.3	0.25	Systemic lupus erythematosus;	chr1:174618545	chr1:174115300~174160004:-
LIHC	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-4.71	3.54e-06	0.00108	-0.29	-0.25	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
LIHC	cis	rs9834975	0.967	rs6438737	ENSG00000272758.4	RP11-299J3.8	4.71	3.54e-06	0.00108	0.27	0.25	Diastolic blood pressure;	chr3:122510127	chr3:122416207~122443180:+
LIHC	cis	rs603446	0.901	rs180344	ENSG00000254851.1	RP11-109L13.1	-4.71	3.54e-06	0.00108	-0.31	-0.25	Triglycerides;	chr11:116742468	chr11:117135528~117138582:+
LIHC	cis	rs5758511	0.68	rs739146	ENSG00000205702.9	CYP2D7	4.71	3.54e-06	0.00108	0.29	0.25	Birth weight;	chr22:42264408	chr22:42140203~42144577:-
LIHC	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-4.71	3.55e-06	0.00108	-0.24	-0.25	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-4.71	3.55e-06	0.00108	-0.27	-0.25	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
LIHC	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-4.71	3.55e-06	0.00108	-0.29	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
LIHC	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-4.71	3.55e-06	0.00108	-0.26	-0.25	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
LIHC	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-4.71	3.55e-06	0.00108	-0.31	-0.25	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
LIHC	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	4.71	3.56e-06	0.00108	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
LIHC	cis	rs1558001	0.799	rs765499	ENSG00000230196.1	DDX43P3	4.71	3.56e-06	0.00108	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81791012	chr7:81610884~81611326:-
LIHC	cis	rs7412746	0.586	rs2864882	ENSG00000231073.1	RP11-316M1.3	4.71	3.56e-06	0.00108	0.24	0.25	Melanoma;	chr1:150910561	chr1:150973123~150975534:+
LIHC	cis	rs643506	0.874	rs640651	ENSG00000254990.4	RP11-108O10.2	4.71	3.56e-06	0.00108	0.26	0.25	Breast cancer;	chr11:111858188	chr11:111768668~111778350:-
LIHC	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	4.71	3.57e-06	0.00109	0.37	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	4.71	3.57e-06	0.00109	0.37	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
LIHC	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	4.71	3.57e-06	0.00109	0.3	0.25	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
LIHC	cis	rs2836974	0.897	rs2836928	ENSG00000255568.3	BRWD1-AS2	4.71	3.57e-06	0.00109	0.29	0.25	Cognitive function;	chr21:39171394	chr21:39313935~39314962:+
LIHC	cis	rs4731207	0.594	rs6968500	ENSG00000224897.5	POT1-AS1	4.71	3.57e-06	0.00109	0.28	0.25	Cutaneous malignant melanoma;	chr7:124791668	chr7:124929873~125179315:+
LIHC	cis	rs875971	0.545	rs73376401	ENSG00000273142.1	RP11-458F8.4	4.71	3.57e-06	0.00109	0.24	0.25	Aortic root size;	chr7:66174841	chr7:66902857~66906297:+
LIHC	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-4.71	3.57e-06	0.00109	-0.3	-0.25	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-4.71	3.57e-06	0.00109	-0.3	-0.25	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-4.71	3.57e-06	0.00109	-0.3	-0.25	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
LIHC	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	4.71	3.58e-06	0.00109	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
LIHC	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	4.71	3.58e-06	0.00109	0.33	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
LIHC	cis	rs875971	0.66	rs3764903	ENSG00000273024.4	INTS4P2	4.71	3.58e-06	0.00109	0.28	0.25	Aortic root size;	chr7:66633495	chr7:65647864~65715661:+
LIHC	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	4.71	3.58e-06	0.00109	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
LIHC	cis	rs591584	0.59	rs10765689	ENSG00000255893.1	RP11-685N10.1	-4.71	3.58e-06	0.00109	-0.25	-0.25	Macrophage Migration Inhibitory Factor levels;	chr11:94589519	chr11:94472908~94473570:-
LIHC	cis	rs202072	0.585	rs3817735	ENSG00000215022.6	RP1-257A7.4	-4.71	3.59e-06	0.00109	-0.26	-0.25	HIV-1 viral setpoint;	chr6:13278416	chr6:13264861~13295586:-
LIHC	cis	rs13315871	1	rs9864325	ENSG00000272182.1	RP11-802O23.3	4.71	3.59e-06	0.00109	0.56	0.25	Cholesterol, total;	chr3:58351119	chr3:58428255~58428815:+
LIHC	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	4.71	3.59e-06	0.00109	0.19	0.25	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
LIHC	cis	rs2243480	0.803	rs13224048	ENSG00000230295.1	RP11-458F8.2	-4.71	3.6e-06	0.00109	-0.26	-0.25	Diabetic kidney disease;	chr7:66528779	chr7:66880708~66882981:+
LIHC	cis	rs804280	0.509	rs12719915	ENSG00000255394.4	C8orf49	-4.71	3.6e-06	0.00109	-0.32	-0.25	Myopia (pathological);	chr8:11928746	chr8:11761256~11763223:+
LIHC	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	4.71	3.6e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
LIHC	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	4.71	3.6e-06	0.0011	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
LIHC	cis	rs6600671	0.934	rs11249429	ENSG00000231429.2	RP11-343N15.2	4.71	3.61e-06	0.0011	0.28	0.25	Hip geometry;	chr1:121549282	chr1:121412719~121429274:+
LIHC	cis	rs643506	0.874	rs625477	ENSG00000254990.4	RP11-108O10.2	4.71	3.61e-06	0.0011	0.27	0.25	Breast cancer;	chr11:111790962	chr11:111768668~111778350:-
LIHC	cis	rs7665090	1	rs2125211	ENSG00000230069.3	LRRC37A15P	4.71	3.61e-06	0.0011	0.25	0.25	Primary biliary cholangitis;	chr4:102638719	chr4:102727274~102730721:-
LIHC	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	4.71	3.61e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
LIHC	cis	rs2932538	0.922	rs12048528	ENSG00000225075.1	RP11-426L16.3	-4.71	3.61e-06	0.0011	-0.32	-0.25	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112667912	chr1:112693688~112696621:-
LIHC	cis	rs7568498	0.517	rs11678856	ENSG00000227403.1	AC009299.3	4.71	3.61e-06	0.0011	0.32	0.25	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161068932	chr2:161244739~161249050:+
LIHC	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-4.71	3.62e-06	0.0011	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
LIHC	cis	rs9525927	0.57	rs9316074	ENSG00000230731.2	RP11-478K15.6	4.71	3.62e-06	0.0011	0.28	0.25	Dupuytren's disease;	chr13:44229045	chr13:44234118~44243192:-
LIHC	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	4.71	3.62e-06	0.0011	0.22	0.25	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
LIHC	cis	rs5758511	0.68	rs5758684	ENSG00000205702.9	CYP2D7	4.71	3.62e-06	0.0011	0.29	0.25	Birth weight;	chr22:42253503	chr22:42140203~42144577:-
LIHC	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	4.71	3.62e-06	0.0011	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	4.71	3.62e-06	0.0011	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	4.71	3.62e-06	0.0011	0.28	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
LIHC	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-4.71	3.62e-06	0.0011	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
LIHC	cis	rs16858210	0.607	rs59321941	ENSG00000234371.6	RPSAP31	4.71	3.62e-06	0.0011	0.33	0.25	Menopause (age at onset);	chr3:183853236	chr3:183884924~183888449:+
LIHC	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	4.71	3.63e-06	0.0011	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	4.71	3.63e-06	0.0011	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
LIHC	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	4.71	3.63e-06	0.0011	0.32	0.25	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
LIHC	cis	rs2739330	0.828	rs4820572	ENSG00000206090.4	AP000350.7	4.71	3.64e-06	0.0011	0.28	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23939998~23942798:+
LIHC	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-4.71	3.64e-06	0.0011	-0.28	-0.25	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
LIHC	cis	rs7662987	0.793	rs28730632	ENSG00000272777.1	RP11-571L19.8	4.71	3.64e-06	0.0011	0.55	0.25	Smoking initiation;	chr4:99074552	chr4:99067256~99068125:-
LIHC	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	4.71	3.64e-06	0.0011	0.44	0.25	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
LIHC	cis	rs5758511	0.68	rs1033459	ENSG00000205702.9	CYP2D7	4.71	3.64e-06	0.00111	0.29	0.25	Birth weight;	chr22:42223061	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.68	rs1033460	ENSG00000205702.9	CYP2D7	4.71	3.64e-06	0.00111	0.29	0.25	Birth weight;	chr22:42223302	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.679	rs55867855	ENSG00000205702.9	CYP2D7	4.71	3.64e-06	0.00111	0.29	0.25	Birth weight;	chr22:42227252	chr22:42140203~42144577:-
LIHC	cis	rs11722779	0.935	rs7681629	ENSG00000230069.3	LRRC37A15P	-4.71	3.64e-06	0.00111	-0.22	-0.25	Schizophrenia;	chr4:102974407	chr4:102727274~102730721:-
LIHC	cis	rs11722779	0.844	rs17033381	ENSG00000230069.3	LRRC37A15P	-4.71	3.64e-06	0.00111	-0.22	-0.25	Schizophrenia;	chr4:102974952	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs4699044	ENSG00000230069.3	LRRC37A15P	-4.71	3.64e-06	0.00111	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.556	rs4699045	ENSG00000230069.3	LRRC37A15P	-4.71	3.64e-06	0.00111	-0.22	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102727274~102730721:-
LIHC	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-4.71	3.64e-06	0.00111	-0.28	-0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
LIHC	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	4.71	3.64e-06	0.00111	0.37	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
LIHC	cis	rs643506	0.874	rs609007	ENSG00000254990.4	RP11-108O10.2	-4.71	3.64e-06	0.00111	-0.27	-0.25	Breast cancer;	chr11:111848870	chr11:111768668~111778350:-
LIHC	cis	rs17818399	0.815	rs17768132	ENSG00000279254.1	RP11-536C12.1	4.71	3.64e-06	0.00111	0.3	0.25	Height;	chr2:46636110	chr2:46668870~46670778:+
LIHC	cis	rs7662987	0.793	rs12106	ENSG00000272777.1	RP11-571L19.8	4.71	3.64e-06	0.00111	0.54	0.25	Smoking initiation;	chr4:99072199	chr4:99067256~99068125:-
LIHC	cis	rs1865760	1	rs3799371	ENSG00000216436.2	HIST1H2APS1	4.71	3.64e-06	0.00111	0.28	0.25	Height;	chr6:25912588	chr6:25732497~25732827:+
LIHC	cis	rs643506	0.874	rs4936786	ENSG00000254990.4	RP11-108O10.2	4.71	3.64e-06	0.00111	0.26	0.25	Breast cancer;	chr11:111856504	chr11:111768668~111778350:-
LIHC	cis	rs2877649	0.51	rs10129168	ENSG00000258744.1	RP11-80A15.1	-4.71	3.65e-06	0.00111	-0.45	-0.25	Smooth-surface caries;	chr14:24436858	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.623	rs3742521	ENSG00000258744.1	RP11-80A15.1	-4.71	3.65e-06	0.00111	-0.45	-0.25	Smooth-surface caries;	chr14:24437309	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.623	rs3742522	ENSG00000258744.1	RP11-80A15.1	-4.71	3.65e-06	0.00111	-0.45	-0.25	Smooth-surface caries;	chr14:24437328	chr14:24501594~24508688:+
LIHC	cis	rs4694744	0.576	rs13141436	ENSG00000264696.1	AC108078.1	4.71	3.65e-06	0.00111	0.38	0.25	Bacteremia;	chr4:69476861	chr4:69479331~69479434:+
LIHC	cis	rs4694744	0.543	rs34285519	ENSG00000264696.1	AC108078.1	4.71	3.65e-06	0.00111	0.38	0.25	Bacteremia;	chr4:69477263	chr4:69479331~69479434:+
LIHC	cis	rs9291683	0.53	rs10939620	ENSG00000250413.1	RP11-448G15.1	4.71	3.65e-06	0.00111	0.32	0.25	Bone mineral density;	chr4:9944508	chr4:10006482~10009725:+
LIHC	cis	rs5758659	0.716	rs86669	ENSG00000227370.1	RP4-669P10.19	-4.71	3.65e-06	0.00111	-0.27	-0.25	Cognitive function;	chr22:42284794	chr22:42132543~42132998:+
LIHC	cis	rs529413	1	rs535699	ENSG00000259237.1	RP11-209E8.1	4.71	3.66e-06	0.00111	0.34	0.25	Itch intensity from mosquito bite adjusted by bite size;	chr15:53249900	chr15:53116365~53129698:+
LIHC	cis	rs6480314	0.522	rs4746756	ENSG00000233590.1	RP11-153K11.3	4.71	3.66e-06	0.00111	0.38	0.25	Optic nerve measurement (disc area);	chr10:68301188	chr10:68233251~68242379:-
LIHC	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	4.71	3.66e-06	0.00111	0.32	0.25	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
LIHC	cis	rs2439831	0.702	rs8033995	ENSG00000166763.7	STRCP1	4.71	3.66e-06	0.00111	0.37	0.25	Lung cancer in ever smokers;	chr15:43721311	chr15:43699488~43718184:-
LIHC	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-4.71	3.67e-06	0.00111	-0.28	-0.25	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
LIHC	cis	rs1020064	0.945	rs1030878	ENSG00000235319.1	AC012360.4	-4.71	3.68e-06	0.00112	-0.34	-0.25	AIDS;	chr2:105294141	chr2:105324210~105330529:+
LIHC	cis	rs1030877	0.515	rs2679895	ENSG00000235319.1	AC012360.4	-4.71	3.68e-06	0.00112	-0.34	-0.25	Obesity-related traits;	chr2:105290023	chr2:105324210~105330529:+
LIHC	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	4.71	3.68e-06	0.00112	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
LIHC	cis	rs11722779	0.658	rs6533044	ENSG00000230069.3	LRRC37A15P	-4.71	3.68e-06	0.00112	-0.22	-0.25	Schizophrenia;	chr4:102965261	chr4:102727274~102730721:-
LIHC	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	4.71	3.69e-06	0.00112	0.2	0.25	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
LIHC	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	4.71	3.69e-06	0.00112	0.29	0.25	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	4.71	3.69e-06	0.00112	0.29	0.25	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
LIHC	cis	rs2834188	1	rs9982088	ENSG00000272659.1	AP000295.10	-4.71	3.69e-06	0.00112	-0.36	-0.25	Narcolepsy;	chr21:33314536	chr21:33309491~33310181:+
LIHC	cis	rs6479901	0.793	rs10761725	ENSG00000232075.1	MRPL35P2	-4.71	3.69e-06	0.00112	-0.27	-0.25	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63634317~63634827:-
LIHC	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-4.71	3.69e-06	0.00112	-0.19	-0.25	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
LIHC	cis	rs61160187	0.51	rs6893642	ENSG00000272308.1	RP11-231G3.1	-4.71	3.69e-06	0.00112	-0.29	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.51	rs3936423	ENSG00000272308.1	RP11-231G3.1	-4.71	3.69e-06	0.00112	-0.29	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.51	rs1445293	ENSG00000272308.1	RP11-231G3.1	-4.71	3.69e-06	0.00112	-0.29	-0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60866457~60866935:-
LIHC	cis	rs4700393	0.967	rs4700394	ENSG00000272308.1	RP11-231G3.1	4.71	3.69e-06	0.00112	0.29	0.25	Intelligence (multi-trait analysis);	chr5:60821375	chr5:60866457~60866935:-
LIHC	cis	rs11098499	0.954	rs10518331	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119402440	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs13133522	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119403269	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs35091806	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119404374	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs35165976	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119404475	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs2389802	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119404577	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs6846442	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119405168	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs71614422	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119438185	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.738	rs34566984	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119440115	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.738	rs34965784	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119440431	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs17009122	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119441248	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.505	rs75122014	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119441271	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs9685777	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119444810	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs71614438	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119450097	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs66506550	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119450290	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs7659501	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119450397	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.657	rs71614442	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119458191	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs2892848	ENSG00000260091.1	RP11-33B1.4	-4.7	3.7e-06	0.00112	-0.18	-0.25	Corneal astigmatism;	chr4:119460186	chr4:119409333~119410233:+
LIHC	cis	rs2836974	0.863	rs8132333	ENSG00000255568.3	BRWD1-AS2	4.7	3.7e-06	0.00112	0.27	0.25	Cognitive function;	chr21:39155974	chr21:39313935~39314962:+
LIHC	cis	rs75920871	0.764	rs4938326	ENSG00000254851.1	RP11-109L13.1	-4.7	3.71e-06	0.00112	-0.51	-0.25	Subjective well-being;	chr11:117034748	chr11:117135528~117138582:+
LIHC	cis	rs1865760	0.566	rs2032449	ENSG00000216436.2	HIST1H2APS1	-4.7	3.71e-06	0.00112	-0.28	-0.25	Height;	chr6:26026371	chr6:25732497~25732827:+
LIHC	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-4.7	3.71e-06	0.00112	-0.26	-0.25	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
LIHC	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	4.7	3.71e-06	0.00112	0.36	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	4.7	3.71e-06	0.00112	0.36	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
LIHC	cis	rs1065852	0.526	rs1062753	ENSG00000237037.8	NDUFA6-AS1	-4.7	3.71e-06	0.00112	-0.34	-0.25	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41996807	chr22:42090931~42137742:+
LIHC	cis	rs643506	0.874	rs680096	ENSG00000254990.4	RP11-108O10.2	4.7	3.71e-06	0.00112	0.26	0.25	Breast cancer;	chr11:111837945	chr11:111768668~111778350:-
LIHC	cis	rs643506	0.874	rs10789849	ENSG00000254990.4	RP11-108O10.2	4.7	3.71e-06	0.00112	0.26	0.25	Breast cancer;	chr11:111845347	chr11:111768668~111778350:-
LIHC	cis	rs4266144	1	rs4266144	ENSG00000241770.1	RP11-555M1.3	-4.7	3.72e-06	0.00112	-0.3	-0.25	Coronary artery disease;	chr3:157134803	chr3:157163452~157169133:+
LIHC	cis	rs73193808	0.666	rs7276548	ENSG00000224649.1	AF124730.4	4.7	3.72e-06	0.00112	0.29	0.25	Coronary artery disease;	chr21:29180518	chr21:29182027~29187795:-
LIHC	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	4.7	3.72e-06	0.00113	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
LIHC	cis	rs4938573	0.526	rs11216973	ENSG00000255239.1	AP002954.6	-4.7	3.72e-06	0.00113	-0.36	-0.25	Follicular lymphoma;	chr11:118716292	chr11:118688039~118690600:-
LIHC	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-4.7	3.72e-06	0.00113	-0.29	-0.25	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
LIHC	cis	rs875971	0.545	rs2460427	ENSG00000273142.1	RP11-458F8.4	-4.7	3.72e-06	0.00113	-0.24	-0.25	Aortic root size;	chr7:66154218	chr7:66902857~66906297:+
LIHC	cis	rs3733589	1	rs3796840	ENSG00000250413.1	RP11-448G15.1	4.7	3.72e-06	0.00113	0.43	0.25	Renal overload gout;	chr4:10006497	chr4:10006482~10009725:+
LIHC	cis	rs17270561	0.943	rs76703022	ENSG00000216436.2	HIST1H2APS1	-4.7	3.73e-06	0.00113	-0.39	-0.25	Iron status biomarkers;	chr6:25703301	chr6:25732497~25732827:+
LIHC	cis	rs12701220	0.894	rs10257744	ENSG00000229043.2	AC091729.9	-4.7	3.73e-06	0.00113	-0.35	-0.25	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1160374~1165267:+
LIHC	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	4.7	3.73e-06	0.00113	0.47	0.25	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
LIHC	cis	rs1558001	0.834	rs2108032	ENSG00000230196.1	DDX43P3	4.7	3.73e-06	0.00113	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81788019	chr7:81610884~81611326:-
LIHC	cis	rs1558001	0.87	rs969705	ENSG00000230196.1	DDX43P3	4.7	3.73e-06	0.00113	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81789770	chr7:81610884~81611326:-
LIHC	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-4.7	3.73e-06	0.00113	-0.3	-0.25	Height;	chr6:109636120	chr6:109382795~109383666:+
LIHC	cis	rs2834188	1	rs1018741	ENSG00000272659.1	AP000295.10	-4.7	3.73e-06	0.00113	-0.36	-0.25	Narcolepsy;	chr21:33314040	chr21:33309491~33310181:+
LIHC	cis	rs2834188	1	rs1018742	ENSG00000272659.1	AP000295.10	-4.7	3.73e-06	0.00113	-0.36	-0.25	Narcolepsy;	chr21:33314076	chr21:33309491~33310181:+
LIHC	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	4.7	3.74e-06	0.00113	0.22	0.25	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
LIHC	cis	rs2998286	0.723	rs332172	ENSG00000254635.4	WAC-AS1	-4.7	3.74e-06	0.00113	-0.32	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28610394	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332186	ENSG00000254635.4	WAC-AS1	-4.7	3.74e-06	0.00113	-0.32	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624674	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332187	ENSG00000254635.4	WAC-AS1	-4.7	3.74e-06	0.00113	-0.32	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624887	chr10:28522652~28532743:-
LIHC	cis	rs748404	0.697	rs493177	ENSG00000166763.7	STRCP1	4.7	3.74e-06	0.00113	0.3	0.25	Lung cancer;	chr15:43251060	chr15:43699488~43718184:-
LIHC	cis	rs1077773	0.509	rs6461315	ENSG00000237773.4	AC003075.4	-4.7	3.74e-06	0.00113	-0.31	-0.25	Ulcerative colitis;Inflammatory bowel disease;	chr7:17408820	chr7:17279834~17299357:-
LIHC	cis	rs79040073	0.53	rs8029506	ENSG00000259531.2	RP11-295H24.3	4.7	3.74e-06	0.00113	0.41	0.25	Lung cancer in ever smokers;	chr15:49274543	chr15:49365124~49366685:-
LIHC	cis	rs1558001	0.87	rs975359	ENSG00000230196.1	DDX43P3	4.7	3.75e-06	0.00113	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81781600	chr7:81610884~81611326:-
LIHC	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	4.7	3.75e-06	0.00113	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
LIHC	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	4.7	3.75e-06	0.00113	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
LIHC	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-4.7	3.76e-06	0.00113	-0.35	-0.25	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
LIHC	cis	rs11098499	0.58	rs12509234	ENSG00000260091.1	RP11-33B1.4	-4.7	3.76e-06	0.00114	-0.18	-0.25	Corneal astigmatism;	chr4:119398279	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs10014719	ENSG00000260091.1	RP11-33B1.4	-4.7	3.76e-06	0.00114	-0.18	-0.25	Corneal astigmatism;	chr4:119399560	chr4:119409333~119410233:+
LIHC	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-4.7	3.76e-06	0.00114	-0.31	-0.25	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-4.7	3.76e-06	0.00114	-0.31	-0.25	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
LIHC	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-4.7	3.76e-06	0.00114	-0.31	-0.25	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
LIHC	cis	rs9834975	0.967	rs12152463	ENSG00000272758.4	RP11-299J3.8	-4.7	3.76e-06	0.00114	-0.28	-0.25	Diastolic blood pressure;	chr3:122381600	chr3:122416207~122443180:+
LIHC	cis	rs1577917	0.654	rs9450284	ENSG00000234155.1	RP11-30P6.6	-4.7	3.76e-06	0.00114	-0.3	-0.25	Response to antipsychotic treatment;	chr6:85489611	chr6:85387219~85390186:-
LIHC	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	4.7	3.77e-06	0.00114	0.21	0.25	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
LIHC	cis	rs9595908	0.9	rs1324415	ENSG00000212293.1	SNORA16	4.7	3.77e-06	0.00114	0.29	0.25	Body mass index;	chr13:32600186	chr13:32420390~32420516:-
LIHC	cis	rs901683	0.702	rs114085432	ENSG00000230869.1	CTGLF10P	-4.7	3.77e-06	0.00114	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45645317	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs115133418	ENSG00000230869.1	CTGLF10P	-4.7	3.77e-06	0.00114	-0.65	-0.25	Mean corpuscular volume;Red blood cell traits;	chr10:45645318	chr10:45678692~45700532:+
LIHC	cis	rs1577917	1	rs10498958	ENSG00000234155.1	RP11-30P6.6	-4.7	3.77e-06	0.00114	-0.33	-0.25	Response to antipsychotic treatment;	chr6:85939987	chr6:85387219~85390186:-
LIHC	cis	rs6445975	0.726	rs6764512	ENSG00000272360.1	RP11-359I18.5	4.7	3.77e-06	0.00114	0.29	0.25	Systemic lupus erythematosus;	chr3:58482509	chr3:58490830~58491291:-
LIHC	cis	rs712039	0.652	rs853197	ENSG00000276054.1	RP11-378E13.3	4.7	3.78e-06	0.00114	0.31	0.25	Tuberculosis;	chr17:37488610	chr17:37386886~37387926:+
LIHC	cis	rs916888	0.773	rs199535	ENSG00000274883.1	Metazoa_SRP	-4.7	3.78e-06	0.00114	-0.39	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45931806~45932083:+
LIHC	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	4.7	3.78e-06	0.00114	0.39	0.25	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
LIHC	cis	rs9595908	0.827	rs7321262	ENSG00000212293.1	SNORA16	4.7	3.79e-06	0.00114	0.29	0.25	Body mass index;	chr13:32597942	chr13:32420390~32420516:-
LIHC	cis	rs11992162	1	rs7460395	ENSG00000255495.1	AC145124.2	4.7	3.79e-06	0.00114	0.31	0.25	Monocyte count;	chr8:11977866	chr8:12194467~12196280:+
LIHC	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	4.7	3.79e-06	0.00114	0.2	0.25	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
LIHC	cis	rs6997458	0.742	rs20571	ENSG00000253549.4	RP11-317J10.2	4.7	3.79e-06	0.00114	0.27	0.25	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85439768	chr8:85441851~85464915:-
LIHC	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	4.7	3.79e-06	0.00114	0.2	0.25	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	4.7	3.79e-06	0.00114	0.2	0.25	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
LIHC	cis	rs9388451	0.626	rs9385383	ENSG00000237742.5	RP11-624M8.1	-4.7	3.79e-06	0.00114	-0.23	-0.25	Brugada syndrome;	chr6:125765144	chr6:125578558~125749190:-
LIHC	cis	rs7119038	0.509	rs11216961	ENSG00000255422.1	AP002954.4	4.7	3.79e-06	0.00114	0.32	0.25	Sjögren's syndrome;	chr11:118709629	chr11:118704607~118750263:+
LIHC	cis	rs11079159	0.628	rs884301	ENSG00000263096.1	RP11-515O17.2	4.7	3.79e-06	0.00114	0.33	0.25	QRS duration;	chr17:55290103	chr17:55271504~55273653:-
LIHC	cis	rs2929278	0.617	rs575082	ENSG00000166763.7	STRCP1	-4.7	3.8e-06	0.00114	-0.32	-0.25	Schizophrenia;	chr15:43817944	chr15:43699488~43718184:-
LIHC	cis	rs2929278	0.617	rs2955969	ENSG00000166763.7	STRCP1	-4.7	3.8e-06	0.00114	-0.32	-0.25	Schizophrenia;	chr15:43822329	chr15:43699488~43718184:-
LIHC	cis	rs12304921	0.748	rs17125375	ENSG00000277201.1	AC087884.1	4.7	3.8e-06	0.00115	0.29	0.25	Type 2 diabetes;	chr12:51105936	chr12:51049921~51050025:+
LIHC	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	4.7	3.81e-06	0.00115	0.27	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
LIHC	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	4.7	3.81e-06	0.00115	0.24	0.25	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	4.7	3.81e-06	0.00115	0.24	0.25	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
LIHC	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	4.7	3.81e-06	0.00115	0.29	0.25	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
LIHC	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	4.7	3.81e-06	0.00115	0.2	0.25	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
LIHC	cis	rs5758511	0.573	rs139558	ENSG00000237037.8	NDUFA6-AS1	4.7	3.81e-06	0.00115	0.29	0.25	Birth weight;	chr22:41793547	chr22:42090931~42137742:+
LIHC	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	4.7	3.81e-06	0.00115	0.28	0.25	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	4.7	3.81e-06	0.00115	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	4.7	3.81e-06	0.00115	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	4.7	3.81e-06	0.00115	0.28	0.25	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	4.7	3.81e-06	0.00115	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
LIHC	cis	rs643506	0.845	rs607327	ENSG00000254990.4	RP11-108O10.2	4.7	3.81e-06	0.00115	0.26	0.25	Breast cancer;	chr11:111824985	chr11:111768668~111778350:-
LIHC	cis	rs643506	0.874	rs663511	ENSG00000254990.4	RP11-108O10.2	4.7	3.81e-06	0.00115	0.26	0.25	Breast cancer;	chr11:111839311	chr11:111768668~111778350:-
LIHC	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-4.7	3.83e-06	0.00115	-0.2	-0.25	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
LIHC	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	4.7	3.83e-06	0.00115	0.23	0.25	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
LIHC	cis	rs2243480	1	rs1638734	ENSG00000230295.1	RP11-458F8.2	-4.7	3.83e-06	0.00115	-0.26	-0.25	Diabetic kidney disease;	chr7:66632552	chr7:66880708~66882981:+
LIHC	cis	rs6480314	0.522	rs10047388	ENSG00000233590.1	RP11-153K11.3	4.7	3.83e-06	0.00115	0.38	0.25	Optic nerve measurement (disc area);	chr10:68300456	chr10:68233251~68242379:-
LIHC	cis	rs10829156	0.66	rs10764587	ENSG00000225527.1	RP11-383B4.4	-4.7	3.83e-06	0.00115	-0.4	-0.25	Sudden cardiac arrest;	chr10:18548901	chr10:18531849~18533336:-
LIHC	cis	rs643506	0.874	rs687152	ENSG00000254990.4	RP11-108O10.2	4.7	3.83e-06	0.00115	0.26	0.25	Breast cancer;	chr11:111850950	chr11:111768668~111778350:-
LIHC	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	4.7	3.83e-06	0.00115	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
LIHC	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-4.7	3.84e-06	0.00116	-0.32	-0.25	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
LIHC	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-4.7	3.84e-06	0.00116	-0.17	-0.25	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
LIHC	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	4.7	3.84e-06	0.00116	0.42	0.25	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
LIHC	cis	rs2749097	0.825	rs6671606	ENSG00000244256.3	RN7SL130P	-4.7	3.85e-06	0.00116	-0.29	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63658197	chr1:63655743~63656047:+
LIHC	cis	rs7119038	0.629	rs10892271	ENSG00000255239.1	AP002954.6	-4.7	3.85e-06	0.00116	-0.35	-0.25	Sjögren's syndrome;	chr11:118727835	chr11:118688039~118690600:-
LIHC	cis	rs17711722	0.522	rs4642526	ENSG00000273024.4	INTS4P2	-4.7	3.85e-06	0.00116	-0.26	-0.25	Calcium levels;	chr7:65751755	chr7:65647864~65715661:+
LIHC	cis	rs2337406	1	rs11846866	ENSG00000274576.2	IGHV2-70	-4.7	3.85e-06	0.00116	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106703003	chr14:106770577~106771020:-
LIHC	cis	rs7208859	0.51	rs216402	ENSG00000266490.1	CTD-2349P21.9	4.7	3.85e-06	0.00116	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	4.7	3.85e-06	0.00116	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs216439	ENSG00000266490.1	CTD-2349P21.9	4.7	3.85e-06	0.00116	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30792372~30792833:+
LIHC	cis	rs1865760	0.566	rs9379821	ENSG00000216436.2	HIST1H2APS1	-4.7	3.85e-06	0.00116	-0.29	-0.25	Height;	chr6:26054040	chr6:25732497~25732827:+
LIHC	cis	rs11098499	0.863	rs12508173	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.18	-0.25	Corneal astigmatism;	chr4:119397371	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.908	rs12504149	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.18	-0.25	Corneal astigmatism;	chr4:119397422	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs17006190	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119497683	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs28685688	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119499179	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs7687843	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119500056	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs2306455	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119500814	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs10031483	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119501481	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs10031665	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119501697	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs3733519	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119502293	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs3733523	ENSG00000260091.1	RP11-33B1.4	-4.7	3.85e-06	0.00116	-0.17	-0.25	Corneal astigmatism;	chr4:119502564	chr4:119409333~119410233:+
LIHC	cis	rs6802315	0.604	rs9881462	ENSG00000272087.1	RP11-379F4.7	4.7	3.86e-06	0.00116	0.28	0.25	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158693120~158693768:-
LIHC	cis	rs643506	0.874	rs631318	ENSG00000254990.4	RP11-108O10.2	-4.7	3.86e-06	0.00116	-0.26	-0.25	Breast cancer;	chr11:111806971	chr11:111768668~111778350:-
LIHC	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-4.69	3.87e-06	0.00116	-0.34	-0.25	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
LIHC	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-4.69	3.87e-06	0.00116	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
LIHC	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-4.69	3.87e-06	0.00116	-0.26	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
LIHC	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	4.69	3.87e-06	0.00116	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
LIHC	cis	rs4766897	0.543	rs10850001	ENSG00000226469.1	ADAM1B	-4.69	3.87e-06	0.00116	-0.27	-0.25	Fibrinogen levels;	chr12:112115228	chr12:111927018~111929017:+
LIHC	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-4.69	3.87e-06	0.00116	-0.38	-0.25	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
LIHC	cis	rs16858210	0.648	rs57604063	ENSG00000234371.6	RPSAP31	4.69	3.87e-06	0.00116	0.33	0.25	Menopause (age at onset);	chr3:183860901	chr3:183884924~183888449:+
LIHC	cis	rs16858210	0.607	rs57874587	ENSG00000234371.6	RPSAP31	4.69	3.87e-06	0.00116	0.33	0.25	Menopause (age at onset);	chr3:183866961	chr3:183884924~183888449:+
LIHC	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	4.69	3.88e-06	0.00117	0.24	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
LIHC	cis	rs2337406	1	rs1858677	ENSG00000274576.2	IGHV2-70	-4.69	3.88e-06	0.00117	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106706828	chr14:106770577~106771020:-
LIHC	cis	rs2060793	0.712	rs10741654	ENSG00000251991.1	RNU7-49P	4.69	3.88e-06	0.00117	0.28	0.25	Vitamin D levels;	chr11:14726506	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.505	rs9971395	ENSG00000251991.1	RNU7-49P	4.69	3.88e-06	0.00117	0.28	0.25	Mitochondrial DNA levels;	chr11:14745580	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.506	rs10741655	ENSG00000251991.1	RNU7-49P	4.69	3.88e-06	0.00117	0.28	0.25	Mitochondrial DNA levels;	chr11:14746838	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.954	rs6834796	ENSG00000260091.1	RP11-33B1.4	-4.69	3.88e-06	0.00117	-0.17	-0.25	Corneal astigmatism;	chr4:119493538	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs11729521	ENSG00000260091.1	RP11-33B1.4	-4.69	3.88e-06	0.00117	-0.17	-0.25	Corneal astigmatism;	chr4:119495633	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs11734241	ENSG00000260091.1	RP11-33B1.4	-4.69	3.88e-06	0.00117	-0.17	-0.25	Corneal astigmatism;	chr4:119495717	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-4.69	3.88e-06	0.00117	-0.26	-0.25	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
LIHC	cis	rs10510102	0.872	rs11200268	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121932661	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11200269	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121934021	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11498944	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121938748	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.81	rs12267347	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121939110	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.808	rs12253007	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121939360	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs79865971	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121941208	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs74318512	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121941465	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12257207	ENSG00000226864.1	ATE1-AS1	4.69	3.88e-06	0.00117	0.42	0.25	Breast cancer;	chr10:121941737	chr10:121928312~121951965:+
LIHC	cis	rs11098499	0.908	rs11098527	ENSG00000260091.1	RP11-33B1.4	-4.69	3.88e-06	0.00117	-0.17	-0.25	Corneal astigmatism;	chr4:119478751	chr4:119409333~119410233:+
LIHC	cis	rs5756813	0.727	rs4820303	ENSG00000233360.4	Z83844.1	4.69	3.88e-06	0.00117	0.32	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37738159	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.727	rs4239889	ENSG00000233360.4	Z83844.1	4.69	3.88e-06	0.00117	0.32	0.25	Optic cup area;Vertical cup-disc ratio;	chr22:37744345	chr22:37641832~37658377:-
LIHC	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	4.69	3.89e-06	0.00117	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
LIHC	cis	rs7412746	0.611	rs4970984	ENSG00000231073.1	RP11-316M1.3	4.69	3.89e-06	0.00117	0.24	0.25	Melanoma;	chr1:150914901	chr1:150973123~150975534:+
LIHC	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-4.69	3.89e-06	0.00117	-0.29	-0.25	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
LIHC	cis	rs960902	0.747	rs7595792	ENSG00000213553.4	RPLP0P6	4.69	3.89e-06	0.00117	0.2	0.25	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37502480	chr2:38481851~38482804:+
LIHC	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-4.69	3.89e-06	0.00117	-0.39	-0.25	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
LIHC	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-4.69	3.89e-06	0.00117	-0.36	-0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
LIHC	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-4.69	3.89e-06	0.00117	-0.33	-0.25	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
LIHC	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-4.69	3.89e-06	0.00117	-0.29	-0.25	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
LIHC	cis	rs6997458	0.742	rs4566	ENSG00000253549.4	RP11-317J10.2	4.69	3.89e-06	0.00117	0.26	0.25	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85448853	chr8:85441851~85464915:-
LIHC	cis	rs9834975	0.903	rs56131302	ENSG00000272758.4	RP11-299J3.8	-4.69	3.89e-06	0.00117	-0.27	-0.25	Diastolic blood pressure;	chr3:122499141	chr3:122416207~122443180:+
LIHC	cis	rs9834975	0.935	rs6438735	ENSG00000272758.4	RP11-299J3.8	-4.69	3.89e-06	0.00117	-0.27	-0.25	Diastolic blood pressure;	chr3:122500539	chr3:122416207~122443180:+
LIHC	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	4.69	3.9e-06	0.00117	0.25	0.25	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
LIHC	cis	rs4862307	0.754	rs6846007	ENSG00000250726.1	RP11-616K6.1	-4.69	3.9e-06	0.00117	-0.27	-0.25	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184070451	chr4:184072403~184073039:+
LIHC	cis	rs6600671	0.966	rs6600664	ENSG00000231429.2	RP11-343N15.2	-4.69	3.91e-06	0.00117	-0.28	-0.25	Hip geometry;	chr1:121480638	chr1:121412719~121429274:+
LIHC	cis	rs6600671	0.932	rs6600663	ENSG00000231429.2	RP11-343N15.2	-4.69	3.91e-06	0.00117	-0.28	-0.25	Hip geometry;	chr1:121480639	chr1:121412719~121429274:+
LIHC	cis	rs748404	0.65	rs556851	ENSG00000166763.7	STRCP1	4.69	3.91e-06	0.00117	0.31	0.25	Lung cancer;	chr15:43279021	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs567357	ENSG00000166763.7	STRCP1	4.69	3.91e-06	0.00117	0.31	0.25	Lung cancer;	chr15:43279192	chr15:43699488~43718184:-
LIHC	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	4.69	3.91e-06	0.00117	0.27	0.25	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
LIHC	cis	rs875971	0.545	rs4441996	ENSG00000273142.1	RP11-458F8.4	-4.69	3.92e-06	0.00118	-0.24	-0.25	Aortic root size;	chr7:66123233	chr7:66902857~66906297:+
LIHC	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	4.69	3.92e-06	0.00118	0.28	0.25	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
LIHC	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	4.69	3.93e-06	0.00118	0.23	0.25	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
LIHC	cis	rs1577917	1	rs10455455	ENSG00000234155.1	RP11-30P6.6	4.69	3.93e-06	0.00118	0.33	0.25	Response to antipsychotic treatment;	chr6:85960496	chr6:85387219~85390186:-
LIHC	cis	rs1865760	0.964	rs6932113	ENSG00000216436.2	HIST1H2APS1	-4.69	3.93e-06	0.00118	-0.27	-0.25	Height;	chr6:25912870	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs7757666	ENSG00000216436.2	HIST1H2APS1	-4.69	3.93e-06	0.00118	-0.27	-0.25	Height;	chr6:25902398	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs6910138	ENSG00000216436.2	HIST1H2APS1	-4.69	3.93e-06	0.00118	-0.27	-0.25	Height;	chr6:25904124	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs6910174	ENSG00000216436.2	HIST1H2APS1	-4.69	3.93e-06	0.00118	-0.27	-0.25	Height;	chr6:25904186	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs6905887	ENSG00000216436.2	HIST1H2APS1	-4.69	3.93e-06	0.00118	-0.27	-0.25	Height;	chr6:25911875	chr6:25732497~25732827:+
LIHC	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	4.69	3.93e-06	0.00118	0.42	0.25	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
LIHC	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-4.69	3.93e-06	0.00118	-0.2	-0.25	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
LIHC	cis	rs5758511	0.68	rs5758681	ENSG00000205702.9	CYP2D7	4.69	3.93e-06	0.00118	0.29	0.25	Birth weight;	chr22:42249085	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.68	rs5758657	ENSG00000205702.9	CYP2D7	4.69	3.93e-06	0.00118	0.29	0.25	Birth weight;	chr22:42222663	chr22:42140203~42144577:-
LIHC	cis	rs1729407	0.786	rs5100	ENSG00000236267.1	AP006216.5	4.69	3.94e-06	0.00118	0.23	0.25	Apolipoprotein A-IV levels;	chr11:116821978	chr11:116813204~116814003:-
LIHC	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-4.69	3.95e-06	0.00119	-0.26	-0.25	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-4.69	3.95e-06	0.00119	-0.26	-0.25	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-4.69	3.95e-06	0.00119	-0.26	-0.25	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
LIHC	cis	rs1165668	0.785	rs1165681	ENSG00000257327.1	RP11-650K20.3	-4.69	3.95e-06	0.00119	-0.29	-0.25	Coronary heart disease (SNP X SNP interaction);	chr12:103931333	chr12:103841451~103844664:+
LIHC	cis	rs2834188	1	rs2834187	ENSG00000272659.1	AP000295.10	-4.69	3.95e-06	0.00119	-0.36	-0.25	Narcolepsy;	chr21:33315105	chr21:33309491~33310181:+
LIHC	cis	rs2836974	0.644	rs7281853	ENSG00000255568.3	BRWD1-AS2	-4.69	3.95e-06	0.00119	-0.21	-0.25	Cognitive function;	chr21:39321564	chr21:39313935~39314962:+
LIHC	cis	rs12554020	0.582	rs7033532	ENSG00000227603.1	RP11-165J3.6	4.69	3.96e-06	0.00119	0.45	0.25	Schizophrenia;	chr9:93644962	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs7038310	ENSG00000227603.1	RP11-165J3.6	4.69	3.96e-06	0.00119	0.45	0.25	Schizophrenia;	chr9:93645638	chr9:93435332~93437121:-
LIHC	cis	rs5758511	0.633	rs5758690	ENSG00000205702.9	CYP2D7	4.69	3.96e-06	0.00119	0.29	0.25	Birth weight;	chr22:42272289	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.68	rs1001586	ENSG00000205702.9	CYP2D7	4.69	3.96e-06	0.00119	0.29	0.25	Birth weight;	chr22:42274287	chr22:42140203~42144577:-
LIHC	cis	rs8067287	0.688	rs11078356	ENSG00000205312.7	KRT17P4	-4.69	3.96e-06	0.00119	-0.38	-0.25	Diabetic kidney disease;	chr17:16942894	chr17:16847635~16852777:-
LIHC	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-4.69	3.96e-06	0.00119	-0.27	-0.25	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
LIHC	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-4.69	3.97e-06	0.00119	-0.36	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
LIHC	cis	rs2310173	0.575	rs2110563	ENSG00000281162.1	LINC01127	-4.69	3.97e-06	0.00119	-0.27	-0.25	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102011971	chr2:101962056~101987167:+
LIHC	cis	rs2243480	1	rs2533288	ENSG00000230295.1	RP11-458F8.2	-4.69	3.97e-06	0.00119	-0.26	-0.25	Diabetic kidney disease;	chr7:66591724	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs2707844	ENSG00000230295.1	RP11-458F8.2	-4.69	3.97e-06	0.00119	-0.26	-0.25	Diabetic kidney disease;	chr7:66594522	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1796220	ENSG00000230295.1	RP11-458F8.2	-4.69	3.97e-06	0.00119	-0.26	-0.25	Diabetic kidney disease;	chr7:66597113	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs2707831	ENSG00000230295.1	RP11-458F8.2	-4.69	3.97e-06	0.00119	-0.26	-0.25	Diabetic kidney disease;	chr7:66597524	chr7:66880708~66882981:+
LIHC	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-4.69	3.98e-06	0.00119	-0.32	-0.25	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
LIHC	cis	rs71520386	0.632	rs2286500	ENSG00000228649.7	AC005682.5	-4.69	3.98e-06	0.00119	-0.32	-0.25	Fibrinogen levels;	chr7:22817185	chr7:22854178~22861579:+
LIHC	cis	rs6997458	0.713	rs1543852	ENSG00000253549.4	RP11-317J10.2	4.69	3.98e-06	0.00119	0.27	0.25	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85440529	chr8:85441851~85464915:-
LIHC	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-4.69	3.98e-06	0.00119	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-4.69	3.98e-06	0.00119	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
LIHC	cis	rs2998286	0.723	rs332177	ENSG00000254635.4	WAC-AS1	-4.69	3.98e-06	0.00119	-0.32	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28618221	chr10:28522652~28532743:-
LIHC	cis	rs7937890	0.507	rs4463820	ENSG00000251991.1	RNU7-49P	4.69	3.98e-06	0.00119	0.27	0.25	Mitochondrial DNA levels;	chr11:14534796	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.865	rs4001305	ENSG00000260091.1	RP11-33B1.4	-4.69	3.98e-06	0.00119	-0.18	-0.25	Corneal astigmatism;	chr4:119438081	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs3890049	ENSG00000260091.1	RP11-33B1.4	-4.69	3.98e-06	0.00119	-0.17	-0.25	Corneal astigmatism;	chr4:119405128	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs67265404	ENSG00000260091.1	RP11-33B1.4	-4.69	3.98e-06	0.00119	-0.17	-0.25	Corneal astigmatism;	chr4:119438115	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs71629403	ENSG00000260091.1	RP11-33B1.4	-4.69	3.98e-06	0.00119	-0.17	-0.25	Corneal astigmatism;	chr4:119451412	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs28571712	ENSG00000260091.1	RP11-33B1.4	-4.69	3.98e-06	0.00119	-0.17	-0.25	Corneal astigmatism;	chr4:119454825	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs9994730	ENSG00000260091.1	RP11-33B1.4	-4.69	3.98e-06	0.00119	-0.17	-0.25	Corneal astigmatism;	chr4:119460409	chr4:119409333~119410233:+
LIHC	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-4.69	3.98e-06	0.00119	-0.31	-0.25	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
LIHC	cis	rs10833905	0.818	rs10833876	ENSG00000246225.5	RP11-17A1.3	-4.69	3.98e-06	0.00119	-0.33	-0.25	Sudden cardiac arrest;	chr11:22985076	chr11:22829380~22945393:+
LIHC	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-4.69	3.99e-06	0.00119	-0.25	-0.25	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
LIHC	cis	rs5758511	0.68	rs739147	ENSG00000205702.9	CYP2D7	4.69	3.99e-06	0.00119	0.29	0.25	Birth weight;	chr22:42275060	chr22:42140203~42144577:-
LIHC	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-4.69	3.99e-06	0.00119	-0.22	-0.25	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
LIHC	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-4.69	3.99e-06	0.0012	-0.28	-0.25	Height;	chr2:46611108	chr2:46668870~46670778:+
LIHC	cis	rs748404	0.697	rs493444	ENSG00000166763.7	STRCP1	4.69	3.99e-06	0.0012	0.31	0.25	Lung cancer;	chr15:43274272	chr15:43699488~43718184:-
LIHC	cis	rs1862618	0.853	rs1423621	ENSG00000271828.1	CTD-2310F14.1	4.69	3.99e-06	0.0012	0.34	0.25	Initial pursuit acceleration;	chr5:56805208	chr5:56927874~56929573:+
LIHC	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-4.69	3.99e-06	0.0012	-0.23	-0.25	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
LIHC	cis	rs1558001	0.87	rs2158729	ENSG00000230196.1	DDX43P3	4.69	4e-06	0.0012	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81790712	chr7:81610884~81611326:-
LIHC	cis	rs12554020	0.504	rs74369348	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93664902	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs76863038	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93666143	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs56310424	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93666313	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.504	rs12551694	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93666619	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs12555927	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93666800	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs3829059	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93668874	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs76499753	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93670155	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs1963	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93670315	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs76244171	ENSG00000227603.1	RP11-165J3.6	4.69	4e-06	0.0012	0.45	0.25	Schizophrenia;	chr9:93673473	chr9:93435332~93437121:-
LIHC	cis	rs2739330	0.828	rs2330635	ENSG00000206090.4	AP000350.7	4.69	4e-06	0.0012	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23939998~23942798:+
LIHC	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	4.69	4.01e-06	0.0012	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	4.69	4.01e-06	0.0012	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
LIHC	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	4.69	4.01e-06	0.0012	0.17	0.25	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
LIHC	cis	rs2797160	0.651	rs1268093	ENSG00000237742.5	RP11-624M8.1	4.69	4.01e-06	0.0012	0.23	0.25	Endometrial cancer;	chr6:125708089	chr6:125578558~125749190:-
LIHC	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	4.69	4.01e-06	0.0012	0.28	0.25	Depression;	chr6:28273214	chr6:28943877~28944537:+
LIHC	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	4.69	4.01e-06	0.0012	0.28	0.25	Depression;	chr6:28273215	chr6:28943877~28944537:+
LIHC	cis	rs916888	0.531	rs183211	ENSG00000260075.1	NSFP1	4.69	4.01e-06	0.0012	0.3	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46372855~46487141:+
LIHC	cis	rs6901152	0.525	rs974754	ENSG00000217648.1	RP1-95L4.4	-4.69	4.02e-06	0.0012	-0.29	-0.25	Acute lymphoblastic leukemia (childhood);	chr6:143366384	chr6:143342246~143343383:+
LIHC	cis	rs7119038	0.629	rs73001429	ENSG00000255239.1	AP002954.6	-4.69	4.02e-06	0.0012	-0.33	-0.25	Sjögren's syndrome;	chr11:118732456	chr11:118688039~118690600:-
LIHC	cis	rs11089937	0.568	rs59356111	ENSG00000211639.2	IGLV4-60	4.69	4.02e-06	0.0012	0.21	0.25	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.626	rs5757019	ENSG00000211639.2	IGLV4-60	4.69	4.02e-06	0.0012	0.21	0.25	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22162199~22162681:+
LIHC	cis	rs11779988	0.545	rs427168	ENSG00000253671.1	RP11-806O11.1	-4.69	4.02e-06	0.0012	-0.33	-0.25	Breast cancer;	chr8:17927320	chr8:17808941~17820868:+
LIHC	cis	rs11779988	0.545	rs4124900	ENSG00000253671.1	RP11-806O11.1	-4.69	4.02e-06	0.0012	-0.33	-0.25	Breast cancer;	chr8:17927757	chr8:17808941~17820868:+
LIHC	cis	rs5769765	0.837	rs8142737	ENSG00000278869.1	CITF22-49E9.3	4.69	4.02e-06	0.0012	0.36	0.25	Schizophrenia;	chr22:49898241	chr22:49933198~49934074:-
LIHC	cis	rs11779988	0.545	rs422746	ENSG00000253671.1	RP11-806O11.1	-4.69	4.02e-06	0.0012	-0.33	-0.25	Breast cancer;	chr8:17926977	chr8:17808941~17820868:+
LIHC	cis	rs1865760	1	rs3799372	ENSG00000216436.2	HIST1H2APS1	-4.69	4.02e-06	0.0012	-0.27	-0.25	Height;	chr6:25922083	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.963	rs1540273	ENSG00000216436.2	HIST1H2APS1	-4.69	4.02e-06	0.0012	-0.27	-0.25	Height;	chr6:25923930	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs9358895	ENSG00000216436.2	HIST1H2APS1	-4.69	4.02e-06	0.0012	-0.27	-0.25	Height;	chr6:25924427	chr6:25732497~25732827:+
LIHC	cis	rs875971	0.545	rs316328	ENSG00000273142.1	RP11-458F8.4	-4.69	4.02e-06	0.0012	-0.22	-0.25	Aortic root size;	chr7:66143851	chr7:66902857~66906297:+
LIHC	cis	rs2929278	0.617	rs3087657	ENSG00000166763.7	STRCP1	4.69	4.02e-06	0.0012	0.3	0.25	Schizophrenia;	chr15:43771661	chr15:43699488~43718184:-
LIHC	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	4.69	4.02e-06	0.0012	0.3	0.25	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
LIHC	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-4.69	4.03e-06	0.0012	-0.44	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
LIHC	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	4.69	4.03e-06	0.0012	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	4.69	4.03e-06	0.00121	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
LIHC	cis	rs1003645	1	rs9908216	ENSG00000275944.1	RP11-104J23.1	4.69	4.03e-06	0.00121	0.24	0.25	Blood protein levels;	chr17:36018981	chr17:36001419~36011618:+
LIHC	cis	rs17818399	0.781	rs34449783	ENSG00000279254.1	RP11-536C12.1	-4.69	4.03e-06	0.00121	-0.3	-0.25	Height;	chr2:46636416	chr2:46668870~46670778:+
LIHC	cis	rs17818399	0.815	rs17768138	ENSG00000279254.1	RP11-536C12.1	-4.69	4.03e-06	0.00121	-0.3	-0.25	Height;	chr2:46641078	chr2:46668870~46670778:+
LIHC	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	4.69	4.04e-06	0.00121	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	4.69	4.04e-06	0.00121	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
LIHC	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-4.69	4.04e-06	0.00121	-0.24	-0.25	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
LIHC	cis	rs2739330	0.828	rs5760107	ENSG00000206090.4	AP000350.7	4.69	4.04e-06	0.00121	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23939998~23942798:+
LIHC	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	4.69	4.04e-06	0.00121	0.25	0.25	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
LIHC	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-4.69	4.04e-06	0.00121	-0.33	-0.25	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-4.69	4.04e-06	0.00121	-0.33	-0.25	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
LIHC	cis	rs61041384	1	rs76872194	ENSG00000256092.2	RP13-942N8.1	-4.69	4.04e-06	0.00121	-0.39	-0.25	Schizophrenia;	chr12:123208816	chr12:123363868~123366113:+
LIHC	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	4.69	4.04e-06	0.00121	0.2	0.25	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
LIHC	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	4.68	4.05e-06	0.00121	0.27	0.25	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
LIHC	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	4.68	4.05e-06	0.00121	0.33	0.25	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
LIHC	cis	rs10510102	0.872	rs3862129	ENSG00000226864.1	ATE1-AS1	4.68	4.05e-06	0.00121	0.39	0.25	Breast cancer;	chr10:121824460	chr10:121928312~121951965:+
LIHC	cis	rs7208859	0.673	rs216409	ENSG00000266490.1	CTD-2349P21.9	-4.68	4.05e-06	0.00121	-0.29	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30792372~30792833:+
LIHC	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	4.68	4.06e-06	0.00121	0.33	0.25	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	4.68	4.06e-06	0.00121	0.33	0.25	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	4.68	4.06e-06	0.00121	0.33	0.25	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	4.68	4.06e-06	0.00121	0.33	0.25	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	4.68	4.06e-06	0.00121	0.33	0.25	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	4.68	4.06e-06	0.00121	0.33	0.25	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
LIHC	cis	rs4660214	0.666	rs1537818	ENSG00000182109.6	RP11-69E11.4	-4.68	4.06e-06	0.00121	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39522280~39546187:-
LIHC	cis	rs11971779	0.793	rs11764426	ENSG00000273391.1	RP11-634H22.1	4.68	4.06e-06	0.00121	0.23	0.25	Diisocyanate-induced asthma;	chr7:139339304	chr7:139359032~139359566:-
LIHC	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-4.68	4.06e-06	0.00121	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-4.68	4.06e-06	0.00121	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-4.68	4.06e-06	0.00121	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-4.68	4.06e-06	0.00121	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-4.68	4.06e-06	0.00121	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-4.68	4.06e-06	0.00121	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-4.68	4.06e-06	0.00121	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
LIHC	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-4.68	4.06e-06	0.00121	-0.25	-0.25	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-4.68	4.06e-06	0.00121	-0.25	-0.25	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-4.68	4.06e-06	0.00121	-0.25	-0.25	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-4.68	4.06e-06	0.00121	-0.25	-0.25	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-4.68	4.06e-06	0.00121	-0.25	-0.25	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
LIHC	cis	rs11971779	0.715	rs6467856	ENSG00000273391.1	RP11-634H22.1	4.68	4.06e-06	0.00121	0.22	0.25	Diisocyanate-induced asthma;	chr7:139442553	chr7:139359032~139359566:-
LIHC	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	4.68	4.07e-06	0.00121	0.37	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
LIHC	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-4.68	4.07e-06	0.00121	-0.17	-0.25	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
LIHC	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	4.68	4.07e-06	0.00122	0.37	0.25	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
LIHC	cis	rs2929278	0.617	rs663214	ENSG00000166763.7	STRCP1	-4.68	4.08e-06	0.00122	-0.3	-0.25	Schizophrenia;	chr15:43821584	chr15:43699488~43718184:-
LIHC	cis	rs11079159	0.637	rs7218159	ENSG00000263096.1	RP11-515O17.2	-4.68	4.08e-06	0.00122	-0.44	-0.25	QRS duration;	chr17:55277434	chr17:55271504~55273653:-
LIHC	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	4.68	4.08e-06	0.00122	0.48	0.25	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
LIHC	cis	rs6445975	0.726	rs6762098	ENSG00000272360.1	RP11-359I18.5	-4.68	4.08e-06	0.00122	-0.29	-0.25	Systemic lupus erythematosus;	chr3:58482701	chr3:58490830~58491291:-
LIHC	cis	rs5769765	0.862	rs138897	ENSG00000278869.1	CITF22-49E9.3	4.68	4.08e-06	0.00122	0.37	0.25	Schizophrenia;	chr22:49837419	chr22:49933198~49934074:-
LIHC	cis	rs4650994	0.525	rs4650996	ENSG00000273384.1	RP5-1098D14.1	4.68	4.08e-06	0.00122	0.31	0.25	HDL cholesterol;HDL cholesterol levels;	chr1:178548230	chr1:178651706~178652282:+
LIHC	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-4.68	4.09e-06	0.00122	-0.26	-0.25	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
LIHC	cis	rs929596	0.556	rs4477910	ENSG00000233445.1	RPL17P11	4.68	4.09e-06	0.00122	0.28	0.25	Total bilirubin levels in HIV-1 infection;	chr2:233735091	chr2:233721522~233722065:-
LIHC	cis	rs3733585	0.674	rs7375643	ENSG00000250413.1	RP11-448G15.1	4.68	4.09e-06	0.00122	0.31	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10006482~10009725:+
LIHC	cis	rs11089937	0.524	rs2877021	ENSG00000211639.2	IGLV4-60	4.68	4.09e-06	0.00122	0.21	0.25	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22162199~22162681:+
LIHC	cis	rs6479901	0.588	rs10740105	ENSG00000232075.1	MRPL35P2	-4.68	4.09e-06	0.00122	-0.28	-0.25	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63634317~63634827:-
LIHC	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-4.68	4.09e-06	0.00122	-0.28	-0.25	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
LIHC	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	4.68	4.09e-06	0.00122	0.28	0.25	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	4.68	4.09e-06	0.00122	0.28	0.25	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	4.68	4.09e-06	0.00122	0.28	0.25	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
LIHC	cis	rs2929278	0.561	rs62018952	ENSG00000275601.1	AC011330.13	4.68	4.1e-06	0.00122	0.31	0.25	Schizophrenia;	chr15:43788539	chr15:43642389~43643023:-
LIHC	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-4.68	4.1e-06	0.00122	-0.26	-0.25	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.908	rs7696649	ENSG00000260091.1	RP11-33B1.4	-4.68	4.1e-06	0.00122	-0.18	-0.25	Corneal astigmatism;	chr4:119401022	chr4:119409333~119410233:+
LIHC	cis	rs860295	0.541	rs11264359	ENSG00000203761.5	MSTO2P	-4.68	4.11e-06	0.00122	-0.2	-0.25	Body mass index;	chr1:155313038	chr1:155745829~155750137:+
LIHC	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	4.68	4.11e-06	0.00122	0.39	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
LIHC	cis	rs8024893	0.841	rs79265647	ENSG00000270055.1	CTD-3092A11.2	-4.68	4.11e-06	0.00122	-0.41	-0.25	Red cell distribution width;	chr15:31251362	chr15:30487963~30490313:+
LIHC	cis	rs12291225	0.877	rs11023160	ENSG00000251991.1	RNU7-49P	4.68	4.11e-06	0.00123	0.26	0.25	Sense of smell;	chr11:14242679	chr11:14478892~14478953:+
LIHC	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	4.68	4.11e-06	0.00123	0.28	0.25	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
LIHC	cis	rs8064024	0.68	rs3747613	ENSG00000267077.1	RP11-127I20.5	-4.68	4.12e-06	0.00123	-0.25	-0.25	Cancer;	chr16:4858503	chr16:4795265~4796532:-
LIHC	cis	rs1577917	0.958	rs10944147	ENSG00000234155.1	RP11-30P6.6	4.68	4.12e-06	0.00123	0.33	0.25	Response to antipsychotic treatment;	chr6:85841068	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs13201730	ENSG00000234155.1	RP11-30P6.6	4.68	4.12e-06	0.00123	0.33	0.25	Response to antipsychotic treatment;	chr6:85846929	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12196377	ENSG00000234155.1	RP11-30P6.6	4.68	4.12e-06	0.00123	0.33	0.25	Response to antipsychotic treatment;	chr6:85857057	chr6:85387219~85390186:-
LIHC	cis	rs417065	0.516	rs6701941	ENSG00000227634.1	RP11-431K24.3	-4.68	4.12e-06	0.00123	-0.3	-0.25	Psoriasis;	chr1:8208655	chr1:8208672~8215210:+
LIHC	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-4.68	4.12e-06	0.00123	-0.26	-0.25	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
LIHC	cis	rs9326248	0.52	rs74830	ENSG00000236267.1	AP006216.5	-4.68	4.12e-06	0.00123	-0.25	-0.25	Blood protein levels;	chr11:117219842	chr11:116813204~116814003:-
LIHC	cis	rs755249	0.874	rs61779310	ENSG00000182109.6	RP11-69E11.4	4.68	4.13e-06	0.00123	0.32	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.833	rs61779313	ENSG00000182109.6	RP11-69E11.4	4.68	4.13e-06	0.00123	0.32	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39522280~39546187:-
LIHC	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	4.68	4.13e-06	0.00123	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	4.68	4.13e-06	0.00123	0.28	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
LIHC	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	4.68	4.13e-06	0.00123	0.26	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
LIHC	cis	rs11098499	0.954	rs6848389	ENSG00000260091.1	RP11-33B1.4	-4.68	4.14e-06	0.00123	-0.17	-0.25	Corneal astigmatism;	chr4:119481467	chr4:119409333~119410233:+
LIHC	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	4.68	4.14e-06	0.00123	0.25	0.25	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
LIHC	cis	rs5769765	0.955	rs6520066	ENSG00000278869.1	CITF22-49E9.3	4.68	4.14e-06	0.00123	0.36	0.25	Schizophrenia;	chr22:49901340	chr22:49933198~49934074:-
LIHC	cis	rs2243480	1	rs6964245	ENSG00000230295.1	RP11-458F8.2	4.68	4.15e-06	0.00123	0.26	0.25	Diabetic kidney disease;	chr7:66253730	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs6964530	ENSG00000230295.1	RP11-458F8.2	4.68	4.15e-06	0.00123	0.26	0.25	Diabetic kidney disease;	chr7:66253864	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs10807701	ENSG00000230295.1	RP11-458F8.2	4.68	4.15e-06	0.00123	0.26	0.25	Diabetic kidney disease;	chr7:66259699	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1499613	ENSG00000230295.1	RP11-458F8.2	4.68	4.15e-06	0.00123	0.26	0.25	Diabetic kidney disease;	chr7:66265873	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1553174	ENSG00000230295.1	RP11-458F8.2	4.68	4.15e-06	0.00123	0.26	0.25	Diabetic kidney disease;	chr7:66266207	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs10950032	ENSG00000230295.1	RP11-458F8.2	4.68	4.15e-06	0.00123	0.26	0.25	Diabetic kidney disease;	chr7:66273604	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1392104	ENSG00000230295.1	RP11-458F8.2	4.68	4.15e-06	0.00123	0.26	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66880708~66882981:+
LIHC	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-4.68	4.15e-06	0.00124	-0.29	-0.25	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-4.68	4.15e-06	0.00124	-0.29	-0.25	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-4.68	4.15e-06	0.00124	-0.29	-0.25	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-4.68	4.15e-06	0.00124	-0.29	-0.25	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
LIHC	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	4.68	4.15e-06	0.00124	0.42	0.25	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
LIHC	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-4.68	4.15e-06	0.00124	-0.32	-0.25	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
LIHC	cis	rs11971779	0.588	rs2003531	ENSG00000273391.1	RP11-634H22.1	4.68	4.16e-06	0.00124	0.22	0.25	Diisocyanate-induced asthma;	chr7:139441832	chr7:139359032~139359566:-
LIHC	cis	rs748404	0.697	rs546170	ENSG00000166763.7	STRCP1	4.68	4.16e-06	0.00124	0.3	0.25	Lung cancer;	chr15:43272651	chr15:43699488~43718184:-
LIHC	cis	rs1322639	0.614	rs6925201	ENSG00000261039.2	RP11-417E7.2	4.68	4.16e-06	0.00124	0.32	0.25	Pulse pressure;	chr6:169163262	chr6:169175304~169182740:-
LIHC	cis	rs6487679	1	rs7298108	ENSG00000111788.10	RP11-22B23.1	-4.68	4.16e-06	0.00124	-0.28	-0.25	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9277235~9313241:+
LIHC	cis	rs755249	0.501	rs661316	ENSG00000182109.6	RP11-69E11.4	4.68	4.17e-06	0.00124	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39522280~39546187:-
LIHC	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-4.68	4.17e-06	0.00124	-0.25	-0.25	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-4.68	4.17e-06	0.00124	-0.25	-0.25	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
LIHC	cis	rs4356975	0.697	rs6849081	ENSG00000196472.4	RP13-644M16.4	4.68	4.17e-06	0.00124	0.27	0.25	Obesity-related traits;	chr4:69144840	chr4:69181660~69182372:+
LIHC	cis	rs4356975	0.649	rs59421013	ENSG00000196472.4	RP13-644M16.4	4.68	4.17e-06	0.00124	0.27	0.25	Obesity-related traits;	chr4:69149131	chr4:69181660~69182372:+
LIHC	cis	rs4356975	0.697	rs58039330	ENSG00000196472.4	RP13-644M16.4	4.68	4.17e-06	0.00124	0.27	0.25	Obesity-related traits;	chr4:69149529	chr4:69181660~69182372:+
LIHC	cis	rs4356975	0.66	rs60567038	ENSG00000196472.4	RP13-644M16.4	4.68	4.17e-06	0.00124	0.27	0.25	Obesity-related traits;	chr4:69150135	chr4:69181660~69182372:+
LIHC	cis	rs4356975	0.697	rs58366569	ENSG00000196472.4	RP13-644M16.4	4.68	4.17e-06	0.00124	0.27	0.25	Obesity-related traits;	chr4:69150626	chr4:69181660~69182372:+
LIHC	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-4.68	4.18e-06	0.00124	-0.28	-0.25	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
LIHC	cis	rs17301013	0.932	rs1653627	ENSG00000227373.4	RP11-160H22.5	-4.68	4.18e-06	0.00124	-0.3	-0.25	Systemic lupus erythematosus;	chr1:174771879	chr1:174115300~174160004:-
LIHC	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-4.68	4.18e-06	0.00124	-0.27	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
LIHC	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	4.68	4.18e-06	0.00124	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
LIHC	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	4.68	4.19e-06	0.00125	0.17	0.25	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
LIHC	cis	rs3812762	0.692	rs10840116	ENSG00000254860.4	TMEM9B-AS1	-4.68	4.19e-06	0.00125	-0.26	-0.25	Hypospadias;	chr11:8743570	chr11:8964675~8977527:+
LIHC	cis	rs30380	1	rs27529	ENSG00000272109.1	CTD-2260A17.3	-4.68	4.19e-06	0.00125	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96804353~96806105:+
LIHC	cis	rs17270561	0.943	rs76703022	ENSG00000272810.1	U91328.22	-4.68	4.19e-06	0.00125	-0.32	-0.25	Iron status biomarkers;	chr6:25703301	chr6:26013241~26013757:+
LIHC	cis	rs7937890	0.559	rs10766184	ENSG00000251991.1	RNU7-49P	4.68	4.19e-06	0.00125	0.27	0.25	Mitochondrial DNA levels;	chr11:14521031	chr11:14478892~14478953:+
LIHC	cis	rs12478296	1	rs66612947	ENSG00000261186.2	RP11-341N2.1	-4.68	4.2e-06	0.00125	-0.35	-0.25	Obesity-related traits;	chr2:242093811	chr2:242087351~242088457:-
LIHC	cis	rs1577917	1	rs12205548	ENSG00000234155.1	RP11-30P6.6	4.68	4.2e-06	0.00125	0.33	0.25	Response to antipsychotic treatment;	chr6:86050052	chr6:85387219~85390186:-
LIHC	cis	rs2976388	0.647	rs2164307	ENSG00000253196.1	RP11-706C16.7	4.68	4.2e-06	0.00125	0.24	0.25	Urinary tract infection frequency;	chr8:142707413	chr8:142763116~142766427:+
LIHC	cis	rs5758511	0.68	rs17002902	ENSG00000205702.9	CYP2D7	4.68	4.2e-06	0.00125	0.29	0.25	Birth weight;	chr22:42229503	chr22:42140203~42144577:-
LIHC	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	4.68	4.2e-06	0.00125	0.32	0.25	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
LIHC	cis	rs5758511	0.634	rs1001587	ENSG00000205702.9	CYP2D7	4.68	4.2e-06	0.00125	0.29	0.25	Birth weight;	chr22:42274105	chr22:42140203~42144577:-
LIHC	cis	rs2836974	0.897	rs8132419	ENSG00000255568.3	BRWD1-AS2	4.68	4.2e-06	0.00125	0.27	0.25	Cognitive function;	chr21:39155901	chr21:39313935~39314962:+
LIHC	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	4.68	4.2e-06	0.00125	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
LIHC	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-4.68	4.2e-06	0.00125	-0.36	-0.25	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
LIHC	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	4.68	4.21e-06	0.00125	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
LIHC	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-4.68	4.21e-06	0.00125	-0.32	-0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
LIHC	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-4.68	4.21e-06	0.00125	-0.29	-0.25	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
LIHC	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	4.68	4.21e-06	0.00125	0.41	0.25	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
LIHC	cis	rs875971	0.545	rs73376394	ENSG00000273142.1	RP11-458F8.4	4.68	4.22e-06	0.00125	0.23	0.25	Aortic root size;	chr7:66172694	chr7:66902857~66906297:+
LIHC	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-4.68	4.22e-06	0.00125	-0.29	-0.25	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-4.68	4.22e-06	0.00125	-0.29	-0.25	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-4.68	4.22e-06	0.00125	-0.29	-0.25	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-4.68	4.22e-06	0.00125	-0.29	-0.25	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-4.68	4.22e-06	0.00125	-0.29	-0.25	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
LIHC	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	4.68	4.22e-06	0.00125	0.33	0.25	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
LIHC	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	4.68	4.22e-06	0.00125	0.22	0.25	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
LIHC	cis	rs4706831	0.647	rs9350847	ENSG00000272129.1	RP11-250B2.6	4.68	4.23e-06	0.00126	0.24	0.25	Joint mobility (Beighton score);	chr6:80179300	chr6:80355424~80356859:+
LIHC	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	4.68	4.23e-06	0.00126	0.19	0.25	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
LIHC	cis	rs4660214	0.666	rs4617393	ENSG00000182109.6	RP11-69E11.4	-4.68	4.23e-06	0.00126	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474551	chr1:39522280~39546187:-
LIHC	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	4.68	4.23e-06	0.00126	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
LIHC	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	4.68	4.23e-06	0.00126	0.22	0.25	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
LIHC	cis	rs7119038	0.509	rs10892260	ENSG00000255422.1	AP002954.4	4.67	4.24e-06	0.00126	0.32	0.25	Sjögren's syndrome;	chr11:118712816	chr11:118704607~118750263:+
LIHC	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	4.67	4.24e-06	0.00126	0.45	0.25	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
LIHC	cis	rs61041384	0.661	rs77015199	ENSG00000256092.2	RP13-942N8.1	-4.67	4.24e-06	0.00126	-0.38	-0.25	Schizophrenia;	chr12:123197090	chr12:123363868~123366113:+
LIHC	cis	rs61041384	0.661	rs74240768	ENSG00000256092.2	RP13-942N8.1	-4.67	4.24e-06	0.00126	-0.38	-0.25	Schizophrenia;	chr12:123199429	chr12:123363868~123366113:+
LIHC	cis	rs61041384	0.661	rs74240769	ENSG00000256092.2	RP13-942N8.1	-4.67	4.24e-06	0.00126	-0.38	-0.25	Schizophrenia;	chr12:123203681	chr12:123363868~123366113:+
LIHC	cis	rs61041384	0.661	rs74917517	ENSG00000256092.2	RP13-942N8.1	-4.67	4.24e-06	0.00126	-0.38	-0.25	Schizophrenia;	chr12:123204258	chr12:123363868~123366113:+
LIHC	cis	rs61041384	0.661	rs4759407	ENSG00000256092.2	RP13-942N8.1	-4.67	4.24e-06	0.00126	-0.38	-0.25	Schizophrenia;	chr12:123205127	chr12:123363868~123366113:+
LIHC	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	4.67	4.25e-06	0.00126	0.42	0.25	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
LIHC	cis	rs6901152	0.525	rs989696	ENSG00000217648.1	RP1-95L4.4	-4.67	4.25e-06	0.00126	-0.29	-0.25	Acute lymphoblastic leukemia (childhood);	chr6:143373165	chr6:143342246~143343383:+
LIHC	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	4.67	4.25e-06	0.00126	0.29	0.25	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
LIHC	cis	rs11098499	0.954	rs3733520	ENSG00000260091.1	RP11-33B1.4	-4.67	4.25e-06	0.00126	-0.17	-0.25	Corneal astigmatism;	chr4:119502325	chr4:119409333~119410233:+
LIHC	cis	rs755249	0.501	rs2484133	ENSG00000182109.6	RP11-69E11.4	4.67	4.25e-06	0.00126	0.26	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39522280~39546187:-
LIHC	cis	rs11064837	0.504	rs746297	ENSG00000248636.5	RP11-768F21.1	4.67	4.25e-06	0.00126	0.4	0.25	Schizophrenia;	chr12:119604996	chr12:119387987~119668079:-
LIHC	cis	rs6997458	0.606	rs1493302	ENSG00000253549.4	RP11-317J10.2	4.67	4.25e-06	0.00126	0.26	0.25	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85437051	chr8:85441851~85464915:-
LIHC	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	4.67	4.26e-06	0.00126	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
LIHC	cis	rs1558001	0.87	rs6960640	ENSG00000230196.1	DDX43P3	4.67	4.26e-06	0.00126	0.26	0.25	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81794268	chr7:81610884~81611326:-
LIHC	cis	rs10871290	0.65	rs28484753	ENSG00000261079.1	RP11-252A24.3	4.67	4.26e-06	0.00126	0.27	0.25	Breast cancer;	chr16:74455497	chr16:74367462~74369826:+
LIHC	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	4.67	4.26e-06	0.00126	0.2	0.25	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
LIHC	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-4.67	4.26e-06	0.00126	-0.21	-0.25	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-4.67	4.26e-06	0.00126	-0.21	-0.25	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
LIHC	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-4.67	4.26e-06	0.00126	-0.41	-0.25	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
LIHC	cis	rs1005277	0.579	rs1740737	ENSG00000276805.1	RP11-291L22.6	4.67	4.27e-06	0.00126	0.3	0.25	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs2749616	ENSG00000276805.1	RP11-291L22.6	4.67	4.27e-06	0.00126	0.3	0.25	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs1780146	ENSG00000276805.1	RP11-291L22.6	4.67	4.27e-06	0.00126	0.3	0.25	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38451030~38451785:+
LIHC	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-4.67	4.27e-06	0.00127	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-4.67	4.27e-06	0.00127	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-4.67	4.27e-06	0.00127	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
LIHC	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	4.67	4.28e-06	0.00127	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
LIHC	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-4.67	4.28e-06	0.00127	-0.3	-0.24	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
LIHC	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-4.67	4.28e-06	0.00127	-0.3	-0.24	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
LIHC	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-4.67	4.28e-06	0.00127	-0.25	-0.24	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
LIHC	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	4.67	4.29e-06	0.00127	0.22	0.24	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
LIHC	cis	rs61041384	0.661	rs79033960	ENSG00000256092.2	RP13-942N8.1	-4.67	4.29e-06	0.00127	-0.38	-0.24	Schizophrenia;	chr12:123196388	chr12:123363868~123366113:+
LIHC	cis	rs11671005	0.735	rs11084544	ENSG00000269473.1	CTD-2619J13.19	4.67	4.29e-06	0.00127	0.4	0.24	Mean platelet volume;	chr19:58428760	chr19:58440448~58445849:+
LIHC	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	4.67	4.3e-06	0.00127	0.28	0.24	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
LIHC	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	4.67	4.3e-06	0.00127	0.22	0.24	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
LIHC	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	4.67	4.3e-06	0.00127	0.28	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
LIHC	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-4.67	4.3e-06	0.00127	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-4.67	4.3e-06	0.00127	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
LIHC	cis	rs2834288	0.5	rs2834304	ENSG00000237945.6	LINC00649	4.67	4.3e-06	0.00127	0.32	0.24	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33915534~33977691:+
LIHC	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-4.67	4.3e-06	0.00127	-0.25	-0.24	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
LIHC	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-4.67	4.3e-06	0.00127	-0.38	-0.24	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
LIHC	cis	rs2929278	0.617	rs11070410	ENSG00000166763.7	STRCP1	-4.67	4.31e-06	0.00127	-0.32	-0.24	Schizophrenia;	chr15:43764847	chr15:43699488~43718184:-
LIHC	cis	rs28829049	0.597	rs12745238	ENSG00000270728.1	RP4-657E11.10	-4.67	4.31e-06	0.00127	-0.22	-0.24	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19067216	chr1:19297080~19297903:+
LIHC	cis	rs2310173	0.575	rs719248	ENSG00000281162.1	LINC01127	-4.67	4.31e-06	0.00128	-0.27	-0.24	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102007413	chr2:101962056~101987167:+
LIHC	cis	rs2072510	0.683	rs2660840	ENSG00000257878.1	RP11-256L6.3	-4.67	4.32e-06	0.00128	-0.22	-0.24	Metabolite levels (small molecules and protein measures);	chr12:96038729	chr12:95996521~96011489:+
LIHC	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	4.67	4.32e-06	0.00128	0.28	0.24	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
LIHC	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	4.67	4.32e-06	0.00128	0.3	0.24	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
LIHC	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-4.67	4.33e-06	0.00128	-0.21	-0.24	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
LIHC	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	4.67	4.33e-06	0.00128	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
LIHC	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-4.67	4.33e-06	0.00128	-0.28	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
LIHC	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	4.67	4.33e-06	0.00128	0.28	0.24	Height;	chr3:53082835	chr3:53064283~53065091:-
LIHC	cis	rs4650994	0.789	rs2476559	ENSG00000273384.1	RP5-1098D14.1	-4.67	4.34e-06	0.00128	-0.29	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178623784	chr1:178651706~178652282:+
LIHC	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-4.67	4.34e-06	0.00128	-0.27	-0.24	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
LIHC	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	4.67	4.34e-06	0.00128	0.22	0.24	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
LIHC	cis	rs72675573	1	rs72675573	ENSG00000235612.1	RP1-158P9.1	-4.67	4.35e-06	0.00129	-0.32	-0.24	Monocyte count;	chr1:56171209	chr1:56145721~56155224:+
LIHC	cis	rs916888	0.61	rs199452	ENSG00000260075.1	NSFP1	4.67	4.35e-06	0.00129	0.3	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46372855~46487141:+
LIHC	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	4.67	4.36e-06	0.00129	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
LIHC	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	4.67	4.36e-06	0.00129	0.22	0.24	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	4.67	4.36e-06	0.00129	0.22	0.24	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	4.67	4.36e-06	0.00129	0.22	0.24	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
LIHC	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	4.67	4.36e-06	0.00129	0.28	0.24	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
LIHC	cis	rs643506	0.874	rs1633471	ENSG00000254990.4	RP11-108O10.2	4.67	4.37e-06	0.00129	0.26	0.24	Breast cancer;	chr11:111819607	chr11:111768668~111778350:-
LIHC	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	4.67	4.37e-06	0.00129	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	4.67	4.37e-06	0.00129	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
LIHC	cis	rs1865760	1	rs6938233	ENSG00000216436.2	HIST1H2APS1	-4.67	4.37e-06	0.00129	-0.27	-0.24	Height;	chr6:25913849	chr6:25732497~25732827:+
LIHC	cis	rs9326248	0.52	rs236919	ENSG00000236267.1	AP006216.5	4.67	4.37e-06	0.00129	0.24	0.24	Blood protein levels;	chr11:117224645	chr11:116813204~116814003:-
LIHC	cis	rs5758511	0.68	rs5758651	ENSG00000205702.9	CYP2D7	4.67	4.37e-06	0.00129	0.29	0.24	Birth weight;	chr22:42213142	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.68	rs5758652	ENSG00000205702.9	CYP2D7	4.67	4.37e-06	0.00129	0.29	0.24	Birth weight;	chr22:42216402	chr22:42140203~42144577:-
LIHC	cis	rs10871290	0.551	rs3863435	ENSG00000261079.1	RP11-252A24.3	-4.67	4.37e-06	0.00129	-0.28	-0.24	Breast cancer;	chr16:74431498	chr16:74367462~74369826:+
LIHC	cis	rs7209700	0.862	rs2015729	ENSG00000228782.6	CTD-2026D20.3	-4.67	4.38e-06	0.00129	-0.27	-0.24	IgG glycosylation;	chr17:47277127	chr17:47450568~47492492:-
LIHC	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	4.67	4.38e-06	0.00129	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
LIHC	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-4.67	4.38e-06	0.00129	-0.3	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
LIHC	cis	rs227275	0.554	rs6810668	ENSG00000230069.3	LRRC37A15P	-4.67	4.38e-06	0.00129	-0.22	-0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102727274~102730721:-
LIHC	cis	rs875971	0.502	rs6460311	ENSG00000273142.1	RP11-458F8.4	-4.67	4.38e-06	0.00129	-0.24	-0.24	Aortic root size;	chr7:66646886	chr7:66902857~66906297:+
LIHC	cis	rs529413	1	rs529413	ENSG00000259237.1	RP11-209E8.1	-4.67	4.38e-06	0.00129	-0.33	-0.24	Itch intensity from mosquito bite adjusted by bite size;	chr15:53250548	chr15:53116365~53129698:+
LIHC	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-4.67	4.38e-06	0.00129	-0.24	-0.24	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
LIHC	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-4.67	4.38e-06	0.00129	-0.29	-0.24	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
LIHC	cis	rs61041384	0.661	rs74240770	ENSG00000256092.2	RP13-942N8.1	-4.67	4.39e-06	0.00129	-0.38	-0.24	Schizophrenia;	chr12:123207195	chr12:123363868~123366113:+
LIHC	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	4.67	4.39e-06	0.0013	0.32	0.24	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
LIHC	cis	rs7412746	0.658	rs12410394	ENSG00000231073.1	RP11-316M1.3	4.67	4.39e-06	0.0013	0.25	0.24	Melanoma;	chr1:150887710	chr1:150973123~150975534:+
LIHC	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	4.67	4.4e-06	0.0013	0.26	0.24	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
LIHC	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	4.67	4.4e-06	0.0013	0.25	0.24	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
LIHC	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-4.67	4.41e-06	0.0013	-0.23	-0.24	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
LIHC	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-4.67	4.41e-06	0.0013	-0.23	-0.24	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
LIHC	cis	rs3733589	1	rs13151113	ENSG00000250413.1	RP11-448G15.1	4.67	4.41e-06	0.0013	0.44	0.24	Renal overload gout;	chr4:10016554	chr4:10006482~10009725:+
LIHC	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-4.67	4.41e-06	0.0013	-0.27	-0.24	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
LIHC	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	4.67	4.41e-06	0.0013	0.28	0.24	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
LIHC	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-4.67	4.41e-06	0.0013	-0.35	-0.24	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
LIHC	cis	rs4660214	0.666	rs10888682	ENSG00000182109.6	RP11-69E11.4	-4.67	4.41e-06	0.0013	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.666	rs11205698	ENSG00000182109.6	RP11-69E11.4	-4.67	4.41e-06	0.0013	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39522280~39546187:-
LIHC	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	4.67	4.41e-06	0.0013	0.34	0.24	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	4.67	4.41e-06	0.0013	0.34	0.24	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	4.67	4.41e-06	0.0013	0.34	0.24	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	4.67	4.41e-06	0.0013	0.34	0.24	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
LIHC	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	4.67	4.41e-06	0.0013	0.34	0.24	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	4.67	4.41e-06	0.0013	0.34	0.24	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	4.67	4.41e-06	0.0013	0.34	0.24	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
LIHC	cis	rs17711722	0.522	rs6957759	ENSG00000273024.4	INTS4P2	-4.67	4.41e-06	0.0013	-0.26	-0.24	Calcium levels;	chr7:65806798	chr7:65647864~65715661:+
LIHC	cis	rs1075265	0.553	rs2692532	ENSG00000272156.1	RP11-477N3.1	-4.67	4.42e-06	0.0013	-0.3	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54082554~54085066:+
LIHC	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-4.67	4.42e-06	0.0013	-0.28	-0.24	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
LIHC	cis	rs116175783	0.557	rs2303318	ENSG00000227403.1	AC009299.3	4.67	4.43e-06	0.00131	0.38	0.24	Intelligence (multi-trait analysis);	chr2:161367984	chr2:161244739~161249050:+
LIHC	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	4.67	4.43e-06	0.00131	0.54	0.24	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
LIHC	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	4.67	4.43e-06	0.00131	0.54	0.24	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
LIHC	cis	rs7119038	0.509	rs11216960	ENSG00000255422.1	AP002954.4	4.67	4.43e-06	0.00131	0.32	0.24	Sjögren's syndrome;	chr11:118707164	chr11:118704607~118750263:+
LIHC	cis	rs7119038	0.509	rs10892256	ENSG00000255422.1	AP002954.4	4.67	4.43e-06	0.00131	0.32	0.24	Sjögren's syndrome;	chr11:118707996	chr11:118704607~118750263:+
LIHC	cis	rs7119038	0.509	rs10892257	ENSG00000255422.1	AP002954.4	4.67	4.43e-06	0.00131	0.32	0.24	Sjögren's syndrome;	chr11:118708618	chr11:118704607~118750263:+
LIHC	cis	rs7119038	0.509	rs10790261	ENSG00000255422.1	AP002954.4	-4.67	4.43e-06	0.00131	-0.32	-0.24	Sjögren's syndrome;	chr11:118709038	chr11:118704607~118750263:+
LIHC	cis	rs7665090	0.87	rs228616	ENSG00000230069.3	LRRC37A15P	4.67	4.43e-06	0.00131	0.23	0.24	Primary biliary cholangitis;	chr4:102658534	chr4:102727274~102730721:-
LIHC	cis	rs11098499	0.738	rs28408407	ENSG00000260091.1	RP11-33B1.4	-4.67	4.43e-06	0.00131	-0.17	-0.24	Corneal astigmatism;	chr4:119454875	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs1809406	ENSG00000260091.1	RP11-33B1.4	-4.67	4.43e-06	0.00131	-0.17	-0.24	Corneal astigmatism;	chr4:119455967	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs2389809	ENSG00000260091.1	RP11-33B1.4	-4.67	4.43e-06	0.00131	-0.17	-0.24	Corneal astigmatism;	chr4:119456244	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.697	rs10020027	ENSG00000260091.1	RP11-33B1.4	-4.67	4.43e-06	0.00131	-0.17	-0.24	Corneal astigmatism;	chr4:119460724	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.779	rs7356491	ENSG00000260091.1	RP11-33B1.4	-4.67	4.43e-06	0.00131	-0.17	-0.24	Corneal astigmatism;	chr4:119460819	chr4:119409333~119410233:+
LIHC	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	4.66	4.44e-06	0.00131	0.19	0.24	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
LIHC	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-4.66	4.44e-06	0.00131	-0.29	-0.24	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
LIHC	cis	rs1247318	1	rs1247329	ENSG00000243831.1	RP1-81D8.4	4.66	4.44e-06	0.00131	0.34	0.24	Aging;	chr6:160906725	chr6:160666228~160676523:-
LIHC	cis	rs1247318	1	rs1247327	ENSG00000243831.1	RP1-81D8.4	4.66	4.44e-06	0.00131	0.34	0.24	Aging;	chr6:160907424	chr6:160666228~160676523:-
LIHC	cis	rs1247318	1	rs1247326	ENSG00000243831.1	RP1-81D8.4	4.66	4.44e-06	0.00131	0.34	0.24	Aging;	chr6:160907524	chr6:160666228~160676523:-
LIHC	cis	rs1247318	1	rs1247323	ENSG00000243831.1	RP1-81D8.4	4.66	4.44e-06	0.00131	0.34	0.24	Aging;	chr6:160908981	chr6:160666228~160676523:-
LIHC	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
LIHC	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	4.66	4.45e-06	0.00131	0.32	0.24	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
LIHC	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	4.66	4.45e-06	0.00131	0.22	0.24	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
LIHC	cis	rs7412746	0.611	rs12410869	ENSG00000231073.1	RP11-316M1.3	4.66	4.45e-06	0.00131	0.24	0.24	Melanoma;	chr1:150883677	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.611	rs36008098	ENSG00000231073.1	RP11-316M1.3	4.66	4.45e-06	0.00131	0.24	0.24	Melanoma;	chr1:150884330	chr1:150973123~150975534:+
LIHC	cis	rs11648785	0.661	rs870856	ENSG00000221819.5	GAS8-AS1	-4.66	4.45e-06	0.00131	-0.32	-0.24	Tanning;	chr16:90023055	chr16:90028908~90029367:-
LIHC	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	4.66	4.46e-06	0.00131	0.33	0.24	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
LIHC	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	4.66	4.46e-06	0.00131	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
LIHC	cis	rs496547	0.52	rs11216963	ENSG00000255422.1	AP002954.4	4.66	4.46e-06	0.00131	0.32	0.24	Hip minimal joint space width;	chr11:118710105	chr11:118704607~118750263:+
LIHC	cis	rs4694744	0.624	rs1569344	ENSG00000264696.1	AC108078.1	4.66	4.47e-06	0.00132	0.38	0.24	Bacteremia;	chr4:69475674	chr4:69479331~69479434:+
LIHC	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-4.66	4.47e-06	0.00132	-0.21	-0.24	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
LIHC	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-4.66	4.47e-06	0.00132	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
LIHC	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-4.66	4.47e-06	0.00132	-0.22	-0.24	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
LIHC	cis	rs2439831	0.867	rs45585139	ENSG00000205771.5	CATSPER2P1	-4.66	4.48e-06	0.00132	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43408229	chr15:43726918~43747094:-
LIHC	cis	rs10975870	0.847	rs7876040	ENSG00000236924.1	RP11-390F4.6	-4.66	4.48e-06	0.00132	-0.3	-0.24	Body mass index;	chr9:6936305	chr9:6645956~6670635:+
LIHC	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-4.66	4.48e-06	0.00132	-0.25	-0.24	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
LIHC	cis	rs4660214	0.724	rs10888683	ENSG00000182109.6	RP11-69E11.4	4.66	4.48e-06	0.00132	0.25	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157997	chr1:39522280~39546187:-
LIHC	cis	rs4660456	0.576	rs2780948	ENSG00000237899.1	RP4-739H11.3	-4.66	4.49e-06	0.00132	-0.3	-0.24	Platelet count;	chr1:40776205	chr1:40669089~40687588:-
LIHC	cis	rs712039	1	rs712039	ENSG00000276054.1	RP11-378E13.3	4.66	4.49e-06	0.00132	0.29	0.24	Tuberculosis;	chr17:37490447	chr17:37386886~37387926:+
LIHC	cis	rs11671005	0.57	rs73062110	ENSG00000269473.1	CTD-2619J13.19	4.66	4.49e-06	0.00132	0.4	0.24	Mean platelet volume;	chr19:58425275	chr19:58440448~58445849:+
LIHC	cis	rs113835537	0.668	rs12223908	ENSG00000255517.5	CTD-3074O7.5	-4.66	4.49e-06	0.00132	-0.36	-0.24	Airway imaging phenotypes;	chr11:66573301	chr11:66473490~66480233:-
LIHC	cis	rs2439831	0.85	rs2228368	ENSG00000166763.7	STRCP1	4.66	4.49e-06	0.00132	0.38	0.24	Lung cancer in ever smokers;	chr15:43809812	chr15:43699488~43718184:-
LIHC	cis	rs2880765	0.566	rs17553790	ENSG00000259630.2	CTD-2262B20.1	4.66	4.49e-06	0.00132	0.34	0.24	Coronary artery disease;	chr15:85470434	chr15:85415228~85415633:+
LIHC	cis	rs2562456	0.917	rs11085463	ENSG00000268555.1	RP11-678G14.3	4.66	4.49e-06	0.00132	0.31	0.24	Pain;	chr19:21568500	chr19:21570822~21587322:-
LIHC	cis	rs643506	0.79	rs688095	ENSG00000254990.4	RP11-108O10.2	4.66	4.49e-06	0.00132	0.26	0.24	Breast cancer;	chr11:111808047	chr11:111768668~111778350:-
LIHC	cis	rs643506	0.817	rs658373	ENSG00000254990.4	RP11-108O10.2	4.66	4.49e-06	0.00132	0.26	0.24	Breast cancer;	chr11:111812267	chr11:111768668~111778350:-
LIHC	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	4.66	4.5e-06	0.00132	0.29	0.24	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
LIHC	cis	rs10871290	0.881	rs7498574	ENSG00000261079.1	RP11-252A24.3	-4.66	4.5e-06	0.00132	-0.28	-0.24	Breast cancer;	chr16:74438763	chr16:74367462~74369826:+
LIHC	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	4.66	4.5e-06	0.00132	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
LIHC	cis	rs3734905	1	rs1033458	ENSG00000266896.1	RP1-266L20.9	4.66	4.51e-06	0.00133	0.3	0.24	HIV-1 control;	chr6:169594698	chr6:169770413~169772042:+
LIHC	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	4.66	4.51e-06	0.00133	0.22	0.24	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
LIHC	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	4.66	4.51e-06	0.00133	0.29	0.24	Height;	chr6:109672088	chr6:109382795~109383666:+
LIHC	cis	rs11668505	1	rs11666244	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47842984	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs11666316	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47843246	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs11670620	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47843268	chr19:47863483~47865341:-
LIHC	cis	rs11668505	0.965	rs12459855	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47843664	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs12459926	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47843831	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs12984385	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47844114	chr19:47863483~47865341:-
LIHC	cis	rs11668505	0.804	rs34982374	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47844196	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs11667492	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47844342	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs12977458	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47844857	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs11668505	ENSG00000259108.2	CTD-3098H1.2	4.66	4.51e-06	0.00133	0.32	0.24	Lung function (FVC);	chr19:47845106	chr19:47863483~47865341:-
LIHC	cis	rs6445975	0.531	rs6804460	ENSG00000272360.1	RP11-359I18.5	4.66	4.51e-06	0.00133	0.33	0.24	Systemic lupus erythematosus;	chr3:58380130	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.666	rs6445974	ENSG00000272360.1	RP11-359I18.5	4.66	4.51e-06	0.00133	0.33	0.24	Systemic lupus erythematosus;	chr3:58381110	chr3:58490830~58491291:-
LIHC	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-4.66	4.51e-06	0.00133	-0.31	-0.24	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
LIHC	cis	rs3096299	0.967	rs16965692	ENSG00000261118.1	RP11-104N10.1	4.66	4.51e-06	0.00133	0.25	0.24	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89492017~89504460:-
LIHC	cis	rs11098499	0.954	rs10008392	ENSG00000260091.1	RP11-33B1.4	-4.66	4.52e-06	0.00133	-0.18	-0.24	Corneal astigmatism;	chr4:119397684	chr4:119409333~119410233:+
LIHC	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-4.66	4.52e-06	0.00133	-0.32	-0.24	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
LIHC	cis	rs755249	1	rs2293476	ENSG00000182109.6	RP11-69E11.4	-4.66	4.53e-06	0.00133	-0.33	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39522280~39546187:-
LIHC	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	4.66	4.53e-06	0.00133	0.29	0.24	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
LIHC	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	4.66	4.53e-06	0.00133	0.19	0.24	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
LIHC	cis	rs79040073	0.53	rs17475228	ENSG00000259531.2	RP11-295H24.3	4.66	4.54e-06	0.00133	0.4	0.24	Lung cancer in ever smokers;	chr15:49269619	chr15:49365124~49366685:-
LIHC	cis	rs2749097	0.825	rs2749100	ENSG00000244256.3	RN7SL130P	4.66	4.54e-06	0.00133	0.28	0.24	Alcohol consumption (transferrin glycosylation);	chr1:63659308	chr1:63655743~63656047:+
LIHC	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	4.66	4.54e-06	0.00134	0.38	0.24	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	4.66	4.54e-06	0.00134	0.38	0.24	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
LIHC	cis	rs643506	0.874	rs618031	ENSG00000254990.4	RP11-108O10.2	4.66	4.55e-06	0.00134	0.27	0.24	Breast cancer;	chr11:111778139	chr11:111768668~111778350:-
LIHC	cis	rs2836974	0.829	rs34227163	ENSG00000255568.3	BRWD1-AS2	4.66	4.55e-06	0.00134	0.28	0.24	Cognitive function;	chr21:39180017	chr21:39313935~39314962:+
LIHC	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-4.66	4.55e-06	0.00134	-0.26	-0.24	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
LIHC	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	4.66	4.55e-06	0.00134	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	4.66	4.55e-06	0.00134	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
LIHC	cis	rs3733589	1	rs35249656	ENSG00000250413.1	RP11-448G15.1	4.66	4.55e-06	0.00134	0.39	0.24	Renal overload gout;	chr4:10036918	chr4:10006482~10009725:+
LIHC	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	4.66	4.55e-06	0.00134	0.32	0.24	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
LIHC	cis	rs2836974	0.602	rs2836987	ENSG00000255568.3	BRWD1-AS2	-4.66	4.55e-06	0.00134	-0.2	-0.24	Cognitive function;	chr21:39334668	chr21:39313935~39314962:+
LIHC	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	4.66	4.55e-06	0.00134	0.38	0.24	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
LIHC	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	4.66	4.55e-06	0.00134	0.34	0.24	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
LIHC	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	4.66	4.56e-06	0.00134	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	4.66	4.56e-06	0.00134	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
LIHC	cis	rs11098499	0.662	rs13108589	ENSG00000260091.1	RP11-33B1.4	-4.66	4.56e-06	0.00134	-0.17	-0.24	Corneal astigmatism;	chr4:119346947	chr4:119409333~119410233:+
LIHC	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-4.66	4.57e-06	0.00134	-0.3	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
LIHC	cis	rs960902	0.747	rs13387905	ENSG00000213553.4	RPLP0P6	4.66	4.57e-06	0.00134	0.2	0.24	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37501482	chr2:38481851~38482804:+
LIHC	cis	rs960902	0.747	rs9941697	ENSG00000213553.4	RPLP0P6	4.66	4.57e-06	0.00134	0.2	0.24	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37501544	chr2:38481851~38482804:+
LIHC	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-4.66	4.57e-06	0.00134	-0.25	-0.24	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
LIHC	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	4.66	4.57e-06	0.00134	0.19	0.24	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	4.66	4.57e-06	0.00134	0.19	0.24	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	4.66	4.57e-06	0.00134	0.19	0.24	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	4.66	4.57e-06	0.00134	0.19	0.24	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	4.66	4.57e-06	0.00134	0.19	0.24	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	4.66	4.57e-06	0.00134	0.19	0.24	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
LIHC	cis	rs4934494	0.689	rs17127588	ENSG00000232936.4	RP11-80H5.2	4.66	4.57e-06	0.00134	0.29	0.24	Red blood cell count;	chr10:89815887	chr10:89645282~89650667:+
LIHC	cis	rs1577917	1	rs12196411	ENSG00000234155.1	RP11-30P6.6	4.66	4.58e-06	0.00134	0.33	0.24	Response to antipsychotic treatment;	chr6:86070044	chr6:85387219~85390186:-
LIHC	cis	rs11671005	0.735	rs34873624	ENSG00000269473.1	CTD-2619J13.19	4.66	4.58e-06	0.00134	0.4	0.24	Mean platelet volume;	chr19:58432035	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.693	rs34230465	ENSG00000269473.1	CTD-2619J13.19	4.66	4.58e-06	0.00134	0.4	0.24	Mean platelet volume;	chr19:58432209	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs3764529	ENSG00000269473.1	CTD-2619J13.19	4.66	4.58e-06	0.00134	0.4	0.24	Mean platelet volume;	chr19:58433722	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs1122955	ENSG00000269473.1	CTD-2619J13.19	4.66	4.58e-06	0.00134	0.4	0.24	Mean platelet volume;	chr19:58434836	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11668814	ENSG00000269473.1	CTD-2619J13.19	4.66	4.58e-06	0.00134	0.4	0.24	Mean platelet volume;	chr19:58435466	chr19:58440448~58445849:+
LIHC	cis	rs11971779	0.838	rs4728468	ENSG00000273391.1	RP11-634H22.1	4.66	4.58e-06	0.00134	0.23	0.24	Diisocyanate-induced asthma;	chr7:139438232	chr7:139359032~139359566:-
LIHC	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-4.66	4.58e-06	0.00134	-0.25	-0.24	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
LIHC	cis	rs1865760	0.566	rs9467663	ENSG00000216436.2	HIST1H2APS1	-4.66	4.58e-06	0.00134	-0.28	-0.24	Height;	chr6:26021228	chr6:25732497~25732827:+
LIHC	cis	rs5758511	0.68	rs5758687	ENSG00000205702.9	CYP2D7	4.66	4.59e-06	0.00135	0.29	0.24	Birth weight;	chr22:42260582	chr22:42140203~42144577:-
LIHC	cis	rs4694744	0.576	rs13142440	ENSG00000264696.1	AC108078.1	4.66	4.59e-06	0.00135	0.37	0.24	Bacteremia;	chr4:69480846	chr4:69479331~69479434:+
LIHC	cis	rs4694744	0.576	rs13119049	ENSG00000264696.1	AC108078.1	4.66	4.59e-06	0.00135	0.37	0.24	Bacteremia;	chr4:69480847	chr4:69479331~69479434:+
LIHC	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-4.66	4.59e-06	0.00135	-0.28	-0.24	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
LIHC	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-4.66	4.59e-06	0.00135	-0.31	-0.24	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
LIHC	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	4.66	4.6e-06	0.00135	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	4.66	4.6e-06	0.00135	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	4.66	4.6e-06	0.00135	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
LIHC	cis	rs1558001	0.87	rs2158728	ENSG00000230196.1	DDX43P3	-4.66	4.6e-06	0.00135	-0.26	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81783286	chr7:81610884~81611326:-
LIHC	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-4.66	4.61e-06	0.00135	-0.25	-0.24	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
LIHC	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-4.66	4.61e-06	0.00135	-0.28	-0.24	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
LIHC	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-4.66	4.61e-06	0.00135	-0.28	-0.24	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
LIHC	cis	rs728616	0.867	rs17098720	ENSG00000225484.5	NUTM2B-AS1	-4.66	4.61e-06	0.00135	-0.53	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80080480	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.717	rs12414332	ENSG00000225484.5	NUTM2B-AS1	-4.66	4.61e-06	0.00135	-0.53	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80081199	chr10:79663088~79826594:-
LIHC	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-4.66	4.61e-06	0.00135	-0.32	-0.24	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
LIHC	cis	rs1005277	0.691	rs2474558	ENSG00000276805.1	RP11-291L22.6	-4.66	4.61e-06	0.00135	-0.31	-0.24	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38451030~38451785:+
LIHC	cis	rs3733585	0.806	rs11723382	ENSG00000250413.1	RP11-448G15.1	4.66	4.62e-06	0.00135	0.31	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10006482~10009725:+
LIHC	cis	rs5756813	0.754	rs762982	ENSG00000233360.4	Z83844.1	-4.66	4.62e-06	0.00135	-0.32	-0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37748228	chr22:37641832~37658377:-
LIHC	cis	rs12681287	0.604	rs71502657	ENSG00000254088.1	SLC2A3P4	4.66	4.62e-06	0.00135	0.29	0.24	Caudate activity during reward;	chr8:86466552	chr8:86503591~86505061:+
LIHC	cis	rs7809950	1	rs12668402	ENSG00000238832.1	snoU109	-4.66	4.62e-06	0.00135	-0.3	-0.24	Coronary artery disease;	chr7:107532575	chr7:107603363~107603507:+
LIHC	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-4.66	4.62e-06	0.00135	-0.37	-0.24	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
LIHC	cis	rs4731207	1	rs4731207	ENSG00000224897.5	POT1-AS1	-4.66	4.63e-06	0.00136	-0.29	-0.24	Cutaneous malignant melanoma;	chr7:124756591	chr7:124929873~125179315:+
LIHC	cis	rs17711722	0.522	rs62469933	ENSG00000273024.4	INTS4P2	-4.66	4.63e-06	0.00136	-0.26	-0.24	Calcium levels;	chr7:65800652	chr7:65647864~65715661:+
LIHC	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.66	4.64e-06	0.00136	0.3	0.24	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
LIHC	cis	rs6480314	0.831	rs11813170	ENSG00000233590.1	RP11-153K11.3	-4.66	4.64e-06	0.00136	-0.36	-0.24	Optic nerve measurement (disc area);	chr10:68215366	chr10:68233251~68242379:-
LIHC	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	4.65	4.64e-06	0.00136	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
LIHC	cis	rs6901152	0.508	rs1345990	ENSG00000217648.1	RP1-95L4.4	-4.65	4.64e-06	0.00136	-0.29	-0.24	Acute lymphoblastic leukemia (childhood);	chr6:143365727	chr6:143342246~143343383:+
LIHC	cis	rs7937890	0.561	rs2575849	ENSG00000251991.1	RNU7-49P	4.65	4.65e-06	0.00136	0.26	0.24	Mitochondrial DNA levels;	chr11:14518093	chr11:14478892~14478953:+
LIHC	cis	rs2032447	0.714	rs199726	ENSG00000242387.1	HIST1H2APS2	4.65	4.65e-06	0.00136	0.31	0.24	Intelligence (multi-trait analysis);	chr6:25953132	chr6:25882026~25882395:-
LIHC	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-4.65	4.65e-06	0.00136	-0.25	-0.24	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-4.65	4.65e-06	0.00136	-0.25	-0.24	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-4.65	4.65e-06	0.00136	-0.25	-0.24	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
LIHC	cis	rs7208859	0.623	rs55724095	ENSG00000266490.1	CTD-2349P21.9	4.65	4.65e-06	0.00136	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.568	rs9903854	ENSG00000266490.1	CTD-2349P21.9	4.65	4.65e-06	0.00136	0.31	0.24	Body mass index;	chr17:30826980	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs80355557	ENSG00000266490.1	CTD-2349P21.9	4.65	4.65e-06	0.00136	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9911173	ENSG00000266490.1	CTD-2349P21.9	4.65	4.65e-06	0.00136	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30792372~30792833:+
LIHC	cis	rs7121538	1	rs61884030	ENSG00000251991.1	RNU7-49P	-4.65	4.66e-06	0.00136	-0.35	-0.24	HDL cholesterol;	chr11:14422997	chr11:14478892~14478953:+
LIHC	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-4.65	4.66e-06	0.00136	-0.28	-0.24	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
LIHC	cis	rs17270561	0.887	rs9358870	ENSG00000272810.1	U91328.22	-4.65	4.66e-06	0.00136	-0.32	-0.24	Iron status biomarkers;	chr6:25718982	chr6:26013241~26013757:+
LIHC	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	4.65	4.66e-06	0.00137	0.28	0.24	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	4.65	4.66e-06	0.00137	0.28	0.24	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
LIHC	cis	rs9326248	0.52	rs6589602	ENSG00000236267.1	AP006216.5	4.65	4.66e-06	0.00137	0.25	0.24	Blood protein levels;	chr11:117166349	chr11:116813204~116814003:-
LIHC	cis	rs9326248	0.539	rs7120565	ENSG00000236267.1	AP006216.5	4.65	4.66e-06	0.00137	0.25	0.24	Blood protein levels;	chr11:117172233	chr11:116813204~116814003:-
LIHC	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-4.65	4.67e-06	0.00137	-0.31	-0.24	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
LIHC	cis	rs5758511	0.633	rs5751258	ENSG00000205702.9	CYP2D7	4.65	4.67e-06	0.00137	0.29	0.24	Birth weight;	chr22:42267865	chr22:42140203~42144577:-
LIHC	cis	rs1065852	0.526	rs739296	ENSG00000237037.8	NDUFA6-AS1	4.65	4.67e-06	0.00137	0.33	0.24	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993944	chr22:42090931~42137742:+
LIHC	cis	rs202072	0.729	rs8541	ENSG00000215022.6	RP1-257A7.4	-4.65	4.67e-06	0.00137	-0.29	-0.24	HIV-1 viral setpoint;	chr6:13290006	chr6:13264861~13295586:-
LIHC	cis	rs3812762	0.871	rs3844100	ENSG00000254860.4	TMEM9B-AS1	-4.65	4.67e-06	0.00137	-0.26	-0.24	Hypospadias;	chr11:8796261	chr11:8964675~8977527:+
LIHC	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-4.65	4.67e-06	0.00137	-0.32	-0.24	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
LIHC	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-4.65	4.67e-06	0.00137	-0.32	-0.24	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
LIHC	cis	rs875971	0.66	rs10263935	ENSG00000273024.4	INTS4P2	-4.65	4.67e-06	0.00137	-0.27	-0.24	Aortic root size;	chr7:66631041	chr7:65647864~65715661:+
LIHC	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	4.65	4.67e-06	0.00137	0.2	0.24	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
LIHC	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-4.65	4.68e-06	0.00137	-0.38	-0.24	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
LIHC	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-4.65	4.68e-06	0.00137	-0.48	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
LIHC	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-4.65	4.68e-06	0.00137	-0.48	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
LIHC	cis	rs7210990	0.931	rs1029809	ENSG00000234324.1	RPL9P2	4.65	4.69e-06	0.00137	0.3	0.24	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16252921	chr17:15443639~15444191:+
LIHC	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	4.65	4.69e-06	0.00137	0.29	0.24	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
LIHC	cis	rs7119038	0.818	rs6421571	ENSG00000255239.1	AP002954.6	4.65	4.7e-06	0.00137	0.36	0.24	Sjögren's syndrome;	chr11:118873063	chr11:118688039~118690600:-
LIHC	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	4.65	4.7e-06	0.00137	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
LIHC	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	4.65	4.7e-06	0.00138	0.23	0.24	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
LIHC	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	4.65	4.71e-06	0.00138	0.49	0.24	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
LIHC	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-4.65	4.71e-06	0.00138	-0.3	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-4.65	4.71e-06	0.00138	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
LIHC	cis	rs2976388	0.669	rs1836633	ENSG00000253196.1	RP11-706C16.7	4.65	4.71e-06	0.00138	0.24	0.24	Urinary tract infection frequency;	chr8:142693174	chr8:142763116~142766427:+
LIHC	cis	rs79040073	0.53	rs17396612	ENSG00000259531.2	RP11-295H24.3	4.65	4.71e-06	0.00138	0.4	0.24	Lung cancer in ever smokers;	chr15:49257746	chr15:49365124~49366685:-
LIHC	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-4.65	4.71e-06	0.00138	-0.35	-0.24	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
LIHC	cis	rs7914558	0.966	rs3902934	ENSG00000236937.2	PTGES3P4	4.65	4.72e-06	0.00138	0.29	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102845595~102845950:+
LIHC	cis	rs10833905	1	rs10430910	ENSG00000246225.5	RP11-17A1.3	-4.65	4.72e-06	0.00138	-0.3	-0.24	Sudden cardiac arrest;	chr11:23015273	chr11:22829380~22945393:+
LIHC	cis	rs7914558	0.902	rs7092200	ENSG00000236937.2	PTGES3P4	4.65	4.72e-06	0.00138	0.29	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103085115	chr10:102845595~102845950:+
LIHC	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-4.65	4.72e-06	0.00138	-0.28	-0.24	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
LIHC	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-4.65	4.72e-06	0.00138	-0.27	-0.24	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
LIHC	cis	rs7937890	0.504	rs2575822	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14498305	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575823	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14499808	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597221	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14505529	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs6486197	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14508328	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597219	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14509320	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597217	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14511337	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575852	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14511822	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.531	rs2597216	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14512370	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575853	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14512417	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs1548074	ENSG00000251991.1	RNU7-49P	4.65	4.73e-06	0.00138	0.26	0.24	Mitochondrial DNA levels;	chr11:14513279	chr11:14478892~14478953:+
LIHC	cis	rs30380	1	rs26510	ENSG00000272109.1	CTD-2260A17.3	-4.65	4.73e-06	0.00138	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96804353~96806105:+
LIHC	cis	rs1005277	0.579	rs1740732	ENSG00000275858.1	RP11-291L22.8	4.65	4.73e-06	0.00138	0.27	0.24	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38450738~38451069:-
LIHC	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	4.65	4.73e-06	0.00138	0.32	0.24	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
LIHC	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-4.65	4.73e-06	0.00138	-0.3	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
LIHC	cis	rs12554020	0.582	rs74842678	ENSG00000227603.1	RP11-165J3.6	4.65	4.74e-06	0.00138	0.45	0.24	Schizophrenia;	chr9:93658926	chr9:93435332~93437121:-
LIHC	cis	rs916888	0.779	rs199528	ENSG00000274883.1	Metazoa_SRP	-4.65	4.74e-06	0.00138	-0.39	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45931806~45932083:+
LIHC	cis	rs916888	0.821	rs199525	ENSG00000274883.1	Metazoa_SRP	-4.65	4.74e-06	0.00138	-0.39	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45931806~45932083:+
LIHC	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-4.65	4.74e-06	0.00138	-0.25	-0.24	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-4.65	4.74e-06	0.00138	-0.25	-0.24	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
LIHC	cis	rs6802315	0.575	rs1864508	ENSG00000272087.1	RP11-379F4.7	4.65	4.74e-06	0.00138	0.28	0.24	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158693120~158693768:-
LIHC	cis	rs8024893	0.764	rs7182545	ENSG00000270055.1	CTD-3092A11.2	-4.65	4.74e-06	0.00138	-0.35	-0.24	Red cell distribution width;	chr15:31239638	chr15:30487963~30490313:+
LIHC	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	4.65	4.74e-06	0.00138	0.31	0.24	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
LIHC	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-4.65	4.74e-06	0.00139	-0.28	-0.24	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
LIHC	cis	rs3733589	0.744	rs6821843	ENSG00000250413.1	RP11-448G15.1	-4.65	4.74e-06	0.00139	-0.39	-0.24	Renal overload gout;	chr4:10050904	chr4:10006482~10009725:+
LIHC	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-4.65	4.74e-06	0.00139	-0.25	-0.24	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
LIHC	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	4.65	4.75e-06	0.00139	0.26	0.24	Asthma;	chr2:102446466	chr2:102438713~102440475:+
LIHC	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-4.65	4.75e-06	0.00139	-0.31	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
LIHC	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-4.65	4.75e-06	0.00139	-0.25	-0.24	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-4.65	4.75e-06	0.00139	-0.25	-0.24	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
LIHC	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-4.65	4.75e-06	0.00139	-0.31	-0.24	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
LIHC	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	4.65	4.75e-06	0.00139	0.38	0.24	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
LIHC	cis	rs3733589	0.59	rs35201034	ENSG00000250413.1	RP11-448G15.1	4.65	4.75e-06	0.00139	0.38	0.24	Renal overload gout;	chr4:10005827	chr4:10006482~10009725:+
LIHC	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-4.65	4.76e-06	0.00139	-0.3	-0.24	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
LIHC	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-4.65	4.76e-06	0.00139	-0.36	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
LIHC	cis	rs11671005	0.735	rs11668420	ENSG00000269473.1	CTD-2619J13.19	4.65	4.76e-06	0.00139	0.4	0.24	Mean platelet volume;	chr19:58426469	chr19:58440448~58445849:+
LIHC	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	4.65	4.76e-06	0.00139	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	4.65	4.76e-06	0.00139	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
LIHC	cis	rs4862307	0.754	rs6846208	ENSG00000250726.1	RP11-616K6.1	4.65	4.77e-06	0.00139	0.27	0.24	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184070550	chr4:184072403~184073039:+
LIHC	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	4.65	4.77e-06	0.00139	0.23	0.24	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
LIHC	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	4.65	4.78e-06	0.00139	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
LIHC	cis	rs12304921	0.622	rs67466786	ENSG00000277201.1	AC087884.1	4.65	4.78e-06	0.00139	0.28	0.24	Type 2 diabetes;	chr12:51111553	chr12:51049921~51050025:+
LIHC	cis	rs12304921	0.683	rs60910794	ENSG00000277201.1	AC087884.1	4.65	4.78e-06	0.00139	0.28	0.24	Type 2 diabetes;	chr12:51113851	chr12:51049921~51050025:+
LIHC	cis	rs12304921	0.626	rs73105025	ENSG00000277201.1	AC087884.1	4.65	4.78e-06	0.00139	0.28	0.24	Type 2 diabetes;	chr12:51114623	chr12:51049921~51050025:+
LIHC	cis	rs116139393	0.656	rs10244591	ENSG00000187953.9	PMS2CL	-4.65	4.79e-06	0.0014	-0.25	-0.24	Alzheimer's disease (APOE e4 interaction);	chr7:6731467	chr7:6710128~6753862:+
LIHC	cis	rs1322639	0.614	rs6900964	ENSG00000261039.2	RP11-417E7.2	-4.65	4.79e-06	0.0014	-0.34	-0.24	Pulse pressure;	chr6:169166668	chr6:169175304~169182740:-
LIHC	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	4.65	4.79e-06	0.0014	0.27	0.24	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	4.65	4.79e-06	0.0014	0.27	0.24	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
LIHC	cis	rs6683071	0.601	rs3002129	ENSG00000272750.1	RP11-378J18.8	4.65	4.8e-06	0.0014	0.28	0.24	Cognitive performance;	chr1:222681993	chr1:222658867~222661512:-
LIHC	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	4.65	4.8e-06	0.0014	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
LIHC	cis	rs8177253	0.633	rs10935073	ENSG00000244062.1	RP11-404G16.2	4.65	4.8e-06	0.0014	0.25	0.24	Iron status biomarkers;	chr3:133720340	chr3:133760300~133762363:+
LIHC	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	4.65	4.8e-06	0.0014	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
LIHC	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	4.65	4.8e-06	0.0014	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
LIHC	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	4.65	4.8e-06	0.0014	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
LIHC	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-4.65	4.8e-06	0.0014	-0.29	-0.24	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
LIHC	cis	rs1865760	0.602	rs9467662	ENSG00000216436.2	HIST1H2APS1	-4.65	4.8e-06	0.0014	-0.28	-0.24	Height;	chr6:26021099	chr6:25732497~25732827:+
LIHC	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-4.65	4.81e-06	0.0014	-0.25	-0.24	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-4.65	4.81e-06	0.0014	-0.25	-0.24	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
LIHC	cis	rs603446	0.935	rs180376	ENSG00000254851.1	RP11-109L13.1	-4.65	4.81e-06	0.0014	-0.3	-0.24	Triglycerides;	chr11:116719323	chr11:117135528~117138582:+
LIHC	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	4.65	4.81e-06	0.0014	0.22	0.24	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
LIHC	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	4.65	4.81e-06	0.0014	0.42	0.24	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
LIHC	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	4.65	4.81e-06	0.0014	0.3	0.24	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
LIHC	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-4.65	4.82e-06	0.0014	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
LIHC	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	4.65	4.82e-06	0.0014	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
LIHC	cis	rs2439831	0.85	rs16950562	ENSG00000166763.7	STRCP1	4.65	4.82e-06	0.0014	0.38	0.24	Lung cancer in ever smokers;	chr15:43744166	chr15:43699488~43718184:-
LIHC	cis	rs643506	0.817	rs1940392	ENSG00000254990.4	RP11-108O10.2	4.65	4.82e-06	0.0014	0.26	0.24	Breast cancer;	chr11:111906122	chr11:111768668~111778350:-
LIHC	cis	rs72634501	0.568	rs590214	ENSG00000182109.6	RP11-69E11.4	4.65	4.83e-06	0.00141	0.26	0.24	HDL cholesterol;	chr1:39146821	chr1:39522280~39546187:-
LIHC	cis	rs1420585	1	rs12597905	ENSG00000260769.1	RP11-491F9.5	-4.65	4.83e-06	0.00141	-0.31	-0.24	Pursuit maintenance gain;	chr16:48968092	chr16:49337167~49338993:+
LIHC	cis	rs2836974	0.897	rs1541102	ENSG00000255568.3	BRWD1-AS2	4.65	4.84e-06	0.00141	0.28	0.24	Cognitive function;	chr21:39256839	chr21:39313935~39314962:+
LIHC	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	4.65	4.84e-06	0.00141	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
LIHC	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	4.65	4.84e-06	0.00141	0.29	0.24	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
LIHC	cis	rs2439831	1	rs527921	ENSG00000166763.7	STRCP1	-4.65	4.84e-06	0.00141	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43478218	chr15:43699488~43718184:-
LIHC	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	4.65	4.84e-06	0.00141	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
LIHC	cis	rs4650994	0.593	rs2811309	ENSG00000273384.1	RP5-1098D14.1	-4.65	4.84e-06	0.00141	-0.3	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178638549	chr1:178651706~178652282:+
LIHC	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-4.65	4.84e-06	0.00141	-0.26	-0.24	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
LIHC	cis	rs1865760	0.602	rs2157050	ENSG00000216436.2	HIST1H2APS1	-4.65	4.84e-06	0.00141	-0.28	-0.24	Height;	chr6:26020203	chr6:25732497~25732827:+
LIHC	cis	rs2836974	0.568	rs414850	ENSG00000255568.3	BRWD1-AS2	4.65	4.84e-06	0.00141	0.21	0.24	Cognitive function;	chr21:39171411	chr21:39313935~39314962:+
LIHC	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	4.65	4.84e-06	0.00141	0.25	0.24	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
LIHC	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	4.65	4.85e-06	0.00141	0.22	0.24	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	4.65	4.85e-06	0.00141	0.22	0.24	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	4.65	4.85e-06	0.00141	0.22	0.24	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	4.65	4.85e-06	0.00141	0.22	0.24	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	4.65	4.85e-06	0.00141	0.22	0.24	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	4.65	4.85e-06	0.00141	0.22	0.24	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	4.65	4.85e-06	0.00141	0.22	0.24	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
LIHC	cis	rs11098499	0.618	rs35265692	ENSG00000260091.1	RP11-33B1.4	-4.65	4.85e-06	0.00141	-0.17	-0.24	Corneal astigmatism;	chr4:119403980	chr4:119409333~119410233:+
LIHC	cis	rs755249	0.508	rs6703800	ENSG00000182109.6	RP11-69E11.4	-4.65	4.85e-06	0.00141	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39522280~39546187:-
LIHC	cis	rs4660214	0.724	rs12117785	ENSG00000182109.6	RP11-69E11.4	-4.65	4.85e-06	0.00141	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39522280~39546187:-
LIHC	cis	rs4694744	0.583	rs1569342	ENSG00000264696.1	AC108078.1	4.65	4.85e-06	0.00141	0.38	0.24	Bacteremia;	chr4:69475832	chr4:69479331~69479434:+
LIHC	cis	rs2439831	0.85	rs544122	ENSG00000166763.7	STRCP1	4.65	4.85e-06	0.00141	0.37	0.24	Lung cancer in ever smokers;	chr15:43483534	chr15:43699488~43718184:-
LIHC	cis	rs901683	0.702	rs73292848	ENSG00000230869.1	CTGLF10P	-4.65	4.86e-06	0.00141	-0.53	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45674304	chr10:45678692~45700532:+
LIHC	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-4.65	4.86e-06	0.00141	-0.29	-0.24	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
LIHC	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-4.64	4.86e-06	0.00142	-0.28	-0.24	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
LIHC	cis	rs17711722	0.565	rs4717276	ENSG00000273024.4	INTS4P2	-4.64	4.87e-06	0.00142	-0.26	-0.24	Calcium levels;	chr7:65829754	chr7:65647864~65715661:+
LIHC	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-4.64	4.87e-06	0.00142	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
LIHC	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-4.64	4.87e-06	0.00142	-0.25	-0.24	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
LIHC	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-4.64	4.87e-06	0.00142	-0.37	-0.24	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
LIHC	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	4.64	4.88e-06	0.00142	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.562	rs216408	ENSG00000266490.1	CTD-2349P21.9	-4.64	4.89e-06	0.00142	-0.29	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30792372~30792833:+
LIHC	cis	rs2253762	0.527	rs11200323	ENSG00000226864.1	ATE1-AS1	-4.64	4.89e-06	0.00142	-0.39	-0.24	Breast cancer;	chr10:122008869	chr10:121928312~121951965:+
LIHC	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-4.64	4.89e-06	0.00142	-0.3	-0.24	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
LIHC	cis	rs113084984	0.634	rs12466575	ENSG00000271952.1	RP11-245G13.2	-4.64	4.89e-06	0.00142	-0.32	-0.24	Breast cancer;	chr2:11523294	chr2:10878269~10885118:+
LIHC	cis	rs7412746	0.621	rs11204749	ENSG00000231073.1	RP11-316M1.3	4.64	4.89e-06	0.00142	0.24	0.24	Melanoma;	chr1:150957087	chr1:150973123~150975534:+
LIHC	cis	rs6442522	0.809	rs17041143	ENSG00000249786.6	EAF1-AS1	4.64	4.9e-06	0.00142	0.29	0.24	Uric acid levels;	chr3:15444338	chr3:15436171~15455940:-
LIHC	cis	rs7208859	0.623	rs9906957	ENSG00000266490.1	CTD-2349P21.9	4.64	4.9e-06	0.00142	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30792372~30792833:+
LIHC	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-4.64	4.9e-06	0.00142	-0.3	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-4.64	4.9e-06	0.00142	-0.3	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
LIHC	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-4.64	4.9e-06	0.00142	-0.28	-0.24	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
LIHC	cis	rs2312236	0.673	rs67425138	ENSG00000225171.2	DUTP6	-4.64	4.9e-06	0.00143	-0.32	-0.24	Post-traumatic stress disorder;	chr1:166744413	chr1:166868748~166869209:+
LIHC	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	4.64	4.9e-06	0.00143	0.29	0.24	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	4.64	4.9e-06	0.00143	0.29	0.24	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
LIHC	cis	rs3758785	0.623	rs13447720	ENSG00000255893.1	RP11-685N10.1	-4.64	4.91e-06	0.00143	-0.29	-0.24	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94432160	chr11:94472908~94473570:-
LIHC	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	4.64	4.91e-06	0.00143	0.29	0.24	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	4.64	4.91e-06	0.00143	0.29	0.24	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
LIHC	cis	rs1577917	1	rs1415753	ENSG00000234155.1	RP11-30P6.6	4.64	4.91e-06	0.00143	0.33	0.24	Response to antipsychotic treatment;	chr6:86043356	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1577919	ENSG00000234155.1	RP11-30P6.6	4.64	4.91e-06	0.00143	0.33	0.24	Response to antipsychotic treatment;	chr6:86047578	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12203493	ENSG00000234155.1	RP11-30P6.6	4.64	4.91e-06	0.00143	0.33	0.24	Response to antipsychotic treatment;	chr6:86048924	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12665321	ENSG00000234155.1	RP11-30P6.6	4.64	4.91e-06	0.00143	0.33	0.24	Response to antipsychotic treatment;	chr6:86059571	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12203924	ENSG00000234155.1	RP11-30P6.6	4.64	4.91e-06	0.00143	0.33	0.24	Response to antipsychotic treatment;	chr6:86066694	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12196175	ENSG00000234155.1	RP11-30P6.6	4.64	4.91e-06	0.00143	0.33	0.24	Response to antipsychotic treatment;	chr6:86069652	chr6:85387219~85390186:-
LIHC	cis	rs748404	0.578	rs4547312	ENSG00000166763.7	STRCP1	4.64	4.91e-06	0.00143	0.3	0.24	Lung cancer;	chr15:43339940	chr15:43699488~43718184:-
LIHC	cis	rs11671005	0.735	rs11667591	ENSG00000269473.1	CTD-2619J13.19	4.64	4.91e-06	0.00143	0.4	0.24	Mean platelet volume;	chr19:58426270	chr19:58440448~58445849:+
LIHC	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	4.64	4.92e-06	0.00143	0.26	0.24	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
LIHC	cis	rs7412746	0.634	rs12096831	ENSG00000231073.1	RP11-316M1.3	4.64	4.92e-06	0.00143	0.24	0.24	Melanoma;	chr1:150891637	chr1:150973123~150975534:+
LIHC	cis	rs7914558	1	rs3740387	ENSG00000236937.2	PTGES3P4	4.64	4.92e-06	0.00143	0.29	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102845595~102845950:+
LIHC	cis	rs13083990	1	rs13083990	ENSG00000272758.4	RP11-299J3.8	4.64	4.93e-06	0.00143	0.26	0.24	Cardiac Troponin-T levels;	chr3:122295719	chr3:122416207~122443180:+
LIHC	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-4.64	4.93e-06	0.00143	-0.31	-0.24	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
LIHC	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-4.64	4.93e-06	0.00143	-0.31	-0.24	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
LIHC	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-4.64	4.94e-06	0.00143	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
LIHC	cis	rs72675573	1	rs1331861	ENSG00000235612.1	RP1-158P9.1	-4.64	4.94e-06	0.00143	-0.31	-0.24	Monocyte count;	chr1:56170733	chr1:56145721~56155224:+
LIHC	cis	rs11064837	0.504	rs11064846	ENSG00000248636.5	RP11-768F21.1	4.64	4.94e-06	0.00143	0.39	0.24	Schizophrenia;	chr12:119616346	chr12:119387987~119668079:-
LIHC	cis	rs2929278	0.617	rs524908	ENSG00000166763.7	STRCP1	-4.64	4.95e-06	0.00144	-0.32	-0.24	Schizophrenia;	chr15:43895793	chr15:43699488~43718184:-
LIHC	cis	rs916888	0.647	rs199449	ENSG00000260075.1	NSFP1	4.64	4.95e-06	0.00144	0.3	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46372855~46487141:+
LIHC	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	4.64	4.96e-06	0.00144	0.22	0.24	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
LIHC	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-4.64	4.96e-06	0.00144	-0.29	-0.24	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
LIHC	cis	rs2565722	0.583	rs2489945	ENSG00000243831.1	RP1-81D8.4	-4.64	4.96e-06	0.00144	-0.33	-0.24	Blood protein levels;	chr6:160876692	chr6:160666228~160676523:-
LIHC	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-4.64	4.96e-06	0.00144	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-4.64	4.96e-06	0.00144	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
LIHC	cis	rs9341808	0.617	rs9294170	ENSG00000272129.1	RP11-250B2.6	4.64	4.96e-06	0.00144	0.23	0.24	Sitting height ratio;	chr6:80104363	chr6:80355424~80356859:+
LIHC	cis	rs6545883	0.525	rs1729662	ENSG00000271889.1	RP11-493E12.1	4.64	4.97e-06	0.00144	0.29	0.24	Tuberculosis;	chr2:61164170	chr2:61151433~61162105:-
LIHC	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-4.64	4.97e-06	0.00144	-0.27	-0.24	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
LIHC	cis	rs7474896	0.561	rs2474603	ENSG00000263064.2	RP11-291L22.7	4.64	4.97e-06	0.00144	0.32	0.24	Obesity (extreme);	chr10:38156754	chr10:38448689~38448949:+
LIHC	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	4.64	4.97e-06	0.00144	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
LIHC	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	4.64	4.97e-06	0.00144	0.29	0.24	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
LIHC	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	4.64	4.98e-06	0.00144	0.33	0.24	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
LIHC	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-4.64	4.98e-06	0.00144	-0.45	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
LIHC	cis	rs2836974	0.899	rs2836938	ENSG00000255568.3	BRWD1-AS2	4.64	4.98e-06	0.00145	0.27	0.24	Cognitive function;	chr21:39202265	chr21:39313935~39314962:+
LIHC	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-4.64	4.98e-06	0.00145	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-4.64	4.98e-06	0.00145	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
LIHC	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-4.64	4.98e-06	0.00145	-0.38	-0.24	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
LIHC	cis	rs9890032	0.618	rs1979507	ENSG00000263531.1	RP13-753N3.1	4.64	4.99e-06	0.00145	0.33	0.24	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30863921~30864940:-
LIHC	cis	rs4694744	0.576	rs28419590	ENSG00000264696.1	AC108078.1	4.64	4.99e-06	0.00145	0.37	0.24	Bacteremia;	chr4:69480962	chr4:69479331~69479434:+
LIHC	cis	rs4694744	0.576	rs1977017	ENSG00000264696.1	AC108078.1	4.64	4.99e-06	0.00145	0.37	0.24	Bacteremia;	chr4:69481634	chr4:69479331~69479434:+
LIHC	cis	rs10829156	0.786	rs7077786	ENSG00000240291.1	RP11-499P20.2	4.64	4.99e-06	0.00145	0.39	0.24	Sudden cardiac arrest;	chr10:18603453	chr10:18513115~18545651:-
LIHC	cis	rs2929278	0.617	rs524908	ENSG00000275601.1	AC011330.13	4.64	4.99e-06	0.00145	0.3	0.24	Schizophrenia;	chr15:43895793	chr15:43642389~43643023:-
LIHC	cis	rs9595066	0.627	rs4432167	ENSG00000230731.2	RP11-478K15.6	-4.64	5e-06	0.00145	-0.29	-0.24	Schizophrenia;	chr13:44178225	chr13:44234118~44243192:-
LIHC	cis	rs916888	0.61	rs199444	ENSG00000260075.1	NSFP1	4.64	5e-06	0.00145	0.3	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46372855~46487141:+
LIHC	cis	rs916888	0.61	rs199442	ENSG00000260075.1	NSFP1	4.64	5e-06	0.00145	0.3	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46372855~46487141:+
LIHC	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	4.64	5e-06	0.00145	0.37	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
LIHC	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	4.64	5.01e-06	0.00145	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
LIHC	cis	rs12887734	0.524	rs4906364	ENSG00000258534.1	CTD-2134A5.4	-4.64	5.01e-06	0.00145	-0.27	-0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103854366~103880111:-
LIHC	cis	rs12571093	0.571	rs4517412	ENSG00000233590.1	RP11-153K11.3	4.64	5.01e-06	0.00145	0.38	0.24	Optic nerve measurement (disc area);	chr10:68303779	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.571	rs7097498	ENSG00000233590.1	RP11-153K11.3	4.64	5.01e-06	0.00145	0.38	0.24	Optic nerve measurement (disc area);	chr10:68303780	chr10:68233251~68242379:-
LIHC	cis	rs1865760	0.963	rs9356991	ENSG00000216436.2	HIST1H2APS1	-4.64	5.02e-06	0.00146	-0.27	-0.24	Height;	chr6:25901530	chr6:25732497~25732827:+
LIHC	cis	rs7665090	0.87	rs228614	ENSG00000230069.3	LRRC37A15P	4.64	5.02e-06	0.00146	0.23	0.24	Primary biliary cholangitis;	chr4:102657480	chr4:102727274~102730721:-
LIHC	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-4.64	5.02e-06	0.00146	-0.26	-0.24	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-4.64	5.02e-06	0.00146	-0.26	-0.24	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
LIHC	cis	rs4650994	0.525	rs17361286	ENSG00000273384.1	RP5-1098D14.1	4.64	5.03e-06	0.00146	0.31	0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178552781	chr1:178651706~178652282:+
LIHC	cis	rs3096299	0.967	rs2965935	ENSG00000261118.1	RP11-104N10.1	-4.64	5.03e-06	0.00146	-0.24	-0.24	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89492017~89504460:-
LIHC	cis	rs2836974	0.932	rs6517523	ENSG00000255568.3	BRWD1-AS2	4.64	5.04e-06	0.00146	0.28	0.24	Cognitive function;	chr21:39185406	chr21:39313935~39314962:+
LIHC	cis	rs12304921	0.748	rs12580097	ENSG00000277201.1	AC087884.1	4.64	5.04e-06	0.00146	0.28	0.24	Type 2 diabetes;	chr12:51107103	chr12:51049921~51050025:+
LIHC	cis	rs6442522	0.809	rs972685	ENSG00000249786.6	EAF1-AS1	4.64	5.04e-06	0.00146	0.29	0.24	Uric acid levels;	chr3:15442762	chr3:15436171~15455940:-
LIHC	cis	rs2243480	1	rs1723267	ENSG00000228409.4	CCT6P1	4.64	5.04e-06	0.00146	0.26	0.24	Diabetic kidney disease;	chr7:66008327	chr7:65751142~65763354:+
LIHC	cis	rs7208859	0.623	rs79607958	ENSG00000266490.1	CTD-2349P21.9	4.64	5.05e-06	0.00146	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs75136574	ENSG00000266490.1	CTD-2349P21.9	4.64	5.05e-06	0.00146	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs77544470	ENSG00000266490.1	CTD-2349P21.9	4.64	5.05e-06	0.00146	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30792372~30792833:+
LIHC	cis	rs1247318	0.95	rs935183	ENSG00000243831.1	RP1-81D8.4	4.64	5.05e-06	0.00146	0.34	0.24	Aging;	chr6:160914221	chr6:160666228~160676523:-
LIHC	cis	rs1247318	1	rs935182	ENSG00000243831.1	RP1-81D8.4	4.64	5.05e-06	0.00146	0.34	0.24	Aging;	chr6:160914344	chr6:160666228~160676523:-
LIHC	cis	rs6951245	0.554	rs35126802	ENSG00000229043.2	AC091729.9	-4.64	5.05e-06	0.00146	-0.44	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1160374~1165267:+
LIHC	cis	rs6951245	0.554	rs78999139	ENSG00000229043.2	AC091729.9	-4.64	5.05e-06	0.00146	-0.44	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1160374~1165267:+
LIHC	cis	rs6951245	0.58	rs78894484	ENSG00000229043.2	AC091729.9	-4.64	5.05e-06	0.00146	-0.44	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1160374~1165267:+
LIHC	cis	rs6951245	0.554	rs4724294	ENSG00000229043.2	AC091729.9	-4.64	5.05e-06	0.00146	-0.44	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1160374~1165267:+
LIHC	cis	rs4731207	0.844	rs12673697	ENSG00000224897.5	POT1-AS1	-4.64	5.05e-06	0.00146	-0.29	-0.24	Cutaneous malignant melanoma;	chr7:124754952	chr7:124929873~125179315:+
LIHC	cis	rs2836974	0.899	rs34176878	ENSG00000255568.3	BRWD1-AS2	4.64	5.05e-06	0.00146	0.28	0.24	Cognitive function;	chr21:39176929	chr21:39313935~39314962:+
LIHC	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	4.64	5.06e-06	0.00146	0.2	0.24	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
LIHC	cis	rs7121538	1	rs7121538	ENSG00000251991.1	RNU7-49P	-4.64	5.06e-06	0.00146	-0.35	-0.24	HDL cholesterol;	chr11:14482917	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-4.64	5.06e-06	0.00147	-0.25	-0.24	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
LIHC	cis	rs3733589	0.59	rs7657096	ENSG00000250413.1	RP11-448G15.1	4.64	5.07e-06	0.00147	0.39	0.24	Renal overload gout;	chr4:10002376	chr4:10006482~10009725:+
LIHC	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-4.64	5.07e-06	0.00147	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-4.64	5.07e-06	0.00147	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-4.64	5.07e-06	0.00147	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-4.64	5.07e-06	0.00147	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
LIHC	cis	rs2243480	1	rs73150014	ENSG00000230295.1	RP11-458F8.2	-4.64	5.07e-06	0.00147	-0.26	-0.24	Diabetic kidney disease;	chr7:65985932	chr7:66880708~66882981:+
LIHC	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	4.64	5.07e-06	0.00147	0.28	0.24	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
LIHC	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-4.64	5.07e-06	0.00147	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
LIHC	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	4.64	5.08e-06	0.00147	0.31	0.24	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	4.64	5.08e-06	0.00147	0.31	0.24	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	4.64	5.08e-06	0.00147	0.31	0.24	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
LIHC	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	4.63	5.09e-06	0.00147	0.2	0.24	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
LIHC	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	4.63	5.1e-06	0.00147	0.2	0.24	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
LIHC	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-4.63	5.1e-06	0.00147	-0.25	-0.24	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-4.63	5.1e-06	0.00147	-0.25	-0.24	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-4.63	5.1e-06	0.00147	-0.25	-0.24	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-4.63	5.1e-06	0.00147	-0.25	-0.24	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-4.63	5.1e-06	0.00147	-0.25	-0.24	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
LIHC	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	4.63	5.1e-06	0.00148	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
LIHC	cis	rs35395352	1	rs35395352	ENSG00000227634.1	RP11-431K24.3	-4.63	5.1e-06	0.00148	-0.3	-0.24	Strep throat;	chr1:8206769	chr1:8208672~8215210:+
LIHC	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	4.63	5.1e-06	0.00148	0.2	0.24	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	4.63	5.11e-06	0.00148	0.2	0.24	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
LIHC	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	4.63	5.11e-06	0.00148	0.29	0.24	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
LIHC	cis	rs11971779	0.774	rs7785906	ENSG00000273391.1	RP11-634H22.1	4.63	5.11e-06	0.00148	0.23	0.24	Diisocyanate-induced asthma;	chr7:139437906	chr7:139359032~139359566:-
LIHC	cis	rs748404	0.697	rs530188	ENSG00000166763.7	STRCP1	4.63	5.11e-06	0.00148	0.3	0.24	Lung cancer;	chr15:43253116	chr15:43699488~43718184:-
LIHC	cis	rs3015497	0.554	rs8011039	ENSG00000269906.1	RP11-248J18.2	4.63	5.11e-06	0.00148	0.31	0.24	Mean platelet volume;	chr14:50624549	chr14:50662511~50663178:-
LIHC	cis	rs703842	0.963	rs2069506	ENSG00000270039.1	RP11-571M6.17	-4.63	5.11e-06	0.00148	-0.35	-0.24	Multiple sclerosis;	chr12:57749071	chr12:57803838~57804415:+
LIHC	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-4.63	5.11e-06	0.00148	-0.25	-0.24	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
LIHC	cis	rs12157904	1	rs6000842	ENSG00000233360.4	Z83844.1	4.63	5.12e-06	0.00148	0.47	0.24	Response to anti-depressant treatment in major depressive disorder;	chr22:37610246	chr22:37641832~37658377:-
LIHC	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	4.63	5.12e-06	0.00148	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	4.63	5.12e-06	0.00148	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	4.63	5.12e-06	0.00148	0.31	0.24	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	4.63	5.12e-06	0.00148	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	4.63	5.12e-06	0.00148	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
LIHC	cis	rs2735413	0.918	rs1922612	ENSG00000276007.1	RP11-358L22.3	-4.63	5.12e-06	0.00148	-0.27	-0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78019086	chr16:78123243~78124332:+
LIHC	cis	rs5769765	0.908	rs7410601	ENSG00000278869.1	CITF22-49E9.3	4.63	5.15e-06	0.00149	0.38	0.24	Schizophrenia;	chr22:49923539	chr22:49933198~49934074:-
LIHC	cis	rs5769765	0.671	rs138833	ENSG00000278869.1	CITF22-49E9.3	4.63	5.15e-06	0.00149	0.36	0.24	Schizophrenia;	chr22:49785269	chr22:49933198~49934074:-
LIHC	cis	rs2439831	1	rs2601014	ENSG00000166763.7	STRCP1	4.63	5.15e-06	0.00149	0.38	0.24	Lung cancer in ever smokers;	chr15:43463815	chr15:43699488~43718184:-
LIHC	cis	rs4356203	0.905	rs651513	ENSG00000272034.1	SNORD14A	-4.63	5.16e-06	0.00149	-0.26	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17177781	chr11:17074654~17074744:-
LIHC	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-4.63	5.16e-06	0.00149	-0.24	-0.24	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
LIHC	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	4.63	5.17e-06	0.00149	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
LIHC	cis	rs7131987	0.845	rs7299861	ENSG00000257176.2	RP11-996F15.2	-4.63	5.17e-06	0.00149	-0.28	-0.24	QT interval;	chr12:29256734	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.934	rs7316004	ENSG00000257176.2	RP11-996F15.2	-4.63	5.17e-06	0.00149	-0.28	-0.24	QT interval;	chr12:29258765	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.903	rs2216853	ENSG00000257176.2	RP11-996F15.2	-4.63	5.17e-06	0.00149	-0.28	-0.24	QT interval;	chr12:29260315	chr12:29280418~29317848:-
LIHC	cis	rs7131987	0.868	rs10771508	ENSG00000257176.2	RP11-996F15.2	-4.63	5.17e-06	0.00149	-0.28	-0.24	QT interval;	chr12:29261278	chr12:29280418~29317848:-
LIHC	cis	rs643506	0.874	rs673679	ENSG00000254990.4	RP11-108O10.2	4.63	5.17e-06	0.00149	0.26	0.24	Breast cancer;	chr11:111816076	chr11:111768668~111778350:-
LIHC	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-4.63	5.17e-06	0.00149	-0.23	-0.24	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
LIHC	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-4.63	5.17e-06	0.00149	-0.23	-0.24	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
LIHC	cis	rs4660456	0.556	rs823674	ENSG00000237899.1	RP4-739H11.3	-4.63	5.18e-06	0.00149	-0.29	-0.24	Platelet count;	chr1:40774799	chr1:40669089~40687588:-
LIHC	cis	rs1247318	1	rs1247328	ENSG00000243831.1	RP1-81D8.4	4.63	5.19e-06	0.0015	0.34	0.24	Aging;	chr6:160907039	chr6:160666228~160676523:-
LIHC	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	4.63	5.19e-06	0.0015	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	4.63	5.19e-06	0.0015	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
LIHC	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	4.63	5.19e-06	0.0015	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
LIHC	cis	rs712039	0.652	rs866465	ENSG00000276054.1	RP11-378E13.3	4.63	5.2e-06	0.0015	0.31	0.24	Tuberculosis;	chr17:37499298	chr17:37386886~37387926:+
LIHC	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	4.63	5.21e-06	0.0015	0.2	0.24	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
LIHC	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-4.63	5.21e-06	0.0015	-0.29	-0.24	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
LIHC	cis	rs929596	0.793	rs13009407	ENSG00000233445.1	RPL17P11	4.63	5.22e-06	0.0015	0.37	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233743701	chr2:233721522~233722065:-
LIHC	cis	rs2998286	0.723	rs332154	ENSG00000254635.4	WAC-AS1	-4.63	5.22e-06	0.00151	-0.31	-0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28591465	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.723	rs332156	ENSG00000254635.4	WAC-AS1	-4.63	5.22e-06	0.00151	-0.31	-0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28593152	chr10:28522652~28532743:-
LIHC	cis	rs2348418	0.733	rs7294486	ENSG00000247934.4	RP11-967K21.1	-4.63	5.23e-06	0.00151	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28163298~28190738:-
LIHC	cis	rs5758511	0.508	rs58099562	ENSG00000237037.8	NDUFA6-AS1	-4.63	5.24e-06	0.00151	-0.45	-0.24	Birth weight;	chr22:42057768	chr22:42090931~42137742:+
LIHC	cis	rs2243480	0.901	rs12530490	ENSG00000230295.1	RP11-458F8.2	4.63	5.24e-06	0.00151	0.25	0.24	Diabetic kidney disease;	chr7:66226660	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs7778911	ENSG00000230295.1	RP11-458F8.2	4.63	5.24e-06	0.00151	0.25	0.24	Diabetic kidney disease;	chr7:66229519	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1979823	ENSG00000230295.1	RP11-458F8.2	4.63	5.24e-06	0.00151	0.25	0.24	Diabetic kidney disease;	chr7:66239626	chr7:66880708~66882981:+
LIHC	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	4.63	5.24e-06	0.00151	0.22	0.24	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
LIHC	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-4.63	5.24e-06	0.00151	-0.31	-0.24	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
LIHC	cis	rs9595908	0.9	rs731414	ENSG00000212293.1	SNORA16	4.63	5.24e-06	0.00151	0.28	0.24	Body mass index;	chr13:32601160	chr13:32420390~32420516:-
LIHC	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	4.63	5.24e-06	0.00151	0.31	0.24	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
LIHC	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	4.63	5.25e-06	0.00151	0.32	0.24	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
LIHC	cis	rs4660214	0.666	rs6600290	ENSG00000182109.6	RP11-69E11.4	-4.63	5.25e-06	0.00151	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39522280~39546187:-
LIHC	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	4.63	5.25e-06	0.00151	0.24	0.24	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
LIHC	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	4.63	5.25e-06	0.00151	0.22	0.24	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
LIHC	cis	rs2032447	0.714	rs129129	ENSG00000242387.1	HIST1H2APS2	4.63	5.26e-06	0.00152	0.3	0.24	Intelligence (multi-trait analysis);	chr6:25960801	chr6:25882026~25882395:-
LIHC	cis	rs9400467	0.508	rs1676863	ENSG00000271789.1	RP5-1112D6.7	-4.63	5.26e-06	0.00152	-0.24	-0.24	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111297126~111298510:+
LIHC	cis	rs7914558	1	rs10509757	ENSG00000236937.2	PTGES3P4	4.63	5.26e-06	0.00152	0.28	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102845595~102845950:+
LIHC	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	4.63	5.26e-06	0.00152	0.26	0.24	Asthma;	chr2:102437614	chr2:102438713~102440475:+
LIHC	cis	rs2836974	0.831	rs6517521	ENSG00000255568.3	BRWD1-AS2	4.63	5.26e-06	0.00152	0.28	0.24	Cognitive function;	chr21:39179662	chr21:39313935~39314962:+
LIHC	cis	rs11079159	0.958	rs11656277	ENSG00000263096.1	RP11-515O17.2	4.63	5.27e-06	0.00152	0.33	0.24	QRS duration;	chr17:55293686	chr17:55271504~55273653:-
LIHC	cis	rs4731207	0.967	rs2299902	ENSG00000224897.5	POT1-AS1	-4.63	5.27e-06	0.00152	-0.29	-0.24	Cutaneous malignant melanoma;	chr7:124757760	chr7:124929873~125179315:+
LIHC	cis	rs4731207	0.967	rs3807544	ENSG00000224897.5	POT1-AS1	-4.63	5.27e-06	0.00152	-0.29	-0.24	Cutaneous malignant melanoma;	chr7:124760651	chr7:124929873~125179315:+
LIHC	cis	rs9595908	0.9	rs9595890	ENSG00000212293.1	SNORA16	4.63	5.27e-06	0.00152	0.28	0.24	Body mass index;	chr13:32597518	chr13:32420390~32420516:-
LIHC	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-4.63	5.27e-06	0.00152	-0.31	-0.24	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
LIHC	cis	rs8028182	0.636	rs62027181	ENSG00000260269.4	CTD-2323K18.1	-4.63	5.28e-06	0.00152	-0.3	-0.24	Sudden cardiac arrest;	chr15:75547611	chr15:75527150~75601205:-
LIHC	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	4.63	5.28e-06	0.00152	0.32	0.24	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
LIHC	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	4.63	5.28e-06	0.00152	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	4.63	5.28e-06	0.00152	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	4.63	5.28e-06	0.00152	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
LIHC	cis	rs6480314	0.522	rs4363487	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68301809	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs10762214	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68302555	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs12769008	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68302836	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs61857263	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68303370	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.614	rs7067601	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68304213	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.571	rs10740295	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68304313	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs10733843	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68304752	chr10:68233251~68242379:-
LIHC	cis	rs12571093	0.571	rs10823175	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68306024	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs4746759	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68306040	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.522	rs4746760	ENSG00000233590.1	RP11-153K11.3	4.63	5.28e-06	0.00152	0.38	0.24	Optic nerve measurement (disc area);	chr10:68306122	chr10:68233251~68242379:-
LIHC	cis	rs17818399	0.815	rs62136873	ENSG00000279254.1	RP11-536C12.1	-4.63	5.28e-06	0.00152	-0.3	-0.24	Height;	chr2:46634098	chr2:46668870~46670778:+
LIHC	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	4.63	5.29e-06	0.00152	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
LIHC	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-4.63	5.29e-06	0.00152	-0.25	-0.24	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-4.63	5.29e-06	0.00152	-0.25	-0.24	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-4.63	5.29e-06	0.00152	-0.25	-0.24	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-4.63	5.29e-06	0.00152	-0.25	-0.24	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
LIHC	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-4.63	5.3e-06	0.00152	-0.28	-0.24	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
LIHC	cis	rs2877649	0.59	rs11538256	ENSG00000258744.1	RP11-80A15.1	-4.63	5.3e-06	0.00152	-0.5	-0.24	Smooth-surface caries;	chr14:24440423	chr14:24501594~24508688:+
LIHC	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	4.63	5.3e-06	0.00152	0.28	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
LIHC	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-4.63	5.3e-06	0.00153	-0.3	-0.24	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
LIHC	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	4.63	5.3e-06	0.00153	0.28	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
LIHC	cis	rs4698412	0.646	rs4698120	ENSG00000214846.4	RP11-115L11.1	-4.63	5.31e-06	0.00153	-0.29	-0.24	Parkinson's disease;	chr4:15741709	chr4:15730962~15731627:-
LIHC	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	4.63	5.31e-06	0.00153	0.38	0.24	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
LIHC	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	4.63	5.31e-06	0.00153	0.37	0.24	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	4.63	5.31e-06	0.00153	0.37	0.24	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	4.63	5.31e-06	0.00153	0.37	0.24	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	4.63	5.31e-06	0.00153	0.37	0.24	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	4.63	5.31e-06	0.00153	0.37	0.24	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
LIHC	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	4.63	5.31e-06	0.00153	0.37	0.24	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	4.63	5.31e-06	0.00153	0.37	0.24	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
LIHC	cis	rs7119038	0.818	rs10892287	ENSG00000255239.1	AP002954.6	4.63	5.31e-06	0.00153	0.35	0.24	Sjögren's syndrome;	chr11:118772290	chr11:118688039~118690600:-
LIHC	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-4.63	5.32e-06	0.00153	-0.26	-0.24	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
LIHC	cis	rs5756813	0.754	rs5750495	ENSG00000233360.4	Z83844.1	-4.63	5.32e-06	0.00153	-0.31	-0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37783113	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.668	rs6000881	ENSG00000233360.4	Z83844.1	-4.62	5.33e-06	0.00153	-0.29	-0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37758537	chr22:37641832~37658377:-
LIHC	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-4.62	5.33e-06	0.00153	-0.26	-0.24	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
LIHC	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	4.62	5.33e-06	0.00153	0.27	0.24	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
LIHC	cis	rs6600671	1	rs7532615	ENSG00000231429.2	RP11-343N15.2	4.62	5.34e-06	0.00154	0.27	0.24	Hip geometry;	chr1:121430980	chr1:121412719~121429274:+
LIHC	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	4.62	5.34e-06	0.00154	0.29	0.24	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
LIHC	cis	rs2032447	0.641	rs442601	ENSG00000242387.1	HIST1H2APS2	4.62	5.35e-06	0.00154	0.31	0.24	Intelligence (multi-trait analysis);	chr6:25934296	chr6:25882026~25882395:-
LIHC	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	4.62	5.35e-06	0.00154	0.3	0.24	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
LIHC	cis	rs5769707	0.967	rs9616701	ENSG00000235111.1	RP1-29C18.8	-4.62	5.35e-06	0.00154	-0.28	-0.24	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49612657~49615716:-
LIHC	cis	rs5756813	0.668	rs4821704	ENSG00000233360.4	Z83844.1	4.62	5.36e-06	0.00154	0.29	0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37750578	chr22:37641832~37658377:-
LIHC	cis	rs1030877	0.521	rs2576747	ENSG00000235319.1	AC012360.4	-4.62	5.36e-06	0.00154	-0.29	-0.24	Obesity-related traits;	chr2:105362219	chr2:105324210~105330529:+
LIHC	cis	rs931127	0.512	rs58950470	ENSG00000265874.1	MIR4489	4.62	5.36e-06	0.00154	0.35	0.24	Systemic lupus erythematosus;	chr11:65616284	chr11:65649192~65649253:+
LIHC	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	4.62	5.36e-06	0.00154	0.21	0.24	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	4.62	5.36e-06	0.00154	0.21	0.24	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	4.62	5.36e-06	0.00154	0.21	0.24	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
LIHC	cis	rs10510102	0.872	rs12248004	ENSG00000226864.1	ATE1-AS1	4.62	5.36e-06	0.00154	0.44	0.24	Breast cancer;	chr10:121972215	chr10:121928312~121951965:+
LIHC	cis	rs11098499	0.954	rs10006706	ENSG00000260091.1	RP11-33B1.4	-4.62	5.37e-06	0.00154	-0.17	-0.24	Corneal astigmatism;	chr4:119487997	chr4:119409333~119410233:+
LIHC	cis	rs11668505	1	rs7248427	ENSG00000259108.2	CTD-3098H1.2	4.62	5.37e-06	0.00154	0.31	0.24	Lung function (FVC);	chr19:47842904	chr19:47863483~47865341:-
LIHC	cis	rs17376456	0.825	rs10075217	ENSG00000251023.1	RP11-549J18.1	-4.62	5.37e-06	0.00154	-0.47	-0.24	Diabetic retinopathy;	chr5:93841068	chr5:93860669~93863825:-
LIHC	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	4.62	5.38e-06	0.00155	0.22	0.24	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
LIHC	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-4.62	5.38e-06	0.00155	-0.31	-0.24	Height;	chr3:53084188	chr3:53064283~53065091:-
LIHC	cis	rs72675573	0.925	rs12116494	ENSG00000235612.1	RP1-158P9.1	-4.62	5.39e-06	0.00155	-0.32	-0.24	Monocyte count;	chr1:56166668	chr1:56145721~56155224:+
LIHC	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	4.62	5.39e-06	0.00155	0.28	0.24	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	4.62	5.39e-06	0.00155	0.28	0.24	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	4.62	5.39e-06	0.00155	0.28	0.24	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
LIHC	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	4.62	5.39e-06	0.00155	0.26	0.24	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
LIHC	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	4.62	5.4e-06	0.00155	0.29	0.24	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
LIHC	cis	rs16858210	0.542	rs12636826	ENSG00000234371.6	RPSAP31	4.62	5.4e-06	0.00155	0.33	0.24	Menopause (age at onset);	chr3:183840793	chr3:183884924~183888449:+
LIHC	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	4.62	5.4e-06	0.00155	0.38	0.24	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
LIHC	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	4.62	5.4e-06	0.00155	0.27	0.24	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
LIHC	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-4.62	5.4e-06	0.00155	-0.29	-0.24	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
LIHC	cis	rs9467711	0.591	rs13206501	ENSG00000216436.2	HIST1H2APS1	4.62	5.4e-06	0.00155	0.62	0.24	Autism spectrum disorder or schizophrenia;	chr6:26109920	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs16891315	ENSG00000216436.2	HIST1H2APS1	4.62	5.4e-06	0.00155	0.62	0.24	Autism spectrum disorder or schizophrenia;	chr6:26111528	chr6:25732497~25732827:+
LIHC	cis	rs1247318	1	rs1247361	ENSG00000243831.1	RP1-81D8.4	4.62	5.4e-06	0.00155	0.35	0.24	Aging;	chr6:160920237	chr6:160666228~160676523:-
LIHC	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	4.62	5.4e-06	0.00155	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
LIHC	cis	rs17818399	0.547	rs7607633	ENSG00000239332.4	LINC01119	-4.62	5.41e-06	0.00155	-0.34	-0.24	Height;	chr2:46532288	chr2:46816697~46859007:+
LIHC	cis	rs11098499	0.909	rs10026736	ENSG00000260091.1	RP11-33B1.4	-4.62	5.41e-06	0.00155	-0.18	-0.24	Corneal astigmatism;	chr4:119463167	chr4:119409333~119410233:+
LIHC	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-4.62	5.42e-06	0.00156	-0.22	-0.24	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
LIHC	cis	rs875971	0.545	rs316316	ENSG00000273142.1	RP11-458F8.4	-4.62	5.42e-06	0.00156	-0.23	-0.24	Aortic root size;	chr7:66149270	chr7:66902857~66906297:+
LIHC	cis	rs7914558	1	rs1890184	ENSG00000236937.2	PTGES3P4	4.62	5.42e-06	0.00156	0.28	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102845595~102845950:+
LIHC	cis	rs2033711	0.503	rs6510141	ENSG00000269473.1	CTD-2619J13.19	-4.62	5.42e-06	0.00156	-0.3	-0.24	Uric acid clearance;	chr19:58374419	chr19:58440448~58445849:+
LIHC	cis	rs1865760	0.566	rs2032443	ENSG00000216436.2	HIST1H2APS1	-4.62	5.42e-06	0.00156	-0.28	-0.24	Height;	chr6:26046574	chr6:25732497~25732827:+
LIHC	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	4.62	5.43e-06	0.00156	0.29	0.24	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
LIHC	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	4.62	5.43e-06	0.00156	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
LIHC	cis	rs748404	0.697	rs501884	ENSG00000166763.7	STRCP1	4.62	5.43e-06	0.00156	0.3	0.24	Lung cancer;	chr15:43261784	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs504417	ENSG00000166763.7	STRCP1	4.62	5.43e-06	0.00156	0.3	0.24	Lung cancer;	chr15:43262028	chr15:43699488~43718184:-
LIHC	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-4.62	5.43e-06	0.00156	-0.38	-0.24	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
LIHC	cis	rs7914558	1	rs8139	ENSG00000236937.2	PTGES3P4	4.62	5.43e-06	0.00156	0.29	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102845595~102845950:+
LIHC	cis	rs12304921	0.683	rs17125401	ENSG00000277201.1	AC087884.1	4.62	5.44e-06	0.00156	0.28	0.24	Type 2 diabetes;	chr12:51120569	chr12:51049921~51050025:+
LIHC	cis	rs9326248	0.581	rs7120515	ENSG00000236267.1	AP006216.5	4.62	5.44e-06	0.00156	0.25	0.24	Blood protein levels;	chr11:117121210	chr11:116813204~116814003:-
LIHC	cis	rs8028182	0.636	rs28623700	ENSG00000260269.4	CTD-2323K18.1	-4.62	5.44e-06	0.00156	-0.3	-0.24	Sudden cardiac arrest;	chr15:75557373	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.577	rs28693593	ENSG00000260269.4	CTD-2323K18.1	-4.62	5.44e-06	0.00156	-0.3	-0.24	Sudden cardiac arrest;	chr15:75557435	chr15:75527150~75601205:-
LIHC	cis	rs2310173	0.575	rs2071008	ENSG00000281162.1	LINC01127	-4.62	5.45e-06	0.00156	-0.27	-0.24	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101998817	chr2:101962056~101987167:+
LIHC	cis	rs11146838	1	rs11146838	ENSG00000099251.13	HSD17B7P2	4.62	5.45e-06	0.00156	0.29	0.24	Breast cancer;	chr10:38856846	chr10:38356380~38378505:+
LIHC	cis	rs9834975	1	rs9834975	ENSG00000272758.4	RP11-299J3.8	-4.62	5.45e-06	0.00156	-0.27	-0.24	Diastolic blood pressure;	chr3:122398816	chr3:122416207~122443180:+
LIHC	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-4.62	5.45e-06	0.00156	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
LIHC	cis	rs5758511	0.68	rs5758692	ENSG00000237037.8	NDUFA6-AS1	-4.62	5.46e-06	0.00157	-0.31	-0.24	Birth weight;	chr22:42273023	chr22:42090931~42137742:+
LIHC	cis	rs1865760	0.928	rs9295673	ENSG00000216436.2	HIST1H2APS1	-4.62	5.47e-06	0.00157	-0.27	-0.24	Height;	chr6:25911866	chr6:25732497~25732827:+
LIHC	cis	rs10510102	0.872	rs7906462	ENSG00000226864.1	ATE1-AS1	4.62	5.47e-06	0.00157	0.39	0.24	Breast cancer;	chr10:121948098	chr10:121928312~121951965:+
LIHC	cis	rs2310173	0.575	rs4850993	ENSG00000281162.1	LINC01127	-4.62	5.47e-06	0.00157	-0.26	-0.24	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102006004	chr2:101962056~101987167:+
LIHC	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-4.62	5.48e-06	0.00157	-0.25	-0.24	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-4.62	5.48e-06	0.00157	-0.25	-0.24	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-4.62	5.48e-06	0.00157	-0.25	-0.24	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-4.62	5.48e-06	0.00157	-0.25	-0.24	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
LIHC	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-4.62	5.48e-06	0.00157	-0.31	-0.24	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
LIHC	cis	rs1865760	0.623	rs12216125	ENSG00000216436.2	HIST1H2APS1	-4.62	5.49e-06	0.00157	-0.32	-0.24	Height;	chr6:25997230	chr6:25732497~25732827:+
LIHC	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	4.62	5.49e-06	0.00157	0.25	0.24	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
LIHC	cis	rs58950470	0.521	rs7950197	ENSG00000265874.1	MIR4489	-4.62	5.5e-06	0.00158	-0.3	-0.24	Schizophrenia;	chr11:65678655	chr11:65649192~65649253:+
LIHC	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-4.62	5.5e-06	0.00158	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
LIHC	cis	rs17036023	1	rs17036023	ENSG00000203865.8	ATP1A1-AS1	4.62	5.5e-06	0.00158	0.42	0.24	Asthma (childhood onset);	chr1:116587089	chr1:116392247~116418622:-
LIHC	cis	rs12554020	0.786	rs75395683	ENSG00000227603.1	RP11-165J3.6	4.62	5.51e-06	0.00158	0.37	0.24	Schizophrenia;	chr9:93415128	chr9:93435332~93437121:-
LIHC	cis	rs12554020	1	rs55846141	ENSG00000227603.1	RP11-165J3.6	4.62	5.51e-06	0.00158	0.37	0.24	Schizophrenia;	chr9:93427679	chr9:93435332~93437121:-
LIHC	cis	rs2836974	0.739	rs12482181	ENSG00000255568.3	BRWD1-AS2	4.62	5.51e-06	0.00158	0.28	0.24	Cognitive function;	chr21:39176926	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.897	rs14194	ENSG00000255568.3	BRWD1-AS2	4.62	5.51e-06	0.00158	0.28	0.24	Cognitive function;	chr21:39177540	chr21:39313935~39314962:+
LIHC	cis	rs5756813	0.754	rs13057133	ENSG00000233360.4	Z83844.1	4.62	5.51e-06	0.00158	0.31	0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37783466	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.754	rs11705616	ENSG00000233360.4	Z83844.1	4.62	5.51e-06	0.00158	0.31	0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37784480	chr22:37641832~37658377:-
LIHC	cis	rs748404	0.697	rs505249	ENSG00000166763.7	STRCP1	4.62	5.51e-06	0.00158	0.3	0.24	Lung cancer;	chr15:43267762	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-4.62	5.51e-06	0.00158	-0.25	-0.24	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
LIHC	cis	rs9896933	0.887	rs78483419	ENSG00000263063.1	RP11-388C12.1	-4.62	5.51e-06	0.00158	-0.34	-0.24	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82913008	chr17:82713908~82716255:-
LIHC	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	4.62	5.51e-06	0.00158	0.31	0.24	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	4.62	5.51e-06	0.00158	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	4.62	5.51e-06	0.00158	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	4.62	5.51e-06	0.00158	0.31	0.24	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	4.62	5.51e-06	0.00158	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	4.62	5.51e-06	0.00158	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	4.62	5.51e-06	0.00158	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
LIHC	cis	rs11098499	0.954	rs3733524	ENSG00000260091.1	RP11-33B1.4	-4.62	5.52e-06	0.00158	-0.17	-0.24	Corneal astigmatism;	chr4:119502574	chr4:119409333~119410233:+
LIHC	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-4.62	5.52e-06	0.00158	-0.25	-0.24	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
LIHC	cis	rs7474896	0.507	rs2474555	ENSG00000263064.2	RP11-291L22.7	4.62	5.52e-06	0.00158	0.32	0.24	Obesity (extreme);	chr10:38176292	chr10:38448689~38448949:+
LIHC	cis	rs643506	1	rs1788955	ENSG00000254990.4	RP11-108O10.2	4.62	5.52e-06	0.00158	0.27	0.24	Breast cancer;	chr11:111760274	chr11:111768668~111778350:-
LIHC	cis	rs4650994	0.524	rs2209170	ENSG00000273384.1	RP5-1098D14.1	-4.62	5.53e-06	0.00158	-0.3	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178638253	chr1:178651706~178652282:+
LIHC	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-4.62	5.54e-06	0.00159	-0.29	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-4.62	5.54e-06	0.00159	-0.29	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
LIHC	cis	rs7119038	0.509	rs11216964	ENSG00000255422.1	AP002954.4	4.62	5.56e-06	0.00159	0.31	0.24	Sjögren's syndrome;	chr11:118711186	chr11:118704607~118750263:+
LIHC	cis	rs7119038	0.509	rs10892259	ENSG00000255422.1	AP002954.4	4.62	5.56e-06	0.00159	0.31	0.24	Sjögren's syndrome;	chr11:118712293	chr11:118704607~118750263:+
LIHC	cis	rs7412746	0.611	rs72704679	ENSG00000231073.1	RP11-316M1.3	4.62	5.56e-06	0.00159	0.24	0.24	Melanoma;	chr1:150925001	chr1:150973123~150975534:+
LIHC	cis	rs9733	0.526	rs6587542	ENSG00000231073.1	RP11-316M1.3	4.62	5.56e-06	0.00159	0.24	0.24	Tonsillectomy;	chr1:150935225	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.611	rs4970931	ENSG00000231073.1	RP11-316M1.3	4.62	5.56e-06	0.00159	0.24	0.24	Melanoma;	chr1:150938251	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.611	rs9661876	ENSG00000231073.1	RP11-316M1.3	4.62	5.56e-06	0.00159	0.24	0.24	Melanoma;	chr1:150938435	chr1:150973123~150975534:+
LIHC	cis	rs9733	0.503	rs7556451	ENSG00000231073.1	RP11-316M1.3	4.62	5.56e-06	0.00159	0.24	0.24	Tonsillectomy;	chr1:150940666	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.611	rs2271076	ENSG00000231073.1	RP11-316M1.3	4.62	5.56e-06	0.00159	0.24	0.24	Melanoma;	chr1:150944181	chr1:150973123~150975534:+
LIHC	cis	rs8067287	0.688	rs8081126	ENSG00000205312.7	KRT17P4	4.62	5.56e-06	0.00159	0.37	0.24	Diabetic kidney disease;	chr17:16942048	chr17:16847635~16852777:-
LIHC	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-4.62	5.56e-06	0.00159	-0.25	-0.24	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
LIHC	cis	rs5758511	0.68	rs5758698	ENSG00000205702.9	CYP2D7	4.62	5.57e-06	0.00159	0.29	0.24	Birth weight;	chr22:42288812	chr22:42140203~42144577:-
LIHC	cis	rs2929278	0.561	rs62018952	ENSG00000166763.7	STRCP1	-4.62	5.57e-06	0.00159	-0.32	-0.24	Schizophrenia;	chr15:43788539	chr15:43699488~43718184:-
LIHC	cis	rs2060793	0.539	rs962025	ENSG00000251991.1	RNU7-49P	4.62	5.57e-06	0.00159	0.27	0.24	Vitamin D levels;	chr11:14618744	chr11:14478892~14478953:+
LIHC	cis	rs875971	0.545	rs6970498	ENSG00000273142.1	RP11-458F8.4	4.61	5.57e-06	0.00159	0.23	0.24	Aortic root size;	chr7:66275908	chr7:66902857~66906297:+
LIHC	cis	rs2932538	0.845	rs6682678	ENSG00000225075.1	RP11-426L16.3	-4.61	5.57e-06	0.00159	-0.32	-0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112664298	chr1:112693688~112696621:-
LIHC	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-4.61	5.57e-06	0.00159	-0.3	-0.24	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
LIHC	cis	rs57502260	1	rs57502260	ENSG00000212093.1	AP000807.1	4.61	5.58e-06	0.00159	0.3	0.24	Total body bone mineral density (age 45-60);	chr11:68453437	chr11:68506083~68506166:-
LIHC	cis	rs57502260	0.764	rs7105218	ENSG00000212093.1	AP000807.1	4.61	5.58e-06	0.00159	0.3	0.24	Total body bone mineral density (age 45-60);	chr11:68454993	chr11:68506083~68506166:-
LIHC	cis	rs75920871	0.61	rs11216169	ENSG00000254851.1	RP11-109L13.1	-4.61	5.58e-06	0.00159	-0.5	-0.24	Subjective well-being;	chr11:116873673	chr11:117135528~117138582:+
LIHC	cis	rs4934494	0.768	rs3740034	ENSG00000232936.4	RP11-80H5.2	4.61	5.58e-06	0.0016	0.28	0.24	Red blood cell count;	chr10:89634902	chr10:89645282~89650667:+
LIHC	cis	rs7937890	0.559	rs2597188	ENSG00000251991.1	RNU7-49P	4.61	5.58e-06	0.0016	0.26	0.24	Mitochondrial DNA levels;	chr11:14495360	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597187	ENSG00000251991.1	RNU7-49P	4.61	5.58e-06	0.0016	0.26	0.24	Mitochondrial DNA levels;	chr11:14495473	chr11:14478892~14478953:+
LIHC	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	4.61	5.59e-06	0.0016	0.31	0.24	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
LIHC	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	4.61	5.59e-06	0.0016	0.23	0.24	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
LIHC	cis	rs748404	0.723	rs560134	ENSG00000166763.7	STRCP1	4.61	5.6e-06	0.0016	0.3	0.24	Lung cancer;	chr15:43263501	chr15:43699488~43718184:-
LIHC	cis	rs12887734	0.524	rs12888002	ENSG00000258534.1	CTD-2134A5.4	-4.61	5.6e-06	0.0016	-0.27	-0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103854366~103880111:-
LIHC	cis	rs7937890	0.559	rs2167160	ENSG00000251991.1	RNU7-49P	4.61	5.6e-06	0.0016	0.26	0.24	Mitochondrial DNA levels;	chr11:14485903	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.531	rs2575859	ENSG00000251991.1	RNU7-49P	4.61	5.6e-06	0.0016	0.26	0.24	Mitochondrial DNA levels;	chr11:14489190	chr11:14478892~14478953:+
LIHC	cis	rs6445975	0.726	rs7616659	ENSG00000272360.1	RP11-359I18.5	-4.61	5.6e-06	0.0016	-0.29	-0.24	Systemic lupus erythematosus;	chr3:58481860	chr3:58490830~58491291:-
LIHC	cis	rs4356203	0.543	rs214081	ENSG00000260196.1	RP1-239B22.5	-4.61	5.6e-06	0.0016	-0.29	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17380649~17383531:+
LIHC	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	4.61	5.61e-06	0.0016	0.37	0.24	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
LIHC	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	4.61	5.62e-06	0.00161	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	4.61	5.62e-06	0.00161	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	4.61	5.62e-06	0.00161	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	4.61	5.62e-06	0.00161	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
LIHC	cis	rs11098499	0.754	rs10213554	ENSG00000260091.1	RP11-33B1.4	4.61	5.62e-06	0.00161	0.17	0.24	Corneal astigmatism;	chr4:119339630	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-4.61	5.62e-06	0.00161	-0.26	-0.24	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	4.61	5.62e-06	0.00161	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
LIHC	cis	rs28829049	0.508	rs4578242	ENSG00000270728.1	RP4-657E11.10	-4.61	5.62e-06	0.00161	-0.22	-0.24	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19065071	chr1:19297080~19297903:+
LIHC	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	4.61	5.63e-06	0.00161	0.37	0.24	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	4.61	5.63e-06	0.00161	0.37	0.24	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
LIHC	cis	rs3893377	0.848	rs10023845	ENSG00000214846.4	RP11-115L11.1	-4.61	5.63e-06	0.00161	-0.31	-0.24	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15739628	chr4:15730962~15731627:-
LIHC	cis	rs728616	0.867	rs2152548	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.63e-06	0.00161	-0.57	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79663088~79826594:-
LIHC	cis	rs3738443	0.868	rs7546908	ENSG00000259865.1	RP11-488L18.10	-4.61	5.64e-06	0.00161	-0.21	-0.24	Alcohol dependence;	chr1:247200531	chr1:247187281~247188526:-
LIHC	cis	rs12701220	0.817	rs1058729	ENSG00000229043.2	AC091729.9	-4.61	5.64e-06	0.00161	-0.33	-0.24	Bronchopulmonary dysplasia;	chr7:1047647	chr7:1160374~1165267:+
LIHC	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-4.61	5.64e-06	0.00161	-0.24	-0.24	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
LIHC	cis	rs4660214	0.724	rs7554301	ENSG00000182109.6	RP11-69E11.4	-4.61	5.64e-06	0.00161	-0.26	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177792	chr1:39522280~39546187:-
LIHC	cis	rs748404	0.578	rs2584701	ENSG00000166763.7	STRCP1	4.61	5.64e-06	0.00161	0.3	0.24	Lung cancer;	chr15:43392741	chr15:43699488~43718184:-
LIHC	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	4.61	5.64e-06	0.00161	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
LIHC	cis	rs4356203	0.543	rs214093	ENSG00000260196.1	RP1-239B22.5	-4.61	5.65e-06	0.00161	-0.3	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.519	rs214092	ENSG00000260196.1	RP1-239B22.5	-4.61	5.65e-06	0.00161	-0.3	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17380649~17383531:+
LIHC	cis	rs1322639	0.614	rs9455889	ENSG00000261039.2	RP11-417E7.2	-4.61	5.65e-06	0.00161	-0.33	-0.24	Pulse pressure;	chr6:169165992	chr6:169175304~169182740:-
LIHC	cis	rs2348418	0.733	rs4931078	ENSG00000247934.4	RP11-967K21.1	-4.61	5.65e-06	0.00161	-0.22	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28163298~28190738:-
LIHC	cis	rs244293	0.831	rs8072090	ENSG00000275710.1	RP11-257O5.4	4.61	5.65e-06	0.00161	0.26	0.24	Menarche (age at onset);	chr17:55097073	chr17:54964474~54964679:+
LIHC	cis	rs2836974	0.932	rs13048178	ENSG00000255568.3	BRWD1-AS2	4.61	5.65e-06	0.00161	0.27	0.24	Cognitive function;	chr21:39189086	chr21:39313935~39314962:+
LIHC	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-4.61	5.65e-06	0.00161	-0.32	-0.24	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
LIHC	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-4.61	5.66e-06	0.00161	-0.25	-0.24	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
LIHC	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-4.61	5.66e-06	0.00162	-0.29	-0.24	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
LIHC	cis	rs2797160	0.904	rs1612274	ENSG00000237742.5	RP11-624M8.1	4.61	5.66e-06	0.00162	0.25	0.24	Endometrial cancer;	chr6:125693761	chr6:125578558~125749190:-
LIHC	cis	rs7809950	0.862	rs12112877	ENSG00000238832.1	snoU109	-4.61	5.66e-06	0.00162	-0.3	-0.24	Coronary artery disease;	chr7:107300879	chr7:107603363~107603507:+
LIHC	cis	rs728616	0.867	rs57257258	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.67e-06	0.00162	-0.52	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80084264	chr10:79663088~79826594:-
LIHC	cis	rs728616	1	rs728616	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.67e-06	0.00162	-0.52	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:79663088~79826594:-
LIHC	cis	rs728616	1	rs728615	ENSG00000225484.5	NUTM2B-AS1	-4.61	5.67e-06	0.00162	-0.52	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:79663088~79826594:-
LIHC	cis	rs3096299	0.967	rs2965932	ENSG00000261118.1	RP11-104N10.1	-4.61	5.67e-06	0.00162	-0.25	-0.24	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89492017~89504460:-
LIHC	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00162	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00162	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-4.61	5.67e-06	0.00162	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
LIHC	cis	rs73193808	0.59	rs9981735	ENSG00000224649.1	AF124730.4	4.61	5.67e-06	0.00162	0.28	0.24	Coronary artery disease;	chr21:29195543	chr21:29182027~29187795:-
LIHC	cis	rs73193808	0.59	rs9982010	ENSG00000224649.1	AF124730.4	4.61	5.67e-06	0.00162	0.28	0.24	Coronary artery disease;	chr21:29195855	chr21:29182027~29187795:-
LIHC	cis	rs11079159	0.628	rs884303	ENSG00000263096.1	RP11-515O17.2	4.61	5.68e-06	0.00162	0.32	0.24	QRS duration;	chr17:55289939	chr17:55271504~55273653:-
LIHC	cis	rs7937890	0.559	rs6486193	ENSG00000251991.1	RNU7-49P	4.61	5.68e-06	0.00162	0.23	0.24	Mitochondrial DNA levels;	chr11:14416061	chr11:14478892~14478953:+
LIHC	cis	rs638893	1	rs636736	ENSG00000255239.1	AP002954.6	4.61	5.68e-06	0.00162	0.42	0.24	Vitiligo;	chr11:118834436	chr11:118688039~118690600:-
LIHC	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-4.61	5.68e-06	0.00162	-0.24	-0.24	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
LIHC	cis	rs1865760	1	rs7739966	ENSG00000216436.2	HIST1H2APS1	-4.61	5.68e-06	0.00162	-0.27	-0.24	Height;	chr6:25905812	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs56118523	ENSG00000216436.2	HIST1H2APS1	-4.61	5.68e-06	0.00162	-0.27	-0.24	Height;	chr6:25908747	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs12209482	ENSG00000216436.2	HIST1H2APS1	-4.61	5.68e-06	0.00162	-0.27	-0.24	Height;	chr6:25909001	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.963	rs3846838	ENSG00000216436.2	HIST1H2APS1	-4.61	5.68e-06	0.00162	-0.27	-0.24	Height;	chr6:25911547	chr6:25732497~25732827:+
LIHC	cis	rs916888	0.61	rs199446	ENSG00000260075.1	NSFP1	-4.61	5.68e-06	0.00162	-0.3	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46372855~46487141:+
LIHC	cis	rs916888	0.61	rs199536	ENSG00000260075.1	NSFP1	-4.61	5.68e-06	0.00162	-0.3	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46372855~46487141:+
LIHC	cis	rs2243480	1	rs313803	ENSG00000230295.1	RP11-458F8.2	-4.61	5.69e-06	0.00162	-0.25	-0.24	Diabetic kidney disease;	chr7:66049744	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs313802	ENSG00000230295.1	RP11-458F8.2	-4.61	5.69e-06	0.00162	-0.25	-0.24	Diabetic kidney disease;	chr7:66051386	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.803	rs403089	ENSG00000230295.1	RP11-458F8.2	-4.61	5.69e-06	0.00162	-0.25	-0.24	Diabetic kidney disease;	chr7:66052736	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs458291	ENSG00000230295.1	RP11-458F8.2	-4.61	5.69e-06	0.00162	-0.25	-0.24	Diabetic kidney disease;	chr7:66055492	chr7:66880708~66882981:+
LIHC	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-4.61	5.69e-06	0.00162	-0.47	-0.24	Gout;	chr7:66723871	chr7:66654538~66669855:+
LIHC	cis	rs10129255	0.584	rs11161001	ENSG00000211970.3	IGHV4-61	-4.61	5.7e-06	0.00163	-0.19	-0.24	Kawasaki disease;	chr14:106652664	chr14:106639119~106639657:-
LIHC	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-4.61	5.7e-06	0.00163	-0.36	-0.24	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
LIHC	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-4.61	5.71e-06	0.00163	-0.29	-0.24	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
LIHC	cis	rs4578769	0.959	rs3851816	ENSG00000265943.1	RP11-739L10.1	4.61	5.71e-06	0.00163	0.31	0.24	Eosinophil percentage of white cells;	chr18:22866880	chr18:22699481~22933764:-
LIHC	cis	rs72675573	0.788	rs12568575	ENSG00000235612.1	RP1-158P9.1	-4.61	5.72e-06	0.00163	-0.33	-0.24	Monocyte count;	chr1:56103537	chr1:56145721~56155224:+
LIHC	cis	rs58950470	0.849	rs7122657	ENSG00000265874.1	MIR4489	4.61	5.72e-06	0.00163	0.35	0.24	Schizophrenia;	chr11:65610557	chr11:65649192~65649253:+
LIHC	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	4.61	5.72e-06	0.00163	0.28	0.24	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
LIHC	cis	rs7131987	0.868	rs11050151	ENSG00000257176.2	RP11-996F15.2	-4.61	5.73e-06	0.00163	-0.27	-0.24	QT interval;	chr12:29250075	chr12:29280418~29317848:-
LIHC	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-4.61	5.73e-06	0.00163	-0.27	-0.24	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
LIHC	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-4.61	5.74e-06	0.00163	-0.3	-0.24	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
LIHC	cis	rs6480314	0.522	rs10762210	ENSG00000233590.1	RP11-153K11.3	4.61	5.74e-06	0.00163	0.37	0.24	Optic nerve measurement (disc area);	chr10:68290860	chr10:68233251~68242379:-
LIHC	cis	rs2439831	1	rs2256764	ENSG00000166763.7	STRCP1	4.61	5.74e-06	0.00163	0.37	0.24	Lung cancer in ever smokers;	chr15:43443565	chr15:43699488~43718184:-
LIHC	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-4.61	5.75e-06	0.00164	-0.29	-0.24	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-4.61	5.75e-06	0.00164	-0.29	-0.24	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
LIHC	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	4.61	5.75e-06	0.00164	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
LIHC	cis	rs3733589	1	rs3733589	ENSG00000250413.1	RP11-448G15.1	-4.61	5.76e-06	0.00164	-0.43	-0.24	Renal overload gout;	chr4:9985700	chr4:10006482~10009725:+
LIHC	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-4.61	5.76e-06	0.00164	-0.28	-0.24	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
LIHC	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-4.61	5.77e-06	0.00164	-0.28	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
LIHC	cis	rs6723226	0.572	rs176404	ENSG00000276334.1	AL133243.1	-4.61	5.77e-06	0.00164	-0.27	-0.24	Intelligence (multi-trait analysis);	chr2:32413778	chr2:32521927~32523547:+
LIHC	cis	rs12701220	0.894	rs10263252	ENSG00000229043.2	AC091729.9	-4.61	5.77e-06	0.00164	-0.34	-0.24	Bronchopulmonary dysplasia;	chr7:1010313	chr7:1160374~1165267:+
LIHC	cis	rs5758511	0.689	rs5758691	ENSG00000205702.9	CYP2D7	4.61	5.77e-06	0.00164	0.28	0.24	Birth weight;	chr22:42272498	chr22:42140203~42144577:-
LIHC	cis	rs2439831	1	rs7173487	ENSG00000166763.7	STRCP1	4.61	5.77e-06	0.00164	0.37	0.24	Lung cancer in ever smokers;	chr15:43458041	chr15:43699488~43718184:-
LIHC	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-4.61	5.77e-06	0.00164	-0.31	-0.24	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
LIHC	cis	rs73193808	0.614	rs11088112	ENSG00000224649.1	AF124730.4	4.61	5.78e-06	0.00164	0.28	0.24	Coronary artery disease;	chr21:29193915	chr21:29182027~29187795:-
LIHC	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	4.61	5.78e-06	0.00165	0.23	0.24	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
LIHC	cis	rs2337406	0.778	rs58113768	ENSG00000274576.2	IGHV2-70	-4.61	5.79e-06	0.00165	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106700213	chr14:106770577~106771020:-
LIHC	cis	rs13315871	1	rs4362735	ENSG00000272182.1	RP11-802O23.3	4.61	5.79e-06	0.00165	0.59	0.24	Cholesterol, total;	chr3:58444166	chr3:58428255~58428815:+
LIHC	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	4.61	5.79e-06	0.00165	0.29	0.24	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	4.61	5.79e-06	0.00165	0.29	0.24	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	4.61	5.79e-06	0.00165	0.29	0.24	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
LIHC	cis	rs75920871	0.764	rs80259223	ENSG00000254851.1	RP11-109L13.1	-4.61	5.81e-06	0.00165	-0.51	-0.24	Subjective well-being;	chr11:117053602	chr11:117135528~117138582:+
LIHC	cis	rs6480314	0.831	rs1900009	ENSG00000233590.1	RP11-153K11.3	-4.6	5.83e-06	0.00166	-0.36	-0.24	Optic nerve measurement (disc area);	chr10:68217940	chr10:68233251~68242379:-
LIHC	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-4.6	5.83e-06	0.00166	-0.39	-0.24	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
LIHC	cis	rs2243480	1	rs466983	ENSG00000230295.1	RP11-458F8.2	-4.6	5.84e-06	0.00166	-0.25	-0.24	Diabetic kidney disease;	chr7:66055509	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1723269	ENSG00000228409.4	CCT6P1	4.6	5.84e-06	0.00166	0.26	0.24	Diabetic kidney disease;	chr7:66007799	chr7:65751142~65763354:+
LIHC	cis	rs1865760	1	rs9358893	ENSG00000216436.2	HIST1H2APS1	-4.6	5.84e-06	0.00166	-0.27	-0.24	Height;	chr6:25921533	chr6:25732497~25732827:+
LIHC	cis	rs7119038	0.779	rs73005502	ENSG00000255239.1	AP002954.6	-4.6	5.84e-06	0.00166	-0.35	-0.24	Sjögren's syndrome;	chr11:118827197	chr11:118688039~118690600:-
LIHC	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	4.6	5.84e-06	0.00166	0.33	0.24	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
LIHC	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	4.6	5.84e-06	0.00166	0.34	0.24	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
LIHC	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	4.6	5.84e-06	0.00166	0.3	0.24	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	4.6	5.84e-06	0.00166	0.3	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
LIHC	cis	rs8064024	0.65	rs12926178	ENSG00000267077.1	RP11-127I20.5	-4.6	5.85e-06	0.00166	-0.25	-0.24	Cancer;	chr16:4855914	chr16:4795265~4796532:-
LIHC	cis	rs1865760	1	rs3830057	ENSG00000216436.2	HIST1H2APS1	-4.6	5.86e-06	0.00166	-0.27	-0.24	Height;	chr6:25918282	chr6:25732497~25732827:+
LIHC	cis	rs1865760	1	rs3752421	ENSG00000216436.2	HIST1H2APS1	-4.6	5.86e-06	0.00166	-0.27	-0.24	Height;	chr6:25918460	chr6:25732497~25732827:+
LIHC	cis	rs929596	0.561	rs11891311	ENSG00000233445.1	RPL17P11	-4.6	5.86e-06	0.00166	-0.28	-0.24	Total bilirubin levels in HIV-1 infection;	chr2:233730664	chr2:233721522~233722065:-
LIHC	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-4.6	5.86e-06	0.00167	-0.29	-0.24	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-4.6	5.86e-06	0.00167	-0.29	-0.24	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-4.6	5.86e-06	0.00167	-0.29	-0.24	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
LIHC	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-4.6	5.86e-06	0.00167	-0.25	-0.24	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
LIHC	cis	rs712039	0.652	rs853232	ENSG00000276054.1	RP11-378E13.3	4.6	5.87e-06	0.00167	0.3	0.24	Tuberculosis;	chr17:37481076	chr17:37386886~37387926:+
LIHC	cis	rs1865760	1	rs9467636	ENSG00000216436.2	HIST1H2APS1	-4.6	5.87e-06	0.00167	-0.27	-0.24	Height;	chr6:25919321	chr6:25732497~25732827:+
LIHC	cis	rs3893377	0.848	rs10222984	ENSG00000214846.4	RP11-115L11.1	4.6	5.87e-06	0.00167	0.3	0.24	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15740080	chr4:15730962~15731627:-
LIHC	cis	rs1558001	0.84	rs34619691	ENSG00000230196.1	DDX43P3	-4.6	5.87e-06	0.00167	-0.26	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81831584	chr7:81610884~81611326:-
LIHC	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-4.6	5.87e-06	0.00167	-0.21	-0.24	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
LIHC	cis	rs61041384	0.661	rs74240781	ENSG00000256092.2	RP13-942N8.1	-4.6	5.88e-06	0.00167	-0.39	-0.24	Schizophrenia;	chr12:123308154	chr12:123363868~123366113:+
LIHC	cis	rs2834288	0.5	rs881230	ENSG00000237945.6	LINC00649	4.6	5.88e-06	0.00167	0.31	0.24	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33915534~33977691:+
LIHC	cis	rs2834288	0.5	rs881231	ENSG00000237945.6	LINC00649	4.6	5.88e-06	0.00167	0.31	0.24	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33915534~33977691:+
LIHC	cis	rs2834288	0.5	rs7280837	ENSG00000237945.6	LINC00649	4.6	5.88e-06	0.00167	0.31	0.24	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33915534~33977691:+
LIHC	cis	rs2834288	0.5	rs4817602	ENSG00000237945.6	LINC00649	4.6	5.88e-06	0.00167	0.31	0.24	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33915534~33977691:+
LIHC	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	4.6	5.88e-06	0.00167	0.22	0.24	Breast size;	chr12:9219433	chr12:9277235~9313241:+
LIHC	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	4.6	5.88e-06	0.00167	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
LIHC	cis	rs3733589	0.744	rs16892493	ENSG00000250413.1	RP11-448G15.1	-4.6	5.89e-06	0.00167	-0.39	-0.24	Renal overload gout;	chr4:10040023	chr4:10006482~10009725:+
LIHC	cis	rs12554020	0.685	rs55893789	ENSG00000227603.1	RP11-165J3.6	4.6	5.89e-06	0.00167	0.36	0.24	Schizophrenia;	chr9:93408608	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.681	rs78759589	ENSG00000227603.1	RP11-165J3.6	4.6	5.89e-06	0.00167	0.36	0.24	Schizophrenia;	chr9:93409518	chr9:93435332~93437121:-
LIHC	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-4.6	5.89e-06	0.00167	-0.26	-0.24	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
LIHC	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	4.6	5.89e-06	0.00167	0.22	0.24	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
LIHC	cis	rs875971	0.638	rs35986979	ENSG00000273024.4	INTS4P2	4.6	5.9e-06	0.00167	0.27	0.24	Aortic root size;	chr7:66624003	chr7:65647864~65715661:+
LIHC	cis	rs2834288	0.5	rs2051189	ENSG00000237945.6	LINC00649	4.6	5.9e-06	0.00167	0.31	0.24	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33915534~33977691:+
LIHC	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	4.6	5.9e-06	0.00168	0.2	0.24	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	4.6	5.9e-06	0.00168	0.2	0.24	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
LIHC	cis	rs2932538	0.922	rs7527076	ENSG00000225075.1	RP11-426L16.3	4.6	5.9e-06	0.00168	0.31	0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112607859	chr1:112693688~112696621:-
LIHC	cis	rs2932538	0.846	rs7546203	ENSG00000225075.1	RP11-426L16.3	4.6	5.9e-06	0.00168	0.31	0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112611907	chr1:112693688~112696621:-
LIHC	cis	rs79040073	0.563	rs73392233	ENSG00000259531.2	RP11-295H24.3	4.6	5.91e-06	0.00168	0.4	0.24	Lung cancer in ever smokers;	chr15:49214881	chr15:49365124~49366685:-
LIHC	cis	rs79040073	0.53	rs79452929	ENSG00000259531.2	RP11-295H24.3	4.6	5.91e-06	0.00168	0.4	0.24	Lung cancer in ever smokers;	chr15:49216166	chr15:49365124~49366685:-
LIHC	cis	rs79040073	0.53	rs57560518	ENSG00000259531.2	RP11-295H24.3	4.6	5.91e-06	0.00168	0.4	0.24	Lung cancer in ever smokers;	chr15:49218760	chr15:49365124~49366685:-
LIHC	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-4.6	5.91e-06	0.00168	-0.27	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
LIHC	cis	rs2072510	0.932	rs2070614	ENSG00000257715.1	RP11-256L6.2	-4.6	5.91e-06	0.00168	-0.25	-0.24	Metabolite levels (small molecules and protein measures);	chr12:95996558	chr12:96025323~96027971:+
LIHC	cis	rs8064024	0.62	rs9923349	ENSG00000267077.1	RP11-127I20.5	4.6	5.92e-06	0.00168	0.25	0.24	Cancer;	chr16:4855123	chr16:4795265~4796532:-
LIHC	cis	rs7412746	0.658	rs6669855	ENSG00000231073.1	RP11-316M1.3	4.6	5.92e-06	0.00168	0.24	0.24	Melanoma;	chr1:150888753	chr1:150973123~150975534:+
LIHC	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	4.6	5.92e-06	0.00168	0.17	0.24	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
LIHC	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-4.6	5.92e-06	0.00168	-0.26	-0.24	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
LIHC	cis	rs9595908	1	rs9591143	ENSG00000212293.1	SNORA16	4.6	5.92e-06	0.00168	0.28	0.24	Body mass index;	chr13:32585301	chr13:32420390~32420516:-
LIHC	cis	rs9595908	1	rs9591145	ENSG00000212293.1	SNORA16	4.6	5.92e-06	0.00168	0.28	0.24	Body mass index;	chr13:32587322	chr13:32420390~32420516:-
LIHC	cis	rs9595908	1	rs3742320	ENSG00000212293.1	SNORA16	4.6	5.92e-06	0.00168	0.28	0.24	Body mass index;	chr13:32590281	chr13:32420390~32420516:-
LIHC	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-4.6	5.93e-06	0.00168	-0.26	-0.24	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
LIHC	cis	rs4578769	0.842	rs8093152	ENSG00000265943.1	RP11-739L10.1	4.6	5.94e-06	0.00168	0.31	0.24	Eosinophil percentage of white cells;	chr18:22867925	chr18:22699481~22933764:-
LIHC	cis	rs6545883	0.525	rs1729658	ENSG00000271889.1	RP11-493E12.1	4.6	5.94e-06	0.00168	0.28	0.24	Tuberculosis;	chr2:61146385	chr2:61151433~61162105:-
LIHC	cis	rs7760535	0.93	rs10872069	ENSG00000255389.1	C6orf3	-4.6	5.94e-06	0.00169	-0.26	-0.24	Metabolic traits;	chr6:111540523	chr6:111599875~111602295:+
LIHC	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-4.6	5.94e-06	0.00169	-0.38	-0.24	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
LIHC	cis	rs7131987	0.903	rs7970390	ENSG00000257176.2	RP11-996F15.2	-4.6	5.95e-06	0.00169	-0.27	-0.24	QT interval;	chr12:29245722	chr12:29280418~29317848:-
LIHC	cis	rs9595066	0.627	rs4394973	ENSG00000230731.2	RP11-478K15.6	-4.6	5.95e-06	0.00169	-0.28	-0.24	Schizophrenia;	chr13:44179173	chr13:44234118~44243192:-
LIHC	cis	rs2932538	0.922	rs2932535	ENSG00000225075.1	RP11-426L16.3	-4.6	5.97e-06	0.00169	-0.31	-0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112658790	chr1:112693688~112696621:-
LIHC	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	4.6	5.97e-06	0.00169	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
LIHC	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-4.6	5.97e-06	0.00169	-0.25	-0.24	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
LIHC	cis	rs7131987	0.509	rs11050173	ENSG00000275476.1	RP11-996F15.4	-4.6	5.98e-06	0.00169	-0.3	-0.24	QT interval;	chr12:29288540	chr12:29277397~29277882:-
LIHC	cis	rs728616	0.867	rs56235549	ENSG00000225484.5	NUTM2B-AS1	-4.6	5.98e-06	0.00169	-0.54	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80075192	chr10:79663088~79826594:-
LIHC	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-4.6	5.98e-06	0.0017	-0.27	-0.24	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
LIHC	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-4.6	5.98e-06	0.0017	-0.36	-0.24	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
LIHC	cis	rs17818399	0.547	rs7607308	ENSG00000239332.4	LINC01119	-4.6	5.98e-06	0.0017	-0.34	-0.24	Height;	chr2:46531965	chr2:46816697~46859007:+
LIHC	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-4.6	5.99e-06	0.0017	-0.25	-0.24	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
LIHC	cis	rs2245008	0.774	rs253135	ENSG00000260932.1	RP11-483P21.6	-4.6	5.99e-06	0.0017	-0.43	-0.24	Pursuit maintenance gain;	chr16:83945238	chr16:83929796~83931223:-
LIHC	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	4.6	5.99e-06	0.0017	0.29	0.24	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
LIHC	cis	rs2834288	0.5	rs2834305	ENSG00000237945.6	LINC00649	4.6	5.99e-06	0.0017	0.31	0.24	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33915534~33977691:+
LIHC	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	4.6	6e-06	0.0017	0.24	0.24	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
LIHC	cis	rs6472235	0.681	rs58881093	ENSG00000272010.1	CTD-3025N20.3	-4.6	6.01e-06	0.0017	-0.33	-0.24	Plateletcrit;Myopia (pathological);	chr8:65952396	chr8:65591850~65592472:-
LIHC	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	4.6	6.01e-06	0.0017	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
LIHC	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-4.6	6.01e-06	0.0017	-0.26	-0.24	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
LIHC	cis	rs2348418	0.733	rs2019011	ENSG00000247934.4	RP11-967K21.1	4.6	6.02e-06	0.00171	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28163298~28190738:-
LIHC	cis	rs2836974	0.568	rs2142111	ENSG00000255568.3	BRWD1-AS2	4.6	6.02e-06	0.00171	0.21	0.24	Cognitive function;	chr21:39177363	chr21:39313935~39314962:+
LIHC	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-4.6	6.03e-06	0.00171	-0.26	-0.24	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
LIHC	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-4.6	6.03e-06	0.00171	-0.25	-0.24	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
LIHC	cis	rs875971	0.528	rs801213	ENSG00000273142.1	RP11-458F8.4	-4.6	6.03e-06	0.00171	-0.23	-0.24	Aortic root size;	chr7:66549931	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs801212	ENSG00000273142.1	RP11-458F8.4	-4.6	6.03e-06	0.00171	-0.23	-0.24	Aortic root size;	chr7:66550643	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs73152714	ENSG00000273142.1	RP11-458F8.4	4.6	6.03e-06	0.00171	0.23	0.24	Aortic root size;	chr7:66534641	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs4718364	ENSG00000273142.1	RP11-458F8.4	4.6	6.03e-06	0.00171	0.23	0.24	Aortic root size;	chr7:66536353	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs6961853	ENSG00000273142.1	RP11-458F8.4	4.6	6.03e-06	0.00171	0.23	0.24	Aortic root size;	chr7:66537035	chr7:66902857~66906297:+
LIHC	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	4.6	6.04e-06	0.00171	0.39	0.24	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
LIHC	cis	rs2243480	1	rs34970380	ENSG00000230295.1	RP11-458F8.2	-4.6	6.04e-06	0.00171	-0.26	-0.24	Diabetic kidney disease;	chr7:65966506	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs73148097	ENSG00000230295.1	RP11-458F8.2	-4.6	6.04e-06	0.00171	-0.26	-0.24	Diabetic kidney disease;	chr7:65966800	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs906134	ENSG00000230295.1	RP11-458F8.2	-4.6	6.04e-06	0.00171	-0.26	-0.24	Diabetic kidney disease;	chr7:65979301	chr7:66880708~66882981:+
LIHC	cis	rs748404	0.578	rs2012467	ENSG00000205771.5	CATSPER2P1	-4.6	6.04e-06	0.00171	-0.29	-0.24	Lung cancer;	chr15:43398367	chr15:43726918~43747094:-
LIHC	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	4.6	6.05e-06	0.00171	0.33	0.24	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
LIHC	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	4.6	6.05e-06	0.00171	0.35	0.24	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
LIHC	cis	rs9388451	0.626	rs3799712	ENSG00000237742.5	RP11-624M8.1	-4.6	6.05e-06	0.00171	-0.23	-0.24	Brugada syndrome;	chr6:125753957	chr6:125578558~125749190:-
LIHC	cis	rs17301013	0.932	rs2987869	ENSG00000227373.4	RP11-160H22.5	-4.6	6.05e-06	0.00171	-0.29	-0.24	Systemic lupus erythematosus;	chr1:174820269	chr1:174115300~174160004:-
LIHC	cis	rs17301013	0.827	rs1793309	ENSG00000227373.4	RP11-160H22.5	-4.6	6.05e-06	0.00171	-0.29	-0.24	Systemic lupus erythematosus;	chr1:174826199	chr1:174115300~174160004:-
LIHC	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	4.6	6.06e-06	0.00171	0.21	0.24	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
LIHC	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-4.6	6.06e-06	0.00172	-0.23	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
LIHC	cis	rs9291683	0.526	rs7695555	ENSG00000250413.1	RP11-448G15.1	-4.6	6.07e-06	0.00172	-0.32	-0.24	Bone mineral density;	chr4:10000032	chr4:10006482~10009725:+
LIHC	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-4.6	6.07e-06	0.00172	-0.35	-0.24	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
LIHC	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-4.6	6.07e-06	0.00172	-0.35	-0.24	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
LIHC	cis	rs6997458	0.712	rs9987281	ENSG00000253549.4	RP11-317J10.2	-4.6	6.07e-06	0.00172	-0.26	-0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85436601	chr8:85441851~85464915:-
LIHC	cis	rs901683	0.702	rs78757497	ENSG00000230869.1	CTGLF10P	-4.6	6.08e-06	0.00172	-0.52	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45666470	chr10:45678692~45700532:+
LIHC	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-4.6	6.09e-06	0.00172	-0.3	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
LIHC	cis	rs12304921	0.816	rs67478184	ENSG00000277201.1	AC087884.1	4.6	6.09e-06	0.00172	0.28	0.24	Type 2 diabetes;	chr12:51114267	chr12:51049921~51050025:+
LIHC	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-4.6	6.09e-06	0.00172	-0.25	-0.24	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
LIHC	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-4.6	6.09e-06	0.00172	-0.28	-0.24	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
LIHC	cis	rs12304921	0.748	rs56847302	ENSG00000277201.1	AC087884.1	4.59	6.1e-06	0.00173	0.28	0.24	Type 2 diabetes;	chr12:51113093	chr12:51049921~51050025:+
LIHC	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	4.59	6.1e-06	0.00173	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	4.59	6.1e-06	0.00173	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	4.59	6.1e-06	0.00173	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	4.59	6.1e-06	0.00173	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	4.59	6.1e-06	0.00173	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	4.59	6.1e-06	0.00173	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	4.59	6.1e-06	0.00173	0.33	0.24	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
LIHC	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	4.59	6.1e-06	0.00173	0.41	0.24	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
LIHC	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-4.59	6.11e-06	0.00173	-0.25	-0.24	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
LIHC	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-4.59	6.11e-06	0.00173	-0.37	-0.24	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
LIHC	cis	rs1165668	0.785	rs2070908	ENSG00000257327.1	RP11-650K20.3	-4.59	6.11e-06	0.00173	-0.28	-0.24	Coronary heart disease (SNP X SNP interaction);	chr12:103930404	chr12:103841451~103844664:+
LIHC	cis	rs7937890	0.559	rs2575836	ENSG00000251991.1	RNU7-49P	4.59	6.11e-06	0.00173	0.26	0.24	Mitochondrial DNA levels;	chr11:14476318	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575837	ENSG00000251991.1	RNU7-49P	4.59	6.11e-06	0.00173	0.26	0.24	Mitochondrial DNA levels;	chr11:14476455	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575838	ENSG00000251991.1	RNU7-49P	4.59	6.11e-06	0.00173	0.26	0.24	Mitochondrial DNA levels;	chr11:14476675	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.535	rs2575857	ENSG00000251991.1	RNU7-49P	4.59	6.11e-06	0.00173	0.26	0.24	Mitochondrial DNA levels;	chr11:14479750	chr11:14478892~14478953:+
LIHC	cis	rs2243480	1	rs1723269	ENSG00000230295.1	RP11-458F8.2	-4.59	6.12e-06	0.00173	-0.25	-0.24	Diabetic kidney disease;	chr7:66007799	chr7:66880708~66882981:+
LIHC	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	4.59	6.12e-06	0.00173	0.27	0.24	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
LIHC	cis	rs2243480	1	rs1039664	ENSG00000230295.1	RP11-458F8.2	-4.59	6.13e-06	0.00173	-0.25	-0.24	Diabetic kidney disease;	chr7:65984729	chr7:66880708~66882981:+
LIHC	cis	rs11098499	0.866	rs72676074	ENSG00000260091.1	RP11-33B1.4	-4.59	6.13e-06	0.00173	-0.17	-0.24	Corneal astigmatism;	chr4:119438686	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-4.59	6.15e-06	0.00174	-0.25	-0.24	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-4.59	6.15e-06	0.00174	-0.25	-0.24	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
LIHC	cis	rs2836974	0.932	rs2234543	ENSG00000255568.3	BRWD1-AS2	4.59	6.15e-06	0.00174	0.27	0.24	Cognitive function;	chr21:39200146	chr21:39313935~39314962:+
LIHC	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	4.59	6.15e-06	0.00174	0.23	0.24	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
LIHC	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-4.59	6.15e-06	0.00174	-0.25	-0.24	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-4.59	6.15e-06	0.00174	-0.25	-0.24	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-4.59	6.15e-06	0.00174	-0.25	-0.24	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
LIHC	cis	rs1062753	0.527	rs6002560	ENSG00000237037.8	NDUFA6-AS1	4.59	6.15e-06	0.00174	0.34	0.24	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41960882	chr22:42090931~42137742:+
LIHC	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-4.59	6.16e-06	0.00174	-0.22	-0.24	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
LIHC	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-4.59	6.17e-06	0.00174	-0.32	-0.24	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-4.59	6.17e-06	0.00174	-0.32	-0.24	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-4.59	6.17e-06	0.00174	-0.32	-0.24	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-4.59	6.17e-06	0.00174	-0.32	-0.24	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-4.59	6.17e-06	0.00174	-0.32	-0.24	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
LIHC	cis	rs2929278	0.617	rs575082	ENSG00000275601.1	AC011330.13	4.59	6.17e-06	0.00174	0.3	0.24	Schizophrenia;	chr15:43817944	chr15:43642389~43643023:-
LIHC	cis	rs2929278	0.617	rs2955969	ENSG00000275601.1	AC011330.13	4.59	6.17e-06	0.00174	0.3	0.24	Schizophrenia;	chr15:43822329	chr15:43642389~43643023:-
LIHC	cis	rs2337406	0.85	rs11161008	ENSG00000274576.2	IGHV2-70	-4.59	6.17e-06	0.00174	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106705261	chr14:106770577~106771020:-
LIHC	cis	rs2976388	0.573	rs1529865	ENSG00000253196.1	RP11-706C16.7	4.59	6.18e-06	0.00174	0.23	0.24	Urinary tract infection frequency;	chr8:142707753	chr8:142763116~142766427:+
LIHC	cis	rs2976388	0.609	rs1560986	ENSG00000253196.1	RP11-706C16.7	4.59	6.18e-06	0.00174	0.23	0.24	Urinary tract infection frequency;	chr8:142708357	chr8:142763116~142766427:+
LIHC	cis	rs2976388	0.609	rs2376491	ENSG00000253196.1	RP11-706C16.7	4.59	6.18e-06	0.00174	0.23	0.24	Urinary tract infection frequency;	chr8:142709516	chr8:142763116~142766427:+
LIHC	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-4.59	6.18e-06	0.00175	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
LIHC	cis	rs1577917	1	rs12661204	ENSG00000234155.1	RP11-30P6.6	4.59	6.19e-06	0.00175	0.32	0.24	Response to antipsychotic treatment;	chr6:85968868	chr6:85387219~85390186:-
LIHC	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-4.59	6.19e-06	0.00175	-0.25	-0.24	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-4.59	6.19e-06	0.00175	-0.25	-0.24	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
LIHC	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-4.59	6.19e-06	0.00175	-0.25	-0.24	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-4.59	6.19e-06	0.00175	-0.25	-0.24	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
LIHC	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-4.59	6.19e-06	0.00175	-0.31	-0.24	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
LIHC	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	4.59	6.2e-06	0.00175	0.31	0.24	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
LIHC	cis	rs875971	0.545	rs66594357	ENSG00000273142.1	RP11-458F8.4	4.59	6.2e-06	0.00175	0.23	0.24	Aortic root size;	chr7:66327797	chr7:66902857~66906297:+
LIHC	cis	rs79349575	0.811	rs1057897	ENSG00000248278.1	SUMO2P17	4.59	6.2e-06	0.00175	0.3	0.24	Type 2 diabetes;	chr17:48928147	chr17:48874860~48908983:-
LIHC	cis	rs2836974	0.568	rs8130795	ENSG00000255568.3	BRWD1-AS2	4.59	6.2e-06	0.00175	0.2	0.24	Cognitive function;	chr21:39178057	chr21:39313935~39314962:+
LIHC	cis	rs11722228	0.508	rs2241472	ENSG00000261490.1	RP11-448G15.3	4.59	6.2e-06	0.00175	0.32	0.24	Urate levels;Serum uric acid levels;Gout;	chr4:10084278	chr4:10068089~10073019:-
LIHC	cis	rs58749629	1	rs58749629	ENSG00000269549.2	RP3-461P17.10	4.59	6.21e-06	0.00175	0.49	0.24	Abdominal aortic aneurysm;	chr20:45942678	chr20:45445431~45448580:+
LIHC	cis	rs7474896	0.616	rs2505239	ENSG00000263064.2	RP11-291L22.7	4.59	6.21e-06	0.00175	0.32	0.24	Obesity (extreme);	chr10:38151837	chr10:38448689~38448949:+
LIHC	cis	rs1005277	0.522	rs289643	ENSG00000099251.13	HSD17B7P2	4.59	6.21e-06	0.00175	0.28	0.24	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38356380~38378505:+
LIHC	cis	rs1865760	0.566	rs10807006	ENSG00000216436.2	HIST1H2APS1	-4.59	6.21e-06	0.00175	-0.28	-0.24	Height;	chr6:26048524	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs7772312	ENSG00000216436.2	HIST1H2APS1	-4.59	6.21e-06	0.00175	-0.28	-0.24	Height;	chr6:26049388	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.508	rs9379820	ENSG00000216436.2	HIST1H2APS1	-4.59	6.21e-06	0.00175	-0.28	-0.24	Height;	chr6:26049696	chr6:25732497~25732827:+
LIHC	cis	rs2834288	0.5	rs7277248	ENSG00000237945.6	LINC00649	4.59	6.22e-06	0.00175	0.31	0.24	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33915534~33977691:+
LIHC	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	4.59	6.22e-06	0.00175	0.22	0.24	Breast size;	chr12:9220266	chr12:9277235~9313241:+
LIHC	cis	rs748404	0.697	rs475227	ENSG00000166763.7	STRCP1	4.59	6.22e-06	0.00176	0.3	0.24	Lung cancer;	chr15:43254248	chr15:43699488~43718184:-
LIHC	cis	rs4660214	0.666	rs11205696	ENSG00000182109.6	RP11-69E11.4	-4.59	6.22e-06	0.00176	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39522280~39546187:-
LIHC	cis	rs1577917	0.916	rs12198730	ENSG00000234155.1	RP11-30P6.6	4.59	6.23e-06	0.00176	0.32	0.24	Response to antipsychotic treatment;	chr6:85845420	chr6:85387219~85390186:-
LIHC	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-4.59	6.23e-06	0.00176	-0.32	-0.24	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
LIHC	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-4.59	6.24e-06	0.00176	-0.26	-0.24	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
LIHC	cis	rs12554020	0.582	rs7038293	ENSG00000227603.1	RP11-165J3.6	4.59	6.24e-06	0.00176	0.44	0.24	Schizophrenia;	chr9:93646314	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.582	rs79049472	ENSG00000227603.1	RP11-165J3.6	4.59	6.24e-06	0.00176	0.44	0.24	Schizophrenia;	chr9:93647116	chr9:93435332~93437121:-
LIHC	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-4.59	6.24e-06	0.00176	-0.25	-0.24	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-4.59	6.24e-06	0.00176	-0.25	-0.24	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
LIHC	cis	rs7809950	1	rs12667527	ENSG00000238832.1	snoU109	-4.59	6.26e-06	0.00177	-0.29	-0.24	Coronary artery disease;	chr7:107446524	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs4727680	ENSG00000238832.1	snoU109	-4.59	6.26e-06	0.00177	-0.29	-0.24	Coronary artery disease;	chr7:107446962	chr7:107603363~107603507:+
LIHC	cis	rs2836974	0.932	rs6517526	ENSG00000255568.3	BRWD1-AS2	4.59	6.26e-06	0.00177	0.27	0.24	Cognitive function;	chr21:39209604	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.932	rs6517527	ENSG00000255568.3	BRWD1-AS2	4.59	6.26e-06	0.00177	0.27	0.24	Cognitive function;	chr21:39209825	chr21:39313935~39314962:+
LIHC	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-4.59	6.27e-06	0.00177	-0.31	-0.24	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
LIHC	cis	rs2932538	0.922	rs9429694	ENSG00000225075.1	RP11-426L16.3	4.59	6.28e-06	0.00177	0.31	0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112615667	chr1:112693688~112696621:-
LIHC	cis	rs1577917	0.958	rs12665542	ENSG00000234155.1	RP11-30P6.6	4.59	6.28e-06	0.00177	0.32	0.24	Response to antipsychotic treatment;	chr6:85834725	chr6:85387219~85390186:-
LIHC	cis	rs960902	0.747	rs13009200	ENSG00000213553.4	RPLP0P6	4.59	6.29e-06	0.00177	0.2	0.24	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37485353	chr2:38481851~38482804:+
LIHC	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-4.59	6.29e-06	0.00177	-0.31	-0.24	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
LIHC	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	4.59	6.29e-06	0.00177	0.27	0.24	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	4.59	6.29e-06	0.00177	0.27	0.24	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
LIHC	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-4.59	6.29e-06	0.00177	-0.25	-0.24	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-4.59	6.29e-06	0.00177	-0.25	-0.24	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
LIHC	cis	rs929596	0.556	rs10168416	ENSG00000233445.1	RPL17P11	4.59	6.3e-06	0.00178	0.27	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233688441	chr2:233721522~233722065:-
LIHC	cis	rs804280	0.662	rs11250164	ENSG00000255495.1	AC145124.2	-4.59	6.31e-06	0.00178	-0.3	-0.24	Myopia (pathological);	chr8:11753177	chr8:12194467~12196280:+
LIHC	cis	rs72675573	1	rs12145670	ENSG00000235612.1	RP1-158P9.1	-4.59	6.31e-06	0.00178	-0.31	-0.24	Monocyte count;	chr1:56172718	chr1:56145721~56155224:+
LIHC	cis	rs1577917	0.958	rs1591438	ENSG00000234155.1	RP11-30P6.6	4.59	6.32e-06	0.00178	0.32	0.24	Response to antipsychotic treatment;	chr6:85815496	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs1591437	ENSG00000234155.1	RP11-30P6.6	4.59	6.32e-06	0.00178	0.32	0.24	Response to antipsychotic treatment;	chr6:85815587	chr6:85387219~85390186:-
LIHC	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	4.59	6.32e-06	0.00178	0.31	0.24	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
LIHC	cis	rs6977955	1	rs11495981	ENSG00000234336.5	JAZF1-AS1	4.59	6.33e-06	0.00178	0.34	0.24	Allergic disease (asthma, hay fever or eczema);	chr7:28137682	chr7:28180322~28243917:+
LIHC	cis	rs7412746	0.658	rs4970982	ENSG00000231073.1	RP11-316M1.3	4.59	6.33e-06	0.00178	0.24	0.24	Melanoma;	chr1:150892608	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs11204739	ENSG00000231073.1	RP11-316M1.3	4.59	6.33e-06	0.00178	0.24	0.24	Melanoma;	chr1:150893284	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs12097963	ENSG00000231073.1	RP11-316M1.3	4.59	6.33e-06	0.00178	0.24	0.24	Melanoma;	chr1:150897974	chr1:150973123~150975534:+
LIHC	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-4.59	6.33e-06	0.00178	-0.25	-0.24	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
LIHC	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	4.59	6.34e-06	0.00178	0.4	0.24	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
LIHC	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-4.59	6.34e-06	0.00178	-0.33	-0.24	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
LIHC	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	4.59	6.34e-06	0.00179	0.2	0.24	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
LIHC	cis	rs17818399	0.547	rs35178974	ENSG00000239332.4	LINC01119	-4.59	6.34e-06	0.00179	-0.34	-0.24	Height;	chr2:46536759	chr2:46816697~46859007:+
LIHC	cis	rs11064837	0.504	rs11064850	ENSG00000248636.5	RP11-768F21.1	4.59	6.35e-06	0.00179	0.38	0.24	Schizophrenia;	chr12:119617981	chr12:119387987~119668079:-
LIHC	cis	rs11064837	0.504	rs10774508	ENSG00000248636.5	RP11-768F21.1	4.59	6.35e-06	0.00179	0.38	0.24	Schizophrenia;	chr12:119632301	chr12:119387987~119668079:-
LIHC	cis	rs875971	0.545	rs2420612	ENSG00000273142.1	RP11-458F8.4	4.59	6.36e-06	0.00179	0.23	0.24	Aortic root size;	chr7:66536825	chr7:66902857~66906297:+
LIHC	cis	rs1160985	0.967	rs7259620	ENSG00000214855.8	APOC1P1	-4.59	6.36e-06	0.00179	-0.29	-0.24	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44904531	chr19:44926804~44931386:+
LIHC	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-4.59	6.36e-06	0.00179	-0.33	-0.24	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
LIHC	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	4.59	6.36e-06	0.00179	0.3	0.24	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
LIHC	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-4.59	6.36e-06	0.00179	-0.26	-0.24	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
LIHC	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-4.59	6.37e-06	0.00179	-0.27	-0.24	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
LIHC	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	4.59	6.37e-06	0.00179	0.31	0.24	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
LIHC	cis	rs1499614	0.901	rs2178742	ENSG00000230295.1	RP11-458F8.2	-4.58	6.38e-06	0.00179	-0.26	-0.24	Gout;	chr7:66732812	chr7:66880708~66882981:+
LIHC	cis	rs1153858	1	rs1554521	ENSG00000259433.2	CTD-2651B20.4	4.58	6.38e-06	0.0018	0.33	0.24	Homoarginine levels;	chr15:45371991	chr15:45330209~45332634:-
LIHC	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	4.58	6.39e-06	0.0018	0.39	0.24	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
LIHC	cis	rs10829156	0.898	rs7923072	ENSG00000240291.1	RP11-499P20.2	4.58	6.4e-06	0.0018	0.37	0.24	Sudden cardiac arrest;	chr10:18649305	chr10:18513115~18545651:-
LIHC	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	4.58	6.4e-06	0.0018	0.28	0.24	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	4.58	6.4e-06	0.0018	0.28	0.24	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
LIHC	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	4.58	6.4e-06	0.0018	0.29	0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
LIHC	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	4.58	6.4e-06	0.0018	0.2	0.24	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
LIHC	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	4.58	6.4e-06	0.0018	0.37	0.24	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	4.58	6.4e-06	0.0018	0.37	0.24	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
LIHC	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	4.58	6.4e-06	0.0018	0.37	0.24	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	4.58	6.4e-06	0.0018	0.37	0.24	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	4.58	6.4e-06	0.0018	0.37	0.24	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	4.58	6.4e-06	0.0018	0.37	0.24	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
LIHC	cis	rs7121538	0.932	rs34055103	ENSG00000251991.1	RNU7-49P	-4.58	6.4e-06	0.0018	-0.35	-0.24	HDL cholesterol;	chr11:14524935	chr11:14478892~14478953:+
LIHC	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	4.58	6.41e-06	0.0018	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
LIHC	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-4.58	6.42e-06	0.0018	-0.22	-0.24	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
LIHC	cis	rs10510102	0.872	rs11814703	ENSG00000226864.1	ATE1-AS1	4.58	6.42e-06	0.0018	0.41	0.24	Breast cancer;	chr10:121964774	chr10:121928312~121951965:+
LIHC	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	4.58	6.42e-06	0.0018	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
LIHC	cis	rs17818399	0.547	rs13020299	ENSG00000239332.4	LINC01119	-4.58	6.43e-06	0.00181	-0.34	-0.24	Height;	chr2:46531578	chr2:46816697~46859007:+
LIHC	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	4.58	6.43e-06	0.00181	0.21	0.24	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
LIHC	cis	rs2836974	0.897	rs35391055	ENSG00000255568.3	BRWD1-AS2	4.58	6.43e-06	0.00181	0.27	0.24	Cognitive function;	chr21:39153590	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.897	rs2836924	ENSG00000255568.3	BRWD1-AS2	4.58	6.43e-06	0.00181	0.27	0.24	Cognitive function;	chr21:39153713	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.897	rs4817996	ENSG00000255568.3	BRWD1-AS2	4.58	6.43e-06	0.00181	0.27	0.24	Cognitive function;	chr21:39153833	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.897	rs6517513	ENSG00000255568.3	BRWD1-AS2	4.58	6.43e-06	0.00181	0.27	0.24	Cognitive function;	chr21:39154952	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.899	rs6517514	ENSG00000255568.3	BRWD1-AS2	4.58	6.43e-06	0.00181	0.27	0.24	Cognitive function;	chr21:39155169	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.829	rs8128191	ENSG00000255568.3	BRWD1-AS2	4.58	6.43e-06	0.00181	0.27	0.24	Cognitive function;	chr21:39155385	chr21:39313935~39314962:+
LIHC	cis	rs1729407	0.659	rs2542050	ENSG00000236267.1	AP006216.5	4.58	6.44e-06	0.00181	0.23	0.24	Apolipoprotein A-IV levels;	chr11:116826401	chr11:116813204~116814003:-
LIHC	cis	rs1223397	1	rs1232392	ENSG00000215022.6	RP1-257A7.4	-4.58	6.44e-06	0.00181	-0.28	-0.24	Blood pressure;	chr6:13272439	chr6:13264861~13295586:-
LIHC	cis	rs5758511	0.68	rs56111723	ENSG00000205702.9	CYP2D7	4.58	6.44e-06	0.00181	0.28	0.24	Birth weight;	chr22:42268877	chr22:42140203~42144577:-
LIHC	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	4.58	6.45e-06	0.00181	0.38	0.24	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
LIHC	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	4.58	6.45e-06	0.00181	0.28	0.24	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
LIHC	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	4.58	6.45e-06	0.00181	0.41	0.24	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
LIHC	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-4.58	6.46e-06	0.00181	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
LIHC	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	4.58	6.46e-06	0.00181	0.23	0.24	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
LIHC	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-4.58	6.47e-06	0.00181	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
LIHC	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	4.58	6.47e-06	0.00181	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
LIHC	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-4.58	6.47e-06	0.00182	-0.25	-0.24	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
LIHC	cis	rs875971	0.642	rs35526611	ENSG00000273024.4	INTS4P2	4.58	6.47e-06	0.00182	0.27	0.24	Aortic root size;	chr7:66629021	chr7:65647864~65715661:+
LIHC	cis	rs2932538	0.961	rs1238	ENSG00000225075.1	RP11-426L16.3	-4.58	6.47e-06	0.00182	-0.31	-0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112671475	chr1:112693688~112696621:-
LIHC	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-4.58	6.48e-06	0.00182	-0.32	-0.24	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
LIHC	cis	rs1005277	0.563	rs2505215	ENSG00000276805.1	RP11-291L22.6	4.58	6.48e-06	0.00182	0.29	0.24	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.563	rs2505216	ENSG00000276805.1	RP11-291L22.6	4.58	6.48e-06	0.00182	0.29	0.24	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.563	rs2800550	ENSG00000276805.1	RP11-291L22.6	4.58	6.48e-06	0.00182	0.29	0.24	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs2749612	ENSG00000276805.1	RP11-291L22.6	4.58	6.48e-06	0.00182	0.29	0.24	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38451030~38451785:+
LIHC	cis	rs6801605	0.743	rs4687752	ENSG00000271916.1	RP11-884K10.6	-4.58	6.48e-06	0.00182	-0.31	-0.24	Blood protein levels;	chr3:53850191	chr3:53797764~53798019:-
LIHC	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	4.58	6.48e-06	0.00182	0.37	0.24	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
LIHC	cis	rs2976388	0.647	rs2585154	ENSG00000253196.1	RP11-706C16.7	4.58	6.49e-06	0.00182	0.23	0.24	Urinary tract infection frequency;	chr8:142702067	chr8:142763116~142766427:+
LIHC	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	4.58	6.49e-06	0.00182	0.31	0.24	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
LIHC	cis	rs748404	0.601	rs489964	ENSG00000205771.5	CATSPER2P1	4.58	6.49e-06	0.00182	0.29	0.24	Lung cancer;	chr15:43225356	chr15:43726918~43747094:-
LIHC	cis	rs2348418	0.8	rs6487667	ENSG00000247934.4	RP11-967K21.1	-4.58	6.5e-06	0.00182	-0.22	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28163298~28190738:-
LIHC	cis	rs2929278	0.588	rs688009	ENSG00000275601.1	AC011330.13	-4.58	6.5e-06	0.00182	-0.3	-0.24	Schizophrenia;	chr15:43864104	chr15:43642389~43643023:-
LIHC	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	4.58	6.5e-06	0.00182	0.27	0.24	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
LIHC	cis	rs712039	0.652	rs34711199	ENSG00000276054.1	RP11-378E13.3	4.58	6.51e-06	0.00182	0.3	0.24	Tuberculosis;	chr17:37497933	chr17:37386886~37387926:+
LIHC	cis	rs875971	0.545	rs2173571	ENSG00000273142.1	RP11-458F8.4	4.58	6.51e-06	0.00182	0.23	0.24	Aortic root size;	chr7:66305392	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs11770063	ENSG00000273142.1	RP11-458F8.4	4.58	6.51e-06	0.00182	0.23	0.24	Aortic root size;	chr7:66318029	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs3936065	ENSG00000273142.1	RP11-458F8.4	4.58	6.51e-06	0.00182	0.23	0.24	Aortic root size;	chr7:66325577	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs4718335	ENSG00000273142.1	RP11-458F8.4	4.58	6.51e-06	0.00182	0.23	0.24	Aortic root size;	chr7:66339619	chr7:66902857~66906297:+
LIHC	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	4.58	6.51e-06	0.00183	0.17	0.24	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
LIHC	cis	rs2348418	0.701	rs6487670	ENSG00000247934.4	RP11-967K21.1	-4.58	6.51e-06	0.00183	-0.22	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28163298~28190738:-
LIHC	cis	rs1577917	1	rs955197	ENSG00000234155.1	RP11-30P6.6	4.58	6.51e-06	0.00183	0.32	0.24	Response to antipsychotic treatment;	chr6:86019957	chr6:85387219~85390186:-
LIHC	cis	rs2439831	1	rs689754	ENSG00000166763.7	STRCP1	4.58	6.52e-06	0.00183	0.34	0.24	Lung cancer in ever smokers;	chr15:43483697	chr15:43699488~43718184:-
LIHC	cis	rs3733589	1	rs3796831	ENSG00000250413.1	RP11-448G15.1	4.58	6.52e-06	0.00183	0.42	0.24	Renal overload gout;	chr4:10014328	chr4:10006482~10009725:+
LIHC	cis	rs7121538	0.932	rs11023242	ENSG00000251991.1	RNU7-49P	-4.58	6.52e-06	0.00183	-0.35	-0.24	HDL cholesterol;	chr11:14507553	chr11:14478892~14478953:+
LIHC	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-4.58	6.52e-06	0.00183	-0.18	-0.24	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
LIHC	cis	rs2749097	0.825	rs11208264	ENSG00000244256.3	RN7SL130P	-4.58	6.52e-06	0.00183	-0.27	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63659401	chr1:63655743~63656047:+
LIHC	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-4.58	6.53e-06	0.00183	-0.22	-0.24	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
LIHC	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	4.58	6.54e-06	0.00183	0.38	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
LIHC	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	4.58	6.56e-06	0.00184	0.28	0.24	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
LIHC	cis	rs10995505	0.589	rs2896496	ENSG00000232075.1	MRPL35P2	-4.58	6.56e-06	0.00184	-0.26	-0.24	Intelligence (multi-trait analysis);	chr10:63123622	chr10:63634317~63634827:-
LIHC	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	4.58	6.56e-06	0.00184	0.3	0.24	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
LIHC	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-4.58	6.56e-06	0.00184	-0.29	-0.24	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
LIHC	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-4.58	6.57e-06	0.00184	-0.24	-0.24	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
LIHC	cis	rs2932538	0.961	rs2932539	ENSG00000225075.1	RP11-426L16.3	-4.58	6.57e-06	0.00184	-0.31	-0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112673164	chr1:112693688~112696621:-
LIHC	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-4.58	6.57e-06	0.00184	-0.27	-0.24	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
LIHC	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-4.58	6.58e-06	0.00184	-0.21	-0.24	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
LIHC	cis	rs5756813	0.646	rs875300	ENSG00000233360.4	Z83844.1	-4.58	6.58e-06	0.00184	-0.29	-0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37761798	chr22:37641832~37658377:-
LIHC	cis	rs12701220	0.894	rs12701348	ENSG00000229043.2	AC091729.9	-4.58	6.58e-06	0.00184	-0.33	-0.24	Bronchopulmonary dysplasia;	chr7:999821	chr7:1160374~1165267:+
LIHC	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	4.58	6.59e-06	0.00184	0.48	0.24	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
LIHC	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	4.58	6.59e-06	0.00185	0.25	0.24	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
LIHC	cis	rs9675120	0.675	rs8072476	ENSG00000262006.1	RP11-700H6.4	-4.58	6.6e-06	0.00185	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr17:50845858	chr17:50909637~50910232:-
LIHC	cis	rs2243480	1	rs73142166	ENSG00000230295.1	RP11-458F8.2	-4.58	6.6e-06	0.00185	-0.26	-0.24	Diabetic kidney disease;	chr7:65910845	chr7:66880708~66882981:+
LIHC	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-4.58	6.6e-06	0.00185	-0.28	-0.24	Height;	chr2:46627225	chr2:46668870~46670778:+
LIHC	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	4.58	6.6e-06	0.00185	0.35	0.24	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
LIHC	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-4.58	6.6e-06	0.00185	-0.29	-0.24	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
LIHC	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	4.58	6.62e-06	0.00185	0.29	0.24	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
LIHC	cis	rs2739330	0.791	rs4822458	ENSG00000206090.4	AP000350.7	4.58	6.63e-06	0.00185	0.28	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23939998~23942798:+
LIHC	cis	rs5758511	0.596	rs55644935	ENSG00000205702.9	CYP2D7	4.58	6.63e-06	0.00185	0.28	0.24	Birth weight;	chr22:42270063	chr22:42140203~42144577:-
LIHC	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-4.58	6.63e-06	0.00186	-0.28	-0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
LIHC	cis	rs2749097	0.825	rs11208260	ENSG00000244256.3	RN7SL130P	-4.58	6.63e-06	0.00186	-0.28	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63657608	chr1:63655743~63656047:+
LIHC	cis	rs2243480	1	rs4718333	ENSG00000230295.1	RP11-458F8.2	4.58	6.64e-06	0.00186	0.25	0.24	Diabetic kidney disease;	chr7:66307771	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs7792391	ENSG00000230295.1	RP11-458F8.2	4.58	6.64e-06	0.00186	0.25	0.24	Diabetic kidney disease;	chr7:66308442	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs10247526	ENSG00000230295.1	RP11-458F8.2	4.58	6.64e-06	0.00186	0.25	0.24	Diabetic kidney disease;	chr7:66315709	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.908	rs1532573	ENSG00000230295.1	RP11-458F8.2	4.58	6.64e-06	0.00186	0.25	0.24	Diabetic kidney disease;	chr7:66333815	chr7:66880708~66882981:+
LIHC	cis	rs10829156	0.699	rs1917209	ENSG00000225527.1	RP11-383B4.4	-4.58	6.65e-06	0.00186	-0.39	-0.24	Sudden cardiac arrest;	chr10:18543631	chr10:18531849~18533336:-
LIHC	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	4.58	6.65e-06	0.00186	0.29	0.24	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
LIHC	cis	rs2929278	0.589	rs11638972	ENSG00000166763.7	STRCP1	-4.58	6.65e-06	0.00186	-0.3	-0.24	Schizophrenia;	chr15:43782493	chr15:43699488~43718184:-
LIHC	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	4.58	6.65e-06	0.00186	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
LIHC	cis	rs1729407	0.565	rs2849173	ENSG00000236267.1	AP006216.5	4.58	6.66e-06	0.00186	0.23	0.24	Apolipoprotein A-IV levels;	chr11:116826605	chr11:116813204~116814003:-
LIHC	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	4.58	6.66e-06	0.00186	0.33	0.24	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
LIHC	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	4.58	6.66e-06	0.00186	0.3	0.24	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
LIHC	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-4.58	6.66e-06	0.00186	-0.27	-0.24	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
LIHC	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	4.58	6.67e-06	0.00186	0.31	0.24	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	4.58	6.67e-06	0.00186	0.31	0.24	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	4.58	6.67e-06	0.00186	0.31	0.24	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	4.58	6.67e-06	0.00186	0.31	0.24	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
LIHC	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	4.58	6.67e-06	0.00186	0.35	0.24	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
LIHC	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-4.58	6.67e-06	0.00186	-0.27	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
LIHC	cis	rs2337406	0.714	rs2337463	ENSG00000274576.2	IGHV2-70	-4.57	6.67e-06	0.00187	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106816066	chr14:106770577~106771020:-
LIHC	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	4.57	6.67e-06	0.00187	0.19	0.24	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
LIHC	cis	rs58950470	0.887	rs1784223	ENSG00000265874.1	MIR4489	4.57	6.68e-06	0.00187	0.34	0.24	Schizophrenia;	chr11:65612777	chr11:65649192~65649253:+
LIHC	cis	rs3733589	0.744	rs7685958	ENSG00000250413.1	RP11-448G15.1	4.57	6.69e-06	0.00187	0.39	0.24	Renal overload gout;	chr4:10041226	chr4:10006482~10009725:+
LIHC	cis	rs748404	0.65	rs518234	ENSG00000166763.7	STRCP1	4.57	6.69e-06	0.00187	0.3	0.24	Lung cancer;	chr15:43281223	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.65	rs518261	ENSG00000166763.7	STRCP1	4.57	6.69e-06	0.00187	0.3	0.24	Lung cancer;	chr15:43281231	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-4.57	6.7e-06	0.00187	-0.25	-0.24	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
LIHC	cis	rs4650994	0.816	rs2811301	ENSG00000273384.1	RP5-1098D14.1	-4.57	6.7e-06	0.00187	-0.28	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178625061	chr1:178651706~178652282:+
LIHC	cis	rs2439831	0.85	rs12441861	ENSG00000166763.7	STRCP1	4.57	6.71e-06	0.00187	0.37	0.24	Lung cancer in ever smokers;	chr15:43768685	chr15:43699488~43718184:-
LIHC	cis	rs6565180	0.926	rs4788413	ENSG00000183604.13	SMG1P5	4.57	6.72e-06	0.00188	0.26	0.24	Tonsillectomy;	chr16:30399124	chr16:30267553~30335374:-
LIHC	cis	rs6061231	0.518	rs639836	ENSG00000273619.1	RP5-908M14.9	4.57	6.72e-06	0.00188	0.19	0.24	Colorectal cancer;	chr20:62351167	chr20:62386303~62386970:-
LIHC	cis	rs2243480	1	rs56016656	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65918494	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.803	rs55700941	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65924813	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs36033484	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65925571	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34193460	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65928123	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34560516	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65939105	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs57057549	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65940751	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.808	rs12698508	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65946971	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs2961102	ENSG00000230295.1	RP11-458F8.2	-4.57	6.73e-06	0.00188	-0.26	-0.24	Diabetic kidney disease;	chr7:65959671	chr7:66880708~66882981:+
LIHC	cis	rs5756813	0.754	rs4820307	ENSG00000233360.4	Z83844.1	4.57	6.73e-06	0.00188	0.31	0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37779948	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.754	rs4820308	ENSG00000233360.4	Z83844.1	4.57	6.73e-06	0.00188	0.31	0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37780209	chr22:37641832~37658377:-
LIHC	cis	rs929596	0.561	rs6431625	ENSG00000233445.1	RPL17P11	4.57	6.73e-06	0.00188	0.28	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233729266	chr2:233721522~233722065:-
LIHC	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-4.57	6.73e-06	0.00188	-0.28	-0.24	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
LIHC	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-4.57	6.74e-06	0.00188	-0.23	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
LIHC	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	4.57	6.74e-06	0.00188	0.26	0.24	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
LIHC	cis	rs17301013	0.896	rs3118980	ENSG00000227373.4	RP11-160H22.5	-4.57	6.75e-06	0.00188	-0.29	-0.24	Systemic lupus erythematosus;	chr1:174793701	chr1:174115300~174160004:-
LIHC	cis	rs7709377	0.516	rs56322212	ENSG00000271918.1	CTD-2287O16.5	4.57	6.75e-06	0.00188	0.29	0.24	Metabolite levels  (X-11787);	chr5:116161992	chr5:116083807~116085416:-
LIHC	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	4.57	6.75e-06	0.00188	0.19	0.24	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	4.57	6.75e-06	0.00188	0.19	0.24	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
LIHC	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	4.57	6.75e-06	0.00188	0.24	0.24	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
LIHC	cis	rs8028182	0.636	rs8028277	ENSG00000260269.4	CTD-2323K18.1	-4.57	6.75e-06	0.00188	-0.3	-0.24	Sudden cardiac arrest;	chr15:75391744	chr15:75527150~75601205:-
LIHC	cis	rs4356203	0.543	rs214088	ENSG00000260196.1	RP1-239B22.5	-4.57	6.75e-06	0.00188	-0.29	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.519	rs214084	ENSG00000260196.1	RP1-239B22.5	-4.57	6.75e-06	0.00188	-0.29	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.519	rs214082	ENSG00000260196.1	RP1-239B22.5	-4.57	6.75e-06	0.00188	-0.29	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17380649~17383531:+
LIHC	cis	rs728616	0.867	rs17606361	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.75e-06	0.00188	-0.54	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80085655	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.764	rs61859016	ENSG00000225484.5	NUTM2B-AS1	-4.57	6.75e-06	0.00188	-0.54	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80092744	chr10:79663088~79826594:-
LIHC	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-4.57	6.77e-06	0.00189	-0.25	-0.24	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
LIHC	cis	rs11089937	0.559	rs2330014	ENSG00000211639.2	IGLV4-60	4.57	6.77e-06	0.00189	0.21	0.24	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22162199~22162681:+
LIHC	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-4.57	6.78e-06	0.00189	-0.28	-0.24	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
LIHC	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-4.57	6.78e-06	0.00189	-0.28	-0.24	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
LIHC	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-4.57	6.78e-06	0.00189	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
LIHC	cis	rs17270561	0.943	rs4478398	ENSG00000216436.2	HIST1H2APS1	-4.57	6.79e-06	0.00189	-0.38	-0.24	Iron status biomarkers;	chr6:25694456	chr6:25732497~25732827:+
LIHC	cis	rs10995505	0.589	rs4601646	ENSG00000232075.1	MRPL35P2	-4.57	6.79e-06	0.00189	-0.26	-0.24	Intelligence (multi-trait analysis);	chr10:63120520	chr10:63634317~63634827:-
LIHC	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-4.57	6.8e-06	0.0019	-0.25	-0.24	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
LIHC	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	4.57	6.81e-06	0.0019	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
LIHC	cis	rs75920871	0.609	rs1473177	ENSG00000254851.1	RP11-109L13.1	-4.57	6.81e-06	0.0019	-0.49	-0.24	Subjective well-being;	chr11:116888616	chr11:117135528~117138582:+
LIHC	cis	rs10871290	0.881	rs4099290	ENSG00000261079.1	RP11-252A24.3	-4.57	6.81e-06	0.0019	-0.28	-0.24	Breast cancer;	chr16:74434991	chr16:74367462~74369826:+
LIHC	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	4.57	6.82e-06	0.0019	0.45	0.24	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
LIHC	cis	rs2562456	0.876	rs62110202	ENSG00000268555.1	RP11-678G14.3	4.57	6.82e-06	0.0019	0.31	0.24	Pain;	chr19:21571799	chr19:21570822~21587322:-
LIHC	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	4.57	6.83e-06	0.0019	0.42	0.24	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
LIHC	cis	rs755249	0.508	rs10888688	ENSG00000182109.6	RP11-69E11.4	-4.57	6.83e-06	0.0019	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39522280~39546187:-
LIHC	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-4.57	6.83e-06	0.0019	-0.23	-0.24	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
LIHC	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	4.57	6.83e-06	0.0019	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
LIHC	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	4.57	6.83e-06	0.0019	0.3	0.24	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
LIHC	cis	rs2877649	1	rs2076946	ENSG00000258744.1	RP11-80A15.1	-4.57	6.83e-06	0.0019	-0.47	-0.24	Smooth-surface caries;	chr14:24482617	chr14:24501594~24508688:+
LIHC	cis	rs4660214	0.724	rs11205695	ENSG00000182109.6	RP11-69E11.4	-4.57	6.84e-06	0.0019	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39522280~39546187:-
LIHC	cis	rs3733589	1	rs4345181	ENSG00000250413.1	RP11-448G15.1	4.57	6.85e-06	0.00191	0.42	0.24	Renal overload gout;	chr4:10025240	chr4:10006482~10009725:+
LIHC	cis	rs1520333	0.602	rs967426	ENSG00000254352.1	RP11-578O24.2	4.57	6.86e-06	0.00191	0.25	0.24	Multiple sclerosis;	chr8:78585664	chr8:78723796~78724136:-
LIHC	cis	rs2834188	0.889	rs1467849	ENSG00000272659.1	AP000295.10	-4.57	6.86e-06	0.00191	-0.35	-0.24	Narcolepsy;	chr21:33309764	chr21:33309491~33310181:+
LIHC	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	4.57	6.87e-06	0.00191	0.36	0.24	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
LIHC	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	4.57	6.87e-06	0.00191	0.31	0.24	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
LIHC	cis	rs2749097	0.825	rs2658432	ENSG00000244256.3	RN7SL130P	-4.57	6.87e-06	0.00191	-0.28	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63659153	chr1:63655743~63656047:+
LIHC	cis	rs2749097	0.825	rs2819176	ENSG00000244256.3	RN7SL130P	-4.57	6.87e-06	0.00191	-0.28	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63659159	chr1:63655743~63656047:+
LIHC	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	4.57	6.88e-06	0.00191	0.19	0.24	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
LIHC	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-4.57	6.88e-06	0.00191	-0.25	-0.24	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
LIHC	cis	rs556990	0.574	rs473598	ENSG00000269125.1	RP11-98F14.11	-4.57	6.88e-06	0.00191	-0.28	-0.24	Blood protein levels;	chr13:113146875	chr13:113165002~113165183:-
LIHC	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-4.57	6.88e-06	0.00191	-0.25	-0.24	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
LIHC	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-4.57	6.89e-06	0.00192	-0.32	-0.24	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
LIHC	cis	rs12931792	0.682	rs12373113	ENSG00000183604.13	SMG1P5	4.57	6.89e-06	0.00192	0.22	0.24	Tonsillectomy;	chr16:30176192	chr16:30267553~30335374:-
LIHC	cis	rs12931792	0.682	rs12373078	ENSG00000183604.13	SMG1P5	4.57	6.89e-06	0.00192	0.22	0.24	Tonsillectomy;	chr16:30176355	chr16:30267553~30335374:-
LIHC	cis	rs75920871	0.688	rs76972960	ENSG00000254851.1	RP11-109L13.1	-4.57	6.89e-06	0.00192	-0.51	-0.24	Subjective well-being;	chr11:117045962	chr11:117135528~117138582:+
LIHC	cis	rs929596	0.517	rs1875263	ENSG00000233445.1	RPL17P11	4.57	6.89e-06	0.00192	0.28	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233716976	chr2:233721522~233722065:-
LIHC	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	4.57	6.89e-06	0.00192	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
LIHC	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	4.57	6.9e-06	0.00192	0.19	0.24	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
LIHC	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	4.57	6.9e-06	0.00192	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
LIHC	cis	rs4578769	0.765	rs35998712	ENSG00000266850.1	RP11-370A5.1	-4.57	6.9e-06	0.00192	-0.29	-0.24	Eosinophil percentage of white cells;	chr18:22873654	chr18:22723491~22907721:-
LIHC	cis	rs2739330	0.796	rs5760106	ENSG00000206090.4	AP000350.7	-4.57	6.91e-06	0.00192	-0.27	-0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23939998~23942798:+
LIHC	cis	rs7193541	0.965	rs4402594	ENSG00000262904.1	TMPOP2	-4.57	6.91e-06	0.00192	-0.21	-0.24	Multiple myeloma;	chr16:74667462	chr16:74667506~74668706:+
LIHC	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-4.57	6.91e-06	0.00192	-0.27	-0.24	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
LIHC	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-4.57	6.91e-06	0.00192	-0.27	-0.24	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
LIHC	cis	rs12304921	0.683	rs12582592	ENSG00000277201.1	AC087884.1	4.57	6.92e-06	0.00192	0.28	0.24	Type 2 diabetes;	chr12:51119825	chr12:51049921~51050025:+
LIHC	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	4.57	6.93e-06	0.00192	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
LIHC	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-4.57	6.93e-06	0.00192	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
LIHC	cis	rs17301013	0.729	rs12094143	ENSG00000227373.4	RP11-160H22.5	4.57	6.93e-06	0.00193	0.29	0.24	Systemic lupus erythematosus;	chr1:174511986	chr1:174115300~174160004:-
LIHC	cis	rs763121	0.853	rs1062687	ENSG00000273076.1	RP3-508I15.22	4.57	6.93e-06	0.00193	0.27	0.24	Menopause (age at onset);	chr22:38738710	chr22:38743495~38743910:+
LIHC	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-4.57	6.94e-06	0.00193	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
LIHC	cis	rs30380	1	rs151964	ENSG00000272109.1	CTD-2260A17.3	-4.57	6.94e-06	0.00193	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96804353~96806105:+
LIHC	cis	rs8028182	0.636	rs8036884	ENSG00000260269.4	CTD-2323K18.1	-4.57	6.94e-06	0.00193	-0.3	-0.24	Sudden cardiac arrest;	chr15:75570552	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs4075522	ENSG00000260269.4	CTD-2323K18.1	-4.57	6.94e-06	0.00193	-0.3	-0.24	Sudden cardiac arrest;	chr15:75571994	chr15:75527150~75601205:-
LIHC	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	4.57	6.94e-06	0.00193	0.25	0.24	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
LIHC	cis	rs12291225	0.877	rs2303974	ENSG00000251991.1	RNU7-49P	4.57	6.94e-06	0.00193	0.26	0.24	Sense of smell;	chr11:14243433	chr11:14478892~14478953:+
LIHC	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-4.57	6.94e-06	0.00193	-0.29	-0.24	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
LIHC	cis	rs603446	0.967	rs180340	ENSG00000254851.1	RP11-109L13.1	-4.57	6.95e-06	0.00193	-0.3	-0.24	Triglycerides;	chr11:116745686	chr11:117135528~117138582:+
LIHC	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	4.57	6.95e-06	0.00193	0.38	0.24	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
LIHC	cis	rs2243480	1	rs35820085	ENSG00000230295.1	RP11-458F8.2	-4.57	6.95e-06	0.00193	-0.26	-0.24	Diabetic kidney disease;	chr7:65977771	chr7:66880708~66882981:+
LIHC	cis	rs957448	0.796	rs72674824	ENSG00000253704.1	RP11-267M23.4	4.57	6.95e-06	0.00193	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94477053	chr8:94553722~94569745:+
LIHC	cis	rs5758511	0.68	rs1107554	ENSG00000205702.9	CYP2D7	4.57	6.95e-06	0.00193	0.28	0.24	Birth weight;	chr22:42271588	chr22:42140203~42144577:-
LIHC	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	4.57	6.95e-06	0.00193	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
LIHC	cis	rs11710088	0.707	rs35551531	ENSG00000244503.1	RP11-278L15.6	4.57	6.96e-06	0.00193	0.25	0.24	QRS duration;	chr3:149489199	chr3:149494660~149495995:+
LIHC	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	4.57	6.96e-06	0.00193	0.29	0.24	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
LIHC	cis	rs9467711	0.591	rs60512607	ENSG00000216436.2	HIST1H2APS1	4.57	6.96e-06	0.00193	0.62	0.24	Autism spectrum disorder or schizophrenia;	chr6:26053943	chr6:25732497~25732827:+
LIHC	cis	rs3893377	0.848	rs3893376	ENSG00000214846.4	RP11-115L11.1	4.57	6.96e-06	0.00193	0.3	0.24	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15740451	chr4:15730962~15731627:-
LIHC	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-4.57	6.96e-06	0.00193	-0.28	-0.24	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
LIHC	cis	rs240993	0.909	rs11153279	ENSG00000271789.1	RP5-1112D6.7	4.57	6.97e-06	0.00194	0.24	0.24	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111297126~111298510:+
LIHC	cis	rs748404	0.697	rs498227	ENSG00000166763.7	STRCP1	4.56	6.98e-06	0.00194	0.3	0.24	Lung cancer;	chr15:43280854	chr15:43699488~43718184:-
LIHC	cis	rs2243480	0.901	rs778732	ENSG00000230295.1	RP11-458F8.2	-4.56	6.98e-06	0.00194	-0.25	-0.24	Diabetic kidney disease;	chr7:66357373	chr7:66880708~66882981:+
LIHC	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-4.56	6.98e-06	0.00194	-0.27	-0.24	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
LIHC	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	4.56	6.98e-06	0.00194	0.19	0.24	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
LIHC	cis	rs6997458	0.742	rs6988475	ENSG00000253549.4	RP11-317J10.2	4.56	6.98e-06	0.00194	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85471039	chr8:85441851~85464915:-
LIHC	cis	rs11064837	0.504	rs2393522	ENSG00000248636.5	RP11-768F21.1	4.56	6.98e-06	0.00194	0.38	0.24	Schizophrenia;	chr12:119617552	chr12:119387987~119668079:-
LIHC	cis	rs916888	0.61	rs199438	ENSG00000260075.1	NSFP1	4.56	6.98e-06	0.00194	0.29	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46372855~46487141:+
LIHC	cis	rs651907	0.557	rs3094297	ENSG00000244119.1	PDCL3P4	4.56	7e-06	0.00194	0.24	0.24	Colorectal cancer;	chr3:101680416	chr3:101712472~101713191:+
LIHC	cis	rs3015497	0.653	rs2356455	ENSG00000269906.1	RP11-248J18.2	4.56	7e-06	0.00194	0.3	0.24	Mean platelet volume;	chr14:50626424	chr14:50662511~50663178:-
LIHC	cis	rs916888	0.61	rs199529	ENSG00000274883.1	Metazoa_SRP	-4.56	7e-06	0.00194	-0.36	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45931806~45932083:+
LIHC	cis	rs875971	0.545	rs73146609	ENSG00000273142.1	RP11-458F8.4	4.56	7.01e-06	0.00194	0.23	0.24	Aortic root size;	chr7:66302477	chr7:66902857~66906297:+
LIHC	cis	rs7937890	0.559	rs2597196	ENSG00000251991.1	RNU7-49P	-4.56	7.02e-06	0.00195	-0.26	-0.24	Mitochondrial DNA levels;	chr11:14470055	chr11:14478892~14478953:+
LIHC	cis	rs2310173	0.966	rs7588933	ENSG00000281162.1	LINC01127	-4.56	7.02e-06	0.00195	-0.26	-0.24	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102046190	chr2:101962056~101987167:+
LIHC	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	4.56	7.03e-06	0.00195	0.27	0.24	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
LIHC	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	4.56	7.03e-06	0.00195	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
LIHC	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-4.56	7.03e-06	0.00195	-0.23	-0.24	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
LIHC	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-4.56	7.03e-06	0.00195	-0.23	-0.24	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
LIHC	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-4.56	7.03e-06	0.00195	-0.23	-0.24	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
LIHC	cis	rs2439831	0.681	rs825740	ENSG00000166763.7	STRCP1	4.56	7.04e-06	0.00195	0.33	0.24	Lung cancer in ever smokers;	chr15:43300210	chr15:43699488~43718184:-
LIHC	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	4.56	7.04e-06	0.00195	0.28	0.24	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	4.56	7.04e-06	0.00195	0.28	0.24	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	4.56	7.04e-06	0.00195	0.28	0.24	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	4.56	7.04e-06	0.00195	0.28	0.24	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	4.56	7.04e-06	0.00195	0.28	0.24	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
LIHC	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-4.56	7.04e-06	0.00195	-0.41	-0.24	Depression;	chr6:28103220	chr6:28115628~28116551:+
LIHC	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-4.56	7.05e-06	0.00195	-0.35	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-4.56	7.05e-06	0.00195	-0.35	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
LIHC	cis	rs3812762	0.871	rs11042068	ENSG00000254860.4	TMEM9B-AS1	4.56	7.05e-06	0.00195	0.27	0.24	Hypospadias;	chr11:8794052	chr11:8964675~8977527:+
LIHC	cis	rs11779988	0.545	rs454692	ENSG00000253671.1	RP11-806O11.1	-4.56	7.05e-06	0.00196	-0.31	-0.24	Breast cancer;	chr8:17931789	chr8:17808941~17820868:+
LIHC	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-4.56	7.07e-06	0.00196	-0.4	-0.24	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
LIHC	cis	rs7665090	0.87	rs228613	ENSG00000230069.3	LRRC37A15P	4.56	7.07e-06	0.00196	0.23	0.24	Primary biliary cholangitis;	chr4:102656308	chr4:102727274~102730721:-
LIHC	cis	rs8028182	0.636	rs7163451	ENSG00000260269.4	CTD-2323K18.1	-4.56	7.07e-06	0.00196	-0.3	-0.24	Sudden cardiac arrest;	chr15:75568735	chr15:75527150~75601205:-
LIHC	cis	rs7914558	0.966	rs10883817	ENSG00000236937.2	PTGES3P4	4.56	7.08e-06	0.00196	0.28	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102845595~102845950:+
LIHC	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-4.56	7.08e-06	0.00196	-0.27	-0.24	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
LIHC	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	4.56	7.08e-06	0.00196	0.27	0.24	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
LIHC	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	4.56	7.08e-06	0.00196	0.27	0.24	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
LIHC	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	4.56	7.08e-06	0.00196	0.27	0.24	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
LIHC	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	4.56	7.08e-06	0.00196	0.27	0.24	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
LIHC	cis	rs2243480	1	rs56291018	ENSG00000230295.1	RP11-458F8.2	-4.56	7.08e-06	0.00196	-0.25	-0.24	Diabetic kidney disease;	chr7:65925352	chr7:66880708~66882981:+
LIHC	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-4.56	7.08e-06	0.00196	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-4.56	7.08e-06	0.00196	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-4.56	7.08e-06	0.00196	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
LIHC	cis	rs1247318	1	rs1247360	ENSG00000243831.1	RP1-81D8.4	4.56	7.09e-06	0.00196	0.35	0.24	Aging;	chr6:160920176	chr6:160666228~160676523:-
LIHC	cis	rs7809950	1	rs7786801	ENSG00000238832.1	snoU109	-4.56	7.09e-06	0.00196	-0.29	-0.24	Coronary artery disease;	chr7:107445444	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs10234355	ENSG00000238832.1	snoU109	-4.56	7.09e-06	0.00196	-0.29	-0.24	Coronary artery disease;	chr7:107446072	chr7:107603363~107603507:+
LIHC	cis	rs7216064	0.589	rs7213585	ENSG00000278740.1	RP11-147L13.14	4.56	7.09e-06	0.00197	0.29	0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68066200	chr17:68188547~68189165:+
LIHC	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-4.56	7.1e-06	0.00197	-0.31	-0.24	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
LIHC	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	4.56	7.1e-06	0.00197	0.22	0.24	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	4.56	7.1e-06	0.00197	0.22	0.24	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
LIHC	cis	rs10829156	0.625	rs10828906	ENSG00000225527.1	RP11-383B4.4	-4.56	7.11e-06	0.00197	-0.38	-0.24	Sudden cardiac arrest;	chr10:18552866	chr10:18531849~18533336:-
LIHC	cis	rs17818399	0.547	rs4952831	ENSG00000239332.4	LINC01119	-4.56	7.11e-06	0.00197	-0.34	-0.24	Height;	chr2:46534042	chr2:46816697~46859007:+
LIHC	cis	rs17818399	0.547	rs4952833	ENSG00000239332.4	LINC01119	-4.56	7.11e-06	0.00197	-0.34	-0.24	Height;	chr2:46534895	chr2:46816697~46859007:+
LIHC	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-4.56	7.11e-06	0.00197	-0.34	-0.24	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
LIHC	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	4.56	7.12e-06	0.00197	0.24	0.24	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
LIHC	cis	rs513088	0.515	rs579100	ENSG00000225171.2	DUTP6	-4.56	7.12e-06	0.00197	-0.29	-0.24	Schizophrenia;	chr1:166705052	chr1:166868748~166869209:+
LIHC	cis	rs12304921	0.872	rs17122760	ENSG00000277201.1	AC087884.1	4.56	7.12e-06	0.00197	0.27	0.24	Type 2 diabetes;	chr12:51125323	chr12:51049921~51050025:+
LIHC	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-4.56	7.12e-06	0.00197	-0.31	-0.24	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
LIHC	cis	rs7809950	1	rs3801944	ENSG00000238832.1	snoU109	4.56	7.12e-06	0.00197	0.29	0.24	Coronary artery disease;	chr7:107615103	chr7:107603363~107603507:+
LIHC	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-4.56	7.13e-06	0.00197	-0.25	-0.24	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
LIHC	cis	rs10833905	0.756	rs16910406	ENSG00000246225.5	RP11-17A1.3	4.56	7.13e-06	0.00197	0.31	0.24	Sudden cardiac arrest;	chr11:22984200	chr11:22829380~22945393:+
LIHC	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-4.56	7.13e-06	0.00197	-0.3	-0.24	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
LIHC	cis	rs8028182	0.636	rs4451914	ENSG00000260269.4	CTD-2323K18.1	-4.56	7.14e-06	0.00198	-0.3	-0.24	Sudden cardiac arrest;	chr15:75447483	chr15:75527150~75601205:-
LIHC	cis	rs1223397	0.938	rs3817741	ENSG00000215022.6	RP1-257A7.4	4.56	7.15e-06	0.00198	0.28	0.24	Blood pressure;	chr6:13279275	chr6:13264861~13295586:-
LIHC	cis	rs7809950	1	rs10258385	ENSG00000238832.1	snoU109	4.56	7.15e-06	0.00198	0.29	0.24	Coronary artery disease;	chr7:107602905	chr7:107603363~107603507:+
LIHC	cis	rs1322639	0.614	rs9364356	ENSG00000261039.2	RP11-417E7.2	-4.56	7.16e-06	0.00198	-0.33	-0.24	Pulse pressure;	chr6:169167013	chr6:169175304~169182740:-
LIHC	cis	rs1030877	0.557	rs2576752	ENSG00000235319.1	AC012360.4	-4.56	7.16e-06	0.00198	-0.29	-0.24	Obesity-related traits;	chr2:105362304	chr2:105324210~105330529:+
LIHC	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	4.56	7.16e-06	0.00198	0.36	0.24	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
LIHC	cis	rs79349575	0.783	rs1994970	ENSG00000248278.1	SUMO2P17	-4.56	7.17e-06	0.00198	-0.29	-0.24	Type 2 diabetes;	chr17:48936765	chr17:48874860~48908983:-
LIHC	cis	rs7216064	0.532	rs3890640	ENSG00000278740.1	RP11-147L13.14	-4.56	7.17e-06	0.00198	-0.29	-0.24	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68188547~68189165:+
LIHC	cis	rs72675573	0.888	rs12144217	ENSG00000235612.1	RP1-158P9.1	-4.56	7.17e-06	0.00198	-0.31	-0.24	Monocyte count;	chr1:56156019	chr1:56145721~56155224:+
LIHC	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	4.56	7.18e-06	0.00199	0.38	0.24	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
LIHC	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-4.56	7.18e-06	0.00199	-0.3	-0.24	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
LIHC	cis	rs7586970	0.583	rs16829088	ENSG00000224063.4	AC007319.1	4.56	7.18e-06	0.00199	0.36	0.24	Coronary heart disease;	chr2:187527181	chr2:187003220~187554663:+
LIHC	cis	rs17301013	0.932	rs2987874	ENSG00000227373.4	RP11-160H22.5	-4.56	7.18e-06	0.00199	-0.29	-0.24	Systemic lupus erythematosus;	chr1:174801053	chr1:174115300~174160004:-
LIHC	cis	rs6600671	1	rs10794671	ENSG00000231429.2	RP11-343N15.2	-4.56	7.18e-06	0.00199	-0.27	-0.24	Hip geometry;	chr1:121426382	chr1:121412719~121429274:+
LIHC	cis	rs6600671	1	rs1856572	ENSG00000231429.2	RP11-343N15.2	-4.56	7.18e-06	0.00199	-0.27	-0.24	Hip geometry;	chr1:121427719	chr1:121412719~121429274:+
LIHC	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-4.56	7.19e-06	0.00199	-0.28	-0.24	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
LIHC	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-4.56	7.19e-06	0.00199	-0.29	-0.24	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
LIHC	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	4.56	7.19e-06	0.00199	0.2	0.24	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
LIHC	cis	rs11064837	0.504	rs11064845	ENSG00000248636.5	RP11-768F21.1	-4.56	7.19e-06	0.00199	-0.38	-0.24	Schizophrenia;	chr12:119614124	chr12:119387987~119668079:-
LIHC	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-4.56	7.2e-06	0.00199	-0.23	-0.24	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
LIHC	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	4.56	7.2e-06	0.00199	0.2	0.24	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
LIHC	cis	rs2243480	1	rs781150	ENSG00000230295.1	RP11-458F8.2	-4.56	7.2e-06	0.00199	-0.25	-0.24	Diabetic kidney disease;	chr7:66015986	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs313798	ENSG00000230295.1	RP11-458F8.2	-4.56	7.2e-06	0.00199	-0.25	-0.24	Diabetic kidney disease;	chr7:66028044	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35396113	ENSG00000230295.1	RP11-458F8.2	-4.56	7.2e-06	0.00199	-0.25	-0.24	Diabetic kidney disease;	chr7:66030474	chr7:66880708~66882981:+
LIHC	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-4.56	7.2e-06	0.00199	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
LIHC	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-4.56	7.21e-06	0.00199	-0.29	-0.24	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
LIHC	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-4.56	7.21e-06	0.00199	-0.28	-0.24	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
LIHC	cis	rs30380	1	rs30187	ENSG00000272109.1	CTD-2260A17.3	-4.56	7.21e-06	0.00199	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96804353~96806105:+
LIHC	cis	rs875971	0.66	rs1860468	ENSG00000273024.4	INTS4P2	4.56	7.21e-06	0.00199	0.27	0.24	Aortic root size;	chr7:66642265	chr7:65647864~65715661:+
LIHC	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	4.56	7.21e-06	0.00199	0.21	0.24	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
LIHC	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	4.56	7.22e-06	0.002	0.29	0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
LIHC	cis	rs7702057	0.53	rs3946989	ENSG00000271918.1	CTD-2287O16.5	4.56	7.22e-06	0.002	0.33	0.24	Amyotrophic lateral sclerosis;	chr5:116078431	chr5:116083807~116085416:-
LIHC	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	4.56	7.22e-06	0.002	0.39	0.24	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
LIHC	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-4.56	7.22e-06	0.002	-0.25	-0.24	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
LIHC	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-4.56	7.22e-06	0.002	-0.25	-0.24	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
LIHC	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-4.56	7.23e-06	0.002	-0.28	-0.24	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
LIHC	cis	rs6940638	0.637	rs13217239	ENSG00000216901.1	AL022393.7	4.56	7.23e-06	0.002	0.34	0.24	Intelligence (multi-trait analysis);	chr6:27287188	chr6:28176188~28176674:+
LIHC	cis	rs7702057	0.53	rs17138834	ENSG00000271918.1	CTD-2287O16.5	-4.56	7.23e-06	0.002	-0.32	-0.24	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116083807~116085416:-
LIHC	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-4.56	7.24e-06	0.002	-0.25	-0.24	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
LIHC	cis	rs7119038	0.779	rs11217045	ENSG00000255239.1	AP002954.6	-4.56	7.25e-06	0.002	-0.35	-0.24	Sjögren's syndrome;	chr11:118827156	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.865	rs11217046	ENSG00000255239.1	AP002954.6	-4.56	7.25e-06	0.002	-0.35	-0.24	Sjögren's syndrome;	chr11:118828198	chr11:118688039~118690600:-
LIHC	cis	rs1005277	0.522	rs289645	ENSG00000099251.13	HSD17B7P2	4.56	7.25e-06	0.002	0.28	0.24	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38356380~38378505:+
LIHC	cis	rs11079159	0.606	rs4239192	ENSG00000263096.1	RP11-515O17.2	4.56	7.25e-06	0.002	0.3	0.24	QRS duration;	chr17:55299143	chr17:55271504~55273653:-
LIHC	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-4.56	7.25e-06	0.002	-0.31	-0.24	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
LIHC	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	4.56	7.26e-06	0.002	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
LIHC	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-4.56	7.26e-06	0.002	-0.2	-0.24	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
LIHC	cis	rs2245008	0.774	rs253136	ENSG00000260932.1	RP11-483P21.6	4.56	7.26e-06	0.002	0.41	0.24	Pursuit maintenance gain;	chr16:83945996	chr16:83929796~83931223:-
LIHC	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	4.56	7.26e-06	0.002	0.36	0.24	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
LIHC	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-4.56	7.26e-06	0.00201	-0.33	-0.24	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
LIHC	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-4.56	7.27e-06	0.00201	-0.22	-0.24	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
LIHC	cis	rs2243480	0.908	rs55876148	ENSG00000230295.1	RP11-458F8.2	-4.56	7.27e-06	0.00201	-0.26	-0.24	Diabetic kidney disease;	chr7:65914813	chr7:66880708~66882981:+
LIHC	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	4.56	7.27e-06	0.00201	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
LIHC	cis	rs7119038	0.629	rs10892273	ENSG00000255239.1	AP002954.6	-4.56	7.28e-06	0.00201	-0.33	-0.24	Sjögren's syndrome;	chr11:118732100	chr11:118688039~118690600:-
LIHC	cis	rs4718428	1	rs4718428	ENSG00000273142.1	RP11-458F8.4	-4.56	7.28e-06	0.00201	-0.23	-0.24	Corneal structure;	chr7:66956459	chr7:66902857~66906297:+
LIHC	cis	rs113835537	0.877	rs77239910	ENSG00000255517.5	CTD-3074O7.5	-4.56	7.29e-06	0.00201	-0.43	-0.24	Airway imaging phenotypes;	chr11:66562168	chr11:66473490~66480233:-
LIHC	cis	rs1714507	0.533	rs1435642	ENSG00000272087.1	RP11-379F4.7	-4.56	7.29e-06	0.00201	-0.26	-0.24	Subjective well-being;	chr3:158582432	chr3:158693120~158693768:-
LIHC	cis	rs7587476	1	rs1542173	ENSG00000229267.2	AC072062.1	4.56	7.29e-06	0.00201	0.31	0.24	Neuroblastoma;	chr2:214792836	chr2:214810229~214963274:+
LIHC	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	4.56	7.29e-06	0.00201	0.17	0.24	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
LIHC	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-4.55	7.3e-06	0.00202	-0.28	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
LIHC	cis	rs2243480	0.901	rs778730	ENSG00000230295.1	RP11-458F8.2	-4.55	7.3e-06	0.00202	-0.25	-0.24	Diabetic kidney disease;	chr7:66358338	chr7:66880708~66882981:+
LIHC	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-4.55	7.31e-06	0.00202	-0.3	-0.24	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-4.55	7.31e-06	0.00202	-0.3	-0.24	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
LIHC	cis	rs11637445	0.589	rs4776989	ENSG00000260657.2	RP11-315D16.4	-4.55	7.31e-06	0.00202	-0.34	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr15:67838346	chr15:68267792~68277994:-
LIHC	cis	rs3733589	0.59	rs6836200	ENSG00000250413.1	RP11-448G15.1	-4.55	7.31e-06	0.00202	-0.4	-0.24	Renal overload gout;	chr4:9985291	chr4:10006482~10009725:+
LIHC	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	4.55	7.32e-06	0.00202	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	4.55	7.32e-06	0.00202	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	4.55	7.32e-06	0.00202	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	4.55	7.32e-06	0.00202	0.27	0.24	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	4.55	7.32e-06	0.00202	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
LIHC	cis	rs7709377	0.516	rs7701736	ENSG00000271918.1	CTD-2287O16.5	4.55	7.32e-06	0.00202	0.29	0.24	Metabolite levels  (X-11787);	chr5:116185318	chr5:116083807~116085416:-
LIHC	cis	rs6997458	0.742	rs10111039	ENSG00000253549.4	RP11-317J10.2	4.55	7.33e-06	0.00202	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85484427	chr8:85441851~85464915:-
LIHC	cis	rs6442522	0.772	rs3846127	ENSG00000249786.6	EAF1-AS1	4.55	7.34e-06	0.00202	0.28	0.24	Uric acid levels;	chr3:15450020	chr3:15436171~15455940:-
LIHC	cis	rs2032447	0.839	rs199750	ENSG00000242387.1	HIST1H2APS2	-4.55	7.34e-06	0.00202	-0.3	-0.24	Intelligence (multi-trait analysis);	chr6:26016234	chr6:25882026~25882395:-
LIHC	cis	rs8064024	0.901	rs930855	ENSG00000267077.1	RP11-127I20.5	4.55	7.34e-06	0.00203	0.24	0.24	Cancer;	chr16:4814178	chr16:4795265~4796532:-
LIHC	cis	rs2072510	0.683	rs2540486	ENSG00000257878.1	RP11-256L6.3	-4.55	7.35e-06	0.00203	-0.21	-0.24	Metabolite levels (small molecules and protein measures);	chr12:96037229	chr12:95996521~96011489:+
LIHC	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	4.55	7.35e-06	0.00203	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	4.55	7.35e-06	0.00203	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
LIHC	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	4.55	7.35e-06	0.00203	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
LIHC	cis	rs8064024	0.783	rs2341986	ENSG00000267077.1	RP11-127I20.5	4.55	7.35e-06	0.00203	0.24	0.24	Cancer;	chr16:4769495	chr16:4795265~4796532:-
LIHC	cis	rs11098499	0.754	rs1980025	ENSG00000260091.1	RP11-33B1.4	4.55	7.35e-06	0.00203	0.17	0.24	Corneal astigmatism;	chr4:119331651	chr4:119409333~119410233:+
LIHC	cis	rs2243480	1	rs1723267	ENSG00000230295.1	RP11-458F8.2	-4.55	7.36e-06	0.00203	-0.25	-0.24	Diabetic kidney disease;	chr7:66008327	chr7:66880708~66882981:+
LIHC	cis	rs3733589	0.59	rs16892419	ENSG00000250413.1	RP11-448G15.1	-4.55	7.36e-06	0.00203	-0.38	-0.24	Renal overload gout;	chr4:10034078	chr4:10006482~10009725:+
LIHC	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	4.55	7.37e-06	0.00203	0.24	0.24	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
LIHC	cis	rs5760092	0.755	rs4585126	ENSG00000228039.3	KB-1125A3.10	-4.55	7.37e-06	0.00203	-0.31	-0.24	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23963780~23964374:+
LIHC	cis	rs7131987	0.903	rs2194520	ENSG00000257176.2	RP11-996F15.2	-4.55	7.37e-06	0.00203	-0.28	-0.24	QT interval;	chr12:29270779	chr12:29280418~29317848:-
LIHC	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-4.55	7.39e-06	0.00204	-0.25	-0.24	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
LIHC	cis	rs1577917	0.958	rs12215232	ENSG00000234155.1	RP11-30P6.6	4.55	7.39e-06	0.00204	0.33	0.24	Response to antipsychotic treatment;	chr6:86075712	chr6:85387219~85390186:-
LIHC	cis	rs2749592	0.513	rs1208708	ENSG00000275858.1	RP11-291L22.8	4.55	7.4e-06	0.00204	0.26	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38450738~38451069:-
LIHC	cis	rs2348418	0.765	rs12368743	ENSG00000247934.4	RP11-967K21.1	-4.55	7.4e-06	0.00204	-0.22	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28163298~28190738:-
LIHC	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-4.55	7.4e-06	0.00204	-0.29	-0.24	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
LIHC	cis	rs2070488	0.813	rs3749387	ENSG00000229589.1	ACVR2B-AS1	4.55	7.4e-06	0.00204	0.27	0.24	Electrocardiographic conduction measures;	chr3:38454702	chr3:38451027~38454820:-
LIHC	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-4.55	7.41e-06	0.00204	-0.23	-0.24	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
LIHC	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	4.55	7.41e-06	0.00204	0.33	0.24	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	4.55	7.41e-06	0.00204	0.33	0.24	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
LIHC	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	4.55	7.41e-06	0.00204	0.33	0.24	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
LIHC	cis	rs3812762	1	rs3812762	ENSG00000254860.4	TMEM9B-AS1	4.55	7.41e-06	0.00204	0.27	0.24	Hypospadias;	chr11:8730093	chr11:8964675~8977527:+
LIHC	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-4.55	7.42e-06	0.00204	-0.28	-0.24	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
LIHC	cis	rs916888	0.61	rs199454	ENSG00000260075.1	NSFP1	-4.55	7.42e-06	0.00204	-0.29	-0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46372855~46487141:+
LIHC	cis	rs7119038	0.629	rs11217000	ENSG00000255239.1	AP002954.6	-4.55	7.43e-06	0.00205	-0.33	-0.24	Sjögren's syndrome;	chr11:118734275	chr11:118688039~118690600:-
LIHC	cis	rs12478296	0.786	rs28802397	ENSG00000261186.2	RP11-341N2.1	-4.55	7.43e-06	0.00205	-0.34	-0.24	Obesity-related traits;	chr2:242107579	chr2:242087351~242088457:-
LIHC	cis	rs2836974	0.568	rs428602	ENSG00000255568.3	BRWD1-AS2	4.55	7.44e-06	0.00205	0.2	0.24	Cognitive function;	chr21:39175078	chr21:39313935~39314962:+
LIHC	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-4.55	7.45e-06	0.00205	-0.24	-0.24	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-4.55	7.45e-06	0.00205	-0.24	-0.24	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
LIHC	cis	rs2834188	0.924	rs2007849	ENSG00000272659.1	AP000295.10	-4.55	7.45e-06	0.00205	-0.35	-0.24	Narcolepsy;	chr21:33308811	chr21:33309491~33310181:+
LIHC	cis	rs2834188	0.924	rs6517160	ENSG00000272659.1	AP000295.10	-4.55	7.45e-06	0.00205	-0.35	-0.24	Narcolepsy;	chr21:33311207	chr21:33309491~33310181:+
LIHC	cis	rs73198271	0.583	rs11781985	ENSG00000253893.2	FAM85B	-4.55	7.46e-06	0.00205	-0.33	-0.24	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8167819~8226614:-
LIHC	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-4.55	7.46e-06	0.00205	-0.25	-0.24	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
LIHC	cis	rs2243480	1	rs781157	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66013324	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs781156	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66014154	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs781149	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66016297	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs451396	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66019087	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs58207111	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66021736	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs1167613	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66022452	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs1715235	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66023407	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs313799	ENSG00000228409.4	CCT6P1	4.55	7.47e-06	0.00206	0.26	0.24	Diabetic kidney disease;	chr7:66029343	chr7:65751142~65763354:+
LIHC	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	4.55	7.47e-06	0.00206	0.37	0.24	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
LIHC	cis	rs116139393	0.536	rs13247186	ENSG00000187953.9	PMS2CL	-4.55	7.47e-06	0.00206	-0.25	-0.24	Alzheimer's disease (APOE e4 interaction);	chr7:6729524	chr7:6710128~6753862:+
LIHC	cis	rs7209700	0.778	rs3851807	ENSG00000228782.6	CTD-2026D20.3	-4.55	7.48e-06	0.00206	-0.26	-0.24	IgG glycosylation;	chr17:47274153	chr17:47450568~47492492:-
LIHC	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-4.55	7.49e-06	0.00206	-0.26	-0.24	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
LIHC	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	4.55	7.49e-06	0.00206	0.28	0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
LIHC	cis	rs10181042	0.514	rs1177288	ENSG00000271889.1	RP11-493E12.1	4.55	7.49e-06	0.00206	0.28	0.24	Crohn's disease;	chr2:61125850	chr2:61151433~61162105:-
LIHC	cis	rs17270561	0.943	rs4478398	ENSG00000272810.1	U91328.22	-4.55	7.49e-06	0.00206	-0.32	-0.24	Iron status biomarkers;	chr6:25694456	chr6:26013241~26013757:+
LIHC	cis	rs12304921	0.625	rs17125369	ENSG00000277201.1	AC087884.1	4.55	7.51e-06	0.00207	0.28	0.24	Type 2 diabetes;	chr12:51102876	chr12:51049921~51050025:+
LIHC	cis	rs1075232	0.655	rs78959602	ENSG00000270055.1	CTD-3092A11.2	-4.55	7.51e-06	0.00207	-0.47	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31268581	chr15:30487963~30490313:+
LIHC	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-4.55	7.52e-06	0.00207	-0.21	-0.24	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
LIHC	cis	rs643506	0.845	rs7114594	ENSG00000254990.4	RP11-108O10.2	4.55	7.52e-06	0.00207	0.26	0.24	Breast cancer;	chr11:111897389	chr11:111768668~111778350:-
LIHC	cis	rs5769765	0.773	rs7410304	ENSG00000278869.1	CITF22-49E9.3	4.55	7.53e-06	0.00207	0.37	0.24	Schizophrenia;	chr22:49923187	chr22:49933198~49934074:-
LIHC	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	4.55	7.53e-06	0.00207	0.25	0.24	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
LIHC	cis	rs6085948	1	rs6054856	ENSG00000228888.1	LINC01428	-4.55	7.54e-06	0.00207	-0.32	-0.24	Interleukin-10 levels;	chr20:7266592	chr20:7146467~7254202:-
LIHC	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-4.55	7.54e-06	0.00207	-0.27	-0.24	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
LIHC	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-4.55	7.55e-06	0.00208	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
LIHC	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-4.55	7.55e-06	0.00208	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-4.55	7.55e-06	0.00208	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
LIHC	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-4.55	7.55e-06	0.00208	-0.27	-0.24	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
LIHC	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-4.55	7.55e-06	0.00208	-0.27	-0.24	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
LIHC	cis	rs4650994	0.816	rs2811303	ENSG00000273384.1	RP5-1098D14.1	-4.55	7.56e-06	0.00208	-0.28	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178626511	chr1:178651706~178652282:+
LIHC	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	4.55	7.56e-06	0.00208	0.31	0.24	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
LIHC	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	4.55	7.56e-06	0.00208	0.19	0.24	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
LIHC	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	4.55	7.56e-06	0.00208	0.17	0.24	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
LIHC	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	4.55	7.57e-06	0.00208	0.22	0.24	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
LIHC	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-4.55	7.57e-06	0.00208	-0.36	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
LIHC	cis	rs2932538	0.961	rs4838960	ENSG00000225075.1	RP11-426L16.3	-4.55	7.57e-06	0.00208	-0.3	-0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112621010	chr1:112693688~112696621:-
LIHC	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-4.55	7.57e-06	0.00208	-0.29	-0.24	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-4.55	7.57e-06	0.00208	-0.29	-0.24	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
LIHC	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	4.55	7.58e-06	0.00208	0.4	0.24	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
LIHC	cis	rs2836974	0.932	rs11910151	ENSG00000255568.3	BRWD1-AS2	4.55	7.58e-06	0.00208	0.27	0.24	Cognitive function;	chr21:39188336	chr21:39313935~39314962:+
LIHC	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-4.55	7.59e-06	0.00209	-0.26	-0.24	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
LIHC	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-4.55	7.59e-06	0.00209	-0.29	-0.24	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
LIHC	cis	rs12887734	0.524	rs4906363	ENSG00000258534.1	CTD-2134A5.4	-4.55	7.59e-06	0.00209	-0.27	-0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103854366~103880111:-
LIHC	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-4.55	7.59e-06	0.00209	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
LIHC	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	4.55	7.61e-06	0.00209	0.29	0.24	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
LIHC	cis	rs2932538	0.961	rs2932534	ENSG00000225075.1	RP11-426L16.3	4.55	7.61e-06	0.00209	0.3	0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112658175	chr1:112693688~112696621:-
LIHC	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-4.55	7.61e-06	0.00209	-0.25	-0.24	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
LIHC	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-4.55	7.62e-06	0.00209	-0.36	-0.24	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
LIHC	cis	rs4662750	0.527	rs10164978	ENSG00000236682.1	AC068282.3	4.55	7.62e-06	0.00209	0.31	0.24	Renal cell carcinoma;	chr2:127627649	chr2:127389130~127400580:+
LIHC	cis	rs2749097	0.825	rs10889436	ENSG00000244256.3	RN7SL130P	-4.54	7.64e-06	0.0021	-0.28	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63658226	chr1:63655743~63656047:+
LIHC	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	4.54	7.64e-06	0.0021	0.27	0.24	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
LIHC	cis	rs7915414	0.951	rs2901783	ENSG00000230338.1	MTND4P19	4.54	7.64e-06	0.0021	0.25	0.24	Clopidogrel active metabolite levels;	chr10:94693342	chr10:94774156~94774633:-
LIHC	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	4.54	7.64e-06	0.0021	0.27	0.24	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
LIHC	cis	rs6600671	0.967	rs4844613	ENSG00000231429.2	RP11-343N15.2	-4.54	7.64e-06	0.0021	-0.27	-0.24	Hip geometry;	chr1:121431913	chr1:121412719~121429274:+
LIHC	cis	rs79349575	0.749	rs519537	ENSG00000248278.1	SUMO2P17	4.54	7.64e-06	0.0021	0.29	0.24	Type 2 diabetes;	chr17:48893778	chr17:48874860~48908983:-
LIHC	cis	rs7809950	0.953	rs1468336	ENSG00000238832.1	snoU109	4.54	7.65e-06	0.0021	0.29	0.24	Coronary artery disease;	chr7:107567805	chr7:107603363~107603507:+
LIHC	cis	rs9425766	0.679	rs4650945	ENSG00000227373.4	RP11-160H22.5	-4.54	7.66e-06	0.0021	-0.29	-0.24	Life satisfaction;	chr1:174114966	chr1:174115300~174160004:-
LIHC	cis	rs2243480	0.831	rs57294491	ENSG00000230295.1	RP11-458F8.2	4.54	7.66e-06	0.0021	0.25	0.24	Diabetic kidney disease;	chr7:66219914	chr7:66880708~66882981:+
LIHC	cis	rs2836974	0.897	rs2836933	ENSG00000255568.3	BRWD1-AS2	4.54	7.66e-06	0.0021	0.27	0.24	Cognitive function;	chr21:39192276	chr21:39313935~39314962:+
LIHC	cis	rs6997458	0.742	rs2307075	ENSG00000253549.4	RP11-317J10.2	4.54	7.66e-06	0.0021	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85475999	chr8:85441851~85464915:-
LIHC	cis	rs16858210	0.874	rs10937153	ENSG00000234371.6	RPSAP31	-4.54	7.67e-06	0.0021	-0.3	-0.24	Menopause (age at onset);	chr3:183845137	chr3:183884924~183888449:+
LIHC	cis	rs7224610	0.57	rs963955	ENSG00000263096.1	RP11-515O17.2	-4.54	7.67e-06	0.0021	-0.31	-0.24	Urate levels;	chr17:55309465	chr17:55271504~55273653:-
LIHC	cis	rs11971779	0.793	rs4728464	ENSG00000273391.1	RP11-634H22.1	-4.54	7.67e-06	0.0021	-0.22	-0.24	Diisocyanate-induced asthma;	chr7:139332924	chr7:139359032~139359566:-
LIHC	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	4.54	7.67e-06	0.00211	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	4.54	7.67e-06	0.00211	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
LIHC	cis	rs783540	0.5	rs7163840	ENSG00000278603.1	RP13-608F4.5	-4.54	7.67e-06	0.00211	-0.31	-0.24	Schizophrenia;	chr15:82729551	chr15:82472203~82472426:+
LIHC	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	4.54	7.68e-06	0.00211	0.26	0.24	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
LIHC	cis	rs748404	0.697	rs574065	ENSG00000166763.7	STRCP1	-4.54	7.68e-06	0.00211	-0.29	-0.24	Lung cancer;	chr15:43258457	chr15:43699488~43718184:-
LIHC	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	4.54	7.68e-06	0.00211	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
LIHC	cis	rs10829156	0.898	rs6482565	ENSG00000240291.1	RP11-499P20.2	4.54	7.68e-06	0.00211	0.37	0.24	Sudden cardiac arrest;	chr10:18611664	chr10:18513115~18545651:-
LIHC	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-4.54	7.68e-06	0.00211	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
LIHC	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-4.54	7.68e-06	0.00211	-0.32	-0.24	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
LIHC	cis	rs6545883	0.525	rs1177274	ENSG00000271889.1	RP11-493E12.1	4.54	7.68e-06	0.00211	0.28	0.24	Tuberculosis;	chr2:61141397	chr2:61151433~61162105:-
LIHC	cis	rs2877649	1	rs8020496	ENSG00000258744.1	RP11-80A15.1	4.54	7.69e-06	0.00211	0.45	0.24	Smooth-surface caries;	chr14:24484544	chr14:24501594~24508688:+
LIHC	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-4.54	7.7e-06	0.00211	-0.24	-0.24	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-4.54	7.7e-06	0.00211	-0.25	-0.24	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
LIHC	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	4.54	7.7e-06	0.00211	0.29	0.24	Height;	chr6:109438349	chr6:109382795~109383666:+
LIHC	cis	rs12478296	0.786	rs72620862	ENSG00000261186.2	RP11-341N2.1	-4.54	7.71e-06	0.00211	-0.34	-0.24	Obesity-related traits;	chr2:242102636	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs66466023	ENSG00000261186.2	RP11-341N2.1	-4.54	7.71e-06	0.00211	-0.34	-0.24	Obesity-related traits;	chr2:242104000	chr2:242087351~242088457:-
LIHC	cis	rs12478296	0.901	rs56318767	ENSG00000261186.2	RP11-341N2.1	-4.54	7.71e-06	0.00211	-0.34	-0.24	Obesity-related traits;	chr2:242104440	chr2:242087351~242088457:-
LIHC	cis	rs1247318	1	rs1247321	ENSG00000243831.1	RP1-81D8.4	4.54	7.71e-06	0.00211	0.34	0.24	Aging;	chr6:160911178	chr6:160666228~160676523:-
LIHC	cis	rs2565722	0.583	rs2465841	ENSG00000243831.1	RP1-81D8.4	4.54	7.71e-06	0.00212	0.32	0.24	Blood protein levels;	chr6:160874122	chr6:160666228~160676523:-
LIHC	cis	rs2565722	0.622	rs1937483	ENSG00000243831.1	RP1-81D8.4	4.54	7.71e-06	0.00212	0.32	0.24	Blood protein levels;	chr6:160874566	chr6:160666228~160676523:-
LIHC	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-4.54	7.72e-06	0.00212	-0.31	-0.24	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
LIHC	cis	rs11637445	0.589	rs7497457	ENSG00000260657.2	RP11-315D16.4	-4.54	7.72e-06	0.00212	-0.34	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr15:67840385	chr15:68267792~68277994:-
LIHC	cis	rs5756813	0.646	rs3788528	ENSG00000233360.4	Z83844.1	-4.54	7.72e-06	0.00212	-0.28	-0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37750426	chr22:37641832~37658377:-
LIHC	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	4.54	7.73e-06	0.00212	0.29	0.24	Height;	chr6:109441033	chr6:109382795~109383666:+
LIHC	cis	rs6997458	0.742	rs1908075	ENSG00000253549.4	RP11-317J10.2	4.54	7.73e-06	0.00212	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434567	chr8:85441851~85464915:-
LIHC	cis	rs6997458	0.742	rs11985733	ENSG00000253549.4	RP11-317J10.2	4.54	7.73e-06	0.00212	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434845	chr8:85441851~85464915:-
LIHC	cis	rs6997458	0.742	rs11985029	ENSG00000253549.4	RP11-317J10.2	4.54	7.73e-06	0.00212	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85434887	chr8:85441851~85464915:-
LIHC	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-4.54	7.73e-06	0.00212	-0.28	-0.24	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
LIHC	cis	rs3916	0.794	rs10431386	ENSG00000277423.1	RP11-173P15.9	-4.54	7.73e-06	0.00212	-0.27	-0.24	Urinary metabolites (H-NMR features);	chr12:120691123	chr12:120703867~120704282:+
LIHC	cis	rs1160985	0.967	rs1038026	ENSG00000214855.8	APOC1P1	-4.54	7.74e-06	0.00212	-0.29	-0.24	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44901805	chr19:44926804~44931386:+
LIHC	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	4.54	7.74e-06	0.00212	0.37	0.24	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	4.54	7.74e-06	0.00212	0.37	0.24	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
LIHC	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-4.54	7.74e-06	0.00212	-0.45	-0.24	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
LIHC	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-4.54	7.75e-06	0.00212	-0.27	-0.24	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
LIHC	cis	rs11089937	0.626	rs5757013	ENSG00000211639.2	IGLV4-60	4.54	7.75e-06	0.00212	0.2	0.24	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22162199~22162681:+
LIHC	cis	rs11089937	0.626	rs5757014	ENSG00000211639.2	IGLV4-60	4.54	7.75e-06	0.00212	0.2	0.24	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22162199~22162681:+
LIHC	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-4.54	7.75e-06	0.00212	-0.31	-0.24	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
LIHC	cis	rs2243480	1	rs437889	ENSG00000230295.1	RP11-458F8.2	-4.54	7.75e-06	0.00213	-0.25	-0.24	Diabetic kidney disease;	chr7:66044247	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs402418	ENSG00000230295.1	RP11-458F8.2	-4.54	7.75e-06	0.00213	-0.25	-0.24	Diabetic kidney disease;	chr7:66044482	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.803	rs423187	ENSG00000230295.1	RP11-458F8.2	-4.54	7.75e-06	0.00213	-0.25	-0.24	Diabetic kidney disease;	chr7:66044512	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs431318	ENSG00000230295.1	RP11-458F8.2	-4.54	7.75e-06	0.00213	-0.25	-0.24	Diabetic kidney disease;	chr7:66046610	chr7:66880708~66882981:+
LIHC	cis	rs61160187	0.583	rs6449503	ENSG00000272308.1	RP11-231G3.1	4.54	7.76e-06	0.00213	0.28	0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60866457~60866935:-
LIHC	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.54	7.77e-06	0.00213	0.29	0.24	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
LIHC	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.54	7.77e-06	0.00213	0.29	0.24	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
LIHC	cis	rs11148252	0.904	rs9526927	ENSG00000278238.1	RP11-245D16.4	-4.54	7.78e-06	0.00213	-0.23	-0.24	Lewy body disease;	chr13:52477492	chr13:52454775~52455331:-
LIHC	cis	rs960902	0.592	rs6753503	ENSG00000213553.4	RPLP0P6	-4.54	7.78e-06	0.00213	-0.19	-0.24	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37509024	chr2:38481851~38482804:+
LIHC	cis	rs75920871	0.61	rs74341458	ENSG00000254851.1	RP11-109L13.1	-4.54	7.79e-06	0.00213	-0.48	-0.24	Subjective well-being;	chr11:116880833	chr11:117135528~117138582:+
LIHC	cis	rs12291225	0.679	rs11369	ENSG00000251991.1	RNU7-49P	4.54	7.8e-06	0.00214	0.26	0.24	Sense of smell;	chr11:14266550	chr11:14478892~14478953:+
LIHC	cis	rs12291225	0.679	rs11238	ENSG00000251991.1	RNU7-49P	-4.54	7.8e-06	0.00214	-0.26	-0.24	Sense of smell;	chr11:14266582	chr11:14478892~14478953:+
LIHC	cis	rs6480314	0.542	rs7078967	ENSG00000233590.1	RP11-153K11.3	-4.54	7.8e-06	0.00214	-0.36	-0.24	Optic nerve measurement (disc area);	chr10:68266564	chr10:68233251~68242379:-
LIHC	cis	rs17270561	0.779	rs12209218	ENSG00000216436.2	HIST1H2APS1	-4.54	7.81e-06	0.00214	-0.37	-0.24	Iron status biomarkers;	chr6:25887548	chr6:25732497~25732827:+
LIHC	cis	rs728616	0.867	rs56271768	ENSG00000225484.5	NUTM2B-AS1	-4.54	7.81e-06	0.00214	-0.5	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:79663088~79826594:-
LIHC	cis	rs763121	0.853	rs138706	ENSG00000273076.1	RP3-508I15.22	4.54	7.82e-06	0.00214	0.27	0.24	Menopause (age at onset);	chr22:38741829	chr22:38743495~38743910:+
LIHC	cis	rs4578769	0.959	rs6507323	ENSG00000265943.1	RP11-739L10.1	-4.54	7.82e-06	0.00214	-0.3	-0.24	Eosinophil percentage of white cells;	chr18:22846715	chr18:22699481~22933764:-
LIHC	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	4.54	7.83e-06	0.00214	0.25	0.24	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
LIHC	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	4.54	7.83e-06	0.00214	0.31	0.24	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
LIHC	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-4.54	7.83e-06	0.00214	-0.23	-0.24	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
LIHC	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	4.54	7.84e-06	0.00215	0.44	0.24	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
LIHC	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-4.54	7.84e-06	0.00215	-0.31	-0.24	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-4.54	7.84e-06	0.00215	-0.31	-0.24	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-4.54	7.84e-06	0.00215	-0.31	-0.24	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
LIHC	cis	rs2735413	0.958	rs1922611	ENSG00000276007.1	RP11-358L22.3	-4.54	7.84e-06	0.00215	-0.27	-0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78019224	chr16:78123243~78124332:+
LIHC	cis	rs2735413	1	rs2735413	ENSG00000276007.1	RP11-358L22.3	-4.54	7.84e-06	0.00215	-0.27	-0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78019746	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.957	rs2735414	ENSG00000276007.1	RP11-358L22.3	-4.54	7.84e-06	0.00215	-0.27	-0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78019761	chr16:78123243~78124332:+
LIHC	cis	rs9890032	0.57	rs8068504	ENSG00000263531.1	RP13-753N3.1	4.54	7.85e-06	0.00215	0.32	0.24	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30863921~30864940:-
LIHC	cis	rs7044106	0.791	rs10818473	ENSG00000238181.2	AHCYP2	-4.54	7.85e-06	0.00215	-0.27	-0.24	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120720673~120721972:+
LIHC	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	4.54	7.85e-06	0.00215	0.26	0.24	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	4.54	7.85e-06	0.00215	0.26	0.24	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	4.54	7.85e-06	0.00215	0.26	0.24	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	4.54	7.85e-06	0.00215	0.26	0.24	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	4.54	7.85e-06	0.00215	0.26	0.24	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
LIHC	cis	rs763121	0.853	rs138709	ENSG00000273076.1	RP3-508I15.22	4.54	7.86e-06	0.00215	0.27	0.24	Menopause (age at onset);	chr22:38743211	chr22:38743495~38743910:+
LIHC	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	4.54	7.86e-06	0.00215	0.27	0.24	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
LIHC	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-4.54	7.86e-06	0.00215	-0.23	-0.24	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-4.54	7.86e-06	0.00215	-0.23	-0.24	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
LIHC	cis	rs929596	0.585	rs2018985	ENSG00000233445.1	RPL17P11	4.54	7.86e-06	0.00215	0.28	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233740214	chr2:233721522~233722065:-
LIHC	cis	rs2337406	1	rs11850709	ENSG00000274576.2	IGHV2-70	-4.54	7.86e-06	0.00215	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106670844	chr14:106770577~106771020:-
LIHC	cis	rs10883723	0.518	rs10786679	ENSG00000236937.2	PTGES3P4	-4.54	7.86e-06	0.00215	-0.33	-0.24	Allergic disease (asthma, hay fever or eczema);	chr10:102555910	chr10:102845595~102845950:+
LIHC	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	4.54	7.87e-06	0.00215	0.18	0.24	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
LIHC	cis	rs79040073	0.53	rs3784630	ENSG00000259531.2	RP11-295H24.3	4.54	7.87e-06	0.00215	0.39	0.24	Lung cancer in ever smokers;	chr15:49322952	chr15:49365124~49366685:-
LIHC	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	4.54	7.88e-06	0.00215	0.17	0.24	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
LIHC	cis	rs11671005	0.735	rs45617039	ENSG00000269473.1	CTD-2619J13.19	4.54	7.88e-06	0.00215	0.4	0.24	Mean platelet volume;	chr19:58439729	chr19:58440448~58445849:+
LIHC	cis	rs1247318	0.806	rs585649	ENSG00000243831.1	RP1-81D8.4	4.54	7.88e-06	0.00216	0.34	0.24	Aging;	chr6:160943752	chr6:160666228~160676523:-
LIHC	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-4.54	7.88e-06	0.00216	-0.35	-0.24	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
LIHC	cis	rs1865760	1	rs2071301	ENSG00000216436.2	HIST1H2APS1	-4.54	7.89e-06	0.00216	-0.26	-0.24	Height;	chr6:25914035	chr6:25732497~25732827:+
LIHC	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	4.54	7.89e-06	0.00216	0.17	0.24	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
LIHC	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	4.54	7.89e-06	0.00216	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
LIHC	cis	rs2932538	0.961	rs10745332	ENSG00000225075.1	RP11-426L16.3	-4.54	7.9e-06	0.00216	-0.31	-0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112646431	chr1:112693688~112696621:-
LIHC	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-4.54	7.9e-06	0.00216	-0.26	-0.24	Asthma;	chr2:102438096	chr2:102438713~102440475:+
LIHC	cis	rs9388451	0.626	rs7748729	ENSG00000237742.5	RP11-624M8.1	-4.54	7.9e-06	0.00216	-0.22	-0.24	Brugada syndrome;	chr6:125756235	chr6:125578558~125749190:-
LIHC	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	4.54	7.91e-06	0.00216	0.27	0.24	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
LIHC	cis	rs875971	0.638	rs6960778	ENSG00000273024.4	INTS4P2	4.54	7.91e-06	0.00216	0.27	0.24	Aortic root size;	chr7:66606610	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs7807930	ENSG00000273024.4	INTS4P2	4.54	7.91e-06	0.00216	0.27	0.24	Aortic root size;	chr7:66622178	chr7:65647864~65715661:+
LIHC	cis	rs61160187	0.51	rs7709716	ENSG00000272308.1	RP11-231G3.1	-4.54	7.91e-06	0.00216	-0.29	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800056	chr5:60866457~60866935:-
LIHC	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-4.54	7.93e-06	0.00217	-0.23	-0.24	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-4.54	7.93e-06	0.00217	-0.23	-0.24	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
LIHC	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-4.54	7.93e-06	0.00217	-0.23	-0.24	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-4.54	7.93e-06	0.00217	-0.23	-0.24	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
LIHC	cis	rs643506	1	rs643506	ENSG00000254990.4	RP11-108O10.2	4.54	7.93e-06	0.00217	0.27	0.24	Breast cancer;	chr11:111765903	chr11:111768668~111778350:-
LIHC	cis	rs643506	1	rs612345	ENSG00000254990.4	RP11-108O10.2	4.54	7.93e-06	0.00217	0.27	0.24	Breast cancer;	chr11:111768398	chr11:111768668~111778350:-
LIHC	cis	rs643506	0.967	rs2850248	ENSG00000254990.4	RP11-108O10.2	4.54	7.93e-06	0.00217	0.27	0.24	Breast cancer;	chr11:111774100	chr11:111768668~111778350:-
LIHC	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-4.54	7.93e-06	0.00217	-0.2	-0.24	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
LIHC	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	4.54	7.93e-06	0.00217	0.37	0.24	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
LIHC	cis	rs9304742	1	rs9304742	ENSG00000213801.4	ZNF816-ZNF321P	4.54	7.93e-06	0.00217	0.23	0.24	Psoriasis;	chr19:52948038	chr19:52927135~52942601:-
LIHC	cis	rs58950470	0.927	rs1193851	ENSG00000265874.1	MIR4489	4.54	7.93e-06	0.00217	0.34	0.24	Schizophrenia;	chr11:65618735	chr11:65649192~65649253:+
LIHC	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	4.54	7.94e-06	0.00217	0.19	0.24	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
LIHC	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	4.54	7.94e-06	0.00217	0.27	0.24	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
LIHC	cis	rs1577917	1	rs12663690	ENSG00000234155.1	RP11-30P6.6	-4.54	7.95e-06	0.00217	-0.31	-0.24	Response to antipsychotic treatment;	chr6:85930444	chr6:85387219~85390186:-
LIHC	cis	rs2929278	0.546	rs686666	ENSG00000166763.7	STRCP1	4.54	7.95e-06	0.00217	0.32	0.24	Schizophrenia;	chr15:43869352	chr15:43699488~43718184:-
LIHC	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	4.54	7.95e-06	0.00217	0.2	0.24	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
LIHC	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-4.54	7.96e-06	0.00217	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-4.54	7.96e-06	0.00217	-0.29	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
LIHC	cis	rs929596	0.597	rs10173355	ENSG00000233445.1	RPL17P11	4.54	7.96e-06	0.00218	0.27	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233688675	chr2:233721522~233722065:-
LIHC	cis	rs61160187	0.51	rs10077663	ENSG00000272308.1	RP11-231G3.1	-4.54	7.97e-06	0.00218	-0.29	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60866457~60866935:-
LIHC	cis	rs3733589	0.744	rs10516197	ENSG00000250413.1	RP11-448G15.1	4.54	7.97e-06	0.00218	0.38	0.24	Renal overload gout;	chr4:10040476	chr4:10006482~10009725:+
LIHC	cis	rs12291225	0.679	rs1043237	ENSG00000251991.1	RNU7-49P	4.54	7.97e-06	0.00218	0.25	0.24	Sense of smell;	chr11:14267507	chr11:14478892~14478953:+
LIHC	cis	rs929596	0.639	rs7571915	ENSG00000233445.1	RPL17P11	4.54	7.98e-06	0.00218	0.26	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233677928	chr2:233721522~233722065:-
LIHC	cis	rs929596	0.556	rs10202865	ENSG00000233445.1	RPL17P11	4.54	7.98e-06	0.00218	0.26	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233679061	chr2:233721522~233722065:-
LIHC	cis	rs11779988	0.545	rs415840	ENSG00000253671.1	RP11-806O11.1	-4.54	7.98e-06	0.00218	-0.32	-0.24	Breast cancer;	chr8:17924625	chr8:17808941~17820868:+
LIHC	cis	rs6997458	0.742	rs10091566	ENSG00000253549.4	RP11-317J10.2	4.53	7.98e-06	0.00218	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85429330	chr8:85441851~85464915:-
LIHC	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-4.53	7.98e-06	0.00218	-0.24	-0.24	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
LIHC	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	4.53	7.99e-06	0.00218	0.27	0.24	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
LIHC	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	4.53	7.99e-06	0.00218	0.38	0.24	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
LIHC	cis	rs901683	0.85	rs73291113	ENSG00000230869.1	CTGLF10P	-4.53	7.99e-06	0.00218	-0.51	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45599617	chr10:45678692~45700532:+
LIHC	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-4.53	7.99e-06	0.00218	-0.32	-0.24	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-4.53	7.99e-06	0.00218	-0.32	-0.24	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-4.53	7.99e-06	0.00218	-0.32	-0.24	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
LIHC	cis	rs7193541	0.965	rs7199068	ENSG00000262904.1	TMPOP2	-4.53	8e-06	0.00218	-0.21	-0.24	Multiple myeloma;	chr16:74664365	chr16:74667506~74668706:+
LIHC	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	4.53	8e-06	0.00218	0.28	0.24	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
LIHC	cis	rs79040073	0.53	rs113085328	ENSG00000259531.2	RP11-295H24.3	4.53	8e-06	0.00218	0.39	0.24	Lung cancer in ever smokers;	chr15:49223704	chr15:49365124~49366685:-
LIHC	cis	rs3733589	1	rs10516195	ENSG00000250413.1	RP11-448G15.1	4.53	8.01e-06	0.00219	0.43	0.24	Renal overload gout;	chr4:10000209	chr4:10006482~10009725:+
LIHC	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-4.53	8.02e-06	0.00219	-0.26	-0.24	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
LIHC	cis	rs9834975	0.935	rs6438724	ENSG00000272758.4	RP11-299J3.8	-4.53	8.02e-06	0.00219	-0.27	-0.24	Diastolic blood pressure;	chr3:122364841	chr3:122416207~122443180:+
LIHC	cis	rs12478296	1	rs55742408	ENSG00000261186.2	RP11-341N2.1	-4.53	8.03e-06	0.00219	-0.34	-0.24	Obesity-related traits;	chr2:242098926	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs12469535	ENSG00000261186.2	RP11-341N2.1	-4.53	8.03e-06	0.00219	-0.34	-0.24	Obesity-related traits;	chr2:242101996	chr2:242087351~242088457:-
LIHC	cis	rs1501911	0.611	rs1875529	ENSG00000248489.1	CTD-2007H13.3	-4.53	8.04e-06	0.00219	-0.36	-0.24	Lung function (FEV1/FVC);	chr5:99033350	chr5:98929171~98995013:+
LIHC	cis	rs2998286	0.643	rs332181	ENSG00000254635.4	WAC-AS1	-4.53	8.04e-06	0.00219	-0.31	-0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621187	chr10:28522652~28532743:-
LIHC	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	4.53	8.05e-06	0.0022	0.3	0.24	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
LIHC	cis	rs2836974	0.602	rs8130854	ENSG00000255568.3	BRWD1-AS2	-4.53	8.05e-06	0.0022	-0.2	-0.24	Cognitive function;	chr21:39335115	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.605	rs2836988	ENSG00000255568.3	BRWD1-AS2	-4.53	8.05e-06	0.0022	-0.2	-0.24	Cognitive function;	chr21:39336049	chr21:39313935~39314962:+
LIHC	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	4.53	8.06e-06	0.0022	0.29	0.24	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	4.53	8.06e-06	0.0022	0.29	0.24	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	4.53	8.06e-06	0.0022	0.29	0.24	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	4.53	8.06e-06	0.0022	0.29	0.24	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	4.53	8.06e-06	0.0022	0.29	0.24	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
LIHC	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	4.53	8.06e-06	0.0022	0.36	0.24	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
LIHC	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	4.53	8.07e-06	0.0022	0.34	0.24	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
LIHC	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	4.53	8.07e-06	0.0022	0.24	0.24	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
LIHC	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	4.53	8.07e-06	0.0022	0.24	0.24	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
LIHC	cis	rs10995505	0.589	rs10822140	ENSG00000232075.1	MRPL35P2	-4.53	8.07e-06	0.0022	-0.26	-0.24	Intelligence (multi-trait analysis);	chr10:63123267	chr10:63634317~63634827:-
LIHC	cis	rs9595908	0.897	rs10083285	ENSG00000212293.1	SNORA16	4.53	8.08e-06	0.0022	0.27	0.24	Body mass index;	chr13:32557205	chr13:32420390~32420516:-
LIHC	cis	rs6433895	0.667	rs35702511	ENSG00000236153.1	AC104076.3	-4.53	8.08e-06	0.0022	-0.33	-0.24	Lymphocyte counts;	chr2:181153379	chr2:180979427~180980090:-
LIHC	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	4.53	8.08e-06	0.0022	0.21	0.24	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
LIHC	cis	rs2932538	0.922	rs61818800	ENSG00000225075.1	RP11-426L16.3	4.53	8.09e-06	0.0022	0.31	0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112605949	chr1:112693688~112696621:-
LIHC	cis	rs11668505	0.965	rs3745752	ENSG00000259108.2	CTD-3098H1.2	4.53	8.09e-06	0.0022	0.3	0.24	Lung function (FVC);	chr19:47836043	chr19:47863483~47865341:-
LIHC	cis	rs1577917	0.916	rs12203358	ENSG00000234155.1	RP11-30P6.6	4.53	8.09e-06	0.0022	0.31	0.24	Response to antipsychotic treatment;	chr6:85893506	chr6:85387219~85390186:-
LIHC	cis	rs875971	0.502	rs11769702	ENSG00000273142.1	RP11-458F8.4	4.53	8.09e-06	0.00221	0.23	0.24	Aortic root size;	chr7:66255529	chr7:66902857~66906297:+
LIHC	cis	rs202072	0.585	rs1512414	ENSG00000215022.6	RP1-257A7.4	-4.53	8.1e-06	0.00221	-0.25	-0.24	HIV-1 viral setpoint;	chr6:13276183	chr6:13264861~13295586:-
LIHC	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	4.53	8.1e-06	0.00221	0.37	0.24	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
LIHC	cis	rs853679	0.723	rs1736904	ENSG00000216901.1	AL022393.7	4.53	8.1e-06	0.00221	0.29	0.24	Depression;	chr6:28251492	chr6:28176188~28176674:+
LIHC	cis	rs7586970	0.556	rs7573488	ENSG00000224063.4	AC007319.1	4.53	8.1e-06	0.00221	0.36	0.24	Coronary heart disease;	chr2:187533353	chr2:187003220~187554663:+
LIHC	cis	rs7586970	0.583	rs6434220	ENSG00000224063.4	AC007319.1	4.53	8.1e-06	0.00221	0.36	0.24	Coronary heart disease;	chr2:187537266	chr2:187003220~187554663:+
LIHC	cis	rs643506	0.715	rs11214031	ENSG00000254990.4	RP11-108O10.2	4.53	8.11e-06	0.00221	0.26	0.24	Breast cancer;	chr11:111895315	chr11:111768668~111778350:-
LIHC	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-4.53	8.12e-06	0.00221	-0.28	-0.24	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
LIHC	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-4.53	8.13e-06	0.00221	-0.21	-0.24	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
LIHC	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-4.53	8.13e-06	0.00221	-0.25	-0.24	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
LIHC	cis	rs2877649	0.793	rs78218947	ENSG00000258744.1	RP11-80A15.1	-4.53	8.13e-06	0.00221	-0.49	-0.24	Smooth-surface caries;	chr14:24437590	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs80093911	ENSG00000258744.1	RP11-80A15.1	-4.53	8.13e-06	0.00221	-0.49	-0.24	Smooth-surface caries;	chr14:24437634	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs77629187	ENSG00000258744.1	RP11-80A15.1	-4.53	8.13e-06	0.00221	-0.49	-0.24	Smooth-surface caries;	chr14:24437749	chr14:24501594~24508688:+
LIHC	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	4.53	8.13e-06	0.00222	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
LIHC	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	4.53	8.13e-06	0.00222	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
LIHC	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-4.53	8.14e-06	0.00222	-0.31	-0.24	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
LIHC	cis	rs74181299	0.684	rs1420183	ENSG00000225889.6	AC074289.1	4.53	8.14e-06	0.00222	0.27	0.24	Pulse pressure;	chr2:65082854	chr2:64143239~64252859:+
LIHC	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	4.53	8.14e-06	0.00222	0.19	0.24	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
LIHC	cis	rs11668505	0.965	rs11667607	ENSG00000259108.2	CTD-3098H1.2	4.53	8.15e-06	0.00222	0.3	0.24	Lung function (FVC);	chr19:47835459	chr19:47863483~47865341:-
LIHC	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	4.53	8.15e-06	0.00222	0.37	0.24	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
LIHC	cis	rs8177253	0.632	rs6782523	ENSG00000244062.1	RP11-404G16.2	4.53	8.15e-06	0.00222	0.24	0.24	Iron status biomarkers;	chr3:133720073	chr3:133760300~133762363:+
LIHC	cis	rs7665090	0.87	rs227361	ENSG00000230069.3	LRRC37A15P	-4.53	8.15e-06	0.00222	-0.22	-0.24	Primary biliary cholangitis;	chr4:102665820	chr4:102727274~102730721:-
LIHC	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-4.53	8.16e-06	0.00222	-0.3	-0.24	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
LIHC	cis	rs2688482	0.512	rs3103954	ENSG00000185485.13	SDHAP1	4.53	8.16e-06	0.00222	0.28	0.24	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195959748~195990318:-
LIHC	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	4.53	8.17e-06	0.00222	0.29	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
LIHC	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	4.53	8.17e-06	0.00222	0.29	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
LIHC	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	4.53	8.17e-06	0.00222	0.29	0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
LIHC	cis	rs887829	0.694	rs6749496	ENSG00000233445.1	RPL17P11	4.53	8.18e-06	0.00223	0.28	0.24	Metabolic traits;Metabolite levels;Cholelithiasis-related traits in sickle cell anemia;Total bilirubin levels in HIV-1 infection;Bilirubin levels;Serum metabolite levels;Blood metabolite levels;	chr2:233715640	chr2:233721522~233722065:-
LIHC	cis	rs16958440	0.867	rs77348110	ENSG00000267724.1	RP11-49K24.8	4.53	8.18e-06	0.00223	0.37	0.24	Sitting height ratio;	chr18:47147796	chr18:47105946~47108062:+
LIHC	cis	rs6997458	0.742	rs955007	ENSG00000253549.4	RP11-317J10.2	4.53	8.18e-06	0.00223	0.25	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85458166	chr8:85441851~85464915:-
LIHC	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	4.53	8.18e-06	0.00223	0.37	0.24	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
LIHC	cis	rs11673344	0.548	rs2058852	ENSG00000226686.6	LINC01535	4.53	8.19e-06	0.00223	0.33	0.24	Obesity-related traits;	chr19:37673701	chr19:37251912~37265535:+
LIHC	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	4.53	8.19e-06	0.00223	0.32	0.24	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	4.53	8.19e-06	0.00223	0.32	0.24	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
LIHC	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	4.53	8.19e-06	0.00223	0.19	0.24	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
LIHC	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	4.53	8.2e-06	0.00223	0.26	0.24	Depression;	chr6:28314871	chr6:28943877~28944537:+
LIHC	cis	rs12887734	0.546	rs12886637	ENSG00000258534.1	CTD-2134A5.4	4.53	8.2e-06	0.00223	0.26	0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103854366~103880111:-
LIHC	cis	rs2834188	0.924	rs2834177	ENSG00000272659.1	AP000295.10	-4.53	8.22e-06	0.00223	-0.34	-0.24	Narcolepsy;	chr21:33304501	chr21:33309491~33310181:+
LIHC	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	4.53	8.22e-06	0.00224	0.27	0.24	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
LIHC	cis	rs2439831	0.702	rs2467402	ENSG00000166763.7	STRCP1	-4.53	8.23e-06	0.00224	-0.36	-0.24	Lung cancer in ever smokers;	chr15:43732292	chr15:43699488~43718184:-
LIHC	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	4.53	8.23e-06	0.00224	0.27	0.24	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
LIHC	cis	rs7208859	0.673	rs423151	ENSG00000266490.1	CTD-2349P21.9	4.53	8.23e-06	0.00224	0.28	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30792372~30792833:+
LIHC	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-4.53	8.24e-06	0.00224	-0.29	-0.24	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
LIHC	cis	rs712039	0.617	rs853201	ENSG00000276054.1	RP11-378E13.3	4.53	8.24e-06	0.00224	0.3	0.24	Tuberculosis;	chr17:37444086	chr17:37386886~37387926:+
LIHC	cis	rs2948294	0.545	rs11776397	ENSG00000253981.4	ALG1L13P	4.53	8.24e-06	0.00224	0.28	0.24	Red cell distribution width;	chr8:8257639	chr8:8236003~8244667:-
LIHC	cis	rs7121538	0.932	rs16930180	ENSG00000251991.1	RNU7-49P	-4.53	8.25e-06	0.00224	-0.35	-0.24	HDL cholesterol;	chr11:14450731	chr11:14478892~14478953:+
LIHC	cis	rs6479891	0.63	rs4545434	ENSG00000232075.1	MRPL35P2	4.53	8.25e-06	0.00224	0.27	0.24	Arthritis (juvenile idiopathic);	chr10:63115985	chr10:63634317~63634827:-
LIHC	cis	rs2439831	0.85	rs7169988	ENSG00000166763.7	STRCP1	4.53	8.25e-06	0.00224	0.37	0.24	Lung cancer in ever smokers;	chr15:43768237	chr15:43699488~43718184:-
LIHC	cis	rs957448	0.503	rs752460	ENSG00000253704.1	RP11-267M23.4	4.53	8.25e-06	0.00224	0.27	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94553722~94569745:+
LIHC	cis	rs12681366	0.801	rs4735293	ENSG00000253704.1	RP11-267M23.4	4.53	8.25e-06	0.00224	0.27	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94553722~94569745:+
LIHC	cis	rs11722228	0.549	rs56146302	ENSG00000261490.1	RP11-448G15.3	4.53	8.26e-06	0.00224	0.31	0.24	Urate levels;Serum uric acid levels;Gout;	chr4:10079428	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.549	rs55848383	ENSG00000261490.1	RP11-448G15.3	4.53	8.26e-06	0.00224	0.31	0.24	Urate levels;Serum uric acid levels;Gout;	chr4:10079493	chr4:10068089~10073019:-
LIHC	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	4.53	8.26e-06	0.00225	0.19	0.24	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
LIHC	cis	rs2439831	0.85	rs3825783	ENSG00000166763.7	STRCP1	4.53	8.27e-06	0.00225	0.37	0.24	Lung cancer in ever smokers;	chr15:43810111	chr15:43699488~43718184:-
LIHC	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	4.53	8.28e-06	0.00225	0.27	0.24	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
LIHC	cis	rs160451	0.966	rs218886	ENSG00000251136.7	RP11-37B2.1	-4.53	8.28e-06	0.00225	-0.21	-0.24	Leprosy;	chr8:89678365	chr8:89609409~89757727:-
LIHC	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-4.53	8.29e-06	0.00225	-0.25	-0.24	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
LIHC	cis	rs160451	0.933	rs218888	ENSG00000251136.7	RP11-37B2.1	-4.53	8.3e-06	0.00225	-0.21	-0.24	Leprosy;	chr8:89679693	chr8:89609409~89757727:-
LIHC	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-4.53	8.3e-06	0.00226	-0.24	-0.24	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
LIHC	cis	rs950027	0.787	rs1153845	ENSG00000259433.2	CTD-2651B20.4	4.53	8.31e-06	0.00226	0.32	0.24	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45330209~45332634:-
LIHC	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	4.53	8.32e-06	0.00226	0.37	0.24	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
LIHC	cis	rs7702057	0.53	rs6890263	ENSG00000271918.1	CTD-2287O16.5	4.53	8.32e-06	0.00226	0.32	0.24	Amyotrophic lateral sclerosis;	chr5:116079739	chr5:116083807~116085416:-
LIHC	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	4.53	8.33e-06	0.00226	0.3	0.24	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
LIHC	cis	rs2333021	0.689	rs2535897	ENSG00000259015.1	RP11-109N23.6	-4.53	8.34e-06	0.00227	-0.28	-0.24	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72967514	chr14:72960595~72961993:+
LIHC	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-4.53	8.34e-06	0.00227	-0.28	-0.24	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
LIHC	cis	rs11079159	0.606	rs4239193	ENSG00000263096.1	RP11-515O17.2	4.52	8.35e-06	0.00227	0.3	0.24	QRS duration;	chr17:55299163	chr17:55271504~55273653:-
LIHC	cis	rs1247318	1	rs1247308	ENSG00000243831.1	RP1-81D8.4	4.52	8.35e-06	0.00227	0.34	0.24	Aging;	chr6:160916170	chr6:160666228~160676523:-
LIHC	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	4.52	8.36e-06	0.00227	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
LIHC	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-4.52	8.36e-06	0.00227	-0.3	-0.24	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-4.52	8.36e-06	0.00227	-0.3	-0.24	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
LIHC	cis	rs734999	0.545	rs6698817	ENSG00000225931.3	RP3-395M20.7	-4.52	8.36e-06	0.00227	-0.25	-0.24	Ulcerative colitis;	chr1:2632744	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.545	rs12752515	ENSG00000225931.3	RP3-395M20.7	-4.52	8.36e-06	0.00227	-0.25	-0.24	Ulcerative colitis;	chr1:2633026	chr1:2566410~2569888:+
LIHC	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	4.52	8.37e-06	0.00227	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
LIHC	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	4.52	8.37e-06	0.00227	0.31	0.24	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
LIHC	cis	rs875971	0.545	rs6460298	ENSG00000273142.1	RP11-458F8.4	4.52	8.37e-06	0.00227	0.23	0.24	Aortic root size;	chr7:66442783	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs35459055	ENSG00000273142.1	RP11-458F8.4	4.52	8.37e-06	0.00227	0.23	0.24	Aortic root size;	chr7:66479399	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs75577046	ENSG00000273142.1	RP11-458F8.4	4.52	8.37e-06	0.00227	0.23	0.24	Aortic root size;	chr7:66493729	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs3735147	ENSG00000273142.1	RP11-458F8.4	4.52	8.37e-06	0.00227	0.23	0.24	Aortic root size;	chr7:66505541	chr7:66902857~66906297:+
LIHC	cis	rs11098499	0.663	rs9996501	ENSG00000260091.1	RP11-33B1.4	-4.52	8.37e-06	0.00227	-0.17	-0.24	Corneal astigmatism;	chr4:119317763	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.697	rs28458294	ENSG00000260091.1	RP11-33B1.4	-4.52	8.37e-06	0.00227	-0.17	-0.24	Corneal astigmatism;	chr4:119317769	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.663	rs28369503	ENSG00000260091.1	RP11-33B1.4	-4.52	8.37e-06	0.00227	-0.17	-0.24	Corneal astigmatism;	chr4:119317770	chr4:119409333~119410233:+
LIHC	cis	rs61160187	0.51	rs6872863	ENSG00000272308.1	RP11-231G3.1	-4.52	8.38e-06	0.00227	-0.28	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792321	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.527	rs6873181	ENSG00000272308.1	RP11-231G3.1	-4.52	8.38e-06	0.00227	-0.28	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792423	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.527	rs6894672	ENSG00000272308.1	RP11-231G3.1	-4.52	8.38e-06	0.00227	-0.28	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792428	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.51	rs4235481	ENSG00000272308.1	RP11-231G3.1	-4.52	8.38e-06	0.00227	-0.28	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797560	chr5:60866457~60866935:-
LIHC	cis	rs7044106	0.791	rs4836830	ENSG00000238181.2	AHCYP2	-4.52	8.38e-06	0.00227	-0.27	-0.24	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120720673~120721972:+
LIHC	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-4.52	8.39e-06	0.00228	-0.31	-0.24	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
LIHC	cis	rs10510102	0.872	rs12246728	ENSG00000226864.1	ATE1-AS1	4.52	8.39e-06	0.00228	0.4	0.24	Breast cancer;	chr10:121966618	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12261371	ENSG00000226864.1	ATE1-AS1	4.52	8.39e-06	0.00228	0.4	0.24	Breast cancer;	chr10:121966686	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.808	rs17102804	ENSG00000226864.1	ATE1-AS1	4.52	8.39e-06	0.00228	0.4	0.24	Breast cancer;	chr10:121968365	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12265369	ENSG00000226864.1	ATE1-AS1	4.52	8.39e-06	0.00228	0.4	0.24	Breast cancer;	chr10:121968455	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs12265542	ENSG00000226864.1	ATE1-AS1	4.52	8.39e-06	0.00228	0.4	0.24	Breast cancer;	chr10:121968740	chr10:121928312~121951965:+
LIHC	cis	rs10510102	0.872	rs11200293	ENSG00000226864.1	ATE1-AS1	4.52	8.39e-06	0.00228	0.4	0.24	Breast cancer;	chr10:121969195	chr10:121928312~121951965:+
LIHC	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-4.52	8.39e-06	0.00228	-0.28	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
LIHC	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	4.52	8.4e-06	0.00228	0.19	0.24	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
LIHC	cis	rs929596	0.606	rs10178992	ENSG00000233445.1	RPL17P11	4.52	8.4e-06	0.00228	0.27	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233749231	chr2:233721522~233722065:-
LIHC	cis	rs929596	0.606	rs7604115	ENSG00000233445.1	RPL17P11	4.52	8.4e-06	0.00228	0.27	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233749470	chr2:233721522~233722065:-
LIHC	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	4.52	8.4e-06	0.00228	0.27	0.24	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
LIHC	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	4.52	8.4e-06	0.00228	0.27	0.24	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
LIHC	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	4.52	8.4e-06	0.00228	0.24	0.24	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
LIHC	cis	rs11668505	1	rs66475008	ENSG00000259108.2	CTD-3098H1.2	4.52	8.4e-06	0.00228	0.3	0.24	Lung function (FVC);	chr19:47846054	chr19:47863483~47865341:-
LIHC	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	4.52	8.41e-06	0.00228	0.37	0.24	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
LIHC	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-4.52	8.41e-06	0.00228	-0.32	-0.24	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
LIHC	cis	rs5758659	0.819	rs134871	ENSG00000227370.1	RP4-669P10.19	-4.52	8.42e-06	0.00228	-0.25	-0.24	Cognitive function;	chr22:42256710	chr22:42132543~42132998:+
LIHC	cis	rs11951515	0.508	rs11958046	ENSG00000248240.1	RP11-159F24.5	-4.52	8.43e-06	0.00228	-0.3	-0.24	Metabolite levels  (X-11787);	chr5:43583287	chr5:43515274~43525310:+
LIHC	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-4.52	8.43e-06	0.00228	-0.3	-0.24	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
LIHC	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	4.52	8.43e-06	0.00229	0.29	0.24	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
LIHC	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	4.52	8.44e-06	0.00229	0.45	0.24	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
LIHC	cis	rs603446	0.967	rs180370	ENSG00000254851.1	RP11-109L13.1	-4.52	8.45e-06	0.00229	-0.29	-0.24	Triglycerides;	chr11:116721649	chr11:117135528~117138582:+
LIHC	cis	rs703842	1	rs2072052	ENSG00000270039.1	RP11-571M6.17	-4.52	8.45e-06	0.00229	-0.34	-0.24	Multiple sclerosis;	chr12:57752936	chr12:57803838~57804415:+
LIHC	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-4.52	8.46e-06	0.00229	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
LIHC	cis	rs2836974	0.533	rs418298	ENSG00000255568.3	BRWD1-AS2	4.52	8.47e-06	0.0023	0.21	0.24	Cognitive function;	chr21:39164728	chr21:39313935~39314962:+
LIHC	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	4.52	8.47e-06	0.0023	0.27	0.24	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
LIHC	cis	rs2243480	1	rs6958420	ENSG00000230295.1	RP11-458F8.2	4.52	8.47e-06	0.0023	0.25	0.24	Diabetic kidney disease;	chr7:66286184	chr7:66880708~66882981:+
LIHC	cis	rs603446	0.967	rs2849179	ENSG00000254851.1	RP11-109L13.1	-4.52	8.48e-06	0.0023	-0.29	-0.24	Triglycerides;	chr11:116750080	chr11:117135528~117138582:+
LIHC	cis	rs7702057	0.53	rs1567331	ENSG00000271918.1	CTD-2287O16.5	4.52	8.48e-06	0.0023	0.32	0.24	Amyotrophic lateral sclerosis;	chr5:116078627	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs1567332	ENSG00000271918.1	CTD-2287O16.5	4.52	8.48e-06	0.0023	0.32	0.24	Amyotrophic lateral sclerosis;	chr5:116078690	chr5:116083807~116085416:-
LIHC	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-4.52	8.49e-06	0.0023	-0.37	-0.24	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
LIHC	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-4.52	8.49e-06	0.0023	-0.37	-0.24	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
LIHC	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-4.52	8.49e-06	0.0023	-0.37	-0.24	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
LIHC	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-4.52	8.49e-06	0.0023	-0.24	-0.24	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
LIHC	cis	rs7829975	0.742	rs12547493	ENSG00000254340.1	RP11-10A14.3	-4.52	8.49e-06	0.0023	-0.26	-0.24	Mood instability;	chr8:8804024	chr8:9141424~9145435:+
LIHC	cis	rs160451	0.933	rs218889	ENSG00000251136.7	RP11-37B2.1	-4.52	8.5e-06	0.0023	-0.21	-0.24	Leprosy;	chr8:89679935	chr8:89609409~89757727:-
LIHC	cis	rs11971779	0.68	rs7808740	ENSG00000273391.1	RP11-634H22.1	4.52	8.51e-06	0.0023	0.21	0.24	Diisocyanate-induced asthma;	chr7:139344209	chr7:139359032~139359566:-
LIHC	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	4.52	8.51e-06	0.0023	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
LIHC	cis	rs1005277	0.579	rs1614236	ENSG00000275858.1	RP11-291L22.8	4.52	8.51e-06	0.0023	0.27	0.24	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38450738~38451069:-
LIHC	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	4.52	8.52e-06	0.0023	0.37	0.24	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	4.52	8.52e-06	0.0023	0.37	0.24	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	4.52	8.52e-06	0.0023	0.37	0.24	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
LIHC	cis	rs651907	0.557	rs3806654	ENSG00000244119.1	PDCL3P4	4.52	8.52e-06	0.00231	0.24	0.24	Colorectal cancer;	chr3:101677685	chr3:101712472~101713191:+
LIHC	cis	rs1577917	1	rs12201741	ENSG00000234155.1	RP11-30P6.6	4.52	8.52e-06	0.00231	0.31	0.24	Response to antipsychotic treatment;	chr6:85892901	chr6:85387219~85390186:-
LIHC	cis	rs1558001	0.811	rs56118176	ENSG00000230196.1	DDX43P3	-4.52	8.52e-06	0.00231	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81847201	chr7:81610884~81611326:-
LIHC	cis	rs3733585	0.781	rs6449183	ENSG00000250413.1	RP11-448G15.1	4.52	8.52e-06	0.00231	0.3	0.24	Cleft plate (environmental tobacco smoke interaction);	chr4:9969067	chr4:10006482~10009725:+
LIHC	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-4.52	8.53e-06	0.00231	-0.22	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
LIHC	cis	rs2834188	0.924	rs2409487	ENSG00000272659.1	AP000295.10	-4.52	8.54e-06	0.00231	-0.35	-0.24	Narcolepsy;	chr21:33312653	chr21:33309491~33310181:+
LIHC	cis	rs6061231	0.597	rs624313	ENSG00000273619.1	RP5-908M14.9	4.52	8.55e-06	0.00231	0.19	0.24	Colorectal cancer;	chr20:62352356	chr20:62386303~62386970:-
LIHC	cis	rs4650994	0.623	rs35854525	ENSG00000273384.1	RP5-1098D14.1	-4.52	8.55e-06	0.00231	-0.3	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178649469	chr1:178651706~178652282:+
LIHC	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	4.52	8.56e-06	0.00232	0.45	0.24	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
LIHC	cis	rs2929278	0.617	rs533143	ENSG00000275601.1	AC011330.13	-4.52	8.56e-06	0.00232	-0.29	-0.24	Schizophrenia;	chr15:43896656	chr15:43642389~43643023:-
LIHC	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-4.52	8.57e-06	0.00232	-0.27	-0.24	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-4.52	8.57e-06	0.00232	-0.27	-0.24	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
LIHC	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-4.52	8.57e-06	0.00232	-0.21	-0.24	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
LIHC	cis	rs11079159	0.565	rs4794563	ENSG00000263096.1	RP11-515O17.2	4.52	8.57e-06	0.00232	0.3	0.24	QRS duration;	chr17:55304524	chr17:55271504~55273653:-
LIHC	cis	rs651907	0.557	rs3864012	ENSG00000244119.1	PDCL3P4	4.52	8.58e-06	0.00232	0.24	0.24	Colorectal cancer;	chr3:101678779	chr3:101712472~101713191:+
LIHC	cis	rs72634501	0.517	rs6600289	ENSG00000182109.6	RP11-69E11.4	-4.52	8.58e-06	0.00232	-0.25	-0.24	HDL cholesterol;	chr1:39148140	chr1:39522280~39546187:-
LIHC	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	4.52	8.59e-06	0.00232	0.27	0.24	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
LIHC	cis	rs2243480	1	rs781150	ENSG00000228409.4	CCT6P1	4.52	8.61e-06	0.00233	0.26	0.24	Diabetic kidney disease;	chr7:66015986	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs313798	ENSG00000228409.4	CCT6P1	4.52	8.61e-06	0.00233	0.26	0.24	Diabetic kidney disease;	chr7:66028044	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35396113	ENSG00000228409.4	CCT6P1	4.52	8.61e-06	0.00233	0.26	0.24	Diabetic kidney disease;	chr7:66030474	chr7:65751142~65763354:+
LIHC	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-4.52	8.62e-06	0.00233	-0.29	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
LIHC	cis	rs11671005	0.693	rs11668821	ENSG00000269473.1	CTD-2619J13.19	4.52	8.62e-06	0.00233	0.39	0.24	Mean platelet volume;	chr19:58444446	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.616	rs12980907	ENSG00000269473.1	CTD-2619J13.19	4.52	8.62e-06	0.00233	0.39	0.24	Mean platelet volume;	chr19:58444959	chr19:58440448~58445849:+
LIHC	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	4.52	8.62e-06	0.00233	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
LIHC	cis	rs643506	0.874	rs634983	ENSG00000254990.4	RP11-108O10.2	4.52	8.62e-06	0.00233	0.25	0.24	Breast cancer;	chr11:111876703	chr11:111768668~111778350:-
LIHC	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	4.52	8.62e-06	0.00233	0.23	0.24	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
LIHC	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-4.52	8.62e-06	0.00233	-0.26	-0.24	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
LIHC	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-4.52	8.62e-06	0.00233	-0.26	-0.24	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
LIHC	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	4.52	8.62e-06	0.00233	0.18	0.24	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
LIHC	cis	rs11971779	0.527	rs1076349	ENSG00000273391.1	RP11-634H22.1	4.52	8.63e-06	0.00233	0.22	0.24	Diisocyanate-induced asthma;	chr7:139441748	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.65	rs4732380	ENSG00000273391.1	RP11-634H22.1	4.52	8.63e-06	0.00233	0.22	0.24	Diisocyanate-induced asthma;	chr7:139442113	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.715	rs6467853	ENSG00000273391.1	RP11-634H22.1	4.52	8.63e-06	0.00233	0.22	0.24	Diisocyanate-induced asthma;	chr7:139442281	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.715	rs6467854	ENSG00000273391.1	RP11-634H22.1	4.52	8.63e-06	0.00233	0.22	0.24	Diisocyanate-induced asthma;	chr7:139442337	chr7:139359032~139359566:-
LIHC	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	4.52	8.63e-06	0.00233	0.37	0.24	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
LIHC	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	4.52	8.63e-06	0.00233	0.24	0.24	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
LIHC	cis	rs7119038	0.774	rs73005423	ENSG00000255239.1	AP002954.6	-4.52	8.64e-06	0.00233	-0.34	-0.24	Sjögren's syndrome;	chr11:118810370	chr11:118688039~118690600:-
LIHC	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	4.52	8.65e-06	0.00234	0.23	0.24	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	4.52	8.65e-06	0.00234	0.23	0.24	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
LIHC	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-4.52	8.66e-06	0.00234	-0.25	-0.24	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-4.52	8.66e-06	0.00234	-0.25	-0.24	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
LIHC	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-4.52	8.67e-06	0.00234	-0.27	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
LIHC	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-4.52	8.67e-06	0.00234	-0.32	-0.24	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
LIHC	cis	rs4356203	0.87	rs214925	ENSG00000272034.1	SNORD14A	-4.52	8.67e-06	0.00234	-0.26	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17213037	chr11:17074654~17074744:-
LIHC	cis	rs2243480	1	rs781157	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66013324	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs781156	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66014154	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs781149	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66016297	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs451396	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66019087	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs58207111	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66021736	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1167613	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66022452	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1715235	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66023407	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs313799	ENSG00000230295.1	RP11-458F8.2	-4.52	8.68e-06	0.00234	-0.25	-0.24	Diabetic kidney disease;	chr7:66029343	chr7:66880708~66882981:+
LIHC	cis	rs4561483	0.801	rs33660	ENSG00000261560.1	RP11-166B2.3	-4.52	8.69e-06	0.00235	-0.27	-0.24	Testicular germ cell tumor;	chr16:11868001	chr16:11881075~11882569:-
LIHC	cis	rs4356203	0.519	rs214083	ENSG00000260196.1	RP1-239B22.5	-4.52	8.69e-06	0.00235	-0.29	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17380649~17383531:+
LIHC	cis	rs57502260	1	rs56312530	ENSG00000212093.1	AP000807.1	4.52	8.69e-06	0.00235	0.3	0.24	Total body bone mineral density (age 45-60);	chr11:68451947	chr11:68506083~68506166:-
LIHC	cis	rs2929278	0.617	rs11070410	ENSG00000275601.1	AC011330.13	4.52	8.7e-06	0.00235	0.29	0.24	Schizophrenia;	chr15:43764847	chr15:43642389~43643023:-
LIHC	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	4.52	8.7e-06	0.00235	0.38	0.24	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
LIHC	cis	rs4650994	0.623	rs2248666	ENSG00000213057.5	C1orf220	-4.52	8.71e-06	0.00235	-0.2	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178651466	chr1:178542752~178548889:+
LIHC	cis	rs2243480	0.522	rs73150635	ENSG00000230295.1	RP11-458F8.2	-4.52	8.71e-06	0.00235	-0.27	-0.24	Diabetic kidney disease;	chr7:66507503	chr7:66880708~66882981:+
LIHC	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-4.52	8.71e-06	0.00235	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
LIHC	cis	rs2976388	0.565	rs2572905	ENSG00000253196.1	RP11-706C16.7	4.52	8.71e-06	0.00235	0.23	0.24	Urinary tract infection frequency;	chr8:142715686	chr8:142763116~142766427:+
LIHC	cis	rs2976388	0.647	rs2572906	ENSG00000253196.1	RP11-706C16.7	4.52	8.71e-06	0.00235	0.23	0.24	Urinary tract infection frequency;	chr8:142716851	chr8:142763116~142766427:+
LIHC	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	4.52	8.71e-06	0.00235	0.26	0.24	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
LIHC	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-4.52	8.72e-06	0.00235	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
LIHC	cis	rs60733400	0.817	rs4648657	ENSG00000225931.3	RP3-395M20.7	-4.52	8.72e-06	0.00235	-0.25	-0.24	Multiple sclerosis;	chr1:2629296	chr1:2566410~2569888:+
LIHC	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-4.52	8.72e-06	0.00235	-0.29	-0.24	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
LIHC	cis	rs17270561	1	rs17270561	ENSG00000216436.2	HIST1H2APS1	4.51	8.73e-06	0.00235	0.36	0.24	Iron status biomarkers;	chr6:25820211	chr6:25732497~25732827:+
LIHC	cis	rs6442522	0.966	rs3856828	ENSG00000249786.6	EAF1-AS1	4.51	8.73e-06	0.00235	0.27	0.24	Uric acid levels;	chr3:15447490	chr3:15436171~15455940:-
LIHC	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	4.51	8.73e-06	0.00235	0.35	0.24	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
LIHC	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-4.51	8.73e-06	0.00235	-0.28	-0.24	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-4.51	8.73e-06	0.00235	-0.28	-0.24	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
LIHC	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	4.51	8.73e-06	0.00236	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
LIHC	cis	rs10510102	0.872	rs12259144	ENSG00000226864.1	ATE1-AS1	4.51	8.75e-06	0.00236	0.4	0.24	Breast cancer;	chr10:121965433	chr10:121928312~121951965:+
LIHC	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	4.51	8.75e-06	0.00236	0.24	0.24	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
LIHC	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	4.51	8.76e-06	0.00236	0.3	0.24	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
LIHC	cis	rs7567389	0.568	rs7568070	ENSG00000236682.1	AC068282.3	-4.51	8.76e-06	0.00236	-0.36	-0.24	Self-rated health;	chr2:127195478	chr2:127389130~127400580:+
LIHC	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-4.51	8.76e-06	0.00236	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-4.51	8.76e-06	0.00236	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
LIHC	cis	rs921968	0.565	rs586194	ENSG00000272555.1	RP11-459I19.1	-4.51	8.77e-06	0.00236	-0.26	-0.24	Mean corpuscular hemoglobin concentration;	chr2:218745710	chr2:218818690~218819144:+
LIHC	cis	rs748404	0.723	rs573169	ENSG00000166763.7	STRCP1	4.51	8.79e-06	0.00237	0.29	0.24	Lung cancer;	chr15:43258383	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs524547	ENSG00000166763.7	STRCP1	4.51	8.79e-06	0.00237	0.29	0.24	Lung cancer;	chr15:43258825	chr15:43699488~43718184:-
LIHC	cis	rs901683	0.85	rs113722818	ENSG00000230869.1	CTGLF10P	-4.51	8.79e-06	0.00237	-0.57	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45597760	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs112184470	ENSG00000230869.1	CTGLF10P	-4.51	8.79e-06	0.00237	-0.57	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45597854	chr10:45678692~45700532:+
LIHC	cis	rs9595908	1	rs7992980	ENSG00000212293.1	SNORA16	4.51	8.79e-06	0.00237	0.27	0.24	Body mass index;	chr13:32607005	chr13:32420390~32420516:-
LIHC	cis	rs17270561	0.887	rs9358870	ENSG00000216436.2	HIST1H2APS1	-4.51	8.81e-06	0.00237	-0.37	-0.24	Iron status biomarkers;	chr6:25718982	chr6:25732497~25732827:+
LIHC	cis	rs1247318	1	rs9364580	ENSG00000243831.1	RP1-81D8.4	4.51	8.81e-06	0.00237	0.34	0.24	Aging;	chr6:160901895	chr6:160666228~160676523:-
LIHC	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-4.51	8.81e-06	0.00237	-0.25	-0.24	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
LIHC	cis	rs4578769	0.788	rs12962334	ENSG00000266850.1	RP11-370A5.1	4.51	8.82e-06	0.00238	0.26	0.24	Eosinophil percentage of white cells;	chr18:22897971	chr18:22723491~22907721:-
LIHC	cis	rs875971	0.571	rs78668714	ENSG00000273142.1	RP11-458F8.4	4.51	8.82e-06	0.00238	0.23	0.24	Aortic root size;	chr7:66474464	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs73150604	ENSG00000273142.1	RP11-458F8.4	4.51	8.82e-06	0.00238	0.23	0.24	Aortic root size;	chr7:66480545	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs7810213	ENSG00000273142.1	RP11-458F8.4	4.51	8.82e-06	0.00238	0.23	0.24	Aortic root size;	chr7:66481592	chr7:66902857~66906297:+
LIHC	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	4.51	8.82e-06	0.00238	0.32	0.24	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
LIHC	cis	rs6565180	0.783	rs9888967	ENSG00000183604.13	SMG1P5	4.51	8.83e-06	0.00238	0.25	0.24	Tonsillectomy;	chr16:30396658	chr16:30267553~30335374:-
LIHC	cis	rs875971	0.545	rs1796219	ENSG00000273142.1	RP11-458F8.4	-4.51	8.83e-06	0.00238	-0.23	-0.24	Aortic root size;	chr7:66645977	chr7:66902857~66906297:+
LIHC	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-4.51	8.83e-06	0.00238	-0.27	-0.24	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
LIHC	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	4.51	8.83e-06	0.00238	0.37	0.24	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
LIHC	cis	rs7893279	0.505	rs12762481	ENSG00000225527.1	RP11-383B4.4	4.51	8.84e-06	0.00238	0.33	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18640251	chr10:18531849~18533336:-
LIHC	cis	rs2735413	0.75	rs67126435	ENSG00000276007.1	RP11-358L22.3	4.51	8.84e-06	0.00238	0.32	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78032540	chr16:78123243~78124332:+
LIHC	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-4.51	8.85e-06	0.00238	-0.39	-0.24	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
LIHC	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	4.51	8.85e-06	0.00238	0.24	0.24	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
LIHC	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-4.51	8.86e-06	0.00238	-0.28	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
LIHC	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	4.51	8.86e-06	0.00239	0.26	0.24	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
LIHC	cis	rs1005277	0.691	rs2474558	ENSG00000275858.1	RP11-291L22.8	-4.51	8.86e-06	0.00239	-0.27	-0.24	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38450738~38451069:-
LIHC	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-4.51	8.87e-06	0.00239	-0.18	-0.24	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
LIHC	cis	rs2243480	1	rs316331	ENSG00000230295.1	RP11-458F8.2	4.51	8.87e-06	0.00239	0.25	0.24	Diabetic kidney disease;	chr7:66139635	chr7:66880708~66882981:+
LIHC	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	4.51	8.87e-06	0.00239	0.28	0.24	Height;	chr6:109384228	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	4.51	8.87e-06	0.00239	0.28	0.24	Height;	chr6:109385087	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	4.51	8.87e-06	0.00239	0.28	0.24	Height;	chr6:109387685	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	4.51	8.87e-06	0.00239	0.28	0.24	Height;	chr6:109388256	chr6:109382795~109383666:+
LIHC	cis	rs929596	0.793	rs2741045	ENSG00000233445.1	RPL17P11	4.51	8.87e-06	0.00239	0.34	0.24	Total bilirubin levels in HIV-1 infection;	chr2:233671494	chr2:233721522~233722065:-
LIHC	cis	rs875971	0.545	rs75840613	ENSG00000273142.1	RP11-458F8.4	4.51	8.88e-06	0.00239	0.23	0.24	Aortic root size;	chr7:66376399	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs73148639	ENSG00000273142.1	RP11-458F8.4	4.51	8.88e-06	0.00239	0.23	0.24	Aortic root size;	chr7:66390342	chr7:66902857~66906297:+
LIHC	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	4.51	8.88e-06	0.00239	0.25	0.24	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
LIHC	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-4.51	8.89e-06	0.00239	-0.42	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
LIHC	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-4.51	8.9e-06	0.00239	-0.22	-0.24	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
LIHC	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-4.51	8.9e-06	0.00239	-0.29	-0.24	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
LIHC	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-4.51	8.9e-06	0.00239	-0.25	-0.24	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
LIHC	cis	rs11779988	0.545	rs398806	ENSG00000253671.1	RP11-806O11.1	-4.51	8.91e-06	0.0024	-0.31	-0.24	Breast cancer;	chr8:17928717	chr8:17808941~17820868:+
LIHC	cis	rs11779988	0.545	rs438873	ENSG00000253671.1	RP11-806O11.1	-4.51	8.91e-06	0.0024	-0.31	-0.24	Breast cancer;	chr8:17929007	chr8:17808941~17820868:+
LIHC	cis	rs901683	0.702	rs113019116	ENSG00000230869.1	CTGLF10P	-4.51	8.91e-06	0.0024	-0.57	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45598491	chr10:45678692~45700532:+
LIHC	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	4.51	8.91e-06	0.0024	0.26	0.24	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
LIHC	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-4.51	8.91e-06	0.0024	-0.29	-0.24	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
LIHC	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-4.51	8.92e-06	0.0024	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-4.51	8.92e-06	0.0024	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
LIHC	cis	rs2274273	0.719	rs17740551	ENSG00000258413.1	RP11-665C16.6	-4.51	8.92e-06	0.0024	-0.3	-0.24	Protein biomarker;	chr14:55284607	chr14:55262767~55272075:-
LIHC	cis	rs17270561	0.779	rs12210620	ENSG00000216436.2	HIST1H2APS1	-4.51	8.93e-06	0.0024	-0.36	-0.24	Iron status biomarkers;	chr6:25884557	chr6:25732497~25732827:+
LIHC	cis	rs4694744	0.576	rs13104260	ENSG00000264696.1	AC108078.1	4.51	8.94e-06	0.0024	0.35	0.24	Bacteremia;	chr4:69482372	chr4:69479331~69479434:+
LIHC	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-4.51	8.95e-06	0.0024	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-4.51	8.95e-06	0.0024	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
LIHC	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	4.51	8.95e-06	0.00241	0.31	0.24	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	4.51	8.95e-06	0.00241	0.31	0.24	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
LIHC	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	4.51	8.95e-06	0.00241	0.31	0.24	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
LIHC	cis	rs2688482	0.512	rs3103953	ENSG00000185485.13	SDHAP1	-4.51	8.95e-06	0.00241	-0.27	-0.24	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195959748~195990318:-
LIHC	cis	rs4578769	0.959	rs9945114	ENSG00000265943.1	RP11-739L10.1	4.51	8.96e-06	0.00241	0.3	0.24	Eosinophil percentage of white cells;	chr18:22884044	chr18:22699481~22933764:-
LIHC	cis	rs2880765	0.545	rs11631739	ENSG00000259630.2	CTD-2262B20.1	-4.51	8.96e-06	0.00241	-0.33	-0.24	Coronary artery disease;	chr15:85469347	chr15:85415228~85415633:+
LIHC	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-4.51	8.96e-06	0.00241	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
LIHC	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-4.51	8.96e-06	0.00241	-0.28	-0.24	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
LIHC	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	4.51	8.96e-06	0.00241	0.29	0.24	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
LIHC	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-4.51	8.97e-06	0.00241	-0.24	-0.24	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
LIHC	cis	rs748404	0.578	rs2584701	ENSG00000205771.5	CATSPER2P1	-4.51	8.97e-06	0.00241	-0.28	-0.24	Lung cancer;	chr15:43392741	chr15:43726918~43747094:-
LIHC	cis	rs3733589	0.59	rs6849736	ENSG00000250413.1	RP11-448G15.1	4.51	8.98e-06	0.00241	0.4	0.24	Renal overload gout;	chr4:9985159	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.59	rs6849962	ENSG00000250413.1	RP11-448G15.1	4.51	8.98e-06	0.00241	0.4	0.24	Renal overload gout;	chr4:9985279	chr4:10006482~10009725:+
LIHC	cis	rs4356203	0.525	rs111416579	ENSG00000272034.1	SNORD14A	-4.51	8.98e-06	0.00241	-0.25	-0.24	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17227461	chr11:17074654~17074744:-
LIHC	cis	rs79040073	0.53	rs73394357	ENSG00000259531.2	RP11-295H24.3	4.51	8.99e-06	0.00241	0.38	0.24	Lung cancer in ever smokers;	chr15:49300314	chr15:49365124~49366685:-
LIHC	cis	rs3812762	0.879	rs10743089	ENSG00000254860.4	TMEM9B-AS1	4.51	8.99e-06	0.00241	0.25	0.24	Hypospadias;	chr11:8766621	chr11:8964675~8977527:+
LIHC	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	4.51	9.01e-06	0.00242	0.24	0.24	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
LIHC	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-4.51	9.01e-06	0.00242	-0.37	-0.24	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
LIHC	cis	rs763121	0.853	rs138704	ENSG00000273076.1	RP3-508I15.22	4.51	9.01e-06	0.00242	0.26	0.24	Menopause (age at onset);	chr22:38737405	chr22:38743495~38743910:+
LIHC	cis	rs950169	0.544	rs12913702	ENSG00000259295.5	CSPG4P12	4.51	9.02e-06	0.00242	0.33	0.24	Schizophrenia;	chr15:84609953	chr15:85191438~85213905:+
LIHC	cis	rs950169	0.509	rs71395455	ENSG00000259295.5	CSPG4P12	4.51	9.02e-06	0.00242	0.33	0.24	Schizophrenia;	chr15:84610573	chr15:85191438~85213905:+
LIHC	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-4.51	9.02e-06	0.00242	-0.36	-0.24	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
LIHC	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	4.51	9.03e-06	0.00242	0.37	0.24	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
LIHC	cis	rs7224610	1	rs7224610	ENSG00000263096.1	RP11-515O17.2	4.51	9.04e-06	0.00243	0.33	0.24	Urate levels;	chr17:55287427	chr17:55271504~55273653:-
LIHC	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	4.51	9.04e-06	0.00243	0.31	0.24	Height;	chr3:53085313	chr3:53064283~53065091:-
LIHC	cis	rs2976388	0.609	rs2585148	ENSG00000253196.1	RP11-706C16.7	4.51	9.04e-06	0.00243	0.23	0.24	Urinary tract infection frequency;	chr8:142714775	chr8:142763116~142766427:+
LIHC	cis	rs921968	0.565	rs6723334	ENSG00000272555.1	RP11-459I19.1	4.51	9.05e-06	0.00243	0.25	0.24	Mean corpuscular hemoglobin concentration;	chr2:218764580	chr2:218818690~218819144:+
LIHC	cis	rs6901152	0.525	rs1424932	ENSG00000217648.1	RP1-95L4.4	-4.51	9.06e-06	0.00243	-0.28	-0.24	Acute lymphoblastic leukemia (childhood);	chr6:143372811	chr6:143342246~143343383:+
LIHC	cis	rs5758511	0.508	rs28715885	ENSG00000237037.8	NDUFA6-AS1	-4.51	9.06e-06	0.00243	-0.45	-0.24	Birth weight;	chr22:42045087	chr22:42090931~42137742:+
LIHC	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-4.51	9.07e-06	0.00243	-0.25	-0.24	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
LIHC	cis	rs2075423	1	rs2075423	ENSG00000274895.1	RP11-478J18.2	4.51	9.07e-06	0.00243	0.27	0.24	Type 2 diabetes;	chr1:213981376	chr1:213983793~213986419:-
LIHC	cis	rs916888	0.738	rs199515	ENSG00000274883.1	Metazoa_SRP	4.51	9.07e-06	0.00243	0.35	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45931806~45932083:+
LIHC	cis	rs3733589	0.59	rs16892449	ENSG00000250413.1	RP11-448G15.1	4.51	9.07e-06	0.00243	0.38	0.24	Renal overload gout;	chr4:10036967	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.744	rs55668232	ENSG00000250413.1	RP11-448G15.1	4.51	9.07e-06	0.00243	0.38	0.24	Renal overload gout;	chr4:10038538	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.744	rs16892474	ENSG00000250413.1	RP11-448G15.1	4.51	9.07e-06	0.00243	0.38	0.24	Renal overload gout;	chr4:10038596	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.744	rs10516196	ENSG00000250413.1	RP11-448G15.1	4.51	9.07e-06	0.00243	0.38	0.24	Renal overload gout;	chr4:10039341	chr4:10006482~10009725:+
LIHC	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	4.51	9.07e-06	0.00243	0.31	0.24	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
LIHC	cis	rs2243480	1	rs313809	ENSG00000230295.1	RP11-458F8.2	-4.51	9.07e-06	0.00243	-0.25	-0.24	Diabetic kidney disease;	chr7:66034996	chr7:66880708~66882981:+
LIHC	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-4.51	9.08e-06	0.00244	-0.28	-0.24	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
LIHC	cis	rs17772222	0.917	rs1950806	ENSG00000258789.1	RP11-507K2.3	-4.51	9.08e-06	0.00244	-0.29	-0.24	Coronary artery calcification;	chr14:88774412	chr14:88551597~88552493:+
LIHC	cis	rs7546	0.504	rs2015319	ENSG00000267077.1	RP11-127I20.5	-4.51	9.08e-06	0.00244	-0.25	-0.24	Cancer;	chr16:4886279	chr16:4795265~4796532:-
LIHC	cis	rs3733589	0.661	rs12511989	ENSG00000250413.1	RP11-448G15.1	4.51	9.08e-06	0.00244	0.42	0.24	Renal overload gout;	chr4:10050034	chr4:10006482~10009725:+
LIHC	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	4.51	9.08e-06	0.00244	0.28	0.24	Height;	chr6:109454855	chr6:109382795~109383666:+
LIHC	cis	rs12571093	0.773	rs7895164	ENSG00000233590.1	RP11-153K11.3	-4.51	9.09e-06	0.00244	-0.35	-0.24	Optic nerve measurement (disc area);	chr10:68225658	chr10:68233251~68242379:-
LIHC	cis	rs2243480	1	rs313813	ENSG00000230295.1	RP11-458F8.2	-4.51	9.09e-06	0.00244	-0.25	-0.24	Diabetic kidney disease;	chr7:66038513	chr7:66880708~66882981:+
LIHC	cis	rs2739330	0.752	rs2330634	ENSG00000206090.4	AP000350.7	4.51	9.09e-06	0.00244	0.28	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23939998~23942798:+
LIHC	cis	rs72675573	0.675	rs1331860	ENSG00000235612.1	RP1-158P9.1	-4.51	9.1e-06	0.00244	-0.31	-0.24	Monocyte count;	chr1:56165771	chr1:56145721~56155224:+
LIHC	cis	rs7412746	0.552	rs4970980	ENSG00000231073.1	RP11-316M1.3	4.51	9.11e-06	0.00244	0.24	0.24	Melanoma;	chr1:150892516	chr1:150973123~150975534:+
LIHC	cis	rs12478296	1	rs56387669	ENSG00000261186.2	RP11-341N2.1	-4.51	9.11e-06	0.00244	-0.34	-0.24	Obesity-related traits;	chr2:242101738	chr2:242087351~242088457:-
LIHC	cis	rs8028182	0.636	rs4486847	ENSG00000260269.4	CTD-2323K18.1	-4.51	9.11e-06	0.00244	-0.3	-0.24	Sudden cardiac arrest;	chr15:75436190	chr15:75527150~75601205:-
LIHC	cis	rs8028182	0.636	rs4886703	ENSG00000260269.4	CTD-2323K18.1	-4.51	9.11e-06	0.00244	-0.3	-0.24	Sudden cardiac arrest;	chr15:75438025	chr15:75527150~75601205:-
LIHC	cis	rs960902	0.713	rs7557408	ENSG00000213553.4	RPLP0P6	-4.5	9.12e-06	0.00245	-0.2	-0.24	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37515158	chr2:38481851~38482804:+
LIHC	cis	rs4218	0.701	rs56375269	ENSG00000277144.1	RP11-59H7.4	-4.5	9.13e-06	0.00245	-0.26	-0.24	Social communication problems;	chr15:59137741	chr15:59115547~59116089:-
LIHC	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	4.5	9.13e-06	0.00245	0.21	0.24	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
LIHC	cis	rs3733589	1	rs35933067	ENSG00000250413.1	RP11-448G15.1	4.5	9.14e-06	0.00245	0.42	0.24	Renal overload gout;	chr4:9998884	chr4:10006482~10009725:+
LIHC	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	4.5	9.15e-06	0.00245	0.33	0.24	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
LIHC	cis	rs9896933	0.778	rs80112422	ENSG00000263063.1	RP11-388C12.1	-4.5	9.16e-06	0.00246	-0.33	-0.24	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82869843	chr17:82713908~82716255:-
LIHC	cis	rs9896933	0.775	rs79299098	ENSG00000263063.1	RP11-388C12.1	-4.5	9.16e-06	0.00246	-0.33	-0.24	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82873068	chr17:82713908~82716255:-
LIHC	cis	rs2836974	0.897	rs2836927	ENSG00000255568.3	BRWD1-AS2	4.5	9.16e-06	0.00246	0.27	0.24	Cognitive function;	chr21:39171290	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.899	rs8127087	ENSG00000255568.3	BRWD1-AS2	4.5	9.16e-06	0.00246	0.27	0.24	Cognitive function;	chr21:39172576	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.897	rs2836932	ENSG00000255568.3	BRWD1-AS2	4.5	9.16e-06	0.00246	0.27	0.24	Cognitive function;	chr21:39174791	chr21:39313935~39314962:+
LIHC	cis	rs16958440	0.867	rs12386076	ENSG00000267724.1	RP11-49K24.8	4.5	9.17e-06	0.00246	0.37	0.24	Sitting height ratio;	chr18:47146969	chr18:47105946~47108062:+
LIHC	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	4.5	9.18e-06	0.00246	0.2	0.24	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
LIHC	cis	rs875971	0.66	rs801193	ENSG00000273024.4	INTS4P2	4.5	9.19e-06	0.00246	0.26	0.24	Aortic root size;	chr7:66565625	chr7:65647864~65715661:+
LIHC	cis	rs4356975	0.697	rs66666893	ENSG00000196472.4	RP13-644M16.4	4.5	9.2e-06	0.00246	0.26	0.24	Obesity-related traits;	chr4:69133393	chr4:69181660~69182372:+
LIHC	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-4.5	9.2e-06	0.00246	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
LIHC	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-4.5	9.2e-06	0.00246	-0.26	-0.24	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
LIHC	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-4.5	9.2e-06	0.00246	-0.24	-0.24	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
LIHC	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
LIHC	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-4.5	9.2e-06	0.00247	-0.25	-0.24	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
LIHC	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-4.5	9.21e-06	0.00247	-0.18	-0.24	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
LIHC	cis	rs7208859	0.673	rs9898858	ENSG00000266490.1	CTD-2349P21.9	4.5	9.21e-06	0.00247	0.3	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs55658077	ENSG00000266490.1	CTD-2349P21.9	4.5	9.21e-06	0.00247	0.3	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9899692	ENSG00000266490.1	CTD-2349P21.9	4.5	9.21e-06	0.00247	0.3	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30792372~30792833:+
LIHC	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	4.5	9.21e-06	0.00247	0.25	0.24	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
LIHC	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	4.5	9.21e-06	0.00247	0.2	0.24	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	4.5	9.21e-06	0.00247	0.2	0.24	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	4.5	9.21e-06	0.00247	0.2	0.24	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
LIHC	cis	rs58785573	0.624	rs2126526	ENSG00000231160.8	KLF3-AS1	-4.5	9.21e-06	0.00247	-0.21	-0.24	Lymphocyte percentage of white cells;	chr4:38617068	chr4:38612701~38664883:-
LIHC	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	4.5	9.21e-06	0.00247	0.3	0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
LIHC	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-4.5	9.22e-06	0.00247	-0.44	-0.24	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
LIHC	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	4.5	9.22e-06	0.00247	0.44	0.24	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
LIHC	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-4.5	9.23e-06	0.00247	-0.32	-0.24	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
LIHC	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-4.5	9.23e-06	0.00247	-0.25	-0.24	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
LIHC	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-4.5	9.24e-06	0.00247	-0.33	-0.24	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
LIHC	cis	rs1061377	0.585	rs3733271	ENSG00000249685.1	RP11-360F5.3	4.5	9.25e-06	0.00248	0.29	0.24	Uric acid levels;	chr4:39047948	chr4:39133913~39135608:+
LIHC	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	4.5	9.25e-06	0.00248	0.2	0.24	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
LIHC	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	4.5	9.26e-06	0.00248	0.18	0.24	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
LIHC	cis	rs6061231	0.571	rs482010	ENSG00000273619.1	RP5-908M14.9	4.5	9.26e-06	0.00248	0.19	0.24	Colorectal cancer;	chr20:62352495	chr20:62386303~62386970:-
LIHC	cis	rs2243480	1	rs1499614	ENSG00000230295.1	RP11-458F8.2	-4.5	9.26e-06	0.00248	-0.25	-0.24	Diabetic kidney disease;	chr7:66265811	chr7:66880708~66882981:+
LIHC	cis	rs3096299	0.838	rs3102384	ENSG00000261118.1	RP11-104N10.1	4.5	9.27e-06	0.00248	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89345253	chr16:89492017~89504460:-
LIHC	cis	rs6802315	0.604	rs9863103	ENSG00000272087.1	RP11-379F4.7	-4.5	9.27e-06	0.00248	-0.27	-0.24	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158693120~158693768:-
LIHC	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-4.5	9.28e-06	0.00248	-0.32	-0.24	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
LIHC	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-4.5	9.28e-06	0.00248	-0.28	-0.24	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
LIHC	cis	rs1061377	0.585	rs12648581	ENSG00000249685.1	RP11-360F5.3	4.5	9.28e-06	0.00248	0.29	0.24	Uric acid levels;	chr4:39054024	chr4:39133913~39135608:+
LIHC	cis	rs10991814	0.557	rs77696699	ENSG00000273381.1	RP11-305L7.7	4.5	9.29e-06	0.00248	0.27	0.24	Neutrophil percentage of granulocytes;	chr9:91235591	chr9:91206175~91210299:-
LIHC	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	4.5	9.29e-06	0.00249	0.3	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
LIHC	cis	rs11671005	0.735	rs56292587	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58407699	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs56290606	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58407953	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.651	rs11878203	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58408683	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11878198	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58408935	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11666716	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58409585	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs34511020	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58409929	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11666303	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58411135	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs34152946	ENSG00000269473.1	CTD-2619J13.19	4.5	9.29e-06	0.00249	0.4	0.24	Mean platelet volume;	chr19:58411896	chr19:58440448~58445849:+
LIHC	cis	rs6802315	0.573	rs7635993	ENSG00000272087.1	RP11-379F4.7	4.5	9.3e-06	0.00249	0.27	0.24	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158693120~158693768:-
LIHC	cis	rs30380	1	rs246454	ENSG00000272109.1	CTD-2260A17.3	-4.5	9.3e-06	0.00249	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96804353~96806105:+
LIHC	cis	rs30380	0.922	rs246453	ENSG00000272109.1	CTD-2260A17.3	-4.5	9.3e-06	0.00249	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96804353~96806105:+
LIHC	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-4.5	9.3e-06	0.00249	-0.27	-0.24	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
LIHC	cis	rs875971	0.545	rs2279757	ENSG00000273142.1	RP11-458F8.4	4.5	9.31e-06	0.00249	0.23	0.24	Aortic root size;	chr7:66363676	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs11766183	ENSG00000273142.1	RP11-458F8.4	4.5	9.31e-06	0.00249	0.23	0.24	Aortic root size;	chr7:66374173	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs1065265	ENSG00000273142.1	RP11-458F8.4	4.5	9.31e-06	0.00249	0.23	0.24	Aortic root size;	chr7:66376216	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs7811204	ENSG00000273142.1	RP11-458F8.4	4.5	9.31e-06	0.00249	0.23	0.24	Aortic root size;	chr7:66387213	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs4718348	ENSG00000273142.1	RP11-458F8.4	4.5	9.32e-06	0.00249	0.23	0.24	Aortic root size;	chr7:66441589	chr7:66902857~66906297:+
LIHC	cis	rs11098499	0.866	rs7665125	ENSG00000260091.1	RP11-33B1.4	-4.5	9.32e-06	0.00249	-0.16	-0.24	Corneal astigmatism;	chr4:119480924	chr4:119409333~119410233:+
LIHC	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	4.5	9.32e-06	0.00249	0.21	0.24	Breast size;	chr12:9220132	chr12:9277235~9313241:+
LIHC	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	4.5	9.32e-06	0.00249	0.37	0.24	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
LIHC	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-4.5	9.33e-06	0.00249	-0.37	-0.24	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
LIHC	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	4.5	9.33e-06	0.0025	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
LIHC	cis	rs1558001	0.87	rs4732409	ENSG00000230196.1	DDX43P3	-4.5	9.35e-06	0.0025	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81808557	chr7:81610884~81611326:-
LIHC	cis	rs1558001	0.87	rs4732410	ENSG00000230196.1	DDX43P3	-4.5	9.35e-06	0.0025	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81808559	chr7:81610884~81611326:-
LIHC	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	4.5	9.35e-06	0.0025	0.44	0.24	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
LIHC	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-4.5	9.36e-06	0.0025	-0.29	-0.24	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
LIHC	cis	rs2243480	1	rs427044	ENSG00000230295.1	RP11-458F8.2	-4.5	9.37e-06	0.0025	-0.24	-0.24	Diabetic kidney disease;	chr7:66043558	chr7:66880708~66882981:+
LIHC	cis	rs7208859	0.573	rs73267873	ENSG00000266490.1	CTD-2349P21.9	4.5	9.37e-06	0.0025	0.29	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.561	rs4085382	ENSG00000266490.1	CTD-2349P21.9	4.5	9.37e-06	0.0025	0.29	0.24	Body mass index;	chr17:30744184	chr17:30792372~30792833:+
LIHC	cis	rs6433895	0.71	rs11692625	ENSG00000236153.1	AC104076.3	-4.5	9.39e-06	0.00251	-0.33	-0.24	Lymphocyte counts;	chr2:181150757	chr2:180979427~180980090:-
LIHC	cis	rs7119038	0.629	rs10892272	ENSG00000255239.1	AP002954.6	-4.5	9.39e-06	0.00251	-0.32	-0.24	Sjögren's syndrome;	chr11:118731998	chr11:118688039~118690600:-
LIHC	cis	rs61160187	0.505	rs4235482	ENSG00000272308.1	RP11-231G3.1	-4.5	9.4e-06	0.00251	-0.28	-0.24	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797785	chr5:60866457~60866935:-
LIHC	cis	rs2243480	1	rs2462569	ENSG00000228409.4	CCT6P1	-4.5	9.4e-06	0.00251	-0.25	-0.24	Diabetic kidney disease;	chr7:66009859	chr7:65751142~65763354:+
LIHC	cis	rs6997458	0.742	rs13269441	ENSG00000253549.4	RP11-317J10.2	4.5	9.4e-06	0.00251	0.26	0.24	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85418406	chr8:85441851~85464915:-
LIHC	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	4.5	9.41e-06	0.00251	0.26	0.24	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
LIHC	cis	rs1005277	0.579	rs1780116	ENSG00000275858.1	RP11-291L22.8	4.5	9.41e-06	0.00251	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38450738~38451069:-
LIHC	cis	rs11098499	0.754	rs9991959	ENSG00000260091.1	RP11-33B1.4	4.5	9.43e-06	0.00252	0.17	0.24	Corneal astigmatism;	chr4:119332618	chr4:119409333~119410233:+
LIHC	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	4.5	9.43e-06	0.00252	0.37	0.24	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
LIHC	cis	rs12478296	0.892	rs60042638	ENSG00000261186.2	RP11-341N2.1	-4.5	9.44e-06	0.00252	-0.34	-0.24	Obesity-related traits;	chr2:242096556	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs12474070	ENSG00000261186.2	RP11-341N2.1	-4.5	9.44e-06	0.00252	-0.34	-0.24	Obesity-related traits;	chr2:242097587	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs56102931	ENSG00000261186.2	RP11-341N2.1	-4.5	9.44e-06	0.00252	-0.34	-0.24	Obesity-related traits;	chr2:242097785	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs55732177	ENSG00000261186.2	RP11-341N2.1	-4.5	9.44e-06	0.00252	-0.34	-0.24	Obesity-related traits;	chr2:242097855	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs55758933	ENSG00000261186.2	RP11-341N2.1	-4.5	9.44e-06	0.00252	-0.34	-0.24	Obesity-related traits;	chr2:242098138	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs55717005	ENSG00000261186.2	RP11-341N2.1	-4.5	9.44e-06	0.00252	-0.34	-0.24	Obesity-related traits;	chr2:242098920	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs55814222	ENSG00000261186.2	RP11-341N2.1	-4.5	9.44e-06	0.00252	-0.34	-0.24	Obesity-related traits;	chr2:242099015	chr2:242087351~242088457:-
LIHC	cis	rs6445975	0.666	rs12489103	ENSG00000272360.1	RP11-359I18.5	4.5	9.45e-06	0.00252	0.31	0.24	Systemic lupus erythematosus;	chr3:58387440	chr3:58490830~58491291:-
LIHC	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	4.5	9.46e-06	0.00252	0.29	0.24	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
LIHC	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	4.5	9.46e-06	0.00253	0.23	0.24	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
LIHC	cis	rs1577917	0.958	rs10944168	ENSG00000234155.1	RP11-30P6.6	4.5	9.47e-06	0.00253	0.31	0.24	Response to antipsychotic treatment;	chr6:85970438	chr6:85387219~85390186:-
LIHC	cis	rs7915414	0.951	rs68157779	ENSG00000230338.1	MTND4P19	4.5	9.48e-06	0.00253	0.25	0.24	Clopidogrel active metabolite levels;	chr10:94672932	chr10:94774156~94774633:-
LIHC	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	4.5	9.48e-06	0.00253	0.24	0.24	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
LIHC	cis	rs417065	0.516	rs7548511	ENSG00000227634.1	RP11-431K24.3	-4.5	9.48e-06	0.00253	-0.28	-0.24	Psoriasis;	chr1:8207453	chr1:8208672~8215210:+
LIHC	cis	rs17270561	0.887	rs12201170	ENSG00000216436.2	HIST1H2APS1	-4.5	9.5e-06	0.00253	-0.37	-0.24	Iron status biomarkers;	chr6:25866019	chr6:25732497~25732827:+
LIHC	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-4.5	9.5e-06	0.00254	-0.25	-0.24	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
LIHC	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	4.5	9.5e-06	0.00254	0.28	0.24	Height;	chr6:109452743	chr6:109382795~109383666:+
LIHC	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	4.5	9.5e-06	0.00254	0.24	0.24	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
LIHC	cis	rs5756813	0.811	rs4396807	ENSG00000233360.4	Z83844.1	4.5	9.51e-06	0.00254	0.29	0.24	Optic cup area;Vertical cup-disc ratio;	chr22:37742372	chr22:37641832~37658377:-
LIHC	cis	rs11971779	0.68	rs10274480	ENSG00000273391.1	RP11-634H22.1	4.5	9.51e-06	0.00254	0.21	0.24	Diisocyanate-induced asthma;	chr7:139367682	chr7:139359032~139359566:-
LIHC	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-4.5	9.51e-06	0.00254	-0.26	-0.24	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
LIHC	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-4.5	9.51e-06	0.00254	-0.26	-0.24	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
LIHC	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	4.5	9.52e-06	0.00254	0.24	0.24	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
LIHC	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-4.5	9.53e-06	0.00254	-0.25	-0.24	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
LIHC	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-4.5	9.53e-06	0.00254	-0.29	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
LIHC	cis	rs11637445	0.603	rs1478941	ENSG00000260657.2	RP11-315D16.4	-4.49	9.56e-06	0.00255	-0.33	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr15:67834803	chr15:68267792~68277994:-
LIHC	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	4.49	9.57e-06	0.00255	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
LIHC	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-4.49	9.57e-06	0.00255	-0.21	-0.24	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
LIHC	cis	rs2739330	0.796	rs5760097	ENSG00000206090.4	AP000350.7	4.49	9.59e-06	0.00256	0.28	0.24	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23939998~23942798:+
LIHC	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	4.49	9.6e-06	0.00256	0.21	0.24	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
LIHC	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-4.49	9.61e-06	0.00256	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
LIHC	cis	rs3733589	1	rs16891923	ENSG00000250413.1	RP11-448G15.1	4.49	9.61e-06	0.00256	0.43	0.24	Renal overload gout;	chr4:9995037	chr4:10006482~10009725:+
LIHC	cis	rs643506	1	rs647080	ENSG00000254990.4	RP11-108O10.2	4.49	9.61e-06	0.00256	0.26	0.24	Breast cancer;	chr11:111738450	chr11:111768668~111778350:-
LIHC	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-4.49	9.62e-06	0.00256	-0.3	-0.24	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
LIHC	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	4.49	9.62e-06	0.00256	0.26	0.24	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
LIHC	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-4.49	9.62e-06	0.00256	-0.29	-0.24	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
LIHC	cis	rs11098499	0.863	rs6534139	ENSG00000260091.1	RP11-33B1.4	4.49	9.62e-06	0.00257	0.17	0.24	Corneal astigmatism;	chr4:119528301	chr4:119409333~119410233:+
LIHC	cis	rs11668505	0.965	rs12985683	ENSG00000259108.2	CTD-3098H1.2	4.49	9.62e-06	0.00257	0.3	0.24	Lung function (FVC);	chr19:47836597	chr19:47863483~47865341:-
LIHC	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-4.49	9.62e-06	0.00257	-0.25	-0.24	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
LIHC	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-4.49	9.62e-06	0.00257	-0.25	-0.24	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
LIHC	cis	rs11971779	0.793	rs11772447	ENSG00000273391.1	RP11-634H22.1	4.49	9.63e-06	0.00257	0.22	0.24	Diisocyanate-induced asthma;	chr7:139348843	chr7:139359032~139359566:-
LIHC	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	4.49	9.64e-06	0.00257	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
LIHC	cis	rs2439831	0.717	rs28495368	ENSG00000166763.7	STRCP1	4.49	9.64e-06	0.00257	0.37	0.24	Lung cancer in ever smokers;	chr15:43603444	chr15:43699488~43718184:-
LIHC	cis	rs2243480	1	rs313807	ENSG00000228409.4	CCT6P1	4.49	9.64e-06	0.00257	0.25	0.24	Diabetic kidney disease;	chr7:66034494	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs313808	ENSG00000228409.4	CCT6P1	4.49	9.64e-06	0.00257	0.25	0.24	Diabetic kidney disease;	chr7:66034886	chr7:65751142~65763354:+
LIHC	cis	rs28475163	0.958	rs7395116	ENSG00000251661.3	RP11-326C3.11	4.49	9.65e-06	0.00257	0.32	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:324880	chr11:318640~325631:+
LIHC	cis	rs763512	0.504	rs58201617	ENSG00000276054.1	RP11-378E13.3	4.49	9.67e-06	0.00257	0.29	0.24	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37505345	chr17:37386886~37387926:+
LIHC	cis	rs2072510	0.932	rs10859999	ENSG00000257715.1	RP11-256L6.2	4.49	9.67e-06	0.00258	0.24	0.24	Metabolite levels (small molecules and protein measures);	chr12:95997556	chr12:96025323~96027971:+
LIHC	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	4.49	9.68e-06	0.00258	0.27	0.24	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
LIHC	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	4.49	9.68e-06	0.00258	0.21	0.24	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
LIHC	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-4.49	9.68e-06	0.00258	-0.32	-0.24	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
LIHC	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	4.49	9.68e-06	0.00258	0.28	0.24	Height;	chr6:109449796	chr6:109382795~109383666:+
LIHC	cis	rs2032366	0.63	rs7235404	ENSG00000267279.1	RP11-879F14.2	4.49	9.69e-06	0.00258	0.29	0.24	Obesity-related traits;	chr18:61628753	chr18:61585746~61606916:-
LIHC	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-4.49	9.69e-06	0.00258	-0.28	-0.24	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
LIHC	cis	rs72675573	0.821	rs12563043	ENSG00000235612.1	RP1-158P9.1	-4.49	9.71e-06	0.00258	-0.32	-0.24	Monocyte count;	chr1:56107650	chr1:56145721~56155224:+
LIHC	cis	rs7809950	0.906	rs2395907	ENSG00000238832.1	snoU109	4.49	9.71e-06	0.00258	0.29	0.24	Coronary artery disease;	chr7:107612859	chr7:107603363~107603507:+
LIHC	cis	rs11722228	0.549	rs73212828	ENSG00000261490.1	RP11-448G15.3	4.49	9.72e-06	0.00259	0.31	0.24	Urate levels;Serum uric acid levels;Gout;	chr4:10077132	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.549	rs73212830	ENSG00000261490.1	RP11-448G15.3	4.49	9.72e-06	0.00259	0.31	0.24	Urate levels;Serum uric acid levels;Gout;	chr4:10077135	chr4:10068089~10073019:-
LIHC	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	4.49	9.72e-06	0.00259	0.31	0.24	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
LIHC	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	4.49	9.72e-06	0.00259	0.3	0.24	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
LIHC	cis	rs3733589	0.59	rs6822023	ENSG00000250413.1	RP11-448G15.1	4.49	9.72e-06	0.00259	0.38	0.24	Renal overload gout;	chr4:10050970	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.59	rs6837659	ENSG00000250413.1	RP11-448G15.1	4.49	9.72e-06	0.00259	0.38	0.24	Renal overload gout;	chr4:10050986	chr4:10006482~10009725:+
LIHC	cis	rs7044106	0.791	rs4837793	ENSG00000238181.2	AHCYP2	-4.49	9.73e-06	0.00259	-0.27	-0.24	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120720673~120721972:+
LIHC	cis	rs7809950	1	rs2520265	ENSG00000238832.1	snoU109	-4.49	9.73e-06	0.00259	-0.29	-0.24	Coronary artery disease;	chr7:107540786	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2712191	ENSG00000238832.1	snoU109	-4.49	9.73e-06	0.00259	-0.29	-0.24	Coronary artery disease;	chr7:107542279	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs10267907	ENSG00000238832.1	snoU109	-4.49	9.73e-06	0.00259	-0.29	-0.24	Coronary artery disease;	chr7:107544021	chr7:107603363~107603507:+
LIHC	cis	rs2243480	1	rs778729	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66359432	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs778687	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66370832	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs778679	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66375924	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs778704	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66398480	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs778693	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66407358	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs778691	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66408105	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs13235972	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66418618	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34192067	ENSG00000230295.1	RP11-458F8.2	-4.49	9.74e-06	0.00259	-0.25	-0.24	Diabetic kidney disease;	chr7:66422670	chr7:66880708~66882981:+
LIHC	cis	rs4650994	0.789	rs2811300	ENSG00000273384.1	RP5-1098D14.1	-4.49	9.75e-06	0.00259	-0.28	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178621259	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.816	rs1074896	ENSG00000273384.1	RP5-1098D14.1	-4.49	9.75e-06	0.00259	-0.28	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178622055	chr1:178651706~178652282:+
LIHC	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	4.49	9.75e-06	0.00259	0.24	0.24	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
LIHC	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	4.49	9.75e-06	0.00259	0.26	0.24	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	4.49	9.75e-06	0.00259	0.26	0.24	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	4.49	9.76e-06	0.00259	0.27	0.24	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	4.49	9.76e-06	0.00259	0.27	0.24	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
LIHC	cis	rs875971	0.638	rs10249404	ENSG00000273024.4	INTS4P2	4.49	9.76e-06	0.0026	0.26	0.24	Aortic root size;	chr7:66581737	chr7:65647864~65715661:+
LIHC	cis	rs17818399	0.547	rs12997164	ENSG00000239332.4	LINC01119	-4.49	9.76e-06	0.0026	-0.33	-0.24	Height;	chr2:46531607	chr2:46816697~46859007:+
LIHC	cis	rs10129255	0.5	rs7159033	ENSG00000223648.3	IGHV3-64	4.49	9.77e-06	0.0026	0.17	0.24	Kawasaki disease;	chr14:106701709	chr14:106643132~106658258:-
LIHC	cis	rs12478296	1	rs56136197	ENSG00000261186.2	RP11-341N2.1	-4.49	9.77e-06	0.0026	-0.34	-0.24	Obesity-related traits;	chr2:242101726	chr2:242087351~242088457:-
LIHC	cis	rs9595908	0.9	rs731413	ENSG00000212293.1	SNORA16	4.49	9.77e-06	0.0026	0.27	0.24	Body mass index;	chr13:32601519	chr13:32420390~32420516:-
LIHC	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-4.49	9.77e-06	0.0026	-0.21	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
LIHC	cis	rs7734985	0.772	rs10045777	ENSG00000250551.1	RP11-254I22.1	-4.49	9.77e-06	0.0026	-0.3	-0.24	IgG glycosylation;	chr5:96096049	chr5:96050115~96215519:+
LIHC	cis	rs7637701	0.773	rs9859058	ENSG00000243926.1	TIPARP-AS1	4.49	9.77e-06	0.0026	0.21	0.24	Breast cancer;	chr3:156795028	chr3:156671862~156674378:-
LIHC	cis	rs17270561	0.887	rs717551	ENSG00000216436.2	HIST1H2APS1	-4.49	9.77e-06	0.0026	-0.37	-0.24	Iron status biomarkers;	chr6:25855396	chr6:25732497~25732827:+
LIHC	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-4.49	9.79e-06	0.0026	-0.3	-0.24	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
LIHC	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	4.49	9.8e-06	0.0026	0.2	0.24	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
LIHC	cis	rs12701220	0.894	rs8591	ENSG00000229043.2	AC091729.9	-4.49	9.8e-06	0.00261	-0.33	-0.24	Bronchopulmonary dysplasia;	chr7:997163	chr7:1160374~1165267:+
LIHC	cis	rs1729407	0.625	rs2727789	ENSG00000236267.1	AP006216.5	4.49	9.82e-06	0.00261	0.22	0.24	Apolipoprotein A-IV levels;	chr11:116826171	chr11:116813204~116814003:-
LIHC	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	4.49	9.82e-06	0.00261	0.27	0.24	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
LIHC	cis	rs11064881	1	rs11064881	ENSG00000278344.1	RP11-18C24.8	4.49	9.82e-06	0.00261	0.65	0.24	Inflammatory bowel disease;Ulcerative colitis;	chr12:119709120	chr12:120500735~120501090:-
LIHC	cis	rs7193541	0.965	rs7199068	ENSG00000261079.1	RP11-252A24.3	4.49	9.83e-06	0.00261	0.26	0.24	Multiple myeloma;	chr16:74664365	chr16:74367462~74369826:+
LIHC	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	4.49	9.83e-06	0.00261	0.28	0.24	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
LIHC	cis	rs919433	0.927	rs1429412	ENSG00000231621.1	AC013264.2	4.49	9.83e-06	0.00261	0.22	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197197991~197199273:+
LIHC	cis	rs919433	0.927	rs3843857	ENSG00000231621.1	AC013264.2	4.49	9.83e-06	0.00261	0.22	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197331241	chr2:197197991~197199273:+
LIHC	cis	rs6745190	0.557	rs34504038	ENSG00000236153.1	AC104076.3	-4.49	9.83e-06	0.00261	-0.33	-0.24	White blood cell count;	chr2:181128227	chr2:180979427~180980090:-
LIHC	cis	rs2243480	1	rs7804223	ENSG00000230295.1	RP11-458F8.2	4.49	9.85e-06	0.00262	0.25	0.24	Diabetic kidney disease;	chr7:66199572	chr7:66880708~66882981:+
LIHC	cis	rs2932538	0.922	rs12125361	ENSG00000225075.1	RP11-426L16.3	4.49	9.85e-06	0.00262	0.3	0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112602157	chr1:112693688~112696621:-
LIHC	cis	rs6433895	0.677	rs11688120	ENSG00000236153.1	AC104076.3	-4.49	9.87e-06	0.00262	-0.33	-0.24	Lymphocyte counts;	chr2:181133223	chr2:180979427~180980090:-
LIHC	cis	rs6433895	0.677	rs35725888	ENSG00000236153.1	AC104076.3	-4.49	9.87e-06	0.00262	-0.33	-0.24	Lymphocyte counts;	chr2:181133900	chr2:180979427~180980090:-
LIHC	cis	rs6433895	0.677	rs35076700	ENSG00000236153.1	AC104076.3	-4.49	9.87e-06	0.00262	-0.33	-0.24	Lymphocyte counts;	chr2:181134597	chr2:180979427~180980090:-
LIHC	cis	rs6433895	0.677	rs72887083	ENSG00000236153.1	AC104076.3	-4.49	9.87e-06	0.00262	-0.33	-0.24	Lymphocyte counts;	chr2:181134803	chr2:180979427~180980090:-
LIHC	cis	rs9525927	0.57	rs9533797	ENSG00000230731.2	RP11-478K15.6	4.49	9.87e-06	0.00262	0.27	0.24	Dupuytren's disease;	chr13:44225232	chr13:44234118~44243192:-
LIHC	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-4.49	9.88e-06	0.00262	-0.26	-0.24	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
LIHC	cis	rs11089937	0.626	rs5757011	ENSG00000211639.2	IGLV4-60	4.49	9.88e-06	0.00262	0.2	0.24	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22162199~22162681:+
LIHC	cis	rs9595908	0.931	rs55645971	ENSG00000212293.1	SNORA16	4.49	9.88e-06	0.00262	0.27	0.24	Body mass index;	chr13:32615452	chr13:32420390~32420516:-
LIHC	cis	rs7615952	0.512	rs2979336	ENSG00000171084.14	FAM86JP	4.49	9.89e-06	0.00263	0.36	0.24	Blood pressure (smoking interaction);	chr3:125638626	chr3:125916620~125930024:+
LIHC	cis	rs2439831	0.681	rs7168940	ENSG00000166763.7	STRCP1	4.49	9.89e-06	0.00263	0.33	0.24	Lung cancer in ever smokers;	chr15:43341136	chr15:43699488~43718184:-
LIHC	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-4.49	9.89e-06	0.00263	-0.28	-0.24	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
LIHC	cis	rs3858145	0.506	rs10762224	ENSG00000233590.1	RP11-153K11.3	4.49	9.89e-06	0.00263	0.31	0.24	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68326556	chr10:68233251~68242379:-
LIHC	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	4.49	9.89e-06	0.00263	0.24	0.24	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
LIHC	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	4.49	9.9e-06	0.00263	0.3	0.24	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
LIHC	cis	rs11098499	0.863	rs1010740	ENSG00000260091.1	RP11-33B1.4	4.49	9.9e-06	0.00263	0.17	0.24	Corneal astigmatism;	chr4:119542254	chr4:119409333~119410233:+
LIHC	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-4.49	9.9e-06	0.00263	-0.27	-0.24	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
LIHC	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	4.49	9.9e-06	0.00263	0.29	0.24	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
LIHC	cis	rs8028182	0.636	rs7166737	ENSG00000260269.4	CTD-2323K18.1	-4.49	9.9e-06	0.00263	-0.3	-0.24	Sudden cardiac arrest;	chr15:75390172	chr15:75527150~75601205:-
LIHC	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	4.49	9.91e-06	0.00263	0.37	0.24	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
LIHC	cis	rs11098499	0.863	rs1383532	ENSG00000260091.1	RP11-33B1.4	4.49	9.92e-06	0.00263	0.17	0.24	Corneal astigmatism;	chr4:119513249	chr4:119409333~119410233:+
LIHC	cis	rs2243480	0.901	rs34807232	ENSG00000230295.1	RP11-458F8.2	-4.49	9.92e-06	0.00263	-0.25	-0.24	Diabetic kidney disease;	chr7:66500146	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs35823062	ENSG00000230295.1	RP11-458F8.2	-4.49	9.92e-06	0.00263	-0.25	-0.24	Diabetic kidney disease;	chr7:66500834	chr7:66880708~66882981:+
LIHC	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	4.49	9.92e-06	0.00263	0.33	0.24	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
LIHC	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-4.49	9.92e-06	0.00263	-0.19	-0.24	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
LIHC	cis	rs9595908	0.897	rs12429688	ENSG00000212293.1	SNORA16	4.49	9.92e-06	0.00263	0.28	0.24	Body mass index;	chr13:32572075	chr13:32420390~32420516:-
LIHC	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	4.49	9.95e-06	0.00264	0.45	0.24	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	4.49	9.95e-06	0.00264	0.45	0.24	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
LIHC	cis	rs7615952	0.605	rs11708269	ENSG00000171084.14	FAM86JP	4.49	9.95e-06	0.00264	0.56	0.24	Blood pressure (smoking interaction);	chr3:125613306	chr3:125916620~125930024:+
LIHC	cis	rs7412746	0.611	rs1889741	ENSG00000231073.1	RP11-316M1.3	4.49	9.95e-06	0.00264	0.23	0.24	Melanoma;	chr1:150896569	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.611	rs66847267	ENSG00000231073.1	RP11-316M1.3	4.49	9.95e-06	0.00264	0.23	0.24	Melanoma;	chr1:150902697	chr1:150973123~150975534:+
LIHC	cis	rs11098499	0.954	rs28572238	ENSG00000260091.1	RP11-33B1.4	-4.49	9.95e-06	0.00264	-0.17	-0.24	Corneal astigmatism;	chr4:119395531	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs28714195	ENSG00000260091.1	RP11-33B1.4	-4.49	9.95e-06	0.00264	-0.17	-0.24	Corneal astigmatism;	chr4:119395795	chr4:119409333~119410233:+
LIHC	cis	rs4965006	0.915	rs7969545	ENSG00000273568.1	RP11-417L19.6	4.49	9.96e-06	0.00264	0.3	0.24	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934612	chr12:131934642~131934928:+
LIHC	cis	rs1865760	0.516	rs9379818	ENSG00000216436.2	HIST1H2APS1	-4.49	9.96e-06	0.00264	-0.27	-0.24	Height;	chr6:26022978	chr6:25732497~25732827:+
LIHC	cis	rs5769765	0.72	rs138820	ENSG00000278869.1	CITF22-49E9.3	4.48	9.97e-06	0.00265	0.33	0.24	Schizophrenia;	chr22:49770430	chr22:49933198~49934074:-
LIHC	cis	rs2932538	0.961	rs6537746	ENSG00000225075.1	RP11-426L16.3	-4.48	9.97e-06	0.00265	-0.3	-0.24	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112620907	chr1:112693688~112696621:-
LIHC	cis	rs9675120	0.781	rs7212152	ENSG00000262006.1	RP11-700H6.4	-4.48	9.98e-06	0.00265	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr17:50838870	chr17:50909637~50910232:-
LIHC	cis	rs9675120	0.672	rs7225619	ENSG00000262006.1	RP11-700H6.4	-4.48	9.98e-06	0.00265	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr17:50838889	chr17:50909637~50910232:-
LIHC	cis	rs3733589	1	rs34644460	ENSG00000250413.1	RP11-448G15.1	4.48	9.98e-06	0.00265	0.42	0.24	Renal overload gout;	chr4:10016015	chr4:10006482~10009725:+
LIHC	cis	rs3733589	1	rs35271694	ENSG00000250413.1	RP11-448G15.1	4.48	9.98e-06	0.00265	0.42	0.24	Renal overload gout;	chr4:10016214	chr4:10006482~10009725:+
LIHC	cis	rs875971	0.545	rs6969224	ENSG00000273142.1	RP11-458F8.4	4.48	9.98e-06	0.00265	0.23	0.24	Aortic root size;	chr7:66370011	chr7:66902857~66906297:+
LIHC	cis	rs2337406	1	rs11161002	ENSG00000274576.2	IGHV2-70	-4.48	9.99e-06	0.00265	-0.27	-0.24	Alzheimer's disease (late onset);	chr14:106702202	chr14:106770577~106771020:-
LIHC	cis	rs9527	0.545	rs35756290	ENSG00000236937.2	PTGES3P4	4.48	1e-05	0.00265	0.36	0.24	Arsenic metabolism;	chr10:102825815	chr10:102845595~102845950:+
LIHC	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-4.48	1e-05	0.00265	-0.46	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
LIHC	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-4.48	1e-05	0.00265	-0.46	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
LIHC	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-4.48	1e-05	0.00265	-0.28	-0.24	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
LIHC	cis	rs6480314	0.831	rs17538164	ENSG00000233590.1	RP11-153K11.3	4.48	1e-05	0.00265	0.35	0.24	Optic nerve measurement (disc area);	chr10:68215920	chr10:68233251~68242379:-
LIHC	cis	rs901683	0.702	rs78034568	ENSG00000230869.1	CTGLF10P	-4.48	1e-05	0.00265	-0.53	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45654132	chr10:45678692~45700532:+
LIHC	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	4.48	1e-05	0.00265	0.35	0.24	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
LIHC	cis	rs9388451	0.626	rs3799708	ENSG00000237742.5	RP11-624M8.1	-4.48	1e-05	0.00265	-0.22	-0.24	Brugada syndrome;	chr6:125757384	chr6:125578558~125749190:-
LIHC	cis	rs2284219	0.964	rs255098	ENSG00000196295.10	AC005154.6	-4.48	1e-05	0.00265	-0.17	-0.24	Type 2 diabetes;	chr7:30687711	chr7:30516309~30594809:-
LIHC	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	4.48	1e-05	0.00265	0.3	0.24	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
LIHC	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-4.48	1e-05	0.00266	-0.35	-0.24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
LIHC	cis	rs3733589	0.59	rs3733590	ENSG00000250413.1	RP11-448G15.1	4.48	1e-05	0.00266	0.4	0.24	Renal overload gout;	chr4:9985602	chr4:10006482~10009725:+
LIHC	cis	rs921968	0.565	rs2272188	ENSG00000272555.1	RP11-459I19.1	4.48	1e-05	0.00266	0.25	0.24	Mean corpuscular hemoglobin concentration;	chr2:218747559	chr2:218818690~218819144:+
LIHC	cis	rs13083990	0.881	rs13085674	ENSG00000272758.4	RP11-299J3.8	-4.48	1e-05	0.00266	-0.25	-0.24	Cardiac Troponin-T levels;	chr3:122292504	chr3:122416207~122443180:+
LIHC	cis	rs13083990	0.881	rs13085498	ENSG00000272758.4	RP11-299J3.8	4.48	1e-05	0.00266	0.25	0.24	Cardiac Troponin-T levels;	chr3:122292516	chr3:122416207~122443180:+
LIHC	cis	rs2439831	0.85	rs3736180	ENSG00000166763.7	STRCP1	4.48	1e-05	0.00266	0.36	0.24	Lung cancer in ever smokers;	chr15:43814426	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28684672	ENSG00000166763.7	STRCP1	4.48	1e-05	0.00266	0.36	0.24	Lung cancer in ever smokers;	chr15:43815464	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs12440573	ENSG00000166763.7	STRCP1	4.48	1e-05	0.00266	0.36	0.24	Lung cancer in ever smokers;	chr15:43816799	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-4.48	1e-05	0.00266	-0.28	-0.24	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-4.48	1e-05	0.00266	-0.28	-0.24	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-4.48	1e-05	0.00266	-0.28	-0.24	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-4.48	1e-05	0.00266	-0.28	-0.24	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-4.48	1e-05	0.00266	-0.28	-0.24	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-4.48	1e-05	0.00266	-0.28	-0.24	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
LIHC	cis	rs79349575	0.783	rs903567	ENSG00000248278.1	SUMO2P17	4.48	1e-05	0.00266	0.29	0.24	Type 2 diabetes;	chr17:48902956	chr17:48874860~48908983:-
LIHC	cis	rs3782123	0.514	rs11246007	ENSG00000277290.1	RP11-326C3.16	-4.48	1e-05	0.00266	-0.28	-0.24	Red cell distribution width;Glycated hemoglobin levels;	chr11:221584	chr11:243099~243483:-
LIHC	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	4.48	1e-05	0.00266	0.37	0.24	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
LIHC	cis	rs79349575	0.783	rs62075818	ENSG00000248278.1	SUMO2P17	4.48	1e-05	0.00266	0.29	0.24	Type 2 diabetes;	chr17:48904965	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs9912829	ENSG00000248278.1	SUMO2P17	4.48	1e-05	0.00266	0.29	0.24	Type 2 diabetes;	chr17:48905387	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs62075820	ENSG00000248278.1	SUMO2P17	4.48	1e-05	0.00266	0.29	0.24	Type 2 diabetes;	chr17:48905809	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs4294857	ENSG00000248278.1	SUMO2P17	4.48	1e-05	0.00266	0.29	0.24	Type 2 diabetes;	chr17:48906029	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs61576918	ENSG00000248278.1	SUMO2P17	4.48	1e-05	0.00266	0.29	0.24	Type 2 diabetes;	chr17:48908231	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.729	rs62075824	ENSG00000248278.1	SUMO2P17	4.48	1e-05	0.00266	0.29	0.24	Type 2 diabetes;	chr17:48909317	chr17:48874860~48908983:-
LIHC	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	4.48	1.01e-05	0.00267	0.23	0.24	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
LIHC	cis	rs2243480	1	rs4149468	ENSG00000230295.1	RP11-458F8.2	-4.48	1.01e-05	0.00267	-0.24	-0.24	Diabetic kidney disease;	chr7:66360703	chr7:66880708~66882981:+
LIHC	cis	rs748404	0.697	rs1814323	ENSG00000166763.7	STRCP1	-4.48	1.01e-05	0.00267	-0.29	-0.24	Lung cancer;	chr15:43271039	chr15:43699488~43718184:-
LIHC	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-4.48	1.01e-05	0.00267	-0.46	-0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
LIHC	cis	rs948562	0.947	rs75708979	ENSG00000280010.1	AP001350.4	4.48	1.01e-05	0.00267	0.43	0.24	Lymphoma;	chr11:58662312	chr11:58627435~58628528:+
LIHC	cis	rs948562	0.947	rs78629620	ENSG00000280010.1	AP001350.4	4.48	1.01e-05	0.00267	0.43	0.24	Lymphoma;	chr11:58662329	chr11:58627435~58628528:+
LIHC	cis	rs7044106	0.791	rs4837792	ENSG00000238181.2	AHCYP2	-4.48	1.01e-05	0.00267	-0.27	-0.24	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.791	rs10985000	ENSG00000238181.2	AHCYP2	-4.48	1.01e-05	0.00267	-0.27	-0.24	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120720673~120721972:+
LIHC	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-4.48	1.01e-05	0.00267	-0.3	-0.24	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
LIHC	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-4.48	1.01e-05	0.00267	-0.24	-0.24	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
LIHC	cis	rs2976388	0.692	rs2978983	ENSG00000253196.1	RP11-706C16.7	4.48	1.01e-05	0.00267	0.23	0.24	Urinary tract infection frequency;	chr8:142684424	chr8:142763116~142766427:+
LIHC	cis	rs1865760	0.566	rs9348706	ENSG00000216436.2	HIST1H2APS1	-4.48	1.01e-05	0.00267	-0.28	-0.24	Height;	chr6:26065253	chr6:25732497~25732827:+
LIHC	cis	rs2562456	0.617	rs34203148	ENSG00000268555.1	RP11-678G14.3	4.48	1.01e-05	0.00267	0.31	0.24	Pain;	chr19:21590743	chr19:21570822~21587322:-
LIHC	cis	rs7809950	1	rs6976607	ENSG00000238832.1	snoU109	4.48	1.01e-05	0.00268	0.29	0.24	Coronary artery disease;	chr7:107582956	chr7:107603363~107603507:+
LIHC	cis	rs7412746	0.611	rs11204747	ENSG00000231073.1	RP11-316M1.3	-4.48	1.01e-05	0.00268	-0.23	-0.24	Melanoma;	chr1:150954676	chr1:150973123~150975534:+
LIHC	cis	rs11671005	0.735	rs3826684	ENSG00000269473.1	CTD-2619J13.19	4.48	1.01e-05	0.00268	0.39	0.24	Mean platelet volume;	chr19:58407338	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs3826683	ENSG00000269473.1	CTD-2619J13.19	4.48	1.01e-05	0.00268	0.39	0.24	Mean platelet volume;	chr19:58407366	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs3826682	ENSG00000269473.1	CTD-2619J13.19	4.48	1.01e-05	0.00268	0.39	0.24	Mean platelet volume;	chr19:58407381	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs3826681	ENSG00000269473.1	CTD-2619J13.19	4.48	1.01e-05	0.00268	0.39	0.24	Mean platelet volume;	chr19:58407397	chr19:58440448~58445849:+
LIHC	cis	rs2836974	0.897	rs7280375	ENSG00000255568.3	BRWD1-AS2	-4.48	1.01e-05	0.00268	-0.27	-0.24	Cognitive function;	chr21:39180482	chr21:39313935~39314962:+
LIHC	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-4.48	1.01e-05	0.00268	-0.27	-0.24	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
LIHC	cis	rs1005277	0.602	rs1831315	ENSG00000276805.1	RP11-291L22.6	4.48	1.01e-05	0.00268	0.29	0.24	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38451030~38451785:+
LIHC	cis	rs3733589	0.59	rs73100621	ENSG00000250413.1	RP11-448G15.1	4.48	1.01e-05	0.00268	0.41	0.24	Renal overload gout;	chr4:9984715	chr4:10006482~10009725:+
LIHC	cis	rs875971	0.66	rs7807944	ENSG00000273024.4	INTS4P2	4.48	1.01e-05	0.00268	0.26	0.24	Aortic root size;	chr7:66622208	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs10950036	ENSG00000273142.1	RP11-458F8.4	4.48	1.01e-05	0.00268	0.23	0.24	Aortic root size;	chr7:66353241	chr7:66902857~66906297:+
LIHC	cis	rs16958440	0.867	rs79420880	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47137316	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs78720782	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47137644	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs79231363	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47138716	chr18:47105946~47108062:+
LIHC	cis	rs76297747	1	rs76297747	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Response to paliperidone in schizophrenia (Multivariate);	chr18:47139286	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs78854354	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47140553	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs79078752	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47141091	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs61689863	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47142786	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs80064497	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47143282	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs78547658	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47143481	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.867	rs12386092	ENSG00000267724.1	RP11-49K24.8	4.48	1.01e-05	0.00268	0.37	0.24	Sitting height ratio;	chr18:47145687	chr18:47105946~47108062:+
LIHC	cis	rs12157904	1	rs3761443	ENSG00000233360.4	Z83844.1	4.48	1.02e-05	0.00269	0.49	0.24	Response to anti-depressant treatment in major depressive disorder;	chr22:37607228	chr22:37641832~37658377:-
LIHC	cis	rs12157904	1	rs6000840	ENSG00000233360.4	Z83844.1	4.48	1.02e-05	0.00269	0.49	0.24	Response to anti-depressant treatment in major depressive disorder;	chr22:37608637	chr22:37641832~37658377:-
LIHC	cis	rs10991814	0.557	rs76379507	ENSG00000273381.1	RP11-305L7.7	4.48	1.02e-05	0.00269	0.27	0.24	Neutrophil percentage of granulocytes;	chr9:91232926	chr9:91206175~91210299:-
LIHC	cis	rs10510102	0.872	rs11200292	ENSG00000226864.1	ATE1-AS1	4.48	1.02e-05	0.00269	0.4	0.24	Breast cancer;	chr10:121967383	chr10:121928312~121951965:+
LIHC	cis	rs1729407	0.632	rs2071523	ENSG00000236267.1	AP006216.5	4.48	1.02e-05	0.00269	0.22	0.24	Apolipoprotein A-IV levels;	chr11:116826628	chr11:116813204~116814003:-
LIHC	cis	rs7914558	0.505	rs12260436	ENSG00000236937.2	PTGES3P4	4.48	1.02e-05	0.00269	0.29	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102981357	chr10:102845595~102845950:+
LIHC	cis	rs901683	1	rs17157919	ENSG00000230869.1	CTGLF10P	4.48	1.02e-05	0.00269	0.55	0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45548644	chr10:45678692~45700532:+
LIHC	cis	rs8024893	0.764	rs7178760	ENSG00000270055.1	CTD-3092A11.2	4.48	1.02e-05	0.00269	0.34	0.24	Red cell distribution width;	chr15:31239170	chr15:30487963~30490313:+
LIHC	cis	rs1247318	0.853	rs1247325	ENSG00000243831.1	RP1-81D8.4	4.48	1.02e-05	0.00269	0.33	0.24	Aging;	chr6:160907638	chr6:160666228~160676523:-
LIHC	cis	rs79349575	0.783	rs832410	ENSG00000248278.1	SUMO2P17	4.48	1.02e-05	0.00269	0.29	0.24	Type 2 diabetes;	chr17:48895503	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs318095	ENSG00000248278.1	SUMO2P17	4.48	1.02e-05	0.00269	0.29	0.24	Type 2 diabetes;	chr17:48897372	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs318096	ENSG00000248278.1	SUMO2P17	4.48	1.02e-05	0.00269	0.29	0.24	Type 2 diabetes;	chr17:48898008	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.777	rs28517720	ENSG00000248278.1	SUMO2P17	4.48	1.02e-05	0.00269	0.29	0.24	Type 2 diabetes;	chr17:48899394	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.756	rs2643361	ENSG00000248278.1	SUMO2P17	4.48	1.02e-05	0.00269	0.29	0.24	Type 2 diabetes;	chr17:48900100	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.749	rs2546491	ENSG00000248278.1	SUMO2P17	4.48	1.02e-05	0.00269	0.29	0.24	Type 2 diabetes;	chr17:48900554	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs962272	ENSG00000248278.1	SUMO2P17	4.48	1.02e-05	0.00269	0.29	0.24	Type 2 diabetes;	chr17:48900921	chr17:48874860~48908983:-
LIHC	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	4.48	1.02e-05	0.00269	0.47	0.24	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
LIHC	cis	rs734999	0.545	rs7368072	ENSG00000225931.3	RP3-395M20.7	4.48	1.02e-05	0.00269	0.25	0.24	Ulcerative colitis;	chr1:2624686	chr1:2566410~2569888:+
LIHC	cis	rs75920871	0.688	rs55703909	ENSG00000254851.1	RP11-109L13.1	-4.48	1.02e-05	0.00269	-0.47	-0.24	Subjective well-being;	chr11:117114150	chr11:117135528~117138582:+
LIHC	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-4.48	1.02e-05	0.00269	-0.43	-0.24	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
LIHC	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-4.48	1.02e-05	0.0027	-0.3	-0.24	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
LIHC	cis	rs1577917	0.958	rs12208227	ENSG00000234155.1	RP11-30P6.6	4.48	1.02e-05	0.0027	0.31	0.24	Response to antipsychotic treatment;	chr6:85961226	chr6:85387219~85390186:-
LIHC	cis	rs4578769	0.765	rs35151054	ENSG00000266850.1	RP11-370A5.1	-4.48	1.02e-05	0.0027	-0.28	-0.24	Eosinophil percentage of white cells;	chr18:22818375	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs72882153	ENSG00000266850.1	RP11-370A5.1	-4.48	1.02e-05	0.0027	-0.28	-0.24	Eosinophil percentage of white cells;	chr18:22823275	chr18:22723491~22907721:-
LIHC	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	4.48	1.02e-05	0.0027	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
LIHC	cis	rs875971	0.66	rs79009421	ENSG00000273024.4	INTS4P2	4.48	1.02e-05	0.00271	0.26	0.24	Aortic root size;	chr7:66603522	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs6460308	ENSG00000273024.4	INTS4P2	4.48	1.02e-05	0.00271	0.26	0.24	Aortic root size;	chr7:66619753	chr7:65647864~65715661:+
LIHC	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-4.48	1.03e-05	0.00271	-0.37	-0.24	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
LIHC	cis	rs1005277	0.579	rs1780130	ENSG00000276805.1	RP11-291L22.6	4.48	1.03e-05	0.00271	0.29	0.24	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38451030~38451785:+
LIHC	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	4.48	1.03e-05	0.00271	0.24	0.24	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
LIHC	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-4.48	1.03e-05	0.00271	-0.29	-0.24	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
LIHC	cis	rs2836974	0.897	rs12481860	ENSG00000255568.3	BRWD1-AS2	4.48	1.03e-05	0.00271	0.27	0.24	Cognitive function;	chr21:39165910	chr21:39313935~39314962:+
LIHC	cis	rs2836974	0.863	rs6517519	ENSG00000255568.3	BRWD1-AS2	4.48	1.03e-05	0.00271	0.27	0.24	Cognitive function;	chr21:39168319	chr21:39313935~39314962:+
LIHC	cis	rs7637701	0.713	rs9867857	ENSG00000243926.1	TIPARP-AS1	4.48	1.03e-05	0.00271	0.21	0.24	Breast cancer;	chr3:156773371	chr3:156671862~156674378:-
LIHC	cis	rs2929278	0.617	rs694461	ENSG00000275601.1	AC011330.13	4.48	1.03e-05	0.00271	0.29	0.24	Schizophrenia;	chr15:43803865	chr15:43642389~43643023:-
LIHC	cis	rs2998286	0.862	rs2998285	ENSG00000254635.4	WAC-AS1	4.48	1.03e-05	0.00271	0.28	0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504310	chr10:28522652~28532743:-
LIHC	cis	rs2998286	0.862	rs4237390	ENSG00000254635.4	WAC-AS1	-4.48	1.03e-05	0.00271	-0.28	-0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504497	chr10:28522652~28532743:-
LIHC	cis	rs9467711	0.591	rs6940007	ENSG00000216436.2	HIST1H2APS1	4.48	1.03e-05	0.00271	0.61	0.24	Autism spectrum disorder or schizophrenia;	chr6:25931729	chr6:25732497~25732827:+
LIHC	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	4.48	1.03e-05	0.00271	0.24	0.24	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
LIHC	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	4.48	1.03e-05	0.00271	0.24	0.24	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	4.48	1.03e-05	0.00271	0.24	0.24	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
LIHC	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	4.48	1.03e-05	0.00271	0.24	0.24	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
LIHC	cis	rs683257	0.636	rs17070386	ENSG00000234147.1	RP3-460G2.2	4.48	1.03e-05	0.00272	0.38	0.24	Facial emotion recognition (angry faces);	chr6:140850424	chr6:140845958~140852924:-
LIHC	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	4.48	1.03e-05	0.00272	0.37	0.24	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	4.48	1.03e-05	0.00272	0.37	0.24	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	4.48	1.03e-05	0.00272	0.37	0.24	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
LIHC	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-4.48	1.03e-05	0.00272	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
LIHC	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	4.48	1.03e-05	0.00272	0.24	0.24	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
LIHC	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-4.48	1.03e-05	0.00272	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
LIHC	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-4.48	1.03e-05	0.00272	-0.26	-0.24	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
LIHC	cis	rs875971	0.66	rs10950044	ENSG00000273024.4	INTS4P2	4.48	1.03e-05	0.00272	0.26	0.24	Aortic root size;	chr7:66577989	chr7:65647864~65715661:+
LIHC	cis	rs1400745	0.729	rs28472856	ENSG00000258738.1	RP11-73E17.2	4.48	1.03e-05	0.00272	0.29	0.24	Monocyte count;	chr14:34862951	chr14:34874343~34876459:+
LIHC	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	4.48	1.03e-05	0.00272	0.31	0.24	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
LIHC	cis	rs2565722	0.665	rs2465854	ENSG00000243831.1	RP1-81D8.4	-4.48	1.03e-05	0.00273	-0.32	-0.24	Blood protein levels;	chr6:160889878	chr6:160666228~160676523:-
LIHC	cis	rs1577917	0.958	rs11756615	ENSG00000234155.1	RP11-30P6.6	4.48	1.03e-05	0.00273	0.31	0.24	Response to antipsychotic treatment;	chr6:85970117	chr6:85387219~85390186:-
LIHC	cis	rs875971	0.545	rs12670811	ENSG00000228409.4	CCT6P1	-4.48	1.03e-05	0.00273	-0.2	-0.24	Aortic root size;	chr7:66358032	chr7:65751142~65763354:+
LIHC	cis	rs921968	0.565	rs608047	ENSG00000272555.1	RP11-459I19.1	4.48	1.03e-05	0.00273	0.25	0.24	Mean corpuscular hemoglobin concentration;	chr2:218751187	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs692049	ENSG00000272555.1	RP11-459I19.1	-4.48	1.03e-05	0.00273	-0.25	-0.24	Mean corpuscular hemoglobin concentration;	chr2:218758055	chr2:218818690~218819144:+
LIHC	cis	rs7607369	0.719	rs690882	ENSG00000272555.1	RP11-459I19.1	-4.48	1.03e-05	0.00273	-0.25	-0.24	Amyotrophic lateral sclerosis;Red blood cell count;	chr2:218775897	chr2:218818690~218819144:+
LIHC	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-4.48	1.04e-05	0.00273	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
LIHC	cis	rs13315871	1	rs9862969	ENSG00000272182.1	RP11-802O23.3	4.48	1.04e-05	0.00273	0.58	0.24	Cholesterol, total;	chr3:58356190	chr3:58428255~58428815:+
LIHC	cis	rs13315871	1	rs11715445	ENSG00000272182.1	RP11-802O23.3	4.48	1.04e-05	0.00273	0.58	0.24	Cholesterol, total;	chr3:58358161	chr3:58428255~58428815:+
LIHC	cis	rs3812762	0.871	rs11603335	ENSG00000254860.4	TMEM9B-AS1	-4.48	1.04e-05	0.00274	-0.25	-0.24	Hypospadias;	chr11:8788297	chr11:8964675~8977527:+
LIHC	cis	rs901683	0.85	rs112997714	ENSG00000230869.1	CTGLF10P	-4.48	1.04e-05	0.00274	-0.5	-0.24	Mean corpuscular volume;Red blood cell traits;	chr10:45601768	chr10:45678692~45700532:+
LIHC	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-4.48	1.04e-05	0.00274	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
LIHC	cis	rs734999	0.545	rs4648565	ENSG00000225931.3	RP3-395M20.7	-4.48	1.04e-05	0.00274	-0.25	-0.24	Ulcerative colitis;	chr1:2638584	chr1:2566410~2569888:+
LIHC	cis	rs4561483	0.801	rs33631	ENSG00000261560.1	RP11-166B2.3	-4.48	1.04e-05	0.00274	-0.26	-0.24	Testicular germ cell tumor;	chr16:11901530	chr16:11881075~11882569:-
LIHC	cis	rs2877649	1	rs2332352	ENSG00000258744.1	RP11-80A15.1	4.48	1.04e-05	0.00274	0.45	0.24	Smooth-surface caries;	chr14:24484774	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs2877649	ENSG00000258744.1	RP11-80A15.1	4.48	1.04e-05	0.00274	0.45	0.24	Smooth-surface caries;	chr14:24484796	chr14:24501594~24508688:+
LIHC	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-4.48	1.04e-05	0.00274	-0.32	-0.24	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	4.48	1.04e-05	0.00274	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	4.48	1.04e-05	0.00274	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	4.48	1.04e-05	0.00274	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
LIHC	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-4.48	1.04e-05	0.00274	-0.3	-0.24	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
LIHC	cis	rs1558001	0.84	rs10435298	ENSG00000230196.1	DDX43P3	-4.48	1.04e-05	0.00274	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81800792	chr7:81610884~81611326:-
LIHC	cis	rs1558001	0.84	rs17155517	ENSG00000230196.1	DDX43P3	-4.48	1.04e-05	0.00274	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81801380	chr7:81610884~81611326:-
LIHC	cis	rs1558001	0.87	rs9332389	ENSG00000230196.1	DDX43P3	-4.48	1.04e-05	0.00274	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81802463	chr7:81610884~81611326:-
LIHC	cis	rs1558001	0.87	rs35555877	ENSG00000230196.1	DDX43P3	-4.48	1.04e-05	0.00274	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81809611	chr7:81610884~81611326:-
LIHC	cis	rs6977955	1	rs740122	ENSG00000234336.5	JAZF1-AS1	-4.47	1.04e-05	0.00275	-0.34	-0.24	Allergic disease (asthma, hay fever or eczema);	chr7:28126823	chr7:28180322~28243917:+
LIHC	cis	rs10129255	0.646	rs55995061	ENSG00000211970.3	IGHV4-61	-4.47	1.04e-05	0.00275	-0.18	-0.24	Kawasaki disease;	chr14:106799309	chr14:106639119~106639657:-
LIHC	cis	rs4650994	0.623	rs12121188	ENSG00000213057.5	C1orf220	-4.47	1.04e-05	0.00275	-0.2	-0.24	HDL cholesterol;HDL cholesterol levels;	chr1:178653364	chr1:178542752~178548889:+
LIHC	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-4.47	1.04e-05	0.00275	-0.29	-0.24	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
LIHC	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	4.47	1.05e-05	0.00275	0.36	0.24	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
LIHC	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	4.47	1.05e-05	0.00275	0.27	0.24	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
LIHC	cis	rs72675573	0.925	rs1304824	ENSG00000235612.1	RP1-158P9.1	-4.47	1.05e-05	0.00276	-0.31	-0.24	Monocyte count;	chr1:56158342	chr1:56145721~56155224:+
LIHC	cis	rs2494250	0.542	rs4269772	ENSG00000231434.1	RP11-144L1.8	-4.47	1.05e-05	0.00276	-0.29	-0.24	Select biomarker traits;	chr1:159320871	chr1:158523672~158525838:+
LIHC	cis	rs58785573	0.624	rs337605	ENSG00000231160.8	KLF3-AS1	-4.47	1.05e-05	0.00276	-0.22	-0.24	Lymphocyte percentage of white cells;	chr4:38646132	chr4:38612701~38664883:-
LIHC	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	4.47	1.05e-05	0.00276	0.19	0.24	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
LIHC	cis	rs79349575	0.783	rs4793991	ENSG00000248278.1	SUMO2P17	4.47	1.05e-05	0.00276	0.29	0.24	Type 2 diabetes;	chr17:48924439	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.715	rs62075844	ENSG00000248278.1	SUMO2P17	4.47	1.05e-05	0.00276	0.29	0.24	Type 2 diabetes;	chr17:48925027	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.749	rs957557	ENSG00000248278.1	SUMO2P17	4.47	1.05e-05	0.00276	0.29	0.24	Type 2 diabetes;	chr17:48925859	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.749	rs12601672	ENSG00000248278.1	SUMO2P17	4.47	1.05e-05	0.00276	0.29	0.24	Type 2 diabetes;	chr17:48929131	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs17635252	ENSG00000248278.1	SUMO2P17	4.47	1.05e-05	0.00276	0.29	0.24	Type 2 diabetes;	chr17:48929588	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs56046215	ENSG00000248278.1	SUMO2P17	4.47	1.05e-05	0.00276	0.29	0.24	Type 2 diabetes;	chr17:48931395	chr17:48874860~48908983:-
LIHC	cis	rs1558001	0.87	rs62465439	ENSG00000230196.1	DDX43P3	-4.47	1.05e-05	0.00276	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81806289	chr7:81610884~81611326:-
LIHC	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-4.47	1.05e-05	0.00276	-0.28	-0.24	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
LIHC	cis	rs1558001	0.87	rs2194752	ENSG00000230196.1	DDX43P3	-4.47	1.05e-05	0.00276	-0.25	-0.24	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81803802	chr7:81610884~81611326:-
LIHC	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	4.47	1.05e-05	0.00276	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	4.47	1.05e-05	0.00276	0.32	0.24	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
LIHC	cis	rs9527	1	rs9527	ENSG00000236937.2	PTGES3P4	4.47	1.05e-05	0.00276	0.36	0.24	Arsenic metabolism;	chr10:102863821	chr10:102845595~102845950:+
LIHC	cis	rs9843304	0.624	rs13061914	ENSG00000244503.1	RP11-278L15.6	4.47	1.05e-05	0.00276	0.24	0.24	Gallstone disease;	chr3:149484345	chr3:149494660~149495995:+
LIHC	cis	rs9843304	0.529	rs61382471	ENSG00000244503.1	RP11-278L15.6	4.47	1.05e-05	0.00276	0.24	0.24	Gallstone disease;	chr3:149484373	chr3:149494660~149495995:+
LIHC	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	4.47	1.05e-05	0.00276	0.28	0.24	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
LIHC	cis	rs3733589	1	rs13118801	ENSG00000250413.1	RP11-448G15.1	4.47	1.05e-05	0.00277	0.42	0.24	Renal overload gout;	chr4:9996192	chr4:10006482~10009725:+
LIHC	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-4.47	1.05e-05	0.00277	-0.29	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
LIHC	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-4.47	1.05e-05	0.00277	-0.25	-0.24	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
LIHC	cis	rs9304742	0.962	rs1044467	ENSG00000213801.4	ZNF816-ZNF321P	4.47	1.05e-05	0.00277	0.23	0.24	Psoriasis;	chr19:52949516	chr19:52927135~52942601:-
LIHC	cis	rs1005277	0.579	rs1780121	ENSG00000275858.1	RP11-291L22.8	4.47	1.05e-05	0.00277	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1780122	ENSG00000275858.1	RP11-291L22.8	4.47	1.05e-05	0.00277	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1780145	ENSG00000275858.1	RP11-291L22.8	4.47	1.05e-05	0.00277	0.26	0.24	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38450738~38451069:-
LIHC	cis	rs79349575	0.749	rs1057902	ENSG00000248278.1	SUMO2P17	4.47	1.05e-05	0.00277	0.29	0.24	Type 2 diabetes;	chr17:48928226	chr17:48874860~48908983:-
LIHC	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-4.47	1.06e-05	0.00277	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-4.47	1.06e-05	0.00277	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-4.47	1.06e-05	0.00277	-0.26	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
LIHC	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	4.47	1.06e-05	0.00277	0.26	0.24	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
LIHC	cis	rs1400745	0.756	rs799683	ENSG00000258738.1	RP11-73E17.2	4.47	1.06e-05	0.00278	0.29	0.24	Monocyte count;	chr14:34880030	chr14:34874343~34876459:+
LIHC	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-4.47	1.06e-05	0.00278	-0.21	-0.24	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
LIHC	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-4.47	1.06e-05	0.00278	-0.3	-0.24	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
LIHC	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	4.47	1.06e-05	0.00278	0.24	0.24	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
LIHC	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	4.47	1.06e-05	0.00278	0.24	0.24	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
LIHC	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	4.47	1.06e-05	0.00278	0.24	0.24	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
LIHC	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	4.47	1.06e-05	0.00278	0.24	0.24	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
LIHC	cis	rs7224610	0.966	rs3794748	ENSG00000263096.1	RP11-515O17.2	4.47	1.06e-05	0.00278	0.34	0.24	Urate levels;	chr17:55287811	chr17:55271504~55273653:-
LIHC	cis	rs10871290	0.881	rs3863439	ENSG00000261079.1	RP11-252A24.3	-4.47	1.06e-05	0.00278	-0.27	-0.24	Breast cancer;	chr16:74436746	chr16:74367462~74369826:+
LIHC	cis	rs875971	0.66	rs2013222	ENSG00000273024.4	INTS4P2	4.47	1.06e-05	0.00278	0.26	0.24	Aortic root size;	chr7:66570949	chr7:65647864~65715661:+
LIHC	cis	rs79349575	0.783	rs9747646	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48939520	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs62075852	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48939814	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs12601858	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48940115	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.749	rs8182364	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48940663	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.681	rs56080003	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48941687	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs4793995	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48942037	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs4793996	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48942235	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.715	rs4793997	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48942310	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs4793998	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48942537	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.749	rs2270574	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48944908	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs4794000	ENSG00000248278.1	SUMO2P17	4.47	1.06e-05	0.00278	0.29	0.24	Type 2 diabetes;	chr17:48945393	chr17:48874860~48908983:-
LIHC	cis	rs1318937	1	rs3821639	ENSG00000224660.1	SH3BP5-AS1	4.47	1.06e-05	0.00278	0.23	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264159	chr3:15254184~15264493:+
LIHC	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	4.47	1.06e-05	0.00278	0.22	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
LIHC	cis	rs1352413	0.881	rs2299269	ENSG00000275834.1	RP11-440E5.1	-4.47	1.06e-05	0.00278	-0.31	-0.24	Knee osteoarthritis;	chr7:95990065	chr7:96306810~96306874:+
LIHC	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-4.47	1.06e-05	0.00278	-0.22	-0.24	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
LIHC	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	4.47	1.06e-05	0.00278	0.19	0.24	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
LIHC	cis	rs3758785	0.737	rs12270338	ENSG00000255893.1	RP11-685N10.1	4.47	1.06e-05	0.00278	0.27	0.24	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94414298	chr11:94472908~94473570:-
LIHC	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-4.47	1.06e-05	0.00278	-0.35	-0.24	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
LIHC	cis	rs2072510	0.593	rs2660892	ENSG00000257715.1	RP11-256L6.2	-4.47	1.06e-05	0.00278	-0.37	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96027200	chr12:96025323~96027971:+
LIHC	cis	rs11779988	0.545	rs431961	ENSG00000253671.1	RP11-806O11.1	-4.47	1.06e-05	0.00279	-0.31	-0.23	Breast cancer;	chr8:17928695	chr8:17808941~17820868:+
LIHC	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-4.47	1.06e-05	0.00279	-0.18	-0.23	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
LIHC	cis	rs651907	0.535	rs13084113	ENSG00000244119.1	PDCL3P4	4.47	1.06e-05	0.00279	0.24	0.23	Colorectal cancer;	chr3:101815195	chr3:101712472~101713191:+
LIHC	cis	rs1400745	0.756	rs799682	ENSG00000258738.1	RP11-73E17.2	4.47	1.06e-05	0.00279	0.29	0.23	Monocyte count;	chr14:34880778	chr14:34874343~34876459:+
LIHC	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	4.47	1.06e-05	0.00279	0.23	0.23	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	4.47	1.06e-05	0.00279	0.23	0.23	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
LIHC	cis	rs755249	1	rs4660303	ENSG00000182109.6	RP11-69E11.4	4.47	1.06e-05	0.00279	0.34	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39522280~39546187:-
LIHC	cis	rs2439831	0.867	rs2614811	ENSG00000166763.7	STRCP1	4.47	1.06e-05	0.00279	0.37	0.23	Lung cancer in ever smokers;	chr15:43621289	chr15:43699488~43718184:-
LIHC	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-4.47	1.06e-05	0.00279	-0.26	-0.23	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
LIHC	cis	rs960902	0.592	rs7588494	ENSG00000213553.4	RPLP0P6	-4.47	1.06e-05	0.00279	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37509738	chr2:38481851~38482804:+
LIHC	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-4.47	1.06e-05	0.00279	-0.24	-0.23	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-4.47	1.06e-05	0.00279	-0.24	-0.23	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
LIHC	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	4.47	1.06e-05	0.00279	0.28	0.23	Height;	chr6:109371573	chr6:109382795~109383666:+
LIHC	cis	rs748404	0.631	rs2412781	ENSG00000166763.7	STRCP1	-4.47	1.07e-05	0.0028	-0.29	-0.23	Lung cancer;	chr15:43375702	chr15:43699488~43718184:-
LIHC	cis	rs5758659	0.633	rs762995	ENSG00000227370.1	RP4-669P10.19	-4.47	1.07e-05	0.0028	-0.26	-0.23	Cognitive function;	chr22:42276118	chr22:42132543~42132998:+
LIHC	cis	rs11671005	0.735	rs11671591	ENSG00000269473.1	CTD-2619J13.19	-4.47	1.07e-05	0.0028	-0.39	-0.23	Mean platelet volume;	chr19:58406970	chr19:58440448~58445849:+
LIHC	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	4.47	1.07e-05	0.0028	0.21	0.23	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
LIHC	cis	rs709400	0.859	rs942863	ENSG00000258534.1	CTD-2134A5.4	4.47	1.07e-05	0.0028	0.36	0.23	Body mass index;	chr14:103554931	chr14:103854366~103880111:-
LIHC	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-4.47	1.07e-05	0.0028	-0.22	-0.23	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
LIHC	cis	rs6085948	0.861	rs2224055	ENSG00000228888.1	LINC01428	-4.47	1.07e-05	0.0028	-0.39	-0.23	Interleukin-10 levels;	chr20:7253521	chr20:7146467~7254202:-
LIHC	cis	rs748404	0.697	rs473554	ENSG00000166763.7	STRCP1	4.47	1.07e-05	0.0028	0.3	0.23	Lung cancer;	chr15:43276009	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs530683	ENSG00000166763.7	STRCP1	-4.47	1.07e-05	0.0028	-0.3	-0.23	Lung cancer;	chr15:43276801	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-4.47	1.07e-05	0.0028	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
LIHC	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	4.47	1.07e-05	0.00281	0.27	0.23	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
LIHC	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	4.47	1.07e-05	0.00281	0.26	0.23	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
LIHC	cis	rs10080237	0.564	rs2490232	ENSG00000272129.1	RP11-250B2.6	-4.47	1.07e-05	0.00281	-0.23	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80105085	chr6:80355424~80356859:+
LIHC	cis	rs9525927	0.521	rs4942298	ENSG00000230731.2	RP11-478K15.6	4.47	1.07e-05	0.00281	0.27	0.23	Dupuytren's disease;	chr13:44224486	chr13:44234118~44243192:-
LIHC	cis	rs202072	1	rs202070	ENSG00000215022.6	RP1-257A7.4	-4.47	1.07e-05	0.00281	-0.25	-0.23	HIV-1 viral setpoint;	chr6:13267706	chr6:13264861~13295586:-
LIHC	cis	rs2980436	1	rs2980436	ENSG00000253426.4	RP11-10A14.4	-4.47	1.07e-05	0.00281	-0.34	-0.23	Schizophrenia;	chr8:8234503	chr8:9151742~9168136:+
LIHC	cis	rs2243480	1	rs73142162	ENSG00000230295.1	RP11-458F8.2	-4.47	1.07e-05	0.00281	-0.25	-0.23	Diabetic kidney disease;	chr7:65909309	chr7:66880708~66882981:+
LIHC	cis	rs755249	0.567	rs4660603	ENSG00000182109.6	RP11-69E11.4	-4.47	1.07e-05	0.00281	-0.31	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39522280~39546187:-
LIHC	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-4.47	1.07e-05	0.00281	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
LIHC	cis	rs7809950	0.911	rs7778250	ENSG00000238832.1	snoU109	4.47	1.07e-05	0.00281	0.29	0.23	Coronary artery disease;	chr7:107584120	chr7:107603363~107603507:+
LIHC	cis	rs734999	0.566	rs12748729	ENSG00000225931.3	RP3-395M20.7	-4.47	1.07e-05	0.00281	-0.25	-0.23	Ulcerative colitis;	chr1:2627301	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.545	rs12730932	ENSG00000225931.3	RP3-395M20.7	-4.47	1.07e-05	0.00281	-0.25	-0.23	Ulcerative colitis;	chr1:2628150	chr1:2566410~2569888:+
LIHC	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-4.47	1.07e-05	0.00281	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
LIHC	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	4.47	1.07e-05	0.00281	0.26	0.23	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
LIHC	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	4.47	1.07e-05	0.00281	0.26	0.23	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
LIHC	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-4.47	1.07e-05	0.00281	-0.25	-0.23	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-4.47	1.07e-05	0.00281	-0.25	-0.23	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-4.47	1.07e-05	0.00281	-0.25	-0.23	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-4.47	1.07e-05	0.00281	-0.25	-0.23	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	4.47	1.07e-05	0.00282	0.25	0.23	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
LIHC	cis	rs11098499	0.863	rs3736115	ENSG00000260091.1	RP11-33B1.4	4.47	1.07e-05	0.00282	0.17	0.23	Corneal astigmatism;	chr4:119567548	chr4:119409333~119410233:+
LIHC	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-4.47	1.07e-05	0.00282	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
LIHC	cis	rs4578769	0.729	rs72882140	ENSG00000266850.1	RP11-370A5.1	-4.47	1.08e-05	0.00282	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22805952	chr18:22723491~22907721:-
LIHC	cis	rs72627509	0.638	rs1608165	ENSG00000269949.1	RP11-738E22.3	4.47	1.08e-05	0.00282	0.31	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57028551	chr4:56960927~56961373:-
LIHC	cis	rs2320952	0.874	rs11078853	ENSG00000263400.5	TMEM220-AS1	-4.47	1.08e-05	0.00282	-0.25	-0.23	Gut microbiome composition (winter);	chr17:10588844	chr17:10729777~10815164:+
LIHC	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-4.47	1.08e-05	0.00282	-0.29	-0.23	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
LIHC	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-4.47	1.08e-05	0.00282	-0.23	-0.23	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
LIHC	cis	rs9595908	0.965	rs8000071	ENSG00000212293.1	SNORA16	4.47	1.08e-05	0.00282	0.27	0.23	Body mass index;	chr13:32551236	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.965	rs7984903	ENSG00000212293.1	SNORA16	4.47	1.08e-05	0.00282	0.27	0.23	Body mass index;	chr13:32552002	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.965	rs7318297	ENSG00000212293.1	SNORA16	4.47	1.08e-05	0.00282	0.27	0.23	Body mass index;	chr13:32563835	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.9	rs7994229	ENSG00000212293.1	SNORA16	4.47	1.08e-05	0.00283	0.27	0.23	Body mass index;	chr13:32586568	chr13:32420390~32420516:-
LIHC	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	4.47	1.08e-05	0.00283	0.36	0.23	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
LIHC	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	4.47	1.08e-05	0.00283	0.38	0.23	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
LIHC	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	4.47	1.08e-05	0.00283	0.31	0.23	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
LIHC	cis	rs2072510	0.722	rs2247330	ENSG00000257878.1	RP11-256L6.3	4.47	1.08e-05	0.00283	0.2	0.23	Metabolite levels (small molecules and protein measures);	chr12:96030344	chr12:95996521~96011489:+
LIHC	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-4.47	1.08e-05	0.00283	-0.24	-0.23	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
LIHC	cis	rs875971	0.545	rs10261710	ENSG00000273142.1	RP11-458F8.4	4.47	1.08e-05	0.00283	0.23	0.23	Aortic root size;	chr7:66249202	chr7:66902857~66906297:+
LIHC	cis	rs13083990	0.919	rs3792289	ENSG00000272758.4	RP11-299J3.8	4.47	1.08e-05	0.00283	0.26	0.23	Cardiac Troponin-T levels;	chr3:122274753	chr3:122416207~122443180:+
LIHC	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	4.47	1.08e-05	0.00283	0.32	0.23	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
LIHC	cis	rs901683	0.702	rs74940001	ENSG00000230869.1	CTGLF10P	-4.47	1.08e-05	0.00283	-0.52	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45648846	chr10:45678692~45700532:+
LIHC	cis	rs734999	0.545	rs28690427	ENSG00000225931.3	RP3-395M20.7	-4.47	1.08e-05	0.00283	-0.25	-0.23	Ulcerative colitis;	chr1:2640384	chr1:2566410~2569888:+
LIHC	cis	rs2877649	0.51	rs10083368	ENSG00000258744.1	RP11-80A15.1	-4.47	1.08e-05	0.00283	-0.43	-0.23	Smooth-surface caries;	chr14:24438978	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.51	rs10083369	ENSG00000258744.1	RP11-80A15.1	-4.47	1.08e-05	0.00283	-0.43	-0.23	Smooth-surface caries;	chr14:24439005	chr14:24501594~24508688:+
LIHC	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	4.47	1.08e-05	0.00283	0.25	0.23	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
LIHC	cis	rs61160187	0.51	rs10076679	ENSG00000272308.1	RP11-231G3.1	-4.47	1.08e-05	0.00283	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795124	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.527	rs10076742	ENSG00000272308.1	RP11-231G3.1	-4.47	1.08e-05	0.00283	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.527	rs6890201	ENSG00000272308.1	RP11-231G3.1	-4.47	1.08e-05	0.00283	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795365	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.51	rs6875456	ENSG00000272308.1	RP11-231G3.1	-4.47	1.08e-05	0.00283	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795503	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.51	rs6894750	ENSG00000272308.1	RP11-231G3.1	-4.47	1.08e-05	0.00283	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795729	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.51	rs6876335	ENSG00000272308.1	RP11-231G3.1	-4.47	1.08e-05	0.00283	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795991	chr5:60866457~60866935:-
LIHC	cis	rs61160187	0.51	rs6449501	ENSG00000272308.1	RP11-231G3.1	-4.47	1.08e-05	0.00283	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60796860	chr5:60866457~60866935:-
LIHC	cis	rs9675120	0.675	rs7214434	ENSG00000262006.1	RP11-700H6.4	-4.47	1.08e-05	0.00283	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50849904	chr17:50909637~50910232:-
LIHC	cis	rs9675120	0.675	rs7214603	ENSG00000262006.1	RP11-700H6.4	-4.47	1.08e-05	0.00283	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50850021	chr17:50909637~50910232:-
LIHC	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	4.47	1.08e-05	0.00283	0.33	0.23	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
LIHC	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	4.47	1.08e-05	0.00284	0.37	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
LIHC	cis	rs79040073	0.53	rs73396206	ENSG00000259531.2	RP11-295H24.3	4.47	1.08e-05	0.00284	0.38	0.23	Lung cancer in ever smokers;	chr15:49323632	chr15:49365124~49366685:-
LIHC	cis	rs17301013	0.932	rs1653632	ENSG00000227373.4	RP11-160H22.5	-4.47	1.08e-05	0.00284	-0.28	-0.23	Systemic lupus erythematosus;	chr1:174786459	chr1:174115300~174160004:-
LIHC	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-4.47	1.08e-05	0.00284	-0.22	-0.23	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
LIHC	cis	rs6688613	0.685	rs4657613	ENSG00000225171.2	DUTP6	-4.47	1.09e-05	0.00284	-0.26	-0.23	Refractive astigmatism;	chr1:166901641	chr1:166868748~166869209:+
LIHC	cis	rs11098499	0.697	rs11941899	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119461603	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.821	rs28665282	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119463031	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.738	rs10026493	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119463039	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs7681214	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119464165	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.908	rs71614449	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119465900	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs35063680	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119465947	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs34858317	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119465955	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs17046116	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119466104	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs17046118	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119466341	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs7654587	ENSG00000260091.1	RP11-33B1.4	-4.47	1.09e-05	0.00284	-0.17	-0.23	Corneal astigmatism;	chr4:119467251	chr4:119409333~119410233:+
LIHC	cis	rs4453827	1	rs28675949	ENSG00000271916.1	RP11-884K10.6	4.47	1.09e-05	0.00284	0.49	0.23	Blood protein levels;	chr3:53708376	chr3:53797764~53798019:-
LIHC	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-4.47	1.09e-05	0.00284	-0.23	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
LIHC	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-4.47	1.09e-05	0.00284	-0.25	-0.23	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
LIHC	cis	rs734999	0.545	rs10797441	ENSG00000225931.3	RP3-395M20.7	4.47	1.09e-05	0.00285	0.25	0.23	Ulcerative colitis;	chr1:2620221	chr1:2566410~2569888:+
LIHC	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	4.47	1.09e-05	0.00285	0.26	0.23	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
LIHC	cis	rs10833905	1	rs10833877	ENSG00000246225.5	RP11-17A1.3	-4.47	1.09e-05	0.00285	-0.31	-0.23	Sudden cardiac arrest;	chr11:22988269	chr11:22829380~22945393:+
LIHC	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-4.47	1.09e-05	0.00285	-0.3	-0.23	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
LIHC	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-4.47	1.09e-05	0.00285	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-4.47	1.09e-05	0.00285	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
LIHC	cis	rs2310173	0.898	rs4851533	ENSG00000281162.1	LINC01127	-4.47	1.09e-05	0.00285	-0.26	-0.23	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102035208	chr2:101962056~101987167:+
LIHC	cis	rs6887276	0.538	rs35897671	ENSG00000245937.6	LINC01184	-4.46	1.09e-05	0.00285	-0.28	-0.23	Height;	chr5:128014053	chr5:127940426~128083172:-
LIHC	cis	rs11671005	0.695	rs8106061	ENSG00000269473.1	CTD-2619J13.19	4.46	1.09e-05	0.00285	0.39	0.23	Mean platelet volume;	chr19:58406623	chr19:58440448~58445849:+
LIHC	cis	rs2439831	0.867	rs2260160	ENSG00000275601.1	AC011330.13	-4.46	1.09e-05	0.00285	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43603445	chr15:43642389~43643023:-
LIHC	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	4.46	1.09e-05	0.00285	0.3	0.23	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
LIHC	cis	rs1075232	0.655	rs80220087	ENSG00000270055.1	CTD-3092A11.2	-4.46	1.09e-05	0.00285	-0.46	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31263614	chr15:30487963~30490313:+
LIHC	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	4.46	1.09e-05	0.00285	0.26	0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
LIHC	cis	rs12554020	0.582	rs12552323	ENSG00000227603.1	RP11-165J3.6	-4.46	1.09e-05	0.00286	-0.4	-0.23	Schizophrenia;	chr9:93680532	chr9:93435332~93437121:-
LIHC	cis	rs2243480	1	rs313807	ENSG00000230295.1	RP11-458F8.2	-4.46	1.09e-05	0.00286	-0.24	-0.23	Diabetic kidney disease;	chr7:66034494	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs313808	ENSG00000230295.1	RP11-458F8.2	-4.46	1.09e-05	0.00286	-0.24	-0.23	Diabetic kidney disease;	chr7:66034886	chr7:66880708~66882981:+
LIHC	cis	rs9400467	0.528	rs456865	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.09e-05	0.00286	-0.23	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111297126~111298510:+
LIHC	cis	rs30380	1	rs469758	ENSG00000272109.1	CTD-2260A17.3	-4.46	1.09e-05	0.00286	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96804353~96806105:+
LIHC	cis	rs30380	1	rs30379	ENSG00000272109.1	CTD-2260A17.3	-4.46	1.09e-05	0.00286	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96804353~96806105:+
LIHC	cis	rs30380	1	rs30380	ENSG00000272109.1	CTD-2260A17.3	-4.46	1.09e-05	0.00286	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96804353~96806105:+
LIHC	cis	rs4453827	1	rs10510765	ENSG00000271916.1	RP11-884K10.6	-4.46	1.09e-05	0.00286	-0.45	-0.23	Blood protein levels;	chr3:53712179	chr3:53797764~53798019:-
LIHC	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-4.46	1.09e-05	0.00286	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
LIHC	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	4.46	1.1e-05	0.00286	0.28	0.23	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
LIHC	cis	rs875971	0.522	rs1968127	ENSG00000273024.4	INTS4P2	4.46	1.1e-05	0.00287	0.26	0.23	Aortic root size;	chr7:66591816	chr7:65647864~65715661:+
LIHC	cis	rs7809950	0.953	rs2520263	ENSG00000238832.1	snoU109	-4.46	1.1e-05	0.00287	-0.28	-0.23	Coronary artery disease;	chr7:107538674	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2520264	ENSG00000238832.1	snoU109	-4.46	1.1e-05	0.00287	-0.28	-0.23	Coronary artery disease;	chr7:107538899	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.773	rs62483722	ENSG00000238832.1	snoU109	-4.46	1.1e-05	0.00287	-0.28	-0.23	Coronary artery disease;	chr7:107545904	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.906	rs62483723	ENSG00000238832.1	snoU109	-4.46	1.1e-05	0.00287	-0.28	-0.23	Coronary artery disease;	chr7:107545913	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.953	rs2520267	ENSG00000238832.1	snoU109	-4.46	1.1e-05	0.00287	-0.28	-0.23	Coronary artery disease;	chr7:107547052	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2712214	ENSG00000238832.1	snoU109	-4.46	1.1e-05	0.00287	-0.28	-0.23	Coronary artery disease;	chr7:107547586	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2712215	ENSG00000238832.1	snoU109	-4.46	1.1e-05	0.00287	-0.28	-0.23	Coronary artery disease;	chr7:107547762	chr7:107603363~107603507:+
LIHC	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-4.46	1.1e-05	0.00287	-0.25	-0.23	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-4.46	1.1e-05	0.00287	-0.25	-0.23	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
LIHC	cis	rs9341808	0.527	rs2505946	ENSG00000272129.1	RP11-250B2.6	4.46	1.1e-05	0.00287	0.23	0.23	Sitting height ratio;	chr6:80100966	chr6:80355424~80356859:+
LIHC	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-4.46	1.1e-05	0.00287	-0.29	-0.23	Height;	chr2:46617930	chr2:46668870~46670778:+
LIHC	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	4.46	1.1e-05	0.00287	0.28	0.23	Height;	chr6:109530435	chr6:109382795~109383666:+
LIHC	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	4.46	1.1e-05	0.00287	0.44	0.23	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
LIHC	cis	rs13083990	0.747	rs6438720	ENSG00000272758.4	RP11-299J3.8	-4.46	1.1e-05	0.00287	-0.26	-0.23	Cardiac Troponin-T levels;	chr3:122298385	chr3:122416207~122443180:+
LIHC	cis	rs7193541	0.826	rs56143602	ENSG00000262904.1	TMPOP2	-4.46	1.1e-05	0.00287	-0.2	-0.23	Multiple myeloma;	chr16:74660794	chr16:74667506~74668706:+
LIHC	cis	rs4650994	0.789	rs2761471	ENSG00000273384.1	RP5-1098D14.1	-4.46	1.1e-05	0.00287	-0.28	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178630213	chr1:178651706~178652282:+
LIHC	cis	rs9425766	0.626	rs6691053	ENSG00000200674.1	RN7SKP160	4.46	1.1e-05	0.00288	0.28	0.23	Life satisfaction;	chr1:173899817	chr1:173791548~173791887:+
LIHC	cis	rs1577917	0.958	rs2121594	ENSG00000234155.1	RP11-30P6.6	4.46	1.1e-05	0.00288	0.31	0.23	Response to antipsychotic treatment;	chr6:85867136	chr6:85387219~85390186:-
LIHC	cis	rs11722228	0.522	rs881641	ENSG00000261490.1	RP11-448G15.3	4.46	1.1e-05	0.00288	0.32	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10132123	chr4:10068089~10073019:-
LIHC	cis	rs9595908	0.965	rs9595893	ENSG00000212293.1	SNORA16	4.46	1.1e-05	0.00288	0.27	0.23	Body mass index;	chr13:32601656	chr13:32420390~32420516:-
LIHC	cis	rs4694744	0.576	rs13116232	ENSG00000264696.1	AC108078.1	-4.46	1.1e-05	0.00288	-0.35	-0.23	Bacteremia;	chr4:69492807	chr4:69479331~69479434:+
LIHC	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	4.46	1.1e-05	0.00288	0.19	0.23	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
LIHC	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	4.46	1.11e-05	0.00289	0.24	0.23	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
LIHC	cis	rs2836974	0.583	rs2410124	ENSG00000255568.3	BRWD1-AS2	-4.46	1.11e-05	0.00289	-0.2	-0.23	Cognitive function;	chr21:39332834	chr21:39313935~39314962:+
LIHC	cis	rs72675573	0.821	rs1331857	ENSG00000235612.1	RP1-158P9.1	-4.46	1.11e-05	0.00289	-0.32	-0.23	Monocyte count;	chr1:56108494	chr1:56145721~56155224:+
LIHC	cis	rs2243480	1	rs313809	ENSG00000228409.4	CCT6P1	4.46	1.11e-05	0.00289	0.25	0.23	Diabetic kidney disease;	chr7:66034996	chr7:65751142~65763354:+
LIHC	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	4.46	1.11e-05	0.0029	0.32	0.23	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
LIHC	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-4.46	1.11e-05	0.0029	-0.29	-0.23	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
LIHC	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-4.46	1.11e-05	0.0029	-0.18	-0.23	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
LIHC	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	4.46	1.11e-05	0.0029	0.27	0.23	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
LIHC	cis	rs1005277	0.579	rs1740737	ENSG00000275858.1	RP11-291L22.8	4.46	1.11e-05	0.0029	0.26	0.23	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs2749616	ENSG00000275858.1	RP11-291L22.8	4.46	1.11e-05	0.0029	0.26	0.23	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs1780146	ENSG00000275858.1	RP11-291L22.8	4.46	1.11e-05	0.0029	0.26	0.23	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38450738~38451069:-
LIHC	cis	rs2836974	0.831	rs34294410	ENSG00000255568.3	BRWD1-AS2	4.46	1.11e-05	0.0029	0.27	0.23	Cognitive function;	chr21:39183234	chr21:39313935~39314962:+
LIHC	cis	rs2439831	0.681	rs484846	ENSG00000166763.7	STRCP1	4.46	1.11e-05	0.0029	0.32	0.23	Lung cancer in ever smokers;	chr15:43308605	chr15:43699488~43718184:-
LIHC	cis	rs755249	0.883	rs12035330	ENSG00000182109.6	RP11-69E11.4	4.46	1.11e-05	0.00291	0.26	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39522280~39546187:-
LIHC	cis	rs875971	0.502	rs2465121	ENSG00000228409.4	CCT6P1	4.46	1.11e-05	0.00291	0.2	0.23	Aortic root size;	chr7:66156017	chr7:65751142~65763354:+
LIHC	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-4.46	1.11e-05	0.00291	-0.29	-0.23	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
LIHC	cis	rs643506	0.774	rs11214033	ENSG00000254990.4	RP11-108O10.2	-4.46	1.11e-05	0.00291	-0.25	-0.23	Breast cancer;	chr11:111898978	chr11:111768668~111778350:-
LIHC	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	4.46	1.12e-05	0.00291	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
LIHC	cis	rs2439831	0.85	rs28509275	ENSG00000275601.1	AC011330.13	-4.46	1.12e-05	0.00291	-0.36	-0.23	Lung cancer in ever smokers;	chr15:43805907	chr15:43642389~43643023:-
LIHC	cis	rs2243480	1	rs1723270	ENSG00000230295.1	RP11-458F8.2	-4.46	1.12e-05	0.00291	-0.25	-0.23	Diabetic kidney disease;	chr7:66004843	chr7:66880708~66882981:+
LIHC	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-4.46	1.12e-05	0.00291	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
LIHC	cis	rs2836974	0.897	rs2836929	ENSG00000255568.3	BRWD1-AS2	4.46	1.12e-05	0.00291	0.27	0.23	Cognitive function;	chr21:39171885	chr21:39313935~39314962:+
LIHC	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-4.46	1.12e-05	0.00291	-0.28	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
LIHC	cis	rs7702057	0.53	rs7728055	ENSG00000271918.1	CTD-2287O16.5	4.46	1.12e-05	0.00291	0.32	0.23	Amyotrophic lateral sclerosis;	chr5:116078170	chr5:116083807~116085416:-
LIHC	cis	rs12554020	0.786	rs12551314	ENSG00000227603.1	RP11-165J3.6	4.46	1.12e-05	0.00291	0.33	0.23	Schizophrenia;	chr9:93617515	chr9:93435332~93437121:-
LIHC	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-4.46	1.12e-05	0.00292	-0.27	-0.23	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
LIHC	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-4.46	1.12e-05	0.00292	-0.27	-0.23	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
LIHC	cis	rs7709377	0.516	rs73257286	ENSG00000271918.1	CTD-2287O16.5	4.46	1.12e-05	0.00292	0.28	0.23	Metabolite levels  (X-11787);	chr5:116200654	chr5:116083807~116085416:-
LIHC	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-4.46	1.12e-05	0.00292	-0.25	-0.23	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-4.46	1.12e-05	0.00292	-0.25	-0.23	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-4.46	1.12e-05	0.00292	-0.25	-0.23	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
LIHC	cis	rs1577917	1	rs12201735	ENSG00000234155.1	RP11-30P6.6	4.46	1.12e-05	0.00292	0.31	0.23	Response to antipsychotic treatment;	chr6:85947221	chr6:85387219~85390186:-
LIHC	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	4.46	1.12e-05	0.00292	0.31	0.23	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
LIHC	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-4.46	1.12e-05	0.00292	-0.44	-0.23	Depression;	chr6:28119105	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-4.46	1.12e-05	0.00292	-0.44	-0.23	Depression;	chr6:28124907	chr6:28115628~28116551:+
LIHC	cis	rs4578769	0.694	rs72882142	ENSG00000266850.1	RP11-370A5.1	-4.46	1.12e-05	0.00292	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22806755	chr18:22723491~22907721:-
LIHC	cis	rs6565180	0.888	rs8060853	ENSG00000183604.13	SMG1P5	4.46	1.12e-05	0.00292	0.25	0.23	Tonsillectomy;	chr16:30392537	chr16:30267553~30335374:-
LIHC	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-4.46	1.12e-05	0.00292	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
LIHC	cis	rs11079159	0.651	rs2287223	ENSG00000263096.1	RP11-515O17.2	4.46	1.12e-05	0.00293	0.3	0.23	QRS duration;	chr17:55315491	chr17:55271504~55273653:-
LIHC	cis	rs748404	0.578	rs507178	ENSG00000166763.7	STRCP1	4.46	1.12e-05	0.00293	0.29	0.23	Lung cancer;	chr15:43317937	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-4.46	1.12e-05	0.00293	-0.25	-0.23	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
LIHC	cis	rs1558001	0.87	rs2216951	ENSG00000230196.1	DDX43P3	-4.46	1.12e-05	0.00293	-0.25	-0.23	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81804008	chr7:81610884~81611326:-
LIHC	cis	rs10510102	0.808	rs11200296	ENSG00000226864.1	ATE1-AS1	4.46	1.13e-05	0.00293	0.41	0.23	Breast cancer;	chr10:121971956	chr10:121928312~121951965:+
LIHC	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-4.46	1.13e-05	0.00293	-0.29	-0.23	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
LIHC	cis	rs2283831	0.536	rs9608503	ENSG00000213707.2	HMGB1P10	-4.46	1.13e-05	0.00293	-0.28	-0.23	Anti-saccade response;	chr22:26561505	chr22:26560526~26561088:+
LIHC	cis	rs2283831	0.56	rs9613212	ENSG00000213707.2	HMGB1P10	-4.46	1.13e-05	0.00293	-0.28	-0.23	Anti-saccade response;	chr22:26561808	chr22:26560526~26561088:+
LIHC	cis	rs2283831	0.56	rs9613213	ENSG00000213707.2	HMGB1P10	-4.46	1.13e-05	0.00293	-0.28	-0.23	Anti-saccade response;	chr22:26562138	chr22:26560526~26561088:+
LIHC	cis	rs2283831	0.58	rs9608504	ENSG00000213707.2	HMGB1P10	-4.46	1.13e-05	0.00293	-0.28	-0.23	Anti-saccade response;	chr22:26562216	chr22:26560526~26561088:+
LIHC	cis	rs2283831	0.56	rs9608505	ENSG00000213707.2	HMGB1P10	-4.46	1.13e-05	0.00293	-0.28	-0.23	Anti-saccade response;	chr22:26562352	chr22:26560526~26561088:+
LIHC	cis	rs2283831	0.56	rs9613214	ENSG00000213707.2	HMGB1P10	-4.46	1.13e-05	0.00293	-0.28	-0.23	Anti-saccade response;	chr22:26562376	chr22:26560526~26561088:+
LIHC	cis	rs79349575	0.783	rs58591767	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48948714	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs59270107	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48948823	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs62078370	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48949474	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs11079844	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48950972	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs62078372	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48951627	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs12602933	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48951918	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs4794003	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48952542	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs12602746	ENSG00000248278.1	SUMO2P17	4.46	1.13e-05	0.00293	0.29	0.23	Type 2 diabetes;	chr17:48954379	chr17:48874860~48908983:-
LIHC	cis	rs699371	0.507	rs10149538	ENSG00000270000.1	RP3-449M8.9	4.46	1.13e-05	0.00293	0.27	0.23	Height;	chr14:74458694	chr14:74471930~74472360:-
LIHC	cis	rs11098499	0.78	rs7680914	ENSG00000260091.1	RP11-33B1.4	-4.46	1.13e-05	0.00294	-0.17	-0.23	Corneal astigmatism;	chr4:119641898	chr4:119409333~119410233:+
LIHC	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-4.46	1.13e-05	0.00294	-0.23	-0.23	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
LIHC	cis	rs11098499	0.575	rs907204	ENSG00000260091.1	RP11-33B1.4	-4.46	1.13e-05	0.00294	-0.17	-0.23	Corneal astigmatism;	chr4:119317499	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.575	rs907205	ENSG00000260091.1	RP11-33B1.4	-4.46	1.13e-05	0.00294	-0.17	-0.23	Corneal astigmatism;	chr4:119317509	chr4:119409333~119410233:+
LIHC	cis	rs17301013	0.9	rs1793300	ENSG00000227373.4	RP11-160H22.5	-4.46	1.13e-05	0.00294	-0.29	-0.23	Systemic lupus erythematosus;	chr1:174768559	chr1:174115300~174160004:-
LIHC	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-4.46	1.13e-05	0.00294	-0.25	-0.23	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-4.46	1.13e-05	0.00294	-0.25	-0.23	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-4.46	1.13e-05	0.00294	-0.25	-0.23	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-4.46	1.13e-05	0.00294	-0.25	-0.23	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-4.46	1.13e-05	0.00294	-0.25	-0.23	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-4.46	1.13e-05	0.00294	-0.25	-0.23	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
LIHC	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-4.46	1.13e-05	0.00294	-0.27	-0.23	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
LIHC	cis	rs7637701	0.713	rs9818780	ENSG00000243926.1	TIPARP-AS1	4.46	1.13e-05	0.00294	0.21	0.23	Breast cancer;	chr3:156774969	chr3:156671862~156674378:-
LIHC	cis	rs7637701	0.713	rs9878566	ENSG00000243926.1	TIPARP-AS1	4.46	1.13e-05	0.00294	0.21	0.23	Breast cancer;	chr3:156775424	chr3:156671862~156674378:-
LIHC	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-4.46	1.13e-05	0.00294	-0.25	-0.23	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
LIHC	cis	rs10829156	0.699	rs7911922	ENSG00000225527.1	RP11-383B4.4	-4.46	1.13e-05	0.00294	-0.37	-0.23	Sudden cardiac arrest;	chr10:18542768	chr10:18531849~18533336:-
LIHC	cis	rs9595908	0.965	rs4941612	ENSG00000212293.1	SNORA16	4.46	1.13e-05	0.00294	0.28	0.23	Body mass index;	chr13:32549791	chr13:32420390~32420516:-
LIHC	cis	rs9843304	0.501	rs34540967	ENSG00000244503.1	RP11-278L15.6	4.46	1.13e-05	0.00295	0.24	0.23	Gallstone disease;	chr3:149486594	chr3:149494660~149495995:+
LIHC	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	4.46	1.13e-05	0.00295	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
LIHC	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	4.46	1.13e-05	0.00295	0.35	0.23	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
LIHC	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-4.46	1.13e-05	0.00295	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
LIHC	cis	rs11951515	0.508	rs1366410	ENSG00000248240.1	RP11-159F24.5	-4.46	1.13e-05	0.00295	-0.29	-0.23	Metabolite levels  (X-11787);	chr5:43601508	chr5:43515274~43525310:+
LIHC	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	4.46	1.13e-05	0.00295	0.24	0.23	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
LIHC	cis	rs748404	0.697	rs1095389	ENSG00000166763.7	STRCP1	4.46	1.13e-05	0.00295	0.29	0.23	Lung cancer;	chr15:43274473	chr15:43699488~43718184:-
LIHC	cis	rs1318937	1	rs2046725	ENSG00000224660.1	SH3BP5-AS1	4.46	1.14e-05	0.00295	0.23	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253651	chr3:15254184~15264493:+
LIHC	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	4.46	1.14e-05	0.00295	0.17	0.23	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
LIHC	cis	rs202072	1	rs202072	ENSG00000215022.6	RP1-257A7.4	4.46	1.14e-05	0.00296	0.25	0.23	HIV-1 viral setpoint;	chr6:13267979	chr6:13264861~13295586:-
LIHC	cis	rs8064024	1	rs8064024	ENSG00000267077.1	RP11-127I20.5	-4.46	1.14e-05	0.00296	-0.23	-0.23	Cancer;	chr16:4805278	chr16:4795265~4796532:-
LIHC	cis	rs4561483	0.667	rs3743590	ENSG00000261560.1	RP11-166B2.3	-4.46	1.14e-05	0.00296	-0.25	-0.23	Testicular germ cell tumor;	chr16:11836480	chr16:11881075~11882569:-
LIHC	cis	rs7412746	0.658	rs4970988	ENSG00000231073.1	RP11-316M1.3	-4.46	1.14e-05	0.00296	-0.23	-0.23	Melanoma;	chr1:150977586	chr1:150973123~150975534:+
LIHC	cis	rs875971	0.66	rs10215132	ENSG00000273024.4	INTS4P2	4.46	1.14e-05	0.00296	0.26	0.23	Aortic root size;	chr7:66589419	chr7:65647864~65715661:+
LIHC	cis	rs11064837	0.525	rs739422	ENSG00000248636.5	RP11-768F21.1	4.46	1.14e-05	0.00296	0.38	0.23	Schizophrenia;	chr12:119604701	chr12:119387987~119668079:-
LIHC	cis	rs72675573	0.821	rs1412216	ENSG00000235612.1	RP1-158P9.1	-4.46	1.14e-05	0.00296	-0.31	-0.23	Monocyte count;	chr1:56100245	chr1:56145721~56155224:+
LIHC	cis	rs1075232	0.579	rs58156651	ENSG00000270055.1	CTD-3092A11.2	-4.46	1.14e-05	0.00296	-0.44	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31456864	chr15:30487963~30490313:+
LIHC	cis	rs11098499	0.78	rs12504773	ENSG00000260091.1	RP11-33B1.4	-4.46	1.14e-05	0.00296	-0.17	-0.23	Corneal astigmatism;	chr4:119640994	chr4:119409333~119410233:+
LIHC	cis	rs1247318	0.856	rs2465871	ENSG00000243831.1	RP1-81D8.4	4.46	1.14e-05	0.00296	0.31	0.23	Aging;	chr6:160900556	chr6:160666228~160676523:-
LIHC	cis	rs6480314	0.522	rs10740294	ENSG00000233590.1	RP11-153K11.3	4.45	1.14e-05	0.00296	0.36	0.23	Optic nerve measurement (disc area);	chr10:68301595	chr10:68233251~68242379:-
LIHC	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	4.45	1.14e-05	0.00296	0.3	0.23	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
LIHC	cis	rs79349575	0.783	rs28409394	ENSG00000248278.1	SUMO2P17	4.45	1.14e-05	0.00296	0.29	0.23	Type 2 diabetes;	chr17:48920756	chr17:48874860~48908983:-
LIHC	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	4.45	1.14e-05	0.00296	0.36	0.23	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.512	rs2979351	ENSG00000171084.14	FAM86JP	4.45	1.14e-05	0.00296	0.36	0.23	Blood pressure (smoking interaction);	chr3:125644755	chr3:125916620~125930024:+
LIHC	cis	rs4862307	0.836	rs6829678	ENSG00000250726.1	RP11-616K6.1	-4.45	1.14e-05	0.00296	-0.25	-0.23	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184080478	chr4:184072403~184073039:+
LIHC	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-4.45	1.14e-05	0.00296	-0.23	-0.23	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
LIHC	cis	rs2749592	0.513	rs9417249	ENSG00000263064.2	RP11-291L22.7	-4.45	1.14e-05	0.00297	-0.24	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37548227	chr10:38448689~38448949:+
LIHC	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	4.45	1.14e-05	0.00297	0.25	0.23	Asthma;	chr2:102418659	chr2:102438713~102440475:+
LIHC	cis	rs12478296	0.901	rs7420176	ENSG00000261186.2	RP11-341N2.1	-4.45	1.14e-05	0.00297	-0.31	-0.23	Obesity-related traits;	chr2:242063126	chr2:242087351~242088457:-
LIHC	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	4.45	1.14e-05	0.00297	0.44	0.23	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
LIHC	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-4.45	1.14e-05	0.00297	-0.23	-0.23	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
LIHC	cis	rs11722228	0.522	rs77691548	ENSG00000261490.1	RP11-448G15.3	4.45	1.14e-05	0.00297	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10134491	chr4:10068089~10073019:-
LIHC	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	4.45	1.14e-05	0.00297	0.21	0.23	Breast size;	chr12:9232939	chr12:9277235~9313241:+
LIHC	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	4.45	1.14e-05	0.00297	0.28	0.23	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	4.45	1.14e-05	0.00297	0.28	0.23	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	4.45	1.14e-05	0.00297	0.28	0.23	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	4.45	1.14e-05	0.00297	0.28	0.23	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
LIHC	cis	rs12554020	0.581	rs4255201	ENSG00000227603.1	RP11-165J3.6	4.45	1.14e-05	0.00298	0.38	0.23	Schizophrenia;	chr9:93401055	chr9:93435332~93437121:-
LIHC	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-4.45	1.14e-05	0.00298	-0.19	-0.23	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
LIHC	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-4.45	1.15e-05	0.00298	-0.21	-0.23	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
LIHC	cis	rs748404	0.601	rs502157	ENSG00000205771.5	CATSPER2P1	4.45	1.15e-05	0.00298	0.29	0.23	Lung cancer;	chr15:43236375	chr15:43726918~43747094:-
LIHC	cis	rs7734985	0.728	rs6556904	ENSG00000250551.1	RP11-254I22.1	-4.45	1.15e-05	0.00298	-0.29	-0.23	IgG glycosylation;	chr5:96159933	chr5:96050115~96215519:+
LIHC	cis	rs9353324	1	rs9444356	ENSG00000203875.9	SNHG5	-4.45	1.15e-05	0.00298	-0.51	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85651200	chr6:85660950~85678736:-
LIHC	cis	rs6545883	0.525	rs1621048	ENSG00000271889.1	RP11-493E12.1	-4.45	1.15e-05	0.00298	-0.27	-0.23	Tuberculosis;	chr2:61137081	chr2:61151433~61162105:-
LIHC	cis	rs17772222	0.876	rs12587598	ENSG00000258789.1	RP11-507K2.3	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery calcification;	chr14:88729474	chr14:88551597~88552493:+
LIHC	cis	rs79349575	0.783	rs17708633	ENSG00000248278.1	SUMO2P17	4.45	1.15e-05	0.00298	0.29	0.23	Type 2 diabetes;	chr17:48934258	chr17:48874860~48908983:-
LIHC	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-4.45	1.15e-05	0.00298	-0.26	-0.23	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
LIHC	cis	rs10833905	1	rs10766991	ENSG00000246225.5	RP11-17A1.3	-4.45	1.15e-05	0.00298	-0.31	-0.23	Sudden cardiac arrest;	chr11:22987325	chr11:22829380~22945393:+
LIHC	cis	rs9595908	0.929	rs34916533	ENSG00000212293.1	SNORA16	4.45	1.15e-05	0.00298	0.29	0.23	Body mass index;	chr13:32500537	chr13:32420390~32420516:-
LIHC	cis	rs72675573	0.925	rs706405	ENSG00000235612.1	RP1-158P9.1	-4.45	1.15e-05	0.00298	-0.3	-0.23	Monocyte count;	chr1:56162133	chr1:56145721~56155224:+
LIHC	cis	rs61160187	0.51	rs4482855	ENSG00000272308.1	RP11-231G3.1	-4.45	1.15e-05	0.00298	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800670	chr5:60866457~60866935:-
LIHC	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.954	rs2520245	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107496983	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.954	rs2520247	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107503501	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2712201	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107505119	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2520249	ENSG00000238832.1	snoU109	-4.45	1.15e-05	0.00298	-0.28	-0.23	Coronary artery disease;	chr7:107506303	chr7:107603363~107603507:+
LIHC	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	4.45	1.15e-05	0.00298	0.25	0.23	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
LIHC	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	4.45	1.15e-05	0.00298	0.25	0.23	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
LIHC	cis	rs13083990	0.919	rs10934578	ENSG00000272758.4	RP11-299J3.8	-4.45	1.15e-05	0.00299	-0.25	-0.23	Cardiac Troponin-T levels;	chr3:122258435	chr3:122416207~122443180:+
LIHC	cis	rs6997458	0.652	rs7827051	ENSG00000253549.4	RP11-317J10.2	4.45	1.15e-05	0.00299	0.26	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85425619	chr8:85441851~85464915:-
LIHC	cis	rs113084984	0.642	rs35417544	ENSG00000271952.1	RP11-245G13.2	-4.45	1.15e-05	0.00299	-0.29	-0.23	Breast cancer;	chr2:11540277	chr2:10878269~10885118:+
LIHC	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	4.45	1.15e-05	0.00299	0.36	0.23	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
LIHC	cis	rs4356975	0.899	rs7677996	ENSG00000250919.1	RP11-813N20.3	-4.45	1.15e-05	0.00299	-0.24	-0.23	Obesity-related traits;	chr4:69075473	chr4:69027831~69044578:+
LIHC	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-4.45	1.15e-05	0.00299	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
LIHC	cis	rs61041384	1	rs4759367	ENSG00000256092.2	RP13-942N8.1	-4.45	1.15e-05	0.00299	-0.37	-0.23	Schizophrenia;	chr12:123171997	chr12:123363868~123366113:+
LIHC	cis	rs1865760	0.566	rs2051544	ENSG00000216436.2	HIST1H2APS1	-4.45	1.15e-05	0.003	-0.27	-0.23	Height;	chr6:26070865	chr6:25732497~25732827:+
LIHC	cis	rs11951515	0.509	rs12521249	ENSG00000248240.1	RP11-159F24.5	4.45	1.16e-05	0.003	0.29	0.23	Metabolite levels  (X-11787);	chr5:43558527	chr5:43515274~43525310:+
LIHC	cis	rs4356975	0.83	rs7435274	ENSG00000250919.1	RP11-813N20.3	-4.45	1.16e-05	0.003	-0.24	-0.23	Obesity-related traits;	chr4:69050281	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.83	rs7438808	ENSG00000250919.1	RP11-813N20.3	-4.45	1.16e-05	0.003	-0.24	-0.23	Obesity-related traits;	chr4:69050666	chr4:69027831~69044578:+
LIHC	cis	rs2932538	1	rs2932538	ENSG00000225075.1	RP11-426L16.3	-4.45	1.16e-05	0.003	-0.3	-0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112673921	chr1:112693688~112696621:-
LIHC	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-4.45	1.16e-05	0.003	-0.25	-0.23	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
LIHC	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	4.45	1.16e-05	0.003	0.43	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
LIHC	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	4.45	1.16e-05	0.003	0.43	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
LIHC	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	4.45	1.16e-05	0.003	0.43	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
LIHC	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	4.45	1.16e-05	0.003	0.43	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
LIHC	cis	rs3733585	0.683	rs13112015	ENSG00000250413.1	RP11-448G15.1	4.45	1.16e-05	0.003	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9932172	chr4:10006482~10009725:+
LIHC	cis	rs3733585	0.66	rs13122290	ENSG00000250413.1	RP11-448G15.1	4.45	1.16e-05	0.003	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9932208	chr4:10006482~10009725:+
LIHC	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-4.45	1.16e-05	0.00301	-0.28	-0.23	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
LIHC	cis	rs13083990	0.919	rs3804590	ENSG00000272758.4	RP11-299J3.8	4.45	1.16e-05	0.00301	0.26	0.23	Cardiac Troponin-T levels;	chr3:122259226	chr3:122416207~122443180:+
LIHC	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-4.45	1.16e-05	0.00301	-0.29	-0.23	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
LIHC	cis	rs803923	0.56	rs811688	ENSG00000230894.1	RP11-67K19.3	4.45	1.16e-05	0.00301	0.3	0.23	Lung function (FEV1/FVC);	chr9:116648461	chr9:116568449~116586328:+
LIHC	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	4.45	1.16e-05	0.00301	0.35	0.23	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
LIHC	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-4.45	1.16e-05	0.00301	-0.31	-0.23	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
LIHC	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	4.45	1.16e-05	0.00301	0.24	0.23	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
LIHC	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	4.45	1.16e-05	0.00301	0.37	0.23	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	4.45	1.16e-05	0.00301	0.37	0.23	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
LIHC	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	4.45	1.16e-05	0.00302	0.36	0.23	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
LIHC	cis	rs417065	1	rs11588420	ENSG00000227634.1	RP11-431K24.3	-4.45	1.16e-05	0.00302	-0.31	-0.23	Psoriasis;	chr1:8200696	chr1:8208672~8215210:+
LIHC	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	4.45	1.16e-05	0.00302	0.35	0.23	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
LIHC	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-4.45	1.16e-05	0.00302	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
LIHC	cis	rs734999	0.505	rs4648659	ENSG00000225931.3	RP3-395M20.7	-4.45	1.17e-05	0.00302	-0.25	-0.23	Ulcerative colitis;	chr1:2629464	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.545	rs28532547	ENSG00000225931.3	RP3-395M20.7	-4.45	1.17e-05	0.00302	-0.25	-0.23	Ulcerative colitis;	chr1:2629847	chr1:2566410~2569888:+
LIHC	cis	rs2929278	0.561	rs2927071	ENSG00000275601.1	AC011330.13	-4.45	1.17e-05	0.00302	-0.29	-0.23	Schizophrenia;	chr15:43626883	chr15:43642389~43643023:-
LIHC	cis	rs30380	1	rs30378	ENSG00000272109.1	CTD-2260A17.3	-4.45	1.17e-05	0.00302	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96804353~96806105:+
LIHC	cis	rs17301013	0.9	rs1754351	ENSG00000227373.4	RP11-160H22.5	-4.45	1.17e-05	0.00302	-0.29	-0.23	Systemic lupus erythematosus;	chr1:174762458	chr1:174115300~174160004:-
LIHC	cis	rs901683	1	rs9422653	ENSG00000230869.1	CTGLF10P	4.45	1.17e-05	0.00302	0.54	0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45553470	chr10:45678692~45700532:+
LIHC	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-4.45	1.17e-05	0.00303	-0.29	-0.23	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
LIHC	cis	rs3812762	0.917	rs10743087	ENSG00000254860.4	TMEM9B-AS1	-4.45	1.17e-05	0.00303	-0.24	-0.23	Hypospadias;	chr11:8764511	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	4.45	1.17e-05	0.00304	0.23	0.23	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
LIHC	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	4.45	1.17e-05	0.00304	0.24	0.23	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
LIHC	cis	rs2836974	0.899	rs35774464	ENSG00000255568.3	BRWD1-AS2	4.45	1.17e-05	0.00304	0.27	0.23	Cognitive function;	chr21:39208243	chr21:39313935~39314962:+
LIHC	cis	rs875971	0.545	rs67397473	ENSG00000228409.4	CCT6P1	-4.45	1.17e-05	0.00304	-0.2	-0.23	Aortic root size;	chr7:66168318	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs10950027	ENSG00000228409.4	CCT6P1	-4.45	1.17e-05	0.00304	-0.2	-0.23	Aortic root size;	chr7:66169164	chr7:65751142~65763354:+
LIHC	cis	rs7637701	0.773	rs4098	ENSG00000243926.1	TIPARP-AS1	4.45	1.17e-05	0.00304	0.21	0.23	Breast cancer;	chr3:156783274	chr3:156671862~156674378:-
LIHC	cis	rs7637701	0.773	rs7623691	ENSG00000243926.1	TIPARP-AS1	-4.45	1.17e-05	0.00304	-0.21	-0.23	Breast cancer;	chr3:156790921	chr3:156671862~156674378:-
LIHC	cis	rs921968	0.591	rs3731877	ENSG00000272555.1	RP11-459I19.1	-4.45	1.17e-05	0.00304	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218737776	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs7562426	ENSG00000272555.1	RP11-459I19.1	-4.45	1.17e-05	0.00304	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218740395	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs1079177	ENSG00000272555.1	RP11-459I19.1	-4.45	1.17e-05	0.00304	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218741206	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs755112	ENSG00000272555.1	RP11-459I19.1	-4.45	1.17e-05	0.00304	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218741329	chr2:218818690~218819144:+
LIHC	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-4.45	1.17e-05	0.00304	-0.46	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
LIHC	cis	rs763121	0.853	rs1056610	ENSG00000273076.1	RP3-508I15.22	-4.45	1.17e-05	0.00304	-0.26	-0.23	Menopause (age at onset);	chr22:38684073	chr22:38743495~38743910:+
LIHC	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	4.45	1.18e-05	0.00304	0.26	0.23	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
LIHC	cis	rs875971	0.545	rs73142265	ENSG00000228409.4	CCT6P1	-4.45	1.18e-05	0.00305	-0.2	-0.23	Aortic root size;	chr7:66234510	chr7:65751142~65763354:+
LIHC	cis	rs17270561	1	rs17270561	ENSG00000272810.1	U91328.22	4.45	1.18e-05	0.00305	0.3	0.23	Iron status biomarkers;	chr6:25820211	chr6:26013241~26013757:+
LIHC	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	4.45	1.18e-05	0.00305	0.27	0.23	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
LIHC	cis	rs4356975	0.83	rs10012607	ENSG00000250919.1	RP11-813N20.3	-4.45	1.18e-05	0.00305	-0.24	-0.23	Obesity-related traits;	chr4:69048866	chr4:69027831~69044578:+
LIHC	cis	rs2836974	0.897	rs8132295	ENSG00000255568.3	BRWD1-AS2	-4.45	1.18e-05	0.00305	-0.26	-0.23	Cognitive function;	chr21:39155848	chr21:39313935~39314962:+
LIHC	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-4.45	1.18e-05	0.00305	-0.31	-0.23	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
LIHC	cis	rs9595908	0.965	rs12323094	ENSG00000212293.1	SNORA16	4.45	1.18e-05	0.00305	0.28	0.23	Body mass index;	chr13:32569227	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.965	rs12323101	ENSG00000212293.1	SNORA16	4.45	1.18e-05	0.00305	0.28	0.23	Body mass index;	chr13:32569269	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.965	rs1123462	ENSG00000212293.1	SNORA16	4.45	1.18e-05	0.00305	0.28	0.23	Body mass index;	chr13:32571325	chr13:32420390~32420516:-
LIHC	cis	rs728616	0.614	rs35193855	ENSG00000225484.5	NUTM2B-AS1	-4.45	1.18e-05	0.00305	-0.43	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028739	chr10:79663088~79826594:-
LIHC	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	4.45	1.18e-05	0.00306	0.19	0.23	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	4.45	1.18e-05	0.00306	0.19	0.23	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
LIHC	cis	rs7208859	0.673	rs4131618	ENSG00000266490.1	CTD-2349P21.9	4.45	1.18e-05	0.00306	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30792372~30792833:+
LIHC	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	4.45	1.18e-05	0.00306	0.28	0.23	Height;	chr6:109366911	chr6:109382795~109383666:+
LIHC	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-4.45	1.18e-05	0.00306	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
LIHC	cis	rs17270561	0.636	rs2070642	ENSG00000216436.2	HIST1H2APS1	-4.45	1.18e-05	0.00306	-0.28	-0.23	Iron status biomarkers;	chr6:25830984	chr6:25732497~25732827:+
LIHC	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	4.45	1.18e-05	0.00306	0.38	0.23	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	4.45	1.18e-05	0.00306	0.38	0.23	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
LIHC	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	4.45	1.18e-05	0.00306	0.38	0.23	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
LIHC	cis	rs960902	0.747	rs62135565	ENSG00000213553.4	RPLP0P6	4.45	1.18e-05	0.00306	0.19	0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37490364	chr2:38481851~38482804:+
LIHC	cis	rs7119038	0.865	rs7117261	ENSG00000255239.1	AP002954.6	4.45	1.18e-05	0.00306	0.35	0.23	Sjögren's syndrome;	chr11:118870448	chr11:118688039~118690600:-
LIHC	cis	rs240993	0.812	rs9374262	ENSG00000271789.1	RP5-1112D6.7	4.45	1.18e-05	0.00306	0.28	0.23	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111297126~111298510:+
LIHC	cis	rs2929278	0.589	rs7174732	ENSG00000275601.1	AC011330.13	4.45	1.18e-05	0.00306	0.29	0.23	Schizophrenia;	chr15:43746265	chr15:43642389~43643023:-
LIHC	cis	rs748404	0.604	rs2278857	ENSG00000166763.7	STRCP1	4.45	1.18e-05	0.00306	0.28	0.23	Lung cancer;	chr15:43340351	chr15:43699488~43718184:-
LIHC	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-4.45	1.19e-05	0.00307	-0.36	-0.23	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
LIHC	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	4.45	1.19e-05	0.00307	0.37	0.23	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	4.45	1.19e-05	0.00307	0.37	0.23	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
LIHC	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-4.45	1.19e-05	0.00307	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
LIHC	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-4.45	1.19e-05	0.00308	-0.23	-0.23	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
LIHC	cis	rs3733589	0.59	rs12642537	ENSG00000250413.1	RP11-448G15.1	4.44	1.19e-05	0.00308	0.38	0.23	Renal overload gout;	chr4:10035997	chr4:10006482~10009725:+
LIHC	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	4.44	1.19e-05	0.00308	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
LIHC	cis	rs921968	0.565	rs7599568	ENSG00000272555.1	RP11-459I19.1	-4.44	1.19e-05	0.00308	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218743096	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs3755045	ENSG00000272555.1	RP11-459I19.1	-4.44	1.19e-05	0.00308	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218744439	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs2037622	ENSG00000272555.1	RP11-459I19.1	-4.44	1.19e-05	0.00308	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218744717	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs2272191	ENSG00000272555.1	RP11-459I19.1	-4.44	1.19e-05	0.00308	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218745053	chr2:218818690~218819144:+
LIHC	cis	rs7607369	0.714	rs2272190	ENSG00000272555.1	RP11-459I19.1	-4.44	1.19e-05	0.00308	-0.25	-0.23	Amyotrophic lateral sclerosis;Red blood cell count;	chr2:218745272	chr2:218818690~218819144:+
LIHC	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	4.44	1.19e-05	0.00308	0.28	0.23	Height;	chr6:109380457	chr6:109382795~109383666:+
LIHC	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	4.44	1.19e-05	0.00308	0.28	0.23	Height;	chr6:109380990	chr6:109382795~109383666:+
LIHC	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-4.44	1.19e-05	0.00309	-0.31	-0.23	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
LIHC	cis	rs929596	0.793	rs2602376	ENSG00000233445.1	RPL17P11	4.44	1.19e-05	0.00309	0.34	0.23	Total bilirubin levels in HIV-1 infection;	chr2:233673405	chr2:233721522~233722065:-
LIHC	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	4.44	1.2e-05	0.00309	0.26	0.23	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
LIHC	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-4.44	1.2e-05	0.00309	-0.44	-0.23	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
LIHC	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-4.44	1.2e-05	0.00309	-0.44	-0.23	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
LIHC	cis	rs10829156	0.786	rs7093907	ENSG00000240291.1	RP11-499P20.2	4.44	1.2e-05	0.00309	0.38	0.23	Sudden cardiac arrest;	chr10:18587225	chr10:18513115~18545651:-
LIHC	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	4.44	1.2e-05	0.0031	0.21	0.23	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
LIHC	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	4.44	1.2e-05	0.0031	0.28	0.23	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
LIHC	cis	rs2243480	0.706	rs34466769	ENSG00000230295.1	RP11-458F8.2	-4.44	1.2e-05	0.0031	-0.22	-0.23	Diabetic kidney disease;	chr7:65988305	chr7:66880708~66882981:+
LIHC	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	4.44	1.2e-05	0.0031	0.26	0.23	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
LIHC	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	4.44	1.2e-05	0.0031	0.26	0.23	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
LIHC	cis	rs17270561	0.779	rs78589800	ENSG00000216436.2	HIST1H2APS1	-4.44	1.2e-05	0.0031	-0.36	-0.23	Iron status biomarkers;	chr6:25883272	chr6:25732497~25732827:+
LIHC	cis	rs2929278	0.562	rs8033846	ENSG00000275601.1	AC011330.13	4.44	1.2e-05	0.0031	0.29	0.23	Schizophrenia;	chr15:43743165	chr15:43642389~43643023:-
LIHC	cis	rs4578769	0.959	rs11082184	ENSG00000265943.1	RP11-739L10.1	4.44	1.2e-05	0.0031	0.3	0.23	Eosinophil percentage of white cells;	chr18:22872288	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.959	rs12964817	ENSG00000265943.1	RP11-739L10.1	4.44	1.2e-05	0.0031	0.3	0.23	Eosinophil percentage of white cells;	chr18:22876657	chr18:22699481~22933764:-
LIHC	cis	rs763512	0.504	rs11652399	ENSG00000276054.1	RP11-378E13.3	4.44	1.2e-05	0.0031	0.3	0.23	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37509679	chr17:37386886~37387926:+
LIHC	cis	rs11951515	0.508	rs7706431	ENSG00000248240.1	RP11-159F24.5	-4.44	1.2e-05	0.0031	-0.29	-0.23	Metabolite levels  (X-11787);	chr5:43582321	chr5:43515274~43525310:+
LIHC	cis	rs11951515	0.508	rs6898866	ENSG00000248240.1	RP11-159F24.5	-4.44	1.2e-05	0.0031	-0.29	-0.23	Metabolite levels  (X-11787);	chr5:43586273	chr5:43515274~43525310:+
LIHC	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-4.44	1.2e-05	0.0031	-0.22	-0.23	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
LIHC	cis	rs9467603	0.925	rs1892253	ENSG00000216436.2	HIST1H2APS1	4.44	1.2e-05	0.0031	0.51	0.23	Intelligence (multi-trait analysis);	chr6:25782086	chr6:25732497~25732827:+
LIHC	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-4.44	1.2e-05	0.00311	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
LIHC	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-4.44	1.2e-05	0.00311	-0.29	-0.23	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
LIHC	cis	rs6445975	0.572	rs6768547	ENSG00000272360.1	RP11-359I18.5	-4.44	1.2e-05	0.00311	-0.32	-0.23	Systemic lupus erythematosus;	chr3:58449242	chr3:58490830~58491291:-
LIHC	cis	rs4862307	0.836	rs4507404	ENSG00000250726.1	RP11-616K6.1	-4.44	1.2e-05	0.00311	-0.25	-0.23	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184082614	chr4:184072403~184073039:+
LIHC	cis	rs202072	0.725	rs202071	ENSG00000215022.6	RP1-257A7.4	-4.44	1.2e-05	0.00311	-0.25	-0.23	HIV-1 viral setpoint;	chr6:13267926	chr6:13264861~13295586:-
LIHC	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	4.44	1.2e-05	0.00311	0.26	0.23	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
LIHC	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	4.44	1.21e-05	0.00311	0.36	0.23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
LIHC	cis	rs950169	0.922	rs11638445	ENSG00000259295.5	CSPG4P12	4.44	1.21e-05	0.00311	0.33	0.23	Schizophrenia;	chr15:84594463	chr15:85191438~85213905:+
LIHC	cis	rs6545883	0.525	rs2049747	ENSG00000271889.1	RP11-493E12.1	-4.44	1.21e-05	0.00311	-0.28	-0.23	Tuberculosis;	chr2:61137019	chr2:61151433~61162105:-
LIHC	cis	rs2749097	0.825	rs6670731	ENSG00000244256.3	RN7SL130P	-4.44	1.21e-05	0.00311	-0.28	-0.23	Alcohol consumption (transferrin glycosylation);	chr1:63657487	chr1:63655743~63656047:+
LIHC	cis	rs4650994	0.524	rs2761465	ENSG00000273384.1	RP5-1098D14.1	-4.44	1.21e-05	0.00311	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178610269	chr1:178651706~178652282:+
LIHC	cis	rs10256972	0.524	rs6945202	ENSG00000199023.2	MIR339	-4.44	1.21e-05	0.00312	-0.27	-0.23	Endometriosis;Longevity;	chr7:1076922	chr7:1022935~1023045:-
LIHC	cis	rs11098499	0.754	rs1849457	ENSG00000260091.1	RP11-33B1.4	-4.44	1.21e-05	0.00312	-0.17	-0.23	Corneal astigmatism;	chr4:119333200	chr4:119409333~119410233:+
LIHC	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	4.44	1.21e-05	0.00312	0.23	0.23	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	4.44	1.21e-05	0.00312	0.23	0.23	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	4.44	1.21e-05	0.00312	0.23	0.23	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
LIHC	cis	rs12554020	0.686	rs12553775	ENSG00000227603.1	RP11-165J3.6	4.44	1.21e-05	0.00312	0.42	0.23	Schizophrenia;	chr9:93630107	chr9:93435332~93437121:-
LIHC	cis	rs7508	0.511	rs438818	ENSG00000253671.1	RP11-806O11.1	-4.44	1.21e-05	0.00313	-0.28	-0.23	Atrial fibrillation;	chr8:18042052	chr8:17808941~17820868:+
LIHC	cis	rs1865760	0.622	rs9295685	ENSG00000216436.2	HIST1H2APS1	-4.44	1.21e-05	0.00313	-0.27	-0.23	Height;	chr6:26071497	chr6:25732497~25732827:+
LIHC	cis	rs2688482	0.557	rs3103952	ENSG00000207650.1	MIR570	4.44	1.21e-05	0.00313	0.3	0.23	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195699401~195699497:+
LIHC	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	4.44	1.21e-05	0.00313	0.28	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
LIHC	cis	rs17711722	0.522	rs62469933	ENSG00000226002.1	RP11-460N20.5	4.44	1.21e-05	0.00313	0.25	0.23	Calcium levels;	chr7:65800652	chr7:65084103~65100232:+
LIHC	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-4.44	1.21e-05	0.00313	-0.28	-0.23	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-4.44	1.21e-05	0.00313	-0.28	-0.23	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-4.44	1.21e-05	0.00313	-0.28	-0.23	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
LIHC	cis	rs9675120	0.638	rs8079519	ENSG00000262006.1	RP11-700H6.4	-4.44	1.21e-05	0.00313	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50855456	chr17:50909637~50910232:-
LIHC	cis	rs9675120	0.638	rs9910819	ENSG00000262006.1	RP11-700H6.4	-4.44	1.21e-05	0.00313	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50855845	chr17:50909637~50910232:-
LIHC	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-4.44	1.21e-05	0.00313	-0.27	-0.23	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
LIHC	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	4.44	1.22e-05	0.00314	0.36	0.23	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
LIHC	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-4.44	1.22e-05	0.00314	-0.27	-0.23	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
LIHC	cis	rs901683	0.85	rs73291121	ENSG00000230869.1	CTGLF10P	-4.44	1.22e-05	0.00314	-0.56	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45601956	chr10:45678692~45700532:+
LIHC	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-4.44	1.22e-05	0.00314	-0.28	-0.23	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-4.44	1.22e-05	0.00314	-0.28	-0.23	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
LIHC	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-4.44	1.22e-05	0.00314	-0.28	-0.23	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
LIHC	cis	rs79349575	0.783	rs4399576	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48932473	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.687	rs12602179	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48932672	chr17:48874860~48908983:-
LIHC	cis	rs875971	0.545	rs11767262	ENSG00000273142.1	RP11-458F8.4	4.44	1.22e-05	0.00315	0.22	0.23	Aortic root size;	chr7:66302237	chr7:66902857~66906297:+
LIHC	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	4.44	1.22e-05	0.00315	0.23	0.23	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
LIHC	cis	rs763121	0.853	rs10135	ENSG00000273076.1	RP3-508I15.22	-4.44	1.22e-05	0.00315	-0.26	-0.23	Menopause (age at onset);	chr22:38686169	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.785	rs5750646	ENSG00000273076.1	RP3-508I15.22	4.44	1.22e-05	0.00315	0.26	0.23	Menopause (age at onset);	chr22:38617825	chr22:38743495~38743910:+
LIHC	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-4.44	1.22e-05	0.00315	-0.19	-0.23	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
LIHC	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-4.44	1.22e-05	0.00315	-0.46	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
LIHC	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-4.44	1.22e-05	0.00315	-0.46	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
LIHC	cis	rs1075232	1	rs34959140	ENSG00000270055.1	CTD-3092A11.2	-4.44	1.22e-05	0.00315	-0.46	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30487963~30490313:+
LIHC	cis	rs79349575	0.749	rs46521	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48911167	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.749	rs318093	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48911992	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.745	rs170319	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48914169	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs318090	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48914390	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.721	rs3744608	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48915871	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.651	rs4378658	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48916008	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs12453374	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48917484	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs12453394	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48917608	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs62075838	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48919070	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs62075839	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48919072	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs4255820	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48919221	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.811	rs12601072	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48920636	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.749	rs58838744	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48921540	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.811	rs60708039	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48922011	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.783	rs55771415	ENSG00000248278.1	SUMO2P17	4.44	1.22e-05	0.00315	0.29	0.23	Type 2 diabetes;	chr17:48922575	chr17:48874860~48908983:-
LIHC	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	4.44	1.22e-05	0.00315	0.42	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
LIHC	cis	rs9326248	0.501	rs4938351	ENSG00000236267.1	AP006216.5	4.44	1.22e-05	0.00315	0.24	0.23	Blood protein levels;	chr11:117151636	chr11:116813204~116814003:-
LIHC	cis	rs9834975	0.967	rs9823467	ENSG00000272758.4	RP11-299J3.8	-4.44	1.22e-05	0.00315	-0.26	-0.23	Diastolic blood pressure;	chr3:122403245	chr3:122416207~122443180:+
LIHC	cis	rs4650994	0.524	rs1998544	ENSG00000273384.1	RP5-1098D14.1	-4.44	1.23e-05	0.00316	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178636141	chr1:178651706~178652282:+
LIHC	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-4.44	1.23e-05	0.00316	-0.28	-0.23	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
LIHC	cis	rs6600671	0.899	rs2319971	ENSG00000227082.1	CH17-437K3.1	-4.44	1.23e-05	0.00316	-0.31	-0.23	Hip geometry;	chr1:121485184	chr1:121396754~121463129:+
LIHC	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	4.44	1.23e-05	0.00316	0.35	0.23	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
LIHC	cis	rs7809950	0.954	rs2520241	ENSG00000238832.1	snoU109	-4.44	1.23e-05	0.00316	-0.29	-0.23	Coronary artery disease;	chr7:107494998	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.954	rs2520242	ENSG00000238832.1	snoU109	4.44	1.23e-05	0.00316	0.29	0.23	Coronary artery disease;	chr7:107495875	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs17154077	ENSG00000238832.1	snoU109	4.44	1.23e-05	0.00316	0.28	0.23	Coronary artery disease;	chr7:107437496	chr7:107603363~107603507:+
LIHC	cis	rs2739330	0.828	rs5751770	ENSG00000206090.4	AP000350.7	4.44	1.23e-05	0.00316	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23939998~23942798:+
LIHC	cis	rs875971	0.545	rs2707851	ENSG00000273142.1	RP11-458F8.4	-4.44	1.23e-05	0.00317	-0.22	-0.23	Aortic root size;	chr7:66624178	chr7:66902857~66906297:+
LIHC	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	4.44	1.23e-05	0.00317	0.25	0.23	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
LIHC	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	4.44	1.23e-05	0.00317	0.26	0.23	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	4.44	1.23e-05	0.00317	0.26	0.23	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	4.44	1.23e-05	0.00317	0.26	0.23	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	4.44	1.23e-05	0.00317	0.26	0.23	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	4.44	1.23e-05	0.00317	0.26	0.23	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	4.44	1.23e-05	0.00317	0.26	0.23	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
LIHC	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	4.44	1.23e-05	0.00317	0.21	0.23	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
LIHC	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-4.44	1.23e-05	0.00317	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
LIHC	cis	rs7546	0.504	rs2075636	ENSG00000267077.1	RP11-127I20.5	-4.44	1.23e-05	0.00317	-0.24	-0.23	Cancer;	chr16:4888320	chr16:4795265~4796532:-
LIHC	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	4.44	1.23e-05	0.00317	0.17	0.23	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
LIHC	cis	rs3733589	0.744	rs13135351	ENSG00000250413.1	RP11-448G15.1	4.44	1.23e-05	0.00317	0.38	0.23	Renal overload gout;	chr4:10031901	chr4:10006482~10009725:+
LIHC	cis	rs901683	0.571	rs7898761	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45614085	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs77637903	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45614661	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs41301625	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45615591	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs77592696	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45616087	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs74699241	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45616268	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs75205426	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45616583	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76251295	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45616763	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs77337258	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45617343	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76974099	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45622334	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs78628569	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45624952	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs77820027	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45627820	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76608282	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45627863	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs79353548	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45628673	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs112121507	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45628891	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs79180351	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45630238	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs74482366	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45631441	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76549378	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45632385	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs75085022	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45633821	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.571	rs77407875	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45634138	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs113009703	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45634407	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs77820794	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45634720	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76612219	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45635258	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs79180736	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45637045	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs74895607	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45638171	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs78230012	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45638760	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.571	rs79050563	ENSG00000230869.1	CTGLF10P	-4.44	1.23e-05	0.00317	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45639532	chr10:45678692~45700532:+
LIHC	cis	rs950169	0.656	rs748455	ENSG00000259295.5	CSPG4P12	4.44	1.23e-05	0.00317	0.33	0.23	Schizophrenia;	chr15:84606344	chr15:85191438~85213905:+
LIHC	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	4.44	1.23e-05	0.00317	0.47	0.23	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
LIHC	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	4.44	1.23e-05	0.00317	0.47	0.23	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
LIHC	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	4.44	1.23e-05	0.00317	0.47	0.23	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
LIHC	cis	rs11098499	0.908	rs28559989	ENSG00000260091.1	RP11-33B1.4	-4.44	1.23e-05	0.00318	-0.17	-0.23	Corneal astigmatism;	chr4:119465472	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs28632018	ENSG00000260091.1	RP11-33B1.4	-4.44	1.23e-05	0.00318	-0.17	-0.23	Corneal astigmatism;	chr4:119465575	chr4:119409333~119410233:+
LIHC	cis	rs4718428	0.576	rs12698546	ENSG00000230295.1	RP11-458F8.2	-4.44	1.23e-05	0.00318	-0.2	-0.23	Corneal structure;	chr7:66801919	chr7:66880708~66882981:+
LIHC	cis	rs8064024	0.676	rs2075467	ENSG00000267077.1	RP11-127I20.5	-4.44	1.24e-05	0.00318	-0.23	-0.23	Cancer;	chr16:4823241	chr16:4795265~4796532:-
LIHC	cis	rs12744310	0.526	rs11209858	ENSG00000235358.1	RP11-399E6.1	-4.44	1.24e-05	0.00318	-0.3	-0.23	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316522	chr1:41242373~41284861:+
LIHC	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-4.44	1.24e-05	0.00318	-0.24	-0.23	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
LIHC	cis	rs17711722	0.522	rs6957759	ENSG00000226002.1	RP11-460N20.5	4.44	1.24e-05	0.00318	0.25	0.23	Calcium levels;	chr7:65806798	chr7:65084103~65100232:+
LIHC	cis	rs643506	0.845	rs2850245	ENSG00000254990.4	RP11-108O10.2	4.44	1.24e-05	0.00318	0.25	0.23	Breast cancer;	chr11:111890014	chr11:111768668~111778350:-
LIHC	cis	rs16917919	0.688	rs11007642	ENSG00000225527.1	RP11-383B4.4	-4.44	1.24e-05	0.00318	-0.32	-0.23	Brain structure (hippocampal volume);	chr10:18915313	chr10:18531849~18533336:-
LIHC	cis	rs6997458	0.785	rs6996345	ENSG00000253549.4	RP11-317J10.2	4.44	1.24e-05	0.00318	0.26	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85418846	chr8:85441851~85464915:-
LIHC	cis	rs6997458	0.774	rs6984619	ENSG00000253549.4	RP11-317J10.2	4.44	1.24e-05	0.00318	0.26	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85419149	chr8:85441851~85464915:-
LIHC	cis	rs734999	0.545	rs7368105	ENSG00000225931.3	RP3-395M20.7	4.44	1.24e-05	0.00318	0.25	0.23	Ulcerative colitis;	chr1:2625109	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.545	rs7364820	ENSG00000225931.3	RP3-395M20.7	4.44	1.24e-05	0.00318	0.25	0.23	Ulcerative colitis;	chr1:2625270	chr1:2566410~2569888:+
LIHC	cis	rs1062753	0.527	rs62240998	ENSG00000237037.8	NDUFA6-AS1	-4.44	1.24e-05	0.00319	-0.33	-0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41958697	chr22:42090931~42137742:+
LIHC	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	4.44	1.24e-05	0.00319	0.32	0.23	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
LIHC	cis	rs734999	0.588	rs6668149	ENSG00000225931.3	RP3-395M20.7	-4.44	1.24e-05	0.00319	-0.25	-0.23	Ulcerative colitis;	chr1:2626869	chr1:2566410~2569888:+
LIHC	cis	rs2060793	0.519	rs1403247	ENSG00000251991.1	RNU7-49P	-4.44	1.24e-05	0.00319	-0.26	-0.23	Vitamin D levels;	chr11:14611024	chr11:14478892~14478953:+
LIHC	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	4.44	1.24e-05	0.00319	0.21	0.23	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	4.44	1.24e-05	0.00319	0.21	0.23	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
LIHC	cis	rs5758511	0.514	rs5751240	ENSG00000205702.9	CYP2D7	4.44	1.24e-05	0.00319	0.28	0.23	Birth weight;	chr22:42199252	chr22:42140203~42144577:-
LIHC	cis	rs61160187	0.527	rs6449500	ENSG00000272308.1	RP11-231G3.1	-4.44	1.24e-05	0.00319	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:60866457~60866935:-
LIHC	cis	rs748404	0.697	rs555001	ENSG00000166763.7	STRCP1	4.43	1.24e-05	0.00319	0.29	0.23	Lung cancer;	chr15:43253530	chr15:43699488~43718184:-
LIHC	cis	rs17818399	0.781	rs4952837	ENSG00000279254.1	RP11-536C12.1	-4.43	1.24e-05	0.0032	-0.29	-0.23	Height;	chr2:46638595	chr2:46668870~46670778:+
LIHC	cis	rs17818399	0.781	rs6746598	ENSG00000279254.1	RP11-536C12.1	-4.43	1.24e-05	0.0032	-0.29	-0.23	Height;	chr2:46638634	chr2:46668870~46670778:+
LIHC	cis	rs7709377	0.516	rs73257302	ENSG00000271918.1	CTD-2287O16.5	4.43	1.24e-05	0.0032	0.28	0.23	Metabolite levels  (X-11787);	chr5:116207391	chr5:116083807~116085416:-
LIHC	cis	rs17711722	0.565	rs73372653	ENSG00000273024.4	INTS4P2	-4.43	1.24e-05	0.0032	-0.25	-0.23	Calcium levels;	chr7:65977808	chr7:65647864~65715661:+
LIHC	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	4.43	1.25e-05	0.0032	0.36	0.23	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
LIHC	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	4.43	1.25e-05	0.0032	0.36	0.23	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
LIHC	cis	rs2735413	0.56	rs73562716	ENSG00000276007.1	RP11-358L22.3	4.43	1.25e-05	0.0032	0.29	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78092518	chr16:78123243~78124332:+
LIHC	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	4.43	1.25e-05	0.0032	0.26	0.23	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
LIHC	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	4.43	1.25e-05	0.0032	0.26	0.23	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
LIHC	cis	rs11951515	0.508	rs7705166	ENSG00000248240.1	RP11-159F24.5	-4.43	1.25e-05	0.00321	-0.29	-0.23	Metabolite levels  (X-11787);	chr5:43587346	chr5:43515274~43525310:+
LIHC	cis	rs7216064	0.589	rs8072723	ENSG00000278740.1	RP11-147L13.14	-4.43	1.25e-05	0.00321	-0.28	-0.23	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68188547~68189165:+
LIHC	cis	rs860295	0.775	rs1749410	ENSG00000203761.5	MSTO2P	4.43	1.25e-05	0.00321	0.2	0.23	Body mass index;	chr1:155874274	chr1:155745829~155750137:+
LIHC	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-4.43	1.25e-05	0.00321	-0.46	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
LIHC	cis	rs7809950	0.678	rs17153981	ENSG00000238832.1	snoU109	-4.43	1.25e-05	0.00321	-0.3	-0.23	Coronary artery disease;	chr7:107281661	chr7:107603363~107603507:+
LIHC	cis	rs2836974	0.863	rs12483216	ENSG00000255568.3	BRWD1-AS2	4.43	1.25e-05	0.00321	0.26	0.23	Cognitive function;	chr21:39167688	chr21:39313935~39314962:+
LIHC	cis	rs7568498	0.517	rs197261	ENSG00000227403.1	AC009299.3	4.43	1.25e-05	0.00321	0.3	0.23	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161048312	chr2:161244739~161249050:+
LIHC	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-4.43	1.25e-05	0.00322	-0.28	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-4.43	1.25e-05	0.00322	-0.28	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-4.43	1.25e-05	0.00322	-0.28	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
LIHC	cis	rs728616	0.867	rs61859022	ENSG00000225484.5	NUTM2B-AS1	-4.43	1.25e-05	0.00322	-0.52	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79663088~79826594:-
LIHC	cis	rs763512	0.504	rs853216	ENSG00000276054.1	RP11-378E13.3	4.43	1.25e-05	0.00322	0.3	0.23	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37502902	chr17:37386886~37387926:+
LIHC	cis	rs7412746	0.524	rs58304714	ENSG00000231073.1	RP11-316M1.3	4.43	1.25e-05	0.00322	0.24	0.23	Melanoma;	chr1:150859085	chr1:150973123~150975534:+
LIHC	cis	rs4356975	0.932	rs7657426	ENSG00000250919.1	RP11-813N20.3	-4.43	1.25e-05	0.00322	-0.23	-0.23	Obesity-related traits;	chr4:69079291	chr4:69027831~69044578:+
LIHC	cis	rs1577917	0.958	rs11755048	ENSG00000234155.1	RP11-30P6.6	4.43	1.25e-05	0.00322	0.32	0.23	Response to antipsychotic treatment;	chr6:85804616	chr6:85387219~85390186:-
LIHC	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-4.43	1.25e-05	0.00322	-0.31	-0.23	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
LIHC	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	4.43	1.25e-05	0.00322	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
LIHC	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-4.43	1.26e-05	0.00322	-0.22	-0.23	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
LIHC	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-4.43	1.26e-05	0.00322	-0.22	-0.23	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
LIHC	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-4.43	1.26e-05	0.00322	-0.22	-0.23	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
LIHC	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-4.43	1.26e-05	0.00322	-0.22	-0.23	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
LIHC	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-4.43	1.26e-05	0.00322	-0.28	-0.23	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
LIHC	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	4.43	1.26e-05	0.00323	0.24	0.23	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	4.43	1.26e-05	0.00323	0.24	0.23	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
LIHC	cis	rs734999	0.588	rs876938	ENSG00000225931.3	RP3-395M20.7	4.43	1.26e-05	0.00323	0.25	0.23	Ulcerative colitis;	chr1:2591773	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.588	rs745368	ENSG00000225931.3	RP3-395M20.7	4.43	1.26e-05	0.00323	0.25	0.23	Ulcerative colitis;	chr1:2592766	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.566	rs10752747	ENSG00000225931.3	RP3-395M20.7	4.43	1.26e-05	0.00323	0.25	0.23	Ulcerative colitis;	chr1:2593476	chr1:2566410~2569888:+
LIHC	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-4.43	1.26e-05	0.00323	-0.26	-0.23	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
LIHC	cis	rs921968	0.565	rs7603709	ENSG00000272555.1	RP11-459I19.1	-4.43	1.26e-05	0.00323	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218777878	chr2:218818690~218819144:+
LIHC	cis	rs2284219	0.929	rs12533248	ENSG00000196295.10	AC005154.6	-4.43	1.26e-05	0.00323	-0.17	-0.23	Type 2 diabetes;	chr7:30678973	chr7:30516309~30594809:-
LIHC	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-4.43	1.26e-05	0.00323	-0.25	-0.23	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
LIHC	cis	rs7208859	0.673	rs11656845	ENSG00000266490.1	CTD-2349P21.9	4.43	1.26e-05	0.00323	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-4.43	1.26e-05	0.00323	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
LIHC	cis	rs875971	0.545	rs4718325	ENSG00000228409.4	CCT6P1	-4.43	1.26e-05	0.00324	-0.19	-0.23	Aortic root size;	chr7:66215323	chr7:65751142~65763354:+
LIHC	cis	rs9675120	0.747	rs4366750	ENSG00000262006.1	RP11-700H6.4	-4.43	1.26e-05	0.00324	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50843073	chr17:50909637~50910232:-
LIHC	cis	rs9675120	0.747	rs4306561	ENSG00000262006.1	RP11-700H6.4	-4.43	1.26e-05	0.00324	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50843194	chr17:50909637~50910232:-
LIHC	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-4.43	1.26e-05	0.00324	-0.27	-0.23	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
LIHC	cis	rs9532669	0.89	rs2324738	ENSG00000168852.11	TPTE2P5	4.43	1.26e-05	0.00324	0.25	0.23	Cervical cancer;	chr13:40925242	chr13:40822296~40921749:-
LIHC	cis	rs9532669	0.963	rs2324739	ENSG00000168852.11	TPTE2P5	4.43	1.26e-05	0.00324	0.25	0.23	Cervical cancer;	chr13:40925479	chr13:40822296~40921749:-
LIHC	cis	rs42490	0.528	rs7004089	ENSG00000251136.7	RP11-37B2.1	4.43	1.26e-05	0.00324	0.2	0.23	Leprosy;	chr8:89688329	chr8:89609409~89757727:-
LIHC	cis	rs4578769	0.765	rs998184	ENSG00000266850.1	RP11-370A5.1	-4.43	1.26e-05	0.00324	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22925006	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs4800440	ENSG00000266850.1	RP11-370A5.1	-4.43	1.26e-05	0.00324	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22928158	chr18:22723491~22907721:-
LIHC	cis	rs17711722	0.523	rs313812	ENSG00000226002.1	RP11-460N20.5	-4.43	1.26e-05	0.00324	-0.24	-0.23	Calcium levels;	chr7:66040056	chr7:65084103~65100232:+
LIHC	cis	rs1223397	1	rs1223402	ENSG00000215022.6	RP1-257A7.4	-4.43	1.26e-05	0.00324	-0.27	-0.23	Blood pressure;	chr6:13271408	chr6:13264861~13295586:-
LIHC	cis	rs7208859	0.673	rs11657270	ENSG00000266490.1	CTD-2349P21.9	4.43	1.26e-05	0.00324	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30792372~30792833:+
LIHC	cis	rs17301013	0.932	rs1754349	ENSG00000227373.4	RP11-160H22.5	-4.43	1.26e-05	0.00324	-0.28	-0.23	Systemic lupus erythematosus;	chr1:174837663	chr1:174115300~174160004:-
LIHC	cis	rs2929278	0.561	rs3099045	ENSG00000275601.1	AC011330.13	-4.43	1.26e-05	0.00324	-0.29	-0.23	Schizophrenia;	chr15:43631757	chr15:43642389~43643023:-
LIHC	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-4.43	1.26e-05	0.00324	-0.25	-0.23	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
LIHC	cis	rs2439831	0.85	rs3742982	ENSG00000166763.7	STRCP1	4.43	1.26e-05	0.00324	0.36	0.23	Lung cancer in ever smokers;	chr15:43884483	chr15:43699488~43718184:-
LIHC	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-4.43	1.26e-05	0.00324	-0.3	-0.23	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
LIHC	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	4.43	1.27e-05	0.00325	0.29	0.23	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
LIHC	cis	rs1160985	0.967	rs741780	ENSG00000214855.8	APOC1P1	-4.43	1.27e-05	0.00325	-0.28	-0.23	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44901174	chr19:44926804~44931386:+
LIHC	cis	rs11216126	1	rs11216126	ENSG00000254851.1	RP11-109L13.1	4.43	1.27e-05	0.00325	0.33	0.23	HDL cholesterol;	chr11:116746524	chr11:117135528~117138582:+
LIHC	cis	rs2439831	0.867	rs2927072	ENSG00000166763.7	STRCP1	4.43	1.27e-05	0.00325	0.36	0.23	Lung cancer in ever smokers;	chr15:43630200	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.867	rs2920781	ENSG00000166763.7	STRCP1	4.43	1.27e-05	0.00325	0.36	0.23	Lung cancer in ever smokers;	chr15:43632484	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.764	rs2447193	ENSG00000166763.7	STRCP1	4.43	1.27e-05	0.00325	0.36	0.23	Lung cancer in ever smokers;	chr15:43637535	chr15:43699488~43718184:-
LIHC	cis	rs651907	0.557	rs11712748	ENSG00000244119.1	PDCL3P4	4.43	1.27e-05	0.00325	0.24	0.23	Colorectal cancer;	chr3:101664718	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs7651406	ENSG00000244119.1	PDCL3P4	4.43	1.27e-05	0.00325	0.24	0.23	Colorectal cancer;	chr3:101674452	chr3:101712472~101713191:+
LIHC	cis	rs875971	0.545	rs6950988	ENSG00000273142.1	RP11-458F8.4	4.43	1.27e-05	0.00325	0.22	0.23	Aortic root size;	chr7:66511428	chr7:66902857~66906297:+
LIHC	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-4.43	1.27e-05	0.00325	-0.22	-0.23	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
LIHC	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-4.43	1.27e-05	0.00325	-0.22	-0.23	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
LIHC	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-4.43	1.27e-05	0.00325	-0.22	-0.23	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
LIHC	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-4.43	1.27e-05	0.00325	-0.22	-0.23	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
LIHC	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-4.43	1.27e-05	0.00325	-0.22	-0.23	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
LIHC	cis	rs2439831	0.867	rs2470134	ENSG00000275601.1	AC011330.13	4.43	1.27e-05	0.00325	0.34	0.23	Lung cancer in ever smokers;	chr15:43557688	chr15:43642389~43643023:-
LIHC	cis	rs13083990	0.919	rs13095172	ENSG00000272758.4	RP11-299J3.8	4.43	1.27e-05	0.00325	0.25	0.23	Cardiac Troponin-T levels;	chr3:122271410	chr3:122416207~122443180:+
LIHC	cis	rs1165668	0.755	rs10735390	ENSG00000257327.1	RP11-650K20.3	4.43	1.27e-05	0.00325	0.27	0.23	Coronary heart disease (SNP X SNP interaction);	chr12:103917953	chr12:103841451~103844664:+
LIHC	cis	rs3733589	0.744	rs59234705	ENSG00000250413.1	RP11-448G15.1	4.43	1.27e-05	0.00325	0.37	0.23	Renal overload gout;	chr4:10025121	chr4:10006482~10009725:+
LIHC	cis	rs755249	1	rs4660293	ENSG00000182109.6	RP11-69E11.4	-4.43	1.27e-05	0.00325	-0.31	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39522280~39546187:-
LIHC	cis	rs7809950	1	rs2395883	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107449225	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs4727681	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107455699	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs7782057	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107458432	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs28714607	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107465808	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs3801954	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107476603	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.954	rs2712193	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107485440	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2520277	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107489789	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.953	rs2237670	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107491040	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2237672	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107491118	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2237673	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107491135	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.911	rs1015411	ENSG00000238832.1	snoU109	-4.43	1.27e-05	0.00325	-0.28	-0.23	Coronary artery disease;	chr7:107495167	chr7:107603363~107603507:+
LIHC	cis	rs7208859	0.673	rs9903862	ENSG00000266490.1	CTD-2349P21.9	4.43	1.27e-05	0.00325	0.31	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879415	chr17:30792372~30792833:+
LIHC	cis	rs2348418	0.701	rs1463570	ENSG00000247934.4	RP11-967K21.1	-4.43	1.27e-05	0.00325	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28156095	chr12:28163298~28190738:-
LIHC	cis	rs6569038	0.557	rs9374777	ENSG00000253194.1	RP11-351A11.1	-4.43	1.27e-05	0.00326	-0.31	-0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119056334	chr6:118934785~119031541:+
LIHC	cis	rs6439153	0.933	rs7648877	ENSG00000231305.3	RP11-723O4.2	4.43	1.27e-05	0.00326	0.26	0.23	Pneumococcal bacteremia;	chr3:128991137	chr3:128861313~128871540:-
LIHC	cis	rs7208859	0.673	rs2433	ENSG00000266490.1	CTD-2349P21.9	4.43	1.27e-05	0.00326	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30792372~30792833:+
LIHC	cis	rs11951515	0.508	rs6860493	ENSG00000248240.1	RP11-159F24.5	-4.43	1.27e-05	0.00326	-0.29	-0.23	Metabolite levels  (X-11787);	chr5:43602611	chr5:43515274~43525310:+
LIHC	cis	rs1030877	0.515	rs3828300	ENSG00000235319.1	AC012360.4	4.43	1.27e-05	0.00326	0.33	0.23	Obesity-related traits;	chr2:105284650	chr2:105324210~105330529:+
LIHC	cis	rs901683	0.571	rs73292811	ENSG00000230869.1	CTGLF10P	-4.43	1.27e-05	0.00326	-0.49	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45618673	chr10:45678692~45700532:+
LIHC	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	4.43	1.27e-05	0.00326	0.44	0.23	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
LIHC	cis	rs3812762	0.868	rs7934519	ENSG00000254860.4	TMEM9B-AS1	-4.43	1.27e-05	0.00326	-0.25	-0.23	Hypospadias;	chr11:8770434	chr11:8964675~8977527:+
LIHC	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	4.43	1.27e-05	0.00326	0.28	0.23	Height;	chr6:109382524	chr6:109382795~109383666:+
LIHC	cis	rs2036707	0.744	rs9555412	ENSG00000277246.1	RP11-153I24.4	-4.43	1.27e-05	0.00326	-0.46	-0.23	Obesity-related traits;	chr13:107826853	chr13:108267320~108267734:+
LIHC	cis	rs12478296	1	rs73007140	ENSG00000261186.2	RP11-341N2.1	-4.43	1.27e-05	0.00326	-0.31	-0.23	Obesity-related traits;	chr2:242068605	chr2:242087351~242088457:-
LIHC	cis	rs755249	0.958	rs2068663	ENSG00000182109.6	RP11-69E11.4	4.43	1.27e-05	0.00327	0.32	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39522280~39546187:-
LIHC	cis	rs11668505	0.965	rs12463238	ENSG00000259108.2	CTD-3098H1.2	4.43	1.27e-05	0.00327	0.3	0.23	Lung function (FVC);	chr19:47842526	chr19:47863483~47865341:-
LIHC	cis	rs11668505	1	rs11666203	ENSG00000259108.2	CTD-3098H1.2	4.43	1.27e-05	0.00327	0.3	0.23	Lung function (FVC);	chr19:47842684	chr19:47863483~47865341:-
LIHC	cis	rs6997458	0.742	rs3758076	ENSG00000253549.4	RP11-317J10.2	4.43	1.28e-05	0.00327	0.25	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463306	chr8:85441851~85464915:-
LIHC	cis	rs1160985	0.967	rs760136	ENSG00000214855.8	APOC1P1	-4.43	1.28e-05	0.00327	-0.28	-0.23	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44900601	chr19:44926804~44931386:+
LIHC	cis	rs6439153	0.743	rs71331685	ENSG00000231305.3	RP11-723O4.2	4.43	1.28e-05	0.00327	0.26	0.23	Pneumococcal bacteremia;	chr3:128992582	chr3:128861313~128871540:-
LIHC	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-4.43	1.28e-05	0.00327	-0.28	-0.23	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
LIHC	cis	rs9595908	0.655	rs56080053	ENSG00000212293.1	SNORA16	4.43	1.28e-05	0.00328	0.27	0.23	Body mass index;	chr13:32720045	chr13:32420390~32420516:-
LIHC	cis	rs929596	0.793	rs2741046	ENSG00000233445.1	RPL17P11	4.43	1.28e-05	0.00329	0.34	0.23	Total bilirubin levels in HIV-1 infection;	chr2:233671603	chr2:233721522~233722065:-
LIHC	cis	rs7208859	0.673	rs12103759	ENSG00000266490.1	CTD-2349P21.9	4.43	1.28e-05	0.00329	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs59029591	ENSG00000266490.1	CTD-2349P21.9	4.43	1.28e-05	0.00329	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73265633	ENSG00000266490.1	CTD-2349P21.9	4.43	1.28e-05	0.00329	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9913782	ENSG00000266490.1	CTD-2349P21.9	4.43	1.28e-05	0.00329	0.3	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30792372~30792833:+
LIHC	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	4.43	1.28e-05	0.00329	0.24	0.23	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
LIHC	cis	rs3733585	0.682	rs13124563	ENSG00000250413.1	RP11-448G15.1	-4.43	1.28e-05	0.00329	-0.3	-0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9925929	chr4:10006482~10009725:+
LIHC	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	4.43	1.28e-05	0.00329	0.32	0.23	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	4.43	1.28e-05	0.00329	0.32	0.23	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	4.43	1.28e-05	0.00329	0.32	0.23	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	4.43	1.28e-05	0.00329	0.32	0.23	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
LIHC	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	4.43	1.28e-05	0.00329	0.32	0.23	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
LIHC	cis	rs72675573	0.852	rs6703713	ENSG00000235612.1	RP1-158P9.1	-4.43	1.28e-05	0.00329	-0.31	-0.23	Monocyte count;	chr1:56151289	chr1:56145721~56155224:+
LIHC	cis	rs3015497	0.616	rs3825571	ENSG00000269906.1	RP11-248J18.2	4.43	1.28e-05	0.00329	0.29	0.23	Mean platelet volume;	chr14:50585400	chr14:50662511~50663178:-
LIHC	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-4.43	1.29e-05	0.00329	-0.22	-0.23	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
LIHC	cis	rs643506	1	rs4936675	ENSG00000254990.4	RP11-108O10.2	4.43	1.29e-05	0.00329	0.26	0.23	Breast cancer;	chr11:111752364	chr11:111768668~111778350:-
LIHC	cis	rs6430585	0.528	rs309161	ENSG00000231890.6	DARS-AS1	4.43	1.29e-05	0.00329	0.32	0.23	Corneal structure;	chr2:135931179	chr2:135985176~136022593:+
LIHC	cis	rs8028182	0.636	rs10152155	ENSG00000260269.4	CTD-2323K18.1	-4.43	1.29e-05	0.00329	-0.3	-0.23	Sudden cardiac arrest;	chr15:75409213	chr15:75527150~75601205:-
LIHC	cis	rs9527	0.662	rs4919686	ENSG00000236937.2	PTGES3P4	4.43	1.29e-05	0.00329	0.35	0.23	Arsenic metabolism;	chr10:102832492	chr10:102845595~102845950:+
LIHC	cis	rs812925	0.515	rs1177308	ENSG00000212978.6	AC016747.3	-4.43	1.29e-05	0.0033	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61160119	chr2:61141592~61144969:-
LIHC	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-4.43	1.29e-05	0.0033	-0.24	-0.23	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
LIHC	cis	rs2243480	1	rs1039664	ENSG00000228409.4	CCT6P1	4.43	1.29e-05	0.0033	0.25	0.23	Diabetic kidney disease;	chr7:65984729	chr7:65751142~65763354:+
LIHC	cis	rs7412746	0.611	rs4970985	ENSG00000231073.1	RP11-316M1.3	-4.43	1.29e-05	0.0033	-0.23	-0.23	Melanoma;	chr1:150914966	chr1:150973123~150975534:+
LIHC	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-4.43	1.29e-05	0.0033	-0.27	-0.23	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
LIHC	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-4.43	1.29e-05	0.0033	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
LIHC	cis	rs9646944	0.519	rs1041973	ENSG00000234389.1	AC007278.3	-4.43	1.29e-05	0.0033	-0.26	-0.23	Blood protein levels;	chr2:102339008	chr2:102438713~102440475:+
LIHC	cis	rs1030877	0.557	rs2278501	ENSG00000235319.1	AC012360.4	4.43	1.29e-05	0.0033	0.28	0.23	Obesity-related traits;	chr2:105363049	chr2:105324210~105330529:+
LIHC	cis	rs9467711	0.591	rs6903228	ENSG00000216436.2	HIST1H2APS1	4.43	1.29e-05	0.0033	0.56	0.23	Autism spectrum disorder or schizophrenia;	chr6:25902819	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs9461222	ENSG00000216436.2	HIST1H2APS1	4.43	1.29e-05	0.0033	0.56	0.23	Autism spectrum disorder or schizophrenia;	chr6:25904883	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.591	rs9467635	ENSG00000216436.2	HIST1H2APS1	4.43	1.29e-05	0.0033	0.56	0.23	Autism spectrum disorder or schizophrenia;	chr6:25908938	chr6:25732497~25732827:+
LIHC	cis	rs73198271	0.751	rs617813	ENSG00000253893.2	FAM85B	4.43	1.29e-05	0.0033	0.29	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8167819~8226614:-
LIHC	cis	rs812925	0.553	rs1177307	ENSG00000212978.6	AC016747.3	-4.43	1.29e-05	0.00331	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61160253	chr2:61141592~61144969:-
LIHC	cis	rs4578769	0.959	rs3851819	ENSG00000265943.1	RP11-739L10.1	4.43	1.29e-05	0.00331	0.3	0.23	Eosinophil percentage of white cells;	chr18:22881321	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.959	rs3851820	ENSG00000265943.1	RP11-739L10.1	4.43	1.29e-05	0.00331	0.3	0.23	Eosinophil percentage of white cells;	chr18:22881359	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.918	rs3851821	ENSG00000265943.1	RP11-739L10.1	4.43	1.29e-05	0.00331	0.3	0.23	Eosinophil percentage of white cells;	chr18:22882492	chr18:22699481~22933764:-
LIHC	cis	rs17270561	0.514	rs10946805	ENSG00000216436.2	HIST1H2APS1	-4.43	1.29e-05	0.00331	-0.36	-0.23	Iron status biomarkers;	chr6:26077663	chr6:25732497~25732827:+
LIHC	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-4.43	1.29e-05	0.00331	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-4.43	1.29e-05	0.00331	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
LIHC	cis	rs2735413	0.914	rs2707604	ENSG00000276007.1	RP11-358L22.3	-4.43	1.3e-05	0.00331	-0.27	-0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78020956	chr16:78123243~78124332:+
LIHC	cis	rs7726839	0.54	rs72703079	ENSG00000271781.1	CTD-2589H19.6	-4.43	1.3e-05	0.00331	-0.35	-0.23	Obesity-related traits;	chr5:595058	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs61580655	ENSG00000271781.1	CTD-2589H19.6	-4.43	1.3e-05	0.00331	-0.35	-0.23	Obesity-related traits;	chr5:597449	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs57306627	ENSG00000271781.1	CTD-2589H19.6	-4.43	1.3e-05	0.00331	-0.35	-0.23	Obesity-related traits;	chr5:597528	chr5:675826~676616:+
LIHC	cis	rs748404	0.578	rs510108	ENSG00000166763.7	STRCP1	4.43	1.3e-05	0.00331	0.29	0.23	Lung cancer;	chr15:43313241	chr15:43699488~43718184:-
LIHC	cis	rs1165668	0.727	rs2722176	ENSG00000257327.1	RP11-650K20.3	4.43	1.3e-05	0.00331	0.27	0.23	Coronary heart disease (SNP X SNP interaction);	chr12:103920165	chr12:103841451~103844664:+
LIHC	cis	rs1165668	0.785	rs2583223	ENSG00000257327.1	RP11-650K20.3	4.43	1.3e-05	0.00331	0.27	0.23	Coronary heart disease (SNP X SNP interaction);	chr12:103923063	chr12:103841451~103844664:+
LIHC	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-4.43	1.3e-05	0.00331	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
LIHC	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-4.42	1.3e-05	0.00332	-0.23	-0.23	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
LIHC	cis	rs7546	0.504	rs2075637	ENSG00000267077.1	RP11-127I20.5	-4.42	1.3e-05	0.00332	-0.24	-0.23	Cancer;	chr16:4888279	chr16:4795265~4796532:-
LIHC	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	4.42	1.3e-05	0.00332	0.35	0.23	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	4.42	1.3e-05	0.00332	0.35	0.23	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	4.42	1.3e-05	0.00332	0.35	0.23	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	4.42	1.3e-05	0.00332	0.35	0.23	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	4.42	1.3e-05	0.00332	0.35	0.23	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
LIHC	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	4.42	1.3e-05	0.00332	0.23	0.23	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
LIHC	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	4.42	1.3e-05	0.00332	0.18	0.23	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	4.42	1.3e-05	0.00332	0.18	0.23	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
LIHC	cis	rs4650994	0.517	rs2761473	ENSG00000273384.1	RP5-1098D14.1	-4.42	1.3e-05	0.00332	-0.28	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178640623	chr1:178651706~178652282:+
LIHC	cis	rs921968	0.529	rs6729341	ENSG00000272555.1	RP11-459I19.1	-4.42	1.3e-05	0.00332	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218746711	chr2:218818690~218819144:+
LIHC	cis	rs2562456	0.724	rs58001930	ENSG00000268555.1	RP11-678G14.3	4.42	1.3e-05	0.00332	0.29	0.23	Pain;	chr19:21560061	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.754	rs55771551	ENSG00000268555.1	RP11-678G14.3	4.42	1.3e-05	0.00332	0.29	0.23	Pain;	chr19:21563578	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.561	rs12610883	ENSG00000268555.1	RP11-678G14.3	4.42	1.3e-05	0.00332	0.29	0.23	Pain;	chr19:21567257	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.837	rs11085462	ENSG00000268555.1	RP11-678G14.3	4.42	1.3e-05	0.00332	0.29	0.23	Pain;	chr19:21567449	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.793	rs7259708	ENSG00000268555.1	RP11-678G14.3	4.42	1.3e-05	0.00332	0.29	0.23	Pain;	chr19:21567846	chr19:21570822~21587322:-
LIHC	cis	rs703842	0.616	rs10783850	ENSG00000270039.1	RP11-571M6.17	-4.42	1.3e-05	0.00332	-0.34	-0.23	Multiple sclerosis;	chr12:57835594	chr12:57803838~57804415:+
LIHC	cis	rs56205728	0.582	rs1869901	ENSG00000273855.1	RP11-133K1.12	4.42	1.3e-05	0.00333	0.26	0.23	Schizophrenia;	chr15:40303426	chr15:40285468~40285909:-
LIHC	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-4.42	1.3e-05	0.00333	-0.27	-0.23	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
LIHC	cis	rs6439153	0.933	rs9822511	ENSG00000231305.3	RP11-723O4.2	4.42	1.3e-05	0.00333	0.26	0.23	Pneumococcal bacteremia;	chr3:128986724	chr3:128861313~128871540:-
LIHC	cis	rs6745190	0.906	rs1829365	ENSG00000236153.1	AC104076.3	4.42	1.3e-05	0.00333	0.34	0.23	White blood cell count;	chr2:181020894	chr2:180979427~180980090:-
LIHC	cis	rs11233413	0.874	rs11233440	ENSG00000246067.6	RAB30-AS1	4.42	1.3e-05	0.00333	0.32	0.23	Economic and political preferences (feminism/equality);	chr11:83047195	chr11:83072066~83106719:+
LIHC	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-4.42	1.31e-05	0.00333	-0.24	-0.23	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
LIHC	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-4.42	1.31e-05	0.00333	-0.24	-0.23	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
LIHC	cis	rs4356975	0.83	rs10012215	ENSG00000250919.1	RP11-813N20.3	-4.42	1.31e-05	0.00333	-0.23	-0.23	Obesity-related traits;	chr4:69048448	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.83	rs10012240	ENSG00000250919.1	RP11-813N20.3	-4.42	1.31e-05	0.00333	-0.23	-0.23	Obesity-related traits;	chr4:69048519	chr4:69027831~69044578:+
LIHC	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-4.42	1.31e-05	0.00333	-0.23	-0.23	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
LIHC	cis	rs1558001	0.84	rs17155560	ENSG00000230196.1	DDX43P3	-4.42	1.31e-05	0.00334	-0.25	-0.23	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81837426	chr7:81610884~81611326:-
LIHC	cis	rs9896933	0.832	rs79103992	ENSG00000263063.1	RP11-388C12.1	-4.42	1.31e-05	0.00334	-0.33	-0.23	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82897607	chr17:82713908~82716255:-
LIHC	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-4.42	1.31e-05	0.00334	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
LIHC	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-4.42	1.31e-05	0.00334	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
LIHC	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-4.42	1.31e-05	0.00334	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
LIHC	cis	rs4453827	1	rs35657034	ENSG00000271916.1	RP11-884K10.6	4.42	1.31e-05	0.00334	0.48	0.23	Blood protein levels;	chr3:53708773	chr3:53797764~53798019:-
LIHC	cis	rs875971	0.638	rs6460305	ENSG00000273024.4	INTS4P2	4.42	1.31e-05	0.00334	0.26	0.23	Aortic root size;	chr7:66595421	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs10272357	ENSG00000273024.4	INTS4P2	4.42	1.31e-05	0.00334	0.26	0.23	Aortic root size;	chr7:66598087	chr7:65647864~65715661:+
LIHC	cis	rs11098499	0.909	rs7681978	ENSG00000260091.1	RP11-33B1.4	-4.42	1.31e-05	0.00334	-0.17	-0.23	Corneal astigmatism;	chr4:119462620	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs13134665	ENSG00000260091.1	RP11-33B1.4	-4.42	1.31e-05	0.00334	-0.17	-0.23	Corneal astigmatism;	chr4:119505275	chr4:119409333~119410233:+
LIHC	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-4.42	1.31e-05	0.00335	-0.3	-0.23	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
LIHC	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-4.42	1.31e-05	0.00335	-0.27	-0.23	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
LIHC	cis	rs2284219	0.964	rs255097	ENSG00000196295.10	AC005154.6	-4.42	1.31e-05	0.00335	-0.17	-0.23	Type 2 diabetes;	chr7:30687343	chr7:30516309~30594809:-
LIHC	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-4.42	1.32e-05	0.00336	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
LIHC	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	4.42	1.32e-05	0.00336	0.24	0.23	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
LIHC	cis	rs79349575	0.715	rs55724082	ENSG00000248278.1	SUMO2P17	4.42	1.32e-05	0.00336	0.29	0.23	Type 2 diabetes;	chr17:48940517	chr17:48874860~48908983:-
LIHC	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-4.42	1.32e-05	0.00336	-0.27	-0.23	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
LIHC	cis	rs3845817	0.868	rs702938	ENSG00000281920.1	RP11-418H16.1	4.42	1.32e-05	0.00337	0.28	0.23	Bipolar disorder;	chr2:65520308	chr2:65623272~65628424:+
LIHC	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-4.42	1.32e-05	0.00337	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
LIHC	cis	rs812925	0.511	rs11886950	ENSG00000212978.6	AC016747.3	-4.42	1.32e-05	0.00337	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61172182	chr2:61141592~61144969:-
LIHC	cis	rs11723261	0.513	rs2353623	ENSG00000211553.1	AC253576.2	-4.42	1.32e-05	0.00337	-0.24	-0.23	Immune response to smallpox vaccine (IL-6);	chr4:95673	chr4:136461~136568:+
LIHC	cis	rs921968	0.565	rs7573999	ENSG00000272555.1	RP11-459I19.1	-4.42	1.32e-05	0.00337	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218736669	chr2:218818690~218819144:+
LIHC	cis	rs2439831	0.867	rs3101443	ENSG00000166763.7	STRCP1	4.42	1.32e-05	0.00337	0.36	0.23	Lung cancer in ever smokers;	chr15:43620174	chr15:43699488~43718184:-
LIHC	cis	rs2929278	0.588	rs1975364	ENSG00000166763.7	STRCP1	4.42	1.32e-05	0.00337	0.31	0.23	Schizophrenia;	chr15:43857991	chr15:43699488~43718184:-
LIHC	cis	rs734999	0.545	rs28568531	ENSG00000225931.3	RP3-395M20.7	4.42	1.32e-05	0.00338	0.25	0.23	Ulcerative colitis;	chr1:2624201	chr1:2566410~2569888:+
LIHC	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-4.42	1.33e-05	0.00338	-0.33	-0.23	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
LIHC	cis	rs12701220	0.894	rs34712249	ENSG00000229043.2	AC091729.9	-4.42	1.33e-05	0.00338	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:996998	chr7:1160374~1165267:+
LIHC	cis	rs755249	0.917	rs61781393	ENSG00000182109.6	RP11-69E11.4	4.42	1.33e-05	0.00338	0.33	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39522280~39546187:-
LIHC	cis	rs79349575	0.783	rs2088139	ENSG00000248278.1	SUMO2P17	4.42	1.33e-05	0.00338	0.29	0.23	Type 2 diabetes;	chr17:48922748	chr17:48874860~48908983:-
LIHC	cis	rs8031584	1	rs8031584	ENSG00000270015.1	RP11-540B6.6	-4.42	1.33e-05	0.00338	-0.3	-0.23	Huntington's disease progression;	chr15:30995140	chr15:30926514~30928407:+
LIHC	cis	rs4578769	0.765	rs12458947	ENSG00000266850.1	RP11-370A5.1	-4.42	1.33e-05	0.00338	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22856655	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.729	rs12454969	ENSG00000266850.1	RP11-370A5.1	-4.42	1.33e-05	0.00338	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22893042	chr18:22723491~22907721:-
LIHC	cis	rs2283831	0.524	rs9613210	ENSG00000213707.2	HMGB1P10	-4.42	1.33e-05	0.00338	-0.28	-0.23	Anti-saccade response;	chr22:26560529	chr22:26560526~26561088:+
LIHC	cis	rs3733589	0.59	rs4502681	ENSG00000250413.1	RP11-448G15.1	-4.42	1.33e-05	0.00338	-0.41	-0.23	Renal overload gout;	chr4:9988548	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.744	rs6820616	ENSG00000250413.1	RP11-448G15.1	4.42	1.33e-05	0.00339	0.37	0.23	Renal overload gout;	chr4:10028452	chr4:10006482~10009725:+
LIHC	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-4.42	1.33e-05	0.00339	-0.27	-0.23	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
LIHC	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	4.42	1.33e-05	0.00339	0.21	0.23	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
LIHC	cis	rs2243480	1	rs1964692	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:65989196	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs2456483	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:65996588	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs2949697	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:65999249	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1701750	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:66002158	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1701758	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:66005214	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs1701759	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:66005945	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs13247184	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:65893941	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35283677	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:65894246	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35421653	ENSG00000230295.1	RP11-458F8.2	-4.42	1.33e-05	0.00339	-0.25	-0.23	Diabetic kidney disease;	chr7:65898442	chr7:66880708~66882981:+
LIHC	cis	rs3733589	0.59	rs16892420	ENSG00000250413.1	RP11-448G15.1	4.42	1.33e-05	0.00339	0.37	0.23	Renal overload gout;	chr4:10034091	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.59	rs3822250	ENSG00000250413.1	RP11-448G15.1	4.42	1.33e-05	0.00339	0.37	0.23	Renal overload gout;	chr4:10035006	chr4:10006482~10009725:+
LIHC	cis	rs11233413	0.874	rs17504704	ENSG00000246067.6	RAB30-AS1	4.42	1.33e-05	0.00339	0.32	0.23	Economic and political preferences (feminism/equality);	chr11:83034485	chr11:83072066~83106719:+
LIHC	cis	rs11064837	0.504	rs7310148	ENSG00000248636.5	RP11-768F21.1	4.42	1.33e-05	0.00339	0.37	0.23	Schizophrenia;	chr12:119615925	chr12:119387987~119668079:-
LIHC	cis	rs4879656	0.5	rs12553806	ENSG00000236184.1	TCEA1P4	-4.42	1.33e-05	0.0034	-0.37	-0.23	Menopause (age at onset);	chr9:33083374	chr9:32979560~32980403:-
LIHC	cis	rs9843304	0.529	rs4681510	ENSG00000244503.1	RP11-278L15.6	4.42	1.33e-05	0.0034	0.23	0.23	Gallstone disease;	chr3:149483786	chr3:149494660~149495995:+
LIHC	cis	rs9843304	0.529	rs4681511	ENSG00000244503.1	RP11-278L15.6	4.42	1.33e-05	0.0034	0.23	0.23	Gallstone disease;	chr3:149483792	chr3:149494660~149495995:+
LIHC	cis	rs1865760	0.516	rs9358903	ENSG00000216436.2	HIST1H2APS1	-4.42	1.33e-05	0.0034	-0.27	-0.23	Height;	chr6:26061721	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.516	rs9393683	ENSG00000216436.2	HIST1H2APS1	-4.42	1.33e-05	0.0034	-0.27	-0.23	Height;	chr6:26065970	chr6:25732497~25732827:+
LIHC	cis	rs921968	0.565	rs7594046	ENSG00000272555.1	RP11-459I19.1	4.42	1.34e-05	0.0034	0.25	0.23	Mean corpuscular hemoglobin concentration;	chr2:218759447	chr2:218818690~218819144:+
LIHC	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	4.42	1.34e-05	0.0034	0.31	0.23	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
LIHC	cis	rs4578769	0.765	rs3844226	ENSG00000266850.1	RP11-370A5.1	-4.42	1.34e-05	0.0034	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22866817	chr18:22723491~22907721:-
LIHC	cis	rs8031584	0.679	rs34017474	ENSG00000270055.1	CTD-3092A11.2	-4.42	1.34e-05	0.0034	-0.27	-0.23	Huntington's disease progression;	chr15:30938408	chr15:30487963~30490313:+
LIHC	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-4.42	1.34e-05	0.0034	-0.28	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
LIHC	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	4.42	1.34e-05	0.0034	0.29	0.23	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	4.42	1.34e-05	0.0034	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
LIHC	cis	rs8028182	0.636	rs4564532	ENSG00000260269.4	CTD-2323K18.1	-4.42	1.34e-05	0.00341	-0.29	-0.23	Sudden cardiac arrest;	chr15:75413955	chr15:75527150~75601205:-
LIHC	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	4.42	1.34e-05	0.00341	0.28	0.23	Height;	chr6:109428824	chr6:109382795~109383666:+
LIHC	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00341	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00341	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00341	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00341	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00341	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
LIHC	cis	rs2565722	0.583	rs2465875	ENSG00000243831.1	RP1-81D8.4	4.42	1.34e-05	0.00341	0.31	0.23	Blood protein levels;	chr6:160877372	chr6:160666228~160676523:-
LIHC	cis	rs2565722	0.583	rs2465874	ENSG00000243831.1	RP1-81D8.4	4.42	1.34e-05	0.00341	0.31	0.23	Blood protein levels;	chr6:160877560	chr6:160666228~160676523:-
LIHC	cis	rs1015362	0.503	rs1883708	ENSG00000276073.1	RP5-1125A11.7	-4.42	1.34e-05	0.00341	-0.3	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33985617~33988989:-
LIHC	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	4.42	1.34e-05	0.00341	0.27	0.23	Height;	chr4:55451489	chr4:55363971~55395847:-
LIHC	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-4.42	1.34e-05	0.00341	-0.24	-0.23	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
LIHC	cis	rs10833905	1	rs28776242	ENSG00000246225.5	RP11-17A1.3	-4.42	1.34e-05	0.00341	-0.3	-0.23	Sudden cardiac arrest;	chr11:22986516	chr11:22829380~22945393:+
LIHC	cis	rs2310173	0.966	rs10185424	ENSG00000281162.1	LINC01127	-4.42	1.34e-05	0.00341	-0.24	-0.23	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102046427	chr2:101962056~101987167:+
LIHC	cis	rs1247318	1	rs1247313	ENSG00000243831.1	RP1-81D8.4	4.42	1.34e-05	0.00341	0.33	0.23	Aging;	chr6:160914988	chr6:160666228~160676523:-
LIHC	cis	rs3733589	0.59	rs12499734	ENSG00000250413.1	RP11-448G15.1	-4.42	1.34e-05	0.00341	-0.38	-0.23	Renal overload gout;	chr4:10050137	chr4:10006482~10009725:+
LIHC	cis	rs2072510	1	rs2660897	ENSG00000257715.1	RP11-256L6.2	-4.42	1.34e-05	0.00341	-0.24	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96031654	chr12:96025323~96027971:+
LIHC	cis	rs1865760	0.566	rs2858993	ENSG00000216436.2	HIST1H2APS1	-4.42	1.34e-05	0.00342	-0.27	-0.23	Height;	chr6:26087628	chr6:25732497~25732827:+
LIHC	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	4.42	1.34e-05	0.00342	0.35	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
LIHC	cis	rs2439831	0.85	rs7183809	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00342	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43828670	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs3759790	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00342	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43828832	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs68079546	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00342	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43844759	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs56909447	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00342	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43845420	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28476182	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00342	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43847445	chr15:43642389~43643023:-
LIHC	cis	rs2439831	0.85	rs28696802	ENSG00000275601.1	AC011330.13	-4.42	1.34e-05	0.00342	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43848197	chr15:43642389~43643023:-
LIHC	cis	rs9467711	0.591	rs34525648	ENSG00000216436.2	HIST1H2APS1	4.42	1.34e-05	0.00342	0.56	0.23	Autism spectrum disorder or schizophrenia;	chr6:25914625	chr6:25732497~25732827:+
LIHC	cis	rs1165668	0.755	rs2583283	ENSG00000257327.1	RP11-650K20.3	4.42	1.34e-05	0.00342	0.27	0.23	Coronary heart disease (SNP X SNP interaction);	chr12:103919865	chr12:103841451~103844664:+
LIHC	cis	rs3893377	0.848	rs11933202	ENSG00000214846.4	RP11-115L11.1	4.42	1.35e-05	0.00342	0.29	0.23	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15742905	chr4:15730962~15731627:-
LIHC	cis	rs1247318	1	rs1247362	ENSG00000243831.1	RP1-81D8.4	4.42	1.35e-05	0.00342	0.33	0.23	Aging;	chr6:160921628	chr6:160666228~160676523:-
LIHC	cis	rs1247318	0.901	rs1247364	ENSG00000243831.1	RP1-81D8.4	4.42	1.35e-05	0.00342	0.33	0.23	Aging;	chr6:160921706	chr6:160666228~160676523:-
LIHC	cis	rs748404	0.578	rs478028	ENSG00000166763.7	STRCP1	4.42	1.35e-05	0.00342	0.29	0.23	Lung cancer;	chr15:43318574	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.578	rs552701	ENSG00000166763.7	STRCP1	4.42	1.35e-05	0.00342	0.29	0.23	Lung cancer;	chr15:43321612	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.578	rs573615	ENSG00000166763.7	STRCP1	4.42	1.35e-05	0.00342	0.29	0.23	Lung cancer;	chr15:43322083	chr15:43699488~43718184:-
LIHC	cis	rs7759633	0.502	rs9458005	ENSG00000224477.4	RP1-81D8.3	4.42	1.35e-05	0.00342	0.32	0.23	Triglycerides;	chr6:160697545	chr6:160698288~160700632:+
LIHC	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	4.42	1.35e-05	0.00342	0.33	0.23	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
LIHC	cis	rs6723226	0.679	rs116617324	ENSG00000276334.1	AL133243.1	-4.42	1.35e-05	0.00342	-0.25	-0.23	Intelligence (multi-trait analysis);	chr2:32397641	chr2:32521927~32523547:+
LIHC	cis	rs9595908	1	rs9595908	ENSG00000212293.1	SNORA16	4.42	1.35e-05	0.00342	0.27	0.23	Body mass index;	chr13:32610151	chr13:32420390~32420516:-
LIHC	cis	rs7809950	1	rs2520268	ENSG00000238832.1	snoU109	-4.42	1.35e-05	0.00342	-0.28	-0.23	Coronary artery disease;	chr7:107550716	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2520269	ENSG00000238832.1	snoU109	-4.42	1.35e-05	0.00342	-0.28	-0.23	Coronary artery disease;	chr7:107550882	chr7:107603363~107603507:+
LIHC	cis	rs2976388	0.609	rs2717605	ENSG00000253196.1	RP11-706C16.7	4.42	1.35e-05	0.00343	0.23	0.23	Urinary tract infection frequency;	chr8:142719597	chr8:142763116~142766427:+
LIHC	cis	rs651907	0.557	rs11924013	ENSG00000244119.1	PDCL3P4	4.42	1.35e-05	0.00343	0.24	0.23	Colorectal cancer;	chr3:101647854	chr3:101712472~101713191:+
LIHC	cis	rs12209785	1	rs10485422	ENSG00000231769.2	RP1-8B1.4	4.42	1.35e-05	0.00343	0.34	0.23	Survival in pancreatic cancer;	chr6:45521455	chr6:46097093~46129706:-
LIHC	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	4.42	1.35e-05	0.00343	0.19	0.23	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
LIHC	cis	rs11098499	0.754	rs17049949	ENSG00000260091.1	RP11-33B1.4	-4.42	1.35e-05	0.00343	-0.16	-0.23	Corneal astigmatism;	chr4:119334135	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs7689729	ENSG00000260091.1	RP11-33B1.4	-4.42	1.35e-05	0.00343	-0.16	-0.23	Corneal astigmatism;	chr4:119335037	chr4:119409333~119410233:+
LIHC	cis	rs10028773	0.7	rs7690338	ENSG00000260091.1	RP11-33B1.4	-4.42	1.35e-05	0.00343	-0.16	-0.23	Educational attainment;	chr4:119335313	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs3956464	ENSG00000260091.1	RP11-33B1.4	-4.42	1.35e-05	0.00343	-0.16	-0.23	Corneal astigmatism;	chr4:119335609	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.619	rs28502463	ENSG00000260091.1	RP11-33B1.4	-4.42	1.35e-05	0.00343	-0.16	-0.23	Corneal astigmatism;	chr4:119335868	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.648	rs2002047	ENSG00000260091.1	RP11-33B1.4	-4.42	1.35e-05	0.00343	-0.16	-0.23	Corneal astigmatism;	chr4:119336073	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.775	rs2002049	ENSG00000260091.1	RP11-33B1.4	-4.42	1.35e-05	0.00343	-0.16	-0.23	Corneal astigmatism;	chr4:119336262	chr4:119409333~119410233:+
LIHC	cis	rs1396485	0.66	rs6874747	ENSG00000271918.1	CTD-2287O16.5	4.42	1.35e-05	0.00343	0.28	0.23	Inflammatory biomarkers;	chr5:116196852	chr5:116083807~116085416:-
LIHC	cis	rs875971	0.545	rs1638735	ENSG00000273142.1	RP11-458F8.4	4.42	1.35e-05	0.00343	0.23	0.23	Aortic root size;	chr7:66630751	chr7:66902857~66906297:+
LIHC	cis	rs4948102	0.69	rs35844144	ENSG00000226278.1	PSPHP1	-4.42	1.35e-05	0.00343	-0.27	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:55982832	chr7:55764797~55773288:+
LIHC	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-4.42	1.35e-05	0.00343	-0.27	-0.23	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
LIHC	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-4.42	1.35e-05	0.00343	-0.27	-0.23	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
LIHC	cis	rs6480314	0.711	rs61854659	ENSG00000233590.1	RP11-153K11.3	-4.42	1.35e-05	0.00344	-0.39	-0.23	Optic nerve measurement (disc area);	chr10:68182967	chr10:68233251~68242379:-
LIHC	cis	rs1400745	0.729	rs1741196	ENSG00000258738.1	RP11-73E17.2	4.42	1.35e-05	0.00344	0.29	0.23	Monocyte count;	chr14:34877814	chr14:34874343~34876459:+
LIHC	cis	rs2243480	1	rs313814	ENSG00000230295.1	RP11-458F8.2	-4.42	1.35e-05	0.00344	-0.24	-0.23	Diabetic kidney disease;	chr7:66038306	chr7:66880708~66882981:+
LIHC	cis	rs12701220	0.69	rs10243973	ENSG00000229043.2	AC091729.9	-4.42	1.35e-05	0.00344	-0.32	-0.23	Bronchopulmonary dysplasia;	chr7:1025347	chr7:1160374~1165267:+
LIHC	cis	rs12216125	0.554	rs6942196	ENSG00000216436.2	HIST1H2APS1	-4.42	1.36e-05	0.00344	-0.27	-0.23	Iron status biomarkers;	chr6:26072576	chr6:25732497~25732827:+
LIHC	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-4.42	1.36e-05	0.00344	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-4.42	1.36e-05	0.00344	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
LIHC	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-4.42	1.36e-05	0.00344	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
LIHC	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-4.42	1.36e-05	0.00344	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
LIHC	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-4.42	1.36e-05	0.00344	-0.27	-0.23	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
LIHC	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-4.42	1.36e-05	0.00344	-0.27	-0.23	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
LIHC	cis	rs960902	0.592	rs10199137	ENSG00000213553.4	RPLP0P6	-4.42	1.36e-05	0.00344	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37508238	chr2:38481851~38482804:+
LIHC	cis	rs17818399	0.815	rs35837037	ENSG00000279254.1	RP11-536C12.1	-4.41	1.36e-05	0.00344	-0.29	-0.23	Height;	chr2:46634161	chr2:46668870~46670778:+
LIHC	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	4.41	1.36e-05	0.00344	0.37	0.23	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
LIHC	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-4.41	1.36e-05	0.00344	-0.23	-0.23	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
LIHC	cis	rs617219	0.698	rs10514159	ENSG00000251675.1	CTC-458I2.2	4.41	1.36e-05	0.00345	0.26	0.23	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79300221	chr5:80128361~80143883:+
LIHC	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-4.41	1.36e-05	0.00345	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
LIHC	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-4.41	1.36e-05	0.00345	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
LIHC	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-4.41	1.36e-05	0.00345	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
LIHC	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-4.41	1.36e-05	0.00345	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-4.41	1.36e-05	0.00345	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
LIHC	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-4.41	1.36e-05	0.00345	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
LIHC	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	4.41	1.36e-05	0.00345	0.32	0.23	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
LIHC	cis	rs7193541	0.694	rs3896277	ENSG00000261079.1	RP11-252A24.3	4.41	1.36e-05	0.00345	0.26	0.23	Multiple myeloma;	chr16:74446796	chr16:74367462~74369826:+
LIHC	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	4.41	1.36e-05	0.00345	0.26	0.23	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
LIHC	cis	rs2562456	0.682	rs11085464	ENSG00000268555.1	RP11-678G14.3	4.41	1.36e-05	0.00345	0.29	0.23	Pain;	chr19:21568976	chr19:21570822~21587322:-
LIHC	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	4.41	1.36e-05	0.00346	0.18	0.23	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
LIHC	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	4.41	1.36e-05	0.00346	0.29	0.23	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
LIHC	cis	rs7208859	0.573	rs216442	ENSG00000266490.1	CTD-2349P21.9	4.41	1.36e-05	0.00346	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	4.41	1.36e-05	0.00346	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	4.41	1.36e-05	0.00346	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
LIHC	cis	rs617219	0.66	rs7705607	ENSG00000251675.1	CTC-458I2.2	4.41	1.36e-05	0.00346	0.26	0.23	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79313890	chr5:80128361~80143883:+
LIHC	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-4.41	1.36e-05	0.00346	-0.29	-0.23	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
LIHC	cis	rs5756813	0.661	rs2285178	ENSG00000233360.4	Z83844.1	4.41	1.36e-05	0.00346	0.29	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37809982	chr22:37641832~37658377:-
LIHC	cis	rs921968	0.565	rs6708192	ENSG00000272555.1	RP11-459I19.1	-4.41	1.36e-05	0.00346	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218727504	chr2:218818690~218819144:+
LIHC	cis	rs9595908	0.758	rs9591219	ENSG00000212293.1	SNORA16	4.41	1.36e-05	0.00346	0.26	0.23	Body mass index;	chr13:32653020	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.758	rs9591220	ENSG00000212293.1	SNORA16	4.41	1.36e-05	0.00346	0.26	0.23	Body mass index;	chr13:32653059	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9591226	ENSG00000212293.1	SNORA16	4.41	1.36e-05	0.00346	0.26	0.23	Body mass index;	chr13:32655322	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs7335546	ENSG00000212293.1	SNORA16	4.41	1.36e-05	0.00346	0.26	0.23	Body mass index;	chr13:32658197	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9591228	ENSG00000212293.1	SNORA16	4.41	1.36e-05	0.00346	0.26	0.23	Body mass index;	chr13:32658632	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596051	ENSG00000212293.1	SNORA16	4.41	1.36e-05	0.00346	0.26	0.23	Body mass index;	chr13:32666528	chr13:32420390~32420516:-
LIHC	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	4.41	1.36e-05	0.00346	0.22	0.23	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
LIHC	cis	rs2998286	0.723	rs332139	ENSG00000254635.4	WAC-AS1	-4.41	1.36e-05	0.00346	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570150	chr10:28522652~28532743:-
LIHC	cis	rs72675573	0.852	rs12125786	ENSG00000235612.1	RP1-158P9.1	-4.41	1.36e-05	0.00346	-0.3	-0.23	Monocyte count;	chr1:56151040	chr1:56145721~56155224:+
LIHC	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-4.41	1.36e-05	0.00346	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
LIHC	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-4.41	1.36e-05	0.00346	-0.29	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
LIHC	cis	rs7709377	0.516	rs13362436	ENSG00000271918.1	CTD-2287O16.5	4.41	1.36e-05	0.00346	0.27	0.23	Metabolite levels  (X-11787);	chr5:116207285	chr5:116083807~116085416:-
LIHC	cis	rs11098499	0.754	rs28643450	ENSG00000260091.1	RP11-33B1.4	-4.41	1.37e-05	0.00346	-0.16	-0.23	Corneal astigmatism;	chr4:119324087	chr4:119409333~119410233:+
LIHC	cis	rs2932538	0.922	rs12750023	ENSG00000225075.1	RP11-426L16.3	4.41	1.37e-05	0.00346	0.3	0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112575707	chr1:112693688~112696621:-
LIHC	cis	rs2932538	0.922	rs12137107	ENSG00000225075.1	RP11-426L16.3	4.41	1.37e-05	0.00346	0.3	0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112584815	chr1:112693688~112696621:-
LIHC	cis	rs2932538	0.922	rs12758377	ENSG00000225075.1	RP11-426L16.3	4.41	1.37e-05	0.00346	0.3	0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112594599	chr1:112693688~112696621:-
LIHC	cis	rs2348418	0.702	rs10843116	ENSG00000247934.4	RP11-967K21.1	-4.41	1.37e-05	0.00346	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28162248	chr12:28163298~28190738:-
LIHC	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-4.41	1.37e-05	0.00346	-0.29	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
LIHC	cis	rs812925	0.533	rs35507645	ENSG00000212978.6	AC016747.3	-4.41	1.37e-05	0.00346	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61169631	chr2:61141592~61144969:-
LIHC	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-4.41	1.37e-05	0.00347	-0.22	-0.23	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
LIHC	cis	rs2834188	0.924	rs2040107	ENSG00000272659.1	AP000295.10	4.41	1.37e-05	0.00347	0.33	0.23	Narcolepsy;	chr21:33303657	chr21:33309491~33310181:+
LIHC	cis	rs17373728	1	rs17373728	ENSG00000249395.2	CASC9	-4.41	1.37e-05	0.00347	-0.25	-0.23	Diabetic kidney disease;	chr8:75313281	chr8:75223404~75324741:-
LIHC	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	4.41	1.37e-05	0.00347	0.26	0.23	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
LIHC	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	4.41	1.37e-05	0.00347	0.37	0.23	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
LIHC	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-4.41	1.37e-05	0.00347	-0.27	-0.23	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
LIHC	cis	rs72675573	0.788	rs12137066	ENSG00000235612.1	RP1-158P9.1	-4.41	1.37e-05	0.00348	-0.3	-0.23	Monocyte count;	chr1:56065183	chr1:56145721~56155224:+
LIHC	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-4.41	1.37e-05	0.00348	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
LIHC	cis	rs11098499	0.954	rs7437420	ENSG00000260091.1	RP11-33B1.4	-4.41	1.37e-05	0.00348	-0.17	-0.23	Corneal astigmatism;	chr4:119391748	chr4:119409333~119410233:+
LIHC	cis	rs1577917	0.958	rs12199832	ENSG00000234155.1	RP11-30P6.6	4.41	1.37e-05	0.00348	0.31	0.23	Response to antipsychotic treatment;	chr6:85943030	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12207374	ENSG00000234155.1	RP11-30P6.6	4.41	1.37e-05	0.00348	0.31	0.23	Response to antipsychotic treatment;	chr6:85946927	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12213740	ENSG00000234155.1	RP11-30P6.6	4.41	1.37e-05	0.00348	0.31	0.23	Response to antipsychotic treatment;	chr6:85947015	chr6:85387219~85390186:-
LIHC	cis	rs6745190	0.512	rs35482602	ENSG00000236153.1	AC104076.3	-4.41	1.37e-05	0.00348	-0.32	-0.23	White blood cell count;	chr2:181130594	chr2:180979427~180980090:-
LIHC	cis	rs17711722	0.565	rs4717276	ENSG00000226002.1	RP11-460N20.5	4.41	1.37e-05	0.00348	0.25	0.23	Calcium levels;	chr7:65829754	chr7:65084103~65100232:+
LIHC	cis	rs17301013	0.932	rs1653626	ENSG00000227373.4	RP11-160H22.5	-4.41	1.37e-05	0.00348	-0.29	-0.23	Systemic lupus erythematosus;	chr1:174770348	chr1:174115300~174160004:-
LIHC	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	4.41	1.37e-05	0.00348	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
LIHC	cis	rs61160187	0.51	rs10072745	ENSG00000272308.1	RP11-231G3.1	-4.41	1.38e-05	0.00348	-0.28	-0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:60866457~60866935:-
LIHC	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	4.41	1.38e-05	0.00348	0.26	0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	4.41	1.38e-05	0.00348	0.26	0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
LIHC	cis	rs875971	0.545	rs801199	ENSG00000273142.1	RP11-458F8.4	-4.41	1.38e-05	0.00348	-0.22	-0.23	Aortic root size;	chr7:66560286	chr7:66902857~66906297:+
LIHC	cis	rs875971	0.545	rs1638724	ENSG00000273142.1	RP11-458F8.4	-4.41	1.38e-05	0.00348	-0.22	-0.23	Aortic root size;	chr7:66575494	chr7:66902857~66906297:+
LIHC	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-4.41	1.38e-05	0.00349	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
LIHC	cis	rs1865760	0.566	rs9379825	ENSG00000216436.2	HIST1H2APS1	-4.41	1.38e-05	0.00349	-0.27	-0.23	Height;	chr6:26083643	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs9467672	ENSG00000216436.2	HIST1H2APS1	-4.41	1.38e-05	0.00349	-0.27	-0.23	Height;	chr6:26083676	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs9295688	ENSG00000216436.2	HIST1H2APS1	-4.41	1.38e-05	0.00349	-0.27	-0.23	Height;	chr6:26083989	chr6:25732497~25732827:+
LIHC	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-4.41	1.38e-05	0.00349	-0.23	-0.23	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
LIHC	cis	rs2275906	1	rs2275906	ENSG00000216436.2	HIST1H2APS1	4.41	1.38e-05	0.00349	0.45	0.23	Urate levels in lean individuals;	chr6:25773581	chr6:25732497~25732827:+
LIHC	cis	rs2275906	1	rs72843517	ENSG00000216436.2	HIST1H2APS1	4.41	1.38e-05	0.00349	0.45	0.23	Urate levels in lean individuals;	chr6:25773785	chr6:25732497~25732827:+
LIHC	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	4.41	1.38e-05	0.0035	0.35	0.23	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
LIHC	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-4.41	1.38e-05	0.0035	-0.29	-0.23	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
LIHC	cis	rs763121	0.853	rs6001175	ENSG00000273076.1	RP3-508I15.22	4.41	1.38e-05	0.0035	0.26	0.23	Menopause (age at onset);	chr22:38622329	chr22:38743495~38743910:+
LIHC	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-4.41	1.38e-05	0.0035	-0.22	-0.23	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
LIHC	cis	rs651907	0.557	rs7645391	ENSG00000244119.1	PDCL3P4	4.41	1.38e-05	0.0035	0.24	0.23	Colorectal cancer;	chr3:101642662	chr3:101712472~101713191:+
LIHC	cis	rs7662987	0.793	rs78790289	ENSG00000272777.1	RP11-571L19.8	4.41	1.38e-05	0.0035	0.51	0.23	Smoking initiation;	chr4:99066736	chr4:99067256~99068125:-
LIHC	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	4.41	1.39e-05	0.0035	0.19	0.23	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
LIHC	cis	rs6085948	0.861	rs6054847	ENSG00000228888.1	LINC01428	-4.41	1.39e-05	0.00351	-0.42	-0.23	Interleukin-10 levels;	chr20:7249794	chr20:7146467~7254202:-
LIHC	cis	rs6085948	0.861	rs11908494	ENSG00000228888.1	LINC01428	-4.41	1.39e-05	0.00351	-0.42	-0.23	Interleukin-10 levels;	chr20:7250266	chr20:7146467~7254202:-
LIHC	cis	rs7412746	0.658	rs11582281	ENSG00000231073.1	RP11-316M1.3	4.41	1.39e-05	0.00351	0.24	0.23	Melanoma;	chr1:150854355	chr1:150973123~150975534:+
LIHC	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-4.41	1.39e-05	0.00351	-0.28	-0.23	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
LIHC	cis	rs875971	0.66	rs12698534	ENSG00000273024.4	INTS4P2	-4.41	1.39e-05	0.00351	-0.26	-0.23	Aortic root size;	chr7:66521858	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs62465434	ENSG00000273024.4	INTS4P2	-4.41	1.39e-05	0.00351	-0.26	-0.23	Aortic root size;	chr7:66540165	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs13224319	ENSG00000273024.4	INTS4P2	-4.41	1.39e-05	0.00351	-0.26	-0.23	Aortic root size;	chr7:66542376	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs801217	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66545590	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.638	rs801216	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66546680	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs801211	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66550702	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.638	rs801205	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66557157	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.617	rs810400	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66557902	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.638	rs3898855	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66571411	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.638	rs10278816	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66572000	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs10281080	ENSG00000273024.4	INTS4P2	4.41	1.39e-05	0.00351	0.26	0.23	Aortic root size;	chr7:66577454	chr7:65647864~65715661:+
LIHC	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	4.41	1.39e-05	0.00352	0.24	0.23	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
LIHC	cis	rs2033711	0.503	rs7254299	ENSG00000269473.1	CTD-2619J13.19	4.41	1.39e-05	0.00352	0.27	0.23	Uric acid clearance;	chr19:58373598	chr19:58440448~58445849:+
LIHC	cis	rs7131987	0.903	rs7308125	ENSG00000275476.1	RP11-996F15.4	-4.41	1.39e-05	0.00352	-0.27	-0.23	QT interval;	chr12:29272278	chr12:29277397~29277882:-
LIHC	cis	rs921968	0.565	rs11896209	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218734545	chr2:218818690~218819144:+
LIHC	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	4.41	1.39e-05	0.00352	0.26	0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
LIHC	cis	rs921968	0.565	rs4674329	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218730784	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs4674330	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218730987	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436069	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218732462	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436070	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218733237	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436071	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218733318	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6761437	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218733369	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436072	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218733372	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6757772	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218753774	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs3770220	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218754827	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs3770219	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218755043	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs3821035	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218755500	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs13412324	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218755798	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs7599365	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218755843	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.54	rs7582329	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218756186	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs12611632	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218756535	chr2:218818690~218819144:+
LIHC	cis	rs7607369	0.719	rs12613545	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Amyotrophic lateral sclerosis;Red blood cell count;	chr2:218758781	chr2:218818690~218819144:+
LIHC	cis	rs7607369	0.719	rs7567622	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Amyotrophic lateral sclerosis;Red blood cell count;	chr2:218759826	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs35358516	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218761000	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs1529382	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218761766	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs7605055	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218762327	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs62191658	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218765571	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.519	rs62191659	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218765787	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.521	rs56923478	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218773816	chr2:218818690~218819144:+
LIHC	cis	rs7607369	0.718	rs6727147	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Amyotrophic lateral sclerosis;Red blood cell count;	chr2:218774301	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436082	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218774707	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436083	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218774996	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436084	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218775059	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6745700	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218775139	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs6436086	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218775402	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs7599945	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218776805	chr2:218818690~218819144:+
LIHC	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-4.41	1.39e-05	0.00352	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
LIHC	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	4.41	1.39e-05	0.00352	0.23	0.23	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
LIHC	cis	rs921968	0.565	rs6436081	ENSG00000272555.1	RP11-459I19.1	-4.41	1.39e-05	0.00352	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218773161	chr2:218818690~218819144:+
LIHC	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-4.41	1.4e-05	0.00352	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
LIHC	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-4.41	1.4e-05	0.00352	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
LIHC	cis	rs8064024	0.681	rs1395602	ENSG00000267077.1	RP11-127I20.5	4.41	1.4e-05	0.00352	0.24	0.23	Cancer;	chr16:4861238	chr16:4795265~4796532:-
LIHC	cis	rs1577917	1	rs12196037	ENSG00000234155.1	RP11-30P6.6	4.41	1.4e-05	0.00353	0.31	0.23	Response to antipsychotic treatment;	chr6:85984913	chr6:85387219~85390186:-
LIHC	cis	rs11079159	1	rs10445344	ENSG00000263096.1	RP11-515O17.2	4.41	1.4e-05	0.00353	0.32	0.23	QRS duration;	chr17:55290427	chr17:55271504~55273653:-
LIHC	cis	rs2072510	0.722	rs2540496	ENSG00000257878.1	RP11-256L6.3	-4.41	1.4e-05	0.00353	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96012725	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.722	rs2540495	ENSG00000257878.1	RP11-256L6.3	-4.41	1.4e-05	0.00353	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96012945	chr12:95996521~96011489:+
LIHC	cis	rs638893	1	rs28827279	ENSG00000255239.1	AP002954.6	4.41	1.4e-05	0.00353	0.38	0.23	Vitiligo;	chr11:118830054	chr11:118688039~118690600:-
LIHC	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	4.41	1.4e-05	0.00353	0.26	0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
LIHC	cis	rs875971	0.545	rs1267814	ENSG00000273142.1	RP11-458F8.4	-4.41	1.4e-05	0.00353	-0.22	-0.23	Aortic root size;	chr7:66579422	chr7:66902857~66906297:+
LIHC	cis	rs916888	0.647	rs199524	ENSG00000260075.1	NSFP1	-4.41	1.4e-05	0.00353	-0.29	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46372855~46487141:+
LIHC	cis	rs960902	0.747	rs17020823	ENSG00000213553.4	RPLP0P6	4.41	1.4e-05	0.00353	0.19	0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37489925	chr2:38481851~38482804:+
LIHC	cis	rs709400	0.93	rs28513222	ENSG00000258534.1	CTD-2134A5.4	4.41	1.4e-05	0.00353	0.36	0.23	Body mass index;	chr14:103561732	chr14:103854366~103880111:-
LIHC	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	4.41	1.4e-05	0.00353	0.27	0.23	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
LIHC	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	4.41	1.4e-05	0.00353	0.29	0.23	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
LIHC	cis	rs1223397	1	rs1223399	ENSG00000215022.6	RP1-257A7.4	-4.41	1.4e-05	0.00353	-0.27	-0.23	Blood pressure;	chr6:13270988	chr6:13264861~13295586:-
LIHC	cis	rs4356975	0.798	rs4694588	ENSG00000250919.1	RP11-813N20.3	4.41	1.4e-05	0.00353	0.23	0.23	Obesity-related traits;	chr4:69044664	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.83	rs7693166	ENSG00000250919.1	RP11-813N20.3	4.41	1.4e-05	0.00353	0.23	0.23	Obesity-related traits;	chr4:69044866	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.83	rs6422321	ENSG00000250919.1	RP11-813N20.3	4.41	1.4e-05	0.00353	0.23	0.23	Obesity-related traits;	chr4:69044911	chr4:69027831~69044578:+
LIHC	cis	rs748404	0.723	rs512431	ENSG00000166763.7	STRCP1	-4.41	1.4e-05	0.00353	-0.28	-0.23	Lung cancer;	chr15:43249741	chr15:43699488~43718184:-
LIHC	cis	rs1247318	1	rs1781546	ENSG00000243831.1	RP1-81D8.4	4.41	1.4e-05	0.00354	0.33	0.23	Aging;	chr6:160915375	chr6:160666228~160676523:-
LIHC	cis	rs1247318	1	rs1663025	ENSG00000243831.1	RP1-81D8.4	4.41	1.4e-05	0.00354	0.33	0.23	Aging;	chr6:160915377	chr6:160666228~160676523:-
LIHC	cis	rs1247318	1	rs1247310	ENSG00000243831.1	RP1-81D8.4	4.41	1.4e-05	0.00354	0.33	0.23	Aging;	chr6:160915496	chr6:160666228~160676523:-
LIHC	cis	rs1247318	0.853	rs1247309	ENSG00000243831.1	RP1-81D8.4	4.41	1.4e-05	0.00354	0.33	0.23	Aging;	chr6:160915604	chr6:160666228~160676523:-
LIHC	cis	rs10912872	0.634	rs10912842	ENSG00000231424.2	RP1-45C12.1	4.41	1.4e-05	0.00354	0.25	0.23	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171365688	chr1:171247580~171251794:-
LIHC	cis	rs11637445	0.603	rs7183168	ENSG00000260657.2	RP11-315D16.4	-4.41	1.4e-05	0.00354	-0.32	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr15:67829145	chr15:68267792~68277994:-
LIHC	cis	rs755249	0.917	rs61232586	ENSG00000182109.6	RP11-69E11.4	4.41	1.4e-05	0.00354	0.33	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39522280~39546187:-
LIHC	cis	rs875971	0.545	rs2420456	ENSG00000273142.1	RP11-458F8.4	4.41	1.4e-05	0.00354	0.22	0.23	Aortic root size;	chr7:66280619	chr7:66902857~66906297:+
LIHC	cis	rs6439153	0.933	rs11711812	ENSG00000231305.3	RP11-723O4.2	4.41	1.4e-05	0.00354	0.25	0.23	Pneumococcal bacteremia;	chr3:128989711	chr3:128861313~128871540:-
LIHC	cis	rs728616	0.867	rs61858980	ENSG00000225484.5	NUTM2B-AS1	-4.41	1.4e-05	0.00354	-0.51	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.867	rs2152550	ENSG00000225484.5	NUTM2B-AS1	-4.41	1.4e-05	0.00354	-0.51	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:79663088~79826594:-
LIHC	cis	rs875971	0.545	rs10261710	ENSG00000228409.4	CCT6P1	-4.41	1.41e-05	0.00354	-0.2	-0.23	Aortic root size;	chr7:66249202	chr7:65751142~65763354:+
LIHC	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	4.41	1.41e-05	0.00355	0.29	0.23	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
LIHC	cis	rs5758511	0.689	rs17478227	ENSG00000237037.8	NDUFA6-AS1	4.41	1.41e-05	0.00355	0.47	0.23	Birth weight;	chr22:42258321	chr22:42090931~42137742:+
LIHC	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	4.41	1.41e-05	0.00355	0.19	0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
LIHC	cis	rs4650994	0.816	rs2811301	ENSG00000213057.5	C1orf220	-4.41	1.41e-05	0.00355	-0.19	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178625061	chr1:178542752~178548889:+
LIHC	cis	rs1005277	0.691	rs2474558	ENSG00000099251.13	HSD17B7P2	-4.41	1.41e-05	0.00355	-0.28	-0.23	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38356380~38378505:+
LIHC	cis	rs7129556	0.69	rs648601	ENSG00000254459.1	RP11-91P24.7	4.41	1.41e-05	0.00355	0.38	0.23	Weight loss (gastric bypass surgery);	chr11:77875864	chr11:77829654~77872262:-
LIHC	cis	rs11648785	0.777	rs4433810	ENSG00000221819.5	GAS8-AS1	-4.41	1.41e-05	0.00355	-0.32	-0.23	Tanning;	chr16:90032058	chr16:90028908~90029367:-
LIHC	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-4.41	1.41e-05	0.00355	-0.24	-0.23	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
LIHC	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-4.41	1.41e-05	0.00356	-0.28	-0.23	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-4.41	1.41e-05	0.00356	-0.28	-0.23	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
LIHC	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-4.41	1.41e-05	0.00356	-0.2	-0.23	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
LIHC	cis	rs1865760	0.532	rs2794719	ENSG00000216436.2	HIST1H2APS1	-4.41	1.41e-05	0.00356	-0.27	-0.23	Height;	chr6:26088662	chr6:25732497~25732827:+
LIHC	cis	rs11098499	0.754	rs10212714	ENSG00000260091.1	RP11-33B1.4	-4.41	1.41e-05	0.00356	-0.16	-0.23	Corneal astigmatism;	chr4:119333147	chr4:119409333~119410233:+
LIHC	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	4.41	1.41e-05	0.00356	0.22	0.23	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
LIHC	cis	rs13083990	0.959	rs10934583	ENSG00000272758.4	RP11-299J3.8	4.41	1.41e-05	0.00356	0.25	0.23	Cardiac Troponin-T levels;	chr3:122294557	chr3:122416207~122443180:+
LIHC	cis	rs13083990	0.92	rs13061521	ENSG00000272758.4	RP11-299J3.8	4.41	1.41e-05	0.00356	0.25	0.23	Cardiac Troponin-T levels;	chr3:122295835	chr3:122416207~122443180:+
LIHC	cis	rs1005277	0.577	rs4934906	ENSG00000099251.13	HSD17B7P2	4.41	1.41e-05	0.00356	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38356380~38378505:+
LIHC	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-4.41	1.41e-05	0.00356	-0.29	-0.23	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
LIHC	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-4.41	1.41e-05	0.00356	-0.29	-0.23	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
LIHC	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-4.41	1.41e-05	0.00356	-0.22	-0.23	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
LIHC	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	4.41	1.41e-05	0.00356	0.24	0.23	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
LIHC	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-4.41	1.41e-05	0.00357	-0.24	-0.23	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
LIHC	cis	rs2836974	0.533	rs4817999	ENSG00000255568.3	BRWD1-AS2	-4.41	1.42e-05	0.00357	-0.2	-0.23	Cognitive function;	chr21:39182429	chr21:39313935~39314962:+
LIHC	cis	rs6480314	0.831	rs1900007	ENSG00000233590.1	RP11-153K11.3	-4.41	1.42e-05	0.00357	-0.34	-0.23	Optic nerve measurement (disc area);	chr10:68218018	chr10:68233251~68242379:-
LIHC	cis	rs11971779	0.666	rs6467847	ENSG00000273391.1	RP11-634H22.1	4.4	1.42e-05	0.00357	0.21	0.23	Diisocyanate-induced asthma;	chr7:139394690	chr7:139359032~139359566:-
LIHC	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-4.4	1.42e-05	0.00357	-0.26	-0.23	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
LIHC	cis	rs755249	0.958	rs61781370	ENSG00000182109.6	RP11-69E11.4	4.4	1.42e-05	0.00357	0.33	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39522280~39546187:-
LIHC	cis	rs812925	0.533	rs60997156	ENSG00000212978.6	AC016747.3	-4.4	1.42e-05	0.00357	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61169404	chr2:61141592~61144969:-
LIHC	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-4.4	1.42e-05	0.00357	-0.24	-0.23	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
LIHC	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	4.4	1.42e-05	0.00357	0.27	0.23	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
LIHC	cis	rs960902	0.592	rs10865125	ENSG00000213553.4	RPLP0P6	-4.4	1.42e-05	0.00357	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37510740	chr2:38481851~38482804:+
LIHC	cis	rs6802315	0.575	rs57932243	ENSG00000272087.1	RP11-379F4.7	4.4	1.42e-05	0.00358	0.27	0.23	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158693120~158693768:-
LIHC	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-4.4	1.42e-05	0.00358	-0.26	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
LIHC	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	4.4	1.42e-05	0.00358	0.27	0.23	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
LIHC	cis	rs7937890	0.559	rs1116739	ENSG00000251991.1	RNU7-49P	4.4	1.42e-05	0.00358	0.25	0.23	Mitochondrial DNA levels;	chr11:14467636	chr11:14478892~14478953:+
LIHC	cis	rs748404	0.66	rs509306	ENSG00000166763.7	STRCP1	4.4	1.42e-05	0.00358	0.28	0.23	Lung cancer;	chr15:43422973	chr15:43699488~43718184:-
LIHC	cis	rs1165668	0.816	rs1866072	ENSG00000257327.1	RP11-650K20.3	4.4	1.42e-05	0.00358	0.27	0.23	Coronary heart disease (SNP X SNP interaction);	chr12:103916928	chr12:103841451~103844664:+
LIHC	cis	rs3733585	0.683	rs6449140	ENSG00000250413.1	RP11-448G15.1	4.4	1.42e-05	0.00358	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9934813	chr4:10006482~10009725:+
LIHC	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	4.4	1.42e-05	0.00358	0.27	0.23	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
LIHC	cis	rs11098499	0.909	rs73842633	ENSG00000260091.1	RP11-33B1.4	-4.4	1.42e-05	0.00358	-0.17	-0.23	Corneal astigmatism;	chr4:119454309	chr4:119409333~119410233:+
LIHC	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-4.4	1.42e-05	0.00358	-0.28	-0.23	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
LIHC	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-4.4	1.42e-05	0.00358	-0.28	-0.23	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
LIHC	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	4.4	1.42e-05	0.00359	0.23	0.23	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
LIHC	cis	rs6801605	0.743	rs1025689	ENSG00000271916.1	RP11-884K10.6	-4.4	1.42e-05	0.00359	-0.3	-0.23	Blood protein levels;	chr3:53849695	chr3:53797764~53798019:-
LIHC	cis	rs6745190	0.953	rs12989967	ENSG00000236153.1	AC104076.3	-4.4	1.43e-05	0.00359	-0.35	-0.23	White blood cell count;	chr2:181040627	chr2:180979427~180980090:-
LIHC	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	4.4	1.43e-05	0.00359	0.27	0.23	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
LIHC	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
LIHC	cis	rs901683	0.702	rs76551593	ENSG00000230869.1	CTGLF10P	-4.4	1.43e-05	0.00359	-0.52	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45615533	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs76831684	ENSG00000230869.1	CTGLF10P	-4.4	1.43e-05	0.00359	-0.52	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45620584	chr10:45678692~45700532:+
LIHC	cis	rs12554020	0.892	rs76488437	ENSG00000227603.1	RP11-165J3.6	4.4	1.43e-05	0.00359	0.33	0.23	Schizophrenia;	chr9:93605514	chr9:93435332~93437121:-
LIHC	cis	rs12554020	0.681	rs80062429	ENSG00000227603.1	RP11-165J3.6	4.4	1.43e-05	0.00359	0.33	0.23	Schizophrenia;	chr9:93608830	chr9:93435332~93437121:-
LIHC	cis	rs2060793	0.712	rs10832290	ENSG00000251991.1	RNU7-49P	4.4	1.43e-05	0.00359	0.26	0.23	Vitamin D levels;	chr11:14650684	chr11:14478892~14478953:+
LIHC	cis	rs2060793	0.774	rs1403249	ENSG00000251991.1	RNU7-49P	4.4	1.43e-05	0.00359	0.26	0.23	Vitamin D levels;	chr11:14651438	chr11:14478892~14478953:+
LIHC	cis	rs2060793	0.741	rs7119073	ENSG00000251991.1	RNU7-49P	4.4	1.43e-05	0.00359	0.26	0.23	Vitamin D levels;	chr11:14669416	chr11:14478892~14478953:+
LIHC	cis	rs2060793	0.741	rs4344519	ENSG00000251991.1	RNU7-49P	4.4	1.43e-05	0.00359	0.26	0.23	Vitamin D levels;	chr11:14701347	chr11:14478892~14478953:+
LIHC	cis	rs2060793	0.712	rs11023310	ENSG00000251991.1	RNU7-49P	4.4	1.43e-05	0.00359	0.26	0.23	Vitamin D levels;	chr11:14703717	chr11:14478892~14478953:+
LIHC	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-4.4	1.43e-05	0.00359	-0.26	-0.23	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
LIHC	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
LIHC	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
LIHC	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
LIHC	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-4.4	1.43e-05	0.00359	-0.26	-0.23	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
LIHC	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	4.4	1.43e-05	0.0036	0.22	0.23	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
LIHC	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	4.4	1.43e-05	0.0036	0.22	0.23	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
LIHC	cis	rs960902	0.818	rs60691585	ENSG00000213553.4	RPLP0P6	4.4	1.43e-05	0.0036	0.19	0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37487285	chr2:38481851~38482804:+
LIHC	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	4.4	1.43e-05	0.0036	0.27	0.23	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
LIHC	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	4.4	1.43e-05	0.0036	0.27	0.23	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
LIHC	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-4.4	1.43e-05	0.0036	-0.27	-0.23	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
LIHC	cis	rs3738443	0.868	rs56029850	ENSG00000259865.1	RP11-488L18.10	4.4	1.43e-05	0.0036	0.21	0.23	Alcohol dependence;	chr1:247201027	chr1:247187281~247188526:-
LIHC	cis	rs3738443	0.868	rs55643126	ENSG00000259865.1	RP11-488L18.10	4.4	1.43e-05	0.0036	0.21	0.23	Alcohol dependence;	chr1:247201042	chr1:247187281~247188526:-
LIHC	cis	rs2243480	1	rs464895	ENSG00000230295.1	RP11-458F8.2	-4.4	1.43e-05	0.00361	-0.24	-0.23	Diabetic kidney disease;	chr7:66062119	chr7:66880708~66882981:+
LIHC	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	4.4	1.43e-05	0.00361	0.27	0.23	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
LIHC	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	4.4	1.44e-05	0.00361	0.27	0.23	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
LIHC	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-4.4	1.44e-05	0.00361	-0.3	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
LIHC	cis	rs2072510	0.593	rs2540499	ENSG00000257878.1	RP11-256L6.3	4.4	1.44e-05	0.00361	0.3	0.23	Metabolite levels (small molecules and protein measures);	chr12:96006091	chr12:95996521~96011489:+
LIHC	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-4.4	1.44e-05	0.00361	-0.45	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
LIHC	cis	rs9896933	0.623	rs77166830	ENSG00000263063.1	RP11-388C12.1	-4.4	1.44e-05	0.00362	-0.33	-0.23	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82875649	chr17:82713908~82716255:-
LIHC	cis	rs875971	0.545	rs73142245	ENSG00000228409.4	CCT6P1	-4.4	1.44e-05	0.00362	-0.19	-0.23	Aortic root size;	chr7:66226662	chr7:65751142~65763354:+
LIHC	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	4.4	1.44e-05	0.00362	0.26	0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
LIHC	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	4.4	1.44e-05	0.00362	0.27	0.23	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
LIHC	cis	rs2834655	0.861	rs11088296	ENSG00000237945.6	LINC00649	-4.4	1.44e-05	0.00362	-0.43	-0.23	Immune response to smallpox vaccine (IL-6);	chr21:34865249	chr21:33915534~33977691:+
LIHC	cis	rs7208859	0.673	rs9911989	ENSG00000266490.1	CTD-2349P21.9	-4.4	1.44e-05	0.00362	-0.29	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30792372~30792833:+
LIHC	cis	rs1865760	0.566	rs1539183	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26074823	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs9295686	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26081755	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.532	rs9295687	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26082482	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs4529296	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26082907	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs1971509	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26085549	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.532	rs2006736	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26085789	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs1800702	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26086235	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.566	rs2794720	ENSG00000216436.2	HIST1H2APS1	-4.4	1.44e-05	0.00362	-0.27	-0.23	Height;	chr6:26086974	chr6:25732497~25732827:+
LIHC	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-4.4	1.44e-05	0.00363	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
LIHC	cis	rs7809950	1	rs2057837	ENSG00000238832.1	snoU109	4.4	1.44e-05	0.00363	0.28	0.23	Coronary artery disease;	chr7:107582280	chr7:107603363~107603507:+
LIHC	cis	rs7044106	0.791	rs10985001	ENSG00000238181.2	AHCYP2	-4.4	1.45e-05	0.00363	-0.27	-0.23	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120720673~120721972:+
LIHC	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	4.4	1.45e-05	0.00363	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	4.4	1.45e-05	0.00363	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
LIHC	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	4.4	1.45e-05	0.00363	0.29	0.23	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	4.4	1.45e-05	0.00363	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	4.4	1.45e-05	0.00363	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	4.4	1.45e-05	0.00363	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
LIHC	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	4.4	1.45e-05	0.00363	0.36	0.23	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
LIHC	cis	rs11098499	0.779	rs28495013	ENSG00000260091.1	RP11-33B1.4	-4.4	1.45e-05	0.00364	-0.17	-0.23	Corneal astigmatism;	chr4:119454676	chr4:119409333~119410233:+
LIHC	cis	rs2834288	0.5	rs766425	ENSG00000237945.6	LINC00649	4.4	1.45e-05	0.00364	0.3	0.23	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33915534~33977691:+
LIHC	cis	rs651907	0.557	rs17347644	ENSG00000244119.1	PDCL3P4	4.4	1.45e-05	0.00364	0.24	0.23	Colorectal cancer;	chr3:101828889	chr3:101712472~101713191:+
LIHC	cis	rs2834188	0.669	rs1467845	ENSG00000272659.1	AP000295.10	-4.4	1.45e-05	0.00364	-0.32	-0.23	Narcolepsy;	chr21:33294071	chr21:33309491~33310181:+
LIHC	cis	rs9326248	0.52	rs2735183	ENSG00000236267.1	AP006216.5	4.4	1.45e-05	0.00364	0.24	0.23	Blood protein levels;	chr11:117144479	chr11:116813204~116814003:-
LIHC	cis	rs3015497	0.586	rs12587821	ENSG00000269906.1	RP11-248J18.2	4.4	1.45e-05	0.00364	0.29	0.23	Mean platelet volume;	chr14:50625836	chr14:50662511~50663178:-
LIHC	cis	rs3015497	0.586	rs12587842	ENSG00000269906.1	RP11-248J18.2	4.4	1.45e-05	0.00364	0.29	0.23	Mean platelet volume;	chr14:50625844	chr14:50662511~50663178:-
LIHC	cis	rs12478296	0.786	rs6721704	ENSG00000261186.2	RP11-341N2.1	-4.4	1.45e-05	0.00364	-0.31	-0.23	Obesity-related traits;	chr2:242052772	chr2:242087351~242088457:-
LIHC	cis	rs2562456	0.876	rs11085467	ENSG00000268555.1	RP11-678G14.3	4.4	1.45e-05	0.00364	0.29	0.23	Pain;	chr19:21569041	chr19:21570822~21587322:-
LIHC	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	4.4	1.45e-05	0.00364	0.34	0.23	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
LIHC	cis	rs17711722	0.522	rs4642526	ENSG00000226002.1	RP11-460N20.5	4.4	1.45e-05	0.00364	0.25	0.23	Calcium levels;	chr7:65751755	chr7:65084103~65100232:+
LIHC	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-4.4	1.45e-05	0.00364	-0.27	-0.23	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
LIHC	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-4.4	1.45e-05	0.00365	-0.3	-0.23	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
LIHC	cis	rs2243480	0.522	rs12698511	ENSG00000230295.1	RP11-458F8.2	-4.4	1.45e-05	0.00365	-0.26	-0.23	Diabetic kidney disease;	chr7:66009932	chr7:66880708~66882981:+
LIHC	cis	rs783540	0.521	rs28719490	ENSG00000278603.1	RP13-608F4.5	4.4	1.45e-05	0.00365	0.31	0.23	Schizophrenia;	chr15:82720688	chr15:82472203~82472426:+
LIHC	cis	rs11098499	0.908	rs28499576	ENSG00000260091.1	RP11-33B1.4	-4.4	1.45e-05	0.00365	-0.17	-0.23	Corneal astigmatism;	chr4:119465522	chr4:119409333~119410233:+
LIHC	cis	rs6442522	1	rs6778562	ENSG00000249786.6	EAF1-AS1	4.4	1.45e-05	0.00365	0.27	0.23	Uric acid levels;	chr3:15441268	chr3:15436171~15455940:-
LIHC	cis	rs960902	0.71	rs2192943	ENSG00000213553.4	RPLP0P6	-4.4	1.45e-05	0.00365	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37504317	chr2:38481851~38482804:+
LIHC	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	4.4	1.45e-05	0.00365	0.26	0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
LIHC	cis	rs7809950	1	rs2066735	ENSG00000238832.1	snoU109	-4.4	1.46e-05	0.00366	-0.28	-0.23	Coronary artery disease;	chr7:107548274	chr7:107603363~107603507:+
LIHC	cis	rs2337406	1	rs79452530	ENSG00000274576.2	IGHV2-70	-4.4	1.46e-05	0.00366	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106699992	chr14:106770577~106771020:-
LIHC	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-4.4	1.46e-05	0.00366	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
LIHC	cis	rs901683	0.85	rs73291122	ENSG00000230869.1	CTGLF10P	-4.4	1.46e-05	0.00366	-0.55	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45603955	chr10:45678692~45700532:+
LIHC	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	4.4	1.46e-05	0.00366	0.35	0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
LIHC	cis	rs2739330	0.828	rs2877178	ENSG00000206090.4	AP000350.7	4.4	1.46e-05	0.00366	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23939998~23942798:+
LIHC	cis	rs330048	0.545	rs11774353	ENSG00000254340.1	RP11-10A14.3	4.4	1.46e-05	0.00366	0.22	0.23	Systemic lupus erythematosus;	chr8:9295617	chr8:9141424~9145435:+
LIHC	cis	rs150992	0.507	rs377731	ENSG00000248489.1	CTD-2007H13.3	4.4	1.46e-05	0.00367	0.31	0.23	Body mass index;	chr5:98996535	chr5:98929171~98995013:+
LIHC	cis	rs748404	0.697	rs564946	ENSG00000166763.7	STRCP1	4.4	1.46e-05	0.00367	0.29	0.23	Lung cancer;	chr15:43264074	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.723	rs565658	ENSG00000166763.7	STRCP1	4.4	1.46e-05	0.00367	0.29	0.23	Lung cancer;	chr15:43264109	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs579651	ENSG00000166763.7	STRCP1	4.4	1.46e-05	0.00367	0.29	0.23	Lung cancer;	chr15:43266178	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs473016	ENSG00000166763.7	STRCP1	4.4	1.46e-05	0.00367	0.29	0.23	Lung cancer;	chr15:43266625	chr15:43699488~43718184:-
LIHC	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	4.4	1.46e-05	0.00367	0.26	0.23	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
LIHC	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	4.4	1.46e-05	0.00367	0.26	0.23	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
LIHC	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-4.4	1.47e-05	0.00368	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
LIHC	cis	rs2337406	1	rs11849532	ENSG00000274576.2	IGHV2-70	-4.4	1.47e-05	0.00368	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106669877	chr14:106770577~106771020:-
LIHC	cis	rs4356975	0.768	rs4518318	ENSG00000250919.1	RP11-813N20.3	4.4	1.47e-05	0.00368	0.23	0.23	Obesity-related traits;	chr4:69045479	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.83	rs4351079	ENSG00000250919.1	RP11-813N20.3	4.4	1.47e-05	0.00368	0.23	0.23	Obesity-related traits;	chr4:69045631	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.798	rs4607293	ENSG00000250919.1	RP11-813N20.3	4.4	1.47e-05	0.00368	0.23	0.23	Obesity-related traits;	chr4:69045714	chr4:69027831~69044578:+
LIHC	cis	rs338389	0.542	rs8036189	ENSG00000260657.2	RP11-315D16.4	-4.4	1.47e-05	0.00368	-0.38	-0.23	Survival in rectal cancer;	chr15:68000614	chr15:68267792~68277994:-
LIHC	cis	rs2348418	0.864	rs7957495	ENSG00000247934.4	RP11-967K21.1	-4.4	1.47e-05	0.00369	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:28163298~28190738:-
LIHC	cis	rs752590	0.806	rs874898	ENSG00000274877.1	RP11-65I12.1	-4.4	1.47e-05	0.00369	-0.3	-0.23	Mucinous ovarian carcinoma;	chr2:113216619	chr2:113237595~113240825:+
LIHC	cis	rs2976388	0.632	rs2585139	ENSG00000253196.1	RP11-706C16.7	4.4	1.47e-05	0.00369	0.23	0.23	Urinary tract infection frequency;	chr8:142726757	chr8:142763116~142766427:+
LIHC	cis	rs11121022	0.601	rs707455	ENSG00000269925.1	RP3-467L1.6	4.4	1.47e-05	0.00369	0.22	0.23	Morning vs. evening chronotype;	chr1:7765251	chr1:7776383~7776775:+
LIHC	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-4.4	1.47e-05	0.00369	-0.26	-0.23	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
LIHC	cis	rs9896933	0.832	rs77512810	ENSG00000263063.1	RP11-388C12.1	-4.4	1.47e-05	0.0037	-0.32	-0.23	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82846713	chr17:82713908~82716255:-
LIHC	cis	rs9896933	0.832	rs75552659	ENSG00000263063.1	RP11-388C12.1	-4.4	1.47e-05	0.0037	-0.32	-0.23	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82846754	chr17:82713908~82716255:-
LIHC	cis	rs113084984	0.718	rs7568108	ENSG00000271952.1	RP11-245G13.2	-4.4	1.47e-05	0.0037	-0.28	-0.23	Breast cancer;	chr2:11543198	chr2:10878269~10885118:+
LIHC	cis	rs16858210	0.607	rs953419	ENSG00000234371.6	RPSAP31	-4.4	1.47e-05	0.0037	-0.31	-0.23	Menopause (age at onset);	chr3:183868095	chr3:183884924~183888449:+
LIHC	cis	rs7809950	1	rs2520271	ENSG00000238832.1	snoU109	-4.4	1.47e-05	0.0037	-0.28	-0.23	Coronary artery disease;	chr7:107554504	chr7:107603363~107603507:+
LIHC	cis	rs3733589	0.744	rs35782952	ENSG00000250413.1	RP11-448G15.1	4.4	1.47e-05	0.0037	0.37	0.23	Renal overload gout;	chr4:10044471	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.744	rs35334203	ENSG00000250413.1	RP11-448G15.1	4.4	1.47e-05	0.0037	0.37	0.23	Renal overload gout;	chr4:10044547	chr4:10006482~10009725:+
LIHC	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	4.4	1.47e-05	0.0037	0.17	0.23	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
LIHC	cis	rs58950470	0.927	rs1205259	ENSG00000265874.1	MIR4489	4.4	1.48e-05	0.0037	0.34	0.23	Schizophrenia;	chr11:65625224	chr11:65649192~65649253:+
LIHC	cis	rs75920871	0.541	rs76690043	ENSG00000254851.1	RP11-109L13.1	-4.4	1.48e-05	0.0037	-0.47	-0.23	Subjective well-being;	chr11:116930813	chr11:117135528~117138582:+
LIHC	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-4.4	1.48e-05	0.0037	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
LIHC	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-4.4	1.48e-05	0.0037	-0.24	-0.23	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
LIHC	cis	rs9992667	0.955	rs6855993	ENSG00000231160.8	KLF3-AS1	4.4	1.48e-05	0.0037	0.31	0.23	Eosinophil percentage of granulocytes;	chr4:38607291	chr4:38612701~38664883:-
LIHC	cis	rs9650657	0.547	rs11250099	ENSG00000255394.4	C8orf49	4.4	1.48e-05	0.00371	0.29	0.23	Neuroticism;	chr8:10961147	chr8:11761256~11763223:+
LIHC	cis	rs9595908	0.929	rs7328939	ENSG00000212293.1	SNORA16	4.4	1.48e-05	0.00371	0.27	0.23	Body mass index;	chr13:32552711	chr13:32420390~32420516:-
LIHC	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	4.4	1.48e-05	0.00371	0.27	0.23	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
LIHC	cis	rs901683	0.702	rs76041951	ENSG00000230869.1	CTGLF10P	-4.39	1.48e-05	0.00371	-0.61	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45609715	chr10:45678692~45700532:+
LIHC	cis	rs7809950	1	rs2237676	ENSG00000238832.1	snoU109	-4.39	1.48e-05	0.00371	-0.28	-0.23	Coronary artery disease;	chr7:107557634	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs2253146	ENSG00000238832.1	snoU109	-4.39	1.48e-05	0.00371	-0.28	-0.23	Coronary artery disease;	chr7:107559874	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.953	rs2253271	ENSG00000238832.1	snoU109	-4.39	1.48e-05	0.00371	-0.28	-0.23	Coronary artery disease;	chr7:107560807	chr7:107603363~107603507:+
LIHC	cis	rs11722228	0.521	rs12501336	ENSG00000261490.1	RP11-448G15.3	4.39	1.48e-05	0.00371	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10135727	chr4:10068089~10073019:-
LIHC	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	4.39	1.48e-05	0.00372	0.28	0.23	Height;	chr6:109375003	chr6:109382795~109383666:+
LIHC	cis	rs9595908	0.785	rs7326809	ENSG00000212293.1	SNORA16	4.39	1.48e-05	0.00372	0.26	0.23	Body mass index;	chr13:32662135	chr13:32420390~32420516:-
LIHC	cis	rs2717559	0.561	rs7841267	ENSG00000253196.1	RP11-706C16.7	-4.39	1.48e-05	0.00372	-0.26	-0.23	Urinary tract infection frequency;	chr8:142800267	chr8:142763116~142766427:+
LIHC	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-4.39	1.49e-05	0.00372	-0.28	-0.23	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
LIHC	cis	rs9467711	0.538	rs9467632	ENSG00000216436.2	HIST1H2APS1	4.39	1.49e-05	0.00372	0.56	0.23	Autism spectrum disorder or schizophrenia;	chr6:25889478	chr6:25732497~25732827:+
LIHC	cis	rs2739330	0.828	rs2154593	ENSG00000206090.4	AP000350.7	4.39	1.49e-05	0.00372	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23939998~23942798:+
LIHC	cis	rs6480314	0.764	rs7898034	ENSG00000233590.1	RP11-153K11.3	4.39	1.49e-05	0.00372	0.33	0.23	Optic nerve measurement (disc area);	chr10:68217859	chr10:68233251~68242379:-
LIHC	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	4.39	1.49e-05	0.00372	0.35	0.23	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
LIHC	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-4.39	1.49e-05	0.00372	-0.25	-0.23	Asthma;	chr2:102394777	chr2:102438713~102440475:+
LIHC	cis	rs72675573	0.925	rs72675569	ENSG00000235612.1	RP1-158P9.1	-4.39	1.49e-05	0.00373	-0.3	-0.23	Monocyte count;	chr1:56160903	chr1:56145721~56155224:+
LIHC	cis	rs748404	0.578	rs576557	ENSG00000166763.7	STRCP1	4.39	1.49e-05	0.00373	0.28	0.23	Lung cancer;	chr15:43305539	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs475261	ENSG00000166763.7	STRCP1	4.39	1.49e-05	0.00373	0.29	0.23	Lung cancer;	chr15:43254258	chr15:43699488~43718184:-
LIHC	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-4.39	1.49e-05	0.00373	-0.23	-0.23	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
LIHC	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-4.39	1.49e-05	0.00373	-0.23	-0.23	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
LIHC	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-4.39	1.49e-05	0.00373	-0.22	-0.23	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
LIHC	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-4.39	1.49e-05	0.00374	-0.26	-0.23	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
LIHC	cis	rs180358	0.568	rs1268353	ENSG00000254851.1	RP11-109L13.1	4.39	1.49e-05	0.00374	0.3	0.23	Multiple sclerosis (severity);	chr11:116768976	chr11:117135528~117138582:+
LIHC	cis	rs7412746	0.658	rs897815	ENSG00000231073.1	RP11-316M1.3	-4.39	1.49e-05	0.00374	-0.23	-0.23	Melanoma;	chr1:150906625	chr1:150973123~150975534:+
LIHC	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	4.39	1.49e-05	0.00374	0.26	0.23	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
LIHC	cis	rs875971	0.545	rs1547529	ENSG00000273142.1	RP11-458F8.4	4.39	1.49e-05	0.00374	0.22	0.23	Aortic root size;	chr7:66258859	chr7:66902857~66906297:+
LIHC	cis	rs2243480	1	rs73150014	ENSG00000228409.4	CCT6P1	4.39	1.49e-05	0.00374	0.25	0.23	Diabetic kidney disease;	chr7:65985932	chr7:65751142~65763354:+
LIHC	cis	rs812925	0.512	rs1729674	ENSG00000212978.6	AC016747.3	-4.39	1.49e-05	0.00374	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61162602	chr2:61141592~61144969:-
LIHC	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	4.39	1.5e-05	0.00374	0.26	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
LIHC	cis	rs6546886	0.536	rs7589197	ENSG00000217702.2	RP11-287D1.4	4.39	1.5e-05	0.00375	0.27	0.23	Dialysis-related mortality;	chr2:74095342	chr2:74130583~74135395:+
LIHC	cis	rs638893	1	rs638893	ENSG00000255239.1	AP002954.6	4.39	1.5e-05	0.00375	0.38	0.23	Vitiligo;	chr11:118827828	chr11:118688039~118690600:-
LIHC	cis	rs11098499	0.789	rs10212719	ENSG00000260091.1	RP11-33B1.4	-4.39	1.5e-05	0.00375	-0.16	-0.23	Corneal astigmatism;	chr4:119333282	chr4:119409333~119410233:+
LIHC	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-4.39	1.5e-05	0.00375	-0.25	-0.23	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
LIHC	cis	rs11089937	0.597	rs5757007	ENSG00000211639.2	IGLV4-60	4.39	1.5e-05	0.00375	0.2	0.23	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22162199~22162681:+
LIHC	cis	rs523522	0.571	rs11065120	ENSG00000278344.1	RP11-18C24.8	4.39	1.5e-05	0.00375	0.29	0.23	High light scatter reticulocyte count;	chr12:120437653	chr12:120500735~120501090:-
LIHC	cis	rs4356975	1	rs4356975	ENSG00000250919.1	RP11-813N20.3	-4.39	1.5e-05	0.00375	-0.24	-0.23	Obesity-related traits;	chr4:69106745	chr4:69027831~69044578:+
LIHC	cis	rs11098499	0.754	rs878376	ENSG00000260091.1	RP11-33B1.4	-4.39	1.5e-05	0.00376	-0.16	-0.23	Corneal astigmatism;	chr4:119316547	chr4:119409333~119410233:+
LIHC	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-4.39	1.5e-05	0.00376	-0.24	-0.23	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
LIHC	cis	rs338389	0.542	rs7494835	ENSG00000260657.2	RP11-315D16.4	-4.39	1.5e-05	0.00376	-0.37	-0.23	Survival in rectal cancer;	chr15:68001993	chr15:68267792~68277994:-
LIHC	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-4.39	1.5e-05	0.00376	-0.31	-0.23	Height;	chr3:53029854	chr3:53064283~53065091:-
LIHC	cis	rs11098499	0.754	rs938056	ENSG00000260091.1	RP11-33B1.4	-4.39	1.5e-05	0.00376	-0.16	-0.23	Corneal astigmatism;	chr4:119316298	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-4.39	1.5e-05	0.00376	-0.23	-0.23	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
LIHC	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	4.39	1.51e-05	0.00377	0.18	0.23	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
LIHC	cis	rs3733589	0.744	rs36036984	ENSG00000250413.1	RP11-448G15.1	4.39	1.51e-05	0.00377	0.37	0.23	Renal overload gout;	chr4:10042008	chr4:10006482~10009725:+
LIHC	cis	rs7119038	0.818	rs4936444	ENSG00000255239.1	AP002954.6	4.39	1.51e-05	0.00377	0.34	0.23	Sjögren's syndrome;	chr11:118872629	chr11:118688039~118690600:-
LIHC	cis	rs734999	0.572	rs2985857	ENSG00000225931.3	RP3-395M20.7	-4.39	1.51e-05	0.00377	-0.24	-0.23	Ulcerative colitis;	chr1:2601185	chr1:2566410~2569888:+
LIHC	cis	rs7412746	0.634	rs72704658	ENSG00000231073.1	RP11-316M1.3	4.39	1.51e-05	0.00377	0.24	0.23	Melanoma;	chr1:150860534	chr1:150973123~150975534:+
LIHC	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-4.39	1.51e-05	0.00377	-0.27	-0.23	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
LIHC	cis	rs13083990	0.959	rs1472621	ENSG00000272758.4	RP11-299J3.8	4.39	1.51e-05	0.00377	0.25	0.23	Cardiac Troponin-T levels;	chr3:122293879	chr3:122416207~122443180:+
LIHC	cis	rs13083990	0.959	rs10934582	ENSG00000272758.4	RP11-299J3.8	4.39	1.51e-05	0.00377	0.25	0.23	Cardiac Troponin-T levels;	chr3:122294507	chr3:122416207~122443180:+
LIHC	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	4.39	1.51e-05	0.00377	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
LIHC	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	4.39	1.51e-05	0.00378	0.35	0.23	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
LIHC	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-4.39	1.51e-05	0.00378	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
LIHC	cis	rs3733589	1	rs16868271	ENSG00000250413.1	RP11-448G15.1	4.39	1.51e-05	0.00378	0.41	0.23	Renal overload gout;	chr4:9987423	chr4:10006482~10009725:+
LIHC	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	4.39	1.51e-05	0.00378	0.25	0.23	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
LIHC	cis	rs1318937	1	rs3773469	ENSG00000224660.1	SH3BP5-AS1	4.39	1.51e-05	0.00378	0.21	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15266733	chr3:15254184~15264493:+
LIHC	cis	rs1005277	0.579	rs1780137	ENSG00000275858.1	RP11-291L22.8	4.39	1.52e-05	0.00379	0.26	0.23	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38450738~38451069:-
LIHC	cis	rs2243480	0.908	rs4718273	ENSG00000228409.4	CCT6P1	-4.39	1.52e-05	0.00379	-0.25	-0.23	Diabetic kidney disease;	chr7:65751112	chr7:65751142~65763354:+
LIHC	cis	rs10829156	0.755	rs10732437	ENSG00000240291.1	RP11-499P20.2	4.39	1.52e-05	0.00379	0.36	0.23	Sudden cardiac arrest;	chr10:18626973	chr10:18513115~18545651:-
LIHC	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-4.39	1.52e-05	0.00379	-0.3	-0.23	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
LIHC	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	4.39	1.52e-05	0.00379	0.24	0.23	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
LIHC	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	4.39	1.52e-05	0.00379	0.24	0.23	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
LIHC	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	4.39	1.52e-05	0.00379	0.25	0.23	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	4.39	1.52e-05	0.00379	0.25	0.23	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
LIHC	cis	rs6445975	0.715	rs6769100	ENSG00000272360.1	RP11-359I18.5	4.39	1.52e-05	0.00379	0.27	0.23	Systemic lupus erythematosus;	chr3:58274272	chr3:58490830~58491291:-
LIHC	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	4.39	1.52e-05	0.00379	0.24	0.23	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
LIHC	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	4.39	1.52e-05	0.00379	0.24	0.23	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
LIHC	cis	rs55726902	1	rs73107980	ENSG00000276691.1	RP5-1057I20.5	4.39	1.52e-05	0.00379	0.44	0.23	Allergic disease (asthma, hay fever or eczema);	chr12:47793818	chr12:47788426~47788971:+
LIHC	cis	rs6480314	0.831	rs11813125	ENSG00000233590.1	RP11-153K11.3	4.39	1.52e-05	0.00379	0.34	0.23	Optic nerve measurement (disc area);	chr10:68215276	chr10:68233251~68242379:-
LIHC	cis	rs950881	0.932	rs72823619	ENSG00000234389.1	AC007278.3	4.39	1.52e-05	0.00379	0.31	0.23	Allergy;	chr2:102308155	chr2:102438713~102440475:+
LIHC	cis	rs7829975	0.56	rs17154599	ENSG00000173295.6	FAM86B3P	-4.39	1.52e-05	0.00379	-0.31	-0.23	Mood instability;	chr8:8693908	chr8:8228595~8244865:+
LIHC	cis	rs4578769	0.765	rs72882147	ENSG00000266850.1	RP11-370A5.1	-4.39	1.52e-05	0.0038	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22816590	chr18:22723491~22907721:-
LIHC	cis	rs4650994	0.505	rs2811291	ENSG00000273384.1	RP5-1098D14.1	-4.39	1.52e-05	0.0038	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178605082	chr1:178651706~178652282:+
LIHC	cis	rs4578769	0.788	rs12962334	ENSG00000265943.1	RP11-739L10.1	4.39	1.52e-05	0.0038	0.28	0.23	Eosinophil percentage of white cells;	chr18:22897971	chr18:22699481~22933764:-
LIHC	cis	rs12478296	0.786	rs13409307	ENSG00000261186.2	RP11-341N2.1	-4.39	1.52e-05	0.0038	-0.3	-0.23	Obesity-related traits;	chr2:242053348	chr2:242087351~242088457:-
LIHC	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	4.39	1.52e-05	0.0038	0.26	0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
LIHC	cis	rs651907	0.557	rs34947019	ENSG00000244119.1	PDCL3P4	4.39	1.52e-05	0.0038	0.24	0.23	Colorectal cancer;	chr3:101813391	chr3:101712472~101713191:+
LIHC	cis	rs11722228	0.508	rs9732	ENSG00000261490.1	RP11-448G15.3	4.39	1.52e-05	0.0038	0.3	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10075034	chr4:10068089~10073019:-
LIHC	cis	rs12291225	0.839	rs4757244	ENSG00000251991.1	RNU7-49P	-4.39	1.52e-05	0.00381	-0.24	-0.23	Sense of smell;	chr11:14237109	chr11:14478892~14478953:+
LIHC	cis	rs2739330	0.828	rs5760108	ENSG00000206090.4	AP000350.7	4.39	1.52e-05	0.00381	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23939998~23942798:+
LIHC	cis	rs2439831	0.867	rs11856184	ENSG00000166763.7	STRCP1	4.39	1.52e-05	0.00381	0.36	0.23	Lung cancer in ever smokers;	chr15:43626964	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.867	rs2447211	ENSG00000166763.7	STRCP1	4.39	1.52e-05	0.00381	0.36	0.23	Lung cancer in ever smokers;	chr15:43644153	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.571	rs2470121	ENSG00000166763.7	STRCP1	4.39	1.52e-05	0.00381	0.36	0.23	Lung cancer in ever smokers;	chr15:43645420	chr15:43699488~43718184:-
LIHC	cis	rs4244255	1	rs17116149	ENSG00000260461.1	RP11-541N10.3	-4.39	1.53e-05	0.00381	-0.39	-0.23	Differentiated thyroid cancer;	chr10:103928292	chr10:103877374~103879761:-
LIHC	cis	rs8005677	0.798	rs4982711	ENSG00000257285.4	RP11-298I3.1	4.39	1.53e-05	0.00381	0.23	0.23	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:22929609~22955562:+
LIHC	cis	rs4650994	0.507	rs2811312	ENSG00000273384.1	RP5-1098D14.1	-4.39	1.53e-05	0.00381	-0.29	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178648468	chr1:178651706~178652282:+
LIHC	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	4.39	1.53e-05	0.00381	0.22	0.23	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
LIHC	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	4.39	1.53e-05	0.00381	0.31	0.23	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
LIHC	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	4.39	1.53e-05	0.00381	0.31	0.23	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
LIHC	cis	rs4718428	1	rs12534637	ENSG00000273142.1	RP11-458F8.4	-4.39	1.53e-05	0.00381	-0.23	-0.23	Corneal structure;	chr7:66862667	chr7:66902857~66906297:+
LIHC	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	4.39	1.53e-05	0.00382	0.36	0.23	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
LIHC	cis	rs950169	0.881	rs72750843	ENSG00000259295.5	CSPG4P12	4.39	1.53e-05	0.00382	0.33	0.23	Schizophrenia;	chr15:84592552	chr15:85191438~85213905:+
LIHC	cis	rs7702057	0.53	rs3087831	ENSG00000271918.1	CTD-2287O16.5	4.39	1.53e-05	0.00383	0.32	0.23	Amyotrophic lateral sclerosis;	chr5:116084901	chr5:116083807~116085416:-
LIHC	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-4.39	1.53e-05	0.00383	-0.26	-0.23	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
LIHC	cis	rs3733589	0.744	rs3775941	ENSG00000250413.1	RP11-448G15.1	4.39	1.54e-05	0.00383	0.37	0.23	Renal overload gout;	chr4:10023469	chr4:10006482~10009725:+
LIHC	cis	rs2439831	0.85	rs2957637	ENSG00000166763.7	STRCP1	4.39	1.54e-05	0.00383	0.36	0.23	Lung cancer in ever smokers;	chr15:43658920	chr15:43699488~43718184:-
LIHC	cis	rs11668505	1	rs12974951	ENSG00000259108.2	CTD-3098H1.2	4.39	1.54e-05	0.00383	0.3	0.23	Lung function (FVC);	chr19:47842671	chr19:47863483~47865341:-
LIHC	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-4.39	1.54e-05	0.00384	-0.27	-0.23	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
LIHC	cis	rs4578769	0.918	rs8089471	ENSG00000265943.1	RP11-739L10.1	4.39	1.54e-05	0.00384	0.29	0.23	Eosinophil percentage of white cells;	chr18:22892994	chr18:22699481~22933764:-
LIHC	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-4.39	1.54e-05	0.00384	-0.38	-0.23	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
LIHC	cis	rs2929278	0.588	rs688009	ENSG00000166763.7	STRCP1	4.39	1.54e-05	0.00384	0.3	0.23	Schizophrenia;	chr15:43864104	chr15:43699488~43718184:-
LIHC	cis	rs58749629	1	rs73128528	ENSG00000269549.2	RP3-461P17.10	4.39	1.54e-05	0.00384	0.58	0.23	Abdominal aortic aneurysm;	chr20:45953548	chr20:45445431~45448580:+
LIHC	cis	rs7119038	0.818	rs4936441	ENSG00000255239.1	AP002954.6	4.39	1.54e-05	0.00384	0.34	0.23	Sjögren's syndrome;	chr11:118854951	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.865	rs10892299	ENSG00000255239.1	AP002954.6	-4.39	1.54e-05	0.00384	-0.34	-0.23	Sjögren's syndrome;	chr11:118856134	chr11:118688039~118690600:-
LIHC	cis	rs10790268	1	rs10790268	ENSG00000255239.1	AP002954.6	4.39	1.54e-05	0.00384	0.34	0.23	Rheumatoid arthritis;	chr11:118858682	chr11:118688039~118690600:-
LIHC	cis	rs7119038	0.73	rs10790269	ENSG00000255239.1	AP002954.6	4.39	1.54e-05	0.00384	0.34	0.23	Sjögren's syndrome;	chr11:118858747	chr11:118688039~118690600:-
LIHC	cis	rs11671005	0.695	rs11673069	ENSG00000269473.1	CTD-2619J13.19	4.39	1.54e-05	0.00384	0.39	0.23	Mean platelet volume;	chr19:58423551	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs12981875	ENSG00000269473.1	CTD-2619J13.19	4.39	1.54e-05	0.00384	0.39	0.23	Mean platelet volume;	chr19:58423763	chr19:58440448~58445849:+
LIHC	cis	rs3738443	0.817	rs6698690	ENSG00000259865.1	RP11-488L18.10	4.39	1.54e-05	0.00384	0.21	0.23	Alcohol dependence;	chr1:247199176	chr1:247187281~247188526:-
LIHC	cis	rs3738443	0.868	rs7551871	ENSG00000259865.1	RP11-488L18.10	4.39	1.54e-05	0.00384	0.21	0.23	Alcohol dependence;	chr1:247199888	chr1:247187281~247188526:-
LIHC	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-4.39	1.54e-05	0.00385	-0.23	-0.23	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-4.39	1.54e-05	0.00385	-0.23	-0.23	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
LIHC	cis	rs7412746	0.622	rs72704654	ENSG00000231073.1	RP11-316M1.3	4.39	1.54e-05	0.00385	0.24	0.23	Melanoma;	chr1:150853934	chr1:150973123~150975534:+
LIHC	cis	rs7176527	1	rs7176527	ENSG00000189136.7	UBE2Q2P1	-4.38	1.55e-05	0.00385	-0.2	-0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84526781~84571216:-
LIHC	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-4.38	1.55e-05	0.00386	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-4.38	1.55e-05	0.00386	-0.44	-0.23	Depression;	chr6:28173682	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-4.38	1.55e-05	0.00386	-0.44	-0.23	Depression;	chr6:28175340	chr6:28115628~28116551:+
LIHC	cis	rs1729407	0.814	rs2071521	ENSG00000236267.1	AP006216.5	-4.38	1.55e-05	0.00387	-0.22	-0.23	Apolipoprotein A-IV levels;	chr11:116827132	chr11:116813204~116814003:-
LIHC	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-4.38	1.55e-05	0.00387	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
LIHC	cis	rs948562	1	rs3829218	ENSG00000280010.1	AP001350.4	4.38	1.55e-05	0.00387	0.41	0.23	Lymphoma;	chr11:58563836	chr11:58627435~58628528:+
LIHC	cis	rs7702057	0.53	rs3087832	ENSG00000271918.1	CTD-2287O16.5	4.38	1.55e-05	0.00387	0.32	0.23	Amyotrophic lateral sclerosis;	chr5:116084931	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs74583480	ENSG00000271918.1	CTD-2287O16.5	4.38	1.55e-05	0.00387	0.32	0.23	Amyotrophic lateral sclerosis;	chr5:116085200	chr5:116083807~116085416:-
LIHC	cis	rs7702057	0.53	rs73780832	ENSG00000271918.1	CTD-2287O16.5	4.38	1.55e-05	0.00387	0.32	0.23	Amyotrophic lateral sclerosis;	chr5:116085208	chr5:116083807~116085416:-
LIHC	cis	rs529413	0.57	rs524607	ENSG00000259237.1	RP11-209E8.1	4.38	1.56e-05	0.00387	0.32	0.23	Itch intensity from mosquito bite adjusted by bite size;	chr15:53244544	chr15:53116365~53129698:+
LIHC	cis	rs11098499	0.82	rs13128602	ENSG00000260091.1	RP11-33B1.4	4.38	1.56e-05	0.00387	0.17	0.23	Corneal astigmatism;	chr4:119538211	chr4:119409333~119410233:+
LIHC	cis	rs12478296	0.901	rs67423532	ENSG00000261186.2	RP11-341N2.1	-4.38	1.56e-05	0.00387	-0.31	-0.23	Obesity-related traits;	chr2:242062568	chr2:242087351~242088457:-
LIHC	cis	rs12478296	0.901	rs67951957	ENSG00000261186.2	RP11-341N2.1	-4.38	1.56e-05	0.00387	-0.31	-0.23	Obesity-related traits;	chr2:242062750	chr2:242087351~242088457:-
LIHC	cis	rs12478296	0.792	rs3924263	ENSG00000261186.2	RP11-341N2.1	-4.38	1.56e-05	0.00387	-0.31	-0.23	Obesity-related traits;	chr2:242063016	chr2:242087351~242088457:-
LIHC	cis	rs12478296	1	rs7420157	ENSG00000261186.2	RP11-341N2.1	-4.38	1.56e-05	0.00387	-0.31	-0.23	Obesity-related traits;	chr2:242063053	chr2:242087351~242088457:-
LIHC	cis	rs1865760	0.566	rs3752419	ENSG00000216436.2	HIST1H2APS1	-4.38	1.56e-05	0.00388	-0.27	-0.23	Height;	chr6:26027205	chr6:25732497~25732827:+
LIHC	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-4.38	1.56e-05	0.00388	-0.3	-0.23	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
LIHC	cis	rs748404	0.697	rs531910	ENSG00000166763.7	STRCP1	4.38	1.56e-05	0.00388	0.29	0.23	Lung cancer;	chr15:43268409	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs491804	ENSG00000166763.7	STRCP1	4.38	1.56e-05	0.00388	0.29	0.23	Lung cancer;	chr15:43268627	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.697	rs492743	ENSG00000166763.7	STRCP1	4.38	1.56e-05	0.00388	0.29	0.23	Lung cancer;	chr15:43268747	chr15:43699488~43718184:-
LIHC	cis	rs948562	0.895	rs11229537	ENSG00000280010.1	AP001350.4	4.38	1.56e-05	0.00388	0.41	0.23	Lymphoma;	chr11:58585392	chr11:58627435~58628528:+
LIHC	cis	rs17270561	0.636	rs1185977	ENSG00000216436.2	HIST1H2APS1	-4.38	1.56e-05	0.00388	-0.28	-0.23	Iron status biomarkers;	chr6:25828826	chr6:25732497~25732827:+
LIHC	cis	rs1247318	1	rs1247365	ENSG00000243831.1	RP1-81D8.4	4.38	1.56e-05	0.00388	0.33	0.23	Aging;	chr6:160921896	chr6:160666228~160676523:-
LIHC	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-4.38	1.56e-05	0.00389	-0.27	-0.23	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
LIHC	cis	rs9595908	1	rs9591165	ENSG00000212293.1	SNORA16	4.38	1.56e-05	0.00389	0.26	0.23	Body mass index;	chr13:32611016	chr13:32420390~32420516:-
LIHC	cis	rs950169	0.922	rs11633534	ENSG00000259295.5	CSPG4P12	4.38	1.56e-05	0.00389	0.32	0.23	Schizophrenia;	chr15:84581411	chr15:85191438~85213905:+
LIHC	cis	rs8028182	0.636	rs4462560	ENSG00000260269.4	CTD-2323K18.1	4.38	1.56e-05	0.00389	0.3	0.23	Sudden cardiac arrest;	chr15:75355623	chr15:75527150~75601205:-
LIHC	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-4.38	1.56e-05	0.00389	-0.25	-0.23	Asthma;	chr2:102377873	chr2:102438713~102440475:+
LIHC	cis	rs1400745	0.718	rs799681	ENSG00000258738.1	RP11-73E17.2	4.38	1.56e-05	0.00389	0.29	0.23	Monocyte count;	chr14:34881373	chr14:34874343~34876459:+
LIHC	cis	rs6480314	0.708	rs11812723	ENSG00000233590.1	RP11-153K11.3	-4.38	1.56e-05	0.00389	-0.36	-0.23	Optic nerve measurement (disc area);	chr10:68215014	chr10:68233251~68242379:-
LIHC	cis	rs417065	1	rs12745477	ENSG00000227634.1	RP11-431K24.3	-4.38	1.56e-05	0.00389	-0.31	-0.23	Psoriasis;	chr1:8204397	chr1:8208672~8215210:+
LIHC	cis	rs12478296	0.901	rs7423119	ENSG00000261186.2	RP11-341N2.1	-4.38	1.56e-05	0.00389	-0.31	-0.23	Obesity-related traits;	chr2:242063337	chr2:242087351~242088457:-
LIHC	cis	rs2739330	0.828	rs4822451	ENSG00000206090.4	AP000350.7	4.38	1.56e-05	0.00389	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23939998~23942798:+
LIHC	cis	rs921968	0.619	rs1554623	ENSG00000272555.1	RP11-459I19.1	-4.38	1.56e-05	0.00389	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218741454	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs1554622	ENSG00000272555.1	RP11-459I19.1	-4.38	1.56e-05	0.00389	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218741495	chr2:218818690~218819144:+
LIHC	cis	rs1577917	1	rs10455456	ENSG00000234155.1	RP11-30P6.6	4.38	1.56e-05	0.00389	0.3	0.23	Response to antipsychotic treatment;	chr6:85960604	chr6:85387219~85390186:-
LIHC	cis	rs860295	0.665	rs11264367	ENSG00000203761.5	MSTO2P	-4.38	1.57e-05	0.00389	-0.19	-0.23	Body mass index;	chr1:155367547	chr1:155745829~155750137:+
LIHC	cis	rs1075265	0.563	rs2542588	ENSG00000272156.1	RP11-477N3.1	4.38	1.57e-05	0.00389	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54082554~54085066:+
LIHC	cis	rs9595908	0.965	rs35193668	ENSG00000212293.1	SNORA16	4.38	1.57e-05	0.0039	0.28	0.23	Body mass index;	chr13:32518792	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.965	rs2239748	ENSG00000212293.1	SNORA16	4.38	1.57e-05	0.0039	0.28	0.23	Body mass index;	chr13:32527680	chr13:32420390~32420516:-
LIHC	cis	rs6901152	0.525	rs2216918	ENSG00000217648.1	RP1-95L4.4	-4.38	1.57e-05	0.0039	-0.28	-0.23	Acute lymphoblastic leukemia (childhood);	chr6:143368254	chr6:143342246~143343383:+
LIHC	cis	rs11148252	0.904	rs7321964	ENSG00000278238.1	RP11-245D16.4	-4.38	1.57e-05	0.0039	-0.22	-0.23	Lewy body disease;	chr13:52466687	chr13:52454775~52455331:-
LIHC	cis	rs4694744	0.576	rs13145834	ENSG00000264696.1	AC108078.1	4.38	1.57e-05	0.0039	0.34	0.23	Bacteremia;	chr4:69493350	chr4:69479331~69479434:+
LIHC	cis	rs4694744	0.576	rs10518061	ENSG00000264696.1	AC108078.1	4.38	1.57e-05	0.0039	0.34	0.23	Bacteremia;	chr4:69493442	chr4:69479331~69479434:+
LIHC	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	4.38	1.57e-05	0.0039	0.23	0.23	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
LIHC	cis	rs5742933	0.857	rs13021611	ENSG00000253559.1	OSGEPL1-AS1	4.38	1.57e-05	0.0039	0.31	0.23	Ferritin levels;	chr2:189700038	chr2:189762704~189765556:+
LIHC	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-4.38	1.57e-05	0.0039	-0.28	-0.23	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
LIHC	cis	rs494453	0.922	rs531692	ENSG00000227811.2	FAM212B-AS1	-4.38	1.57e-05	0.0039	-0.25	-0.23	Osteoporosis-related phenotypes;	chr1:111691954	chr1:111739841~111747798:+
LIHC	cis	rs9675120	0.708	rs9893135	ENSG00000262006.1	RP11-700H6.4	-4.38	1.57e-05	0.0039	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50844519	chr17:50909637~50910232:-
LIHC	cis	rs929596	0.639	rs2070959	ENSG00000233445.1	RPL17P11	4.38	1.57e-05	0.0039	0.26	0.23	Total bilirubin levels in HIV-1 infection;	chr2:233693545	chr2:233721522~233722065:-
LIHC	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-4.38	1.57e-05	0.0039	-0.23	-0.23	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
LIHC	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-4.38	1.57e-05	0.0039	-0.23	-0.23	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
LIHC	cis	rs2836974	0.583	rs9636957	ENSG00000255568.3	BRWD1-AS2	-4.38	1.57e-05	0.0039	-0.19	-0.23	Cognitive function;	chr21:39333921	chr21:39313935~39314962:+
LIHC	cis	rs9843304	0.529	rs4681512	ENSG00000244503.1	RP11-278L15.6	4.38	1.57e-05	0.00391	0.23	0.23	Gallstone disease;	chr3:149485654	chr3:149494660~149495995:+
LIHC	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-4.38	1.57e-05	0.00391	-0.25	-0.23	Asthma;	chr2:102393077	chr2:102438713~102440475:+
LIHC	cis	rs9595908	0.965	rs9591180	ENSG00000212293.1	SNORA16	4.38	1.57e-05	0.00391	0.27	0.23	Body mass index;	chr13:32622864	chr13:32420390~32420516:-
LIHC	cis	rs17270561	0.723	rs12192635	ENSG00000216436.2	HIST1H2APS1	-4.38	1.57e-05	0.00391	-0.35	-0.23	Iron status biomarkers;	chr6:25880679	chr6:25732497~25732827:+
LIHC	cis	rs11722228	0.521	rs56403947	ENSG00000261490.1	RP11-448G15.3	4.38	1.57e-05	0.00391	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10110905	chr4:10068089~10073019:-
LIHC	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-4.38	1.57e-05	0.00391	-0.26	-0.23	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-4.38	1.57e-05	0.00391	-0.26	-0.23	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-4.38	1.57e-05	0.00391	-0.26	-0.23	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-4.38	1.57e-05	0.00391	-0.26	-0.23	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-4.38	1.57e-05	0.00391	-0.26	-0.23	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
LIHC	cis	rs11098499	0.863	rs7678400	ENSG00000260091.1	RP11-33B1.4	-4.38	1.57e-05	0.00391	-0.17	-0.23	Corneal astigmatism;	chr4:119540802	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs1480936	ENSG00000260091.1	RP11-33B1.4	-4.38	1.57e-05	0.00391	-0.17	-0.23	Corneal astigmatism;	chr4:119541706	chr4:119409333~119410233:+
LIHC	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	4.38	1.58e-05	0.00391	0.27	0.23	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
LIHC	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	4.38	1.58e-05	0.00392	0.28	0.23	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	4.38	1.58e-05	0.00392	0.28	0.23	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
LIHC	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-4.38	1.58e-05	0.00392	-0.29	-0.23	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
LIHC	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	4.38	1.58e-05	0.00392	0.31	0.23	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
LIHC	cis	rs5742933	0.857	rs12471217	ENSG00000253559.1	OSGEPL1-AS1	4.38	1.58e-05	0.00392	0.3	0.23	Ferritin levels;	chr2:189707337	chr2:189762704~189765556:+
LIHC	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-4.38	1.58e-05	0.00393	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-4.38	1.58e-05	0.00393	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-4.38	1.58e-05	0.00393	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
LIHC	cis	rs875971	0.619	rs12533585	ENSG00000273024.4	INTS4P2	-4.38	1.58e-05	0.00393	-0.26	-0.23	Aortic root size;	chr7:66519618	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs28698552	ENSG00000273024.4	INTS4P2	-4.38	1.58e-05	0.00393	-0.26	-0.23	Aortic root size;	chr7:66540031	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs801192	ENSG00000273024.4	INTS4P2	4.38	1.58e-05	0.00393	0.26	0.23	Aortic root size;	chr7:66566965	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs801190	ENSG00000273024.4	INTS4P2	4.38	1.58e-05	0.00393	0.26	0.23	Aortic root size;	chr7:66568046	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.66	rs3857686	ENSG00000273024.4	INTS4P2	4.38	1.58e-05	0.00393	0.26	0.23	Aortic root size;	chr7:66571204	chr7:65647864~65715661:+
LIHC	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-4.38	1.58e-05	0.00393	-0.28	-0.23	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
LIHC	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-4.38	1.58e-05	0.00393	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-4.38	1.58e-05	0.00393	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-4.38	1.58e-05	0.00393	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-4.38	1.58e-05	0.00393	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-4.38	1.58e-05	0.00393	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
LIHC	cis	rs803923	0.585	rs803914	ENSG00000230894.1	RP11-67K19.3	-4.38	1.58e-05	0.00393	-0.3	-0.23	Lung function (FEV1/FVC);	chr9:116654425	chr9:116568449~116586328:+
LIHC	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-4.38	1.58e-05	0.00393	-0.27	-0.23	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
LIHC	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-4.38	1.58e-05	0.00393	-0.24	-0.23	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
LIHC	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	4.38	1.58e-05	0.00393	0.36	0.23	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
LIHC	cis	rs11668505	1	rs12982537	ENSG00000259108.2	CTD-3098H1.2	4.38	1.59e-05	0.00394	0.29	0.23	Lung function (FVC);	chr19:47842073	chr19:47863483~47865341:-
LIHC	cis	rs921968	0.565	rs7595901	ENSG00000272555.1	RP11-459I19.1	-4.38	1.59e-05	0.00394	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218742208	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs2272189	ENSG00000272555.1	RP11-459I19.1	-4.38	1.59e-05	0.00394	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218745599	chr2:218818690~218819144:+
LIHC	cis	rs7474896	0.583	rs11011346	ENSG00000263064.2	RP11-291L22.7	4.38	1.59e-05	0.00394	0.28	0.23	Obesity (extreme);	chr10:37720555	chr10:38448689~38448949:+
LIHC	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-4.38	1.59e-05	0.00394	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
LIHC	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-4.38	1.59e-05	0.00394	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
LIHC	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-4.38	1.59e-05	0.00394	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
LIHC	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-4.38	1.59e-05	0.00394	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
LIHC	cis	rs803923	0.56	rs811458	ENSG00000230894.1	RP11-67K19.3	-4.38	1.59e-05	0.00394	-0.29	-0.23	Lung function (FEV1/FVC);	chr9:116642992	chr9:116568449~116586328:+
LIHC	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	4.38	1.59e-05	0.00394	0.35	0.23	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
LIHC	cis	rs6487679	1	rs6487679	ENSG00000111788.10	RP11-22B23.1	4.38	1.59e-05	0.00394	0.28	0.23	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9277235~9313241:+
LIHC	cis	rs1075265	0.575	rs2692531	ENSG00000272156.1	RP11-477N3.1	-4.38	1.59e-05	0.00394	-0.28	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54082554~54085066:+
LIHC	cis	rs9595908	1	rs9595905	ENSG00000212293.1	SNORA16	4.38	1.59e-05	0.00395	0.26	0.23	Body mass index;	chr13:32609266	chr13:32420390~32420516:-
LIHC	cis	rs16958440	1	rs61316646	ENSG00000267724.1	RP11-49K24.8	4.38	1.59e-05	0.00395	0.36	0.23	Sitting height ratio;	chr18:47084299	chr18:47105946~47108062:+
LIHC	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-4.38	1.59e-05	0.00395	-0.26	-0.23	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
LIHC	cis	rs7809950	1	rs10243340	ENSG00000238832.1	snoU109	-4.38	1.59e-05	0.00395	-0.28	-0.23	Coronary artery disease;	chr7:107450510	chr7:107603363~107603507:+
LIHC	cis	rs13315871	0.615	rs7618604	ENSG00000272182.1	RP11-802O23.3	4.38	1.59e-05	0.00395	0.46	0.23	Cholesterol, total;	chr3:58372058	chr3:58428255~58428815:+
LIHC	cis	rs2562456	0.792	rs2562398	ENSG00000268555.1	RP11-678G14.3	-4.38	1.59e-05	0.00395	-0.29	-0.23	Pain;	chr19:21540147	chr19:21570822~21587322:-
LIHC	cis	rs921968	0.565	rs13408305	ENSG00000272555.1	RP11-459I19.1	-4.38	1.59e-05	0.00395	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218763460	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.528	rs13382651	ENSG00000272555.1	RP11-459I19.1	-4.38	1.59e-05	0.00395	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218763468	chr2:218818690~218819144:+
LIHC	cis	rs2717559	0.522	rs10956987	ENSG00000253196.1	RP11-706C16.7	-4.38	1.59e-05	0.00396	-0.25	-0.23	Urinary tract infection frequency;	chr8:142805197	chr8:142763116~142766427:+
LIHC	cis	rs2243480	0.522	rs431168	ENSG00000230295.1	RP11-458F8.2	-4.38	1.59e-05	0.00396	-0.26	-0.23	Diabetic kidney disease;	chr7:66046617	chr7:66880708~66882981:+
LIHC	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-4.38	1.6e-05	0.00396	-0.31	-0.23	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
LIHC	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	4.38	1.6e-05	0.00396	0.2	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
LIHC	cis	rs7412746	0.588	rs10305664	ENSG00000231073.1	RP11-316M1.3	4.38	1.6e-05	0.00396	0.24	0.23	Melanoma;	chr1:150867210	chr1:150973123~150975534:+
LIHC	cis	rs11098499	0.754	rs878372	ENSG00000260091.1	RP11-33B1.4	-4.38	1.6e-05	0.00396	-0.16	-0.23	Corneal astigmatism;	chr4:119317625	chr4:119409333~119410233:+
LIHC	cis	rs113084984	0.634	rs7582396	ENSG00000271952.1	RP11-245G13.2	4.38	1.6e-05	0.00396	0.29	0.23	Breast cancer;	chr2:11524223	chr2:10878269~10885118:+
LIHC	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	4.38	1.6e-05	0.00397	0.34	0.23	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
LIHC	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-4.38	1.6e-05	0.00397	-0.44	-0.23	Depression;	chr6:28159062	chr6:28115628~28116551:+
LIHC	cis	rs8028182	0.549	rs4886696	ENSG00000260269.4	CTD-2323K18.1	4.38	1.6e-05	0.00397	0.29	0.23	Sudden cardiac arrest;	chr15:75372229	chr15:75527150~75601205:-
LIHC	cis	rs7894407	0.76	rs1163072	ENSG00000236937.2	PTGES3P4	-4.38	1.6e-05	0.00397	-0.26	-0.23	White matter hyperintensity burden;	chr10:103264621	chr10:102845595~102845950:+
LIHC	cis	rs4650994	0.789	rs2476559	ENSG00000213057.5	C1orf220	-4.38	1.6e-05	0.00397	-0.19	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178623784	chr1:178542752~178548889:+
LIHC	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-4.38	1.6e-05	0.00397	-0.27	-0.23	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
LIHC	cis	rs4578769	0.879	rs7243408	ENSG00000266850.1	RP11-370A5.1	4.38	1.6e-05	0.00397	0.27	0.23	Eosinophil percentage of white cells;	chr18:22861647	chr18:22723491~22907721:-
LIHC	cis	rs9573567	0.609	rs9565164	ENSG00000261553.4	RP11-29G8.3	-4.38	1.6e-05	0.00398	-0.4	-0.23	Red blood cell count;Mean corpuscular volume;	chr13:75465240	chr13:75549773~75807120:+
LIHC	cis	rs9457247	0.935	rs427824	ENSG00000227598.1	RP1-167A14.2	-4.38	1.61e-05	0.00398	-0.25	-0.23	Crohn's disease;	chr6:166990430	chr6:166969626~166999065:-
LIHC	cis	rs2998286	0.723	rs332191	ENSG00000254635.4	WAC-AS1	-4.38	1.61e-05	0.00398	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28632196	chr10:28522652~28532743:-
LIHC	cis	rs2312236	0.714	rs10918573	ENSG00000225171.2	DUTP6	4.38	1.61e-05	0.00399	0.3	0.23	Post-traumatic stress disorder;	chr1:166749647	chr1:166868748~166869209:+
LIHC	cis	rs11098499	0.82	rs28578366	ENSG00000260091.1	RP11-33B1.4	4.38	1.61e-05	0.00399	0.16	0.23	Corneal astigmatism;	chr4:119615750	chr4:119409333~119410233:+
LIHC	cis	rs7587476	0.906	rs2734674	ENSG00000229267.2	AC072062.1	4.38	1.61e-05	0.00399	0.3	0.23	Neuroblastoma;	chr2:214794171	chr2:214810229~214963274:+
LIHC	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	4.38	1.61e-05	0.00399	0.25	0.23	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
LIHC	cis	rs2301573	1	rs2301573	ENSG00000251474.5	RPL32P3	4.38	1.61e-05	0.00399	0.25	0.23	Hip circumference;	chr3:129587076	chr3:129382922~129399655:-
LIHC	cis	rs919433	0.927	rs13032495	ENSG00000231621.1	AC013264.2	4.38	1.61e-05	0.004	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197197991~197199273:+
LIHC	cis	rs4650994	0.816	rs2761470	ENSG00000273384.1	RP5-1098D14.1	-4.38	1.61e-05	0.004	-0.27	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178626898	chr1:178651706~178652282:+
LIHC	cis	rs6893782	0.887	rs6596075	ENSG00000233006.5	AC034220.3	4.38	1.61e-05	0.004	0.33	0.23	Acylcarnitine levels;	chr5:132406536	chr5:132311285~132369916:-
LIHC	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-4.38	1.61e-05	0.004	-0.26	-0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
LIHC	cis	rs1223397	0.651	rs402705	ENSG00000215022.6	RP1-257A7.4	-4.37	1.62e-05	0.004	-0.24	-0.23	Blood pressure;	chr6:13296207	chr6:13264861~13295586:-
LIHC	cis	rs3812762	0.879	rs4929910	ENSG00000254860.4	TMEM9B-AS1	-4.37	1.62e-05	0.004	-0.24	-0.23	Hypospadias;	chr11:8763322	chr11:8964675~8977527:+
LIHC	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-4.37	1.62e-05	0.004	-0.26	-0.23	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
LIHC	cis	rs948562	1	rs79475579	ENSG00000280010.1	AP001350.4	4.37	1.62e-05	0.00401	0.4	0.23	Lymphoma;	chr11:58528427	chr11:58627435~58628528:+
LIHC	cis	rs948562	1	rs111901203	ENSG00000280010.1	AP001350.4	4.37	1.62e-05	0.00401	0.4	0.23	Lymphoma;	chr11:58530069	chr11:58627435~58628528:+
LIHC	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	4.37	1.62e-05	0.00401	0.25	0.23	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
LIHC	cis	rs921968	0.565	rs7580147	ENSG00000272555.1	RP11-459I19.1	-4.37	1.62e-05	0.00401	-0.25	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218778313	chr2:218818690~218819144:+
LIHC	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	4.37	1.62e-05	0.00401	0.37	0.23	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	4.37	1.62e-05	0.00401	0.37	0.23	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
LIHC	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	4.37	1.62e-05	0.00401	0.27	0.23	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	4.37	1.62e-05	0.00401	0.27	0.23	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
LIHC	cis	rs13083990	0.919	rs3749208	ENSG00000272758.4	RP11-299J3.8	4.37	1.62e-05	0.00401	0.25	0.23	Cardiac Troponin-T levels;	chr3:122261437	chr3:122416207~122443180:+
LIHC	cis	rs2243480	1	rs2462569	ENSG00000230295.1	RP11-458F8.2	4.37	1.62e-05	0.00401	0.24	0.23	Diabetic kidney disease;	chr7:66009859	chr7:66880708~66882981:+
LIHC	cis	rs748404	0.578	rs2278856	ENSG00000166763.7	STRCP1	4.37	1.62e-05	0.00401	0.28	0.23	Lung cancer;	chr15:43339158	chr15:43699488~43718184:-
LIHC	cis	rs2976388	0.609	rs2572907	ENSG00000253196.1	RP11-706C16.7	4.37	1.62e-05	0.00402	0.22	0.23	Urinary tract infection frequency;	chr8:142720520	chr8:142763116~142766427:+
LIHC	cis	rs2976388	0.609	rs2572908	ENSG00000253196.1	RP11-706C16.7	4.37	1.62e-05	0.00402	0.22	0.23	Urinary tract infection frequency;	chr8:142721218	chr8:142763116~142766427:+
LIHC	cis	rs2976388	0.609	rs2717602	ENSG00000253196.1	RP11-706C16.7	4.37	1.62e-05	0.00402	0.22	0.23	Urinary tract infection frequency;	chr8:142724265	chr8:142763116~142766427:+
LIHC	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-4.37	1.62e-05	0.00402	-0.22	-0.23	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
LIHC	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	4.37	1.62e-05	0.00402	0.28	0.23	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
LIHC	cis	rs4578769	1	rs4578769	ENSG00000265943.1	RP11-739L10.1	4.37	1.62e-05	0.00402	0.29	0.23	Eosinophil percentage of white cells;	chr18:22815141	chr18:22699481~22933764:-
LIHC	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	4.37	1.62e-05	0.00402	0.25	0.23	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
LIHC	cis	rs1577917	1	rs68171315	ENSG00000234155.1	RP11-30P6.6	4.37	1.63e-05	0.00402	0.3	0.23	Response to antipsychotic treatment;	chr6:85997682	chr6:85387219~85390186:-
LIHC	cis	rs1865760	0.516	rs9295684	ENSG00000216436.2	HIST1H2APS1	-4.37	1.63e-05	0.00403	-0.27	-0.23	Height;	chr6:26069441	chr6:25732497~25732827:+
LIHC	cis	rs9595908	0.965	rs9337	ENSG00000212293.1	SNORA16	4.37	1.63e-05	0.00403	0.28	0.23	Body mass index;	chr13:32517104	chr13:32420390~32420516:-
LIHC	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-4.37	1.63e-05	0.00403	-0.31	-0.23	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
LIHC	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-4.37	1.63e-05	0.00403	-0.27	-0.23	Height;	chr3:53074760	chr3:53064283~53065091:-
LIHC	cis	rs7208859	0.673	rs17826219	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs61223749	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs3764420	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs3764421	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11651858	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs36056619	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9909497	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11080135	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9894876	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs60020217	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs73277974	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73277978	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11657391	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs58089675	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73263755	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9899349	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11652358	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9891179	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9891413	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73263776	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11650271	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9889968	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs61348930	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.614	rs28758251	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9899943	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11080138	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73265612	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11658435	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73265624	ENSG00000266490.1	CTD-2349P21.9	4.37	1.63e-05	0.00403	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30792372~30792833:+
LIHC	cis	rs1223397	1	rs1223403	ENSG00000215022.6	RP1-257A7.4	-4.37	1.63e-05	0.00403	-0.27	-0.23	Blood pressure;	chr6:13271580	chr6:13264861~13295586:-
LIHC	cis	rs11951515	0.508	rs10065689	ENSG00000248240.1	RP11-159F24.5	-4.37	1.63e-05	0.00404	-0.29	-0.23	Metabolite levels  (X-11787);	chr5:43604156	chr5:43515274~43525310:+
LIHC	cis	rs3733589	0.744	rs57897925	ENSG00000250413.1	RP11-448G15.1	4.37	1.63e-05	0.00404	0.37	0.23	Renal overload gout;	chr4:10051657	chr4:10006482~10009725:+
LIHC	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	4.37	1.63e-05	0.00404	0.25	0.23	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
LIHC	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-4.37	1.64e-05	0.00404	-0.27	-0.23	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
LIHC	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	4.37	1.64e-05	0.00404	0.3	0.23	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
LIHC	cis	rs10129255	0.872	rs10133674	ENSG00000223648.3	IGHV3-64	4.37	1.64e-05	0.00404	0.17	0.23	Kawasaki disease;	chr14:106692788	chr14:106643132~106658258:-
LIHC	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	4.37	1.64e-05	0.00404	0.19	0.23	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
LIHC	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	4.37	1.64e-05	0.00405	0.22	0.23	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
LIHC	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	4.37	1.64e-05	0.00405	0.27	0.23	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	4.37	1.64e-05	0.00405	0.27	0.23	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
LIHC	cis	rs2243480	1	rs1638734	ENSG00000232546.1	RP11-458F8.1	-4.37	1.64e-05	0.00405	-0.26	-0.23	Diabetic kidney disease;	chr7:66632552	chr7:66848496~66858136:+
LIHC	cis	rs875971	0.545	rs73376401	ENSG00000228409.4	CCT6P1	-4.37	1.64e-05	0.00405	-0.19	-0.23	Aortic root size;	chr7:66174841	chr7:65751142~65763354:+
LIHC	cis	rs1816213	1	rs16859180	ENSG00000273466.1	RP11-548H3.1	4.37	1.64e-05	0.00406	0.34	0.23	Diastolic blood pressure;	chr2:218688745	chr2:218633256~218634014:-
LIHC	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	4.37	1.64e-05	0.00406	0.34	0.23	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
LIHC	cis	rs2243480	1	rs6460260	ENSG00000228409.4	CCT6P1	-4.37	1.64e-05	0.00406	-0.25	-0.23	Diabetic kidney disease;	chr7:65750468	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs6460261	ENSG00000228409.4	CCT6P1	-4.37	1.64e-05	0.00406	-0.25	-0.23	Diabetic kidney disease;	chr7:65750593	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs4718270	ENSG00000228409.4	CCT6P1	4.37	1.64e-05	0.00406	0.25	0.23	Diabetic kidney disease;	chr7:65737415	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs2900904	ENSG00000228409.4	CCT6P1	4.37	1.64e-05	0.00406	0.25	0.23	Diabetic kidney disease;	chr7:65739282	chr7:65751142~65763354:+
LIHC	cis	rs6940638	0.662	rs7759694	ENSG00000216901.1	AL022393.7	4.37	1.64e-05	0.00406	0.32	0.23	Intelligence (multi-trait analysis);	chr6:27273177	chr6:28176188~28176674:+
LIHC	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	4.37	1.64e-05	0.00406	0.23	0.23	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
LIHC	cis	rs9834975	0.967	rs6768280	ENSG00000272758.4	RP11-299J3.8	4.37	1.64e-05	0.00406	0.25	0.23	Diastolic blood pressure;	chr3:122406205	chr3:122416207~122443180:+
LIHC	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-4.37	1.65e-05	0.00406	-0.25	-0.23	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
LIHC	cis	rs17826219	0.706	rs9905827	ENSG00000266490.1	CTD-2349P21.9	4.37	1.65e-05	0.00407	0.29	0.23	Body mass index;	chr17:30865150	chr17:30792372~30792833:+
LIHC	cis	rs11233413	0.874	rs5018628	ENSG00000246067.6	RAB30-AS1	4.37	1.65e-05	0.00407	0.32	0.23	Economic and political preferences (feminism/equality);	chr11:83041195	chr11:83072066~83106719:+
LIHC	cis	rs17301013	0.869	rs3133270	ENSG00000227373.4	RP11-160H22.5	-4.37	1.65e-05	0.00407	-0.28	-0.23	Systemic lupus erythematosus;	chr1:174819547	chr1:174115300~174160004:-
LIHC	cis	rs2739330	0.828	rs5760098	ENSG00000206090.4	AP000350.7	4.37	1.65e-05	0.00407	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23939998~23942798:+
LIHC	cis	rs3812762	0.912	rs10769954	ENSG00000254860.4	TMEM9B-AS1	-4.37	1.65e-05	0.00407	-0.25	-0.23	Hypospadias;	chr11:8762166	chr11:8964675~8977527:+
LIHC	cis	rs4356203	0.519	rs214097	ENSG00000260196.1	RP1-239B22.5	-4.37	1.65e-05	0.00407	-0.28	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17380649~17383531:+
LIHC	cis	rs748404	0.66	rs690446	ENSG00000166763.7	STRCP1	4.37	1.65e-05	0.00407	0.28	0.23	Lung cancer;	chr15:43469066	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs518288	ENSG00000166763.7	STRCP1	4.37	1.65e-05	0.00407	0.28	0.23	Lung cancer;	chr15:43471801	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs690472	ENSG00000166763.7	STRCP1	4.37	1.65e-05	0.00407	0.28	0.23	Lung cancer;	chr15:43472170	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.631	rs560191	ENSG00000166763.7	STRCP1	4.37	1.65e-05	0.00407	0.28	0.23	Lung cancer;	chr15:43475576	chr15:43699488~43718184:-
LIHC	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	4.37	1.65e-05	0.00407	0.3	0.23	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
LIHC	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	4.37	1.65e-05	0.00407	0.36	0.23	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	4.37	1.65e-05	0.00407	0.36	0.23	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
LIHC	cis	rs9353324	1	rs7745560	ENSG00000203875.9	SNHG5	4.37	1.65e-05	0.00408	0.45	0.23	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85660950~85678736:-
LIHC	cis	rs11098499	0.754	rs7672594	ENSG00000260091.1	RP11-33B1.4	-4.37	1.65e-05	0.00408	-0.16	-0.23	Corneal astigmatism;	chr4:119327388	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs7672778	ENSG00000260091.1	RP11-33B1.4	-4.37	1.65e-05	0.00408	-0.16	-0.23	Corneal astigmatism;	chr4:119327430	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs12513083	ENSG00000260091.1	RP11-33B1.4	-4.37	1.65e-05	0.00408	-0.16	-0.23	Corneal astigmatism;	chr4:119328457	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs12509621	ENSG00000260091.1	RP11-33B1.4	-4.37	1.65e-05	0.00408	-0.16	-0.23	Corneal astigmatism;	chr4:119328505	chr4:119409333~119410233:+
LIHC	cis	rs75920871	0.688	rs1473326	ENSG00000254851.1	RP11-109L13.1	-4.37	1.65e-05	0.00408	-0.48	-0.23	Subjective well-being;	chr11:116952956	chr11:117135528~117138582:+
LIHC	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	4.37	1.65e-05	0.00408	0.28	0.23	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
LIHC	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-4.37	1.66e-05	0.00408	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
LIHC	cis	rs3733589	1	rs13106922	ENSG00000250413.1	RP11-448G15.1	4.37	1.66e-05	0.00409	0.37	0.23	Renal overload gout;	chr4:10020135	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.744	rs13114106	ENSG00000250413.1	RP11-448G15.1	4.37	1.66e-05	0.00409	0.37	0.23	Renal overload gout;	chr4:10020501	chr4:10006482~10009725:+
LIHC	cis	rs3733589	0.744	rs3756234	ENSG00000250413.1	RP11-448G15.1	4.37	1.66e-05	0.00409	0.37	0.23	Renal overload gout;	chr4:10020850	chr4:10006482~10009725:+
LIHC	cis	rs9341808	0.527	rs7453746	ENSG00000272129.1	RP11-250B2.6	4.37	1.66e-05	0.00409	0.22	0.23	Sitting height ratio;	chr6:80100296	chr6:80355424~80356859:+
LIHC	cis	rs748404	0.66	rs2602141	ENSG00000166763.7	STRCP1	4.37	1.66e-05	0.00409	0.28	0.23	Lung cancer;	chr15:43432448	chr15:43699488~43718184:-
LIHC	cis	rs901683	0.702	rs4326742	ENSG00000230869.1	CTGLF10P	-4.37	1.66e-05	0.00409	-0.55	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45607788	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs4576771	ENSG00000230869.1	CTGLF10P	-4.37	1.66e-05	0.00409	-0.55	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45607790	chr10:45678692~45700532:+
LIHC	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-4.37	1.66e-05	0.0041	-0.27	-0.23	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
LIHC	cis	rs4578769	0.918	rs9957390	ENSG00000265943.1	RP11-739L10.1	4.37	1.66e-05	0.0041	0.29	0.23	Eosinophil percentage of white cells;	chr18:22840421	chr18:22699481~22933764:-
LIHC	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-4.37	1.66e-05	0.0041	-0.24	-0.23	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
LIHC	cis	rs5770917	1	rs5770924	ENSG00000273272.1	CTA-384D8.34	4.37	1.66e-05	0.0041	0.34	0.23	Narcolepsy;	chr22:50586113	chr22:50542650~50543011:+
LIHC	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-4.37	1.66e-05	0.0041	-0.23	-0.23	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
LIHC	cis	rs2749097	0.825	rs35477997	ENSG00000244256.3	RN7SL130P	-4.37	1.66e-05	0.0041	-0.27	-0.23	Alcohol consumption (transferrin glycosylation);	chr1:63656834	chr1:63655743~63656047:+
LIHC	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-4.37	1.66e-05	0.0041	-0.24	-0.23	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
LIHC	cis	rs7937890	0.505	rs1403248	ENSG00000251991.1	RNU7-49P	4.37	1.66e-05	0.0041	0.26	0.23	Mitochondrial DNA levels;	chr11:14657471	chr11:14478892~14478953:+
LIHC	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-4.37	1.67e-05	0.0041	-0.24	-0.23	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
LIHC	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	4.37	1.67e-05	0.00411	0.27	0.23	Height;	chr6:109395761	chr6:109382795~109383666:+
LIHC	cis	rs755249	0.567	rs61779308	ENSG00000182109.6	RP11-69E11.4	4.37	1.67e-05	0.00411	0.32	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39522280~39546187:-
LIHC	cis	rs9467711	0.584	rs34391493	ENSG00000216436.2	HIST1H2APS1	4.37	1.67e-05	0.00411	0.55	0.23	Autism spectrum disorder or schizophrenia;	chr6:26022420	chr6:25732497~25732827:+
LIHC	cis	rs651907	0.535	rs9830943	ENSG00000244119.1	PDCL3P4	4.37	1.67e-05	0.00411	0.24	0.23	Colorectal cancer;	chr3:101710055	chr3:101712472~101713191:+
LIHC	cis	rs783540	0.5	rs7178459	ENSG00000278603.1	RP13-608F4.5	4.37	1.67e-05	0.00411	0.31	0.23	Schizophrenia;	chr15:82729632	chr15:82472203~82472426:+
LIHC	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-4.37	1.67e-05	0.00411	-0.31	-0.23	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
LIHC	cis	rs7809950	1	rs4730245	ENSG00000238832.1	snoU109	-4.37	1.67e-05	0.00412	-0.28	-0.23	Coronary artery disease;	chr7:107446849	chr7:107603363~107603507:+
LIHC	cis	rs6445975	0.612	rs6763103	ENSG00000272360.1	RP11-359I18.5	4.37	1.67e-05	0.00412	0.32	0.23	Systemic lupus erythematosus;	chr3:58451618	chr3:58490830~58491291:-
LIHC	cis	rs9304742	0.962	rs12459008	ENSG00000213801.4	ZNF816-ZNF321P	-4.37	1.67e-05	0.00413	-0.23	-0.23	Psoriasis;	chr19:52951536	chr19:52927135~52942601:-
LIHC	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	4.37	1.67e-05	0.00413	0.36	0.23	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	4.37	1.67e-05	0.00413	0.36	0.23	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	4.37	1.67e-05	0.00413	0.36	0.23	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
LIHC	cis	rs4660214	0.724	rs3931300	ENSG00000182109.6	RP11-69E11.4	-4.37	1.68e-05	0.00413	-0.25	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39195175	chr1:39522280~39546187:-
LIHC	cis	rs6442522	0.772	rs2278961	ENSG00000249786.6	EAF1-AS1	4.37	1.68e-05	0.00413	0.26	0.23	Uric acid levels;	chr3:15451300	chr3:15436171~15455940:-
LIHC	cis	rs1865760	0.516	rs9393684	ENSG00000216436.2	HIST1H2APS1	-4.37	1.68e-05	0.00413	-0.27	-0.23	Height;	chr6:26075303	chr6:25732497~25732827:+
LIHC	cis	rs1400745	0.718	rs1200414	ENSG00000258738.1	RP11-73E17.2	4.37	1.68e-05	0.00413	0.28	0.23	Monocyte count;	chr14:34861687	chr14:34874343~34876459:+
LIHC	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	4.37	1.68e-05	0.00414	0.3	0.23	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
LIHC	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	4.37	1.68e-05	0.00414	0.25	0.23	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
LIHC	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-4.37	1.68e-05	0.00414	-0.24	-0.23	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
LIHC	cis	rs10028773	0.7	rs7671797	ENSG00000260091.1	RP11-33B1.4	-4.37	1.68e-05	0.00414	-0.16	-0.23	Educational attainment;	chr4:119327002	chr4:119409333~119410233:+
LIHC	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-4.37	1.68e-05	0.00414	-0.37	-0.23	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
LIHC	cis	rs1115240	0.891	rs17111488	ENSG00000257842.4	NOVA1-AS1	4.37	1.68e-05	0.00414	0.21	0.23	Educational attainment (years of education);	chr14:26638054	chr14:26598412~26806467:+
LIHC	cis	rs734999	0.545	rs10752748	ENSG00000225931.3	RP3-395M20.7	4.37	1.68e-05	0.00415	0.24	0.23	Ulcerative colitis;	chr1:2613201	chr1:2566410~2569888:+
LIHC	cis	rs763121	0.853	rs6001173	ENSG00000273076.1	RP3-508I15.22	4.37	1.68e-05	0.00415	0.26	0.23	Menopause (age at onset);	chr22:38619297	chr22:38743495~38743910:+
LIHC	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	4.37	1.68e-05	0.00415	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
LIHC	cis	rs11098499	0.644	rs34835603	ENSG00000260091.1	RP11-33B1.4	-4.37	1.69e-05	0.00415	-0.16	-0.23	Corneal astigmatism;	chr4:119632273	chr4:119409333~119410233:+
LIHC	cis	rs5758511	0.689	rs17002947	ENSG00000237037.8	NDUFA6-AS1	4.37	1.69e-05	0.00415	0.44	0.23	Birth weight;	chr22:42292526	chr22:42090931~42137742:+
LIHC	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-4.37	1.69e-05	0.00415	-0.36	-0.23	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
LIHC	cis	rs7702057	0.53	rs56953556	ENSG00000271918.1	CTD-2287O16.5	4.36	1.69e-05	0.00416	0.31	0.23	Amyotrophic lateral sclerosis;	chr5:116076903	chr5:116083807~116085416:-
LIHC	cis	rs763121	0.819	rs5757160	ENSG00000273076.1	RP3-508I15.22	4.36	1.69e-05	0.00416	0.26	0.23	Menopause (age at onset);	chr22:38593641	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.853	rs5757166	ENSG00000273076.1	RP3-508I15.22	4.36	1.69e-05	0.00416	0.26	0.23	Menopause (age at onset);	chr22:38599380	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.853	rs1569716	ENSG00000273076.1	RP3-508I15.22	4.36	1.69e-05	0.00416	0.26	0.23	Menopause (age at onset);	chr22:38602514	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.819	rs5757169	ENSG00000273076.1	RP3-508I15.22	4.36	1.69e-05	0.00416	0.26	0.23	Menopause (age at onset);	chr22:38607490	chr22:38743495~38743910:+
LIHC	cis	rs686320	0.748	rs673753	ENSG00000245532.5	NEAT1	-4.36	1.69e-05	0.00416	-0.32	-0.23	Hip circumference adjusted for BMI;	chr11:65438546	chr11:65422774~65445540:+
LIHC	cis	rs9675120	0.675	rs4586493	ENSG00000262006.1	RP11-700H6.4	-4.36	1.69e-05	0.00416	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50847104	chr17:50909637~50910232:-
LIHC	cis	rs7662987	0.793	rs28730602	ENSG00000272777.1	RP11-571L19.8	4.36	1.69e-05	0.00416	0.54	0.23	Smoking initiation;	chr4:99080531	chr4:99067256~99068125:-
LIHC	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	4.36	1.69e-05	0.00416	0.29	0.23	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
LIHC	cis	rs3845817	0.67	rs840787	ENSG00000281920.1	RP11-418H16.1	-4.36	1.69e-05	0.00416	-0.27	-0.23	Bipolar disorder;	chr2:65548756	chr2:65623272~65628424:+
LIHC	cis	rs1075265	0.597	rs10490471	ENSG00000272156.1	RP11-477N3.1	-4.36	1.69e-05	0.00416	-0.28	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54082554~54085066:+
LIHC	cis	rs10181042	0.514	rs1177289	ENSG00000271889.1	RP11-493E12.1	4.36	1.69e-05	0.00417	0.27	0.23	Crohn's disease;	chr2:61126121	chr2:61151433~61162105:-
LIHC	cis	rs6723226	0.572	rs176411	ENSG00000276334.1	AL133243.1	4.36	1.69e-05	0.00417	0.25	0.23	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32521927~32523547:+
LIHC	cis	rs3733589	0.744	rs13142273	ENSG00000250413.1	RP11-448G15.1	4.36	1.7e-05	0.00418	0.37	0.23	Renal overload gout;	chr4:9940335	chr4:10006482~10009725:+
LIHC	cis	rs2439831	0.717	rs690170	ENSG00000275601.1	AC011330.13	-4.36	1.7e-05	0.00418	-0.35	-0.23	Lung cancer in ever smokers;	chr15:43518224	chr15:43642389~43643023:-
LIHC	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	4.36	1.7e-05	0.00418	0.23	0.23	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
LIHC	cis	rs11733284	0.515	rs7667425	ENSG00000259959.1	RP11-121C2.2	-4.36	1.7e-05	0.00418	-0.22	-0.23	Gout;Renal underexcretion gout;	chr4:48014453	chr4:47840122~47844339:-
LIHC	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-4.36	1.7e-05	0.00418	-0.27	-0.23	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
LIHC	cis	rs4578769	0.959	rs3851816	ENSG00000266850.1	RP11-370A5.1	4.36	1.7e-05	0.00418	0.27	0.23	Eosinophil percentage of white cells;	chr18:22866880	chr18:22723491~22907721:-
LIHC	cis	rs7587476	1	rs2121285	ENSG00000229267.2	AC072062.1	4.36	1.7e-05	0.00418	0.3	0.23	Neuroblastoma;	chr2:214791444	chr2:214810229~214963274:+
LIHC	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	4.36	1.7e-05	0.00418	0.27	0.23	Height;	chr3:53073764	chr3:53064283~53065091:-
LIHC	cis	rs6445975	1	rs7653734	ENSG00000272360.1	RP11-359I18.5	4.36	1.7e-05	0.00419	0.29	0.23	Systemic lupus erythematosus;	chr3:58387158	chr3:58490830~58491291:-
LIHC	cis	rs2243480	0.522	rs778717	ENSG00000230295.1	RP11-458F8.2	-4.36	1.7e-05	0.00419	-0.26	-0.23	Diabetic kidney disease;	chr7:66383164	chr7:66880708~66882981:+
LIHC	cis	rs875971	0.545	rs316305	ENSG00000228409.4	CCT6P1	4.36	1.7e-05	0.00419	0.19	0.23	Aortic root size;	chr7:66152984	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs316306	ENSG00000228409.4	CCT6P1	4.36	1.7e-05	0.00419	0.19	0.23	Aortic root size;	chr7:66153687	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs10950025	ENSG00000228409.4	CCT6P1	-4.36	1.7e-05	0.00419	-0.19	-0.23	Aortic root size;	chr7:66158946	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.52	rs12666485	ENSG00000228409.4	CCT6P1	-4.36	1.7e-05	0.00419	-0.19	-0.23	Aortic root size;	chr7:66160135	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs67688847	ENSG00000228409.4	CCT6P1	-4.36	1.7e-05	0.00419	-0.19	-0.23	Aortic root size;	chr7:66161064	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs12673308	ENSG00000228409.4	CCT6P1	-4.36	1.7e-05	0.00419	-0.19	-0.23	Aortic root size;	chr7:66166374	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs6460281	ENSG00000228409.4	CCT6P1	-4.36	1.71e-05	0.00419	-0.19	-0.23	Aortic root size;	chr7:66216128	chr7:65751142~65763354:+
LIHC	cis	rs1865760	0.551	rs9461230	ENSG00000216436.2	HIST1H2APS1	-4.36	1.71e-05	0.00419	-0.27	-0.23	Height;	chr6:26019012	chr6:25732497~25732827:+
LIHC	cis	rs11098499	0.789	rs9991166	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119316696	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.708	rs10005237	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119316742	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs10213267	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119317919	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs10212775	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119318089	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs11732087	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119318676	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs2964	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119318976	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs1511025	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119319083	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs12510269	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119320491	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs12506610	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119320504	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.743	rs10003567	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119320519	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs10006259	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119320990	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs28652763	ENSG00000260091.1	RP11-33B1.4	-4.36	1.71e-05	0.0042	-0.16	-0.23	Corneal astigmatism;	chr4:119321157	chr4:119409333~119410233:+
LIHC	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-4.36	1.71e-05	0.0042	-0.26	-0.23	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
LIHC	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-4.36	1.71e-05	0.0042	-0.27	-0.23	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
LIHC	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-4.36	1.71e-05	0.0042	-0.44	-0.23	Depression;	chr6:28139579	chr6:28115628~28116551:+
LIHC	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	4.36	1.71e-05	0.0042	0.37	0.23	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
LIHC	cis	rs901683	0.85	rs79022473	ENSG00000230869.1	CTGLF10P	-4.36	1.71e-05	0.0042	-0.58	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45606320	chr10:45678692~45700532:+
LIHC	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-4.36	1.71e-05	0.0042	-0.29	-0.23	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
LIHC	cis	rs6802315	0.604	rs2364927	ENSG00000272087.1	RP11-379F4.7	4.36	1.71e-05	0.00421	0.26	0.23	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158693120~158693768:-
LIHC	cis	rs7893279	0.543	rs11597737	ENSG00000225527.1	RP11-383B4.4	4.36	1.71e-05	0.00421	0.32	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18670162	chr10:18531849~18533336:-
LIHC	cis	rs6982751	0.673	rs4841464	ENSG00000255310.2	AF131215.2	-4.36	1.71e-05	0.00421	-0.35	-0.23	Asthma and hay fever;	chr8:10949721	chr8:11107788~11109726:-
LIHC	cis	rs9675120	1	rs7207028	ENSG00000262006.1	RP11-700H6.4	4.36	1.71e-05	0.00421	0.24	0.23	Cerebrospinal fluid biomarker levels;	chr17:50838691	chr17:50909637~50910232:-
LIHC	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-4.36	1.71e-05	0.00421	-0.41	-0.23	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
LIHC	cis	rs2744375	1	rs2744373	ENSG00000261189.1	RP3-512B11.3	4.36	1.71e-05	0.00421	0.4	0.23	Resting heart rate;	chr6:7554294	chr6:7540451~7541338:-
LIHC	cis	rs11098499	0.82	rs13122709	ENSG00000260091.1	RP11-33B1.4	-4.36	1.72e-05	0.00421	-0.17	-0.23	Corneal astigmatism;	chr4:119634201	chr4:119409333~119410233:+
LIHC	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-4.36	1.72e-05	0.00421	-0.28	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
LIHC	cis	rs2036707	0.744	rs9555413	ENSG00000277246.1	RP11-153I24.4	-4.36	1.72e-05	0.00422	-0.45	-0.23	Obesity-related traits;	chr13:107828388	chr13:108267320~108267734:+
LIHC	cis	rs7044106	0.791	rs4836829	ENSG00000238181.2	AHCYP2	-4.36	1.72e-05	0.00422	-0.26	-0.23	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120720673~120721972:+
LIHC	cis	rs763121	0.853	rs138705	ENSG00000273076.1	RP3-508I15.22	4.36	1.72e-05	0.00422	0.26	0.23	Menopause (age at onset);	chr22:38737798	chr22:38743495~38743910:+
LIHC	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-4.36	1.72e-05	0.00422	-0.29	-0.23	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
LIHC	cis	rs6445975	0.666	rs12635366	ENSG00000272360.1	RP11-359I18.5	-4.36	1.72e-05	0.00422	-0.3	-0.23	Systemic lupus erythematosus;	chr3:58412739	chr3:58490830~58491291:-
LIHC	cis	rs9876781	1	rs1459242	ENSG00000229759.1	MRPS18AP1	-4.36	1.72e-05	0.00423	-0.24	-0.23	Longevity;	chr3:48372047	chr3:48256350~48256938:-
LIHC	cis	rs5756813	0.661	rs2246503	ENSG00000233360.4	Z83844.1	4.36	1.72e-05	0.00423	0.29	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37808533	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.661	rs5995500	ENSG00000233360.4	Z83844.1	4.36	1.72e-05	0.00423	0.29	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37808633	chr22:37641832~37658377:-
LIHC	cis	rs1558001	0.84	rs12707460	ENSG00000230196.1	DDX43P3	-4.36	1.72e-05	0.00423	-0.24	-0.23	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81816773	chr7:81610884~81611326:-
LIHC	cis	rs960902	0.869	rs6735123	ENSG00000213553.4	RPLP0P6	-4.36	1.72e-05	0.00423	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37508721	chr2:38481851~38482804:+
LIHC	cis	rs6442522	0.809	rs2290537	ENSG00000249786.6	EAF1-AS1	4.36	1.72e-05	0.00423	0.27	0.23	Uric acid levels;	chr3:15414210	chr3:15436171~15455940:-
LIHC	cis	rs11722228	0.549	rs3796818	ENSG00000261490.1	RP11-448G15.3	4.36	1.72e-05	0.00423	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10096352	chr4:10068089~10073019:-
LIHC	cis	rs921968	0.541	rs933995	ENSG00000272555.1	RP11-459I19.1	-4.36	1.73e-05	0.00424	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218785995	chr2:218818690~218819144:+
LIHC	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	4.36	1.73e-05	0.00424	0.21	0.23	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
LIHC	cis	rs12936587	0.535	rs8065154	ENSG00000223979.2	SMCR2	-4.36	1.73e-05	0.00424	-0.3	-0.23	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17711633	chr17:17674026~17677688:-
LIHC	cis	rs1577917	0.917	rs35283633	ENSG00000234155.1	RP11-30P6.6	4.36	1.73e-05	0.00424	0.3	0.23	Response to antipsychotic treatment;	chr6:85981069	chr6:85387219~85390186:-
LIHC	cis	rs12216125	0.549	rs9358905	ENSG00000216436.2	HIST1H2APS1	-4.36	1.73e-05	0.00424	-0.27	-0.23	Iron status biomarkers;	chr6:26077611	chr6:25732497~25732827:+
LIHC	cis	rs113084984	0.718	rs12994182	ENSG00000271952.1	RP11-245G13.2	-4.36	1.73e-05	0.00424	-0.28	-0.23	Breast cancer;	chr2:11543772	chr2:10878269~10885118:+
LIHC	cis	rs5756813	0.635	rs11089856	ENSG00000233360.4	Z83844.1	4.36	1.73e-05	0.00424	0.28	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37809777	chr22:37641832~37658377:-
LIHC	cis	rs11098499	0.754	rs1511017	ENSG00000260091.1	RP11-33B1.4	-4.36	1.73e-05	0.00424	-0.16	-0.23	Corneal astigmatism;	chr4:119329650	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.789	rs12498994	ENSG00000260091.1	RP11-33B1.4	-4.36	1.73e-05	0.00424	-0.16	-0.23	Corneal astigmatism;	chr4:119329663	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs12507565	ENSG00000260091.1	RP11-33B1.4	-4.36	1.73e-05	0.00424	-0.16	-0.23	Corneal astigmatism;	chr4:119329966	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.826	rs12511640	ENSG00000260091.1	RP11-33B1.4	-4.36	1.73e-05	0.00424	-0.16	-0.23	Corneal astigmatism;	chr4:119330093	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs1980026	ENSG00000260091.1	RP11-33B1.4	-4.36	1.73e-05	0.00424	-0.16	-0.23	Corneal astigmatism;	chr4:119330488	chr4:119409333~119410233:+
LIHC	cis	rs11648785	0.777	rs3785183	ENSG00000221819.5	GAS8-AS1	-4.36	1.73e-05	0.00424	-0.31	-0.23	Tanning;	chr16:90029153	chr16:90028908~90029367:-
LIHC	cis	rs244293	0.831	rs7207057	ENSG00000275710.1	RP11-257O5.4	-4.36	1.73e-05	0.00425	-0.24	-0.23	Menarche (age at onset);	chr17:55095607	chr17:54964474~54964679:+
LIHC	cis	rs11779988	0.545	rs436506	ENSG00000253671.1	RP11-806O11.1	4.36	1.73e-05	0.00425	0.31	0.23	Breast cancer;	chr8:17940734	chr8:17808941~17820868:+
LIHC	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-4.36	1.73e-05	0.00425	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
LIHC	cis	rs1876905	0.539	rs240969	ENSG00000271789.1	RP5-1112D6.7	4.36	1.73e-05	0.00425	0.27	0.23	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111297126~111298510:+
LIHC	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	4.36	1.73e-05	0.00425	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
LIHC	cis	rs709400	0.93	rs61996717	ENSG00000258534.1	CTD-2134A5.4	4.36	1.73e-05	0.00425	0.34	0.23	Body mass index;	chr14:103582234	chr14:103854366~103880111:-
LIHC	cis	rs11098499	0.754	rs9999724	ENSG00000260091.1	RP11-33B1.4	-4.36	1.73e-05	0.00425	-0.16	-0.23	Corneal astigmatism;	chr4:119318789	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs714899	ENSG00000260091.1	RP11-33B1.4	-4.36	1.73e-05	0.00425	-0.16	-0.23	Corneal astigmatism;	chr4:119321880	chr4:119409333~119410233:+
LIHC	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-4.36	1.73e-05	0.00425	-0.27	-0.23	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
LIHC	cis	rs1318937	0.915	rs78365740	ENSG00000224660.1	SH3BP5-AS1	4.36	1.74e-05	0.00426	0.23	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15258339	chr3:15254184~15264493:+
LIHC	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-4.36	1.74e-05	0.00426	-0.28	-0.23	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-4.36	1.74e-05	0.00426	-0.28	-0.23	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
LIHC	cis	rs6430585	0.528	rs2278682	ENSG00000231890.6	DARS-AS1	-4.36	1.74e-05	0.00426	-0.31	-0.23	Corneal structure;	chr2:135985573	chr2:135985176~136022593:+
LIHC	cis	rs11671005	0.693	rs11669665	ENSG00000269473.1	CTD-2619J13.19	4.36	1.74e-05	0.00427	0.39	0.23	Mean platelet volume;	chr19:58420518	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.693	rs11084542	ENSG00000269473.1	CTD-2619J13.19	4.36	1.74e-05	0.00427	0.39	0.23	Mean platelet volume;	chr19:58420732	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11084543	ENSG00000269473.1	CTD-2619J13.19	4.36	1.74e-05	0.00427	0.39	0.23	Mean platelet volume;	chr19:58421334	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11881000	ENSG00000269473.1	CTD-2619J13.19	4.36	1.74e-05	0.00427	0.39	0.23	Mean platelet volume;	chr19:58421421	chr19:58440448~58445849:+
LIHC	cis	rs875971	0.545	rs10950029	ENSG00000228409.4	CCT6P1	-4.36	1.74e-05	0.00427	-0.19	-0.23	Aortic root size;	chr7:66169334	chr7:65751142~65763354:+
LIHC	cis	rs11637445	0.627	rs4776988	ENSG00000260657.2	RP11-315D16.4	-4.36	1.74e-05	0.00427	-0.32	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr15:67831813	chr15:68267792~68277994:-
LIHC	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	4.36	1.74e-05	0.00427	0.31	0.23	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
LIHC	cis	rs17270561	0.609	rs1165181	ENSG00000216436.2	HIST1H2APS1	-4.36	1.74e-05	0.00427	-0.28	-0.23	Iron status biomarkers;	chr6:25825162	chr6:25732497~25732827:+
LIHC	cis	rs1420585	0.932	rs4785155	ENSG00000260769.1	RP11-491F9.5	4.36	1.74e-05	0.00428	0.29	0.23	Pursuit maintenance gain;	chr16:48969867	chr16:49337167~49338993:+
LIHC	cis	rs1558001	0.84	rs2367739	ENSG00000230196.1	DDX43P3	4.36	1.75e-05	0.00428	0.24	0.23	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81829036	chr7:81610884~81611326:-
LIHC	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	4.36	1.75e-05	0.00429	0.22	0.23	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
LIHC	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-4.36	1.75e-05	0.00429	-0.26	-0.23	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
LIHC	cis	rs7208859	0.673	rs999796	ENSG00000264538.5	SUZ12P1	-4.36	1.75e-05	0.00429	-0.23	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30709299~30790908:+
LIHC	cis	rs11722228	0.508	rs3796826	ENSG00000261490.1	RP11-448G15.3	4.36	1.75e-05	0.00429	0.3	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10091104	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.508	rs3796825	ENSG00000261490.1	RP11-448G15.3	4.36	1.75e-05	0.00429	0.3	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10091255	chr4:10068089~10073019:-
LIHC	cis	rs875971	0.545	rs316316	ENSG00000228409.4	CCT6P1	4.36	1.75e-05	0.0043	0.19	0.23	Aortic root size;	chr7:66149270	chr7:65751142~65763354:+
LIHC	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	4.36	1.75e-05	0.0043	0.36	0.23	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	4.36	1.75e-05	0.0043	0.36	0.23	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	4.36	1.75e-05	0.0043	0.36	0.23	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
LIHC	cis	rs617219	0.819	rs1870058	ENSG00000251675.1	CTC-458I2.2	-4.36	1.75e-05	0.0043	-0.26	-0.23	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79297335	chr5:80128361~80143883:+
LIHC	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-4.36	1.76e-05	0.0043	-0.29	-0.23	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
LIHC	cis	rs12216125	0.801	rs56107510	ENSG00000216436.2	HIST1H2APS1	-4.36	1.76e-05	0.0043	-0.31	-0.23	Iron status biomarkers;	chr6:25987208	chr6:25732497~25732827:+
LIHC	cis	rs5769707	0.967	rs17182154	ENSG00000235111.1	RP1-29C18.8	-4.36	1.76e-05	0.0043	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49612657~49615716:-
LIHC	cis	rs6480314	0.831	rs2166221	ENSG00000233590.1	RP11-153K11.3	4.36	1.76e-05	0.0043	0.33	0.23	Optic nerve measurement (disc area);	chr10:68222541	chr10:68233251~68242379:-
LIHC	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-4.36	1.76e-05	0.0043	-0.29	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
LIHC	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	4.36	1.76e-05	0.00431	0.35	0.23	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
LIHC	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	4.36	1.76e-05	0.00431	0.27	0.23	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
LIHC	cis	rs529413	0.57	rs500895	ENSG00000259237.1	RP11-209E8.1	4.36	1.76e-05	0.00431	0.32	0.23	Itch intensity from mosquito bite adjusted by bite size;	chr15:53243478	chr15:53116365~53129698:+
LIHC	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-4.36	1.76e-05	0.00431	-0.31	-0.23	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
LIHC	cis	rs2877649	0.793	rs118096303	ENSG00000258744.1	RP11-80A15.1	-4.36	1.76e-05	0.00431	-0.48	-0.23	Smooth-surface caries;	chr14:24483328	chr14:24501594~24508688:+
LIHC	cis	rs11098499	0.754	rs17595608	ENSG00000260091.1	RP11-33B1.4	-4.35	1.76e-05	0.00431	-0.16	-0.23	Corneal astigmatism;	chr4:119329351	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs1980027	ENSG00000260091.1	RP11-33B1.4	-4.35	1.76e-05	0.00431	-0.16	-0.23	Corneal astigmatism;	chr4:119330422	chr4:119409333~119410233:+
LIHC	cis	rs6480314	0.831	rs6480317	ENSG00000233590.1	RP11-153K11.3	4.35	1.76e-05	0.00431	0.33	0.23	Optic nerve measurement (disc area);	chr10:68216837	chr10:68233251~68242379:-
LIHC	cis	rs4925386	1	rs2151512	ENSG00000226332.2	RP11-157P1.4	-4.35	1.76e-05	0.00431	-0.24	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62305432~62306325:-
LIHC	cis	rs2739330	0.828	rs5760099	ENSG00000206090.4	AP000350.7	4.35	1.76e-05	0.00431	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23939998~23942798:+
LIHC	cis	rs11098499	0.754	rs2036857	ENSG00000260091.1	RP11-33B1.4	-4.35	1.76e-05	0.00432	-0.16	-0.23	Corneal astigmatism;	chr4:119328085	chr4:119409333~119410233:+
LIHC	cis	rs5758511	0.508	rs2413667	ENSG00000237037.8	NDUFA6-AS1	-4.35	1.77e-05	0.00433	-0.43	-0.23	Birth weight;	chr22:42076233	chr22:42090931~42137742:+
LIHC	cis	rs4694744	0.576	rs4554145	ENSG00000264696.1	AC108078.1	4.35	1.77e-05	0.00434	0.34	0.23	Bacteremia;	chr4:69485570	chr4:69479331~69479434:+
LIHC	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-4.35	1.77e-05	0.00434	-0.28	-0.23	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
LIHC	cis	rs11216126	0.524	rs61905084	ENSG00000254851.1	RP11-109L13.1	4.35	1.77e-05	0.00434	0.32	0.23	HDL cholesterol;	chr11:116739578	chr11:117135528~117138582:+
LIHC	cis	rs11722228	0.508	rs3822246	ENSG00000261490.1	RP11-448G15.3	4.35	1.77e-05	0.00434	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10093074	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.549	rs73212853	ENSG00000261490.1	RP11-448G15.3	4.35	1.77e-05	0.00434	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10094606	chr4:10068089~10073019:-
LIHC	cis	rs1577917	1	rs12190604	ENSG00000234155.1	RP11-30P6.6	4.35	1.77e-05	0.00434	0.3	0.23	Response to antipsychotic treatment;	chr6:86006497	chr6:85387219~85390186:-
LIHC	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-4.35	1.77e-05	0.00434	-0.25	-0.23	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
LIHC	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	4.35	1.77e-05	0.00434	0.38	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
LIHC	cis	rs6085948	1	rs6085948	ENSG00000228888.1	LINC01428	4.35	1.77e-05	0.00434	0.31	0.23	Interleukin-10 levels;	chr20:7252703	chr20:7146467~7254202:-
LIHC	cis	rs875971	0.545	rs1796217	ENSG00000273142.1	RP11-458F8.4	-4.35	1.78e-05	0.00434	-0.22	-0.23	Aortic root size;	chr7:66620931	chr7:66902857~66906297:+
LIHC	cis	rs651907	0.535	rs34743741	ENSG00000244119.1	PDCL3P4	4.35	1.78e-05	0.00434	0.24	0.23	Colorectal cancer;	chr3:101813604	chr3:101712472~101713191:+
LIHC	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-4.35	1.78e-05	0.00434	-0.27	-0.23	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
LIHC	cis	rs7702057	0.53	rs17138841	ENSG00000271918.1	CTD-2287O16.5	4.35	1.78e-05	0.00435	0.31	0.23	Amyotrophic lateral sclerosis;	chr5:116077109	chr5:116083807~116085416:-
LIHC	cis	rs2072510	0.683	rs2246973	ENSG00000257878.1	RP11-256L6.3	-4.35	1.78e-05	0.00435	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96034097	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.683	rs2246972	ENSG00000257878.1	RP11-256L6.3	-4.35	1.78e-05	0.00435	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96034111	chr12:95996521~96011489:+
LIHC	cis	rs7709377	0.516	rs7726794	ENSG00000271918.1	CTD-2287O16.5	4.35	1.78e-05	0.00435	0.28	0.23	Metabolite levels  (X-11787);	chr5:116130293	chr5:116083807~116085416:-
LIHC	cis	rs9896933	0.778	rs80243549	ENSG00000263063.1	RP11-388C12.1	-4.35	1.78e-05	0.00436	-0.33	-0.23	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82863609	chr17:82713908~82716255:-
LIHC	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	4.35	1.78e-05	0.00436	0.25	0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
LIHC	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	4.35	1.78e-05	0.00436	0.29	0.23	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
LIHC	cis	rs875971	0.502	rs6460311	ENSG00000273024.4	INTS4P2	4.35	1.78e-05	0.00436	0.26	0.23	Aortic root size;	chr7:66646886	chr7:65647864~65715661:+
LIHC	cis	rs1400745	0.756	rs3783316	ENSG00000258738.1	RP11-73E17.2	4.35	1.78e-05	0.00436	0.28	0.23	Monocyte count;	chr14:34867986	chr14:34874343~34876459:+
LIHC	cis	rs6430585	0.528	rs3098102	ENSG00000231890.6	DARS-AS1	-4.35	1.79e-05	0.00436	-0.31	-0.23	Corneal structure;	chr2:135897263	chr2:135985176~136022593:+
LIHC	cis	rs11671005	0.735	rs12986387	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58415848	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11667723	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58416122	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.693	rs11668757	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58416932	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs11668789	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58416942	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs35652377	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58417833	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs3764532	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58417855	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs3088284	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58418060	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.735	rs12981649	ENSG00000269473.1	CTD-2619J13.19	4.35	1.79e-05	0.00437	0.38	0.23	Mean platelet volume;	chr19:58418676	chr19:58440448~58445849:+
LIHC	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-4.35	1.79e-05	0.00437	-0.25	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
LIHC	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-4.35	1.79e-05	0.00437	-0.26	-0.23	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
LIHC	cis	rs12478296	1	rs6739247	ENSG00000261186.2	RP11-341N2.1	-4.35	1.79e-05	0.00437	-0.33	-0.23	Obesity-related traits;	chr2:242097038	chr2:242087351~242088457:-
LIHC	cis	rs6893782	0.887	rs274552	ENSG00000233006.5	AC034220.3	4.35	1.79e-05	0.00437	0.32	0.23	Acylcarnitine levels;	chr5:132391654	chr5:132311285~132369916:-
LIHC	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-4.35	1.79e-05	0.00437	-0.29	-0.23	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
LIHC	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	4.35	1.79e-05	0.00437	0.27	0.23	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
LIHC	cis	rs17818399	0.781	rs13024534	ENSG00000279254.1	RP11-536C12.1	-4.35	1.79e-05	0.00437	-0.28	-0.23	Height;	chr2:46632247	chr2:46668870~46670778:+
LIHC	cis	rs17818399	0.675	rs35949012	ENSG00000279254.1	RP11-536C12.1	-4.35	1.79e-05	0.00437	-0.28	-0.23	Height;	chr2:46633262	chr2:46668870~46670778:+
LIHC	cis	rs17818399	0.815	rs17768018	ENSG00000279254.1	RP11-536C12.1	-4.35	1.79e-05	0.00437	-0.28	-0.23	Height;	chr2:46634872	chr2:46668870~46670778:+
LIHC	cis	rs7412746	0.658	rs6660845	ENSG00000231073.1	RP11-316M1.3	4.35	1.79e-05	0.00437	0.24	0.23	Melanoma;	chr1:150868590	chr1:150973123~150975534:+
LIHC	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	4.35	1.79e-05	0.00438	0.3	0.23	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
LIHC	cis	rs10266483	0.654	rs6962076	ENSG00000164669.11	INTS4P1	4.35	1.79e-05	0.00438	0.36	0.23	Response to statin therapy;	chr7:64559214	chr7:65141225~65234216:+
LIHC	cis	rs2448490	0.642	rs507859	ENSG00000265874.1	MIR4489	4.35	1.79e-05	0.00438	0.29	0.23	Platelet count;	chr11:65704511	chr11:65649192~65649253:+
LIHC	cis	rs4578769	0.765	rs11082173	ENSG00000266850.1	RP11-370A5.1	-4.35	1.79e-05	0.00438	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22858048	chr18:22723491~22907721:-
LIHC	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.35	1.79e-05	0.00438	-0.31	-0.23	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-4.35	1.79e-05	0.00438	-0.31	-0.23	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
LIHC	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	4.35	1.79e-05	0.00438	0.38	0.23	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
LIHC	cis	rs1400745	0.756	rs3783314	ENSG00000258738.1	RP11-73E17.2	4.35	1.79e-05	0.00438	0.28	0.23	Monocyte count;	chr14:34868178	chr14:34874343~34876459:+
LIHC	cis	rs5756813	0.661	rs11703407	ENSG00000233360.4	Z83844.1	4.35	1.8e-05	0.00439	0.29	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37804117	chr22:37641832~37658377:-
LIHC	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	4.35	1.8e-05	0.00439	0.36	0.23	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
LIHC	cis	rs7809950	1	rs2712189	ENSG00000238832.1	snoU109	-4.35	1.8e-05	0.00439	-0.28	-0.23	Coronary artery disease;	chr7:107555302	chr7:107603363~107603507:+
LIHC	cis	rs11722228	0.549	rs41268389	ENSG00000261490.1	RP11-448G15.3	4.35	1.8e-05	0.00439	0.3	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10097653	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.521	rs62288520	ENSG00000261490.1	RP11-448G15.3	4.35	1.8e-05	0.00439	0.3	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10098050	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.549	rs62288521	ENSG00000261490.1	RP11-448G15.3	4.35	1.8e-05	0.00439	0.3	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10098148	chr4:10068089~10073019:-
LIHC	cis	rs11098499	0.779	rs10011097	ENSG00000260091.1	RP11-33B1.4	-4.35	1.8e-05	0.00439	-0.17	-0.23	Corneal astigmatism;	chr4:119389204	chr4:119409333~119410233:+
LIHC	cis	rs5756813	0.635	rs12160750	ENSG00000233360.4	Z83844.1	4.35	1.8e-05	0.00439	0.29	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37803047	chr22:37641832~37658377:-
LIHC	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-4.35	1.8e-05	0.0044	-0.27	-0.23	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
LIHC	cis	rs9834975	0.935	rs6798997	ENSG00000272758.4	RP11-299J3.8	-4.35	1.8e-05	0.0044	-0.26	-0.23	Diastolic blood pressure;	chr3:122355857	chr3:122416207~122443180:+
LIHC	cis	rs9304742	0.962	rs1808106	ENSG00000213801.4	ZNF816-ZNF321P	4.35	1.8e-05	0.0044	0.23	0.23	Psoriasis;	chr19:52949691	chr19:52927135~52942601:-
LIHC	cis	rs9907295	0.818	rs4796112	ENSG00000270871.1	AC015849.19	-4.35	1.8e-05	0.0044	-0.24	-0.23	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35816717~35830293:-
LIHC	cis	rs1003645	1	rs8075916	ENSG00000278690.1	RP11-104J23.2	4.35	1.8e-05	0.0044	0.27	0.23	Blood protein levels;	chr17:36016808	chr17:36012504~36012891:+
LIHC	cis	rs6997458	0.869	rs11261474	ENSG00000253549.4	RP11-317J10.2	4.35	1.8e-05	0.0044	0.25	0.23	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85382421	chr8:85441851~85464915:-
LIHC	cis	rs9450351	0.744	rs9450299	ENSG00000203875.9	SNHG5	-4.35	1.81e-05	0.00441	-0.55	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85562103	chr6:85660950~85678736:-
LIHC	cis	rs9450351	0.744	rs6930543	ENSG00000203875.9	SNHG5	-4.35	1.81e-05	0.00441	-0.55	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85562658	chr6:85660950~85678736:-
LIHC	cis	rs6442522	0.78	rs13068150	ENSG00000249786.6	EAF1-AS1	4.35	1.81e-05	0.00441	0.27	0.23	Uric acid levels;	chr3:15397434	chr3:15436171~15455940:-
LIHC	cis	rs6442522	0.78	rs13095978	ENSG00000249786.6	EAF1-AS1	4.35	1.81e-05	0.00441	0.27	0.23	Uric acid levels;	chr3:15399603	chr3:15436171~15455940:-
LIHC	cis	rs728616	0.867	rs41302709	ENSG00000225484.5	NUTM2B-AS1	-4.35	1.81e-05	0.00441	-0.5	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047522	chr10:79663088~79826594:-
LIHC	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-4.35	1.81e-05	0.00441	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
LIHC	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	4.35	1.81e-05	0.00441	0.26	0.23	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
LIHC	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-4.35	1.81e-05	0.00441	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
LIHC	cis	rs3096299	0.781	rs2965819	ENSG00000261118.1	RP11-104N10.1	-4.35	1.81e-05	0.00441	-0.23	-0.23	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89492017~89504460:-
LIHC	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	4.35	1.81e-05	0.00441	0.17	0.23	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
LIHC	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-4.35	1.81e-05	0.00441	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-4.35	1.81e-05	0.00441	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
LIHC	cis	rs11098499	0.644	rs2389880	ENSG00000260091.1	RP11-33B1.4	-4.35	1.81e-05	0.00441	-0.16	-0.23	Corneal astigmatism;	chr4:119638715	chr4:119409333~119410233:+
LIHC	cis	rs11671005	0.735	rs11670871	ENSG00000269473.1	CTD-2619J13.19	-4.35	1.81e-05	0.00442	-0.38	-0.23	Mean platelet volume;	chr19:58429147	chr19:58440448~58445849:+
LIHC	cis	rs6085948	1	rs4815987	ENSG00000228888.1	LINC01428	4.35	1.81e-05	0.00442	0.31	0.23	Interleukin-10 levels;	chr20:7259968	chr20:7146467~7254202:-
LIHC	cis	rs6085948	0.953	rs6117725	ENSG00000228888.1	LINC01428	4.35	1.81e-05	0.00442	0.31	0.23	Interleukin-10 levels;	chr20:7262362	chr20:7146467~7254202:-
LIHC	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-4.35	1.81e-05	0.00442	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
LIHC	cis	rs651907	0.535	rs36060163	ENSG00000244119.1	PDCL3P4	4.35	1.81e-05	0.00442	0.24	0.23	Colorectal cancer;	chr3:101642119	chr3:101712472~101713191:+
LIHC	cis	rs9573567	0.609	rs79938109	ENSG00000261553.4	RP11-29G8.3	-4.35	1.81e-05	0.00442	-0.4	-0.23	Red blood cell count;Mean corpuscular volume;	chr13:75467476	chr13:75549773~75807120:+
LIHC	cis	rs812925	0.855	rs777592	ENSG00000212978.6	AC016747.3	-4.35	1.81e-05	0.00442	-0.26	-0.23	Immature fraction of reticulocytes;	chr2:61191208	chr2:61141592~61144969:-
LIHC	cis	rs7508	0.511	rs208025	ENSG00000253671.1	RP11-806O11.1	-4.35	1.81e-05	0.00442	-0.29	-0.23	Atrial fibrillation;	chr8:18020661	chr8:17808941~17820868:+
LIHC	cis	rs2243480	1	rs160643	ENSG00000230295.1	RP11-458F8.2	-4.35	1.81e-05	0.00442	-0.23	-0.23	Diabetic kidney disease;	chr7:66093235	chr7:66880708~66882981:+
LIHC	cis	rs755249	0.567	rs72661961	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.532	rs61779277	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.532	rs61779278	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs2296172	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs61779279	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs76111861	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs72661965	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs6668369	ENSG00000182109.6	RP11-69E11.4	4.35	1.81e-05	0.00442	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39522280~39546187:-
LIHC	cis	rs1577917	1	rs12215037	ENSG00000234155.1	RP11-30P6.6	4.35	1.82e-05	0.00443	0.3	0.23	Response to antipsychotic treatment;	chr6:86017913	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1337850	ENSG00000234155.1	RP11-30P6.6	4.35	1.82e-05	0.00443	0.3	0.23	Response to antipsychotic treatment;	chr6:86019385	chr6:85387219~85390186:-
LIHC	cis	rs11098499	0.615	rs28850368	ENSG00000260091.1	RP11-33B1.4	-4.35	1.82e-05	0.00443	-0.16	-0.23	Corneal astigmatism;	chr4:119633158	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.644	rs28787668	ENSG00000260091.1	RP11-33B1.4	-4.35	1.82e-05	0.00443	-0.16	-0.23	Corneal astigmatism;	chr4:119633532	chr4:119409333~119410233:+
LIHC	cis	rs5758659	0.679	rs134870	ENSG00000227370.1	RP4-669P10.19	-4.35	1.82e-05	0.00443	-0.25	-0.23	Cognitive function;	chr22:42256311	chr22:42132543~42132998:+
LIHC	cis	rs7824557	0.583	rs2736306	ENSG00000255394.4	C8orf49	4.35	1.82e-05	0.00443	0.31	0.23	Retinal vascular caliber;	chr8:11382253	chr8:11761256~11763223:+
LIHC	cis	rs3096299	0.781	rs2170839	ENSG00000261118.1	RP11-104N10.1	4.35	1.82e-05	0.00443	0.23	0.23	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89492017~89504460:-
LIHC	cis	rs11098499	0.754	rs2036860	ENSG00000260091.1	RP11-33B1.4	-4.35	1.82e-05	0.00443	-0.16	-0.23	Corneal astigmatism;	chr4:119327779	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs2036856	ENSG00000260091.1	RP11-33B1.4	-4.35	1.82e-05	0.00443	-0.16	-0.23	Corneal astigmatism;	chr4:119328133	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs4443261	ENSG00000260091.1	RP11-33B1.4	-4.35	1.82e-05	0.00443	-0.16	-0.23	Corneal astigmatism;	chr4:119328146	chr4:119409333~119410233:+
LIHC	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-4.35	1.82e-05	0.00443	-0.27	-0.23	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
LIHC	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	4.35	1.82e-05	0.00444	0.29	0.23	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
LIHC	cis	rs1003645	1	rs9908216	ENSG00000278690.1	RP11-104J23.2	4.35	1.82e-05	0.00444	0.27	0.23	Blood protein levels;	chr17:36018981	chr17:36012504~36012891:+
LIHC	cis	rs12304921	0.683	rs73103154	ENSG00000277201.1	AC087884.1	4.35	1.82e-05	0.00445	0.27	0.23	Type 2 diabetes;	chr12:51074729	chr12:51049921~51050025:+
LIHC	cis	rs2877649	1	rs78804957	ENSG00000258744.1	RP11-80A15.1	-4.35	1.82e-05	0.00445	-0.45	-0.23	Smooth-surface caries;	chr14:24479999	chr14:24501594~24508688:+
LIHC	cis	rs2877649	1	rs1951137	ENSG00000258744.1	RP11-80A15.1	-4.35	1.82e-05	0.00445	-0.45	-0.23	Smooth-surface caries;	chr14:24481497	chr14:24501594~24508688:+
LIHC	cis	rs875971	0.619	rs2302918	ENSG00000273024.4	INTS4P2	-4.35	1.82e-05	0.00445	-0.25	-0.23	Aortic root size;	chr7:66535945	chr7:65647864~65715661:+
LIHC	cis	rs7915414	0.951	rs2094296	ENSG00000230338.1	MTND4P19	4.35	1.82e-05	0.00445	0.24	0.23	Clopidogrel active metabolite levels;	chr10:94663648	chr10:94774156~94774633:-
LIHC	cis	rs1577917	1	rs12205336	ENSG00000234155.1	RP11-30P6.6	4.35	1.83e-05	0.00445	0.3	0.23	Response to antipsychotic treatment;	chr6:86012649	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12209127	ENSG00000234155.1	RP11-30P6.6	4.35	1.83e-05	0.00445	0.3	0.23	Response to antipsychotic treatment;	chr6:86014709	chr6:85387219~85390186:-
LIHC	cis	rs6439153	0.933	rs34193129	ENSG00000231305.3	RP11-723O4.2	4.35	1.83e-05	0.00445	0.25	0.23	Pneumococcal bacteremia;	chr3:128972564	chr3:128861313~128871540:-
LIHC	cis	rs7809950	0.954	rs62482543	ENSG00000238832.1	snoU109	-4.35	1.83e-05	0.00445	-0.28	-0.23	Coronary artery disease;	chr7:107440211	chr7:107603363~107603507:+
LIHC	cis	rs7809950	1	rs1544336	ENSG00000238832.1	snoU109	-4.35	1.83e-05	0.00445	-0.28	-0.23	Coronary artery disease;	chr7:107441970	chr7:107603363~107603507:+
LIHC	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-4.35	1.83e-05	0.00445	-0.35	-0.23	Depression;	chr6:28230678	chr6:28115628~28116551:+
LIHC	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	4.35	1.83e-05	0.00445	0.28	0.23	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	4.35	1.83e-05	0.00445	0.28	0.23	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
LIHC	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-4.35	1.83e-05	0.00446	-0.21	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
LIHC	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	4.35	1.83e-05	0.00446	0.25	0.23	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	4.35	1.83e-05	0.00446	0.25	0.23	Asthma;	chr2:102388870	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	4.35	1.83e-05	0.00446	0.25	0.23	Asthma;	chr2:102389644	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	4.35	1.83e-05	0.00446	0.25	0.23	Asthma;	chr2:102389988	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	4.35	1.83e-05	0.00446	0.25	0.23	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
LIHC	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	4.35	1.83e-05	0.00447	0.21	0.23	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
LIHC	cis	rs950881	0.866	rs72823628	ENSG00000234389.1	AC007278.3	4.35	1.83e-05	0.00447	0.3	0.23	Allergy;	chr2:102312157	chr2:102438713~102440475:+
LIHC	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	4.35	1.83e-05	0.00447	0.37	0.23	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
LIHC	cis	rs7809950	0.906	rs2253269	ENSG00000238832.1	snoU109	-4.35	1.83e-05	0.00447	-0.28	-0.23	Coronary artery disease;	chr7:107560669	chr7:107603363~107603507:+
LIHC	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	4.35	1.84e-05	0.00447	0.26	0.23	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
LIHC	cis	rs28475163	1	rs28475163	ENSG00000251661.3	RP11-326C3.11	-4.35	1.84e-05	0.00447	-0.32	-0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr11:327143	chr11:318640~325631:+
LIHC	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	4.34	1.84e-05	0.00448	0.36	0.23	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
LIHC	cis	rs11098499	0.955	rs7685268	ENSG00000260091.1	RP11-33B1.4	-4.34	1.84e-05	0.00448	-0.17	-0.23	Corneal astigmatism;	chr4:119241033	chr4:119409333~119410233:+
LIHC	cis	rs12478296	0.681	rs6598999	ENSG00000261186.2	RP11-341N2.1	-4.34	1.84e-05	0.00448	-0.3	-0.23	Obesity-related traits;	chr2:242052254	chr2:242087351~242088457:-
LIHC	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-4.34	1.84e-05	0.00448	-0.24	-0.23	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
LIHC	cis	rs2932538	0.961	rs6537747	ENSG00000225075.1	RP11-426L16.3	-4.34	1.84e-05	0.00448	-0.28	-0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112636975	chr1:112693688~112696621:-
LIHC	cis	rs3733585	0.654	rs4447863	ENSG00000250413.1	RP11-448G15.1	4.34	1.84e-05	0.00448	0.3	0.23	Cleft plate (environmental tobacco smoke interaction);	chr4:9937345	chr4:10006482~10009725:+
LIHC	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-4.34	1.84e-05	0.00448	-0.26	-0.23	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
LIHC	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102374753	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-4.34	1.84e-05	0.00448	-0.25	-0.23	Asthma;	chr2:102374909	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102379885	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102381261	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102381819	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102382514	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102382943	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-4.34	1.84e-05	0.00448	-0.25	-0.23	Asthma;	chr2:102399682	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102394452	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102399227	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102402540	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102402571	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102403325	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102403679	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102404807	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma;	chr2:102407218	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	4.34	1.84e-05	0.00448	0.25	0.23	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
LIHC	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	4.34	1.84e-05	0.00448	0.29	0.23	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
LIHC	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	4.34	1.84e-05	0.00448	0.29	0.23	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
LIHC	cis	rs6445975	0.617	rs60962024	ENSG00000272360.1	RP11-359I18.5	4.34	1.84e-05	0.00449	0.3	0.23	Systemic lupus erythematosus;	chr3:58404485	chr3:58490830~58491291:-
LIHC	cis	rs921968	0.565	rs6436073	ENSG00000272555.1	RP11-459I19.1	-4.34	1.85e-05	0.00449	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218753514	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs12612395	ENSG00000272555.1	RP11-459I19.1	-4.34	1.85e-05	0.00449	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218756919	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs13408427	ENSG00000272555.1	RP11-459I19.1	-4.34	1.85e-05	0.00449	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218763666	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs35189512	ENSG00000272555.1	RP11-459I19.1	-4.34	1.85e-05	0.00449	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218764036	chr2:218818690~218819144:+
LIHC	cis	rs709400	0.827	rs2274269	ENSG00000258534.1	CTD-2134A5.4	4.34	1.85e-05	0.00449	0.35	0.23	Body mass index;	chr14:103562909	chr14:103854366~103880111:-
LIHC	cis	rs2735413	0.958	rs2735401	ENSG00000276007.1	RP11-358L22.3	4.34	1.85e-05	0.00449	0.26	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78023206	chr16:78123243~78124332:+
LIHC	cis	rs1865760	0.566	rs9366634	ENSG00000216436.2	HIST1H2APS1	-4.34	1.85e-05	0.0045	-0.26	-0.23	Height;	chr6:26072168	chr6:25732497~25732827:+
LIHC	cis	rs6442522	0.809	rs6805196	ENSG00000249786.6	EAF1-AS1	4.34	1.85e-05	0.0045	0.27	0.23	Uric acid levels;	chr3:15410471	chr3:15436171~15455940:-
LIHC	cis	rs10829156	0.66	rs4338439	ENSG00000240291.1	RP11-499P20.2	4.34	1.85e-05	0.0045	0.37	0.23	Sudden cardiac arrest;	chr10:18594220	chr10:18513115~18545651:-
LIHC	cis	rs11098499	0.754	rs66900435	ENSG00000260091.1	RP11-33B1.4	-4.34	1.85e-05	0.0045	-0.16	-0.23	Corneal astigmatism;	chr4:119328270	chr4:119409333~119410233:+
LIHC	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-4.34	1.85e-05	0.0045	-0.27	-0.23	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
LIHC	cis	rs1075232	1	rs67634762	ENSG00000270055.1	CTD-3092A11.2	-4.34	1.86e-05	0.00451	-0.44	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30487963~30490313:+
LIHC	cis	rs709400	0.93	rs57447494	ENSG00000258534.1	CTD-2134A5.4	4.34	1.86e-05	0.00451	0.35	0.23	Body mass index;	chr14:103568232	chr14:103854366~103880111:-
LIHC	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-4.34	1.86e-05	0.00451	-0.26	-0.23	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
LIHC	cis	rs3733589	0.744	rs2240723	ENSG00000250413.1	RP11-448G15.1	4.34	1.86e-05	0.00452	0.36	0.23	Renal overload gout;	chr4:10019527	chr4:10006482~10009725:+
LIHC	cis	rs9457247	1	rs404222	ENSG00000227598.1	RP1-167A14.2	-4.34	1.86e-05	0.00452	-0.24	-0.23	Crohn's disease;	chr6:166988662	chr6:166969626~166999065:-
LIHC	cis	rs2060793	0.519	rs10766187	ENSG00000251991.1	RNU7-49P	4.34	1.86e-05	0.00452	0.25	0.23	Vitamin D levels;	chr11:14603836	chr11:14478892~14478953:+
LIHC	cis	rs2348418	0.864	rs7960369	ENSG00000247934.4	RP11-967K21.1	4.34	1.86e-05	0.00452	0.21	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28561569	chr12:28163298~28190738:-
LIHC	cis	rs921968	0.565	rs1078803	ENSG00000272555.1	RP11-459I19.1	4.34	1.86e-05	0.00452	0.24	0.23	Mean corpuscular hemoglobin concentration;	chr2:218741815	chr2:218818690~218819144:+
LIHC	cis	rs11233413	0.874	rs4943870	ENSG00000246067.6	RAB30-AS1	4.34	1.86e-05	0.00452	0.31	0.23	Economic and political preferences (feminism/equality);	chr11:83042198	chr11:83072066~83106719:+
LIHC	cis	rs921968	0.565	rs1541777	ENSG00000272555.1	RP11-459I19.1	-4.34	1.86e-05	0.00453	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218722568	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs4672897	ENSG00000272555.1	RP11-459I19.1	-4.34	1.86e-05	0.00453	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218723411	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.591	rs6717107	ENSG00000272555.1	RP11-459I19.1	-4.34	1.86e-05	0.00453	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218723974	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.528	rs35695178	ENSG00000272555.1	RP11-459I19.1	-4.34	1.86e-05	0.00453	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218724441	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.528	rs13022583	ENSG00000272555.1	RP11-459I19.1	-4.34	1.86e-05	0.00453	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218724452	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs35594672	ENSG00000272555.1	RP11-459I19.1	-4.34	1.86e-05	0.00453	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218724557	chr2:218818690~218819144:+
LIHC	cis	rs921968	0.565	rs12694439	ENSG00000272555.1	RP11-459I19.1	-4.34	1.86e-05	0.00453	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218726148	chr2:218818690~218819144:+
LIHC	cis	rs901683	0.85	rs12098366	ENSG00000230869.1	CTGLF10P	-4.34	1.86e-05	0.00453	-0.58	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45596168	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs80174235	ENSG00000230869.1	CTGLF10P	-4.34	1.86e-05	0.00453	-0.58	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45596370	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs75402959	ENSG00000230869.1	CTGLF10P	-4.34	1.86e-05	0.00453	-0.58	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45597359	chr10:45678692~45700532:+
LIHC	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	4.34	1.86e-05	0.00453	0.36	0.23	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
LIHC	cis	rs12549025	0.782	rs11781222	ENSG00000253390.1	CTC-756D1.2	-4.34	1.86e-05	0.00453	-0.27	-0.23	Reticulocyte fraction of red cells;	chr8:23532058	chr8:23458601~23484971:+
LIHC	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-4.34	1.86e-05	0.00453	-0.28	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
LIHC	cis	rs6480314	0.711	rs61857176	ENSG00000233590.1	RP11-153K11.3	-4.34	1.87e-05	0.00453	-0.38	-0.23	Optic nerve measurement (disc area);	chr10:68186207	chr10:68233251~68242379:-
LIHC	cis	rs2739330	0.828	rs5760102	ENSG00000206090.4	AP000350.7	4.34	1.87e-05	0.00453	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23939998~23942798:+
LIHC	cis	rs1729407	0.814	rs2542051	ENSG00000236267.1	AP006216.5	-4.34	1.87e-05	0.00453	-0.22	-0.23	Apolipoprotein A-IV levels;	chr11:116827022	chr11:116813204~116814003:-
LIHC	cis	rs2976388	0.669	rs2976391	ENSG00000253196.1	RP11-706C16.7	4.34	1.87e-05	0.00454	0.22	0.23	Urinary tract infection frequency;	chr8:142681306	chr8:142763116~142766427:+
LIHC	cis	rs7487637	0.529	rs56389811	ENSG00000276691.1	RP5-1057I20.5	4.34	1.87e-05	0.00454	0.41	0.23	Mononucleosis;	chr12:47811575	chr12:47788426~47788971:+
LIHC	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	4.34	1.87e-05	0.00454	0.36	0.23	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
LIHC	cis	rs709400	0.894	rs61996721	ENSG00000258534.1	CTD-2134A5.4	4.34	1.87e-05	0.00454	0.34	0.23	Body mass index;	chr14:103595015	chr14:103854366~103880111:-
LIHC	cis	rs3733589	1	rs36058283	ENSG00000250413.1	RP11-448G15.1	4.34	1.87e-05	0.00454	0.41	0.23	Renal overload gout;	chr4:10006888	chr4:10006482~10009725:+
LIHC	cis	rs3733589	1	rs67968745	ENSG00000250413.1	RP11-448G15.1	4.34	1.87e-05	0.00454	0.41	0.23	Renal overload gout;	chr4:10007125	chr4:10006482~10009725:+
LIHC	cis	rs11668505	1	rs12462534	ENSG00000259108.2	CTD-3098H1.2	4.34	1.87e-05	0.00454	0.29	0.23	Lung function (FVC);	chr19:47841313	chr19:47863483~47865341:-
LIHC	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-4.34	1.87e-05	0.00454	-0.23	-0.23	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
LIHC	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-4.34	1.87e-05	0.00455	-0.27	-0.23	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
LIHC	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-4.34	1.87e-05	0.00455	-0.23	-0.23	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
LIHC	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-4.34	1.87e-05	0.00455	-0.34	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
LIHC	cis	rs748404	0.631	rs7163288	ENSG00000166763.7	STRCP1	4.34	1.87e-05	0.00455	0.28	0.23	Lung cancer;	chr15:43379157	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs693510	ENSG00000166763.7	STRCP1	4.34	1.88e-05	0.00455	0.28	0.23	Lung cancer;	chr15:43422427	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs690512	ENSG00000166763.7	STRCP1	4.34	1.88e-05	0.00455	0.28	0.23	Lung cancer;	chr15:43425480	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs542898	ENSG00000166763.7	STRCP1	4.34	1.88e-05	0.00455	0.28	0.23	Lung cancer;	chr15:43427194	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs2249952	ENSG00000166763.7	STRCP1	4.34	1.88e-05	0.00455	0.28	0.23	Lung cancer;	chr15:43428335	chr15:43699488~43718184:-
LIHC	cis	rs2836974	0.897	rs68090597	ENSG00000255568.3	BRWD1-AS2	4.34	1.88e-05	0.00456	0.26	0.23	Cognitive function;	chr21:39163707	chr21:39313935~39314962:+
LIHC	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-4.34	1.88e-05	0.00456	-0.31	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
LIHC	cis	rs2836974	0.549	rs34160989	ENSG00000255568.3	BRWD1-AS2	4.34	1.88e-05	0.00456	0.34	0.23	Cognitive function;	chr21:39182192	chr21:39313935~39314962:+
LIHC	cis	rs7702057	0.53	rs17138848	ENSG00000271918.1	CTD-2287O16.5	4.34	1.88e-05	0.00456	0.31	0.23	Amyotrophic lateral sclerosis;	chr5:116083606	chr5:116083807~116085416:-
LIHC	cis	rs2932538	0.922	rs999923	ENSG00000225075.1	RP11-426L16.3	4.34	1.88e-05	0.00456	0.3	0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112567926	chr1:112693688~112696621:-
LIHC	cis	rs2932538	0.922	rs6690169	ENSG00000225075.1	RP11-426L16.3	4.34	1.88e-05	0.00456	0.3	0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112572352	chr1:112693688~112696621:-
LIHC	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-4.34	1.88e-05	0.00457	-0.26	-0.23	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
LIHC	cis	rs494453	0.922	rs476515	ENSG00000227811.2	FAM212B-AS1	-4.34	1.88e-05	0.00457	-0.25	-0.23	Osteoporosis-related phenotypes;	chr1:111672454	chr1:111739841~111747798:+
LIHC	cis	rs4578769	0.842	rs8093152	ENSG00000266850.1	RP11-370A5.1	4.34	1.88e-05	0.00457	0.27	0.23	Eosinophil percentage of white cells;	chr18:22867925	chr18:22723491~22907721:-
LIHC	cis	rs11098499	0.82	rs28535956	ENSG00000260091.1	RP11-33B1.4	4.34	1.88e-05	0.00457	0.16	0.23	Corneal astigmatism;	chr4:119615703	chr4:119409333~119410233:+
LIHC	cis	rs2348418	0.733	rs7955080	ENSG00000247934.4	RP11-967K21.1	-4.34	1.88e-05	0.00457	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28153972	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.733	rs12229219	ENSG00000247934.4	RP11-967K21.1	-4.34	1.88e-05	0.00457	-0.21	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28158414	chr12:28163298~28190738:-
LIHC	cis	rs921968	0.541	rs933994	ENSG00000272555.1	RP11-459I19.1	-4.34	1.88e-05	0.00457	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218785893	chr2:218818690~218819144:+
LIHC	cis	rs2243480	1	rs1964692	ENSG00000228409.4	CCT6P1	4.34	1.88e-05	0.00457	0.25	0.23	Diabetic kidney disease;	chr7:65989196	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs2456483	ENSG00000228409.4	CCT6P1	4.34	1.88e-05	0.00457	0.25	0.23	Diabetic kidney disease;	chr7:65996588	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs2949697	ENSG00000228409.4	CCT6P1	4.34	1.88e-05	0.00457	0.25	0.23	Diabetic kidney disease;	chr7:65999249	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs1701750	ENSG00000228409.4	CCT6P1	4.34	1.88e-05	0.00457	0.25	0.23	Diabetic kidney disease;	chr7:66002158	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs1701758	ENSG00000228409.4	CCT6P1	4.34	1.88e-05	0.00457	0.25	0.23	Diabetic kidney disease;	chr7:66005214	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs1701759	ENSG00000228409.4	CCT6P1	4.34	1.88e-05	0.00457	0.25	0.23	Diabetic kidney disease;	chr7:66005945	chr7:65751142~65763354:+
LIHC	cis	rs11779988	0.545	rs397096	ENSG00000253671.1	RP11-806O11.1	4.34	1.89e-05	0.00457	0.3	0.23	Breast cancer;	chr8:17941339	chr8:17808941~17820868:+
LIHC	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	4.34	1.89e-05	0.00457	0.23	0.23	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
LIHC	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	4.34	1.89e-05	0.00457	0.22	0.23	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
LIHC	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	4.34	1.89e-05	0.00458	0.28	0.23	Height;	chr6:109429207	chr6:109382795~109383666:+
LIHC	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-4.34	1.89e-05	0.00458	-0.23	-0.23	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
LIHC	cis	rs9532669	0.926	rs7799	ENSG00000239827.7	SUGT1P3	-4.34	1.89e-05	0.00458	-0.29	-0.23	Cervical cancer;	chr13:40958916	chr13:40908159~40921774:-
LIHC	cis	rs2243480	1	rs6966322	ENSG00000230295.1	RP11-458F8.2	4.34	1.89e-05	0.00459	0.24	0.23	Diabetic kidney disease;	chr7:66181767	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs4145008	ENSG00000230295.1	RP11-458F8.2	4.34	1.89e-05	0.00459	0.24	0.23	Diabetic kidney disease;	chr7:66182524	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs4718315	ENSG00000230295.1	RP11-458F8.2	4.34	1.89e-05	0.00459	0.24	0.23	Diabetic kidney disease;	chr7:66183554	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs4718316	ENSG00000230295.1	RP11-458F8.2	4.34	1.89e-05	0.00459	0.24	0.23	Diabetic kidney disease;	chr7:66183744	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs1873494	ENSG00000230295.1	RP11-458F8.2	4.34	1.89e-05	0.00459	0.24	0.23	Diabetic kidney disease;	chr7:66184912	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs6959002	ENSG00000230295.1	RP11-458F8.2	4.34	1.89e-05	0.00459	0.24	0.23	Diabetic kidney disease;	chr7:66185509	chr7:66880708~66882981:+
LIHC	cis	rs748404	0.578	rs2012467	ENSG00000166763.7	STRCP1	4.34	1.9e-05	0.0046	0.28	0.23	Lung cancer;	chr15:43398367	chr15:43699488~43718184:-
LIHC	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	4.34	1.9e-05	0.0046	0.27	0.23	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
LIHC	cis	rs7915414	0.802	rs12762067	ENSG00000230338.1	MTND4P19	4.34	1.9e-05	0.0046	0.24	0.23	Clopidogrel active metabolite levels;	chr10:94638576	chr10:94774156~94774633:-
LIHC	cis	rs875971	0.545	rs73142233	ENSG00000228409.4	CCT6P1	-4.34	1.9e-05	0.0046	-0.19	-0.23	Aortic root size;	chr7:66221293	chr7:65751142~65763354:+
LIHC	cis	rs2072510	0.569	rs2540488	ENSG00000257715.1	RP11-256L6.2	-4.34	1.9e-05	0.00461	-0.32	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96032967	chr12:96025323~96027971:+
LIHC	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	4.34	1.9e-05	0.00461	0.27	0.23	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
LIHC	cis	rs11079159	0.606	rs876720	ENSG00000263096.1	RP11-515O17.2	-4.34	1.9e-05	0.00461	-0.3	-0.23	QRS duration;	chr17:55289154	chr17:55271504~55273653:-
LIHC	cis	rs56046484	0.75	rs12900078	ENSG00000259630.2	CTD-2262B20.1	-4.34	1.9e-05	0.00461	-0.47	-0.23	Testicular germ cell tumor;	chr15:84980738	chr15:85415228~85415633:+
LIHC	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	4.34	1.9e-05	0.00461	0.3	0.23	Height;	chr3:53073584	chr3:53064283~53065091:-
LIHC	cis	rs6442522	0.809	rs12494163	ENSG00000249786.6	EAF1-AS1	4.34	1.91e-05	0.00461	0.26	0.23	Uric acid levels;	chr3:15382327	chr3:15436171~15455940:-
LIHC	cis	rs3733589	1	rs13117275	ENSG00000250413.1	RP11-448G15.1	4.34	1.91e-05	0.00461	0.42	0.23	Renal overload gout;	chr4:10006618	chr4:10006482~10009725:+
LIHC	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	4.34	1.91e-05	0.00462	0.27	0.23	Height;	chr6:109361318	chr6:109382795~109383666:+
LIHC	cis	rs2243480	1	rs2420171	ENSG00000230295.1	RP11-458F8.2	4.34	1.91e-05	0.00462	0.24	0.23	Diabetic kidney disease;	chr7:66172773	chr7:66880708~66882981:+
LIHC	cis	rs875971	0.545	rs67775320	ENSG00000228409.4	CCT6P1	-4.34	1.91e-05	0.00462	-0.19	-0.23	Aortic root size;	chr7:66193792	chr7:65751142~65763354:+
LIHC	cis	rs244293	0.868	rs12453779	ENSG00000275710.1	RP11-257O5.4	-4.34	1.91e-05	0.00462	-0.24	-0.23	Menarche (age at onset);	chr17:55094748	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.831	rs7209029	ENSG00000275710.1	RP11-257O5.4	-4.34	1.91e-05	0.00462	-0.24	-0.23	Menarche (age at onset);	chr17:55095685	chr17:54964474~54964679:+
LIHC	cis	rs1223397	0.938	rs3734878	ENSG00000215022.6	RP1-257A7.4	-4.34	1.91e-05	0.00462	-0.31	-0.23	Blood pressure;	chr6:13288618	chr6:13264861~13295586:-
LIHC	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	4.34	1.91e-05	0.00462	0.36	0.23	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
LIHC	cis	rs748404	0.66	rs689767	ENSG00000166763.7	STRCP1	4.34	1.91e-05	0.00462	0.28	0.23	Lung cancer;	chr15:43429879	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs2439845	ENSG00000166763.7	STRCP1	4.34	1.91e-05	0.00462	0.28	0.23	Lung cancer;	chr15:43430412	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.631	rs2467745	ENSG00000166763.7	STRCP1	4.34	1.91e-05	0.00462	0.28	0.23	Lung cancer;	chr15:43430544	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs2439846	ENSG00000166763.7	STRCP1	4.34	1.91e-05	0.00462	0.28	0.23	Lung cancer;	chr15:43448772	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs2467741	ENSG00000166763.7	STRCP1	4.34	1.91e-05	0.00462	0.28	0.23	Lung cancer;	chr15:43450428	chr15:43699488~43718184:-
LIHC	cis	rs4561483	0.801	rs33637	ENSG00000261560.1	RP11-166B2.3	-4.34	1.91e-05	0.00463	-0.26	-0.23	Testicular germ cell tumor;	chr16:11896018	chr16:11881075~11882569:-
LIHC	cis	rs11098499	0.697	rs28655325	ENSG00000260091.1	RP11-33B1.4	-4.34	1.91e-05	0.00463	-0.16	-0.23	Corneal astigmatism;	chr4:119451844	chr4:119409333~119410233:+
LIHC	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	4.34	1.91e-05	0.00463	0.33	0.23	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
LIHC	cis	rs2060793	0.519	rs7931378	ENSG00000251991.1	RNU7-49P	4.34	1.91e-05	0.00463	0.25	0.23	Vitamin D levels;	chr11:14592869	chr11:14478892~14478953:+
LIHC	cis	rs17711722	0.565	rs4275112	ENSG00000226002.1	RP11-460N20.5	-4.34	1.91e-05	0.00463	-0.24	-0.23	Calcium levels;	chr7:65733651	chr7:65084103~65100232:+
LIHC	cis	rs1075265	0.62	rs2542584	ENSG00000272156.1	RP11-477N3.1	-4.34	1.91e-05	0.00463	-0.27	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54082554~54085066:+
LIHC	cis	rs860295	0.775	rs822505	ENSG00000203761.5	MSTO2P	4.34	1.91e-05	0.00463	0.19	0.23	Body mass index;	chr1:155876737	chr1:155745829~155750137:+
LIHC	cis	rs860295	0.775	rs822509	ENSG00000203761.5	MSTO2P	4.34	1.91e-05	0.00463	0.19	0.23	Body mass index;	chr1:155881020	chr1:155745829~155750137:+
LIHC	cis	rs2072510	0.722	rs763874	ENSG00000257878.1	RP11-256L6.3	-4.34	1.91e-05	0.00463	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96026435	chr12:95996521~96011489:+
LIHC	cis	rs1577917	1	rs12216203	ENSG00000234155.1	RP11-30P6.6	4.34	1.92e-05	0.00463	0.3	0.23	Response to antipsychotic treatment;	chr6:85965583	chr6:85387219~85390186:-
LIHC	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	4.34	1.92e-05	0.00464	0.17	0.23	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
LIHC	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-4.34	1.92e-05	0.00464	-0.27	-0.23	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
LIHC	cis	rs11098499	0.863	rs3822190	ENSG00000260091.1	RP11-33B1.4	-4.34	1.92e-05	0.00464	-0.17	-0.23	Corneal astigmatism;	chr4:119506943	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs3822191	ENSG00000260091.1	RP11-33B1.4	-4.34	1.92e-05	0.00464	-0.17	-0.23	Corneal astigmatism;	chr4:119506946	chr4:119409333~119410233:+
LIHC	cis	rs2243480	1	rs709607	ENSG00000232546.1	RP11-458F8.1	4.34	1.92e-05	0.00464	0.26	0.23	Diabetic kidney disease;	chr7:65984554	chr7:66848496~66858136:+
LIHC	cis	rs496547	0.756	rs562059	ENSG00000255422.1	AP002954.4	-4.34	1.92e-05	0.00464	-0.28	-0.23	Hip minimal joint space width;	chr11:118731349	chr11:118704607~118750263:+
LIHC	cis	rs3812762	0.917	rs905289	ENSG00000254860.4	TMEM9B-AS1	-4.34	1.92e-05	0.00464	-0.24	-0.23	Hypospadias;	chr11:8732005	chr11:8964675~8977527:+
LIHC	cis	rs1577917	0.958	rs11756510	ENSG00000234155.1	RP11-30P6.6	4.33	1.92e-05	0.00465	0.3	0.23	Response to antipsychotic treatment;	chr6:85990076	chr6:85387219~85390186:-
LIHC	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	4.33	1.92e-05	0.00465	0.35	0.23	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
LIHC	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-4.33	1.92e-05	0.00465	-0.3	-0.23	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
LIHC	cis	rs9457247	0.756	rs2345572	ENSG00000227598.1	RP1-167A14.2	-4.33	1.92e-05	0.00466	-0.24	-0.23	Crohn's disease;	chr6:166989953	chr6:166969626~166999065:-
LIHC	cis	rs1499614	1	rs1267817	ENSG00000232546.1	RP11-458F8.1	-4.33	1.93e-05	0.00466	-0.26	-0.23	Gout;	chr7:66645053	chr7:66848496~66858136:+
LIHC	cis	rs116139393	0.54	rs13224907	ENSG00000187953.9	PMS2CL	-4.33	1.93e-05	0.00466	-0.24	-0.23	Alzheimer's disease (APOE e4 interaction);	chr7:6734261	chr7:6710128~6753862:+
LIHC	cis	rs1577917	1	rs12664335	ENSG00000234155.1	RP11-30P6.6	-4.33	1.93e-05	0.00466	-0.29	-0.23	Response to antipsychotic treatment;	chr6:85888056	chr6:85387219~85390186:-
LIHC	cis	rs9341808	1	rs9341808	ENSG00000272129.1	RP11-250B2.6	4.33	1.93e-05	0.00466	0.23	0.23	Sitting height ratio;	chr6:80243540	chr6:80355424~80356859:+
LIHC	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-4.33	1.93e-05	0.00467	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
LIHC	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-4.33	1.93e-05	0.00467	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
LIHC	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	4.33	1.93e-05	0.00467	0.37	0.23	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
LIHC	cis	rs1729407	0.709	rs2098453	ENSG00000236267.1	AP006216.5	4.33	1.93e-05	0.00467	0.22	0.23	Apolipoprotein A-IV levels;	chr11:116825964	chr11:116813204~116814003:-
LIHC	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-4.33	1.93e-05	0.00468	-0.18	-0.23	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
LIHC	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	4.33	1.93e-05	0.00468	0.36	0.23	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
LIHC	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-4.33	1.94e-05	0.00468	-0.27	-0.23	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
LIHC	cis	rs169313	0.556	rs7220819	ENSG00000264016.2	CTC-297N7.9	-4.33	1.94e-05	0.00468	-0.28	-0.23	Relative hand skill in reading disability;	chr17:10663157	chr17:10741267~10769016:-
LIHC	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	4.33	1.94e-05	0.00468	0.27	0.23	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
LIHC	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-4.33	1.94e-05	0.00469	-0.23	-0.23	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
LIHC	cis	rs8028182	0.636	rs7175852	ENSG00000260269.4	CTD-2323K18.1	-4.33	1.94e-05	0.00469	-0.29	-0.23	Sudden cardiac arrest;	chr15:75402194	chr15:75527150~75601205:-
LIHC	cis	rs709400	0.93	rs2274268	ENSG00000258534.1	CTD-2134A5.4	4.33	1.94e-05	0.00469	0.35	0.23	Body mass index;	chr14:103563041	chr14:103854366~103880111:-
LIHC	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-4.33	1.94e-05	0.00469	-0.24	-0.23	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
LIHC	cis	rs2524005	1	rs2524005	ENSG00000272236.1	XXbac-BPG170G13.32	-4.33	1.94e-05	0.00469	-0.31	-0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29751965~29752207:-
LIHC	cis	rs4862307	0.836	rs11132220	ENSG00000250726.1	RP11-616K6.1	-4.33	1.94e-05	0.00469	-0.25	-0.23	Serum dimethylarginine levels (asymmetric/symetric ratio);	chr4:184076094	chr4:184072403~184073039:+
LIHC	cis	rs4934494	0.689	rs11185895	ENSG00000232936.4	RP11-80H5.2	-4.33	1.94e-05	0.0047	-0.26	-0.23	Red blood cell count;	chr10:89817482	chr10:89645282~89650667:+
LIHC	cis	rs831571	0.636	rs56228642	ENSG00000280620.1	SCAANT1	4.33	1.94e-05	0.0047	0.34	0.23	Type 2 diabetes;	chr3:64090083	chr3:63911518~63911772:-
LIHC	cis	rs9652601	0.959	rs2058531	ENSG00000274038.1	RP11-66H6.4	-4.33	1.94e-05	0.0047	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11078252	chr16:11056556~11057034:+
LIHC	cis	rs1005277	0.522	rs289650	ENSG00000099251.13	HSD17B7P2	4.33	1.94e-05	0.0047	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38356380~38378505:+
LIHC	cis	rs113084984	0.538	rs11686574	ENSG00000271952.1	RP11-245G13.2	-4.33	1.95e-05	0.0047	-0.26	-0.23	Breast cancer;	chr2:11543881	chr2:10878269~10885118:+
LIHC	cis	rs734999	0.588	rs2985859	ENSG00000225931.3	RP3-395M20.7	-4.33	1.95e-05	0.0047	-0.24	-0.23	Ulcerative colitis;	chr1:2600977	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.588	rs3001837	ENSG00000225931.3	RP3-395M20.7	-4.33	1.95e-05	0.0047	-0.24	-0.23	Ulcerative colitis;	chr1:2601067	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.55	rs2985855	ENSG00000225931.3	RP3-395M20.7	-4.33	1.95e-05	0.0047	-0.24	-0.23	Ulcerative colitis;	chr1:2599933	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.588	rs6689711	ENSG00000225931.3	RP3-395M20.7	-4.33	1.95e-05	0.0047	-0.24	-0.23	Ulcerative colitis;	chr1:2600028	chr1:2566410~2569888:+
LIHC	cis	rs2836974	0.932	rs73221193	ENSG00000255568.3	BRWD1-AS2	4.33	1.95e-05	0.0047	0.26	0.23	Cognitive function;	chr21:39182767	chr21:39313935~39314962:+
LIHC	cis	rs755249	0.917	rs61781392	ENSG00000182109.6	RP11-69E11.4	4.33	1.95e-05	0.0047	0.33	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39522280~39546187:-
LIHC	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-4.33	1.95e-05	0.0047	-0.24	-0.23	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
LIHC	cis	rs7915414	0.951	rs2104543	ENSG00000230338.1	MTND4P19	4.33	1.95e-05	0.00471	0.24	0.23	Clopidogrel active metabolite levels;	chr10:94670214	chr10:94774156~94774633:-
LIHC	cis	rs2243480	0.706	rs6460257	ENSG00000164669.11	INTS4P1	4.33	1.95e-05	0.00471	0.35	0.23	Diabetic kidney disease;	chr7:65731813	chr7:65141225~65234216:+
LIHC	cis	rs9675120	0.638	rs7216662	ENSG00000262006.1	RP11-700H6.4	-4.33	1.95e-05	0.00471	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50859850	chr17:50909637~50910232:-
LIHC	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-4.33	1.95e-05	0.00471	-0.26	-0.23	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
LIHC	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-4.33	1.95e-05	0.00471	-0.31	-0.23	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
LIHC	cis	rs3812762	0.912	rs10769953	ENSG00000254860.4	TMEM9B-AS1	-4.33	1.95e-05	0.00471	-0.25	-0.23	Hypospadias;	chr11:8756805	chr11:8964675~8977527:+
LIHC	cis	rs1005277	0.579	rs1740732	ENSG00000099251.13	HSD17B7P2	4.33	1.95e-05	0.00471	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38356380~38378505:+
LIHC	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-4.33	1.95e-05	0.00471	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
LIHC	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-4.33	1.95e-05	0.00471	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
LIHC	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-4.33	1.95e-05	0.00471	-0.3	-0.23	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
LIHC	cis	rs2284219	0.894	rs1076291	ENSG00000196295.10	AC005154.6	-4.33	1.95e-05	0.00471	-0.16	-0.23	Type 2 diabetes;	chr7:30672979	chr7:30516309~30594809:-
LIHC	cis	rs2284219	0.894	rs1076292	ENSG00000196295.10	AC005154.6	-4.33	1.95e-05	0.00471	-0.16	-0.23	Type 2 diabetes;	chr7:30673085	chr7:30516309~30594809:-
LIHC	cis	rs2284219	0.894	rs2251002	ENSG00000196295.10	AC005154.6	-4.33	1.95e-05	0.00471	-0.16	-0.23	Type 2 diabetes;	chr7:30673228	chr7:30516309~30594809:-
LIHC	cis	rs7119038	0.865	rs7951740	ENSG00000255239.1	AP002954.6	4.33	1.95e-05	0.00472	0.34	0.23	Sjögren's syndrome;	chr11:118869709	chr11:118688039~118690600:-
LIHC	cis	rs709400	0.894	rs10143293	ENSG00000258534.1	CTD-2134A5.4	4.33	1.96e-05	0.00472	0.34	0.23	Body mass index;	chr14:103596677	chr14:103854366~103880111:-
LIHC	cis	rs1865760	0.532	rs1061482	ENSG00000216436.2	HIST1H2APS1	-4.33	1.96e-05	0.00472	-0.27	-0.23	Height;	chr6:26086471	chr6:25732497~25732827:+
LIHC	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-4.33	1.96e-05	0.00472	-0.25	-0.23	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
LIHC	cis	rs7208859	0.673	rs1347360	ENSG00000266490.1	CTD-2349P21.9	4.33	1.96e-05	0.00473	0.28	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30792372~30792833:+
LIHC	cis	rs734999	0.545	rs4648356	ENSG00000225931.3	RP3-395M20.7	4.33	1.96e-05	0.00473	0.24	0.23	Ulcerative colitis;	chr1:2792599	chr1:2566410~2569888:+
LIHC	cis	rs11098499	0.644	rs7676296	ENSG00000260091.1	RP11-33B1.4	-4.33	1.96e-05	0.00473	-0.16	-0.23	Corneal astigmatism;	chr4:119634532	chr4:119409333~119410233:+
LIHC	cis	rs4834770	1	rs878375	ENSG00000245958.5	RP11-33B1.1	-4.33	1.97e-05	0.00474	-0.22	-0.23	Blood protein levels;	chr4:119316419	chr4:119454791~119552025:+
LIHC	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	4.33	1.97e-05	0.00475	0.21	0.23	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
LIHC	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-4.33	1.97e-05	0.00475	-0.18	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
LIHC	cis	rs11722228	0.549	rs2241488	ENSG00000261490.1	RP11-448G15.3	4.33	1.97e-05	0.00475	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10099507	chr4:10068089~10073019:-
LIHC	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	4.33	1.97e-05	0.00475	0.41	0.23	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
LIHC	cis	rs7665090	0.714	rs5026475	ENSG00000248971.2	KRT8P46	-4.33	1.97e-05	0.00475	-0.23	-0.23	Primary biliary cholangitis;	chr4:102633664	chr4:102728746~102730171:-
LIHC	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-4.33	1.97e-05	0.00475	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
LIHC	cis	rs7208859	0.673	rs73277967	ENSG00000266490.1	CTD-2349P21.9	4.33	1.97e-05	0.00475	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs2269915	ENSG00000266490.1	CTD-2349P21.9	4.33	1.97e-05	0.00475	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs2269916	ENSG00000266490.1	CTD-2349P21.9	4.33	1.97e-05	0.00475	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11649765	ENSG00000266490.1	CTD-2349P21.9	4.33	1.97e-05	0.00475	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30792372~30792833:+
LIHC	cis	rs4650994	0.623	rs7534394	ENSG00000213057.5	C1orf220	-4.33	1.97e-05	0.00475	-0.2	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178653625	chr1:178542752~178548889:+
LIHC	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-4.33	1.97e-05	0.00475	-0.17	-0.23	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
LIHC	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-4.33	1.97e-05	0.00476	-0.29	-0.23	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
LIHC	cis	rs79349575	0.87	rs12941262	ENSG00000248278.1	SUMO2P17	4.33	1.97e-05	0.00476	0.28	0.23	Type 2 diabetes;	chr17:48889675	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.778	rs12950328	ENSG00000248278.1	SUMO2P17	4.33	1.97e-05	0.00476	0.28	0.23	Type 2 diabetes;	chr17:48889699	chr17:48874860~48908983:-
LIHC	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-4.33	1.97e-05	0.00476	-0.23	-0.23	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
LIHC	cis	rs5758511	0.689	rs55906806	ENSG00000237037.8	NDUFA6-AS1	-4.33	1.97e-05	0.00476	-0.47	-0.23	Birth weight;	chr22:42248465	chr22:42090931~42137742:+
LIHC	cis	rs1062753	0.527	rs2187959	ENSG00000237037.8	NDUFA6-AS1	-4.33	1.97e-05	0.00476	-0.32	-0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41951840	chr22:42090931~42137742:+
LIHC	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-4.33	1.98e-05	0.00476	-0.41	-0.23	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
LIHC	cis	rs72634501	0.568	rs6679564	ENSG00000182109.6	RP11-69E11.4	-4.33	1.98e-05	0.00476	-0.24	-0.23	HDL cholesterol;	chr1:39151408	chr1:39522280~39546187:-
LIHC	cis	rs948562	1	rs12365551	ENSG00000280010.1	AP001350.4	4.33	1.98e-05	0.00477	0.4	0.23	Lymphoma;	chr11:58590895	chr11:58627435~58628528:+
LIHC	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-4.33	1.98e-05	0.00477	-0.23	-0.23	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
LIHC	cis	rs11098499	0.57	rs6832740	ENSG00000260091.1	RP11-33B1.4	-4.33	1.98e-05	0.00477	-0.16	-0.23	Corneal astigmatism;	chr4:119624981	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.644	rs6855918	ENSG00000260091.1	RP11-33B1.4	-4.33	1.98e-05	0.00477	-0.16	-0.23	Corneal astigmatism;	chr4:119625144	chr4:119409333~119410233:+
LIHC	cis	rs2836974	0.8	rs73221174	ENSG00000255568.3	BRWD1-AS2	4.33	1.98e-05	0.00477	0.26	0.23	Cognitive function;	chr21:39169013	chr21:39313935~39314962:+
LIHC	cis	rs11668505	1	rs12985570	ENSG00000259108.2	CTD-3098H1.2	4.33	1.98e-05	0.00477	0.29	0.23	Lung function (FVC);	chr19:47845683	chr19:47863483~47865341:-
LIHC	cis	rs6430585	0.528	rs309166	ENSG00000231890.6	DARS-AS1	-4.33	1.98e-05	0.00477	-0.31	-0.23	Corneal structure;	chr2:135909917	chr2:135985176~136022593:+
LIHC	cis	rs6430585	0.591	rs309170	ENSG00000231890.6	DARS-AS1	-4.33	1.98e-05	0.00477	-0.31	-0.23	Corneal structure;	chr2:135915205	chr2:135985176~136022593:+
LIHC	cis	rs11098499	0.691	rs9996644	ENSG00000260091.1	RP11-33B1.4	-4.33	1.98e-05	0.00477	-0.16	-0.23	Corneal astigmatism;	chr4:119317722	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.691	rs9996494	ENSG00000260091.1	RP11-33B1.4	-4.33	1.98e-05	0.00477	-0.16	-0.23	Corneal astigmatism;	chr4:119317725	chr4:119409333~119410233:+
LIHC	cis	rs812925	0.512	rs1177309	ENSG00000212978.6	AC016747.3	-4.33	1.98e-05	0.00477	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61158113	chr2:61141592~61144969:-
LIHC	cis	rs921968	0.565	rs4674328	ENSG00000272555.1	RP11-459I19.1	-4.33	1.98e-05	0.00478	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218728480	chr2:218818690~218819144:+
LIHC	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	4.33	1.98e-05	0.00478	0.23	0.23	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
LIHC	cis	rs10991814	0.557	rs79342869	ENSG00000273381.1	RP11-305L7.7	4.33	1.98e-05	0.00478	0.26	0.23	Neutrophil percentage of granulocytes;	chr9:91225500	chr9:91206175~91210299:-
LIHC	cis	rs2243480	1	rs1546059	ENSG00000230295.1	RP11-458F8.2	4.33	1.98e-05	0.00478	0.24	0.23	Diabetic kidney disease;	chr7:66189722	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs6958289	ENSG00000230295.1	RP11-458F8.2	4.33	1.98e-05	0.00478	0.24	0.23	Diabetic kidney disease;	chr7:66192124	chr7:66880708~66882981:+
LIHC	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	4.33	1.98e-05	0.00478	0.22	0.23	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
LIHC	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	4.33	1.99e-05	0.00479	0.31	0.23	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
LIHC	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	4.33	1.99e-05	0.00479	0.25	0.23	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
LIHC	cis	rs6445975	0.617	rs4470539	ENSG00000272360.1	RP11-359I18.5	4.33	1.99e-05	0.00479	0.3	0.23	Systemic lupus erythematosus;	chr3:58418759	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.666	rs9822328	ENSG00000272360.1	RP11-359I18.5	4.33	1.99e-05	0.00479	0.3	0.23	Systemic lupus erythematosus;	chr3:58422110	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.666	rs6767291	ENSG00000272360.1	RP11-359I18.5	4.33	1.99e-05	0.00479	0.3	0.23	Systemic lupus erythematosus;	chr3:58423183	chr3:58490830~58491291:-
LIHC	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-4.33	1.99e-05	0.00479	-0.27	-0.23	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
LIHC	cis	rs4356203	0.87	rs10832748	ENSG00000260196.1	RP1-239B22.5	-4.33	1.99e-05	0.00479	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17230184	chr11:17380649~17383531:+
LIHC	cis	rs2072510	0.932	rs2070614	ENSG00000257878.1	RP11-256L6.3	-4.33	1.99e-05	0.00479	-0.21	-0.23	Metabolite levels (small molecules and protein measures);	chr12:95996558	chr12:95996521~96011489:+
LIHC	cis	rs11098499	0.754	rs1546503	ENSG00000260091.1	RP11-33B1.4	-4.33	1.99e-05	0.0048	-0.16	-0.23	Corneal astigmatism;	chr4:119320012	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.708	rs1546506	ENSG00000260091.1	RP11-33B1.4	-4.33	1.99e-05	0.0048	-0.16	-0.23	Corneal astigmatism;	chr4:119320085	chr4:119409333~119410233:+
LIHC	cis	rs11722228	0.549	rs73212863	ENSG00000261490.1	RP11-448G15.3	4.33	1.99e-05	0.0048	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10102549	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.508	rs73212864	ENSG00000261490.1	RP11-448G15.3	4.33	1.99e-05	0.0048	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10102567	chr4:10068089~10073019:-
LIHC	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-4.33	1.99e-05	0.0048	-0.28	-0.23	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
LIHC	cis	rs948562	0.947	rs1938601	ENSG00000280010.1	AP001350.4	4.33	2e-05	0.0048	0.41	0.23	Lymphoma;	chr11:58646988	chr11:58627435~58628528:+
LIHC	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-4.33	2e-05	0.00481	-0.24	-0.23	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-4.33	2e-05	0.00481	-0.24	-0.23	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-4.33	2e-05	0.00481	-0.24	-0.23	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
LIHC	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-4.33	2e-05	0.00481	-0.24	-0.23	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
LIHC	cis	rs16858210	0.874	rs55666767	ENSG00000234371.6	RPSAP31	4.33	2e-05	0.00481	0.3	0.23	Menopause (age at onset);	chr3:183855447	chr3:183884924~183888449:+
LIHC	cis	rs17376456	0.877	rs12716460	ENSG00000251023.1	RP11-549J18.1	-4.33	2e-05	0.00481	-0.48	-0.23	Diabetic retinopathy;	chr5:94081028	chr5:93860669~93863825:-
LIHC	cis	rs2832191	0.511	rs7278227	ENSG00000176054.6	RPL23P2	-4.33	2e-05	0.00481	-0.26	-0.23	Dental caries;	chr21:29110386	chr21:28997613~28998033:-
LIHC	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	4.33	2e-05	0.00481	0.42	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
LIHC	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	4.33	2e-05	0.00481	0.22	0.23	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
LIHC	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	4.33	2e-05	0.00481	0.37	0.23	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	4.33	2e-05	0.00481	0.37	0.23	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
LIHC	cis	rs9457247	1	rs444988	ENSG00000227598.1	RP1-167A14.2	-4.33	2e-05	0.00482	-0.24	-0.23	Crohn's disease;	chr6:166976186	chr6:166969626~166999065:-
LIHC	cis	rs9457247	1	rs408080	ENSG00000227598.1	RP1-167A14.2	-4.33	2e-05	0.00482	-0.24	-0.23	Crohn's disease;	chr6:166979034	chr6:166969626~166999065:-
LIHC	cis	rs7894407	0.76	rs4917386	ENSG00000236937.2	PTGES3P4	-4.33	2e-05	0.00482	-0.27	-0.23	White matter hyperintensity burden;	chr10:103247771	chr10:102845595~102845950:+
LIHC	cis	rs2243480	1	rs59794892	ENSG00000230295.1	RP11-458F8.2	-4.32	2e-05	0.00482	-0.24	-0.23	Diabetic kidney disease;	chr7:65950886	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.803	rs36004293	ENSG00000230295.1	RP11-458F8.2	-4.32	2e-05	0.00482	-0.24	-0.23	Diabetic kidney disease;	chr7:65951525	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.803	rs35268390	ENSG00000230295.1	RP11-458F8.2	-4.32	2e-05	0.00482	-0.24	-0.23	Diabetic kidney disease;	chr7:65951549	chr7:66880708~66882981:+
LIHC	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-4.32	2.01e-05	0.00482	-0.27	-0.23	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
LIHC	cis	rs7208859	0.614	rs73265646	ENSG00000266490.1	CTD-2349P21.9	4.32	2.01e-05	0.00482	0.28	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30792372~30792833:+
LIHC	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	4.32	2.01e-05	0.00483	0.26	0.23	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
LIHC	cis	rs755249	0.567	rs4660214	ENSG00000182109.6	RP11-69E11.4	4.32	2.01e-05	0.00483	0.29	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39522280~39546187:-
LIHC	cis	rs12681366	0.839	rs2931632	ENSG00000253704.1	RP11-267M23.4	4.32	2.01e-05	0.00483	0.26	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94553722~94569745:+
LIHC	cis	rs3204270	0.684	rs57405099	ENSG00000281517.1	Metazoa_SRP	-4.32	2.01e-05	0.00483	-0.43	-0.23	Dental caries;	chr17:81670035	chr17:81718849~81719095:-
LIHC	cis	rs734999	0.588	rs2843401	ENSG00000225931.3	RP3-395M20.7	-4.32	2.01e-05	0.00483	-0.24	-0.23	Ulcerative colitis;	chr1:2596694	chr1:2566410~2569888:+
LIHC	cis	rs748404	0.697	rs471122	ENSG00000166763.7	STRCP1	-4.32	2.01e-05	0.00483	-0.28	-0.23	Lung cancer;	chr15:43266376	chr15:43699488~43718184:-
LIHC	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	4.32	2.01e-05	0.00484	0.16	0.23	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
LIHC	cis	rs9527	0.615	rs4919685	ENSG00000236937.2	PTGES3P4	4.32	2.01e-05	0.00484	0.34	0.23	Arsenic metabolism;	chr10:102827605	chr10:102845595~102845950:+
LIHC	cis	rs728616	0.867	rs55835350	ENSG00000225484.5	NUTM2B-AS1	-4.32	2.01e-05	0.00484	-0.52	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.867	rs79904324	ENSG00000225484.5	NUTM2B-AS1	-4.32	2.01e-05	0.00484	-0.52	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.867	rs41297151	ENSG00000225484.5	NUTM2B-AS1	-4.32	2.01e-05	0.00484	-0.52	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.867	rs17096197	ENSG00000225484.5	NUTM2B-AS1	-4.32	2.01e-05	0.00484	-0.52	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:79663088~79826594:-
LIHC	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-4.32	2.02e-05	0.00485	-0.24	-0.23	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
LIHC	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-4.32	2.02e-05	0.00485	-0.3	-0.23	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
LIHC	cis	rs734999	0.588	rs2764848	ENSG00000225931.3	RP3-395M20.7	-4.32	2.02e-05	0.00485	-0.24	-0.23	Ulcerative colitis;	chr1:2599255	chr1:2566410~2569888:+
LIHC	cis	rs2797160	0.904	rs2326292	ENSG00000237742.5	RP11-624M8.1	-4.32	2.02e-05	0.00485	-0.23	-0.23	Endometrial cancer;	chr6:125678528	chr6:125578558~125749190:-
LIHC	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-4.32	2.02e-05	0.00485	-0.18	-0.23	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
LIHC	cis	rs9843304	0.529	rs72996050	ENSG00000244503.1	RP11-278L15.6	4.32	2.02e-05	0.00485	0.23	0.23	Gallstone disease;	chr3:149484846	chr3:149494660~149495995:+
LIHC	cis	rs2998286	1	rs2998286	ENSG00000254635.4	WAC-AS1	-4.32	2.02e-05	0.00485	-0.24	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491444	chr10:28522652~28532743:-
LIHC	cis	rs75920871	0.614	rs117287138	ENSG00000254851.1	RP11-109L13.1	-4.32	2.02e-05	0.00485	-0.48	-0.23	Subjective well-being;	chr11:116924163	chr11:117135528~117138582:+
LIHC	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-4.32	2.02e-05	0.00485	-0.29	-0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
LIHC	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-4.32	2.02e-05	0.00486	-0.22	-0.23	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
LIHC	cis	rs4650994	1	rs4077194	ENSG00000273384.1	RP5-1098D14.1	-4.32	2.02e-05	0.00486	-0.26	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178564697	chr1:178651706~178652282:+
LIHC	cis	rs11098499	0.909	rs11723757	ENSG00000260091.1	RP11-33B1.4	-4.32	2.02e-05	0.00486	-0.17	-0.23	Corneal astigmatism;	chr4:119378514	chr4:119409333~119410233:+
LIHC	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-4.32	2.02e-05	0.00486	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-4.32	2.02e-05	0.00486	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-4.32	2.02e-05	0.00486	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
LIHC	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-4.32	2.02e-05	0.00486	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
LIHC	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-4.32	2.03e-05	0.00487	-0.23	-0.23	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
LIHC	cis	rs11098499	0.865	rs11098513	ENSG00000260091.1	RP11-33B1.4	-4.32	2.03e-05	0.00487	-0.17	-0.23	Corneal astigmatism;	chr4:119394920	chr4:119409333~119410233:+
LIHC	cis	rs1160985	1	rs1160985	ENSG00000214855.8	APOC1P1	-4.32	2.03e-05	0.00487	-0.27	-0.23	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44900155	chr19:44926804~44931386:+
LIHC	cis	rs8024893	1	rs6493544	ENSG00000270055.1	CTD-3092A11.2	4.32	2.03e-05	0.00487	0.32	0.23	Red cell distribution width;	chr15:31245356	chr15:30487963~30490313:+
LIHC	cis	rs2412819	0.599	rs2470120	ENSG00000275601.1	AC011330.13	-4.32	2.03e-05	0.00488	-0.28	-0.23	Lung cancer;	chr15:43636872	chr15:43642389~43643023:-
LIHC	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	4.32	2.03e-05	0.00488	0.19	0.23	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
LIHC	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-4.32	2.03e-05	0.00488	-0.25	-0.23	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
LIHC	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-4.32	2.04e-05	0.00489	-0.29	-0.23	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-4.32	2.04e-05	0.00489	-0.29	-0.23	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
LIHC	cis	rs948562	1	rs76435840	ENSG00000280010.1	AP001350.4	4.32	2.04e-05	0.00489	0.4	0.23	Lymphoma;	chr11:58518508	chr11:58627435~58628528:+
LIHC	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-4.32	2.04e-05	0.00489	-0.35	-0.23	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
LIHC	cis	rs2337406	0.925	rs873533	ENSG00000274576.2	IGHV2-70	-4.32	2.04e-05	0.00489	-0.26	-0.23	Alzheimer's disease (late onset);	chr14:106667442	chr14:106770577~106771020:-
LIHC	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-4.32	2.04e-05	0.00489	-0.27	-0.23	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
LIHC	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-4.32	2.04e-05	0.00489	-0.32	-0.23	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-4.32	2.04e-05	0.00489	-0.32	-0.23	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
LIHC	cis	rs748404	0.631	rs7167882	ENSG00000166763.7	STRCP1	4.32	2.04e-05	0.00489	0.28	0.23	Lung cancer;	chr15:43386465	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.863	rs13136462	ENSG00000260091.1	RP11-33B1.4	-4.32	2.04e-05	0.00489	-0.16	-0.23	Corneal astigmatism;	chr4:119622018	chr4:119409333~119410233:+
LIHC	cis	rs28829049	0.57	rs12060125	ENSG00000270728.1	RP4-657E11.10	4.32	2.04e-05	0.0049	0.21	0.23	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19064614	chr1:19297080~19297903:+
LIHC	cis	rs875971	0.545	rs2460427	ENSG00000228409.4	CCT6P1	4.32	2.04e-05	0.0049	0.19	0.23	Aortic root size;	chr7:66154218	chr7:65751142~65763354:+
LIHC	cis	rs7809950	0.678	rs7803151	ENSG00000238832.1	snoU109	-4.32	2.04e-05	0.0049	-0.29	-0.23	Coronary artery disease;	chr7:107293801	chr7:107603363~107603507:+
LIHC	cis	rs2688482	0.557	rs3103952	ENSG00000185485.13	SDHAP1	4.32	2.04e-05	0.0049	0.26	0.23	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195959748~195990318:-
LIHC	cis	rs12478296	0.901	rs6731775	ENSG00000261186.2	RP11-341N2.1	-4.32	2.04e-05	0.0049	-0.31	-0.23	Obesity-related traits;	chr2:242057292	chr2:242087351~242088457:-
LIHC	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	4.32	2.04e-05	0.0049	0.26	0.23	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
LIHC	cis	rs960902	0.818	rs4353628	ENSG00000213553.4	RPLP0P6	-4.32	2.04e-05	0.0049	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37512369	chr2:38481851~38482804:+
LIHC	cis	rs3015497	0.616	rs6572678	ENSG00000269906.1	RP11-248J18.2	4.32	2.05e-05	0.00491	0.28	0.23	Mean platelet volume;	chr14:50623397	chr14:50662511~50663178:-
LIHC	cis	rs3015497	0.616	rs4901044	ENSG00000269906.1	RP11-248J18.2	4.32	2.05e-05	0.00491	0.28	0.23	Mean platelet volume;	chr14:50623577	chr14:50662511~50663178:-
LIHC	cis	rs2929278	0.589	rs2411284	ENSG00000275601.1	AC011330.13	4.32	2.05e-05	0.00491	0.28	0.23	Schizophrenia;	chr15:43746701	chr15:43642389~43643023:-
LIHC	cis	rs960902	0.592	rs4503968	ENSG00000213553.4	RPLP0P6	-4.32	2.05e-05	0.00491	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37507073	chr2:38481851~38482804:+
LIHC	cis	rs4356203	0.875	rs11024136	ENSG00000260196.1	RP1-239B22.5	-4.32	2.05e-05	0.00491	-0.28	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17042850	chr11:17380649~17383531:+
LIHC	cis	rs831571	1	rs17069791	ENSG00000280620.1	SCAANT1	4.32	2.05e-05	0.00491	0.36	0.23	Type 2 diabetes;	chr3:64066603	chr3:63911518~63911772:-
LIHC	cis	rs7044106	0.762	rs13291660	ENSG00000238181.2	AHCYP2	-4.32	2.05e-05	0.00491	-0.26	-0.23	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120720673~120721972:+
LIHC	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-4.32	2.05e-05	0.00491	-0.37	-0.23	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
LIHC	cis	rs2717559	0.542	rs34147336	ENSG00000253196.1	RP11-706C16.7	-4.32	2.05e-05	0.00491	-0.26	-0.23	Urinary tract infection frequency;	chr8:142803453	chr8:142763116~142766427:+
LIHC	cis	rs11098499	0.722	rs28713555	ENSG00000260091.1	RP11-33B1.4	-4.32	2.05e-05	0.00491	-0.16	-0.23	Corneal astigmatism;	chr4:119330840	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.743	rs11098501	ENSG00000260091.1	RP11-33B1.4	-4.32	2.05e-05	0.00491	-0.16	-0.23	Corneal astigmatism;	chr4:119330862	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs11098502	ENSG00000260091.1	RP11-33B1.4	-4.32	2.05e-05	0.00491	-0.16	-0.23	Corneal astigmatism;	chr4:119330908	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.708	rs11732686	ENSG00000260091.1	RP11-33B1.4	-4.32	2.05e-05	0.00491	-0.16	-0.23	Corneal astigmatism;	chr4:119331175	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs11724409	ENSG00000260091.1	RP11-33B1.4	-4.32	2.05e-05	0.00491	-0.16	-0.23	Corneal astigmatism;	chr4:119331206	chr4:119409333~119410233:+
LIHC	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	4.32	2.05e-05	0.00492	0.25	0.23	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
LIHC	cis	rs960902	0.592	rs4450582	ENSG00000213553.4	RPLP0P6	-4.32	2.05e-05	0.00492	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37506998	chr2:38481851~38482804:+
LIHC	cis	rs2243480	1	rs4718334	ENSG00000230295.1	RP11-458F8.2	4.32	2.05e-05	0.00492	0.23	0.23	Diabetic kidney disease;	chr7:66324467	chr7:66880708~66882981:+
LIHC	cis	rs417065	1	rs72635712	ENSG00000227634.1	RP11-431K24.3	-4.32	2.06e-05	0.00493	-0.31	-0.23	Psoriasis;	chr1:8199415	chr1:8208672~8215210:+
LIHC	cis	rs1005277	0.579	rs2103938	ENSG00000099251.13	HSD17B7P2	4.32	2.06e-05	0.00493	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38356380~38378505:+
LIHC	cis	rs9595908	0.645	rs7983065	ENSG00000212293.1	SNORA16	4.32	2.06e-05	0.00493	0.27	0.23	Body mass index;	chr13:32806648	chr13:32420390~32420516:-
LIHC	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	4.32	2.06e-05	0.00493	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
LIHC	cis	rs9388451	0.626	rs3734637	ENSG00000237742.5	RP11-624M8.1	-4.32	2.06e-05	0.00493	-0.21	-0.23	Brugada syndrome;	chr6:125760173	chr6:125578558~125749190:-
LIHC	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	4.32	2.06e-05	0.00493	0.2	0.23	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
LIHC	cis	rs2032447	0.61	rs189911	ENSG00000242387.1	HIST1H2APS2	4.32	2.06e-05	0.00494	0.29	0.23	Intelligence (multi-trait analysis);	chr6:25965714	chr6:25882026~25882395:-
LIHC	cis	rs748404	0.66	rs2467742	ENSG00000166763.7	STRCP1	4.32	2.06e-05	0.00494	0.28	0.23	Lung cancer;	chr15:43458039	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.69	rs2244981	ENSG00000166763.7	STRCP1	4.32	2.06e-05	0.00494	0.28	0.23	Lung cancer;	chr15:43460553	chr15:43699488~43718184:-
LIHC	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-4.32	2.06e-05	0.00494	-0.18	-0.23	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
LIHC	cis	rs9457247	0.967	rs1794696	ENSG00000227598.1	RP1-167A14.2	-4.32	2.07e-05	0.00495	-0.24	-0.23	Crohn's disease;	chr6:166982686	chr6:166969626~166999065:-
LIHC	cis	rs1928295	0.786	rs957512	ENSG00000233569.1	RP11-500B12.1	4.32	2.07e-05	0.00495	0.24	0.23	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117643427	chr9:117648606~117657027:+
LIHC	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-4.32	2.07e-05	0.00495	-0.28	-0.23	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
LIHC	cis	rs6471393	0.861	rs2976372	ENSG00000253848.1	RP11-10N23.5	-4.32	2.07e-05	0.00495	-0.25	-0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93690797	chr8:93741193~93744534:+
LIHC	cis	rs1499614	1	rs1267818	ENSG00000232546.1	RP11-458F8.1	-4.32	2.07e-05	0.00495	-0.26	-0.23	Gout;	chr7:66642037	chr7:66848496~66858136:+
LIHC	cis	rs13287066	0.669	rs10992728	ENSG00000227603.1	RP11-165J3.6	4.32	2.07e-05	0.00495	0.25	0.23	Intelligence (multi-trait analysis);	chr9:93416386	chr9:93435332~93437121:-
LIHC	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	4.32	2.07e-05	0.00495	0.23	0.23	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
LIHC	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-4.32	2.07e-05	0.00496	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
LIHC	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-4.32	2.07e-05	0.00496	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
LIHC	cis	rs61041384	0.661	rs3759111	ENSG00000256092.2	RP13-942N8.1	4.32	2.07e-05	0.00496	0.35	0.23	Schizophrenia;	chr12:123203227	chr12:123363868~123366113:+
LIHC	cis	rs703842	1	rs2069502	ENSG00000270039.1	RP11-571M6.17	4.32	2.07e-05	0.00496	0.33	0.23	Multiple sclerosis;	chr12:57750882	chr12:57803838~57804415:+
LIHC	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	4.32	2.07e-05	0.00496	0.26	0.23	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
LIHC	cis	rs3812762	0.917	rs2873297	ENSG00000254860.4	TMEM9B-AS1	-4.32	2.07e-05	0.00496	-0.24	-0.23	Hypospadias;	chr11:8769680	chr11:8964675~8977527:+
LIHC	cis	rs11098499	0.82	rs6829903	ENSG00000260091.1	RP11-33B1.4	-4.32	2.07e-05	0.00496	-0.16	-0.23	Corneal astigmatism;	chr4:119585729	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs7669520	ENSG00000260091.1	RP11-33B1.4	-4.32	2.07e-05	0.00496	-0.16	-0.23	Corneal astigmatism;	chr4:119594123	chr4:119409333~119410233:+
LIHC	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-4.32	2.07e-05	0.00496	-0.27	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
LIHC	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.08e-05	0.00497	-0.22	-0.23	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-4.32	2.08e-05	0.00497	-0.22	-0.23	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
LIHC	cis	rs7412746	0.658	rs10305714	ENSG00000231073.1	RP11-316M1.3	-4.32	2.08e-05	0.00497	-0.22	-0.23	Melanoma;	chr1:150828179	chr1:150973123~150975534:+
LIHC	cis	rs11064837	0.504	rs7310536	ENSG00000248636.5	RP11-768F21.1	4.32	2.08e-05	0.00497	0.35	0.23	Schizophrenia;	chr12:119616268	chr12:119387987~119668079:-
LIHC	cis	rs11064837	0.504	rs7972445	ENSG00000248636.5	RP11-768F21.1	4.32	2.08e-05	0.00497	0.35	0.23	Schizophrenia;	chr12:119617604	chr12:119387987~119668079:-
LIHC	cis	rs13315871	1	rs9850717	ENSG00000272182.1	RP11-802O23.3	4.32	2.08e-05	0.00497	0.53	0.23	Cholesterol, total;	chr3:58366148	chr3:58428255~58428815:+
LIHC	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	4.32	2.08e-05	0.00497	0.34	0.23	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
LIHC	cis	rs7044106	0.718	rs1981021	ENSG00000238181.2	AHCYP2	-4.32	2.08e-05	0.00497	-0.26	-0.23	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.734	rs1981020	ENSG00000238181.2	AHCYP2	-4.32	2.08e-05	0.00497	-0.26	-0.23	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120720673~120721972:+
LIHC	cis	rs60733400	0.782	rs4648564	ENSG00000225931.3	RP3-395M20.7	-4.32	2.08e-05	0.00497	-0.24	-0.23	Multiple sclerosis;	chr1:2630730	chr1:2566410~2569888:+
LIHC	cis	rs1005277	0.557	rs2983338	ENSG00000099251.13	HSD17B7P2	4.32	2.08e-05	0.00498	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38356380~38378505:+
LIHC	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-4.32	2.08e-05	0.00498	-0.23	-0.23	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
LIHC	cis	rs8064024	0.87	rs6500635	ENSG00000267077.1	RP11-127I20.5	4.32	2.08e-05	0.00498	0.23	0.23	Cancer;	chr16:4817564	chr16:4795265~4796532:-
LIHC	cis	rs9450351	0.744	rs9362247	ENSG00000203875.9	SNHG5	-4.32	2.08e-05	0.00498	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85822546	chr6:85660950~85678736:-
LIHC	cis	rs9450351	0.744	rs6913958	ENSG00000203875.9	SNHG5	-4.32	2.08e-05	0.00498	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85825481	chr6:85660950~85678736:-
LIHC	cis	rs6439153	0.967	rs61480393	ENSG00000231305.3	RP11-723O4.2	4.32	2.09e-05	0.00498	0.25	0.23	Pneumococcal bacteremia;	chr3:128980916	chr3:128861313~128871540:-
LIHC	cis	rs6439153	1	rs6439153	ENSG00000231305.3	RP11-723O4.2	4.32	2.09e-05	0.00498	0.25	0.23	Pneumococcal bacteremia;	chr3:128982287	chr3:128861313~128871540:-
LIHC	cis	rs1005277	0.563	rs2505215	ENSG00000275858.1	RP11-291L22.8	4.32	2.09e-05	0.00499	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.563	rs2505216	ENSG00000275858.1	RP11-291L22.8	4.32	2.09e-05	0.00499	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.563	rs2800550	ENSG00000275858.1	RP11-291L22.8	4.32	2.09e-05	0.00499	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs2749612	ENSG00000275858.1	RP11-291L22.8	4.32	2.09e-05	0.00499	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38450738~38451069:-
LIHC	cis	rs1400745	0.812	rs72678789	ENSG00000258738.1	RP11-73E17.2	-4.32	2.09e-05	0.00499	-0.28	-0.23	Monocyte count;	chr14:34878995	chr14:34874343~34876459:+
LIHC	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-4.32	2.09e-05	0.00499	-0.25	-0.23	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
LIHC	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-4.32	2.09e-05	0.00499	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
LIHC	cis	rs7580658	0.545	rs59318157	ENSG00000236682.1	AC068282.3	-4.32	2.09e-05	0.00499	-0.28	-0.23	Protein C levels;	chr2:127192498	chr2:127389130~127400580:+
LIHC	cis	rs7702057	0.53	rs17138850	ENSG00000271918.1	CTD-2287O16.5	4.32	2.09e-05	0.005	0.31	0.23	Amyotrophic lateral sclerosis;	chr5:116085317	chr5:116083807~116085416:-
LIHC	cis	rs6723226	0.638	rs6543657	ENSG00000276334.1	AL133243.1	4.31	2.09e-05	0.005	0.25	0.23	Intelligence (multi-trait analysis);	chr2:32480017	chr2:32521927~32523547:+
LIHC	cis	rs901683	1	rs9422651	ENSG00000230869.1	CTGLF10P	-4.31	2.09e-05	0.005	-0.53	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45552008	chr10:45678692~45700532:+
LIHC	cis	rs948562	1	rs948562	ENSG00000280010.1	AP001350.4	4.31	2.09e-05	0.005	0.39	0.23	Lymphoma;	chr11:58580292	chr11:58627435~58628528:+
LIHC	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	4.31	2.09e-05	0.005	0.28	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
LIHC	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-4.31	2.09e-05	0.005	-0.26	-0.23	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
LIHC	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-4.31	2.1e-05	0.005	-0.31	-0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
LIHC	cis	rs7193541	0.826	rs56143602	ENSG00000261079.1	RP11-252A24.3	4.31	2.1e-05	0.005	0.25	0.23	Multiple myeloma;	chr16:74660794	chr16:74367462~74369826:+
LIHC	cis	rs11098499	0.754	rs12711071	ENSG00000260091.1	RP11-33B1.4	-4.31	2.1e-05	0.00501	-0.16	-0.23	Corneal astigmatism;	chr4:119319779	chr4:119409333~119410233:+
LIHC	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	4.31	2.1e-05	0.00501	0.26	0.23	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
LIHC	cis	rs1144713	0.6	rs2683489	ENSG00000276115.1	RP11-817I4.2	-4.31	2.1e-05	0.00501	-0.24	-0.23	Obesity-related traits;	chr12:32098247	chr12:32352349~32354144:+
LIHC	cis	rs7044106	0.762	rs7044226	ENSG00000238181.2	AHCYP2	-4.31	2.1e-05	0.00501	-0.26	-0.23	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120720673~120721972:+
LIHC	cis	rs734999	0.588	rs2843402	ENSG00000225931.3	RP3-395M20.7	-4.31	2.1e-05	0.00501	-0.24	-0.23	Ulcerative colitis;	chr1:2597243	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.588	rs2764842	ENSG00000225931.3	RP3-395M20.7	-4.31	2.1e-05	0.00501	-0.24	-0.23	Ulcerative colitis;	chr1:2597753	chr1:2566410~2569888:+
LIHC	cis	rs9595908	0.622	rs7983267	ENSG00000212293.1	SNORA16	4.31	2.1e-05	0.00501	0.26	0.23	Body mass index;	chr13:32806767	chr13:32420390~32420516:-
LIHC	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-4.31	2.1e-05	0.00501	-0.28	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
LIHC	cis	rs9595908	0.965	rs11840502	ENSG00000212293.1	SNORA16	4.31	2.1e-05	0.00502	0.26	0.23	Body mass index;	chr13:32624572	chr13:32420390~32420516:-
LIHC	cis	rs2739330	0.685	rs4822453	ENSG00000206090.4	AP000350.7	4.31	2.1e-05	0.00502	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23939998~23942798:+
LIHC	cis	rs494453	0.885	rs496296	ENSG00000227811.2	FAM212B-AS1	-4.31	2.1e-05	0.00502	-0.26	-0.23	Osteoporosis-related phenotypes;	chr1:111682034	chr1:111739841~111747798:+
LIHC	cis	rs494453	0.883	rs1099800	ENSG00000227811.2	FAM212B-AS1	-4.31	2.1e-05	0.00502	-0.26	-0.23	Osteoporosis-related phenotypes;	chr1:111682961	chr1:111739841~111747798:+
LIHC	cis	rs2877649	0.793	rs3814810	ENSG00000258744.1	RP11-80A15.1	-4.31	2.1e-05	0.00502	-0.47	-0.23	Smooth-surface caries;	chr14:24439189	chr14:24501594~24508688:+
LIHC	cis	rs901683	1	rs71496622	ENSG00000230869.1	CTGLF10P	-4.31	2.11e-05	0.00503	-0.55	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45586140	chr10:45678692~45700532:+
LIHC	cis	rs11098499	0.71	rs4145952	ENSG00000260091.1	RP11-33B1.4	-4.31	2.11e-05	0.00503	-0.16	-0.23	Corneal astigmatism;	chr4:119234651	chr4:119409333~119410233:+
LIHC	cis	rs734999	0.588	rs2843404	ENSG00000225931.3	RP3-395M20.7	-4.31	2.11e-05	0.00503	-0.24	-0.23	Ulcerative colitis;	chr1:2599119	chr1:2566410~2569888:+
LIHC	cis	rs17818399	0.926	rs7590693	ENSG00000279254.1	RP11-536C12.1	-4.31	2.11e-05	0.00503	-0.28	-0.23	Height;	chr2:46596853	chr2:46668870~46670778:+
LIHC	cis	rs2243480	1	rs2420170	ENSG00000230295.1	RP11-458F8.2	4.31	2.11e-05	0.00503	0.24	0.23	Diabetic kidney disease;	chr7:66191066	chr7:66880708~66882981:+
LIHC	cis	rs5756813	0.688	rs5995498	ENSG00000233360.4	Z83844.1	4.31	2.11e-05	0.00503	0.28	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37800566	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.661	rs7286550	ENSG00000233360.4	Z83844.1	4.31	2.11e-05	0.00503	0.28	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37800753	chr22:37641832~37658377:-
LIHC	cis	rs7119038	0.818	rs715412	ENSG00000255239.1	AP002954.6	-4.31	2.11e-05	0.00503	-0.33	-0.23	Sjögren's syndrome;	chr11:118813901	chr11:118688039~118690600:-
LIHC	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-4.31	2.11e-05	0.00504	-0.23	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
LIHC	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-4.31	2.11e-05	0.00504	-0.22	-0.23	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-4.31	2.11e-05	0.00504	-0.22	-0.23	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-4.31	2.11e-05	0.00504	-0.22	-0.23	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
LIHC	cis	rs7131987	1	rs7131987	ENSG00000257176.2	RP11-996F15.2	-4.31	2.11e-05	0.00504	-0.26	-0.23	QT interval;	chr12:29253555	chr12:29280418~29317848:-
LIHC	cis	rs11098499	0.863	rs59732491	ENSG00000260091.1	RP11-33B1.4	-4.31	2.11e-05	0.00504	-0.16	-0.23	Corneal astigmatism;	chr4:119568433	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs11723090	ENSG00000260091.1	RP11-33B1.4	-4.31	2.11e-05	0.00504	-0.16	-0.23	Corneal astigmatism;	chr4:119569437	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs11098532	ENSG00000260091.1	RP11-33B1.4	-4.31	2.11e-05	0.00504	-0.16	-0.23	Corneal astigmatism;	chr4:119569571	chr4:119409333~119410233:+
LIHC	cis	rs1005277	0.522	rs9418276	ENSG00000099251.13	HSD17B7P2	4.31	2.11e-05	0.00504	0.26	0.23	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.522	rs7072977	ENSG00000099251.13	HSD17B7P2	4.31	2.11e-05	0.00504	0.26	0.23	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38356380~38378505:+
LIHC	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	4.31	2.11e-05	0.00504	0.26	0.23	Height;	chr4:55409063	chr4:55363971~55395847:-
LIHC	cis	rs11951515	0.508	rs10059993	ENSG00000248240.1	RP11-159F24.5	-4.31	2.11e-05	0.00504	-0.28	-0.23	Metabolite levels  (X-11787);	chr5:43598250	chr5:43515274~43525310:+
LIHC	cis	rs7208859	0.623	rs122898	ENSG00000264538.5	SUZ12P1	4.31	2.11e-05	0.00504	0.23	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30709299~30790908:+
LIHC	cis	rs2439831	0.85	rs3816792	ENSG00000166763.7	STRCP1	-4.31	2.12e-05	0.00505	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43824788	chr15:43699488~43718184:-
LIHC	cis	rs73193808	0.639	rs2832248	ENSG00000212479.2	U3	4.31	2.12e-05	0.00505	0.26	0.23	Coronary artery disease;	chr21:29184660	chr21:29180425~29180639:-
LIHC	cis	rs79349575	0.721	rs9904645	ENSG00000248278.1	SUMO2P17	4.31	2.12e-05	0.00505	0.28	0.23	Type 2 diabetes;	chr17:48892303	chr17:48874860~48908983:-
LIHC	cis	rs7129556	0.69	rs695046	ENSG00000254459.1	RP11-91P24.7	4.31	2.12e-05	0.00506	0.38	0.23	Weight loss (gastric bypass surgery);	chr11:77883308	chr11:77829654~77872262:-
LIHC	cis	rs9467711	0.651	rs2237228	ENSG00000216436.2	HIST1H2APS1	4.31	2.12e-05	0.00506	0.6	0.23	Autism spectrum disorder or schizophrenia;	chr6:26104402	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.722	rs35825164	ENSG00000216436.2	HIST1H2APS1	4.31	2.12e-05	0.00506	0.6	0.23	Autism spectrum disorder or schizophrenia;	chr6:26117176	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs13206443	ENSG00000216436.2	HIST1H2APS1	4.31	2.12e-05	0.00506	0.6	0.23	Autism spectrum disorder or schizophrenia;	chr6:26119017	chr6:25732497~25732827:+
LIHC	cis	rs4792901	0.659	rs8073121	ENSG00000267747.1	RP11-392O1.4	-4.31	2.12e-05	0.00506	-0.27	-0.23	Dupuytren's disease;	chr17:43465554	chr17:43544785~43610338:+
LIHC	cis	rs2072510	0.722	rs2540489	ENSG00000257878.1	RP11-256L6.3	-4.31	2.12e-05	0.00506	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96032724	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.683	rs2246990	ENSG00000257878.1	RP11-256L6.3	-4.31	2.12e-05	0.00506	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96033524	chr12:95996521~96011489:+
LIHC	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-4.31	2.12e-05	0.00506	-0.26	-0.23	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
LIHC	cis	rs860295	0.58	rs12032720	ENSG00000203761.5	MSTO2P	-4.31	2.12e-05	0.00506	-0.19	-0.23	Body mass index;	chr1:155305169	chr1:155745829~155750137:+
LIHC	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-4.31	2.12e-05	0.00506	-0.27	-0.23	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-4.31	2.12e-05	0.00506	-0.27	-0.23	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-4.31	2.12e-05	0.00506	-0.27	-0.23	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-4.31	2.12e-05	0.00506	-0.27	-0.23	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-4.31	2.12e-05	0.00506	-0.27	-0.23	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
LIHC	cis	rs916888	0.647	rs199523	ENSG00000260075.1	NSFP1	-4.31	2.12e-05	0.00506	-0.28	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46372855~46487141:+
LIHC	cis	rs7474896	0.583	rs10764144	ENSG00000263064.2	RP11-291L22.7	4.31	2.13e-05	0.00507	0.27	0.23	Obesity (extreme);	chr10:37686804	chr10:38448689~38448949:+
LIHC	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-4.31	2.13e-05	0.00507	-0.29	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
LIHC	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-4.31	2.13e-05	0.00507	-0.29	-0.23	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
LIHC	cis	rs4700393	0.967	rs921897	ENSG00000272308.1	RP11-231G3.1	-4.31	2.13e-05	0.00507	-0.27	-0.23	Intelligence (multi-trait analysis);	chr5:60793310	chr5:60866457~60866935:-
LIHC	cis	rs11874381	0.582	rs8093891	ENSG00000267322.2	SNHG22	4.31	2.13e-05	0.00507	0.27	0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49680213	chr18:49814023~49851059:+
LIHC	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-4.31	2.13e-05	0.00507	-0.23	-0.23	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
LIHC	cis	rs10801727	0.597	rs4658174	ENSG00000225492.5	GBP1P1	-4.31	2.13e-05	0.00507	-0.22	-0.23	Parental extreme longevity (95 years and older);	chr1:89446540	chr1:89407679~89426243:+
LIHC	cis	rs10801727	0.597	rs1599152	ENSG00000225492.5	GBP1P1	-4.31	2.13e-05	0.00507	-0.22	-0.23	Parental extreme longevity (95 years and older);	chr1:89448737	chr1:89407679~89426243:+
LIHC	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-4.31	2.13e-05	0.00508	-0.26	-0.23	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
LIHC	cis	rs875971	0.545	rs7783889	ENSG00000273142.1	RP11-458F8.4	4.31	2.13e-05	0.00508	0.22	0.23	Aortic root size;	chr7:66283366	chr7:66902857~66906297:+
LIHC	cis	rs901683	1	rs9422655	ENSG00000230869.1	CTGLF10P	-4.31	2.13e-05	0.00508	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45555960	chr10:45678692~45700532:+
LIHC	cis	rs748404	0.66	rs2444251	ENSG00000166763.7	STRCP1	4.31	2.13e-05	0.00508	0.28	0.23	Lung cancer;	chr15:43496397	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.66	rs548704	ENSG00000166763.7	STRCP1	4.31	2.13e-05	0.00508	0.28	0.23	Lung cancer;	chr15:43499508	chr15:43699488~43718184:-
LIHC	cis	rs11971779	0.68	rs4732379	ENSG00000273391.1	RP11-634H22.1	4.31	2.13e-05	0.00508	0.21	0.23	Diisocyanate-induced asthma;	chr7:139438068	chr7:139359032~139359566:-
LIHC	cis	rs7726839	0.54	rs3792720	ENSG00000271781.1	CTD-2589H19.6	-4.31	2.14e-05	0.00509	-0.34	-0.23	Obesity-related traits;	chr5:642913	chr5:675826~676616:+
LIHC	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	4.31	2.14e-05	0.00509	0.36	0.23	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
LIHC	cis	rs10129255	1	rs4612959	ENSG00000224373.3	IGHV4-59	4.31	2.14e-05	0.00509	0.18	0.23	Kawasaki disease;	chr14:106767055	chr14:106627249~106627825:-
LIHC	cis	rs244293	0.831	rs12453699	ENSG00000275710.1	RP11-257O5.4	-4.31	2.14e-05	0.00509	-0.24	-0.23	Menarche (age at onset);	chr17:55094485	chr17:54964474~54964679:+
LIHC	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	4.31	2.14e-05	0.0051	0.27	0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
LIHC	cis	rs2749592	0.531	rs1208559	ENSG00000276805.1	RP11-291L22.6	-4.31	2.14e-05	0.0051	-0.27	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38451030~38451785:+
LIHC	cis	rs2808510	0.756	rs6427827	ENSG00000230623.2	RP11-469A15.2	4.31	2.14e-05	0.0051	0.26	0.23	Myopia;	chr1:200429259	chr1:200473920~200478293:+
LIHC	cis	rs4356975	0.932	rs4694611	ENSG00000250919.1	RP11-813N20.3	-4.31	2.14e-05	0.0051	-0.22	-0.23	Obesity-related traits;	chr4:69079387	chr4:69027831~69044578:+
LIHC	cis	rs812925	0.559	rs2600667	ENSG00000212978.6	AC016747.3	-4.31	2.14e-05	0.0051	-0.25	-0.23	Immature fraction of reticulocytes;	chr2:61177796	chr2:61141592~61144969:-
LIHC	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	4.31	2.14e-05	0.0051	0.31	0.23	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
LIHC	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	4.31	2.14e-05	0.0051	0.31	0.23	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
LIHC	cis	rs2932538	0.885	rs6693880	ENSG00000225075.1	RP11-426L16.3	4.31	2.15e-05	0.00511	0.29	0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112567639	chr1:112693688~112696621:-
LIHC	cis	rs10912872	0.672	rs7516677	ENSG00000231424.2	RP1-45C12.1	4.31	2.15e-05	0.00511	0.24	0.23	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171372697	chr1:171247580~171251794:-
LIHC	cis	rs651907	0.557	rs12629954	ENSG00000244119.1	PDCL3P4	4.31	2.15e-05	0.00511	0.23	0.23	Colorectal cancer;	chr3:101641779	chr3:101712472~101713191:+
LIHC	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-4.31	2.15e-05	0.00511	-0.37	-0.23	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
LIHC	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	4.31	2.15e-05	0.00511	0.36	0.23	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
LIHC	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	4.31	2.15e-05	0.00511	0.36	0.23	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
LIHC	cis	rs10129255	0.879	rs7160512	ENSG00000211970.3	IGHV4-61	-4.31	2.15e-05	0.00511	-0.17	-0.23	Kawasaki disease;	chr14:106694574	chr14:106639119~106639657:-
LIHC	cis	rs10129255	0.879	rs7159157	ENSG00000211970.3	IGHV4-61	-4.31	2.15e-05	0.00511	-0.17	-0.23	Kawasaki disease;	chr14:106694578	chr14:106639119~106639657:-
LIHC	cis	rs6480314	0.522	rs10762212	ENSG00000233590.1	RP11-153K11.3	4.31	2.15e-05	0.00511	0.36	0.23	Optic nerve measurement (disc area);	chr10:68295190	chr10:68233251~68242379:-
LIHC	cis	rs5756813	0.661	rs6000898	ENSG00000233360.4	Z83844.1	4.31	2.15e-05	0.00512	0.28	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37806392	chr22:37641832~37658377:-
LIHC	cis	rs5756813	0.635	rs6000899	ENSG00000233360.4	Z83844.1	4.31	2.15e-05	0.00512	0.28	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37807789	chr22:37641832~37658377:-
LIHC	cis	rs4561483	0.831	rs2018199	ENSG00000261560.1	RP11-166B2.3	-4.31	2.15e-05	0.00512	-0.25	-0.23	Testicular germ cell tumor;	chr16:11847111	chr16:11881075~11882569:-
LIHC	cis	rs295490	0.748	rs17494356	ENSG00000272656.1	RP11-219D15.3	4.31	2.15e-05	0.00512	0.68	0.23	PR interval in Tripanosoma cruzi seropositivity;	chr3:139465126	chr3:139349024~139349371:-
LIHC	cis	rs651907	0.557	rs62284198	ENSG00000244119.1	PDCL3P4	4.31	2.15e-05	0.00512	0.23	0.23	Colorectal cancer;	chr3:101755855	chr3:101712472~101713191:+
LIHC	cis	rs4718428	1	rs1830070	ENSG00000273142.1	RP11-458F8.4	-4.31	2.15e-05	0.00512	-0.22	-0.23	Corneal structure;	chr7:66884684	chr7:66902857~66906297:+
LIHC	cis	rs1005277	0.529	rs1780125	ENSG00000099251.13	HSD17B7P2	4.31	2.15e-05	0.00512	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.502	rs2800484	ENSG00000099251.13	HSD17B7P2	4.31	2.15e-05	0.00512	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs2800485	ENSG00000099251.13	HSD17B7P2	4.31	2.15e-05	0.00512	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38356380~38378505:+
LIHC	cis	rs2337406	0.714	rs7152055	ENSG00000274576.2	IGHV2-70	-4.31	2.16e-05	0.00513	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106818996	chr14:106770577~106771020:-
LIHC	cis	rs12946454	0.727	rs4792858	ENSG00000267288.2	RP13-890H12.2	-4.31	2.16e-05	0.00513	-0.25	-0.23	Systolic blood pressure;	chr17:45167333	chr17:45168800~45171584:-
LIHC	cis	rs734999	0.545	rs6666430	ENSG00000225931.3	RP3-395M20.7	4.31	2.16e-05	0.00513	0.24	0.23	Ulcerative colitis;	chr1:2782407	chr1:2566410~2569888:+
LIHC	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	4.31	2.16e-05	0.00513	0.23	0.23	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
LIHC	cis	rs875971	0.545	rs17138156	ENSG00000228409.4	CCT6P1	-4.31	2.16e-05	0.00514	-0.19	-0.23	Aortic root size;	chr7:66249708	chr7:65751142~65763354:+
LIHC	cis	rs11098499	0.644	rs3806808	ENSG00000260091.1	RP11-33B1.4	-4.31	2.16e-05	0.00514	-0.16	-0.23	Corneal astigmatism;	chr4:119629930	chr4:119409333~119410233:+
LIHC	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	4.31	2.16e-05	0.00514	0.35	0.23	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
LIHC	cis	rs6500637	0.631	rs12921187	ENSG00000267077.1	RP11-127I20.5	-4.31	2.16e-05	0.00514	-0.24	-0.23	Cancer;	chr16:4893018	chr16:4795265~4796532:-
LIHC	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	4.31	2.16e-05	0.00514	0.23	0.23	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
LIHC	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-4.31	2.16e-05	0.00514	-0.24	-0.23	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
LIHC	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	4.31	2.16e-05	0.00514	0.43	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
LIHC	cis	rs11098499	0.644	rs7693919	ENSG00000260091.1	RP11-33B1.4	-4.31	2.17e-05	0.00515	-0.16	-0.23	Corneal astigmatism;	chr4:119619416	chr4:119409333~119410233:+
LIHC	cis	rs875971	0.545	rs1796222	ENSG00000273142.1	RP11-458F8.4	-4.31	2.17e-05	0.00515	-0.21	-0.23	Aortic root size;	chr7:66592167	chr7:66902857~66906297:+
LIHC	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-4.31	2.17e-05	0.00515	-0.22	-0.23	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
LIHC	cis	rs748404	0.66	rs690012	ENSG00000166763.7	STRCP1	4.31	2.17e-05	0.00515	0.28	0.23	Lung cancer;	chr15:43427557	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.863	rs13140391	ENSG00000260091.1	RP11-33B1.4	-4.31	2.17e-05	0.00516	-0.16	-0.23	Corneal astigmatism;	chr4:119582282	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs13140409	ENSG00000260091.1	RP11-33B1.4	-4.31	2.17e-05	0.00516	-0.16	-0.23	Corneal astigmatism;	chr4:119582305	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs6833334	ENSG00000260091.1	RP11-33B1.4	-4.31	2.17e-05	0.00516	-0.16	-0.23	Corneal astigmatism;	chr4:119583072	chr4:119409333~119410233:+
LIHC	cis	rs6445975	0.666	rs11710823	ENSG00000272360.1	RP11-359I18.5	4.31	2.17e-05	0.00516	0.3	0.23	Systemic lupus erythematosus;	chr3:58410766	chr3:58490830~58491291:-
LIHC	cis	rs11233413	0.829	rs11233422	ENSG00000246067.6	RAB30-AS1	-4.31	2.17e-05	0.00516	-0.3	-0.23	Economic and political preferences (feminism/equality);	chr11:83019480	chr11:83072066~83106719:+
LIHC	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-4.31	2.18e-05	0.00517	-0.22	-0.23	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
LIHC	cis	rs960902	0.561	rs4517954	ENSG00000213553.4	RPLP0P6	-4.31	2.18e-05	0.00517	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37507278	chr2:38481851~38482804:+
LIHC	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-4.31	2.18e-05	0.00517	-0.17	-0.23	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
LIHC	cis	rs11722228	0.522	rs7681250	ENSG00000261490.1	RP11-448G15.3	4.31	2.18e-05	0.00518	0.29	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10131389	chr4:10068089~10073019:-
LIHC	cis	rs11722228	0.522	rs7662229	ENSG00000261490.1	RP11-448G15.3	4.31	2.18e-05	0.00518	0.29	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10131390	chr4:10068089~10073019:-
LIHC	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-4.31	2.18e-05	0.00518	-0.25	-0.23	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
LIHC	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-4.31	2.18e-05	0.00518	-0.25	-0.23	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
LIHC	cis	rs6901152	0.508	rs1424926	ENSG00000217648.1	RP1-95L4.4	-4.31	2.18e-05	0.00518	-0.27	-0.23	Acute lymphoblastic leukemia (childhood);	chr6:143366538	chr6:143342246~143343383:+
LIHC	cis	rs7119038	0.865	rs4936443	ENSG00000255239.1	AP002954.6	4.31	2.18e-05	0.00518	0.33	0.23	Sjögren's syndrome;	chr11:118870155	chr11:118688039~118690600:-
LIHC	cis	rs11098499	0.863	rs11098531	ENSG00000260091.1	RP11-33B1.4	-4.31	2.18e-05	0.00518	-0.16	-0.23	Corneal astigmatism;	chr4:119543846	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs28718422	ENSG00000260091.1	RP11-33B1.4	-4.31	2.18e-05	0.00518	-0.16	-0.23	Corneal astigmatism;	chr4:119545149	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.818	rs12498599	ENSG00000260091.1	RP11-33B1.4	-4.31	2.18e-05	0.00518	-0.16	-0.23	Corneal astigmatism;	chr4:119547348	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs10009626	ENSG00000260091.1	RP11-33B1.4	-4.31	2.18e-05	0.00518	-0.16	-0.23	Corneal astigmatism;	chr4:119548850	chr4:119409333~119410233:+
LIHC	cis	rs41313321	0.541	rs1468648	ENSG00000272696.1	RP11-339B21.13	-4.3	2.18e-05	0.00519	-0.3	-0.23	Coenzyme Q10 levels;	chr9:128295706	chr9:128316337~128316909:+
LIHC	cis	rs9876781	1	rs898225	ENSG00000229759.1	MRPS18AP1	-4.3	2.18e-05	0.00519	-0.24	-0.23	Longevity;	chr3:48371689	chr3:48256350~48256938:-
LIHC	cis	rs75920871	0.764	rs74428560	ENSG00000254851.1	RP11-109L13.1	-4.3	2.19e-05	0.00519	-0.46	-0.23	Subjective well-being;	chr11:117119266	chr11:117135528~117138582:+
LIHC	cis	rs2749592	0.611	rs176888	ENSG00000263064.2	RP11-291L22.7	4.3	2.19e-05	0.00519	0.24	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:38117233	chr10:38448689~38448949:+
LIHC	cis	rs1577917	1	rs10944170	ENSG00000234155.1	RP11-30P6.6	4.3	2.19e-05	0.0052	0.3	0.23	Response to antipsychotic treatment;	chr6:85975751	chr6:85387219~85390186:-
LIHC	cis	rs6504622	0.539	rs4968248	ENSG00000263766.4	RP11-580I16.2	4.3	2.19e-05	0.0052	0.26	0.23	Orofacial clefts;	chr17:46915762	chr17:47603860~47649420:-
LIHC	cis	rs9457247	1	rs398278	ENSG00000227598.1	RP1-167A14.2	-4.3	2.19e-05	0.0052	-0.24	-0.23	Crohn's disease;	chr6:166974681	chr6:166969626~166999065:-
LIHC	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	4.3	2.19e-05	0.0052	0.22	0.23	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
LIHC	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-4.3	2.19e-05	0.0052	-0.3	-0.23	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-4.3	2.19e-05	0.0052	-0.3	-0.23	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-4.3	2.19e-05	0.0052	-0.3	-0.23	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-4.3	2.19e-05	0.0052	-0.3	-0.23	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-4.3	2.19e-05	0.0052	-0.3	-0.23	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
LIHC	cis	rs1005277	0.579	rs932538	ENSG00000276805.1	RP11-291L22.6	4.3	2.19e-05	0.0052	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.541	rs2472177	ENSG00000276805.1	RP11-291L22.6	4.3	2.19e-05	0.0052	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs2472178	ENSG00000276805.1	RP11-291L22.6	4.3	2.19e-05	0.0052	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs2474572	ENSG00000276805.1	RP11-291L22.6	4.3	2.19e-05	0.0052	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs2505198	ENSG00000276805.1	RP11-291L22.6	4.3	2.19e-05	0.0052	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.579	rs2008449	ENSG00000276805.1	RP11-291L22.6	-4.3	2.19e-05	0.0052	-0.27	-0.23	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38451030~38451785:+
LIHC	cis	rs56080343	0.515	rs73222056	ENSG00000275409.1	RP11-131L12.4	-4.3	2.19e-05	0.0052	-0.31	-0.23	Neuroticism;	chr12:118215875	chr12:118430147~118430699:+
LIHC	cis	rs6480314	0.831	rs7080267	ENSG00000233590.1	RP11-153K11.3	-4.3	2.19e-05	0.0052	-0.32	-0.23	Optic nerve measurement (disc area);	chr10:68220993	chr10:68233251~68242379:-
LIHC	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-4.3	2.19e-05	0.0052	-0.28	-0.23	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
LIHC	cis	rs7985	0.935	rs4280	ENSG00000244625.4	MIATNB	4.3	2.19e-05	0.00521	0.25	0.23	Electroencephalogram traits;	chr22:26671082	chr22:26672767~26780207:+
LIHC	cis	rs1023500	1	rs6002552	ENSG00000237037.8	NDUFA6-AS1	-4.3	2.19e-05	0.00521	-0.31	-0.23	Schizophrenia;	chr22:41942347	chr22:42090931~42137742:+
LIHC	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-4.3	2.2e-05	0.00521	-0.26	-0.23	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
LIHC	cis	rs4578769	0.879	rs12963622	ENSG00000266850.1	RP11-370A5.1	4.3	2.2e-05	0.00521	0.26	0.23	Eosinophil percentage of white cells;	chr18:22859594	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.879	rs7241050	ENSG00000266850.1	RP11-370A5.1	4.3	2.2e-05	0.00521	0.26	0.23	Eosinophil percentage of white cells;	chr18:22860300	chr18:22723491~22907721:-
LIHC	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	4.3	2.2e-05	0.00521	0.23	0.23	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
LIHC	cis	rs2735413	0.958	rs7192416	ENSG00000276007.1	RP11-358L22.3	-4.3	2.2e-05	0.00521	-0.26	-0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78029246	chr16:78123243~78124332:+
LIHC	cis	rs4356975	0.932	rs4694612	ENSG00000250919.1	RP11-813N20.3	-4.3	2.2e-05	0.00521	-0.22	-0.23	Obesity-related traits;	chr4:69079446	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs56879009	ENSG00000250919.1	RP11-813N20.3	-4.3	2.2e-05	0.00521	-0.22	-0.23	Obesity-related traits;	chr4:69079589	chr4:69027831~69044578:+
LIHC	cis	rs3812762	0.843	rs2292046	ENSG00000254860.4	TMEM9B-AS1	-4.3	2.2e-05	0.00521	-0.24	-0.23	Hypospadias;	chr11:8785632	chr11:8964675~8977527:+
LIHC	cis	rs2243480	1	rs1723270	ENSG00000228409.4	CCT6P1	4.3	2.2e-05	0.00521	0.25	0.23	Diabetic kidney disease;	chr7:66004843	chr7:65751142~65763354:+
LIHC	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	4.3	2.2e-05	0.00521	0.28	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
LIHC	cis	rs6472235	0.681	rs34174890	ENSG00000272010.1	CTD-3025N20.3	-4.3	2.2e-05	0.00521	-0.31	-0.23	Plateletcrit;Myopia (pathological);	chr8:65954892	chr8:65591850~65592472:-
LIHC	cis	rs6472235	0.681	rs67768803	ENSG00000272010.1	CTD-3025N20.3	-4.3	2.2e-05	0.00521	-0.31	-0.23	Plateletcrit;Myopia (pathological);	chr8:65955957	chr8:65591850~65592472:-
LIHC	cis	rs6472235	0.681	rs66644630	ENSG00000272010.1	CTD-3025N20.3	-4.3	2.2e-05	0.00521	-0.31	-0.23	Plateletcrit;Myopia (pathological);	chr8:65956483	chr8:65591850~65592472:-
LIHC	cis	rs9450351	0.744	rs9450313	ENSG00000203875.9	SNHG5	-4.3	2.2e-05	0.00522	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85684419	chr6:85660950~85678736:-
LIHC	cis	rs9353324	1	rs9351066	ENSG00000203875.9	SNHG5	-4.3	2.2e-05	0.00522	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85689099	chr6:85660950~85678736:-
LIHC	cis	rs1223397	0.938	rs35511719	ENSG00000215022.6	RP1-257A7.4	-4.3	2.2e-05	0.00522	-0.3	-0.23	Blood pressure;	chr6:13282210	chr6:13264861~13295586:-
LIHC	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-4.3	2.2e-05	0.00522	-0.25	-0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
LIHC	cis	rs709400	0.93	rs57447494	ENSG00000269958.1	RP11-73M18.8	4.3	2.2e-05	0.00522	0.31	0.23	Body mass index;	chr14:103568232	chr14:103696353~103697163:+
LIHC	cis	rs42490	0.576	rs388866	ENSG00000251136.7	RP11-37B2.1	-4.3	2.2e-05	0.00522	-0.2	-0.23	Leprosy;	chr8:89856604	chr8:89609409~89757727:-
LIHC	cis	rs1577917	0.883	rs2782263	ENSG00000234155.1	RP11-30P6.6	4.3	2.2e-05	0.00522	0.28	0.23	Response to antipsychotic treatment;	chr6:86081589	chr6:85387219~85390186:-
LIHC	cis	rs2243480	1	rs316327	ENSG00000230295.1	RP11-458F8.2	4.3	2.2e-05	0.00522	0.24	0.23	Diabetic kidney disease;	chr7:66144214	chr7:66880708~66882981:+
LIHC	cis	rs7412746	0.634	rs7521592	ENSG00000231073.1	RP11-316M1.3	4.3	2.2e-05	0.00522	0.24	0.23	Melanoma;	chr1:150849215	chr1:150973123~150975534:+
LIHC	cis	rs6430585	0.528	rs309113	ENSG00000231890.6	DARS-AS1	-4.3	2.2e-05	0.00522	-0.31	-0.23	Corneal structure;	chr2:135979890	chr2:135985176~136022593:+
LIHC	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-4.3	2.2e-05	0.00523	-0.28	-0.23	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-4.3	2.2e-05	0.00523	-0.28	-0.23	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
LIHC	cis	rs6430585	0.528	rs309133	ENSG00000231890.6	DARS-AS1	-4.3	2.2e-05	0.00523	-0.31	-0.23	Corneal structure;	chr2:135994272	chr2:135985176~136022593:+
LIHC	cis	rs2243480	1	rs34970380	ENSG00000228409.4	CCT6P1	4.3	2.2e-05	0.00523	0.25	0.23	Diabetic kidney disease;	chr7:65966506	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs73148097	ENSG00000228409.4	CCT6P1	4.3	2.2e-05	0.00523	0.25	0.23	Diabetic kidney disease;	chr7:65966800	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs906134	ENSG00000228409.4	CCT6P1	4.3	2.2e-05	0.00523	0.25	0.23	Diabetic kidney disease;	chr7:65979301	chr7:65751142~65763354:+
LIHC	cis	rs2948294	0.588	rs12544596	ENSG00000253981.4	ALG1L13P	4.3	2.2e-05	0.00523	0.26	0.23	Red cell distribution width;	chr8:8258824	chr8:8236003~8244667:-
LIHC	cis	rs9353324	1	rs7771366	ENSG00000203875.9	SNHG5	-4.3	2.2e-05	0.00523	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85582193	chr6:85660950~85678736:-
LIHC	cis	rs9450351	0.744	rs6902638	ENSG00000203875.9	SNHG5	-4.3	2.2e-05	0.00523	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85608881	chr6:85660950~85678736:-
LIHC	cis	rs748404	0.69	rs2467737	ENSG00000166763.7	STRCP1	4.3	2.21e-05	0.00523	0.28	0.23	Lung cancer;	chr15:43444990	chr15:43699488~43718184:-
LIHC	cis	rs2797160	0.904	rs1739370	ENSG00000237742.5	RP11-624M8.1	4.3	2.21e-05	0.00524	0.23	0.23	Endometrial cancer;	chr6:125690085	chr6:125578558~125749190:-
LIHC	cis	rs2744375	0.6	rs2008748	ENSG00000261189.1	RP3-512B11.3	4.3	2.21e-05	0.00524	0.29	0.23	Resting heart rate;	chr6:7551445	chr6:7540451~7541338:-
LIHC	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.21e-05	0.00524	-0.22	-0.23	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.21e-05	0.00524	-0.22	-0.23	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.21e-05	0.00524	-0.22	-0.23	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
LIHC	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-4.3	2.21e-05	0.00524	-0.28	-0.23	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
LIHC	cis	rs12701220	0.947	rs1007765	ENSG00000229043.2	AC091729.9	-4.3	2.21e-05	0.00524	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:993169	chr7:1160374~1165267:+
LIHC	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-4.3	2.22e-05	0.00525	-0.27	-0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
LIHC	cis	rs2439831	0.867	rs45585139	ENSG00000166763.7	STRCP1	4.3	2.22e-05	0.00525	0.37	0.23	Lung cancer in ever smokers;	chr15:43408229	chr15:43699488~43718184:-
LIHC	cis	rs12304921	0.683	rs56060103	ENSG00000277201.1	AC087884.1	4.3	2.22e-05	0.00525	0.27	0.23	Type 2 diabetes;	chr12:51058879	chr12:51049921~51050025:+
LIHC	cis	rs3812762	0.879	rs1079452	ENSG00000254860.4	TMEM9B-AS1	4.3	2.22e-05	0.00525	0.24	0.23	Hypospadias;	chr11:8757625	chr11:8964675~8977527:+
LIHC	cis	rs950169	0.65	rs12902052	ENSG00000259295.5	CSPG4P12	4.3	2.22e-05	0.00525	0.32	0.23	Schizophrenia;	chr15:84582607	chr15:85191438~85213905:+
LIHC	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	4.3	2.22e-05	0.00525	0.36	0.23	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
LIHC	cis	rs4356975	0.932	rs7662632	ENSG00000250919.1	RP11-813N20.3	-4.3	2.22e-05	0.00526	-0.22	-0.23	Obesity-related traits;	chr4:69062256	chr4:69027831~69044578:+
LIHC	cis	rs10510102	0.748	rs11200297	ENSG00000226864.1	ATE1-AS1	4.3	2.22e-05	0.00526	0.39	0.23	Breast cancer;	chr10:121972916	chr10:121928312~121951965:+
LIHC	cis	rs11098499	0.826	rs4472123	ENSG00000260091.1	RP11-33B1.4	-4.3	2.22e-05	0.00526	-0.16	-0.23	Corneal astigmatism;	chr4:119315475	chr4:119409333~119410233:+
LIHC	cis	rs3758785	0.679	rs11819857	ENSG00000255893.1	RP11-685N10.1	-4.3	2.22e-05	0.00526	-0.27	-0.23	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94495070	chr11:94472908~94473570:-
LIHC	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-4.3	2.22e-05	0.00526	-0.27	-0.23	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
LIHC	cis	rs875971	0.545	rs1909508	ENSG00000273142.1	RP11-458F8.4	4.3	2.22e-05	0.00526	0.22	0.23	Aortic root size;	chr7:66301366	chr7:66902857~66906297:+
LIHC	cis	rs1115240	0.685	rs1950409	ENSG00000257842.4	NOVA1-AS1	4.3	2.22e-05	0.00526	0.23	0.23	Educational attainment (years of education);	chr14:26594861	chr14:26598412~26806467:+
LIHC	cis	rs11098499	0.955	rs1397608	ENSG00000260091.1	RP11-33B1.4	-4.3	2.23e-05	0.00527	-0.17	-0.23	Corneal astigmatism;	chr4:119240589	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.955	rs7684942	ENSG00000260091.1	RP11-33B1.4	-4.3	2.23e-05	0.00527	-0.17	-0.23	Corneal astigmatism;	chr4:119241046	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.779	rs7699346	ENSG00000260091.1	RP11-33B1.4	-4.3	2.23e-05	0.00527	-0.16	-0.23	Corneal astigmatism;	chr4:119389387	chr4:119409333~119410233:+
LIHC	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-4.3	2.23e-05	0.00527	-0.28	-0.23	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-4.3	2.23e-05	0.00527	-0.28	-0.23	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-4.3	2.23e-05	0.00527	-0.28	-0.23	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
LIHC	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-4.3	2.23e-05	0.00527	-0.27	-0.23	Height;	chr2:46615271	chr2:46668870~46670778:+
LIHC	cis	rs27434	0.605	rs1230366	ENSG00000272109.1	CTD-2260A17.3	-4.3	2.23e-05	0.00527	-0.31	-0.23	Ankylosing spondylitis;	chr5:96859577	chr5:96804353~96806105:+
LIHC	cis	rs72627509	0.638	rs12648928	ENSG00000269949.1	RP11-738E22.3	4.3	2.23e-05	0.00527	0.32	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57036340	chr4:56960927~56961373:-
LIHC	cis	rs734999	0.588	rs10910099	ENSG00000225931.3	RP3-395M20.7	-4.3	2.23e-05	0.00527	-0.24	-0.23	Ulcerative colitis;	chr1:2602113	chr1:2566410~2569888:+
LIHC	cis	rs1247318	0.806	rs638141	ENSG00000243831.1	RP1-81D8.4	4.3	2.23e-05	0.00527	0.33	0.23	Aging;	chr6:160940856	chr6:160666228~160676523:-
LIHC	cis	rs113084984	0.597	rs10803739	ENSG00000271952.1	RP11-245G13.2	-4.3	2.23e-05	0.00527	-0.29	-0.23	Breast cancer;	chr2:11527501	chr2:10878269~10885118:+
LIHC	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-4.3	2.23e-05	0.00527	-0.24	-0.23	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
LIHC	cis	rs948562	0.947	rs76985515	ENSG00000280010.1	AP001350.4	4.3	2.23e-05	0.00527	0.41	0.23	Lymphoma;	chr11:58604321	chr11:58627435~58628528:+
LIHC	cis	rs948562	0.947	rs7482383	ENSG00000280010.1	AP001350.4	4.3	2.23e-05	0.00527	0.41	0.23	Lymphoma;	chr11:58602225	chr11:58627435~58628528:+
LIHC	cis	rs948562	0.947	rs78176302	ENSG00000280010.1	AP001350.4	4.3	2.23e-05	0.00527	0.41	0.23	Lymphoma;	chr11:58615176	chr11:58627435~58628528:+
LIHC	cis	rs948562	0.947	rs11541682	ENSG00000280010.1	AP001350.4	4.3	2.23e-05	0.00527	0.41	0.23	Lymphoma;	chr11:58618279	chr11:58627435~58628528:+
LIHC	cis	rs79349575	0.594	rs1985785	ENSG00000248278.1	SUMO2P17	4.3	2.23e-05	0.00528	0.28	0.23	Type 2 diabetes;	chr17:48890426	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.685	rs1124829	ENSG00000248278.1	SUMO2P17	4.3	2.23e-05	0.00528	0.28	0.23	Type 2 diabetes;	chr17:48890435	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.721	rs1008834	ENSG00000248278.1	SUMO2P17	4.3	2.23e-05	0.00528	0.28	0.23	Type 2 diabetes;	chr17:48890646	chr17:48874860~48908983:-
LIHC	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-4.3	2.23e-05	0.00528	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
LIHC	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-4.3	2.23e-05	0.00528	-0.34	-0.23	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
LIHC	cis	rs893363	0.559	rs877484	ENSG00000271916.1	RP11-884K10.6	4.3	2.23e-05	0.00528	0.29	0.23	Axial length;	chr3:53812897	chr3:53797764~53798019:-
LIHC	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	4.3	2.23e-05	0.00528	0.23	0.23	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
LIHC	cis	rs12946454	0.668	rs4792867	ENSG00000267288.2	RP13-890H12.2	-4.3	2.23e-05	0.00528	-0.25	-0.23	Systolic blood pressure;	chr17:45172077	chr17:45168800~45171584:-
LIHC	cis	rs12946454	0.621	rs11651809	ENSG00000267288.2	RP13-890H12.2	-4.3	2.23e-05	0.00528	-0.25	-0.23	Systolic blood pressure;	chr17:45178314	chr17:45168800~45171584:-
LIHC	cis	rs4356203	0.783	rs7113964	ENSG00000260196.1	RP1-239B22.5	-4.3	2.24e-05	0.00529	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234374	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs11024208	ENSG00000260196.1	RP1-239B22.5	-4.3	2.24e-05	0.00529	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17238432	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.678	rs1125737	ENSG00000260196.1	RP1-239B22.5	-4.3	2.24e-05	0.00529	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17242386	chr11:17380649~17383531:+
LIHC	cis	rs11779988	0.545	rs439374	ENSG00000253671.1	RP11-806O11.1	-4.3	2.24e-05	0.00529	-0.29	-0.23	Breast cancer;	chr8:17929309	chr8:17808941~17820868:+
LIHC	cis	rs4578769	0.959	rs3911557	ENSG00000265943.1	RP11-739L10.1	-4.3	2.24e-05	0.00529	-0.28	-0.23	Eosinophil percentage of white cells;	chr18:22892600	chr18:22699481~22933764:-
LIHC	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	4.3	2.24e-05	0.00529	0.27	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
LIHC	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-4.3	2.24e-05	0.00529	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
LIHC	cis	rs3812762	0.912	rs11042058	ENSG00000254860.4	TMEM9B-AS1	4.3	2.24e-05	0.00529	0.26	0.23	Hypospadias;	chr11:8742268	chr11:8964675~8977527:+
LIHC	cis	rs9675120	0.742	rs9905568	ENSG00000262006.1	RP11-700H6.4	-4.3	2.24e-05	0.0053	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50842718	chr17:50909637~50910232:-
LIHC	cis	rs12478296	0.901	rs9653611	ENSG00000261186.2	RP11-341N2.1	-4.3	2.25e-05	0.00531	-0.3	-0.23	Obesity-related traits;	chr2:242064805	chr2:242087351~242088457:-
LIHC	cis	rs12478296	0.818	rs57194240	ENSG00000261186.2	RP11-341N2.1	-4.3	2.25e-05	0.00531	-0.3	-0.23	Obesity-related traits;	chr2:242069394	chr2:242087351~242088457:-
LIHC	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-4.3	2.25e-05	0.00531	-0.27	-0.23	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
LIHC	cis	rs60733400	0.5	rs72644697	ENSG00000225931.3	RP3-395M20.7	4.3	2.25e-05	0.00531	0.24	0.23	Multiple sclerosis;	chr1:2602166	chr1:2566410~2569888:+
LIHC	cis	rs7726839	0.54	rs4957080	ENSG00000271781.1	CTD-2589H19.6	4.3	2.25e-05	0.00531	0.35	0.23	Obesity-related traits;	chr5:644437	chr5:675826~676616:+
LIHC	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.25e-05	0.00531	-0.22	-0.23	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-4.3	2.25e-05	0.00531	-0.22	-0.23	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
LIHC	cis	rs17818399	1	rs17818399	ENSG00000279254.1	RP11-536C12.1	-4.3	2.25e-05	0.00531	-0.27	-0.23	Height;	chr2:46598887	chr2:46668870~46670778:+
LIHC	cis	rs901683	1	rs9422657	ENSG00000230869.1	CTGLF10P	-4.3	2.25e-05	0.00531	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45557613	chr10:45678692~45700532:+
LIHC	cis	rs948562	0.947	rs17489568	ENSG00000280010.1	AP001350.4	4.3	2.25e-05	0.00532	0.41	0.23	Lymphoma;	chr11:58622534	chr11:58627435~58628528:+
LIHC	cis	rs494453	0.922	rs2473843	ENSG00000227811.2	FAM212B-AS1	-4.3	2.25e-05	0.00532	-0.26	-0.23	Osteoporosis-related phenotypes;	chr1:111698035	chr1:111739841~111747798:+
LIHC	cis	rs494453	0.845	rs2477427	ENSG00000227811.2	FAM212B-AS1	-4.3	2.25e-05	0.00532	-0.26	-0.23	Osteoporosis-related phenotypes;	chr1:111698072	chr1:111739841~111747798:+
LIHC	cis	rs6439153	0.967	rs9821769	ENSG00000231305.3	RP11-723O4.2	4.3	2.25e-05	0.00532	0.25	0.23	Pneumococcal bacteremia;	chr3:129007423	chr3:128861313~128871540:-
LIHC	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	4.3	2.25e-05	0.00532	0.24	0.23	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
LIHC	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	4.3	2.25e-05	0.00532	0.36	0.23	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
LIHC	cis	rs2929278	0.617	rs693919	ENSG00000166763.7	STRCP1	-4.3	2.25e-05	0.00532	-0.29	-0.23	Schizophrenia;	chr15:43810130	chr15:43699488~43718184:-
LIHC	cis	rs67478160	0.643	rs6575997	ENSG00000258534.1	CTD-2134A5.4	4.3	2.25e-05	0.00532	0.24	0.23	Schizophrenia;	chr14:103762209	chr14:103854366~103880111:-
LIHC	cis	rs794185	0.652	rs2633844	ENSG00000231249.1	ITPR1-AS1	-4.3	2.26e-05	0.00532	-0.24	-0.23	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470207	chr3:4490891~4493163:-
LIHC	cis	rs1005277	0.579	rs1621040	ENSG00000099251.13	HSD17B7P2	4.3	2.26e-05	0.00533	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38356380~38378505:+
LIHC	cis	rs901683	1	rs9422652	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45552486	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs9422441	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45552605	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs9422442	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45552630	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs17157928	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45552781	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs77649955	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45555241	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs74874679	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45555285	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs9422654	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45555953	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs17451208	ENSG00000230869.1	CTGLF10P	-4.3	2.26e-05	0.00533	-0.54	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45556457	chr10:45678692~45700532:+
LIHC	cis	rs116139393	0.561	rs62439737	ENSG00000187953.9	PMS2CL	-4.3	2.26e-05	0.00533	-0.23	-0.23	Alzheimer's disease (APOE e4 interaction);	chr7:6740179	chr7:6710128~6753862:+
LIHC	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-4.3	2.26e-05	0.00533	-0.2	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
LIHC	cis	rs6500637	0.57	rs1049205	ENSG00000267077.1	RP11-127I20.5	-4.3	2.26e-05	0.00533	-0.24	-0.23	Cancer;	chr16:4892098	chr16:4795265~4796532:-
LIHC	cis	rs2439831	0.717	rs2447198	ENSG00000275601.1	AC011330.13	-4.3	2.26e-05	0.00533	-0.34	-0.23	Lung cancer in ever smokers;	chr15:43602920	chr15:43642389~43643023:-
LIHC	cis	rs763121	0.626	rs5750643	ENSG00000273076.1	RP3-508I15.22	4.3	2.26e-05	0.00534	0.25	0.23	Menopause (age at onset);	chr22:38613012	chr22:38743495~38743910:+
LIHC	cis	rs9937943	0.512	rs13335886	ENSG00000261079.1	RP11-252A24.3	-4.3	2.26e-05	0.00534	-0.28	-0.23	Neutrophil percentage of white cells;	chr16:74543263	chr16:74367462~74369826:+
LIHC	cis	rs2300206	1	rs2300206	ENSG00000275784.1	RP5-1125A11.6	-4.3	2.26e-05	0.00534	-0.26	-0.23	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33989480~33991818:-
LIHC	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	4.3	2.26e-05	0.00534	0.26	0.23	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
LIHC	cis	rs710865	0.527	rs2275403	ENSG00000270728.1	RP4-657E11.10	4.3	2.27e-05	0.00534	0.21	0.23	Brain structure;	chr1:19231219	chr1:19297080~19297903:+
LIHC	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	4.3	2.27e-05	0.00534	0.35	0.23	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
LIHC	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-4.3	2.27e-05	0.00534	-0.26	-0.23	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
LIHC	cis	rs734999	0.545	rs6666788	ENSG00000225931.3	RP3-395M20.7	-4.3	2.27e-05	0.00535	-0.24	-0.23	Ulcerative colitis;	chr1:2636061	chr1:2566410~2569888:+
LIHC	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	4.3	2.27e-05	0.00535	0.27	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
LIHC	cis	rs2243480	1	rs937108	ENSG00000230295.1	RP11-458F8.2	-4.3	2.27e-05	0.00535	-0.24	-0.23	Diabetic kidney disease;	chr7:65963465	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35542501	ENSG00000230295.1	RP11-458F8.2	-4.3	2.27e-05	0.00535	-0.24	-0.23	Diabetic kidney disease;	chr7:65966228	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.711	rs1626926	ENSG00000230295.1	RP11-458F8.2	-4.3	2.27e-05	0.00535	-0.24	-0.23	Diabetic kidney disease;	chr7:65970805	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.708	rs781141	ENSG00000230295.1	RP11-458F8.2	-4.3	2.27e-05	0.00535	-0.24	-0.23	Diabetic kidney disease;	chr7:65973566	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs781142	ENSG00000230295.1	RP11-458F8.2	-4.3	2.27e-05	0.00535	-0.24	-0.23	Diabetic kidney disease;	chr7:65973791	chr7:66880708~66882981:+
LIHC	cis	rs12887734	0.524	rs4900599	ENSG00000258534.1	CTD-2134A5.4	-4.3	2.27e-05	0.00535	-0.25	-0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103854366~103880111:-
LIHC	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-4.3	2.27e-05	0.00535	-0.34	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-4.3	2.27e-05	0.00535	-0.34	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
LIHC	cis	rs11648785	0.81	rs4354938	ENSG00000221819.5	GAS8-AS1	-4.3	2.27e-05	0.00535	-0.31	-0.23	Tanning;	chr16:90032420	chr16:90028908~90029367:-
LIHC	cis	rs2284219	1	rs2284219	ENSG00000196295.10	AC005154.6	-4.3	2.27e-05	0.00535	-0.16	-0.23	Type 2 diabetes;	chr7:30674820	chr7:30516309~30594809:-
LIHC	cis	rs2284219	0.964	rs733453	ENSG00000196295.10	AC005154.6	-4.3	2.27e-05	0.00535	-0.16	-0.23	Type 2 diabetes;	chr7:30675157	chr7:30516309~30594809:-
LIHC	cis	rs2932538	0.961	rs3013441	ENSG00000225075.1	RP11-426L16.3	-4.3	2.27e-05	0.00536	-0.29	-0.23	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112649983	chr1:112693688~112696621:-
LIHC	cis	rs860295	0.58	rs6672284	ENSG00000203761.5	MSTO2P	-4.3	2.27e-05	0.00536	-0.19	-0.23	Body mass index;	chr1:155308172	chr1:155745829~155750137:+
LIHC	cis	rs36093924	0.646	rs5996094	ENSG00000227370.1	RP4-669P10.19	4.3	2.27e-05	0.00536	0.27	0.23	Intelligence;	chr22:41951056	chr22:42132543~42132998:+
LIHC	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-4.3	2.27e-05	0.00536	-0.26	-0.23	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
LIHC	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-4.3	2.28e-05	0.00537	-0.21	-0.23	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
LIHC	cis	rs617219	0.819	rs4704552	ENSG00000251675.1	CTC-458I2.2	4.3	2.28e-05	0.00537	0.26	0.23	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79284545	chr5:80128361~80143883:+
LIHC	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-4.3	2.28e-05	0.00537	-0.27	-0.23	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
LIHC	cis	rs748404	0.69	rs1079309	ENSG00000166763.7	STRCP1	4.3	2.28e-05	0.00537	0.28	0.23	Lung cancer;	chr15:43490966	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.69	rs2924369	ENSG00000166763.7	STRCP1	-4.3	2.28e-05	0.00537	-0.28	-0.23	Lung cancer;	chr15:43485787	chr15:43699488~43718184:-
LIHC	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-4.3	2.28e-05	0.00537	-0.29	-0.23	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
LIHC	cis	rs11671005	0.651	rs10402325	ENSG00000269473.1	CTD-2619J13.19	4.29	2.28e-05	0.00537	0.39	0.23	Mean platelet volume;	chr19:58402140	chr19:58440448~58445849:+
LIHC	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	4.29	2.28e-05	0.00537	0.23	0.23	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
LIHC	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	4.29	2.28e-05	0.00537	0.26	0.23	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
LIHC	cis	rs11148252	0.904	rs9536079	ENSG00000278238.1	RP11-245D16.4	-4.29	2.28e-05	0.00537	-0.21	-0.23	Lewy body disease;	chr13:52456430	chr13:52454775~52455331:-
LIHC	cis	rs9532669	0.963	rs1056835	ENSG00000168852.11	TPTE2P5	4.29	2.28e-05	0.00537	0.25	0.23	Cervical cancer;	chr13:40932585	chr13:40822296~40921749:-
LIHC	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-4.29	2.28e-05	0.00538	-0.25	-0.23	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
LIHC	cis	rs901683	0.85	rs78990676	ENSG00000230869.1	CTGLF10P	-4.29	2.28e-05	0.00538	-0.56	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45606277	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs112114291	ENSG00000230869.1	CTGLF10P	-4.29	2.28e-05	0.00538	-0.56	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45606562	chr10:45678692~45700532:+
LIHC	cis	rs875971	0.502	rs1796227	ENSG00000273142.1	RP11-458F8.4	-4.29	2.28e-05	0.00538	-0.21	-0.23	Aortic root size;	chr7:66622032	chr7:66902857~66906297:+
LIHC	cis	rs748404	0.66	rs694725	ENSG00000166763.7	STRCP1	4.29	2.29e-05	0.00539	0.28	0.23	Lung cancer;	chr15:43464012	chr15:43699488~43718184:-
LIHC	cis	rs12157904	0.744	rs13055343	ENSG00000233360.4	Z83844.1	4.29	2.29e-05	0.00539	0.47	0.23	Response to anti-depressant treatment in major depressive disorder;	chr22:37609137	chr22:37641832~37658377:-
LIHC	cis	rs2439831	0.867	rs2447208	ENSG00000166763.7	STRCP1	4.29	2.29e-05	0.00539	0.34	0.23	Lung cancer in ever smokers;	chr15:43641697	chr15:43699488~43718184:-
LIHC	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-4.29	2.29e-05	0.00539	-0.23	-0.23	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
LIHC	cis	rs2739330	0.929	rs5751775	ENSG00000206090.4	AP000350.7	4.29	2.29e-05	0.00539	0.26	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23939998~23942798:+
LIHC	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	4.29	2.29e-05	0.00539	0.18	0.23	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	4.29	2.29e-05	0.00539	0.18	0.23	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	4.29	2.29e-05	0.00539	0.18	0.23	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	4.29	2.29e-05	0.00539	0.18	0.23	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	4.29	2.29e-05	0.00539	0.18	0.23	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	4.29	2.29e-05	0.00539	0.18	0.23	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
LIHC	cis	rs8064024	0.87	rs930854	ENSG00000267077.1	RP11-127I20.5	4.29	2.29e-05	0.0054	0.22	0.23	Cancer;	chr16:4814100	chr16:4795265~4796532:-
LIHC	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-4.29	2.29e-05	0.0054	-0.33	-0.23	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
LIHC	cis	rs875971	0.545	rs73378304	ENSG00000228409.4	CCT6P1	-4.29	2.29e-05	0.0054	-0.19	-0.23	Aortic root size;	chr7:66175760	chr7:65751142~65763354:+
LIHC	cis	rs2797160	0.837	rs1739364	ENSG00000237742.5	RP11-624M8.1	-4.29	2.29e-05	0.0054	-0.23	-0.23	Endometrial cancer;	chr6:125701237	chr6:125578558~125749190:-
LIHC	cis	rs875971	0.545	rs6969224	ENSG00000273024.4	INTS4P2	-4.29	2.29e-05	0.0054	-0.26	-0.23	Aortic root size;	chr7:66370011	chr7:65647864~65715661:+
LIHC	cis	rs7131987	0.903	rs11050153	ENSG00000257176.2	RP11-996F15.2	-4.29	2.3e-05	0.0054	-0.26	-0.23	QT interval;	chr12:29252215	chr12:29280418~29317848:-
LIHC	cis	rs1247318	1	rs1247363	ENSG00000243831.1	RP1-81D8.4	4.29	2.3e-05	0.00541	0.36	0.23	Aging;	chr6:160921658	chr6:160666228~160676523:-
LIHC	cis	rs1200821	0.529	rs2505707	ENSG00000263064.2	RP11-291L22.7	4.29	2.3e-05	0.00541	0.24	0.23	Hemostatic factors and hematological phenotypes;	chr10:37512326	chr10:38448689~38448949:+
LIHC	cis	rs7709377	0.597	rs57484726	ENSG00000271918.1	CTD-2287O16.5	4.29	2.3e-05	0.00541	0.27	0.23	Metabolite levels  (X-11787);	chr5:116178348	chr5:116083807~116085416:-
LIHC	cis	rs1005277	0.54	rs1814077	ENSG00000099251.13	HSD17B7P2	4.29	2.3e-05	0.00541	0.26	0.23	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38356380~38378505:+
LIHC	cis	rs748404	0.578	rs512628	ENSG00000166763.7	STRCP1	4.29	2.3e-05	0.00541	0.28	0.23	Lung cancer;	chr15:43326536	chr15:43699488~43718184:-
LIHC	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	4.29	2.3e-05	0.00541	0.35	0.23	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
LIHC	cis	rs4356203	0.87	rs10741724	ENSG00000260196.1	RP1-239B22.5	-4.29	2.3e-05	0.00541	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231604	chr11:17380649~17383531:+
LIHC	cis	rs11098499	0.863	rs3775841	ENSG00000260091.1	RP11-33B1.4	-4.29	2.3e-05	0.00541	-0.16	-0.23	Corneal astigmatism;	chr4:119504622	chr4:119409333~119410233:+
LIHC	cis	rs46522	0.585	rs79049364	ENSG00000248278.1	SUMO2P17	4.29	2.3e-05	0.00542	0.28	0.23	Coronary heart disease;	chr17:48937629	chr17:48874860~48908983:-
LIHC	cis	rs79349575	0.811	rs80032154	ENSG00000248278.1	SUMO2P17	4.29	2.3e-05	0.00542	0.28	0.23	Type 2 diabetes;	chr17:48937630	chr17:48874860~48908983:-
LIHC	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	4.29	2.3e-05	0.00542	0.24	0.23	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
LIHC	cis	rs417065	0.516	rs11121129	ENSG00000227634.1	RP11-431K24.3	4.29	2.3e-05	0.00542	0.28	0.23	Psoriasis;	chr1:8208035	chr1:8208672~8215210:+
LIHC	cis	rs875971	0.545	rs7787063	ENSG00000228409.4	CCT6P1	-4.29	2.3e-05	0.00542	-0.19	-0.23	Aortic root size;	chr7:66164012	chr7:65751142~65763354:+
LIHC	cis	rs494453	0.922	rs498787	ENSG00000227811.2	FAM212B-AS1	-4.29	2.31e-05	0.00542	-0.25	-0.23	Osteoporosis-related phenotypes;	chr1:111690722	chr1:111739841~111747798:+
LIHC	cis	rs11722228	0.522	rs2241468	ENSG00000261490.1	RP11-448G15.3	4.29	2.31e-05	0.00543	0.31	0.23	Urate levels;Serum uric acid levels;Gout;	chr4:10112281	chr4:10068089~10073019:-
LIHC	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-4.29	2.31e-05	0.00543	-0.33	-0.23	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
LIHC	cis	rs13083990	0.8	rs13061727	ENSG00000272758.4	RP11-299J3.8	4.29	2.31e-05	0.00543	0.25	0.23	Cardiac Troponin-T levels;	chr3:122288504	chr3:122416207~122443180:+
LIHC	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	4.29	2.31e-05	0.00543	0.33	0.23	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
LIHC	cis	rs11098499	1	rs13435802	ENSG00000260091.1	RP11-33B1.4	4.29	2.31e-05	0.00543	0.17	0.23	Corneal astigmatism;	chr4:119256805	chr4:119409333~119410233:+
LIHC	cis	rs17027258	0.609	rs4851005	ENSG00000234389.1	AC007278.3	-4.29	2.31e-05	0.00543	-0.22	-0.23	White blood cell types;	chr2:102395092	chr2:102438713~102440475:+
LIHC	cis	rs2284219	1	rs2267715	ENSG00000196295.10	AC005154.6	-4.29	2.31e-05	0.00544	-0.16	-0.23	Type 2 diabetes;	chr7:30676471	chr7:30516309~30594809:-
LIHC	cis	rs2070488	0.965	rs2284819	ENSG00000229589.1	ACVR2B-AS1	4.29	2.31e-05	0.00544	0.26	0.23	Electrocardiographic conduction measures;	chr3:38515670	chr3:38451027~38454820:-
LIHC	cis	rs11098499	0.754	rs7672372	ENSG00000260091.1	RP11-33B1.4	-4.29	2.31e-05	0.00544	-0.16	-0.23	Corneal astigmatism;	chr4:119327251	chr4:119409333~119410233:+
LIHC	cis	rs916888	0.821	rs199513	ENSG00000274883.1	Metazoa_SRP	4.29	2.32e-05	0.00544	0.34	0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45931806~45932083:+
LIHC	cis	rs7893279	0.505	rs7904949	ENSG00000225527.1	RP11-383B4.4	4.29	2.32e-05	0.00544	0.32	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18624533	chr10:18531849~18533336:-
LIHC	cis	rs7893279	0.505	rs4468242	ENSG00000225527.1	RP11-383B4.4	4.29	2.32e-05	0.00544	0.32	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18633730	chr10:18531849~18533336:-
LIHC	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	4.29	2.32e-05	0.00545	0.22	0.23	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
LIHC	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	4.29	2.32e-05	0.00545	0.23	0.23	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
LIHC	cis	rs7809950	0.862	rs62482502	ENSG00000238832.1	snoU109	-4.29	2.32e-05	0.00545	-0.28	-0.23	Coronary artery disease;	chr7:107347365	chr7:107603363~107603507:+
LIHC	cis	rs11098499	0.863	rs6835635	ENSG00000260091.1	RP11-33B1.4	-4.29	2.32e-05	0.00545	-0.16	-0.23	Corneal astigmatism;	chr4:119537712	chr4:119409333~119410233:+
LIHC	cis	rs6480314	0.831	rs10740287	ENSG00000233590.1	RP11-153K11.3	4.29	2.32e-05	0.00545	0.33	0.23	Optic nerve measurement (disc area);	chr10:68214133	chr10:68233251~68242379:-
LIHC	cis	rs3733589	0.744	rs13148476	ENSG00000250413.1	RP11-448G15.1	4.29	2.32e-05	0.00546	0.36	0.23	Renal overload gout;	chr4:10023774	chr4:10006482~10009725:+
LIHC	cis	rs1005277	0.54	rs2474598	ENSG00000276805.1	RP11-291L22.6	-4.29	2.32e-05	0.00546	-0.27	-0.23	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38451030~38451785:+
LIHC	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-4.29	2.32e-05	0.00546	-0.22	-0.23	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
LIHC	cis	rs6745190	0.953	rs4667005	ENSG00000236153.1	AC104076.3	-4.29	2.32e-05	0.00546	-0.29	-0.23	White blood cell count;	chr2:180997852	chr2:180979427~180980090:-
LIHC	cis	rs11098499	0.754	rs4107728	ENSG00000260091.1	RP11-33B1.4	-4.29	2.32e-05	0.00546	-0.16	-0.23	Corneal astigmatism;	chr4:119332755	chr4:119409333~119410233:+
LIHC	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-4.29	2.33e-05	0.00546	-0.23	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
LIHC	cis	rs960902	0.714	rs10198396	ENSG00000213553.4	RPLP0P6	-4.29	2.33e-05	0.00546	-0.19	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37514999	chr2:38481851~38482804:+
LIHC	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-4.29	2.33e-05	0.00547	-0.26	-0.23	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
LIHC	cis	rs10801727	0.597	rs7534759	ENSG00000225492.5	GBP1P1	-4.29	2.33e-05	0.00547	-0.22	-0.23	Parental extreme longevity (95 years and older);	chr1:89447069	chr1:89407679~89426243:+
LIHC	cis	rs10801727	0.597	rs9427980	ENSG00000225492.5	GBP1P1	-4.29	2.33e-05	0.00547	-0.22	-0.23	Parental extreme longevity (95 years and older);	chr1:89447849	chr1:89407679~89426243:+
LIHC	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-4.29	2.33e-05	0.00547	-0.23	-0.23	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-4.29	2.33e-05	0.00547	-0.23	-0.23	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-4.29	2.33e-05	0.00547	-0.23	-0.23	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-4.29	2.33e-05	0.00547	-0.23	-0.23	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-4.29	2.33e-05	0.00547	-0.23	-0.23	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
LIHC	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	4.29	2.33e-05	0.00547	0.2	0.23	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
LIHC	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-4.29	2.33e-05	0.00547	-0.39	-0.23	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
LIHC	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-4.29	2.33e-05	0.00548	-0.25	-0.23	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
LIHC	cis	rs11098499	0.789	rs1980024	ENSG00000260091.1	RP11-33B1.4	-4.29	2.33e-05	0.00548	-0.16	-0.23	Corneal astigmatism;	chr4:119331892	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.754	rs34425882	ENSG00000260091.1	RP11-33B1.4	-4.29	2.33e-05	0.00548	-0.16	-0.23	Corneal astigmatism;	chr4:119332022	chr4:119409333~119410233:+
LIHC	cis	rs703842	0.616	rs1875125	ENSG00000270039.1	RP11-571M6.17	-4.29	2.33e-05	0.00548	-0.33	-0.23	Multiple sclerosis;	chr12:57833458	chr12:57803838~57804415:+
LIHC	cis	rs9876781	1	rs9815103	ENSG00000229759.1	MRPS18AP1	4.29	2.34e-05	0.00548	0.24	0.23	Longevity;	chr3:48372725	chr3:48256350~48256938:-
LIHC	cis	rs6445975	0.666	rs6773099	ENSG00000272360.1	RP11-359I18.5	4.29	2.34e-05	0.00548	0.3	0.23	Systemic lupus erythematosus;	chr3:58417725	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.578	rs6782218	ENSG00000272360.1	RP11-359I18.5	4.29	2.34e-05	0.00548	0.3	0.23	Systemic lupus erythematosus;	chr3:58423038	chr3:58490830~58491291:-
LIHC	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	4.29	2.34e-05	0.00549	0.17	0.23	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
LIHC	cis	rs11098499	0.954	rs4309825	ENSG00000260091.1	RP11-33B1.4	4.29	2.34e-05	0.00549	0.16	0.23	Corneal astigmatism;	chr4:119393726	chr4:119409333~119410233:+
LIHC	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	4.29	2.34e-05	0.00549	0.3	0.23	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
LIHC	cis	rs11148252	0.904	rs3892337	ENSG00000278238.1	RP11-245D16.4	-4.29	2.34e-05	0.00549	-0.22	-0.23	Lewy body disease;	chr13:52455350	chr13:52454775~52455331:-
LIHC	cis	rs875971	0.545	rs12671152	ENSG00000273142.1	RP11-458F8.4	4.29	2.34e-05	0.00549	0.23	0.23	Aortic root size;	chr7:66311140	chr7:66902857~66906297:+
LIHC	cis	rs11874381	0.582	rs8083571	ENSG00000267322.2	SNHG22	4.29	2.34e-05	0.00549	0.27	0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49691751	chr18:49814023~49851059:+
LIHC	cis	rs2072510	0.722	rs2660895	ENSG00000257878.1	RP11-256L6.3	-4.29	2.34e-05	0.00549	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96029669	chr12:95996521~96011489:+
LIHC	cis	rs2243480	1	rs56291018	ENSG00000228409.4	CCT6P1	4.29	2.34e-05	0.0055	0.25	0.23	Diabetic kidney disease;	chr7:65925352	chr7:65751142~65763354:+
LIHC	cis	rs7129556	0.737	rs10899404	ENSG00000254459.1	RP11-91P24.7	4.29	2.34e-05	0.0055	0.37	0.23	Weight loss (gastric bypass surgery);	chr11:77751747	chr11:77829654~77872262:-
LIHC	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	4.29	2.34e-05	0.0055	0.24	0.23	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
LIHC	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	4.29	2.34e-05	0.0055	0.46	0.23	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
LIHC	cis	rs9952991	0.941	rs9952749	ENSG00000260302.1	RP11-973H7.1	-4.29	2.35e-05	0.0055	-0.34	-0.23	Inflammatory skin disease;	chr18:12780457	chr18:12774651~12775923:-
LIHC	cis	rs9952991	0.943	rs9952753	ENSG00000260302.1	RP11-973H7.1	-4.29	2.35e-05	0.0055	-0.34	-0.23	Inflammatory skin disease;	chr18:12780464	chr18:12774651~12775923:-
LIHC	cis	rs9952991	1	rs9952991	ENSG00000260302.1	RP11-973H7.1	-4.29	2.35e-05	0.0055	-0.34	-0.23	Inflammatory skin disease;	chr18:12780465	chr18:12774651~12775923:-
LIHC	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	4.29	2.35e-05	0.0055	0.23	0.23	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	4.29	2.35e-05	0.0055	0.23	0.23	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
LIHC	cis	rs4578769	0.879	rs7244549	ENSG00000266850.1	RP11-370A5.1	4.29	2.35e-05	0.0055	0.26	0.23	Eosinophil percentage of white cells;	chr18:22866052	chr18:22723491~22907721:-
LIHC	cis	rs875971	0.502	rs11769702	ENSG00000273024.4	INTS4P2	-4.29	2.35e-05	0.00551	-0.26	-0.23	Aortic root size;	chr7:66255529	chr7:65647864~65715661:+
LIHC	cis	rs2243480	1	rs160633	ENSG00000228409.4	CCT6P1	4.29	2.35e-05	0.00551	0.24	0.23	Diabetic kidney disease;	chr7:66063241	chr7:65751142~65763354:+
LIHC	cis	rs9907295	1	rs9908011	ENSG00000270871.1	AC015849.19	4.29	2.35e-05	0.00551	0.24	0.23	Fibroblast growth factor basic levels;	chr17:35908371	chr17:35816717~35830293:-
LIHC	cis	rs1005277	0.579	rs1780139	ENSG00000099251.13	HSD17B7P2	4.29	2.35e-05	0.00551	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38356380~38378505:+
LIHC	cis	rs4356975	0.932	rs72852450	ENSG00000250919.1	RP11-813N20.3	-4.29	2.35e-05	0.00551	-0.23	-0.23	Obesity-related traits;	chr4:69079704	chr4:69027831~69044578:+
LIHC	cis	rs12478296	0.892	rs11893879	ENSG00000261186.2	RP11-341N2.1	-4.29	2.35e-05	0.00552	-0.3	-0.23	Obesity-related traits;	chr2:242068260	chr2:242087351~242088457:-
LIHC	cis	rs2717559	0.522	rs35816096	ENSG00000253196.1	RP11-706C16.7	-4.29	2.35e-05	0.00552	-0.25	-0.23	Urinary tract infection frequency;	chr8:142803522	chr8:142763116~142766427:+
LIHC	cis	rs11098499	0.954	rs6857105	ENSG00000260091.1	RP11-33B1.4	-4.29	2.35e-05	0.00552	-0.17	-0.23	Corneal astigmatism;	chr4:119301143	chr4:119409333~119410233:+
LIHC	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	4.29	2.35e-05	0.00552	0.23	0.23	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
LIHC	cis	rs11064837	0.504	rs7311445	ENSG00000248636.5	RP11-768F21.1	4.29	2.35e-05	0.00552	0.35	0.23	Schizophrenia;	chr12:119616292	chr12:119387987~119668079:-
LIHC	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-4.29	2.35e-05	0.00552	-0.3	-0.23	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
LIHC	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-4.29	2.35e-05	0.00552	-0.3	-0.23	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
LIHC	cis	rs2439831	0.681	rs2278859	ENSG00000166763.7	STRCP1	4.29	2.35e-05	0.00552	0.31	0.23	Lung cancer in ever smokers;	chr15:43340762	chr15:43699488~43718184:-
LIHC	cis	rs2243480	1	rs9769882	ENSG00000230295.1	RP11-458F8.2	4.29	2.36e-05	0.00553	0.24	0.23	Diabetic kidney disease;	chr7:66177938	chr7:66880708~66882981:+
LIHC	cis	rs7412746	0.611	rs7532045	ENSG00000231073.1	RP11-316M1.3	4.29	2.36e-05	0.00553	0.23	0.23	Melanoma;	chr1:150849371	chr1:150973123~150975534:+
LIHC	cis	rs875971	0.545	rs316328	ENSG00000228409.4	CCT6P1	4.29	2.36e-05	0.00553	0.18	0.23	Aortic root size;	chr7:66143851	chr7:65751142~65763354:+
LIHC	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-4.29	2.36e-05	0.00553	-0.24	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
LIHC	cis	rs9952991	0.883	rs2847293	ENSG00000260302.1	RP11-973H7.1	-4.29	2.36e-05	0.00553	-0.33	-0.23	Inflammatory skin disease;	chr18:12782449	chr18:12774651~12775923:-
LIHC	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-4.29	2.36e-05	0.00554	-0.17	-0.23	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
LIHC	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-4.29	2.36e-05	0.00554	-0.44	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
LIHC	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-4.29	2.36e-05	0.00554	-0.44	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
LIHC	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	4.29	2.36e-05	0.00554	0.35	0.23	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
LIHC	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	4.29	2.37e-05	0.00554	0.23	0.23	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
LIHC	cis	rs948562	1	rs11229535	ENSG00000280010.1	AP001350.4	4.29	2.37e-05	0.00554	0.4	0.23	Lymphoma;	chr11:58580913	chr11:58627435~58628528:+
LIHC	cis	rs11098499	0.779	rs80242894	ENSG00000260091.1	RP11-33B1.4	-4.29	2.37e-05	0.00554	-0.16	-0.23	Corneal astigmatism;	chr4:119454597	chr4:119409333~119410233:+
LIHC	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-4.29	2.37e-05	0.00554	-0.24	-0.23	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
LIHC	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	4.29	2.37e-05	0.00554	0.24	0.23	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
LIHC	cis	rs10510102	0.872	rs11200267	ENSG00000273891.1	RP11-500G22.5	4.29	2.37e-05	0.00555	0.31	0.23	Breast cancer;	chr10:121929851	chr10:121965764~121967700:+
LIHC	cis	rs4650994	0.544	rs2811306	ENSG00000273384.1	RP5-1098D14.1	-4.29	2.37e-05	0.00555	-0.28	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178630113	chr1:178651706~178652282:+
LIHC	cis	rs7508	0.511	rs371922	ENSG00000253671.1	RP11-806O11.1	-4.29	2.37e-05	0.00555	-0.28	-0.23	Atrial fibrillation;	chr8:18042494	chr8:17808941~17820868:+
LIHC	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-4.29	2.37e-05	0.00555	-0.29	-0.23	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
LIHC	cis	rs11767557	1	rs56402156	ENSG00000229153.4	EPHA1-AS1	4.29	2.37e-05	0.00555	0.35	0.23	Alzheimer's disease (late onset);	chr7:143406388	chr7:143407813~143523449:+
LIHC	cis	rs3812762	0.879	rs3844099	ENSG00000254860.4	TMEM9B-AS1	-4.29	2.37e-05	0.00555	-0.24	-0.23	Hypospadias;	chr11:8786705	chr11:8964675~8977527:+
LIHC	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-4.29	2.37e-05	0.00555	-0.18	-0.23	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
LIHC	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	4.29	2.37e-05	0.00556	0.24	0.23	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
LIHC	cis	rs3812762	0.957	rs6484008	ENSG00000254860.4	TMEM9B-AS1	-4.29	2.37e-05	0.00556	-0.24	-0.23	Hypospadias;	chr11:8732601	chr11:8964675~8977527:+
LIHC	cis	rs11710088	0.634	rs13095959	ENSG00000244503.1	RP11-278L15.6	4.29	2.38e-05	0.00556	0.24	0.23	QRS duration;	chr3:149489409	chr3:149494660~149495995:+
LIHC	cis	rs17270561	0.609	rs1165208	ENSG00000216436.2	HIST1H2APS1	-4.29	2.38e-05	0.00556	-0.28	-0.23	Iron status biomarkers;	chr6:25803676	chr6:25732497~25732827:+
LIHC	cis	rs5769707	0.521	rs5769719	ENSG00000235111.1	RP1-29C18.8	-4.29	2.38e-05	0.00556	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.521	rs5769720	ENSG00000235111.1	RP1-29C18.8	-4.29	2.38e-05	0.00556	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49612657~49615716:-
LIHC	cis	rs5769707	0.521	rs5770633	ENSG00000235111.1	RP1-29C18.8	-4.29	2.38e-05	0.00556	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49612657~49615716:-
LIHC	cis	rs4073416	0.712	rs12586842	ENSG00000276116.2	FUT8-AS1	4.29	2.38e-05	0.00557	0.27	0.23	N-glycan levels;	chr14:65678304	chr14:65411170~65412690:-
LIHC	cis	rs875971	0.545	rs17138149	ENSG00000228409.4	CCT6P1	-4.29	2.38e-05	0.00557	-0.19	-0.23	Aortic root size;	chr7:66228193	chr7:65751142~65763354:+
LIHC	cis	rs75920871	0.764	rs76136280	ENSG00000254851.1	RP11-109L13.1	-4.28	2.38e-05	0.00557	-0.46	-0.23	Subjective well-being;	chr11:116917775	chr11:117135528~117138582:+
LIHC	cis	rs10129255	0.576	rs2157616	ENSG00000211972.2	IGHV3-66	4.28	2.38e-05	0.00557	0.17	0.23	Kawasaki disease;	chr14:106767802	chr14:106675017~106675544:-
LIHC	cis	rs3096299	0.754	rs3096296	ENSG00000261118.1	RP11-104N10.1	4.28	2.38e-05	0.00557	0.23	0.23	Multiple myeloma (IgH translocation);	chr16:89344602	chr16:89492017~89504460:-
LIHC	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	4.28	2.38e-05	0.00558	0.23	0.23	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
LIHC	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	4.28	2.38e-05	0.00558	0.28	0.23	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
LIHC	cis	rs17270561	0.779	rs17271767	ENSG00000216436.2	HIST1H2APS1	-4.28	2.38e-05	0.00558	-0.34	-0.23	Iron status biomarkers;	chr6:25886693	chr6:25732497~25732827:+
LIHC	cis	rs755249	0.567	rs61783378	ENSG00000182109.6	RP11-69E11.4	4.28	2.38e-05	0.00558	0.3	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39522280~39546187:-
LIHC	cis	rs2284219	0.964	rs2284218	ENSG00000196295.10	AC005154.6	-4.28	2.38e-05	0.00558	-0.17	-0.23	Type 2 diabetes;	chr7:30674717	chr7:30516309~30594809:-
LIHC	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-4.28	2.38e-05	0.00558	-0.22	-0.23	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
LIHC	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-4.28	2.38e-05	0.00558	-0.36	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
LIHC	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	4.28	2.39e-05	0.00558	0.26	0.23	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
LIHC	cis	rs2243480	0.901	rs57126451	ENSG00000230295.1	RP11-458F8.2	-4.28	2.39e-05	0.00559	-0.24	-0.23	Diabetic kidney disease;	chr7:65951319	chr7:66880708~66882981:+
LIHC	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	4.28	2.39e-05	0.00559	0.24	0.23	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
LIHC	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	4.28	2.39e-05	0.00559	0.28	0.23	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
LIHC	cis	rs787274	0.543	rs4978509	ENSG00000271631.1	RP11-408O19.5	4.28	2.39e-05	0.00559	0.36	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr9:112873361	chr9:112885158~112885767:+
LIHC	cis	rs875971	0.545	rs316324	ENSG00000228409.4	CCT6P1	4.28	2.39e-05	0.00559	0.19	0.23	Aortic root size;	chr7:66145627	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs316323	ENSG00000228409.4	CCT6P1	4.28	2.39e-05	0.00559	0.19	0.23	Aortic root size;	chr7:66146002	chr7:65751142~65763354:+
LIHC	cis	rs79349575	0.783	rs4793992	ENSG00000248278.1	SUMO2P17	4.28	2.39e-05	0.00559	0.28	0.23	Type 2 diabetes;	chr17:48930845	chr17:48874860~48908983:-
LIHC	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-4.28	2.39e-05	0.00559	-0.39	-0.23	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
LIHC	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-4.28	2.39e-05	0.0056	-0.22	-0.23	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
LIHC	cis	rs9341808	0.905	rs9343977	ENSG00000272129.1	RP11-250B2.6	4.28	2.4e-05	0.0056	0.23	0.23	Sitting height ratio;	chr6:80257284	chr6:80355424~80356859:+
LIHC	cis	rs2348418	0.864	rs2175464	ENSG00000247934.4	RP11-967K21.1	-4.28	2.4e-05	0.0056	-0.2	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28564178	chr12:28163298~28190738:-
LIHC	cis	rs948562	0.895	rs7484263	ENSG00000280010.1	AP001350.4	4.28	2.4e-05	0.0056	0.39	0.23	Lymphoma;	chr11:58608080	chr11:58627435~58628528:+
LIHC	cis	rs651907	0.535	rs35810977	ENSG00000244119.1	PDCL3P4	4.28	2.4e-05	0.0056	0.23	0.23	Colorectal cancer;	chr3:101812536	chr3:101712472~101713191:+
LIHC	cis	rs2439831	0.85	rs16965120	ENSG00000166763.7	STRCP1	4.28	2.4e-05	0.00561	0.35	0.23	Lung cancer in ever smokers;	chr15:43808144	chr15:43699488~43718184:-
LIHC	cis	rs2744375	0.6	rs2744362	ENSG00000261189.1	RP3-512B11.3	4.28	2.4e-05	0.00561	0.29	0.23	Resting heart rate;	chr6:7550975	chr6:7540451~7541338:-
LIHC	cis	rs2243480	1	rs937108	ENSG00000228409.4	CCT6P1	4.28	2.4e-05	0.00561	0.24	0.23	Diabetic kidney disease;	chr7:65963465	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35542501	ENSG00000228409.4	CCT6P1	4.28	2.4e-05	0.00561	0.24	0.23	Diabetic kidney disease;	chr7:65966228	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.711	rs1626926	ENSG00000228409.4	CCT6P1	4.28	2.4e-05	0.00561	0.24	0.23	Diabetic kidney disease;	chr7:65970805	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.708	rs781141	ENSG00000228409.4	CCT6P1	4.28	2.4e-05	0.00561	0.24	0.23	Diabetic kidney disease;	chr7:65973566	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs781142	ENSG00000228409.4	CCT6P1	4.28	2.4e-05	0.00561	0.24	0.23	Diabetic kidney disease;	chr7:65973791	chr7:65751142~65763354:+
LIHC	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-4.28	2.4e-05	0.00561	-0.2	-0.23	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
LIHC	cis	rs12681366	0.919	rs13248829	ENSG00000253704.1	RP11-267M23.4	4.28	2.4e-05	0.00561	0.26	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94553722~94569745:+
LIHC	cis	rs11247230	0.901	rs2411841	ENSG00000270127.2	RP11-526I2.5	4.28	2.4e-05	0.00561	0.27	0.23	Optic cup area;	chr15:100652046	chr15:100547765~100550153:-
LIHC	cis	rs709400	0.93	rs10134399	ENSG00000258534.1	CTD-2134A5.4	4.28	2.41e-05	0.00562	0.34	0.23	Body mass index;	chr14:103617120	chr14:103854366~103880111:-
LIHC	cis	rs4925386	0.959	rs4925385	ENSG00000226332.2	RP11-157P1.4	-4.28	2.41e-05	0.00562	-0.23	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62305432~62306325:-
LIHC	cis	rs4925386	0.921	rs11204472	ENSG00000226332.2	RP11-157P1.4	-4.28	2.41e-05	0.00562	-0.23	-0.23	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62305432~62306325:-
LIHC	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	4.28	2.41e-05	0.00562	0.25	0.23	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
LIHC	cis	rs9652601	0.845	rs7184615	ENSG00000274038.1	RP11-66H6.4	-4.28	2.41e-05	0.00562	-0.27	-0.23	Systemic lupus erythematosus;	chr16:11071685	chr16:11056556~11057034:+
LIHC	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	4.28	2.41e-05	0.00562	0.29	0.23	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
LIHC	cis	rs6480314	0.711	rs61857177	ENSG00000233590.1	RP11-153K11.3	-4.28	2.41e-05	0.00562	-0.38	-0.23	Optic nerve measurement (disc area);	chr10:68187015	chr10:68233251~68242379:-
LIHC	cis	rs2310173	0.575	rs4851527	ENSG00000281162.1	LINC01127	4.28	2.41e-05	0.00563	0.24	0.23	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102005914	chr2:101962056~101987167:+
LIHC	cis	rs4561483	0.832	rs171656	ENSG00000261560.1	RP11-166B2.3	-4.28	2.41e-05	0.00563	-0.25	-0.23	Testicular germ cell tumor;	chr16:11859310	chr16:11881075~11882569:-
LIHC	cis	rs2243480	1	rs13247184	ENSG00000228409.4	CCT6P1	4.28	2.41e-05	0.00563	0.25	0.23	Diabetic kidney disease;	chr7:65893941	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35283677	ENSG00000228409.4	CCT6P1	4.28	2.41e-05	0.00563	0.25	0.23	Diabetic kidney disease;	chr7:65894246	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35421653	ENSG00000228409.4	CCT6P1	4.28	2.41e-05	0.00563	0.25	0.23	Diabetic kidney disease;	chr7:65898442	chr7:65751142~65763354:+
LIHC	cis	rs11064837	0.55	rs11064849	ENSG00000248636.5	RP11-768F21.1	4.28	2.41e-05	0.00563	0.39	0.23	Schizophrenia;	chr12:119616782	chr12:119387987~119668079:-
LIHC	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-4.28	2.42e-05	0.00564	-0.26	-0.23	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-4.28	2.42e-05	0.00564	-0.26	-0.23	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
LIHC	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-4.28	2.42e-05	0.00564	-0.28	-0.23	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
LIHC	cis	rs950881	0.932	rs72823632	ENSG00000234389.1	AC007278.3	4.28	2.42e-05	0.00564	0.3	0.23	Allergy;	chr2:102315074	chr2:102438713~102440475:+
LIHC	cis	rs950881	0.932	rs72823635	ENSG00000234389.1	AC007278.3	4.28	2.42e-05	0.00564	0.3	0.23	Allergy;	chr2:102315152	chr2:102438713~102440475:+
LIHC	cis	rs950881	1	rs950881	ENSG00000234389.1	AC007278.3	4.28	2.42e-05	0.00564	0.3	0.23	Allergy;	chr2:102316052	chr2:102438713~102440475:+
LIHC	cis	rs950881	0.932	rs10179458	ENSG00000234389.1	AC007278.3	4.28	2.42e-05	0.00564	0.3	0.23	Allergy;	chr2:102318514	chr2:102438713~102440475:+
LIHC	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-4.28	2.42e-05	0.00564	-0.44	-0.23	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
LIHC	cis	rs9595908	0.931	rs7998440	ENSG00000212293.1	SNORA16	4.28	2.42e-05	0.00564	0.26	0.23	Body mass index;	chr13:32551069	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.965	rs7991314	ENSG00000212293.1	SNORA16	4.28	2.42e-05	0.00564	0.26	0.23	Body mass index;	chr13:32551937	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.965	rs7328733	ENSG00000212293.1	SNORA16	4.28	2.42e-05	0.00564	0.26	0.23	Body mass index;	chr13:32552600	chr13:32420390~32420516:-
LIHC	cis	rs2060793	0.741	rs10741653	ENSG00000251991.1	RNU7-49P	4.28	2.42e-05	0.00564	0.25	0.23	Vitamin D levels;	chr11:14683294	chr11:14478892~14478953:+
LIHC	cis	rs9400467	0.528	rs465796	ENSG00000271789.1	RP5-1112D6.7	-4.28	2.42e-05	0.00564	-0.22	-0.23	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111297126~111298510:+
LIHC	cis	rs2739330	0.828	rs4822454	ENSG00000206090.4	AP000350.7	4.28	2.42e-05	0.00565	0.27	0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23939998~23942798:+
LIHC	cis	rs2333021	0.78	rs2243596	ENSG00000259015.1	RP11-109N23.6	-4.28	2.42e-05	0.00565	-0.27	-0.23	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72961952	chr14:72960595~72961993:+
LIHC	cis	rs4938303	0.633	rs567209	ENSG00000254851.1	RP11-109L13.1	4.28	2.42e-05	0.00565	0.31	0.23	Triglycerides;	chr11:116664111	chr11:117135528~117138582:+
LIHC	cis	rs75920871	0.688	rs77320801	ENSG00000254851.1	RP11-109L13.1	-4.28	2.42e-05	0.00565	-0.47	-0.23	Subjective well-being;	chr11:116965633	chr11:117135528~117138582:+
LIHC	cis	rs2749592	0.55	rs7917262	ENSG00000276805.1	RP11-291L22.6	-4.28	2.42e-05	0.00565	-0.27	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38451030~38451785:+
LIHC	cis	rs2749592	0.55	rs9733309	ENSG00000276805.1	RP11-291L22.6	-4.28	2.42e-05	0.00565	-0.27	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38451030~38451785:+
LIHC	cis	rs2749592	0.55	rs7081464	ENSG00000276805.1	RP11-291L22.6	-4.28	2.42e-05	0.00565	-0.27	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38451030~38451785:+
LIHC	cis	rs2749592	0.531	rs994804	ENSG00000276805.1	RP11-291L22.6	-4.28	2.42e-05	0.00565	-0.27	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38451030~38451785:+
LIHC	cis	rs7726839	0.54	rs12517638	ENSG00000271781.1	CTD-2589H19.6	-4.28	2.42e-05	0.00565	-0.34	-0.23	Obesity-related traits;	chr5:645369	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs4957081	ENSG00000271781.1	CTD-2589H19.6	-4.28	2.42e-05	0.00565	-0.34	-0.23	Obesity-related traits;	chr5:646303	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs72705097	ENSG00000271781.1	CTD-2589H19.6	-4.28	2.42e-05	0.00565	-0.34	-0.23	Obesity-related traits;	chr5:654952	chr5:675826~676616:+
LIHC	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	4.28	2.43e-05	0.00565	0.17	0.23	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
LIHC	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	4.28	2.43e-05	0.00565	0.17	0.23	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
LIHC	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	4.28	2.43e-05	0.00566	0.26	0.23	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
LIHC	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-4.28	2.43e-05	0.00566	-0.27	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
LIHC	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-4.28	2.43e-05	0.00566	-0.27	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
LIHC	cis	rs2744375	0.6	rs2078438	ENSG00000261189.1	RP3-512B11.3	4.28	2.43e-05	0.00566	0.29	0.23	Resting heart rate;	chr6:7552996	chr6:7540451~7541338:-
LIHC	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-4.28	2.43e-05	0.00566	-0.35	-0.23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
LIHC	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	4.28	2.43e-05	0.00566	0.25	0.23	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
LIHC	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	4.28	2.43e-05	0.00566	0.3	0.23	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
LIHC	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-4.28	2.43e-05	0.00566	-0.27	-0.23	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
LIHC	cis	rs9952991	0.527	rs2847259	ENSG00000260302.1	RP11-973H7.1	-4.28	2.43e-05	0.00566	-0.29	-0.23	Inflammatory skin disease;	chr18:12775822	chr18:12774651~12775923:-
LIHC	cis	rs1499614	1	rs34250985	ENSG00000230295.1	RP11-458F8.2	-4.28	2.43e-05	0.00567	-0.26	-0.23	Gout;	chr7:66696075	chr7:66880708~66882981:+
LIHC	cis	rs2717559	0.542	rs2717590	ENSG00000253196.1	RP11-706C16.7	-4.28	2.43e-05	0.00567	-0.25	-0.23	Urinary tract infection frequency;	chr8:142819296	chr8:142763116~142766427:+
LIHC	cis	rs875971	0.545	rs1796219	ENSG00000273024.4	INTS4P2	4.28	2.43e-05	0.00567	0.26	0.23	Aortic root size;	chr7:66645977	chr7:65647864~65715661:+
LIHC	cis	rs1577917	1	rs12207610	ENSG00000234155.1	RP11-30P6.6	4.28	2.43e-05	0.00567	0.29	0.23	Response to antipsychotic treatment;	chr6:85978298	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs12203457	ENSG00000234155.1	RP11-30P6.6	4.28	2.43e-05	0.00567	0.29	0.23	Response to antipsychotic treatment;	chr6:85979559	chr6:85387219~85390186:-
LIHC	cis	rs160451	1	rs160449	ENSG00000251136.7	RP11-37B2.1	4.28	2.44e-05	0.00568	0.21	0.23	Leprosy;	chr8:89648287	chr8:89609409~89757727:-
LIHC	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	4.28	2.44e-05	0.00568	0.23	0.23	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	4.28	2.44e-05	0.00568	0.23	0.23	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	4.28	2.44e-05	0.00568	0.23	0.23	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	4.28	2.44e-05	0.00568	0.23	0.23	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
LIHC	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	4.28	2.44e-05	0.00568	0.23	0.23	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	4.28	2.44e-05	0.00568	0.23	0.23	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
LIHC	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	4.28	2.44e-05	0.00568	0.23	0.23	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
LIHC	cis	rs12571093	0.773	rs3740588	ENSG00000233590.1	RP11-153K11.3	4.28	2.44e-05	0.00568	0.34	0.23	Optic nerve measurement (disc area);	chr10:68261079	chr10:68233251~68242379:-
LIHC	cis	rs27434	0.605	rs2351012	ENSG00000272109.1	CTD-2260A17.3	-4.28	2.44e-05	0.00568	-0.3	-0.23	Ankylosing spondylitis;	chr5:96856044	chr5:96804353~96806105:+
LIHC	cis	rs919433	0.889	rs10931782	ENSG00000231621.1	AC013264.2	4.28	2.44e-05	0.00568	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197346855	chr2:197197991~197199273:+
LIHC	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-4.28	2.44e-05	0.00569	-0.27	-0.23	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
LIHC	cis	rs875971	0.545	rs4441996	ENSG00000228409.4	CCT6P1	4.28	2.44e-05	0.00569	0.19	0.23	Aortic root size;	chr7:66123233	chr7:65751142~65763354:+
LIHC	cis	rs6445975	0.666	rs3922713	ENSG00000272360.1	RP11-359I18.5	4.28	2.44e-05	0.00569	0.3	0.23	Systemic lupus erythematosus;	chr3:58398061	chr3:58490830~58491291:-
LIHC	cis	rs27434	0.615	rs61112531	ENSG00000272109.1	CTD-2260A17.3	4.28	2.44e-05	0.00569	0.3	0.23	Ankylosing spondylitis;	chr5:96856117	chr5:96804353~96806105:+
LIHC	cis	rs7208859	0.673	rs9889755	ENSG00000266490.1	CTD-2349P21.9	-4.28	2.44e-05	0.00569	-0.27	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30792372~30792833:+
LIHC	cis	rs10829156	0.741	rs9731044	ENSG00000240291.1	RP11-499P20.2	4.28	2.45e-05	0.0057	0.37	0.23	Sudden cardiac arrest;	chr10:18605356	chr10:18513115~18545651:-
LIHC	cis	rs10829156	0.538	rs61840846	ENSG00000240291.1	RP11-499P20.2	4.28	2.45e-05	0.0057	0.37	0.23	Sudden cardiac arrest;	chr10:18606393	chr10:18513115~18545651:-
LIHC	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	4.28	2.45e-05	0.0057	0.32	0.23	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
LIHC	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	4.28	2.45e-05	0.0057	0.32	0.23	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
LIHC	cis	rs948562	0.947	rs7481388	ENSG00000280010.1	AP001350.4	4.28	2.45e-05	0.0057	0.38	0.23	Lymphoma;	chr11:58592143	chr11:58627435~58628528:+
LIHC	cis	rs1005277	0.579	rs1740735	ENSG00000099251.13	HSD17B7P2	4.28	2.45e-05	0.0057	0.27	0.23	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38356380~38378505:+
LIHC	cis	rs3812762	0.917	rs11042066	ENSG00000254860.4	TMEM9B-AS1	-4.28	2.45e-05	0.0057	-0.23	-0.23	Hypospadias;	chr11:8788013	chr11:8964675~8977527:+
LIHC	cis	rs6088765	0.596	rs7280	ENSG00000126005.14	MMP24-AS1	-4.28	2.45e-05	0.0057	-0.29	-0.23	Ulcerative colitis;	chr20:35276681	chr20:35216462~35278131:-
LIHC	cis	rs6480314	0.711	rs78671884	ENSG00000233590.1	RP11-153K11.3	-4.28	2.45e-05	0.0057	-0.38	-0.23	Optic nerve measurement (disc area);	chr10:68192669	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.711	rs61857181	ENSG00000233590.1	RP11-153K11.3	-4.28	2.45e-05	0.0057	-0.38	-0.23	Optic nerve measurement (disc area);	chr10:68193771	chr10:68233251~68242379:-
LIHC	cis	rs7208859	0.673	rs73263785	ENSG00000266490.1	CTD-2349P21.9	4.28	2.45e-05	0.0057	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs55904046	ENSG00000266490.1	CTD-2349P21.9	4.28	2.45e-05	0.0057	0.29	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30792372~30792833:+
LIHC	cis	rs5756813	0.661	rs2071910	ENSG00000233360.4	Z83844.1	4.28	2.45e-05	0.00571	0.28	0.23	Optic cup area;Vertical cup-disc ratio;	chr22:37808252	chr22:37641832~37658377:-
LIHC	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	4.28	2.45e-05	0.00571	0.21	0.23	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
LIHC	cis	rs73198271	0.855	rs57301822	ENSG00000253893.2	FAM85B	4.28	2.45e-05	0.00571	0.35	0.23	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751132	chr8:8167819~8226614:-
LIHC	cis	rs960902	0.818	rs58694726	ENSG00000213553.4	RPLP0P6	4.28	2.45e-05	0.00571	0.19	0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37491553	chr2:38481851~38482804:+
LIHC	cis	rs7586604	0.608	rs2115600	ENSG00000230393.1	AC092667.2	4.28	2.45e-05	0.00571	0.29	0.23	Cannabis dependence symptom count;	chr2:99781169	chr2:100104919~100107504:+
LIHC	cis	rs2749592	0.611	rs2505199	ENSG00000263064.2	RP11-291L22.7	4.28	2.46e-05	0.00572	0.24	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:38103529	chr10:38448689~38448949:+
LIHC	cis	rs2749592	0.588	rs2505192	ENSG00000263064.2	RP11-291L22.7	4.28	2.46e-05	0.00572	0.24	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr10:38106095	chr10:38448689~38448949:+
LIHC	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	4.28	2.46e-05	0.00572	0.27	0.23	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
LIHC	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-4.28	2.46e-05	0.00572	-0.23	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
LIHC	cis	rs9450351	0.546	rs9344550	ENSG00000203875.9	SNHG5	-4.28	2.46e-05	0.00572	-0.48	-0.23	Interferon gamma-induced protein 10 levels;	chr6:85829000	chr6:85660950~85678736:-
LIHC	cis	rs11767557	1	rs11763230	ENSG00000229153.4	EPHA1-AS1	4.28	2.46e-05	0.00572	0.35	0.23	Alzheimer's disease (late onset);	chr7:143411748	chr7:143407813~143523449:+
LIHC	cis	rs921968	0.54	rs6746040	ENSG00000272555.1	RP11-459I19.1	-4.28	2.46e-05	0.00572	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218724167	chr2:218818690~218819144:+
LIHC	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	4.28	2.46e-05	0.00573	0.26	0.23	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
LIHC	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-4.28	2.46e-05	0.00573	-0.29	-0.23	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
LIHC	cis	rs9675120	0.638	rs4626	ENSG00000262006.1	RP11-700H6.4	-4.28	2.46e-05	0.00573	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr17:50863061	chr17:50909637~50910232:-
LIHC	cis	rs7702057	0.53	rs7703978	ENSG00000271918.1	CTD-2287O16.5	4.28	2.46e-05	0.00573	0.31	0.23	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116083807~116085416:-
LIHC	cis	rs9843304	0.585	rs9842139	ENSG00000244503.1	RP11-278L15.6	-4.28	2.46e-05	0.00573	-0.28	-0.23	Gallstone disease;	chr3:149489730	chr3:149494660~149495995:+
LIHC	cis	rs12701220	0.842	rs10236293	ENSG00000229043.2	AC091729.9	-4.28	2.47e-05	0.00574	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:993001	chr7:1160374~1165267:+
LIHC	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	4.28	2.47e-05	0.00574	0.18	0.23	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
LIHC	cis	rs11096990	0.964	rs16988409	ENSG00000249685.1	RP11-360F5.3	4.28	2.47e-05	0.00574	0.3	0.23	Cognitive function;	chr4:39267730	chr4:39133913~39135608:+
LIHC	cis	rs1005277	0.505	rs7917943	ENSG00000275858.1	RP11-291L22.8	-4.28	2.47e-05	0.00574	-0.25	-0.23	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38450738~38451069:-
LIHC	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-4.28	2.47e-05	0.00574	-0.26	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
LIHC	cis	rs2562456	0.652	rs4809145	ENSG00000268555.1	RP11-678G14.3	4.28	2.47e-05	0.00574	0.3	0.23	Pain;	chr19:21597907	chr19:21570822~21587322:-
LIHC	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	4.28	2.47e-05	0.00574	0.24	0.23	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
LIHC	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-4.28	2.47e-05	0.00575	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
LIHC	cis	rs2032447	0.736	rs115810	ENSG00000242387.1	HIST1H2APS2	4.28	2.47e-05	0.00575	0.3	0.23	Intelligence (multi-trait analysis);	chr6:25975655	chr6:25882026~25882395:-
LIHC	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-4.28	2.47e-05	0.00575	-0.21	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
LIHC	cis	rs10871290	0.881	rs11649338	ENSG00000261079.1	RP11-252A24.3	-4.28	2.47e-05	0.00575	-0.25	-0.23	Breast cancer;	chr16:74437522	chr16:74367462~74369826:+
LIHC	cis	rs2439831	0.85	rs11856795	ENSG00000166763.7	STRCP1	4.28	2.47e-05	0.00575	0.35	0.23	Lung cancer in ever smokers;	chr15:43868384	chr15:43699488~43718184:-
LIHC	cis	rs4578769	0.959	rs9955664	ENSG00000265943.1	RP11-739L10.1	4.28	2.47e-05	0.00575	0.29	0.23	Eosinophil percentage of white cells;	chr18:22901330	chr18:22699481~22933764:-
LIHC	cis	rs7508	0.511	rs2237853	ENSG00000253671.1	RP11-806O11.1	-4.28	2.47e-05	0.00575	-0.3	-0.23	Atrial fibrillation;	chr8:18020371	chr8:17808941~17820868:+
LIHC	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-4.28	2.47e-05	0.00575	-0.18	-0.23	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
LIHC	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	4.28	2.47e-05	0.00575	0.27	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
LIHC	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-4.28	2.47e-05	0.00575	-0.23	-0.23	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
LIHC	cis	rs494453	0.845	rs523650	ENSG00000227811.2	FAM212B-AS1	-4.28	2.48e-05	0.00576	-0.25	-0.23	Osteoporosis-related phenotypes;	chr1:111699642	chr1:111739841~111747798:+
LIHC	cis	rs9595908	0.785	rs12428283	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32653775	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596035	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32654803	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs4942791	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32663085	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9591230	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32663944	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs2874282	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32665876	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596057	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32669831	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596059	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32670145	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596060	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32670467	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs7317147	ENSG00000212293.1	SNORA16	4.28	2.48e-05	0.00577	0.25	0.23	Body mass index;	chr13:32670838	chr13:32420390~32420516:-
LIHC	cis	rs244293	0.965	rs244352	ENSG00000275710.1	RP11-257O5.4	-4.28	2.48e-05	0.00577	-0.25	-0.23	Menarche (age at onset);	chr17:55118117	chr17:54964474~54964679:+
LIHC	cis	rs9303401	0.555	rs8073699	ENSG00000265415.1	CTD-2510F5.4	4.28	2.48e-05	0.00577	0.16	0.23	Cognitive test performance;	chr17:59158956	chr17:59202677~59203829:-
LIHC	cis	rs901683	0.85	rs60791882	ENSG00000230869.1	CTGLF10P	-4.28	2.48e-05	0.00577	-0.52	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45604590	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs73291195	ENSG00000230869.1	CTGLF10P	-4.28	2.48e-05	0.00577	-0.52	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45605573	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs73291198	ENSG00000230869.1	CTGLF10P	-4.28	2.48e-05	0.00577	-0.52	-0.23	Mean corpuscular volume;Red blood cell traits;	chr10:45605638	chr10:45678692~45700532:+
LIHC	cis	rs7412746	0.658	rs72704652	ENSG00000231073.1	RP11-316M1.3	4.28	2.48e-05	0.00577	0.24	0.23	Melanoma;	chr1:150846994	chr1:150973123~150975534:+
LIHC	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	4.28	2.48e-05	0.00577	0.2	0.23	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
LIHC	cis	rs11233413	0.874	rs4515990	ENSG00000246067.6	RAB30-AS1	4.27	2.48e-05	0.00577	0.31	0.23	Economic and political preferences (feminism/equality);	chr11:83041420	chr11:83072066~83106719:+
LIHC	cis	rs921968	0.565	rs3731876	ENSG00000272555.1	RP11-459I19.1	-4.27	2.48e-05	0.00577	-0.24	-0.23	Mean corpuscular hemoglobin concentration;	chr2:218738096	chr2:218818690~218819144:+
LIHC	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-4.27	2.49e-05	0.00578	-0.24	-0.23	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
LIHC	cis	rs11098499	1	rs11098500	ENSG00000260091.1	RP11-33B1.4	-4.27	2.49e-05	0.00578	-0.16	-0.23	Corneal astigmatism;	chr4:119298084	chr4:119409333~119410233:+
LIHC	cis	rs2072510	0.569	rs61937880	ENSG00000257878.1	RP11-256L6.3	-4.27	2.49e-05	0.00578	-0.3	-0.23	Metabolite levels (small molecules and protein measures);	chr12:95997089	chr12:95996521~96011489:+
LIHC	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-4.27	2.49e-05	0.00579	-0.24	-0.23	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
LIHC	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	4.27	2.49e-05	0.00579	0.22	0.23	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
LIHC	cis	rs2072510	0.722	rs2247323	ENSG00000257878.1	RP11-256L6.3	-4.27	2.49e-05	0.00579	-0.19	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96030478	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.722	rs2247313	ENSG00000257878.1	RP11-256L6.3	-4.27	2.49e-05	0.00579	-0.19	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96030669	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.722	rs2247309	ENSG00000257878.1	RP11-256L6.3	-4.27	2.49e-05	0.00579	-0.19	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96030764	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.75	rs2660898	ENSG00000257878.1	RP11-256L6.3	-4.27	2.49e-05	0.00579	-0.19	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96032219	chr12:95996521~96011489:+
LIHC	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	4.27	2.49e-05	0.00579	0.29	0.23	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
LIHC	cis	rs4356203	0.87	rs214922	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215576	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs214921	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215914	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs214918	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17218302	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs214915	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220226	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs214914	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220345	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.84	rs214911	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220691	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs214910	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221242	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs214909	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221731	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs603618	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17224815	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.905	rs618331	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17225789	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs7949699	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17226161	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs10832745	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228128	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs11024204	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228258	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs10832746	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228406	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs10832747	ENSG00000260196.1	RP1-239B22.5	-4.27	2.5e-05	0.0058	-0.27	-0.23	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228472	chr11:17380649~17383531:+
LIHC	cis	rs9595908	0.965	rs9595795	ENSG00000212293.1	SNORA16	4.27	2.5e-05	0.0058	0.27	0.23	Body mass index;	chr13:32548658	chr13:32420390~32420516:-
LIHC	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-4.27	2.5e-05	0.0058	-0.25	-0.23	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
LIHC	cis	rs960902	0.747	rs6724538	ENSG00000213553.4	RPLP0P6	-4.27	2.5e-05	0.00581	-0.18	-0.23	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37500875	chr2:38481851~38482804:+
LIHC	cis	rs2243480	0.711	rs2420172	ENSG00000230295.1	RP11-458F8.2	4.27	2.5e-05	0.00581	0.24	0.23	Diabetic kidney disease;	chr7:66170354	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs6974723	ENSG00000230295.1	RP11-458F8.2	4.27	2.5e-05	0.00581	0.24	0.23	Diabetic kidney disease;	chr7:66172952	chr7:66880708~66882981:+
LIHC	cis	rs875971	0.545	rs73146609	ENSG00000273024.4	INTS4P2	-4.27	2.5e-05	0.00581	-0.26	-0.23	Aortic root size;	chr7:66302477	chr7:65647864~65715661:+
LIHC	cis	rs11098499	0.909	rs11723839	ENSG00000260091.1	RP11-33B1.4	-4.27	2.5e-05	0.00581	-0.16	-0.23	Corneal astigmatism;	chr4:119378518	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs12506546	ENSG00000260091.1	RP11-33B1.4	-4.27	2.5e-05	0.00581	-0.16	-0.23	Corneal astigmatism;	chr4:119380463	chr4:119409333~119410233:+
LIHC	cis	rs7129556	0.69	rs947841	ENSG00000254459.1	RP11-91P24.7	4.27	2.5e-05	0.00582	0.37	0.23	Weight loss (gastric bypass surgery);	chr11:77881863	chr11:77829654~77872262:-
LIHC	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	4.27	2.5e-05	0.00582	0.26	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
LIHC	cis	rs11098499	0.863	rs3775843	ENSG00000260091.1	RP11-33B1.4	-4.27	2.51e-05	0.00582	-0.16	-0.23	Corneal astigmatism;	chr4:119506689	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs3775844	ENSG00000260091.1	RP11-33B1.4	-4.27	2.51e-05	0.00582	-0.16	-0.23	Corneal astigmatism;	chr4:119506878	chr4:119409333~119410233:+
LIHC	cis	rs6480314	0.519	rs3998872	ENSG00000233590.1	RP11-153K11.3	-4.27	2.51e-05	0.00582	-0.37	-0.23	Optic nerve measurement (disc area);	chr10:68184845	chr10:68233251~68242379:-
LIHC	cis	rs4356975	0.509	rs5014975	ENSG00000196472.4	RP13-644M16.4	4.27	2.51e-05	0.00582	0.25	0.23	Obesity-related traits;	chr4:69130244	chr4:69181660~69182372:+
LIHC	cis	rs4356975	0.867	rs6600869	ENSG00000250919.1	RP11-813N20.3	-4.27	2.51e-05	0.00583	-0.22	-0.23	Obesity-related traits;	chr4:69075937	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.836	rs6600870	ENSG00000250919.1	RP11-813N20.3	-4.27	2.51e-05	0.00583	-0.22	-0.23	Obesity-related traits;	chr4:69075944	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs7442394	ENSG00000250919.1	RP11-813N20.3	-4.27	2.51e-05	0.00583	-0.22	-0.23	Obesity-related traits;	chr4:69076309	chr4:69027831~69044578:+
LIHC	cis	rs2072510	0.593	rs2247304	ENSG00000257715.1	RP11-256L6.2	-4.27	2.51e-05	0.00583	-0.31	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96030887	chr12:96025323~96027971:+
LIHC	cis	rs638893	0.578	rs500254	ENSG00000255422.1	AP002954.4	4.27	2.51e-05	0.00583	0.5	0.23	Vitiligo;	chr11:118808071	chr11:118704607~118750263:+
LIHC	cis	rs709400	0.832	rs55864158	ENSG00000258534.1	CTD-2134A5.4	4.27	2.51e-05	0.00583	0.34	0.23	Body mass index;	chr14:103602242	chr14:103854366~103880111:-
LIHC	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	4.27	2.51e-05	0.00583	0.28	0.23	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
LIHC	cis	rs244293	0.76	rs12945393	ENSG00000275710.1	RP11-257O5.4	4.27	2.51e-05	0.00583	0.25	0.23	Menarche (age at onset);	chr17:54967882	chr17:54964474~54964679:+
LIHC	cis	rs113084984	0.718	rs1865574	ENSG00000271952.1	RP11-245G13.2	-4.27	2.52e-05	0.00584	-0.28	-0.23	Breast cancer;	chr2:11541312	chr2:10878269~10885118:+
LIHC	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	4.27	2.52e-05	0.00584	0.25	0.23	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
LIHC	cis	rs3733589	0.744	rs2276963	ENSG00000250413.1	RP11-448G15.1	4.27	2.52e-05	0.00584	0.36	0.23	Renal overload gout;	chr4:10021215	chr4:10006482~10009725:+
LIHC	cis	rs17713451	0.593	rs74882587	ENSG00000204894.4	RP11-208G20.2	4.27	2.52e-05	0.00584	0.46	0.23	Interleukin-4 levels;	chr7:151581002	chr7:152367171~152367260:+
LIHC	cis	rs6439153	0.933	rs6799008	ENSG00000231305.3	RP11-723O4.2	4.27	2.52e-05	0.00584	0.25	0.23	Pneumococcal bacteremia;	chr3:128998544	chr3:128861313~128871540:-
LIHC	cis	rs709400	0.643	rs11621777	ENSG00000258534.1	CTD-2134A5.4	4.27	2.52e-05	0.00585	0.34	0.23	Body mass index;	chr14:103605753	chr14:103854366~103880111:-
LIHC	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	4.27	2.52e-05	0.00585	0.2	0.23	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
LIHC	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	4.27	2.52e-05	0.00585	0.29	0.23	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
LIHC	cis	rs2072510	0.722	rs2540490	ENSG00000257878.1	RP11-256L6.3	-4.27	2.52e-05	0.00585	-0.2	-0.23	Metabolite levels (small molecules and protein measures);	chr12:96032494	chr12:95996521~96011489:+
LIHC	cis	rs160451	0.966	rs2101854	ENSG00000251136.7	RP11-37B2.1	4.27	2.52e-05	0.00585	0.2	0.23	Leprosy;	chr8:89663517	chr8:89609409~89757727:-
LIHC	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-4.27	2.52e-05	0.00585	-0.39	-0.23	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
LIHC	cis	rs5760092	0.572	rs738806	ENSG00000206090.4	AP000350.7	4.27	2.52e-05	0.00585	0.3	0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23939998~23942798:+
LIHC	cis	rs6901152	0.525	rs1424927	ENSG00000217648.1	RP1-95L4.4	-4.27	2.52e-05	0.00585	-0.27	-0.23	Acute lymphoblastic leukemia (childhood);	chr6:143367996	chr6:143342246~143343383:+
LIHC	cis	rs2243480	1	rs78803505	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65917585	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34933526	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65918212	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34577383	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65920739	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs6949812	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65922114	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs6970243	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65923503	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs7794661	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65924743	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs7795242	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65925107	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.708	rs35310401	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65925372	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35058610	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65925938	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs2177703	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65926730	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35432774	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65928032	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs56985706	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65929575	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs60683927	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65929781	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs58062456	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65929865	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34529418	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65938222	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.901	rs35087093	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65940221	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35046236	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65943626	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs36068983	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65944004	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs68189316	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65944182	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.803	rs34804747	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65947955	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs11538349	ENSG00000230295.1	RP11-458F8.2	-4.27	2.53e-05	0.00586	-0.24	-0.23	Diabetic kidney disease;	chr7:65956884	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.831	rs7806717	ENSG00000230295.1	RP11-458F8.2	4.27	2.53e-05	0.00586	0.24	0.23	Diabetic kidney disease;	chr7:65928187	chr7:66880708~66882981:+
LIHC	cis	rs4650994	0.524	rs2476558	ENSG00000273384.1	RP5-1098D14.1	-4.27	2.53e-05	0.00586	-0.28	-0.23	HDL cholesterol;HDL cholesterol levels;	chr1:178611818	chr1:178651706~178652282:+
LIHC	cis	rs1075232	0.655	rs28451043	ENSG00000270055.1	CTD-3092A11.2	-4.27	2.53e-05	0.00586	-0.44	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31295359	chr15:30487963~30490313:+
LIHC	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-4.27	2.53e-05	0.00586	-0.18	-0.23	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
LIHC	cis	rs728616	0.717	rs111403425	ENSG00000225484.5	NUTM2B-AS1	-4.27	2.53e-05	0.00586	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.867	rs78131725	ENSG00000225484.5	NUTM2B-AS1	-4.27	2.53e-05	0.00586	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.867	rs12411407	ENSG00000225484.5	NUTM2B-AS1	-4.27	2.53e-05	0.00586	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:79663088~79826594:-
LIHC	cis	rs728616	0.867	rs61859008	ENSG00000225484.5	NUTM2B-AS1	-4.27	2.53e-05	0.00586	-0.49	-0.23	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:79663088~79826594:-
LIHC	cis	rs1876905	0.539	rs240962	ENSG00000271789.1	RP5-1112D6.7	4.27	2.53e-05	0.00587	0.26	0.22	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111297126~111298510:+
LIHC	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	4.27	2.53e-05	0.00587	0.34	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
LIHC	cis	rs4604234	0.573	rs11961361	ENSG00000272129.1	RP11-250B2.6	-4.27	2.53e-05	0.00587	-0.35	-0.22	Cancer;	chr6:80294840	chr6:80355424~80356859:+
LIHC	cis	rs4604234	0.541	rs11963917	ENSG00000272129.1	RP11-250B2.6	-4.27	2.53e-05	0.00587	-0.35	-0.22	Cancer;	chr6:80294843	chr6:80355424~80356859:+
LIHC	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-4.27	2.53e-05	0.00587	-0.26	-0.22	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
LIHC	cis	rs2749592	0.588	rs2504144	ENSG00000263064.2	RP11-291L22.7	4.27	2.53e-05	0.00587	0.24	0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:38094597	chr10:38448689~38448949:+
LIHC	cis	rs7809950	1	rs2293658	ENSG00000238832.1	snoU109	-4.27	2.53e-05	0.00587	-0.27	-0.22	Coronary artery disease;	chr7:107630122	chr7:107603363~107603507:+
LIHC	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-4.27	2.54e-05	0.00588	-0.17	-0.22	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
LIHC	cis	rs603446	0.541	rs59854309	ENSG00000254851.1	RP11-109L13.1	4.27	2.54e-05	0.00589	0.29	0.22	Triglycerides;	chr11:116696047	chr11:117135528~117138582:+
LIHC	cis	rs5742933	0.817	rs2033870	ENSG00000253559.1	OSGEPL1-AS1	-4.27	2.54e-05	0.00589	-0.29	-0.22	Ferritin levels;	chr2:189739104	chr2:189762704~189765556:+
LIHC	cis	rs7809950	0.798	rs2701687	ENSG00000238832.1	snoU109	4.27	2.54e-05	0.00589	0.25	0.22	Coronary artery disease;	chr7:107664183	chr7:107603363~107603507:+
LIHC	cis	rs709400	0.894	rs56017123	ENSG00000258534.1	CTD-2134A5.4	4.27	2.55e-05	0.0059	0.34	0.22	Body mass index;	chr14:103608940	chr14:103854366~103880111:-
LIHC	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-4.27	2.55e-05	0.0059	-0.25	-0.22	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
LIHC	cis	rs3845817	0.868	rs702891	ENSG00000281920.1	RP11-418H16.1	4.27	2.55e-05	0.0059	0.27	0.22	Bipolar disorder;	chr2:65531316	chr2:65623272~65628424:+
LIHC	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	4.27	2.55e-05	0.0059	0.26	0.22	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	4.27	2.55e-05	0.0059	0.26	0.22	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
LIHC	cis	rs8177253	0.665	rs6774822	ENSG00000244062.1	RP11-404G16.2	4.27	2.55e-05	0.0059	0.22	0.22	Iron status biomarkers;	chr3:133723168	chr3:133760300~133762363:+
LIHC	cis	rs3758785	0.679	rs13447595	ENSG00000255893.1	RP11-685N10.1	-4.27	2.55e-05	0.0059	-0.26	-0.22	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94489524	chr11:94472908~94473570:-
LIHC	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	4.27	2.55e-05	0.00591	0.23	0.22	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
LIHC	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-4.27	2.55e-05	0.00591	-0.22	-0.22	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-4.27	2.55e-05	0.00591	-0.22	-0.22	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
LIHC	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-4.27	2.55e-05	0.00591	-0.27	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
LIHC	cis	rs13083990	0.881	rs12635478	ENSG00000272758.4	RP11-299J3.8	4.27	2.55e-05	0.00591	0.24	0.22	Cardiac Troponin-T levels;	chr3:122289706	chr3:122416207~122443180:+
LIHC	cis	rs3845817	0.832	rs702883	ENSG00000281920.1	RP11-418H16.1	-4.27	2.55e-05	0.00591	-0.27	-0.22	Bipolar disorder;	chr2:65524951	chr2:65623272~65628424:+
LIHC	cis	rs3845817	0.838	rs702886	ENSG00000281920.1	RP11-418H16.1	-4.27	2.55e-05	0.00591	-0.27	-0.22	Bipolar disorder;	chr2:65526176	chr2:65623272~65628424:+
LIHC	cis	rs4578769	0.959	rs6507323	ENSG00000266850.1	RP11-370A5.1	-4.27	2.56e-05	0.00592	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22846715	chr18:22723491~22907721:-
LIHC	cis	rs1865760	0.516	rs10807007	ENSG00000216436.2	HIST1H2APS1	-4.27	2.56e-05	0.00592	-0.26	-0.22	Height;	chr6:26048703	chr6:25732497~25732827:+
LIHC	cis	rs1865760	0.516	rs9379819	ENSG00000216436.2	HIST1H2APS1	-4.27	2.56e-05	0.00592	-0.26	-0.22	Height;	chr6:26049591	chr6:25732497~25732827:+
LIHC	cis	rs9527	0.59	rs12355120	ENSG00000236937.2	PTGES3P4	4.27	2.56e-05	0.00592	0.29	0.22	Arsenic metabolism;	chr10:103092409	chr10:102845595~102845950:+
LIHC	cis	rs1075265	0.518	rs13414393	ENSG00000272156.1	RP11-477N3.1	-4.27	2.56e-05	0.00592	-0.27	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54082554~54085066:+
LIHC	cis	rs3812762	0.871	rs2173999	ENSG00000254860.4	TMEM9B-AS1	-4.27	2.56e-05	0.00593	-0.24	-0.22	Hypospadias;	chr11:8756530	chr11:8964675~8977527:+
LIHC	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-4.27	2.56e-05	0.00593	-0.28	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
LIHC	cis	rs4578769	0.879	rs7235234	ENSG00000266850.1	RP11-370A5.1	4.27	2.56e-05	0.00593	0.26	0.22	Eosinophil percentage of white cells;	chr18:22864239	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.879	rs9950650	ENSG00000266850.1	RP11-370A5.1	4.27	2.56e-05	0.00593	0.26	0.22	Eosinophil percentage of white cells;	chr18:22864537	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.733	rs7226388	ENSG00000266850.1	RP11-370A5.1	4.27	2.56e-05	0.00593	0.26	0.22	Eosinophil percentage of white cells;	chr18:22865371	chr18:22723491~22907721:-
LIHC	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	4.27	2.57e-05	0.00594	0.18	0.22	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
LIHC	cis	rs11121022	0.965	rs11121021	ENSG00000269925.1	RP3-467L1.6	-4.27	2.57e-05	0.00594	-0.23	-0.22	Morning vs. evening chronotype;	chr1:7775639	chr1:7776383~7776775:+
LIHC	cis	rs2074193	1	rs2074193	ENSG00000257906.1	RP1-90J4.1	-4.27	2.57e-05	0.00594	-0.29	-0.22	Migraine with aura;	chr12:47377646	chr12:47415008~47420179:+
LIHC	cis	rs748404	0.66	rs493377	ENSG00000166763.7	STRCP1	4.27	2.57e-05	0.00594	0.28	0.22	Lung cancer;	chr15:43481269	chr15:43699488~43718184:-
LIHC	cis	rs4578769	0.959	rs4800137	ENSG00000265943.1	RP11-739L10.1	4.27	2.57e-05	0.00594	0.29	0.22	Eosinophil percentage of white cells;	chr18:22899721	chr18:22699481~22933764:-
LIHC	cis	rs12887734	0.546	rs66676135	ENSG00000258534.1	CTD-2134A5.4	-4.27	2.57e-05	0.00594	-0.25	-0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103854366~103880111:-
LIHC	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	4.27	2.57e-05	0.00595	0.36	0.22	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
LIHC	cis	rs9400467	0.528	rs56827	ENSG00000271789.1	RP5-1112D6.7	-4.27	2.57e-05	0.00595	-0.22	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111297126~111298510:+
LIHC	cis	rs4578769	0.959	rs3851819	ENSG00000266850.1	RP11-370A5.1	4.27	2.57e-05	0.00595	0.26	0.22	Eosinophil percentage of white cells;	chr18:22881321	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.959	rs3851820	ENSG00000266850.1	RP11-370A5.1	4.27	2.57e-05	0.00595	0.26	0.22	Eosinophil percentage of white cells;	chr18:22881359	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.918	rs3851821	ENSG00000266850.1	RP11-370A5.1	4.27	2.57e-05	0.00595	0.26	0.22	Eosinophil percentage of white cells;	chr18:22882492	chr18:22723491~22907721:-
LIHC	cis	rs950881	0.932	rs72823621	ENSG00000234389.1	AC007278.3	4.27	2.57e-05	0.00595	0.3	0.22	Allergy;	chr2:102308975	chr2:102438713~102440475:+
LIHC	cis	rs9595908	0.827	rs9595885	ENSG00000212293.1	SNORA16	4.27	2.57e-05	0.00595	0.26	0.22	Body mass index;	chr13:32593913	chr13:32420390~32420516:-
LIHC	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-4.27	2.57e-05	0.00595	-0.24	-0.22	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
LIHC	cis	rs13043901	0.539	rs6097480	ENSG00000197670.6	RP4-724E16.2	-4.27	2.57e-05	0.00595	-0.22	-0.22	Type 2 diabetes (age of onset);	chr20:53560021	chr20:53552770~53575863:+
LIHC	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	4.27	2.57e-05	0.00596	0.3	0.22	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
LIHC	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	4.27	2.58e-05	0.00596	0.35	0.22	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
LIHC	cis	rs1223397	0.938	rs9381884	ENSG00000215022.6	RP1-257A7.4	-4.27	2.58e-05	0.00597	-0.27	-0.22	Blood pressure;	chr6:13278556	chr6:13264861~13295586:-
LIHC	cis	rs11971779	0.68	rs7785903	ENSG00000273391.1	RP11-634H22.1	4.27	2.58e-05	0.00597	0.2	0.22	Diisocyanate-induced asthma;	chr7:139437897	chr7:139359032~139359566:-
LIHC	cis	rs9457247	0.935	rs9348211	ENSG00000227598.1	RP1-167A14.2	4.27	2.58e-05	0.00597	0.24	0.22	Crohn's disease;	chr6:166961685	chr6:166969626~166999065:-
LIHC	cis	rs6920364	1	rs6920364	ENSG00000227598.1	RP1-167A14.2	4.27	2.58e-05	0.00597	0.24	0.22	Lung cancer;	chr6:166962978	chr6:166969626~166999065:-
LIHC	cis	rs9457247	1	rs2769352	ENSG00000227598.1	RP1-167A14.2	4.27	2.58e-05	0.00597	0.24	0.22	Crohn's disease;	chr6:166965131	chr6:166969626~166999065:-
LIHC	cis	rs2998286	0.723	rs332189	ENSG00000254635.4	WAC-AS1	-4.27	2.58e-05	0.00597	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28628292	chr10:28522652~28532743:-
LIHC	cis	rs4578769	0.959	rs9945114	ENSG00000266850.1	RP11-370A5.1	4.27	2.58e-05	0.00598	0.26	0.22	Eosinophil percentage of white cells;	chr18:22884044	chr18:22723491~22907721:-
LIHC	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-4.27	2.59e-05	0.00598	-0.26	-0.22	Height;	chr2:46616492	chr2:46668870~46670778:+
LIHC	cis	rs7989332	1	rs7989332	ENSG00000275964.1	RP11-61K9.3	-4.27	2.59e-05	0.00598	-0.3	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20476436	chr13:19863858~19865048:+
LIHC	cis	rs3812762	0.879	rs10769959	ENSG00000254860.4	TMEM9B-AS1	-4.27	2.59e-05	0.00598	-0.25	-0.22	Hypospadias;	chr11:8797286	chr11:8964675~8977527:+
LIHC	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-4.27	2.59e-05	0.00598	-0.24	-0.22	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
LIHC	cis	rs4578769	1	rs4578769	ENSG00000266850.1	RP11-370A5.1	4.27	2.59e-05	0.00598	0.26	0.22	Eosinophil percentage of white cells;	chr18:22815141	chr18:22723491~22907721:-
LIHC	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	4.26	2.59e-05	0.00599	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
LIHC	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	4.26	2.59e-05	0.00599	0.25	0.22	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
LIHC	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	4.26	2.59e-05	0.00599	0.23	0.22	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	4.26	2.59e-05	0.00599	0.23	0.22	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	4.26	2.59e-05	0.00599	0.23	0.22	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
LIHC	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-4.26	2.59e-05	0.00599	-0.24	-0.22	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
LIHC	cis	rs4578769	0.918	rs9957390	ENSG00000266850.1	RP11-370A5.1	4.26	2.59e-05	0.00599	0.26	0.22	Eosinophil percentage of white cells;	chr18:22840421	chr18:22723491~22907721:-
LIHC	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	4.26	2.59e-05	0.00599	0.27	0.22	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
LIHC	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-4.26	2.59e-05	0.00599	-0.27	-0.22	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
LIHC	cis	rs3812762	0.871	rs10734637	ENSG00000254860.4	TMEM9B-AS1	-4.26	2.59e-05	0.00599	-0.24	-0.22	Hypospadias;	chr11:8766678	chr11:8964675~8977527:+
LIHC	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	4.26	2.59e-05	0.00599	0.26	0.22	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
LIHC	cis	rs2115630	0.936	rs11073663	ENSG00000259295.5	CSPG4P12	-4.26	2.59e-05	0.00599	-0.26	-0.22	P wave terminal force;	chr15:84717037	chr15:85191438~85213905:+
LIHC	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	4.26	2.59e-05	0.00599	0.25	0.22	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
LIHC	cis	rs4218	0.597	rs4775114	ENSG00000277144.1	RP11-59H7.4	-4.26	2.6e-05	0.006	-0.25	-0.22	Social communication problems;	chr15:59059635	chr15:59115547~59116089:-
LIHC	cis	rs6745190	0.557	rs13011738	ENSG00000236153.1	AC104076.3	-4.26	2.6e-05	0.006	-0.32	-0.22	White blood cell count;	chr2:181121015	chr2:180979427~180980090:-
LIHC	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-4.26	2.6e-05	0.00601	-0.23	-0.22	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
LIHC	cis	rs11098499	0.909	rs28884220	ENSG00000260091.1	RP11-33B1.4	-4.26	2.6e-05	0.00601	-0.16	-0.22	Corneal astigmatism;	chr4:119386056	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs28793658	ENSG00000260091.1	RP11-33B1.4	-4.26	2.6e-05	0.00601	-0.16	-0.22	Corneal astigmatism;	chr4:119386059	chr4:119409333~119410233:+
LIHC	cis	rs875971	0.522	rs781144	ENSG00000273024.4	INTS4P2	-4.26	2.6e-05	0.00601	-0.27	-0.22	Aortic root size;	chr7:65975357	chr7:65647864~65715661:+
LIHC	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	4.26	2.6e-05	0.00601	0.29	0.22	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
LIHC	cis	rs4356975	0.932	rs4694604	ENSG00000250919.1	RP11-813N20.3	-4.26	2.6e-05	0.00601	-0.22	-0.22	Obesity-related traits;	chr4:69072745	chr4:69027831~69044578:+
LIHC	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	4.26	2.61e-05	0.00602	0.35	0.22	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
LIHC	cis	rs2243480	1	rs34136756	ENSG00000230295.1	RP11-458F8.2	-4.26	2.61e-05	0.00602	-0.24	-0.22	Diabetic kidney disease;	chr7:65916269	chr7:66880708~66882981:+
LIHC	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-4.26	2.61e-05	0.00602	-0.23	-0.22	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
LIHC	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-4.26	2.61e-05	0.00602	-0.23	-0.22	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
LIHC	cis	rs1062753	0.527	rs6519296	ENSG00000237037.8	NDUFA6-AS1	-4.26	2.61e-05	0.00602	-0.32	-0.22	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41952598	chr22:42090931~42137742:+
LIHC	cis	rs12887734	0.569	rs66953418	ENSG00000258534.1	CTD-2134A5.4	-4.26	2.61e-05	0.00603	-0.25	-0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103854366~103880111:-
LIHC	cis	rs10833905	1	rs10833895	ENSG00000246225.5	RP11-17A1.3	-4.26	2.61e-05	0.00603	-0.29	-0.22	Sudden cardiac arrest;	chr11:23006951	chr11:22829380~22945393:+
LIHC	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	4.26	2.61e-05	0.00603	0.25	0.22	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
LIHC	cis	rs7893279	0.505	rs7072624	ENSG00000225527.1	RP11-383B4.4	4.26	2.61e-05	0.00603	0.32	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18670865	chr10:18531849~18533336:-
LIHC	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	4.26	2.62e-05	0.00604	0.27	0.22	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
LIHC	cis	rs703842	0.616	rs10877024	ENSG00000270039.1	RP11-571M6.17	-4.26	2.62e-05	0.00604	-0.33	-0.22	Multiple sclerosis;	chr12:57832926	chr12:57803838~57804415:+
LIHC	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	4.26	2.62e-05	0.00605	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
LIHC	cis	rs709400	0.859	rs7693	ENSG00000258534.1	CTD-2134A5.4	4.26	2.62e-05	0.00605	0.34	0.22	Body mass index;	chr14:103557367	chr14:103854366~103880111:-
LIHC	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	4.26	2.62e-05	0.00605	0.33	0.22	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
LIHC	cis	rs4561483	0.801	rs33649	ENSG00000261560.1	RP11-166B2.3	-4.26	2.62e-05	0.00605	-0.26	-0.22	Testicular germ cell tumor;	chr16:11885751	chr16:11881075~11882569:-
LIHC	cis	rs1558001	1	rs1558001	ENSG00000230196.1	DDX43P3	4.26	2.63e-05	0.00606	0.24	0.22	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81777764	chr7:81610884~81611326:-
LIHC	cis	rs748404	0.66	rs2467738	ENSG00000166763.7	STRCP1	4.26	2.63e-05	0.00606	0.28	0.22	Lung cancer;	chr15:43447738	chr15:43699488~43718184:-
LIHC	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-4.26	2.63e-05	0.00606	-0.26	-0.22	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
LIHC	cis	rs12478296	1	rs12478296	ENSG00000261186.2	RP11-341N2.1	4.26	2.63e-05	0.00606	0.31	0.22	Obesity-related traits;	chr2:242106609	chr2:242087351~242088457:-
LIHC	cis	rs11098499	0.779	rs6815934	ENSG00000260091.1	RP11-33B1.4	-4.26	2.63e-05	0.00607	-0.15	-0.22	Corneal astigmatism;	chr4:119346155	chr4:119409333~119410233:+
LIHC	cis	rs9595908	0.568	rs4942923	ENSG00000212293.1	SNORA16	4.26	2.63e-05	0.00607	0.26	0.22	Body mass index;	chr13:32806887	chr13:32420390~32420516:-
LIHC	cis	rs481331	0.932	rs210228	ENSG00000185904.10	LINC00839	-4.26	2.63e-05	0.00607	-0.42	-0.22	Systemic juvenile idiopathic arthritis;	chr10:42507610	chr10:42475543~42495336:+
LIHC	cis	rs699371	0.507	rs10149787	ENSG00000270000.1	RP3-449M8.9	-4.26	2.63e-05	0.00608	-0.26	-0.22	Height;	chr14:74458749	chr14:74471930~74472360:-
LIHC	cis	rs9527	0.615	rs10883781	ENSG00000236937.2	PTGES3P4	4.26	2.64e-05	0.00608	0.34	0.22	Arsenic metabolism;	chr10:102821373	chr10:102845595~102845950:+
LIHC	cis	rs11951515	0.508	rs67261887	ENSG00000248240.1	RP11-159F24.5	-4.26	2.64e-05	0.00608	-0.28	-0.22	Metabolite levels  (X-11787);	chr5:43612339	chr5:43515274~43525310:+
LIHC	cis	rs4650994	0.544	rs2476560	ENSG00000273384.1	RP5-1098D14.1	-4.26	2.64e-05	0.00609	-0.28	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178625784	chr1:178651706~178652282:+
LIHC	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-4.26	2.64e-05	0.00609	-0.27	-0.22	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
LIHC	cis	rs6445975	0.617	rs13071422	ENSG00000272360.1	RP11-359I18.5	4.26	2.64e-05	0.00609	0.29	0.22	Systemic lupus erythematosus;	chr3:58413086	chr3:58490830~58491291:-
LIHC	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-4.26	2.64e-05	0.00609	-0.21	-0.22	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
LIHC	cis	rs7474896	0.616	rs2505239	ENSG00000120555.12	SEPT7P9	4.26	2.64e-05	0.00609	0.33	0.22	Obesity (extreme);	chr10:38151837	chr10:38383069~38402916:-
LIHC	cis	rs2032447	0.839	rs199751	ENSG00000242387.1	HIST1H2APS2	4.26	2.64e-05	0.0061	0.29	0.22	Intelligence (multi-trait analysis);	chr6:26015355	chr6:25882026~25882395:-
LIHC	cis	rs617219	0.819	rs6889156	ENSG00000251675.1	CTC-458I2.2	4.26	2.64e-05	0.0061	0.26	0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79301096	chr5:80128361~80143883:+
LIHC	cis	rs617219	0.819	rs6889383	ENSG00000251675.1	CTC-458I2.2	4.26	2.64e-05	0.0061	0.26	0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79301235	chr5:80128361~80143883:+
LIHC	cis	rs617219	0.819	rs7711939	ENSG00000251675.1	CTC-458I2.2	4.26	2.64e-05	0.0061	0.26	0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79303696	chr5:80128361~80143883:+
LIHC	cis	rs71007656	1	rs71007656	ENSG00000099251.13	HSD17B7P2	4.26	2.65e-05	0.0061	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38356380~38378505:+
LIHC	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-4.26	2.65e-05	0.0061	-0.27	-0.22	Height;	chr6:109380015	chr6:109382795~109383666:+
LIHC	cis	rs3812762	0.868	rs7952335	ENSG00000254860.4	TMEM9B-AS1	-4.26	2.65e-05	0.0061	-0.24	-0.22	Hypospadias;	chr11:8732484	chr11:8964675~8977527:+
LIHC	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-4.26	2.65e-05	0.0061	-0.29	-0.22	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
LIHC	cis	rs12701220	0.817	rs59471534	ENSG00000229043.2	AC091729.9	-4.26	2.65e-05	0.00611	-0.3	-0.22	Bronchopulmonary dysplasia;	chr7:1045588	chr7:1160374~1165267:+
LIHC	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	4.26	2.65e-05	0.00611	0.25	0.22	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
LIHC	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-4.26	2.65e-05	0.00611	-0.22	-0.22	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
LIHC	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-4.26	2.65e-05	0.00611	-0.29	-0.22	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
LIHC	cis	rs1023500	0.505	rs134891	ENSG00000226450.2	CYP2D8P	4.26	2.65e-05	0.00611	0.25	0.22	Schizophrenia;	chr22:42279876	chr22:42149886~42155001:-
LIHC	cis	rs1577917	1	rs10455158	ENSG00000234155.1	RP11-30P6.6	4.26	2.65e-05	0.00611	0.29	0.22	Response to antipsychotic treatment;	chr6:85963107	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs34106666	ENSG00000234155.1	RP11-30P6.6	4.26	2.65e-05	0.00611	0.29	0.22	Response to antipsychotic treatment;	chr6:85966540	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs1337844	ENSG00000234155.1	RP11-30P6.6	4.26	2.65e-05	0.00611	0.29	0.22	Response to antipsychotic treatment;	chr6:85967555	chr6:85387219~85390186:-
LIHC	cis	rs11098499	1	rs10029750	ENSG00000260091.1	RP11-33B1.4	-4.26	2.65e-05	0.00611	-0.17	-0.22	Corneal astigmatism;	chr4:119251388	chr4:119409333~119410233:+
LIHC	cis	rs42490	0.51	rs13278061	ENSG00000251136.7	RP11-37B2.1	-4.26	2.65e-05	0.00611	-0.2	-0.22	Leprosy;	chr8:89686032	chr8:89609409~89757727:-
LIHC	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	4.26	2.65e-05	0.00612	0.25	0.22	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
LIHC	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-4.26	2.65e-05	0.00612	-0.29	-0.22	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
LIHC	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-4.26	2.65e-05	0.00612	-0.29	-0.22	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
LIHC	cis	rs709400	0.77	rs7142883	ENSG00000258534.1	CTD-2134A5.4	4.26	2.65e-05	0.00612	0.34	0.22	Body mass index;	chr14:103600308	chr14:103854366~103880111:-
LIHC	cis	rs875971	0.54	rs35510581	ENSG00000273024.4	INTS4P2	4.26	2.66e-05	0.00612	0.26	0.22	Aortic root size;	chr7:66113790	chr7:65647864~65715661:+
LIHC	cis	rs1023500	1	rs6002554	ENSG00000237037.8	NDUFA6-AS1	-4.26	2.66e-05	0.00613	-0.31	-0.22	Schizophrenia;	chr22:41943091	chr22:42090931~42137742:+
LIHC	cis	rs17270561	0.525	rs10484432	ENSG00000216436.2	HIST1H2APS1	-4.26	2.66e-05	0.00613	-0.35	-0.22	Iron status biomarkers;	chr6:26008648	chr6:25732497~25732827:+
LIHC	cis	rs1499614	1	rs2659913	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66692349	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs2707840	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66693028	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs2659911	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66693433	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs2707838	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66694214	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs60326618	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66701371	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs2707830	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66702658	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs2707828	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66706390	chr7:66553805~66554199:-
LIHC	cis	rs1499614	0.803	rs1922723	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66710076	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs2659903	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66715944	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs2141924	ENSG00000275400.1	RP4-756H11.5	4.26	2.66e-05	0.00613	0.3	0.22	Gout;	chr7:66721259	chr7:66553805~66554199:-
LIHC	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	4.26	2.66e-05	0.00614	0.2	0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
LIHC	cis	rs113084984	0.718	rs7568223	ENSG00000271952.1	RP11-245G13.2	-4.26	2.67e-05	0.00614	-0.28	-0.22	Breast cancer;	chr2:11543297	chr2:10878269~10885118:+
LIHC	cis	rs113084984	0.718	rs7558961	ENSG00000271952.1	RP11-245G13.2	-4.26	2.67e-05	0.00614	-0.28	-0.22	Breast cancer;	chr2:11543324	chr2:10878269~10885118:+
LIHC	cis	rs113084984	0.718	rs7609384	ENSG00000271952.1	RP11-245G13.2	-4.26	2.67e-05	0.00614	-0.28	-0.22	Breast cancer;	chr2:11543505	chr2:10878269~10885118:+
LIHC	cis	rs4578769	0.879	rs3863524	ENSG00000266850.1	RP11-370A5.1	4.26	2.67e-05	0.00614	0.26	0.22	Eosinophil percentage of white cells;	chr18:22881319	chr18:22723491~22907721:-
LIHC	cis	rs2243480	1	rs34702770	ENSG00000228409.4	CCT6P1	4.26	2.67e-05	0.00614	0.24	0.22	Diabetic kidney disease;	chr7:65879836	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.803	rs35480979	ENSG00000228409.4	CCT6P1	4.26	2.67e-05	0.00614	0.24	0.22	Diabetic kidney disease;	chr7:65892097	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs34637256	ENSG00000228409.4	CCT6P1	4.26	2.67e-05	0.00614	0.24	0.22	Diabetic kidney disease;	chr7:65895144	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35391607	ENSG00000228409.4	CCT6P1	4.26	2.67e-05	0.00614	0.24	0.22	Diabetic kidney disease;	chr7:65895842	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs13220979	ENSG00000228409.4	CCT6P1	4.26	2.67e-05	0.00614	0.24	0.22	Diabetic kidney disease;	chr7:65898217	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs34974928	ENSG00000228409.4	CCT6P1	4.26	2.67e-05	0.00614	0.24	0.22	Diabetic kidney disease;	chr7:65899019	chr7:65751142~65763354:+
LIHC	cis	rs1005277	0.579	rs1780133	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1780136	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1780138	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.602	rs1780141	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.541	rs1740741	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.528	rs2057228	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1740742	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.602	rs1740743	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1740745	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1740747	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1740749	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1780115	ENSG00000099251.13	HSD17B7P2	4.26	2.67e-05	0.00614	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38356380~38378505:+
LIHC	cis	rs3916	0.794	rs10431384	ENSG00000277423.1	RP11-173P15.9	-4.26	2.67e-05	0.00614	-0.25	-0.22	Urinary metabolites (H-NMR features);	chr12:120689544	chr12:120703867~120704282:+
LIHC	cis	rs3738443	0.868	rs61840048	ENSG00000259865.1	RP11-488L18.10	4.26	2.67e-05	0.00614	0.21	0.22	Alcohol dependence;	chr1:247199829	chr1:247187281~247188526:-
LIHC	cis	rs2749592	0.55	rs7917262	ENSG00000275858.1	RP11-291L22.8	-4.26	2.67e-05	0.00614	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38450738~38451069:-
LIHC	cis	rs2749592	0.55	rs9733309	ENSG00000275858.1	RP11-291L22.8	-4.26	2.67e-05	0.00614	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38450738~38451069:-
LIHC	cis	rs2749592	0.55	rs7081464	ENSG00000275858.1	RP11-291L22.8	-4.26	2.67e-05	0.00614	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38450738~38451069:-
LIHC	cis	rs2749592	0.531	rs994804	ENSG00000275858.1	RP11-291L22.8	-4.26	2.67e-05	0.00614	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38450738~38451069:-
LIHC	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-4.26	2.67e-05	0.00614	-0.23	-0.22	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-4.26	2.67e-05	0.00615	-0.27	-0.22	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
LIHC	cis	rs2278034	0.578	rs881753	ENSG00000229178.1	AC069513.4	4.26	2.67e-05	0.00615	0.24	0.22	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195655565~195657927:-
LIHC	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	4.26	2.67e-05	0.00615	0.4	0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
LIHC	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-4.26	2.67e-05	0.00615	-0.22	-0.22	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
LIHC	cis	rs11098499	0.675	rs11098534	ENSG00000260091.1	RP11-33B1.4	-4.26	2.67e-05	0.00615	-0.16	-0.22	Corneal astigmatism;	chr4:119635617	chr4:119409333~119410233:+
LIHC	cis	rs1023500	0.505	rs134887	ENSG00000226450.2	CYP2D8P	4.26	2.67e-05	0.00615	0.25	0.22	Schizophrenia;	chr22:42278233	chr22:42149886~42155001:-
LIHC	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	4.26	2.67e-05	0.00615	0.2	0.22	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
LIHC	cis	rs1005277	0.505	rs1208689	ENSG00000275858.1	RP11-291L22.8	4.26	2.67e-05	0.00615	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38450738~38451069:-
LIHC	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	4.26	2.68e-05	0.00616	0.27	0.22	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
LIHC	cis	rs2842992	0.692	rs9347342	ENSG00000237927.1	RP3-393E18.2	-4.26	2.68e-05	0.00616	-0.26	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159586955~159589169:-
LIHC	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-4.26	2.68e-05	0.00616	-0.27	-0.22	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
LIHC	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-4.26	2.68e-05	0.00616	-0.27	-0.22	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
LIHC	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-4.26	2.68e-05	0.00616	-0.27	-0.22	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
LIHC	cis	rs875971	0.545	rs2173571	ENSG00000273024.4	INTS4P2	-4.26	2.68e-05	0.00616	-0.26	-0.22	Aortic root size;	chr7:66305392	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs11770063	ENSG00000273024.4	INTS4P2	-4.26	2.68e-05	0.00616	-0.26	-0.22	Aortic root size;	chr7:66318029	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs3936065	ENSG00000273024.4	INTS4P2	-4.26	2.68e-05	0.00616	-0.26	-0.22	Aortic root size;	chr7:66325577	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs4718335	ENSG00000273024.4	INTS4P2	-4.26	2.68e-05	0.00616	-0.26	-0.22	Aortic root size;	chr7:66339619	chr7:65647864~65715661:+
LIHC	cis	rs11098499	0.779	rs7674500	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119382438	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs4507344	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119386330	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.697	rs4373140	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119386543	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs13113483	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119387884	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.542	rs10440343	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119388632	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs28668716	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119388720	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.542	rs7677836	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119389483	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs10002083	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119389997	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs10024844	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119390373	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs4345162	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119391804	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.657	rs4463052	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119392103	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs13151285	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119393586	chr4:119409333~119410233:+
LIHC	cis	rs2439831	0.618	rs999026	ENSG00000166763.7	STRCP1	4.26	2.68e-05	0.00616	0.31	0.22	Lung cancer in ever smokers;	chr15:43398017	chr15:43699488~43718184:-
LIHC	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-4.26	2.68e-05	0.00616	-0.28	-0.22	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
LIHC	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-4.26	2.68e-05	0.00616	-0.28	-0.22	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
LIHC	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-4.26	2.68e-05	0.00616	-0.28	-0.22	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
LIHC	cis	rs11098499	0.863	rs7664986	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119508797	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.818	rs10008791	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119510314	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs11736416	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119510506	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs3775845	ENSG00000260091.1	RP11-33B1.4	-4.26	2.68e-05	0.00616	-0.16	-0.22	Corneal astigmatism;	chr4:119511292	chr4:119409333~119410233:+
LIHC	cis	rs9595908	0.606	rs4942922	ENSG00000212293.1	SNORA16	4.26	2.68e-05	0.00616	0.26	0.22	Body mass index;	chr13:32806832	chr13:32420390~32420516:-
LIHC	cis	rs11671005	0.693	rs34023391	ENSG00000269473.1	CTD-2619J13.19	4.26	2.68e-05	0.00616	0.39	0.22	Mean platelet volume;	chr19:58402001	chr19:58440448~58445849:+
LIHC	cis	rs11671005	0.693	rs11666928	ENSG00000269473.1	CTD-2619J13.19	4.26	2.68e-05	0.00616	0.39	0.22	Mean platelet volume;	chr19:58402864	chr19:58440448~58445849:+
LIHC	cis	rs1005277	0.505	rs7099777	ENSG00000275858.1	RP11-291L22.8	-4.26	2.68e-05	0.00616	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38450738~38451069:-
LIHC	cis	rs2243480	1	rs56016656	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65918494	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.803	rs55700941	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65924813	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs36033484	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65925571	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs34193460	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65928123	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs34560516	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65939105	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs57057549	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65940751	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.808	rs12698508	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65946971	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs2961102	ENSG00000228409.4	CCT6P1	4.26	2.68e-05	0.00616	0.25	0.22	Diabetic kidney disease;	chr7:65959671	chr7:65751142~65763354:+
LIHC	cis	rs1077773	0.509	rs2123745	ENSG00000237773.4	AC003075.4	-4.26	2.68e-05	0.00616	-0.28	-0.22	Ulcerative colitis;Inflammatory bowel disease;	chr7:17401458	chr7:17279834~17299357:-
LIHC	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	4.26	2.68e-05	0.00616	0.33	0.22	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
LIHC	cis	rs7809950	0.798	rs2701684	ENSG00000238832.1	snoU109	4.26	2.68e-05	0.00617	0.25	0.22	Coronary artery disease;	chr7:107659082	chr7:107603363~107603507:+
LIHC	cis	rs2998286	0.637	rs332113	ENSG00000254635.4	WAC-AS1	-4.26	2.69e-05	0.00617	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28634806	chr10:28522652~28532743:-
LIHC	cis	rs11098499	0.955	rs6815725	ENSG00000260091.1	RP11-33B1.4	-4.26	2.69e-05	0.00617	-0.17	-0.22	Corneal astigmatism;	chr4:119237255	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.955	rs1551	ENSG00000260091.1	RP11-33B1.4	-4.26	2.69e-05	0.00617	-0.17	-0.22	Corneal astigmatism;	chr4:119237345	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.955	rs11931312	ENSG00000260091.1	RP11-33B1.4	-4.26	2.69e-05	0.00617	-0.17	-0.22	Corneal astigmatism;	chr4:119237868	chr4:119409333~119410233:+
LIHC	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-4.26	2.69e-05	0.00618	-0.29	-0.22	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-4.26	2.69e-05	0.00618	-0.29	-0.22	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-4.26	2.69e-05	0.00618	-0.29	-0.22	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
LIHC	cis	rs12478296	0.581	rs56142391	ENSG00000261186.2	RP11-341N2.1	-4.26	2.69e-05	0.00618	-0.29	-0.22	Obesity-related traits;	chr2:242050097	chr2:242087351~242088457:-
LIHC	cis	rs9907295	1	rs11650409	ENSG00000270871.1	AC015849.19	-4.26	2.69e-05	0.00619	-0.23	-0.22	Fibroblast growth factor basic levels;	chr17:35907949	chr17:35816717~35830293:-
LIHC	cis	rs60733400	0.818	rs10909839	ENSG00000225931.3	RP3-395M20.7	4.26	2.69e-05	0.00619	0.24	0.22	Multiple sclerosis;	chr1:2791865	chr1:2566410~2569888:+
LIHC	cis	rs6442522	1	rs9847430	ENSG00000249786.6	EAF1-AS1	4.26	2.7e-05	0.00619	0.25	0.22	Uric acid levels;	chr3:15408133	chr3:15436171~15455940:-
LIHC	cis	rs6442522	1	rs13075694	ENSG00000249786.6	EAF1-AS1	4.26	2.7e-05	0.00619	0.25	0.22	Uric acid levels;	chr3:15408893	chr3:15436171~15455940:-
LIHC	cis	rs6442522	1	rs13075773	ENSG00000249786.6	EAF1-AS1	4.26	2.7e-05	0.00619	0.25	0.22	Uric acid levels;	chr3:15409062	chr3:15436171~15455940:-
LIHC	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	4.26	2.7e-05	0.0062	0.17	0.22	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
LIHC	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	4.26	2.7e-05	0.0062	0.36	0.22	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
LIHC	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	4.26	2.7e-05	0.0062	0.36	0.22	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
LIHC	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-4.26	2.7e-05	0.0062	-0.27	-0.22	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
LIHC	cis	rs72675573	0.821	rs41533449	ENSG00000235612.1	RP1-158P9.1	-4.26	2.7e-05	0.0062	-0.29	-0.22	Monocyte count;	chr1:56065750	chr1:56145721~56155224:+
LIHC	cis	rs763121	0.853	rs2267395	ENSG00000273076.1	RP3-508I15.22	4.26	2.7e-05	0.0062	0.25	0.22	Menopause (age at onset);	chr22:38717898	chr22:38743495~38743910:+
LIHC	cis	rs4356975	0.692	rs7691361	ENSG00000250919.1	RP11-813N20.3	-4.26	2.7e-05	0.0062	-0.22	-0.22	Obesity-related traits;	chr4:69077628	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.72	rs7691362	ENSG00000250919.1	RP11-813N20.3	-4.26	2.7e-05	0.0062	-0.22	-0.22	Obesity-related traits;	chr4:69077631	chr4:69027831~69044578:+
LIHC	cis	rs9304742	0.962	rs12461778	ENSG00000213801.4	ZNF816-ZNF321P	4.26	2.7e-05	0.00621	0.22	0.22	Psoriasis;	chr19:52951710	chr19:52927135~52942601:-
LIHC	cis	rs9304742	0.962	rs12461796	ENSG00000213801.4	ZNF816-ZNF321P	4.26	2.7e-05	0.00621	0.22	0.22	Psoriasis;	chr19:52951835	chr19:52927135~52942601:-
LIHC	cis	rs9304742	0.962	rs12150933	ENSG00000213801.4	ZNF816-ZNF321P	4.26	2.7e-05	0.00621	0.22	0.22	Psoriasis;	chr19:52951968	chr19:52927135~52942601:-
LIHC	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-4.26	2.7e-05	0.00621	-0.27	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
LIHC	cis	rs17376456	0.877	rs10476601	ENSG00000251023.1	RP11-549J18.1	-4.25	2.7e-05	0.00621	-0.48	-0.22	Diabetic retinopathy;	chr5:94066817	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs7728736	ENSG00000251023.1	RP11-549J18.1	-4.25	2.7e-05	0.00621	-0.48	-0.22	Diabetic retinopathy;	chr5:94068572	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs12153788	ENSG00000251023.1	RP11-549J18.1	-4.25	2.7e-05	0.00621	-0.48	-0.22	Diabetic retinopathy;	chr5:94069732	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.809	rs12152763	ENSG00000251023.1	RP11-549J18.1	-4.25	2.7e-05	0.00621	-0.48	-0.22	Diabetic retinopathy;	chr5:94069804	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs10072592	ENSG00000251023.1	RP11-549J18.1	-4.25	2.7e-05	0.00621	-0.48	-0.22	Diabetic retinopathy;	chr5:94070284	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs10044139	ENSG00000251023.1	RP11-549J18.1	-4.25	2.7e-05	0.00621	-0.48	-0.22	Diabetic retinopathy;	chr5:94072098	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs10514380	ENSG00000251023.1	RP11-549J18.1	-4.25	2.7e-05	0.00621	-0.48	-0.22	Diabetic retinopathy;	chr5:94073665	chr5:93860669~93863825:-
LIHC	cis	rs6442522	1	rs11918807	ENSG00000249786.6	EAF1-AS1	4.25	2.7e-05	0.00621	0.25	0.22	Uric acid levels;	chr3:15404770	chr3:15436171~15455940:-
LIHC	cis	rs11098499	1	rs28374891	ENSG00000260091.1	RP11-33B1.4	-4.25	2.7e-05	0.00621	-0.17	-0.22	Corneal astigmatism;	chr4:119262395	chr4:119409333~119410233:+
LIHC	cis	rs1023500	0.505	rs134885	ENSG00000226450.2	CYP2D8P	4.25	2.7e-05	0.00621	0.24	0.22	Schizophrenia;	chr22:42277805	chr22:42149886~42155001:-
LIHC	cis	rs6430585	0.528	rs309122	ENSG00000231890.6	DARS-AS1	-4.25	2.71e-05	0.00621	-0.31	-0.22	Corneal structure;	chr2:136004283	chr2:135985176~136022593:+
LIHC	cis	rs875971	0.545	rs10950036	ENSG00000273024.4	INTS4P2	-4.25	2.71e-05	0.00621	-0.26	-0.22	Aortic root size;	chr7:66353241	chr7:65647864~65715661:+
LIHC	cis	rs901683	1	rs36074276	ENSG00000230869.1	CTGLF10P	-4.25	2.71e-05	0.00621	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45560293	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs77651228	ENSG00000230869.1	CTGLF10P	-4.25	2.71e-05	0.00621	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45560681	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs9422658	ENSG00000230869.1	CTGLF10P	-4.25	2.71e-05	0.00621	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45564219	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35934513	ENSG00000230869.1	CTGLF10P	-4.25	2.71e-05	0.00621	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45564333	chr10:45678692~45700532:+
LIHC	cis	rs763121	0.819	rs138700	ENSG00000273076.1	RP3-508I15.22	4.25	2.71e-05	0.00621	0.25	0.22	Menopause (age at onset);	chr22:38733994	chr22:38743495~38743910:+
LIHC	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	4.25	2.71e-05	0.00622	0.23	0.22	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
LIHC	cis	rs6442522	0.898	rs2219251	ENSG00000249786.6	EAF1-AS1	4.25	2.71e-05	0.00622	0.25	0.22	Uric acid levels;	chr3:15387661	chr3:15436171~15455940:-
LIHC	cis	rs11064837	0.56	rs7952841	ENSG00000248636.5	RP11-768F21.1	4.25	2.71e-05	0.00622	0.38	0.22	Schizophrenia;	chr12:119620349	chr12:119387987~119668079:-
LIHC	cis	rs2998286	0.723	rs332151	ENSG00000254635.4	WAC-AS1	-4.25	2.71e-05	0.00622	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585331	chr10:28522652~28532743:-
LIHC	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-4.25	2.71e-05	0.00622	-0.27	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
LIHC	cis	rs6048205	0.881	rs945982	ENSG00000259974.2	LINC00261	4.25	2.71e-05	0.00623	0.32	0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22553503	chr20:22547671~22578642:-
LIHC	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	4.25	2.71e-05	0.00623	0.24	0.22	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
LIHC	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-4.25	2.71e-05	0.00623	-0.23	-0.22	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
LIHC	cis	rs9467711	0.651	rs72834677	ENSG00000216436.2	HIST1H2APS1	4.25	2.72e-05	0.00623	0.6	0.22	Autism spectrum disorder or schizophrenia;	chr6:26106376	chr6:25732497~25732827:+
LIHC	cis	rs9467711	0.651	rs13200797	ENSG00000216436.2	HIST1H2APS1	4.25	2.72e-05	0.00623	0.6	0.22	Autism spectrum disorder or schizophrenia;	chr6:26122729	chr6:25732497~25732827:+
LIHC	cis	rs2243480	1	rs67728539	ENSG00000230295.1	RP11-458F8.2	-4.25	2.72e-05	0.00624	-0.24	-0.22	Diabetic kidney disease;	chr7:65913137	chr7:66880708~66882981:+
LIHC	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	4.25	2.72e-05	0.00624	0.23	0.22	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
LIHC	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	4.25	2.72e-05	0.00625	0.27	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
LIHC	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	4.25	2.72e-05	0.00625	0.27	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
LIHC	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	4.25	2.72e-05	0.00625	0.25	0.22	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
LIHC	cis	rs2243480	1	rs73142162	ENSG00000228409.4	CCT6P1	4.25	2.73e-05	0.00626	0.25	0.22	Diabetic kidney disease;	chr7:65909309	chr7:65751142~65763354:+
LIHC	cis	rs1023500	1	rs6002548	ENSG00000237037.8	NDUFA6-AS1	-4.25	2.73e-05	0.00626	-0.31	-0.22	Schizophrenia;	chr22:41941036	chr22:42090931~42137742:+
LIHC	cis	rs1115240	0.947	rs56303656	ENSG00000257842.4	NOVA1-AS1	4.25	2.73e-05	0.00626	0.21	0.22	Educational attainment (years of education);	chr14:26638715	chr14:26598412~26806467:+
LIHC	cis	rs875971	0.545	rs10950036	ENSG00000228409.4	CCT6P1	-4.25	2.73e-05	0.00626	-0.19	-0.22	Aortic root size;	chr7:66353241	chr7:65751142~65763354:+
LIHC	cis	rs2739330	0.892	rs5751776	ENSG00000206090.4	AP000350.7	4.25	2.73e-05	0.00627	0.26	0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23939998~23942798:+
LIHC	cis	rs12554020	0.892	rs75625893	ENSG00000227603.1	RP11-165J3.6	4.25	2.73e-05	0.00627	0.32	0.22	Schizophrenia;	chr9:93605006	chr9:93435332~93437121:-
LIHC	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-4.25	2.73e-05	0.00627	-0.19	-0.22	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
LIHC	cis	rs4356975	0.806	rs12648808	ENSG00000250919.1	RP11-813N20.3	-4.25	2.74e-05	0.00627	-0.22	-0.22	Obesity-related traits;	chr4:69075351	chr4:69027831~69044578:+
LIHC	cis	rs13242816	1	rs3807995	ENSG00000279086.1	RP11-667F14.1	4.25	2.74e-05	0.00627	0.4	0.22	P wave duration;	chr7:116557922	chr7:116209234~116211511:-
LIHC	cis	rs6472235	0.681	rs4129057	ENSG00000272010.1	CTD-3025N20.3	-4.25	2.74e-05	0.00627	-0.31	-0.22	Plateletcrit;Myopia (pathological);	chr8:65943911	chr8:65591850~65592472:-
LIHC	cis	rs9646944	0.578	rs13418548	ENSG00000234389.1	AC007278.3	4.25	2.74e-05	0.00628	0.3	0.22	Blood protein levels;	chr2:102300779	chr2:102438713~102440475:+
LIHC	cis	rs6745190	0.861	rs7349232	ENSG00000236153.1	AC104076.3	-4.25	2.74e-05	0.00629	-0.32	-0.22	White blood cell count;	chr2:181088627	chr2:180979427~180980090:-
LIHC	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	4.25	2.75e-05	0.00629	0.2	0.22	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
LIHC	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-4.25	2.75e-05	0.00629	-0.22	-0.22	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
LIHC	cis	rs6951245	0.507	rs11976805	ENSG00000229043.2	AC091729.9	-4.25	2.75e-05	0.0063	-0.31	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1160374~1165267:+
LIHC	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	4.25	2.75e-05	0.0063	0.17	0.22	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
LIHC	cis	rs11148252	0.904	rs7990581	ENSG00000278238.1	RP11-245D16.4	-4.25	2.75e-05	0.0063	-0.21	-0.22	Lewy body disease;	chr13:52445298	chr13:52454775~52455331:-
LIHC	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	4.25	2.75e-05	0.0063	0.23	0.22	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	4.25	2.75e-05	0.0063	0.23	0.22	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
LIHC	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-4.25	2.75e-05	0.0063	-0.45	-0.22	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
LIHC	cis	rs6430585	0.528	rs309119	ENSG00000231890.6	DARS-AS1	-4.25	2.75e-05	0.0063	-0.31	-0.22	Corneal structure;	chr2:135952802	chr2:135985176~136022593:+
LIHC	cis	rs2060793	0.519	rs10832285	ENSG00000251991.1	RNU7-49P	4.25	2.75e-05	0.00631	0.25	0.22	Vitamin D levels;	chr11:14628031	chr11:14478892~14478953:+
LIHC	cis	rs2929278	0.617	rs4617832	ENSG00000275601.1	AC011330.13	4.25	2.75e-05	0.00631	0.28	0.22	Schizophrenia;	chr15:43738381	chr15:43642389~43643023:-
LIHC	cis	rs763121	0.853	rs5750671	ENSG00000273076.1	RP3-508I15.22	4.25	2.75e-05	0.00631	0.25	0.22	Menopause (age at onset);	chr22:38698614	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.853	rs926299	ENSG00000273076.1	RP3-508I15.22	4.25	2.75e-05	0.00631	0.25	0.22	Menopause (age at onset);	chr22:38699693	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.785	rs6001203	ENSG00000273076.1	RP3-508I15.22	4.25	2.75e-05	0.00631	0.25	0.22	Menopause (age at onset);	chr22:38703597	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.853	rs6001204	ENSG00000273076.1	RP3-508I15.22	4.25	2.75e-05	0.00631	0.25	0.22	Menopause (age at onset);	chr22:38704234	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.853	rs2267393	ENSG00000273076.1	RP3-508I15.22	4.25	2.75e-05	0.00631	0.25	0.22	Menopause (age at onset);	chr22:38705614	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.853	rs2267394	ENSG00000273076.1	RP3-508I15.22	4.25	2.75e-05	0.00631	0.25	0.22	Menopause (age at onset);	chr22:38705628	chr22:38743495~38743910:+
LIHC	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	4.25	2.76e-05	0.00631	0.23	0.22	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
LIHC	cis	rs4578769	0.729	rs16973538	ENSG00000266850.1	RP11-370A5.1	4.25	2.76e-05	0.00631	0.27	0.22	Eosinophil percentage of white cells;	chr18:22899823	chr18:22723491~22907721:-
LIHC	cis	rs651907	0.557	rs59596156	ENSG00000244119.1	PDCL3P4	4.25	2.76e-05	0.00632	0.23	0.22	Colorectal cancer;	chr3:101675373	chr3:101712472~101713191:+
LIHC	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-4.25	2.76e-05	0.00632	-0.27	-0.22	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
LIHC	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	4.25	2.76e-05	0.00632	0.26	0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
LIHC	cis	rs4266144	1	rs4561781	ENSG00000241770.1	RP11-555M1.3	4.25	2.76e-05	0.00632	0.26	0.22	Coronary artery disease;	chr3:157135154	chr3:157163452~157169133:+
LIHC	cis	rs11216126	1	rs34637368	ENSG00000254851.1	RP11-109L13.1	4.25	2.76e-05	0.00632	0.35	0.22	HDL cholesterol;	chr11:116748889	chr11:117135528~117138582:+
LIHC	cis	rs901683	1	rs34011467	ENSG00000230869.1	CTGLF10P	-4.25	2.76e-05	0.00632	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45564310	chr10:45678692~45700532:+
LIHC	cis	rs2243480	1	rs34136756	ENSG00000232546.1	RP11-458F8.1	-4.25	2.76e-05	0.00632	-0.25	-0.22	Diabetic kidney disease;	chr7:65916269	chr7:66848496~66858136:+
LIHC	cis	rs752590	0.943	rs13407583	ENSG00000189223.12	PAX8-AS1	-4.25	2.76e-05	0.00632	-0.36	-0.22	Mucinous ovarian carcinoma;	chr2:113210163	chr2:113211522~113276581:+
LIHC	cis	rs4356203	0.87	rs10766381	ENSG00000260196.1	RP1-239B22.5	-4.25	2.76e-05	0.00632	-0.27	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17380649~17383531:+
LIHC	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	4.25	2.76e-05	0.00632	0.36	0.22	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
LIHC	cis	rs202072	0.725	rs445590	ENSG00000215022.6	RP1-257A7.4	-4.25	2.76e-05	0.00633	-0.25	-0.22	HIV-1 viral setpoint;	chr6:13280632	chr6:13264861~13295586:-
LIHC	cis	rs1577917	1	rs1018184	ENSG00000234155.1	RP11-30P6.6	-4.25	2.76e-05	0.00633	-0.29	-0.22	Response to antipsychotic treatment;	chr6:85938757	chr6:85387219~85390186:-
LIHC	cis	rs8177253	0.763	rs6797713	ENSG00000244062.1	RP11-404G16.2	4.25	2.76e-05	0.00633	0.22	0.22	Iron status biomarkers;	chr3:133755988	chr3:133760300~133762363:+
LIHC	cis	rs6442522	0.966	rs6792128	ENSG00000249786.6	EAF1-AS1	4.25	2.77e-05	0.00633	0.25	0.22	Uric acid levels;	chr3:15417350	chr3:15436171~15455940:-
LIHC	cis	rs1865760	0.566	rs9358904	ENSG00000216436.2	HIST1H2APS1	-4.25	2.77e-05	0.00633	-0.26	-0.22	Height;	chr6:26068338	chr6:25732497~25732827:+
LIHC	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	4.25	2.77e-05	0.00633	0.4	0.22	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
LIHC	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-4.25	2.77e-05	0.00634	-0.25	-0.22	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
LIHC	cis	rs9527	0.59	rs3861984	ENSG00000236937.2	PTGES3P4	4.25	2.77e-05	0.00634	0.28	0.22	Arsenic metabolism;	chr10:103157223	chr10:102845595~102845950:+
LIHC	cis	rs1555322	0.872	rs2425046	ENSG00000126005.14	MMP24-AS1	-4.25	2.77e-05	0.00634	-0.45	-0.22	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35216462~35278131:-
LIHC	cis	rs2439831	1	rs2439850	ENSG00000166763.7	STRCP1	4.25	2.77e-05	0.00634	0.32	0.22	Lung cancer in ever smokers;	chr15:43492656	chr15:43699488~43718184:-
LIHC	cis	rs683257	1	rs117661682	ENSG00000234147.1	RP3-460G2.2	-4.25	2.77e-05	0.00634	-0.42	-0.22	Facial emotion recognition (angry faces);	chr6:140832838	chr6:140845958~140852924:-
LIHC	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	4.25	2.77e-05	0.00634	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	4.25	2.77e-05	0.00634	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
LIHC	cis	rs3020736	0.5	rs11090076	ENSG00000226450.2	CYP2D8P	-4.25	2.77e-05	0.00634	-0.28	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42149886~42155001:-
LIHC	cis	rs2361718	0.967	rs2361719	ENSG00000261978.1	CTD-2529O21.2	-4.25	2.77e-05	0.00634	-0.24	-0.22	Yeast infection;	chr17:80129604	chr17:80023894~80026107:+
LIHC	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	4.25	2.77e-05	0.00635	0.19	0.22	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
LIHC	cis	rs7894407	0.76	rs1163085	ENSG00000236937.2	PTGES3P4	4.25	2.78e-05	0.00635	0.27	0.22	White matter hyperintensity burden;	chr10:103279484	chr10:102845595~102845950:+
LIHC	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-4.25	2.78e-05	0.00635	-0.3	-0.22	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
LIHC	cis	rs7119038	0.865	rs4938573	ENSG00000255239.1	AP002954.6	4.25	2.78e-05	0.00635	0.33	0.22	Sjögren's syndrome;	chr11:118871133	chr11:118688039~118690600:-
LIHC	cis	rs875971	0.545	rs2279757	ENSG00000273024.4	INTS4P2	-4.25	2.78e-05	0.00635	-0.26	-0.22	Aortic root size;	chr7:66363676	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs11766183	ENSG00000273024.4	INTS4P2	-4.25	2.78e-05	0.00635	-0.26	-0.22	Aortic root size;	chr7:66374173	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs1065265	ENSG00000273024.4	INTS4P2	-4.25	2.78e-05	0.00635	-0.26	-0.22	Aortic root size;	chr7:66376216	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs7811204	ENSG00000273024.4	INTS4P2	-4.25	2.78e-05	0.00635	-0.26	-0.22	Aortic root size;	chr7:66387213	chr7:65647864~65715661:+
LIHC	cis	rs11098499	0.909	rs79026312	ENSG00000260091.1	RP11-33B1.4	-4.25	2.78e-05	0.00635	-0.16	-0.22	Corneal astigmatism;	chr4:119519522	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs35111518	ENSG00000260091.1	RP11-33B1.4	-4.25	2.78e-05	0.00635	-0.16	-0.22	Corneal astigmatism;	chr4:119519527	chr4:119409333~119410233:+
LIHC	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-4.25	2.78e-05	0.00635	-0.25	-0.22	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
LIHC	cis	rs2348418	0.864	rs7977817	ENSG00000247934.4	RP11-967K21.1	4.25	2.78e-05	0.00636	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28562549	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.831	rs7977525	ENSG00000247934.4	RP11-967K21.1	4.25	2.78e-05	0.00636	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28562584	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.864	rs7977850	ENSG00000247934.4	RP11-967K21.1	4.25	2.78e-05	0.00636	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28562715	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.864	rs11609924	ENSG00000247934.4	RP11-967K21.1	4.25	2.78e-05	0.00636	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28563197	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.864	rs7968563	ENSG00000247934.4	RP11-967K21.1	4.25	2.78e-05	0.00636	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.864	rs2137072	ENSG00000247934.4	RP11-967K21.1	4.25	2.78e-05	0.00636	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28163298~28190738:-
LIHC	cis	rs3733589	0.744	rs13122112	ENSG00000250413.1	RP11-448G15.1	4.25	2.78e-05	0.00636	0.36	0.22	Renal overload gout;	chr4:10019780	chr4:10006482~10009725:+
LIHC	cis	rs4948102	0.731	rs4948099	ENSG00000226278.1	PSPHP1	4.25	2.78e-05	0.00636	0.25	0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56004557	chr7:55764797~55773288:+
LIHC	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	4.25	2.78e-05	0.00636	0.29	0.22	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
LIHC	cis	rs3772760	0.744	rs3772764	ENSG00000240622.1	RPL7P15	-4.25	2.78e-05	0.00636	-0.42	-0.22	Amyotrophic lateral sclerosis;	chr3:124481954	chr3:124151960~124153063:-
LIHC	cis	rs2688482	0.557	rs2550236	ENSG00000185485.13	SDHAP1	4.25	2.78e-05	0.00637	0.25	0.22	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195959748~195990318:-
LIHC	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	4.25	2.78e-05	0.00637	0.26	0.22	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
LIHC	cis	rs202072	0.769	rs445591	ENSG00000215022.6	RP1-257A7.4	-4.25	2.79e-05	0.00637	-0.25	-0.22	HIV-1 viral setpoint;	chr6:13280634	chr6:13264861~13295586:-
LIHC	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-4.25	2.79e-05	0.00637	-0.27	-0.22	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
LIHC	cis	rs113084984	0.538	rs12994384	ENSG00000271952.1	RP11-245G13.2	-4.25	2.79e-05	0.00637	-0.25	-0.22	Breast cancer;	chr2:11543839	chr2:10878269~10885118:+
LIHC	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-4.25	2.79e-05	0.00637	-0.22	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
LIHC	cis	rs9907295	0.681	rs9912284	ENSG00000270871.1	AC015849.19	4.25	2.79e-05	0.00637	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35816717~35830293:-
LIHC	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-4.25	2.79e-05	0.00638	-0.24	-0.22	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
LIHC	cis	rs11710088	0.74	rs13069729	ENSG00000244503.1	RP11-278L15.6	-4.25	2.79e-05	0.00638	-0.28	-0.22	QRS duration;	chr3:149473092	chr3:149494660~149495995:+
LIHC	cis	rs7044106	0.762	rs10984974	ENSG00000238181.2	AHCYP2	-4.25	2.79e-05	0.00639	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120720673~120721972:+
LIHC	cis	rs6901152	0.525	rs1424930	ENSG00000217648.1	RP1-95L4.4	-4.25	2.8e-05	0.00639	-0.27	-0.22	Acute lymphoblastic leukemia (childhood);	chr6:143371223	chr6:143342246~143343383:+
LIHC	cis	rs6901152	0.525	rs4645437	ENSG00000217648.1	RP1-95L4.4	-4.25	2.8e-05	0.00639	-0.27	-0.22	Acute lymphoblastic leukemia (childhood);	chr6:143371531	chr6:143342246~143343383:+
LIHC	cis	rs1023500	0.505	rs134874	ENSG00000226450.2	CYP2D8P	4.25	2.8e-05	0.00639	0.24	0.22	Schizophrenia;	chr22:42265138	chr22:42149886~42155001:-
LIHC	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	4.25	2.8e-05	0.00639	0.25	0.22	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
LIHC	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	4.25	2.8e-05	0.00639	0.23	0.22	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
LIHC	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-4.25	2.8e-05	0.00639	-0.24	-0.22	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
LIHC	cis	rs2243480	0.706	rs34466769	ENSG00000164669.11	INTS4P1	4.25	2.8e-05	0.0064	0.35	0.22	Diabetic kidney disease;	chr7:65988305	chr7:65141225~65234216:+
LIHC	cis	rs2744375	0.6	rs2237102	ENSG00000261189.1	RP3-512B11.3	4.25	2.8e-05	0.0064	0.28	0.22	Resting heart rate;	chr6:7551912	chr6:7540451~7541338:-
LIHC	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	4.25	2.8e-05	0.0064	0.43	0.22	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
LIHC	cis	rs9652601	0.879	rs9926367	ENSG00000274038.1	RP11-66H6.4	-4.25	2.8e-05	0.0064	-0.28	-0.22	Systemic lupus erythematosus;	chr16:10999322	chr16:11056556~11057034:+
LIHC	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	4.25	2.8e-05	0.0064	0.36	0.22	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	4.25	2.8e-05	0.0064	0.36	0.22	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	4.25	2.8e-05	0.0064	0.36	0.22	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	4.25	2.8e-05	0.0064	0.36	0.22	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
LIHC	cis	rs4356203	0.87	rs214926	ENSG00000260196.1	RP1-239B22.5	-4.25	2.8e-05	0.0064	-0.27	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17210255	chr11:17380649~17383531:+
LIHC	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-4.25	2.8e-05	0.0064	-0.27	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
LIHC	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	4.25	2.8e-05	0.0064	0.45	0.22	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
LIHC	cis	rs1876905	0.539	rs240969	ENSG00000272356.1	RP5-1112D6.8	4.25	2.8e-05	0.0064	0.21	0.22	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111309203~111313517:+
LIHC	cis	rs617219	0.819	rs6453434	ENSG00000251675.1	CTC-458I2.2	4.25	2.8e-05	0.0064	0.26	0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79274396	chr5:80128361~80143883:+
LIHC	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-4.25	2.81e-05	0.00641	-0.23	-0.22	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
LIHC	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-4.25	2.81e-05	0.00641	-0.45	-0.22	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
LIHC	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	4.25	2.81e-05	0.00641	0.23	0.22	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	4.25	2.81e-05	0.00641	0.23	0.22	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	4.25	2.81e-05	0.00641	0.23	0.22	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
LIHC	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	4.25	2.81e-05	0.00641	0.23	0.22	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
LIHC	cis	rs3010562	1	rs3010562	ENSG00000216966.1	RP11-568A7.1	-4.25	2.81e-05	0.00642	-0.23	-0.22	Gut microbiome composition (summer and winter);	chr6:167351763	chr6:167208631~167208897:-
LIHC	cis	rs4938303	0.671	rs2008915	ENSG00000236267.1	AP006216.5	4.25	2.81e-05	0.00642	0.23	0.22	Triglycerides;	chr11:116732418	chr11:116813204~116814003:-
LIHC	cis	rs1200821	0.559	rs9418267	ENSG00000263064.2	RP11-291L22.7	-4.25	2.81e-05	0.00642	-0.23	-0.22	Hemostatic factors and hematological phenotypes;	chr10:37531023	chr10:38448689~38448949:+
LIHC	cis	rs75920871	0.688	rs7109876	ENSG00000254851.1	RP11-109L13.1	-4.25	2.81e-05	0.00642	-0.43	-0.22	Subjective well-being;	chr11:116977932	chr11:117135528~117138582:+
LIHC	cis	rs4356975	0.932	rs4400060	ENSG00000250919.1	RP11-813N20.3	-4.25	2.81e-05	0.00642	-0.22	-0.22	Obesity-related traits;	chr4:69071215	chr4:69027831~69044578:+
LIHC	cis	rs12701220	0.894	rs2141274	ENSG00000229043.2	AC091729.9	-4.25	2.81e-05	0.00642	-0.31	-0.22	Bronchopulmonary dysplasia;	chr7:995081	chr7:1160374~1165267:+
LIHC	cis	rs12701220	0.817	rs1058727	ENSG00000229043.2	AC091729.9	-4.25	2.81e-05	0.00642	-0.3	-0.22	Bronchopulmonary dysplasia;	chr7:1047459	chr7:1160374~1165267:+
LIHC	cis	rs7129556	0.645	rs598071	ENSG00000254459.1	RP11-91P24.7	4.25	2.81e-05	0.00642	0.36	0.22	Weight loss (gastric bypass surgery);	chr11:77849606	chr11:77829654~77872262:-
LIHC	cis	rs7129556	0.69	rs12285765	ENSG00000254459.1	RP11-91P24.7	4.25	2.81e-05	0.00642	0.36	0.22	Weight loss (gastric bypass surgery);	chr11:77857989	chr11:77829654~77872262:-
LIHC	cis	rs7129556	0.728	rs628668	ENSG00000254459.1	RP11-91P24.7	4.25	2.81e-05	0.00642	0.36	0.22	Weight loss (gastric bypass surgery);	chr11:77866448	chr11:77829654~77872262:-
LIHC	cis	rs7129556	0.69	rs588217	ENSG00000254459.1	RP11-91P24.7	-4.25	2.81e-05	0.00642	-0.36	-0.22	Weight loss (gastric bypass surgery);	chr11:77872330	chr11:77829654~77872262:-
LIHC	cis	rs2348418	1	rs2348418	ENSG00000247934.4	RP11-967K21.1	4.25	2.81e-05	0.00643	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28536581	chr12:28163298~28190738:-
LIHC	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-4.25	2.82e-05	0.00643	-0.29	-0.22	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
LIHC	cis	rs1501911	0.611	rs7712408	ENSG00000248489.1	CTD-2007H13.3	-4.25	2.82e-05	0.00643	-0.34	-0.22	Lung function (FEV1/FVC);	chr5:99020633	chr5:98929171~98995013:+
LIHC	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-4.24	2.82e-05	0.00644	-0.24	-0.22	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
LIHC	cis	rs9457247	1	rs364451	ENSG00000227598.1	RP1-167A14.2	-4.24	2.82e-05	0.00644	-0.24	-0.22	Crohn's disease;	chr6:166971268	chr6:166969626~166999065:-
LIHC	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	4.24	2.82e-05	0.00644	0.26	0.22	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
LIHC	cis	rs734999	0.524	rs4648448	ENSG00000225931.3	RP3-395M20.7	4.24	2.82e-05	0.00644	0.24	0.22	Ulcerative colitis;	chr1:2779144	chr1:2566410~2569888:+
LIHC	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-4.24	2.82e-05	0.00644	-0.26	-0.22	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
LIHC	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-4.24	2.83e-05	0.00645	-0.22	-0.22	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
LIHC	cis	rs875971	0.571	rs78668714	ENSG00000228409.4	CCT6P1	-4.24	2.83e-05	0.00645	-0.19	-0.22	Aortic root size;	chr7:66474464	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs73150604	ENSG00000228409.4	CCT6P1	-4.24	2.83e-05	0.00645	-0.19	-0.22	Aortic root size;	chr7:66480545	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs7810213	ENSG00000228409.4	CCT6P1	-4.24	2.83e-05	0.00645	-0.19	-0.22	Aortic root size;	chr7:66481592	chr7:65751142~65763354:+
LIHC	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	4.24	2.83e-05	0.00645	0.29	0.22	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
LIHC	cis	rs1075232	0.655	rs77987193	ENSG00000270055.1	CTD-3092A11.2	-4.24	2.83e-05	0.00645	-0.44	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31296055	chr15:30487963~30490313:+
LIHC	cis	rs763121	0.853	rs5750633	ENSG00000273076.1	RP3-508I15.22	4.24	2.83e-05	0.00646	0.25	0.22	Menopause (age at onset);	chr22:38597462	chr22:38743495~38743910:+
LIHC	cis	rs4694744	0.576	rs41297373	ENSG00000264696.1	AC108078.1	4.24	2.83e-05	0.00646	0.33	0.22	Bacteremia;	chr4:69491476	chr4:69479331~69479434:+
LIHC	cis	rs4694744	0.576	rs41297371	ENSG00000264696.1	AC108078.1	4.24	2.83e-05	0.00646	0.33	0.22	Bacteremia;	chr4:69491511	chr4:69479331~69479434:+
LIHC	cis	rs4694744	0.576	rs41297367	ENSG00000264696.1	AC108078.1	4.24	2.83e-05	0.00646	0.33	0.22	Bacteremia;	chr4:69491851	chr4:69479331~69479434:+
LIHC	cis	rs4694744	0.576	rs13139888	ENSG00000264696.1	AC108078.1	4.24	2.83e-05	0.00646	0.33	0.22	Bacteremia;	chr4:69492158	chr4:69479331~69479434:+
LIHC	cis	rs734999	0.566	rs6424092	ENSG00000225931.3	RP3-395M20.7	-4.24	2.83e-05	0.00646	-0.24	-0.22	Ulcerative colitis;	chr1:2601460	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.588	rs10910098	ENSG00000225931.3	RP3-395M20.7	4.24	2.83e-05	0.00646	0.24	0.22	Ulcerative colitis;	chr1:2601811	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.588	rs60520190	ENSG00000225931.3	RP3-395M20.7	4.24	2.83e-05	0.00646	0.24	0.22	Ulcerative colitis;	chr1:2602267	chr1:2566410~2569888:+
LIHC	cis	rs9907295	0.748	rs78672421	ENSG00000270871.1	AC015849.19	4.24	2.83e-05	0.00646	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35837325	chr17:35816717~35830293:-
LIHC	cis	rs6439153	0.933	rs1871951	ENSG00000231305.3	RP11-723O4.2	4.24	2.84e-05	0.00646	0.25	0.22	Pneumococcal bacteremia;	chr3:129001644	chr3:128861313~128871540:-
LIHC	cis	rs6439153	0.933	rs6769662	ENSG00000231305.3	RP11-723O4.2	4.24	2.84e-05	0.00646	0.25	0.22	Pneumococcal bacteremia;	chr3:129002467	chr3:128861313~128871540:-
LIHC	cis	rs6439153	0.967	rs12695512	ENSG00000231305.3	RP11-723O4.2	4.24	2.84e-05	0.00646	0.25	0.22	Pneumococcal bacteremia;	chr3:129003239	chr3:128861313~128871540:-
LIHC	cis	rs6439153	0.967	rs12695513	ENSG00000231305.3	RP11-723O4.2	4.24	2.84e-05	0.00646	0.25	0.22	Pneumococcal bacteremia;	chr3:129003469	chr3:128861313~128871540:-
LIHC	cis	rs11098499	0.913	rs10010696	ENSG00000260091.1	RP11-33B1.4	-4.24	2.84e-05	0.00646	-0.17	-0.22	Corneal astigmatism;	chr4:119243148	chr4:119409333~119410233:+
LIHC	cis	rs12908161	0.683	rs12903256	ENSG00000259295.5	CSPG4P12	4.24	2.84e-05	0.00647	0.28	0.22	Schizophrenia;	chr15:84764910	chr15:85191438~85213905:+
LIHC	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-4.24	2.84e-05	0.00647	-0.23	-0.22	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-4.24	2.84e-05	0.00647	-0.23	-0.22	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-4.24	2.84e-05	0.00647	-0.23	-0.22	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
LIHC	cis	rs734999	0.588	rs4648653	ENSG00000225931.3	RP3-395M20.7	4.24	2.84e-05	0.00647	0.24	0.22	Ulcerative colitis;	chr1:2604456	chr1:2566410~2569888:+
LIHC	cis	rs17270561	0.723	rs12213243	ENSG00000216436.2	HIST1H2APS1	-4.24	2.84e-05	0.00648	-0.35	-0.22	Iron status biomarkers;	chr6:25889880	chr6:25732497~25732827:+
LIHC	cis	rs6061231	0.544	rs2427314	ENSG00000226332.2	RP11-157P1.4	4.24	2.84e-05	0.00648	0.25	0.22	Colorectal cancer;	chr20:62398610	chr20:62305432~62306325:-
LIHC	cis	rs752590	0.887	rs68090726	ENSG00000189223.12	PAX8-AS1	-4.24	2.84e-05	0.00648	-0.36	-0.22	Mucinous ovarian carcinoma;	chr2:113205258	chr2:113211522~113276581:+
LIHC	cis	rs4913250	0.514	rs7133322	ENSG00000273824.1	RP11-81H14.1	-4.24	2.84e-05	0.00648	-0.28	-0.22	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr12:67541047	chr12:68426331~68427737:-
LIHC	cis	rs4578769	0.836	rs3844227	ENSG00000265943.1	RP11-739L10.1	4.24	2.84e-05	0.00648	0.28	0.22	Eosinophil percentage of white cells;	chr18:22871067	chr18:22699481~22933764:-
LIHC	cis	rs7044106	0.708	rs10984992	ENSG00000238181.2	AHCYP2	-4.24	2.85e-05	0.00649	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120720673~120721972:+
LIHC	cis	rs4356975	0.932	rs4400061	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69071281	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs4446390	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69071328	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs7434389	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69071698	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.896	rs58496756	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69072070	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.599	rs7660019	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69072135	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.574	rs7660021	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69072143	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.549	rs7687692	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69072154	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.899	rs7687725	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69072229	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs4516791	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69072402	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs4694605	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69072777	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs4694607	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69073025	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.899	rs4410590	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69073381	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs4611997	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69073429	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.899	rs4412058	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69073715	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs7436912	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69074077	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs72852416	ENSG00000250919.1	RP11-813N20.3	-4.24	2.85e-05	0.00649	-0.22	-0.22	Obesity-related traits;	chr4:69075085	chr4:69027831~69044578:+
LIHC	cis	rs6430585	0.528	rs6711493	ENSG00000231890.6	DARS-AS1	-4.24	2.85e-05	0.00649	-0.3	-0.22	Corneal structure;	chr2:135934983	chr2:135985176~136022593:+
LIHC	cis	rs1005277	0.505	rs13503	ENSG00000275858.1	RP11-291L22.8	-4.24	2.85e-05	0.0065	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.505	rs7069702	ENSG00000275858.1	RP11-291L22.8	-4.24	2.85e-05	0.0065	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38450738~38451069:-
LIHC	cis	rs960902	0.713	rs6757678	ENSG00000213553.4	RPLP0P6	4.24	2.85e-05	0.0065	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37496467	chr2:38481851~38482804:+
LIHC	cis	rs10510102	0.872	rs7907815	ENSG00000226864.1	ATE1-AS1	4.24	2.85e-05	0.0065	0.38	0.22	Breast cancer;	chr10:121965951	chr10:121928312~121951965:+
LIHC	cis	rs11098499	0.697	rs4560394	ENSG00000260091.1	RP11-33B1.4	-4.24	2.85e-05	0.0065	-0.16	-0.22	Corneal astigmatism;	chr4:119392280	chr4:119409333~119410233:+
LIHC	cis	rs1405130	0.935	rs2386495	ENSG00000224287.2	MSL3P1	4.24	2.85e-05	0.0065	0.26	0.22	Coronary artery disease;	chr2:234667576	chr2:233865437~233868444:-
LIHC	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-4.24	2.86e-05	0.0065	-0.18	-0.22	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
LIHC	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-4.24	2.86e-05	0.00651	-0.23	-0.22	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
LIHC	cis	rs6430585	0.528	rs309165	ENSG00000231890.6	DARS-AS1	-4.24	2.86e-05	0.00651	-0.3	-0.22	Corneal structure;	chr2:135909731	chr2:135985176~136022593:+
LIHC	cis	rs6430585	0.528	rs309158	ENSG00000231890.6	DARS-AS1	-4.24	2.86e-05	0.00651	-0.3	-0.22	Corneal structure;	chr2:135922964	chr2:135985176~136022593:+
LIHC	cis	rs4578769	0.765	rs10432158	ENSG00000266850.1	RP11-370A5.1	-4.24	2.86e-05	0.00651	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22826406	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs10432159	ENSG00000266850.1	RP11-370A5.1	-4.24	2.86e-05	0.00651	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22826596	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs16972382	ENSG00000266850.1	RP11-370A5.1	-4.24	2.86e-05	0.00651	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22831403	chr18:22723491~22907721:-
LIHC	cis	rs4926298	0.89	rs1017180	ENSG00000228887.3	EEF1DP1	4.24	2.86e-05	0.00652	0.2	0.22	Bipolar disorder;	chr19:13083958	chr19:14070342~14071237:+
LIHC	cis	rs3733589	1	rs12646380	ENSG00000250413.1	RP11-448G15.1	4.24	2.86e-05	0.00652	0.4	0.22	Renal overload gout;	chr4:9989878	chr4:10006482~10009725:+
LIHC	cis	rs6445975	0.572	rs4320076	ENSG00000272360.1	RP11-359I18.5	4.24	2.87e-05	0.00653	0.3	0.22	Systemic lupus erythematosus;	chr3:58419557	chr3:58490830~58491291:-
LIHC	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-4.24	2.87e-05	0.00653	-0.21	-0.22	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
LIHC	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-4.24	2.87e-05	0.00653	-0.27	-0.22	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
LIHC	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-4.24	2.87e-05	0.00653	-0.26	-0.22	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
LIHC	cis	rs755249	0.567	rs41270807	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.53	rs16826087	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs3754346	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs16826093	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs41270811	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs61779274	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs17264671	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs4660690	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs61779275	ENSG00000182109.6	RP11-69E11.4	4.24	2.87e-05	0.00653	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39522280~39546187:-
LIHC	cis	rs4650994	0.816	rs2761470	ENSG00000213057.5	C1orf220	-4.24	2.87e-05	0.00653	-0.19	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178626898	chr1:178542752~178548889:+
LIHC	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-4.24	2.87e-05	0.00654	-0.29	-0.22	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
LIHC	cis	rs6430585	0.591	rs309118	ENSG00000231890.6	DARS-AS1	-4.24	2.87e-05	0.00654	-0.3	-0.22	Corneal structure;	chr2:135988654	chr2:135985176~136022593:+
LIHC	cis	rs1005277	0.602	rs1831315	ENSG00000275858.1	RP11-291L22.8	4.24	2.88e-05	0.00655	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38450738~38451069:-
LIHC	cis	rs901683	1	rs9422440	ENSG00000230869.1	CTGLF10P	-4.24	2.88e-05	0.00655	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45549677	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs78363416	ENSG00000230869.1	CTGLF10P	-4.24	2.88e-05	0.00655	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45550686	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34138033	ENSG00000230869.1	CTGLF10P	-4.24	2.88e-05	0.00655	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45551064	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35036712	ENSG00000230869.1	CTGLF10P	-4.24	2.88e-05	0.00655	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45551262	chr10:45678692~45700532:+
LIHC	cis	rs7937890	0.599	rs2597204	ENSG00000251991.1	RNU7-49P	4.24	2.88e-05	0.00655	0.25	0.22	Mitochondrial DNA levels;	chr11:14459471	chr11:14478892~14478953:+
LIHC	cis	rs7474896	0.583	rs11011341	ENSG00000263064.2	RP11-291L22.7	4.24	2.88e-05	0.00655	0.27	0.22	Obesity (extreme);	chr10:37709572	chr10:38448689~38448949:+
LIHC	cis	rs7474896	0.609	rs1830612	ENSG00000263064.2	RP11-291L22.7	4.24	2.88e-05	0.00655	0.27	0.22	Obesity (extreme);	chr10:37710955	chr10:38448689~38448949:+
LIHC	cis	rs3845817	0.868	rs702942	ENSG00000281920.1	RP11-418H16.1	-4.24	2.88e-05	0.00655	-0.27	-0.22	Bipolar disorder;	chr2:65529831	chr2:65623272~65628424:+
LIHC	cis	rs3845817	0.832	rs702945	ENSG00000281920.1	RP11-418H16.1	-4.24	2.88e-05	0.00655	-0.27	-0.22	Bipolar disorder;	chr2:65534098	chr2:65623272~65628424:+
LIHC	cis	rs3845817	0.868	rs702896	ENSG00000281920.1	RP11-418H16.1	-4.24	2.88e-05	0.00655	-0.27	-0.22	Bipolar disorder;	chr2:65535089	chr2:65623272~65628424:+
LIHC	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-4.24	2.88e-05	0.00655	-0.24	-0.22	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
LIHC	cis	rs901683	1	rs71496610	ENSG00000230869.1	CTGLF10P	-4.24	2.88e-05	0.00655	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45526198	chr10:45678692~45700532:+
LIHC	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	4.24	2.88e-05	0.00655	0.16	0.22	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
LIHC	cis	rs6445975	0.666	rs4681844	ENSG00000272360.1	RP11-359I18.5	-4.24	2.88e-05	0.00655	-0.31	-0.22	Systemic lupus erythematosus;	chr3:58346719	chr3:58490830~58491291:-
LIHC	cis	rs6480314	0.831	rs6480316	ENSG00000233590.1	RP11-153K11.3	4.24	2.88e-05	0.00656	0.33	0.22	Optic nerve measurement (disc area);	chr10:68212943	chr10:68233251~68242379:-
LIHC	cis	rs6480314	0.831	rs7071208	ENSG00000233590.1	RP11-153K11.3	4.24	2.88e-05	0.00656	0.33	0.22	Optic nerve measurement (disc area);	chr10:68213350	chr10:68233251~68242379:-
LIHC	cis	rs9450351	0.744	rs9450294	ENSG00000203875.9	SNHG5	-4.24	2.88e-05	0.00656	-0.44	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85540712	chr6:85660950~85678736:-
LIHC	cis	rs11098499	0.644	rs10012252	ENSG00000260091.1	RP11-33B1.4	-4.24	2.88e-05	0.00656	-0.16	-0.22	Corneal astigmatism;	chr4:119637984	chr4:119409333~119410233:+
LIHC	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-4.24	2.89e-05	0.00657	-0.29	-0.22	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
LIHC	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-4.24	2.89e-05	0.00657	-0.29	-0.22	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
LIHC	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	4.24	2.89e-05	0.00657	0.23	0.22	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	4.24	2.89e-05	0.00657	0.23	0.22	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
LIHC	cis	rs2032447	0.869	rs2230655	ENSG00000242387.1	HIST1H2APS2	-4.24	2.89e-05	0.00657	-0.29	-0.22	Intelligence (multi-trait analysis);	chr6:26033278	chr6:25882026~25882395:-
LIHC	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-4.24	2.89e-05	0.00658	-0.25	-0.22	Asthma;	chr2:102401592	chr2:102438713~102440475:+
LIHC	cis	rs7044106	0.762	rs12003646	ENSG00000238181.2	AHCYP2	-4.24	2.89e-05	0.00658	-0.26	-0.22	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120720673~120721972:+
LIHC	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-4.24	2.89e-05	0.00658	-0.23	-0.22	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
LIHC	cis	rs11098499	0.661	rs10015965	ENSG00000260091.1	RP11-33B1.4	-4.24	2.89e-05	0.00658	-0.15	-0.22	Corneal astigmatism;	chr4:119347082	chr4:119409333~119410233:+
LIHC	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	4.24	2.89e-05	0.00658	0.29	0.22	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
LIHC	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	4.24	2.89e-05	0.00658	0.29	0.22	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
LIHC	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	4.24	2.89e-05	0.00658	0.29	0.22	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
LIHC	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	4.24	2.89e-05	0.00658	0.29	0.22	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
LIHC	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	4.24	2.89e-05	0.00658	0.29	0.22	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
LIHC	cis	rs2120243	0.504	rs114107407	ENSG00000244515.1	KRT18P34	-4.24	2.9e-05	0.00658	-0.21	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157344846	chr3:157162663~157163932:-
LIHC	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	4.24	2.9e-05	0.00658	0.29	0.22	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
LIHC	cis	rs7208859	0.673	rs56846352	ENSG00000266490.1	CTD-2349P21.9	4.24	2.9e-05	0.00658	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30792372~30792833:+
LIHC	cis	rs10829156	0.796	rs6482567	ENSG00000240291.1	RP11-499P20.2	4.24	2.9e-05	0.00659	0.35	0.22	Sudden cardiac arrest;	chr10:18625860	chr10:18513115~18545651:-
LIHC	cis	rs960902	0.747	rs62135566	ENSG00000213553.4	RPLP0P6	4.24	2.9e-05	0.00659	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37491787	chr2:38481851~38482804:+
LIHC	cis	rs2243480	1	rs34136756	ENSG00000228409.4	CCT6P1	4.24	2.9e-05	0.00659	0.24	0.22	Diabetic kidney disease;	chr7:65916269	chr7:65751142~65763354:+
LIHC	cis	rs4073416	0.691	rs10483785	ENSG00000276116.2	FUT8-AS1	4.24	2.9e-05	0.00659	0.27	0.22	N-glycan levels;	chr14:65752799	chr14:65411170~65412690:-
LIHC	cis	rs2739330	0.892	rs4822455	ENSG00000206090.4	AP000350.7	4.24	2.9e-05	0.00659	0.26	0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23939998~23942798:+
LIHC	cis	rs2838568	0.967	rs2838569	ENSG00000277352.1	KB-68A7.2	-4.24	2.9e-05	0.00659	-0.26	-0.22	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;	chr21:44478340	chr21:44494874~44495519:+
LIHC	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	4.24	2.9e-05	0.00659	0.27	0.22	Height;	chr4:55415153	chr4:55363971~55395847:-
LIHC	cis	rs4561483	0.799	rs33635	ENSG00000261560.1	RP11-166B2.3	-4.24	2.9e-05	0.00659	-0.24	-0.22	Testicular germ cell tumor;	chr16:11898087	chr16:11881075~11882569:-
LIHC	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	4.24	2.9e-05	0.00659	0.43	0.22	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
LIHC	cis	rs1023500	1	rs1023499	ENSG00000237037.8	NDUFA6-AS1	-4.24	2.9e-05	0.00659	-0.31	-0.22	Schizophrenia;	chr22:41944578	chr22:42090931~42137742:+
LIHC	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-4.24	2.9e-05	0.0066	-0.22	-0.22	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
LIHC	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	4.24	2.9e-05	0.0066	0.32	0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
LIHC	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-4.24	2.91e-05	0.00661	-0.23	-0.22	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-4.24	2.91e-05	0.00661	-0.23	-0.22	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
LIHC	cis	rs875971	0.577	rs35072105	ENSG00000273024.4	INTS4P2	4.24	2.91e-05	0.00661	0.26	0.22	Aortic root size;	chr7:66144830	chr7:65647864~65715661:+
LIHC	cis	rs763121	0.853	rs5757253	ENSG00000273076.1	RP3-508I15.22	4.24	2.91e-05	0.00661	0.25	0.22	Menopause (age at onset);	chr22:38708315	chr22:38743495~38743910:+
LIHC	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-4.24	2.91e-05	0.00661	-0.28	-0.22	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
LIHC	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-4.24	2.91e-05	0.00661	-0.28	-0.22	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
LIHC	cis	rs11098499	0.535	rs7671759	ENSG00000260091.1	RP11-33B1.4	-4.24	2.91e-05	0.00662	-0.16	-0.22	Corneal astigmatism;	chr4:119326939	chr4:119409333~119410233:+
LIHC	cis	rs4578769	0.959	rs3863525	ENSG00000265943.1	RP11-739L10.1	4.24	2.91e-05	0.00662	0.28	0.22	Eosinophil percentage of white cells;	chr18:22898714	chr18:22699481~22933764:-
LIHC	cis	rs3758785	0.565	rs598645	ENSG00000255893.1	RP11-685N10.1	4.24	2.91e-05	0.00662	0.23	0.22	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94338579	chr11:94472908~94473570:-
LIHC	cis	rs9907295	0.818	rs4796115	ENSG00000270871.1	AC015849.19	4.24	2.92e-05	0.00662	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35841315	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.901	rs78905197	ENSG00000270871.1	AC015849.19	4.24	2.92e-05	0.00662	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.901	rs3760326	ENSG00000270871.1	AC015849.19	4.24	2.92e-05	0.00662	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35853493	chr17:35816717~35830293:-
LIHC	cis	rs2310173	0.575	rs13022757	ENSG00000281162.1	LINC01127	-4.24	2.92e-05	0.00662	-0.24	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101997084	chr2:101962056~101987167:+
LIHC	cis	rs960902	0.747	rs2216117	ENSG00000213553.4	RPLP0P6	4.24	2.92e-05	0.00663	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37496025	chr2:38481851~38482804:+
LIHC	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-4.24	2.92e-05	0.00663	-0.24	-0.22	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
LIHC	cis	rs10129255	1	rs10134517	ENSG00000224373.3	IGHV4-59	4.24	2.92e-05	0.00663	0.18	0.22	Kawasaki disease;	chr14:106718498	chr14:106627249~106627825:-
LIHC	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	4.24	2.92e-05	0.00663	0.29	0.22	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
LIHC	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	4.24	2.92e-05	0.00663	0.29	0.22	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
LIHC	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	4.24	2.92e-05	0.00663	0.29	0.22	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
LIHC	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	4.24	2.92e-05	0.00663	0.28	0.22	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
LIHC	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-4.24	2.92e-05	0.00663	-0.26	-0.22	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
LIHC	cis	rs77204473	1	rs77204473	ENSG00000254851.1	RP11-109L13.1	4.24	2.92e-05	0.00663	0.52	0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934348	chr11:117135528~117138582:+
LIHC	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	4.24	2.92e-05	0.00663	0.36	0.22	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
LIHC	cis	rs494453	0.922	rs2477428	ENSG00000227811.2	FAM212B-AS1	-4.24	2.92e-05	0.00663	-0.25	-0.22	Osteoporosis-related phenotypes;	chr1:111671634	chr1:111739841~111747798:+
LIHC	cis	rs9527	0.59	rs10509766	ENSG00000236937.2	PTGES3P4	4.24	2.92e-05	0.00663	0.28	0.22	Arsenic metabolism;	chr10:103166577	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.64	rs35195396	ENSG00000236937.2	PTGES3P4	4.24	2.92e-05	0.00663	0.28	0.22	Arsenic metabolism;	chr10:103169013	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.614	rs11191589	ENSG00000236937.2	PTGES3P4	4.24	2.92e-05	0.00663	0.28	0.22	Arsenic metabolism;	chr10:103170625	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs3740386	ENSG00000236937.2	PTGES3P4	4.24	2.92e-05	0.00663	0.28	0.22	Arsenic metabolism;	chr10:103171294	chr10:102845595~102845950:+
LIHC	cis	rs1005277	0.579	rs1780130	ENSG00000275858.1	RP11-291L22.8	4.24	2.92e-05	0.00664	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38450738~38451069:-
LIHC	cis	rs2060793	0.552	rs939968	ENSG00000251991.1	RNU7-49P	4.24	2.92e-05	0.00664	0.25	0.22	Vitamin D levels;	chr11:14608134	chr11:14478892~14478953:+
LIHC	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-4.24	2.93e-05	0.00665	-0.25	-0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
LIHC	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	4.24	2.93e-05	0.00665	0.26	0.22	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
LIHC	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	4.24	2.93e-05	0.00666	0.16	0.22	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
LIHC	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	4.24	2.93e-05	0.00666	0.22	0.22	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
LIHC	cis	rs2348418	0.831	rs7296538	ENSG00000247934.4	RP11-967K21.1	-4.24	2.93e-05	0.00666	-0.21	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28558850	chr12:28163298~28190738:-
LIHC	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	4.24	2.94e-05	0.00666	0.25	0.22	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
LIHC	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-4.24	2.94e-05	0.00666	-0.27	-0.22	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
LIHC	cis	rs10028773	0.6	rs4001390	ENSG00000260091.1	RP11-33B1.4	-4.24	2.94e-05	0.00667	-0.15	-0.22	Educational attainment;	chr4:119344628	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.691	rs2136911	ENSG00000260091.1	RP11-33B1.4	-4.24	2.94e-05	0.00667	-0.15	-0.22	Corneal astigmatism;	chr4:119344704	chr4:119409333~119410233:+
LIHC	cis	rs10028773	0.568	rs6838457	ENSG00000260091.1	RP11-33B1.4	-4.24	2.94e-05	0.00667	-0.15	-0.22	Educational attainment;	chr4:119346212	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.535	rs10005542	ENSG00000260091.1	RP11-33B1.4	-4.24	2.94e-05	0.00667	-0.15	-0.22	Corneal astigmatism;	chr4:119347147	chr4:119409333~119410233:+
LIHC	cis	rs17270561	0.562	rs74293932	ENSG00000216436.2	HIST1H2APS1	-4.24	2.94e-05	0.00667	-0.34	-0.22	Iron status biomarkers;	chr6:26014583	chr6:25732497~25732827:+
LIHC	cis	rs2243480	1	rs78803505	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65917585	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs34933526	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65918212	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs34577383	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65920739	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs6949812	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65922114	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs6970243	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65923503	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs7794661	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65924743	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs7795242	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65925107	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.708	rs35310401	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65925372	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35058610	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65925938	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs2177703	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65926730	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35432774	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65928032	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.831	rs7806717	ENSG00000228409.4	CCT6P1	-4.24	2.94e-05	0.00667	-0.24	-0.22	Diabetic kidney disease;	chr7:65928187	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs56985706	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65929575	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs60683927	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65929781	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs58062456	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65929865	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs34529418	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65938222	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs35087093	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65940221	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35046236	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65943626	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs36068983	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65944004	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs68189316	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65944182	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.803	rs34804747	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65947955	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs11538349	ENSG00000228409.4	CCT6P1	4.24	2.94e-05	0.00667	0.24	0.22	Diabetic kidney disease;	chr7:65956884	chr7:65751142~65763354:+
LIHC	cis	rs7121538	0.756	rs1966615	ENSG00000251991.1	RNU7-49P	-4.24	2.94e-05	0.00667	-0.32	-0.22	HDL cholesterol;	chr11:14403354	chr11:14478892~14478953:+
LIHC	cis	rs875971	0.545	rs6979636	ENSG00000273024.4	INTS4P2	-4.24	2.94e-05	0.00667	-0.25	-0.22	Aortic root size;	chr7:66276638	chr7:65647864~65715661:+
LIHC	cis	rs55966801	0.68	rs17655730	ENSG00000279672.1	CMB9-55F22.1	4.24	2.94e-05	0.00667	0.35	0.22	Plateletcrit;	chr11:270715	chr11:779617~780755:+
LIHC	cis	rs2243480	1	rs73142166	ENSG00000232546.1	RP11-458F8.1	-4.24	2.94e-05	0.00667	-0.26	-0.22	Diabetic kidney disease;	chr7:65910845	chr7:66848496~66858136:+
LIHC	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	4.24	2.94e-05	0.00667	0.24	0.22	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
LIHC	cis	rs748404	0.631	rs6493083	ENSG00000166763.7	STRCP1	4.23	2.94e-05	0.00667	0.27	0.22	Lung cancer;	chr15:43345787	chr15:43699488~43718184:-
LIHC	cis	rs11064837	0.523	rs1978107	ENSG00000248636.5	RP11-768F21.1	4.23	2.94e-05	0.00667	0.38	0.22	Schizophrenia;	chr12:119663909	chr12:119387987~119668079:-
LIHC	cis	rs2072510	0.569	rs7134860	ENSG00000257878.1	RP11-256L6.3	-4.23	2.94e-05	0.00668	-0.29	-0.22	Metabolite levels (small molecules and protein measures);	chr12:95996580	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.569	rs7134975	ENSG00000257878.1	RP11-256L6.3	-4.23	2.94e-05	0.00668	-0.29	-0.22	Metabolite levels (small molecules and protein measures);	chr12:95996642	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.569	rs7306086	ENSG00000257878.1	RP11-256L6.3	-4.23	2.94e-05	0.00668	-0.29	-0.22	Metabolite levels (small molecules and protein measures);	chr12:95996724	chr12:95996521~96011489:+
LIHC	cis	rs3204270	0.639	rs62080199	ENSG00000281517.1	Metazoa_SRP	-4.23	2.95e-05	0.00668	-0.43	-0.22	Dental caries;	chr17:81660876	chr17:81718849~81719095:-
LIHC	cis	rs338389	0.542	rs7182139	ENSG00000260657.2	RP11-315D16.4	-4.23	2.95e-05	0.00668	-0.36	-0.22	Survival in rectal cancer;	chr15:67993116	chr15:68267792~68277994:-
LIHC	cis	rs3204270	0.714	rs7189	ENSG00000281517.1	Metazoa_SRP	-4.23	2.95e-05	0.00668	-0.42	-0.22	Dental caries;	chr17:81701867	chr17:81718849~81719095:-
LIHC	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	4.23	2.95e-05	0.00669	0.23	0.22	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
LIHC	cis	rs6471393	0.861	rs2976374	ENSG00000253848.1	RP11-10N23.5	4.23	2.95e-05	0.0067	0.24	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93691945	chr8:93741193~93744534:+
LIHC	cis	rs812925	0.784	rs1177304	ENSG00000212978.6	AC016747.3	-4.23	2.96e-05	0.0067	-0.25	-0.22	Immature fraction of reticulocytes;	chr2:61161029	chr2:61141592~61144969:-
LIHC	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	4.23	2.96e-05	0.0067	0.26	0.22	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
LIHC	cis	rs901683	1	rs71494793	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45489644	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs71494794	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45489836	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs71515355	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45489908	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34415465	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45490132	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12768131	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45491000	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12763205	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45491047	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35187216	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45491172	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.681	rs71494795	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45492297	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs34019727	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45492303	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs75712637	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45492744	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs78220003	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45492900	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35303148	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45493806	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12764652	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45496530	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12778980	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45498763	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34081402	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45498979	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs35081812	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45500341	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71494797	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45502010	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35326978	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45502264	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34879733	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45502313	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35918870	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45502830	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71494798	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45503532	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35394192	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45505313	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12764485	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45507139	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71494800	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45507506	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12773463	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45508183	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35172875	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45508712	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71494802	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45510176	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496603	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45510201	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35294227	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45511350	chr10:45678692~45700532:+
LIHC	cis	rs35993099	1	rs35993099	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular hemoglobin;Red blood cell count;	chr10:45511519	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496605	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45514370	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496606	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45514650	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs71496607	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45514868	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35504302	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45515057	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12772485	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45515973	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs115391636	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45516597	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12781186	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45517990	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12779198	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45518099	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12762495	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45518167	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs17157880	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45519040	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35131026	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45519311	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs17157884	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45520494	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496608	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45521684	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs78913745	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45524463	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.867	rs17157885	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45524646	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs17157887	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45524900	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496609	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45525583	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs36070535	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45526790	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12764693	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45527879	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35902429	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45528887	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34897497	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45529229	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs76805415	ENSG00000230869.1	CTGLF10P	-4.23	2.96e-05	0.0067	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45530715	chr10:45678692~45700532:+
LIHC	cis	rs7208859	0.673	rs216410	ENSG00000266490.1	CTD-2349P21.9	-4.23	2.96e-05	0.0067	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30792372~30792833:+
LIHC	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-4.23	2.96e-05	0.0067	-0.24	-0.22	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
LIHC	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-4.23	2.96e-05	0.0067	-0.24	-0.22	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
LIHC	cis	rs6480314	0.831	rs7904069	ENSG00000233590.1	RP11-153K11.3	-4.23	2.96e-05	0.0067	-0.32	-0.22	Optic nerve measurement (disc area);	chr10:68220436	chr10:68233251~68242379:-
LIHC	cis	rs11079159	0.917	rs12452367	ENSG00000263096.1	RP11-515O17.2	4.23	2.96e-05	0.00671	0.3	0.22	QRS duration;	chr17:55297249	chr17:55271504~55273653:-
LIHC	cis	rs1577917	1	rs955196	ENSG00000234155.1	RP11-30P6.6	-4.23	2.96e-05	0.00671	-0.29	-0.22	Response to antipsychotic treatment;	chr6:86020233	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs11755864	ENSG00000234155.1	RP11-30P6.6	4.23	2.97e-05	0.00671	0.28	0.22	Response to antipsychotic treatment;	chr6:85982073	chr6:85387219~85390186:-
LIHC	cis	rs638893	0.947	rs1170396	ENSG00000255239.1	AP002954.6	4.23	2.97e-05	0.00672	0.38	0.22	Vitiligo;	chr11:118833108	chr11:118688039~118690600:-
LIHC	cis	rs9652601	0.959	rs12925642	ENSG00000274038.1	RP11-66H6.4	-4.23	2.97e-05	0.00672	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11077745	chr16:11056556~11057034:+
LIHC	cis	rs6480314	0.764	rs2394462	ENSG00000233590.1	RP11-153K11.3	4.23	2.97e-05	0.00672	0.31	0.22	Optic nerve measurement (disc area);	chr10:68221986	chr10:68233251~68242379:-
LIHC	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	4.23	2.97e-05	0.00672	0.23	0.22	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
LIHC	cis	rs812925	0.537	rs10208769	ENSG00000271889.1	RP11-493E12.1	-4.23	2.97e-05	0.00673	-0.27	-0.22	Immature fraction of reticulocytes;	chr2:61378479	chr2:61151433~61162105:-
LIHC	cis	rs4578769	0.879	rs7244549	ENSG00000265943.1	RP11-739L10.1	4.23	2.98e-05	0.00673	0.28	0.22	Eosinophil percentage of white cells;	chr18:22866052	chr18:22699481~22933764:-
LIHC	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	4.23	2.98e-05	0.00674	0.26	0.22	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
LIHC	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	4.23	2.98e-05	0.00674	0.36	0.22	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
LIHC	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-4.23	2.98e-05	0.00674	-0.22	-0.22	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
LIHC	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	4.23	2.98e-05	0.00674	0.25	0.22	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	4.23	2.98e-05	0.00674	0.25	0.22	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
LIHC	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	4.23	2.98e-05	0.00674	0.25	0.22	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
LIHC	cis	rs2540513	0.643	rs34573	ENSG00000241556.1	RP11-490G8.1	-4.23	2.98e-05	0.00674	-0.24	-0.22	Small intestine neuroendocrine tumor;	chr12:96129926	chr12:95467397~95467861:-
LIHC	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-4.23	2.98e-05	0.00675	-0.28	-0.22	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
LIHC	cis	rs2243480	0.901	rs73142137	ENSG00000232546.1	RP11-458F8.1	-4.23	2.98e-05	0.00675	-0.26	-0.22	Diabetic kidney disease;	chr7:65878455	chr7:66848496~66858136:+
LIHC	cis	rs3204270	0.639	rs11871678	ENSG00000281517.1	Metazoa_SRP	-4.23	2.98e-05	0.00675	-0.41	-0.22	Dental caries;	chr17:81687255	chr17:81718849~81719095:-
LIHC	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	4.23	2.98e-05	0.00675	0.26	0.22	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
LIHC	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-4.23	2.98e-05	0.00675	-0.26	-0.22	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
LIHC	cis	rs2598107	0.601	rs13240429	ENSG00000211698.2	TRGV4	-4.23	2.99e-05	0.00675	-0.26	-0.22	Dupuytren's disease;	chr7:37921233	chr7:38353715~38354517:-
LIHC	cis	rs6439153	0.933	rs900381	ENSG00000231305.3	RP11-723O4.2	4.23	2.99e-05	0.00675	0.25	0.22	Pneumococcal bacteremia;	chr3:128994612	chr3:128861313~128871540:-
LIHC	cis	rs11733284	0.63	rs2048157	ENSG00000259959.1	RP11-121C2.2	-4.23	2.99e-05	0.00676	-0.21	-0.22	Gout;Renal underexcretion gout;	chr4:48021329	chr4:47840122~47844339:-
LIHC	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	4.23	2.99e-05	0.00676	0.36	0.22	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
LIHC	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	4.23	2.99e-05	0.00676	0.36	0.22	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
LIHC	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	4.23	2.99e-05	0.00676	0.36	0.22	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
LIHC	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	4.23	2.99e-05	0.00676	0.36	0.22	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
LIHC	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	4.23	2.99e-05	0.00676	0.36	0.22	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
LIHC	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	4.23	2.99e-05	0.00676	0.36	0.22	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
LIHC	cis	rs2439831	1	rs471229	ENSG00000166763.7	STRCP1	4.23	2.99e-05	0.00676	0.31	0.22	Lung cancer in ever smokers;	chr15:43441796	chr15:43699488~43718184:-
LIHC	cis	rs2439831	1	rs2439841	ENSG00000166763.7	STRCP1	4.23	2.99e-05	0.00676	0.31	0.22	Lung cancer in ever smokers;	chr15:43442551	chr15:43699488~43718184:-
LIHC	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	4.23	2.99e-05	0.00676	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
LIHC	cis	rs113084984	0.718	rs12620490	ENSG00000271952.1	RP11-245G13.2	-4.23	2.99e-05	0.00676	-0.27	-0.22	Breast cancer;	chr2:11542670	chr2:10878269~10885118:+
LIHC	cis	rs11096990	0.613	rs12643415	ENSG00000249207.1	RP11-360F5.1	4.23	2.99e-05	0.00677	0.22	0.22	Cognitive function;	chr4:39270375	chr4:39112677~39126818:-
LIHC	cis	rs6951245	0.554	rs10246354	ENSG00000229043.2	AC091729.9	-4.23	3e-05	0.00677	-0.41	-0.22	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1160374~1165267:+
LIHC	cis	rs17834679	1	rs17834679	ENSG00000243680.1	RPL37P23	-4.23	3e-05	0.00677	-0.19	-0.22	Alopecia areata;	chr19:51766834	chr19:52143043~52143336:+
LIHC	cis	rs7474896	0.616	rs1985260	ENSG00000263064.2	RP11-291L22.7	4.23	3e-05	0.00677	0.3	0.22	Obesity (extreme);	chr10:38145162	chr10:38448689~38448949:+
LIHC	cis	rs12887734	0.546	rs12885509	ENSG00000258534.1	CTD-2134A5.4	-4.23	3e-05	0.00677	-0.25	-0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103854366~103880111:-
LIHC	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-4.23	3e-05	0.00677	-0.34	-0.22	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
LIHC	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-4.23	3e-05	0.00677	-0.41	-0.22	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
LIHC	cis	rs11779988	0.501	rs3760	ENSG00000253671.1	RP11-806O11.1	-4.23	3e-05	0.00678	-0.28	-0.22	Breast cancer;	chr8:18028836	chr8:17808941~17820868:+
LIHC	cis	rs763121	0.853	rs2284073	ENSG00000273076.1	RP3-508I15.22	4.23	3e-05	0.00678	0.25	0.22	Menopause (age at onset);	chr22:38709943	chr22:38743495~38743910:+
LIHC	cis	rs1115240	0.947	rs56150758	ENSG00000257842.4	NOVA1-AS1	4.23	3e-05	0.00678	0.2	0.22	Educational attainment (years of education);	chr14:26636268	chr14:26598412~26806467:+
LIHC	cis	rs11098499	0.618	rs6858383	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119375617	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.697	rs6832410	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119375645	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.865	rs1112817	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119376645	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.779	rs10016060	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119377257	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs10005644	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119377322	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.697	rs10016448	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119377690	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.657	rs9996569	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119377849	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.908	rs11729050	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119378911	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs28429722	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119378938	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.954	rs10014845	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119379922	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs34868248	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119521275	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs3733525	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119525893	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs3775847	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119526487	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs3775848	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119526569	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs10013305	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119529269	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs3775849	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119529753	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.818	rs7688802	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119530513	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs7695620	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119531621	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs12502389	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119533036	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.821	rs3775852	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119533401	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.82	rs6534140	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119534156	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs7657849	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119534339	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs10034450	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119534494	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs1480939	ENSG00000260091.1	RP11-33B1.4	-4.23	3e-05	0.00678	-0.16	-0.22	Corneal astigmatism;	chr4:119535772	chr4:119409333~119410233:+
LIHC	cis	rs4356975	0.932	rs7692377	ENSG00000250919.1	RP11-813N20.3	-4.23	3.01e-05	0.00679	-0.22	-0.22	Obesity-related traits;	chr4:69078113	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs61612343	ENSG00000250919.1	RP11-813N20.3	-4.23	3.01e-05	0.00679	-0.22	-0.22	Obesity-related traits;	chr4:69078247	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs7679418	ENSG00000250919.1	RP11-813N20.3	-4.23	3.01e-05	0.00679	-0.22	-0.22	Obesity-related traits;	chr4:69078533	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs7680156	ENSG00000250919.1	RP11-813N20.3	-4.23	3.01e-05	0.00679	-0.22	-0.22	Obesity-related traits;	chr4:69078868	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs7698430	ENSG00000250919.1	RP11-813N20.3	-4.23	3.01e-05	0.00679	-0.22	-0.22	Obesity-related traits;	chr4:69078897	chr4:69027831~69044578:+
LIHC	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-4.23	3.01e-05	0.00679	-0.3	-0.22	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
LIHC	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-4.23	3.01e-05	0.00679	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
LIHC	cis	rs4694744	1	rs4694744	ENSG00000264696.1	AC108078.1	-4.23	3.01e-05	0.00679	-0.3	-0.22	Bacteremia;	chr4:69460938	chr4:69479331~69479434:+
LIHC	cis	rs4650994	0.789	rs2811300	ENSG00000213057.5	C1orf220	-4.23	3.01e-05	0.00679	-0.19	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178621259	chr1:178542752~178548889:+
LIHC	cis	rs4650994	0.816	rs1074896	ENSG00000213057.5	C1orf220	-4.23	3.01e-05	0.00679	-0.19	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178622055	chr1:178542752~178548889:+
LIHC	cis	rs17772222	0.874	rs61984746	ENSG00000258789.1	RP11-507K2.3	-4.23	3.01e-05	0.0068	-0.26	-0.22	Coronary artery calcification;	chr14:88668136	chr14:88551597~88552493:+
LIHC	cis	rs17711722	0.523	rs365896	ENSG00000226002.1	RP11-460N20.5	-4.23	3.01e-05	0.0068	-0.23	-0.22	Calcium levels;	chr7:66045710	chr7:65084103~65100232:+
LIHC	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	4.23	3.01e-05	0.0068	0.28	0.22	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
LIHC	cis	rs755249	1	rs755249	ENSG00000182109.6	RP11-69E11.4	4.23	3.01e-05	0.0068	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39522280~39546187:-
LIHC	cis	rs10833905	1	rs12420168	ENSG00000246225.5	RP11-17A1.3	-4.23	3.01e-05	0.0068	-0.29	-0.22	Sudden cardiac arrest;	chr11:23002244	chr11:22829380~22945393:+
LIHC	cis	rs10833905	1	rs11026893	ENSG00000246225.5	RP11-17A1.3	-4.23	3.01e-05	0.0068	-0.29	-0.22	Sudden cardiac arrest;	chr11:23002690	chr11:22829380~22945393:+
LIHC	cis	rs10833905	1	rs7932620	ENSG00000246225.5	RP11-17A1.3	-4.23	3.01e-05	0.0068	-0.29	-0.22	Sudden cardiac arrest;	chr11:23003174	chr11:22829380~22945393:+
LIHC	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	4.23	3.01e-05	0.0068	0.31	0.22	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
LIHC	cis	rs755249	0.588	rs6665948	ENSG00000182109.6	RP11-69E11.4	-4.23	3.02e-05	0.00681	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39522280~39546187:-
LIHC	cis	rs960902	0.747	rs13412538	ENSG00000213553.4	RPLP0P6	4.23	3.02e-05	0.00681	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37497480	chr2:38481851~38482804:+
LIHC	cis	rs3015497	0.789	rs11621971	ENSG00000269906.1	RP11-248J18.2	-4.23	3.02e-05	0.00682	-0.28	-0.22	Mean platelet volume;	chr14:50657809	chr14:50662511~50663178:-
LIHC	cis	rs3015497	0.789	rs923908	ENSG00000269906.1	RP11-248J18.2	4.23	3.02e-05	0.00682	0.28	0.22	Mean platelet volume;	chr14:50656877	chr14:50662511~50663178:-
LIHC	cis	rs11098499	0.863	rs10030660	ENSG00000260091.1	RP11-33B1.4	-4.23	3.02e-05	0.00682	-0.16	-0.22	Corneal astigmatism;	chr4:119515549	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs13149407	ENSG00000260091.1	RP11-33B1.4	-4.23	3.02e-05	0.00682	-0.16	-0.22	Corneal astigmatism;	chr4:119516670	chr4:119409333~119410233:+
LIHC	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-4.23	3.02e-05	0.00682	-0.23	-0.22	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-4.23	3.02e-05	0.00682	-0.23	-0.22	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
LIHC	cis	rs75920871	0.764	rs4938338	ENSG00000254851.1	RP11-109L13.1	-4.23	3.02e-05	0.00682	-0.45	-0.22	Subjective well-being;	chr11:117102178	chr11:117135528~117138582:+
LIHC	cis	rs617219	0.746	rs7724909	ENSG00000251675.1	CTC-458I2.2	-4.23	3.02e-05	0.00682	-0.26	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79263809	chr5:80128361~80143883:+
LIHC	cis	rs734999	0.588	rs3748819	ENSG00000225931.3	RP3-395M20.7	4.23	3.02e-05	0.00682	0.24	0.22	Ulcerative colitis;	chr1:2593527	chr1:2566410~2569888:+
LIHC	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-4.23	3.03e-05	0.00683	-0.27	-0.22	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
LIHC	cis	rs9527	0.59	rs10883839	ENSG00000236937.2	PTGES3P4	4.23	3.03e-05	0.00683	0.29	0.22	Arsenic metabolism;	chr10:103160584	chr10:102845595~102845950:+
LIHC	cis	rs9595908	0.606	rs4942925	ENSG00000212293.1	SNORA16	4.23	3.03e-05	0.00683	0.26	0.22	Body mass index;	chr13:32807106	chr13:32420390~32420516:-
LIHC	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-4.23	3.03e-05	0.00683	-0.27	-0.22	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
LIHC	cis	rs2929278	0.617	rs12908467	ENSG00000275601.1	AC011330.13	4.23	3.03e-05	0.00684	0.28	0.22	Schizophrenia;	chr15:43755232	chr15:43642389~43643023:-
LIHC	cis	rs6445975	0.666	rs4613423	ENSG00000272360.1	RP11-359I18.5	-4.23	3.03e-05	0.00684	-0.31	-0.22	Systemic lupus erythematosus;	chr3:58355841	chr3:58490830~58491291:-
LIHC	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	4.23	3.03e-05	0.00684	0.2	0.22	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
LIHC	cis	rs2929278	0.617	rs663214	ENSG00000275601.1	AC011330.13	4.23	3.03e-05	0.00684	0.26	0.22	Schizophrenia;	chr15:43821584	chr15:43642389~43643023:-
LIHC	cis	rs901683	1	rs12766550	ENSG00000230869.1	CTGLF10P	-4.23	3.03e-05	0.00684	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45515907	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12775527	ENSG00000230869.1	CTGLF10P	-4.23	3.03e-05	0.00684	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45529542	chr10:45678692~45700532:+
LIHC	cis	rs6745190	0.953	rs6704750	ENSG00000236153.1	AC104076.3	4.23	3.04e-05	0.00685	0.3	0.22	White blood cell count;	chr2:180964847	chr2:180979427~180980090:-
LIHC	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-4.23	3.04e-05	0.00685	-0.27	-0.22	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
LIHC	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-4.23	3.04e-05	0.00685	-0.27	-0.22	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
LIHC	cis	rs9457247	0.935	rs2149093	ENSG00000227598.1	RP1-167A14.2	4.23	3.04e-05	0.00685	0.24	0.22	Crohn's disease;	chr6:166959557	chr6:166969626~166999065:-
LIHC	cis	rs9907295	0.818	rs4796109	ENSG00000270871.1	AC015849.19	4.23	3.04e-05	0.00685	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35811904	chr17:35816717~35830293:-
LIHC	cis	rs4650994	0.623	rs2248666	ENSG00000273384.1	RP5-1098D14.1	-4.23	3.04e-05	0.00685	-0.27	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178651466	chr1:178651706~178652282:+
LIHC	cis	rs6442522	1	rs6762167	ENSG00000249786.6	EAF1-AS1	-4.23	3.04e-05	0.00685	-0.25	-0.22	Uric acid levels;	chr3:15403530	chr3:15436171~15455940:-
LIHC	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-4.23	3.04e-05	0.00685	-0.22	-0.22	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
LIHC	cis	rs901683	1	rs71494792	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45487601	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35632234	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45487931	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs36070902	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45488529	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34195613	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45534926	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35824277	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45535029	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs12765244	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45536593	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496612	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45537057	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496613	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45537125	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs17157898	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45541761	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs36054203	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45542413	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12776291	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45543059	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12781506	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45543254	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs12774453	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45543473	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34309840	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45543913	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs36109121	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45544063	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35034867	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45544117	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs75595592	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45544482	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs9422439	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45545025	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs9422650	ENSG00000230869.1	CTGLF10P	-4.23	3.04e-05	0.00685	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45550313	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12779976	ENSG00000230869.1	CTGLF10P	4.23	3.04e-05	0.00685	0.54	0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45547484	chr10:45678692~45700532:+
LIHC	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-4.23	3.04e-05	0.00685	-0.23	-0.22	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
LIHC	cis	rs17464492	0.593	rs12541832	ENSG00000246228.5	CASC8	4.23	3.04e-05	0.00685	0.25	0.22	Prostate-specific antigen levels (conditioned on lead SNPs);	chr8:127340926	chr8:127289817~127482139:-
LIHC	cis	rs755249	0.567	rs61779284	ENSG00000182109.6	RP11-69E11.4	4.23	3.04e-05	0.00686	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39522280~39546187:-
LIHC	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	4.23	3.04e-05	0.00686	0.26	0.22	Height;	chr4:55502504	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	4.23	3.04e-05	0.00686	0.26	0.22	Height;	chr4:55508982	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	4.23	3.04e-05	0.00686	0.26	0.22	Height;	chr4:55509442	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	4.23	3.04e-05	0.00686	0.26	0.22	Height;	chr4:55510177	chr4:55363971~55395847:-
LIHC	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-4.23	3.04e-05	0.00686	-0.29	-0.22	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
LIHC	cis	rs6832769	1	rs6554286	ENSG00000272969.1	RP11-528I4.2	-4.23	3.04e-05	0.00686	-0.27	-0.22	Personality dimensions;	chr4:55534137	chr4:55547112~55547889:+
LIHC	cis	rs2070488	0.965	rs2051215	ENSG00000229589.1	ACVR2B-AS1	-4.23	3.04e-05	0.00686	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38518854	chr3:38451027~38454820:-
LIHC	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-4.23	3.05e-05	0.00686	-0.26	-0.22	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
LIHC	cis	rs9906944	0.707	rs4794019	ENSG00000248278.1	SUMO2P17	-4.23	3.05e-05	0.00686	-0.36	-0.22	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49029928	chr17:48874860~48908983:-
LIHC	cis	rs8177253	0.665	rs9869535	ENSG00000244062.1	RP11-404G16.2	4.23	3.05e-05	0.00687	0.22	0.22	Iron status biomarkers;	chr3:133732737	chr3:133760300~133762363:+
LIHC	cis	rs2932538	0.922	rs11102508	ENSG00000225075.1	RP11-426L16.3	4.23	3.05e-05	0.00687	0.28	0.22	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112598553	chr1:112693688~112696621:-
LIHC	cis	rs2932538	0.922	rs6537745	ENSG00000225075.1	RP11-426L16.3	4.23	3.05e-05	0.00687	0.28	0.22	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112611458	chr1:112693688~112696621:-
LIHC	cis	rs617219	0.787	rs12189006	ENSG00000251675.1	CTC-458I2.2	-4.23	3.05e-05	0.00687	-0.25	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79243849	chr5:80128361~80143883:+
LIHC	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	4.23	3.05e-05	0.00688	0.36	0.22	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
LIHC	cis	rs2739330	0.828	rs2186366	ENSG00000206090.4	AP000350.7	-4.23	3.05e-05	0.00688	-0.26	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23939998~23942798:+
LIHC	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-4.23	3.05e-05	0.00688	-0.25	-0.22	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
LIHC	cis	rs2070488	1	rs1002676	ENSG00000229589.1	ACVR2B-AS1	-4.23	3.06e-05	0.00689	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38403441	chr3:38451027~38454820:-
LIHC	cis	rs73193808	0.614	rs2832251	ENSG00000212479.2	U3	4.23	3.06e-05	0.0069	0.26	0.22	Coronary artery disease;	chr21:29187231	chr21:29180425~29180639:-
LIHC	cis	rs12157904	1	rs13055987	ENSG00000233360.4	Z83844.1	4.23	3.06e-05	0.0069	0.47	0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37609434	chr22:37641832~37658377:-
LIHC	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	4.23	3.07e-05	0.0069	0.36	0.22	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
LIHC	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	4.23	3.07e-05	0.0069	0.26	0.22	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
LIHC	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	4.23	3.07e-05	0.00691	0.52	0.22	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
LIHC	cis	rs2749592	0.513	rs1208708	ENSG00000276805.1	RP11-291L22.6	4.23	3.07e-05	0.00691	0.27	0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38451030~38451785:+
LIHC	cis	rs5758511	0.689	rs45441993	ENSG00000237037.8	NDUFA6-AS1	-4.23	3.07e-05	0.00691	-0.44	-0.22	Birth weight;	chr22:42075734	chr22:42090931~42137742:+
LIHC	cis	rs7129556	0.701	rs10899399	ENSG00000254459.1	RP11-91P24.7	4.22	3.07e-05	0.00691	0.38	0.22	Weight loss (gastric bypass surgery);	chr11:77698787	chr11:77829654~77872262:-
LIHC	cis	rs7893279	0.505	rs7919487	ENSG00000225527.1	RP11-383B4.4	4.22	3.07e-05	0.00691	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18579870	chr10:18531849~18533336:-
LIHC	cis	rs4578769	0.959	rs4800430	ENSG00000265943.1	RP11-739L10.1	4.22	3.07e-05	0.00691	0.28	0.22	Eosinophil percentage of white cells;	chr18:22803299	chr18:22699481~22933764:-
LIHC	cis	rs11148252	0.904	rs9568734	ENSG00000278238.1	RP11-245D16.4	-4.22	3.07e-05	0.00692	-0.21	-0.22	Lewy body disease;	chr13:52430087	chr13:52454775~52455331:-
LIHC	cis	rs3738443	0.868	rs6660351	ENSG00000259865.1	RP11-488L18.10	4.22	3.07e-05	0.00692	0.22	0.22	Alcohol dependence;	chr1:247184526	chr1:247187281~247188526:-
LIHC	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	4.22	3.08e-05	0.00692	0.23	0.22	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
LIHC	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	4.22	3.08e-05	0.00692	0.25	0.22	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
LIHC	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-4.22	3.08e-05	0.00692	-0.29	-0.22	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-4.22	3.08e-05	0.00692	-0.29	-0.22	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-4.22	3.08e-05	0.00692	-0.29	-0.22	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-4.22	3.08e-05	0.00692	-0.29	-0.22	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-4.22	3.08e-05	0.00692	-0.29	-0.22	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
LIHC	cis	rs7923609	0.875	rs10761741	ENSG00000232075.1	MRPL35P2	-4.22	3.08e-05	0.00692	-0.25	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63306426	chr10:63634317~63634827:-
LIHC	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	4.22	3.08e-05	0.00693	0.42	0.22	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
LIHC	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-4.22	3.08e-05	0.00693	-0.22	-0.22	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
LIHC	cis	rs8005677	0.649	rs11629120	ENSG00000257285.4	RP11-298I3.1	-4.22	3.08e-05	0.00693	-0.23	-0.22	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:22929609~22955562:+
LIHC	cis	rs6445975	0.666	rs4553989	ENSG00000272360.1	RP11-359I18.5	4.22	3.08e-05	0.00694	0.3	0.22	Systemic lupus erythematosus;	chr3:58395393	chr3:58490830~58491291:-
LIHC	cis	rs11233413	0.874	rs12422142	ENSG00000246067.6	RAB30-AS1	4.22	3.09e-05	0.00694	0.3	0.22	Economic and political preferences (feminism/equality);	chr11:83043119	chr11:83072066~83106719:+
LIHC	cis	rs9675120	0.821	rs7207294	ENSG00000262006.1	RP11-700H6.4	-4.22	3.09e-05	0.00694	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr17:50838483	chr17:50909637~50910232:-
LIHC	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	4.22	3.09e-05	0.00694	0.2	0.22	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
LIHC	cis	rs1865760	0.625	rs9393681	ENSG00000216436.2	HIST1H2APS1	-4.22	3.09e-05	0.00695	-0.25	-0.22	Height;	chr6:26008032	chr6:25732497~25732827:+
LIHC	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	4.22	3.09e-05	0.00695	0.19	0.22	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
LIHC	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	4.22	3.09e-05	0.00695	0.19	0.22	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
LIHC	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	4.22	3.09e-05	0.00695	0.22	0.22	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
LIHC	cis	rs1223397	0.938	rs17767967	ENSG00000215022.6	RP1-257A7.4	-4.22	3.09e-05	0.00696	-0.29	-0.22	Blood pressure;	chr6:13281835	chr6:13264861~13295586:-
LIHC	cis	rs4845875	0.626	rs4845882	ENSG00000242349.4	NPPA-AS1	4.22	3.09e-05	0.00696	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11783110	chr1:11841017~11848079:+
LIHC	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-4.22	3.1e-05	0.00696	-0.22	-0.22	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
LIHC	cis	rs2243480	1	rs4718269	ENSG00000228409.4	CCT6P1	-4.22	3.1e-05	0.00696	-0.24	-0.22	Diabetic kidney disease;	chr7:65735810	chr7:65751142~65763354:+
LIHC	cis	rs2348418	0.966	rs7316797	ENSG00000247934.4	RP11-967K21.1	4.22	3.1e-05	0.00696	0.21	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28529776	chr12:28163298~28190738:-
LIHC	cis	rs6480314	0.831	rs10733840	ENSG00000233590.1	RP11-153K11.3	4.22	3.1e-05	0.00697	0.3	0.22	Optic nerve measurement (disc area);	chr10:68220464	chr10:68233251~68242379:-
LIHC	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-4.22	3.1e-05	0.00697	-0.28	-0.22	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
LIHC	cis	rs901683	1	rs901683	ENSG00000230869.1	CTGLF10P	-4.22	3.1e-05	0.00698	-0.52	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45470974	chr10:45678692~45700532:+
LIHC	cis	rs638893	0.842	rs480791	ENSG00000255239.1	AP002954.6	4.22	3.1e-05	0.00698	0.4	0.22	Vitiligo;	chr11:118833546	chr11:118688039~118690600:-
LIHC	cis	rs4925386	1	rs6121990	ENSG00000226332.2	RP11-157P1.4	-4.22	3.1e-05	0.00698	-0.23	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62305432~62306325:-
LIHC	cis	rs12468226	0.689	rs73989733	ENSG00000272966.1	RP11-686O6.1	4.22	3.11e-05	0.00698	0.39	0.22	Urate levels;	chr2:202115241	chr2:202336739~202337200:+
LIHC	cis	rs4561483	0.798	rs33629	ENSG00000261560.1	RP11-166B2.3	-4.22	3.11e-05	0.00698	-0.24	-0.22	Testicular germ cell tumor;	chr16:11903633	chr16:11881075~11882569:-
LIHC	cis	rs4356975	0.932	rs4694610	ENSG00000250919.1	RP11-813N20.3	-4.22	3.11e-05	0.00698	-0.22	-0.22	Obesity-related traits;	chr4:69079224	chr4:69027831~69044578:+
LIHC	cis	rs4356203	0.87	rs2171615	ENSG00000260196.1	RP1-239B22.5	-4.22	3.11e-05	0.00698	-0.27	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17380649~17383531:+
LIHC	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-4.22	3.11e-05	0.00699	-0.3	-0.22	Height;	chr3:53093751	chr3:53064283~53065091:-
LIHC	cis	rs2439831	0.618	rs8023508	ENSG00000275601.1	AC011330.13	4.22	3.11e-05	0.00699	0.32	0.22	Lung cancer in ever smokers;	chr15:43883905	chr15:43642389~43643023:-
LIHC	cis	rs11098499	0.554	rs2175381	ENSG00000260091.1	RP11-33B1.4	-4.22	3.11e-05	0.00699	-0.15	-0.22	Corneal astigmatism;	chr4:119344812	chr4:119409333~119410233:+
LIHC	cis	rs4578769	0.765	rs55762801	ENSG00000266850.1	RP11-370A5.1	-4.22	3.11e-05	0.00699	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22807096	chr18:22723491~22907721:-
LIHC	cis	rs244293	0.801	rs2541241	ENSG00000275710.1	RP11-257O5.4	-4.22	3.12e-05	0.00701	-0.24	-0.22	Menarche (age at onset);	chr17:54995632	chr17:54964474~54964679:+
LIHC	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	4.22	3.12e-05	0.00701	0.27	0.22	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
LIHC	cis	rs72675573	0.852	rs72675552	ENSG00000235612.1	RP1-158P9.1	-4.22	3.12e-05	0.00701	-0.29	-0.22	Monocyte count;	chr1:56138851	chr1:56145721~56155224:+
LIHC	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-4.22	3.13e-05	0.00703	-0.23	-0.22	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
LIHC	cis	rs9450351	0.744	rs7749600	ENSG00000203875.9	SNHG5	-4.22	3.13e-05	0.00704	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85624372	chr6:85660950~85678736:-
LIHC	cis	rs9450351	0.744	rs9344538	ENSG00000203875.9	SNHG5	-4.22	3.13e-05	0.00704	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85625243	chr6:85660950~85678736:-
LIHC	cis	rs9450351	0.744	rs9450307	ENSG00000203875.9	SNHG5	-4.22	3.13e-05	0.00704	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85634633	chr6:85660950~85678736:-
LIHC	cis	rs9450351	0.744	rs9450309	ENSG00000203875.9	SNHG5	-4.22	3.13e-05	0.00704	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85639025	chr6:85660950~85678736:-
LIHC	cis	rs2598107	0.601	rs71546608	ENSG00000211698.2	TRGV4	-4.22	3.13e-05	0.00704	-0.27	-0.22	Dupuytren's disease;	chr7:37900850	chr7:38353715~38354517:-
LIHC	cis	rs1115240	0.947	rs1010727	ENSG00000257842.4	NOVA1-AS1	-4.22	3.14e-05	0.00704	-0.21	-0.22	Educational attainment (years of education);	chr14:26647971	chr14:26598412~26806467:+
LIHC	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-4.22	3.14e-05	0.00704	-0.24	-0.22	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
LIHC	cis	rs2998286	0.723	rs332162	ENSG00000254635.4	WAC-AS1	-4.22	3.14e-05	0.00705	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599960	chr10:28522652~28532743:-
LIHC	cis	rs6445975	1	rs6445975	ENSG00000272360.1	RP11-359I18.5	4.22	3.14e-05	0.00705	0.28	0.22	Systemic lupus erythematosus;	chr3:58384450	chr3:58490830~58491291:-
LIHC	cis	rs3204270	0.639	rs7216239	ENSG00000281517.1	Metazoa_SRP	-4.22	3.14e-05	0.00705	-0.41	-0.22	Dental caries;	chr17:81693157	chr17:81718849~81719095:-
LIHC	cis	rs2243480	1	rs35825738	ENSG00000232546.1	RP11-458F8.1	-4.22	3.14e-05	0.00705	-0.25	-0.22	Diabetic kidney disease;	chr7:65853040	chr7:66848496~66858136:+
LIHC	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-4.22	3.14e-05	0.00705	-0.25	-0.22	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
LIHC	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-4.22	3.14e-05	0.00705	-0.25	-0.22	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
LIHC	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-4.22	3.14e-05	0.00705	-0.27	-0.22	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
LIHC	cis	rs30380	0.688	rs27524	ENSG00000272109.1	CTD-2260A17.3	-4.22	3.14e-05	0.00705	-0.29	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96804353~96806105:+
LIHC	cis	rs938554	0.513	rs3733588	ENSG00000250413.1	RP11-448G15.1	4.22	3.14e-05	0.00705	0.3	0.22	Blood metabolite levels;	chr4:9995679	chr4:10006482~10009725:+
LIHC	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-4.22	3.15e-05	0.00706	-0.27	-0.22	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
LIHC	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	4.22	3.15e-05	0.00706	0.32	0.22	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
LIHC	cis	rs8024893	0.764	rs8035110	ENSG00000270055.1	CTD-3092A11.2	4.22	3.15e-05	0.00706	0.33	0.22	Red cell distribution width;	chr15:31241884	chr15:30487963~30490313:+
LIHC	cis	rs8024893	0.764	rs8036245	ENSG00000270055.1	CTD-3092A11.2	4.22	3.15e-05	0.00706	0.33	0.22	Red cell distribution width;	chr15:31242211	chr15:30487963~30490313:+
LIHC	cis	rs6860806	0.507	rs2631372	ENSG00000263597.1	MIR3936	4.22	3.15e-05	0.00707	0.24	0.22	Breast cancer;	chr5:132367886	chr5:132365490~132365599:-
LIHC	cis	rs2072510	0.966	rs11108372	ENSG00000257715.1	RP11-256L6.2	-4.22	3.15e-05	0.00707	-0.23	-0.22	Metabolite levels (small molecules and protein measures);	chr12:96000739	chr12:96025323~96027971:+
LIHC	cis	rs2439831	1	rs690436	ENSG00000166763.7	STRCP1	4.22	3.15e-05	0.00707	0.31	0.22	Lung cancer in ever smokers;	chr15:43469007	chr15:43699488~43718184:-
LIHC	cis	rs2439831	1	rs2264239	ENSG00000166763.7	STRCP1	4.22	3.15e-05	0.00707	0.31	0.22	Lung cancer in ever smokers;	chr15:43473335	chr15:43699488~43718184:-
LIHC	cis	rs812925	0.512	rs7558954	ENSG00000212978.6	AC016747.3	-4.22	3.15e-05	0.00707	-0.24	-0.22	Immature fraction of reticulocytes;	chr2:61157771	chr2:61141592~61144969:-
LIHC	cis	rs6901152	0.561	rs1424929	ENSG00000217648.1	RP1-95L4.4	-4.22	3.15e-05	0.00707	-0.26	-0.22	Acute lymphoblastic leukemia (childhood);	chr6:143371109	chr6:143342246~143343383:+
LIHC	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	4.22	3.15e-05	0.00708	0.33	0.22	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
LIHC	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-4.22	3.15e-05	0.00708	-0.26	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
LIHC	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-4.22	3.15e-05	0.00708	-0.22	-0.22	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
LIHC	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-4.22	3.16e-05	0.00708	-0.28	-0.22	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
LIHC	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	4.22	3.16e-05	0.00708	0.23	0.22	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
LIHC	cis	rs7809950	1	rs10276604	ENSG00000238832.1	snoU109	4.22	3.16e-05	0.00709	0.26	0.22	Coronary artery disease;	chr7:107576293	chr7:107603363~107603507:+
LIHC	cis	rs11098499	0.599	rs3864142	ENSG00000260091.1	RP11-33B1.4	-4.22	3.16e-05	0.00709	-0.15	-0.22	Corneal astigmatism;	chr4:119345036	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.605	rs6833140	ENSG00000260091.1	RP11-33B1.4	-4.22	3.16e-05	0.00709	-0.15	-0.22	Corneal astigmatism;	chr4:119345667	chr4:119409333~119410233:+
LIHC	cis	rs1223397	0.651	rs202021	ENSG00000215022.6	RP1-257A7.4	-4.22	3.16e-05	0.00709	-0.24	-0.22	Blood pressure;	chr6:13302609	chr6:13264861~13295586:-
LIHC	cis	rs12887734	0.524	rs17791722	ENSG00000258534.1	CTD-2134A5.4	-4.22	3.16e-05	0.00709	-0.25	-0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103819873	chr14:103854366~103880111:-
LIHC	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	4.22	3.16e-05	0.00709	0.18	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
LIHC	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	4.22	3.16e-05	0.00709	0.18	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
LIHC	cis	rs2348418	0.639	rs11049350	ENSG00000247934.4	RP11-967K21.1	-4.22	3.16e-05	0.00709	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28113042	chr12:28163298~28190738:-
LIHC	cis	rs4578769	0.879	rs7243408	ENSG00000265943.1	RP11-739L10.1	4.22	3.16e-05	0.0071	0.28	0.22	Eosinophil percentage of white cells;	chr18:22861647	chr18:22699481~22933764:-
LIHC	cis	rs9527	0.59	rs2281877	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103106305	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs10786738	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103109694	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs1807298	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103110461	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs2182348	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103112927	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs1926037	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103118253	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.567	rs6584539	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103119645	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs2148200	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103120090	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.614	rs2153774	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103121278	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs10883834	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103121645	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.545	rs7915816	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103121993	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.568	rs1926036	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103124055	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs1541213	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103125573	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs10883836	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103131441	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs11191572	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103133380	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs12415199	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103135779	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs34104646	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103136321	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.567	rs11191573	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103137059	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs11191578	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103142580	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.641	rs34130454	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103143881	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs7897663	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103145847	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs12775302	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103151599	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.59	rs12414232	ENSG00000236937.2	PTGES3P4	4.22	3.16e-05	0.0071	0.28	0.22	Arsenic metabolism;	chr10:103154734	chr10:102845595~102845950:+
LIHC	cis	rs2739330	0.652	rs2000469	ENSG00000228039.3	KB-1125A3.10	4.22	3.17e-05	0.0071	0.27	0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23963780~23964374:+
LIHC	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-4.22	3.17e-05	0.0071	-0.25	-0.22	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
LIHC	cis	rs10833905	1	rs1465521	ENSG00000246225.5	RP11-17A1.3	-4.22	3.17e-05	0.0071	-0.29	-0.22	Sudden cardiac arrest;	chr11:23010880	chr11:22829380~22945393:+
LIHC	cis	rs11098499	0.955	rs13129661	ENSG00000260091.1	RP11-33B1.4	-4.22	3.17e-05	0.00711	-0.17	-0.22	Corneal astigmatism;	chr4:119231754	chr4:119409333~119410233:+
LIHC	cis	rs4925386	0.625	rs3810550	ENSG00000226332.2	RP11-157P1.4	4.22	3.17e-05	0.00711	0.27	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62305432~62306325:-
LIHC	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-4.22	3.17e-05	0.00711	-0.23	-0.22	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
LIHC	cis	rs9525927	0.553	rs2773283	ENSG00000227258.4	SMIM2-AS1	-4.22	3.17e-05	0.00711	-0.24	-0.22	Dupuytren's disease;	chr13:44225727	chr13:44110451~44240517:+
LIHC	cis	rs1005277	0.522	rs289643	ENSG00000275858.1	RP11-291L22.8	4.22	3.17e-05	0.00711	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38450738~38451069:-
LIHC	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-4.22	3.17e-05	0.00711	-0.22	-0.22	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-4.22	3.17e-05	0.00711	-0.22	-0.22	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-4.22	3.17e-05	0.00711	-0.22	-0.22	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-4.22	3.17e-05	0.00711	-0.22	-0.22	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-4.22	3.17e-05	0.00711	-0.22	-0.22	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
LIHC	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-4.22	3.17e-05	0.00711	-0.18	-0.22	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
LIHC	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-4.22	3.17e-05	0.00711	-0.18	-0.22	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
LIHC	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-4.22	3.17e-05	0.00711	-0.22	-0.22	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
LIHC	cis	rs7044106	0.791	rs4617229	ENSG00000238181.2	AHCYP2	-4.22	3.17e-05	0.00712	-0.26	-0.22	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120720673~120721972:+
LIHC	cis	rs17818399	0.962	rs7565274	ENSG00000279254.1	RP11-536C12.1	-4.22	3.18e-05	0.00712	-0.28	-0.22	Height;	chr2:46614722	chr2:46668870~46670778:+
LIHC	cis	rs7208859	0.614	rs216412	ENSG00000266490.1	CTD-2349P21.9	-4.22	3.18e-05	0.00712	-0.26	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30792372~30792833:+
LIHC	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-4.22	3.18e-05	0.00712	-0.28	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
LIHC	cis	rs921968	0.565	rs6704575	ENSG00000272555.1	RP11-459I19.1	4.22	3.18e-05	0.00712	0.24	0.22	Mean corpuscular hemoglobin concentration;	chr2:218724871	chr2:218818690~218819144:+
LIHC	cis	rs919433	0.89	rs979020	ENSG00000231621.1	AC013264.2	4.22	3.18e-05	0.00712	0.2	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305025	chr2:197197991~197199273:+
LIHC	cis	rs2439831	0.764	rs12324584	ENSG00000166763.7	STRCP1	4.22	3.18e-05	0.00712	0.31	0.22	Lung cancer in ever smokers;	chr15:43391248	chr15:43699488~43718184:-
LIHC	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-4.22	3.18e-05	0.00713	-0.26	-0.22	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
LIHC	cis	rs8177253	0.665	rs9869257	ENSG00000244062.1	RP11-404G16.2	4.22	3.18e-05	0.00713	0.22	0.22	Iron status biomarkers;	chr3:133732568	chr3:133760300~133762363:+
LIHC	cis	rs8177253	0.665	rs9831392	ENSG00000244062.1	RP11-404G16.2	4.22	3.18e-05	0.00713	0.22	0.22	Iron status biomarkers;	chr3:133732629	chr3:133760300~133762363:+
LIHC	cis	rs2070488	1	rs13058903	ENSG00000229589.1	ACVR2B-AS1	-4.22	3.18e-05	0.00713	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38471874	chr3:38451027~38454820:-
LIHC	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-4.22	3.18e-05	0.00713	-0.32	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
LIHC	cis	rs9907295	1	rs9908525	ENSG00000270871.1	AC015849.19	4.22	3.19e-05	0.00714	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35908605	chr17:35816717~35830293:-
LIHC	cis	rs7208859	0.673	rs78799101	ENSG00000266490.1	CTD-2349P21.9	4.22	3.19e-05	0.00714	0.29	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30792372~30792833:+
LIHC	cis	rs950881	0.799	rs72823669	ENSG00000234389.1	AC007278.3	4.22	3.19e-05	0.00714	0.3	0.22	Allergy;	chr2:102365573	chr2:102438713~102440475:+
LIHC	cis	rs17214007	0.877	rs2075515	ENSG00000263335.1	AF001548.5	-4.22	3.19e-05	0.00714	-0.29	-0.22	Cognitive function;	chr16:15778462	chr16:15726674~15732993:+
LIHC	cis	rs2243480	0.908	rs55876148	ENSG00000232546.1	RP11-458F8.1	-4.22	3.19e-05	0.00714	-0.25	-0.22	Diabetic kidney disease;	chr7:65914813	chr7:66848496~66858136:+
LIHC	cis	rs7635879	0.702	rs4687494	ENSG00000230102.6	RP11-407B7.1	-4.22	3.19e-05	0.00715	-0.21	-0.22	Breastfeeding duration;	chr3:194010581	chr3:194005259~194070970:-
LIHC	cis	rs875971	0.545	rs6460298	ENSG00000228409.4	CCT6P1	-4.22	3.19e-05	0.00715	-0.19	-0.22	Aortic root size;	chr7:66442783	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs35459055	ENSG00000228409.4	CCT6P1	-4.22	3.19e-05	0.00715	-0.19	-0.22	Aortic root size;	chr7:66479399	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs75577046	ENSG00000228409.4	CCT6P1	-4.22	3.19e-05	0.00715	-0.19	-0.22	Aortic root size;	chr7:66493729	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs3735147	ENSG00000228409.4	CCT6P1	-4.22	3.19e-05	0.00715	-0.19	-0.22	Aortic root size;	chr7:66505541	chr7:65751142~65763354:+
LIHC	cis	rs893363	0.522	rs2241807	ENSG00000271916.1	RP11-884K10.6	-4.22	3.19e-05	0.00715	-0.27	-0.22	Axial length;	chr3:53823131	chr3:53797764~53798019:-
LIHC	cis	rs7044106	0.791	rs2416797	ENSG00000238181.2	AHCYP2	-4.22	3.19e-05	0.00715	-0.26	-0.22	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.791	rs2416798	ENSG00000238181.2	AHCYP2	-4.22	3.19e-05	0.00715	-0.26	-0.22	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120720673~120721972:+
LIHC	cis	rs2998286	0.636	rs2772436	ENSG00000254635.4	WAC-AS1	-4.22	3.19e-05	0.00715	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28644655	chr10:28522652~28532743:-
LIHC	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-4.22	3.19e-05	0.00715	-0.28	-0.22	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-4.22	3.19e-05	0.00715	-0.28	-0.22	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-4.22	3.19e-05	0.00715	-0.28	-0.22	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
LIHC	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-4.22	3.19e-05	0.00715	-0.36	-0.22	Depression;	chr6:28192182	chr6:28115628~28116551:+
LIHC	cis	rs9952991	0.941	rs2542151	ENSG00000260302.1	RP11-973H7.1	-4.22	3.2e-05	0.00716	-0.33	-0.22	Inflammatory skin disease;	chr18:12779948	chr18:12774651~12775923:-
LIHC	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	4.22	3.2e-05	0.00716	0.2	0.22	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
LIHC	cis	rs3795324	0.793	rs60294056	ENSG00000227741.1	RP11-536C5.7	-4.22	3.2e-05	0.00716	-0.31	-0.22	Microalbuminuria;	chr1:160661318	chr1:160202199~160208869:-
LIHC	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-4.22	3.2e-05	0.00716	-0.26	-0.22	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
LIHC	cis	rs1075232	1	rs66581165	ENSG00000270055.1	CTD-3092A11.2	-4.22	3.2e-05	0.00716	-0.43	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30487963~30490313:+
LIHC	cis	rs1075265	0.54	rs2542587	ENSG00000272156.1	RP11-477N3.1	-4.22	3.2e-05	0.00716	-0.27	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54082554~54085066:+
LIHC	cis	rs1075265	0.563	rs2692537	ENSG00000272156.1	RP11-477N3.1	-4.22	3.2e-05	0.00716	-0.27	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54082554~54085066:+
LIHC	cis	rs7937890	0.572	rs2597202	ENSG00000251991.1	RNU7-49P	4.21	3.2e-05	0.00717	0.25	0.22	Mitochondrial DNA levels;	chr11:14463099	chr11:14478892~14478953:+
LIHC	cis	rs7809950	1	rs7793613	ENSG00000238832.1	snoU109	-4.21	3.2e-05	0.00717	-0.26	-0.22	Coronary artery disease;	chr7:107610039	chr7:107603363~107603507:+
LIHC	cis	rs11098499	0.908	rs1002152	ENSG00000260091.1	RP11-33B1.4	-4.21	3.2e-05	0.00717	-0.16	-0.22	Corneal astigmatism;	chr4:119352232	chr4:119409333~119410233:+
LIHC	cis	rs1405130	0.869	rs12995365	ENSG00000224287.2	MSL3P1	4.21	3.2e-05	0.00717	0.27	0.22	Coronary artery disease;	chr2:234657059	chr2:233865437~233868444:-
LIHC	cis	rs12157904	1	rs5995478	ENSG00000233360.4	Z83844.1	4.21	3.2e-05	0.00717	0.47	0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37604461	chr22:37641832~37658377:-
LIHC	cis	rs6439153	0.933	rs810952	ENSG00000231305.3	RP11-723O4.2	4.21	3.2e-05	0.00717	0.24	0.22	Pneumococcal bacteremia;	chr3:128967062	chr3:128861313~128871540:-
LIHC	cis	rs11098499	1	rs35643470	ENSG00000260091.1	RP11-33B1.4	-4.21	3.21e-05	0.00718	-0.16	-0.22	Corneal astigmatism;	chr4:119263793	chr4:119409333~119410233:+
LIHC	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	4.21	3.21e-05	0.00718	0.22	0.22	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
LIHC	cis	rs6445975	0.915	rs11130633	ENSG00000272360.1	RP11-359I18.5	4.21	3.21e-05	0.00718	0.27	0.22	Systemic lupus erythematosus;	chr3:58385065	chr3:58490830~58491291:-
LIHC	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-4.21	3.21e-05	0.00718	-0.28	-0.22	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
LIHC	cis	rs2439831	0.867	rs2447196	ENSG00000166763.7	STRCP1	-4.21	3.21e-05	0.00718	-0.34	-0.22	Lung cancer in ever smokers;	chr15:43601620	chr15:43699488~43718184:-
LIHC	cis	rs12701220	0.817	rs7798459	ENSG00000229043.2	AC091729.9	-4.21	3.21e-05	0.00719	-0.3	-0.22	Bronchopulmonary dysplasia;	chr7:1048329	chr7:1160374~1165267:+
LIHC	cis	rs7208859	0.573	rs8078182	ENSG00000266490.1	CTD-2349P21.9	4.21	3.21e-05	0.00719	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30792372~30792833:+
LIHC	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-4.21	3.21e-05	0.00719	-0.23	-0.22	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
LIHC	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-4.21	3.21e-05	0.00719	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
LIHC	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-4.21	3.21e-05	0.00719	-0.28	-0.22	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
LIHC	cis	rs794185	0.714	rs2633860	ENSG00000231249.1	ITPR1-AS1	-4.21	3.21e-05	0.00719	-0.25	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4457662	chr3:4490891~4493163:-
LIHC	cis	rs6061231	0.556	rs6121571	ENSG00000226332.2	RP11-157P1.4	4.21	3.21e-05	0.00719	0.25	0.22	Colorectal cancer;	chr20:62402267	chr20:62305432~62306325:-
LIHC	cis	rs875971	0.83	rs587360	ENSG00000232559.3	GS1-124K5.12	4.21	3.22e-05	0.00719	0.18	0.22	Aortic root size;	chr7:66057711	chr7:66554588~66576923:-
LIHC	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	4.21	3.22e-05	0.0072	0.33	0.22	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
LIHC	cis	rs9467711	0.591	rs68149500	ENSG00000216436.2	HIST1H2APS1	4.21	3.22e-05	0.0072	0.58	0.22	Autism spectrum disorder or schizophrenia;	chr6:26111043	chr6:25732497~25732827:+
LIHC	cis	rs169313	0.556	rs7220819	ENSG00000263400.5	TMEM220-AS1	-4.21	3.22e-05	0.0072	-0.27	-0.22	Relative hand skill in reading disability;	chr17:10663157	chr17:10729777~10815164:+
LIHC	cis	rs3096299	0.781	rs3102381	ENSG00000261118.1	RP11-104N10.1	4.21	3.22e-05	0.00721	0.22	0.22	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89492017~89504460:-
LIHC	cis	rs295490	0.667	rs78684868	ENSG00000272656.1	RP11-219D15.3	4.21	3.22e-05	0.00721	0.65	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139485651	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs74636199	ENSG00000272656.1	RP11-219D15.3	4.21	3.22e-05	0.00721	0.65	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139493679	chr3:139349024~139349371:-
LIHC	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-4.21	3.22e-05	0.00721	-0.28	-0.22	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
LIHC	cis	rs2998286	0.597	rs1272396	ENSG00000254635.4	WAC-AS1	-4.21	3.22e-05	0.00721	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28643416	chr10:28522652~28532743:-
LIHC	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	4.21	3.22e-05	0.00721	0.31	0.22	Height;	chr6:109737797	chr6:109382795~109383666:+
LIHC	cis	rs8177376	0.581	rs512577	ENSG00000254905.1	RP11-712L6.7	-4.21	3.22e-05	0.00721	-0.24	-0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126222046	chr11:126292922~126294254:-
LIHC	cis	rs875971	0.545	rs73376394	ENSG00000228409.4	CCT6P1	-4.21	3.22e-05	0.00721	-0.18	-0.22	Aortic root size;	chr7:66172694	chr7:65751142~65763354:+
LIHC	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-4.21	3.23e-05	0.00721	-0.27	-0.22	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
LIHC	cis	rs11079159	0.637	rs4147524	ENSG00000263096.1	RP11-515O17.2	4.21	3.23e-05	0.00721	0.39	0.22	QRS duration;	chr17:55274249	chr17:55271504~55273653:-
LIHC	cis	rs2562456	0.876	rs11085465	ENSG00000268555.1	RP11-678G14.3	-4.21	3.23e-05	0.00721	-0.28	-0.22	Pain;	chr19:21568988	chr19:21570822~21587322:-
LIHC	cis	rs7714584	0.793	rs11949375	ENSG00000197083.10	ZNF300P1	4.21	3.23e-05	0.00722	0.35	0.22	Crohn's disease;	chr5:150823418	chr5:150930645~150946289:-
LIHC	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-4.21	3.23e-05	0.00722	-0.26	-0.22	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
LIHC	cis	rs9450351	0.744	rs7744309	ENSG00000203875.9	SNHG5	-4.21	3.23e-05	0.00723	-0.47	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85556764	chr6:85660950~85678736:-
LIHC	cis	rs5758511	0.689	rs62240864	ENSG00000237037.8	NDUFA6-AS1	-4.21	3.23e-05	0.00723	-0.46	-0.22	Birth weight;	chr22:42167883	chr22:42090931~42137742:+
LIHC	cis	rs1075265	0.587	rs2949811	ENSG00000272156.1	RP11-477N3.1	-4.21	3.23e-05	0.00723	-0.27	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54082554~54085066:+
LIHC	cis	rs1115240	0.898	rs11159911	ENSG00000257842.4	NOVA1-AS1	-4.21	3.24e-05	0.00723	-0.21	-0.22	Educational attainment (years of education);	chr14:26594193	chr14:26598412~26806467:+
LIHC	cis	rs4356975	0.932	rs7654272	ENSG00000250919.1	RP11-813N20.3	-4.21	3.24e-05	0.00724	-0.22	-0.22	Obesity-related traits;	chr4:69074144	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.932	rs6600867	ENSG00000250919.1	RP11-813N20.3	-4.21	3.24e-05	0.00724	-0.22	-0.22	Obesity-related traits;	chr4:69074157	chr4:69027831~69044578:+
LIHC	cis	rs938554	0.513	rs1014290	ENSG00000250413.1	RP11-448G15.1	-4.21	3.24e-05	0.00724	-0.3	-0.22	Blood metabolite levels;	chr4:10000237	chr4:10006482~10009725:+
LIHC	cis	rs11098499	0.863	rs3822192	ENSG00000260091.1	RP11-33B1.4	-4.21	3.24e-05	0.00724	-0.16	-0.22	Corneal astigmatism;	chr4:119524565	chr4:119409333~119410233:+
LIHC	cis	rs948562	0.947	rs7945889	ENSG00000280010.1	AP001350.4	4.21	3.24e-05	0.00724	0.39	0.22	Lymphoma;	chr11:58609262	chr11:58627435~58628528:+
LIHC	cis	rs7474896	0.559	rs10740949	ENSG00000263064.2	RP11-291L22.7	4.21	3.24e-05	0.00724	0.27	0.22	Obesity (extreme);	chr10:37689507	chr10:38448689~38448949:+
LIHC	cis	rs7474896	0.609	rs11011336	ENSG00000263064.2	RP11-291L22.7	4.21	3.24e-05	0.00724	0.27	0.22	Obesity (extreme);	chr10:37696388	chr10:38448689~38448949:+
LIHC	cis	rs7474896	0.583	rs4934898	ENSG00000263064.2	RP11-291L22.7	4.21	3.24e-05	0.00724	0.27	0.22	Obesity (extreme);	chr10:37701467	chr10:38448689~38448949:+
LIHC	cis	rs17774123	0.901	rs79373064	ENSG00000257808.1	RP11-1136G11.8	4.21	3.24e-05	0.00724	0.4	0.22	Diastolic blood pressure;	chr12:53867904	chr12:53159586~53161000:+
LIHC	cis	rs6997458	0.742	rs7841178	ENSG00000253549.4	RP11-317J10.2	-4.21	3.24e-05	0.00725	-0.24	-0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85425690	chr8:85441851~85464915:-
LIHC	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-4.21	3.24e-05	0.00725	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
LIHC	cis	rs7208859	0.623	rs58908911	ENSG00000266490.1	CTD-2349P21.9	4.21	3.24e-05	0.00725	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30792372~30792833:+
LIHC	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	4.21	3.24e-05	0.00725	0.27	0.22	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
LIHC	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	4.21	3.25e-05	0.00725	0.2	0.22	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
LIHC	cis	rs7044106	0.762	rs10818471	ENSG00000238181.2	AHCYP2	-4.21	3.25e-05	0.00725	-0.26	-0.22	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120720673~120721972:+
LIHC	cis	rs2744375	0.6	rs2744372	ENSG00000261189.1	RP3-512B11.3	-4.21	3.25e-05	0.00725	-0.27	-0.22	Resting heart rate;	chr6:7554233	chr6:7540451~7541338:-
LIHC	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	4.21	3.25e-05	0.00726	0.28	0.22	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
LIHC	cis	rs755249	0.567	rs61779306	ENSG00000182109.6	RP11-69E11.4	4.21	3.25e-05	0.00726	0.31	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs41270821	ENSG00000182109.6	RP11-69E11.4	4.21	3.25e-05	0.00726	0.31	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs2296175	ENSG00000182109.6	RP11-69E11.4	4.21	3.25e-05	0.00726	0.31	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39522280~39546187:-
LIHC	cis	rs1005277	0.691	rs2474558	ENSG00000120555.12	SEPT7P9	-4.21	3.25e-05	0.00727	-0.27	-0.22	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38383069~38402916:-
LIHC	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-4.21	3.25e-05	0.00727	-0.28	-0.22	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
LIHC	cis	rs4578769	0.959	rs9961893	ENSG00000265943.1	RP11-739L10.1	4.21	3.25e-05	0.00727	0.28	0.22	Eosinophil percentage of white cells;	chr18:22849805	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.959	rs11082169	ENSG00000265943.1	RP11-739L10.1	4.21	3.25e-05	0.00727	0.28	0.22	Eosinophil percentage of white cells;	chr18:22850034	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.959	rs2100191	ENSG00000265943.1	RP11-739L10.1	4.21	3.25e-05	0.00727	0.28	0.22	Eosinophil percentage of white cells;	chr18:22851428	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.959	rs2100190	ENSG00000265943.1	RP11-739L10.1	4.21	3.25e-05	0.00727	0.28	0.22	Eosinophil percentage of white cells;	chr18:22851857	chr18:22699481~22933764:-
LIHC	cis	rs72675573	0.852	rs12145789	ENSG00000235612.1	RP1-158P9.1	-4.21	3.26e-05	0.00727	-0.29	-0.22	Monocyte count;	chr1:56141397	chr1:56145721~56155224:+
LIHC	cis	rs72675573	0.852	rs72675557	ENSG00000235612.1	RP1-158P9.1	-4.21	3.26e-05	0.00727	-0.29	-0.22	Monocyte count;	chr1:56142821	chr1:56145721~56155224:+
LIHC	cis	rs72675573	0.852	rs12118277	ENSG00000235612.1	RP1-158P9.1	-4.21	3.26e-05	0.00727	-0.29	-0.22	Monocyte count;	chr1:56143624	chr1:56145721~56155224:+
LIHC	cis	rs72675573	0.852	rs12142826	ENSG00000235612.1	RP1-158P9.1	-4.21	3.26e-05	0.00727	-0.29	-0.22	Monocyte count;	chr1:56146214	chr1:56145721~56155224:+
LIHC	cis	rs6723226	0.65	rs6729952	ENSG00000276334.1	AL133243.1	4.21	3.26e-05	0.00728	0.24	0.22	Intelligence (multi-trait analysis);	chr2:32539855	chr2:32521927~32523547:+
LIHC	cis	rs1577917	1	rs12215903	ENSG00000234155.1	RP11-30P6.6	4.21	3.26e-05	0.00728	0.29	0.22	Response to antipsychotic treatment;	chr6:85965310	chr6:85387219~85390186:-
LIHC	cis	rs11098499	0.863	rs9884402	ENSG00000260091.1	RP11-33B1.4	-4.21	3.26e-05	0.00728	-0.16	-0.22	Corneal astigmatism;	chr4:119568827	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.731	rs9995026	ENSG00000260091.1	RP11-33B1.4	-4.21	3.26e-05	0.00728	-0.16	-0.22	Corneal astigmatism;	chr4:119569344	chr4:119409333~119410233:+
LIHC	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-4.21	3.26e-05	0.00728	-0.25	-0.22	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
LIHC	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	4.21	3.26e-05	0.00728	0.38	0.22	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
LIHC	cis	rs8024893	1	rs8038787	ENSG00000270055.1	CTD-3092A11.2	4.21	3.26e-05	0.00728	0.31	0.22	Red cell distribution width;	chr15:31246171	chr15:30487963~30490313:+
LIHC	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	4.21	3.26e-05	0.00728	0.35	0.22	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
LIHC	cis	rs709400	0.859	rs7154948	ENSG00000258534.1	CTD-2134A5.4	4.21	3.26e-05	0.00728	0.34	0.22	Body mass index;	chr14:103556607	chr14:103854366~103880111:-
LIHC	cis	rs17772222	0.876	rs12436982	ENSG00000258789.1	RP11-507K2.3	-4.21	3.26e-05	0.00728	-0.26	-0.22	Coronary artery calcification;	chr14:88689862	chr14:88551597~88552493:+
LIHC	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	4.21	3.26e-05	0.00728	0.29	0.22	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
LIHC	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma;	chr2:102426252	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma;	chr2:102427407	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma;	chr2:102427715	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma;	chr2:102431747	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma;	chr2:102432120	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma;	chr2:102432614	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	4.21	3.26e-05	0.00728	0.24	0.22	Asthma;	chr2:102433405	chr2:102438713~102440475:+
LIHC	cis	rs4925386	1	rs6089351	ENSG00000226332.2	RP11-157P1.4	-4.21	3.26e-05	0.00729	-0.23	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62305432~62306325:-
LIHC	cis	rs4925386	0.959	rs6121989	ENSG00000226332.2	RP11-157P1.4	-4.21	3.26e-05	0.00729	-0.23	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62305432~62306325:-
LIHC	cis	rs10833905	0.941	rs11026897	ENSG00000246225.5	RP11-17A1.3	-4.21	3.27e-05	0.00729	-0.29	-0.22	Sudden cardiac arrest;	chr11:23005501	chr11:22829380~22945393:+
LIHC	cis	rs6442522	1	rs6442522	ENSG00000249786.6	EAF1-AS1	4.21	3.27e-05	0.00729	0.25	0.22	Uric acid levels;	chr3:15399049	chr3:15436171~15455940:-
LIHC	cis	rs763512	0.504	rs1051838	ENSG00000276054.1	RP11-378E13.3	4.21	3.27e-05	0.00729	0.28	0.22	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37510731	chr17:37386886~37387926:+
LIHC	cis	rs7412746	0.658	rs7526489	ENSG00000231073.1	RP11-316M1.3	4.21	3.27e-05	0.0073	0.23	0.22	Melanoma;	chr1:150753762	chr1:150973123~150975534:+
LIHC	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	4.21	3.27e-05	0.0073	0.25	0.22	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
LIHC	cis	rs9595908	0.785	rs9596032	ENSG00000212293.1	SNORA16	4.21	3.27e-05	0.0073	0.25	0.22	Body mass index;	chr13:32654708	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.746	rs2301393	ENSG00000212293.1	SNORA16	4.21	3.27e-05	0.0073	0.25	0.22	Body mass index;	chr13:32658298	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs7985656	ENSG00000212293.1	SNORA16	4.21	3.27e-05	0.0073	0.25	0.22	Body mass index;	chr13:32664414	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596056	ENSG00000212293.1	SNORA16	4.21	3.27e-05	0.0073	0.25	0.22	Body mass index;	chr13:32669402	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs3783267	ENSG00000212293.1	SNORA16	4.21	3.27e-05	0.0073	0.25	0.22	Body mass index;	chr13:32670719	chr13:32420390~32420516:-
LIHC	cis	rs9303401	0.703	rs8077052	ENSG00000265415.1	CTD-2510F5.4	4.21	3.28e-05	0.00731	0.16	0.22	Cognitive test performance;	chr17:59131560	chr17:59202677~59203829:-
LIHC	cis	rs2749592	0.918	rs1208653	ENSG00000263064.2	RP11-291L22.7	-4.21	3.28e-05	0.00731	-0.24	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37964898	chr10:38448689~38448949:+
LIHC	cis	rs2120243	0.533	rs1500921	ENSG00000244515.1	KRT18P34	-4.21	3.28e-05	0.00731	-0.21	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157337638	chr3:157162663~157163932:-
LIHC	cis	rs2120243	0.533	rs62278578	ENSG00000244515.1	KRT18P34	-4.21	3.28e-05	0.00731	-0.21	-0.22	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338078	chr3:157162663~157163932:-
LIHC	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	4.21	3.28e-05	0.00731	0.23	0.22	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
LIHC	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	4.21	3.28e-05	0.00732	0.22	0.22	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
LIHC	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	4.21	3.28e-05	0.00732	0.29	0.22	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
LIHC	cis	rs2562456	0.837	rs62110205	ENSG00000268555.1	RP11-678G14.3	4.21	3.28e-05	0.00732	0.29	0.22	Pain;	chr19:21577269	chr19:21570822~21587322:-
LIHC	cis	rs603446	0.703	rs1263151	ENSG00000254851.1	RP11-109L13.1	-4.21	3.28e-05	0.00732	-0.26	-0.22	Triglycerides;	chr11:116770312	chr11:117135528~117138582:+
LIHC	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	4.21	3.28e-05	0.00732	0.21	0.22	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
LIHC	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-4.21	3.29e-05	0.00733	-0.34	-0.22	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
LIHC	cis	rs7208859	0.673	rs11654331	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73277964	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11652409	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9896095	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs58920731	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73277984	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs73277986	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs12103588	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.614	rs9914534	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11658344	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs9900144	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs11656121	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs11650973	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs56085216	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11650305	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs11654914	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9914271	ENSG00000266490.1	CTD-2349P21.9	4.21	3.29e-05	0.00733	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30792372~30792833:+
LIHC	cis	rs2911132	0.62	rs1065407	ENSG00000248734.2	CTD-2260A17.1	4.21	3.29e-05	0.00733	0.3	0.22	Urate levels (BMI interaction);	chr5:96776379	chr5:96784777~96785999:+
LIHC	cis	rs7044106	0.791	rs2416799	ENSG00000238181.2	AHCYP2	-4.21	3.29e-05	0.00733	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.791	rs10984998	ENSG00000238181.2	AHCYP2	-4.21	3.29e-05	0.00733	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120720673~120721972:+
LIHC	cis	rs1005277	0.579	rs932538	ENSG00000275858.1	RP11-291L22.8	4.21	3.29e-05	0.00733	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.541	rs2472177	ENSG00000275858.1	RP11-291L22.8	4.21	3.29e-05	0.00733	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs2472178	ENSG00000275858.1	RP11-291L22.8	4.21	3.29e-05	0.00733	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs2474572	ENSG00000275858.1	RP11-291L22.8	4.21	3.29e-05	0.00733	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs2505198	ENSG00000275858.1	RP11-291L22.8	4.21	3.29e-05	0.00733	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.579	rs2008449	ENSG00000275858.1	RP11-291L22.8	-4.21	3.29e-05	0.00733	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38450738~38451069:-
LIHC	cis	rs2932538	0.961	rs6690292	ENSG00000225075.1	RP11-426L16.3	-4.21	3.29e-05	0.00733	-0.28	-0.22	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112645797	chr1:112693688~112696621:-
LIHC	cis	rs11098499	0.955	rs56386062	ENSG00000260091.1	RP11-33B1.4	-4.21	3.29e-05	0.00733	-0.17	-0.22	Corneal astigmatism;	chr4:119233980	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.955	rs4145951	ENSG00000260091.1	RP11-33B1.4	-4.21	3.29e-05	0.00733	-0.17	-0.22	Corneal astigmatism;	chr4:119234662	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.955	rs35916640	ENSG00000260091.1	RP11-33B1.4	-4.21	3.29e-05	0.00733	-0.17	-0.22	Corneal astigmatism;	chr4:119234697	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.955	rs13113112	ENSG00000260091.1	RP11-33B1.4	-4.21	3.29e-05	0.00733	-0.17	-0.22	Corneal astigmatism;	chr4:119234885	chr4:119409333~119410233:+
LIHC	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	4.21	3.29e-05	0.00733	0.24	0.22	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
LIHC	cis	rs763121	0.819	rs5757161	ENSG00000273076.1	RP3-508I15.22	4.21	3.29e-05	0.00733	0.25	0.22	Menopause (age at onset);	chr22:38594657	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.925	rs5757165	ENSG00000273076.1	RP3-508I15.22	4.21	3.29e-05	0.00733	0.25	0.22	Menopause (age at onset);	chr22:38598572	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.925	rs4821797	ENSG00000273076.1	RP3-508I15.22	4.21	3.29e-05	0.00733	0.25	0.22	Menopause (age at onset);	chr22:38620177	chr22:38743495~38743910:+
LIHC	cis	rs2243480	0.908	rs55876148	ENSG00000228409.4	CCT6P1	4.21	3.29e-05	0.00734	0.24	0.22	Diabetic kidney disease;	chr7:65914813	chr7:65751142~65763354:+
LIHC	cis	rs7044106	0.718	rs1960421	ENSG00000238181.2	AHCYP2	-4.21	3.29e-05	0.00734	-0.26	-0.22	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120720673~120721972:+
LIHC	cis	rs75920871	0.544	rs76868258	ENSG00000254851.1	RP11-109L13.1	-4.21	3.3e-05	0.00734	-0.45	-0.22	Subjective well-being;	chr11:117122576	chr11:117135528~117138582:+
LIHC	cis	rs4356203	0.87	rs7937176	ENSG00000260196.1	RP1-239B22.5	-4.21	3.3e-05	0.00734	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17380649~17383531:+
LIHC	cis	rs1005277	0.505	rs7917943	ENSG00000276805.1	RP11-291L22.6	-4.21	3.3e-05	0.00734	-0.27	-0.22	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38451030~38451785:+
LIHC	cis	rs12681287	0.608	rs13270090	ENSG00000254088.1	SLC2A3P4	-4.21	3.3e-05	0.00734	-0.27	-0.22	Caudate activity during reward;	chr8:86541069	chr8:86503591~86505061:+
LIHC	cis	rs1823913	1	rs1454749	ENSG00000227542.1	AC092614.2	4.21	3.3e-05	0.00734	0.23	0.22	Obesity-related traits;	chr2:191240909	chr2:191229165~191246172:-
LIHC	cis	rs10510102	0.872	rs11814703	ENSG00000273891.1	RP11-500G22.5	4.21	3.3e-05	0.00734	0.3	0.22	Breast cancer;	chr10:121964774	chr10:121965764~121967700:+
LIHC	cis	rs2333021	0.689	rs2535901	ENSG00000259015.1	RP11-109N23.6	-4.21	3.3e-05	0.00734	-0.26	-0.22	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72965734	chr14:72960595~72961993:+
LIHC	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-4.21	3.3e-05	0.00735	-0.23	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
LIHC	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	4.21	3.3e-05	0.00735	0.27	0.22	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
LIHC	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-4.21	3.3e-05	0.00735	-0.35	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-4.21	3.3e-05	0.00735	-0.35	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-4.21	3.3e-05	0.00735	-0.35	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
LIHC	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	4.21	3.3e-05	0.00735	0.22	0.22	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
LIHC	cis	rs6449502	0.858	rs6894795	ENSG00000272308.1	RP11-231G3.1	-4.21	3.3e-05	0.00736	-0.33	-0.22	Mean platelet volume;	chr5:60825535	chr5:60866457~60866935:-
LIHC	cis	rs6449502	0.858	rs4410607	ENSG00000272308.1	RP11-231G3.1	-4.21	3.3e-05	0.00736	-0.33	-0.22	Mean platelet volume;	chr5:60830439	chr5:60866457~60866935:-
LIHC	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	4.21	3.31e-05	0.00736	0.27	0.22	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	4.21	3.31e-05	0.00736	0.27	0.22	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
LIHC	cis	rs9450351	0.744	rs9450295	ENSG00000203875.9	SNHG5	-4.21	3.31e-05	0.00737	-0.47	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85548156	chr6:85660950~85678736:-
LIHC	cis	rs1023500	1	rs1047997	ENSG00000237037.8	NDUFA6-AS1	-4.21	3.31e-05	0.00737	-0.31	-0.22	Schizophrenia;	chr22:41938949	chr22:42090931~42137742:+
LIHC	cis	rs6445975	0.666	rs4075152	ENSG00000272360.1	RP11-359I18.5	-4.21	3.31e-05	0.00737	-0.29	-0.22	Systemic lupus erythematosus;	chr3:58399467	chr3:58490830~58491291:-
LIHC	cis	rs4356203	0.87	rs7925692	ENSG00000260196.1	RP1-239B22.5	4.21	3.31e-05	0.00737	0.27	0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17380649~17383531:+
LIHC	cis	rs2439831	0.85	rs28564774	ENSG00000166763.7	STRCP1	4.21	3.32e-05	0.00738	0.34	0.22	Lung cancer in ever smokers;	chr15:43833277	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28513374	ENSG00000166763.7	STRCP1	4.21	3.32e-05	0.00738	0.34	0.22	Lung cancer in ever smokers;	chr15:43833297	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs12441984	ENSG00000166763.7	STRCP1	4.21	3.32e-05	0.00738	0.34	0.22	Lung cancer in ever smokers;	chr15:43834087	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs7169322	ENSG00000166763.7	STRCP1	4.21	3.32e-05	0.00738	0.34	0.22	Lung cancer in ever smokers;	chr15:43838816	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.85	rs28707214	ENSG00000166763.7	STRCP1	4.21	3.32e-05	0.00738	0.34	0.22	Lung cancer in ever smokers;	chr15:43839425	chr15:43699488~43718184:-
LIHC	cis	rs9876781	1	rs7630741	ENSG00000229759.1	MRPS18AP1	4.21	3.32e-05	0.00738	0.23	0.22	Longevity;	chr3:48378233	chr3:48256350~48256938:-
LIHC	cis	rs875971	0.8	rs427557	ENSG00000232559.3	GS1-124K5.12	4.21	3.32e-05	0.00738	0.18	0.22	Aortic root size;	chr7:66054263	chr7:66554588~66576923:-
LIHC	cis	rs11971779	0.638	rs77668044	ENSG00000273391.1	RP11-634H22.1	4.21	3.32e-05	0.00738	0.22	0.22	Diisocyanate-induced asthma;	chr7:139426339	chr7:139359032~139359566:-
LIHC	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-4.21	3.32e-05	0.00738	-0.29	-0.22	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
LIHC	cis	rs34375054	0.553	rs12581512	ENSG00000279233.1	RP11-158L12.4	4.21	3.32e-05	0.00739	0.2	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125137716	chr12:125138245~125141711:+
LIHC	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-4.21	3.32e-05	0.00739	-0.27	-0.22	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
LIHC	cis	rs2243480	1	rs67728539	ENSG00000232546.1	RP11-458F8.1	-4.21	3.32e-05	0.00739	-0.25	-0.22	Diabetic kidney disease;	chr7:65913137	chr7:66848496~66858136:+
LIHC	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-4.21	3.32e-05	0.00739	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
LIHC	cis	rs494453	0.922	rs484495	ENSG00000227811.2	FAM212B-AS1	-4.21	3.32e-05	0.00739	-0.25	-0.22	Osteoporosis-related phenotypes;	chr1:111693680	chr1:111739841~111747798:+
LIHC	cis	rs960902	1	rs960902	ENSG00000213553.4	RPLP0P6	4.21	3.33e-05	0.0074	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37504522	chr2:38481851~38482804:+
LIHC	cis	rs4578769	0.959	rs4800430	ENSG00000266850.1	RP11-370A5.1	4.21	3.33e-05	0.0074	0.26	0.22	Eosinophil percentage of white cells;	chr18:22803299	chr18:22723491~22907721:-
LIHC	cis	rs10833905	0.756	rs4923046	ENSG00000246225.5	RP11-17A1.3	-4.21	3.33e-05	0.0074	-0.3	-0.22	Sudden cardiac arrest;	chr11:22969127	chr11:22829380~22945393:+
LIHC	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	4.21	3.33e-05	0.0074	0.25	0.22	Shingles;	chr7:38346957	chr7:38353715~38354517:-
LIHC	cis	rs1115240	0.947	rs4297616	ENSG00000257842.4	NOVA1-AS1	-4.21	3.33e-05	0.0074	-0.21	-0.22	Educational attainment (years of education);	chr14:26643673	chr14:26598412~26806467:+
LIHC	cis	rs244293	0.862	rs11079146	ENSG00000275710.1	RP11-257O5.4	-4.21	3.33e-05	0.0074	-0.24	-0.22	Menarche (age at onset);	chr17:55016761	chr17:54964474~54964679:+
LIHC	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	4.21	3.33e-05	0.0074	0.26	0.22	Height;	chr4:55527164	chr4:55363971~55395847:-
LIHC	cis	rs244293	0.831	rs2111097	ENSG00000275710.1	RP11-257O5.4	-4.21	3.33e-05	0.00741	-0.24	-0.22	Menarche (age at onset);	chr17:55013113	chr17:54964474~54964679:+
LIHC	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	4.21	3.33e-05	0.00741	0.25	0.22	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
LIHC	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	4.21	3.33e-05	0.00741	0.25	0.22	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
LIHC	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-4.21	3.34e-05	0.00742	-0.29	-0.22	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
LIHC	cis	rs28829049	0.597	rs2296107	ENSG00000270728.1	RP4-657E11.10	-4.2	3.34e-05	0.00742	-0.2	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19150155	chr1:19297080~19297903:+
LIHC	cis	rs11671005	0.651	rs35117909	ENSG00000269473.1	CTD-2619J13.19	4.2	3.34e-05	0.00742	0.39	0.22	Mean platelet volume;	chr19:58401539	chr19:58440448~58445849:+
LIHC	cis	rs7915414	0.951	rs1998591	ENSG00000230338.1	MTND4P19	4.2	3.34e-05	0.00742	0.23	0.22	Clopidogrel active metabolite levels;	chr10:94648221	chr10:94774156~94774633:-
LIHC	cis	rs7915414	0.901	rs1998590	ENSG00000230338.1	MTND4P19	4.2	3.34e-05	0.00742	0.23	0.22	Clopidogrel active metabolite levels;	chr10:94648248	chr10:94774156~94774633:-
LIHC	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	4.2	3.34e-05	0.00743	0.29	0.22	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
LIHC	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-4.2	3.34e-05	0.00743	-0.26	-0.22	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
LIHC	cis	rs548181	0.736	rs543389	ENSG00000254671.2	STT3A-AS1	-4.2	3.34e-05	0.00743	-0.41	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125594946	chr11:125570284~125592568:-
LIHC	cis	rs901683	1	rs35047800	ENSG00000230869.1	CTGLF10P	-4.2	3.34e-05	0.00743	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45593599	chr10:45678692~45700532:+
LIHC	cis	rs4356203	0.87	rs214919	ENSG00000260196.1	RP1-239B22.5	-4.2	3.35e-05	0.00743	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.87	rs214916	ENSG00000260196.1	RP1-239B22.5	-4.2	3.35e-05	0.00743	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17380649~17383531:+
LIHC	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	4.2	3.35e-05	0.00744	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
LIHC	cis	rs11098499	0.954	rs59866101	ENSG00000260091.1	RP11-33B1.4	-4.2	3.35e-05	0.00744	-0.16	-0.22	Corneal astigmatism;	chr4:119375436	chr4:119409333~119410233:+
LIHC	cis	rs244293	0.801	rs11655949	ENSG00000275710.1	RP11-257O5.4	-4.2	3.35e-05	0.00744	-0.24	-0.22	Menarche (age at onset);	chr17:55092522	chr17:54964474~54964679:+
LIHC	cis	rs1577917	1	rs10944169	ENSG00000234155.1	RP11-30P6.6	4.2	3.35e-05	0.00744	0.28	0.22	Response to antipsychotic treatment;	chr6:85973318	chr6:85387219~85390186:-
LIHC	cis	rs1023500	0.505	rs134901	ENSG00000226450.2	CYP2D8P	4.2	3.35e-05	0.00745	0.25	0.22	Schizophrenia;	chr22:42287514	chr22:42149886~42155001:-
LIHC	cis	rs2735413	0.914	rs1922608	ENSG00000276007.1	RP11-358L22.3	-4.2	3.35e-05	0.00745	-0.26	-0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78031242	chr16:78123243~78124332:+
LIHC	cis	rs9326248	0.515	rs2727793	ENSG00000280143.1	AP000892.6	4.2	3.35e-05	0.00745	0.25	0.22	Blood protein levels;	chr11:116812658	chr11:117204967~117210292:+
LIHC	cis	rs4356203	0.905	rs7939750	ENSG00000260196.1	RP1-239B22.5	-4.2	3.35e-05	0.00745	-0.27	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17380649~17383531:+
LIHC	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	4.2	3.35e-05	0.00745	0.24	0.22	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
LIHC	cis	rs2243480	1	rs313814	ENSG00000228409.4	CCT6P1	4.2	3.35e-05	0.00745	0.24	0.22	Diabetic kidney disease;	chr7:66038306	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs6460276	ENSG00000228409.4	CCT6P1	-4.2	3.35e-05	0.00745	-0.18	-0.22	Aortic root size;	chr7:66182290	chr7:65751142~65763354:+
LIHC	cis	rs8005677	0.828	rs12589539	ENSG00000257285.4	RP11-298I3.1	4.2	3.35e-05	0.00745	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:22929609~22955562:+
LIHC	cis	rs875971	0.545	rs6950988	ENSG00000228409.4	CCT6P1	-4.2	3.35e-05	0.00745	-0.19	-0.22	Aortic root size;	chr7:66511428	chr7:65751142~65763354:+
LIHC	cis	rs787274	0.543	rs10116897	ENSG00000271631.1	RP11-408O19.5	4.2	3.36e-05	0.00745	0.35	0.22	Age-related hearing impairment (SNP x SNP interaction);	chr9:112871199	chr9:112885158~112885767:+
LIHC	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	4.2	3.36e-05	0.00746	0.27	0.22	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
LIHC	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-4.2	3.36e-05	0.00746	-0.34	-0.22	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
LIHC	cis	rs9907295	1	rs9913488	ENSG00000270871.1	AC015849.19	4.2	3.36e-05	0.00746	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs9912571	ENSG00000270871.1	AC015849.19	4.2	3.36e-05	0.00746	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs9912793	ENSG00000270871.1	AC015849.19	4.2	3.36e-05	0.00746	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs11655533	ENSG00000270871.1	AC015849.19	4.2	3.36e-05	0.00746	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35816717~35830293:-
LIHC	cis	rs2243480	1	rs35820085	ENSG00000228409.4	CCT6P1	4.2	3.36e-05	0.00746	0.24	0.22	Diabetic kidney disease;	chr7:65977771	chr7:65751142~65763354:+
LIHC	cis	rs11733284	0.962	rs4694879	ENSG00000259959.1	RP11-121C2.2	4.2	3.36e-05	0.00746	0.2	0.22	Gout;Renal underexcretion gout;	chr4:48030339	chr4:47840122~47844339:-
LIHC	cis	rs12589282	1	rs12589282	ENSG00000257285.4	RP11-298I3.1	-4.2	3.36e-05	0.00747	-0.21	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs);	chr14:22468664	chr14:22929609~22955562:+
LIHC	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	4.2	3.37e-05	0.00747	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
LIHC	cis	rs2929278	0.617	rs3087657	ENSG00000275601.1	AC011330.13	-4.2	3.37e-05	0.00747	-0.26	-0.22	Schizophrenia;	chr15:43771661	chr15:43642389~43643023:-
LIHC	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	4.2	3.37e-05	0.00747	0.29	0.22	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
LIHC	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	4.2	3.37e-05	0.00747	0.29	0.22	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
LIHC	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	4.2	3.37e-05	0.00747	0.29	0.22	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
LIHC	cis	rs2299116	1	rs2299116	ENSG00000225264.3	ZNRF2P2	-4.2	3.37e-05	0.00748	-0.25	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28775622	chr7:29598795~29685255:-
LIHC	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	4.2	3.37e-05	0.00748	0.2	0.22	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
LIHC	cis	rs1005277	0.638	rs1005278	ENSG00000263064.2	RP11-291L22.7	-4.2	3.37e-05	0.00748	-0.23	-0.22	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38448689~38448949:+
LIHC	cis	rs2243480	1	rs55895244	ENSG00000230295.1	RP11-458F8.2	-4.2	3.37e-05	0.00748	-0.23	-0.22	Diabetic kidney disease;	chr7:65922691	chr7:66880708~66882981:+
LIHC	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-4.2	3.37e-05	0.00748	-0.23	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
LIHC	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-4.2	3.37e-05	0.00749	-0.26	-0.22	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
LIHC	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	4.2	3.37e-05	0.00749	0.22	0.22	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
LIHC	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	4.2	3.37e-05	0.00749	0.22	0.22	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
LIHC	cis	rs7915414	0.756	rs1010570	ENSG00000230338.1	MTND4P19	4.2	3.37e-05	0.00749	0.23	0.22	Clopidogrel active metabolite levels;	chr10:94686875	chr10:94774156~94774633:-
LIHC	cis	rs2439831	0.681	rs524527	ENSG00000166763.7	STRCP1	-4.2	3.37e-05	0.00749	-0.31	-0.22	Lung cancer in ever smokers;	chr15:43306918	chr15:43699488~43718184:-
LIHC	cis	rs1115240	0.685	rs56777534	ENSG00000257842.4	NOVA1-AS1	4.2	3.37e-05	0.00749	0.22	0.22	Educational attainment (years of education);	chr14:26627899	chr14:26598412~26806467:+
LIHC	cis	rs6442522	0.809	rs749845	ENSG00000249786.6	EAF1-AS1	4.2	3.38e-05	0.00749	0.24	0.22	Uric acid levels;	chr3:15422811	chr3:15436171~15455940:-
LIHC	cis	rs9326248	0.581	rs7120515	ENSG00000280143.1	AP000892.6	4.2	3.38e-05	0.00749	0.26	0.22	Blood protein levels;	chr11:117121210	chr11:117204967~117210292:+
LIHC	cis	rs27434	0.605	rs152468	ENSG00000272109.1	CTD-2260A17.3	-4.2	3.38e-05	0.00749	-0.3	-0.22	Ankylosing spondylitis;	chr5:96831833	chr5:96804353~96806105:+
LIHC	cis	rs7806994	1	rs7806994	ENSG00000226278.1	PSPHP1	-4.2	3.38e-05	0.0075	-0.42	-0.22	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55764797~55773288:+
LIHC	cis	rs295490	0.748	rs77016755	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139392125	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs61034702	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139395105	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs115177972	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139410696	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs77876369	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139412070	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs77131232	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139415468	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.588	rs75694829	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139416582	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs76520271	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139422441	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs77343695	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139430617	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.667	rs79661321	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139434762	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs77036655	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139436231	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs75472377	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139439365	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.667	rs76728176	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441574	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs76522909	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139444006	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs61680644	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139455729	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.667	rs79829464	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456842	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs77347345	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139459863	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs17560106	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139461388	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.667	rs2289350	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139462436	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs80323892	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139464658	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs3772876	ENSG00000272656.1	RP11-219D15.3	4.2	3.38e-05	0.0075	0.66	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469035	chr3:139349024~139349371:-
LIHC	cis	rs2598107	0.601	rs3807194	ENSG00000211698.2	TRGV4	-4.2	3.38e-05	0.0075	-0.26	-0.22	Dupuytren's disease;	chr7:37912789	chr7:38353715~38354517:-
LIHC	cis	rs8177253	0.763	rs12769	ENSG00000244062.1	RP11-404G16.2	4.2	3.39e-05	0.00751	0.22	0.22	Iron status biomarkers;	chr3:133755484	chr3:133760300~133762363:+
LIHC	cis	rs57502260	0.834	rs3736228	ENSG00000212093.1	AP000807.1	-4.2	3.39e-05	0.00751	-0.28	-0.22	Total body bone mineral density (age 45-60);	chr11:68433827	chr11:68506083~68506166:-
LIHC	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	4.2	3.39e-05	0.00751	0.29	0.22	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
LIHC	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	4.2	3.39e-05	0.00751	0.26	0.22	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
LIHC	cis	rs35343117	1	rs35343117	ENSG00000259630.2	CTD-2262B20.1	-4.2	3.39e-05	0.00752	-0.32	-0.22	Psoriasis;	chr15:85535884	chr15:85415228~85415633:+
LIHC	cis	rs12681366	0.801	rs12549544	ENSG00000253704.1	RP11-267M23.4	4.2	3.39e-05	0.00753	0.26	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94553722~94569745:+
LIHC	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-4.2	3.39e-05	0.00753	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
LIHC	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-4.2	3.4e-05	0.00753	-0.24	-0.22	Asthma;	chr2:102374328	chr2:102438713~102440475:+
LIHC	cis	rs1900005	0.519	rs2894061	ENSG00000233590.1	RP11-153K11.3	-4.2	3.4e-05	0.00754	-0.32	-0.22	Vertical cup-disc ratio;	chr10:68191152	chr10:68233251~68242379:-
LIHC	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-4.2	3.4e-05	0.00754	-0.22	-0.22	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
LIHC	cis	rs11098499	0.863	rs12498539	ENSG00000260091.1	RP11-33B1.4	-4.2	3.4e-05	0.00754	-0.16	-0.22	Corneal astigmatism;	chr4:119547215	chr4:119409333~119410233:+
LIHC	cis	rs9907295	0.901	rs9898132	ENSG00000270871.1	AC015849.19	4.2	3.4e-05	0.00754	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35869187	chr17:35816717~35830293:-
LIHC	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-4.2	3.4e-05	0.00754	-0.26	-0.22	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
LIHC	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-4.2	3.41e-05	0.00755	-0.42	-0.22	Depression;	chr6:28076050	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-4.2	3.41e-05	0.00755	-0.42	-0.22	Depression;	chr6:28085045	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-4.2	3.41e-05	0.00755	-0.42	-0.22	Depression;	chr6:28111963	chr6:28115628~28116551:+
LIHC	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-4.2	3.41e-05	0.00755	-0.26	-0.22	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
LIHC	cis	rs72634501	0.517	rs7522362	ENSG00000182109.6	RP11-69E11.4	-4.2	3.41e-05	0.00755	-0.23	-0.22	HDL cholesterol;	chr1:39139419	chr1:39522280~39546187:-
LIHC	cis	rs2932538	0.922	rs12143068	ENSG00000225075.1	RP11-426L16.3	4.2	3.41e-05	0.00756	0.28	0.22	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112595488	chr1:112693688~112696621:-
LIHC	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-4.2	3.41e-05	0.00756	-0.28	-0.22	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
LIHC	cis	rs7580658	0.545	rs12477559	ENSG00000236682.1	AC068282.3	-4.2	3.41e-05	0.00756	-0.27	-0.22	Protein C levels;	chr2:127194221	chr2:127389130~127400580:+
LIHC	cis	rs2439831	0.867	rs3809481	ENSG00000166763.7	STRCP1	4.2	3.41e-05	0.00756	0.36	0.22	Lung cancer in ever smokers;	chr15:43370631	chr15:43699488~43718184:-
LIHC	cis	rs2070488	1	rs2268753	ENSG00000229589.1	ACVR2B-AS1	4.2	3.42e-05	0.00757	0.25	0.22	Electrocardiographic conduction measures;	chr3:38458698	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs2268757	ENSG00000229589.1	ACVR2B-AS1	4.2	3.42e-05	0.00757	0.25	0.22	Electrocardiographic conduction measures;	chr3:38464362	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs2276540	ENSG00000229589.1	ACVR2B-AS1	4.2	3.42e-05	0.00757	0.25	0.22	Electrocardiographic conduction measures;	chr3:38471016	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs2268758	ENSG00000229589.1	ACVR2B-AS1	4.2	3.42e-05	0.00757	0.25	0.22	Electrocardiographic conduction measures;	chr3:38472558	chr3:38451027~38454820:-
LIHC	cis	rs17270561	1	rs12211184	ENSG00000216436.2	HIST1H2APS1	-4.2	3.42e-05	0.00757	-0.34	-0.22	Iron status biomarkers;	chr6:25823546	chr6:25732497~25732827:+
LIHC	cis	rs17270561	1	rs79867288	ENSG00000216436.2	HIST1H2APS1	-4.2	3.42e-05	0.00757	-0.34	-0.22	Iron status biomarkers;	chr6:25828188	chr6:25732497~25732827:+
LIHC	cis	rs17270561	1	rs12200962	ENSG00000216436.2	HIST1H2APS1	-4.2	3.42e-05	0.00757	-0.34	-0.22	Iron status biomarkers;	chr6:25828758	chr6:25732497~25732827:+
LIHC	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-4.2	3.42e-05	0.00757	-0.27	-0.22	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
LIHC	cis	rs2243480	1	rs313803	ENSG00000232546.1	RP11-458F8.1	-4.2	3.42e-05	0.00758	-0.25	-0.22	Diabetic kidney disease;	chr7:66049744	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs313802	ENSG00000232546.1	RP11-458F8.1	-4.2	3.42e-05	0.00758	-0.25	-0.22	Diabetic kidney disease;	chr7:66051386	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.803	rs403089	ENSG00000232546.1	RP11-458F8.1	-4.2	3.42e-05	0.00758	-0.25	-0.22	Diabetic kidney disease;	chr7:66052736	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs458291	ENSG00000232546.1	RP11-458F8.1	-4.2	3.42e-05	0.00758	-0.25	-0.22	Diabetic kidney disease;	chr7:66055492	chr7:66848496~66858136:+
LIHC	cis	rs11098499	0.863	rs1383533	ENSG00000260091.1	RP11-33B1.4	-4.2	3.42e-05	0.00758	-0.16	-0.22	Corneal astigmatism;	chr4:119513421	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs2291185	ENSG00000260091.1	RP11-33B1.4	-4.2	3.42e-05	0.00758	-0.16	-0.22	Corneal astigmatism;	chr4:119513678	chr4:119409333~119410233:+
LIHC	cis	rs2032447	0.772	rs199754	ENSG00000242387.1	HIST1H2APS2	4.2	3.42e-05	0.00758	0.29	0.22	Intelligence (multi-trait analysis);	chr6:25992081	chr6:25882026~25882395:-
LIHC	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	4.2	3.42e-05	0.00758	0.39	0.22	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
LIHC	cis	rs12549025	0.536	rs9644075	ENSG00000253390.1	CTC-756D1.2	-4.2	3.42e-05	0.00758	-0.27	-0.22	Reticulocyte fraction of red cells;	chr8:23502448	chr8:23458601~23484971:+
LIHC	cis	rs1729407	0.706	rs595049	ENSG00000236267.1	AP006216.5	4.2	3.42e-05	0.00758	0.21	0.22	Apolipoprotein A-IV levels;	chr11:116828729	chr11:116813204~116814003:-
LIHC	cis	rs27434	0.602	rs2927620	ENSG00000272109.1	CTD-2260A17.3	-4.2	3.43e-05	0.00759	-0.3	-0.22	Ankylosing spondylitis;	chr5:96845594	chr5:96804353~96806105:+
LIHC	cis	rs10829156	0.898	rs10741120	ENSG00000240291.1	RP11-499P20.2	4.2	3.43e-05	0.00759	0.36	0.22	Sudden cardiac arrest;	chr10:18641063	chr10:18513115~18545651:-
LIHC	cis	rs7121538	0.756	rs12421378	ENSG00000251991.1	RNU7-49P	-4.2	3.43e-05	0.00759	-0.32	-0.22	HDL cholesterol;	chr11:14402689	chr11:14478892~14478953:+
LIHC	cis	rs2299116	1	rs13233430	ENSG00000225264.3	ZNRF2P2	-4.2	3.43e-05	0.00759	-0.25	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28777807	chr7:29598795~29685255:-
LIHC	cis	rs2299116	1	rs35341608	ENSG00000225264.3	ZNRF2P2	-4.2	3.43e-05	0.00759	-0.25	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28777894	chr7:29598795~29685255:-
LIHC	cis	rs2299116	1	rs34399011	ENSG00000225264.3	ZNRF2P2	-4.2	3.43e-05	0.00759	-0.25	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28777991	chr7:29598795~29685255:-
LIHC	cis	rs11098499	1	rs3749591	ENSG00000260091.1	RP11-33B1.4	-4.2	3.44e-05	0.0076	-0.16	-0.22	Corneal astigmatism;	chr4:119292875	chr4:119409333~119410233:+
LIHC	cis	rs1075265	0.62	rs10192626	ENSG00000272156.1	RP11-477N3.1	-4.2	3.44e-05	0.0076	-0.27	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54082554~54085066:+
LIHC	cis	rs9907295	0.901	rs4795095	ENSG00000270871.1	AC015849.19	4.2	3.44e-05	0.00762	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35870296	chr17:35816717~35830293:-
LIHC	cis	rs2797160	0.904	rs1418637	ENSG00000237742.5	RP11-624M8.1	-4.2	3.45e-05	0.00762	-0.23	-0.22	Endometrial cancer;	chr6:125671407	chr6:125578558~125749190:-
LIHC	cis	rs7044106	0.762	rs10760115	ENSG00000238181.2	AHCYP2	-4.2	3.45e-05	0.00762	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120720673~120721972:+
LIHC	cis	rs2243480	1	rs12698509	ENSG00000228409.4	CCT6P1	4.2	3.45e-05	0.00763	0.24	0.22	Diabetic kidney disease;	chr7:65953889	chr7:65751142~65763354:+
LIHC	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-4.2	3.45e-05	0.00763	-0.25	-0.22	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
LIHC	cis	rs7726839	0.54	rs72703078	ENSG00000271781.1	CTD-2589H19.6	-4.2	3.45e-05	0.00763	-0.34	-0.22	Obesity-related traits;	chr5:594872	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs72703083	ENSG00000271781.1	CTD-2589H19.6	-4.2	3.45e-05	0.00763	-0.34	-0.22	Obesity-related traits;	chr5:595250	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs55929359	ENSG00000271781.1	CTD-2589H19.6	-4.2	3.45e-05	0.00763	-0.34	-0.22	Obesity-related traits;	chr5:595841	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs58599998	ENSG00000271781.1	CTD-2589H19.6	-4.2	3.45e-05	0.00763	-0.34	-0.22	Obesity-related traits;	chr5:595972	chr5:675826~676616:+
LIHC	cis	rs7726839	0.507	rs56282020	ENSG00000271781.1	CTD-2589H19.6	-4.2	3.45e-05	0.00763	-0.34	-0.22	Obesity-related traits;	chr5:596586	chr5:675826~676616:+
LIHC	cis	rs7726839	0.507	rs60068988	ENSG00000271781.1	CTD-2589H19.6	-4.2	3.45e-05	0.00763	-0.34	-0.22	Obesity-related traits;	chr5:597553	chr5:675826~676616:+
LIHC	cis	rs57221529	0.709	rs72703090	ENSG00000271781.1	CTD-2589H19.6	-4.2	3.45e-05	0.00763	-0.34	-0.22	Lung disease severity in cystic fibrosis;	chr5:598199	chr5:675826~676616:+
LIHC	cis	rs6565180	0.888	rs12921440	ENSG00000183604.13	SMG1P5	4.2	3.46e-05	0.00764	0.23	0.22	Tonsillectomy;	chr16:30397444	chr16:30267553~30335374:-
LIHC	cis	rs6723226	0.721	rs3769600	ENSG00000276334.1	AL133243.1	-4.2	3.46e-05	0.00765	-0.24	-0.22	Intelligence (multi-trait analysis);	chr2:32391811	chr2:32521927~32523547:+
LIHC	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	4.2	3.46e-05	0.00765	0.26	0.22	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
LIHC	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	4.2	3.46e-05	0.00765	0.27	0.22	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	4.2	3.46e-05	0.00765	0.27	0.22	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	4.2	3.46e-05	0.00765	0.27	0.22	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
LIHC	cis	rs3845817	0.703	rs702919	ENSG00000281920.1	RP11-418H16.1	-4.2	3.46e-05	0.00765	-0.26	-0.22	Bipolar disorder;	chr2:65545157	chr2:65623272~65628424:+
LIHC	cis	rs9450351	0.744	rs9450304	ENSG00000203875.9	SNHG5	-4.2	3.47e-05	0.00766	-0.49	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85620141	chr6:85660950~85678736:-
LIHC	cis	rs7474896	0.583	rs10827817	ENSG00000263064.2	RP11-291L22.7	4.2	3.47e-05	0.00766	0.27	0.22	Obesity (extreme);	chr10:37709046	chr10:38448689~38448949:+
LIHC	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	4.2	3.47e-05	0.00766	0.26	0.22	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
LIHC	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-4.2	3.47e-05	0.00766	-0.27	-0.22	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
LIHC	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-4.2	3.47e-05	0.00767	-0.26	-0.22	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
LIHC	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-4.2	3.47e-05	0.00767	-0.23	-0.22	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
LIHC	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-4.2	3.47e-05	0.00767	-0.27	-0.22	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
LIHC	cis	rs11096990	1	rs11096990	ENSG00000249685.1	RP11-360F5.3	4.2	3.47e-05	0.00767	0.3	0.22	Cognitive function;	chr4:39285329	chr4:39133913~39135608:+
LIHC	cis	rs12887734	0.546	rs4906376	ENSG00000258534.1	CTD-2134A5.4	-4.2	3.47e-05	0.00767	-0.25	-0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805828	chr14:103854366~103880111:-
LIHC	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-4.2	3.47e-05	0.00767	-0.21	-0.22	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-4.2	3.47e-05	0.00767	-0.21	-0.22	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-4.2	3.47e-05	0.00767	-0.21	-0.22	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-4.2	3.47e-05	0.00767	-0.21	-0.22	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-4.2	3.47e-05	0.00767	-0.21	-0.22	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-4.2	3.47e-05	0.00767	-0.21	-0.22	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-4.2	3.47e-05	0.00767	-0.21	-0.22	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
LIHC	cis	rs17774123	0.901	rs17712839	ENSG00000257808.1	RP11-1136G11.8	4.2	3.48e-05	0.00768	0.41	0.22	Diastolic blood pressure;	chr12:53866962	chr12:53159586~53161000:+
LIHC	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-4.2	3.48e-05	0.00768	-0.33	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-4.2	3.48e-05	0.00768	-0.33	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
LIHC	cis	rs8005677	0.77	rs56180741	ENSG00000257285.4	RP11-298I3.1	4.2	3.48e-05	0.00768	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:22929609~22955562:+
LIHC	cis	rs8005677	0.828	rs3794452	ENSG00000257285.4	RP11-298I3.1	4.2	3.48e-05	0.00768	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:22929609~22955562:+
LIHC	cis	rs8005677	0.828	rs4981450	ENSG00000257285.4	RP11-298I3.1	4.2	3.48e-05	0.00768	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:22929609~22955562:+
LIHC	cis	rs4650994	0.816	rs2811304	ENSG00000273384.1	RP5-1098D14.1	-4.2	3.48e-05	0.00768	-0.25	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178627659	chr1:178651706~178652282:+
LIHC	cis	rs7893279	0.505	rs7923480	ENSG00000225527.1	RP11-383B4.4	4.19	3.48e-05	0.00769	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18616736	chr10:18531849~18533336:-
LIHC	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	4.19	3.48e-05	0.00769	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
LIHC	cis	rs11098499	1	rs12506395	ENSG00000260091.1	RP11-33B1.4	-4.19	3.48e-05	0.00769	-0.16	-0.22	Corneal astigmatism;	chr4:119263939	chr4:119409333~119410233:+
LIHC	cis	rs10829156	0.898	rs7923072	ENSG00000225527.1	RP11-383B4.4	-4.19	3.49e-05	0.00769	-0.36	-0.22	Sudden cardiac arrest;	chr10:18649305	chr10:18531849~18533336:-
LIHC	cis	rs4925386	1	rs4925382	ENSG00000226332.2	RP11-157P1.4	-4.19	3.49e-05	0.0077	-0.23	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62305432~62306325:-
LIHC	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	4.19	3.49e-05	0.0077	0.2	0.22	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
LIHC	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	4.19	3.49e-05	0.0077	0.27	0.22	Height;	chr6:109423238	chr6:109382795~109383666:+
LIHC	cis	rs6430585	0.528	rs309120	ENSG00000231890.6	DARS-AS1	-4.19	3.49e-05	0.0077	-0.3	-0.22	Corneal structure;	chr2:135951217	chr2:135985176~136022593:+
LIHC	cis	rs6430585	0.528	rs3112496	ENSG00000231890.6	DARS-AS1	-4.19	3.49e-05	0.0077	-0.3	-0.22	Corneal structure;	chr2:135953494	chr2:135985176~136022593:+
LIHC	cis	rs16958440	1	rs62096471	ENSG00000267724.1	RP11-49K24.8	4.19	3.49e-05	0.0077	0.34	0.22	Sitting height ratio;	chr18:47117443	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs4609941	ENSG00000267724.1	RP11-49K24.8	4.19	3.49e-05	0.0077	0.34	0.22	Sitting height ratio;	chr18:47119120	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs57928699	ENSG00000267724.1	RP11-49K24.8	4.19	3.49e-05	0.0077	0.34	0.22	Sitting height ratio;	chr18:47119222	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs60854219	ENSG00000267724.1	RP11-49K24.8	4.19	3.49e-05	0.0077	0.34	0.22	Sitting height ratio;	chr18:47120293	chr18:47105946~47108062:+
LIHC	cis	rs10829156	0.898	rs6482565	ENSG00000225527.1	RP11-383B4.4	-4.19	3.49e-05	0.0077	-0.36	-0.22	Sudden cardiac arrest;	chr10:18611664	chr10:18531849~18533336:-
LIHC	cis	rs9527	1	rs12416687	ENSG00000236937.2	PTGES3P4	4.19	3.49e-05	0.0077	0.34	0.22	Arsenic metabolism;	chr10:102869254	chr10:102845595~102845950:+
LIHC	cis	rs10129255	0.879	rs7160512	ENSG00000223648.3	IGHV3-64	4.19	3.49e-05	0.00771	0.16	0.22	Kawasaki disease;	chr14:106694574	chr14:106643132~106658258:-
LIHC	cis	rs10129255	0.879	rs7159157	ENSG00000223648.3	IGHV3-64	4.19	3.49e-05	0.00771	0.16	0.22	Kawasaki disease;	chr14:106694578	chr14:106643132~106658258:-
LIHC	cis	rs931127	0.595	rs11227248	ENSG00000265874.1	MIR4489	4.19	3.5e-05	0.00771	0.35	0.22	Systemic lupus erythematosus;	chr11:65660707	chr11:65649192~65649253:+
LIHC	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-4.19	3.5e-05	0.00771	-0.24	-0.22	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
LIHC	cis	rs9675120	0.638	rs8071494	ENSG00000262006.1	RP11-700H6.4	4.19	3.5e-05	0.00772	0.24	0.22	Cerebrospinal fluid biomarker levels;	chr17:50850488	chr17:50909637~50910232:-
LIHC	cis	rs6545883	0.503	rs1665272	ENSG00000271889.1	RP11-493E12.1	4.19	3.5e-05	0.00772	0.26	0.22	Tuberculosis;	chr2:61152151	chr2:61151433~61162105:-
LIHC	cis	rs7937890	0.532	rs2575833	ENSG00000251991.1	RNU7-49P	4.19	3.5e-05	0.00773	0.24	0.22	Mitochondrial DNA levels;	chr11:14470959	chr11:14478892~14478953:+
LIHC	cis	rs6479901	0.501	rs4414112	ENSG00000232075.1	MRPL35P2	-4.19	3.5e-05	0.00773	-0.25	-0.22	Intelligence (multi-trait analysis);	chr10:63115786	chr10:63634317~63634827:-
LIHC	cis	rs2562456	0.876	rs62110163	ENSG00000268555.1	RP11-678G14.3	4.19	3.5e-05	0.00773	0.28	0.22	Pain;	chr19:21546020	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.761	rs35008138	ENSG00000268555.1	RP11-678G14.3	4.19	3.5e-05	0.00773	0.28	0.22	Pain;	chr19:21548822	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.833	rs2681388	ENSG00000268555.1	RP11-678G14.3	4.19	3.5e-05	0.00773	0.28	0.22	Pain;	chr19:21549451	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.876	rs2681370	ENSG00000268555.1	RP11-678G14.3	4.19	3.5e-05	0.00773	0.28	0.22	Pain;	chr19:21554036	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.876	rs11668606	ENSG00000268555.1	RP11-678G14.3	4.19	3.5e-05	0.00773	0.28	0.22	Pain;	chr19:21554618	chr19:21570822~21587322:-
LIHC	cis	rs2562456	0.876	rs2681395	ENSG00000268555.1	RP11-678G14.3	4.19	3.5e-05	0.00773	0.28	0.22	Pain;	chr19:21555338	chr19:21570822~21587322:-
LIHC	cis	rs1115240	0.947	rs7154726	ENSG00000257842.4	NOVA1-AS1	-4.19	3.51e-05	0.00773	-0.21	-0.22	Educational attainment (years of education);	chr14:26649170	chr14:26598412~26806467:+
LIHC	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	4.19	3.51e-05	0.00773	0.23	0.22	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
LIHC	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	4.19	3.51e-05	0.00773	0.4	0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
LIHC	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-4.19	3.51e-05	0.00774	-0.27	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
LIHC	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	4.19	3.51e-05	0.00774	0.22	0.22	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	4.19	3.51e-05	0.00774	0.22	0.22	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
LIHC	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-4.19	3.51e-05	0.00774	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
LIHC	cis	rs2072510	0.932	rs10859999	ENSG00000257878.1	RP11-256L6.3	4.19	3.52e-05	0.00776	0.2	0.22	Metabolite levels (small molecules and protein measures);	chr12:95997556	chr12:95996521~96011489:+
LIHC	cis	rs7044106	0.791	rs7036196	ENSG00000238181.2	AHCYP2	-4.19	3.52e-05	0.00776	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.791	rs3904196	ENSG00000238181.2	AHCYP2	-4.19	3.52e-05	0.00776	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120720673~120721972:+
LIHC	cis	rs2762353	0.776	rs1165190	ENSG00000242387.1	HIST1H2APS2	4.19	3.52e-05	0.00776	0.25	0.22	Blood metabolite levels;	chr6:25847791	chr6:25882026~25882395:-
LIHC	cis	rs17772222	0.876	rs12586348	ENSG00000258789.1	RP11-507K2.3	-4.19	3.53e-05	0.00777	-0.26	-0.22	Coronary artery calcification;	chr14:88643523	chr14:88551597~88552493:+
LIHC	cis	rs7044106	0.791	rs7036766	ENSG00000238181.2	AHCYP2	-4.19	3.53e-05	0.00777	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120720673~120721972:+
LIHC	cis	rs2749592	0.531	rs10764134	ENSG00000275858.1	RP11-291L22.8	-4.19	3.53e-05	0.00777	-0.24	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38450738~38451069:-
LIHC	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-4.19	3.53e-05	0.00777	-0.19	-0.22	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
LIHC	cis	rs9467711	0.591	rs10484433	ENSG00000216436.2	HIST1H2APS1	4.19	3.53e-05	0.00778	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26030264	chr6:25732497~25732827:+
LIHC	cis	rs79349575	0.721	rs4794004	ENSG00000248278.1	SUMO2P17	4.19	3.53e-05	0.00778	0.28	0.22	Type 2 diabetes;	chr17:48961109	chr17:48874860~48908983:-
LIHC	cis	rs9907295	0.818	rs11658222	ENSG00000270871.1	AC015849.19	4.19	3.53e-05	0.00778	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35825092	chr17:35816717~35830293:-
LIHC	cis	rs7615952	0.546	rs16836896	ENSG00000171084.14	FAM86JP	4.19	3.53e-05	0.00778	0.37	0.22	Blood pressure (smoking interaction);	chr3:125592418	chr3:125916620~125930024:+
LIHC	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-4.19	3.54e-05	0.00779	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
LIHC	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	4.19	3.54e-05	0.00779	0.27	0.22	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
LIHC	cis	rs1075265	0.508	rs12621225	ENSG00000272156.1	RP11-477N3.1	-4.19	3.54e-05	0.00779	-0.27	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54082554~54085066:+
LIHC	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	4.19	3.54e-05	0.00779	0.26	0.22	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
LIHC	cis	rs9457247	0.602	rs12208359	ENSG00000227598.1	RP1-167A14.2	-4.19	3.54e-05	0.00779	-0.24	-0.22	Crohn's disease;	chr6:167044967	chr6:166969626~166999065:-
LIHC	cis	rs7937890	0.598	rs10734225	ENSG00000251991.1	RNU7-49P	4.19	3.54e-05	0.0078	0.25	0.22	Mitochondrial DNA levels;	chr11:14421448	chr11:14478892~14478953:+
LIHC	cis	rs2688482	0.557	rs2550236	ENSG00000207650.1	MIR570	4.19	3.54e-05	0.0078	0.28	0.22	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195699401~195699497:+
LIHC	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-4.19	3.54e-05	0.0078	-0.23	-0.22	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
LIHC	cis	rs9527	0.544	rs3781280	ENSG00000236937.2	PTGES3P4	4.19	3.54e-05	0.0078	0.28	0.22	Arsenic metabolism;	chr10:103104086	chr10:102845595~102845950:+
LIHC	cis	rs4650994	0.816	rs2811303	ENSG00000213057.5	C1orf220	-4.19	3.54e-05	0.00781	-0.18	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178626511	chr1:178542752~178548889:+
LIHC	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-4.19	3.55e-05	0.00782	-0.26	-0.22	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
LIHC	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	4.19	3.55e-05	0.00782	0.34	0.22	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
LIHC	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	4.19	3.55e-05	0.00782	0.31	0.22	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
LIHC	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	4.19	3.55e-05	0.00782	0.31	0.22	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
LIHC	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	4.19	3.55e-05	0.00782	0.31	0.22	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
LIHC	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	4.19	3.55e-05	0.00782	0.23	0.22	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
LIHC	cis	rs4578769	0.959	rs11082184	ENSG00000266850.1	RP11-370A5.1	4.19	3.55e-05	0.00782	0.26	0.22	Eosinophil percentage of white cells;	chr18:22872288	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.959	rs12964817	ENSG00000266850.1	RP11-370A5.1	4.19	3.55e-05	0.00782	0.26	0.22	Eosinophil percentage of white cells;	chr18:22876657	chr18:22723491~22907721:-
LIHC	cis	rs960902	0.592	rs7571760	ENSG00000213553.4	RPLP0P6	-4.19	3.55e-05	0.00782	-0.18	-0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37515615	chr2:38481851~38482804:+
LIHC	cis	rs755249	0.529	rs4660732	ENSG00000182109.6	RP11-69E11.4	4.19	3.55e-05	0.00782	0.29	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39522280~39546187:-
LIHC	cis	rs875971	0.545	rs6970498	ENSG00000228409.4	CCT6P1	-4.19	3.55e-05	0.00782	-0.19	-0.22	Aortic root size;	chr7:66275908	chr7:65751142~65763354:+
LIHC	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-4.19	3.55e-05	0.00782	-0.26	-0.22	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
LIHC	cis	rs8064024	0.649	rs9934930	ENSG00000267077.1	RP11-127I20.5	4.19	3.55e-05	0.00782	0.23	0.22	Cancer;	chr16:4852037	chr16:4795265~4796532:-
LIHC	cis	rs875971	0.502	rs11769702	ENSG00000228409.4	CCT6P1	-4.19	3.55e-05	0.00782	-0.19	-0.22	Aortic root size;	chr7:66255529	chr7:65751142~65763354:+
LIHC	cis	rs6832769	1	rs9312662	ENSG00000272969.1	RP11-528I4.2	-4.19	3.56e-05	0.00783	-0.26	-0.22	Personality dimensions;	chr4:55520204	chr4:55547112~55547889:+
LIHC	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	4.19	3.56e-05	0.00783	0.18	0.22	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
LIHC	cis	rs948562	0.947	rs2298607	ENSG00000280010.1	AP001350.4	4.19	3.56e-05	0.00783	0.38	0.22	Lymphoma;	chr11:58637026	chr11:58627435~58628528:+
LIHC	cis	rs7208859	0.673	rs999797	ENSG00000266490.1	CTD-2349P21.9	4.19	3.56e-05	0.00783	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30792372~30792833:+
LIHC	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	4.19	3.56e-05	0.00783	0.29	0.22	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
LIHC	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	4.19	3.56e-05	0.00783	0.29	0.22	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
LIHC	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	4.19	3.56e-05	0.00783	0.29	0.22	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
LIHC	cis	rs2348418	0.864	rs2137071	ENSG00000247934.4	RP11-967K21.1	4.19	3.56e-05	0.00783	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28163298~28190738:-
LIHC	cis	rs9595908	0.785	rs9591236	ENSG00000212293.1	SNORA16	4.19	3.56e-05	0.00784	0.25	0.22	Body mass index;	chr13:32671667	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs6561499	ENSG00000212293.1	SNORA16	4.19	3.56e-05	0.00784	0.25	0.22	Body mass index;	chr13:32681075	chr13:32420390~32420516:-
LIHC	cis	rs7216064	0.636	rs4638	ENSG00000278740.1	RP11-147L13.14	-4.19	3.56e-05	0.00784	-0.26	-0.22	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68188547~68189165:+
LIHC	cis	rs7216064	0.601	rs35453056	ENSG00000278740.1	RP11-147L13.14	-4.19	3.56e-05	0.00784	-0.26	-0.22	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68188547~68189165:+
LIHC	cis	rs7216064	0.628	rs62084702	ENSG00000278740.1	RP11-147L13.14	-4.19	3.56e-05	0.00784	-0.26	-0.22	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68188547~68189165:+
LIHC	cis	rs2877649	0.793	rs75612696	ENSG00000258744.1	RP11-80A15.1	-4.19	3.57e-05	0.00784	-0.45	-0.22	Smooth-surface caries;	chr14:24499862	chr14:24501594~24508688:+
LIHC	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	4.19	3.57e-05	0.00784	0.21	0.22	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
LIHC	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	4.19	3.57e-05	0.00785	0.35	0.22	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
LIHC	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	4.19	3.57e-05	0.00785	0.35	0.22	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
LIHC	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-4.19	3.57e-05	0.00785	-0.27	-0.22	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
LIHC	cis	rs1928295	0.786	rs7032255	ENSG00000233569.1	RP11-500B12.1	4.19	3.57e-05	0.00785	0.23	0.22	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117637809	chr9:117648606~117657027:+
LIHC	cis	rs686320	0.748	rs580933	ENSG00000245532.5	NEAT1	-4.19	3.57e-05	0.00786	-0.33	-0.22	Hip circumference adjusted for BMI;	chr11:65429413	chr11:65422774~65445540:+
LIHC	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	4.19	3.57e-05	0.00786	0.25	0.22	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
LIHC	cis	rs4578769	0.722	rs55943912	ENSG00000266850.1	RP11-370A5.1	-4.19	3.57e-05	0.00786	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22938388	chr18:22723491~22907721:-
LIHC	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-4.19	3.58e-05	0.00787	-0.27	-0.22	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
LIHC	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00787	0.24	0.22	Asthma;	chr2:102415109	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00787	0.24	0.22	Asthma;	chr2:102415289	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00787	0.24	0.22	Asthma;	chr2:102417501	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00787	0.24	0.22	Asthma;	chr2:102418383	chr2:102438713~102440475:+
LIHC	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-4.19	3.58e-05	0.00787	-0.28	-0.22	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
LIHC	cis	rs72627509	0.638	rs12642622	ENSG00000269949.1	RP11-738E22.3	4.19	3.58e-05	0.00787	0.32	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57036110	chr4:56960927~56961373:-
LIHC	cis	rs2735413	0.914	rs2262658	ENSG00000276007.1	RP11-358L22.3	-4.19	3.58e-05	0.00787	-0.25	-0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78026370	chr16:78123243~78124332:+
LIHC	cis	rs734999	0.545	rs9970196	ENSG00000225931.3	RP3-395M20.7	-4.19	3.58e-05	0.00787	-0.24	-0.22	Ulcerative colitis;	chr1:2642639	chr1:2566410~2569888:+
LIHC	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-4.19	3.58e-05	0.00787	-0.21	-0.22	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
LIHC	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	4.19	3.58e-05	0.00787	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
LIHC	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-4.19	3.58e-05	0.00787	-0.28	-0.22	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
LIHC	cis	rs603446	1	rs1145208	ENSG00000254851.1	RP11-109L13.1	-4.19	3.58e-05	0.00788	-0.28	-0.22	Triglycerides;	chr11:116767269	chr11:117135528~117138582:+
LIHC	cis	rs1005277	0.505	rs7099777	ENSG00000276805.1	RP11-291L22.6	-4.19	3.58e-05	0.00788	-0.27	-0.22	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38451030~38451785:+
LIHC	cis	rs2243480	1	rs67728539	ENSG00000228409.4	CCT6P1	4.19	3.58e-05	0.00788	0.24	0.22	Diabetic kidney disease;	chr7:65913137	chr7:65751142~65763354:+
LIHC	cis	rs8177253	0.665	rs12493887	ENSG00000244062.1	RP11-404G16.2	4.19	3.58e-05	0.00788	0.22	0.22	Iron status biomarkers;	chr3:133721893	chr3:133760300~133762363:+
LIHC	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma;	chr2:102419319	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma;	chr2:102419875	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma;	chr2:102423587	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	4.19	3.58e-05	0.00788	0.24	0.22	Asthma;	chr2:102423717	chr2:102438713~102440475:+
LIHC	cis	rs6061231	0.654	rs2427322	ENSG00000226332.2	RP11-157P1.4	4.19	3.59e-05	0.00788	0.24	0.22	Colorectal cancer;	chr20:62404314	chr20:62305432~62306325:-
LIHC	cis	rs7937890	0.531	rs2575828	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14462646	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575829	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14463475	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597201	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14463858	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597200	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14464054	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575830	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14464056	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575831	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14464648	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.532	rs2575832	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14467264	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597197	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00788	0.24	0.22	Mitochondrial DNA levels;	chr11:14468286	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.644	rs10009566	ENSG00000260091.1	RP11-33B1.4	-4.19	3.59e-05	0.00789	-0.16	-0.22	Corneal astigmatism;	chr4:119637453	chr4:119409333~119410233:+
LIHC	cis	rs1005277	0.505	rs1208689	ENSG00000276805.1	RP11-291L22.6	4.19	3.59e-05	0.00789	0.27	0.22	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.522	rs289648	ENSG00000099251.13	HSD17B7P2	4.19	3.59e-05	0.00789	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38356380~38378505:+
LIHC	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	4.19	3.59e-05	0.00789	0.25	0.22	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
LIHC	cis	rs5758659	0.716	rs2143138	ENSG00000227370.1	RP4-669P10.19	-4.19	3.59e-05	0.00789	-0.24	-0.22	Cognitive function;	chr22:42222334	chr22:42132543~42132998:+
LIHC	cis	rs4578769	0.765	rs1609463	ENSG00000266850.1	RP11-370A5.1	-4.19	3.59e-05	0.00789	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22824144	chr18:22723491~22907721:-
LIHC	cis	rs2060793	0.741	rs4757268	ENSG00000251991.1	RNU7-49P	4.19	3.59e-05	0.00789	0.25	0.22	Vitamin D levels;	chr11:14789216	chr11:14478892~14478953:+
LIHC	cis	rs11098499	0.955	rs35197422	ENSG00000260091.1	RP11-33B1.4	-4.19	3.59e-05	0.0079	-0.16	-0.22	Corneal astigmatism;	chr4:119248159	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.955	rs1511015	ENSG00000260091.1	RP11-33B1.4	-4.19	3.59e-05	0.0079	-0.16	-0.22	Corneal astigmatism;	chr4:119249318	chr4:119409333~119410233:+
LIHC	cis	rs2348418	0.864	rs1343859	ENSG00000247934.4	RP11-967K21.1	4.19	3.6e-05	0.0079	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28559537	chr12:28163298~28190738:-
LIHC	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-4.19	3.6e-05	0.0079	-0.31	-0.22	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
LIHC	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-4.19	3.6e-05	0.0079	-0.23	-0.22	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
LIHC	cis	rs9992667	0.955	rs922334	ENSG00000231160.8	KLF3-AS1	4.19	3.6e-05	0.0079	0.29	0.22	Eosinophil percentage of granulocytes;	chr4:38615137	chr4:38612701~38664883:-
LIHC	cis	rs8177253	0.574	rs6775042	ENSG00000244062.1	RP11-404G16.2	4.19	3.6e-05	0.0079	0.22	0.22	Iron status biomarkers;	chr3:133723401	chr3:133760300~133762363:+
LIHC	cis	rs2439831	0.85	rs61390361	ENSG00000166763.7	STRCP1	4.19	3.6e-05	0.00791	0.35	0.22	Lung cancer in ever smokers;	chr15:43867644	chr15:43699488~43718184:-
LIHC	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-4.19	3.6e-05	0.00791	-0.33	-0.22	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
LIHC	cis	rs1023500	0.505	rs134899	ENSG00000226450.2	CYP2D8P	4.19	3.6e-05	0.00791	0.25	0.22	Schizophrenia;	chr22:42287024	chr22:42149886~42155001:-
LIHC	cis	rs244293	0.795	rs11079150	ENSG00000275710.1	RP11-257O5.4	-4.19	3.6e-05	0.00791	-0.24	-0.22	Menarche (age at onset);	chr17:55017700	chr17:54964474~54964679:+
LIHC	cis	rs7131987	0.834	rs11050167	ENSG00000275476.1	RP11-996F15.4	-4.19	3.61e-05	0.00792	-0.27	-0.22	QT interval;	chr12:29273454	chr12:29277397~29277882:-
LIHC	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	4.19	3.61e-05	0.00792	0.29	0.22	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
LIHC	cis	rs417065	1	rs417065	ENSG00000227634.1	RP11-431K24.3	-4.19	3.61e-05	0.00792	-0.3	-0.22	Psoriasis;	chr1:8204052	chr1:8208672~8215210:+
LIHC	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-4.19	3.61e-05	0.00792	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
LIHC	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-4.19	3.61e-05	0.00792	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
LIHC	cis	rs9675120	0.963	rs7225019	ENSG00000262006.1	RP11-700H6.4	-4.19	3.61e-05	0.00792	-0.23	-0.22	Cerebrospinal fluid biomarker levels;	chr17:50838518	chr17:50909637~50910232:-
LIHC	cis	rs2929278	0.589	rs11638972	ENSG00000275601.1	AC011330.13	4.19	3.61e-05	0.00793	0.26	0.22	Schizophrenia;	chr15:43782493	chr15:43642389~43643023:-
LIHC	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-4.19	3.61e-05	0.00793	-0.27	-0.22	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
LIHC	cis	rs1823913	1	rs10445782	ENSG00000227542.1	AC092614.2	-4.19	3.61e-05	0.00793	-0.23	-0.22	Obesity-related traits;	chr2:191236639	chr2:191229165~191246172:-
LIHC	cis	rs1823913	1	rs4853561	ENSG00000227542.1	AC092614.2	-4.19	3.61e-05	0.00793	-0.23	-0.22	Obesity-related traits;	chr2:191242980	chr2:191229165~191246172:-
LIHC	cis	rs4879656	0.593	rs13297493	ENSG00000225693.1	LAGE3P1	4.19	3.61e-05	0.00793	0.28	0.22	Menopause (age at onset);	chr9:33049603	chr9:33019682~33020165:-
LIHC	cis	rs1823913	1	rs6704784	ENSG00000227542.1	AC092614.2	-4.19	3.61e-05	0.00793	-0.23	-0.22	Obesity-related traits;	chr2:191244832	chr2:191229165~191246172:-
LIHC	cis	rs2243480	1	rs1618893	ENSG00000232546.1	RP11-458F8.1	-4.19	3.61e-05	0.00793	-0.23	-0.22	Diabetic kidney disease;	chr7:66631132	chr7:66848496~66858136:+
LIHC	cis	rs6997458	0.935	rs7824715	ENSG00000253549.4	RP11-317J10.2	4.19	3.62e-05	0.00793	0.24	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85366148	chr8:85441851~85464915:-
LIHC	cis	rs10829156	0.607	rs7908550	ENSG00000240291.1	RP11-499P20.2	4.19	3.62e-05	0.00794	0.36	0.22	Sudden cardiac arrest;	chr10:18573282	chr10:18513115~18545651:-
LIHC	cis	rs921968	0.565	rs6733892	ENSG00000272555.1	RP11-459I19.1	-4.19	3.62e-05	0.00794	-0.23	-0.22	Mean corpuscular hemoglobin concentration;	chr2:218751279	chr2:218818690~218819144:+
LIHC	cis	rs3204270	0.759	rs8065104	ENSG00000281517.1	Metazoa_SRP	-4.19	3.62e-05	0.00794	-0.41	-0.22	Dental caries;	chr17:81705575	chr17:81718849~81719095:-
LIHC	cis	rs2243480	1	rs427044	ENSG00000228409.4	CCT6P1	4.19	3.62e-05	0.00794	0.23	0.22	Diabetic kidney disease;	chr7:66043558	chr7:65751142~65763354:+
LIHC	cis	rs17772222	0.837	rs57118463	ENSG00000258789.1	RP11-507K2.3	-4.19	3.62e-05	0.00794	-0.26	-0.22	Coronary artery calcification;	chr14:88665822	chr14:88551597~88552493:+
LIHC	cis	rs7800244	0.848	rs62447755	ENSG00000146666.5	LINC00525	-4.19	3.62e-05	0.00794	-0.35	-0.22	Hepatitis C induced liver fibrosis;	chr7:47750564	chr7:47761476~47766772:+
LIHC	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-4.19	3.62e-05	0.00794	-0.38	-0.22	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
LIHC	cis	rs6430585	0.528	rs660002	ENSG00000231890.6	DARS-AS1	-4.19	3.62e-05	0.00794	-0.3	-0.22	Corneal structure;	chr2:135965934	chr2:135985176~136022593:+
LIHC	cis	rs6496667	0.509	rs2253419	ENSG00000213471.7	TTLL13P	4.19	3.62e-05	0.00794	0.29	0.22	Rheumatoid arthritis;	chr15:90402643	chr15:90249530~90265482:+
LIHC	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	4.19	3.62e-05	0.00795	0.18	0.22	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
LIHC	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	4.19	3.62e-05	0.00795	0.22	0.22	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
LIHC	cis	rs1223397	0.651	rs449727	ENSG00000215022.6	RP1-257A7.4	-4.19	3.62e-05	0.00795	-0.23	-0.22	Blood pressure;	chr6:13296078	chr6:13264861~13295586:-
LIHC	cis	rs6801605	0.743	rs4687751	ENSG00000271916.1	RP11-884K10.6	-4.19	3.63e-05	0.00795	-0.29	-0.22	Blood protein levels;	chr3:53849883	chr3:53797764~53798019:-
LIHC	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	4.19	3.63e-05	0.00796	0.21	0.22	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
LIHC	cis	rs9907295	0.71	rs9894083	ENSG00000270871.1	AC015849.19	4.19	3.63e-05	0.00796	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35842151	chr17:35816717~35830293:-
LIHC	cis	rs17772222	0.636	rs77528165	ENSG00000258789.1	RP11-507K2.3	-4.18	3.63e-05	0.00796	-0.27	-0.22	Coronary artery calcification;	chr14:88794249	chr14:88551597~88552493:+
LIHC	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	4.18	3.63e-05	0.00796	0.25	0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
LIHC	cis	rs11098499	0.739	rs10031033	ENSG00000260091.1	RP11-33B1.4	-4.18	3.64e-05	0.00797	-0.15	-0.22	Corneal astigmatism;	chr4:119230297	chr4:119409333~119410233:+
LIHC	cis	rs8059260	0.935	rs9928255	ENSG00000274038.1	RP11-66H6.4	-4.18	3.64e-05	0.00797	-0.29	-0.22	Alcohol consumption over the past year;	chr16:11027408	chr16:11056556~11057034:+
LIHC	cis	rs728616	0.867	rs56123058	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.64e-05	0.00798	-0.5	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:79663088~79826594:-
LIHC	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	4.18	3.64e-05	0.00798	0.29	0.22	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
LIHC	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	4.18	3.64e-05	0.00798	0.42	0.22	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
LIHC	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	4.18	3.64e-05	0.00798	0.42	0.22	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	4.18	3.64e-05	0.00798	0.42	0.22	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	4.18	3.64e-05	0.00798	0.42	0.22	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
LIHC	cis	rs2243480	1	rs316329	ENSG00000230295.1	RP11-458F8.2	-4.18	3.64e-05	0.00798	-0.23	-0.22	Diabetic kidney disease;	chr7:66143429	chr7:66880708~66882981:+
LIHC	cis	rs603446	0.55	rs1787698	ENSG00000254851.1	RP11-109L13.1	4.18	3.64e-05	0.00799	0.29	0.22	Triglycerides;	chr11:116693846	chr11:117135528~117138582:+
LIHC	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	4.18	3.64e-05	0.00799	0.29	0.22	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
LIHC	cis	rs912057	1	rs912057	ENSG00000261211.1	RP1-80N2.3	-4.18	3.64e-05	0.00799	-0.22	-0.22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;	chr6:6736698	chr6:6680309~6683633:-
LIHC	cis	rs6565180	0.888	rs13333093	ENSG00000183604.13	SMG1P5	4.18	3.65e-05	0.00799	0.23	0.22	Tonsillectomy;	chr16:30395948	chr16:30267553~30335374:-
LIHC	cis	rs2243480	0.901	rs57126451	ENSG00000228409.4	CCT6P1	4.18	3.65e-05	0.00799	0.24	0.22	Diabetic kidney disease;	chr7:65951319	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs801199	ENSG00000228409.4	CCT6P1	4.18	3.65e-05	0.00799	0.18	0.22	Aortic root size;	chr7:66560286	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs1638724	ENSG00000228409.4	CCT6P1	4.18	3.65e-05	0.00799	0.18	0.22	Aortic root size;	chr7:66575494	chr7:65751142~65763354:+
LIHC	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	4.18	3.65e-05	0.008	0.25	0.22	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
LIHC	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	4.18	3.65e-05	0.008	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
LIHC	cis	rs7809950	0.862	rs58391518	ENSG00000238832.1	snoU109	-4.18	3.65e-05	0.008	-0.27	-0.22	Coronary artery disease;	chr7:107390342	chr7:107603363~107603507:+
LIHC	cis	rs6439153	0.933	rs2630262	ENSG00000231305.3	RP11-723O4.2	-4.18	3.65e-05	0.008	-0.24	-0.22	Pneumococcal bacteremia;	chr3:128958255	chr3:128861313~128871540:-
LIHC	cis	rs12468226	0.689	rs17656903	ENSG00000272966.1	RP11-686O6.1	-4.18	3.65e-05	0.008	-0.39	-0.22	Urate levels;	chr2:202106312	chr2:202336739~202337200:+
LIHC	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-4.18	3.65e-05	0.008	-0.45	-0.22	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-4.18	3.65e-05	0.008	-0.45	-0.22	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
LIHC	cis	rs4144027	0.904	rs10438244	ENSG00000258534.1	CTD-2134A5.4	4.18	3.65e-05	0.008	0.25	0.22	Blood metabolite levels;	chr14:103879848	chr14:103854366~103880111:-
LIHC	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-4.18	3.65e-05	0.008	-0.28	-0.22	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
LIHC	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	4.18	3.65e-05	0.00801	0.26	0.22	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
LIHC	cis	rs11671005	0.611	rs36090113	ENSG00000269473.1	CTD-2619J13.19	4.18	3.65e-05	0.00801	0.39	0.22	Mean platelet volume;	chr19:58401017	chr19:58440448~58445849:+
LIHC	cis	rs728616	0.867	rs7906286	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.66e-05	0.00801	-0.46	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80074279	chr10:79663088~79826594:-
LIHC	cis	rs4578769	0.765	rs9949825	ENSG00000266850.1	RP11-370A5.1	-4.18	3.66e-05	0.00801	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22806055	chr18:22723491~22907721:-
LIHC	cis	rs202072	1	rs202077	ENSG00000215022.6	RP1-257A7.4	-4.18	3.66e-05	0.00802	-0.25	-0.22	HIV-1 viral setpoint;	chr6:13271206	chr6:13264861~13295586:-
LIHC	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-4.18	3.66e-05	0.00802	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
LIHC	cis	rs244293	0.864	rs244374	ENSG00000275710.1	RP11-257O5.4	-4.18	3.66e-05	0.00802	-0.24	-0.22	Menarche (age at onset);	chr17:55106393	chr17:54964474~54964679:+
LIHC	cis	rs1005277	0.522	rs9417256	ENSG00000099251.13	HSD17B7P2	4.18	3.66e-05	0.00802	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38356380~38378505:+
LIHC	cis	rs2462686	1	rs2462686	ENSG00000272556.1	RP11-638I8.1	4.18	3.66e-05	0.00803	0.32	0.22	Major depressive disorder;	chr7:45942861	chr7:45814602~45815263:+
LIHC	cis	rs1115240	0.947	rs11623268	ENSG00000257842.4	NOVA1-AS1	-4.18	3.67e-05	0.00803	-0.21	-0.22	Educational attainment (years of education);	chr14:26636263	chr14:26598412~26806467:+
LIHC	cis	rs1115240	0.947	rs11627577	ENSG00000257842.4	NOVA1-AS1	-4.18	3.67e-05	0.00803	-0.21	-0.22	Educational attainment (years of education);	chr14:26636355	chr14:26598412~26806467:+
LIHC	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	4.18	3.67e-05	0.00803	0.35	0.22	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
LIHC	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	4.18	3.67e-05	0.00803	0.23	0.22	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
LIHC	cis	rs2744375	0.544	rs2744365	ENSG00000261189.1	RP3-512B11.3	4.18	3.67e-05	0.00804	0.28	0.22	Resting heart rate;	chr6:7551787	chr6:7540451~7541338:-
LIHC	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	4.18	3.67e-05	0.00804	0.36	0.22	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
LIHC	cis	rs8064029	0.655	rs77468976	ENSG00000267077.1	RP11-127I20.5	4.18	3.67e-05	0.00804	0.29	0.22	Cancer;	chr16:4819249	chr16:4795265~4796532:-
LIHC	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	4.18	3.67e-05	0.00804	0.31	0.22	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
LIHC	cis	rs2598107	0.568	rs4723717	ENSG00000211698.2	TRGV4	-4.18	3.68e-05	0.00805	-0.26	-0.22	Dupuytren's disease;	chr7:37929206	chr7:38353715~38354517:-
LIHC	cis	rs1876905	0.539	rs240962	ENSG00000272356.1	RP5-1112D6.8	4.18	3.68e-05	0.00805	0.21	0.22	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111309203~111313517:+
LIHC	cis	rs9876781	1	rs2885510	ENSG00000229759.1	MRPS18AP1	-4.18	3.68e-05	0.00805	-0.23	-0.22	Longevity;	chr3:48376736	chr3:48256350~48256938:-
LIHC	cis	rs7893279	0.505	rs12766105	ENSG00000225527.1	RP11-383B4.4	4.18	3.68e-05	0.00805	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18584296	chr10:18531849~18533336:-
LIHC	cis	rs79349575	0.716	rs46522	ENSG00000248278.1	SUMO2P17	4.18	3.68e-05	0.00805	0.28	0.22	Type 2 diabetes;	chr17:48911235	chr17:48874860~48908983:-
LIHC	cis	rs9565309	0.579	rs9634731	ENSG00000274898.1	AC001226.7	4.18	3.68e-05	0.00806	0.38	0.22	Morning vs. evening chronotype;	chr13:77022696	chr13:77027944~77028482:+
LIHC	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	4.18	3.68e-05	0.00806	0.33	0.22	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
LIHC	cis	rs728616	0.867	rs1537835	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.68e-05	0.00806	-0.46	-0.22	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80070396	chr10:79663088~79826594:-
LIHC	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	4.18	3.68e-05	0.00806	0.2	0.22	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
LIHC	cis	rs2880765	0.566	rs17553249	ENSG00000259630.2	CTD-2262B20.1	-4.18	3.68e-05	0.00806	-0.32	-0.22	Coronary artery disease;	chr15:85463463	chr15:85415228~85415633:+
LIHC	cis	rs10833905	1	rs11026880	ENSG00000246225.5	RP11-17A1.3	-4.18	3.68e-05	0.00806	-0.29	-0.22	Sudden cardiac arrest;	chr11:22994273	chr11:22829380~22945393:+
LIHC	cis	rs7412746	0.658	rs12068264	ENSG00000231073.1	RP11-316M1.3	4.18	3.68e-05	0.00806	0.23	0.22	Melanoma;	chr1:150754853	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs2230061	ENSG00000231073.1	RP11-316M1.3	4.18	3.68e-05	0.00806	0.23	0.22	Melanoma;	chr1:150755063	chr1:150973123~150975534:+
LIHC	cis	rs2744375	0.6	rs2237104	ENSG00000261189.1	RP3-512B11.3	-4.18	3.69e-05	0.00807	-0.27	-0.22	Resting heart rate;	chr6:7551939	chr6:7540451~7541338:-
LIHC	cis	rs9527	0.83	rs10883790	ENSG00000236937.2	PTGES3P4	4.18	3.69e-05	0.00807	0.29	0.22	Arsenic metabolism;	chr10:102881198	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.83	rs11191440	ENSG00000236937.2	PTGES3P4	4.18	3.69e-05	0.00807	0.29	0.22	Arsenic metabolism;	chr10:102881754	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.83	rs11191442	ENSG00000236937.2	PTGES3P4	4.18	3.69e-05	0.00807	0.29	0.22	Arsenic metabolism;	chr10:102883839	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.83	rs12249194	ENSG00000236937.2	PTGES3P4	4.18	3.69e-05	0.00807	0.29	0.22	Arsenic metabolism;	chr10:102883941	chr10:102845595~102845950:+
LIHC	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	4.18	3.69e-05	0.00807	0.21	0.22	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
LIHC	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	4.18	3.69e-05	0.00807	0.21	0.22	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
LIHC	cis	rs6723108	0.517	rs1530555	ENSG00000224043.6	CCNT2-AS1	-4.18	3.69e-05	0.00807	-0.31	-0.22	Type 2 diabetes;	chr2:134842169	chr2:134735464~134918710:-
LIHC	cis	rs875971	0.571	rs160641	ENSG00000228409.4	CCT6P1	4.18	3.69e-05	0.00807	0.19	0.22	Aortic root size;	chr7:66112359	chr7:65751142~65763354:+
LIHC	cis	rs2390582	0.564	rs74472546	ENSG00000231613.1	RP5-943J3.1	4.18	3.69e-05	0.00808	0.45	0.22	Coronary artery calcification;	chr1:90304318	chr1:89788914~89790492:+
LIHC	cis	rs2390582	0.607	rs4658152	ENSG00000231613.1	RP5-943J3.1	4.18	3.69e-05	0.00808	0.45	0.22	Coronary artery calcification;	chr1:90305596	chr1:89788914~89790492:+
LIHC	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-4.18	3.69e-05	0.00808	-0.22	-0.22	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
LIHC	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-4.18	3.69e-05	0.00808	-0.22	-0.22	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
LIHC	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-4.18	3.69e-05	0.00808	-0.27	-0.22	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
LIHC	cis	rs151234	0.676	rs151320	ENSG00000259982.1	CDC37P1	4.18	3.69e-05	0.00808	0.5	0.22	Platelet distribution width;	chr16:28557357	chr16:28700294~28701540:-
LIHC	cis	rs7044106	0.762	rs1411158	ENSG00000238181.2	AHCYP2	-4.18	3.69e-05	0.00808	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120720673~120721972:+
LIHC	cis	rs8064024	0.619	rs9935080	ENSG00000267077.1	RP11-127I20.5	4.18	3.69e-05	0.00808	0.23	0.22	Cancer;	chr16:4852206	chr16:4795265~4796532:-
LIHC	cis	rs12157904	1	rs35103516	ENSG00000233360.4	Z83844.1	4.18	3.69e-05	0.00808	0.47	0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37605741	chr22:37641832~37658377:-
LIHC	cis	rs12157904	1	rs71317058	ENSG00000233360.4	Z83844.1	4.18	3.69e-05	0.00808	0.47	0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37605821	chr22:37641832~37658377:-
LIHC	cis	rs7474896	0.507	rs2474555	ENSG00000120555.12	SEPT7P9	4.18	3.69e-05	0.00808	0.32	0.22	Obesity (extreme);	chr10:38176292	chr10:38383069~38402916:-
LIHC	cis	rs2243480	1	rs3885839	ENSG00000228409.4	CCT6P1	4.18	3.69e-05	0.00808	0.24	0.22	Diabetic kidney disease;	chr7:65825416	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs3813708	ENSG00000228409.4	CCT6P1	4.18	3.69e-05	0.00808	0.24	0.22	Diabetic kidney disease;	chr7:65840645	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs73142122	ENSG00000228409.4	CCT6P1	4.18	3.69e-05	0.00808	0.24	0.22	Diabetic kidney disease;	chr7:65846311	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs73142137	ENSG00000228409.4	CCT6P1	4.18	3.69e-05	0.00808	0.24	0.22	Diabetic kidney disease;	chr7:65878455	chr7:65751142~65763354:+
LIHC	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-4.18	3.7e-05	0.00808	-0.17	-0.22	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
LIHC	cis	rs481331	0.866	rs34920187	ENSG00000185904.10	LINC00839	4.18	3.7e-05	0.00809	0.41	0.22	Systemic juvenile idiopathic arthritis;	chr10:42497070	chr10:42475543~42495336:+
LIHC	cis	rs7131987	0.675	rs3847678	ENSG00000257176.2	RP11-996F15.2	4.18	3.7e-05	0.00809	0.25	0.22	QT interval;	chr12:29398627	chr12:29280418~29317848:-
LIHC	cis	rs10129255	0.957	rs4387509	ENSG00000224373.3	IGHV4-59	4.18	3.7e-05	0.00809	0.18	0.22	Kawasaki disease;	chr14:106704386	chr14:106627249~106627825:-
LIHC	cis	rs1005277	0.505	rs7917943	ENSG00000099251.13	HSD17B7P2	-4.18	3.7e-05	0.0081	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38356380~38378505:+
LIHC	cis	rs2439831	1	rs2439831	ENSG00000166763.7	STRCP1	4.18	3.7e-05	0.0081	0.31	0.22	Lung cancer in ever smokers;	chr15:43492277	chr15:43699488~43718184:-
LIHC	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	4.18	3.7e-05	0.0081	0.2	0.22	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	4.18	3.7e-05	0.0081	0.2	0.22	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	4.18	3.7e-05	0.0081	0.2	0.22	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
LIHC	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	4.18	3.7e-05	0.0081	0.2	0.22	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
LIHC	cis	rs7208859	0.673	rs11656462	ENSG00000266490.1	CTD-2349P21.9	4.18	3.7e-05	0.0081	0.28	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30792372~30792833:+
LIHC	cis	rs2524005	1	rs2524005	ENSG00000229390.1	MICD	-4.18	3.7e-05	0.0081	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29970801~29972464:-
LIHC	cis	rs853679	0.545	rs35949109	ENSG00000204709.4	LINC01556	4.18	3.71e-05	0.0081	0.38	0.22	Depression;	chr6:28058148	chr6:28943877~28944537:+
LIHC	cis	rs718433	0.717	rs12893255	ENSG00000258441.1	LINC00641	-4.18	3.71e-05	0.0081	-0.2	-0.22	Intraocular pressure;	chr14:21773162	chr14:21200079~21206900:-
LIHC	cis	rs11098499	0.954	rs6820115	ENSG00000260091.1	RP11-33B1.4	-4.18	3.71e-05	0.00811	-0.15	-0.22	Corneal astigmatism;	chr4:119477027	chr4:119409333~119410233:+
LIHC	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-4.18	3.71e-05	0.00811	-0.27	-0.22	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
LIHC	cis	rs17774123	0.851	rs17775712	ENSG00000257808.1	RP11-1136G11.8	4.18	3.71e-05	0.00812	0.41	0.22	Diastolic blood pressure;	chr12:53892581	chr12:53159586~53161000:+
LIHC	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-4.18	3.72e-05	0.00812	-0.25	-0.22	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
LIHC	cis	rs113835537	0.866	rs59566349	ENSG00000255517.5	CTD-3074O7.5	-4.18	3.72e-05	0.00812	-0.39	-0.22	Airway imaging phenotypes;	chr11:66598523	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.935	rs1127145	ENSG00000255517.5	CTD-3074O7.5	-4.18	3.72e-05	0.00812	-0.39	-0.22	Airway imaging phenotypes;	chr11:66605834	chr11:66473490~66480233:-
LIHC	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-4.18	3.72e-05	0.00813	-0.25	-0.22	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
LIHC	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	4.18	3.72e-05	0.00813	0.24	0.22	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
LIHC	cis	rs1005277	0.579	rs2472183	ENSG00000276805.1	RP11-291L22.6	4.18	3.73e-05	0.00814	0.27	0.22	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38451030~38451785:+
LIHC	cis	rs7989332	0.925	rs9506494	ENSG00000275964.1	RP11-61K9.3	-4.18	3.73e-05	0.00814	-0.25	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20473719	chr13:19863858~19865048:+
LIHC	cis	rs4578769	0.879	rs12963622	ENSG00000265943.1	RP11-739L10.1	4.18	3.73e-05	0.00814	0.28	0.22	Eosinophil percentage of white cells;	chr18:22859594	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.879	rs7241050	ENSG00000265943.1	RP11-739L10.1	4.18	3.73e-05	0.00814	0.28	0.22	Eosinophil percentage of white cells;	chr18:22860300	chr18:22699481~22933764:-
LIHC	cis	rs2929278	0.617	rs693919	ENSG00000275601.1	AC011330.13	4.18	3.73e-05	0.00814	0.27	0.22	Schizophrenia;	chr15:43810130	chr15:43642389~43643023:-
LIHC	cis	rs3772760	1	rs3755672	ENSG00000240622.1	RPL7P15	-4.18	3.73e-05	0.00814	-0.41	-0.22	Amyotrophic lateral sclerosis;	chr3:124447661	chr3:124151960~124153063:-
LIHC	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-4.18	3.73e-05	0.00815	-0.19	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
LIHC	cis	rs62246343	0.605	rs7650141	ENSG00000206573.7	THUMPD3-AS1	-4.18	3.73e-05	0.00815	-0.25	-0.22	Fibrinogen levels;	chr3:9407726	chr3:9349689~9398579:-
LIHC	cis	rs17376456	0.825	rs13156202	ENSG00000251023.1	RP11-549J18.1	4.18	3.73e-05	0.00815	0.45	0.22	Diabetic retinopathy;	chr5:93822015	chr5:93860669~93863825:-
LIHC	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	4.18	3.73e-05	0.00815	0.36	0.22	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
LIHC	cis	rs1577917	0.959	rs34258068	ENSG00000234155.1	RP11-30P6.6	4.18	3.73e-05	0.00815	0.29	0.22	Response to antipsychotic treatment;	chr6:85969731	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs884841	ENSG00000234155.1	RP11-30P6.6	4.18	3.73e-05	0.00815	0.29	0.22	Response to antipsychotic treatment;	chr6:85970582	chr6:85387219~85390186:-
LIHC	cis	rs1577917	0.958	rs884842	ENSG00000234155.1	RP11-30P6.6	4.18	3.73e-05	0.00815	0.29	0.22	Response to antipsychotic treatment;	chr6:85970679	chr6:85387219~85390186:-
LIHC	cis	rs901683	1	rs12773263	ENSG00000230869.1	CTGLF10P	-4.18	3.73e-05	0.00816	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45488898	chr10:45678692~45700532:+
LIHC	cis	rs1577917	0.958	rs11758508	ENSG00000234155.1	RP11-30P6.6	-4.18	3.74e-05	0.00816	-0.28	-0.22	Response to antipsychotic treatment;	chr6:85797160	chr6:85387219~85390186:-
LIHC	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	4.18	3.74e-05	0.00817	0.22	0.22	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
LIHC	cis	rs7044106	0.791	rs10984995	ENSG00000238181.2	AHCYP2	-4.18	3.74e-05	0.00817	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120720673~120721972:+
LIHC	cis	rs2834188	0.889	rs2040108	ENSG00000272659.1	AP000295.10	-4.18	3.74e-05	0.00817	-0.32	-0.22	Narcolepsy;	chr21:33303853	chr21:33309491~33310181:+
LIHC	cis	rs4356203	0.818	rs214927	ENSG00000260196.1	RP1-239B22.5	-4.18	3.74e-05	0.00817	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17209698	chr11:17380649~17383531:+
LIHC	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-4.18	3.74e-05	0.00817	-0.26	-0.22	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
LIHC	cis	rs4356975	0.83	rs6422322	ENSG00000250919.1	RP11-813N20.3	-4.18	3.74e-05	0.00818	-0.22	-0.22	Obesity-related traits;	chr4:69055571	chr4:69027831~69044578:+
LIHC	cis	rs2070488	0.965	rs6805386	ENSG00000229589.1	ACVR2B-AS1	-4.18	3.75e-05	0.00818	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38516430	chr3:38451027~38454820:-
LIHC	cis	rs2070488	0.965	rs6599209	ENSG00000229589.1	ACVR2B-AS1	-4.18	3.75e-05	0.00818	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38516706	chr3:38451027~38454820:-
LIHC	cis	rs4578769	0.765	rs1609464	ENSG00000266850.1	RP11-370A5.1	-4.18	3.75e-05	0.00818	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22844191	chr18:22723491~22907721:-
LIHC	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-4.18	3.75e-05	0.00818	-0.25	-0.22	Height;	chr2:46609300	chr2:46668870~46670778:+
LIHC	cis	rs417065	1	rs72635711	ENSG00000227634.1	RP11-431K24.3	-4.18	3.75e-05	0.00818	-0.3	-0.22	Psoriasis;	chr1:8199243	chr1:8208672~8215210:+
LIHC	cis	rs1065852	0.906	rs9611734	ENSG00000205702.9	CYP2D7	4.18	3.75e-05	0.00818	0.26	0.22	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42106066	chr22:42140203~42144577:-
LIHC	cis	rs7474896	0.583	rs34185758	ENSG00000263064.2	RP11-291L22.7	4.18	3.75e-05	0.00818	0.27	0.22	Obesity (extreme);	chr10:37701926	chr10:38448689~38448949:+
LIHC	cis	rs17270561	0.562	rs74293932	ENSG00000272810.1	U91328.22	-4.18	3.75e-05	0.00819	-0.29	-0.22	Iron status biomarkers;	chr6:26014583	chr6:26013241~26013757:+
LIHC	cis	rs6445975	0.666	rs4681680	ENSG00000272360.1	RP11-359I18.5	-4.18	3.75e-05	0.00819	-0.3	-0.22	Systemic lupus erythematosus;	chr3:58346490	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.666	rs9817356	ENSG00000272360.1	RP11-359I18.5	-4.18	3.75e-05	0.00819	-0.3	-0.22	Systemic lupus erythematosus;	chr3:58349846	chr3:58490830~58491291:-
LIHC	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-4.18	3.76e-05	0.00819	-0.21	-0.22	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
LIHC	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-4.18	3.76e-05	0.00819	-0.21	-0.22	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
LIHC	cis	rs2032447	0.869	rs199752	ENSG00000242387.1	HIST1H2APS2	4.18	3.76e-05	0.0082	0.28	0.22	Intelligence (multi-trait analysis);	chr6:26012647	chr6:25882026~25882395:-
LIHC	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	4.18	3.76e-05	0.0082	0.32	0.22	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
LIHC	cis	rs17774123	0.901	rs2366134	ENSG00000257808.1	RP11-1136G11.8	4.18	3.76e-05	0.0082	0.41	0.22	Diastolic blood pressure;	chr12:53875183	chr12:53159586~53161000:+
LIHC	cis	rs7923609	0.875	rs10740118	ENSG00000232075.1	MRPL35P2	4.18	3.76e-05	0.0082	0.25	0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63341447	chr10:63634317~63634827:-
LIHC	cis	rs7893279	0.505	rs4748497	ENSG00000225527.1	RP11-383B4.4	4.18	3.76e-05	0.0082	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18618105	chr10:18531849~18533336:-
LIHC	cis	rs2439831	0.681	rs825739	ENSG00000166763.7	STRCP1	4.18	3.76e-05	0.0082	0.3	0.22	Lung cancer in ever smokers;	chr15:43300230	chr15:43699488~43718184:-
LIHC	cis	rs2348418	0.864	rs7978086	ENSG00000247934.4	RP11-967K21.1	4.18	3.76e-05	0.0082	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28163298~28190738:-
LIHC	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-4.18	3.76e-05	0.0082	-0.28	-0.22	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
LIHC	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-4.18	3.76e-05	0.00821	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
LIHC	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	4.18	3.76e-05	0.00821	0.25	0.22	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
LIHC	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-4.18	3.76e-05	0.00821	-0.25	-0.22	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
LIHC	cis	rs295490	0.831	rs3772871	ENSG00000272656.1	RP11-219D15.3	-4.18	3.77e-05	0.00821	-0.6	-0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522774	chr3:139349024~139349371:-
LIHC	cis	rs804280	0.662	rs11784693	ENSG00000255394.4	C8orf49	-4.18	3.77e-05	0.00821	-0.31	-0.22	Myopia (pathological);	chr8:11753165	chr8:11761256~11763223:+
LIHC	cis	rs2072510	0.593	rs2540498	ENSG00000257878.1	RP11-256L6.3	-4.18	3.77e-05	0.00822	-0.28	-0.22	Metabolite levels (small molecules and protein measures);	chr12:96006791	chr12:95996521~96011489:+
LIHC	cis	rs1874124	0.577	rs2807880	ENSG00000238078.1	LINC01352	4.18	3.77e-05	0.00822	0.4	0.22	Cholesterol, total;	chr1:220869661	chr1:220829255~220832429:+
LIHC	cis	rs17772222	0.917	rs61986670	ENSG00000258789.1	RP11-507K2.3	-4.18	3.77e-05	0.00822	-0.26	-0.22	Coronary artery calcification;	chr14:88730875	chr14:88551597~88552493:+
LIHC	cis	rs17818399	0.815	rs17819022	ENSG00000279254.1	RP11-536C12.1	-4.18	3.77e-05	0.00822	-0.28	-0.22	Height;	chr2:46623432	chr2:46668870~46670778:+
LIHC	cis	rs860295	0.871	rs34632540	ENSG00000203761.5	MSTO2P	4.18	3.77e-05	0.00822	0.18	0.22	Body mass index;	chr1:155642406	chr1:155745829~155750137:+
LIHC	cis	rs2749592	0.531	rs10764134	ENSG00000276805.1	RP11-291L22.6	-4.18	3.77e-05	0.00823	-0.26	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38451030~38451785:+
LIHC	cis	rs2243480	1	rs160633	ENSG00000230295.1	RP11-458F8.2	-4.18	3.78e-05	0.00823	-0.23	-0.22	Diabetic kidney disease;	chr7:66063241	chr7:66880708~66882981:+
LIHC	cis	rs11098499	0.863	rs1480940	ENSG00000260091.1	RP11-33B1.4	-4.18	3.78e-05	0.00824	-0.16	-0.22	Corneal astigmatism;	chr4:119536527	chr4:119409333~119410233:+
LIHC	cis	rs875971	0.545	rs12670811	ENSG00000273142.1	RP11-458F8.4	4.18	3.78e-05	0.00824	0.21	0.22	Aortic root size;	chr7:66358032	chr7:66902857~66906297:+
LIHC	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-4.18	3.78e-05	0.00824	-0.27	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
LIHC	cis	rs7208859	0.673	rs11652370	ENSG00000266490.1	CTD-2349P21.9	4.18	3.78e-05	0.00825	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30792372~30792833:+
LIHC	cis	rs2439831	1	rs2253708	ENSG00000166763.7	STRCP1	4.17	3.79e-05	0.00825	0.31	0.22	Lung cancer in ever smokers;	chr15:43505075	chr15:43699488~43718184:-
LIHC	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	4.17	3.79e-05	0.00825	0.2	0.22	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
LIHC	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	4.17	3.79e-05	0.00825	0.2	0.22	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
LIHC	cis	rs2598107	0.601	rs6968647	ENSG00000211698.2	TRGV4	-4.17	3.79e-05	0.00825	-0.26	-0.22	Dupuytren's disease;	chr7:37923320	chr7:38353715~38354517:-
LIHC	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	4.17	3.79e-05	0.00825	0.26	0.22	Height;	chr4:55564241	chr4:55363971~55395847:-
LIHC	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	4.17	3.79e-05	0.00826	0.16	0.22	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
LIHC	cis	rs17772222	0.917	rs12434935	ENSG00000258789.1	RP11-507K2.3	-4.17	3.79e-05	0.00826	-0.26	-0.22	Coronary artery calcification;	chr14:88645449	chr14:88551597~88552493:+
LIHC	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	4.17	3.79e-05	0.00826	0.35	0.22	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
LIHC	cis	rs4356203	0.87	rs10832751	ENSG00000260196.1	RP1-239B22.5	-4.17	3.8e-05	0.00827	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17380649~17383531:+
LIHC	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	4.17	3.8e-05	0.00827	0.25	0.22	Height;	chr6:109355573	chr6:109382795~109383666:+
LIHC	cis	rs2243480	1	rs313813	ENSG00000232546.1	RP11-458F8.1	-4.17	3.8e-05	0.00827	-0.24	-0.22	Diabetic kidney disease;	chr7:66038513	chr7:66848496~66858136:+
LIHC	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.8e-05	0.00827	-0.21	-0.22	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.8e-05	0.00827	-0.21	-0.22	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.8e-05	0.00827	-0.21	-0.22	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.8e-05	0.00827	-0.21	-0.22	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.8e-05	0.00827	-0.21	-0.22	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.8e-05	0.00827	-0.21	-0.22	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.8e-05	0.00827	-0.21	-0.22	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
LIHC	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	4.17	3.8e-05	0.00828	0.3	0.22	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
LIHC	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	4.17	3.8e-05	0.00828	0.3	0.22	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
LIHC	cis	rs12681287	0.64	rs10086340	ENSG00000254088.1	SLC2A3P4	4.17	3.8e-05	0.00828	0.25	0.22	Caudate activity during reward;	chr8:86434560	chr8:86503591~86505061:+
LIHC	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-4.17	3.8e-05	0.00828	-0.24	-0.22	Breast cancer;	chr11:825777	chr11:777578~784297:+
LIHC	cis	rs2243480	1	rs73142166	ENSG00000228409.4	CCT6P1	4.17	3.8e-05	0.00829	0.24	0.22	Diabetic kidney disease;	chr7:65910845	chr7:65751142~65763354:+
LIHC	cis	rs72634501	0.542	rs2134472	ENSG00000182109.6	RP11-69E11.4	-4.17	3.81e-05	0.00829	-0.23	-0.22	HDL cholesterol;	chr1:39137542	chr1:39522280~39546187:-
LIHC	cis	rs2243480	1	rs10807702	ENSG00000230295.1	RP11-458F8.2	-4.17	3.81e-05	0.00829	-0.23	-0.22	Diabetic kidney disease;	chr7:66302856	chr7:66880708~66882981:+
LIHC	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-4.17	3.81e-05	0.00829	-0.27	-0.22	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
LIHC	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	4.17	3.81e-05	0.00829	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
LIHC	cis	rs7216064	0.655	rs8078543	ENSG00000278740.1	RP11-147L13.14	-4.17	3.81e-05	0.00829	-0.26	-0.22	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68188547~68189165:+
LIHC	cis	rs7216064	0.636	rs62084696	ENSG00000278740.1	RP11-147L13.14	-4.17	3.81e-05	0.00829	-0.26	-0.22	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68188547~68189165:+
LIHC	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-4.17	3.81e-05	0.00829	-0.28	-0.22	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
LIHC	cis	rs7474896	0.583	rs10827818	ENSG00000263064.2	RP11-291L22.7	4.17	3.81e-05	0.0083	0.26	0.22	Obesity (extreme);	chr10:37711928	chr10:38448689~38448949:+
LIHC	cis	rs7474896	0.583	rs7071147	ENSG00000263064.2	RP11-291L22.7	4.17	3.81e-05	0.0083	0.26	0.22	Obesity (extreme);	chr10:37714448	chr10:38448689~38448949:+
LIHC	cis	rs7474896	0.583	rs10740950	ENSG00000263064.2	RP11-291L22.7	4.17	3.81e-05	0.0083	0.26	0.22	Obesity (extreme);	chr10:37714568	chr10:38448689~38448949:+
LIHC	cis	rs7474896	0.583	rs11011347	ENSG00000263064.2	RP11-291L22.7	4.17	3.81e-05	0.0083	0.26	0.22	Obesity (extreme);	chr10:37730336	chr10:38448689~38448949:+
LIHC	cis	rs9843304	0.528	rs9860963	ENSG00000244503.1	RP11-278L15.6	-4.17	3.81e-05	0.0083	-0.28	-0.22	Gallstone disease;	chr3:149479678	chr3:149494660~149495995:+
LIHC	cis	rs10129255	0.913	rs28861466	ENSG00000224373.3	IGHV4-59	4.17	3.82e-05	0.00831	0.18	0.22	Kawasaki disease;	chr14:106718572	chr14:106627249~106627825:-
LIHC	cis	rs9525916	0.967	rs9533775	ENSG00000230731.2	RP11-478K15.6	-4.17	3.82e-05	0.00831	-0.25	-0.22	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44234118~44243192:-
LIHC	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	4.17	3.82e-05	0.00831	0.25	0.22	Height;	chr4:55387515	chr4:55363971~55395847:-
LIHC	cis	rs1729407	0.649	rs2849176	ENSG00000236267.1	AP006216.5	-4.17	3.82e-05	0.00831	-0.21	-0.22	Apolipoprotein A-IV levels;	chr11:116826205	chr11:116813204~116814003:-
LIHC	cis	rs9450351	0.744	rs9362248	ENSG00000203875.9	SNHG5	-4.17	3.82e-05	0.00831	-0.47	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85847249	chr6:85660950~85678736:-
LIHC	cis	rs9450351	0.744	rs9342047	ENSG00000203875.9	SNHG5	-4.17	3.82e-05	0.00831	-0.47	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85869115	chr6:85660950~85678736:-
LIHC	cis	rs4650994	0.816	rs2209169	ENSG00000213057.5	C1orf220	-4.17	3.82e-05	0.00831	-0.18	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178632357	chr1:178542752~178548889:+
LIHC	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-4.17	3.82e-05	0.00832	-0.23	-0.22	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
LIHC	cis	rs11098499	0.955	rs1511018	ENSG00000260091.1	RP11-33B1.4	-4.17	3.82e-05	0.00832	-0.16	-0.22	Corneal astigmatism;	chr4:119240425	chr4:119409333~119410233:+
LIHC	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-4.17	3.83e-05	0.00832	-0.24	-0.22	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
LIHC	cis	rs787274	0.543	rs1324930	ENSG00000271631.1	RP11-408O19.5	-4.17	3.83e-05	0.00833	-0.34	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr9:112872359	chr9:112885158~112885767:+
LIHC	cis	rs5758511	0.514	rs5758580	ENSG00000205702.9	CYP2D7	4.17	3.83e-05	0.00833	0.26	0.22	Birth weight;	chr22:42097871	chr22:42140203~42144577:-
LIHC	cis	rs4650994	0.905	rs12753251	ENSG00000273384.1	RP5-1098D14.1	4.17	3.83e-05	0.00834	0.27	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178560763	chr1:178651706~178652282:+
LIHC	cis	rs7809950	1	rs986994	ENSG00000238832.1	snoU109	-4.17	3.83e-05	0.00834	-0.26	-0.22	Coronary artery disease;	chr7:107463670	chr7:107603363~107603507:+
LIHC	cis	rs75920871	0.764	rs17120347	ENSG00000254851.1	RP11-109L13.1	-4.17	3.83e-05	0.00834	-0.46	-0.22	Subjective well-being;	chr11:117125823	chr11:117135528~117138582:+
LIHC	cis	rs8041227	0.525	rs4304986	ENSG00000259772.5	RP11-16E12.2	4.17	3.84e-05	0.00834	0.3	0.22	Eosinophilic esophagitis;	chr15:31226833	chr15:31221999~31230838:-
LIHC	cis	rs4148008	0.564	rs6501769	ENSG00000267250.1	RP11-118B18.2	-4.17	3.84e-05	0.00835	-0.29	-0.22	HDL cholesterol;	chr17:68823677	chr17:68793549~68797822:-
LIHC	cis	rs8064024	0.625	rs960006	ENSG00000267077.1	RP11-127I20.5	4.17	3.84e-05	0.00835	0.23	0.22	Cancer;	chr16:4861194	chr16:4795265~4796532:-
LIHC	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-4.17	3.84e-05	0.00835	-0.24	-0.22	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
LIHC	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-4.17	3.84e-05	0.00835	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
LIHC	cis	rs4578769	0.729	rs12456875	ENSG00000266850.1	RP11-370A5.1	-4.17	3.84e-05	0.00835	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22830208	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs67551099	ENSG00000266850.1	RP11-370A5.1	-4.17	3.84e-05	0.00835	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22831167	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs12455548	ENSG00000266850.1	RP11-370A5.1	-4.17	3.84e-05	0.00835	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22831514	chr18:22723491~22907721:-
LIHC	cis	rs2762353	0.562	rs1165206	ENSG00000242387.1	HIST1H2APS2	4.17	3.84e-05	0.00835	0.25	0.22	Blood metabolite levels;	chr6:25867338	chr6:25882026~25882395:-
LIHC	cis	rs7208859	0.673	rs7211776	ENSG00000266490.1	CTD-2349P21.9	4.17	3.84e-05	0.00835	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs9912122	ENSG00000266490.1	CTD-2349P21.9	4.17	3.84e-05	0.00835	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30792372~30792833:+
LIHC	cis	rs2797160	1	rs6904069	ENSG00000237742.5	RP11-624M8.1	-4.17	3.84e-05	0.00836	-0.21	-0.22	Endometrial cancer;	chr6:125673988	chr6:125578558~125749190:-
LIHC	cis	rs11098499	0.955	rs13114751	ENSG00000260091.1	RP11-33B1.4	-4.17	3.84e-05	0.00836	-0.16	-0.22	Corneal astigmatism;	chr4:119235462	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.913	rs35271032	ENSG00000260091.1	RP11-33B1.4	-4.17	3.84e-05	0.00836	-0.16	-0.22	Corneal astigmatism;	chr4:119235504	chr4:119409333~119410233:+
LIHC	cis	rs3812762	0.833	rs35670750	ENSG00000254860.4	TMEM9B-AS1	4.17	3.84e-05	0.00836	0.26	0.22	Hypospadias;	chr11:8760897	chr11:8964675~8977527:+
LIHC	cis	rs17464492	0.569	rs687279	ENSG00000246228.5	CASC8	-4.17	3.84e-05	0.00836	-0.25	-0.22	Prostate-specific antigen levels (conditioned on lead SNPs);	chr8:127332379	chr8:127289817~127482139:-
LIHC	cis	rs11098499	1	rs11098499	ENSG00000260091.1	RP11-33B1.4	-4.17	3.85e-05	0.00836	-0.16	-0.22	Corneal astigmatism;	chr4:119266456	chr4:119409333~119410233:+
LIHC	cis	rs2243480	0.708	rs13242216	ENSG00000232546.1	RP11-458F8.1	-4.17	3.85e-05	0.00836	-0.25	-0.22	Diabetic kidney disease;	chr7:66433290	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs67536397	ENSG00000232546.1	RP11-458F8.1	-4.17	3.85e-05	0.00836	-0.25	-0.22	Diabetic kidney disease;	chr7:66482930	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs58669269	ENSG00000232546.1	RP11-458F8.1	-4.17	3.85e-05	0.00836	-0.25	-0.22	Diabetic kidney disease;	chr7:66486966	chr7:66848496~66858136:+
LIHC	cis	rs12887734	0.524	rs722637	ENSG00000258534.1	CTD-2134A5.4	4.17	3.85e-05	0.00837	0.24	0.22	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103795386	chr14:103854366~103880111:-
LIHC	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	4.17	3.85e-05	0.00837	0.17	0.22	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
LIHC	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-4.17	3.85e-05	0.00837	-0.25	-0.22	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
LIHC	cis	rs6445975	0.666	rs4518147	ENSG00000272360.1	RP11-359I18.5	4.17	3.85e-05	0.00837	0.29	0.22	Systemic lupus erythematosus;	chr3:58407847	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.578	rs6772652	ENSG00000272360.1	RP11-359I18.5	4.17	3.85e-05	0.00837	0.29	0.22	Systemic lupus erythematosus;	chr3:58420966	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.572	rs12485999	ENSG00000272360.1	RP11-359I18.5	4.17	3.85e-05	0.00837	0.29	0.22	Systemic lupus erythematosus;	chr3:58424036	chr3:58490830~58491291:-
LIHC	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-4.17	3.86e-05	0.00838	-0.27	-0.22	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
LIHC	cis	rs7044106	0.762	rs1886337	ENSG00000238181.2	AHCYP2	-4.17	3.86e-05	0.00839	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.762	rs3904197	ENSG00000238181.2	AHCYP2	-4.17	3.86e-05	0.00839	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120720673~120721972:+
LIHC	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-4.17	3.86e-05	0.00839	-0.26	-0.22	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
LIHC	cis	rs9532669	0.926	rs2875421	ENSG00000168852.11	TPTE2P5	4.17	3.86e-05	0.00839	0.25	0.22	Cervical cancer;	chr13:40936536	chr13:40822296~40921749:-
LIHC	cis	rs755249	0.567	rs72661927	ENSG00000182109.6	RP11-69E11.4	4.17	3.86e-05	0.00839	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39522280~39546187:-
LIHC	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	4.17	3.86e-05	0.00839	0.16	0.22	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
LIHC	cis	rs734999	0.87	rs2147905	ENSG00000225931.3	RP3-395M20.7	-4.17	3.86e-05	0.00839	-0.24	-0.22	Ulcerative colitis;	chr1:2551482	chr1:2566410~2569888:+
LIHC	cis	rs7044106	0.708	rs10760113	ENSG00000238181.2	AHCYP2	-4.17	3.86e-05	0.00839	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120720673~120721972:+
LIHC	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-4.17	3.86e-05	0.0084	-0.26	-0.22	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
LIHC	cis	rs1823913	1	rs10445783	ENSG00000227542.1	AC092614.2	-4.17	3.86e-05	0.0084	-0.23	-0.22	Obesity-related traits;	chr2:191236772	chr2:191229165~191246172:-
LIHC	cis	rs60432013	0.584	rs3764167	ENSG00000279656.1	RP11-298I3.6	4.17	3.87e-05	0.0084	0.43	0.22	Red cell distribution width;	chr14:23050766	chr14:23023083~23024217:-
LIHC	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	4.17	3.87e-05	0.0084	0.18	0.22	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
LIHC	cis	rs11216126	0.556	rs1893460	ENSG00000254851.1	RP11-109L13.1	4.17	3.87e-05	0.0084	0.3	0.22	HDL cholesterol;	chr11:116732961	chr11:117135528~117138582:+
LIHC	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-4.17	3.87e-05	0.0084	-0.21	-0.22	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
LIHC	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	4.17	3.87e-05	0.00841	0.21	0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
LIHC	cis	rs10829156	0.755	rs10732437	ENSG00000225527.1	RP11-383B4.4	-4.17	3.87e-05	0.00841	-0.36	-0.22	Sudden cardiac arrest;	chr10:18626973	chr10:18531849~18533336:-
LIHC	cis	rs9907295	0.71	rs4796113	ENSG00000270871.1	AC015849.19	4.17	3.87e-05	0.00841	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35832562	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.818	rs4796114	ENSG00000270871.1	AC015849.19	4.17	3.87e-05	0.00841	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35832653	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.818	rs3785764	ENSG00000270871.1	AC015849.19	4.17	3.87e-05	0.00841	0.24	0.22	Fibroblast growth factor basic levels;	chr17:35833760	chr17:35816717~35830293:-
LIHC	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	4.17	3.87e-05	0.00841	0.34	0.22	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
LIHC	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	4.17	3.87e-05	0.00841	0.3	0.22	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
LIHC	cis	rs2070488	0.965	rs2154778	ENSG00000229589.1	ACVR2B-AS1	-4.17	3.87e-05	0.00841	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38512148	chr3:38451027~38454820:-
LIHC	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	4.17	3.87e-05	0.00841	0.36	0.22	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
LIHC	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	4.17	3.88e-05	0.00842	0.26	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
LIHC	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	4.17	3.88e-05	0.00842	0.38	0.22	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
LIHC	cis	rs875971	0.545	rs1267814	ENSG00000228409.4	CCT6P1	4.17	3.88e-05	0.00843	0.18	0.22	Aortic root size;	chr7:66579422	chr7:65751142~65763354:+
LIHC	cis	rs113084984	0.684	rs4669745	ENSG00000271952.1	RP11-245G13.2	-4.17	3.88e-05	0.00843	-0.27	-0.22	Breast cancer;	chr2:11541446	chr2:10878269~10885118:+
LIHC	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-4.17	3.88e-05	0.00843	-0.25	-0.22	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
LIHC	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-4.17	3.88e-05	0.00843	-0.25	-0.22	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
LIHC	cis	rs893363	0.522	rs2241808	ENSG00000271916.1	RP11-884K10.6	-4.17	3.89e-05	0.00844	-0.27	-0.22	Axial length;	chr3:53822626	chr3:53797764~53798019:-
LIHC	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	4.17	3.89e-05	0.00844	0.26	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
LIHC	cis	rs9341808	1	rs1359239	ENSG00000272129.1	RP11-250B2.6	4.17	3.89e-05	0.00845	0.23	0.22	Sitting height ratio;	chr6:80246429	chr6:80355424~80356859:+
LIHC	cis	rs2494250	0.542	rs12140039	ENSG00000231434.1	RP11-144L1.8	-4.17	3.89e-05	0.00845	-0.27	-0.22	Select biomarker traits;	chr1:159359410	chr1:158523672~158525838:+
LIHC	cis	rs8005677	0.611	rs11624528	ENSG00000257285.4	RP11-298I3.1	4.17	3.89e-05	0.00845	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:22929609~22955562:+
LIHC	cis	rs860295	0.58	rs10908461	ENSG00000203761.5	MSTO2P	-4.17	3.89e-05	0.00845	-0.19	-0.22	Body mass index;	chr1:155305936	chr1:155745829~155750137:+
LIHC	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-4.17	3.89e-05	0.00845	-0.17	-0.22	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
LIHC	cis	rs6430585	0.528	rs309142	ENSG00000231890.6	DARS-AS1	-4.17	3.89e-05	0.00845	-0.3	-0.22	Corneal structure;	chr2:135957754	chr2:135985176~136022593:+
LIHC	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-4.17	3.9e-05	0.00846	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
LIHC	cis	rs2072510	0.966	rs1990611	ENSG00000257715.1	RP11-256L6.2	-4.17	3.9e-05	0.00846	-0.22	-0.22	Metabolite levels (small molecules and protein measures);	chr12:96020206	chr12:96025323~96027971:+
LIHC	cis	rs875971	0.522	rs1880556	ENSG00000273024.4	INTS4P2	-4.17	3.9e-05	0.00846	-0.26	-0.22	Aortic root size;	chr7:65967557	chr7:65647864~65715661:+
LIHC	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	4.17	3.9e-05	0.00846	0.28	0.22	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
LIHC	cis	rs763121	0.853	rs4821798	ENSG00000273076.1	RP3-508I15.22	4.17	3.9e-05	0.00846	0.24	0.22	Menopause (age at onset);	chr22:38625160	chr22:38743495~38743910:+
LIHC	cis	rs10761256	0.835	rs10992841	ENSG00000227603.1	RP11-165J3.6	4.17	3.9e-05	0.00847	0.26	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr9:93667833	chr9:93435332~93437121:-
LIHC	cis	rs16958440	1	rs62096476	ENSG00000267724.1	RP11-49K24.8	4.17	3.9e-05	0.00847	0.34	0.22	Sitting height ratio;	chr18:47132250	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs62096478	ENSG00000267724.1	RP11-49K24.8	4.17	3.9e-05	0.00847	0.34	0.22	Sitting height ratio;	chr18:47136038	chr18:47105946~47108062:+
LIHC	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	4.17	3.9e-05	0.00847	0.25	0.22	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
LIHC	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	4.17	3.9e-05	0.00847	0.31	0.22	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
LIHC	cis	rs9652601	0.779	rs7203793	ENSG00000274038.1	RP11-66H6.4	-4.17	3.9e-05	0.00847	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11088277	chr16:11056556~11057034:+
LIHC	cis	rs2243480	1	rs383402	ENSG00000230295.1	RP11-458F8.2	4.17	3.91e-05	0.00848	0.23	0.22	Diabetic kidney disease;	chr7:66121666	chr7:66880708~66882981:+
LIHC	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	4.17	3.91e-05	0.00848	0.29	0.22	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
LIHC	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	4.17	3.91e-05	0.00848	0.29	0.22	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
LIHC	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	4.17	3.91e-05	0.00848	0.29	0.22	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
LIHC	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	4.17	3.91e-05	0.00848	0.2	0.22	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
LIHC	cis	rs9595908	0.785	rs9596058	ENSG00000212293.1	SNORA16	4.17	3.91e-05	0.00848	0.25	0.22	Body mass index;	chr13:32669938	chr13:32420390~32420516:-
LIHC	cis	rs12681287	0.64	rs7841690	ENSG00000254088.1	SLC2A3P4	-4.17	3.91e-05	0.00849	-0.26	-0.22	Caudate activity during reward;	chr8:86353130	chr8:86503591~86505061:+
LIHC	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	4.17	3.91e-05	0.00849	0.27	0.22	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
LIHC	cis	rs3733589	1	rs3756231	ENSG00000250413.1	RP11-448G15.1	-4.17	3.91e-05	0.00849	-0.38	-0.22	Renal overload gout;	chr4:10023920	chr4:10006482~10009725:+
LIHC	cis	rs2598107	0.601	rs71546610	ENSG00000211698.2	TRGV4	-4.17	3.91e-05	0.00849	-0.26	-0.22	Dupuytren's disease;	chr7:37916793	chr7:38353715~38354517:-
LIHC	cis	rs2598107	0.601	rs35850626	ENSG00000211698.2	TRGV4	-4.17	3.91e-05	0.00849	-0.26	-0.22	Dupuytren's disease;	chr7:37918865	chr7:38353715~38354517:-
LIHC	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	4.17	3.92e-05	0.0085	0.25	0.22	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	4.17	3.92e-05	0.0085	0.25	0.22	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
LIHC	cis	rs7044106	0.791	rs10984994	ENSG00000238181.2	AHCYP2	4.17	3.92e-05	0.0085	0.25	0.22	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120720673~120721972:+
LIHC	cis	rs2439831	0.85	rs8032649	ENSG00000166763.7	STRCP1	-4.17	3.92e-05	0.00851	-0.34	-0.22	Lung cancer in ever smokers;	chr15:43842724	chr15:43699488~43718184:-
LIHC	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	4.17	3.92e-05	0.00851	0.17	0.22	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
LIHC	cis	rs2243480	1	rs59794892	ENSG00000232546.1	RP11-458F8.1	-4.17	3.93e-05	0.00852	-0.25	-0.22	Diabetic kidney disease;	chr7:65950886	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.803	rs36004293	ENSG00000232546.1	RP11-458F8.1	-4.17	3.93e-05	0.00852	-0.25	-0.22	Diabetic kidney disease;	chr7:65951525	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.803	rs35268390	ENSG00000232546.1	RP11-458F8.1	-4.17	3.93e-05	0.00852	-0.25	-0.22	Diabetic kidney disease;	chr7:65951549	chr7:66848496~66858136:+
LIHC	cis	rs1247318	0.507	rs1247330	ENSG00000243831.1	RP1-81D8.4	4.17	3.93e-05	0.00852	0.28	0.22	Aging;	chr6:160905618	chr6:160666228~160676523:-
LIHC	cis	rs6445975	0.666	rs4390943	ENSG00000272360.1	RP11-359I18.5	-4.17	3.93e-05	0.00852	-0.29	-0.22	Systemic lupus erythematosus;	chr3:58390912	chr3:58490830~58491291:-
LIHC	cis	rs638893	1	rs649338	ENSG00000255239.1	AP002954.6	4.17	3.93e-05	0.00852	0.38	0.22	Vitiligo;	chr11:118834945	chr11:118688039~118690600:-
LIHC	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	4.17	3.93e-05	0.00852	0.26	0.22	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
LIHC	cis	rs4561483	0.549	rs154149	ENSG00000261560.1	RP11-166B2.3	-4.17	3.93e-05	0.00852	-0.25	-0.22	Testicular germ cell tumor;	chr16:11862261	chr16:11881075~11882569:-
LIHC	cis	rs7044106	0.762	rs7357638	ENSG00000238181.2	AHCYP2	-4.17	3.93e-05	0.00853	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120720673~120721972:+
LIHC	cis	rs6445975	0.666	rs57621305	ENSG00000272360.1	RP11-359I18.5	-4.17	3.94e-05	0.00854	-0.3	-0.22	Systemic lupus erythematosus;	chr3:58361017	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.666	rs4681683	ENSG00000272360.1	RP11-359I18.5	-4.17	3.94e-05	0.00854	-0.3	-0.22	Systemic lupus erythematosus;	chr3:58361958	chr3:58490830~58491291:-
LIHC	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-4.17	3.94e-05	0.00854	-0.27	-0.22	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
LIHC	cis	rs494453	0.922	rs480578	ENSG00000227811.2	FAM212B-AS1	-4.17	3.94e-05	0.00854	-0.25	-0.22	Osteoporosis-related phenotypes;	chr1:111709839	chr1:111739841~111747798:+
LIHC	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-4.17	3.94e-05	0.00854	-0.34	-0.22	Depression;	chr6:28231053	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-4.17	3.94e-05	0.00854	-0.34	-0.22	Depression;	chr6:28232159	chr6:28115628~28116551:+
LIHC	cis	rs1115240	0.947	rs8010856	ENSG00000257842.4	NOVA1-AS1	-4.17	3.94e-05	0.00855	-0.2	-0.22	Educational attainment (years of education);	chr14:26639592	chr14:26598412~26806467:+
LIHC	cis	rs4148323	1	rs4148323	ENSG00000228445.1	UGT1A2P	-4.17	3.94e-05	0.00855	-0.28	-0.22	Bilirubin levels;	chr2:233760498	chr2:233747214~233748079:+
LIHC	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	4.17	3.94e-05	0.00855	0.26	0.22	Height;	chr6:109706740	chr6:109382795~109383666:+
LIHC	cis	rs3812762	0.879	rs3763920	ENSG00000254860.4	TMEM9B-AS1	4.17	3.95e-05	0.00855	0.23	0.22	Hypospadias;	chr11:8787040	chr11:8964675~8977527:+
LIHC	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-4.16	3.95e-05	0.00855	-0.28	-0.22	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
LIHC	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	4.16	3.95e-05	0.00856	0.3	0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
LIHC	cis	rs9450351	0.744	rs35510369	ENSG00000203875.9	SNHG5	-4.16	3.95e-05	0.00856	-0.48	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85556411	chr6:85660950~85678736:-
LIHC	cis	rs9400467	0.528	rs6933627	ENSG00000271789.1	RP5-1112D6.7	-4.16	3.95e-05	0.00856	-0.21	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111297126~111298510:+
LIHC	cis	rs7937890	0.559	rs2034480	ENSG00000251991.1	RNU7-49P	4.16	3.95e-05	0.00857	0.24	0.22	Mitochondrial DNA levels;	chr11:14445377	chr11:14478892~14478953:+
LIHC	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	4.16	3.95e-05	0.00857	0.25	0.22	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
LIHC	cis	rs7937890	0.504	rs2575847	ENSG00000251991.1	RNU7-49P	4.16	3.95e-05	0.00857	0.24	0.22	Mitochondrial DNA levels;	chr11:14449626	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2575825	ENSG00000251991.1	RNU7-49P	4.16	3.95e-05	0.00857	0.24	0.22	Mitochondrial DNA levels;	chr11:14450550	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.532	rs2575827	ENSG00000251991.1	RNU7-49P	4.16	3.95e-05	0.00857	0.24	0.22	Mitochondrial DNA levels;	chr11:14453969	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.532	rs2256884	ENSG00000251991.1	RNU7-49P	4.16	3.95e-05	0.00857	0.24	0.22	Mitochondrial DNA levels;	chr11:14454856	chr11:14478892~14478953:+
LIHC	cis	rs7937890	0.559	rs2597206	ENSG00000251991.1	RNU7-49P	4.16	3.95e-05	0.00857	0.24	0.22	Mitochondrial DNA levels;	chr11:14455992	chr11:14478892~14478953:+
LIHC	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	4.16	3.95e-05	0.00857	0.45	0.22	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
LIHC	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-4.16	3.96e-05	0.00857	-0.24	-0.22	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
LIHC	cis	rs7474896	0.583	rs12776092	ENSG00000263064.2	RP11-291L22.7	4.16	3.96e-05	0.00857	0.26	0.22	Obesity (extreme);	chr10:37726867	chr10:38448689~38448949:+
LIHC	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	4.16	3.96e-05	0.00858	0.28	0.22	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
LIHC	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	4.16	3.96e-05	0.00858	0.24	0.22	Asthma;	chr2:102411180	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	4.16	3.96e-05	0.00858	0.24	0.22	Asthma;	chr2:102411191	chr2:102438713~102440475:+
LIHC	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	4.16	3.96e-05	0.00858	0.24	0.22	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	4.16	3.96e-05	0.00858	0.24	0.22	Asthma;	chr2:102412435	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	4.16	3.96e-05	0.00858	0.24	0.22	Asthma;	chr2:102412461	chr2:102438713~102440475:+
LIHC	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	4.16	3.96e-05	0.00858	0.24	0.22	Asthma;	chr2:102412524	chr2:102438713~102440475:+
LIHC	cis	rs2439831	0.681	rs3742971	ENSG00000166763.7	STRCP1	-4.16	3.96e-05	0.00858	-0.3	-0.22	Lung cancer in ever smokers;	chr15:43330718	chr15:43699488~43718184:-
LIHC	cis	rs8007846	0.539	rs67957534	ENSG00000276116.2	FUT8-AS1	4.16	3.96e-05	0.00858	0.27	0.22	Multiple sclerosis--Brain Glutamate Levels;	chr14:65657867	chr14:65411170~65412690:-
LIHC	cis	rs2310173	0.575	rs757918	ENSG00000281162.1	LINC01127	-4.16	3.96e-05	0.00858	-0.23	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101996837	chr2:101962056~101987167:+
LIHC	cis	rs12681287	0.605	rs6471296	ENSG00000254088.1	SLC2A3P4	-4.16	3.96e-05	0.00858	-0.26	-0.22	Caudate activity during reward;	chr8:86362425	chr8:86503591~86505061:+
LIHC	cis	rs2439831	0.867	rs12443102	ENSG00000166763.7	STRCP1	4.16	3.96e-05	0.00858	0.34	0.22	Lung cancer in ever smokers;	chr15:43639905	chr15:43699488~43718184:-
LIHC	cis	rs72675573	0.852	rs1331859	ENSG00000235612.1	RP1-158P9.1	-4.16	3.96e-05	0.00858	-0.29	-0.22	Monocyte count;	chr1:56128439	chr1:56145721~56155224:+
LIHC	cis	rs763121	0.819	rs5750629	ENSG00000273076.1	RP3-508I15.22	4.16	3.96e-05	0.00859	0.25	0.22	Menopause (age at onset);	chr22:38589060	chr22:38743495~38743910:+
LIHC	cis	rs7893279	0.505	rs12785031	ENSG00000225527.1	RP11-383B4.4	4.16	3.97e-05	0.00859	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18611240	chr10:18531849~18533336:-
LIHC	cis	rs948562	0.947	rs2186381	ENSG00000280010.1	AP001350.4	4.16	3.97e-05	0.00859	0.36	0.22	Lymphoma;	chr11:58630320	chr11:58627435~58628528:+
LIHC	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	4.16	3.97e-05	0.00859	0.26	0.22	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
LIHC	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	4.16	3.97e-05	0.0086	0.25	0.22	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	4.16	3.97e-05	0.0086	0.25	0.22	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	4.16	3.97e-05	0.0086	0.25	0.22	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
LIHC	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-4.16	3.97e-05	0.0086	-0.22	-0.22	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
LIHC	cis	rs6832769	0.961	rs6824955	ENSG00000272969.1	RP11-528I4.2	4.16	3.97e-05	0.0086	0.26	0.22	Personality dimensions;	chr4:55450969	chr4:55547112~55547889:+
LIHC	cis	rs113835537	0.935	rs79106199	ENSG00000255517.5	CTD-3074O7.5	-4.16	3.97e-05	0.0086	-0.38	-0.22	Airway imaging phenotypes;	chr11:66653047	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.935	rs117131621	ENSG00000255517.5	CTD-3074O7.5	-4.16	3.97e-05	0.0086	-0.38	-0.22	Airway imaging phenotypes;	chr11:66654863	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.935	rs57043177	ENSG00000255517.5	CTD-3074O7.5	-4.16	3.97e-05	0.0086	-0.38	-0.22	Airway imaging phenotypes;	chr11:66655676	chr11:66473490~66480233:-
LIHC	cis	rs2243480	1	rs35820085	ENSG00000232546.1	RP11-458F8.1	-4.16	3.97e-05	0.0086	-0.25	-0.22	Diabetic kidney disease;	chr7:65977771	chr7:66848496~66858136:+
LIHC	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	4.16	3.97e-05	0.0086	0.29	0.22	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
LIHC	cis	rs4682868	0.611	rs734969	ENSG00000273328.4	RP11-141M3.6	4.16	3.98e-05	0.00861	0.22	0.22	Monocyte percentage of white cells;	chr3:42876414	chr3:42809414~42908105:+
LIHC	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	4.16	3.98e-05	0.00861	0.35	0.22	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
LIHC	cis	rs6500637	0.86	rs11644917	ENSG00000267077.1	RP11-127I20.5	-4.16	3.98e-05	0.00861	-0.24	-0.22	Cancer;	chr16:4890386	chr16:4795265~4796532:-
LIHC	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	4.16	3.98e-05	0.00861	0.35	0.22	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
LIHC	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	4.16	3.98e-05	0.00861	0.18	0.22	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
LIHC	cis	rs7474896	0.561	rs2474603	ENSG00000120555.12	SEPT7P9	4.16	3.98e-05	0.00861	0.32	0.22	Obesity (extreme);	chr10:38156754	chr10:38383069~38402916:-
LIHC	cis	rs9353324	1	rs9353324	ENSG00000203875.9	SNHG5	-4.16	3.98e-05	0.00862	-0.48	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85653156	chr6:85660950~85678736:-
LIHC	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-4.16	3.98e-05	0.00862	-0.25	-0.22	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
LIHC	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	4.16	3.98e-05	0.00862	0.25	0.22	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
LIHC	cis	rs66887589	0.807	rs7694483	ENSG00000260091.1	RP11-33B1.4	-4.16	3.98e-05	0.00862	-0.14	-0.22	Diastolic blood pressure;	chr4:119484774	chr4:119409333~119410233:+
LIHC	cis	rs9652601	0.843	rs7204643	ENSG00000274038.1	RP11-66H6.4	4.16	3.98e-05	0.00862	0.28	0.22	Systemic lupus erythematosus;	chr16:11073746	chr16:11056556~11057034:+
LIHC	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-4.16	3.99e-05	0.00863	-0.29	-0.22	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
LIHC	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-4.16	3.99e-05	0.00863	-0.28	-0.22	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
LIHC	cis	rs60733400	0.667	rs4385650	ENSG00000225931.3	RP3-395M20.7	4.16	3.99e-05	0.00863	0.24	0.22	Multiple sclerosis;	chr1:2568459	chr1:2566410~2569888:+
LIHC	cis	rs2998286	0.723	rs1034087	ENSG00000254635.4	WAC-AS1	-4.16	3.99e-05	0.00863	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28643143	chr10:28522652~28532743:-
LIHC	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-4.16	3.99e-05	0.00863	-0.3	-0.22	Height;	chr3:53080524	chr3:53064283~53065091:-
LIHC	cis	rs1115240	0.898	rs2332816	ENSG00000257842.4	NOVA1-AS1	-4.16	3.99e-05	0.00863	-0.2	-0.22	Educational attainment (years of education);	chr14:26635642	chr14:26598412~26806467:+
LIHC	cis	rs2717559	0.542	rs11777634	ENSG00000253196.1	RP11-706C16.7	-4.16	3.99e-05	0.00864	-0.24	-0.22	Urinary tract infection frequency;	chr8:142806541	chr8:142763116~142766427:+
LIHC	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	4.16	3.99e-05	0.00864	0.19	0.22	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
LIHC	cis	rs338389	0.542	rs12594726	ENSG00000260657.2	RP11-315D16.4	-4.16	3.99e-05	0.00864	-0.36	-0.22	Survival in rectal cancer;	chr15:67994440	chr15:68267792~68277994:-
LIHC	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	4.16	3.99e-05	0.00864	0.34	0.22	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
LIHC	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-4.16	3.99e-05	0.00864	-0.25	-0.22	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
LIHC	cis	rs79349575	0.716	rs595767	ENSG00000248278.1	SUMO2P17	4.16	4e-05	0.00864	0.27	0.22	Type 2 diabetes;	chr17:48880625	chr17:48874860~48908983:-
LIHC	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	4.16	4e-05	0.00864	0.2	0.22	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
LIHC	cis	rs803923	0.52	rs35910339	ENSG00000230894.1	RP11-67K19.3	-4.16	4e-05	0.00865	-0.28	-0.22	Lung function (FEV1/FVC);	chr9:116632085	chr9:116568449~116586328:+
LIHC	cis	rs7121538	0.756	rs76613195	ENSG00000251991.1	RNU7-49P	-4.16	4e-05	0.00865	-0.31	-0.22	HDL cholesterol;	chr11:14405856	chr11:14478892~14478953:+
LIHC	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-4.16	4e-05	0.00866	-0.25	-0.22	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
LIHC	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	4.16	4e-05	0.00866	0.21	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
LIHC	cis	rs11745587	0.539	rs6897597	ENSG00000233006.5	AC034220.3	4.16	4e-05	0.00866	0.24	0.22	Asthma;	chr5:132407773	chr5:132311285~132369916:-
LIHC	cis	rs921968	0.565	rs2059717	ENSG00000272555.1	RP11-459I19.1	-4.16	4e-05	0.00866	-0.24	-0.22	Mean corpuscular hemoglobin concentration;	chr2:218735593	chr2:218818690~218819144:+
LIHC	cis	rs875971	0.545	rs1796222	ENSG00000273024.4	INTS4P2	4.16	4e-05	0.00866	0.25	0.22	Aortic root size;	chr7:66592167	chr7:65647864~65715661:+
LIHC	cis	rs1005277	0.505	rs10827835	ENSG00000275858.1	RP11-291L22.8	-4.16	4.01e-05	0.00866	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38450738~38451069:-
LIHC	cis	rs9876781	1	rs4858817	ENSG00000229759.1	MRPS18AP1	-4.16	4.01e-05	0.00866	-0.23	-0.22	Longevity;	chr3:48375266	chr3:48256350~48256938:-
LIHC	cis	rs4578769	0.918	rs8089471	ENSG00000266850.1	RP11-370A5.1	4.16	4.01e-05	0.00867	0.26	0.22	Eosinophil percentage of white cells;	chr18:22892994	chr18:22723491~22907721:-
LIHC	cis	rs875971	0.502	rs1796227	ENSG00000273024.4	INTS4P2	4.16	4.01e-05	0.00867	0.25	0.22	Aortic root size;	chr7:66622032	chr7:65647864~65715661:+
LIHC	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	4.16	4.01e-05	0.00867	0.26	0.22	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
LIHC	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	4.16	4.01e-05	0.00867	0.34	0.22	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
LIHC	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	4.16	4.02e-05	0.00868	0.39	0.22	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
LIHC	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	4.16	4.02e-05	0.00868	0.25	0.22	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
LIHC	cis	rs11722228	0.508	rs61335146	ENSG00000261490.1	RP11-448G15.3	4.16	4.02e-05	0.00868	0.28	0.22	Urate levels;Serum uric acid levels;Gout;	chr4:10129169	chr4:10068089~10073019:-
LIHC	cis	rs16958440	1	rs62096474	ENSG00000267724.1	RP11-49K24.8	4.16	4.02e-05	0.00868	0.34	0.22	Sitting height ratio;	chr18:47121133	chr18:47105946~47108062:+
LIHC	cis	rs16958440	0.737	rs16958699	ENSG00000267724.1	RP11-49K24.8	4.16	4.02e-05	0.00868	0.34	0.22	Sitting height ratio;	chr18:47128475	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs16958701	ENSG00000267724.1	RP11-49K24.8	4.16	4.02e-05	0.00868	0.34	0.22	Sitting height ratio;	chr18:47128870	chr18:47105946~47108062:+
LIHC	cis	rs8064024	0.676	rs9926458	ENSG00000267077.1	RP11-127I20.5	4.16	4.02e-05	0.00869	0.22	0.22	Cancer;	chr16:4822627	chr16:4795265~4796532:-
LIHC	cis	rs1223397	1	rs1223397	ENSG00000215022.6	RP1-257A7.4	-4.16	4.02e-05	0.00869	-0.24	-0.22	Blood pressure;	chr6:13270713	chr6:13264861~13295586:-
LIHC	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	4.16	4.02e-05	0.00869	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
LIHC	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	4.16	4.02e-05	0.00869	0.16	0.22	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
LIHC	cis	rs7129556	0.621	rs663674	ENSG00000254459.1	RP11-91P24.7	4.16	4.02e-05	0.00869	0.35	0.22	Weight loss (gastric bypass surgery);	chr11:77881476	chr11:77829654~77872262:-
LIHC	cis	rs417065	1	rs12140347	ENSG00000227634.1	RP11-431K24.3	-4.16	4.03e-05	0.0087	-0.29	-0.22	Psoriasis;	chr1:8200139	chr1:8208672~8215210:+
LIHC	cis	rs9652601	0.959	rs11865121	ENSG00000274038.1	RP11-66H6.4	-4.16	4.03e-05	0.0087	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11072831	chr16:11056556~11057034:+
LIHC	cis	rs3758785	0.623	rs75164831	ENSG00000255893.1	RP11-685N10.1	-4.16	4.03e-05	0.0087	-0.27	-0.22	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410667	chr11:94472908~94473570:-
LIHC	cis	rs3758785	0.562	rs79850307	ENSG00000255893.1	RP11-685N10.1	-4.16	4.03e-05	0.0087	-0.27	-0.22	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94411859	chr11:94472908~94473570:-
LIHC	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-4.16	4.03e-05	0.0087	-0.21	-0.22	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
LIHC	cis	rs875971	0.502	rs1796227	ENSG00000228409.4	CCT6P1	4.16	4.03e-05	0.0087	0.18	0.22	Aortic root size;	chr7:66622032	chr7:65751142~65763354:+
LIHC	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	4.16	4.03e-05	0.00871	0.28	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
LIHC	cis	rs780096	0.526	rs11682621	ENSG00000234072.1	AC074117.10	-4.16	4.03e-05	0.00871	-0.21	-0.22	Total body bone mineral density;	chr2:27526802	chr2:27356246~27367622:+
LIHC	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-4.16	4.03e-05	0.00871	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
LIHC	cis	rs1115240	0.947	rs11159938	ENSG00000257842.4	NOVA1-AS1	-4.16	4.03e-05	0.00871	-0.2	-0.22	Educational attainment (years of education);	chr14:26637780	chr14:26598412~26806467:+
LIHC	cis	rs1115240	0.898	rs10134225	ENSG00000257842.4	NOVA1-AS1	-4.16	4.03e-05	0.00871	-0.2	-0.22	Educational attainment (years of education);	chr14:26574517	chr14:26598412~26806467:+
LIHC	cis	rs1115240	0.898	rs2017442	ENSG00000257842.4	NOVA1-AS1	-4.16	4.03e-05	0.00871	-0.2	-0.22	Educational attainment (years of education);	chr14:26576572	chr14:26598412~26806467:+
LIHC	cis	rs1115240	0.853	rs11159900	ENSG00000257842.4	NOVA1-AS1	-4.16	4.03e-05	0.00871	-0.2	-0.22	Educational attainment (years of education);	chr14:26582164	chr14:26598412~26806467:+
LIHC	cis	rs6433895	0.71	rs7581267	ENSG00000236153.1	AC104076.3	-4.16	4.04e-05	0.00872	-0.32	-0.22	Lymphocyte counts;	chr2:181143574	chr2:180979427~180980090:-
LIHC	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-4.16	4.04e-05	0.00872	-0.19	-0.22	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
LIHC	cis	rs2072510	0.569	rs61937881	ENSG00000257878.1	RP11-256L6.3	-4.16	4.04e-05	0.00872	-0.29	-0.22	Metabolite levels (small molecules and protein measures);	chr12:95999809	chr12:95996521~96011489:+
LIHC	cis	rs2072510	0.569	rs17677343	ENSG00000257878.1	RP11-256L6.3	-4.16	4.04e-05	0.00872	-0.29	-0.22	Metabolite levels (small molecules and protein measures);	chr12:96003303	chr12:95996521~96011489:+
LIHC	cis	rs1115240	0.731	rs12587726	ENSG00000257842.4	NOVA1-AS1	-4.16	4.04e-05	0.00872	-0.2	-0.22	Educational attainment (years of education);	chr14:26587118	chr14:26598412~26806467:+
LIHC	cis	rs1115240	0.898	rs9323839	ENSG00000257842.4	NOVA1-AS1	-4.16	4.04e-05	0.00872	-0.2	-0.22	Educational attainment (years of education);	chr14:26587583	chr14:26598412~26806467:+
LIHC	cis	rs2243480	1	rs34815098	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65827267	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs4548056	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65833886	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs7456042	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65834791	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35735127	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65835436	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.901	rs35256305	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65841418	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs73142121	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65846219	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.803	rs34004500	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65847191	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs35825738	ENSG00000228409.4	CCT6P1	4.16	4.04e-05	0.00872	0.24	0.22	Diabetic kidney disease;	chr7:65853040	chr7:65751142~65763354:+
LIHC	cis	rs2070488	0.931	rs6599212	ENSG00000229589.1	ACVR2B-AS1	-4.16	4.04e-05	0.00873	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38517415	chr3:38451027~38454820:-
LIHC	cis	rs72627509	0.587	rs17087401	ENSG00000269949.1	RP11-738E22.3	4.16	4.04e-05	0.00873	0.31	0.22	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57034989	chr4:56960927~56961373:-
LIHC	cis	rs2243480	1	rs55895244	ENSG00000228409.4	CCT6P1	4.16	4.05e-05	0.00873	0.24	0.22	Diabetic kidney disease;	chr7:65922691	chr7:65751142~65763354:+
LIHC	cis	rs1223397	0.938	rs13205692	ENSG00000215022.6	RP1-257A7.4	-4.16	4.05e-05	0.00873	-0.29	-0.22	Blood pressure;	chr6:13291328	chr6:13264861~13295586:-
LIHC	cis	rs4873772	0.834	rs7842068	ENSG00000253608.1	RP11-770E5.1	4.16	4.05e-05	0.00874	0.25	0.22	Lobe attachment (rater-scored or self-reported);	chr8:47670402	chr8:48551567~48698510:+
LIHC	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-4.16	4.05e-05	0.00874	-0.29	-0.22	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
LIHC	cis	rs755249	0.567	rs61779309	ENSG00000182109.6	RP11-69E11.4	4.16	4.05e-05	0.00874	0.3	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39522280~39546187:-
LIHC	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	4.16	4.05e-05	0.00874	0.27	0.22	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
LIHC	cis	rs1005277	0.522	rs7090858	ENSG00000099251.13	HSD17B7P2	-4.16	4.05e-05	0.00874	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38356380~38378505:+
LIHC	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-4.16	4.05e-05	0.00875	-0.25	-0.22	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
LIHC	cis	rs17818399	1	rs62136864	ENSG00000279254.1	RP11-536C12.1	-4.16	4.05e-05	0.00875	-0.26	-0.22	Height;	chr2:46601985	chr2:46668870~46670778:+
LIHC	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-4.16	4.05e-05	0.00875	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
LIHC	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	4.16	4.05e-05	0.00875	0.18	0.22	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
LIHC	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	4.16	4.05e-05	0.00875	0.31	0.22	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
LIHC	cis	rs9532669	0.963	rs1056824	ENSG00000168852.11	TPTE2P5	4.16	4.06e-05	0.00875	0.24	0.22	Cervical cancer;	chr13:40932748	chr13:40822296~40921749:-
LIHC	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	4.16	4.06e-05	0.00876	0.29	0.22	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
LIHC	cis	rs1876905	0.539	rs240958	ENSG00000271789.1	RP5-1112D6.7	4.16	4.06e-05	0.00876	0.25	0.22	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111297126~111298510:+
LIHC	cis	rs1077773	0.531	rs11766278	ENSG00000237773.4	AC003075.4	-4.16	4.06e-05	0.00876	-0.27	-0.22	Ulcerative colitis;Inflammatory bowel disease;	chr7:17410907	chr7:17279834~17299357:-
LIHC	cis	rs3015497	0.763	rs2934689	ENSG00000269906.1	RP11-248J18.2	4.16	4.06e-05	0.00876	0.28	0.22	Mean platelet volume;	chr14:50651609	chr14:50662511~50663178:-
LIHC	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	4.16	4.07e-05	0.00877	0.18	0.22	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	4.16	4.07e-05	0.00877	0.18	0.22	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
LIHC	cis	rs3812762	0.833	rs3850933	ENSG00000254860.4	TMEM9B-AS1	-4.16	4.07e-05	0.00878	-0.23	-0.22	Hypospadias;	chr11:8779588	chr11:8964675~8977527:+
LIHC	cis	rs875971	0.545	rs66594357	ENSG00000273024.4	INTS4P2	-4.16	4.07e-05	0.00878	-0.25	-0.22	Aortic root size;	chr7:66327797	chr7:65647864~65715661:+
LIHC	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-4.16	4.07e-05	0.00878	-0.25	-0.22	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
LIHC	cis	rs12468226	0.689	rs60584169	ENSG00000272966.1	RP11-686O6.1	4.16	4.07e-05	0.00879	0.39	0.22	Urate levels;	chr2:202111695	chr2:202336739~202337200:+
LIHC	cis	rs4356203	0.87	rs7342262	ENSG00000260196.1	RP1-239B22.5	-4.16	4.08e-05	0.00879	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17380649~17383531:+
LIHC	cis	rs10857712	0.754	rs2297031	ENSG00000214279.11	SCART1	-4.16	4.08e-05	0.00879	-0.27	-0.22	Systemic lupus erythematosus;	chr10:133419150	chr10:133453928~133523558:+
LIHC	cis	rs875971	0.545	rs2420456	ENSG00000273024.4	INTS4P2	-4.16	4.08e-05	0.00879	-0.25	-0.22	Aortic root size;	chr7:66280619	chr7:65647864~65715661:+
LIHC	cis	rs9303401	0.734	rs8073316	ENSG00000265415.1	CTD-2510F5.4	-4.16	4.08e-05	0.0088	-0.15	-0.22	Cognitive test performance;	chr17:59134020	chr17:59202677~59203829:-
LIHC	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	4.16	4.08e-05	0.0088	0.42	0.22	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
LIHC	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-4.16	4.08e-05	0.0088	-0.27	-0.22	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
LIHC	cis	rs6547741	1	rs4666009	ENSG00000234072.1	AC074117.10	4.16	4.08e-05	0.00881	0.2	0.22	Oral cavity cancer;	chr2:27635125	chr2:27356246~27367622:+
LIHC	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	4.16	4.09e-05	0.00881	0.23	0.22	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	4.16	4.09e-05	0.00881	0.23	0.22	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
LIHC	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	4.16	4.09e-05	0.00881	0.23	0.22	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	4.16	4.09e-05	0.00881	0.23	0.22	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
LIHC	cis	rs4578769	0.765	rs35998712	ENSG00000265943.1	RP11-739L10.1	-4.16	4.09e-05	0.00881	-0.29	-0.22	Eosinophil percentage of white cells;	chr18:22873654	chr18:22699481~22933764:-
LIHC	cis	rs9341808	0.905	rs3805903	ENSG00000272129.1	RP11-250B2.6	4.16	4.09e-05	0.00881	0.22	0.22	Sitting height ratio;	chr6:80266112	chr6:80355424~80356859:+
LIHC	cis	rs7412746	0.611	rs2256355	ENSG00000231073.1	RP11-316M1.3	4.16	4.09e-05	0.00881	0.22	0.22	Melanoma;	chr1:150839318	chr1:150973123~150975534:+
LIHC	cis	rs11098499	0.913	rs11098496	ENSG00000260091.1	RP11-33B1.4	-4.16	4.09e-05	0.00882	-0.16	-0.22	Corneal astigmatism;	chr4:119246311	chr4:119409333~119410233:+
LIHC	cis	rs1115240	0.812	rs7156412	ENSG00000257842.4	NOVA1-AS1	-4.16	4.09e-05	0.00882	-0.2	-0.22	Educational attainment (years of education);	chr14:26574623	chr14:26598412~26806467:+
LIHC	cis	rs1023500	0.505	rs134878	ENSG00000226450.2	CYP2D8P	4.16	4.09e-05	0.00882	0.24	0.22	Schizophrenia;	chr22:42267868	chr22:42149886~42155001:-
LIHC	cis	rs12209785	1	rs12209785	ENSG00000231769.2	RP1-8B1.4	4.16	4.09e-05	0.00882	0.34	0.22	Survival in pancreatic cancer;	chr6:45538385	chr6:46097093~46129706:-
LIHC	cis	rs6445975	0.688	rs2271633	ENSG00000272360.1	RP11-359I18.5	-4.16	4.09e-05	0.00882	-0.25	-0.22	Systemic lupus erythematosus;	chr3:58274346	chr3:58490830~58491291:-
LIHC	cis	rs2283831	0.506	rs9613209	ENSG00000213707.2	HMGB1P10	-4.16	4.09e-05	0.00882	-0.27	-0.22	Anti-saccade response;	chr22:26560426	chr22:26560526~26561088:+
LIHC	cis	rs1005277	0.522	rs11011343	ENSG00000099251.13	HSD17B7P2	4.16	4.1e-05	0.00882	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38356380~38378505:+
LIHC	cis	rs61160187	0.51	rs10057395	ENSG00000272308.1	RP11-231G3.1	-4.16	4.1e-05	0.00882	-0.27	-0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792967	chr5:60866457~60866935:-
LIHC	cis	rs9876781	1	rs725309	ENSG00000229759.1	MRPS18AP1	-4.16	4.1e-05	0.00883	-0.23	-0.22	Longevity;	chr3:48377218	chr3:48256350~48256938:-
LIHC	cis	rs9907295	0.901	rs9907121	ENSG00000270871.1	AC015849.19	4.16	4.1e-05	0.00883	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.901	rs4796118	ENSG00000270871.1	AC015849.19	4.16	4.1e-05	0.00883	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.901	rs9914401	ENSG00000270871.1	AC015849.19	4.16	4.1e-05	0.00883	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35861810	chr17:35816717~35830293:-
LIHC	cis	rs12157904	1	rs12160480	ENSG00000233360.4	Z83844.1	4.16	4.1e-05	0.00883	0.47	0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37602224	chr22:37641832~37658377:-
LIHC	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	4.16	4.1e-05	0.00884	0.22	0.22	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
LIHC	cis	rs3845817	0.838	rs697150	ENSG00000281920.1	RP11-418H16.1	-4.16	4.1e-05	0.00884	-0.26	-0.22	Bipolar disorder;	chr2:65522950	chr2:65623272~65628424:+
LIHC	cis	rs8005677	0.798	rs61977741	ENSG00000257285.4	RP11-298I3.1	4.16	4.1e-05	0.00884	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:22929609~22955562:+
LIHC	cis	rs529413	0.57	rs553000	ENSG00000259237.1	RP11-209E8.1	4.16	4.11e-05	0.00884	0.3	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr15:53242389	chr15:53116365~53129698:+
LIHC	cis	rs8005677	0.828	rs2295680	ENSG00000257285.4	RP11-298I3.1	-4.16	4.11e-05	0.00884	-0.22	-0.22	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:22929609~22955562:+
LIHC	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	4.16	4.11e-05	0.00884	0.2	0.22	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
LIHC	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	4.16	4.11e-05	0.00885	0.25	0.22	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
LIHC	cis	rs1115240	0.898	rs12323384	ENSG00000257842.4	NOVA1-AS1	4.16	4.11e-05	0.00885	0.2	0.22	Educational attainment (years of education);	chr14:26588286	chr14:26598412~26806467:+
LIHC	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-4.16	4.11e-05	0.00886	-0.18	-0.22	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
LIHC	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-4.16	4.11e-05	0.00886	-0.18	-0.22	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
LIHC	cis	rs28829049	0.536	rs12405382	ENSG00000270728.1	RP4-657E11.10	-4.16	4.11e-05	0.00886	-0.21	-0.22	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19222487	chr1:19297080~19297903:+
LIHC	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	4.16	4.11e-05	0.00886	0.23	0.22	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
LIHC	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-4.15	4.12e-05	0.00886	-0.24	-0.22	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
LIHC	cis	rs41369048	0.858	rs2807866	ENSG00000272823.1	RP11-295M18.6	-4.15	4.12e-05	0.00886	-0.36	-0.22	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907587	chr1:220828676~220829211:-
LIHC	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-4.15	4.12e-05	0.00886	-0.23	-0.22	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
LIHC	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-4.15	4.12e-05	0.00886	-0.23	-0.22	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
LIHC	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-4.15	4.12e-05	0.00886	-0.23	-0.22	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
LIHC	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	4.15	4.12e-05	0.00887	0.19	0.22	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
LIHC	cis	rs1005277	0.54	rs289638	ENSG00000099251.13	HSD17B7P2	4.15	4.12e-05	0.00887	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.54	rs7903942	ENSG00000099251.13	HSD17B7P2	-4.15	4.12e-05	0.00887	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38356380~38378505:+
LIHC	cis	rs9907295	0.605	rs11652192	ENSG00000270871.1	AC015849.19	4.15	4.12e-05	0.00887	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35833174	chr17:35816717~35830293:-
LIHC	cis	rs11098499	0.644	rs10050092	ENSG00000260091.1	RP11-33B1.4	-4.15	4.12e-05	0.00887	-0.15	-0.22	Corneal astigmatism;	chr4:119610930	chr4:119409333~119410233:+
LIHC	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	4.15	4.12e-05	0.00887	0.28	0.22	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
LIHC	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	4.15	4.13e-05	0.00888	0.27	0.22	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
LIHC	cis	rs8005677	0.649	rs11629120	ENSG00000279656.1	RP11-298I3.6	-4.15	4.13e-05	0.00888	-0.25	-0.22	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:23023083~23024217:-
LIHC	cis	rs2877649	0.793	rs75089419	ENSG00000258744.1	RP11-80A15.1	-4.15	4.13e-05	0.00889	-0.45	-0.22	Smooth-surface caries;	chr14:24505850	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs2073335	ENSG00000258744.1	RP11-80A15.1	-4.15	4.13e-05	0.00889	-0.45	-0.22	Smooth-surface caries;	chr14:24505955	chr14:24501594~24508688:+
LIHC	cis	rs617219	0.819	rs72766705	ENSG00000251675.1	CTC-458I2.2	-4.15	4.13e-05	0.00889	-0.25	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79266177	chr5:80128361~80143883:+
LIHC	cis	rs617219	0.819	rs2607140	ENSG00000251675.1	CTC-458I2.2	-4.15	4.13e-05	0.00889	-0.25	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79267404	chr5:80128361~80143883:+
LIHC	cis	rs9400467	0.528	rs10872066	ENSG00000271789.1	RP5-1112D6.7	-4.15	4.13e-05	0.00889	-0.21	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111297126~111298510:+
LIHC	cis	rs703842	0.642	rs10876994	ENSG00000270039.1	RP11-571M6.17	-4.15	4.13e-05	0.00889	-0.31	-0.22	Multiple sclerosis;	chr12:57670954	chr12:57803838~57804415:+
LIHC	cis	rs5758659	0.716	rs5758661	ENSG00000227370.1	RP4-669P10.19	-4.15	4.13e-05	0.0089	-0.24	-0.22	Cognitive function;	chr22:42228439	chr22:42132543~42132998:+
LIHC	cis	rs2598107	0.601	rs1975641	ENSG00000211698.2	TRGV4	-4.15	4.13e-05	0.0089	-0.26	-0.22	Dupuytren's disease;	chr7:37923748	chr7:38353715~38354517:-
LIHC	cis	rs2598107	0.601	rs3734952	ENSG00000211698.2	TRGV4	-4.15	4.13e-05	0.0089	-0.26	-0.22	Dupuytren's disease;	chr7:37925563	chr7:38353715~38354517:-
LIHC	cis	rs2749592	0.531	rs10764134	ENSG00000099251.13	HSD17B7P2	-4.15	4.13e-05	0.0089	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38356380~38378505:+
LIHC	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-4.15	4.14e-05	0.0089	-0.27	-0.22	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
LIHC	cis	rs2836974	0.965	rs9941894	ENSG00000255568.3	BRWD1-AS2	4.15	4.14e-05	0.0089	0.25	0.22	Cognitive function;	chr21:39262132	chr21:39313935~39314962:+
LIHC	cis	rs1023500	0.505	rs134886	ENSG00000226450.2	CYP2D8P	-4.15	4.14e-05	0.0089	-0.24	-0.22	Schizophrenia;	chr22:42277850	chr22:42149886~42155001:-
LIHC	cis	rs4682868	0.611	rs7614670	ENSG00000273328.4	RP11-141M3.6	4.15	4.14e-05	0.0089	0.22	0.22	Monocyte percentage of white cells;	chr3:42879906	chr3:42809414~42908105:+
LIHC	cis	rs4682868	0.581	rs7630617	ENSG00000273328.4	RP11-141M3.6	4.15	4.14e-05	0.0089	0.22	0.22	Monocyte percentage of white cells;	chr3:42880157	chr3:42809414~42908105:+
LIHC	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-4.15	4.14e-05	0.0089	-0.21	-0.22	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
LIHC	cis	rs2348418	0.864	rs7304776	ENSG00000247934.4	RP11-967K21.1	4.15	4.14e-05	0.0089	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28560634	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.864	rs11049714	ENSG00000247934.4	RP11-967K21.1	4.15	4.14e-05	0.0089	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28561162	chr12:28163298~28190738:-
LIHC	cis	rs9929218	0.551	rs2296408	ENSG00000260459.2	FTLP14	-4.15	4.14e-05	0.00891	-0.25	-0.22	Colorectal cancer;	chr16:68679920	chr16:68822587~68823070:+
LIHC	cis	rs16858210	0.647	rs67397446	ENSG00000234371.6	RPSAP31	4.15	4.14e-05	0.00891	0.32	0.22	Menopause (age at onset);	chr3:183900355	chr3:183884924~183888449:+
LIHC	cis	rs2115630	0.936	rs6496318	ENSG00000259295.5	CSPG4P12	-4.15	4.14e-05	0.00891	-0.26	-0.22	P wave terminal force;	chr15:84671998	chr15:85191438~85213905:+
LIHC	cis	rs2115630	0.902	rs8023276	ENSG00000259295.5	CSPG4P12	-4.15	4.14e-05	0.00891	-0.26	-0.22	P wave terminal force;	chr15:84676407	chr15:85191438~85213905:+
LIHC	cis	rs1005277	0.505	rs200935	ENSG00000275858.1	RP11-291L22.8	4.15	4.14e-05	0.00891	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.505	rs200936	ENSG00000275858.1	RP11-291L22.8	4.15	4.14e-05	0.00891	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.505	rs200937	ENSG00000275858.1	RP11-291L22.8	4.15	4.14e-05	0.00891	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38450738~38451069:-
LIHC	cis	rs11767557	1	rs11762262	ENSG00000229153.4	EPHA1-AS1	4.15	4.14e-05	0.00891	0.34	0.22	Alzheimer's disease (late onset);	chr7:143410783	chr7:143407813~143523449:+
LIHC	cis	rs2243480	1	rs437889	ENSG00000228409.4	CCT6P1	4.15	4.14e-05	0.00891	0.23	0.22	Diabetic kidney disease;	chr7:66044247	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs402418	ENSG00000228409.4	CCT6P1	4.15	4.14e-05	0.00891	0.23	0.22	Diabetic kidney disease;	chr7:66044482	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.803	rs423187	ENSG00000228409.4	CCT6P1	4.15	4.14e-05	0.00891	0.23	0.22	Diabetic kidney disease;	chr7:66044512	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs431318	ENSG00000228409.4	CCT6P1	4.15	4.14e-05	0.00891	0.23	0.22	Diabetic kidney disease;	chr7:66046610	chr7:65751142~65763354:+
LIHC	cis	rs794185	0.652	rs2819584	ENSG00000231249.1	ITPR1-AS1	-4.15	4.14e-05	0.00891	-0.24	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470566	chr3:4490891~4493163:-
LIHC	cis	rs75920871	0.609	rs11216187	ENSG00000254851.1	RP11-109L13.1	-4.15	4.15e-05	0.00891	-0.43	-0.22	Subjective well-being;	chr11:116916432	chr11:117135528~117138582:+
LIHC	cis	rs1023500	1	rs1023500	ENSG00000237037.8	NDUFA6-AS1	4.15	4.15e-05	0.00892	0.29	0.22	Schizophrenia;	chr22:41944840	chr22:42090931~42137742:+
LIHC	cis	rs617219	0.819	rs2607145	ENSG00000251675.1	CTC-458I2.2	-4.15	4.15e-05	0.00892	-0.25	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79256577	chr5:80128361~80143883:+
LIHC	cis	rs617219	0.819	rs2591389	ENSG00000251675.1	CTC-458I2.2	-4.15	4.15e-05	0.00892	-0.25	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79259385	chr5:80128361~80143883:+
LIHC	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	4.15	4.15e-05	0.00892	0.26	0.22	Height;	chr4:55529786	chr4:55363971~55395847:-
LIHC	cis	rs919433	0.929	rs4850788	ENSG00000231621.1	AC013264.2	4.15	4.15e-05	0.00892	0.2	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318216	chr2:197197991~197199273:+
LIHC	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	4.15	4.15e-05	0.00893	0.25	0.22	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
LIHC	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	4.15	4.15e-05	0.00893	0.36	0.22	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	4.15	4.15e-05	0.00893	0.36	0.22	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
LIHC	cis	rs1005277	0.505	rs200910	ENSG00000275858.1	RP11-291L22.8	4.15	4.15e-05	0.00893	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38450738~38451069:-
LIHC	cis	rs875971	0.545	rs75840613	ENSG00000273024.4	INTS4P2	-4.15	4.16e-05	0.00894	-0.25	-0.22	Aortic root size;	chr7:66376399	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.545	rs73148639	ENSG00000273024.4	INTS4P2	-4.15	4.16e-05	0.00894	-0.25	-0.22	Aortic root size;	chr7:66390342	chr7:65647864~65715661:+
LIHC	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	4.15	4.16e-05	0.00894	0.41	0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
LIHC	cis	rs17818399	0.781	rs12105006	ENSG00000239332.4	LINC01119	4.15	4.16e-05	0.00895	0.3	0.22	Height;	chr2:46635447	chr2:46816697~46859007:+
LIHC	cis	rs62246343	0.516	rs2251166	ENSG00000206573.7	THUMPD3-AS1	4.15	4.17e-05	0.00895	0.25	0.22	Fibrinogen levels;	chr3:9400053	chr3:9349689~9398579:-
LIHC	cis	rs72675573	0.852	rs778121	ENSG00000235612.1	RP1-158P9.1	-4.15	4.17e-05	0.00895	-0.28	-0.22	Monocyte count;	chr1:56154596	chr1:56145721~56155224:+
LIHC	cis	rs2749097	0.696	rs12129559	ENSG00000244256.3	RN7SL130P	-4.15	4.17e-05	0.00895	-0.28	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63680890	chr1:63655743~63656047:+
LIHC	cis	rs8177253	0.665	rs10935074	ENSG00000244062.1	RP11-404G16.2	4.15	4.17e-05	0.00896	0.22	0.22	Iron status biomarkers;	chr3:133722848	chr3:133760300~133762363:+
LIHC	cis	rs875971	0.545	rs73146609	ENSG00000228409.4	CCT6P1	-4.15	4.17e-05	0.00896	-0.18	-0.22	Aortic root size;	chr7:66302477	chr7:65751142~65763354:+
LIHC	cis	rs1577917	1	rs34581302	ENSG00000234155.1	RP11-30P6.6	4.15	4.17e-05	0.00896	0.29	0.22	Response to antipsychotic treatment;	chr6:85996230	chr6:85387219~85390186:-
LIHC	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-4.15	4.17e-05	0.00896	-0.22	-0.22	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
LIHC	cis	rs340849	0.901	rs340841	ENSG00000274895.1	RP11-478J18.2	4.15	4.17e-05	0.00896	0.23	0.22	Alzheimer's disease;	chr1:213951127	chr1:213983793~213986419:-
LIHC	cis	rs734999	0.545	rs10797436	ENSG00000225931.3	RP3-395M20.7	4.15	4.17e-05	0.00896	0.23	0.22	Ulcerative colitis;	chr1:2606910	chr1:2566410~2569888:+
LIHC	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-4.15	4.17e-05	0.00896	-0.25	-0.22	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
LIHC	cis	rs1005277	0.505	rs200939	ENSG00000275858.1	RP11-291L22.8	4.15	4.17e-05	0.00897	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38450738~38451069:-
LIHC	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-4.15	4.17e-05	0.00897	-0.24	-0.22	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
LIHC	cis	rs1005277	0.505	rs719569	ENSG00000275858.1	RP11-291L22.8	-4.15	4.17e-05	0.00897	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.522	rs200943	ENSG00000275858.1	RP11-291L22.8	4.15	4.17e-05	0.00897	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38450738~38451069:-
LIHC	cis	rs7131987	0.675	rs1436322	ENSG00000257176.2	RP11-996F15.2	4.15	4.18e-05	0.00897	0.24	0.22	QT interval;	chr12:29401872	chr12:29280418~29317848:-
LIHC	cis	rs860295	0.871	rs6688636	ENSG00000203761.5	MSTO2P	4.15	4.18e-05	0.00897	0.17	0.22	Body mass index;	chr1:155509106	chr1:155745829~155750137:+
LIHC	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-4.15	4.18e-05	0.00897	-0.28	-0.22	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
LIHC	cis	rs2877649	0.623	rs4555074	ENSG00000258744.1	RP11-80A15.1	-4.15	4.18e-05	0.00898	-0.45	-0.22	Smooth-surface caries;	chr14:24503136	chr14:24501594~24508688:+
LIHC	cis	rs901683	1	rs35968565	ENSG00000230869.1	CTGLF10P	-4.15	4.18e-05	0.00899	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45580748	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs75820736	ENSG00000230869.1	CTGLF10P	-4.15	4.18e-05	0.00899	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45580788	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496621	ENSG00000230869.1	CTGLF10P	-4.15	4.18e-05	0.00899	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45580900	chr10:45678692~45700532:+
LIHC	cis	rs2243480	1	rs59794892	ENSG00000228409.4	CCT6P1	4.15	4.18e-05	0.00899	0.24	0.22	Diabetic kidney disease;	chr7:65950886	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.803	rs36004293	ENSG00000228409.4	CCT6P1	4.15	4.18e-05	0.00899	0.24	0.22	Diabetic kidney disease;	chr7:65951525	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.803	rs35268390	ENSG00000228409.4	CCT6P1	4.15	4.18e-05	0.00899	0.24	0.22	Diabetic kidney disease;	chr7:65951549	chr7:65751142~65763354:+
LIHC	cis	rs755249	0.753	rs72663529	ENSG00000182109.6	RP11-69E11.4	4.15	4.19e-05	0.00899	0.22	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39522280~39546187:-
LIHC	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	4.15	4.19e-05	0.00899	0.25	0.22	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
LIHC	cis	rs7586970	0.583	rs35935664	ENSG00000224063.4	AC007319.1	4.15	4.19e-05	0.009	0.33	0.22	Coronary heart disease;	chr2:187531609	chr2:187003220~187554663:+
LIHC	cis	rs7586970	0.583	rs34893125	ENSG00000224063.4	AC007319.1	4.15	4.19e-05	0.009	0.33	0.22	Coronary heart disease;	chr2:187532612	chr2:187003220~187554663:+
LIHC	cis	rs7760535	0.735	rs240974	ENSG00000271789.1	RP5-1112D6.7	-4.15	4.19e-05	0.009	-0.21	-0.22	Metabolic traits;	chr6:111328113	chr6:111297126~111298510:+
LIHC	cis	rs11671005	0.735	rs12977592	ENSG00000269473.1	CTD-2619J13.19	4.15	4.2e-05	0.00902	0.34	0.22	Mean platelet volume;	chr19:58449689	chr19:58440448~58445849:+
LIHC	cis	rs4356975	0.932	rs12648830	ENSG00000250919.1	RP11-813N20.3	4.15	4.2e-05	0.00902	0.22	0.22	Obesity-related traits;	chr4:69075436	chr4:69027831~69044578:+
LIHC	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-4.15	4.2e-05	0.00902	-0.28	-0.22	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
LIHC	cis	rs4938303	0.633	rs12799441	ENSG00000254851.1	RP11-109L13.1	4.15	4.21e-05	0.00904	0.31	0.22	Triglycerides;	chr11:116687799	chr11:117135528~117138582:+
LIHC	cis	rs3020736	0.5	rs2413669	ENSG00000226450.2	CYP2D8P	-4.15	4.21e-05	0.00904	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs6002618	ENSG00000226450.2	CYP2D8P	-4.15	4.21e-05	0.00904	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42149886~42155001:-
LIHC	cis	rs1023500	0.551	rs61665536	ENSG00000226450.2	CYP2D8P	-4.15	4.21e-05	0.00904	-0.27	-0.22	Schizophrenia;	chr22:42116609	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs2413672	ENSG00000226450.2	CYP2D8P	-4.15	4.21e-05	0.00904	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs6002623	ENSG00000226450.2	CYP2D8P	-4.15	4.21e-05	0.00904	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs764481	ENSG00000226450.2	CYP2D8P	-4.15	4.21e-05	0.00904	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42149886~42155001:-
LIHC	cis	rs7893279	0.505	rs4748499	ENSG00000225527.1	RP11-383B4.4	4.15	4.21e-05	0.00904	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18621441	chr10:18531849~18533336:-
LIHC	cis	rs7893279	0.505	rs12769425	ENSG00000225527.1	RP11-383B4.4	4.15	4.21e-05	0.00904	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18622185	chr10:18531849~18533336:-
LIHC	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-4.15	4.22e-05	0.00904	-0.23	-0.22	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
LIHC	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-4.15	4.22e-05	0.00905	-0.17	-0.22	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
LIHC	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-4.15	4.22e-05	0.00905	-0.17	-0.22	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
LIHC	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-4.15	4.22e-05	0.00905	-0.17	-0.22	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
LIHC	cis	rs113084984	0.718	rs4669747	ENSG00000271952.1	RP11-245G13.2	-4.15	4.22e-05	0.00905	-0.27	-0.22	Breast cancer;	chr2:11544189	chr2:10878269~10885118:+
LIHC	cis	rs2243480	1	rs12698509	ENSG00000232546.1	RP11-458F8.1	-4.15	4.22e-05	0.00905	-0.24	-0.22	Diabetic kidney disease;	chr7:65953889	chr7:66848496~66858136:+
LIHC	cis	rs2744375	0.6	rs874646	ENSG00000261189.1	RP3-512B11.3	4.15	4.22e-05	0.00905	0.28	0.22	Resting heart rate;	chr6:7550458	chr6:7540451~7541338:-
LIHC	cis	rs17772222	0.917	rs58984912	ENSG00000258789.1	RP11-507K2.3	-4.15	4.22e-05	0.00905	-0.26	-0.22	Coronary artery calcification;	chr14:88698172	chr14:88551597~88552493:+
LIHC	cis	rs2243480	1	rs437889	ENSG00000232546.1	RP11-458F8.1	-4.15	4.22e-05	0.00906	-0.24	-0.22	Diabetic kidney disease;	chr7:66044247	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs402418	ENSG00000232546.1	RP11-458F8.1	-4.15	4.22e-05	0.00906	-0.24	-0.22	Diabetic kidney disease;	chr7:66044482	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.803	rs423187	ENSG00000232546.1	RP11-458F8.1	-4.15	4.22e-05	0.00906	-0.24	-0.22	Diabetic kidney disease;	chr7:66044512	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs431318	ENSG00000232546.1	RP11-458F8.1	-4.15	4.22e-05	0.00906	-0.24	-0.22	Diabetic kidney disease;	chr7:66046610	chr7:66848496~66858136:+
LIHC	cis	rs4578769	0.836	rs3936488	ENSG00000266850.1	RP11-370A5.1	4.15	4.22e-05	0.00906	0.26	0.22	Eosinophil percentage of white cells;	chr18:22874459	chr18:22723491~22907721:-
LIHC	cis	rs2299116	1	rs34276478	ENSG00000225264.3	ZNRF2P2	-4.15	4.22e-05	0.00906	-0.25	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28776481	chr7:29598795~29685255:-
LIHC	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	4.15	4.23e-05	0.00906	0.27	0.22	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
LIHC	cis	rs4578769	0.879	rs3863524	ENSG00000265943.1	RP11-739L10.1	4.15	4.23e-05	0.00906	0.28	0.22	Eosinophil percentage of white cells;	chr18:22881319	chr18:22699481~22933764:-
LIHC	cis	rs244293	0.831	rs11079147	ENSG00000275710.1	RP11-257O5.4	-4.15	4.23e-05	0.00906	-0.23	-0.22	Menarche (age at onset);	chr17:55017393	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.831	rs11079149	ENSG00000275710.1	RP11-257O5.4	-4.15	4.23e-05	0.00906	-0.23	-0.22	Menarche (age at onset);	chr17:55017685	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.795	rs11079151	ENSG00000275710.1	RP11-257O5.4	-4.15	4.23e-05	0.00906	-0.23	-0.22	Menarche (age at onset);	chr17:55018005	chr17:54964474~54964679:+
LIHC	cis	rs11098499	0.863	rs9997631	ENSG00000260091.1	RP11-33B1.4	-4.15	4.23e-05	0.00906	-0.16	-0.22	Corneal astigmatism;	chr4:119548840	chr4:119409333~119410233:+
LIHC	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
LIHC	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-4.15	4.23e-05	0.00906	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
LIHC	cis	rs4453827	0.563	rs10510766	ENSG00000271916.1	RP11-884K10.6	4.15	4.23e-05	0.00906	0.49	0.22	Blood protein levels;	chr3:53777314	chr3:53797764~53798019:-
LIHC	cis	rs9652601	0.779	rs725613	ENSG00000274038.1	RP11-66H6.4	-4.15	4.23e-05	0.00907	-0.26	-0.22	Systemic lupus erythematosus;	chr16:11075826	chr16:11056556~11057034:+
LIHC	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-4.15	4.23e-05	0.00908	-0.27	-0.22	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
LIHC	cis	rs2243480	0.708	rs35825036	ENSG00000232546.1	RP11-458F8.1	-4.15	4.24e-05	0.00908	-0.25	-0.22	Diabetic kidney disease;	chr7:66521515	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs13237037	ENSG00000232546.1	RP11-458F8.1	-4.15	4.24e-05	0.00908	-0.25	-0.22	Diabetic kidney disease;	chr7:66532895	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.901	rs13237344	ENSG00000232546.1	RP11-458F8.1	-4.15	4.24e-05	0.00908	-0.25	-0.22	Diabetic kidney disease;	chr7:66557269	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs1796228	ENSG00000232546.1	RP11-458F8.1	-4.15	4.24e-05	0.00908	-0.25	-0.22	Diabetic kidney disease;	chr7:66568097	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs1267820	ENSG00000232546.1	RP11-458F8.1	-4.15	4.24e-05	0.00908	-0.25	-0.22	Diabetic kidney disease;	chr7:66585308	chr7:66848496~66858136:+
LIHC	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-4.15	4.24e-05	0.00908	-0.17	-0.22	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
LIHC	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	4.15	4.24e-05	0.00908	0.22	0.22	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	4.15	4.24e-05	0.00909	0.27	0.22	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
LIHC	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	4.15	4.24e-05	0.00909	0.25	0.22	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
LIHC	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	4.15	4.24e-05	0.00909	0.25	0.22	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
LIHC	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-4.15	4.24e-05	0.00909	-0.26	-0.22	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
LIHC	cis	rs66887589	0.807	rs13134517	ENSG00000260091.1	RP11-33B1.4	-4.15	4.24e-05	0.00909	-0.14	-0.22	Diastolic blood pressure;	chr4:119484107	chr4:119409333~119410233:+
LIHC	cis	rs66887589	0.837	rs6534135	ENSG00000260091.1	RP11-33B1.4	-4.15	4.24e-05	0.00909	-0.14	-0.22	Diastolic blood pressure;	chr4:119485147	chr4:119409333~119410233:+
LIHC	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-4.15	4.25e-05	0.00909	-0.27	-0.22	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
LIHC	cis	rs1005277	0.505	rs13503	ENSG00000099251.13	HSD17B7P2	-4.15	4.25e-05	0.0091	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.505	rs7069702	ENSG00000099251.13	HSD17B7P2	-4.15	4.25e-05	0.0091	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38356380~38378505:+
LIHC	cis	rs4356975	0.83	rs6600868	ENSG00000250919.1	RP11-813N20.3	-4.15	4.25e-05	0.0091	-0.22	-0.22	Obesity-related traits;	chr4:69075923	chr4:69027831~69044578:+
LIHC	cis	rs11098499	0.913	rs12186259	ENSG00000245958.5	RP11-33B1.1	-4.15	4.25e-05	0.0091	-0.24	-0.22	Corneal astigmatism;	chr4:119230884	chr4:119454791~119552025:+
LIHC	cis	rs3845817	0.801	rs2438102	ENSG00000281920.1	RP11-418H16.1	-4.15	4.25e-05	0.0091	-0.26	-0.22	Bipolar disorder;	chr2:65530223	chr2:65623272~65628424:+
LIHC	cis	rs875971	0.545	rs2420612	ENSG00000228409.4	CCT6P1	-4.15	4.25e-05	0.0091	-0.18	-0.22	Aortic root size;	chr7:66536825	chr7:65751142~65763354:+
LIHC	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	4.15	4.25e-05	0.0091	0.26	0.22	Height;	chr4:55495262	chr4:55363971~55395847:-
LIHC	cis	rs11763353	0.593	rs6969348	ENSG00000235828.5	RPL36AP26	-4.15	4.25e-05	0.0091	-0.21	-0.22	Blood trace element (Zn levels);	chr7:15571007	chr7:15701435~15701752:-
LIHC	cis	rs2739330	0.796	rs2154594	ENSG00000206090.4	AP000350.7	-4.15	4.25e-05	0.00911	-0.26	-0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23939998~23942798:+
LIHC	cis	rs6449502	1	rs6869332	ENSG00000272308.1	RP11-231G3.1	4.15	4.25e-05	0.00911	0.32	0.22	Mean platelet volume;	chr5:60833534	chr5:60866457~60866935:-
LIHC	cis	rs9652601	0.779	rs9929994	ENSG00000274038.1	RP11-66H6.4	-4.15	4.25e-05	0.00911	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11084388	chr16:11056556~11057034:+
LIHC	cis	rs11651753	0.613	rs3096	ENSG00000264920.1	RP11-6N17.4	-4.15	4.25e-05	0.00911	-0.23	-0.22	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47952066	chr17:47891255~47895812:-
LIHC	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-4.15	4.26e-05	0.00912	-0.27	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
LIHC	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	4.15	4.26e-05	0.00912	0.28	0.22	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
LIHC	cis	rs17270561	0.525	rs10484432	ENSG00000272810.1	U91328.22	-4.15	4.26e-05	0.00912	-0.28	-0.22	Iron status biomarkers;	chr6:26008648	chr6:26013241~26013757:+
LIHC	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-4.15	4.26e-05	0.00913	-0.31	-0.22	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
LIHC	cis	rs1223397	0.651	rs641758	ENSG00000215022.6	RP1-257A7.4	-4.15	4.26e-05	0.00913	-0.23	-0.22	Blood pressure;	chr6:13300270	chr6:13264861~13295586:-
LIHC	cis	rs901683	1	rs78661209	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45579491	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12766764	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45584065	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35070150	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45584385	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs76469200	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45584585	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs79490183	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45584793	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35183191	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45585169	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34163035	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45585271	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12779637	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45585648	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12772102	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45585653	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35183751	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45585910	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34516867	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45586289	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35049879	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45586296	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs36102549	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45586595	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs4442500	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45587050	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35916836	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45587068	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12763285	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45587421	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71499567	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45588508	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35506889	ENSG00000230869.1	CTGLF10P	-4.15	4.26e-05	0.00913	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45589189	chr10:45678692~45700532:+
LIHC	cis	rs10129255	0.913	rs10140943	ENSG00000224373.3	IGHV4-59	4.15	4.27e-05	0.00913	0.18	0.22	Kawasaki disease;	chr14:106767441	chr14:106627249~106627825:-
LIHC	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	4.15	4.27e-05	0.00913	0.2	0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
LIHC	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	4.15	4.27e-05	0.00914	0.26	0.22	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
LIHC	cis	rs295490	0.748	rs80175427	ENSG00000272656.1	RP11-219D15.3	4.15	4.27e-05	0.00914	0.63	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139498904	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs17494482	ENSG00000272656.1	RP11-219D15.3	4.15	4.27e-05	0.00914	0.63	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499028	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs2882080	ENSG00000272656.1	RP11-219D15.3	4.15	4.27e-05	0.00914	0.63	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499109	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs2882081	ENSG00000272656.1	RP11-219D15.3	4.15	4.27e-05	0.00914	0.63	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499427	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs7428398	ENSG00000272656.1	RP11-219D15.3	4.15	4.27e-05	0.00914	0.63	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499687	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs77398474	ENSG00000272656.1	RP11-219D15.3	4.15	4.27e-05	0.00914	0.63	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139502307	chr3:139349024~139349371:-
LIHC	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-4.15	4.27e-05	0.00914	-0.21	-0.22	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
LIHC	cis	rs2348418	0.864	rs7304540	ENSG00000247934.4	RP11-967K21.1	4.15	4.27e-05	0.00915	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28560489	chr12:28163298~28190738:-
LIHC	cis	rs7893279	0.505	rs11812341	ENSG00000225527.1	RP11-383B4.4	4.15	4.28e-05	0.00915	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18607994	chr10:18531849~18533336:-
LIHC	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-4.15	4.28e-05	0.00916	-0.29	-0.22	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
LIHC	cis	rs72675573	0.852	rs12133795	ENSG00000235612.1	RP1-158P9.1	-4.15	4.28e-05	0.00916	-0.29	-0.22	Monocyte count;	chr1:56126545	chr1:56145721~56155224:+
LIHC	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	4.15	4.28e-05	0.00916	0.16	0.22	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
LIHC	cis	rs10912872	0.531	rs12407579	ENSG00000231424.2	RP1-45C12.1	4.15	4.29e-05	0.00917	0.23	0.22	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171371553	chr1:171247580~171251794:-
LIHC	cis	rs66887589	0.774	rs9307477	ENSG00000260091.1	RP11-33B1.4	-4.14	4.29e-05	0.00917	-0.14	-0.22	Diastolic blood pressure;	chr4:119500654	chr4:119409333~119410233:+
LIHC	cis	rs9300255	0.596	rs10773002	ENSG00000256092.2	RP13-942N8.1	-4.14	4.29e-05	0.00918	-0.26	-0.22	Neutrophil percentage of white cells;	chr12:123262414	chr12:123363868~123366113:+
LIHC	cis	rs2749592	0.918	rs4934590	ENSG00000263064.2	RP11-291L22.7	-4.14	4.3e-05	0.00919	-0.24	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37588641	chr10:38448689~38448949:+
LIHC	cis	rs901683	1	rs71496623	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45590418	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496624	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45590501	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.867	rs34144887	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45590945	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.867	rs71496625	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45591201	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs36100685	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45591406	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34574958	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45591592	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12779005	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45591926	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34539215	ENSG00000230869.1	CTGLF10P	-4.14	4.3e-05	0.00919	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45591930	chr10:45678692~45700532:+
LIHC	cis	rs7615952	0.546	rs2979307	ENSG00000171084.14	FAM86JP	-4.14	4.3e-05	0.0092	-0.37	-0.22	Blood pressure (smoking interaction);	chr3:125590730	chr3:125916620~125930024:+
LIHC	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-4.14	4.31e-05	0.0092	-0.26	-0.22	Height;	chr6:109405874	chr6:109382795~109383666:+
LIHC	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	4.14	4.31e-05	0.0092	0.22	0.22	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
LIHC	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	4.14	4.31e-05	0.0092	0.21	0.22	Height;	chr5:37481330	chr5:36666214~36725195:-
LIHC	cis	rs73193808	0.639	rs7277858	ENSG00000212479.2	U3	4.14	4.31e-05	0.0092	0.25	0.22	Coronary artery disease;	chr21:29180556	chr21:29180425~29180639:-
LIHC	cis	rs11668505	0.965	rs12981169	ENSG00000259108.2	CTD-3098H1.2	4.14	4.31e-05	0.00921	0.28	0.22	Lung function (FVC);	chr19:47848623	chr19:47863483~47865341:-
LIHC	cis	rs2790457	0.958	rs2532741	ENSG00000254635.4	WAC-AS1	-4.14	4.31e-05	0.00921	-0.21	-0.22	Multiple myeloma;	chr10:28574879	chr10:28522652~28532743:-
LIHC	cis	rs2070488	0.931	rs7630012	ENSG00000229589.1	ACVR2B-AS1	-4.14	4.31e-05	0.00921	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38510759	chr3:38451027~38454820:-
LIHC	cis	rs3096299	0.685	rs4785571	ENSG00000261118.1	RP11-104N10.1	4.14	4.32e-05	0.00922	0.2	0.22	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89492017~89504460:-
LIHC	cis	rs4356203	0.905	rs7938820	ENSG00000260196.1	RP1-239B22.5	4.14	4.32e-05	0.00922	0.26	0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17380649~17383531:+
LIHC	cis	rs3020736	0.519	rs5996116	ENSG00000226450.2	CYP2D8P	-4.14	4.32e-05	0.00922	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42149886~42155001:-
LIHC	cis	rs12554020	0.892	rs75678521	ENSG00000227603.1	RP11-165J3.6	4.14	4.32e-05	0.00922	0.31	0.22	Schizophrenia;	chr9:93600744	chr9:93435332~93437121:-
LIHC	cis	rs755249	0.567	rs61782157	ENSG00000182109.6	RP11-69E11.4	4.14	4.32e-05	0.00922	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39522280~39546187:-
LIHC	cis	rs7893279	0.505	rs11815228	ENSG00000225527.1	RP11-383B4.4	4.14	4.32e-05	0.00923	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18590899	chr10:18531849~18533336:-
LIHC	cis	rs938554	0.513	rs4529048	ENSG00000250413.1	RP11-448G15.1	-4.14	4.33e-05	0.00923	-0.3	-0.22	Blood metabolite levels;	chr4:9995488	chr4:10006482~10009725:+
LIHC	cis	rs244293	0.657	rs4829	ENSG00000275710.1	RP11-257O5.4	4.14	4.33e-05	0.00923	0.25	0.22	Menarche (age at onset);	chr17:54961954	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.73	rs3213757	ENSG00000275710.1	RP11-257O5.4	4.14	4.33e-05	0.00923	0.25	0.22	Menarche (age at onset);	chr17:54964496	chr17:54964474~54964679:+
LIHC	cis	rs1577917	1	rs1999852	ENSG00000234155.1	RP11-30P6.6	4.14	4.33e-05	0.00924	0.28	0.22	Response to antipsychotic treatment;	chr6:85996020	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs35797755	ENSG00000234155.1	RP11-30P6.6	4.14	4.33e-05	0.00924	0.28	0.22	Response to antipsychotic treatment;	chr6:85996836	chr6:85387219~85390186:-
LIHC	cis	rs9896933	0.723	rs7224189	ENSG00000263063.1	RP11-388C12.1	-4.14	4.33e-05	0.00924	-0.29	-0.22	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82824351	chr17:82713908~82716255:-
LIHC	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	4.14	4.33e-05	0.00924	0.29	0.22	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
LIHC	cis	rs9907295	0.581	rs4251751	ENSG00000270871.1	AC015849.19	4.14	4.33e-05	0.00924	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35823733	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.748	rs4251752	ENSG00000270871.1	AC015849.19	4.14	4.33e-05	0.00924	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35823900	chr17:35816717~35830293:-
LIHC	cis	rs7044106	0.762	rs10739570	ENSG00000238181.2	AHCYP2	-4.14	4.33e-05	0.00924	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120720673~120721972:+
LIHC	cis	rs1247318	1	rs1247319	ENSG00000243831.1	RP1-81D8.4	4.14	4.33e-05	0.00924	0.3	0.22	Aging;	chr6:160912828	chr6:160666228~160676523:-
LIHC	cis	rs748404	0.587	rs690276	ENSG00000166763.7	STRCP1	4.14	4.33e-05	0.00925	0.27	0.22	Lung cancer;	chr15:43412360	chr15:43699488~43718184:-
LIHC	cis	rs1005277	0.522	rs289649	ENSG00000099251.13	HSD17B7P2	4.14	4.34e-05	0.00925	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38356380~38378505:+
LIHC	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-4.14	4.34e-05	0.00926	-0.27	-0.22	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
LIHC	cis	rs9976767	0.637	rs11909930	ENSG00000225218.1	AP001628.6	-4.14	4.34e-05	0.00926	-0.21	-0.22	Type 1 diabetes;	chr21:42402091	chr21:42831040~42836477:-
LIHC	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	4.14	4.34e-05	0.00926	0.25	0.22	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
LIHC	cis	rs6445975	0.666	rs9311674	ENSG00000272360.1	RP11-359I18.5	4.14	4.34e-05	0.00926	0.29	0.22	Systemic lupus erythematosus;	chr3:58404975	chr3:58490830~58491291:-
LIHC	cis	rs804280	0.525	rs1004712	ENSG00000255394.4	C8orf49	4.14	4.34e-05	0.00926	0.26	0.22	Myopia (pathological);	chr8:11764784	chr8:11761256~11763223:+
LIHC	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-4.14	4.34e-05	0.00926	-0.22	-0.22	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
LIHC	cis	rs921968	0.565	rs7586384	ENSG00000272555.1	RP11-459I19.1	-4.14	4.34e-05	0.00926	-0.23	-0.22	Mean corpuscular hemoglobin concentration;	chr2:218718174	chr2:218818690~218819144:+
LIHC	cis	rs340849	0.617	rs17710847	ENSG00000274895.1	RP11-478J18.2	-4.14	4.34e-05	0.00927	-0.25	-0.22	Alzheimer's disease;	chr1:213929776	chr1:213983793~213986419:-
LIHC	cis	rs7044106	0.762	rs1158554	ENSG00000238181.2	AHCYP2	-4.14	4.34e-05	0.00927	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120720673~120721972:+
LIHC	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-4.14	4.34e-05	0.00927	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-4.14	4.34e-05	0.00927	-0.22	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
LIHC	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	4.14	4.35e-05	0.00928	0.25	0.22	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
LIHC	cis	rs875971	0.545	rs11767262	ENSG00000273024.4	INTS4P2	-4.14	4.35e-05	0.00928	-0.25	-0.22	Aortic root size;	chr7:66302237	chr7:65647864~65715661:+
LIHC	cis	rs4356203	0.811	rs214920	ENSG00000260196.1	RP1-239B22.5	-4.14	4.35e-05	0.00928	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17216402	chr11:17380649~17383531:+
LIHC	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-4.14	4.35e-05	0.00928	-0.23	-0.22	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
LIHC	cis	rs1075265	0.704	rs10084374	ENSG00000272156.1	RP11-477N3.1	-4.14	4.35e-05	0.00929	-0.25	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54082554~54085066:+
LIHC	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	4.14	4.36e-05	0.0093	0.31	0.22	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
LIHC	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	4.14	4.36e-05	0.0093	0.31	0.22	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
LIHC	cis	rs7560272	0.538	rs2001436	ENSG00000204872.3	NAT8B	-4.14	4.36e-05	0.0093	-0.3	-0.22	Schizophrenia;	chr2:73701838	chr2:73700576~73701340:-
LIHC	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	4.14	4.36e-05	0.0093	0.23	0.22	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
LIHC	cis	rs2243480	1	rs56291018	ENSG00000232546.1	RP11-458F8.1	-4.14	4.36e-05	0.00931	-0.25	-0.22	Diabetic kidney disease;	chr7:65925352	chr7:66848496~66858136:+
LIHC	cis	rs2744375	0.6	rs2744371	ENSG00000261189.1	RP3-512B11.3	4.14	4.37e-05	0.00931	0.27	0.22	Resting heart rate;	chr6:7553941	chr6:7540451~7541338:-
LIHC	cis	rs2744375	0.6	rs2744368	ENSG00000261189.1	RP3-512B11.3	4.14	4.37e-05	0.00931	0.28	0.22	Resting heart rate;	chr6:7553157	chr6:7540451~7541338:-
LIHC	cis	rs2744375	0.6	rs2744369	ENSG00000261189.1	RP3-512B11.3	4.14	4.37e-05	0.00931	0.28	0.22	Resting heart rate;	chr6:7553237	chr6:7540451~7541338:-
LIHC	cis	rs12554020	0.582	rs2001609	ENSG00000227603.1	RP11-165J3.6	4.14	4.37e-05	0.00931	0.38	0.22	Schizophrenia;	chr9:93633081	chr9:93435332~93437121:-
LIHC	cis	rs875971	0.545	rs1796226	ENSG00000228409.4	CCT6P1	-4.14	4.37e-05	0.00932	-0.18	-0.22	Aortic root size;	chr7:66622723	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.54	rs35510581	ENSG00000164669.11	INTS4P1	4.14	4.38e-05	0.00933	0.3	0.22	Aortic root size;	chr7:66113790	chr7:65141225~65234216:+
LIHC	cis	rs11098499	0.954	rs12505469	ENSG00000260091.1	RP11-33B1.4	-4.14	4.38e-05	0.00933	-0.16	-0.22	Corneal astigmatism;	chr4:119328430	chr4:119409333~119410233:+
LIHC	cis	rs1153858	1	rs9783731	ENSG00000259433.2	CTD-2651B20.4	4.14	4.38e-05	0.00934	0.29	0.22	Homoarginine levels;	chr15:45350686	chr15:45330209~45332634:-
LIHC	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-4.14	4.38e-05	0.00934	-0.23	-0.22	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
LIHC	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-4.14	4.38e-05	0.00934	-0.26	-0.22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
LIHC	cis	rs2762353	0.603	rs9393670	ENSG00000242387.1	HIST1H2APS2	-4.14	4.38e-05	0.00934	-0.25	-0.22	Blood metabolite levels;	chr6:25788833	chr6:25882026~25882395:-
LIHC	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-4.14	4.39e-05	0.00934	-0.27	-0.22	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-4.14	4.39e-05	0.00934	-0.27	-0.22	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
LIHC	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-4.14	4.39e-05	0.00934	-0.27	-0.22	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
LIHC	cis	rs56080343	0.515	rs73222056	ENSG00000275759.1	RP11-131L12.3	-4.14	4.39e-05	0.00934	-0.31	-0.22	Neuroticism;	chr12:118215875	chr12:118428281~118428870:+
LIHC	cis	rs11098499	0.863	rs7699064	ENSG00000260091.1	RP11-33B1.4	4.14	4.39e-05	0.00934	0.16	0.22	Corneal astigmatism;	chr4:119507154	chr4:119409333~119410233:+
LIHC	cis	rs2735413	0.918	rs7197254	ENSG00000276007.1	RP11-358L22.3	-4.14	4.39e-05	0.00934	-0.25	-0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78029456	chr16:78123243~78124332:+
LIHC	cis	rs17818399	0.548	rs1989720	ENSG00000239332.4	LINC01119	-4.14	4.39e-05	0.00935	-0.29	-0.22	Height;	chr2:46627225	chr2:46816697~46859007:+
LIHC	cis	rs12291225	0.883	rs1864658	ENSG00000251991.1	RNU7-49P	-4.14	4.39e-05	0.00935	-0.23	-0.22	Sense of smell;	chr11:14234898	chr11:14478892~14478953:+
LIHC	cis	rs17772222	0.917	rs17188207	ENSG00000258789.1	RP11-507K2.3	-4.14	4.39e-05	0.00935	-0.26	-0.22	Coronary artery calcification;	chr14:88699579	chr14:88551597~88552493:+
LIHC	cis	rs3812762	0.879	rs10769952	ENSG00000254860.4	TMEM9B-AS1	-4.14	4.39e-05	0.00935	-0.23	-0.22	Hypospadias;	chr11:8755153	chr11:8964675~8977527:+
LIHC	cis	rs755249	0.567	rs61779285	ENSG00000182109.6	RP11-69E11.4	4.14	4.39e-05	0.00935	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs3768301	ENSG00000182109.6	RP11-69E11.4	4.14	4.39e-05	0.00935	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39522280~39546187:-
LIHC	cis	rs10510102	0.872	rs116521083	ENSG00000273891.1	RP11-500G22.5	4.14	4.39e-05	0.00936	0.29	0.22	Breast cancer;	chr10:121950611	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.748	rs4589226	ENSG00000273891.1	RP11-500G22.5	4.14	4.39e-05	0.00936	0.29	0.22	Breast cancer;	chr10:121951073	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.81	rs34738294	ENSG00000273891.1	RP11-500G22.5	4.14	4.39e-05	0.00936	0.29	0.22	Breast cancer;	chr10:121951357	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12258234	ENSG00000273891.1	RP11-500G22.5	4.14	4.39e-05	0.00936	0.29	0.22	Breast cancer;	chr10:121952828	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.515	rs11200285	ENSG00000273891.1	RP11-500G22.5	4.14	4.39e-05	0.00936	0.29	0.22	Breast cancer;	chr10:121953931	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs75831447	ENSG00000273891.1	RP11-500G22.5	4.14	4.39e-05	0.00936	0.29	0.22	Breast cancer;	chr10:121953963	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.63	rs79960726	ENSG00000273891.1	RP11-500G22.5	4.14	4.39e-05	0.00936	0.29	0.22	Breast cancer;	chr10:121954358	chr10:121965764~121967700:+
LIHC	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	4.14	4.4e-05	0.00936	0.24	0.22	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
LIHC	cis	rs4266144	1	rs4266144	ENSG00000243176.4	RP11-550I24.2	-4.14	4.4e-05	0.00937	-0.28	-0.22	Coronary artery disease;	chr3:157134803	chr3:157175223~157381265:+
LIHC	cis	rs7474896	0.583	rs12783272	ENSG00000263064.2	RP11-291L22.7	4.14	4.4e-05	0.00937	0.26	0.22	Obesity (extreme);	chr10:37735957	chr10:38448689~38448949:+
LIHC	cis	rs709400	0.859	rs942863	ENSG00000258914.1	CTD-2134A5.3	4.14	4.4e-05	0.00937	0.32	0.22	Body mass index;	chr14:103554931	chr14:103875055~103877478:+
LIHC	cis	rs7412746	0.563	rs3768013	ENSG00000231073.1	RP11-316M1.3	4.14	4.4e-05	0.00937	0.22	0.22	Melanoma;	chr1:150842935	chr1:150973123~150975534:+
LIHC	cis	rs6442522	0.737	rs905640	ENSG00000249786.6	EAF1-AS1	4.14	4.4e-05	0.00937	0.25	0.22	Uric acid levels;	chr3:15454333	chr3:15436171~15455940:-
LIHC	cis	rs5742933	0.744	rs12693557	ENSG00000253559.1	OSGEPL1-AS1	4.14	4.4e-05	0.00937	0.29	0.22	Ferritin levels;	chr2:189726211	chr2:189762704~189765556:+
LIHC	cis	rs5742933	0.817	rs13035966	ENSG00000253559.1	OSGEPL1-AS1	4.14	4.4e-05	0.00937	0.29	0.22	Ferritin levels;	chr2:189726507	chr2:189762704~189765556:+
LIHC	cis	rs7893279	0.505	rs2171922	ENSG00000225527.1	RP11-383B4.4	4.14	4.4e-05	0.00937	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18646977	chr10:18531849~18533336:-
LIHC	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-4.14	4.4e-05	0.00937	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
LIHC	cis	rs2390582	0.607	rs34627995	ENSG00000231613.1	RP5-943J3.1	4.14	4.41e-05	0.00938	0.45	0.22	Coronary artery calcification;	chr1:90302369	chr1:89788914~89790492:+
LIHC	cis	rs960902	0.648	rs11124584	ENSG00000213553.4	RPLP0P6	4.14	4.41e-05	0.00938	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37484714	chr2:38481851~38482804:+
LIHC	cis	rs960902	0.648	rs11124585	ENSG00000213553.4	RPLP0P6	4.14	4.41e-05	0.00938	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37484749	chr2:38481851~38482804:+
LIHC	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	4.14	4.41e-05	0.00938	0.18	0.22	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	4.14	4.41e-05	0.00938	0.18	0.22	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	4.14	4.41e-05	0.00938	0.18	0.22	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
LIHC	cis	rs2348418	0.864	rs6487689	ENSG00000247934.4	RP11-967K21.1	4.14	4.41e-05	0.00938	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28560101	chr12:28163298~28190738:-
LIHC	cis	rs11733284	0.894	rs321630	ENSG00000259959.1	RP11-121C2.2	4.14	4.41e-05	0.00939	0.2	0.22	Gout;Renal underexcretion gout;	chr4:48016153	chr4:47840122~47844339:-
LIHC	cis	rs11733284	0.963	rs321631	ENSG00000259959.1	RP11-121C2.2	4.14	4.41e-05	0.00939	0.2	0.22	Gout;Renal underexcretion gout;	chr4:48016212	chr4:47840122~47844339:-
LIHC	cis	rs875971	0.545	rs6969224	ENSG00000228409.4	CCT6P1	-4.14	4.41e-05	0.00939	-0.18	-0.22	Aortic root size;	chr7:66370011	chr7:65751142~65763354:+
LIHC	cis	rs2749592	0.55	rs10764135	ENSG00000275858.1	RP11-291L22.8	-4.14	4.41e-05	0.00939	-0.24	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38450738~38451069:-
LIHC	cis	rs2749592	0.55	rs12255038	ENSG00000275858.1	RP11-291L22.8	-4.14	4.41e-05	0.00939	-0.24	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38450738~38451069:-
LIHC	cis	rs2749592	0.505	rs7915670	ENSG00000275858.1	RP11-291L22.8	-4.14	4.41e-05	0.00939	-0.24	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38450738~38451069:-
LIHC	cis	rs1115240	0.785	rs12588828	ENSG00000257842.4	NOVA1-AS1	-4.14	4.41e-05	0.00939	-0.2	-0.22	Educational attainment (years of education);	chr14:26594587	chr14:26598412~26806467:+
LIHC	cis	rs8005677	0.828	rs12437151	ENSG00000257285.4	RP11-298I3.1	4.14	4.42e-05	0.0094	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:22929609~22955562:+
LIHC	cis	rs2243480	1	rs73142162	ENSG00000232546.1	RP11-458F8.1	-4.14	4.42e-05	0.0094	-0.25	-0.22	Diabetic kidney disease;	chr7:65909309	chr7:66848496~66858136:+
LIHC	cis	rs10510102	0.872	rs12240306	ENSG00000273891.1	RP11-500G22.5	4.14	4.42e-05	0.0094	0.29	0.22	Breast cancer;	chr10:121963391	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12240308	ENSG00000273891.1	RP11-500G22.5	4.14	4.42e-05	0.0094	0.29	0.22	Breast cancer;	chr10:121963407	chr10:121965764~121967700:+
LIHC	cis	rs10129255	1	rs10129319	ENSG00000224373.3	IGHV4-59	4.14	4.42e-05	0.0094	0.17	0.22	Kawasaki disease;	chr14:106767996	chr14:106627249~106627825:-
LIHC	cis	rs4356975	0.83	rs4235114	ENSG00000250919.1	RP11-813N20.3	-4.14	4.42e-05	0.00941	-0.22	-0.22	Obesity-related traits;	chr4:69056953	chr4:69027831~69044578:+
LIHC	cis	rs6445975	0.666	rs11130629	ENSG00000272360.1	RP11-359I18.5	4.14	4.43e-05	0.00941	0.3	0.22	Systemic lupus erythematosus;	chr3:58366872	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.572	rs7642018	ENSG00000272360.1	RP11-359I18.5	4.14	4.43e-05	0.00941	0.3	0.22	Systemic lupus erythematosus;	chr3:58367536	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.666	rs9867320	ENSG00000272360.1	RP11-359I18.5	4.14	4.43e-05	0.00941	0.3	0.22	Systemic lupus erythematosus;	chr3:58369546	chr3:58490830~58491291:-
LIHC	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-4.14	4.43e-05	0.00941	-0.27	-0.22	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
LIHC	cis	rs260461	0.92	rs79259289	ENSG00000268516.2	CTD-3138B18.5	-4.14	4.43e-05	0.00941	-0.23	-0.22	Attention deficit hyperactivity disorder;	chr19:58240891	chr19:58257270~58278808:-
LIHC	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-4.14	4.43e-05	0.00942	-0.3	-0.22	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
LIHC	cis	rs4356975	0.83	rs6600865	ENSG00000250919.1	RP11-813N20.3	-4.14	4.43e-05	0.00943	-0.22	-0.22	Obesity-related traits;	chr4:69057904	chr4:69027831~69044578:+
LIHC	cis	rs2762353	0.718	rs1165207	ENSG00000242387.1	HIST1H2APS2	4.14	4.43e-05	0.00943	0.25	0.22	Blood metabolite levels;	chr6:25865038	chr6:25882026~25882395:-
LIHC	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-4.14	4.43e-05	0.00943	-0.26	-0.22	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
LIHC	cis	rs2036707	1	rs58806855	ENSG00000277246.1	RP11-153I24.4	-4.14	4.43e-05	0.00943	-0.39	-0.22	Obesity-related traits;	chr13:107831721	chr13:108267320~108267734:+
LIHC	cis	rs901683	1	rs12761573	ENSG00000230869.1	CTGLF10P	-4.14	4.44e-05	0.00943	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45584069	chr10:45678692~45700532:+
LIHC	cis	rs919433	0.927	rs6759834	ENSG00000231621.1	AC013264.2	4.14	4.44e-05	0.00943	0.2	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197340136	chr2:197197991~197199273:+
LIHC	cis	rs875971	0.545	rs2279757	ENSG00000228409.4	CCT6P1	-4.14	4.44e-05	0.00943	-0.18	-0.22	Aortic root size;	chr7:66363676	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs11766183	ENSG00000228409.4	CCT6P1	-4.14	4.44e-05	0.00943	-0.18	-0.22	Aortic root size;	chr7:66374173	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs1065265	ENSG00000228409.4	CCT6P1	-4.14	4.44e-05	0.00943	-0.18	-0.22	Aortic root size;	chr7:66376216	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs7811204	ENSG00000228409.4	CCT6P1	-4.14	4.44e-05	0.00943	-0.18	-0.22	Aortic root size;	chr7:66387213	chr7:65751142~65763354:+
LIHC	cis	rs5769707	0.967	rs5769698	ENSG00000279345.1	RP3-522J7.7	-4.14	4.44e-05	0.00944	-0.19	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49805452~49807208:+
LIHC	cis	rs11098499	1	rs13116504	ENSG00000260091.1	RP11-33B1.4	-4.14	4.44e-05	0.00944	-0.16	-0.22	Corneal astigmatism;	chr4:119288257	chr4:119409333~119410233:+
LIHC	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	4.14	4.44e-05	0.00944	0.27	0.22	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
LIHC	cis	rs1165668	0.816	rs1866069	ENSG00000257327.1	RP11-650K20.3	-4.14	4.44e-05	0.00944	-0.25	-0.22	Coronary heart disease (SNP X SNP interaction);	chr12:103916767	chr12:103841451~103844664:+
LIHC	cis	rs10761256	0.835	rs10761255	ENSG00000227603.1	RP11-165J3.6	4.14	4.44e-05	0.00944	0.26	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr9:93670902	chr9:93435332~93437121:-
LIHC	cis	rs1115240	0.947	rs7140993	ENSG00000257842.4	NOVA1-AS1	4.14	4.44e-05	0.00944	0.2	0.22	Educational attainment (years of education);	chr14:26637960	chr14:26598412~26806467:+
LIHC	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	4.14	4.45e-05	0.00945	0.18	0.22	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
LIHC	cis	rs9595908	0.746	rs7985640	ENSG00000212293.1	SNORA16	4.14	4.45e-05	0.00946	0.25	0.22	Body mass index;	chr13:32698228	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9591252	ENSG00000212293.1	SNORA16	4.14	4.45e-05	0.00946	0.25	0.22	Body mass index;	chr13:32698297	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596083	ENSG00000212293.1	SNORA16	4.14	4.45e-05	0.00946	0.25	0.22	Body mass index;	chr13:32700494	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs4942829	ENSG00000212293.1	SNORA16	4.14	4.45e-05	0.00946	0.25	0.22	Body mass index;	chr13:32708994	chr13:32420390~32420516:-
LIHC	cis	rs734999	0.545	rs10910105	ENSG00000225931.3	RP3-395M20.7	4.14	4.45e-05	0.00946	0.23	0.22	Ulcerative colitis;	chr1:2606770	chr1:2566410~2569888:+
LIHC	cis	rs734999	0.545	rs10910106	ENSG00000225931.3	RP3-395M20.7	4.14	4.45e-05	0.00946	0.23	0.22	Ulcerative colitis;	chr1:2607447	chr1:2566410~2569888:+
LIHC	cis	rs6433895	0.677	rs34825850	ENSG00000236153.1	AC104076.3	-4.14	4.45e-05	0.00946	-0.31	-0.22	Lymphocyte counts;	chr2:181140599	chr2:180979427~180980090:-
LIHC	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-4.14	4.46e-05	0.00946	-0.24	-0.22	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
LIHC	cis	rs17376456	0.877	rs12109629	ENSG00000251023.1	RP11-549J18.1	-4.14	4.46e-05	0.00947	-0.46	-0.22	Diabetic retinopathy;	chr5:94023997	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs12153501	ENSG00000251023.1	RP11-549J18.1	-4.14	4.46e-05	0.00947	-0.46	-0.22	Diabetic retinopathy;	chr5:94025161	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs12153506	ENSG00000251023.1	RP11-549J18.1	-4.14	4.46e-05	0.00947	-0.46	-0.22	Diabetic retinopathy;	chr5:94025248	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs10078194	ENSG00000251023.1	RP11-549J18.1	-4.14	4.46e-05	0.00947	-0.46	-0.22	Diabetic retinopathy;	chr5:94028605	chr5:93860669~93863825:-
LIHC	cis	rs6496044	0.507	rs410522	ENSG00000259630.2	CTD-2262B20.1	4.14	4.46e-05	0.00947	0.23	0.22	Interstitial lung disease;	chr15:85663813	chr15:85415228~85415633:+
LIHC	cis	rs73198271	0.813	rs56007835	ENSG00000253893.2	FAM85B	4.14	4.46e-05	0.00947	0.34	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8167819~8226614:-
LIHC	cis	rs8177253	0.665	rs12639304	ENSG00000244062.1	RP11-404G16.2	4.14	4.46e-05	0.00947	0.22	0.22	Iron status biomarkers;	chr3:133722750	chr3:133760300~133762363:+
LIHC	cis	rs6745190	0.512	rs13026070	ENSG00000236153.1	AC104076.3	-4.14	4.46e-05	0.00947	-0.31	-0.22	White blood cell count;	chr2:181126695	chr2:180979427~180980090:-
LIHC	cis	rs6745190	0.557	rs13031518	ENSG00000236153.1	AC104076.3	-4.14	4.46e-05	0.00947	-0.31	-0.22	White blood cell count;	chr2:181127032	chr2:180979427~180980090:-
LIHC	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	4.14	4.46e-05	0.00948	0.21	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
LIHC	cis	rs4356975	0.83	rs4235113	ENSG00000250919.1	RP11-813N20.3	-4.14	4.46e-05	0.00948	-0.22	-0.22	Obesity-related traits;	chr4:69056739	chr4:69027831~69044578:+
LIHC	cis	rs4578769	0.765	rs11662489	ENSG00000266850.1	RP11-370A5.1	-4.14	4.46e-05	0.00948	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22816959	chr18:22723491~22907721:-
LIHC	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	4.14	4.46e-05	0.00948	0.26	0.22	Height;	chr4:55493557	chr4:55363971~55395847:-
LIHC	cis	rs4650994	0.524	rs2811299	ENSG00000273384.1	RP5-1098D14.1	-4.14	4.47e-05	0.00948	-0.27	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178617242	chr1:178651706~178652282:+
LIHC	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	4.14	4.47e-05	0.00948	0.25	0.22	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
LIHC	cis	rs11098499	0.954	rs10006877	ENSG00000260091.1	RP11-33B1.4	-4.14	4.47e-05	0.00948	-0.16	-0.22	Corneal astigmatism;	chr4:119321638	chr4:119409333~119410233:+
LIHC	cis	rs2243480	0.803	rs36127118	ENSG00000228409.4	CCT6P1	4.14	4.47e-05	0.00948	0.23	0.22	Diabetic kidney disease;	chr7:66100518	chr7:65751142~65763354:+
LIHC	cis	rs2877649	0.793	rs74780198	ENSG00000258744.1	RP11-80A15.1	-4.14	4.47e-05	0.00949	-0.45	-0.22	Smooth-surface caries;	chr14:24498714	chr14:24501594~24508688:+
LIHC	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-4.14	4.47e-05	0.00949	-0.19	-0.22	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
LIHC	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-4.13	4.47e-05	0.00949	-0.22	-0.22	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
LIHC	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-4.13	4.47e-05	0.00949	-0.22	-0.22	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
LIHC	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-4.13	4.47e-05	0.00949	-0.22	-0.22	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
LIHC	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-4.13	4.47e-05	0.00949	-0.22	-0.22	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
LIHC	cis	rs6061231	0.583	rs2427313	ENSG00000226332.2	RP11-157P1.4	4.13	4.47e-05	0.00949	0.25	0.22	Colorectal cancer;	chr20:62395619	chr20:62305432~62306325:-
LIHC	cis	rs13242816	1	rs3807993	ENSG00000279086.1	RP11-667F14.1	4.13	4.47e-05	0.00949	0.38	0.22	P wave duration;	chr7:116557518	chr7:116209234~116211511:-
LIHC	cis	rs4925386	1	rs6121990	ENSG00000273619.1	RP5-908M14.9	4.13	4.47e-05	0.00949	0.18	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62386303~62386970:-
LIHC	cis	rs901683	0.867	rs35003524	ENSG00000230869.1	CTGLF10P	-4.13	4.47e-05	0.00949	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45591333	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs78766622	ENSG00000230869.1	CTGLF10P	-4.13	4.47e-05	0.00949	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45592071	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34618850	ENSG00000230869.1	CTGLF10P	-4.13	4.47e-05	0.00949	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45592415	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35670420	ENSG00000230869.1	CTGLF10P	-4.13	4.47e-05	0.00949	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45592604	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs36053776	ENSG00000230869.1	CTGLF10P	-4.13	4.47e-05	0.00949	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45592697	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35713143	ENSG00000230869.1	CTGLF10P	-4.13	4.47e-05	0.00949	-0.54	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45592711	chr10:45678692~45700532:+
LIHC	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-4.13	4.47e-05	0.00949	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-4.13	4.47e-05	0.00949	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-4.13	4.47e-05	0.00949	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
LIHC	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	4.13	4.48e-05	0.0095	0.34	0.22	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
LIHC	cis	rs6471393	0.964	rs12056877	ENSG00000253848.1	RP11-10N23.5	-4.13	4.48e-05	0.0095	-0.24	-0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93710234	chr8:93741193~93744534:+
LIHC	cis	rs8177253	0.634	rs6798547	ENSG00000244062.1	RP11-404G16.2	4.13	4.48e-05	0.0095	0.21	0.22	Iron status biomarkers;	chr3:133729655	chr3:133760300~133762363:+
LIHC	cis	rs8177253	0.665	rs7646118	ENSG00000244062.1	RP11-404G16.2	4.13	4.48e-05	0.0095	0.21	0.22	Iron status biomarkers;	chr3:133731195	chr3:133760300~133762363:+
LIHC	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	4.13	4.48e-05	0.0095	0.25	0.22	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
LIHC	cis	rs9527	0.615	rs11191401	ENSG00000236937.2	PTGES3P4	4.13	4.48e-05	0.0095	0.33	0.22	Arsenic metabolism;	chr10:102813646	chr10:102845595~102845950:+
LIHC	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-4.13	4.48e-05	0.0095	-0.23	-0.22	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
LIHC	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-4.13	4.48e-05	0.0095	-0.21	-0.22	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
LIHC	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	4.13	4.48e-05	0.0095	0.27	0.22	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
LIHC	cis	rs17818399	0.653	rs34050156	ENSG00000239332.4	LINC01119	-4.13	4.48e-05	0.0095	-0.31	-0.22	Height;	chr2:46550507	chr2:46816697~46859007:+
LIHC	cis	rs617219	0.819	rs2591387	ENSG00000251675.1	CTC-458I2.2	-4.13	4.48e-05	0.00951	-0.25	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79262602	chr5:80128361~80143883:+
LIHC	cis	rs7568498	0.759	rs6728594	ENSG00000235724.7	AC009299.2	4.13	4.49e-05	0.00952	0.29	0.22	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161011641	chr2:161222785~161308303:-
LIHC	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	4.13	4.49e-05	0.00952	0.24	0.22	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
LIHC	cis	rs4561483	0.801	rs251723	ENSG00000261560.1	RP11-166B2.3	-4.13	4.5e-05	0.00953	-0.25	-0.22	Testicular germ cell tumor;	chr16:11859223	chr16:11881075~11882569:-
LIHC	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-4.13	4.5e-05	0.00953	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-4.13	4.5e-05	0.00953	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
LIHC	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-4.13	4.5e-05	0.00953	-0.25	-0.22	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-4.13	4.5e-05	0.00953	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-4.13	4.5e-05	0.00953	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
LIHC	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-4.13	4.5e-05	0.00953	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
LIHC	cis	rs7044106	0.791	rs10984997	ENSG00000238181.2	AHCYP2	-4.13	4.5e-05	0.00953	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120720673~120721972:+
LIHC	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	4.13	4.5e-05	0.00953	0.35	0.22	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
LIHC	cis	rs1223397	0.651	rs2439537	ENSG00000215022.6	RP1-257A7.4	-4.13	4.5e-05	0.00954	-0.24	-0.22	Blood pressure;	chr6:13307592	chr6:13264861~13295586:-
LIHC	cis	rs603446	0.84	rs180329	ENSG00000254851.1	RP11-109L13.1	-4.13	4.5e-05	0.00954	-0.27	-0.22	Triglycerides;	chr11:116752242	chr11:117135528~117138582:+
LIHC	cis	rs1005277	0.522	rs1208767	ENSG00000099251.13	HSD17B7P2	4.13	4.5e-05	0.00954	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38356380~38378505:+
LIHC	cis	rs1876905	0.539	rs240958	ENSG00000272356.1	RP5-1112D6.8	4.13	4.5e-05	0.00954	0.2	0.22	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111309203~111313517:+
LIHC	cis	rs193541	0.501	rs3943379	ENSG00000263432.2	RN7SL689P	4.13	4.5e-05	0.00954	0.33	0.22	Glucose homeostasis traits;	chr5:122720442	chr5:123022487~123022783:-
LIHC	cis	rs193541	0.502	rs2061511	ENSG00000263432.2	RN7SL689P	4.13	4.5e-05	0.00954	0.33	0.22	Glucose homeostasis traits;	chr5:122721032	chr5:123022487~123022783:-
LIHC	cis	rs73193808	0.614	rs9976839	ENSG00000212479.2	U3	4.13	4.51e-05	0.00954	0.25	0.22	Coronary artery disease;	chr21:29190389	chr21:29180425~29180639:-
LIHC	cis	rs4650994	0.623	rs12121188	ENSG00000273384.1	RP5-1098D14.1	-4.13	4.51e-05	0.00955	-0.27	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178653364	chr1:178651706~178652282:+
LIHC	cis	rs1400745	0.756	rs10136352	ENSG00000258738.1	RP11-73E17.2	4.13	4.51e-05	0.00955	0.27	0.22	Monocyte count;	chr14:34865349	chr14:34874343~34876459:+
LIHC	cis	rs7044106	0.762	rs10491783	ENSG00000238181.2	AHCYP2	-4.13	4.51e-05	0.00955	-0.24	-0.22	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.762	rs966397	ENSG00000238181.2	AHCYP2	-4.13	4.51e-05	0.00955	-0.24	-0.22	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120720673~120721972:+
LIHC	cis	rs12157904	1	rs12157904	ENSG00000233360.4	Z83844.1	-4.13	4.51e-05	0.00955	-0.42	-0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37586005	chr22:37641832~37658377:-
LIHC	cis	rs4578769	0.879	rs7235234	ENSG00000265943.1	RP11-739L10.1	4.13	4.51e-05	0.00955	0.28	0.22	Eosinophil percentage of white cells;	chr18:22864239	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.879	rs9950650	ENSG00000265943.1	RP11-739L10.1	4.13	4.51e-05	0.00955	0.28	0.22	Eosinophil percentage of white cells;	chr18:22864537	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.733	rs7226388	ENSG00000265943.1	RP11-739L10.1	4.13	4.51e-05	0.00955	0.28	0.22	Eosinophil percentage of white cells;	chr18:22865371	chr18:22699481~22933764:-
LIHC	cis	rs734999	0.505	rs60687045	ENSG00000225931.3	RP3-395M20.7	4.13	4.51e-05	0.00955	0.23	0.22	Ulcerative colitis;	chr1:2608164	chr1:2566410~2569888:+
LIHC	cis	rs2243480	0.803	rs13224048	ENSG00000232546.1	RP11-458F8.1	-4.13	4.51e-05	0.00956	-0.25	-0.22	Diabetic kidney disease;	chr7:66528779	chr7:66848496~66858136:+
LIHC	cis	rs960902	0.747	rs7593333	ENSG00000213553.4	RPLP0P6	4.13	4.51e-05	0.00956	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37498569	chr2:38481851~38482804:+
LIHC	cis	rs6997458	0.839	rs1390712	ENSG00000253549.4	RP11-317J10.2	4.13	4.51e-05	0.00956	0.24	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85395020	chr8:85441851~85464915:-
LIHC	cis	rs6472235	0.656	rs11995784	ENSG00000272010.1	CTD-3025N20.3	-4.13	4.52e-05	0.00956	-0.3	-0.22	Plateletcrit;Myopia (pathological);	chr8:65967906	chr8:65591850~65592472:-
LIHC	cis	rs6472235	0.656	rs11993927	ENSG00000272010.1	CTD-3025N20.3	-4.13	4.52e-05	0.00956	-0.3	-0.22	Plateletcrit;Myopia (pathological);	chr8:65969407	chr8:65591850~65592472:-
LIHC	cis	rs6472235	0.656	rs11994927	ENSG00000272010.1	CTD-3025N20.3	-4.13	4.52e-05	0.00956	-0.3	-0.22	Plateletcrit;Myopia (pathological);	chr8:65970615	chr8:65591850~65592472:-
LIHC	cis	rs6472235	0.609	rs11985589	ENSG00000272010.1	CTD-3025N20.3	-4.13	4.52e-05	0.00956	-0.3	-0.22	Plateletcrit;Myopia (pathological);	chr8:65972076	chr8:65591850~65592472:-
LIHC	cis	rs6496667	0.557	rs2601203	ENSG00000213471.7	TTLL13P	4.13	4.52e-05	0.00956	0.29	0.22	Rheumatoid arthritis;	chr15:90414897	chr15:90249530~90265482:+
LIHC	cis	rs2494250	0.542	rs11265174	ENSG00000231434.1	RP11-144L1.8	-4.13	4.52e-05	0.00956	-0.26	-0.22	Select biomarker traits;	chr1:159350569	chr1:158523672~158525838:+
LIHC	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-4.13	4.52e-05	0.00956	-0.32	-0.22	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
LIHC	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	4.13	4.52e-05	0.00956	0.22	0.22	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
LIHC	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	4.13	4.52e-05	0.00956	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
LIHC	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	4.13	4.52e-05	0.00957	0.35	0.22	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
LIHC	cis	rs1823913	1	rs7574570	ENSG00000227542.1	AC092614.2	-4.13	4.52e-05	0.00957	-0.23	-0.22	Obesity-related traits;	chr2:191233790	chr2:191229165~191246172:-
LIHC	cis	rs6449502	1	rs6889730	ENSG00000272308.1	RP11-231G3.1	-4.13	4.52e-05	0.00957	-0.33	-0.22	Mean platelet volume;	chr5:60825270	chr5:60866457~60866935:-
LIHC	cis	rs3015497	0.616	rs7152874	ENSG00000269906.1	RP11-248J18.2	4.13	4.52e-05	0.00957	0.27	0.22	Mean platelet volume;	chr14:50579322	chr14:50662511~50663178:-
LIHC	cis	rs9652601	0.959	rs7198621	ENSG00000274038.1	RP11-66H6.4	-4.13	4.52e-05	0.00958	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11073601	chr16:11056556~11057034:+
LIHC	cis	rs6832769	1	rs7667849	ENSG00000272969.1	RP11-528I4.2	-4.13	4.52e-05	0.00958	-0.26	-0.22	Personality dimensions;	chr4:55522032	chr4:55547112~55547889:+
LIHC	cis	rs6745190	0.748	rs6735373	ENSG00000236153.1	AC104076.3	4.13	4.52e-05	0.00958	0.29	0.22	White blood cell count;	chr2:181065907	chr2:180979427~180980090:-
LIHC	cis	rs1005277	0.505	rs13503	ENSG00000276805.1	RP11-291L22.6	-4.13	4.52e-05	0.00958	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.505	rs7069702	ENSG00000276805.1	RP11-291L22.6	-4.13	4.52e-05	0.00958	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38451030~38451785:+
LIHC	cis	rs11722228	0.522	rs73212880	ENSG00000261490.1	RP11-448G15.3	4.13	4.52e-05	0.00958	0.29	0.22	Urate levels;Serum uric acid levels;Gout;	chr4:10114068	chr4:10068089~10073019:-
LIHC	cis	rs10129255	1	rs10129255	ENSG00000224373.3	IGHV4-59	-4.13	4.52e-05	0.00958	-0.17	-0.22	Kawasaki disease;	chr14:106767970	chr14:106627249~106627825:-
LIHC	cis	rs7412746	0.621	rs72704656	ENSG00000231073.1	RP11-316M1.3	4.13	4.53e-05	0.00958	0.23	0.22	Melanoma;	chr1:150855831	chr1:150973123~150975534:+
LIHC	cis	rs17711722	1	rs17711722	ENSG00000273024.4	INTS4P2	4.13	4.53e-05	0.00958	0.26	0.22	Calcium levels;	chr7:65806210	chr7:65647864~65715661:+
LIHC	cis	rs17711722	0.675	rs6947132	ENSG00000273024.4	INTS4P2	4.13	4.53e-05	0.00958	0.26	0.22	Calcium levels;	chr7:65808508	chr7:65647864~65715661:+
LIHC	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-4.13	4.53e-05	0.00958	-0.26	-0.22	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
LIHC	cis	rs11098499	0.722	rs7673476	ENSG00000260091.1	RP11-33B1.4	-4.13	4.53e-05	0.00958	-0.15	-0.22	Corneal astigmatism;	chr4:119327528	chr4:119409333~119410233:+
LIHC	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	4.13	4.53e-05	0.00959	0.23	0.22	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
LIHC	cis	rs12468226	0.689	rs73989731	ENSG00000272966.1	RP11-686O6.1	4.13	4.53e-05	0.00959	0.39	0.22	Urate levels;	chr2:202109309	chr2:202336739~202337200:+
LIHC	cis	rs529413	0.641	rs1520413	ENSG00000259237.1	RP11-209E8.1	4.13	4.53e-05	0.00959	0.3	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr15:53239216	chr15:53116365~53129698:+
LIHC	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	4.13	4.53e-05	0.0096	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	4.13	4.53e-05	0.0096	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	4.13	4.53e-05	0.0096	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
LIHC	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	4.13	4.53e-05	0.0096	0.24	0.22	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
LIHC	cis	rs6430585	0.528	rs6743537	ENSG00000231890.6	DARS-AS1	-4.13	4.54e-05	0.0096	-0.32	-0.22	Corneal structure;	chr2:135945031	chr2:135985176~136022593:+
LIHC	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	4.13	4.54e-05	0.0096	0.2	0.22	Breast size;	chr12:9228263	chr12:9277235~9313241:+
LIHC	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	4.13	4.54e-05	0.0096	0.26	0.22	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
LIHC	cis	rs2562456	0.917	rs2681377	ENSG00000268555.1	RP11-678G14.3	-4.13	4.54e-05	0.0096	-0.28	-0.22	Pain;	chr19:21533718	chr19:21570822~21587322:-
LIHC	cis	rs6433895	0.677	rs6716261	ENSG00000236153.1	AC104076.3	-4.13	4.54e-05	0.0096	-0.29	-0.22	Lymphocyte counts;	chr2:181166505	chr2:180979427~180980090:-
LIHC	cis	rs757081	0.676	rs567033	ENSG00000272034.1	SNORD14A	-4.13	4.54e-05	0.00961	-0.23	-0.22	Systolic blood pressure;	chr11:17185463	chr11:17074654~17074744:-
LIHC	cis	rs757081	0.676	rs677042	ENSG00000272034.1	SNORD14A	-4.13	4.54e-05	0.00961	-0.23	-0.22	Systolic blood pressure;	chr11:17185533	chr11:17074654~17074744:-
LIHC	cis	rs1023500	1	rs9620001	ENSG00000237037.8	NDUFA6-AS1	-4.13	4.54e-05	0.00961	-0.3	-0.22	Schizophrenia;	chr22:41934225	chr22:42090931~42137742:+
LIHC	cis	rs3845817	0.733	rs702906	ENSG00000281920.1	RP11-418H16.1	-4.13	4.55e-05	0.00962	-0.25	-0.22	Bipolar disorder;	chr2:65539745	chr2:65623272~65628424:+
LIHC	cis	rs7044106	0.708	rs920745	ENSG00000238181.2	AHCYP2	-4.13	4.55e-05	0.00962	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.734	rs10491784	ENSG00000238181.2	AHCYP2	-4.13	4.55e-05	0.00962	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120720673~120721972:+
LIHC	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	4.13	4.55e-05	0.00963	0.26	0.22	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
LIHC	cis	rs9400467	0.528	rs459403	ENSG00000271789.1	RP5-1112D6.7	-4.13	4.55e-05	0.00963	-0.21	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111297126~111298510:+
LIHC	cis	rs875971	0.545	rs7783889	ENSG00000273024.4	INTS4P2	-4.13	4.55e-05	0.00963	-0.25	-0.22	Aortic root size;	chr7:66283366	chr7:65647864~65715661:+
LIHC	cis	rs2243480	1	rs34970380	ENSG00000232546.1	RP11-458F8.1	-4.13	4.55e-05	0.00963	-0.25	-0.22	Diabetic kidney disease;	chr7:65966506	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.901	rs73148097	ENSG00000232546.1	RP11-458F8.1	-4.13	4.55e-05	0.00963	-0.25	-0.22	Diabetic kidney disease;	chr7:65966800	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs906134	ENSG00000232546.1	RP11-458F8.1	-4.13	4.55e-05	0.00963	-0.25	-0.22	Diabetic kidney disease;	chr7:65979301	chr7:66848496~66858136:+
LIHC	cis	rs2439831	0.85	rs9944216	ENSG00000166763.7	STRCP1	-4.13	4.55e-05	0.00963	-0.34	-0.22	Lung cancer in ever smokers;	chr15:43868575	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.863	rs3822194	ENSG00000260091.1	RP11-33B1.4	-4.13	4.55e-05	0.00963	-0.16	-0.22	Corneal astigmatism;	chr4:119550493	chr4:119409333~119410233:+
LIHC	cis	rs7044106	0.762	rs1547268	ENSG00000238181.2	AHCYP2	-4.13	4.56e-05	0.00963	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.762	rs1547267	ENSG00000238181.2	AHCYP2	-4.13	4.56e-05	0.00963	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120720673~120721972:+
LIHC	cis	rs7044106	0.762	rs4142158	ENSG00000238181.2	AHCYP2	-4.13	4.56e-05	0.00963	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120720673~120721972:+
LIHC	cis	rs11098499	0.863	rs17050695	ENSG00000260091.1	RP11-33B1.4	-4.13	4.56e-05	0.00964	-0.15	-0.22	Corneal astigmatism;	chr4:119568372	chr4:119409333~119410233:+
LIHC	cis	rs11722228	0.522	rs1109472	ENSG00000261490.1	RP11-448G15.3	4.13	4.56e-05	0.00964	0.28	0.22	Urate levels;Serum uric acid levels;Gout;	chr4:10132824	chr4:10068089~10073019:-
LIHC	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-4.13	4.56e-05	0.00964	-0.26	-0.22	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-4.13	4.56e-05	0.00964	-0.26	-0.22	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
LIHC	cis	rs11064837	0.504	rs7973772	ENSG00000248636.5	RP11-768F21.1	-4.13	4.56e-05	0.00964	-0.35	-0.22	Schizophrenia;	chr12:119648932	chr12:119387987~119668079:-
LIHC	cis	rs7586970	0.549	rs13035938	ENSG00000224063.4	AC007319.1	4.13	4.56e-05	0.00964	0.34	0.22	Coronary heart disease;	chr2:187525385	chr2:187003220~187554663:+
LIHC	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	4.13	4.56e-05	0.00964	0.32	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
LIHC	cis	rs12304921	0.748	rs17125258	ENSG00000277201.1	AC087884.1	4.13	4.56e-05	0.00965	0.26	0.22	Type 2 diabetes;	chr12:51051896	chr12:51049921~51050025:+
LIHC	cis	rs4561483	0.831	rs2075158	ENSG00000261560.1	RP11-166B2.3	4.13	4.56e-05	0.00965	0.24	0.22	Testicular germ cell tumor;	chr16:11851374	chr16:11881075~11882569:-
LIHC	cis	rs6048205	0.764	rs1203868	ENSG00000259974.2	LINC00261	4.13	4.57e-05	0.00965	0.33	0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22551374	chr20:22547671~22578642:-
LIHC	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-4.13	4.57e-05	0.00965	-0.22	-0.22	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
LIHC	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	4.13	4.57e-05	0.00965	0.26	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
LIHC	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-4.13	4.57e-05	0.00966	-0.34	-0.22	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
LIHC	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	4.13	4.57e-05	0.00966	0.24	0.22	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
LIHC	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-4.13	4.57e-05	0.00966	-0.26	-0.22	Height;	chr2:46609767	chr2:46668870~46670778:+
LIHC	cis	rs763121	0.853	rs2076028	ENSG00000273076.1	RP3-508I15.22	4.13	4.57e-05	0.00966	0.25	0.22	Menopause (age at onset);	chr22:38754445	chr22:38743495~38743910:+
LIHC	cis	rs875971	0.545	rs1796226	ENSG00000273024.4	INTS4P2	-4.13	4.57e-05	0.00966	-0.25	-0.22	Aortic root size;	chr7:66622723	chr7:65647864~65715661:+
LIHC	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	4.13	4.57e-05	0.00966	0.25	0.22	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
LIHC	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	4.13	4.57e-05	0.00966	0.21	0.22	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
LIHC	cis	rs11098499	0.954	rs878373	ENSG00000260091.1	RP11-33B1.4	-4.13	4.58e-05	0.00967	-0.16	-0.22	Corneal astigmatism;	chr4:119316329	chr4:119409333~119410233:+
LIHC	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-4.13	4.58e-05	0.00967	-0.22	-0.22	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-4.13	4.58e-05	0.00967	-0.22	-0.22	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
LIHC	cis	rs2243480	0.615	rs34363376	ENSG00000232546.1	RP11-458F8.1	-4.13	4.58e-05	0.00967	-0.25	-0.22	Diabetic kidney disease;	chr7:66474549	chr7:66848496~66858136:+
LIHC	cis	rs4925386	1	rs4925382	ENSG00000273619.1	RP5-908M14.9	4.13	4.58e-05	0.00967	0.18	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62386303~62386970:-
LIHC	cis	rs1005277	0.54	rs2474598	ENSG00000275858.1	RP11-291L22.8	-4.13	4.58e-05	0.00967	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38450738~38451069:-
LIHC	cis	rs6433895	0.71	rs56692685	ENSG00000236153.1	AC104076.3	-4.13	4.58e-05	0.00968	-0.28	-0.22	Lymphocyte counts;	chr2:181147366	chr2:180979427~180980090:-
LIHC	cis	rs2598107	0.601	rs7807170	ENSG00000211698.2	TRGV4	-4.13	4.58e-05	0.00968	-0.27	-0.22	Dupuytren's disease;	chr7:37894980	chr7:38353715~38354517:-
LIHC	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-4.13	4.59e-05	0.00969	-0.39	-0.22	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
LIHC	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-4.13	4.59e-05	0.00969	-0.39	-0.22	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
LIHC	cis	rs2243480	1	rs13310597	ENSG00000232546.1	RP11-458F8.1	-4.13	4.59e-05	0.00969	-0.25	-0.22	Diabetic kidney disease;	chr7:66133553	chr7:66848496~66858136:+
LIHC	cis	rs6456156	0.586	rs1358883	ENSG00000227598.1	RP1-167A14.2	4.13	4.59e-05	0.00969	0.22	0.22	Primary biliary cholangitis;	chr6:167053945	chr6:166969626~166999065:-
LIHC	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	4.13	4.6e-05	0.0097	0.25	0.22	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
LIHC	cis	rs2562456	0.917	rs2681376	ENSG00000268555.1	RP11-678G14.3	-4.13	4.6e-05	0.00971	-0.28	-0.22	Pain;	chr19:21532723	chr19:21570822~21587322:-
LIHC	cis	rs295490	0.748	rs58234450	ENSG00000272656.1	RP11-219D15.3	4.13	4.6e-05	0.00971	0.62	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139481465	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs114423015	ENSG00000272656.1	RP11-219D15.3	4.13	4.6e-05	0.00971	0.62	0.22	PR interval in Tripanosoma cruzi seropositivity;	chr3:139488980	chr3:139349024~139349371:-
LIHC	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-4.13	4.6e-05	0.00971	-0.27	-0.22	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
LIHC	cis	rs17774123	0.901	rs11830203	ENSG00000257808.1	RP11-1136G11.8	4.13	4.6e-05	0.00972	0.4	0.22	Diastolic blood pressure;	chr12:53870638	chr12:53159586~53161000:+
LIHC	cis	rs4356975	0.83	rs4481286	ENSG00000250919.1	RP11-813N20.3	-4.13	4.6e-05	0.00972	-0.22	-0.22	Obesity-related traits;	chr4:69056631	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.83	rs4583828	ENSG00000250919.1	RP11-813N20.3	-4.13	4.6e-05	0.00972	-0.22	-0.22	Obesity-related traits;	chr4:69056669	chr4:69027831~69044578:+
LIHC	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-4.13	4.6e-05	0.00972	-0.17	-0.22	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
LIHC	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-4.13	4.6e-05	0.00972	-0.17	-0.22	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
LIHC	cis	rs2361701	0.636	rs1982244	ENSG00000275479.1	RP11-334C17.6	4.13	4.6e-05	0.00972	0.22	0.22	IgG glycosylation;	chr17:80095149	chr17:80149627~80149798:+
LIHC	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	4.13	4.61e-05	0.00972	0.43	0.22	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
LIHC	cis	rs2299116	0.962	rs62442194	ENSG00000225264.3	ZNRF2P2	-4.13	4.61e-05	0.00972	-0.25	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28776584	chr7:29598795~29685255:-
LIHC	cis	rs2299116	0.962	rs62442195	ENSG00000225264.3	ZNRF2P2	-4.13	4.61e-05	0.00972	-0.25	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28776890	chr7:29598795~29685255:-
LIHC	cis	rs2439831	0.681	rs1549523	ENSG00000166763.7	STRCP1	4.13	4.61e-05	0.00972	0.3	0.22	Lung cancer in ever smokers;	chr15:43331991	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.681	rs1549525	ENSG00000166763.7	STRCP1	4.13	4.61e-05	0.00972	0.3	0.22	Lung cancer in ever smokers;	chr15:43335657	chr15:43699488~43718184:-
LIHC	cis	rs1005277	0.505	rs7099777	ENSG00000099251.13	HSD17B7P2	-4.13	4.61e-05	0.00972	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38356380~38378505:+
LIHC	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-4.13	4.61e-05	0.00973	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
LIHC	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	4.13	4.61e-05	0.00974	0.23	0.22	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	4.13	4.61e-05	0.00974	0.23	0.22	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	4.13	4.61e-05	0.00974	0.23	0.22	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
LIHC	cis	rs4938303	0.633	rs61906081	ENSG00000254851.1	RP11-109L13.1	4.13	4.62e-05	0.00974	0.31	0.22	Triglycerides;	chr11:116666342	chr11:117135528~117138582:+
LIHC	cis	rs4073416	0.712	rs2411351	ENSG00000276116.2	FUT8-AS1	4.13	4.62e-05	0.00974	0.26	0.22	N-glycan levels;	chr14:65704823	chr14:65411170~65412690:-
LIHC	cis	rs9906944	0.933	rs12945020	ENSG00000248278.1	SUMO2P17	-4.13	4.62e-05	0.00975	-0.37	-0.22	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49005413	chr17:48874860~48908983:-
LIHC	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-4.13	4.62e-05	0.00975	-0.31	-0.22	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-4.13	4.62e-05	0.00975	-0.31	-0.22	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-4.13	4.62e-05	0.00975	-0.31	-0.22	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-4.13	4.62e-05	0.00975	-0.31	-0.22	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-4.13	4.62e-05	0.00975	-0.31	-0.22	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-4.13	4.62e-05	0.00975	-0.31	-0.22	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
LIHC	cis	rs7208859	0.673	rs11655623	ENSG00000266490.1	CTD-2349P21.9	4.13	4.62e-05	0.00976	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.573	rs73277960	ENSG00000266490.1	CTD-2349P21.9	4.13	4.62e-05	0.00976	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.623	rs73263788	ENSG00000266490.1	CTD-2349P21.9	4.13	4.62e-05	0.00976	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30792372~30792833:+
LIHC	cis	rs7208859	0.673	rs12949860	ENSG00000266490.1	CTD-2349P21.9	4.13	4.62e-05	0.00976	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30792372~30792833:+
LIHC	cis	rs875971	0.545	rs2420456	ENSG00000228409.4	CCT6P1	-4.13	4.63e-05	0.00976	-0.18	-0.22	Aortic root size;	chr7:66280619	chr7:65751142~65763354:+
LIHC	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	4.13	4.63e-05	0.00977	0.18	0.22	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
LIHC	cis	rs2072510	1	rs2072512	ENSG00000257715.1	RP11-256L6.2	-4.13	4.63e-05	0.00977	-0.22	-0.22	Metabolite levels (small molecules and protein measures);	chr12:96015198	chr12:96025323~96027971:+
LIHC	cis	rs2072510	1	rs1978331	ENSG00000257715.1	RP11-256L6.2	-4.13	4.63e-05	0.00977	-0.22	-0.22	Metabolite levels (small molecules and protein measures);	chr12:96015423	chr12:96025323~96027971:+
LIHC	cis	rs4578769	0.918	rs8085287	ENSG00000265943.1	RP11-739L10.1	4.13	4.63e-05	0.00977	0.27	0.22	Eosinophil percentage of white cells;	chr18:22884208	chr18:22699481~22933764:-
LIHC	cis	rs2243480	1	rs56016656	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65918494	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.803	rs55700941	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65924813	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs36033484	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65925571	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs34193460	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65928123	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs34560516	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65939105	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs57057549	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65940751	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.808	rs12698508	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65946971	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs2961102	ENSG00000232546.1	RP11-458F8.1	-4.13	4.63e-05	0.00977	-0.25	-0.22	Diabetic kidney disease;	chr7:65959671	chr7:66848496~66858136:+
LIHC	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-4.13	4.64e-05	0.00978	-0.26	-0.22	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
LIHC	cis	rs4578769	0.836	rs3936488	ENSG00000265943.1	RP11-739L10.1	4.13	4.64e-05	0.00978	0.28	0.22	Eosinophil percentage of white cells;	chr18:22874459	chr18:22699481~22933764:-
LIHC	cis	rs1005277	0.505	rs1208689	ENSG00000099251.13	HSD17B7P2	4.13	4.64e-05	0.00978	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38356380~38378505:+
LIHC	cis	rs11098499	1	rs6837898	ENSG00000260091.1	RP11-33B1.4	-4.13	4.64e-05	0.00979	-0.16	-0.22	Corneal astigmatism;	chr4:119257999	chr4:119409333~119410233:+
LIHC	cis	rs803903	0.883	rs1090025	ENSG00000230894.1	RP11-67K19.3	-4.13	4.64e-05	0.00979	-0.28	-0.22	Breast cancer;	chr9:116677596	chr9:116568449~116586328:+
LIHC	cis	rs5758511	0.68	rs5758698	ENSG00000237037.8	NDUFA6-AS1	-4.13	4.64e-05	0.00979	-0.28	-0.22	Birth weight;	chr22:42288812	chr22:42090931~42137742:+
LIHC	cis	rs6496044	0.507	rs2467096	ENSG00000259630.2	CTD-2262B20.1	4.13	4.64e-05	0.00979	0.23	0.22	Interstitial lung disease;	chr15:85667447	chr15:85415228~85415633:+
LIHC	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-4.13	4.64e-05	0.00979	-0.26	-0.22	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
LIHC	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-4.13	4.64e-05	0.00979	-0.26	-0.22	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
LIHC	cis	rs1577917	1	rs12216328	ENSG00000234155.1	RP11-30P6.6	4.13	4.65e-05	0.00979	0.29	0.22	Response to antipsychotic treatment;	chr6:85993700	chr6:85387219~85390186:-
LIHC	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-4.13	4.65e-05	0.0098	-0.26	-0.22	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
LIHC	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-4.13	4.65e-05	0.0098	-0.26	-0.22	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
LIHC	cis	rs17214007	0.778	rs17213271	ENSG00000263335.1	AF001548.5	-4.13	4.65e-05	0.0098	-0.32	-0.22	Cognitive function;	chr16:15770487	chr16:15726674~15732993:+
LIHC	cis	rs73183643	0.666	rs2690943	ENSG00000239486.1	RP11-163E9.1	4.13	4.65e-05	0.0098	0.29	0.22	Basal cell carcinoma;	chr7:101759452	chr7:102380465~102382737:-
LIHC	cis	rs12681287	0.64	rs13253296	ENSG00000254088.1	SLC2A3P4	4.13	4.65e-05	0.0098	0.25	0.22	Caudate activity during reward;	chr8:86436016	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.604	rs34227066	ENSG00000254088.1	SLC2A3P4	4.13	4.65e-05	0.0098	0.25	0.22	Caudate activity during reward;	chr8:86437137	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs34794500	ENSG00000254088.1	SLC2A3P4	4.13	4.65e-05	0.0098	0.25	0.22	Caudate activity during reward;	chr8:86437766	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs7833049	ENSG00000254088.1	SLC2A3P4	-4.13	4.65e-05	0.0098	-0.25	-0.22	Caudate activity during reward;	chr8:86433669	chr8:86503591~86505061:+
LIHC	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	4.13	4.65e-05	0.00981	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
LIHC	cis	rs2348418	0.765	rs11049381	ENSG00000247934.4	RP11-967K21.1	-4.13	4.65e-05	0.00981	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162107	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.765	rs10843117	ENSG00000247934.4	RP11-967K21.1	-4.13	4.65e-05	0.00981	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162457	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.765	rs7954851	ENSG00000247934.4	RP11-967K21.1	-4.13	4.65e-05	0.00981	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162909	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.765	rs7954877	ENSG00000247934.4	RP11-967K21.1	-4.13	4.65e-05	0.00981	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28163008	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.765	rs10843118	ENSG00000247934.4	RP11-967K21.1	-4.13	4.65e-05	0.00981	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28164396	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.966	rs1527578	ENSG00000247934.4	RP11-967K21.1	4.13	4.65e-05	0.00981	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.966	rs16932891	ENSG00000247934.4	RP11-967K21.1	4.13	4.65e-05	0.00981	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.966	rs2881910	ENSG00000247934.4	RP11-967K21.1	4.13	4.65e-05	0.00981	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28163298~28190738:-
LIHC	cis	rs2243480	1	rs73150014	ENSG00000232546.1	RP11-458F8.1	-4.13	4.65e-05	0.00981	-0.25	-0.22	Diabetic kidney disease;	chr7:65985932	chr7:66848496~66858136:+
LIHC	cis	rs9450351	0.744	rs6913147	ENSG00000203875.9	SNHG5	-4.13	4.66e-05	0.00981	-0.45	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85800641	chr6:85660950~85678736:-
LIHC	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-4.13	4.66e-05	0.00981	-0.22	-0.22	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
LIHC	cis	rs2808510	0.826	rs36003362	ENSG00000230623.2	RP11-469A15.2	-4.13	4.66e-05	0.00981	-0.25	-0.22	Myopia;	chr1:200397960	chr1:200473920~200478293:+
LIHC	cis	rs10510102	0.872	rs12246728	ENSG00000273891.1	RP11-500G22.5	4.13	4.66e-05	0.00982	0.29	0.22	Breast cancer;	chr10:121966618	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12261371	ENSG00000273891.1	RP11-500G22.5	4.13	4.66e-05	0.00982	0.29	0.22	Breast cancer;	chr10:121966686	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.808	rs17102804	ENSG00000273891.1	RP11-500G22.5	4.13	4.66e-05	0.00982	0.29	0.22	Breast cancer;	chr10:121968365	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12265369	ENSG00000273891.1	RP11-500G22.5	4.13	4.66e-05	0.00982	0.29	0.22	Breast cancer;	chr10:121968455	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12265542	ENSG00000273891.1	RP11-500G22.5	4.13	4.66e-05	0.00982	0.29	0.22	Breast cancer;	chr10:121968740	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs11200293	ENSG00000273891.1	RP11-500G22.5	4.13	4.66e-05	0.00982	0.29	0.22	Breast cancer;	chr10:121969195	chr10:121965764~121967700:+
LIHC	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-4.12	4.66e-05	0.00982	-0.21	-0.22	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
LIHC	cis	rs6048205	0.892	rs1203889	ENSG00000259974.2	LINC00261	-4.12	4.66e-05	0.00983	-0.31	-0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22566283	chr20:22547671~22578642:-
LIHC	cis	rs2243480	1	rs937108	ENSG00000232546.1	RP11-458F8.1	-4.12	4.66e-05	0.00983	-0.24	-0.22	Diabetic kidney disease;	chr7:65963465	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs35542501	ENSG00000232546.1	RP11-458F8.1	-4.12	4.66e-05	0.00983	-0.24	-0.22	Diabetic kidney disease;	chr7:65966228	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.711	rs1626926	ENSG00000232546.1	RP11-458F8.1	-4.12	4.66e-05	0.00983	-0.24	-0.22	Diabetic kidney disease;	chr7:65970805	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.708	rs781141	ENSG00000232546.1	RP11-458F8.1	-4.12	4.66e-05	0.00983	-0.24	-0.22	Diabetic kidney disease;	chr7:65973566	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs781142	ENSG00000232546.1	RP11-458F8.1	-4.12	4.66e-05	0.00983	-0.24	-0.22	Diabetic kidney disease;	chr7:65973791	chr7:66848496~66858136:+
LIHC	cis	rs113835537	0.935	rs75863187	ENSG00000255517.5	CTD-3074O7.5	-4.12	4.67e-05	0.00983	-0.38	-0.22	Airway imaging phenotypes;	chr11:66675990	chr11:66473490~66480233:-
LIHC	cis	rs9595908	0.785	rs60088097	ENSG00000212293.1	SNORA16	4.12	4.67e-05	0.00983	0.25	0.22	Body mass index;	chr13:32678043	chr13:32420390~32420516:-
LIHC	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	4.12	4.67e-05	0.00983	0.29	0.22	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
LIHC	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	4.12	4.67e-05	0.00984	0.41	0.22	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
LIHC	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	4.12	4.67e-05	0.00984	0.41	0.22	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
LIHC	cis	rs4144027	0.904	rs10438244	ENSG00000258914.1	CTD-2134A5.3	4.12	4.67e-05	0.00984	0.23	0.22	Blood metabolite levels;	chr14:103879848	chr14:103875055~103877478:+
LIHC	cis	rs1005277	0.522	rs9418276	ENSG00000276805.1	RP11-291L22.6	4.12	4.67e-05	0.00984	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.522	rs7072977	ENSG00000276805.1	RP11-291L22.6	4.12	4.67e-05	0.00984	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38451030~38451785:+
LIHC	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	4.12	4.67e-05	0.00984	0.27	0.22	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
LIHC	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-4.12	4.68e-05	0.00985	-0.26	-0.22	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
LIHC	cis	rs244293	0.701	rs4793784	ENSG00000275710.1	RP11-257O5.4	4.12	4.68e-05	0.00986	0.25	0.22	Menarche (age at onset);	chr17:54961069	chr17:54964474~54964679:+
LIHC	cis	rs4578769	0.959	rs3911557	ENSG00000266850.1	RP11-370A5.1	-4.12	4.68e-05	0.00986	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22892600	chr18:22723491~22907721:-
LIHC	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.68e-05	0.00986	-0.21	-0.22	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.68e-05	0.00986	-0.21	-0.22	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
LIHC	cis	rs6480314	0.711	rs16925246	ENSG00000233590.1	RP11-153K11.3	4.12	4.68e-05	0.00986	0.36	0.22	Optic nerve measurement (disc area);	chr10:68188569	chr10:68233251~68242379:-
LIHC	cis	rs7208859	0.673	rs2470251	ENSG00000266490.1	CTD-2349P21.9	4.12	4.68e-05	0.00986	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30792372~30792833:+
LIHC	cis	rs7042864	0.506	rs989820	ENSG00000225531.1	RP11-196I18.3	4.12	4.68e-05	0.00986	0.3	0.22	Tonometry;	chr9:108114562	chr9:107116829~107117557:+
LIHC	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	4.12	4.69e-05	0.00986	0.18	0.22	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	4.12	4.69e-05	0.00986	0.18	0.22	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
LIHC	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	4.12	4.69e-05	0.00986	0.18	0.22	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
LIHC	cis	rs4356975	0.83	rs4413468	ENSG00000250919.1	RP11-813N20.3	-4.12	4.69e-05	0.00987	-0.22	-0.22	Obesity-related traits;	chr4:69061845	chr4:69027831~69044578:+
LIHC	cis	rs1075232	1	rs1075232	ENSG00000270055.1	CTD-3092A11.2	-4.12	4.69e-05	0.00987	-0.42	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31449013	chr15:30487963~30490313:+
LIHC	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-4.12	4.69e-05	0.00987	-0.24	-0.22	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
LIHC	cis	rs1577917	1	rs12212733	ENSG00000234155.1	RP11-30P6.6	4.12	4.69e-05	0.00987	0.28	0.22	Response to antipsychotic treatment;	chr6:86016295	chr6:85387219~85390186:-
LIHC	cis	rs9527	0.59	rs7067663	ENSG00000236937.2	PTGES3P4	4.12	4.69e-05	0.00987	0.28	0.22	Arsenic metabolism;	chr10:103123893	chr10:102845595~102845950:+
LIHC	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	4.12	4.69e-05	0.00988	0.35	0.22	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
LIHC	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	4.12	4.69e-05	0.00988	0.35	0.22	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
LIHC	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	4.12	4.69e-05	0.00988	0.35	0.22	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
LIHC	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	4.12	4.69e-05	0.00988	0.35	0.22	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
LIHC	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	4.12	4.69e-05	0.00988	0.35	0.22	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
LIHC	cis	rs6445975	0.956	rs7612923	ENSG00000272360.1	RP11-359I18.5	4.12	4.69e-05	0.00988	0.27	0.22	Systemic lupus erythematosus;	chr3:58388706	chr3:58490830~58491291:-
LIHC	cis	rs734999	0.545	rs41300092	ENSG00000225931.3	RP3-395M20.7	4.12	4.69e-05	0.00988	0.23	0.22	Ulcerative colitis;	chr1:2606399	chr1:2566410~2569888:+
LIHC	cis	rs875971	0.83	rs427575	ENSG00000232559.3	GS1-124K5.12	4.12	4.69e-05	0.00988	0.18	0.22	Aortic root size;	chr7:66054232	chr7:66554588~66576923:-
LIHC	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	4.12	4.69e-05	0.00988	0.25	0.22	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
LIHC	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-4.12	4.7e-05	0.00988	-0.25	-0.22	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
LIHC	cis	rs6480314	0.636	rs10509298	ENSG00000233590.1	RP11-153K11.3	-4.12	4.7e-05	0.00989	-0.36	-0.22	Optic nerve measurement (disc area);	chr10:68176982	chr10:68233251~68242379:-
LIHC	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	4.12	4.7e-05	0.00989	0.23	0.22	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
LIHC	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-4.12	4.7e-05	0.00989	-0.22	-0.22	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-4.12	4.7e-05	0.00989	-0.22	-0.22	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-4.12	4.7e-05	0.00989	-0.22	-0.22	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
LIHC	cis	rs17270561	0.562	rs12199626	ENSG00000216436.2	HIST1H2APS1	-4.12	4.7e-05	0.0099	-0.34	-0.22	Iron status biomarkers;	chr6:26013376	chr6:25732497~25732827:+
LIHC	cis	rs801193	0.548	rs2659904	ENSG00000232559.3	GS1-124K5.12	4.12	4.7e-05	0.0099	0.17	0.22	Aortic root size;	chr7:66713615	chr7:66554588~66576923:-
LIHC	cis	rs7923609	0.846	rs7896518	ENSG00000232075.1	MRPL35P2	-4.12	4.7e-05	0.0099	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63344740	chr10:63634317~63634827:-
LIHC	cis	rs7412746	0.658	rs1027699	ENSG00000231073.1	RP11-316M1.3	4.12	4.71e-05	0.0099	0.22	0.22	Melanoma;	chr1:150839236	chr1:150973123~150975534:+
LIHC	cis	rs1075265	0.73	rs6713088	ENSG00000272156.1	RP11-477N3.1	-4.12	4.71e-05	0.00991	-0.25	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54082554~54085066:+
LIHC	cis	rs9896933	0.708	rs9908751	ENSG00000263063.1	RP11-388C12.1	4.12	4.71e-05	0.00991	0.27	0.22	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82833954	chr17:82713908~82716255:-
LIHC	cis	rs75920871	0.589	rs2306473	ENSG00000254851.1	RP11-109L13.1	-4.12	4.71e-05	0.00991	-0.41	-0.22	Subjective well-being;	chr11:117227236	chr11:117135528~117138582:+
LIHC	cis	rs804280	1	rs804280	ENSG00000255495.1	AC145124.2	4.12	4.71e-05	0.00991	0.28	0.22	Myopia (pathological);	chr8:11755189	chr8:12194467~12196280:+
LIHC	cis	rs734999	0.505	rs4073285	ENSG00000225931.3	RP3-395M20.7	4.12	4.71e-05	0.00991	0.23	0.22	Ulcerative colitis;	chr1:2608357	chr1:2566410~2569888:+
LIHC	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.71e-05	0.00991	-0.21	-0.22	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
LIHC	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-4.12	4.72e-05	0.00992	-0.39	-0.22	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
LIHC	cis	rs7809950	0.678	rs2107317	ENSG00000238832.1	snoU109	-4.12	4.72e-05	0.00992	-0.28	-0.22	Coronary artery disease;	chr7:107259240	chr7:107603363~107603507:+
LIHC	cis	rs875971	0.545	rs1796226	ENSG00000273142.1	RP11-458F8.4	4.12	4.72e-05	0.00992	0.21	0.22	Aortic root size;	chr7:66622723	chr7:66902857~66906297:+
LIHC	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	4.12	4.72e-05	0.00992	0.26	0.22	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	4.12	4.72e-05	0.00992	0.26	0.22	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
LIHC	cis	rs2439831	0.681	rs11858152	ENSG00000166763.7	STRCP1	4.12	4.72e-05	0.00993	0.3	0.22	Lung cancer in ever smokers;	chr15:43341998	chr15:43699488~43718184:-
LIHC	cis	rs2562456	0.652	rs62110214	ENSG00000268555.1	RP11-678G14.3	4.12	4.72e-05	0.00993	0.29	0.22	Pain;	chr19:21592406	chr19:21570822~21587322:-
LIHC	cis	rs2299116	1	rs35910392	ENSG00000225264.3	ZNRF2P2	4.12	4.73e-05	0.00994	0.25	0.22	Serum thyroid-stimulating hormone levels;	chr7:28778195	chr7:29598795~29685255:-
LIHC	cis	rs1577917	1	rs7760207	ENSG00000234155.1	RP11-30P6.6	4.12	4.73e-05	0.00994	0.28	0.22	Response to antipsychotic treatment;	chr6:86011982	chr6:85387219~85390186:-
LIHC	cis	rs860295	0.871	rs6696888	ENSG00000203761.5	MSTO2P	4.12	4.73e-05	0.00994	0.18	0.22	Body mass index;	chr1:155539091	chr1:155745829~155750137:+
LIHC	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-4.12	4.73e-05	0.00994	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
LIHC	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-4.12	4.73e-05	0.00995	-0.25	-0.22	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
LIHC	cis	rs875971	0.528	rs801213	ENSG00000228409.4	CCT6P1	4.12	4.73e-05	0.00995	0.18	0.22	Aortic root size;	chr7:66549931	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs801212	ENSG00000228409.4	CCT6P1	4.12	4.73e-05	0.00995	0.18	0.22	Aortic root size;	chr7:66550643	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs73152714	ENSG00000228409.4	CCT6P1	-4.12	4.73e-05	0.00995	-0.18	-0.22	Aortic root size;	chr7:66534641	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs4718364	ENSG00000228409.4	CCT6P1	-4.12	4.73e-05	0.00995	-0.18	-0.22	Aortic root size;	chr7:66536353	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs6961853	ENSG00000228409.4	CCT6P1	-4.12	4.73e-05	0.00995	-0.18	-0.22	Aortic root size;	chr7:66537035	chr7:65751142~65763354:+
LIHC	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.73e-05	0.00995	-0.21	-0.22	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
LIHC	cis	rs3015497	0.648	rs10144512	ENSG00000269906.1	RP11-248J18.2	4.12	4.74e-05	0.00996	0.27	0.22	Mean platelet volume;	chr14:50615553	chr14:50662511~50663178:-
LIHC	cis	rs763121	0.853	rs6519120	ENSG00000273076.1	RP3-508I15.22	-4.12	4.74e-05	0.00996	-0.26	-0.22	Menopause (age at onset);	chr22:38595388	chr22:38743495~38743910:+
LIHC	cis	rs10833905	0.775	rs10833889	ENSG00000246225.5	RP11-17A1.3	-4.12	4.74e-05	0.00996	-0.28	-0.22	Sudden cardiac arrest;	chr11:23001805	chr11:22829380~22945393:+
LIHC	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	4.12	4.74e-05	0.00996	0.27	0.22	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
LIHC	cis	rs1005277	0.579	rs2472183	ENSG00000275858.1	RP11-291L22.8	4.12	4.74e-05	0.00996	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38450738~38451069:-
LIHC	cis	rs3015497	0.616	rs10131107	ENSG00000269906.1	RP11-248J18.2	4.12	4.74e-05	0.00997	0.27	0.22	Mean platelet volume;	chr14:50595737	chr14:50662511~50663178:-
LIHC	cis	rs9652601	0.881	rs11860603	ENSG00000274038.1	RP11-66H6.4	-4.12	4.74e-05	0.00997	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11071160	chr16:11056556~11057034:+
LIHC	cis	rs734999	0.545	rs3890745	ENSG00000225931.3	RP3-395M20.7	-4.12	4.75e-05	0.00997	-0.23	-0.22	Ulcerative colitis;	chr1:2622185	chr1:2566410~2569888:+
LIHC	cis	rs801193	0.613	rs2016325	ENSG00000273142.1	RP11-458F8.4	4.12	4.75e-05	0.00997	0.23	0.22	Aortic root size;	chr7:66858513	chr7:66902857~66906297:+
LIHC	cis	rs8005677	0.741	rs1043675	ENSG00000257285.4	RP11-298I3.1	-4.12	4.75e-05	0.00997	-0.22	-0.22	Cognitive ability (multi-trait analysis);	chr14:22987106	chr14:22929609~22955562:+
LIHC	cis	rs748404	0.631	rs28702649	ENSG00000166763.7	STRCP1	4.12	4.75e-05	0.00998	0.27	0.22	Lung cancer;	chr15:43356431	chr15:43699488~43718184:-
LIHC	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-4.12	4.75e-05	0.00998	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
LIHC	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	4.12	4.75e-05	0.00998	0.34	0.22	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
LIHC	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-4.12	4.75e-05	0.00998	-0.26	-0.22	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
LIHC	cis	rs875971	0.545	rs2173571	ENSG00000228409.4	CCT6P1	-4.12	4.75e-05	0.00998	-0.18	-0.22	Aortic root size;	chr7:66305392	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs11770063	ENSG00000228409.4	CCT6P1	-4.12	4.75e-05	0.00998	-0.18	-0.22	Aortic root size;	chr7:66318029	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs3936065	ENSG00000228409.4	CCT6P1	-4.12	4.75e-05	0.00998	-0.18	-0.22	Aortic root size;	chr7:66325577	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs4718335	ENSG00000228409.4	CCT6P1	-4.12	4.75e-05	0.00998	-0.18	-0.22	Aortic root size;	chr7:66339619	chr7:65751142~65763354:+
LIHC	cis	rs3020736	0.5	rs1801311	ENSG00000226450.2	CYP2D8P	-4.12	4.75e-05	0.00998	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42149886~42155001:-
LIHC	cis	rs7809950	0.834	rs2712199	ENSG00000238832.1	snoU109	-4.12	4.76e-05	0.00999	-0.27	-0.22	Coronary artery disease;	chr7:107499794	chr7:107603363~107603507:+
LIHC	cis	rs10129255	1	rs10141557	ENSG00000224373.3	IGHV4-59	4.12	4.76e-05	0.00999	0.18	0.22	Kawasaki disease;	chr14:106767990	chr14:106627249~106627825:-
LIHC	cis	rs57675369	1	rs57675369	ENSG00000251000.1	AC008592.3	4.12	4.76e-05	0.00999	0.37	0.22	Immature fraction of reticulocytes;	chr5:95826714	chr5:95834424~95835046:-
LIHC	cis	rs3015497	0.753	rs4643225	ENSG00000269906.1	RP11-248J18.2	4.12	4.76e-05	0.00999	0.28	0.22	Mean platelet volume;	chr14:50655487	chr14:50662511~50663178:-
LIHC	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-4.12	4.76e-05	0.00999	-0.28	-0.22	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
LIHC	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-4.12	4.76e-05	0.00999	-0.28	-0.22	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
LIHC	cis	rs2243480	1	rs12698509	ENSG00000230295.1	RP11-458F8.2	-4.12	4.76e-05	0.00999	-0.23	-0.22	Diabetic kidney disease;	chr7:65953889	chr7:66880708~66882981:+
LIHC	cis	rs763121	0.925	rs17032	ENSG00000273076.1	RP3-508I15.22	4.12	4.76e-05	0.01	0.23	0.22	Menopause (age at onset);	chr22:38734838	chr22:38743495~38743910:+
LIHC	cis	rs57502260	0.704	rs72936570	ENSG00000212093.1	AP000807.1	4.12	4.76e-05	0.01	0.3	0.22	Total body bone mineral density (age 45-60);	chr11:68539671	chr11:68506083~68506166:-
LIHC	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-4.12	4.76e-05	0.01	-0.26	-0.22	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
LIHC	cis	rs7586604	0.608	rs10204617	ENSG00000230393.1	AC092667.2	4.12	4.76e-05	0.01	0.28	0.22	Cannabis dependence symptom count;	chr2:99789291	chr2:100104919~100107504:+
LIHC	cis	rs7586604	0.608	rs62147565	ENSG00000230393.1	AC092667.2	4.12	4.76e-05	0.01	0.28	0.22	Cannabis dependence symptom count;	chr2:99792258	chr2:100104919~100107504:+
LIHC	cis	rs7586604	0.608	rs2309650	ENSG00000230393.1	AC092667.2	4.12	4.76e-05	0.01	0.28	0.22	Cannabis dependence symptom count;	chr2:99792312	chr2:100104919~100107504:+
LIHC	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-4.12	4.77e-05	0.01	-0.3	-0.22	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
LIHC	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.77e-05	0.01	-0.21	-0.22	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
LIHC	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	4.12	4.77e-05	0.01	0.26	0.22	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
LIHC	cis	rs9907295	0.901	rs4251729	ENSG00000270871.1	AC015849.19	4.12	4.77e-05	0.01	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35818348	chr17:35816717~35830293:-
LIHC	cis	rs929596	0.793	rs2741044	ENSG00000233445.1	RPL17P11	4.12	4.77e-05	0.01	0.32	0.22	Total bilirubin levels in HIV-1 infection;	chr2:233670722	chr2:233721522~233722065:-
LIHC	cis	rs4650994	1	rs10913568	ENSG00000273384.1	RP5-1098D14.1	4.12	4.77e-05	0.01	0.27	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178544276	chr1:178651706~178652282:+
LIHC	cis	rs2243480	0.831	rs7806717	ENSG00000232546.1	RP11-458F8.1	4.12	4.77e-05	0.01	0.24	0.22	Diabetic kidney disease;	chr7:65928187	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs78803505	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65917585	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs34933526	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65918212	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs34577383	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65920739	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs6949812	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65922114	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs6970243	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65923503	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs7794661	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65924743	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs7795242	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65925107	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.708	rs35310401	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65925372	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs35058610	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65925938	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs2177703	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65926730	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs35432774	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65928032	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs56985706	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65929575	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs60683927	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65929781	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs58062456	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65929865	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs34529418	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65938222	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.901	rs35087093	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65940221	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs35046236	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65943626	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs36068983	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65944004	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs68189316	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65944182	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.803	rs34804747	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65947955	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs11538349	ENSG00000232546.1	RP11-458F8.1	-4.12	4.77e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:65956884	chr7:66848496~66858136:+
LIHC	cis	rs3812762	0.879	rs10743088	ENSG00000254860.4	TMEM9B-AS1	-4.12	4.77e-05	0.01	-0.23	-0.22	Hypospadias;	chr11:8766073	chr11:8964675~8977527:+
LIHC	cis	rs4650994	1	rs10798615	ENSG00000273384.1	RP5-1098D14.1	4.12	4.78e-05	0.01	0.27	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178544760	chr1:178651706~178652282:+
LIHC	cis	rs2070488	0.965	rs1065800	ENSG00000229589.1	ACVR2B-AS1	-4.12	4.78e-05	0.01	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38524989	chr3:38451027~38454820:-
LIHC	cis	rs6480314	0.831	rs6480318	ENSG00000233590.1	RP11-153K11.3	-4.12	4.78e-05	0.01	-0.3	-0.22	Optic nerve measurement (disc area);	chr10:68224348	chr10:68233251~68242379:-
LIHC	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	4.12	4.78e-05	0.01	0.21	0.22	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
LIHC	cis	rs2877649	0.793	rs79461934	ENSG00000258744.1	RP11-80A15.1	-4.12	4.78e-05	0.01	-0.45	-0.22	Smooth-surface caries;	chr14:24485438	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs112628162	ENSG00000258744.1	RP11-80A15.1	-4.12	4.78e-05	0.01	-0.45	-0.22	Smooth-surface caries;	chr14:24491459	chr14:24501594~24508688:+
LIHC	cis	rs2877649	0.793	rs76857510	ENSG00000258744.1	RP11-80A15.1	-4.12	4.78e-05	0.01	-0.45	-0.22	Smooth-surface caries;	chr14:24498552	chr14:24501594~24508688:+
LIHC	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-4.12	4.78e-05	0.01	-0.21	-0.22	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
LIHC	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-4.12	4.78e-05	0.01	-0.21	-0.22	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
LIHC	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-4.12	4.78e-05	0.01	-0.26	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
LIHC	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.78e-05	0.01	-0.21	-0.22	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.78e-05	0.01	-0.21	-0.22	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
LIHC	cis	rs7474896	0.616	rs2474561	ENSG00000120555.12	SEPT7P9	4.12	4.78e-05	0.01	0.29	0.22	Obesity (extreme);	chr10:38084616	chr10:38383069~38402916:-
LIHC	cis	rs6433895	0.71	rs34467063	ENSG00000236153.1	AC104076.3	-4.12	4.79e-05	0.01	-0.32	-0.22	Lymphocyte counts;	chr2:181149252	chr2:180979427~180980090:-
LIHC	cis	rs2243480	1	rs2533288	ENSG00000232546.1	RP11-458F8.1	-4.12	4.79e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:66591724	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs2707844	ENSG00000232546.1	RP11-458F8.1	-4.12	4.79e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:66594522	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs1796220	ENSG00000232546.1	RP11-458F8.1	-4.12	4.79e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:66597113	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs2707831	ENSG00000232546.1	RP11-458F8.1	-4.12	4.79e-05	0.01	-0.24	-0.22	Diabetic kidney disease;	chr7:66597524	chr7:66848496~66858136:+
LIHC	cis	rs4970988	0.607	rs7548516	ENSG00000231073.1	RP11-316M1.3	-4.12	4.79e-05	0.01	-0.23	-0.22	Urate levels;	chr1:151007805	chr1:150973123~150975534:+
LIHC	cis	rs617219	0.889	rs1316776	ENSG00000251675.1	CTC-458I2.2	-4.12	4.79e-05	0.01	-0.24	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79134784	chr5:80128361~80143883:+
LIHC	cis	rs617219	0.889	rs10042338	ENSG00000251675.1	CTC-458I2.2	-4.12	4.79e-05	0.01	-0.24	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79135254	chr5:80128361~80143883:+
LIHC	cis	rs1223397	0.938	rs34505804	ENSG00000215022.6	RP1-257A7.4	-4.12	4.79e-05	0.01	-0.29	-0.22	Blood pressure;	chr6:13292282	chr6:13264861~13295586:-
LIHC	cis	rs9527	0.59	rs10786741	ENSG00000236937.2	PTGES3P4	4.12	4.79e-05	0.01	0.28	0.22	Arsenic metabolism;	chr10:103179425	chr10:102845595~102845950:+
LIHC	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	4.12	4.79e-05	0.01	0.35	0.22	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	4.12	4.79e-05	0.01	0.35	0.22	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
LIHC	cis	rs11098499	0.863	rs58452170	ENSG00000260091.1	RP11-33B1.4	-4.12	4.79e-05	0.01	-0.16	-0.22	Corneal astigmatism;	chr4:119538519	chr4:119409333~119410233:+
LIHC	cis	rs2439831	0.867	rs2260160	ENSG00000166763.7	STRCP1	4.12	4.79e-05	0.01	0.34	0.22	Lung cancer in ever smokers;	chr15:43603445	chr15:43699488~43718184:-
LIHC	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-4.12	4.79e-05	0.0101	-0.2	-0.22	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
LIHC	cis	rs6472235	0.656	rs72650541	ENSG00000272010.1	CTD-3025N20.3	-4.12	4.8e-05	0.0101	-0.3	-0.22	Plateletcrit;Myopia (pathological);	chr8:65966056	chr8:65591850~65592472:-
LIHC	cis	rs6472235	0.656	rs62506593	ENSG00000272010.1	CTD-3025N20.3	-4.12	4.8e-05	0.0101	-0.3	-0.22	Plateletcrit;Myopia (pathological);	chr8:65966114	chr8:65591850~65592472:-
LIHC	cis	rs6472235	0.656	rs16932382	ENSG00000272010.1	CTD-3025N20.3	-4.12	4.8e-05	0.0101	-0.3	-0.22	Plateletcrit;Myopia (pathological);	chr8:65966241	chr8:65591850~65592472:-
LIHC	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	4.12	4.8e-05	0.0101	0.24	0.22	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
LIHC	cis	rs1223397	0.702	rs13191897	ENSG00000215022.6	RP1-257A7.4	-4.12	4.8e-05	0.0101	-0.29	-0.22	Blood pressure;	chr6:13288196	chr6:13264861~13295586:-
LIHC	cis	rs4578769	0.765	rs11082147	ENSG00000266850.1	RP11-370A5.1	-4.12	4.8e-05	0.0101	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22806559	chr18:22723491~22907721:-
LIHC	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.8e-05	0.0101	-0.21	-0.22	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.8e-05	0.0101	-0.21	-0.22	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.8e-05	0.0101	-0.21	-0.22	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.8e-05	0.0101	-0.21	-0.22	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.8e-05	0.0101	-0.21	-0.22	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.8e-05	0.0101	-0.21	-0.22	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-4.12	4.8e-05	0.0101	-0.21	-0.22	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
LIHC	cis	rs2243480	1	rs313832	ENSG00000232546.1	RP11-458F8.1	-4.12	4.8e-05	0.0101	-0.24	-0.22	Diabetic kidney disease;	chr7:66085904	chr7:66848496~66858136:+
LIHC	cis	rs2320952	0.874	rs11078853	ENSG00000264016.2	CTC-297N7.9	-4.12	4.81e-05	0.0101	-0.23	-0.22	Gut microbiome composition (winter);	chr17:10588844	chr17:10741267~10769016:-
LIHC	cis	rs4578769	0.765	rs16972427	ENSG00000266850.1	RP11-370A5.1	-4.12	4.81e-05	0.0101	-0.26	-0.22	Eosinophil percentage of white cells;	chr18:22833393	chr18:22723491~22907721:-
LIHC	cis	rs703842	0.616	rs10783851	ENSG00000270039.1	RP11-571M6.17	4.12	4.81e-05	0.0101	0.31	0.22	Multiple sclerosis;	chr12:57837372	chr12:57803838~57804415:+
LIHC	cis	rs603446	0.586	rs1787690	ENSG00000254851.1	RP11-109L13.1	4.12	4.81e-05	0.0101	0.28	0.22	Triglycerides;	chr11:116697800	chr11:117135528~117138582:+
LIHC	cis	rs603446	0.586	rs947986	ENSG00000254851.1	RP11-109L13.1	4.12	4.81e-05	0.0101	0.28	0.22	Triglycerides;	chr11:116698488	chr11:117135528~117138582:+
LIHC	cis	rs481331	0.741	rs7072200	ENSG00000185904.10	LINC00839	4.12	4.81e-05	0.0101	0.4	0.22	Systemic juvenile idiopathic arthritis;	chr10:42657970	chr10:42475543~42495336:+
LIHC	cis	rs6442522	0.809	rs13081119	ENSG00000249786.6	EAF1-AS1	-4.12	4.81e-05	0.0101	-0.25	-0.22	Uric acid levels;	chr3:15409514	chr3:15436171~15455940:-
LIHC	cis	rs734999	0.588	rs2260976	ENSG00000225931.3	RP3-395M20.7	-4.12	4.81e-05	0.0101	-0.23	-0.22	Ulcerative colitis;	chr1:2596239	chr1:2566410~2569888:+
LIHC	cis	rs10833905	1	rs77438393	ENSG00000246225.5	RP11-17A1.3	-4.12	4.82e-05	0.0101	-0.28	-0.22	Sudden cardiac arrest;	chr11:22991177	chr11:22829380~22945393:+
LIHC	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	4.12	4.82e-05	0.0101	0.19	0.22	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
LIHC	cis	rs2739330	0.753	rs4822452	ENSG00000206090.4	AP000350.7	4.12	4.82e-05	0.0101	0.26	0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23939998~23942798:+
LIHC	cis	rs9907295	0.688	rs4572457	ENSG00000270871.1	AC015849.19	4.12	4.82e-05	0.0101	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35813645	chr17:35816717~35830293:-
LIHC	cis	rs2243480	0.803	rs35480979	ENSG00000230295.1	RP11-458F8.2	-4.12	4.82e-05	0.0101	-0.23	-0.22	Diabetic kidney disease;	chr7:65892097	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34637256	ENSG00000230295.1	RP11-458F8.2	-4.12	4.82e-05	0.0101	-0.23	-0.22	Diabetic kidney disease;	chr7:65895144	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs35391607	ENSG00000230295.1	RP11-458F8.2	-4.12	4.82e-05	0.0101	-0.23	-0.22	Diabetic kidney disease;	chr7:65895842	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs13220979	ENSG00000230295.1	RP11-458F8.2	-4.12	4.82e-05	0.0101	-0.23	-0.22	Diabetic kidney disease;	chr7:65898217	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs34974928	ENSG00000230295.1	RP11-458F8.2	-4.12	4.82e-05	0.0101	-0.23	-0.22	Diabetic kidney disease;	chr7:65899019	chr7:66880708~66882981:+
LIHC	cis	rs3015497	0.789	rs10133849	ENSG00000269906.1	RP11-248J18.2	4.12	4.82e-05	0.0101	0.28	0.22	Mean platelet volume;	chr14:50654982	chr14:50662511~50663178:-
LIHC	cis	rs6496667	0.509	rs2657948	ENSG00000213471.7	TTLL13P	4.12	4.82e-05	0.0101	0.28	0.22	Rheumatoid arthritis;	chr15:90405385	chr15:90249530~90265482:+
LIHC	cis	rs7923609	0.818	rs10822159	ENSG00000232075.1	MRPL35P2	-4.12	4.82e-05	0.0101	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63336490	chr10:63634317~63634827:-
LIHC	cis	rs4561483	0.801	rs8061189	ENSG00000261560.1	RP11-166B2.3	4.12	4.82e-05	0.0101	0.25	0.22	Testicular germ cell tumor;	chr16:11857892	chr16:11881075~11882569:-
LIHC	cis	rs16958440	1	rs60422392	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47095102	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs2289130	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47100259	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs62096463	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47102557	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs62096464	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47102836	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs16958440	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47106513	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs75800624	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47107234	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs62096466	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47109800	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs76594057	ENSG00000267724.1	RP11-49K24.8	4.12	4.82e-05	0.0101	0.33	0.22	Sitting height ratio;	chr18:47110901	chr18:47105946~47108062:+
LIHC	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	4.12	4.82e-05	0.0101	0.27	0.22	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
LIHC	cis	rs755249	0.567	rs113214136	ENSG00000182109.6	RP11-69E11.4	4.12	4.83e-05	0.0101	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs3768302	ENSG00000182109.6	RP11-69E11.4	4.12	4.83e-05	0.0101	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.532	rs17343193	ENSG00000182109.6	RP11-69E11.4	4.12	4.83e-05	0.0101	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs61779300	ENSG00000182109.6	RP11-69E11.4	4.12	4.83e-05	0.0101	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39522280~39546187:-
LIHC	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	4.12	4.83e-05	0.0101	0.26	0.22	Height;	chr6:109421257	chr6:109382795~109383666:+
LIHC	cis	rs4604234	0.708	rs11966262	ENSG00000272129.1	RP11-250B2.6	-4.12	4.83e-05	0.0101	-0.34	-0.22	Cancer;	chr6:80294867	chr6:80355424~80356859:+
LIHC	cis	rs77972916	0.614	rs80323638	ENSG00000234936.1	AC010883.5	4.12	4.83e-05	0.0101	0.47	0.22	Granulocyte percentage of myeloid white cells;	chr2:43242476	chr2:43229573~43233394:+
LIHC	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-4.12	4.83e-05	0.0101	-0.22	-0.22	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
LIHC	cis	rs6893782	0.83	rs274553	ENSG00000233006.5	AC034220.3	-4.12	4.83e-05	0.0101	-0.3	-0.22	Acylcarnitine levels;	chr5:132390140	chr5:132311285~132369916:-
LIHC	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	4.12	4.83e-05	0.0101	0.17	0.22	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
LIHC	cis	rs10833905	1	rs112686297	ENSG00000246225.5	RP11-17A1.3	-4.12	4.83e-05	0.0101	-0.28	-0.22	Sudden cardiac arrest;	chr11:23001448	chr11:22829380~22945393:+
LIHC	cis	rs2115630	0.936	rs8033459	ENSG00000259295.5	CSPG4P12	-4.12	4.84e-05	0.0101	-0.26	-0.22	P wave terminal force;	chr15:84710027	chr15:85191438~85213905:+
LIHC	cis	rs875971	0.545	rs1909508	ENSG00000273024.4	INTS4P2	-4.12	4.84e-05	0.0101	-0.25	-0.22	Aortic root size;	chr7:66301366	chr7:65647864~65715661:+
LIHC	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	4.12	4.84e-05	0.0101	0.25	0.22	Height;	chr4:55528801	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	4.12	4.84e-05	0.0101	0.25	0.22	Height;	chr4:55529387	chr4:55363971~55395847:-
LIHC	cis	rs1247318	1	rs1247302	ENSG00000243831.1	RP1-81D8.4	4.12	4.84e-05	0.0101	0.31	0.22	Aging;	chr6:160925412	chr6:160666228~160676523:-
LIHC	cis	rs1005277	0.522	rs9418276	ENSG00000275858.1	RP11-291L22.8	4.12	4.84e-05	0.0101	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38450738~38451069:-
LIHC	cis	rs1005277	0.522	rs7072977	ENSG00000275858.1	RP11-291L22.8	4.12	4.84e-05	0.0101	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38450738~38451069:-
LIHC	cis	rs4650994	1	rs4650994	ENSG00000273384.1	RP5-1098D14.1	-4.12	4.84e-05	0.0101	-0.26	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546177	chr1:178651706~178652282:+
LIHC	cis	rs11098499	0.909	rs28555550	ENSG00000260091.1	RP11-33B1.4	-4.12	4.84e-05	0.0101	-0.16	-0.22	Corneal astigmatism;	chr4:119289885	chr4:119409333~119410233:+
LIHC	cis	rs11098499	1	rs28419773	ENSG00000260091.1	RP11-33B1.4	-4.12	4.84e-05	0.0101	-0.16	-0.22	Corneal astigmatism;	chr4:119289906	chr4:119409333~119410233:+
LIHC	cis	rs11098499	1	rs11726229	ENSG00000260091.1	RP11-33B1.4	-4.12	4.84e-05	0.0101	-0.16	-0.22	Corneal astigmatism;	chr4:119290425	chr4:119409333~119410233:+
LIHC	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-4.12	4.84e-05	0.0101	-0.34	-0.22	Depression;	chr6:28240414	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-4.12	4.84e-05	0.0101	-0.34	-0.22	Depression;	chr6:28240780	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-4.12	4.84e-05	0.0101	-0.34	-0.22	Depression;	chr6:28241324	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-4.12	4.84e-05	0.0101	-0.34	-0.22	Depression;	chr6:28241753	chr6:28115628~28116551:+
LIHC	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-4.12	4.84e-05	0.0101	-0.34	-0.22	Depression;	chr6:28242515	chr6:28115628~28116551:+
LIHC	cis	rs7809950	0.678	rs2237665	ENSG00000238832.1	snoU109	-4.12	4.85e-05	0.0101	-0.28	-0.22	Coronary artery disease;	chr7:107266553	chr7:107603363~107603507:+
LIHC	cis	rs10871290	1	rs11149710	ENSG00000261079.1	RP11-252A24.3	-4.12	4.85e-05	0.0101	-0.25	-0.22	Breast cancer;	chr16:74438648	chr16:74367462~74369826:+
LIHC	cis	rs6710529	1	rs6710529	ENSG00000272555.1	RP11-459I19.1	-4.12	4.85e-05	0.0101	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr2:218780830	chr2:218818690~218819144:+
LIHC	cis	rs2749592	0.55	rs4934881	ENSG00000275858.1	RP11-291L22.8	-4.12	4.85e-05	0.0101	-0.24	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38450738~38451069:-
LIHC	cis	rs2976388	0.59	rs3736011	ENSG00000253196.1	RP11-706C16.7	-4.12	4.85e-05	0.0101	-0.22	-0.22	Urinary tract infection frequency;	chr8:142736371	chr8:142763116~142766427:+
LIHC	cis	rs2976388	0.59	rs7828042	ENSG00000253196.1	RP11-706C16.7	-4.12	4.85e-05	0.0101	-0.22	-0.22	Urinary tract infection frequency;	chr8:142737965	chr8:142763116~142766427:+
LIHC	cis	rs2976388	0.59	rs10110970	ENSG00000253196.1	RP11-706C16.7	-4.12	4.85e-05	0.0101	-0.22	-0.22	Urinary tract infection frequency;	chr8:142738992	chr8:142763116~142766427:+
LIHC	cis	rs6679677	0.543	rs1230680	ENSG00000232450.1	RP4-730K3.3	-4.12	4.85e-05	0.0101	-0.29	-0.22	Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis;	chr1:113754148	chr1:113698884~113699631:-
LIHC	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-4.12	4.85e-05	0.0101	-0.32	-0.22	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
LIHC	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.85e-05	0.0102	-0.23	-0.22	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
LIHC	cis	rs6997458	0.874	rs13252971	ENSG00000253549.4	RP11-317J10.2	4.12	4.85e-05	0.0102	0.23	0.22	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85357055	chr8:85441851~85464915:-
LIHC	cis	rs2070488	0.965	rs2051216	ENSG00000229589.1	ACVR2B-AS1	-4.12	4.85e-05	0.0102	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38520797	chr3:38451027~38454820:-
LIHC	cis	rs41341749	0.831	rs854684	ENSG00000275944.1	RP11-104J23.1	-4.12	4.86e-05	0.0102	-0.21	-0.22	Blood protein levels;	chr17:35985179	chr17:36001419~36011618:+
LIHC	cis	rs7412746	0.611	rs4319334	ENSG00000231073.1	RP11-316M1.3	4.11	4.86e-05	0.0102	0.22	0.22	Melanoma;	chr1:150794346	chr1:150973123~150975534:+
LIHC	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	4.11	4.86e-05	0.0102	0.22	0.22	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
LIHC	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	4.11	4.86e-05	0.0102	0.22	0.22	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
LIHC	cis	rs6456156	0.586	rs9459862	ENSG00000227598.1	RP1-167A14.2	4.11	4.86e-05	0.0102	0.23	0.22	Primary biliary cholangitis;	chr6:167073523	chr6:166969626~166999065:-
LIHC	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	4.11	4.86e-05	0.0102	0.18	0.22	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
LIHC	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-4.11	4.86e-05	0.0102	-0.26	-0.22	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
LIHC	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-4.11	4.87e-05	0.0102	-0.26	-0.22	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
LIHC	cis	rs2749592	0.55	rs10764135	ENSG00000276805.1	RP11-291L22.6	-4.11	4.87e-05	0.0102	-0.26	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38451030~38451785:+
LIHC	cis	rs2749592	0.55	rs12255038	ENSG00000276805.1	RP11-291L22.6	-4.11	4.87e-05	0.0102	-0.26	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38451030~38451785:+
LIHC	cis	rs2749592	0.505	rs7915670	ENSG00000276805.1	RP11-291L22.6	-4.11	4.87e-05	0.0102	-0.26	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38451030~38451785:+
LIHC	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-4.11	4.87e-05	0.0102	-0.27	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
LIHC	cis	rs901683	1	rs34268168	ENSG00000230869.1	CTGLF10P	-4.11	4.87e-05	0.0102	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45493078	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12774690	ENSG00000230869.1	CTGLF10P	-4.11	4.87e-05	0.0102	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45494297	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71499566	ENSG00000230869.1	CTGLF10P	-4.11	4.87e-05	0.0102	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45500567	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71494799	ENSG00000230869.1	CTGLF10P	-4.11	4.87e-05	0.0102	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45507408	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496611	ENSG00000230869.1	CTGLF10P	-4.11	4.87e-05	0.0102	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45526284	chr10:45678692~45700532:+
LIHC	cis	rs7916410	0.505	rs11595406	ENSG00000233590.1	RP11-153K11.3	-4.11	4.87e-05	0.0102	-0.31	-0.22	Optic disc area;	chr10:68185542	chr10:68233251~68242379:-
LIHC	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-4.11	4.87e-05	0.0102	-0.34	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
LIHC	cis	rs1577917	1	rs34281561	ENSG00000234155.1	RP11-30P6.6	4.11	4.87e-05	0.0102	0.28	0.22	Response to antipsychotic treatment;	chr6:85992154	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs35419329	ENSG00000234155.1	RP11-30P6.6	4.11	4.87e-05	0.0102	0.28	0.22	Response to antipsychotic treatment;	chr6:85992573	chr6:85387219~85390186:-
LIHC	cis	rs2439831	1	rs689596	ENSG00000166763.7	STRCP1	4.11	4.87e-05	0.0102	0.3	0.22	Lung cancer in ever smokers;	chr15:43469519	chr15:43699488~43718184:-
LIHC	cis	rs11098499	0.82	rs11737395	ENSG00000260091.1	RP11-33B1.4	-4.11	4.88e-05	0.0102	-0.16	-0.22	Corneal astigmatism;	chr4:119599549	chr4:119409333~119410233:+
LIHC	cis	rs13315871	0.585	rs12107189	ENSG00000272182.1	RP11-802O23.3	4.11	4.88e-05	0.0102	0.42	0.22	Cholesterol, total;	chr3:58363295	chr3:58428255~58428815:+
LIHC	cis	rs864537	0.618	rs2988277	ENSG00000273160.1	RP11-104L21.3	-4.11	4.88e-05	0.0102	-0.3	-0.22	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167462115	chr1:167457742~167459891:-
LIHC	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	4.11	4.88e-05	0.0102	0.25	0.22	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
LIHC	cis	rs6433895	0.677	rs72888919	ENSG00000236153.1	AC104076.3	-4.11	4.89e-05	0.0102	-0.28	-0.22	Lymphocyte counts;	chr2:181162274	chr2:180979427~180980090:-
LIHC	cis	rs11098499	1	rs6849889	ENSG00000260091.1	RP11-33B1.4	-4.11	4.89e-05	0.0102	-0.16	-0.22	Corneal astigmatism;	chr4:119265193	chr4:119409333~119410233:+
LIHC	cis	rs960902	1	rs2192944	ENSG00000213553.4	RPLP0P6	4.11	4.89e-05	0.0102	0.18	0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37504151	chr2:38481851~38482804:+
LIHC	cis	rs7607369	0.58	rs7568196	ENSG00000272555.1	RP11-459I19.1	-4.11	4.89e-05	0.0102	-0.25	-0.22	Amyotrophic lateral sclerosis;Red blood cell count;	chr2:218787650	chr2:218818690~218819144:+
LIHC	cis	rs2286503	0.65	rs1990279	ENSG00000226329.2	AC005682.6	4.11	4.89e-05	0.0102	0.26	0.22	Fibrinogen;	chr7:22851123	chr7:22863874~22881350:-
LIHC	cis	rs2439831	0.681	rs28653441	ENSG00000166763.7	STRCP1	4.11	4.89e-05	0.0102	0.3	0.22	Lung cancer in ever smokers;	chr15:43385064	chr15:43699488~43718184:-
LIHC	cis	rs1322639	0.614	rs4708414	ENSG00000261039.2	RP11-417E7.2	-4.11	4.89e-05	0.0102	-0.22	-0.22	Pulse pressure;	chr6:169174049	chr6:169175304~169182740:-
LIHC	cis	rs919433	0.889	rs12472355	ENSG00000231621.1	AC013264.2	4.11	4.89e-05	0.0102	0.2	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197341116	chr2:197197991~197199273:+
LIHC	cis	rs4650994	1	rs4511075	ENSG00000273384.1	RP5-1098D14.1	4.11	4.9e-05	0.0102	0.27	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178549501	chr1:178651706~178652282:+
LIHC	cis	rs4650994	1	rs12138541	ENSG00000273384.1	RP5-1098D14.1	4.11	4.9e-05	0.0102	0.27	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178549572	chr1:178651706~178652282:+
LIHC	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-4.11	4.9e-05	0.0102	-0.21	-0.22	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
LIHC	cis	rs12681287	0.64	rs7007855	ENSG00000254088.1	SLC2A3P4	-4.11	4.9e-05	0.0102	-0.25	-0.22	Caudate activity during reward;	chr8:86417262	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.57	rs10956830	ENSG00000254088.1	SLC2A3P4	-4.11	4.9e-05	0.0102	-0.25	-0.22	Caudate activity during reward;	chr8:86418254	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.604	rs28378899	ENSG00000254088.1	SLC2A3P4	-4.11	4.9e-05	0.0102	-0.25	-0.22	Caudate activity during reward;	chr8:86422271	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs10098356	ENSG00000254088.1	SLC2A3P4	-4.11	4.9e-05	0.0102	-0.25	-0.22	Caudate activity during reward;	chr8:86430438	chr8:86503591~86505061:+
LIHC	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-4.11	4.9e-05	0.0102	-0.22	-0.22	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
LIHC	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-4.11	4.9e-05	0.0102	-0.27	-0.22	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
LIHC	cis	rs9907295	0.748	rs4795091	ENSG00000270871.1	AC015849.19	4.11	4.9e-05	0.0102	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35814874	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.71	rs4795092	ENSG00000270871.1	AC015849.19	4.11	4.9e-05	0.0102	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35814967	chr17:35816717~35830293:-
LIHC	cis	rs752590	0.774	rs6755077	ENSG00000189223.12	PAX8-AS1	-4.11	4.9e-05	0.0102	-0.35	-0.22	Mucinous ovarian carcinoma;	chr2:113195931	chr2:113211522~113276581:+
LIHC	cis	rs752590	0.887	rs7603621	ENSG00000189223.12	PAX8-AS1	-4.11	4.9e-05	0.0102	-0.35	-0.22	Mucinous ovarian carcinoma;	chr2:113196407	chr2:113211522~113276581:+
LIHC	cis	rs2470135	1	rs2470135	ENSG00000275601.1	AC011330.13	-4.11	4.91e-05	0.0102	-0.26	-0.22	Diastolic blood pressure;	chr15:43703591	chr15:43642389~43643023:-
LIHC	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.91e-05	0.0103	-0.23	-0.22	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
LIHC	cis	rs5758659	0.729	rs134866	ENSG00000227370.1	RP4-669P10.19	-4.11	4.91e-05	0.0103	-0.24	-0.22	Cognitive function;	chr22:42254657	chr22:42132543~42132998:+
LIHC	cis	rs5742933	0.857	rs11685425	ENSG00000253559.1	OSGEPL1-AS1	4.11	4.91e-05	0.0103	0.28	0.22	Ferritin levels;	chr2:189747977	chr2:189762704~189765556:+
LIHC	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	4.11	4.92e-05	0.0103	0.25	0.22	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
LIHC	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	4.11	4.92e-05	0.0103	0.25	0.22	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
LIHC	cis	rs11098499	0.722	rs1814814	ENSG00000260091.1	RP11-33B1.4	-4.11	4.92e-05	0.0103	-0.15	-0.22	Corneal astigmatism;	chr4:119336969	chr4:119409333~119410233:+
LIHC	cis	rs7923609	0.812	rs10822155	ENSG00000232075.1	MRPL35P2	-4.11	4.92e-05	0.0103	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63311455	chr10:63634317~63634827:-
LIHC	cis	rs2439831	1	rs561863	ENSG00000166763.7	STRCP1	4.11	4.92e-05	0.0103	0.3	0.22	Lung cancer in ever smokers;	chr15:43469154	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.867	rs689616	ENSG00000166763.7	STRCP1	4.11	4.92e-05	0.0103	0.3	0.22	Lung cancer in ever smokers;	chr15:43469703	chr15:43699488~43718184:-
LIHC	cis	rs2439831	1	rs689647	ENSG00000166763.7	STRCP1	4.11	4.92e-05	0.0103	0.3	0.22	Lung cancer in ever smokers;	chr15:43469998	chr15:43699488~43718184:-
LIHC	cis	rs2439831	1	rs2251538	ENSG00000166763.7	STRCP1	4.11	4.92e-05	0.0103	0.3	0.22	Lung cancer in ever smokers;	chr15:43475011	chr15:43699488~43718184:-
LIHC	cis	rs2494250	0.542	rs9782926	ENSG00000231434.1	RP11-144L1.8	-4.11	4.92e-05	0.0103	-0.26	-0.22	Select biomarker traits;	chr1:159353602	chr1:158523672~158525838:+
LIHC	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	4.11	4.92e-05	0.0103	0.26	0.22	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
LIHC	cis	rs860295	0.871	rs11582072	ENSG00000203761.5	MSTO2P	4.11	4.92e-05	0.0103	0.18	0.22	Body mass index;	chr1:155507779	chr1:155745829~155750137:+
LIHC	cis	rs7726839	0.54	rs72703087	ENSG00000271781.1	CTD-2589H19.6	-4.11	4.92e-05	0.0103	-0.33	-0.22	Obesity-related traits;	chr5:597914	chr5:675826~676616:+
LIHC	cis	rs8177253	0.606	rs6787177	ENSG00000244062.1	RP11-404G16.2	4.11	4.93e-05	0.0103	0.21	0.22	Iron status biomarkers;	chr3:133731876	chr3:133760300~133762363:+
LIHC	cis	rs8064024	0.65	rs8056889	ENSG00000267077.1	RP11-127I20.5	4.11	4.93e-05	0.0103	0.22	0.22	Cancer;	chr16:4853242	chr16:4795265~4796532:-
LIHC	cis	rs2904804	0.792	rs2904795	ENSG00000224251.5	RP11-499O7.7	4.11	4.93e-05	0.0103	0.28	0.22	Economic and political preferences (immigration/crime);	chr10:4962125	chr10:4995488~4997380:+
LIHC	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-4.11	4.93e-05	0.0103	-0.28	-0.22	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
LIHC	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	4.11	4.93e-05	0.0103	0.19	0.22	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
LIHC	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-4.11	4.93e-05	0.0103	-0.28	-0.22	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
LIHC	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	4.11	4.93e-05	0.0103	0.28	0.22	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
LIHC	cis	rs4650994	1	rs12138561	ENSG00000273384.1	RP5-1098D14.1	4.11	4.93e-05	0.0103	0.27	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178549649	chr1:178651706~178652282:+
LIHC	cis	rs875971	0.528	rs801213	ENSG00000224316.1	RP11-479O9.2	-4.11	4.93e-05	0.0103	-0.21	-0.22	Aortic root size;	chr7:66549931	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.545	rs801212	ENSG00000224316.1	RP11-479O9.2	-4.11	4.93e-05	0.0103	-0.21	-0.22	Aortic root size;	chr7:66550643	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.545	rs73152714	ENSG00000224316.1	RP11-479O9.2	4.11	4.93e-05	0.0103	0.21	0.22	Aortic root size;	chr7:66534641	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.545	rs4718364	ENSG00000224316.1	RP11-479O9.2	4.11	4.93e-05	0.0103	0.21	0.22	Aortic root size;	chr7:66536353	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.545	rs6961853	ENSG00000224316.1	RP11-479O9.2	4.11	4.93e-05	0.0103	0.21	0.22	Aortic root size;	chr7:66537035	chr7:65773620~65802067:+
LIHC	cis	rs1005277	0.54	rs2145487	ENSG00000099251.13	HSD17B7P2	4.11	4.93e-05	0.0103	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.54	rs4934907	ENSG00000099251.13	HSD17B7P2	4.11	4.93e-05	0.0103	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.54	rs11011351	ENSG00000099251.13	HSD17B7P2	4.11	4.93e-05	0.0103	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38356380~38378505:+
LIHC	cis	rs6471393	0.964	rs2914942	ENSG00000253848.1	RP11-10N23.5	-4.11	4.94e-05	0.0103	-0.24	-0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93714189	chr8:93741193~93744534:+
LIHC	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-4.11	4.94e-05	0.0103	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
LIHC	cis	rs9675120	0.925	rs3803884	ENSG00000262006.1	RP11-700H6.4	-4.11	4.94e-05	0.0103	-0.23	-0.22	Cerebrospinal fluid biomarker levels;	chr17:50841678	chr17:50909637~50910232:-
LIHC	cis	rs7937890	1	rs6486190	ENSG00000251991.1	RNU7-49P	4.11	4.95e-05	0.0103	0.23	0.22	Mitochondrial DNA levels;	chr11:14379670	chr11:14478892~14478953:+
LIHC	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	4.11	4.95e-05	0.0103	0.25	0.22	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
LIHC	cis	rs1577917	1	rs12207305	ENSG00000234155.1	RP11-30P6.6	4.11	4.95e-05	0.0103	0.28	0.22	Response to antipsychotic treatment;	chr6:86013784	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12199784	ENSG00000234155.1	RP11-30P6.6	4.11	4.95e-05	0.0103	0.28	0.22	Response to antipsychotic treatment;	chr6:86017090	chr6:85387219~85390186:-
LIHC	cis	rs3015497	0.753	rs12881776	ENSG00000269906.1	RP11-248J18.2	4.11	4.95e-05	0.0103	0.28	0.22	Mean platelet volume;	chr14:50669612	chr14:50662511~50663178:-
LIHC	cis	rs1023500	1	rs10154646	ENSG00000237037.8	NDUFA6-AS1	-4.11	4.95e-05	0.0103	-0.3	-0.22	Schizophrenia;	chr22:41935405	chr22:42090931~42137742:+
LIHC	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-4.11	4.95e-05	0.0103	-0.28	-0.22	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-4.11	4.95e-05	0.0103	-0.28	-0.22	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-4.11	4.95e-05	0.0103	-0.28	-0.22	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
LIHC	cis	rs7121538	0.551	rs12421455	ENSG00000251991.1	RNU7-49P	-4.11	4.96e-05	0.0103	-0.35	-0.22	HDL cholesterol;	chr11:14511995	chr11:14478892~14478953:+
LIHC	cis	rs1223397	0.651	rs453877	ENSG00000215022.6	RP1-257A7.4	-4.11	4.96e-05	0.0103	-0.23	-0.22	Blood pressure;	chr6:13297231	chr6:13264861~13295586:-
LIHC	cis	rs16958440	1	rs16958432	ENSG00000267724.1	RP11-49K24.8	4.11	4.96e-05	0.0103	0.33	0.22	Sitting height ratio;	chr18:47105402	chr18:47105946~47108062:+
LIHC	cis	rs12936587	0.935	rs12449964	ENSG00000223979.2	SMCR2	-4.11	4.96e-05	0.0103	-0.26	-0.22	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17641390	chr17:17674026~17677688:-
LIHC	cis	rs11148252	0.669	rs4884320	ENSG00000278238.1	RP11-245D16.4	-4.11	4.96e-05	0.0103	-0.21	-0.22	Lewy body disease;	chr13:52432779	chr13:52454775~52455331:-
LIHC	cis	rs2439831	0.681	rs7175434	ENSG00000166763.7	STRCP1	4.11	4.96e-05	0.0104	0.3	0.22	Lung cancer in ever smokers;	chr15:43336344	chr15:43699488~43718184:-
LIHC	cis	rs2243480	1	rs55895244	ENSG00000232546.1	RP11-458F8.1	-4.11	4.96e-05	0.0104	-0.24	-0.22	Diabetic kidney disease;	chr7:65922691	chr7:66848496~66858136:+
LIHC	cis	rs2283831	0.524	rs2187862	ENSG00000213707.2	HMGB1P10	-4.11	4.97e-05	0.0104	-0.27	-0.22	Anti-saccade response;	chr22:26559320	chr22:26560526~26561088:+
LIHC	cis	rs73081554	0.505	rs2063644	ENSG00000272360.1	RP11-359I18.5	-4.11	4.97e-05	0.0104	-0.31	-0.22	Rheumatoid arthritis;	chr3:58345215	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.666	rs13077234	ENSG00000272360.1	RP11-359I18.5	4.11	4.97e-05	0.0104	0.3	0.22	Systemic lupus erythematosus;	chr3:58450978	chr3:58490830~58491291:-
LIHC	cis	rs4356975	0.932	rs60814050	ENSG00000250919.1	RP11-813N20.3	-4.11	4.97e-05	0.0104	-0.22	-0.22	Obesity-related traits;	chr4:69063770	chr4:69027831~69044578:+
LIHC	cis	rs3015497	0.616	rs34061700	ENSG00000269906.1	RP11-248J18.2	4.11	4.97e-05	0.0104	0.27	0.22	Mean platelet volume;	chr14:50618142	chr14:50662511~50663178:-
LIHC	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-4.11	4.98e-05	0.0104	-0.21	-0.22	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
LIHC	cis	rs2243480	0.901	rs57126451	ENSG00000232546.1	RP11-458F8.1	-4.11	4.98e-05	0.0104	-0.24	-0.22	Diabetic kidney disease;	chr7:65951319	chr7:66848496~66858136:+
LIHC	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	4.11	4.98e-05	0.0104	0.24	0.22	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
LIHC	cis	rs1075265	0.563	rs2692536	ENSG00000272156.1	RP11-477N3.1	-4.11	4.98e-05	0.0104	-0.26	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54082554~54085066:+
LIHC	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-4.11	4.98e-05	0.0104	-0.25	-0.22	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
LIHC	cis	rs1577917	0.917	rs35038582	ENSG00000234155.1	RP11-30P6.6	4.11	4.98e-05	0.0104	0.28	0.22	Response to antipsychotic treatment;	chr6:86011587	chr6:85387219~85390186:-
LIHC	cis	rs10857712	0.754	rs1052582	ENSG00000214279.11	SCART1	-4.11	4.98e-05	0.0104	-0.27	-0.22	Systemic lupus erythematosus;	chr10:133420336	chr10:133453928~133523558:+
LIHC	cis	rs1577917	1	rs12199516	ENSG00000234155.1	RP11-30P6.6	4.11	4.98e-05	0.0104	0.28	0.22	Response to antipsychotic treatment;	chr6:86016503	chr6:85387219~85390186:-
LIHC	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	4.11	4.99e-05	0.0104	0.32	0.22	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
LIHC	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	4.11	4.99e-05	0.0104	0.17	0.22	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
LIHC	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	4.11	4.99e-05	0.0104	0.35	0.22	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
LIHC	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	4.11	4.99e-05	0.0104	0.35	0.22	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
LIHC	cis	rs7989332	0.89	rs4770042	ENSG00000275964.1	RP11-61K9.3	-4.11	4.99e-05	0.0104	-0.26	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20480765	chr13:19863858~19865048:+
LIHC	cis	rs987724	0.515	rs1574980	ENSG00000243926.1	TIPARP-AS1	4.11	4.99e-05	0.0104	0.24	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156917639	chr3:156671862~156674378:-
LIHC	cis	rs987724	0.501	rs2321293	ENSG00000243926.1	TIPARP-AS1	4.11	4.99e-05	0.0104	0.24	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156931311	chr3:156671862~156674378:-
LIHC	cis	rs2243480	1	rs313831	ENSG00000230295.1	RP11-458F8.2	-4.11	4.99e-05	0.0104	-0.23	-0.22	Diabetic kidney disease;	chr7:66086239	chr7:66880708~66882981:+
LIHC	cis	rs901683	1	rs71494791	ENSG00000230869.1	CTGLF10P	-4.11	4.99e-05	0.0104	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45482883	chr10:45678692~45700532:+
LIHC	cis	rs17818399	0.612	rs4952834	ENSG00000239332.4	LINC01119	-4.11	5e-05	0.0104	-0.3	-0.22	Height;	chr2:46550323	chr2:46816697~46859007:+
LIHC	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-4.11	5e-05	0.0104	-0.33	-0.22	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
LIHC	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-4.11	5e-05	0.0104	-0.33	-0.22	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
LIHC	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	4.11	5e-05	0.0104	0.22	0.22	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
LIHC	cis	rs875971	0.545	rs75840613	ENSG00000228409.4	CCT6P1	-4.11	5e-05	0.0104	-0.18	-0.22	Aortic root size;	chr7:66376399	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs73148639	ENSG00000228409.4	CCT6P1	-4.11	5e-05	0.0104	-0.18	-0.22	Aortic root size;	chr7:66390342	chr7:65751142~65763354:+
LIHC	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-4.11	5.01e-05	0.0104	-0.21	-0.22	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
LIHC	cis	rs6439153	0.901	rs2630263	ENSG00000231305.3	RP11-723O4.2	4.11	5.01e-05	0.0104	0.24	0.22	Pneumococcal bacteremia;	chr3:128969475	chr3:128861313~128871540:-
LIHC	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	4.11	5.01e-05	0.0104	0.21	0.22	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
LIHC	cis	rs113084984	0.718	rs4669744	ENSG00000271952.1	RP11-245G13.2	-4.11	5.01e-05	0.0104	-0.27	-0.22	Breast cancer;	chr2:11541442	chr2:10878269~10885118:+
LIHC	cis	rs4578769	0.649	rs6507433	ENSG00000265943.1	RP11-739L10.1	4.11	5.01e-05	0.0104	0.28	0.22	Eosinophil percentage of white cells;	chr18:23011784	chr18:22699481~22933764:-
LIHC	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-4.11	5.01e-05	0.0104	-0.3	-0.22	Height;	chr3:53052712	chr3:53064283~53065091:-
LIHC	cis	rs1223397	0.938	rs35549743	ENSG00000215022.6	RP1-257A7.4	-4.11	5.01e-05	0.0104	-0.29	-0.22	Blood pressure;	chr6:13294122	chr6:13264861~13295586:-
LIHC	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-4.11	5.01e-05	0.0104	-0.21	-0.22	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
LIHC	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-4.11	5.01e-05	0.0104	-0.23	-0.22	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
LIHC	cis	rs7809950	0.678	rs62483640	ENSG00000238832.1	snoU109	-4.11	5.02e-05	0.0104	-0.28	-0.22	Coronary artery disease;	chr7:107259769	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.678	rs62483641	ENSG00000238832.1	snoU109	-4.11	5.02e-05	0.0104	-0.28	-0.22	Coronary artery disease;	chr7:107261296	chr7:107603363~107603507:+
LIHC	cis	rs7809950	0.678	rs2395869	ENSG00000238832.1	snoU109	-4.11	5.02e-05	0.0105	-0.28	-0.22	Coronary artery disease;	chr7:107299653	chr7:107603363~107603507:+
LIHC	cis	rs6445975	0.666	rs6793328	ENSG00000272360.1	RP11-359I18.5	4.11	5.02e-05	0.0105	0.29	0.22	Systemic lupus erythematosus;	chr3:58429145	chr3:58490830~58491291:-
LIHC	cis	rs4925386	1	rs6089351	ENSG00000273619.1	RP5-908M14.9	4.11	5.03e-05	0.0105	0.17	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62386303~62386970:-
LIHC	cis	rs4925386	0.959	rs6121989	ENSG00000273619.1	RP5-908M14.9	4.11	5.03e-05	0.0105	0.17	0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62386303~62386970:-
LIHC	cis	rs748404	0.631	rs8042688	ENSG00000166763.7	STRCP1	4.11	5.03e-05	0.0105	0.27	0.22	Lung cancer;	chr15:43346327	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.631	rs4296223	ENSG00000166763.7	STRCP1	4.11	5.03e-05	0.0105	0.27	0.22	Lung cancer;	chr15:43353048	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.631	rs6493084	ENSG00000166763.7	STRCP1	4.11	5.03e-05	0.0105	0.27	0.22	Lung cancer;	chr15:43355429	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.631	rs12905772	ENSG00000166763.7	STRCP1	4.11	5.03e-05	0.0105	0.27	0.22	Lung cancer;	chr15:43356246	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.676	rs4401024	ENSG00000166763.7	STRCP1	4.11	5.03e-05	0.0105	0.27	0.22	Lung cancer;	chr15:43358137	chr15:43699488~43718184:-
LIHC	cis	rs748404	0.631	rs6493086	ENSG00000166763.7	STRCP1	4.11	5.03e-05	0.0105	0.27	0.22	Lung cancer;	chr15:43363196	chr15:43699488~43718184:-
LIHC	cis	rs6048205	0.764	rs6082743	ENSG00000259974.2	LINC00261	4.11	5.03e-05	0.0105	0.34	0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22545748	chr20:22547671~22578642:-
LIHC	cis	rs73193808	0.639	rs2832241	ENSG00000212479.2	U3	4.11	5.03e-05	0.0105	0.25	0.22	Coronary artery disease;	chr21:29179715	chr21:29180425~29180639:-
LIHC	cis	rs17772222	0.874	rs78077739	ENSG00000258789.1	RP11-507K2.3	-4.11	5.03e-05	0.0105	-0.26	-0.22	Coronary artery calcification;	chr14:88741176	chr14:88551597~88552493:+
LIHC	cis	rs9467711	0.591	rs7748167	ENSG00000216436.2	HIST1H2APS1	4.11	5.03e-05	0.0105	0.49	0.22	Autism spectrum disorder or schizophrenia;	chr6:25904424	chr6:25732497~25732827:+
LIHC	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	4.11	5.03e-05	0.0105	0.24	0.22	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
LIHC	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-4.11	5.03e-05	0.0105	-0.29	-0.22	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
LIHC	cis	rs17214007	0.877	rs10852376	ENSG00000263335.1	AF001548.5	4.11	5.04e-05	0.0105	0.28	0.22	Cognitive function;	chr16:15778216	chr16:15726674~15732993:+
LIHC	cis	rs7044106	0.762	rs10984972	ENSG00000238181.2	AHCYP2	-4.11	5.04e-05	0.0105	-0.25	-0.22	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120720673~120721972:+
LIHC	cis	rs1577917	1	rs12190598	ENSG00000234155.1	RP11-30P6.6	4.11	5.04e-05	0.0105	0.29	0.22	Response to antipsychotic treatment;	chr6:85976356	chr6:85387219~85390186:-
LIHC	cis	rs4938303	0.633	rs12800436	ENSG00000254851.1	RP11-109L13.1	4.11	5.04e-05	0.0105	0.32	0.22	Triglycerides;	chr11:116688086	chr11:117135528~117138582:+
LIHC	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-4.11	5.04e-05	0.0105	-0.29	-0.22	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
LIHC	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	4.11	5.04e-05	0.0105	0.25	0.22	Height;	chr4:55483718	chr4:55363971~55395847:-
LIHC	cis	rs6048205	0.773	rs1203871	ENSG00000259974.2	LINC00261	-4.11	5.05e-05	0.0105	-0.32	-0.22	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr20:22555042	chr20:22547671~22578642:-
LIHC	cis	rs2243480	0.522	rs1638736	ENSG00000230295.1	RP11-458F8.2	-4.11	5.05e-05	0.0105	-0.25	-0.22	Diabetic kidney disease;	chr7:66627321	chr7:66880708~66882981:+
LIHC	cis	rs748404	0.66	rs690367	ENSG00000166763.7	STRCP1	-4.11	5.05e-05	0.0105	-0.27	-0.22	Lung cancer;	chr15:43456106	chr15:43699488~43718184:-
LIHC	cis	rs11585357	0.671	rs2501776	ENSG00000186301.8	MST1P2	4.11	5.05e-05	0.0105	0.31	0.22	Hair shape;	chr1:17292784	chr1:16645622~16650289:+
LIHC	cis	rs938554	0.513	rs3775948	ENSG00000250413.1	RP11-448G15.1	-4.11	5.05e-05	0.0105	-0.3	-0.22	Blood metabolite levels;	chr4:9993558	chr4:10006482~10009725:+
LIHC	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	4.11	5.05e-05	0.0105	0.18	0.22	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
LIHC	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-4.11	5.06e-05	0.0105	-0.31	-0.22	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
LIHC	cis	rs1799810	0.523	rs11683986	ENSG00000231731.6	AC010976.2	4.11	5.06e-05	0.0105	0.21	0.22	Self-rated health;	chr2:127438822	chr2:127455394~127514623:+
LIHC	cis	rs9907295	0.901	rs9898152	ENSG00000270871.1	AC015849.19	4.11	5.06e-05	0.0105	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35869211	chr17:35816717~35830293:-
LIHC	cis	rs9907295	0.901	rs78023535	ENSG00000270871.1	AC015849.19	4.11	5.06e-05	0.0105	0.23	0.22	Fibroblast growth factor basic levels;	chr17:35869598	chr17:35816717~35830293:-
LIHC	cis	rs2274459	0.545	rs72896150	ENSG00000224557.6	HLA-DPB2	-4.11	5.06e-05	0.0105	-0.42	-0.22	Obesity (extreme);	chr6:33825319	chr6:33112451~33129084:+
LIHC	cis	rs17772222	0.917	rs17260380	ENSG00000258789.1	RP11-507K2.3	-4.11	5.06e-05	0.0105	-0.26	-0.22	Coronary artery calcification;	chr14:88682142	chr14:88551597~88552493:+
LIHC	cis	rs755249	0.567	rs3818806	ENSG00000182109.6	RP11-69E11.4	4.1	5.06e-05	0.0105	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs41270799	ENSG00000182109.6	RP11-69E11.4	4.1	5.06e-05	0.0105	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39522280~39546187:-
LIHC	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	4.1	5.06e-05	0.0105	0.25	0.22	Height;	chr4:55486718	chr4:55363971~55395847:-
LIHC	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-4.1	5.07e-05	0.0105	-0.27	-0.22	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
LIHC	cis	rs6745190	0.953	rs13029368	ENSG00000236153.1	AC104076.3	-4.1	5.07e-05	0.0105	-0.32	-0.22	White blood cell count;	chr2:180993441	chr2:180979427~180980090:-
LIHC	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	4.1	5.07e-05	0.0105	0.31	0.22	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
LIHC	cis	rs17270561	0.609	rs1165211	ENSG00000216436.2	HIST1H2APS1	-4.1	5.07e-05	0.0105	-0.26	-0.22	Iron status biomarkers;	chr6:25800694	chr6:25732497~25732827:+
LIHC	cis	rs4578769	0.765	rs1584428	ENSG00000266850.1	RP11-370A5.1	4.1	5.08e-05	0.0105	0.25	0.22	Eosinophil percentage of white cells;	chr18:22807886	chr18:22723491~22907721:-
LIHC	cis	rs7809950	0.768	rs62482493	ENSG00000238832.1	snoU109	-4.1	5.08e-05	0.0105	-0.28	-0.22	Coronary artery disease;	chr7:107311134	chr7:107603363~107603507:+
LIHC	cis	rs4356975	0.83	rs7666894	ENSG00000250919.1	RP11-813N20.3	-4.1	5.08e-05	0.0105	-0.21	-0.22	Obesity-related traits;	chr4:69078780	chr4:69027831~69044578:+
LIHC	cis	rs338389	0.591	rs8037902	ENSG00000260657.2	RP11-315D16.4	4.1	5.08e-05	0.0105	0.27	0.22	Survival in rectal cancer;	chr15:67988365	chr15:68267792~68277994:-
LIHC	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-4.1	5.08e-05	0.0105	-0.21	-0.22	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
LIHC	cis	rs987724	0.515	rs344073	ENSG00000243926.1	TIPARP-AS1	-4.1	5.08e-05	0.0105	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156829224	chr3:156671862~156674378:-
LIHC	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	4.1	5.08e-05	0.0105	0.22	0.22	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
LIHC	cis	rs6061231	0.518	rs639836	ENSG00000226332.2	RP11-157P1.4	-4.1	5.09e-05	0.0106	-0.22	-0.22	Colorectal cancer;	chr20:62351167	chr20:62305432~62306325:-
LIHC	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-4.1	5.09e-05	0.0106	-0.17	-0.22	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
LIHC	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-4.1	5.09e-05	0.0106	-0.24	-0.22	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
LIHC	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-4.1	5.09e-05	0.0106	-0.28	-0.22	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-4.1	5.09e-05	0.0106	-0.28	-0.22	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-4.1	5.09e-05	0.0106	-0.28	-0.22	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-4.1	5.09e-05	0.0106	-0.28	-0.22	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-4.1	5.09e-05	0.0106	-0.28	-0.22	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-4.1	5.09e-05	0.0106	-0.28	-0.22	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
LIHC	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-4.1	5.09e-05	0.0106	-0.28	-0.22	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
LIHC	cis	rs17464492	0.593	rs61044379	ENSG00000246228.5	CASC8	4.1	5.09e-05	0.0106	0.24	0.22	Prostate-specific antigen levels (conditioned on lead SNPs);	chr8:127339709	chr8:127289817~127482139:-
LIHC	cis	rs17464492	0.593	rs28759353	ENSG00000246228.5	CASC8	4.1	5.09e-05	0.0106	0.24	0.22	Prostate-specific antigen levels (conditioned on lead SNPs);	chr8:127340118	chr8:127289817~127482139:-
LIHC	cis	rs9952991	0.941	rs2014857	ENSG00000260302.1	RP11-973H7.1	-4.1	5.09e-05	0.0106	-0.32	-0.22	Inflammatory skin disease;	chr18:12774327	chr18:12774651~12775923:-
LIHC	cis	rs9952991	0.883	rs2847260	ENSG00000260302.1	RP11-973H7.1	-4.1	5.09e-05	0.0106	-0.32	-0.22	Inflammatory skin disease;	chr18:12775592	chr18:12774651~12775923:-
LIHC	cis	rs9952991	0.883	rs2542147	ENSG00000260302.1	RP11-973H7.1	-4.1	5.09e-05	0.0106	-0.32	-0.22	Inflammatory skin disease;	chr18:12775852	chr18:12774651~12775923:-
LIHC	cis	rs481331	0.866	rs11499095	ENSG00000185904.10	LINC00839	4.1	5.09e-05	0.0106	0.4	0.22	Systemic juvenile idiopathic arthritis;	chr10:42488077	chr10:42475543~42495336:+
LIHC	cis	rs481331	0.866	rs1855450	ENSG00000185904.10	LINC00839	4.1	5.09e-05	0.0106	0.4	0.22	Systemic juvenile idiopathic arthritis;	chr10:42488259	chr10:42475543~42495336:+
LIHC	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	4.1	5.09e-05	0.0106	0.25	0.22	Height;	chr4:55407965	chr4:55363971~55395847:-
LIHC	cis	rs2762353	0.718	rs1165160	ENSG00000242387.1	HIST1H2APS2	4.1	5.1e-05	0.0106	0.25	0.22	Blood metabolite levels;	chr6:25864228	chr6:25882026~25882395:-
LIHC	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	4.1	5.1e-05	0.0106	0.31	0.22	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
LIHC	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	4.1	5.1e-05	0.0106	0.25	0.22	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
LIHC	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	4.1	5.1e-05	0.0106	0.25	0.22	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
LIHC	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	4.1	5.1e-05	0.0106	0.25	0.22	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
LIHC	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	4.1	5.1e-05	0.0106	0.25	0.22	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
LIHC	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-4.1	5.11e-05	0.0106	-0.17	-0.22	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
LIHC	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-4.1	5.11e-05	0.0106	-0.25	-0.22	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
LIHC	cis	rs7989332	0.662	rs9552200	ENSG00000275964.1	RP11-61K9.3	4.1	5.11e-05	0.0106	0.27	0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20487462	chr13:19863858~19865048:+
LIHC	cis	rs2665103	0.61	rs56398167	ENSG00000259429.4	UBE2Q2P2	-4.1	5.11e-05	0.0106	-0.23	-0.22	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82355142~82420075:+
LIHC	cis	rs875971	0.522	rs1701760	ENSG00000273024.4	INTS4P2	-4.1	5.11e-05	0.0106	-0.26	-0.22	Aortic root size;	chr7:66008701	chr7:65647864~65715661:+
LIHC	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-4.1	5.11e-05	0.0106	-0.21	-0.22	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
LIHC	cis	rs72739697	0.892	rs72739688	ENSG00000231084.2	CTA-253N17.1	-4.1	5.11e-05	0.0106	-0.41	-0.22	Itch intensity from mosquito bite adjusted by bite size;	chr1:185034239	chr1:185171335~185171710:-
LIHC	cis	rs2439831	1	rs527921	ENSG00000275601.1	AC011330.13	4.1	5.12e-05	0.0106	0.31	0.22	Lung cancer in ever smokers;	chr15:43478218	chr15:43642389~43643023:-
LIHC	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	4.1	5.12e-05	0.0106	0.25	0.22	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
LIHC	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-4.1	5.12e-05	0.0106	-0.21	-0.22	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
LIHC	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-4.1	5.12e-05	0.0106	-0.23	-0.22	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
LIHC	cis	rs10510102	0.872	rs12259144	ENSG00000273891.1	RP11-500G22.5	4.1	5.12e-05	0.0106	0.29	0.22	Breast cancer;	chr10:121965433	chr10:121965764~121967700:+
LIHC	cis	rs3204270	0.639	rs62080213	ENSG00000281517.1	Metazoa_SRP	-4.1	5.12e-05	0.0106	-0.42	-0.22	Dental caries;	chr17:81675501	chr17:81718849~81719095:-
LIHC	cis	rs72634501	0.54	rs16826036	ENSG00000182109.6	RP11-69E11.4	4.1	5.12e-05	0.0106	0.28	0.22	HDL cholesterol;	chr1:39292127	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs16826038	ENSG00000182109.6	RP11-69E11.4	4.1	5.12e-05	0.0106	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs41270803	ENSG00000182109.6	RP11-69E11.4	4.1	5.12e-05	0.0106	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs61783376	ENSG00000182109.6	RP11-69E11.4	4.1	5.12e-05	0.0106	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs4660636	ENSG00000182109.6	RP11-69E11.4	4.1	5.12e-05	0.0106	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39522280~39546187:-
LIHC	cis	rs7915414	0.951	rs1326837	ENSG00000230338.1	MTND4P19	-4.1	5.12e-05	0.0106	-0.22	-0.22	Clopidogrel active metabolite levels;	chr10:94626449	chr10:94774156~94774633:-
LIHC	cis	rs1530530	0.881	rs17081048	ENSG00000253771.4	TPTE2P1	-4.1	5.13e-05	0.0106	-0.46	-0.22	Obesity-related traits;	chr13:24692250	chr13:24924677~24968487:-
LIHC	cis	rs1005277	0.505	rs10827835	ENSG00000099251.13	HSD17B7P2	-4.1	5.13e-05	0.0106	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38356380~38378505:+
LIHC	cis	rs7985	1	rs1894720	ENSG00000244625.4	MIATNB	4.1	5.13e-05	0.0106	0.24	0.22	Electroencephalogram traits;	chr22:26671261	chr22:26672767~26780207:+
LIHC	cis	rs7985	0.967	rs73163299	ENSG00000244625.4	MIATNB	4.1	5.13e-05	0.0106	0.24	0.22	Electroencephalogram traits;	chr22:26671680	chr22:26672767~26780207:+
LIHC	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	4.1	5.13e-05	0.0106	0.25	0.22	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
LIHC	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	4.1	5.13e-05	0.0106	0.25	0.22	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
LIHC	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	4.1	5.13e-05	0.0106	0.25	0.22	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
LIHC	cis	rs17772222	0.876	rs61983303	ENSG00000258789.1	RP11-507K2.3	-4.1	5.13e-05	0.0106	-0.26	-0.22	Coronary artery calcification;	chr14:88764459	chr14:88551597~88552493:+
LIHC	cis	rs17772222	0.917	rs2224333	ENSG00000258789.1	RP11-507K2.3	-4.1	5.13e-05	0.0106	-0.26	-0.22	Coronary artery calcification;	chr14:88768748	chr14:88551597~88552493:+
LIHC	cis	rs17772222	0.917	rs12590826	ENSG00000258789.1	RP11-507K2.3	-4.1	5.13e-05	0.0106	-0.26	-0.22	Coronary artery calcification;	chr14:88769357	chr14:88551597~88552493:+
LIHC	cis	rs9876781	1	rs7653691	ENSG00000229759.1	MRPS18AP1	-4.1	5.14e-05	0.0106	-0.23	-0.22	Longevity;	chr3:48378199	chr3:48256350~48256938:-
LIHC	cis	rs6433895	0.677	rs111242075	ENSG00000236153.1	AC104076.3	-4.1	5.14e-05	0.0106	-0.28	-0.22	Lymphocyte counts;	chr2:181162212	chr2:180979427~180980090:-
LIHC	cis	rs7129556	0.69	rs24356	ENSG00000254459.1	RP11-91P24.7	4.1	5.14e-05	0.0106	0.35	0.22	Weight loss (gastric bypass surgery);	chr11:77856482	chr11:77829654~77872262:-
LIHC	cis	rs7131987	0.903	rs67517901	ENSG00000275476.1	RP11-996F15.4	-4.1	5.14e-05	0.0106	-0.25	-0.22	QT interval;	chr12:29268413	chr12:29277397~29277882:-
LIHC	cis	rs7131987	0.903	rs6487796	ENSG00000275476.1	RP11-996F15.4	-4.1	5.14e-05	0.0106	-0.25	-0.22	QT interval;	chr12:29269831	chr12:29277397~29277882:-
LIHC	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	4.1	5.14e-05	0.0106	0.26	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
LIHC	cis	rs12681287	0.64	rs4587306	ENSG00000254088.1	SLC2A3P4	-4.1	5.14e-05	0.0106	-0.26	-0.22	Caudate activity during reward;	chr8:86373282	chr8:86503591~86505061:+
LIHC	cis	rs875971	0.545	rs2707851	ENSG00000273024.4	INTS4P2	4.1	5.14e-05	0.0106	0.25	0.22	Aortic root size;	chr7:66624178	chr7:65647864~65715661:+
LIHC	cis	rs4253772	1	rs4253766	ENSG00000260708.1	CTA-29F11.1	4.1	5.14e-05	0.0107	0.44	0.22	Cholesterol, total;LDL cholesterol;	chr22:46228008	chr22:46761894~46762563:-
LIHC	cis	rs938554	0.513	rs11943372	ENSG00000250413.1	RP11-448G15.1	-4.1	5.14e-05	0.0107	-0.29	-0.22	Blood metabolite levels;	chr4:9997722	chr4:10006482~10009725:+
LIHC	cis	rs316274	1	rs316274	ENSG00000273384.1	RP5-1098D14.1	4.1	5.14e-05	0.0107	0.26	0.22	Immune response to smallpox vaccine (IL-6);	chr1:178173073	chr1:178651706~178652282:+
LIHC	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-4.1	5.15e-05	0.0107	-0.28	-0.22	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
LIHC	cis	rs481331	0.866	rs12259795	ENSG00000185904.10	LINC00839	4.1	5.15e-05	0.0107	0.41	0.22	Systemic juvenile idiopathic arthritis;	chr10:42488627	chr10:42475543~42495336:+
LIHC	cis	rs7893279	0.505	rs12778992	ENSG00000225527.1	RP11-383B4.4	4.1	5.15e-05	0.0107	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18611218	chr10:18531849~18533336:-
LIHC	cis	rs10829156	0.738	rs4748502	ENSG00000225527.1	RP11-383B4.4	-4.1	5.15e-05	0.0107	-0.34	-0.22	Sudden cardiac arrest;	chr10:18647032	chr10:18531849~18533336:-
LIHC	cis	rs7131987	0.903	rs1035604	ENSG00000275476.1	RP11-996F15.4	-4.1	5.16e-05	0.0107	-0.25	-0.22	QT interval;	chr12:29240169	chr12:29277397~29277882:-
LIHC	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-4.1	5.16e-05	0.0107	-0.27	-0.22	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
LIHC	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	4.1	5.16e-05	0.0107	0.27	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
LIHC	cis	rs2070488	0.965	rs1870915	ENSG00000229589.1	ACVR2B-AS1	4.1	5.17e-05	0.0107	0.25	0.22	Electrocardiographic conduction measures;	chr3:38452737	chr3:38451027~38454820:-
LIHC	cis	rs2070488	0.965	rs3749386	ENSG00000229589.1	ACVR2B-AS1	4.1	5.17e-05	0.0107	0.25	0.22	Electrocardiographic conduction measures;	chr3:38454574	chr3:38451027~38454820:-
LIHC	cis	rs2243480	0.803	rs36127118	ENSG00000230295.1	RP11-458F8.2	-4.1	5.17e-05	0.0107	-0.22	-0.22	Diabetic kidney disease;	chr7:66100518	chr7:66880708~66882981:+
LIHC	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-4.1	5.17e-05	0.0107	-0.24	-0.22	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
LIHC	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	4.1	5.17e-05	0.0107	0.24	0.22	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
LIHC	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	4.1	5.17e-05	0.0107	0.33	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
LIHC	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	4.1	5.17e-05	0.0107	0.33	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
LIHC	cis	rs2439831	0.681	rs7176849	ENSG00000166763.7	STRCP1	4.1	5.17e-05	0.0107	0.3	0.22	Lung cancer in ever smokers;	chr15:43389229	chr15:43699488~43718184:-
LIHC	cis	rs4578769	0.959	rs9961893	ENSG00000266850.1	RP11-370A5.1	4.1	5.17e-05	0.0107	0.25	0.22	Eosinophil percentage of white cells;	chr18:22849805	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.959	rs11082169	ENSG00000266850.1	RP11-370A5.1	4.1	5.17e-05	0.0107	0.25	0.22	Eosinophil percentage of white cells;	chr18:22850034	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.959	rs2100191	ENSG00000266850.1	RP11-370A5.1	4.1	5.17e-05	0.0107	0.25	0.22	Eosinophil percentage of white cells;	chr18:22851428	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.959	rs2100190	ENSG00000266850.1	RP11-370A5.1	4.1	5.17e-05	0.0107	0.25	0.22	Eosinophil percentage of white cells;	chr18:22851857	chr18:22723491~22907721:-
LIHC	cis	rs3015497	0.586	rs7144714	ENSG00000269906.1	RP11-248J18.2	4.1	5.17e-05	0.0107	0.27	0.22	Mean platelet volume;	chr14:50611867	chr14:50662511~50663178:-
LIHC	cis	rs875971	0.54	rs736270	ENSG00000273024.4	INTS4P2	-4.1	5.18e-05	0.0107	-0.26	-0.22	Aortic root size;	chr7:65963835	chr7:65647864~65715661:+
LIHC	cis	rs3812762	0.879	rs4929934	ENSG00000254860.4	TMEM9B-AS1	-4.1	5.18e-05	0.0107	-0.23	-0.22	Hypospadias;	chr11:8756242	chr11:8964675~8977527:+
LIHC	cis	rs2072510	1	rs2540492	ENSG00000257715.1	RP11-256L6.2	-4.1	5.18e-05	0.0107	-0.22	-0.22	Metabolite levels (small molecules and protein measures);	chr12:96023881	chr12:96025323~96027971:+
LIHC	cis	rs875971	0.545	rs1547529	ENSG00000228409.4	CCT6P1	-4.1	5.18e-05	0.0107	-0.18	-0.22	Aortic root size;	chr7:66258859	chr7:65751142~65763354:+
LIHC	cis	rs73193808	0.639	rs9984810	ENSG00000212479.2	U3	4.1	5.18e-05	0.0107	0.25	0.22	Coronary artery disease;	chr21:29181059	chr21:29180425~29180639:-
LIHC	cis	rs73193808	0.614	rs4817274	ENSG00000212479.2	U3	4.1	5.18e-05	0.0107	0.25	0.22	Coronary artery disease;	chr21:29181296	chr21:29180425~29180639:-
LIHC	cis	rs73193808	0.639	rs9976274	ENSG00000212479.2	U3	4.1	5.18e-05	0.0107	0.25	0.22	Coronary artery disease;	chr21:29181615	chr21:29180425~29180639:-
LIHC	cis	rs73193808	0.59	rs2832244	ENSG00000212479.2	U3	4.1	5.18e-05	0.0107	0.25	0.22	Coronary artery disease;	chr21:29181713	chr21:29180425~29180639:-
LIHC	cis	rs17826219	0.568	rs59858012	ENSG00000266490.1	CTD-2349P21.9	4.1	5.18e-05	0.0107	0.29	0.22	Body mass index;	chr17:30751564	chr17:30792372~30792833:+
LIHC	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	4.1	5.18e-05	0.0107	0.26	0.22	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
LIHC	cis	rs3020736	0.5	rs4147641	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs4147640	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42149886~42155001:-
LIHC	cis	rs1023500	0.507	rs6002600	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Schizophrenia;	chr22:42092902	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs6002601	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs6002604	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs5996109	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs5996110	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs9620026	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs28791586	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs2839708	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs6519306	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42149886~42155001:-
LIHC	cis	rs3020736	0.5	rs6002614	ENSG00000226450.2	CYP2D8P	-4.1	5.19e-05	0.0107	-0.27	-0.22	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42149886~42155001:-
LIHC	cis	rs2348418	0.639	rs2347595	ENSG00000247934.4	RP11-967K21.1	-4.1	5.19e-05	0.0107	-0.2	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28109947	chr12:28163298~28190738:-
LIHC	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-4.1	5.19e-05	0.0107	-0.25	-0.22	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
LIHC	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-4.1	5.19e-05	0.0107	-0.25	-0.22	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
LIHC	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-4.1	5.19e-05	0.0107	-0.25	-0.22	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
LIHC	cis	rs2243480	1	rs422164	ENSG00000230295.1	RP11-458F8.2	-4.1	5.19e-05	0.0107	-0.22	-0.22	Diabetic kidney disease;	chr7:66121618	chr7:66880708~66882981:+
LIHC	cis	rs4713118	0.662	rs149969	ENSG00000219891.2	ZSCAN12P1	4.1	5.19e-05	0.0107	0.3	0.22	Parkinson's disease;	chr6:28009959	chr6:28091154~28093664:+
LIHC	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-4.1	5.19e-05	0.0107	-0.26	-0.22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
LIHC	cis	rs875971	0.545	rs7783889	ENSG00000228409.4	CCT6P1	-4.1	5.19e-05	0.0107	-0.18	-0.22	Aortic root size;	chr7:66283366	chr7:65751142~65763354:+
LIHC	cis	rs9367716	0.912	rs9382695	ENSG00000215190.7	LINC00680	-4.1	5.19e-05	0.0107	-0.24	-0.22	Coronary artery disease;	chr6:57245256	chr6:57946074~57961501:-
LIHC	cis	rs9457247	1	rs2757042	ENSG00000227598.1	RP1-167A14.2	4.1	5.2e-05	0.0107	0.23	0.22	Crohn's disease;	chr6:166957746	chr6:166969626~166999065:-
LIHC	cis	rs951005	0.808	rs28524729	ENSG00000281491.1	DNAJB5-AS1	-4.1	5.2e-05	0.0107	-0.41	-0.22	Rheumatoid arthritis;	chr9:34712322	chr9:34985410~34989379:-
LIHC	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	4.1	5.2e-05	0.0108	0.32	0.22	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
LIHC	cis	rs2072510	0.569	rs7970524	ENSG00000257878.1	RP11-256L6.3	-4.1	5.2e-05	0.0108	-0.27	-0.22	Metabolite levels (small molecules and protein measures);	chr12:95996374	chr12:95996521~96011489:+
LIHC	cis	rs6545883	0.718	rs2694624	ENSG00000271889.1	RP11-493E12.1	4.1	5.21e-05	0.0108	0.26	0.22	Tuberculosis;	chr2:61445178	chr2:61151433~61162105:-
LIHC	cis	rs10801727	0.521	rs9428027	ENSG00000225492.5	GBP1P1	4.1	5.21e-05	0.0108	0.21	0.22	Parental extreme longevity (95 years and older);	chr1:89438986	chr1:89407679~89426243:+
LIHC	cis	rs16958440	1	rs60228288	ENSG00000267724.1	RP11-49K24.8	4.1	5.21e-05	0.0108	0.33	0.22	Sitting height ratio;	chr18:47114041	chr18:47105946~47108062:+
LIHC	cis	rs951005	0.808	rs12348592	ENSG00000281491.1	DNAJB5-AS1	-4.1	5.21e-05	0.0108	-0.44	-0.22	Rheumatoid arthritis;	chr9:34711835	chr9:34985410~34989379:-
LIHC	cis	rs2243480	1	rs1723270	ENSG00000232546.1	RP11-458F8.1	-4.1	5.21e-05	0.0108	-0.25	-0.22	Diabetic kidney disease;	chr7:66004843	chr7:66848496~66858136:+
LIHC	cis	rs4879656	0.593	rs7041702	ENSG00000225693.1	LAGE3P1	4.1	5.22e-05	0.0108	0.28	0.22	Menopause (age at onset);	chr9:33053432	chr9:33019682~33020165:-
LIHC	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	4.1	5.22e-05	0.0108	0.26	0.22	Height;	chr4:55566291	chr4:55363971~55395847:-
LIHC	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-4.1	5.22e-05	0.0108	-0.25	-0.22	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
LIHC	cis	rs2243480	1	rs465359	ENSG00000230295.1	RP11-458F8.2	-4.1	5.22e-05	0.0108	-0.22	-0.22	Diabetic kidney disease;	chr7:66093177	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs462853	ENSG00000230295.1	RP11-458F8.2	-4.1	5.22e-05	0.0108	-0.22	-0.22	Diabetic kidney disease;	chr7:66093180	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs160644	ENSG00000230295.1	RP11-458F8.2	-4.1	5.22e-05	0.0108	-0.22	-0.22	Diabetic kidney disease;	chr7:66093199	chr7:66880708~66882981:+
LIHC	cis	rs73198271	0.586	rs3789850	ENSG00000253893.2	FAM85B	4.1	5.22e-05	0.0108	0.31	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8829335	chr8:8167819~8226614:-
LIHC	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-4.1	5.22e-05	0.0108	-0.23	-0.22	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
LIHC	cis	rs7208859	0.673	rs28588622	ENSG00000266490.1	CTD-2349P21.9	4.1	5.22e-05	0.0108	0.27	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30792372~30792833:+
LIHC	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	4.1	5.22e-05	0.0108	0.3	0.22	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
LIHC	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-4.1	5.23e-05	0.0108	-0.24	-0.22	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
LIHC	cis	rs2348418	0.864	rs11049716	ENSG00000247934.4	RP11-967K21.1	4.1	5.23e-05	0.0108	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28163298~28190738:-
LIHC	cis	rs2348418	0.864	rs7136843	ENSG00000247934.4	RP11-967K21.1	4.1	5.23e-05	0.0108	0.2	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28163298~28190738:-
LIHC	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	4.1	5.23e-05	0.0108	0.25	0.22	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
LIHC	cis	rs755249	0.756	rs72637908	ENSG00000182109.6	RP11-69E11.4	4.1	5.24e-05	0.0108	0.23	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39522280~39546187:-
LIHC	cis	rs9527	0.615	rs2152915	ENSG00000236937.2	PTGES3P4	4.1	5.24e-05	0.0108	0.27	0.22	Arsenic metabolism;	chr10:102931975	chr10:102845595~102845950:+
LIHC	cis	rs9595908	0.568	rs4942926	ENSG00000212293.1	SNORA16	4.1	5.24e-05	0.0108	0.25	0.22	Body mass index;	chr13:32807204	chr13:32420390~32420516:-
LIHC	cis	rs10510102	0.872	rs11200292	ENSG00000273891.1	RP11-500G22.5	4.1	5.24e-05	0.0108	0.29	0.22	Breast cancer;	chr10:121967383	chr10:121965764~121967700:+
LIHC	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	4.1	5.24e-05	0.0108	0.27	0.22	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
LIHC	cis	rs73193808	0.614	rs2245023	ENSG00000212479.2	U3	4.1	5.24e-05	0.0108	0.25	0.22	Coronary artery disease;	chr21:29174539	chr21:29180425~29180639:-
LIHC	cis	rs617219	0.853	rs3829809	ENSG00000251675.1	CTC-458I2.2	4.1	5.24e-05	0.0108	0.24	0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79227709	chr5:80128361~80143883:+
LIHC	cis	rs734999	0.566	rs4648563	ENSG00000225931.3	RP3-395M20.7	4.1	5.24e-05	0.0108	0.23	0.22	Ulcerative colitis;	chr1:2604563	chr1:2566410~2569888:+
LIHC	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-4.1	5.24e-05	0.0108	-0.21	-0.22	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
LIHC	cis	rs2070488	0.965	rs6599206	ENSG00000229589.1	ACVR2B-AS1	-4.1	5.25e-05	0.0108	-0.25	-0.22	Electrocardiographic conduction measures;	chr3:38503858	chr3:38451027~38454820:-
LIHC	cis	rs3738443	1	rs3738443	ENSG00000259865.1	RP11-488L18.10	-4.1	5.25e-05	0.0108	-0.22	-0.22	Alcohol dependence;	chr1:247184887	chr1:247187281~247188526:-
LIHC	cis	rs6545883	0.562	rs777588	ENSG00000271889.1	RP11-493E12.1	4.1	5.25e-05	0.0108	0.26	0.22	Tuberculosis;	chr2:61199685	chr2:61151433~61162105:-
LIHC	cis	rs10833905	1	rs3909703	ENSG00000246225.5	RP11-17A1.3	-4.1	5.25e-05	0.0108	-0.28	-0.22	Sudden cardiac arrest;	chr11:22999094	chr11:22829380~22945393:+
LIHC	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-4.1	5.25e-05	0.0108	-0.27	-0.22	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
LIHC	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-4.1	5.26e-05	0.0109	-0.27	-0.22	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
LIHC	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-4.1	5.26e-05	0.0109	-0.22	-0.22	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
LIHC	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-4.1	5.26e-05	0.0109	-0.22	-0.22	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
LIHC	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-4.1	5.26e-05	0.0109	-0.22	-0.22	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
LIHC	cis	rs11098499	0.615	rs28551750	ENSG00000260091.1	RP11-33B1.4	-4.1	5.26e-05	0.0109	-0.15	-0.22	Corneal astigmatism;	chr4:119343746	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.691	rs9995716	ENSG00000260091.1	RP11-33B1.4	-4.1	5.26e-05	0.0109	-0.15	-0.22	Corneal astigmatism;	chr4:119343841	chr4:119409333~119410233:+
LIHC	cis	rs7193541	0.694	rs3896277	ENSG00000262904.1	TMPOP2	-4.1	5.26e-05	0.0109	-0.19	-0.22	Multiple myeloma;	chr16:74446796	chr16:74667506~74668706:+
LIHC	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-4.1	5.26e-05	0.0109	-0.28	-0.22	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
LIHC	cis	rs2299116	0.886	rs2237351	ENSG00000225264.3	ZNRF2P2	-4.1	5.27e-05	0.0109	-0.24	-0.22	Serum thyroid-stimulating hormone levels;	chr7:28748640	chr7:29598795~29685255:-
LIHC	cis	rs7044106	0.762	rs1324473	ENSG00000238181.2	AHCYP2	4.1	5.27e-05	0.0109	0.24	0.22	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120720673~120721972:+
LIHC	cis	rs748404	0.631	rs11070399	ENSG00000166763.7	STRCP1	4.1	5.27e-05	0.0109	0.27	0.22	Lung cancer;	chr15:43354149	chr15:43699488~43718184:-
LIHC	cis	rs6517329	0.674	rs1543655	ENSG00000231106.2	LINC01436	4.1	5.27e-05	0.0109	0.24	0.22	Schizophrenia;	chr21:36111076	chr21:36005338~36007838:+
LIHC	cis	rs2665103	0.61	rs1972460	ENSG00000259429.4	UBE2Q2P2	-4.1	5.27e-05	0.0109	-0.22	-0.22	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82355142~82420075:+
LIHC	cis	rs1005277	0.505	rs200939	ENSG00000099251.13	HSD17B7P2	4.1	5.27e-05	0.0109	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38356380~38378505:+
LIHC	cis	rs860295	0.702	rs11264366	ENSG00000203761.5	MSTO2P	-4.09	5.28e-05	0.0109	-0.18	-0.22	Body mass index;	chr1:155365620	chr1:155745829~155750137:+
LIHC	cis	rs603446	0.55	rs1784118	ENSG00000254851.1	RP11-109L13.1	4.09	5.28e-05	0.0109	0.28	0.22	Triglycerides;	chr11:116694339	chr11:117135528~117138582:+
LIHC	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	4.09	5.28e-05	0.0109	0.28	0.22	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
LIHC	cis	rs1005277	0.505	rs200910	ENSG00000099251.13	HSD17B7P2	4.09	5.28e-05	0.0109	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.522	rs200943	ENSG00000099251.13	HSD17B7P2	4.09	5.29e-05	0.0109	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.505	rs719569	ENSG00000099251.13	HSD17B7P2	-4.09	5.29e-05	0.0109	-0.25	-0.22	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38356380~38378505:+
LIHC	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	4.09	5.29e-05	0.0109	0.29	0.22	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
LIHC	cis	rs1005277	0.505	rs200935	ENSG00000099251.13	HSD17B7P2	4.09	5.29e-05	0.0109	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.505	rs200936	ENSG00000099251.13	HSD17B7P2	4.09	5.29e-05	0.0109	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.505	rs200937	ENSG00000099251.13	HSD17B7P2	4.09	5.29e-05	0.0109	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38356380~38378505:+
LIHC	cis	rs4650994	0.967	rs4650998	ENSG00000273384.1	RP5-1098D14.1	4.09	5.3e-05	0.0109	0.26	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178562715	chr1:178651706~178652282:+
LIHC	cis	rs4819852	0.958	rs2238792	ENSG00000215493.3	XXbac-B562F10.11	-4.09	5.3e-05	0.0109	-0.18	-0.22	Pulse pressure;	chr22:19995690	chr22:20450122~20451824:+
LIHC	cis	rs703842	0.642	rs73123375	ENSG00000270039.1	RP11-571M6.17	-4.09	5.3e-05	0.0109	-0.31	-0.22	Multiple sclerosis;	chr12:57669881	chr12:57803838~57804415:+
LIHC	cis	rs66887589	0.837	rs7661498	ENSG00000260091.1	RP11-33B1.4	-4.09	5.3e-05	0.0109	-0.14	-0.22	Diastolic blood pressure;	chr4:119486953	chr4:119409333~119410233:+
LIHC	cis	rs2980436	1	rs2980436	ENSG00000254340.1	RP11-10A14.3	-4.09	5.3e-05	0.0109	-0.23	-0.22	Schizophrenia;	chr8:8234503	chr8:9141424~9145435:+
LIHC	cis	rs2243480	1	rs465359	ENSG00000228409.4	CCT6P1	4.09	5.3e-05	0.0109	0.23	0.22	Diabetic kidney disease;	chr7:66093177	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs462853	ENSG00000228409.4	CCT6P1	4.09	5.3e-05	0.0109	0.23	0.22	Diabetic kidney disease;	chr7:66093180	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs160644	ENSG00000228409.4	CCT6P1	4.09	5.3e-05	0.0109	0.23	0.22	Diabetic kidney disease;	chr7:66093199	chr7:65751142~65763354:+
LIHC	cis	rs6832769	1	rs7670225	ENSG00000272969.1	RP11-528I4.2	4.09	5.31e-05	0.0109	0.26	0.22	Personality dimensions;	chr4:55501851	chr4:55547112~55547889:+
LIHC	cis	rs6832769	0.925	rs3817444	ENSG00000272969.1	RP11-528I4.2	4.09	5.31e-05	0.0109	0.26	0.22	Personality dimensions;	chr4:55509814	chr4:55547112~55547889:+
LIHC	cis	rs6832769	0.826	rs10462035	ENSG00000272969.1	RP11-528I4.2	4.09	5.31e-05	0.0109	0.26	0.22	Personality dimensions;	chr4:55513011	chr4:55547112~55547889:+
LIHC	cis	rs6832769	0.961	rs2177127	ENSG00000272969.1	RP11-528I4.2	4.09	5.31e-05	0.0109	0.26	0.22	Personality dimensions;	chr4:55513792	chr4:55547112~55547889:+
LIHC	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	4.09	5.31e-05	0.0109	0.35	0.22	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
LIHC	cis	rs12681366	0.801	rs12682524	ENSG00000253704.1	RP11-267M23.4	4.09	5.31e-05	0.0109	0.25	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94553722~94569745:+
LIHC	cis	rs2070488	0.932	rs1841776	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38439236	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs1841777	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38443328	chr3:38451027~38454820:-
LIHC	cis	rs2070488	0.965	rs13093640	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38445685	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs7373816	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38448952	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs13079757	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38449953	chr3:38451027~38454820:-
LIHC	cis	rs2070488	0.965	rs2366123	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38451662	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs3792527	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38451721	chr3:38451027~38454820:-
LIHC	cis	rs2070488	0.965	rs3762788	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38452361	chr3:38451027~38454820:-
LIHC	cis	rs2070488	1	rs762317	ENSG00000229589.1	ACVR2B-AS1	4.09	5.32e-05	0.0109	0.25	0.22	Electrocardiographic conduction measures;	chr3:38456168	chr3:38451027~38454820:-
LIHC	cis	rs6452524	0.71	rs7708124	ENSG00000271862.1	RP11-343L5.2	4.09	5.32e-05	0.011	0.25	0.22	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83049376~83050964:-
LIHC	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	4.09	5.32e-05	0.011	0.25	0.22	Height;	chr4:55491150	chr4:55363971~55395847:-
LIHC	cis	rs11098499	0.722	rs10006192	ENSG00000260091.1	RP11-33B1.4	-4.09	5.32e-05	0.011	-0.15	-0.22	Corneal astigmatism;	chr4:119341867	chr4:119409333~119410233:+
LIHC	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	4.09	5.32e-05	0.011	0.24	0.22	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
LIHC	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	4.09	5.32e-05	0.011	0.24	0.22	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
LIHC	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	4.09	5.32e-05	0.011	0.24	0.22	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
LIHC	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	4.09	5.32e-05	0.011	0.24	0.22	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
LIHC	cis	rs875971	0.545	rs1796217	ENSG00000273024.4	INTS4P2	4.09	5.32e-05	0.011	0.24	0.22	Aortic root size;	chr7:66620931	chr7:65647864~65715661:+
LIHC	cis	rs4650994	0.967	rs4650992	ENSG00000273384.1	RP5-1098D14.1	4.09	5.32e-05	0.011	0.26	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546000	chr1:178651706~178652282:+
LIHC	cis	rs4650994	1	rs4650993	ENSG00000273384.1	RP5-1098D14.1	4.09	5.32e-05	0.011	0.26	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546052	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.935	rs12039531	ENSG00000273384.1	RP5-1098D14.1	4.09	5.32e-05	0.011	0.26	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546477	chr1:178651706~178652282:+
LIHC	cis	rs4650994	1	rs10798616	ENSG00000273384.1	RP5-1098D14.1	4.09	5.32e-05	0.011	0.26	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546507	chr1:178651706~178652282:+
LIHC	cis	rs755249	0.567	rs4660543	ENSG00000182109.6	RP11-69E11.4	4.09	5.32e-05	0.011	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39522280~39546187:-
LIHC	cis	rs2744375	1	rs2744375	ENSG00000261189.1	RP3-512B11.3	4.09	5.32e-05	0.011	0.37	0.22	Resting heart rate;	chr6:7554606	chr6:7540451~7541338:-
LIHC	cis	rs1577917	1	rs36096931	ENSG00000234155.1	RP11-30P6.6	4.09	5.33e-05	0.011	0.28	0.22	Response to antipsychotic treatment;	chr6:85983416	chr6:85387219~85390186:-
LIHC	cis	rs9652601	0.959	rs9934969	ENSG00000274038.1	RP11-66H6.4	-4.09	5.33e-05	0.011	-0.27	-0.22	Systemic lupus erythematosus;	chr16:11072145	chr16:11056556~11057034:+
LIHC	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	4.09	5.33e-05	0.011	0.25	0.22	Height;	chr4:55452921	chr4:55363971~55395847:-
LIHC	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-4.09	5.33e-05	0.011	-0.31	-0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
LIHC	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-4.09	5.33e-05	0.011	-0.26	-0.22	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
LIHC	cis	rs9952991	0.941	rs7237497	ENSG00000260302.1	RP11-973H7.1	-4.09	5.33e-05	0.011	-0.32	-0.22	Inflammatory skin disease;	chr18:12777326	chr18:12774651~12775923:-
LIHC	cis	rs9952991	0.882	rs2847274	ENSG00000260302.1	RP11-973H7.1	-4.09	5.33e-05	0.011	-0.32	-0.22	Inflammatory skin disease;	chr18:12777604	chr18:12774651~12775923:-
LIHC	cis	rs12946454	0.696	rs4792819	ENSG00000267288.2	RP13-890H12.2	-4.09	5.33e-05	0.011	-0.24	-0.22	Systolic blood pressure;	chr17:45170590	chr17:45168800~45171584:-
LIHC	cis	rs6545883	0.929	rs6705235	ENSG00000271889.1	RP11-493E12.1	4.09	5.34e-05	0.011	0.26	0.22	Tuberculosis;	chr2:61486445	chr2:61151433~61162105:-
LIHC	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-4.09	5.34e-05	0.011	-0.22	-0.22	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
LIHC	cis	rs6942407	0.64	rs4728690	ENSG00000224046.1	AC005076.5	-4.09	5.34e-05	0.011	-0.2	-0.22	Food allergy;	chr7:87224688	chr7:87151423~87152420:-
LIHC	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-4.09	5.34e-05	0.011	-0.34	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
LIHC	cis	rs3845817	0.808	rs702895	ENSG00000281920.1	RP11-418H16.1	-4.09	5.34e-05	0.011	-0.26	-0.22	Bipolar disorder;	chr2:65534933	chr2:65623272~65628424:+
LIHC	cis	rs875971	0.545	rs1638735	ENSG00000228409.4	CCT6P1	-4.09	5.34e-05	0.011	-0.19	-0.22	Aortic root size;	chr7:66630751	chr7:65751142~65763354:+
LIHC	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	4.09	5.34e-05	0.011	0.21	0.22	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
LIHC	cis	rs875971	0.522	rs4718286	ENSG00000273024.4	INTS4P2	-4.09	5.34e-05	0.011	-0.26	-0.22	Aortic root size;	chr7:65827777	chr7:65647864~65715661:+
LIHC	cis	rs17711722	0.585	rs6942660	ENSG00000273024.4	INTS4P2	-4.09	5.34e-05	0.011	-0.26	-0.22	Calcium levels;	chr7:65837419	chr7:65647864~65715661:+
LIHC	cis	rs17711722	0.701	rs55773927	ENSG00000273024.4	INTS4P2	-4.09	5.34e-05	0.011	-0.26	-0.22	Calcium levels;	chr7:65872915	chr7:65647864~65715661:+
LIHC	cis	rs17711722	0.727	rs35850374	ENSG00000273024.4	INTS4P2	-4.09	5.34e-05	0.011	-0.26	-0.22	Calcium levels;	chr7:65892789	chr7:65647864~65715661:+
LIHC	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-4.09	5.34e-05	0.011	-0.32	-0.22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
LIHC	cis	rs2494250	0.542	rs12041803	ENSG00000231434.1	RP11-144L1.8	-4.09	5.34e-05	0.011	-0.27	-0.22	Select biomarker traits;	chr1:159341817	chr1:158523672~158525838:+
LIHC	cis	rs2243480	1	rs13247184	ENSG00000232546.1	RP11-458F8.1	-4.09	5.34e-05	0.011	-0.25	-0.22	Diabetic kidney disease;	chr7:65893941	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs35283677	ENSG00000232546.1	RP11-458F8.1	-4.09	5.34e-05	0.011	-0.25	-0.22	Diabetic kidney disease;	chr7:65894246	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs35421653	ENSG00000232546.1	RP11-458F8.1	-4.09	5.34e-05	0.011	-0.25	-0.22	Diabetic kidney disease;	chr7:65898442	chr7:66848496~66858136:+
LIHC	cis	rs10857712	0.754	rs2297032	ENSG00000214279.11	SCART1	-4.09	5.34e-05	0.011	-0.27	-0.22	Systemic lupus erythematosus;	chr10:133421076	chr10:133453928~133523558:+
LIHC	cis	rs4792901	0.722	rs12603085	ENSG00000267747.1	RP11-392O1.4	-4.09	5.35e-05	0.011	-0.25	-0.22	Dupuytren's disease;	chr17:43468479	chr17:43544785~43610338:+
LIHC	cis	rs113835537	0.935	rs117480267	ENSG00000255517.5	CTD-3074O7.5	-4.09	5.35e-05	0.011	-0.38	-0.22	Airway imaging phenotypes;	chr11:66631125	chr11:66473490~66480233:-
LIHC	cis	rs864745	0.967	rs1635852	ENSG00000234336.5	JAZF1-AS1	4.09	5.35e-05	0.011	0.29	0.22	Crohn's disease;Type 2 diabetes;	chr7:28149792	chr7:28180322~28243917:+
LIHC	cis	rs763121	0.853	rs4821810	ENSG00000273076.1	RP3-508I15.22	4.09	5.35e-05	0.011	0.24	0.22	Menopause (age at onset);	chr22:38676093	chr22:38743495~38743910:+
LIHC	cis	rs763121	0.853	rs5757234	ENSG00000273076.1	RP3-508I15.22	4.09	5.35e-05	0.011	0.24	0.22	Menopause (age at onset);	chr22:38676681	chr22:38743495~38743910:+
LIHC	cis	rs340849	0.967	rs340868	ENSG00000274895.1	RP11-478J18.2	4.09	5.35e-05	0.011	0.23	0.22	Alzheimer's disease;	chr1:213955877	chr1:213983793~213986419:-
LIHC	cis	rs7893279	0.505	rs4748496	ENSG00000225527.1	RP11-383B4.4	4.09	5.36e-05	0.011	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18618028	chr10:18531849~18533336:-
LIHC	cis	rs951005	0.808	rs10972207	ENSG00000281491.1	DNAJB5-AS1	4.09	5.36e-05	0.011	0.39	0.22	Rheumatoid arthritis;	chr9:34713751	chr9:34985410~34989379:-
LIHC	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	4.09	5.36e-05	0.011	0.25	0.22	Height;	chr4:55561053	chr4:55363971~55395847:-
LIHC	cis	rs6496667	0.533	rs886491	ENSG00000213471.7	TTLL13P	4.09	5.37e-05	0.011	0.28	0.22	Rheumatoid arthritis;	chr15:90449983	chr15:90249530~90265482:+
LIHC	cis	rs3812762	0.826	rs2292045	ENSG00000254860.4	TMEM9B-AS1	4.09	5.37e-05	0.011	0.25	0.22	Hypospadias;	chr11:8785162	chr11:8964675~8977527:+
LIHC	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	4.09	5.37e-05	0.011	0.25	0.22	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
LIHC	cis	rs4561483	0.832	rs33645	ENSG00000261560.1	RP11-166B2.3	-4.09	5.37e-05	0.011	-0.25	-0.22	Testicular germ cell tumor;	chr16:11891344	chr16:11881075~11882569:-
LIHC	cis	rs1075265	0.621	rs2542593	ENSG00000272156.1	RP11-477N3.1	-4.09	5.38e-05	0.0111	-0.26	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54082554~54085066:+
LIHC	cis	rs875971	0.545	rs66594357	ENSG00000228409.4	CCT6P1	-4.09	5.38e-05	0.0111	-0.18	-0.22	Aortic root size;	chr7:66327797	chr7:65751142~65763354:+
LIHC	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	4.09	5.38e-05	0.0111	0.32	0.22	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
LIHC	cis	rs11098499	0.909	rs1546504	ENSG00000260091.1	RP11-33B1.4	-4.09	5.38e-05	0.0111	-0.16	-0.22	Corneal astigmatism;	chr4:119320024	chr4:119409333~119410233:+
LIHC	cis	rs875971	0.545	rs6970498	ENSG00000273024.4	INTS4P2	-4.09	5.38e-05	0.0111	-0.25	-0.22	Aortic root size;	chr7:66275908	chr7:65647864~65715661:+
LIHC	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	4.09	5.38e-05	0.0111	0.25	0.22	Height;	chr4:55540928	chr4:55363971~55395847:-
LIHC	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-4.09	5.38e-05	0.0111	-0.24	-0.22	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
LIHC	cis	rs6832769	1	rs4865008	ENSG00000272969.1	RP11-528I4.2	-4.09	5.38e-05	0.0111	-0.26	-0.22	Personality dimensions;	chr4:55544688	chr4:55547112~55547889:+
LIHC	cis	rs11763353	0.627	rs6948002	ENSG00000235828.5	RPL36AP26	-4.09	5.38e-05	0.0111	-0.21	-0.22	Blood trace element (Zn levels);	chr7:15574487	chr7:15701435~15701752:-
LIHC	cis	rs603446	0.55	rs1784119	ENSG00000254851.1	RP11-109L13.1	4.09	5.38e-05	0.0111	0.28	0.22	Triglycerides;	chr11:116692089	chr11:117135528~117138582:+
LIHC	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	4.09	5.38e-05	0.0111	0.28	0.22	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
LIHC	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	4.09	5.38e-05	0.0111	0.24	0.22	Asthma;	chr2:102410644	chr2:102438713~102440475:+
LIHC	cis	rs1577917	0.876	rs1582126	ENSG00000234155.1	RP11-30P6.6	4.09	5.39e-05	0.0111	0.29	0.22	Response to antipsychotic treatment;	chr6:85987487	chr6:85387219~85390186:-
LIHC	cis	rs2243480	1	rs316307	ENSG00000228409.4	CCT6P1	4.09	5.39e-05	0.0111	0.23	0.22	Diabetic kidney disease;	chr7:66105184	chr7:65751142~65763354:+
LIHC	cis	rs16958440	1	rs62096469	ENSG00000267724.1	RP11-49K24.8	4.09	5.39e-05	0.0111	0.33	0.22	Sitting height ratio;	chr18:47111927	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs62096470	ENSG00000267724.1	RP11-49K24.8	4.09	5.39e-05	0.0111	0.33	0.22	Sitting height ratio;	chr18:47115095	chr18:47105946~47108062:+
LIHC	cis	rs9675120	0.747	rs9303565	ENSG00000262006.1	RP11-700H6.4	-4.09	5.4e-05	0.0111	-0.23	-0.22	Cerebrospinal fluid biomarker levels;	chr17:50843432	chr17:50909637~50910232:-
LIHC	cis	rs7923609	0.846	rs7073753	ENSG00000232075.1	MRPL35P2	-4.09	5.4e-05	0.0111	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63303060	chr10:63634317~63634827:-
LIHC	cis	rs1005277	0.522	rs289645	ENSG00000275858.1	RP11-291L22.8	4.09	5.4e-05	0.0111	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38450738~38451069:-
LIHC	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	4.09	5.4e-05	0.0111	0.19	0.22	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
LIHC	cis	rs11841001	0.556	rs17065026	ENSG00000261105.4	LMO7-AS1	4.09	5.4e-05	0.0111	0.43	0.22	Corneal astigmatism;	chr13:75779020	chr13:75604700~75635994:-
LIHC	cis	rs75920871	0.61	rs888246	ENSG00000254851.1	RP11-109L13.1	-4.09	5.4e-05	0.0111	-0.47	-0.22	Subjective well-being;	chr11:116853516	chr11:117135528~117138582:+
LIHC	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-4.09	5.4e-05	0.0111	-0.2	-0.22	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
LIHC	cis	rs72675573	0.821	rs7547019	ENSG00000235612.1	RP1-158P9.1	-4.09	5.4e-05	0.0111	-0.3	-0.22	Monocyte count;	chr1:56060374	chr1:56145721~56155224:+
LIHC	cis	rs7615952	0.512	rs4234285	ENSG00000171084.14	FAM86JP	4.09	5.4e-05	0.0111	0.33	0.22	Blood pressure (smoking interaction);	chr3:125685633	chr3:125916620~125930024:+
LIHC	cis	rs7615952	0.546	rs2976733	ENSG00000171084.14	FAM86JP	4.09	5.4e-05	0.0111	0.33	0.22	Blood pressure (smoking interaction);	chr3:125695294	chr3:125916620~125930024:+
LIHC	cis	rs4879656	0.545	rs1537254	ENSG00000225693.1	LAGE3P1	4.09	5.4e-05	0.0111	0.27	0.22	Menopause (age at onset);	chr9:33004341	chr9:33019682~33020165:-
LIHC	cis	rs875971	0.505	rs2462573	ENSG00000273024.4	INTS4P2	4.09	5.41e-05	0.0111	0.25	0.22	Aortic root size;	chr7:66042405	chr7:65647864~65715661:+
LIHC	cis	rs7338174	0.655	rs9316535	ENSG00000236778.6	INTS6-AS1	4.09	5.41e-05	0.0111	0.42	0.22	Mitochondrial DNA levels;	chr13:51329329	chr13:51452367~51552364:+
LIHC	cis	rs74233809	0.636	rs284851	ENSG00000236937.2	PTGES3P4	4.09	5.41e-05	0.0111	0.29	0.22	Birth weight;	chr10:102818774	chr10:102845595~102845950:+
LIHC	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-4.09	5.41e-05	0.0111	-0.26	-0.22	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
LIHC	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-4.09	5.41e-05	0.0111	-0.26	-0.22	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
LIHC	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-4.09	5.41e-05	0.0111	-0.28	-0.22	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
LIHC	cis	rs2562456	0.833	rs2562507	ENSG00000268555.1	RP11-678G14.3	-4.09	5.41e-05	0.0111	-0.27	-0.22	Pain;	chr19:21543535	chr19:21570822~21587322:-
LIHC	cis	rs17270561	0.666	rs1937129	ENSG00000216436.2	HIST1H2APS1	-4.09	5.42e-05	0.0111	-0.25	-0.22	Iron status biomarkers;	chr6:25788904	chr6:25732497~25732827:+
LIHC	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-4.09	5.42e-05	0.0111	-0.33	-0.22	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
LIHC	cis	rs8005677	0.828	rs2295682	ENSG00000257285.4	RP11-298I3.1	4.09	5.42e-05	0.0111	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:22929609~22955562:+
LIHC	cis	rs9595908	0.869	rs7983457	ENSG00000212293.1	SNORA16	-4.09	5.42e-05	0.0111	-0.25	-0.22	Body mass index;	chr13:32631797	chr13:32420390~32420516:-
LIHC	cis	rs4578769	0.765	rs35151054	ENSG00000265943.1	RP11-739L10.1	-4.09	5.42e-05	0.0111	-0.28	-0.22	Eosinophil percentage of white cells;	chr18:22818375	chr18:22699481~22933764:-
LIHC	cis	rs4578769	0.765	rs72882153	ENSG00000265943.1	RP11-739L10.1	-4.09	5.42e-05	0.0111	-0.28	-0.22	Eosinophil percentage of white cells;	chr18:22823275	chr18:22699481~22933764:-
LIHC	cis	rs950027	1	rs950027	ENSG00000259433.2	CTD-2651B20.4	4.09	5.43e-05	0.0111	0.31	0.22	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45330209~45332634:-
LIHC	cis	rs2243480	1	rs427044	ENSG00000232546.1	RP11-458F8.1	-4.09	5.43e-05	0.0111	-0.24	-0.22	Diabetic kidney disease;	chr7:66043558	chr7:66848496~66858136:+
LIHC	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	4.09	5.43e-05	0.0111	0.21	0.22	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	4.09	5.43e-05	0.0111	0.21	0.22	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	4.09	5.43e-05	0.0111	0.21	0.22	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	4.09	5.43e-05	0.0111	0.21	0.22	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	4.09	5.43e-05	0.0111	0.21	0.22	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
LIHC	cis	rs2243480	1	rs160642	ENSG00000228409.4	CCT6P1	4.09	5.43e-05	0.0111	0.23	0.22	Diabetic kidney disease;	chr7:66093386	chr7:65751142~65763354:+
LIHC	cis	rs2243480	0.614	rs34032527	ENSG00000228409.4	CCT6P1	4.09	5.43e-05	0.0111	0.23	0.22	Diabetic kidney disease;	chr7:66100154	chr7:65751142~65763354:+
LIHC	cis	rs17711722	0.583	rs10085415	ENSG00000273024.4	INTS4P2	4.09	5.43e-05	0.0111	0.26	0.22	Calcium levels;	chr7:65628655	chr7:65647864~65715661:+
LIHC	cis	rs755249	0.567	rs112672438	ENSG00000182109.6	RP11-69E11.4	4.09	5.43e-05	0.0111	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs16825921	ENSG00000182109.6	RP11-69E11.4	4.09	5.43e-05	0.0111	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39522280~39546187:-
LIHC	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-4.09	5.43e-05	0.0111	-0.43	-0.22	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-4.09	5.43e-05	0.0111	-0.43	-0.22	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-4.09	5.43e-05	0.0111	-0.43	-0.22	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-4.09	5.43e-05	0.0111	-0.43	-0.22	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-4.09	5.43e-05	0.0111	-0.43	-0.22	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-4.09	5.43e-05	0.0111	-0.43	-0.22	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
LIHC	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-4.09	5.43e-05	0.0111	-0.43	-0.22	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
LIHC	cis	rs433598	0.753	rs163274	ENSG00000260201.2	RP11-143N13.2	4.09	5.43e-05	0.0111	0.22	0.22	Schizophrenia;	chr16:20661013	chr16:20580999~20586640:+
LIHC	cis	rs7989332	0.89	rs35891640	ENSG00000275964.1	RP11-61K9.3	-4.09	5.43e-05	0.0111	-0.24	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20476035	chr13:19863858~19865048:+
LIHC	cis	rs875971	0.545	rs11767262	ENSG00000228409.4	CCT6P1	-4.09	5.43e-05	0.0111	-0.18	-0.22	Aortic root size;	chr7:66302237	chr7:65751142~65763354:+
LIHC	cis	rs875971	0.545	rs801199	ENSG00000224316.1	RP11-479O9.2	-4.09	5.43e-05	0.0111	-0.21	-0.22	Aortic root size;	chr7:66560286	chr7:65773620~65802067:+
LIHC	cis	rs875971	0.545	rs1638724	ENSG00000224316.1	RP11-479O9.2	-4.09	5.43e-05	0.0111	-0.21	-0.22	Aortic root size;	chr7:66575494	chr7:65773620~65802067:+
LIHC	cis	rs6449502	0.92	rs158926	ENSG00000272308.1	RP11-231G3.1	-4.09	5.44e-05	0.0112	-0.29	-0.22	Mean platelet volume;	chr5:60955380	chr5:60866457~60866935:-
LIHC	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-4.09	5.44e-05	0.0112	-0.33	-0.22	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
LIHC	cis	rs11671005	0.695	rs12972898	ENSG00000269473.1	CTD-2619J13.19	4.09	5.44e-05	0.0112	0.37	0.22	Mean platelet volume;	chr19:58445521	chr19:58440448~58445849:+
LIHC	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	4.09	5.45e-05	0.0112	0.33	0.22	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
LIHC	cis	rs17774123	0.851	rs12425339	ENSG00000257808.1	RP11-1136G11.8	4.09	5.45e-05	0.0112	0.4	0.22	Diastolic blood pressure;	chr12:53882713	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.851	rs79275870	ENSG00000257808.1	RP11-1136G11.8	4.09	5.45e-05	0.0112	0.4	0.22	Diastolic blood pressure;	chr12:53890227	chr12:53159586~53161000:+
LIHC	cis	rs2439831	0.681	rs999047	ENSG00000166763.7	STRCP1	4.09	5.45e-05	0.0112	0.3	0.22	Lung cancer in ever smokers;	chr15:43396718	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.614	rs2467733	ENSG00000166763.7	STRCP1	4.09	5.45e-05	0.0112	0.3	0.22	Lung cancer in ever smokers;	chr15:43401130	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.681	rs2444036	ENSG00000166763.7	STRCP1	4.09	5.45e-05	0.0112	0.3	0.22	Lung cancer in ever smokers;	chr15:43401910	chr15:43699488~43718184:-
LIHC	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	4.09	5.45e-05	0.0112	0.31	0.22	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
LIHC	cis	rs6471393	0.964	rs2976366	ENSG00000253848.1	RP11-10N23.5	-4.09	5.45e-05	0.0112	-0.23	-0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93708829	chr8:93741193~93744534:+
LIHC	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	4.09	5.45e-05	0.0112	0.21	0.22	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
LIHC	cis	rs2439831	0.681	rs540388	ENSG00000166763.7	STRCP1	4.09	5.46e-05	0.0112	0.3	0.22	Lung cancer in ever smokers;	chr15:43314296	chr15:43699488~43718184:-
LIHC	cis	rs17711722	0.701	rs781145	ENSG00000273024.4	INTS4P2	-4.09	5.46e-05	0.0112	-0.26	-0.22	Calcium levels;	chr7:65975383	chr7:65647864~65715661:+
LIHC	cis	rs2333021	0.689	rs2998006	ENSG00000259015.1	RP11-109N23.6	-4.09	5.46e-05	0.0112	-0.26	-0.22	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72962406	chr14:72960595~72961993:+
LIHC	cis	rs2333021	0.689	rs8010674	ENSG00000259015.1	RP11-109N23.6	-4.09	5.46e-05	0.0112	-0.26	-0.22	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72962458	chr14:72960595~72961993:+
LIHC	cis	rs763121	0.853	rs1043441	ENSG00000273076.1	RP3-508I15.22	4.09	5.47e-05	0.0112	0.24	0.22	Menopause (age at onset);	chr22:38734959	chr22:38743495~38743910:+
LIHC	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	4.09	5.48e-05	0.0112	0.27	0.22	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
LIHC	cis	rs960902	0.818	rs2192942	ENSG00000213553.4	RPLP0P6	-4.09	5.48e-05	0.0112	-0.18	-0.22	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37504350	chr2:38481851~38482804:+
LIHC	cis	rs6449502	1	rs6871557	ENSG00000272308.1	RP11-231G3.1	-4.09	5.48e-05	0.0112	-0.32	-0.22	Mean platelet volume;	chr5:60821679	chr5:60866457~60866935:-
LIHC	cis	rs938554	0.578	rs7663032	ENSG00000250413.1	RP11-448G15.1	-4.09	5.48e-05	0.0112	-0.29	-0.22	Blood metabolite levels;	chr4:9992214	chr4:10006482~10009725:+
LIHC	cis	rs7607369	0.714	rs4674338	ENSG00000272555.1	RP11-459I19.1	4.09	5.48e-05	0.0112	0.25	0.22	Amyotrophic lateral sclerosis;Red blood cell count;	chr2:218782764	chr2:218818690~218819144:+
LIHC	cis	rs72675573	0.852	rs11206747	ENSG00000235612.1	RP1-158P9.1	-4.09	5.49e-05	0.0112	-0.28	-0.22	Monocyte count;	chr1:56140977	chr1:56145721~56155224:+
LIHC	cis	rs1005277	0.563	rs2505215	ENSG00000099251.13	HSD17B7P2	4.09	5.49e-05	0.0112	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.563	rs2505216	ENSG00000099251.13	HSD17B7P2	4.09	5.49e-05	0.0112	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.563	rs2800550	ENSG00000099251.13	HSD17B7P2	4.09	5.49e-05	0.0112	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs2749612	ENSG00000099251.13	HSD17B7P2	4.09	5.49e-05	0.0112	0.25	0.22	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38356380~38378505:+
LIHC	cis	rs10833905	1	rs12421624	ENSG00000246225.5	RP11-17A1.3	-4.09	5.49e-05	0.0113	-0.28	-0.22	Sudden cardiac arrest;	chr11:22994882	chr11:22829380~22945393:+
LIHC	cis	rs7587476	0.505	rs777323	ENSG00000229267.2	AC072062.1	4.09	5.49e-05	0.0113	0.27	0.22	Neuroblastoma;	chr2:214873761	chr2:214810229~214963274:+
LIHC	cis	rs3738443	0.645	rs55768801	ENSG00000259865.1	RP11-488L18.10	4.09	5.49e-05	0.0113	0.18	0.22	Alcohol dependence;	chr1:247199688	chr1:247187281~247188526:-
LIHC	cis	rs6471393	0.964	rs2914944	ENSG00000253848.1	RP11-10N23.5	-4.09	5.49e-05	0.0113	-0.23	-0.22	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93711815	chr8:93741193~93744534:+
LIHC	cis	rs713477	1	rs8014526	ENSG00000258413.1	RP11-665C16.6	4.08	5.5e-05	0.0113	0.24	0.22	Pediatric bone mineral content (femoral neck);	chr14:55418336	chr14:55262767~55272075:-
LIHC	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	4.08	5.5e-05	0.0113	0.25	0.22	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	4.08	5.5e-05	0.0113	0.25	0.22	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
LIHC	cis	rs12157904	1	rs6000841	ENSG00000233360.4	Z83844.1	4.08	5.5e-05	0.0113	0.44	0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37609930	chr22:37641832~37658377:-
LIHC	cis	rs12157904	1	rs5995482	ENSG00000233360.4	Z83844.1	4.08	5.5e-05	0.0113	0.44	0.22	Response to anti-depressant treatment in major depressive disorder;	chr22:37610374	chr22:37641832~37658377:-
LIHC	cis	rs4578769	0.879	rs11659315	ENSG00000266850.1	RP11-370A5.1	-4.08	5.5e-05	0.0113	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22836405	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.879	rs11659384	ENSG00000266850.1	RP11-370A5.1	-4.08	5.5e-05	0.0113	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22836662	chr18:22723491~22907721:-
LIHC	cis	rs7989332	0.925	rs7329649	ENSG00000275964.1	RP11-61K9.3	-4.08	5.5e-05	0.0113	-0.24	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20475948	chr13:19863858~19865048:+
LIHC	cis	rs1665050	0.842	rs1665049	ENSG00000259250.1	RP11-50C13.1	-4.08	5.5e-05	0.0113	-0.22	-0.22	Atopic dermatitis;	chr15:58998453	chr15:58587507~58591676:+
LIHC	cis	rs1075265	0.587	rs2542585	ENSG00000272156.1	RP11-477N3.1	-4.08	5.51e-05	0.0113	-0.26	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54082554~54085066:+
LIHC	cis	rs7989332	0.925	rs6490585	ENSG00000275964.1	RP11-61K9.3	-4.08	5.51e-05	0.0113	-0.25	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20478159	chr13:19863858~19865048:+
LIHC	cis	rs72829446	0.53	rs72827503	ENSG00000263316.1	RP11-530N7.3	4.08	5.51e-05	0.0113	0.44	0.22	Androgen levels;	chr17:7467949	chr17:6954098~6978960:-
LIHC	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-4.08	5.51e-05	0.0113	-0.17	-0.22	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
LIHC	cis	rs4578769	0.765	rs57308197	ENSG00000266850.1	RP11-370A5.1	-4.08	5.51e-05	0.0113	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22874272	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs61311054	ENSG00000266850.1	RP11-370A5.1	-4.08	5.51e-05	0.0113	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22906406	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs10502430	ENSG00000266850.1	RP11-370A5.1	-4.08	5.51e-05	0.0113	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22916946	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.681	rs72887615	ENSG00000266850.1	RP11-370A5.1	-4.08	5.51e-05	0.0113	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22928638	chr18:22723491~22907721:-
LIHC	cis	rs4578769	0.765	rs898000	ENSG00000266850.1	RP11-370A5.1	-4.08	5.51e-05	0.0113	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22929109	chr18:22723491~22907721:-
LIHC	cis	rs1200821	0.529	rs4934856	ENSG00000263064.2	RP11-291L22.7	-4.08	5.51e-05	0.0113	-0.23	-0.22	Hemostatic factors and hematological phenotypes;	chr10:37518919	chr10:38448689~38448949:+
LIHC	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-4.08	5.51e-05	0.0113	-0.22	-0.22	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
LIHC	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-4.08	5.51e-05	0.0113	-0.27	-0.22	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
LIHC	cis	rs4694744	0.576	rs13151870	ENSG00000264696.1	AC108078.1	4.08	5.51e-05	0.0113	0.33	0.22	Bacteremia;	chr4:69490285	chr4:69479331~69479434:+
LIHC	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	4.08	5.51e-05	0.0113	0.35	0.22	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
LIHC	cis	rs10510102	0.872	rs11200277	ENSG00000273891.1	RP11-500G22.5	4.08	5.52e-05	0.0113	0.28	0.22	Breast cancer;	chr10:121944295	chr10:121965764~121967700:+
LIHC	cis	rs7131987	0.903	rs1991114	ENSG00000275476.1	RP11-996F15.4	-4.08	5.52e-05	0.0113	-0.25	-0.22	QT interval;	chr12:29239149	chr12:29277397~29277882:-
LIHC	cis	rs901683	1	rs12779204	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45568807	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs34670342	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45570714	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496619	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45572647	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs113862353	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45573138	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35001302	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45573488	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35585999	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45574711	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.702	rs34176769	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45575579	chr10:45678692~45700532:+
LIHC	cis	rs901683	0.85	rs35150810	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45575694	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs74411575	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45576519	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs79752400	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45576640	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs71496620	ENSG00000230869.1	CTGLF10P	-4.08	5.52e-05	0.0113	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45578881	chr10:45678692~45700532:+
LIHC	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-4.08	5.52e-05	0.0113	-0.21	-0.22	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
LIHC	cis	rs2739330	0.929	rs5751777	ENSG00000206090.4	AP000350.7	4.08	5.52e-05	0.0113	0.25	0.22	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23939998~23942798:+
LIHC	cis	rs6061231	0.631	rs2427317	ENSG00000226332.2	RP11-157P1.4	4.08	5.52e-05	0.0113	0.23	0.22	Colorectal cancer;	chr20:62400669	chr20:62305432~62306325:-
LIHC	cis	rs6061231	0.631	rs2427318	ENSG00000226332.2	RP11-157P1.4	4.08	5.52e-05	0.0113	0.23	0.22	Colorectal cancer;	chr20:62400671	chr20:62305432~62306325:-
LIHC	cis	rs755249	0.567	rs2018212	ENSG00000182109.6	RP11-69E11.4	4.08	5.52e-05	0.0113	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs4660751	ENSG00000182109.6	RP11-69E11.4	4.08	5.52e-05	0.0113	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39522280~39546187:-
LIHC	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-4.08	5.52e-05	0.0113	-0.2	-0.22	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
LIHC	cis	rs638893	1	rs113641235	ENSG00000255239.1	AP002954.6	-4.08	5.52e-05	0.0113	-0.49	-0.22	Vitiligo;	chr11:118829555	chr11:118688039~118690600:-
LIHC	cis	rs7726839	0.574	rs12522955	ENSG00000271781.1	CTD-2589H19.6	-4.08	5.53e-05	0.0113	-0.33	-0.22	Obesity-related traits;	chr5:639116	chr5:675826~676616:+
LIHC	cis	rs7937890	0.559	rs2597208	ENSG00000251991.1	RNU7-49P	4.08	5.53e-05	0.0113	0.23	0.22	Mitochondrial DNA levels;	chr11:14450783	chr11:14478892~14478953:+
LIHC	cis	rs6600671	0.934	rs67718113	ENSG00000227082.1	CH17-437K3.1	4.08	5.53e-05	0.0113	0.3	0.22	Hip geometry;	chr1:121497112	chr1:121396754~121463129:+
LIHC	cis	rs6445975	0.617	rs6762478	ENSG00000272360.1	RP11-359I18.5	4.08	5.53e-05	0.0113	0.29	0.22	Systemic lupus erythematosus;	chr3:58418084	chr3:58490830~58491291:-
LIHC	cis	rs6893782	0.887	rs274548	ENSG00000233006.5	AC034220.3	-4.08	5.53e-05	0.0113	-0.3	-0.22	Acylcarnitine levels;	chr5:132395115	chr5:132311285~132369916:-
LIHC	cis	rs6893782	0.83	rs2897160	ENSG00000233006.5	AC034220.3	-4.08	5.53e-05	0.0113	-0.3	-0.22	Acylcarnitine levels;	chr5:132405806	chr5:132311285~132369916:-
LIHC	cis	rs8002861	0.87	rs9567293	ENSG00000274001.1	RP11-5G9.5	4.08	5.53e-05	0.0113	0.25	0.22	Leprosy;	chr13:43873107	chr13:43877715~43878163:-
LIHC	cis	rs17772222	0.917	rs61983300	ENSG00000258789.1	RP11-507K2.3	-4.08	5.53e-05	0.0113	-0.26	-0.22	Coronary artery calcification;	chr14:88754047	chr14:88551597~88552493:+
LIHC	cis	rs17772222	0.876	rs78068036	ENSG00000258789.1	RP11-507K2.3	-4.08	5.53e-05	0.0113	-0.26	-0.22	Coronary artery calcification;	chr14:88754817	chr14:88551597~88552493:+
LIHC	cis	rs244293	0.965	rs11079153	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55098662	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs7224560	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55099178	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs2529507	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55103911	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.894	rs244372	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55107851	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.929	rs244371	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55107864	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.931	rs244370	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55107906	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.929	rs181728	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55108442	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244369	ENSG00000275710.1	RP11-257O5.4	-4.08	5.53e-05	0.0113	-0.23	-0.22	Menarche (age at onset);	chr17:55108700	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244368	ENSG00000275710.1	RP11-257O5.4	4.08	5.53e-05	0.0113	0.23	0.22	Menarche (age at onset);	chr17:55109176	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244366	ENSG00000275710.1	RP11-257O5.4	4.08	5.53e-05	0.0113	0.23	0.22	Menarche (age at onset);	chr17:55109939	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244365	ENSG00000275710.1	RP11-257O5.4	4.08	5.53e-05	0.0113	0.23	0.22	Menarche (age at onset);	chr17:55110040	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244363	ENSG00000275710.1	RP11-257O5.4	4.08	5.53e-05	0.0113	0.23	0.22	Menarche (age at onset);	chr17:55111532	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244356	ENSG00000275710.1	RP11-257O5.4	4.08	5.53e-05	0.0113	0.23	0.22	Menarche (age at onset);	chr17:55116448	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.899	rs244355	ENSG00000275710.1	RP11-257O5.4	4.08	5.53e-05	0.0113	0.23	0.22	Menarche (age at onset);	chr17:55116724	chr17:54964474~54964679:+
LIHC	cis	rs13315871	0.615	rs7625655	ENSG00000272182.1	RP11-802O23.3	-4.08	5.54e-05	0.0113	-0.4	-0.22	Cholesterol, total;	chr3:58351996	chr3:58428255~58428815:+
LIHC	cis	rs763121	0.925	rs9611008	ENSG00000273076.1	RP3-508I15.22	4.08	5.54e-05	0.0113	0.24	0.22	Menopause (age at onset);	chr22:38702782	chr22:38743495~38743910:+
LIHC	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-4.08	5.55e-05	0.0114	-0.26	-0.22	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
LIHC	cis	rs987724	0.515	rs453219	ENSG00000243926.1	TIPARP-AS1	4.08	5.55e-05	0.0114	0.24	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856463	chr3:156671862~156674378:-
LIHC	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	4.08	5.55e-05	0.0114	0.36	0.22	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
LIHC	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-4.08	5.56e-05	0.0114	-0.27	-0.22	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
LIHC	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-4.08	5.56e-05	0.0114	-0.25	-0.22	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
LIHC	cis	rs17818399	0.62	rs1080871	ENSG00000239332.4	LINC01119	-4.08	5.56e-05	0.0114	-0.28	-0.22	Height;	chr2:46627569	chr2:46816697~46859007:+
LIHC	cis	rs17818399	0.62	rs7598578	ENSG00000239332.4	LINC01119	-4.08	5.56e-05	0.0114	-0.28	-0.22	Height;	chr2:46629946	chr2:46816697~46859007:+
LIHC	cis	rs17818399	0.62	rs1598517	ENSG00000239332.4	LINC01119	-4.08	5.56e-05	0.0114	-0.28	-0.22	Height;	chr2:46630262	chr2:46816697~46859007:+
LIHC	cis	rs17818399	0.62	rs6739397	ENSG00000239332.4	LINC01119	-4.08	5.56e-05	0.0114	-0.28	-0.22	Height;	chr2:46631182	chr2:46816697~46859007:+
LIHC	cis	rs4650994	1	rs4650994	ENSG00000213057.5	C1orf220	-4.08	5.56e-05	0.0114	-0.18	-0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546177	chr1:178542752~178548889:+
LIHC	cis	rs4650994	0.967	rs4650992	ENSG00000213057.5	C1orf220	4.08	5.56e-05	0.0114	0.19	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546000	chr1:178542752~178548889:+
LIHC	cis	rs4650994	1	rs4650993	ENSG00000213057.5	C1orf220	4.08	5.56e-05	0.0114	0.19	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546052	chr1:178542752~178548889:+
LIHC	cis	rs4650994	0.935	rs12039531	ENSG00000213057.5	C1orf220	4.08	5.56e-05	0.0114	0.19	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546477	chr1:178542752~178548889:+
LIHC	cis	rs4650994	1	rs10798616	ENSG00000213057.5	C1orf220	4.08	5.56e-05	0.0114	0.19	0.22	HDL cholesterol;HDL cholesterol levels;	chr1:178546507	chr1:178542752~178548889:+
LIHC	cis	rs2243480	1	rs34702770	ENSG00000232546.1	RP11-458F8.1	-4.08	5.57e-05	0.0114	-0.24	-0.22	Diabetic kidney disease;	chr7:65879836	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.803	rs35480979	ENSG00000232546.1	RP11-458F8.1	-4.08	5.57e-05	0.0114	-0.24	-0.22	Diabetic kidney disease;	chr7:65892097	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs34637256	ENSG00000232546.1	RP11-458F8.1	-4.08	5.57e-05	0.0114	-0.24	-0.22	Diabetic kidney disease;	chr7:65895144	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs35391607	ENSG00000232546.1	RP11-458F8.1	-4.08	5.57e-05	0.0114	-0.24	-0.22	Diabetic kidney disease;	chr7:65895842	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs13220979	ENSG00000232546.1	RP11-458F8.1	-4.08	5.57e-05	0.0114	-0.24	-0.22	Diabetic kidney disease;	chr7:65898217	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs34974928	ENSG00000232546.1	RP11-458F8.1	-4.08	5.57e-05	0.0114	-0.24	-0.22	Diabetic kidney disease;	chr7:65899019	chr7:66848496~66858136:+
LIHC	cis	rs7726839	0.54	rs72703095	ENSG00000271781.1	CTD-2589H19.6	-4.08	5.57e-05	0.0114	-0.33	-0.22	Obesity-related traits;	chr5:601674	chr5:675826~676616:+
LIHC	cis	rs755249	0.567	rs72637906	ENSG00000182109.6	RP11-69E11.4	4.08	5.57e-05	0.0114	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs67886352	ENSG00000182109.6	RP11-69E11.4	4.08	5.57e-05	0.0114	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs66727439	ENSG00000182109.6	RP11-69E11.4	4.08	5.57e-05	0.0114	0.28	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39522280~39546187:-
LIHC	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-4.08	5.57e-05	0.0114	-0.2	-0.22	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
LIHC	cis	rs9304742	0.924	rs8111196	ENSG00000213801.4	ZNF816-ZNF321P	4.08	5.57e-05	0.0114	0.22	0.22	Psoriasis;	chr19:52953970	chr19:52927135~52942601:-
LIHC	cis	rs9304742	0.888	rs8111514	ENSG00000213801.4	ZNF816-ZNF321P	4.08	5.57e-05	0.0114	0.22	0.22	Psoriasis;	chr19:52953993	chr19:52927135~52942601:-
LIHC	cis	rs9304742	0.888	rs8112137	ENSG00000213801.4	ZNF816-ZNF321P	4.08	5.57e-05	0.0114	0.22	0.22	Psoriasis;	chr19:52954002	chr19:52927135~52942601:-
LIHC	cis	rs7083	0.967	rs558590	ENSG00000254851.1	RP11-109L13.1	4.08	5.58e-05	0.0114	0.31	0.22	Blood protein levels;	chr11:117268405	chr11:117135528~117138582:+
LIHC	cis	rs889014	1	rs12517986	ENSG00000204758.6	CTC-308K20.1	4.08	5.58e-05	0.0114	0.31	0.22	Height;	chr5:173568157	chr5:172954786~172959392:-
LIHC	cis	rs4891159	0.79	rs17059379	ENSG00000265778.2	RP11-17M16.2	4.08	5.58e-05	0.0114	0.25	0.22	Longevity;	chr18:76448360	chr18:76491652~76493918:+
LIHC	cis	rs6480314	1	rs6480314	ENSG00000233590.1	RP11-153K11.3	4.08	5.58e-05	0.0114	0.32	0.22	Optic nerve measurement (disc area);	chr10:68207690	chr10:68233251~68242379:-
LIHC	cis	rs2808510	1	rs2808500	ENSG00000230623.2	RP11-469A15.2	-4.08	5.58e-05	0.0114	-0.25	-0.22	Myopia;	chr1:200361351	chr1:200473920~200478293:+
LIHC	cis	rs929596	0.563	rs1105879	ENSG00000233445.1	RPL17P11	4.08	5.58e-05	0.0114	0.23	0.22	Total bilirubin levels in HIV-1 infection;	chr2:233693556	chr2:233721522~233722065:-
LIHC	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	4.08	5.58e-05	0.0114	0.34	0.22	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
LIHC	cis	rs244293	0.965	rs12453615	ENSG00000275710.1	RP11-257O5.4	-4.08	5.58e-05	0.0114	-0.23	-0.22	Menarche (age at onset);	chr17:55100148	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs2628326	ENSG00000275710.1	RP11-257O5.4	-4.08	5.58e-05	0.0114	-0.23	-0.22	Menarche (age at onset);	chr17:55100922	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs2787504	ENSG00000275710.1	RP11-257O5.4	-4.08	5.58e-05	0.0114	-0.23	-0.22	Menarche (age at onset);	chr17:55100980	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244364	ENSG00000275710.1	RP11-257O5.4	4.08	5.58e-05	0.0114	0.23	0.22	Menarche (age at onset);	chr17:55110919	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244360	ENSG00000275710.1	RP11-257O5.4	4.08	5.58e-05	0.0114	0.23	0.22	Menarche (age at onset);	chr17:55114342	chr17:54964474~54964679:+
LIHC	cis	rs6860806	0.507	rs272878	ENSG00000263597.1	MIR3936	-4.08	5.59e-05	0.0114	-0.24	-0.22	Breast cancer;	chr5:132336076	chr5:132365490~132365599:-
LIHC	cis	rs7617480	0.61	rs4955420	ENSG00000270441.1	RP11-694I15.7	-4.08	5.59e-05	0.0114	-0.31	-0.22	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49140086~49160851:-
LIHC	cis	rs113835537	0.935	rs11550057	ENSG00000255517.5	CTD-3074O7.5	-4.08	5.59e-05	0.0114	-0.38	-0.22	Airway imaging phenotypes;	chr11:66625409	chr11:66473490~66480233:-
LIHC	cis	rs113835537	0.935	rs15969	ENSG00000255517.5	CTD-3074O7.5	-4.08	5.59e-05	0.0114	-0.38	-0.22	Airway imaging phenotypes;	chr11:66626916	chr11:66473490~66480233:-
LIHC	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-4.08	5.59e-05	0.0114	-0.25	-0.22	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
LIHC	cis	rs9527	0.615	rs11191489	ENSG00000236937.2	PTGES3P4	4.08	5.59e-05	0.0114	0.27	0.22	Arsenic metabolism;	chr10:102980811	chr10:102845595~102845950:+
LIHC	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	4.08	5.59e-05	0.0114	0.25	0.22	Height;	chr4:55548666	chr4:55363971~55395847:-
LIHC	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	4.08	5.59e-05	0.0114	0.24	0.22	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
LIHC	cis	rs643506	0.845	rs762550	ENSG00000254990.4	RP11-108O10.2	4.08	5.6e-05	0.0114	0.24	0.22	Breast cancer;	chr11:111912376	chr11:111768668~111778350:-
LIHC	cis	rs9595908	0.709	rs56347753	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32721685	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.669	rs9596149	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32722533	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.709	rs4281583	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32722781	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.686	rs9596155	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32724002	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.709	rs7322827	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32724396	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.629	rs9596156	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32724977	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.669	rs7319787	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32728320	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.669	rs7331529	ENSG00000212293.1	SNORA16	4.08	5.6e-05	0.0114	0.25	0.22	Body mass index;	chr13:32728409	chr13:32420390~32420516:-
LIHC	cis	rs755249	0.529	rs3768299	ENSG00000182109.6	RP11-69E11.4	4.08	5.6e-05	0.0114	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39522280~39546187:-
LIHC	cis	rs6832769	1	rs10016506	ENSG00000272969.1	RP11-528I4.2	-4.08	5.6e-05	0.0114	-0.26	-0.22	Personality dimensions;	chr4:55530507	chr4:55547112~55547889:+
LIHC	cis	rs2658782	0.507	rs4457713	ENSG00000279684.1	RP11-755E23.2	-4.08	5.6e-05	0.0114	-0.31	-0.22	Pulmonary function decline;	chr11:93304264	chr11:93286629~93288903:-
LIHC	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	4.08	5.6e-05	0.0114	0.2	0.22	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
LIHC	cis	rs10080237	0.564	rs2490224	ENSG00000272129.1	RP11-250B2.6	4.08	5.6e-05	0.0114	0.21	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80100116	chr6:80355424~80356859:+
LIHC	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-4.08	5.61e-05	0.0114	-0.21	-0.22	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
LIHC	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	4.08	5.61e-05	0.0114	0.24	0.22	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
LIHC	cis	rs4561483	0.801	rs33643	ENSG00000261560.1	RP11-166B2.3	-4.08	5.61e-05	0.0115	-0.25	-0.22	Testicular germ cell tumor;	chr16:11892292	chr16:11881075~11882569:-
LIHC	cis	rs755249	0.762	rs1775654	ENSG00000182109.6	RP11-69E11.4	4.08	5.61e-05	0.0115	0.23	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39522280~39546187:-
LIHC	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-4.08	5.61e-05	0.0115	-0.2	-0.22	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
LIHC	cis	rs1005277	0.505	rs10827835	ENSG00000276805.1	RP11-291L22.6	-4.08	5.61e-05	0.0115	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38451030~38451785:+
LIHC	cis	rs12468226	1	rs76021735	ENSG00000272966.1	RP11-686O6.1	4.08	5.61e-05	0.0115	0.36	0.22	Urate levels;	chr2:202511476	chr2:202336739~202337200:+
LIHC	cis	rs12468226	1	rs57080353	ENSG00000272966.1	RP11-686O6.1	4.08	5.61e-05	0.0115	0.36	0.22	Urate levels;	chr2:202511824	chr2:202336739~202337200:+
LIHC	cis	rs12468226	0.81	rs3736578	ENSG00000272966.1	RP11-686O6.1	4.08	5.61e-05	0.0115	0.36	0.22	Urate levels;	chr2:202519989	chr2:202336739~202337200:+
LIHC	cis	rs12468226	1	rs116439150	ENSG00000272966.1	RP11-686O6.1	4.08	5.61e-05	0.0115	0.36	0.22	Urate levels;	chr2:202523814	chr2:202336739~202337200:+
LIHC	cis	rs12468226	1	rs12467409	ENSG00000272966.1	RP11-686O6.1	4.08	5.61e-05	0.0115	0.36	0.22	Urate levels;	chr2:202529625	chr2:202336739~202337200:+
LIHC	cis	rs17270561	0.562	rs12199626	ENSG00000272810.1	U91328.22	-4.08	5.62e-05	0.0115	-0.28	-0.22	Iron status biomarkers;	chr6:26013376	chr6:26013241~26013757:+
LIHC	cis	rs7412746	0.658	rs3768016	ENSG00000231073.1	RP11-316M1.3	4.08	5.62e-05	0.0115	0.22	0.22	Melanoma;	chr1:150837443	chr1:150973123~150975534:+
LIHC	cis	rs9400467	0.528	rs11153280	ENSG00000271789.1	RP5-1112D6.7	-4.08	5.62e-05	0.0115	-0.21	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111297126~111298510:+
LIHC	cis	rs3758785	0.623	rs77241189	ENSG00000255893.1	RP11-685N10.1	-4.08	5.62e-05	0.0115	-0.26	-0.22	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410151	chr11:94472908~94473570:-
LIHC	cis	rs11098499	0.569	rs10023641	ENSG00000260091.1	RP11-33B1.4	-4.08	5.62e-05	0.0115	-0.14	-0.22	Corneal astigmatism;	chr4:119337255	chr4:119409333~119410233:+
LIHC	cis	rs17834679	0.957	rs59546961	ENSG00000243680.1	RPL37P23	-4.08	5.62e-05	0.0115	-0.19	-0.22	Alopecia areata;	chr19:51766957	chr19:52143043~52143336:+
LIHC	cis	rs901683	0.85	rs12778143	ENSG00000230869.1	CTGLF10P	-4.08	5.62e-05	0.0115	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45568092	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs12776336	ENSG00000230869.1	CTGLF10P	-4.08	5.62e-05	0.0115	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45568463	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs33997730	ENSG00000230869.1	CTGLF10P	-4.08	5.62e-05	0.0115	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45572665	chr10:45678692~45700532:+
LIHC	cis	rs901683	1	rs35639934	ENSG00000230869.1	CTGLF10P	-4.08	5.62e-05	0.0115	-0.53	-0.22	Mean corpuscular volume;Red blood cell traits;	chr10:45575179	chr10:45678692~45700532:+
LIHC	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-4.08	5.62e-05	0.0115	-0.17	-0.22	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
LIHC	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-4.08	5.62e-05	0.0115	-0.32	-0.22	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
LIHC	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-4.08	5.63e-05	0.0115	-0.21	-0.22	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
LIHC	cis	rs3015497	0.616	rs1494181	ENSG00000269906.1	RP11-248J18.2	4.08	5.64e-05	0.0115	0.27	0.22	Mean platelet volume;	chr14:50589882	chr14:50662511~50663178:-
LIHC	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	4.08	5.64e-05	0.0115	0.25	0.22	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
LIHC	cis	rs875971	0.522	rs7784623	ENSG00000273024.4	INTS4P2	-4.08	5.64e-05	0.0115	-0.26	-0.22	Aortic root size;	chr7:65930047	chr7:65647864~65715661:+
LIHC	cis	rs10995505	0.589	rs1553789	ENSG00000232075.1	MRPL35P2	4.08	5.64e-05	0.0115	0.24	0.22	Intelligence (multi-trait analysis);	chr10:63119469	chr10:63634317~63634827:-
LIHC	cis	rs10871290	0.551	rs3863435	ENSG00000214331.7	RP11-252A24.2	-4.08	5.64e-05	0.0115	-0.18	-0.22	Breast cancer;	chr16:74431498	chr16:74332402~74368240:-
LIHC	cis	rs12210905	0.92	rs9393802	ENSG00000216901.1	AL022393.7	4.08	5.65e-05	0.0115	0.36	0.22	Hip circumference adjusted for BMI;	chr6:27275326	chr6:28176188~28176674:+
LIHC	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	4.08	5.65e-05	0.0115	0.19	0.22	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
LIHC	cis	rs803923	0.585	rs803931	ENSG00000230894.1	RP11-67K19.3	-4.08	5.65e-05	0.0115	-0.27	-0.22	Lung function (FEV1/FVC);	chr9:116696405	chr9:116568449~116586328:+
LIHC	cis	rs1223397	0.651	rs202023	ENSG00000215022.6	RP1-257A7.4	-4.08	5.65e-05	0.0115	-0.23	-0.22	Blood pressure;	chr6:13304426	chr6:13264861~13295586:-
LIHC	cis	rs3015497	0.526	rs10136630	ENSG00000269906.1	RP11-248J18.2	4.08	5.66e-05	0.0115	0.26	0.22	Mean platelet volume;	chr14:50579756	chr14:50662511~50663178:-
LIHC	cis	rs11247230	1	rs11247230	ENSG00000270127.2	RP11-526I2.5	4.08	5.66e-05	0.0115	0.24	0.22	Optic cup area;	chr15:100656800	chr15:100547765~100550153:-
LIHC	cis	rs10857712	0.95	rs11101744	ENSG00000214279.11	SCART1	-4.08	5.66e-05	0.0115	-0.26	-0.22	Systemic lupus erythematosus;	chr10:133412537	chr10:133453928~133523558:+
LIHC	cis	rs10510102	0.808	rs11200296	ENSG00000273891.1	RP11-500G22.5	4.08	5.66e-05	0.0115	0.3	0.22	Breast cancer;	chr10:121971956	chr10:121965764~121967700:+
LIHC	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	4.08	5.67e-05	0.0115	0.22	0.22	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
LIHC	cis	rs57502260	0.704	rs72936599	ENSG00000212093.1	AP000807.1	4.08	5.67e-05	0.0115	0.29	0.22	Total body bone mineral density (age 45-60);	chr11:68552937	chr11:68506083~68506166:-
LIHC	cis	rs3015497	0.789	rs1389652	ENSG00000269906.1	RP11-248J18.2	4.08	5.67e-05	0.0116	0.27	0.22	Mean platelet volume;	chr14:50658522	chr14:50662511~50663178:-
LIHC	cis	rs6860806	0.507	rs2631369	ENSG00000263597.1	MIR3936	-4.08	5.67e-05	0.0116	-0.23	-0.22	Breast cancer;	chr5:132369574	chr5:132365490~132365599:-
LIHC	cis	rs274567	0.501	rs2631368	ENSG00000263597.1	MIR3936	-4.08	5.67e-05	0.0116	-0.23	-0.22	Blood metabolite levels;	chr5:132369605	chr5:132365490~132365599:-
LIHC	cis	rs12468226	1	rs2350809	ENSG00000272966.1	RP11-686O6.1	4.08	5.67e-05	0.0116	0.35	0.22	Urate levels;	chr2:202464210	chr2:202336739~202337200:+
LIHC	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	4.08	5.67e-05	0.0116	0.19	0.22	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
LIHC	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	4.08	5.68e-05	0.0116	0.22	0.22	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	4.08	5.68e-05	0.0116	0.22	0.22	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	4.08	5.68e-05	0.0116	0.22	0.22	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	4.08	5.68e-05	0.0116	0.22	0.22	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	4.08	5.68e-05	0.0116	0.22	0.22	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	4.08	5.68e-05	0.0116	0.22	0.22	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
LIHC	cis	rs57502260	0.573	rs11228294	ENSG00000212093.1	AP000807.1	4.08	5.68e-05	0.0116	0.25	0.22	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:68506083~68506166:-
LIHC	cis	rs11671005	0.656	rs11672609	ENSG00000269473.1	CTD-2619J13.19	4.08	5.68e-05	0.0116	0.4	0.22	Mean platelet volume;	chr19:58495557	chr19:58440448~58445849:+
LIHC	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-4.08	5.68e-05	0.0116	-0.21	-0.22	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-4.08	5.68e-05	0.0116	-0.21	-0.22	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
LIHC	cis	rs9952991	0.883	rs2542148	ENSG00000260302.1	RP11-973H7.1	-4.08	5.68e-05	0.0116	-0.32	-0.22	Inflammatory skin disease;	chr18:12777574	chr18:12774651~12775923:-
LIHC	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-4.08	5.68e-05	0.0116	-0.23	-0.22	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
LIHC	cis	rs617219	0.746	rs2591391	ENSG00000251675.1	CTC-458I2.2	-4.08	5.68e-05	0.0116	-0.25	-0.22	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79250632	chr5:80128361~80143883:+
LIHC	cis	rs11696277	0.518	rs6044739	ENSG00000232333.1	RPS27AP2	-4.08	5.69e-05	0.0116	-0.3	-0.22	Gut microbiome composition (summer);	chr20:17335297	chr20:17516843~17517307:+
LIHC	cis	rs9326248	0.574	rs1263173	ENSG00000280143.1	AP000892.6	4.08	5.69e-05	0.0116	0.24	0.22	Blood protein levels;	chr11:116810292	chr11:117204967~117210292:+
LIHC	cis	rs2243480	1	rs313831	ENSG00000228409.4	CCT6P1	4.08	5.69e-05	0.0116	0.23	0.22	Diabetic kidney disease;	chr7:66086239	chr7:65751142~65763354:+
LIHC	cis	rs860295	0.836	rs35615695	ENSG00000203761.5	MSTO2P	4.08	5.69e-05	0.0116	0.17	0.22	Body mass index;	chr1:155531223	chr1:155745829~155750137:+
LIHC	cis	rs1005277	0.505	rs200939	ENSG00000276805.1	RP11-291L22.6	4.08	5.69e-05	0.0116	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38451030~38451785:+
LIHC	cis	rs11874381	0.582	rs6507943	ENSG00000267322.2	SNHG22	4.08	5.69e-05	0.0116	0.25	0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49686717	chr18:49814023~49851059:+
LIHC	cis	rs7119038	0.818	rs10892294	ENSG00000255239.1	AP002954.6	4.08	5.7e-05	0.0116	0.3	0.22	Sjögren's syndrome;	chr11:118796648	chr11:118688039~118690600:-
LIHC	cis	rs1005277	0.505	rs200935	ENSG00000276805.1	RP11-291L22.6	4.08	5.7e-05	0.0116	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.505	rs200936	ENSG00000276805.1	RP11-291L22.6	4.08	5.7e-05	0.0116	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.505	rs200937	ENSG00000276805.1	RP11-291L22.6	4.08	5.7e-05	0.0116	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38451030~38451785:+
LIHC	cis	rs417065	1	rs11588819	ENSG00000227634.1	RP11-431K24.3	-4.08	5.7e-05	0.0116	-0.28	-0.22	Psoriasis;	chr1:8200885	chr1:8208672~8215210:+
LIHC	cis	rs748404	0.631	rs3809482	ENSG00000166763.7	STRCP1	4.08	5.7e-05	0.0116	0.27	0.22	Lung cancer;	chr15:43369604	chr15:43699488~43718184:-
LIHC	cis	rs11121022	1	rs11121022	ENSG00000269925.1	RP3-467L1.6	-4.08	5.7e-05	0.0116	-0.22	-0.22	Morning vs. evening chronotype;	chr1:7776599	chr1:7776383~7776775:+
LIHC	cis	rs8032158	0.502	rs2136385	ENSG00000279145.1	RP11-547D13.1	4.08	5.7e-05	0.0116	0.22	0.22	Keloid;	chr15:55943047	chr15:55171972~55178175:-
LIHC	cis	rs4694744	0.538	rs13111134	ENSG00000264696.1	AC108078.1	4.08	5.7e-05	0.0116	0.32	0.22	Bacteremia;	chr4:69489093	chr4:69479331~69479434:+
LIHC	cis	rs1023500	0.505	rs134889	ENSG00000226450.2	CYP2D8P	4.08	5.71e-05	0.0116	0.24	0.22	Schizophrenia;	chr22:42278344	chr22:42149886~42155001:-
LIHC	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	4.08	5.71e-05	0.0116	0.36	0.22	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
LIHC	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-4.08	5.71e-05	0.0116	-0.26	-0.22	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
LIHC	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	4.08	5.71e-05	0.0116	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
LIHC	cis	rs1499614	0.803	rs1796229	ENSG00000232546.1	RP11-458F8.1	-4.08	5.71e-05	0.0116	-0.24	-0.22	Gout;	chr7:66654674	chr7:66848496~66858136:+
LIHC	cis	rs1499614	0.901	rs3936	ENSG00000232546.1	RP11-458F8.1	-4.08	5.71e-05	0.0116	-0.24	-0.22	Gout;	chr7:66661502	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs160642	ENSG00000230295.1	RP11-458F8.2	-4.08	5.71e-05	0.0116	-0.22	-0.22	Diabetic kidney disease;	chr7:66093386	chr7:66880708~66882981:+
LIHC	cis	rs2243480	0.614	rs34032527	ENSG00000230295.1	RP11-458F8.2	-4.08	5.71e-05	0.0116	-0.22	-0.22	Diabetic kidney disease;	chr7:66100154	chr7:66880708~66882981:+
LIHC	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	4.08	5.71e-05	0.0116	0.19	0.22	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
LIHC	cis	rs933688	1	rs12651840	ENSG00000281357.1	ARRDC3-AS1	4.08	5.71e-05	0.0116	0.27	0.22	Smoking behavior;	chr5:91433775	chr5:91380349~91439085:+
LIHC	cis	rs933688	1	rs2052553	ENSG00000281357.1	ARRDC3-AS1	4.08	5.71e-05	0.0116	0.27	0.22	Smoking behavior;	chr5:91434089	chr5:91380349~91439085:+
LIHC	cis	rs638893	0.853	rs4938549	ENSG00000255239.1	AP002954.6	4.08	5.71e-05	0.0116	0.37	0.22	Vitiligo;	chr11:118830888	chr11:118688039~118690600:-
LIHC	cis	rs638893	0.898	rs530646	ENSG00000255239.1	AP002954.6	4.08	5.71e-05	0.0116	0.37	0.22	Vitiligo;	chr11:118830959	chr11:118688039~118690600:-
LIHC	cis	rs638893	0.947	rs12808822	ENSG00000255239.1	AP002954.6	4.08	5.71e-05	0.0116	0.37	0.22	Vitiligo;	chr11:118831560	chr11:118688039~118690600:-
LIHC	cis	rs875971	0.545	rs1796217	ENSG00000228409.4	CCT6P1	4.08	5.71e-05	0.0116	0.18	0.22	Aortic root size;	chr7:66620931	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs160655	ENSG00000228409.4	CCT6P1	4.08	5.71e-05	0.0116	0.23	0.22	Diabetic kidney disease;	chr7:66068227	chr7:65751142~65763354:+
LIHC	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	4.08	5.71e-05	0.0116	0.32	0.22	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
LIHC	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	4.08	5.71e-05	0.0116	0.32	0.22	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
LIHC	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	4.08	5.71e-05	0.0116	0.34	0.22	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
LIHC	cis	rs1005277	0.505	rs200910	ENSG00000276805.1	RP11-291L22.6	4.08	5.72e-05	0.0116	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38451030~38451785:+
LIHC	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-4.08	5.72e-05	0.0116	-0.22	-0.22	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
LIHC	cis	rs2598107	0.601	rs3807612	ENSG00000211698.2	TRGV4	-4.07	5.73e-05	0.0117	-0.25	-0.22	Dupuytren's disease;	chr7:37918169	chr7:38353715~38354517:-
LIHC	cis	rs1005277	0.505	rs719569	ENSG00000276805.1	RP11-291L22.6	-4.07	5.73e-05	0.0117	-0.26	-0.22	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38451030~38451785:+
LIHC	cis	rs1005277	0.522	rs200943	ENSG00000276805.1	RP11-291L22.6	4.07	5.73e-05	0.0117	0.26	0.22	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38451030~38451785:+
LIHC	cis	rs748404	0.588	rs506120	ENSG00000166763.7	STRCP1	4.07	5.73e-05	0.0117	0.27	0.22	Lung cancer;	chr15:43509826	chr15:43699488~43718184:-
LIHC	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	4.07	5.73e-05	0.0117	0.25	0.22	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	4.07	5.73e-05	0.0117	0.25	0.22	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
LIHC	cis	rs10829156	0.796	rs6482567	ENSG00000225527.1	RP11-383B4.4	-4.07	5.73e-05	0.0117	-0.36	-0.22	Sudden cardiac arrest;	chr10:18625860	chr10:18531849~18533336:-
LIHC	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	4.07	5.73e-05	0.0117	0.3	0.22	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
LIHC	cis	rs5758511	0.514	rs5751221	ENSG00000205702.9	CYP2D7	4.07	5.73e-05	0.0117	0.25	0.22	Birth weight;	chr22:42120362	chr22:42140203~42144577:-
LIHC	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	4.07	5.74e-05	0.0117	0.27	0.22	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
LIHC	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	4.07	5.74e-05	0.0117	0.27	0.22	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
LIHC	cis	rs603446	0.56	rs1240781	ENSG00000254851.1	RP11-109L13.1	4.07	5.74e-05	0.0117	0.28	0.22	Triglycerides;	chr11:116704101	chr11:117135528~117138582:+
LIHC	cis	rs7131987	0.903	rs11050161	ENSG00000275476.1	RP11-996F15.4	-4.07	5.74e-05	0.0117	-0.25	-0.22	QT interval;	chr12:29267116	chr12:29277397~29277882:-
LIHC	cis	rs7131987	0.903	rs11050162	ENSG00000275476.1	RP11-996F15.4	-4.07	5.74e-05	0.0117	-0.25	-0.22	QT interval;	chr12:29267121	chr12:29277397~29277882:-
LIHC	cis	rs55966801	0.853	rs505404	ENSG00000277290.1	RP11-326C3.16	-4.07	5.74e-05	0.0117	-0.26	-0.22	Plateletcrit;	chr11:243268	chr11:243099~243483:-
LIHC	cis	rs6504622	0.755	rs12939753	ENSG00000262879.4	RP11-156P1.3	-4.07	5.74e-05	0.0117	-0.23	-0.22	Orofacial clefts;	chr17:47104133	chr17:46984045~47100323:-
LIHC	cis	rs7893279	0.505	rs2130531	ENSG00000225527.1	RP11-383B4.4	4.07	5.74e-05	0.0117	0.3	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18658450	chr10:18531849~18533336:-
LIHC	cis	rs7893279	0.505	rs11015435	ENSG00000225527.1	RP11-383B4.4	4.07	5.74e-05	0.0117	0.3	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18659143	chr10:18531849~18533336:-
LIHC	cis	rs9906944	0.898	rs9909861	ENSG00000248278.1	SUMO2P17	-4.07	5.74e-05	0.0117	-0.37	-0.22	Intelligence (multi-trait analysis);Body fat percentage;	chr17:49002054	chr17:48874860~48908983:-
LIHC	cis	rs3733589	0.744	rs3775939	ENSG00000250413.1	RP11-448G15.1	4.07	5.74e-05	0.0117	0.35	0.22	Renal overload gout;	chr4:10023672	chr4:10006482~10009725:+
LIHC	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-4.07	5.74e-05	0.0117	-0.26	-0.22	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
LIHC	cis	rs6452524	1	rs11958314	ENSG00000271862.1	RP11-343L5.2	4.07	5.74e-05	0.0117	0.25	0.22	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83049376~83050964:-
LIHC	cis	rs6452524	0.686	rs6452517	ENSG00000271862.1	RP11-343L5.2	4.07	5.74e-05	0.0117	0.25	0.22	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83049376~83050964:-
LIHC	cis	rs4578769	0.802	rs66816194	ENSG00000266850.1	RP11-370A5.1	-4.07	5.75e-05	0.0117	-0.25	-0.22	Eosinophil percentage of white cells;	chr18:22895554	chr18:22723491~22907721:-
LIHC	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-4.07	5.75e-05	0.0117	-0.41	-0.22	Depression;	chr6:28200565	chr6:28115628~28116551:+
LIHC	cis	rs7923609	0.846	rs9787438	ENSG00000232075.1	MRPL35P2	-4.07	5.75e-05	0.0117	-0.24	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63278270	chr10:63634317~63634827:-
LIHC	cis	rs12681366	0.881	rs3019149	ENSG00000253704.1	RP11-267M23.4	4.07	5.75e-05	0.0117	0.26	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94553722~94569745:+
LIHC	cis	rs10833905	1	rs57275726	ENSG00000246225.5	RP11-17A1.3	-4.07	5.75e-05	0.0117	-0.27	-0.22	Sudden cardiac arrest;	chr11:23024166	chr11:22829380~22945393:+
LIHC	cis	rs1874124	0.577	rs2807872	ENSG00000238078.1	LINC01352	-4.07	5.75e-05	0.0117	-0.36	-0.22	Cholesterol, total;	chr1:220866908	chr1:220829255~220832429:+
LIHC	cis	rs6445975	0.667	rs2037123	ENSG00000272360.1	RP11-359I18.5	-4.07	5.75e-05	0.0117	-0.25	-0.22	Systemic lupus erythematosus;	chr3:58253466	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.575	rs7614726	ENSG00000272360.1	RP11-359I18.5	-4.07	5.75e-05	0.0117	-0.25	-0.22	Systemic lupus erythematosus;	chr3:58257562	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.667	rs34532954	ENSG00000272360.1	RP11-359I18.5	-4.07	5.75e-05	0.0117	-0.25	-0.22	Systemic lupus erythematosus;	chr3:58257867	chr3:58490830~58491291:-
LIHC	cis	rs4356203	0.905	rs7927240	ENSG00000260196.1	RP1-239B22.5	-4.07	5.76e-05	0.0117	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.905	rs7946165	ENSG00000260196.1	RP1-239B22.5	-4.07	5.76e-05	0.0117	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.875	rs7939614	ENSG00000260196.1	RP1-239B22.5	-4.07	5.76e-05	0.0117	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.905	rs9919600	ENSG00000260196.1	RP1-239B22.5	-4.07	5.76e-05	0.0117	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17380649~17383531:+
LIHC	cis	rs4356203	0.905	rs9919540	ENSG00000260196.1	RP1-239B22.5	-4.07	5.76e-05	0.0117	-0.26	-0.22	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17380649~17383531:+
LIHC	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	4.07	5.76e-05	0.0117	0.25	0.22	Height;	chr4:55522229	chr4:55363971~55395847:-
LIHC	cis	rs794185	0.592	rs304078	ENSG00000231249.1	ITPR1-AS1	-4.07	5.76e-05	0.0117	-0.24	-0.22	Multiple sclerosis--Brain Glutamate Levels;	chr3:4491474	chr3:4490891~4493163:-
LIHC	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	4.07	5.76e-05	0.0117	0.21	0.22	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
LIHC	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-4.07	5.76e-05	0.0117	-0.23	-0.22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
LIHC	cis	rs4578769	0.765	rs8091950	ENSG00000266850.1	RP11-370A5.1	4.07	5.76e-05	0.0117	0.25	0.22	Eosinophil percentage of white cells;	chr18:22859136	chr18:22723491~22907721:-
LIHC	cis	rs7893279	0.505	rs12766314	ENSG00000225527.1	RP11-383B4.4	4.07	5.76e-05	0.0117	0.31	0.22	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18584361	chr10:18531849~18533336:-
LIHC	cis	rs1928295	0.786	rs10983720	ENSG00000233569.1	RP11-500B12.1	4.07	5.76e-05	0.0117	0.22	0.22	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117625209	chr9:117648606~117657027:+
LIHC	cis	rs1928295	0.75	rs10818054	ENSG00000233569.1	RP11-500B12.1	4.07	5.76e-05	0.0117	0.22	0.22	Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr9:117625739	chr9:117648606~117657027:+
LIHC	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	4.07	5.77e-05	0.0117	0.25	0.22	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
LIHC	cis	rs11671005	0.656	rs55652736	ENSG00000269473.1	CTD-2619J13.19	4.07	5.77e-05	0.0117	0.4	0.22	Mean platelet volume;	chr19:58496199	chr19:58440448~58445849:+
LIHC	cis	rs11098499	0.863	rs10004484	ENSG00000260091.1	RP11-33B1.4	-4.07	5.77e-05	0.0117	-0.16	-0.22	Corneal astigmatism;	chr4:119521273	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.863	rs1155576	ENSG00000260091.1	RP11-33B1.4	-4.07	5.77e-05	0.0117	-0.16	-0.22	Corneal astigmatism;	chr4:119529004	chr4:119409333~119410233:+
LIHC	cis	rs3015497	0.626	rs7150204	ENSG00000269906.1	RP11-248J18.2	4.07	5.77e-05	0.0117	0.28	0.22	Mean platelet volume;	chr14:50670637	chr14:50662511~50663178:-
LIHC	cis	rs72675573	0.852	rs1757915	ENSG00000235612.1	RP1-158P9.1	-4.07	5.77e-05	0.0117	-0.28	-0.22	Monocyte count;	chr1:56150137	chr1:56145721~56155224:+
LIHC	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-4.07	5.78e-05	0.0117	-0.26	-0.22	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
LIHC	cis	rs2762353	0.776	rs942379	ENSG00000242387.1	HIST1H2APS2	4.07	5.78e-05	0.0117	0.25	0.22	Blood metabolite levels;	chr6:25849392	chr6:25882026~25882395:-
LIHC	cis	rs6061231	0.631	rs927133	ENSG00000226332.2	RP11-157P1.4	4.07	5.78e-05	0.0117	0.23	0.22	Colorectal cancer;	chr20:62397053	chr20:62305432~62306325:-
LIHC	cis	rs9652601	0.959	rs12919083	ENSG00000274038.1	RP11-66H6.4	4.07	5.78e-05	0.0117	0.26	0.22	Systemic lupus erythematosus;	chr16:11095073	chr16:11056556~11057034:+
LIHC	cis	rs494453	1	rs494453	ENSG00000227811.2	FAM212B-AS1	-4.07	5.79e-05	0.0118	-0.24	-0.22	Osteoporosis-related phenotypes;	chr1:111649500	chr1:111739841~111747798:+
LIHC	cis	rs1558001	0.84	rs11760903	ENSG00000230196.1	DDX43P3	-4.07	5.79e-05	0.0118	-0.23	-0.22	Gestational age at birth (maternal effect);Spontaneous preterm birth (maternal effect);	chr7:81833131	chr7:81610884~81611326:-
LIHC	cis	rs17270561	0.514	rs10946805	ENSG00000272810.1	U91328.22	-4.07	5.79e-05	0.0118	-0.28	-0.22	Iron status biomarkers;	chr6:26077663	chr6:26013241~26013757:+
LIHC	cis	rs11098499	0.909	rs1546502	ENSG00000260091.1	RP11-33B1.4	-4.07	5.79e-05	0.0118	-0.16	-0.22	Corneal astigmatism;	chr4:119314743	chr4:119409333~119410233:+
LIHC	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-4.07	5.79e-05	0.0118	-0.17	-0.22	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
LIHC	cis	rs79349575	0.783	rs2112617	ENSG00000248278.1	SUMO2P17	4.07	5.79e-05	0.0118	0.27	0.22	Type 2 diabetes;	chr17:48899763	chr17:48874860~48908983:-
LIHC	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	4.07	5.79e-05	0.0118	0.35	0.22	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
LIHC	cis	rs755249	0.567	rs66531516	ENSG00000182109.6	RP11-69E11.4	4.07	5.79e-05	0.0118	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39522280~39546187:-
LIHC	cis	rs7726839	0.54	rs12520279	ENSG00000271781.1	CTD-2589H19.6	-4.07	5.8e-05	0.0118	-0.33	-0.22	Obesity-related traits;	chr5:657176	chr5:675826~676616:+
LIHC	cis	rs7726839	0.54	rs4957083	ENSG00000271781.1	CTD-2589H19.6	-4.07	5.8e-05	0.0118	-0.33	-0.22	Obesity-related traits;	chr5:659228	chr5:675826~676616:+
LIHC	cis	rs6901152	0.525	rs6570557	ENSG00000217648.1	RP1-95L4.4	-4.07	5.8e-05	0.0118	-0.25	-0.22	Acute lymphoblastic leukemia (childhood);	chr6:143370470	chr6:143342246~143343383:+
LIHC	cis	rs2885805	0.596	rs343763	ENSG00000259834.1	RP11-284N8.3	-4.07	5.8e-05	0.0118	-0.18	-0.22	Cytomegalovirus antibody response;	chr1:110810039	chr1:110653560~110657040:-
LIHC	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-4.07	5.81e-05	0.0118	-0.31	-0.22	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
LIHC	cis	rs8037137	0.731	rs78029804	ENSG00000258725.1	PRC1-AS1	-4.07	5.81e-05	0.0118	-0.28	-0.22	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90995690	chr15:90966345~90988624:+
LIHC	cis	rs2749592	0.55	rs10764135	ENSG00000099251.13	HSD17B7P2	-4.07	5.81e-05	0.0118	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38356380~38378505:+
LIHC	cis	rs2749592	0.55	rs12255038	ENSG00000099251.13	HSD17B7P2	-4.07	5.81e-05	0.0118	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38356380~38378505:+
LIHC	cis	rs2749592	0.505	rs7915670	ENSG00000099251.13	HSD17B7P2	-4.07	5.81e-05	0.0118	-0.25	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38356380~38378505:+
LIHC	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.81e-05	0.0118	-0.21	-0.22	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
LIHC	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-4.07	5.81e-05	0.0118	-0.22	-0.22	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
LIHC	cis	rs6442522	0.933	rs6442518	ENSG00000249786.6	EAF1-AS1	4.07	5.81e-05	0.0118	0.24	0.22	Uric acid levels;	chr3:15380543	chr3:15436171~15455940:-
LIHC	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-4.07	5.81e-05	0.0118	-0.25	-0.22	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
LIHC	cis	rs6472235	0.632	rs11985554	ENSG00000272010.1	CTD-3025N20.3	-4.07	5.81e-05	0.0118	-0.31	-0.22	Plateletcrit;Myopia (pathological);	chr8:65972004	chr8:65591850~65592472:-
LIHC	cis	rs831571	0.653	rs73120967	ENSG00000280620.1	SCAANT1	4.07	5.82e-05	0.0118	0.32	0.21	Type 2 diabetes;	chr3:64084696	chr3:63911518~63911772:-
LIHC	cis	rs7917772	0.503	rs11191347	ENSG00000236937.2	PTGES3P4	-4.07	5.82e-05	0.0118	-0.29	-0.21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102591860	chr10:102845595~102845950:+
LIHC	cis	rs2762353	0.718	rs1747550	ENSG00000242387.1	HIST1H2APS2	4.07	5.82e-05	0.0118	0.25	0.21	Blood metabolite levels;	chr6:25851305	chr6:25882026~25882395:-
LIHC	cis	rs5769707	0.749	rs7286706	ENSG00000235111.1	RP1-29C18.8	-4.07	5.82e-05	0.0118	-0.25	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49612657~49615716:-
LIHC	cis	rs2613514	1	rs16970811	ENSG00000204277.1	RP11-219G17.4	4.07	5.82e-05	0.0118	0.32	0.21	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78095099	chr17:78261349~78278492:-
LIHC	cis	rs7915414	0.901	rs34870400	ENSG00000230338.1	MTND4P19	4.07	5.82e-05	0.0118	0.23	0.21	Clopidogrel active metabolite levels;	chr10:94675066	chr10:94774156~94774633:-
LIHC	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-4.07	5.82e-05	0.0118	-0.25	-0.21	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
LIHC	cis	rs11733284	0.894	rs321628	ENSG00000259959.1	RP11-121C2.2	4.07	5.83e-05	0.0118	0.2	0.21	Gout;Renal underexcretion gout;	chr4:48014858	chr4:47840122~47844339:-
LIHC	cis	rs2243480	1	rs313831	ENSG00000232546.1	RP11-458F8.1	-4.07	5.83e-05	0.0118	-0.24	-0.21	Diabetic kidney disease;	chr7:66086239	chr7:66848496~66858136:+
LIHC	cis	rs244293	0.831	rs12450607	ENSG00000275710.1	RP11-257O5.4	-4.07	5.83e-05	0.0118	-0.23	-0.21	Menarche (age at onset);	chr17:55049894	chr17:54964474~54964679:+
LIHC	cis	rs4925386	0.681	rs2427294	ENSG00000273619.1	RP5-908M14.9	-4.07	5.83e-05	0.0118	-0.2	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352201	chr20:62386303~62386970:-
LIHC	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-4.07	5.83e-05	0.0118	-0.22	-0.21	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
LIHC	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-4.07	5.83e-05	0.0118	-0.25	-0.21	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
LIHC	cis	rs7989332	0.89	rs4770040	ENSG00000275964.1	RP11-61K9.3	-4.07	5.83e-05	0.0118	-0.24	-0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20474349	chr13:19863858~19865048:+
LIHC	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-4.07	5.83e-05	0.0118	-0.33	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
LIHC	cis	rs4934494	0.834	rs3740033	ENSG00000232936.4	RP11-80H5.2	-4.07	5.83e-05	0.0118	-0.23	-0.21	Red blood cell count;	chr10:89634639	chr10:89645282~89650667:+
LIHC	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-4.07	5.84e-05	0.0118	-0.25	-0.21	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
LIHC	cis	rs9595908	0.785	rs7328827	ENSG00000212293.1	SNORA16	4.07	5.84e-05	0.0118	0.24	0.21	Body mass index;	chr13:32686650	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs3858846	ENSG00000212293.1	SNORA16	4.07	5.84e-05	0.0118	0.24	0.21	Body mass index;	chr13:32687408	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs7981925	ENSG00000212293.1	SNORA16	4.07	5.84e-05	0.0118	0.24	0.21	Body mass index;	chr13:32693706	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs9596081	ENSG00000212293.1	SNORA16	4.07	5.84e-05	0.0118	0.24	0.21	Body mass index;	chr13:32698405	chr13:32420390~32420516:-
LIHC	cis	rs9595908	0.785	rs7326314	ENSG00000212293.1	SNORA16	4.07	5.84e-05	0.0118	0.24	0.21	Body mass index;	chr13:32706422	chr13:32420390~32420516:-
LIHC	cis	rs10829156	0.898	rs7095666	ENSG00000225527.1	RP11-383B4.4	4.07	5.84e-05	0.0118	0.33	0.21	Sudden cardiac arrest;	chr10:18650538	chr10:18531849~18533336:-
LIHC	cis	rs7809950	0.815	rs62482495	ENSG00000238832.1	snoU109	-4.07	5.84e-05	0.0118	-0.28	-0.21	Coronary artery disease;	chr7:107324564	chr7:107603363~107603507:+
LIHC	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-4.07	5.84e-05	0.0118	-0.32	-0.21	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
LIHC	cis	rs10510102	0.748	rs11200297	ENSG00000273891.1	RP11-500G22.5	4.07	5.84e-05	0.0118	0.29	0.21	Breast cancer;	chr10:121972916	chr10:121965764~121967700:+
LIHC	cis	rs6445975	0.617	rs11130641	ENSG00000272360.1	RP11-359I18.5	4.07	5.84e-05	0.0118	0.28	0.21	Systemic lupus erythematosus;	chr3:58432202	chr3:58490830~58491291:-
LIHC	cis	rs2282930	0.874	rs2299156	ENSG00000228897.1	CTD-2021A8.2	-4.07	5.84e-05	0.0119	-0.29	-0.21	Bone mineral density;	chr7:50696707	chr7:51386363~51387101:-
LIHC	cis	rs12681287	0.64	rs7832493	ENSG00000254088.1	SLC2A3P4	-4.07	5.85e-05	0.0119	-0.25	-0.21	Caudate activity during reward;	chr8:86359304	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs7816275	ENSG00000254088.1	SLC2A3P4	-4.07	5.85e-05	0.0119	-0.25	-0.21	Caudate activity during reward;	chr8:86361175	chr8:86503591~86505061:+
LIHC	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	4.07	5.85e-05	0.0119	0.26	0.21	Height;	chr4:55413708	chr4:55363971~55395847:-
LIHC	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-4.07	5.85e-05	0.0119	-0.23	-0.21	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
LIHC	cis	rs763121	0.925	rs4821815	ENSG00000273076.1	RP3-508I15.22	4.07	5.85e-05	0.0119	0.24	0.21	Menopause (age at onset);	chr22:38709702	chr22:38743495~38743910:+
LIHC	cis	rs3204270	0.53	rs57707013	ENSG00000281517.1	Metazoa_SRP	-4.07	5.85e-05	0.0119	-0.39	-0.21	Dental caries;	chr17:81668251	chr17:81718849~81719095:-
LIHC	cis	rs8177253	0.665	rs11921527	ENSG00000244062.1	RP11-404G16.2	4.07	5.85e-05	0.0119	0.21	0.21	Iron status biomarkers;	chr3:133722323	chr3:133760300~133762363:+
LIHC	cis	rs13315871	0.615	rs6793358	ENSG00000272182.1	RP11-802O23.3	4.07	5.86e-05	0.0119	0.41	0.21	Cholesterol, total;	chr3:58370727	chr3:58428255~58428815:+
LIHC	cis	rs4650994	1	rs4354501	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178555461	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.967	rs6681043	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178556822	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.625	rs6681348	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178557136	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.625	rs6681354	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178557144	chr1:178651706~178652282:+
LIHC	cis	rs4650994	1	rs10913571	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178557513	chr1:178651706~178652282:+
LIHC	cis	rs4650994	1	rs10913572	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178557583	chr1:178651706~178652282:+
LIHC	cis	rs4650994	0.935	rs4652306	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178559071	chr1:178651706~178652282:+
LIHC	cis	rs4650994	1	rs6660445	ENSG00000273384.1	RP5-1098D14.1	4.07	5.86e-05	0.0119	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178559736	chr1:178651706~178652282:+
LIHC	cis	rs2243480	0.803	rs160649	ENSG00000228409.4	CCT6P1	4.07	5.86e-05	0.0119	0.23	0.21	Diabetic kidney disease;	chr7:66078212	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs160648	ENSG00000228409.4	CCT6P1	4.07	5.86e-05	0.0119	0.23	0.21	Diabetic kidney disease;	chr7:66078397	chr7:65751142~65763354:+
LIHC	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-4.07	5.87e-05	0.0119	-0.25	-0.21	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
LIHC	cis	rs9907295	1	rs9303693	ENSG00000270871.1	AC015849.19	4.07	5.87e-05	0.0119	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35913595	chr17:35816717~35830293:-
LIHC	cis	rs4660214	0.568	rs967530	ENSG00000182109.6	RP11-69E11.4	-4.07	5.87e-05	0.0119	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39130465	chr1:39522280~39546187:-
LIHC	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	4.07	5.87e-05	0.0119	0.17	0.21	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
LIHC	cis	rs10510102	0.872	rs12246693	ENSG00000273891.1	RP11-500G22.5	4.07	5.87e-05	0.0119	0.28	0.21	Breast cancer;	chr10:121957373	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12248806	ENSG00000273891.1	RP11-500G22.5	4.07	5.87e-05	0.0119	0.28	0.21	Breast cancer;	chr10:121958638	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12255832	ENSG00000273891.1	RP11-500G22.5	4.07	5.87e-05	0.0119	0.28	0.21	Breast cancer;	chr10:121958762	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs12247367	ENSG00000273891.1	RP11-500G22.5	4.07	5.87e-05	0.0119	0.28	0.21	Breast cancer;	chr10:121961556	chr10:121965764~121967700:+
LIHC	cis	rs10510102	0.872	rs10887032	ENSG00000273891.1	RP11-500G22.5	-4.07	5.87e-05	0.0119	-0.28	-0.21	Breast cancer;	chr10:121955887	chr10:121965764~121967700:+
LIHC	cis	rs11098499	0.874	rs13139045	ENSG00000260091.1	RP11-33B1.4	-4.07	5.88e-05	0.0119	-0.15	-0.21	Corneal astigmatism;	chr4:119247433	chr4:119409333~119410233:+
LIHC	cis	rs2253762	0.54	rs10887037	ENSG00000226864.1	ATE1-AS1	4.07	5.88e-05	0.0119	0.36	0.21	Breast cancer;	chr10:121997572	chr10:121928312~121951965:+
LIHC	cis	rs35099186	0.583	rs12290068	ENSG00000255062.1	RP11-712L6.5	-4.07	5.88e-05	0.0119	-0.28	-0.21	Coronary artery disease;	chr11:126391669	chr11:126294298~126304318:-
LIHC	cis	rs55966801	0.898	rs551419	ENSG00000277290.1	RP11-326C3.16	-4.07	5.88e-05	0.0119	-0.26	-0.21	Plateletcrit;	chr11:240844	chr11:243099~243483:-
LIHC	cis	rs755249	0.567	rs16826000	ENSG00000182109.6	RP11-69E11.4	4.07	5.88e-05	0.0119	0.28	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs16826009	ENSG00000182109.6	RP11-69E11.4	4.07	5.88e-05	0.0119	0.28	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs4660208	ENSG00000182109.6	RP11-69E11.4	4.07	5.88e-05	0.0119	0.28	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39522280~39546187:-
LIHC	cis	rs2735413	0.958	rs11150034	ENSG00000276007.1	RP11-358L22.3	-4.07	5.89e-05	0.0119	-0.25	-0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78032472	chr16:78123243~78124332:+
LIHC	cis	rs2735413	0.914	rs12448754	ENSG00000276007.1	RP11-358L22.3	-4.07	5.89e-05	0.0119	-0.25	-0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78032850	chr16:78123243~78124332:+
LIHC	cis	rs13242816	1	rs62469031	ENSG00000279086.1	RP11-667F14.1	4.07	5.89e-05	0.0119	0.38	0.21	P wave duration;	chr7:116555787	chr7:116209234~116211511:-
LIHC	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-4.07	5.89e-05	0.0119	-0.25	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
LIHC	cis	rs617219	0.726	rs3733893	ENSG00000251675.1	CTC-458I2.2	-4.07	5.9e-05	0.0119	-0.24	-0.21	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79236835	chr5:80128361~80143883:+
LIHC	cis	rs11977715	0.538	rs43063	ENSG00000233942.1	AC004012.1	-4.07	5.9e-05	0.0119	-0.3	-0.21	Middle childhood and early adolescence aggressive behavior;	chr7:95480475	chr7:95471835~95473998:+
LIHC	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	4.07	5.9e-05	0.0119	0.25	0.21	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
LIHC	cis	rs11971779	0.941	rs28395455	ENSG00000273391.1	RP11-634H22.1	4.07	5.9e-05	0.0119	0.23	0.21	Diisocyanate-induced asthma;	chr7:139351240	chr7:139359032~139359566:-
LIHC	cis	rs6445975	1	rs2176082	ENSG00000272360.1	RP11-359I18.5	-4.07	5.91e-05	0.012	-0.28	-0.21	Systemic lupus erythematosus;	chr3:58345459	chr3:58490830~58491291:-
LIHC	cis	rs295490	0.748	rs78681436	ENSG00000272656.1	RP11-219D15.3	4.07	5.91e-05	0.012	0.6	0.21	PR interval in Tripanosoma cruzi seropositivity;	chr3:139510715	chr3:139349024~139349371:-
LIHC	cis	rs295490	0.748	rs79854429	ENSG00000272656.1	RP11-219D15.3	4.07	5.91e-05	0.012	0.6	0.21	PR interval in Tripanosoma cruzi seropositivity;	chr3:139512550	chr3:139349024~139349371:-
LIHC	cis	rs244293	0.965	rs244357	ENSG00000275710.1	RP11-257O5.4	4.07	5.91e-05	0.012	0.23	0.21	Menarche (age at onset);	chr17:55115820	chr17:54964474~54964679:+
LIHC	cis	rs6832769	1	rs35767091	ENSG00000272969.1	RP11-528I4.2	4.07	5.91e-05	0.012	0.26	0.21	Personality dimensions;	chr4:55480556	chr4:55547112~55547889:+
LIHC	cis	rs2749592	0.55	rs4934881	ENSG00000276805.1	RP11-291L22.6	-4.07	5.92e-05	0.012	-0.26	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38451030~38451785:+
LIHC	cis	rs7809950	0.954	rs2712229	ENSG00000238832.1	snoU109	4.07	5.92e-05	0.012	0.24	0.21	Coronary artery disease;	chr7:107654881	chr7:107603363~107603507:+
LIHC	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	4.07	5.92e-05	0.012	0.35	0.21	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
LIHC	cis	rs1023500	0.529	rs133375	ENSG00000226450.2	CYP2D8P	4.07	5.92e-05	0.012	0.26	0.21	Schizophrenia;	chr22:42070505	chr22:42149886~42155001:-
LIHC	cis	rs2439831	0.681	rs484029	ENSG00000166763.7	STRCP1	4.07	5.92e-05	0.012	0.29	0.21	Lung cancer in ever smokers;	chr15:43327362	chr15:43699488~43718184:-
LIHC	cis	rs6436017	0.589	rs1424918	ENSG00000199121.3	MIR26B	4.07	5.92e-05	0.012	0.25	0.21	Breast cancer;	chr2:217876772	chr2:218402637~218402746:+
LIHC	cis	rs4919694	1	rs12268849	ENSG00000236937.2	PTGES3P4	4.07	5.92e-05	0.012	0.39	0.21	Arsenic metabolism;	chr10:102977925	chr10:102845595~102845950:+
LIHC	cis	rs6832769	1	rs28670674	ENSG00000272969.1	RP11-528I4.2	-4.07	5.92e-05	0.012	-0.26	-0.21	Personality dimensions;	chr4:55540936	chr4:55547112~55547889:+
LIHC	cis	rs2243480	1	rs2257790	ENSG00000230295.1	RP11-458F8.2	-4.07	5.92e-05	0.012	-0.23	-0.21	Diabetic kidney disease;	chr7:66135463	chr7:66880708~66882981:+
LIHC	cis	rs2243480	1	rs316332	ENSG00000230295.1	RP11-458F8.2	-4.07	5.92e-05	0.012	-0.23	-0.21	Diabetic kidney disease;	chr7:66139312	chr7:66880708~66882981:+
LIHC	cis	rs17270561	0.887	rs12201170	ENSG00000272810.1	U91328.22	-4.07	5.93e-05	0.012	-0.29	-0.21	Iron status biomarkers;	chr6:25866019	chr6:26013241~26013757:+
LIHC	cis	rs755249	0.532	rs2296173	ENSG00000182109.6	RP11-69E11.4	4.07	5.94e-05	0.012	0.28	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs3118014	ENSG00000182109.6	RP11-69E11.4	4.07	5.94e-05	0.012	0.28	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39522280~39546187:-
LIHC	cis	rs7937890	0.967	rs963212	ENSG00000251991.1	RNU7-49P	-4.07	5.94e-05	0.012	-0.23	-0.21	Mitochondrial DNA levels;	chr11:14303186	chr11:14478892~14478953:+
LIHC	cis	rs7937890	1	rs2970334	ENSG00000251991.1	RNU7-49P	-4.07	5.94e-05	0.012	-0.23	-0.21	Mitochondrial DNA levels;	chr11:14307809	chr11:14478892~14478953:+
LIHC	cis	rs2739330	0.734	rs2000467	ENSG00000206090.4	AP000350.7	-4.07	5.94e-05	0.012	-0.25	-0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23939998~23942798:+
LIHC	cis	rs6997458	0.785	rs1389247	ENSG00000253549.4	RP11-317J10.2	4.07	5.94e-05	0.012	0.24	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85410354	chr8:85441851~85464915:-
LIHC	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	4.07	5.95e-05	0.012	0.23	0.21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
LIHC	cis	rs1023500	0.573	rs8135801	ENSG00000226450.2	CYP2D8P	-4.07	5.95e-05	0.012	-0.26	-0.21	Schizophrenia;	chr22:42079564	chr22:42149886~42155001:-
LIHC	cis	rs2243480	1	rs160646	ENSG00000228409.4	CCT6P1	4.07	5.95e-05	0.012	0.23	0.21	Diabetic kidney disease;	chr7:66091293	chr7:65751142~65763354:+
LIHC	cis	rs2243480	1	rs1039664	ENSG00000232546.1	RP11-458F8.1	-4.07	5.95e-05	0.012	-0.24	-0.21	Diabetic kidney disease;	chr7:65984729	chr7:66848496~66858136:+
LIHC	cis	rs4578769	0.722	rs72887683	ENSG00000265943.1	RP11-739L10.1	-4.07	5.96e-05	0.012	-0.28	-0.21	Eosinophil percentage of white cells;	chr18:22981366	chr18:22699481~22933764:-
LIHC	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
LIHC	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
LIHC	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-4.07	5.96e-05	0.012	-0.21	-0.21	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
LIHC	cis	rs6977955	0.627	rs1513275	ENSG00000234336.5	JAZF1-AS1	4.07	5.96e-05	0.0121	0.32	0.21	Allergic disease (asthma, hay fever or eczema);	chr7:28219614	chr7:28180322~28243917:+
LIHC	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-4.06	5.97e-05	0.0121	-0.22	-0.21	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
LIHC	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-4.06	5.97e-05	0.0121	-0.32	-0.21	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
LIHC	cis	rs17774123	0.901	rs2590706	ENSG00000257808.1	RP11-1136G11.8	4.06	5.97e-05	0.0121	0.39	0.21	Diastolic blood pressure;	chr12:53876492	chr12:53159586~53161000:+
LIHC	cis	rs7893279	0.505	rs3740104	ENSG00000225527.1	RP11-383B4.4	4.06	5.97e-05	0.0121	0.31	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18648793	chr10:18531849~18533336:-
LIHC	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-4.06	5.97e-05	0.0121	-0.2	-0.21	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
LIHC	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-4.06	5.97e-05	0.0121	-0.2	-0.21	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
LIHC	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	4.06	5.98e-05	0.0121	0.34	0.21	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	4.06	5.98e-05	0.0121	0.34	0.21	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	4.06	5.98e-05	0.0121	0.34	0.21	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
LIHC	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	4.06	5.98e-05	0.0121	0.34	0.21	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
LIHC	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-4.06	5.98e-05	0.0121	-0.17	-0.21	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
LIHC	cis	rs7412746	0.503	rs72704639	ENSG00000231073.1	RP11-316M1.3	4.06	5.98e-05	0.0121	0.21	0.21	Melanoma;	chr1:150825859	chr1:150973123~150975534:+
LIHC	cis	rs7208859	0.673	rs11651802	ENSG00000266490.1	CTD-2349P21.9	4.06	5.98e-05	0.0121	0.28	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30792372~30792833:+
LIHC	cis	rs10857712	1	rs10857712	ENSG00000214279.11	SCART1	-4.06	5.98e-05	0.0121	-0.26	-0.21	Systemic lupus erythematosus;	chr10:133412162	chr10:133453928~133523558:+
LIHC	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-4.06	5.99e-05	0.0121	-0.26	-0.21	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
LIHC	cis	rs8064024	0.508	rs2037912	ENSG00000267077.1	RP11-127I20.5	-4.06	5.99e-05	0.0121	-0.22	-0.21	Cancer;	chr16:4883938	chr16:4795265~4796532:-
LIHC	cis	rs16902947	0.592	rs4869655	ENSG00000245711.2	NADK2-AS1	4.06	5.99e-05	0.0121	0.18	0.21	Serum tamsulosin hydrochloride concentration;	chr5:36350739	chr5:36221055~36221902:+
LIHC	cis	rs6745190	0.906	rs6706565	ENSG00000236153.1	AC104076.3	4.06	5.99e-05	0.0121	0.29	0.21	White blood cell count;	chr2:181065685	chr2:180979427~180980090:-
LIHC	cis	rs4218	0.648	rs12441973	ENSG00000277144.1	RP11-59H7.4	-4.06	5.99e-05	0.0121	-0.24	-0.21	Social communication problems;	chr15:59057016	chr15:59115547~59116089:-
LIHC	cis	rs1005277	0.522	rs289649	ENSG00000275858.1	RP11-291L22.8	4.06	5.99e-05	0.0121	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38450738~38451069:-
LIHC	cis	rs6142102	0.923	rs2268078	ENSG00000275784.1	RP5-1125A11.6	-4.06	5.99e-05	0.0121	-0.25	-0.21	Skin pigmentation;	chr20:34008898	chr20:33989480~33991818:-
LIHC	cis	rs2976388	0.566	rs6998746	ENSG00000253741.1	CTD-2292P10.4	-4.06	6e-05	0.0121	-0.26	-0.21	Urinary tract infection frequency;	chr8:142721038	chr8:142702252~142726973:-
LIHC	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-4.06	6e-05	0.0121	-0.27	-0.21	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
LIHC	cis	rs7893279	0.505	rs7897159	ENSG00000225527.1	RP11-383B4.4	4.06	6e-05	0.0121	0.31	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18642651	chr10:18531849~18533336:-
LIHC	cis	rs794185	0.653	rs2819586	ENSG00000231249.1	ITPR1-AS1	-4.06	6e-05	0.0121	-0.23	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470108	chr3:4490891~4493163:-
LIHC	cis	rs794185	0.686	rs2633843	ENSG00000231249.1	ITPR1-AS1	-4.06	6e-05	0.0121	-0.23	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470109	chr3:4490891~4493163:-
LIHC	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-4.06	6.01e-05	0.0121	-0.28	-0.21	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
LIHC	cis	rs66887589	0.775	rs6843229	ENSG00000260091.1	RP11-33B1.4	-4.06	6.01e-05	0.0121	-0.14	-0.21	Diastolic blood pressure;	chr4:119502932	chr4:119409333~119410233:+
LIHC	cis	rs3738443	0.83	rs6684181	ENSG00000259865.1	RP11-488L18.10	4.06	6.01e-05	0.0121	0.22	0.21	Alcohol dependence;	chr1:247184669	chr1:247187281~247188526:-
LIHC	cis	rs11098499	0.865	rs28634456	ENSG00000260091.1	RP11-33B1.4	-4.06	6.01e-05	0.0121	-0.16	-0.21	Corneal astigmatism;	chr4:119454623	chr4:119409333~119410233:+
LIHC	cis	rs11098499	0.909	rs78332141	ENSG00000260091.1	RP11-33B1.4	-4.06	6.01e-05	0.0121	-0.16	-0.21	Corneal astigmatism;	chr4:119454627	chr4:119409333~119410233:+
LIHC	cis	rs3015497	0.616	rs1389650	ENSG00000269906.1	RP11-248J18.2	4.06	6.01e-05	0.0121	0.27	0.21	Mean platelet volume;	chr14:50614731	chr14:50662511~50663178:-
LIHC	cis	rs2976388	0.609	rs2585153	ENSG00000253196.1	RP11-706C16.7	4.06	6.01e-05	0.0121	0.2	0.21	Urinary tract infection frequency;	chr8:142703927	chr8:142763116~142766427:+
LIHC	cis	rs1223397	0.702	rs1223400	ENSG00000215022.6	RP1-257A7.4	-4.06	6.02e-05	0.0122	-0.25	-0.21	Blood pressure;	chr6:13271010	chr6:13264861~13295586:-
LIHC	cis	rs9595908	0.869	rs55880225	ENSG00000212293.1	SNORA16	4.06	6.02e-05	0.0122	0.25	0.21	Body mass index;	chr13:32616733	chr13:32420390~32420516:-
LIHC	cis	rs4578769	0.729	rs72882140	ENSG00000265943.1	RP11-739L10.1	-4.06	6.02e-05	0.0122	-0.28	-0.21	Eosinophil percentage of white cells;	chr18:22805952	chr18:22699481~22933764:-
LIHC	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	4.06	6.03e-05	0.0122	0.26	0.21	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
LIHC	cis	rs6445975	0.667	rs6445963	ENSG00000272360.1	RP11-359I18.5	-4.06	6.03e-05	0.0122	-0.25	-0.21	Systemic lupus erythematosus;	chr3:58248752	chr3:58490830~58491291:-
LIHC	cis	rs6445975	0.667	rs2292676	ENSG00000272360.1	RP11-359I18.5	-4.06	6.03e-05	0.0122	-0.25	-0.21	Systemic lupus erythematosus;	chr3:58250201	chr3:58490830~58491291:-
LIHC	cis	rs7923609	0.846	rs7098181	ENSG00000232075.1	MRPL35P2	-4.06	6.03e-05	0.0122	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267383	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.846	rs10761731	ENSG00000232075.1	MRPL35P2	-4.06	6.03e-05	0.0122	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267850	chr10:63634317~63634827:-
LIHC	cis	rs617219	0.553	rs114964313	ENSG00000251675.1	CTC-458I2.2	-4.06	6.03e-05	0.0122	-0.24	-0.21	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79137749	chr5:80128361~80143883:+
LIHC	cis	rs4578769	0.694	rs72882142	ENSG00000265943.1	RP11-739L10.1	-4.06	6.03e-05	0.0122	-0.28	-0.21	Eosinophil percentage of white cells;	chr18:22806755	chr18:22699481~22933764:-
LIHC	cis	rs734999	0.588	rs11585048	ENSG00000225931.3	RP3-395M20.7	4.06	6.03e-05	0.0122	0.23	0.21	Ulcerative colitis;	chr1:2602648	chr1:2566410~2569888:+
LIHC	cis	rs6433895	0.677	rs11693055	ENSG00000236153.1	AC104076.3	-4.06	6.03e-05	0.0122	-0.28	-0.21	Lymphocyte counts;	chr2:181168567	chr2:180979427~180980090:-
LIHC	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	4.06	6.04e-05	0.0122	0.25	0.21	Height;	chr4:55489895	chr4:55363971~55395847:-
LIHC	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-4.06	6.04e-05	0.0122	-0.36	-0.21	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
LIHC	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-4.06	6.04e-05	0.0122	-0.36	-0.21	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
LIHC	cis	rs2439831	0.85	rs28524541	ENSG00000166763.7	STRCP1	4.06	6.04e-05	0.0122	0.33	0.21	Lung cancer in ever smokers;	chr15:43832633	chr15:43699488~43718184:-
LIHC	cis	rs17376456	0.877	rs13165147	ENSG00000251023.1	RP11-549J18.1	-4.06	6.04e-05	0.0122	-0.45	-0.21	Diabetic retinopathy;	chr5:94086509	chr5:93860669~93863825:-
LIHC	cis	rs4578769	0.765	rs12456384	ENSG00000266850.1	RP11-370A5.1	-4.06	6.04e-05	0.0122	-0.25	-0.21	Eosinophil percentage of white cells;	chr18:22841032	chr18:22723491~22907721:-
LIHC	cis	rs1005277	0.522	rs1208681	ENSG00000099251.13	HSD17B7P2	4.06	6.04e-05	0.0122	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38356380~38378505:+
LIHC	cis	rs4650994	0.789	rs2761471	ENSG00000213057.5	C1orf220	-4.06	6.04e-05	0.0122	-0.18	-0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178630213	chr1:178542752~178548889:+
LIHC	cis	rs2598107	0.601	rs1014938	ENSG00000211698.2	TRGV4	-4.06	6.04e-05	0.0122	-0.25	-0.21	Dupuytren's disease;	chr7:37901550	chr7:38353715~38354517:-
LIHC	cis	rs875971	0.545	rs1796219	ENSG00000228409.4	CCT6P1	4.06	6.04e-05	0.0122	0.19	0.21	Aortic root size;	chr7:66645977	chr7:65751142~65763354:+
LIHC	cis	rs9843304	0.528	rs12488126	ENSG00000244503.1	RP11-278L15.6	-4.06	6.04e-05	0.0122	-0.27	-0.21	Gallstone disease;	chr3:149474889	chr3:149494660~149495995:+
LIHC	cis	rs1008953	0.95	rs1548227	ENSG00000227477.1	STK4-AS1	4.06	6.04e-05	0.0122	0.22	0.21	Psoriasis;	chr20:45354870	chr20:44963794~44966402:-
LIHC	cis	rs3015497	0.789	rs2934688	ENSG00000269906.1	RP11-248J18.2	4.06	6.05e-05	0.0122	0.27	0.21	Mean platelet volume;	chr14:50645642	chr14:50662511~50663178:-
LIHC	cis	rs2243480	1	rs160639	ENSG00000228409.4	CCT6P1	4.06	6.05e-05	0.0122	0.23	0.21	Diabetic kidney disease;	chr7:66115000	chr7:65751142~65763354:+
LIHC	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-4.06	6.05e-05	0.0122	-0.29	-0.21	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
LIHC	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	4.06	6.05e-05	0.0122	0.18	0.21	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
LIHC	cis	rs901683	0.85	rs112297763	ENSG00000230869.1	CTGLF10P	-4.06	6.05e-05	0.0122	-0.46	-0.21	Mean corpuscular volume;Red blood cell traits;	chr10:45573988	chr10:45678692~45700532:+
LIHC	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	4.06	6.05e-05	0.0122	0.24	0.21	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
LIHC	cis	rs17774123	0.901	rs1596370	ENSG00000257808.1	RP11-1136G11.8	-4.06	6.05e-05	0.0122	-0.39	-0.21	Diastolic blood pressure;	chr12:53881482	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs182714	ENSG00000257808.1	RP11-1136G11.8	-4.06	6.05e-05	0.0122	-0.39	-0.21	Diastolic blood pressure;	chr12:53887178	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2590713	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53869758	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2254753	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53870550	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2254752	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53870569	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2586701	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53872176	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2254525	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53872629	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2586702	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53872761	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2586703	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53872783	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.851	rs2586704	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53872836	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.755	rs34613738	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53872862	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.755	rs2586705	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53872957	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs1899664	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53873362	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2699929	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53873702	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2254397	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53873920	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2699927	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53875794	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2577862	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53876470	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2590707	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53877648	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs117359066	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53879488	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2590708	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53880331	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs1073061	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53880625	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs182713	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53880840	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2590711	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53882945	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs324267	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53883199	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.851	rs324268	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53883336	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs324269	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53883577	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs324270	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53884323	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs2247520	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53884642	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs324271	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53885533	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs324272	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53886487	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs188962	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53887408	chr12:53159586~53161000:+
LIHC	cis	rs17774123	0.901	rs167776	ENSG00000257808.1	RP11-1136G11.8	4.06	6.05e-05	0.0122	0.39	0.21	Diastolic blood pressure;	chr12:53887797	chr12:53159586~53161000:+
LIHC	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-4.06	6.05e-05	0.0122	-0.23	-0.21	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
LIHC	cis	rs58785573	1	rs58785573	ENSG00000231160.8	KLF3-AS1	-4.06	6.06e-05	0.0122	-0.19	-0.21	Lymphocyte percentage of white cells;	chr4:38652152	chr4:38612701~38664883:-
LIHC	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-4.06	6.06e-05	0.0122	-0.22	-0.21	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-4.06	6.06e-05	0.0122	-0.22	-0.21	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-4.06	6.06e-05	0.0122	-0.22	-0.21	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
LIHC	cis	rs2243480	1	rs313832	ENSG00000230295.1	RP11-458F8.2	-4.06	6.07e-05	0.0122	-0.23	-0.21	Diabetic kidney disease;	chr7:66085904	chr7:66880708~66882981:+
LIHC	cis	rs4767841	0.625	rs12302281	ENSG00000248636.5	RP11-768F21.1	-4.06	6.07e-05	0.0122	-0.27	-0.21	Urgency urinary incontinence;	chr12:119800693	chr12:119387987~119668079:-
LIHC	cis	rs755249	0.567	rs16825939	ENSG00000182109.6	RP11-69E11.4	4.06	6.07e-05	0.0122	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs16825942	ENSG00000182109.6	RP11-69E11.4	4.06	6.07e-05	0.0122	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39522280~39546187:-
LIHC	cis	rs755249	0.567	rs72661925	ENSG00000182109.6	RP11-69E11.4	4.06	6.07e-05	0.0122	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39522280~39546187:-
LIHC	cis	rs919433	0.889	rs6711624	ENSG00000231621.1	AC013264.2	4.06	6.07e-05	0.0122	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197342883	chr2:197197991~197199273:+
LIHC	cis	rs919433	0.889	rs12693816	ENSG00000231621.1	AC013264.2	4.06	6.07e-05	0.0122	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343696	chr2:197197991~197199273:+
LIHC	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	4.06	6.07e-05	0.0122	0.25	0.21	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
LIHC	cis	rs6600233	0.77	rs7185768	ENSG00000268836.1	LA16c-OS12.2	4.06	6.07e-05	0.0122	0.25	0.21	High light scatter reticulocyte percentage of red cells;	chr16:115782	chr16:185748~186294:-
LIHC	cis	rs10129255	1	rs10129407	ENSG00000224373.3	IGHV4-59	4.06	6.07e-05	0.0122	0.17	0.21	Kawasaki disease;	chr14:106767956	chr14:106627249~106627825:-
LIHC	cis	rs8077577	0.747	rs12449313	ENSG00000260647.1	RP1-178F10.1	4.06	6.07e-05	0.0122	0.27	0.21	Obesity-related traits;	chr17:18317696	chr17:18268080~18268828:+
LIHC	cis	rs10078	0.51	rs2278248	ENSG00000248925.1	CTD-2083E4.6	4.06	6.08e-05	0.0122	0.26	0.21	Fat distribution (HIV);	chr5:469455	chr5:269858~271516:-
LIHC	cis	rs10871290	0.801	rs3851726	ENSG00000261079.1	RP11-252A24.3	-4.06	6.08e-05	0.0122	-0.25	-0.21	Breast cancer;	chr16:74437746	chr16:74367462~74369826:+
LIHC	cis	rs2562456	0.958	rs2562508	ENSG00000268555.1	RP11-678G14.3	-4.06	6.08e-05	0.0122	-0.27	-0.21	Pain;	chr19:21543479	chr19:21570822~21587322:-
LIHC	cis	rs6887276	0.504	rs1003136	ENSG00000245937.6	LINC01184	4.06	6.08e-05	0.0122	0.25	0.21	Height;	chr5:128012123	chr5:127940426~128083172:-
LIHC	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-4.06	6.08e-05	0.0122	-0.29	-0.21	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
LIHC	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-4.06	6.08e-05	0.0122	-0.31	-0.21	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
LIHC	cis	rs1267303	0.798	rs1267302	ENSG00000227857.2	RP4-533D7.5	4.06	6.08e-05	0.0123	0.29	0.21	Monobrow;	chr1:46524873	chr1:46134531~46139081:+
LIHC	cis	rs6479901	0.501	rs7084396	ENSG00000232075.1	MRPL35P2	-4.06	6.08e-05	0.0123	-0.24	-0.21	Intelligence (multi-trait analysis);	chr10:63116965	chr10:63634317~63634827:-
LIHC	cis	rs17772222	0.917	rs7157149	ENSG00000258789.1	RP11-507K2.3	-4.06	6.09e-05	0.0123	-0.26	-0.21	Coronary artery calcification;	chr14:88765501	chr14:88551597~88552493:+
LIHC	cis	rs6449502	0.748	rs1445292	ENSG00000272308.1	RP11-231G3.1	-4.06	6.09e-05	0.0123	-0.3	-0.21	Mean platelet volume;	chr5:60824295	chr5:60866457~60866935:-
LIHC	cis	rs2598107	0.601	rs4720265	ENSG00000211698.2	TRGV4	-4.06	6.09e-05	0.0123	-0.25	-0.21	Dupuytren's disease;	chr7:37905144	chr7:38353715~38354517:-
LIHC	cis	rs6061231	0.597	rs624313	ENSG00000226332.2	RP11-157P1.4	-4.06	6.09e-05	0.0123	-0.22	-0.21	Colorectal cancer;	chr20:62352356	chr20:62305432~62306325:-
LIHC	cis	rs686320	1	rs72643572	ENSG00000245532.5	NEAT1	4.06	6.09e-05	0.0123	0.29	0.21	Hip circumference adjusted for BMI;	chr11:65483496	chr11:65422774~65445540:+
LIHC	cis	rs9907295	1	rs11653051	ENSG00000270871.1	AC015849.19	4.06	6.09e-05	0.0123	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35909166	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs11653016	ENSG00000270871.1	AC015849.19	4.06	6.09e-05	0.0123	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35909756	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs9889977	ENSG00000270871.1	AC015849.19	4.06	6.09e-05	0.0123	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35910691	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs9894799	ENSG00000270871.1	AC015849.19	4.06	6.09e-05	0.0123	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35911085	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs9903590	ENSG00000270871.1	AC015849.19	4.06	6.09e-05	0.0123	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35911286	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs9897665	ENSG00000270871.1	AC015849.19	4.06	6.09e-05	0.0123	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35911595	chr17:35816717~35830293:-
LIHC	cis	rs9907295	1	rs9912049	ENSG00000270871.1	AC015849.19	4.06	6.09e-05	0.0123	0.23	0.21	Fibroblast growth factor basic levels;	chr17:35912530	chr17:35816717~35830293:-
LIHC	cis	rs9595908	0.536	rs73452706	ENSG00000212293.1	SNORA16	4.06	6.09e-05	0.0123	0.24	0.21	Body mass index;	chr13:32718155	chr13:32420390~32420516:-
LIHC	cis	rs11098499	0.955	rs35434465	ENSG00000260091.1	RP11-33B1.4	-4.06	6.09e-05	0.0123	-0.16	-0.21	Corneal astigmatism;	chr4:119248223	chr4:119409333~119410233:+
LIHC	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-4.06	6.1e-05	0.0123	-0.23	-0.21	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
LIHC	cis	rs7726839	0.54	rs72705030	ENSG00000271781.1	CTD-2589H19.6	-4.06	6.1e-05	0.0123	-0.33	-0.21	Obesity-related traits;	chr5:645447	chr5:675826~676616:+
LIHC	cis	rs7412746	0.658	rs2275235	ENSG00000231073.1	RP11-316M1.3	4.06	6.11e-05	0.0123	0.22	0.21	Melanoma;	chr1:150757803	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs11204723	ENSG00000231073.1	RP11-316M1.3	4.06	6.11e-05	0.0123	0.22	0.21	Melanoma;	chr1:150759142	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs4537557	ENSG00000231073.1	RP11-316M1.3	4.06	6.11e-05	0.0123	0.22	0.21	Melanoma;	chr1:150761960	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs2864869	ENSG00000231073.1	RP11-316M1.3	4.06	6.11e-05	0.0123	0.22	0.21	Melanoma;	chr1:150762179	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.634	rs3754212	ENSG00000231073.1	RP11-316M1.3	4.06	6.11e-05	0.0123	0.22	0.21	Melanoma;	chr1:150765724	chr1:150973123~150975534:+
LIHC	cis	rs7412746	0.658	rs6657388	ENSG00000231073.1	RP11-316M1.3	4.06	6.11e-05	0.0123	0.22	0.21	Melanoma;	chr1:150776310	chr1:150973123~150975534:+
LIHC	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	4.06	6.11e-05	0.0123	0.21	0.21	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
LIHC	cis	rs71520386	0.561	rs10274260	ENSG00000228649.7	AC005682.5	-4.06	6.12e-05	0.0123	-0.26	-0.21	Fibrinogen levels;	chr7:22805227	chr7:22854178~22861579:+
LIHC	cis	rs617219	0.889	rs1627316	ENSG00000251675.1	CTC-458I2.2	-4.06	6.12e-05	0.0123	-0.24	-0.21	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79136621	chr5:80128361~80143883:+
LIHC	cis	rs617219	0.892	rs1717566	ENSG00000251675.1	CTC-458I2.2	-4.06	6.12e-05	0.0123	-0.24	-0.21	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79136785	chr5:80128361~80143883:+
LIHC	cis	rs9675120	0.817	rs11079937	ENSG00000262006.1	RP11-700H6.4	-4.06	6.12e-05	0.0123	-0.23	-0.21	Cerebrospinal fluid biomarker levels;	chr17:50853604	chr17:50909637~50910232:-
LIHC	cis	rs72675573	0.821	rs1331854	ENSG00000235612.1	RP1-158P9.1	-4.06	6.12e-05	0.0123	-0.3	-0.21	Monocyte count;	chr1:56058879	chr1:56145721~56155224:+
LIHC	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	4.06	6.13e-05	0.0123	0.18	0.21	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
LIHC	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-4.06	6.13e-05	0.0123	-0.29	-0.21	Height;	chr3:53027969	chr3:53064283~53065091:-
LIHC	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-4.06	6.13e-05	0.0123	-0.29	-0.21	Height;	chr3:53029908	chr3:53064283~53065091:-
LIHC	cis	rs57502260	0.573	rs12291008	ENSG00000212093.1	AP000807.1	4.06	6.13e-05	0.0123	0.24	0.21	Total body bone mineral density (age 45-60);	chr11:68621604	chr11:68506083~68506166:-
LIHC	cis	rs17376456	0.877	rs10061080	ENSG00000251023.1	RP11-549J18.1	-4.06	6.14e-05	0.0123	-0.45	-0.21	Diabetic retinopathy;	chr5:94084854	chr5:93860669~93863825:-
LIHC	cis	rs9595908	0.544	rs7328213	ENSG00000212293.1	SNORA16	4.06	6.14e-05	0.0123	0.26	0.21	Body mass index;	chr13:32803692	chr13:32420390~32420516:-
LIHC	cis	rs9467773	0.804	rs2073526	ENSG00000241549.7	GUSBP2	-4.06	6.14e-05	0.0123	-0.22	-0.21	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26871484~26956554:-
LIHC	cis	rs10510102	0.516	rs10887034	ENSG00000226864.1	ATE1-AS1	4.06	6.14e-05	0.0123	0.38	0.21	Breast cancer;	chr10:121973996	chr10:121928312~121951965:+
LIHC	cis	rs1005277	0.579	rs1780121	ENSG00000099251.13	HSD17B7P2	4.06	6.14e-05	0.0123	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1780122	ENSG00000099251.13	HSD17B7P2	4.06	6.14e-05	0.0123	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38356380~38378505:+
LIHC	cis	rs1005277	0.579	rs1780145	ENSG00000099251.13	HSD17B7P2	4.06	6.14e-05	0.0123	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38356380~38378505:+
LIHC	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	4.06	6.14e-05	0.0123	0.22	0.21	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
LIHC	cis	rs17464492	0.592	rs13270266	ENSG00000246228.5	CASC8	4.06	6.14e-05	0.0123	0.24	0.21	Prostate-specific antigen levels (conditioned on lead SNPs);	chr8:127341840	chr8:127289817~127482139:-
LIHC	cis	rs7722022	0.961	rs58870274	ENSG00000253428.1	CTB-43E15.2	4.06	6.15e-05	0.0124	0.22	0.21	Adiponectin levels;	chr5:173521529	chr5:173689459~173705849:+
LIHC	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	4.06	6.16e-05	0.0124	0.24	0.21	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
LIHC	cis	rs875971	0.522	rs1917563	ENSG00000273024.4	INTS4P2	4.06	6.16e-05	0.0124	0.26	0.21	Aortic root size;	chr7:65950660	chr7:65647864~65715661:+
LIHC	cis	rs4578769	0.765	rs60721147	ENSG00000266850.1	RP11-370A5.1	-4.06	6.16e-05	0.0124	-0.25	-0.21	Eosinophil percentage of white cells;	chr18:22848569	chr18:22723491~22907721:-
LIHC	cis	rs481331	0.611	rs12264895	ENSG00000185904.10	LINC00839	4.06	6.16e-05	0.0124	0.4	0.21	Systemic juvenile idiopathic arthritis;	chr10:42695001	chr10:42475543~42495336:+
LIHC	cis	rs481331	0.741	rs7088389	ENSG00000185904.10	LINC00839	4.06	6.16e-05	0.0124	0.4	0.21	Systemic juvenile idiopathic arthritis;	chr10:42695806	chr10:42475543~42495336:+
LIHC	cis	rs481331	0.741	rs7099013	ENSG00000185904.10	LINC00839	4.06	6.16e-05	0.0124	0.4	0.21	Systemic juvenile idiopathic arthritis;	chr10:42696291	chr10:42475543~42495336:+
LIHC	cis	rs9652601	0.919	rs12924729	ENSG00000274038.1	RP11-66H6.4	-4.06	6.17e-05	0.0124	-0.26	-0.21	Systemic lupus erythematosus;	chr16:11093926	chr16:11056556~11057034:+
LIHC	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-4.06	6.17e-05	0.0124	-0.25	-0.21	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
LIHC	cis	rs617219	0.889	rs36177073	ENSG00000251675.1	CTC-458I2.2	-4.06	6.17e-05	0.0124	-0.24	-0.21	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79136934	chr5:80128361~80143883:+
LIHC	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-4.06	6.17e-05	0.0124	-0.33	-0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
LIHC	cis	rs7044106	0.762	rs10760107	ENSG00000238181.2	AHCYP2	-4.06	6.17e-05	0.0124	-0.24	-0.21	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120720673~120721972:+
LIHC	cis	rs11098499	0.863	rs3822195	ENSG00000260091.1	RP11-33B1.4	-4.06	6.17e-05	0.0124	-0.15	-0.21	Corneal astigmatism;	chr4:119550505	chr4:119409333~119410233:+
LIHC	cis	rs763121	0.853	rs2235230	ENSG00000273076.1	RP3-508I15.22	-4.06	6.18e-05	0.0124	-0.26	-0.21	Menopause (age at onset);	chr22:38728462	chr22:38743495~38743910:+
LIHC	cis	rs17818399	0.645	rs35870739	ENSG00000239332.4	LINC01119	-4.06	6.18e-05	0.0124	-0.31	-0.21	Height;	chr2:46557092	chr2:46816697~46859007:+
LIHC	cis	rs4650994	0.544	rs2476561	ENSG00000273384.1	RP5-1098D14.1	4.06	6.18e-05	0.0124	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178650765	chr1:178651706~178652282:+
LIHC	cis	rs11098499	0.865	rs10213221	ENSG00000260091.1	RP11-33B1.4	-4.06	6.18e-05	0.0124	-0.15	-0.21	Corneal astigmatism;	chr4:119334771	chr4:119409333~119410233:+
LIHC	cis	rs6430585	0.528	rs3099429	ENSG00000231890.6	DARS-AS1	-4.06	6.18e-05	0.0124	-0.3	-0.21	Corneal structure;	chr2:135898012	chr2:135985176~136022593:+
LIHC	cis	rs17818399	0.817	rs17767994	ENSG00000279254.1	RP11-536C12.1	4.06	6.18e-05	0.0124	0.27	0.21	Height;	chr2:46632940	chr2:46668870~46670778:+
LIHC	cis	rs6472827	0.794	rs4439117	ENSG00000253983.2	RP1-16A9.1	4.06	6.18e-05	0.0124	0.27	0.21	Uterine fibroids;	chr8:74207475	chr8:74199396~74208441:+
LIHC	cis	rs6832769	0.961	rs28790098	ENSG00000272969.1	RP11-528I4.2	-4.06	6.19e-05	0.0124	-0.25	-0.21	Personality dimensions;	chr4:55531942	chr4:55547112~55547889:+
LIHC	cis	rs244293	0.795	rs12940239	ENSG00000275710.1	RP11-257O5.4	4.06	6.19e-05	0.0124	0.24	0.21	Menarche (age at onset);	chr17:54991569	chr17:54964474~54964679:+
LIHC	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-4.06	6.19e-05	0.0124	-0.25	-0.21	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
LIHC	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	4.06	6.19e-05	0.0124	0.25	0.21	Height;	chr4:55514802	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	4.06	6.19e-05	0.0124	0.25	0.21	Height;	chr4:55516548	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	4.06	6.19e-05	0.0124	0.25	0.21	Height;	chr4:55516744	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	4.06	6.19e-05	0.0124	0.25	0.21	Height;	chr4:55517185	chr4:55363971~55395847:-
LIHC	cis	rs2032447	0.702	rs199753	ENSG00000242387.1	HIST1H2APS2	4.06	6.19e-05	0.0124	0.28	0.21	Intelligence (multi-trait analysis);	chr6:26001660	chr6:25882026~25882395:-
LIHC	cis	rs1876905	0.539	rs457497	ENSG00000272356.1	RP5-1112D6.8	4.06	6.19e-05	0.0124	0.2	0.21	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111309203~111313517:+
LIHC	cis	rs11098499	0.863	rs1552095	ENSG00000260091.1	RP11-33B1.4	-4.06	6.2e-05	0.0124	-0.16	-0.21	Corneal astigmatism;	chr4:119539151	chr4:119409333~119410233:+
LIHC	cis	rs56046484	0.703	rs116893322	ENSG00000259630.2	CTD-2262B20.1	-4.06	6.2e-05	0.0124	-0.42	-0.21	Testicular germ cell tumor;	chr15:84981397	chr15:85415228~85415633:+
LIHC	cis	rs57221529	0.608	rs11749927	ENSG00000271781.1	CTD-2589H19.6	-4.06	6.2e-05	0.0124	-0.3	-0.21	Lung disease severity in cystic fibrosis;	chr5:668727	chr5:675826~676616:+
LIHC	cis	rs244293	0.965	rs244311	ENSG00000275710.1	RP11-257O5.4	4.06	6.2e-05	0.0125	0.23	0.21	Menarche (age at onset);	chr17:55135442	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244312	ENSG00000275710.1	RP11-257O5.4	4.06	6.2e-05	0.0125	0.23	0.21	Menarche (age at onset);	chr17:55135836	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244313	ENSG00000275710.1	RP11-257O5.4	4.06	6.2e-05	0.0125	0.23	0.21	Menarche (age at onset);	chr17:55136971	chr17:54964474~54964679:+
LIHC	cis	rs244293	0.965	rs244314	ENSG00000275710.1	RP11-257O5.4	4.06	6.2e-05	0.0125	0.23	0.21	Menarche (age at onset);	chr17:55137156	chr17:54964474~54964679:+
LIHC	cis	rs763121	0.719	rs138699	ENSG00000273076.1	RP3-508I15.22	4.06	6.2e-05	0.0125	0.25	0.21	Menopause (age at onset);	chr22:38733703	chr22:38743495~38743910:+
LIHC	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-4.06	6.21e-05	0.0125	-0.22	-0.21	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
LIHC	cis	rs12145833	0.538	rs10926977	ENSG00000253326.2	RP11-261C10.7	-4.06	6.21e-05	0.0125	-0.44	-0.21	Obesity (early onset extreme);	chr1:243248065	chr1:243054861~243056394:-
LIHC	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	4.06	6.21e-05	0.0125	0.26	0.21	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
LIHC	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-4.06	6.21e-05	0.0125	-0.24	-0.21	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
LIHC	cis	rs11098499	0.913	rs67073020	ENSG00000260091.1	RP11-33B1.4	-4.05	6.21e-05	0.0125	-0.16	-0.21	Corneal astigmatism;	chr4:119231402	chr4:119409333~119410233:+
LIHC	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	4.05	6.21e-05	0.0125	0.4	0.21	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
LIHC	cis	rs3015497	0.789	rs3015496	ENSG00000269906.1	RP11-248J18.2	4.05	6.22e-05	0.0125	0.27	0.21	Mean platelet volume;	chr14:50647333	chr14:50662511~50663178:-
LIHC	cis	rs2439831	1	rs2444032	ENSG00000166763.7	STRCP1	4.05	6.22e-05	0.0125	0.3	0.21	Lung cancer in ever smokers;	chr15:43463148	chr15:43699488~43718184:-
LIHC	cis	rs57502260	0.679	rs72936524	ENSG00000212093.1	AP000807.1	4.05	6.22e-05	0.0125	0.29	0.21	Total body bone mineral density (age 45-60);	chr11:68508430	chr11:68506083~68506166:-
LIHC	cis	rs2717559	0.542	rs11774823	ENSG00000253196.1	RP11-706C16.7	-4.05	6.22e-05	0.0125	-0.24	-0.21	Urinary tract infection frequency;	chr8:142806152	chr8:142763116~142766427:+
LIHC	cis	rs787274	0.543	rs62576453	ENSG00000271631.1	RP11-408O19.5	4.05	6.22e-05	0.0125	0.35	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr9:112867641	chr9:112885158~112885767:+
LIHC	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	4.05	6.22e-05	0.0125	0.25	0.21	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
LIHC	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-4.05	6.23e-05	0.0125	-0.32	-0.21	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
LIHC	cis	rs1499614	0.901	rs2178742	ENSG00000275400.1	RP4-756H11.5	4.05	6.23e-05	0.0125	0.29	0.21	Gout;	chr7:66732812	chr7:66553805~66554199:-
LIHC	cis	rs2243480	1	rs160639	ENSG00000230295.1	RP11-458F8.2	-4.05	6.23e-05	0.0125	-0.22	-0.21	Diabetic kidney disease;	chr7:66115000	chr7:66880708~66882981:+
LIHC	cis	rs7985	1	rs3752603	ENSG00000244625.4	MIATNB	4.05	6.23e-05	0.0125	0.23	0.21	Electroencephalogram traits;	chr22:26668531	chr22:26672767~26780207:+
LIHC	cis	rs7985	1	rs7985	ENSG00000244625.4	MIATNB	4.05	6.23e-05	0.0125	0.23	0.21	Electroencephalogram traits;	chr22:26670572	chr22:26672767~26780207:+
LIHC	cis	rs2120243	0.533	rs1392798	ENSG00000244515.1	KRT18P34	4.05	6.23e-05	0.0125	0.2	0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338498	chr3:157162663~157163932:-
LIHC	cis	rs6893782	0.945	rs7705826	ENSG00000233006.5	AC034220.3	-4.05	6.23e-05	0.0125	-0.3	-0.21	Acylcarnitine levels;	chr5:132396764	chr5:132311285~132369916:-
LIHC	cis	rs6893782	1	rs6893782	ENSG00000233006.5	AC034220.3	-4.05	6.23e-05	0.0125	-0.3	-0.21	Acylcarnitine levels;	chr5:132403741	chr5:132311285~132369916:-
LIHC	cis	rs6893782	0.945	rs2405522	ENSG00000233006.5	AC034220.3	-4.05	6.23e-05	0.0125	-0.3	-0.21	Acylcarnitine levels;	chr5:132406004	chr5:132311285~132369916:-
LIHC	cis	rs11637445	0.677	rs3784713	ENSG00000260657.2	RP11-315D16.4	-4.05	6.23e-05	0.0125	-0.3	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780675	chr15:68267792~68277994:-
LIHC	cis	rs11637445	0.677	rs12441598	ENSG00000260657.2	RP11-315D16.4	-4.05	6.23e-05	0.0125	-0.3	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780867	chr15:68267792~68277994:-
LIHC	cis	rs6832769	0.961	rs11735267	ENSG00000272969.1	RP11-528I4.2	4.05	6.23e-05	0.0125	0.26	0.21	Personality dimensions;	chr4:55481120	chr4:55547112~55547889:+
LIHC	cis	rs3845817	0.671	rs840785	ENSG00000281920.1	RP11-418H16.1	-4.05	6.24e-05	0.0125	-0.25	-0.21	Bipolar disorder;	chr2:65541842	chr2:65623272~65628424:+
LIHC	cis	rs3845817	0.703	rs702915	ENSG00000281920.1	RP11-418H16.1	-4.05	6.24e-05	0.0125	-0.25	-0.21	Bipolar disorder;	chr2:65543462	chr2:65623272~65628424:+
LIHC	cis	rs3845817	0.703	rs1673458	ENSG00000281920.1	RP11-418H16.1	-4.05	6.24e-05	0.0125	-0.25	-0.21	Bipolar disorder;	chr2:65544512	chr2:65623272~65628424:+
LIHC	cis	rs2976388	0.669	rs2585135	ENSG00000253196.1	RP11-706C16.7	-4.05	6.24e-05	0.0125	-0.22	-0.21	Urinary tract infection frequency;	chr8:142732775	chr8:142763116~142766427:+
LIHC	cis	rs875971	0.505	rs1723275	ENSG00000273024.4	INTS4P2	4.05	6.24e-05	0.0125	0.25	0.21	Aortic root size;	chr7:66039646	chr7:65647864~65715661:+
LIHC	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	4.05	6.24e-05	0.0125	0.21	0.21	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
LIHC	cis	rs11010290	0.639	rs17511194	ENSG00000269952.1	RP11-324I22.3	-4.05	6.24e-05	0.0125	-0.35	-0.21	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr10:35747852	chr10:35210416~35210750:+
LIHC	cis	rs8026198	0.929	rs3743006	ENSG00000260571.1	BNIP3P5	-4.05	6.24e-05	0.0125	-0.3	-0.21	Fibrinogen levels;	chr15:42353570	chr15:42313687~42314386:+
LIHC	cis	rs27434	0.66	rs26493	ENSG00000272109.1	CTD-2260A17.3	-4.05	6.25e-05	0.0125	-0.29	-0.21	Ankylosing spondylitis;	chr5:96819615	chr5:96804353~96806105:+
LIHC	cis	rs4650994	1	rs17361251	ENSG00000213057.5	C1orf220	4.05	6.25e-05	0.0125	0.18	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178551442	chr1:178542752~178548889:+
LIHC	cis	rs4650994	1	rs17276527	ENSG00000213057.5	C1orf220	4.05	6.25e-05	0.0125	0.18	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178551545	chr1:178542752~178548889:+
LIHC	cis	rs9303401	0.632	rs7222087	ENSG00000265415.1	CTD-2510F5.4	4.05	6.25e-05	0.0125	0.15	0.21	Cognitive test performance;	chr17:59144258	chr17:59202677~59203829:-
LIHC	cis	rs6500637	0.591	rs2075466	ENSG00000267077.1	RP11-127I20.5	4.05	6.25e-05	0.0125	0.24	0.21	Cancer;	chr16:4822969	chr16:4795265~4796532:-
LIHC	cis	rs13287066	0.692	rs7020852	ENSG00000227603.1	RP11-165J3.6	4.05	6.25e-05	0.0125	0.25	0.21	Intelligence (multi-trait analysis);	chr9:93400978	chr9:93435332~93437121:-
LIHC	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	4.05	6.25e-05	0.0125	0.25	0.21	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
LIHC	cis	rs638893	0.898	rs587816	ENSG00000255239.1	AP002954.6	4.05	6.25e-05	0.0125	0.47	0.21	Vitiligo;	chr11:118819162	chr11:118688039~118690600:-
LIHC	cis	rs638893	0.898	rs577121	ENSG00000255239.1	AP002954.6	4.05	6.25e-05	0.0125	0.47	0.21	Vitiligo;	chr11:118819841	chr11:118688039~118690600:-
LIHC	cis	rs202072	1	rs202074	ENSG00000215022.6	RP1-257A7.4	-4.05	6.26e-05	0.0125	-0.25	-0.21	HIV-1 viral setpoint;	chr6:13269131	chr6:13264861~13295586:-
LIHC	cis	rs938554	0.513	rs3775947	ENSG00000250413.1	RP11-448G15.1	-4.05	6.26e-05	0.0126	-0.3	-0.21	Blood metabolite levels;	chr4:9993616	chr4:10006482~10009725:+
LIHC	cis	rs11098499	0.955	rs11944880	ENSG00000260091.1	RP11-33B1.4	4.05	6.26e-05	0.0126	0.16	0.21	Corneal astigmatism;	chr4:119238179	chr4:119409333~119410233:+
LIHC	cis	rs7412746	0.566	rs2864871	ENSG00000231073.1	RP11-316M1.3	4.05	6.26e-05	0.0126	0.22	0.21	Melanoma;	chr1:150794488	chr1:150973123~150975534:+
LIHC	cis	rs295490	0.748	rs2289348	ENSG00000272656.1	RP11-219D15.3	4.05	6.26e-05	0.0126	0.61	0.21	PR interval in Tripanosoma cruzi seropositivity;	chr3:139445424	chr3:139349024~139349371:-
LIHC	cis	rs17818399	0.89	rs34752561	ENSG00000279254.1	RP11-536C12.1	-4.05	6.27e-05	0.0126	-0.27	-0.21	Height;	chr2:46623011	chr2:46668870~46670778:+
LIHC	cis	rs6732160	0.691	rs6728147	ENSG00000272702.1	RP11-44N22.3	-4.05	6.27e-05	0.0126	-0.24	-0.21	Intelligence (multi-trait analysis);	chr2:73196362	chr2:73113018~73115907:+
LIHC	cis	rs755249	0.567	rs1126313	ENSG00000182109.6	RP11-69E11.4	-4.05	6.27e-05	0.0126	-0.27	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39522280~39546187:-
LIHC	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-4.05	6.27e-05	0.0126	-0.21	-0.21	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
LIHC	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	4.05	6.28e-05	0.0126	0.27	0.21	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
LIHC	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	4.05	6.28e-05	0.0126	0.36	0.21	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
LIHC	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-4.05	6.28e-05	0.0126	-0.21	-0.21	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
LIHC	cis	rs9467603	0.925	rs1892251	ENSG00000216436.2	HIST1H2APS1	-4.05	6.28e-05	0.0126	-0.48	-0.21	Intelligence (multi-trait analysis);	chr6:25769121	chr6:25732497~25732827:+
LIHC	cis	rs9467603	0.858	rs1937126	ENSG00000216436.2	HIST1H2APS1	-4.05	6.28e-05	0.0126	-0.48	-0.21	Intelligence (multi-trait analysis);	chr6:25769380	chr6:25732497~25732827:+
LIHC	cis	rs3768716	0.5	rs777329	ENSG00000229267.2	AC072062.1	4.05	6.28e-05	0.0126	0.27	0.21	Neuroblastoma;	chr2:214877871	chr2:214810229~214963274:+
LIHC	cis	rs7617480	0.61	rs10865954	ENSG00000270441.1	RP11-694I15.7	-4.05	6.28e-05	0.0126	-0.31	-0.21	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chr3:49140086~49160851:-
LIHC	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-4.05	6.28e-05	0.0126	-0.21	-0.21	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
LIHC	cis	rs10829156	0.773	rs7909552	ENSG00000225527.1	RP11-383B4.4	-4.05	6.28e-05	0.0126	-0.34	-0.21	Sudden cardiac arrest;	chr10:18620407	chr10:18531849~18533336:-
LIHC	cis	rs4578769	0.918	rs4800138	ENSG00000265943.1	RP11-739L10.1	-4.05	6.29e-05	0.0126	-0.27	-0.21	Eosinophil percentage of white cells;	chr18:22934334	chr18:22699481~22933764:-
LIHC	cis	rs6997458	0.904	rs725605	ENSG00000253549.4	RP11-317J10.2	4.05	6.29e-05	0.0126	0.24	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85354657	chr8:85441851~85464915:-
LIHC	cis	rs6997458	0.904	rs1532424	ENSG00000253549.4	RP11-317J10.2	4.05	6.29e-05	0.0126	0.24	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85355963	chr8:85441851~85464915:-
LIHC	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	4.05	6.29e-05	0.0126	0.25	0.21	Height;	chr4:55490176	chr4:55363971~55395847:-
LIHC	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	4.05	6.29e-05	0.0126	0.25	0.21	Height;	chr4:55490228	chr4:55363971~55395847:-
LIHC	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-4.05	6.29e-05	0.0126	-0.22	-0.21	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
LIHC	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	4.05	6.3e-05	0.0126	0.27	0.21	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
LIHC	cis	rs875971	0.545	rs1267814	ENSG00000224316.1	RP11-479O9.2	-4.05	6.3e-05	0.0126	-0.2	-0.21	Aortic root size;	chr7:66579422	chr7:65773620~65802067:+
LIHC	cis	rs9341808	0.6	rs590641	ENSG00000272129.1	RP11-250B2.6	4.05	6.3e-05	0.0126	0.23	0.21	Sitting height ratio;	chr6:80256766	chr6:80355424~80356859:+
LIHC	cis	rs12468226	1	rs11899836	ENSG00000272966.1	RP11-686O6.1	4.05	6.3e-05	0.0126	0.36	0.21	Urate levels;	chr2:202371316	chr2:202336739~202337200:+
LIHC	cis	rs2448490	0.642	rs573589	ENSG00000265874.1	MIR4489	4.05	6.3e-05	0.0126	0.27	0.21	Platelet count;	chr11:65716510	chr11:65649192~65649253:+
LIHC	cis	rs12681287	0.64	rs7846090	ENSG00000254088.1	SLC2A3P4	4.05	6.3e-05	0.0126	0.25	0.21	Caudate activity during reward;	chr8:86455495	chr8:86503591~86505061:+
LIHC	cis	rs8177876	0.749	rs12927828	ENSG00000261061.1	RP11-303E16.2	-4.05	6.3e-05	0.0126	-0.29	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81030770~81031485:+
LIHC	cis	rs2439831	1	rs2584726	ENSG00000166763.7	STRCP1	4.05	6.3e-05	0.0126	0.3	0.21	Lung cancer in ever smokers;	chr15:43423184	chr15:43699488~43718184:-
LIHC	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	4.05	6.31e-05	0.0126	0.18	0.21	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
LIHC	cis	rs11637445	0.677	rs1564278	ENSG00000260657.2	RP11-315D16.4	-4.05	6.31e-05	0.0126	-0.3	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr15:67815050	chr15:68267792~68277994:-
LIHC	cis	rs2070488	0.965	rs2366119	ENSG00000229589.1	ACVR2B-AS1	4.05	6.31e-05	0.0126	0.24	0.21	Electrocardiographic conduction measures;	chr3:38442962	chr3:38451027~38454820:-
LIHC	cis	rs9952991	0.941	rs2847278	ENSG00000260302.1	RP11-973H7.1	-4.05	6.31e-05	0.0126	-0.32	-0.21	Inflammatory skin disease;	chr18:12778716	chr18:12774651~12775923:-
LIHC	cis	rs9952991	0.941	rs2542149	ENSG00000260302.1	RP11-973H7.1	-4.05	6.31e-05	0.0126	-0.32	-0.21	Inflammatory skin disease;	chr18:12779019	chr18:12774651~12775923:-
LIHC	cis	rs9952991	0.941	rs2847280	ENSG00000260302.1	RP11-973H7.1	-4.05	6.31e-05	0.0126	-0.32	-0.21	Inflammatory skin disease;	chr18:12779343	chr18:12774651~12775923:-
LIHC	cis	rs9952991	0.941	rs2542150	ENSG00000260302.1	RP11-973H7.1	-4.05	6.31e-05	0.0126	-0.32	-0.21	Inflammatory skin disease;	chr18:12779764	chr18:12774651~12775923:-
LIHC	cis	rs703842	0.928	rs724834	ENSG00000270039.1	RP11-571M6.17	-4.05	6.31e-05	0.0126	-0.3	-0.21	Multiple sclerosis;	chr12:57786633	chr12:57803838~57804415:+
LIHC	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-4.05	6.32e-05	0.0127	-0.35	-0.21	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
LIHC	cis	rs4561483	0.798	rs456325	ENSG00000261560.1	RP11-166B2.3	-4.05	6.32e-05	0.0127	-0.24	-0.21	Testicular germ cell tumor;	chr16:11918705	chr16:11881075~11882569:-
LIHC	cis	rs901683	1	rs10508896	ENSG00000230869.1	CTGLF10P	-4.05	6.32e-05	0.0127	-0.5	-0.21	Mean corpuscular volume;Red blood cell traits;	chr10:45535195	chr10:45678692~45700532:+
LIHC	cis	rs4356975	0.932	rs4694602	ENSG00000250919.1	RP11-813N20.3	-4.05	6.32e-05	0.0127	-0.21	-0.21	Obesity-related traits;	chr4:69070955	chr4:69027831~69044578:+
LIHC	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-4.05	6.33e-05	0.0127	-0.25	-0.21	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
LIHC	cis	rs987724	0.515	rs9870137	ENSG00000243926.1	TIPARP-AS1	4.05	6.33e-05	0.0127	0.24	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898867	chr3:156671862~156674378:-
LIHC	cis	rs3733589	1	rs16891926	ENSG00000250413.1	RP11-448G15.1	4.05	6.34e-05	0.0127	0.43	0.21	Renal overload gout;	chr4:9995228	chr4:10006482~10009725:+
LIHC	cis	rs12681287	0.608	rs13273338	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86441132	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs13258126	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86441149	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs13256765	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86445604	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs12678720	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86445700	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs13253261	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86446271	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs13253515	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86446367	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs12541793	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86450329	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs12679811	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86453141	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs13264364	ENSG00000254088.1	SLC2A3P4	4.05	6.34e-05	0.0127	0.25	0.21	Caudate activity during reward;	chr8:86454156	chr8:86503591~86505061:+
LIHC	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-4.05	6.34e-05	0.0127	-0.27	-0.21	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
LIHC	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-4.05	6.34e-05	0.0127	-0.26	-0.21	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
LIHC	cis	rs1577917	1	rs11758849	ENSG00000234155.1	RP11-30P6.6	4.05	6.34e-05	0.0127	0.28	0.21	Response to antipsychotic treatment;	chr6:85998544	chr6:85387219~85390186:-
LIHC	cis	rs2348418	0.932	rs7968515	ENSG00000247934.4	RP11-967K21.1	4.05	6.34e-05	0.0127	0.2	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28163298~28190738:-
LIHC	cis	rs1499614	1	rs1882655	ENSG00000275400.1	RP4-756H11.5	-4.05	6.35e-05	0.0127	-0.29	-0.21	Gout;	chr7:66682070	chr7:66553805~66554199:-
LIHC	cis	rs1499614	0.831	rs3800822	ENSG00000275400.1	RP4-756H11.5	-4.05	6.35e-05	0.0127	-0.29	-0.21	Gout;	chr7:66682162	chr7:66553805~66554199:-
LIHC	cis	rs1499614	1	rs1638731	ENSG00000275400.1	RP4-756H11.5	4.05	6.35e-05	0.0127	0.29	0.21	Gout;	chr7:66679692	chr7:66553805~66554199:-
LIHC	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-4.05	6.35e-05	0.0127	-0.28	-0.21	Height;	chr3:53085518	chr3:53064283~53065091:-
LIHC	cis	rs7044106	0.762	rs7024046	ENSG00000238181.2	AHCYP2	-4.05	6.36e-05	0.0127	-0.24	-0.21	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120720673~120721972:+
LIHC	cis	rs10943724	0.799	rs6913206	ENSG00000272129.1	RP11-250B2.6	4.05	6.36e-05	0.0127	0.24	0.21	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80472345	chr6:80355424~80356859:+
LIHC	cis	rs3015497	0.616	rs11157759	ENSG00000269906.1	RP11-248J18.2	4.05	6.36e-05	0.0127	0.27	0.21	Mean platelet volume;	chr14:50620545	chr14:50662511~50663178:-
LIHC	cis	rs2439831	0.702	rs495175	ENSG00000166763.7	STRCP1	4.05	6.36e-05	0.0127	0.3	0.21	Lung cancer in ever smokers;	chr15:43506486	chr15:43699488~43718184:-
LIHC	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	4.05	6.36e-05	0.0127	0.24	0.21	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	4.05	6.36e-05	0.0127	0.24	0.21	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	4.05	6.36e-05	0.0127	0.24	0.21	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	4.05	6.36e-05	0.0127	0.24	0.21	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	4.05	6.36e-05	0.0127	0.24	0.21	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs316317	ENSG00000232546.1	RP11-458F8.1	-4.05	6.36e-05	0.0127	-0.24	-0.21	Diabetic kidney disease;	chr7:66148650	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-4.05	6.36e-05	0.0127	-0.24	-0.21	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-4.05	6.36e-05	0.0127	-0.24	-0.21	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
LIHC	cis	rs11763353	0.627	rs6951635	ENSG00000235828.5	RPL36AP26	-4.05	6.37e-05	0.0127	-0.21	-0.21	Blood trace element (Zn levels);	chr7:15571071	chr7:15701435~15701752:-
LIHC	cis	rs16958440	1	rs62096468	ENSG00000267724.1	RP11-49K24.8	4.05	6.37e-05	0.0127	0.33	0.21	Sitting height ratio;	chr18:47111195	chr18:47105946~47108062:+
LIHC	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-4.05	6.37e-05	0.0127	-0.2	-0.21	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
LIHC	cis	rs911186	0.812	rs3800316	ENSG00000216901.1	AL022393.7	4.05	6.37e-05	0.0127	0.35	0.21	Autism spectrum disorder or schizophrenia;	chr6:27288323	chr6:28176188~28176674:+
LIHC	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-4.05	6.38e-05	0.0128	-0.21	-0.21	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
LIHC	cis	rs5758511	0.514	rs5751211	ENSG00000205702.9	CYP2D7	4.05	6.38e-05	0.0128	0.25	0.21	Birth weight;	chr22:42090052	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.514	rs3985938	ENSG00000205702.9	CYP2D7	4.05	6.38e-05	0.0128	0.25	0.21	Birth weight;	chr22:42115723	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.514	rs5758586	ENSG00000205702.9	CYP2D7	4.05	6.38e-05	0.0128	0.25	0.21	Birth weight;	chr22:42121467	chr22:42140203~42144577:-
LIHC	cis	rs5758511	0.514	rs5751222	ENSG00000205702.9	CYP2D7	4.05	6.38e-05	0.0128	0.25	0.21	Birth weight;	chr22:42121918	chr22:42140203~42144577:-
LIHC	cis	rs875971	0.522	rs6960048	ENSG00000273024.4	INTS4P2	-4.05	6.38e-05	0.0128	-0.25	-0.21	Aortic root size;	chr7:65943052	chr7:65647864~65715661:+
LIHC	cis	rs7915414	0.951	rs749744	ENSG00000230338.1	MTND4P19	4.05	6.38e-05	0.0128	0.23	0.21	Clopidogrel active metabolite levels;	chr10:94646838	chr10:94774156~94774633:-
LIHC	cis	rs4578769	0.959	rs9955664	ENSG00000266850.1	RP11-370A5.1	4.05	6.38e-05	0.0128	0.25	0.21	Eosinophil percentage of white cells;	chr18:22901330	chr18:22723491~22907721:-
LIHC	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	4.05	6.38e-05	0.0128	0.19	0.21	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
LIHC	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	4.05	6.38e-05	0.0128	0.26	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
LIHC	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-4.05	6.39e-05	0.0128	-0.38	-0.21	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
LIHC	cis	rs4578769	0.918	rs8085287	ENSG00000266850.1	RP11-370A5.1	4.05	6.39e-05	0.0128	0.25	0.21	Eosinophil percentage of white cells;	chr18:22884208	chr18:22723491~22907721:-
LIHC	cis	rs9527	0.615	rs10883804	ENSG00000236937.2	PTGES3P4	4.05	6.39e-05	0.0128	0.27	0.21	Arsenic metabolism;	chr10:102946763	chr10:102845595~102845950:+
LIHC	cis	rs72634501	0.517	rs6684217	ENSG00000182109.6	RP11-69E11.4	-4.05	6.39e-05	0.0128	-0.23	-0.21	HDL cholesterol;	chr1:39121606	chr1:39522280~39546187:-
LIHC	cis	rs12681287	0.57	rs4961188	ENSG00000254088.1	SLC2A3P4	-4.05	6.39e-05	0.0128	-0.25	-0.21	Caudate activity during reward;	chr8:86370804	chr8:86503591~86505061:+
LIHC	cis	rs12681287	0.64	rs4490816	ENSG00000254088.1	SLC2A3P4	-4.05	6.39e-05	0.0128	-0.25	-0.21	Caudate activity during reward;	chr8:86372709	chr8:86503591~86505061:+
LIHC	cis	rs433598	0.964	rs234279	ENSG00000260201.2	RP11-143N13.2	4.05	6.39e-05	0.0128	0.22	0.21	Schizophrenia;	chr16:20677307	chr16:20580999~20586640:+
LIHC	cis	rs2070488	1	rs13072809	ENSG00000229589.1	ACVR2B-AS1	4.05	6.4e-05	0.0128	0.24	0.21	Electrocardiographic conduction measures;	chr3:38426680	chr3:38451027~38454820:-
LIHC	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	4.05	6.4e-05	0.0128	0.26	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
LIHC	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	4.05	6.4e-05	0.0128	0.22	0.21	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
LIHC	cis	rs8177876	0.749	rs11865207	ENSG00000261061.1	RP11-303E16.2	-4.05	6.4e-05	0.0128	-0.29	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81030770~81031485:+
LIHC	cis	rs12681287	0.64	rs67123356	ENSG00000254088.1	SLC2A3P4	4.05	6.41e-05	0.0128	0.25	0.21	Caudate activity during reward;	chr8:86441763	chr8:86503591~86505061:+
LIHC	cis	rs7923609	0.905	rs7088799	ENSG00000232075.1	MRPL35P2	-4.05	6.41e-05	0.0128	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256414	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.756	rs7080386	ENSG00000232075.1	MRPL35P2	-4.05	6.41e-05	0.0128	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63288546	chr10:63634317~63634827:-
LIHC	cis	rs7923609	0.778	rs7075195	ENSG00000232075.1	MRPL35P2	-4.05	6.41e-05	0.0128	-0.24	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63290899	chr10:63634317~63634827:-
LIHC	cis	rs1115240	0.898	rs1245196	ENSG00000257842.4	NOVA1-AS1	-4.05	6.41e-05	0.0128	-0.2	-0.21	Educational attainment (years of education);	chr14:26565476	chr14:26598412~26806467:+
LIHC	cis	rs1115240	0.853	rs1951073	ENSG00000257842.4	NOVA1-AS1	-4.05	6.41e-05	0.0128	-0.2	-0.21	Educational attainment (years of education);	chr14:26565906	chr14:26598412~26806467:+
LIHC	cis	rs1115240	0.898	rs178159	ENSG00000257842.4	NOVA1-AS1	-4.05	6.41e-05	0.0128	-0.2	-0.21	Educational attainment (years of education);	chr14:26567912	chr14:26598412~26806467:+
LIHC	cis	rs1577917	0.958	rs13207354	ENSG00000234155.1	RP11-30P6.6	4.05	6.41e-05	0.0128	0.28	0.21	Response to antipsychotic treatment;	chr6:85990545	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12204365	ENSG00000234155.1	RP11-30P6.6	4.05	6.41e-05	0.0128	0.28	0.21	Response to antipsychotic treatment;	chr6:85990814	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs12663651	ENSG00000234155.1	RP11-30P6.6	4.05	6.41e-05	0.0128	0.28	0.21	Response to antipsychotic treatment;	chr6:85991937	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs34852683	ENSG00000234155.1	RP11-30P6.6	4.05	6.41e-05	0.0128	0.28	0.21	Response to antipsychotic treatment;	chr6:85992612	chr6:85387219~85390186:-
LIHC	cis	rs1577917	1	rs6936048	ENSG00000234155.1	RP11-30P6.6	4.05	6.41e-05	0.0128	0.28	0.21	Response to antipsychotic treatment;	chr6:85992890	chr6:85387219~85390186:-
LIHC	cis	rs55966801	0.786	rs72865316	ENSG00000279672.1	CMB9-55F22.1	4.05	6.41e-05	0.0128	0.36	0.21	Plateletcrit;	chr11:247028	chr11:779617~780755:+
LIHC	cis	rs9595908	0.965	rs9595903	ENSG00000212293.1	SNORA16	4.05	6.41e-05	0.0128	0.25	0.21	Body mass index;	chr13:32608003	chr13:32420390~32420516:-
LIHC	cis	rs72675573	0.852	rs1331858	ENSG00000235612.1	RP1-158P9.1	-4.05	6.41e-05	0.0128	-0.28	-0.21	Monocyte count;	chr1:56113658	chr1:56145721~56155224:+
LIHC	cis	rs72675573	0.852	rs12119549	ENSG00000235612.1	RP1-158P9.1	-4.05	6.41e-05	0.0128	-0.28	-0.21	Monocyte count;	chr1:56115063	chr1:56145721~56155224:+
LIHC	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-4.05	6.42e-05	0.0128	-0.25	-0.21	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
LIHC	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-4.05	6.42e-05	0.0128	-0.25	-0.21	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
LIHC	cis	rs4650994	1	rs4076205	ENSG00000273384.1	RP5-1098D14.1	4.05	6.42e-05	0.0128	0.26	0.21	HDL cholesterol;HDL cholesterol levels;	chr1:178565022	chr1:178651706~178652282:+
LIHC	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-4.05	6.42e-05	0.0128	-0.31	-0.21	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
LIHC	cis	rs9527	0.615	rs3897401	ENSG00000236937.2	PTGES3P4	4.05	6.42e-05	0.0128	0.27	0.21	Arsenic metabolism;	chr10:102936622	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.615	rs36045108	ENSG00000236937.2	PTGES3P4	4.05	6.42e-05	0.0128	0.27	0.21	Arsenic metabolism;	chr10:102938172	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.615	rs7917295	ENSG00000236937.2	PTGES3P4	4.05	6.42e-05	0.0128	0.27	0.21	Arsenic metabolism;	chr10:102941430	chr10:102845595~102845950:+
LIHC	cis	rs9527	0.568	rs12772775	ENSG00000236937.2	PTGES3P4	4.05	6.42e-05	0.0128	0.27	0.21	Arsenic metabolism;	chr10:102943242	chr10:102845595~102845950:+
LIHC	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-4.05	6.43e-05	0.0128	-0.26	-0.21	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
LIHC	cis	rs9341808	0.667	rs806783	ENSG00000272129.1	RP11-250B2.6	-4.05	6.43e-05	0.0128	-0.22	-0.21	Sitting height ratio;	chr6:80233226	chr6:80355424~80356859:+
LIHC	cis	rs9457247	0.602	rs10484530	ENSG00000227598.1	RP1-167A14.2	-4.05	6.43e-05	0.0128	-0.23	-0.21	Crohn's disease;	chr6:167048074	chr6:166969626~166999065:-
LIHC	cis	rs1005277	0.522	rs289643	ENSG00000276805.1	RP11-291L22.6	4.05	6.43e-05	0.0128	0.26	0.21	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38451030~38451785:+
LIHC	cis	rs13434995	0.537	rs7340797	ENSG00000273257.1	RP11-177J6.1	4.05	6.43e-05	0.0128	0.33	0.21	Adiponectin levels;	chr4:55363681	chr4:55387949~55388271:+
LIHC	cis	rs7647973	0.58	rs4955432	ENSG00000270441.1	RP11-694I15.7	-4.05	6.44e-05	0.0129	-0.3	-0.21	Menarche (age at onset);	chr3:49229339	chr3:49140086~49160851:-
LIHC	cis	rs7647973	0.6	rs11920267	ENSG00000270441.1	RP11-694I15.7	-4.05	6.44e-05	0.0129	-0.3	-0.21	Menarche (age at onset);	chr3:49238531	chr3:49140086~49160851:-
LIHC	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-4.05	6.44e-05	0.0129	-0.27	-0.21	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
LIHC	cis	rs2439831	0.717	rs2447198	ENSG00000166763.7	STRCP1	4.05	6.44e-05	0.0129	0.34	0.21	Lung cancer in ever smokers;	chr15:43602920	chr15:43699488~43718184:-
LIHC	cis	rs9633402	0.697	rs4925735	ENSG00000259865.1	RP11-488L18.10	4.05	6.44e-05	0.0129	0.26	0.21	Systemic juvenile idiopathic arthritis;	chr1:247837017	chr1:247187281~247188526:-
LIHC	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-4.05	6.45e-05	0.0129	-0.23	-0.21	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
LIHC	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-4.05	6.45e-05	0.0129	-0.27	-0.21	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
LIHC	cis	rs1005277	0.522	rs1208684	ENSG00000099251.13	HSD17B7P2	4.05	6.45e-05	0.0129	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38356380~38378505:+
LIHC	cis	rs2439831	0.85	rs558656	ENSG00000166763.7	STRCP1	4.05	6.46e-05	0.0129	0.3	0.21	Lung cancer in ever smokers;	chr15:43431316	chr15:43699488~43718184:-
LIHC	cis	rs2439831	1	rs2467739	ENSG00000166763.7	STRCP1	4.05	6.46e-05	0.0129	0.3	0.21	Lung cancer in ever smokers;	chr15:43447998	chr15:43699488~43718184:-
LIHC	cis	rs2439831	1	rs2245790	ENSG00000166763.7	STRCP1	4.05	6.46e-05	0.0129	0.3	0.21	Lung cancer in ever smokers;	chr15:43452259	chr15:43699488~43718184:-
LIHC	cis	rs6061231	0.571	rs482010	ENSG00000226332.2	RP11-157P1.4	-4.05	6.46e-05	0.0129	-0.22	-0.21	Colorectal cancer;	chr20:62352495	chr20:62305432~62306325:-
LIHC	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.46e-05	0.0129	-0.25	-0.21	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
LIHC	cis	rs1005277	0.54	rs1987431	ENSG00000099251.13	HSD17B7P2	4.05	6.46e-05	0.0129	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38356380~38378505:+
LIHC	cis	rs4925386	0.759	rs2427293	ENSG00000226332.2	RP11-157P1.4	-4.05	6.46e-05	0.0129	-0.25	-0.21	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62305432~62306325:-
LIHC	cis	rs4356203	0.87	rs7936310	ENSG00000260196.1	RP1-239B22.5	4.05	6.46e-05	0.0129	0.26	0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17380649~17383531:+
LIHC	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	4.05	6.47e-05	0.0129	0.3	0.21	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
LIHC	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	4.05	6.47e-05	0.0129	0.3	0.21	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
LIHC	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-4.05	6.47e-05	0.0129	-0.31	-0.21	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-4.05	6.47e-05	0.0129	-0.31	-0.21	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-4.05	6.47e-05	0.0129	-0.31	-0.21	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-4.05	6.47e-05	0.0129	-0.31	-0.21	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-4.05	6.47e-05	0.0129	-0.31	-0.21	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
LIHC	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-4.05	6.47e-05	0.0129	-0.31	-0.21	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
LIHC	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	4.05	6.47e-05	0.0129	0.25	0.21	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	4.05	6.47e-05	0.0129	0.25	0.21	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
LIHC	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	4.05	6.47e-05	0.0129	0.25	0.21	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
LIHC	cis	rs6142102	0.961	rs1007090	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.47e-05	0.0129	-0.25	-0.21	Skin pigmentation;	chr20:33995065	chr20:33989480~33991818:-
LIHC	cis	rs6142102	0.923	rs2284377	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.47e-05	0.0129	-0.25	-0.21	Skin pigmentation;	chr20:33998876	chr20:33989480~33991818:-
LIHC	cis	rs6142102	0.961	rs2284378	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.47e-05	0.0129	-0.25	-0.21	Skin pigmentation;	chr20:34000289	chr20:33989480~33991818:-
LIHC	cis	rs6142102	0.961	rs2284379	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.47e-05	0.0129	-0.25	-0.21	Skin pigmentation;	chr20:34006836	chr20:33989480~33991818:-
LIHC	cis	rs6142102	0.961	rs2268080	ENSG00000275784.1	RP5-1125A11.6	-4.05	6.47e-05	0.0129	-0.25	-0.21	Skin pigmentation;	chr20:34009910	chr20:33989480~33991818:-
LIHC	cis	rs4682868	0.581	rs6774801	ENSG00000273328.4	RP11-141M3.6	-4.04	6.47e-05	0.0129	-0.21	-0.21	Monocyte percentage of white cells;	chr3:42882284	chr3:42809414~42908105:+
LIHC	cis	rs651907	0.557	rs11917682	ENSG00000244119.1	PDCL3P4	4.04	6.48e-05	0.0129	0.22	0.21	Colorectal cancer;	chr3:101636583	chr3:101712472~101713191:+
LIHC	cis	rs651907	0.557	rs12629658	ENSG00000244119.1	PDCL3P4	4.04	6.48e-05	0.0129	0.22	0.21	Colorectal cancer;	chr3:101637691	chr3:101712472~101713191:+
LIHC	cis	rs875971	0.505	rs1167386	ENSG00000273024.4	INTS4P2	4.04	6.48e-05	0.0129	0.25	0.21	Aortic root size;	chr7:66048109	chr7:65647864~65715661:+
LIHC	cis	rs875971	0.505	rs1167385	ENSG00000273024.4	INTS4P2	4.04	6.48e-05	0.0129	0.25	0.21	Aortic root size;	chr7:66048321	chr7:65647864~65715661:+
LIHC	cis	rs7208859	0.673	rs9895684	ENSG00000266490.1	CTD-2349P21.9	4.04	6.48e-05	0.0129	0.27	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30792372~30792833:+
LIHC	cis	rs875971	0.545	rs13311962	ENSG00000228409.4	CCT6P1	4.04	6.49e-05	0.0129	0.18	0.21	Aortic root size;	chr7:66603142	chr7:65751142~65763354:+
LIHC	cis	rs794185	0.714	rs2633861	ENSG00000231249.1	ITPR1-AS1	-4.04	6.49e-05	0.0129	-0.24	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4457864	chr3:4490891~4493163:-
LIHC	cis	rs875971	0.662	rs448725	ENSG00000232559.3	GS1-124K5.12	4.04	6.49e-05	0.0129	0.17	0.21	Aortic root size;	chr7:66049641	chr7:66554588~66576923:-
LIHC	cis	rs875971	0.658	rs432667	ENSG00000232559.3	GS1-124K5.12	4.04	6.49e-05	0.0129	0.17	0.21	Aortic root size;	chr7:66049646	chr7:66554588~66576923:-
LIHC	cis	rs1555322	0.556	rs7272884	ENSG00000279253.1	RP4-614O4.13	-4.04	6.49e-05	0.0129	-0.29	-0.21	Attention deficit hyperactivity disorder;	chr20:35295212	chr20:35262727~35264187:-
LIHC	cis	rs2348418	0.639	rs10459086	ENSG00000247934.4	RP11-967K21.1	-4.04	6.5e-05	0.013	-0.2	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28115511	chr12:28163298~28190738:-
LIHC	cis	rs11779988	0.516	rs426498	ENSG00000253671.1	RP11-806O11.1	-4.04	6.5e-05	0.013	-0.26	-0.21	Breast cancer;	chr8:18039649	chr8:17808941~17820868:+
LIHC	cis	rs6686842	0.562	rs213769	ENSG00000235358.1	RP11-399E6.1	4.04	6.5e-05	0.013	0.25	0.21	Height;	chr1:41149686	chr1:41242373~41284861:+
LIHC	cis	rs3015497	0.616	rs7154131	ENSG00000269906.1	RP11-248J18.2	4.04	6.5e-05	0.013	0.26	0.21	Mean platelet volume;	chr14:50579808	chr14:50662511~50663178:-
LIHC	cis	rs10912872	0.564	rs11807475	ENSG00000231424.2	RP1-45C12.1	4.04	6.5e-05	0.013	0.23	0.21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr1:171371960	chr1:171247580~171251794:-
LIHC	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	4.04	6.5e-05	0.013	0.35	0.21	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	4.04	6.5e-05	0.013	0.35	0.21	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
LIHC	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	4.04	6.5e-05	0.013	0.35	0.21	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
LIHC	cis	rs2736340	0.539	rs9644687	ENSG00000255310.2	AF131215.2	-4.04	6.51e-05	0.013	-0.18	-0.21	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465516	chr8:11107788~11109726:-
LIHC	cis	rs6439153	0.839	rs2624901	ENSG00000231305.3	RP11-723O4.2	-4.04	6.51e-05	0.013	-0.22	-0.21	Pneumococcal bacteremia;	chr3:128958345	chr3:128861313~128871540:-
LIHC	cis	rs55966801	0.68	rs6541	ENSG00000279672.1	CMB9-55F22.1	4.04	6.51e-05	0.013	0.35	0.21	Plateletcrit;	chr11:252851	chr11:779617~780755:+
LIHC	cis	rs1023500	0.551	rs133371	ENSG00000226450.2	CYP2D8P	4.04	6.51e-05	0.013	0.26	0.21	Schizophrenia;	chr22:42069570	chr22:42149886~42155001:-
LIHC	cis	rs1023500	0.573	rs133374	ENSG00000226450.2	CYP2D8P	4.04	6.51e-05	0.013	0.26	0.21	Schizophrenia;	chr22:42069937	chr22:42149886~42155001:-
LIHC	cis	rs1023500	0.573	rs133378	ENSG00000226450.2	CYP2D8P	4.04	6.51e-05	0.013	0.26	0.21	Schizophrenia;	chr22:42071691	chr22:42149886~42155001:-
LIHC	cis	rs1023500	0.573	rs133382	ENSG00000226450.2	CYP2D8P	4.04	6.51e-05	0.013	0.26	0.21	Schizophrenia;	chr22:42075770	chr22:42149886~42155001:-
LIHC	cis	rs8060686	0.516	rs1971546	ENSG00000261469.1	RP11-96D1.6	-4.04	6.52e-05	0.013	-0.25	-0.21	HDL cholesterol;Metabolic syndrome;	chr16:68246990	chr16:68236845~68237667:-
LIHC	cis	rs8060686	0.516	rs73612297	ENSG00000261469.1	RP11-96D1.6	-4.04	6.52e-05	0.013	-0.25	-0.21	HDL cholesterol;Metabolic syndrome;	chr16:68250851	chr16:68236845~68237667:-
LIHC	cis	rs7208859	0.673	rs79541516	ENSG00000266490.1	CTD-2349P21.9	4.04	6.52e-05	0.013	0.27	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30792372~30792833:+
LIHC	cis	rs1443267	0.935	rs7210267	ENSG00000265542.4	RP11-60A24.3	-4.04	6.52e-05	0.013	-0.33	-0.21	Obstetric antiphospholipid syndrome;	chr17:57848208	chr17:57771946~57834749:-
LIHC	cis	rs7044106	0.762	rs4837789	ENSG00000238181.2	AHCYP2	-4.04	6.53e-05	0.013	-0.24	-0.21	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120720673~120721972:+
LIHC	cis	rs14027	0.512	rs4871528	ENSG00000279347.1	RP11-85I17.2	4.04	6.53e-05	0.013	0.21	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119700371	chr8:119838736~119840385:-
LIHC	cis	rs1005277	0.579	rs1780116	ENSG00000099251.13	HSD17B7P2	4.04	6.53e-05	0.013	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38356380~38378505:+
LIHC	cis	rs2337406	0.925	rs34064152	ENSG00000274576.2	IGHV2-70	-4.04	6.53e-05	0.013	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106700364	chr14:106770577~106771020:-
LIHC	cis	rs3808502	0.527	rs2736374	ENSG00000255495.1	AC145124.2	-4.04	6.54e-05	0.013	-0.28	-0.21	Neuroticism;	chr8:11256319	chr8:12194467~12196280:+
LIHC	cis	rs2797160	1	rs2211418	ENSG00000237742.5	RP11-624M8.1	-4.04	6.54e-05	0.013	-0.21	-0.21	Endometrial cancer;	chr6:125674357	chr6:125578558~125749190:-
LIHC	cis	rs1106684	1	rs1106683	ENSG00000233559.1	AC016831.7	4.04	6.54e-05	0.013	0.37	0.21	Body mass index;	chr7:131768766	chr7:130853720~130928649:+
LIHC	cis	rs11098499	0.954	rs1546505	ENSG00000260091.1	RP11-33B1.4	-4.04	6.54e-05	0.013	-0.16	-0.21	Corneal astigmatism;	chr4:119320069	chr4:119409333~119410233:+
LIHC	cis	rs6997458	0.742	rs9969643	ENSG00000253549.4	RP11-317J10.2	4.04	6.54e-05	0.013	0.23	0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85453758	chr8:85441851~85464915:-
LIHC	cis	rs1005277	0.579	rs1614236	ENSG00000099251.13	HSD17B7P2	4.04	6.55e-05	0.013	0.25	0.21	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38356380~38378505:+
LIHC	cis	rs7224610	0.931	rs7223342	ENSG00000263096.1	RP11-515O17.2	4.04	6.55e-05	0.013	0.31	0.21	Urate levels;	chr17:55292233	chr17:55271504~55273653:-
LIHC	cis	rs2439831	0.867	rs2584702	ENSG00000166763.7	STRCP1	4.04	6.55e-05	0.013	0.3	0.21	Lung cancer in ever smokers;	chr15:43392716	chr15:43699488~43718184:-
LIHC	cis	rs2439831	0.867	rs2243434	ENSG00000166763.7	STRCP1	4.04	6.55e-05	0.013	0.3	0.21	Lung cancer in ever smokers;	chr15:43397669	chr15:43699488~43718184:-
LIHC	cis	rs3015497	0.789	rs3015500	ENSG00000269906.1	RP11-248J18.2	4.04	6.55e-05	0.013	0.27	0.21	Mean platelet volume;	chr14:50642159	chr14:50662511~50663178:-
LIHC	cis	rs638893	0.717	rs622690	ENSG00000255239.1	AP002954.6	4.04	6.56e-05	0.0131	0.37	0.21	Vitiligo;	chr11:118833556	chr11:118688039~118690600:-
LIHC	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-4.04	6.56e-05	0.0131	-0.21	-0.21	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
LIHC	cis	rs8177876	0.822	rs16954582	ENSG00000261061.1	RP11-303E16.2	-4.04	6.56e-05	0.0131	-0.3	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81030770~81031485:+
LIHC	cis	rs6745190	0.906	rs13019038	ENSG00000236153.1	AC104076.3	-4.04	6.56e-05	0.0131	-0.28	-0.21	White blood cell count;	chr2:181082907	chr2:180979427~180980090:-
LIHC	cis	rs295490	0.667	rs75356853	ENSG00000272656.1	RP11-219D15.3	4.04	6.56e-05	0.0131	0.62	0.21	PR interval in Tripanosoma cruzi seropositivity;	chr3:139324055	chr3:139349024~139349371:-
LIHC	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-4.04	6.56e-05	0.0131	-0.25	-0.21	Height;	chr6:109444615	chr6:109382795~109383666:+
LIHC	cis	rs17376456	0.877	rs66696214	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94088828	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.778	rs10440717	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94089147	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs9314095	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94089790	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs10064520	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94091653	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs55832164	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94100874	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs17315943	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94107125	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs34184666	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94108879	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs28633397	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94111343	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs9314099	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94111670	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs9314100	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94111689	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs10059230	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94114642	chr5:93860669~93863825:-
LIHC	cis	rs17376456	0.877	rs10070390	ENSG00000251023.1	RP11-549J18.1	-4.04	6.56e-05	0.0131	-0.45	-0.21	Diabetic retinopathy;	chr5:94116640	chr5:93860669~93863825:-
LIHC	cis	rs4356203	0.87	rs1979603	ENSG00000260196.1	RP1-239B22.5	-4.04	6.57e-05	0.0131	-0.25	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17380649~17383531:+
LIHC	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	4.04	6.57e-05	0.0131	0.22	0.21	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
LIHC	cis	rs11098499	0.78	rs7692994	ENSG00000260091.1	RP11-33B1.4	-4.04	6.57e-05	0.0131	-0.15	-0.21	Corneal astigmatism;	chr4:119506334	chr4:119409333~119410233:+
LIHC	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-4.04	6.58e-05	0.0131	-0.22	-0.21	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
LIHC	cis	rs2120243	0.647	rs60676003	ENSG00000244515.1	KRT18P34	-4.04	6.58e-05	0.0131	-0.21	-0.21	Hepatocellular carcinoma in hepatitis B infection;	chr3:157430150	chr3:157162663~157163932:-
LIHC	cis	rs8060686	0.516	rs2290700	ENSG00000261469.1	RP11-96D1.6	-4.04	6.58e-05	0.0131	-0.25	-0.21	HDL cholesterol;Metabolic syndrome;	chr16:68255080	chr16:68236845~68237667:-
LIHC	cis	rs8060686	0.516	rs2290699	ENSG00000261469.1	RP11-96D1.6	-4.04	6.58e-05	0.0131	-0.25	-0.21	HDL cholesterol;Metabolic syndrome;	chr16:68255156	chr16:68236845~68237667:-
LIHC	cis	rs8060686	0.516	rs8062085	ENSG00000261469.1	RP11-96D1.6	-4.04	6.58e-05	0.0131	-0.25	-0.21	HDL cholesterol;Metabolic syndrome;	chr16:68255410	chr16:68236845~68237667:-
LIHC	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	4.04	6.58e-05	0.0131	0.31	0.21	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
LIHC	cis	rs2562456	0.874	rs2562408	ENSG00000268555.1	RP11-678G14.3	-4.04	6.58e-05	0.0131	-0.27	-0.21	Pain;	chr19:21527079	chr19:21570822~21587322:-
LIHC	cis	rs2598107	0.532	rs7807193	ENSG00000211698.2	TRGV4	-4.04	6.58e-05	0.0131	-0.25	-0.21	Dupuytren's disease;	chr7:37895071	chr7:38353715~38354517:-
LIHC	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	4.04	6.58e-05	0.0131	0.26	0.21	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
LIHC	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-4.04	6.58e-05	0.0131	-0.26	-0.21	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
LIHC	cis	rs55966801	0.68	rs72882962	ENSG00000279672.1	CMB9-55F22.1	4.04	6.58e-05	0.0131	0.36	0.21	Plateletcrit;	chr11:269129	chr11:779617~780755:+
LIHC	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-4.04	6.58e-05	0.0131	-0.22	-0.21	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
LIHC	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-4.04	6.58e-05	0.0131	-0.21	-0.21	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
LIHC	cis	rs6430585	0.528	rs309159	ENSG00000231890.6	DARS-AS1	-4.04	6.59e-05	0.0131	-0.3	-0.21	Corneal structure;	chr2:135927370	chr2:135985176~136022593:+
LIHC	cis	rs4965006	1	rs4965006	ENSG00000273568.1	RP11-417L19.6	4.04	6.59e-05	0.0131	0.27	0.21	Posterior cortical atrophy and Alzheimer's disease;	chr12:131934988	chr12:131934642~131934928:+
LIHC	cis	rs5769765	1	rs761879	ENSG00000278869.1	CITF22-49E9.3	-4.04	6.59e-05	0.0131	-0.33	-0.21	Schizophrenia;	chr22:49847562	chr22:49933198~49934074:-
LIHC	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-4.04	6.59e-05	0.0131	-0.23	-0.21	Asthma;	chr2:102392894	chr2:102438713~102440475:+
LIHC	cis	rs916888	0.61	rs142167	ENSG00000260075.1	NSFP1	-4.04	6.59e-05	0.0131	-0.26	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46372855~46487141:+
LIHC	cis	rs9976767	0.608	rs11909987	ENSG00000225218.1	AP001628.6	-4.04	6.6e-05	0.0131	-0.21	-0.21	Type 1 diabetes;	chr21:42402293	chr21:42831040~42836477:-
LIHC	cis	rs5770917	1	rs5770911	ENSG00000273272.1	CTA-384D8.34	4.04	6.6e-05	0.0131	0.31	0.21	Narcolepsy;	chr22:50572812	chr22:50542650~50543011:+
LIHC	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-4.04	6.6e-05	0.0131	-0.22	-0.21	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
LIHC	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-4.04	6.6e-05	0.0131	-0.22	-0.21	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
LIHC	cis	rs2072510	0.9	rs2110762	ENSG00000257715.1	RP11-256L6.2	-4.04	6.6e-05	0.0131	-0.22	-0.21	Metabolite levels (small molecules and protein measures);	chr12:96008756	chr12:96025323~96027971:+
LIHC	cis	rs2439831	0.681	rs478104	ENSG00000166763.7	STRCP1	4.04	6.6e-05	0.0131	0.29	0.21	Lung cancer in ever smokers;	chr15:43302702	chr15:43699488~43718184:-
LIHC	cis	rs7083	0.935	rs2509211	ENSG00000254851.1	RP11-109L13.1	4.04	6.6e-05	0.0131	0.31	0.21	Blood protein levels;	chr11:117266917	chr11:117135528~117138582:+
LIHC	cis	rs7083	1	rs524085	ENSG00000254851.1	RP11-109L13.1	4.04	6.6e-05	0.0131	0.31	0.21	Blood protein levels;	chr11:117266931	chr11:117135528~117138582:+
LIHC	cis	rs6480314	0.656	rs2394459	ENSG00000233590.1	RP11-153K11.3	-4.04	6.6e-05	0.0131	-0.29	-0.21	Optic nerve measurement (disc area);	chr10:68221679	chr10:68233251~68242379:-
LIHC	cis	rs12468226	0.689	rs17651413	ENSG00000272966.1	RP11-686O6.1	4.04	6.6e-05	0.0131	0.38	0.21	Urate levels;	chr2:202104086	chr2:202336739~202337200:+
LIHC	cis	rs160451	0.966	rs1603289	ENSG00000251136.7	RP11-37B2.1	4.04	6.6e-05	0.0131	0.19	0.21	Leprosy;	chr8:89655405	chr8:89609409~89757727:-
LIHC	cis	rs2283792	0.74	rs8138075	ENSG00000224086.5	LL22NC03-86G7.1	-4.04	6.61e-05	0.0131	-0.22	-0.21	Multiple sclerosis;	chr22:21755092	chr22:21938293~21977632:+
LIHC	cis	rs16958440	1	rs2289132	ENSG00000267724.1	RP11-49K24.8	4.04	6.61e-05	0.0131	0.33	0.21	Sitting height ratio;	chr18:47075921	chr18:47105946~47108062:+
LIHC	cis	rs16958440	1	rs2289131	ENSG00000267724.1	RP11-49K24.8	4.04	6.61e-05	0.0131	0.33	0.21	Sitting height ratio;	chr18:47076493	chr18:47105946~47108062:+
LIHC	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-4.04	6.61e-05	0.0131	-0.23	-0.21	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
LIHC	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	4.04	6.61e-05	0.0131	0.22	0.21	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
LIHC	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-4.04	6.61e-05	0.0131	-0.39	-0.21	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
LIHC	cis	rs73081554	0.505	rs7626442	ENSG00000272360.1	RP11-359I18.5	-4.04	6.61e-05	0.0132	-0.29	-0.21	Rheumatoid arthritis;	chr3:58352985	chr3:58490830~58491291:-
LIHC	cis	rs4218	0.597	rs62002544	ENSG00000277144.1	RP11-59H7.4	-4.04	6.62e-05	0.0132	-0.24	-0.21	Social communication problems;	chr15:59066663	chr15:59115547~59116089:-
LIHC	cis	rs9595908	0.785	rs9596109	ENSG00000212293.1	SNORA16	4.04	6.62e-05	0.0132	0.24	0.21	Body mass index;	chr13:32712611	chr13:32420390~32420516:-
LIHC	cis	rs794185	0.657	rs2633846	ENSG00000231249.1	ITPR1-AS1	-4.04	6.62e-05	0.0132	-0.23	-0.21	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471781	chr3:4490891~4493163:-
LIHC	cis	rs4356975	0.83	rs3922514	ENSG00000250919.1	RP11-813N20.3	-4.04	6.62e-05	0.0132	-0.21	-0.21	Obesity-related traits;	chr4:69060905	chr4:69027831~69044578:+
LIHC	cis	rs4356975	0.83	rs28775401	ENSG00000250919.1	RP11-813N20.3	-4.04	6.62e-05	0.0132	-0.21	-0.21	Obesity-related traits;	chr4:69060999	chr4:69027831~69044578:+
LIHC	cis	rs2836974	0.867	rs77959119	ENSG00000255568.3	BRWD1-AS2	4.04	6.63e-05	0.0132	0.24	0.21	Cognitive function;	chr21:39170842	chr21:39313935~39314962:+
LIHC	cis	rs2598107	0.505	rs10435156	ENSG00000211698.2	TRGV4	-4.04	6.63e-05	0.0132	-0.25	-0.21	Dupuytren's disease;	chr7:37896128	chr7:38353715~38354517:-
LIHC	cis	rs1005277	0.683	rs7923868	ENSG00000275858.1	RP11-291L22.8	4.04	6.63e-05	0.0132	0.24	0.21	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38450738~38451069:-
LIHC	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-4.04	6.63e-05	0.0132	-0.26	-0.21	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
LIHC	cis	rs709400	0.859	rs7693	ENSG00000258914.1	CTD-2134A5.3	4.04	6.63e-05	0.0132	0.31	0.21	Body mass index;	chr14:103557367	chr14:103875055~103877478:+
LIHC	cis	rs4356203	0.87	rs214901	ENSG00000260196.1	RP1-239B22.5	4.04	6.64e-05	0.0132	0.25	0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206181	chr11:17380649~17383531:+
LIHC	cis	rs2998286	0.678	rs1755205	ENSG00000254635.4	WAC-AS1	-4.04	6.64e-05	0.0132	-0.26	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28644828	chr10:28522652~28532743:-
LIHC	cis	rs1062753	0.731	rs11090065	ENSG00000237037.8	NDUFA6-AS1	-4.04	6.64e-05	0.0132	-0.29	-0.21	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41988167	chr22:42090931~42137742:+
LIHC	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-4.04	6.64e-05	0.0132	-0.21	-0.21	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
LIHC	cis	rs10857712	0.703	rs12253520	ENSG00000214279.11	SCART1	-4.04	6.65e-05	0.0132	-0.26	-0.21	Systemic lupus erythematosus;	chr10:133421817	chr10:133453928~133523558:+
LIHC	cis	rs10857712	0.703	rs1056521	ENSG00000214279.11	SCART1	-4.04	6.65e-05	0.0132	-0.26	-0.21	Systemic lupus erythematosus;	chr10:133422386	chr10:133453928~133523558:+
LIHC	cis	rs4356203	0.875	rs7125607	ENSG00000260196.1	RP1-239B22.5	-4.04	6.65e-05	0.0132	-0.26	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074603	chr11:17380649~17383531:+
LIHC	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	4.04	6.65e-05	0.0132	0.27	0.21	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
LIHC	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	4.04	6.65e-05	0.0132	0.29	0.21	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
LIHC	cis	rs2243480	1	rs313832	ENSG00000228409.4	CCT6P1	4.04	6.65e-05	0.0132	0.23	0.21	Diabetic kidney disease;	chr7:66085904	chr7:65751142~65763354:+
LIHC	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-4.04	6.66e-05	0.0132	-0.26	-0.21	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
LIHC	cis	rs17270561	0.666	rs12209856	ENSG00000216436.2	HIST1H2APS1	-4.04	6.66e-05	0.0132	-0.25	-0.21	Iron status biomarkers;	chr6:25793445	chr6:25732497~25732827:+
LIHC	cis	rs755249	0.567	rs67020650	ENSG00000182109.6	RP11-69E11.4	4.04	6.66e-05	0.0132	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39522280~39546187:-
LIHC	cis	rs1115240	0.853	rs10129655	ENSG00000257842.4	NOVA1-AS1	4.04	6.66e-05	0.0132	0.2	0.21	Educational attainment (years of education);	chr14:26569709	chr14:26598412~26806467:+
LIHC	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	4.04	6.66e-05	0.0132	0.26	0.21	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
LIHC	cis	rs2243480	1	rs1964692	ENSG00000232546.1	RP11-458F8.1	-4.04	6.66e-05	0.0132	-0.24	-0.21	Diabetic kidney disease;	chr7:65989196	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.901	rs2456483	ENSG00000232546.1	RP11-458F8.1	-4.04	6.66e-05	0.0132	-0.24	-0.21	Diabetic kidney disease;	chr7:65996588	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.901	rs2949697	ENSG00000232546.1	RP11-458F8.1	-4.04	6.66e-05	0.0132	-0.24	-0.21	Diabetic kidney disease;	chr7:65999249	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs1701750	ENSG00000232546.1	RP11-458F8.1	-4.04	6.66e-05	0.0132	-0.24	-0.21	Diabetic kidney disease;	chr7:66002158	chr7:66848496~66858136:+
LIHC	cis	rs2243480	1	rs1701758	ENSG00000232546.1	RP11-458F8.1	-4.04	6.66e-05	0.0132	-0.24	-0.21	Diabetic kidney disease;	chr7:66005214	chr7:66848496~66858136:+
LIHC	cis	rs2243480	0.901	rs1701759	ENSG00000232546.1	RP11-458F8.1	-4.04	6.66e-05	0.0132	-0.24	-0.21	Diabetic kidney disease;	chr7:66005945	chr7:66848496~66858136:+
LIHC	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-4.04	6.66e-05	0.0132	-0.21	-0.21	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
LIHC	cis	rs2980439	0.525	rs2980508	ENSG00000173295.6	FAM86B3P	4.04	6.66e-05	0.0132	0.27	0.21	Neuroticism;	chr8:8314210	chr8:8228595~8244865:+
LIHC	cis	rs2598107	0.601	rs17171212	ENSG00000211698.2	TRGV4	4.04	6.66e-05	0.0132	0.25	0.21	Dupuytren's disease;	chr7:37925363	chr7:38353715~38354517:-
LIHC	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-4.04	6.66e-05	0.0132	-0.27	-0.21	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
LIHC	cis	rs3020736	0.5	rs8138678	ENSG00000226450.2	CYP2D8P	-4.04	6.66e-05	0.0132	-0.26	-0.21	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42149886~42155001:-
LIHC	cis	rs244293	0.899	rs8080876	ENSG00000275710.1	RP11-257O5.4	-4.04	6.66e-05	0.0132	-0.23	-0.21	Menarche (age at onset);	chr17:55097906	chr17:54964474~54964679:+
LIHC	cis	rs4218	0.681	rs12913177	ENSG00000277144.1	RP11-59H7.4	4.04	6.66e-05	0.0132	0.23	0.21	Social communication problems;	chr15:59066273	chr15:59115547~59116089:-
LIHC	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-4.04	6.67e-05	0.0132	-0.17	-0.21	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
LIHC	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-4.04	6.67e-05	0.0132	-0.24	-0.21	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
LIHC	cis	rs638893	0.947	rs515707	ENSG00000255239.1	AP002954.6	4.04	6.67e-05	0.0132	0.46	0.21	Vitiligo;	chr11:118814772	chr11:118688039~118690600:-
LIHC	cis	rs7893279	0.505	rs12770851	ENSG00000225527.1	RP11-383B4.4	4.04	6.68e-05	0.0133	0.3	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18584223	chr10:18531849~18533336:-
LIHC	cis	rs875971	0.545	rs12670811	ENSG00000273024.4	INTS4P2	-4.04	6.68e-05	0.0133	-0.24	-0.21	Aortic root size;	chr7:66358032	chr7:65647864~65715661:+
LIHC	cis	rs10829156	0.898	rs4748504	ENSG00000225527.1	RP11-383B4.4	-4.04	6.68e-05	0.0133	-0.35	-0.21	Sudden cardiac arrest;	chr10:18651868	chr10:18531849~18533336:-
LIHC	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	4.04	6.68e-05	0.0133	0.27	0.21	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
LIHC	cis	rs2599510	0.811	rs2710628	ENSG000002